PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	GORMAN, LK; SHOOK, BL; BECKER, DP				GORMAN, LK; SHOOK, BL; BECKER, DP			TRAUMATIC BRAIN INJURY PRODUCES IMPAIRMENTS IN LONG-TERM AND RECENT MEMORY	BRAIN RESEARCH			English	Article						LONG-TERM MEMORY; RECENT MEMORY; TRAUMATIC BRAIN INJURY; POSTTRAUMATIC AMNESIA; ANTEROGRADE AMNESIA; RETROGRADE AMNESIA	FLUID-PERCUSSION MODEL; CEREBRAL BLOOD-FLOW; RAT	Traumatic brain injury (TBI) in humans typically produces neurological suppression and a longer lasting impairment of memory clinically defined as post-traumatic amnesia. An animal model that reliably reproduces the physiological changes associated with TBI was used to assess the memory deficits following brain injury. Prior to TBI, rats were trained to perform one of four tasks that assessed either motor performance, long-term or recent memory. Rats were randomly assigned to one of three groups (anesthesia only, sham operation or fluid percussion). Following fluid percussion, used to produce TBI, rats were tested for 6 test sessions. The first session occurred 1-2 min after the experimental manipulation. The next 5 sessions followed the training schedule maintained prior to experimental manipulation. Differences in long-term memory occurred only in the first post-operative test session. Differences in recent memory performance were found across all 6 test sessions. The memory deficits were clearly dissociated from motor deficits. The similar memory deficits observed following human head injury and the experimentally produced TBI injury demonstrate that fluid percussion is a useful approach to examine underlying neurobiological mechanisms involved in head injury and possible clinical interventions.	UNIV CALIF LOS ANGELES,SCH MED,DEPT SURG,DIV NEUROSURG,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT ANAT & CELL BIOL,LOS ANGELES,CA 90024							BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUNNETT SB, 1985, PSYCHOPHARMACOLOGY, V87, P357, DOI 10.1007/BF00432721; FISHER CM, 1966, NEUROLOGY, V16, P826, DOI 10.1212/WNL.16.8.826; GENARELLI TA, 1985, CENTRAL NERVOUS SYST, P391; GENARELLI TA, 1982, ANN NEUROL, V12, P564; GROAT RA, 1945, J NEUROSURG, V2, P26, DOI 10.3171/jns.1945.2.1.0026; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; O'Keefe J., 1978, HIPPOCAMPUS COGNITIV; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; OLTON DS, 1977, SCI AM, V236, P82, DOI 10.1038/scientificamerican0677-82; OLTON DS, 1979, NEUROBIOLOGY HIPPOCA, P355; OLTON DS, 1979, BEH BRIAN SCI, V2, P353; OMMAYA A K, 1971, International Journal of Neuroscience, V1, P371, DOI 10.3109/00207457109146986; PARKINSON D, 1978, NEUROSURGERY, V3, P176, DOI 10.1227/00006123-197809000-00008; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; ROSENER MJ, 1983, INTRACRANIAL PRESSUR, P301; Russell WR, 1935, LANCET, V2, P762; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; Squire L. R., 1984, NEUROBIOLOGY LEARNIN, P3; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WILKINS RH, 1985, NEUROSURGERY, P34	30	41	43	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUN 18	1993	614	1-2					29	36		10.1016/0006-8993(93)91014-J			8	Neurosciences	Neurosciences & Neurology	LJ044	WOS:A1993LJ04400005	8348320				2021-06-18	
J	YLVISAKER, M				YLVISAKER, M			COMMUNICATION OUTCOME IN CHILDREN AND ADOLESCENTS WITH TRAUMATIC BRAIN INJURY	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							CLOSED-HEAD-INJURY; FRONTAL-LOBE DAMAGE; ACQUIRED APHASIA; NEUROPSYCHOLOGICAL SEQUELAE; COGNITIVE SEQUELAE; PREFRONTAL CORTEX; CHILDHOOD; LANGUAGE; DISCOURSE; ADULTS	This article gives a brief review of investigations of speech and language impairment after paediatric traumatic brain injury (TBI) and describes possible effects of frontal lobe injury on non-aphasic disorders of communication. The relation between age and outcome after brain injury in children is also considered. Procedures for overcoming chronic obstacles to effective supports and services for students returning to school after TBI are described briefly. Although most children with normal development of language at the time of their injury experience generally satisfactory recovery of speech and language skills, there is considerable variation within this population. The most likely communication challenges relate to the socially skilled application of available speech and language skills, not their possession.	COLL ST ROSE,DEPT COMMUN DISORDERS,ALBANY,NY 12203							Ackerly SS, 1964, FRONTAL GRANULAR COR, P192; ALAJOUANINE T, 1965, BRAIN, V88, P653, DOI 10.1093/brain/88.4.653; ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; ARAM D, 1988, LANGUAGE COMMUNICATI; ARAM DM, 1985, J CLIN EXP NEUROPSYC, V7, P55, DOI 10.1080/01688638508401242; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; BENTON A, 1991, DEV NEUROPSYCHOL, V7, P275, DOI 10.1080/87565649109540495; Bigler E D, 1988, Arch Clin Neuropsychol, V3, P279, DOI 10.1016/0887-6177(88)90020-0; BLOSSER JL, 1989, TOP LANG DISORD, V9, P67, DOI 10.1097/00011363-198903000-00007; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BRUCE DA, 1979, CHILD BRAIN, V5, P174; CAMPBELL TF, 1990, J SPEECH HEAR DISORD, V55, P567, DOI 10.1044/jshd.5503.567; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1985, DEV MED CHILD NEUROL, V27, P72; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; COOPER JA, 1987, J SPEECH HEAR DISORD, V52, P251, DOI 10.1044/jshd.5203.251; DENNIS M, 1991, DEV NEUROPSYCHOL, V7, P327, DOI 10.1080/87565649109540497; DENNIS M, 1992, TOP LANG DISORD, V13, P66, DOI 10.1097/00011363-199211000-00008; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, 1985, HEAD INJURY REHABILI, P71; FINGER S, 1991, DEV NEUROPSYCHOL, V7, P261, DOI 10.1080/87565649109540494; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Golden C. J., 1981, NEUROPSYCHOLOGICAL A, P277; GOLDMAN PS, 1971, EXP NEUROL, V32, P366, DOI 10.1016/0014-4886(71)90005-7; GOLDMAN PS, 1977, NATURE, V267, P613, DOI 10.1038/267613a0; GRATTAN LM, 1991, DEV NEUROPSYCHOL, V7, P283, DOI 10.1080/87565649109540496; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; HARTLEY L, 1991, BRAIN INJURY, V8, P267; Hartley Leila L., 1992, Seminars in Speech and Language, V13, P264, DOI 10.1055/s-2008-1064202; HECAEN H, 1976, BRAIN LANG, V3, P114, DOI 10.1016/0093-934X(76)90009-2; HECAEN H, 1984, EARLY BRAIN DAMAGE, V1, P277; HOLLAND A, 1985, PROSPECTIVE STUDY OU; Jordan F M, 1988, Brain Inj, V2, P179, DOI 10.3109/02699058809150943; JORDAN FM, 1991, J SPEECH HEAR RES, V34, P572, DOI 10.1044/jshr.3403.572; KATZ DI, 1992, J HEAD TRAUMA REHAB, V7, P1; Kennard MA, 1942, MT SINAI J MED, V9, P594; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KOLB B, 1989, AM PSYCHOL, V44, P1203, DOI 10.1037/0003-066X.44.9.1203; LENNEBERG EH, 1967, BIOL F LANGUAGE; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1983, ARCH NEUROL-CHICAGO, V40, P601, DOI 10.1001/archneur.1983.04050090037004; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; Luria A. R., 1966, HIGHER CORTICAL FUNC; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MATEER CA, 1991, DEV NEUROPSYCHOL, V7, P359, DOI 10.1080/87565649109540498; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; PANG D, 1985, HEAD INJURY REHABILI, P1; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; PETTERSON L, 1988, THESIS U MINNESOTA; RAHN A, 1991, 12TH ANN S RES CHILD; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; SAVAGE R, IN PRESS ED PROGRAMM; STELLING MW, 1986, AM J DIS CHILD, V140, P710, DOI 10.1001/archpedi.1986.02140210108037; Stuss D.T., 1986, FRONTAL LOBES; SZEKERES SF, 1985, HEAD INJURY REHABILI, P219; VANDONGEN HR, 1977, CORTEX, V13, P131, DOI 10.1016/S0010-9452(77)80004-X; WELSH MC, 1988, DEV NEUROPSYCHOL, V4, P199, DOI 10.1080/87565648809540405; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; WOODS BT, 1979, ANN NEUROL, V6, P405, DOI 10.1002/ana.410060505; YLVISAKER M, 1989, TOP LANG DISORD, V9, P34, DOI 10.1097/00011363-198903000-00005; Ylvisaker M, 1991, J HEAD TRAUMA REHAB, V6, P10, DOI DOI 10.1097/00001199-199103000-00006; YLVISAKER M, IN PRESS ED PROGRAMM; YLVISAKER M, 1992, ADV CHILD NEUROPSYCH, V1, P168; YLVISAKER M, 1981, OCT INT S TRAUM BRAI; YLVISAKER M, 1985, NOV WORKSH PRES PED	76	41	42	1	12	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE, EAST SUSSEX, ENGLAND BN3 2FA	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		1993	3	4					367	387		10.1080/09602019308401447			21	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	MR361	WOS:A1993MR36100005					2021-06-18	
J	SUNDERLAND, PM; HEILBRUN, MP				SUNDERLAND, PM; HEILBRUN, MP			ESTIMATING ENERGY-EXPENDITURE IN TRAUMATIC BRAIN INJURY - COMPARISON OF INDIRECT CALORIMETRY WITH PREDICTIVE FORMULAS	NEUROSURGERY			English	Article						ENTERAL NUTRITION; INDIRECT CALORIMETRY; MEASURED ENERGY EXPENDITURE; NUTRITIONAL REQUIREMENTS; PARENTERAL NUTRITION; PREDICTED ENERGY EXPENDITURE; TRAUMATIC BRAIN INJURY	TOTAL PARENTERAL-NUTRITION; SEVERE HEAD-INJURY; METABOLIC RESPONSE; GAS-EXCHANGE; PATIENT; COMA	A HIGH DEGREE of variability in energy expenditure has characterized the metabolic response to traumatic brain injury. A goal of parenteral or enteral repletion in this population is the precise estimation of caloric requirement to avoid complications associated with overfeeding and underfeeding. The first aim of this study was to evaluate three predictive formulas for comparison to measured energy expenditure (MEE) derived from indirect calorimetry in patients with traumatic brain injury. A total of 385 measurements were obtained in 102 patients and were compared concurrently with these predictive formulas. The best predictive method in this phase (bivariate regression) yielded r = 0.39 and P < 0.001 (231 repeated measures). This best prediction, when compared with MEE, however, was able to capture values within 75 to 125% of MEE in only 56% of measurements. The two remaining formulas yielded r = 0.38 (P < 0.001) and r = 0.23 (P < 0.001) in 386 and 267 repeated measures, respectively. The second aim of this study was to evaluate the ability of additional nutritional markers to improve predictive ability. Regression analyses were performed on nutritional markers including indices of severity of injury, concurrent drug therapy, vital signs, neurological status, gluconeogenesis, protein synthesis/excretion, and immune response. The statistical results of the analysis on these multiple nutritional markers showed only heart rate, temperature, and number of days elapsed after injury to be significant predictors of MEE by indirect calorimetry in multiple regression analyses (R = 0.32; P < 0.001). These data suggest clinically significant discrepancies between MEE and these predictive formulas. Further regression analyses with additional variables did not result in substantially improved prediction. The ability to decipher the meaning of specific metabolic indicators and to make reasonable clinical decisions as to specific caloric supplementation may be tenuous when estimating energy expenditure with predictive formulas. The routine use of indirect calorimetry to guide caloric supplementation in patients with traumatic brain injury is warranted.		SUNDERLAND, PM (corresponding author), UNIV UTAH,SCH MED,DIV NEUROSURG,RM 3B409,50 N MED DRIVE,SALT LAKE CITY,UT 84132, USA.						BLACKBURN GL, 1989, NUTRITIONAL MED CASE, P2175; CAMPBELL SM, 1988, JPEN-PARENTER ENTER, V12, P610, DOI 10.1177/0148607188012006610; CERRA FB, 1982, CATABOLIC PHASE, P29; CHIOLERO R, 1989, JPEN-PARENTER ENTER, V13, P5, DOI 10.1177/014860718901300105; CHIOLERO RL, 1989, CRIT CARE MED, V17, P328, DOI 10.1097/00003246-198904000-00006; CLIFTON GL, 1986, J NEUROSURG, V64, P895, DOI 10.3171/jns.1986.64.6.0895; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; DEUTSCHMAN CS, 1986, J NEUROSURG, V64, P89, DOI 10.3171/jns.1986.64.1.0089; DICKERSON RN, 1990, J AM COLL NUTR, V9, P86; FELL D, 1984, CRIT CARE MED, V12, P649, DOI 10.1097/00003246-198408000-00009; FLEMING CR, 1988, NUTR METAB, P752; HAUSMANN D, 1985, INTENS CARE MED, V11, P80; JEEJEEBHOY KN, 1988, NUTR METAB, P60; KINNEY JM, 1988, NUTR METAB, P656; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Konstantinidis N. N., 1984, NUTR SUPPORT SERV, V4, P41; MAKK LJK, 1990, CRIT CARE MED, V18, P1320, DOI 10.1097/00003246-199012000-00003; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MOORE R, 1989, J TRAUMA, V29, P1633, DOI 10.1097/00005373-198912000-00007; NORUSIS M, 1988, STATISTICAL PACKAGE; Ott L, 1990, Nutr Clin Pract, V5, P68, DOI 10.1177/011542659000500268; OTT L, 1991, J NEUROSURG, V74, P738, DOI 10.3171/jns.1991.74.5.0738; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; ROBERTSON CS, 1984, NEUROSURGERY, V15, P307, DOI 10.1227/00006123-198409000-00003; SAX HC, 1988, JPEN-PARENTER ENTER, V12, P615, DOI 10.1177/0148607188012006615; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TWYMAN DL, 1989, NUTRITIONAL MED CASE, P10; WESTENSKOW DR, 1984, CRIT CARE MED, V12, P183, DOI 10.1097/00003246-198403000-00006; WESTENSKOW DR, 1988, JPEN-PARENTER ENTER, V12, P20, DOI 10.1177/014860718801200120; WILMORE D, 1977, METABOLIC MANAGEMENT; YOUNG B, 1985, NEUROSURGERY, V17, P784, DOI 10.1227/00006123-198511000-00010; 1989, STATISTICS GUIDE SPS, pB20	32	41	41	0	3	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	AUG	1992	31	2					246	253		10.1227/00006123-199208000-00009			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	JJ520	WOS:A1992JJ52000009	1513430				2021-06-18	
J	HEINZE, HJ; MUNTE, TF; GOBIET, W; NIEMANN, H; RUFF, RM				HEINZE, HJ; MUNTE, TF; GOBIET, W; NIEMANN, H; RUFF, RM			PARALLEL AND SERIAL VISUAL-SEARCH AFTER CLOSED HEAD-INJURY - ELECTROPHYSIOLOGICAL EVIDENCE FOR PERCEPTUAL DYSFUNCTIONS	NEUROPSYCHOLOGIA			English	Article							EVENT-RELATED POTENTIALS; BILATERAL STIMULUS ARRAYS; INDEX FOCUSED ATTENTION; MILD	Event-related potentials (ERPs) were recorded from closed head injury (CHI) patients at least 2 years postinjury and from controls in order to assess their parallel and serial processing abilities during visual search. In Experiment 1, stimuli consisted of arrays of eight triangles; half of the arrays contained a target item. In the "feature-present" condition, the target item was a triangle with an additional horizontal line that could be detected automatically and in parallel, while in the "feature-absent" condition all items except for the target triangle had an additional horizontal line, thus requiring a serial search. In Experiment 2, stimuli consisted of eight solid bars (50%), seven solid bars and a vertical open bar (25%), and seven solid bars and a horizontal open bar (25%): the array containing the horizontal bar served as a target. By recording ERPs to the arrays containing vertical open bars, which were similar to the target items, parallel processing of "pop-out" stimuli could be studied in the absence of any overt response. ERP data were compared with the results of neuropsychological and neuroimaging (MRI, CAT) examination. Patient exhibited a decreased behavioral performance both in the parallel and in the serial processing mode. Furthermore, abnormalities of early and intermediate ERP components (P1, N1, P2, N2) were found, whereas the late component (P3) was less affected by CHI. The results were interpreted as an index of CHI-induced dysfunctions in perceptual processes such as simple feature registration and early target discrimination. It was suggested that these dysfunctions contribute to impairments of parallel as well as serial processes in visual search.	UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143; NEUROL KLIN HESS OLDENDORF,OLDENDORF,GERMANY; EPILEPSIEZENTRUM BETHEL,BETHEL,GERMANY	HEINZE, HJ (corresponding author), MED SCH HANNOVER,DEPT NEUROL,KONSTANTY GUTSCHOW STR 8,W-3000 HANNOVER 61,GERMANY.		Munte, Thomas/C-2077-2014				ABT K, 1987, METHOD INFORM MED, V26, P77; ABT K, 1983, NEUROPSYCHOBIOLOGY, V9, P47, DOI 10.1159/000117937; BENYISHAI Y, 1987, NEUROPSYCHOLOGICAL R; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; CAMPBELL K, 1986, EEG S, V38; Curry S H, 1980, Prog Brain Res, V54, P507, DOI 10.1016/S0079-6123(08)61668-4; Donchin E, 1986, PSYCHOPHYSIOLOGY SYS, P244; Duncan J, 1985, ATTENTION PERFORM, P85; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; HARTER MR, 1984, VARIETIES ATTENTION, P292; HEINZE HJ, 1990, ELECTROEN CLIN NEURO, V75, P511, DOI 10.1016/0013-4694(90)90138-A; Hillyard A.S., 1987, HDB PHYSL NERVOUS SY, P519; HILLYARD SA, 1990, MACHINERY OF THE MIND, P186; JULESZ B, 1984, DYNAMIC ASPECTS NEOC, P120; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; LUCK S J, 1988, Society for Neuroscience Abstracts, V14, P1013; LUCK SJ, 1990, PERCEPT PSYCHOPHYS, V48, P603, DOI 10.3758/BF03211606; LUCK SJ, 1990, ELECTROEN CLIN NEURO, V75, P528, DOI 10.1016/0013-4694(90)90139-B; Marr D., 1982, VISION COMPUTATIONAL; MCCALLUM WC, 1973, ELECTROEN CLIN NEURO, V35, P449, DOI 10.1016/0013-4694(73)90020-5; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; PAPANICOLAOU AC, 1984, NEUROSURGERY, V14, P676, DOI 10.1227/00006123-198406000-00005; POSNER MI, 1987, NEUROBEHAVIORAL RECO, P390; RIZZO PA, 1978, ELECTROEN CLIN NEURO, V45, P281, DOI 10.1016/0013-4694(78)90012-3; RUFF RM, 1986, PERCEPT MOTOR SKILL, V62, P407, DOI 10.2466/pms.1986.62.2.407; RUFF RM, 1987, DEV NEUROPSYCHOL, V3, P37, DOI 10.1080/87565648709540362; RUFF RM, 1986, SAN DIEGO NEUROPSYCH; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1989, BRAIN, V112, P489, DOI 10.1093/brain/112.2.489; Schneider W., 1984, VARIETIES ATTENTION, P1; Tewes U., 1991, HAMBURG WECHSLER INT, V2; TREISMAN A, 1985, J EXP PSYCHOL GEN, V114, P285, DOI 10.1037/0096-3445.114.3.285; TREISMAN A, 1985, COMPUT VISION GRAPH, V31, P156, DOI 10.1016/S0734-189X(85)80004-9; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; Trites R, 1977, NEUROPSYCHOLOGICAL T; ULLMAN S, 1984, COGNITION, V18, P97, DOI 10.1016/0010-0277(84)90023-4; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; ZOMEREN AHV, 1987, NEUROBEHAVIORAL RECO, P398	40	41	41	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia	JUN	1992	30	6					495	514		10.1016/0028-3932(92)90054-P			20	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	JC958	WOS:A1992JC95800001	1641115				2021-06-18	
J	STUSS, DT; STETHEM, LL; PICTON, TW; LEECH, EE; PELCHAT, G				STUSS, DT; STETHEM, LL; PICTON, TW; LEECH, EE; PELCHAT, G			TRAUMATIC BRAIN INJURY, AGING AND REACTION-TIME	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article									UNIV OTTAWA,SCH MED NEUROL,OTTAWA K1N 6N5,ONTARIO,CANADA; UNIV OTTAWA,SCH PSYCHOL,OTTAWA K1N 6N5,ONTARIO,CANADA; UNIV OTTAWA,HUMAN NEUROSCI RES UNIT,OTTAWA K1N 6N5,ONTARIO,CANADA; OTTAWA GEN HOSP,OTTAWA K1H 8L6,ONTARIO,CANADA							Albert M., 1980, NEW DIRECTIONS MEMOR, P403; ALEXANDER MP, 1982, PSYCHIAT ASPECTS NEU, P219; ANDERS TR, 1973, DEV PSYCHOL, V9, P411, DOI 10.1037/h0034930; BENTON AL, 1958, J ABNORMAL SOCIAL PS, V54, P109; BIRREN JE, 1980, PSYCHOL ISSUES, P293; BLACKBURN H L, 1955, Confin Neurol, V15, P327; Cerella J., 1980, PSYCHOL ISSUES, P332; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHOWN SM, 1961, J GERONTOL, V16, P353, DOI 10.1093/geronj/16.4.353; CLIFTON GL, 1980, J NEUROSURG, V52, P619; COHEN G, 1983, J GERONTOL, V38, P447, DOI 10.1093/geronj/38.4.447; COURVILLE CB, 1937, PATHOLOGY CENTRAL NE; CUMMINGS J, 1983, DEMENTIA CLIN APPROA; DENCKER SJ, 1958, ACTA PSYCHIAT NEUROL, V33, P122; DUARA R, 1984, ANN NEUROL, V16, P702, DOI 10.1002/ana.410160613; Dupui P, 1984, Monogr Neural Sci, V11, P131; Fuster JM., 1980, PREFRONTAL CORTEX; GAYLORD SA, 1975, J GERONTOL, V30, P674; GRIEW S, 1958, GERONTOLOGY, V2, P284, DOI 10.1159/000210764; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; GRUBBS FE, 1969, TECHNOMETRICS, V11, P1, DOI 10.2307/1266761; HOWELL SC, 1972, PERCEPT MOTOR SKILL, V34, P732, DOI 10.2466/pms.1972.34.3.732; KEMPER T, 1984, CLIN NEUROLOGY AGING, P9; KINSBOURNE M, 1974, INT J AGING HUM DEV, V5, P41, DOI 10.2190/N46C-2A38-2AQV-26TU; KLAYMAN J, 1987, PSYCHOL REV, V94, P211, DOI 10.1037/0033-295X.94.2.211; KLENSCH H, 1973, FORTSCHR NEUROL PSYC, V41, P575; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Luria A. R, 1973, WORKING BRAIN; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2nd; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MADDEN DJ, 1983, DEV PSYCHOL, V19, P499, DOI 10.1037/0012-1649.19.4.499; Miller E, 1970, Cortex, V6, P121; MISTLERLACHMAN JL, 1977, J GERONTOL, V32, P68, DOI 10.1093/geronj/32.1.68; MOSCOVITCH M, 1983, CAN J PSYCHOL, V37, P331, DOI 10.1037/h0080743; NORRMAN B, 1961, ACTA PSYCHIAT SCAND, V37, P236, DOI 10.1111/j.1600-0447.1961.tb07359.x; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; RABBITT P, 1965, J GERONTOL, V20, P233, DOI 10.1093/geronj/20.2.233; RABBITT P, 1977, HDB PSYCHOL AGING, P606; RABBITT PMA, 1968, HUM AGING BEHAV, P75; Salthouse T. A., 1985, HDB AGING HDB PSYCHO, P400; Schaie K. W., 1980, HDB MENTAL HLTH AGIN, P262; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; Stuss D.T., 1986, FRONTAL LOBES; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; Welford A. T, 1980, HDB MENTAL HLTH AGIN, P192; Welford AT., 1977, HDB PSYCHOL AGING; WETHERICK NE, 1965, GERONTOLOGIA, V77, P89; WRIGHT LL, 1979, J GERONTOL, V34, P704, DOI 10.1093/geronj/34.5.704	56	41	41	0	4	CANADIAN J NEUROL SCI INC	CALGARY	PO BOX 4220, STATION C EDITORIAL & SUBSCRIPTION SERV, CALGARY AB T2T 5N1, CANADA	0317-1671			CAN J NEUROL SCI	Can. J. Neurol. Sci.	MAY	1989	16	2					161	167		10.1017/S0317167100028833			7	Clinical Neurology	Neurosciences & Neurology	U6083	WOS:A1989U608300002	2731082	Bronze			2021-06-18	
J	SHOHAMI, E; SHAPIRA, Y; COTEV, S				SHOHAMI, E; SHAPIRA, Y; COTEV, S			EXPERIMENTAL CLOSED HEAD-INJURY IN RATS - PROSTAGLANDIN PRODUCTION IN A NONINJURED ZONE	NEUROSURGERY			English	Article									HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT ANESTHESIOL,IL-91010 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,INTENS CARE UNIT,IL-91010 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,TRAUMA RES CTR,IL-91010 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,HADASSAH HOSP,IL-91010 JERUSALEM,ISRAEL	SHOHAMI, E (corresponding author), HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT PHARMACOL,IL-91010 JERUSALEM,ISRAEL.						ABDELHALIM MS, 1980, PROSTAGLANDINS, V19, P249, DOI 10.1016/0090-6980(80)90023-4; AMES A, 1968, AM J PATHOL, V52, P437; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; DEMPSEY RJ, 1986, J NEUROSURG, V64, P118, DOI 10.3171/jns.1986.64.1.0118; DEUTSCHMAN CS, 1986, J NEUROSURG, V64, P89, DOI 10.3171/jns.1986.64.1.0089; ELLIS EF, 1979, AM J PHYSIOL, V237, pH381; FORSTERMANN U, 1982, BRAIN RES, V240, P303, DOI 10.1016/0006-8993(82)90225-6; GAUDET RJ, 1980, J NEUROCHEM, V35, P653, DOI 10.1111/j.1471-4159.1980.tb03704.x; GERRITSEN ME, 1981, PROSTAGLANDINS, V22, P553, DOI 10.1016/0090-6980(81)90065-4; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GRYGLEWSKI RJ, 1982, PHARMACOL RES COMMUN, V14, P879, DOI 10.1016/S0031-6989(82)80012-X; HALLENBECK JM, 1979, STROKE, V10, P629, DOI 10.1161/01.STR.10.6.629; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; HOSSMANN KA, 1974, BRAIN RES, V81, P59, DOI 10.1016/0006-8993(74)90478-8; HOSSMANN KA, 1973, ARCH NEUROL-CHICAGO, V29, P375, DOI 10.1001/archneur.1973.00490300037004; KAGSTROM E, 1983, J CEREBR BLOOD F MET, V3, P183, DOI 10.1038/jcbfm.1983.25; KAGSTROM E, 1983, J CEREBR BLOOD F MET, V3, P170, DOI 10.1038/jcbfm.1983.24; KATZMAN R, 1973, BRAIN ELECTROLYTES F; KEMPSKI O, 1987, STROKE, V18, P111, DOI 10.1161/01.STR.18.1.111; LEFER AM, 1980, PHARMACOLOGY, V21, P206, DOI 10.1159/000137434; LEFER AM, 1978, SCIENCE, V200, P52, DOI 10.1126/science.345441; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASUDA Y, 1986, N-S ARCH PHARMACOL, V334, P282, DOI 10.1007/BF00508783; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MONCADA S, 1976, NATURE, V263, P663, DOI 10.1038/263663a0; MOSKOWITZ MA, 1984, SCIENCE, V224, P886, DOI 10.1126/science.6719118; NIKOLOV R, 1982, METHOD FIND EXP CLIN, V4, P211; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; PAPPIUS HM, 1983, J CEREBR BLOOD F MET, V3, P448, DOI 10.1038/jcbfm.1983.71; ROSEN R, 1981, EUR J PHARMACOL, V69, P489, DOI 10.1016/0014-2999(81)90454-4; SEREGI A, 1985, BRAIN RES, V337, P171, DOI 10.1016/0006-8993(85)91626-9; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1982, STROKE, V13, P494, DOI 10.1161/01.STR.13.4.494; WAGNER KR, 1985, J NEUROSURG, V63, P88, DOI 10.3171/jns.1985.63.1.0088; WEKSLER BB, 1977, P NATL ACAD SCI USA, V74, P3922, DOI 10.1073/pnas.74.9.3922; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617	37	41	41	0	3	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	MAY	1988	22	5					859	863		10.1227/00006123-198805000-00007			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	N2659	WOS:A1988N265900009	3164097				2021-06-18	
J	WILLIAMS, JM; GOMES, F; DRUDGE, OW; KESSLER, M				WILLIAMS, JM; GOMES, F; DRUDGE, OW; KESSLER, M			PREDICTING OUTCOME FROM CLOSED HEAD-INJURY BY EARLY ASSESSMENT OF TRAUMA SEVERITY	JOURNAL OF NEUROSURGERY			English	Article									UNIV VERMONT,DEPT SURG,DIV NEUROSURG,BURLINGTON,VT 05405; UNIV VERMONT,DEPT PSYCHOL,BURLINGTON,VT 05405	WILLIAMS, JM (corresponding author), MEMPHIS STATE UNIV,DEPT PSYCHOL,MEMPHIS,TN 38152, USA.						BENTON A, 1979, CENTRAL NERVOUS SYST, P220; Boll TJ, 1981, HDB CLIN NEUROPSYCHO, P577; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; COOPER PR, 1979, J NEUROSURG, V51, P307, DOI 10.3171/jns.1979.51.3.0307; DRUDGE OW, 1984, J CLIN PSYCHOL, V40, P259, DOI 10.1002/1097-4679(198401)40:1<259::AID-JCLP2270400149>3.0.CO;2-C; Fleischer A S, 1976, Surg Neurol, V6, P31; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; Klove H, 1972, Scand J Rehabil Med, V4, P55; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; MANDLEBERG IA, 1976, J NEUROL NEUROSUR PS, V39, P1001, DOI 10.1136/jnnp.39.10.1001; MILLER E, 1979, BRIT J SOC CLIN PSYC, V18, P87, DOI 10.1111/j.2044-8260.1979.tb00310.x; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; NUNNALLY J, 1978, PSYCHOMETRIC THEORY, P138; Ruesch J, 1944, AM J PSYCHIAT, V100, P480, DOI 10.1176/ajp.100.4.480; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; TEASDALE G, 1974, LANCET, V2, P81; TOOTH G, 1947, J NEUROL NEUROSUR PS, V10, P1, DOI 10.1136/jnnp.10.1.1; WILSON RS, 1978, J CONSULT CLIN PSYCH, V46, P1554, DOI 10.1037/0022-006X.46.6.1554; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300; 1971, CLIN EXAMINATIONS NE, P202	26	41	41	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.		1984	61	3					581	585		10.3171/jns.1984.61.3.0581			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	TG601	WOS:A1984TG60100022	6747697				2021-06-18	
J	Henry, RJ; Ritzel, RM; Barrett, JP; Doran, SJ; Jiao, Y; Leach, JB; Szeto, GL; Wu, JF; Stoica, BA; Faden, AI; Loane, DJ				Henry, Rebecca J.; Ritzel, Rodney M.; Barrett, James P.; Doran, Sarah J.; Jiao, Yun; Leach, Jennie B.; Szeto, Gregory L.; Wu, Junfang; Stoica, Bogdan A.; Faden, Alan, I; Loane, David J.			Microglial Depletion with CSF1R Inhibitor During Chronic Phase of Experimental Traumatic Brain Injury Reduces Neurodegeneration and Neurological Deficits	JOURNAL OF NEUROSCIENCE			English	Article						CSF1R; functional recovery; microglia; neurodegeneration; neuroinflammation; traumatic brain injury	NADPH OXIDASE; NLRP3 INFLAMMASOME; PROGENITOR-CELL; NEURONAL LOSS; NEUROINFLAMMATION; ACTIVATION; EXPRESSION; DEMENTIA; PREVENTS; RISK	Chronic neuroinflammation with sustained microglial activation occurs following severe traumatic brain injury (TBI) and is believed to contribute to subsequent neurodegeneration and neurological deficits. Microglia, the primary innate immune cells in brain, are dependent on colony stimulating factor 1 receptor (CSF1R) signaling for their survival. In this preclinical study, we examined the effects of delayed depletion of chronically activated microglia on functional recovery and neurodegeneration up to 3 months postinjury. A CSF1R inhibitor, Plexxikon (PLX) 5622, was administered to adult male C57BL/6J mice at 1 month after controlled cortical impact to remove chronically activated microglia, and the inhibitor was withdrawn 1-week later to allow for microglial repopulation. Following TBI, the repopulated microglia displayed a ramified morphology similar to that of Sham uninjured mice, whereas microglia in vehicle-treated TBI mice showed the typical chronic posttraumatic hypertrophic morphology. PLX5622 treatment limited TBI-associated neuropathological changes at 3 months postinjury; these included a smaller cortical lesion, reduced hippocampal neuron cell death, and decreased NOX2-and NLRP3 inflammasome-associated neuroinflammation. Furthermore, delayed depletion of chronically activated microglia after TBI led to widespread changes in the cortical transcriptome and altered gene pathways involved in neuroinflammation, oxidative stress, and neuroplasticity. Using a variety of complementary neurobehavioral tests, PLX5622-treated TBI mice also had improved long-term motor and cognitive function recovery through 3 months postinjury. Together, these studies demonstrate that chronic phase removal of neurotoxic microglia after TBI using CSF1R inhibitors markedly reduce chronic neuroinflammation and associated neurodegeneration, as well as related motor and cognitive deficits.	[Henry, Rebecca J.; Ritzel, Rodney M.; Barrett, James P.; Doran, Sarah J.; Wu, Junfang; Stoica, Bogdan A.; Faden, Alan, I; Loane, David J.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Henry, Rebecca J.; Ritzel, Rodney M.; Barrett, James P.; Doran, Sarah J.; Wu, Junfang; Stoica, Bogdan A.; Faden, Alan, I; Loane, David J.] Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res STAR Ctr, Baltimore, MD 21201 USA; [Jiao, Yun; Leach, Jennie B.; Szeto, Gregory L.] Univ Maryland, Dept Chem Biochem & Environm Engn, Baltimore, MD 21250 USA; [Szeto, Gregory L.] Univ Maryland, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA; [Szeto, Gregory L.] Univ Maryland, Dept Microbiol & Immunol, Sch Med, Baltimore, MD 21201 USA; [Stoica, Bogdan A.] Univ Maryland, Dept Radiat Oncol, DTRS, Sch Med, Baltimore, MD 21201 USA; [Stoica, Bogdan A.] Baltimore VA Med Ctr, VA Maryland Hlth Care Syst, Baltimore, MD 21201 USA; [Loane, David J.] Trinity Coll Dublin, Sch Biochem & Immunol, Trinity Biomed Sci Inst, Dublin, Ireland	Henry, RJ; Loane, DJ (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA.; Henry, RJ; Loane, DJ (corresponding author), Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res STAR Ctr, Baltimore, MD 21201 USA.; Loane, DJ (corresponding author), Trinity Coll Dublin, Sch Biochem & Immunol, Trinity Biomed Sci Inst, Dublin, Ireland.	rhenry@som.umaryland.edu; loanedj@tcd.ie		Szeto, Gregory/0000-0001-7604-1333; Henry, Rebecca/0000-0001-8548-1170; Barrett, James/0000-0002-0924-9449; Ritzel, Rodney/0000-0002-0160-2930	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS082308, R01NS037313, R01NS096002, R01NS110756, R21EY029451]; U.S. Department of Veterans AffairsUS Department of Veterans Affairs [1I01 RX001993]; Science Foundation IrelandScience Foundation IrelandEuropean Commission [17/FRL/4860]	This work was supported by the National Institutes of Health (Grant R01NS082308 to D.J.L., Grant R01NS037313 to A.I.F., Grant R01NS096002 to B.A.S., Grant R01NS110756 to D.J.L., A.I.F., and B.A.S., and Grant R21EY029451 to J.B.L.), the U.S. Department of Veterans Affairs (Grant 1I01 RX001993 to B.A.S.), and Science Foundation Ireland (Grant 17/FRL/4860 to D.J.L.). We thank Victoria Meadows and Wesley Shoap for help with neurobehavioral assessment and histology and Plexxikon Inc. for the use of PLX5622.	Adamczak S, 2012, J NEUROSURG, V117, P1119, DOI 10.3171/2012.9.JNS12815; Asai H, 2015, NAT NEUROSCI, V18, P1584, DOI 10.1038/nn.4132; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Barrett JP, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0843-4; Beckmann N, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-018-0510-8; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Cherry JD, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0382-8; Coughlin JM, 2017, JAMA NEUROL, V74, P67, DOI 10.1001/jamaneurol.2016.3764; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Dagher NN, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0366-9; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Doran SJ, 2019, J NEUROTRAUM, V36, P1040, DOI 10.1089/neu.2018.6019; Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995; Elmore MRP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122912; Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040; Erblich B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026317; Faden AI, 2016, BRIT J PHARMACOL, V173, P681, DOI 10.1111/bph.13179; Faden AI, 2015, NEUROTHERAPEUTICS, V12, P143, DOI 10.1007/s13311-014-0319-5; Ferguson S, 2017, J NEUROTRAUM, V34, P1676, DOI 10.1089/neu.2016.4636; Foucher Y, 2012, STAT APPL GENET MOL, V11, DOI 10.1515/1544-6115.1815; Garcia-Cabezas MA, 2016, FRONT NEUROANAT, V10, DOI 10.3389/fnana.2016.00107; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Han JM, 2019, GLIA, V67, P217, DOI 10.1002/glia.23529; Heneka MT, 2018, NAT REV NEUROSCI, V19, P610, DOI 10.1038/s41583-018-0055-7; Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5; Henry RJ, 2019, NEUROTHERAPEUTICS, V16, P216, DOI 10.1007/s13311-018-0665-9; Hume DA, 2019, TRENDS IMMUNOL, V40, P98, DOI 10.1016/j.it.2018.11.007; Jin WN, 2017, J CEREBR BLOOD F MET, V37, P2224, DOI 10.1177/0271678X17694185; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kerr N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0210128; Kumar A, 2016, BRAIN BEHAV IMMUN, V58, P291, DOI 10.1016/j.bbi.2016.07.158; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Kumar RG, 2018, BRAIN INJURY, V32, P383, DOI 10.1080/02699052.2018.1427888; Kuwar R, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1471-y; Lage SL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01284; Li MS, 2017, J CEREBR BLOOD F MET, V37, P2383, DOI 10.1177/0271678X16666551; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Ma MW, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6057609; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; Nandi S, 2012, DEV BIOL, V367, P100, DOI 10.1016/j.ydbio.2012.03.026; Nissen JC, 2018, EXP NEUROL, V307, P24, DOI 10.1016/j.expneurol.2018.05.021; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Olmos-Alonso A, 2016, BRAIN, V139, P891, DOI 10.1093/brain/awv379; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Piao CS, 2013, NEUROBIOL DIS, V54, P252, DOI 10.1016/j.nbd.2012.12.017; Pischiutta F, 2018, EXP NEUROL, V300, P167, DOI 10.1016/j.expneurol.2017.11.003; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rice RA, 2017, GLIA, V65, P931, DOI 10.1002/glia.23135; Rice RA, 2015, J NEUROSCI, V35, P9977, DOI 10.1523/JNEUROSCI.0336-15.2015; Ritzel RM, 2018, J NEUROTRAUM, V35, P1419, DOI 10.1089/neu.2017.5399; Ritzel RM, 2019, NEUROBIOL AGING, V77, P194, DOI 10.1016/j.neurobiolaging.2019.02.010; Rohart F, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005752; Sabaz M, 2014, J HEAD TRAUMA REHAB, V29, pE19, DOI 10.1097/HTR.0b013e31828dc590; Salter MW, 2017, NAT MED, V23, P1018, DOI 10.1038/nm.4397; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Spangenberg E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11674-z; Spangenberg EE, 2016, BRAIN, V139, P1265, DOI 10.1093/brain/aww016; Szalay G, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11499; Villacampa N, 2015, GLIA, V63, P1166, DOI 10.1002/glia.22807; Wang H, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw677; Wheeler DL, 2018, J CLIN INVEST, V128, P931, DOI 10.1172/JCI97229; Wilson L, 2017, LANCET NEUROL, V16, P813, DOI 10.1016/S1474-4422(17)30279-X; Witcher KG, 2018, GLIA, V66, P2719, DOI 10.1002/glia.23523; Xu X, 2018, NEUROBIOL DIS, V117, P15, DOI 10.1016/j.nbd.2018.05.016; Yang XX, 2018, FASEB J, V32, P3336, DOI 10.1096/fj.201700833RR; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511	81	40	41	5	8	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	APR 1	2020	40	14					2960	2974		10.1523/JNEUROSCI.2402-19.2020			15	Neurosciences	Neurosciences & Neurology	KY7ZL	WOS:000522791300016	32094203	Bronze, Green Published	Y	N	2021-06-18	
J	Li, CY; Li, WF; Liu, HH; Zhang, YJ; Chen, GC; Li, ZJ; Wang, QB				Li, Chunyan; Li, Wanfei; Liu, Huanhuan; Zhang, Yejun; Chen, Guangcun; Li, Zijing; Wang, Qiangbin			An Activatable NIR-II Nanoprobe for In Vivo Early Real-Time Diagnosis of Traumatic Brain Injury	ANGEWANDTE CHEMIE-INTERNATIONAL EDITION			English	Article						bioimaging; fluorescent probes; peroxynitrite; second near-infrared window; traumatic brain injury	QUANTUM DOTS; DISEASE; DYE; PEROXYNITRITE; NANOPARTICLES; NANOCRYSTALS; WINDOW; CELLS	Traumatic brain injury (TBI) is one of the most dangerous acute diseases resulting in high morbidity and mortality. Current methods remain limited with respect to early diagnosis and real-time feedback on the pathological process. Herein, a targeted activatable fluorescent nanoprobe (V&A@Ag2S) in the second near-infrared window (NIR-II) is presented for in vivo optical imaging of TBI. Initially, the fluorescence of V&A@Ag2S is turned off owing to energy transfer from Ag2S to the A1094 chromophore. Upon intravenous injection, V&A@Ag2S quickly accumulates in the inflamed vascular endothelium of TBI based on VCAM1-mediated endocytosis, after which the nanoprobe achieves rapid recovery of the NIR-II fluorescence of Ag2S quantum dots (QDs) owing to the bleaching of A1094 by the prodromal biomarker of TBI, peroxynitrite (ONOO-). The nanoprobe offers high specificity, rapid response, and high sensitivity toward ONOO-, providing a convenient approach for in vivo early real-time assessment of TBI.	[Li, Chunyan; Zhang, Yejun; Chen, Guangcun; Wang, Qiangbin] Chinese Acad Sci, Suzhou Key Lab Funct Mol Imaging Technol, CAS Key Lab Nanobio Interface, Div Nanobiomed, Suzhou 215123, Peoples R China; [Li, Chunyan; Zhang, Yejun; Chen, Guangcun; Wang, Qiangbin] Chinese Acad Sci, Suzhou Inst Nanotech & Nanobion, I Lab, Suzhou 215123, Peoples R China; [Li, Chunyan; Zhang, Yejun; Chen, Guangcun; Wang, Qiangbin] Univ Sci & Technol China, Hefei 230036, Anhui, Peoples R China; [Li, Chunyan; Zhang, Yejun; Chen, Guangcun; Wang, Qiangbin] Univ Chinese Acad Sci, Coll Mat Sci & Optoelect Technol, Beijing 100049, Peoples R China; [Li, Wanfei] Suzhou Univ Sci & Technol, Sch Chem Biol & Mat Engn, Res Ctr Nanophoton & Nanoelect Mat, Suzhou 215009, Peoples R China; [Liu, Huanhuan; Li, Zijing] Xiamen Univ, Sch Publ Hlth, Ctr Mol Imaging & Translat Med, Lab Mol Vaccinol & Mol Diagnost,State Key, Xiamen 361102, Fujian, Peoples R China	Li, CY; Wang, QB (corresponding author), Chinese Acad Sci, Suzhou Key Lab Funct Mol Imaging Technol, CAS Key Lab Nanobio Interface, Div Nanobiomed, Suzhou 215123, Peoples R China.; Li, CY; Wang, QB (corresponding author), Chinese Acad Sci, Suzhou Inst Nanotech & Nanobion, I Lab, Suzhou 215123, Peoples R China.; Li, CY; Wang, QB (corresponding author), Univ Sci & Technol China, Hefei 230036, Anhui, Peoples R China.; Li, CY; Wang, QB (corresponding author), Univ Chinese Acad Sci, Coll Mat Sci & Optoelect Technol, Beijing 100049, Peoples R China.; Li, ZJ (corresponding author), Xiamen Univ, Sch Publ Hlth, Ctr Mol Imaging & Translat Med, Lab Mol Vaccinol & Mol Diagnost,State Key, Xiamen 361102, Fujian, Peoples R China.	cyli2012@sinano.ac.cn; zijing.li@xmu.edu.cn; qbwang2008@sinano.ac.cn			National Key Research and Development Program of China [2016YFA0101503, 2017YFA0205503]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [21671198, 21425103, 21501192, 21934007]; Chinese Academy of SciencesChinese Academy of Sciences [XDB32030200, 121E32KYSB20180021, ZDBS-LY-SLH021]; Natural Science Foundation of Jiangsu ProvinceNatural Science Foundation of Jiangsu Province [BK20170066, BE2016682]; Youth Innovation Promotion Association of Chinese Academy of Sciences; CAS Key Laboratory of Nano-Bio Interface [18NBI01]	This work was financially supported by the National Key Research and Development Program of China (Grant Nos. 2016YFA0101503, 2017YFA0205503), National Natural Science Foundation of China (Grant Nos. 21671198, 21425103, 21501192, 21934007), Chinese Academy of Sciences (Grant Nos. XDB32030200, 121E32KYSB20180021, ZDBS-LY-SLH021), Natural Science Foundation of Jiangsu Province (Grant Nos. BK20170066, BE2016682), the Youth Innovation Promotion Association of Chinese Academy of Sciences, and CAS Key Laboratory of Nano-Bio Interface (No. 18NBI01). The authors thank Suzhou NIR-Optics Technologies Co., Ltd. for its instrumental and technical support on the NIR-II imaging.	Adibhatla RM, 2010, ANTIOXID REDOX SIGN, V12, P125, DOI [10.1089/ars.2009.2668, 10.1089/ARS.2009.2668]; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Antaris AL, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15269; Antaris AL, 2016, NAT MATER, V15, P235, DOI [10.1038/NMAT4476, 10.1038/nmat4476]; Arakawa Y., 2008, ANGEW CHEM, V120, P8356; Arakawa Y, 2008, ANGEW CHEM INT EDIT, V47, P8232, DOI 10.1002/anie.200802800; Dong BH, 2013, CHEM MATER, V25, P2503, DOI 10.1021/cm400812v; Drummond GR, 2011, NAT REV DRUG DISCOV, V10, P453, DOI 10.1038/nrd3403; Ghosh D, 2014, P NATL ACAD SCI USA, V111, P13948, DOI 10.1073/pnas.1400821111; Hong G.S., 2012, ANGEW CHEM INT EDIT, V124, P9956, DOI DOI 10.1002/ANGE.201206059; Hong GS, 2014, NAT PHOTONICS, V8, P723, DOI [10.1038/NPHOTON.2014.166, 10.1038/nphoton.2014.166]; Hong GS, 2012, NAT MED, V18, P1841, DOI 10.1038/nm.2995; Hong GS, 2012, ANGEW CHEM INT EDIT, V51, P9818, DOI 10.1002/anie.201206059; Kheirolomoom A, 2015, ACS NANO, V9, P8885, DOI 10.1021/acsnano.5b02611; Li B., 2018, ANGEW CHEM-GER EDIT, V130, P7605, DOI [10.1002/ange.201801226, DOI 10.1002/ANGE.201801226]; Li BH, 2018, ANGEW CHEM INT EDIT, V57, P7483, DOI 10.1002/anie.201801226; Li X, 2015, J AM CHEM SOC, V137, P12296, DOI 10.1021/jacs.5b06865; Naczynski DJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3199; Nahrendorf M, 2006, CIRCULATION, V114, P1504, DOI 10.1161/CIRCULATIONAHA.106.646380; O'Connell KM, 2013, BIOL RES NURS, V15, P253, DOI 10.1177/1099800411431823; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Shao W, 2016, J AM CHEM SOC, V138, P16192, DOI 10.1021/jacs.6b08973; Smith AM, 2009, NAT NANOTECHNOL, V4, P710, DOI 10.1038/nnano.2009.326; Szabo C, 2007, NAT REV DRUG DISCOV, V6, P662, DOI 10.1038/nrd2222; Tian M, 2003, J AM CHEM SOC, V125, P348, DOI 10.1021/ja0209666; Uteshev VV, 2016, CURR PHARM DESIGN, V22, P1986, DOI 10.2174/1381612822666160201115341; Villa I, 2015, NANO RES, V8, P649, DOI 10.1007/s12274-014-0549-1; Wang R., 2015, ANGEW CHEM INT ED EN, V126, P12282, DOI [10.1002/ange.201407420, DOI 10.1002/ANGE.201407420]; Wang R, 2014, ANGEW CHEM INT EDIT, V53, P12086, DOI 10.1002/anie.201407420; Yang YM, 2013, CHEM REV, V113, P192, DOI 10.1021/cr2004103; Zhang JJ, 2019, CHEM SOC REV, V48, P683, DOI 10.1039/c7cs00907k; Zhu SJ, 2017, P NATL ACAD SCI USA, V114, P962, DOI 10.1073/pnas.1617990114	32	40	40	45	172	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1433-7851	1521-3773		ANGEW CHEM INT EDIT	Angew. Chem.-Int. Edit.	JAN 2	2020	59	1					247	252		10.1002/anie.201911803		NOV 2019	6	Chemistry, Multidisciplinary	Chemistry	LE8OR	WOS:000497116800001	31626380				2021-06-18	
J	Pulliam, L; Sun, B; Mustapic, M; Chawla, S; Kapogiannis, D				Pulliam, Lynn; Sun, Bing; Mustapic, Maja; Chawla, Sahil; Kapogiannis, Dimitrios			Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease	JOURNAL OF NEUROVIROLOGY			English	Article						Exosomes; Neurons; Biomarker; HIV; Alzheimer's; Dementia	NEUROFILAMENT LIGHT; SYNAPTIC PROTEINS; BLOOD EXOSOMES; AMYLOID-BETA; HYPOTHESIS; MARKERS	Fluid biomarkers for cognitive impairment have the advantage of being relatively noninvasive and capable of monitoring neuronal and other brain cell health in real time. Biomarkers can predict the onset of dementing illness, but also correlate with cognition in a dynamic way allowing us to follow treatment responses and determine brain recovery. Chronic HIV infection causes cognitive impairment in a subset of individuals suggesting "premature aging." Exosomes are small extracellular vesicles that are shed from all cells. They are important in normal cell-to-cell communication as they contain cellular proteins, mRNA transcripts, and miRNAs. Exosome cargo varies depending on the health of the cell and pathological state; specific proteins/mRNAs and/or miRNAs are present and may serve as biomarkers. Exosomes of variable cellular origin can be isolated from peripheral blood by various methods. Neuron-derived exosomes (NDEs) can be isolated using a precipitation/immunoaffinity approach using antibodies against neuronal cell adhesion molecule L1CAM and the contents queried for central nervous system (CNS) disorders including HIV-associated neurological disorders (HAND) and Alzheimer's disease (AD). As these studies are recent, numerous questions arise including which neuronal proteins are in NDEs and whether their contents differ in different CNS pathologies or with age. In addition, can the NDE cargo predict as well as diagnose cognitive impairment and could exosomal contents be used as therapeutic biomarkers, or theramarkers, of neuronal recovery from effective treatment? This mini-review will show some new data and review recent studies on NDE from individuals with HIV infection and AD. HIV-associated neurocognitive disorders (HAND) are pathologies seen in a subset of individuals with chronic HIV infection. They belong to the spectrum of neurodegenerative diseases that result in death or dysfunction of neurons with similarities to Alzheimer disease (AD) but also distinctive differences (reviewed (Canet et al., Front Cell Neurosci 12: 307, 2018)). Both disorders are difficult to diagnose without neuropsychological testing and both need new biomarkers to judge progression as well as recovery with treatment. Both disorders involve neuroinflammation and several common targets. AD is associated with aging and HIV is thought to initiate premature aging. In HIV infection, amyloid beta (A beta), which is deposited in "plaques" in AD, is soluble and its relevance to HIV-associated cognitive impairment is controversial (Achim et al., J Neuroimmune Pharmacol 4: 190-199, 2009; Rempel and Pulliam, AIDS 19: 127-135, 2005). A beta deposition is required for AD pathological diagnosis, but is not necessarily causative (Barage and Sonawane, Neuropeptides 52: 1-18, 2015; Hardy and Selkoe, Science 297: 353-356, 2002; Morris et al., Acta Neuropathol Commun 2: 135, 2014). Neurofilament light (NF-L) is a surrogate marker in plasma and cerebrospinal fluid (CSF) for neurodegeneration (Abu-Rumeileh et al., Alzheimers Res Ther 10: 3, 2018; Mattsson et al., JAMA Neurol 74: 557-566, 2017) but continues to be a controversial biomarker for both HAND and AD (Gisslen et al., EBioMedicine 3: 135-140, 2016; Kovacs et al., Eur J Neurol 24:1326-e77, 2017; Norgren et al., Brain Res 987: 25-31, 2003; Rolstad et al., J Alzheimers Dis 45: 873-881, 2015; Yilmaz et al., Expert Rev Mol Diagn 17: 761-770, 2017). Blood biomarkers are needed to advance both HAND and AD fields, as blood draws are less costly than neuroimaging and are minimally invasive compared to lumbar punctures required for CSF acquisition. Extracellular vesicles (EVs) are nanoscale membranous vesicles shed from all cells including those of the central nervous system (CNS) and found in all biofluids; they are divided into exosomes (30-150 nm) originating from late endosomes/multivesicular bodies and microvesicles (150-1000 nm) produced through budding of the plasma membrane. Both types of vesicles are implicated in the pathogenesis of neurodegenerative diseases and may provide biomarkers (Bellingham et al., Front Physiol 3: 124, 2012). In this report, we call the vesicles exosomes, since they are the predominant vesicles in our preparations. They are involved in cell-to-cell communication in normal homeostasis and can be carriers of toxic proteins (A beta, tau) (Sardar Sinha et al., Acta Neuropathol 136: 41-56, 2018) shed by cells as waste or actively secreted in a degenerative process (review Gupta and Pulliam, J Neuroinflammation 11: 68, 2014). The idea that exosomes originating from a specific cell can be recovered in the plasma using cellular surface markers of interest is intriguing. Neuron derived exosomes (NDEs) were first described in 2015 and isolated using antibodies against neural cell adhesion molecules NCAM or L1CAM, after total plasma exosome isolation (Fiandaca et al., Alzheimers Dement 11: 600-607 e1, 2015). Characterization of NDEs follows guidelines endorsed by the International Society for Extracellular Vesicles and includes Nanoparticle Tracking Analysis (NTA) to determine EV concentration and average diameter; Western Blots for EV markers; ELISAs for neuronal proteins and transmission EM for visualization (Sun et al., AIDS 31: F9-F17, 2017; Tang et al., FASEB J 30: 3097-106, 2016). This innovative isolation of an exosome sub-population has generated interest in using NDE as biomarkers for neurodegenerative diseases like AD, HAND, traumatic brain injury, posttraumatic stress disorder and more (reviews Agoston et al., Brain Inj 31: 1195-1203, 2017; Gupta and Pulliam, J Neuroinflammation 11: 68, 2014; Hu et al., Cell Death Dis 7: e2481, 2016; Karnati et al., J Neurotrauma, 2018; Osier et al., Mol Neurobiol, 2018). Several biomarkers from plasma NDEs were recently reported by the Pulliam lab to be elevated in general cognitive impairment (Sun et al., AIDS 31: F9-F17, 2017). We review our collective data here on HAND and AD and add to the characterization of plasma NDEs as exciting biomarkers of neurodegeneration.	[Pulliam, Lynn] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; [Pulliam, Lynn] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Pulliam, Lynn; Sun, Bing] Vet Affairs Med Ctr, San Francisco, CA 94121 USA; [Mustapic, Maja; Chawla, Sahil; Kapogiannis, Dimitrios] NIA, Neurosci Lab, Intramural Res Program, NIH, Bldg 10, Bethesda, MD 20892 USA	Pulliam, L (corresponding author), Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.; Pulliam, L (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.; Pulliam, L (corresponding author), Vet Affairs Med Ctr, San Francisco, CA 94121 USA.; Kapogiannis, D (corresponding author), NIA, Neurosci Lab, Intramural Res Program, NIH, Bldg 10, Bethesda, MD 20892 USA.	Lynn.Pulliam@ucsf.edu; kapogiannisd@mail.nih.gov	Mustapic, Maja/AAV-3212-2020; Kapogiannis, Dimitrios/AAW-4934-2020	Kapogiannis, Dimitrios/0000-0003-2181-3118; Pulliam, Lynn/0000-0001-9120-134X	NIMH/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH112483] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21 MH112483] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH112483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000975] Funding Source: NIH RePORTER		Abner EL, 2016, ANN CLIN TRANSL NEUR, V3, P399, DOI 10.1002/acn3.309; Abu-Rumeileh S, 2018, ALZHEIMERS RES THER, V10, DOI 10.1186/s13195-017-0331-1; Achim CL, 2009, J NEUROIMMUNE PHARM, V4, P190, DOI 10.1007/s11481-009-9152-8; Agoston DV, 2017, BRAIN INJURY, V31, P1195, DOI 10.1080/02699052.2017.1357836; Anderson AM, 2018, J NEUROONCOL; Barage SH, 2015, NEUROPEPTIDES, V52, P1, DOI 10.1016/j.npep.2015.06.008; Bellingham SA, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00124; Canet G, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00307; Daily A, 2006, J NEUROVIROL, V12, P153, DOI 10.1080/13550280600760677; Eitan E, 2017, AGING CELL, V16, P1430, DOI 10.1111/acel.12657; Fiandaca MS, 2015, ALZHEIMERS DEMENT, V11, P600, DOI 10.1016/j.jalz.2014.06.008; Gillies JA, 2019, BOUND-LAY METEOROL, V170, P443, DOI 10.1007/s10546-018-0402-2; Gisslen M, 2016, EBIOMEDICINE, V3, P135, DOI 10.1016/j.ebiom.2015.11.036; Goetzl EJ, 2018, FASEB J, V32, P888, DOI 10.1096/fj.201700731R; Goetzl EJ, 2016, FASEB J, V30, P4141, DOI 10.1096/fj.201600816R; Goetzl EJ, 2015, ANN CLIN TRANSL NEUR, V2, P769, DOI 10.1002/acn3.211; Goetzl EJ, 2015, NEUROLOGY, V85, P40, DOI 10.1212/WNL.0000000000001702; Goetzl EJ, 2018, FASEB J; Green DA, 2005, AIDS, V19, P407, DOI 10.1097/01.aids.0000161770.06158.5c; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Gupta A, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-68; Hamlett ED, 2016, ALZHEIMERS DEMENT; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hu GK, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.336; Kapogiannis D, 2015, FASEB J, V29, P589, DOI 10.1096/fj.14-262048; Karnati H.K., 2018, J NEUROTRAUMA; Kovacs GG, 2017, EUR J NEUROL, V24, P1326, DOI 10.1111/ene.13389; Kowal J, 2016, P NATL ACAD SCI USA, V113, pE968, DOI 10.1073/pnas.1521230113; Mattsson N, 2017, JAMA NEUROL, V74, P557, DOI 10.1001/jamaneurol.2016.6117; Morris GP, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0135-5; Mustapic M, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00278; Norgren N, 2003, BRAIN RES, V987, P25, DOI 10.1016/S0006-8993(03)03219-0; Osier N, 2018, MOL NEUROBIOL, V55, P9280, DOI 10.1007/s12035-018-1054-4; Peterson J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116081; Rempel HC, 2005, AIDS, V19, P127, DOI 10.1097/00002030-200501280-00004; Rolstad S, 2015, J ALZHEIMERS DIS, V45, P873, DOI 10.3233/JAD-142694; Sinha MS, 2018, ACTA NEUROPATHOL, V136, P41, DOI 10.1007/s00401-018-1868-1; Sun B, 2017, AIDS, V31, pF9, DOI [10.1097/QAD.0000000000001595, 10.1097/qad.0000000000001595]; Tang N, 2016, FASEB J, V30, P3097, DOI 10.1096/fj.201600368RR; Winston Charisse N, 2016, Alzheimers Dement (Amst), V3, P63, DOI 10.1016/j.dadm.2016.04.001; Yilmaz A, 2017, EXPERT REV MOL DIAGN, V17, P761, DOI 10.1080/14737159.2017.1341313	41	40	42	5	71	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1355-0284	1538-2443		J NEUROVIROL	J. Neurovirol.	OCT	2019	25	5					702	709		10.1007/s13365-018-0695-4			8	Neurosciences; Virology	Neurosciences & Neurology; Virology	JJ9NL	WOS:000494478600008	30610738	Green Accepted			2021-06-18	
J	Kuwar, R; Rolfe, A; Di, L; Xu, HY; He, L; Jiang, YQ; Zhang, SJ; Sun, D				Kuwar, Ram; Rolfe, Andrew; Di, Long; Xu, Hongyu; He, Liu; Jiang, Yuqi; Zhang, Shijun; Sun, Dong			A novel small molecular NLRP3 inflammasome inhibitor alleviates neuroinflammatory response following traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Traumatic brain injury; Neuroinflammation; NLRP3; Inflammasome; Cytokines	INNATE IMMUNE-RESPONSE; PROTEIN-3 INFLAMMASOME; CEREBROSPINAL-FLUID; RAT-BRAIN; ACTIVATION; INTERLEUKIN-1; PATHWAYS; NEUTRALIZATION; CONTRIBUTES; EXPRESSION	BackgroundNeuroinflammation is an essential player in many neurological diseases including traumatic brain injury (TBI). Recent studies have identified that inflammasome complexes are responsible for inflammatory responses in many pathological conditions. Inflammasomes are intracellular multiprotein complexes which regulate the innate immune response, activation of caspase-1, production of pro-inflammatory cytokines IL-1 and IL-18, and induction of cell death (pyroptosis). Among inflammasome family members, the nucleotide-binding domain leucine-rich repeats family protein 3 (NLRP3) is the most extensively studied and its activation is induced following TBI. As a novel target, drug development targeting the formation and activation of NLRP3 inflammasome is a prospective therapy for TBI. We have recently developed a small molecule JC124 with specificity on NLRP3 inflammasome. In this study, we explored the therapeutic value of JC124 for TBI treatment.MethodsAdult male Sprague-Dawley rats were subjected to a moderate cortical impact injury. Following TBI, animals received 4 doses of JC124 treatment with the first dose starting at 30min, the second dose at 6h after TBI, the third and fourth doses at 24 or 30h following TBI, respectively. Animals were sacrificed at 2days post-injury. Brain tissues were processed either for ELISA and western blotting analysis for inflammatory response, or for histological examination to assess degenerative neurons, acute inflammatory cell response and lesion volume.ResultsWe found that post-injury treatment with JC124 significantly decreased the number of injury-induced degenerating neurons, inflammatory cell response in the injured brain, and cortical lesion volume. Injured animals treated with JC124 also had significantly reduced protein expression levels of NLRP3, ASC, IL-1 beta, TNF, iNOS, and caspase-1.ConclusionOur data suggest that our novel NLRP3 inhibitor has a specific anti-inflammatory effect to protect the injured brain following TBI.	[Kuwar, Ram; Rolfe, Andrew; Di, Long; Xu, Hongyu; Sun, Dong] Virginia Commonwealth Univ, Sch Med, Dept Anat & Neurobiol, Med Coll Virginia Campus, Richmond, VA 23298 USA; [Di, Long; Xu, Hongyu; He, Liu; Jiang, Yuqi; Zhang, Shijun] Virginia Commonwealth Univ, Sch Pharm, Dept Med Chem, Med Coll Virginia Campus, Richmond, VA 23298 USA	Kuwar, R (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Anat & Neurobiol, Med Coll Virginia Campus, Richmond, VA 23298 USA.	ram.kuwar@vcuhealth.org; dong.sun@vcuhealth.org		Sun, Dong/0000-0002-3837-7319	Commonwealth of Virginia Health Research Board [236-14-15]; NIA/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG058673]; Alzheimer's Drug Discovery Foundation [20150601]; Commonwealth of Virginia Center on Aging - Alzheimer's and Related Disease Research Award Fund [18-2]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG058673] Funding Source: NIH RePORTER	This work was supported by Commonwealth of Virginia Health Research Board grant (CHRB #236-14-15, DS). It is also supported in part by NIA/NIH (R01AG058673, SZ), Alzheimer's Drug Discovery Foundation (20150601, SZ), Commonwealth of Virginia Center on Aging - Alzheimer's and Related Disease Research Award Fund (18-2, SZ).	Adamczak S, 2012, J NEUROSURG, V117, P1119, DOI 10.3171/2012.9.JNS12815; Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Alboni S, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-9; Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Baldwin AG, 2016, J MED CHEM, V59, P1691, DOI 10.1021/acs.jmedchem.5b01091; Brickler T, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6373506; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806; Daniels MJD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12504; Fulp J, 2018, J MED CHEM, V61, P5412, DOI 10.1021/acs.jmedchem.8b00733; Ge XT, 2018, BRAIN RES, V1697, P10, DOI 10.1016/j.brainres.2018.06.008; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hanamsagar R, 2011, J NEUROCHEM, V119, P736, DOI 10.1111/j.1471-4159.2011.07481.x; Heid ME, 2013, J IMMUNOL, V191, P5230, DOI 10.4049/jimmunol.1301490; Heneka MT, 2013, NATURE, V493, P674, DOI 10.1038/nature11729; Hoegen T, 2011, J IMMUNOL, V187, P5440, DOI 10.4049/jimmunol.1100790; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Irrera N, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00459; Irrera N, 2017, CLIN SCI, V131, P487, DOI 10.1042/CS20160645; Ismael S, 2018, J NEUROTRAUM, V35, P1294, DOI 10.1089/neu.2017.5344; Ismael S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24350-x; Jander S, 2002, J CEREBR BLOOD F MET, V22, P62, DOI 10.1097/00004647-200201000-00008; Jha S, 2010, J NEUROSCI, V30, P15811, DOI 10.1523/JNEUROSCI.4088-10.2010; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Lamkanfi M, 2009, J CELL BIOL, V187, P61, DOI 10.1083/jcb.200903124; Lebeaupin C, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.248; Lee GS, 2012, NATURE, V492, P123, DOI 10.1038/nature11588; Lin C, 2017, EXP NEUROL, V290, P115, DOI 10.1016/j.expneurol.2017.01.005; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Ma J, 2016, INFLAMMATION, V39, P2094, DOI 10.1007/s10753-016-0446-8; Marchetti C, 2015, J CARDIOVASC PHARM, V66, P1, DOI 10.1097/FJC.0000000000000247; Marchetti C, 2014, J CARDIOVASC PHARM, V63, P316, DOI 10.1097/FJC.0000000000000053; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Menge T, 2001, J NEUROSCI RES, V65, P332, DOI 10.1002/jnr.1158; Mortezaee K, 2018, J CELL PHYSIOL, V233, P5160, DOI 10.1002/jcp.26287; Munoz-Planillo R, 2013, IMMUNITY, V38, P1142, DOI 10.1016/j.immuni.2013.05.016; Murakami T, 2012, P NATL ACAD SCI USA, V109, P11282, DOI 10.1073/pnas.1117765109; Perregaux DG, 2001, J PHARMACOL EXP THER, V299, P187; Reid WM, 2010, J NEUROTRAUM, V27, P1243, DOI 10.1089/neu.2010.1270; Ren HL, 2018, STROKE, V49, P184, DOI 10.1161/STROKEAHA.117.018904; Sagulenko V, 2013, CELL DEATH DIFFER, V20, P1149, DOI 10.1038/cdd.2013.37; Simon DW, 2017, NAT REV NEUROL, V13, P572, DOI 10.1038/nrneurol.2017.116; Sun D, 2000, J NEUROPATH EXP NEUR, V59, P1031, DOI 10.1093/jnen/59.12.1031; Sun D, 2011, J NEUROTRAUM, V28, P961, DOI 10.1089/neu.2010.1697; Tan MS, 2013, MOL NEUROBIOL, V48, P875, DOI 10.1007/s12035-013-8475-x; Tramutola A, 2016, J ALZHEIMERS DIS, V52, P359, DOI 10.3233/JAD-151105; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Villapol S, 2017, GLIA, V65, P1423, DOI 10.1002/glia.23171; Wallisch JS, 2017, NEUROCRIT CARE, V27, P44, DOI 10.1007/s12028-017-0378-7; Walsh JG, 2014, NAT REV NEUROSCI, V15, P84, DOI 10.1038/nrn3638; Winkler S, 2015, SEMIN IMMUNOPATHOL, V37, P419, DOI 10.1007/s00281-015-0494-4; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Xu X, 2018, NEUROBIOL DIS, V117, P15, DOI 10.1016/j.nbd.2018.05.016; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Yin J, 2018, MOL NEUROBIOL, V55, P1977, DOI 10.1007/s12035-017-0467-9; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663; Zou P, 2018, MOL MED REP, V17, P3212, DOI 10.3892/mmr.2017.8241	59	40	44	5	11	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	APR 11	2019	16								81	10.1186/s12974-019-1471-y			14	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	HU7DC	WOS:000465440300001	30975164	DOAJ Gold, Green Published			2021-06-18	
J	Gill, J; Latour, L; Diaz-Arrastia, R; Motamedi, V; Turtzo, C; Shahim, P; Mondello, S; DeVoto, C; Veras, E; Hanlon, D; Song, LN; Jeromin, A				Gill, Jessica; Latour, Lawrence; Diaz-Arrastia, Ramon; Motamedi, Vida; Turtzo, Christine; Shahim, Pashtun; Mondello, Stefania; DeVoto, Christina; Veras, Eliseo; Hanlon, David; Song, Linan; Jeromin, Andreas			Glial fibrillary acidic protein elevations relate to neuroimaging abnormalities after mild TBI	NEUROLOGY			English	Article							C-TERMINAL HYDROLASE-L1; TRAUMATIC BRAIN-INJURY; PLASMA-LEVELS; DIAGNOSIS; MARKER	Objectives To determine whether a panel of blood-based biomarkers can discriminate between patients with suspected mild traumatic brain injury (mTBI) with and without neuroimaging findings (CT and MRI). Methods Study participants presented to the emergency department with suspected mTBI (n = 277) with a CT and MRI scan and healthy controls (n = 49). Plasma concentrations of tau, glial fibrillary acidic protein (GFAP), ubiquitin carboxyl-terminal hydrolase L1, and neurofilament light chain (NFL) were measured using the single-molecule array technology. Results Concentrations of GFAP, tau, and NFL were higher in patients with mTBI, compared with those of controls (p's < 0.01). GFAP yielded an area under the curve (AUC) of 0.93 (95% confidence interval [CI] 0.90-0.96), confirming its discriminatory power for distinguishing mTBI from controls. Levels of GFAP, tau, and NFL were higher in patients with trauma-related intracranial findings on CT compared with those with normal CT, with the only significant predictor being GFAP (AUC 0.77, 95% CI 0.70-0.84). Among patients with mTBI, tau, NFL, and GFAP differentiated subjects with and without MRI abnormalities with an AUC of 0.83, with GFAP being the strongest predictor. Combining tau, NFL, and GFAP showed a good discriminatory power (AUC 0.80, 95% CI 0.69-0.90) for detecting MRI abnormalities, even in patients with mTBI with a normal CT. Conclusion Our study confirms GFAP as a promising marker of brain injury in patients with acute mTBI. A combination of various biomarkers linked to different pathophysiologic mechanisms increases diagnostic subgroup accuracy. This multimarker strategy may guide medical decision making, facilitate the use of MRI scanning, and prove valuable in the stratification of patients with brain injuries in future clinical trials. Classification of evidence Class I evidence that blood concentrations of GFAP, tau, and NFL discriminate patients with mTBI with and without neuroimaging findings.	[Gill, Jessica; Motamedi, Vida; DeVoto, Christina] Uniformed Serv Univ Hlth Sci, Natl Inst Hlth, Bethesda, MD 20814 USA; [Gill, Jessica; Shahim, Pashtun] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Natl Inst Nursing Res, Bethesda, MD 20814 USA; [Latour, Lawrence; Turtzo, Christine] NINDS, Biomarker Core, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA; [Latour, Lawrence; Turtzo, Christine] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA; [Diaz-Arrastia, Ramon] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Mondello, Stefania] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Messina, Italy; [Veras, Eliseo; Hanlon, David; Song, Linan; Jeromin, Andreas] Quanterix Corp, Lexington, MA USA	Gill, J (corresponding author), Uniformed Serv Univ Hlth Sci, Natl Inst Hlth, Bethesda, MD 20814 USA.; Gill, J (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Natl Inst Nursing Res, Bethesda, MD 20814 USA.	gillj@mail.nih.gov	Mondello, Stefania/A-1813-2012; Gill, Gill M/Q-2020-2017; Latour, Larry/AAH-5663-2021	Mondello, Stefania/0000-0002-8587-3614; Latour, Larry/0000-0001-6160-5263	National Institute of Nursing Research (NINR) Intramural Research ProgramUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR); National Institute of Neurological Disease and Stroke (NINDS) Team; Center for Neuroscience and Regenerative Medicine, Acute Studies and Biomarker Core; National Football League and General Electric, Head to Head Grant; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS003120] Funding Source: NIH RePORTER	National Institute of Nursing Research (NINR) Intramural Research Program, National Institute of Neurological Disease and Stroke (NINDS) Team, Center for Neuroscience and Regenerative Medicine, Acute Studies and Biomarker Core, National Football League and General Electric, Head to Head Grant.	Amyot F, 2015, J NEUROTRAUM, V32, P1693, DOI 10.1089/neu.2013.3306; Bogoslovsky T, 2017, J NEUROTRAUM, V34, P66, DOI 10.1089/neu.2015.4333; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Korley FK, 2016, J HEAD TRAUMA REHAB, V31, P379, DOI 10.1097/HTR.0000000000000187; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Ljungqvist J, 2017, J NEUROTRAUM, V34, P1124, DOI 10.1089/neu.2016.4496; Metting Z, 2007, LANCET NEUROL, V6, P699, DOI 10.1016/S1474-4422(07)70191-6; Mondello S, J NEUROTRAUMA; Mondello S, 2016, SCI REP-UK, V6, DOI 10.1038/srep28203; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Peacock WF, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00641; Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	14	40	40	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	OCT 9	2018	91	15					E1385	E1389		10.1212/WNL.0000000000006321			5	Clinical Neurology	Neurosciences & Neurology	HD4LZ	WOS:000452500400003	30209234	Green Published			2021-06-18	
J	Giacino, JT; Katz, DI; Schiff, ND; Whyte, J; Ashman, EJ; Ashwal, S; Barbano, R; Hammond, FM; Laureys, S; Ling, GSF; Nakase-Richardson, R; Seel, RT; Yablon, S; Getchius, TSD; Gronseth, GS; Armstrong, MJ				Giacino, Joseph T.; Katz, Douglas, I; Schiff, Nicholas D.; Whyte, John; Ashman, Eric J.; Ashwal, Stephen; Barbano, Richard; Hammond, Flora M.; Laureys, Steven; Ling, Geoffrey S. F.; Nakase-Richardson, Risa; Seel, Ronald T.; Yablon, Stuart; Getchius, Thomas S. D.; Gronseth, Gary S.; Armstrong, Melissa J.			Practice Guideline Update Recommendations Summary: Disorders of Consciousness Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology; the American Congress of Rehabilitation Medicine; and the National Institute on Disability, Independent Living, and Rehabilitation Research	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							PERSISTENT VEGETATIVE STATE; BRAIN-INJURED PATIENTS; LOCKED-IN SYNDROME; INPATIENT REHABILITATION; RECOVERY; SCALE; OUTCOMES; COMA; RESPONSIVENESS; COMORBIDITIES	Objective: To update the 1995 American Academy of Neurology (AAN) practice parameter on persistent vegetative state and the 2002 case definition on minimally conscious state (MCS) and provide care recommendations for patients with prolonged disorders of consciousness (DoC). Methods: Recommendations were based on systematic review evidence, related evidence, care principles, and inferences using a modified Delphi consensus process according to the AAN 2011 process manual, as amended. Recommendations: Clinicians should identify and treat confounding conditions, optimize arousal, and perform serial standardized assessments to improve diagnostic accuracy in adults and children with prolonged DoC (Level B). Clinicians should counsel families that for adults, MCS (vs vegetative state [VS]/ unresponsive wakefulness syndrome [UWS]) and traumatic (vs nontraumatic) etiology are associated with more favorable outcomes (Level B). When prognosis is poor, long-term care must be discussed (Level A), acknowledging that prognosis is not universally poor (Level B). Structural MRI, SPECT, and the Coma Recovery Scale-Revised can assist prognostication in adults (Level B); no tests are shown to improve prognostic accuracy in children. Pain always should be assessed and treated (Level B) and evidence supporting treatment approaches discussed (Level B). Clinicians should prescribe amantadine (100-200 mg bid) for adults with traumatic VS/UWS or MCS (4-16 weeks post injury) to hasten functional recovery and reduce disability early in recovery (Level B). Family counseling concerning children should acknowledge that natural history of recovery, prognosis, and treatment are not established (Level B). Recent evidence indicates that the term chronic VS/UWS should replace permanent VS, with duration specified (Level B). Additional recommendations are included. Published by Elsevier Inc. on behalf of the American Congress of Rehabilitation Medicine	[Giacino, Joseph T.] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA 02129 USA; [Giacino, Joseph T.] Harvard Med Sch, Boston, MA 02115 USA; [Giacino, Joseph T.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Katz, Douglas, I] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02215 USA; [Katz, Douglas, I] Braintree Rehabil Hosp, Boston, MA USA; [Schiff, Nicholas D.] Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY USA; [Whyte, John] Moss Rehabil Res Inst, Elkins Pk, PA USA; [Ashman, Eric J.] Bronson Methodist Hosp, Bronson Neurosci Ctr, Kalamazoo, MI USA; [Ashwal, Stephen] Loma Linda Univ, Sch Med, Div Child Neurol, Dept Pediat, Loma Linda, CA 92350 USA; [Barbano, Richard] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14627 USA; [Hammond, Flora M.] Univ Indiana, Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN USA; [Laureys, Steven] Sart Tillman Liege Univ, Coma Sci Grp GIGA Res, Liege, Belgium; [Laureys, Steven] Sart Tillman Liege Univ, Dept Neurol, Liege, Belgium; [Laureys, Steven] Univ Hosp, Liege, Belgium; [Ling, Geoffrey S. F.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA; [Ling, Geoffrey S. F.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA; [Nakase-Richardson, Risa] US Dept Vet Affairs, James A Haley Vet Hosp, Tampa, FL USA; [Seel, Ronald T.] Shepherd Ctr, Crawford Res Inst, Atlanta, GA USA; [Seel, Ronald T.] Virginia Commonwealth Univ, Sch Med, Dept Phys Med & Rehabil, Ctr Rehabil Sci & Engn, Richmond, VA 23284 USA; [Yablon, Stuart] Univ Mississippi, Sch Med, Div Phys Med & Rehabil, University, MS 38677 USA; [Yablon, Stuart] Methodist Rehabil Ctr, Brain Injury Program, Jackson, MS USA; [Getchius, Thomas S. D.] Heart Rhythm Soc, Washington, DC USA; [Gronseth, Gary S.] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, MO USA; [Armstrong, Melissa J.] Univ Florida, Coll Med, Dept Neurol, Gainesville, FL 32611 USA	Giacino, JT (corresponding author), Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA 02129 USA.; Giacino, JT (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Giacino, JT (corresponding author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.	guidelines@aan.com	Giacino, Joseph/AAF-1952-2021; Laureys, Steven/A-3349-2011; Laureys, Steven/AAN-2097-2021	Giacino, Joseph/0000-0002-7916-9698; Laureys, Steven/0000-0002-3096-3807; Armstrong, Melissa/0000-0002-2163-1907	American Academy of Neurology (AAN); American Congress of Rehabilitation Medicine; National Institute on Disability, Independent Living, and Rehabilitation ResearchUnited States Department of Health & Human Services	This practice guideline was funded by the American Academy of Neurology (AAN), the American Congress of Rehabilitation Medicine, and the National Institute on Disability, Independent Living, and Rehabilitation Research. Authors who serve or served as AAN subcommittee members (E.J.A., S.A., R.B., G.S.G.) or as methodologists (M.J.A., G.S.G.), or who were AAN staff members (T.S.D.G.), were reimbursed by the AAN for expenses related to travel to subcommittee meetings where drafts of manuscripts were reviewed.	Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ANSELL BJ, 1989, ARCH PHYS MED REHAB, V70, P104; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bardin JC, 2011, BRAIN, V134, P769, DOI 10.1093/brain/awr005; Candelieri A, 2011, J NEUROTRAUM, V28, P2013, DOI 10.1089/neu.2011.1885; Childs NL, 1996, NEW ENGL J MED, V334, P24, DOI 10.1056/NEJM199601043340105; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Cortese MD, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0455-5; Davidson GH, 2011, JAMA-J AM MED ASSOC, V305, P1001, DOI 10.1001/jama.2011.259; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; Estraneo A, 2013, NEUROLOGY, V80, P464, DOI 10.1212/WNL.0b013e31827f0f31; Ganesh S, 2013, ARCH PHYS MED REHAB, V94, P1899, DOI 10.1016/j.apmr.2012.12.026; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, NEUROLOGY; Gill-Thwaites H, 2004, BRAIN INJURY, V18, P1255, DOI 10.1080/02699050410001719952; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; Kotchoubey B, 2014, CURR PHARM DESIGN, V20, P4239; Laureys S, 2005, PROG BRAIN RES, V150, P495, DOI 10.1016/S0079-6123(05)50034-7; Lovstad M, 2010, J HEAD TRAUMA REHAB, V25, P349, DOI 10.1097/HTR.0b013e3181cec841; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Majerus S, 2005, PROG BRAIN RES, V150, P397, DOI 10.1016/S0079-6123(05)50028-1; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Monti MM, 2015, NEUROLOGY, V84, P167, DOI 10.1212/WNL.0000000000001123; Nakase-Richardson R, 2013, ARCH PHYS MED REHAB, V94, P1861, DOI 10.1016/j.apmr.2013.05.027; Nakase-Richardson R, 2012, J NEUROTRAUM, V29, P59, DOI 10.1089/neu.2011.1829; Pape TLB, 2005, J REHABIL RES DEV, V42, P1, DOI 10.1682/JRRD.2004.03.0032; RADER MA, 1994, BRAIN INJURY, V8, P309, DOI 10.3109/02699059409150982; Riganello F, 2015, J NEUROTRAUM, V32, P1071, DOI 10.1089/neu.2014.3539; Schnakers C, 2015, PM&R, V7, pS270, DOI 10.1016/j.pmrj.2015.09.016; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Shiel A, 2000, CLIN REHABIL, V14, P408, DOI 10.1191/0269215500cr326oa; Sitt JD, 2014, BRAIN, V137, P2258, DOI 10.1093/brain/awu141; Smart CM, 2008, NAT CLIN PRACT NEURO, V4, P448, DOI 10.1038/ncpneuro0823; Stender J, 2014, LANCET, V384, P514, DOI 10.1016/S0140-6736(14)60042-8; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; Whyte J, 1999, ARCH PHYS MED REHAB, V80, P653, DOI 10.1016/S0003-9993(99)90168-5; Whyte J, 2013, ARCH PHYS MED REHAB, V94, P1851, DOI 10.1016/j.apmr.2013.07.003; Whyte J, 2013, ARCH PHYS MED REHAB, V94, P1877, DOI 10.1016/j.apmr.2012.12.027	40	40	42	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2018	99	9					1699	1709		10.1016/j.apmr.2018.07.001			11	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	GT2YK	WOS:000444366000001	30098791				2021-06-18	
J	Zhang, K; Shi, ZQ; Zhou, JK; Xing, Q; Ma, SS; Li, QH; Zhang, YT; Yao, MH; Wang, XF; Li, Q; Li, JA; Guan, FX				Zhang, Kun; Shi, Zhenqing; Zhou, Jiankang; Xing, Qu; Ma, Shanshan; Li, Qinghua; Zhang, Yanting; Yao, Minghao; Wang, Xiaofeng; Li, Qian; Li, Jingan; Guan, Fangxia			Potential application of an injectable hydrogel scaffold loaded with mesenchymal stem cells for treating traumatic brain injury	JOURNAL OF MATERIALS CHEMISTRY B			English	Article							SMOOTH-MUSCLE-CELLS; ACID MICRO-PATTERN; HYALURONIC-ACID; TITANIUM SURFACE; IV COLLAGEN; ENDOTHELIALIZATION; STRATEGIES; COCULTURE; PHENOTYPE; RECOVERY	In the past few decades, there have been potential applications for stem cell replacement therapy in the treatment of nervous system damage resulting from diseases or traumatic brain injury (TBI). However, the insufficient number of transplanted stem cells and low survival rate caused by a series of negative conditions limit the therapeutic effect. In this contribution, we developed an injectable hydrogel composed of sodium alginate (SA) and hyaluronic acid (HA) as a tissue scaffold to create a more optimal microenvironment for stem cells after implantation. The gelation time of the HA/SA hydrogel exceeded 6 min, which satisfied the requirements for injection performance, and the high ratios of water content and slower degradation speed affirmed that the HA/SA hydrogel is a preferable stem cell scaffold. As a tissue engineering scaffold, the HA/SA hydrogel exhibited appropriately porous structures for stem cell loading and good rheological behavior, which contributed to stem cell differentiation. The in vitro culture experiment proved that the HA/SA scaffold performed well on hUC-MSCs with higher viability ratio and proliferation. Further in vivo tests indicated that the HA/SA scaffold not only protected the injected human umbilical cord mesenchymal stem cells (hUC-MSCs) so that they could maintain a higher survival ratio, but it also contributed to the regeneration of endogenous nerve cells. In summary, this injectable HA/SA hydrogel has the potential to be used for stem cell tissue engineering and support the physiological function recovery of TBI patients.	[Zhang, Kun; Shi, Zhenqing; Zhou, Jiankang; Xing, Qu; Ma, Shanshan; Li, Qinghua; Zhang, Yanting; Yao, Minghao; Guan, Fangxia] Zhengzhou Univ, Sch Life Sci, 100 Sci Rd, Zhengzhou 450001, Henan, Peoples R China; [Zhang, Kun; Guan, Fangxia] Zhengzhou Univ, Affiliated Hosp 1, Ctr Stem Cell & Regenerat Med, 40 Univ Rd, Zhengzhou 450052, Henan, Peoples R China; [Wang, Xiaofeng; Li, Qian] Zhengzhou Univ, Natl Ctr Int Res Micronano Molding Technol, 100 Sci Rd, Zhengzhou 450001, Henan, Peoples R China; [Li, Jingan] Zhengzhou Univ, Sch Mat Sci & Engn, 100 Sci Rd, Zhengzhou 450001, Henan, Peoples R China	Guan, FX (corresponding author), Zhengzhou Univ, Sch Life Sci, 100 Sci Rd, Zhengzhou 450001, Henan, Peoples R China.; Guan, FX (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Ctr Stem Cell & Regenerat Med, 40 Univ Rd, Zhengzhou 450052, Henan, Peoples R China.; Li, JA (corresponding author), Zhengzhou Univ, Sch Mat Sci & Engn, 100 Sci Rd, Zhengzhou 450001, Henan, Peoples R China.	4828713@qq.com; fxguan@126.com			Joint Fund for Fostering Talents of the National Natural Science Foundation of China and Henan province [U1504310]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [NSFC 81471306]; Key Scientific Research Projects of higher education institutions in Henan province [16A430030]; Innovative Research Team in Science and Technology of the University of Henan Province [15IRTSTHN022]; Plan for Scientific Innovation Talent of Henan Province [154200510008]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2014M562333, 2015M582206]; Key Project and Special Foundation of Research, Development and Promotion in Henan province [182102310076]; National Center for International Research of Micro-nano Molding Technology & Key Laboratory for Micro Molding Technology of Henan Province [MMT2017-01]	The study was supported by the Joint Fund for Fostering Talents of the National Natural Science Foundation of China and Henan province (U1504310), National Natural Science Foundation of China (NSFC 81471306), Key Scientific Research Projects of higher education institutions in Henan province (16A430030), the Innovative Research Team in Science and Technology of the University of Henan Province (15IRTSTHN022), the Plan for Scientific Innovation Talent of Henan Province (154200510008), China Postdoctoral Science Foundation (2014M562333 and 2015M582206), Key Project and Special Foundation of Research, Development and Promotion in Henan province (No. 182102310076), and National Center for International Research of Micro-nano Molding Technology & Key Laboratory for Micro Molding Technology of Henan Province (MMT2017-01).	Ata MT, 2016, WORLD NEUROSURG, V89, P355, DOI 10.1016/j.wneu.2016.01.040; Benjamin O, 2018, FOOD HYDROCOLLOID, V75, P95, DOI 10.1016/j.foodhyd.2017.08.033; Bhattacharya DS, 2017, J MATER CHEM B, V5, P8183, DOI [10.1039/c7tb01895a, 10.1039/C7TB01895A]; Boztug K, 2010, NEW ENGL J MED, V363, P1918, DOI 10.1056/NEJMoa1003548; Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007-0197; Chuang TW, 2009, BIOMATERIALS, V30, P5341, DOI 10.1016/j.biomaterials.2009.06.029; Cox CS, 2018, PEDIATR RES, V83, P325, DOI 10.1038/pr.2017.253; Ferreri AJM, 2017, LANCET HAEMATOL, V4, pE510, DOI 10.1016/S2352-3026(17)30174-6; Gombotz WR, 2012, ADV DRUG DELIVER REV, V64, P194, DOI 10.1016/j.addr.2012.09.007; Graser S, 2015, BONE, V79, P150, DOI [10.1016/J.bone.2015.05.033, 10.1016/j.bone.2015.05.033]; Greer K, 2017, BRAIN RES BULL, V134, P38, DOI 10.1016/j.brainresbull.2017.06.016; Hongo-Kohama M, 2017, INT J GYNECOL PATHOL, V36, P582, DOI 10.1097/PGP.0000000000000373; Huang GY, 2012, BIOFABRICATION, V4, DOI 10.1088/1758-5082/4/4/042001; Hunt NC, 2017, ACTA BIOMATER, V49, P329, DOI 10.1016/j.actbio.2016.11.016; Kim YS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183894; Li JG, 2017, ACS APPL MATER INTER, V9, P30343, DOI 10.1021/acsami.7b07444; Li JG, 2016, COLLOID SURFACE B, V145, P410, DOI 10.1016/j.colsurfb.2016.05.024; Li JG, 2015, COLLOID SURFACE B, V128, P201, DOI 10.1016/j.colsurfb.2015.01.010; Li JA, 2015, J MATER SCI, V50, P3226, DOI 10.1007/s10853-015-8889-0; Li JA, 2014, J BIOMED MATER RES A, V102, P1950, DOI 10.1002/jbm.a.34867; Li JG, 2014, MAT SCI ENG C-MATER, V38, P235, DOI 10.1016/j.msec.2014.02.008; Li JG, 2013, EXP CELL RES, V319, P2663, DOI 10.1016/j.yexcr.2013.05.027; Li JG, 2013, COLLOID SURFACE B, V110, P199, DOI 10.1016/j.colsurfb.2013.04.048; Li JG, 2013, APPL SURF SCI, V273, P24, DOI 10.1016/j.apsusc.2013.01.058; Li YX, 2014, GASTROENTEROLOGY, V146, pS527; Lu X, 2017, EXP THER MED, V13, P2247, DOI 10.3892/etm.2017.4283; Marion Donald W, 2006, Prog Neurol Surg, V19, P171, DOI 10.1159/000095191; Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0; Mitkari B, 2014, BEHAV BRAIN RES, V259, P50, DOI 10.1016/j.bbr.2013.10.030; Morris DC, 2017, NEUROSCI LETT, V659, P7, DOI 10.1016/j.neulet.2017.08.064; Park H, 2013, ACTA BIOMATER, V9, P4779, DOI 10.1016/j.actbio.2012.08.033; Petsa A, 2009, IN VITRO CELL DEV-AN, V45, P573, DOI 10.1007/s11626-009-9227-0; Shin J, 2017, BIOMACROMOLECULES, V18, P3060, DOI 10.1021/acs.biomac.7b00568; Summa M, 2018, EUR J PHARM BIOPHARM, V122, P17, DOI 10.1016/j.ejpb.2017.10.004; Tsang KKT, 2012, BRIT J ORAL MAX SURG, V50, P298, DOI 10.1016/j.bjoms.2011.03.004; Wang YS, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00413; Wu F, 2016, ACS APPL MATER INTER, V8, P109, DOI 10.1021/acsami.5b07427; Xu C, 2017, INT J NEUROSCI, V127, P1124, DOI 10.1080/00207454.2017.1325884; Zhao YZ, 2016, J CONTROL RELEASE, V224, P165, DOI 10.1016/j.jconrel.2016.01.017; Zhu Y, 2017, BIOMATERIALS, V147, P133, DOI 10.1016/j.biomaterials.2017.09.018; Zhuo FL, 2017, MAT SCI ENG C-MATER, V81, P1, DOI 10.1016/j.msec.2017.07.029	41	40	40	7	82	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	2050-750X	2050-7518		J MATER CHEM B	J. Mat. Chem. B	MAY 21	2018	6	19					2982	2992		10.1039/c7tb03213g			11	Materials Science, Biomaterials	Materials Science	GK5RR	WOS:000436234900006	32254333				2021-06-18	
J	Chai, C; Song, LJ; Han, SY; Li, XQ; Li, M				Chai, Chang; Song, Lai-Jun; Han, Shuang-Yin; Li, Xi-Qing; Li, Ming			MicroRNA-21 promotes glioma cell proliferation and inhibits senescence and apoptosis by targeting SPRY1 via the PTEN/PI3K/AKT signaling pathway	CNS NEUROSCIENCE & THERAPEUTICS			English	Article						apoptosis; cell senescence; glioma; microRNA-21; PTEN; PI3K; AKT signaling pathway; Sprouty1	HEPATOCELLULAR-CARCINOMA; GLIOBLASTOMA CELLS; MALIGNANT GLIOMA; PI3K/AKT PATHWAY; TUMOR-SUPPRESSOR; EXPRESSION; GROWTH; CANCER; TUMORIGENESIS; ANGIOGENESIS	AimsOur study aims to investigate the effect of microRNA-21 (miR-21) on the proliferation, senescence, and apoptosis of glioma cells by targeting SPRY1 via the PTEN/PI3K/AKT signaling pathway. MethodsGlioma tissues and brain tissues were collected for this study after surgical decompression for traumatic brain injury. RT-qPCR was employed to measure mRNA levels of miR-21, SPRY1, PTEN, PI3K, and AKT, and Western blotting was conducted to determine protein levels of SPRY1, PTEN, PI3K, AKT, p-AKT, Caspase-3, Caspase-9, P53, GSK3, and p-GSK3. Human glioma U87 cells were assigned into the blank, negative control (NC), miR-21 mimics, miR-21 inhibitors, siRNA-SPRY1, and miR-21 inhibitors + siRNA-SPRY1 groups, with human HEB cells serving as the normal group. Cell proliferation, cell cycle, and apoptosis were determined by MTT and flow cytometry, respectively. ResultsCompared with control group, an increased expression of miR-21, PI3K, AKT, p-AKT, P53, and p-GSK3, and a decreased expression of SPRY1, PTEN, Caspase-3, and Caspase-9 were observed in the glioma group, and no significant differences were found in the expression of GSK3. SPRY1 was verified to be the target gene of miR-21. Compared with the blank and NC groups, levels of PI3K, AKT, p-AKT, P53, and p-GSK3 increased while levels of SPRY1, PTEN, Caspase-3, and Caspase-9 decreased in the miR-21 mimics and siRNA-SPRY1 groups; the miR-21 inhibitors group reversed the tendency; furthermore, the miR-21 inhibitors group showed decreased cell proliferation but promoted apoptosis, which were opposite to the results of the miR-21 mimics and siRNA-SPRY1 groups. ConclusionMicroRNA-21 might promote cell proliferation and inhibit cell senescence and apoptosis of human glioma cells by targeting SPRY1 via the PTEN/PI3K/AKT signaling pathway.	[Chai, Chang] Henan Prov Peoples Hosp, Henan Eye Inst, Zhengzhou, Henan, Peoples R China; [Song, Lai-Jun] Zhengzhou Univ, Affiliated Hosp 1, Dept Neurosurg, Zhengzhou, Henan, Peoples R China; [Han, Shuang-Yin] Henan Prov Peoples Hosp, Dept Gastroenterol, Zhengzhou, Henan, Peoples R China; [Li, Xi-Qing] Henan Prov Peoples Hosp, Dept Oncol, Zhengzhou, Henan, Peoples R China; [Li, Ming] Henan Prov Peoples Hosp, Dept Neurosurg, Zhengzhou, Henan, Peoples R China	Li, M (corresponding author), Henan Prov Peoples Hosp, Dept Neurosurg, Zhengzhou, Henan, Peoples R China.	limingfromhn@163.com					Bao ZS, 2014, ONCOL REP, V32, P250, DOI 10.3892/or.2014.3176; Chen Y, 2008, CANCER LETT, V272, P197, DOI 10.1016/j.canlet.2008.06.034; Derlon JM, 2000, EUR J NUCL MED, V27, P778, DOI 10.1007/s002590000260; Falsini B, 2016, BRAIN, V139, P404, DOI 10.1093/brain/awv366; Fang J, 2007, CELL SIGNAL, V19, P2487, DOI 10.1016/j.cellsig.2007.07.025; Gallardo A, 2012, BRIT J CANCER, V106, P1367, DOI 10.1038/bjc.2012.85; Gao SF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03612-0; Haque R, 2017, MOL VIS, V23, P251; Kitagishi Yasuko, 2012, Depress Res Treat, V2012, P752563, DOI 10.1155/2012/752563; Kuracha MR, 2013, DEV BIOL, V383, P227, DOI 10.1016/j.ydbio.2013.09.014; Lin CJ, 2016, TOXICOL APPL PHARM, V304, P59, DOI 10.1016/j.taap.2016.05.018; Liu GL, 2017, J CELL BIOCHEM, V118, P3424, DOI 10.1002/jcb.25999; Liu XL, 2016, TOXICOL LETT, V252, P1, DOI 10.1016/j.toxlet.2016.04.015; Locatelli M, 2010, EUR CYTOKINE NETW, V21, P27, DOI 10.1684/ecn.2009.0184; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Qu Y, 2012, NEUROSCI LETT, V525, P168, DOI 10.1016/j.neulet.2012.07.025; Rychly B, 2008, Cesk Patol, V44, P35; Santosh V, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.02.18; Sathyanarayana P, 2012, BLOOD, V119, P5522, DOI 10.1182/blood-2011-11-392571; Shi L, 2010, BRAIN RES, V1352, P255, DOI 10.1016/j.brainres.2010.07.009; Sun C, 2014, NEUROREPORT, V25, P177, DOI 10.1097/WNR.0000000000000069; Tang C, 2009, ANTI-CANCER DRUG, V20, P249, DOI 10.1097/CAD.0b013e328327d476; Solomon MT, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-299; Tian Y, 2012, INT J ONCOL, V40, P1105, DOI 10.3892/ijo.2011.1306; Tu KS, 2016, INT J ONCOL, V48, P965, DOI 10.3892/ijo.2015.3309; Wang F, 2016, INT J MOL MED, V37, P1421, DOI 10.3892/ijmm.2016.2518; Wang HN, 2012, ONCOL REP, V28, P311, DOI 10.3892/or.2012.1788; Wang L, 2003, INT J MOL MED, V12, P783; Wang P, 2015, CELL SIGNAL, V27, P275, DOI 10.1016/j.cellsig.2014.11.011; Weng WH, 2013, ANTICANCER RES, V33, P5407; Yang CH, 2015, J BIOL CHEM, V290, P6037, DOI 10.1074/jbc.M114.632125; Yue X, 2012, ONCOL REP, V27, P1200, DOI 10.3892/or.2011.1588; Zhang BG, 2012, ONCOL REP, V27, P1019, DOI 10.3892/or.2012.1645; Zhang JG, 2010, CLIN CHIM ACTA, V411, P846, DOI 10.1016/j.cca.2010.02.074; Zhao P, 2015, ONCOTARGET, V6, P31901, DOI 10.18632/oncotarget.5043; Zhou X, 2010, INT J ONCOL, V36, P665, DOI 10.3892/ijo_00000542	36	40	40	1	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1755-5930	1755-5949		CNS NEUROSCI THER	CNS Neurosci. Ther.	MAY	2018	24	5					369	380		10.1111/cns.12785			12	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	GC8PW	WOS:000430058800001	29316313	Bronze, Green Published			2021-06-18	
J	Frik, J; Merl-Pham, J; Plesnila, N; Mattugini, N; Kjell, J; Kraska, J; Gomez, RM; Hauck, SM; Sirko, S; Gotz, M				Frik, Jesica; Merl-Pham, Juliane; Plesnila, Nikolaus; Mattugini, Nicola; Kjell, Jacob; Kraska, Jonas; Gomez, Ricardo M.; Hauck, Stefanie M.; Sirko, Swetlana; Goetz, Magdalena			Cross-talk between monocyte invasion and astrocyte proliferation regulates scarring in brain injury	EMBO REPORTS			English	Article						aryl hydrocarbon receptor; astrogliosis; monocytes; scar formation; sonic hedgehog pathway; traumatic brain injury	ARYL-HYDROCARBON RECEPTOR; SPINAL-CORD-INJURY; REACTIVE ASTROCYTES; COGNITIVE DYSFUNCTION; RADIAL GLIA; CELLS; CCR2; MICROGLIA; SYSTEM; DELETION	Scar formation after brain injury is still poorly understood. To further elucidate such processes, here, we examine the interplay between astrocyte proliferation taking place predominantly at the vascular interface and monocyte invasion. Using genetic mouse models that decrease or increase reactive astrocyte proliferation, we demonstrate inverse effects on monocyte numbers in the injury site. Conversely, reducing monocyte invasion using CCR2(-/-) mice causes a strong increase in astrocyte proliferation, demonstrating an intriguing negative cross-regulation between these cell types at the vascular interface. CCR2(-/-) mice show reduced scar formation with less extracellular matrix deposition, smaller lesion site and increased neuronal coverage. Surprisingly, the GFAP(+) scar area in these mice is also significantly decreased despite increased astrocyte proliferation. Proteomic analysis at the peak of increased astrocyte proliferation reveals a decrease in extracellular matrix synthesizing enzymes in the injury sites of CCR2(-/-) mice, highlighting how early key aspects of scar formation are initiated. Taken together, we provide novel insights into the cross-regulation of juxtavascular proliferating astrocytes and invading monocytes as a crucial mechanism of scar formation upon brain injury.	[Frik, Jesica; Mattugini, Nicola; Kjell, Jacob; Kraska, Jonas; Sirko, Swetlana; Goetz, Magdalena] Ludwig Maximilians Univ Munchen, Biomed Ctr, Physiol Genom, Munich, Germany; [Frik, Jesica; Mattugini, Nicola; Kjell, Jacob; Sirko, Swetlana; Goetz, Magdalena] Helmholtz Ctr Munich, Inst Stem Cell Res, Munich, Germany; [Frik, Jesica; Gomez, Ricardo M.] UNLP, CONICET, Inst Biotecnol & Biol Mol, La Plata, Buenos Aires, Argentina; [Merl-Pham, Juliane; Hauck, Stefanie M.] Helmholtz Ctr Munich, Res Unit Prot Sci, Munich, Germany; [Plesnila, Nikolaus] Univ Munich, Med Sch, Expt Stroke Res, Inst Stroke & Dementia Res, Munich, Germany; [Plesnila, Nikolaus; Goetz, Magdalena] Univ Munich, Excellence Cluster Syst Neurol, SYNERGY, Munich, Germany; [Mattugini, Nicola] Ludwig Maximilians Univ Munchen, Bioctr, Grad Sch System Neurosci, Munich, Germany	Sirko, S; Gotz, M (corresponding author), Ludwig Maximilians Univ Munchen, Biomed Ctr, Physiol Genom, Munich, Germany.; Sirko, S; Gotz, M (corresponding author), Helmholtz Ctr Munich, Inst Stem Cell Res, Munich, Germany.; Gotz, M (corresponding author), Univ Munich, Excellence Cluster Syst Neurol, SYNERGY, Munich, Germany.	swetlana.sirko@med.uni-muenchen.de; magdalena.goetz@helmholtz-muenchen.de	Frik, Jesica/AAI-3992-2021; Plesnila, Nikolaus/T-7522-2019; Gomez, Ricardo M/AAG-9555-2019; Sirko, Swetlana/O-5725-2019; Merl-Pham, Juliane/N-7258-2014; Hauck, Stefanie/B-3300-2013	Gomez, Ricardo M/0000-0002-4001-519X; Sirko, Swetlana/0000-0001-5950-616X; Merl-Pham, Juliane/0000-0002-3422-4083; Mattugini, Nicola/0000-0003-4489-1661; Hauck, Stefanie/0000-0002-1630-6827; Kjell, Jacob/0000-0002-8335-0780; Frik, Jesica/0000-0002-8750-2112	German Research FoundationGerman Research Foundation (DFG) [SFB870]; Synergy Excellence Cluster; ALEARG Program [1757]; Ministry of Education, Science and Technology of Argentina; German Academic Exchange Service (DAAD)Deutscher Akademischer Austausch Dienst (DAAD); Swedish Society for Medical Research (SSMF)	We are particularly grateful to Gabi Jager and Manja Thorwirth for excellent technical assistance. We thank Giacomo Masserdotti for help with statistics and Adam O'Neill for excellent suggestions on the manuscript. We are also thankful to Prof. Dr. Andreas Faissner (Ruhr-University Bochum, Germany) for generously providing the KAF14 antibody and to Elisabetta Petroziello for help with identification of invading immune cells by MACS and FACS. This work was supported by the German Research Foundation to MG via the SFB870, Synergy Excellence Cluster, and the Priority Program 1757, a Scholarship to JF from the ALEARG Program co-funded by the Ministry of Education, Science and Technology of Argentina and the German Academic Exchange Service (DAAD) and to JKj by Swedish Society for Medical Research (SSMF).	Adams KL, 2018, NAT NEUROSCI, V21, P9, DOI 10.1038/s41593-017-0033-9; Alunni A, 2016, DEVELOPMENT, V143, P741, DOI 10.1242/dev.122796; Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; Barbosa JS, 2015, SCIENCE, V348, P789, DOI 10.1126/science.aaa2729; Bardehle S, 2013, NAT NEUROSCI, V16, P580, DOI 10.1038/nn.3371; Barrow LL, 2002, TERATOLOGY, V66, P85, DOI 10.1002/tera.10062; Benner EJ, 2013, NATURE, V497, P369, DOI 10.1038/nature12069; Blake JA, 2015, NUCLEIC ACIDS RES, V43, pD1049, DOI 10.1093/nar/gku1179; Bost F, 1998, EUR J BIOCHEM, V252, P339, DOI 10.1046/j.1432-1327.1998.2520339.x; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Carlen M, 2009, NAT NEUROSCI, V12, P259, DOI 10.1038/nn.2268; Chu HX, 2014, J CEREBR BLOOD F MET, V34, P1425, DOI 10.1038/jcbfm.2014.120; Conductier G, 2010, J NEUROIMMUNOL, V224, P93, DOI 10.1016/j.jneuroim.2010.05.010; D'Mello C, 2009, J NEUROSCI, V29, P2089, DOI 10.1523/JNEUROSCI.3567-08.2009; Dimitrijevic OB, 2007, STROKE, V38, P1345, DOI 10.1161/01.STR.0000259709.16654.8f; Donnelly DJ, 2011, J NEUROSCI, V31, P9910, DOI 10.1523/JNEUROSCI.2114-11.2011; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Filous AR, 2016, PROG NEUROBIOL, V144, P173, DOI 10.1016/j.pneurobio.2016.03.009; Frisen J, 2016, ANNU REV CELL DEV BI, V32, P127, DOI 10.1146/annurev-cellbio-111315-124953; Fujimoto M, 2016, J NEUROSURG, V124, P1693, DOI 10.3171/2015.4.JNS15484; Grosche A, 2016, MOL CELL PROTEOMICS, V15, P462, DOI 10.1074/mcp.M115.052183; Gyoneva S, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0443-0; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Haan N, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0327-3; Hara M, 2017, NAT MED, V23, P818, DOI 10.1038/nm.4354; Hayakawa K, 2016, NEURAL REGEN RES, V11, P529, DOI 10.4103/1673-5374.180725; Heimann G, 2017, CEREB CORTEX, V27, P4213, DOI 10.1093/cercor/bhx112; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Horng S, 2017, J CLIN INVEST, V127, P3136, DOI 10.1172/JCI91301; Howitt J, 2015, J MOL CELL BIOL, V7, P119, DOI 10.1093/jmcb/mjv020; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Jeong JH, 2004, GENE DEV, V18, P937, DOI 10.1101/gad.1190304; Jiang P., 2016, NEUROGENESIS AUSTIN, V3, DOI [10.1080/23262133.2016.1224453, DOI 10.1080/23262133.2016.122445]; Kamphuis W, 2015, GLIA, V63, P1036, DOI 10.1002/glia.22800; Katsumoto A, 2014, J IMMUNOL, V193, P2615, DOI 10.4049/jimmunol.1400716; Kim SK, 2017, GLIA, V65, P1719, DOI 10.1002/glia.23169; Kroehne V, 2011, DEVELOPMENT, V138, P4831, DOI 10.1242/dev.072587; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Long FX, 2001, DEVELOPMENT, V128, P5099; Ly A, 2016, J PROTEOME RES, V15, P1350, DOI 10.1021/acs.jproteome.6b00111; Martin-Lopez E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074039; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Mimura J, 1999, GENE DEV, V13, P20, DOI 10.1101/gad.13.1.20; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Mori T, 2006, GLIA, V54, P21, DOI 10.1002/glia.20350; Nakamura T, 2006, CIRC RES, V98, P1547, DOI 10.1161/01.RES.0000227505.19472.69; Nebert DW, 2017, PROG LIPID RES, V67, P38, DOI 10.1016/j.plipres.2017.06.001; O'Callaghan JP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102003; Plesnila N, 2016, CURR OPIN PHARMACOL, V26, P110, DOI 10.1016/j.coph.2015.10.008; Ransohoff RM, 2016, NAT NEUROSCI, V19, P987, DOI 10.1038/nn.4338; Reaux-Le Goazigo A, 2013, PROG NEUROBIOL, V104, P67, DOI 10.1016/j.pneurobio.2013.02.001; Ren YL, 2017, SCI REP-UK, V7, DOI 10.1038/srep41122; Robel S, 2016, NAT NEUROSCI, V19, P28, DOI 10.1038/nn.4184; Robel S, 2011, J NEUROSCI, V31, P12471, DOI 10.1523/JNEUROSCI.2696-11.2011; Rothhammer V, 2016, NAT MED, V22, P586, DOI 10.1038/nm.4106; Sabelstrom H, 2013, SCIENCE, V342, P637, DOI 10.1126/science.1242576; Saederup N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013693; Sang Q, 2006, J NEUROSCI, V26, P7234, DOI 10.1523/JNEUROSCI.1398-06.2006; Schachtrup C, 2010, J NEUROSCI, V30, P5843, DOI 10.1523/JNEUROSCI.0137-10.2010; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P459, DOI 10.1038/jcbfm.2009.240; Simon C, 2011, GLIA, V59, P869, DOI 10.1002/glia.21156; Sirko S, 2015, GLIA, V63, P2340, DOI 10.1002/glia.22898; Sirko S, 2013, CELL STEM CELL, V12, P426, DOI 10.1016/j.stem.2013.01.019; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Tanaka EM, 2009, NAT REV NEUROSCI, V10, P713, DOI 10.1038/nrn2707; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; Tomita S, 2003, J IMMUNOL, V171, P4113, DOI 10.4049/jimmunol.171.8.4113; Vizcaino JA, 2016, NUCLEIC ACIDS RES, V44, pD447, DOI 10.1093/nar/gkv1145; Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013; Watkins S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5196; Wattananit S, 2016, J NEUROSCI, V36, P4182, DOI 10.1523/JNEUROSCI.4317-15.2016; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]; Wu XW, 2006, GENE DEV, V20, P571, DOI 10.1101/gad.361406; Xie JW, 1998, NATURE, V391, P90; Xu JW, 2017, BEHAV BRAIN RES, V332, P145, DOI 10.1016/j.bbr.2017.05.066; Xu K, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0522-2; Yanagida K, 2017, P NATL ACAD SCI USA, V114, P4531, DOI 10.1073/pnas.1618659114; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283	80	40	41	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1469-221X	1469-3178		EMBO REP	EMBO Rep.	MAY	2018	19	5							e45294	10.15252/embr.201745294			20	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	GF0PS	WOS:000431633800009	29632244	Green Published, Other Gold			2021-06-18	
J	Johnson, JJ; Loeffert, AC; Stokes, J; Olympia, RP; Bramley, H; Hicks, SD				Johnson, Jeremiah J.; Loeffert, Andrea C.; Stokes, Jennifer; Olympia, Robert P.; Bramley, Harry; Hicks, Steven D.			Association of Salivary MicroRNA Changes With Prolonged Concussion Symptoms	JAMA PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; POSTCONCUSSION SYNDROME; MILD; BIOMARKERS; CHILDREN; DIAGNOSIS; PROGNOSIS; KNOWLEDGE	IMPORTANCE Approximately one-third of children who experience a concussion develop prolonged concussion symptoms. To our knowledge, there are currently no objective or easily administered tests for predicting prolonged concussion symptoms. Several studies have identified alterations in epigenetic molecules known as microRNAs (miRNAs) following traumatic brain injury. No studies have examined whether miRNA expression can detect prolonged concussion symptoms. OBJECTIVE To evaluate the efficacy of salivary miRNAs for identifying children with concussion who are at risk for prolonged symptoms. DESIGN, SETTING, AND PARTICIPANTS This prospective cohort study at the Penn State Medical Center observed 52 patients aged 7 to 21 years presenting for evaluation of concussion within 14 days of initial head injury, with follow-up at 4 and 8 weeks, EXPOSURES All patients had a clinical diagnosis of concussion. MAIN OUTCOMES AND MEASURES Salivary miRNA expression was measured at the time of initial clinical presentation in all patients, Patients with a Sport Concussion Assessment Tool (SCAT3) symptom score of 5 or greater on self-report or parent report 4 weeks after injury were designated as having prolonged symptoms. RESULTS Of the 52 included participants, 22 (42%) were female, and the mean (SD) age was 14 (3) years. Participants were split into the prolonged symptom group (n = 30) and acute symptom group (n = 22). Concentrations of 15 salivary miRNAs spatially differentiated prolonged and acute symptom groups on partial least squares discriminant analysis and demonstrated functional relationships with neuronal regulatory pathways. Levels of 5 miRNAs (miR-320c-1. miR-133a-5p. miR-769-5p, let-7a-3p. and miR-1307-3p) accurately identified patients with prolonged symptoms on logistic regression (area under the curve, 0.856; 95% CI, 0.822-0.890). This accuracy exceeded accuracy of symptom burden on child (area under the curve, 0.649; 95% CI, 0.388-0.887) or parent (area under the curve, 0.562; 95% CI, 0.219-0.734) SCAT3 score. Levels of 3 miRNAs were associated with specific symptoms 4 weeks after injury; miR-320c-1 was associated with memory difficulty (R, 0.55; false detection rate, 0,02), miR-S29 was associated with headaches (R, 0.47; false detection rate, 0.04), and let-7b-5p was associated with fatigue (R, 0.45; false detection rate, 0.04). CONCLUSIONS AND RELEVANCE Salivary miRNA levels may identify the duration and character of concussion symptoms. This could reduce parental anxiety and improve care by providing a tool for concussion management. Further validation of this approach is needed.	[Johnson, Jeremiah J.; Loeffert, Andrea C.; Stokes, Jennifer; Olympia, Robert P.; Bramley, Harry; Hicks, Steven D.] Penn State Univ, Penn State Coll Med, Dept Pediat, Mail Code HS83,500 Univ Dr, Hershey, PA 17033 USA; [Olympia, Robert P.] Penn State Univ, Penn State Coll Med, Dept Emergency Med, Hershey, PA 17033 USA	Hicks, SD (corresponding author), Penn State Univ, Penn State Coll Med, Dept Pediat, Mail Code HS83,500 Univ Dr, Hershey, PA 17033 USA.	shicks1@pennstatehealth.psu.edu		Hicks, Steven/0000-0002-9579-6798	Children's Miracle Network [417-51HY-4BFB]; Quadrant Biosciences; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR002015, UL1TR002014] Funding Source: NIH RePORTER	This study was supported by grant 417-51HY-4BFB from the Children's Miracle Network to Dr Hicks and a research agreement with Drs Loeffert and Hicks from Quadrant Biosciences (formerly Motion Intelligence).	Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Babcock L, 2013, PEDIATR EMERG CARE, V29, P458, DOI 10.1097/PEC.0b013e31828a202d; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Balakathiresan N, 2012, J NEUROTRAUM, V29, P1379, DOI 10.1089/neu.2011.2146; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Barlow M, 2011, INT J SPORTS PHYS TH, V6, P150; Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; Bhomia M, 2016, SCI REP-UK, V6, DOI 10.1038/srep28148; Bramley H, 2016, SPORTS MED ARTHROSC, V24, P123, DOI 10.1097/JSA.0000000000000111; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Burton LJ, 1997, PEDIATR EMERG CARE, V13, P1, DOI 10.1097/00006565-199702000-00001; Chandran R, 2017, BRAIN INJURY, V31, P106, DOI 10.1080/02699052.2016.1213420; Di Pietro V, 2017, J NEUROTRAUM, V34, P1948, DOI 10.1089/neu.2016.4857; Gilad S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003148; Hicks SD, J NEUROTRAUMA; Jansen P, 2007, NAT NEUROSCI, V10, P1449, DOI 10.1038/nn2000; Kang HJ, 2001, CELL, V106, P771, DOI 10.1016/S0092-8674(01)00497-4; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Liu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103948; McCarthy MT, 2015, ANN NY ACAD SCI, V1345, P89, DOI 10.1111/nyas.12736; Mitra B, 2017, J CLIN NEUROSCI, V38, P37, DOI 10.1016/j.jocn.2016.12.009; Nam JW, 2014, MOL CELL, V53, P1031, DOI 10.1016/j.molcel.2014.02.013; Pasinetti Giulio M, 2012, Am J Neurodegener Dis, V1, P88; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Scopaz KA, 2013, SPORTS HEALTH, V5, P537, DOI 10.1177/1941738112473059; Scorza KA, 2012, AM FAM PHYSICIAN, V85, P123; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pW460, DOI 10.1093/nar/gkv403; Xia Jianguo, 2016, Curr Protoc Bioinformatics, V55, DOI 10.1002/cpbi.11; Yang T, 2016, J NEUROCHEM, V137, P122, DOI 10.1111/jnc.13534; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Zaits MN, 2014, MOL PSYCHIATR, V19, P848, DOI 10.1038/mp.2013.93; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203; Zemek R, 2013, ACAD EMERG MED, V20, P1041, DOI 10.1111/acem.12220; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	39	40	40	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	JAN	2018	172	1					65	73		10.1001/jamapediatrics.2017.3884			9	Pediatrics	Pediatrics	FR5ZE	WOS:000419144300017	29159407	Bronze, Green Published			2021-06-18	
J	Kempuraj, D; Selvakumar, GP; Thangavel, R; Ahmed, ME; Zaheer, S; Raikwar, SP; Iyer, SS; Bhagavan, SM; Beladakere-Ramaswamy, S; Zaheer, A				Kempuraj, Duraisamy; Selvakumar, Govindhasamy P.; Thangavel, Ramasamy; Ahmed, Mohammad E.; Zaheer, Smita; Raikwar, Sudhanshu P.; Iyer, Shankar S.; Bhagavan, Sachin M.; Beladakere-Ramaswamy, Swathi; Zaheer, Asgar			Mast Cell Activation in Brain Injury, Stress, and Post-traumatic Stress Disorder and Alzheimer's Disease Pathogenesis	FRONTIERS IN NEUROSCIENCE			English	Article						Alzheimer's disease; mast cells; neurodegeneration; neuroinflammation; stress; PTSD	CORTICOTROPIN-RELEASING HORMONE; GLIA MATURATION FACTOR; CENTRAL-NERVOUS-SYSTEM; GROWTH-FACTOR RELEASE; AMYLOID-BETA; MOUSE MODEL; EMERGING ROLE; RISK-FACTOR; CARDIOVASCULAR-DISEASE; COGNITIVE IMPAIRMENT	Mast cells are localized throughout the body and mediate allergic, immune, and inflammatory reactions. They are heterogeneous, tissue-resident, long-lived, and granulated cells. Mast cells increase their numbers in specific site in the body by proliferation, increased recruitment, increased survival, and increased rate of maturation from its progenitors. Mast cells are implicated in brain injuries, neuropsychiatric disorders, stress, neuroinflammation, and neurodegeneration. Brain mast cells are the first responders before microglia in the brain injuries since mast cells can release prestored mediators. Mast cells also can detect amyloid plaque formation during Alzheimer's disease (AD) pathogenesis. Stress conditions activate mast cells to release prestored and newly synthesized inflammatory mediators and induce increased blood-brain barrier permeability, recruitment of immune and inflammatory cells into the brain and neuroinflammation. Stress induces the release of corticotropin-releasing hormone (CRH) from paraventricular nucleus of hypothalamus and mast cells. CRH activates glial cells and mast cells through CRH receptors and releases neuroinflammatory mediators. Stress also increases proinflammatory mediator release in the peripheral systems that can induce and augment neuroinflammation. Post-traumatic stress disorder (PTSD) is a traumatic-chronic stress related mental dysfunction. Currently there is no specific therapy to treat PTSD since its disease mechanisms are not yet clearly understood. Moreover, recent reports indicate that PTSD could induce and augment neuroinflammation and neurodegeneration in the pathogenesis of neurodegenerative diseases. Mast cells play a crucial role in the peripheral inflammation as well as in neuroinflammation due to brain injuries, stress, depression, and PTSD. Therefore, mast cells activation in brain injury, stress, and PTSD may accelerate the pathogenesis of neuroinflammatory and neurodegenerative diseases including AD. This review focusses on how mast cells in brain injuries, stress, and PTSD may promote the pathogenesis of AD. We suggest that inhibition of mast cells activation and brain cells associated inflammatory pathways in the brain injuries, stress, and PTSD can be explored as a new therapeutic target to delay or prevent the pathogenesis and severity of AD.	[Kempuraj, Duraisamy; Selvakumar, Govindhasamy P.; Thangavel, Ramasamy; Ahmed, Mohammad E.; Zaheer, Smita; Raikwar, Sudhanshu P.; Iyer, Shankar S.; Bhagavan, Sachin M.; Beladakere-Ramaswamy, Swathi; Zaheer, Asgar] Univ Missouri, Dept Neurol, Sch Med, Columbia, MO 65211 USA; [Kempuraj, Duraisamy; Selvakumar, Govindhasamy P.; Thangavel, Ramasamy; Ahmed, Mohammad E.; Zaheer, Smita; Raikwar, Sudhanshu P.; Iyer, Shankar S.; Bhagavan, Sachin M.; Beladakere-Ramaswamy, Swathi; Zaheer, Asgar] Univ Missouri, Sch Med, Ctr Translat Neurosci, Columbia, MO 65211 USA; [Kempuraj, Duraisamy; Selvakumar, Govindhasamy P.; Thangavel, Ramasamy; Ahmed, Mohammad E.; Raikwar, Sudhanshu P.; Iyer, Shankar S.; Zaheer, Asgar] US Dept Vet Affairs, Harry S Truman Mem Vet Hosp, Columbia, MO 65201 USA	Kempuraj, D; Zaheer, A (corresponding author), Univ Missouri, Dept Neurol, Sch Med, Columbia, MO 65211 USA.; Kempuraj, D; Zaheer, A (corresponding author), Univ Missouri, Sch Med, Ctr Translat Neurosci, Columbia, MO 65211 USA.; Kempuraj, D; Zaheer, A (corresponding author), US Dept Vet Affairs, Harry S Truman Mem Vet Hosp, Columbia, MO 65201 USA.	duraisamyk@health.missouri.edu; zaheera@health.missouri.edu	duraisamy, kempuraj/R-3043-2019; Ahmed, Mohammad Ejaz/AAU-5742-2020	Raikwar, Sudhanshu/0000-0001-8549-8570	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG048205, NS073670]; Veteran Affairs Merit Award [I01BX002477]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG048205] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health Grants # AG048205, # NS073670, and Veteran Affairs Merit Award # I01BX002477 to AZ.	Ahmed ME, 2017, J ALZHEIMERS DIS, V60, P1143, DOI 10.3233/JAD-170634; Alysandratos KD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048934; Amor S, 2014, IMMUNOLOGY, V141, P287, DOI 10.1111/imm.12134; Andel R, 2012, J AM GERIATR SOC, V60, P60, DOI 10.1111/j.1532-5415.2011.03777.x; Anisman H, 2003, ANN MED, V35, P2, DOI 10.1080/07853890310004075; Anisman H, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003579; Arthur G, 2016, CHEST, V150, P680, DOI 10.1016/j.chest.2016.06.009; Ayyadurai S, 2017, J LEUKOCYTE BIOL, V102, P1299, DOI 10.1189/jlb.2HI0317-088RR; Baglietto-Vargas D, 2015, J NEUROCHEM, V134, P915, DOI 10.1111/jnc.13195; Banks WA, 1995, NEUROIMMUNOMODULAT, V2, P241, DOI 10.1159/000097202; Banuelos-Cabrera I, 2014, ARCH MED RES, V45, P677, DOI 10.1016/j.arcmed.2014.11.010; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Becher B, 2017, NAT REV IMMUNOL, V17, P49, DOI 10.1038/nri.2016.123; BEIL WJ, 1994, J ALLERGY CLIN IMMUN, V94, P531, DOI 10.1016/0091-6749(94)90210-0; Biran V, 2008, BRAIN PATHOL, V18, P1, DOI 10.1111/j.1750-3639.2007.00092.x; Bolos Marta, 2017, BioMolecular Concepts, V8, P37, DOI 10.1515/bmc-2016-0029; Borriello F, 2017, HANDB EXP PHARMACOL, V241, P121, DOI 10.1007/164_2017_18; Breslau Naomi, 2002, J Gend Specif Med, V5, P34; Brown GC, 2015, BRAIN RES, V1628, P288, DOI 10.1016/j.brainres.2015.08.031; Budni J, 2016, CURR ALZHEIMER RES, V13, P1319, DOI 10.2174/1567205013666160819124206; Bulfone-Paus S, 2017, TRENDS IMMUNOL, V38, P657, DOI 10.1016/j.it.2017.01.008; Calcia MA, 2016, PSYCHOPHARMACOLOGY, V233, P1637, DOI 10.1007/s00213-016-4218-9; Cao J, 2006, J UROLOGY, V176, P1208, DOI 10.1016/j.juro.2006.04.026; Cao J, 2006, MOL PHARMACOL, V69, P998, DOI 10.1124/mol.105.019539; Cao J, 2005, J IMMUNOL, V174, P7665, DOI 10.4049/jimmunol.174.12.7665; Castellani ML, 2010, J BIOL REG HOMEOS AG, V24, P229; Castellani ML, 2009, J BIOL REG HOMEOS AG, V23, P11; Chandler N, 2002, BRAIN BEHAV IMMUN, V16, P757, DOI 10.1016/S0889-1591(02)00028-4; Chelombitko MA, 2016, BIOCHEMISTRY-MOSCOW+, V81, P1564, DOI 10.1134/S000629791612018X; Chen MH, 2014, J AM MED DIR ASSOC, V15, P763, DOI 10.1016/j.jamda.2014.06.003; Chen WW, 2016, MOL MED REP, V13, P3391, DOI 10.3892/mmr.2016.4948; Chikahisa S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14162-w; Chikahisa S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078434; Claes SJ, 2004, ANN MED, V36, P50, DOI 10.1080/07853890310017044; Cohen M, 2011, INT J PSYCHIAT MED, V42, P117, DOI 10.2190/PM.42.2.b; Collins-Praino LE, 2017, BRAIN BEHAV IMMUN, V60, P369, DOI 10.1016/j.bbi.2016.09.027; Colombo E, 2016, TRENDS IMMUNOL, V37, P608, DOI 10.1016/j.it.2016.06.006; Corrigan F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0738-9; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; Dams-O'Connor K, 2016, NEURODEGENER DIS MAN, V6, P417, DOI 10.2217/nmt-2016-0017; Dantzer R, 2007, BRAIN BEHAV IMMUN, V21, P153, DOI 10.1016/j.bbi.2006.09.006; De Berardis D, 2006, INT J IMMUNOPATH PH, V19, P721, DOI 10.1177/039463200601900402; de Kloet CS, 2007, PROG BRAIN RES, V167, P287, DOI 10.1016/S0079-6123(07)67025-3; De Simone R, 2015, J NEUROCHEM, V135, P147, DOI 10.1111/jnc.13244; Delpech JC, 2015, NEUROPHARMACOLOGY, V96, P19, DOI 10.1016/j.neuropharm.2014.12.034; Devoto C, 2017, CELL TRANSPLANT, V26, P1169, DOI 10.1177/0963689717714098; DiGangi JA, 2013, CLIN PSYCHOL REV, V33, P728, DOI 10.1016/j.cpr.2013.05.002; Domingues C, 2017, CURR ALZHEIMER RES, V14, P870, DOI 10.2174/1567205014666170317113606; Dong HQ, 2014, MED SCI MONIT BASIC, V20, P200, DOI 10.12659/MSMBR.893093; Dong HQ, 2014, MOL NEUROBIOL, V49, P1487, DOI 10.1007/s12035-014-8697-6; Dursa EK, 2014, J TRAUMA STRESS, V27, P542, DOI 10.1002/jts.21956; Eiland L, 2013, NEUROSCIENCE, V249, P162, DOI 10.1016/j.neuroscience.2012.10.048; Elder GA, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0591-8; Elder GA, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00048; Engebretsen KA, 2016, J EUR ACAD DERMATOL, V30, P223, DOI 10.1111/jdv.13301; Esposito P, 2003, BRAIN RES, V968, P192, DOI 10.1016/S0006-8993(03)02237-6; Esposito P, 2001, BRAIN RES, V888, P117, DOI 10.1016/S0006-8993(00)03026-2; Finch CE, 2007, CURR ALZHEIMER RES, V4, P185, DOI 10.2174/156720507780362254; Finnell JE, 2016, NEUROBIOL STRESS, V4, P1, DOI 10.1016/j.ynstr.2016.04.001; Flatt JD, 2018, ALZHEIMERS DEMENT, V14, P28, DOI 10.1016/j.jalz.2017.04.014; Forsythe P, 2000, INFLAMM RES, V49, P147, DOI 10.1007/s000110050574; Frieri M, 2015, ANN ALLERG ASTHMA IM, V115, P172, DOI 10.1016/j.anai.2015.06.025; Fu AKY, 2016, P NATL ACAD SCI USA, V113, pE2705, DOI 10.1073/pnas.1604032113; Galecki P, 2018, PROG NEURO-PSYCHOPH, V80, P291, DOI 10.1016/j.pnpbp.2017.03.016; GALLI SJ, 1990, LAB INVEST, V62, P5; Galli SJ, 2018, J ALLERGY CLIN IMMUN, V141, P92, DOI 10.1016/j.jaci.2017.05.029; Galli SJ, 2017, NEW ENGL J MED, V376, P1983, DOI 10.1056/NEJMe1702653; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Gangemi S, 2015, ALLERGY, V70, P436, DOI 10.1111/all.12571; Gaudenzio N, 2016, J CLIN INVEST, V126, P3981, DOI 10.1172/JCI85538; Georgin-Lavialle S, 2016, MOL PSYCHIATR, V21, P1511, DOI 10.1038/mp.2015.216; Gilfillan AM, 2011, ADV EXP MED BIOL, V716, P2, DOI 10.1007/978-1-4419-9533-9_1; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; Graziottin A, 2014, GYNECOL ENDOCRINOL, V30, P472, DOI 10.3109/09513590.2014.911280; Groer MW, 2015, BIOL RES NURS, V17, P303, DOI 10.1177/1099800414544949; GRUBER BL, 1995, BLOOD, V86, P2488; Gupta R, 2016, REV NEUROSCIENCE, V27, P93, DOI 10.1515/revneuro-2015-0017; Gurish MF, 2001, J EXP MED, V194, pF1, DOI 10.1084/jem.194.1.F1; Harcha PA, 2015, J NEUROSCI, V35, P9526, DOI 10.1523/JNEUROSCI.3686-14.2015; Hashioka Sadayuki, 2009, Central Nervous System Agents in Medicinal Chemistry, V9, P12; Hayley S, 2011, FRONT BEHAV NEUROSCI, V5, DOI 10.3389/fnbeh.2011.00019; Hendriksen E, 2017, NEUROSCI BIOBEHAV R, V79, P119, DOI 10.1016/j.neubiorev.2017.05.001; Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5; Hoeijmakers L, 2017, BRAIN BEHAV IMMUN, V63, P160, DOI 10.1016/j.bbi.2016.12.023; Honarvar NM, 2017, J MOL NEUROSCI, V61, P289, DOI 10.1007/s12031-016-0857-x; Hong J. T., 2017, CNS NEUROL DISORD-DR, DOI [DOI 10.2174/1871527316666170807130011, 10.2174/1871527316666170807130011]; Hudson CA, 2008, J LEUKOCYTE BIOL, V84, P631, DOI 10.1189/jlb.1207830; IRANI AMA, 1994, ALLERGY PROC, V15, P303, DOI 10.2500/108854194778816472; Jin YX, 2007, DEV NEUROSCI-BASEL, V29, P373, DOI 10.1159/000105478; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Justice NJ, 2015, J NEUROSCI, V35, P2612, DOI 10.1523/JNEUROSCI.3333-14.2015; Kalesnikoff J, 2008, NAT IMMUNOL, V9, P1215, DOI 10.1038/ni.f.216; Kandere-Grzybowska K, 2003, J IMMUNOL, V171, P4830, DOI 10.4049/jimmunol.171.9.4830; Kandere-Grzybowska K, 2003, BRAIN RES, V980, P213, DOI 10.1016/S0006-8993(03)02975-5; Kandere-Grzybowska K, 2006, BRIT J PHARMACOL, V148, P208, DOI 10.1038/sj.bjp.0706695; Karagkouni A, 2013, AUTOIMMUN REV, V12, P947, DOI 10.1016/j.autrev.2013.02.006; Kato TA, 2013, FRONT INTEGR NEUROSC, V7, DOI 10.3389/fnint.2013.00053; Kempuraj D, 2005, BRIT J PHARMACOL, V145, P934, DOI 10.1038/sj.bjp.0706246; Kempuraj D, 2004, ENDOCRINOLOGY, V145, P43, DOI 10.1210/en.2003-0805; Kempuraj D., 2016, J NEUROL NEUROSURG S, V1, P1003; Kempuraj D, 2018, J NEUROIMMUNE PHARM, V13, P100, DOI 10.1007/s11481-017-9766-1; Kempuraj D, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00216; Kempuraj D, 2016, NEUROCHEM RES, V41, P1042, DOI 10.1007/s11064-015-1790-z; Kempuraj D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135776; Kim DY, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-25; King E, 2017, ALZ DIS ASSOC DIS, V31, P346, DOI 10.1097/WAD.0000000000000211; Kokiko-Cochran O, 2016, J NEUROTRAUM, V33, P625, DOI 10.1089/neu.2015.3970; Koran MEI, 2014, HUM GENET, V133, P85, DOI 10.1007/s00439-013-1354-8; Krause K, 2010, CURR ALLERGY ASTHM R, V10, P243, DOI 10.1007/s11882-010-0121-3; Kritas SK, 2014, INT J IMMUNOPATH PH, V27, P163, DOI 10.1177/039463201402700203; Kritas SK, 2014, INT J IMMUNOPATH PH, V27, P15, DOI 10.1177/039463201402700103; Kritikou E, 2016, EUR J PHARMACOL, V778, P103, DOI 10.1016/j.ejphar.2015.04.050; Krystel-Whittemore M, 2016, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00620; Kvetnoi I. M., 2003, Arkhiv Patologii, V65, P36; Lai KSP, 2017, J NEUROL NEUROSUR PS, V88, P876, DOI 10.1136/jnnp-2017-316201; Lerman I, 2016, PSYCHONEUROENDOCRINO, V73, P99, DOI 10.1016/j.psyneuen.2016.07.202; Levy D, 2016, CEPHALALGIA, V36, P915, DOI 10.1177/0333102415617412; Li NN, 2017, BEHAV BRAIN RES, V322, P60, DOI 10.1016/j.bbr.2017.01.006; LIM R, 1989, P NATL ACAD SCI USA, V86, P3901, DOI 10.1073/pnas.86.10.3901; Lindqvist D, 2017, BRAIN BEHAV IMMUN, V59, P260, DOI 10.1016/j.bbi.2016.09.012; Lozada A, 2005, NEUROPATH APPL NEURO, V31, P150, DOI 10.1111/j.1365-2990.2004.00622.x; Lunderius-Andersson C, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00082; Lytinas M, 2003, INT ARCH ALLERGY IMM, V130, P224, DOI 10.1159/000069516; Machado A, 2014, REV NEUROSCIENCE, V25, P785, DOI 10.1515/revneuro-2014-0035; Martin NT, 2016, NAT IMMUNOL, V17, P122, DOI 10.1038/ni.3370; Maslinska D, 2007, INFLAMM RES, V56, pS17, DOI 10.1007/s00011-006-0508-8; McGeer EG, 2010, J ALZHEIMERS DIS, V19, P355, DOI 10.3233/JAD-2010-1219; McGeer PL, 2016, J ALZHEIMERS DIS, V54, P853, DOI 10.3233/JAD-160488; McGeer PL, 2015, EXPERT OPIN THER TAR, V19, P497, DOI 10.1517/14728222.2014.988707; McKittrick CM, 2015, J CEREBR BLOOD F MET, V35, P638, DOI 10.1038/jcbfm.2014.239; McManus RM, 2017, ALZHEIMERS RES THER, V9, DOI 10.1186/s13195-017-0241-2; Mendez MF, 2017, J ALZHEIMERS DIS, V57, P667, DOI 10.3233/JAD-161002; Mendoza C, 2016, MOL CELL ENDOCRINOL, V434, P266, DOI 10.1016/j.mce.2016.05.016; Miller K, 2017, MIL MED, V182, pE1815, DOI 10.7205/MILMED-D-17-00073; Mondelli V, 2017, LANCET PSYCHIAT, V4, P563, DOI 10.1016/S2215-0366(17)30101-3; Moretti R, 2016, J NEUROSCI RES, V94, P1546, DOI 10.1002/jnr.23911; Morgese MG, 2017, EUR J PHARMACOL, V817, P22, DOI 10.1016/j.ejphar.2017.08.031; Muhie S, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.91; Mukai K, 2016, SEMIN IMMUNOPATHOL, V38, P581, DOI 10.1007/s00281-016-0565-1; Nakae S, 2006, J IMMUNOL, V176, P2238, DOI 10.4049/jimmunol.176.4.2238; Nakamura Y, 2017, SCI REP-UK, V7, DOI 10.1038/srep39934; Nautiyal KM, 2008, P NATL ACAD SCI USA, V105, P18053, DOI 10.1073/pnas.0809479105; NELSON RB, 1993, J NEUROCHEM, V61, P567; Nezi M., 2000, ENDOTEXT; Niederhoffer N, 2009, INT J IMMUNOPATH PH, V22, P473, DOI 10.1177/039463200902200224; Niraula A, 2017, NEUROPSYCHOPHARMACOL, V42, P318, DOI 10.1038/npp.2016.185; Nozu T, 2017, J GASTROEN HEPATOL, V32, P1958, DOI 10.1111/jgh.13787; O'Bryant Sid E, 2016, Alzheimers Dement (Amst), V3, P27, DOI 10.1016/j.dadm.2015.12.003; O'Donovan A, 2015, BIOL PSYCHIAT, V77, P365, DOI 10.1016/j.biopsych.2014.06.015; Papadopoulou NG, 2005, J MOL ENDOCRINOL, V35, pR1, DOI 10.1677/jme.1.01833; Pardon MC, 2011, EXP GERONTOL, V46, P170, DOI 10.1016/j.exger.2010.09.006; Passos IC, 2015, LANCET PSYCHIAT, V2, P1002, DOI 10.1016/S2215-0366(15)00309-0; Pedersen WA, 2001, NEUROBIOL DIS, V8, P492, DOI 10.1006/nbdi.2001.0395; Perry VH, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.MCHD-0003-2015; Perry VH, 2014, NAT REV NEUROL, V10, P217, DOI 10.1038/nrneurol.2014.38; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Pervanidou P, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003327; Petra AI, 2014, EXPERT REV CLIN IMMU, V10, P729, DOI 10.1586/1744666X.2014.906302; Piirainen S, 2017, NEUROSCI BIOBEHAV R, V77, P148, DOI 10.1016/j.neubiorev.2017.01.046; Powers A, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/8926840; PURCELL WM, 1995, NEUROCHEM RES, V20, P521, DOI 10.1007/BF01694534; Purcell WM, 1996, NEUROTOXICOLOGY, V17, P845; Qu TT, 2017, NEURAL REGEN RES, V12, P440, DOI 10.4103/1673-5374.202932; Rehman Habib U, 2002, Curr Opin Investig Drugs, V3, P1637; Ribatti D, 2015, EXP CELL RES, V338, P119, DOI 10.1016/j.yexcr.2015.05.013; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; ROTHWELL NJ, 1995, INT J DEV NEUROSCI, V13, P179, DOI 10.1016/0736-5748(95)00018-C; Rozniecki JJ, 2010, BRAIN RES, V1366, P204, DOI 10.1016/j.brainres.2010.09.085; Sant GR, 2007, UROLOGY, V69, P34, DOI 10.1016/j.urology.2006.08.1109; Sawikr Y, 2017, ADV PROTEIN CHEM STR, V108, P33, DOI 10.1016/bs.apcsb.2017.02.001; Sayed BA, 2011, J IMMUNOL, V186, P3294, DOI 10.4049/jimmunol.1003574; Schain M, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0733-2; Setiawan E, 2015, JAMA PSYCHIAT, V72, P268, DOI 10.1001/jamapsychiatry.2014.2427; Shaik-Dasthagirisaheb YB, 2016, ADV CLIN EXP MED, V25, P781, DOI 10.17219/acem/61914; Shishido H, 2016, NEUROSCI LETT, V629, P62, DOI 10.1016/j.neulet.2016.06.066; Skaper SD, 2016, CNS NEUROL DISORD-DR, V15, P1072, DOI 10.2174/1871527315666160829105533; Skaper SD, 2014, CNS NEUROL DISORD-DR, V13, P1654; Skaper SD, 2012, FASEB J, V26, P3103, DOI 10.1096/fj.11-197194; Solomon Z, 2017, J CLIN PSYCHIAT, V78, pE1180, DOI 10.4088/JCP.16m11344; Spangenberg EE, 2017, BRAIN BEHAV IMMUN, V61, P1, DOI 10.1016/j.bbi.2016.07.003; Stolmeier D, 2013, NEUROCHEM RES, V38, P1580, DOI 10.1007/s11064-013-1059-3; Strbian D, 2007, CIRCULATION, V116, P411, DOI 10.1161/CIRCULATIONAHA.106.655423; Strbian D, 2009, ANN MED, V41, P438, DOI 10.1080/07853890902887303; Suurmond J, 2016, EUR J PHARMACOL, V778, P116, DOI 10.1016/j.ejphar.2015.03.085; Tagen M, 2009, J IMMUNOL, V183, P6313, DOI 10.4049/jimmunol.0803422; Thangavel R, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00150; Thangavel R, 2013, NEUROCHEM RES, V38, P1777, DOI 10.1007/s11064-013-1080-6; Theoharides TC, 2005, BRAIN RES REV, V49, P65, DOI 10.1016/j.brainresrev.2004.11.006; Theoharides TC, 2004, TRENDS PHARMACOL SCI, V25, P563, DOI 10.1016/j.tips.2004.09.007; THEOHARIDES TC, 1995, ENDOCRINOLOGY, V136, P5745, DOI 10.1210/en.136.12.5745; Theoharides TC, 2007, FRONT BIOSCI-LANDMRK, V12, P1615, DOI 10.2741/2174; Theoharides TC, 2017, EXP DERMATOL, V26, P751, DOI 10.1111/exd.13288; Theoharides TC, 2016, EUR J PHARMACOL, V778, P96, DOI 10.1016/j.ejphar.2015.03.086; Theoharides TC, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-46; Theoharides TC, 2012, ANN ALLERG ASTHMA IM, V109, P14, DOI 10.1016/j.anai.2012.03.003; Theoharides TC, 2012, BBA-MOL BASIS DIS, V1822, P21, DOI 10.1016/j.bbadis.2010.12.014; Theoharides TC, 2010, P NATL ACAD SCI USA, V107, P4448, DOI 10.1073/pnas.1000803107; Theoharides TC, 2008, J NEUROIMMUNOL, V205, P1, DOI 10.1016/j.jneuroim.2008.09.014; Tsai M, 2011, ADV EXP MED BIOL, V716, P186, DOI 10.1007/978-1-4419-9533-9_11; Tweedie D, 2016, ALZHEIMERS DEMENT, V12, P34, DOI 10.1016/j.jalz.2015.07.489; Vink R, 2003, ACT NEUR S, V86, P257; Wang RY, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/8439594; Wang ZW, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00219; Wernersson S, 2014, NAT REV IMMUNOL, V14, P478, DOI 10.1038/nri3690; Wohleb ES, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00544; Wolf EJ, 2016, PSYCHIAT ANN, V46, P527, DOI 10.3928/00485713-20160729-01; Xiong Z, 2014, J ALZHEIMERS DIS, V40, P297, DOI 10.3233/JAD-132081; Yasuoka S, 2011, BRAIN RES, V1385, P8, DOI 10.1016/j.brainres.2011.02.045; Yehya M, 2018, NEUROCRIT CARE, V28, P288, DOI 10.1007/s12028-017-0416-5; Young JS, 2016, CURR PSYCHIAT REP, V18, DOI 10.1007/s11920-016-0719-9; Yuan HB, 2010, J NEUROSCI RES, V88, P1348, DOI 10.1002/jnr.22304; Zaheer A, 2008, BRAIN RES, V1208, P192, DOI 10.1016/j.brainres.2008.02.093; Zaheer A, 2007, BRAIN RES, V1144, P239, DOI 10.1016/j.brainres.2007.01.075; Zaheer S, 2011, NEUROSCIENCE, V194, P227, DOI 10.1016/j.neuroscience.2011.07.069; Zaheer S, 2011, BRAIN RES, V1373, P230, DOI 10.1016/j.brainres.2010.12.003; Zarnegar B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00310; Zass LJ, 2017, PSYCHIAT GENET, V27, P1, DOI 10.1097/YPG.0000000000000143; Zhang C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181367; Ziemka-Nalecz M, 2017, J NEUROPATH EXP NEUR, V76, P644, DOI 10.1093/jnen/nlx046	219	40	41	0	14	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.	DEC 12	2017	11								703	10.3389/fnins.2017.00703			15	Neurosciences	Neurosciences & Neurology	FP6KD	WOS:000417734000005	29302258	DOAJ Gold, Green Published			2021-06-18	
J	Schultz, V; Stern, RA; Tripodis, Y; Stamm, J; Wrobel, P; Lepage, C; Weir, I; Guenette, JP; Chua, A; Alosco, ML; Baugh, CM; Fritts, NG; Martin, BM; Chaisson, CE; Coleman, MJ; Lin, AP; Pasternak, O; Shenton, ME; Koerte, IK				Schultz, Vivian; Stern, Robert A.; Tripodis, Yorghos; Stamm, Julie; Wrobel, Pawel; Lepage, Christian; Weir, Isabelle; Guenette, Jeffrey P.; Chua, Alicia; Alosco, Michael L.; Baugh, Christine M.; Fritts, Nathan G.; Martin, Brett M.; Chaisson, Christine E.; Coleman, Michael J.; Lin, Alexander P.; Pasternak, Ofer; Shenton, Martha E.; Koerte, Inga K.			Age at First Exposure to Repetitive Head Impacts Is Associated with Smaller Thalamic Volumes in Former Professional American Football Players	JOURNAL OF NEUROTRAUMA			English	Article						age at first exposure; chronic traumatic encephalopathy; repetitive head impacts; sports-related head injury; thalamus	CHRONIC TRAUMATIC ENCEPHALOPATHY; HIGH-SCHOOL; CLINICAL PRESENTATION; BRAIN-INJURY; LATER-LIFE; CONCUSSION; CHILDHOOD; HISTORY; DISEASE; CORTEX	Thalamic atrophy has been associated with exposure to repetitive head impacts (RHI) in professional fighters. The aim of this study is to investigate whether or not age at first exposure (AFE) to RHI is associated with thalamic volume in symptomatic former National Football League (NFL) players at risk for chronic traumatic encephalopathy (CTE). Eighty-six symptomatic former NFL players (mean age = 54.9 +/- 7.9 years) were included. T1-weighted data were acquired on a 3T magnetic resonance imager, and thalamic volumes were derived using FreeSurfer. Mood and behavior, psychomotor speed, and visual and verbal memory were assessed. The association between thalamic volume and AFE to playing football and to number of years playing was calculated. Decreased thalamic volume was associated with more years of play (left: p = 0.03; right: p = 0.03). Younger AFE was associated with decreased right thalamic volume (p = 0.014). This association remained significant after adjusting for total years of play. Decreased left thalamic volume was associated with worse visual memory (p = 0.014), whereas increased right thalamic volume was associated with fewer mood and behavior symptoms (p = 0.003). In our sample of symptomatic former NFL players at risk for CTE, total years of play and AFE were associated with decreased thalamic volume. The effect of AFE on right thalamic volume was almost twice as strong as the effect of total years of play. Our findings confirm previous reports of an association between thalamic volume and exposure to RHI. They suggest further that younger AFE may result in smaller thalamic volume later in life.	[Schultz, Vivian; Stamm, Julie; Wrobel, Pawel; Lepage, Christian; Guenette, Jeffrey P.; Coleman, Michael J.; Lin, Alexander P.; Pasternak, Ofer; Shenton, Martha E.; Koerte, Inga K.] Harvard Med Sch, Brigham & Womens Hosp, Psychiat Neuroimaging Lab, Dept Psychiat, Boston, MA USA; [Schultz, Vivian; Wrobel, Pawel; Koerte, Inga K.] Ludwig Maximilians Univ Munchen, Dept Child & Adolescent Psychiat Psychosomat & Ps, Munich, Germany; [Stern, Robert A.; Tripodis, Yorghos; Stamm, Julie; Alosco, Michael L.; Baugh, Christine M.; Fritts, Nathan G.; Chaisson, Christine E.] Boston Univ, BU Alzheimers Dis & CTE Ctr, Boston, MA 02215 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Tripodis, Yorghos; Weir, Isabelle; Chua, Alicia] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Stamm, Julie] Univ Wisconsin, Dept Kinesiol, Madison, WI USA; [Lepage, Christian] Univ Ottawa, Dept Psychol, Ottawa, ON, Canada; [Guenette, Jeffrey P.; Lin, Alexander P.; Pasternak, Ofer; Shenton, Martha E.] Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, Boston, MA USA; [Baugh, Christine M.] Harvard Univ, Interfac Initiat Hlth Policy, Boston, MA 02115 USA; [Martin, Brett M.; Chaisson, Christine E.] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr, Boston, MA USA; [Lin, Alexander P.] Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, Ctr Clin Spect, Boston, MA USA; [Shenton, Martha E.] VA Boston Healthcare Syst, Brockton Div, Brockton, MA USA; [Shenton, Martha E.; Koerte, Inga K.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA USA	Koerte, IK (corresponding author), Psychiat Neuroimaging Lab, 1249 Boylston St, Boston, MA 02215 USA.	ikoerte@bwh.harvard.edu	, Bob/ABA-8507-2020; Shenton, Martha/V-8780-2019; Baugh, Christine/AAG-2324-2020; Chua, Alicia/AAA-3628-2019	Baugh, Christine/0000-0002-9340-6338; Guenette, Jeffrey/0000-0002-4684-5469; Lepage, Chris/0000-0001-5719-0982; Chua, Alicia/0000-0001-6908-8539; Tripodis, Yorghos/0000-0003-2190-7608	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS 078337, F31 NS 081957, 1F32NS096803-01, P30 AG13846, UL1-TR000157, P41 EB015902, T32GM074905]; JetBlue Airlines; National Football League; NFL Players Association; Else Kroner-Fresenius Foundation, Germany; VA Merit AwardUS Department of Veterans Affairs; Canadian Institutes of Health Research Frederick Banting and Charles Best Doctoral AwardCanadian Institutes of Health Research (CIHR); German Academic Exchange Service PROMOS award; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS093334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846, P30AG019610] Funding Source: NIH RePORTER	The authors extend their appreciation to the study participants who make this work possible. This study was supported by the NIH R01 NS 078337 (RAS, YT, CMB, NGF, BMM, CC); F31 NS 081957 (JMS); 1F32NS096803-01 (MLA); P30 AG13846 (RAS, YT, MLA, CMB, BMM, CC); UL1-TR000157 (RAS); P41 EB015902 (OP); T32GM074905 (IW), and participant travel was partially funded by JetBlue Airlines, the National Football League, and the NFL Players Association. The sponsors had no role in the design or conduct of the study, the collection, analysis, or interpretation of the data, in the preparation, review, or approval of the manuscript, or in the decision to submit the study for publication. This study was also partly supported by the Else Kroner-Fresenius Foundation, Germany (IK), by a VA Merit Award (MES, MC), by the Canadian Institutes of Health Research Frederick Banting and Charles Best Doctoral Award (CL), and by the German Academic Exchange Service PROMOS award (VS). Finally, this work was completed in partial fulfillment of VS's dissertation.	Aggleton JP, 2016, BRAIN, V139, P1877, DOI 10.1093/brain/aww083; Alosco ML, 2017, BRAIN INJURY, V31, P1116, DOI 10.1080/02699052.2017.1294709; Alosco Michael L, 2017, Alzheimers Dement (Amst), V7, P33, DOI 10.1016/j.dadm.2016.11.003; Alosco ML, 2017, J NEUROTRAUM, V34, P772, DOI 10.1089/neu.2016.4536; Banks SJ, 2017, J NEUROTRAUM, V34, P380, DOI 10.1089/neu.2016.4453; BARRATT ES, 1965, PSYCHOL REP, V16, P547, DOI 10.2466/pr0.1965.16.2.547; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Beck A., 1988, MANUAL BECK HOPELESS; Beck A., 1996, MANUAL BDI 2; Bell PT, 2016, NEUROSCI BIOBEHAV R, V71, P313, DOI 10.1016/j.neubiorev.2016.08.036; Bernick C, 2015, BRIT J SPORT MED, V49, P1007, DOI 10.1136/bjsports-2014-093877; BOURGEOIS JP, 1989, P NATL ACAD SCI USA, V86, P4297, DOI 10.1073/pnas.86.11.4297; BROWN GL, 1979, PSYCHIAT RES, V1, P131, DOI 10.1016/0165-1781(79)90053-2; Brown TT, 2012, CURR BIOL, V22, P1693, DOI 10.1016/j.cub.2012.07.002; BUSS AH, 1957, J CONSULT PSYCHOL, V21, P343, DOI 10.1037/h0046900; Cherry JD, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0382-8; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; EFRON B, 1987, J AM STAT ASSOC, V82, P171, DOI 10.2307/2289144; Efron B., 1994, INTRO BOOTSTRAP; Eustache P, 2016, J ALZHEIMERS DIS, V50, P1035, DOI 10.3233/JAD-150353; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Giedd JN, 2008, J ADOLESCENT HEALTH, V42, P335, DOI 10.1016/j.jadohealth.2008.01.007; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Grodin EN, 2017, ADDICT BIOL, V22, P1426, DOI 10.1111/adb.12421; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Heaton R., 1993, WISCONSIN CARD SORTI; Herrero MT, 2002, CHILD NERV SYST, V18, P386, DOI 10.1007/s00381-002-0604-1; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Koerte IK, 2016, J NEUROTRAUM, V33, P346, DOI 10.1089/neu.2015.3880; Koerte IK, 2015, J NEUROTRAUM, V32, P1287, DOI 10.1089/neu.2014.3715; Konstantinou N, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00029; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; Lenihan MW, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0541-5; Lezak M., 2012, NEUROPSYCHOLOGICAL A, V5th; Ling HL, 2017, ACTA NEUROPATHOL, V133, P337, DOI 10.1007/s00401-017-1680-3; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mez J, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0407-7; MILLER IW, 1986, J CONSULT CLIN PSYCH, V54, P724, DOI 10.1037/0022-006X.54.5.724; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Montenigro PH, 2015, ANNU REV CLIN PSYCHO, V11, P309, DOI 10.1146/annurev-clinpsy-032814-112814; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Oh SW, 2014, NATURE, V508, P207, DOI 10.1038/nature13186; Okada N, 2016, MOL PSYCHIATR, V21, P1460, DOI 10.1038/mp.2015.209; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Reitan R. M., 1992, TRAIL MAKING TEST MA; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Robinson S, 2017, J NEUROSCI RES, V95, P1025, DOI 10.1002/jnr.23848; Roth R.M., 2005, BRIEF BEHAV RATING I; Saalmann YB, 2012, SCIENCE, V337, P753, DOI 10.1126/science.1223082; Sherman SM, 2007, CURR OPIN NEUROBIOL, V17, P417, DOI 10.1016/j.conb.2007.07.003; Solomon GS, 2016, AM J SPORT MED, V44, P1106, DOI 10.1177/0363546515626164; Spear LP, 2000, NEUROSCI BIOBEHAV R, V24, P417, DOI 10.1016/S0149-7634(00)00014-2; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; STERN RA, 1999, BOSTON QUALITATIVE S; Stern RA, 2003, NEUROPSYCHOLOGICAL A; Stern RA, 2016, J ALZHEIMERS DIS, V51, P1099, DOI 10.3233/JAD-151028; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; THATCHER RW, 1987, SCIENCE, V236, P1110, DOI 10.1126/science.3576224; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Webb CA, 2014, PSYCHOL MED, V44, P2833, DOI 10.1017/S0033291714000348; Wechsler D., 1997, MANUAL WECHSLER ADUL; Whitford TJ, 2007, HUM BRAIN MAPP, V28, P228, DOI 10.1002/hbm.20273; Young KA, 2008, BRIT J PSYCHIAT, V192, P285, DOI 10.1192/bjp.bp.107.039180; Zagorchev L, 2016, J NEUROTRAUM, V33, P29, DOI 10.1089/neu.2014.3831; Zarei M, 2010, NEUROIMAGE, V49, P1, DOI 10.1016/j.neuroimage.2009.09.001; Zhao YJ, 2014, PSYCHOL MED, V44, P2927, DOI 10.1017/S0033291714000518; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945	79	40	40	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2018	35	2					278	285		10.1089/neu.2017.5145		NOV 2017	8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FT1TA	WOS:000417126000001	28990457	Green Published			2021-06-18	
J	Squair, JW; Belanger, LM; Tsang, A; Ritchie, L; Mac-Thiong, JM; Parent, S; Christie, S; Bailey, C; Dhall, S; Street, J; Ailon, T; Paquette, S; Dea, N; Fisher, CG; Dvorak, MF; West, CR; Kwon, BK				Squair, Jordan W.; Belanger, Lise M.; Tsang, Angela; Ritchie, Leanna; Mac-Thiong, Jean-Marc; Parent, Stefan; Christie, Sean; Bailey, Christopher; Dhall, Sanjay; Street, John; Ailon, Tamir; Paquette, Scott; Dea, Nicolas; Fisher, Charles G.; Dvorak, Marcel F.; West, Christopher R.; Kwon, Brian K.			Spinal cord perfusion pressure predicts neurologic recovery in acute spinal cord injury	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; INTRASPINAL PRESSURE; BLOOD-FLOW; MANAGEMENT; COMPRESSION; GUIDELINES; TRIAL	Objective:To determine whether spinal cord perfusion pressure (SCPP) as measured with a lumbar intrathecal catheter is a more predictive measure of neurologic outcome than the conventionally measured mean arterial pressure (MAP).Methods:A total of 92 individuals with acute spinal cord injury were enrolled in this multicenter prospective observational clinical trial. MAP and CSF pressure (CSFP) were monitored during the first week postinjury. Neurologic impairment was assessed at baseline and at 6 months postinjury. We used logistic regression, systematic iterations of relative risk, and Cox proportional hazard models to examine hemodynamic patterns commensurate with neurologic outcome.Results:We found that SCPP (odds ratio 1.039, p = 0.002) is independently associated with positive neurologic recovery. The relative risk for not recovering neurologic function continually increased as individuals were exposed to SCPP below 50 mm Hg. Individuals who improved in neurologic grade dropped below SCPP of 50 mm Hg fewer times than those who did not improve (p = 0.012). This effect was not observed for MAP or CSFP. Those who were exposed to SCPP below 50 mm Hg were less likely to improve from their baseline neurologic impairment grade (p = 0.0056).Conclusions:We demonstrate that maintaining SCPP above 50 mm Hg is a strong predictor of improved neurologic recovery following spinal cord injury. This suggests that SCPP (the difference between MAP and CSFP) can provide useful information to guide the hemodynamic management of patients with acute spinal cord injury.	[Squair, Jordan W.; Dvorak, Marcel F.; West, Christopher R.; Kwon, Brian K.] Univ British Columbia, ICORD, Vancouver, BC, Canada; [Squair, Jordan W.] Univ British Columbia, MD PhD Training Program, Vancouver, BC, Canada; [Street, John; Fisher, Charles G.; Dvorak, Marcel F.; Kwon, Brian K.] Univ British Columbia, Dept Orthopaed, Vancouver, BC, Canada; [Ailon, Tamir; Paquette, Scott; Dea, Nicolas] Univ British Columbia, Div Neurosurg, Vancouver, BC, Canada; [West, Christopher R.] Univ British Columbia, Vancouver Spine Surg Inst, Blusson Spinal Cord Ctr, Vancouver, BC, Canada; [West, Christopher R.] Univ British Columbia, Sch Kinesiol, Vancouver, BC, Canada; [Belanger, Lise M.; Tsang, Angela; Ritchie, Leanna] Vancouver Gen Hosp, Vancouver Spine Program, Vancouver, BC, Canada; [Mac-Thiong, Jean-Marc; Parent, Stefan] Univ Montreal, Dept Surg, Hop Sacre Coeur Montreal, Montreal, PQ, Canada; [Christie, Sean] Univ Montreal, Chu St Justine, Dept Surg, Montreal, PQ, Canada; [Bailey, Christopher] Univ Western Ontario, Div Orthopaed Surg, London Hlth Sci Ctr, London, ON, Canada; [Dhall, Sanjay] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA	Kwon, BK (corresponding author), Univ British Columbia, ICORD, Vancouver, BC, Canada.; Kwon, BK (corresponding author), Univ British Columbia, Dept Orthopaed, Vancouver, BC, Canada.	brian.kwon@ubc.ca	Parent, Stefan/AAO-7492-2020; West, Christopher/I-4677-2013; Bailey, Chris S/L-7522-2015	Parent, Stefan/0000-0002-4854-2816; Bailey, Chris S/0000-0001-5508-8415; Christie, Sean/0000-0002-3540-6022; West, Christopher/0000-0002-0815-4122; Squair, Jordan/0000-0003-0551-859X; Dvorak, Marcel/0000-0002-9404-8448	Rick Hansen Institute; Vancouver Coastal Health Research Institute (VCHRI); Michael Smith Foundation for Health Research (MSFHR)Michael Smith Foundation for Health Research; Frederick Banting and Charles Best Doctoral Canada Graduate Scholarship; VCH-UBC MD/PhD Studentship from the Canadian Institutes of Health Research; Killam Doctoral Scholarship; UBC	Funding for this clinical trial was primarily received from the Rick Hansen Institute. Additional funds were received from the Vancouver Coastal Health Research Institute (VCHRI) and Michael Smith Foundation for Health Research (MSFHR). J.W.S. is supported by a Frederick Banting and Charles Best Doctoral Canada Graduate Scholarship, a VCH-UBC MD/PhD Studentship from the Canadian Institutes of Health Research, a Killam Doctoral Scholarship, and a Four Year Fellowship from the UBC. M.F.D. is the Paetzold Chair in Spinal Cord Research. C.R.W. is a Scholar of the MSFHR. B.K.K. is the Canada Research Chair in Spinal Cord Injury.	Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Fawcett JW, 2007, SPINAL CORD, V45, P190, DOI 10.1038/sj.sc.3102007; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GRIFFITHS IR, 1978, NEUROLOGY, V28, P1145, DOI 10.1212/WNL.28.11.1145; Hawryluk G, 2015, J NEUROTRAUM, V32, P1958, DOI 10.1089/neu.2014.3778; Inoue T, 2014, J NEUROTRAUM, V31, P284, DOI 10.1089/neu.2013.3061; Jones CF, 2012, SPINE, V37, pE1422, DOI 10.1097/BRS.0b013e31826ba7cd; Kirshblum SC, 2011, J SPINAL CORD MED, V34, P547, DOI 10.1179/107902611X13186000420242; Kwon BK, 2009, J NEUROSURG-SPINE, V10, P181, DOI 10.3171/2008.10.SPINE08217; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Melhem S, 2014, CRIT CARE, V18, DOI 10.1186/cc13713; Phang I, 2015, NEUROCRIT CARE, V23, P414, DOI 10.1007/s12028-015-0153-6; Ploumis A, 2010, SPINAL CORD, V48, P356, DOI 10.1038/sc.2009.150; Readdy WJ, 2016, NEUROSURGERY, V79, P708, DOI 10.1227/NEU.0000000000001249; ROBERTSON CS, 1992, J NEUROTRAUM, V9, pS349; Ryken TC, 2013, NEUROSURGERY, V72, P84, DOI 10.1227/NEU.0b013e318276ee16; Saadoun S, 2017, J NEUROL NEUROSUR PS, V88, P452, DOI 10.1136/jnnp-2016-314600; Vale FL, 1997, J NEUROSURG, V87, P239, DOI 10.3171/jns.1997.87.2.0239; VON EE, 2008, GACETA, V61, P344, DOI DOI 10.1016/J.JCLINEPI.2007.11.008; Walters BC, 2013, NEUROSURGERY, V60, P82, DOI 10.1227/01.neu.0000430319.32247.7f	20	40	42	3	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	OCT 17	2017	89	16					1660	1667		10.1212/WNL.0000000000004519			8	Clinical Neurology	Neurosciences & Neurology	FN4BB	WOS:000415946300009	28916535				2021-06-18	
J	King, LA; Mancini, M; Fino, PC; Chesnutt, J; Swanson, CW; Markwardt, S; Chapman, JC				King, Laurie A.; Mancini, Martina; Fino, Peter C.; Chesnutt, James; Swanson, Clayton W.; Markwardt, Sheila; Chapman, Julie C.			Sensor-Based Balance Measures Outperform Modified Balance Error Scoring System in Identifying Acute Concussion	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Concussion; mTBI; Balance; BESS; Postural sway; Brain injury; Inertial sensors	POSTURAL CONTROL; INTERNATIONAL-CONFERENCE; CEREBRAL CONCUSSION; CONSENSUS STATEMENT; PARKINSONS-DISEASE; FOOTBALL PLAYERS; BRAIN-INJURY; HIGH-SCHOOL; SPORT HELD; GAIT	Balance assessment is an integral component of concussion evaluation and management. Although the modified balance error scoring system (mBESS) is the conventional clinical tool, objective metrics derived from wearable inertial sensors during the mBESS may increase sensitivity in detecting subtle balance deficits post-concussion. The aim of this study was to identify which stance condition and postural sway metrics obtained from an inertial sensor placed on the lumbar spine during the mBESS best discriminate athletes with acute concussion. Fifty-two college athletes in the acute phase of concussion and seventy-six controls participated in this study. Inertial sensor-based measures objectively detected group differences in the acutely concussed group of athletes while the clinical mBESS did not (p < 0.001 and p = 0.06, respectively). Mediolateral postural sway during the simplest condition of the mBESS (double stance) best classified those with acute concussion. Inertial sensors provided a sensitive and objective measure of balance in acute concussion. These results may be developed into practical guidelines to improve and simplify postural sway analysis post-concussion.	[King, Laurie A.; Mancini, Martina; Fino, Peter C.; Swanson, Clayton W.] Oregon Hlth & Sci Univ, Sch Med, Dept Neurol, Parkinson Ctr Oregon, OP32,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA; [Chesnutt, James] Oregon Hlth & Sci Univ, Sch Med, Dept Orthoped & Rehabil, Portland, OR 97201 USA; [Markwardt, Sheila] Oregon Hlth & Sci Univ, Sch Med, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA; [Chapman, Julie C.] Vet Affairs Med Ctr, Dept Neurol, 50 Irving St NW, Washington, DC 20422 USA; [Chapman, Julie C.] Georgetown Univ, Sch Med, Dept Neurol, Washington, DC USA	King, LA (corresponding author), Oregon Hlth & Sci Univ, Sch Med, Dept Neurol, Parkinson Ctr Oregon, OP32,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	kingla@ohsu.edu	Swanson, Clayton W./AAU-1280-2020	Mancini, Martina/0000-0002-4532-3984; Fino, Peter/0000-0002-8621-3706; Swanson, Clayton/0000-0002-2163-610X	Oregon Clinical and Translational Research Institute from the National Center for Advancing Translational Sciences at the National Institutes of Health (NIH) [KL2TR000152]; Eunice Kennedy Shriver National Institute of Child Health & Human Development of the NIH [R21HD080398];  [UL1TR000128]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD080398] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR000152, UL1TR000128] Funding Source: NIH RePORTER	This project was supported by the Oregon Clinical and Translational Research Institute (KL2TR000152) from the National Center for Advancing Translational Sciences at the National Institutes of Health (NIH); (UL1TR000128) and Eunice Kennedy Shriver National Institute of Child Health & Human Development of the NIH under Award Number (R21HD080398). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The authors would like to thank all of the participating universities and athletic trainers who contributed to recruitment of subjects and athletes for their participation. All inertial sensor data presented in this paper was obtained using APDM wearable technologies. The results of this study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data manipulation.	Bauer CM, 2016, Z GERONTOL GERIATR, V49, P232, DOI 10.1007/s00391-015-0885-0; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Brown HJ, 2014, MED SCI SPORT EXER, V46, P1610, DOI 10.1249/MSS.0000000000000263; CARROLL JP, 1993, J BIOMECH, V26, P409, DOI 10.1016/0021-9290(93)90004-X; Catena RD, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-25; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Denke NJ, 2008, J EMERG NURS, V34, P363, DOI 10.1016/j.jen.2008.04.013; Doherty C, 2017, HUM MOVEMENT SCI, V52, P160, DOI 10.1016/j.humov.2017.02.005; Doherty C, 2017, CLIN BIOMECH, V42, P79, DOI 10.1016/j.clinbiomech.2017.01.007; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Fino PC, 2016, GAIT POSTURE, V50, P69, DOI 10.1016/j.gaitpost.2016.08.026; Fino PC, 2016, J BIOMECH, V49, P1983, DOI 10.1016/j.jbiomech.2016.05.004; Fox ZG, 2008, J ATHL TRAINING, V43, P456, DOI 10.4085/1062-6050-43.5.456; Furman GR, 2013, AM J SPORT MED, V41, P1404, DOI 10.1177/0363546513484446; Gao JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024446; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Haran FJ, 2016, J NEUROTRAUM, V33, P705, DOI 10.1089/neu.2015.4060; Horak F, 2015, PHYS THER, V95, P461, DOI 10.2522/ptj.20140253; Howell D, 2015, J BIOMECH, V48, P3364, DOI 10.1016/j.jbiomech.2015.06.014; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Hufschmidt A., 1970, ARCH PSYCHIAT NERVEN, V228, P135; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; Iverson GL, 2013, BRAIN INJURY, V27, P596, DOI 10.3109/02699052.2013.772237; Kelly KC, 2014, J ATHL TRAINING, V49, P665, DOI 10.4085/1062-6050-49.3.25; King LA, 2014, ARCH PHYS MED REHAB, V95, P353, DOI 10.1016/j.apmr.2013.10.015; Liaw A., 2002, R NEWS, V2, P18, DOI DOI 10.1177/154405910408300516; Mak MK, 2003, ARCH PHYS MED REHAB, V84, P683, DOI 10.1016/S0003-9993(03)04810-4; MAKI BE, 1991, J GERONTOL, V46, pM123, DOI 10.1093/geronj/46.4.M123; Mancini Martina, 2011, J Bioeng Biomed Sci, VSuppl 1, P007; Mancini M, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-59; Mancini M, 2011, PARKINSONISM RELAT D, V17, P557, DOI 10.1016/j.parkreldis.2011.05.010; Maurer C, 2005, J NEUROPHYSIOL, V93, P189, DOI 10.1152/jn.00221.2004; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Melzer I, 2010, CLIN BIOMECH, V25, P984, DOI 10.1016/j.clinbiomech.2010.07.007; Miyashita T. L., 2017, SPORTS HEALTH; Mulligan IJ, 2013, SPORTS HEALTH, V5, P22, DOI 10.1177/1941738112467755; O'Connor SM, 2009, J NEUROPHYSIOL, V102, P1411, DOI 10.1152/jn.00131.2009; Parker TM, 2008, MED ENG PHYS, V30, P959, DOI 10.1016/j.medengphy.2007.12.006; Powers KC, 2014, GAIT POSTURE, V39, P611, DOI 10.1016/j.gaitpost.2013.05.026; Prieto TE, 1996, IEEE T BIO-MED ENG, V43, P956, DOI 10.1109/10.532130; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rocchi L, 2004, MED BIOL ENG COMPUT, V42, P71, DOI 10.1007/BF02351013; Rocchi L, 2002, J NEUROL NEUROSUR PS, V73, P267, DOI 10.1136/jnnp.73.3.267; Runkle D., 2010, COMMUNICATION, V29; Schatz P, 2011, CLIN NEUROPSYCHOL, V25, P1042, DOI 10.1080/13854046.2011.556669; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Stel VS, 2003, J CLIN EPIDEMIOL, V56, P659, DOI 10.1016/S0895-4356(03)00082-9; Whitney SL, 2011, GAIT POSTURE, V33, P594, DOI 10.1016/j.gaitpost.2011.01.015; Wilkins JC, 2004, J ATHL TRAINING, V39, P156; Winter DA, 1996, J NEUROPHYSIOL, V75, P2334; Zatsiorsky VM, 1999, MOTOR CONTROL, V3, P28, DOI 10.1123/mcj.3.1.28	57	40	40	2	19	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	SEP	2017	45	9					2135	2145		10.1007/s10439-017-1856-y			11	Engineering, Biomedical	Engineering	FE4QF	WOS:000408197700008	28540448	Green Accepted			2021-06-18	
J	Wright, DK; Liu, SJ; van der Poel, C; McDonald, SJ; Brady, RD; Taylor, L; Yang, L; Gardner, AJ; Ordidge, R; O'Brien, TJ; Johnston, LA; Shultz, SR				Wright, David K.; Liu, Shijie; van der Poel, Chris; McDonald, Stuart J.; Brady, Rhys D.; Taylor, Lily; Yang, Li; Gardner, Andrew J.; Ordidge, Roger; O'Brien, Terence J.; Johnston, Leigh A.; Shultz, Sandy R.			Traumatic Brain Injury Results in Cellular, Structural and Functional Changes Resembling Motor Neuron Disease	CEREBRAL CORTEX			English	Article						amyotrophic lateral sclerosis; MRI; animal model; TDP-43; neurodegeneration	AMYOTROPHIC-LATERAL-SCLEROSIS; VOXEL-BASED MORPHOMETRY; TRANSGENIC MOUSE MODEL; WHITE-MATTER INTEGRITY; CORTICOSPINAL TRACT; HEAD-INJURY; MUSCLE-FIBERS; DIFFUSION MRI; ALS; TDP-43	Traumatic brain injury (TBI) has been suggested to increase the risk of amyotrophic lateral sclerosis (ALS). However, this link remains controversial and as such, here we performed experimental moderate TBI in rats and assessed for the presence of ALS-like pathological and functional abnormalities at both 1 and 12 weeks post-injury. Serial in-vivo magnetic resonance imaging (MRI) demonstrated that rats given a TBI had progressive atrophy of the motor cortices and degeneration of the corticospinal tracts compared with sham-injured rats. Immunofluorescence analyses revealed a progressive reduction in neurons, as well as increased phosphorylated transactive response DNA-binding protein 43 (TDP-43) and cytoplasmic TDP-43, in the motor cortex of rats given a TBI. Rats given a TBI also had fewer spinal cord motor neurons, increased expression of muscle atrophy markers, and altered muscle fiber contractile properties compared with sham-injured rats at 12 weeks, but not 1 week, post-injury. All of these changes occurred in the presence of persisting motor deficits. These findings resemble some of the pathological and functional abnormalities common in ALS and support the notion that TBI can result in a progressive neurodegenerative disease process pathologically bearing similarities to a motor neuron disease.	[Wright, David K.; Ordidge, Roger] Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic 3010, Australia; [Wright, David K.; Johnston, Leigh A.] Florey Inst Neurosci & Mental Hlth, Anim Imaging Facil, Parkville, Vic 3052, Australia; [Liu, Shijie; Taylor, Lily; Yang, Li; O'Brien, Terence J.; Shultz, Sandy R.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3052, Australia; [van der Poel, Chris; McDonald, Stuart J.; Brady, Rhys D.] La Trobe Univ, Dept Physiol Anat & Microbiol, Melbourne, Vic 3086, Australia; [Yang, Li] Kunming Med Univ, Dept Histol & Embryol, Kunming 650000, Yunnan, Peoples R China; [Gardner, Andrew J.] Univ Newcastle, Dept Med & Publ Hlth, Ctr Translat Neurosci & Mental Hlth, Callaghan, NSW 2308, Australia; [Johnston, Leigh A.] Univ Melbourne, Dept Elect & Elect Engn, Parkville, Vic 3010, Australia	Shultz, SR (corresponding author), Univ Melbourne, Dept Med, Off 1-02,Kenneth Myer Bldg, Parkville, Vic 3052, Australia.	sshultz@unimelb.edu.au	Johnston, Leigh A/D-7102-2014	Johnston, Leigh A/0000-0002-5032-4674; O'Brien, Terence/0000-0002-7198-8621; McDonald, Stuart/0000-0001-5190-3179; Wright, David/0000-0002-7535-8651; Ordidge, Roger/0000-0002-1005-3654	Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR); Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [1062653, 1006077]; Victorian Neurotrauma Initiative project [DNP13]; Motor Neurone Disease Research Institute of Australia	This work was supported by a fellowship to SS from the Canadian Institute of Health Research, and grants to SS and TOB from the Australian National Health and Medical Research Council (grant numbers 1062653, 1006077), the Victorian Neurotrauma Initiative project (grant number DNP13), and Motor Neurone Disease Research Institute of Australia.	Agosta F, 2010, AM J NEURORADIOL, V31, P1457, DOI 10.3174/ajnr.A2105; Agosta F, 2009, AMYOTROPH LATERAL SC, V10, P168, DOI 10.1080/17482960802603841; Alves CJ, 2011, BRAIN RES, V1394, P90, DOI 10.1016/j.brainres.2011.02.060; Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; Armon C, 2012, AMYOTROPH LATERAL SC, V13, P351, DOI 10.3109/17482968.2012.660954; Atkin JD, 2005, NEUROMUSCULAR DISORD, V15, P377, DOI 10.1016/j.nmd.2005.02.005; Avants BB, 2011, NEUROIMAGE, V54, P2033, DOI 10.1016/j.neuroimage.2010.09.025; Avants BB, 2010, NEUROIMAGE, V49, P2457, DOI 10.1016/j.neuroimage.2009.09.062; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; Barneoud P, 1997, NEUROREPORT, V8, P2861, DOI 10.1097/00001756-199709080-00012; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Canu E, 2011, AM J NEURORADIOL, V32, P1307, DOI 10.3174/ajnr.A2469; Chang JL, 2005, NEUROLOGY, V65, P75, DOI 10.1212/01.wnl.0000167602.38643.29; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; CHIU AY, 1995, MOL CELL NEUROSCI, V6, P349, DOI 10.1006/mcne.1995.1027; Ciccarelli O, 2009, HUM BRAIN MAPP, V30, P615, DOI 10.1002/hbm.20527; Cirillo M, 2012, AM J NEURORADIOL, V33, P1102, DOI 10.3174/ajnr.A2918; Cosottini M, 2005, RADIOLOGY, V237, P258, DOI 10.1148/radiol.2371041506; Cosottini M, 2010, J COMPUT ASSIST TOMO, V34, P746, DOI 10.1097/RCT.0b013e3181e35129; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Evans TM, 2015, NEUROSCIENCE, V298, P410, DOI 10.1016/j.neuroscience.2015.04.041; Ferraiuolo L, 2011, NAT REV NEUROL, V7, P616, DOI 10.1038/nrneurol.2011.152; Fischer LR, 2004, EXP NEUROL, V185, P232, DOI 10.1016/j.expneurol.2003.10.004; Fournier CN, 2015, NEUROLOGY, V84, P1788, DOI 10.1212/WNL.0000000000001522; Frakes AE, 2014, NEURON, V81, P1009, DOI 10.1016/j.neuron.2014.01.013; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hong YH, 2008, J NEUROIMAGING, V18, P282, DOI 10.1111/j.1552-6569.2007.00153.x; Horner RD, 2003, NEUROLOGY, V61, P742, DOI 10.1212/01.WNL.0000069922.32557.CA; Johnson VE, 2011, ACTA NEUROPATHOL, V122, P715, DOI 10.1007/s00401-011-0909-9; Johnstone VPA, 2015, J NEUROTRAUM, V32, P1333, DOI 10.1089/neu.2014.3785; Jones DK, 2013, NEUROIMAGE, V73, P239, DOI 10.1016/j.neuroimage.2012.06.081; Kassubek J, 2005, AMYOTROPH LATERAL SC, V6, P213, DOI 10.1080/14660820510038538; Keihaninejad S, 2013, NEUROIMAGE, V72, P153, DOI 10.1016/j.neuroimage.2013.01.044; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Kiernan MC, 2011, LANCET, V377, P942, DOI 10.1016/S0140-6736(10)61156-7; Kim HJ, 2014, NAT GENET, V46, P152, DOI 10.1038/ng.2853; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Lee EB, 2012, NAT REV NEUROSCI, V13, P38, DOI 10.1038/nrn3121; Leger B, 2006, FASEB J, V20, P583, DOI 10.1096/fj.05-5249fje; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Lynch GS, 2000, AM J PHYSIOL-CELL PH, V279, pC1290; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Moreno-Igoa M, 2010, J MOL MED, V88, P297, DOI 10.1007/s00109-009-0556-y; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Peters TL, 2013, AMYOTROPH LAT SCL FR, V14, P267, DOI 10.3109/21678421.2012.754043; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Prudlo J, 2012, J NEUROL, V259, P1848, DOI 10.1007/s00415-012-6420-y; Ravits J, 2007, NEUROLOGY, V68, P1576, DOI 10.1212/01.wnl.0000261045.57095.56; Robberecht W, 2013, NAT REV NEUROSCI, V14, P248, DOI 10.1038/nrn3430; Roccatagliata L, 2009, AMYOTROPH LATERAL SC, V10, P47, DOI 10.1080/17482960802267530; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rothstein JD, 2009, ANN NEUROL, V65, pS3, DOI 10.1002/ana.21543; Sage CA, 2009, HUM BRAIN MAPP, V30, P3657, DOI 10.1002/hbm.20794; Schmidt S, 2010, J NEUROL SCI, V291, P22, DOI 10.1016/j.jns.2010.01.011; Seals RM, 2016, AM J EPIDEMIOL, V183, P294, DOI 10.1093/aje/kwv169; Senda J, 2011, AMYOTROPH LATERAL SC, V12, P59, DOI 10.3109/17482968.2010.517850; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; Shultz SR, 2015, BRAIN, V138, P1297, DOI 10.1093/brain/awv053; Shultz SR, 2014, J NEUROTRAUM, V31, P976, DOI 10.1089/neu.2013.3106; Shultz SR, 2014, NEUROTHERAPEUTICS, V11, P347, DOI 10.1007/s13311-014-0258-1; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Tournier JD, 2007, NEUROIMAGE, V35, P1459, DOI 10.1016/j.neuroimage.2007.02.016; Turner MR, 2007, AMYOTROPH LATERAL SC, V8, P343, DOI 10.1080/17482960701538734; Ueyama H, 1998, J NEUROL SCI, V155, P163, DOI 10.1016/S0022-510X(97)00309-2; Wang HK, 2015, NEUROSCIENCE, V300, P94, DOI 10.1016/j.neuroscience.2015.05.013; Wang M.D, 2016, NEUROTOXICOLOGY; Washington PM, 2016, EXP NEUROL, V275, P381, DOI 10.1016/j.expneurol.2015.06.015; Weisskopf MG, 2005, NEUROLOGY, V64, P32, DOI 10.1212/01.WNL.0000148649.17706.D9; WILLIAMS DA, 1993, J PHYSIOL-LONDON, V460, P51, DOI 10.1113/jphysiol.1993.sp019458; Yang ZH, 2014, J CEREBR BLOOD F MET, V34, P1444, DOI 10.1038/jcbfm.2014.105; Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015; Zang DW, 2002, NEUROSCI LETT, V332, P99, DOI 10.1016/S0304-3940(02)00944-8; Zhang JQ, 2014, J NEUROL, V261, P412, DOI 10.1007/s00415-013-7215-5	82	40	40	0	14	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1047-3211	1460-2199		CEREB CORTEX	Cereb. Cortex	SEP	2017	27	9					4503	4515		10.1093/cercor/bhw254			13	Neurosciences	Neurosciences & Neurology	FD9MY	WOS:000407847800017	27566977	Bronze			2021-06-18	
J	Johnson, MA; Williams, TK; Ferencz, SAE; Davidson, AJ; Russo, RM; O'Brien, WT; Galante, JM; Grayson, JK; Neff, LP				Johnson, M. Austin; Williams, Timothy K.; Ferencz, Sarah-Ashley E.; Davidson, Anders J.; Russo, Rachel M.; O'Brien, William T., Sr.; Galante, Joseph M.; Grayson, J. Kevin; Neff, Lucas P.			The effect of resuscitative endovascular balloon occlusion of the aorta, partial aortic occlusion and aggressive blood transfusion on traumatic brain injury in a swine multiple injuries model	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	30th Annual Scientific Assembly of the Eastern-Association-for-the-Surgery-of-Trauma (EAST)	JAN 09-14, 2017	Hollywood, FL	Eastern Assoc Surg Trauma		Traumatic brain injury; shock; endovascular; resuscitation; intra-aortic balloon	CEREBRAL PERFUSION; HEMORRHAGIC-SHOCK; PORCINE MODEL; HEAD-INJURY; INTRACRANIAL-PRESSURE; TORSO HEMORRHAGE; SPINAL-CORD; REBOA; MORTALITY; IMPACT	BACKGROUND: Despite clinical reports of poor outcomes, the degree to which resuscitative endovascular balloon occlusion of the aorta (REBOA) exacerbates traumatic brain injury (TBI) is not known. We hypothesized that combined effects of increased proximal mean arterial pressure (pMAP), carotid blood flow (Qcarotid), and intracranial pressure (ICP) from REBOA would lead to TBI progression compared with partial aortic occlusion (PAO) or no intervention. METHODS: Twenty-one swine underwent a standardized TBI via computer Controlled cortical impact followed by 25% total blood volume rapid hemorrhage. After 30 minutes of hypotension, animals were randomized to 60 minutes of continued hypotension (Control), REBOA, or PAO. REBOA and PAO animals were then weaned from occlusion. All animals were resuscitated with shed blood via a rapid blood infuser. Physiologic parameters were recorded continuously and brain computed tomography obtained at specified intervals. RESULTS: There were no differences in baseline physiology or during the initial 30 minutes of hypotension. During the 60-minute intervention period, REBOA resulted in higher maximal pMAP (REBOA, 105.3 +/- 8.8; PAO, 92.7 +/- 9.2; Control, 48.9 +/- 7.7; p = 0.02) and higher Qcarotid (REBOA, 673.1 +/- 57.9; PAO, 464.2 +/- 53.0; Control, 170.3 +/- 29.4; p < 0.01). Increases in ICP were greatest during blood resuscitation, with Control animals demonstrating the largest peak ICP (Control, 12.8 +/- 1.2; REBOA, 5.1 +/- 0.6; PAO, 9.4 +/- 1.1; p < 0.01). There were no differences in the percentage of animals with hemorrhage progression on CT (Control, 14.3%; 95% confidence interval [CI], 3.6-57.9; REBOA, 28.6%; 95% CI, 3.7-71.0; and PAO, 28.6%; 95% CI, 3.7-71.0). CONCLUSION: In an animal model of TBI and shock, REBOA increased Qcarotid and pMAP, but did not exacerbate TBI progression. PAO resulted in physiology closer to baseline with smaller increases in ICP and pMAP. Rapid blood resuscitation, not REBOA, resulted in the largest increase in ICP after intervention, which occurred in Control animals. Continued studies of the cerebral hemodynamics of aortic occlusion and blood transfusion are required to determine optimal resuscitation strategies for multi-injured patients.Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.	[Johnson, M. Austin] UC Davis Med Ctr, Dept Emergency Med, 2315 Stockton Blvd,4150 V St Suite 2100, Sacramento, CA 95817 USA; [Johnson, M. Austin; Williams, Timothy K.; Ferencz, Sarah-Ashley E.; Davidson, Anders J.; Russo, Rachel M.; Grayson, J. Kevin; Neff, Lucas P.] David Grant Med Ctr, Clin Invest Facil, Travis Afb, CA USA; [Williams, Timothy K.] David Grant Med Ctr, Heart Lung & Vasc Ctr, Travis Afb, CA USA; [Ferencz, Sarah-Ashley E.; Davidson, Anders J.; Russo, Rachel M.; Galante, Joseph M.] UC Davis Med Ctr, Dept Surg, Sacramento, CA USA; [Ferencz, Sarah-Ashley E.] Wright State Univ, Dept Surg, Boonshoft Sch Med, Miami Valley Hosp, Dayton, OH 45435 USA; [O'Brien, William T., Sr.] David Grant Med Ctr, Dept Radiol, Travis Afb, CA USA; [Neff, Lucas P.] Emory Univ, Sch Med, Dept Surg, Div Pediat Surg, Atlanta, GA 30322 USA	Johnson, MA (corresponding author), UC Davis Med Ctr, Dept Emergency Med, 2315 Stockton Blvd,4150 V St Suite 2100, Sacramento, CA 95817 USA.	ausjohnson@ucdavis.edu		Rasmussen, Todd/0000-0003-1120-4116	National Heart, Lung and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K12HL108964]; National Center for Advancing Translational Sciences, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000002, TL1 TR000133]; Clinical Investigation Facility, David Grant Medical Center; Travis Air Force Base, California; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001860] Funding Source: NIH RePORTER	There are no personal conflicts of interest. Dr. Johnson is the recipient of a training grant from the National Heart, Lung and Blood Institute: K12HL108964. This project was partly supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through grant number UL1 TR000002 and TL1 TR000133. The Clinical Investigation Facility, David Grant Medical Center, Travis Air Force Base, California provided funding for this study.	Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Barmparas G, 2014, J TRAUMA ACUTE CARE, V77, P592, DOI 10.1097/TA.0000000000000382; Batchinsky A, 2015, 45 ANN M W TRAUM ASS; Biffl WL, 2015, J TRAUMA ACUTE CARE, V78, P1054, DOI 10.1097/TA.0000000000000609; Butcher I, 2007, J NEUROTRAUM, V24, P294, DOI 10.1089/neu.2006.0032; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Czosnyka M, 2006, ACTA NEUROCHIR SUPPL, V96, P114; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Fortuna G, 2016, J TRAUMA ACUTE CARE, V81, P63, DOI 10.1097/TA.0000000000000996; Fuller G, 2014, INJURY, V45, P612, DOI 10.1016/j.injury.2013.09.008; Hambly PR, 1996, RESUSCITATION, V31, P127, DOI 10.1016/0300-9572(95)00910-8; Hammer M, 2009, CEREBROVASC DIS, V28, P406, DOI 10.1159/000235628; Holcomb JB, 2014, J TRAUMA ACUTE CARE, V76, P888, DOI 10.1097/TA.0000000000000133; Johnson MA, 2016, J TRAUMA ACUTE CARE, V81, pS133, DOI 10.1097/TA.0000000000001146; Juratli TA, 2014, J NEUROTRAUM, V31, P1521, DOI 10.1089/neu.2013.3241; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Lylyk P, 2005, NEUROL RES, V27, pS129, DOI 10.1179/016164105X35512; Malone DL, 2003, J TRAUMA, V54, P898, DOI 10.1097/01.TA.0000060261.10597.5C; Markov NP, 2013, SURGERY, V153, P848, DOI 10.1016/j.surg.2012.12.001; Miller J D, 1972, Prog Brain Res, V35, P411; Norii T, 2015, J TRAUMA ACUTE CARE, V78, P721, DOI 10.1097/TA.0000000000000578; Ogura T, 2015, J TRAUMA ACUTE CARE, V78, P132, DOI 10.1097/TA.0000000000000473; Park TS, 2015, J TRAUMA ACUTE CARE, V79, P930, DOI 10.1097/TA.0000000000000877; Prathep S, 2014, CRIT CARE MED, V42, P142, DOI 10.1097/CCM.0b013e318298a890; Riskin DJ, 2009, J AM COLL SURGEONS, V209, P198, DOI 10.1016/j.jamcollsurg.2009.04.016; Russo RM, 2016, SHOCK, V46, P12, DOI 10.1097/SHK.0000000000000641; Russo RM, 2016, J AM COLL SURGEONS, V223, P359, DOI 10.1016/j.jamcollsurg.2016.04.037; Russo RM, 2016, J TRAUMA ACUTE CARE, V80, P372, DOI 10.1097/TA.0000000000000940; Sellmann T, 2012, DTSCH ARZTEBL INT, V109, P849, DOI 10.3238/arztebl.2012.0849; Shuaib A, 2011, STROKE, V42, P1680, DOI 10.1161/STROKEAHA.110.609933; Slim J., 2014, J EMERGENCY MED, V46, P602; Sondeen JL, 2007, SHOCK, V28, P426, DOI 10.1097/shk.0b013e31804a5791; Strauch JT, 2003, EUR J CARDIO-THORAC, V24, P817, DOI 10.1016/S1010-7940(03)00460-3; Symon L, 1977, Adv Exp Med Biol, V94, P775; Tsurukiri J, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0205-8; Uchino H, 2016, AM J CASE REP, V17, P810, DOI 10.12659/AJCR.900267; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; White JM, 2011, SURGERY, V150, P400, DOI 10.1016/j.surg.2011.06.010; Williams TK, 2016, J TRAUMA ACUTE CARE, V81, P294, DOI 10.1097/TA.0000000000001075; Yuan L, 2005, SPINE, V30, P483, DOI 10.1097/01.brs.0000154622.49240.ff; Zafar SN, 2011, J TRAUMA, V71, P1179, DOI 10.1097/TA.0b013e3182140d38	44	40	40	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUL	2017	83	1					61	70		10.1097/TA.0000000000001518			10	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	EY3VP	WOS:000403903100011	28632582	Green Accepted			2021-06-18	
J	Hauer, J; Houtrow, AJ				Hauer, Julie; Houtrow, Amy J.		Sect Hosp Palliative Med; Council Children Disabilities	Pain Assessment and Treatment in Children With Significant Impairment of the Central Nervous System	PEDIATRICS			English	Article							SEVERE NEUROLOGICAL IMPAIRMENT; INTRATHECAL BACLOFEN THERAPY; TOXIN TYPE-A; SEVERE COGNITIVE IMPAIRMENTS; RANDOMIZED CONTROLLED-TRIAL; PEDIATRIC PALLIATIVE CARE; IRRITABLE-BOWEL-SYNDROME; CENTRAL POSTSTROKE PAIN; SPASTIC CEREBRAL-PALSY; TRAUMATIC BRAIN-INJURY	Pain is a frequent and significant problem for children with impairment of the central nervous system, with the highest frequency and severity occurring in children with the greatest impairment. Despite the significance of the problem, this population remains vulnerable to underrecognition and undertreatment of pain. Barriers to treatment may include uncertainty in identifying pain along with limited experience and fear with the use of medications for pain treatment. Behavioral pain-assessment tools are reviewed in this clinical report, along with other strategies for monitoring pain after an intervention. Sources of pain in this population include acute-onset pain attributable to tissue injury or inflammation resulting in nociceptive pain, with pain then expected to resolve after treatment directed at the source. Other sources can result in chronic intermittent pain that, for many, occurs on a weekly to daily basis, commonly attributed to gastroesophageal reflux, spasticity, and hip subluxation. Most challenging are pain sources attributable to the impaired central nervous system, requiring empirical medication trials directed at causes that cannot be identified by diagnostic tests, such as central neuropathic pain. Interventions reviewed include integrative therapies and medications, such as gabapentinoids, tricyclic antidepressants, alpha-agonists, and opioids. This clinical report aims to address, with evidence-based guidance, the inherent challenges with the goal to improve comfort throughout life in this vulnerable group of children.	[Hauer, Julie] Boston Childrens Hosp, Div Gen Pediat, Complex Care Serv, Boston, MA 02115 USA; [Hauer, Julie] Harvard Med Sch, Boston, MA 02115 USA; [Hauer, Julie] Seven Hills Pediat Ctr, Groton, MA 01450 USA; [Houtrow, Amy J.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Pediat Rehabil Med, Dept Phys Med & Rehabil,UPMC,Rehabil Inst, Pittsburgh, PA 15213 USA	Hauer, J (corresponding author), Boston Childrens Hosp, Div Gen Pediat, Complex Care Serv, Boston, MA 02115 USA.; Hauer, J (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Hauer, J (corresponding author), Seven Hills Pediat Ctr, Groton, MA 01450 USA.						Agrawal S., COMPLEX CILD E MAGAZ; Albright AL, 2003, J NEUROSURG, V98, P291, DOI 10.3171/jns.2003.98.2.0291; Ammerman S, 2015, PEDIATRICS, V135, pE769, DOI 10.1542/peds.2014-4147; [Anonymous], WHO GUID PHARM TREAT; Axelrod FB, 2009, PEDIATRICS, V124, P743, DOI 10.1542/peds.2008-3318; Baguley IJ, 2007, J NEUROL NEUROSUR PS, V78, P539, DOI 10.1136/jnnp.2006.096388; Baguley IJ, 2004, BRAIN INJURY, V18, P409, DOI 10.1080/02699050310001645775; Barwood S, 2000, DEV MED CHILD NEUROL, V42, P116, DOI 10.1017/S0012162200000220; Berde CB, PAIN INFANTS CHILDRE; BIERSDORFF KK, 1994, AM J MENT RETARD, V98, P619; Boldingh EJ, 2014, J PEDIATR ORTHOP B, V23, P86, DOI 10.1097/BPB.0b013e3283651a5d; Bonouvrie LA, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-175; Boyer EW, 2005, NEW ENGL J MED, V352, P1112, DOI 10.1056/NEJMra041867; Breau LM, 2004, DEV MED CHILD NEUROL, V46, P364, DOI 10.1017/S001216220400060X; Breau LM, 2003, ARCH PEDIAT ADOL MED, V157, P1219, DOI 10.1001/archpedi.157.12.1219; Breau LM, 2002, PAIN, V99, P349, DOI 10.1016/S0304-3959(02)00179-3; Breau LM, 2002, ANESTHESIOLOGY, V96, P528, DOI 10.1097/00000542-200203000-00004; BROWNE TR, 1978, NEW ENGL J MED, V299, P812; BROWNE TR, 1976, ARCH NEUROL-CHICAGO, V33, P326, DOI 10.1001/archneur.1976.00500050012003; Bruera Eduardo, 2002, J Palliat Med, V5, P127, DOI 10.1089/10966210252785097; Canavero S, CENTRAL PAIN SYNDROM; Cappuccio G, 2013, JIMD REP, V9, P113, DOI 10.1007/8904_2012_188; Carter B, 2002, J ADV NURS, V38, P449, DOI 10.1046/j.1365-2648.2002.02206.x; Center to Advance Palliative Care, ONC DAIL OR MORPH FO; Chaparro LE, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008943.pub2; Chelimsky G, 2001, CLIN AUTON RES, V11, P383, DOI 10.1007/BF02292771; Chelimsky G, 1999, CLIN PEDIATR, V38, P725, DOI 10.1177/000992289903801205; Chen-Lim ML, 2012, J PEDIATR NURS, V27, P750, DOI 10.1016/j.pedn.2012.03.023; Ciszkowski C, 2009, NEW ENGL J MED, V361, P827, DOI 10.1056/NEJMc0904266; Collin C, 2007, EUR J NEUROL, V14, P290, DOI 10.1111/j.1468-1331.2006.01639.x; Cramton REM, 2012, CURR OPIN PEDIATR, V24, P530, DOI 10.1097/MOP.0b013e328355b2c5; Crosta QR, 2014, J SPEC PEDIATR NURS, V19, P109, DOI 10.1111/jspn.12069; Croxford JL, 2003, CNS DRUGS, V17, P179, DOI 10.2165/00023210-200317030-00004; Cutter NC, 2000, ARCH PHYS MED REHAB, V81, P164, DOI 10.1016/S0003-9993(00)90135-7; Defrin R, 2006, PAIN, V124, P312, DOI 10.1016/j.pain.2006.04.031; Del Fabbro E, 2006, J PALLIAT MED, V9, P422; Delgado MR, 2010, NEUROLOGY, V74, P336, DOI 10.1212/WNL.0b013e3181cbcd2f; Delgado-Aros S, 2005, J CLIN GASTROENTEROL, V39, pS194, DOI 10.1097/01.mcg.0000156114.22598.1b; DeSantana Josimari M, 2008, Curr Rheumatol Rep, V10, P492; Devlin JW, 2009, CRIT CARE CLIN, V25, P431, DOI 10.1016/j.ccc.2009.03.003; Dickerson RN, 2003, NUTRITION, V19, P741, DOI 10.1016/S0899-9007(03)00123-0; Dickerson RN, 2002, JPEN-PARENTER ENTER, V26, P278, DOI 10.1177/0148607102026005278; Dunn HG, 2001, BRAIN DEV-JPN, V23, pS99, DOI 10.1016/S0387-7604(01)00354-0; Dworkin RH, 2007, PAIN, V132, P237, DOI 10.1016/j.pain.2007.08.033; Elawad MA, 2001, DEV MED CHILD NEUROL, V43, P829, DOI 10.1017/S0012162201001505; FDA, 2017, FDA DRUG SAF COMM FD; Feudtner C, 2013, PEDIATRICS, V132, P966, DOI 10.1542/peds.2013-2731; Finnerup NB, 2005, PAIN, V118, P289, DOI 10.1016/j.pain.2005.08.013; Foster-Barber A., 2011, NEUROPADIATRIE, V10, P20; Frese A, 2006, CLIN J PAIN, V22, P252, DOI 10.1097/01.ajp.0000173020.10483.13; Friedrichsdorf SJ, 2007, PEDIATR CLIN N AM, V54, P645, DOI 10.1016/j.pcl.2007.07.007; Gale R, 2017, JPEN-PARENTER ENTER, V41, P1366, DOI 10.1177/0148607116662970; Gardner JS, 2000, PHARMACOTHERAPY, V20, P1423, DOI 10.1592/phco.20.19.1423.34854; Gauger VT, 2009, J PEDIATR ORTHOPED, V29, P588, DOI 10.1097/BPO.0b013e3181b2ba08; Gilles EE., 2011, NEUROPADIATRIE KLIN, V10, P15; Gilron I, 2013, LANCET NEUROL, V12, P1084, DOI 10.1016/S1474-4422(13)70193-5; Gilron I, 2009, LANCET, V374, P1252, DOI 10.1016/S0140-6736(09)61081-3; Hadden KL, 2002, PAIN, V99, P281, DOI 10.1016/S0304-3959(02)00123-9; Haig GM, 2001, J CLIN PHARMACOL, V41, P507, DOI 10.1177/00912700122010384; Haney AL, 2009, PHARMACOTHERAPY, V29, P997, DOI 10.1592/phco.29.8.997; Hansel DE, 2003, PEDIATR NEUROL, V29, P203, DOI 10.1016/S0887-8994(03)00208-X; Hasler ML, 2003, GASTROENTEROL CLIN N, V32, pviii; Hasler WL, 2003, GASTROENTEROL CLIN N, V32, P707, DOI 10.1016/S0889-8553(03)00027-X; Hauer J. M., 2013, CARING CHILDREN WHO; Hauer JM., 2013, CARING CHILDREN WHO, P65; Hauer J, 2012, PROG PALLIAT CARE, V20, P349, DOI 10.1179/1743291X12Y.0000000032; Hauer JM, 2007, PEDIATRICS, V119, pE519, DOI 10.1542/peds.2006-1609; Hauer JM, 2015, J PALLIAT MED, V18, P453, DOI 10.1089/jpm.2014.0359; Hauer JM, 2015, PEDIATR PULM, V50, pE9, DOI 10.1002/ppul.23140; Hauer JM, 2014, CURR OPIN SUPPORT PA, V8, P296, DOI 10.1097/SPC.0000000000000063; Herr K, 2011, PAIN MANAG NURS, V12, P230, DOI 10.1016/j.pmn.2011.10.002; Hogan KA, 2006, J BONE JOINT SURG AM, V88A, P2624, DOI 10.2106/JBJS.E.00918; Houghton LA, 2007, GUT, V56, P1218, DOI 10.1136/gut.2006.110858; Houlihan CM, 2004, DEV MED CHILD NEUROL, V46, P305, DOI 10.1017/S0012162204000507; Hoving MA, 2009, EUR J PAEDIATR NEURO, V13, P247, DOI 10.1016/j.ejpn.2008.05.002; Huang BY, 2008, RADIOGRAPHICS, V28, P417, DOI 10.1148/rg.282075066; Hunt A, 2004, DEV MED CHILD NEUROL, V46, P9, DOI 10.1017/S0012162204000039; Hunt A, 2003, INT J NURS STUD, V40, P171, DOI 10.1016/S0020-7489(02)00058-5; Hunt A, 2007, J PAIN SYMPTOM MANAG, V33, P276, DOI 10.1016/j.jpainsymman.2006.08.011; International Association for the Study of Pain, IASP TAX; Intiso D, 2015, TOXINS, V7, P2454, DOI 10.3390/toxins7072454; Jackson N, 2008, POSTGRAD MED J, V84, P121, DOI 10.1136/pgmj.2007.062117; JAN JE, 1994, PEDIATR NEUROL, V10, P34, DOI 10.1016/0887-8994(94)90064-7; Kalachnik JE, 2003, J AUTISM DEV DISORD, V33, P349, DOI 10.1023/A:1024466819989; Kalachnik JE, 2002, AM J MENT RETARD, V107, P376, DOI 10.1352/0895-8017(2002)107<0376:BBSERA>2.0.CO;2; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Klit H, 2009, LANCET NEUROL, V8, P857, DOI 10.1016/S1474-4422(09)70176-0; Knaus A, 2009, ACTA ORTHOP, V80, P32, DOI 10.1080/17453670902804935; Koller D, 2012, J PEDIATR NURS, V27, P652, DOI 10.1016/j.pedn.2011.08.001; Kong CK, 2005, PEDIATRICS, V116, pE839, DOI 10.1542/peds.2005-1029; Korn-Merker E, 2000, EPILEPSY RES, V38, P27; Kuiken SD, 2005, ALIMENT PHARM THER, V21, P633, DOI 10.1111/j.1365-2036.2005.02392.x; Kuperminc MN, 2010, DEV MED CHILD NEUROL, V52, P824, DOI 10.1111/j.1469-8749.2010.03694.x; Lader M, 2009, CNS DRUGS, V23, P19, DOI 10.2165/0023210-200923010-00002; Lauder GR, 2005, PEDIATR ANESTH, V15, P412, DOI 10.1111/j.1460-9592.2005.01431.x; Lee GY, 2014, PEDIATRICS, V133, P500, DOI 10.1542/peds.2013-2744; Lee KJ, 2005, ALIMENT PHARM THERAP, V22, P981, DOI 10.1111/j.1365-2036.2005.02685.x; Liptak GS, 2005, MENT RETARD DEV D R, V11, P156, DOI 10.1002/mrdd.20066; Lubsch L, 2006, J CHILD NEUROL, V21, P1090, DOI 10.1177/7010.2006.00134; LUNDEBERG T, 1984, PAIN, V20, P13, DOI 10.1016/0304-3959(84)90807-8; LUNDEBERG T, 1987, SCAND J REHABIL MED, V19, P153; Lundy CT, 2009, DEV MED CHILD NEUROL, V51, P705, DOI 10.1111/j.1469-8749.2009.03315.x; Malviya S, 2006, PEDIATR ANESTH, V16, P258, DOI 10.1111/j.1460-9592.2005.01773.x; Mayell A, 2014, PEDIATR ANESTH, V24, P1239, DOI 10.1111/pan.12524; McCluggage HL, 2006, INT J PALLIAT NURS, V12, P254, DOI 10.12968/ijpn.2006.12.6.21450; Mccoy AA, 2006, ARCH PHYS MED REHAB, V87, P1503, DOI 10.1016/j.apmr.2006.07.270; Mink JW, 2013, MOVEMENT DISORD, V28, P921, DOI 10.1002/mds.25548; Moulin DE, 2014, PAIN RES MANAG, V19, P328; Mousa H, 2006, J PEDIATR GASTR NUTR, V43, P185, DOI 10.1097/01.mpg.0000228115.14111.24; Nader R, 2004, CLIN J PAIN, V20, P88, DOI 10.1097/00002508-200403000-00005; Nicholson BD, 2004, NEUROLOGY, V62, pS30, DOI 10.1212/WNL.62.5_suppl_2.S30; Nicholson B, 2008, EXPERT OPIN PHARMACO, V9, P1585, DOI 10.1517/14656566.9.9.1585 ; Nolan J, 2000, ANAESTHESIA, V55, P32, DOI 10.1046/j.1365-2044.2000.01065.x; Oberlander TF, 2001, DEV MED CHILD NEUROL, V43, P138, DOI 10.1017/S0012162201230254; Park ES, 2002, YONSEI MED J, V43, P65, DOI 10.3349/ymj.2002.43.1.65; Peebles KA, 2012, J INTELL DISABIL RES, V56, P441, DOI 10.1111/j.1365-2788.2011.01484.x; Penner M, 2013, PEDIATRICS, V132, pE407, DOI 10.1542/peds.2013-0224; Perquin CW, 2000, PAIN, V87, P51, DOI 10.1016/S0304-3959(00)00269-4; Raphael BS, 2010, CLIN ORTHOP RELAT R, V468, P1845, DOI 10.1007/s11999-009-1167-1; Rattaz C, 2013, PAIN, V154, P2007, DOI 10.1016/j.pain.2013.06.011; Renard D, 2014, BEHAV NEUROL, V2014, DOI 10.1155/2014/154631; Rieger D, 2013, DEV DISABIL RES REV, V17, P269, DOI 10.1002/ddrr.1120; Riss J, 2008, ACTA NEUROL SCAND, V118, P69, DOI 10.1111/j.1600-0404.2008.01004.x; Rivard PF, 2009, CLIN J PAIN, V25, P413, DOI 10.1097/AJP.0b013e31819a6d07; Rocker G, 2012, CAN MED ASSOC J, V184, pE497, DOI 10.1503/cmaj.111758; Roubertie A, 2012, EUR J NEUROL, V19, P1292, DOI 10.1111/j.1468-1331.2011.03649.x; Rusy LM, 2010, ANESTH ANALG, V110, P1393, DOI 10.1213/ANE.0b013e3181d41dc2; Sanger TD, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.1.e89; Seidel S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004844.pub3; Sgouros S, 2007, ACTA NEUROCHIR SUPPL, V97, P193; Siden H, 2008, PAIN CHILDREN PRACTI, P32; Siden HB, 2013, PAIN RES MANAG, V18, P243, DOI 10.1155/2013/193937; Smith H, 2001, Curr Opin Anaesthesiol, V14, P513, DOI 10.1097/00001503-200110000-00009; Smith HAB, 2011, CRIT CARE MED, V39, P150, DOI 10.1097/CCM.0b013e3181feb489; Solodiuk JC, 2014, J PAIN SYMPTOM MANAG, V48, P924, DOI 10.1016/j.jpainsymman.2014.01.006; Solodiuk JC, 2010, PAIN, V150, P231, DOI 10.1016/j.pain.2010.03.016; Stahle-oberg L., 2009, ADV PHYSIOTHERAPY, V11, P137, DOI [10.1080/14038190902906318, DOI 10.1080/14038190902906318]; Stallard P, 2002, J PEDIATR PSYCHOL, V27, P209, DOI 10.1093/jpepsy/27.2.209; Steele R, 2014, ARCH DIS CHILD, V99, P754, DOI 10.1136/archdischild-2013-305246; Strouse TB, 2009, J PALLIAT MED, V12, P1043, DOI 10.1089/jpm.2009.0127; Suedberg LE, 2008, EUR J PAEDIATR NEURO, V12, P89, DOI 10.1016/j.ejpn.2007.06.004; Suresh BSS, 2015, PEDIATR SURG INT, V31, P197, DOI 10.1007/s00383-014-3649-9; Symons FJ, 2011, NEUROSCI BIOBEHAV R, V35, P1266, DOI 10.1016/j.neubiorev.2011.01.002; Taenzer AH, 2010, PEDIATR ANESTH, V20, P135, DOI 10.1111/j.1460-9592.2009.03226.x; Tanaka E, 1999, J CLIN PHARM THER, V24, P347, DOI 10.1046/j.1365-2710.1999.00247.x; Taylor Charles P, 2004, CNS Drug Rev, V10, P183; Tomlinson D, 2010, PEDIATRICS, V126, pE1168, DOI 10.1542/peds.2010-1609; Traube C, 2014, CRIT CARE MED, V42, P656, DOI 10.1097/CCM.0b013e3182a66b76; US Department of Health And Human Services, COMM TERM CRIT ADV E; Valencia FG, 2010, ORTHOP CLIN N AM, V41, P549, DOI 10.1016/j.ocl.2010.07.002; Vernon-Roberts A, 2010, DEV MED CHILD NEUROL, V52, P1099, DOI 10.1111/j.1469-8749.2010.03789.x; Voepel-Lewis T, 2008, ANESTH ANALG, V106, P72, DOI 10.1213/01.ane.0000287680.21212.d0; Williams DG, 2002, BRIT J ANAESTH, V89, P839, DOI 10.1093/bja/aef284; Wusthoff CJ, 2007, PEDIATR CLIN N AM, V54, pxi; Wusthoff CJ, 2007, PEDIATR CLIN N AM, V54, P709, DOI 10.1016/j.pcl.2007.06.004; Zangen T, 2003, J PEDIATR GASTR NUTR, V37, P287, DOI 10.1097/00005176-200309000-00016; Zernikow Boris, 2009, Paediatr Drugs, V11, P129, DOI 10.2165/00148581-200911020-00004; Zier JL, 2008, DEV MED CHILD NEUROL, V50, P854, DOI 10.1111/j.1469-8749.2008.03069.x	158	40	41	0	6	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUN	2017	139	6							e20171002	10.1542/peds.2017-1002			27	Pediatrics	Pediatrics	EW5HJ	WOS:000402536100061	28562301	Bronze			2021-06-18	
J	McMillan, TM; McSkimming, P; Wainman-Lefley, J; Maclean, LM; Hay, J; McConnachie, A; Stewart, W				McMillan, T. M.; McSkimming, P.; Wainman-Lefley, J.; Maclean, L. M.; Hay, J.; McConnachie, A.; Stewart, W.			Long-term health outcomes after exposure to repeated concussion in elite level: rugby union players	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; PROFESSIONAL FOOTBALL PLAYERS; SELF-REPORTED CONCUSSIONS; MILD COGNITIVE IMPAIRMENT; HEAD-INJURY; RECURRENT CONCUSSION; LEAGUE PLAYERS; BRAIN-INJURY; DIAGNOSIS; SYMPTOMS	Background There is continuing concern about effects of concussion in athletes, including risk of the neurodegenerative disease chronic traumatic encephalopathy. However, information on long-term health and wellbeing in former athletes is limited. Method Outcome after exposure to repeated brain injury was investigated in 52 retired male Scottish international rugby players (RIRP) and 29 male controls who were similar in age and social deprivation. Assessment included history of playing rugby and traumatic brain injury, general and mental health, life stress, concussion symptoms, cognitive function, disability and markers of chronic stress (allostatic load). Results The estimated number of concussions in RIRP averaged 14 (median=7; IQR 5-40). Performance was poorer in RIRP than controls on a test of verbal learning (p=0.022) and of fine co-ordination of the dominant hand (p=0.038) and not significantly different on other cognitive tests (p>0.05). There were no significant associations between number of concussions and performance on cognitive tests. Other than a higher incidence of cardiovascular disease in controls, no group differences were detected in general or mental health or estimates of allostatic load. In RIRP, persisting symptoms attributed to concussion were more common if reporting more than nine concussions (p=0.028), although these symptoms were not perceived to affect social or work functioning. Conclusions Despite a high number of concussions in RIRP, differences in mental health, social or work functioning were not found late after injury. Subtle group differences were detected on two cognitive tests, the cause of which is uncertain. Prospective group comparison studies on representative cohorts are required.	[McMillan, T. M.; Wainman-Lefley, J.; Maclean, L. M.] Univ Glasgow, Inst Hlth & Wellbeing, Gartnavel Royal Hosp, Glasgow G120XH, Lanark, Scotland; [McSkimming, P.; McConnachie, A.] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland; [Hay, J.; Stewart, W.] Queen Elizabeth Univ Hosp, Dept Neuropathol, Lab Med Bldg, Glasgow, Lanark, Scotland; [Stewart, W.] Univ Glasgow, Inst Neurosci & Psychol, Glasgow, Lanark, Scotland	McMillan, TM (corresponding author), Univ Glasgow, Inst Hlth & Wellbeing, Gartnavel Royal Hosp, Glasgow G120XH, Lanark, Scotland.	thomas.mcmillan@glasgow.ac.uk		McSkimming, Paula/0000-0002-7330-5425; Stewart, William/0000-0003-2199-2582	Sackler Foundation; Chief Scientist Office [DTF/12/13]; NHS Research Scotland Career Researcher Fellowship	LMM and JH were partly funded by the Sackler Foundation. JW-L was funded by the Chief Scientist Office (DTF/12/13). WS was supported by an NHS Research Scotland Career Researcher Fellowship.	Babor T.F., 1992, GUIDELINES USE PRIMA; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Carroll JD, 2004, J REHABIL MED S 43, P28; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Decq P, 2016, ACTA NEUROCHIR, V158, P289, DOI 10.1007/s00701-015-2681-4; England Professional Rugby Injury Surveillance Project Steering Group. England Professional Rugby Injury Surveillance Project, 2016, ENGL PROF RUDB INJ S; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Hay J, 2016, ANNU REV PATHOL-MECH, V11, P21, DOI 10.1146/annurev-pathol-012615-044116; Hollis SJ, 2009, AM J SPORT MED, V37, P2328, DOI 10.1177/0363546509341032; Juster RP, 2010, NEUROSCI BIOBEHAV R, V35, P2, DOI 10.1016/j.neubiorev.2009.10.002; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; Kerr ZY, 2015, AM J SPORT MED, V43, P606, DOI 10.1177/0363546514562180; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kristman Vicki L, 2014, Arch Phys Med Rehabil, V95, pS265, DOI 10.1016/j.apmr.2013.04.026; Lees R, 2014, STROKE, V45, P3008, DOI 10.1161/STROKEAHA.114.005842; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; Matthews CG, 1964, INSTRUCTION BATTERY; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McMillan TM, 2014, J NEUROL NEUROSUR PS, V85, P1214, DOI 10.1136/jnnp-2013-307279; Meehan W, 2015, NEUROLOGY, V85, P1504, DOI 10.1212/WNL.0000000000001893; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Randolph C, 2013, J INT NEUROPSYCH SOC, V19, P873, DOI 10.1017/S1355617713000805; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Scottish Executive, 2012, SCOTT IND MULT DEPR; Smilek D, 2010, NEUROPSYCHOLOGIA, V48, P2564, DOI 10.1016/j.neuropsychologia.2010.05.002; Smith A., 1982, SYMBOL DIGIT MODALIT; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Snaith RP, 1984, HOSP ANXIETY DEPRESS; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Thornton AE, 2008, J CLIN EXP NEUROPSYC, V30, P398, DOI 10.1080/13803390701443662; Tombaugh TN, 2004, ARCH CLIN NEUROPSYCH, V19, P203, DOI 10.1016/S0887-6177(03)00039-8; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	44	40	40	1	21	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUN	2017	88	6					505	511		10.1136/jnnp-2016-314279			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	EX0JI	WOS:000402906000009	27951526	Green Accepted, Bronze			2021-06-18	
J	Dixon, KJ				Dixon, Kirsty J.			Pathophysiology of Traumatic Brain Injury	PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA			English	Article						Traumatic brain injury; TBI; Pathophysiology; Symptoms; Mild TBI; Concussion; Blast TBI	DIFFUSE AXONAL INJURY; CEREBRAL-BLOOD-FLOW; HEAD-INJURY; NEURONAL LOSS; POSTTRAUMATIC HYPOTHERMIA; OXIDATIVE STRESS; VASCULAR INJURY; BLAST INJURIES; MILD; ENCEPHALOPATHY	Traumatic brain injury (TBI) has become the signature injury of the military conflict in Iraq and Afghanistan and also has a high rate of occurrence in civilian populations in the United States. Although the effects of a moderate to severe brain injury have been investigated for decades, the chronic effects of single and repetitive mild TBI are just beginning to be investigated. Data suggest that the different types and severities of TBI have unique long-term outcomes and thus may represent different types of diseases. Therefore, this review outlines the causes, incidence, symptoms, and pathophysiology of mild, moderate, and severe TBI.	[Dixon, Kirsty J.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, 1223 East Marshall St, Richmond, VA 23298 USA	Dixon, KJ (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, 1223 East Marshall St, Richmond, VA 23298 USA.	Kirsty.dixon@vcuhealth.org					Ahmed F, 2012, ELECTROPHORESIS, V33, P3705, DOI 10.1002/elps.201200299; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Baranova AI, 2008, J NEUROSURG, V109, P502, DOI 10.3171/JNS/2008/109/9/0502; Barrio JR, 2015, P NATL ACAD SCI USA, V112, pE2039, DOI 10.1073/pnas.1409952112; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; *CDCP NAT CTR INJ, 1999, TRAUM BRAIN INJ US R; CELANDER H, 1955, ACTA PHYSIOL SCAND, V33, P14, DOI 10.1111/j.1748-1716.1955.tb01189.x; Centers for Disease Control and Prevention, 2015, C TRAUM BRAIN INJ US; Centers for Disease Control and Prevention National Center for Injury Prevention and Control, 2016, BLAST INJ FACT SHEET; Centers for Disease Control and Prevention National Center for Injury Prevention and Control, 2016, EXPL BLAST INJ PRIM; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Chu SJ, 2005, CRIT CARE MED, V33, P2056, DOI 10.1097/01.CCM.0000178175.54354.EA; Courtney A, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00221; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Department of Veterans Affairs Department of Defense, VA DOD CLIN PRACT GU; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Ditillo M, 2011, J TRAUMA, V71, P373; Divani AA, 2015, J NEUROTRAUM, V32, P1109, DOI 10.1089/neu.2014.3686; Dore-Duffy P, 2011, NEUROL RES, V33, P176, DOI 10.1179/016164111X12881719352372; Ekmark-Lewen S, 2010, RESTOR NEUROL NEUROS, V28, P311, DOI 10.3233/RNN-2010-0529; Eskridge SL, 2013, J REHABIL RES DEV, V50, P7, DOI 10.1682/JRRD.2012.01.0004; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gao GY, 2010, J CEREBR BLOOD F MET, V30, P628, DOI 10.1038/jcbfm.2009.235; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Gilmore CS, 2016, BRAIN BEHAV, V6, DOI 10.1002/brb3.454; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Greer JE, 2013, ACTA NEUROPATHOL, V126, P59, DOI 10.1007/s00401-013-1119-4; Greer JE, 2012, J NEUROSCI, V32, P6682, DOI 10.1523/JNEUROSCI.0881-12.2012; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Hayward NMEA, 2011, J CEREBR BLOOD F MET, V31, P166, DOI 10.1038/jcbfm.2010.67; Hill CS, 2016, TRENDS NEUROSCI, V39, P311, DOI 10.1016/j.tins.2016.03.002; Hoiland RL, 2016, AM J PHYSIOL-REG I, V310, pR398, DOI 10.1152/ajpregu.00270.2015; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Hotta H, 2016, PROG BRAIN RES, V225, P3, DOI 10.1016/bs.pbr.2016.03.001; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jullienne A, 2016, J NEUROSCI RES, V94, P609, DOI 10.1002/jnr.23732; Kanaan NM, 2016, J NEUROPATH EXP NEUR, V75, P19, DOI 10.1093/jnen/nlv001; Kenney K, 2016, EXP NEUROL, V275, P353, DOI 10.1016/j.expneurol.2015.05.019; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Lafrenaye AD, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0405-6; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lossinsky AS, 2004, HISTOL HISTOPATHOL, V19, P535, DOI 10.14670/HH-19.535; Lotocki G, 2011, NEUROSCI LETT, V499, P143, DOI 10.1016/j.neulet.2011.05.056; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Lucas S, 2016, HEADACHE, V56, P323, DOI 10.1111/head.12762; Lucca JJD, 2012, J NEUROL SCI, V318, P146, DOI 10.1016/j.jns.2012.02.002; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McQuire JC, 1998, J NEUROSURG, V89, P526, DOI 10.3171/jns.1998.89.4.0526; Meabon JS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaa9585; Mishra V, 2016, SCI REP-UK, V6, DOI 10.1038/srep26992; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Moro N, 2016, BRAIN RES, V1642, P270, DOI 10.1016/j.brainres.2016.04.005; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; O'Connor CA, 2006, ACTA NEUROCHIR SUPPL, V96, P121; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Pasco A, 2007, J NEUROTRAUM, V24, P1321, DOI 10.1089/neu.2006.0136; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Petkus V, 2016, MEDICINA-LITHUANIA, V52, P46, DOI 10.1016/j.medici.2016.01.004; Rachmany L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079837; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rickards CA, 2015, COMPR PHYSIOL, V5, P1585, DOI 10.1002/cphy.c140058; Ritenour AE, 2010, ANN SURG, V251, P1140, DOI 10.1097/SLA.0b013e3181e01270; Rossle R, 1950, GERMAN AVIATION MED, V2; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Scalfani MT, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.10.008; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; Stein DM, 2011, J TRAUMA, V71, P364, DOI 10.1097/TA.0b013e31822820da; Stein TD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0522-z; Stemper BD, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00031; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Suehiro E, 2003, J NEUROTRAUM, V20, P381, DOI 10.1089/089771503765172336; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Taupin Philippe, 2008, Int J Med Sci, V5, P127; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Tumer N, 2013, NEUROSCI LETT, V544, P62, DOI 10.1016/j.neulet.2013.03.042; Ueda Y, 2003, J NEUROSURG, V99, P899, DOI 10.3171/jns.2003.99.5.0899; Villalba N, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001474; Wang JY, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0631-6; Wei EP, 2009, J NEUROTRAUM, V26, P527, DOI 10.1089/neu.2008.0797; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Yang SH, 2013, SHOCK, V40, P471, DOI 10.1097/SHK.0000000000000037; Zhang YM, 2014, NEUROCHEM RES, V39, P950, DOI 10.1007/s11064-014-1292-4; Zuckerman A, 2017, J NEUROTRAUM, V34, P145, DOI 10.1089/neu.2015.4310	91	40	46	3	21	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1047-9651	1558-1381		PHYS MED REH CLIN N	Phys. Med. Rehabil. Clin. N. Am.	MAY	2017	28	2					215	+		10.1016/j.pmr.2016.12.001			12	Rehabilitation	Rehabilitation	EU5AJ	WOS:000401043700003	28390509				2021-06-18	
J	Emami, P; Czorlich, P; Fritzsche, FS; Westphal, M; Rueger, JM; Lefering, R; Hoffmann, M				Emami, Pedram; Czorlich, Patrick; Fritzsche, Friederike S.; Westphal, Manfred; Rueger, Johannes M.; Lefering, Rolf; Hoffmann, Michael			Impact of Glasgow Coma Scale score and pupil parameters on mortality rate and outcome in pediatric and adult severe traumatic brain injury: a retrospective, multicenter cohort study	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; mortality; outcome; pediatrics	SEVERE HEAD-INJURY; PRACTICAL SCALE; MOTOR SCORE; AGE; ADMISSION; RISK; PREDICTION; CHILDREN; SURVIVAL	OBJECTIVE Prediction of death and functional outcome is essential for determining treatment strategies and allocation of resources for patients with severe traumatic brain injury (TBI). The aim of this study was to evaluate, by using pupillary status and Glasgow Coma Scale (GCS) score, if patients with severe TBI who are <= 15 years old have a lower mortality rate and better outcome than adults with severe TBI. METHODS A retrospective cohort analysis of patients suffering from severe TBI registered in the Trauma Registry of the German Society for Trauma Surgery between 2002 and 2013 was undertaken. Severe TBI was defined as an Abbreviated Injury Scale of the head (AlShead) score of >= 3 and an AIS score for any other part of the body that does not exceed the AlShead score. Only patients with complete data (GCS score, age, and pupil parameters) were included. To assess the impact of GCS score and pupil parameters, the authors also used the recently introduced Eppendorf-Co-logne Scale and divided the study population into 2 groups: children (0-15 years old) and adults (16-55 years old). Each patient's outcome was measured at discharge from the trauma center by using the Glasgow Outcome Scale. RESULTS A total of 9959 patients fulfilled the study inclusion criteria; 888 (8.9%) patients were <= 15 years old (median 10 years). The overall mortality rate and the mortality rate for patients with a GCS of 3 and bilaterally fixed and dilated pupils (19.9% and 16.3%, respectively) were higher for the adults than for the pediatric patients (85% vs 80.9%, respectively), although cardiopulmonary resuscitation rates were significantly higher in the pediatric patients (5.6% vs 8.8%, respectively). In the multivariate logistic regression analysis, no motor response (OR 3.490, 95% CI 2.240-5.435) and fixed pupils (OR 4.197, 95% CI 3.271-5.386) and bilateral dilated pupils (OR 2.848, 95% CI 2.282-3.556) were associated with a higher mortality rate. Patients >= 15 years old had a statistically lower mortality rate (OR 0.536, 95% CI 0.421-0.814; p = 0.001). The rate of good functional outcomes (Glasgow Outcome Scale Score 4 or 5) was higher in pediatric patients than in the adults (72.2% vs 63.1%, respectively). CONCLUSIONS This study found that severe TBI in children aged <= 15 years is associated with a lower mortality rate and superior functional outcome than in adults. Also, children admitted with a missing motor response or fixed and bilaterally dilated pupils also have a lower mortality rate and higher functional outcome than adults with the same initial presentation. Therefore, patients suffering from severe TBI, especially pediatric patients, could benefit from early and aggressive treatment.	[Emami, Pedram; Czorlich, Patrick; Fritzsche, Friederike S.; Westphal, Manfred] Univ Med Ctr Hamburg Eppendorf, Dept Neurosurg, Martinistr 52, D-20246 Hamburg, Germany; [Rueger, Johannes M.; Hoffmann, Michael] Univ Med Ctr Hamburg Eppendorf, Dept Trauma Hand & Reconstruct Surg, Hamburg, Germany; [Lefering, Rolf] Univ Witten Herdecke, Inst Res Operat Med, Cologne, Germany	Czorlich, P (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Neurosurg, Martinistr 52, D-20246 Hamburg, Germany.	p.czorlich@uke.de	Czorlich, Patrick/H-8934-2019		European Journal of Trauma and Emergency; Deutsche Forschungsgemeinschaft (DFG)German Research Foundation (DFG); Federal Highway Research Institute of the Federal Republic of Germany (BAST); Federal Ministry of Education and Research of the Federal Republic of Germany (BMBF)Federal Ministry of Education & Research (BMBF); AUC GmbH, German Trauma Society	Dr. Lefering was paid by the European Journal of Trauma and Emergency for statistical reviews; he is employed by the University of Witten/Herdecke, which has a service agreement with the Akademie der Unfallchirurgie (AUC)/German Society for Trauma Surgery for scientific assistance, annual audit reports, etc.; he has received sponsoring from the Deutsche Forschungsgemeinschaft (DFG), the Federal Highway Research Institute of the Federal Republic of Germany (BAST), the Federal Ministry of Education and Research of the Federal Republic of Germany (BMBF), and several other research foundations; and he also received payments for lectures at the KKS Dusseldorf and Frankfurt, Mibeg, for education in statistics for study nurses, study physicians, and project managers. The TR-DGU is funded by fees from the participating hospitals. AUC GmbH, a 100% affiliate of the German Trauma Society, collects the fees and runs the registry. There is a cooperation-and-service agreement between the AUC and University Witten/Herdecke (Dr. Lefering), which covers statistical support for scientific analyses using the registry data.	Alharfi IM, 2013, J NEUROTRAUM, V30, P361, DOI 10.1089/neu.2012.2410; [Anonymous], 1971, JAMA-J AM MED ASSOC, V215, P277; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Basso A, 2001, WORLD J SURG, V25, P1174; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Billeter AT, 2014, AM J SURG, V207, P459, DOI 10.1016/j.amjsurg.2013.04.015; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Centers for Disease Control and Prevention, 2013, 013 MORT MULT CAUS M; Chamoun RB, 2009, J NEUROSURG, V111, P683, DOI 10.3171/2009.2.JNS08817; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; Federal Statistical Office of the Federal Republic of Germany, DEST DE; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; GALE JL, 1983, NEUROSURGERY, V12, P487, DOI 10.1227/00006123-198305000-00001; Gray AT, 1997, ARCH NEUROL-CHICAGO, V54, P579, DOI 10.1001/archneur.1997.00550170055014; Grote S, 2011, J NEUROTRAUM, V28, P527, DOI 10.1089/neu.2010.1433; Hamill V, 2015, J NEUROTRAUM, V32, P689, DOI 10.1089/neu.2014.3670; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Hoffmann M, 2012, BRIT J SURG, V99, P122, DOI 10.1002/bjs.7707; Hoffmann M, 2012, J TRAUMA ACUTE CARE, V73, P1607, DOI 10.1097/TA.0b013e318270d572; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; JENNETT B, 1975, LANCET, V1, P480; Lefering R, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0476-2; Lieberman JD, 2003, J TRAUMA, V55, P437, DOI 10.1097/01.TA.0000081882.79587.17; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Majdan M, 2015, J NEUROTRAUM, V32, P101, DOI 10.1089/neu.2014.3438; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Pfenninger J, 2002, SWISS MED WKLY, V132, P116; Quigley MR, 1997, J TRAUMA, V42, P7, DOI 10.1097/00005373-199701000-00003; Steudel WI, 2005, ACTA NEUROCHIR, V147, P231, DOI 10.1007/s00701-004-0441-y; TEASDALE G, 1974, LANCET, V2, P81; Tien HC, 2006, J TRAUMA, V60, P274, DOI 10.1097/01.ta.0000197177.13379.f4; Timmons SD, 2011, J TRAUMA, V71, P1172, DOI 10.1097/TA.0b013e31822b0f4b; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237	34	40	42	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2017	126	3					760	767		10.3171/2016.1.JNS152385			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	EL9FT	WOS:000394926200010	27035177				2021-06-18	
J	Hayes, JP; Logue, MW; Sadeh, N; Spielberg, JM; Verfaellie, M; Hayes, SM; Reagan, A; Salat, DH; Wolf, EJ; McGlinchey, RE; Milberg, WP; Stone, A; Schichman, SA; Miller, MW				Hayes, Jasmeet P.; Logue, Mark W.; Sadeh, Naomi; Spielberg, Jeffrey M.; Verfaellie, Mieke; Hayes, Scott M.; Reagan, Andrew; Salat, David H.; Wolf, Erika J.; McGlinchey, Regina E.; Milberg, William P.; Stone, Annjanette; Schichman, Steven A.; Miller, Mark W.			Mild traumatic brain injury is associated with reduced cortical thickness in those at risk for Alzheimer's disease	BRAIN			English	Article						polygenic risk score; MRI; neuroimaging genetics; neurodegenerative; episodic memory	WHITE-MATTER ABNORMALITIES; CLOSED-HEAD INJURY; NEUROPSYCHOLOGICAL MEASURES; APOLIPOPROTEIN E-EPSILON-4; DEMENTIA; MEMORY; ENCEPHALOPATHY; PROGRESSION; PREDICTION; INTEGRITY	Moderate-to-severe traumatic brain injury is one of the strongest environmental risk factors for the development of neurodegenerative diseases such as late-onset Alzheimer's disease, although it is unclear whether mild traumatic brain injury, or concussion, also confers risk. This study examined mild traumatic brain injury and genetic risk as predictors of reduced cortical thickness in brain regions previously associated with early Alzheimer's disease, and their relationship with episodic memory. Participants were 160 Iraq and Afghanistan War veterans between the ages of 19 and 58, many of whom carried mild traumatic brain injury and post-traumatic stress disorder diagnoses. Whole-genome polygenic risk scores for the development of Alzheimer's disease were calculated using summary statistics from the largest Alzheimer's disease genome-wide association study to date. Results showed that mild traumatic brain injury moderated the relationship between genetic risk for Alzheimer's disease and cortical thickness, such that individuals with mild traumatic brain injury and high genetic risk showed reduced cortical thickness in Alzheimer's disease-vulnerable regions. Among males with mild traumatic brain injury, high genetic risk for Alzheimer's disease was associated with cortical thinning as a function of time since injury. A moderated mediation analysis showed that mild traumatic brain injury and high genetic risk indirectly influenced episodic memory performance through cortical thickness, suggesting that cortical thinning in Alzheimer's disease-vulnerable brain regions is a mechanism for reduced memory performance. Finally, analyses that examined the apolipoprotein E4 allele, post-traumatic stress disorder, and genetic risk for schizophrenia and depression confirmed the specificity of the Alzheimer's disease polygenic risk finding. These results provide evidence that mild traumatic brain injury is associated with greater neurodegeneration and reduced memory performance in individuals at genetic risk for Alzheimer's disease, with the caveat that the order of causal effects cannot be inferred from cross-sectional studies. These results underscore the importance of documenting head injuries even within the mild range as they may interact with genetic risk to produce negative long-term health consequences such as neurodegenerative disease.	[Hayes, Jasmeet P.; Logue, Mark W.; Sadeh, Naomi; Reagan, Andrew; Wolf, Erika J.; Miller, Mark W.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA; [Hayes, Jasmeet P.; Sadeh, Naomi; Spielberg, Jeffrey M.; Verfaellie, Mieke; Hayes, Scott M.; Wolf, Erika J.; Miller, Mark W.] Boston Univ, Dept Psychiat, Sch Med, Boston, MA 02118 USA; [Hayes, Jasmeet P.; Spielberg, Jeffrey M.; Hayes, Scott M.; Salat, David H.] VA Boston Healthcare Syst, Neuroimaging Res Vet Ctr, Boston, MA USA; [Logue, Mark W.] Boston Univ, Sch Med, Biomed Genet, Boston, MA 02118 USA; [Logue, Mark W.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Verfaellie, Mieke; Hayes, Scott M.] VA Boston Healthcare Syst, Memory Disorders Res Ctr, Boston, MA USA; [Salat, David H.] Harvard Univ, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA USA; [Salat, David H.] Harvard Univ, Harvard Med Sch, Boston, MA 02115 USA; [McGlinchey, Regina E.; Milberg, William P.] VA Boston Healthcare Syst, Geriatr Res Educ & Clin Ctr, Boston, MA USA; [McGlinchey, Regina E.; Milberg, William P.] VA Boston Healthcare Syst, Translat Res Ctr TBI & Stress Disorders, Boston, MA USA; [McGlinchey, Regina E.; Milberg, William P.] Harvard Med Sch, Dept Psychiat, Boston, MA USA; [Stone, Annjanette; Schichman, Steven A.] Cent Arkansas Vet Healthcare Syst, Res Serv, Pharmacogen Anal Lab, Little Rock, AR USA	Hayes, JP (corresponding author), VA Boston Healthcare Syst, Natl Ctr PTSD 116B2, 150 S Huntington Ave, Boston, MA 02130 USA.	jphayes@bu.edu	Miller, Mark Webber/G-7322-2011; Hayes, Jasmeet/AAN-4150-2020; Hayes, Scott M./AAL-8682-2020; Spielberg, Jeffrey/D-1402-2014	Miller, Mark Webber/0000-0001-6393-8563; Hayes, Jasmeet/0000-0002-5157-0666; Hayes, Scott M./0000-0002-1185-5149; Spielberg, Jeffrey/0000-0001-8348-7157; Wolf, Erika/0000-0003-2666-2435; Verfaellie, Mieke/0000-0001-5535-4584	VA SPiRe award [I21RX001594]; NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH102834]; Translational Research Center for TBI and Stress Disorders (TRACTS), a VA Rehabilitation Research and Development National Network Research Center [B9254-C]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH102834] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I21RX001594] Funding Source: NIH RePORTER	This research was supported by VA SPiRe award I21RX001594, NIMH grant R21MH102834, and the Translational Research Center for TBI and Stress Disorders (TRACTS), a VA Rehabilitation Research and Development National Network Research Center (B9254-C). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.	Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Benson JH, 2013, J HOPKINS APL TECH D, V31, P301; Bigler ED, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00395; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Buckner RL, 2005, J NEUROSCI, V25, P7709, DOI 10.1523/JNEUROSCI.2177-05.2005; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Cole JH, 2015, ANN NEUROL, V77, P571, DOI 10.1002/ana.24367; Crack P, 2009, J NEURAL TRANSM, V116, P1, DOI 10.1007/s00702-008-0145-1; Delis D. C., 2000, CVLT 2 CALIFORNIA VE; Doody RS, 2010, ALZHEIMERS RES THER, V2, DOI [10.1186/alzrt25, 10.1186/alzrt38]; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Fortier CB, 2014, J HEAD TRAUMA REHAB, V29, P89, DOI 10.1097/HTR.0b013e3182865859; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Gatz M, 2006, ARCH GEN PSYCHIAT, V63, P168, DOI 10.1001/archpsyc.63.2.168; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hayes A., 2013, MEDIATION MODERATION; Hayes JP, 2015, NEUROIMAGE-CLIN, V8, P148, DOI 10.1016/j.nicl.2015.04.001; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; Johnson KA, 1998, NEUROLOGY, V50, P1563, DOI 10.1212/WNL.50.6.1563; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Jones L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013950; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KNOPMAN DS, 1989, ARCH NEUROL-CHICAGO, V46, P141, DOI 10.1001/archneur.1989.00520380041011; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802; Lehmann M, 2010, J ALZHEIMERS DIS, V20, P587, DOI 10.3233/JAD-2010-1401; Logue MW, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.12.007; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Merchant-Borna K, 2016, J NEUROTRAUM, V33, P1576, DOI 10.1089/neu.2015.4191; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Miller DR, 2016, HUM BRAIN MAPP, V37, P220, DOI 10.1002/hbm.23022; MINOSHIMA S, 1994, LANCET, V344, P895, DOI 10.1016/S0140-6736(94)92871-1; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Pavlik VN, 2006, DEMENT GERIATR COGN, V22, P367, DOI 10.1159/000095640; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Purcell SM, 2009, NATURE, V460, P748, DOI 10.1038/nature08185; Querbes O, 2009, BRAIN, V132, P2036, DOI 10.1093/brain/awp105; Rapoport M, 2008, J NEUROPSYCH CLIN N, V20, P68, DOI 10.1176/jnp.2008.20.1.68; Ridge PG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079771; Ripke S, 2013, NAT GENET, V45, P1150, DOI 10.1038/ng.2742; Sabuncu MR, 2012, CEREB CORTEX, V22, P2653, DOI 10.1093/cercor/bhr348; Sabuncu MR, 2011, ARCH NEUROL-CHICAGO, V68, P1040, DOI 10.1001/archneurol.2011.167; Sullivan PF, 2013, MOL PSYCHIATR, V18, P497, DOI 10.1038/mp.2012.21; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trotter BB, 2015, BRAIN, V138, P2278, DOI 10.1093/brain/awv139; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Wechsler D., 2001, WECHSLER TEST ADULT; Weintraub S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006171; WELSH K, 1991, ARCH NEUROL-CHICAGO, V48, P278, DOI 10.1001/archneur.1991.00530150046016; WELSH KA, 1992, ARCH NEUROL-CHICAGO, V49, P448, DOI 10.1001/archneur.1992.00530290030008; Wu FB, 2009, AGEING RES REV, V8, P147, DOI 10.1016/j.arr.2009.03.002; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542	60	40	40	2	24	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	MAR	2017	140		3				813	825		10.1093/brain/aww344			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	EP3YH	WOS:000397317100034	28077398	Green Published, Bronze			2021-06-18	
J	Skrifvars, MB; Bailey, M; Presneill, J; French, C; Nichol, A; Little, L; Duranteau, J; Huet, O; Haddad, S; Arabi, Y; McArthur, C; Cooper, DJ; Bellomo, R				Skrifvars, Markus B.; Bailey, Michael; Presneill, Jeffrey; French, Craig; Nichol, Alistair; Little, Lorraine; Duranteau, Jacques; Huet, Olivier; Haddad, Samir; Arabi, Yaseen; McArthur, Colin; Cooper, D. James; Bellomo, Rinaldo		EPO-TBI Investigators; ANZICS Clinical Trials Grp	Venous thromboembolic events in critically ill traumatic brain injury patients	INTENSIVE CARE MEDICINE			English	Article						Erythropoietin; Deep venous thrombosis; Pulmonary embolism; Traumatic brain injury; Venous thromboembolism	THROMBOTIC RISK-FACTORS; UNFRACTIONATED HEPARIN; PLATELET-FUNCTION; EPOETIN-ALPHA; ERYTHROPOIETIN	To estimate the prevalence, risk factors, prophylactic treatment and impact on mortality for venous thromboembolism (VTE) in patients with moderate to severe traumatic brain injury (TBI) treated in the intensive care unit. A post hoc analysis of the erythropoietin in traumatic brain injury (EPO-TBI) trial that included twice-weekly lower limb ultrasound screening. Venous thrombotic events were defined as ultrasound-proven proximal deep venous thrombosis (DVT) or clinically detected pulmonary embolism (PE). Results are reported as events, percentages or medians and interquartile range (IQR). Cox regression analysis was used to calculate adjusted hazard ratios (HR) with 95% confidence intervals (CI) for time to VTE and death. Of 603 patients, 119 (19.7%) developed VTE, mostly comprising DVT (102 patients, 16.9%) with a smaller number of PE events (24 patients, 4.0%). Median time to DVT diagnosis was 6 days (IQR 2-11) and to PE diagnosis 6.5 days (IQR 2-16.5). Mechanical prophylaxis (MP) was used in 91% of patients on day 1, 97% of patients on day 3 and 98% of patients on day 7. Pharmacological prophylaxis was given in 5% of patients on day 1, 30% of patients on day 3 and 57% of patients on day 7. Factors associated with time to VTE were age (HR per year 1.02, 95% CI 1.01-1.03), patient weight (HR per kg 1.01, 95% CI 1-1.02) and TBI severity according to the International Mission for Prognosis and Analysis of Clinical Trials risk of poor outcome (HR per 10% increase 1.12, 95% CI 1.01-1.25). The development of VTE was not associated with mortality (HR 0.92, 95% CI 0.51-1.65). Despite mechanical and pharmacological prophylaxis, VTE occurs in one out of every five patients with TBI treated in the ICU. Higher age, greater weight and greater severity of TBI increase the risk. The development of VTE was not associated with excess mortality.	[Skrifvars, Markus B.; Bailey, Michael; Presneill, Jeffrey; Nichol, Alistair; Little, Lorraine; Cooper, D. James; Bellomo, Rinaldo] Monash Univ, Sch Publ Hlth & Prevent Med, Australian & New Zealand Intens Care Res Ctr, 55 Commercial Rd, Melbourne, Vic 3004, Australia; [Skrifvars, Markus B.] Univ Helsinki, Dept Anaesthesiol Intens Care & Pain Med, Div Intens Care, Helsinki, Finland; [Skrifvars, Markus B.] Helsinki Univ Hosp, Helsinki, Finland; [Presneill, Jeffrey] Royal Melbourne Hosp, Dept Intens Care, Melbourne, Vic, Australia; [French, Craig] Western Hlth, Dept Intens Care, Melbourne, Vic, Australia; [French, Craig] Univ Melbourne, Melbourne, Vic, Australia; [Nichol, Alistair] Univ Coll Dublin, Sch Med & Med Sci, Dublin, Ireland; [Nichol, Alistair; Cooper, D. James] Alfred, Dept Intens Care & Hyperbar Med, Melbourne, Vic, Australia; [Duranteau, Jacques] Univ Paris Sud, Hop Univ Paris Sud, Hop Bicetre, Assistance Publ Hopitaux Paris,Dept Anesthesie Re, Paris, France; [Huet, Olivier] Univ Bretagne Occidentale, CHRU Cavale Blanche, Dept Anaesthesiol & Intens Care Med, Brest, France; [Haddad, Samir; Arabi, Yaseen] King Saud Bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia; [Haddad, Samir; Arabi, Yaseen] King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia; [McArthur, Colin] Auckland City Hosp, Dept Crit Care Med, Auckland, New Zealand; [Bellomo, Rinaldo] Austin Hlth, Dept Intens Care, Melbourne, Vic, Australia	Skrifvars, MB (corresponding author), Monash Univ, Sch Publ Hlth & Prevent Med, Australian & New Zealand Intens Care Res Ctr, 55 Commercial Rd, Melbourne, Vic 3004, Australia.; Skrifvars, MB (corresponding author), Univ Helsinki, Dept Anaesthesiol Intens Care & Pain Med, Div Intens Care, Helsinki, Finland.; Skrifvars, MB (corresponding author), Helsinki Univ Hosp, Helsinki, Finland.	markus.skrifvars@monash.edu	Bailey, Michael J/A-4499-2012; French, Craig/ABF-5087-2020; Cooper, D. James/G-7961-2013; Arabi, Yaseen/ABF-3316-2020	Bailey, Michael J/0000-0002-5551-1401; French, Craig/0000-0003-1363-9711; Cooper, D. James/0000-0002-5872-9051; Arabi, Yaseen/0000-0001-5735-6241; Bellomo, Rinaldo/0000-0002-1650-8939; Nichol, Alistair Dualta/0000-0002-4771-5615; Nichol, Alistair/0000-0002-4689-1238	Finska Lakaresallskapet; Medicinska Understodsforeningen Liv och Halsa; Svenska Kulturfonden	Markus Skrifvars has received unrestricted grant support from Finska Lakaresallskapet, Medicinska Understodsforeningen Liv och Halsa and Svenska Kulturfonden.	Abdel-Aziz H, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0814-z; Ageno W, 2008, CIRCULATION, V117, P93, DOI 10.1161/CIRCULATIONAHA.107.709204; Allen CJ, 2016, J AM COLL SURGEONS, V222, P65, DOI 10.1016/j.jamcollsurg.2015.10.014; Aryafar Hamed, 2010, Semin Intervent Radiol, V27, P68, DOI 10.1055/s-0030-1247890; Beitland S, 2015, INTENS CARE MED, V41, P1209, DOI 10.1007/s00134-015-3840-z; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS32, DOI 10.1089/neu.2007.9991; Cook D, 2011, NEW ENGL J MED, V364, P1305, DOI 10.1056/NEJMoa1014475; Corwin HL, 2007, NEW ENGL J MED, V357, P965, DOI 10.1056/NEJMoa071533; Ekeh AP, 2010, J TRAUMA, V68, P912, DOI 10.1097/TA.0b013e3181b21cad; Franchini M, 2008, THROMB RES, V122, P727, DOI 10.1016/j.thromres.2007.09.010; Garcia-Olivares P, 2014, INTENS CARE MED, V40, P1698, DOI 10.1007/s00134-014-3442-1; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; GLEERUP G, 1995, ANGIOLOGY, V46, P715, DOI 10.1177/000331979504600810; Ho KM, 2010, BRIT J ANAESTH, V105, P596, DOI 10.1093/bja/aeq254; KASJANOVOVA D, 1993, MECH AGEING DEV, V71, P103, DOI 10.1016/0047-6374(93)90039-T; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; Ko A, 2016, JAMA SURG, V151, P1006, DOI 10.1001/jamasurg.2016.1662; Lier H, 2011, INTENS CARE MED, V37, P572, DOI 10.1007/s00134-011-2139-y; Martinelli I, 2010, CRIT CARE MED, V38, pS3, DOI 10.1097/CCM.0b013e3181c9cbd9; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Nichol A, 2015, TRIALS, V16, DOI 10.1186/s13063-014-0528-6; Nunez JM, 2015, AM SURGEON, V81, P605; Ortel TL, 2010, CRIT CARE MED, V38, pS43, DOI 10.1097/CCM.0b013e3181c9ccc8; Phelan HA, 2013, SEMIN THROMB HEMOST, V39, P541, DOI 10.1055/s-0033-1343356; Presneill Jeffrey, 2014, Trials, V15, P501, DOI 10.1186/1745-6215-15-501; Reiff DA, 2009, J TRAUMA, V66, P1436, DOI 10.1097/TA.0b013e31817fdf1c; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Taddei S, 2001, HYPERTENSION, V38, P274, DOI 10.1161/01.HYP.38.2.274; Tracy RP, 2002, AM J GERIATR CARDIOL, V11, P107	30	40	41	1	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	MAR	2017	43	3					419	428		10.1007/s00134-016-4655-2			10	Critical Care Medicine	General & Internal Medicine	EM0CU	WOS:000394987200007	28028552	Green Published			2021-06-18	
J	Svaldi, DO; McCuen, EC; Joshi, C; Robinson, ME; Nho, Y; Hannemann, R; Nauman, EA; Leverenz, LJ; Talavage, TM				Svaldi, Diana O.; McCuen, Emily C.; Joshi, Chetas; Robinson, Meghan E.; Nho, Yeseul; Hannemann, Robert; Nauman, Eric A.; Leverenz, Larry J.; Talavage, Thomas M.			Cerebrovascular reactivity changes in asymptomatic female athletes attributable to high school soccer participation	BRAIN IMAGING AND BEHAVIOR			English	Article						Mild traumatic brain injury; Collision sports; Head impacts; Cerebrovascular reactivity; Soccer	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; COLLEGIATE FOOTBALL PLAYERS; SPORTS-RELATED CONCUSSION; STATES HIGH-SCHOOL; HEAD IMPACTS; BOLD FMRI; FRONTOTEMPORAL DEMENTIA; RECURRENT CONCUSSION; CORTICAL IMPACT	As participation in women's soccer continues to grow and the longevity of female athletes' careers continues to increase, prevention and care for mTBI in women's soccer has become a major concern for female athletes since the long-term risks associated with a history of mTBI are well documented. Among women's sports, soccer exhibits among the highest concussion rates, on par with those of men's football at the collegiate level. Head impact monitoring technology has revealed that "concussive hits" occurring directly before symptomatic injury are not predictive of mTBI, suggesting that the cumulative effect of repetitive head impacts experienced by collision sport athletes should be assessed. Neuroimaging biomarkers have proven to be valuable in detecting brain changes that occur before neurocognitive symptoms in collision sport athletes. Quantifying the relationship between changes in these biomarkers and head impacts experienced by female soccer athletes may prove valuable to developing preventative measures for mTBI. This study paired functional magnetic resonance imaging with head impact monitoring to track cerebrovascular reactivity changes throughout a season and to test whether the observed changes could be attributed to mechanical loading experienced by female athletes participating in high school soccer. Marked cerebrovascular reactivity changes were observed in female soccer athletes, relative both to non-collision sport control measures and pre-season measures and were localized to fronto-temporal aspects of the brain. These changes persisted 4-5 months after the season ended and recovered by 8 months after the season. Segregation of the total soccer cohort into cumulative loading groups revealed that population-level changes were driven by athletes experiencing high cumulative loads, although athletes experiencing lower cumulative loads still contributed to group changes. The results of this study imply a non-linear relationship between cumulative loading and cerebrovascular changes with a threshold, above which the risk, of injury likely increases significantly.	[Svaldi, Diana O.; McCuen, Emily C.; Hannemann, Robert; Nauman, Eric A.; Talavage, Thomas M.] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA; [Joshi, Chetas; Talavage, Thomas M.] Purdue Univ, Sch Elect & Comp Engn, W Lafayette, IN 47907 USA; [Robinson, Meghan E.] Purdue Univ, Sch Chem Engn, W Lafayette, IN 47907 USA; [Nho, Yeseul] Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94729 USA; [Hannemann, Robert] VA Boston Healthcare Syst, Neuroimaging Res Vet NeRVe Ctr, Boston, MA 02130 USA; [Nauman, Eric A.] Purdue Univ, Sch Mech Engn, W Lafayette, IN 47907 USA; [Leverenz, Larry J.] Purdue Univ, Dept Hlth & Kinesiol, W Lafayette, IN 47907 USA; [Nauman, Eric A.; Leverenz, Larry J.; Talavage, Thomas M.] Purdue Univ, Concuss Neuroimaging Consortium, W Lafayette, IN 47907 USA	Svaldi, DO (corresponding author), Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA.	dianaotero7@gmail.com		Svaldi, Diana/0000-0001-6265-1931	BrainScope Company, Inc.; General Electric HealthcareGE Healthcare	This study was funded by BrainScope Company, Inc., and General Electric Healthcare.	Abbas K, 2015, DEV NEUROPSYCHOL, V40, P51, DOI 10.1080/87565641.2014.990455; Ainslie PN, 2008, J PHYSIOL-LONDON, V586, P4005, DOI 10.1113/jphysiol.2008.158279; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Barth JT, 2001, J ATHL TRAINING, V36, P253; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Becelewski Janusz, 2003, Neurol Neurochir Pol, V37, P339; Birn RM, 2008, NEUROIMAGE, V40, P644, DOI 10.1016/j.neuroimage.2007.11.059; Breedlove KM., 2014, ATHLETIC TRAIN SPORT, V6, P119, DOI [10.3928/19425864-20140507-02, DOI 10.3928/19425864-20140507-02]; Bright MG, 2013, NEUROIMAGE, V83, P559, DOI 10.1016/j.neuroimage.2013.07.007; Bright MG, 2009, NEUROIMAGE, V48, P166, DOI 10.1016/j.neuroimage.2009.05.026; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Chan ST, 2015, BRAIN INJURY, V29, P403, DOI 10.3109/02699052.2014.974209; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Fuller CW, 2005, BRIT J SPORT MED, V39, pI3, DOI 10.1136/bjsm.2005.018937; Gao YZ, 2013, CURR NEUROVASC RES, V10, P49, DOI 10.2174/156720213804806016; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2001, J ATHL TRAINING, V36, P228; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Jordan BD, 2000, NEUROLOGY, V54, pA410; Kastrup A, 2001, MAGN RESON IMAGING, V19, P13, DOI 10.1016/S0730-725X(01)00227-2; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Len TK, 2013, BRAIN INJURY, V27, P346, DOI 10.3109/02699052.2012.743185; Lewis PM, 2014, VASCULAR MECH CNS TR; Lipp I, 2015, NEUROIMAGE, V113, P387, DOI 10.1016/j.neuroimage.2015.03.004; Lovell M., 2003, NEUROSURGERY, V98; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; McCuen E. C., 2015, J BIOMECHANICS; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Militana AR, 2016, BRAIN IMAGING BEHAV, V10, P559, DOI 10.1007/s11682-015-9407-3; Morris B, 2015, WHY IS US SO GOOD WO; Murphy K, 2011, NEUROIMAGE, V54, P369, DOI 10.1016/j.neuroimage.2010.07.059; Murrell CJ, 2013, AGE, V35, P905, DOI 10.1007/s11357-012-9414-x; Mutch WAC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102181; Peirce JW, 2007, J NEUROSCI METH, V162, P8, DOI 10.1016/j.jneumeth.2006.11.017; Poole VN, 2015, DEV NEUROPSYCHOL, V40, P12, DOI 10.1080/87565641.2014.984810; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Robinson ME, 2015, DEV NEUROPSYCHOL, V40, P74, DOI 10.1080/87565641.2015.1012204; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Rosso SM, 2003, J NEUROL NEUROSUR PS, V74, P1574, DOI 10.1136/jnnp.74.11.1574; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Shenk TE, 2015, DEV NEUROPSYCHOL, V40, P63, DOI 10.1080/87565641.2015.1014088; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Slobounov S, 2012, CLIN NEUROPHYSIOL, V123, P1755, DOI 10.1016/j.clinph.2011.12.022; Snowden JS, 2002, BRIT J PSYCHIAT, V180, P140, DOI 10.1192/bjp.180.2.140; Svaldi DO, 2015, DEV NEUROPSYCHOL, V40, P80, DOI 10.1080/87565641.2014.973959; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Wang Y, 2015, DEV NEUROPSYCHOL, V40, P40, DOI 10.1080/87565641.2014.979927; Yezhuvath US, 2012, NEUROBIOL AGING, V33, P75, DOI 10.1016/j.neurobiolaging.2010.02.005; Zhang FY, 2002, J NEUROSURG, V97, P963, DOI 10.3171/jns.2002.97.4.0963; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	64	40	40	2	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	FEB	2017	11	1					98	112		10.1007/s11682-016-9509-6			15	Neuroimaging	Neurosciences & Neurology	ET8TT	WOS:000400575300009	26809358				2021-06-18	
J	Sun, LQ; Zhao, MM; Wang, Y; Liu, AH; Lv, M; Li, YX; Yang, XJ; Wu, ZX				Sun, Liqian; Zhao, Manmam; Wang, Yan; Liu, Aihua; Lv, Ming; Li, Youxiang; Yang, Xinjian; Wu, Zhongxue			Neuroprotective effects of miR-27a against traumatic brain injury via suppressing FoxO3a-mediated neuronal autophagy	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						MicroRNA-27a; Traumatic brain injury; FoxO3a; Autophagy; Hippocampus	DOWN-REGULATION; CELL-DEATH; EXPRESSION; ACTIVATION; IMPROVES; FOXO3A	MicroRNA-27a (miR-27a) has been reported to be a brain-specific miRNA and aberrantly expressed in the brain suffered from traumatic brain injury (TBI). The present study is designed to investigate the potential role and molecular mechanism of miR-27a in the pathogenesis of TBI. The level of miR-27a in brain was manipulated by intracerebroventricular injection of lentiviral-encoding miR-27a before TBI induction. Real-time PCR was used to detected miR-27a and Forkhead box O3a (FoxO3a) levels in the hippocampus. Then, we evaluated the impact of miR-27a overexpression on neurological function, brain edema, lesion volume and neuronal autophagy after TBI. The blinding of miR-27a to the 3'UTR of FoxO3a mRNA and its effects on FoxO3a translation were analyzed by luciferase reporter assay and Western blot. The downregulation of miR-27a and the increase in FoxO3a level were observed in the hippocampus post-TBI. Overexpression of miR-27a significantly attenuated neurological deficits and brain injury, especially suppressed autophagic activation after TBI. Furthermore, we identified that miR-27a directly targeted the FoxO3a 3'UTR region to reduced FoxO3a protein expression. Knockdown of FoxO3a significantly reversed high levels of autophagy-related genes induced by TBI. Taken together, Over expression of miR-27a may protect against brain injury via suppressing FoxO3a-mediated neuronal autophagy following TBI. (C) 2016 Elsevier Inc. All rights reserved.	[Sun, Liqian; Liu, Aihua; Lv, Ming; Li, Youxiang; Yang, Xinjian; Wu, Zhongxue] Capital Med Univ, Beijing Neurosurg Inst, Dept Intervent Neuroradiol, 6 Tiantan Xili, Beijing 100050, Peoples R China; [Sun, Liqian; Liu, Aihua; Lv, Ming; Li, Youxiang; Yang, Xinjian; Wu, Zhongxue] Capital Med Univ, Beijing Tiantan Hosp, 6 Tiantan Xili, Beijing 100050, Peoples R China; [Zhao, Manmam; Wang, Yan] North China Univ Sci & Technol, Sch Basic Med Sci, Dept Histol & Embryol, Tangshan 063000, Hebei, Peoples R China	Wu, ZX (corresponding author), Capital Med Univ, Beijing Neurosurg Inst, Dept Intervent Neuroradiol, 6 Tiantan Xili, Beijing 100050, Peoples R China.; Wu, ZX (corresponding author), Capital Med Univ, Beijing Tiantan Hosp, 6 Tiantan Xili, Beijing 100050, Peoples R China.	zhongxuewu@yeah.net		Yang, Xinjian/0000-0001-7306-0125	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81171078]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2015M580117]; Beijing Postdoctoral Research FoundationChina Postdoctoral Science Foundation [2015ZZ-49, 2016ZZ-38]	This work was supported by a grant from the National Natural Science Foundation of China (81171078), the China Postdoctoral Science Foundation (2015M580117), the Project supported by Beijing Postdoctoral Research Foundation (2015ZZ-49 and 2016ZZ-38).	Bahi A, 2014, PSYCHONEUROENDOCRINO, V46, P78, DOI 10.1016/j.psyneuen.2014.04.009; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Chen Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.92; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Harrison EB, 2016, FEBS OPEN BIO, V6, P835, DOI 10.1002/2211-5463.12092; Hoekman MFM, 2006, GENE EXPR PATTERNS, V6, P134, DOI 10.1016/j.modgep.2005.07.003; Kapoor S, 2013, J NEUROSCI, V33, P17398, DOI 10.1523/JNEUROSCI.2756-13.2013; Kim J, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0121-4; Li D., 2014, PLOS ONE, V10; Li MF, 2013, CELL PHYSIOL BIOCHEM, V32, P1776, DOI 10.1159/000356611; Liu H, 2015, IEEE T IND INFORM, V11, P406, DOI 10.1109/TII.2015.2397878; Lodder J, 2015, AUTOPHAGY, V11, P1280, DOI 10.1080/15548627.2015.1058473; Lv Y.-N., 2016, CELL MOL NEUROBIOL, P1; Ma YH, 2010, CANCER LETT, V298, P150, DOI 10.1016/j.canlet.2010.06.012; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Ni HM, 2013, AM J PATHOL, V183, P1815, DOI 10.1016/j.ajpath.2013.08.011; Place RF, 2008, P NATL ACAD SCI USA, V105, P1608, DOI 10.1073/pnas.0707594105; Sabirzhanov B., 2015, CELL DEATH DIFFER; Sabirzhanov B, 2014, J NEUROSCI, V34, P10055, DOI 10.1523/JNEUROSCI.1260-14.2014; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Schratt GM, 2006, NATURE, V439, P283, DOI 10.1038/nature04367; Shenaq M, 2012, J NEUROL SCI, V323, P134, DOI 10.1016/j.jns.2012.08.036; Sun LQ, 2015, MOL MED REP, V11, P4419, DOI 10.3892/mmr.2015.3264; Sun LQ, 2015, BEHAV BRAIN RES, V291, P315, DOI 10.1016/j.bbr.2015.05.049; Taheri S., 2016, J NEUROTRAUMA; Zhuo Y, 2013, CELL PHYSIOL BIOCHEM, V32, P499, DOI 10.1159/000354455	27	40	42	0	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X	1090-2104		BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	JAN 22	2017	482	4					1141	1147		10.1016/j.bbrc.2016.12.001			7	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	EK1XB	WOS:000393720000095	27919684				2021-06-18	
J	Gerson, J; Castillo-Carranza, DL; Sengupta, U; Bodani, R; Prough, DS; DeWitt, DS; Hawkins, BE; Kayed, R				Gerson, Julia; Castillo-Carranza, Diana L.; Sengupta, Urmi; Bodani, Riddhi; Prough, Donald S.; DeWitt, Douglas S.; Hawkins, Bridget E.; Kayed, Rakez			Tau Oligomers Derived from Traumatic Brain Injury Cause Cognitive Impairment and Accelerate Onset of Pathology in Htau Mice	JOURNAL OF NEUROTRAUMA			English	Article						neurodegeneration; tau oligomers; traumatic brain injury	ALZHEIMERS-DISEASE; ENDOGENOUS TAU; HEAD-INJURY; MODEL; BLAST; RAT; NEURODEGENERATION; EPIDEMIOLOGY; AGGREGATION; PROPAGATION	Tau aggregation is a pathological feature of numerous neurodegenerative disorders and has also been shown to occur under certain conditions of traumatic brain injury (TBI). Currently, no effective treatments exist for the long-term effects of TBI. In some cases, TBI not only induces cognitive changes immediately post-injury, but also leads to increased incidence of neurodegeneration later in life. Growing evidence from our lab and others suggests that the oligomeric forms of tau initiate the onset and spread of neurodegenerative tauopathies. Previously, we have shown increased levels of brain-derived tau oligomers in autopsy samples from patients diagnosed with Alzheimer's disease. We have also shown similar increases in tau oligomers in animal models of neurodegenerative diseases and TBI. In the current study, we evaluated the presence of tau oligomers in blast-induced TBI. To test the direct impact of TBI-derived tau oligomer toxicity, we isolated tau oligomers from brains of rats that underwent either a blast-or a fluid percussion injury-induced TBI. Oligomers were characterized biochemically and morphologically and were then injected into hippocampi of mice overexpressing human tau (Htau). Mice were cognitively evaluated and brains were collected for immunological analysis after testing. We found that tau oligomers form as a result of brain injury in two different models of TBI. Additionally, these oligomers accelerated onset of cognitive deficits when injected into brains of Htau mice. Tau oligomer levels increased in the hippocampal injection sites and cerebellum, suggesting that tau oligomers may be responsible for seeding the spread of pathology post-TBI. Our results suggest that tau oligomers play an important role in the toxicity underlying TBI and may be a viable therapeutic target.	[Gerson, Julia; Castillo-Carranza, Diana L.; Sengupta, Urmi; Bodani, Riddhi; Kayed, Rakez] Univ Texas Med Branch, Mitchell Ctr Neurodegenerat Dis, 301 Univ Blvd,Med Res Bldg,Room 10-138C, Galveston, TX 77555 USA; [Gerson, Julia; Castillo-Carranza, Diana L.; Sengupta, Urmi; Bodani, Riddhi; Kayed, Rakez] Univ Texas Med Branch, Dept Neurol, Galveston, TX 77555 USA; [Gerson, Julia; Castillo-Carranza, Diana L.; Sengupta, Urmi; Bodani, Riddhi; Kayed, Rakez] Univ Texas Med Branch, Dept Neurosci, Galveston, TX 77555 USA; [Gerson, Julia; Castillo-Carranza, Diana L.; Sengupta, Urmi; Bodani, Riddhi; Kayed, Rakez] Univ Texas Med Branch, Dept Cell Biol, Galveston, TX 77555 USA; [Prough, Donald S.; DeWitt, Douglas S.; Hawkins, Bridget E.] Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA; [Hawkins, Bridget E.; Kayed, Rakez] Univ Texas Med Branch, Sealy Ctr Vaccine Dev, Galveston, TX 77555 USA; [Prough, Donald S.; DeWitt, Douglas S.; Hawkins, Bridget E.; Kayed, Rakez] Univ Texas Med Branch, Dept Anesthesiol, Moody Project Translat Traumat Brain Injury Res, Galveston, TX 77555 USA	Kayed, R (corresponding author), Univ Texas Med Branch, Mitchell Ctr Neurodegenerat Dis, 301 Univ Blvd,Med Res Bldg,Room 10-138C, Galveston, TX 77555 USA.	rakayed@utmb.edu	Hawkins, Bridget/H-4933-2015; Gerson, Julia/L-3275-2019; Prough, Donald S/G-5793-2013	Hawkins, Bridget/0000-0002-1887-3657; Prough, Donald S/0000-0001-7994-532X; Castillo-Carranza, Diana/0000-0003-2511-949X	Mitchell Center for Neurodegenerative Disease; Sealy Center for Vaccine Development; Darrell K. Royal Research Fund for Alzheimer's Disease; Institute for Rehabilitation and Research/Mission Connect; Moody Project for Translational Traumatic Brain Injury Research	This work was supported, in part, by the Mitchell Center for Neurodegenerative Disease, the Sealy Center for Vaccine Development, Darrell K. Royal Research Fund for Alzheimer's Disease, and the Institute for Rehabilitation and Research/Mission Connect. Additionally, these studies were completed as part of an interdisciplinary research team funded by The Moody Project for Translational Traumatic Brain Injury Research. The authors thank Prof. Giulio Taglialatela and Prof. Yogesh Wairkar for their valuable assistance with this project.	Andorfer C, 2003, J NEUROCHEM, V86, P582, DOI 10.1046/j.1471-4159.2003.01879.x; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Bramlett HM, 2015, J NEUROTRAUM, V32, P1834, DOI 10.1089/neu.2014.3352; Castillo-Carranza DL, 2014, J ALZHEIMERS DIS, V40, pS97, DOI 10.3233/JAD-132477; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Cheng JS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115765; Clavaguera F, 2009, NAT CELL BIOL, V11, P909, DOI 10.1038/ncb1901; de Calignon A, 2012, NEURON, V73, P685, DOI 10.1016/j.neuron.2011.11.033; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; FRIEDLANDER FG, 1946, PROC R SOC LON SER-A, V186, P322, DOI 10.1098/rspa.1946.0046; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Gerson JE, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-73; Gerson JE, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00093; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lasagna-Reeves CA, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-56; Lasagna-Reeves CA, 2012, SCI REP-UK, V2, DOI 10.1038/srep00700; Lasagna-Reeves CA, 2012, FASEB J, V26, P1946, DOI 10.1096/fj.11-199851; Lasagna-Reeves CA, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-39; Lasagna-Reeves CA, 2010, BIOCHEMISTRY-US, V49, P10039, DOI 10.1021/bi1016233; Liliang PC, 2010, RESUSCITATION, V81, P1205, DOI 10.1016/j.resuscitation.2010.05.016; Liu L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031302; Maeda S, 2006, NEUROSCI RES, V54, P197, DOI 10.1016/j.neures.2005.11.009; Maeda S, 2007, BIOCHEMISTRY-US, V46, P3856, DOI 10.1021/bi061359o; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Osier ND, 2015, J NEUROTRAUM, V32, P1861, DOI 10.1089/neu.2014.3680; Patterson KR, 2011, J BIOL CHEM, V286, P23063, DOI 10.1074/jbc.M111.237974; Perez-Polo JR, 2015, J NEUROSCI RES, V93, P549, DOI 10.1002/jnr.23513; Perry DC, 2016, J NEUROSURG, V124, P511, DOI 10.3171/2015.2.JNS14503; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Polydoro M, 2009, J NEUROSCI, V29, P10741, DOI 10.1523/JNEUROSCI.1065-09.2009; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Sengupta U, 2015, BIOL PSYCHIAT, V78, P672, DOI 10.1016/j.biopsych.2014.12.019; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thruman D., 1999, JAMA-J AM MED ASSOC, V282, P954; Tran HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025475; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006; Wu JW, 2013, J BIOL CHEM, V288, P1856, DOI 10.1074/jbc.M112.394528	49	40	40	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2016	33	22					2034	2043		10.1089/neu.2015.4262			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EC4OL	WOS:000388112300007	26729399	Green Published			2021-06-18	
J	Dams-O'Connor, K; Guetta, G; Hahn-Ketter, AE; Fedor, A				Dams-O'Connor, Kristen; Guetta, Gabrielle; Hahn-Ketter, Amanda E.; Fedor, Andrew			Traumatic brain injury as a risk factor for Alzheimer's disease: current knowledge and future directions	NEURODEGENERATIVE DISEASE MANAGEMENT			English	Article						Alzheimer's disease; dementia; traumatic brain injury	FOOTBALL-LEAGUE PLAYER; YOUNG ONSET DEMENTIA; HEAD-INJURY; CEREBROSPINAL-FLUID; APOLIPOPROTEIN-E; POPULATION; ENCEPHALOPATHY; COHORT; PATHOLOGY; SINGLE	There is growing concern about the late effects of traumatic brain injury (TBI). This scoping review summarizes clinical research from the past 10 years that evaluates the relationship between TBI and Alzheimer's disease. This review identified five studies that found increased risk for dementia after TBI, two studies that found no increased risk and four studies that found a relationship only under certain conditions or in specified subsamples. Methodological differences across studies preclude direct comparison of results, and discrepant findings elucidate the complex course of post-TBI neurodegeneration. We discuss the factors that influence the strength and direction of the relationship between TBI and Alzheimer's disease, and the implications of this body of research for patient care and future research.	[Dams-O'Connor, Kristen; Guetta, Gabrielle; Hahn-Ketter, Amanda E.; Fedor, Andrew] Icahn Sch Med Mt Sinai, Dept Rehabil Med, Brain Injury Res Ctr, New York, NY 10029 USA	Dams-O'Connor, K (corresponding author), Icahn Sch Med Mt Sinai, Dept Rehabil Med, Brain Injury Res Ctr, New York, NY 10029 USA.	kristen.dams-o'connor@mountsinai.org		Hahn-Ketter, Amanda/0000-0002-0226-3598	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD074651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086625] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01 HD074651] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 NS086625] Funding Source: Medline		Abner EL, 2014, DEMENT GERIATR COGN, V37, P294, DOI 10.1159/000355478; Administration on Aging, 2016, AG STAT; Alzheimer's Association, 2016, WHAT WE KNOW TOD ALZ; AMADUCCI LA, 1986, NEUROLOGY, V36, P922, DOI 10.1212/WNL.36.7.922; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Anstey KJ, 2013, PREV SCI, V14, P411, DOI 10.1007/s11121-012-0313-2; Arksey H., 2005, INT J SOC RES METHOD, V8, P19, DOI [DOI 10.1080/1364557032000119616, 10.1080/1364557032000119616]; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; CHANDRA V, 1987, NEUROLOGY, V37, P1295, DOI 10.1212/WNL.37.8.1295; Chauhan NB, 2014, RESTOR NEUROL NEUROS, V32, P337, DOI 10.3233/RNN-130354; CLAUDE H, 1939, ANN MED LEG, V19, P173; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; Dams-O'Connor K, 2013, NEUROREHABILITATION, V32, P199, DOI 10.3233/NRE-130838; Dams-O'Connor K, 2016, J AM GERIATR SOC, V64, P844, DOI 10.1111/jgs.14014; Dams-O'Connor K, 2014, J HEAD TRAUMA REHAB, V29, P479, DOI 10.1097/HTR.0000000000000099; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Dijkers M, 2015, WHAT IS SCOPING REV; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FERINISTRAMBI L, 1990, NEUROEPIDEMIOLOGY, V9, P39, DOI 10.1159/000110750; Filer William, 2015, N C Med J, V76, P111; Franzblau M, 2013, MED HYPOTHESES, V81, P842, DOI 10.1016/j.mehy.2013.09.012; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Gardner RC, 2014, ANN NEUROL, V75, P339, DOI 10.1002/ana.24121; Giunta B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-185; Godbolt Alison K, 2014, Arch Phys Med Rehabil, V95, pS245, DOI 10.1016/j.apmr.2013.06.036; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Health IOM COGWA, 2008, GULF WAR HLTH, V7; Helmes E, 2011, BRAIN INJURY, V25, P338, DOI 10.3109/02699052.2011.556104; Johnson VE, 2015, NAT REV NEUROL, V11, DOI 10.1038/nrneurol.2014.241; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2011, ACTA NEUROPATHOL, V122, P715, DOI 10.1007/s00401-011-0909-9; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Masel BE, 2015, J NEUROTRAUM, V32, P1833, DOI 10.1089/neu.2015.29004.bm; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Millspaugh J., 1937, US NAVAL MED B, V35, P297; MOLGAARD CA, 1990, NEUROEPIDEMIOLOGY, V9, P233, DOI 10.1159/000110778; Moretti L, 2012, LANCET NEUROL, V11, P1103, DOI 10.1016/S1474-4422(12)70226-0; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Raby CA, 1998, J NEUROCHEM, V71, P2505; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; RUDELLI R, 1982, ARCH NEUROL-CHICAGO, V39, P570, DOI 10.1001/archneur.1982.00510210040009; Sayed N, 2013, J NEUROTRAUM, V30, P1117, DOI 10.1089/neu.2012.2638; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Suhanov AV, 2006, EUR J NEUROL, V13, P990, DOI 10.1111/j.1468-1331.2006.01391.x; Sundstrom A, 2007, INT PSYCHOGERIATR, V19, P159, DOI 10.1017/S1041610206003498; Tsitsopoulos PP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00079; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Whiteneck GG, 2016, J HEAD TRAUMA REHAB, V31, pE43, DOI 10.1097/HTR.0000000000000141; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554	72	40	40	0	22	FUTURE MEDICINE LTD	LONDON	UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND	1758-2024	1758-2032		NEURODEGENER DIS MAN	Neurodegener. Dis. Manag.	OCT	2016	6	5					417	429		10.2217/nmt-2016-0017			13	Clinical Neurology	Neurosciences & Neurology	EB5ZM	WOS:000387459800007	27599555	Green Published			2021-06-18	
J	Hawryluk, GWJ; Bullock, MR				Hawryluk, Gregory W. J.; Bullock, M. Ross			Past, Present, and Future of Traumatic Brain Injury Research	NEUROSURGERY CLINICS OF NORTH AMERICA			English	Article						Traumatic brain injury (TBI); Research; Secondary injury; Clinical trials; Trends; History; Big data	SEVERE HEAD-INJURY; MITOCHONDRIAL PERMEABILITY TRANSITION; CELLULAR INFLAMMATORY RESPONSE; RANDOMIZED CONTROLLED-TRIALS; DISABILITY RATING-SCALE; EXCITATORY AMINO-ACIDS; SPINAL-CORD CONTUSION; GLASGOW-OUTCOME-SCALE; CLINICAL-TRIALS; CYCLOSPORINE-A	Traumatic brain injury (TBI) is the greatest cause of death and severe disability in young adults; its incidence is increasing in the elderly and in the developing world. Outcome from severe TBI has improved dramatically as a result of advancements in trauma systems and supportive critical care, however we remain without a therapeutic which acts directly to attenuate brain injury. Recognition of secondary injury and its molecular mediators has raised hopes for such targeted treatments. Unfortunately, over 30 late-phase clinical trials investigating promising agents have failed to translate a therapeutic for clinical use. Numerous explanations for this failure have been postulated and are reviewed here. With this historical context we review ongoing research and anticipated future trends which are armed with lessons from past trials, new scientific advances, and improved research infrastructure and funding. There is great hope that these new efforts will finally lead to an effective therapeutic for TBI as well as better clinical management strategies.	[Hawryluk, Gregory W. J.] Univ Utah, Dept Neurosurg, 175 North Med Dr East, Salt Lake City, UT 84132 USA; [Bullock, M. Ross] Univ Miami, Miller Sch Med, Dept Neurosurg, Lois Pope LIFE Ctr,Neurotrauma, 1095 NW 14th Terrace, Miami, FL 33136 USA	Bullock, MR (corresponding author), Univ Miami, Miller Sch Med, Dept Neurosurg, Lois Pope LIFE Ctr,Neurotrauma, 1095 NW 14th Terrace, Miami, FL 33136 USA.	rbullock@med.miami.edu					ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; American College of Surgeons, 2015, BEST PRACT MAN TRAUM; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; [Anonymous], 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3795; [Anonymous], 2001, J Trauma, V51, pS3; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; BRAAKMAN R, 1983, J NEUROSURG, V58, P326, DOI 10.3171/jns.1983.58.3.0326; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P573; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS65; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS91; Brain Trauma Foundation, 2005, GUID FIELD MAN COMB; Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P561; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Bullock R., 1997, TRAUMA CARE, V7, P16; Butcher I, 2007, J NEUROTRAUM, V24, P294, DOI 10.1089/neu.2006.0032; Butcher I, 2007, J NEUROTRAUM, V24, P281, DOI 10.1089/neu.2006.0030; Carney N, 2014, NEUROSURGERY, V75, pS3, DOI 10.1227/NEU.0000000000000433; Cheng F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106680; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Choi SC, 2002, J NEUROTRAUM, V19, P17, DOI 10.1089/089771502753460204; Choi SC, 2001, NEUROL RES, V23, P190, DOI 10.1179/016164101101198325; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Committee N.G., 2015, NCS GUID; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Craton N, 2014, CLIN J SPORT MED, V24, P93, DOI 10.1097/JSM.0000000000000023; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Czogalla A, 2005, CELL MOL LIFE SCI, V62, P1913, DOI 10.1007/s00018-005-5097-0; D'Onofrio G, 2010, ANN EMERG MED, V56, P551, DOI 10.1016/j.annemergmed.2010.06.562; Daoud H, 2014, NEUROCRIT CARE, V20, P427, DOI 10.1007/s12028-013-9879-1; DEARDEN NM, 1986, J NEUROSURG, V64, P81, DOI 10.3171/jns.1986.64.1.0081; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Edwards P, 2005, LANCET, V365, P1957; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Fawcett WJ, 1999, BRIT J ANAESTH, V83, P302, DOI 10.1093/bja/83.2.302; Fehlings MG, 2001, SPINE, V26, pS55, DOI 10.1097/00007632-200112151-00011; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Fleming JC, 2006, BRAIN, V129, P3249, DOI 10.1093/brain/awl296; Gaab M R, 1994, Zentralbl Neurochir, V55, P135; Gabriel Edward J., 2002, Journal of Neurotrauma, V19, P111; GELPKE GJ, 1983, J NEUROSURG, V59, P745, DOI 10.3171/jns.1983.59.5.0745; Georgoff P, 2010, WORLD NEUROSURG, V74, P331, DOI 10.1016/j.wneu.2010.03.025; Ghajar J, 2004, LANCET NEUROL, V3, P708, DOI 10.1016/S1474-4422(04)00932-9; Giunta B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-185; Gogarten W, 1998, J NEUROSURG ANESTH, V10, P101, DOI 10.1097/00008506-199804000-00006; GRAHAM DI, 1985, BRIT J ANAESTH, V57, P3, DOI 10.1093/bja/57.1.3; GRUMME T, 1995, RES EXP MED, V195, P217, DOI 10.1007/BF02576791; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; Harrington M, 2000, LANCET, V355, P2147, DOI 10.1016/S0140-6736(00)02388-6; Harvey LA, 2012, INJURY, V43, P1821, DOI 10.1016/j.injury.2012.07.188; Hawryluk Gregory W J, 2015, Handb Clin Neurol, V127, P15, DOI 10.1016/B978-0-444-52892-6.00002-7; Hawryluk GWJ, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E14; Heath DL, 1997, NEUROSCI LETT, V228, P175, DOI 10.1016/S0304-3940(97)00394-7; Hillard VH, 2004, J NEUROTRAUM, V21, P1405, DOI 10.1089/neu.2004.21.1405; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kochanek PM, 2016, J NEUROTRAUM, V33, P513, DOI 10.1089/neu.2015.4113; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; Kwon BK, 2011, J NEUROTRAUM, V28, P1525, DOI 10.1089/neu.2010.1296; Laine C, 2007, ANN INTERN MED, V146, P450, DOI 10.7326/0003-4819-146-6-200703200-00154; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lingsma H, 2013, J TRAUMA ACUTE CARE, V74, P639, DOI 10.1097/TA.0b013e31827d602e; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; Lu J, 2008, J NEUROTRAUM, V25, P641, DOI 10.1089/neu.2007.0510; Lu Li-quan, 2003, Chin J Traumatol, V6, P302; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Maas Andrew I R, 2015, Handb Clin Neurol, V128, P455, DOI 10.1016/B978-0-444-63521-1.00029-7; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Marmarou A, 1999, J NEUROTRAUM, V16, P431, DOI 10.1089/neu.1999.16.431; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; May MT, 2006, LANCET, V368, P451; Mazzeo AT, 2009, J NEUROTRAUM, V26, P2195, DOI 10.1089/neu.2009.1012; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McEwen ML, 2007, J NEUROTRAUM, V24, P613, DOI 10.1089/neu.2006.9969; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Mehta A, 2010, DEV NEUROSCI-BASEL, V32, P413, DOI 10.1159/000316804; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Merchant RE, 1999, ANN NY ACAD SCI, V890, P42, DOI 10.1111/j.1749-6632.1999.tb07979.x; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Mondello S, 2014, MED RES REV, V34, P503, DOI 10.1002/med.21295; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Muir JK, 1999, EXP NEUROL, V159, P584, DOI 10.1006/exnr.1999.7187; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Murray GD, 1996, ACTA NEUROCHIR, V138, P1163, DOI 10.1007/BF01809745; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Neher MD, 2014, SOUTH MED J, V107, P248, DOI 10.1097/SMJ.0000000000000086; O'Collins VE, 2006, ANN NEUROL, V59, P467, DOI 10.1002/ana.20741; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Okonkwo DO, 2003, NEUROREPORT, V14, P463, DOI 10.1097/01.wnr.0000058958.85541.d3; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Panczykowski DM, 2012, J NEUROTRAUM, V29, P47, DOI 10.1089/neu.2010.1482; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; Qiu WS, 2006, J CLIN NEUROSCI, V13, P995, DOI 10.1016/j.jocn.2006.02.027; Raj R, 2013, NEUROSURGERY, V73, P305, DOI 10.1227/01.neu.0000430326.40763.ec; Rak R, 2000, J NEUROSURG, V92, P646, DOI 10.3171/jns.2000.92.4.0646; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reinert MM, 1999, NEUROL RES, V21, P330, DOI 10.1080/01616412.1999.11740940; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; Roozenbeek B, 2012, CRIT CARE MED, V40, P1609, DOI 10.1097/CCM.0b013e31824519ce; Roozenbeek B, 2012, J NEUROTRAUM, V29, P1306, DOI 10.1089/neu.2011.1988; Roozenbeek B, 2009, CRIT CARE MED, V37, P2683, DOI 10.1097/CCM.0b013e3181ab85ec; Ropper AH, 2012, NEW ENGL J MED, V367, P2539, DOI 10.1056/NEJMe1212289; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; Scott GS, 2005, P NATL ACAD SCI USA, V102, P3483, DOI 10.1073/pnas.0500307102; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Snapinn Steven M, 2000, Curr Control Trials Cardiovasc Med, V1, P19, DOI 10.1186/CVM-1-1-019; Starkov AA, 2004, CELL CALCIUM, V36, P257, DOI 10.1016/j.ceca.2004.02.012; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Struchen MA, 2001, J NEUROTRAUM, V18, P115, DOI 10.1089/08977150150502569; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Talving P, 2013, J NEUROSURG, V119, P1248, DOI 10.3171/2013.7.JNS122255; Tanasescu Radu, 2014, Biomed J, V37, P41, DOI 10.4103/2319-4170.130440; TEASDALE G, 1992, J NEUROTRAUM, V9, pS545; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P463; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Tymianski M, 2011, NAT NEUROSCI, V14, P1369, DOI 10.1038/nn.2951; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vink R, 2010, NEUROTHERAPEUTICS, V7, P1, DOI 10.1016/j.nurt.2009.12.001; Wilson JTL, 2007, NEUROSURGERY, V61, P123, DOI 10.1227/01.neu.0000279732.21145.9e; WOLF AL, 1993, J NEUROSURG, V78, P54, DOI 10.3171/jns.1993.78.1.0054; Wong GKC, 2013, J CLIN NEUROSCI, V20, P1693, DOI 10.1016/j.jocn.2012.12.032; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Yeoman P, 2011, J TRAUMA, V71, P387, DOI 10.1097/TA.0b013e31820ceadd; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; Young Jeffrey S, 2003, Neurosurg Focus, V15, pE2; Yurkewicz L, 2005, J NEUROTRAUM, V22, P1428, DOI 10.1089/neu.2005.22.1428; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547; Zetterberg H, 2015, MOL CELL NEUROSCI, V66, P99, DOI 10.1016/j.mcn.2015.02.003; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4; Zitnay GA, 2008, J NEUROTRAUM, V25, P1135, DOI 10.1089/neu.2008.0599	189	40	43	0	14	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1042-3680	1558-1349		NEUROSURG CLIN N AM	Neurosurg. Clin. N. Am.	OCT	2016	27	4					375	+		10.1016/j.nec.2016.05.002			23	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DY9SQ	WOS:000385475800003	27637391				2021-06-18	
J	Lehman, EJ; Hein, MJ; Gersic, CM				Lehman, Everett J.; Hein, Misty J.; Gersic, Christine M.			Suicide Mortality Among Retired National Football League Players Who Played 5 or More Seasons	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						suicide; football; National Football League; concussion	CHRONIC TRAUMATIC ENCEPHALOPATHY; TABLE ANALYSIS SYSTEM; BRAIN-INJURY; RISK; DEPRESSION; CONCUSSION	Background: There is current disagreement in the scientific literature about the relationship between playing football and suicide risk, particularly among professional players in the National Football League (NFL). While some research indicates players are at high risk of football-related concussions, which may lead to chronic traumatic encephalopathy and suicide, other research finds such a connection to be speculative and unsupported by methodologically sound research. Purpose: To compare the suicide mortality of a cohort of NFL players to what would be expected in the general population of the United States. Study Design: Cohort study; Level of evidence, 3. Methods: A cohort of 3439 NFL players with at least 5 credited playing seasons between 1959 and 1988 was assembled for statistical analysis. The vital status for this cohort was updated through 2013. Standardized mortality ratios (SMRs), the ratio of observed deaths to expected deaths, and 95% CIs were computed for the cohort; 95% CIs that excluded unity were considered statistically significant. For internal comparison purposes, standardized rate ratios were calculated to compare mortality results between players stratified into speed and nonspeed position types. Results: Suicide among this cohort of professional football players was significantly less than would be expected in comparison with the United States population (SMR = 0.47; 95% CI, 0.24-0.82). There were no significant differences in suicide mortality between speed and nonspeed position players. Conclusion: There is no indication of elevated suicide risk in this cohort of professional football players with 5 or more credited seasons of play. Because of the unique nature of this cohort, these study results may not be applicable to professional football players who played fewer than 5 years or to college or high school players.	[Lehman, Everett J.; Hein, Misty J.; Gersic, Christine M.] Ctr Dis Control & Prevent, NIOSH, Cincinnati, OH USA	Lehman, EJ (corresponding author), Care of Trout D, Ctr Dis Control & Prevent, NIOSH, Div Surveillance Hazard Evaluat & Field Studies, 4676 Columbia Pkwy,R-12, Cincinnati, OH 45226 USA.	DYT1@cdc.gov			United States government	One or more of the authors has declared the following potential conflict of interest or source of funding: This study was fully supported by funding from the United States government to the Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health.	Baron SL, 2012, AM J CARDIOL, V109, P889, DOI 10.1016/j.amjcard.2011.10.050; Baum AL, 2005, CLIN SPORT MED, V24, P853, DOI 10.1016/j.csm.2005.06.006; Casson IR, 2014, SPORTS HEALTH, V6, P384, DOI 10.1177/1941738114540270; Castellani RJ, 2015, J NEUROPATH EXP NEUR, V74, P493, DOI 10.1097/NEN.0000000000000193; Centers for Disease Control and Prevention National Institute for Occupational Safety and Health (NIOSH), 1994, NAT FOOTB LEAG PLAYE, P88; Davis ME, 2009, MED SCI SPORTS EXERC, V41, P97; Denney JT, 2009, SOC SCI QUART, V90, P1167, DOI 10.1111/j.1540-6237.2009.00652.x; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Iverson GL, 2015, NEUROSCI BIOBEHAV R, V56, P276, DOI 10.1016/j.neubiorev.2015.05.008; Iverson GL, 2014, BRIT J SPORT MED, V48, P162, DOI 10.1136/bjsports-2013-092935; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Maroon JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117338; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan W, 2015, NEUROLOGY, V85, P1504, DOI 10.1212/WNL.0000000000001893; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Rao AL, 2015, SPORTS HEALTH, V7, P452, DOI 10.1177/1941738115587675; Robinson CF, 2006, J OCCUP ENVIRON MED, V48, P662, DOI 10.1097/01.jom.0000229968.74906.8f; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Schubauer-Berigan MK, 2011, AM J IND MED, V54, P915, DOI 10.1002/ajim.20999; Schwenk TL, 2007, MED SCI SPORT EXER, V39, P599, DOI 10.1249/mss.0b013e31802fa679; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Taioli E, 2007, EUR J PUBLIC HEALTH, V17, P600, DOI 10.1093/eurpub/ckm035; Weir Dr, 2009, NATL FOOTBALL LEAGUE; World Health Organization, 1992, ICD 10 CLASS MENT BE; Wortzel HS, 2013, BEHAV SCI LAW, V31, P721, DOI 10.1002/bsl.2079; Wortzel HS, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/424280	34	40	40	2	33	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	OCT	2016	44	10					2486	2491		10.1177/0363546516645093			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	DY8JC	WOS:000385374900010	27159317	Green Accepted			2021-06-18	
J	Erturk, A; Mentz, S; Stout, EE; Hedehus, M; Dominguez, SL; Neumaier, L; Krammer, F; Llovera, G; Srinivasan, K; Hansen, DV; Liesz, A; Scearce-Levie, KA; Sheng, M				Ertuerk, Ali; Mentz, Susanne; Stout, Erik E.; Hedehus, Maj; Dominguez, Sara L.; Neumaier, Lisa; Krammer, Franziska; Llovera, Gemma; Srinivasan, Karpagam; Hansen, David V.; Liesz, Arthur; Scearce-Levie, Kimberly A.; Sheng, Morgan			Interfering with the Chronic Immune Response Rescues Chronic Degeneration After Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article						3D imaging; axon; degeneration; inflammation; spine; trauma	FRACTALKINE RECEPTOR CX(3)CR1; SPINAL-CORD-INJURY; DENDRITIC SPINES; UNITED-STATES; NITRIC-OXIDE; CELL-DEATH; MICROGLIA; INFLAMMATION; COMPLEMENT; DAMAGE	After traumatic brain injury (TBI), neurons surviving the initial insult can undergo chronic (secondary) degeneration via poorly understood mechanisms, resulting in long-term cognitive impairment. Although a neuroinflammatory response is promptly activated after TBI, it is unknown whether it has a significant role in chronic phases of TBI (> 1 year after injury). Using a closed-head injury model of TBI in mice, we showed by MRI scans that TBI caused substantial degeneration at the lesion site within a few weeks and these did not expand significantly thereafter. However, chronic alterations in neurons were observed, with reduced dendritic spine density lasting > 1 year after injury. In parallel, we found a long-lasting inflammatory response throughout the entire brain. Deletion of one allele of CX(3)CR1, a chemokine receptor, limited infiltration of peripheral immune cells and largely prevented the chronic degeneration of the injured brain and provided a better functional recovery in female, but not male, mice. Therefore, targeting persistent neuroinflammation presents a new therapeutic option to reduce chronic neurodegeneration.	[Ertuerk, Ali; Mentz, Susanne; Neumaier, Lisa; Krammer, Franziska; Llovera, Gemma; Liesz, Arthur] Ludwig Maximilian Univ Munich, Klinikum Univ Munchen, Inst Stroke & Dementia Res, Feodor Lynen Str 17, D-81377 Munich, Germany; [Ertuerk, Ali; Liesz, Arthur] Munich Cluster Syst Neurol SyNergy, D-81377 Munich, Germany; [Ertuerk, Ali; Liesz, Arthur] Grad Sch Neurosci Munich, D-82152 Planegg Martinsried, Germany; [Ertuerk, Ali; Stout, Erik E.; Hedehus, Maj; Dominguez, Sara L.; Srinivasan, Karpagam; Hansen, David V.; Scearce-Levie, Kimberly A.; Sheng, Morgan] Genentech Inc, Dept Neurosci, San Francisco, CA 94080 USA	Erturk, A (corresponding author), Ludwig Maximilian Univ Munich, Klinikum Univ Munchen, Inst Stroke & Dementia Res, Feodor Lynen Str 17, D-81377 Munich, Germany.	Ali.Ertuerk@med.uni-muenchen.de		Sheng, Morgan/0000-0002-8703-5366; Llovera, Gemma/0000-0002-7509-7500; Hansen, David/0000-0001-9679-7189			Aguzzi A, 2013, SCIENCE, V339, P156, DOI 10.1126/science.1227901; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Campbell JN, 2012, J NEUROTRAUM, V29, P201, DOI 10.1089/neu.2011.1761; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; CHAO CC, 1992, J IMMUNOL, V149, P2736; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Clarke LE, 2013, NAT REV NEUROSCI, V14, P311, DOI 10.1038/nrn3484; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Denes A, 2008, J CEREBR BLOOD F MET, V28, P1707, DOI 10.1038/jcbfm.2008.64; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dodt HU, 2007, NAT METHODS, V4, P331, DOI 10.1038/NMETH1036; Donnelly DJ, 2011, J NEUROSCI, V31, P9910, DOI 10.1523/JNEUROSCI.2114-11.2011; Ekmark-Lewen S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-44; Erturk A, 2014, JOVE-J VIS EXP, DOI 10.3791/51382; Erturk A, 2014, J NEUROSCI, V34, P1672, DOI 10.1523/JNEUROSCI.3121-13.2014; Erturk A, 2012, NAT PROTOC, V7, P1983, DOI 10.1038/nprot.2012.119; Erturk A, 2012, NAT MED, V18, P166, DOI 10.1038/nm.2600; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hong S, 2016, SCIENCE, V352, P712, DOI 10.1126/science.aad8373; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Jeong Hey-Kyeong, 2013, Exp Neurobiol, V22, P59, DOI 10.5607/en.2013.22.2.59; Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kamper JE, 2013, EXP NEUROL, V250, P8, DOI 10.1016/j.expneurol.2013.09.016; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kettenmann H, 2013, NEURON, V77, P10, DOI 10.1016/j.neuron.2012.12.023; Kharatishvili I, 2010, CURR OPIN NEUROL, V23, P183, DOI 10.1097/WCO.0b013e32833749e4; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Kyritsis N, 2012, SCIENCE, V338, P1353, DOI 10.1126/science.1228773; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Liesz A, 2011, BRAIN, V134, P704, DOI 10.1093/brain/awr008; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Longhi L, 2013, J CEREBR BLOOD F MET, V33, P1182, DOI 10.1038/jcbfm.2013.65; Lourbopoulos A, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00054; Luong TN, 2011, JOVE-J VIS EXP, DOI 10.3791/2376; Luster AD, 2005, NAT IMMUNOL, V6, P1182, DOI 10.1038/ni1275; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; MALT U, 1988, BRIT J PSYCHIAT, V153, P810, DOI 10.1192/bjp.153.6.810; Masel BE, 2012, J NEUROTRAUM, V29, P2143, DOI 10.1089/neu.2011.2258; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mionnet C, 2010, NAT MED, V16, P1305, DOI 10.1038/nm.2253; Naj AC, 2011, NAT GENET, V43, P436, DOI 10.1038/ng.801; Olesen J, 2012, EUR J NEUROL, V19, P155, DOI 10.1111/j.1468-1331.2011.03590.x; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529; Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Prinz M, 2014, NAT REV NEUROSCI, V15, P300, DOI 10.1038/nrn3722; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; RINK A, 1995, AM J PATHOL, V147, P1575; Rogers JT, 2011, J NEUROSCI, V31, P16241, DOI 10.1523/JNEUROSCI.3667-11.2011; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Salter MW, 2014, CELL, V158, P15, DOI 10.1016/j.cell.2014.06.008; Satake K, 2000, MOL BRAIN RES, V85, P114, DOI 10.1016/S0169-328X(00)00253-9; Saulle M, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/816069; Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026; Sheridan GK, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.130181; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Stephan AH, 2012, ANNU REV NEUROSCI, V35, P369, DOI 10.1146/annurev-neuro-061010-113810; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Winston CN, 2013, J NEUROTRAUM, V30, P1966, DOI 10.1089/neu.2013.2960; Wright DW, 2013, MMWR-MORBID MORTAL W, V62, P549; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zhou HZ, 2012, J NEUROPATH EXP NEUR, V71, P348, DOI 10.1097/NEN.0b013e31824ea078	80	40	40	0	11	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	SEP 21	2016	36	38					9962	9975		10.1523/JNEUROSCI.1898-15.2016			14	Neurosciences	Neurosciences & Neurology	EC3AC	WOS:000387995300020	27656033	Green Published, Bronze			2021-06-18	
J	D'Andrea, A; Conte, M; Cavallaro, M; Scarafile, R; Riegler, L; Cocchia, R; Pezzullo, E; Carbone, A; Natale, F; Santoro, G; Caso, P; Russo, MG; Bossone, E; Calabro, R				D'Andrea, Antonello; Conte, Marianna; Cavallaro, Massimo; Scarafile, Raffaella; Riegler, Lucia; Cocchia, Rosangela; Pezzullo, Enrica; Carbone, Andreina; Natale, Francesco; Santoro, Giuseppe; Caso, Pio; Russo, Maria Giovanna; Bossone, Eduardo; Calabro, Raffaele			Transcranial Doppler ultrasonography: From methodology to major clinical applications	WORLD JOURNAL OF CARDIOLOGY			English	Article						Transcranial Doppler ultrasonography; Lindegaard ratio; Paradoxical embolism; Microembolic signals; Middle cerebral artery; Patent foramen ovale; Cryptogenic STroke; Vasospasm; Acute subarachnoid hemorrhage; Ischemic stroke	PATENT FORAMEN OVALE; ANEURYSMAL SUBARACHNOID HEMORRHAGE; DYNAMIC CEREBRAL AUTOREGULATION; TISSUE-PLASMINOGEN ACTIVATOR; TO-LEFT SHUNT; TRAUMATIC BRAIN-INJURY; BLOOD-FLOW VELOCITY; HEALTH-CARE PROFESSIONALS; CAROTID-ARTERY STENOSIS; ATRIAL SEPTAL ANEURYSM	Non-invasive Doppler ultrasonographic study of cerebral arteries [transcranial Doppler (TCD)] has been extensively applied on both outpatient and inpatient settings. It is performed placing a low-frequency (<= 2 MHz) transducer on the scalp of the patient over specific acoustic windows, in order to visualize the intracranial arterial vessels and to evaluate the cerebral blood flow velocity and its alteration in many different conditions. Nowadays the most widespread indication for TCD in outpatient setting is the research of right to left shunting, responsable of so called "paradoxical embolism", most often due to patency of foramen ovale which is responsable of the majority of cryptogenic strokes occuring in patients younger than 55 years old. TCD also allows to classify the grade of severity of such shunts using the so called "microembolic signal grading score". In addition TCD has found many useful applications in neurocritical care practice. It is useful on both adults and children for day-to-day bedside assessment of critical conditions including vasospasm in subarachnoidal haemorrhage (caused by aneurysm rupture or traumatic injury), traumatic brain injury, brain stem death. It is used also to evaluate cerebral hemodynamic changes after stroke. It also allows to investigate cerebral pressure autoregulation and for the clinical evaluation of cerebral autoregulatory reserve.	[D'Andrea, Antonello; Conte, Marianna; Cavallaro, Massimo; Scarafile, Raffaella; Riegler, Lucia; Cocchia, Rosangela; Pezzullo, Enrica; Carbone, Andreina; Natale, Francesco; Santoro, Giuseppe; Caso, Pio; Russo, Maria Giovanna; Calabro, Raffaele] Univ Naples 2, Integrated Diagnost Cardiol, AORN dei Colli, Monaldi Hosp, Corso Vittorio Emanuele 121A, I-80121 Naples, Italy; [Bossone, Eduardo] Univ Hosp, Dept Cardiol & Cardiac Surg, I-84131 Salerno, Italy	D'Andrea, A (corresponding author), Univ Naples 2, Integrated Diagnost Cardiol, AORN dei Colli, Monaldi Hosp, Corso Vittorio Emanuele 121A, I-80121 Naples, Italy.	antonellodandrea@libero.it	Santoro, Giuseppe/AAC-2104-2019; Bossone, Eduardo/Z-1305-2019	carbone, andreina/0000-0002-2190-7010; RUSSO, Maria Giovanna/0000-0003-3860-6158			AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Aaslid R., 1986, TRANSCRANIAL DOPPLER, P22, DOI DOI 10.1007/978-3-7091-8864-4_3; Adams RJ, 2005, PEDIATR RADIOL, V35, P229, DOI 10.1007/s00247-005-1409-7; Adams RJ, 1997, ANN NEUROL, V42, P699, DOI 10.1002/ana.410420505; Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056/NEJM199807023390102; Alexandrov AV, 2002, NEUROLOGY, V59, P862, DOI 10.1212/WNL.59.6.862; Alexandrov AV, 2001, CIRCULATION, V103, P2897, DOI 10.1161/01.CIR.103.24.2897; Antignani P L, 2012, Int Angiol, V31, P1; Anzola GP, 2004, STROKE, V35, P2140, DOI 10.1161/01.STR.0000137764.07815.de; Arenillas JF, 2001, STROKE, V32, P2898, DOI 10.1161/hs1201.099652; Aries MJH, 2010, STROKE, V41, P2697, DOI 10.1161/STROKEAHA.110.594168; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; ARNOLDS BJ, 1986, ULTRASOUND MED BIOL, V12, P115, DOI 10.1016/0301-5629(86)90016-5; Babikian V, 1993, J Neuroimaging, V3, P242; Baracchini C, 2000, STROKE, V31, P2942, DOI 10.1161/01.STR.31.12.2942; Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; BOGDAHN U, 1990, STROKE, V21, P1680, DOI 10.1161/01.STR.21.12.1680; Bouzat P, 2014, CURR OPIN CRIT CARE, V20, P153, DOI 10.1097/MCC.0000000000000071; BRUNO A, 1988, STROKE, V19, P135, DOI 10.1161/01.STR.19.10.1300; CABANES L, 1993, STROKE, V24, P1865, DOI 10.1161/01.STR.24.12.1865; Camerlingo M, 1996, ITAL J NEUROL SCI, V17, P215, DOI 10.1007/BF01995686; Chang JJ, 2016, AM J NEURORADIOL, V37, P408, DOI 10.3174/ajnr.A4548; Christou I, 2001, J NEUROIMAGING, V11, P236, DOI 10.1111/j.1552-6569.2001.tb00040.x; Christou I, 2000, STROKE, V31, P1812, DOI 10.1161/01.STR.31.8.1812; Clarke N R A, 2004, Eur J Echocardiogr, V5, P176, DOI 10.1016/S1525-2167(03)00076-3; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1998, J NEUROSURG, V88, P802, DOI 10.3171/jns.1998.88.5.0802; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; D'Andrea A, 2011, J CARDIOVASC MED, V12, P527, DOI 10.2459/JCM.0b013e32834976d6; Daniels Cathy, 2004, Eur J Echocardiogr, V5, P449, DOI 10.1016/j.euje.2004.04.004; Demchuk AM, 2001, STROKE, V32, P89, DOI 10.1161/01.STR.32.1.89; Demchuk AM, 2000, J NEUROIMAGING, V10, P1; DITULLIO M, 1992, ANN INTERN MED, V117, P461, DOI 10.7326/0003-4819-117-6-461; Dorsch N, 2011, ACTA NEUROCHIR SUPPL, V110, P5, DOI 10.1007/978-3-7091-0353-1_1; DROSTE DW, 1989, STROKE, V20, P1005, DOI 10.1161/01.STR.20.8.1005; Ducrocq X, 1998, J NEUROL SCI, V160, P41, DOI 10.1016/S0022-510X(98)00188-9; Ducrocq X, 1998, J NEUROL SCI, V159, P145, DOI 10.1016/S0022-510X(98)00158-0; Frontera JA, 2009, STROKE, V40, P1963, DOI 10.1161/STROKEAHA.108.544700; Ghosh S, 2007, POSTGRAD MED J, V83, P173, DOI 10.1136/pgmj.2006.051094; GILLER CA, 1991, ACTA NEUROCHIR, V108, P7, DOI 10.1007/BF01407660; Godart F, 2000, EUR HEART J, V21, P483, DOI 10.1053/euhj.1999.1944; Gonzalez NR, 2007, J NEUROSURG, V107, P1101, DOI 10.3171/JNS-07/12/1101; Gonzalez-Alujas T, 2011, REV ESP CARDIOL, V64, P133, DOI 10.1016/j.recesp.2010.10.009; HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X; Hara H, 2005, J AM COLL CARDIOL, V46, P1768, DOI 10.1016/j.jacc.2005.08.038; HARDERS A, 1985, Neurological Research, V7, P129; HARDERS AG, 1987, J NEUROSURG, V66, P718, DOI 10.3171/jns.1987.66.5.0718; Homma S, 2002, CIRCULATION, V105, P2625, DOI 10.1161/01.CIR.0000017498.88393.44; Inzitari D, 2006, NEUROL SCI, V27, pS225, DOI 10.1007/s10072-006-0622-y; Inzitari D., 2000, Neurological Sciences, V21, P5; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; Jauss M, 2000, CEREBROVASC DIS, V10, P490, DOI 10.1159/000016119; Johansson MC, 2010, J AM SOC ECHOCARDIOG, V23, P1136, DOI 10.1016/j.echo.2010.08.004; Kaps M, 2008, EUR NEUROL, V59, P9, DOI 10.1159/000114455; Kerut EK, 2001, J AM COLL CARDIOL, V38, P613, DOI 10.1016/S0735-1097(01)01427-9; Keyrouz SG, 2007, CRIT CARE, V11, DOI 10.1186/cc5958; Knauth M, 1997, BRIT MED J, V314, P701, DOI 10.1136/bmj.314.7082.701; Kuhl HP, 1999, J AM COLL CARDIOL, V34, P1823, DOI 10.1016/S0735-1097(99)00412-X; KUSHNER MJ, 1991, NEUROLOGY, V41, P109, DOI 10.1212/WNL.41.1.109; Lamy C, 2002, STROKE, V33, P706, DOI 10.1161/hs0302.104543; Lang EW, 2001, CRIT CARE MED, V29, P158, DOI 10.1097/00003246-200101000-00031; Lange MC, 2010, J NEUROL SCI, V293, P106, DOI 10.1016/j.jns.2010.02.003; Lefevre J, 2008, ARCH CARDIOVASC DIS, V101, P213, DOI 10.1016/S1875-2136(08)73695-7; LEVINE BD, 1994, CIRCULATION, V90, P298, DOI 10.1161/01.CIR.90.1.298; Lindegaard K F, 1988, Acta Neurochir Suppl (Wien), V42, P81; Llompart-Pou JA, 2013, ISRN CRITICAL CARE, DOI [10.5402/2013/167468, DOI 10.5402/2013/167468]; Lysakowski C, 2001, STROKE, V32, P2292, DOI 10.1161/hs1001.097108; Marinoni M, 1997, ULTRASOUND MED BIOL, V23, P1275, DOI 10.1016/S0301-5629(97)00077-X; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MARTIN PJ, 1994, STROKE, V25, P390, DOI 10.1161/01.STR.25.2.390; McGirt Matthew J, 2003, J Stroke Cerebrovasc Dis, V12, P88, DOI 10.1053/jscd.2003.10; Meier B, 2003, CIRCULATION, V107, P5, DOI 10.1161/01.CIR.0000046073.34261.C1; MELTZER RS, 1980, J CLIN ULTRASOUND, V8, P121, DOI 10.1002/jcu.1870080205; Mojadidi MK, 2014, JACC-CARDIOVASC IMAG, V7, P236, DOI 10.1016/j.jcmg.2013.12.011; Monteiro LM, 2006, INTENS CARE MED, V32, P1937, DOI 10.1007/s00134-006-0353-9; Moppett IK, 2004, BRIT J ANAESTH, V93, P710, DOI 10.1093/bja/aeh205; Moreno J A, 2000, Neurosurg Focus, V8, pe8; Nicoletto Heather A, 2009, Am J Electroneurodiagnostic Technol, V49, P14; Panerai RB, 1998, PHYSIOL MEAS, V19, P305, DOI 10.1088/0967-3334/19/3/001; Panerai RB, 2008, CARDIOVASC ENG, V8, P42, DOI 10.1007/s10558-007-9044-6; Panerai RB, 2009, CLIN AUTON RES, V19, P197, DOI 10.1007/s10286-009-0011-8; Papaioannou V, 2008, GREEK EJ PERIOP MED, V6, P95; Patel PM, 2009, MILLERS ANESTHESIA, P305; Paulus J, 2014, INTENS CARE MED, V40, P1783, DOI 10.1007/s00134-014-3447-9; Platt Orah S, 2006, Hematology Am Soc Hematol Educ Program, P54; Poularas J, 2006, TRANSPL P, V38, P1213, DOI 10.1016/j.transproceed.2006.02.127; Pristipino C, 2013, G ITAL CARDIOL, V14, P699, DOI 10.1714/1335.14838; Puppo C, 2008, NEUROCRIT CARE, V8, P344, DOI 10.1007/s12028-008-9069-8; Rajamani K, 2001, BIOMED PHARMACOTHER, V55, P247, DOI 10.1016/S0753-3322(01)00063-4; Rasulo EA, 2008, EUR J ANAESTH, V25, P167, DOI 10.1017/S0265021507003341; Razumovsky AY, 1999, ACTA NEUROL SCAND, V99, P65; Reinhard M, 2003, STROKE, V34, P2138, DOI 10.1161/01.STR.0000087788.65566.AC; Rigamonti A, 2008, CAN J ANAESTH, V55, P112, DOI 10.1007/BF03016323; Rowland MJ, 2012, BRIT J ANAESTH, V109, P315, DOI 10.1093/bja/aes264; Saqqur M, 2007, CRIT CARE MED, V35, pS216, DOI 10.1097/01.CCM.0000260633.66384.FB; Sarkar S, 2007, POSTGRAD MED J, V83, P683, DOI 10.1136/pgmj.2007.058602; Schondorf R, 2001, J APPL PHYSIOL, V91, P2493; Serena J, 1998, STROKE, V29, P1322, DOI 10.1161/01.STR.29.7.1322; Shahlaie K, 2011, J NEUROSURG, V115, P602, DOI 10.3171/2011.5.JNS101667; Skjelland M, 2009, STROKE, V40, P230, DOI 10.1161/STROKEAHA.107.513341; Sloan MA, 2004, NEUROLOGY, V62, P1468, DOI 10.1212/WNL.62.9.1468; Sorensen SG, 2010, J INTERV CARDIOL, V23, P575, DOI 10.1111/j.1540-8183.2010.00587.x; Souteyrand G, 2006, EUR J ECHOCARDIOGR, V7, P147, DOI 10.1016/j.euje.2005.04.007; Stolz E, 2008, STROKE, V39, P3255, DOI 10.1161/STROKEAHA.108.522714; Sviri GE, 2006, NEUROSURGERY, V59, P360, DOI 10.1227/01.NEU.0000223502.93013.6E; Tegeler CH, 2013, J NEUROIMAGING, V23, P466, DOI 10.1111/j.1552-6569.2012.00711.x; Tiecks FP, 1996, STROKE, V27, P1177, DOI 10.1161/01.STR.27.7.1177; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Topcuoglu M. Akif, 2002, Curr Treat Options Cardiovasc Med, V4, P373, DOI 10.1007/s11936-002-0017-1; Tsivgoulis G, 2007, STROKE, V38, P1245, DOI 10.1161/01.STR.0000259712.64772.85; Tsivgoulis G, 2009, CURR NEUROL NEUROSCI, V9, P46, DOI 10.1007/s11910-009-0008-7; Ursino M, 2003, MED ENG PHYS, V25, P655, DOI 10.1016/S1350-4533(02)00251-5; Van Camp G, 2000, AM J CARDIOL, V86, P1284, DOI 10.1016/S0002-9149(00)01224-8; van Santbrink H, 2002, ACTA NEUROCHIR, V144, P1141, DOI 10.1007/s00701-002-1012-8; Velat GJ, 2011, WORLD NEUROSURG, V76, P446, DOI 10.1016/j.wneu.2011.02.030; Washington CW, 2011, NEUROCRIT CARE, V15, P312, DOI 10.1007/s12028-011-9594-8; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; White H, 2006, INTENS CARE MED, V32, P981, DOI 10.1007/s00134-006-0173-y; White RP, 1997, STROKE, V28, P1340, DOI 10.1161/01.STR.28.7.1340; WIJDICKS EFM, 1995, NEUROLOGY, V45, P1003, DOI 10.1212/WNL.45.5.1003; Woods TD, 2006, J AM SOC ECHOCARDIOG, V19, P215, DOI 10.1016/j.echo.2005.09.023; Wozniak MA, 1996, J NEUROIMAGING, V6, P87, DOI 10.1111/jon19966287; Wu LA, 2004, ARCH INTERN MED, V164, P950, DOI 10.1001/archinte.164.9.950; Zoghbi WA, 2014, JACC-CARDIOVASC IMAG, V7, P251, DOI 10.1016/j.jcmg.2014.01.007; ZURYNSKI YA, 1995, J NEUROL SCI, V134, P41, DOI 10.1016/0022-510X(95)00178-X	129	40	40	0	1	BAISHIDENG PUBLISHING GROUP INC	PLEASANTON	8226 REGENCY DR, PLEASANTON, CA 94588 USA	1949-8462			WORLD J CARDIOL	World J. Cardiol.	JUL 26	2016	8	7					383	400		10.4330/wjc.v8.i7.383			18	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	DV6ZC	WOS:000383084600001	27468332	Green Published, Other Gold			2021-06-18	
J	Militana, AR; Donahue, MJ; Sills, AK; Solomon, GS; Gregory, AJ; Strother, MK; Morgan, VL				Militana, Adam R.; Donahue, Manus J.; Sills, Allen K.; Solomon, Gary S.; Gregory, Andrew J.; Strother, Megan K.; Morgan, Victoria L.			Alterations in default-mode network connectivity may be influenced by cerebrovascular changes within 1 week of sports related concussion in college varsity athletes: a pilot study	BRAIN IMAGING AND BEHAVIOR			English	Article						Concussion; Cerebrovascular reactivity; Cerebral blood flow; Functional MRI; Functional connectivity	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; CEREBRAL-BLOOD-FLOW; FUNCTIONAL CONNECTIVITY; HEAD-INJURY; VASCULAR REACTIVITY; FMRI DATA; MRI; PERFUSION; RELIABILITY	The goal of this pilot study is to use complementary MRI strategies to quantify and relate cerebrovascular reactivity, resting cerebral blood flow and functional connectivity alterations in the first week following sports concussion in college varsity athletes. Seven college athletes (3F/4M, age = 19.7 +/- 1.2 years) were imaged 3-6 days following a diagnosed sports related concussion and compared to eleven healthy controls with no history of concussion (5M/6F, 18-23 years, 7 athletes). Cerebrovascular reactivity and functional connectivity were measured using functional MRI during a hypercapnia challenge and via resting-state regional partial correlations, respectively. Resting cerebral blood flow was quantified using arterial spin labeling MRI methods. Group comparisons were made within and between 18 regions of interest. Cerebrovascular reactivity was increased after concussion when averaged across all regions of interest (p=0.04), and within some default-mode network regions, the anterior cingulate and the right thalamus (p<0.05) independently. The FC was increased in the concussed athletes within the default-mode network including the left and right hippocampus, precuneus and ventromedial prefrontal cortex (p<0.01), with measures being linearly related to cerebrovascular reactivity in the hippocampus in the concussed athletes. Significant resting cerebral blood flow changes were not detected between the two groups. This study provides evidence for increased cerebrovascular reactivity and functional connectivity in the medial regions of the default-mode network within days of a single sports related concussion in college athletes. Our findings emphasize the utility of complementary cerebrovascular measures in the interpretation of alterations in functional connectivity following concussion.	[Militana, Adam R.; Donahue, Manus J.; Strother, Megan K.; Morgan, Victoria L.] Vanderbilt Univ, Sch Med, Dept Radiol & Radiol Sci, Nashville, TN 37212 USA; [Sills, Allen K.; Solomon, Gary S.] Vanderbilt Univ, Sch Med, Dept Neurosurg, Nashville, TN 37212 USA; [Gregory, Andrew J.] Vanderbilt Univ, Sch Med, Dept Orthoped, Nashville, TN 37212 USA; [Morgan, Victoria L.] Vanderbilt Univ, Dept Radiol, 1161 21st Ave South,AA1105 MCN, Nashville, TN 37232 USA	Morgan, VL (corresponding author), Vanderbilt Univ, Sch Med, Dept Radiol & Radiol Sci, Nashville, TN 37212 USA.; Morgan, VL (corresponding author), Vanderbilt Univ, Dept Radiol, 1161 21st Ave South,AA1105 MCN, Nashville, TN 37232 USA.	victoria.morgan@vanderbilt.edu	Solomon, Gary/K-9011-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54HD083211] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000445] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000445] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54 HD083211] Funding Source: Medline		Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Bartnik-Olson BL, 2014, J NEUROTRAUM, V31, P1497, DOI 10.1089/neu.2013.3213; Becelewski Janusz, 2003, Neurol Neurochir Pol, V37, P339; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Bright MG, 2013, NEUROIMAGE, V83, P559, DOI 10.1016/j.neuroimage.2013.07.007; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Buxton RB, 1998, MAGNET RESON MED, V40, P383, DOI 10.1002/mrm.1910400308; Chen YF, 2011, J MAGN RESON IMAGING, V33, P940, DOI 10.1002/jmri.22345; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cordes D, 2001, AM J NEURORADIOL, V22, P1326; Dai WY, 2008, MAGN RESON MED, V60, P1488, DOI 10.1002/mrm.21790; DETRE JA, 1992, MAGNET RESON MED, V23, P37, DOI 10.1002/mrm.1910230106; Gahm C, 2000, NEUROSURGERY, V46, P169; Gao W, 2012, HUM BRAIN MAPP, V33, P192, DOI 10.1002/hbm.21204; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Glover GH, 2000, MAGNET RESON MED, V44, P162, DOI 10.1002/1522-2594(200007)44:1<162::AID-MRM23>3.3.CO;2-5; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Hare HV, 2013, J CEREBR BLOOD F MET, V33, P1799, DOI 10.1038/jcbfm.2013.131; Jiang L, 2010, MAGN RESON IMAGING, V28, P1283, DOI 10.1016/j.mri.2010.05.002; Johnson B, 2014, J NEUROTRAUM, V31, P1907, DOI 10.1089/neu.2014.3415; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Len TK, 2013, BRAIN INJURY, V27, P346, DOI 10.3109/02699052.2012.743185; Len TK, 2011, MED SCI SPORT EXER, V43, P2241, DOI 10.1249/MSS.0b013e3182249539; Liu PY, 2013, NEUROIMAGE, V78, P415, DOI 10.1016/j.neuroimage.2013.04.053; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Lu HZ, 2008, MAGN RESON MED, V60, P364, DOI 10.1002/mrm.21686; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McQuire JC, 1998, J NEUROSURG, V89, P526, DOI 10.3171/jns.1998.89.4.0526; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Murphy K, 2011, NEUROIMAGE, V54, P369, DOI 10.1016/j.neuroimage.2010.07.059; OGAWA S, 1990, MAGNET RESON MED, V14, P68, DOI 10.1002/mrm.1910140108; Ogoh S, 2009, J APPL PHYSIOL, V107, P1370, DOI 10.1152/japplphysiol.00573.2009; Palacios EM, 2013, JAMA NEUROL, V70, P845, DOI 10.1001/jamaneurol.2013.38; Peebles KC, 2008, J APPL PHYSIOL, V105, P1060, DOI 10.1152/japplphysiol.90613.2008; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; Rogers BP, 2007, MAGN RESON IMAGING, V25, P1347, DOI 10.1016/j.mri.2007.03.007; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Sridharan D, 2008, P NATL ACAD SCI USA, V105, P12569, DOI 10.1073/pnas.0800005105; Strebel S, 1997, SURG NEUROL, V47, P128, DOI 10.1016/S0090-3019(96)00459-4; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; THOMSEN LL, 1995, CEPHALALGIA, V15, P211, DOI 10.1046/j.1468-2982.1995.015003211.x; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wang JJ, 2003, MAGN RESON MED, V50, P599, DOI 10.1002/mrm.10559; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; Zhou YX, 2014, J MAGN RESON IMAGING, V39, P1558, DOI 10.1002/jmri.24310; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413	57	40	40	0	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2016	10	2					559	568		10.1007/s11682-015-9407-3			10	Neuroimaging	Neurosciences & Neurology	DU7JK	WOS:000382390000022	25972119	Green Accepted			2021-06-18	
J	Yengo-Kahn, AM; Hale, AT; Zalneraitis, BH; Zuckerman, SL; Sills, AK; Solomon, GS				Yengo-Kahn, Aaron M.; Hale, Andrew T.; Zalneraitis, Brian H.; Zuckerman, Scott L.; Sills, Allen K.; Solomon, Gary S.			The Sport Concussion Assessment Tool: a systematic review	NEUROSURGICAL FOCUS			English	Article						sideline assessment; Sport Concussion Assessment Tool; Standardized Assessment of Concussion; modified Balance Error Scoring System; sport-related concussion	BASE-LINE ASSOCIATIONS; ERROR SCORING SYSTEM; AMATEUR RUGBY UNION; HIGH-SCHOOL; ICE HOCKEY; STANDARDIZED ASSESSMENT; KING-DEVICK; SIDELINE; SCAT2; YOUTH	Objective Over the last 2 decades, sport-related concussion (SRC) has garnered significant attention. Even with increased awareness and athlete education, sideline recognition and real-time diagnosis remain crucial. The need for an objective and standardized assessment of concussion led to the eventual development of the Sport Concussion Assessment Tool (SCAT) during the Second International Conference on Concussion in Sport in 2004, which is now in its third iteration (SCAT3). In an effort to update our understanding of the most well-known sideline concussion assessment, the authors conducted a systematic review of the SCAT and the evidence supporting its use to date. METHODS English-language titles and abstracts published between 1995 and October 2015 were searched systematically across 4 electronic databases and a review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines adapted for the review of a heterogeneous collection of study designs. Peer-reviewed journal articles were included if they reported quantitative data on any iteration of the SCAT, Standardized Assessment of Concussion (SAC), or modified Balance Error Scoring System (mBESS) data at baseline or following concussion in an exclusively athlete population with any portion older than 13 years of age. Studies that included nonathletes, only children less than 13 years old, exclusively BESS data, exclusively symptom scale data, or a non-SCAT-related assessment were excluded. RESULTS The database search process yielded 549 abstracts, and 105 full-text articles were reviewed with 36 meeting criteria for inclusion. Nineteen studies were associated with the SAC, 1 was associated with the mBESS exclusively, and 16 studies were associated with a full iteration of the SCAT. The majority of these studies (56%) were prospective cohort studies. Male football players were the most common athletes studied. An analysis of the studies focused on baseline differences associated with age, sex, concussion history, and the ability to detect an SRC. CONCLUSIONS Looking toward the upcoming Concussion in Sport Group meeting in fall 2016, one may expect further revision to the SCAT3. However, based on this systematic review, the authors propose further, in-depth study of an already comprehensive concussion test, with acute, diagnostic, as well as long-term use.	[Yengo-Kahn, Aaron M.; Hale, Andrew T.; Zalneraitis, Brian H.; Zuckerman, Scott L.; Sills, Allen K.; Solomon, Gary S.] Vanderbilt Univ, Sch Med, Vanderbilt Sports Concuss Ctr, 1500 21st Ave S,Ste 1506, Nashville, TN 37232 USA; [Zuckerman, Scott L.; Sills, Allen K.; Solomon, Gary S.] Vanderbilt Univ, Sch Med, Dept Neurol Surg, Nashville, TN 37232 USA	Yengo-Kahn, AM (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Sports Concuss Ctr, 1500 21st Ave S,Ste 1506, Nashville, TN 37232 USA.	aaron.m.yengo-kahn@vanderbilt.edu	Yengo-Kahn, Aaron/AAV-7647-2020; Solomon, Gary/K-9011-2019; Meijer, Anna/K-5118-2016	Yengo-Kahn, Aaron/0000-0002-5989-3064; Hale, Andrew/0000-0003-3182-2966	Tennessee Titans; Nashville Predators	Dr. Solomon receives consulting fees from the Tennessee Titans (NFL), the Nashville Predators (NHL), and the athletic departments for several universities. In addition he is a member of the ImPACT advisory board and receives reimbursement for expenses related to board meetings, and also receives royalties from book sales. Dr. Sills is a consulting physician to the Nashville Predators (uncompensated) and also serves as an unaffiliated neurotrauma consultant for the NFL.	Alla S, 2009, BRIT J SPORT MED, V43, pI3, DOI 10.1136/bjsm.2009.058339; Baker JG, 2015, CLIN PEDIATR, V54, P961, DOI 10.1177/0009922815588820; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bonfield CM, 2014, PROG NEUROL SURG, V28, P161, DOI 10.1159/000358777; Curaudeau GA, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.8.FOCUS11186; Echlin PS, 2014, J NEUROSURG, V121, P1331, DOI 10.3171/2014.8.JNS132804; Echlin PS, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12286; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10187; Echlin PS, 2012, NEUROSURG FOCUS, V33, P1, DOI DOI 10.3171/2012.10.F0CUS12286; Galetta KM, 2015, J NEURO-OPHTHALMOL, V35, P235, DOI 10.1097/WNO.0000000000000226; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Glaviano NR, 2015, CLIN J SPORT MED, V25, P373, DOI 10.1097/JSM.0000000000000154; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Hanninen T, 2015, J SCI MED SPORT; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hunt TN, 2009, J ATHL TRAINING, V44, P405, DOI 10.4085/1062-6050-44.4.405; Jinguji TM, 2012, BRIT J SPORT MED, V46, P365, DOI 10.1136/bjsports-2011-090526; Kerr ZY, 2014, BRAIN INJURY, V28, P1009, DOI 10.3109/02699052.2014.904049; King D, 2015, J NEUROL SCI, V351, P58, DOI 10.1016/j.jns.2015.02.035; King D, 2014, SPORTS MED, V44, P449, DOI 10.1007/s40279-013-0134-x; King D, 2013, J NEUROL SCI, V326, P59, DOI 10.1016/j.jns.2013.01.012; King LA, 2014, ARCH PHYS MED REHAB, V95, P353, DOI 10.1016/j.apmr.2013.10.015; Krol AL, 2011, BRAIN INJURY, V25, P1300, DOI 10.3109/02699052.2011.624571; Kurowski BG, 2015, J TRAUMA ACUTE CARE, V79, pS21, DOI 10.1097/TA.0000000000000675; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Nassiri JD, 2002, MIL MED, V167, P873; Okonkwo David O, 2014, Neurosurgery, V75 Suppl 4, pS82, DOI 10.1227/NEU.0000000000000493; Putukian M, 2015, CLIN J SPORT MED, V25, P36, DOI 10.1097/JSM.0000000000000102; Putukian M, 2011, CLIN SPORT MED, V30, P49, DOI 10.1016/j.csm.2010.09.005; Ruhe A, 2014, BRIT J SPORT MED, V48, P102, DOI 10.1136/bjsports-2012-091609; Sabin MJ, 2011, CLIN J SPORT MED, V21, P411, DOI 10.1097/JSM.0b013e318223f3a4; Schmitt DM, 2004, INT J SPORTS MED, V25, P326, DOI 10.1055/s-2004-819941; Schneider KJ, 2010, BRIT J SPORT MED, V44, P1112, DOI 10.1136/bjsm.2009.071266; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; Snyder AR, 2014, CLIN NEUROPSYCHOL, V28, P1091, DOI 10.1080/13854046.2014.952667; Szabo AJ, 2013, J ATHL TRAINING, V48, P851, DOI 10.4085/1062-6050-48.6.20; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Vernau BT, 2015, DEV NEUROPSYCHOL, V40, P7, DOI 10.1080/87565641.2014.971955; Wang Y, 2015, J NEUROTRAUMA; Weber AF, 2013, J ATHL TRAINING, V48, P153, DOI 10.4085/1062-6050-48.1.07; Yengo-Kahn AM, 2015, AM J SPORTS MED; Zimmer A, 2015, APPL NEUROPSYCH-ADUL, V22, P132, DOI 10.1080/23279095.2013.867265; Zimmer A, 2013, J ATHL TRAINING, V48, P659, DOI 10.4085/1062-6050-48.5.06	59	40	41	1	31	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	APR	2016	40	4							E6	10.3171/2016.1.FOCUS15611			14	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DI4NL	WOS:000373476500007	27032923	Bronze			2021-06-18	
J	Kochanek, PM; Bramlett, HM; Shear, DA; Dixon, CE; Mondello, S; Dietrich, WD; Hayes, RL; Wang, KKW; Poloyac, SM; Empey, PE; Povlishock, JT; Mountney, A; Browning, M; Deng-Bryant, Y; Yan, HQ; Jackson, TC; Catania, M; Glushakova, O; Richieri, SP; Tortella, FC				Kochanek, Patrick M.; Bramlett, Helen M.; Shear, Deborah A.; Dixon, C. Edward; Mondello, Stefania; Dietrich, W. Dalton; Hayes, Ronald L.; Wang, Kevin K. W.; Poloyac, Samuel M.; Empey, Philip E.; Povlishock, John T.; Mountney, Andrea; Browning, Megan; Deng-Bryant, Ying; Yan, Hong Q.; Jackson, Travis C.; Catania, Michael; Glushakova, Olena; Richieri, Steven P.; Tortella, Frank C.			Synthesis of Findings, Current Investigations, and Future Directions: Operation Brain Trauma Therapy	JOURNAL OF NEUROTRAUMA			English	Article						traumatic brain injury; therapy; rat; biomarker; controlled cortical impact; pre-clinical modeling; micropig; penetrating ballistic-like brain injury; reproducibility; fluid percussion; drug	CONTROLLED CORTICAL IMPACT; MICROGLIAL ACTIVATION; HEMORRHAGIC-SHOCK; RAT MODEL; INJURY; AMANTADINE; DEFICITS; MICE; NEUROPROTECTION; PERFORMANCE	Operation Brain Trauma Therapy (OBTT) is a fully operational, rigorous, and productive multicenter, pre-clinical drug and circulating biomarker screening consortium for the field of traumatic brain injury (TBI). In this article, we synthesize the findings from the first five therapies tested by OBTT and discuss both the current work that is ongoing and potential future directions. Based on the results generated from the first five therapies tested within the exacting approach used by OBTT, four (nicotinamide, erythropoietin, cyclosporine A, and simvastatin) performed below or well below what was expected based on the published literature. OBTT has identified, however, the early post-TBI administration of levetiracetam as a promising agent and has advanced it to a gyrencephalic large animal model-fluid percussion injury in micropigs. The sixth and seventh therapies have just completed testing (glibenclamide and Kollidon VA 64), and an eighth drug (AER 271) is in testing. Incorporation of circulating brain injury biomarker assessments into these pre-clinical studies suggests considerable potential for diagnostic and theranostic utility of glial fibrillary acidic protein in pre-clinical studies. Given the failures in clinical translation of therapies in TBI, rigorous multicenter, pre-clinical approaches to therapeutic screening such as OBTT may be important for the ultimate translation of therapies to the human condition.	[Kochanek, Patrick M.; Browning, Megan; Jackson, Travis C.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 Fifth Ave, Pittsburgh, PA 15260 USA; [Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA; [Bramlett, Helen M.] Vet Affairs Med Ctr, Bruce W Carter Dept, Miami, FL 33125 USA; [Shear, Deborah A.; Mountney, Andrea; Deng-Bryant, Ying; Tortella, Frank C.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Brain Trauma Neuroprotect Neurorestorat, Silver Spring, MD USA; [Dixon, C. Edward; Yan, Hong Q.] Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Mondello, Stefania] Univ Messina, Dept Neurosci, Messina, Italy; [Hayes, Ronald L.] Banyan Biomarkers Inc, Ctr Neuroprote & Biomarkers Res, Ctr Innovat Res, Alachua, FL USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat & Neurosci, Ctr Neuroprote & Biomarkers Res, Gainesville, FL USA; [Poloyac, Samuel M.; Empey, Philip E.] Univ Pittsburgh, Sch Pharm, Ctr Pharmaceut Sci, Pittsburgh, PA 15260 USA; [Povlishock, John T.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA USA; [Catania, Michael; Glushakova, Olena; Richieri, Steven P.] Banyan Biomarkers, Alachua, FL USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 Fifth Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Empey, Philip/L-9604-2019; Mondello, Stefania/A-1813-2012	Empey, Philip/0000-0001-7474-2339; Mondello, Stefania/0000-0002-8587-3614; Wang, Kevin/0000-0002-9343-6473			Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; Begley CG, 2015, CIRC RES, V116, P116, DOI 10.1161/CIRCRESAHA.114.303819; Begley CG, 2012, NATURE, V483, P531, DOI 10.1038/483531a; Bigler ED, 2014, NEUROLOGY, V82, P1641, DOI 10.1212/WNL.0000000000000395; Bramlett HM, 2016, J NEUROTRAUM, V33, P538, DOI 10.1089/neu.2015.4116; Bramlett HM, 2015, J NEUROTRAUM, V32, P1834, DOI 10.1089/neu.2014.3352; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Browning M, 2016, J NEUROTRAUM, V33, P581, DOI 10.1089/neu.2015.4131; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Darrah SH, 2011, J NEUROTRAUM, V28, P43, DOI 10.1089/neu.2010.1521; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Dixon CE, 2016, J NEUROTRAUM, V33, P553, DOI 10.1089/neu.2015.4122; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Ehrenreich H, 2009, STROKE, V40, pE647, DOI 10.1161/STROKEAHA.109.564872; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Haber M, 2013, EXP NEUROL, V249, P169, DOI 10.1016/j.expneurol.2013.09.002; Hawryluk Gregory W J, 2015, Handb Clin Neurol, V127, P15, DOI 10.1016/B978-0-444-52892-6.00002-7; Hemerka JN, 2012, J NEUROTRAUM, V29, P2192, DOI 10.1089/neu.2011.2303; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Kernie SG, 2015, PEDIATR CRIT CARE ME, V16, P294, DOI 10.1097/PCC.0000000000000347; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Kochanek PM, 2016, J NEUROTRAUM, V33, P513, DOI 10.1089/neu.2015.4113; Kochanek PM, 2015, SEMIN NEUROL, V35, P83, DOI 10.1055/s-0035-1544237; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Lapchak PA, 2013, TRANSL STROKE RES, V4, P279, DOI 10.1007/s12975-012-0209-2; Liao GP, 2015, PEDIATR CRIT CARE ME, V16, P245, DOI 10.1097/PCC.0000000000000324; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Mondello S, 2016, J NEUROTRAUM, V33, P595, DOI 10.1089/neu.2015.4132; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; Mountney A, 2016, J NEUROTRAUM, V33, P567, DOI 10.1089/neu.2015.4130; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Reier Paul J, 2012, Handb Clin Neurol, V109, P411, DOI 10.1016/B978-0-444-52137-8.00026-7; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Shear DA, 2016, J NEUROTRAUM, V33, P523, DOI 10.1089/neu.2015.4115; Shein SL, 2014, J NEUROTRAUM, V31, P1386, DOI 10.1089/neu.2013.2985; Simard JM, 2010, STROKE, V41, P531, DOI 10.1161/STROKEAHA.109.572644; Smith DH, 2015, J NEUROTRAUM, V32, P1725, DOI 10.1089/neu.2014.3861; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Wang HC, 2006, NEUROCRIT CARE, V5, P71, DOI 10.1385/NCC:5:1:71; Wang T, 2014, J NEUROTRAUM, V31, P370, DOI 10.1089/neu.2013.2917; Warner DS, 2014, JAMA NEUROL, V71, P1311, DOI 10.1001/jamaneurol.2014.1238; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304	52	40	40	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 15	2016	33	6					606	614		10.1089/neu.2015.4133			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DG6HN	WOS:000372184800009	26671284				2021-06-18	
J	Andrews, AM; Lutton, EM; Merkel, SF; Razmpour, R; Ramirez, SH				Andrews, Allison M.; Lutton, Evan M.; Merkel, Steven F.; Razmpour, Roshanak; Ramirez, Servio H.			Mechanical Injury Induces Brain Endothelial-Derived Microvesicle Release: Implications for Cerebral Vascular Injury during Traumatic Brain Injury	FRONTIERS IN CELLULAR NEUROSCIENCE			English	Article						blood-brain barrier (BBB); traumatic brain injury; mechanical strain; extracellular microvesicles; tight junction proteins; neuroinflammation	IN-VITRO; BARRIER DISRUPTION; MICROPARTICLE FORMATION; ACTIN CYTOSKELETON; CELLS; MODEL; ACTIVATION; STRETCH; DYSFUNCTION; BIOGENESIS	It is well established that the endothelium responds to mechanical forces induced by changes in shear stress and strain. However, our understanding of vascular remodeling following traumatic brain injury (TBI) remains incomplete. Recently published studies have revealed that lung and umbilical endothelial cells produce extracellular microvesicles (eMVs), such as microparticles, in response to changes in mechanical forces (blood flow and mechanical injury). Yet, to date, no studies have shown whether brain endothelial cells produce eMVs following TBI. The brain endothelium is highly specialized and forms the blood -brain barrier (BBB), which regulates diffusion and transport of solutes into the brain. This specialization is largely due to the presence of tight junction proteins (TJPs) between neighboring endothelial cells. Following TBI, a breakdown in tight junction complexes at the BBB leads to increased permeability, which greatly contributes to the secondary phase of injury. We have therefore tested the hypothesis that brain endothelium responds to mechanical injury, by producing eMVs that contain brain endothelial proteins, specifically TJPs. In our study, primary human adult brain microvascular endothelial cells (BMVFC) were subjected to rapid mechanical injury to simulate the abrupt endothelial disruption that can occur in the primary injury phase of TBI. eMVs were isolated from the media following injury at 2, 6, 24, and 48h. Western blot analysis of eMVs demonstrated a time -dependent increase in TJP occludin, PFCAM-1 and ICAM-1 following mechanical injury. In addition, activation of ARF6, a small GTPase linked to extracellular vesicle production, was increased after injury. To confirm these results in vivo, mice were subjected to sham surgery or TBI and blood plasma was collected 24 h post -injury. Isolation and analysis of eMVs from blood plasma using cryo-FM and flow cytometry revealed elevated levels of vesicles containing occludin following brain trauma. These results indicate that following TBI, the cerebral endothelium undergoes vascular remodeling through shedding of eMVs containing TJPs and endothelial markers. The detection of this shedding potentially allows for a novel methodology for real-time monitoring of cerebral vascular health (remodeling), BBB status and neuroinflammation following a TBI event.	[Andrews, Allison M.; Lutton, Evan M.; Merkel, Steven F.; Razmpour, Roshanak; Ramirez, Servio H.] Temple Univ, Lewis Katz Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19122 USA; [Andrews, Allison M.; Merkel, Steven F.; Ramirez, Servio H.] Shriners Hosp Crippled Children, Pediat Res Ctr, Philadelphia, PA USA; [Ramirez, Servio H.] Temple Univ, Lewis Katz Sch Med, Ctr Subst Abuse Res, Philadelphia, PA 19122 USA	Ramirez, SH (corresponding author), Temple Univ, Lewis Katz Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19122 USA.; Ramirez, SH (corresponding author), Shriners Hosp Crippled Children, Pediat Res Ctr, Philadelphia, PA USA.; Ramirez, SH (corresponding author), Temple Univ, Lewis Katz Sch Med, Ctr Subst Abuse Res, Philadelphia, PA 19122 USA.	servio.ramirez@temple.edu		ramirez, servio/0000-0002-4609-5653	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01NS086570]; Shriners Hospitals for Children [85110-PHI-14]; NIH-NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [T32 DA007237, P30-DA13429]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS086570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA007237, P30DA013429] Funding Source: NIH RePORTER	We would like to thank the Penn Core Facility (particularly Ray Meade and Dr. Dewight Williams) for their help with cryo-EM. This study was supported (in part) by research funding from the NIH: 1R01NS086570 (to SHR) and the Shriners Hospitals for Children: 85110-PHI-14 (to SHR), NIH-NIDA T32 DA007237 (AA), and P30-DA13429 (SHR).	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Aghajanian A, 2008, J THROMB HAEMOST, V6, P1453, DOI 10.1111/j.1538-7836.2008.03087.x; Akers JC, 2013, J NEURO-ONCOL, V113, P1, DOI 10.1007/s11060-013-1084-8; Bernas MJ, 2010, NAT PROTOC, V5, P1265, DOI 10.1038/nprot.2010.76; Boshans RL, 2000, MOL CELL BIOL, V20, P3685, DOI 10.1128/MCB.20.10.3685-3694.2000; Boulanger CM, 2006, HYPERTENSION, V48, P180, DOI 10.1161/01.HYP.0000231507.00962.b5; Brown TD, 2000, J BIOMECH, V33, P3, DOI 10.1016/S0021-9290(99)00177-3; Burger D, 2011, ARTERIOSCL THROM VAS, V31, P1898, DOI 10.1161/ATVBAHA.110.222703; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Chironi GN, 2009, CELL TISSUE RES, V335, P143, DOI 10.1007/s00441-008-0710-9; Cullen DK, 2007, J NEUROSCI RES, V85, P3642, DOI 10.1002/jnr.21434; Dignat-George F, 2011, ARTERIOSCL THROM VAS, V31, P27, DOI 10.1161/ATVBAHA.110.218123; Draeger A, 2011, BIOCHEM PHARMACOL, V81, P703, DOI 10.1016/j.bcp.2010.12.027; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Figueroa DS, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4028037; Forde CT, 2014, BRIT J NEUROSURG, V28, P8, DOI 10.3109/02688697.2013.815317; Friand V, 2015, BIOL CELL, V107, P331, DOI 10.1111/boc.201500010; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Ghossoub R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4477; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hue CD, 2013, J NEUROTRAUM, V30, P1652, DOI 10.1089/neu.2012.2773; Issman L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083680; Jenkins NT, 2013, HYPERTENSION, V61, P615, DOI 10.1161/HYPERTENSIONAHA.111.00561; Jimenez JJ, 2003, THROMB RES, V109, P175, DOI 10.1016/S0049-3848(03)00064-1; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Lai CH, 2005, BRAIN RES REV, V50, P7, DOI 10.1016/j.brainresrev.2005.03.007; Latham SL, 2013, FASEB J, V27, P672, DOI 10.1096/fj.12-216531; Letsiou E, 2015, AM J RESP CELL MOL, V52, P193, DOI 10.1165/rcmb.2013-0347OC; Liu W, 2016, RADIOLOGY, V278, P536, DOI 10.1148/radiol.2015150160; Muralidharan-Chari V, 2009, CURR BIOL, V19, P1875, DOI 10.1016/j.cub.2009.09.059; Pasquier J, 2014, CANCER MICROENVIRON, V7, P41, DOI 10.1007/s12307-013-0142-2; Persidsky Y, 2006, J NEUROIMMUNE PHARM, V1, P223, DOI 10.1007/s11481-006-9025-3; Ramirez SH, 2012, J NEUROSCI, V32, P4004, DOI 10.1523/JNEUROSCI.4628-11.2012; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Rom S, 2015, J CEREBR BLOOD F MET, V35, P28, DOI 10.1038/jcbfm.2014.167; Salvador E, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00323; Salvador E, 2013, JOVE-J VIS EXP, DOI 10.3791/50928; SCHAFFER JL, 1994, J ORTHOP RES, V12, P709, DOI 10.1002/jor.1100120514; Shan RZ, 2016, J NEUROTRAUM, V33, P49, DOI 10.1089/neu.2014.3811; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Simard JM, 2010, J NEUROSURG, V113, P622, DOI 10.3171/2009.11.JNS081052; Tan KT, 2005, ANN MED, V37, P61, DOI 10.1080/07853890410018943; Thal SC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050752; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vion AC, 2013, PULM CIRC, V3, P95, DOI 10.4103/2045-8932.109921; Vion AC, 2013, CIRC RES, V112, P1323, DOI 10.1161/CIRCRESAHA.112.300818; Wang BW, 2003, CARDIOVASC RES, V59, P460, DOI 10.1016/S0008-6363(03)00428-0; Wen JF, 2014, EXP THER MED, V8, P881, DOI 10.3892/etm.2014.1818; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; WINSTON FK, 1989, J APPL PHYSIOL, V67, P397	52	40	40	0	15	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-5102			FRONT CELL NEUROSCI	Front. Cell. Neurosci.	FEB 29	2016	10								43	10.3389/fncel.2016.00043			13	Neurosciences	Neurosciences & Neurology	DE8WW	WOS:000370918400001	26973460	DOAJ Gold, Green Published			2021-06-18	
J	Wen, J; Ribeiro, R; Tanaka, M; Zhang, YM				Wen, Jie; Ribeiro, Rachel; Tanaka, Mikiei; Zhang, Yumin			Activation of CB2 receptor is required for the therapeutic effect of ABHD6 inhibition in experimental autoimmune encephalomyelitis	NEUROPHARMACOLOGY			English	Article						ABHD6; 2-Arachidonoylglycerol; Cannabinoid receptors; Microglia; Inflammation; Demyelination	CENTRAL-NERVOUS-SYSTEM; NF-KAPPA-B; MULTIPLE-SCLEROSIS LESIONS; TRAUMATIC BRAIN-INJURY; MONOACYLGLYCEROL LIPASE; CANNABINOID RECEPTORS; ENDOCANNABINOID SYSTEM; MOUSE MODEL; ALZHEIMERS-DISEASE; MICROGLIAL CELLS	Alpha/beta-hydrolase domain 6 (ABHD6) is a novel 2-arachidonoylglycerol (2-AG) hydrolytic enzyme, that can fine-tune the endocannabinoid signaling in the central nervous system. Recently we and others have demonstrated the protective effect of ABHD6 inhibition in the animal models of traumatic brain injury and epileptic seizures. In this study, we investigated the role of targeting ABHD6 in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). Post-symptom treatment with an ABHD6 inhibitor WWL70 increased the brain levels of 2-AG and ameliorated the clinical signs of EAE, T cells infiltration, microglia activation and the expression of activated leukocyte cell adhesion molecules. The production of iNOS, COX-2, TNF-alpha and IL-1 beta and the phosphorylation of NF-kappa B were also significantly reduced by WWL70 treatment. The neuroprotective effect of WWL70 was demonstrated by increased survival of mature oligodendrocytes, reduced demyelination and axonal loss in WWL70 treated EAE mouse spinal cord. The therapeutic effect of WWL70 on EAE was absent by co-administration of CB2 receptor antagonist, but not CB1 receptor antagonist Consistently, WWL70 did not afford any protection in CB2 receptor knockout mice after EAE induction. Given the increased expression of ABHD6 in microglia/macrophages, but not in T cells, we speculated that inhibition of ABHD6 might enhance 2-AG signaling particularly in microglia/macrophages to exert anti-inflammatory effects via activation of CB2 receptors. These results suggest that inhibition of ABHD6 might be used as an ideal strategy for the treatment of MS and other neurodegenerative diseases. Published by Elsevier Ltd.	[Wen, Jie; Tanaka, Mikiei; Zhang, Yumin] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Ribeiro, Rachel; Zhang, Yumin] Uniformed Serv Univ Hlth Sci, Program Neurosci, Bethesda, MD 20814 USA	Zhang, YM (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	yumin.zhang@usuhs.edu			National Multiple Sclerosis SocietyNational Multiple Sclerosis Society [RG3741]; Defense Medical Research and Development Program [0130-10-00003-00002, 0130-14-0003-00003]; Military Center of Excellence Research Award [306514-1.00-63671]; Uniformed Services University [R0701Z]	This work was supported by grants from the National Multiple Sclerosis Society (RG3741), the Defense Medical Research and Development Program (0130-10-00003-00002 and 0130-14-0003-00003), the Military Center of Excellence Research Award (306514-1.00-63671) and the Uniformed Services University (R0701Z). The authors are grateful to Dr. Sean Moran from the Biomedical Instrumental Center for helping the lipid analysis. All the authors declare no conflict of interest.	Alhouayek M, 2013, P NATL ACAD SCI USA, V110, P17558, DOI 10.1073/pnas.1314017110; Arevalo-Martin A, 2008, BRIT J PHARMACOL, V153, P216, DOI 10.1038/sj.bjp.0707466; Berard JL, 2010, GLIA, V58, P1816, DOI 10.1002/glia.21051; Berard JL, 2010, GLIA, V58, P434, DOI 10.1002/glia.20935; Bhasin M, 2007, BMC IMMUNOL, V8, DOI 10.1186/1471-2172-8-10; Blankman JL, 2007, CHEM BIOL, V14, P1347, DOI 10.1016/j.chembiol.2007.11.006; Blankman JL, 2013, PHARMACOL REV, V65, P849, DOI 10.1124/pr.112.006387; BOWEN MA, 1995, J EXP MED, V181, P2213, DOI 10.1084/jem.181.6.2213; Cabral GA, 2008, BRIT J PHARMACOL, V153, P240, DOI 10.1038/sj.bjp.0707584; Carrier EJ, 2005, CNS NEUROL DISORD-DR, V4, P657, DOI 10.2174/156800705774933023; Carrier EJ, 2004, MOL PHARMACOL, V65, P999, DOI 10.1124/mol.65.4.999; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; Cayrol R, 2008, NAT IMMUNOL, V9, P137, DOI 10.1038/ni1551; Centonze D, 2007, BRAIN, V130, P2543, DOI 10.1093/brain/awm160; Centonze D, 2007, TRENDS PHARMACOL SCI, V28, P180, DOI 10.1016/j.tips.2007.02.004; Chanda PK, 2010, MOL PHARMACOL, V78, P996, DOI 10.1124/mol.110.068304; Chen RQ, 2012, CELL REP, V2, P1329, DOI 10.1016/j.celrep.2012.09.030; Cravatt BF, 2008, ANNU REV BIOCHEM, V77, P383, DOI 10.1146/annurev.biochem.75.101304.124125; de Lago E, 2012, NEUROPHARMACOLOGY, V62, P2299, DOI 10.1016/j.neuropharm.2012.01.030; DeGroot CJA, 1997, J NEUROPATH EXP NEUR, V56, P10, DOI 10.1097/00005072-199701000-00002; Dhopeshwarkar A, 2014, MOL PHARMACOL, V86, P430, DOI 10.1124/mol.114.094649; Docagne F, 2008, EXPERT OPIN THER TAR, V12, P185, DOI [10.1517/14728222.12.2.185, 10.1517/14728222.12.2.185 ]; Engelhardt Britta, 2006, V43, P259, DOI 10.1007/020; Esaki Y, 2010, P NATL ACAD SCI USA, V107, P12233, DOI 10.1073/pnas.0915112107; Gallily R, 2000, EUR J PHARMACOL, V406, pR5, DOI 10.1016/S0014-2999(00)00653-1; Gentile A, 2013, J NEUROIMMUNE PHARM, V8, P651, DOI 10.1007/s11481-013-9436-x; Gimferrer I, 2004, J IMMUNOL, V173, P2262, DOI 10.4049/jimmunol.173.4.2262; Gong JP, 2006, BRAIN RES, V1071, P10, DOI 10.1016/j.brainres.2005.11.035; Guindon J, 2013, PHARMACOL RES, V67, P94, DOI 10.1016/j.phrs.2012.10.013; Hsu KL, 2013, J MED CHEM, V56, P8270, DOI 10.1021/jm400899c; Hwang J, 2010, LIFE SCI, V86, P615, DOI 10.1016/j.lfs.2009.06.003; Katz PS, 2015, J NEUROTRAUM, V32, P297, DOI 10.1089/neu.2014.3508; Kebir H, 2007, NAT MED, V13, P1173, DOI 10.1038/nm1651; Kinsey SG, 2013, J PHARMACOL EXP THER, V345, P492, DOI 10.1124/jpet.112.201426; Kong WM, 2014, CELL IMMUNOL, V287, P1, DOI 10.1016/j.cellimm.2013.11.002; Kubajewska I, 2010, IMMUNOBIOLOGY, V215, P647, DOI 10.1016/j.imbio.2009.08.004; Lourbopoulos A, 2011, BRAIN RES, V1390, P126, DOI 10.1016/j.brainres.2011.03.020; Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q; Mackie K, 2008, J NEUROENDOCRINOL, V20, P10, DOI 10.1111/j.1365-2826.2008.01671.x; Maresz K, 2005, J NEUROCHEM, V95, P437, DOI 10.1111/j.1471-4159.2005.03380.x; Maresz K, 2007, NAT MED, V13, P492, DOI 10.1038/nm1561; Marrs WR, 2010, NAT NEUROSCI, V13, P951, DOI 10.1038/nn.2601; MOYNAGH PN, 1993, BIOCHEM J, V294, P343, DOI 10.1042/bj2940343; Murataeva N, 2014, BRIT J PHARMACOL, V171, P1379, DOI 10.1111/bph.12411; Naydenov AV, 2014, NEURON, V83, P361, DOI 10.1016/j.neuron.2014.06.030; Nomura DK, 2011, SCIENCE, V334, P809, DOI 10.1126/science.1209200; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; Palazuelos J, 2008, J BIOL CHEM, V283, P13320, DOI 10.1074/jbc.M707960200; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pertwee RG, 2014, P NUTR SOC, V73, P96, DOI 10.1017/S0029665113003649; Piro JR, 2012, CELL REP, V1, P617, DOI 10.1016/j.celrep.2012.05.001; Pitt D, 2000, NAT MED, V6, P67, DOI 10.1038/71555; Pryce G, 2007, BRIT J PHARMACOL, V150, P519, DOI 10.1038/sj.bjp.0707003; Ribeiro R, 2013, NEUROSCIENCE, V254, P427, DOI 10.1016/j.neuroscience.2013.09.005; Rom S, 2013, J NEUROIMMUNE PHARM, V8, P608, DOI 10.1007/s11481-013-9445-9; Savinainen JR, 2012, ACTA PHYSIOL, V204, P267, DOI 10.1111/j.1748-1716.2011.02280.x; Schlosburg JE, 2010, NAT NEUROSCI, V13, P1113, DOI 10.1038/nn.2616; Sciolino NR, 2011, PHARMACOL RES, V64, P226, DOI 10.1016/j.phrs.2011.04.010; Sigel E, 2011, P NATL ACAD SCI USA, V108, P18150, DOI 10.1073/pnas.1113444108; SPARACIO SM, 1992, J NEUROIMMUNOL, V39, P231, DOI 10.1016/0165-5728(92)90257-L; Spencer ML, 2004, J BIOL CHEM, V279, P37069, DOI 10.1074/jbc.M402507200; Starossom SC, 2012, IMMUNITY, V37, P249, DOI 10.1016/j.immuni.2012.05.023; Tchantchou F, 2013, J NEUROTRAUM, V30, P565, DOI 10.1089/neu.2012.2647; Tran EH, 1998, J IMMUNOL, V161, P3767; Ueda N, 2011, BIOFACTORS, V37, P1, DOI 10.1002/biof.131; Vana AC, 2011, EXP NEUROL, V231, P45, DOI 10.1016/j.expneurol.2011.05.014; Witting A, 2006, P NATL ACAD SCI USA, V103, P6362, DOI 10.1073/pnas.0510418103; Wu WF, 2013, P NATL ACAD SCI USA, V110, P3543, DOI 10.1073/pnas.1300313110; Zhang J, 2015, J CEREBR BLOOD F MET, V35, P443, DOI 10.1038/jcbfm.2014.216; Zhang MY, 2010, J MASS SPECTROM, V45, P167, DOI 10.1002/jms.1701	70	40	40	1	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	DEC	2015	99						196	209		10.1016/j.neuropharm.2015.07.010			14	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	CY0AA	WOS:000366066800019	26189763	Bronze			2021-06-18	
J	King, D; Hume, P; Gissane, C; Clark, T				King, D.; Hume, P.; Gissane, C.; Clark, T.			Use of the King-Devick test for sideline concussion screening in junior rugby league	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Brain injury; Vision; Eye-movement; Saccadic	SPORTS-RELATED CONCUSSION; HIGH-SCHOOL FOOTBALL; SUBCONCUSSIVE IMPACTS; PLAYERS; TOOL; MANAGEMENT; PARENTS; UNION	Aim: To determine whether the King-Devick (K-D) test used as a sideline test in junior rugby league players over 12 matches in a domestic competition season could identify witnessed and incidentally identified episodes of concussion. Methods: A prospective observational cohort study of a club level junior rugby league team (n = 19) during the 2014 New Zealand competition season involved every player completing two pre-competition season baseline trials of the K-D test. Players removed from match participation, or who reported any signs or symptoms of concussion were assessed on the sideline with the K-D test and referred for further medical assessment. Players with a pre- to post-match K-D test difference >3 s were referred for physician evaluation. Results: The baseline test-retest reliability of the K-D test was high (r(s) = 0.86; p < 0.0001). Seven concussions were medically identified in six players who recorded pre- to post-match K-D test times greater than 3 s (mean change of 7.4 s). Post-season testing of players demonstrated improvement of K-D time scores consistent with learning effects of using the K-D test (67.7 s vs. 62.2 s). Discussion: Although no witnessed concussions occurred during rugby play, six players recorded pre- to post-match changes with a mean delay of 4 s resulting in seven concussions being subsequently confirmed post-match by health practitioners. All players were medically managed for a return to sports participation. Conclusion: The K-D test was quickly and easily administered making it a practical sideline tool as part of the continuum of concussion assessment tools for junior rugby league players. (C) 2015 Elsevier B.V. All rights reserved.	[King, D.; Hume, P.] Auckland Univ Technol, Fac Hlth & Environm Sci, AUT Millennium, SPRINZ, Auckland, New Zealand; [King, D.] Auckland Univ Technol, Fac Hlth & Environm Sci, Dept Paramed, Sch Clin Sci, Auckland, New Zealand; [Gissane, C.] St Marys Univ, Sch Sport Hlth & Appl Sci, Twickenham, Middx, England; [Clark, T.] Australian Coll Phys Educ, Fac Human Performance, Olympic Pk, NSW, Australia	King, D (corresponding author), Hutt Valley Dist Hlth Board, Emergency Dept, Private Bag 31-907, Lower Hutt, New Zealand.	dking@aut.ac.nz	Gissane, Conor/I-3661-2019; Hume, Patria/AAN-5514-2021	Gissane, Conor/0000-0003-4677-3853; Hume, Patria/0000-0003-1847-8128; Clark, Dr Trevor/0000-0002-2853-0068			Bauer JA, 2001, J SPORT SCI, V19, P171, DOI 10.1080/026404101750095312; Broglio SP, 2012, EXERC SPORT SCI REV, V40, P138, DOI 10.1097/JES.0b013e3182524273; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; Davies EC, 2012, NEUROLOGY, V78, pE103, DOI 10.1212/WNL.0b013e318251833d; Dhawan PSA, 2014, NEUROL CLIN PRACT, V82, pS11; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Dziemianowicz MS, 2012, CURR NEUROL NEUROSCI, V12, P547, DOI 10.1007/s11910-012-0299-y; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2015, J NEUROOPHTHALMOL; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Goodrich GL, 2013, OPTOMETRY VISION SCI, V90, P105, DOI 10.1097/OPX.0b013e31827f15a1; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Heitger M., 2008, C P IEEE ENG MED BIO; Heitger MH, 2002, PROG BRAIN RES, V140, P433; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; King D, 2015, J NEUROL SCI, V351, P58, DOI 10.1016/j.jns.2015.02.035; King D., 2010, NZ J SPORTS MED, V37, P52; King D., 2014, NZ J SPORTS MED, V40, P8; King D, 2014, SPORTS MED, V44, P449, DOI 10.1007/s40279-013-0134-x; King D, 2013, J NEUROL SCI, V326, P59, DOI 10.1016/j.jns.2013.01.012; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Krumholtz I, 2000, Optometry, V71, P426; Leong DF, 2014, J SPORT MED PHYS FIT, V54, P70; Lin TP, 2014, PARKINSONISM RELAT D, V20, P226, DOI 10.1016/j.parkreldis.2013.10.009; Marinides Zoe, 2015, Neurol Clin Pract, V5, P25, DOI 10.1212/CPJ.0000000000000060; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKeag DB, 2009, CLIN J SPORT MED, V19, P343, DOI 10.1097/JSM.0b013e3181b2c114; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Moster S, 2014, J NEUROL SCI, V343, P105, DOI 10.1016/j.jns.2014.05.047; O'Donoghue EM., 2009, ATHLETIC TRAINING SP, V1, DOI [DOI 10.3928/19425864-20090427-07, 10.3928/19425864-20090427-07]; Prasad S, 2010, NEUROL CLIN, V28, P641, DOI 10.1016/j.ncl.2010.03.006; Spiotta AM, 2011, WORLD NEUROSURG, V75, P175, DOI 10.1016/j.wneu.2011.01.019; Spradley B., 2014, SPORT J         0314; Stepanek J, 2014, AVIAT SPACE ENVIR MD, V85, P700, DOI 10.3357/ASEM.3645.2014; Sullivan SJ, 2009, CLIN J SPORT MED, V19, P228, DOI 10.1097/JSM.0b013e3181a41e43; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tjarks BJ, 2013, J NEUROL SCI, V334, P148, DOI 10.1016/j.jns.2013.08.015; Upshaw JE, 2012, PEDIATR EMERG CARE, V28, P926, DOI 10.1097/PEC.0b013e318267f674; Webbe FM, 2003, CLIN SPORT MED, V22, P577, DOI 10.1016/S0278-5919(02)00103-5; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8	48	40	40	0	41	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	OCT 15	2015	357	1-2					75	79		10.1016/j.jns.2015.06.069			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CS5SQ	WOS:000362138800012	26152829				2021-06-18	
J	Munce, TA; Dorman, JC; Thompson, PA; Valentine, VD; Bergeron, MF				Munce, Thayne A.; Dorman, Jason C.; Thompson, Paul A.; Valentine, Verle D.; Bergeron, Michael F.			Head Impact Exposure and Neurologic Function of Youth Football Players	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article							SPORTS-RELATED CONCUSSION; HIGH-SCHOOL FOOTBALL; UNITED-STATES; RELIABILITY; INJURY; DIAGNOSIS; LOCATION; BRAIN	Football players are subjected to repetitive impacts that may lead to brain injury and neurologic dysfunction. Knowledge about head impact exposure (HIE) and consequent neurologic function among youth football players is limited. Purpose This study aimed to measure and characterize HIE of youth football players throughout one season and explore associations between HIE and changes in selected clinical measures of neurologic function. Methods Twenty-two youth football players (11-13 yr) wore helmets outfitted with a head impact telemetry (HIT) system to quantify head impact frequency, magnitude, duration, and location. Impact data were collected for each practice (27) and game (9) in a single season. Selected clinical measures of balance, oculomotor performance, reaction time, and self-reported symptoms were assessed before and after the season. Results The median individual head impacts per practice, per game, and throughout the entire season were 9, 12, and 252, respectively. Approximately 50% of all head impacts (6183) had a linear acceleration between 10g and 20g, but nearly 2% were greater than 80g. Overall, the head impact frequency distributions in this study population were similar in magnitude and location as in high school and collegiate football, but total impact frequency was lower. Individual changes in neurologic function were not associated with cumulative HIE. Conclusion This study provides a novel examination of HIE and associations with short-term neurologic function in youth football and notably contributes to the limited HIE data currently available for this population. Whereas youth football players can experience remarkably similar head impact forces as high school players, cumulative subconcussive HIE throughout one youth football season may not be detrimental to short-term clinical measures of neurologic function.	[Munce, Thayne A.; Dorman, Jason C.; Valentine, Verle D.; Bergeron, Michael F.] Sanford Hlth, Sanford Sports Sci Inst, Sioux Falls, SD 57104 USA; [Munce, Thayne A.; Dorman, Jason C.; Valentine, Verle D.; Bergeron, Michael F.] Sanford Res, Sioux Falls, SD USA; [Munce, Thayne A.; Valentine, Verle D.; Bergeron, Michael F.] Univ S Dakota, Sanford Sch Med, Dept Pediat, Sioux Falls, SD USA; [Thompson, Paul A.] Sanford Res, Methodol & Data Anal Div, Sioux Falls, SD USA	Munce, TA (corresponding author), Sanford Sports Sci Inst, 1210 W 18th St,Suite 204, Sioux Falls, SD 57104 USA.	thayne.munce@sanfordhealth.org			Sanford Research, Sioux Falls, SD; South Dakota Junior Football, Inc.	Sanford Research, Sioux Falls, SD, provided financial support for this work.; The authors thank Shanna Kindt, MS, Hannah Nelson, MS, Tryg Odney, MS, and Caitlin Pearl, MS, for their assistance with data collection. The authors also sincerely thank the research volunteers and their parents for their participation in this study, and they greatly appreciate the support of this project by South Dakota Junior Football, Inc.	Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daniel RW, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4027872; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Dorman JC, 2015, J SCI MED SPORT, V18, P2, DOI 10.1016/j.jsams.2013.11.010; Duma SM, 2011, EXERC SPORT SCI REV, V39, P2, DOI 10.1097/JES.0b013e318203dfdb; Eckner JT, 2011, J NEUROTRAUM, V28, P2079, DOI 10.1089/neu.2011.1910; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Meehan WP, 2012, PEDIATRICS, V129, P38, DOI 10.1542/peds.2011-1972; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; Mulligan I, 2012, J ORTHOP SPORT PHYS, V42, P625, DOI 10.2519/jospt.2012.3798; Munce TA, 2014, J CHILD NEUROL, V29, P1601, DOI 10.1177/0883073813509887; ORIDE MKH, 1986, AM J OPTOM PHYS OPT, V63, P419; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; Valentine VD, 2012, MED SCI SPORTS EXERC, p[44, S264]; Young TJ, 2014, CLIN J SPORT MED, V24, P416, DOI 10.1097/JSM.0000000000000055	36	40	41	0	28	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	AUG	2015	47	8					1567	1576		10.1249/MSS.0000000000000591			10	Sport Sciences	Sport Sciences	CM8IF	WOS:000357942200003	25437194				2021-06-18	
J	Yuasa, M; Mignemi, NA; Nyman, JS; Duvall, CL; Schwartz, HS; Okawa, A; Yoshii, T; Bhattacharjee, G; Zhao, CG; Bible, JE; Obremskey, WT; Flick, MJ; Degen, JL; Barnett, JV; Cates, JMM; Schoenecker, JG				Yuasa, Masato; Mignemi, Nicholas A.; Nyman, Jeffry S.; Duvall, Craig L.; Schwartz, Herbert S.; Okawa, Atsushi; Yoshii, Toshitaka; Bhattacharjee, Gourab; Zhao, Chenguang; Bible, Jesse E.; Obremskey, William T.; Flick, Matthew J.; Degen, Jay L.; Barnett, Joey V.; Cates, Justin M. M.; Schoenecker, Jonathan G.			Fibrinolysis is essential for fracture repair and prevention of heterotopic ossification	JOURNAL OF CLINICAL INVESTIGATION			English	Article							TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; PLASMINOGEN DEFICIENCY; CARDIOVASCULAR-DISEASE; IN-VIVO; CIGARETTE-SMOKING; BONE-FORMATION; MICE; FIBRINOGEN; ANGIOGENESIS	Bone formation during fracture repair inevitably initiates within or around extravascular deposits of a fibrin-rich matrix. In addition to a central role in hemostasis, fibrin is thought to enhance bone repair by supporting inflammatory and mesenchymal progenitor egress into the zone of injury. However, given that a failure of efficient fibrin clearance can impede normal wound repair, the precise contribution of fibrin to bone fracture repair, whether supportive or detrimental, is unknown. Here, we employed mice with genetically and pharmacologically imposed deficits in the fibrin precursor fibrinogen and fibrin-degrading plasminogen to explore the hypothesis that fibrin is vital to the initiation of fracture repair, but impaired fibrin clearance results in derangements in bone fracture repair. In contrast to our hypothesis, fibrin was entirely dispensable for long-bone fracture repair, as healing fractures in fibrinogen-deficient mice were indistinguishable from those in control animals. However, failure to clear fibrin from the fracture site in plasminogen-deficient mice severely impaired fracture vascularization, precluded bone union, and resulted in robust heterotopic ossification. Pharmacological fibrinogen depletion in plasminogen-deficient animals restored a normal pattern of fracture repair and substantially limited heterotopic ossification. Fibrin is therefore not essential for fracture repair, but inefficient fibrinolysis decreases endochondral angiogenesis and ossification, thereby inhibiting fracture repair.	[Yuasa, Masato; Mignemi, Nicholas A.; Nyman, Jeffry S.; Schwartz, Herbert S.; Bible, Jesse E.; Obremskey, William T.; Schoenecker, Jonathan G.] Vanderbilt Univ, Med Ctr, Dept Orthopaed, Nashville, TN USA; [Yuasa, Masato; Okawa, Atsushi; Yoshii, Toshitaka] Tokyo Med & Dent Univ, Dept Orthopaed Surg, Tokyo, Japan; [Mignemi, Nicholas A.; Schwartz, Herbert S.; Cates, Justin M. M.; Schoenecker, Jonathan G.] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; [Nyman, Jeffry S.; Duvall, Craig L.] Vanderbilt Univ, Med Ctr, Dept Biomed Engn, Nashville, TN USA; [Nyman, Jeffry S.; Schoenecker, Jonathan G.] Vanderbilt Univ, Med Ctr, Ctr Bone Biol, Nashville, TN USA; [Nyman, Jeffry S.] Tennessee Valley Healthcare Syst, Dept Vet Affairs, Nashville, TN USA; [Bhattacharjee, Gourab; Zhao, Chenguang] ISIS Pharmaceut Inc, Carlsbad, CA USA; [Flick, Matthew J.; Degen, Jay L.] Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA; [Barnett, Joey V.; Schoenecker, Jonathan G.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; [Schoenecker, Jonathan G.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA	Schoenecker, JG (corresponding author), 4202 Doctors Off Tower,2200 Childrens Way, Nashville, TN 37232 USA.	Jon.Schoenecker@vanderbilt.edu	Cates, Justin M/D-5927-2014	Cates, Justin M/0000-0002-7336-5196	Musculoskeletal Transplantation Foundation; Orthopaedic Trauma Association; Vanderbilt Orthopaedic Institute research grant; Caitlin Lovejoy Fund; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL112603] Funding Source: NIH RePORTER	Funding was provided by the Musculoskeletal Transplantation Foundation, the Orthopaedic Trauma Association, a Vanderbilt Orthopaedic Institute research grant, and the Caitlin Lovejoy Fund.	Anitua E, 2004, THROMB HAEMOSTASIS, V91, P4, DOI 10.1160/TH03-07-0440; Aoki K, 2001, BURNS, V27, P569, DOI 10.1016/S0305-4179(01)00011-0; Baker BF, 1997, J BIOL CHEM, V272, P11994, DOI 10.1074/jbc.272.18.11994; Beamer Brandon, 2010, HSS J, V6, P85, DOI 10.1007/s11420-009-9129-4; Bouchard J, 2011, US BONE JOINT INITIA; BROOKES M, 1964, J BONE JOINT SURG BR, V46, P336; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P5899, DOI 10.1073/pnas.93.12.5899; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; Burns DM, 2003, PROG CARDIOVASC DIS, V46, P11, DOI 10.1016/S0033-0620(03)00079-3; Castillo RC, 2005, J ORTHOP TRAUMA, V19, P151, DOI 10.1097/00005131-200503000-00001; Cipriano CA, 2009, J AM ACAD ORTHOP SUR, V17, P689, DOI 10.5435/00124635-200911000-00003; COBB TK, 1994, FOOT ANKLE, V15, P64, DOI 10.1177/107110079401500202; Cole HA, 2014, ARTHRITIS RHEUMATOL, V66, P2222, DOI 10.1002/art.38639; Cole HA, 2013, BONE, V52, P337, DOI 10.1016/j.bone.2012.10.011; Daci E, 1999, J BONE MINER RES, V14, P946, DOI 10.1359/jbmr.1999.14.6.946; Dhillon RS, 2013, J BONE MINER RES, V28, P586, DOI 10.1002/jbmr.1765; Douglas TEL, 2012, J BIOMED MATER RES A, V100A, P1335, DOI 10.1002/jbm.a.34073; Duvall CL, 2004, AM J PHYSIOL-HEART C, V287, pH302, DOI 10.1152/ajpheart.00928.2003; Duvall CL, 2007, J BONE MINER RES, V22, P286, DOI 10.1359/JBMR.061103; Ebraheim NA, 2013, ORTHOP SURG, V5, P46, DOI 10.1111/os.12017; EINHORN TA, 1995, J BONE JOINT SURG AM, V77A, P940, DOI 10.2106/00004623-199506000-00016; Everts V, 2008, BONE, V43, P915, DOI 10.1016/j.bone.2008.07.004; Flick MJ, 2004, EXP BIOL MED, V229, P1105; Forsberg JA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3010168; FOULK DA, 1995, ORTHOPEDICS, V18, P333; Gailit J, 1997, EXP CELL RES, V232, P118, DOI 10.1006/excr.1997.3512; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435; Gerstenfeld LC, 2003, J BONE MINER RES, V18, P1584, DOI 10.1359/jbmr.2003.18.9.1584; Gruber R, 2006, EXP GERONTOL, V41, P1080, DOI 10.1016/j.exger.2006.09.008; Grundy SM, 1999, CIRCULATION, V100, P1134, DOI 10.1161/01.CIR.100.10.1134; HAMMOND JDS, 1959, BRIT J HAEMATOL, V5, P431, DOI 10.1111/j.1365-2141.1959.tb04053.x; Harper J, 1999, NAT MED, V5, P617, DOI 10.1038/9460; Hausman MR, 2001, BONE, V29, P560, DOI 10.1016/S8756-3282(01)00608-1; Hofstra JJ, 2011, J TRAUMA, V70, P1389, DOI 10.1097/TA.0b013e31820f85a7; Kawao N, 2013, J BONE MINER RES, V28, P1561, DOI 10.1002/jbmr.1921; Key JA, 1946, MANAGEMENT FRACTURES; Khalil N, 1996, AM J RESP CELL MOL, V15, P252, DOI 10.1165/ajrcmb.15.2.8703482; Kline AJ, 2009, FOOT ANKLE INT, V30, P1042, DOI 10.3113/FAI.2009.1042; Kolar P, 2010, TISSUE ENG PART B-RE, V16, P427, DOI [10.1089/ten.teb.2009.0687, 10.1089/ten.TEB.2009.0687]; Lehmann W, 2004, BONE, V35, P1247, DOI 10.1016/j.bone.2004.08.017; MACEY LR, 1989, J BONE JOINT SURG AM, V71A, P722, DOI 10.2106/00004623-198971050-00014; Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010; Martino MM, 2013, P NATL ACAD SCI USA, V110, P4563, DOI 10.1073/pnas.1221602110; MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153; Meigs James B, 2010, Diabetes Care, V33, P1865, DOI 10.2337/dc10-0641; Nyman JS, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.31; O'Neill KR, 2012, BONE, V50, P1357, DOI 10.1016/j.bone.2012.03.008; Pandolfi A, 2001, ARTERIOSCL THROM VAS, V21, P1378, DOI 10.1161/hq0801.093667; Ploplis VA, 1998, BLOOD, V91, P2005, DOI 10.1182/blood.V91.6.2005.2005_2005_2009; Potter BK, 2010, J BONE JOINT SURG AM, V92A, P74, DOI 10.2106/JBJS.J.00776; Purnell JQ, 2013, CIRCULATION, V127, P180, DOI 10.1161/CIRCULATIONAHA.111.077487; Robinson M, 2004, J BONE JOINT SURG AM, V86A, P1359, DOI 10.2106/00004623-200407000-00002; Rockwood CA., 2010, ROCKWOOD GREENS FRAC; Rodriguez EK, 2014, INJURY, V45, P554, DOI 10.1016/j.injury.2013.10.042; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; Roth D, 2006, AM J PATHOL, V168, P670, DOI 10.2353/ajpath.2006.050372; Sahni A, 2000, BLOOD, V96, P3772, DOI 10.1182/blood.V96.12.3772.h8003772_3772_3778; Sakellariou VI, 2012, J MUSCULOSKEL NEURON, V12, P230; Schoenecker J, 2010, SPINE, V35, P1008, DOI 10.1097/BRS.0b013e3181d3cffe; Shefelbine SJ, 2005, BONE, V36, P480, DOI 10.1016/j.bone.2004.11.007; Stepien E, 2011, J THROMB THROMBOLYS, V32, P177, DOI 10.1007/s11239-011-0593-6; Suelves M, 2007, J CELL BIOL, V178, P1039, DOI 10.1083/jcb.200705127; SUH TT, 1995, GENE DEV, V9, P2020, DOI 10.1101/gad.9.16.2020; Whither K, 1992, THROMB RES, V65, P469; Willigendael EM, 2004, J VASC SURG, V40, P1158, DOI 10.1016/j.jvs.2004.08.049; Wu Andy C, 2013, Bonekey Rep, V2, P373, DOI 10.1038/bonekey.2013.107; YEE JA, 1993, J CELL PHYSIOL, V157, P528, DOI 10.1002/jcp.1041570312; Yuasa M, 2014, BONE, V67, P208, DOI 10.1016/j.bone.2014.07.002	70	40	43	2	8	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA	0021-9738	1558-8238		J CLIN INVEST	J. Clin. Invest.	AUG	2015	125	8					3117	3131		10.1172/JCI80313			15	Medicine, Research & Experimental	Research & Experimental Medicine	CO3CS	WOS:000359034800022	26214526	Bronze, Green Published			2021-06-18	
J	Blixt, J; Svensson, M; Gunnarson, E; Wanecek, M				Blixt, Jonas; Svensson, Mikael; Gunnarson, Eli; Wanecek, Michael			Aquaporins and blood-brain barrier permeability in early edema development after traumatic brain injury	BRAIN RESEARCH			English	Article						Aquaporin; Blood-brain barrier; Brain injury; Brain edema; Rat; Brain trauma	CEREBRAL-ISCHEMIA; HEAD-INJURY; CELLULAR EDEMA; WATER CHANNELS; RAT MODEL; MICE; DISRUPTION; EXPRESSION; HYPOXIA; VOLUME	Traumatic brain injury (TB!) is a major contributor to mortality and morbidity. The pathophysiology involves development of brain edema. Therapeutic options are limited as the mechanisms are not fully understood. Changes in the function of the blood-brain barrier (BBB), as well as variations in aquaporin expression, have been proposed to be involved in the development of the edema but the contribution of each factor has not been fully elucidated. In order to evaluate these mechanisms, in a potential window of opportunity, the early dynamic response was studied using an animal model causing a moderate TBI. Sprague-Dawley rats were subjected to blunt controlled head trauma and followed for up to four days by magnetic-resonance-imaging, immunohistofluorescence, immunohistochemistry, and quantitative protein analysis. Non-traumatized animals served as controls. TBI resulted in a midline shift and a decrease in Apparent Diffusion Coefficient indicating a hemispheric enlargement due to cytotoxic edema. The tight junction protein Zona Occludens-1 was decreased (-25%) and associated with an increased IgG permeability (+20%) in the perilesional brain tissue in accordance with a BBB breakdown. The total amount of AQP4 protein decreased (-20%). The disruption of the BBB lasted for 4 days while the impact on AQP4 levels disappeared between day 1 and 4. Our findings shows that blunt focal brain injury results in an early development of brain edema involving both cytotoxic and vasogenic components, a persistent BBB breakdown and a temporaxy decrease in AQP4, and indicates that both types of edemas and mechanisms should be targeted in TBI treatment. (C) 2015 Elsevier B.V. All rights reserved.	[Blixt, Jonas] Karolinska Inst, Karolinska Univ Hosp, Dept Anesthesiol & Intens Care, SE-17177 Stockholm, Sweden; [Blixt, Jonas; Wanecek, Michael] Karolinska Inst, Dept Physiol & Pharmacol, SE-17177 Stockholm, Sweden; [Svensson, Mikael] Karolinska Inst, Dept Clin Neurosci, SE-17177 Stockholm, Sweden; [Gunnarson, Eli] Karolinska Inst, Dept Womens & Childrens Hlth, SE-17177 Stockholm, Sweden	Blixt, J (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, SE-17177 Stockholm, Sweden.	Jonas.blixt@karolinska.se; Mikael.svensson@ki.se; Eli.gunnarson@ki.se; Michael.wanecek@ki.se	Wanecek, Michael/AAE-7998-2021; Svensson, Mikael/F-8662-2012	Svensson, Mikael/0000-0003-1179-7003	Swedish Medical Research FoundationSwedish Medical Research Council (SMRC); Swedish Society of Medicine [C330132013]; Magn. Bergvalls Foundation; Karolinska InstitutetKarolinska Institutet [C330132023]; Sallskapet Barnavard; Stockholm County CouncilStockholm County Council; Karolinska InstitutetKarolinska Institutet	The authors would like to thank Tim Baker for proof reading and language help, Britt Meijer and Anette Ebberyd for excellent technical assistance. This Study was supported by the Swedish Medical Research Foundation, the Swedish Society of Medicine (C330132013), Magn. Bergvalls Foundation, Funds from the Karolinska Institutet (C330132023), Sallskapet Barnavard and the Regional Agreement on Medical Training and Clinical Research (ALF) between Stockholm County Council and Karolinska Institutet.	Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Amiry-Moghaddam M, 2004, FASEB J, V18, P542, DOI 10.1096/fj.03-0869fje; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Broman T, 1955, ACTA PSYCH NEUROL, V30, P115, DOI 10.1111/j.1600-0447.1955.tb06051.x; Candelario-Jalil E, 2009, NEUROSCIENCE, V158, P983, DOI 10.1016/j.neuroscience.2008.06.025; Castejon OJ, 1998, J SUBMICR CYTOL PATH, V30, P145; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; GULLANS SR, 1993, ANNU REV MED, V44, P289, DOI 10.1146/annurev.med.44.1.289; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Honeybul S, 2011, J NEUROSURG SCI, V55, P343; Hudak AM, 2014, BRAIN INJURY, V28, P1602, DOI 10.3109/02699052.2014.936039; Jacobs B, 2011, J NEUROTRAUM, V28, P203, DOI 10.1089/neu.2010.1558; Jou IM, 2000, J APPL PHYSIOL, V89, P1766; Ke CS, 2001, NEUROSCI LETT, V301, P21, DOI 10.1016/S0304-3940(01)01589-0; KEMPSKI O, 1987, STROKE, V18, P623, DOI 10.1161/01.STR.18.3.623; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; Kimelberg HK, 2005, GLIA, V50, P389, DOI 10.1002/glia.20174; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; Kleindienst A, 2013, ACTA NEUROCHIR, V155, P151, DOI 10.1007/s00701-012-1558-z; Koyama Junji, 2007, Kobe J Med Sci, V53, P199; Lythgoe MF, 1997, MAGN RESON MED, V38, P662, DOI 10.1002/mrm.1910380421; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Mark KS, 2002, AM J PHYSIOL-HEART C, V282, pH1485, DOI 10.1152/ajpheart.00645.2001; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Nagelhus EA, 2013, PHYSIOL REV, V93, P1543, DOI 10.1152/physrev.00011.2013; Neal CJ, 2007, J NEUROTRAUM, V24, P1609, DOI 10.1089/neu.2007.0301; Nielsen S, 1997, J NEUROSCI, V17, P171; Oliva AA, 2011, NEUROSCIENCE, V180, P272, DOI 10.1016/j.neuroscience.2011.02.020; Papadopoulos MC, 2007, PEDIATR NEPHROL, V22, P778, DOI 10.1007/s00467-006-0411-0; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Papadopoulos MC, 2005, J BIOL CHEM, V280, P13906, DOI 10.1074/jbc.M413627200; Rao KVR, 2007, METAB BRAIN DIS, V22, P265, DOI 10.1007/s11011-007-9063-4; Rao KVR, 2011, J NEUROTRAUM, V28, P371, DOI 10.1089/neu.2010.1705; Reinert M, 2000, ACTA NEUROCHIR SUPPL, V76, P439; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Sword J, 2013, BRAIN, V136, P1446, DOI 10.1093/brain/awt026; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; Taya K, 2010, J NEUROTRAUM, V27, P229, DOI 10.1089/neu.2009.0933; Tourdias T, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-143; Umeda K, 2006, CELL, V126, P741, DOI 10.1016/j.cell.2006.06.043; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vajda Z, 2002, P NATL ACAD SCI USA, V99, P13131, DOI 10.1073/pnas.192457099; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Wen JF, 2014, EXP THER MED, V8, P881, DOI 10.3892/etm.2014.1818	64	40	42	0	18	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUN 22	2015	1611						18	28		10.1016/j.brainres.2015.03.004			11	Neurosciences	Neurosciences & Neurology	CK3PD	WOS:000356127100003	25770057				2021-06-18	
J	Benedict, PA; Baner, NV; Harrold, GK; Moehringer, N; Hasanaj, L; Serrano, LP; Sproul, M; Pagnotta, G; Cardone, DA; Flanagan, SR; Rucker, J; Galetta, SL; Balcer, LJ				Benedict, Peter A.; Baner, Natali V.; Harrold, G. Kyle; Moehringer, Nicholas; Hasanaj, Lisena; Serrano, Liliana P.; Sproul, Mara; Pagnotta, Geraldine; Cardone, Dennis A.; Flanagan, Steven R.; Rucker, Janet; Galetta, Steven L.; Balcer, Laura J.			Gender and age predict outcomes of cognitive, balance and vision testing in a multidisciplinary concussion center	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Concussion; Sports; SCAT2; King-Devick test; Saccades; Cognition	DORSOLATERAL PREFRONTAL CORTEX; SPORTS-RELATED CONCUSSION; VISUAL SCREENING TOOL; KING-DEVICK TEST; NORMATIVE DATA; BRAIN-INJURY; DEPRESSION; SYMPTOMS	Objective: This study examined components of the Sports Concussion Assessment Tool, 3rd Edition (SCAT3) and a vision-based test of rapid number naming (King-Devick [K-D] to evaluate sports and non-sports concussion patients in an outpatient, multidisciplinary concussion center. While the Symptom Evaluation, Standardized Assessment of Concussion (SAC), modified Balance Error Scoring System (BESS), and K-D are used typically for sideline assessment, their use in an outpatient clinical setting following concussion has not been widely investigated. Methods: K-D, BESS, SAC, and SCAT3 Symptom Evaluation scores were analyzed for 206 patients who received concussion care at the Concussion Center at NYU Langone Medical Center. Patient age, gender, referral data, mechanism of injury, time between concussive event and first concussion center appointment, and the first specialty service to evaluate each patient were also analyzed. Results: In this cohort, Symptom Evaluation scores showed a higher severity and a greater number of symptoms to be associated with older age (r = 031, P = 0.002), female gender (P = 0.002, t-test), and longer time between the concussion event and first appointment at the concussion center (r = 0.34, P = 0.008). Performance measures of K-D and BESS also showed associations of worse scores with increasing patient age (r = 0.32-0.54, P <= 0.001), but were similar among males and females and across the spectrum of duration since the concussion event. Patients with greater Symptom Severity Scores also had the greatest numbers of referrals to specialty services in the concussion center (r = 033, P = 0.0008). Worse Immediate Memory scores on SAC testing correlated with slower K-D times, potentially implicating the dorsolateral prefrontal cortex as a commonly involved brain structure. Conclusion: This study demonstrates a novel use of sideline concussion assessment tools for evaluation in the outpatient setting, and implicates age and gender as predictors of outcomes for these tests. (C) 2015 Elsevier B.V. All rights reserved.	[Benedict, Peter A.; Baner, Natali V.; Harrold, G. Kyle; Moehringer, Nicholas; Hasanaj, Lisena; Serrano, Liliana P.; Rucker, Janet; Galetta, Steven L.; Balcer, Laura J.] NYU, Dept Neurol, Sch Med, New York, NY 10016 USA; [Balcer, Laura J.] NYU, Dept Populat Hlth, Sch Med, New York, NY 10016 USA; [Rucker, Janet; Galetta, Steven L.; Balcer, Laura J.] NYU, Dept Ophthalmol, Sch Med, New York, NY 10016 USA; [Sproul, Mara; Pagnotta, Geraldine; Flanagan, Steven R.] NYU, Dept Rehabil Med, Sch Med, New York, NY 10016 USA; [Cardone, Dennis A.] NYU, Dept Orthopaed Sports Med, Sch Med, New York, NY 10016 USA	Balcer, LJ (corresponding author), NYU, Dept Neurol, Sch Med, 240 East 38th St,20th Floor, New York, NY 10016 USA.	peter.benedict@nyumc.org; natali.baner@nyumc.org; george.harrold@nyumc.org; nicholasmoehringer@yahoo.com; lisena.hasanaj@nyumc.org; liliana.serrano2@nyumc.org; mara.sproul@nyumc.org; geraldine.pagnotta@nyumc.org; dennis.cardone@nyumc.org; steven.flanagan@nyumc.org; janet.rucker@nyumc.org; steven.galetta@nyumc.org; laura.balcer@nyumc.org		Rucker, Janet/0000-0002-0397-0999; Flanagan, Steven/0000-0001-9005-5897	NYU School of Medicine	This study was supported in part by the NYU School of Medicine.	Aoki R, 2011, NEUROSCI RES, V70, P189, DOI 10.1016/j.neures.2011.02.011; Choi W, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.01024; Dessy A, 2014, CLIN NEUROL NEUROSUR, V122, P59, DOI 10.1016/j.clineuro.2014.04.003; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2015, J NEUROOPHTHALM 0218; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Iverson GL, 2008, BRAIN INJURY, V22, P147, DOI 10.1080/02699050701867407; King D, 2013, J NEUROL SCI, V326, P59, DOI 10.1016/j.jns.2013.01.012; Koenigs M, 2009, BEHAV BRAIN RES, V201, P239, DOI 10.1016/j.bbr.2009.03.004; Leddy JJ, 2015, CLIN J SPORT MED, V25, P237, DOI 10.1097/JSM.0000000000000128; Leong DF, 2014, J SPORT MED PHYS FIT, V54, P70; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Marinides Z, 2015, NEUROL CLIN PRACT, V5, P25, DOI DOI 10.1212/CPJ.000000000; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Pierrot-Deseilligny C, 2005, ANN NY ACAD SCI, V1039, P239, DOI 10.1196/annals.1325.023; Qin SZ, 2009, BIOL PSYCHIAT, V66, P25, DOI 10.1016/j.biopsych.2009.03.006; Sturzenegger M, 2008, ACTA NEUROL SCAND, V117, P49, DOI 10.1111/j.1600-0404.2007.00939.x; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Ventura RE, 2014, LANCET NEUROL, V13, P1006, DOI 10.1016/S1474-4422(14)70111-5	22	40	40	0	28	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	JUN 15	2015	353	1-2					111	115		10.1016/j.jns.2015.04.029			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CK3PK	WOS:000356127800020	25953343				2021-06-18	
J	Ahmed, F; Plantman, S; Cernak, I; Agoston, DV				Ahmed, Farid; Plantman, Stefan; Cernak, Ibolja; Agoston, Denes V.			The temporal pattern of changes in serum biomarker levels reveals complex and dynamically changing pathologies after exposure to a single low-intensity blast in mice	FRONTIERS IN NEUROLOGY			English	Article						blast; traumatic brain injury; mouse; serum; biomarkers	TRAUMATIC BRAIN-INJURY; VON-WILLEBRAND-FACTOR; TIME-DEPENDENT CHANGES; LIPID-PEROXIDATION; CLEAVED-TAU; MOUSE MODEL; MOLECULAR-MECHANISMS; OXIDATIVE STRESS; CNS INJURY; INFLAMMATION	Time-dependent changes in blood-based protein biomarkers can help identify the pathological processes in blast-induced traumatic brain injury (bTBI), assess injury severity, and monitor disease progression. We obtained blood from control and injured mice (exposed to a single, low-intensity blast) at 2-h, 1-day, 1-week, and 1-month post-injury. We then determined the serum levels of biomarkers related to metabolism (4-HNE, HIF-1 alpha, ceruloplasmin), vascular function (AQP1, AQP4, VEGF, vWF, Flk-1), inflammation (OPN, CINC1, fibrinogen, MIP-1a, OX-44, p38, MMP-8, MCP-1 CCR5, CRP, galectin-1), cell adhesion and the extracellular matrix (integrin alpha 6, TIMP1, TIMP4, Ncad, connexin-43), and axonal (NF-H, Tau), neuronal (NSE, CK-BB) and glial damage (GFAP, S100 beta, MBP) at various post-injury time points. Our findings indicate that the exposure to a single, low-intensity blast results in metabolic and vascular changes, altered cell adhesion, and axonal and neuronal injury in the mouse model of bTBI. Interestingly, serum levels of several inflammatory and astroglial markers were either unchanged or elevated only during the acute and subacute phases of injury. Conversely, serum levels of the majority of biomarkers related to metabolic and vascular functions, cell adhesion, as well as neuronal and axonal damage remained elevated at the termination of the experiment (1 month), indicating long-term systemic and cerebral alterations due to blast. Our findings show that the exposure to a single, low-intensity blast induces complex pathological processes with distinct temporal profiles. Hence, monitoring serum biomarker levels at various post-injury time points may provide enhanced diagnostics in blast-related neurological and multi-system deficits.	[Ahmed, Farid; Agoston, Denes V.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Plantman, Stefan; Agoston, Denes V.] Karolinska Inst, Dept Neurosci, Stockholm, Sweden; [Cernak, Ibolja] Univ Alberta, Fac Rehabil Med, Canadian Mil & Vet Clin Rehabil Res, Edmonton, AB, Canada	Agoston, DV (corresponding author), Uniformed Serv Univ Hlth Sci, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	denes.agoston@usuhs.edu		Ibolja, Cernak/0000-0003-3214-698X	Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [G170AZ]	This work was supported by the Center for Neuroscience and Regenerative Medicine, grant G170AZ. We thank Ms. Alaa Kamnaksh and Mr. John Olson for their editorial help.	Agoston Denes V, 2012, Front Neurol, V3, P107, DOI 10.3389/fneur.2012.00107; Agre P, 2003, FEBS LETT, V555, P72, DOI 10.1016/S0014-5793(03)01083-4; Ahmed F, 2012, ELECTROPHORESIS, V33, P3705, DOI 10.1002/elps.201200299; Ahmed FA, 2013, ELECTROPHORESIS, V34, P2229, DOI 10.1002/elps.201300077; Anderson J, 2009, J NEUROTRAUM, V26, P1557, DOI [10.1089/neu.2008.0765, 10.1089/neu.2008-0765]; Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; [Anonymous], 1944, LANCET, V1, P788; Appelboom G, 2012, ACTA NEUROCHIR, V154, P131, DOI 10.1007/s00701-011-1210-3; Ayton S, 2014, FREE RADICAL BIO MED, V69, P331, DOI 10.1016/j.freeradbiomed.2014.01.041; Badaut J, 2014, BBA-GEN SUBJECTS, V1840, P1554, DOI 10.1016/j.bbagen.2013.10.032; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Bickel C, 2002, AM J CARDIOL, V89, P901, DOI 10.1016/S0002-9149(02)02236-1; Borkakoti N, 1998, PROG BIOPHYS MOL BIO, V70, P73, DOI 10.1016/S0079-6107(98)00003-0; Bowen I.G., 1968, ESTIMATE MANS TOLERA, P1; Braitch Manjit, 2010, Inflammation & Allergy Drug Targets, V9, P249; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brill A, 2012, J THROMB HAEMOST, V10, P1662, DOI 10.1111/j.1538-7836.2012.04820.x; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412; Calabrese E, 2014, J NEUROTRAUM, V31, P938, DOI 10.1089/neu.2013.3144; CARAYON A, 1963, Mem Acad Chir (Paris), V89, P509; Cernak I, 1999, WORLD J SURG, V23, P44, DOI 10.1007/s002689900563; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2015, BRAIN NEUROTRAUMA MO, P629; Cernak I, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00128; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chen WQ, 2008, NEUROBIOL DIS, V31, P433, DOI 10.1016/j.nbd.2008.05.020; Chen Y, 2011, BRAIN INJURY, V25, P641, DOI 10.3109/02699052.2011.580313; Croll SD, 2004, ADV EXP MED BIOL, V548, P57; Dash PK, 2010, J NEUROSCI RES, V88, P1719, DOI 10.1002/jnr.22336; Davalos D, 2012, SEMIN IMMUNOPATHOL, V34, P43, DOI 10.1007/s00281-011-0290-8; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; De Oliveira CO, 2007, J NEUROTRAUM, V24, P1331, DOI 10.1089/neu.2006.0159; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Fujimoto M, 2008, J CEREBR BLOOD F MET, V28, P1674, DOI 10.1038/jcbfm.2008.59; Gardner J, 2006, J NEUROSCI RES, V83, P1281, DOI 10.1002/jnr.20823; Gatson J, 2014, JAMA NEUROL, V71, P677, DOI 10.1001/jamaneurol.2014.443; Gerstner ER, 2009, NAT REV CLIN ONCOL, V6, P229, DOI 10.1038/nrclinonc.2009.14; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gyorgy A, 2011, J NEUROTRAUM, V28, P1121, DOI 10.1089/neu.2010.1561; Gyorgy AB, 2010, J NEUROSCI METH, V192, P96, DOI 10.1016/j.jneumeth.2010.07.029; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hsieh CH, 2008, J IMMUNOL, V181, P2806, DOI 10.4049/jimmunol.181.4.2806; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Jaffee CMS, 2009, CLIN NEUROPSYCHOL, V23, P1291, DOI 10.1080/13854040903307250; Jang YN, 2009, J NEUROSCI, V29, P5974, DOI 10.1523/JNEUROSCI.6178-08.2009; Jean A, 2014, P NATL ACAD SCI USA, V111, P15310, DOI 10.1073/pnas.1415743111; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kamnaksh A, 2014, SCI REP-UK, V4, DOI 10.1038/srep04809; Kamnaksh A, 2012, ELECTROPHORESIS, V33, P3680, DOI 10.1002/elps.201200319; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kanemaru K, 2013, P NATL ACAD SCI USA, V110, P11612, DOI 10.1073/pnas.1300378110; Katayama T, 2009, J PHARMACOL SCI, V109, P88, DOI 10.1254/jphs.08298FP; Kawa L., 2014, J NEUROTRAUMA; Kochanek PM, 2013, J NEUROTRAUM, V30, P920, DOI 10.1089/neu.2013.2862; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Lakis N, 2013, NEUROL RES, V35, P290, DOI 10.1179/1743132813Y.0000000177; Lenting PJ, 2012, J THROMB HAEMOST, V10, P2428, DOI 10.1111/jth.12008; Li AH, 2013, J MOL NEUROSCI, V51, P1052, DOI 10.1007/s12031-013-0084-7; Liliang PC, 2010, J SURG RES, V160, P302, DOI 10.1016/j.jss.2008.12.022; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Ma M, 2008, AM J EMERG MED, V26, P763, DOI 10.1016/j.ajem.2007.10.029; Mac Donald C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055823; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Mendez MF, 2013, BRAIN INJURY, V27, P10, DOI 10.3109/02699052.2012.722252; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Muradashvili N, 2013, BRAIN INJURY, V27, P1508, DOI 10.3109/02699052.2013.823562; Nedergaard M, 2013, SCIENCE, V340, P1529, DOI 10.1126/science.1240514; Niki E, 2008, BIOFACTORS, V34, P171, DOI 10.1002/biof.5520340208; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Povlishock JT, 2013, J NEUROTRAUM, V30, P1, DOI 10.1089/neu.2013.9942; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Rafaels K, 2011, J NEUROTRAUM, V28, P2319, DOI 10.1089/neu.2009.1207; Rafaels KA, 2012, J TRAUMA ACUTE CARE, V73, P895, DOI 10.1097/TA.0b013e31825a760e; Rauch A, 2013, MEDITERR J HEMATOL I, V5, DOI 10.4084/MJHID.2013.046; Romner B, 2001, NEUROSURGERY, V49, P1490, DOI 10.1097/00006123-200112000-00053; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Rosenstein JM, 2004, EXP NEUROL, V187, P246, DOI 10.1016/j.expneurol.2004.01.022; Shenaq M, 2012, J NEUROL SCI, V323, P134, DOI 10.1016/j.jns.2012.08.036; Shin T, 2012, ACTA HISTOCHEM, V114, P749, DOI 10.1016/j.acthis.2012.08.004; Simard JM, 2014, J NEUROTRAUM, V31, P1292, DOI 10.1089/neu.2013.3016; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Tate CM, 2013, J NEUROTRAUM, V30, P1620, DOI 10.1089/neu.2012.2683; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thelin EP, 2013, J NEUROTRAUM, V30, P519, DOI 10.1089/neu.2012.2553; Tsai YD, 2013, BRAIN INJURY, V27, P361, DOI 10.3109/02699052.2012.750738; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Versace A, 2014, MOL PSYCHIATR, V19, P200, DOI 10.1038/mp.2012.188; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Xie K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064907; Yelverton JT, 1996, J TRAUMA, V40, pS111, DOI 10.1097/00005373-199603001-00025	107	40	40	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	JUN 12	2015	6								114	10.3389/fneur.2015.00114			14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CU9FC	WOS:000363848400001	26124743	DOAJ Gold, Green Published			2021-06-18	
J	Baldwin, SA; Larson, MJ; Clayson, PE				Baldwin, Scott A.; Larson, Michael J.; Clayson, Peter E.			The dependability of electrophysiological measurements of performance monitoring in a clinical sample: A generalizability and decision analysis of the ERN and Pe	PSYCHOPHYSIOLOGY			English	Article						Reliability; Error-related negativity; ERN; Error positivity; Pe; Generalizability	MAJOR DEPRESSIVE DISORDER; OBSESSIVE-COMPULSIVE DISORDER; ERROR-RELATED-NEGATIVITY; EVENT-RELATED POTENTIALS; TEST-RETEST RELIABILITY; TRAUMATIC BRAIN-INJURY; CONFLICT ADAPTATION; FUNCTIONAL-SIGNIFICANCE; COGNITIVE CONTROL; ANXIETY DISORDER	Psychometric studies of the ERN, CRN, Pe, and Pc ERPs are increasing. Coherent integration of these results is difficult with classical test theory because the definition of error depends on the measure of reliability. This study used generalizability theory, which extends the ideas of classical test theory, as a framework for evaluating the influence of psychopathology and number of trials on dependability of measurement. Participants included 34 people meeting criteria for major depression, 29 meeting criteria for an anxiety disorder, and 319 controls. For all ERPs, within-person variance was larger than between-person variance across groups, indicating many trials are needed for adequate dependability (at least 13). Slightly fewer trials were needed to achieve adequate dependability in the control group than the pathology groups. Regions of interest had higher dependability than single sensors.	[Baldwin, Scott A.; Larson, Michael J.] Brigham Young Univ, Dept Psychol, Provo, UT 84660 USA; [Clayson, Peter E.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA	Baldwin, SA (corresponding author), Brigham Young Univ, Dept Psychol, 268 TLRB, Provo, UT 84660 USA.	scott_baldwin@byu.edu	Clayson, Peter E/F-5438-2011; Larson, Michael J/C-8543-2012; Clayson, Peter/AAC-9207-2019; Baldwin, Scott/G-4021-2017	Clayson, Peter E/0000-0003-4437-6598; Larson, Michael J/0000-0002-8199-8065; Clayson, Peter/0000-0003-4437-6598; Baldwin, Scott/0000-0003-3428-0437	Brigham Young University College of Family, Home, and Social Sciences	This research was supported by the Brigham Young University College of Family, Home, and Social Sciences.	Aarts K, 2013, J ABNORM PSYCHOL, V122, P939, DOI 10.1037/a0034616; Bartholow BD, 2005, PSYCHOPHYSIOLOGY, V42, P33, DOI 10.1111/j.1469-8986.2005.00258.x; Bates AT, 2004, J PSYCHIATR RES, V38, P347, DOI 10.1016/j.jpsychires.2003.11.002; Brazdil M, 2005, J PSYCHOPHYSIOL, V19, P244, DOI 10.1027/0269-8803.19.4.244; Brennan R. L., 2001, GEN THEORY; Cassidy SM, 2012, PSYCHOPHYSIOLOGY, V49, P659, DOI 10.1111/j.1469-8986.2011.01349.x; Chen SF, 2009, BRAIN RES, V1297, P89, DOI 10.1016/j.brainres.2009.08.003; Chiu PH, 2007, AM J PSYCHIAT, V164, P608, DOI 10.1176/appi.ajp.164.4.608; Clawson A, 2013, PSYCHOPHYSIOLOGY, V50, P711, DOI 10.1111/psyp.12066; Clayson PE, 2013, PSYCHOPHYSIOLOGY, V50, P174, DOI 10.1111/psyp.12001; Clayson PE, 2011, NEUROPSYCHOLOGIA, V49, P1953, DOI 10.1016/j.neuropsychologia.2011.03.023; Clayson PE, 2011, BIOL PSYCHOL, V87, P282, DOI 10.1016/j.biopsycho.2011.03.011; Di Nocera F, 2001, PSYCHOPHYSIOLOGY, V38, P796, DOI 10.1017/S004857720101040X; Dien J, 2010, BRAIN RES, V1355, P126, DOI 10.1016/j.brainres.2010.07.099; Dien J, 2010, J NEUROSCI METH, V187, P138, DOI 10.1016/j.jneumeth.2009.12.009; Endrass T, 2007, EUR J NEUROSCI, V26, P1714, DOI 10.1111/j.1460-9568.2007.05785.x; Endrass T, 2012, PSYCHOPHYSIOLOGY, V49, P733, DOI 10.1111/j.1469-8986.2012.01365.x; Endrass T, 2010, BIOL PSYCHOL, V84, P257, DOI 10.1016/j.biopsycho.2010.02.002; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; FALKENSTEIN M, 1991, ELECTROEN CLIN NEURO, V78, P447, DOI 10.1016/0013-4694(91)90062-9; Falkenstein M, 2000, BIOL PSYCHOL, V51, P87, DOI 10.1016/S0301-0511(99)00031-9; Fallgatter AJ, 2001, CLIN NEUROPHYSIOL, V112, P198, DOI 10.1016/S1388-2457(00)00505-8; Ford JM, 1999, PSYCHOPHYSIOLOGY, V36, P667, DOI 10.1111/1469-8986.3660667; Foti D, 2013, J ABNORM PSYCHOL, V122, P520, DOI 10.1037/a0032618; Gehring WJ, 2000, PSYCHOL SCI, V11, P1, DOI 10.1111/1467-9280.00206; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; Gelman A., 1992, STAT SCI, V7, P457, DOI DOI 10.1214/SS/1177011136; Gelman A, 2006, BAYESIAN ANAL, V1, P515, DOI 10.1214/06-BA117A; Georgiadi E, 2011, PSYCHOPHYSIOLOGY, V48, P1192, DOI 10.1111/j.1469-8986.2011.01198.x; Gottesman II, 2003, AM J PSYCHIAT, V160, P636, DOI 10.1176/appi.ajp.160.4.636; Hajcak G, 2008, AM J PSYCHIAT, V165, P116, DOI 10.1176/appi.ajp.2007.07010143; Hammer A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006553; Herrmann MJ, 2004, COGNITIVE BRAIN RES, V20, P294, DOI 10.1016/j.cogbrainres.2004.02.013; Hoffmann S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017482; Holmes AJ, 2008, ARCH GEN PSYCHIAT, V65, P179, DOI 10.1001/archgenpsychiatry.2007.19; Holmes AJ, 2010, COGN AFFECT BEHAV NE, V10, P119, DOI 10.3758/CABN.10.1.119; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI [10.1037//0033-295X.109.4.679, 10.1037/0033-295X.109.4.679]; Huffmeijer R, 2014, PHYSIOL BEHAV, V130, P13, DOI 10.1016/j.physbeh.2014.03.008; Hughes G, 2011, NEUROPSYCHOLOGIA, V49, P405, DOI 10.1016/j.neuropsychologia.2010.11.036; Johannes S, 2001, PSYCHIAT RES-NEUROIM, V108, P101, DOI 10.1016/S0925-4927(01)00117-2; Junghofer M, 1999, CLIN NEUROPHYSIOL, V110, P1149, DOI 10.1016/S1388-2457(99)00044-9; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P961, DOI 10.1017/S1355617707071305; Larson MJ, 2014, INT J PSYCHOPHYSIOL, V93, P283, DOI 10.1016/j.ijpsycho.2014.06.007; Larson MJ, 2013, BIOL PSYCHOL, V94, P408, DOI 10.1016/j.biopsycho.2013.08.006; Larson MJ, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00308; Larson MJ, 2012, J INT NEUROPSYCH SOC, V18, P323, DOI 10.1017/S1355617711001779; Larson MJ, 2011, PSYCHIAT RES, V187, P198, DOI 10.1016/j.psychres.2010.11.006; Larson MJ, 2010, PSYCHOPHYSIOLOGY, V47, P1167, DOI 10.1111/j.1469-8986.2010.01022.x; Larson MJ, 2009, NEUROREPORT, V20, P1486, DOI 10.1097/WNR.0b013e32833283fe; Masaki H., 2004, JPN J PHYSL PSYCHOL, V22, P3; Meyer A, 2013, PSYCHOPHYSIOLOGY, V50, P1220, DOI 10.1111/psyp.12132; Munte TF, 2008, FRONT HUM NEUROSCI, V1, DOI 10.3389/neuro.09.011.2007; Nieuwenhuis S, 2005, PSYCHIAT RES, V134, P111, DOI 10.1016/j.psychres.2005.02.005; Nieuwenhuis S, 2001, PSYCHOPHYSIOLOGY, V38, P752, DOI 10.1017/S0048577201001111; Nunnally J. C., 1994, PSYCHOMETRIC THEORY; Olvet DM, 2010, PSYCHIAT RES, V179, P30, DOI 10.1016/j.psychres.2010.06.008; Olvet DM, 2009, PSYCHOPHYSIOLOGY, V46, P957, DOI 10.1111/j.1469-8986.2009.00848.x; Olvet DM, 2009, BRAIN RES, V1284, P89, DOI 10.1016/j.brainres.2009.05.079; Olvet DM, 2008, CLIN PSYCHOL REV, V28, P1343, DOI 10.1016/j.cpr.2008.07.003; Overbeek TJM, 2005, J PSYCHOPHYSIOL, V19, P319, DOI 10.1027/0269-8803.19.4.319; Pailing PE, 2004, BRAIN COGNITION, V56, P215, DOI 10.1016/j.bandc.2004.06.005; Pontifex MB, 2010, PSYCHOPHYSIOLOGY, V47, P767, DOI 10.1111/j.1469-8986.2010.00974.x; R Development Core Team, 2012, R LANG ENV STAT COMP; Ruchsow M, 2006, J PSYCHIATR RES, V40, P37, DOI 10.1016/j.jpsychires.2005.02.002; Ruchsow M, 2004, PSYCHOPHYSIOLOGY, V41, P833, DOI 10.1111/j.1469-8986.2004.00237.x; Scheffers MK, 2000, J EXP PSYCHOL HUMAN, V26, P141, DOI 10.1037/0096-1523.26.1.141; Schrijvers D, 2008, CORTEX, V44, P569, DOI 10.1016/j.cortex.2007.08.014; Schrijvers D, 2009, INT J PSYCHOPHYSIOL, V71, P218, DOI 10.1016/j.ijpsycho.2008.09.005; Segalowitz SJ, 2010, PSYCHOPHYSIOLOGY, V47, P260, DOI 10.1111/j.1469-8986.2009.00942.x; Shalgi S, 2009, EUR J NEUROSCI, V29, P1522, DOI 10.1111/j.1460-9568.2009.06690.x; Shavelson R.J., 1991, GENERALIZABILITY THE; Stan Development Team, 2014, STAN C LIB PROB SAMP; Stemmer B, 2004, NEUROPSYCHOLOGIA, V42, P118, DOI 10.1016/S0028-3932(03)00121-0; Stern ER, 2010, PSYCHOPHYSIOLOGY, V47, P913, DOI 10.1111/j.1469-8986.2010.00988.x; Tang YY, 2013, INT J PSYCHOPHYSIOL, V90, P282, DOI 10.1016/j.ijpsycho.2013.09.001; van Veen V, 2002, PHYSIOL BEHAV, V77, P477, DOI 10.1016/S0031-9384(02)00930-7; Vidal F, 2003, BIOL PSYCHOL, V64, P265, DOI 10.1016/S0301-0511(03)00097-8; Vidal F, 2000, BIOL PSYCHOL, V51, P109, DOI 10.1016/S0301-0511(99)00032-0; Weinberg A, 2011, PSYCHOPHYSIOLOGY, V48, P1420, DOI 10.1111/j.1469-8986.2011.01206.x; Weinberg A, 2010, BIOL PSYCHOL, V85, P472, DOI 10.1016/j.biopsycho.2010.09.011; Wiersema JR, 2007, NEUROPSYCHOLOGIA, V45, P1649, DOI 10.1016/j.neuropsychologia.2007.01.004; Yeung N, 2004, PSYCHOL REV, V111, P931, DOI [10.1037/0033-295X.111.4.931, 10.1037/0033-295x.111.4.931]	82	40	40	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0048-5772	1469-8986		PSYCHOPHYSIOLOGY	Psychophysiology	JUN	2015	52	6					790	800		10.1111/psyp.12401			11	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Psychology; Neurosciences & Neurology; Physiology	CI2HL	WOS:000354566600007	25581577				2021-06-18	
J	Muradashvili, N; Benton, RL; Saatman, KE; Tyagi, SC; Lominadze, D				Muradashvili, Nino; Benton, Richard L.; Saatman, Kathryn E.; Tyagi, Suresh C.; Lominadze, David			Ablation of matrix metalloproteinase-9 gene decreases cerebrovascular permeability and fibrinogen deposition post traumatic brain injury in mice	METABOLIC BRAIN DISEASE			English	Article						Caveolae; Cellular prion protein (PrPC); Cerebrovascular permeability; Fibrinogen; Macromolecular leakage; Memory loss	OBJECT RECOGNITION; PRION PROTEIN; IN-VIVO; BLOOD; DISEASE; BINDING; MECHANISMS; EXPRESSION; EDEMA; MODEL	Traumatic brain injury (TBI) is accompanied with enhanced matrix metalloproteinase-9 (MMP-9) activity and elevated levels of plasma fibrinogen (Fg), which is a known inflammatory agent. Activation of MMP-9 and increase in blood content of Fg (i.e. hyperfibrinogenemia, HFg) both contribute to cerebrovascular disorders leading to blood brain barrier disruption. It is well-known that activation of MMP-9 contributes to vascular permeability. It has been shown that at an elevated level (i.e. HFg) Fg disrupts blood brain barrier. However, mechanisms of their actions during TBI are not known. Mild TBI was induced in wild type (WT, C57BL/6 J) and MMP-9 gene knockout (Mmp9(-/-)) homozygous, mice. Pial venular permeability to fluorescein isothiocyanate-conjugated bovine serum albumin in pericontusional area was observed 14 days after injury. Mice memory was tested with a novel object recognition test. Increased expression of Fg endothelial receptor intercellular adhesion protein-1 and formation of caveolae were associated with enhanced activity of MMP-9 causing an increase in pial venular permeability. As a result, an enhanced deposition of Fg and cellular prion protein (PrPC) were found in pericontusional area. These changes were attenuated in Mmp9(-/-) mice and were associated with lesser loss of short-term memory in these mice than in WT mice. Our data suggest that mild TBI-induced increased cerebrovascular permeability enhances deposition of Fg-PrPC and loss of memory, which is ameliorated in the absence of MMP-9 activity. Thus, targeting MMP-9 activity and blood level of Fg can be a possible therapeutic remedy to diminish vasculo-neuronal damage after TBI.	[Muradashvili, Nino; Tyagi, Suresh C.; Lominadze, David] Univ Louisville, Sch Med, Dept Physiol & Biophys, Louisville, KY 40202 USA; [Benton, Richard L.] Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40202 USA; [Benton, Richard L.] Univ Louisville, Sch Med, KSCIRC, Louisville, KY 40202 USA; [Saatman, Kathryn E.] Univ Kentucky, Dept Physiol & Neurosurg & Spinal Cord, Lexington, KY USA; [Saatman, Kathryn E.] Univ Kentucky, Brain Injury Res Ctr SCoBIRC, Lexington, KY USA	Lominadze, D (corresponding author), Univ Louisville, Sch Med, Dept Physiol & Biophys, Bldg A,Room 1115,500 South Preston St, Louisville, KY 40202 USA.	dglomi01@louisville.edu		Lominadze, David/0000-0002-9911-4539	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30 GM-103507, NS-084823, NS-051568]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL071010, R01HL108621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK104653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P30GM103507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS084823, R01NS051568] Funding Source: NIH RePORTER	Supported in part by NIH grants P30 GM-103507 (Pilot Project to D.L.), NS-084823 (to D.L. and S.C.T.), and NS-051568 (to S.C.T.)	Adams RA, 2007, J EXP MED, V204, P571, DOI 10.1084/jem.20061931; Ahn HJ, 2010, P NATL ACAD SCI USA, V107, P21812, DOI 10.1073/pnas.1010373107; ALTIERI DC, 1995, J BIOL CHEM, V270, P696, DOI 10.1074/jbc.270.2.696; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Carson-Walter EB, 2005, CLIN CANCER RES, V11, P7643, DOI 10.1158/1078-0432.CCR-05-1099; Cernich AN, 2010, CURR TREAT OPTION NE, V12, P412, DOI 10.1007/s11940-010-0085-6; Chhabra G, 2010, NEUROL INDIA, V58, P756, DOI 10.4103/0028-3886.72175; Choo AM, 2013, BRAIN, V136, P65, DOI 10.1093/brain/aws286; Chung E, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-130; Cohen Z, 1996, PROG NEUROBIOL, V50, P335, DOI 10.1016/S0301-0082(96)00033-0; Davalos D, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2230; Davalos D, 2012, SEMIN IMMUNOPATHOL, V34, P43, DOI 10.1007/s00281-011-0290-8; del Zoppo GJ, 2009, STROKE, V40, P1687, DOI 10.1161/STROKEAHA.108.527804; DERASMO E, 1993, J MED, V24, P185; ERNST E, 1993, ANN INTERN MED, V118, P956, DOI 10.7326/0003-4819-118-12-199306150-00008; Fernandez-Patron C, 2001, FASEB J, V15, P2230, DOI 10.1096/fj.01-0178com; Fischer MB, 2000, NATURE, V408, P479, DOI 10.1038/35044100; Flick MJ, 2004, J CLIN INVEST, V113, P1596, DOI 10.1172/JCI200420741; Gimbel DA, 2010, J NEUROSCI, V30, P6367, DOI 10.1523/JNEUROSCI.0395-10.2010; Granger DN, 2010, C SERIES INTEGRATED; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Hadass O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076904; Hnasko R, 2002, J ENDOCRINOL, V175, P649, DOI 10.1677/joe.0.1750649; Hu G, 2008, CIRC RES, V102, pE120, DOI 10.1161/CIRCRESAHA.107.167486; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kerlin B, 2004, BLOOD, V103, P1728, DOI 10.1182/blood-2003-08-2886; Lauren J, 2009, NATURE, V457, P1128, DOI 10.1038/nature07761; LETCHER RL, 1981, AM J MED, V70, P1195, DOI 10.1016/0002-9343(81)90827-5; Lishko VK, 2002, BIOCHEMISTRY-US, V41, P12942, DOI 10.1021/bi026324c; Lominadze D, 2006, AM J PHYSIOL-HEART C, V290, pH1206; Lominadze D, 2005, AM J PHYSIOL-HEART C, V288, pH1257, DOI 10.1152/ajpheart.00856.2004; Lominadze D, 2010, ACTA PHYSIOL, V198, P1, DOI 10.1111/j.1748-1716.2009.02037.x; Lominadze D, 1998, AM J HYPERTENS, V11, P784, DOI 10.1016/S0895-7061(98)00056-9; Lyon L, 2012, PSYCHOPHARMACOLOGY, V220, P647, DOI 10.1007/s00213-011-2536-5; Mansoor O, 1997, AM J PHYSIOL-ENDOC M, V273, pE898; Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005; Minshall RD, 2000, J CELL BIOL, V150, P1057, DOI 10.1083/jcb.150.5.1057; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Mozer AB, 2010, CURR NEUROVASC RES, V7, P238; Muradashvili N, 2013, CELL BIOCH BIOPHYSIC; Muradashvili N, 2013, BRAIN INJURY, V27, P1508, DOI 10.3109/02699052.2013.823562; Muradashvili N, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00166; Muradashvili N, 2012, J CEREBR BLOOD F MET, V32, P150, DOI 10.1038/jcbfm.2011.144; Muradashvili N, 2011, BIOCHEM BIOPH RES CO, V413, P509, DOI 10.1016/j.bbrc.2011.07.133; Pahatouridis D, 2010, BRAIN INJURY, V24, P1189, DOI 10.3109/02699052.2010.490510; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Patibandla PK, 2009, J CELL PHYSIOL, V221, P195, DOI 10.1002/jcp.21845; Phillips PG, 2004, AM J PHYSIOL-LUNG C, V286, pL1055, DOI 10.1152/ajplung.00262.2003; Pleasant J, 2011, J NEUROTRAUMA; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Rosell A, 2005, STROKE, V36, P1415, DOI 10.1161/01.STR.0000170641.01047.cc; Rosell A, 2006, STROKE, V37, P1399, DOI 10.1161/01.STR.0000223001.06264.af; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rybarczyk BJ, 2003, BLOOD, V102, P4035, DOI 10.1182/blood-2003-03-0822; Sahni A, 2009, INT J CANCER, V125, P577, DOI 10.1002/ijc.24340; Sangiorgi S, 2013, J NEUROSURG, V118, P763, DOI 10.3171/2012.11.JNS12627; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Sen U, 2009, AM J PHYSIOL-CELL PH, V296, pC840, DOI 10.1152/ajpcell.00515.2008; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Shue EH, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-29; Simionescu M, 2009, CELL TISSUE RES, V335, P27, DOI 10.1007/s00441-008-0688-3; Stan RV, 1999, P NATL ACAD SCI USA, V96, P13203, DOI 10.1073/pnas.96.23.13203; Sun YR, 2011, BRIT J NEUROSURG, V25, P363, DOI 10.3109/02688697.2011.552650; Sun Y, 2009, CIRC RES, V105, P676, DOI 10.1161/CIRCRESAHA.109.201673; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Tyagi N, 2008, MOL CELL BIOCHEM, V307, P13, DOI 10.1007/s11010-007-9579-2; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wei EP, 2009, J NEUROTRAUM, V26, P527, DOI 10.1089/neu.2008.0797; Yamaguchi M, 2007, NEUROSURGERY, V61, P1067, DOI 10.1227/01.neu.0000303203.07866.18; Yu J, 2006, J CLIN INVEST, V116, P1284, DOI 10.1172/JCI27100; Zhang RF, 2012, ANAL BIOCHEM, V427, P116, DOI 10.1016/j.ab.2012.05.008; Zlokovic BV, 2011, TRENDS NEUROSCI, V34, P198, DOI 10.1016/j.tins.2011.01.005	73	40	40	0	6	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0885-7490	1573-7365		METAB BRAIN DIS	Metab. Brain Dis.	APR	2015	30	2					411	426		10.1007/s11011-014-9550-3			16	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	CD2HA	WOS:000350894800007	24771110	Green Accepted			2021-06-18	
J	Quintard, H; Patet, C; Suys, T; Marques-Vidal, P; Oddo, M				Quintard, Herve; Patet, Camille; Suys, Tamarah; Marques-Vidal, Pedro; Oddo, Mauro			Normobaric Hyperoxia is Associated with Increased Cerebral Excitotoxicity After Severe Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Oxygen; Hyperoxia; Brain; Traumatic brain injury; Glutamate; Cerebral microdialysis; Excitotoxicity	SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; ARTERIAL HYPEROXIA; OXYGEN-TOXICITY; METABOLISM; RESUSCITATION; MORTALITY; GLUTAMATE; THERAPY; IMPROVEMENT	Normobaric oxygen therapy is frequently applied in neurocritical care, however, whether supplemental FiO(2) has beneficial cerebral effects is still controversial. We examined in patients with severe traumatic brain injury (TBI) the effect of incremental FiO(2) on cerebral excitotoxicity, quantified by cerebral microdialysis (CMD) glutamate. This was a retrospective analysis of a database of severe TBI patients monitored with CMD and brain tissue oxygen (PbtO(2)). The relationship of FiO(2)-categorized into four separate ranges (< 40, 41-60, 61-80, and > 80 %)-with CMD glutamate was examined using ANOVA with Tukey's post hoc test. A total of 1,130 CMD samples from 36 patients-monitored for a median of 4 days-were examined. After adjusting for brain (PbtO(2), intracranial pressure, cerebral perfusion pressure, lactate/pyruvate ratio, Marshall CT score) and systemic (PaCO2, PaO2, hemoglobin, APACHE score) covariates, high FiO(2) was associated with a progressive increase in CMD glutamate [8.8 (95 % confidence interval 7.4-10.2) A mu mol/L at FiO(2) < 40 % vs. 12.8 (10.9-14.7) A mu mol/L at 41-60 % FiO(2), 19.3 (15.6-23) A mu mol/L at 61-80 % FiO(2), and 22.6 (16.7-28.5) A mu mol/L at FiO(2) > 80 %; multivariate-adjusted p < 0.05]. The threshold of FiO(2)-related increase in CMD glutamate was lower for samples with normal versus low PbtO(2) < 20 mmHg (FiO(2) > 40 % vs. FiO(2) > 60 %). Hyperoxia (PaO2 > 150 mmHg) was also associated with increased CMD glutamate (adjusted p < 0.001). Incremental normobaric FiO(2) levels were associated with increased cerebral excitotoxicity in patients with severe TBI, independent from PbtO(2) and other important cerebral and systemic determinants. These data suggest that supra-normal oxygen may aggravate secondary brain damage after severe TBI.	[Quintard, Herve; Patet, Camille; Suys, Tamarah; Oddo, Mauro] CHU Vaudois, Univ Lausanne Hosp, Neurosci Crit Care Res Grp, Dept Intens Care Med, CH-1011 Lausanne, Switzerland; [Marques-Vidal, Pedro] CHU Vaudois, Univ Lausanne Hosp, Dept Internal Med, CH-1011 Lausanne, Switzerland	Oddo, M (corresponding author), CHU Vaudois, Univ Lausanne Hosp, Neurosci Crit Care Res Grp, Dept Intens Care Med, Rue Bugnon 46,BH 08-623, CH-1011 Lausanne, Switzerland.	mauro.oddo@chuv.ch	Oddo, Mauro/R-3370-2016; Marques-Vidal, Pedro M/C-9449-2009	Oddo, Mauro/0000-0002-6155-2525; Marques-Vidal, Pedro M/0000-0002-4548-8500; Patet, Camille/0000-0001-7009-2543	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [320030_138191]; Novartis Foundation for Biomedical Research; Societe Francaise d'Anesthesie et Reanimation (SFAR)	This work was supported by grants from the Swiss National Science Foundation (Grant No. 320030_138191, to Mauro Oddo), the Novartis Foundation for Biomedical Research (to Mauro Oddo) and the Societe Francaise d'Anesthesie et Reanimation (SFAR) (to Herve Quintard). The authors thank Professor Lucas Liaudet, MD, for helpful scientific discussion.	Beynon C, 2012, J NEUROTRAUM, V29, P2109, DOI 10.1089/neu.2012.2365; Blasiole B, 2013, ANESTHESIOLOGY, V118, P649, DOI 10.1097/ALN.0b013e318280a42d; Bohman LE, 2011, NEUROCRIT CARE, V14, P361, DOI 10.1007/s12028-011-9526-7; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS65; Brain Trauma Foundation American Association of Neurological Surgeons Congress of Neurological Surgeons, 2007, J NEUROTRAUM, V24, pS45, DOI DOI 10.1089/NEU.2007.9989; Brenner M, 2012, ARCH SURG-CHICAGO, V147, P1042, DOI 10.1001/archsurg.2012.1560; Brower RG, 2003, CRIT CARE MED, V31, pS312, DOI 10.1097/01.CCM.0000057909.18362.F6; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; D'Agostino DP, 2013, AM J PHYSIOL-REG I, V304, pR829, DOI 10.1152/ajpregu.00506.2012; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; de Jonge E, 2008, CRIT CARE, V12, DOI 10.1186/cc7150; Diringer MN, 2008, CURR OPIN CRIT CARE, V14, P167, DOI 10.1097/MCC.0b013e3282f57552; Diringer MN, 2007, J NEUROSURG, V106, P526, DOI 10.3171/jns.2007.106.4.526; Fletcher JJ, 2010, NEUROCRIT CARE, V13, P47, DOI 10.1007/s12028-010-9345-2; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Kilgannon JH, 2011, CIRCULATION, V123, P2717, DOI 10.1161/CIRCULATIONAHA.110.001016; Kilgannon JH, 2010, JAMA-J AM MED ASSOC, V303, P2165, DOI 10.1001/jama.2010.707; Kumaria A, 2009, BRIT J NEUROSURG, V23, P576, DOI 10.3109/02688690903050352; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Martini RP, 2009, J NEUROSURG, V111, P644, DOI 10.3171/2009.2.JNS08998; McCarthy MC, 2009, SURGERY, V146, P585, DOI 10.1016/j.surg.2009.06.059; McKenna MC, 2007, J NEUROSCI RES, V85, P3347, DOI 10.1002/jnr.21444; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; MOODY RA, 1970, J NEUROSURG, V32, P51, DOI 10.3171/jns.1970.32.1.0051; Muthuraju S, 2013, J BIOSCIENCES, V38, P93, DOI 10.1007/s12038-012-9290-7; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; Oddo M, 2012, CURR OPIN CRIT CARE, V18, P111, DOI 10.1097/MCC.0b013e32835132a5; Oddo M, 2011, NEUROSURGERY, V69, P1037, DOI 10.1227/NEU.0b013e3182287ca7; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Puccio AM, 2009, J NEUROTRAUM, V26, P1241, DOI [10.1089/neu.2008.0624, 10.1089/neu.2008-0624]; Rangel-Castilla L, 2010, J NEUROTRAUM, V27, P1853, DOI 10.1089/neu.2010.1339; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Rincon F, 2014, J NEUROL NEUROSUR PS, V85, P799, DOI 10.1136/jnnp-2013-305505; Rincon F, 2014, CRIT CARE MED, V42, P387, DOI 10.1097/CCM.0b013e3182a27732; Rockswold SB, 2013, J NEUROSURG, V118, P1317, DOI 10.3171/2013.2.JNS121468; Rockswold SB, 2010, J NEUROSURG, V112, P1080, DOI 10.3171/2009.7.JNS09363; Rostami E, 2013, RESP PHYSIOL NEUROBI, V189, P537, DOI 10.1016/j.resp.2013.08.010; Sala N, 2013, J CEREBR BLOOD F MET, V33, P1815, DOI 10.1038/jcbfm.2013.142; Schmitz T, 2011, J NEUROSCI, V31, P4327, DOI 10.1523/JNEUROSCI.3942-10.2011; Sjoberg F, 2013, J INTERN MED, V274, P505, DOI 10.1111/joim.12139; Solberg R, 2012, FREE RADICAL BIO MED, V53, P1061, DOI 10.1016/j.freeradbiomed.2012.07.022; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Thomas PM, 2003, EPILEPSY RES, V54, P73, DOI 10.1016/S0920-1211(03)00035-4; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Tisdall MM, 2008, J NEUROSURG, V109, P424, DOI 10.3171/JNS/2008/109/9/0424; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Wang MJ, 2009, AM J RESP CELL MOL, V40, P260, DOI 10.1165/rcmb.2008-0135OC	51	40	44	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2015	22	2					243	250		10.1007/s12028-014-0062-0			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	CD9VK	WOS:000351447100010	25168744				2021-06-18	
J	O'Leary, O; Nolan, Y				O'Leary, Olivia; Nolan, Yvonne			Glycogen Synthase Kinase-3 as a Therapeutic Target for Cognitive Dysfunction in Neuropsychiatric Disorders	CNS DRUGS			English	Article							AMYLOID PROTEIN DEPOSITION; POSTMORTEM FRONTAL-CORTEX; EUTHYMIC BIPOLAR PATIENTS; LONG-TERM POTENTIATION; ALZHEIMERS-DISEASE; LITHIUM TREATMENT; BETA-CATENIN; TAU PHOSPHORYLATION; PREFRONTAL CORTEX; TRANSGENIC MODEL	The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) is involved in a broad range of cellular processes including cell proliferation, apoptosis and inflammation. It is now also increasingly acknowledged as having a role to play in cognitive-related processes such as neurogenesis, synaptic plasticity and neural cell survival. Cognitive impairment represents a major debilitating feature of many neurodegenerative and psychiatric disorders, including Alzheimer's disease, mood disorders, schizophrenia and fragile X syndrome, as well as being a result of traumatic brain injury or cranial irradiation. Accordingly, GSK-3 has been identified as an important therapeutic target for cognitive impairment, and recent preclinical studies have yielded important evidence demonstrating that GSK-3 inhibitors may be useful therapeutic interventions for restoring cognitive function in some of these brain disorders. The current review summarises the role of GSK-3 as a regulator of cognitive-dependent functions, examines current preclinical and clinical evidence of the potential of GSK-3 inhibitors as therapeutic agents for cognitive impairments in neuropsychiatric disorders, and offers some insight into the current obstacles that are impeding the clinical use of selective GSK-3 inhibitors in the treatment of cognitive impairment.	[O'Leary, Olivia; Nolan, Yvonne] Natl Univ Ireland Univ Coll Cork, Dept Anat & Neurosci, Cork, Ireland	Nolan, Y (corresponding author), Natl Univ Ireland Univ Coll Cork, Dept Anat & Neurosci, Western Gateway Bldg,Room 3-83, Cork, Ireland.	y.nolan@ucc.ie		Nolan, Yvonne/0000-0003-2426-234X; O'Leary, Olivia/0000-0002-9171-2032	Science Foundation IrelandScience Foundation IrelandEuropean Commission [12/IA/1537]; University College Cork (UCC) Strategic Research Fund	Work in Olivia O'Leary's and Yvonne Nolan's laboratories is currently supported by a Grant from Science Foundation Ireland (12/IA/1537) and the University College Cork (UCC) Strategic Research Fund. No funding was specifically received for the preparation of this article. Olivia O'Leary and Yvonne Nolan declare that they have no conflict of interest.	Alimohamad H, 2005, BIOL PSYCHIAT, V57, P533, DOI 10.1016/j.biopsych.2004.11.036; Altshuler LL, 2004, BIOL PSYCHIAT, V56, P560, DOI 10.1016/j.biopsych.2004.08.002; Aplin AE, 1996, J NEUROCHEM, V67, P699; Avrahami L, 2013, J BIOL CHEM, V288, P1295, DOI 10.1074/jbc.M112.409250; Beasley C, 2001, NEUROSCI LETT, V302, P117, DOI 10.1016/S0304-3940(01)01688-3; Beaulieu JM, 2008, P NATL ACAD SCI USA, V105, P1333, DOI 10.1073/pnas.0711496105; Beaulieu JM, 2012, J PSYCHIATR NEUROSCI, V37, P7, DOI 10.1503/jpn.110011; Beaulieu JM, 2004, P NATL ACAD SCI USA, V101, P5099, DOI 10.1073/pnas.0307921101; Beaulieu JM, 2005, CELL, V122, P261, DOI 10.1016/j.cell.2005.05.012; Benedetti F, 2005, NEUROSCI LETT, V376, P51, DOI 10.1016/j.neulet.2004.11.022; Benedetti F, 2010, GENES BRAIN BEHAV, V9, P365, DOI 10.1111/j.1601-183X.2010.00566.x; Berry-Kravis E, 2008, J DEV BEHAV PEDIATR, V29, P293, DOI 10.1097/DBP.0b013e31817dc447; Bersudsky Y, 2008, BEHAV PHARMACOL, V19, P217, DOI 10.1097/FBP.0b013e3282feb099; Bhat R, 2003, J BIOL CHEM, V278, P45937, DOI 10.1074/jbc.M306268200; Bhat RV, 2002, NEUROSIGNALS, V11, P251, DOI 10.1159/000067423; Blasi G, 2013, AM J PSYCHIAT, V170, P868, DOI 10.1176/appi.ajp.2012.12070908; Caccamo A, 2007, AM J PATHOL, V170, P1669, DOI 10.2353/ajpath.2007.061178; CALEV A, 1986, PSYCHOL MED, V16, P789, DOI 10.1017/S0033291700011806; Carvalho AF, 2007, J CLIN PHARM THER, V32, P415, DOI 10.1111/j.1365-2710.2007.00846.x; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Chan MH, 2012, SCHIZOPHR RES, V136, P96, DOI 10.1016/j.schres.2012.01.024; Chen L, 2011, MOL PHARMACOL, V79, P974, DOI 10.1124/mol.111.071092; Chen LG, 2009, MOL PHARMACOL, V76, P1150, DOI 10.1124/mol.109.056994; Clark L, 2002, BRIT J PSYCHIAT, V180, P313, DOI 10.1192/bjp.180.4.313; Clifford DB, 2013, LANCET INFECT DIS, V13, P976, DOI 10.1016/S1473-3099(13)70269-X; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Cohen Y, 1998, MED ONCOL, V15, P32, DOI 10.1007/BF02787342; Cowen P, 2013, J PSYCHOPHARMACOL, V27, P575, DOI 10.1177/0269881113482531; Crews L, 2009, INT J MOL SCI, V10, P1045, DOI 10.3390/ijms10031045; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Dash PK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024648; De Ferrari GV, 2003, MOL PSYCHIATR, V8, P195, DOI 10.1038/sj.mp.4001208; De Sarno P, 2002, NEUROPHARMACOLOGY, V43, P1158, DOI 10.1016/S0028-3908(02)00215-0; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; del Ser T, 2013, J ALZHEIMERS DIS, V33, P205, DOI 10.3233/JAD-2012-120805; Dewachter I, 2009, NEUROBIOL DIS, V35, P193, DOI 10.1016/j.nbd.2009.04.003; Dias VV, 2012, ACTA PSYCHIAT SCAND, V126, P315, DOI 10.1111/j.1600-0447.2012.01910.x; Ding Y, 2010, NEUROBIOL DIS, V39, P156, DOI 10.1016/j.nbd.2010.03.022; Diniz BS, 2013, NEUROPSYCH DIS TREAT, V9, P493, DOI 10.2147/NDT.S33086; El-Badri SM, 2001, BIPOLAR DISORD, V3, P79, DOI 10.1034/j.1399-5618.2001.030206.x; Eldar-Finkelman H, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00032; Emamian ES, 2004, NAT GENET, V36, P131, DOI 10.1038/ng1296; EMBI N, 1980, EUR J BIOCHEM, V107, P519, DOI 10.1111/j.1432-1033.1980.tb06059.x; Engel T, 2006, J NEUROSCI, V26, P5083, DOI 10.1523/JNEUROSCI.0604-06.2006; ENGELSMANN F, 1988, J CLIN PSYCHOPHARM, V8, P207; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Farr SA, 2014, FREE RADICAL BIO MED, V67, P387, DOI 10.1016/j.freeradbiomed.2013.11.014; Ferreira AS, 2014, EUR ARCH PSYCHIAT CL; Fiorentini A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014382; Forlenza OV, 2012, DRUG AGING, V29, P335, DOI 10.2165/11599180-000000000-00000; Forlenza OV, 2011, BRIT J PSYCHIAT, V198, P351, DOI 10.1192/bjp.bp.110.080044; Franklin AV, 2014, BIOL PSYCHIAT, V75, P198, DOI 10.1016/j.biopsych.2013.08.003; Freland L, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00014; Ghosal K, 2009, P NATL ACAD SCI USA, V106, P18367, DOI 10.1073/pnas.0907652106; Giese KP, 2009, IUBMB LIFE, V61, P516, DOI 10.1002/iub.187; Goldberg JF, 2009, BIPOLAR DISORD, V11, P123, DOI 10.1111/j.1399-5618.2009.00716.x; de Barreda EG, 2010, NEUROBIOL DIS, V37, P622, DOI 10.1016/j.nbd.2009.11.017; GOODE N, 1992, J BIOL CHEM, V267, P16878; Green HF, 2012, NEUROCHEM INT, V61, P666, DOI 10.1016/j.neuint.2012.07.003; Grimes CA, 2001, J NEUROCHEM, V78, P1219, DOI 10.1046/j.1471-4159.2001.00495.x; Guo WX, 2012, HUM MOL GENET, V21, P681, DOI 10.1093/hmg/ddr501; Hampel H, 2009, J CLIN PSYCHIAT, V70, P922, DOI 10.4088/JCP.08m04606; Hendrie HC, 2014, AM J GERIAT PSYCHIAT, V22, P427, DOI 10.1016/j.jagp.2012.10.025; Hernandez F, 2002, J NEUROCHEM, V83, P1529, DOI 10.1046/j.1471-4159.2002.01269.x; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Honig A, 1999, INT CLIN PSYCHOPHARM, V14, P167, DOI 10.1097/00004850-199905030-00003; Hooper C, 2008, J NEUROCHEM, V104, P1433, DOI 10.1111/j.1471-4159.2007.05194.x; Hulsken J, 2000, J CELL SCI, V113, P3545; Hurtado DE, 2012, J NEUROSCI, V32, P7392, DOI 10.1523/JNEUROSCI.0889-12.2012; Ikeda M, 2004, BIOL PSYCHIAT, V56, P698, DOI 10.1016/j.biopsych.2004.07.023; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeya M, 1997, NATURE, V389, P966; Inestrosa NC, 2010, NAT REV NEUROSCI, V11, P77, DOI 10.1038/nrn2755; JOFFE RT, 1988, J CLIN PSYCHOPHARM, V8, P425; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Jung HJ, 2011, NEUROSCI LETT, V487, P139, DOI 10.1016/j.neulet.2010.10.009; Kaidanovich-Beilin O, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00040; Kessing LV, 2010, BIPOLAR DISORD, V12, P87, DOI 10.1111/j.1399-5618.2009.00788.x; Khasraw M, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-131; Kimura T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003540; King MR, 2013, J NEUROSCI RES, V91, P506, DOI 10.1002/jnr.23192; Kirschenbaum F, 2001, J BIOL CHEM, V276, P30701, DOI 10.1074/jbc.M102849200; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kozlovsky N, 2004, J NEURAL TRANSM, V111, P1583, DOI 10.1007/s00702-004-0166-3; Kozlovsky N, 2000, AM J PSYCHIAT, V157, P831, DOI 10.1176/appi.ajp.157.5.831; Kozlovsky N, 2004, J NEURAL TRANSM, V111, P1093, DOI 10.1007/s00702-003-0127-0; Kozlovsky N, 2001, SCHIZOPHR RES, V52, P101, DOI 10.1016/S0920-9964(00)00174-2; Kunick C, 2004, BIOORG MED CHEM LETT, V14, P413, DOI 10.1016/j.bmcl.2003.10.062; Lachman HM, 2007, AM J MED GENET B, V144B, P259, DOI 10.1002/ajmg.b.30498; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Lee KY, 2006, NEUROSCI LETT, V395, P175, DOI 10.1016/j.neulet.2005.10.059; Lee SJ, 2006, NEUROSCI LETT, V409, P134, DOI 10.1016/j.neulet.2006.09.026; Leeds PR, 2014, ACS CHEM NEUROSCI; Lehmann SW, 2013, J AFFECT DISORDERS, V146, P151, DOI 10.1016/j.jad.2012.08.028; Lesort M, 1999, J NEURAL TRANSM, V106, P1217, DOI 10.1007/s007020050235; Letendre SL, 2006, AIDS, V20, P1885, DOI 10.1097/01.aids.0000244208.49123.1b; Leyhe T, 2009, J ALZHEIMERS DIS, V16, P649, DOI 10.3233/JAD-2009-1004; Li HL, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/241864; Li XH, 2004, NEUROPSYCHOPHARMACOL, V29, P1426, DOI 10.1038/sj.npp.1300439; Li XH, 2010, BIPOLAR DISORD, V12, P741, DOI 10.1111/j.1399-5618.2010.00866.x; Li XH, 2007, INT J NEUROPSYCHOPH, V10, P7, DOI 10.1017/S1461145706006547; Li XH, 2007, BIOL PSYCHIAT, V61, P216, DOI 10.1016/j.biopsych.2006.02.027; Li XH, 2010, NEUROPSYCHOPHARMACOL, V35, P2143, DOI 10.1038/npp.2010.105; Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108; Lin YF, 2013, J AFFECT DISORDERS, V147, P401, DOI 10.1016/j.jad.2012.08.025; Lipina TV, 2013, NEUROPHARMACOLOGY, V64, P205, DOI 10.1016/j.neuropharm.2012.06.032; Lopez-Jaramillo C, 2010, J CLIN PSYCHIAT, V71, P1055, DOI 10.4088/JCP.08m04673yel; Lovestone S, 2007, TRENDS NEUROSCI, V30, P142, DOI 10.1016/j.tins.2007.02.002; Ly PTT, 2013, J CLIN INVEST, V123, P224, DOI 10.1172/JCI64516; Macdonald A, 2008, INT J GERIATR PSYCH, V23, P704, DOI 10.1002/gps.1964; Malaterre J, 2012, STEM CELL TRANSL MED, V1, P469, DOI 10.5966/sctm.2011-0046; Mantamadiotis T, 2002, NAT GENET, V31, P47, DOI 10.1038/ng882; Dominguez JM, 2012, J BIOL CHEM, V287, P893, DOI 10.1074/jbc.M111.306472; Marin-Burgin A, 2012, BEHAV BRAIN RES, V227, P391, DOI 10.1016/j.bbr.2011.07.001; Martinez A, 2002, J MED CHEM, V45, P1292, DOI 10.1021/jm011020u; Min WW, 2009, NEUROPHARMACOLOGY, V56, P463, DOI 10.1016/j.neuropharm.2008.09.017; Mines MA, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00035; Monleon S, 2008, EUR NEUROPSYCHOPHARM, V18, P235, DOI 10.1016/j.euroneuro.2007.07.001; Morales-Garcia JA, 2012, ACS CHEM NEUROSCI, V3, P963, DOI 10.1021/cn300110c; Mur M, 2008, ACTA PSYCHIAT SCAND, V118, P373, DOI 10.1111/j.1600-0447.2008.01245.x; Mur M, 2007, J CLIN PSYCHIAT, V68, P1078, DOI 10.4088/JCP.v68n0715; Nadri C, 2004, SCHIZOPHR RES, V71, P377, DOI 10.1016/j.schres.2004.02.020; Nadri C, 2002, PSYCHIAT RES, V112, P51, DOI 10.1016/S0165-1781(02)00191-9; Nishiguchi N, 2006, NEUROSCI LETT, V394, P243, DOI 10.1016/j.neulet.2005.10.042; Noh MY, 2013, BIOCHEM BIOPH RES CO, V435, P274, DOI 10.1016/j.bbrc.2013.04.065; Nunes MA, 2013, CURR ALZHEIMER RES, V10, P104; Nunes PV, 2007, BRIT J PSYCHIAT, V190, P359, DOI 10.1192/bjp.bp.106.029868; O'Brien WT, 2004, J NEUROSCI, V24, P6791, DOI 10.1523/JNEUROSCI.4753-03.2004; O'Leary OF, 2015, EUR J PHARMACOL, V753, P32, DOI 10.1016/j.ejphar.2014.07.046; Onishi T, 2011, J NEUROCHEM, V119, P1330, DOI 10.1111/j.1471-4159.2011.07532.x; Pachet AK, 2003, PSYCHOPHARMACOLOGY, V170, P225, DOI 10.1007/s00213-003-1592-x; Palomo V, 2011, J MED CHEM, V54, P8461, DOI 10.1021/jm200996g; Pandey GN, 2015, BIPOLAR DISORD, V17, P160, DOI 10.1111/bdi.12228; Park SW, 2011, NEUROSCI RES, V71, P335, DOI 10.1016/j.neures.2011.08.010; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; Plotkin B, 2003, J PHARMACOL EXP THER, V305, P974, DOI 10.1124/jpet.102.047381; Polter A, 2010, NEUROPSYCHOPHARMACOL, V35, P1761, DOI 10.1038/npp.2010.43; Polter AM, 2012, CELL SIGNAL, V24, P265, DOI 10.1016/j.cellsig.2011.09.009; Pomara N, 2009, PSYCHOPHARMACOLOGY, V205, P169, DOI 10.1007/s00213-009-1510-y; Quiroz JA, 2010, NEUROPSYCHOBIOLOGY, V62, P50, DOI 10.1159/000314310; Rix LLR, 2014, ACS CHEM BIOL, V9, P353, DOI 10.1021/cb400660a; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rockenstein E, 2007, J NEUROSCI, V27, P1981, DOI 10.1523/JNEUROSCI.4321-06.2007; Roh MS, 2007, EXP MOL MED, V39, P353, DOI 10.1038/emm.2007.39; Ronai Z, 2014, AM J MED GENET B, V165, P217, DOI 10.1002/ajmg.b.32223; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Rybakowski JK, 2010, INT J NEUROPSYCHOPH, V13, P617, DOI 10.1017/S1461145710000404; Saitoh M, 2009, J MED CHEM, V52, P6270, DOI 10.1021/jm900647e; Saitoh M, 2009, BIOORGAN MED CHEM, V17, P2017, DOI 10.1016/j.bmc.2009.01.019; Salinas PC, 2008, ANNU REV NEUROSCI, V31, P339, DOI 10.1146/annurev.neuro.31.060407.125649; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Savitz JB, 2008, BIPOLAR DISORD, V10, P479, DOI 10.1111/j.1399-5618.2008.00591.x; Schouws SNTM, 2010, J AFFECT DISORDERS, V125, P330, DOI 10.1016/j.jad.2009.12.004; Schwab SG, 2005, BIOL PSYCHIAT, V58, P446, DOI 10.1016/j.biopsych.2005.05.005; Senturk V, 2007, BIPOLAR DISORD, V9, P136, DOI 10.1111/j.1399-5618.2007.00481.x; Sereno L, 2009, NEUROBIOL DIS, V35, P359, DOI 10.1016/j.nbd.2009.05.025; Shakoori A, 2007, CANCER SCI, V98, P1388, DOI 10.1111/j.1349-7006.2007.00545.x; Sharma S, 2014, BIOCHEM BIOPH RES CO, V452, P1009, DOI 10.1016/j.bbrc.2014.09.034; SHAW ED, 1987, J ABNORM PSYCHOL, V96, P64, DOI 10.1037/0021-843X.96.1.64; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Silva T, 2014, AGEING RES REV, V15, P116, DOI 10.1016/j.arr.2014.03.008; Sproule BA, 2000, DRUG AGING, V16, P165, DOI 10.2165/00002512-200016030-00002; SQUIRE LR, 1980, AM J PSYCHIAT, V137, P1042; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Stoudemire A, 1998, GEN HOSP PSYCHIAT, V20, P85, DOI 10.1016/S0163-8343(97)00129-1; Sudduth TL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031993; Suganthi M, 2012, BIOL TRACE ELEM RES, V150, P477, DOI 10.1007/s12011-012-9510-x; Sun AJ, 2007, PROSTATE, V67, P976, DOI 10.1002/pros.20586; Sutton LP, 2011, NEUROSCIENCE, V199, P116, DOI 10.1016/j.neuroscience.2011.09.056; Szczepankiewicz A, 2006, NEUROPSYCHOBIOLOGY, V53, P51, DOI 10.1159/000090704; Tang H, 2013, MOL NEUROBIOL, V48, P404, DOI 10.1007/s12035-013-8414-x; Terao T, 2006, PROG NEURO-PSYCHOPH, V30, P1125, DOI 10.1016/j.pnpbp.2006.04.020; Thiselton DL, 2008, BIOL PSYCHIAT, V63, P449, DOI 10.1016/j.biopsych.2007.06.005; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Thotala DK, 2008, CANCER RES, V68, P5859, DOI 10.1158/0008-5472.CAN-07-6327; Toledo EM, 2010, MOL PSYCHIATR, V15, P272, DOI 10.1038/mp.2009.72; Wang JS, 2008, WORLD J GASTROENTERO, V14, P3982, DOI 10.3748/wjg.14.3982; Wingo AP, 2009, J CLIN PSYCHIAT, V70, P1588, DOI 10.4088/JCP.08r04972; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Yao HB, 2002, J CHEM NEUROANAT, V23, P291, DOI 10.1016/S0891-0618(02)00014-5; Yazlovitskaya EM, 2006, CANCER RES, V66, P11179, DOI 10.1158/0008-5472.CAN-06-2740; Yu FS, 2012, J NEUROTRAUM, V29, P2342, DOI 10.1089/neu.2012.2449; Yuskaitis CJ, 2010, BIOCHEM PHARMACOL, V79, P632, DOI 10.1016/j.bcp.2009.09.023; Zerbi F, 1981, Bibl Psychiatr, P190; Zhang X, 2011, J ALZHEIMERS DIS, V24, P739, DOI 10.3233/JAD-2011-101875; Zhou WJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043262; Zhu LQ, 2007, J NEUROSCI, V27, P12211, DOI 10.1523/JNEUROSCI.3321-07.2007; Zhu ZF, 2010, BRAIN RES BULL, V83, P272, DOI 10.1016/j.brainresbull.2010.07.008	190	40	40	0	20	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1172-7047	1179-1934		CNS DRUGS	CNS Drugs	JAN	2015	29	1					1	15		10.1007/s40263-014-0213-z			15	Clinical Neurology; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	AZ6OY	WOS:000348339900001	25380674				2021-06-18	
J	Reiner, A; Heldt, SA; Presley, CS; Guley, NH; Elberger, AJ; Deng, YP; D'Surney, L; Rogers, JT; Ferrell, J; Bu, W; Del Mar, N; Honig, MG; Gurley, SN; Moore, BM				Reiner, Anton; Heldt, Scott A.; Presley, Chaela S.; Guley, Natalie H.; Elberger, Andrea J.; Deng, Yunping; D'Surney, Lauren; Rogers, Joshua T.; Ferrell, Jessica; Bu, Wei; Del Mar, Nobel; Honig, Marcia G.; Gurley, Steven N.; Moore, Bob M., II			Motor, Visual and Emotional Deficits in Mice after Closed-Head Mild Traumatic Brain Injury Are Alleviated by the Novel CB2 Inverse Agonist SMM-189	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES			English	Article						TBI; deficits; microglia; CB2 receptors; therapy	STRIATAL PROJECTION NEURON; GAMMA PKC-GAMMA; CONTRAST SENSITIVITY; OPTIC-NERVE; MOUSE MODEL; CORTICOSPINAL TRACT; LOCOMOTOR BEHAVIOR; IMMUNE-RESPONSES; AXONAL INJURY; BLAST INJURY	We have developed a focal blast model of closed-head mild traumatic brain injury (TBI) in mice. As true for individuals that have experienced mild TBI, mice subjected to 50-60 psi blast show motor, visual and emotional deficits, diffuse axonal injury and microglial activation, but no overt neuron loss. Because microglial activation can worsen brain damage after a concussive event and because microglia can be modulated by their cannabinoid type 2 receptors (CB2), we evaluated the effectiveness of the novel CB2 receptor inverse agonist SMM-189 in altering microglial activation and mitigating deficits after mild TBI. In vitro analysis indicated that SMM-189 converted human microglia from the pro-inflammatory M1 phenotype to the pro-healing M2 phenotype. Studies in mice showed that daily administration of SMM-189 for two weeks beginning shortly after blast greatly reduced the motor, visual, and emotional deficits otherwise evident after 50-60 psi blasts, and prevented brain injury that may contribute to these deficits. Our results suggest that treatment with the CB2 inverse agonist SMM-189 after a mild TBI event can reduce its adverse consequences by beneficially modulating microglial activation. These findings recommend further evaluation of CB2 inverse agonists as a novel therapeutic approach for treating mild TBI.	[Reiner, Anton; Heldt, Scott A.; Guley, Natalie H.; Elberger, Andrea J.; Deng, Yunping; D'Surney, Lauren; Rogers, Joshua T.; Ferrell, Jessica; Bu, Wei; Del Mar, Nobel; Honig, Marcia G.] Univ Tennessee, Hlth Sci Ctr, Dept Anat & Neurobiol, Memphis, TN 38163 USA; [Reiner, Anton] Univ Tennessee, Hlth Sci Ctr, Dept Ophthalmol, Memphis, TN 38163 USA; [Presley, Chaela S.; Gurley, Steven N.; Moore, Bob M., II] Univ Tennessee, Hlth Sci Ctr, Dept Pharmaceut Sci, Memphis, TN 38163 USA	Reiner, A (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Anat & Neurobiol, Memphis, TN 38163 USA.	areiner@uthsc.edu; sheldt@uthsc.edu; cpresle4@uthsc.edu; nhart2@uthsc.edu; aelberge@uthsc.edu; ydeng@uthsc.edu; ldsurney@uthsc.edu; jroger45@uthsc.edu; jferre13@uthsc.edu; wbu1@uthsc.edu; ndelmar@uthsc.edu; mhonig@uthsc.edu; sngurley@comcast.net; bmoore@uthsc.edu	Reiner, Anton/AAG-8860-2020	Reiner, Anton/0000-0002-2146-5232	University of Tennessee Neuroscience Institute; Office of the Dean of the College of Medicine at UTHSC; Methodist Hospitals Endowed Professorship in Neuroscience; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-081370, EY-005298]; Department of DefenseUnited States Department of Defense [W81XWH-10-1-0528]; College of Pharmacy at UTHSC; Research to Prevent Blindness Unrestricted Funds; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY005298] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS081370] Funding Source: NIH RePORTER	The technical assistance of Danielle Howell, Marion Joni, and Rhonda Williams is gratefully acknowledged. Supported by the University of Tennessee Neuroscience Institute (Anton Reiner, Andrea J. Elberger), the Office of the Dean of the College of Medicine at UTHSC (Anton Reiner), the Methodist Hospitals Endowed Professorship in Neuroscience (Anton Reiner), National Institute of Health grant NS-081370 (Anton Reiner), National Institute of Health grant EY-005298 (Anton Reiner), Department of Defense grant W81XWH-10-1-0528 (Tonia S. Rex), the College of Pharmacy at UTHSC (Bob M. Moore), and Research to Prevent Blindness Unrestricted Funds (James C. Fleming).	ABE H, 1993, OPHTHALMOLOGICA, V207, P100, DOI 10.1159/000310413; Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Akimov NP, 2012, BEHAV BRAIN RES, V226, P601, DOI 10.1016/j.bbr.2011.09.030; Al-Hashmi AM, 2011, EXP BRAIN RES, V215, P293, DOI 10.1007/s00221-011-2896-4; Amenta PS, 2012, J NEUROSCI RES, V90, P2293, DOI 10.1002/jnr.23114; Arevalo-Martin A, 2003, J NEUROSCI, V23, P2511; Ashton JC, 2007, CURR NEUROPHARMACOL, V5, P73, DOI 10.2174/157015907780866884; Atwood BK, 2012, PROG NEURO-PSYCHOPH, V38, P16, DOI 10.1016/j.pnpbp.2011.12.001; Baek JH, 2013, J NEUROSCI METH, V216, P87, DOI 10.1016/j.jneumeth.2013.03.021; Bareyre FM, 2005, NAT MED, V11, P1355, DOI 10.1038/nm1331; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Benito C, 2003, J NEUROSCI, V23, P11136; Bhattacharjee H, 2009, BIOORG MED CHEM LETT, V19, P1691, DOI 10.1016/j.bmcl.2009.01.100; Blumbergs P.C., 2008, GREENFIELDS NEUROPAT, P733; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Cockerham GC, 2009, J REHABIL RES DEV, V46, P811, DOI 10.1682/JRRD.2008.08.0109; Cryan JF, 2005, NEUROSCI BIOBEHAV R, V29, P571, DOI 10.1016/j.neubiorev.2005.03.009; Cuthbertson S, 2003, INVEST OPHTH VIS SCI, V44, P3713, DOI 10.1167/iovs.02-1207; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Deng YP, 2013, NEUROBIOL DIS, V60, P89, DOI 10.1016/j.nbd.2013.08.009; DILEO MAS, 1992, DIABETES CARE, V15, P620, DOI 10.2337/diacare.15.5.620; DRAGER UC, 1980, J COMP NEUROL, V191, P383, DOI 10.1002/cne.901910306; Drai D, 2001, NEUROSCI BIOBEHAV R, V25, P409, DOI 10.1016/S0149-7634(01)00022-7; Drai D, 2000, J NEUROSCI METH, V96, P119, DOI 10.1016/S0165-0270(99)00194-6; Ebneter A, 2010, INVEST OPHTH VIS SCI, V51, P6448, DOI 10.1167/iovs.10-5284; Elliott MB, 2011, J NEUROTRAUM, V28, P973, DOI 10.1089/neu.2010.1672; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Firsching R, 2012, J NEUROL SURG PART A, V73, P204, DOI 10.1055/s-0032-1304815; Fujinaga M, 2010, BIOORG MED CHEM LETT, V20, P1565, DOI 10.1016/j.bmcl.2010.01.074; Gorski JA, 2002, J NEUROSCI, V22, P6309; Hashemi H, 2012, OPHTHALMOLOGY, V119, P541, DOI 10.1016/j.ophtha.2011.08.030; Heldt SA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00002; Herry C, 2008, NATURE, V454, P600, DOI 10.1038/nature07166; Hines-Beard J, 2012, EXP EYE RES, V99, P63, DOI 10.1016/j.exer.2012.03.013; Jasnow AM, 2013, J NEUROSCI, V33, P10396, DOI 10.1523/JNEUROSCI.5539-12.2013; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jovanovic Milos, 2012, Acta Chir Iugosl, V59, P73; Kafkafi N, 2003, BEHAV NEUROSCI, V117, P464, DOI 10.1037/0735-7044.117.3.464; Kafkafi N, 2001, J NEUROSCI METH, V109, P111, DOI 10.1016/S0165-0270(01)00392-2; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Koppel J, 2014, MOL MED, V20, P29, DOI 10.2119/molmed.2013.00140.revised; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088; Lieu A, 2013, J NEUROIMMUNOL, V256, P43, DOI 10.1016/j.jneuroim.2013.01.003; Lipkind D, 2004, J APPL PHYSIOL, V97, P347, DOI 10.1152/japplphysiol.00148.2004; Lopez-Rodriguez AB, 2015, CEREB CORTEX, V25, P35, DOI 10.1093/cercor/bht202; Lunn CA, 2008, BRIT J PHARMACOL, V153, P226, DOI 10.1038/sj.bjp.0707480; Lunn CA, 2006, J PHARMACOL EXP THER, V316, P780, DOI 10.1124/JPET.105.093500; Mahan AL, 2012, TRENDS NEUROSCI, V35, P24, DOI 10.1016/j.tins.2011.06.007; MARMOR MF, 1986, BRIT J OPHTHALMOL, V70, P553, DOI 10.1136/bjo.70.7.553; Meade CA, 2000, EXP NEUROL, V166, P307, DOI 10.1006/exnr.2000.7530; Mechoulam R, 2002, Sci STKE, V2002, pre5, DOI 10.1126/stke.2002.129.re5; Meyer MJ, 2010, BRAIN INJURY, V24, P706, DOI 10.3109/02699051003692126; Mohan K, 2013, INVEST OPHTH VIS SCI, V54, P3440, DOI 10.1167/iovs.12-11522; Namjoshi DR, 2013, DIS MODEL MECH, V6, P1325, DOI 10.1242/dmm.011320; Palazuelos J, 2009, BRAIN, V132, P3152, DOI 10.1093/brain/awp239; Patterson ZR, 2012, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00058; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Peskind ER, 2013, J CLIN PSYCHIAT, V74, P180, DOI 10.4088/JCP.12011co1c; Petras JM, 1997, TOXICOLOGY, V121, P41, DOI 10.1016/S0300-483X(97)03654-8; Prusky GT, 2004, INVEST OPHTH VIS SCI, V45, P4611, DOI 10.1167/iovs.04-0541; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Redell JB, 2007, NEUROSCI LETT, V413, P36, DOI 10.1016/j.neulet.2006.11.060; Reiner A, 2012, NEUROBIOL DIS, V47, P75, DOI 10.1016/j.nbd.2012.03.025; Reiner A, 2007, J COMP NEUROL, V505, P603, DOI 10.1002/cne.21515; Rex T., 2013, INVESTIG OPHTHALMOL, V54, P5095; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Rivers Jack Rocky-Jay, 2010, Central Nervous System Agents in Medicinal Chemistry, V10, P47; Romero-Sandoval EA, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-25; Saito N, 2002, J BIOCHEM, V132, P683, DOI 10.1093/oxfordjournals.jbchem.a003274; Schmidt W, 2012, NEUROSCIENCE, V227, P313, DOI 10.1016/j.neuroscience.2012.09.080; Schomberg D, 2012, EXP NEUROL, V234, P262, DOI 10.1016/j.expneurol.2011.12.021; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Smith JA, 2012, BRAIN RES BULL, V87, P10, DOI 10.1016/j.brainresbull.2011.10.004; Stella N, 2010, GLIA, V58, P1017, DOI 10.1002/glia.20983; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Tzekov R, 2014, J NEUROPATH EXP NEUR, V73, P345, DOI 10.1097/NEN.0000000000000059; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; Warner N, 2010, CURR OPIN OPHTHALMOL, V21, P459, DOI 10.1097/ICU.0b013e32833f00c9; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407	86	40	40	0	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	1422-0067			INT J MOL SCI	Int. J. Mol. Sci.	JAN	2015	16	1					758	787		10.3390/ijms16010758			30	Biochemistry & Molecular Biology; Chemistry, Multidisciplinary	Biochemistry & Molecular Biology; Chemistry	AZ7MN	WOS:000348403100043	25561230	DOAJ Gold, Green Published			2021-06-18	
J	Le Roux, P; Menon, DK; Citerio, G; Vespa, P; Bader, MK; Brophy, G; Diringer, MN; Stocchetti, N; Videtta, W; Armonda, R; Badjatia, N; Bosel, J; Chesnut, R; Chou, S; Claassen, J; Czosnyka, M; De Georgia, M; Figaji, A; Fugate, J; Helbok, R; Horowitz, D; Hutchinson, P; Kumar, M; McNett, M; Miller, C; Naidech, A; Oddo, M; Olson, D; O'Phelan, K; Provencio, JJ; Puppo, C; Riker, R; Roberson, C; Schmidt, M; Taccone, F				Le Roux, Peter; Menon, David K.; Citerio, Giuseppe; Vespa, Paul; Bader, Mary Kay; Brophy, Gretchen; Diringer, Michael N.; Stocchetti, Nino; Videtta, Walter; Armonda, Rocco; Badjatia, Neeraj; Boesel, Julian; Chesnut, Randall; Chou, Sherry; Claassen, Jan; Czosnyka, Marek; De Georgia, Michael; Figaji, Anthony; Fugate, Jennifer; Helbok, Raimund; Horowitz, David; Hutchinson, Peter; Kumar, Monisha; McNett, Molly; Miller, Chad; Naidech, Andrew; Oddo, Mauro; Olson, DaiWai; O'Phelan, Kristine; Provencio, J. Javier; Puppo, Corinna; Riker, Richard; Roberson, Claudia; Schmidt, Michael; Taccone, Fabio			The International Multidisciplinary Consensus Conference on Multimodality Monitoring in Neurocritical Care: Evidentiary Tables A Statement for Healthcare Professionals from the Neurocritical Care Society and the European Society of Intensive Care Medicine	NEUROCRITICAL CARE			English	Article						Consensus development conference; Grading of Recommendations Assessment Development and Evaluation (GRADE); Brain metabolism; Brain oxygen; Clinical trials; Intracranial pressure; Microdialysis; Multimodal monitoring; Neuromonitoring; Traumatic brain injury; Brain physiology; Bio-informatics; Biomarkers; Neurocritical care; Clinical guidelines		A variety of technologies have been developed to assist decision-making during the management of patients with acute brain injury who require intensive care. A large body of research has been generated describing these various technologies. The Neurocritical Care Society (NCS) in collaboration with the European Society of Intensive Care Medicine (ESICM), the Society for Critical Care Medicine (SCCM), and the Latin America Brain Injury Consortium (LABIC) organized an international, multidisciplinary consensus conference to perform a systematic review of the published literature to help develop evidence-based practice recommendations on bedside physiologic monitoring. This supplement contains a Consensus Summary Statement with recommendations and individual topic reviews on physiologic processes important in the care of acute brain injury. In this article we provide the evidentiary tables for select topics including systemic hemodynamics, intracranial pressure, brain and systemic oxygenation, EEG, brain metabolism, biomarkers, processes of care and monitoring in emerging economies to provide the clinician ready access to evidence that supports recommendations about neuromonitoring.	[Le Roux, Peter] Lankenau Med Ctr, Brain & Spine Ctr, Wynnewood, PA 19096 USA; [Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Neurosci Crit Care Unit, Cambridge CB2 2QQ, England; [Citerio, Giuseppe] Osped San Gerardo, Dept Anesthesia & Crit Care, NeuroIntens Care Unit, I-20900 Monza, Italy; [Vespa, Paul] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Bader, Mary Kay] Mission Hosp, Neuro Crit Care CNS, Mission Viejo, CA 92691 USA; [Brophy, Gretchen] Virginia Commonwealth Univ, Med Coll Virginia Campus, Richmond, VA 23298 USA; [Diringer, Michael N.] Washington Univ, Neurocrit Care Sect, Dept Neurol, St Louis, MO 63110 USA; [Stocchetti, Nino] Univ Milan, Dept Physiopathol & Transplant, Neuro ICU, Fdn IRCCS Ca Granda Osped Maggiore Policlin, I-20122 Milan, Italy; [Videtta, Walter] Hosp Nacl Prof A Posadas, ICU Neurocrit Care, El Palomar, Buenos Aires, Argentina; [Armonda, Rocco] MedStar Georgetown Univ Hosp, Dept Neurosurg, Medstar Hlth, Washington, DC 20007 USA; [Badjatia, Neeraj] Univ Maryland, Med Ctr, Dept Neurol, Baltimore, MD 21201 USA; [Boesel, Julian] Heidelberg Univ, Hosp Heidelberg, Dept Neurol, D-69120 Heidelberg, Germany; [Chesnut, Randall] Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA; [Chou, Sherry] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA; [Claassen, Jan; Schmidt, Michael] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; [Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 0QQ, England; [De Georgia, Michael] Case Western Reserve Univ, Sch Med, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA; [Figaji, Anthony] Univ Cape Town, Red Cross Childrens Hosp, Inst Child Hlth 617, ZA-7700 Cape Town, South Africa; [Fugate, Jennifer] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA; [Helbok, Raimund] Med Univ Innsbruck, Neurocrit Care Unit, Dept Neurol, A-6020 Innsbruck, Austria; [Horowitz, David] Univ Penn Hlth Syst, Philadelphia, PA 19104 USA; [Hutchinson, Peter] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Cambridge CB2 2QQ, England; [Kumar, Monisha] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA; [McNett, Molly] MetroHlth Syst, Nursing Res, Cleveland, OH 44109 USA; [Miller, Chad] Ohio State Univ, Div Cerebrovasc Dis & Neurocrit Care, Columbus, OH 43210 USA; [Naidech, Andrew] Northwestern Univ Feinberg, Dept Neurol, Chicago, IL 60611 USA; [Oddo, Mauro] Univ Lausanne, CHUV Univ Hosp, Fac Biol & Med, Dept Intens Care Med, CH-08623 Lausanne, Switzerland; [Olson, DaiWai] Univ Texas Southwestern, Dallas, TX 75390 USA; [O'Phelan, Kristine] Univ Miami, Miller Sch Med, Dept Neurol, JMH, Miami, FL 33136 USA; [Provencio, J. Javier] Cleveland Clin, Lerner Coll Med, Cerebrovasc Ctr & Neuroinflammat Res Ctr, Cleveland, OH 44195 USA; [Puppo, Corinna] Univ Republica, Hosp Clin, Intens Care Unit, Montevideo, Uruguay; [Riker, Richard] Maine Med Ctr, Crit Care Med, Portland, ME 04102 USA; [Puppo, Corinna] Baylor Coll Med, Ben Taub Hosp, Dept Neurosurg, Houston, TX 77030 USA; [Taccone, Fabio] Erasme Univ Hosp, Lab Rech Expt, Dept Intens Care, B-1070 Brussels, Belgium	Le Roux, P (corresponding author), Lankenau Med Ctr, Brain & Spine Ctr, Suite 370,Med Sci Bldg,100 East Lancaster Ave, Wynnewood, PA 19096 USA.	lerouxp@mlhs.org; dkm13@wbic.cam.ac.uk; g.citerio@hsgerardo.org; PVespa@mednet.ucla.edu; Marykay.Bader@stjoe.org; gbrophy@vcu.edu; diringerm@neuro.wustl.edu; stocchet@policlinico.mi.it; wvidetta@ar.inter.net; Rocco.Armonda@gmail.com; nbadjatia@umm.edu; Julian.Boesel@med.uni-heidelberg.de; chesnutr@u.washington.edu; schou1@partners.org; jc1439@cumc.columbia.edu; mc141@medschl.cam.ac.uk; michael.degeorgia@uhhospitals.org; anthony.figaji@uct.ac.za; Fugate.Jennifer@mayo.edu; raimund.helbok@uki.at; david.horowitz@uphs.upenn.edu; pjah2@cam.ac.uk; monisha.kumar@uphs.upenn.edu; mmcnett@metrohealth.org; ChadM.Miller@osumc.edu; ANaidech@nmff.org; Mauro.Oddo@chuv.ch; daiwai.olson@utsouthwestern.edu; kophelan@med.miami.edu; provenj@ccf.org; coripuppo@gmail.com; RRiker@cmamaine.com; claudiar@bcm.tmc.edu; mjs2134@columbia.edu; ftaccone@ulb.ac.be	Olson, DaiWai/I-5932-2019; Provencio, Jose Javier/AAG-5114-2021; Chou, Sherry/G-5779-2015; Claassen, Jan/AAA-5451-2020; Oddo, Mauro/R-3370-2016; Stocchetti, Nino/O-7444-2017; Diringer, Michael N/C-1165-2008; Citerio, Giuseppe/B-1839-2015; Helbok, Raimund/AAA-8361-2021	Olson, DaiWai/0000-0002-9280-078X; Provencio, Jose Javier/0000-0003-1298-1806; Oddo, Mauro/0000-0002-6155-2525; Stocchetti, Nino/0000-0003-3250-6834; Diringer, Michael N/0000-0003-2337-5537; Citerio, Giuseppe/0000-0002-5374-3161; Figaji, Anthony/0000-0002-3357-6490; Brophy, Gretchen/0000-0002-4749-2693; czosnyka, marek/0000-0003-2446-8006; Chesnut, Randall/0000-0001-6377-3666; Hutchinson, Peter/0000-0002-2796-1835	National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090, NIHR-RP-R3-12-013] Funding Source: researchfish; Department of HealthEuropean Commission [NIHR-RP-R3-12-013] Funding Source: Medline; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G1002277, G0600986, G0601025] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23 NS073806] Funding Source: Medline		Andrews JC, 2013, J CLIN EPIDEMIOL, V66, P726, DOI 10.1016/j.jclinepi.2013.02.003; Jaeschke R, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a744; Le Roux P, 2014, NEUROCRIT CARE; Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007]; Rochwerg B, 2014, INTENS CARE MED, V40, P877, DOI 10.1007/s00134-014-3273-0	5	40	41	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2014	21			2			297	361		10.1007/s12028-014-0081-x			65	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	CD7AM	WOS:000351242600020	25608916				2021-06-18	
J	Reid, MW; Miller, KJ; Lange, RT; Cooper, DB; Tate, DF; Bailie, J; Brickell, TA; French, LM; Asmussen, S; Kennedy, JE				Reid, Matthew W.; Miller, Kelly J.; Lange, Rael T.; Cooper, Douglas B.; Tate, David F.; Bailie, Jason; Brickell, Tracey A.; French, Louis M.; Asmussen, Sarah; Kennedy, Jan E.			A Multisite Study of the Relationships between Blast Exposures and Symptom Reporting in a Post-Deployment Active Duty Military Population with Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						post-concussion; blast; post-traumatic stress; neurobehavioral symptom inventory; mild traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; OIF/OEF SERVICE MEMBERS; POSTCONCUSSIVE SYMPTOMS; IRAQI FREEDOM; HEALTH; VETERANS; TBI; ASSOCIATIONS; PTSD	Explosive devices have been the most frequent cause of traumatic brain injury (TBI) among deployed contemporary U.S. service members. The purpose of this study was to examine the influence of previous cumulative blast exposures (that did or did not result in TBI) on later post-concussion and post-traumatic symptom reporting after sustaining a mild TBI (MTBI). Participants were 573 service members who sustained MTBI divided into four groups by number of blast exposures (1, 2, 3, and 4-10) and a nonblast control group. Post-concussion symptoms were measured using the Neurobehavioral Symptom Inventory (NSI) and post-traumatic stress disorder (PTSD) symptoms using the Post-traumatic Checklist-Civilian version (PCL-C). Results show groups significantly differed on total NSI scores (p<0.001), where symptom endorsement increased as number of reported blast exposures increased. Total NSI scores were significantly higher for the 3- and 4-10 blast groups compared with the 1- and 2-blast groups with effect sizes ranging from small to moderate (d=0.31 to 0.63). After controlling for PTSD symptoms using the PCL-C total score, NSI total score differences remained between the 4-10-blast group and the 1- and 2-blast groups, but were less pronounced (d=0.35 and d=0.24, respectively). Analyses of NSI subscale scores using PCL-C scores as a covariate revealed significant between-blast group differences on cognitive, sensory, and somatic, but not affective symptoms. Regression analyses revealed that cumulative blast exposures accounted for a small but significant amount of the variance in total NSI scores (4.8%; p=0.009) and total PCL-C scores (2.3%; p<0.001). Among service members exposed to blast, post-concussion symptom reporting increased as a function of cumulative blast exposures. Future research will need to determine the relationship between cumulative blast exposures, symptom reporting, and neuropathological changes.	[Reid, Matthew W.; Miller, Kelly J.; Lange, Rael T.; Cooper, Douglas B.; Tate, David F.; Bailie, Jason; Brickell, Tracey A.; French, Louis M.; Asmussen, Sarah; Kennedy, Jan E.] Def & Vet Brain Injury Ctr, Silver Spring, MD USA; [Reid, Matthew W.; Cooper, Douglas B.; Tate, David F.; Kennedy, Jan E.] San Antonio Mil Med Ctr, San Antonio, TX USA; [Miller, Kelly J.; Lange, Rael T.; Brickell, Tracey A.; French, Louis M.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA; [Brickell, Tracey A.; French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Lange, Rael T.; Brickell, Tracey A.; French, Louis M.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Lange, Rael T.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Bailie, Jason; Asmussen, Sarah] Naval Med Ctr San Diego, San Diego, CA USA; [Asmussen, Sarah] Marine Corps Base Camp Pendleton, Camp Pendleton, CA USA	Reid, MW (corresponding author), Brooke Army Med Ctr, MCHE MDU DVBIC, 3551 Roger Brooke Dr, Jbsa Ft Sam Houston, TX 78234 USA.	matthew.w.reid2.ctr@mail.mil	french, louis/AAB-2083-2020; Tate, David F/I-3963-2013	Tate, David F/0000-0003-0213-1920; french, louis/0000-0002-9451-0604	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [L30 NS063444] Funding Source: Medline		[Anonymous], 2013, MSMR, V20, P9; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Defense and Veteran Brain Injury Center, 2014, DOD WORLDW NUMB TBI; Dolan S, 2012, NEUROPSYCHOL REV, V22, P21, DOI 10.1007/s11065-012-9190-5; Drag LL, 2012, J INT NEUROPSYCH SOC, V18, P576, DOI 10.1017/S1355617712000203; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; King NS, 2008, BRAIN INJURY, V22, P1, DOI 10.1080/02699050701829696; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; MacGregor AJ, 2011, J REHABIL RES DEV, V48, P1269, DOI 10.1682/JRRD.2011.01.0013; MERTON RK, 1968, SCIENCE, V159, P56, DOI 10.1126/science.159.3810.56; Miller KJ, 2013, J HEAD TRAUMA REHAB, V28, P31, DOI 10.1097/HTR.0b013e318255ceae; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Rigg JL, 2011, PM&R, V3, pS380, DOI 10.1016/j.pmrj.2011.08.005; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Taber KH, 2014, J HEAD TRAUMA REHABI; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vanderploeg RD, 2014, J HEAD TRAUMA REHAB, V29, P1, DOI 10.1097/HTR.0b013e318281966e; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023	26	40	40	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2014	31	23					1899	1906		10.1089/neu.2014.3455			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AT6US	WOS:000345075500001	25036531	Green Published			2021-06-18	
J	Shimoda, K; Maeda, T; Tado, M; Yoshino, A; Katayama, Y; Bullock, MR				Shimoda, Kentaro; Maeda, Takeshi; Tado, Masahiro; Yoshino, Atsuo; Katayama, Yoichi; Bullock, M. Ross			Outcome and Surgical Management for Geriatric Traumatic Brain Injury: Analysis of 888 Cases Registered in the Japan Neurotrauma Data Bank	WORLD NEUROSURGERY			English	Article						Elderly; Surgical management; Traumatic brain injury	ACUTE SUBDURAL-HEMATOMA; HEAD-INJURY; INTRACRANIAL HEMATOMAS; OLDER PATIENTS; MAJOR TRAUMA; MORTALITY; AGE; CARE; EVACUATION; SURVIVAL	OBJECTIVE: As the aged population is rapidly growing globally, geriatric traumatic brain injury (TBI) becomes an increasing problem. There are higher mortality and poorer functional outcome in the geriatric TBI population (>= 65 years) compared with younger groups despite neurosurgical interventions. Therefore, current treatment priorities and cost-effectiveness should be critically examined. We evaluated the benefit of surgical management in the elderly (>= 65 years) after TBI. METHODS: A total of 3194 patients with confirmed TBI were enrolled from 1998 to 2011, in the Japan Neurotrauma Data Bank. Retrospective analysis was conducted from the Japan Neurotrauma Data Bank on 888 (28%) patients (>= years) who did and did not undergo surgery. In particular, the effect of low Glasgow coma scale (GCS) (3-5) was compared with outcome with and without surgery. RESULTS: Of all the patients 65 years of age and over, 478 (54%) were given surgical management (craniectomy, craniotomy, or burr-hole evacuation). This group of patients had significantly more favorable outcome at 6 months (18% vs. 7%) and less mortality (62% vs. 81%). However, within this surgical group, patients with initial GCS scores of 3-5 had significantly more unfavorable outcome (96% vs. 79%) and more mortality (87% vs. 57%) compared with those with GCS scores of 6-15. CONCLUSIONS: We confirmed that age is a major determinant of outcome after TBI. In addition, we found that neurosurgical management is associated with the improvement of the prognosis and a decrease in the rate of mortality in geriatric TBI. However, surgical management was not shown to be an effective treatment in elderly patients with GCS scores of 3-5.	[Shimoda, Kentaro; Bullock, M. Ross] Univ Miami, Miller Sch Med, Dept Neurosurg, Miami, FL 33136 USA; [Shimoda, Kentaro; Maeda, Takeshi; Tado, Masahiro; Yoshino, Atsuo; Katayama, Yoichi] Nihon Univ, Sch Med, Dept Neurol Surg, Tokyo 173, Japan	Maeda, T (corresponding author), Nihon Univ, Sch Med, Dept Neurol Surg, Tokyo 173, Japan.	maeda.takeshi@nihon-u.ac.jp			General Insurance Association of Japan; Mitsui Sumitomo Insurance Welfare FoundationMitsui Sumitomo Insurance Welfare Foundation; Japan Brain Foundation	Partial support was provided through The General Insurance Association of Japan, Mitsui Sumitomo Insurance Welfare Foundation, and the Japan Brain Foundation.	ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Bullock AR, 2006, NEUROSURGERY, V58, pVI; CAGETTI B, 1992, BRIT J NEUROSURG, V6, P227, DOI 10.3109/02688699209002930; Calland JF, 2012, J TRAUMA ACUTE CARE, V73, pS345, DOI 10.1097/TA.0b013e318270191f; CARRILLO EH, 1993, SURG GYNECOL OBSTET, V176, P559; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Damadi AA, 2008, J TRAUMA, V64, P745, DOI 10.1097/TA.0b013e3180341fc6; DAY RJ, 1994, MED J AUSTRALIA, V160, P675, DOI 10.5694/j.1326-5377.1994.tb125903.x; DEMARIA EJ, 1987, J TRAUMA, V27, P1200; FINELLI FC, 1989, J TRAUMA, V29, P541, DOI 10.1097/00005373-198905000-00001; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; JAMJOOM A, 1992, BRIT J NEUROSURG, V6, P27, DOI 10.3109/02688699209002898; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; KOTWICA Z, 1992, ACTA NEUROCHIR, V118, P98, DOI 10.1007/BF01401293; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; McIntyre A, 2013, BRAIN INJURY, V27, P31, DOI 10.3109/02699052.2012.700086; Miller RS, 2000, J TRAUMA, V48, P229, DOI 10.1097/00005373-200002000-00006; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Mulligan P, 2013, J NEUROSCI RURAL PRA, V4, P250, DOI 10.4103/0976-3147.118760; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Nakamura N, 2006, NEUROL MED-CHIR, V46, P567, DOI 10.2176/nmc.46.567; National Institute of Population and Social Security Research, 2012, EST POP JAP; O'Neill S, 2012, ARCH GERONTOL GERIAT, V54, pE426, DOI 10.1016/j.archger.2012.01.007; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; Petridis AK, 2009, CENT EUR NEUROSURG, V70, P73, DOI 10.1055/s-0029-1224096; PICKARD JD, 1990, BRIT MED J, V301, P629, DOI 10.1136/bmj.301.6753.629; Ross A M, 1992, J Neurosci Nurs, V24, P88; Roth BJ, 2001, INJURY, V32, P551, DOI 10.1016/S0020-1383(01)00079-1; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; ROZZELLE CJ, 1995, J AM GERIATR SOC, V43, P240, DOI 10.1111/j.1532-5415.1995.tb07329.x; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Thompson HJ, 2008, CRIT CARE MED, V36, P282, DOI 10.1097/01.CCM.0000297884.86058.8A; Tokutomi T, 2008, J NEUROTRAUM, V25, P1407, DOI 10.1089/neu.2008.0577; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37	45	40	40	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	DEC	2014	82	6								10.1016/j.wneu.2014.08.014			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AY5TZ	WOS:000347635900118	25128777	Other Gold			2021-06-18	
J	Sharma, A; Chandran, R; Barry, ES; Bhomia, M; Hutchison, MA; Balakathiresan, NS; Grunberg, NE; Maheshwari, RK				Sharma, Anuj; Chandran, Raghavendar; Barry, Erin S.; Bhomia, Manish; Hutchison, Mary Anne; Balakathiresan, Nagaraja S.; Grunberg, Neil E.; Maheshwari, Radha K.			Identification of Serum MicroRNA Signatures for Diagnosis of Mild Traumatic Brain Injury in a Closed Head Injury Model	PLOS ONE			English	Article							AMYLOID PRECURSOR PROTEIN; ACOUSTIC STARTLE REFLEX; C-TERMINAL HYDROLASE; RAT CEREBRAL-CORTEX; FEMALE RATS; ADULT RATS; NEUROSURGICAL INTERVENTION; INTRACRANIAL LESIONS; PHYSICAL-ACTIVITY; BODY-WEIGHT	Wars in Iraq and Afghanistan have highlighted the problems of diagnosis and treatment of mild traumatic brain injury (mTBI). MTBI is a heterogeneous injury that may lead to the development of neurological and behavioral disorders. In the absence of specific diagnostic markers, mTBI is often unnoticed or misdiagnosed. In this study, mice were induced with increasing levels of mTBI and microRNA (miRNA) changes in the serum were determined. MTBI was induced by varying weight and fall height of the impactor rod resulting in four different severity grades of the mTBI. Injuries were characterized as mild by assessing with the neurobehavioral severity scale-revised (NSS-R) at day 1 post injury. Open field locomotion and acoustic startle response showed behavioral and sensory motor deficits in 3 of the 4 injury groups at day 1 post injury. All of the animals recovered after day 1 with no significant neurobehavioral alteration by day 30 post injury. Serum microRNA (miRNA) profiles clearly differentiated injured from uninjured animals. Overall, the number of miRNAs that were significantly modulated in injured animals over the sham controls increased with the severity of the injury. Thirteen miRNAs were found to identify mTBI regardless of its severity within the mild spectrum of injury. Bioinformatics analyses revealed that the more severe brain injuries were associated with a greater number of miRNAs involved in brain related functions. The evaluation of serum miRNA may help to identify the severity of brain injury and the risk of developing adverse effects after TBI.	[Sharma, Anuj; Chandran, Raghavendar; Bhomia, Manish; Balakathiresan, Nagaraja S.; Maheshwari, Radha K.] Uniformed Serv Univ Hlth Sci, Dept Pathol, Bethesda, MD 20814 USA; [Chandran, Raghavendar] Birla Inst Technol & Sci, Biol Sci Grp, Pilani, Rajasthan, India; [Barry, Erin S.; Hutchison, Mary Anne; Grunberg, Neil E.] Uniformed Serv Univ Hlth Sci, Dept Med & Clin Psychol, Bethesda, MD 20814 USA	Maheshwari, RK (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pathol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	radha.maheshwari@usuhs.edu	Chandran, Raghavendar/AAB-9402-2019; Bhomia, Manish/C-7683-2015; Balakathiresan, Nagaraja Sethuraman/O-3213-2019	Chandran, Raghavendar/0000-0002-7915-2810; Bhomia, Manish/0000-0003-2808-9927; Sharma, Anuj/0000-0001-6906-190X; Balakathiresan, Nagaraja Sethuraman/0000-0001-5756-6070; Barry, Erin/0000-0003-0788-7153	Congressionally Directed Medical Research Programs (CDMRP)United States Department of Defense [D10_I_AR_J6_855]	This study was supported by funding from Congressionally Directed Medical Research Programs (CDMRP), Project# D10_I_AR_J6_855 (PI: Radha K Maheshwari). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ACRI JB, 1994, PSYCHOPHARMACOLOGY, V114, P369, DOI 10.1007/BF02244861; ACRI JB, 1991, PSYCHOPHARMACOLOGY, V104, P244, DOI 10.1007/BF02244186; Alain C, 2008, J COGNITIVE NEUROSCI, V20, P285, DOI 10.1162/jocn.2008.20014; Allegra A, 2012, INT J ONCOL, V41, P1897, DOI 10.3892/ijo.2012.1647; Allison P. D., 1990, SOCIOLOGICAL METHODO, P93, DOI DOI 10.2307/271083; Balakathiresan N, 2012, J NEUROTRAUM, V29, P1379, DOI 10.1089/neu.2011.2146; Bao TH, 2014, J MOL NEUROSCIENCE M; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; BOWEN DJ, 1986, PHARMACOL BIOCHEM BE, V25, P1131, DOI 10.1016/0091-3057(86)90099-7; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Bryan CJ, 2013, J HEAD TRAUMA REHAB, V28, P13, DOI 10.1097/HTR.0b013e31826c73cc; Bye N, 2011, J NEUROSCI RES, V89, P986, DOI 10.1002/jnr.22635; Chen HL, 2010, BIOCHEM BIOPH RES CO, V394, P921, DOI 10.1016/j.bbrc.2010.03.076; Choudhury Y, 2012, J CLIN INVEST, V122, P4059, DOI 10.1172/JCI62925; Corrigan F, 2014, J NEUROCHEM, V128, P196, DOI 10.1111/jnc.12391; Corrigan F, 2012, BRAIN RES, V1451, P87, DOI 10.1016/j.brainres.2012.02.045; D'haene Barbara, 2012, Methods Mol Biol, V822, P261, DOI 10.1007/978-1-61779-427-8_18; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Decembrini S, 2009, P NATL ACAD SCI USA, V106, P21179, DOI 10.1073/pnas.0909167106; Deo A, 2011, J BIOINF COMPUT BIOL, V9, P795, DOI 10.1142/S0219720011005793; Ekdahl Y, 2012, GENOME RES, V22, P1477, DOI 10.1101/gr.131912.111; Elliott BM, 2004, PHARMACOL BIOCHEM BE, V77, P21, DOI 10.1016/j.pbb.2003.09.016; Faraday MM, 1998, PHARMACOL BIOCHEM BE, V61, P281, DOI 10.1016/S0091-3057(98)00094-X; Faraday MM, 2003, PHARMACOL BIOCHEM BE, V74, P325, DOI 10.1016/S0091-3057(02)00999-1; Fischer H., 2013, CRS REP C, P1; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Freund Hans-Joachim, 2003, Adv Neurol, V93, P179; Frugier T, 2012, J NEUROPATH EXP NEUR, V71, P242, DOI 10.1097/NEN.0b013e3182496149; Gao X, 2013, EXP NEUROL, V239, P38, DOI 10.1016/j.expneurol.2012.09.012; Goh CP, 2014, EXP NEUROL, V252, P37, DOI 10.1016/j.expneurol.2013.11.017; Goossens K, 2013, STEM CELLS DEV; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; GRUNBERG NE, 1985, PHARMACOL BIOCHEM BE, V23, P851, DOI 10.1016/0091-3057(85)90081-4; Grunberg NE, 2011, ANN M SOC NEUR WASH; Hamilton KR, 2012, EXP CLIN PSYCHOPHARM, V20, P345, DOI 10.1037/a0029088; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hanell A, 2012, J NEUROTRAUM, V29, P2660, DOI 10.1089/neu.2012.2376; Hausmann R, 2001, INT J LEGAL MED, V114, P338, DOI 10.1007/s004140000199; Itoh T, 2005, NEUROREPORT, V16, P1687, DOI 10.1097/01.wnr.0000183330.44112.ab; Itoh T, 2009, MOL CELL BIOCHEM, V324, P191, DOI 10.1007/s11010-008-0013-1; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; KATZ RJ, 1981, NEUROSCI BIOBEHAV R, V5, P247, DOI 10.1016/0149-7634(81)90005-1; Kawahara Y, 2007, SCIENCE, V315, P1137, DOI 10.1126/science.1138050; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Koch M, 1997, BEHAV BRAIN RES, V89, P35, DOI 10.1016/S0166-4328(97)02296-1; Kumar S, 2005, PSYCHIAT CLIN NEUROS, V59, P466, DOI 10.1111/j.1440-1819.2005.01400.x; Lee YL, 1996, J NEUROSCI, V16, P3775; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Leung AWS, 2011, NEUROIMAGE, V55, P1260, DOI 10.1016/j.neuroimage.2010.12.055; Liu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103948; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marti M, 2005, J NEUROSCI, V25, P9591, DOI 10.1523/JNEUROSCI.2546-05.2005; Mayr M, 2013, ARTERIOSCL THROM VAS, V33, P206, DOI 10.1161/ATVBAHA.112.300141; Moon C, 2004, BRAIN RES, V1028, P238, DOI 10.1016/j.brainres.2004.09.022; Morse DE, 1997, PHARMACOL BIOCHEM BE, V56, P221, DOI 10.1016/S0091-3057(96)00214-6; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; OVERMIER JB, 1967, J COMP PHYSIOL PSYCH, V63, P28, DOI 10.1037/h0024166; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pogoda TK, 2012, J REHABIL RES DEV, V49, P971, DOI 10.1682/JRRD.2011.06.0099; Rapp PE, 2012, J TRAUMA ACUTE CARE, V73, pS13, DOI 10.1097/TA.0b013e318260604b; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Rostami Elham, 2012, Front Neurol, V3, P115, DOI 10.3389/fneur.2012.00115; Sabirzhanov B, 2014, J NEUROSCI, V34, P10055, DOI 10.1523/JNEUROSCI.1260-14.2014; Schirmer L, 2013, BRAIN PATHOL, V23, P2, DOI 10.1111/j.1750-3639.2012.00608.x; SELIGMAN ME, 1967, J EXP PSYCHOL, V74, P1, DOI 10.1037/h0024514; Selwyn R, 2013, J NEUROTRAUM, V30, P1943, DOI 10.1089/neu.2013.2928; Sharma Pushpa, 2012, Int J Crit Illn Inj Sci, V2, P172, DOI 10.4103/2229-5151.100931; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Song JN, 2012, DIGEST DIS SCI, V57, P897, DOI 10.1007/s10620-011-1981-7; SWERDLOW NR, 1992, J PSYCHOPHARMACOL, V6, P176, DOI 10.1177/026988119200600210; Takeuchi Satoru, 2013, Acta Neurochir Suppl, V118, P99, DOI 10.1007/978-3-7091-1434-6_17; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Theeler BJ, 2012, HEADACHE, V52, P732, DOI 10.1111/j.1526-4610.2012.02112.x; Thelin EP, 2013, J NEUROTRAUM, V30, P519, DOI 10.1089/neu.2012.2553; Truettner JS, 2011, J CEREBR BLOOD F MET, V31, P1897, DOI 10.1038/jcbfm.2011.33; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Van Den Heuvel C, 1998, ACT NEUR S, V71, P209; Vlachos IS, 2012, NUCLEIC ACIDS RES, V40, pW498, DOI 10.1093/nar/gks494; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wahid F, 2010, BBA-MOL CELL RES, V1803, P1231, DOI 10.1016/j.bbamcr.2010.06.013; Wang GH, 2013, NEUROTHERAPEUTICS, V10, P124, DOI 10.1007/s13311-012-0157-2; Xing GQ, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00196; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Yarnell AM, 2013, BLAST TRAUMATIC BRAI, P9; Yi X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070306; Yuh EL, 2012, J NEUROTRAUM, V29, P735, DOI 10.1089/neu.2011.2008; Zhang HY, 2011, BRAIN RES, V1383, P62, DOI 10.1016/j.brainres.2011.01.067; Zhang L, 2013, INT J MOL MED, V32, P867, DOI 10.3892/ijmm.2013.1456; Zheng WM, 2013, J NEUROTRAUM, V30, P1872, DOI 10.1089/neu.2010.1579	98	40	40	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2014	9	11							e112019	10.1371/journal.pone.0112019			20	Multidisciplinary Sciences	Science & Technology - Other Topics	AT3WF	WOS:000344863100050	25379886	DOAJ Gold, Green Published			2021-06-18	
J	Kurowski, B; Pomerantz, WJ; Schaiper, C; Gittelman, MA				Kurowski, Brad; Pomerantz, Wendy J.; Schaiper, Courtney; Gittelman, Michael A.			Factors that influence concussion knowledge and self-reported attitudes in high school athletes	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Concussion; sports; adolescents; knowledge	EPIDEMIOLOGY STROBE STATEMENT; SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; 2ND IMPACT SYNDROME; HEAD-INJURY; EDUCATIONAL INTERVENTION; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; FOOTBALL PLAYERS; ICE HOCKEY	BACKGROUND: Many organizations and health care providers support educating high school (HS) athletes about concussions to improve their attitudes and behaviors about reporting. The objectives of this study were to determine if previous education, sport played, and individual factors were associated with better knowledge about concussion and to determine if more knowledge was associated with improved self-reported attitudes toward reporting concussions among HS athletes. METHODS: We conducted a survey of HS athletes aged 13 years to 18 years from two large, urban HSs. Players were recruited from selected seasonal (fall and winter) as well as men and women's sports. During preseason, each participant was given a survey asking about his or her previous education, current knowledge, and self-reported attitudes and behaviors about reporting concussions. Bivariate and multivariate linear regression was used to evaluate the association of age, sex, sport, and previous concussion education with knowledge and self-reported attitudes and behaviors about reporting concussions. RESULTS: Surveys were completed by 496 athletes. The median age was 15 years, and 384 (77.4%) were male. A total of 212 (42.7%) participated in football, 123 (24.8%) in soccer, 89 (17.9%) in basketball, and 72 (14.5%) in wrestling. One hundred sixteen (23.4%) reported a history of concussion. Improved knowledge regarding concussions was not associated with improved self-reported behaviors (p = 0.63) in bivariate regression models. The multivariate model demonstrated that older age (p = 0.01) and female sex (p = 0.03) were associated with better knowledge. Younger age (p = 0.01), female sex (p = 0.0002), and soccer participation (p = 0.02) were associated with better self-reported behaviors around reporting concussions. CONCLUSION: Previous education on concussions was less predictive of knowledge about concussions when controlling for other factors such as sport and sex. Younger age, female sex, and soccer participation were more likely to be associated with better self-reported behaviors. Future studies need to focus on the development of interventions to improve concussion-specific knowledge and behaviors. (Copyright (C) 2014 by Lippincott Williams & Wilkins)	[Kurowski, Brad] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati Childrens Hosp,Div Phys Med & Rehabil, Cincinnati, OH USA; [Kurowski, Brad; Pomerantz, Wendy J.; Schaiper, Courtney; Gittelman, Michael A.] Cincinnati Childrens Hosp, Comprehens Childrens Injury Ctr, Cincinnati, OH USA; [Pomerantz, Wendy J.; Gittelman, Michael A.] Univ Cincinnati, Coll Med, Dept Pediat, Div Emergency Med,Cincinnati Childrens Hosp, Cincinnati, OH USA	Kurowski, B (corresponding author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave,MLC 4009, Cincinnati, OH 45229 USA.	brad.kurowski@cchmc.org			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD074683, K12HD001097] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001425] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR001425] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23 HD074683, L40 HD066480, K12 HD001097] Funding Source: Medline		[Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bloodgood B, 2013, J ADOLESCENT HEALTH, V53, P34, DOI 10.1016/j.jadohealth.2013.01.022; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Bramley HP, 2011, CLIN PEDIAT PHILA, V51, P332; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; CHAFFEE SH, 1986, COMMUN RES, V13, P373, DOI 10.1177/009365086013003006; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10187; Fisher JD, 1996, HEALTH PSYCHOL, V15, P114, DOI 10.1037/0278-6133.15.2.114; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; MERMELSTEIN RJ, 1992, HEALTH PSYCHOL, V11, P371, DOI 10.1037/0278-6133.11.6.371; Miyashita TL, 2013, CLIN J SPORT MED, V23, P349, DOI 10.1097/JSM.0b013e318289c321; Moreno MA, 2012, ARCH PEDIAT ADOL MED, V166, P296, DOI [10.1001/archpediatrics.2012.8, 10.1001/archpediatrics.2012.79]; Moreno MA, 2011, ARCH PEDIAT ADOL MED, V165, P376, DOI 10.1001/archpediatrics.2011.31; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Schatz P, 2011, CLIN NEUROPSYCHOL, V25, P1042, DOI 10.1080/13854046.2011.556669; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Thomas M, 2011, PEDIATRICS, V128, pE1, DOI 10.1542/peds.2010-2743; McLeod TCV, 2008, CLIN J SPORT MED, V18, P235, DOI 10.1097/JSM.0b013e3181705756; von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI 10.1016/j.jclinepi.2007.11.008; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986	35	40	41	0	47	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	SEP	2014	77			1			S12	S17		10.1097/TA.0000000000000316			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AO2BK	WOS:000341120300004	25153048	Green Accepted			2021-06-18	
J	Si, DW; Li, J; Liu, J; Wang, XY; Wei, ZF; Tian, QY; Wang, HT; Liu, G				Si, Daowen; Li, Juan; Liu, Jiang; Wang, Xiaoyin; Wei, Zifeng; Tian, Qingyou; Wang, Haitao; Liu, Gang			Progesterone protects blood-brain barrier function and improves neurological outcome following traumatic brain injury in rats	EXPERIMENTAL AND THERAPEUTIC MEDICINE			English	Article						progesterone; traumatic brain injury; blood-brain barrier; neurological function	SEX STEROID-HORMONES; CEREBRAL-ISCHEMIA; FOCAL ISCHEMIA; ALLOPREGNANOLONE; EXPRESSION; EDEMA; CONTUSION; DAMAGE; CELLS; TRIAL	Inflammatory responses are associated with blood-brain barrier (BBB) dysfunction and neurological deficits following traumatic brain injury (TB!). The aim of the present study was to investigate the effects of progesterone on the expression of the inflammatory mediators prostaglandin E2 (PGE2), cyclooxygenase-2 (COX-2), nuclear factor kappa B (NF kappa B) and tumor necrosis factor-alpha (TNF-alpha) in the brain, BBB permeability, cerebral edema and neurological outcome, as well as to explore the mechanism of its neuroprotective effect. In this study, male rats were randomly divided into three groups: a sham-operated group (SHAM), a TBI group (TBI) and a progesterone treatment group (TBI-PROG). The TBI model was established using a modified Feeney's weight-dropping method. Brain samples were extracted 24 h following injury. The expression levels of COX-2 and NF-kappa B were examined using immunohistochemistry, whilst the expression levels of PGE2 and TNF-alpha were detected by enzyme-linked immuno-sorbent assay. BBB permeability was analyzed using Evans blue and cerebral edema was determined using the dry-wet method. The neurological outcome was evaluated using the modified neurological severity score test. The results revealed that progesterone treatment significantly reduced post-injury inflammatory response, brain edema and Evans blue dye extravasation, and improved neurological scores compared with those in the TBI group. In conclusion, the inhibition of inflammation may be an important mechanism by which progesterone protects the BBB and improves neurological outcome.	[Si, Daowen; Li, Juan; Liu, Jiang; Wei, Zifeng; Tian, Qingyou; Wang, Haitao] Hebei United Univ, Sch Basic Med Sci, Tangshan 063000, Hebei, Peoples R China; [Wang, Xiaoyin] Xinxiang Med Coll, Dept Biochem & Mol Biol, Xinxiang 453000, Henan, Peoples R China; [Liu, Gang] Hebei United Univ, Affiliated Hosp, Dept Neurosurg, Tangshan 063000, Hebei, Peoples R China	Liu, G (corresponding author), Hebei United Univ, Affiliated Hosp, Dept Neurosurg, 57 Jianshenan Rd, Tangshan 063000, Hebei, Peoples R China.	sidaowen@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81201048]; Natural Science Foundation of Hebei Province, ChinaNatural Science Foundation of Hebei Province [H2012401009]	This study was supported by the National Natural Science Foundation of China (81201048) and the Natural Science Foundation of Hebei Province (H2012401009), China.	Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Beaumont A, 2002, ACT NEUR S, V81, P217; Buccellati C, 1998, NEUROSCI LETT, V257, P123, DOI 10.1016/S0304-3940(98)00745-9; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Deutsch ER, 2013, BRAIN RES, V1530, P82, DOI 10.1016/j.brainres.2013.07.014; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Ishrat T, 2010, EXP NEUROL, V226, P183, DOI 10.1016/j.expneurol.2010.08.023; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Knoferl MW, 2001, SHOCK, V16, P479, DOI 10.1097/00024382-200116060-00013; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Li ZY, 2012, J NEUROTRAUM, V29, P343, DOI 10.1089/neu.2011.1807; McIntosh TK, 1996, LAB INVEST, V74, P315; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Shahrokhi N, 2012, PAK J PHARM SCI, V25, P219; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Wali B, 2011, RESTOR NEUROL NEUROS, V29, P61, DOI 10.3233/RNN-2011-0579; Wang JP, 2009, BRAIN RES BULL, V79, P426, DOI 10.1016/j.brainresbull.2009.05.018; Wang XY, 2013, EXP THER MED, V6, P263, DOI 10.3892/etm.2013.1116; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887	30	40	47	0	17	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-0981	1792-1015		EXP THER MED	Exp. Ther. Med.	SEP	2014	8	3					1010	1014		10.3892/etm.2014.1840			5	Medicine, Research & Experimental	Research & Experimental Medicine	AN8KZ	WOS:000340854400056	25120639	Green Published, Bronze			2021-06-18	
J	Yang, ZH; Lin, F; Robertson, CS; Wang, KKW				Yang, Zhihui; Lin, Fan; Robertson, Claudia S.; Wang, Kevin K. W.			Dual vulnerability of TDP-43 to calpain and caspase-3 proteolysis after neurotoxic conditions and traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						calpain; caspase; neurodegeneration; TDP-43; traumatic brain injury	DNA-BINDING PROTEIN-43; FRONTOTEMPORAL LOBAR DEGENERATION; C-TERMINAL FRAGMENTS; ALZHEIMERS-DISEASE; DEPENDENT CLEAVAGE; CSF BIOMARKERS; AGGREGATION; INCLUSIONS; TARGET; FLUID	Transactivation response DNA-binding protein 43 (TDP-43) proteinopathy has recently been reported in chronic traumatic encephalopathy, a neurodegenerative condition linked to prior history of traumatic brain injury (TBI). While TDP-43 appears to be vulnerable to proteolytic modifications under neurodegenerative conditions, the mechanism underlying the contribution of TDP-43 to the pathogenesis of TBI remains unknown. In this study, we first mapped out the calpain or caspase-3 TDP-43 fragmentation patterns by in vitro protease digestion. Concurrently, in cultured cerebrocortical neurons subjected to cell death challenges, we identified distinct TDP-43 breakdown products (BDPs) of 35,33, and 12 kDa that were indicative of dual calpain/caspase attack. Cerebrocortical culture incubated with calpain and caspase-fragmented TDP-43 resulted in neuronal injury. Furthermore, increased TDP-43 BDPs as well as redistributed TDP-43 from the nucleus to the cytoplasm were observed in the mouse cortex in two TBI models: controlled cortical impact injury and overpressure blast-wave-induced brain injury. Finally, TDP-43 and its 35 kDa fragment levels were also elevated in the cerebrospinal fluid (CSF) of severe TBI patients. This is the first evidence that TDP-43 might be involved in acute neuroinjury and TBI pathology, and that TDP-43 and its fragments may have biomarker utilities in TBI patients.	[Yang, Zhihui; Lin, Fan; Wang, Kevin K. W.] Univ Florida, Ctr Neuroprote & Biomarkers Res, Dept Psychiat & Neurosci, Gainesville, FL 32611 USA; [Robertson, Claudia S.] Baylor Coll Med, Ben Taub Gen Hosp, Houston, TX 77030 USA; [Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Yang, ZH (corresponding author), Univ Florida, Ctr Neuroprote & Biomarkers Res, Dept Psychiat & Neurosci, 1149 Newell,Dr L4-100, Gainesville, FL 32611 USA.	zhihuiyang@ufl.edu; kwang@ufl.edu		Wang, Kevin/0000-0002-9343-6473	BSCIRTF fund from the State of Florida	This study is in part supported by BSCIRTF fund from the State of Florida.	Andersson M, 2011, INT J GERIATR PSYCH, V26, P100, DOI 10.1002/gps.2496; BARTUS RT, 1995, NEUROL RES, V17, P249, DOI 10.1080/01616412.1995.11740322; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cushman M, 2010, J CELL SCI, V123, P1191, DOI 10.1242/jcs.051672; Dormann D, 2009, J NEUROCHEM, V110, P1082, DOI 10.1111/j.1471-4159.2009.06211.x; Forman MS, 2007, CURR OPIN NEUROBIOL, V17, P548, DOI 10.1016/j.conb.2007.08.005; Foulds P, 2008, ACTA NEUROPATHOL, V116, P141, DOI 10.1007/s00401-008-0389-8; Guo JL, 2011, J BIOL CHEM, V286, P15317, DOI 10.1074/jbc.M110.209296; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Hook GR, 2014, J NEUROTRAUM, V31, P515, DOI [10.1089/NEU.2013.2944, 10.1089/neu.2013.2944]; Igaz LM, 2008, AM J PATHOL, V173, P182, DOI 10.2353/ajpath.2008.080003; Igaz LM, 2011, J CLIN INVEST, V121, P726, DOI 10.1172/JCI44867; Johnson BS, 2009, J BIOL CHEM, V284, P20329, DOI 10.1074/jbc.M109.010264; Johnson VE, 2011, ACTA NEUROPATHOL, V122, P715, DOI 10.1007/s00401-011-0909-9; Kadokura A, 2009, NEUROPATHOLOGY, V29, P566, DOI 10.1111/j.1440-1789.2009.01017.x; Klimowicz-Bodys MD, 2012, THERIOGENOLOGY, V77, P628, DOI 10.1016/j.theriogenology.2011.09.001; Kuo PH, 2009, NUCLEIC ACIDS RES, V37, P1799, DOI 10.1093/nar/gkp013; Lee EB, 2012, NAT REV NEUROSCI, V13, P38, DOI 10.1038/nrn3121; Li Y, 2010, P NATL ACAD SCI USA, V107, P3169, DOI 10.1073/pnas.0913602107; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Nonaka T, 2009, HUM MOL GENET, V18, P3353, DOI 10.1093/hmg/ddp275; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Rohn TT, 2008, BRAIN RES, V1228, P189, DOI 10.1016/j.brainres.2008.06.094; Rohn Troy T, 2009, Int J Physiol Pathophysiol Pharmacol, V1, P25; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Schwab C, 2008, J NEUROPATH EXP NEUR, V67, P1159, DOI 10.1097/NEN.0b013e31818e8951; Tabaraud F, 2012, ACTA NEUROL SCAND, V125, P416, DOI 10.1111/j.1600-0404.2011.01592.x; Tsitsopoulos PP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00079; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang KKW, 2013, SYSTEMS BIOMARKERS A; Wilson AC, 2011, INT J CLIN EXP PATHO, V4, P147; Yamashita T, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2303; Yang CX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015878; Yokota O, 2009, ACTA NEUROPATHOL, V117, P429, DOI 10.1007/s00401-009-0493-4; Zhang YJ, 2007, J NEUROSCI, V27, P10530, DOI 10.1523/JNEUROSCI.3421-07.2007; Zhang YJ, 2009, P NATL ACAD SCI USA, V106, P7607, DOI 10.1073/pnas.0900688106; Zhang ZQ, 2009, APOPTOSIS, V14, P1289, DOI 10.1007/s10495-009-0405-z	40	40	40	0	16	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2014	34	9					1444	1452		10.1038/jcbfm.2014.105			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	AO4WT	WOS:000341342800005	24917042	Green Published, Bronze			2021-06-18	
J	Dayan, PS; Holmes, JF; Schutzman, S; Schunk, J; Lichenstein, R; Foerster, LA; Hoyle, J; Atabaki, S; Miskin, M; Wisner, D; Zuspan, SJ; Kuppermann, N				Dayan, Peter S.; Holmes, James F.; Schutzman, Sara; Schunk, Jeffrey; Lichenstein, Richard; Foerster, Lillian A.; Hoyle, John, Jr.; Atabaki, Shireen; Miskin, Michelle; Wisner, David; Zuspan, Sally Jo; Kuppermann, Nathan		Pediat Emergency Care Appl Res	Risk of Traumatic Brain Injuries in Children Younger than 24 Months With Isolated Scalp Hematomas	ANNALS OF EMERGENCY MEDICINE			English	Article							BLUNT HEAD TRAUMA; COMPUTED-TOMOGRAPHY; RADIATION-EXPOSURE; SKULL FRACTURE; INFANTS; EMERGENCY	Study objective: We aimed to determine the association between scalp hematoma characteristics and traumatic brain injuries in young children with blunt head trauma who have no other symptoms or signs suggestive of traumatic brain injuries (defined as "isolated scalp hematomas"). Methods: This was a secondary analysis of children younger than 24 months with minor blunt head trauma from a prospective cohort study in 25 Pediatric Emergency Care Applied Research Network emergency departments. Treating clinicians completed a structured data form. For children with isolated scalp hematomas, we determined the prevalence of and association between scalp hematoma characteristics and (1) clinically important traumatic brain injury (death, neurosurgery for traumatic brain injury, intubation >24 hours for traumatic brain injury, or positive computed tomography (CT) scan in association with hospitalization >= 2 nights for traumatic brain injury); and (2) traumatic brain injury on CT. Results: Of 10,659 patients younger than 24 months were enrolled, 2,998 of 10,463 (28.7%) with complete data had isolated scalp hematomas. Clinically important traumatic brain injuries occurred in 12 patients (0.4%; 95% confidence interval [CI] 0.2% to 0.7%); none underwent neurosurgery (95% CI 0% to 0.1%). Of 570 patients (19.0%) for whom CTs were obtained, 50 (8.8%; 95% CI 6.6% to 11.4%) had traumatic brain injuries on CT. Younger age, non-frontal scalp hematoma location, increased scalp hematoma size, and severe injury mechanism were independently associated with traumatic brain injury on CT. Conclusion: In patients younger than 24 months with isolated scalp hematomas, a minority received CTs. Despite the occasional presence of traumatic brain injuries on CT, the prevalence of clinically important traumatic brain injuries was very low, with no patient requiring neurosurgery. Clinicians should use patient age, scalp hematoma location and size, and injury mechanism to help determine which otherwise asymptomatic children should undergo neuroimaging after minor head trauma.	Columbia Univ, Coll Phys & Surg, Div Emergency Med, New York, NY 10027 USA; [Holmes, James F.; Kuppermann, Nathan] Univ Calif Davis, Sch Med, Dept Emergency Med, Sacramento, CA 95817 USA; [Wisner, David] Univ Calif Davis, Sch Med, Dept Surg, Sacramento, CA 95817 USA; [Kuppermann, Nathan] Univ Calif Davis, Sch Med, Dept Pediat, Sacramento, CA 95817 USA; [Schutzman, Sara] Childrens Hosp Boston, Div Emergency Med, Boston, MA USA; [Schunk, Jeffrey; Miskin, Michelle; Zuspan, Sally Jo] Univ Utah, Dept Pediat, Salt Lake City, UT USA; [Lichenstein, Richard] Univ Maryland, Dept Pediat, Baltimore, MD 21201 USA; [Foerster, Lillian A.] Holy Cross Hosp, Silver Spring Emergency Phys, Silver Spring, MD USA; [Hoyle, John, Jr.] Helen DeVos Childrens Hosp, Grand Rapids, MI USA; [Atabaki, Shireen] Childrens Natl Med Ctr, Emergency Div, Washington, DC USA	Dayan, PS (corresponding author), Columbia Univ, Coll Phys & Surg, Div Emergency Med, New York, NY 10027 USA.	psd6@columbia.edu		Holubkov, Richard/0000-0003-0431-3381	Health Resources and Services Administration/Maternal and Child Health Bureau (HRSA/MCHB), Division of Research, Training, and Education (DRTE); Emergency Medical Services of Children (EMSC) Program [R40MC02461]; EMSC program of the MCHB/HRSA [U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, U03MC22685]	By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist and provided the folllowing details: This work was supported by a grant from the Health Resources and Services Administration/Maternal and Child Health Bureau (HRSA/MCHB), Division of Research, Training, and Education (DRTE); and the Emergency Medical Services of Children (EMSC) Program (R40MC02461). The Pediatric Emergency Care Applied Research Network is supported by cooperative agreements U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, and U03MC22685 from the EMSC program of the MCHB/HRSA.	Bin SS, 2010, PEDIATR EMERG CARE, V26, P633, DOI 10.1097/PEC.0b013e3181ef0440; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Frush DP, 2008, PEDIATR RADIOL, V38, pS629, DOI 10.1007/s00247-008-1006-7; Gorelick MH, 2008, ACAD EMERG MED, V15, P812, DOI 10.1111/j.1553-2712.2008.00206.x; Greenes DS, 2001, PEDIATR EMERG CARE, V17, P88, DOI 10.1097/00006565-200104000-00002; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; Gruskin KD, 1999, ARCH PEDIAT ADOL MED, V153, P15; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; National Center for Injury Prevention and Control, TRAUM BRAIN INJ US; Nigrovic LE, 2012, ARCH PEDIAT ADOL MED, V166, P356, DOI 10.1001/archpediatrics.2011.1156; Nigrovic LE, 2011, PEDIATRICS, V127, P1067, DOI 10.1542/peds.2010-3373; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Quayle KS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e11; Rollins MD, 2011, J PEDIATR SURG, V46, P1342, DOI 10.1016/j.jpedsurg.2010.12.019; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; Schutzman SA, PEDIATRICS	16	40	40	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	AUG	2014	64	2					153	162		10.1016/j.annemergmed.2014.02.003			10	Emergency Medicine	Emergency Medicine	AM9PV	WOS:000340214400010	24635991				2021-06-18	
J	Alhilali, LM; Yaeger, K; Collins, M; Fakhran, S				Alhilali, Lea M.; Yaeger, Karl; Collins, Michael; Fakhran, Saeed			Detection of Central White Matter Injury Underlying Vestibulopathy after Mild Traumatic Brain Injury	RADIOLOGY			English	Article							BLAST; HEAD; REHABILITATION; IMPAIRMENT; ACTIVATION; LOCOMOTION; PATTERNS; RECOVERY; VERTIGO; STANCE	Purpose: To determine if central axonal injury underlies vestibulopathy and ocular convergence insufficiency after mild traumatic brain injury (TBI) by using tract-based spatial statistics (TBSS) analysis of diffusion-tensor imaging (DTI). Materials and Methods: The institutional review board approved this study, and the requirement to obtain informed consent was waived. Diffusion-tensor images were retrospectively reviewed in 30 patients with mild TBI and vestibular symptoms and 25 patients with mild TBI and ocular convergence insufficiency. Control subjects consisted of 39 patients with mild TBI without vestibular abnormalities and 17 patients with mild TBI and normal ocular convergence. Fractional anisotropy (FA) maps were generated as a measure of white matter integrity and were analyzed with TBSS regression analysis by using a general linear model. DTI abnormalities were correlated with symptom severity, neurocognitive test scores, and time to recovery with the Pearson correlation coefficient. Results: Compared with control subjects, patients with mild TBI and vestibular symptoms had decreased neurocognitive test scores (P < .05) and FA values in the cerebellum and fusiform gyri (P < .05). Patients with ocular convergence insufficiency had diminished neurocognitive test scores (P < .05) and FA values in the right anterior thalamic radiation and right geniculate nucleus optic tracts (P < .0001). Cerebellar injury showed an inverse correlation with recovery time (R = -0.410, P = .02). Anterior thalamic radiation injury showed correlation with decreased processing speed (R = 0.402, P < .05). Conclusion: DTI findings in patients with mild TBI and vestibulopathy support the hypothesis that posttraumatic vestibulopathy has a central axonal injury component. Peripheral vestibular structures were not assessed, and a superimposed peripheral contribution may exist. DTI evaluation of central vestibular structures may provide a diagnostic imaging tool in these patients and a quantitative biomarker to aid in prognosis.	[Alhilali, Lea M.; Yaeger, Karl; Fakhran, Saeed] Univ Pittsburgh, Med Ctr, Dept Radiol, Div Neuroradiol, Pittsburgh, PA 15213 USA; [Collins, Michael] Univ Pittsburgh, Med Ctr, Dept Orthoped, Div Sports Med, Pittsburgh, PA 15213 USA	Alhilali, LM (corresponding author), Univ Pittsburgh, Med Ctr, Dept Radiol, Div Neuroradiol, 8th Floor,8 North,Presby South Tower, Pittsburgh, PA 15213 USA.	alhilalilm@upmc.edu			ImPACT Applications	L.M.A. No relevant conflicts of interest to disclose. K.Y. No relevant conflicts of interest to disclose. M.C. Financial activities related to the present article: none to disclose. Financial activities not related to the present article: is co-founder and board member of ImPACT Applications. Other relationships: none to disclose. S. F. No relevant conflicts of interest to disclose.	Akin FW, 2011, OTOLARYNG CLIN N AM, V44, P323, DOI 10.1016/j.otc.2011.01.005; Alsalaheen BA, 2013, PHYSIOTHER RES INT, V18, P100, DOI 10.1002/pri.1532; Biesbroek JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060541; BRANDT T, 1991, BRAIN, V114, P2159, DOI 10.1093/brain/114.5.2159; Capo-Aponte JE, 2012, J REHABIL RES DEV, V49, P1377, DOI 10.1682/JRRD.2011.07.0128; Coffman KA, 2011, P NATL ACAD SCI USA, V108, P16068, DOI 10.1073/pnas.1107904108; Dlugaiczyk J, 2011, OTOL NEUROTOL, V32, P1285, DOI 10.1097/MAO.0b013e31822e94d9; Duering M, 2013, NEUROIMAGE, V66, P177, DOI 10.1016/j.neuroimage.2012.10.084; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Gottshall K, 2011, NEUROREHABILITATION, V29, P167, DOI 10.3233/NRE-2011-0691; Jahn K, 2004, NEUROIMAGE, V22, P1722, DOI 10.1016/j.neuroimage.2004.05.017; Jahn K, 2009, ANN NY ACAD SCI, V1164, P229, DOI 10.1111/j.1749-6632.2009.03770.x; Karim AKMR, 2010, ADV COGN PSYCHOL, V6, P103, DOI 10.2478/v10053-008-0080-6; Katsarkas A, 1999, ACTA OTO-LARYNGOL, V119, P745, DOI 10.1080/00016489950180360; KERR AG, 1980, J LARYNGOL OTOL, V94, P107, DOI 10.1017/S0022215100088538; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mahone EM, 2009, J AM ACAD CHILD PSY, V48, P749, DOI 10.1097/CHI.0b013e3181a565f1; Marzo SJ, 2004, LARYNGOSCOPE, V114, P1720, DOI 10.1097/00005537-200410000-00008; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; RUBIN AM, 1995, AM J OTOL, V16, P216; Salimi-Khorshidi G, 2011, NEUROIMAGE, V54, P2006, DOI 10.1016/j.neuroimage.2010.09.088; SCHUKNECHT HF, 1956, ARCHIV OTOLARYNGOL, V63, P513; Schultz BA, 2011, NEUROREHABILITATION, V28, P309, DOI 10.3233/NRE-2011-0659; Sexton CE, 2012, PSYCHOL MED, V42, P1195, DOI 10.1017/S0033291711002352; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Stoodley CJ, 2012, NEUROIMAGE, V59, P1560, DOI 10.1016/j.neuroimage.2011.08.065; Straube Andreas, 2007, V40, P1; Thiagarajan P, 2011, OPHTHAL PHYSL OPT, V31, P456, DOI 10.1111/j.1475-1313.2011.00831.x; YLIKOSKI J, 1982, AM J OTOL, V3, P343	33	40	40	0	6	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	JUL	2014	272	1					224	232		10.1148/radiol.14132670			9	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	AM7GU	WOS:000340034300024	24735411	Bronze			2021-06-18	
J	Han, JL; King, NKK; Neilson, SJ; Gandhi, MP; Ng, I				Han, Julian; King, Nicolas K. K.; Neilson, Sam J.; Gandhi, Mihir P.; Ng, Ivan			External Validation of the CRASH and IMPACT Prognostic Models in Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						external validation; prediction models; prognosis; TBI	INTRACEREBRAL HEMORRHAGE; PREDICTION; MORTALITY; TRIAL	An accurate prognostic model is extremely important in severe traumatic brain injury (TBI) for both patient management and research. Clinical prediction models must be validated both internally and externally before they are considered widely applicable. Our aim is to independently externally validate two prediction models, one developed by the Corticosteroid Randomization After Significant Head injury (CRASH) trial investigators, and the other from the International Mission for Prognosis and Analysis of Clinical Trials in Traumatic Brain Injury (IMPACT) group. We used a cohort of 300 patients with severe TBI (Glasgow Coma Score [GCS] <= 8) consecutively admitted to the National Neuroscience Institute (NNI), Singapore, between February 2006 and December 2009. The CRASH models (base and CT) predict 14 day mortality and 6 month unfavorable outcome. The IMPACT models (core, extended, and laboratory) estimate 6 month mortality and unfavorable outcome. Validation was based on measures of discrimination and calibration. Discrimination was assessed using the area under the receiving operating characteristic curve (AUC), and calibration was assessed using the Hosmer-Lemeshow (H-L) goodness-of-fit test and Cox calibration regression analysis. In the NNI database, the overall observed 14 day mortality was 47.7%, and the observed 6 month unfavorable outcome was 71.0%. The CRASH base model and all three IMPACT models gave an underestimate of the observed values in our cohort when used to predict outcome. Using the CRASH CT model, the predicted 14 day mortality of 46.6% approximated the observed outcome, whereas the predicted 6 month unfavorable outcome was an overestimate at 74.8%. Overall, both the CRASH and IMPACT models showed good discrimination, with AUCs ranging from 0.80 to 0.89, and good overall calibration. We conclude that both the CRASH and IMPACT models satisfactorily predicted outcome in our patients with severe TBI.	[Han, Julian; King, Nicolas K. K.; Ng, Ivan] Natl Inst Neurosci, Dept Neurosurg, Singapore 308433, Singapore; [Neilson, Sam J.] Univ Manchester, Manchester Med Sch, Manchester, Lancs, England; [Gandhi, Mihir P.] Duke Natl Univ Singapore, Ctr Quantitat Med, Grad Sch Med, Singapore, Singapore; [Gandhi, Mihir P.] Singapore Clin Res Inst, Dept Biostat, Singapore, Singapore	King, NKK (corresponding author), Natl Inst Neurosci, Dept Neurosurg, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.	nkkk@gmx.net		Kon Kam King, Nicolas/0000-0002-6009-4411			COX DR, 1958, BIOMETRIKA, V45, P562, DOI 10.1093/biomet/45.3-4.562; Hemphill JC, 2004, STROKE, V35, P1130, DOI 10.1161/01.STR.0000125858.71051.ca; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Justice AC, 1999, ANN INTERN MED, V130, P515, DOI 10.7326/0003-4819-130-6-199903160-00016; Lingsma H, 2013, J TRAUMA ACUTE CARE, V74, P639, DOI 10.1097/TA.0b013e31827d602e; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Menon DK, 2009, CURR OPIN CRIT CARE, V15, P437, DOI 10.1097/MCC.0b013e3283307a26; Morgenstern LB, 2010, STROKE, V41, P2108, DOI 10.1161/STR.0b013e3181ec611b; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Panczykowski DM, 2012, J NEUROTRAUM, V29, P47, DOI 10.1089/neu.2010.1482; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Roozenbeek B, 2012, J NEUROTRAUM, V29, P1306, DOI 10.1089/neu.2011.1988; Skrobik Y, 2006, CAN J ANAESTH, V53, P432, DOI 10.1007/BF03022613; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; TEASDALE G, 1974, LANCET, V2, P81; Vergouwe Y, 2010, AM J EPIDEMIOL, V172, P971, DOI 10.1093/aje/kwq223; Yeoman P, 2011, J TRAUMA, V71, P387, DOI 10.1097/TA.0b013e31820ceadd; Zahuranec DB, 2007, NEUROLOGY, V68, P1651, DOI 10.1212/01.wnl.0000261906.93238.72	22	40	41	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2014	31	13					1146	1152		10.1089/neu.2013.3003			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AL2VK	WOS:000338983500003	24568201				2021-06-18	
J	Liesemer, K; Riva-Cambrin, J; Bennett, KS; Bratton, SL; Tran, H; Metzger, RR; Bennett, TD				Liesemer, Kate; Riva-Cambrin, Jay; Bennett, Kimberly Statler; Bratton, Susan L.; Tran, Henry; Metzger, Ryan R.; Bennett, Tellen D.			Use of Rotterdam CT Scores for Mortality Risk Stratification in Children With Traumatic Brain Injury	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						brain injuries; craniocerebral trauma; intracranial hypertension; neuroradiography; pediatric intensive care unit; pediatrics	SEVERE HEAD-INJURY; COMPUTERIZED-TOMOGRAPHY; OUTCOME PREDICTION; MODEL; CLASSIFICATION; EXPERIENCE; CARE	Objectives: The Rotterdam CT score refined features of the Marshall score and was designed to categorize traumatic brain injury type and severity in adults. The objective of this study was to determine whether the Rotterdam CT score can be used for mortality risk stratification after pediatric traumatic brain injury. Design: In children with moderate to severe traumatic brain injury, a comparison of observed versus predicted mortality was calculated using published model probabilities of adult mortality. Development and validation of a new pediatric mortality model using randomly selected prediction and validation samples from our cohort. Setting: A single level 1 pediatric trauma center. Subjects: Six hundred thirty-two children with moderate or severe traumatic brain injury. Interventions: None. Measurements and Main Results: Sixteen percent of the patients (101 of 632) died prior to hospital discharge. The predicted mortality based on Rotterdam score for adults with moderate or severe traumatic brain injury discriminated pediatric observed mortality well (area under the curve = 0.85; 95% CI, 0.80-0.89) but had poor calibration, overestimating or underestimating mortality for children in several Rotterdam categories. A predictive model based on children with moderate or severe traumatic brain injury from the single center discriminated mortality well (area under the curve, 0.80; 95% CI, 0.68-0.91) and showed good calibration and overall fit. Conclusions: Children with traumatic brain injury have better survival than adults in Rotterdam CT score categories representing less severe injuries but worse survival than adults in higher score categories. A novel, validated pediatric mortality model based on the Rotterdam score is accurate in children with moderate or severe traumatic brain injury and can be used for risk stratification.	[Liesemer, Kate; Riva-Cambrin, Jay; Bennett, Kimberly Statler; Bratton, Susan L.; Metzger, Ryan R.; Bennett, Tellen D.] Univ Utah, Sch Med, Salt Lake City, UT 84158 USA; [Liesemer, Kate; Riva-Cambrin, Jay; Bennett, Kimberly Statler; Bratton, Susan L.; Metzger, Ryan R.; Bennett, Tellen D.] Primary Childrens Med Ctr, Salt Lake City, UT 84158 USA; [Tran, Henry] Univ Rochester, Sch Med, Rochester, NY USA	Bennett, TD (corresponding author), Univ Utah, Sch Med, 295 Chipeta Way,POB 581289, Salt Lake City, UT 84158 USA.	tell.bennett@hsc.utah.edu		Bratton, Susan/0000-0002-4605-8078; Bennett, Tellen/0000-0003-1483-4236	National Institutes of Health/National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [K23HD074620]; CDC-Spina Bifida Registry; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD074620] Funding Source: NIH RePORTER	Dr. Bennett received grant support from the National Institutes of Health/National Cancer Institute (K23HD074620). Dr. Riva-Cambrin received grant support from the CDC-Spina Bifida Registry. Dr. Bratton received support for travel for speaking at the European Academic Society Meeting. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS9; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Bailey BM, 2012, J TRAUMA ACUTE CARE, V72, P263, DOI 10.1097/TA.0b013e31822a9512; Brier G.W., 1950, MONTHLY WEATHER REV, V78, P1, DOI 2.0.CO;2; Chun KA, 2010, J NEUROTRAUM, V27, P325, DOI 10.1089/neu.2009.1115; Teruel GC, 2007, J PEDIATR SURG, V42, P1903, DOI 10.1016/j.jpedsurg.2007.07.020; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; Corral L, 2009, BRAIN INJURY, V23, P403, DOI 10.1080/02699050902788477; COX DR, 1958, BIOMETRIKA, V45, P562, DOI 10.1093/biomet/45.3-4.562; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; Hirsch W, 2002, PAEDIATR ANAESTH, V12, P337, DOI 10.1046/j.1460-9592.2002.00837.x; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Hyam JA, 2006, CRIT CARE, V10, DOI 10.1186/cc5066; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Levin HS, NEUROSURGERY, P443; Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Manktelow BN, 2010, ARCH DIS CHILD-FETAL, V95, pF9, DOI 10.1136/adc.2008.148015; Manktelow BN, 2013, PEDIATRICS, V131, pE425, DOI 10.1542/peds.2012-2189; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Straney L, 2013, PEDIATR CRIT CARE ME, V14, P673, DOI 10.1097/PCC.0b013e31829760cf; Tasaki O, 2009, J TRAUMA, V66, P304, DOI 10.1097/TA.0b013e31815d9d3f; Tasker RC, 2011, BRIT J NEUROSURG, V25, P68, DOI 10.3109/02688697.2010.538770; The Brain Trauma Foundation The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P597; Zebrack M, 2009, PEDIATRICS, V124, P56, DOI 10.1542/peds.2008-1006	35	40	40	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JUL	2014	15	6					554	562		10.1097/PCC.0000000000000150			9	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	AK8WK	WOS:000338709100012	24751786	Green Accepted			2021-06-18	
J	Heyer, GL; Idris, SA				Heyer, Geoffrey L.; Idris, Syed A.			Does Analgesic Overuse Contribute to Chronic Post-traumatic Headaches in Adolescent Concussion Patients?	PEDIATRIC NEUROLOGY			English	Article						medication-overuse headache; concussion; post-traumatic headache; pediatric; TBI; adolescent	TRAUMATIC BRAIN-INJURY; MEDICATION-OVERUSE; CHRONIC MIGRAINE; UNITED-STATES; CLASSIFICATION; EPIDEMIOLOGY; TOPIRAMATE; PREVALENCE; CHILDREN	BACKGROUND: The causes of persistent headache following concussion are poorly understood. The objective of this study is to explore analgesic overuse as a potential cause of chronic post-traumatic headache among adolescents referred to a headache clinic following concussion. METHODS: A retrospective chart review was conducted of all adolescent concussion patients referred to our pediatric headache clinic over the 16-month period between August 1, 2011, and November 30, 2012. Those patients with chronic post-traumatic headaches of 3-12 months' duration who also met International Headache Society criteria for probable medication-overuse headache were identified. Demographic data, concussion symptoms, and headache features were characterized from the initial evaluation and from follow-up visits. RESULTS: Of 104 adolescent concussion patients referred during the study period, 77 had chronic post-traumatic headache of 3-12 months' duration. Fifty-four of 77 (70.1%) met criteria for probable medication-overuse headache. Only simple analgesics were overused. Thirty-seven patients (68.5%) had resolution of headaches or improvements to preconcussion headache patterns after discontinuing analgesics; seven (13%) had no change in headaches or worsening of headaches after discontinuing analgesics and 10 (18.5%) did not discontinue analgesics or were lost to follow-up. CONCLUSION: Excessive use of analgesics postconcussion may contribute to chronic post-traumatic headaches in some adolescents. Management of patients with chronic post-traumatic headache should include analgesic detoxification when medication overuse is suspected.	[Heyer, Geoffrey L.; Idris, Syed A.] Nationwide Childrens Hosp, Dept Pediat, Columbus, OH 43205 USA; [Heyer, Geoffrey L.; Idris, Syed A.] Ohio State Univ, Columbus, OH 43210 USA; [Heyer, Geoffrey L.; Idris, Syed A.] Nationwide Childrens Hosp, Dept Neurol, Columbus, OH 43205 USA	Heyer, GL (corresponding author), Nationwide Childrens Hosp, Dept Pediat, 700 Childrens Dr,ED-5, Columbus, OH 43205 USA.	geoffrey.heyer@nationwidechildrens.org	Heyer, Geoffrey/E-3243-2011	Heyer, Geoffrey/0000-0001-9334-3739			Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Bahra A, 2003, HEADACHE, V43, P179, DOI 10.1046/j.1526-4610.2003.03041.x; Bigal ME, 2004, NEUROLOGY, V63, P843, DOI 10.1212/01.WNL.0000137039.08724.18; Bigal ME, 2004, CEPHALALGIA, V24, P483, DOI 10.1111/j.1468-2982.2004.00691.x; Blume HK, 2012, PEDIATRICS, V129, pE31, DOI 10.1542/peds.2011-1742; Chrisman SP, 2013, BRAIN INJURY, V27, P1, DOI 10.3109/02699052.2012.722251; Colas R, 2004, NEUROLOGY, V62, P1338, DOI 10.1212/01.WNL.0000120545.45443.93; Creac'h C, 2009, HEADACHE, V49, P519, DOI 10.1111/j.1526-4610.2009.01365.x; Diener HC, 2007, CEPHALALGIA, V27, P814, DOI 10.1111/j.1468-2982.2007.01326.x; Diener HC, 2009, CEPHALALGIA, V29, P1021, DOI 10.1111/j.1468-2982.2009.01859.x; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Fuh JL, 2005, PAIN, V119, P49, DOI 10.1016/j.pain.2005.09.034; Gladstone J, 2009, HEADACHE, V49, P1097, DOI 10.1111/j.1526-4610.2009.01461.x; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; Lipton RB, 2001, HEADACHE, V41, P646, DOI 10.1046/j.1526-4610.2001.041007646.x; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; MATHEW NT, 1990, HEADACHE, V30, P634, DOI 10.1111/j.1526-4610.1990.hed3010634.x; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Piazza F, 2012, HEADACHE, V52, P1506, DOI 10.1111/j.1526-4610.2012.02221.x; Radat F, 2008, HEADACHE, V48, P1026, DOI 10.1111/j.1526-4610.2007.00999.x; Rapoport A, 1996, HEADACHE, V36, P14, DOI 10.1046/j.1526-4610.1996.3601014.x; Seifert TD, 2010, CURR PAIN HEADACHE R, V14, P292, DOI 10.1007/s11916-010-0117-7; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Stosch RSV, 2008, CEPHALALGIA, V28, P908, DOI 10.1111/j.1468-2982.2008.01633_1.x; Theeler BJ, 2012, HEADACHE, V52, P732, DOI 10.1111/j.1526-4610.2012.02112.x; Vincent MB, 2012, CURR PAIN HEADACHE R, V16, P80, DOI 10.1007/s11916-011-0229-8; Warner JS, 1996, NEUROLOGY, V46, P915, DOI 10.1212/WNL.46.4.915; Warner JS, 2000, ARCH NEUROL, P57; Wilkinson SM, 2001, HEADACHE, V41, P303, DOI 10.1046/j.1526-4610.2001.111006303.x; Zeeberg P, 2006, CEPHALALGIA, V26, P1192, DOI 10.1111/j.1468-2982.2006.01190.x	32	40	40	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	MAY	2014	50	5					464	468		10.1016/j.pediatrneurol.2014.01.040			5	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	AG9CZ	WOS:000335717600006	24656666				2021-06-18	
J	Sun, D				Sun, Dong			The potential of endogenous neurogenesis for brain repair and regeneration following traumatic brain injury	NEURAL REGENERATION RESEARCH			English	Article						traumatic brain injury; adult neurogenesis; neural stem cells; cell proliferation; hippocampus; subventricular zone; learning and memory function; regeneration; cognition	ADULT HUMAN BRAIN; ENHANCED HIPPOCAMPAL NEUROGENESIS; ENDOTHELIAL GROWTH-FACTOR; DENTATE GYRUS; CELL-PROLIFERATION; GRANULE CELLS; COGNITIVE RECOVERY; PROGENITOR CELLS; CA3 REGION; NEURONAL DIFFERENTIATION	Traumatic brain injury (TBI) is the leading cause of death and disability of persons under 45 years old in the United States, affecting over 1.5 million individuals each year. It had been thought that recovery from such injuries is severely limited due to the inability of the adult bra in to replace damaged neurons. However, recent studies indicate that the mature mammalian central nervous system (CNS) has the potential to replenish damaged neurons by proliferation and neuronal differentiation of adult neural stem/progenitor cells residing in the neurogenic regions in the brain. Furthermore, increasing evidence indicates that these endogenous stem/progenitor cells may play regenerative and reparative roles in response to CNS injuries or diseases. In support of this notion, heightened levels of cell proliferation and neurogenesis have been observed in response to brain trauma or insults suggesting that the brain has the inherent potential to restore populations of damaged or destroyed neurons. This review will discuss the potential functions of adult neurogenesis and recent development of strategies aiming at harnessing this neurogenic capacity in order to repopulate and repair the injured brain.	Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23298 USA	Sun, D (corresponding author), Virginia Commonwealth Univ, Dept Neurosurg, POB 980631,Med Coll Virginia Campus, Richmond, VA 23298 USA.	dsun@vcu.edu					ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; ALVAREZBUYLLA A, 1988, NATURE, V335, P353, DOI 10.1038/335353a0; Banasr M, 2001, EUR J NEUROSCI, V14, P1417, DOI 10.1046/j.0953-816x.2001.01763.x; Bregy A, 2012, EXP NEUROL, V233, P821, DOI 10.1016/j.expneurol.2011.12.008; CAMERON HA, 1994, NEUROSCIENCE, V61, P203, DOI 10.1016/0306-4522(94)90224-0; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215; Curtis MA, 2012, DEV NEUROBIOL, V72, P990, DOI 10.1002/dneu.22028; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Deng W, 2009, J NEUROSCI, V29, P13532, DOI 10.1523/JNEUROSCI.3362-09.2009; Emery DL, 2005, J NEUROTRAUM, V22, P978, DOI 10.1089/neu.2005.22.978; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Gao X, 2009, EXP NEUROL, V219, P516, DOI 10.1016/j.expneurol.2009.07.007; Gheusi C, 2000, P NATL ACAD SCI USA, V97, P1823, DOI 10.1073/pnas.97.4.1823; Gould E, 1999, BIOL PSYCHIAT, V46, P1472, DOI 10.1016/S0006-3223(99)00247-4; Gould E, 2001, P NATL ACAD SCI USA, V98, P10910, DOI 10.1073/pnas.181354698; Gould E, 1997, J NEUROSCI, V17, P2492; Han XD, 2011, J NEUROTRAUM, V28, P995, DOI 10.1089/neu.2010.1563; Hastings NB, 1999, J COMP NEUROL, V413, P146, DOI 10.1002/(SICI)1096-9861(19991011)413:1<146::AID-CNE10>3.0.CO;2-B; Hilton G, 1994, Orthop Nurs, V13, P25, DOI 10.1097/00006416-199407000-00006; Imayoshi I, 2008, NAT NEUROSCI, V11, P1153, DOI 10.1038/nn.2185; Kageyama R, 2012, BEHAV BRAIN RES, V227, P459, DOI 10.1016/j.bbr.2011.04.038; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kempermann G, 1997, P NATL ACAD SCI USA, V94, P10409, DOI 10.1073/pnas.94.19.10409; Kempermann G, 2000, NOVART FDN SYMP, V231, P220, DOI 10.1002/0470870834.ch14; Kempermann G, 1998, CURR BIOL, V8, P939, DOI 10.1016/S0960-9822(07)00377-6; Kirn JR, 1999, J COMP NEUROL, V411, P487; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Kukekov VG, 1999, EXP NEUROL, V156, P333, DOI 10.1006/exnr.1999.7028; Lee C, 2010, J NEUROTRAUM, V27, P541, DOI 10.1089/neu.2009.0905; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Moreno MM, 2009, P NATL ACAD SCI USA, V106, P17980, DOI 10.1073/pnas.0907063106; Murrell W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071334; Nunes MC, 2003, NAT MED, V9, P439, DOI 10.1038/nm837; Parent JM, 2002, EPILEPSY RES, V50, P179, DOI 10.1016/S0920-1211(02)00078-5; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Rola R, 2004, RADIAT RES, V162, P442, DOI 10.1667/RR3234; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103; Schmidt RH, 1999, J NEUROTRAUM, V16, P1139, DOI 10.1089/neu.1999.16.1139; Shors TJ, 2002, HIPPOCAMPUS, V12, P578, DOI 10.1002/hipo.10103; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Snyder JS, 2005, NEUROSCIENCE, V130, P843, DOI 10.1016/j.neuroscience.2004.10.009; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun D, 2010, J NEUROTRAUM, V27, P923, DOI 10.1089/neu.2009.1209; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Tanapat P, 1999, J NEUROSCI, V19, P5792, DOI 10.1523/JNEUROSCI.19-14-05792.1999; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 1999, NAT NEUROSCI, V2, P266; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Zheng WM, 2013, J NEUROTRAUM, V30, P1872, DOI 10.1089/neu.2010.1579	60	40	43	0	11	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	1673-5374	1876-7958		NEURAL REGEN RES	Neural Regen. Res.	APR	2014	9	7					688	692		10.4103/1673-5374.131567			5	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	AH0KF	WOS:000335807100003	25206873	DOAJ Gold, Green Published			2021-06-18	
J	Kierans, AS; Kirov, II; Gonen, O; Haemer, G; Nisenbaum, E; Babb, JS; Grossman, RI; Lui, YW				Kierans, Andrea S.; Kirov, Ivan I.; Gonen, Oded; Haemer, Gillian; Nisenbaum, Eric; Babb, James S.; Grossman, Robert I.; Lui, Yvonne W.			Myoinositol and glutamate complex neurometabolite abnormality after mild traumatic brain injury	NEUROLOGY			English	Article							PROTON MR SPECTROSCOPY; RELAXATION-TIMES; BASAL GANGLIA; MICRODIALYSIS; METABOLISM; REDUCTION; THALAMUS; CHILDREN; SYSTEM	Objective:To obtain quantitative neurometabolite measurements, specifically myoinositol (mI) and glutamate plus glutamine (Glx), markers of glial and neuronal excitation, in deep gray matter structures after mild traumatic brain injury (mTBI) using proton magnetic resonance spectroscopy (H-1-MRS) and to compare these measurements against normal healthy control subjects.Methods:This study approved by the institutional review board is Health Insurance Portability and Accountability Act compliant. T1-weighted MRI and multi-voxel H-1-MRS imaging were acquired at 3 tesla from 26 patients with mTBI an average of 22 days postinjury and from 13 age-matched healthy controls. Two-way analysis of variance was used to compare patients and controls for mean N-acetylaspartate, choline, creatine (Cr), Glx, and mI levels as well as the respective ratios to Cr within the caudate, globus pallidus, putamen, and thalamus.Results:Quantitative putaminal mI was higher in patients with mTBI compared with controls (p = 0.02). Quantitative neurometabolite ratios of putaminal mI and Glx relative to Cr, mI/Cr, and Glx/Cr were also higher among patients with mTBI compared with controls (p = 0.01 and 0.02, respectively). No other differences in neurometabolite levels or ratios were observed in any other brain region evaluated.Conclusion:Increased putaminal mI, mI/Cr, and Glx/Cr in patients after mTBI compared with control subjects supports the notion of a complex glial and excitatory response to injury without concomitant neuronal loss, evidenced by preserved N-acetylaspartate levels in this region.	[Kierans, Andrea S.; Kirov, Ivan I.; Gonen, Oded; Haemer, Gillian; Nisenbaum, Eric; Babb, James S.; Grossman, Robert I.; Lui, Yvonne W.] NYU, Sch Med, Dept Radiol, New York, NY 10003 USA	Lui, YW (corresponding author), NYU, Sch Med, Dept Radiol, New York, NY 10003 USA.	Yvonne.lui@nyumc.org	Kirov, Ivan/I-2792-2019	Kirov, Ivan/0000-0001-5641-8578; Gonen, Oded/0000-0002-3148-2028; Babb, James/0000-0003-1798-1186	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1UL1RR029893, RO1 NS039135, EB01015, RO1 NS050520]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR029893] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB001015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050520, R01NS039135] Funding Source: NIH RePORTER	Supported in part by the following federal grants from the NIH: 1UL1RR029893, RO1 NS039135, EB01015, and RO1 NS050520.	Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/neu.2004.21.1539; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Choi CH, 2006, MAGN RESON MED, V56, P971, DOI 10.1002/mrm.21055; DU YPP, 1994, JMRI-J MAGN RESON IM, V4, P733, DOI 10.1002/jmri.1880040517; Ell SW, 2012, HORIZON NEUROSCIENCE, P29; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fisher SK, 2002, J NEUROCHEM, V82, P736, DOI 10.1046/j.1471-4159.2002.01041.x; Fudge JL, 2003, J NEUROPSYCH CLIN N, V15, P306, DOI 10.1176/jnp.15.3.306; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Garcia-Panach J, 2011, J NEUROTRAUM, V28, P1707, DOI 10.1089/neu.2011.1851; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Goelman G, 2007, MAGN RESON MED, V58, P167, DOI 10.1002/mrm.21251; Goelman G, 2006, MAGN RESON MED, V56, P34, DOI 10.1002/mrm.20942; Grahn JA, 2009, BEHAV BRAIN RES, V199, P53, DOI 10.1016/j.bbr.2008.11.020; Haber SN, 2009, BRAIN RES BULL, V78, P69, DOI 10.1016/j.brainresbull.2008.09.013; Hinzman JM, 2010, J NEUROTRAUM, V27, P889, DOI 10.1089/neu.2009.1238; HU J, 1995, J MAGN RESON SER B, V108, P213, DOI 10.1006/jmrb.1995.1126; Kirov I, 2007, BRAIN INJURY, V21, P1147, DOI 10.1080/02699050701630383; Kirov II, 2008, MAGN RESON MED, V60, P790, DOI 10.1002/mrm.21715; Kirov II, 2013, J NEUROTRAUM, V30, P1200, DOI 10.1089/neu.2012.2696; Kirov II, 2013, J NEUROL, V260, P242, DOI 10.1007/s00415-012-6626-z; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Pascual JM, 2007, J NEUROTRAUM, V24, P944, DOI 10.1089/neu.2006.0190; Pascual O, 2012, P NATL ACAD SCI USA, V109, pE197, DOI 10.1073/pnas.1111098109; Petchprapai Nutthita, 2007, J Neurosci Nurs, V39, P260; Posse S, 2007, MAGN RESON MED, V58, P236, DOI 10.1002/mrm.21287; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Smits M, 2008, AM J NEURORADIOL, V29, P506, DOI 10.3174/ajnr.A0852; Soher BJ, 1998, MAGNET RESON MED, V40, P822, DOI 10.1002/mrm.1910400607; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Traber F, 2004, J MAGN RESON IMAGING, V19, P537, DOI 10.1002/jmri.20053; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578	39	40	40	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	FEB 11	2014	82	6					521	528		10.1212/WNL.0000000000000105			8	Clinical Neurology	Neurosciences & Neurology	AH9VW	WOS:000336493900013	24401686	Green Published			2021-06-18	
J	Lichtenstein, JD; Moser, RS; Schatz, P				Lichtenstein, Jonathan D.; Moser, Rosemarie Scolaro; Schatz, Philip			Age and Test Setting Affect the Prevalence of Invalid Baseline Scores on Neurocognitive Tests	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion testing; baseline testing; validity; neurocognitive testing; group administration; pediatric concussion; ImPACT	HIGH-SCHOOL; NEUROPSYCHOLOGICAL PERFORMANCE; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; BRAIN-INJURY; CONCUSSION; SPORT; MANAGEMENT; DIAGNOSIS; ZURICH	Background: Prevalence rates of invalid baseline scores on computerized neurocognitive assessments for high school, collegiate, and professional athletes have been published in the literature. At present, there is limited research on the prevalence of invalid baseline scores in pre-high school athletes. Hypothesis: Pre-high school athletes assessed with baseline neurocognitive tests would show higher prevalence rates of invalidity than older youth athletes, and those athletes, regardless of age, who were tested in a large group setting would show a higher prevalence rate of invalidity than athletes tested in a small group setting. Study Design: Cross-sectional study; Level of evidence, 3. Methods: A total of 502 athletes between the ages of 10 and 18 years completed preseason baseline neurocognitive tests in "large" or "small" groups. All athletes completed the online version of ImPACT (Immediate Post-Concussion Assessment and Cognitive Testing). Baseline test results that were "flagged" by the computer software as being of suspect validity and labeled with a "++" symbol were identified for analysis. Participants were retrospectively assigned to 2 independent groups: large group or small group. Test administration of the large group occurred off-site in groups of approximately 10 athletes, and test administration of the small group took place at a private-practice neuropsychology center with only 1 to 3 athletes present. Results: Chi-square analyses identified a significantly greater proportion of participants obtaining invalid baseline results on the basis of age; younger athletes produced significantly more invalid baseline scores (7.0%, 17/244) than older athletes (2.7%, 7/258) (chi(2) (1) = 4.99; P = .021). Log-linear analysis revealed a significant age (10-12 years, 13-18 years) 3 size (small, large) interaction effect (chi(2) (4) = 66.1; P < .001) on the prevalence of invalidity, whereby younger athletes tested in larger groups were significantly more likely to provide invalid results (11.9%) than younger athletes tested in smaller groups (5.4%), older athletes tested in larger groups (2.7%), and older athletes tested in smaller groups (2.7%). Conclusion: Younger athletes tend to exhibit a greater prevalence of invalid baseline results on neurocognitive computerized tests than older youth athletes; the prevalence increases when testing is conducted in a large group and nonclinical setting.	[Lichtenstein, Jonathan D.; Moser, Rosemarie Scolaro; Schatz, Philip] Sports Concuss Ctr New Jersey, Lawrenceville, NJ USA	Lichtenstein, JD (corresponding author), Dartmouth Hitchcock Med Ctr, Dept Psychiat, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	lichtenstein.jonathan@gmail.com	Meijer, Anna/K-5118-2016		Sports Concussion Center of New Jersey (SCCNJ); SCCNJ	One or more of the authors has declared the following potential conflict of interest or source of funding: Dr Schatz has served as a consultant to ImPACT Applications Inc. However, ImPACT Applications Inc had no role in the conceptualization of this study, the collection or analysis of data, the writing of the article, or the decision to submit it for publication. R. S. M. is an employee of the Sports Concussion Center of New Jersey (SCCNJ), which funded the study; J.D.L. was an employee of SCCNJ at the time of the study. The work performed toward the completion of this study was funded financially by the SCCNJ.	Aubry M, 2002, PHYSICIAN SPORTSMED, V30, P1; Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Barth JT., 1989, MILD HEAD INJURY, P257; Broglio SP, 2009, CLIN J SPORT MED, V19, P377, DOI 10.1097/JSM.0b013e3181b625fe; Brooks BL, 2013, J NEUROTRAUM, V30, P1469, DOI 10.1089/neu.2012.2720; Butler IJ, 2013, JAMA NEUROL, V70, P636, DOI 10.1001/jamaneurol.2013.2801; Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hunt TN, 2007, ARCH CLIN NEUROPSYCH, V22, P615, DOI 10.1016/j.acn.2007.04.005; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Larini R, MONTCLAIR HIGH SCH F; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lovell MR, IMPACT VERSION 6 0 C; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Moser RS, 2007, PROF PSYCHOL-RES PR, V38, P699, DOI 10.1037/0735-7028.38.6.699; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, APPL NEUROP IN PRESS; Moss A, 2003, BRAIN INJURY, V17, P377, DOI 10.1080/0269905031000070125; New Jersey State Interscholastic Athletic Association, CONC ID MAN RET TO P; Podell K, 2004, STUD NEUROPSYCHOL DE, P375; Schatz P, 2006, SPORTS NEUROPSYCHOLO, P160; Schatz P, 2012, J ATHL TRAINING, V47, P289, DOI 10.4085/1062-6050-47.3.14; Schatz P, 2011, CLIN NEUROPSYCHOL, V25, P1042, DOI 10.1080/13854046.2011.556669; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Schatz P, 2010, ARCH CLIN NEUROPSYCH, V25, P285, DOI 10.1093/arclin/acq022; Schneider KJ, 2013, CLIN J SPORT MED, V23, P267, DOI 10.1097/JSM.0b013e318281f09f; Schwarz A., 2010, NY TIMES, pB14; SPSS Inc, 2010, IBM SPSS MAC VERS 19; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Tabachnick B., 2001, USING MULTIVARIATE S	44	40	40	0	12	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	FEB	2014	42	2					479	484		10.1177/0363546513509225			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	AH6CS	WOS:000336218900035	24243771				2021-06-18	
J	Rostami, E; Krueger, F; Plantman, S; Davidsson, J; Agoston, D; Grafman, J; Risling, M				Rostami, Elham; Krueger, Frank; Plantman, Stefan; Davidsson, Johan; Agoston, Denes; Grafman, Jordan; Risling, Marten			Alteration in BDNF and its receptors, full-length and truncated TrkB and p75(NTR) following penetrating traumatic brain injury	BRAIN RESEARCH			English	Article						BDNF; Traumatic brain injury; TrkB; p75(NTR); Neurotrophins	NERVE GROWTH-FACTOR; P75 NEUROTROPHIN RECEPTOR; TYROSINE PROTEIN-KINASE; MESSENGER-RNA; ENVIRONMENTAL ENRICHMENT; RAT HIPPOCAMPUS; INCREASED EXPRESSION; GENE-EXPRESSION; MULTIPLE ROLES; UP-REGULATION	The evidence that BDNF is involved in neuroprotection, neuronal repair and recovery after traumatic brain injury (TBI) is substantial. We have previously shown that the polymorphism of the human BDNF gene predicts cognitive recovery and outcome following penetrating TBI. The distribution of expression of BONE and its receptors after penetrating TBI has not been investigated. In this study we examined the expression of these genes in a rat model of penetrating TBI. The injury is produced by a controlled penetration of a 2 mm thick needle-shaped object, which is accelerated with a pellet from an air gun. We used in situ hybridization and investigated the mRNA expression of BDNF and its receptors: the full-length and the truncated TrkB and p75(NTR), from 1 day to 8 weeks following penetrating TBI. In addition, the protein level of BDNF in frontal cortex and hippocampus was measured by reverse phase protein microarray (RPPM). The mRNA expression of BDNF and its receptors decreased in the hippocampus in the border zone ipsilateral to the injury while there was an increase in mRNA expression at the contralateral side. The increase in BDNF mRNA expression in the hippocampus was sustained for 2 weeks following injury, with the highest expression noted in the CA3 cell layer. Furthermore, the protein analysis by RPPM showed increased levels of BDNF in the frontal cortex and the hippocampus up to 2 weeks after TBI. At 8 weeks following injury there was an intense labeling of the truncated TrkB receptor and the p75NTR in the area surrounding the cavity. Our study is the first report on the expression of BDNF and its receptors following penetrating TBI and suggests that their expression is altered long after the acute phase of injury. Further studies are needed to investigate if the late expressions of these receptors are beneficial or deleterious. In either case it indicates the possibility to influence the recovery after brain injury during the chronic phase and the development of treatments that may improve the outcome of TBI patients. (C) 2013 Elsevier B.V. All rights reserved.	[Rostami, Elham; Plantman, Stefan; Risling, Marten] Karolinska Inst, Dept Neurosci, SE-17177 Stockholm, Sweden; [Rostami, Elham] Univ Uppsala Hosp, Dept Neurosci & Neurosurg, Uppsala, Sweden; [Krueger, Frank] George Mason Univ, Dept Mol Neurosci, Fairfax, VA 22030 USA; [Krueger, Frank] George Mason Univ, Dept Psychol, Fairfax, VA 22030 USA; [Davidsson, Johan] Chalmers, Div Vehicle Safety, S-41296 Gothenburg, Sweden; [Agoston, Denes] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Grafman, Jordan] Rehabil Inst Chicago, Cognit Neurosci Lab, Chicago, IL USA	Rostami, E (corresponding author), Karolinska Inst, Dept Neurosci, Retzius Vag 8, SE-17177 Stockholm, Sweden.	Elham.rostami@ki.se	Davidsson, Johan/A-3229-2016	Davidsson, Johan/0000-0002-1717-1514; Grafman, Jordan H./0000-0001-8645-4457			BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; Bentley CA, 2000, J NEUROSCI, V20, P7706; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; BIFFO S, 1995, DEVELOPMENT, V121, P2461; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Chen Y, 2009, J INT MED RES, V37, P281, DOI 10.1177/147323000903700201; Dechant G, 2002, NAT NEUROSCI, V5, P1131, DOI 10.1038/nn1102-1131; Ding Q, 2011, NEUROSCIENCE, V192, P773, DOI 10.1016/j.neuroscience.2011.06.032; Drake CT, 1999, J NEUROSCI, V19, P8009; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Eide FF, 1996, J NEUROSCI, V16, P3123; EMFORS P, 1989, NEURON, V2, P1605; Emfors P., 1990, P NATL ACAD SCI USA, V87, P5454; Frade JM, 1996, NATURE, V383, P166; FRISEN J, 1993, P NATL ACAD SCI USA, V90, P4971, DOI 10.1073/pnas.90.11.4971; FRISEN J, 1992, P NATL ACAD SCI USA, V89, P11282, DOI 10.1073/pnas.89.23.11282; Giehl KM, 2001, J NEUROSCI, V21, P3492, DOI 10.1523/JNEUROSCI.21-10-03492.2001; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Gyorgy AB, 2010, J NEUROSCI METH, V192, P96, DOI 10.1016/j.jneumeth.2010.07.029; Haapasalo A, 1999, ONCOGENE, V18, P1285, DOI 10.1038/sj.onc.1202401; Haapasalo A, 2001, BIOCHEM BIOPH RES CO, V280, P1352, DOI 10.1006/bbrc.2001.4296; Hartmann M, 2004, J CELL SCI, V117, P5803, DOI 10.1242/jcs.01511; HAYES RC, 1992, MOL BRAIN RES, V15, P291, DOI 10.1016/0169-328X(92)90120-Z; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hicks RR, 1998, MOL BRAIN RES, V59, P264, DOI 10.1016/S0169-328X(98)00158-2; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Johansson BB, 2004, RESTOR NEUROL NEUROS, V22, P163; Keyvani K, 2004, J NEUROPATH EXP NEUR, V63, P598, DOI 10.1093/jnen/63.6.598; KIRSCHENBAUM B, 1995, P NATL ACAD SCI USA, V92, P210, DOI 10.1073/pnas.92.1.210; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; Krueger F, 2011, J NEUROSCI, V31, P598, DOI 10.1523/JNEUROSCI.1399-10.2011; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; Lipsky RH, 2007, ANN NY ACAD SCI, V1122, P130, DOI 10.1196/annals.1403.009; MERLIO JP, 1993, NEURON, V10, P151, DOI 10.1016/0896-6273(93)90307-D; Michaelsen K, 2010, EUR J NEUROSCI, V32, P1854, DOI 10.1111/j.1460-9568.2010.07460.x; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MUDO G, 1993, NEUROSCIENCE, V57, P901, DOI 10.1016/0306-4522(93)90036-F; Naumann T, 2002, J NEUROSCI, V22, P2409, DOI 10.1523/JNEUROSCI.22-07-02409.2002; Oderfeld-Nowak B, 2003, NEUROSCIENCE, V120, P31, DOI 10.1016/S0306-4522(03)00289-6; Plantman S, 2012, J NEUROTRAUM, V29, P1219, DOI 10.1089/neu.2011.2182; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Rampon C, 2000, P NATL ACAD SCI USA, V97, P12880, DOI 10.1073/pnas.97.23.12880; RISLING M, 1992, J NEUROCYTOL, V21, P79, DOI 10.1007/BF01189007; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; Rostami E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027389; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Schallert T, 2000, J CEREBR BLOOD F MET, V20, P1513, DOI 10.1097/00004647-200011000-00001; Shulga A, 2012, J NEUROSCI, V32, P1757, DOI 10.1523/JNEUROSCI.3282-11.2012; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; TANIUCHI M, 1988, J NEUROSCI, V8, P664; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Underwood CK, 2008, INT J BIOCHEM CELL B, V40, P1664, DOI 10.1016/j.biocel.2007.06.010; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Yacoubian TA, 2000, NAT NEUROSCI, V3, P342; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Zaccaro MC, 2001, J BIOL CHEM, V276, P31023, DOI 10.1074/jbc.M104630200	62	40	43	0	24	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 13	2014	1542						195	205		10.1016/j.brainres.2013.10.047			11	Neurosciences	Neurosciences & Neurology	299UF	WOS:000330420500019	24192075				2021-06-18	
J	Conley, KM; Bolin, DJ; Carek, PJ; Konin, JG; Neal, TL; Violette, D				Conley, Kevin M.; Bolin, Delmas J.; Carek, Peter J.; Konin, Jeff G.; Neal, Timothy L.; Violette, Danielle			National Athletic Trainers' Association Position Statement: Preparticipation Physical Examinations and Disqualifying Conditions	JOURNAL OF ATHLETIC TRAINING			English	Article						medical history; family history; sudden cardiac death; concussion; sickle cell trait; diabetes; heat illness; hydration	SICKLE-CELL TRAIT; SUDDEN CARDIAC DEATH; EXERCISE-INDUCED ASTHMA; HIGH-SCHOOL; HYPERTROPHIC CARDIOMYOPATHY; CARDIOVASCULAR-DISEASE; UNITED-STATES; INDUCED BRONCHOSPASM; COLLISION ACTIVITIES; COMPETITIVE ATHLETE	Objective: To present athletic trainers with recommendations for the content and administration of the preparticipation physical examination (PPE) as well as considerations for determining safe participation in sports and identifying disqualifying conditions. Background: Preparticipation physical examinations have been used routinely for nearly 40 years. However, considerable debate exists as to their efficacy due to the lack of standardization in the process and the lack of conformity in the information that is gathered. With the continuing rise in sports participation at all levels and the growing number of reported cases of sudden death in organized athletics, the sports medicine community should consider adopting a standardized process for conducting the PPE to protect all parties. Recommendations: Recommendations are provided to equip the sports medicine community with the tools necessary to conduct the PPE as effectively and efficiently as possible using available scientific evidence and best practices. In addition, the recommendations will help clinicians identify those conditions that may threaten the health and safety of participants in organized sports, may require further evaluation and intervention, or may result in potential disqualification.	[Conley, Kevin M.] Univ Pittsburgh, Pittsburgh, PA 15260 USA; [Carek, Peter J.] Med Univ S Carolina, Charleston, SC USA; [Konin, Jeff G.] Univ S Florida, Tampa, FL USA; [Neal, Timothy L.] Syracuse Univ, Syracuse, NY 13244 USA; [Violette, Danielle] Washington Hosp, Dept Orthoped & Neurosci, Washington, PA 15301 USA	Conley, KM (corresponding author), Natl Athlet Trainers Assoc, Dept Commun, 1620 Valwood Pkway,Suite 115, Carrollton, TX 75006 USA.		Asad, Saeed A/E-6236-2019; Asad, Saeed A/J-9142-2017	Asad, Saeed A/0000-0002-9242-3806; Asad, Saeed A/0000-0002-9242-3806			American Academy of Family Physicians American Academy of Pediatrics American College of Sports Medicine American Medical Society for Sports Medicine American Orthopaedic Society for Sports Medicine American Osteopathic Academy of Sports Medicine, 2010, PPE PREP PHYS EV; ANDERSON SD, 1971, THORAX, V26, P396, DOI 10.1136/thx.26.4.396; [Anonymous], 2000, Am J Sports Med, V28, P440; [Anonymous], 2000, MED SCI SPORT EXER, V32, P877; [Anonymous], 1994, Arch Pediatr Adolesc Med, V148, P93; [Anonymous], 2010 11 HIGH SCH ATH; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Basavarajaiah S, 2008, J AM COLL CARDIOL, V51, P1033, DOI 10.1016/j.jacc.2007.10.055; Basso C, 2000, J AM COLL CARDIOL, V35, P1493, DOI 10.1016/S0735-1097(00)00566-0; Beckerman J, 2004, CLIN J SPORT MED, V14, P127, DOI 10.1097/00042752-200405000-00004; Bickley LS, 2003, BATES GUIDE PHYS EXA; Blader JC, 2011, ARCH GEN PSYCHIAT, V68, P1276, DOI 10.1001/archgenpsychiatry.2011.84; Bonci CM, 2008, J ATHL TRAINING, V43, P80, DOI 10.4085/1062-6050-43.1.80; Boyajian-O'Neill L, 2004, PHYSICIAN SPORTSMED, V32, P29, DOI 10.1080/00913847.2004.11440756; BRUGADA P, 1992, J AM COLL CARDIOL, V20, P1391, DOI 10.1016/0735-1097(92)90253-J; Buyukyazi G, 2005, J SPORT MED PHYS FIT, V45, P112; Cantu RC, 1999, PHYSICIAN SPORTSMED, V27, P35, DOI 10.3810/psm.1999.08.945; Carek P J, 2001, J Med Liban, V49, P292; Carek PJ, 2003, J FAM PRACTICE, V52, P127; Carek PJ, 1999, CLIN J SPORT MED, V9, P124, DOI 10.1097/00042752-199907000-00002; Carek PJ, 1999, ARCH FAM MED, V8, P307, DOI 10.1001/archfami.8.4.307; Carek PJ, 2007, EVIDENCE BASED SPORT; Carroll J.F.X., 2001, ALCOHOL TREAT Q, V19, P33; Casa DJ, 2000, J ATHL TRAINING, V35, P212; Casa DJ, 2009, J ATHL TRAINING, V44, P332, DOI 10.4085/1062-6050-44.3.332; Chizner MA, 2002, DM-DIS MON, V48, P7, DOI 10.1067/mda.2002.115501; Connes P, 2008, SPORTS MED, V38, P931, DOI 10.2165/00007256-200838110-00004; Corrado D, 2003, J AM COLL CARDIOL, V42, P1959, DOI 10.1016/j.jacc.2003.03.002; Corrado D, 1998, NEW ENGL J MED, V339, P364, DOI 10.1056/NEJM199808063390602; Corrado D, 2006, JAMA-J AM MED ASSOC, V296, P1593, DOI 10.1001/jama.296.13.1593; Corrigan B, 2003, CLIN J SPORT MED, V13, P33, DOI 10.1097/00042752-200301000-00007; Cowell BS, 2003, INT J SPORT NUTR EXE, V13, P277, DOI 10.1123/ijsnem.13.3.277; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Crawford M H, 1979, Adv Intern Med, V24, P311; Di Santolo M, 2008, EUR J APPL PHYSIOL, V102, P703, DOI 10.1007/s00421-007-0647-9; DODGE WF, 1976, J PEDIATR-US, V88, P327, DOI 10.1016/S0022-3476(76)81012-8; Ebell MH, 2004, AM FAM PHYSICIAN, V69, P548; Eberman LE, 2011, J ATHL TRAINING, V46, P176, DOI 10.4085/1062-6050-46.2.176; Eberman LE, 2009, ATHLET THER TODAY, V14, P4, DOI 10.1123/att.14.4.4; Eisenmann JC, 2002, SPORTS MED, V32, P297, DOI 10.2165/00007256-200232050-00002; Eliakim A, 2002, J SPORT MED PHYS FIT, V42, P250; EPSTEIN SE, 1986, J AM COLL CARDIOL, V7, P220, DOI 10.1016/S0735-1097(86)80285-6; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Fallon KE, 2004, CLIN J SPORT MED, V14, P145, DOI 10.1097/00042752-200405000-00007; Fallon KE, 2008, J SCI MED SPORT, V11, P329, DOI 10.1016/j.jsams.2007.02.017; Feinstein RA, 1996, CLIN J SPORT MED, V6, P119; FRANCIS CK, 1980, CATHETER CARDIO DIAG, V6, P73, DOI 10.1002/ccd.1810060109; Fuller CM, 2000, MED SCI SPORT EXER, V32, P887; Fuller CM, 1997, MED SCI SPORT EXER, V29, P1131, DOI 10.1097/00005768-199709000-00003; GARRICK JG, 1980, PEDIATRICS, V66, P803; Garrick JG, 2004, CLIN J SPORT MED, V14, P123, DOI 10.1097/00042752-200405000-00003; Giese EA, 2007, AM FAM PHYSICIAN, V75, P1008; Glover DW, 1998, JAMA-J AM MED ASSOC, V279, P1817, DOI 10.1001/jama.279.22.1817; GOLDBERG B, 1980, PEDIATRICS, V66, P736; GOMEZ JE, 1993, AM J DIS CHILD, V147, P1109, DOI 10.1001/archpedi.1993.02160340095022; Grafe MW, 1997, CLIN SPORT MED, V16, P569, DOI 10.1016/S0278-5919(05)70043-0; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hedreville M, 2009, MED SCI SPORT EXER, V41, P13, DOI 10.1249/MSS.0b013e31818313d0; Holzer K, 2002, J ALLERGY CLIN IMMUN, V110, P374, DOI 10.1067/mai.2002.127784; Huffman EA, 2008, J ATHL TRAINING, V43, P624, DOI 10.4085/1062-6050-43.6.624; HUSTON TP, 1985, NEW ENGL J MED, V313, P24, DOI 10.1056/NEJM198507043130106; Jimenez CC, 2007, J ATHL TRAINING, V42, P536; Joy EA, 2004, CLIN J SPORT MED, V14, P183, DOI 10.1097/00042752-200405000-00012; KARK JA, 1987, NEW ENGL J MED, V317, P781, DOI 10.1056/NEJM198709243171301; KAWABORI I, 1976, J ALLERGY CLIN IMMUN, V58, P447, DOI 10.1016/0091-6749(76)90188-3; Kerle KK, 1996, AM FAM PHYSICIAN, V54, P237; Komatsu Y, 2009, RESPIROLOGY, V14, P217, DOI 10.1111/j.1440-1843.2008.01413.x; Kurowski K, 2000, AM FAM PHYSICIAN, V61, P2683; Le Gallais D, 2007, J APPL PHYSIOL, V103, P2137, DOI 10.1152/japplphysiol.00338.2007; LEWIS JF, 1989, AM J CARDIOL, V64, P1029, DOI 10.1016/0002-9149(89)90802-3; Lippi G, 2006, CLIN CHEM LAB MED, V44, P322, DOI 10.1515/CCLM.2006.056; Lively MW, 1999, CLIN J SPORT MED, V9, P3, DOI 10.1097/00042752-199901000-00002; Lombardo J A, 2001, Clin Cornerstone, V3, P10, DOI 10.1016/S1098-3597(01)90066-3; LOMBARDO JA, 1984, PRIMARY CARE, V11, P3; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Maron BJ, 2007, CARDIOL CLIN, V25, P399, DOI 10.1016/j.ccl.2007.07.006; Maron BJ, 2007, CIRCULATION, V115, P1643, DOI 10.1161/CIRCULATIONAHA.107.181423; Maron BJ, 2009, CIRCULATION, V119, P1085, DOI 10.1161/CIRCULATIONAHA.108.804617; Maron Barry J., 2003, Journal of the American College of Cardiology, V42, P1687, DOI 10.1016/S0735-1097(03)00941-0; Maron BJ, 2003, NEW ENGL J MED, V349, P1064, DOI 10.1056/NEJMra022783; Maron BJ, 2005, J AM COLL CARDIOL, V45, P1318, DOI 10.1016/j.jacc.2005.02.006; MARON BJ, 1987, J AM COLL CARDIOL, V10, P1214, DOI 10.1016/S0735-1097(87)80121-3; Maron BJ, 1998, NEW ENGL J MED, V339, P1632, DOI 10.1056/NEJM199811263392211; Maron BJ, 1998, J AM COLL CARDIOL, V32, P1881, DOI 10.1016/S0735-1097(98)00491-4; Maron BJ, 2003, J AM COLL CARDIOL, V41, P974, DOI 10.1016/S0735-1097(02)02976-5; MARON BJ, 1986, J AM COLL CARDIOL, V7, P204, DOI 10.1016/S0735-1097(86)80283-2; MARON BJ, 1994, J AM COLL CARDIOL, V24, P880, DOI 10.1016/0735-1097(94)90844-3; Maron BJ, 1996, CIRCULATION, V94, P850, DOI 10.1161/01.CIR.94.4.850; MARON BJ, 1995, CIRCULATION, V91, P1596, DOI 10.1161/01.CIR.91.5.1596; MARON BJ, 1980, CIRCULATION, V62, P218, DOI 10.1161/01.CIR.62.2.218; MARON BJ, 1994, AM J CARDIOL, V73, P1098, DOI 10.1016/0002-9149(94)90290-9; Maron BJ, 1996, JAMA-J AM MED ASSOC, V276, P199, DOI 10.1001/jama.276.3.199; Matz SO, 2004, AM J SPORT MED, V32, P608, DOI 10.1177/0363546503262172; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Merikangas KR, 2010, J AM ACAD CHILD PSY, V49, P980, DOI 10.1016/j.jaac.2010.05.017; Metzl JD, 2000, CLIN SPORT MED, V19, P577, DOI 10.1016/S0278-5919(05)70227-1; Miller MG, 2005, J ATHL TRAINING, V40, P224; Mitchell JH, 2005, J AM COLL CARDIOL, V45, P1364, DOI 10.1016/j.jacc.2005.02.015; Mitten MJ, 2005, J AM COLL CARDIOL, V45, P1373, DOI 10.1016/j.jacc.2005.02.019; Moulton MA, 1997, J ATHL TRAINING, V32, P148; Murphy RLH, 2008, RESP CARE, V53, P355; Myers A, 1998, PRIMARY CARE, V25, P225, DOI 10.1016/S0095-4543(05)70334-1; National Collegiate Athletic Association, 2011, 2011 12 NCAA SPORTS; National Collegiate Athletic Association, 2012, NCAA SPORTS SPONS PA; Nichols A W, 1995, Hawaii Med J, V54, P434; Parsons JP, 2007, MED SCI SPORT EXER, V39, P1487, DOI 10.1249/mss.0b013e3180986e45; Pelliccia A, 2000, CIRCULATION, V102, P278; PELLICCIA A, 1995, AM J CARDIOL, V75, P827, DOI 10.1016/S0002-9149(99)80421-4; Pelliccia A, 2008, NEW ENGL J MED, V358, P152, DOI 10.1056/NEJMoa060781; Pigozzi F, 2008, CLIN SPORT MED, V27, P153, DOI 10.1016/j.csm.2007.09.004; RICE SG, 1985, ANN ALLERGY, V55, P790; Rice SG, 2008, PEDIATRICS, V121, P841, DOI 10.1542/peds.2008-0080; RIFAT SF, 1995, J FAM PRACTICE, V41, P42; RISSER WL, 1985, J SCHOOL HEALTH, V55, P270, DOI 10.1111/j.1746-1561.1985.tb04140.x; RISSER WL, 1985, TEX MED, V81, P35; Rodriguez JO, 2003, AM FAM PHYSICIAN, V67, P1481; Roh JLC, 2000, J ATHL TRAINING, V35, P458; Rundell KW, 2008, J ALLERGY CLIN IMMUN, V122, P238, DOI 10.1016/j.jaci.2008.06.014; Rundell KW, 2001, MED SCI SPORT EXER, V33, P208; RUPP NT, 1992, AM J DIS CHILD, V146, P941, DOI 10.1001/archpedi.1992.02160200063028; Sharma S, 1999, BRIT J SPORT MED, V33, P319, DOI 10.1136/bjsm.33.5.319; Shaskey DJ, 2000, SPORTS MED, V29, P27, DOI 10.2165/00007256-200029010-00003; Smith J, 1998, MAYO CLIN PROC, V73, P419; Substance Abuse and Mental Health Services Administration, 2010, RES 2009 NAT SURV DR; THIENE G, 1988, NEW ENGL J MED, V318, P129, DOI 10.1056/NEJM198801213180301; Thompson PD, 2006, JAMA-J AM MED ASSOC, V296, P1648, DOI 10.1001/jama.296.13.1648; Torg JS, 1997, CLIN J SPORT MED, V7, P273, DOI 10.1097/00042752-199710000-00005; TORG JS, 1993, AM J SPORT MED, V21, P640, DOI 10.1177/036354659302100502; U.S. Preventive Services Task Force, 1996, GUID CLIN PREV SERV; Van Thuyne W, 2006, NUTR RES REV, V19, P147, DOI 10.1079/NRR2006122; VANCAMP SP, 1995, MED SCI SPORT EXER, V27, P641; WEILER JM, 1986, CHEST, V90, P23, DOI 10.1378/chest.90.1.23; Wingfield K, 2004, CLIN J SPORT MED, V14, P109, DOI 10.1097/00042752-200405000-00002; Yen KL, 2000, PEDIATR EMERG CARE, V16, P215, DOI 10.1097/00006565-200006000-00021; Zeppilli P, 1990, CARDIOLOGIA SPORT, P269	137	40	40	0	11	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JAN-FEB	2014	49	1					102	120		10.4085/1062-6050-48.6.05			19	Sport Sciences	Sport Sciences	AQ3LX	WOS:000342696500015	24499039	Green Published			2021-06-18	
J	Dinkel, J; Drier, A; Khalilzadeh, O; Perlbarg, V; Czernecki, V; Gupta, R; Gomas, F; Sanchez, P; Dormont, D; Galanaud, D; Stevens, RD; Puybasset, L				Dinkel, J.; Drier, A.; Khalilzadeh, O.; Perlbarg, V.; Czernecki, V.; Gupta, R.; Gomas, F.; Sanchez, P.; Dormont, D.; Galanaud, D.; Stevens, R. D.; Puybasset, L.		NICER Neuro Imaging Coma Emergence	Long-Term White Matter Changes after Severe Traumatic Brain Injury: A 5-Year Prospective	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							AXONAL INJURY; SPATIAL STATISTICS; DIFFUSION; NEUROPLASTICITY; MODERATE; TIME	The authors used DTI to study posttraumatic white matter changes over a 5-year period. Thirteen patients with severe injuries acutely showed significant fractional anisotropy decreases in the corpus callosum and corona radiata when compared with controls. These abnormalities progressed at 2 years and then remained stable until 5 years. The DTI abnormalities correlated with sequelae such as amnesia, aphasia, and dyspraxia. BACKGROUND AND PURPOSE: Extensive white matter damage has been documented in patients with severe traumatic brain injury, yet how this damage evolves in the long term is not well understood. We used DTI to study white matter changes at 5 years after traumatic brain injury. MATERIALS AND METHODS: There were 8 healthy control participants and 13 patients with severe traumatic brain injury who were enrolled in a prospective observational study, which included clinical assessment and brain MR imaging in the acute setting (< 6 weeks) and 2 years and 5 years after injury. Only subjects with mild to moderate disability or no disability at 1 year were included in this analysis. DTI parameters were measured in 20 different brain regions and were normalized to values obtained in an age-matched control group. RESULTS: In the acute setting, fractional anisotropy was significantly lower in the genu and body of the corpus callosum and in the bilateral corona radiata in patients compared with control participants, whereas radial diffusivity was significantly (P < .05) higher in these tracts. At 2 years, fractional anisotropy in these tracts had further decreased and radial diffusivity had increased. No significant changes were detected between 2 and 5 years after injury. The baseline radial diffusivity and fractional anisotropy values in the anterior aspect of the brain stem, genu and body of the corpus callosum, and the right and left corona radiata were significantly (P < .05) associated with neurocognitive sequelae (including amnesia, aphasia, and dyspraxia) at year 5. CONCLUSIONS: DTI changes in major white matter tracts persist up to 5 years after severe traumatic brain injury and are most pronounced in the corpus callosum and corona radiata. Limited structural change is noted in the interval between 2 and 5 years.	[Dinkel, J.; Khalilzadeh, O.; Gupta, R.] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Dinkel, J.] Univ Heidelberg Hosp, Dept Radiol, Heidelberg, Germany; [Drier, A.; Dormont, D.; Galanaud, D.] Grp Hosp Pitie Salpetriere, AP HP, Dept Neuroradiol, Paris, France; [Czernecki, V.] Grp Hosp Pitie Salpetriere, AP HP, Dept Neurol, Paris, France; [Sanchez, P.; Puybasset, L.] Grp Hosp Pitie Salpetriere, AP HP, Dept Anesthesiol & Intens Care, Paris, France; [Perlbarg, V.] Univ Paris 06, INSERM, UMRS 678, F-75013 Paris, France; [Czernecki, V.] Univ Paris 06, INSERM, CRICM UMR S975, F-75013 Paris, France; [Gomas, F.] Louis Mourier Hosp, Dept Anesthesiol & Intens Care, Colombes, France; [Stevens, R. D.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol Crit Care Med, Div Neurosci Crit Care, Baltimore, MD USA	Puybasset, L (corresponding author), Univ Paris 06, Grp Hosp Pitie Salpetriere, Dept Anesthesie Reanimat, 47-83 Bd Hop, F-75013 Paris, France.	louis.puybasset@psl.aphp.fr			French Ministry of Health [P051061 [2005]]; Assistance Publique-Hopitaux de Paris	This study was funded by a grant from the French Ministry of Health (Projet Hospitalier de Recherche Clinique registration # P051061 [2005]) and from departmental funds from the Assistance Publique-Hopitaux de Paris.	Akpinar E, 2007, J COMPUT ASSIST TOMO, V31, P657, DOI 10.1097/RCT.0b013e318033df1a; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Betz J, 2012, J NEUROTRAUM, V29, P1292, DOI 10.1089/neu.2011.2215; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Farbota KD, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00160; Galanaud D, 2012, ANESTHESIOLOGY, V117, P1300, DOI 10.1097/ALN.0b013e3182755558; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Luyt CE, 2012, ANESTHESIOLOGY, V117, P1311, DOI 10.1097/ALN.0b013e318275148c; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mori S., 2005, MRI ATLAS HUMAN WHIT; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Newcombe V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019214; Parvizi J, 2003, BRAIN, V126, P1524, DOI 10.1093/brain/awg166; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Wada T, 2012, AM J NEURORADIOL, V33, P2117, DOI 10.3174/ajnr.A3141; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Young JA, 2011, AM J THER, V18, P70, DOI 10.1097/MJT.0b013e3181e0f1a4; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	30	40	41	0	5	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	JAN	2014	35	1					23	29		10.3174/ajnr.A3616			7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	AD9ER	WOS:000333568100007	23846796	Green Published, Other Gold			2021-06-18	
J	Moore, RD; Hillman, CH; Broglio, SP				Moore, Robert D.; Hillman, Charles H.; Broglio, Steven P.			The Persistent Influence of Concussive Injuries on Cognitive Control and Neuroelectric Function	JOURNAL OF ATHLETIC TRAINING			English	Article						concussions; inhibition; mental flexibility; attention; P3; N2	TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL FUNCTION; INTERNATIONAL-CONFERENCE; RESPONSE-INHIBITION; INTEGRATIVE THEORY; TASK; MEMORY; SPORT; ABNORMALITIES; INTERFERENCE	Context: Increasing attention is being paid to the deleterious effects of sport-related concussion on cognitive and brain health. Objective: To evaluate the influence of concussion incurred during early life on the cognitive control and neuroelectric function of young adults. Design: Cross-sectional study. Setting: Research laboratory. Patients or Other Participants: Forty young adults were separated into groups according to concussive history (0 or 1+). Participants incurred all injuries during sport and recreation before the age of 18 years and were an average of 7.1 +/- 4.0 years from injury at the time of the study. Intervention(s): All participants completed a 3-stimulus oddball task, a numeric switch task, and a modified flanker task during which event-related potentials and behavioral measures were collected. Main Outcome Measure(s): Reaction time, response accuracy, and electroencephalographic activity. Results: Compared with control participants, the concussion group exhibited decreased P3 amplitude during target detection within the oddball task and during the heterogeneous condition of the switch task. The concussion group also displayed increased N2 amplitude during the heterogeneous version of the switch task. Concussion history was associated with response accuracy during the flanker task. Conclusions: People with a history of concussion may demonstrate persistent decrements in neurocognitive function, as evidenced by decreased response accuracy, deficits in the allocation of attentional resources, and increased stimulus-response conflict during tasks requiring variable amounts of cognitive control. Neuroelectric measures of cognitive control may be uniquely sensitive to the persistent and selective decrements of concussion.	[Moore, Robert D.; Hillman, Charles H.] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA; [Broglio, Steven P.] Univ Michigan, Sch Kinesiol, Ann Arbor, MI 48109 USA	Broglio, SP (corresponding author), ATC, 401 Washtenaw Ave, Ann Arbor, MI 48109 USA.	broglio@umich.edu	Meijer, Anna/K-5118-2016; Hillman, Charles/AAD-4828-2019	Hillman, Charles/0000-0002-3722-5612	National Athletic Trainers' Association Research & Education Foundation	We thank the National Athletic Trainers' Association Research & Education Foundation for supporting this project.	Allport A, 1999, ATTENTION SPACE ACTI, P273; Aron AR, 2007, NEUROSCIENTIST, V13, P214, DOI 10.1177/1073858407299288; Aron AR, 2006, J NEUROSCI, V26, P2424, DOI 10.1523/JNEUROSCI.4682-05.2006; Aron AR, 2004, BRAIN, V127, P1561, DOI 10.1093/brain/awh169; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Braver TS, 2003, NEURON, V39, P713, DOI 10.1016/S0896-6273(03)00466-5; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Bush G, 2006, NAT PROTOC, V1, P308, DOI 10.1038/nprot.2006.48; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Clark L, 2007, BIOL PSYCHIAT, V61, P1395, DOI 10.1016/j.biopsych.2006.07.020; Clayson PE, 2011, NEUROPSYCHOLOGIA, V49, P1953, DOI 10.1016/j.neuropsychologia.2011.03.023; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Davidson MC, 2006, NEUROPSYCHOLOGIA, V44, P2037, DOI 10.1016/j.neuropsychologia.2006.02.006; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Diamond A., 2001, PRINCIPLES FRONTAL L, P466; DiGirolamo GJ, 2001, NEUROREPORT, V12, P2065, DOI 10.1097/00001756-200107030-00054; Duncan CC, 2005, INT J PSYCHOPHYSIOL, V58, P133, DOI 10.1016/j.ijpsycho.2005.05.011; DUNCANJOHNSON CC, 1981, PSYCHOPHYSIOLOGY, V18, P207; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Folstein JR, 2008, PSYCHOPHYSIOLOGY, V45, P152, DOI 10.1111/j.1469-8986.2007.00602.x; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gennarelli T. A., 1998, SEM CLIN NEUR, V3, P160; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Grunwald T, 1998, P NATL ACAD SCI USA, V95, P3193, DOI 10.1073/pnas.95.6.3193; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Hecht S, 2005, CLIN J SPORT MED, V15, P281, DOI DOI 10.1097/01.jsm.0000172669.85640.05; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hessen E, 2006, SCAND J PSYCHOL, V47, P245, DOI 10.1111/j.1467-9450.2006.00514.x; Hillman CH, 2006, HEALTH PSYCHOL, V25, P678, DOI 10.1037/0278-6133.25.6.678; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Kiesel A, 2010, PSYCHOL BULL, V136, P849, DOI 10.1037/a0019842; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Knight RT, 1996, NATURE, V383, P256, DOI 10.1038/383256a0; Koch I, 2010, PSYCHON B REV, V17, P1, DOI 10.3758/PBR.17.1.1; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Kumar S, 2009, J NEUROTRAUM, V26, P665, DOI [10.1089/neu.2008.0644, 10.1089/neu.2008-0644]; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Larson MJ, 2011, INT J PSYCHOPHYSIOL, V82, P69, DOI 10.1016/j.ijpsycho.2011.02.018; Livingston SC, 2010, BRAIN INJURY, V24, P904, DOI 10.3109/02699051003789245; Luna B, 2009, ADV CHILD DEV BEHAV, V37, P233, DOI 10.1016/S0065-2407(09)03706-9; Mansfield KL, 2012, PSYCHOPHYSIOLOGY, V49, P756, DOI 10.1111/j.1469-8986.2012.01368.x; Mayr U, 2006, J COGNITIVE NEUROSCI, V18, P14, DOI 10.1162/089892906775250085; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Monsell S, 2003, TRENDS COGN SCI, V7, P134, DOI 10.1016/S1364-6613(03)00028-7; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; National Center for Injury Prevention and Control, 2002, INJ FACT BOOK 2001 2; Nieuwenhuis S, 2003, COGN AFFECT BEHAV NE, V3, P17, DOI 10.3758/CABN.3.1.17; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; NORMAN DA, 1986, CONSCIOUSNESS SELF R, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; Pelczar M, 1997, Neurol Neurochir Pol, V31, P989; Polich J., 2003, DETECTION CHANGE EVE, P83; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Polich J, 2006, INT J PSYCHOPHYSIOL, V60, P172, DOI 10.1016/j.ijpsycho.2005.12.012; Pontifex MB, 2007, CLIN NEUROPHYSIOL, V118, P570, DOI 10.1016/j.clinph.2006.09.029; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Register-Mihalik JK, 2009, SPORTS HEALTH, V1, P61, DOI 10.1177/1941738108325920; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Soltani Maryam, 2000, Critical Reviews in Neurobiology, V14, P199; Spencer KM, 1999, PSYCHOPHYSIOLOGY, V36, P364, DOI 10.1017/S0048577299970749; Stulemeijer M, 2010, J NEUROTRAUM, V27, P1585, DOI 10.1089/neu.2010.1298; Swainson R, 2003, J COGNITIVE NEUROSCI, V15, P785, DOI 10.1162/089892903322370717; Tallus J, 2012, ACTA NEUROL SCAND, V126, P178, DOI 10.1111/j.1600-0404.2011.01623.x; Tay SY, 2010, J NEUROTRAUM, V27, P77, DOI 10.1089/neu.2009.1074; Theriault M, 2009, BRAIN INJURY, V23, P899, DOI 10.1080/02699050903283189; Tremblay S, 2011, J NEUROTRAUM, V28, P493, DOI 10.1089/neu.2010.1615; Verleger R, 1997, PSYCHOPHYSIOLOGY, V34, P131, DOI 10.1111/j.1469-8986.1997.tb02125.x; Witt ST, 2010, BRAIN IMAGING BEHAV, V4, P232, DOI 10.1007/s11682-010-9102-3	85	40	40	0	20	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JAN-FEB	2014	49	1					24	35		10.4085/1062-6050-49.1.01			12	Sport Sciences	Sport Sciences	AQ3LX	WOS:000342696500004	24377962	Bronze, Green Published			2021-06-18	
J	Stone, MC; Albertson, RM; Chen, L; Rolls, MM				Stone, Michelle C.; Albertson, Richard M.; Chen, Li; Rolls, Melissa M.			Dendrite Injury Triggers DLK-Independent Regeneration	CELL REPORTS			English	Article							WALLERIAN DEGENERATION; CAENORHABDITIS-ELEGANS; AXON REGENERATION; DROSOPHILA; NEURONS; KINASE; ORIENTATION; MECHANISMS; POLARITY; MICROTUBULES	Axon injury triggers regeneration through activation of a conserved kinase cascade, which includes the dual leucine zipper kinase (DLK). Although dendrites are damaged during stroke, traumatic brain injury, and seizure, it is not known whether mature neurons monitor dendrite injury and initiate regeneration. We probed the response to dendrite damage using model Drosophila neurons. Two larval neuron types regrew dendrites in distinct ways after all dendrites were removed. Dendrite regeneration was also triggered by injury in adults. Next, we tested whether dendrite injury was initiated with the same machinery as axon injury. Surprisingly, DLK, JNK, and fos were dispensable for dendrite regeneration. Moreover, this MAP kinase pathway was not activated by injury to dendrites. Thus, neurons respond to dendrite damage and initiate regeneration without using the conserved DLK cascade that triggers axon regeneration.	[Stone, Michelle C.; Albertson, Richard M.; Chen, Li; Rolls, Melissa M.] Penn State Univ, University Pk, PA 16802 USA	Rolls, MM (corresponding author), Penn State Univ, University Pk, PA 16802 USA.	mur22@psu.edu	Rolls, Melissa/G-6402-2014	Rolls, Melissa/0000-0002-5021-4360; Stone, Michelle/0000-0001-6215-7933	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 GM085115]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM085115] Funding Source: NIH RePORTER	We are very grateful to the Bloomington Drosophila Stock Center, the Vienna Drosophila RNAi Center, and FlyTrap; all are invaluable resources. Catherine Collins, Wesley Grueber, and Dirk Bohmann generously provided us with Drosophila stocks. Tadashi Uemura provided helpful information for imaging da neurons in adults. Michelle Nguyen kindly helped collect flies and embryos. This work was funded by the NIH (R01 GM085115), and M.M.R. was a Pew Scholar in the Biomedical Sciences.	Abe N, 2008, CURR OPIN NEUROBIOL, V18, P276, DOI 10.1016/j.conb.2008.06.005; Baas PW, 2011, DEV NEUROBIOL, V71, P403, DOI 10.1002/dneu.20818; BAAS PW, 1988, P NATL ACAD SCI USA, V85, P8335, DOI 10.1073/pnas.85.21.8335; Caunt CJ, 2013, FEBS J, V280, P489, DOI 10.1111/j.1742-4658.2012.08716.x; Cho Y, 2012, EMBO J, V31, P3063, DOI 10.1038/emboj.2012.160; Coleman MP, 2010, ANNU REV NEUROSCI, V33, P245, DOI 10.1146/annurev-neuro-060909-153248; Collins CA, 2006, NEURON, V51, P57, DOI 10.1016/j.neuron.2006.05.026; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Ghosh-Roy A, 2010, J NEUROSCI, V30, P3175, DOI 10.1523/JNEUROSCI.5464-09.2010; Gomis-Ruth S, 2008, CURR BIOL, V18, P992, DOI 10.1016/j.cub.2008.06.026; Goodwin PR, 2012, J NEUROSCI, V32, P8158, DOI 10.1523/JNEUROSCI.0251-12.2012; Greenwood SM, 2007, NEUROPHARMACOLOGY, V53, P891, DOI 10.1016/j.neuropharm.2007.10.003; Grueber WB, 2002, DEVELOPMENT, V129, P2867; Huebner EA, 2009, RESULTS PROBL CELL D, V48, P339, DOI 10.1007/400_2009_19; Hughes CL, 2007, MOL CELL NEUROSCI, V35, P383, DOI 10.1016/j.mcn.2007.04.001; Hwang RY, 2007, CURR BIOL, V17, P2105, DOI 10.1016/j.cub.2007.11.029; Kim ME, 2012, NEURON, V73, P79, DOI 10.1016/j.neuron.2011.10.033; Liu K, 2011, ANNU REV NEUROSCI, V34, P131, DOI 10.1146/annurev-neuro-061010-113723; Morin X, 2001, P NATL ACAD SCI USA, V98, P15050, DOI 10.1073/pnas.261408198; Murphy TH, 2008, J NEUROSCI, V28, P1756, DOI 10.1523/JNEUROSCI.5128-07.2008; Nix P, 2011, P NATL ACAD SCI USA, V108, P10738, DOI 10.1073/pnas.1104830108; Nudo RJ, 2006, CURR OPIN NEUROBIOL, V16, P638, DOI 10.1016/j.conb.2006.10.004; O'Brien GS, 2009, CURR BIOL, V19, P2086, DOI 10.1016/j.cub.2009.10.051; Rishal I, 2010, EXP NEUROL, V223, P5, DOI 10.1016/j.expneurol.2009.08.010; Risher WC, 2010, J NEUROSCI, V30, P9859, DOI 10.1523/JNEUROSCI.1917-10.2010; Rolls MM, 2007, NEURAL DEV, V2, DOI 10.1186/1749-8104-2-7; Rolls MM, 2011, DEV NEUROBIOL, V71, P419, DOI 10.1002/dneu.20836; Satoh D, 2008, NAT CELL BIOL, V10, P1164, DOI 10.1038/ncb1776; Shimono K, 2009, NEURAL DEV, V4, DOI 10.1186/1749-8104-4-37; Shin JE, 2012, NEURON, V74, P1015, DOI 10.1016/j.neuron.2012.04.028; Song YQ, 2012, GENE DEV, V26, P1612, DOI 10.1101/gad.193243.112; Stone MC, 2008, MOL BIOL CELL, V19, P4122, DOI 10.1091/mbc.E07-10-1079; Stone MC, 2010, MOL BIOL CELL, V21, P767, DOI 10.1091/mbc.E09-11-0967; Sugimura K, 2003, J NEUROSCI, V23, P3752; Taniguchi K, 2007, DEV BIOL, V311, P251, DOI 10.1016/j.ydbio.2007.08.048; Vargas ME, 2007, ANNU REV NEUROSCI, V30, P153, DOI 10.1146/annurev.neuro.30.051606.094354; Wang JT, 2012, J CELL BIOL, V196, P7, DOI 10.1083/jcb.201108111; Xiong X, 2010, J CELL BIOL, V191, P211, DOI 10.1083/jcb.201006039; Yan D, 2009, CELL, V138, P1005, DOI 10.1016/j.cell.2009.06.023; Zeng LH, 2007, J NEUROSCI, V27, P11604, DOI 10.1523/JNEUROSCI.0983-07.2007; Zheng Y, 2008, NAT CELL BIOL, V10, P1172, DOI 10.1038/ncb1777	41	40	39	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	2211-1247			CELL REP	Cell Reports	JAN	2014	6	2					247	253		10.1016/j.celrep.2013.12.022			7	Cell Biology	Cell Biology	AA5VD	WOS:000331166800002	24412365	DOAJ Gold, Green Accepted			2021-06-18	
J	Finnanger, TG; Skandsen, T; Andersson, S; Lydersen, S; Vik, A; Indredavik, M				Finnanger, Torun Gangaune; Skandsen, Toril; Andersson, Stein; Lydersen, Stian; Vik, Anne; Indredavik, Marit			Differentiated patterns of cognitive impairment 12 months after severe and moderate traumatic brain injury	BRAIN INJURY			English	Article						Craniocerebral trauma; deficits; executive function; longitudinal studies; memory deficits; neurobehavioural signs and symptoms; outcome assessment	CLOSED-HEAD-INJURY; RECOVERY; PERFORMANCE; SPEED; RECOMMENDATIONS; ASSOCIATION; EDUCATION; TESTS; SCALE	Objective: To assess cognitive function at 12 months after moderate and severe traumatic brain injury (TBI) separately, as well as improvement from 3 to 12 months and relationship to global outcome. Methods: Cognitive function among patients with moderate (n = 30, Glasgow Coma Scale score (GCS) 9-3) and severe traumatic brain injury (n = 20, GCS score <= 8), recruited from an unselected neurosurgical cohort, all with MRI performed in the early phase were assessed with a neuropsychological test battery and Glasgow Outcome Scale Extended. Healthy volunteers (n = 47) matched for age, gender and years of education served as controls. Results: Executive function was reduced at 12-months post-injury in patients with both moderate and severe TBI. However, motor function, processing speed and memory were reduced only among patients with severe TBI. Both patients with moderate and severe TBI improved their processing speed and visual memory. Patients with moderate TBI also improved motor function, while patients with severe TBI also improved executive function. Conclusion: Differentiating between patients with moderate and severe TBI yields a more accurate description of cognitive deficits and their improvement over time. Further, executive dysfunction and attention problems affected the ability to resume independent living and employment regardless of injury severity and age.	[Finnanger, Torun Gangaune; Lydersen, Stian; Indredavik, Marit] Norwegian Univ Sci & Technol, Reg Ctr Child & Youth Mental Hlth & Child Welfare, N-7034 Trondheim, Norway; [Finnanger, Torun Gangaune; Indredavik, Marit] Univ Trondheim Hosp, Dept Child & Adolescent Psychiat, St Olavs Hosp, Trondheim, Norway; [Skandsen, Toril] Univ Trondheim Hosp, Clin Phys Med & Rehabil, Trondheim, Norway; [Skandsen, Toril; Vik, Anne] Norwegian Univ Sci & Technol, Dept Neurosci, Fac Med, N-7034 Trondheim, Norway; [Andersson, Stein] Univ Oslo, Dept Psychol, Oslo, Norway; [Vik, Anne] Univ Trondheim Hosp, St Olavs Hosp, Dept Neurosurg, Neuroclinic, Trondheim, Norway	Finnanger, TG (corresponding author), Norwegian Univ Sci & Technol, Reg Ctr Child & Youth Mental Hlth & Child Welfare, N-7034 Trondheim, Norway.	torun.g.finnanger@ntnu.no	Skandsen, Toril/P-6767-2014	Skandsen, Toril/0000-0001-5495-9338	Norwegian ExtraFoundation for Health and Rehabilitation [2010/2/0105]; Central Norway Regional Health Authority (RHA) [47063700]; Norwegian University of Science and Technology (NTNU) [47063700]; SINTEF Unimed Innovation Research Fund [09/9603]	The authors report no conflicts of interest. This work was supported by the Norwegian ExtraFoundation for Health and Rehabilitation (first author, grant number 2010/2/0105); the Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU) (first author, grant number 47063700); and SINTEF Unimed Innovation Research Fund (first author, grant number 09/9603).	Altman DA, 2000, STAT CONFIDENCE, V2nd; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; COLOHAN ART, 1992, J NEUROTRAUM, V9, pS259; Conners C., 2000, CONNERS CONTINUOUS P; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P418, DOI 10.1016/j.apmr.2007.01.010; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Duncan CC, 2005, INT J PSYCHOPHYSIOL, V58, P133, DOI 10.1016/j.ijpsycho.2005.05.011; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Grissom R. J., 2005, EFFECT SIZES RES BRO; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lydersen S, 2009, STAT MED, V28, P1159, DOI 10.1002/sim.3531; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Matthews C, 1964, INSTRUCTION MANUAL A; Meyers J., 1995, REY COMPLEX FIGURE T; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Novack TA, 2000, BRAIN INJURY, V14, P987; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Paolo AM, 1998, ARCH CLIN NEUROPSYCH, V13, P333, DOI 10.1016/S0887-6177(97)00018-8; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P567, DOI 10.1080/13803390500434466; Rentz DM, 2004, NEUROPSYCHOLOGY, V18, P38, DOI 10.1037/0894-4105.18.1.38; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Rosner B., 2011, FUNDAMENTALS BIOSTAT; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Ruff R M, 1986, Arch Clin Neuropsychol, V1, P87, DOI 10.1016/0887-6177(86)90009-0; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Schretlen DJ, 2008, J INT NEUROPSYCH SOC, V14, P436, DOI 10.1017/S1355617708080387; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Skandsen T, 2010, ARCH PHYS MED REHAB, V91, P1904, DOI 10.1016/j.apmr.2010.08.021; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Smith A., 1982, SYMBOL DIGIT MODALIT; Solbakk AK, 2002, CLIN ELECTROENCEPHAL, V33, P102, DOI 10.1177/155005940203300306; Spitz G, 2012, NEUROPSYCHOLOGY, V26, P604, DOI 10.1037/a0029239; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Strong CAH, 2008, J CLIN EXP NEUROPSYC, V30, P885, DOI 10.1080/13803390701858224; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; Trahan DE, 1988, CONTINOUS VISUAL MEM; Wechsler C., 1997, WECHSLER ADULT INTEL; Wechsler D., 2011, WECHLSER ABBREVIATED; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wolfson D., 1993, HALSTEAD REITAN NEUR; Zwaagstra R, 1996, J CLIN EXP NEUROPSYC, V18, P383, DOI 10.1080/01688639608408995	61	40	44	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2013	27	13-14					1606	1616		10.3109/02699052.2013.831127			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	259BW	WOS:000327503400016	24102501				2021-06-18	
J	Joseph, B; Pandit, V; Sadoun, M; Larkins, CG; Kulvatunyou, N; Tang, A; Mino, M; Friese, RS; Rhee, P				Joseph, Bellal; Pandit, Viraj; Sadoun, Moutamn; Larkins, Christopher G.; Kulvatunyou, Narong; Tang, Andrew; Mino, Matthew; Friese, Randall S.; Rhee, Peter			A prospective evaluation of platelet function in patients on antiplatelet therapy with traumatic intracranial hemorrhage	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	43rd Annual Meeting of the Western-Trauma-Association	MAR 03-08, 2013	Snowmass, CO	Western Trauma Assoc		Anti-platelet therapy; platelet transfusion; traumatic brain injury; platelet function; VerifyNow platelet function assay	BRAIN-INJURY; INTRACEREBRAL HEMORRHAGE; ELDERLY-PATIENTS; TRANSFUSION; DYSFUNCTION; RESISTANCE; ASPIRIN; AGENTS; MODEL	BACKGROUND: Platelet transfusion is increasingly used in patients with traumatic intracranial hemorrhage (ICH) on aspirin therapy to minimize the progression of ICH. We hypothesized (null) that platelet transfusion in this cohort of patients does not improve platelet function. METHODS: We performed a prospective interventional trail on patients with traumatic ICH on daily high-dose (325 mg) aspirin therapy. All patients received one pack of apheresis platelets. Blood samples were collected before and 1 hour after platelet transfusion. Platelet function was assessed using Verify Now Platelet Function Assay, and a cutoff of greater than 550 aspirin reaction units was used to define functioning platelets (FP). RESULTS: Twenty-eight patients were enrolled in the study. On presentation, 79% (22 of 28) of the patients had nonfunctioning platelets (NFPs), and transfusion of platelets did not improve platelet function as 81% (18 of 22) still had NFP. Of the 22 patients, 4 converted from NFP to FP after transfusion. There was no difference in the progression of ICH (37.5% vs. 30%, p = 0.7) or neurosurgical intervention (12.5% vs. 15%, p = 0.86) between patients with FP and NFP after platelet transfusion. CONCLUSION: Administration of one pack of apheresis platelet did not improve platelet function. In our study, progression of ICH and the need for neurosurgical intervention were independent of platelet function. Further randomized clinical trials are required to assess both the dose dependence effect and role of platelet transfusion in patients on antiplatelet therapy with traumatic ICH. (Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Joseph, Bellal; Pandit, Viraj; Sadoun, Moutamn; Larkins, Christopher G.; Kulvatunyou, Narong; Tang, Andrew; Mino, Matthew; Friese, Randall S.; Rhee, Peter] Univ Arizona, Dept Surg, Div Trauma Emergency Surg Crit Care & Burns, Tucson, AZ 85724 USA	Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Crit Care & Acute Care Surg, 1501 N Campbell Ave,Rm 5411,POB 245063, Tucson, AZ 85724 USA.	bjoseph@surgery.arizona.edu					Bachelani AM, 2011, SURGERY, V150, P836, DOI 10.1016/j.surg.2011.07.059; COLEMAN J, 2004, POINT CARE, V3, P77; Ducruet AF, 2010, NEUROL RES, V32, P706, DOI 10.1179/174313209X459129; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feher G, 2009, CLIN GENET, V75, P1, DOI 10.1111/j.1399-0004.2008.01105.x; Greer DM, 2010, CNS DRUGS, V24, P1027, DOI 10.2165/11539160-000000000-00000; Joseph B, AM SURG IN PRESS; Joseph B, 2013, J TRAUMA ACUTE CARE, V75, P102, DOI 10.1097/TA.0b013e3182946667; Joseph B, 2013, J TRAUMA ACUTE CARE, V74, P248, DOI 10.1097/TA.0b013e3182788a40; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; McMillian WD, 2009, J TRAUMA, V66, P942, DOI 10.1097/TA.0b013e3181978e7b; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; Nishijima DK, 2012, J TRAUMA ACUTE CARE, V72, P1658, DOI 10.1097/TA.0b013e318256dfc5; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Sillesen M, 2013, J TRAUMA ACUTE CARE, V74, P1252, DOI 10.1097/TA.0b013e31828c7a6b; Toyoda K, 2005, NEUROLOGY, V65, P1000, DOI 10.1212/01.wnl.0000179178.37713.69; van Werkum JW, 2008, PLATELETS, V19, P479, DOI 10.1080/09537100802317918; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Washington CW, 2011, J TRAUMA, V71, P358, DOI 10.1097/TA.0b013e318220ad7e	19	40	42	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	DEC	2013	75	6					990	994		10.1097/TA.0b013e3182a96591			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	300IR	WOS:000330458100012	24256671				2021-06-18	
J	Tan, ZJ; Turner, RC; Leon, RL; Li, XL; Hongpaisan, J; Zheng, W; Logsdon, AF; Naser, ZJ; Alkon, DL; Rosen, CL; Huber, JD				Tan, Zhenjun; Turner, Ryan C.; Leon, Rachel L.; Li, Xinlan; Hongpaisan, Jarin; Zheng, Wen; Logsdon, Aric F.; Naser, Zachary J.; Alkon, Daniel L.; Rosen, Charles L.; Huber, Jason D.			Bryostatin Improves Survival and Reduces Ischemic Brain Injury in Aged Rats After Acute Ischemic Stroke	STROKE			English	Article						aging; blood-brain barrier; infarction; protein kinase C; tissue plasminogen activator	PROTEIN-KINASE-C; DISEASE TRANSGENIC MICE; ALZHEIMERS-DISEASE; POSTHYPOXIC REOXYGENATION; FUNCTIONAL RECOVERY; REPERFUSION INJURY; CEREBRAL-ISCHEMIA; ENDOTHELIAL-CELLS; PKC; ACTIVATION	Background and Purpose Bryostatin, a potent protein kinase C (PKC) activator, has demonstrated therapeutic efficacy in preclinical models of associative memory, Alzheimer disease, global ischemia, and traumatic brain injury. In this study, we tested the hypothesis that administration of bryostatin provides a therapeutic benefit in reducing brain injury and improving stroke outcome using a clinically relevant model of cerebral ischemia with tissue plasminogen activator reperfusion in aged rats. Methods Acute cerebral ischemia was produced by reversible occlusion of the right middle cerebral artery (MCAO) in 18- to 20-month-old female Sprague-Dawley rats using an autologous blood clot with tissue plasminogen activator-mediated reperfusion. Bryostatin was administered at 6 hours post-MCAO, then at 3, 6, 9, 12, 15, and 18 days after MCAO. Functional assessment was conducted at 2, 7, 14, and 21 days after MCAO. Lesion volume and hemispheric swelling/atrophy were performed at 2, 7, and 21 days post-MCAO. Histological assessment of PKC isozymes was performed at 24 hours post-MCAO. Results Bryostatin-treated rats showed improved survival post-MCAO, especially during the first 4 days. Repeated administration of bryostatin post-MCAO resulted in reduced infarct volume, hemispheric swelling/atrophy, and improved neurological function at 21 days post-MCAO. Changes in PKC expression and epsilon PKC expression in neurons were noted in bryostatin-treated rats at 24 hours post-MCAO. Conclusions Repeated bryostatin administration post-MCAO protected the brain from severe neurological injury post-MCAO. Bryostatin treatment improved survival rate, reduced lesion volume, salvaged tissue in infarcted hemisphere by reducing necrosis and peri-infarct astrogliosis, and improved functional outcome after MCAO.	[Tan, Zhenjun; Turner, Ryan C.; Leon, Rachel L.; Li, Xinlan; Naser, Zachary J.; Rosen, Charles L.] W Virginia Univ, Hlth Sci Ctr, Dept Neurosurg, Sch Med, Morgantown, WV 26506 USA; [Hongpaisan, Jarin; Zheng, Wen; Alkon, Daniel L.] W Virginia Univ, Hlth Sci Ctr, Blanchette Rockefeller Neurosci Inst, Morgantown, WV 26506 USA; [Logsdon, Aric F.; Huber, Jason D.] W Virginia Univ, Hlth Sci Ctr, Dept Basic Pharmaceut Sci, Sch Pharm, Morgantown, WV 26506 USA	Huber, JD (corresponding author), W Virginia Univ, Hlth Sci Ctr, Morgantown, WV 26506 USA.	jdhuber@hsc.wvu.edu	Leon, Rachel/AAJ-2673-2021	Turner, Ryan/0000-0001-5523-0645	National Institutes of Health's National Institute of Neurological Disorders and Stroke [RO1 NS061954]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061954] Funding Source: NIH RePORTER	This study was supported by a grant from National Institutes of Health's National Institute of Neurological Disorders and Stroke (RO1 NS061954 to J.D.H.).	Alkon DL, 2007, TRENDS PHARMACOL SCI, V28, P51, DOI 10.1016/j.tips.2006.12.002; Badan I, 2003, J CEREBR BLOOD F MET, V23, P845, DOI 10.1097/01.WCB.0000071883.63724.A7; Bright R, 2005, STROKE, V36, P2781, DOI 10.1161/01.STR.0000189996.71237.f7; Bright R, 2008, NEUROSCI LETT, V441, P120, DOI 10.1016/j.neulet.2008.05.080; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; DiNapoli VA, 2010, NEUROSCIENCE, V170, P633, DOI 10.1016/j.neuroscience.2010.07.011; DiNapoli VA, 2008, NEUROBIOL AGING, V29, P753, DOI 10.1016/j.neurobiolaging.2006.12.007; DiNapoli VA, 2006, J NEUROSCI METH, V154, P233, DOI 10.1016/j.jneumeth.2005.12.026; ENKVIST MOK, 1992, J NEUROCHEM, V59, P519, DOI 10.1111/j.1471-4159.1992.tb09401.x; Etcheberrigaray R, 2004, P NATL ACAD SCI USA, V101, P11141, DOI 10.1073/pnas.0403921101; Fleegal MA, 2005, AM J PHYSIOL-HEART C, V289, pH2012, DOI 10.1152/ajpheart.00495.2005; Hongpaisan J, 2007, P NATL ACAD SCI USA, V104, P19571, DOI 10.1073/pnas.0709311104; Hongpaisan J, 2011, J NEUROSCI, V31, P630, DOI 10.1523/JNEUROSCI.5209-10.2011; Joseph C, 2012, J CEREBR BLOOD F MET, V32, P1632, DOI 10.1038/jcbfm.2012.65; Katzan IL, 2004, ARCH NEUROL-CHICAGO, V61, P346, DOI 10.1001/archneur.61.3.346; KRIZBAI I, 1995, J NEUROCHEM, V65, P459; Matsumoto S, 2004, J CEREBR BLOOD F MET, V24, P54, DOI 10.1097/01.WCB.0000095920.70924.F5; Popa-Wagner A, 2011, AGEING RES REV, V10, P71, DOI 10.1016/j.arr.2009.10.008; Quattrone A, 2001, P NATL ACAD SCI USA, V98, P11668, DOI 10.1073/pnas.191388398; Reshef A, 1997, NEUROSCI LETT, V238, P37, DOI 10.1016/S0304-3940(97)00841-0; Rosen CL, 2005, J NEUROSURG, V103, P687, DOI 10.3171/jns.2005.103.4.0687; Selvatici R, 2003, J NEUROSCI RES, V71, P64, DOI 10.1002/jnr.10464; Shirai Y, 2008, FEBS J, V275, P3988, DOI 10.1111/j.1742-4658.2008.06556.x; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Skaper SD, 2001, ANN NY ACAD SCI, V939, P11; Sonobe Y, 2009, J BIOL CHEM, V284, P31834, DOI 10.1074/jbc.M109.025940; Sun MK, 2008, P NATL ACAD SCI USA, V105, P13620, DOI 10.1073/pnas.0805952105; Sun MK, 2009, P NATL ACAD SCI USA, V106, P14676, DOI 10.1073/pnas.0907842106; Willis CL, 2010, J CEREBR BLOOD F MET, V30, P1847, DOI 10.1038/jcbfm.2010.119; Zhao CT, 2009, P NATL ACAD SCI USA, V106, P21353, DOI 10.1073/pnas.0812872106; Zohar O, 2011, NEUROBIOL DIS, V41, P329, DOI 10.1016/j.nbd.2010.10.001	31	40	43	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499	1524-4628		STROKE	Stroke	DEC	2013	44	12					3490	3497		10.1161/STROKEAHA.113.002411			8	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	257LR	WOS:000327386300323	24172582	Green Accepted, Bronze			2021-06-18	
J	Foebel, AD; Hirdes, JP; Heckman, GA; Kergoat, MJ; Patten, S; Marrie, RA				Foebel, Andrea D.; Hirdes, John P.; Heckman, George A.; Kergoat, Marie-Jeanne; Patten, Scott; Marrie, Ruth Ann		Ideas PNC Res Team	Diagnostic data for neurological conditions in interRAI assessments in home care, nursing home and mental health care settings: a validity study	BMC HEALTH SERVICES RESEARCH			English	Article						Diagnostic validity; Nursing homes; Home care; Psychiatry; interRAI	MINIMUM DATA SET; RESIDENT ASSESSMENT INSTRUMENT; QUALITY INDICATORS; HEART-FAILURE; OLDER-PEOPLE; RELIABILITY; INFORMATION; ADJUSTMENT; SERVICES; EUROPE	Background: The interRAI suite of assessment instruments can provide valuable information to support person-specific care planning across the continuum of care. Comprehensive clinical information is collected with these instruments, including disease diagnoses. In Canada, interRAI data holdings represent some of the largest repositories of clinical information in the country for persons with neurological conditions. This study examined the accuracy of the diagnostic information captured by interRAI instruments designed for use in the home care, long-term care and mental health care settings as compared with national administrative databases. Methods: The interRAI assessments were matched with an inpatient hospital record and emergency department (ED) visit record in the preceding 90 days. Diagnoses captured on the interRAI instruments were compared to those recorded in either administrative record for each individual. Diagnostic validity was examined through sensitivity, specificity and positive predictive value analysis for the following conditions: multiple sclerosis, epilepsy, Alzheimer's disease and other dementias, Parkinson's disease, traumatic brain injury, stroke, diabetes mellitus, heart failure and reactive airway disease. Results: In the three large study samples (home care: n = 128,448; long-term care: n = 26,644; mental health: n = 13,812), interRAI diagnoses demonstrated high specificity when compared to administrative records, for both neurological conditions (range 0.80 - 1.00) and comparative chronic diseases (range 0.83 - 1.00). Sensitivity and positive predictive values (PPV) were more varied by specific diagnosis, with sensitivities and PPV for neurological conditions ranging from 0.23 to 0.94 and 0.14 to 0.77, respectively. The interRAI assessments routinely captured more cases of the diagnoses of interest than the administrative records. Conclusions: The interRAI assessment collected accurate information about disease diagnoses when compared to administrative records within three months. Such information is likely relevant to day-to-day care in these three environments and can be used to inform care planning and resource allocation decisions.	[Foebel, Andrea D.; Hirdes, John P.; Heckman, George A.] Univ Waterloo, Sch Publ Hlth & Hlth Syst, Waterloo, ON N2L 3G1, Canada; [Kergoat, Marie-Jeanne] Inst Univ Geriatrie Montreal, Montreal, PQ, Canada; [Patten, Scott] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; [Marrie, Ruth Ann] Univ Manitoba, Dept Med, Winnipeg, MB, Canada; [Marrie, Ruth Ann] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB R3T 2N2, Canada	Foebel, AD (corresponding author), Univ Waterloo, Sch Publ Hlth & Hlth Syst, Waterloo, ON N2L 3G1, Canada.	adfoebel@uwaterloo.ca	Patten, Scott/B-4434-2011	Patten, Scott/0000-0001-9871-4041; Heckman, George/0000-0003-3847-3287; Marrie, Ruth Ann/0000-0002-1855-5595	Public Health Agency of Canada; Ontario Home Care Research and Knowledge Exchange Chair; Ontario Ministry of Health and Long Term CareMinistry of Health and Long-Term Care, Ontario; Don Paty Career Development Award from the MS Society of Canada	This study is part of the National Population Health Study of Neurological Conditions. We wish to acknowledge the membership of Neurological Health Charities Canada and the Public Health Agency of Canada for their contribution to the success of this initiative. Funding for the study was provided by the Public Health Agency of Canada. In addition, Dr. Hirdes' participation is supported through the Ontario Home Care Research and Knowledge Exchange Chair funded by the Ontario Ministry of Health and Long Term Care. Dr. Marrie is supported, in part, by a Don Paty Career Development Award from the MS Society of Canada. The opinions expressed in this publication are those of the authors/researchers, and do not necessarily reflect the official views of the Public Health Agency of Canada or the Ontario Ministry of Health and Long Term Care.	Berg K, 2002, HEALTH CARE FINANC R, V23, P19; Bernabei R, 2009, HAZZARDS GERIATRIC M, P69; Brand CA, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-281; Canadian Home Care Association, 1877, PORTR HOM CAR CAN EX; Canadian Institute for Health Information (CIHI), ICD 10 CA CCI IMPL S; Canadian Institute for Health Information (CIHI), ONT MENT HLTH REP SY; Canadian Institute for Health Information (CIHI),, DISCH ABSTR DAT DAD; Canadian Institute for Health Information (CIHI), CONT CAR REP SYST CC; Canadian Institute for Health Information (CIHI), INT STAT CLASS DIS R; Canadian Institute for Health Information (CIHI), HOM CAR REP SYST HCR; Canadian Institute for Health Information (CIHI), 2005, DAT QUAL DISCH ABSTR; Canadian Institute for Health Information-CIHI, 2010, RAI MDS 2 0 CAN VERS; Canadian Institute for Health Information-CIHI, 2010, RAI HC MAN CAN VERS; Carpenter GI, 2006, AGE AGEING, V35, P327, DOI 10.1093/ageing/afl038; Carpenter I, 2004, AGING CLIN EXP RES, V16, P259; CIHI, 2002, DISCH ABSTR DAT DAT; Daamen MAMJ, 2010, SCAND J CARING SCI, V24, P202, DOI 10.1111/j.1471-6712.2009.00708.x; Dalby DM, 2005, BMC HEALTH SERV RES, V5, DOI 10.1186/1472-6963-5-7; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Foebel AD, 2011, CHRONIC DIS CAN, V31, P49; FRIES BE, 1994, MED CARE, V32, P668, DOI 10.1097/00005650-199407000-00002; Fries BE, 1997, AGE AGEING, V26, P13, DOI 10.1093/ageing/26.suppl_2.13; Gambassi G, 1998, MED CARE, V36, P167, DOI 10.1097/00005650-199802000-00006; Gray LC, 2008, J AM GERIATR SOC, V56, P536, DOI 10.1111/j.1532-5415.2007.01590.x; Gray LC, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-71; HAWES C, 1995, GERONTOLOGIST, V35, P172, DOI 10.1093/geront/35.2.172; Hirdes J P, 2000, Hosp Q, V4, P44; Hirdes J P, 1999, Healthc Manage Forum, V12, P30; Hirdes JP, 2011, CAN J AGING, V30, P371, DOI 10.1017/S0714980811000304; Hirdes JP, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-277; Hirdes JP, 2004, GERONTOLOGIST, V44, P665, DOI 10.1093/geront/44.5.665; Hirdes JP, 2002, J BEHAV HEALTH SER R, V29, P419, DOI 10.1007/BF02287348; Hirdes JP, 2010, INTERRAI INTERRAI ME; Jones RN, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-96; Juurlink D, I CLIN EVALUATIVE SC; Landi F, 2000, MED CARE, V38, P1184, DOI 10.1097/00005650-200012000-00005; Martin L, 2009, J PSYCHIATR MENT HLT, V16, P646, DOI 10.1111/j.1365-2850.2009.01429.x; Martin L., 2007, J POLICY PRACT INTEL, V4, P23, DOI [DOI 10.1111/J.1741-1130.2006.00094.X, 10.1111/j/17411130.2006.00094.x, DOI 10.1111/J/17411130.2006.00094.X]; Martin L, 2011, J INTELLECT DISABILI, V15, P131, DOI 10.1177/1744629511413506; Mor V, 2003, BMC HEALTH SERV RES, V3, DOI 10.1186/1472-6963-3-20; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; Morris JN, 2000, CAN J AGING, V19, P87, DOI 10.1017/S071498080001391X; Morris JN, 1997, J AM GERIATR SOC, V45, P1017, DOI 10.1111/j.1532-5415.1997.tb02975.x; Onder G, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-5; Poss J W, 2008, Healthc Manage Forum, V21, P33; Poss JW, 2008, MED CARE, V46, P380, DOI 10.1097/MLR.0b013e31815c3b6c; Public Health Agency of Canada (PHAC), NAT POP HLTH STUD NE; Wodchis WP, 2008, MED CARE, V46, P882, DOI 10.1097/MLR.0b013e3181789471	48	40	40	0	20	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1472-6963		BMC HEALTH SERV RES	BMC Health Serv. Res.	NOV 1	2013	13								457	10.1186/1472-6963-13-457			11	Health Care Sciences & Services	Health Care Sciences & Services	AC0YW	WOS:000332222400001	24176093	DOAJ Gold, Green Published			2021-06-18	
J	Ford, JH; Giovanello, KS; Guskiewicz, KM				Ford, Jaclyn H.; Giovanello, Kelly S.; Guskiewicz, Kevin M.			Episodic Memory in Former Professional Football Players with a History of Concussion: An Event-Related Functional Neuroimaging Study	JOURNAL OF NEUROTRAUMA			English	Article						cognitive function; head trauma; MRI	MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN INJURY; ASSOCIATIVE INFORMATION; RELATIONAL RETRIEVAL; RECURRENT CONCUSSION; HIGH-SCHOOL; ITEM; RECOLLECTION; FAMILIARITY; HIPPOCAMPAL	Previous research has demonstrated that sport-related concussions can have short-term effects on cognitive processes, but the long-term consequences are less understood and warrant more research. This study was the first to use event-related functional magnetic resonance imaging (fMRI) to examine long-term differences in neural activity during memory tasks in former athletes who have sustained multiple sport-related concussions. In an event-related fMRI study, former football players reporting multiple sport-related concussions (i.e., three or more) were compared with players who reported fewer than three concussions during a memory paradigm examining item memory (i.e., memory for the particular elements of an event) and relational memory (i.e., memory for the relationships between elements). Behaviorally, we observed that concussion history did not significantly affect behavioral performance, because persons in the low and high concussion groups had equivalent performance on both memory tasks, and in addition, that concussion history was not associated with any behavioral memory measures. Despite demonstrating equivalent behavioral performance, the two groups of former players demonstrated different neural recruitment patterns during relational memory retrieval, suggesting that multiple concussions may be associated with functional inefficiencies in the relational memory network. In addition, the number of previous concussions significantly correlated with functional activity in a number of brain regions, including the medial temporal lobe and inferior parietal lobe. Our results provide important insights in understanding the long-term functional consequences of sustaining multiple sports-related concussions.	[Ford, Jaclyn H.; Giovanello, Kelly S.] Univ N Carolina, Dept Psychol, Chapel Hill, NC USA; [Giovanello, Kelly S.] Univ N Carolina, Biomed Res Imaging Ctr, Chapel Hill, NC USA; [Guskiewicz, Kevin M.] Univ N Carolina, Ctr Study Retired Athletes, Chapel Hill, NC USA; [Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA	Ford, JH (corresponding author), Boston Coll, Dept Psychol, McGuinn Hall,Room 511, Brookline, MA 02467 USA.	JaclynHFord@gmail.com		Guskiewicz, Kevin/0000-0002-8682-2130	National Institutes on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG028774]; Martek Biosciences Corporation; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K01AG028774] Funding Source: NIH RePORTER	The authors would like to thank Amy Matthews and Candice Goerger for their assistance in completing this work. This work was supported by National Institutes on Aging (AG028774 to KSG) and the Martek Biosciences Corporation (KMG).	Adjutant General's Office, 1944, ARM IND TEST BATT MA; Anderson ND, 2008, NEUROPSYCHOLOGY, V22, P177, DOI 10.1037/0894-4105.22.2.177; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Benton L, 1976, MULTILINGUAL APHASIA; Broglio SP, 2012, EXERC SPORT SCI REV, V40, P138, DOI 10.1097/JES.0b013e3182524273; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Buckner RL, 2003, J NEUROSCI, V23, P3999; Burock MA, 1998, NEUROREPORT, V9, P3735, DOI 10.1097/00001756-199811160-00030; *CDCP, 2007, MORTALITY MORBIDITY, V0056; CLARK SE, 1992, MEM COGNITION, V20, P231, DOI 10.3758/BF03199660; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Donnell AJ, 2007, ARCH CLIN NEUROPSYCH, V22, P917, DOI 10.1016/j.acn.2007.06.007; Eichenbaum H, 2007, ANNU REV NEUROSCI, V30, P123, DOI 10.1146/annurev.neuro.30.051606.094328; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Fisher SRA, 1932, STAT METHODS RES WOR; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fowler KS, 2002, J INT NEUROPSYCH SOC, V8, P58, DOI 10.1017/S1355617701020069; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giovanello KS, 2012, J INT NEUROPSYCH SOC, V18, P886, DOI 10.1017/S1355617712000689; Giovanello KS, 2012, J COGNITIVE NEUROSCI, V24, P159, DOI 10.1162/jocn_a_00113; Giovanello KS, 2009, HIPPOCAMPUS, V19, P111, DOI 10.1002/hipo.20491; Giovanello KS, 2004, HIPPOCAMPUS, V14, P5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Gutchess AH, 2007, SOC NEUROSCI-UK, V2, P117, DOI 10.1080/17470910701399029; HOCKLEY WE, 1992, J EXP PSYCHOL LEARN, V18, P1321, DOI 10.1037/0278-7393.18.6.1321; Hockley WE, 1999, MEM COGNITION, V27, P657, DOI 10.3758/BF03211559; Ivanoiu A, 2005, J NEUROL, V252, P47, DOI 10.1007/s00415-005-0597-2; Jantzen KJ, 2010, J HEAD TRAUMA REHAB, V25, P256, DOI 10.1097/HTR.0b013e3181e5477c; Kaplan E., 1983, BOSTON NAMING TEST; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Lazar NA, 2002, NEUROIMAGE, V16, P538, DOI 10.1006/nimg.2002.1107; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Lieberman MD, 2009, SOC COGN AFFECT NEUR, V4, P423, DOI 10.1093/scan/nsp052; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; Ricker JH, 2001, J CLIN EXP NEUROPSYC, V23, P196, DOI 10.1076/jcen.23.2.196.1204; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; Talairach J., 1988, COPLANAR STEREOTAXIC; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Troyer AK, 2008, NEUROPSYCHOLOGY, V22, P10, DOI 10.1037/0894-4105.22.1.10; Tulving E., 1983, ELEMENTS EPISODIC ME; Vilberg KL, 2009, NEUROREPORT, V20, P1295, DOI 10.1097/WNR.0b013e3283306798; Wechsler D., 2001, WECHSLER TEST ADULT; Wheeler ME, 2004, NEUROIMAGE, V21, P1337, DOI 10.1016/j.neuroimage.2003.11.001; Yonelinas AP, 1997, MEM COGNITION, V25, P747, DOI 10.3758/BF03211318; Yonelinas AP, 2001, J EXP PSYCHOL GEN, V130, P361, DOI 10.1037//0096-3445.130.3.361; Yonelinas AP, 2005, J NEUROSCI, V25, P3002, DOI 10.1523/JNEUROSCI.5295-04.2005	52	40	40	0	57	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2013	30	20					1683	1701		10.1089/neu.2012.2535			19	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	232JW	WOS:000325491000001	23679098	Green Published			2021-06-18	
J	Miyashita, TL; Timpson, WM; Frye, MA; Gloeckner, GW				Miyashita, Theresa L.; Timpson, William M.; Frye, Melinda A.; Gloeckner, Gene W.			The Impact of an Educational Intervention on College Athletes' Knowledge of Concussions	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussions; college athletes; educational intervention	FOOTBALL PLAYERS; SPORTS CONCUSSION; INJURY; EPIDEMIOLOGY; PREVENTION; DEPRESSION; SYMPTOMS; HEALTH	Objective: The purpose of this study was to determine college athletes' knowledge regarding concussions and to determine if an educational lecture before their sport season would improve their knowledge and reporting of concussions. Design: Cross-sectional study. Setting: University classroom. Participants: Seventy National College Athletic Association Division II men's/women's soccer players and men's/women's basketball players. Interventions: Educational lecture regarding the basics of concussions. Main Outcome Measures: Descriptive statistics, ANOVAs, and a paired sample t test determined the athletes' knowledge of concussion before and after the season and the impact of the educational intervention. Results: A paired sample t test indicated that the athletes scored better on the postseason concussion knowledge assessment [t(49) = 10.34, P < 0.000, d = 1.47]. Conclusions: After an educational intervention, athletes demonstrated an improvement in their knowledge on concussions.	[Miyashita, Theresa L.] Metropolitan State Univ Denver, Dept Human Performance & Sport, Denver, CO 80204 USA; [Timpson, William M.; Frye, Melinda A.; Gloeckner, Gene W.] Colorado State Univ, Sch Educ, Ft Collins, CO 80523 USA	Miyashita, TL (corresponding author), Metropolitan State Univ Denver, Dept Human Performance & Sport, 1201 5th St,CB 25, Denver, CO 80204 USA.	tdelano@msudenver.edu					Arnheim D, 2011, HEAD FACE EYES EARS, P786; Campino A, 2009, ACTA PAEDIATR, V98, P782, DOI 10.1111/j.1651-2227.2009.01234.x; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Kuehl MD, 2010, CLIN J SPORT MED, V20, P86, DOI 10.1097/JSM.0b013e3181cf4534; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Marineau C, 2007, J AM ACAD PHY ASSIST, V20, P22; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Mevsim V, 2009, EUR J CONTRACEP REPR, V14, P144, DOI 10.1080/13625180802451201; Mrazik M, 2011, CLIN J SPORT MED, V21, P315, DOI 10.1097/JSM.0b013e31821e2b78; Patel AV, 2007, J ATHL TRAINING, V42, P66; Register-Mihalik J, 2007, CLIN J SPORT MED, V17, P282, DOI 10.1097/JSM.0b013e31804ca68a; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Sallis RE, 2000, MED SCI SPORT EXER, V32, P1820, DOI 10.1097/00005768-200011000-00002; Sefton J, 2003, THESIS CENTRAL CONNE; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; McLeod TCV, 2008, CLIN J SPORT MED, V18, P235, DOI 10.1097/JSM.0b013e3181705756	28	40	40	0	39	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2013	23	5					349	353		10.1097/JSM.0b013e318289c321			5	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	212YD	WOS:000324017900005	23528843				2021-06-18	
J	Shirazi-Zand, Z; Ahmad-Molaei, L; Motamedi, F; Naderi, N				Shirazi-Zand, Zahra; Ahmad-Molaei, Leila; Motamedi, Fereshteh; Naderi, Nima			The role of potassium BK channels in anticonvulsant effect of cannabidiol in pentylenetetrazole and maximal electroshock models of seizure in mice	EPILEPSY & BEHAVIOR			English	Article						Cannabidiol; Paxilline; Pentylenetetrazole; Maximal electroshock; Seizure	CA2+-ACTIVATED K+ CHANNELS; CLOSED-HEAD INJURY; ACTION-POTENTIAL REPOLARIZATION; RAT-BRAIN; AFTER-HYPERPOLARIZATION; SPIKE REPOLARIZATION; CULTURED HIPPOCAMPAL; DRUG-INTERACTIONS; CALCIUM-CHANNELS; CANNABINOIDS	Cannabidiol is a nonpsychoactive member of phytocannabinoids that produces various pharmacological effects that are not mediated through putative CB1/CB2 cannabinoid receptors and their related effectors. In this study, we examined the effect of the i.c.v. administration of potassium BK channel blocker paxilline alone and in combination with cannabidiol in protection against pentylenetetrazol (PTZ)-and maximal electroshock (MES)-induced seizure in mice. In the PTZ-induced seizure model, i.c.v. administration of cannabidiol caused a significant increase in seizure threshold compared with the control group. Moreover, while i.c.v. administration of various doses of paxilline did not produce significant change in the VIZ-induced seizure threshold in mice, coadministration of cannabidiol and paxilline attenuated the antiseizure effect of cannabidiol in VIZ-induced tonic seizures. In the MES model of seizure, both cannabidiol and paxilline per se produced significant increase in percent protection against electroshock-induced seizure. However, coadministration of cannabidiol and paxilline did not produce significant interaction in their antiseizure effect in the MES test. The results of the present study showed a protective effect of cannabidiol in both PTZ and MES models of seizure. These results suggested a BK channel-mediated antiseizure action of cannabidiol in PTZ model of seizure. However, such an interaction might not exist in MES-induced convulsion. (C) 2013 Elsevier Inc. All rights reserved.	[Shirazi-Zand, Zahra; Ahmad-Molaei, Leila; Motamedi, Fereshteh; Naderi, Nima] Shahid Beheshti Univ Med Sci, Neurosci Res Ctr, Tehran 1996835113, Iran; [Naderi, Nima] Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Pharmacol & Toxicol, Tehran 1996835113, Iran	Naderi, N (corresponding author), Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Pharmacol & Toxicol, 2660 Vali E Asr Ave,POB 14155-6153, Tehran 1996835113, Iran.	naderi@sbmu.ac.ir	Naderi, Nima/U-5410-2018	Naderi, Nima/0000-0003-4591-8918; Motamedi, Fereshteh/0000-0003-4030-8627	Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Iran	This work was supported by a grant from the Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Iran.	ADAMS PR, 1982, NATURE, V296, P746, DOI 10.1038/296746a0; ALGER BE, 1988, J PHYSIOL-LONDON, V399, P191; BENOWITZ NL, 1980, CLIN PHARMACOL THER, V28, P115, DOI 10.1038/clpt.1980.139; Bhattacharyya S, 2009, ARCH GEN PSYCHIAT, V66, P442, DOI 10.1001/archgenpsychiatry.2009.17; BLATZ AL, 1984, J GEN PHYSIOL, V84, P1, DOI 10.1085/jgp.84.1.1; Brenner R, 2005, NAT NEUROSCI, V8, P1752, DOI 10.1038/nn1573; Brenowitz SD, 2003, J NEUROSCI, V23, P6373; Brew HM, 2007, J NEUROPHYSIOL, V98, P1501, DOI 10.1152/jn.00640.2006; CARLINI EA, 1973, J PHARM PHARMACOL, V25, P664, DOI 10.1111/j.2042-7158.1973.tb10660.x; Carrier EJ, 2006, P NATL ACAD SCI USA, V103, P7895, DOI 10.1073/pnas.0511232103; Castaldo P, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-02-j0003.2002; CAULFIELD MP, 1992, BRIT J PHARMACOL, V106, P231, DOI 10.1111/j.1476-5381.1992.tb14321.x; CHESHER GB, 1974, PSYCHOPHARMACOLOGIA, V37, P255, DOI 10.1007/BF00421539; CONSROE P, 1981, J CLIN PHARMACOL, V21, pS428, DOI 10.1002/j.1552-4604.1981.tb02623.x; CONSROE P, 1982, EUR J PHARMACOL, V83, P293, DOI 10.1016/0014-2999(82)90264-3; CONSROE PF, 1975, JAMA-J AM MED ASSOC, V234, P306, DOI 10.1001/jama.234.3.306; CUNHA JM, 1980, PHARMACOLOGY, V21, P175, DOI 10.1159/000137430; Drysdale AJ, 2006, NEUROPHARMACOLOGY, V50, P621, DOI 10.1016/j.neuropharm.2005.11.008; Drysdale AJ, 2003, CURR MED CHEM, V10, P2719, DOI 10.2174/0929867033456387; Du W, 2005, NAT GENET, V37, P733, DOI 10.1038/ng1585; ELLISON JM, 1990, J CLIN PSYCHIAT, V51, P439; ESHHAR N, 1995, EUR J PHARMACOL, V283, P19, DOI 10.1016/0014-2999(95)00271-L; Esposito G, 2006, NEUROSCI LETT, V399, P91, DOI 10.1016/j.neulet.2006.01.047; Faber ESL, 2003, J PHYSIOL-LONDON, V552, P483, DOI 10.1113/jphysiol.2003.050120; FRAGOSOVELOZ J, 1990, EUR J PHARMACOL, V178, P275, DOI 10.1016/0014-2999(90)90106-G; GENNINGS C, 1990, J PHARMACOL EXP THER, V252, P208; Gordon E, 2001, EPILEPSIA, V42, P1266, DOI 10.1046/j.1528-1157.2001.19301.x; Gu N, 2007, J PHYSIOL-LONDON, V580, P859, DOI 10.1113/jphysiol.2006.126367; GUIMARAES FS, 1994, GEN PHARMACOL, V25, P161, DOI 10.1016/0306-3623(94)90027-2; Hampson RE, 2000, J NEUROPHYSIOL, V84, P2356; Hayase T, 2001, Nihon Arukoru Yakubutsu Igakkai Zasshi, V36, P596; HOLLISTER LE, 1973, EXPERIENTIA, V29, P825, DOI 10.1007/BF01946311; Holmes GL, 2008, PEDIATR NEUROL, V38, P151, DOI 10.1016/j.pediatrneurol.2007.09.008; Hu H, 2001, J NEUROSCI, V21, P9585, DOI 10.1523/JNEUROSCI.21-24-09585.2001; Iuvone T, 2004, J NEUROCHEM, V89, P134, DOI 10.1111/j.1471-4159.2003.02327.x; Jones NA, 2010, J PHARMACOL EXP THER, V332, P569, DOI 10.1124/jpet.109.159145; Kaplan BLF, 2003, J PHARMACOL EXP THER, V306, P1077, DOI 10.1124/jpet.103.051961; KARLER R, 1981, J CLIN PHARMACOL, V21, pS437, DOI 10.1002/j.1552-4604.1981.tb02624.x; KARLER R, 1989, NEUROPHARMACOLOGY, V28, P775, DOI 10.1016/0028-3908(89)90166-4; Knaus HG, 1996, J NEUROSCI, V16, P955; KNAUS HG, 1994, BIOCHEMISTRY-US, V33, P5819, DOI 10.1021/bi00185a021; LANCASTER B, 1987, J PHYSIOL-LONDON, V389, P187, DOI 10.1113/jphysiol.1987.sp016653; Lastres-Becker I, 2005, NEUROBIOL DIS, V19, P96, DOI 10.1016/j.nbd.2004.11.009; Leweke FM, 2000, PHARMACOL BIOCHEM BE, V66, P175, DOI 10.1016/S0091-3057(00)00201-X; LITCHFIELD JT, 1949, J PHARMACOL EXP THER, V96, P99; LOSCHER W, 1991, EPILEPSY RES, V8, P171, DOI 10.1016/0920-1211(91)90062-K; Lutz B, 2004, BIOCHEM PHARMACOL, V68, P1691, DOI 10.1016/j.bcp.2004.07.007; MACKIE K, 1992, P NATL ACAD SCI USA, V89, P3825, DOI 10.1073/pnas.89.9.3825; MARTY A, 1989, TRENDS NEUROSCI, V12, P420, DOI 10.1016/0166-2236(89)90090-8; MECHOULAM R, 1963, TETRAHEDRON, V19, P2073, DOI 10.1016/0040-4020(63)85022-X; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; Netzeband JG, 1999, J NEUROSCI, V19, P8765, DOI 10.1523/JNEUROSCI.19-20-08765.1999; Paxinos G., 2008, MOUSE BRAIN STEREOTA, V3rd; PEREZREY.M, 1973, EXPERIENTIA, V29, P1009; Pertwee RG, 2004, PHARM THERAPEUTIC PO; Raffaelli G, 2004, J PHYSIOL-LONDON, V557, P147, DOI 10.1113/jphysiol.2004.062661; Rho JM, 1999, DEV NEUROSCI-BASEL, V21, P320, DOI 10.1159/000017381; Robbe D, 2001, J NEUROSCI, V21, P109, DOI 10.1523/JNEUROSCI.21-01-00109.2001; Ryan D, 2009, J NEUROSCI, V29, P2053, DOI 10.1523/JNEUROSCI.4212-08.2009; SAH PAJ, 1992, J NEUROPHYSIOL, V68, P1834; Sanchez M, 1996, NEUROPHARMACOLOGY, V35, P963, DOI 10.1016/0028-3908(96)00137-2; SCHWINDT PC, 1988, J NEUROPHYSIOL, V59, P424; Scuderi C, 2009, PHYTOTHER RES, V23, P597, DOI 10.1002/ptr.2625; SEGAL M, 1984, J NEUROSCI, V4, P604; Shao LR, 1999, J PHYSIOL-LONDON, V521, P135, DOI 10.1111/j.1469-7793.1999.00135.x; Sheehan JJ, 2009, EPILEPSIA, V50, P711, DOI 10.1111/j.1528-1167.2008.01888.x; Shen MX, 1998, MOL PHARMACOL, V54, P459; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shruti S, 2008, NEUROBIOL DIS, V30, P323, DOI 10.1016/j.nbd.2008.02.002; Sim-Selley LJ, 2002, J PHARMACOL EXP THER, V303, P36, DOI 10.1124/jpet.102.035618; STORM JF, 1987, J PHYSIOL-LONDON, V385, P733, DOI 10.1113/jphysiol.1987.sp016517; STORM JF, 1987, BRAIN RES, V435, P387, DOI 10.1016/0006-8993(87)91631-3; Storm JF, 2006, ABSTR SOC NEUROSCI, V627, pD23; TsengCrank J, 1996, P NATL ACAD SCI USA, V93, P9200, DOI 10.1073/pnas.93.17.9200; TURKANIS SA, 1977, PSYCHOPHARMACOLOGY, V52, P207, DOI 10.1007/BF00439112; Twitchell W, 1997, J NEUROPHYSIOL, V78, P43; Usami N, 1998, CHEM PHARM BULL, V46, P1462; van der Stelt M, 2005, EMBO J, V24, P3026, DOI 10.1038/sj.emboj.7600784; VENANCE L, 1995, NATURE, V376, P590, DOI 10.1038/376590a0; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; Wallace MJ, 2001, EUR J PHARMACOL, V428, P51, DOI 10.1016/S0014-2999(01)01243-2; Wanner SG, 1999, BIOCHEMISTRY-US, V38, P5392, DOI 10.1021/bi983040c; Womack MD, 2002, EUR J NEUROSCI, V16, P1214, DOI 10.1046/j.1460-9568.2002.02171.x	84	40	40	0	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050	1525-5069		EPILEPSY BEHAV	Epilepsy Behav.	JUL	2013	28	1					1	7		10.1016/j.yebeh.2013.03.009			7	Behavioral Sciences; Clinical Neurology; Psychiatry	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	164QB	WOS:000320423500001	23644464				2021-06-18	
J	Vagnozzi, R; Signoretti, S; Floris, R; Marziali, S; Manara, M; Amorini, AM; Belli, A; Di Pietro, V; D'Urso, S; Pastore, FS; Lazzarino, G; Tavazzi, B				Vagnozzi, Roberto; Signoretti, Stefano; Floris, Roberto; Marziali, Simone; Manara, Massimo; Amorini, Angela M.; Belli, Antonio; Di Pietro, Valentina; D'Urso, Serafina; Pastore, Francesco S.; Lazzarino, Giuseppe; Tavazzi, Barbara			Decrease in N-Acetylaspartate Following Concussion May Be Coupled to Decrease in Creatine	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain vulnerability; concussion; creatine; H-1 magnetic resonance spectroscopy; mild traumatic brain injury; N-acetylaspartate; sports-related concussion	TRAUMATIC BRAIN-INJURY; MAGNETIC-RESONANCE-SPECTROSCOPY; METABOLIC ACETATE THERAPY; MITOCHONDRIAL DYSFUNCTION; TEMPORAL WINDOW; VULNERABILITY; GUANIDINOACETATE; PATHOPHYSIOLOGY; IMPAIRMENT; DEFICIENCY	Objectives: To assess the time course changes in N-acetylaspartate (NAA) and creatine (Cr) levels in the brain of athletes who suffered a sport-related concussion. Participants: Eleven nonconsecutive athletes with concussive head injury and 11 sex-and age-matched control volunteers Main outcome measures: At 3, 15, 30, and 45 days postinjury, athletes were examined by proton magnetic resonance spectroscopy for the determination of NAA, Cr, and choline (Cho) levels. Proton magnetic resonance spectroscopic data recorded for the control group were used for comparison. Results: Compared with controls (2.18 +/- 0.19), athletes showed an increase in the NAA/Cr ratio at 3 (2.71 +/- 0.16; P <.01) and 15 (2.54 +/- 0.21; P <.01) days postconcussion, followed by a decrease and subsequent normalization at 30 (1.95 +/- 0.16, P <.05) and 45 (2.17 +/- 0.20; P < .05) days postconcussion. The NAA/Cho ratio decreased at 3, 15, and 30 days postinjury (P < .01 compared with controls), with no differences observed in controls at 45 days postconcussion. Compared with controls, significant increase in the Cho/Cr ratio after 3 (+ 33%, P < .01) and 15 (+ 31.5%, P < .01) days postinjury was observed whereas no differences were recorded at 30 and 45 days postinjury. Conclusions: This cohort of athletes indicates that concussion may cause concomitant decrease in cerebral NAA and Cr levels. This provokes longer time for normalization of metabolism, as well as longer time for resolution of concussion-associated clinical symptoms.	[Vagnozzi, Roberto; Floris, Roberto; Marziali, Simone; D'Urso, Serafina; Pastore, Francesco S.] Univ Roma Tor Vergata, Dept Biomed & Prevent, Div Neurotraumatol & Neuroradiol, Rome, Italy; [Signoretti, Stefano] San Camillo Hosp, Div Neurosurg, Dept Neurosci Head & Neck Surg, Rome, Italy; [Manara, Massimo] Assoc Sports Phys Parma, FMSI, Parma, Italy; [Amorini, Angela M.; Tavazzi, Barbara] Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy; [Lazzarino, Giuseppe] Univ Catania, Div Biochem & Mol Biol, Dept Biol Geol & Environm Sci, Catania, Italy; [Belli, Antonio; Di Pietro, Valentina] Univ Birmingham, Coll Med & Dent Sci, Sch Clin & Expt Med, Neuropharmacol & Neurobiol Sect, Birmingham, W Midlands, England; [Belli, Antonio; Di Pietro, Valentina] Univ Hosp Birmingham, NIHR Surg Reconstruct & Microbiol Res Ctr, Birmingham, W Midlands, England	Lazzarino, G (corresponding author), Dept Biol Geol & Environm Sci, Div Biochem & Mol Biol, Viale A Doria 6, I-95125 Catania, Italy.	lazzarig@unict.it	floris, roberto/AAC-2396-2019; Signoretti, stefano/AAL-5631-2020; TAVAZZI, BARBARA/AAB-9830-2019; Belli, Antonio/I-3799-2015; pastore, francesco saverio/D-3827-2012; lazzarino, giuseppe/K-2277-2015	Signoretti, stefano/0000-0002-8086-1622; TAVAZZI, BARBARA/0000-0001-8743-0895; Belli, Antonio/0000-0002-3211-9933; pastore, francesco saverio/0000-0002-2041-5161; Marziali, Simone/0000-0002-5805-5501; Di Pietro, Valentina/0000-0001-9430-4723; AMORINI, Angela Maria/0000-0003-3525-9955; lazzarino, giuseppe/0000-0002-5917-7279	University of Rome	This work has been supported in part by research funds of University of Rome "Tor Vergata," Catholic University of Rome, and University of Catania. The authors thank Mr Salvatore Meo for his technical assistance in preparing the artwork for the manuscript.	Arun P, 2010, J INHERIT METAB DIS, V33, P195, DOI 10.1007/s10545-010-9100-z; Arun P, 2010, J NEUROTRAUM, V27, P293, DOI 10.1089/neu.2009.0994; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Baslow MH, 2003, J MOL NEUROSCI, V21, P185, DOI 10.1385/JMN:21:3:185; Beard E, 2010, J NEUROCHEM, V115, P297, DOI 10.1111/j.1471-4159.2010.06935.x; Darwish RS, 2010, NEUROCRIT CARE, V12, P337, DOI 10.1007/s12028-009-9328-3; Deng-Bryant Y, 2011, J NEUROTRAUM, V28, P1813, DOI 10.1089/neu.2011.1822; DiFiori JP, 2010, CURR SPORT MED REP, V9, P35, DOI 10.1249/JSR.0b013e3181caba67; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Royes LF, 2008, NEUROCHEM INT, V53, P33, DOI 10.1016/j.neuint.2008.04.008; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Giza CC, 2001, J ATHL TRAINING, V36, P228; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Gruber S, 2008, EUR J RADIOL, V68, P320, DOI 10.1016/j.ejrad.2007.08.038; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; HOVDA DA, 1983, INTRACRANIAL PRESSUR, V8, P469; Johnson B, 2012, J NEUROTRAUM, V29, P2297, DOI 10.1089/neu.2011.2294; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kilbaugh TJ, 2011, J NEUROTRAUM, V28, P763, DOI 10.1089/neu.2010.1635; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mayers LB, 2012, J CLIN EXP NEUROPSYC, V34, P235, DOI 10.1080/13803395.2011.630655; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Rigotti DJ, 2007, AM J NEURORADIOL, V28, P1843, DOI 10.3174/ajnr.A0774; Sakellaris G, 2006, J TRAUMA, V61, P322, DOI 10.1097/01.ta.0000230269.46108.d5; Sakellaris G, 2008, ACTA PAEDIATR, V97, P31, DOI 10.1111/j.1651-2227.2007.00529.x; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Senaratne R, 2009, PSYCHIAT RES-NEUROIM, V172, P205, DOI 10.1016/j.pscychresns.2008.07.007; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; Signoretti S, 2010, MOL CELL BIOCHEM, V333, P269, DOI 10.1007/s11010-009-0228-9; Stockler S, 1996, AM J HUM GENET, V58, P914; Stockler Sylvia, 2007, V46, P149; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Tachikawa M, 2008, J NEUROCHEM, V107, P768, DOI 10.1111/j.1471-4159.2008.05652.x; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	50	40	41	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2013	28	4					284	292		10.1097/HTR.0b013e3182795045			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	298ZO	WOS:000330363900006	23249772	Green Published			2021-06-18	
J	van Hout, WMMT; Van Cann, EM; Abbink, JH; Koole, R				van Hout, Wouter M. M. T.; Van Cann, Ellen M.; Abbink, Jan H.; Koole, Ronald			An epidemiological study of maxillofacial fractures requiring surgical treatment at a tertiary trauma centre between 2005 and 2010	BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY			English	Article						Trauma; Fracture; Maxillofacial fracture; Facial skeleton; Neurotrauma; Concomitant injury; Helmet	ETIOLOGY; INJURIES	The epidemiology of maxillofacial fractures shows considerable regional variation as a result of local demographic and socioeconomic factors. We have assessed the epidemiological characteristics of such fractures at our centre in The Netherlands. The medical records of 394 patients who were treated surgically for maxillofacial fractures between 1 January 2005 and 31 December 2010 were analysed retrospectively. The male:female ratio was 3:1. There was a peak incidence in the second and third decades of life among men. The number of injured patients/year remained stable during the selected period. The incidence was highest in the spring and at weekends. Fractures of the mandible and zygoma were the most common. Road traffic crashes were the most common cause of injury (42%) and mainly involved bicycles. A total of 165 (15%) of the patients were intoxicated, and 142 patients (36%) had other serious injuries. Most patients (n = 248, 63%) were treated within a day of presentation. Two hundred and thirty-two patients (59%) spent 4 days or fewer in hospital. The presence of other injuries was associated with a prolonged stay in hospital. Groups at particular risk of maxillofacial fractures are young men and cyclists. The use of helmets by cyclists could achieve a large reduction in injuries to the brain and upper face. (C) 2012 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.	[van Hout, Wouter M. M. T.; Van Cann, Ellen M.; Abbink, Jan H.; Koole, Ronald] Univ Med Ctr Utrecht, Dept Oral & Maxillofacial Surg, NL-3584 CX Utrecht, Netherlands	Van Cann, EM (corresponding author), Univ Med Ctr Utrecht, Dept Oral & Maxillofacial Surg, Heidelberglaan 100,POB 85500, NL-3584 CX Utrecht, Netherlands.	e.m.vancann@umcutrecht.nl		Abbink, Jan Hendrik/0000-0002-6542-0167			Bormann KH, 2009, J ORAL MAXIL SURG, V67, P1251, DOI 10.1016/j.joms.2008.09.022; Buchanan Jessica, 2005, N Z Med J, V118, pU1529; Calderoni DR, 2011, J CRANIO MAXILL SURG, V39, P593, DOI 10.1016/j.jcms.2010.11.018; DEJOY DM, 1992, ACCIDENT ANAL PREV, V24, P237, DOI 10.1016/0001-4575(92)90003-2; Hogg NJV, 2000, J TRAUMA, V49, P425, DOI 10.1097/00005373-200009000-00007; Hutchison IL, 1998, BRIT J ORAL MAX SURG, V36, P3, DOI 10.1016/S0266-4356(98)90739-2; Thompson DC, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001855; van Beek GJ, 1999, INT J ORAL MAX SURG, V28, P424, DOI 10.1016/S0901-5027(99)80055-1	8	40	42	0	12	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0266-4356	1532-1940		BRIT J ORAL MAX SURG	Br. J. Oral Maxillofac. Surg.	JUL	2013	51	5					416	420		10.1016/j.bjoms.2012.11.002			5	Dentistry, Oral Surgery & Medicine; Surgery	Dentistry, Oral Surgery & Medicine; Surgery	178WY	WOS:000321479300009	23218202				2021-06-18	
J	Carter, L; Russell, PN; Helton, WS				Carter, Leonie; Russell, Paul N.; Helton, William S.			Target predictability, sustained attention, and response inhibition	BRAIN AND COGNITION			English	Article						Near-infrared spectroscopy; Executive control; Response inhibition; Sustained attention; Vigilance	TRAUMATIC BRAIN-INJURY; SIGNAL-REGULARITY; TASK; VIGILANCE; PERFORMANCE; SENSITIVITY; SALIENCE; FAILURES; STIMULI; THOUGHT	We examined whether the sustained attention to response task is a better measure of response inhibition or sustained attention. Participants performed a number detection task for 37.3 min using either a Sustained Attention to Response Task (SARI; high Go low No-Go) or a more traditionally formatted vigilance task (TFT; high No-Go low Go) response format. Participants performed these tasks using either a regular fixed ordered stimuli set (1-9, sequentially repeated), in which the target number appeared predictably, or a random order (1-9, random presentation), in which the target number appeared at random. We utilized functional near infrared spectroscopy (fNIRS) to measure cerebral oxygenation levels in the right and left frontal areas. We also used post-task participant reports of arousal, and conscious thoughts occurring during the tasks. Performance differed for the both response format and target predictability. Greater right than left frontal hemisphere activation occurred in the TFT than the SART with time-on-task. In addition, the SARI response format resulted in elevated self-reports of task-related thoughts than the TFT response format. The results suggest the SARI, random or fixed ordered, places high response inhibition, not necessarily sustained attention, demands on participants. Elevated levels of task-related thoughts during the SART format condition in comparison to the TFT condition does not appear to be in accord with the claim that the SART induces mindlessness. (C) 2013 Elsevier Inc. All rights reserved.	[Carter, Leonie; Russell, Paul N.; Helton, William S.] Univ Canterbury, Dept Psychol, Christchurch 1, New Zealand	Helton, WS (corresponding author), Univ Canterbury, Dept Psychol, Private Bag 4800, Christchurch 1, New Zealand.	Deak_Helton@canterbury.ac.nz					Aaslid R., 1986, TRANSCRANIAL DOPPLER, P39; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Bengson JJ, 2012, NEUROIMAGE, V59, P1534, DOI 10.1016/j.neuroimage.2011.08.034; Bonnefond A, 2010, BEHAV BRAIN RES, V211, P185, DOI 10.1016/j.bbr.2010.03.030; Chan RCK, 2009, COGN BEHAV NEUROL, V22, P180, DOI 10.1097/WNN.0b013e3181b7ef84; Chan RCK, 2005, CLIN REHABIL, V19, P188, DOI 10.1191/0269215505cr838oa; Chan RCK, 2001, BRAIN INJURY, V15, P819, DOI 10.1080/02699050119721; Cheyne JA, 2009, COGNITION, V111, P98, DOI 10.1016/j.cognition.2008.12.009; Cheyne JA, 2006, CONSCIOUS COGN, V15, P578, DOI 10.1016/j.concog.2005.11.009; Christoff K, 2009, P NATL ACAD SCI USA, V106, P8719, DOI 10.1073/pnas.0900234106; Davies D.R., 1982, PSYCHOL VIGILANCE; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Farrin L, 2003, J NEUROPSYCH CLIN N, V15, P98, DOI 10.1176/appi.neuropsych.15.1.98; Garavan H, 2002, NEUROIMAGE, V17, P1820, DOI 10.1006/nimg.2002.1326; Greene CM, 2009, NEUROPSYCHOLOGIA, V47, P591, DOI 10.1016/j.neuropsychologia.2008.10.003; Hancock P. A., 2002, ERGON DES, V10, P6, DOI DOI 10.1177/106480460201000103; Helton WS, 2008, ACTA PSYCHOL, V129, P18, DOI 10.1016/j.actpsy.2008.04.002; Helton WS, 2007, J CLIN EXP NEUROPSYC, V29, P545, DOI 10.1080/13803390600814757; Helton WS, 2012, HUM FACTORS, V54, P189, DOI 10.1177/0018720811430503; Helton WS, 2011, CONSCIOUS COGN, V20, P1732, DOI 10.1016/j.concog.2011.02.011; Helton WS, 2011, HUM FACTORS, V53, P132, DOI 10.1177/0018720811401385; Helton WS, 2011, EXP BRAIN RES, V209, P401, DOI 10.1007/s00221-011-2563-9; Helton WS, 2011, PSYCHOL RES-PSYCH FO, V75, P384, DOI 10.1007/s00426-010-0316-1; Helton WS, 2010, BRAIN COGNITION, V74, P75, DOI 10.1016/j.bandc.2010.06.008; Helton WS, 2010, NEUROPSYCHOLOGIA, V48, P1683, DOI 10.1016/j.neuropsychologia.2010.02.014; Helton WS, 2010, CONSCIOUS COGN, V19, P77, DOI 10.1016/j.concog.2010.01.006; Helton WS, 2009, J CLIN EXP NEUROPSYC, V31, P39, DOI 10.1080/13803390801978856; Helton WS, 2005, BRIT J PSYCHOL, V96, P249, DOI 10.1348/000712605X38369; Helton WS, 1999, CURR PSYCHOL, V18, P311, DOI 10.1007/s12144-999-1006-2; LOGAN GD, 1984, PSYCHOL REV, V91, P295, DOI 10.1037/0033-295X.91.3.295; Mackworth NH, 1948, Q J EXP PSYCHOL, V1, P6, DOI 10.1080/17470214808416738; Manly T, 2003, NEUROCASE, V9, P340, DOI 10.1076/neur.9.4.340.15553; Matthews G., 1999, PERSONALITY PSYCHOL, V7, P335, DOI DOI 10.1177/154193120404801107; Matthews G, 2002, EMOTION, V2, P315, DOI 10.1037//1528-3542.2.4.315; Maxwell S. E., 1990, DESIGNING EXPT ANAL; McVay JC, 2009, J EXP PSYCHOL LEARN, V35, P196, DOI 10.1037/a0014104; O'Connell RG, 2009, J COGNITIVE NEUROSCI, V21, P93, DOI 10.1162/jocn.2009.21008; O'Connor C, 2011, NEUROPSYCHOLOGY, V25, P535, DOI 10.1037/a0022767; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Ossowski U, 2011, CONSCIOUS COGN, V20, P1649, DOI 10.1016/j.concog.2011.08.015; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; SEE JE, 1995, PSYCHOL BULL, V117, P230, DOI 10.1037/0033-2909.117.2.230; Seli P, 2012, CONSCIOUS COGN, V21, P277, DOI 10.1016/j.concog.2011.09.017; Smallwood J, 2007, COGNITION EMOTION, V21, P816, DOI 10.1080/02699930600911531; Stevenson H, 2011, BRAIN COGNITION, V77, P215, DOI 10.1016/j.bandc.2011.08.007; Temple JG, 2000, HUM FACTORS, V42, P183, DOI 10.1518/001872000779656480; Warm J. S., 1984, SUSTAINED ATTENTION; WARM JS, 1992, B PSYCHONOMIC SOC, V30, P297; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012	50	40	41	1	38	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626	1090-2147		BRAIN COGNITION	Brain Cogn.	JUN	2013	82	1					35	42		10.1016/j.bandc.2013.02.002			8	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	130AH	WOS:000317884600005	23501702				2021-06-18	
J	Kargi, AY; Merriam, GR				Kargi, Atil Y.; Merriam, George R.			Diagnosis and treatment of growth hormone deficiency in adults	NATURE REVIEWS ENDOCRINOLOGY			English	Article							QUALITY-OF-LIFE; GH REPLACEMENT THERAPY; TRAUMATIC BRAIN-INJURY; INTIMA-MEDIA THICKNESS; BONE-MINERAL DENSITY; CARDIOVASCULAR RISK MARKERS; INSULIN TOLERANCE-TEST; LONG-TERM MORTALITY; BODY-COMPOSITION; HYPOPITUITARY PATIENTS	The availability of synthetic recombinant human growth hormone (GH) in potentially unlimited quantities since the 1980s has improved understanding of the many nonstatural effects of GH on metabolism, body composition, physical and psychological function, as well as the consequences of GH deficiency in adult life. Adult GH deficiency is now recognized as a distinct if nonspecific syndrome with considerable adverse health consequences. GH replacement therapy in lower doses than those used in children can reverse many of these abnormalities and restore functional capacities toward or even to normal; if dosed appropriately, GH therapy has few adverse effects. Although some doubts remain about possible long-term risks of childhood GH therapy, most registries of adult GH replacement therapy, albeit limited in study size and duration, have not shown an increased incidence of cancers or of cardiovascular morbidity or mortality.	[Kargi, Atil Y.] Univ Miami, Miller Sch Med, Div Endocrinol Diabet & Metab, Miami, FL 33136 USA; [Merriam, George R.] Vet Affairs Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA; [Merriam, George R.] Univ Washington, Sch Med, Seattle, WA 98195 USA	Merriam, GR (corresponding author), Vet Affairs Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Box 356426, Seattle, WA 98195 USA.	merriam@uw.edu			National Institute of Aging, US National Institutes of Health	The authors thank P. Asberry, S. Brickle, M. Kletke and L. Smith for their assistance with the work of the research group. The authors gratefully acknowledge research support from the National Institute of Aging, US National Institutes of Health, and from the facilities and resources of the US Department of Veterans Affairs Puget Sound Health Care System.	Abs R, 1999, CLIN ENDOCRINOL, V50, P703, DOI 10.1046/j.1365-2265.1999.00695.x; Abs R, 2006, EUR J ENDOCRINOL, V155, P79, DOI 10.1530/eje.1.02179; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aguiar-Oliveira MH, 2010, J CLIN ENDOCR METAB, V95, P714, DOI 10.1210/jc.2009-1879; Aimaretti G, 2004, GROWTH HORM IGF RES, V14, pS114, DOI 10.1016/j.ghir.2004.03.025; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Aimaretti G, 1998, J CLIN ENDOCR METAB, V83, P1615, DOI 10.1210/jc.83.5.1615; AlShoumer KAS, 1996, EUR J ENDOCRINOL, V135, P559, DOI 10.1530/eje.0.1350559; Andreassen T. T., 2001, Journal of Musculoskeletal & Neuronal Interactions, V2, P49; Arnold JR, 2009, CLIN ENDOCRINOL, V70, P435, DOI 10.1111/j.1365-2265.2008.03391.x; Attanasio AF, 1997, J CLIN ENDOCR METAB, V82, P82, DOI 10.1210/jc.82.1.82; Attanasio AF, 2002, J CLIN ENDOCR METAB, V87, P1600, DOI 10.1210/jc.87.4.1600; Bates AS, 1996, J CLIN ENDOCR METAB, V81, P1169, DOI 10.1210/jc.81.3.1169; Baum HBA, 1998, J CLIN ENDOCR METAB, V83, P3184, DOI 10.1210/jc.83.9.3184; Baum HBA, 1996, ANN INTERN MED, V125, P883, DOI 10.7326/0003-4819-125-11-199612010-00003; Beauregard C, 2008, J CLIN ENDOCR METAB, V93, P2063, DOI 10.1210/jc.2007-2371; BESHYAH SA, 1995, CLIN ENDOCRINOL, V42, P179, DOI 10.1111/j.1365-2265.1995.tb01860.x; Bidlingmaier M, 2006, J CLIN ENDOCR METAB, V91, P2926, DOI 10.1210/jc.2006-0514; Biller BMK, 2002, J CLIN ENDOCR METAB, V87, P2067, DOI 10.1210/jcem.87.5.8509; Binder G, 2004, HORM RES, V62, P84, DOI 10.1159/000079539; Bravenboer N, 1996, BONE, V18, P551, DOI 10.1016/8756-3282(96)00069-5; Burman P, 1997, J CLIN ENDOCR METAB, V82, P550, DOI 10.1210/jc.82.2.550; Carel JC, 2012, J CLIN ENDOCR METAB, V97, P416, DOI 10.1210/jc.2011-1995; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; Chihara K, 2007, EUR J ENDOCRINOL, V157, P19, DOI 10.1530/EJE-07-0066; Child CJ, 2011, EUR J ENDOCRINOL, V165, P217, DOI 10.1530/EJE-11-0286; Claessen KMJA, 2013, J CLIN ENDOCR METAB, V98, P352, DOI 10.1210/jc.2012-2940; Clayton PE, 2011, NAT REV ENDOCRINOL, V7, P11, DOI 10.1038/nrendo.2010.171; Clemmons DR, 2010, CURR OPIN ENDOCRINOL, V17, P377, DOI 10.1097/MED.0b013e32833b6bc7; CLEMMONS DR, 1991, ANNU REV NUTR, V11, P393, DOI 10.1146/annurev.nu.11.070191.002141; Climent V, 2007, CURR MED CHEM, V14, P1399, DOI 10.2174/092986707780831195; Colao A, 2004, CLIN ENDOCRINOL, V61, P360, DOI 10.1111/j.1365-2265.2004.02105.x; Colao A, 2008, J CLIN ENDOCR METAB, V93, P3416, DOI 10.1210/jc.2007-2810; Cook DM, 2009, ENDOCR PRACT, V15, P580, DOI 10.4158/EP.15.6.580; Corneli G, 2005, EUR J ENDOCRINOL, V153, P257, DOI 10.1530/eje.1.01967; CUNEO RC, 1993, METABOLISM, V42, P1519, DOI 10.1016/0026-0495(93)90145-E; CUNEO RC, 1992, CLIN ENDOCRINOL, V37, P387, DOI 10.1111/j.1365-2265.1992.tb02347.x; Darzy KH, 2003, J CLIN ENDOCR METAB, V88, P95, DOI 10.1210/jc.2002-021094; DAVIDSON MB, 1987, ENDOCR REV, V8, P115, DOI 10.1210/edrv-8-2-115; DEBOER H, 1994, METABOLISM, V43, P199, DOI 10.1016/0026-0495(94)90245-3; DEBOER H, 1994, J BONE MINER RES, V9, P1319; Drake WM, 2001, CLIN ENDOCRINOL, V54, P525, DOI 10.1046/j.1365-2265.2001.01246.x; Ezzat S, 2002, J CLIN ENDOCR METAB, V87, P2725, DOI 10.1210/jc.87.6.2725; Frystyk J, 2010, GROWTH HORM IGF RES, V20, P8, DOI 10.1016/j.ghir.2009.09.004; Giavoli C, 2004, J CLIN ENDOCR METAB, V89, P5397, DOI 10.1210/jc.2004-1114; Gibney J, 1999, J CLIN ENDOCR METAB, V84, P2596, DOI 10.1210/jc.84.8.2596; Gilchrist FJ, 2002, CLIN ENDOCRINOL, V57, P363, DOI 10.1046/j.1365-2265.2002.01608.x; Gleeson HK, 2004, J CLIN ENDOCR METAB, V89, P662, DOI 10.1210/jc.2003-031224; Gotherstrom G, 2007, J CLIN ENDOCR METAB, V92, P1442, DOI 10.1210/jc.2006-1487; Gotherstrom G, 2007, EUR J ENDOCRINOL, V156, P55, DOI 10.1530/eje.1.02317; Gotherstrom G, 2009, J CLIN ENDOCR METAB, V94, P809, DOI 10.1210/jc.2008-1538; Hartman ML, 2002, J CLIN ENDOCR METAB, V87, P477, DOI 10.1210/jc.87.2.477; Hersch EC, 2008, CLIN INTERV AGING, V3, P121; Hilding A, 1999, J CLIN ENDOCR METAB, V84, P2013, DOI 10.1210/jc.84.6.2013; Ho KKY, 2007, EUR J ENDOCRINOL, V157, P695, DOI 10.1530/EJE-07-0631; HO KY, 1987, J CLIN ENDOCR METAB, V64, P51, DOI 10.1210/jcem-64-1-51; Hoffman AR, 2004, J CLIN ENDOCR METAB, V89, P2048, DOI 10.1210/jc.2003-030346; HOLMES SJ, 1995, CLIN ENDOCRINOL, V43, P143, DOI 10.1111/j.1365-2265.1995.tb01908.x; HOLMES SJ, 1995, CLIN ENDOCRINOL, V43, P151, DOI 10.1111/j.1365-2265.1995.tb01909.x; HOLMES SJ, 1994, J CLIN ENDOCR METAB, V78, P669, DOI 10.1210/jc.78.3.669; Johannsson G, 1996, J CLIN ENDOCR METAB, V81, P2865, DOI 10.1210/jc.81.8.2865; Johannsson G, 2002, J CLIN ENDOCR METAB, V87, P1743, DOI 10.1210/jc.87.4.1743; Johannsson G, 1997, J CLIN ENDOCR METAB, V82, P727, DOI 10.1210/jc.82.3.727; JOHANSSON JO, 1995, METABOLISM, V44, P1126, DOI 10.1016/0026-0495(95)90004-7; Jorgensen J O L, 2005, J Endocrinol Invest, V28, P47; Karavitaki N, 2006, CLIN ENDOCRINOL, V64, P556, DOI 10.1111/j.1365-2265.2006.02508.x; Kargi AY, 2012, CURR OPIN ENDOCRINOL, V19, P300, DOI 10.1097/MED.0b013e32835430da; KAUFMAN JM, 1992, J CLIN ENDOCR METAB, V74, P118, DOI 10.1210/jc.74.1.118; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Koltowska-Haggstrom M, 2009, EUR J ENDOCRINOL, V161, pS51, DOI 10.1530/EJE-09-0266; Lanning NJ, 2006, REV ENDOCR METAB DIS, V7, P225, DOI 10.1007/s11154-007-9025-5; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; Leonsson M, 2002, CLIN ENDOCRINOL, V57, P751, DOI 10.1046/j.1365-2265.2002.01663.x; Longobardi S, 1996, J CLIN ENDOCR METAB, V81, P1244, DOI 10.1210/jc.81.3.1244; Losa M, 2008, THYROID, V18, P1249, DOI 10.1089/thy.2008.0266; Maison P, 2003, CIRCULATION, V108, P2648, DOI 10.1161/01.CIR.0000100720.01867.1D; Maison P, 2004, J CLIN ENDOCR METAB, V89, P2192, DOI 10.1210/jc.2003-030840; Maiter D, 2006, EUR J ENDOCRINOL, V155, P253, DOI 10.1530/eje.1.02209; McKenna SP, 1999, QUAL LIFE RES, V8, P373, DOI 10.1023/A:1008987922774; MEROLA B, 1993, J CLIN ENDOCR METAB, V77, P1658, DOI 10.1210/jc.77.6.1658; Moe KE, 1998, J GERONTOL A-BIOL, V53, pB117, DOI 10.1093/gerona/53A.2.B117; Molitch ME, 2011, J CLIN ENDOCR METAB, V96, P1587, DOI 10.1210/jc.2011-0179; Moller N, 2009, CLIN NUTR, V28, P597, DOI 10.1016/j.clnu.2009.08.015; Moller N, 2009, ENDOCR REV, V30, P152, DOI 10.1210/er.2008-0027; Monson JP, 2007, CLIN ENDOCRINOL, V67, P623, DOI 10.1111/j.1365-2265.2007.02935.x; Moock J, 2009, EUR J ENDOCRINOL, V160, P17, DOI 10.1530/EJE-08-0738; Mulder RL, 2009, CANCER TREAT REV, V35, P616, DOI 10.1016/j.ctrv.2009.06.004; Murata M, 2003, EUR J ENDOCRINOL, V148, P333, DOI 10.1530/eje.0.1480333; Murray RD, 2004, J CLIN ENDOCR METAB, V89, P1124, DOI 10.1210/jc.2003-030685; Murray RD, 1999, CLIN ENDOCRINOL, V51, P565, DOI 10.1046/j.1365-2265.1999.00838.x; Ohlsson C, 1998, ENDOCR REV, V19, P55, DOI 10.1210/er.19.1.55; Oliveira JLM, 2007, J CLIN ENDOCR METAB, V92, P4664, DOI 10.1210/jc.2007-1636; Olsson DS, 2009, EUR J ENDOCRINOL, V161, P663, DOI 10.1530/EJE-09-0572; PARKIN JM, 1974, ARCH DIS CHILD, V49, P904, DOI 10.1136/adc.49.11.904; Petersenn S, 2002, EUR J ENDOCRINOL, V146, P667, DOI 10.1530/eje.0.1460667; Pfeifer M, 1999, J CLIN ENDOCR METAB, V84, P453, DOI 10.1210/jc.84.2.453; Popovic V, 2000, LANCET, V356, P1137, DOI 10.1016/S0140-6736(00)02755-0; RABEN MS, 1962, NEW ENGL J MED, V266, P31, DOI 10.1056/NEJM196201042660109; RABINOWITZ D, 1963, NATURE, V199, P913, DOI 10.1038/199913a0; ROSEN T, 1993, ACTA ENDOCRINOL-COP, V129, P201, DOI 10.1530/acta.0.1290201; Rosen T, 1997, EUR J ENDOCRINOL, V137, P240, DOI 10.1530/eje.0.1370240; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; Rosilio M, 2004, J CLIN ENDOCR METAB, V89, P1684, DOI 10.1210/jc.2003-030134; SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605; Sassolas G, 1999, EUR J ENDOCRINOL, V141, P595, DOI 10.1530/eje.0.1410595; Sathiavageeswaran M, 2007, EUR J ENDOCRINOL, V156, P439, DOI 10.1530/eje.1.02346; Savendahl L, 2012, J CLIN ENDOCR METAB, V97, pE213, DOI 10.1210/jc.2011-2882; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2007, LANCET, V369, P1461, DOI 10.1016/S0140-6736(07)60673-4; Sesmilo G, 2001, J CLIN ENDOCR METAB, V86, P1518, DOI 10.1210/jc.86.4.1518; Sesmilo G, 2000, ANN INTERN MED, V133, P111, DOI 10.7326/0003-4819-133-2-200007180-00010; SHAH A, 1992, BRIT MED J, V304, P173, DOI 10.1136/bmj.304.6820.173; Sherlock M, 2010, ENDOCR REV, V31, P301, DOI 10.1210/er.2009-0033; Sklar CA, 2002, J CLIN ENDOCR METAB, V87, P3136, DOI 10.1210/jc.87.7.3136; Smith JC, 2002, CLIN ENDOCRINOL, V56, P493, DOI 10.1046/j.1365-2265.2002.01514.x; Stochholm K, 2007, EUR J ENDOCRINOL, V157, P9, DOI 10.1530/EJE-07-0013; Stochholm K, 2007, HORM RES, V68, P173, DOI 10.1159/000110618; Stochholm K, 2006, EUR J ENDOCRINOL, V155, P61, DOI 10.1530/eje.1.02191; Svensson J, 2003, J CLIN ENDOCR METAB, V88, P2061, DOI 10.1210/jc.2002-020901; Takala J, 1999, NEW ENGL J MED, V341, P785, DOI 10.1056/NEJM199909093411102; Tanriverdi F, 2010, PITUITARY, V13, P146, DOI 10.1007/s11102-009-0215-x; Tauber M, 1997, J CLIN ENDOCR METAB, V82, P352, DOI 10.1210/jc.82.2.352; Tomlinson JW, 2001, LANCET, V357, P425, DOI 10.1016/S0140-6736(00)04006-X; TOOGOOD AA, 1994, CLIN ENDOCRINOL, V41, P511, DOI 10.1111/j.1365-2265.1994.tb02583.x; Toogood AA, 1997, ACTA PAEDIATR, V86, P117; Urushihara H, 2007, EUR J ENDOCRINOL, V156, P637, DOI 10.1530/EJE-07-0016; van der Klaauw AA, 2007, EUR J ENDOCRINOL, V156, P455, DOI 10.1530/EJE-06-0699; van der Lely AJ, 2004, ENDOCR REV, V25, P426, DOI 10.1210/er.2002-0029; Vestergaard P, 1997, HORM METAB RES, V29, P106, DOI 10.1055/s-2007-979000; Vi TN, 2009, PITUITARY, V12, P125, DOI 10.1007/s11102-008-0101-y; Wacharasindhu S, 1996, CLIN ENDOCRINOL, V45, P553, DOI 10.1046/j.1365-2265.1996.00850.x; WEAVER JU, 1994, CLIN ENDOCRINOL, V41, P639, DOI 10.1111/j.1365-2265.1994.tb01830.x; Widdowson WM, 2008, J CLIN ENDOCR METAB, V93, P4413, DOI 10.1210/jc.2008-1239; Woodhouse LJ, 2006, ENDOCR REV, V27, P287, DOI 10.1210/er.2004-0022; Wuster C, 2001, J BONE MINER RES, V16, P398, DOI 10.1359/jbmr.2001.16.2.398; Yuen KCJ, 2009, J CLIN ENDOCR METAB, V94, P2702, DOI 10.1210/jc.2009-0299	136	40	43	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1759-5029	1759-5037		NAT REV ENDOCRINOL	Nat. Rev. Endocrinol.	JUN	2013	9	6					335	345		10.1038/nrendo.2013.77			11	Endocrinology & Metabolism	Endocrinology & Metabolism	149QK	WOS:000319335900007	23629539				2021-06-18	
J	Redell, JB; Moore, AN; Grill, RJ; Johnson, D; Zhao, J; Liu, Y; Dash, PK				Redell, John B.; Moore, Anthony N.; Grill, Raymond J.; Johnson, Daniel; Zhao, Jing; Liu, Yin; Dash, Pramod K.			Analysis of Functional Pathways Altered after Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						bioinformatics; GFAP; IL-1 beta; MIP-1 alpha; neuroinflammation; UCHL1	CONTROLLED CORTICAL IMPACT; POSTTRAUMATIC-STRESS-DISORDER; LATERAL FLUID PERCUSSION; HEAD-INJURY; BEHAVIORAL DEFICITS; ENDOTHELIAL-CELLS; AXONAL PATHOLOGY; MESSENGER-RNAS; MOUSE MODEL; C-FOS	Concussive injury (or mild traumatic brain injury; mTBI) can exhibit features of focal or diffuse injury patterns. We compared and contrasted the cellular and molecular responses after mild controlled cortical impact (mCCI; a focal injury) or fluid percussion injury (FPI; a diffuse injury) in rats. The rationale for this comparative analysis was to investigate the brain's response to mild diffuse versus mild focal injury to identify common molecular changes triggered by these injury modalities and to determine the functional pathways altered after injury that may provide novel targets for therapeutic intervention. Microarrays containing probes against 21,792 unique messenger RNAs (mRNAs) were used to investigate the changes in cortical mRNA expression levels at 3 and 24 h postinjury. Of the 354 mRNAs with significantly altered expression levels after mCCI, over 89% (316 mRNAs) were also contained within the mild FPI (mFPI) data set. However, mFPI initiated a more widespread molecular response, with over 2300 mRNAs differentially expressed. Bioinformatic analysis of annotated Gene Ontology molecular function and biological pathway terms showed a significant overrepresentation of genes belonging to inflammation, stress, and signaling categories in both data sets. We therefore examined changes in the protein levels of a panel of 23 cytokines and chemokines in cortical extracts using a Luminex-based bead immunoassay and detected significant increases in macrophage inflammatory protein (MIP)-1 alpha (CCL3), GRO-KC (CXCL1), interleukin (IL)-1 alpha, IL-1 beta, and IL-6. Immunohistochemical localization of MIP-1 alpha and IL-1 beta showed marked increases at 3 h postinjury in the cortical vasculature and microglia, respectively, that were largely resolved by 24 h postinjury. Our findings demonstrate that both focal and diffuse mTBI trigger many shared pathobiological processes (e.g., inflammatory responses) that could be targeted for mechanism-based therapeutic interventions.	[Redell, John B.; Moore, Anthony N.; Johnson, Daniel; Zhao, Jing; Liu, Yin; Dash, Pramod K.] Univ Texas Hlth Sci Ctr Houston, Dept Neurobiol & Anat, Houston, TX 77225 USA; [Grill, Raymond J.] Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77225 USA	Dash, PK (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Neurobiol & Anat, POB 20036, Houston, TX 77225 USA.	p.dash@uth.tmc.edu		Dash, Pramod/0000-0001-6746-1002	Department of Defense (DoD)United States Department of Defense [W81XWH-08-2-0134]; Institute for Rehabilitation and Research/Mission Connect; National Center for Research Resources (NCRR)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR027359]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR027359] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM) [R01LM010022] Funding Source: NIH RePORTER	This work was supported by grants from the Department of Defense (DoD; W81XWH-08-2-0134), The Institute for Rehabilitation and Research/Mission Connect, and award number S10RR027359 from the National Center for Research Resources (NCRR). The content is solely the responsibility of the authors, and does not necessarily represent the official views of the DoD, the NCRR, or the National Institutes of Health.	Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berardini TZ, 2010, NUCLEIC ACIDS RES, V38, pD331, DOI 10.1093/nar/gkp1018; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Carbon S, 2009, BIOINFORMATICS, V25, P288, DOI 10.1093/bioinformatics/btn615; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; Chui R, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-1; Colgan NC, 2010, J NEUROTRAUM, V27, P1265, DOI 10.1089/neu.2009.1267; Creamer M, 2005, BEHAV RES THER, V43, P1383, DOI 10.1016/j.brat.2004.11.001; d'Hemecourt P, 2011, CLIN SPORTS MED, V30, pviii; d'Hemecourt P, 2011, CLIN SPORT MED, V30, P63, DOI 10.1016/j.csm.2010.08.008; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; Golding EA, 2003, J CEREBR BLOOD F MET, V23, P210, DOI 10.1097/01.WCB.0000044739.64940.B5; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Israelsson C, 2009, J NEUROTRAUM, V26, P1307, DOI [10.1089/neu.2008.0676, 10.1089/neu.2008-0676]; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rothwell N, 2003, BRAIN BEHAV IMMUN, V17, P152, DOI 10.1016/S0889-1591(02)00098-3; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schultz BA, 2011, NEUROREHABILITATION, V28, P309, DOI 10.3233/NRE-2011-0659; Sherer M, 2009, ARCH PHYS MED REHAB, V90, P1749, DOI 10.1016/j.apmr.2009.05.011; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Sosin DM, 1996, BRAIN INJURY, V10, P47; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zhang WD, 2000, J CEREBR BLOOD F MET, V20, P967, DOI 10.1097/00004647-200006000-00009; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	59	40	40	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2013	30	9			SI		752	764		10.1089/neu.2012.2437			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	145BJ	WOS:000318987600007	22913729	Green Published			2021-06-18	
J	Guo, H; Zhao, Z; Yang, Q; Wang, M; Bell, RD; Wang, S; Chow, N; Davis, TP; Griffin, JH; Goldman, SA; Zlokovic, BV				Guo, Huang; Zhao, Zhen; Yang, Qi; Wang, Min; Bell, Robert D.; Wang, Su; Chow, Nienwen; Davis, Thomas P.; Griffin, John H.; Goldman, Steven A.; Zlokovic, Berislav V.			An Activated Protein C Analog Stimulates Neuronal Production by Human Neural Progenitor Cells via a PAR1-PAR3-S1PR(1)-Akt Pathway	JOURNAL OF NEUROSCIENCE			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; STEM-CELLS; BRAIN; ANTICOAGULANT; DIFFERENTIATION; PROLIFERATION; NEUROGENESIS; MIGRATION; MODULATION; RECEPTOR-1	Activated protein C (APC) is a protease with anticoagulant and cell-signaling activities. In the CNS, APC and its analogs with reduced anticoagulant activity but preserved cell signaling activities, such as 3K3A-APC, exert neuroprotective, vasculoprotective, and anti-inflammatory effects. Murine APC promotes subependymal neurogenesis in rodents in vivo after ischemic and traumatic brain injury. Whether human APC can influence neuronal production from resident progenitor cells in humans is unknown. Here we show that 3K3A-APC, but not S360A-APC (an enzymatically inactive analog of APC), stimulates neuronal mitogenesis and differentiation from fetal human neural stem and progenitor cells (NPCs). The effects of 3K3A-APC on proliferation and differentiation were comparable to those obtained with fibroblast growth factor and brain-derived growth factor, respectively. Its promoting effect on neuronal differentiation was accompanied by inhibition of astroglial differentiation. In addition, 3K3A-APC exerted modest anti-apoptotic effects during neuronal production. These effects appeared to be mediated through specific protease activated receptors (PARs) and sphingosine-1-phosphate receptors (S1PRs), in that siRNA-mediated inhibition of PARs 1-4 and S1PRs 1-5 revealed that PAR1, PAR3, and S1PR(1) are required for the neurogenic effects of 3K3A-APC. 3K3A-APC activated Akt, a downstream target of S1PR(1), which was inhibited by S1PR(1), PAR1, and PAR3 silencing. Adenoviral transduction of NPCs with a kinase-defective Akt mutant abolished the effects of 3K3A-APC on NPCs, confirming a key role of Akt activation in 3K3A-APC-mediated neurogenesis. Therefore, APC and its pharmacological analogs, by influencing PAR and S1PR signals in resident neural progenitor cells, may be potent modulators of both development and repair in the human CNS.	[Guo, Huang; Zhao, Zhen; Yang, Qi; Wang, Min; Zlokovic, Berislav V.] Univ So Calif, Keck Sch Med, Zilkha Neurogenet Inst, Ctr Neurodegenerat & Regenerat, Los Angeles, CA 90089 USA; [Guo, Huang; Zhao, Zhen; Yang, Qi; Wang, Min; Zlokovic, Berislav V.] Univ So Calif, Keck Sch Med, Dept Physiol & Biophys, Los Angeles, CA 90089 USA; [Bell, Robert D.] Univ Rochester, Med Ctr, Ctr Neurodegenerat & Vasc Brain Disorders, Rochester, NY 14642 USA; [Bell, Robert D.] Univ Rochester, Med Ctr, Dept Neurosurg, Rochester, NY 14642 USA; [Wang, Su; Goldman, Steven A.] Univ Rochester, Med Ctr, Dept Neurol, Ctr Translat Neuromed, Rochester, NY 14642 USA; [Chow, Nienwen] ZZ Biotech LLC, Rochester, NY 14642 USA; [Davis, Thomas P.] Univ Arizona, Dept Med Pharmacol, Coll Med, Blood Brain Barrier Res Lab, Tucson, AZ 85724 USA; [Griffin, John H.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Zlokovic, BV (corresponding author), Univ So Calif, Keck Sch Med, Zilkha Neurogenet Inst, Room 101,1501 San Pablo St, Los Angeles, CA 90089 USA.	zlokovic@usc.edu	zhao, zhen/A-2080-2012; davis, thomas p/F-3244-2015	zhao, zhen/0000-0001-8967-5570; davis, thomas p/0000-0001-8465-4973; Griffin, John/0000-0002-4302-2547; Goldman, Steven/0000-0002-5498-4303	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL63290, HL52246, R01NS75345, R01NS39559]; New York Stem Cell Research Board; National Cancer Institute Cancer Center Shared Grant [5P30 CA014089]; University of Southern California Provost Funds; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA014089] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL063290, R37HL052246, R01HL052246] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS075345, R01NS039559] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (Grant #HL63290 to B.Z., Grant #HL52246 to J.H.G., and Grants #R01NS75345 to R01NS39559 to S. G.), as well as by the New York Stem Cell Research Board. We thank Dr. Robert Freeman(University of Rochester Medical Center, Rochester, NY) for providing the Ad. AktK179A construct, Dr. Joe G.N. Garcia (University of Chicago, Chicago, IL) for providing the Ad. EDG1 construct, and Dr. Abhay Sagare and Theresa Barrett for technical help and discussion. The flow cytometry study and cell cycle analysis were performed at the University of Southern California Broad California Institute of Restorative Medicine Center Flow Cytometry Core Facility, which is supported by the National Cancer Institute Cancer Center Shared Grant 5P30 CA014089 and the University of Southern California Provost Funds.	Breunig JJ, 2007, CELL STEM CELL, V1, P612, DOI 10.1016/j.stem.2007.11.008; Cheng T, 2006, NAT MED, V12, P1278, DOI 10.1038/nm1498; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Davis MD, 2005, J BIOL CHEM, V280, P9833, DOI 10.1074/jbc.M412356200; Dayer AG, 2007, BRAIN, V130, P2962, DOI 10.1093/brain/awm200; Deane R, 2009, J CEREBR BLOOD F MET, V29, P25, DOI 10.1038/jcbfm.2008.117; Durbec Pascale, 2008, V438, P213, DOI 10.1007/978-1-59745-133-8_18; Feistritzer C, 2005, BLOOD, V105, P3178, DOI 10.1182/blood-2004-10-3985; Finigan JH, 2005, J BIOL CHEM, V280, P17286, DOI 10.1074/jbc.M412427200; Gale AJ, 2002, J BIOL CHEM, V277, P28836, DOI 10.1074/jbc.M204363200; Goldman SA, 1997, J NEUROBIOL, V32, P554, DOI 10.1002/(SICI)1097-4695(19970605)32:6<554::AID-NEU2>3.0.CO;2-Z; Goldman SA, 2001, HIGH YIELD SELECTION; Griffin JH, 2012, INT J HEMATOL, V95, P333, DOI 10.1007/s12185-012-1059-0; Guo H, 2004, NEURON, V41, P563, DOI 10.1016/S0896-6273(04)00019-4; Guo HA, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-13; Guo H, 2009, J NEUROCHEM, V109, P116, DOI 10.1111/j.1471-4159.2009.05921.x; Guo H, 2009, EUR J NEUROSCI, V29, P1119, DOI 10.1111/j.1460-9568.2009.06664.x; Harada J, 2004, J NEUROCHEM, V88, P1026, DOI 10.1046/j.1471-4159.2003.02219.x; Hirabayashi Y, 2004, DEVELOPMENT, V131, P2791, DOI 10.1242/dev.01165; Jossin Y, 2007, MOL CELL BIOL, V27, P7113, DOI 10.1128/MCB.00928-07; Karumbayaram S, 2009, STEM CELLS, V27, P806, DOI 10.1002/stem.31; Kerschen EJ, 2007, J EXP MED, V204, P2439, DOI 10.1084/jem.20070404; Kim JY, 2009, NEURON, V63, P761, DOI 10.1016/j.neuron.2009.08.008; Kim WR, 2011, DEV GROWTH DIFFER, V53, P225, DOI 10.1111/j.1440-169X.2010.01226.x; Kimura A, 2007, STEM CELLS, V25, P115, DOI 10.1634/stemcells.2006-0223; KIRSCHENBAUM B, 1995, P NATL ACAD SCI USA, V92, P210, DOI 10.1073/pnas.92.1.210; Kong H, 2008, J CELL SCI, V121, P4029, DOI 10.1242/jcs.035758; Liu D, 2004, NAT MED, V10, P1379, DOI 10.1038/nm1122; Mao YW, 2009, CELL, V136, P1017, DOI 10.1016/j.cell.2008.12.044; Morales-Ruiz M, 2001, J BIOL CHEM, V276, P19672, DOI 10.1074/jbc.M009993200; Mosnier LO, 2007, BLOOD, V109, P3161, DOI 10.1182/blood-2006-09-003004; Mosnier LO, 2004, BLOOD, V104, P1740, DOI 10.1182/blood-2004-01-0110; Nakamura M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020717; Okada Y, 2008, STEM CELLS, V26, P3086, DOI 10.1634/stemcells.2008-0293; Otaegi G, 2006, J CELL SCI, V119, P2739, DOI 10.1242/jcs.03012; Peltier J, 2007, DEV NEUROBIOL, V67, P1348, DOI 10.1002/dneu.20506; Petraglia AL, 2010, NEUROSURGERY, V66, P165, DOI 10.1227/01.NEU.0000363148.49779.68; Pincus DW, 1998, ANN NEUROL, V43, P576, DOI 10.1002/ana.410430505; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Robel S, 2011, NAT REV NEUROSCI, V12, P88, DOI 10.1038/nrn2978; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Sahni V, 2010, NAT REV NEUROL, V6, P363, DOI 10.1038/nrneurol.2010.73; Sakayori N, 2011, GENES CELLS, V16, P778, DOI 10.1111/j.1365-2443.2011.01527.x; Saxe JP, 2007, CHEM BIOL, V14, P1019, DOI 10.1016/j.chembiol.2007.07.016; Schaphorst KL, 2003, AM J PHYSIOL-LUNG C, V285, pL258, DOI 10.1152/ajplung.00311.2002; Sierra A, 2010, CELL STEM CELL, V7, P483, DOI 10.1016/j.stem.2010.08.014; Silva A, 2009, J NEUROSCI RES, V87, P1986, DOI 10.1002/jnr.22041; Sun LX, 2004, J CLIN INVEST, V113, P1364, DOI 10.1172/JCI200420001; Thiyagarajan M, 2008, J NEUROSCI, V28, P12788, DOI 10.1523/JNEUROSCI.3485-08.2008; Walker CT, 2010, BRAIN RES, V1347, P125, DOI 10.1016/j.brainres.2010.05.075; Wang L, 2005, J CEREBR BLOOD F MET, V25, P1150, DOI 10.1038/sj.jcbfm.9600112; Wang S, 2010, J NEUROSCI, V30, P14635, DOI 10.1523/JNEUROSCI.1729-10.2010; Wang YM, 2012, STROKE, V43, P2444, DOI 10.1161/STROKEAHA.112.658997; Wang YM, 2009, STROKE, V40, P1864, DOI 10.1161/STROKEAHA.108.536680; Williams PD, 2012, CURR PHARM DESIGN, V18, P4215; Zhong ZH, 2009, J CLIN INVEST, V119, P3437, DOI 10.1172/JCI38476; Zlokovic BV, 2011, NAT REV NEUROSCI, V12, P723, DOI 10.1038/nrn3114; Zlokovic BV, 2011, TRENDS NEUROSCI, V34, P198, DOI 10.1016/j.tins.2011.01.005	58	40	42	0	18	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	APR 3	2013	33	14					6181	+		10.1523/JNEUROSCI.4491-12.2013			11	Neurosciences	Neurosciences & Neurology	120QP	WOS:000317186800031	23554499	Bronze, Green Accepted, Green Published			2021-06-18	
J	Russo, E; di Paola, ED; Gareri, P; Siniscalchi, A; Labate, A; Gallelli, L; Citraro, R; De Sarro, G				Russo, Emilio; di Paola, Eugenio Donato; Gareri, Pietro; Siniscalchi, Antonio; Labate, Angelo; Gallelli, Luca; Citraro, Rita; De Sarro, Giovambattista			Pharmacodynamic potentiation of antiepileptic drugs' effects by some HMG-CoA reductase inhibitors against audiogenic seizures in DBA/2 mice	PHARMACOLOGICAL RESEARCH			English	Article						Epilepsy; Cholesterol; Statins; Anticonvulsant potency; Pharmacodynamic; AEDs; Drug-drug Interaction	HIPPOCAMPAL CELL-DEATH; ACID-INDUCED SEIZURES; HYPERKINETIC MOVEMENT-DISORDERS; DEEP PREPIRIFORM CORTEX; TEMPORAL-LOBE EPILEPSY; NITRIC-OXIDE SYNTHASE; CORTICAL-NEURONS; INDUCED EXCITOTOXICITY; ATORVASTATIN TREATMENT; NEUROLOGICAL DEFICIT	It is known that the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are effective in both the primary and the secondary prevention of ischemic heart disease. Increasing evidence indicates that statins have protective effects in several neurological diseases including stroke, cerebral ischemia, Parkinson disease, multiple sclerosis, traumatic brain injury and epilepsy. The aim of the present research was to evaluate the effects of some HMG-CoA reductase inhibitors (i.e. lovastatin, simvastatin, atorvastatin, fluvastatin and pravastatin) commonly used for the treatment of hypercholesterolemia in the DBA/2 mice, an animal model of generalized tonic-clonic seizures. Furthermore, the co-administration of these compounds with some antiepileptic drugs (AEDs; i.e. carbamazepine, diazepam, felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate and valproate) was studied in order to identify possible positive pharmacological interactions. Simvastatin only was active against both the tonic and clonic phase of audiogenic seizures, whereas the other statins tested were only partially effective against the tonic phase with the following order of potency: lovastatin > fluvastatin > atorvastatin; pravastatin was completely ineffective up to the dose of 150 mg/kg. The co-administration of ineffective doses of all statins with AEDs generally increased the potency of the latter reducing their ED50 values. In particular, simvastatin was the most active in potentiating the activity of AEDs and the combinations of statins with carbamazepine, diazepam, felbamate, lamotrigine, topiramate and valproate were the most favorable, whereas, the co-administrations with the other AEDs studied was in most cases neutral. The increase in potency was generally associated with an enhancement of motor impairment (TD50); however, the therapeutic index (TD50/ED50) of combined treatment of AEDs with statins was predominantly more favorable than control. Statins administration did not significantly affect the total plasma but, in some cases, it increased the free plasma levels and the brain concentrations of some of the AEDs studied (i.e. carbamazepine, diazepam, phenytoin and valproate); however, these alterations where not statistically significant. Therefore, with the exception of the latter compounds, we might exclude pharmacokinetic interactions and conclude that for the most of AEDs, potentiation was of pharmacodynamic nature. In conclusion, simvastatin, fluvastatin, lovastatin and atorvastatin showed an additive anticonvulsant effect when co-administered with some AEDs, most notably carbamazepine, diazepam, felbamate, lamotrigine, topiramate and valproate, implicating a possible therapeutic relevance of such drug combinations. The present results suggest that statins, besides the beneficial cardiovascular effects, might be able to affect brain areas, which might participate in the regulation of seizure susceptibility. (C) 2013 Published by Elsevier Ltd.	[Russo, Emilio; di Paola, Eugenio Donato; Gareri, Pietro; Gallelli, Luca; Citraro, Rita; De Sarro, Giovambattista] Magna Graecia Univ Catanzaro, Clin Pharmacol Unit, Dept Hlth Sci, Sch Med, I-88100 Catanzaro, Italy; [Siniscalchi, Antonio] Annunziata Hosp, Neurol Unit, Dept Neurosci, Cosenza, Italy; [Labate, Angelo] Magna Graecia Univ Catanzaro, Sch Med, Inst Neurol, I-88100 Catanzaro, Italy	De Sarro, G (corresponding author), Magna Graecia Univ Catanzaro, Clin Pharmacol Unit, Dept Hlth Sci, Sch Med, Viale Europa, I-88100 Catanzaro, Italy.	desarro@unicz.it	gallelli, luca/A-5180-2011; Siniscalchi, Antonio/H-7143-2019; Russo, Emilio/G-5241-2010	gallelli, luca/0000-0003-0858-7902; Russo, Emilio/0000-0002-1279-8123; De Sarro, Giovambattista/0000-0002-7629-6579; Labate, Angelo/0000-0002-8827-7324; Citraro, Rita/0000-0001-6746-6751	Italian Ministry of Education, University and Research (MIUR, Cofin, Rome)Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN); National Research Council (CNR, Rome)Consiglio Nazionale delle Ricerche (CNR)	This work was supported by the Italian Ministry of Education, University and Research (MIUR, Cofin 2007, Rome) and the National Research Council (CNR, Rome). Both were not involved in study design, collection, analysis and interpretation of data.	Bialer M, 2010, EPILEPSY RES, V92, P89, DOI 10.1016/j.eplepsyres.2010.09.001; Bosel J, 2005, J NEUROCHEM, V92, P1386, DOI 10.1111/j.1471-4159.2004.02980.x; Candrilli SD, 2010, EPILEPSY RES, V91, P260, DOI 10.1016/j.eplepsyres.2010.07.021; Canevini MP, 2010, EPILEPSIA, V51, P797, DOI 10.1111/j.1528-1167.2010.02520.x; Citraro R, 2011, EPILEPSY RES, V95, P60, DOI 10.1016/j.eplepsyres.2011.02.013; Comparato C, 2001, NUTR METAB CARDIOVAS, V11, P328; Corsini A, 2007, VASC HEALTH RISK MAN, V3, P611; De Luca G, 2005, PHARMACOL BIOCHEM BE, V81, P47, DOI 10.1016/j.pbb.2005.02.012; De Luca G, 2006, PHARMACOL BIOCHEM BE, V85, P804, DOI 10.1016/j.pbb.2006.11.016; De Sarro G, 1998, EUR J PHARMACOL, V349, P179, DOI 10.1016/S0014-2999(98)00193-9; De Sarro G, 2002, EUR J PHARMACOL, V442, P205, DOI 10.1016/S0014-2999(02)01536-4; De Sarro G, 2000, EUR J PHARMACOL, V394, P275, DOI 10.1016/S0014-2999(00)00086-8; De Sarro G, 2012, PHARMACOL RES, V65, P285, DOI 10.1016/j.phrs.2011.11.005; DESARRO G, 1993, EUR J PHARMACOL, V230, P151, DOI 10.1016/0014-2999(93)90797-L; DESARRO GB, 1991, FUNDAM CLIN PHARM, V5, P503; di Paola ED, 2007, EPILEPSY RES, V75, P112, DOI 10.1016/j.eptepsyres.2007.04.008; DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322; Endres M, 2005, J CEREBR BLOOD F MET, V25, P1093, DOI 10.1038/sj.jcbfm.9600116; Etminan M, 2010, NEUROLOGY, V75, P1496, DOI 10.1212/WNL.0b013e3181f96253; Fischer W, 2004, BASIC CLIN PHARMACOL, V94, P79, DOI 10.1111/j.1742-7843.2004.pto940205.x; Funck VR, 2011, EPILEPSIA, V52, P2094, DOI 10.1111/j.1528-1167.2011.03261.x; Gambardella Antonio, 2008, Neuropsychiatr Dis Treat, V4, P33; Gidal BE, 2009, NEUROLOGY, V72, P419, DOI 10.1212/01.wnl.0000341789.77291.8d; Gitto R, 2007, BIOORGAN MED CHEM, V15, P5417, DOI 10.1016/j.bmc.2007.05.059; Golomb BA, 2008, NEUROLOGY, V70, P2349, DOI 10.1212/01.wnl.0000317006.87071.b1; GUILLOT F, 1993, J CARDIOVASC PHARM, V21, P339, DOI 10.1097/00005344-199302000-00022; Hamelin BA, 1998, TRENDS PHARMACOL SCI, V19, P26, DOI 10.1016/S0165-6147(97)01147-4; Holtzman CW, 2006, PHARMACOTHERAPY, V26, P1601, DOI 10.1592/phco.26.11.1601; Johnson-Anuna LN, 2005, J PHARMACOL EXP THER, V312, P786, DOI 10.1124/jpet.104.075028; Labate A, 2012, EPILEPTIC DISORD, V14, P163, DOI 10.1684/epd.2012.0497; Laufs U, 2000, STROKE, V31, P2442, DOI 10.1161/01.STR.31.10.2442; Lee DK, 2012, CELL PHYSIOL BIOCHEM, V30, P499, DOI 10.1159/000341433; Lee JK, 2008, NEUROSCI LETT, V440, P260, DOI 10.1016/j.neulet.2008.05.112; Lee SH, 2008, J NEUROL SCI, V275, P64, DOI 10.1016/j.jns.2008.07.029; Levy RH, 2007, INT REV NEUROBIOL, V81, P235, DOI 10.1016/S0074-7742(06)81015-9; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Luoni C, 2011, EPILEPSIA, V52, P2181, DOI 10.1111/j.1528-1167.2011.03325.x; Meldrum BS, 1997, EPILEPSIA, V38, pS7, DOI 10.1111/j.1528-1157.1997.tb05204.x; Moezi L, 2012, EPILEPSY BEHAV, V23, P399, DOI 10.1016/j.yebeh.2012.02.001; Moldrich RX, 2003, EUR J PHARMACOL, V476, P3, DOI 10.1016/S0014-2999(03)02149-6; Monetti M, 2007, PHARMACOL RES, V55, P441, DOI 10.1016/j.phrs.2007.02.001; Naval NS, 2009, NEUROL RES, V31, P425, DOI 10.1179/174313208X353686; Pelaia G, 2012, CELL PROLIFERAT, V45, P557, DOI 10.1111/j.1365-2184.2012.00846.x; Piermartiri TCB, 2010, EXP NEUROL, V226, P274, DOI 10.1016/j.expneurol.2010.08.030; Piermartiri TCB, 2009, NEUROTOX RES, V16, P106, DOI 10.1007/s12640-009-9057-6; Ponce J, 2008, STROKE, V39, P1269, DOI 10.1161/STROKEAHA.107.498923; Ramirez C, 2011, J ALZHEIMERS DIS, V24, P161, DOI 10.3233/JAD-2010-101653; Rangel P, 2005, ARQ NEURO-PSIQUIAT, V63, P972, DOI 10.1590/S0004-282X2005000600013; Russo E, 2004, NEUROPHARMACOLOGY, V46, P865, DOI 10.1016/j.neuropharm.2003.11.028; Russo E, 2004, BRIT J PHARMACOL, V141, P285, DOI 10.1038/sj.bjp.0705617; Russo E, 2013, NEUROPHARMACOLOGY, V64, P371, DOI 10.1016/j.neuropharm.2012.06.039; Russo E, 2010, EPILEPSIA, V51, P1560, DOI 10.1111/j.1528-1167.2009.02400.x; Selley ML, 2005, BRAIN RES, V1037, P1, DOI 10.1016/j.brainres.2004.02.083; Serbanescu I, 2004, J LIPID RES, V45, P2038, DOI 10.1194/jlr.M400097-JLR200; Shimamura M, 2007, STROKE, V38, P3251, DOI 10.1161/STROKEAHA.107.485045; Sierra S, 2011, J ALZHEIMERS DIS, V23, P307, DOI 10.3233/JAD-2010-101179; Siniscalchi A, 2012, PHARMACOL RES, V65, P171, DOI 10.1016/j.phrs.2011.09.003; Siniscalchi A, 2010, CURR NEUROPHARMACOL, V8, P359, DOI 10.2174/157015910793358187; Siniscalchi Antonio, 2011, Ann Pharmacother, V45, pe33, DOI 10.1345/aph.1Q013; Siniscalchi A, 2012, PHARMACOL REP, V64, P24, DOI 10.1016/S1734-1140(12)70727-2; Stepien KM, 2012, EUR J PHARMACOL, V674, P20, DOI 10.1016/j.ejphar.2011.10.030; TURPIN JC, 1991, DEV NEUROSCI-BASEL, V13, P304, DOI 10.1159/000112177; Uzum G, 2010, EPILEPSY BEHAV, V19, P284, DOI 10.1016/j.yebeh.2010.07.024; van Vliet EA, 2011, EPILEPSIA, V52, P1319, DOI 10.1111/j.1528-1167.2011.03073.x; Wang Q, 2008, NEUROSCIENCE, V154, P1100, DOI 10.1016/j.neuroscience.2008.04.026; Wang Q, 2009, EXP NEUROL, V216, P132, DOI 10.1016/j.expneurol.2008.11.016; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; Wolozin B, 2007, BMC MED, V5, DOI 10.1186/1741-7015-5-20; Zacco A, 2003, J NEUROSCI, V23, P11104	69	40	40	0	19	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	1043-6618			PHARMACOL RES	Pharmacol. Res.	APR	2013	70	1					1	12		10.1016/j.phrs.2012.12.002			12	Pharmacology & Pharmacy	Pharmacology & Pharmacy	117BG	WOS:000316926500001	23253428				2021-06-18	
J	Asemota, AO; George, BP; Bowman, SM; Haider, AH; Schneider, EB				Asemota, Anthony O.; George, Benjamin P.; Bowman, Steven M.; Haider, Adil H.; Schneider, Eric B.			Causes and Trends in Traumatic Brain Injury for United States Adolescents	JOURNAL OF NEUROTRAUMA			English	Article						epidemiology; head trauma; pediatric brain injury; TBI	OUTCOMES; PREVALENCE; ADULTS; IMPACT	Traumatic brain injury (TBI) is a leading cause of death and disability among United States adolescents. The authors sought to determine causes and trends for TBI-related hospitalizations in the United States adolescent population (10-19 years). The authors identified common causes and trends of adolescent TBI, overall and within 2-year age categories, using hospitalization data from 2005 to 2009 in the Nationwide Inpatient Sample. The leading cause of adolescent TBI overall was motor vehicle occupant accidents (35%), which are also the leading cause in the 14-15, 16-17, and 18-19 year age groups. Falls were the cause of most TBI in the 10-11 year (23%) and 12-13 year (20%) age groups. For both unintentional and intentional mechanisms of injury, there was evidence of increasing hospitalizations with increasing age. From 2005 to 2009, the overall annual incidence of adolescent TBI hospitalizations decreased 21% from an estimated 75.5-59.3 per 100,000 (p < 0.001). These rates declined for mild, moderate, and severe TBI, and decreased for 2-year age groups, except for the 18-19 year-old group. For TBI attributable to motor vehicle occupants, rates declined 27% from 27.6 to 20.2 per 100,000 (p < 0.001). Motor vehicle occupant injuries account for 42% of in-hospital mortality from adolescent TBI; however, firearms are the most lethal mechanism with 46% proportional mortality among victims of firearm-related TBI. Rates of adolescent TBI-related hospitalizations have decreased overall. Motor vehicle accidents and firearms were identified as leading causes of injury and mortality for adolescent TBI, and represent potential targets for intervention.	[Asemota, Anthony O.; George, Benjamin P.; Haider, Adil H.; Schneider, Eric B.] Johns Hopkins Univ, Sch Med, Dept Surg, Ctr Surg Trials & Outcomes Res, Baltimore, MD 21287 USA; [Asemota, Anthony O.; George, Benjamin P.; Haider, Adil H.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [George, Benjamin P.] Univ Rochester, Sch Med & Dent, Rochester, NY USA; [Bowman, Steven M.] Natl Univ, Dept Community Hlth, Technol & Hlth Sci Ctr, San Diego, CA USA	Asemota, AO (corresponding author), Johns Hopkins Univ, Sch Med, Dept Surg, Ctr Surg Trials & Outcomes Res, 600 N Wolfe St,Blalock 618, Baltimore, MD 21287 USA.	aasemota@jhsph.edu		George, Benjamin/0000-0001-9966-5632			Agency for Healthcare Research and Quality, 2009, INTR HCUP NAT INP SA; Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; [Anonymous], 1997, ICDMAP 90 INJ SEV CO; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barrett M., 2010, HCUP METHODS SERIES, Vx0023; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finklestein EA, 2006, INCIDENCE EC BURDEN; Haider AH, 2011, J PEDIATR SURG, V46, P1557, DOI 10.1016/j.jpedsurg.2011.04.055; HUIZINGA D, 2000, COOCCURENCE DELINQUE; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; MOFFITT TE, 1993, PSYCHOL REV, V100, P674, DOI 10.1037/0033-295X.100.4.674; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Ruggles S., 2010, INTEGRATED PUBLIC US; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; U.S. Department of Transportation, 2012, TRAFF VOL TRENDS; Westfall JM, 2001, MED CARE, V39, P459, DOI 10.1097/00005650-200105000-00006; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	26	40	43	0	25	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2013	30	2					67	75		10.1089/neu.2012.2605			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	069NT	WOS:000313444000001	22989254				2021-06-18	
J	Doherty, A				Doherty, Alison			"It Takes a Village:" Interdisciplinary Research for Sport Management	JOURNAL OF SPORT MANAGEMENT			English	Article							PSYCHOLOGY; CONCUSSION; BAD	This paper, from the Dr. Earle F. Zeigler Award Lecture presented at the NASSM 2012 Conference in Seattle, outlines the merits and challenges of interdisciplinary research for the field of sport management. This alternative approach involves relating, integrating, and relocating disciplinary thinking to arrive at a mutually-determined research problem that represents new ways of conceptualizing phenomena. It enables moving away from the monodisciplinary research that characterizes much of our field to examine phenomena from different angles, and perhaps more effectively close the research-practice gap with knowledge derived from multiple perspectives. The author argues that it is time to engage in interdisciplinary research in sport management as no one discipline has all the answers; rather, "it takes a village" to solve the complex problems in our world.	Univ Western Ontario, Sch Kinesiol, London, ON, Canada	Doherty, A (corresponding author), Univ Western Ontario, Sch Kinesiol, London, ON, Canada.						Aboelela SW, 2007, HEALTH SERV RES, V42, P329, DOI 10.1111/j.1475-6773.2006.00621.x; Amis J, 2005, J SPORT MANAGE, V19, P355, DOI 10.1123/jsm.19.4.355; Andrew D.P.S., 2009, INT J SPORT MANAGEME, V5, P73, DOI 10.1504/IJSMM.2009.021751; Bruhn JG, 1995, INTEGR PHYS BEH SCI, V30, P331, DOI 10.1007/BF02691605; Bruhn JG, 2000, INTEGR PHYS BEH SCI, V35, P58, DOI 10.1007/BF02911166; Buller H, 2009, AREA, V41, P395, DOI 10.1111/j.1475-4762.2008.00856.x; Chalip L, 2006, J SPORT MANAGE, V20, P1, DOI 10.1123/jsm.20.1.1; Chelladurai P., 2009, MANAGING ORG SPORT P; Choi BCK, 2006, CLIN INVEST MED, V29, P351; Clinton Hillary Rodham, 1996, IT TAKES VILLAGE OTH; Costa CA, 2005, J SPORT MANAGE, V19, P117, DOI 10.1123/jsm.19.2.117; CROW GM, 1992, AM EDUC RES J, V29, P737, DOI 10.2307/1163405; Culverhouse Gay, 2011, THROWAWAY PLAYERS CO; Cuneen J, 2004, J SPORT MANAGE, V18, P1, DOI 10.1123/jsm.18.1.1; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; DeNeui D. L., 1996, Journal of Sport and Social Issues, V20, P69, DOI 10.1177/019372396020001006; Doherty A., 2012, SPORT MANAGEMENT REV, DOI [10.1016/j.smr.2011.112.006, DOI 10.1016/J.SMR.2011.112.006]; Doherty A. J., 1998, Sport Management Review, V1, P1, DOI 10.1016/S1441-3523(98)70097-X; Eitzen D. S., 2012, FAIR FOUL MYTHS PARA; Frisby W, 2005, J SPORT MANAGE, V19, P1, DOI 10.1123/jsm.19.1.1; Giulianotti R, 2010, J SPORT SOC ISSUES, V34, P49, DOI 10.1177/0193723509354042; Goldberg DS, 2008, HEC FORUM, V20, P337, DOI 10.1007/s10730-008-9079-0; Greenhow A., 2011, SPORTS LAW EJOURNAL; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Hecht AN, 2002, SENTON HALL J SPORTS, V12, P17; Hokowhitu B., MAI REV, V1; Hoye Russell, 2009, SPORT MANAGEMENT PRI; Inglis S, 2007, J SPORT MANAGE, V21, P1, DOI 10.1123/jsm.21.1.1; Kidd B, 2008, SPORT SOC, V11, P370, DOI 10.1080/17430430802019268; Kim S. M., 2008, Sport Marketing Quarterly, V17, P109; Love A, 2012, SPORT MANAG REV, V15, P244, DOI 10.1016/j.smr.2011.08.001; Mahony DF, 2008, J SPORT MANAGE, V22, P1, DOI 10.1123/jsm.22.1.1; Mair H, 2006, LEISURE SCI, V28, P197, DOI 10.1080/01490400500484099; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maton KI, 2006, AM J COMMUN PSYCHOL, V38, P9, DOI 10.1007/s10464-006-9062-3; McGrath RG, 2007, ACAD MANAGE J, V50, P1365; National Academy of Sciences, 2005, FAC INT RES; Osborne B., 2012, ANN C N AM SOC SPORT; Oughton E, 2009, AREA, V41, P385, DOI 10.1111/j.1475-4762.2009.00903.x; Pederson P.M., 2011, CONT SPORT MANAGEMEN; Peetz T.B., 2011, SPORT MARKET Q, V20, P209; Pitts B.G., 2005, SMART J BUSINESS MAN, V2, P33; Pitts BG, 2001, J SPORT MANAGE, V15, P1, DOI 10.1123/jsm.15.1.1; Popper K.R., 1963, CONJECTURES REFUTATT; Porter AL, 2006, RES EVALUAT, V15, P187, DOI 10.3152/147154406781775841; Reich SM, 2006, AM J COMMUN PSYCHOL, V38, P51, DOI 10.1007/s10464-006-9064-1; Rhoten D., 2004, ITEMS ISSUES, V5, P6; Sa CM, 2008, HIGH EDUC, V55, P537, DOI 10.1007/s10734-007-9073-5; Sandberg J, 2011, ACAD MANAGE REV, V36, P338; Schwarz E. C., 2011, International Journal of Sport Management and Marketing, V7, P33, DOI 10.1504/IJSMM.2010.029710; Spence G. B., 2012, INT COACHING PSYCHOL, V7, P122; Thibault L, 2009, J SPORT MANAGE, V23, P1, DOI 10.1123/jsm.23.1.1; van Knippenberg D, 2011, ORGAN PSYCHOL REV, V1, P3, DOI 10.1177/2041386610386427; Watson T. J., 1997, BRIT J MANAGE, V5, P3, DOI [10.1111/1467-8551.00034, DOI 10.1111/1467-8551.00034]; Watson TJ, 1994, SEARCH MANAGEMENT; Weingart P., 2000, PRACTISING INTERDISC, P25; Weiss MR, 2008, QUEST, V60, P63, DOI 10.1080/00336297.2008.10483569; Zeigler E.R, 2011, ANN C N AM SOC SPORT; Zeigler EF, 2007, J SPORT MANAGE, V21, P297, DOI 10.1123/jsm.21.3.297; Zeigler EF, 2003, QUEST, V55, P285, DOI 10.1080/00336297.2003.10491805; ZEIGLER EF, 1975, ADM THEORY PRACTICE	62	40	40	1	23	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	0888-4773	1543-270X		J SPORT MANAGE	J.Sport Manage.	JAN	2013	27	1					1	10					10	Hospitality, Leisure, Sport & Tourism; Management; Sport Sciences	Social Sciences - Other Topics; Business & Economics; Sport Sciences	075VR	WOS:000313915800001					2021-06-18	
J	Ennis, N; Rosenbloom, BN; Canzian, S; Topolovec-Vranic, J				Ennis, Naomi; Rosenbloom, Brittany N.; Canzian, Sonya; Topolovec-Vranic, Jane			Depression and anxiety in parent versus spouse caregivers of adult patients with traumatic brain injury: A systematic review	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Depression; Anxiety; Traumatic brain injury; Systematic review; Caregivers	SEVERE HEAD-INJURY; PSYCHOLOGICAL DISTRESS; RELATIVES; INDIVIDUALS; TBI; REHABILITATION; ADJUSTMENT; BURDEN; HEALTH; IMPACT	A systematic review of studies which evaluated depression and anxiety in parent versus spouse caregivers of adults with traumatic brain injury (TBI) was conducted. Demographic variables of the TBI patients and caregivers, study design, measurement tools used, and outcomes reported were collected. Twenty-four studies met the inclusion criteria and were evaluated for methodological quality. While the majority of studies revealed no significant differences between caregiver types on measures of depression and/or anxiety, there was a great deal of variation in methodology and quality between the studies. Overall, high levels of caregiver distress were exposed, regardless of caregiver type (parent versus spouse). There is a need for qualitative and quantitative research designs in order to elucidate the factors that put caregivers at risk for depression and anxiety.	[Ennis, Naomi; Rosenbloom, Brittany N.; Canzian, Sonya; Topolovec-Vranic, Jane] St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Topolovec-Vranic, Jane] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada	Topolovec-Vranic, J (corresponding author), St Michaels Hosp, Trauma & Neurosurg Program, 30 Bond St,Bond 4-016, Toronto, ON M5B 1W8, Canada.	topolovec-vranicj@smh.ca	Topolovec-Vranic, Jane/A-5293-2013	Topolovec-Vranic, Jane/0000-0001-7695-4212	Ontario Neurotrauma Foundation [2008-ABI-THC-600]	Funding was provided by the Ontario Neurotrauma Foundation (2008-ABI-THC-600).	Anderson MI, 2009, BRAIN INJURY, V23, P931, DOI 10.3109/02699050903302336; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Blais MC, 2005, BRAIN INJURY, V19, P1223, DOI 10.1080/02699050500309387; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Flanagan DAJ, 1998, BRIT J CLIN PSYCHOL, V37, P431, DOI 10.1111/j.2044-8260.1998.tb01400.x; FLORIAN V, 1991, NEUROPSYCHOLOGY, V5, P267, DOI DOI 10.1037/0894-4105.5.4.267; Florian V., 1989, BRAIN INJURY, V3, P210, DOI 10.3109/02699058909029637; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kolakowsky-Hayner SA, 1999, NEUROREHABILITATION, V13, P27; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Layman DE, 2005, BRAIN INJURY, V19, P909, DOI 10.1080/02699050500109928; Leathem J, 1996, BRAIN INJURY, V10, P27; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; Livingston M G, 1987, Brain Inj, V1, P33, DOI 10.3109/02699058709034442; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 2002, J CLIN EXP NEUROPSYC, V24, P434, DOI 10.1076/jcen.24.4.434.1030; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; McPherson KM, 2000, DISABIL REHABIL, V22, P683, DOI 10.1080/096382800445489; Morris KC, 2001, BRAIN INJURY, V15, P239, DOI 10.1080/02699050010004068; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; PETERS L C, 1992, Brain Injury, V6, P461, DOI 10.3109/02699059209008141; Phelan SM, 2011, DISABIL HEALTH J, V4, P177, DOI 10.1016/j.dhjo.2011.03.003; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Rotondi AJ, 2007, J HEAD TRAUMA REHAB, V22, P14, DOI 10.1097/00001199-200701000-00002; Sady MD, 2010, ARCH PHYS MED REHAB, V91, P1542, DOI 10.1016/j.apmr.2010.07.012; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; Stebbins P, 2001, REHABIL PSYCHOL, V46, P178, DOI 10.1037/0090-5550.46.2.178; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Zeigler E A, 1999, J Neurosci Nurs, V31, P106	48	40	43	1	26	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JAN 1	2013	23	1					1	18		10.1080/09602011.2012.712871			18	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	096BD	WOS:000315377800001	22897335				2021-06-18	
J	Falahati, S; Breu, M; Waickman, AT; Phillips, AW; Arauz, EJ; Snyder, S; Porambo, M; Goeral, K; Comi, AM; Wilson, MA; Johnston, MV; Fatemi, A				Falahati, Sina; Breu, Markus; Waickman, Adam T.; Phillips, Andre W.; Arauz, Edwin J.; Snyder, Sophie; Porambo, Michael; Goeral, Katharina; Comi, Anne M.; Wilson, Mary Ann; Johnston, Michael V.; Fatemi, Ali			Ischemia-Induced Neuroinflammation Is Associated with Disrupted Development of Oligodendrocyte Progenitors in a Model of Periventricular Leukomalacia	DEVELOPMENTAL NEUROSCIENCE			English	Article						Infants; Inflammation; Ischemia; Microglia; Neonatal ischemic periventricular leukomalacia; Oligodendrocyte progenitor; White matter	WHITE-MATTER INJURY; CENTRAL-NERVOUS-SYSTEM; TRAUMATIC BRAIN-INJURY; PROTEIN 18 KDA; ACTIVATED MICROGLIA; PRETERM INFANTS; PRECURSOR CELLS; CEREBRAL-PALSY; NITRIC-OXIDE; NEONATAL-RATS	Microglial activation in crossing white matter tracts is a hallmark of noncystic periventricular leukomalacia (PVL), the leading pathology underlying cerebral palsy in prematurely born infants. Recent studies indicate that neuroinflammation within an early time window can produce long-lasting defects in oligodendroglial maturation, myelination deficit, as well as disruption of transcription factors important in oligodendroglial maturation. We recently reported an ischemic mouse model of PVL, induced by unilateral neonatal carotid artery ligation, leading to selective long-lasting bilateral myelination deficits, ipsilateral thinning of the corpus callosum, ventriculomegaly, as well as evidence of axonopathy. Here, we report that permanent unilateral carotid ligation on postnatal day 5 in CD-1 mice induces an inflammatory response, as defined by microglial activation and recruitment, as well as significant changes in cytokine expression (increased IL-1 beta, IL-6, TGF-beta(1), and TNF-alpha) following ischemia. Transient reduction in counts of oligodendrocyte progenitor cells (OPCs) at 24 and 48 h after ischemia, a shift in OPC cell size and morphology towards the more immature form, as well as likely migration of OPCs were found. These OPC changes were topographically associated with areas showing microglial activation, and OPC counts negatively correlated with increased microglial staining. The presented data show a striking neuroinflammatory response in an ischemia-induced model of PVL, associated with oligodendroglial injury. Future studies modulating the neuroinflammatory response in this model may contribute to a better understanding of the interaction between microglia and OPCs in PVL and open opportunities for future therapies. Copyright (C) 2013 S. Karger AG, Basel	[Falahati, Sina; Breu, Markus; Phillips, Andre W.; Arauz, Edwin J.; Snyder, Sophie; Porambo, Michael; Goeral, Katharina; Comi, Anne M.; Wilson, Mary Ann; Johnston, Michael V.; Fatemi, Ali] Kennedy Krieger Inst, Hugo W Moser Res Inst, Baltimore, MD 21205 USA; [Falahati, Sina; Breu, Markus; Phillips, Andre W.; Goeral, Katharina; Comi, Anne M.; Wilson, Mary Ann; Johnston, Michael V.; Fatemi, Ali] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA; [Comi, Anne M.; Johnston, Michael V.; Fatemi, Ali] Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA; [Wilson, Mary Ann] Johns Hopkins Univ, Dept Neurosci, Baltimore, MD USA; [Waickman, Adam T.] Johns Hopkins Univ, Grad Program Immunol, Baltimore, MD USA; [Falahati, Sina; Breu, Markus; Goeral, Katharina] Med Univ Vienna, Vienna, Austria	Fatemi, A (corresponding author), Kennedy Krieger Inst, 707 N Broadway,500I, Baltimore, MD 21205 USA.	fatemi@kennedykrieger.org		Goeral, Katharina/0000-0002-5209-6169; Waickman, Adam/0000-0002-4536-6714; Breu, Markus/0000-0003-3825-5749	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K08NS063956, R01NS028208, R01NS061969]; Child Neurology Foundation; Miracle for Megan Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54HD079123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [T32AI007247] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061969, K08NS063956, R01NS028208] Funding Source: NIH RePORTER	The authors would like to thank Ms. Patrice Carr and Ms. Karen Connor for their kind assistance with the immunohistochemial studies. This study was funded by the National Institute of Health (K08NS063956 to A. F., R01NS028208 to M.V.J., R01NS061969 to A. C.), Child Neurology Foundation (to A. F.), and the Miracle for Megan Foundation (to A.F.).	Back SA, 2005, NAT MED, V11, P966, DOI 10.1038/nm1279; Back SA, 2002, J NEUROSCI, V22, P455, DOI 10.1523/JNEUROSCI.22-02-00455.2002; Back SA, 2007, STROKE, V38, P724, DOI 10.1161/01.STR.0000254729.27386.05; Bal-Price A, 2001, J NEUROSCI, V21, P6480; Baud O, 2004, BRAIN PATHOL, V14, P1; Bechmann I, 2007, BLOOD BRAIN BARRIERS, P167; Billiards SS, 2008, BRAIN PATHOL, V18, P153, DOI 10.1111/j.1750-3639.2007.00107.x; Butovsky O, 2006, J CLIN INVEST, V116, P905, DOI 10.1172/JCI26836; Craig A, 2003, EXP NEUROL, V181, P231, DOI 10.1016/S0014-4886(03)00032-3; Dammann O, 2007, ACTA PAEDIATR, V96, P6, DOI 10.1111/j.1651-2227.2007.00097.x; Deng WB, 2010, NAT REV NEUROL, V6, P328, DOI 10.1038/nrneurol.2010.53; Derugin N, 2000, STROKE, V31, P1752, DOI 10.1161/01.STR.31.7.1752; Dommergues MA, 2003, NEUROSCIENCE, V121, P619, DOI 10.1016/S0306-4522(03)00558-X; Donnelly DJ, 2009, J NEUROSCI METH, V181, P36, DOI 10.1016/j.jneumeth.2009.04.010; Fatemi A, 2011, J CEREBR BLOOD F MET, V31, P2009, DOI 10.1038/jcbfm.2011.68; Fatemi A, 2009, CLIN PERINATOL, V36, P835, DOI 10.1016/j.clp.2009.07.011; Favrais G, 2011, ANN NEUROL, V70, P550, DOI 10.1002/ana.22489; Filipovic R, 2005, ANN NY ACAD SCI, V1048, P166, DOI 10.1196/annals.1342.015; Fleiss B, 2012, LANCET NEUROL, V11, P556, DOI 10.1016/S1474-4422(12)70058-3; Hagberg H, 2012, ANN NEUROL, V71, P444, DOI 10.1002/ana.22620; Hamrick SEG, 2004, J PEDIATR-US, V145, P593, DOI 10.1016/j.jpeds.2004.05.042; Haynes RL, 2005, J COMP NEUROL, V484, P156, DOI 10.1002/cne.20453; Itoh T, 2002, J NEUROCHEM, V81, P390, DOI 10.1046/j.1471-4159.2002.00866.x; Johnson S, 2007, SEMIN FETAL NEONAT M, V12, P363, DOI 10.1016/j.siny.2007.05.004; Johnston MV, 2011, LANCET NEUROL, V10, P372, DOI 10.1016/S1474-4422(11)70016-3; Judas M, 2005, AM J NEURORADIOL, V26, P2671; Kadhim H, 2002, NEUROLOGY, V58, P1125, DOI 10.1212/WNL.58.7.1125; Kadhim H, 2001, NEUROLOGY, V56, P1278, DOI 10.1212/WNL.56.10.1278; Khwaja O, 2008, ARCH DIS CHILD-FETAL, V93, pF153, DOI 10.1136/adc.2006.108837; Leviton A, 2005, ANN NEUROL, V58, P821, DOI 10.1002/ana.20662; Li JR, 2005, P NATL ACAD SCI USA, V102, P9936, DOI 10.1073/pnas.0502552102; Lin CY, 2010, ANN NEUROL, V68, P204, DOI 10.1002/ana.22049; Lipton SA, 1996, BRAIN PATHOL, V6, P507, DOI 10.1111/j.1750-3639.1996.tb00879.x; Litt J, 2005, J LEARN DISABIL-US, V38, P130, DOI 10.1177/00222194050380020301; Malaeb S, 2009, J CHILD NEUROL, V24, P1119, DOI 10.1177/0883073809338066; Mallard C, 2003, NEUROCHEM RES, V28, P215, DOI 10.1023/A:1022368915400; Mildner A, 2011, J NEUROSCI, V31, P11159, DOI 10.1523/JNEUROSCI.6209-10.2011; Miller BA, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-28; Monier A, 2007, J NEUROPATH EXP NEUR, V66, P372, DOI 10.1097/nen.0b013e3180517b46; Monier A, 2006, J COMP NEUROL, V499, P565, DOI 10.1002/cne.21123; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Nakajima Kazuyuki, 2004, Curr Drug Targets Cardiovasc Haematol Disord, V4, P65, DOI 10.2174/1568006043481284; *NAT CTR HLTH STAT, FIN NAT DAT; Olah M, 2012, GLIA, V60, P306, DOI 10.1002/glia.21266; Olivier P, 2005, J NEUROPATH EXP NEUR, V64, P998, DOI 10.1097/01.jnen.0000187052.81889.57; Palacios N, 2005, J NEUROCHEM, V95, P1091, DOI 10.1111/j.1471-4159.2005.03419.x; Pang Y, 2010, NEUROSCIENCE, V166, P464, DOI 10.1016/j.neuroscience.2009.12.040; Rakic S, 2000, EUR J NEUROSCI, V12, P2721, DOI 10.1046/j.1460-9568.2000.00153.x; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ransohoff RM, 2010, NATURE, V468, P253, DOI 10.1038/nature09615; Rhodes KE, 2006, NEUROSCIENCE, V140, P87, DOI 10.1016/j.neuroscience.2006.01.055; Rupprecht R, 2010, NAT REV DRUG DISCOV, V9, P971, DOI 10.1038/nrd3295; Sent E, 2006, MENT RETARD DEV D R, V12, P97, DOI 10.1002/mrdd.20106; Siebert JR, 2011, J NEUROCHEM, V119, P176, DOI 10.1111/j.1471-4159.2011.07370.x; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Tahraoui SL, 2001, BRAIN PATHOL, V11, P56; Talbott JF, 2007, EXP NEUROL, V204, P485, DOI 10.1016/j.expneurol.2006.12.013; Taylor DL, 2010, J NEUROSCI RES, V88, P1632, DOI 10.1002/jnr.22335; Venneti S, 2006, PROG NEUROBIOL, V80, P308, DOI 10.1016/j.pneurobio.2006.10.002; Verney C, 2012, J NEUROPATH EXP NEUR, V71, P251, DOI 10.1097/NEN.0b013e3182496429; Verney C, 2010, J ANAT, V217, P436, DOI 10.1111/j.1469-7580.2010.01245.x; Volpe JJ, 2011, ANN NEUROL, V70, P525, DOI 10.1002/ana.22533; Volpe JJ, 2009, LANCET NEUROL, V8, P110, DOI 10.1016/S1474-4422(08)70294-1; Yoon BH, 1997, AM J OBSTET GYNECOL, V177, P406, DOI 10.1016/S0002-9378(97)70206-0	64	40	44	0	8	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2013	35	2-3					182	196		10.1159/000346682			15	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	178JX	WOS:000321445100008	23445614	Green Accepted, Bronze			2021-06-18	
J	Macera, CA; Aralis, HJ; Rauh, MJ; MacGregor, AJ				Macera, Caroline A.; Aralis, Hilary J.; Rauh, Mitchell J.; MacGregor, Andrew J.			Do Sleep Problems Mediate the Relationship between Traumatic Brain Injury and Development of Mental Health Symptoms after Deployment?	SLEEP			English	Article						Posttraumatic stress disorder; sleep problems; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; DISTURBANCE; INSOMNIA; IRAQ; DEPRESSION; PREVALENCE; PATTERNS; PREDICTS	Study Objectives: Military members screening positive for blast-related traumatic brain injury (TBI) may subsequently screen positive for posttraumatic stress disorder (PTSD) or depression. The role of sleep as a mediating factor in the development of mental health symptoms was explored. Design: Prospective study with symptoms evaluated at two time points. Setting: Postdeployment service in Iraq, Afghanistan, or Kuwait during 2008 and 2009. Participants: There were 29,640 US Navy and Marine Corps men (29,019 who did not screen positive for PTSD at baseline, 27,702 who did not screen positive for depression at baseline, and 27,320 who did not screen positive at baseline for either condition). Measurements and Results: After controlling for sleep problems, the adjusted odds of receiving a positive PTSD screening at follow-up decreased from 1.61 (95% confidence interval [CI] 1.21-2.14) to 1.32 (95% CI 0.99-1.77) for a subject screening positive for TBI relative to a subject screening negative, suggesting that sleep problems mediated 26% of TBI's effect on development of PTSD. Likewise, after controlling for sleep problems, the adjusted odds of receiving a positive depression screening decreased from 1.41 (95% CI 1.11-1.80) to 1.15 (95% CI 0.90-1.47), suggesting that sleep problems mediated 41% of TBI's effect on development of depression. Results were similar for those with either PTSD or depression (37% mediated). Conclusions: These results suggest that sleep problems mediate the effect of a positive TBI screening on the development of mental health disorders, and sleep problems may be an early indicator of risk for PTSD or depression.	[Macera, Caroline A.] USN, Dept Warfighter Performance, Hlth Res Ctr, DHAPP, San Diego, CA 92106 USA	Macera, CA (corresponding author), USN, Dept Warfighter Performance, Hlth Res Ctr, DHAPP, 140 Sylvester Rd, San Diego, CA 92106 USA.	carol.macera@med.navy.mil		MacGregor, Andrew/0000-0003-1020-7390	U.S. Navy Bureau of Medicine and Surgery [60818]	This work was supported by the U.S. Navy Bureau of Medicine and Surgery under Work Unit No. 60818. The views expressed are those of the authors and do not reflect the official policy or position of the Department of the Navy, Department of Defense, or the US Government. Approved for public release; distribution is unlimited. This research was conducted in compliance with all applicable federal regulations governing the protection of human subjects (protocol NHRC. 2009.0020).	Asmundson GJG, 2000, BEHAV RES THER, V38, P203, DOI 10.1016/S0005-7967(99)00061-3; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Bryant RA, 2010, SLEEP, V33, P69, DOI 10.1093/sleep/33.1.69; Buysse DJ, 2008, SLEEP, V31, P473, DOI 10.1093/sleep/31.4.473; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Deployment Health Clinical Center, ASD HA MEM IMPL REV; Gelis LA, 2010, MIL MED, V175, P567, DOI 10.7205/MILMED-D-09-00123; Herr N.R., MEDIATION DICHOTOMOU; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; King DW, 1998, PSYCHOL ASSESSMENT, V10, P90, DOI 10.1037/1040-3590.10.2.90; Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C; Lewis V, 2009, MIL MED, V174, P948, DOI 10.7205/MILMED-D-04-0208; MacKinnon D P, 2000, Prev Sci, V1, P173, DOI 10.1023/A:1026595011371; MACKINNON DP, 1993, EVALUATION REV, V17, P144, DOI 10.1177/0193841X9301700202; MACKINNON DP, 1995, MULTIVAR BEHAV RES, V30, P41, DOI 10.1207/s15327906mbr3001_3; McLay RN, 2010, MIL MED, V175, P759, DOI 10.7205/MILMED-D-10-00193; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Peterson AL, 2008, MIL MED, V173, P230, DOI 10.7205/MILMED.173.3.230; Picchioni D, 2010, MIL PSYCHOL, V22, P340, DOI 10.1080/08995605.2010.491844; Preacher K, CALCULATION SOBEL TE; Prins A, 2003, PRIMARY CARE PSYCHIA, V9, P9; Rao V, 2011, J NEUROPSYCH CLIN N, V23, P201, DOI 10.1176/appi.neuropsych.23.2.201; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Seelig AD, 2010, SLEEP, V33, P1615, DOI 10.1093/sleep/33.12.1615; Warner CH, 2011, ARCH GEN PSYCHIAT, V68, P1065, DOI 10.1001/archgenpsychiatry.2011.112; Wright KM, 2008, MIL MED, V173, P411, DOI 10.7205/MILMED.173.5.411; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	33	40	42	0	15	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0161-8105	1550-9109		SLEEP	Sleep	JAN 1	2013	36	1					83	90		10.5665/sleep.2306			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	063LT	WOS:000313001200013	23288974	Green Published, Bronze			2021-06-18	
J	Plach, HL; Sells, CH				Plach, Heidi Lynn; Sells, Carol Haertlein			Occupational Performance Needs of Young Veterans	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						adaptation, psychological; independent living; motivation; occupational therapy; social participation; veterans health	POSTTRAUMATIC-STRESS-DISORDER; IRAQ; AFGHANISTAN	OBJECTIVE. We examined the occupational performance issues facing young U.S. veterans (aged 20-29 yr) who served in Iraq and Afghanistan. Perceived challenges in occupational performance, the most common mental health and brain injuries of war, and motivations for participation in daily occupations upon return to civilian life were identified. METHOD. Thirty young veterans from Operation Iraqi Freedom and Operation Enduring Freedom were interviewed using the Canadian Occupational Performance Measure (Law et al., 2005). They were also screened for posttraumatic stress disorder, traumatic brain injury, major depression, and alcohol abuse or dependency. RESULTS. The top five occupational performance challenges were engagement in relationships, school, physical health, sleeping, and driving. The health conditions screened positive for 23%-77% of respondents. CONCLUSION. This study identified challenges faced by today's young veterans when reintegrating into the community and daily life. Strategies for occupational therapy practitioners to aid veterans in community reintegration are discussed. Plach, H. L., & Sells, C. H. (2013). Occupational performance needs of young veterans. American Journal of Occupational Therapy, 67, 73-81. http://dx.dotorg/10.5014/ajot.2013.003871	[Plach, Heidi Lynn; Sells, Carol Haertlein] Univ Wisconsin, Dept Occupat Sci & Technol, Milwaukee, WI 53201 USA	Plach, HL (corresponding author), Univ Wisconsin, Dept Occupat Sci & Technol, POB 413, Milwaukee, WI 53201 USA.	bertrahl@uwm.edu					Babor T. F., 1992, AUDIT ALCOHOL USE DI, V4, P1; Berg AO, 2004, ANN INTERN MED, V140, P554, DOI 10.7326/0003-4819-140-7-200404060-00016; Briere J. N., 2006, PRINCIPLES TRAUMA TH; Burman ML, 2004, J STUD ALCOHOL, V65, P621, DOI 10.15288/jsa.2004.65.621; Cahill Shawn P, 2005, Psychiatry (Edgmont), V2, P34; Centers for Disease Control and Prevention (CDC), 2009, SUIC FACTS GLANC; Creamer M, 2004, PSYCHOTHERAPY, V41, P388, DOI 10.1037/0033-3204.41.4.388; Creswell J. W., 2017, DESIGNING CONDUCTING; Defense and Veterans Brain Injury Center, 2011, TBI FACTS; Defense and Veterans Brain Injury Center, 2007, 3 QUEST DVBIC TBI SC; Defense Manpower Data Center, 2011, CAS SUMM REAS; Dum M, 2008, ADDICT BEHAV, V33, P381, DOI 10.1016/j.addbeh.2007.09.017; Ebell MH, 2008, AM FAM PHYSICIAN, V78, P244; Eibner C., 2008, INVISIBLE WOUNDS WAR, P169; Gilbody S, 2007, J GEN INTERN MED, V22, P1596, DOI 10.1007/s11606-007-0333-y; Hasselkus B. R., 2002, MEANING EVERYDAY OCC, P41; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Law M., 2005, CANADIAN OCCUPATIONA, V4th ed; Merriam S.A., 2002, QUALITATIVE RES PRAC; Munoz JP, 2006, OCCUP THER HEALTH CA, V20, P135, DOI [10.1300/J003v20n03_09, 10.1080/J003v20n03_09]; Office of the Surgeon Multi-National Force-Iraq & Office of the Surgeon General U.S. Army Medical Command, 2009, 6 MHAT USA MED COMM; Office of the Surgeon Multi-National Force-Iraq & Office of the Surgeon General U.S. Army Medical Command, 2008, 5 MHAT USA MED COMM; Prins A, 2003, PRIMARY CARE PSYCHIA, V9, P9; Reger GM, 2006, MIL PSYCHOL, V18, P297, DOI 10.1207/s15327876mp1804_4; Reinert DF, 2007, ALCOHOL CLIN EXP RES, V31, P185, DOI 10.1111/j.1530-0277.2006.00295.x; Schwab KA, 2006, NEUROLOGY, V66, pA235; Sollinger J. M., 2008, INVISIBLE WOUNDS WAR, P19; Tanielian T., 2008, INVISIBLE WOUNDS WAR, P3; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Tompkins TL, 2009, J PRIM PREV, V30, P131, DOI 10.1007/s10935-009-0171-2; Tryssenaar J, 1999, Can J Occup Ther, V66, P188; U.S. Department of Defense, 2012, OP IR FREED OP END F; Vogel E. E., 1961, EVENTS LEADING FORMA; Wyman PA, 2008, J CONSULT CLIN PSYCH, V76, P104, DOI 10.1037/0022-006X.76.1.104; Young JE, 2001, CLIN HDB PSYCHOL DIS, P264	36	40	40	0	18	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490	1943-7676		AM J OCCUP THER	Am. J. Occup. Ther.	JAN-FEB	2013	67	1					73	81		10.5014/ajot.2013.003871			9	Rehabilitation	Rehabilitation	073UO	WOS:000313768800009	23245785	Bronze			2021-06-18	
J	Raj, R; Bendel, S; Reinikainen, M; Kivisaari, R; Siironen, J; Lang, M; Skrifvars, M				Raj, Rahul; Bendel, Stepani; Reinikainen, Matti; Kivisaari, Riku; Siironen, Jari; Lang, Maarit; Skrifvars, Markus			Hyperoxemia and long-term outcome after traumatic brain injury	CRITICAL CARE			English	Article						Arterial oxygen tension; Neurocritical care; Oxygenation; Traumatic brain injury; Hyperoxemia; Intensive care; Mortality; Mechanical ventilation	SEVERE HEAD-INJURY; ACUTE LUNG INJURY; TISSUE OXYGEN; NORMOBARIC HYPEROXIA; VENTILATED PATIENTS; ARTERIAL HYPEROXIA; PROGNOSTIC VALUE; INSPIRED OXYGEN; CARDIAC-ARREST; ASSOCIATION	Introduction: The relationship between hyperoxemia and outcome in patients with traumatic brain injury (TBI) is controversial. We sought to investigate the independent relationship between hyperoxemia and long-term mortality in patients with moderate-to-severe traumatic brain injury. Methods: The Finnish Intensive Care Consortium database was screened for mechanically ventilated patients with a moderate-to-severe TBI. Patients were categorized, according to the highest measured alveolar-arterial O-2 gradient or the lowest measured PaO2 value during the first 24 hours of ICU admission, to hypoxemia (<10.0 kPa), normoxemia (10.0 to 13.3 kPa) and hyperoxemia (>13.3 kPa). We adjusted for markers of illness severity to evaluate the independent relationship between hyperoxemia and 6-month mortality. Results: A total of 1,116 patients were included in the study, of which 16% (n = 174) were hypoxemic, 51% (n = 567) normoxemic and 33% (n = 375) hyperoxemic. The total 6-month mortality was 39% (n = 435). A significant association between hyperoxemia and a decreased risk of mortality was found in univariate analysis (P = 0.012). However, after adjusting for markers of illness severity in a multivariate logistic regression model hyperoxemia showed no independent relationship with 6-month mortality (hyperoxemia vs. normoxemia OR 0.88, 95% CI 0. 63 to 1.22, P = 0.43; hyperoxemia vs. hypoxemia OR 0.97, 95% CI 0.63 to 1.50, P = 0.90). Conclusion: Hyperoxemia in the first 24 hours of ICU admission after a moderate-to-severe TBI is not predictive of 6-month mortality.	[Raj, Rahul; Kivisaari, Riku; Siironen, Jari; Skrifvars, Markus] Univ Helsinki, Cent Hosp, Dept Neurosurg, FI-00029 Hus Helsinki, Finland; [Bendel, Stepani; Lang, Maarit] Kuopio Univ Hosp, Dept Intens Care Med, Kuopio 70211, Finland; [Reinikainen, Matti] North Karelia Cent Hosp, Dept Intens Care Med, Joensuu 80210, Finland; [Skrifvars, Markus] Univ Helsinki, Cent Hosp, Dept Anesthesiol & Intens Care Med, Helsinki, Finland	Raj, R (corresponding author), Univ Helsinki, Cent Hosp, Dept Neurosurg, Topeliuksenkatu 5, FI-00029 Hus Helsinki, Finland.	rahul.br.raj@icloud.com	Raj, Rahul/K-7693-2012	Raj, Rahul/0000-0003-4243-9591; Reinikainen, Matti/0000-0001-6878-3740	Helsinki University Hospital EVO grant [TYH2012142]; Medicinska Understodsforeningen Liv och Halsa	The study was funded by a Helsinki University Hospital EVO grant (TYH2012142) and Medicinska Understodsforeningen Liv och Halsa.	Adamides AA, 2006, ANZ J SURG, V76, P163, DOI 10.1111/j.1445-2197.2006.03674.x; Altemeier WA, 2007, CURR OPIN CRIT CARE, V13, P73, DOI 10.1097/MCC.0b013e32801162cb; Asher SR, 2013, J NEUROSURG ANESTH, V25, P168, DOI 10.1097/ANA.0b013e318283d350; Bellomo R, 2011, CRIT CARE, V15, DOI 10.1186/cc10090; Beynon C, 2012, J NEUROTRAUM, V29, P2109, DOI 10.1089/neu.2012.2365; Bohman LE, 2011, NEUROCRIT CARE, V14, P361, DOI 10.1007/s12028-011-9526-7; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS65; Brain Trauma Foundation, 2007, J NEUROTRAUMA S, V24, pS1; Brenner M, 2012, ARCH SURG-CHICAGO, V147, P1042, DOI 10.1001/archsurg.2012.1560; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; de Graaff AE, 2011, INTENS CARE MED, V37, P46, DOI 10.1007/s00134-010-2025-z; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; Eastwood G, 2012, INTENS CARE MED, V38, P91, DOI 10.1007/s00134-011-2419-6; Fehlings MG, 2007, J NEUROSURG, V106, P525, DOI 10.3171/jns.2007.106.4.525; Floyd TF, 2003, J APPL PHYSIOL, V95, P2453, DOI 10.1152/japplphysiol.00303.2003; Gole Y, 2011, EUR J APPL PHYSIOL, V111, P937, DOI 10.1007/s00421-010-1711-4; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kallet RH, 2013, RESP CARE, V58, P123, DOI 10.4187/respcare.01963; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; Kilgannon JH, 2010, JAMA-J AM MED ASSOC, V303, P2165, DOI 10.1001/jama.2010.707; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kumaria A, 2009, BRIT J NEUROSURG, V23, P576, DOI 10.3109/02688690903050352; Longhi L, 2002, ACT NEUR S, V81, P315; Longmore JM, 2011, OXFORD HDB CLIN MED; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mascia L, 2007, CRIT CARE MED, V35, P1815, DOI 10.1097/01.CCM.0000275269.77467.DF; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Nangunoori R, 2012, NEUROCRIT CARE, V17, P131, DOI 10.1007/s12028-011-9621-9; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Nelskyla A, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-35; Pascual JL, 2011, J TRAUMA, V70, P535, DOI 10.1097/TA.0b013e31820b59de; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Reinikainen M, 2012, ACTA ANAESTH SCAND, V56, P1114, DOI 10.1111/j.1399-6576.2012.02669.x; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Sarrafzadeh A S, 2000, Neurosurg Focus, V9, pe2; Sinclair SE, 2004, CRIT CARE MED, V32, P2496, DOI 10.1097/01.CCM.0000148231.04642.8D; Singhal AB, 2005, STROKE, V36, P797, DOI 10.1161/01.STR.0000158914.66827.2e; Singhal AB, 2002, J CEREBR BLOOD F MET, V22, P861, DOI 10.1097/00004647-200207000-00011; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Young P, 2012, CRIT CARE RESUSC, V14, P14	50	40	41	1	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2013	17	4							R177	10.1186/cc12856			10	Critical Care Medicine	General & Internal Medicine	AB1GO	WOS:000331539700050	23958227	DOAJ Gold, Green Published			2021-06-18	
J	Roquilly, A; Loutrel, O; Cinotti, R; Rosenczweig, E; Flet, L; Mahe, PJ; Dumont, R; Chupin, AM; Peneau, C; Lejus, C; Blanloeil, Y; Volteau, C; Asehnoune, K				Roquilly, Antoine; Loutrel, Olivier; Cinotti, Raphael; Rosenczweig, Elise; Flet, Laurent; Mahe, Pierre Joachim; Dumont, Romain; Chupin, Anne Marie; Peneau, Catherine; Lejus, Corinne; Blanloeil, Yvonnick; Volteau, Christelle; Asehnoune, Karim			Balanced versus chloride-rich solutions for fluid resuscitation in brain-injured patients: a randomised double-blind pilot study	CRITICAL CARE			English	Article							LACTATED RINGERS SOLUTION; SALINE-BASED HETASTARCH; ACID-BASE; METABOLIC-ACIDOSIS; HEAD-INJURY; MANAGEMENT; MORTALITY; STATEMENT; CONSENSUS; INFUSION	Introduction: We sought to investigate whether the use of balanced solutions reduces the incidence of hyperchloraemic acidosis without increasing the risk for intracranial hypertension in patients with severe brain injury. Methods: We conducted a single-centre, two-arm, randomised, double-blind, pilot controlled trial in Nantes, France. Patients with severe traumatic brain injury (Glasgow Coma Scale score <= 8) or subarachnoid haemorrhage (World Federation of Neurosurgical Society grade III or higher) who were mechanically ventilated were randomised within the first 12 hours after brain injury to receive either isotonic balanced solutions (crystalloid and hydroxyethyl starch; balanced group) or isotonic sodium chloride solutions (crystalloid and hydroxyethyl starch; saline group) for 48 hours. The primary endpoint was the occurrence of hyperchloraemic metabolic acidosis within 48 hours. Results: Forty-two patients were included, of whom one patient in each group was excluded (one consent withdrawn and one use of forbidden therapy). Nineteen patients (95%) in the saline group and thirteen (65%) in the balanced group presented with hyperchloraemic acidosis within the first 48 hours (hazard ratio = 0.28, 95% confidence interval [CI] = 0.11 to 0.70; P = 0.006). In the saline group, pH (P = .004) and strong ion deficit (P = 0.047) were lower and chloraemia was higher (P = 0.002) than in the balanced group. Intracranial pressure was not different between the study groups (mean difference 4 mmHg [-1;8]; P = 0.088). Seven patients (35%) in the saline group and eight (40%) in the balanced group developed intracranial hypertension (P = 0.744). Three patients (14%) in the saline group and five (25%) in the balanced group died (P = 0.387). Conclusions: This study provides evidence that balanced solutions reduce the incidence of hyperchloraemic acidosis in brain-injured patients compared to saline solutions. Even if the study was not powered sufficiently for this endpoint, intracranial pressure did not appear different between groups.	[Roquilly, Antoine; Loutrel, Olivier; Mahe, Pierre Joachim; Dumont, Romain; Chupin, Anne Marie; Peneau, Catherine; Lejus, Corinne; Blanloeil, Yvonnick] CHU Nantes, Hotel Dieu, Serv Anesthesie Reanimat, F-44000 Nantes, France; [Cinotti, Raphael; Blanloeil, Yvonnick] CHU Nantes, Hop Laennec, Serv Anesthesie Reanimat, F-44000 Nantes, France; [Rosenczweig, Elise] CHU Nantes, Serv Reanimat Med Polyvalente, F-44000 Nantes, France; [Flet, Laurent] CHU Nantes, DIEU Essais Clin, Serv HOTEL, F-44000 Nantes, France; [Volteau, Christelle] CHU Nantes, Cellule Biostat Cellule Promot Rech Clin, F-44000 Nantes, France	Asehnoune, K (corresponding author), CHU Nantes, Hotel Dieu, Serv Anesthesie Reanimat, F-44000 Nantes, France.	karim.asehnoune@chu-nantes.fr	FLET, Laurent/X-1192-2019; Roquilly, Antoine/P-9826-2017; Deriche, Mohamed/A-9871-2008	FLET, Laurent/0000-0001-8305-7085; Deriche, Mohamed/0000-0002-5287-1874	B-BRAUN MEDICAL; University Hospital of Nantes (UHN)	We gratefully acknowledge Delphine Flattres for her critical help with the study and the nurses and medical team of the Surgical Intensive Care Units of Nantes University Hospital for technical assistance. This work was supported by B-BRAUN MEDICAL. B-BRAUN MEDICAL provided the solutions but was not involved in the study design, patient recruitment, data collection and analysis, report writing and publication. The University Hospital of Nantes (UHN) sponsored the study. UHN stored the data, ensured the monitoring of the study. The biostatistics unit (Christelle Volteau) of UHN performed the statistical analysis. The local pharmacist (Laurent Flet) blinded the solutions. The results were presented (abstract) at the 53th congress of the French Congress of Anaesthesia and Critical Care Medicine (SFAR 2011).	Adrogue HJ, 2000, NEW ENGL J MED, V342, P1581, DOI 10.1056/NEJM200005253422107; Andrews PJD, 2008, INTENS CARE MED, V34, P1362, DOI 10.1007/s00134-008-1103-y; [Anonymous], 2007, J NEUROTRAUMA S1, V24, pS1, DOI DOI 10.1089/NEU.2006.0209; Audibert G, 2012, Ann Fr Anesth Reanim, V31, pe109, DOI 10.1016/j.annfar.2012.04.014; Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; Blanloeil Y, 2002, ANN FR ANESTH, V21, P211, DOI 10.1016/S0750-7658(02)00572-5; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Gan TJ, 1999, ANESTH ANALG, V88, P992, DOI 10.1097/00000539-199905000-00005; Gattas DJ, 2012, ANESTH ANALG, V114, P159, DOI 10.1213/ANE.0b013e318236b4d6; Ichai C, 2009, INTENS CARE MED, V35, P471, DOI 10.1007/s00134-008-1283-5; Jayakumar AR, 2010, METAB BRAIN DIS, V25, P31, DOI 10.1007/s11011-010-9180-3; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Kellum JA, 2005, CRIT CARE, V9, P500, DOI 10.1186/cc3789; Kellum JA, 2000, CRIT CARE, V4, P6, DOI 10.1186/cc644; Kiraly LN, 2006, J TRAUMA, V61, P57, DOI 10.1097/01.ta.0000220373.29743.69; Lepelletier D, 2010, J NEUROSURG ANESTH, V22, P32, DOI 10.1097/ANA.0b013e3181bdf52f; Martin G, 2002, J CARDIOTHOR VASC AN, V16, P441, DOI 10.1053/jcan.2002.125146; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; MCFARLANE C, 1994, ANAESTHESIA, V49, P779; Reinhart K, 2012, INTENS CARE MED, V38, P368, DOI 10.1007/s00134-012-2472-9; Roche AM, 2006, ANESTH ANALG, V102, P1274, DOI 10.1213/01.ane.0000197694.48429.94; Roche AM, 2002, ANAESTHESIA, V57, P950, DOI 10.1046/j.1365-2044.2002.02707.x; Roquilly A, 2011, CRIT CARE, V15, DOI 10.1186/cc10522; Scheingraber S, 1999, ANESTHESIOLOGY, V90, P1265, DOI 10.1097/00000542-199905000-00007; Shackford SR, 1998, J TRAUMA, V44, P50, DOI 10.1097/00005373-199801000-00004; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; STEWART PA, 1983, CAN J PHYSIOL PHARM, V61, P1444, DOI 10.1139/y83-207; Todd SR, 2007, J TRAUMA, V62, P636, DOI 10.1097/TA.0b013e31802ee521; WAKIM KG, 1970, J AMER MED ASSOC, V214, P1710, DOI 10.1001/jama.1970.03180090074027; Waters JH, 1999, CRIT CARE MED, V27, P2142, DOI 10.1097/00003246-199910000-00011; WILCOX CS, 1983, J CLIN INVEST, V71, P726, DOI 10.1172/JCI110820; Wilkes NJ, 2002, ANESTH ANALG, V94, P538, DOI 10.1097/00000539-200203000-00011; Wilkes NJ, 2001, ANESTH ANALG, V93, P811, DOI 10.1097/00000539-200110000-00003; Williams EL, 1999, ANESTH ANALG, V88, P999, DOI 10.1097/00000539-199905000-00006; Yunos NM, 2012, JAMA-J AM MED ASSOC, V308, P1566, DOI 10.1001/jama.2012.13356; Yunos NM, 2011, CRIT CARE MED, V39, P2419, DOI 10.1097/CCM.0b013e31822571e5; Yunos NM, 2010, CRIT CARE, V14, DOI 10.1186/cc9052	38	40	43	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2013	17	2							R77	10.1186/cc12686			13	Critical Care Medicine	General & Internal Medicine	264OG	WOS:000327887300042	23601796	DOAJ Gold, Green Published			2021-06-18	
J	De Beaumont, L; Henry, LC; Gosselin, N				De Beaumont, Louis; Henry, Luke C.; Gosselin, Nadia			Long-term functional alterations in sports concussion	NEUROSURGICAL FOCUS			English	Article						sports concussion; neurophysiology; long-term effect; cognition; motor function; neuropsychology	HUMAN MOTOR CORTEX; COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; PAIRED ASSOCIATIVE STIMULATION; GABA(B) RECEPTOR AGONIST; ELECTROPHYSIOLOGICAL ABNORMALITIES; MULTIPLE CONCUSSIONS; CEREBRAL CONCUSSION; POSTURAL CONTROL; NCAA CONCUSSION	In this review the authors discuss persistent and cumulative alterations in both cognitive and motor function after sports concussions detected with some of the newest, most sophisticated brain investigation techniques. Ranging from subclinical neurophysiological alterations in young concussed athletes to quantifiable cognitive and motor function declines in former athletes in late adulthood with concussions sustained decades earlier, this review is also intended to provide new insights into the neuropathophysiology of sports concussion. (http://thejns.org/doi/abs/10.3171/2012.9.FOCUS12278)	[De Beaumont, Louis] Univ Quebec Trois Rivieres, Dept Psychol, Trois Rivieres, PQ G9A 5H7, Canada; [De Beaumont, Louis; Gosselin, Nadia] Montreal Sacred Heart Hosp, Res Ctr, Montreal, PQ, Canada; [Henry, Luke C.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA	De Beaumont, L (corresponding author), Univ Quebec Trois Rivieres, Dept Psychol, Michel Sarrazin Hall,CP 500, Trois Rivieres, PQ G9A 5H7, Canada.	louis.de.beaumont@umontreal.ca					Abbruzzese G, 2002, J CLIN NEUROPHYSIOL, V19, P307, DOI 10.1097/00004691-200208000-00005; Allen JS, 2005, AM J HUM BIOL, V17, P673, DOI 10.1002/ajhb.20439; Barbeau E, 2004, NEUROLOGY, V62, P1317, DOI 10.1212/01.WNL.0000120548.24298.DB; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; Carrillo C, 2010, J CLIN MICROBIOL, V48, P4094, DOI 10.1128/JCM.01081-10; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Craik FIM, 2006, TRENDS COGN SCI, V10, P131, DOI 10.1016/j.tics.2006.01.007; CRAIK FIM, 1999, HDB AGING COGNITION; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; DONCHIN E, 1966, IEEE T BIO-MED ENG, VBM13, P131, DOI 10.1109/TBME.1966.4502423; Gaetz M, 2000, BRAIN INJURY, V14, P1077; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Geurts ACH, 2005, GAIT POSTURE, V22, P267, DOI 10.1016/j.gaitpost.2004.10.002; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Heilbronner RL, 2009, ARCH CLIN NEUROPSYCH, V24, P11, DOI 10.1093/arclin/acp005; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hollister JR, 2008, VIROLOGY, V373, P411, DOI 10.1016/j.virol.2007.12.019; INGHILLERI M, 1993, J PHYSIOL-LONDON, V466, P521; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kobayashi M, 2003, LANCET NEUROL, V2, P145, DOI 10.1016/S1474-4422(03)00321-1; Koop MM, 2008, MOVEMENT DISORD, V23, P1262, DOI 10.1002/mds.22077; Lefaucheur JP, 2006, MOVEMENT DISORD, V21, P1350, DOI 10.1002/mds.20966; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McDonnell MN, 2007, EXP BRAIN RES, V180, P181, DOI 10.1007/s00221-006-0849-0; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McNamara RK, 1996, PHARMACOL BIOCHEM BE, V53, P303, DOI 10.1016/0091-3057(95)02025-X; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; POLICH J, 1988, J CLIN NEUROPHYSIOL, V5, P287, DOI 10.1097/00004691-198807000-00004; Polich John, 2004, Phys Med Rehabil Clin N Am, V15, P133, DOI 10.1016/S1047-9651(03)00109-8; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Restivo DA, 2004, FUNCT NEUROL, V19, P37; Rioult-Pedotti MS, 1998, NAT NEUROSCI, V1, P230, DOI 10.1038/678; Rioult-Pedotti MS, 2000, SCIENCE, V290, P533, DOI 10.1126/science.290.5491.533; SELKOE DJ, 1991, NATURE, V354, P432, DOI 10.1038/354432a0; Stefan K, 2002, J PHYSIOL-LONDON, V543, P699, DOI 10.1113/jphysiol.2002.023317; Stefan K, 2000, BRAIN, V123, P572, DOI 10.1093/brain/123.3.572; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Theriault M, 2009, BRAIN INJURY, V23, P899, DOI 10.1080/02699050903283189; Tremblay S, 2012, CEREB CORTEX; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Ziemann U, 2004, J NEUROSCI, V24, P1666, DOI 10.1523/JNEUROSCI.5016-03.2004; Zillmer E. A., 2001, PRINCIPLES NEUROPSYC	71	40	40	0	54	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	DEC	2012	33	6							E8	10.3171/2012.9.FOCUS12278			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	048GI	WOS:000311898500009	23199431	Bronze			2021-06-18	
J	Zuckerman, SL; Solomon, GS; Forbes, JA; Haase, RF; Sills, AK; Lovell, MR				Zuckerman, Scott L.; Solomon, Gary S.; Forbes, Jonathan A.; Haase, Richard F.; Sills, Allen K.; Lovell, Mark R.			Response to acute concussive injury in soccer players: is gender a modifying factor? Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						sports-related concussion; gender; soccer; trauma; mild traumatic brain injury; Immediate Postconcussion Assessment and Cognitive Testing	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; TEST-RETEST RELIABILITY; SEX-DIFFERENCES; HIGH-SCHOOL; NEUROPSYCHOLOGICAL ASSESSMENT; UNITED-STATES; IMPACT; SYMPTOMS; SCORES	Object. Several studies have suggested a gender difference in response to sports-related concussion (SRC). The Concussion in Sport group did not include gender as a modifying factor in SRC, concluding that the evidence at that point was equivocal. In the present study the authors endeavored to assess acute neurocognitive and symptom responses to an SRC in equivalent cohorts of male and female soccer players. The authors hypothesized that female athletes would experience greater levels of acute symptoms and neurocognitive impairment than males. Methods. Baseline symptom and neurocognitive scores were determined in 40 male and 40 female soccer players by using the Immediate Postconcussion Assessment and Cognitive Testing (ImPACT) scale prior to any SRC. After sustaining an SRC, each athlete completed postconcussion ImPACT tests and was carefully matched on a wide array of biopsychosocial variables. Baseline symptom and neurocognitive test scores were compared, and their acute symptoms and neurocognitive responses to concussive injury were assessed. Results. Specific a priori hypotheses about differences between males and females at baseline and at postconcussion measurements of verbal and visual memory ImPACT scores were evaluated according to simple main effects of the gender variable and according to baseline-to-postconcussion main effect and interaction of 2 x 2 split-plot ANOVA. Neither the interaction nor the main effects nor the simple main effects for either ImPACT variable were found to be statistically significant. Exploratory ANOVAs applied to the remaining ImPACT variables of visual-motor speed, reaction time, impulse control, and symptom total scores revealed only a single statistically significant baseline-to-postconcussion main effect for the symptom total. Conclusions. The results failed to replicate prior findings of gender-specific baseline neurocognitive differences in verbal and visual memory. The findings also indicated no differential gender-based acute response to concussion (symptoms or neurocognitive scores) among high school soccer players. The implications of these findings for the inclusion of gender as a modifying factor in this tightly matched cohort are addressed. Potential explanations for the null findings are discussed. (http://thejns.org/doi/abs/10.3171/2012.8.PEDS12139)	[Zuckerman, Scott L.] Vanderbilt Univ, Med Ctr, Dept Neurol Surg, Sch Med, Nashville, TN 37232 USA; [Solomon, Gary S.] Vanderbilt Univ, Sch Med, Vanderbilt Sports Concuss Ctr, Dept Psychiat, Nashville, TN 37232 USA; [Solomon, Gary S.] Vanderbilt Univ, Sch Med, Vanderbilt Sports Concuss Ctr, Dept Neurol Surg, Nashville, TN 37232 USA; [Forbes, Jonathan A.; Sills, Allen K.] SUNY Albany, Dept Educ & Counseling Psychol, Albany, NY 12222 USA; [Lovell, Mark R.] ImPACT Applicat, Pittsburgh, PA USA	Zuckerman, SL (corresponding author), Vanderbilt Univ, Med Ctr, Dept Neurol Surg, Sch Med, T-4224 Med Ctr N, Nashville, TN 37232 USA.	scott.zuckerman@vanderbilt.edu	Solomon, Gary/K-9011-2019				Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Brown CN, 2007, J ATHL TRAINING, V42, P515; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson G, 2002, ARCH CLIN NEUROPSYCH, V17, P769; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Lidvall H F, 1974, Acta Neurol Scand Suppl, V56, P3; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, IMPACT 2007 6 0 CLIN; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maxwell SE, 2004, DESIGNING EXPT ANAL, P920; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; *NAT COLL ATHL ASS, 2010, 1981 82 2008 09 NCAA; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; RENCHER AC, 1990, COMMUN STAT SIMULAT, V19, P535, DOI 10.1080/03610919008812874; RUTHERFORD WH, 1977, LANCET, V1, P1; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Weiss EM, 2003, PERS INDIV DIFFER, V35, P863, DOI 10.1016/S0191-8869(02)00288-X	34	40	40	0	37	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707			J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	DEC	2012	10	6					504	510		10.3171/2012.8.PEDS12139			7	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	042IE	WOS:000311464100010	23030348	Bronze			2021-06-18	
J	Chuang, TJ; Lin, KC; Chio, CC; Wang, CC; Chang, CP; Kuo, JR				Chuang, Tai-Jen; Lin, Kao-Chang; Chio, Chung-Ching; Wang, Che-Chuan; Chang, Chin-Ping; Kuo, Jinn-Rung			Effects of secretome obtained from normoxia-preconditioned human mesenchymal stem cells in traumatic brain injury rats	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Secretome; human mesenchymal stem cell; fluid percussion injury; cell apoptosis; Sprague-Dawley rats	MARROW STROMAL CELLS; BONE; EXPRESSION; ANGIOGENESIS; VEGF; TRANSPLANTATION; NEUROGENESIS; HYPOXIA; STROKE; MACROPHAGES	BACKGROUND: The aim of the present study was to investigate whether secretome obtained from normoxia-preconditioned human mesenchymal stem cells causes attenuation of traumatic brain injury (TBI), induced by fluid percussion injury. METHODS: Anaesthetized male Sprague-Dawley rats, immediately after the onset of fluid percussion TBI, were divided into two major groups and given the vehicle solution (1 mL) or secretome (500 mu g) intravenously. Another group of rats was used as sham-operated controls. The functional outcome such as motor (maximum grasp angle) was evaluated by an inclined plane test. Cellular infarction volume was calculated by triphenyltetrazolium chloride staining. Neuronal loss, apoptosis, and neurotrophic factor such as vascular epithelial growth factor (VEGF) expression in the cortex were measured by immunofluorescence staining. All the parameters were assessed on Day 3 after injury. RESULTS: Compared with those of the sham-operated controls, the motor deficits and cerebral infarction of rats after TBI were significantly attenuated by secretome therapy. The TBI-induced neuronal loss and apoptosis were also significantly reduced by secretome therapy. Furthermore, VEGF-positive cells in the ischemic cortex after TBI were further significantly increased by secretome therapy. CONCLUSION: Our results demonstrate that intravenous injection of secretome from normoxia-preconditioned human mesenchymal stem cells may ameliorate TBI-induced rats by reducing neuronal cell loss and apoptosis and promoting VEGF production, resulting in functional outcome improvement. We also recommend that secretome from normoxia-preconditioned human mesenchymal stem cells could be a promising treatment strategy for traumatic brain injury. (J Trauma Acute Care Surg. 2012; 73: 1161-1167. Copyright (c) 2012 by Lippincott Williams & Wilkins)	[Chio, Chung-Ching; Wang, Che-Chuan; Kuo, Jinn-Rung] Chi Mei Med Ctr, Dept Neurosurg, Tainan 708, Taiwan; [Chuang, Tai-Jen] Liou Ying Chi Mei Med Ctr, Dept Intens Care Unit, Tainan, Taiwan; [Lin, Kao-Chang] Chi Mei Med Ctr, Dept Neurol, Tainan 708, Taiwan; [Lin, Kao-Chang; Chang, Chin-Ping; Kuo, Jinn-Rung] So Taiwan Univ, Dept Biotechnol, Tainan, Taiwan	Kuo, JR (corresponding author), Chi Mei Med Ctr, Dept Neurosurg, 901 Jong Hwa Rd, Tainan 708, Taiwan.	cmh7520@mail.chimei.org.tw			 [CLFHR10101]	The project was supported by CLFHR10101.	Adamides AA, 2006, ANZ J SURG, V76, P163, DOI 10.1111/j.1445-2197.2006.03674.x; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Chen Q, 2005, J NEUROSCI RES, V80, P611, DOI 10.1002/jnr.20494; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Flanagan Steven R, 2008, Neuropsychiatr Dis Treat, V4, P877; FRIEDENSTEIN AJ, 1974, TRANSPLANTATION, V17, P331, DOI 10.1097/00007890-197404000-00001; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Harichandan A, 2011, BEST PRACT RES CL HA, V24, P25, DOI 10.1016/j.beha.2011.01.001; Jeon SH, 2007, J LEUKOCYTE BIOL, V81, P557, DOI 10.1189/jlb.0806517; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Kim HJ, 2008, J NEUROTRAUM, V10, P2008; Kooreman NG, 2010, J R SOC INTERFACE, V7, pS753, DOI 10.1098/rsif.2010.0353.focus; Kuo JR, 2010, J TRAUMA, V69, P1467, DOI 10.1097/TA.0b013e3181f31b06; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Manoonkitiwongsa PS, 2001, J CEREBR BLOOD F MET, V21, P1223, DOI 10.1097/00004647-200110000-00011; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Modo M, 2003, NEUROREPORT, V14, P39, DOI 10.1097/00001756-200301200-00007; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Oh JS, 2010, NEUROSCI LETT, V472, P215, DOI 10.1016/j.neulet.2010.02.008; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; Prockop DJ, 2007, CLIN PHARMACOL THER, V82, P241, DOI 10.1038/sj.clpt.6100313; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Rosova I, 2008, STEM CELLS, V26, P2173, DOI 10.1634/stemcells.2007-1104; Shen LH, 2007, J CEREBR BLOOD F MET, V27, P6, DOI 10.1038/sj.jcbfm.9600311; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Tipoe George L., 2006, Cardiovascular & Hematological Agents in Medicinal Chemistry, V4, P199, DOI 10.2174/187152506777698290; van Zanten ARH, 2005, CRIT CARE MED, V33, P1449, DOI 10.1097/01.CCM.0000166710.64724.34	39	40	43	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	NOV	2012	73	5					1161	1167		10.1097/TA.0b013e318265d128			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	043VF	WOS:000311577100023	22976425				2021-06-18	
J	Wood, JN; Feudtner, C; Medina, SP; Luan, XQ; Localio, R; Rubin, DM				Wood, Joanne N.; Feudtner, Chris; Medina, Sheyla P.; Luan, Xianqun; Localio, Russell; Rubin, David M.			Variation in Occult Injury Screening for Children With Suspected Abuse in Selected US Children's Hospitals	PEDIATRICS			English	Article						child abuse; child maltreatment; femur fracture; traumatic brain injury	HEAD-INJURY; SKELETAL SURVEYS; YOUNG-CHILDREN; FRACTURES; INFANTS; CARE; IDENTIFICATION; MANAGEMENT; DIAGNOSIS; EVALUATE	OBJECTIVE: To describe variation across selected US children's hospitals in screening for occult fractures in children <2 years old diagnosed with physical abuse and in infants <1 year old who have injuries associated with a high likelihood of physical abuse. METHODS: We performed a retrospective study of children <2 years old with a diagnosis of physical abuse and infants <1 year old with non-motor vehicle crash-associated traumatic brain injuries or femur fractures admitted to 40 hospitals within the Pediatric Hospital Information System database from January 1, 1999, to December 31, 2009. We examined variation among the hospitals in the performance of screening for occult fractures as defined by receipt of skeletal survey or radionuclide bone scan. Marginal standardization implemented with logistic regression analysis was used to examine hospital variation after adjusting for patient demographic characteristics, injury severity, and year of admission. RESULTS: Screening for occult fractures was performed in 83% of the 10 170 children <2 years old with a diagnosis of physical abuse, 68% of the 9942 infants who had a traumatic brain injury, and 77% of the 2975 infants who had femur fractures. After adjustment for patient characteristics, injury severity, and year of admission, hospitals varied significantly in use of screening for occult fractures in all 3 groups of children. CONCLUSIONS: The observed variation in screening for occult fractures in young victims of physical abuse and infants who have injuries associated with a high likelihood of abuse underscores opportunities to improve the quality of care provided to this vulnerable population. Pediatrics 2012;130:853-860	[Wood, Joanne N.; Feudtner, Chris; Medina, Sheyla P.; Luan, Xianqun; Localio, Russell; Rubin, David M.] Childrens Hosp Philadelphia, Div Gen Pediat, Philadelphia, PA 19104 USA; [Wood, Joanne N.; Feudtner, Chris; Medina, Sheyla P.; Luan, Xianqun; Localio, Russell; Rubin, David M.] Childrens Hosp Philadelphia, PolicyLab, Philadelphia, PA 19104 USA; [Wood, Joanne N.; Feudtner, Chris; Rubin, David M.] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Localio, Russell] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA	Wood, JN (corresponding author), Childrens Hosp Philadelphia, Div Gen Pediat, 3535 Market St,Room 1517, Philadelphia, PA 19104 USA.	woodjo@email.chop.edu	Feudtner, Chris/AAI-1126-2019	Feudtner, Chris/0000-0002-5879-0434; Wood, Joanne/0000-0001-6431-8024	National Institute of Child Health and Human Development grantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1K23HD071967-01]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD071967] Funding Source: NIH RePORTER	Dr Wood has received salary funding from the National Institute of Child Health and Human Development grant (1K23HD071967-01).	American College of Radiology, 2011, ACR SPR PRACT GUID S; Belfer RA, 2001, AM J EMERG MED, V19, P122, DOI 10.1053/ajem.2001.21345; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; Christakis DA, 2005, PEDIATRICS, V115, P878, DOI 10.1542/peds.2004-1299; DeGraw M, 2010, PEDIATRICS, V125, pE295, DOI 10.1542/peds.2009-1478; Di Pietro MA, 2009, PEDIATRICS, V123, P1430, DOI 10.1542/peds.2009-0558; Duffy SO, 2011, PEDIATRICS, V127, pE47, DOI 10.1542/peds.2010-0298; Fisher BT., 2012, PHARMACOEPIDEMIOLOGY, P244; Flaherty EG, 2000, ARCH PEDIAT ADOL MED, V154, P489, DOI 10.1001/archpedi.154.5.489; Flaherty EG, 2008, PEDIATRICS, V122, P611, DOI 10.1542/peds.2007-2311; Flaherty EG, 2006, CHILD MALTREATMENT, V11, P361, DOI 10.1177/1077559506292287; Gerber JS, 2010, PEDIATRICS, V126, P1067, DOI 10.1542/peds.2010-1275; Graubard BI, 1999, BIOMETRICS, V55, P652, DOI 10.1111/j.0006-341X.1999.00652.x; GROSS RH, 1983, J PEDIATR ORTHOPED, V3, P341, DOI 10.1097/01241398-198307000-00012; Guerra CE, 2007, J GEN INTERN MED, V22, P1681, DOI 10.1007/s11606-007-0396-9; HAMPTON RL, 1985, AM J PUBLIC HEALTH, V75, P56, DOI 10.2105/AJPH.75.1.56; Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215; Hicks RA, 2007, PEDIATR EMERG CARE, V23, P308, DOI 10.1097/01.pec.0000270174.39228.30; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Jenny C, 2007, PEDIATRICS, V119, P1232, DOI 10.1542/peds.2007-0883; Karmazyn B, 2011, AM J ROENTGENOL, V197, pW159, DOI 10.2214/AJR.10.5733; King WK, 2006, PEDIATR EMERG CARE, V22, P211, DOI 10.1097/01.pec.0000208180.94166.dd; Kokorowski PJ, 2010, PEDIATRICS, V126, pE576, DOI 10.1542/peds.2010-0747; Korn EL, 1999, ANAL HLTH SURVEYS, V1st; Lane WG, 2007, CLIN ORTHOP RELAT R, P219, DOI 10.1097/BLO.0b013e31805c0849; Lane WG, 2002, JAMA-J AM MED ASSOC, V288, P1603, DOI 10.1001/jama.288.13.1603; Laskey AL, 2004, J PEDIATR-US, V144, P719, DOI 10.1016/j.jpeds.2004.02.023; Leventhal JM, 2010, PEDIATRICS, V126, pE104, DOI 10.1542/peds.2009-1076; Madlon-Kay DJ, 2012, J AM BOARD FAM MED, V25, P437, DOI 10.3122/jabfm.2012.04.110307; Mandelstam SA, 2003, ARCH DIS CHILD, V88, P387, DOI 10.1136/adc.88.5.387; Mannix R, 2012, J PEDIATR-US, V160, P136, DOI 10.1016/j.jpeds.2011.06.024; Myhre MC, 2007, ACTA PAEDIATR, V96, P1159, DOI 10.1111/j.1651-2227.2007.00356.x; *NAT ASS CHILDR HO, 2006, DEF CHILDR HOSP ROL; National Association of Children's Hospitals and Related Institutions, 2009, RESP CHILD MALTR 200; National Association of Children's Hospitals and Related Institutions, 2006, 2005 SURV FIND CHILD; Oral R, 2003, PEDIATR EMERG CARE, V19, P148, DOI 10.1097/01.pec.0000081234.20228.33; Oral R, 2008, PEDIATR EMERG CARE, V24, P816, DOI 10.1097/PEC.0b013e31818e9f5d; Rangel EL, 2009, J PEDIATR SURG, V44, P1229, DOI 10.1016/j.jpedsurg.2009.02.044; Ravichandiran N, 2010, PEDIATRICS, V125, P60, DOI 10.1542/peds.2008-3794; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Rogers WH, 1993, STATA TECHNICAL B, V13, P19, DOI DOI 10.1016/J.IJFORECAST.2005.03.004; Rubin DM, 2003, PEDIATRICS, V111, P1382, DOI 10.1542/peds.111.6.1382; Schwend RM, 2000, J PEDIATR ORTHOPED, V20, P475, DOI 10.1097/00004694-200007000-00010; Sege RD, 2008, ARCH DIS CHILD, V93, P822, DOI 10.1136/adc.2006.100545; Sobota A, 2012, PEDIATR BLOOD CANCER, V58, P61, DOI 10.1002/pbc.23221; Tarini BA, 2007, J HOSP MED, V2, P69, DOI 10.1002/jhm.169; Thackeray JD, 2007, PEDIATR EMERG CARE, V23, P735, DOI 10.1097/PEC.0b013e3181568039; Tien I, 2002, PEDIATRICS, V110, P1226, DOI 10.1542/peds.110.6.1226; Trokel M, 2006, PEDIATRICS, V117, P722, DOI 10.1542/peds.2004-2731; Vernacchio L, 2007, PEDIATRICS, V120, P281, DOI 10.1542/peds.2006-3601; Wood JN, 2009, PEDIATRICS, V123; Wood JN, 2010, PEDIATRICS, V126, P408, DOI 10.1542/peds.2010-0031	52	40	40	0	4	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	NOV	2012	130	5					853	860		10.1542/peds.2012-0244			8	Pediatrics	Pediatrics	029OT	WOS:000310505900054	23071208	Green Published			2021-06-18	
J	das Nair, R; Lincoln, NB				das Nair, Roshan; Lincoln, Nadina B.			Evaluation of Rehabilitation of Memory in Neurological Disabilities (ReMiND): a randomized controlled trial	CLINICAL REHABILITATION			English	Article						Memory; cognitive impairment; randomized controlled trial; group; cognitive rehabilitation	OF-THE-LITERATURE; COGNITIVE REHABILITATION; BRAIN-INJURY; MODEL	Objective: The evidence for the effectiveness of memory rehabilitation is inconclusive. The aim was to compare the effectiveness of two group memory rehabilitation programmes with a self-help group control. Design: Single-blind randomized controlled trial. Participants: Participants with memory problems following traumatic brain injury, stroke or multiple sclerosis were recruited from community settings. Interventions: Participants were randomly allocated, in cohorts of four, to compensation or restitution group treatment programmes or a self-help group control. All programmes were manual-based and comprised two individual and ten weekly group sessions. Main measures: Memory functions, mood, and activities of daily living were assessed at baseline and five and seven months after randomization. Results: There were 72 participants (mean age 47.7, SD 10.2 years; 32 men). There was no significant effect of treatment on the Everyday Memory Questionnaire (P = 0.97). At seven months the mean scores were comparable (restitution 36.6, compensation 41.0, self-help 44.1). However, there was a significant difference between groups on the Internal Memory Aids Questionnaire (P = 0.002). The compensation and restitution groups each used significantly more internal memory aids than the self-help group (P < 0.01). There were no statistically significant differences between the groups on measures of mood, adjustment and activities of daily living (P > 0.05). Conclusions: There results show few statistically significant effects of either compensation or restitution memory group treatment as compared with a self-help group control. Further randomized trials of memory rehabilitation are needed.	[das Nair, Roshan; Lincoln, Nadina B.] Univ Nottingham, IWHO, Nottingham NG8 1BB, England	das Nair, R (corresponding author), Univ Nottingham, IWHO, B09,Int House,Jubilee Campus, Nottingham NG8 1BB, England.	roshan.nair@nottingham.ac.uk		das Nair, Roshan/0000-0001-8143-7893	Stroke Association; RemediScience Foundation Ireland [2006/05]; Universities UK (Overseas Research Students Award Scheme); University of Nottingham	The research was supported by grants from The Stroke Association, Remedi (2006/05), Universities UK (Overseas Research Students Award Scheme), and the University of Nottingham.	Baddeley AD, 1994, DOORS PEOPLE TEST VI; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Coughlan AK, 1988, CLIN REHABIL, V2, P207, DOI DOI 10.1177/026921558800200305; das Nair R, COCHRANE DA IN PRESS; das Nair R, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002293.pub3; Dirette DK, 1999, J HEAD TRAUMA REHAB, V14, P595, DOI 10.1097/00001199-199912000-00008; Doornhein K, 1998, NEUROPSYCHOL REHABIL, V8, P393, DOI 10.1080/713755579; Evans JJ, 2006, J NEUROL, V253, P520, DOI 10.1007/s00415-006-0014-5; GOLDBERG R, 1988, USERS GUIDE GEN HLTH; Held JM, 1999, NEUROSCIENCE REHABIL, P419; Hildebrandt H, 2006, J NEUROL, V253, P512, DOI 10.1007/s00415-006-0013-6; Katz DI, 2006, COGNITIVE REHABILITA; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; McKinlay W, 1999, REHABILITATION ADULT, V3, P74; Nouri F, 1987, CLIN REHABIL, V1, P233; Powell T, 2003, BRAIN INJURY WORK BO; RAO SM, 1995, CURR OPIN NEUROL, V8, P216, DOI 10.1097/00019052-199506000-00010; Regard M., 1981, COGNITIVE RIGIDITY F; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; RUFF R M, 1990, Brain Injury, V4, P339, DOI 10.3109/02699059009026187; Skeel RL, 2001, REHABILITATION NEURO, P53; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; Syder D., 1993, SHEFFIELD SCREENING; Wade DT, 2004, BMJ-BRIT MED J, V329, P1398, DOI 10.1136/bmj.329.7479.1398; Wade DT, 2003, CLIN REHABIL, V17, P349, DOI 10.1191/0269215503cr619ed; WATSON M, 1988, PSYCHOL MED, V18, P203, DOI 10.1017/S0033291700002026; Wechsler D, 1998, WECHSLER MEMORY SCAL; Williamson D. J. G., 1996, NEUROPSYCHOLOGY CLIN, P9, DOI [10.1037/10198-001, DOI 10.1037/10198-001]; Wilson, 1991, NATL ADULT READING T; Wilson B., 1999, RIVERMEAD BEHAV MEMO; Wilson BA, 2002, NEUROPSYCHOL REHABIL, V12, P97, DOI 10.1080/09602010244000020; Wilson BA, 1984, CLIN MANAGEMENT MEMO; World Health Organization, 2001, INT CLASS FUNCT DIS	37	40	40	0	28	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	OCT	2012	26	10					894	903		10.1177/0269215511435424			10	Rehabilitation	Rehabilitation	004ZN	WOS:000308720200004	22324056	Green Accepted			2021-06-18	
J	Patel, MB; McKenna, JW; Alvarez, JM; Sugiura, A; Jenkins, JM; Guillamondegui, OD; Pandharipande, PP				Patel, Mayur B.; McKenna, John W.; Alvarez, JoAnn M.; Sugiura, Ayaka; Jenkins, Judith M.; Guillamondegui, Oscar D.; Pandharipande, Pratik P.			Decreasing adrenergic or sympathetic hyperactivity after severe traumatic brain injury using propranolol and clonidine (DASH After TBI Study): study protocol for a randomized controlled trial	TRIALS			English	Article						Traumatic brain injury; Sympathetic hyperactivity; Sympathetic storm; Autonomic dysfunction; Adrenergic blockade; Beta-blocker; Alpha(2)-agonist; Propranolol; Clonidine; Agitation	BETA-BLOCKER EXPOSURE; COMMON DATA ELEMENTS; CEREBRAL PERFUSION; TARGETED THERAPY; HEAD-INJURY; CATECHOLAMINES; DEXMEDETOMIDINE; RECOMMENDATIONS; PRINCIPLES; AGITATION	Background: Severe TBI, defined as a Glasgow Coma Scale <= 8, increases intracranial pressure and activates the sympathetic nervous system. Sympathetic hyperactivity after TBI manifests as catecholamine excess, hypertension, abnormal heart rate variability, and agitation, and is associated with poor neuropsychological outcome. Propranolol and clonidine are centrally acting drugs that may decrease sympathetic outflow, brain edema, and agitation. However, there is no prospective randomized evidence available demonstrating the feasibility, outcome benefits, and safety for adrenergic blockade after TBI. Methods/Design: The DASH after TBI study is an actively accruing, single-center, randomized, double-blinded, placebo-controlled, two-arm trial, where one group receives centrally acting sympatholytic drugs, propranolol (1 mg intravenously every 6 h for 7 days) and clonidine (0.1 mg per tube every 12 h for 7 days), and the other group, double placebo, within 48 h of severe TBI. The study uses a weighted adaptive minimization randomization with categories of age and Marshall head CT classification. Feasibility will be assessed by ability to provide a neuroradiology read for randomization, by treatment contamination, and by treatment compliance. The primary endpoint is reduction in plasma norepinephrine level as measured on day 8. Secondary endpoints include comprehensive plasma and urine catecholamine levels, heart rate variability, arrhythmia occurrence, infections, agitation measures using the Richmond Agitation-Sedation Scale and Agitated Behavior scale, medication use (antihypertensive, sedative, analgesic, and antipsychotic), coma-free days, ventilator-free days, length of stay, and mortality. Neuropsychological outcomes will be measured at hospital discharge and at 3 and 12 months. The domains tested will include global executive function, memory, processing speed, visual-spatial, and behavior. Other assessments include the Extended Glasgow Outcome Scale and Quality of Life after Brain Injury scale. Safety parameters evaluated will include cardiac complications. Discussion: The DASH After TBI Study is the first randomized, double-blinded, placebo-controlled trial powered to determine feasibility and investigate safety and outcomes associated with adrenergic blockade in patients with severe TBI. If the study results in positive trends, this could provide pilot evidence for a larger multicenter randomized clinical trial. If there is no effect of therapy, this trial would still provide a robust prospective description of sympathetic hyperactivity after TBI.	[Patel, Mayur B.; Pandharipande, Pratik P.] Nashville VA Med Ctr, Vet Affairs VA Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA; [Patel, Mayur B.; McKenna, John W.; Sugiura, Ayaka; Jenkins, Judith M.; Guillamondegui, Oscar D.] Vanderbilt Univ, Med Ctr, Div Trauma & Surg Crit Care, Dept Surg, Nashville, TN 37212 USA; [Alvarez, JoAnn M.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA; [Pandharipande, Pratik P.] Vanderbilt Univ, Med Ctr, Div Crit Care, Dept Anesthesia, Nashville, TN 37212 USA	Patel, MB (corresponding author), Nashville VA Med Ctr, Vet Affairs VA Tennessee Valley Healthcare Syst, 1310 24th Ave S, Nashville, TN 37212 USA.	mayur.b.patel@Vanderbilt.edu	Patel, Mayur/K-2363-2013	Pandharipande, Pratik/0000-0002-1389-8580; Sugiura, Ayaka/0000-0001-5326-5019	Vanderbilt Institute for Clinical and Translational Research via National Center for Advancing Translational Sciences [UL1TR000445]; AHRQ Health Services [5T32HS013833-08]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [T32HS013833] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000445] Funding Source: NIH RePORTER	The DASH After TBI Study is an investigator-initiated trial supported by Vanderbilt Institute for Clinical and Translational Research award to MBP via CTSA award number UL1TR000445 from the National Center for Advancing Translational Sciences. Its contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health. This CTSA grant also supports the Vanderbilt REDCap infrastructure, the Clinical Research Center used in this trial for catecholamine endpoints, and provides biostatistical support. AHRQ Health Services 5T32HS013833-08 and the Division of Trauma also supported MBP.	Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P347, DOI 10.1111/j.1399-6576.1995.tb04075.x; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P917; Chan AKM, 2010, EXPERT OPIN PHARMACO, V11, P2849, DOI 10.1517/14656566.2010.511613; Choi Y, 2006, COGN BEHAV NEUROL, V19, P204, DOI 10.1097/01.wnn.0000213919.95266.0d; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Dizdarevic K, 2012, CLIN NEUROL NEUROSUR, V114, P142, DOI 10.1016/j.clineuro.2011.10.005; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M; Fleminger S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003299.pub2; Grande PO, 1997, J TRAUMA, V42, pS23, DOI 10.1097/00005373-199705001-00005; GREENDYKE RM, 1986, J NERV MENT DIS, V174, P290, DOI 10.1097/00005053-198605000-00005; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; HE HB, 1992, J CHROMATOGR-BIOMED, V574, P213, DOI 10.1016/0378-4347(92)80032-L; Heffernan DS, 2010, J TRAUMA, V69, P1602, DOI 10.1097/TA.0b013e3181f2d3e8; Hinson HE, 2012, CURR OPIN CRIT CARE, V18, P139, DOI 10.1097/MCC.0b013e3283513290; HOFFMAN WE, 1991, ANESTH ANALG, V73, P460; Horner J, 2012, RAPACHE WEB APPL DEV; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kroes MCW, 2010, J NEUROSCI, V30, P3959, DOI 10.1523/JNEUROSCI.5469-09.2010; Ley EJ, 2010, J TRAUMA, V68, P353, DOI 10.1097/TA.0b013e3181c8269a; Ley EJ, 2009, J TRAUMA, V66, P154, DOI 10.1097/TA.0b013e31819388be; LIU MY, 1995, J FORMOS MED ASSOC, V94, P386; Lv LQ, 2010, J NEUROTRAUM, V27, P1945, DOI 10.1089/neu.2010.1391; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Menon DK, 2009, CURR OPIN CRIT CARE, V15, P437, DOI 10.1097/MCC.0b013e3283307a26; Mowery NT, 2008, J TRAUMA, V65, P621, DOI 10.1097/TA.0b013e3181837980; Nordstrom CH, 2005, NEUROCRIT CARE, V2, P83, DOI 10.1385/NCC:2:1:083; Nott MT, 2006, BRAIN INJURY, V20, P1175, DOI 10.1080/02699050601049114; Nott MT, 2010, BRAIN INJURY, V24, P1214, DOI 10.3109/02699052.2010.506858; Oei NYL, 2010, NEUROBIOL LEARN MEM, V93, P388, DOI 10.1016/j.nlm.2009.12.005; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; PAYEN D, 1990, CRIT CARE MED, V18, P392, DOI 10.1097/00003246-199004000-00008; Perkes I, 2010, ANN NEUROL, V68, P126, DOI 10.1002/ana.22066; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; R Development Core Team, 2011, R LANG ENV STAT COMP; Rabinstein AA, 2008, CURR TREAT OPTION N, V10, P151, DOI 10.1007/s11940-008-0016-y; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Riordan WP, 2007, J TRAUMA, V63, P503, DOI 10.1097/TA.0b013e3181271c34; Schneider JS, 2010, BEHAV BRAIN RES, V211, P236, DOI 10.1016/j.bbr.2010.03.040; Schulz KF, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-18; Tran TY, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E8; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; WOOLF PD, 1988, AM J PHYSIOL, V254, pE287; WOOLF PD, 1992, ARCH SURG-CHICAGO, V127, P899	51	40	41	0	13	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1745-6215			TRIALS	Trials	SEP 26	2012	13								177	10.1186/1745-6215-13-177			9	Medicine, Research & Experimental	Research & Experimental Medicine	053HQ	WOS:000312262500001	23013802	DOAJ Gold, Green Published			2021-06-18	
J	Adams, RS; Larson, MJ; Corrigan, JD; Horgan, CM; Williams, TV				Adams, Rachel Sayko; Larson, Mary Jo; Corrigan, John D.; Horgan, Constance M.; Williams, Thomas V.			Frequent Binge Drinking After Combat-Acquired Traumatic Brain Injury Among Active Duty Military Personnel With a Past Year Combat Deployment	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						binge drinking; combat; deployment; military personnel; posttraumatic stress disorder; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE USE DISORDERS; PERSISTENT POSTCONCUSSIVE SYMPTOMS; ALCOHOL-USE; PRIMARY-CARE; DEPRESSIVE-DISORDERS; SERVICE MEMBERS; US MILITARY; IRAQ; VETERANS	Objective: To determine whether combat-acquired traumatic brain injury (TBI) is associated with postdeployment frequent binge drinking among a random sample of active duty military personnel. Participants: Active duty military personnel who returned home within the past year from deployment to a combat theater of operations and completed a survey health assessment (N = 7155). Methods: Cross-sectional observational study with multivariate analysis of responses to the 2008 Department of Defense Survey of Health Related Behaviors Among Active Duty Military Personnel, an anonymous, random, population-based assessment of the armed forces. Main Measures: Frequent binge drinking: 5 or more drinks on the same occasion, at least once per week, in the past 30 days. TBI-AC: self-reported altered consciousness only; loss of consciousness (LOC) of less than 1 minute (TBI-LOC <1); and LOC of 1 minute or greater (TBI-LOC 1+) after combat injury event exposure. Results: Of active duty military personnel who had a past year combat deployment, 25.6% were frequent binge drinkers and 13.9% reported experiencing a TBI on the deployment, primarily TBI-AC (7.5%). In regression models adjusting for demographics and positive screen for posttraumatic stress disorder, active duty military personnel with TBI had increased odds of frequent binge drinking compared with those with no injury exposure or without TBI: TBI-AC (adjusted odds ratio, 1.48; 95% confidence interval, 1.18-1.84); TBI-LOC 1+ (adjusted odds ratio, 1.67; 95% confidence interval, 1.002.79). Conclusions: Traumatic brain injury was significantly associated with past month frequent binge drinking after controlling for posttraumatic stress disorder, combat exposure, and other covariates.	[Adams, Rachel Sayko; Larson, Mary Jo; Horgan, Constance M.] Brandeis Univ, Heller Sch Social Policy & Management, Waltham, MA 02454 USA; [Larson, Mary Jo; Horgan, Constance M.] Brandeis Univ, Inst Behav Hlth, Waltham, MA 02454 USA; [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Williams, Thomas V.] Long Term Studies Def Hlth Cost Assessment & Prog, TRICARE Management Act, Dept Def, Falls Church, VA USA	Adams, RS (corresponding author), Brandeis Univ, Heller Sch Social Policy & Management, 415 South St,Mailstop 035, Waltham, MA 02454 USA.	radams@brandeis.edu	Adams, Rachel/AAH-4653-2020		Ruth L. Kirschstein National Research Service Award from the National Institute on Alcohol Abuse and Alcoholism [F31 AA021030, T32 AA007567]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [T32AA007567, F31AA021030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA030150] Funding Source: NIH RePORTER	Ms Adams conducted this research with predoctoral fellowship dissertation support from a Ruth L. Kirschstein National Research Service Award from the National Institute on Alcohol Abuse and Alcoholism (F31 AA021030) and an institutional training grant (T32 AA007567). Ms Adams acknowledges the support of dissertation committee members Drs Grant Ritter and Robert M. Bray for their review of her research proposal as well as the programming support of Mr Lee Panas.	Adams RS, 2012, J SOC WORK PRACT ADD, V12, P28, DOI 10.1080/1533256X.2012.647580; [Anonymous], 2007, STAT STAT SOFTW COMP; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Bray RM, 2009, DEP DEFENSE SURVEY H; Bray RM, 2010, MIL MED, V175, P390, DOI 10.7205/MILMED-D-09-00132; Brewer RD, 2005, JAMA-J AM MED ASSOC, V294, P616, DOI 10.1001/jama.294.5.616; Brown JM, 2007, 2006 UNIT LEVEL INFL; BURNAM MA, 1988, MED CARE, V26, P775, DOI 10.1097/00005650-198808000-00004; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Centers for Disease Control and Prevention, 2003, C MILD TRAUM BRAIN I; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; Corrigan JD, 2008, JAMA-J AM MED ASSOC, V300, P720, DOI 10.1001/jama.300.6.720; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2012, BRAIN INJURY, V26, P139, DOI 10.3109/02699052.2011.648705; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; DOD Deployment Health Clinical Center, 2010, ENH POSTD HLTH ASS P; Federman EB, 2000, MIL PSYCHOL, V12, P205, DOI 10.1207/S15327876MP1203_3; Ferrier-Auerbach AG, 2009, ADDICT BEHAV, V34, P625, DOI 10.1016/j.addbeh.2009.03.027; Fiellin DA, 2000, ARCH INTERN MED, V160, P1977, DOI 10.1001/archinte.160.13.1977; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; FRENCH LM, 2010, MILITARY NEUROPSYCHO, P101; Heltemes KJ, 2011, MIL MED, V176, P147, DOI 10.7205/MILMED-D-10-00191; Hingson RW, 2009, PEDIATRICS, V123, P1477, DOI 10.1542/peds.2008-2176; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Institute of Medicine, 2008, GULF WAR HLTH, V7; Institute of Medicine, 2010, RET HOM IR AFGH PREL; Jacobson IG, 2008, JAMA-J AM MED ASSOC, V300, P663, DOI 10.1001/jama.300.6.663; Kaner EFS, 2009, DRUG ALCOHOL REV, V28, P301, DOI 10.1111/j.1465-3362.2009.00071.x; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; Larson MJ, 2012, J SOC WORK PRACT ADD, V12, P6, DOI 10.1080/1533256X.2012.647586; Mattiko MJ, 2011, ADDICT BEHAV, V36, P608, DOI 10.1016/j.addbeh.2011.01.023; McQueen J, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD005191, 10.1002/14651858.CD005191.pub3]; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Naimi TS, 2009, AM J PREV MED, V37, P314, DOI 10.1016/j.amepre.2009.06.013; Naimi TS, 2003, JAMA-J AM MED ASSOC, V289, P70, DOI 10.1001/jama.289.1.70; *NAT I ALC AB ALC, 2005, NIH PUBL; Ong AL, 2008, MIL MED, V173, P871, DOI 10.7205/MILMED.173.9.871; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; Ramchand R, 2011, MIL PSYCHOL, V23, P6, DOI 10.1080/08995605.2011.534407; Rona RJ, 2012, J HEAD TRAUMA REHAB, V27, P33, DOI 10.1097/HTR.0b013e318212f814; ROST K, 1993, MED CARE, V31, P189, DOI 10.1097/00005650-199303000-00001; Saitz R, 2005, NEW ENGL J MED, V352, P596, DOI 10.1056/NEJMcp042262; Santiago PN, 2010, PSYCHIAT SERV, V61, P575, DOI 10.1176/ps.2010.61.6.575; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Shen YC, 2012, AM J PUBLIC HEALTH, V102, pS80, DOI 10.2105/AJPH.2011.300425; Shively SB, 2012, J HEAD TRAUMA REHAB, V27, P234, DOI 10.1097/HTR.0b013e318250e9dd; Skidmore WC, 2011, SOC WORK HEALTH CARE, V50, P85, DOI 10.1080/00981389.2010.522913; Spera C, 2011, J STUD ALCOHOL DRUGS, V72, P5, DOI 10.15288/jsad.2011.72.5; Stahre MA, 2009, AM J PREV MED, V36, P208, DOI 10.1016/j.amepre.2008.10.017; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; The Center for Substance Abuse Research, 2009, CESAR FAX, V7; Tourangeau R, 1996, PUBLIC OPIN QUART, V60, P275, DOI 10.1086/297751; Weathers F. W., 1993, ANN M INT SOC TRAUM; Wilk JE, 2010, DRUG ALCOHOL DEPEN, V108, P115, DOI 10.1016/j.drugalcdep.2009.12.003; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f	58	40	40	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2012	27	5					349	360		10.1097/HTR.0b013e318268db94			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	004OQ	WOS:000308691400089	22955100	Green Accepted			2021-06-18	
J	Colamonico, J; Formella, A; Bradley, W				Colamonico, Jennifer; Formella, Andrea; Bradley, Walter			Pseudobulbar Affect: Burden of Illness in the USA	ADVANCES IN THERAPY			English	Article						Burden of illness; Health status; Occupational function; Pseudobulbar affect; Quality of life; Social function	AMYOTROPHIC-LATERAL-SCLEROSIS; HEALTH SURVEY SF-36; MULTIPLE-SCLEROSIS; SHORT-FORM; EMOTIONAL INCONTINENCE; PARKINSONS-DISEASE; DEXTROMETHORPHAN/QUINIDINE; PRODUCTIVITY; PREVALENCE; EMPLOYMENT	Pseudobulbar affect (PBA) is characterized by involuntary and uncontrollable laughing and/or crying episodes, occurring secondary to neurological disease or injury. The impact of PBA on social and occupational function, health status, quality of life (QOL), and quality of relationships (QOR) is not well studied. This US survey conducted by Harris Interactive compared health status and daily function of patients with and without PBA. Eligible respondents were Harris Panel Online registrants previously diagnosed with stroke, multiple sclerosis, Parkinson's disease, Alzheimer's disease, traumatic brain injury, or amyotrophic lateral sclerosis, or primary, nonpaid caregivers for such patients who were too debilitated to participate. PBA was identified by a Center for Neurologic Study lability scale score of 13 or greater. Measures included the 36-item short form health survey (SF-36), the work productivity and impairment (WPAI) questionnaire, visual analog scales (VAS) for impact of PBA symptoms on QOL and QOR, and customized questions related to burden and impact of involuntary laughing/crying episodes on patients' lives. Survey responses were weighted to adjust for the relative proportion of the primary neurological conditions in the overall population and between group differences in patient age and gender. PBA and non-PBA group responses were compared using two-tailed t tests adjusted for severity of the primary neurological conditions. The 1,052 respondents included 399 PBA group participants and 653 controls. The PBA group showed significantly worse scores versus non-PBA controls on component and summary SF-36 scores (P < 0.05 for all), VAS scores (P < 0.05 for both), and WPAI scores (P < 0.05). Among PBA group respondents, PBA contributed a great deal to or was the main cause of patients becoming housebound for 24% and being moved to supervised living placement for 9% of respondents. PBA is associated with considerable burden incremental to that of the underlying neurological conditions, affecting QOL, QOR, health status, and social and occupational functioning.	[Formella, Andrea] Avanir Pharmaceut Inc, Aliso Viejo, CA 92656 USA; [Colamonico, Jennifer] Harris Interact Inc, New York, NY USA; [Bradley, Walter] Univ Miami, Miller Sch Med, Miami, FL 33136 USA	Formella, A (corresponding author), Avanir Pharmaceut Inc, 20 Enterprise,Suite 200, Aliso Viejo, CA 92656 USA.	aformella@avanir.com	Formella, Andrea/AAE-4073-2020	Formella, Andrea/0000-0003-2737-7898	Avanir Pharmaceuticals, Inc.	J. Colamonico has nothing to disclose. A. Formella has received personal compensation for activities with Avanir Pharmaceuticals, Inc., as an employee. W. Bradley has received research grants from Avanir Pharmaceuticals, Inc.	ANDRESEN EM, 1994, AM J PREV MED, V10, P77; Arciniegas D B, 2000, Semin Clin Neuropsychiatry, V5, P290, DOI 10.1053/scnp.2000.9554; Brooks BR, 2004, NEUROLOGY, V63, P1364; Calvert T, 1998, J NEUROL NEUROSUR PS, V65, P928, DOI 10.1136/jnnp.65.6.928; Cedarbaum JM, 1997, J NEUROL SCI, V152, pS1, DOI 10.1016/S0022-510X(97)00237-2; Choi-Kwon S, 2002, CEREBROVASC DIS, V13, P31, DOI 10.1159/000047743; Cummings JL, 2006, CNS SPECTRUMS, V11, P1; Dark FL, 1996, AUST NZ J PSYCHIAT, V30, P472, DOI 10.3109/00048679609065020; Davison C, 1939, ARCH NEURO PSYCHIATR, V42, P595, DOI 10.1001/archneurpsyc.1939.02270220011001; Edgley K, 1991, CANADIAN J REHABILIT, V4, P127; Faul M, 2010, TRAUMATIC BRAIN INJU, P13, DOI DOI 10.3171/2009.10.JNS091500; Feinstein A, 1997, ARCH NEUROL-CHICAGO, V54, P1116, DOI 10.1001/archneur.1997.00550210050012; Feinstein A, 1999, MULT SCLER, V5, P69, DOI 10.1177/135245859900500201; Guajardo VD, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-826; Hagell P, 2007, J NEUROL NEUROSUR PS, V78, P1191, DOI 10.1136/jnnp.2006.111161; HOUSE A, 1989, BMJ-BRIT MED J, V298, P991, DOI 10.1136/bmj.298.6679.991; JENKINSON C, 1995, AGE AGEING, V24, P505, DOI 10.1093/ageing/24.6.505; Julian LJ, 2008, J NEUROL, V255, P1354, DOI 10.1007/s00415-008-0910-y; Lantz MS, 2005, CLIN GERIATR MED, V13, P14; LAWTON MP, 1969, GERONTOLOGIST, V9, P9, DOI 10.1093/geront/9.1.9; McCullagh S, 1999, J NEUROL SCI, V169, P43, DOI 10.1016/S0022-510X(99)00214-2; Moore SR, 1997, J NEUROL NEUROSUR PS, V63, P89, DOI 10.1136/jnnp.63.1.89; Morrow SA, 2010, CLIN NEUROPSYCHOL, V24, P1131, DOI 10.1080/13854046.2010.511272; Ownsworth T, 2008, DISABIL REHABIL, V30, P531, DOI 10.1080/09638280701355694; Panitch HS, 2006, ANN NEUROL, V59, P780, DOI 10.1002/ana.20828; Petracca GM, 2009, J NEUROPSYCH CLIN N, V21, P406, DOI 10.1176/appi.neuropsych.21.4.406; Phuong L, 2009, PARKINSONISM RELAT D, V15, P511, DOI 10.1016/j.parkreldis.2009.01.001; Pioro EP, 2010, ANN NEUROL, V68, P693, DOI 10.1002/ana.22093; REILLY MC, 1993, PHARMACOECONOMICS, V4, P353, DOI 10.2165/00019053-199304050-00006; Schiffer R, 2005, J NEUROPSYCH CLIN N, V17, P447, DOI 10.1176/appi.neuropsych.17.4.447; SCHWAB R, 1969, 3 S PARK DIS MAY 20; Siddiqui MS, 2009, WORLD J BIOL PSYCHIA, V10, P234, DOI 10.1080/15622970701639445; Smith RA, 2004, MULT SCLER, V10, P1; STARR LB, 1983, EXP AGING RES, V9, P101, DOI 10.1080/03610738308258434; Strowd RE, 2010, J NEUROL, V257, P1382, DOI 10.1007/s00415-010-5550-3; Tang WK, 2009, J INT NEUROPSYCH SOC, V15, P62, DOI 10.1017/S1355617708090061; Tateno A, 2004, J NEUROPSYCH CLIN N, V16, P426, DOI 10.1176/appi.neuropsych.16.4.426; VITALIANO PP, 1991, GERONTOLOGIST, V31, P76, DOI 10.1093/geront/31.1.76; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wilson SAK, 1924, J NEUROL PSYCHOPATHO, V4, P299; Work SS, 2011, ADV THER, V28, P586, DOI 10.1007/s12325-011-0031-3; Wortzel HS, 2008, CNS DRUGS, V22, P531, DOI 10.2165/00023210-200822070-00001	42	40	40	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0741-238X	1865-8652		ADV THER	Adv. Ther.	SEP	2012	29	9					775	798		10.1007/s12325-012-0043-7			24	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	006KL	WOS:000308818000005	22941524	Bronze			2021-06-18	
J	Max, JE; Wilde, EA; Bigler, ED; MacLeod, M; Vasquez, AC; Schmidt, AT; Chapman, SB; Hotz, G; Yang, TT; Levin, HS				Max, Jeffrey E.; Wilde, Elisabeth A.; Bigler, Erin D.; MacLeod, Marianne; Vasquez, Ana C.; Schmidt, Adam T.; Chapman, Sandra B.; Hotz, Gillian; Yang, Tony T.; Levin, Harvey S.			Psychiatric Disorders After Pediatric Traumatic Brain Injury: A Prospective, Longitudinal, Controlled Study	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							PERSONALITY-CHANGE; CEREBRAL TRAUMA; HEAD-INJURIES; CHILDREN; ADOLESCENTS; SYMPTOMATOLOGY; RELIABILITY; LIFETIME; VALIDITY; PREDICTORS	The objective was to examine the effects of traumatic brain injury (TBI), as compared with orthopedic injury (OI), relative to the risk for psychiatric disorder. There has only been one previous prospective study of this nature. Participants were age 7-17 years at the time of hospitalization for either TBI (complicated mild-to-severe) or OI. The study used a prospective, longitudinal, controlled design, with standardized psychiatric assessments conducted at baseline (reflecting pre-injury functioning) and 3 months post-injury. Assessments of pre-injury psychiatric, adaptive functioning, family adversity, and family psychiatric history status were conducted. Severity of injury was assessed by standard clinical scales. The outcome measure was the presence of a psychiatric disorder not present before the injury ("novel"), during the first 3 months after TBI. Enrolled participants (N=141) included children with TBI (N=75) and with OI (N=66). The analyses focused on 118 children (84%) (TBI: N=65; OI: N=53) who returned for follow-up assessment at 3 months. Novel psychiatric disorder (NPD) occurred significantly more frequently in the TBI (32/65; 49%) than the OI (7/53; 13%) group. This difference was not accounted for by pre-injury lifetime psychiatric status; pre-injury adaptive functioning; pre-injury family adversity, family psychiatric history, socioeconomic status, injury severity, or age at injury. Furthermore, none of these variables significantly discriminated between children with TBI who developed, versus those who did not develop, NPD. These findings suggest that children with complicated mild-to-severe TBI are at significantly higher risk than OI-controls for the development of NPD in the first 3 months after injury. (The Journal of Neuropsychiatry and Clinical Neurosciences 2012; 24:427-436)	[Max, Jeffrey E.] Univ Calif San Diego, Rady Childrens Hosp, Dept Psychiat, San Diego, CA 92123 USA; [Wilde, Elisabeth A.; MacLeod, Marianne; Vasquez, Ana C.; Schmidt, Adam T.; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol & Neurosci, Provo, UT 84602 USA; [Chapman, Sandra B.] Univ Texas Dallas, Ctr BrainHlth, Dallas, TX 75230 USA; [Hotz, Gillian] Univ Miami, Miller Sch Med, Dept Neurosurg, Miami, FL 33136 USA; [Yang, Tony T.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA	Max, JE (corresponding author), Univ Calif San Diego, Rady Childrens Hosp, Dept Psychiat, 3020 Childrens Way,MC 5018, San Diego, CA 92123 USA.	jmax@ucsd.edu			National Institute of Mental Health (NIMH) Grant [K-08 MH01800]; National Institute of Neurological Disorders and Stroke (NINDS) GrantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800, R01MH085734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This study was supported by National Institute of Mental Health (NIMH) Grant K-08 MH01800 (Dr. Max) and National Institute of Neurological Disorders and Stroke (NINDS) Grant NS-21889 (Dr. Levin).	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Anderson V, 2012, DISABIL REHABIL, V34, P1639, DOI 10.3109/09638288.2012.656789; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; *ASS ADV AUT MED, 1990, ABBR INJ SCAL; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; BENDER L, 1956, PSYCHOPATHOLOGY CHIL, P66; BLACK P, 1969, LATE EFFECTS HEAD IN, P142; Blau A, 1936, ARCH NEURO PSYCHIATR, V35, P723, DOI 10.1001/archneurpsyc.1936.02260040031003; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; DILLON H, 1961, JAMA-J AM MED ASSOC, V175, P86, DOI 10.1001/jama.1961.03040020012003; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Harrington JA, 1958, J MENT SCI, P1205; Hjern B, 1964, ACTA PAEDIATR, P152; Kasanin J, 1929, J NERV MENT DIS, V69, P385, DOI 10.1097/00005053-192904000-00002; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Keenan HT, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1984; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; LECKMAN JF, 1982, ARCH GEN PSYCHIAT, V39, P879; LEHMKUHL G, 1990, BRAIN BEHAV CHILD PS, P267; Luis CA, 2002, J CLIN EXP NEUROPSYC, V24, P270, DOI 10.1076/jcen.24.3.270.982; Massagli TL, 2004, ARCH PHYS MED REHAB, V85, P1428, DOI 10.1016/j.apmr.2003.12.036; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1997, BRAIN INJURY, V11, P699; Max JE, 1997, J AM ACAD CHILD PSY, V36, P404, DOI 10.1097/00004583-199703000-00020; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1998, J AM ACAD PSYCHIATRY, V26, P247; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1595, DOI 10.1016/S0890-8567(09)66570-9; Max JE, 1998, J NEUROPSYCH CLIN N, V10, P290, DOI 10.1176/jnp.10.3.290; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; Max JE, J AM ACAD C IN PRESS; Moos R, 1994, LIFE STRESSORS SOCIA; OTTO U, 1960, Acta Paedopsychiatr, V27, P6; Reynolds C.R., 2004, BEHAV ASSESSMENT SYS; Rune V, 1970, ACTA PAEDIATR SC   S, V209, P3; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; SHAFFER D, 1975, OUTCOME SEVERE DAMAG, P191; Sparrow S, 2005, VINELAND ADAPTIVE BE; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; Strecker EA, 1924, ARCH NEURO PSYCHIATR, V12, P443, DOI 10.1001/archneurpsyc.1924.02200040092006; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Vasa RA, 2004, BIOL PSYCHIAT, V55, P208, DOI 10.1016/S0006-3223(03)00708-X; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates K.O., 2012, ARCH PEDIAT ADOLESC	55	40	40	0	20	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FAL	2012	24	4					427	436		10.1176/appi.neuropsych.12060149			10	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	057WK	WOS:000312594700038	23224448				2021-06-18	
J	Quirk, BJ; Torbey, M; Buchmann, E; Verma, S; Whelan, HT				Quirk, Brendan J.; Torbey, Michel; Buchmann, Ellen; Verma, Sumit; Whelan, Harry T.			Near-Infrared Photobiomodulation in an Animal Model of Traumatic Brain Injury: Improvements at the Behavioral and Biochemical Levels	PHOTOMEDICINE AND LASER SURGERY			English	Article							EMITTING DIODE IRRADIATION; CONTROLLED CORTICAL IMPACT; MITOCHONDRIAL DYSFUNCTION; BAX; APOPTOSIS; TRANSLOCATION; MEMBRANE; ACTIN; BCL-2; CELLS	Objective: The purpose of this was to evaluate the neuroprotective effects of near-infrared (NIR) light using an in-vivo rodent model of traumatic brain injury (TBI), controlled cortical impact (CCI), and to characterize changes at the behavioral and biochemical levels. Background data: NIR upregulates mitochondrial function, and decreases oxidative stress. Mitochondrial oxidative stress and apoptosis are important in TBI. NIR enhanced cell viability and mitochondrial function in previous in-vitro TBI models, supporting potential NIR in-vivo benefits. Methods: Sprague-Dawley rats were divided into three groups: severe TBI, sham surgery, and anesthetization only (behavioral response only). Cohorts in each group were administered either no NIR or NIR. They received two 670 nm LED treatments (5 min, 50 mW/cm(2), 15J/cm(2)) per day for 72 h (chemical analysis) or 10 days (behavioral). During the recovery period, animals were tested for locomotor and behavioral activities using a TruScan device. Frozen brain tissue was obtained at 72 h and evaluated for apoptotic markers and reduced glutathione (GSH) levels. Results: Significant differences were seen in the TBI plus and minus NIR (TBI+/-) and sham plus and minus NIR (S+/-) comparisons for some of the TruScan nose poke parameters. A statistically significant decrease was found in the Bax pro-apoptotic marker attributable to NIR exposure, along with lesser increases in Bcl-2 anti-apoptotic marker and GSH levels. Conclusions: These results show statistically significant, preclinical outcomes that support the use of NIR treatment after TBI in effecting changes at the behavioral, cellular, and chemical levels.	[Whelan, Harry T.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Torbey, Michel] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA	Whelan, HT (corresponding author), Med Coll Wisconsin, Dept Neurol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	hwhelan@mcw.edu			Defense Advanced Research Projects Agency (DARPA)United States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [W911NF-09-0117, 56482LSDRP09267]; Bleser Endowed Chair in Neurology; Baumann Research Endowment	This work was supported by the Defense Advanced Research Projects Agency (DARPA) Grant # W911NF-09-0117, Project # 56482LSDRP09267 (to Dr. Whelan), and the Bleser Endowed Chair in Neurology (to Dr. Whelan), as well as the Baumann Research Endowment (to Dr. Whelan). We gratefully acknowledge Brandi Jones and Joeylynn Nawrocki for technical assistance as well as Debbie Dye for administrative support in preparation of the manuscript.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Dittmer A, 2006, ELECTROPHORESIS, V27, P2844, DOI 10.1002/elps.200500785; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011-1344(98)00219-X; Karu T. I., 2003, LOW POWER LASER THER; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MANVELYAN H, 2006, GEORGIAN MED NEWS, V140, P1306; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Monks TJ, 1999, TOXICOL SCI, V51, P161, DOI 10.1093/toxsci/51.2.161; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814; Oron A, 2012, J NEUROTRAUM, V29, P401, DOI 10.1089/neu.2011.2062; Quirk Brendan J, 2012, Front Biosci (Elite Ed), V4, P818; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Tang HL, 2006, BIOCHEM J, V396, P1, DOI 10.1042/BJ20060241; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Whelan HT, 2003, J CLIN LASER MED SUR, V21, P67, DOI 10.1089/104454703765035484; Whelan HT, 2001, J CLIN LASER MED SUR, V19, P305, DOI 10.1089/104454701753342758; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	22	40	41	1	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1549-5418			PHOTOMED LASER SURG	Photomed. Laser Surg.	SEP	2012	30	9					523	529		10.1089/pho.2012.3261			7	Surgery	Surgery	996JM	WOS:000308081600004	22793787	Green Published			2021-06-18	
J	Kelly, MP; Coldren, RL; Parish, RV; Dretsch, MN; Russell, ML				Kelly, Mark P.; Coldren, Rodney L.; Parish, Robert V.; Dretsch, Michael N.; Russell, Michael L.			Assessment of Acute Concussion in the Combat Environment	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Concussion; Military; Neuropsychological testing; Combat; Automated Neuropsychological Assessment Metrics	TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; NEUROPSYCHOLOGICAL ASSESSMENT; SPORTS; MILITARY; RECOVERY; IMPACT; SENSITIVITY; PERFORMANCE; VALIDATION	Despite the prevalence of concussion in soldiers deployed to Iraq and Afghanistan, neuropsychological tests used to assist in concussion management have not been validated on the battlefield. This study evaluated the validity of the Automated Neuropsychological Assessment Metrics (ANAM) in the combat environment. Cases meeting criteria for concussion, healthy controls, and injured controls were assessed. Soldiers were administered the ANAM, traditional neuropsychological tests, and a background questionnaire. Cases were enrolled within 72 h of concussion. Cases exhibited poorer performance than controls on all ANAM subtests, with significant differences on simple reaction time (SRT), procedural reaction time (PRT), code substitution, and matching to sample (p .001). Discriminant ability of scores on SRT and PRT subtests was 71, which improved to 76 when pre-deployment baseline scores were available. An exploratory clinical decision tool incorporating ANAM scores and symptoms improved discriminant ability to 81. Results provide initial validation of the ANAM for detecting acute effects of battlefield concussion.	[Kelly, Mark P.; Parish, Robert V.] Walter Reed Army Med Ctr, Dept Psychol, Washington, DC 20307 USA; [Coldren, Rodney L.] USA, Publ Hlth Command, Directorate Epidemiol & Dis Surveillance, Aberdeen Proving Ground, MD USA; [Dretsch, Michael N.] USA, Aeromed Res Lab, Warfighter & Hlth Div, Ft Rucker, AL USA; [Russell, Michael L.] USA, Med Command Headquarters, Behav Hlth Div, Ft Sam Houston, TX USA	Kelly, MP (corresponding author), Walter Reed Natl Mil Med Ctr, Dept Psychol, Bldg 10,7th Floor,7NE, Bethesda, MD 20889 USA.	mark.kelly1@us.army.mil			U.S. Army Medical Research Acquisition Activity [W81XWIH-09-2-0057]	This work was supported in part by the U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, Maryland 21702- 5014, Project W81XWIH-09-2-0057.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barr W., 2008, TXB CLIN NEUROPSYCHO, P660; Barth J., 2010, MILITARY NEUROPSYCHO, P127; Barth JT., 1989, MILD HEAD INJURY, P257; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Cernich AN, 2007, ARCH CLIN NEUROPSYCH, V22, pS39, DOI 10.1016/j.acn.2006.10.004; Coldren RL, 2011, MIL MED, V176, pIV; Coldren RL, 2010, MIL MED, V175, P477, DOI 10.7205/MILMED-D-09-00258; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Defense and Veterans Brain Injury Center, 2011, DOD WORLDWIDE NUMB T; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Department of Defense, 2007, 07030 DEP DEF; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger DM, 2002, J HEAD TRAUMA REHAB, V17, P458, DOI 10.1097/00001199-200210000-00007; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; Giza CC, 2001, J ATHL TRAINING, V36, P228; Greiffenstein M. F., 2010, MILITARY NEUROPSYCHO, P81; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Heaton R., 1997, REVISED COMPREHENSIV; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Kabat MH, 2001, CLIN NEUROPSYCHOL, V15, P498, DOI 10.1076/clin.15.4.498.1882; Kane RL, 2007, ARCH CLIN NEUROPSYCH, V22, pS115, DOI 10.1016/j.acn.2006.10.006; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McNeil J., 2010, MILITARY NEUROPSYCHO, P361; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Peterson L.S., 2008, ANN M SW ED RES ASS; Reeves DL, 2007, ARCH CLIN NEUROPSYCH, V22, pS15, DOI 10.1016/j.acn.2006.10.013; RIEGELMAN RK, 2004, STUDYING STUDY TESTI; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2010, MILITARY NEUROPSYCHO, P321; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Wesensten N., 2010, MILITARY NEUROPSYCHO, P297; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f	65	40	41	0	13	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUN	2012	27	4					375	388		10.1093/arclin/acs036			14	Psychology, Clinical; Psychology	Psychology	944JX	WOS:000304198300001	22491730				2021-06-18	
J	Luo, P; Chen, T; Zhao, YB; Xu, HX; Huo, K; Zhao, MM; Yang, YF; Fei, Z				Luo, Peng; Chen, Tao; Zhao, Yongbo; Xu, Haoxiang; Huo, Kai; Zhao, Mingming; Yang, Yuefan; Fei, Zhou			Protective effect of Homer 1a against hydrogen peroxide-induced oxidative stress in PC12 cells	FREE RADICAL RESEARCH			English	Article						reactive oxygen species; mitochondria; apoptosis; antioxidant; postsynaptic density; calcium homeostasis	METABOTROPIC GLUTAMATE RECEPTORS; SYNAPTIC PLASTICITY; GENE-EXPRESSION; TRAUMATIC BRAIN; CYTOCHROME-C; MOUSE MODEL; PROTEIN; FAMILY; MITOCHONDRIA; APOPTOSIS	Oxidative stress-induced cell damage is involved in many neurological diseases. Homer protein, as an important scaffold protein at postsynaptic density, regulates synaptic structure and function. Here, we reported that hydrogen peroxide (H2O2) induced the expression of Homer 1a. Down-regulation of Homer 1a with a specific small interfering RNA (siRNA) exacerbated H2O2-induced cell injury. Up-regulation of Homer 1a by lentivirus transfection did not affect the anti-oxidant activity, but significantly reduced the reactive oxygen species (ROS) production and lipid peroxidation after H2O2-induced oxidative stress. Overexpression of Homer 1a attenuated the loss of mitochondrial membrane potential (MMP) and ATP production induced by H2O2, and subsequently inhibited mitochondrial dysfunction-induced cytochrome c release, increase of Bax/Bcl-2 ratio and caspase-9/caspase-3 activity. Furthermore, in the presence of BAPTA-AM, an intracellular free-calcium (Ca2+) chelator, overexpression of Homer 1a had no significant effects on H2O2-induced oxidative stress. These results suggest that Homer 1a has protective effects against H2O2-induced oxidative stress by reducing ROS accumulation and activation of mitochondrial apoptotic pathway, and these protective effects are dependent on the regulation of intracellular Ca2+ homeostasis.	[Luo, Peng; Chen, Tao; Zhao, Yongbo; Xu, Haoxiang; Huo, Kai; Zhao, Mingming; Yang, Yuefan; Fei, Zhou] Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, Xian 710032, Peoples R China	Fei, Z (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, 15 Changle Xi Rd, Xian 710032, Peoples R China.	feizhou@fmmu.edu.cn	Yang, Yuefan/AAJ-9136-2020	Luo, Peng/0000-0003-0746-939X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30670796, 30930093]; 863 High-Tech ProjectNational High Technology Research and Development Program of China [2009AA02Z419]	The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article. The work was supported by National Natural Science Foundation of China (No. 30670796, No. 30930093) and the 863 High-Tech Project (2009AA02Z419).	Ageta H, 2001, MOL BRAIN RES, V97, P186, DOI 10.1016/S0169-328X(01)00303-5; Avery SV, 2011, BIOCHEM J, V434, P201, DOI 10.1042/BJ20101695; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Chen H, 2011, ANTIOXID REDOX SIGN, V14, P1505, DOI 10.1089/ars.2010.3576; Chen M, 2007, J BIOL CHEM, V282, P33888, DOI 10.1074/jbc.M702969200; Chen T, 2012, FREE RADICAL BIO MED, V52, P208, DOI 10.1016/j.freeradbiomed.2011.10.451; Circu ML, 2010, FREE RADICAL BIO MED, V48, P749, DOI 10.1016/j.freeradbiomed.2009.12.022; Denisova NA, 1999, FREE RADICAL BIO MED, V27, P1292, DOI 10.1016/S0891-5849(99)00163-X; Dickey CA, 2003, J NEUROSCI, V23, P5219; Dietrich JB, 2007, SYNAPSE, V61, P587, DOI 10.1002/syn.20412; Droge W, 2002, PHYSIOL REV, V82, P47; Gleichmann M, 2011, ANTIOXID REDOX SIGN, V14, P1261, DOI 10.1089/ars.2010.3386; Govek EE, 2004, NAT NEUROSCI, V7, P364, DOI 10.1038/nn1210; Guerrero AD, 2008, APOPTOSIS, V13, P177, DOI 10.1007/s10495-007-0139-8; Hernandez-Garcia D, 2010, FREE RADICAL BIO MED, V49, P130, DOI 10.1016/j.freeradbiomed.2010.03.020; Huang WD, 2005, NEUROSCI LETT, V389, P46, DOI 10.1016/j.neulet.2005.07.014; Huber KM, 2002, P NATL ACAD SCI USA, V99, P7746, DOI 10.1073/pnas.122205699; Karbowski M, 2012, ACTA NEUROPATHOL, V123, P157, DOI 10.1007/s00401-011-0921-0; Kato A, 1997, FEBS LETT, V412, P183, DOI 10.1016/S0014-5793(97)00775-8; Kato A, 1998, J BIOL CHEM, V273, P23969, DOI 10.1074/jbc.273.37.23969; Knackstedt LA, 2010, J NEUROSCI, V30, P7984, DOI 10.1523/JNEUROSCI.1244-10.2010; Kwon SH, 2011, NEUROCHEM INT, V58, P533, DOI 10.1016/j.neuint.2011.01.012; Li RC, 2008, BRAIN RES, V1190, P159, DOI 10.1016/j.brainres.2007.11.022; Li SY, 2010, FREE RADICAL BIO MED, V48, P597, DOI 10.1016/j.freeradbiomed.2009.12.004; Liu WB, 2010, NEUROCHEM INT, V57, P206, DOI 10.1016/j.neuint.2010.05.011; Maroto R, 1997, J NEUROCHEM, V69, P514; Marrone DF, 2008, J NEUROSCI, V28, P1030, DOI 10.1523/JNEUROSCI.4235-07.2008; Martinou JC, 2011, DEV CELL, V21, P92, DOI 10.1016/j.devcel.2011.06.017; McCoy MK, 2012, ANTIOXID REDOX SIGN, V16, P869, DOI [10.1089/ars.2011.4019, 10.1089/ars.2011.4074]; McManus MJ, 2011, J NEUROSCI, V31, P15703, DOI 10.1523/JNEUROSCI.0552-11.2011; Miletic G, 2009, ANESTH ANALG, V109, P2000, DOI 10.1213/ANE.0b013e3181beea9b; Oberst A, 2008, CELL DEATH DIFFER, V15, P1139, DOI 10.1038/cdd.2008.65; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; Olmez I, 2012, NEUROCHEM INT, V60, P208, DOI 10.1016/j.neuint.2011.11.009; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; Potschka H, 2002, EUR J NEUROSCI, V16, P2157, DOI 10.1046/j.1460-9568.2002.02265.x; Rezvani K, 2007, J NEUROSCI, V27, P10508, DOI 10.1523/JNEUROSCI.3353-07.2007; Roselli F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006011; Sanchez-Gallego JI, 2010, FREE RADICAL BIO MED, V48, P1444, DOI 10.1016/j.freeradbiomed.2010.02.034; Sun J, 1998, FEBS LETT, V437, P304, DOI 10.1016/S0014-5793(98)01256-3; Tappe A, 2006, NAT MED, V12, P677, DOI 10.1038/nm1406; Tiago T, 2011, CELL CALCIUM, V49, P174, DOI 10.1016/j.ceca.2011.01.009; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Twiddy D, 2004, J BIOL CHEM, V279, P19665, DOI 10.1074/jbc.M311388200; von Bernhardi R, 2012, ANTIOXID REDOX SIGN, V16, P974, DOI 10.1089/ars.2011.4082; Worley PF, 2007, CELL CALCIUM, V42, P363, DOI 10.1016/j.ceca.2007.05.007; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8; Yano M, 2005, NEUROSCIENCE, V132, P855, DOI 10.1016/j.neuroscience.2004.12.019; Yeo JE, 2007, BBA-MOL BASIS DIS, V1772, P1199, DOI 10.1016/j.bbadis.2007.09.004; Zhang SH, 2010, J MOL NEUROSCI, V40, P311, DOI 10.1007/s12031-009-9285-5	52	40	40	1	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1071-5762	1029-2470		FREE RADICAL RES	Free Radic. Res.	JUN	2012	46	6					766	776		10.3109/10715762.2012.678340			11	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	939RW	WOS:000303832700007	22435683				2021-06-18	
J	O'Connor, SS; Zatzick, DF; Wang, J; Temkin, N; Koepsell, TD; Jaffe, KM; Durbin, D; Vavilala, MS; Dorsch, A; Rivara, FP				O'Connor, Stephen S.; Zatzick, Douglas F.; Wang, Jin; Temkin, Nancy; Koepsell, Thomas D.; Jaffe, Kenneth M.; Durbin, Dennis; Vavilala, Monica S.; Dorsch, Andrea; Rivara, Frederick P.			Association between posttraumatic stress, depression, and functional impairments in adolescents 24 months after traumatic brain injury	JOURNAL OF TRAUMATIC STRESS			English	Article							QUALITY-OF-LIFE; PATIENT HEALTH QUESTIONNAIRE-9; PSYCHIATRIC-DISORDERS; SYMPTOMS; CHILDREN; VALIDITY; OUTCOMES; RELIABILITY; TERM; CARE	The degree to which postinjury posttraumatic stress disorder (PTSD) and/or depressive symptoms in adolescents are associated with cognitive and functional impairments at 12 and 24 months after traumatic brain injury (TBI) is not yet known. The current study used a prospective cohort design, with baseline assessment and 3-, 12-, and 24-month followup, and recruited a cohort of 228 adolescents ages 1417 years who sustained either a TBI (n = 189) or an isolated arm injury (n = 39). Linear mixed-effects regression was used to assess differences in depressive and PTSD symptoms between TBI and arm-injured patients and to assess the association between 3-month PTSD and depressive symptoms and cognitive and functional outcomes. Results indicated that patients who sustained a mild TBI without intracranial hemorrhage reported significantly worse PTSD (Hedges g = 0.49, p = .01; Model R2 = .38) symptoms across time as compared to the arm injured control group. Greater levels of PTSD symptoms were associated with poorer school (?2 = .07, p = .03; Model R2 = .36) and physical (?2 = .11, p = .01; Model R2 = .23) functioning, whereas greater depressive symptoms were associated with poorer school (?2 = .06, p = .05; Model R2 = .39) functioning.	[O'Connor, Stephen S.; Zatzick, Douglas F.] Univ Washington, Dept Psychiat & Behav Sci, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Temkin, Nancy] Univ Washington, Dept Neurol Surg, Dept Biostat, Seattle, WA 98104 USA; [Koepsell, Thomas D.] Univ Washington, Dept Epidemiol, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Jaffe, Kenneth M.] Univ Washington, Dept Rehabil Med, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Durbin, Dennis] Childrens Hosp Philadelphia, Dept Emergency Med, Philadelphia, PA 19104 USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Vavilala, Monica S.; Rivara, Frederick P.] Univ Washington, Dept Pediat, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Dorsch, Andrea] Seattle Childrens Hosp, Div Rehabil Psychol, Seattle, WA USA	O'Connor, SS (corresponding author), Univ Washington, Dept Psychiat, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA.	oconnor7@u.washington.edu			AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [T32/HS013835] Funding Source: Medline		American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Gerring JP, 2002, J AM ACAD CHILD PSY, V41, P157, DOI 10.1097/00004583-200202000-00009; Hajek CA, 2010, BRAIN INJURY, V24, P100, DOI 10.3109/02699050903508226; Hedeker D., 2006, LONGITUDINAL DATA AN; Holbrook TL, 2005, J TRAUMA, V58, P764, DOI 10.1097/01.TA.0000159247.48547.7D; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Marr AL., 2004, CENTRAL NERVOUS SYST; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Rabe-Hesketh S., 2008, MULTILEVEL LONGITUDI; Ramchand R, 2008, J CONSULT CLIN PSYCH, V76, P668, DOI 10.1037/0022-006X.76.4.668; Richardson LP, 2010, PEDIATRICS, V126, P1117, DOI 10.1542/peds.2010-0852; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Rivara FP, 2011, HEALTH SERV RES, V46, P964, DOI 10.1111/j.1475-6773.2010.01236.x; Schnurr PP, 2006, J CONSULT CLIN PSYCH, V74, P707, DOI 10.1037/0022-006X.74.4.707; StataCorp, 2009, STAT STAT SOFTW REL; Steinberg Alan M, 2004, Curr Psychiatry Rep, V6, P96, DOI 10.1007/s11920-004-0048-2; Terrell F, 2008, J AM COLL SURGEONS, V207, P630, DOI 10.1016/j.jamcollsurg.2008.05.021; Varni James W, 2005, Expert Rev Pharmacoecon Outcomes Res, V5, P705, DOI 10.1586/14737167.5.6.705; Varni JW, 2011, QUAL LIFE RES, V20, P913, DOI 10.1007/s11136-010-9823-1; Varni JW, 2002, CANCER-AM CANCER SOC, V94, P2090, DOI 10.1002/cncr.10428; WRIGHT SP, 1992, BIOMETRICS, V48, P1005, DOI 10.2307/2532694; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Zatzick D, 2004, ARCH GEN PSYCHIAT, V61, P498, DOI 10.1001/archpsyc.61.5.498; Zatzick DF, 2008, ARCH PEDIAT ADOL MED, V162, P642, DOI 10.1001/archpedi.162.7.642; Zatzick DF, 2011, PSYCHIAT SERV, V62, P264, DOI 10.1176/ps.62.3.pss6203_0264	34	40	40	1	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-9867	1573-6598		J TRAUMA STRESS	J. Trauma Stress	JUN	2012	25	3					264	271		10.1002/jts.21704			8	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	962VV	WOS:000305576500009	22729979				2021-06-18	
J	Cameron, KL; Marshall, SW; Sturdivant, RX; Lincoln, AE				Cameron, Kenneth L.; Marshall, Stephen W.; Sturdivant, Rodney X.; Lincoln, Andrew E.			Trends in the Incidence of Physician-Diagnosed Mild Traumatic Brain Injury among Active Duty U.S. Military Personnel between 1997 and 2007	JOURNAL OF NEUROTRAUMA			English	Article						epidemiology; mild traumatic brain injury; military; trends	POSTTRAUMATIC-STRESS-DISORDER; MEDICAL SURVEILLANCE; SERVICE MEMBERS; CONCUSSION; SPORTS; COMBAT; RECOMMENDATIONS; EPIDEMIOLOGY; DISLOCATION; DEPLOYMENT	Mild traumatic brain injury (mTBI) has been described as the most common form of traumatic brain injury within military populations; however, few epidemiologic studies have examined incidence rates for mTBI in this population. The objective of this study was to examine trends in the incidence of mTBI among active-duty U. S. service members between 1997 and 2007. Specifically, we were interested in evaluating trends in the incidence rates in relation to the initiation of combat operations in Iraq and Afghanistan. A retrospective cohort study was conducted utilizing data extracted from the Defense Medical Surveillance System to identify all incident cases of mTBI within the study population. The primary outcome of interest was the incidence rate of mTBI per 1000 person-years. Multivariable Poisson regression was used to analyze the data. There were 98,012 mTBI cases and 14,956,955 person-years of follow-up, for an overall incidence rate of 6.55 (95% CI 6.51,6.59) per 1000 person-years. There was a steady increase in the mTBI rate over time. The average change in the mTBI rate was 8.5% (95% CI 8.2%, 8.8%) per year; however, the rate rose dramatically in the last 2 years of the study period. Overall, for 2006-2007 versus 1997-2005, the rate ratio was 1.61 (95% CI 1.58,1.65). The greatest increase in the rate of mTBI was observed among those serving in Iraq, who experienced a 38.4% (95% CI 35.4%, 41.1%) annual increase in new cases. The observed increase in the incidence of mTBI in this population has significant policy implications in terms of allocating appropriate health care resources.	[Cameron, Kenneth L.] US Mil Acad, Keller Army Hosp, West Point, NY 10996 USA; [Sturdivant, Rodney X.] US Mil Acad, Dept Math Sci, West Point, NY 10996 USA; [Marshall, Stephen W.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; [Lincoln, Andrew E.] Union Mem Hosp, MedStar Hlth Res Inst, Baltimore, MD USA	Cameron, KL (corresponding author), US Mil Acad, Keller Army Hosp, 900 Washington Rd, West Point, NY 10996 USA.	kenneth.cameron@amedd.army.mil		Cameron, Kenneth/0000-0002-6276-4482; Marshall, Stephen/0000-0002-2664-9233	Congressionally Directed Medical Research Program's Post-Traumatic Stress Disorder and Traumatic Brain Injury Research Program [W81XWH-08-2-0152]	The views and opinions expressed are those of the authors and do not represent the official policy of the U.S. Army, Department of Defense, or the U. S. government. We would like to thank Dr. Angie Eick-Cost and her staff from the Armed Forces Health Surveillance Center for assisting our research team with data acquisition. We would also like to acknowledge the U.S. service members on active duty during the study period between 1997 and 2007 for their selfless commitment to serve our nation. Finally, we would like to recognize the active-duty and civilian providers and support staff that coordinated and delivered the medical care for this cohort throughout the military health system. This project was supported by the Congressionally Directed Medical Research Program's Post-Traumatic Stress Disorder and Traumatic Brain Injury Research Program Award no. W81XWH-08-2-0152.	Army Medical Surveillance Activity, 2004, DEF MED EP DAT US GU; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Brundage JF, 2000, MIL MED, V165, P505; Cameron KL, 2010, J ATHL TRAINING, V45, P29, DOI 10.4085/1062-6050-45.1.29; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Chrisman S.P., 2011, CLIN PEDIAT PHILA; Ciminera P, 2007, AM J TROP MED HYG, V76, P275, DOI 10.4269/ajtmh.2007.76.275; *DEF VET BRAIN INJ, 2006, CLIN PRACT GUID REC; Ellenbogen RG, 2010, WORLD NEUROSURG, V74, P560, DOI 10.1016/j.wneu.2010.11.016; FROME EL, 1985, AM J EPIDEMIOL, V121, P309, DOI 10.1093/oxfordjournals.aje.a114001; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, INT J EPIDEMIOL, V36, P327, DOI 10.1093/ije/dym013; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Hsiao M, 2010, AM J SPORT MED, V38, P1997, DOI 10.1177/0363546510371423; Joint Improvised Explosive Device Defeat Organization, 2008, ANN REP FY 2008 DEP, P1; Joint Improvised Explosive Device Defeat Organization, 2007, AIDS EP UPD, P1; Jones BH, 2010, AM J PREV MED, V38, pS42, DOI 10.1016/j.amepre.2009.10.014; Kennedy JE, 2010, NEUROREHABILITATION, V26, P191, DOI 10.3233/NRE-2010-0555; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Maruta J, 2010, ANN NY ACAD SCI, V1208, P58, DOI 10.1111/j.1749-6632.2010.05695.x; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McCrea M.A, 2008, MILD TRAUMATIC BRAIN, P153; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Owens BD, 2009, J BONE JOINT SURG AM, V91A, P791, DOI 10.2106/JBJS.H.00514; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Rubertone MV, 2002, AM J PUBLIC HEALTH, V92, P1900, DOI 10.2105/AJPH.92.12.1900; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Street AE, 2009, CLIN PSYCHOL REV, V29, P685, DOI 10.1016/j.cpr.2009.08.007; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wilson ALG, 2009, SOC PSYCH PSYCH EPID, V44, P473, DOI 10.1007/s00127-008-0461-7	39	40	41	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2012	29	7					1313	1321		10.1089/neu.2011.2168			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	933TC	WOS:000303384600004	22332633				2021-06-18	
J	Ettenhofer, ML; Barry, DM				Ettenhofer, Mark L.; Barry, David M.			A Comparison of Long-Term Postconcussive Symptoms between University Students with and without a History of Mild Traumatic Brain Injury or Orthopedic Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Traumatic brain injury; Concussion; Postconcussive symptoms; Post-Concussion Syndrome; Chronic; Orthopedic injury; Postconcussional Disorder	POST-CONCUSSION SYMPTOMS; HEAD-INJURY; QUESTIONNAIRE; COMPLAINTS	Mild traumatic brain injury (mild TBI) is often associated with postconcussive symptoms such as headache, memory problems, and irritability. However, high rates of similar symptoms in groups without a history of TBI raise questions about the clinical validity of the postconcussive syndrome. This study was conducted to address these issues through systematic examination of symptoms reported by those with and without a history of mild TBI or orthopedic injury. Responses to the Postconcussion Syndrome Checklist (PCSC), demographic information, and medical history were collected via online questionnaire from 3027 non-referred university students (2280 without a history of mild TBI or orthopedic injury, 491 with a history of orthopedic injury, and 256 with post-acute mild TBI). Although the mild TBI group reported higher mean levels of symptoms, confirmatory factor analyses demonstrated that symptoms clustered into parallel cognitive, somatic, affective, and sensory factors in all three groups. Despite modestly higher mean symptoms among those with a history of mild TBI, symptom clusters did not differ from non-TBI groups. These findings cast doubts about the clinical validity of the "postconcussive syndrome" and raise questions about pathways by which mild TBI and other factors may influence the expression of chronic symptoms. (JINS, 2012, 18, 451-460)	[Ettenhofer, Mark L.; Barry, David M.] Uniformed Serv Univ Hlth Sci, Dept Med & Clin Psychol, Bethesda, MD 20814 USA	Ettenhofer, ML (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Med & Clin Psychol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	mark.ettenhofer@usuhs.mil	Ettenhofer, Mark L./J-7171-2019	Ettenhofer, Mark L./0000-0001-9381-7578			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Axelrod BN, 1996, PSYCHOL ASSESSMENT, V8, P422, DOI 10.1037/1040-3590.8.4.422; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Birnbaum MH, 2004, ANNU REV PSYCHOL, V55, P803, DOI 10.1146/annurev.psych.55.090902.141601; BOHNEN NJ, 1995, J NEUROL REHABIL, V9, P33; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cheung GW, 2002, STRUCT EQU MODELING, V9, P233, DOI 10.1207/S15328007SEM0902_5; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Gunstad J, 2002, J INT NEUROPSYCH SOC, V8, P37, DOI 10.1017/S1355617701020045; Herrmann N, 2009, J NEUROPSYCH CLIN N, V21, P181, DOI 10.1176/appi.neuropsych.21.2.181; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McCrea M, 2008, MILD TRAUMATIC BRAIN; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Piland SG, 2003, J ATHL TRAINING, V38, P104; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Sullivan K, 2011, J HEAD TRAUMA REHAB, V26, P170, DOI 10.1097/HTR.0b013e3181e47f95; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; World Health Organization, 1992, ICD 10 INT STAT CLAS	37	40	40	0	11	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2012	18	3					451	460		10.1017/S1355617711001895			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	937VG	WOS:000303690500007	22321647				2021-06-18	
J	Marco, EJ; Harrell, KM; Brown, WS; Hill, SS; Jeremy, RJ; Kramer, JH; Sherr, EH; Paul, LK				Marco, Elysa J.; Harrell, Kathryn M.; Brown, Warren S.; Hill, Susanna S.; Jeremy, Rita J.; Kramer, Joel H.; Sherr, Elliott H.; Paul, Lynn K.			Processing Speed Delays Contribute to Executive Function Deficits in Individuals with Agenesis of the Corpus Callosum	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Absence of the corpus callosum; Human information processing; Inhibition; Stroop Paradigm; Trail Making Test; Cognition	TRAUMATIC BRAIN-INJURY; METHYLPHENIDATE; ABNORMALITIES; COGNITION	Corpus callosum malformation and dysfunction are increasingly recognized causes of cognitive and behavioral disability. Individuals with agenesis of the corpus callosum (AgCC) offer unique insights regarding the cognitive skills that depend specifically upon callosal connectivity. We examined the impact of AgCC on cognitive inhibition, flexibility, and processing speed using the Color-Word Interference Test (CWIT) and Trail Making Test (TMT) from the Delis-Kaplan Executive Function System. We compared 36 individuals with AgCC and IQs within the normal range to 56 matched controls. The AgCC cohort was impaired on timed measures of inhibition and flexibility; however, group differences on CWIT inhibition, CWIT Inhibition/Switching and TMT Number-Letter Switching appear to be largely explained by slow performance in basic operations such as color naming and letter sequencing. On CWIT Inhibition/Switching, the AgCC group was found to commit significantly more errors which suggests that slow performance is not secondary to a cautious strategy. Therefore, while individuals with agenesis of the corpus callosum show real deficits on tasks of executive function, this impairment appears to be primarily a consequence of slow cognitive processing. Additional studies are needed to investigate the impact of AgCC on other aspects of higher order cortical function. (JINS, 2012, 18, 521-529)	[Paul, Lynn K.] CALTECH, Div Humanities & Social Sci, Pasadena, CA 91125 USA; [Marco, Elysa J.; Hill, Susanna S.; Kramer, Joel H.; Sherr, Elliott H.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Marco, Elysa J.; Kramer, Joel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA; [Marco, Elysa J.; Sherr, Elliott H.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA; [Harrell, Kathryn M.; Brown, Warren S.; Jeremy, Rita J.; Paul, Lynn K.] Fuller Grad Sch Psychol, Travis Res Inst, Pasadena, CA USA; Univ Calif San Francisco, Clin & Translat Sci Inst, Pediat Clin Res Ctr, San Francisco, CA 94143 USA	Paul, LK (corresponding author), CALTECH, Div Humanities & Social Sci, 1200 E Calif Blvd,HSS 228-77, Pasadena, CA 91125 USA.	lkpaul@hss.caltech.edu		Hill, Susanna/0000-0001-5376-1872; Paul, Lynn/0000-0002-3128-8313	Simons Foundation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K-02 NS052192, R01 NS058721, K12 NS01692, 1K23MH083890-01, KL2 R12024130]; UCSF; NIH/NCRR UCSF-CTSIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR024131]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024131, KL2RR024130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH083890, P50MH094258] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K12NS001692, K02NS052192, R01NS058721] Funding Source: NIH RePORTER	We thank the participants and their families for making this study possible and the D-KEFS team for the generous contribution of their data. Portions of this study served as the Master's Thesis of the co-first author, Kathryn Harrell, at the Fuller Graduate School of Psychology. This work was supported by the Simons Foundation (L.K.P. on grant held by Ralph Adolphs at Caltech), National Institutes of Health (E.H.S., K-02 NS052192, R01 NS058721; E.J.M., K12 NS01692, 1K23MH083890-01; EMS, E.J.M. and R.J.J., KL2 R12024130), and the UCSF Program for Breakthrough Biomedical Research (E.H.S.); and R.J.J., NIH/NCRR UCSF-CTSI Grant Number UL1 RR024131. No conflicts of interest exist. Drs. Marco and Harrell contributed equally to this manuscript.	Badaruddin DH, 2007, CHILD PSYCHIAT HUM D, V38, P287, DOI 10.1007/s10578-007-0065-6; Beauchamp M, 2011, DEV NEUROPSYCHOL, V36, P578, DOI 10.1080/87565641.2011.555572; Brown WS, 1999, NEUROPSYCHOLOGIA, V37, P1165, DOI 10.1016/S0028-3932(99)00011-1; Brown WS, 2005, NEUROPSYCHOLOGIA, V43, P906, DOI 10.1016/j.neuropsychologia.2004.09.008; Brown WS., 2000, COGN NEUROPSYCHIATRY, V5, P135, DOI [10.1080/135468000395781, DOI 10.1080/135468000395781]; DAVID AS, 1992, NEUROPSYCHOLOGIA, V30, P161, DOI 10.1016/0028-3932(92)90025-H; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Fisher M, 2010, SCHIZOPHRENIA BULL, V36, P869, DOI 10.1093/schbul/sbn170; Glass HC, 2008, AM J MED GENET A, V146A, P2495, DOI 10.1002/ajmg.a.32418; Grynszpan O, 2011, PSYCHOL MED, V41, P163, DOI 10.1017/S0033291710000607; Imamura T, 1994, Behav Neurol, V7, P43, DOI 10.3233/BEN-1994-7201; Jeeves M, 2001, CORTEX, V37, P643, DOI 10.1016/S0010-9452(08)70611-7; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Mueller KLO, 2009, BEHAV NEUROSCI, V123, P1000, DOI 10.1037/a0016868; Nakata Y, 2009, AM J NEURORADIOL, V30, P1142, DOI 10.3174/ajnr.A1527; PARDO JV, 1990, P NATL ACAD SCI USA, V87, P256, DOI 10.1073/pnas.87.1.256; Parry AMM, 2003, BRAIN, V126, P2750, DOI 10.1093/brain/awg284; Paul LK, 2003, BRAIN LANG, V85, P313, DOI 10.1016/S0093-934X(03)00062-2; Paul LK, 2007, NAT REV NEUROSCI, V8, P287, DOI 10.1038/nrn2107; Paul LK, 2011, J NEURODEV DISORD, V3, P3, DOI 10.1007/s11689-010-9059-y; Sawyer E, 2008, ANN PHARMACOTHER, V42, P247, DOI 10.1345/aph.1K284; Schieffer B.M., 1999, DISS ABSTR INT B, V62; SOLURSH LP, 1965, J NERV MENT DIS, V141, P180, DOI 10.1097/00005053-196508000-00005; Symington SH, 2010, SOC NEUROSCI-UK, V5, P296, DOI 10.1080/17470910903462419; Tang PH, 2009, AM J NEURORADIOL, V30, P257, DOI 10.3174/ajnr.A1331; Tenovuo O, 2005, PROG NEURO-PSYCHOPH, V29, P61, DOI 10.1016/j.pnpbp.2004.10.006; Turk AA, 2010, NEUROPSYCHOLOGIA, V48, P43, DOI 10.1016/j.neuropsychologia.2009.08.009; Voineskos AN, 2012, NEUROBIOL AGING, V33, P21, DOI 10.1016/j.neurobiolaging.2010.02.009; Wahl M, 2009, AM J NEURORADIOL, V30, P282, DOI 10.3174/ajnr.A1361; Wechsler D., 2003, WECHSLER INTELLIGENC; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D, 1997, WAIS 3 ADM SCORING M; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Wolinsky FD, 2010, INT PSYCHOGERIATR, V22, P470, DOI 10.1017/S1041610209991281	35	40	42	0	14	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2012	18	3					521	529		10.1017/S1355617712000045			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	937VG	WOS:000303690500014	22390821	Green Accepted			2021-06-18	
J	Ng, SY; Semple, BD; Morganti-Kossmann, MC; Bye, N				Ng, Si Yun; Semple, Bridgette D.; Morganti-Kossmann, M. Cristina; Bye, Nicole			Attenuation of Microglial Activation with Minocycline Is Not Associated with Changes in Neurogenesis after Focal Traumatic Brain Injury in Adult Mice	JOURNAL OF NEUROTRAUMA			English	Article						adult neurogenesis; closed head injury; microglia; minocycline; traumatic brain injury	SPINAL-CORD-INJURY; CEREBRAL-ARTERY OCCLUSION; CENTRAL-NERVOUS-SYSTEM; CLOSED-HEAD INJURY; NEURAL STEM-CELLS; HIPPOCAMPAL NEUROGENESIS; INTRACEREBRAL HEMORRHAGE; CELLULAR PROLIFERATION; CORTICAL NEUROGENESIS; GLIAL PROLIFERATION	Neurogenesis is stimulated following injury to the adult brain and could potentially contribute to tissue repair. However, evidence suggests that microglia activated in response to injury are detrimental to the survival of new neurons, thus limiting the neurogenic response. The aim of this study was to determine the effect of the anti-inflammatory drug minocycline on neurogenesis and functional recovery after a closed head injury model of focal traumatic brain injury (TBI). Beginning 30 min after trauma, minocycline was administered for up to 2 weeks and bromodeoxyuridine was given on days 1-4 to label proliferating cells. Neurological outcome and motor function were evaluated over 6 weeks using the Neurological Severity Score (NSS) and ledged beam task. Microglial activation was assessed in the pericontusional cortex and hippocampus at 1 week post-trauma, using immunohistochemistry to detect F4/80. Following immunolabeling of bromodeoxyuridine, double-cortin, and NeuN, cells undergoing distinct stages of neurogenesis, including proliferation, neuronal differentiation, neuroblast migration, and long-term survival, were quantified at 1 and 6 weeks in the hippocampal dentate gyrus, as well as in the subventricular zone of the lateral ventricles and the pericontusional cortex. Our results show that minocycline successfully reduced microglial activation and promoted early neurological recovery that was sustained over 6 weeks. We also show for the first time in the closed head injury model, that early stages of neurogenesis were stimulated in the hippocampus and subventricular zone; however, no increase in new mature neurons occurred. Contrary to our hypothesis, despite the attenuation of activated microglia, minocycline did not support neurogenesis in the hippocampus, lateral ventricles, or pericontusional cortex, with none of the neurogenic stages being affected by treatment. These data provide evidence that a general suppression of microglial activation is insufficient to enhance neuronal production, suggesting that further work is required to elucidate the relationship between microglia and neurogenesis after TBI.	[Ng, Si Yun; Semple, Bridgette D.; Morganti-Kossmann, M. Cristina; Bye, Nicole] Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Ng, Si Yun; Semple, Bridgette D.; Morganti-Kossmann, M. Cristina; Bye, Nicole] Monash Univ, Dept Surg, Clayton, Vic 3800, Australia	Bye, N (corresponding author), Alfred Hosp, Natl Trauma Res Inst, 4th Floor,Burnet Tower,89 Commercial Rd, Melbourne, Vic 3004, Australia.	nicole.bye@monash.edu		Morganti-Kossmann, Cristina/0000-0002-0807-2063	Victorian Neurotrauma Initiative (VNI); Transport Accident Commission (TAC); Alfred Research Trust; Australian GovernmentAustralian GovernmentCGIAR	This research was supported by the Victorian Neurotrauma Initiative (VNI), Transport Accident Commission (TAC), and Alfred Research Trust, through research grants and fellowships to C. M. K. and N.B., and by the Australian Government through an Australian Postgraduate Award to B. D. S. The authors would like to thank Dr. Iska Carmichael of Monash Micro Imaging (AMREP), for training and assistance with confocal microscopy.	Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Arvin KL, 2002, ANN NEUROL, V52, P54, DOI 10.1002/ana.10242; Butovsky O, 2006, MOL CELL NEUROSCI, V31, P149, DOI 10.1016/j.mcn.2005.10.006; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Bye N, 2011, J NEUROSCI RES, V89, P986, DOI 10.1002/jnr.22635; Carty ML, 2008, INT J DEV NEUROSCI, V26, P477, DOI 10.1016/j.ijdevneu.2008.02.005; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Craig CG, 1996, J NEUROSCI, V16, P2649; Das S, 2008, J NEUROSCI RES, V86, P1199, DOI 10.1002/jnr.21585; Das S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017225; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Doetsch F, 1996, P NATL ACAD SCI USA, V93, P14895, DOI 10.1073/pnas.93.25.14895; Ekdahl CT, 2009, NEUROSCIENCE, V158, P1021, DOI 10.1016/j.neuroscience.2008.06.052; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fox C, 2005, J CEREBR BLOOD F MET, V25, P1138, DOI 10.1038/sj.jcbfm.9600121; Gu WG, 2000, J CEREBR BLOOD F MET, V20, P1166, DOI 10.1097/00004647-200008000-00002; Hastings NB, 1999, J COMP NEUROL, V413, P146, DOI 10.1002/(SICI)1096-9861(19991011)413:1<146::AID-CNE10>3.0.CO;2-B; He Y, 2001, BRAIN RES, V909, P187, DOI 10.1016/S0006-8993(01)02681-6; Hoehn BD, 2005, STROKE, V36, P2718, DOI 10.1161/01.STR.0000190020.30282.cc; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Iosif RE, 2006, J NEUROSCI, V26, P9703, DOI 10.1523/JNEUROSCI.2723-06.2006; Jiang W, 2001, STROKE, V32, P1201, DOI 10.1161/01.STR.32.5.1201; Kluska MM, 2005, NEUROSCIENCE, V135, P723, DOI 10.1016/j.neuroscience.2005.06.082; Kolb B, 2007, J CEREBR BLOOD F MET, V27, P983, DOI 10.1038/sj.jcbfm.9600402; Koo JW, 2008, P NATL ACAD SCI USA, V105, P751, DOI 10.1073/pnas.0708092105; Krady JK, 2005, DIABETES, V54, P1559, DOI 10.2337/diabetes.54.5.1559; Liu Y, 2010, NEUROSCIENCE, V166, P241, DOI 10.1016/j.neuroscience.2009.12.026; Liu YP, 2005, BRAIN RES, V1054, P152, DOI 10.1016/j.brainres.2005.06.085; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Magavi SS, 2000, NATURE, V405, P951; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Monje ML, 2002, NAT MED, V8, P955, DOI 10.1038/nm749; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morimoto N, 2005, BRAIN RES, V1044, P8, DOI 10.1016/j.brainres.2005.02.062; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Pencea V, 2001, J NEUROSCI, V21, P6706; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Rock RB, 2004, CLIN MICROBIOL REV, V17, P942, DOI 10.1128/CMR.17.4.942-964.2004; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Salman H, 2004, J NEUROTRAUM, V21, P283, DOI 10.1089/089771504322972077; Schmidt OI., 2004, EUR J TRAUMA, V30, P135, DOI [10.1007/s00068-004-1394-9, DOI 10.1007/S00068-004-1394-9]; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Vallieres L, 2002, J NEUROSCI, V22, P486, DOI 10.1523/JNEUROSCI.22-02-00486.2002; Wang CX, 2003, BRAIN RES, V963, P327, DOI 10.1016/S0006-8993(02)04045-3; Wasserman JK, 2007, BRAIN RES, V1136, P208, DOI 10.1016/j.brainres.2006.12.035; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Wu JM, 2009, NEUROL RES, V31, P183, DOI 10.1179/174313209X385680; Xu L, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-7; Yan YP, 2007, J CEREBR BLOOD F MET, V27, P1213, DOI 10.1038/sj.jcbfm.9600432; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Ziebell JM, 2011, BRAIN RES, V1414, P94, DOI 10.1016/j.brainres.2011.07.056	66	40	41	0	14	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2012	29	7					1410	1425		10.1089/neu.2011.2188			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	933TC	WOS:000303384600015	22260446				2021-06-18	
J	Perez, K; Novoa, AM; Santamarina-Rubio, E; Narvaez, Y; Arrufat, V; Borrell, C; Cabeza, E; Cirera, E; Ferrando, J; Garcia-Altes, A; Gonzalez-Luque, JC; Lizarbe, V; Martin-Cantera, C; Segui-Gomez, M; Suelves, JM				Perez, Katherine; Novoa, Ana M.; Santamarina-Rubio, Elena; Narvaez, Yislenz; Arrufat, Vita; Borrell, Carme; Cabeza, Elena; Cirera, Eva; Ferrando, Josep; Garcia-Altes, Anna; Carlos Gonzalez-Luque, Juan; Lizarbe, Vicenta; Martin-Cantera, Carlos; Segui-Gomez, Maria; Suelves, Josep M.		Spanish Soc Epidemiology	Incidence trends of traumatic spinal cord injury and traumatic brain injury in Spain, 2000-2009	ACCIDENT ANALYSIS AND PREVENTION			English	Article						Spinal cord injury; Traumatic brain injury; Trauma; Epidemiology; Traffic accidents	ROAD TRAFFIC INJURIES; HEAD-INJURY; EPIDEMIOLOGY; PEOPLE; NUMBER; REDUCE	Aims: The The aim of the present study was to estimate the incidence of hospital discharges for traumatic spinal cord injury (TSCI) and traumatic brain injury (TBI) in Spain by injury circumstances (traffic crashes and others), injury severity, gender and age group and to describe its trends over the period 2000-2009. Methods: It is a study of trends that includes hospital discharges with a primary diagnosis of TSCI or TBI. Crude and age-standardised rates were calculated per million inhabitants. Changes in rates between 2000 and 2009 were assessed through calculation of the relative risk adjusted for age, using Poisson regression. Results: Between 2000 and 2009 in Spain, 10,274 patients were admitted for traumatic TSCI, and 206,503 for TBI. The annual incidence rate for TSCI was 23.5 per million, that for TBI was 472.6 per million. The overall incidence rate for TSCI fell significantly between 2000 and 2009 by 24.2% (traffic-related 40.9%, other 12.9%), as did that for TBI (23.8% overall, 60.2% traffic-related, with no change for other circumstances). Among people aged 65 years and over, no change was observed for TSCI, incidence of TBI fell significantly when due to traffic crashes, but there was a dramatic increase of 87% in men and 89.3% in women when due to other circumstances. Conclusions: Over the last decade the incidence of these types of injury has fallen significantly when the injury resulted from traffic crashes, and to a lesser extent when from other circumstances. However TBI incidence among people aged 65 and over injured in non-traffic-related circumstances has risen dramatically. (C) 2011 Elsevier Ltd. All rights reserved.	[Perez, Katherine; Novoa, Ana M.; Santamarina-Rubio, Elena; Narvaez, Yislenz; Borrell, Carme] Agencia Salut Pub Barcelona, Barcelona 08023, Spain; [Perez, Katherine; Novoa, Ana M.; Santamarina-Rubio, Elena; Borrell, Carme; Garcia-Altes, Anna] Inst Salud Carlos III, CIBER Epidemiol & Salud Publ CIBERESP, Madrid 28029, Spain; [Perez, Katherine; Novoa, Ana M.; Santamarina-Rubio, Elena; Borrell, Carme; Ferrando, Josep; Garcia-Altes, Anna] Inst Biomed Res IIB St Pau, Barcelona 08025, Spain; [Arrufat, Vita] Conselleria Sanitat Generalitat Valenciana, Negociat Programes Promocio Salut, Ctr Salut Publ Area 02, Castellon de La Plana 12003, Spain; [Cabeza, Elena] Conselleria Salut & Consum Illes Balears, Palma de Mallorca, Spain; [Cirera, Eva] Univ Vic, Fac Ciencies Salut & Benestar, Vic 08500, Spain; [Ferrando, Josep] IES Alexandre Satorras, Barcelona 08304, Spain; [Carlos Gonzalez-Luque, Juan] Direcc Gen Traf, Minist Interior, Observ Nacl Seguridad Vial, Madrid 28071, Spain; [Lizarbe, Vicenta] Minist Sanidad Polit Social & Igualdad, Madrid 28014, Spain; [Martin-Cantera, Carlos] IDIAP Jordi Gol, Unitat Suport Recerca Barcelona, Barcelona 08006, Spain; [Segui-Gomez, Maria] Univ Navarra, European Ctr Injury Prevent, Navarra 31080, Spain; [Suelves, Josep M.] Dept Salut Generalitat Catalunya, Barcelona 08005, Spain	Perez, K (corresponding author), Agencia Salut Pub Barcelona, Pl Lesseps 1, Barcelona 08023, Spain.	cperez@aspb.cat	Cirera, Eva/F-1407-2015; Martin Cantera, Carlos/D-2693-2011; Suelves, Josep M/F-9080-2011	Cirera, Eva/0000-0002-0381-358X; Martin Cantera, Carlos/0000-0003-0656-8126; Suelves, Josep M/0000-0002-7716-6944; Narvaez-Martinez, Alejandra/0000-0002-0287-7653; Perez, Katherine/0000-0001-5892-2807; Borrell, Carme/0000-0002-1170-2505; GONZALEZ-LUQUE, JUAN CARLOS/0000-0002-4044-8403; Gonzalez-Luque, Juan Carlos/0000-0001-8081-0377			BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Barker-Collo SL, 2009, NEUROEPIDEMIOLOGY, V32, P32, DOI 10.1159/000170090; Benavides F.G., 2011, SEGURIDAD SALUD TRAB, V62, P22; Castillo-Manzano JI, 2011, J SAFETY RES, V42, P223, DOI 10.1016/j.jsr.2011.03.004; Castillo-Manzano JI, 2010, ACCIDENT ANAL PREV, V42, P1310, DOI 10.1016/j.aap.2010.02.009; Chiu WT, 2010, ASIA-PAC J PUBLIC HE, V22, P9, DOI 10.1177/1010539509355470; Clark D., 2011, ICDPIC STATA MODULE; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Direccion General de Trafico, 2006, MEM ACT SEG VIAL 200; Direccion General de Trafico, 2007, MEM ACT SEG VIAL 200; Direccion General de Trafico, 2009, BAL 2 AN PERM PUNT; Direccion General de Trafico, 2010, PRINC CIFR SEG VIAL; Dryden DM, 2003, CAN J NEUROL SCI, V30, P113, DOI 10.1017/S0317167100053373; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Frick KD, 2010, J AM GERIATR SOC, V58, P136, DOI 10.1111/j.1532-5415.2009.02575.x; Gillespie LD., 2003, Cochrane Database Syst Rev, V4, DOI DOI 10.1002/14651858.CD007146.PUB2; Hu GQ, 2010, INJURY PREV, V16, P26, DOI 10.1136/ip.2009.023481; Jamieson LM, 2007, INJURY PREV, V13, P243, DOI 10.1136/ip.2007.015354; Kannus P, 2007, J GERONTOL A-BIOL, V62, P180, DOI 10.1093/gerona/62.2.180; Lieutaud T, 2010, J NEUROTRAUM, V27, P1101, DOI 10.1089/neu.2009.1197; Martins F, 1998, SPINAL CORD, V36, P574, DOI 10.1038/sj.sc.3100657; Nobunaga AI, 1999, ARCH PHYS MED REHAB, V80, P1372, DOI 10.1016/S0003-9993(99)90247-2; Novoa AM, 2011, B WORLD HEALTH ORGAN, V89, P422, DOI 10.2471/BLT.10.082180; Novoa AM, 2011, J EPIDEMIOL COMMUN H, V65, P218, DOI 10.1136/jech.2009.094029; Novoa AM, 2010, AM J PUBLIC HEALTH, V100, P2220, DOI 10.2105/AJPH.2010.192104; O'Connor PJ, 2006, ACCIDENT ANAL PREV, V38, P71, DOI 10.1016/j.aap.2005.03.025; Peden M., 2002, INJURY LEADING CAUSE; Perez K., 2006, AM J PUBLIC HLTH; Rodriguez J.I., 2009, TRAFICO SEGURIDAD VI, V197, P42; Stephenson S, 2005, ACCIDENT ANAL PREV, V37, P825, DOI 10.1016/j.aap.2005.03.024; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; [United Nations WHO], 2011, WHO DEC ACT ROAD SAF; van den Berg MEL, 2010, NEUROEPIDEMIOLOGY, V34, P184, DOI 10.1159/000279335; Van Den Berg M, 2011, J NEUROTRAUM, V28, P469, DOI 10.1089/neu.2010.1608; VAZQUEZBARQUERO A, 1992, EUR J EPIDEMIOL, V8, P832, DOI 10.1007/BF00145328	36	40	43	0	18	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575	1879-2057		ACCIDENT ANAL PREV	Accid. Anal. Prev.	MAY	2012	46						37	44		10.1016/j.aap.2011.12.004			8	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	926MI	WOS:000302834700005	22310041				2021-06-18	
J	Kabadi, SV; Stoica, BA; Loane, DJ; Byrnes, KR; Hanscom, M; Cabatbat, RM; Tan, MT; Faden, AI				Kabadi, Shruti V.; Stoica, Bogdan A.; Loane, David J.; Byrnes, Kimberly R.; Hanscom, Marie; Cabatbat, Rainier M.; Tan, Ming T.; Faden, Alan I.			Cyclin D1 Gene Ablation Confers Neuroprotection in Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cell cycle; controlled cortical impact; cyclin D1; neuroinflammation; neuroprotection	CONTROLLED CORTICAL IMPACT; NEURONAL CELL-DEATH; SPINAL-CORD-INJURY; ALZHEIMERS-DISEASE; CEREBRAL-ISCHEMIA; IN-VITRO; OBJECT RECOGNITION; DEPENDENT KINASES; SPATIAL MEMORY; CNS INJURY	Cell cycle activation (CCA) is one of the principal secondary injury mechanisms following brain trauma, and it leads to neuronal cell death, microglial activation, and neurological dysfunction. Cyclin D1 (CD1) is a key modulator of CCA and is upregulated in neurons and microglia following traumatic brain injury (TBI). In this study we subjected CD1-wild-type (CD1(+/+)) and knockout (CD1(-/-)) mice to controlled cortical impact (CCI) injury to evaluate the role of CD1 in post-traumatic neurodegeneration and neuroinflammation. As early as 24 h post-injury, CD1(+/+) mice showed markers of CCA in the injured hemisphere, including increased CD1, E2F1, and proliferating cell nuclear antigen (PCNA), as well as increased Fluoro-Jade B staining, indicating neuronal degeneration. Progressive neuronal loss in the hippocampus was observed through 21 days post-injury in these mice, which correlated with a decline in cognitive function. Microglial activation in the injured hemisphere peaked at 7 days post-injury, with sustained increases at 21 days. In contrast, CD1(-/-) mice showed reduced CCA and neurodegeneration at 24 h, as well as improved cognitive function, attenuated hippocampal neuronal cell loss, decreased lesion volume, and cortical microglial activation at 21 days post-injury. These findings indicate that CD1-dependent CCA plays a significant role in the neuroinflammation, progressive neurodegeneration, and related neurological dysfunction resulting from TBI. Our results further substantiate the proposed role of CCA in post-traumatic secondary injury, and suggest that inhibition of CD1 may be a key therapeutic target for TBI.	[Kabadi, Shruti V.; Stoica, Bogdan A.; Loane, David J.; Hanscom, Marie; Cabatbat, Rainier M.; Faden, Alan I.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA; [Kabadi, Shruti V.; Stoica, Bogdan A.; Loane, David J.; Hanscom, Marie; Cabatbat, Rainier M.; Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Kabadi, Shruti V.; Stoica, Bogdan A.; Loane, David J.; Byrnes, Kimberly R.; Cabatbat, Rainier M.; Faden, Alan I.] Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA; [Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD USA; [Tan, Ming T.] Univ Maryland, Greenebaum Canc Ctr, Div Biostat, Baltimore, MD 21201 USA	Faden, AI (corresponding author), Organized Res Ctr, 419 W Redwood St,Suite 225, Baltimore, MD 21201 USA.	afaden@anes.umm.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Loane, David/0000-0003-0393-3503; Byrnes, Kimberly/0000-0002-7501-7734; Hanscom, Marie/0000-0001-8308-135X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS052568]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052568] Funding Source: NIH RePORTER	We thank Kelly Wilson, Nicole Hockenbury, Michael Dinizo, David Knipp, and Michael Murray for expert technical assistance. This work was supported by a grant from the National Institutes of Health (R01 NS052568).	Akirav I, 2006, CEREB CORTEX, V16, P1759, DOI 10.1093/cercor/bhj114; Arendt T, 2003, PROG NEUROBIOL, V71, P83, DOI 10.1016/j.pneurobio.2003.09.007; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Broadbent NJ, 2010, LEARN MEMORY, V17, P794, DOI 10.1101/lm.1650110; Byrnes KR, 2007, BRAIN, V130, P2977, DOI 10.1093/brain/awm179; Byrnes KR, 2007, NEUROCHEM RES, V32, P1799, DOI 10.1007/s11064-007-9312-2; Cernak I, 2005, CELL CYCLE, V4, P1286, DOI 10.4161/cc.4.9.1996; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; DAVIS EJ, 1994, BRAIN RES BULL, V34, P73, DOI 10.1016/0361-9230(94)90189-9; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Eikelenboom P, 2002, GLIA, V40, P232, DOI 10.1002/glia.10146; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; Gilbert PE, 2009, PROG NEURO-PSYCHOPH, V33, P774, DOI 10.1016/j.pnpbp.2009.03.037; Greene LA, 2004, CELL DEATH DIFFER, V11, P49, DOI 10.1038/sj.cdd.4401341; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Herrup K, 2007, NAT REV NEUROSCI, V8, P368, DOI 10.1038/nrn2124; Hilton GD, 2008, J CEREBR BLOOD F MET, V28, P1845, DOI 10.1038/jcbfm.2008.75; IIZUKA H, 1990, STROKE, V21, P790, DOI 10.1161/01.STR.21.5.790; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019; Lee I, 2005, BEHAV NEUROSCI, V119, P145, DOI 10.1037/0735-7044.119.1.145; Lee I, 2004, HIPPOCAMPUS, V14, P66, DOI 10.1002/hipo.10167; Li Y, 1997, J CEREBR BLOOD F MET, V17, P846, DOI 10.1097/00004647-199708000-00003; Liu DX, 2004, J NEUROSCI, V24, P8720, DOI 10.1523/JNEUROSCI.1821-04.2004; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nandoe RDS, 2002, J ALZHEIMERS DIS, V4, P303, DOI 10.3233/JAD-2002-4405; Nguyen MD, 2003, J NEUROSCI, V23, P2131; Piao Chun-Shu, 2012, NEUROBIOLOGY DIS; Raina AK, 2000, J NEUROSCI RES, V61, P128, DOI 10.1002/1097-4547(20000715)61:2<128::AID-JNR2>3.0.CO;2-H; Rashidian J, 2005, P NATL ACAD SCI USA, V102, P14080, DOI 10.1073/pnas.0500099102; Redish AD, 1998, NEURAL COMPUT, V10, P73, DOI 10.1162/089976698300017908; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Small DL, 2001, BRAIN RES, V900, P26, DOI 10.1016/S0006-8993(01)02102-3; Soltys Z, 2001, J NEUROSCI RES, V63, P90, DOI 10.1002/1097-4547(20010101)63:1<90::AID-JNR11>3.0.CO;2-9; Stoica BA, 2009, NEUROTOX RES, V16, P221, DOI 10.1007/s12640-009-9050-0; Swanton C, 2004, LANCET ONCOL, V5, P27, DOI 10.1016/S1470-2045(03)01321-4; Verdaguer E, 2004, J PHARMACOL EXP THER, V308, P609, DOI 10.1124/jpet.103.057497; Yang Y, 2003, J NEUROSCI, V23, P2557; Zhan XH, 2008, BRAIN RES, V1234, P183, DOI 10.1016/j.brainres.2008.07.094; Zhu Z, 2007, GLIA, V55, P546, DOI 10.1002/glia.20476	53	40	40	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	5					813	+		10.1089/neu.2011.1980			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	907TZ	WOS:000301442900010	21895533	Green Published			2021-06-18	
J	Testa, R; Bennett, P; Ponsford, J				Testa, Renee; Bennett, Pauleen; Ponsford, Jennie			Factor Analysis of Nineteen Executive Function Tests in a Healthy Adult Population	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Executive function; Executive dysfunction; Frontal lobe; Neuropsychological tests; Cognition	FRONTAL-LOBE DYSFUNCTION; TRAUMATIC BRAIN-INJURY; DUAL-TASK PERFORMANCE; PREFRONTAL CORTEX; NEUROPSYCHOLOGICAL FINDINGS; DYSEXECUTIVE SYMPTOMS; STRATEGY APPLICATION; ANTERIOR CINGULATE; DECISION-MAKING; WORKING-MEMORY	Although there has been some progress in identifying the range of skills that comprise the executive neurocognitive system, their assessment has proved to be a challenge. Operationalization of executive functions (EFs) may be progressed by identifying the cognitive constructs that underlie EF test performance via principal components analysis. The underlying factor structure of 19 EF tests was examined in a non-clinical sample of 200 adults (mean age 30.8 [1864] years); the sample comprised 97 men. Findings revealed only weak correlations between various measures derived from the EF tests. Exploratory factor analysis revealed a model comprising six independent factors, consistent with previous reports, describing the functions of the EF system. The factors comprised: Prospective Working Memory, Set-Shifting and Interference Management, Task Analysis, Response Inhibition, Strategy Generation and Regulation, and Self-Monitoring and Set-Maintenance. Results confirm the diverse and heterogeneous nature of EFs and caution against conceptualizations that underestimate its complexity. Furthermore, variability within the normal executive system is evident, and further research is required to understand executive functioning in healthy populations.	[Testa, Renee] Univ Melbourne, Melbourne Neuropsychiat Ctr, Melbourne, Vic 3053, Australia; [Testa, Renee; Bennett, Pauleen; Ponsford, Jennie] Monash Univ, Dept Psychiat & Psychol, Melbourne, Vic 3004, Australia	Testa, R (corresponding author), Univ Melbourne, Melbourne Neuropsychiat Ctr, Alan Gilbert Bldg,161 Barry St, Melbourne, Vic 3053, Australia.	rtesta@unimelb.edu.au	Bennett, Pauleen/C-2138-2016	Bennett, Pauleen/0000-0001-5864-4464			Amieva H, 2003, BRAIN COGNITION, V53, P129, DOI 10.1016/S0278-2626(03)00094-0; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P319, DOI 10.1080/713755568; Anderson V., 2000, CLIN NEUROPSYCHOL, V1, P247; Ardila A, 2008, BRAIN COGNITION, V68, P92, DOI 10.1016/j.bandc.2008.03.003; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Australian Bureau of Statistics, 2001, 2001 NAT CONS POP HO; Baddeley A, 1997, NEUROPSYCHOLOGY, V11, P187, DOI 10.1037/0894-4105.11.2.187; Baddeley A, 1996, PHILOS T ROY SOC B, V351, P1397, DOI 10.1098/rstb.1996.0123; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Benke T, 2003, NEUROCASE, V9, P70, DOI 10.1076/neur.9.1.70.14374; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P606, DOI 10.1017/S1355617705050721; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; Blakemore SJ, 2006, J CHILD PSYCHOL PSYC, V47, P296, DOI 10.1111/j.1469-7610.2006.01611.x; Brugger P, 1997, PERCEPT MOTOR SKILL, V84, P627, DOI 10.2466/pms.1997.84.2.627; Burgess P. W., 1997, METHODOLOGY FRONTAL, P81, DOI DOI 10.1024//1016-264X.10.2.123; Burgess PW, 1996, CORTEX, V32, P241, DOI 10.1016/S0010-9452(96)80049-9; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; Burgess PW, 2000, PSYCHOL RES-PSYCH FO, V63, P279, DOI 10.1007/s004269900006; Carter CS, 1999, REV NEUROSCIENCE, V10, P49; CHALMERS D, 1993, INT J BEHAV DEV, V16, P191, DOI 10.1177/016502549301600206; Chan RCK, 2001, BRIT J PSYCHOL, V92, P551, DOI 10.1348/000712601162338; Charlton RA, 2006, NEUROLOGY, V66, P217, DOI 10.1212/01.wnl.0000194256.15247.83; Chayer C, 2001, Curr Neurol Neurosci Rep, V1, P547, DOI 10.1007/s11910-001-0060-4; Cicerone KD, 1997, ARCH CLIN NEUROPSYCH, V12, P173, DOI 10.1016/S0887-6177(96)00022-4; Cohen JD, 2000, NAT NEUROSCI, V3, P421, DOI 10.1038/74783; de Oliveira-Souza R, 2001, NEUROCASE, V7, P383, DOI 10.1076/neur.7.5.383.16244; De Vaus D., 2002, ANAL SOCIAL SCI DATA; Denckla M.B., 1994, FRAMES REFERENCE ASS, P117; Denckla M.B., 1996, ATTENTION MEMORY EXE, P263; Duncan J, 1997, COGNITIVE NEUROPSYCH, V14, P713, DOI 10.1080/026432997381420; Duncan J, 2000, TRENDS NEUROSCI, V23, P475, DOI 10.1016/S0166-2236(00)01633-7; Eslinger P. J., 1996, ATTENTION MEMORY EXE, P367; Eslinger PJ, 2004, BRAIN COGNITION, V55, P84, DOI 10.1016/s0278-2626(03)00281-1; Fabrigar LR, 1999, PSYCHOL METHODS, V4, P272, DOI 10.1037/1082-989X.4.3.272; Fassbender C, 2004, COGNITIVE BRAIN RES, V20, P132, DOI 10.1016/j.cogbrainres.2004.02.007; Floyd FJ, 1995, PSYCHOL ASSESSMENT, V7, P286, DOI 10.1037/1040-3590.7.3.286; FUSTER JM, 1991, PROG BRAIN RES, V87, P201; Godbout L, 2005, BRAIN INJURY, V19, P337, DOI 10.1080/02699050400005093; Golden C., 1978, STROOP COLOUR WORD T; GOLDMANRAKIC PS, 1987, CHILD DEV, V58, P601, DOI 10.1111/j.1467-8624.1987.tb01404.x; Gorsuch R. L., 1983, FACTOR ANAL; Gothelf D, 2005, MENT RETARD DEV D R, V11, P331, DOI 10.1002/mrdd.20089; Grafman J, 1995, ANN NY ACAD SCI, V769, P337, DOI 10.1111/j.1749-6632.1995.tb38149.x; Halstead W., 1947, BRAIN INTELLIGENCE C; Handler J., 1994, HANDB NEUR, P125; Heaton R. K, 1981, WISCONSIN CARD SORTI; Himanen L, 2005, BRAIN INJURY, V19, P93, DOI 10.1080/02699050410001720031; Holmes AJ, 2005, SCHIZOPHR RES, V76, P199, DOI 10.1016/j.schres.2005.01.021; Hornak J, 2004, J COGNITIVE NEUROSCI, V16, P463, DOI 10.1162/089892904322926791; Jacobs R, 2002, CHILD NEUROPSYCHOL, V8, P93, DOI 10.1076/chin.8.2.93.8726; JASON GW, 1985, NEUROPSYCHOLOGIA, V23, P463, DOI 10.1016/0028-3932(85)90002-8; Kline P., 1998, NEW PSYCHOMETRICS SC; Kline P., 1994, EASY GUIDE FACTOR AN; LEVINE B, 1995, J CLIN EXP NEUROPSYC, V17, P740, DOI 10.1080/01688639508405164; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; LEZAK MD, 1993, J HEAD TRAUMA REHAB, V8, P24, DOI DOI 10.1097/00001199-199303000-00004; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Manes F, 2002, BRAIN, V125, P624, DOI 10.1093/brain/awf049; McDonald CR, 2005, J INT NEUROPSYCH SOC, V11, P477, DOI 10.1017/S1355617705050484; Miller L., 1990, COGN REHABIL, V8, P14; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Miyake A, 2001, J EXP PSYCHOL GEN, V130, P621, DOI 10.1037/0096-3445.130.4.621; Mosher F.A., 1966, STUDIES COGNITIVE GR, P86; NAUTA WJH, 1971, J PSYCHIAT RES, V8, P167, DOI 10.1016/0022-3956(71)90017-3; Nelson HE, 1982, NATL ADULT READING T; Norman D.A., 1986, CONSCIOUSNESS SELF R, V4, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; Nunnally J. C., 1994, PSYCHOMETRIC THEORY; Pantelis C, 2003, AUST NZ J PSYCHIAT, V37, P399, DOI 10.1046/j.1440-1614.2003.01193.x; PASSINGHAM RE, 1985, PHILOS T ROY SOC B, V308, P101, DOI 10.1098/rstb.1985.0013; Phillips LH, 1997, Methodology of frontal " and executive function, P191; Pineda DA, 2003, INT J NEUROSCI, V113, P397, DOI 10.1080/00207450390162164; Porteus S.D., 1965, PORTEUS MAZE TEST 50; Reitan R. M., 1992, TRAIL MAKING TEST MA; Robbins TW, 1998, J INT NEUROPSYCH SOC, V4, P474, DOI 10.1017/s1355617798455073; Roth RM, 2004, PSYCHIAT CLIN N AM, V27, P83, DOI 10.1016/S0193-953X(03)00112-6; Ruff R. M., 1988, RUFF FIGURAL FLUENCY; Schnirman GM, 1998, ASSESSMENT, V5, P355, DOI 10.1177/107319119800500404; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1978, CORTEX, V14, P294, DOI 10.1016/S0010-9452(78)80055-0; SHALLICE T, 1991, PSYCHOL MED, V21, P661, DOI 10.1017/S0033291700022303; SHUTE GE, 1990, DEV NEUROPSYCHOL, V6, P1, DOI 10.1080/87565649009540445; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; Storey E, 1999, ARCH NEUROL-CHICAGO, V56, P43, DOI 10.1001/archneur.56.1.43; Stuss D. T., 2007, HUMAN FRONTAL LOBES, P292; Stuss D.T., 1986, FRONTAL LOBES; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Szameitat AJ, 2002, J COGNITIVE NEUROSCI, V14, P1184, DOI 10.1162/089892902760807195; Tabachnick BG, 2013, USING MULTIVARIATE S; Tamm L, 2002, J AM ACAD CHILD PSY, V41, P1231, DOI 10.1097/00004583-200210000-00013; Taylor SF, 2004, NEUROIMAGE, V21, P1045, DOI 10.1016/j.neuroimage.2003.10.032; Tekin S, 2002, J PSYCHOSOM RES, V53, P647, DOI 10.1016/S0022-3999(02)00428-2; TESTA R, 2009, NEUROPSYCHOLOGICAL M; van der Werf SP, 2000, NEUROPSY NEUROPSY BE, V13, P199; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilson BA, 1998, NEUROPSYCHOL REHABIL, V8, P213, DOI 10.1080/713755570; Zimmerman ME, 2006, AM J GERIAT PSYCHIAT, V14, P823, DOI 10.1097/01.JGP.0000238502.40963.ac	99	40	41	1	38	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAR	2012	27	2					213	224		10.1093/arclin/acr112			12	Psychology, Clinical; Psychology	Psychology	895HL	WOS:000300486900011	22314610	Green Published, Bronze			2021-06-18	
J	Berdichevsky, Y; Dzhala, V; Mail, M; Staley, KJ				Berdichevsky, Yevgeny; Dzhala, Volodymyr; Mail, Michelle; Staley, Kevin J.			Interictal spikes, seizures and ictal cell death are not necessary for post-traumatic epileptogenesis in vitro	NEUROBIOLOGY OF DISEASE			English	Article						Epilepsy; Epileptogenesis; Traumatic brain injury; Phenytoin; Neuronal death; Activity; Interictal; Ictal	TEMPORAL-LOBE EPILEPSY; ORGANOTYPIC SLICE CULTURES; INDUCED STATUS EPILEPTICUS; HEAD-INJURY; ANTIEPILEPTIC DRUGS; DENTATE GYRUS; CYTO-TOXICITY; GRANULE CELLS; AXONAL INJURY; BRAIN-INJURY	Clinical studies indicate that phenytoin prevents acute post-traumatic seizures but not subsequent post-traumatic epilepsy. We explored this phenomenon using organotypic hippocampal slice cultures as a model of severe traumatic brain injury. Hippocampal slices were cultured for up to eight weeks, during which acute and chronic electrical recordings revealed a characteristic evolution of spontaneous epileptiform discharges, including interictal spikes, seizure activity and electrical status epilepticus. Cell death exhibited an early peak immediately following slicing, and a later secondary peak that coincided with the peak of seizure-like activity. The secondary peak in neuronal death was abolished by either blockade of glutamatergic transmission with kynurenic acid or by elimination of ictal activity and status epilepticus with phenytoin. Withdrawal of kynurenic acid or phenytoin was followed by a sharp increase in spontaneous seizure activity. Phenytoin's anticonvulsant and neuroprotective effects failed after four weeks of continuous administration. These data support the clinical findings that after brain injury, anticonvulsants prevent seizures but not epilepsy or the development of anticonvulsant resistance. We extend the clinical data by showing that secondary neuronal death is correlated with ictal but not interictal activity, and that blocking all three of these sequelae of brain injury does not prevent epileptogenesis in this in vitro model. (C) 2011 Elsevier Inc. All rights reserved.	[Berdichevsky, Yevgeny; Dzhala, Volodymyr; Mail, Michelle; Staley, Kevin J.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA	Staley, KJ (corresponding author), MGH Neurol, CNY 114,Room 2600,114 16th St, Charlestown, MA 02129 USA.	kstaley@partners.org		Berdichevsky, Yevgeny/0000-0001-7539-601X	National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Epilepsy Foundation (EFA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS077908, R21NS072258] Funding Source: NIH RePORTER	This work was supported by National Institute of Neurological Disorders and Stroke (NINDS) and Epilepsy Foundation (EFA).	Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; [Anonymous], 1974, Electroencephalogr Clin Neurophysiol, V37, P538; Ben-Ari Y, 2010, EPILEPSY CURR, V10, P118, DOI 10.1111/j.1535-7511.2010.01376.x; Berdichevsky Y, 2009, J NEUROSCI METH, V178, P59, DOI 10.1016/j.jneumeth.2008.11.016; Berg AT, 2008, CURR OPIN NEUROL, V21, P173, DOI 10.1097/WCO.0b013e3282f36ccd; Bernhardt BC, 2009, NEUROLOGY, V72, P1747, DOI 10.1212/01.wnl.0000345969.57574.f5; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Buckmaster PS, 2004, EPILEPSIA, V45, P452, DOI 10.1111/j.0013-9580.2004.67103.x; Chatrian GE, 1974, ELECTROENCEPHALOGR C, V37, P521; Chen JWY, 2009, J REHABIL RES DEV, V46, P685, DOI 10.1682/JRRD.2008.09.0130; Cossart R, 2001, NAT NEUROSCI, V4, P52; CRONIN J, 1988, BRAIN RES, V474, P181, DOI 10.1016/0006-8993(88)90681-6; DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; DUNCAN JS, 1987, EPILEPSIA, V28, P259, DOI 10.1111/j.1528-1157.1987.tb04216.x; Dyhrfjeld-Johnsen J, 2010, J CLIN NEUROPHYSIOL, V27, P418, DOI 10.1097/WNP.0b013e3181fe0709; Esclapez M, 1999, J COMP NEUROL, V408, P449, DOI 10.1002/(SICI)1096-9861(19990614)408:4<449::AID-CNE1>3.0.CO;2-R; Fuerst D, 2003, ANN NEUROL, V53, P413, DOI 10.1002/ana.10509; Gahwiler BH, 1997, TRENDS NEUROSCI, V20, P471, DOI 10.1016/S0166-2236(97)01122-3; Giblin KA, 2010, NEUROSCIENTIST, V16, P253, DOI 10.1177/1073858409354385; Graber KD, 2004, ANN NEUROL, V55, P860, DOI 10.1002/ana.20124; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; GRONDAHL TO, 1993, J NEUROSURG, V78, P938, DOI 10.3171/jns.1993.78.6.0938; Haut SR, 2002, EPILEPSIA, V43, P711, DOI 10.1046/j.1528-1157.2002.26401.x; Henshall DC, 2004, ANN NEUROL, V55, P485, DOI 10.1002/ana.20001; Houweling AR, 2005, CEREB CORTEX, V15, P834, DOI 10.1093/cercor/bhh184; Jefferys JGR, 2003, EPILEPSIA, V44, P44, DOI 10.1111/j.0013-9580.2003.12004.x; JENNETT B, 1973, LANCET, V2, P652; Kadam SD, 2010, J NEUROSCI, V30, P404, DOI 10.1523/JNEUROSCI.4093-09.2010; Kirov SA, 1999, J NEUROSCI, V19, P2876; Kobayashi M, 2003, J NEUROSCI, V23, P2440; KORZENIEWSKI C, 1983, J IMMUNOL METHODS, V64, P313, DOI 10.1016/0022-1759(83)90438-6; LAURBERG S, 1981, J COMP NEUROL, V200, P433, DOI 10.1002/cne.902000310; Loscher W, 2010, PHARMACOL REV, V62, P668, DOI 10.1124/pr.110.003046; Lowenstein DH, 1999, EPILEPSIA, V40, P120, DOI 10.1111/j.1528-1157.1999.tb02000.x; MCBAIN CJ, 1989, J NEUROSCI METH, V27, P35, DOI 10.1016/0165-0270(89)90051-4; Meldrum BS, 2002, PROG BRAIN RES, V135, P3; MELDRUM BS, 1973, EXPERIENTIA, V29, P561, DOI 10.1007/BF01926665; MELDRUM BS, 1973, ARCH NEUROL-CHICAGO, V28, P10, DOI 10.1001/archneur.1973.00490190028002; MILLER LDP, 1994, NEUROSCIENCE, V63, P471, DOI 10.1016/0306-4522(94)90544-4; OKAZAKI MM, 1995, J COMP NEUROL, V352, P515, DOI 10.1002/cne.903520404; Pitkanen A, 2011, NEUROSCI LETT, V497, P163, DOI 10.1016/j.neulet.2011.02.033; Pitkanen A, 2010, EPILEPSIA, V51, P2, DOI 10.1111/j.1528-1167.2010.02602.x; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Rocha Luisa L, 2007, Epilepsy Curr, V7, P77, DOI 10.1111/j.1535-7511.2007.00178.x; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Schierhout G, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000173; SEGAL MM, 1994, J NEUROPHYSIOL, V72, P1874; Shinnar S, 2010, NEUROLOGY, V74, P624, DOI 10.1212/WNL.0b013e3181d0ce5b; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; Smith BN, 2001, J NEUROPHYSIOL, V85, P1, DOI 10.1152/jn.2001.85.1.1; Staley K, 2005, NEUROSCIENTIST, V11, P272, DOI 10.1177/1073858405278239; STEWARD O, 1978, BRAIN RES, V149, P216, DOI 10.1016/0006-8993(78)90601-7; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; Sutula TP, 2007, PROG BRAIN RES, V163, P541, DOI 10.1016/S0079-6123(07)63029-5; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; White AM, 2006, J NEUROSCI METH, V152, P255, DOI 10.1016/j.jneumeth.2005.09.014; White A, 2010, EPILEPSIA, V51, P371, DOI 10.1111/j.1528-1167.2009.02339.x; Williams PA, 2009, J NEUROSCI, V29, P2103, DOI 10.1523/JNEUROSCI.0980-08.2009; WILLMORE LJ, 1978, SCIENCE, V200, P1501, DOI 10.1126/science.96527; Zhang W, 2009, J NEUROSCI, V29, P14247, DOI 10.1523/JNEUROSCI.3842-09.2009	64	40	40	0	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961			NEUROBIOL DIS	Neurobiol. Dis.	FEB	2012	45	2					774	785		10.1016/j.nbd.2011.11.001			12	Neurosciences	Neurosciences & Neurology	881QC	WOS:000299500200012	22115940	Green Accepted			2021-06-18	
J	Golaszewski, SM; Bergmann, J; Christova, M; Kunz, AB; Kronbichler, M; Rafolt, D; Gallasch, E; Staffen, W; Trinka, E; Nardone, R				Golaszewski, Stefan M.; Bergmann, Juergen; Christova, Monica; Kunz, Alexander B.; Kronbichler, Martin; Rafolt, Dietmar; Gallasch, Eugen; Staffen, Wolfgang; Trinka, Eugen; Nardone, Raffaele			Modulation of motor cortex excitability by different levels of whole-hand afferent electrical stimulation	CLINICAL NEUROPHYSIOLOGY			English	Article						Transcranial magnetic stimulation; Mesh-glove; Motor cortex excitability; Somatosensory stimulation; Neuroplasticity	PERIPHERAL-NERVE STIMULATION; CORTICAL PLASTICITY; INHIBITION; ATTENTION; INPUT; TENS	Objective: In a previous transcranial magnetic stimulation (TMS) study we demonstrated that suprathreshold mesh-glove (MG) whole-hand stimulation elicits lasting changes in motor cortical excitability. Currently, there is no consensus with regard to the optimal parameters for the induction of sensorimotor cortical plasticity using peripheral electrical stimulation. Thus, in the present study we explore the modulatory effects of MG stimulation at different stimulus intensities and different frequencies in order to identify an optimal stimulation protocol. Methods: MG stimulation was performed on 12 healthy subjects in separate sessions at different stimulation levels: sub-sensory at 50 Hz, sensory at 50 Hz and motor at 2 Hz. To verify if stimulation at lower frequencies is less effective, an additional experiment at sensory level with 2 Hz was performed. TMS was used to assess motor threshold (MT), motor evoked potentials (MEPs) recruitment curve (RC), short latency intracortical inhibition (SICI) and intracortical facilitation (ICF) to paired-pulse TMS at baseline (T0), immediately after (T1) and 1 h (T2) after 30 min of MG stimulation. F-wave studies were performed to assess spinal motoneuron excitability. Results: MG stimulation at sub-sensory/50 Hz and sensory/2 Hz level determines no significant cortical excitability changes; at sensory/50 Hz level and at motor/2 Hz level we found decreased MT, increased MEP RC as well as reduced SICI and increased ICF at T1 and T2. Conclusions: MG stimulation at sensory/50 Hz and motor/2 Hz level induces similar long-lasting modulatory effects on motor cortical excitability. Both the strength of the corticospinal projections and the intracortical networks are influenced to the same extend. Significance: The study provides further evidence that stimulation intensity and frequency can independently modulate motor cortical plasticity. The selection of optimal stimulation parameters has potentially important implications for the neurorehabilitation of patients after brain damage (e. g. stroke, traumatic brain injury) with hand motor deficits. (C) 2011 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Golaszewski, Stefan M.; Kunz, Alexander B.; Staffen, Wolfgang; Trinka, Eugen; Nardone, Raffaele] Paracelsus Med Univ Salzburg, Dept Neurol, A-5020 Salzburg, Austria; [Golaszewski, Stefan M.; Bergmann, Juergen; Kunz, Alexander B.; Kronbichler, Martin; Staffen, Wolfgang] Paracelsus Med Univ Salzburg, Inst Neurosci, A-5020 Salzburg, Austria; [Golaszewski, Stefan M.] Med Univ Innsbruck, Dept Psychiat, fMRI Lab, Innsbruck, Austria; [Bergmann, Juergen; Kronbichler, Martin] Paris Lodron Univ Salzburg, Dept Psychol, Salzburg, Austria; [Bergmann, Juergen; Kronbichler, Martin] Paris Lodron Univ Salzburg, Ctr Neurocognit Res, Salzburg, Austria; [Christova, Monica; Gallasch, Eugen] Med Univ Graz, Inst Physiol, Graz, Austria; [Rafolt, Dietmar] Med Univ Vienna, Ctr Biomed Engn & Med Phys, Vienna, Austria; [Nardone, Raffaele] F Tappeiner Hosp, Dept Neurol, Meran, Italy	Golaszewski, SM (corresponding author), Paracelsus Med Univ Salzburg, Dept Neurol, Ignaz Harrer Str 79, A-5020 Salzburg, Austria.	S.Golaszewski@salk.at	Kronbichler, Martin/A-5599-2008	Kronbichler, Martin/0000-0003-2240-2812; Kunz, Alexander/0000-0002-8455-8436; Nardone, Raffaele/0000-0001-5243-6760; Trinka, Eugen/0000-0002-5950-2692	Austrian National Bank [13221, 10109]; Paracelsus Medical University Salzburg, Austria [05/02/011]; Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, Houston, Texas, USA	This work was supported by Grants Nos. 13221 and 10109 from the Austrian National Bank and by a Grant No. 05/02/011 from the Paracelsus Medical University Salzburg, Austria. The authors wish to thank Dr. Meta and Prof. Dr. Milan Dimitrijevic from the Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, Houston, Texas, USA, for their support and continuous encouragement while working on this study.	Charlton CS, 2003, J NEUROL SCI, V208, P79, DOI 10.1016/S0022-510X(02)00443-4; Chipchase LS, 2011, CLIN NEUROPHYSIOL, V122, P456, DOI 10.1016/j.clinph.2010.07.025; CHRISTOVA M, 2011, EUR J APPL PHYSL; DENGLER R, 1992, MUSCLE NERVE, V15, P1138, DOI 10.1002/mus.880151013; Fernandez-del-Olmo M, 2008, CLIN NEUROPHYSIOL, V119, P1834, DOI 10.1016/j.clinph.2008.04.002; Fraser C, 2002, NEURON, V34, P831, DOI 10.1016/S0896-6273(02)00705-5; Golaszewski S, 1999, SCAND J REHABIL MED, V31, P165; Golaszewski SM, 2004, NEUROLOGY, V62, P2262, DOI 10.1212/WNL.62.12.2262; Golaszewski SM, 2010, CLIN NEUROPHYSIOL, V121, P248, DOI 10.1016/j.clinph.2009.09.024; Hallett M, 1999, EEG CL N SU, V50, P85; Kaelin-Lang A, 2002, J PHYSIOL-LONDON, V540, P623, DOI 10.1113/jphysiol.2001.012801; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Lin JZ, 2004, MUSCLE NERVE, V30, P289, DOI 10.1002/mus.20110; Mima T, 2004, NEUROSCI LETT, V355, P85, DOI 10.1016/j.neulet.2003.10.045; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Ridding MC, 2005, EXP BRAIN RES, V163, P335, DOI 10.1007/s00221-004-2176-7; Ridding MC, 2000, EXP BRAIN RES, V131, P135, DOI 10.1007/s002219900269; Rosenkranz K, 2004, J PHYSIOL-LONDON, V561, P307, DOI 10.1113/jphysiol.2004.069328; Stefan K, 2004, J NEUROPHYSIOL, V92, P66, DOI 10.1152/jn.00383.2003; Tinazzi M, 2005, EXP BRAIN RES, V161, P457, DOI 10.1007/s00221-004-2091-y; Zittel S, 2007, EXP BRAIN RES, V176, P425, DOI 10.1007/s00221-006-0624-2	21	40	40	0	15	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457			CLIN NEUROPHYSIOL	Clin. Neurophysiol.	JAN	2012	123	1					193	199		10.1016/j.clinph.2011.06.010			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	865QG	WOS:000298324800025	21764634				2021-06-18	
J	Menon, K; Ward, RE; Gaboury, I; Thomas, M; Joffe, A; Burns, K; Cook, D				Menon, Kusum; Ward, Roxanne E.; Gaboury, Isabelle; Thomas, Margot; Joffe, Ari; Burns, Karen; Cook, Deborah			Factors affecting consent in pediatric critical care research	INTENSIVE CARE MEDICINE			English	Article						Ethics; Consent; Informed consent; Pediatric critical care	TRAUMATIC BRAIN-INJURY; INFORMED-CONSENT; CLINICAL-RESEARCH; CHALLENGES; EMERGENCY; HEPARIN; INFANTS; TRIALS	Consent for research is a difficult and unpredictable process in pediatric critical care populations. The objectives of this study were to describe consent rates in pediatric critical care research and their association with patient, legal guardian, consent process, and study design-related factors. A prospective, cohort study was conducted from 2009 to 2010 in six tertiary care pediatric intensive care units (PICU) in Canada with legal guardians of patients who were approached for consent for any ongoing PICU research study. Data were recorded on details of the consent process for all consent encounters. We recorded 271 consent encounters. The overall consent rate was 80.1% (217/271). We observed higher consent rates when the research assistant was introduced by a member of the clinical team prior to approaching the family (89.7 vs. 77.7%; P = 0.04). Legal guardians of cardiac surgery patients were less likely to provide consent than those of all other patients (75.3 vs. 86.0%; P = 0.03). There was no difference in consent rates between therapeutic (117/145, 80.7%) versus non-therapeutic studies (100/126, 79.4%; P = 0.88). This study provides future researchers with consent data for determination of recruitment rates, sample sizes, budget estimations, and study timelines. Future pediatric critical care studies should consider incorporating the lower consent rates in cardiac surgery patients and routine introduction of the research assistant to the family by a member of the patient's care team into their study designs. The potential influence of parental factors on consent rates in pediatric critical care studies requires further research.	[Menon, Kusum] Childrens Hosp Eastern Ontario, Pediat Intens Care Unit, Ottawa, ON K1S 3H2, Canada; [Menon, Kusum] Univ Ottawa, Dept Pediat, Ottawa, ON K1N 6N5, Canada; [Menon, Kusum; Ward, Roxanne E.] Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON K1S 3H2, Canada; [Gaboury, Isabelle] Univ Sherbrooke, Sherbrooke, PQ J1K 2R1, Canada; [Joffe, Ari] Univ Alberta, Stollery Childrens Hosp, John Dossetor Hlth Eth Ctr, Edmonton, AB, Canada; [Burns, Karen] St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Cook, Deborah] McMaster Univ Hlth Sci, Hamilton, ON, Canada	Menon, K (corresponding author), Childrens Hosp Eastern Ontario, Pediat Intens Care Unit, 401 Smyth Rd, Ottawa, ON K1S 3H2, Canada.	menon@cheo.on.ca			Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR)	This study was funded by the Canadian Institutes of Health Research (CIHR).	Baren JM, 1999, ACAD EMERG MED, V6, P1210, DOI 10.1111/j.1553-2712.1999.tb00135.x; Breslow N E, 1987, IARC Sci Publ, P1; Choong K, 2009, AM J RESP CRIT CARE, V180, P632, DOI 10.1164/rccm.200902-0221OC; Flagel D C, 2000, IRB, V22, P1, DOI 10.2307/3564220; Glickman SW, 2008, ANN EMERG MED, V51, P775, DOI 10.1016/j.annemergmed.2007.11.002; Gruenwald CE, 2010, J AM COLL CARDIOL, V56, P1794, DOI 10.1016/j.jacc.2010.06.046; Hoehn KS, 2005, ARCH DIS CHILD-FETAL, V90, P267, DOI 10.1136/adc.2004.065078; Huckabay L M, 1999, Dimens Crit Care Nurs, V18, P36, DOI 10.1097/00003465-199903000-00009; Hulst JM, 2005, INTENS CARE MED, V31, P880, DOI 10.1007/s00134-005-2647-8; Huskins WC, 2011, NEW ENGL J MED, V364, P1407, DOI 10.1056/NEJMoa1000373; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Lacroix J, 2007, NEW ENGL J MED, V356, P1609, DOI 10.1056/NEJMoa066240; Laird N M, 1990, Int J Technol Assess Health Care, V6, P5; LaMontagne L L, 1994, Clin Nurs Res, V3, P104, DOI 10.1177/105477389400300204; Menon K, 2010, AM J RESP CRIT CARE, V182, P246, DOI 10.1164/rccm.200911-1738OC; Morris MC, 2007, J PEDIATR-US, V151, P532, DOI 10.1016/j.jpeds.2007.04.032; Morris MC, 2006, CRIT CARE MED, V34, P2567, DOI 10.1097/01.CCM.0000239115.76603.55; Natale JE, 2006, DEV NEUROSCI-BASEL, V28, P276, DOI 10.1159/000094154; Pierro A, 1997, LANCET, V349, P1703, DOI 10.1016/S0140-6736(05)62681-5; Sammons Helen M, 2007, BMC Pediatr, V7, P12, DOI 10.1186/1471-2431-7-12; Schroeder AR, 2010, PEDIATR CRIT CARE ME, V11, P489, DOI 10.1097/PCC.0b013e3181ce6e29; Simon CM, 2004, J CLIN ONCOL, V22, P2708, DOI 10.1200/JCO.2004.10.034; Singhal Nalini, 2002, J Perinatol, V22, P57, DOI 10.1038/sj.jp.7210608; Sturdivant L, 2009, CRIT CARE NURS Q, V32, P149, DOI 10.1097/CNQ.0b013e3181a27f6d; Vlasselaers D, 2009, LANCET, V373, P547, DOI 10.1016/S0140-6736(09)60044-1; WALTERSPIEL JN, 1990, PEDIATRICS, V85, P119; Zupancic JAF, 1997, PEDIATRICS, V99, pE61	27	40	40	0	6	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	JAN	2012	38	1					153	159		10.1007/s00134-011-2412-0			7	Critical Care Medicine	General & Internal Medicine	858YM	WOS:000297839600022	22120768	Bronze			2021-06-18	
J	Ocwieja, KE; Mihalik, JP; Marshall, SW; Schmidt, JD; Trulock, SC; Guskiewicz, KM				Ocwieja, Karen E.; Mihalik, Jason P.; Marshall, Stephen W.; Schmidt, Julianne D.; Trulock, Scott C.; Guskiewicz, Kevin M.			The Effect of Play Type and Collision Closing Distance on Head Impact Biomechanics	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Biomechanics; Concussion; Helmet; Injury threshold; Mild traumatic brain injury	COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL FOOTBALL; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; NCAA CONCUSSION; GAME IMPACTS; EPIDEMIOLOGY; PERFORMANCE; RISK	Football accounts for 55% of concussions to collegiate athletes. In the National Football League, players are at a greater risk for concussion during kickoffs and punts compared to rushing and passing plays. The two primary purposes of this study were to determine if game-related special teams head impacts were greater in magnitude than head impacts sustained during offensive and defensive plays, and to better understand the effect closing distance between players (short vs. long) had on head impact magnitude. Collegiate football players were enrolled in a prospective cohort study assessing head impact biomechanics during special teams, offensive, and defensive collisions; long closing distance (>= 10 yards) and short closing distance (<10 yards) impacts were also studied. Data were analyzed using random intercepts general linear mixed models. Long closing distance collisions generated more severe head impacts than short closing distances. Collisions occurring on special teams plays over long closing distances were most severe while collisions occurring on special teams and defensive plays over short closing distances resulted in the least severe impacts. Decreasing the impact severity of collisions in collegiate football may be accomplished by reducing the closing distance prior to impact.	[Ocwieja, Karen E.; Mihalik, Jason P.; Schmidt, Julianne D.; Guskiewicz, Kevin M.] Univ N Carolina, Matthew A Gfeller Sport Related Traumat Brain Inj, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA; [Ocwieja, Karen E.] US Olymp Comm, Lake Placid, NY USA; [Marshall, Stephen W.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA; [Marshall, Stephen W.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC 27599 USA; [Trulock, Scott C.] Univ N Carolina, Campus Hlth Serv, Chapel Hill, NC 27599 USA	Mihalik, JP (corresponding author), Univ N Carolina, Matthew A Gfeller Sport Related Traumat Brain Inj, Dept Exercise & Sport Sci, 2207 Stallings Evans Sports Med Complex,Campus Bo, Chapel Hill, NC 27599 USA.	jmihalik@email.unc.edu		Guskiewicz, Kevin/0000-0002-8682-2130; Marshall, Stephen/0000-0002-2664-9233; Mihalik, Jason/0000-0001-6085-8322	Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; National Athletic Trainers' Association Research & Education Foundation; National Operating Committee on Standards for Athletic Equipment	This study was supported in part by the Centers for Disease Control and Prevention, National Athletic Trainers' Association Research & Education Foundation, and the National Operating Committee on Standards for Athletic Equipment.	Broglio S. P., 2010, MED SCI SPORTS EXERC; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Dick R, 2007, J ATHL TRAINING, V42, P221; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hamberger A, 2009, NEUROSURGERY, V64, P1174, DOI 10.1227/01.NEU.0000316855.40986.2A; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Kuehl MD, 2010, CLIN J SPORT MED, V20, P86, DOI 10.1097/JSM.0b013e3181cf4534; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mueller F. O., 2010, ANN SURVEY FOOTBALL, P30; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Pellman Elliot J, 2006, Neurosurg Focus, V21, pE12; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	29	40	40	0	17	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964			ANN BIOMED ENG	Ann. Biomed. Eng.	JAN	2012	40	1			SI		90	96		10.1007/s10439-011-0401-7			7	Engineering, Biomedical	Engineering	895HJ	WOS:000300486700008	21994061	Green Published			2021-06-18	
J	Smith, RL; Lin, JC; Adelson, PD; Kochanek, PM; Fink, EL; Wisniewski, SR; Bayir, H; Tyler-Kabara, EC; Clark, RSB; Brown, SD; Bell, MJ				Smith, Rebecca L.; Lin, John C.; Adelson, P. David; Kochanek, Patrick M.; Fink, Ericka L.; Wisniewski, Stephen R.; Bayir, Huelya; Tyler-Kabara, Elizabeth C.; Clark, Robert S. B.; Brown, S. Danielle; Bell, Michael J.			Relationship between hyperglycemia and outcome in children with severe traumatic brain injury	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; hyperglycemia; outcome	SEVERE HEAD-INJURY; INSULIN THERAPY PROTECTS; BLOOD-GLUCOSE CONTROL; PERIOPERATIVE HYPERGLYCEMIA; ADMISSION HYPERGLYCEMIA; MODERATE HYPOTHERMIA; INFECTIONS; MORTALITY; SURGERY; STRICT	Objective: To determine the relationship between hyperglycemia and outcome in infants and children after severe traumatic brain injury. Design: Retrospective review of a prospectively collected Pediatric Neurotrauma Registry. Setting and Patients: Children admitted after severe traumatic brain injury (postresuscitation Glasgow Coma Scale <= 8) were studied (1999-2004). A subset of children (n = 28) were concurrently enrolled in a randomized, controlled clinical trial of early hypothermia for neuroprotection. Interventions: Demographic data, serum glucose concentrations, and outcome assessments were collected. Methods and Main Results: Children (n = 57) were treated with a standard traumatic brain injury protocol. Exogenous glucose was withheld for 48 hrs after injury unless hypoglycemia was observed (blood glucose <70 mg/dL). Early (first 48 hrs) and Late (49-168 hrs) time periods were defined and mean blood glucose concentrations were calculated. Additionally, children were categorized based on peak blood glucose concentrations during each time period (normal, blood glucose <150 mg/dL; mild hyperglycemia, blood glucose <= 200 mg/dL; severe hyperglycemia, blood glucose >200 mg/dL). In the Late period, an association between elevated mean serum glucose concentration and outcome was observed (133.5 +/- 5.6 mg/dL in the unfavorable group vs. 115.4 +/- 4.1 mg/dL in favorable group, p = .02). This association continued to be significant after correcting for injury severity, age, and exposure to insulin (p = .03). Similarly, in the Late period, children within the severe hyperglycemia group had decreased incidence of good outcome compared to children within the other glycemic groups (% good outcome: normal, 61.9%; mild hyperglycemia, 73.7%; severe hyperglycemia, 33.3%; p = .05). However, when adjusted for exposure to insulin, this relationship was no longer statistically significant. Conclusions: In children with severe traumatic brain injury, hyperglycemia beyond the initial 48 hrs is associated with poor outcome. This relationship was observed in both our analysis of mean blood glucose concentrations as well as among the patients with episodic severe hyperglycemia. This observation suggests a relationship between hyperglycemia and outcome from traumatic brain injury. However, only a prospective study can answer the important question of whether manipulating serum glucose concentration can improve outcome after traumatic brain injury in children. (Pediatr Crit Care Med 2012; 13:85-91)	[Smith, Rebecca L.; Kochanek, Patrick M.; Fink, Ericka L.; Bayir, Huelya; Clark, Robert S. B.; Bell, Michael J.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Tyler-Kabara, Elizabeth C.; Bell, Michael J.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Wisniewski, Stephen R.] Univ Pittsburgh, Dept Epidemiol & Biostat, Pittsburgh, PA 15260 USA; [Smith, Rebecca L.; Kochanek, Patrick M.; Fink, Ericka L.; Bayir, Huelya; Clark, Robert S. B.; Bell, Michael J.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Lin, John C.] Wilford Hall, Dept Pediat, San Antonio, TX USA; [Adelson, P. David; Brown, S. Danielle] Phoenix Childrens Hosp, Dept Neurol Surg, Phoenix, AZ USA	Smith, RL (corresponding author), Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA.	smithr3@upmc.edu	Kochanek, Patrick M/D-2371-2015; Adelson, David/W-2083-2019; Smith, Rebecca L/N-5911-2014; Tyler-Kabara, Elizabeth/H-4930-2013	Kochanek, Patrick M/0000-0002-2627-913X; Tyler-Kabara, Elizabeth/0000-0003-3286-1094; Fink, Ericka/0000-0002-3683-4571; Wisniewski, Stephen/0000-0002-3877-9860	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD040686]; Cyberonics; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER	Supported, in part, by a grant from NIH (T32 HD040686) to Dr. Smith.; Dr. Adelson is employed with Phoenix Children's Hospital; has consulted for Traumtec, Inc; received honoraria/speaking fees from Cyberonics; and received grant support from the NIH. The remaining authors have not disclosed any potential conflicts of interest.	Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Ambiru S, 2008, J HOSP INFECT, V68, P230, DOI 10.1016/j.jhin.2007.12.002; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Cochran A, 2003, J TRAUMA, V55, P1035, DOI 10.1097/01.TA.0000031175.96507.48; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; Hansen TK, 2003, J CLIN ENDOCR METAB, V88, P1082, DOI 10.1210/jc.2002-021478; Hirshberg E, 2008, PEDIATR CRIT CARE ME, V9, P361, DOI 10.1097/PCC.0b013e318172d401; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Klein GW, 2008, J PEDIATR-US, V153, P379, DOI 10.1016/j.jpeds.2008.04.012; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Langouche L, 2005, J CLIN INVEST, V115, P2277, DOI 10.1172/JCI25385; LUNDGREN J, 1991, EXP BRAIN RES, V84, P91; Marton E, 2007, CHILD NERV SYST, V23, P873, DOI 10.1007/s00381-007-0314-9; MICHAUD LJ, 1991, J TRAUMA, V31, P1356, DOI 10.1097/00005373-199110000-00007; Paret G, 1999, J ACCID EMERG MED, V16, P186; PARISH RA, 1988, J TRAUMA, V28, P517, DOI 10.1097/00005373-198804000-00017; Preissig CM, 2009, PEDIATR CARDIOL, V30, P1098, DOI 10.1007/s00246-009-9512-4; Ramos M, 2008, ANN SURG, V248, P585, DOI 10.1097/SLA.0b013e31818990d1; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Salim A, 2009, AM SURGEON, V75, P25; Sharma D, 2009, ANESTH ANALG, V108, P81, DOI 10.1213/ane.0b013e31818a6f32; Ulate KP, 2008, PEDIATRICS, V122, pE898, DOI 10.1542/peds.2008-0871; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Vanhorebeek I, 2005, LANCET, V365, P53, DOI 10.1016/S0140-6736(04)17665-4; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vriesendorp TM, 2004, EUR J VASC ENDOVASC, V28, P520, DOI 10.1016/j.ejvs.2004.08.006; Walia S, 2002, INJURY, V33, P339, DOI 10.1016/S0020-1383(02)00053-0; Yang SY, 1995, SURG NEUROL, V44, P373, DOI 10.1016/0090-3019(96)80243-6; Yates AR, 2006, PEDIATR CRIT CARE ME, V7, P351, DOI 10.1097/01.PCC.0000227755.96700.98; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007; Yung M, 2008, PEDIATR CRIT CARE ME, V9, P147, DOI 10.1097/PCC.0b013e3181668c22	35	40	44	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JAN	2012	13	1					85	91		10.1097/PCC.0b013e3182192c30			7	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	875YT	WOS:000299073000026	21499170	Green Accepted			2021-06-18	
J	Takahashi, N; Higuchi, T; Shiotani, M; Hirose, Y; Shibuya, H; Yamanouchi, H; Hashidate, H; Funayama, K				Takahashi, Naoya; Higuchi, Takeshi; Shiotani, Motoi; Hirose, Yasuo; Shibuya, Hiroyuki; Yamanouchi, Haruo; Hashidate, Hideki; Funayama, Kazuhisa			The effectiveness of postmortem multidetector computed tomography in the detection of fatal findings related to cause of non-traumatic death in the emergency department	EUROPEAN RADIOLOGY			English	Article						Postmortem CT; Emergency department; Postmortem imaging; Forensic imaging; Sudden death	MINIMALLY INVASIVE AUTOPSY; CONVENTIONAL AUTOPSY; IMAGING FINDINGS; VIRTUAL AUTOPSY; CT; INJURY; MRI; ANGIOGRAPHY; HEMORRHAGE; EXPERIENCE	To investigate the diagnostic performance of postmortem multidetector computed tomography (PMMDCT) for the detection of fatal findings related to causes of non-traumatic death in the emergency department (ED). 494 consecutive cases of clinically diagnosed non-traumatic death in ED involving PMMDCT were enrolled. The fatal findings were detected on PMMDCT and classified as definite or possible findings. These findings were confirmed by autopsy in 20 cases. The fatal findings were detected in 188 subjects (38.1%) including 122 with definite (24.7%) and 66 with possible finding (13.4%). Definite findings included 21 cases of intracranial vascular lesions, 84 with intra-thoracic haemorrhage, 13 with retroperitoneal haemorrhage and one with oesophagogastric haemorrhage. In three patients who had initially been diagnosed with non-traumatic death, PMMDCT revealed fatal traumatic findings. Two definite findings (two haemopericardiums) and seven possible findings (two intestinal obstructions, one each of multiple liver tumours central pulmonary artery dilatation, pulmonary congestion, peritoneal haematoma, and brain oedema) were confirmed by autopsy. The causes of death were not determined in cases with possible findings without autopsy. PMMDCT is a feasible tool for detecting morphological fatal findings in non-traumatic death in ED. It is important to know the ability and limitation of PMMDCT. aEuro cent Postmortem multi-detector CT (MDCT) can reveal the cause of non-traumatic death. aEuro cent Postmortem MDCT is quick and can be widely available. aEuro cent Postmortem MDCT is acceptable to those relatives who object to invasive autopsy. aEuro cent MDCT cannot establish the cause of death in all patients.	[Takahashi, Naoya; Higuchi, Takeshi; Shiotani, Motoi] Niigata City Gen Hosp, Dept Diagnost Radiol, Chuo Ku, Niigata 9501197, Japan; [Hirose, Yasuo] Niigata City Gen Hosp, Dept Emergency & Crit Care, Niigata 9501197, Japan; [Shibuya, Hiroyuki; Hashidate, Hideki] Niigata City Gen Hosp, Dept Pathol, Niigata 9501197, Japan; [Yamanouchi, Haruo; Funayama, Kazuhisa] Niigata Univ, Dept Community Prevent Med, Div Legal Med, Grad Sch Med & Dent Sci, Niigata, Japan	Takahashi, N (corresponding author), Niigata City Gen Hosp, Dept Diagnost Radiol, Chuo Ku, 463-7 Shumoku, Niigata 9501197, Japan.	nandtr@gmail.com					Anon J, 2008, J MAGN RESON IMAGING, V28, P823, DOI 10.1002/jmri.21495; Bolliger SA, 2008, EUR RADIOL, V18, P273, DOI 10.1007/s00330-007-0737-4; Bolliger SA, 2010, AM J ROENTGENOL, V195, P1051, DOI 10.2214/AJR.10.4600; Christe A, 2008, EUR RADIOL, V18, P283, DOI 10.1007/s00330-007-0745-4; Christe A, 2009, J TRAUMA, V66, P1302, DOI 10.1097/TA.0b013e31818c1441; Ezawa H., 2007, RECHTSMEDIZIN, V17, P19, DOI [10.1007/s00194-006-0409-8, DOI 10.1007/S00194-006-0409-8]; Harcke HT, 2008, AM J ROENTGENOL, V190, pW106, DOI 10.2214/AJR.07.2754; Hoey BA, 2007, J TRAUMA, V63, P979, DOI 10.1097/TA.0b013e318154011f; Iino M, 2010, J FORENSIC SCI, V55, P1251, DOI 10.1111/j.1556-4029.2010.01430.x; Jackowski C, 2011, EUR RADIOL, V21, P70, DOI 10.1007/s00330-010-1884-6; Leth Peter Mygind, 2007, Forensic Sci Med Pathol, V3, P65, DOI 10.1385/FSMP:3:1:65; Levy AD, 2006, RADIOLOGY, V240, P522, DOI 10.1148/radiol.2402050972; Loughrey MB, 2000, ULSTER MED J, V69, P83; Mitka M, 2007, JAMA-J AM MED ASSOC, V298, P392, DOI 10.1001/jama.298.4.392; Mushtaq F, 2005, EMERG MED J, V22, P718, DOI 10.1136/emj.2004.018721; Oyake Yuji, 2006, Radiat Med, V24, P493, DOI 10.1007/s11604-006-0061-y; Quigley M, 2003, EMERG MED J, V20, P349, DOI 10.1136/emj.20.4.349; Rieger M, 2009, J TRAUMA, V66, P648, DOI 10.1097/TA.0b013e31816275f3; Roberts ISD, 2003, HISTOPATHOLOGY, V42, P424, DOI 10.1046/j.1365-2559.2003.01614.x; Ross S, 2008, AM J ROENTGENOL, V190, P1380, DOI 10.2214/AJR.07.3082; Scholing M, 2009, EUR RADIOL, V19, P2333, DOI 10.1007/s00330-009-1440-4; Shiotani S, 2008, RADIAT MED, V26, P253, DOI 10.1007/s11604-007-0223-6; Shiotani Seiji, 2004, Radiat Med, V22, P405; Shiotani S, 2011, LEGAL MED-TOKYO, V13, P151, DOI 10.1016/j.legalmed.2010.12.008; Shojania KG, 2008, NEW ENGL J MED, V358, P873, DOI 10.1056/NEJMp0707996; Shojania KG, 2003, JAMA-J AM MED ASSOC, V289, P2849, DOI 10.1001/jama.289.21.2849; Sochor MR, 2008, J TRAUMA, V65, P659, DOI 10.1097/TA.0b013e3181238d66; Takahashi N, 2010, AM J ROENTGENOL, V195, pW388, DOI 10.2214/AJR.10.4442; Takahashi N, 2009, JPN J RADIOL, V27, P316, DOI 10.1007/s11604-009-0340-5; Watts Geoff, 2010, BMJ, V341, pc6600, DOI 10.1136/bmj.c6600; Weustink AC, 2009, RADIOLOGY, V250, P897, DOI 10.1148/radiol.2503080421; Yamazaki K, 2006, FORENSIC SCI INT, V162, P163, DOI 10.1016/j.forsciint.2006.06.020; Yen K, 2007, FORENSIC SCI INT, V173, P21, DOI 10.1016/j.forsciint.2007.01.027	33	40	41	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0938-7994			EUR RADIOL	Eur. Radiol.	JAN	2012	22	1					152	160		10.1007/s00330-011-2248-6			9	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	857UX	WOS:000297749100016	21861187				2021-06-18	
J	Cope, EC; Morris, DR; Scrimgeour, AG; VanLandingham, JW; Levenson, CW				Cope, Elise C.; Morris, Deborah R.; Scrimgeour, Angus G.; VanLandingham, Jacob W.; Levenson, Cathy W.			Zinc supplementation provides behavioral resiliency in a rat model of traumatic brain injury	PHYSIOLOGY & BEHAVIOR			English	Article						Zinc; TBI; Depression; Anxiety; Anhedonia; Spatial memory	LOWER SERUM ZINC; MAJOR DEPRESSION; DEFICIENCY; CHELATION; MEMORY	Depression, anxiety, and impairments in learning and memory are all associated with traumatic brain injury (TBI). Because of the strong link between zinc deficiency, depression, and anxiety, in both humans and rodent models, we hypothesized that dietary zinc supplementation prior to injury could provide behavioral resiliency to lessen the severity of these outcomes after TBI. Rats were fed a marginal zinc deficient (5 ppm), zinc adequate (30 ppm), or zinc supplemented (180 ppm) diet for 4 weeks followed by a moderately-severe TBI using the well-established model of controlled cortical impact (CCI). Following CCI, rats displayed depression-like behaviors as measured by the 2-bottle saccharin preference test for anhedonia. Injury also resulted in evidence of stress and impairments in Morris water maze (MWM) performance compared to sham-injured controls. While moderate zinc deficiency did not worsen outcomes following TBI, rats that were fed the zinc supplemented diet for 4 weeks showed significantly attenuated increases in adrenal weight (p < 0.05) as well as reduced depression-like behaviors (p < 0.001). Supplementation prior to injury improved resilience such that there was not only significant improvements in cognitive behavior compared to injured rats fed an adequate diet (p < 0.01), there were no significant differences between supplemented and sham-operated rats in MWM performance at any point in the 10-day trial. These data suggest a role for supplemental zinc in preventing cognitive and behavioral deficits associated with TBI. (C) 2011 Elsevier Inc. All rights reserved.	[Cope, Elise C.; Morris, Deborah R.; VanLandingham, Jacob W.; Levenson, Cathy W.] Florida State Univ, Coll Med, Dept Biomed Sci, Tallahassee, FL 32306 USA; [VanLandingham, Jacob W.; Levenson, Cathy W.] Florida State Univ, Coll Med, Program Neurosci, Tallahassee, FL 32306 USA; [Scrimgeour, Angus G.] USA, Environm Med Res Inst, Mil Nutr Div, Natick, MA USA	Levenson, CW (corresponding author), Florida State Univ, Coll Med, Dept Biomed Sci, Tallahassee, FL 32306 USA.	cathy.levenson@med.fsu.edu		Levenson, Cathy W/0000-0003-4463-3136; Cope, Elise/0000-0001-6239-690X	U.S. Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM081382] Funding Source: NIH RePORTER	The authors would like to thank Dr. Vincent Salters at the National High Magnetic Field Laboratory (Tallahassee, FL) for his assistance with the brain zinc measurements, Shannon Gower-Winter, MS for excellent technical and editorial assistance, and the U.S. Army Medical Research and Material Command who funded this work.	Boroujeni ST, 2009, BIOL TRACE ELEM RES, V130, P48, DOI 10.1007/s12011-008-8312-7; Cekic M, 2011, NEUROBIOL AGING, V32, P864, DOI 10.1016/j.neurobiolaging.2009.04.017; Chu Y, 2003, PHYSIOL BEHAV, V78, P569, DOI 10.1016/S0031-9384(03)00041-6; Cope EC, 2010, CURR OPIN CLIN NUTR, V13, P685, DOI 10.1097/MCO.0b013e32833df61a; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Hellmich HL, 2008, NEUROSCI LETT, V440, P155, DOI 10.1016/j.neulet.2008.05.068; Hellmich HL, 2004, NEUROSCI LETT, V355, P221, DOI 10.1016/j.neulet.2003.10.074; IOM, 2006, MIN REQ MIL PERS LEV; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; MAES M, 1994, J AFFECT DISORDERS, V31, P135, DOI 10.1016/0165-0327(94)90117-1; Maes M, 1999, J AFFECT DISORDERS, V56, P189, DOI 10.1016/S0165-0327(99)00011-7; Maes M, 1997, BIOL PSYCHIAT, V42, P349, DOI 10.1016/S0006-3223(96)00365-4; MCCLAIN CJ, 1986, J NEUROSURG, V64, P224, DOI 10.3171/jns.1986.64.2.0224; Penkowa M, 2001, J NEUROTRAUM, V18, P447, DOI 10.1089/089771501750171056; Rich NJ, 2010, J NEUROSCI RES, V88, P2933, DOI 10.1002/jnr.22443; Salters VJM, 2010, CHEM GEOL, V273, P151, DOI 10.1016/j.chemgeo.2010.02.010; Siwek M, 2009, J AFFECT DISORDERS, V118, P187, DOI 10.1016/j.jad.2009.02.014; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Takeda A, 2007, BEHAV BRAIN RES, V177, P1, DOI 10.1016/j.bbr.2006.11.023; Tassabehji NM, 2008, PHYSIOL BEHAV, V95, P365, DOI 10.1016/j.physbeh.2008.06.017; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Yeiser EC, 2002, NUTR NEUROSCI, V5, P345, DOI 10.1080/1028415021000033811; Young B, 1996, J NEUROTRAUM, V13, P25, DOI 10.1089/neu.1996.13.25	25	40	43	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0031-9384			PHYSIOL BEHAV	Physiol. Behav.	OCT 24	2011	104	5					942	947		10.1016/j.physbeh.2011.06.007			6	Psychology, Biological; Behavioral Sciences	Psychology; Behavioral Sciences	837MP	WOS:000296208200040	21699908	Green Accepted			2021-06-18	
J	McAllister, TW; McDonald, BC; Flashman, LA; Ferrell, RB; Tosteson, TD; Yanofsky, NN; Grove, MR; Saykin, AJ				McAllister, Thomas W.; McDonald, Brenna C.; Flashman, Laura A.; Ferrell, Richard B.; Tosteson, Tor D.; Yanofsky, Norman N.; Grove, Margaret R.; Saykin, Andrew J.			Alpha-2 adrenergic challenge with guanfacine one month after mild traumatic brain injury: Altered working memory and BOLD response	INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						Traumatic brain injury; Alpha-2 adrenergic agonist; Working memory; Functional MRI; Guanfacine	CORTICAL COGNITIVE FUNCTION; PREFRONTAL CORTEX; ALPHA-2 ANTAGONIST; AGED RATS; PERFORMANCE; AGONIST; MECHANISMS; DEFICITS; REVERSAL; MONKEYS	Alterations in working memory (WM) are common after traumatic brain injury (TBI). Frontal catecholaminergic systems, including the alpha-2 adrenergic system, modulate WM function and may be affected in TBI. We hypothesized that administration of an alpha-2 adrenergic agonist might improve WM after mild TBI (MTBI). Thirteen individuals with MTBI 1 month after injury and 14 healthy controls (HC) were challenged with guanfacine and placebo prior to administration of a verbal WM functional MRI task. Guanfacine was associated with improved WM performance in the MTBI but not the HC group. On guanfacine the MTBI group showed increased activation within a WM task-specific region of interest. Findings are consistent with the hypothesis that alterations in WM after MTBI may be improved with the alpha-2 agonist guanfacine. (C) 2011 Elsevier B.V. All rights reserved.	[McAllister, Thomas W.; McDonald, Brenna C.; Flashman, Laura A.; Ferrell, Richard B.; Grove, Margaret R.; Saykin, Andrew J.] Dartmouth Med Sch, Dept Psychiat, Sect Neuropsychiat, Lebanon, NH USA; [McDonald, Brenna C.; Saykin, Andrew J.] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, Ctr Neuroimaging, Indianapolis, IN USA; [Tosteson, Tor D.] Dartmouth Med Sch, Dept Community & Family Med, Lebanon, NH USA; [Yanofsky, Norman N.] Dartmouth Med Sch, Sect Emergency Med, Lebanon, NH USA	McAllister, TW (corresponding author), Dartmouth Hitchcock Med Ctr, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	thomas.w.mcallister@dartmouth.edu	Saykin, Andrew/A-1318-2007	Saykin, Andrew/0000-0002-1376-8532; Ferrell, Richard/0000-0002-7492-210X	NIDRR [H133G70031, H133000136]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS40472-01]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040472] Funding Source: NIH RePORTER	This research was supported in part by NIDRR Grants H133G70031 and H133000136 and NIH Grant R01 NS40472-01. The authors would like to thank Brian Greenlee and Kaloyan Tanev, Neuropsychiatry Fellows, James Ford and Heather Pixley, Department of Psychiatry, and Robert Ferranti, Alice Davison, Shreve Soule and Robert Shaffer, Department of Radiology, for their assistance on this project.	Anticevic A, 2010, NEUROIMAGE, V49, P2638, DOI 10.1016/j.neuroimage.2009.11.008; Arnsten A F, 1998, Adv Pharmacol, V42, P764; Arnsten AFT, 1998, TRENDS COGN SCI, V2, P436, DOI 10.1016/S1364-6613(98)01240-6; ARNSTEN AFT, 1988, J NEUROSCI, V8, P4287; Arnsten AFT, 1996, ARCH GEN PSYCHIAT, V53, P448; Arnsten AFT, 2005, BIOL PSYCHIAT, V57, P1377, DOI 10.1016/j.biopsych.2004.08.019; ARNSTEN AFT, 1985, SCIENCE, V230, P1273, DOI 10.1126/science.2999977; Avery RA, 2000, NEUROPSYCHOPHARMACOL, V23, P240, DOI 10.1016/S0893-133X(00)00111-1; Barth AMI, 2008, J NEUROPHYSIOL, V99, P394, DOI 10.1152/jn.00943.2007; BARTUS RT, 1978, J GERONTOL, V33, P858, DOI 10.1093/geronj/33.6.858; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Birnbaum S, 1999, BIOL PSYCHIAT, V46, P1266, DOI 10.1016/S0006-3223(99)00138-9; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; CAI JX, 1993, BRAIN RES, V614, P191; CARLSON S, 1992, BEHAV NEURAL BIOL, V58, P113, DOI 10.1016/0163-1047(92)90327-Z; Chen KW, 2004, NEUROIMAGE, V22, P134, DOI 10.1016/j.neuroimage.2004.01.002; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Clerkin SM, 2009, BIOL PSYCHIAT, V66, P307, DOI 10.1016/j.biopsych.2009.04.013; Crossley NA, 2009, HUM BRAIN MAPP, V30, P4129, DOI 10.1002/hbm.20834; Delis DC, 2000, CALIFORNIA VERBAL LE; Delis DC, 1987, CALIFORNIA VERBAL LE; Delis DC, 2001, DELISKAPLAN EXECUTIV; First MB., 1997, STRUCTURED CLIN INTE; Franowicz JS, 1998, PSYCHOPHARMACOLOGY, V136, P8, DOI 10.1007/s002130050533; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Gordon M., 1986, GORDON DIAGNOSTIC SY; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Holmes AP, 1998, NEUROIMAGE, V7, pS754, DOI DOI 10.1016/S1053-8119(18)31587-8; HUNT RD, 1995, J AM ACAD CHILD PSY, V34, P50, DOI 10.1097/00004583-199501000-00013; Jakala P, 1999, NEUROPSYCHOPHARMACOL, V20, P460, DOI 10.1016/S0893-133X(98)00127-4; Jakala P, 1999, NEUROPSYCHOPHARMACOL, V20, P119, DOI 10.1016/S0893-133X(98)00055-4; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; Kobori N, 2006, J NEUROTRAUM, V23, P1094, DOI 10.1089/neu.2006.23.1094; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LUINE V, 1990, BRAIN RES, V537, P271, DOI 10.1016/0006-8993(90)90368-L; McAllister T. W., 2008, COGNITIVE NEUROREHAB, P298; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McMillan TM, 1997, CURR OPIN NEUROL, V10, P479, DOI 10.1097/00019052-199712000-00008; Nejad AB, 2011, WORLD J BIOL PSYCHIA, V12, P271, DOI 10.3109/15622975.2010.556199; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Rama P, 1996, PHARMACOL BIOCHEM BE, V55, P415, DOI 10.1016/S0091-3057(96)00111-6; Ramos BP, 2006, LEARN MEMORY, V13, P770, DOI 10.1101/lm.298006; Reitan R.M., 1993, HALSTEADREITAN NEURO; SIRVIO J, 1991, BEHAV NEURAL BIOL, V56, P101, DOI 10.1016/0163-1047(91)90327-M; Spreen O., 1998, COMPENDIUM NEUROPSYC, P447; Steere JC, 1997, BEHAV NEUROSCI, V111, P883; Tanila H, 1996, BRAIN RES BULL, V40, P117, DOI 10.1016/0361-9230(96)00026-3; The Psychological Corporation, 1997, WAIS 3 WECHSL AD INT; Tomasi D, 2006, HUM BRAIN MAPP, V27, P694, DOI 10.1002/hbm.20211; Wang M, 2007, CELL, V129, P397, DOI 10.1016/j.cell.2007.03.015; Whyte J, 2000, J INT NEUROPSYCH SOC, V6, P1, DOI 10.1017/S1355617700611013; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME	58	40	41	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0167-8760	1872-7697		INT J PSYCHOPHYSIOL	Int. J. Psychophysiol.	OCT	2011	82	1			SI		107	114		10.1016/j.ijpsycho.2011.06.022			8	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Psychology; Neurosciences & Neurology; Physiology	859PZ	WOS:000297889600012	21767584	Green Accepted			2021-06-18	
J	Wallace, DM; Shafazand, S; Ramos, AR; Carvalho, DZ; Gardener, H; Lorenzo, D; Wohlgemuth, WK				Wallace, D. M.; Shafazand, S.; Ramos, A. R.; Carvalho, D. Z.; Gardener, H.; Lorenzo, D.; Wohlgemuth, W. K.			Insomnia characteristics and clinical correlates in Operation Enduring Freedom/Operation Iraqi Freedom veterans with post-traumatic stress disorder and mild traumatic brain injury: An exploratory study	SLEEP MEDICINE			English	Article						Veterans; Traumatic brain injury; Insomnia; Post-traumatic stress disorder; Actigraphy; Sleep disturbances	SHORT-SLEEP DURATION; COMBAT-RELATED PTSD; MINOR HEAD-INJURY; QUALITY-OF-LIFE; DISTURBANCE; ACTIGRAPHY; SYMPTOMS; MILITARY; VALIDITY; CONSEQUENCES	Background: There is limited data on chronic insomnia in Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) veterans, in whom post-traumatic stress disorder (PTSD) and mild traumatic brain injury (mTBI) often co-exist. Our aim was to compare sleep characteristics of three groups of OEF/OIF veterans: (1) healthy sleepers (HS), (2) those with insomnia associated with PTSD and mTBI (PTSD-mTBI), and (3) those with insomnia associated with PTSD alone. Methods: Consecutive veterans with insomnia complaints (>6 months) were recruited over 6 months from the Miami VA Post Deployment clinic. Participants completed a sleep disorders clinical interview, medical history, and questionnaires about insomnia, sleepiness, pain, fatigue, depression, PTSD, and health-related quality of life. They underwent polysomnography (PSG) with 2 weeks of actigraphy (ACT) and sleep diaries. Results: There were no differences in demographics or most questionnaire responses between PTSD and PTSD-mTBI groups. Subjective daytime sleepiness was significantly greater in PTSD-mTBI subjects compared with HS and PTSD participants. Significant co-morbid sleep disorders were noted in insomnia patients. PSG and ACT wake after sleep onset was significantly shorter in PTSD-mTBI subjects as compared with PTSD participants. Conclusion: Insomnia patients with PTSD-mTBI were subjectively sleepier despite spending less time awake during the night than PTSD subjects, possibly as a consequence of head trauma. Published by Elsevier B.V.	[Wallace, D. M.; Ramos, A. R.; Lorenzo, D.; Wohlgemuth, W. K.] Vet Affairs Med Ctr, Bruce W Carter Dept, Dept Neurol, Miami, FL 33125 USA; [Wallace, D. M.; Gardener, H.; Lorenzo, D.; Wohlgemuth, W. K.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA; [Shafazand, S.] Univ Miami, Dept Med, Div Pulm Crit Care & Sleep Med, Miami, FL USA; [Carvalho, D. Z.] Univ Fed Rio Grande do Sul, Neurol Serv, Hosp Clin Porto Alegre, Sch Med, Porto Alegre, RS, Brazil	Wallace, DM (corresponding author), Vet Affairs Med Ctr, Bruce W Carter Dept, Dept Neurol, 1201 NW 16th St, Miami, FL 33125 USA.	dwallace@med.miami.edu	Wallace, Douglas/AAL-3719-2020; Ramos, Alberto/X-4249-2019	Wallace, Douglas/0000-0002-8982-1088; Carvalho, Diego/0000-0002-8822-1638			American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS, V2nd; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Breslau N, 2004, ARCH GEN PSYCHIAT, V61, P508, DOI 10.1001/archpsyc.61.5.508; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Ledesma RD, 2009, TUTOR QUANT METHODS, V5, P25, DOI 10.20982/tqmp.05.1.p025; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Gelis LA, 2010, MIL MED, V175, P567, DOI 10.7205/MILMED-D-09-00123; Germain A, 2008, SLEEP MED REV, V12, P185, DOI 10.1016/j.smrv.2007.09.003; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iber C, 2007, AASM MANUAL SCORING; JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376; Katz DA, 2002, J FAM PRACTICE, V51, P229; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Kaynak H, 2006, EUR J NEUROL, V13, P1333, DOI 10.1111/j.1468-1331.2006.01499.x; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kobayashi I, 2007, PSYCHOPHYSIOLOGY, V44, P660, DOI 10.1111/j.1469-8986.2007.537.x; Krakow B, 2004, J TRAUMA STRESS, V17, P257, DOI 10.1023/B:JOTS.0000029269.29098.67; Lam SP, 2008, J CLIN PSYCHIAT, V69, P1374, DOI 10.4088/JCP.v69n0904; Leger D, 2001, PSYCHOSOM MED, V63, P49, DOI 10.1097/00006842-200101000-00006; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Lichstein KL, 2006, SLEEP, V29, P232; Littner M, 2003, SLEEP, V26, P337, DOI 10.1093/sleep/26.3.337; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; McLay RN, 2010, MIL MED, V175, P759, DOI 10.7205/MILMED-D-10-00193; Meissel K., 2010, ACSPRI SOC SCI METH; MELLMAN TA, 1995, BIOL PSYCHIAT, V38, P174, DOI 10.1016/0006-3223(94)00238-X; Mellman TA, 2002, AM J PSYCHIAT, V159, P1696, DOI 10.1176/appi.ajp.159.10.1696; Mellman TA, 1997, SLEEP, V20, P46, DOI 10.1093/sleep/20.1.46; Sanchez-Ortuno MM, 2010, J CLIN SLEEP MED, V6, P21; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Peterson AL, 2008, MIL MED, V173, P230, DOI 10.7205/MILMED.173.3.230; Romano J., 2006, PROC ANN M FLORIDA A, P1; ROSS RJ, 1994, SLEEP, V17, P723, DOI 10.1093/sleep/17.8.723; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Seelig AD, 2010, SLEEP, V33, P1615, DOI 10.1093/sleep/33.12.1615; Storch EA, 2004, DEPRESS ANXIETY, V19, P187, DOI 10.1002/da.20002; Thase ME, 2005, GEN HOSP PSYCHIAT, V27, P100, DOI 10.1016/j.genhosppsych.2004.09.006; Ulmer CS, 2011, J CLIN SLEEP MED, V7, P57; Vallieres A, 2003, SLEEP, V26, P902, DOI 10.1093/sleep/26.7.902; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Vgontzas AN, 2010, SLEEP, V33, P1159, DOI 10.1093/sleep/33.9.1159; Vgontzas AN, 2009, DIABETES CARE, V32, P1980, DOI 10.2337/dc09-0284; Vgontzas AN, 2009, SLEEP, V32, P491, DOI 10.1093/sleep/32.4.491; Weathers F.W., 1991, PCL M DSM 4; Westermeyer J, 2007, J ANXIETY DISORD, V21, P966, DOI 10.1016/j.janxdis.2006.11.009; Wilson S, 2005, DRUGS, V65, P927, DOI 10.2165/00003495-200565070-00003; Wohlgemuth WK, 1999, PSYCHOPHYSIOLOGY, V36, P233, DOI 10.1111/1469-8986.3620233; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	55	40	40	0	14	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1389-9457	1878-5506		SLEEP MED	Sleep Med.	OCT	2011	12	9					850	859		10.1016/j.sleep.2011.06.004			10	Clinical Neurology	Neurosciences & Neurology	858FG	WOS:000297780700008	21925943				2021-06-18	
J	Jin, W; Kong, J; Wang, HD; Wu, J; Lu, TY; Jiang, J; Ni, HB; Liang, WB				Jin, Wei; Kong, Jie; Wang, Handong; Wu, Jun; Lu, Tianyu; Jiang, Jian; Ni, Hongbin; Liang, Weibang			Protective effect of tert-butylhydroquinone on cerebral inflammatory response following traumatic brain injury in mice	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						tBHQ; Traumatic brain injury; Nrf2; Inflammatory response	NF-KAPPA-B; NRF2-DRIVEN ANTIOXIDANT RESPONSE; GLUTATHIONE-S-TRANSFERASE; OXIDATIVE STRESS; IN-VIVO; CELL-DEATH; INDUCTION; NRF2; ACTIVATION; TBHQ	Aim: Antioxidant transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) has been shown in our previous studies to play a crucial role in protection against TBI induced inflammatory response in the brain. The objective of this study was to test whether tert-butylhydroquinone (tBHQ), a novel Nrf2 activator, can protect mice brain against TBI-induced inflammatory damage. Methods: Adult male ICR mice were randomly divided into three groups: (1) sham + vehicle group; (2) TBI + vehicle group; and (3) TBI + tBHQ group (n = 12 per group). Closed head injury was adopted using Hall's weight-dropping method. We measured Nrf2 and nuclear factor kappa B (NF-kappa B) binding activities by electrophoretic mobility shift assay (EMSA), concentrations of tumour necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta) and interleukin-6 (IL-6) by enzyme-linked immunosorbent assay (ELISA), brain oedema by wet/dry weight method, and cortical apoptosis by terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) analysis. Results: Induction of the Nrf2 activity by tBHQ markedly decreased NF-kappa B activation and inflammatory cytokine production in the injured brain. Administration of tBHQ also significantly attenuated TBI-induced brain oedema and cortical apoptosis. Conclusion: Pre-treatment with tBHQ could attenuate the cerebral inflammatory response after TBI. (C) 2011 Elsevier Ltd. All rights reserved.	[Jin, Wei; Kong, Jie; Wu, Jun; Lu, Tianyu; Jiang, Jian; Ni, Hongbin; Liang, Weibang] Nanjing Univ, Sch Med, Drum Tower Hosp, Dept Neurosurg, Nanjing 210008, Jiangsu Prov, Peoples R China; [Wang, Handong] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu Prov, Peoples R China	Ni, HB (corresponding author), Nanjing Univ, Sch Med, Drum Tower Hosp, Dept Neurosurg, 321 Zhongshan Rd, Nanjing 210008, Jiangsu Prov, Peoples R China.	glyy110@163.com; njneurosurgery@yahoo.com.cn			Drum Tower Hospital of China	This work was supported by grants from Drum Tower Hospital of China. We thank Dr. Li-zhi Xu for technical assistance.	Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baines J, 1999, WHO TECH REP SER, V884, P1; Calkins MJ, 2005, P NATL ACAD SCI USA, V102, P244, DOI 10.1073/pnas.0408487101; Chen F, 1999, CLIN CHEM, V45, P7; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hellal F, 2004, NEUROSCI LETT, V357, P21, DOI 10.1016/j.neulet.2003.12.036; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Hutchison JS, 2001, J NEUROTRAUM, V18, P1333, DOI 10.1089/08977150152725632; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Jin W, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/725174; Johnson DA, 2002, J NEUROCHEM, V81, P1233, DOI 10.1046/j.1471-4159.2002.00913.x; Keum YS, 2006, PHARM RES, V23, P2586, DOI 10.1007/s11095-006-9094-2; Koh K, 2009, BIOCHEM BIOPH RES CO, V380, P449, DOI 10.1016/j.bbrc.2009.01.082; Kraft AD, 2004, J NEUROSCI, V24, P1101, DOI 10.1523/JNEUROSCI.3817-03.2004; Lamb JG, 2000, DRUG METAB DISPOS, V28, P1018; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; Li J, 2005, TOXICOL SCI, V83, P313, DOI 10.1093/toxsci/kfi027; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003; Nakamura Y, 2003, BIOCHEMISTRY-US, V42, P4300, DOI 10.1021/bi0340090; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Nishizono S, 2000, BIOSCI BIOTECH BIOCH, V64, P1153, DOI 10.1271/bbb.64.1153; Osburn WO, 2006, ARCH BIOCHEM BIOPHYS, V454, P7, DOI 10.1016/j.abb.2006.08.005; Shih AY, 2005, J NEUROSCI, V25, P10321, DOI 10.1523/JNEUROSCI.4014-05.2005; Shih AY, 2005, J BIOL CHEM, V280, P22925, DOI 10.1074/jbc.M414635200; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Thimmulappa RK, 2006, J CLIN INVEST, V116, P984, DOI 10.1172/JCI25790; Vargas MR, 2008, J NEUROSCI, V28, P13574, DOI 10.1523/JNEUROSCI.4099-08.2008; Yan D, 2010, BIOCHEM PHARMACOL, V80, P144, DOI 10.1016/j.bcp.2010.03.004	35	40	41	1	15	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	JUL	2011	42	7					714	718		10.1016/j.injury.2011.03.009			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	772OL	WOS:000291243100017	21466884				2021-06-18	
J	Mrazik, M; Bawani, F; Krol, AL				Mrazik, Martin; Bawani, Farzad; Krol, Andrea L.			Sport-Related Concussions: Knowledge Translation Among Minor Hockey Coaches	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussions; symptoms; pediatric; mild traumatic brain injury; knowledge	TRAUMATIC BRAIN-INJURY; TO-PLAY GUIDELINES; RETURN; MANAGEMENT; CHILD	Objective: The objective of this study was to investigate minor hockey coaches' knowledge base of sport-related concussions. Design: Cross-sectional survey. Setting: Subjects independently completed the written survey at preseason organizational meetings. Participants: One hundred seventy-eight active coaches spanning 5 age levels (ages 5-15 years). Coaches reported 2.62 +/- 3.73 years of coaching experience. Main Outcome Measures: Resources where coaches obtained information about concussions, perceptions of variables associated with concussions, knowledge level of issues associated with concussions, and decision-making practices. Results: Newspapers and magazines were the most frequent source of information regarding concussions, yet were rated as not very helpful. Family physicians were less frequently sought but were rated as most helpful. A majority of coaches reported limited knowledge about concussions but rated this knowledge as being important. There was a significant relationship between head coaching experience and concussion knowledge [R(2)= 0.09, F3,156 = 4.41, P = 0.005]. Most coaches demonstrated a good knowledge base of common issues associated with concussions, and a majority of individuals correctly identified return-to-play practices. Conclusions: A majority of minor hockey coaches correctly recognized and understood issues related to sport-related concussions. Results suggested that knowledge translation through various formal and informal sources has had a positive effect. However, a majority of coaches reported having limited knowledge about concussions yet consider it an important topic.	[Mrazik, Martin; Bawani, Farzad; Krol, Andrea L.] Univ Alberta, Dept Educ Psychol, Edmonton, AB T6G 2G5, Canada	Mrazik, M (corresponding author), Univ Alberta, Dept Educ Psychol, 6-135 Educ Bldg N, Edmonton, AB T6G 2G5, Canada.	mrazik@ualberta.ca			Alberta Centre for Injury Control Research	Supported by the Alberta Centre for Injury Control Research operating grant. The authors report no conflicts of interest.	Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Goodman D, 2002, CLIN J SPORT MED, V12, P265, DOI 10.1097/00042752-200209000-00001; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Injury Prevention and Control, INJ PREV CONTR TRAUM; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Lovell MR, 2008, CURR SPORT MED REP, V7, P12, DOI 10.1097/01.CSMR.0000308671.45558.e2; Mackenzie JA, 2005, BRIT J CLIN PSYCHOL, V44, P417, DOI 10.1348/014466505X35696; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; Mulhern S, 2006, J PSYCHOSOM RES, V61, P439, DOI 10.1016/j.jpsychores.2006.03.004; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Purcell L, 2009, BRIT J SPORT MED, V43, pI51, DOI 10.1136/bjsm.2009.058214; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Yang J, 2008, BRIT J SPORT MED, V42, P664, DOI 10.1136/bjsm.2007.040923	20	40	40	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2011	21	4					315	319		10.1097/JSM.0b013e31821e2b78			5	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	786DY	WOS:000292284700006	21694594				2021-06-18	
J	Murnane, OD; Akin, FW; Kelly, JK; Byrd, S				Murnane, Owen D.; Akin, Faith W.; Kelly, J. Kip; Byrd, Stephanie			Effects of Stimulus and Recording Parameters on the Air Conduction Ocular Vestibular Evoked Myogenic Potential	JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY			English	Article						Ocular reflexes; ocular vestibular evoked myogenic potentials; otoliths; saccule; utricle; vestibular evoked myogenic potentials	SUPERIOR CANAL DEHISCENCE; VESTIBULOOCULAR REFLEXES; EXTRAOCULAR POTENTIALS; ENDOLYMPHATIC HYDROPS; MENIERES-DISEASE; SOUND; BONE; FREQUENCY; VIBRATION; MUSCLES	Background: Vestibular evoked myogenic potentials (VEMPs) have been recorded from the sternocleidomastoid muscle (cervical VEMP or cVEMP) and more recently from the eye muscles (ocular VEMP or oVEMP) in response to air conduction and bone conduction stimuli. Both cVEMPs and oVEMPs are mediated by the otoliths and thereby provide diagnostic information that is complementary to videonystagmography and rotational chair tests. In contrast to the air conduction cVEMP, which originates from the saccule/inferior vestibular nerve, recent evidence suggests the possibility that the air conduction oVEMP may be. mediated by the utricle/superior vestibular nerve. The oVEMP, therefore, may provide complementary diagnostic information relative to the cVEMP. There are relatively few studies, however, that have quantified the effects of stimulus and recording parameters on the air conduction oVEMP, and there is a paucity of normative data. Purpose: To evaluate the effects of several stimulus and recording parameters on the air conduction oVEMP and to establish normative data for clinical use. Research Design: A prospective repeated measures design was utilized. Study Sample: Forty-seven young adults with no history of neurologic disease, hearing loss, middle ear pathology, open or closed head injury, cervical injury, or audiovestibular disorder participated in the study. Data Collection and Analysis: The effects of stimulus frequency, stimulus level, gaze elevation, and recording electrode location on the amplitude and latency of the oVEMP for monaural air conduction stimuli were assessed using repeated measures analyses of variance in an initial group of 17 participants. The optimal stimulus and recording parameters obtained in the initial group were used subsequently to obtain oVEMPs from 30 additional participants. Results: The effects of stimulus frequency, stimulus level, gaze elevation, and electrode location on the response prevalence, amplitude, and latency of the oVEMP for monaural air conduction stimuli were significant. The maximum N1-P1 amplitude and response prevalence were obtained for contralateral oVEMPs using a 500 Hz tone burst presented at 125 dB (peak) SPL during upward gaze at an elevation of 30 degrees. Conclusions: The optimal stimulus and recording parameters quantified in this study were used to establish normative data that may be useful for the clinical application of the air conduction oVEMP.	[Murnane, Owen D.; Akin, Faith W.; Kelly, J. Kip; Byrd, Stephanie] James H Quillen VAMC, Mountain Home, TN 37684 USA; [Murnane, Owen D.; Akin, Faith W.] E Tennessee State Univ, Dept Speech Pathol & Audiol, Johnson City, TN 37614 USA	Murnane, OD (corresponding author), James H Quillen VAMC, Mountain Home, TN 37684 USA.	owen.murnane@va.gov			Auditory and Vestibular Dysfunction Research Enhancement Award Program; Rehabilitation Research and Development Service, Department of Veterans Affairs, Washington, D.C.US Department of Veterans Affairs;  [C6065R]	This work was supported by a Merit Review (C6065R) and the Auditory and Vestibular Dysfunction Research Enhancement Award Program sponsored by the Rehabilitation Research and Development Service, Department of Veterans Affairs, Washington, D.C.	Akin F W, 2001, J Am Acad Audiol, V12, P445; American National Standards Institute, 2004, S362004 ANSI; Cheng PW, 2009, CLIN NEUROPHYSIOL, V120, P1841, DOI 10.1016/j.clinph.2009.08.002; Chihara Y, 2007, CLIN NEUROPHYSIOL, V118, P2745, DOI 10.1016/j.clinph.2007.08.005; Chihara Y, 2009, NEUROREPORT, V20, P1491, DOI 10.1097/WNR.0b013e3283329b4a; Chihara Y, 2009, CLIN NEUROPHYSIOL, V120, P581, DOI 10.1016/j.clinph.2008.12.030; Colebatch JG, 2010, CLIN NEUROPHYSIOL, V121, P124, DOI 10.1016/j.clinph.2009.09.026; Curthoys IS, 2011, CLIN NEUROPHYSIOL, V122, P611, DOI 10.1016/j.clinph.2010.07.018; Curthoys IS, 2011, EXP BRAIN RES, V210, P347, DOI 10.1007/s00221-010-2499-5; Curthoys IS, 2010, CLIN NEUROPHYSIOL, V121, P977, DOI 10.1016/j.clinph.2010.01.025; Curthoys IS, 2010, CLIN NEUROPHYSIOL, V121, P132, DOI 10.1016/j.clinph.2009.09.027; de Waele C, 2001, EXP BRAIN RES, V141, P541, DOI 10.1007/s00221-001-0894-7; Govender S, 2009, CLIN NEUROPHYSIOL, V120, P1386, DOI 10.1016/j.clinph.2009.04.017; Halmagyi GM, 2010, CLIN NEUROPHYSIOL, V121, P631, DOI 10.1016/j.clinph.2010.01.035; Iwasaki S, 2007, NEUROLOGY, V68, P1227, DOI 10.1212/01.wnl.0000259064.80564.21; Iwasaki S, 2009, CLIN NEUROPHYSIOL, V120, P588, DOI 10.1016/j.clinph.2008.12.036; LEIGH RJ, 1999, NEUROLOGY EYE MOVEME, P3; Lewis A, 2010, J OTOLARYNGOL-HEAD N, V39, P491, DOI 10.2310/7070.2010.090205; Manzari L, 2010, OTOLARYNG HEAD NECK, V143, P274, DOI 10.1016/j.otohns.2010.03.020; Manzari L, 2010, EUR ARCH OTO-RHINO-L, V267, P1487, DOI 10.1007/s00405-010-1317-9; Murnane Owen D., 2009, Seminars in Hearing, V30, P267, DOI 10.1055/s-0029-1241127; Murofushi T, 2010, EUR ARCH OTO-RHINO-L, V267, P995, DOI 10.1007/s00405-010-1246-7; OKUNO T, 1987, ANN OTO RHINOL LARYN, V96, P438, DOI 10.1177/000348948709600418; PAPARELLA MM, 1985, ACTA OTO-LARYNGOL, V99, P445, DOI 10.3109/00016488509108936; Park HJ, 2010, CLIN NEUROPHYSIOL, V121, P85, DOI 10.1016/j.clinph.2009.10.003; PORTER JD, 2003, ADLERS PHYSL EYE CLI, P787; Rodionov V, 1996, ANN OTO RHINOL LARYN, V105, P43, DOI 10.1177/000348949610500107; Rodionov V, 1996, EVOKED POTENTIAL, V100, P354, DOI 10.1016/0168-5597(96)95515-X; Rosengren SM, 2008, J NEUROL NEUROSUR PS, V79, P559, DOI 10.1136/jnnp.2007.126730; Rosengren SM, 2010, CLIN NEUROPHYSIOL, V121, P636, DOI 10.1016/j.clinph.2009.10.016; Rosengren SM, 2009, CLIN NEUROPHYSIOL, V120, P569, DOI 10.1016/j.clinph.2008.12.001; Rosengren SM, 2005, CLIN NEUROPHYSIOL, V116, P1938, DOI 10.1016/j.clinph.2005.03.019; ROSENHALL U, 1972, ANN OTO RHINOL LARYN, V81, P339, DOI 10.1177/000348947208100305; SCHUKNECHT HF, 1986, ANN OTO RHINOL LARYN, V95, P36, DOI 10.1177/000348948609500108; Smulders YE, 2009, CLIN NEUROPHYSIOL, V120, P1567, DOI 10.1016/j.clinph.2009.06.008; Sohmer H, 1999, EEG CL N SU, V50, P226; Su HC, 2004, OTOL NEUROTOL, V25, P977, DOI 10.1097/00129492-200411000-00019; Taylor RL, CLIN NEUROP IN PRESS; Todd NPM, 2008, CLIN NEUROPHYSIOL, V119, P1638, DOI 10.1016/j.clinph.2008.03.009; Todd NPM, 2009, NEUROSCI LETT, V451, P175, DOI 10.1016/j.neulet.2008.12.055; Todd NPM, 2007, CLIN NEUROPHYSIOL, V118, P381, DOI 10.1016/j.clinph.2006.09.025; Todd NPM, 2010, CLIN NEUROPHYSIOL, V121, P978, DOI 10.1016/j.clinph.2010.01.026; Uzun-Coruhlu H, 2007, HEARING RES, V233, P77, DOI 10.1016/j.heares.2007.07.008; Wang SJ, 2009, CLIN NEUROPHYSIOL, V120, P420, DOI 10.1016/j.clinph.2008.10.157; Welgampola MS, 2008, NEUROLOGY, V70, P464, DOI 10.1212/01.wnl.0000299084.76250.4a; Welgampola MS, 2010, OTOLARYNG HEAD NECK, V143, P281, DOI 10.1016/j.otohns.2010.05.024; Welgampola MS, 2009, CLIN NEUROPHYSIOL, V120, P158, DOI 10.1016/j.clinph.2008.06.020; Welgampola MS, 2001, OTOL NEUROTOL, V22, P796, DOI 10.1097/00129492-200111000-00014; Welgampola MS, 2001, CLIN NEUROPHYSIOL, V112, P1971, DOI 10.1016/S1388-2457(01)00645-9; WRIGHT CG, 1979, ANN OTO RHINOL LARYN, V88, P267, DOI 10.1177/000348947908800220; Zhou W, 2004, EXP BRAIN RES, V156, P129, DOI 10.1007/s00221-003-1778-9	51	40	44	0	13	AMER ACAD AUDIOLOGY	RESTON	11730 PLAZA DR, STE 300, RESTON, VA 20190 USA	1050-0545			J AM ACAD AUDIOL	J. Am. Acad. Audiol.	JUL-AUG	2011	22	7			SI		469	480		10.3766/jaaa.22.7.7			12	Audiology & Speech-Language Pathology; Otorhinolaryngology	Audiology & Speech-Language Pathology; Otorhinolaryngology	831DD	WOS:000295708000007	21993052				2021-06-18	
J	Helfer, TM; Jordan, NN; Lee, RB; Pietrusiak, P; Cave, K; Schairer, K				Helfer, Thomas M.; Jordan, Nikki N.; Lee, Robyn B.; Pietrusiak, Paul; Cave, Kara; Schairer, Kim			Noise-Induced Hearing Injury and Comorbidities Among Postdeployment U.S. Army Soldiers: April 2003-June 2009	AMERICAN JOURNAL OF AUDIOLOGY			English	Article						noise-induced hearing injury; mild traumatic brain injury; posttraumatic stress disorder; blast trauma; speech-language disorders	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; LOSS PREVENTION PROGRAMS; BLAST; IRAQ; POPULATIONS; UPDATE; TEAM; DUTY; EAR	Purpose: To evaluate noise-induced hearing injury (NIHI) and blast-related comorbidities among U.S. Army soldiers in an effort to understand the morbidity burden and future health service requirements for wounded war fighters returning from the Central Command Area of Responsibility, predominantly from Iraq and Afghanistan deployments. Method: Inpatient and outpatient records with diagnosed NIHI or blast-related comorbidities (e.g., significant threshold shift [STS], noise-induced hearing loss, tinnitus, sensorineural hearing loss, eardrum perforations, mild traumatic brain injury, and posttraumatic stress disorder) were extracted for active duty soldiers returning from combat deployments. Records were limited to those within 6 months of the soldier's return date from April 2003 through June 2009. To account for changes in STS coding practice, STS rates observed after October 1, 2006, were used to extrapolate prior probable postdeployment STS. Results: Statistically significant increases were observed for tinnitus, dizziness, eardrum perforations, and speech-language disorders. The combination of observed and extrapolated STS yielded a conservative estimate of 27,427 cases. Conclusions: Estimates can be used to forecast resource requirements for hearing services among veterans. This article could serve as a guide for resourcing and innovating prevention measures and treatment in this population. Data provided may also serve as a baseline for evaluating prevention measures.	[Helfer, Thomas M.; Jordan, Nikki N.; Lee, Robyn B.; Pietrusiak, Paul] USA, Publ Hlth Command Provis, Inst Publ Hlth, Gunpowder, MD USA; [Cave, Kara] Blanchfield Army Community Hosp, Ft Campbell, KY USA; [Schairer, Kim] Univ Wisconsin, Madison, WI 53706 USA	Helfer, TM (corresponding author), USA, Publ Hlth Command Provis, Inst Publ Hlth, Gunpowder, MD USA.	thomas.helfer@us.army.mil					Adera T, 2000, AM IND HYG ASSOC J, V61, P11, DOI 10.1202/0002-8894(2000)061<0011:UOCPFE>2.0.CO;2; ADERA T, 1993, J OCCUP ENVIRON MED, V35, P568, DOI 10.1097/00043764-199306000-00012; Adera T, 1995, J Am Acad Audiol, V6, P302; Adera T, 1997, AM J IND MED, V31, P243, DOI 10.1002/(SICI)1097-0274(199702)31:2<243::AID-AJIM14>3.0.CO;2-1; Adera T, 2000, AM IND HYG ASSOC J, V61, P161, DOI 10.1202/0002-8894(2000)061<0161:TTAOHL>2.0.CO;2; ADERA T, 1993, MIL MED, V11, P697; *ARM FORC HLTH SUR, 2008, MED SURVEILLANCE MON, V15, P36; *ARM FORC HLTH SUR, 2010, 2009 TBI CAT PEN SEV; Casscells SW, 2007, TRAUMATIC BRAIN INJU; Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; Fagelson Marc A, 2007, Am J Audiol, V16, P107, DOI 10.1044/1059-0889(2007/015); Fausti SA, 2005, J REHABIL RES DEV, V42, P45, DOI 10.1682/JRRD.2005.02.0039; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; HELFER T, 2009, FORC HLTH PROT C ALB; HELFER T, 2008, FORC HLTH PROT C ALB; Helfer T M, 2000, Am J Audiol, V9, P75, DOI 10.1044/1059-0889(2000/008); Helfer Thomas M, 2005, Am J Audiol, V14, P161, DOI 10.1044/1059-0889(2005/018); Helmick KM, 2007, FEDERAL PRACTITIONER, V24, P58; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Humes LE, 2006, NOISE MILITARY SERVI; *I MED NAT AC SCI, 2010, PREL ASS READJ NEEDS; *I MED NAT AC SCI, 1999, MEAS HLTH PERF PUBL; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Jaffee CMS, 2009, CLIN NEUROPSYCHOL, V23, P1291, DOI 10.1080/13854040903307250; Jordan Nikki N., 2009, Seminars in Hearing, V30, P28, DOI 10.1055/s-0028-1111104; KERR AG, 1975, J LARYNGOL OTOL, V89, P131, DOI 10.1017/S002221510008018X; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lew HL, 2007, J REHABIL RES DEV, V44, pVII; Lewine JD, 2002, AM J PSYCHIAT, V159, P1689, DOI 10.1176/appi.ajp.159.10.1689; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Metzger LJ, 2009, PSYCHOPHYSIOLOGY, V46, P172, DOI 10.1111/j.1469-8986.2008.00720.x; Meyer JD, 2002, OCCUP MED-OXFORD, V52, P75, DOI 10.1093/occmed/52.2.75; PAHOR AL, 1981, J LARYNGOL OTOL, V95, P399, DOI 10.1017/S0022215100090873; PAIGE SR, 1990, BIOL PSYCHIAT, V27, P419, DOI 10.1016/0006-3223(90)90552-D; Schulz T. Y., 2004, HEARING HLTH, V21, P18; Scott SG, 2005, FEDERAL PRACTITIONER, V22, P67; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tufts JB, 2009, J AM ACAD AUDIOL, V20, P539, DOI 10.3766/jaaa.20.9.3; *UN BIOST UT WORK, 2009, COD GUID; *US DEP ARM, 2006, PRED HEAR READ TEST; *US DEP ARM, 2006, CONC SOLD BATTL; *US DEP ARM, 2009, POSTD AUD; *US DEP DEF, 2008, POSTD HLTH ASS; *US DEP DEF, 2004, DOD HEAR CONS PROGR; *US DEP HHS, 2008, INT CLASS DIS 9 REV; *USA, 2009, FREQ ASK QUEST TRAUM; Verbeek JH, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006396.pub2; WALBY AP, 1986, J LARYNGOL OTOL, V100, P411, DOI 10.1017/S0022215100099412; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071; YETISER S, 1993, MIL MED, V158, P803	53	40	42	0	8	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1059-0889	1558-9137		AM J AUDIOL	Am. J. Audiol.	JUN	2011	20	1					33	41		10.1044/1059-0889(2011/10-0033)			9	Audiology & Speech-Language Pathology; Otorhinolaryngology	Audiology & Speech-Language Pathology; Otorhinolaryngology	782IP	WOS:000292002000005	21474555				2021-06-18	
J	Mar, J; Arrospide, A; Begiristain, JM; Larranaga, I; Elosegui, E; Oliva-Moreno, J				Mar, Javier; Arrospide, Arantzazu; Maria Begiristain, Jose; Larranaga, Isabel; Elosegui, Elena; Oliva-Moreno, Juan			The impact of acquired brain damage in terms of epidemiology, economics and loss in quality of life	BMC NEUROLOGY			English	Article							MENTAL-ILLNESS; CANARY-ISLANDS; INFORMAL CARE; HEALTH SURVEY; COSTS; STROKE; BURDEN; DISEASE; INJURY; SF-36	Background: Patients with acquired brain damage (ABD) have suffered a brain lesion that interrupts vital development in the physical, psychological and social spheres. Stroke and traumatic brain injury (TBI) are the two main causes. The objectives of this study were to estimate the incidence and prevalence of ABD in the population of the Basque Country and Navarre in 2008, to calculate the associated cost of the care required and finally to assess the loss in health-related quality of life. Methods: On the one hand, a cross-sectional survey was carried out, in order to estimate the incidence of ABD and its consequences in terms of costs and loss in quality of life from the evolution of a sample of patients diagnosed with stroke and TBI. On the other hand, a discrete event simulation model was built that enabled the prevalence of ABD to be estimated. Finally, a calculation was made of the formal and informal costs of ABD in the population of the Basque Country and Navarre (2,750,000 people). Results: The cross-sectional study showed that the incidences of ABD caused by stroke and TBI were 61.8 and 12.5 cases per 100,000 per year respectively, while the overall prevalence was 657 cases per 100,000 people. The SF-36 physical and mental component scores were 28.9 and 44.5 respectively. The total economic burden was calculated to be 382.14 million euro per year, distributed between 215.27 and 166.87 of formal and informal burden respectively. The average cost per individual was 21,040 (sic) per year. Conclusions: The main conclusion of this study is that ABD has a high impact in both epidemiological and economic terms as well as loss in quality of life. The overall prevalence obtained is equivalent to 0.7% of the total population. The substantial economic burden is distributed nearly evenly between formal and informal costs. Specifically, it was found that the physical dimensions of quality of life are the most severely affected. The prevalence-based approach showed adequate to estimate the population impact of ABD and the resources needed to compensate the disability.	[Mar, Javier] Alto Deba Hosp, Clin Management Serv, Arrasate Mondragon, Spain; [Mar, Javier; Arrospide, Arantzazu] Alto Deba Hosp, Hlth Res Unit W Gipuzkoa, Arrasate Mondragon, Spain; [Maria Begiristain, Jose; Larranaga, Isabel; Elosegui, Elena] Govt Basque Country, Gipuzkoa Reg Off Hlth, Donostia San Sebastian, Spain; [Oliva-Moreno, Juan] Univ Castilla La Mancha, Toledo Fac Legal & Social Sci, Toledo, Spain	Mar, J (corresponding author), Alto Deba Hosp, Clin Management Serv, Arrasate Mondragon, Spain.	javier.marmedina@osakidetza.net	Oliva, Juan/A-1299-2011	Oliva, Juan/0000-0002-8997-0307; Arrospide, Arantzazu/0000-0003-3537-6588; Larranaga, Isabel/0000-0003-2231-6447			ALONSO J, 1995, MED CLIN-BARCELONA, V104, P771; Arrazola A, 2005, REV NEUROLOGIA, V40, P326, DOI 10.33588/rn.4006.2004435; Badia X, 1999, MED CLIN-BARCELONA, V112, P79; Cohen J, 1977, STAT POWER ANAL BEHA, P8; Comas M, 2008, VALUE HEALTH, V11, P1203, DOI 10.1111/j.1524-4733.2008.00322.x; Comas-Herrera A, 2006, AGEING SOC, V26, P285, DOI 10.1017/S0144686X05004289; *CONS INT SIST NAC, 2009, ESTR ICT SIST NAC SA; *DEP SAN, ENC SAL PAIS VASC ES; DRUMMOND MF, 1997, METHODS EC EVALUATIO, V2, P52; Evers SMAA, 2004, STROKE, V35, P1209, DOI 10.1161/01.STR.0000125860.48180.48; Hankey GJ, 2005, STROKE TREATMENT PRE, P1, DOI [10.1017/CBO9780511526893, DOI 10.1017/CBO9780511526893]; Hervas A, 2007, GAC SANIT, V21, P444, DOI 10.1157/13112236; Hewer RL, 2003, HDB NEUROLOGICAL REH, P5; Hilden J, 2008, MED DECIS MAKING, V28, P460, DOI 10.1177/0272989X08321903; Hu TW, 2006, J MENT HEALTH POLICY, V9, P3; *I NAC EST, ENC ESP ENC TRIM COS; Kayani NA, 2009, PUBLIC HEALTH REP, V124, P551, DOI 10.1177/003335490912400412; Kelton W. D., 2007, SIMULATION ARENA; Knapp M, 2007, DEMENTIA UK FULL REP; LAWTON MP, 1969, GERONTOLOGIST, V9, P9, DOI 10.1093/geront/9.1.9; Lopez-Bastida J, 2008, MOVEMENT DISORD, V23, P212, DOI 10.1002/mds.21798; Lopez-Bastida J, 2006, NEUROLOGY, V67, P2186, DOI 10.1212/01.wnl.0000249311.80411.93; Lopez-Bastida J, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-55; MAHONEY F I, 1965, Md State Med J, V14, P61; Mar J, 2008, NEUROEPIDEMIOLOGY, V31, P57, DOI 10.1159/000140096; Mar J, 2010, VALUE HEALTH, V13, P69, DOI 10.1111/j.1524-4733.2009.00655.x; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Oliva-Moreno J, 2009, EUR J HEALTH ECON, V10, P361, DOI 10.1007/s10198-008-0135-0; Ommaya AK, 1996, J TRAUMA, V40, P211, DOI 10.1097/00005373-199602000-00007; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P29; Rothwell PM, 2001, LANCET, V357, P1612, DOI 10.1016/S0140-6736(00)04730-9; van den Berg B, 2006, SOC SCI MED, V62, P835, DOI 10.1016/j.socscimed.2005.06.046; van den Berg Bernard, 2004, Eur J Health Econ, V5, P36, DOI 10.1007/s10198-003-0189-y; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Youman P, 2003, PHARMACOECONOMICS, V21, P43, DOI 10.2165/00019053-200321001-00005	37	40	43	0	17	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1471-2377		BMC NEUROL	BMC Neurol.	APR 18	2011	11								46	10.1186/1471-2377-11-46			11	Clinical Neurology	Neurosciences & Neurology	766VD	WOS:000290813700001	21496356	DOAJ Gold, Green Published			2021-06-18	
J	Ljungqvist, J; Nilsson, D; Ljungberg, M; Sorbo, A; Esbjornsson, E; Eriksson-Ritzen, C; Skoglund, T				Ljungqvist, Johan; Nilsson, Daniel; Ljungberg, Maria; Sorbo, Ann; Esbjornsson, Eva; Eriksson-Ritzen, Catherine; Skoglund, Thomas			Longitudinal study of the diffusion tensor imaging properties of the corpus callosum in acute and chronic diffuse axonal injury	BRAIN INJURY			English	Article						Traumatic brain injury; axonal injury; MRI; outcome measures	TRAUMATIC BRAIN-INJURY; WHITE-MATTER; NEUROPSYCHOMETRIC TESTS; WALLERIAN DEGENERATION; CORTICOSPINAL TRACT; WATER DIFFUSION; SERIAL CHANGES; ACUTE MILD; FOLLOW-UP; ANISOTROPY	Background: Magnetic resonance diffusion tensor imaging (MR-DTI) is used increasingly to detect diffuse axonal injury (DAI) after traumatic brain injury (TBI). Primary objective: The primary objective was to investigate the changes in the diffusion properties of the corpus callosum in the acute phase and 6 months after TBI and to examine the correlation between DTI parameters and clinical outcome. Research design: Longitudinal prospective study. Methods and procedures: MR-DTI was performed in eight patients with suspected DAI within 11 days and at 6 months post-injury. Six controls were also examined. Fractional anisotropy (FA), trace and parallel and perpendicular diffusivity of the corpus callosum were analysed. The main outcome was the extended Glasgow Outcome Scale score, assessed at 6 months. Main outcomes and results: A significant reduction in FA in the corpus callosum was seen in the acute phase in patients compared with the healthy controls. There was no significant change in the parallel or perpendicular eigenvalues or trace. At 6 months, a significant reduction in FA and a significant increase in trace and perpendicular eigenvalues were noticed compared with controls. Conclusions: The diffusion properties of the corpus callosum correlated with clinical outcome in this longitudinal investigation.	[Ljungqvist, Johan; Nilsson, Daniel; Eriksson-Ritzen, Catherine; Skoglund, Thomas] Sahlgrens Univ Hosp, Dept Neurosurg, SE-41345 Gothenburg, Sweden; [Ljungberg, Maria] Sahlgrens Univ Hosp, MR Ctr, SE-41345 Gothenburg, Sweden; [Sorbo, Ann] Uddevalla Cent Hosp, Dept Neurol & Rehabil, Uddevalla, Sweden; [Esbjornsson, Eva] Sahlgrens Univ Hosp, Dept Clin Neurosci & Rehabil, SE-41345 Gothenburg, Sweden	Ljungqvist, J (corresponding author), Sahlgrens Univ Hosp, Dept Neurosurg, SE-41345 Gothenburg, Sweden.	johan.ljungqvist@vgregion.se	Nilsson, Daniel/AAF-3868-2020	Sorbo, Ann/0000-0002-6744-6942	Health and Medical Care Committee of Vastra Gotaland; Foundation for Medical Imaging	This work was supported by grants from the Health and Medical Care Committee of Vastra Gotaland and the Foundation for Medical Imaging in Memory of Erik Lysholm.	ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beaulieu C, 1996, MAGNET RESON MED, V36, P627, DOI 10.1002/mrm.1910360419; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Concha L, 2006, NEUROIMAGE, V32, P1090, DOI 10.1016/j.neuroimage.2006.04.187; Gass A, 2001, J NEUROL SCI, V186, pS15, DOI 10.1016/S0022-510X(01)00487-7; Good P., 2000, PERMUTATION TESTS PR; Gulani V, 2001, MAGNET RESON MED, V45, P191, DOI 10.1002/1522-2594(200102)45:2<191::AID-MRM1025>3.0.CO;2-9; Han BS, 2007, NEUROREHABILITATION, V22, P151; Hou DJ, 2007, J NEUROTRAUM, V24, P1558, DOI 10.1089/neu.2007.0339; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Kanaan RA, 2006, PSYCHIAT RES-NEUROIM, V146, P73, DOI 10.1016/j.pscychresns.2005.11.002; Kerschensteiner M, 2005, NAT MED, V11, P572, DOI 10.1038/nm1229; Kim M, 2006, NEUROIMAGE, V32, P1243, DOI 10.1016/j.neuroimage.2006.06.006; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2010, J HEAD TRAUMA REHAB, V25, P31, DOI 10.1097/HTR.0b013e3181bff331; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Oouchi H, 2007, AM J NEURORADIOL, V28, P1102, DOI 10.3174/ajnr.A0488; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Prigatano GP, 1993, BNI Q, V9, P2; Prigatano GP, 1995, ADM SCORING MANUAL B; Prigatano GP, 2008, BNI SCREEN HIGHER CE; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Skoglund TS, 2008, ACTA RADIOL, V49, P98, DOI 10.1080/02841850701561372; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; Takahashi S, 2002, NEUROSCI LETT, V332, P45, DOI 10.1016/S0304-3940(02)00914-X; Wakamoto H, 2006, J CHILD NEUROL, V21, P566, DOI 10.1177/08830738060210071401; Werring DJ, 2000, BRAIN, V123, P1667, DOI 10.1093/brain/123.8.1667; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P139, DOI 10.1097/00004728-199801000-00027; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	43	40	41	0	2	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	2011	25	4					370	378		10.3109/02699052.2011.558038			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	739RL	WOS:000288735600006	21355671				2021-06-18	
J	Arbisi, PA; Polusny, MA; Erbes, CR; Thuras, P; Reddy, MK				Arbisi, Paul A.; Polusny, Melissa A.; Erbes, Christopher R.; Thuras, Paul; Reddy, Madhavi K.			The Minnesota Multiphasic Personality Inventory-2 Restructured Form in National Guard Soldiers Screening Positive for Posttraumatic Stress Disorder and Mild Traumatic Brain Injury	PSYCHOLOGICAL ASSESSMENT			English	Article						Minnesota Multiphasic Personality Inventory-2 Restructured Form; blast injury; mild traumatic brain injury; posttraumatic stress disorder; assessment	INTERNALIZING SUBTYPES; INCREMENTAL VALIDITY; ANXIETY DISORDERS; SYMPTOM INVENTORY; MMPI-2 SCORES; RC SCALES; PTSD; IRAQ; TBI; VETERANS	The Minnesota Multiphasic Personality Inventory-2 Restructured Form (MMPI-2 RF) was administered to 251 National Guard soldiers who had recently returned from deployment to Iraq. Soldiers were also administered questionnaires to identify posttraumatic stress disorder (PTSD) and mild traumatic brain injury (mTBI). On the basis of responses to the screening instruments, the National Guard soldiers who produced a valid MMPI-2 RF were classified into four groups: 21 soldiers who screened positive for PTSD only, 33 soldiers who screened positive for mTBI only, 9 soldiers who screened positive for both conditions, and 166 soldiers who did not screen positive for either condition. Results showed that the MMPI-2 RF was able to differentiate across the groups with the MMPI-2 RF specific problem scale Anxiety adding incrementally to MMPI-2 Restructured Clinical scales in predicting PTSD. Both MMPI-2 RC 1 (Somatic Complaints) and MMPI-2 RF head pain complaints predicted mTBI screen but did not add incrementally to each other. Of note, all of the MMPI-2 RF validity scales associated with overreporting, including Symptom Validity-Revised (FBS-r), were not significantly elevated in the mTBI group. These findings support the use of the MMPI-2 RF in assessing PTSD in non-treatment-seeking veterans. This further suggests that a positive screen for mTBI alone is not associated with significant emotional disturbance.	[Arbisi, Paul A.] Minneapolis Vet Affairs Med Ctr, Psychol Serv 116B, Minneapolis, MN 55417 USA; [Arbisi, Paul A.; Polusny, Melissa A.; Erbes, Christopher R.; Thuras, Paul; Reddy, Madhavi K.] Univ Minnesota, Dept Psychiat, Sch Med, St Paul, MN USA; [Arbisi, Paul A.] Univ Minnesota, Dept Psychol, St Paul, MN USA	Arbisi, PA (corresponding author), Minneapolis Vet Affairs Med Ctr, Psychol Serv 116B, 1 Vet Dr, Minneapolis, MN 55417 USA.	paul.arbisi@va.gov	Polusny, Melissa/X-8158-2019; Polusny, Melissa Anderson/N-8112-2014	Polusny, Melissa/0000-0002-4932-305X; Polusny, Melissa Anderson/0000-0002-4932-305X			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Arbisi P. A., 2006, PSYCHOL SERV, V3, P249, DOI DOI 10.1037/1541-1559.3.4.249; ARBISI PA, 2004, 112 ANN CONV AM PSYC; Arbisi PA, 2008, J PERS ASSESS, V90, P122, DOI 10.1080/00223890701845146; Arbisi PA, 2010, ASSESSMENT, V17, P406, DOI 10.1177/1073191110376163; Archer RP, 2006, J PERS ASSESS, V87, P84, DOI 10.1207/s15327752jpa8701_07; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Ben-Porath Y.S., 2008, MMPI 2 RF MINNESOTA; BIGOS SJ, 1991, SPINE, V16, P1, DOI 10.1097/00007632-199101000-00001; Broomhall LGJ, 2009, J NERV MENT DIS, V197, P178, DOI 10.1097/NMD.0b013e318199fe7f; Camara WJ, 2000, PROF PSYCHOL-RES PR, V31, P141, DOI 10.1037/0735-7028.31.2.141; CLARK LA, 1996, SCHEDULE NONADAPTIVE; Dohrenwend BP, 2006, SCIENCE, V313, P979, DOI 10.1126/science.1128944; Efendov AA, 2008, PSYCHOL ASSESSMENT, V20, P317, DOI 10.1037/a0013870; Gamez W, 2007, J ANXIETY DISORD, V21, P526, DOI 10.1016/j.janxdis.2006.08.003; Greenblatt RL, 1999, J CLIN PSYCHOL, V55, P217, DOI 10.1002/(SICI)1097-4679(199902)55:2<217::AID-JCLP9>3.0.CO;2-I; Herman D., 1993, ANN CONV INT SOC TRA; Hessen E, 2009, BRAIN INJURY, V23, P234, DOI 10.1080/02699050902748349; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Jones E, 2006, PHILOS T R SOC B, V361, P533, DOI 10.1098/rstb.2006.1814; KEANE TM, 1984, J CONSULT CLIN PSYCH, V52, P888, DOI 10.1037/0022-006X.52.5.888; Kehle SM, 2010, J TRAUMA STRESS, V23, P33, DOI 10.1002/jts.20480; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lyons JA, 1999, J TRAUMA STRESS, V12, P175, DOI 10.1023/A:1024710803042; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; McCrea M, 2008, CLIN NEUROPSYCHOL, V22, P10, DOI 10.1080/13854040701760981; Miller MW, 2004, J ABNORM PSYCHOL, V113, P636, DOI 10.1037/0021-843X.113.4.636; Miller MW, 2003, CLIN PSYCHOL-SCI PR, V10, P373, DOI 10.1093/clipsy/bpg040; Miller MW, 2003, PSYCHOL ASSESSMENT, V15, P205, DOI 10.1037/1040-3590.15.2.205; PENK WE, 2005, MMPI 2 PRACTITIONERS, P121; Polusny MA, 2011, PSYCHOL MED, V41, P687, DOI 10.1017/S0033291710002047; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Schell T.L., 2008, INVISIBLE WOUNDS WAR, DOI [10.7249/mg720-1ccf.12, DOI 10.7249/MG720-1CCF.12]; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Tellegen A., 2003, MMPI 2 RESTRUCTURED; Tellegen A., 2008, MMPI 2 RF MINNESOTA; Terhakopian A, 2008, J TRAUMA STRESS, V21, P290, DOI 10.1002/jts.20341; Thomas ML, 2009, CLIN NEUROPSYCHOL, V23, P1067, DOI 10.1080/13854040902795000; Watson D, 2005, J ABNORM PSYCHOL, V114, P522, DOI 10.1037/0021-843X.114.4.522; Wolf EJ, 2008, PSYCHOL ASSESSMENT, V20, P327, DOI 10.1037/a0012948; Wygant DB, 2007, ARCH CLIN NEUROPSYCH, V22, P489, DOI 10.1016/j.acn.2007.01.027; Youngjohn JR, 1997, PSYCHOL ASSESSMENT, V9, P177, DOI 10.1037/1040-3590.9.3.177	47	40	40	0	7	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1040-3590			PSYCHOL ASSESSMENT	Psychol. Assess.	MAR	2011	23	1					203	214		10.1037/a0021339			12	Psychology, Clinical	Psychology	729KT	WOS:000287949200017	21381845				2021-06-18	
J	West, LK; Curtis, KL; Greve, KW; Bianchini, KJ				West, Laura K.; Curtis, Kelly L.; Greve, Kevin W.; Bianchini, Kevin J.			Memory in traumatic brain injury: The effects of injury severity and effort on the Wechsler Memory Scale-III	JOURNAL OF NEUROPSYCHOLOGY			English	Article							MALINGERED NEUROCOGNITIVE DYSFUNCTION; DIGIT RECOGNITION TEST; MILD HEAD TRAUMA; CLASSIFICATION ACCURACY; HEALTHY-ADULTS; TEST-SCORES; WMS-III; INDICATORS; EXAGGERATION; METAANALYSIS	This study examined the effects of traumatic brain injury (TBI) on Wechsler Memory Scale-III (WMS-III) performance. Since poor effort potentially contaminates results, effort was explicitly assessed and controlled using two well-validated cognitive validity indicators, the Portland Digit Recognition Test (PDRT) and Reliable Digit Span (RDS). Participants were 44 mild TBI patients with good effort, 48 mild TBI patients with poor effort, and 40 moderate-severe TBI patients with good effort. A dose-response relationship between injury severity and WMS-III performance was demonstrated. Effect size calculations showed that the good effort mild TBI patients did not differ from normal (average Cohen's d = 0.07) while moderate-severe TBI had a moderate effect on VVMS-III scores (average Cohen's d = -0.52). Consistent with previous literature, the moderate-severe TBI group scored the lowest on WMS-III Visual indices. Effort had a larger effect than injury severity on WMS-III scores (average Cohen's d = -1.27). Clinical implications of these findings are discussed.	[West, Laura K.; Curtis, Kelly L.; Greve, Kevin W.; Bianchini, Kevin J.] Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; [Curtis, Kelly L.; Greve, Kevin W.; Bianchini, Kevin J.] Jefferson Neurobehav Grp, Metairie, LA USA	Greve, KW (corresponding author), Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 2009, ARCH CLIN NEUROPSYCH, V24, P31, DOI 10.1093/arclin/acn001; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 2003, J CLIN EXP NEUROPSYC, V25, P420, DOI 10.1076/jcen.25.3.420.13806; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; BINDER LM, 1993, PORTLAND DIGIT RECOG; Brooks BL, 2008, J INT NEUROPSYCH SOC, V14, P463, DOI 10.1017/S1355617708080521; Butcher J. N., 1989, MMPI 2 MANUAL ADM SC; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd, pXXI; Curtis KL, 2006, ARCH CLIN NEUROPSYCH, V21, P544; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Doane BM, 2005, CLIN NEUROPSYCHOL, V19, P99, DOI 10.1080/13854040490524100; Fisher D C, 2000, Appl Neuropsychol, V7, P126, DOI 10.1207/S15324826AN0703_2; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Green P, 2003, BRAIN INJURY, V17, P479, DOI 10.1080/0269905031000070242; Green P, 2001, NEUROREHABILITATION, V16, P237; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 1996, WORD MEMORY TEST USE; Green Paul, 2007, Phys Med Rehabil Clin N Am, V18, P43, DOI 10.1016/j.pmr.2006.11.002; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P816, DOI 10.1080/13854040500346610; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Hawkins KA, 1998, CLIN NEUROPSYCHOL, V12, P535, DOI 10.1076/clin.12.4.535.7236; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Lange RT, 2006, J CLIN EXP NEUROPSYC, V28, P294, DOI 10.1080/13803390490918156; Langeluddecke PM, 2005, J CLIN EXP NEUROPSYC, V27, P576, DOI 10.1080/13803390490918372; Langeluddecke PM, 2003, ARCH CLIN NEUROPSYCH, V18, P181, DOI 10.1016/S0887-6177(01)00195-0; LARRABEE GJ, 2007, EVALUATION MALINGERI, P334; Lipsey MW, 2000, PRACTICAL METAANALYS, V49; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Ord JS, 2008, CLIN NEUROPSYCHOL, V22, P689, DOI 10.1080/13854040701425437; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; REY A, 1964, EXAMIN CLIN PSYCHOL; Reznek L, 2005, BRAIN INJURY, V19, P539, DOI 10.1080/02699050400005242; Rohling ML, 2010, CLIN NEUROPSYCHOL, V24, P119, DOI 10.1080/13854040903307243; SCHERER M, 2005, FORENSIC NEUROPSYCHO, P237; Schretlen DJ, 2008, J INT NEUROPSYCH SOC, V14, P436, DOI 10.1017/S1355617708080387; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Stevens A, 2008, PSYCHIAT RES, V157, P191, DOI 10.1016/j.psychres.2007.01.003; Suhr J. A., 2007, ASSESSMENT MALINGERE; Tombaugh TN, 1996, TEST MEMORY MALINGER; Warrington EK., 1984, RECOGNITION MEMORY T; Wechsler D., 2002, WAIS 3 WMS 3 TECHNIC; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; WECHSLER DA, 1997, WAIS 3 WMS 2 TECHNIC; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]	54	40	40	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1748-6645	1748-6653		J NEUROPSYCHOL	J. Neuropsychol.	MAR	2011	5		1				114	125		10.1348/174866410X521434			12	Psychology; Psychology, Experimental	Psychology	739NK	WOS:000288724600006	21366889				2021-06-18	
J	Shin, SS; Bray, ER; Zhang, CQ; Dixon, CE				Shin, Samuel S.; Bray, Eric R.; Zhang, Cathy Q.; Dixon, C. Edward			Traumatic brain injury reduces striatal tyrosine hydroxylase activity and potassium-evoked dopamine release in rats	BRAIN RESEARCH			English	Article						Dopamine; Traumatic; Microdialysis; Tyrosine; Hydroxylase; Phosphorylation	CONTROLLED CORTICAL IMPACT; WATER MAZE PERFORMANCE; CATECHOLAMINE SYNTHESIS; AMANTADINE; PHOSPHORYLATION; RECOVERY; AMPHETAMINE; MICRODIALYSIS; ACETYLCHOLINE; DYSFUNCTION	There is increasing evidence that traumatic brain injury (TBI) induces hypofunction of the striatal dopaminergic system, the mechanisms of which are unknown. In this study, we analyzed the activity of striatal tyrosine hydroxylase (TH) in rats at 1 day, 1 week, and 4 weeks after TBI using the controlled cortical impact model. There were no changes in the level of TH phosphorylated at serine 40 site (pser40TH) at 1 day or 4 weeks. At 1 week, injured animals showed decreased pser40TH to 73.9 +/- 7.3% (p <= 0.05) of sham injured rats. The in vivo TH activity assay showed no significant difference between injured and sham rats at 1 day. However, there was a decreased activity in injured rats to 62.1 +/- 8.2% (p <= 0.05) and 68.8 +/- 6.2% (p <= 0.05) of sham injured rats at 1 and 4 weeks, respectively. Also, the activity of protein kinase A, which activates TH, decreased at 1 week (injured: 87.8 +/- 2.8%, sham: 100.0 +/- 4.2%, p <= 0.05). To study the release activity of dopamine after injury, potassium (80 mM)-evoked dopamine release was measured by microdialysis in awake, freely moving rats. Dialysates were collected and analyzed by high-performance liquid chromatography. There were no significant differences in dopamine release at 1 day and 4 weeks between sham and injured groups. At 1 week, there was a significant decrease (injured: 0.067 +/- 0.015 mu M, sham: 0.127 +/- 0.027 mu M, p <= 0.05). These results suggest that TBI-induced dopamine neurotransmission deficits are, at least in part, attributable to deficits in TH activity. (C) 2010 Published by Elsevier B.V.	[Dixon, C. Edward] Univ Pittsburgh, Dept Neurosurg, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA	Dixon, CE (corresponding author), Univ Pittsburgh, Dept Neurosurg, Brain Trauma Res Ctr, 3434 5th Ave,Suite 201, Pittsburgh, PA 15260 USA.	dixonec@upmc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1F30NS067731-01, 5R01NS060672-02]; Pittsburgh Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060672, F30NS067731] Funding Source: NIH RePORTER	We would like to thank Ruth Perez and Teresa Hastings for insightful comments and suggestions. This project is supported by NIH grant 1F30NS067731-01, NIH grant 5R01NS060672-02, and the Copeland Fund of the Pittsburgh Foundation.	Agut J, 2000, ANN NY ACAD SCI, V920, P332; ANDEN NE, 1964, LIFE SCI, V3, P523, DOI 10.1016/0024-3205(64)90161-4; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; BAK IJ, 1972, J NEURAL TRANSM, V33, P45, DOI 10.1007/BF01244727; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Barbay S, 2009, NEUROREHABILITATION, V25, P5, DOI 10.3233/NRE-2009-0495; Dixon CE, 1997, BRAIN RES, V749, P127, DOI 10.1016/S0006-8993(96)01310-8; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dunkley PR, 2004, J NEUROCHEM, V91, P1025, DOI 10.1111/j.1471-4159.2004.02797.x; FAIRBROTHER IS, 1990, J NEUROCHEM, V54, P1844, DOI 10.1111/j.1471-4159.1990.tb04881.x; FEENEY DM, 1981, P W PHARMACOL SOC, V24, P15; GIANUTSOS G, 1985, EUR J PHARMACOL, V110, P357, DOI 10.1016/0014-2999(85)90564-3; Harada K, 1996, J NEUROCHEM, V67, P629; HOKFELT T, 1977, MED BIOL, V55, P21; Hornstein A, 1996, BRAIN INJURY, V10, P145, DOI 10.1080/026990596124647; Jedynak JP, 2002, J NEUROCHEM, V82, P382, DOI 10.1046/j.1471-4159.2002.00982.x; KLINE AE, 1994, PHARMACOL BIOCHEM BE, V48, P773, DOI 10.1016/0091-3057(94)90345-X; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kobori N, 2006, J NEUROTRAUM, V23, P1094, DOI 10.1089/neu.2006.23.1094; Koeda T, 1998, BRAIN DEV-JPN, V20, P124, DOI 10.1016/S0387-7604(98)00004-7; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; Lal S, 1988, Brain Inj, V2, P225, DOI 10.3109/02699058809150946; Lindgren N, 2000, J NEUROCHEM, V74, P2470, DOI 10.1046/j.1471-4159.2000.0742470.x; Massucci JL, 2004, NEUROSCI LETT, V372, P127, DOI 10.1016/j.neulet.2004.09.026; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Napolitano E, 2005, MED SCI MONITOR, V11, pRA212; Phillips JP, 2003, J HEAD TRAUMA REHAB, V18, P342, DOI 10.1097/00001199-200307000-00005; Sawyer E, 2008, ANN PHARMACOTHER, V42, P247, DOI 10.1345/aph.1K284; Shui HA, 1998, NEUROSCI LETT, V257, P1, DOI 10.1016/S0304-3940(98)00801-5; Stanford JA, 2000, INT J DEV NEUROSCI, V18, P411, DOI 10.1016/S0736-5748(00)00009-5; Urbanavicius J, 2007, J NEUROCHEM, V102, P723, DOI 10.1111/j.1471-4159.2007.04560.x; Von Voigtlander P F, 1971, Science, V174, P408, DOI 10.1126/science.174.4007.408; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wang L, 2005, J MOL NEUROSCI, V27, P137, DOI 10.1385/JMN:27:1:137; Wanger AK, 2009, J NEUROCHEM, V110, P801, DOI 10.1111/j.1471-4159.2009.06155.x; WAYMIRE JC, 1988, J BIOL CHEM, V263, P12439; Wilson MS, 2005, J NEUROSCI RES, V80, P85, DOI 10.1002/jnr.20419; Yan HQ, 2007, BRAIN RES, V1134, P171, DOI 10.1016/j.brainres.2006.11.087	39	40	40	0	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 19	2011	1369						208	215		10.1016/j.brainres.2010.10.096			8	Neurosciences	Neurosciences & Neurology	714GE	WOS:000286794700022	21047500	Green Accepted			2021-06-18	
J	Dougherty, AL; MacGregor, AJ; Han, PP; Heltemes, KJ; Galarneau, MR				Dougherty, Amber L.; MacGregor, Andrew J.; Han, Peggy P.; Heltemes, Kevin J.; Galarneau, Michael R.			Visual dysfunction following blast-related traumatic brain injury from the battlefield	BRAIN INJURY			English	Article						TBI; ocular and visual disorder; combat injury; military	SEVERITY SCORE; NECK INJURIES; IMPAIRMENT; SOLDIERS; REGISTRY; HEAD; CARE; IRAQ	Primary objective: To assess the occurrence of ocular and visual disorders following blast-related traumatic brain injury (TBI) in Operation Iraqi Freedom. Research design: Retrospective cohort study. Methods and procedures: A total of 2254 US service members with blast-related combat injuries were identified for analysis from the Expeditionary Medical Encounter Database. Medical record information near the point of injury was used to assess factors associated with the diagnosis of ocular/visual disorder within 12 months after injury, including severity of TBI. Main outcomes and results: Of 2254 service members, 837 (37.1%) suffered a blast-related TBI and 1417 (62.9%) had other blast-related injuries. Two-hundred and one (8.9%) were diagnosed with an ocular or visual disorder within 12 months after blast injury. Compared with service members with other injuries, odds of ocular/visual disorder were significantly higher for service members with moderate TBI (odds ratio (OR) = 1.58, 95% confidence interval (CI) = 1.02-2.45) and serious to critical TBI (OR = 14.26, 95% CI = 7.00-29.07). Conclusions: Blast-related TBI is strongly associated with visual dysfunction within 1 year after injury and the odds of disorder appears to increase with severity of brain injury. Comprehensive vision examinations following TBI in theatre may be necessary.	[Dougherty, Amber L.; MacGregor, Andrew J.; Han, Peggy P.; Heltemes, Kevin J.; Galarneau, Michael R.] USN, Hlth Res Ctr, Dept Med Modeling Simulat & Mission Support, San Diego, CA 92106 USA	Dougherty, AL (corresponding author), USN, Hlth Res Ctr, Dept Med Modeling Simulat & Mission Support, 140 Sylvester Rd, San Diego, CA 92106 USA.	amber.dougherty@med.navy.mil		MacGregor, Andrew/0000-0003-1020-7390	US Navy Bureau of Medicine and Surgery, Washington, DC [60808]	Declaration of interest: This work was supported by the US Navy Bureau of Medicine and Surgery, Washington, DC, under Work Unit No. 60808. The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Navy, Department of Defense, or the US Government.	BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Champion HR, 2003, J TRAUMA, V54, pS13, DOI 10.1097/01.TA.0000057151.02906.27; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; Department of Defence Task Force on Mental Health, 2007, ACH VIS REP DEP DEF; Dougherty AL, 2009, INJURY, V40, P772, DOI 10.1016/j.injury.2009.02.014; Galarneau MR, 2006, MIL MED, V171, P691, DOI 10.7205/MILMED.171.8.691; Gennarelli TA, 2005, ABBREVIATED INJURY S; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; IOM, 2009, GULF WAR HLTH, V7; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; McKenna K, 2006, BRAIN INJURY, V20, P507, DOI 10.1080/02699050600664368; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Poggi G, 2000, BRAIN INJURY, V14, P833, DOI 10.1080/026990500421930; REISTER FA, 1973, BATTLE CASUALTIES ME, pCH3; REISTER FA, 1975, MED STAT WORLD WAR 2, P21; SCHLAGETER K, 1993, BRAIN INJURY, V7, P439, DOI 10.3109/02699059309029687; Suchoff Irwin B, 2008, Optometry, V79, P259, DOI 10.1016/j.optm.2007.10.012; Thurman DJ., 1995, GUIDELINES SURVEILLA; Wade AL, 2007, J TRAUMA, V63, P836, DOI 10.1097/01.ta.0000251453.54663.66; Xydakis MS, 2005, OTOLARYNG HEAD NECK, V133, P497, DOI 10.1016/j.otohns.2005.07.003	23	40	41	0	7	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2011	25	1					8	13		10.3109/02699052.2010.536195			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	731JI	WOS:000288101700002	21117919				2021-06-18	
J	Graham, MR; Myers, T; Evans, P; Davies, B; Cooper, SM; Bhattacharya, K; Grace, FM; Baker, JS				Graham, M. R.; Myers, T.; Evans, P.; Davies, B.; Cooper, S. M.; Bhattacharya, K.; Grace, F. M.; Baker, J. S.			DIRECT HITS TO THE HEAD DURING AMATEUR BOXING IS ASSOCIATED WITH A RISE IN SERUM BIOMARKERS FOR BRAIN INJURY	INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY			English	Article						boxing; brain injury; S100-B; Neuron-specific enolase (NSE)	NEURON-SPECIFIC ENOLASE; BIOCHEMICAL MARKERS; S-100B PROTEIN; DAMAGE; CONCUSSION; SPORTS; TISSUE; PLASMA; CELLS	Boxing exposes participants to the physiological response to high intensity exercise and also to direct body and brain trauma. Amateur boxing is increasing and females have also been included in the Olympics. The aim of this study is to assess the stress response and possible brain injury incurred during a match by measuring serum biomarkers associated with stress and cellular brain injury before and after combat. Sixteen male amateur boxers were studied retrospectively. The study population was divided into two groups: (a) a group that received predominantly punches to the head (PTH) and (b) a group that received predominantly punches to the body (PTB). Blood samples were taken before and five minutes after each contest. They were analysed for S-100B, neuron-specific enolase (NSE), creatine kinase (CK) and cortisol. The PTH group received direct contacts to the head (not blocked, parried or avoided) and to the body (n=8, age: 17.6 +/- 5.3, years; height: 1.68 +/- 0.13, meters; mass: 65.4 +/- 20.3, kg). The PTB group received punches to the body including blocked and parried punches, but received no direct punches to the head, (n=8, mean +/- SD, age: 19.1 +/- 3.2 years; height: 1.70 +/- 0.75, meters; mass: 68.5 +/- 15 kg). Significant increases (P<0.05) were observed between pre- and post-combat serum concentrations in serum concentrations in PTH of S-100B (0.35 +/- 0.61 vs. 0.54 +/- 0.73, mu g.L(-1)) NSE (19.7 +/- 14 vs.31.1 +/- 26.6, ng.ml(-1)) and cortisol (373 +/- 202 vs. 756 +/- 93, nmol.L(-1)). Significant increases (P<0.05) of creatine kinase were recorded in both groups. This study demonstrates significant elevations in neurochemical biomarkers in boxers who received direct blows to the head. However, further work is required to quantify this volumetric brain damage and long term clinical sequelae.	[Graham, M. R.] Glyndwr Univ, Wrexham LL11 2AW, Wales; [Graham, M. R.; Myers, T.] Newman Univ Coll, Birmingham, W Midlands, England; [Evans, P.] Royal Gwent Hosp, Newport NPT 2VB, Gwent, Wales; [Davies, B.] Univ Glamorgan, Pontypridd CF37 1DL, M Glam, Wales; [Cooper, S. M.] Univ Wales Inst, Cardiff, S Glam, Wales; [Bhattacharya, K.] Royal Infirm Edinburgh NHS Trust, Dept Cardiovasc Surg, Edinburgh, Midlothian, Scotland; [Grace, F. M.; Baker, J. S.] Univ W Scotland, Sch Sci, Hamilton, Scotland	Graham, MR (corresponding author), Glyndwr Univ, Wrexham LL11 2AW, Wales.	drgraham.ac.uk@live.co.uk	Grace, Fergal/N-7324-2016	Grace, Fergal/0000-0002-3144-5999			*AIBA, 2003, RUL INT COMP TOURN; *AM BOX ASS ENGL L, 2009, GUID WOM GIRLS START, P1; Dietrich MO, 2003, CAN J APPL PHYSIOL, V28, P710, DOI 10.1139/h03-054; DILL DB, 1974, J APPL PHYSIOL, V37, P247; Duval F, 2006, PSYCHONEUROENDOCRINO, V31, P876, DOI 10.1016/j.psyneuen.2006.04.003; Foy K, 2009, BRIT J HOSP MED, V70, P440, DOI 10.12968/hmed.2009.70.8.43536; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Halley Michelle K, 2004, Pediatr Crit Care Med, V5, P230, DOI 10.1097/01.PCC.0000123543.40224.73; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Jordan BD, 2009, CLIN SPORT MED, V28, P561, DOI 10.1016/j.csm.2009.07.005; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; KING LR, 1970, ANN SURG, V172, P975, DOI 10.1097/00000658-197012000-00008; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; Kosakevitch-Ricbourg L, 2006, Rev Stomatol Chir Maxillofac, V107, P211, DOI 10.1016/S0035-1768(06)77043-7; Loosemore Mike, 2008, Br J Sports Med, V42, P564; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; SCHMECHEL D, 1978, NATURE, V276, P834, DOI 10.1038/276834a0; Shave R, 2010, J AM COLL CARDIOL, V56, P169, DOI 10.1016/j.jacc.2010.03.037; Shinozaki K, 2009, RESUSCITATION, V80, P870, DOI 10.1016/j.resuscitation.2009.05.005; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Springborg Jtiaocnob Bertram, 2009, Ugeskr Laeger, V171, P978; Stalnacke BM, 2006, BRIT J SPORT MED, V40, P313, DOI 10.1136/bjsm.2005.021584; Thiruppathy SP, 2004, ACTA NEUROCHIR, V146, P1075, DOI 10.1007/s00701-004-0335-z; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; White C, 2007, BRIT MED J, V335, P469, DOI 10.1136/bmj.39328.486100.DB; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Zazryn TR, 2009, PHYS MED REH CLIN N, V20, P227, DOI 10.1016/j.pmr.2008.10.004; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277	29	40	40	1	23	BIOLIFE SAS	SILVA MARINA (TE)	VIA S STEFANO 39 BIS, 64029 SILVA MARINA (TE), ITALY	0394-6320			INT J IMMUNOPATH PH	Int. J. Immunopathol. Pharmacol.	JAN-MAR	2011	24	1					119	125		10.1177/039463201102400114			7	Immunology; Pathology; Pharmacology & Pharmacy	Immunology; Pathology; Pharmacology & Pharmacy	761BQ	WOS:000290370100014	21496394	Bronze			2021-06-18	
J	Guilfoyle, MR; Seeley, HM; Corteen, E; Harkin, C; Richards, H; Menon, DK; Hutchinson, PJ				Guilfoyle, Mathew R.; Seeley, Helen M.; Corteen, Elizabeth; Harkin, Christine; Richards, Hugh; Menon, David K.; Hutchinson, Peter J.			Assessing Quality of Life after Traumatic Brain Injury: Examination of the Short Form 36 Health Survey	JOURNAL OF NEUROTRAUMA			English	Article						outcome assessment; quality of life; SF-36; traumatic brain injury; validation	AMYOTROPHIC-LATERAL-SCLEROSIS; SURVEY SF-36; SURVEY QUESTIONNAIRE; MULTIPLE-SCLEROSIS; SCALING ASSUMPTIONS; OUTCOME MEASURE; RELIABILITY; VALIDITY; STROKE; TESTS	Measuring health-related quality of life (HRQoL) has an important role in the comprehensive assessment of patient recovery following traumatic brain injury (TBI). We examined the validity of domain and summary scores derived from the Medical Outcomes Survey 36-Item Short Form Health Questionnaire (SF-36) as outcome measures for TBI in a prospective study of 514 patients with a range of functional impairment (Glasgow Outcome Scale-Extended [GOSE] scores 3-8). Item scaling criteria for the eight domain scores were tested and principal component analysis was used to examine if physical and mental component summary scores were valid. External validity was assessed by comparison with GOSE. Mean response, variance, and distribution of the items were largely equivalent, and item-own scale correlations corrected for overlap all exceeded the threshold for equivalent contribution to domain scores and convergent validity. All corrected item-own scale correlations were greater than the respective item-other correlations indicating no scaling failures, and reliability coefficients for the domain scores were high and substantially more than the inter-domain correlations. Overall, criteria for summing items into domain scores were satisfied, and there was a significant relationship of increasing score with more favorable GOSE class across all domains. However, there were floor and/or ceiling effects in four of the eight domains, and principal component analysis of the domain scores demonstrated only a unidimensional structure to the data. We conclude that individual SF-36 domain scores are valid measures of HRQoL in TBI patients, but that the physical and mental component summaries should be interpreted with caution.	[Guilfoyle, Mathew R.; Seeley, Helen M.; Corteen, Elizabeth; Harkin, Christine; Richards, Hugh; Hutchinson, Peter J.] Addenbrookes Hosp, Acad Dept Neurosurg, Cambridge CB2 2QQ, England; [Menon, David K.] Addenbrookes Hosp, Univ Dept Anaesthesia, Cambridge CB2 2QQ, England	Guilfoyle, MR (corresponding author), Addenbrookes Hosp, Acad Dept Neurosurg, Box 167,Hills Rd, Cambridge CB2 2QQ, England.	mathew.guilfoyle@addenbrookes.nhs.uk		Corteen, Elizabeth/0000-0002-3069-9655	Philip King Royal College of Surgeons of England; Academy of Medical Sciences Health Foundation; U.K. Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC); National Institute of Health Research Specialist Biomedical Research Centre; Evelyn Trust; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G0601025, G9439390, G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	M.R.G. is supported by the Philip King Royal College of Surgeons of England Research Fellowship. P.J.H. is supported by an Academy of Medical Sciences Health Foundation Senior Surgical Scientist Fellowship. D.K.M. is supported by the U.K. Medical Research Council, the National Institute of Health Research Specialist Biomedical Research Centre, and the Evelyn Trust.	Baron R, 2006, SPINE, V31, P2575, DOI 10.1097/01.brs.0000240694.83621.52; Bowling A, 1999, J PUBLIC HEALTH MED, V21, P255, DOI 10.1093/pubmed/21.3.255; Brazier J, 1998, J CLIN EPIDEMIOL, V51, P1115, DOI 10.1016/S0895-4356(98)00103-6; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Dallmeijer AJ, 2007, J REHABIL MED, V39, P163, DOI 10.2340/16501977-0024; Edwards SGM, 2002, BRIT MED J, V324, P1493, DOI 10.1136/bmj.324.7352.1493; Fayers P.M., 2005, ASSESSING QUALITY LI; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; GARRATT AM, 1993, BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; Hagell P, 2008, J NEUROL, V255, P246, DOI 10.1007/s00415-008-0708-y; Higginson IJ, 2001, BRIT MED J, V322, P1297, DOI 10.1136/bmj.322.7297.1297; Hobart J, 2001, J NEUROL NEUROSUR PS, V71, P363, DOI 10.1136/jnnp.71.3.363; Hobart JC, 2002, STROKE, V33, P1348, DOI 10.1161/01.STR.0000015030.59594.B3; Jacoby A, 1999, QUAL LIFE RES, V8, P351, DOI 10.1023/A:1008902728574; Jenkinson C, 2002, J NEUROL, V249, P178, DOI 10.1007/PL00007861; Jenkinson C, 1996, UK SF 36 ANAL INTERP; Likert R., 1932, ARCH PSYCHOL, V22, P1; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; Nunnally J. C., 1994, PSYCHOMETRIC THEORY; O'Mahony PG, 1998, AGE AGEING, V27, P19, DOI 10.1093/ageing/27.1.19; Rothwell PM, 1997, BMJ-BRIT MED J, V314, P1580, DOI 10.1136/bmj.314.7094.1580; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE., 1993, SF 36 HLTH SURVEY MA; Ware JE., 1994, SF 36 PHYS MENTAL HL, V1st; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204	26	40	40	0	3	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2010	27	12					2173	2181		10.1089/neu.2010.1353			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	691PN	WOS:000285093400007	20939701				2021-06-18	
J	Herrera, JJ; Sundberg, LM; Zentilin, L; Giacca, M; Narayana, PA				Herrera, Juan J.; Sundberg, Laura M.; Zentilin, Lorena; Giacca, Mauro; Narayana, Ponnada A.			Sustained Expression of Vascular Endothelial Growth Factor and Angiopoietin-1 Improves Blood-Spinal Cord Barrier Integrity and Functional Recovery after Spinal Cord Injury	JOURNAL OF NEUROTRAUMA			English	Article						angiopoietin-1; magnetic resonance imaging; traumatic spinal cord injury; vascular endothelial growth factor; viral mediated transfection	RECOMBINANT ADENOASSOCIATED VIRUS; GENE-TRANSFER; BRAIN-BARRIER; TIE2 RECEPTOR; RATING-SCALE; VEGF; PERMEABILITY; ANGIOGENESIS; ISCHEMIA; NEOVASCULARIZATION	Spinal cord injury (SCI) results in immediate disruption of the spinal vascular network, triggering an ischemic environment and initiating secondary degeneration. Promoting angiogenesis and vascular stability through the induction of vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang-1), respectively, provides a possible therapeutic approach in treating SCI. We examined whether supplementing the injured environment with these two factors, which are significantly reduced following injury, has an effect on lesion size and functional outcome. Sustained delivery of both VEGF(165) and Ang-1 was realized using viral vectors based on the adeno-associated virus (AAV), which were injected directly into the lesion epicenter immediately after injury. Our results indicate that the combined treatment with VEGF and Ang-1 resulted in both reduced hyperintense lesion volume and vascular stabilization, as determined by magnetic resonance imaging (MRI). Western blot analysis indicated that the viral vector expression was maintained into the chronic phase of injury, and that the use of the AAV vectors did not exacerbate infiltration of microglia into the lesion epicenter. The combined treatment with AAV-VEGF and AAV-Ang-1 improved locomotor recovery in the chronic phase of injury. These results indicate that combining angiogenesis with vascular stabilization may have potential therapeutic applications following SCI.	[Herrera, Juan J.; Sundberg, Laura M.; Narayana, Ponnada A.] Univ Texas Hlth Sci Ctr Houston, Dept Diagnost & Intervent Imaging, Houston, TX 77030 USA; [Zentilin, Lorena; Giacca, Mauro] Int Ctr Genet Engn & Biotechnol, Mol Med Lab, I-34012 Trieste, Italy; [Giacca, Mauro] Univ Trieste, Fac Med, Dept Biomed, Trieste, Italy	Herrera, JJ (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Diagnost & Intervent Imaging, 6431 Fannin,MSE R102F, Houston, TX 77030 USA.	Juan.Herrera@uth.tmc.edu	Giacca, Mauro/J-9287-2016	Giacca, Mauro/0000-0003-2927-7225	NIH/National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS045624]; NIH/National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10 RR17205-01]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR017205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045624] Funding Source: NIH RePORTER	This work is supported by NIH/National Institute of Neurological Disorders and Stroke (NINDS) grant NS045624 to P.A.N. The 7-T MRI scanner was funded by the NIH/National Center for Research Resources under the High End Instrumentation Program (grant S10 RR17205-01 to P.A.N.). The NIH is not responsible for the contents of this manuscript.	Arsic N, 2003, MOL THER, V7, P450, DOI 10.1016/S1525-0016(03)00034-0; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Benest AV, 2006, MICROCIRCULATION, V13, P423, DOI 10.1080/10739680600775940; Bilgen M, 2001, MAGNET RESON MED, V45, P614, DOI 10.1002/mrm.1083; Bitto A, 2008, CLIN SCI, V114, P707, DOI 10.1042/CS20070250; BRESNAHAN JC, 1987, EXP NEUROL, V95, P548, DOI 10.1016/0014-4886(87)90299-8; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Chen F, 2007, EUR J PHARMACOL, V568, P222, DOI 10.1016/j.ejphar.2007.04.047; Chen F, 2007, ACTA PHARMACOL SIN, V28, P493, DOI 10.1111/j.1745-7254.2007.00527.x; Cohen DM, 2009, NMR BIOMED, V22, P332, DOI 10.1002/nbm.1343; Croll SD, 2001, MOL NEUROBIOL, V23, P121, DOI 10.1385/MN:23:2-3:121; Croll SD, 2004, EXP NEUROL, V187, P388, DOI 10.1016/j.expneurol.2004.02.010; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Deo AA, 2006, J NEUROSCI RES, V83, P801, DOI 10.1002/jnr.20783; FEHLINGS MG, 1989, ELECTROEN CLIN NEURO, V74, P241, DOI 10.1016/0168-5597(89)90055-5; Fenyes DA, 1998, MAGN RESON IMAGING, V16, P1249, DOI 10.1016/S0730-725X(98)00093-9; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Findley CM, 2007, ARTERIOSCL THROM VAS, V27, P2619, DOI 10.1161/ATVBAHA.107.150482; Fisher KJ, 1997, NAT MED, V3, P306, DOI 10.1038/nm0397-306; Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481; Han S, 2010, BRAIN, V133, P1026, DOI 10.1093/brain/awq034; Harrigan MR, 2003, ACTA NEUROCHIR, V145, P49, DOI 10.1007/s00701-002-1035-1; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; Hayashi T, 1998, J CEREBR BLOOD F MET, V18, P887, DOI 10.1097/00004647-199808000-00009; Hermens WTJMC, 1998, PROG NEUROBIOL, V55, P399, DOI 10.1016/S0301-0082(98)00007-0; Herrera JJ, 2009, J NEUROTRAUM, V26, P995, DOI [10.1089/neu.2008.0779, 10.1089/neu.2008-0779]; HOLTZ A, 1990, NEUROSURGERY, V26, P952, DOI 10.1227/00006123-199006000-00005; Hori S, 2004, J NEUROCHEM, V89, P503, DOI 10.1111/j.1471-4159.2004.02343.x; Kaya D, 2005, J CEREBR BLOOD F MET, V25, P1111, DOI 10.1038/sj.jcbfm.9600109; Lang-Lazdunski L, 2000, STROKE, V31, P208, DOI 10.1161/01.STR.31.1.208; Lee SW, 2009, INT J MOL MED, V23, P279, DOI 10.3892/ijmm_00000128; Lin TN, 2000, J CEREBR BLOOD F MET, V20, P387, DOI 10.1097/00004647-200002000-00021; Liu Y, 2010, NEUROBIOL DIS, V37, P384, DOI 10.1016/j.nbd.2009.10.018; MEANS ED, 1983, J NEUROPATH EXP NEUR, V42, P707, DOI 10.1097/00005072-198311000-00009; Mills CD, 2001, J NEUROTRAUM, V18, P1091, DOI 10.1089/08977150152693773; Neufeld G, 1999, FASEB J, V13, P9; Nourhaghighi N, 2003, LAB INVEST, V83, P1211, DOI 10.1097/01.LAB.0000082383.40635.FE; Patel CB, 2009, J NEUROTRAUM, V26, P1005, DOI 10.1089/neu.2008.0860; Peng XM, 2006, ANN NEUROL, V59, P843, DOI 10.1002/ana.20855; Popovich PG, 2003, TRENDS PHARMACOL SCI, V24, P13, DOI 10.1016/S0165-6147(02)00006-8; Proescholdt MA, 2002, J NEUROPATH EXP NEUR, V61, P914, DOI 10.1093/jnen/61.10.914; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; Scheff SW, 2002, J NEUROTRAUM, V19, P1251, DOI 10.1089/08977150260338038; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Snyder RO, 1997, HUM GENE THER, V8, P1891, DOI 10.1089/hum.1997.8.16-1891; Suidan GL, 2010, J IMMUNOL, V184, P1031, DOI 10.4049/jimmunol.0902773; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Svensson EC, 1999, CIRCULATION, V99, P201, DOI 10.1161/01.CIR.99.2.201; Taoka Y, 2000, J NEUROTRAUM, V17, P219, DOI 10.1089/neu.2000.17.219; TATOR CH, 1991, NEUROCHIRURGIE, V37, P291; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Tofts PS, 1999, J MAGN RESON IMAGING, V10, P223, DOI 10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S; WEIRICH SD, 1990, SPINE, V15, P630, DOI 10.1097/00007632-199007000-00004; Widenfalk J, 2003, NEUROSCIENCE, V120, P951, DOI 10.1016/S0306-4522(03)00399-3; Zacchigna S, 2007, HUM GENE THER, V18, P515, DOI 10.1089/hum.2006.162; Zhang ZG, 2002, J CEREBR BLOOD F MET, V22, P379, DOI 10.1097/00004647-200204000-00002; Zhang ZG, 2002, NEUROSCIENCE, V113, P683, DOI 10.1016/S0306-4522(02)00175-6; Zhao YJ, 2010, NEUROL RES, V32, P748, DOI 10.1179/016164109X12445616596562	62	40	44	2	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2010	27	11					2067	2076		10.1089/neu.2010.1403			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	682BZ	WOS:000284375500013	20799882	Green Published			2021-06-18	
J	Brazinova, A; Mauritz, W; Leitgeb, J; Wilbacher, I; Majdan, M; Janciak, I; Rusnak, M				Brazinova, Alexandra; Mauritz, Walter; Leitgeb, Johannes; Wilbacher, Ingrid; Majdan, Marek; Janciak, Ivan; Rusnak, Martin			Outcomes of Patients with Severe Traumatic Brain Injury Who Have Glasgow Coma Scale Scores of 3 or 4 and Are Over 65 Years Old	JOURNAL OF NEUROTRAUMA			English	Article						Glasgow Coma Scale; Glasgow Outcome Scale; old age; traumatic brain injury	SEVERE HEAD-INJURY; PROSPECTIVE MULTICENTER; DATA-BANK; MANAGEMENT; IMPACT; EPIDEMIOLOGY; MORTALITY; DESIGN; GENDER; TRIAL	The goal of this study was to investigate the outcomes of patients with traumatic brain injury (TBI) who had Glasgow Coma Scale (GCS) scores of 3 or 4, and were aged 66 years or older. Between January 2001 and December 2005, 13 European centers enrolled patients with severe brain trauma. Data sets of all patients who had a GCS score of 3 or 4 and were 66 years of age or older were analyzed. Outcomes were classified according to the Glasgow Outcome Scale (GOS) 12 months post-trauma as "favorable" (GOS score of 4 or 5), or "unfavorable" (GOS score of 1-3); relevant data for patients of the two groups were compared. Variables were analyzed by univariate analyses (chi-square, Wilcoxon-Mann-Whitney, and Fisher's exact tests), and a p value of <0.05 was considered significant. We analyzed 100 patients identified from the database as having GCS scores of 3 or 4 and age over 65 years. Factors having significant effects on outcomes were worse results of the Injury Severity Score (ISS), Trauma and Injury Severity Score (TRISS), and Abbreviated Injury Scale (AIS) for the head. Closed or partially closed basal cisterns and/or midline shift >15mm were also associated with unfavorable outcomes, as was subarachnoid hemorrhage (SAH). Patients with GCS scores of 3 or 4 who are older than 65 years have a poor, but not hopeless, prognosis. Confirmed factors predicting poor prognosis for this group of patients were closed basal cisterns and midline shift >15mm on the first CT scan. Factors possibly related to favorable outcomes were female gender, lower trauma severity, open or partially open basal cisterns, and no midline shift on the first CT scan.	[Brazinova, Alexandra; Janciak, Ivan] Int Neurotrauma Res Org, Data & IT, A-1080 Vienna, Austria; [Brazinova, Alexandra; Majdan, Marek] Trnava Univ, Dept Publ Hlth, Fac Hlth & Social Serv, Trnava, Slovakia; [Mauritz, Walter] Trauma Hosp Lorenz Boehler, Vienna, Austria; [Leitgeb, Johannes] Med Univ Vienna, Dept Trauma Surg, Vienna, Austria; [Wilbacher, Ingrid] Social Insurance Co, Vienna, Austria	Brazinova, A (corresponding author), Int Neurotrauma Res Org, Data & IT, Molkergasse 4-3, A-1080 Vienna, Austria.	abrazinova@igeh.org	Majdan, Marek/K-5017-2012; Rusnak, Martin/K-9349-2016; Brazinova, Alexandra/C-4265-2016	Majdan, Marek/0000-0001-8037-742X; Rusnak, Martin/0000-0003-3321-1042; Brazinova, Alexandra/0000-0003-0625-256X; Mauritz, Walter/0000-0001-9043-3712	European UnionEuropean Commission [ICA2-CT-2002-100]; Austrian Worker's Compensation Board (AUVA) [FK 33/2003]; "Jubilaumsfonds" of the Austrian National Bank [8987]; INRO	The data used for this study were collected for a project funded by a European Union grant (Project "Research-Treat-TBI"; 6th Framework Program: INCO-DEV: International Cooperation with Developing Countries 1998-2002; contract number : ICA2-CT-2002-100), and for another project funded by the Austrian Worker's Compensation Board (AUVA; contract number FK 33/2003), and by the "Jubilaumsfonds" of the Austrian National Bank (project number 8987). INRO was supported by an annual grant from Mrs. Ala Auersperg-Isham and Mr. Ralph Isham, and by donations from various other sources.	Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; DE LA PLATA CAM, 2008, ARCH PHYS MED REHAB, V89, P896; Dessau Ram Benny, 2008, Ugeskr Laeger, V170, P328; Gerber Linda M, 2009, J Trauma Manag Outcomes, V3, P9, DOI 10.1186/1752-2897-3-9; Guha A, 2004, POSTGRAD MED J, V80, P650, DOI 10.1136/pgmj.2004.019570; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; Leitgeb J, 2007, WIEN KLIN WOCHENSCHR, V119, P56, DOI 10.1007/s00508-006-0764-1; Lemcke J, 2010, ACTA NEUROCHIR SUPPL, V106, P231, DOI 10.1007/978-3-211-98811-4_43; Lenartova L, 2007, WIEN KLIN WOCHENSCHR, V119, P35, DOI 10.1007/s00508-006-0762-3; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Mauritz W, 2008, EUR J PUBLIC HEALTH, V18, P575, DOI 10.1093/eurpub/ckn079; Mauritz W, 2007, WIEN KLIN WOCHENSCHR, V119, P46, DOI 10.1007/s00508-006-0763-2; Mauritz W, 2009, EUR J EMERG MED, V16, P153, DOI 10.1097/MEJ.0b013e32832a0864; Nijboer JMM, 2010, INJURY, V41, P52, DOI 10.1016/j.injury.2009.05.030; Ottochian M, 2009, AM J SURG, V197, P155, DOI 10.1016/j.amjsurg.2008.09.008; Pascrell B Jr, 2001, N J Med, V98, P47; Rosso A, 2007, WIEN KLIN WOCHENSCHR, V119, P29, DOI 10.1007/s00508-006-0761-4; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P64, DOI 10.1007/s00508-006-0765-0; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P23, DOI 10.1007/s00508-006-0760-5; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Slieker FJA, 2008, NEUROSURGERY, V62, P1321, DOI 10.1227/01.neu.0000333304.79931.4d; STEIN SC, 2009, J NEUROSURG     0911; Tokutomi T, 2008, J NEUROTRAUM, V25, P1407, DOI 10.1089/neu.2008.0577; Utomo WK, 2009, INJURY, V40, P973, DOI 10.1016/j.injury.2009.05.034	34	40	41	0	15	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2010	27	9					1549	1555		10.1089/neu.2010.1315			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	649TJ	WOS:000281796500001	20597653				2021-06-18	
J	Williams, G; Galna, B; Morris, ME; Olver, J				Williams, Gavin; Galna, Brook; Morris, Meg E.; Olver, John			Spatiotemporal Deficits and Kinematic Classification of Gait Following a Traumatic Brain Injury: A Systematic Review	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						assessment; brain trauma; gait disorders/ataxia; rehabilitation; review literature	BOTULINUM-TOXIN-A; INTRATHECAL BACLOFEN; SPASTIC HEMIPLEGIA; HEAD-INJURY; RECOVERY; REHABILITATION; PATTERNS; BALANCE; PERFORMANCE; AMBULATION	Objective: To identify the key biomechanical gait abnormalities resulting from traumatic brain injury (TBI) and determine whether the abnormalities support a system for the classification of gait disorders. Design: Systematic review with data from quantitative studies synthesized in a narrative format. Participants: Adults with TBI. Outcome measures: Spatiotemporal, kinematic, and kinetic parameters of classification systems. Results: The search identified 38 articles that reported on various methods for gait assessment in TBI. Three-dimensional gait analysis (3DGA) was used in 15 studies, primarily to quantify spatiotemporal parameters. Results revealed that people with a TBI walked more slowly with shorter steps and greater mediolateral sway following TBI. Stepping over obstacles, walking with eyes closed, or performing dual tasks accentuated gait deficits. Only one small study reported kinematic data for the major lower limb joints in 8 well recovered patients. One further study used 3DGA to classify the gait patterns of people with TBI but this classification was based on methods developed for stroke and cerebral palsy. No studies attempted to develop a classification system on the basis of the gait disorders of people with TBI. Conclusion: Although the studies were generally of high quality, little is known about the nature of gait disorders following TBI. Classification based on systematic description of gait disorders following TBI has not been attempted.	[Williams, Gavin] Epworth Med Fdn, Physiotherapy Dept, Richmond, Vic 3121, Australia; [Williams, Gavin; Galna, Brook; Morris, Meg E.] Univ Melbourne, Sch Physiotherapy, Ctr Hlth Exercise & Sports Med, Melbourne, Vic, Australia	Williams, G (corresponding author), Epworth Med Fdn, Physiotherapy Dept, 89 Bridge Rd, Richmond, Vic 3121, Australia.	gavin.williams@epworth.org.au		Olver, John/0000-0001-7069-1191; Morris, Meg/0000-0002-0114-4175; Williams, Gavin/0000-0003-2758-7473; Galna, Brook/0000-0002-5890-1894			Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; BOGATAJ U, 1989, PHYS THER, V69, P319, DOI 10.1093/ptj/69.5.319; BROWN DSO, 1992, ARCH PHYS MED REHAB, V73, P758; Brown TH, 2005, J HEAD TRAUMA REHAB, V20, P402, DOI 10.1097/00001199-200509000-00002; Cantin JF, 2007, BRAIN INJURY, V21, P327, DOI 10.1080/02699050701209972; Chang FM, 2006, J PEDIATR ORTHOPED, V26, P612, DOI 10.1097/01.bpo.0000229970.55694.5c; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Chua KSG, 2000, ARCH PHYS MED REHAB, V81, P1432, DOI 10.1053/apmr.2000.9395; Cioni M, 2006, AM J PHYS MED REHAB, V85, P600, DOI 10.1097/01.phm.0000223216.50068.bc; de Morais MC, 2008, GAIT POSTURE, V28, P316, DOI 10.1016/j.gaitpost.2008.01.013; Duong TT, 2004, ARCH PHYS MED REHAB, V85, P1291, DOI 10.1016/j.apmr.2003.11.032; Esquenazi A, 2004, J HEAD TRAUMA REHAB, V19, P109, DOI 10.1097/00001199-200403000-00004; Fahn S., 1987, RECENT DEV PARKINSON, P153; Fock J, 2004, BRAIN INJURY, V18, P57, DOI 10.1080/0269905031000149498; Freivogel S, 2008, BRAIN INJURY, V22, P625, DOI 10.1080/02699050801941771; Gradenigo B, 2002, EURA MEDICOPHYS, V38, P215; Haggard P, 2000, J NEUROL NEUROSUR PS, V69, P479, DOI 10.1136/jnnp.69.4.479; Horn TS, 2005, ARCH PHYS MED REHAB, V86, P1127, DOI 10.1016/j.apmr.2004.11.013; Hosalkar H, 2008, CLIN ORTHOP RELAT R, V466, P2500, DOI 10.1007/s11999-008-0395-0; Katz DI, 2004, ARCH PHYS MED REHAB, V85, P865, DOI 10.1016/j.apmr.2003.11.020; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; Kerrigan DC, 1996, ARCH PHYS MED REHAB, V77, P645, DOI 10.1016/S0003-9993(96)90002-7; KNUTSSON E, 1979, BRAIN, V102, P405, DOI 10.1093/brain/102.2.405; Law M., 2002, EVIDENCE BASED REHAB; LEE EH, 1992, ARCH PHYS MED REHAB, V73, P642; Lee LW, 1997, AM J PHYS MED REHAB, V76, P502, DOI 10.1097/00002060-199711000-00013; Macdonald GM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub2; MALEZIC M, 1992, J REHABIL RES DEV, V29, P41, DOI 10.1682/JRRD.1992.10.0041; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Medley A, 2006, BRAIN INJURY, V20, P1403, DOI 10.1080/02699050601082057; Molteni F, 1995, EUR J NEUROL, V2, P61; Mossberg KA, 2008, PHYS THER, V88, P77, DOI 10.2522/ptj.20070022; Mulroy S, 2003, GAIT POSTURE, V18, P114, DOI 10.1016/S0966-6362(02)00165-0; NAJENSON T, 1975, SCAND J REHABIL MED, V7, P101; Niechwiej-Szwedo E, 2007, GAIT POSTURE, V25, P70, DOI 10.1016/j.gaitpost.2006.01.002; Ochi F, 1999, J HEAD TRAUMA REHAB, V14, P105, DOI 10.1097/00001199-199904000-00002; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Perry J, 1999, J HEAD TRAUMA REHAB, V14, P116, DOI 10.1097/00001199-199904000-00003; Pohl M, 2006, CLIN REHABIL, V20, P324, DOI 10.1191/0269215506cr951oa; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; Remy-Neris O, 2003, ARCH PHYS MED REHAB, V84, P643, DOI 10.1016/S0003-9993(02)04906-7; Richardson D, 2000, J NEUROL NEUROSUR PS, V69, P499, DOI 10.1136/jnnp.69.4.499; Rinne MB, 2006, J REHABIL MED, V38, P224, DOI 10.1080/16501970600582989; Rodda JM, 2004, J BONE JOINT SURG BR, V86B, P251, DOI 10.1302/0301-620X.86B2.13878; Swaine BR, 1996, BRAIN INJURY, V10, P347, DOI 10.1080/026990596124368; SWEENEY JK, 1983, PHYS THER, V63, P2018, DOI 10.1093/ptj/63.12.2018; Thurman DJ, 1999, TRAUMATIC BRAIN INJU; Toro B, 2003, ARCH PHYS MED REHAB, V84, P1878, DOI 10.1016/S0003-9993(03)00482-9; Vallee M, 2006, ARCH PHYS MED REHAB, V87, P806, DOI 10.1016/j.apmr.2006.02.031; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Watson MJ, 2007, DISABIL REHABIL, V29, P231, DOI 10.1080/09638280600756299; Williams G, 2004, AM J PHYS MED REHAB, V83, P910, DOI 10.1097/01.PHM.0000146503.25221.1D; Wilson DJ, 2006, AM J PHYS MED REHAB, V85, P68, DOI 10.1097/01.phm.0000193507.28759.37; Wilson DJ, 2002, BRAIN INJURY, V16, P259, DOI 10.1080/02699050110103922; WINTERS TF, 1987, J BONE JOINT SURG AM, V69A, P437	57	40	41	0	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2010	25	5					366	374		10.1097/HTR.0b013e3181cd3600			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	649JR	WOS:000281765400010	20142759				2021-06-18	
J	Ariyannur, PS; Moffett, JR; Madhavarao, CN; Arun, P; Vishnu, N; Jacobowitz, DM; Hallows, WC; Denu, JM; Namboodiri, AMA				Ariyannur, Prasanth S.; Moffett, John R.; Madhavarao, Chikkathur N.; Arun, Peethambaran; Vishnu, Nisha; Jacobowitz, David M.; Hallows, William C.; Denu, John M.; Namboodiri, Aryan M. A.			Nuclear-Cytoplasmic Localization of Acetyl Coenzyme A Synthetase-1 in the Rat Brain	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						immunohistochemistry; acetate; histone acetylation; gene expression; lipid synthesis; traumatic brain injury; N-acetylaspartate; oligodendrocytes; neurons	L-ASPARTIC ACID; N-ACETYLASPARTATE SYNTHESIS; ATP-CITRATE LYASE; COA SYNTHETASE; HISTONE ACETYLATION; A SYNTHETASE; ACETATE; ENZYME; ASPARTOACYLASE; ACETYLCHOLINE	Acetyl coenzyme A synthetase-1 (AceCS1) catalyzes the synthesis of acetyl coenzyme A from acetate and coenzyme A and is thought to play diverse roles ranging from fatty acid synthesis to gene regulation. By using an affinity-purified antibody generated against an 18-mer peptide sequence of AceCS1 and a polyclonal antibody directed against recombinant AceCS1 protein, we examined the expression of AceCS1 in the rat brain. AceCS1 immunoreactivity in the adult rat brain was present predominantly in cell nuclei, with only light to moderate cytoplasmic staining in some neurons, axons, and oligodendrocytes. Some nonneuronal cell nuclei were very strongly immunoreactive, including those of some oligodendrocytes, whereas neuronal nuclei ranged from unstained to moderately stained. Both antibodies stained some neuronal cell bodies and axons, especially in the hindbrain. AceCS1 immunoreactivity was stronger and more widespread in the brains of 18-day-old rats than in adults, with increased expression in oligodendrocytes and neurons, including cortical pyramidal cells. Expression of AceCS1 was substantially up-regulated in neurons throughout the brain after controlled cortical impact injury. The strong AceCS1 expression observed in the nuclei of CNS cells during brain development and after injury is consistent with a role in nuclear histone acetylation and therefore the regulation of chromatin structure and gene expression. The cytoplasmic staining observed in some oligodendrocytes, especially during postnatal brain development, suggests an additional role in CNS lipid synthesis and myelination. Neuronal and axonal localization implicates AceCS1 in cytoplasmic acetylation reactions in some neurons. J. Comp. Neurol. 518:2952-2977, 2010. (C) 2010 Wiley-Liss, Inc.	[Ariyannur, Prasanth S.; Moffett, John R.; Madhavarao, Chikkathur N.; Arun, Peethambaran; Vishnu, Nisha; Jacobowitz, David M.; Namboodiri, Aryan M. A.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Mol & Cell Biol Program, Bethesda, MD 20814 USA; [Ariyannur, Prasanth S.; Moffett, John R.; Madhavarao, Chikkathur N.; Arun, Peethambaran; Vishnu, Nisha; Jacobowitz, David M.; Namboodiri, Aryan M. A.] Uniformed Serv Univ Hlth Sci, Neurosci Program, Bethesda, MD 20814 USA; [Hallows, William C.; Denu, John M.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biomol Chem, Madison, WI 53706 USA	Namboodiri, AMA (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Mol & Cell Biol Program, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	anamboodiri@usuhs.mil	Ariyannur, Prasanth S./C-1280-2008	Ariyannur, Prasanth S./0000-0003-0888-8094; Madhavarao, Chikkathur/0000-0003-3392-1159	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS39387]; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [ZO-1-MH-00388-31 LCS]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM065386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [Z01MH000388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039387] Funding Source: NIH RePORTER	Grant sponsor: National Institutes of Health; Grant number: RO1 NS39387 (to A.M.A.N.); Grant sponsor: National Institute of Mental Health; Grant number: ZO-1-MH-00388-31 LCS (to D.M.J.).	Ariyannur PS, 2008, BRAIN RES, V1227, P34, DOI 10.1016/j.brainres.2008.06.040; Arun P, 2010, J NEUROTRAUM, V27, P293, DOI 10.1089/neu.2009.0994; Arun P, 2009, NEUROCHEM INT, V55, P219, DOI 10.1016/j.neuint.2009.03.003; Baurle J, 1999, NEUROREPORT, V10, P3517; BENJAMIN AM, 1981, SCIENCE, V213, P1495, DOI 10.1126/science.7280667; Blum S, 1999, J MAGN RESON, V136, P219, DOI 10.1006/jmre.1998.1618; Boumezbeur F, 2010, J CEREBR BLOOD F MET, V30, P211, DOI 10.1038/jcbfm.2009.197; Carroll PT, 1997, BRAIN RES, V753, P47, DOI 10.1016/S0006-8993(96)01485-0; Falcon AA, 2010, MOL CELL BIOCHEM, V333, P99, DOI 10.1007/s11010-009-0209-z; Fujino T, 2001, J BIOL CHEM, V276, P11420, DOI 10.1074/jbc.M008782200; Goldberg R P, 1980, Adv Exp Med Biol, V132, P413; GOLDSTEIN FB, 1969, J BIOL CHEM, V244, P4257; Hallows WC, 2006, P NATL ACAD SCI USA, V103, P10230, DOI 10.1073/pnas.0604392103; Hershfield JR, 2006, FASEB J, V20, P2139, DOI 10.1096/fj.05-5358fje; IMESCH E, 1984, INT J BIOCHEM, V16, P875, DOI 10.1016/0020-711X(84)90146-0; Ingram-Smith Cheryl, 2007, Archaea, V2, P95; KAUL R, 1993, NAT GENET, V5, P118, DOI 10.1038/ng1093-118; KAUL R, 1991, J NEUROCHEM, V56, P129, DOI 10.1111/j.1471-4159.1991.tb02571.x; Kirmani BF, 2003, DEV BRAIN RES, V140, P105, DOI 10.1016/S0165-3806(02)00592-8; Kirmani BF, 2002, MOL BRAIN RES, V107, P176, DOI 10.1016/S0169-328X(02)00490-4; Klugmann M, 2003, NEUROREPORT, V14, P1837, DOI 10.1097/00001756-200310060-00016; KORNACKER MS, 1965, BIOCHEM J, V94, P209, DOI 10.1042/bj0940209; Kuang Y, 2007, J BIOCHEM BIOPH METH, V70, P649, DOI 10.1016/j.jbbm.2007.02.008; KWOK YN, 1982, J NEUROCHEM, V39, P16, DOI 10.1111/j.1471-4159.1982.tb04696.x; Loikkanen D, 2002, MECH DEVELOP, V115, P139, DOI 10.1016/S0925-4773(02)00097-7; Lu ZH, 2004, MOL BRAIN RES, V122, P71, DOI 10.1016/j.molbrainres.2003.12.002; Luong A, 2000, J BIOL CHEM, V275, P26458, DOI 10.1074/jbc.M004160200; Madhavarao CN, 2005, P NATL ACAD SCI USA, V102, P5221, DOI 10.1073/pnas.0409184102; Madhavarao CN, 2004, J COMP NEUROL, V472, P318, DOI 10.1002/cne.20080; Madhavarao CN, 2003, J NEUROCHEM, V86, P824, DOI 10.1046/j.1471-4159.2003.01905.x; MASSA PT, 1982, NEUROSCIENCE, V7, P523; MIYAKE M, 1981, J NEUROCHEM, V36, P804, DOI 10.1111/j.1471-4159.1981.tb01665.x; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; Namboodiri MAA, 2000, MOL BRAIN RES, V77, P285, DOI 10.1016/S0169-328X(00)00068-1; Papay R, 2006, J COMP NEUROL, V497, P209, DOI 10.1002/cne.20992; POW DV, 1993, J NEUROSCI METH, V48, P51, DOI 10.1016/S0165-0270(05)80007-X; Sakakibara I, 2009, CELL METAB, V9, P191, DOI 10.1016/j.cmet.2008.12.008; Schwer B, 2008, CELL METAB, V7, P104, DOI 10.1016/j.cmet.2007.11.006; SKUTCHES CL, 1979, J CLIN INVEST, V64, P708, DOI 10.1172/JCI109513; Sone H, 2002, AM J PHYSIOL-ENDOC M, V282, pE222, DOI 10.1152/ajpendo.00189.2001; Spange S, 2009, INT J BIOCHEM CELL B, V41, P185, DOI 10.1016/j.biocel.2008.08.027; Starai VJ, 2002, SCIENCE, V298, P2390, DOI 10.1126/science.1077650; Suematsu N, 2002, ACTA BIOCHIM POL, V49, P937; SZUTOWICZ A, 1980, J NEUROCHEM, V35, P775, DOI 10.1111/j.1471-4159.1980.tb07073.x; Takahashi H, 2006, MOL CELL, V23, P207, DOI 10.1016/j.molcel.2006.05.040; TALLAN HH, 1957, J BIOL CHEM, V224, P41; Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097; WOODNUTT G, 1978, BIOCHEM J, V175, P757, DOI 10.1042/bj1750757	48	40	40	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9967	1096-9861		J COMP NEUROL	J. Comp. Neurol.	AUG 1	2010	518	15					2952	2977		10.1002/cne.22373			26	Neurosciences; Zoology	Neurosciences & Neurology; Zoology	615EO	WOS:000279116500004	20533355	Green Accepted			2021-06-18	
J	Pardini, M; Krueger, F; Raymont, V; Grafman, J				Pardini, Matteo; Krueger, Frank; Raymont, Vanessa; Grafman, Jordan			Ventromedial prefrontal cortex modulates fatigue after penetrating traumatic brain injury	NEUROLOGY			English	Article							MULTIPLE-SCLEROSIS; MACAQUE MONKEYS; HEAD-INJURY; DISORDERS; DEPRESSION; REGIONS; SCALE; RAT; MRI	Background: Fatigue is a common and disabling symptom in neurologic disorders including traumatic penetrating brain injury (PBI). Despite fatigue's prevalence and impact on quality of life, its pathophysiology is not understood. Studies on effort perception in healthy subjects, animal behavioral paradigms, and recent evidence in different clinical populations suggest that ventromedial prefrontal cortex could play a significant role in fatigue pathophysiology in neurologic conditions. Methods: We enrolled 97 PBI patients and 37 control subjects drawn from the Vietnam Head Injury Study registry. Fatigue was assessed with a self-report questionnaire and a clinician-rated instrument; lesion location and volume were evaluated on CT scans. PBI patients were divided in 3 groups according to lesion location: a nonfrontal lesion group, a ventromedial prefrontal cortex lesion (vmPFC) group, and a dorso/lateral prefrontal cortex (d/lPFC) group. Fatigue scores were compared among the 3 PBI groups and the healthy controls. Results: Individuals with vmPFC lesions were significantly more fatigued than individuals with d/lPFC lesions, individuals with nonfrontal lesions, and healthy controls, while these 3 latter groups were equally fatigued. VmPFC volume was correlated with fatigue scores, showing that the larger the lesion volume, the higher the fatigue scores. Conclusions: We demonstrated that ventromedial prefrontal cortex lesion (vmPFC) plays a critical role in penetrating brain injury-related fatigue, providing a rationale to link fatigue to different vmPFC functions such as effort and reward perception. The identification of the anatomic and cognitive basis of fatigue can contribute to developing pathophysiology-based treatments for this disabling symptom. Neurology (R) 2010; 74: 749-754	[Pardini, Matteo; Krueger, Frank; Raymont, Vanessa; Grafman, Jordan] NINCDS, Cognit Neurosci Sect, NIH, Bethesda, MD 20892 USA; [Pardini, Matteo] Univ Genoa, Dept Neurosci Ophthalmol & Genet, Genoa, Italy; [Krueger, Frank] George Mason Univ, Krasnow Inst Adv Study, Fairfax, VA 22030 USA; [Raymont, Vanessa] Natl Naval Med Ctr, Vietnam Head Injury Study, Henry M Jackson Fdn, Bethesda, MD USA	Grafman, J (corresponding author), NINCDS, Cognit Neurosci Sect, NIH, Bldg 10,Room 7D43,MSC 1440, Bethesda, MD 20892 USA.	GrafmanJ@ninds.nih.gov	Pardini, Matteo/F-8414-2010	Pardini, Matteo/0000-0002-4740-1982; Grafman, Jordan H./0000-0001-8645-4457	NIH/National Institute of Neurological Disorders and Stroke/CNSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Henry M. Jackson Foundation [DAMD17-01-1-0675]; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS002792, ZIANS003024] Funding Source: NIH RePORTER	Supported by the Intramural Research Program of the NIH/National Institute of Neurological Disorders and Stroke/CNS and project grant from the United States Army Medical Research and Material Command and administered by the Henry M. Jackson Foundation (Vietnam Head Injury Study Phase III: A 30 Year Post-Injury Follow-Up Study: Grant number: DAMD17-01-1-0675).; Dr. Pardini, Dr. Krueger, and Dr. Raymont report no disclosures. Dr. Grafman serves as Coeditor of Cortex and receives research support from the Intramural Research Program NIH/NINDS and the Henry M. Jackson Foundation.	Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; BLOMSTRAND E, 1989, ACTA PHYSIOL SCAND, V136, P473, DOI 10.1111/j.1748-1716.1989.tb08689.x; BRUNO RL, 1994, ARCH PHYS MED REHAB, V75, P498; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Carmichael ST, 1996, J COMP NEUROL, V371, P179, DOI 10.1002/(SICI)1096-9861(19960722)371:2<179::AID-CNE1>3.0.CO;2-#; Chaudhuri A, 2000, J NEUROL SCI, V179, P34, DOI 10.1016/S0022-510X(00)00411-1; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; Cleare AJ, 2003, ENDOCR REV, V24, P236, DOI 10.1210/er.2002-0014; Cornuz J, 2006, CAN MED ASSOC J, V174, P765, DOI 10.1503/cmaj.1031153; DeLuca J, 2008, J NEUROL SCI, V270, P28, DOI 10.1016/j.jns.2008.01.018; First M., 1994, STRUCTURED CLIN INTE; Flachenecker P, 2002, MULT SCLER J, V8, P523, DOI 10.1191/1352458502ms839oa; Ketter TA, 1999, NEUROLOGY, V53, pS53; KIRCHNER WK, 1958, J EXP PSYCHOL, V55, P352, DOI 10.1037/h0043688; Koenigs M, 2008, NAT NEUROSCI, V11, P232, DOI 10.1038/nn2032; Koenigs M, 2008, J NEUROSCI, V28, P12341, DOI 10.1523/JNEUROSCI.2324-08.2008; Krueger F, 2009, TRENDS COGN SCI, V13, P103, DOI 10.1016/j.tics.2008.12.005; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Merkelbach S, 2001, MULT SCLER, V7, P320, DOI 10.1177/135245850100700508; Ongur D, 1998, J COMP NEUROL, V401, P480; Raymont V, 2008, BRAIN, V131, P543, DOI 10.1093/brain/awm300; Romani A, 2008, NEUROL SCI, V29, pS247, DOI 10.1007/s10072-008-0952-z; Rosen HJ, 2005, BRAIN, V128, P2612, DOI 10.1093/brain/awh628; Sepulcre J, 2009, MULT SCLER J, V15, P337, DOI 10.1177/1352458508098373; Solomon J, 2007, COMPUT METH PROG BIO, V86, P245, DOI 10.1016/j.cmpb.2007.02.006; Starkstein SE, 2008, J NEUROL NEUROSUR PS, V79, P1088, DOI 10.1136/jnnp.2007.136895; THORPE SJ, 1983, EXP BRAIN RES, V49, P93; Tranel D, 2005, BRAIN, V128, P2872, DOI 10.1093/brain/awh643; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Walton ME, 2002, J NEUROSCI, V22, P10996	31	40	40	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAR 2	2010	74	9					749	754		10.1212/WNL.0b013e3181d25b6b			6	Clinical Neurology	Neurosciences & Neurology	562GG	WOS:000275037300009	20194914	Green Published			2021-06-18	
J	Babikian, T; Prins, ML; Cai, Y; Barkhoudarian, G; Hartonian, I; Hovda, DA; Giza, CC				Babikian, Talin; Prins, Mayumi L.; Cai, Yan; Barkhoudarian, Garni; Hartonian, Ivet; Hovda, David A.; Giza, Christopher C.			Molecular and Physiological Responses to Juvenile Traumatic Brain Injury: Focus on Growth and Metabolism	DEVELOPMENTAL NEUROSCIENCE			English	Article						Growth; Metabolism; Traumatic brain injury, experimental; Traumatic brain injury, juvenile; Oxidative stress; Gene expression; Growth factor	CEREBRAL GLUCOSE-UTILIZATION; CONTROLLED CORTICAL IMPACT; ATTENUATES EDEMA FORMATION; KETONE-BODY UTILIZATION; RAT-BRAIN; DIETARY RESTRICTION; OXIDATIVE DAMAGE; GENE-EXPRESSION; KETOGENIC DIET; GLUTATHIONE-PEROXIDASE	Traumatic brain injury (TBI), one of the most frequent causes of neurologic and neurobehavioral morbidity in the pediatric population, can result in lifelong challenges not only for patients, but also for their families. Survivors of a brain injury experienced during childhood - when the brain is undergoing a period of rapid development - frequently experience unique challenges as the consequences of their injuries are overlaid on normal developmental changes. Experimental studies have significantly advanced our understanding of the mechanisms and underlying molecular underpinnings of the injury response and recovery process following a TBI in the developing brain. In this paper, normal and TBI-related alterations in growth, development and metabolism are comprehensively reviewed in the postweanling/juvenile age range in the rat (postnatal days 21-60). As part of this review, TBI-related changes in gene expression are presented, with a focus on the injury-induced alterations related to cerebral growth and metabolism, and discussed in the context of existing literature related to physiological and behavioral responses to experimental TBI. Increasing evidence from the existing literature and from our own gene microarray data indicates that molecular responses related to growth, development and metabolism may play a particularly important role in the injury response and the recovery trajectory following developmental TBI. While gene expression analysis shows many of these changes occur at the level of transcription, a comprehensive review of other studies suggests that the control of metabolic substrates may preferentially be regulated through changes in transporters and enzymatic activity. The interrelation between cellular metabolism and activity-dependent neuroplasticity shows great promise as an area for future study for an optimal translation of experimental data to clinical TBI, with the ultimate goal of guiding therapeutic interventions. Copyright (C) 2010 S. Karger AG, Basel	[Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Brain Injury Res Ctr, Dept Neurosurg,Semel Inst, Los Angeles, CA 90095 USA; [Babikian, Talin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat, Los Angeles, CA 90095 USA; [Hovda, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Hartonian, Ivet; Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA; [Hartonian, Ivet; Giza, Christopher C.] Mattel Childrens Hosp UCLA, Div Pediat Neurol, Los Angeles, CA USA	Giza, CC (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, UCLA Brain Injury Res Ctr, Dept Neurosurg,Semel Inst, 10833 Le Conte Blvd,Room 18-218B, Los Angeles, CA 90095 USA.	cgiza@mednet.ucla.edu	Prins, Mayumi/J-9571-2015	Prins, Mayumi/0000-0001-7694-9739	Child Neurology Foundation/Winokur Family Foundation;  [NS27544];  [NS02197];  [NS057420];  [NS058489]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS002197, P01NS058489, K02NS057420, R01NS027544] Funding Source: NIH RePORTER	This study was supported by the NS27544, NS02197, NS057420, NS058489 and the Child Neurology Foundation/Winokur Family Foundation.	Anson RM, 2003, P NATL ACAD SCI USA, V100, P6216, DOI 10.1073/pnas.1035720100; Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; ASPBERG A, 1992, DEV BRAIN RES, V66, P55, DOI 10.1016/0165-3806(92)90139-N; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; BEAR MF, 1990, J NEUROSCI, V10, P909; Berardini TZ, 2010, NUCLEIC ACIDS RES, V38, pD331, DOI 10.1093/nar/gkp1018; Bockhorst KH, 2008, J NEUROSCI RES, V86, P1520, DOI 10.1002/jnr.21607; Cherian L, 2004, J NEUROTRAUM, V21, P1196; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chugani HT, 1999, NEUROSCIENTIST, V5, P29, DOI 10.1177/107385849900500105; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; CHUGANI HT, 1991, J CEREBR BLOOD F MET, V11, P35, DOI 10.1038/jcbfm.1991.4; CHUGANI HT, 1986, SCIENCE, V231, P840, DOI 10.1126/science.3945811; Chugani HT, 1998, PREV MED, V27, P184, DOI 10.1006/pmed.1998.0274; CRANE SC, 1983, J NUTR, V113, P1063; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; DENGBRYANT Y, J NEUROTRAUMA UNPUB; Dreiem A, 2005, TOXICOL SCI, V87, P156, DOI 10.1093/toxsci/kfi224; Duan WZ, 2001, J MOL NEUROSCI, V16, P1, DOI 10.1385/JMN:16:1:1; Escartin C, 2007, J NEUROSCI, V27, P7094, DOI 10.1523/JNEUROSCI.0174-07.2007; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fontan-Lozano A, 2008, MOL NEUROBIOL, V38, P167, DOI 10.1007/s12035-008-8040-1; Fontan-Lozano A, 2007, J NEUROSCI, V27, P10185, DOI 10.1523/JNEUROSCI.2757-07.2007; Gerhart DZ, 1997, AM J PHYSIOL-ENDOC M, V273, pE207; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Giza CC, 2009, DEV NEUROREHABIL, V12, P255, DOI 10.3109/17518420903087558; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; HAWKINS RA, 1971, BIOCHEM J, V122, P13, DOI 10.1042/bj1220013; HAWKINS RA, 1979, SCIENCE, V205, P325, DOI 10.1126/science.451608; HAWKINS RA, 1986, AM J PHYSIOL, V250, pE169; Hovda DA, 1996, J CEREBR BLOOD F MET, V16, P134, DOI 10.1097/00004647-199601000-00016; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; HUTTENLOCHER PR, 1979, BRAIN RES, V163, P195; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; JACOBS B, 1995, CEREB CORTEX, V5, P222, DOI 10.1093/cercor/5.3.222; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Kawamata T, 1997, ACT NEUR S, V70, P191; KENNEDY C, 1982, ANN NEUROL, V12, P333, DOI 10.1002/ana.410120404; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; Lomax J, 2005, BRIEF BIOINFORM, V6, P298, DOI 10.1093/bib/6.3.298; Maalouf M, 2009, BRAIN RES REV, V59, P293, DOI 10.1016/j.brainresrev.2008.09.002; Magistretti Pierre J., 1995, P657; Markham A, 2004, EUR J NEUROSCI, V20, P1189, DOI 10.1111/j.1460-9568.2004.03578.x; Mattson MP, 2001, MECH AGEING DEV, V122, P757, DOI 10.1016/S0047-6374(01)00226-3; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; MAVELLI I, 1982, BIOCHEM J, V204, P535, DOI 10.1042/bj2040535; McCall AL, 1996, J CEREBR BLOOD F MET, V16, P69, DOI 10.1097/00004647-199601000-00008; MILLER AL, 1981, INT REV NEUROBIOL, P47; Mori T, 1998, ACT NEUR S, V71, P120; NEHLIG A, 1991, NEUROSCIENCE, V40, P871, DOI 10.1016/0306-4522(91)90018-J; OHATA M, 1981, BRAIN, V104, P319, DOI 10.1093/brain/104.2.319; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; PARDRIDGE WM, 1990, J BIOL CHEM, V265, P18035; Passineau MJ, 2000, AM J PHYSIOL-HEART C, V279, pH924; Potter WB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008996; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Prins ML, 2008, J CEREBR BLOOD F MET, V28, P1, DOI 10.1038/sj.jcbfm.9600543; Prins ML, 2009, J NEUROTRAUM, V26, P1083, DOI [10.1089/neu.2008.0769, 10.1089/neu.2008-0769]; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Ramamurthy S, 2006, J PHYSIOL-LONDON, V574, P85, DOI 10.1113/jphysiol.2006.110122; RAUSCHECKER JP, 1987, IMPRINTING CORTICAL, P193; Rheims S, 2009, J NEUROCHEM, V110, P1330, DOI 10.1111/j.1471-4159.2009.06230.x; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.2307/3454543; Sakurai T, 2002, DIABETES, V51, P430, DOI 10.2337/diabetes.51.2.430; Sharma S, 2009, NEUROSCIENCE, V161, P1037, DOI 10.1016/j.neuroscience.2009.04.042; Simpson IA, 1999, J NEUROCHEM, V72, P238, DOI 10.1046/j.1471-4159.1999.0720238.x; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Spreen O., 1995, DEV NEUROPSYCHOLOGY; SUTTON RL, 1994, ACTA NEUROCHIR, P446; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Urabe T, 1996, J NEUROCHEM, V67, P265; Vannucci SJ, 1998, DEV BRAIN RES, V107, P255, DOI 10.1016/S0165-3806(98)00021-2; Vannucci SJ, 2003, AM J PHYSIOL-ENDOC M, V285, pE1127, DOI 10.1152/ajpendo.00187.2003; Vega C, 2006, J NEUROCHEM, V97, P872, DOI 10.1111/j.1471-4159.2006.03790.x; WIGGINS RC, 1986, NEUROTOXICOLOGY, V7, P103; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhang F, 2005, J NEUROSCI RES, V79, P139, DOI 10.1002/jnr.20312	90	40	40	0	5	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2010	32	5-6					431	441		10.1159/000320667			11	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	725RO	WOS:000287663900011	21071915	Green Published, Bronze			2021-06-18	
J	James, ML; Wang, HC; Venkatraman, T; Song, PP; Lascola, CD; Laskowitz, DT				James, Michael L.; Wang, Haichen; Venkatraman, Talaignair; Song, Pingping; Lascola, Christopher D.; Laskowitz, Daniel T.			Brain Natriuretic Peptide Improves Long-Term Functional Recovery after Acute CNS Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						brain natriuretic peptide; cerebral blood flow; intracerebral hemorrhage; nesiritide; neuroinflammation; neuroprotection; traumatic brain injury	CEREBRAL-BLOOD-FLOW; NITRIC-OXIDE SYNTHASE; INTRACEREBRAL HEMORRHAGE; ANGIOTENSIN-II; PLASMA-CONCENTRATIONS; ISCHEMIC-STROKE; HEART-FAILURE; L-ARGININE; INFLAMMATION; ATRIAL	There is emerging evidence to suggest that brain natriuretic peptide (BNP) is elevated after acute brain injury, and that it may play an adaptive role in recovery through augmentation of cerebral blood flow (CBF). Through a series of experiments, we tested the hypothesis that the administration of BNP after different acute mechanisms of central nervous system (CNS) injury could improve functional recovery by improving CBF. C57 wild-type mice were exposed to either pneumatic-induced closed traumatic brain injury (TBI) or collagenase-induced intracerebral hemorrhage (ICH). After injury, either nesiritide (hBNP) (8 mu g/kg) or normal saline were administered via tail vein injection at 30 min and 4 h. The mice then underwent functional neurological testing via rotorod latency over the following 5 days and neurocognitive testing via Morris water maze testing on days 24-28. Cerebral blood flow (CBF) was assessed by laser Doppler from 25 to 90 min after injury. After ICH, mRNA polymerase chain reaction (PCR) and histochemical staining were performed during the acute injury phase (<24 h) to determine the effects on inflammation. Following TBI and ICH, administration of hBNP was associated with improved functional performance as assessed by rotorod and Morris water maze latencies (p < 0.01). CBF was increased (p < 0.05), and inflammatory markers (TNF-alpha and IL-6; p < 0.05), activated microglial (F4/80; p < 0.05), and neuronal degeneration (Fluoro-Jade B; p < 0.05) were reduced in mice receiving hBNP. hBNP improves neurological function in murine models of TBI and ICH, and was associated with enhanced CBF and downregulation of neuroinflammatory responses. hBNP may represent a novel therapeutic strategy after acute CNS injury.	[James, Michael L.; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; [James, Michael L.; Wang, Haichen; Song, Pingping; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC 27710 USA; [Venkatraman, Talaignair; Lascola, Christopher D.] Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA; [Song, Pingping; Lascola, Christopher D.; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	James, ML (corresponding author), Duke Univ, Med Ctr 3094, Durham, NC 27710 USA.	james040@mc.duke.edu	James, Michael L./AAJ-5592-2020; Lascola, Christopher D/B-9126-2017	James, Michael L./0000-0002-8715-5210; Lascola, Christopher D/0000-0002-8031-782X	FAER Mentored Research	This study was made possible through funding from the FAER Mentored Research Training Grant (M.L.J.).	Brosnan MJ, 1999, HYPERTENSION, V33, P290, DOI 10.1161/01.HYP.33.1.290; Burger AJ, 2002, AM HEART J, V144, P1102, DOI 10.1067/mhj.2002.125620; CLARKSON PBM, 1995, CLIN SCI, V88, P159, DOI 10.1042/cs0880159; Di Angelantonlo E, 2007, J NEUROL SCI, V260, P139, DOI 10.1016/j.jns.2007.04.018; Fainardi E, 2008, NEURORADIOLOGY, V50, P729, DOI 10.1007/s00234-008-0402-x; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hlatky R, 2003, J NEUROTRAUM, V20, P995, DOI 10.1089/089771503770195849; Holscher C, 1999, BEHAV BRAIN RES, V100, P225, DOI 10.1016/S0166-4328(98)00134-X; Ito T, 2001, J RENIN-ANGIO-ALDO S, V2, P174, DOI 10.3317/jraas.2001.024; Ito T, 2002, STROKE, V33, P2297, DOI 10.1161/01.STR.0000027274.03779.F3; James ML, 2009, STROKE, V40, P632, DOI 10.1161/STROKEAHA.108.530402; James ML, 2008, NEUROCRIT CARE, V9, P139, DOI 10.1007/s12028-007-9030-2; Jensen JK, 2006, CEREBROVASC DIS, V22, P439, DOI 10.1159/000094997; Kasama S, 2004, J NUCL MED, V45, P1108; Kirchhoff C, 2006, J NEUROTRAUM, V23, P943, DOI 10.1089/neu.2006.23.943; Konig D, 2007, EXERC IMMUNOL REV, V13, P15; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Laskowitz DT, 2009, STROKE, V40, P77, DOI 10.1161/STROKEAHA.108.516377; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu DC, 2008, SURG NEUROL, V69, P226, DOI 10.1016/j.surneu.2007.02.051; Luchner A, 2004, CARDIOVASC RES, V63, P443, DOI 10.1016/j.cardiores.2004.05.004; Luo ZY, 2000, J CLIN INVEST, V106, P493, DOI 10.1172/JCI9419; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Ma KK, 2004, J MOL CELL CARDIOL, V36, P505, DOI 10.1016/j.yjmcc.2004.01.001; McGirt MJ, 2004, NEUROSURGERY, V54, P1369, DOI 10.1227/01.NEU.0000125016.37332.50; McGrath MF, 2005, TRENDS ENDOCRIN MET, V16, P469, DOI 10.1016/j.tem.2005.10.007; Meirovich YF, 2008, J HEART LUNG TRANSPL, V27, P31, DOI 10.1016/j.healun.2007.09.025; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; Modrego Pedro J, 2008, Int J Med Sci, V5, P18; Montaner J, 2008, STROKE, V39, P2280, DOI 10.1161/STROKEAHA.107.505354; MORIKAWA E, 1994, STROKE, V25, P429, DOI 10.1161/01.STR.25.2.429; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MUKOYAMA M, 1991, J CLIN INVEST, V87, P1402, DOI 10.1172/JCI115146; Mun-Bryce S, 2006, BRAIN RES, V1073, P481, DOI 10.1016/j.brainres.2005.12.071; Mun-Bryce S, 2004, BRAIN RES, V1026, P218, DOI 10.1016/j.brainres.2004.08.023; Nakagawa K, 2005, CEREBROVASC DIS, V19, P157, DOI 10.1159/000083249; Nguyen AP, 2008, CURR NEUROVASC RES, V5, P171, DOI 10.2174/156720208785425710; Orakcioglu B, 2008, NEUROCRIT CARE, V8, P448, DOI 10.1007/s12028-007-9047-6; Powner DJ, 2007, NEUROCRIT CARE, V7, P119, DOI 10.1007/s12028-007-0079-8; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; ROSENBERG GA, 1990, ACT NEUR S, V51, P280; Rubattu S, 2008, AM J HYPERTENS, V21, P733, DOI 10.1038/ajh.2008.174; Saavedra JM, 2005, CELL MOL NEUROBIOL, V25, P485, DOI 10.1007/s10571-005-4011-5; Sakata Y, 2001, J HYPERTENS, V19, P1905, DOI 10.1097/00004872-200110000-00027; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; Sviri GE, 2006, ACTA NEUROCHIR, V148, P529, DOI 10.1007/s00701-005-0666-4; Tamura N, 2000, P NATL ACAD SCI USA, V97, P4239, DOI 10.1073/pnas.070371497; Tsuchiya D, 2003, BRAIN RES, V970, P131, DOI 10.1016/S0006-8993(03)02300-X; Vesely DL, 2009, J INVEST MED, V57, P29, DOI 10.2310/JIM.0b013e3181948b37; Wang H, 2007, NEUROSCIENCE, V144, P1324, DOI 10.1016/j.neuroscience.2006.11.017; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; West MJ, 1996, J COMP NEUROL, V370, P11; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Yamada M, 2000, J CEREBR BLOOD F MET, V20, P709, DOI 10.1097/00004647-200004000-00008; Yancy CW, 2004, AM J CARDIOL, V94, P595, DOI 10.1016/j.amjcard.2004.05.022; Yemisci M, 2008, CEREBROVASC DIS, V26, P190, DOI 10.1159/000145327; Young JB, 2002, JAMA-J AM MED ASSOC, V287, P1531; Zhou J, 2005, J CEREBR BLOOD F MET, V25, P878, DOI 10.1038/sj.jcbfm.9600082	62	40	42	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2010	27	1					217	228		10.1089/neu.2009.1022			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	548RF	WOS:000273983200019	19803787				2021-06-18	
S	McAllister, TW; Stein, MB		Barchas, JD; Difede, J		McAllister, Thomas W.; Stein, Murray B.			Effects of psychological and biomechanical trauma on brain and behavior	PSYCHIATRIC AND NEUROLOGIC ASPECTS OF WAR	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	89th Annual Conference of the Association for Research in Nervous and Mental Disease	DEC 16, 2009	Rockefeller Univ, New York, NY		Rockefeller Univ	traumatic brain injury (TBI); posttraumatic stress disorder (PTSD); psychological trauma; biomechanical trauma; behavior	POSTTRAUMATIC-STRESS-DISORDER; INJURY-INDUCED NEUROTRAUMA; HEAD-INJURY; BLAST INJURY; COGNITIVE REHABILITATION; POSTCONCUSSIVE SYMPTOMS; CEREBRAL AUTOREGULATION; PSYCHIATRIC SEQUELAE; MAJOR DEPRESSION; COMBAT VETERANS	The current conflicts in Iraq and Afghanistan have resulted in a large cohort of military personnel exposed to combat-related psychological trauma as well as biomechanical trauma, including proximity to blast events. Historically, the long-term effects of both types of trauma have been viewed as having different neural substrates, with some controversy over the proper attribution of such symptoms evident after each of the major conflicts of the last century. Recently, great effort has been directed toward distinguishing which neuropsychiatric sequelae are due to which type of trauma. Of interest, however, is that the chronic effects of exposure to either process are associated with a significant overlap in clinical symptoms. Furthermore, similar brain regions are vulnerable to the effects of either psychological or biomechanical trauma, raising the possibility that shared mechanisms may underlie the clinically observed overlap in symptom profile. This paper reviews the literature on the neural substrate of biomechanical and psychological injury and discusses the implications for evaluation and treatment of the neuropsychiatric sequelae of these processes.	[McAllister, Thomas W.] Dartmouth Med Sch, Dept Psychiat, Sect Neuropsychiat, Lebanon, NH 03756 USA; [Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Stein, Murray B.] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA; [Stein, Murray B.] VA San Diego Healthcare Syst, San Diego, CA USA	McAllister, TW (corresponding author), Dartmouth Med Sch, Dept Psychiat, Sect Neuropsychiat, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	thomas.w.mcallister@dartmouth.edu			NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD048176, 1R01HD047242, 1R01HD48638]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1RO1NS055020]; CDCCentre National de la Recherche Scientifique (CNRS)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01/CE001254]; DoD/CDMRPUnited States Department of Defense [PT075446, W81XWH08-2-0159]; NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K24MH64122]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638, R01HD048176, R01HD047242] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01CE001254] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K24MH064122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055020] Funding Source: NIH RePORTER	Supported in part by grants NICHD R01 HD048176, 1R01HD047242, and 1R01HD48638; NINDS 1RO1NS055020; CDC R01/CE001254; DoD/CDMRP PT075446; NIMH K24MH64122; DoD/CDMRP W81XWH08-2-0159.	Alavi A, 1996, J NUCL MED, V37, P1170; Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; Arciniegas David B, 2003, Curr Psychiatry Rep, V5, P391, DOI 10.1007/s11920-003-0074-5; ARVIGO F, 1985, SURG NEUROL, V24, P211, DOI 10.1016/0090-3019(85)90187-9; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bremner J Douglas, 2007, Expert Rev Neurother, V7, P393, DOI 10.1586/14737175.7.4.393; Breslau N, 2006, ARCH GEN PSYCHIAT, V63, P1238, DOI 10.1001/archpsyc.63.11.1238; Broomhall LGJ, 2009, J NERV MENT DIS, V197, P178, DOI 10.1097/NMD.0b013e318199fe7f; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Bryant RA, 2009, J INT NEUROPSYCH SOC, V15, P862, DOI 10.1017/S1355617709990671; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Charney DS, 2004, AM J PSYCHIAT, V161, P195, DOI 10.1176/appi.ajp.161.2.195; CHARNEY DS, 1993, ARCH GEN PSYCHIAT, V50, P294; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; CHEN YR, 2009, J MANAGE, V26, P1; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; COSETTI M, TXB TRAUMAT IN PRESS; CRAMER F, 1949, ARCH NEURO PSYCHIATR, V61, P1; CRAMER F, 1947, J NERV MENT DIS, V106, P602; Davis M, 2001, MOL PSYCHIATR, V6, P13, DOI 10.1038/sj.mp.4000812; DEBELLIS MD, 1994, J CLIN ENDOCR METAB, V78, P249, DOI 10.1210/jc.78.2.249; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Friedman M.J., 2007, HDB PTSD SCI PRACTIC, P376; FRIEDMAN MJ, 1994, PSYCHIAT CLIN N AM, V17, P265; FRIEDMAN MJ, 1994, TOXICOL IND HEALTH, V10, P449; FRIEDMAN MJ, 2001, P 17 ANN M INT SOC T; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Gennarelli T. A., 2005, TXB TRAUMATIC BRAIN, P27; Giza CC, 2001, J ATHL TRAINING, V36, P228; Harvey AG, 2003, J INT NEUROPSYCH SOC, V9, P663, DOI 10.1017/S1355617703940069; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; Harvey AG, 1998, BRAIN INJURY, V12, P147, DOI 10.1080/026990598122773; Hattori N, 2009, J NUCL MED, V50, P1054, DOI 10.2967/jnumed.108.060368; Heim C, 2001, AM J PSYCHIAT, V158, P575, DOI 10.1176/appi.ajp.158.4.575; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Institute of Medicine, 2009, GULF WAR HLTH, V7; Institute of Medicine Committee on Treatment of Posttraumatic Stress Disorder, 2008, TREATM POSTTR STRESS; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; KAPOOR N, TXB TRAUMAT IN PRESS; Kocsis JD, 2009, J REHABIL RES DEV, V46, P667, DOI 10.1682/JRRD.2008.08.0100; Koren D, 2005, AM J PSYCHIAT, V162, P276, DOI 10.1176/appi.ajp.162.2.276; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kremen WS, 2007, ARCH GEN PSYCHIAT, V64, P361, DOI 10.1001/archpsyc.64.3.361; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; LEMIEUX AM, 1995, PSYCHOSOM MED, V57, P105, DOI 10.1097/00006842-199503000-00002; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2009, CLIN NEUROPSYCHOL, V23, P1338, DOI 10.1080/13854040903277289; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; MCEWEN BS, 1992, BIOL PSYCHIAT, V31, P177, DOI 10.1016/0006-3223(92)90204-D; Mollica RF, 2002, BRIT J PSYCHIAT, V181, P339, DOI 10.1192/bjp.181.4.339; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Neumeister A, 2005, BIOL PSYCHIAT, V57, P935, DOI 10.1016/j.biopsych.2005.01.016; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Park E, 2006, J NEUROPATH EXP NEUR, V65, P226, DOI 10.1097/01.jnen.0000202888.29705.93; Pitman RK, 2006, ANN NY ACAD SCI, V1071, P242, DOI 10.1196/annals.1364.019; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Raskind MA, 2007, BIOL PSYCHIAT, V61, P928, DOI 10.1016/j.biopsych.2006.06.032; Rasmusson A., 2002, GENDER PTSD, P43; Rasmusson AM, 2001, BIOL PSYCHIAT, V50, P965, DOI 10.1016/S0006-3223(01)01264-1; Sapolsky RM, 2000, BIOL PSYCHIAT, V48, P755, DOI 10.1016/S0006-3223(00)00971-9; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Simmons AN, 2008, BIOL PSYCHIAT, V64, P681, DOI 10.1016/j.biopsych.2008.05.027; Southwick S. M., 2007, HDB PTSD SCI PRACTIC, P166; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Strebel S, 1997, SURG NEUROL, V47, P128, DOI 10.1016/S0090-3019(96)00459-4; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Vaishnavi S, 2009, PSYCHOSOMATICS, V50, P198, DOI 10.1176/appi.psy.50.3.198; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Vermetten E, 2002, DEPRESS ANXIETY, V16, P14, DOI 10.1002/da.10017; Wallister TW, 2008, WORLD PSYCHIATRY, V7, P3; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; Yehuda R, 2002, PSYCHIAT CLIN N AM, V25, P341, DOI 10.1016/S0193-953X(02)00002-3; YEHUDA R, 1995, ARCH GEN PSYCHIAT, V52, P583	111	40	41	1	11	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA	0077-8923		978-1-57331-804-4	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2010	1208						46	57		10.1111/j.1749-6632.2010.05720.x			12	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	BSK28	WOS:000284742000007	20955325	Green Accepted			2021-06-18	
J	Sandhir, R; Berman, NEJ				Sandhir, Rajat; Berman, Nancy E. J.			Age-dependent response of CCAAT/enhancer binding proteins following traumatic brain injury in mice	NEUROCHEMISTRY INTERNATIONAL			English	Article						Traumatic brain injury; Inflammation; CCAAT enhancer binding proteins; Transcription factors; C/EBP alpha; C/EBP beta; C/EBP delta; CHOP; Aging	ENDOPLASMIC-RETICULUM STRESS; C/EBP TRANSCRIPTION FACTORS; CONTROLLED CORTICAL IMPACT; GENE-EXPRESSION; ALZHEIMERS-DISEASE; CEREBRAL-ISCHEMIA; BETA; INFLAMMATION; CYTOKINES; CELLS	Exacerbated inflammatory responses have been reported following traumatic injury to the aged brain. The present study was designed to investigate the involvement of the transcription factors belonging to the CCAAT/enhancer binding protein (C/EBP) family that regulate expression of many of the pro-inflammatory genes which show increased expression following injury to the aged brain. Controlled cortical impact injury was induced in adult (5-6 months) and aged (22-24 months) C57/BL6 mice. C/EBP mRNA and protein expression were analyzed in injured cortex at 1, 3, and 7 days post-injury. Expression of C/EBP alpha was reduced relative to baseline at day 1 in both adult and aged mice, whereas, it increased at days 3 and 7 post-injury. No significant differences were observed between adult and aged brain. Upregulation of C/EBP beta was observed I day following injury in both the adult and aged brain, but there were no major age-related differences in mRNA levels. However, there was higher C/EBP beta protein in the aged brain. C/EBP delta expression increased beginning 1 day post-injury in both adult and aged brain. In this case, the increase in C/EBP delta expression was higher in the aged brain than in the adult at all time points studied. Expression of CCAAT/enhancer binding protein homologous protein (CHOP), a transcription factor involved in ER stress and protein unfolding responses, was also up-regulated in response to injury, but CHOP levels were significantly lower in the aged than the adult brain. Based on these results, we conclude that differential expression of C/EBP P, 8 and CHOP might contribute to the hyper-inflammatory response and poor prognosis following traumatic brain injury in the elderly patients. In addition elevated C/EBP delta levels following TBI in the aged brain may play a role in the link between TBI and Alzheimer's disease. (C) 2009 Elsevier Ltd. All rights reserved.	[Sandhir, Rajat; Berman, Nancy E. J.] Univ Kansas, Med Ctr, Steve Palermo Nerve Regenerat Lab, Kansas City, KS 66160 USA; [Sandhir, Rajat; Berman, Nancy E. J.] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA	Berman, NEJ (corresponding author), Univ Kansas, Med Ctr, Steve Palermo Nerve Regenerat Lab, Mail Stop 3038,3901 Rainbow Blvd, Kansas City, KS 66160 USA.	nberman@kumc.edu			Steve Palermo Endowment; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 AG031140, P30 HD02528]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD002528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG031140] Funding Source: NIH RePORTER	The authors acknowledge the assistance of Eugene Gregory in carrying out the work and Dr. Y.Y. He for his help with controlled cortical impact injury. The study was supported in part by the Steve Palermo Endowment and the National Institute of Health (R01 AG031140 and research core support P30 HD02528).	Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; ANDERSON J, 2009, J NEUROTRAUMA; Cardinaux JR, 2000, GLIA, V29, P91, DOI 10.1002/(SICI)1098-1136(20000101)29:1<91::AID-GLIA9>3.3.CO;2-9; Choi BK, 2009, EXP BRAIN RES, V193, P581, DOI 10.1007/s00221-008-1660-x; Cloutier A, 2009, J IMMUNOL, V182, P563, DOI 10.4049/jimmunol.182.1.563; Cortes-Canteli M, 2004, J BIOL CHEM, V279, P14409, DOI 10.1074/jbc.M313253200; Cortes-Canteli M, 2008, J CELL SCI, V121, P1224, DOI 10.1242/jcs.025031; Ejarque-Ortiz A, 2007, GLIA, V55, P178, DOI 10.1002/glia.20446; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hwang IK, 2007, NEUROCHEM RES, V32, P1530, DOI 10.1007/s11064-007-9345-6; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jacobs David G, 2003, Curr Opin Crit Care, V9, P535, DOI 10.1097/00075198-200312000-00012; Johnson J, 1994, LIVER GENE EXPRESSIO, P231; Kalvakolanu DV, 2005, J INTERF CYTOK RES, V25, P757, DOI 10.1089/jir.2005.25.757; Kapadia R, 2006, J NEUROCHEM, V98, P1718, DOI 10.1111/j.1471-4159.2006.04056.x; Kleinig TJ, 2009, CURR OPIN NEUROL, V22, P294, DOI 10.1097/WCO.0b013e32832b4db3; Li RN, 2004, NEUROBIOL AGING, V25, P991, DOI 10.1016/j.neurobiolaging.2003.10.016; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Martin GS, 2006, CRIT CARE MED, V34, P15, DOI 10.1097/01.CCM.0000194535.82812.BA; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nadeau S, 2005, MOL CELL NEUROSCI, V29, P525, DOI 10.1016/j.mcn.2005.04.004; Naidoo N, 2008, J NEUROSCI, V28, P6539, DOI 10.1523/JNEUROSCI.5685-07.2008; Nerlov C, 2007, TRENDS CELL BIOL, V17, P318, DOI 10.1016/j.tcb.2007.07.004; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Paschen W, 1998, MOL BRAIN RES, V60, P115, DOI 10.1016/S0169-328X(98)00180-6; Paschen W, 2004, J NEUROCHEM, V88, P983, DOI 10.1046/j.1471-4159.2003.02218.x; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Rabek JP, 1998, BBA-GENE STRUCT EXPR, V1398, P137, DOI 10.1016/S0167-4781(98)00038-4; Rhinn H, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-62; Sandhir R, 2004, NEUROSCI LETT, V369, P28, DOI 10.1016/j.neulet.2004.07.032; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Sterneck E, 1998, P NATL ACAD SCI USA, V95, P10908, DOI 10.1073/pnas.95.18.10908; Stokely ME, 2008, J NEUROTRAUM, V25, P52, DOI 10.1089/neu.2007.0397; Szegezdi E, 2003, ANN NY ACAD SCI, V1010, P186, DOI 10.1196/annals.1299.032; Tanaka R, 2002, J CEREBR BLOOD F MET, V22, P280, DOI 10.1097/00004647-200203000-00005; TANSEY MG, 2009, ENCY NEUROSCIENCE, P131; Tengku-Muhammad TS, 2000, CYTOKINE, V12, P1430, DOI 10.1006/cyto.2000.0711; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Ubeda M, 1999, MOL CELL BIOL, V19, P7589; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Walton M, 1998, MOL BRAIN RES, V61, P11, DOI 10.1016/S0169-328X(98)00169-7; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; Won JS, 2003, J NEUROSCI, V23, P7470; Xiong W, 2001, NUCLEIC ACIDS RES, V29, P3087, DOI 10.1093/nar/29.14.3087; Yi JH, 2007, NEUROCHEM INT, V50, P1014, DOI 10.1016/j.neuint.2007.04.019; Yiangou M, 2001, BBA-GENE STRUCT EXPR, V1518, P47, DOI 10.1016/S0167-4781(01)00165-8	53	40	42	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	JAN	2010	56	1					188	193		10.1016/j.neuint.2009.10.002			6	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	569JZ	WOS:000275593700025	19833158	Green Accepted			2021-06-18	
J	Shorland, J; Douglas, JM				Shorland, Joanna; Douglas, Jacinta M.			Understanding the role of communication in maintaining and forming friendships following traumatic brain injury	BRAIN INJURY			English	Article						Communication; friendship; conversational skills; social participation; brain injury	FACIAL EXPRESSION; EMOTION RECOGNITION; DISCOURSE; DEFICITS; PEOPLE; SELF; INTEGRATION; COMPETENCE; ABILITIES; INSIGHTS	Research design: A qualitative approach based on Grounded Theory. Methods and procedures: Purposive sampling of two participants living in the community at a minimum of 2 years post-severe TBI was utilized. Data was collected via in-depth semi-structured interviews. Transcripts were analysed for categories and themes. Outcomes and results: Three major themes were evident: (1) The experience of friendship following TBI, (2) Changes to conversational skill and (3) Opening up to others. Communication change was important in the experience of friendships in so much as difficulties with conversational skill impacted on participation levels and self-disclosure. Participants identified aspects of communication associated with difficulties when interacting with friends and peers. Conclusions: Participants' stories illustrate the need to address post-TBI communication difficulties within social contexts. Further research addressing communication difficulties that impact on friendships specific to gender, age and time post-injury is warranted.	[Shorland, Joanna; Douglas, Jacinta M.] La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3086, Australia	Douglas, JM (corresponding author), La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3086, Australia.	j.douglas@latrobe.edu.au	Douglas, Jacinta M/C-2380-2009	Shorland, Joanna/0000-0001-6761-0346; Douglas, Jacinta/0000-0003-0940-6624			Bluff R., 2005, QUALITATIVE RES HLTH, P147; BROWNE J, 2004, RES METHODS NURSING, P624; Burleson B.R., 1996, COMMUN REP, V9, P127, DOI [10.1080/08934219609367645, DOI 10.1080/08934219609367645]; Burleson B. R., 1992, SO COMMUNICATION J, V57, P260, DOI DOI 10.1080/10417949209372873; Coelho C. A., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; COELHO CA, 1999, BRAIN DAM B, P55; Crisp R., 1993, DISABILITY HANDICAP, V8, P393, DOI [DOI 10.1080/02674649366780371, 10.1080/02674649366780371]; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Douglas JM, 2007, APHASIOLOGY, V21, P1181, DOI 10.1080/02687030600980950; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Douglas JM, 2006, BRAIN IMPAIR, V7, P107, DOI DOI 10.1375/BRIM.7.2.107; DOUGLAS JM, 2010, J SPEECH LA IN PRESS, V53; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Glaser B. G., 1967, DISCOVERY GROUNDED T; Godfrey HPD, 2000, APHASIOLOGY, V14, P433, DOI 10.1080/026870300401441; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Hartley L. L., 1995, COGNITIVE COMMUNICAT; Holosko M, 1989, CANADIAN J REHABILIT, V2, P145; Hoofien D, 2001, BRAIN INJURY, V15, P189; Ietswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148, DOI 10.1016/j.neuropsychologia.2007.08.002; Karlovits T, 1999, BRAIN INJURY, V13, P845; Kilov AM, 2009, APHASIOLOGY, V23, P584, DOI 10.1080/02687030701855382; Kinsella G, 1989, Int Disabil Stud, V11, P9; Knox L, 2009, BRAIN COGNITION, V69, P442, DOI 10.1016/j.bandc.2008.09.009; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; Kraus J, 2000, HEAD INJURY, P1; Lincoln Y.S., 1985, NATURALISTIC INQUIRY, V75; Llewellyn G., 2004, HDB RES METHODS NURS, V2nd edn, P210; MAYS N, 2000, QUALITATIVE RES HLTH, P89; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; Minichiello V, 2004, HDB RES METHODS NURS, P411; Morse J., 2002, READ ME 1 USERS GUID; Muenchberger H, 2008, BRAIN INJURY, V22, P979, DOI 10.1080/02699050802530532; Nochi M, 1997, DISABIL SOC, V12, P533, DOI 10.1080/09687599727119; Nochi M, 1998, QUAL HEALTH RES, V8, P665, DOI 10.1177/104973239800800507; Nussbaum J., 1994, INTERPERSONAL COMMUN, P209; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Paterson J., 2002, REHABILITATION NURSI, V27, P13, DOI [10.1002/j.2048-7940.2002.tb01973.x, DOI 10.1002/J.2048-7940.2002.TB01973.X]; Ponsford J., 1995, TRAUMATIC BRAIN INJU, P1; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow P, 1997, BRAIN INJURY, V11, P409; Snow PC, 2000, BRAIN INJURY, V14, P397; Strauss A., 1990, BASICS QUALITATIVE R; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 2000, APHASIOLOGY, V14, P365, DOI 10.1080/026870300401414; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; Ylvisaker M., 2006, BRAIN IMPAIR, V7, P246, DOI DOI 10.1375/BRIM.7.3.246	56	40	41	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	4					569	580		10.3109/02699051003610441			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	570ML	WOS:000275682300001	20235759				2021-06-18	
J	Harris, NG; Carmichael, ST; Hovda, DA; Sutton, RL				Harris, N. G.; Carmichael, S. T.; Hovda, D. A.; Sutton, R. L.			Traumatic Brain Injury Results in Disparate Regions of Chondroitin Sulfate Proteoglycan Expression That Are Temporally Limited	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						chondroitin sulfate proteoglycans; cortex; immunohistochemistry; mRNA; RT-PCR; traumatic brain injury; controlled cortical impact injury; perineuronal nets	SPINAL-CORD-INJURY; CENTRAL-NERVOUS-SYSTEM; ADULT-RAT; EXTRACELLULAR-MATRIX; FUNCTIONAL RECOVERY; CORTICAL CONTUSION; GLIAL SCAR; REACTIVE ASTROCYTES; AXON REGENERATION; PERINEURONAL NETS	Axonal injury is a major hallmark of traumatic brain injury (TBI), and it seems likely that therapies directed toward enhancing axon repair could potentially improve functional outcomes. One potential target is chondroitin sulfate proteoglycans (CSPGs), which are major axon growth inhibitory molecules that are generally, but not always, up-regulated after central nervous system injury. The current study was designed to determine temporal changes in cerebral cortical mRNA or protein expression levels of CSPGs and to determine their regional localization and cellular association by using immunohistochemistry in a controlled cortical impact model of TBI. The results showed significant increases in versican mRNA at 4 and 14 days after TBI but no change in neurocan, aggrecan, or phosphacan. Semiquantitative Western blot (WB) analysis of cortical CSPG protein expression revealed a significant ipsilateral decrease of all CSPGs at 1 day after TBI. Lower CSPG protein levels were sustained until at least 14 days, after which the levels began to normalize. Immunohistochemistry data confirm previous reports of regional increases in CSPG proteins after CNS injury, seen primarily within the developing glial scar after TBI, but also corroborate the WB data by revealing wide areas of pericontusional tissue that are deficient in both extracellular and perineuronal net-associated CSPGs. Given the evidence that CSPGs are largely inhibitory to axonal growth, we interpret these data to indicate a potential for regional spontaneous plasticity after TBI. If this were the case, the gradual normalization of CSPG proteins over time postinjury would suggest that this may be temporally as well as regionally limited. (C) 2009 Wiley-Liss, Inc.	[Harris, N. G.; Hovda, D. A.; Sutton, R. L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Harris, N. G.; Hovda, D. A.; Sutton, R. L.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Carmichael, S. T.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; [Hovda, D. A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	Harris, NG (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Box 957039, Los Angeles, CA 90095 USA.	ngharris@mednet.ucla.edu		Carmichael, S Thomas/0000-0002-1169-9203; Harris, Neil/0000-0002-1965-6750	NIH NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS055910]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055910] Funding Source: NIH RePORTER	UCLA Brain Injury Research Center; NIH NINDS	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Asher RA, 2000, J NEUROSCI, V20, P2427; Asher RA, 2002, J NEUROSCI, V22, P2225, DOI 10.1523/JNEUROSCI.22-06-02225.2002; ASHER RA, 1995, GLIA, V13, P294, DOI 10.1002/glia.440130406; Aya-ay J, 2005, EXP NEUROL, V193, P149, DOI 10.1016/j.expneurol.2004.11.021; Barritt AW, 2006, J NEUROSCI, V26, P10856, DOI 10.1523/JNEUROSCI.2980-06.2006; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Carmichael ST, 2005, EXP NEUROL, V193, P291, DOI 10.1016/j.expneurol.2005.01.004; CASTROALAMANCOS MA, 1995, NEUROSCIENCE, V68, P793, DOI 10.1016/0306-4522(95)00178-L; Celio MR, 1998, TRENDS NEUROSCI, V21, P510, DOI 10.1016/S0166-2236(98)01298-3; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen SF, 2004, J CEREBR BLOOD F MET, V24, P1025, DOI 10.1097/01.WCB.0000129415.34520.47; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Deepa SS, 2006, J BIOL CHEM, V281, P17789, DOI 10.1074/jbc.M600544200; Dityatev A, 2007, DEV NEUROBIOL, V67, P570, DOI 10.1002/dneu.20361; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dobbertin A, 2003, MOL CELL NEUROSCI, V24, P951, DOI 10.1016/S1044-7431(03)00257-4; DOMOWICZ M, 1995, DEV BIOL, V171, P655, DOI 10.1006/dbio.1995.1312; Dubreuil CI, 2006, EXP NEUROL, V198, P361, DOI 10.1016/j.expneurol.2005.12.002; Emery DL, 2000, J COMP NEUROL, V424, P521; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Garwood J, 2003, J BIOL CHEM, V278, P24164, DOI 10.1074/jbc.M211721200; Harrison DC, 2000, MOL BRAIN RES, V75, P143, DOI 10.1016/S0169-328X(99)00305-8; HORNIK K, 2008, R PROJECT STAT COMPU; Houle JD, 2006, J NEUROSCI, V26, P7405, DOI 10.1523/JNEUROSCI.1166-06.2006; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Jain A, 2004, J NEUROSCI RES, V77, P299, DOI 10.1002/jnr.20161; Jaworski DM, 1999, EXP NEUROL, V157, P327, DOI 10.1006/exnr.1999.7062; Jones LL, 2003, EXP NEUROL, V182, P399, DOI 10.1016/S0014-4886(03)00087-6; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; Koprivica V, 2005, SCIENCE, V310, P106, DOI 10.1126/science.1115462; Lander C, 1998, J NEUROSCI, V18, P174; Lemons ML, 1999, EXP NEUROL, V160, P51, DOI 10.1006/exnr.1999.7184; Lemons ML, 2001, J NEUROSCI, V21, P4772, DOI 10.1523/JNEUROSCI.21-13-04772.2001; LEVINE JM, 1994, J NEUROSCI, V14, P4716; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; Maeda N, 1996, DEVELOPMENT, V122, P647; Marklund N, 2006, EXP NEUROL, V197, P70, DOI 10.1016/j.expneurol.2005.08.029; Matsui F, 2005, J NEUROSCI RES, V81, P837, DOI 10.1002/jnr.20603; Matsui F, 2002, NEUROSCIENCE, V112, P773, DOI 10.1016/S0306-4522(02)00136-7; McKeon RJ, 1999, J NEUROSCI, V19, P10778; MIES G, 1991, J CEREBR BLOOD F MET, V11, P753, DOI 10.1038/jcbfm.1991.132; Miyata S, 2004, BRAIN RES, V1017, P163, DOI 10.1016/j.brainres.2004.05.034; Moon LDF, 2002, NEUROSCIENCE, V109, P101, DOI 10.1016/S0306-4522(01)00457-2; Moon LDF, 2001, NAT NEUROSCI, V4, P465; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Okamoto M, 2003, EXP NEUROL, V184, P179, DOI 10.1016/S0014-4886(03)00251-6; Ong WY, 1999, NEUROSCIENCE, V92, P83, DOI 10.1016/S0306-4522(98)00751-9; OOHIRA A, 1994, NEUROSCIENCE, V60, P145, DOI 10.1016/0306-4522(94)90210-0; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Properzi F, 2003, BIOCHEM SOC T, V31, P335, DOI 10.1042/BST0310335; Rasband W.S., 2008, IMAGEJ; Rauch U, 2004, CELL MOL LIFE SCI, V61, P2031, DOI 10.1007/s00018-004-4043-x; Reeves TM, 2003, J NEUROSCI, V23, P10182; Sandvig A, 2004, GLIA, V46, P225, DOI 10.1002/glia.10315; Seidenbecher CI, 2002, J NEUROCHEM, V83, P738, DOI 10.1046/j.1471-4159.2002.01183.x; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith GM, 2005, GLIA, V52, P209, DOI 10.1002/glia.20236; Smith JM, 2007, BRAIN, V130, P915, DOI 10.1093/brain/awl393; Soares S, 2007, EUR J NEUROSCI, V26, P1446, DOI 10.1111/j.1460-9568.2007.05794.x; SUTTON RL, 1994, ACTA NEUROCHIR, P446; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Tang XF, 2003, J NEUROSCI RES, V71, P427, DOI 10.1002/jnr.10523; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Thompson HJ, 2006, EUR J NEUROSCI, V24, P3063, DOI 10.1111/j.1460-9568.2006.05197.x; Tropea D, 2003, J NEUROSCI, V23, P7034, DOI 10.1523/JNEUROSCI.23-18-07034.2003; Yick LW, 2003, EXP NEUROL, V182, P160, DOI 10.1016/S0014-4886(02)00052-3	73	40	42	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	OCT	2009	87	13					2937	2950		10.1002/jnr.22115			14	Neurosciences	Neurosciences & Neurology	492SB	WOS:000269678600013	19437549	Green Accepted			2021-06-18	
J	Saggar, V; Mittal, RS; Vyas, MC				Saggar, Vineet; Mittal, Radhey S.; Vyas, M. C.			Hemostatic Abnormalities in Patients with Closed Head Injuries and Their Role in Predicting Early Mortality	JOURNAL OF NEUROTRAUMA			English	Article						coagulopathy; DIC; hemostatic abnormalities; traumatic brain injury	DISSEMINATED INTRAVASCULAR COAGULATION; BRAIN-INJURY; TRAUMA PATIENTS; COAGULOPATHY	Abnormalities of blood coagulation are frequently found in patients following traumatic brain injury. Exposure to thromboplastin, which is abundant in brain, plays an important role in initiating coagulopathy. Eighty patients of moderate-to-severe head injury were screened for platelet count, prothombin time (PT), activated partial thromboplastin time (a-PPTK), fibrinogen degradation product levels (FDP), D-dimer levels, and disseminated intravascular coagulation scores (DIC), calculated within the first 24 hours of injury. Increased consumptive coagulopathy at admission, as reflected by high DIC scores, predicted mortality in both moderate and severe head injury patients with a high degree of accuracy (p<0.001). Similarly, increased PT, FDP, and D-dimer values correlated with higher mortality in both groups, but platelet counts and a-PPTK values correlated with mortality only in the severe head injury group. From this study we conclude that hemostatic abnormalities are independent predictors of early mortality in moderate-to-severe head injury patients.	[Saggar, Vineet; Mittal, Radhey S.] SMS Med Coll & Hosp, Dept Neurosurg, Jaipur, Rajasthan, India; [Vyas, M. C.] Cent Bur Hlth Intelligence, FSU, Jaipur, Rajasthan, India	Saggar, V (corresponding author), SMS Med Coll & Hosp, Dept Neurosurg, Residence Room 208 RD Hostel, Jaipur, Rajasthan, India.	memymyselfus@yahoo.co.in					Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; ENDERSON BL, 1991, J TRAUMA, V31, P1240, DOI 10.1097/00005373-199109000-00007; FARINGER PD, 1993, J TRAUMA, V34, P481, DOI 10.1097/00005373-199304000-00002; Gando S, 1999, ANN SURG, V229, P121, DOI 10.1097/00000658-199901000-00016; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Halpern CH, 2008, J NEUROTRAUM, V25, P997, DOI 10.1089/neu.2008.0548; HOOTS WK, 1996, NEUROTRAUMA, P673; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; KERNEY TJ, 1992, J TRAUMA, V32, P608; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; UEDA S, 1985, J NEUROL NEUROSUR PS, V48, P58, DOI 10.1136/jnnp.48.1.58; VANDERSANDE JJ, 1978, J NEUROSURG, V49, P357, DOI 10.3171/jns.1978.49.3.0357; VECHT CJ, 1975, J NEUROL NEUROSUR PS, V38, P567, DOI 10.1136/jnnp.38.6.567	14	40	43	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2009	26	10					1665	1668		10.1089/neu.2008.0799			4	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	507CT	WOS:000270829200005	19697972				2021-06-18	
J	Jumisko, E; Lexell, J; Soderberg, S				Jumisko, Eija; Lexell, Jan; Soderberg, Siv			The meaning of feeling well in people with moderate or severe traumatic brain injury	JOURNAL OF CLINICAL NURSING			English	Article						brain injury; hermeneutics; interpretation; phenomenological; traumatic; wellbeing	QUALITY-OF-LIFE; SATISFACTION; SELF; INDIVIDUALS; EXPERIENCE; NARRATIVES; ISSUES; SAMPLE; MODEL	Aim. The aim of this study was to elucidate the meaning of feeling well for people with moderate or severe traumatic brain injury. Background. Considerable attention has been given to research consequences, quality of life and satisfaction with life in people with traumatic brain injury. Most studies reveal negative aspects of living with traumatic brain injury. Knowledge that provides an understanding of the meaning of feeling well for people with a traumatic brain injury entails the possibility that they could receive support to feel well, despite their injury. Design. This study used a qualitative research approach, as the aim was to elucidate meaning. Methods. Data were collected through qualitative research interviews with two women and six men with moderate or severe traumatic brain injury who had lived with the injury for between 7-15 years. A phenomenological hermeneutic method was used to interpret the data. Results. The meaning of feeling well for people with moderate or severe traumatic brain injury was that the initially unfamiliar life with traumatic brain injury became familiar. This included finding strength, regaining control over everyday life, being close to someone and being good enough. People with traumatic brain injury felt well when they became reconciled with the circumstances of their life and created a new entity in that life, in which their complete health had been lost. Relevance to clinical practice. This study helps professionals to enhance their understanding and awareness of the possibilities for people with moderate or severe traumatic brain injury to feel well. The study showed that people with traumatic brain injury needed a lot of strength to achieve this. Professionals can help them to feel well by getting to know them and thus find ways to support the person's feeling of wellbeing.	[Jumisko, Eija; Soderberg, Siv] Lulea Univ Technol, Div Nursing, Dept Hlth Sci, SE-97187 Lulea, Sweden; [Lexell, Jan] Univ Lund Hosp, Dept Rehabil, S-22185 Lund, Sweden	Soderberg, S (corresponding author), Lulea Univ Technol, Div Nursing, Dept Hlth Sci, SE-97187 Lulea, Sweden.	siv.soderberg@hu.se		Lexell, Jan/0000-0001-5294-3332	Patient Association for People with Brain Injuries in Sweden (Hjarnkraft)	We thank the participants of this study and the Patient Association for People with Brain Injuries in Sweden (Hjarnkraft). We also thank Pat Shrimpton for editing the language of this manuscript.	Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; ARISTOTELES, 1967, NIKOMACHISKA ETIKEN; Backhouse M, 1999, AUST OCCUP THER J, V46, P99, DOI DOI 10.1046/J.1440-1630.1999.00183.X; BREWIN J, 2001, BRIT J THERAPY REHAB, V8, P218; Buber M., 1997, DISTANS RELATION; Chamberlain DJ, 2006, J ADV NURS, V54, P407, DOI 10.1111/j.1365-2648.2006.03840.x; Conneeley A. L., 2002, BRIT J OCCUPATIONAL, V65, P356; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Duff Diane, 2006, Axone, V27, P9; Eriksson K., 2006, SUFFERING HUMAN BEIN; Eriksson K, 1987, PAUSEN BESKRIVNING V; Gadamer H-G, 2003, GATFULLA HALSAN ESSA; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Guba E.G., 1989, 4 GENERATION EVALUAT; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Hicken BL, 2002, J REHABIL RES DEV, V39, P359; Jacobsson LJ, 2007, ACTA NEUROL SCAND, V116, P300, DOI 10.1111/j.1600-0404.2007.00896.x; Johnson B P, 1995, J Neurosci Nurs, V27, P113; Johnston MV, 2002, ARCH PHYS MED REHAB, V83, pS26, DOI 10.1053/apmr.2002.37100; JUMISKO E, 2005, J NEUROSCIENCE NURSI, V36, P20; Layman DE, 2005, BRAIN INJURY, V19, P909, DOI 10.1080/02699050500109928; Lindseth A, 2004, SCAND J CARING SCI, V18, P145, DOI 10.1111/j.1471-6712.2004.00258.x; McColl MA, 2000, ARCH PHYS MED REHAB, V81, P817, DOI 10.1053/apmr.2000.5567; Morse JM, 2000, QUAL HEALTH RES, V10, P3, DOI 10.1177/104973200129118183; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Nochi M, 1997, DISABIL SOC, V12, P533, DOI 10.1080/09687599727119; Nochi M, 1998, QUAL HEALTH RES, V8, P665, DOI 10.1177/104973239800800507; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Paterson B, 2002, QUAL HEALTH RES, V12, P399, DOI 10.1177/104973202129119973; PATERSON B, 2003, QUALITATIVE HLTH RES, V12, P987; Paterson BL, 2001, J NURS SCHOLARSHIP, V33, P21, DOI 10.1111/j.1547-5069.2001.00021.x; Paterson J., 2002, REHABILITATION NURSI, V27, P13, DOI [10.1002/j.2048-7940.2002.tb01973.x, DOI 10.1002/J.2048-7940.2002.TB01973.X]; PAULI E, 1937, KAMP ELLER RESIGNATI; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; PriceLackey P, 1996, AM J OCCUP THER, V50, P306, DOI 10.5014/ajot.50.4.306; Ricoeur, 1976, INTERPRETATION THEOR; Robertson-Malt S, 1999, J ADV NURS, V29, P290, DOI 10.1046/j.1365-2648.1999.00830.x; Sandelowski M, 1998, RES NURS HEALTH, V21, P467, DOI 10.1002/(SICI)1098-240X(199810)21:5<467::AID-NUR9>3.3.CO;2-X; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Strandberg T, 2006, VUXNA MED FORVARVAD; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; Toombs SK., 1993, MEANING ILLNESS PHEN; Warren L, 1996, J REHABIL RES DEV, V33, P404; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WIKLUND L, 2000, THESIS ABO AKAD ABO; 1998, CONSENS STATEME 1026, V16, P1	48	40	40	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0962-1067	1365-2702		J CLIN NURS	J. Clin. Nurs.	AUG	2009	18	16					2273	2281		10.1111/j.1365-2702.2008.02738.x			9	Nursing	Nursing	467PS	WOS:000267753400004	19583660				2021-06-18	
J	Noori, AJ; Al-Obaidi, WA				Noori, Arass Jalal; Al-Obaidi, Wesal Ali			Traumatic dental injuries among primary school children in Sulaimani city, Iraq	DENTAL TRAUMATOLOGY			English	Article							PERMANENT INCISORS; SCHOOLCHILDREN; BRAZIL; PREVALENCE; TEETH	A cross-sectional survey was carried out through clinical examination of anterior teeth among 4015, 6- to 13-year-old children enrolled in 20 public primary schools of Sulaimani city, northern Iraq. The prevalence and pattern of traumatized anterior teeth were studied in relation to age, gender, type of injury, dental treatment needs, place and cause of the trauma in addition to occlusal relation and upper lip position. The prevalence of children with traumatic dental injuries was found to be 6.1% (243 children) of the total sample. Age and gender were highly significantly associated with dental trauma (P < 0.001). Males were more affected than females and the prevalence increased with age. Simple enamel fracture was the most common type of injury followed by enamel-dentine fracture and concussion. The maxillary central incisors were found to be most affected by trauma followed by mandibular central incisors and the maxillary lateral incisors. The number of injured teeth per child was 1.38 (totally 336 anterior teeth were found with dental trauma) and single tooth trauma was the most common type (69.5%). Results showed that only 7% of the traumatized anterior teeth received treatment and about half (48.7%) of the remaining traumatized teeth did not need dental treatments, while the least treatment type needed was extraction (3.5%). The highest proportions of traumatized children were found with class II division 1 malocclusion and inadequate upper lip coverage. Falls and playing were the most common causes of dental injury, while home was the most common place of trauma occurrence. The present study revealed a relatively low prevalence of dental trauma, but still this figure represents a large number of children. Therefore, educational programs are to be initiated for the community regarding causes, prevention and treatments of traumatic dental injuries.	[Noori, Arass Jalal] Univ Sulaimani, Coll Dent, Sulaimani, Iraq; [Al-Obaidi, Wesal Ali] Univ Baghdad, Coll Dent, Baghdad, Iraq	Noori, AJ (corresponding author), Univ Sulaimani, Coll Dent, Sulaimani, Iraq.	dr.arass@yahoo.com	Noori, Arass/Y-5247-2019	Noori, Arass/0000-0001-9968-6978			Al-Jundi SH, 2002, DENT TRAUMATOL, V18, P181, DOI 10.1034/j.1600-9657.2002.02081.x; Al-Obaidi W, 2002, IRAQI DENT J, V30, P207; Al-Obaidi W, 2002, IRAQI DENT J, V29, P299; ALHAYALI A, 1998, THESIS U BAGHDAD BAG; ALKASSAB AG, 2005, THESIS U BAGHDAD BAG; ALSAYYAB M, 1992, IRAQI DENT J, V1, P37; Andreasen JO, 1981, TRAUMATIC INJURIES T, P19; Baghdady VS, 1981, J DENT RES, V2, P67; Brin I, 1984, Pediatr Dent, V6, P78; Cortes MID, 2002, COMMUNITY DENT ORAL, V30, P193; Cortes MIS, 2001, DENT TRAUMATOL, V17, P22, DOI 10.1034/j.1600-9657.2001.170105.x; ELSAMARRAI S, 1989, THESIS U BAGHDAD BAG; FALOMO B, 1986, J DENT CHILD, V53, P119; GARCIA-GODOY F, 1981, Journal of Pedodontics, V5, P295; Jackson D., 1962, BRIT DENT J, V112, P147; JARVINEN S, 1978, ACTA ODONTOL SCAND, V36, P359, DOI 10.3109/00016357809029088; Kania MJ, 1996, ANGLE ORTHOD, V66, P423; Marcenes W, 2000, INT DENT J, V50, P87, DOI 10.1002/j.1875-595X.2000.tb00804.x; McDonald RE, 2004, DENT CHILD ADOLESCEN, V8th; MILLS JR, 1987, PRINCIPLES PRACTICE, V1, P18; Petersson HG, 1996, EUR J ORAL SCI, V104, P436; Rai S B, 1998, J Indian Soc Pedod Prev Dent, V16, P44; Sennhenn-Kirchner S, 2006, DENT TRAUMATOL, V22, P237, DOI 10.1111/j.1600-9657.2006.00383.x; Skaare AB, 2003, DENT TRAUMATOL, V19, P304, DOI 10.1046/j.1600-4469.2003.00211.x; STOCKWELL AJ, 1988, COMMUNITY DENT ORAL, V16, P294, DOI 10.1111/j.1600-0528.1988.tb01779.x; Sullivan Debra D, 2002, JAAPA, V15, P48; Traebert Jefferson, 2003, Oral Health Prev Dent, V1, P317; Traebert J, 2006, DENT TRAUMATOL, V22, P173, DOI 10.1111/j.1600-9657.2006.00359.x; Wilson S, 1997, PEDIATR EMERG CARE, V13, P12, DOI 10.1097/00006565-199702000-00004; YAGOT KH, 1988, COMMUNITY DENT ORAL, V16, P292, DOI 10.1111/j.1600-0528.1988.tb01778.x	30	40	44	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1600-4469	1600-9657		DENT TRAUMATOL	Dent. Traumatol.	AUG	2009	25	4					442	446		10.1111/j.1600-9657.2009.00791.x			5	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	469FP	WOS:000267881600015	19496800				2021-06-18	
J	Schlenk, F; Vajkoczy, P; Sarrafzadeh, A				Schlenk, Florian; Vajkoczy, Peter; Sarrafzadeh, Asita			Inpatient Hyperglycemia Following Aneurysmal Subarachnoid Hemorrhage: Relation to Cerebral Metabolism and Outcome	NEUROCRITICAL CARE			English	Article						Cerebral metabolism; Microdialysis; Subarachnoid hemorrhage; Hyperglycemia; Glucose; Outcome	INTENSIVE INSULIN THERAPY; CRITICALLY-ILL PATIENTS; TRAUMATIC BRAIN-INJURY; INTRACEREBRAL MICRODIALYSIS; ENERGY-METABOLISM; PLASMA-GLUCOSE; COMPLICATIONS; IMPACT; VALUES; VASOSPASM	Despite its clear association with impaired prognosis, it remains controversial whether hyperglycemia after aneurysmal subarachnoid hemorrhage (SAH) actively contributes to neuronal damage. This study aimed to identify a threshold for blood glucose predicting unfavorable outcome, and to evaluate differences in cerebral metabolism in normo and hyperglycemic SAH patients. Prospectively, blood glucose and cerebral metabolism, measured by cerebral microdialysis, were evaluated in 178 patients (WFNS grade I-V; age 51.6 +/- A 12.4 years) during days 1-7 after SAH. Patients were classified into groups with mean blood glucose levels a parts per thousand currency sign/> 6.1 mmol/l (110 mg/dl) and 7.8 mmol/l (140 mg/dl). Glasgow Outcome Score was assessed after 12 months. Higher inpatient blood glucose was associated with impaired prognosis, with a threshold of 7.5 mmol/l (135 mg/dl) distinguishing best between favorable and unfavorable outcome. Inpatient glucose levels > 6.1 mmol/l (110 mg/dl) were associated with higher cerebral lactate and lactate/pyruvate ratio (P < 0.05). Cerebral glucose was elevated only at blood levels > 7.8 mmol/l (140 mg/dl). Inpatient glucose levels above 7.8 mmol/l (140 mg/dl) were independent predictors of unfavorable outcome and mortality. Blood glucose levels > 7.8 mmol/l (140 mg/dl), but not levels > 6.1 mmol/l (110 mg/dl), independently predicted unfavorable outcome. While blood glucose levels > 6.1 mmol/l (110 mg/dl) were already associated with slight metabolic derangements, cerebral glucose increased only at blood levels > 7.8 mmol/l (140 mg/dl). Considering the risks associated with tight glycemic control, a moderate regimen accepting blood glucose levels up to 7.8 mmol/l (140 mg/dl) might be more reasonable after SAH.	[Schlenk, Florian; Vajkoczy, Peter; Sarrafzadeh, Asita] Charite Univ Med Berlin, Charite Campus Virchow Med Ctr, Dept Neurosurg, D-13353 Berlin, Germany	Sarrafzadeh, A (corresponding author), Charite Univ Med Berlin, Charite Campus Virchow Med Ctr, Dept Neurosurg, Augustenburger Pl 1, D-13353 Berlin, Germany.	asita.sarrafzadeh@charite.de					Arabi YM, 2008, CRIT CARE MED, V36, P3190, DOI 10.1097/CCM.0b013e31818f21aa; Badjatia N, 2005, CRIT CARE MED, V33, P1603, DOI 10.1097/01.CCM.0000168054.60538.2B; Bell DA, 2005, BRIT J NEUROSURG, V19, P21, DOI 10.1080/02688690500089423; Bilotta Federico, 2007, J Neurosurg Anesthesiol, V19, P156, DOI 10.1097/ANA.0b013e3180338e69; BLACK CT, 1990, J TRAUMA, V30, P830, DOI 10.1097/00005373-199007000-00012; BLACK CT, 1990, J TRAUMA, V30, P832, DOI DOI 10.1097/00005373-199007000-00012; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Diaz-Parejo P, 2003, INTENS CARE MED, V29, P544, DOI 10.1007/s00134-003-1669-3; DRAKE CG, 1988, J NEUROSURG, V68, P985; Falciglia M, 2007, CURR OPIN CLIN NUTR, V10, P498, DOI 10.1097/MCO.0b013e3281a3bf0a; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Frontera JA, 2006, STROKE, V37, P199, DOI 10.1161/01.STR.0000194960.73883.0f; Frontera JA, 2008, NEUROSURGERY, V62, P80, DOI 10.1227/01.NEU.0000311064.18368.EA; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; JENNETT B, 1975, LANCET, V1, P480; KATSURA K, 1992, EUR J NEUROSCI, V4, P166, DOI 10.1111/j.1460-9568.1992.tb00863.x; Lanzino G, 1999, J NEUROSURG, V90, P1018, DOI 10.3171/jns.1999.90.6.1018; LANZINO G, 1993, J NEUROSURG, V79, P885, DOI 10.3171/jns.1993.79.6.0885; LI PA, 1995, NEUROBIOL DIS, V2, P97, DOI 10.1006/nbdi.1995.0010; Nilsson OG, 1996, ACT NEUR S, V67, P45; Oddo M, 2008, CRIT CARE MED, V36, P3233, DOI 10.1097/CCM.0b013e31818f4026; Prakash A, 2008, CURR OPIN ANESTHESIO, V21, P565, DOI 10.1097/ACO.0b013e32830f44e4; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Samuelsson C, 2007, J CEREBR BLOOD F MET, V27, P1309, DOI 10.1038/sj.jcbfm.9600433; Sarrafzadeh A, 2004, J NEUROSURG, V100, P400, DOI 10.3171/jns.2004.100.3.0400; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; Schlenk F, 2008, INTENS CARE MED, V34, P1200, DOI 10.1007/s00134-008-1044-5; Schlenk F, 2008, CRIT CARE, V12, DOI 10.1186/cc6776; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; WOO E, 1988, STROKE, V19, P1359, DOI 10.1161/01.STR.19.11.1359	37	40	44	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2009	11	1					56	63		10.1007/s12028-009-9222-z			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	468AU	WOS:000267786400011	19418265				2021-06-18	
J	Lima, FD; Oliveira, MS; Furian, AF; Souza, MA; Rambo, LM; Ribeiro, LR; Silva, LFA; Retamoso, LT; Hoffmann, MS; Magni, DV; Pereira, L; Fighera, MR; Mello, CF; Royes, LFF				Lima, Frederico Diniz; Oliveira, Mauro Schneider; Furian, Ana Flavia; Souza, Mauren Assis; Rambo, Leonardo Magno; Ribeiro, Leandro Rodrigo; Almeida Silva, Luiz Fernando; Retamoso, Leandro Thies; Hoffmann, Mauricio Scopel; Magni, Danieli Valnes; Pereira, Leticia; Fighera, Michele Rechia; Mello, Carlos Fernando; Freire Royes, Luiz Fernando			Adaptation to oxidative challenge induced by chronic physical exercise prevents Na+,K+-ATPase activity inhibition after traumatic brain injury	BRAIN RESEARCH			English	Article						Traumatic brain injury; Na+,K+-ATPase; Oxidative damage; Physical exercise	NA+-K+-ATPASE; LATERAL FLUID PERCUSSION; INDUCED ENDOCYTOSIS; EPITHELIAL-CELLS; FREE-RADICALS; RAT-BRAIN; STRESS; LACTATE; METABOLISM; HIPPOCAMPAL	Physical exercise is likely to alter brain function and to afford neuroprotection in several neurological diseases. Although the favorable effects of physical exercise on traumatic brain injury (TBI) patients is well known, little information is available regarding the role of free radicals in the improvement induced by physical exercise in an experimental model of TBI induced by fluid percussion injury (FPI). Thus, we investigated whether 6 weeks of swimming training protects against oxidative damage (measured by protein carbonylation and thiobarbituric acid-reactive substances-TBARS) and neurochemical alterations represented by immunodetection of a subunit and activity of Na+,K+-ATPase after FPI in cerebral cortex of rats. Statistical analysis revealed that physical training protected against FPI-induced TBARS and protein carbonylation increase. In addition, physical training was effective against Na+,K+-ATPase enzyme activity inhibition and alpha(1) subunit level decrease after FPI. Pearson's correlation analysis revealed that the decrease in levels of catalytic alpha(1) subunit of Na+,K+-ATPase induced FPI correlated with TBARS and protein carbonylation content increase. Furthermore, the effective protection exerted by physical training against FPI-induced free radical correlated with the immunocontent of the catalytic alpha(1) subunit maintenance. These data suggest that TBI-induced reactive oxygen species (ROS) generation decreases Na+,K+-ATPase activity by decreasing the total number of enzyme molecules, and that physical exercise protects against this effect. Therefore, the effective protection of selected targets, such as Na+,K+-ATPase induced by physical training, supports the idea that physical training may exert prophylactic effects on neuronal cell dysfunction and damage associated with TBI. Published by Elsevier B.V.	[Almeida Silva, Luiz Fernando; Retamoso, Leandro Thies] Univ Fed Santa Maria, Dept Metodos & Tecn Desport, Ctr Educ Fis & Desportos, BR-97105900 Santa Maria, RS, Brazil; [Lima, Frederico Diniz; Oliveira, Mauro Schneider; Furian, Ana Flavia; Souza, Mauren Assis; Rambo, Leonardo Magno; Ribeiro, Leandro Rodrigo; Almeida Silva, Luiz Fernando; Retamoso, Leandro Thies; Hoffmann, Mauricio Scopel; Pereira, Leticia; Fighera, Michele Rechia; Mello, Carlos Fernando; Freire Royes, Luiz Fernando] Univ Fed Santa Maria, Dept Fisiol, Ctr Ciencias Saude, Lab Neurotoxicidade & Psicofarmacol, BR-97105900 Santa Maria, RS, Brazil; [Oliveira, Mauro Schneider; Furian, Ana Flavia; Fighera, Michele Rechia] Univ Fed Rio Grande do Sul, Programa Posgrad Ciencias Biol Bioquim, BR-90035003 Porto Alegre, RS, Brazil; [Magni, Danieli Valnes; Freire Royes, Luiz Fernando] Univ Fed Santa Maria, Dept Quim, Lab Neurotoxicidade, Ctr Ciencias Nat & Exatas, BR-97105900 Santa Maria, RS, Brazil; [Fighera, Michele Rechia; Freire Royes, Luiz Fernando] Univ Fed Santa Maria, Dept Pediat, Ctr Ciencias Saude, BR-97105900 Santa Maria, RS, Brazil	Royes, LFF (corresponding author), Univ Fed Santa Maria, Dept Metodos & Tecn Desport, Ctr Educ Fis & Desportos, BR-97105900 Santa Maria, RS, Brazil.	nandoroyes@yahoo.com.br	Rambo, Leonardo/F-8195-2012; Souza, Mauren/A-7990-2015; Hoffmann, Mauricio/AAM-9899-2020; Fighera, Michele R/J-9576-2014; Oliveira, Mauro Schneider/G-3437-2012; Mello, Carlos/C-7188-2013	Hoffmann, Mauricio/0000-0003-4232-3169; Oliveira, Mauro Schneider/0000-0002-5381-1208; Mello, Carlos/0000-0002-1326-1045; Ribeiro, Leandro/0000-0002-8442-4075; Rambo, Leonardo/0000-0002-4769-3663; Almeida Silva, Luiz Fernando/0000-0002-7621-4836	CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [500120/2003-0]; CAPESCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [80-23]	Work supported by CNPq (grant: 500120/2003-0). C.F. Mello and A.F. Furian are the recipients of CNPq fellowships. M.S. Oliveira is the recipient of a CAPES fellowship. We confirm that we have read the journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. in addition, we would like to state that all authors have seen and approved the study and that no part of the work has been published or is under consideration for publication elsewhere. Moreover, the present study was supported by government funding and has no financial or other relationship that might lead to a conflict of interest. We also would like to declare that all experiments were carried out according to the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23) revised 1996, and that the University Ethics Committee approved the respective protocols.	Ang ET, 2007, CURR MED CHEM, V14, P2564, DOI 10.2174/092986707782023280; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Arida RM, 1999, EPILEPSY RES, V37, P45, DOI 10.1016/S0920-1211(99)00032-7; Banjac A, 2001, PHYSIOL RES, V50, P411; Bentzer P, 2000, J NEUROTRAUM, V17, P441, DOI 10.1089/neu.2000.17.441; Bertorello AM, 1999, AM J PHYSIOL-LUNG C, V276, pL20; BOHANNON RW, 1993, CURR OPIN NEUROL, V6, P765, DOI 10.1097/00019052-199310000-00015; Boveris A, 2008, IUBMB LIFE, V60, P308, DOI 10.1002/iub.46; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carvalho JF, 2005, COMP BIOCHEM PHYS A, V140, P409, DOI 10.1016/j.cbpb.2004.12.002; Chen ZP, 2006, AM J RESP CELL MOL, V35, P127, DOI 10.1165/rcmb.2006-0044OC; Chibalin AV, 1999, J BIOL CHEM, V274, P1920, DOI 10.1074/jbc.274.4.1920; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Dada LA, 2003, J CLIN INVEST, V111, P1057, DOI 10.1172/JCI200316826; Daggan RN, 2000, MED SCI SPORT EXER, V32, P2024, DOI 10.1097/00005768-200012000-00009; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; Dencher NA, 2007, ANN NY ACAD SCI, V1100, P291, DOI 10.1196/annals.1395.030; Dobrota D, 1999, CELL MOL NEUROBIOL, V19, P141, DOI 10.1023/A:1006909927287; Donovan CM, 2000, MED SCI SPORT EXER, V32, P772, DOI 10.1097/00005768-200004000-00009; Endres M, 2003, ANN NEUROL, V54, P582, DOI 10.1002/ana.10722; Erickson KI, 2009, BRIT J SPORT MED, V43, P22, DOI 10.1136/bjsm.2008.052498; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fiske CH, 1925, J BIOL CHEM, V66, P375; FORDYCE DE, 1991, BEHAV BRAIN RES, V46, P123, DOI 10.1016/S0166-4328(05)80105-6; Gladden LB, 2000, MED SCI SPORT EXER, V32, P764, DOI 10.1097/00005768-200004000-00008; Gobatto CA, 2001, COMP BIOCHEM PHYS A, V130, P21, DOI 10.1016/S1095-6433(01)00362-2; Hicks RR, 1998, RESTOR NEUROL NEUROS, V12, P41; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Jamme I, 1995, NEUROREPORT, V7, P333; Jones AM, 2000, SPORTS MED, V29, P373, DOI 10.2165/00007256-200029060-00001; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Kramer AF, 2006, J APPL PHYSIOL, V101, P1237, DOI 10.1152/japplphysiol.00500.2006; LEES GJ, 1990, NEUROSCI LETT, V120, P159, DOI 10.1016/0304-3940(90)90027-7; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; Li S, 2001, NEUROSCIENCE, V107, P675, DOI 10.1016/S0306-4522(01)00385-2; Lima FD, 2008, BEHAV BRAIN RES, V193, P306, DOI 10.1016/j.bbr.2008.05.013; Marquezi ML, 2003, INT J SPORT NUTR EXE, V13, P65, DOI 10.1123/ijsnem.13.1.65; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Oliveira MS, 2004, NEUROSCIENCE, V128, P721, DOI 10.1016/j.neuroscience.2004.07.012; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Packer L, 2008, FREE RADICAL BIO MED, V44, P123, DOI 10.1016/j.freeradbiomed.2007.05.031; Packer L, 2007, FREE RADICAL RES, V41, P951, DOI 10.1080/10715760701490975; Pari L, 2007, TOXICOLOGY, V234, P44, DOI 10.1016/j.tox.2007.01.021; Potts Mathew B, 2006, NeuroRx, V3, P143; PRADA FJA, 2004, R BRAS CIEN MOV, V12, P29; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Siems WG, 1996, FREE RADICAL BIO MED, V20, P215, DOI 10.1016/0891-5849(95)02041-1; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Smith AD, 2003, EXP NEUROL, V184, P31, DOI 10.1016/j.expneurol.2003.08.017; Soustiel JF, 2007, NEUROL RES, V29, P654, DOI 10.1179/016164107X240017; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; STUMMER W, 1994, STROKE, V25, P1862, DOI 10.1161/01.STR.25.9.1862; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Tillerson JL, 2003, NEUROSCIENCE, V119, P899, DOI 10.1016/S0306-4522(03)00096-4; Toldy A, 2005, BRAIN RES BULL, V65, P487, DOI 10.1016/j.brainresbull.2005.02.028; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005; Vaynman S, 2005, NEUROREHAB NEURAL RE, V19, P283, DOI 10.1177/1545968305280753; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Voltarelli FA, 2002, BRAZ J MED BIOL RES, V35, P1389, DOI 10.1590/S0100-879X2002001100018; Wang RY, 2001, BRAIN RES, V922, P140, DOI 10.1016/S0006-8993(01)03154-7; WANNAMETHEE G, 1992, BRIT MED J, V304, P597, DOI 10.1136/bmj.304.6827.597; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wyse ATS, 2000, NEUROREPORT, V11, P2331, DOI 10.1097/00001756-200007140-00052; YAN LJ, 1995, ANAL BIOCHEM, V228, P349, DOI 10.1006/abio.1995.1362; Yilmaz G, 2007, TOHOKU J EXP MED, V211, P23, DOI 10.1620/tjem.211.23	69	40	40	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 7	2009	1279						147	155		10.1016/j.brainres.2009.04.052			9	Neurosciences	Neurosciences & Neurology	466PI	WOS:000267674100016	19422810				2021-06-18	
J	Svoboda, E; Richards, B				Svoboda, Eva; Richards, Brian			Compensating for anterograde amnesia: A new training method that capitalizes on emerging smartphone technologies	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Memory disorders; Rehabilitation; Technology; Neuropsychology; Program evaluation; Cognition	TRAUMATIC BRAIN-INJURY; MEMORY AID; IMPAIRED PATIENTS; FOLLOW-UP; REHABILITATION; ACQUISITION; PEOPLE; SKILL; DISCRIMINATION; INDIVIDUALS	Following a neuropathological event, individuals left with moderate-to-severe memory Impairment are unable to reliably form new memories. The most common challenges involve the capacity to perform a task in the future and to consciously recall a recent event. Disruption of these memory processes leaves the individual trapped in the present,, unable to stay oil track, and alienated from ongoing events. Memory research has demonstrated that implicit memory is often preserved despite severe explicit memory impairment and that preserved memory systems call provide avenues for acquiring new skills and knowledge. A within-subject single-case A(1)-B(1)-A(2)-B(2) experimental design was used to introduce ail established theory-driven training program of technology use for individuals with moderate-to-severe memory impairment. We describe its application to enabling RR, all individual with memory impairment postcolloid cyst removal, to independently support her memory using a commercial smartphone. RR showed successful outcome on both objective and qualitative measures of memory functioning. Moreover, she demonstrated consistent and creative generalization of acquired smartphone skills across a broad range of real-life memory-demanding Circumstances. Our findings suggest that individuals with moderate-to-severe memory impairment are able to capitalize oil emerging commercial technology to support their memory. (JINS, 2009, 15, 629-638.)	[Svoboda, Eva; Richards, Brian] Baycrest, Cognit & Behav Hlth Program, Toronto, ON M6A 2E1, Canada	Svoboda, E (corresponding author), Baycrest, Cognit & Behav Hlth Program, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	esvoboda@baycrest.org					BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; BROOKS DN, 1976, NEUROPSYCHOLOGIA, V14, P111, DOI 10.1016/0028-3932(76)90012-9; Cullen C. N., 1976, NURS TIMES, V72, P45; Donaghy S, 1998, BRAIN INJURY, V12, P1061, DOI 10.1080/026990598121963; Doyon J, 2003, NEUROPSYCHOLOGIA, V41, P252, DOI 10.1016/S0028-3932(02)00158-6; Evans JJ, 2003, J INT NEUROPSYCH SOC, V9, P925, DOI 10.1017/S1355617703960127; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; Gentry T, 2008, BRAIN INJURY, V22, P19, DOI 10.1080/02699050701810688; GLISKY EL, 1986, NEUROPSYCHOLOGIA, V24, P313, DOI 10.1016/0028-3932(86)90017-5; GLISKY EL, 1987, NEUROPSYCHOLOGIA, V25, P893, DOI 10.1016/0028-3932(87)90094-7; GLISKY EL, 1995, NEUROPSYCHOL REHABIL, V5, P299, DOI 10.1080/09602019508401474; Goldstein G, 1998, J REHABIL RES DEV, V35, P238; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Henson RNA, 2003, PROG NEUROBIOL, V70, P53, DOI 10.1016/S0301-0082(03)00086-8; Kim HJ, 1999, BRAIN INJURY, V13, P147, DOI 10.1080/026990599121818; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; MAYLOR EA, 1990, Q J EXP PSYCHOL-A, V42, P471, DOI 10.1080/14640749008401233; MILNER B, 1968, NEUROPSYCHOLOGIA, V6, P215, DOI 10.1016/0028-3932(68)90021-3; Moscovitch M., 1982, AGING COGNITIVE PROC, P55; Oddy M, 2004, NEUROPSYCHOL REHABIL, V14, P481, DOI 10.1080/09602010343000309; RICHARDS B, 1990, J CLIN EXPT NEUROPSY, V12, P395; Schacter Daniel, 1994, P1; Schacter DL, 2004, NAT REV NEUROSCI, V5, P853, DOI 10.1038/nrn1534; SIDMAN M, 1967, J EXP ANAL BEHAV, V10, P3, DOI 10.1901/jeab.1967.10-3; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; Squires EJ, 1996, NEUROPSYCHOL REHABIL, V6, P55, DOI 10.1080/713755494; Stapleton S, 2007, BRAIN INJURY, V21, P401, DOI 10.1080/02699050701252030; TERRACE HS, 1963, J EXP ANAL BEHAV, V6, P1, DOI 10.1901/jeab.1963.6-1; Troyer AK, 2002, J GERONTOL B-PSYCHOL, V57, pP19, DOI 10.1093/geronb/57.1.P19; TULVING E, 1990, SCIENCE, V247, P301, DOI 10.1126/science.2296719; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Wade TK, 2001, BRAIN INJURY, V15, P305, DOI 10.1080/026990501750111256; WILSON BA, 1989, CORTEX, V25, P115, DOI 10.1016/S0010-9452(89)80011-5; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wu M., 2007, UNIVERSAL USABILITY, P317; Yasuda K, 2002, NEUROPSYCHOL REHABIL, V12, P155, DOI 10.1080/09602010143000239	38	40	42	0	28	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2009	15	4					629	638		10.1017/S1355617709090791			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	470EU	WOS:000267958600017	19588540				2021-06-18	
J	Wade, SL; Walz, NC; Carey, JC; Williams, KM				Wade, Shari L.; Walz, Nicolay Chertkoff; Carey, JoAnne C.; Williams, Kendra M.			Brief Report: Description of Feasibility and Satisfaction Findings from an Innovative Online Family Problem-solving Intervention for Adolescents following Traumatic Brain Injury	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article; Proceedings Paper	New Frontiers in Pediatric Brain Injury Meeting	2007	San Diego, CA			acquired brain injury; adolescent; telehealth	CHILDREN	ObjectiveTo describe feasibility and satisfaction findings from an innovative online family problem-solving intervention for adolescents with traumatic brain injury (TBI).MethodsNine adolescents who sustained a moderate to severe TBI in the previous 24 months and their families participated in a novel, online, manualized treatment program (Teen Online Problem Solving, TOPS) consisting of 10 web-based sessions providing information and interactive exercises on cognitive, social, and behavioral skills typically affected by TBI. Web-based sessions were followed by synchronous video conferences with a therapist to review target skills and apply the problem-solving process to family goals.ResultsAll teens and consenting parents completed at least 10 sessions. The website and videoconferences received moderate to high ratings on helpfulness and ease of use. Parents and teens reported increased knowledge regarding targeted knowledge and skills. ConclusionsFindings support the acceptability of TOPS for adolescent TBI.	[Wade, Shari L.] Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Div Pediat Phys Med & Rehabil,Dept Pediat, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA	Wade, SL (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Div Pediat Phys Med & Rehabil,Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org			NHGRI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI) [HG133G050239] Funding Source: Medline		Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Carey JC, 2008, CYBERPSYCHOL BEHAV, V11, P188, DOI 10.1089/cpb.2007.0025; GOODMAN SH, 1995, J ABNORM CHILD PSYCH, V23, P473, DOI 10.1007/BF01447209; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Laatsch L, 2007, J HEAD TRAUMA REHAB, V22, P248, DOI 10.1097/01.HTR.0000281841.92720.0a; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Norman S, 2006, J PSYCHIATR MENT HLT, V13, P771, DOI 10.1111/j.1365-2850.2006.01033.x; Ritterband LM, 2003, J CONSULT CLIN PSYCH, V71, P910, DOI 10.1037/0022-006X.71.5.910; Rotondi AJ, 2005, J HEAD TRAUMA REHAB, V20, P173, DOI 10.1097/00001199-200503000-00005; Spence SH, 2003, J CONSULT CLIN PSYCH, V71, P3, DOI 10.1037/0022-006X.71.1.3; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; 2007, PARENT TEENAGER INTE	14	40	40	0	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693	1465-735X		J PEDIATR PSYCHOL	J. Pediatr. Psychol.	JUN	2009	34	5					517	522		10.1093/jpepsy/jsn081			6	Psychology, Developmental	Psychology	449TH	WOS:000266352400008	18667477	Green Published, Bronze			2021-06-18	
J	Davis, LC; Sander, AM; Struchen, MA; Sherer, M; Nakase-Richardson, R; Malec, JF				Davis, Lynne C.; Sander, Angelle M.; Struchen, Margaret A.; Sherer, Mark; Nakase-Richardson, Risa; Malec, James F.			Medical and Psychosocial Predictors of Caregiver Distress and Perceived Burden Following Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						caregivers; caregiver distress; traumatic brain injury	DISABILITY RATING-SCALE; BLUNT HEAD-INJURY; DEPRESSIVE SYMPTOMS; SOCIAL SUPPORT; PSYCHOLOGICAL DISTRESS; FAMILY CAREGIVERS; ELDERLY-PATIENTS; RELATIVES; ADJUSTMENT; RECOVERY	Objective: To determine whether caregivers' medical and psychiatric histories, coping style, and social support predict global distress and perceived burden. Design: Correlational, cohort study. Participants: A total of 114 caregivers of persons with moderate to severe traumatic brain injury, assessed 1 year postinjury. Measures: Ratings of caregivers' medical and psychiatric history; Disability Rating Scale; Ways of Coping Questionnaire; Multidimensional Scale of Perceived Social Support; Brief Symptom Inventory; and Modified Caregiver Appraisal Scale. Results: Caregivers' medical and psychiatric histories predicted global distress, after accounting for education, sex, income, and relationship, as well as disability of the person with injury. Increased use of escape-avoidance as a coping strategy was related to increased distress. Perceived burden was predicted by disability in the person with injury, use of escape-avoidance, and perceived social support. Conclusions: Caregivers' preinjury functioning is more predictive of global distress, whereas the functioning of the person with injury is more predictive of injury-related burden. Caregivers' medical and psychiatric histories are important considerations when targeting interventions; global stress management strategies may be as important as assisting with injury-related issues.	[Davis, Lynne C.] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX 77019 USA; [Davis, Lynne C.; Sander, Angelle M.; Struchen, Margaret A.; Sherer, Mark] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Nakase-Richardson, Risa] Methodist Rehabil Ctr, Dept Neuropsychol, Jackson, MS USA; [Nakase-Richardson, Risa] James A Haley Vet Hosp, Psychol Serv, Tampa, FL 33612 USA; [Malec, James F.] Rehabil Hosp Indiana, Indianapolis, IN USA	Davis, LC (corresponding author), TIRR Mem Hermann, Brain Injury Res Ctr, 2323 S Shepherd Dr,Ste 907, Houston, TX 77019 USA.	lynne.davis@memorialhermann.org			National Institute on Disability and Rehabilitation Research, US Department of EducationUS Department of Education [H133A980058, H133A70015, H133A980035, H133A980036, H133B031117, H133A070043]	This work was supported in part 4 grants from the National Institute on Disability and Rehabilitation Research, US Department of Education (grant H133A980058, H133A70015, H133A980035, H133A980036, H133B031117, H133A070043).	ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Chwalisz K, 1996, REHABIL PSYCHOL, V41, P91, DOI 10.1037/0090-5550.41.2.91; CHWALISZ K, 1992, REHABIL PSYCHOL, V37, P189, DOI 10.1037/h0079103; DAHLSTROM WG, 1969, MMPI RES DEV CLIN AP; De Jonge P, 2006, PSYCHOSOMATICS, V47, P33, DOI 10.1176/appi.psy.47.1.33; de Jonge P, 2004, AM J GERIAT PSYCHIAT, V12, P57, DOI 10.1176/appi.ajgp.12.1.57; Derogatis L, 1993, BRIEF SYMPTOM INVENT; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; FOLKMAN S, 1980, J HEALTH SOC BEHAV, V21, P219, DOI 10.2307/2136617; Folkman S., 1988, MANUAL WAYS COPING Q; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Goldberg D.P, 1972, DETECTION PSYCHIAT I; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; JENNETT B, 1975, LANCET, V1, P480; Katz S, 2005, BRAIN INJURY, V19, P59, DOI 10.1080/02699050410001719970; KAZARIAN SS, 1991, J COMMUNITY PSYCHOL, V19, P150, DOI 10.1002/1520-6629(199104)19:2<150::AID-JCOP2290190206>3.0.CO;2-J; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; KRAUS JF, 1986, AM J PUBLIC HEALTH, V76, P1345, DOI 10.2105/AJPH.76.11.1345; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LAWTON MP, 1989, J GERONTOL, V44, pP61, DOI 10.1093/geronj/44.3.P61; Lazarus R.S., 1984, STRESS APPRAISAL COP; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Machamer J, 2002, J CLIN EXP NEUROPSYC, V24, P420, DOI 10.1076/jcen.24.4.420.1040; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; McCauley SR, 2001, J INT NEUROPSYCH SOC, V7, P457, DOI 10.1017/S1355617701744025; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Minnes P, 2000, BRAIN INJURY, V14, P737; Nijboer C, 1999, CANCER, V86, P577, DOI 10.1002/(SICI)1097-0142(19990815)86:4<577::AID-CNCR6>3.0.CO;2-S; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Ranchor AV, 2002, QUAL LIFE RES, V11, P101, DOI 10.1023/A:1015053623843; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Sander AM, 2003, ARCH PHYS MED REHAB, V84, P197, DOI 10.1053/apmr.2003.50105; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; SANDER AM, 2006, BRAIN INJURY MED; Struchen MA, 2002, J HEAD TRAUMA REHAB, V17, P132, DOI 10.1097/00001199-200204000-00005; TEASDALE G, 1974, LANCET, V2, P81; Testa JA, 2006, J HEAD TRAUMA REHAB, V21, P236, DOI 10.1097/00001199-200605000-00004; United States Department of Health and Human Services, 2001, MENT HLTH REP SURG G; VITALIANO PP, 1991, PSYCHOL AGING, V6, P392, DOI 10.1037/0882-7974.6.3.392; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; ZIMET GD, 1988, J PERS ASSESS, V52, P30, DOI 10.1207/s15327752jpa5201_2	60	40	41	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2009	24	3					145	154		10.1097/HTR.0b013e3181a0b291			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	448HD	WOS:000266252800001	19461362				2021-06-18	
J	Young, ME; Clark, MH; Goffus, A; Hoane, MR				Young, Michael E.; Clark, M. H.; Goffus, Andrea; Hoane, Michael R.			Mixed effects modeling of Morris water maze data: Advantages and cautionary notes	LEARNING AND MOTIVATION			English	Article						Learning curves; Nonlinear analysis; Repeated measures; Monte Carlo simulation	TRAUMATIC BRAIN-INJURY; LONGITUDINAL DATA; RATS	Morris water maze data are most commonly analyzed using repeated measures analysis of variance in which daily test sessions are analyzed as an unordered categorical variable. This approach, however, may lack power, relies heavily on post hoc tests of daily performance that can complicate interpretation, and does not target the nonlinear trends evidenced in learning data. The present project used Monte Carlo simulation to compare the relative strengths of the traditional approach with both linear and nonlinear mixed effects modeling that identifies the learning function for each animal and condition. Both trend-based mixed effects modeling approaches showed much greater sensitivity to identifying real effects, and the nonlinear approach provided uniformly better fits of learning trends. The common practice of removing a rat from the maze after 90 s, however, proved more problematic for the nonlinear approach and produced an underestimate of y-axis intercepts. (c) 2008 Elsevier Inc. All rights reserved.	[Young, Michael E.; Clark, M. H.; Goffus, Andrea; Hoane, Michael R.] So Illinois Univ, Dept Psychol, Carbondale, IL 62901 USA	Young, ME (corresponding author), So Illinois Univ, Dept Psychol, Mailcode 6502, Carbondale, IL 62901 USA.	meyoung@siu.edu	Young, Michael E./G-5388-2014	Young, Michael E./0000-0003-1493-9548; Hoane, Michael/0000-0001-7779-2657			Bates D.M., 1988, NONLINEAR REGRESSION; Cohen J., 1983, APPL MULTIPLE REGRES; Cudeck R, 2007, ANNU REV PSYCHOL, V58, P615, DOI 10.1146/annurev.psych.58.110405.085520; Davidian M, 2003, J AGR BIOL ENVIR ST, V8, P387, DOI 10.1198/1085711032697; DeFord SM, 2001, PHARMACOL BIOCHEM BE, V69, P611, DOI 10.1016/S0091-3057(01)00559-7; ESTES WK, 1950, PSYCHOL REV, V57, P94, DOI 10.1037/0033-295X.101.2.282; Everitt BS, 1998, BRIT J PSYCHIAT, V172, P7, DOI 10.1192/bjp.172.1.7; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gueorguieva R, 2004, ARCH GEN PSYCHIAT, V61, P310, DOI 10.1001/archpsyc.61.3.310; Gulliksen H, 1942, PSYCHOMETRIKA, V7, P171, DOI 10.1007/BF02288615; Hoane MR, 2007, MAGNESIUM RES, V20, P229; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Jonsson EN, 2000, AAPS PHARMSCI, V2, part. no.; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Macmillan N. A., 2004, DETECTION THEORY USE; Maxwell SE, 2004, PSYCHOL METHODS, V9, P147, DOI 10.1037/1082-989X.9.2.147; Pinheiro JC., 2004, MIXED EFFECTS MODELS; Pitt MA, 2002, TRENDS COGN SCI, V6, P421, DOI 10.1016/S1364-6613(02)01964-2; Shkedy Z, 2005, J BIOPHARM STAT, V15, P205, DOI 10.1081/BIP-200048815; SHULL RL, 1991, EXPT ANAL BEHAV, V2, P243; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006	21	40	40	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0023-9690			LEARN MOTIV	Learn. Motiv.	MAY	2009	40	2					160	177		10.1016/j.lmot.2008.10.004			18	Psychology, Biological; Psychology, Experimental	Psychology	429LG	WOS:000264921300005					2021-06-18	
J	Crawford, F; Wood, M; Ferguson, S; Mathura, V; Gupta, P; Humphrey, J; Mouzon, B; Laporte, V; Margenthaler, E; O'Steen, B; Hayes, R; Roses, A; Mullan, M				Crawford, F.; Wood, M.; Ferguson, S.; Mathura, V.; Gupta, P.; Humphrey, J.; Mouzon, B.; Laporte, V.; Margenthaler, E.; O'Steen, B.; Hayes, R.; Roses, A.; Mullan, M.			APOLIPOPROTEIN E-GENOTYPE DEPENDENT HIPPOCAMPAL AND CORTICAL RESPONSES TO TRAUMATIC BRAIN INJURY	NEUROSCIENCE			English	Article						apolipoprotein E; traumatic brain injury; genomic; Ingenuity Pathway Analysis; microarray	CLOSED-HEAD INJURY; INTIMA-MEDIA THICKNESS; CENTRAL-NERVOUS-SYSTEM; TRANSGENIC MICE; ALZHEIMERS-DISEASE; ENVIRONMENTAL STIMULATION; MITOCHONDRIAL BIOGENESIS; ENHANCED NEUROGENESIS; NEURONS; EXPRESSION	The different alleles of the apolipoprotein E gene (APOE-gene, ApoE-protein) have been reported to influence recovery after traumatic brain injury (TBI) in both human patients and animal models, with the e4 allele typically conferring poorer prognosis for recovery. How the E4 allele, and consequently the ApoE4 isoform, affects recovery is unknown, but proposed mechanisms include neurogenesis, inflammatory response and amyloid processing or metabolism. Using the controlled cortical impact (CCI) model of brain injury and microarray technology we have characterized the genomic response to injury in the brains of APOE2, APOE3 and APOE4 transgenic mice and identified quantitatively and qualitatively significantly different profiles of gene expression in both the hippocampus and the cortex of the APOE3 mice compared to APOE4. The observed gene regulation predicts functional consequences including effects on inflammatory processes, cell growth and proliferation, and cellular signaling, and may suggest that the poor recovery post-TBI in APOE4 animals and human patients is less likely to result from a specific activation of neurodegenerative mechanisms than a loss of reparative capability. (C) 2009 IBRO. Published by Elsevier Ltd. All rights reserved.	[Crawford, F.; Wood, M.; Ferguson, S.; Mathura, V.; Gupta, P.; Humphrey, J.; Mouzon, B.; Laporte, V.; Margenthaler, E.; Mullan, M.] Roskamp Inst, Sarasota, FL 34243 USA; [Crawford, F.; Wood, M.; Ferguson, S.; Humphrey, J.; Mouzon, B.; Mullan, M.] James A Haley Vet Hosp, Tampa, FL 33612 USA; [O'Steen, B.] Univ Florida, McKnight Brain Inst, Dept Neurosci, Gainesville, FL 32610 USA; [Hayes, R.] Banyan Biomarkers, Alachua, FL 32615 USA; [Roses, A.] Duke Univ, R David Thomas Execut Training Ctr, Durham, NC 27708 USA	Crawford, F (corresponding author), Roskamp Inst, 2040 Whitfield Ave, Sarasota, FL 34243 USA.	fcrawford@rfdn.org		Mullan, Michael/0000-0002-1473-7527	VA Merit awardUS Department of Veterans Affairs	This work was made possible by a VA Merit award to Dr. F. Crawford and the generosity of Robert and Diane Roskamp.	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Belinson H, 2008, J NEUROSCI, V28, P4690, DOI 10.1523/JNEUROSCI.5633-07.2008; Braun H, 2002, J NEUROTRAUM, V19, P975, DOI 10.1089/089771502320317122; Brecht WJ, 2004, J NEUROSCI, V24, P2527, DOI 10.1523/JNEUROSCI.4315-03.2004; Brodbeck J, 2008, P NATL ACAD SCI USA, V105, P1343, DOI 10.1073/pnas.0709906104; Brown CM, 2007, ENDOCRINOLOGY, V148, P3383, DOI 10.1210/en.2006-1200; Brown R, 2008, NEUROSCI LETT, V432, P73, DOI 10.1016/j.neulet.2007.12.008; Buttini M, 1999, J NEUROSCI, V19, P4867; Chang SJ, 2005, P NATL ACAD SCI USA, V102, P18694, DOI 10.1073/pnas.0508254102; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; Chen SA, 2005, J ALZHEIMERS DIS, V7, P25; Chiba S, 2007, J REPROD DEVELOP, V53, P297, DOI 10.1262/jrd.18108; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; D Roses A, 2007, PHARMACOGENOMICS J, V7, P10, DOI 10.1038/sj.tpj.6500397; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Debett S, 2006, STROKE, V37, P2917, DOI 10.1161/01.STR.0000249011.94055.00; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Ezra Y, 2003, NEUROSCIENCE, V121, P315, DOI 10.1016/S0306-4522(03)00436-6; Guo L, 2004, J MOL NEUROSCI, V23, P205, DOI 10.1385/JMN:23:3:205; HAN SH, 1994, J NEUROPATH EXP NEUR, V53, P535, DOI 10.1097/00005072-199409000-00013; HAN SH, 1994, EXP NEUROL, V128, P13, DOI 10.1006/exnr.1994.1108; Harris FM, 2003, P NATL ACAD SCI USA, V100, P10966, DOI 10.1073/pnas.1434398100; HARTMANN H, 1994, BIOCHEM BIOPH RES CO, V200, P1185, DOI 10.1006/bbrc.1994.1576; Hillen T, 2000, J INTERN MED, V247, P679, DOI 10.1046/j.1365-2796.2000.00681.x; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Ilveskoski E, 1999, CIRCULATION, V100, P608, DOI 10.1161/01.CIR.100.6.608; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kohara K, 2002, HYPERTENS RES, V25, P31, DOI 10.1291/hypres.25.31; Lessner SM, 2002, AM J PATHOL, V160, P2145, DOI 10.1016/S0002-9440(10)61163-7; Levi O, 2003, NEUROBIOL DIS, V13, P273, DOI 10.1016/S0969-9961(03)00045-7; Levi O, 2007, J NEUROCHEM, V103, P1031, DOI 10.1111/j.1471-4159.2007.04810.x; Levi O, 2007, J NEUROCHEM, V100, P202, DOI 10.1111/j.1471-4159.2006.04189.x; Li Z, 2004, CELL, V119, P873, DOI 10.1016/j.cell.2004.11.003; Liu MC, 2006, BIOCHEM J, V394, P715, DOI 10.1042/BJ20050905; Maezawa I, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-10; Mahley RW, 2006, P NATL ACAD SCI USA, V103, P5644, DOI 10.1073/pnas.0600549103; Misra UK, 2001, J LEUKOCYTE BIOL, V70, P677; Morris DC, 2007, NEUROSCI LETT, V418, P170, DOI 10.1016/j.neulet.2007.03.039; Muller W, 1998, BRAIN PATHOL, V8, P641; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; Ophir G, 2005, NEUROBIOL DIS, V20, P709, DOI 10.1016/j.nbd.2005.05.002; Ophir G, 2003, NEUROBIOL DIS, V12, P56, DOI 10.1016/S0969-9961(02)00005-0; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; Ramos EM, 2006, ARCH NEUROL-CHICAGO, V63, P1165, DOI 10.1001/archneur.63.8.1165; Rasbach KA, 2007, J BIOL CHEM, V282, P2355, DOI 10.1074/jbc.M608009200; Reynolds IJ, 2004, J BIOENERG BIOMEMBR, V36, P283, DOI 10.1023/B:JOBB.0000041754.78313.c2; Rintoul GL, 2003, J NEUROSCI, V23, P7881; Roses AD, 1998, NEUROBIOL AGING, V19, pS53, DOI 10.1016/S0197-4580(98)00030-X; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Sasaki T, 2006, J NEUROSCI RES, V84, P1187, DOI 10.1002/jnr.21036; Seki Tatsunori, 2003, Anatomical Science International, V78, P69, DOI 10.1046/j.0022-7722.2003.00043.x; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Strum JC, 2007, J ALZHEIMERS DIS, V11, P45; Sun YL, 1998, J NEUROSCI, V18, P3261; Tesseur I, 2000, AM J PATHOL, V157, P1495, DOI 10.1016/S0002-9440(10)64788-8; Tolar M, 1999, J NEUROSCI, V19, P7100, DOI 10.1523/JNEUROSCI.19-16-07100.1999; Tsoi LM, 2007, ARCH BIOCHEM BIOPHYS, V460, P33, DOI 10.1016/j.abb.2007.01.019; Tziakas DN, 2006, J AM COLL CARDIOL, V48, P2471, DOI 10.1016/j.jacc.2006.08.032; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Wang H, 2007, NEUROSCIENCE, V144, P1324, DOI 10.1016/j.neuroscience.2006.11.017; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; Wang XS, 1997, J CELL PHYSIOL, V173, P73, DOI 10.1002/(SICI)1097-4652(199710)173:1<73::AID-JCP9>3.0.CO;2-G; Westrick RJ, 2001, CIRCULATION, V103, P3044, DOI 10.1161/hc2501.092492; Williams KR, 1997, NEUROBIOL DIS, V4, P58, DOI 10.1006/nbdi.1997.0131; Xu PT, 1996, NEUROBIOL DIS, V3, P229, DOI 10.1006/nbdi.1996.0023; YIN W, 2008, STROKE          0821	69	40	42	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	APR 10	2009	159	4					1349	1362		10.1016/j.neuroscience.2009.01.033			14	Neurosciences	Neurosciences & Neurology	432JR	WOS:000265129800017	19409232				2021-06-18	
J	Adamo, MA; Drazin, D; Waldman, JB				Adamo, Matthew A.; Drazin, Doniel; Waldman, John B.			Decompressive craniectomy and postoperative complication management in infants and toddlers with severe traumatic brain injuries Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article; Proceedings Paper	Annual Meeting of the American-Association-of-Neurological-Surgeons/Congress of Neurological Surgeons Joint Section on Disorders of the Spine and Peripheral Nerves	MAR 01, 2008	Orlando, FL	Amer Assoc Neurol Surg		complication; decompressive craniectomy; head trauma; outcome; traumatic brain injury	HEAD-INJURY; CHILDREN; HYPOTHERMIA	Object. Infants with severe traumatic brain injury represent a therapeutic challenge. The internal absence of open space within the infant cranial vault makes volume increases poorly tolerated. This report presents 7 cases of decompressive craniectomy in infants with cerebral edema. Methods. The authors reviewed the medical charts of infants with brain injuries who presented to Albany Medical Center Hospital between January 2004 and July 2007. Variables that were examined included patient age, physical examination results at admission, positive imaging findings, surgery performed, complications, requirement of permanent CSF diversion, and physical examination results at discharge and outpatient follow-up using the King's Outcome Scale for Childhood Head Injury. Seven infants met the inclusion criteria for the study. Six infants experienced nonaccidental trauma, and I had a large infarction of the middle cerebral artery territory secondary to a carotid dissection. At admission, all patients were minimally responsive, 4 had equal and minimally reactive pupils, 3 had anisocoria with the enlarged pupil on the same side as the brain lesion, and all had right-sided hemiparesis. Six patients received a left hemicraniectomy, whereas I received a left frontal craniectomy. In all cases, bone was cultured and stored at the bone bank. Results. Postoperatively, 3 patients who developed draining CSF fistulas needed insertions of external ventricular drains, with incisions oversewn using nylon sutures and a liquid bonding agent. After prolonged CSF drainage and wound care, these patients all developed epidural and subdural empyemas necessitating surgical drainage and debridement. Methicillin-resistant Staphylococcus aureus was found in 2 patients and Enterococcus in the third. All patients developed hydrocephalus necessitating the insertion of a ventriculoperitoneal shunt, and all had bone replaced within 1-6 months from the time of the original operation. Two patients required reoperation due to bone resorption. At outpatient follow-up visits, all had scores of 3 or 4 on the King's Outcome Scale for Childhood Head Injury. Each patient was awake, interactive, and could sit, as well as either crawl or walk with assistance. All had persistent, improving right-sided hemiparesis and spasticity. Conclusions. Despite poor initial examination results, infants with severe traumatic brain injury can safely undergo decompressive craniectomy with reasonable neurological recovery. Postoperative complications must be anticipated and treated appropriately. Due to the high rate of CSF fistulas encountered in this study, it appears reasonable to recommend both the suturing in of a dural augmentation graft and the placement of either a subdural drain or a ventriculostomy catheter to relieve pressure on the healing surgical incision. Also, one might want to consider using a T-shaped incision as opposed to the traditional reverse question mark-shaped incision because wound healing may be compromised due to the potential interruption of the circulation to the posterior and inferior limb with this latter incision. (DOI: 10.3171/2008.12.PEDS08310)	[Adamo, Matthew A.] UPMC, Childrens Hosp, Dept Neurosurg, Pittsburgh, PA 15213 USA; [Drazin, Doniel; Waldman, John B.] Albany Med Ctr, Div Neurosurg, Albany, NY USA	Adamo, MA (corresponding author), UPMC, Childrens Hosp, Dept Neurosurg, 3705 5th Ave,3rd Floor,Purple Bldg, Pittsburgh, PA 15213 USA.	matthew.a.adamo@gmail.com					Calvert S, 2008, DEV MED CHILD NEUROL, V50, P426, DOI 10.1111/j.1469-8749.2008.02061.x; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Gasser S, 2003, J NEUROSURG ANESTH, V15, P240, DOI 10.1097/00008506-200307000-00012; Golden N, 2005, J CLIN NEUROSCI, V12, P235, DOI 10.1016/j.jocn.2004.11.001; Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Miyake H, 2002, CHILD NERV SYST, V18, P500, DOI 10.1007/s00381-002-0596-x; Ok SH, 2005, ACTA ANAESTH SCAND, V49, P883, DOI 10.1111/j.1399-6576.2005.00728.x; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Qiu Wu-si, 2005, Chin J Traumatol, V8, P27; Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361; Rutigliano D, 2006, J PEDIATR SURG, V41, P83, DOI 10.1016/j.jpedsurg.2005.10.010	13	40	43	0	8	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	APR	2009	3	4					334	339		10.3171/2008.12.PEDS08310			6	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	424UT	WOS:000264594500018	19338415				2021-06-18	
J	Caso, JR; Hurtado, O; Pereira, MP; Garcia-Bueno, B; Menchen, L; Alou, L; Gomez-Lus, ML; Moro, MA; Lizasoain, I; Leza, JC				Caso, Javier R.; Hurtado, Olivia; Pereira, Marta P.; Garcia-Bueno, Borja; Menchen, Luis; Alou, Luis; Luisa Gomez-Lus, Maria; Moro, Maria A.; Lizasoain, Ignacio; Leza, Juan C.			Colonic bacterial translocation as a possible factor in stress-worsening experimental stroke outcome	AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY			English	Article						stress; stroke; bacterial translocation; intestinal barrier; stroke outcome	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; TOLL-LIKE RECEPTOR-4; GASTROINTESTINAL-TRACT; BARRIER FUNCTION; INNATE IMMUNITY; INFLAMMATION; RATS; NEUROPROTECTION; PERMEABILITY	Caso JR, Hurtado O, Pereira MP, Garcia-Bueno B, Menchen L, Alou L, Gomez-Lus ML, Moro MA, Lizasoain I, Leza JC. Colonic bacterial translocation as a possible factor in stress-worsening experimental stroke outcome. Am J Physiol Regul Integr Comp Physiol 296: R979-R985, 2009. First published February 4, 2009; doi:10.1152/ajpregu.90825.2008.-Stress is known to be one of the risk factors of stroke, but only a few experimental studies have examined the possible mechanisms by which prior stress may affect stroke outcome. In stroke patients, infections impede neurological recovery and increase morbidity as well as mortality. We previously reported that stress induces a bacterial translocation and that prior immobilization stress worsens experimental stroke outcome through mechanisms that involve inflammatory mediators such as release of proinflammatory cytokines and enzyme activation. We now investigate whether bacterial translocation from the intestinal flora of rats with stress before experimental ischemia is involved in stroke outcome. We used an experimental paradigm consisting of exposure of Fischer rats to repeated immobilization sessions before permanent middle cerebral artery occlusion (MCAO). The presence of bacteria and the levels and expression of different mediators involved in the bacterial translocation were analyzed. Our results indicate that stress before stroke is related to the presence of bacteria in different organs (mesenteric nodes, spleen, liver, and lung) after MCAO and increases inflammatory colonic parameters (such as cyclooxygenase-2, inducible nitric oxide synthase, and myeloperoxidase), but decreases colonic immunoglobulin A, and these results are correlated with colonic inflammation and bacterial translocation. Understanding the implication of bacterial translocation during stress-induced stroke worsening is of great potential clinical relevance, given the high incidence of infections after severe stroke and their main role in mortality and morbidity in stroke patients.	[Caso, Javier R.; Hurtado, Olivia; Pereira, Marta P.; Garcia-Bueno, Borja; Menchen, Luis; Moro, Maria A.; Lizasoain, Ignacio; Leza, Juan C.] Univ Complutense, Fac Med, Dept Pharmacol, E-28040 Madrid, Spain; [Menchen, Luis] Univ Complutense, Fac Med, Dept Microbiol 1, E-28040 Madrid, Spain; [Menchen, Luis] Hosp Gen Univ Gregorio Maranon, Serv Aparato Digestivo, Madrid, Spain; [Menchen, Luis] CIBEREHD, Madrid, Spain; [Garcia-Bueno, Borja; Leza, Juan C.] CIBERSAM, Ctr Invest Biomed Red Salud Mental, Madrid, Spain	Leza, JC (corresponding author), Univ Complutense, Fac Med, Dept Pharmacol, E-28040 Madrid, Spain.	jcleza@med.ucm.es	Pereira, Marta/L-3208-2014; Caso, Javier R./G-2243-2017; Gomez-Lus, Maria Luisa/N-5295-2016; HURTADO, OLIVIA/E-7248-2012; Lizasoain, Ignacio/K-9844-2014; Moro, Maria/K-6396-2014; Garcia-Bueno, Borja/ABG-7536-2020; Alou, Luis/B-8170-2011; Pereira, Marta/ABF-7999-2020	Pereira, Marta/0000-0002-9347-957X; Caso, Javier R./0000-0001-8622-749X; Gomez-Lus, Maria Luisa/0000-0002-8832-1751; HURTADO, OLIVIA/0000-0001-5735-7092; Lizasoain, Ignacio/0000-0002-6028-7379; Moro, Maria/0000-0003-1010-8237; Alou, Luis/0000-0002-0859-008X; Pereira, Marta/0000-0002-9347-957X; Garcia Bueno, Borja/0000-0001-7320-1530; Menchen, Luis/0000-0001-9490-3726; LEZA, JUAN CARLOS/0000-0002-9901-0094	Spanish Ministry of Science and Technology and HealthSpanish Government [SAF2007-63138, RD06/0026/0005, S-BIO-0170/2006, SAF2005-05960, SAF2006-01753]	This work was supported by the following grants from the Spanish Ministry of Science and Technology and Health (CIBERSam): SAF2007-63138 (J. C. Leza), RD06/0026/0005 (I. Lizasoain), S-BIO-0170/2006 MULTIMAG (I. Lizasoain), SAF2005-05960 (I. Lizasoain), and SAF2006-01753 (M. A. Moro).	Ando T, 2000, AM J PHYSIOL-REG I, V279, pR2164; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Cao CX, 2007, BIOCHEM BIOPH RES CO, V353, P509, DOI 10.1016/j.bbrc.2006.12.057; Caso JR, 2006, NEUROSCIENCE, V142, P59, DOI 10.1016/j.neuroscience.2006.06.009; Caso JR, 2008, CURR MOL MED, V8, P299, DOI 10.2174/156652408784533751; Caso JR, 2008, STROKE, V39, P1314, DOI 10.1161/STROKEAHA.107.498212; Caso JR, 2007, EUR NEUROPSYCHOPHARM, V17, P600, DOI 10.1016/j.euroneuro.2007.02.009; Caso JR, 2007, CIRCULATION, V115, P1599, DOI 10.1161/CIRCULATIONAHA.106.603431; Chamorro A, 2005, STROKE, V36, P1495, DOI 10.1161/01.STR.0000170644.15504.49; Collins SM, 2001, AM J PHYSIOL-GASTR L, V280, pG315; Colon AL, 2004, DIGEST DIS SCI, V49, P1713, DOI 10.1023/B:DDAS.0000043391.64073.e4; De Cristobal J, 2001, J NEUROCHEM, V79, P456, DOI 10.1046/j.1471-4159.2001.00600.x; DeVries AC, 2001, P NATL ACAD SCI USA, V98, P11824, DOI 10.1073/pnas.201215298; Domercq M, 2004, TRENDS PHARMACOL SCI, V25, P609, DOI 10.1016/j.tips.2004.10.001; Faries PL, 1998, J TRAUMA, V44, P1031, DOI 10.1097/00005373-199806000-00016; Ferrier L, 2003, GASTROENTEROLOGY, V125, P795, DOI 10.1016/S0016-5085(03)01057-6; GRISHAM MB, 1988, DIG DIS SCI S, V33, P6; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Hayakawa K, 2008, STROKE, V39, P951, DOI 10.1161/STROKEAHA.107.495820; Iso H, 2002, CIRCULATION, V106, P1229, DOI 10.1161/01.CIR.0000028145.58654.41; Lehnardt S, 2007, J NEUROIMMUNOL, V190, P28, DOI 10.1016/j.jneuroim.2007.07.023; Lindsberg PJ, 2003, STROKE, V34, P2518, DOI 10.1161/01.STR.0000089015.51603.CC; Lipski J, 2007, NEUROSCIENCE, V146, P617, DOI 10.1016/j.neuroscience.2007.02.003; Mackensen GB, 2001, J NEUROSCI, V21, P4582, DOI 10.1523/JNEUROSCI.21-13-04582.2001; Madrigal JLM, 2003, BRAIN RES, V979, P137, DOI 10.1016/S0006-8993(03)02892-0; Meddings JB, 2000, GASTROENTEROLOGY, V119, P1019, DOI 10.1053/gast.2000.18152; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Meisel C, 2004, STROKE, V35, P2, DOI 10.1161/01.STR.0000109041.89959.4C; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Nguyen MD, 2002, NAT REV NEUROSCI, V3, P216, DOI 10.1038/nrn752; Ponferrada A, 2007, GASTROENTEROLOGY, V132, P1791, DOI 10.1053/j.gastro.2007.02.032; Prass K, 2003, J EXP MED, V198, P725, DOI 10.1084/jem.20021098; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; SAUNDERS PR, 1994, AM J PHYSIOL-GASTR L, V267, pG794; Soderholm JD, 2001, AM J PHYSIOL-GASTR L, V280, pG7; STENDAHL O, 1983, INT ARCH ALLER A IMM, V70, P277, DOI 10.1159/000233335; Sugo N, 2002, STROKE, V33, P1660, DOI 10.1161/01.STR.0000016967.76805.BF; Swank GM, 1996, WORLD J SURG, V20, P411, DOI 10.1007/s002689900065; Tang SC, 2007, P NATL ACAD SCI USA, V104, P13798, DOI 10.1073/pnas.0702553104; Truelsen T, 2003, STROKE, V34, P856, DOI 10.1161/01.STR.0000062345.80774.40; WIRA CR, 1990, J IMMUNOL, V144, P142	42	40	45	0	13	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6119	1522-1490		AM J PHYSIOL-REG I	Am. J. Physiol.-Regul. Integr. Comp. Physiol.	APR	2009	296	4					R979	R985		10.1152/ajpregu.90825.2008			7	Physiology	Physiology	424KH	WOS:000264565100015	19193944				2021-06-18	
J	Brennan, LK; Rubin, D; Christianm, CW; Duhaime, AC; Mirchandani, HG; Rorke-Adams, LB				Brennan, Laura K.; Rubin, David; Christianm, Cindy W.; Duhaime, Ann-Christine; Mirchandani, Haresh G.; Rorke-Adams, Lucy B.			Neck injuries in young pediatric homicide victims Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						abusive head trauma; cervical cord injury; neck injury	SHAKEN BABY SYNDROME; TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; NONACCIDENTAL HEAD-INJURY; CHILD-ABUSE; RADIOGRAPHIC ABNORMALITY; INFANT SYNDROME; NEUROPATHOLOGY; SHAKING; DAMAGE	Object. In this study, the authors estimate the prevalence of injuries to the soft tissue of the neck, cervical vertebrae, and cervical spinal cord among victims of abusive head trauma to better understand these injuries and their relationship to other pathophysiological findings commonly found in children with fatal abusive head trauma. Methods. The population included all homicide victims 2 years of age and younger from the city of Philadelphia, Pennysivania, who underwent a comprehensive postmortem examination at the Office of the Medical Examiner between 1995 and 2003. A retrospective review of all available postmortem records was performed, and data regarding numerous pathological findings, as well as the patient's clinical history and demographic information, were abstracted. Data were described using means and standard deviations for continuous variables, and frequency and ranges for categorical variables. Chi-square analyses were used to test for the association of neck injuries with different types of brain injury. Results. The sample included 52 children, 41 (79%) of whom died of abusive head trauma. Of these, 29 (71%) had primary cervical cord injuries: in 21 there were parenchymal injuries, in 24 meningeal hemorrhages, and in 16, nerve root avulsion/dorsal root ganglion hemorrhage were evident. Six children with abusive head trauma had no evidence of an impact to the head, and all 6 had primary cervical spinal cord injury (SCI). No child had a spinal fracture. Six of 29 children (21%) with primary cervical SCIs had soft-tissue (ligamentous or muscular) injuries to the neck, and 14 (48%) had brainstem injuries. There was a significant association of primary cervical SCI with cerebral edema (p = 0.036) but not with hypoxia-ischemia, infarction, or herniation. Conclusions. Cervical SCI is a frequent but not universal finding in young children with fatal abusive head trauma. In the present study, parenchymal and/or root injury usually occurred without evidence of muscular or ligamentous damage, or of bone dislocation or fracture. Moreover, associated brainstem injuries were not always seen. Although there was a significant association of primary cervical cord injury with cerebral edema, there was no direct relationship to brainstem herniation, hypoxia-ischemia, or infarction. This suggests that cervical spinal trauma is only 1 factor in the pathogenesis of these lesions. (DOI: 10.3171/2008.11.PEDS0835)	[Brennan, Laura K.; Rubin, David; Christianm, Cindy W.] Childrens Hosp Philadelphia, Div Gen Pediat, Philadelphia, PA 19104 USA; [Brennan, Laura K.; Rubin, David; Christianm, Cindy W.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Duhaime, Ann-Christine] Dartmouth Hitchcock Med Ctr, Dept Neurosurg, Lebanon, NH 03766 USA; [Mirchandani, Haresh G.; Rorke-Adams, Lucy B.] Off Med Examiner City Philadelphia, Philadelphia, PA USA; [Rorke-Adams, Lucy B.] Childrens Hosp Philadelphia, Div Anat Pathol, Philadelphia, PA 19104 USA	Brennan, LK (corresponding author), Childrens Hosp Philadelphia, Div Gen Pediat, 34th St & Civic Ctr Blvd, Philadelphia, PA 19104 USA.	brennanl@email.chop.edu					Bandak FA, 2005, FORENSIC SCI INT, V151, P71, DOI 10.1016/j.forsciint.2005.02.033; Barlow Karen, 2004, Pediatr Rehabil, V7, P195, DOI 10.1080/13638490410001715331; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Bayir H, 2006, DEV NEUROSCI-BASEL, V28, P420, DOI 10.1159/000094168; BENZEL EC, 1989, SOUTHERN MED J, V82, P1347, DOI 10.1097/00007611-198911000-00005; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Biousse V, 2002, AM J OPHTHALMOL, V133, P249, DOI 10.1016/S0002-9394(01)01366-6; Biron D, 2005, CHILD ABUSE NEGLECT, V29, P1347, DOI 10.1016/j.chiabu.2005.05.003; Bonnier Christine, 2004, Pediatr Rehabil, V7, P165, DOI 10.1080/13638490410001703325; Brown RL, 2001, J PEDIATR SURG, V36, P1107, DOI 10.1053/jpsu.2001.25665; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1946, AM J ROENTGENOL, V56, P163; DUHAIME AC, 1992, PEDIATRICS, V90, P179; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; Feldman KW, 1997, CHILD ABUSE NEGLECT, V21, P199, DOI 10.1016/S0145-2134(96)00145-7; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Ghatan S, 2002, NEUROSURG CLIN N AM, V13, P227, DOI 10.1016/S1042-3680(01)00002-X; Gleckman AM, 2000, J FORENSIC SCI, V45, P1151; GRABB PA, 1994, NEUROSURGERY, V35, P406, DOI 10.1227/00006123-199409000-00007; Graham E M, 1997, J Matern Fetal Med, V6, P1; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; Judkins AR, 2004, AM J FOREN MED PATH, V25, P29, DOI 10.1097/01.paf.0000113811.85110.54; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kemp AM, 2003, ARCH DIS CHILD, V88, P472, DOI 10.1136/adc.88.6.472; KEWALRAMANI LS, 1980, PARAPLEGIA, V18, P206, DOI 10.1038/sc.1980.36; King WJ, 2003, CAN MED ASSOC J, V168, P155; Leestma JE, 2005, AM J FOREN MED PATH, V26, P199, DOI 10.1097/01.paf.0000164228.79784.5a; Margulies S, 2006, FORENSIC SCI INT, V164, P278, DOI 10.1016/j.forsciint.2005.12.018; MCGRORY BE, 1977, ANN NEUROL, V2, P82, DOI 10.1002/ana.410020116; MERTEN DF, 1984, PEDIATR RADIOL, V14, P272, DOI 10.1007/BF01601874; MUNGER CE, 1993, AM J FOREN MED PATH, V14, P193, DOI 10.1097/00000433-199309000-00004; PANG D, 1989, J TRAUMA, V29, P654, DOI 10.1097/00005373-198905000-00021; PANG D, 1982, J NEUROSURG, V57, P114, DOI 10.3171/jns.1982.57.1.0114; PIATT JH, 1995, PEDIATRICS, V96, P780; Ranjith RK, 2002, J PEDIATR ORTHOP B, V11, P329, DOI 10.1097/00009957-200210000-00011; Rooks VJ, 1998, PEDIATR RADIOL, V28, P193, DOI 10.1007/s002470050330; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; SNEED RC, 1988, AM J DIS CHILD, V142, P965, DOI 10.1001/archpedi.1988.02150090063023; Starling SP, 2004, ARCH PEDIAT ADOL MED, V158, P454, DOI 10.1001/archpedi.158.5.454; SWISCHUK LE, 1969, RADIOLOGY, V92, P733, DOI 10.1148/92.4.733; Thomas NH, 1995, PEDIATR NEUROSURG, V23, P188, DOI 10.1159/000120957; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596	46	40	40	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707			J NEUROS-PEDIATR	J. Neurosurg.-Pediatr.	MAR	2009	3	3					232	239		10.3171/2008.11.PEDS0835			8	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	414MO	WOS:000263868300014	19338471				2021-06-18	
J	Tagliaferri, F; Compagnone, C; Yoganandan, N; Gennarelli, TA				Tagliaferri, Fernanda; Compagnone, Christian; Yoganandan, Narayan; Gennarelli, Thomas A.			Traumatic Brain Injury After Frontal Crashes: Relationship With Body Mass Index	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Frontal crashes; Motor-vehicle accidents; Body mass index; Obesity	OBESITY; HABITUS; DEATH	Background: Previous studies had demonstrated that injury severity and risk of death after motor-vehicle crashes are related to human body characteristics. The purpose of this study was to clarify the relationship between body mass index (BMI) and head injury severity in front seat passengers after a frontal collision. Methods: Data from all front seat occupants with at least one injury, older than 16 years old involved in a frontal collision from 1993 to 2005 were retrieved from the National Automotive Sampling System (NASS) database. Patient and collision characteristics were analyzed. Two cohorts were defined according to BMI < or >= 30 kg/m(2). Results: A total of 6,977 patients were included in this study, 5,918 (85%) had complete data on weight and height. Patient's mean age was 37 18 years old, the median ISS was 6, interquartile range (IQR) 15, and 61 % were men. The mortality rate was positively associated to the crash delta velocity (DV) (p < 0.0001). The use of restraint system reduced the risk of death (p = 0.01). There was a significant increase in fatal outcome (p < 0.0001; RR 1.84 95% CI 1.61-2.1) and injury severity (ISS >25 p < 0.0001; RR 1.36 95% CI 1.19-1.54) in the obese cohort. Obese patients had higher chances of halving a maximum head injury (Abbreviated Injury Score head = 6) than those not obese (p = 0.003; RR 1.97 95% CI 1.522.55). Conclusion: Obese passengers are more likely to suffer a more severe head trauma after a frontal collision. Further studies with computational models are needed to determine the precise role of BMI on brain injury-related biomechanical metrics.	[Tagliaferri, Fernanda] Osped Cesare Magati, Scandiano, Italy; [Compagnone, Christian] Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; [Yoganandan, Narayan; Gennarelli, Thomas A.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA	Gennarelli, TA (corresponding author), 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	tgenn@mcw.edu		Compagnone, Christian/0000-0001-9951-5503			Arbabi S, 2003, J TRAUMA, V54, P1090, DOI 10.1097/01.TA.0000064449.11809.48; *ASS ADV AUT MED, 1990, ABBR INJ SCAL; BOULANGER BR, 1992, J TRAUMA, V33, P228, DOI 10.1097/00005373-199208000-00011; Brown CVR, 2006, J TRAUMA, V61, P572, DOI 10.1097/01.ta.0000200842.19740.38; Ford ES, 2005, OBES RES, V13, P118, DOI 10.1038/oby.2005.15; Larsson I, 2004, INT J OBESITY, V28, P1317, DOI 10.1038/sj.ijo.0802732; Mock CN, 2002, ACCIDENT ANAL PREV, V34, P221, DOI 10.1016/S0001-4575(01)00017-3; Mokdad AH, 2004, JAMA-J AM MED ASSOC, V291, P1238, DOI 10.1001/jama.291.10.1238; Moran SG, 2002, J TRAUMA, V52, P1116, DOI 10.1097/00005373-200206000-00015; ROSS R, 1994, AM J CLIN NUTR, V59, P1277; Wang Stewart C, 2003, Annu Proc Assoc Adv Automot Med, V47, P545	11	40	40	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2009	66	3					727	729		10.1097/TA.0b013e31815edefd			3	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	419ZU	WOS:000264259000023	19276745				2021-06-18	
J	Cavinato, M; Freo, U; Ori, C; Zorzi, M; Tonin, P; Piccione, F; Merico, A				Cavinato, Marianna; Freo, Ulderico; Ori, Carlo; Zorzi, Manuel; Tonin, Paolo; Piccione, Francesco; Merico, Antonio			Post-acute P300 predicts recovery of consciousness from traumatic vegetative state	BRAIN INJURY			English	Article						Brainstem auditory evoked potentials; Disability Rating Scale; electroencephalogram; P300; sensory evoked potentials; vegetative state	COGNITIVE EVOKED-POTENTIALS; SEVERE BRAIN-INJURY; POSTANOXIC COMA; DISORDERS; PROGNOSIS; RESPONSES; SCALE; EEG	Background: Evoked potentials allow one to assess functional integrity of sensory pathways projecting to primary sensory cortices and event-related potentials assess higher order cortical functions associated with stimulus detection and decision-making. Evoked and event-related potentials have been used to predict emergence from coma. This study aimed to determine whether they can help prediction of consciousness recovery in post-traumatic vegetative state (VS). Methods: Thirty-four patients in post-traumatic VS were assessed clinically and neurophysiologically at 2-3 months after injury and followed up to 1 year. Patients were assessed with the Disability Rating Scale (DRS) and with electroencephalogram (EEG), brainstem auditory (BAEP) and somatosensory evoked potentials (SEP) and P300. Demographic, clinical and neurophysiological measures were analysed by descriptive and logistic regression techniques. Results: At 1 year from injury, 26 patients (76%) had recovered consciousness and eight patients (24%) had not. In univariate analyses, a detectable P300, a reactive EEG and lower DRS scores were found at entry assessment more frequently (p<0.05) in patients who later recovered consciousness than in those who did not. Logistic regression analysis revealed that P300 was the only factor contributing to prediction of conscious recovery with an area under the ROC curve of 0.94 (95% CI, 0.80-0.99). Conclusions: P300 is a strong predictor of conscious recovery in VS.	[Freo, Ulderico] Univ Padua, Dipartimento Farmacol & Anestesiol, Ist Anestesia & Terapia Intens, I-35121 Padua, Italy; [Cavinato, Marianna; Tonin, Paolo; Piccione, Francesco; Merico, Antonio] Osped IRCCS, Ist Cura San Camillo, Venice, Lido, Italy; [Zorzi, Manuel] Ist Oncol Veneto, Padua, Italy	Freo, U (corresponding author), Univ Padua, Dipartimento Farmacol & Anestesiol, Ist Anestesia & Terapia Intens, Via C Battisti 267, I-35121 Padua, Italy.	ulderico.freo@unipd.it	Zorzi, Manuel/J-7029-2016; Piccione, Francesco/K-7214-2016; Freo, Ulderico/V-8249-2017; Tonin, Paolo/K-7483-2016	Zorzi, Manuel/0000-0001-6025-5214; Piccione, Francesco/0000-0002-0173-903X; Freo, Ulderico/0000-0001-6183-2909; Tonin, Paolo/0000-0002-4867-1378; merico, antonio/0000-0001-6783-1333; Cavinato, Marianna/0000-0003-4158-9766			Amantini A, 2005, CLIN NEUROPHYSIOL, V116, P229, DOI 10.1016/j.clinph.2004.07.008; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Carter BG, 2005, INTENS CARE MED, V31, P765, DOI 10.1007/s00134-005-2633-1; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Coleman MR, 2008, INT ANESTHESIOL CLIN, V46, P147, DOI 10.1097/AIA.0b013e318181adcc; de Beyl DZ, 2007, NEUROLOGY, V68, P877, DOI 10.1212/01.wnl.0000260053.80913.b6; Eilander HJ, 2005, BRAIN INJURY, V19, P425, DOI 10.1080/02699050400025299; Fischer C, 2004, NEUROLOGY, V63, P669, DOI 10.1212/01.WNL.0000134670.10384.E2; Guerit JM, 2000, ACTA NEUROL BELG, V100, P229; HARRIS DP, 1990, EAR HEARING, V11, P340, DOI 10.1097/00003446-199010000-00004; Holeckova I, 2006, BRAIN RES, V1082, P142, DOI 10.1016/j.brainres.2006.01.089; Horovitz SG, 2004, NEUROIMAGE, V22, P1587, DOI 10.1016/j.neuroimage.2004.04.018; JENNETT B, 1972, LANCET, V1, P734; Kotchoubey B, 2005, CLIN NEUROPHYSIOL, V116, P2441, DOI 10.1016/j.clinph.2005.03.028; Laureys S, 2007, CURR OPIN NEUROL, V20, P609, DOI 10.1097/WCO.0b013e3282f1d6dd; Logi F, 2003, CLIN NEUROPHYSIOL, V114, P1615, DOI 10.1016/S1388-2457(03)00086-5; Macciocchi S, 2008, ARCH PHYS MED REHAB, V89, P1350, DOI 10.1016/j.apmr.2007.11.055; MEYER E, 1991, ANN NEUROL, V29, P440, DOI 10.1002/ana.410290418; Moritz CH, 2001, MAGN RESON IMAGING, V19, P1129, DOI 10.1016/S0730-725X(01)00432-5; *MULT TASK FORC, 1994, NEW ENGL J MED, V333, P1572; Mutschler V, 1996, NEUROPHYSIOL CLIN, V26, P158, DOI 10.1016/0987-7053(96)89626-2; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Rappaport M, 2005, NEUROPSYCHOL REHABIL, V15, P442, DOI 10.1080/09602010443000335; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Ruytjens L, 2007, EUR J NUCL MED MOL I, V34, P2073, DOI 10.1007/s00259-007-0517-z; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; SYNEK VM, 1990, CLIN ELECTROENCEPHAL, V21, P25, DOI 10.1177/155005949002100111; Vanhaudenhuyse A, 2008, NEUROCRIT CARE, V8, P262, DOI 10.1007/s12028-007-9016-0; Wijnen VJM, 2007, CLIN NEUROPHYSIOL, V118, P597, DOI 10.1016/j.clinph.2006.11.020; Zeman A, 2001, BRAIN, V124, P1263, DOI 10.1093/brain/124.7.1263	30	40	50	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	12					973	980		10.3109/02699050903373493			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	529YL	WOS:000272555200005	19831494				2021-06-18	
J	Chen, JWY; Ruff, RL; Eavey, R; Wasterlain, CG				Chen, James W. Y.; Ruff, Robert L.; Eavey, Roland; Wasterlain, Claude G.			Posttraumatic epilepsy and treatment	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						anticonvulsants; brain imaging; posttraumatic epilepsy; posttraumatic stress disorder; refractory seizures; rehabilitation; seizures; traumatic brain injury; unprovoked seizures; veterans	POST-TRAUMATIC EPILEPSY; HEAD-INJURY; SEIZURES; PROPHYLAXIS; PHENYTOIN; RISK; ANTICONVULSANT; AGENTS	Posttraumatic epilepsy (PTE) is a major long-term complication of traumatic brain injury (TBI). PTE usually develops within 5 years of head injury. The risk for developing PTE varies with TBI type. Both Korean and Vietnam war veterans with penetrating TBI had a 53% risk of developing PTE. The risk of developing PTE is between 10% and 25% in combat-associated closed-head trauma with positive brain imaging and about 5% in moderately severe closed-head injury without imaging finding. We do not know the risk of PTE among Operation Iraqi Freedom/Operation Enduring Freedom veterans with minimal TBI because of blast exposure. Partial seizures may manifest with subtle behavioral alterations that can be mistaken for manifestations of posttraumatic stress disorder and improperly treated. Accidents and medical complications commonly occur during seizures. Sudden unexpected death in epilepsy is most frequent among 20- to 40-year-olds. Seizures increase the likelihood of refractory seizures years after TBI. Seizures are also a social stigma that compromise veterans' reintegration into society. People with uncontrolled epilepsy are not allowed to drive and have difficulty obtaining or maintaining employment. Optimal seizure control is essential to the physical and emotional health of veterans with TBI and to their ability to lead productive lives.	[Chen, James W. Y.; Eavey, Roland; Wasterlain, Claude G.] VA Greater Los Angeles Healthcare Syst, Dept Vet Affairs, Los Angeles, CA USA; [Chen, James W. Y.; Eavey, Roland; Wasterlain, Claude G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; [Ruff, Robert L.] Louis Stokes Cleveland VA Med Ctr, Neurol Serv, Cleveland, OH USA; [Ruff, Robert L.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA	Chen, JWY (corresponding author), W Los Angeles VA Healthcare Ctr, Neurol MC 127,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	jwychen@ucla.edu	Ritter, Stefanie L/D-9312-2012	Chen, James/0000-0002-3220-138X	Veterans AffairsUS Department of Veterans Affairs [I01BX000273] Funding Source: NIH RePORTER; BLRD VA [I01 BX000273] Funding Source: Medline		Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; CAVENESS WF, 1962, J NEUROSURG, V19, P122, DOI 10.3171/jns.1962.19.2.0122; CAVENESS WF, 1976, EPILEPSIA, V17, P207, DOI 10.1111/j.1528-1157.1976.tb03398.x; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; Hernandez TD, 1997, TRENDS PHARMACOL SCI, V18, P59, DOI 10.1016/S0165-6147(96)01027-9; Jennett B, 1979, Adv Neurol, V22, P137; MANAKA S, 1992, JPN J PSYCHIAT NEUR, V46, P311; MURRI L, 1992, ITAL J NEUROL SCI, V13, P755, DOI 10.1007/BF02229161; PRICE DJ, 1980, PLACE SODIUM VALPROA, P23; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Schierhout G, 1998, J NEUROL NEUROSUR PS, V64, P108, DOI 10.1136/jnnp.64.1.108; SERVIT Z, 1981, EPILEPSIA, V22, P315, DOI 10.1111/j.1528-1157.1981.tb04115.x; Tanielian T, 2008, INVISIBLE WOUNDS WAR; TAYLOR DC, 1980, J NEUROL NEUROSUR PS, V43, P758, DOI 10.1136/jnnp.43.9.758; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 2001, DRUGS, V61, P1045, DOI 10.2165/00003495-200161080-00002; WOHNS RNW, 1979, J NEUROSURG, V51, P507, DOI 10.3171/jns.1979.51.4.0507; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; YOUNG B, 1979, EPILEPSIA, V20, P671, DOI 10.1111/j.1528-1157.1979.tb04851.x	21	40	43	0	5	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2009	46	6					685	695		10.1682/JRRD.2008.09.0130			11	Rehabilitation	Rehabilitation	531BQ	WOS:000272638100006	20104398	Bronze			2021-06-18	
J	Hutchinson, P; O'Connell, M; Seal, A; Nortje, J; Timofeev, I; Al-Rawi, P; Coles, J; Fryer, T; Menon, D; Pickard, J; Carpenter, K				Hutchinson, Peter J.; O'Connell, Mark T.; Seal, Alex; Nortje, Jurgens; Timofeev, Ivan; Al-Rawi, Pippa G.; Coles, Jonathan P.; Fryer, Timothy D.; Menon, David K.; Pickard, John D.; Carpenter, Keri L. H.			A combined microdialysis and FDG-PET study of glucose metabolism in head injury	ACTA NEUROCHIRURGICA			English	Article						Microdialysis; Positron emission tomography; Cerebral metabolism; Glucose; Glycolysis; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; POSITRON-EMISSION-TOMOGRAPHY; PENTOSE-PHOSPHATE PATHWAY; CEREBRAL-BLOOD-FLOW; INTRACEREBRAL MICRODIALYSIS; SUBARACHNOID HEMORRHAGE; ENERGY-METABOLISM; ISCHEMIA; FLUX; MECHANISMS	Microdialysis continuously monitors the chemistry of a small focal volume of the cerebral extracellular space. Positron emission tomography (PET) establishes metabolism of the whole brain but only for the scan's duration. This study's objective was to apply these techniques together, in patients with traumatic brain injury, to assess the relationship between microdialysis (extracellular glucose, lactate, pyruvate, and the lactate/pyruvate (L/P) ratio as a marker of anaerobic metabolism) and PET parameters of glucose metabolism using the glucose analogue [F-18]-fluorodeoxyglucose (FDG). In particular, we aimed to determine the fate of glucose in terms of differential metabolism to pyruvate and lactate. Microdialysis catheters (CMA70 or CMA71) were inserted into the cerebral cortex of 17 patients with major head injury. Microdialysis was performed during FDG-PET scans with regions of interest for PET analysis defined by the location of the gold-tipped microdialysis catheter. Microdialysate analysis was performed on a CMA600 analyser. There was significant linear relationship between the PET-derived parameter of glucose metabolism (regional cerebral metabolic rate of glucose; CMRglc) and levels of lactate (r = 0.778, p < 0.0001) and pyruvate (r = 0.799, p < 0.0001), but not with the L/P ratio. The results suggest that in this population of patients, glucose was metabolised to both lactate and pyruvate, but was not associated with an increase in the L/P ratio. This suggests an increase in glucose metabolism to both lactate and pyruvate, as opposed to a shift towards anaerobic metabolism.	[Hutchinson, Peter J.; O'Connell, Mark T.; Seal, Alex; Timofeev, Ivan; Al-Rawi, Pippa G.; Pickard, John D.; Carpenter, Keri L. H.] Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Cambridge CB2 0QQ, England; [Nortje, Jurgens; Coles, Jonathan P.; Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Dept Med, Div Anaesthesia, Cambridge CB2 0QQ, England; [Hutchinson, Peter J.; O'Connell, Mark T.; Nortje, Jurgens; Coles, Jonathan P.; Fryer, Timothy D.; Menon, David K.; Pickard, John D.; Carpenter, Keri L. H.] Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Dept Clin Neurosci, Cambridge CB2 0QQ, England	Carpenter, K (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Box 167,Hills Rd, Cambridge CB2 0QQ, England.	pjah2@cam.ac.uk; mark.oconnell@probescientific.com; aseal@interchange.ubc.ca; jurgens.nortje@nnuh.nhs.uk; it227@cam.ac.uk; pga20@medschl.cam.ac.uk; jpc44@wbic.cam.ac.uk; tdf21@wbic.cam.ac.uk; dkm13@wbic.cam.ac.uk; jdp1000@wbic.cam.ac.uk; klc1000@wbic.cam.ac.uk	Timofeev, Ivan/AAE-7019-2019	O'Connell, Mark/0000-0001-6272-8767; Carpenter, Keri/0000-0001-8236-7727; Timofeev, Ivan/0000-0002-1168-0393	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390 ID 65883]; Academy of Medical Sciences /Health Foundation; KLHC; MRC (Acute Brain Injury Programme Grant)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); National Institute for Health Research Biomedical Research Centre, Cambridge. ITNational Institute for Health Research (NIHR); Codman and the Evelyn Trus; PGA; Stroke Association, UK; PJH, Academy of Medical Sciences / Health Foundation Senior Surgical Scientist Fellowship; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G0001237, G9439390] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	We gratefully acknowledge the following. Study support: the Medical Research Council (Grant No G9439390 ID 65883) and the Academy of Medical Sciences /Health Foundation. Authors' support: KLHC, the MRC (Acute Brain Injury Programme Grant) and the National Institute for Health Research Biomedical Research Centre, Cambridge. IT, Codman and the Evelyn Trust; PGA, the Stroke Association, UK; PJH, Academy of Medical Sciences / Health Foundation Senior Surgical Scientist Fellowship. Technical assistance: L Maskell. Statistical advice: H Richards.	ARCHER DP, 1990, J CEREBR BLOOD F MET, V10, P624, DOI 10.1038/jcbfm.1990.114; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Bartnik BL, 2007, J NEUROTRAUM, V24, P1079, DOI 10.1089/neu.2006.0210; Bartnik BL, 2007, J NEUROTRAUM, V24, P181, DOI 10.1089/neu.2006.0038; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Dohmen C, 2005, BRAIN RES, V1037, P43, DOI 10.1016/j.brainres.2004.12.046; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; Engstrom M, 2005, J NEUROSURG, V102, P460, DOI 10.3171/jns.2005.102.3.0460; Feng DG, 1995, IEEE T MED IMAGING, V14, P697, DOI 10.1109/42.476111; Fox JEM, 2000, J PHYSIOL-LONDON, V529, P285, DOI 10.1111/j.1469-7793.2000.00285.x; Hattori N, 2003, J NUCL MED, V44, P1709; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; HUANG SC, 1980, AM J PHYSIOL, V238, pE69; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Hutchinson PJA, 2000, BRIT J NEUROSURG, V14, P46; KINAHAN PE, 1989, IEEE T NUCL SCI, V36, P964, DOI 10.1109/23.34585; LAMMERTSMA AA, 1987, J CEREBR BLOOD F MET, V7, P161, DOI 10.1038/jcbfm.1987.39; Lee JY, 2001, J NEUROSCI, V21; McKenna MC, 2006, BIOCHEM PHARMACOL, V71, P399, DOI 10.1016/j.bcp.2005.10.011; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Moncada S, 2006, J NEUROCHEM, V97, P1676, DOI 10.1111/j.1471-4159.2006.03988.x; Noske DP, 2005, SURG NEUROL, V64, P109, DOI 10.1016/j.surneu.2004.09.036; O'Connell MT, 2005, ACTA NEUROCHIR SUPPL, V95, P165; PATLAK CS, 1983, J CEREBR BLOOD F MET, V3, P1, DOI 10.1038/jcbfm.1983.1; Pellerin L, 2003, NEUROCHEM INT, V43, P331, DOI 10.1016/S0197-0186(03)00020-2; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Pierre K, 2005, J NEUROCHEM, V94, P1, DOI 10.1111/j.1471-4159.2005.03168.x; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Samuelsson C, 2007, J CEREBR BLOOD F MET, V27, P1309, DOI 10.1038/sj.jcbfm.9600433; Shulman RG, 1999, P NATL ACAD SCI USA, V96, P3245, DOI 10.1073/pnas.96.6.3245; Simpson IA, 2007, J CEREBR BLOOD F MET, V27, P1766, DOI 10.1038/sj.jcbfm.9600521; Spanaki MV, 1999, NEUROLOGY, V53, P1518, DOI 10.1212/WNL.53.7.1518; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; 1992, LANCET, V339, P1326	43	40	41	0	5	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	JAN	2009	151	1					51	61		10.1007/s00701-008-0169-1			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	399EY	WOS:000262784400006	19099177				2021-06-18	
J	Shi, JX; Xiang, HY; Wheeler, K; Smith, GA; Stallones, L; Groner, J; Wang, ZZ				Shi, Junxin; Xiang, Huiyun; Wheeler, Krista; Smith, Gary A.; Stallones, Lorann; Groner, Jonathan; Wang, Zengzhen			Costs, mortality likelihood and outcomes of hospitalized US children with traumatic brain injuries	BRAIN INJURY			English	Article						Children; costs; outcome; traumatic brain injury; predictive mortality likelihood level	UNITED-STATES; RISK-FACTORS; SHORT-TERM; POPULATION; CLASSIFICATION; HYPERACTIVITY; ADOLESCENTS; PREVALENCE; CHILDHOOD; SEVERITY	Primary objective: To examine the hospitalization costs and discharge outcomes of US children with TBI and to evaluate a severity measure, the predictive mortality likelihood level. Research design: Data from the 2006 Healthcare Cost and Utilization Project Kids' Inpatient Database (KID) were used to report the national estimates and characteristics of TBI-associated hospitalizations among US children 20 years of age. The percentage of children with TBI caused by motor vehicle crashes (MVC) and falls was calculated according to the predictive mortality likelihood levels (PMLL), death in hospital and discharge into long-term rehabilitation facilities. Associations with the PMLL, discharge outcomes and average hospital charges were examined. Results: In 2006, there were an estimated 58 900 TBI-associated hospitalizations among US children, accounting for $2.56 billion in hospital charges. MVCs caused 38.9% and falls caused 21.2% of TBI hospitalizations. The PMLL was strongly associated with TBI type, length of hospital stay, hospital charges and discharge disposition. About 4% of children with fall or MVC related TBIs died in hospital and 9% were discharged into long-term facilities. Conclusion: The PMLL may provide a useful tool to assess characteristics and treatment outcomes of hospitalized TBI children, but more research is still needed.	[Shi, Junxin; Xiang, Huiyun; Wheeler, Krista; Smith, Gary A.] Ohio State Univ, Coll Med, Nationwide Childrens Hosp, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA; [Groner, Jonathan] Ohio State Univ, Coll Med, Nationwide Childrens Hosp, Trauma Program, Columbus, OH 43205 USA; [Stallones, Lorann] Colorado State Univ, Colorado Injury Control Res Ctr, Ft Collins, CO 80523 USA; [Wang, Zengzhen] Tongji Med Coll, Sch Publ Hlth, Wuhan, Hubei, Peoples R China	Xiang, HY (corresponding author), Ohio State Univ, Coll Med, Nationwide Childrens Hosp, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	huiyun.xiang@nationwidechildrens.org	Stallones, Lorann/AAC-6248-2021; Xiang, Huiyun/E-4335-2011; Groner, Jonathan/E-3156-2011	Stallones, Lorann/0000-0001-7616-582X; Wheeler, Krista/0000-0003-3728-8928; Groner, Jonathan/0000-0002-0998-593X	National Institutes of Health Fogarty International CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [1D43TW007257-01A2]; National Center for Injury Prevention and Control, Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE001172-01]; FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [D43TW007257] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001172] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025755] Funding Source: NIH RePORTER	Dr J. Shi was a trainee of the USA-China Agricultural Injury Research Training project, funded by a grant from the National Institutes of Health Fogarty International Center (PIs: L. Stallones and H. Xiang, Grant #: 1D43TW007257-01A2).r This study was supported by grants from the National Institutes of Health Fogarty International Center (PIs: L. Stallones and H. Xiang, Grant #: 1D43TW007257-01A2) and the National Center for Injury Prevention and Control, Centers for Disease Control and Prevention (PI: H. Xiang, Grant #: R49/CE001172-01).	Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; CATALE C, 2008, J CLIN EXPT NEUROPSY, V31, P1; *CDCP, 2001, TRAUM BRAIN INJ US A; *CDCP, REC FRAM E COD GROUP; Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; Dedoukou X, 2004, ARCH PEDIAT ADOL MED, V158, P1002, DOI 10.1001/archpedi.158.10.1002; DePompei R, 2008, J HEAD TRAUMA REHAB, V23, P191, DOI 10.1097/01.HTR.0000327251.16010.3b; Ganesalingam K, 2008, J PEDIATR PSYCHOL, V33, P621, DOI 10.1093/jpepsy/jsm133; Guice KS, 2007, J TRAUMA, V63, pS68, DOI 10.1097/TA.0b013e31815acbb6; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; HCUP Kids' Inpatient Database (KID), 2006, HEALTHC COST UT PROJ; Javouhey E, 2006, ACCIDENT ANAL PREV, V38, P225, DOI 10.1016/j.aap.2005.08.001; Kendrick D, 2008, AM J PREV MED, V35, P370, DOI 10.1016/j.amepre.2008.06.038; Khambalia A, 2006, INJURY PREV, V12, P378, DOI 10.1136/ip.2006.012161; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Mandalis A, 2007, DEV NEUROPSYCHOL, V32, P683, DOI 10.1080/87565640701376045; Marr AL., 2004, CENTRAL NERVOUS SYST; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; *MEDST GROUP INC, 2001, DIS STAG SOFTW US GU; *NAT HIGHW TRANSP, 2006, TRAFF SAF FACTS 2005; Pickelsimer EE, 2007, J HEAD TRAUMA REHAB, V22, P1, DOI 10.1097/00001199-200701000-00001; *POSTCR TRAUM CAR, 2003, REP POSTCR TRAUM CAR; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Ragnarsson KT, 2006, J HEAD TRAUMA REHAB, V21, P379, DOI 10.1097/00001199-200609000-00002; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Runyan CW, 2005, AM J PREV MED, V28, P116, DOI 10.1016/j.amepre.2004.09.018; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; *SAS I, 2004, STAT AN SOFTW SAS VE; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Simons-Morton B, 2007, J SAFETY RES, V38, P193, DOI 10.1016/j.jsr.2007.02.007; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Stancin T, 2008, J DEV BEHAV PEDIATR, V29, P253, DOI 10.1097/DBP.0b013e31816b6b0f; Taylor HG, 2008, J INT NEUROPSYCH SOC, V14, P734, DOI 10.1017/S1355617708081150; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; *US BUR CENS, 2008, MONTHL POSTC CIV NON; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; Verger K, 2000, BRAIN INJURY, V14, P495; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	45	40	41	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	7-8					602	611	PII 912685334	10.1080/02699050903014907			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	462QL	WOS:000267370600003	19557562	Green Accepted			2021-06-18	
J	Kreitschmann-Andermahr, I; Poll, EM; Reineke, A; Gilsbach, JM; Brabant, G; Buchfelder, M; Fassbender, W; Faust, M; Kann, PH; Wallaschofski, H				Kreitschmann-Andermahr, I.; Poll, E. M.; Reineke, A.; Gilsbach, J. M.; Brabant, G.; Buchfelder, M.; Fassbender, W.; Faust, M.; Kann, P. H.; Wallaschofski, H.			Growth hormone deficient patients after traumatic brain injury - Baseline characteristics and benefits after growth hormone replacement - An analysis of the German KIMS database	GROWTH HORMONE & IGF RESEARCH			English	Article						Traumatic brain injury; Hypopituitarism; Quality of life; Growth hormone deficiency; Pituitary	QUALITY-OF-LIFE; PITUITARY-FUNCTION; CHILDHOOD-ONSET; ADULT-ONSET; FACTOR-I; HYPOPITUITARISM; DYSFUNCTION; CHOLESTEROL; PREVALENCE; INSUFFICIENCY	Objective: In recent years, traumatic brain in jury (TBI) has been identified as a significant cause of growth hormone deficiency (GHD). The aim of the present study was to characterize adult TBI patients with GHD to elucidate the effect of human growth hormone (hGH) replacement in TBI patients as documented in the German Pfizer International Metabolic (KIMS) database. Design: As of October 2006, 84 TBI patients had been included in the German KIMS database (n = 28 childhood-onset and 54 adult-onset GHD). All 84 TBI patients were matched with 84 patients with GHD due to non-functioning pituitary adenoma (NFPA) also included in this database. Analysis of clinical and outcome variables was performed, with comparisons of childhood vs. adult TBI. and TBI vs. NFPA patients, at baseline and one-year follow-up. Results: TBI patients with GHD were significantly younger at the onset Of pituitary disease and exhibited a significantly longer time span between GHD diagnosis and KIMS entry than NFPA patients. Those KIMS patients who had Sustained their TBI in childhood were of significantly shorter stature than adult-onset. TBI patients. At 1-year follow-up, insulin-like growth factor I (IGF-1) standard deviation score levels had returned to the normal range and quality of life (QoL), as measured by QoL- Assessment of Growth Hormone Deficiency in Adults (AGHDA) questionnaire, improved significantly in TBI as in NFPA patients. Conclusion: This analysis provides preliminary data that TBI patients with GHD benefit from hGH replacement in terms of improved QoL in a similar Fashion as do NFPA patients. Moreover. it suggests that belated diagnosis and treatment in childhood-onset GHD due to TBI might be related to a shorter final height in these children. (C) 2008 Elsevier Ltd. All rights reserved.	[Kreitschmann-Andermahr, I.; Poll, E. M.; Reineke, A.; Gilsbach, J. M.] Univ Aachen, Rhein Westfal TH Aachen, Dept Neurosurg, D-52074 Aachen, Germany; [Brabant, G.] Christie Hosp, Dept Endocrinol, Manchester, Lancs, England; [Buchfelder, M.] Univ Erlangen Nurnberg, Dept Neurosurg, Erlangen, Germany; [Fassbender, W.] Dept Internal Med Kempen, Kempen, Germany; [Faust, M.] Univ Cologne, Dept Internal Med 2, D-5000 Cologne 41, Germany; [Kann, P. H.] Univ Marburg, Div Endocrinol & Diabetol, D-35032 Marburg, Germany; [Wallaschofski, H.] Ernst Moritz Arndt Univ Greifswald, Dept Gastroenterol Endocrinol & Nutr, D-17487 Greifswald, Germany	Kreitschmann-Andermahr, I (corresponding author), Univ Aachen, Rhein Westfal TH Aachen, Dept Neurosurg, Pauwelsstr 30, D-52074 Aachen, Germany.	ikreitschmann-andermahr@ukaachen.de					ACERINI CL, 2007, PITUITARY; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Attanasio AF, 1997, J CLIN ENDOCR METAB, V82, P82, DOI 10.1210/jc.82.1.82; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Casanueva FF, 2005, ARCH PHYS MED REHAB, V86, P463, DOI 10.1016/j.apmr.2004.05.018; FOSSATI P, 1982, CLIN CHEM, V28, P2077; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; Hesse V, 1997, SOZIALPADIATRIE, V19, P20; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kendall-Taylor P, 2005, EUR J ENDOCRINOL, V152, P557, DOI 10.1530/eje.1.01877; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; LIE RF, 1976, CLIN CHEM, V22, P1627; Lissett CA, 2002, CLIN ENDOCRINOL, V57, P35, DOI 10.1046/j.1365-2265.2002.01556.x; LOPESVIRELLA MF, 1977, CLIN CHEM, V23, P882; McKenna SP, 1999, QUAL LIFE RES, V8, P373, DOI 10.1023/A:1008987922774; Mukherjee A, 2003, J CLIN ENDOCR METAB, V88, P5865, DOI 10.1210/jc.2002-021741; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Schneider HJ, 2006, EUR J ENDOCRINOL, V155, P553, DOI 10.1530/eje.1.02258; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2007, LANCET, V369, P1461, DOI 10.1016/S0140-6736(07)60673-4; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476	27	40	41	0	2	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1096-6374	1532-2238		GROWTH HORM IGF RES	Growth Horm. IGF Res.	DEC	2008	18	6					472	478		10.1016/j.ghir.2008.08.007			7	Cell Biology; Endocrinology & Metabolism	Cell Biology; Endocrinology & Metabolism	386KH	WOS:000261881600002	18829359				2021-06-18	
J	Ramakrishna, R; Stiefel, M; Udoteuk, J; Spiotta, A; Levine, JM; Kofke, WA; Zager, E; Yang, W; LeRoux, P				Ramakrishna, Rohan; Stiefel, Michael; Udoteuk, Joshua; Spiotta, Alejandro; Levine, Joshua M.; Kofke, W. Andrew; Zager, Eric; Yang, Wei; LeRoux, Peter			Brain oxygen tension and outcome in patients with aneurysmal subarachnoid hemorrhage Clinical article	JOURNAL OF NEUROSURGERY			English	Article						brain tissue oxygen; cerebral perfusion pressure; subarachnoid hemorrhage	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; INTRACRANIAL ANEURYSM; ELDERLY PATIENTS; MENSTRUAL-CYCLE; SEX-DIFFERENCES; GRADE PATIENTS; HEALTHY WOMEN; TISSUE OXYGEN; NORMAL VALUES	Object Poor Outcome is common after aneurysmal subarachnoid hemorrhage (SAH). Clinical studies Suggest that cerebral hypoxia after traumatic brain injury is associated with poor Outcome. In this study we examined the relationship between brain oxygen tension (PbtO(2)) and death I after aneurysmal SAH. Methods. Forty-six patients, including 34 women and 12 men (Glasgow Coma Scale Score :5 8 and median age 8.5 bears) who underwent PbtO(2) monitoring were studied prospectively during a 2-year period in a neurosurgical intensive care unit at a University Level I Trauma Center. Brain oxygen tension, intracranial pressure (ICP), mean arterial pressure, cerebral perfusion pressure (CIPP), and brain temperature were continuously monitored. and treatment was directed toward ICP. CPR and PbtO(2) targets. The relationship between PbtO(2) and 1-month survival was examined. Results. Data were available from 5424 hours of PbtO(2) monitoring. For the entire cohort the mean ICP. CPR and PbtO(2) were 13.85 +/- 2.40, 84.05 +/- 3.41. and 30.79 +/- 1.91 mm Hg, respectively. Twenty-five patients died (54%). The mean daily PbtO(2) was higher in survivors than nonsurvivors (33.94 +/- 2.74 vs 28.14 +/- 2.59 mm Hg p = 0.05). In addition. survivors had significantly shorter episodes of compromised PbtO(2) (defined as 15-25 mm Hg) than nonsurvivors (125.85 +/- 15.44 vs 271.14 +/- 55.23 minutes; p < 0.01). Intracranial pressure was similar in survivors and nonsurvivors. In contrast, the average CPP was significantly lower in nonsurvivors than survivors (76.96 +/- 5.50 vs 92.49 +/- 2.75 mm Hg (p = 0.01). When PbtO(2) was stratified according to CPP level, Survivors had higher PbtO(2) levels. Following logistic regression, the number of episodes of compromised PbtO, (odds ratio 1.1, 95% confidence interval 1.003-1.2) and number of episodes of cerebral hypoxia (< 15 mm Hg: odds ratio 1.3. 95% confidence interval 1.0-1.7) were more frequent in those who died. Conclusions. Patient deaths after SAH may be associated with a lower mean PbtO, and longer periods of compromised cerebral oxygenation than ill Survivors. This knowledge may be used to help direct therapy. (DOI: 10.3171.JNS.2008.109.12.1075)	[Ramakrishna, Rohan; Stiefel, Michael; Udoteuk, Joshua; Spiotta, Alejandro; Levine, Joshua M.; Kofke, W. Andrew; Zager, Eric; LeRoux, Peter] Univ Penn, Dept Neurosurg, Philadelphia, PA 19107 USA; [Levine, Joshua M.] Univ Penn, Dept Neurol, Philadelphia, PA 19107 USA; [Levine, Joshua M.; Kofke, W. Andrew] Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19107 USA; [Yang, Wei] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19107 USA	LeRoux, P (corresponding author), Univ Penn, Dept Neurosurg, 330 S 9th St, Philadelphia, PA 19107 USA.	lerouxp@uphs.upenn.edu	Yang, Wei/A-9223-2009	Yang, Wei/0000-0001-8984-4389			ABOUKHALIL B, 1994, CRIT CARE MED, V22, P633, DOI 10.1097/00003246-199404000-00020; Bardt TF, 1998, ACT NEUR S, V71, P153; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Dings J, 1998, NEUROL RES, V20, pS71; FRIDRIKSSON SM, 1995, NEUROSURGERY, V37, P627, DOI 10.1227/00006123-199510000-00004; Geary GG, 2000, AM J PHYSIOL-HEART C, V279, pH511; GUR RC, 1987, ARCH GEN PSYCHIAT, V44, P617; HUGOSSON R, 1973, ACTA NEUROCHIR, V28, P157, DOI 10.1007/BF01432227; INAGAWA T, 1993, J NEUROSURG, V78, P554, DOI 10.3171/jns.1993.78.4.0554; INAGAWA T, 1988, J NEUROSURG, V69, P332, DOI 10.3171/jns.1988.69.3.0332; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; KETY S S, 1956, J Chronic Dis, V3, P478, DOI 10.1016/0021-9681(56)90146-1; Krejza J, 2005, AM J NEURORADIOL, V26, P730; Krejza J, 2003, ULTRASOUND OBST GYN, V22, P627, DOI 10.1002/uog.907; LEENDERS KL, 1990, BRAIN, V113, P27, DOI 10.1093/brain/113.1.27; LeRoux PD, 1996, J NEUROSURG, V85, P39, DOI 10.3171/jns.1996.85.1.0039; MALONEYWILENSKY E, 2007, NEUROCRIT CARE, V6, P216; MATHEW RJ, 1986, BIOL PSYCHIAT, V21, P907, DOI 10.1016/0006-3223(86)90264-7; MATSUDA H, 1984, STROKE, V15, P336, DOI 10.1161/01.STR.15.2.336; McKhann GM, 2004, MANAGEMENT CEREBRAL, P431; Meixensberger J, 2003, NEUROL RES, V25, P445, DOI 10.1179/016164103101201823; OHMAN J, 1991, J NEUROSURG, V74, P14, DOI 10.3171/jns.1991.74.1.0014; OSULLIVAN MG, 1994, BRIT J NEUROSURG, V8, P23, DOI 10.3109/02688699409002389; PANTANO P, 1984, STROKE, V15, P635, DOI 10.1161/01.STR.15.4.635; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; RODRIGUEZ G, 1988, J CEREBR BLOOD F MET, V8, P783, DOI 10.1038/jcbfm.1988.133; ROOTWELT K, 1986, SCAND J CLIN LAB INV, V46, P97; SAKAKI S, 1989, CLIN NEUROL NEUROSUR, V91, P21, DOI 10.1016/S0303-8467(89)80004-6; Schwertz DW, 2001, HEART LUNG, V30, P401, DOI 10.1067/mhl.2001.118764; SENGUPTA RP, 1978, BRIT MED J, V2, P246, DOI 10.1136/bmj.2.6132.246; SHAW TG, 1984, NEUROLOGY, V34, P855, DOI 10.1212/WNL.34.7.855; SHIRAHATA N, 1985, J COMPUT ASSIST TOMO, V9, P861, DOI 10.1097/00004728-198509000-00004; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; SOLERTE SB, 1988, BRIT J OBSTET GYNAEC, V95, P1305, DOI 10.1111/j.1471-0528.1988.tb06822.x; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Vath A, 2002, ACT NEUR S, V81, P307; Waddell TK, 1999, J HYPERTENS, V17, P413, DOI 10.1097/00004872-199917030-00015; WANG S, 2004, MANAGEMENT CEREBRAL, P409; WHITE RE, 1995, CIRC RES, V77, P936, DOI 10.1161/01.RES.77.5.936; Yang SH, 2001, J CEREBR BLOOD F MET, V21, P174, DOI 10.1097/00004647-200102000-00009	45	40	40	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2008	109	6					1075	1082		10.3171/JNS.2008.109.12.1075			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	376SY	WOS:000261204500018	19035722				2021-06-18	
J	Tian, HL; Geng, Z; Cui, YH; Hu, J; Xu, T; Cao, HL; Chen, SW; Chen, H				Tian, Heng-Li; Geng, Zhi; Cui, Yu-Hui; Hu, Jin; Xu, Tao; Cao, He-Li; Chen, Shi-Wen; Chen, Hao			Risk factors for posttraumatic cerebral infarction in patients with moderate or severe head trauma	NEUROSURGICAL REVIEW			English	Article						posttraumatic cerebral infarction; traumatic brain injury; risk factor; logistic regression analysis	DECOMPRESSIVE CRANIECTOMY; ISCHEMIC-STROKE; ARTERIAL SPASM; INJURY; BRAIN; HYDROCEPHALUS; HYPERTENSION; CIRCULATION; HERNIATION; VASOSPASM	We examined the incidence and timing of posttraumatic cerebral infarction (PTCI) and provide predictive factors for the development of PTCI in patients with moderate or severe traumatic brain injury. Three hundred and fifty-three consecutive patients with moderate or severe head trauma were retrospectively reviewed to determine the incidence and timing of PTCI and to evaluate the effects of age, gender, admission Glasgow Coma Scores (GCS), decompressive craniectomy, brain herniation, and low systolic blood pressure (BP) on the development of cerebral infarction. Risk factors for posttraumatic cerebral infarction were evaluated using logistic regression analysis. PTCI was observed in 36 (11.96%) of the 353 patients, and in a majority of cases, cerebral infarction developed within 2 weeks after injury. Poor admission GCS (P<0.01), low systolic BP (P<0.01), brain herniation (P<0.05), and decompression craniotomy (P<0.05) were significantly associated with the development of PTCI. No relationship was found between PTCI and gender or increased age. Posttraumatic cerebral infarction is a relatively common complication in patients with head trauma that develops early in the clinical course. Low GCS, low systolic BP, brain herniation, and decompression craniotomy may be risk factors for PTCI in patients with moderate or severe traumatic brain injury.	[Tian, Heng-Li; Cui, Yu-Hui; Hu, Jin; Xu, Tao; Cao, He-Li; Chen, Hao] Shanghai Jiao Tong Univ, Dept Neurosurg, Shanghai Peoples Hosp 6, Shanghai 200030, Peoples R China; [Geng, Zhi] Shanghai Jiao Tong Univ, Dept Neurol, Shanghai Peoples Hosp 6, Shanghai 200030, Peoples R China; [Chen, Shi-Wen] Shanghai Jiao Tong Univ, Dept Radiol, Shanghai Peoples Hosp 6, Shanghai 200030, Peoples R China	Chen, H (corresponding author), Shanghai Jiao Tong Univ, Dept Neurosurg, Shanghai Peoples Hosp 6, Shanghai 200030, Peoples R China.	chenhao_316@yahoo.com.cn		Chen, Hao/0000-0002-9943-9237	Shanghai Municipal Health Bureau [054011]; Shanghai Science and Technology Council [03ZR14059]	This study was supported by the Shanghai Municipal Health Bureau (grant no. 054011) and Shanghai Science and Technology Council (grant no. 03ZR14059).	Abe M, 2003, SURG NEUROL, V59, P464, DOI 10.1016/S0090-3019(03)00078-8; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Czosnyka M, 2000, J NEUROL NEUROSUR PS, V68, P246; Droste DW, 2003, ACTA NEUROL SCAND, V107, P241, DOI 10.1034/j.1600-0404.2003.00098.x; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; Ivanusa M, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-26; MACPHERS.P, 1973, J NEUROL NEUROSUR PS, V36, P1069, DOI 10.1136/jnnp.36.6.1069; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; Messing-Junger AM, 2003, ZBL NEUROCHIR, V64, P171; MIRVIS SE, 1990, AM J ROENTGENOL, V154, P1293, DOI 10.2214/ajr.154.6.2110744; Moulin T, 1997, EUR NEUROL, V38, P10, DOI 10.1159/000112896; PASQUALIN A, 1984, NEUROSURGERY, V15, P855, DOI 10.1227/00006123-198412000-00015; PHILLIPS SJ, 1992, ARCH INTERN MED, V152, P938, DOI 10.1001/archinte.152.5.938; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; ROTHFUS WE, 1987, AM J NEURORADIOL, V8, P1073; SACCO RL, 1995, NEUROLOGY, V45, pS10; SATO M, 1986, NEUROSURGERY, V18, P300, DOI 10.1227/00006123-198603000-00007; SHAPIRO K, 1985, J NEUROSURG, V63, P76, DOI 10.3171/jns.1985.63.1.0076; Tomberg T A, 1989, Zh Vopr Neirokhir Im N N Burdenko, P23; Uhl E, 2004, J NEUROL NEUROSUR PS, V75, P270; WEISBERG LA, 1979, COMPUT TOMOGR, V3, P15, DOI 10.1016/0363-8235(75)90004-6; WILKINS RH, 1970, J NEUROSURG, V32, P626, DOI 10.3171/jns.1970.32.6.0626; Yang Xiao-feng, 2005, J Zhejiang Univ Sci B, V6, P644, DOI 10.1631/jzus.2005.B0644; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005; Zubkov AY, 1999, J NEUROTRAUM, V16, P763, DOI 10.1089/neu.1999.16.763	25	40	54	0	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5607			NEUROSURG REV	Neurosurg. Rev.	OCT	2008	31	4					431	436		10.1007/s10143-008-0153-5			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	344YF	WOS:000258962500015	18704527				2021-06-18	
J	Yuh, EL; Gean, AD; Manley, GT; Callen, AL; Wintermark, M				Yuh, Esther L.; Gean, Alisa D.; Manley, Geoffrey T.; Callen, Andrew L.; Wintermark, Max			Computer-Aided Assessment of Head Computed Tomography (CT) Studies in Patients with Suspected Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	International Symposium on Traumatic Brain Injury Research Priorities	OCT 13-16, 2005	Johnstown, PA	John P Murtha Neursci & Pain Inst, Natl Brain Injury Res, Treatments & Training Fdn, Brain Injury Assoc Amer		adult brain injury; animal studies; blood-brain barrier dysfunction; intracranial pressure; therapeutic approaches for the treatment of CNS injury	ACUTE INTRACRANIAL HEMORRHAGE; SCAN INTERPRETATION; PULMONARY NODULES; CLASSIFICATION; SENSITIVITY; PERFORMANCE; PREDICTION	In this study, we sought to determine the accuracy of a computer algorithm that automatically assesses head computed tomography (CT) studies in patients with suspected traumatic brain injury (TBI) for features of intracranial hemorrhage and mass effect, employing a neuroradiologist's interpretation as the gold standard. To this end, we designed a suite of computer algorithms that evaluates in a fully automated fashion the presence of intracranial blood and/or mass effect based on the following CT findings: (1) presence or absence of a subdural or epidural hematoma, (2) presence or absence of subarachnoid hemorrhage, (3) presence or absence of an intraparenchymal hematoma, (4) presence or absence of clinically significant midline shift (>= 5 mm), and (5) normal, partly effaced, or completely effaced basal cisterns. The algorithm displays abnormal findings as color overlays on the original head CT images, and calculates the volume of each type of blood collection, the midline shift, and the volume of the basal cisterns, based on the above-described features. Thresholds and parameters yielding optimal accuracy of the computer algorithm were determined using a development sample of 33 selected, nonconsecutive patients. The software was then applied to a validation sample of 250 consecutive patients evaluated for suspicion of acute TBI at our institution in 2006 -2007. Software detection of the presence of at least one noncontrast CT (NCT) feature of acute TBI demonstrated high sensitivity of 98% and high negative predictive value (NPV) of 99%. There was actually only one false negative case, where a very subtle subdural hematoma, extending exclusively along the falx, was diagnosed by the neuroradiologist, while the case was considered as normal by the computer algorithm. The software was excellent at detecting the presence of mass effect and intracranial hemorrhage, but showed some disagreements with the neuroradiologist in quantifying the degree of mass effect and characterizing the type of intracranial hemorrhage. In summary, we have developed a fully automated computer algorithm that demonstrated excellent sensitivity for acute intracranial hemorrhage and clinically significant midline shift, while maintaining intermediate specificity. Further studies are required to evaluate the potential favorable impact of this software on facilitating workflow and improving diagnostic accuracy when used as a screening aid by physicians with different levels of experience.	[Yuh, Esther L.; Gean, Alisa D.; Callen, Andrew L.; Wintermark, Max] Univ Calif San Francisco, Dept Radiol, Neuroradiol Sect, San Francisco, CA 94143 USA; [Yuh, Esther L.; Gean, Alisa D.; Manley, Geoffrey T.; Callen, Andrew L.; Wintermark, Max] San Francisco Gen Hosp, San Francisco, CA 94110 USA; [Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Gean, Alisa D.; Manley, Geoffrey T.; Wintermark, Max] Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA	Wintermark, M (corresponding author), Univ Calif San Francisco, Dept Radiol, Neuroradiol Sect, 505 Parnassus Ave,Box 0628, San Francisco, CA 94143 USA.	Max.Wintermark@radiology.ucsf.edu		Wintermark, Max/0000-0002-6726-3951			ALFARO D, 1995, ANN EMERG MED, V25, P169, DOI 10.1016/S0196-0644(95)70319-5; Baker ME, 2007, RADIOLOGY, V245, P140, DOI 10.1148/radiol.2451061116; Beyer F, 2007, EUR RADIOL, V17, P2941, DOI 10.1007/s00330-007-0667-1; BRANCATO B, 2007, BREAST CANC IN PRESS; Chan T, 2008, ACAD RADIOL, V15, P290, DOI 10.1016/j.acra.2007.09.022; Chan T, 2007, COMPUT MED IMAG GRAP, V31, P285, DOI 10.1016/j.compmedimag.2007.02.010; CHANTAL WPM, 2006, J CLIN EPIDEMIOL, V59, P132; Chesnut RM, 2000, J NEUROTRAUM, V17, P555; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Das M, 2006, RADIOLOGY, V241, P564, DOI 10.1148/radiol.2412051139; Erly WK, 2003, AM J ROENTGENOL, V180, P1727, DOI 10.2214/ajr.180.6.1801727; Fenton JJ, 2007, NEW ENGL J MED, V356, P1399, DOI 10.1056/NEJMoa066099; Khoo NC, 2007, EMERG MED AUSTRALAS, V19, P122, DOI 10.1111/j.1742-6723.2007.00914.x; Lal NR, 2000, AM J NEURORADIOL, V21, P124; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; Wysoki MG, 1998, RADIOLOGY, V208, P125, DOI 10.1148/radiology.208.1.9646802	19	40	40	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2008	25	10					1163	1172		10.1089/neu.2008.0590			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	370XK	WOS:000260796200004	18986221				2021-06-18	
J	Casey, PA; Mckenna, MC; Fiskum, G; Saraswati, M; Robertson, CL				Casey, Paula A.; Mckenna, Mary C.; Fiskum, Gary; Saraswati, Manda; Robertson, Courtney L.			Early and sustained alterations in cerebral metabolism after traumatic brain injury in immature rats	JOURNAL OF NEUROTRAUMA			English	Article						N-acetyl aspartate; development; lactate; mitochondria; NMR spectroscopy	MAGNETIC-RESONANCE-SPECTROSCOPY; PROTON MR SPECTROSCOPY; CLOSED-HEAD INJURY; L-ASPARTIC ACID; ENERGY-METABOLISM; NERVOUS-SYSTEM; IN-VIVO; MITOCHONDRIAL DYSFUNCTION; H-1-NMR SPECTROSCOPY; OUTCOME PREDICTION	Although studies have shown alterations in cerebral metabolism after traumatic brain injury (TBI), clinical data in the developing brain is limited. We hypothesized that post-traumatic metabolic changes occur early (< 24 h) and persist for up to 1 week. Immature rats underwent TBI to the left parietal cortex. Brains were removed at 4 h, 24 h, and 7 days after injury, and separated into ipsilateral (injured) and contralateral (control) hemispheres. Proton nuclear magnetic resonance (NMR) spectra were obtained, and spectra were analyzed for N-acetyl-aspartate (NAA), lactate (Lac), creatine (Cr), choline, and alanine, with metabolite ratios determined (NAA/Cr, Lac/Cr). There were no metabolic differences at any time in sham controls between cerebral hemispheres. At 4 and 24 h, there was an increase in Lac/Cr, reflecting increased glycolysis and/or decreased oxidative metabolism. At 24 h and 7 days, there was a decrease in NAA/Cr, indicating loss of neuronal integrity. The NAA/Lac ratio was decreased (similar to 15-20%) at all times (4 h, 24 h, 7 days) in the injured hemisphere of TBI rats. In conclusion, metabolic derangements begin early (< 24 h) after TBI in the immature rat and are sustained for up to 7 days. Evaluation of early metabolic alterations after TBI could identify novel targets for neuroprotection in the developing brain.	[Casey, Paula A.; Mckenna, Mary C.; Saraswati, Manda; Robertson, Courtney L.] Univ Maryland, Dept Pediat, Sch Med, Baltimore, MD 21201 USA; [Fiskum, Gary; Robertson, Courtney L.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA	Robertson, CL (corresponding author), Univ Maryland, Dept Pediat, Sch Med, 22 S Greene St,N5E13, Baltimore, MD 21201 USA.	croberts@peds.umaryland.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD016596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS042805] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD 16596] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08 NS 42805] Funding Source: Medline		Ashwal S, 1997, ANN NEUROL, V41, P470, DOI 10.1002/ana.410410410; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/neu.2004.21.1539; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Barkovich AJ, 1999, AM J NEURORADIOL, V20, P1399; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Bates T E, 1989, NMR Biomed, V2, P225, DOI 10.1002/nbm.1940020509; Bogaert YE, 2000, EXP NEUROL, V161, P115, DOI 10.1006/exnr.1999.7250; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; BURRI R, 1990, NEUROCHEM RES, V15, P1009, DOI 10.1007/BF00965747; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; COHEN Y, 1991, MAGNET RESON MED, V17, P225, DOI 10.1002/mrm.1910170125; DADAMO AF, 1966, J NEUROCHEM, V13, P961, DOI 10.1111/j.1471-4159.1966.tb10292.x; DAVIES SEC, 1995, J NEUROCHEM, V64, P742; Dienel GA, 2003, NEUROCHEM INT, V43, P339, DOI 10.1016/S0197-0186(03)00021-4; Federico F, 1997, J NEUROL NEUROSUR PS, V62, P239, DOI 10.1136/jnnp.62.3.239; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Gasparovic C, 2001, J NEUROTRAUM, V18, P241, DOI 10.1089/08977150151070856; Godbolt AK, 2006, NEUROLOGY, V66, P718, DOI 10.1212/01.wnl.0000201237.05869.df; Harris NG, 1997, J NEUROCHEM, V68, P305; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Hazany S, 2007, NEURORADIOLOGY, V49, P121, DOI 10.1007/s00234-006-0167-z; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Holshouser BA, 2006, J MAGN RESON IMAGING, V24, P33, DOI 10.1002/jmri.20607; Hunter JV, 2005, AM J NEURORADIOL, V26, P482; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Keenan HT, 2007, PEDIATRICS, V119, pE616, DOI 10.1542/peds.2006-2313; Kochanek AR, 2006, DEV NEUROSCI-BASEL, V28, P410, DOI 10.1159/000094167; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; LOPEZVILLEGAS D, 1995, MAGNET RESON MED, V34, P32, DOI 10.1002/mrm.1910340107; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Makoroff KL, 2005, PEDIATR RADIOL, V35, P668, DOI 10.1007/s00247-005-1441-7; Malik GK, 2002, EUR J RADIOL, V43, P6, DOI 10.1016/S0720-048X(01)00435-1; Marino S, 2007, J NEUROL NEUROSUR PS, V78, P501, DOI 10.1136/jnnp.2006.099796; Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCKENNA MC, 1994, DEV NEUROSCI-BASEL, V16, P291, DOI 10.1159/000112122; McKenna MC, 2006, BASIC NEUROCHEMISTRY, P531; MEIJER AJ, 1974, BIOCHIM BIOPHYS ACTA, V346, P213, DOI 10.1016/0304-4173(74)90001-9; O'Brien J, 2007, NEUROCHEM RES, V32, P597, DOI 10.1007/s11064-006-9132-9; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Pascual JM, 2007, J NEUROTRAUM, V24, P944, DOI 10.1089/neu.2006.0190; PATEL TB, 1979, BIOCHEM J, V184, P539, DOI 10.1042/bj1840539; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; PETROFF OAC, 1992, NEUROLOGY, V42, P1349, DOI 10.1212/WNL.42.7.1349; Richards EM, 2007, STROKE, V38, P1578, DOI 10.1161/STROKEAHA.106.473967; Richards EM, 2006, FREE RADICAL BIO MED, V40, P1960, DOI 10.1016/j.freeradbiomed.2006.01.022; Robertson CL, 2004, DEV BRAIN RES, V151, P141, DOI 10.1016/j.devbrainres.2004.04.007; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Robertson CL, 2006, DEV NEUROSCI-BASEL, V28, P432, DOI 10.1159/000094169; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Satrustegui J, 2007, J NEUROSCI RES, V85, P3359, DOI 10.1002/jnr.21299; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Serres S, 2004, J BIOL CHEM, V279, P47881, DOI 10.1074/jbc.M409429200; Shu SK, 1997, PEDIATR NEUROL, V17, P309, DOI 10.1016/S0887-8994(97)00140-9; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Soustiel JF, 2005, J NEUROTRAUM, V22, P955, DOI 10.1089/neu.2005.22.955; TALLAN HH, 1956, J BIOL CHEM, V219, P257; TAYLOR DL, 1995, J NEUROCHEM, V65, P275; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Viant MR, 2005, NMR BIOMED, V18, P507, DOI 10.1002/nbm.980; Yeo RA, 2006, J NEUROTRAUM, V23, P1427, DOI 10.1089/neu.2006.23.1427; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zwingmann C, 2001, GLIA, V34, P200, DOI 10.1002/glia.1054	73	40	40	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2008	25	6					603	614		10.1089/neu.2007.0481			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	326BW	WOS:000257633900004	18454682	Green Published			2021-06-18	
J	Chiaretti, A; Antonelli, A; Riccardi, R; Genovese, O; Pezzotti, P; Di Rocco, C; Tortorolo, L; Piedimonte, G				Chiaretti, Antonio; Antonelli, Alessia; Riccardi, Riccardo; Genovese, Orazio; Pezzotti, Patrizio; Di Rocco, Concezio; Tortorolo, Luca; Piedimonte, Giovanni			Nerve growth factor expression correlates with severity and outcome of traumatic brain injury in children	EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY			English	Article						children; cytokines; neuroprotection; neurotrophic factors; traumatic brain injury	NECROSIS-FACTOR-ALPHA; HYPOXIC-ISCHEMIC ENCEPHALOPATHY; CONTROLLED CORTICAL IMPACT; CEREBROSPINAL-FLUID; NEUROTROPHIC FACTOR; HEAD-INJURY; CHOLINERGIC NEURONS; FACTOR PROTECTS; NEONATAL-RAT; INTERLEUKIN-6	Background: Secondary brain damage after traumatic brain injury (TBI) involves neuro-inflammatory mechanisms, mainly dependent on the intracerebral production of cytokines. In particular, interleukin 1 beta (IL-1 beta) is associated with neuronal damage, while interleukin 6 (IL-6) exerts a neuroprotective role due to its ability to modulate neurotrophins biosynthesis. However, the relationship between these cytokines and neurotrophins with the severity and outcome of TBI remains still controversial. Aims: To determine whether the concentration of IL-1 beta and IL-6 and neurotrophins (nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glial-derived neurotrophic factor (GDNF)) in the cerebrospinal fluid (CSF) of children with TBI correlates with the severity of the injury and its neurologic outcome. Methods: Prospective observational clinical study in a university hospital. CSF samples were collected from 27 children at 2 h (Time T1) and 48 h (Time T2) after severe TBI, and from 21 matched controls. Severity of TBI was evaluated by GCS and neurologic outcome by GOS. CSF concentrations of cytokines and neurotrophins were measured by immunoenzymatic assays. Results: Early NGF and IL-1 beta concentrations (T1) correlated significantly with the severity of head injury, whereas no correlation was found for IL-6, BDNF, and GDNF. Furthermore, higher NGF and IL-6 and lower IL-1 beta expression at T2 were associated with better neurologic outcomes. No significant association was found between BDNF or GDNF expression and neurologic outcome. Conclusions: NGF concentration in CSF is a useful marker of brain damage following severe TBI and its up-regulation, in the first 48 h after head injury together with lower IL-1 beta expression, correlates with a favorable neurologic outcome. Clinical and prognostic information may also be obtained from IL-6 expression. (C) 2007 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.	[Chiaretti, Antonio; Antonelli, Alessia; Genovese, Orazio; Tortorolo, Luca] Catholic Univ, Sch Med, Paediat Intens Care Unit, Rome, Italy; [Riccardi, Riccardo] Catholic Univ, Sch Med, Dept Paediat, Rome, Italy; [Pezzotti, Patrizio] Agcy Publ Hlth Lazio Reg, Rome, Italy; [Di Rocco, Concezio] Catholic Univ, Sch Med, Rome, Italy; [Piedimonte, Giovanni] W Virginia Univ, Sch Med, Dept Paediat, Morgantown, WV 26506 USA	Chiaretti, A (corresponding author), Catholic Univ, Sch Med, Paediat Intens Care Unit, Rome, Italy.	achiaretti@yahoo.it		GENOVESE, Orazio/0000-0002-1989-1363; RICCARDI, RICCARDO/0000-0001-7515-6622	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL061007] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL061007] Funding Source: NIH RePORTER		Almli CR, 2000, EXP NEUROL, V166, P99, DOI 10.1006/exnr.2000.7492; Aly H, 2006, BRAIN DEV-JPN, V28, P178, DOI 10.1016/j.braindev.2005.06.006; Amick Jonathan E., 2001, Pediatr Crit Care Med, V2, P260, DOI 10.1097/00130478-200107000-00013; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Cai ZW, 2004, PEDIATR RES, V56, P377, DOI 10.1203/01.PDR.0000134249.92944.14; Calza L, 2003, P NATL ACAD SCI USA, V100, P7325, DOI 10.1073/pnas.1132092100; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; Chiaretti A, 2005, NEUROL RES, V27, P741, DOI 10.1179/016164105X35611; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; Dietrich WD, 2004, ACTA NEUROCHIR SUPPL, V89, P69; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; FINKLESTEIN SP, 1996, ADV NEUROL, V71, P7; FINKLESTEIN SP, 1996, ADV NEUROL, V71, P413; HAMA T, 1989, NEUROSCI LETT, V104, P340, DOI 10.1016/0304-3940(89)90600-9; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Holtzman DM, 1996, ANN NEUROL, V39, P114, DOI 10.1002/ana.410390117; Ikeda T, 2000, ACTA NEUROPATHOL, V100, P161, DOI 10.1007/s004019900162; Johnston MV, 2005, BRAIN PATHOL, V15, P234; Jonhagen ME, 1998, DEMENT GERIATR COGN, V9, P246, DOI 10.1159/000017069; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; LONGO FM, 1984, EXP NEUROL, V84, P207, DOI 10.1016/0014-4886(84)90016-5; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; OLSON L, 1992, J NEURAL TRANSM-PARK, V4, P79, DOI 10.1007/BF02257624; Oygur N, 1998, ARCH DIS CHILD-FETAL, V79, pF190, DOI 10.1136/fn.79.3.F190; PATTERSON SL, 1993, BRAIN RES, V605, P43, DOI 10.1016/0006-8993(93)91354-U; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Stahel PF, 1998, NEUROSCI LETT, V249, P123, DOI 10.1016/S0304-3940(98)00410-8; Viscardi RM, 2004, PEDIATR RES, V55, P1009, DOI 10.1203/01.pdr.0000127015.60185.8a; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Wilde GJC, 2000, EUR J NEUROSCI, V12, P3863, DOI 10.1046/j.1460-9568.2000.00273.x; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Zhou Zheng, 2003, Journal of Basic and Clinical Physiology and Pharmacology, V14, P217	50	40	43	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1090-3798			EUR J PAEDIATR NEURO	Eur. J. Paediatr. Neurol.	MAY	2008	12	3					195	204		10.1016/j.ejpn.2007.07.016			10	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	311NW	WOS:000256607900006	17881264	Green Accepted			2021-06-18	
J	Brewer, BR; Klatzky, R; Matsuoka, Y				Brewer, Bambi Roberts; Klatzky, Roberta; Matsuoka, Yoky			Visual feedback distortion in a robotic environment for hand rehabilitation	BRAIN RESEARCH BULLETIN			English	Article						visual distortion; visual feedback; hand rehabilitation; robotic rehabilitation	RESEARCH ARM TEST; MANUAL DISCRIMINATION; FORCE CONTROL; STROKE; WEIGHT; RELIABILITY; INTENSITY; GRASP; TOUCH; SPAN	Robotic therapy offers a means of enhancing rehabilitation for individuals with chronic stroke or traumatic brain injury. The present research targets members of this population who demonstrate learned nonuse, a tendency to use affected limbs below the level of the individual's true capability. These individuals may not strive for difficult goals in therapy, which ultimately hampers their progress and the outcome of rehabilitation. Our research uses a paradigm called visual feedback distortion in which the visual feedback corresponding to force or distance is gradually changed by an imperceptible amount to encourage improved performance. Our first set of experiments was designed to assess the limits of imperceptible distortion for visual feedback concerning the force exerted or the distance moved by the index finger. A second set of experiments used these limits to gradually distort visual feedback in order to manipulate a subject's force or distance response. Based on this work, we designed a paradigm applying visual feedback distortion to the rehabilitation of individuals with chronic stroke and traumatic brain injury. Initial tests are reported for two subjects who participated in a six-week rehabilitation protocol. Each patient followed visual feedback distortion to levels of performance above that predicted by her performance during an initial assessment. Both patients showed functional improvements after participating in the study. Visual feedback distortion may provide a way to help a patient move beyond his or her self-assessed "best" performance, improving the outcome of robotic rehabilitation. (c) 2008 Elsevier Inc. All rights reserved.	[Brewer, Bambi Roberts; Klatzky, Roberta; Matsuoka, Yoky] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA	Brewer, BR (corresponding author), Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA.	bbrewer@pitt.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A020502] Funding Source: Medline		Atkinson J. W., 1964, INTRO MOTIVATION; BANDURA A, 1986, ORGAN BEHAV HUM DEC, V38, P92, DOI 10.1016/0749-5978(86)90028-2; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BERLINER JE, 1973, J ACOUST SOC AM, V53, P1270, DOI 10.1121/1.1913465; Boian R, 2002, STUD HEALTH TECHNOL, V85, P64; Brewer BR, 2006, P IEEE, V94, P1739, DOI 10.1109/JPROC.2006.880715; Brewer BR, 2005, IEEE T NEUR SYS REH, V13, P1, DOI 10.1109/TNSRE.2005.843443; BREWER BR, 2006, 5 INT WORKSH VIRT RE; BRODIE EE, 1984, PERCEPT PSYCHOPHYS, V36, P477, DOI 10.3758/BF03207502; Burgar CG, 2000, J REHABIL RES DEV, V37, P663; COLE KJ, 1991, J MOTOR BEHAV, V23, P251, DOI 10.1080/00222895.1991.9942036; DURLACH NI, 1989, PERCEPT PSYCHOPHYS, V46, P29, DOI 10.3758/BF03208071; Ernst MO, 2002, NATURE, V415, P429, DOI 10.1038/415429a; Fitzgibbons PJ, 2001, J ACOUST SOC AM, V109, P2955, DOI 10.1121/1.1371760; Gescheider GA., 1976, PSYCHOPHYSICS METHOD; Hermsdorfer J, 2003, CLIN NEUROPHYSIOL, V114, P915, DOI 10.1016/S1388-2457(03)00042-7; JARIC S, 1994, EXP BRAIN RES, V100, P353; JONES LA, 1989, PERCEPTION, V18, P681, DOI 10.1068/p180681; Kim JS, 1996, STROKE, V27, P677, DOI 10.1161/01.STR.27.4.677; Kopp B, 1997, ARCH PHYS MED REHAB, V78, P615, DOI 10.1016/S0003-9993(97)90427-5; Krebs H I, 1998, IEEE Trans Rehabil Eng, V6, P75, DOI 10.1109/86.662623; Krebs HI, 2000, J REHABIL RES DEV, V37, P639; PANG XD, 1991, PERCEPT PSYCHOPHYS, V49, P531, DOI 10.3758/BF03212187; Patton JL, 2006, EXP BRAIN RES, V168, P368, DOI 10.1007/s00221-005-0097-8; RAJ DV, 1985, BRAIN, V108, P95, DOI 10.1093/brain/108.1.95; ROCK I, 1964, SCIENCE, V143, P594, DOI 10.1126/science.143.3606.594; ROSS HE, 1987, Q J EXP PSYCHOL-A, V39, P77, DOI 10.1080/02724988743000042; SHIMOKATA H, 1995, GERONTOLOGY, V41, P267; Shinomori K, 2001, J OPT SOC AM A, V18, P310, DOI 10.1364/JOSAA.18.000310; SRINIVASAN MA, 1996, ASME DYN SYST CONTR, P555; STEVENS JC, 1995, SOMATOSENS MOT RES, V12, P29, DOI 10.3109/08990229509063140; TAN HZ, 1989, J ACOUST SOC AM, V86, P981, DOI 10.1121/1.398733; TAN HZ, 1995, PERCEPT PSYCHOPHYS, V57, P495, DOI 10.3758/BF03213075; TAUB E, 1994, PL S BEHAV, P185; TAUB E, ARM MOTOR ABILITY TE; van der Lee JH, 2001, J REHABIL MED, V33, P110; Van der Lee JH, 2001, ARCH PHYS MED REHAB, V82, P14, DOI 10.1053/apmr.2001.18668; VANDEWEGHE M, 2006, IEEE S HAPT INT VIRT; WELCH RB, 1980, PSYCHOL BULL, V88, P638, DOI 10.1037/0033-2909.88.3.638	39	40	40	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.	APR 15	2008	75	6					804	813		10.1016/j.brainresbull.2008.01.006			10	Neurosciences	Neurosciences & Neurology	297MT	WOS:000255621500012	18394527				2021-06-18	
J	Gaylord, KM; Cooper, DB; Mercado, JM; Kennedy, JE; Yoder, LH; Holcomb, JB				Gaylord, Kathryn M.; Cooper, Douglas B.; Mercado, Janyna M.; Kennedy, Jan E.; Yoder, Linda H.; Holcomb, John B.			Incidence of posttraumatic stress disorder and mild traumatic brain injury in burned service members: Preliminary report	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						burn injury; blast injury; PTSD; mild TBI	MENTAL-DISORDERS; HEALTH-PROBLEMS; BLAST INJURY; SYMPTOMS; OUTCOMES; IRAQ; AFGHANISTAN; OPERATIONS; MILITARY; CARE	Background: Although sustaining physical injury in theater increases service members' risk for posttraumatic stress disorder (PTSD), exposure to explosive munitions may increase the risk of mild traumatic brain injury (mTBI). We hypothesized a higher incidence of PTSD and mTBI in service members who sustained both burn and explosion injuries than in nonexplosion exposed service members. Methods: A retrospective review of PTSD and mTBI assessments was completed on burned service members between September 2005 and August 2006. Subjects were divided into cohort groups: (1) PTSD and mTBI, (2) PTSD and no mTBI, (3) mTBI and no PTSD, (4) no mTBI and no PTSD. Specific criteria used for group classification were based on subjects' total score on Posttraumatic Stress Disorder Checklist, Military version (PCL-M), clinical interview, and record review to meet American Congress of Rehabilitation Medicine criteria for mTBI. Descriptive analyses were used. Results: Seventy-six service members met the inclusion criteria. The incidence rate of PTSD was 32% and mTBI was 41%. Eighteen percent screened positive for PTSD and mTBI; 13% screened positive for PTSD, but not mTBI; 23% screened positive for mTBI but not PTSD; 46% did not screen positive for either PTSD or mTBI. Conclusion: Given the high incidence of these disorders in burned service members, further screening of PTSD and TBI appears warranted. Because symptom presentation in PTSD and mTBI is clinically similar in acute and subacute stages, and treatments can vary widely, further research investigating symptom profiles of PTSD and mTBI is warranted.	[Gaylord, Kathryn M.; Holcomb, John B.] USAISR, Ft Sam Houston, TX 78234 USA; [Cooper, Douglas B.; Mercado, Janyna M.] Brooke Army Med Ctr, Dept Behav Med, Ft Sam Houston, TX 78234 USA; [Kennedy, Jan E.] Wilford Hall USAF Med Ctr, Dept Neurol, Def & Vet Brain Injury Ctr, Lackland AFB, TX 78236 USA; [Yoder, Linda H.] Univ Texas Austin, Sch Nursing, Austin, TX 78712 USA	Gaylord, KM (corresponding author), USAISR, 3400 Rawley E Chambers Rd, Ft Sam Houston, TX 78234 USA.	kathryn.gaylord@amedd.army.mil					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Baur KM, 1998, J BURN CARE REHABIL, V19, P230, DOI 10.1097/00004630-199805000-00009; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Cancio LC, 2005, J BURN CARE REHABIL, V26, P151, DOI 10.1097/01.BCR.0000155540.31879.FB; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chambers J, 1996, J TRAUMA, V41, P976, DOI 10.1097/00005373-199612000-00006; Defense and Veterans Brain Injury Center Working Group, 2006, AC MAN MILD TRAUM BR; Dobie DJ, 2004, ARCH INTERN MED, V164, P394, DOI 10.1001/archinte.164.4.394; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; Hoge CW, 2006, JAMA-J AM MED ASSOC, V296, P2678, DOI 10.1001/jama.296.22.2678-b; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hoge CW, 2005, AM J PSYCHIAT, V162, P585, DOI 10.1176/appi.ajp.162.3.585; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; Holcomb JB, 2007, ANN SURG, V245, P986, DOI 10.1097/01.sla.0000259433.03754.98; Jackson JC, 2007, J TRAUMA, V62, P80, DOI 10.1097/TA.0b013e31802ce9bd; Kraus J. F., 1999, REHABILITATION ADULT, P3; Michaels AJ, 1998, J TRAUMA, V44, P644, DOI 10.1097/00005373-199804000-00013; Michaels AJ, 2000, J TRAUMA, V48, P841, DOI 10.1097/00005373-200005000-00007; Narrow WE, 2002, ARCH GEN PSYCHIAT, V59, P115, DOI 10.1001/archpsyc.59.2.115; Scott SG, 2005, FEDERAL PRACTITIONER, V22, P67; TEASDALE G, 1974, LANCET, V2, P81; Van Loey NEE, 2003, J TRAUMA STRESS, V16, P361, DOI 10.1023/A:1024465902416; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weathers F, 1995, TRAUMATIC STRESS THE, P103	29	40	41	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2008	64	2		S			S200	S204		10.1097/TA.0b013e318160ba42			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	265UJ	WOS:000253386200054	18376167				2021-06-18	
J	Bodenburg, S; Dopslaff, N				Bodenburg, Sebastian; Dopslaff, Nina			The dysexecutive questionnaire advanced - Item and test score characteristics, 4-factor solution, and severity classification	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article						frontal lobe; cognition disorders; social behavior; neuropsychological tests	TRAUMATIC BRAIN-INJURY; EXECUTIVE DYSFUNCTION; NEUROPSYCHOLOGY	The Dysexecutive Questionnaire (DEX, Wilson et al., Behavioral assessment of the dysexecutive syndrome, 1996) is a standardized instrument to measure possible behavioral changes as a result of the dysexecutive syndrome. Although initially intended only as a qualitative instrument, the DEX has also been used increasingly to address quantitative problems. Until now there have not been more fundamental statistical analyses of the questionnaire's testing quality. The present study is based on an unselected sample of 191 patients with acquired brain injury and reports on the data relating to the quality of the items, the reliability and the factorial structure of the DEX Item 3 displayed too great an item difficulty, whereas item 11 was not sufficiently discriminating. The DEX's reliability in self-rating is r = 0.85. In addition to presenting the statistical values of the tests, a clinical severity classification of the overall scores of the 4 found factors and of the questionnaire as a whole is carried out on the basis of quartile standards.	[Bodenburg, Sebastian] Neuropsychol Praxis, D-20095 Hamburg, Germany; [Bodenburg, Sebastian; Dopslaff, Nina] Univ Hamburg, Dept Psychol, Hamburg, Germany	Bodenburg, S (corresponding author), Neuropsychol Praxis, Moenckebergstr 19, D-20095 Hamburg, Germany.	sb_nph@t-online.de					Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P606, DOI 10.1017/S1355617705050721; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P376, DOI 10.1017/S1355617705050423; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Chan RCK, 2001, BRIT J PSYCHOL, V92, P551, DOI 10.1348/000712601162338; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; FOSTER JK, 1994, COGNITIVE NEUROPSYCH, V11, P133, DOI 10.1080/02643299408251971; Kim E, 2002, NEUROREHABILITATION, V17, P297; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Lienert G.A., 1969, TESTAUFBAU TESTANALY; MCCARTHY RA, 1990, COGNITIVE NEUROPSYCH; Mullan DJ, 2006, AM J PHYS, V74, P10, DOI 10.1119/1.2110548; RYLANDER G, 1939, ACTA PSYCH NEUROL S, V20, P5; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Shaw P, 2005, J COGNITIVE NEUROSCI, V17, P1410, DOI 10.1162/0898929054985491; Spinella M, 2004, INT J NEUROSCI, V114, P1581, DOI 10.1080/00207450490509339; STEEGMANN AT, 1962, SURGERY, V52, P952; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Ufer K., 2000, BEHAV ASSESSMENT DYS; Wechsler, 1981, WAIS R MANUAL; Wilson BA, 1996, BEHAV ASSESSMENT DYS	22	40	40	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-3018	1539-736X		J NERV MENT DIS	J. Nerv. Ment. Dis.	JAN	2008	196	1					75	78		10.1097/NMD.0b013e31815faa2b			4	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	253IN	WOS:000252512000012	18195646				2021-06-18	
J	McHugh, L; Wood, RL				McHugh, Louise; Wood, Rodger L.			Using a temporal discounting paradigm to measure decision-making and impulsivity following traumatic brain injury: A pilot study	BRAIN INJURY			English	Article						temporal discounting; traumatic brain injury; decision-making; impulsivity	DELAY; REWARDS; PERSONALITY; BEHAVIOR; AMYGDALA; CHOICE	Primary objective: This study reports on a pilot study using a temporal discounting paradigm and a standardized impulsivity questionnaire to examine decision-making in a group of brain injured patients and age matched controls. Methods and procedures: Participants were asked to choose between a larger reward available at a specified time in the future and smaller reward available immediately. Outcome and results: Each of the two groups demonstrated temporal discounting; that is, the subjective value of the reward decreased with increasing delay. However, the TBI group discounted more than the controls, suggesting that their decision-making was more impulsive. Conclusion: The results suggest that a temporal discounting paradigm might be a useful method of assessing decision-making after head trauma, especially in cases where capacity to make decisions about financial awards is an issue or in respect of money management generally.	[McHugh, Louise] Univ Wales Swansea, Sch Human Sci, Brain Injury Res Grp, Dept Psychol, Swansea SA2 8PP, W Glam, Wales	McHugh, L (corresponding author), Univ Wales Swansea, Sch Human Sci, Brain Injury Res Grp, Dept Psychol, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.	l.mchugh@swansea.ac.uk		McHugh, Louise/0000-0002-2526-4649			Ainslie G., 2001, BREAKDOWN WILL; Bechara A, 2003, ANN NY ACAD SCI, V985, P356, DOI 10.1111/j.1749-6632.2003.tb07094.x; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A, 1999, J NEUROSCI, V19, P5473; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Crawford J. R., 1992, HDB NEUROPSYCHOLOGIC, P21; Crean JP, 2000, EXP CLIN PSYCHOPHARM, V8, P155, DOI 10.1037/1064-1297.8.2.155; Critchfield TS, 2001, J APPL BEHAV ANAL, V34, P101, DOI 10.1901/jaba.2001.34-101; Dixon MR, 2005, BEHAV INTERVENT, V20, P101, DOI 10.1002/bin.173; FEINGOLD A, 1994, PSYCHOL BULL, V116, P429, DOI 10.1037/0033-2909.116.3.429; Fossati A, 2002, PERCEPT MOTOR SKILL, V95, P621, DOI 10.2466/PMS.95.6.621-635; Green L, 1999, J EXP PSYCHOL LEARN, V25, P418, DOI 10.1037/0278-7393.25.2.418; GREEN L, 1993, BEHAV PHILOS, V21, P37; Greve KW, 2001, BRAIN INJURY, V15, P255; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Johnson MW, 2002, J EXP ANAL BEHAV, V77, P129, DOI 10.1901/jeab.2002.77-129; Kirby KN, 1996, PSYCHON B REV, V3, P100, DOI 10.3758/BF03210748; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Mateer C. A., 1999, COGNITIVE NEUROREHAB, P314; MISCHEL W, 1989, SCIENCE, V244, P933, DOI 10.1126/science.2658056; Monterosso J, 2001, ADDICTION, V96, P1825, DOI 10.1046/j.1360-0443.2001.9612182512.x; MYERSON J, 1995, J EXP ANAL BEHAV, V64, P263, DOI 10.1901/jeab.1995.64-263; PATTERSON CM, 1993, PSYCHOL REV, V100, P716, DOI 10.1037/0033-295X.100.4.716; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; RACHLIN H, 1972, J EXP ANAL BEHAV, V17, P15, DOI 10.1901/jeab.1972.17-15; Richards JB, 1999, J EXP ANAL BEHAV, V71, P121, DOI 10.1901/jeab.1999.71-121; Weber EU, 2007, PSYCHOL SCI, V18, P516, DOI 10.1111/j.1467-9280.2007.01932.x; Wood RL, 2001, BRAIN DAM B, P3; Yarkoni T, 2005, J EXP ANAL BEHAV, V84, P537, DOI 10.1901/jeab.2005.121-04	29	40	41	0	14	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	9					715	721		10.1080/02699050802263027			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	336NS	WOS:000258371600009	18608202				2021-06-18	
J	Perez-Barcena, J; Llompart-Pou, JA; Homar, J; Abadal, JM; Raurich, JM; Frontera, G; Brell, M; Ibanez, J; Ibanez, J				Perez-Barcena, Jon; Llompart-Pou, Juan A.; Homar, Javier; Abadal, Josep M.; Raurich, Joan M.; Frontera, Guillem; Brell, Marta; Ibanez, Javier; Ibanez, Jordi			Pentobarbital versus thiopental in the treatment of refractory intracranial hypertension in patients with traumatic brain injury: a randomized controlled trial	CRITICAL CARE			English	Article							SEVERE HEAD-INJURY; LIPID-PEROXIDATION; INTENSIVE-CARE; PROTECTION; DRAINAGE	Introduction Experimental research has demonstrated that the level of neuroprotection conferred by the various barbiturates is not equal. Until now no controlled studies have been conducted to compare their effectiveness, even though the Brain Trauma Foundation Guidelines recommend that such studies be undertaken. The objectives of the present study were to assess the effectiveness of pentobarbital and thiopental in terms of controlling refractory intracranial hypertension in patients with severe traumatic brain injury, and to evaluate the adverse effects of treatment. Methods This was a prospective, randomized, cohort study comparing two treatments: pentobarbital and thiopental. Patients who had suffered a severe traumatic brain injury (Glasgow Coma Scale score after resuscitation <= 8 points or neurological deterioration during the first week after trauma) and with refractory intracranial hypertension (intracranial pressure > 20 mmHg) first-tier measures, in accordance with the Brain Trauma Foundation Guidelines. Results A total of 44 patients (22 in each group) were included over a 5-year period. There were no statistically significant differences in ' baseline characteristics, except for admission computed cranial tomography characteristics, using the Traumatic Coma Data Bank classification. Uncontrollable intracranial pressure occurred in 11 patients (50%) in the thiopental treatment group and in 18 patients (82%) in the pentobarbital group (P = 0.03). Under logistic regression analysis -undertaken in an effort to adjust for the cranial tomography characteristics, which were unfavourable for pentobarbital -thiopental was more effective than pentobarbital in terms of controlling intracranial pressure (odds ratio = 5.1, 95% confidence interval 1.2 to 21.9; P = 0.027). There were no significant differences between the two groups with respect to the incidence of arterial hypotension or infection. Conclusions Thiopental appeared to be more effective than pentobarbital in controlling intracranial hypertension refractory to first-tier measures. These findings should be interpreted with caution because of the imbalance in cranial tomography characteristics and the different dosages employed in the two arms of the study. The incidence of adverse effects was similar in both groups. Trial Registration (Trial registration: US Clinical Trials registry NCT00622570.)	[Perez-Barcena, Jon; Llompart-Pou, Juan A.; Homar, Javier; Abadal, Josep M.; Raurich, Joan M.; Ibanez, Jordi] Son Dureta Univ Hosp, Intens Care Med Dept, Palma de Mallorca 07014, Spain; [Perez-Barcena, Jon] Univ Autonoma Barcelona, Dept Surg, Bellaterra 08193, Spain; [Frontera, Guillem] Son Dureta Univ Hosp, Invest Unit, Palma de Mallorca 07014, Spain; [Brell, Marta; Ibanez, Javier] Son Dureta Univ Hosp, Dept Neurosurg, Palma de Mallorca 07014, Spain	Perez-Barcena, J (corresponding author), Son Dureta Univ Hosp, Intens Care Med Dept, Andrea Doria 55, Palma de Mallorca 07014, Spain.	jperez@hsd.es		Ibanez, Javier/0000-0003-3735-8332	Spanish government's Fondo de Investigacion SanitariaInstituto de Salud Carlos III [FIS PI020642]	This research was supported by a public grant from the Spanish government's Fondo de Investigacion Sanitaria (FIS PI020642), awarded to Dr J Perez Barcena. This public institution will not gain or lose financially from the publication of this manuscript in any way.	Abadal-Centellas JM, 2007, J TRAUMA, V62, P282, DOI 10.1097/01.ta.0000199422.01949.78; Almaas R, 2000, ANESTHESIOLOGY, V92, P764, DOI 10.1097/00000542-200003000-00020; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P537; Brain Trauma Foundation; American Association of Neurological Surgeons, 2007, J NEUROTRAUM, V24, pS71, DOI [10.1089/neu.2007.9985, DOI 10.1089/NEU.2007.9985]; Cole DJ, 2001, CAN J ANAESTH, V48, P807, DOI 10.1007/BF03016699; Drummond JC, 1996, ANESTHESIOLOGY, V85, P1504, DOI 10.1097/00000542-199612000-00050; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; HATANO Y, 1989, ANESTHESIOLOGY, V71, P80, DOI 10.1097/00000542-198907000-00015; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; Moreno R, 1999, INTENS CARE MED, V25, P686, DOI 10.1007/s001340050931; Munch EC, 2001, CRIT CARE MED, V29, P976; Perez-Barcena J, 2005, NEUROCIRUGIA, V16, P5; ROBERTS I, 2000, COCHRANE DB SYST REV, V2; ROESCH C, 1983, ANESTH ANALG, V62, P49; Servadei F, 2000, NEUROSURGERY, V46, P70; Shibuta S, 1998, BRIT J PHARMACOL, V124, P804, DOI 10.1038/sj.bjp.0701884; SMITH DS, 1980, ANESTHESIOLOGY, V53, P186, DOI 10.1097/00000542-198009000-00002; STEEN PA, 1980, ANESTHESIOLOGY, V53, P183; Stocchetti N, 2008, INTENS CARE MED, V34, P461, DOI 10.1007/s00134-007-0948-9; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587	23	40	40	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2008	12	4							R112	10.1186/cc6999			10	Critical Care Medicine	General & Internal Medicine	360UF	WOS:000260082700028	18759980	DOAJ Gold, Green Published			2021-06-18	
J	Struchen, MA; Pappadis, MR; Mazzei, DK; Clark, AN; Davis, LC; Sander, AM				Struchen, Margaret A.; Pappadis, Monique R.; Mazzei, Diana K.; Clark, Allison N.; Davis, Lynne C.; Sander, Angelle M.			Perceptions of communication abilities for persons with traumatic brain injury: Validity of the La Trobe Communication Questionnaire	BRAIN INJURY			English	Article						Traumatic brain injury; communication; assessment	HEAD-INJURY; SEQUELAE	Primary objective: To further evaluate the construct validity of the La Trobe Communication Questionnaire (LCQ) and to investigate the extent to which self-ratings of adults with traumatic brain injury compared to ratings made by close others and self-ratings made by non-injured matched controls. Research design: Prospective cohort study. Methods and procedures: Two hundred and seventy-six adults with TBI (121 of which are 1-year post-injury and previously enrolled in TBI Model Systems and 155 of which were consecutively admitted to a Level 1 trauma centre and were at least 6-months post-injury) completed the La Trobe Communication Questionnaire. In addition, for the TBI Model systems sample, 88 friends/family members and 80 non-injured matched controls participated. Main outcomes and results: Principle components analysis with varimax rotation yielded four factors: Initiation/Conversational Flow, Disinhibition/Impulsivity, Conversational Effectiveness and Partner Sensitivity, which were found to have adequate internal consistency. Adequate discriminative validity was obtained in comparing adults with TBI to non-injured matched controls, while no significant differences were found between self-ratings of communication abilities by adults with TBI and those made by close others. Conclusions: Additional support for the LCQ as a useful measure of perceived social communication abilities was obtained. Confirmatory factor analysis with a larger sample of adults with TBI will be a useful step in further development of this tool.	[Struchen, Margaret A.; Clark, Allison N.; Davis, Lynne C.; Sander, Angelle M.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Struchen, Margaret A.; Pappadis, Monique R.; Mazzei, Diana K.; Clark, Allison N.; Davis, Lynne C.; Sander, Angelle M.] Mem Hermann TIRR, Houston, TX USA; [Pappadis, Monique R.] Univ Houston, Houston, TX USA	Struchen, MA (corresponding author), Brain Injury Res Ctr, 2323 Shepherd,Suite 907, Houston, TX USA.	struchen@bcm.edu	Pappadis, Monique/Q-8639-2016	Pappadis, Monique/0000-0003-4742-4380	National Institute on Disability and Rehabilitation Research, US Department of EducationUS Department of Education [H133G010152, H133B031117]	This work was supported in part by grants from the National Institute on Disability and Rehabilitation Research, US Department of Education ( Grant #: H133G010152 and H133B031117). Appreciation is also extended to Laura Rosas, MA, and Patricia Terrell Smith, MA, for their assistance with data collection and to the Harris County Hospital District.	BERGLAND MM, 1991, REHABIL COUNS BULL, V35, P5; BOAKE C, 1991, COGNITIVE REHABILITA, P181; Bracy C. A., 2005, BRAIN IMPAIR, V6, P1, DOI [10.1375/brim.6.1.1.65476., DOI 10.1375/BRIM.6.1.1.65476, DOI 10.1375/brim.6.1.1.65476]; Brooks D N, 1979, Int Rehabil Med, V1, P160; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; Damico JS, 1985, COMMUNICATION SKILLS, P165; Douglas JM, 2007, APHASIOLOGY, V21, P1181, DOI 10.1080/02687030600980950; Douglas JM, 2007, J HEAD TRAUMA REHAB, V22, P31, DOI 10.1097/00001199-200701000-00004; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Grice P, 1975, SYNTAX SEMANTICS, VIII, P41; Hartley L. L., 1995, COGNITIVE COMMUNICAT; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; Kreutzer JS., 1999, NEUROBEHAVIORAL FUNC; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; MARSH NV, 1999, BRAIN DAM B, P175; McGann W, 1997, BRAIN INJURY, V11, P621, DOI 10.1080/026990597123179; MCNEILLBROWN D, 1997, INT PERSPECTIVES TRA, P247; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; SNOW P, 2000, BRAIN IMPAIR, V1, P57; Stein S. C., 1996, NEUROTRAUMA, P31; Struchen MA, 2003, J INT NEUROPSYCH SOC, V9, P255; Tabachnick BG, 2007, USING MULTIVARIATE S	30	40	40	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	12					940	951	PII 905461235	10.1080/02699050802425410			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	371RV	WOS:000260849900005	19005886				2021-06-18	
J	Stone, TW; Forrest, CM; Mackay, GM; Stoy, N; Darlington, LG				Stone, T. W.; Forrest, C. M.; Mackay, G. M.; Stoy, N.; Darlington, L. G.			Tryptophan, adenosine, neurodegeneration and neuroprotection	METABOLIC BRAIN DISEASE			English	Article; Proceedings Paper	4th International Hannover Conference on Hepatic Encephalopathy	JUN, 2006	Radebeul, GERMANY	Solvay Pharmaceut		glutamate; NMDA; ischaemia; neurodegeneration; neuroprotection	QUINOLINIC ACID ACCUMULATION; PERIPHERAL-BLOOD MONOCYTES/MACROPHAGES; EXPERIMENTAL HEPATIC-ENCEPHALOPATHY; CEREBRAL CORTICAL SLICES; TRAUMATIC BRAIN-INJURY; NEURONAL CELL-DEATH; KYNURENIC ACID; CEREBROSPINAL-FLUID; RAT HIPPOCAMPUS; SPINAL-CORD	This review summarises the potential contributions of two groups of compounds to cerebral dysfunction and damage in metabolic disease. The kynurenines are oxidised metabolites of tryptophan, the kynurenine pathway being the major route for tryptophan catabolism in most tissues. The pathway includes quinolinic acid - an agonist at N-methyl-D-aspartate (NMDA) receptors, kynurenic acid - an antagonist at glutamate and nicotinic receptors, and other redox active compounds that are able to generate free radicals under many physiological and pathological conditions. The pathway is activated in immune-competent cells, including glia in the central nervous system, and may contribute substantially to delayed neuronal damage following an infarct or metabolic insult. Adenosine is an ubiquitous purine that can protect neurons by suppressing excitatory neurotransmitter release, reducing calcium fluxes and inhibiting NMDA receptors. The extent of brain injury is critically dependent on the balance between the two opposing forces of kynurenines and purines.	Univ Glasgow, Inst Biomed & Life Sci, W Med Bldg, Glasgow G12 8QQ, Lanark, Scotland; Epsom Gen Hosp, Epsom KT18 7EG, Surrey, England	Stone, TW (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, W Med Bldg, Glasgow G12 8QQ, Lanark, Scotland.	t.w.stone@bio.gla.ac.uk	Stone, Trevor/M-7904-2015	Stone, Trevor/0000-0002-5532-0031			Albrecht J, 2005, METAB BRAIN DIS, V20, P253, DOI 10.1007/s11011-005-7904-6; ANDINE P, 1990, BRIT J PHARMACOL, V100, P814, DOI 10.1111/j.1476-5381.1990.tb14097.x; ARVIN B, 1989, BRIT J PHARMACOL, V98, P225, DOI 10.1111/j.1476-5381.1989.tb16886.x; Baratte S, 1998, MOL BRAIN RES, V59, P50, DOI 10.1016/S0169-328X(98)00136-3; BARTRUP JT, 1990, BRAIN RES, V530, P330, DOI 10.1016/0006-8993(90)91305-Z; BASILE AS, 1995, GASTROENTEROLOGY, V108, P818, DOI 10.1016/0016-5085(95)90456-5; Behan WMH, 1999, BRIT J PHARMACOL, V128, P1754, DOI 10.1038/sj.bjp.0702940; Behan WMH, 2002, BRIT J PHARMACOL, V135, P1435, DOI 10.1038/sj.bjp.0704613; Bell MJ, 1999, CRIT CARE MED, V27, P493, DOI 10.1097/00003246-199903000-00023; BERGQVIST PBF, 1995, J NEUROCHEM, V65, P2235; Bergqvist PBF, 1996, NEUROPSYCHOPHARMACOL, V15, P382, DOI 10.1016/0893-133X(95)00256-D; BIRCH PJ, 1988, EUR J PHARMACOL, V154, P85, DOI 10.1016/0014-2999(88)90367-6; BLIGHT AR, 1995, BRAIN, V118, P735, DOI 10.1093/brain/118.3.735; BLIGHT AR, 1993, BRAIN RES, V632, P314, DOI 10.1016/0006-8993(93)91167-Q; Blight AR, 1997, J NEUROTRAUM, V14, P89, DOI 10.1089/neu.1997.14.89; BUTCHER SP, 1990, STROKE, V21, P1727, DOI 10.1161/01.STR.21.12.1727; Cheng P, 1999, J POROUS MEDIA, V2, P19, DOI 10.1615/JPorMedia.v2.i1.20; CONNICK JH, 1989, NEUROSCI LETT, V101, P191, DOI 10.1016/0304-3940(89)90529-6; DAVAL JL, 1989, BRAIN RES, V491, P212, DOI 10.1016/0006-8993(89)90058-9; DEMENDONCA A, 1995, NEUROREPORT, V6, P1097, DOI 10.1097/00001756-199505300-00006; DYKENS JA, 1987, BIOCHEM PHARMACOL, V36, P211, DOI 10.1016/0006-2952(87)90691-5; DYKENS JA, 1989, BIOCHEM PHARMACOL, V38, P1555, DOI 10.1016/0006-2952(89)90301-8; EASTMAN CL, 1989, BRAIN RES, V495, P225, DOI 10.1016/0006-8993(89)90216-3; EASTMAN CL, 1990, NEUROCHEM RES, V15, P1101, DOI 10.1007/BF01101711; ESPEY MG, 1995, J LEUKOCYTE BIOL, V57, P199; Espey MG, 1997, NEUROREPORT, V8, P431, DOI 10.1097/00001756-199701200-00011; GALARRAGA E, 1990, BRAIN RES, V512, P269, DOI 10.1016/0006-8993(90)90636-P; Gao NF, 2002, MATER LETT, V55, P61, DOI 10.1016/S0167-577X(01)00620-6; GIULIAN D, 1993, P NATL ACAD SCI USA, V90, P2769, DOI 10.1073/pnas.90.7.2769; GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832; HAGBERG H, 1987, J NEUROCHEM, V49, P227, DOI 10.1111/j.1471-4159.1987.tb03419.x; HERON A, 1994, BRAIN RES, V641, P217, DOI 10.1016/0006-8993(94)90149-X; Heyes MP, 1996, BIOCHEM J, V320, P595, DOI 10.1042/bj3200595; HEYES MP, 1992, BRAIN, V115, P1249, DOI 10.1093/brain/115.5.1249; HEYES MP, 1990, J CEREBR BLOOD F MET, V10, P660, DOI 10.1038/jcbfm.1990.119; HEYES MP, 1989, BRAIN RES, V491, P173, DOI 10.1016/0006-8993(89)90101-7; HEYES MP, 1990, J NEUROCHEM, V55, P338, DOI 10.1111/j.1471-4159.1990.tb08857.x; HIRAKU Y, 1995, CARCINOGENESIS, V16, P349, DOI 10.1093/carcin/16.2.349; Holt DE, 2002, AM J VET RES, V63, P1167, DOI 10.2460/ajvr.2002.63.1167; Hosseinzadeh H, 1998, J NEURAL TRANSM, V105, P161, DOI 10.1007/s007020050045; Jalan R, 2003, INT J BIOCHEM CELL B, V35, P1175, DOI 10.1016/S1357-2725(02)00396-5; Jones PA, 1998, BRAIN RES, V800, P328, DOI 10.1016/S0006-8993(98)00540-X; Jones PA, 1998, NEUROSCIENCE, V85, P229, DOI 10.1016/S0306-4522(97)00613-1; Kerr SJ, 1995, J NEUROVIROL, V1, P375, DOI 10.3109/13550289509111027; Kerr SJ, 1998, AIDS, V12, P355, DOI 10.1097/00002030-199804000-00003; KHASPEKOV L, 1989, J NEUROSCI RES, V22, P150, DOI 10.1002/jnr.490220207; KIM JP, 1987, NEUROSCIENCE, V23, P423, DOI 10.1016/0306-4522(87)90066-2; Kitano T, 2004, NEUROCHEM INT, V44, P83, DOI 10.1016/S0197-0186(03)00124-4; Klejman A, 2005, NEUROCHEM INT, V47, P51, DOI 10.1016/j.neuint.2005.04.006; Kocki T, 2002, J NEUROSCI RES, V68, P622, DOI 10.1002/jnr.10243; Kosenko E, 2004, J NEUROCHEM, V89, P1101, DOI 10.1111/j.1471-4159.2004.02426.x; Kosenko E, 2003, NEUROCHEM INT, V43, P493, DOI 10.1016/S0197-0186(03)00039-1; Latini S, 1999, BRIT J PHARMACOL, V127, P729, DOI 10.1038/sj.bjp.0702591; LAU YS, 1993, J NEUROCHEM, V60, P768, DOI 10.1111/j.1471-4159.1993.tb03215.x; LEES GJ, 1993, J NEUROL SCI, V114, P119, DOI 10.1016/0022-510X(93)90285-7; MACGREGOR DG, 1993, BRIT J PHARMACOL, V110, P470, DOI 10.1111/j.1476-5381.1993.tb13834.x; MACGREGOR DG, 1993, BRIT J PHARMACOL, V109, P316, DOI 10.1111/j.1476-5381.1993.tb13572.x; MacGregor DG, 1996, BRAIN RES, V725, P115, DOI 10.1016/0006-8993(96)00342-3; Matsusue E, 2005, AM J NEURORADIOL, V26, P347; MICHAELIS ML, 1979, LIFE SCI, V24, P2083, DOI 10.1016/0024-3205(79)90082-1; Moffett JR, 1997, EXP NEUROL, V144, P287, DOI 10.1006/exnr.1996.6365; MOFFETT JR, 1994, CELL TISSUE RES, V278, P461; MOFFETT JR, 1993, BRAIN RES, V623, P337, DOI 10.1016/0006-8993(93)91450-7; Monopoli A, 1998, NEUROREPORT, V9, P3955, DOI 10.1097/00001756-199812010-00034; MORONI F, 1986, J NEUROCHEM, V47, P1667, DOI 10.1111/j.1471-4159.1986.tb13071.x; MORONI F, 1986, J NEUROCHEM, V46, P869, DOI 10.1111/j.1471-4159.1986.tb13052.x; Nakagami Y, 1996, JPN J PHARMACOL, V71, P183, DOI 10.1254/jjp.71.183; Nakai M, 1999, MOL BRAIN RES, V64, P59, DOI 10.1016/S0169-328X(98)00310-6; Nakao N, 1997, NEUROSCIENCE, V76, P749, DOI 10.1016/S0306-4522(96)00223-0; Namboodiri AMA, 1996, J NEUROVIROL, V2, P433, DOI 10.3109/13550289609146910; Nikbakht MR, 2001, EUR J PHARMACOL, V427, P13, DOI 10.1016/S0014-2999(01)01171-2; Norenberg W, 1997, BRIT J PHARMACOL, V122, P71, DOI 10.1038/sj.bjp.0701347; O'Kane EM, 1998, EUR J PHARMACOL, V362, P17, DOI 10.1016/S0014-2999(98)00730-4; Okuda S, 1998, J NEUROCHEM, V70, P299; Okuda S, 1996, P NATL ACAD SCI USA, V93, P12553, DOI 10.1073/pnas.93.22.12553; Ongini E, 1997, ANN NY ACAD SCI, V825, P30, DOI 10.1111/j.1749-6632.1997.tb48412.x; Ongini E, 2001, DRUG DEVELOP RES, V52, P379, DOI 10.1002/ddr.1137; PEARSON SJ, 1991, J CHROMATOGR-BIOMED, V565, P436, DOI 10.1016/0378-4347(91)80406-3; PEARSON SJ, 1992, NEUROSCI LETT, V144, P199, DOI 10.1016/0304-3940(92)90749-W; PEARSON SJ, 1995, J NEURAL TRANSM-GEN, V102, P67, DOI 10.1007/BF01276566; Pemberton LA, 1997, J INTERF CYTOK RES, V17, P589, DOI 10.1089/jir.1997.17.589; PERKINS MN, 1982, BRAIN RES, V247, P184, DOI 10.1016/0006-8993(82)91048-4; Phillis JW, 1995, BRAIN RES, V705, P79, DOI 10.1016/0006-8993(95)01153-6; Pierri M, 2005, NEUROPHARMACOLOGY, V48, P517, DOI 10.1016/j.neuropharm.2004.11.009; POPOVICH PG, 1994, BRAIN RES, V633, P348, DOI 10.1016/0006-8993(94)91560-1; Rao KVR, 2005, NEUROCHEM RES, V30, P1311, DOI 10.1007/s11064-005-8803-2; Rao KVR, 2005, NEUROCHEM INT, V47, P31, DOI 10.1016/j.neuint.2005.04.004; REGENOLD JT, 1990, N-S ARCH PHARMACOL, V341, P225; Reinhard JF, 1998, NEUROCHEM RES, V23, P661, DOI 10.1023/A:1022438822023; REYNOLDS GP, 1989, LANCET, V2, P979; RIOS C, 1991, NEUROCHEM RES, V16, P1139, DOI 10.1007/BF00966592; ROBINSON MB, 1992, PEDIATR RES, V32, P483, DOI 10.1203/00006450-199210000-00021; RUDOLPHI KA, 1992, CEREBROVAS BRAIN MET, V4, P346; SAITO K, 1992, NEUROSCIENCE, V51, P25, DOI 10.1016/0306-4522(92)90467-G; SAITO K, 1994, NEUROSCI LETT, V178, P211, DOI 10.1016/0304-3940(94)90761-7; Saran T, 2004, J NEUROSCI RES, V75, P436, DOI 10.1002/jnr.10862; Saran T, 1998, BRAIN RES, V787, P348, DOI 10.1016/S0006-8993(98)00031-6; SARDAR AM, 1995, J NEUROCHEM, V64, P932; SCHOLZ KP, 1992, NEURON, V8, P1139, DOI 10.1016/0896-6273(92)90134-Y; SCHWARCZ R, 1983, SCIENCE, V219, P316, DOI 10.1126/science.6849138; SCHWARCZ R, 1988, P NATL ACAD SCI USA, V85, P4079, DOI 10.1073/pnas.85.11.4079; Shahraki A, 2004, EUR J NEUROSCI, V20, P719, DOI 10.1111/j.1460-9568.2004.03502.x; SHEADOWN MJ, 1996, DRUG DEVELOP RES, V38, P108; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; Southgate GS, 1998, J CHEM NEUROANAT, V14, P151, DOI 10.1016/S0891-0618(98)00026-X; SPIGNOLI G, 1984, EUR J PHARMACOL, V97, P341, DOI 10.1016/0014-2999(84)90475-8; STONE TW, 1993, PHARMACOL REV, V45, P309; Stone TW, 2001, PROG NEUROBIOL, V64, P185, DOI 10.1016/S0301-0082(00)00032-0; STONE TW, 1981, EUR J PHARMACOL, V72, P411, DOI 10.1016/0014-2999(81)90587-2; Stone TW, 2002, NAT REV DRUG DISCOV, V1, P609, DOI 10.1038/nrd870; Stone TW, 2000, TRENDS PHARMACOL SCI, V21, P149, DOI 10.1016/S0165-6147(00)01451-6; Stone TW, 2000, EUR J MED CHEM, V35, P179, DOI 10.1016/S0223-5234(00)00121-5; Sung V, 1997, CELL TISSUE RES, V290, P633, DOI 10.1007/s004410050969; TOMINAGA K, 1992, NEUROSCIENCE, V30, P451; Von Lubitz DKJE, 1999, EUR J PHARMACOL, V369, P313, DOI 10.1016/S0014-2999(99)00073-4; VONLUBITZ DKEJ, 1989, NEUROSCIENCE, V30, P451, DOI 10.1016/0306-4522(89)90265-0; VonLubitz DKJE, 1995, EUR J PHARMACOL, V287, P295, DOI 10.1016/0014-2999(95)00498-X; WHETSELL WO, 1989, NEUROSCI LETT, V97, P271, DOI 10.1016/0304-3940(89)90609-5; WINN HR, 1979, CIRC RES, V45, P486, DOI 10.1161/01.RES.45.4.486; YAMAMOTO H, 1994, PEDIATR NEUROL, V10, P9, DOI 10.1016/0887-8994(94)90060-4	120	40	41	0	9	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0885-7490			METAB BRAIN DIS	Metab. Brain Dis.	DEC	2007	22	3-4					337	352		10.1007/s11011-007-9064-3			16	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	223OD	WOS:000250379500012	17712616				2021-06-18	
J	Wang, YF; Luo, WB; Reiser, G				Wang, Yingfei; Luo, Weibo; Reiser, Georg			Activation of protease-activated receptors in astrocytes evokes a novel neuroprotective pathway through release of chemokines of the growth-regulated oncogene/cytokine-induced neutrophil chemoattractant family	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						cytokine-induced neutrophil chemoattractant; growth-regulated oncogene; neuroprotection; rat astrocytes; signal transduction; thrombin	TRAUMATIC BRAIN-INJURY; APOPTOTIC CELL-DEATH; RAT ASTROCYTES; GLIAL-CELLS; THROMBIN; PROTEINASE; NEURONS; DISEASE; GDNF; NEURODEGENERATION	Activation of protease-activated receptors (PARs) is known to exert neuroprotection when low concentrations of the agonist protease thrombin are applied. However, the mechanism of protection is still unclear. Here, we showed that activation of multiple PARs, including PAR-1, PAR-2 and PAR-4, was able to elevate the release of the chemokine cytokine-induced neutrophil chemoattractant (CINC)-3 from rat astrocytes, in addition to evoking CINC-1 secretion. Different molecular mechanisms were identified as being involved in the secretion of CINC-1 and CINC-3, upon activation of different PARs. Importantly, we found that both CINC-1 and CINC-3 could signal to rat cortical neurons. Both chemokines acted via CXCR2 to prevent C-2-ceramide-induced cytochrome c release from mitochondria. Consequently CINC-1 and CINC-3 protected neurons from apoptosis. We further revealed that conditioned media obtained from PAR-activated astrocytes similarly protected cortical neurons against C-2-ceramide-induced cell death. The neuroprotection was considerably suppressed by a CXCR2 antagonist. CXCR2 is the cognate receptor for CINC. Therefore, our findings demonstrate that PAR-activated astrocytes are able to protect neurons against neurodegeneration and cell death via regulation of the secretion of chemokines CINC-1 and CINC-3. These data indicate a previously unknown mechanism for astrocyte-mediated neuroprotection achieved by PAR activation.	Univ Magdeburg, Fak Med, Inst Neurobiochem, D-39120 Magdeburg, Germany	Reiser, G (corresponding author), Univ Magdeburg, Fak Med, Inst Neurobiochem, Leipziger Str 44, D-39120 Magdeburg, Germany.	georg.reiser@med.ovgu.de		Luo, Weibo/0000-0002-1992-0320; wang, yingfei/0000-0002-8723-252X			Arai T, 2006, J NEUROPATH EXP NEUR, V65, P19, DOI 10.1097/01.jnen.0000196133.74087.cb; Brewer GJ, 1997, J NEUROSCI METH, V71, P143, DOI 10.1016/S0165-0270(96)00136-7; Campbell SJ, 2003, FASEB J, V17, P1168, DOI 10.1096/fj.02-0757fje; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Donovan FM, 1998, J BIOL CHEM, V273, P12746, DOI 10.1074/jbc.273.21.12746; ENGELE J, 1991, J NEUROSCI RES, V30, P359, DOI 10.1002/jnr.490300212; Ishida Y, 2006, J NEUROPATH EXP NEUR, V65, P66, DOI 10.1097/01.jnen.0000195941.48033.eb; Kalehua AN, 2004, EXP CELL RES, V297, P197, DOI 10.1016/j.yexcr.2004.02.031; Limatola C, 2000, P NATL ACAD SCI USA, V97, P6197, DOI 10.1073/pnas.090105997; Lozada A, 2005, NEUROPATH APPL NEURO, V31, P150, DOI 10.1111/j.1365-2990.2004.00622.x; Luo WB, 2006, J BIOL CHEM, V281, P7927, DOI 10.1074/jbc.M510784200; Magistretti PJ, 1999, NEWS PHYSIOL SCI, V14, P177, DOI 10.1152/physiologyonline.1999.14.5.177; Maragakis NJ, 2006, NAT CLIN PRACT NEURO, V2, P679, DOI 10.1038/ncpneuro0355; Nedergaard M, 2005, GLIA, V50, P281, DOI 10.1002/glia.20205; Nicole O, 2005, J NEUROSCI, V25, P4319, DOI 10.1523/JNEUROSCI.5200-04.2005; Nishina K, 2005, AM J RESP CELL MOL, V33, P505, DOI 10.1165/rcmb.2005-0113OC; Park KW, 2001, NEUROSCI RES, V40, P315, DOI 10.1016/S0168-0102(01)00242-5; Rohatgi T, 2004, NEUROSCIENTIST, V10, P501, DOI 10.1177/1073858404269955; Sawada K, 2000, J NEUROCHEM, V74, P1731, DOI 10.1046/j.1471-4159.2000.0741731.x; Shibata F, 2000, CYTOKINE, V12, P1368, DOI 10.1006/cyto.2000.0739; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Trendelenburg G, 2005, GLIA, V50, P307, DOI 10.1002/glia.20204; Walton KM, 1999, MOL NEUROBIOL, V19, P43, DOI 10.1007/BF02741377; Wang H, 2002, AM J PHYSIOL-CELL PH, V283, pC1351, DOI 10.1152/ajpcell.00001.2002; Wang H, 2002, GLIA, V37, P53, DOI 10.1002/glia.10012; Wang YF, 2007, J NEUROCHEM, V103, P814, DOI 10.1111/j.1471-4159.2007.04803.x; Wang YF, 2007, BIOCHEM J, V401, P65, DOI 10.1042/BJ20060732; Wang YF, 2006, J NEUROCHEM, V99, P759, DOI 10.1111/j.1471-4159.2006.04105.x; Wang YF, 2006, J NEUROCHEM, V98, P1046, DOI 10.1111/j.1471-4159.2006.03950.x; Watson K, 2005, MOL PHARMACOL, V67, P757, DOI 10.1124/mol.104.004812; Xi GH, 2003, J NEUROCHEM, V84, P3, DOI 10.1046/j.1471-4159.2003.01268.x; YAMASAKI Y, 1995, STROKE, V26, P318, DOI 10.1161/01.STR.26.2.318	33	40	45	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	DEC	2007	26	11					3159	3168		10.1111/j.1460-9568.2007.05938.x			10	Neurosciences	Neurosciences & Neurology	232NK	WOS:000251026200016	18005059				2021-06-18	
J	Kerby, JD; MacLennan, PA; Burton, JN; McGwin, G; Rue, LW				Kerby, Jeffrey D.; MacLennan, Paul A.; Burton, Jon N.; McGwin, Gerald, Jr.; Rue, Loring W., III			Agreement between prehospital and emergency department Glasgow Coma Scores	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	65th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 28-30, 2006	New Orleans, LA	Amer Assoc Surg Trauma		traumatic brain injury; Glasgow Coma Score; prehospital GCS assessment; emergency department GCS assessment	TRAUMA PATIENTS; SCALE; RELIABILITY; TRIAGE	Background:. The Glasgow Coma Scale (GCS) score is widely accepted as the cornerstone in the assessment of neurologic function after trauma and is being used to select patients for enrollment in prehospital (Ph) intervention trials. This study was performed to assess the degree of agreement between Ph-GCS and emergency department (ED)-GCS scores in our trauma system patients. Methods: From January 1, 2000, through November 30, 2003, 3,669 Emergency Medical System records were linked to our institution's trauma registry. Patients were classified according to their Ph-GCS and ED-GCS scores: 13 to 15, mild; 9 to 12, moderate; and 3 to 8, severe injury. Weighted kappa-coefficients and their 95% confidence intervals were used to examine the agreement between Ph-GCS and ED-GCS patient classifications. Results: Percent agreement was high for the mild category (97.9%) but diminished for moderate (9.3%) and severe (63.3%) groups. Overall, the kappa-coefficient was 0.53 (95% confidence interval 0.48-0.58), indicating moderate agreement. By GCS component, kappa-coefficients were similar, ranging from 0.52 for the verbal component to 0.48 for the eye and motor components. kappa-values decreased even further for those with longer (i.e. >= 20 minutes) transport times. Conclusion: In this study, differences between Ph-GCS and ED-GCS were seen in the patient population with moderate to severe head injury. Individual component score agreement was moderate for all categories, with agreement worsening for patients with longer transport times. Although this suggests improvement in the patient's condition during transport, inter-rater variability between Ph and ED personnel cannot be excluded. The utility of Ph-GCS in Ph interventional trials for determining the presence of significant head injury will need to be further evaluated.	Univ Alabama, Sch Med, Dept Surg, Div Gen Surg, Birmingham, AL USA; Univ Alabama, Ctr Injury Sci, Birmingham, AL USA; Univ Alabama, Sch Publ Hlth, Dept Epidemiol & Intl Hlth, Birmingham, AL USA	MacLennan, PA (corresponding author), Univ Alabama, 120 Kracke Bldg, 1922 7th Ave S, Birmingham, AL 35294 USA.	paul.maclennan@ccc.uab.edu		Kerby, Jeffrey/0000-0001-7368-1124			Arbabi S, 2004, J TRAUMA, V56, P1029, DOI 10.1097/01.TA.0000123036.20919.4B; Bazarian JJ, 2003, BRAIN INJURY, V17, P553, DOI 10.1080/0269905031000070260; BOUZARTH WF, 1978, J NEUROSURG, V49, P477; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; JENNETT B, 1977, LANCET, V1, P878; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MENEGAZZI JJ, 1993, J TRAUMA, V34, P46, DOI 10.1097/00005373-199301000-00008; MEREDITH W, 1995, J TRAUMA, V38, P129, DOI 10.1097/00005373-199501000-00030; Newgard CD, 2006, ACAD EMERG MED, V13, P69, DOI 10.1197/j.aem.2005.07.029; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; STOKES ME, 1995, CATEGORICAL DATA ANA, P99; TEASDALE G, 1974, LANCET, V2, P81; REGIONAL SYSTEM TRAU; RESUSCITATION OUTCOM	16	40	47	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2007	63	5					1026	1031		10.1097/TA.0b013e318157d9e8			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	232BX	WOS:000250994200013	17993947				2021-06-18	
J	Alyagari, V; Diringer, MN				Alyagari, Venkatesh; Diringer, Michael N.			Fever control and its impact on outcomes: What is the evidence?	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						fever; non-narcotic analgesics; cerebrovascular accident; traumatic brain injury; intensive care	INTENSIVE-CARE-UNIT; ACUTE ISCHEMIC-STROKE; ELEVATED BODY-TEMPERATURE; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; LENGTH-OF-STAY; CLINICAL-TRIAL; CARDIAC-ARREST; EARLY HYPERTHERMIA; FEBRILE CHILDREN	Fever is common in a variety of neurological disorders. There is abundant experimental evidence suggesting that fever leads to, or exacerbates, neuronal injury in conditions such as cerebral ischemia and traumatic brain injury. However, conclusive evidence linking control of fever to improved outcomes is lacking. It has been difficult to design studies looking at the impact of fever control on outcome, in part because traditional methods of fever control are ineffective. Recently, several new devices to control temperature have become available. These devices appear to be more effective than conventional means and might allow us to design studies that definitively answer the question: "Does controlling fever improve outcome?" (C) 2007 Elsevier B.V. All rights reserved.	Univ Illinois, Dept Neurol & Rehabil, NPI, Chicago, IL 60062 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Alyagari, V (corresponding author), Univ Illinois, Dept Neurol & Rehabil, NPI, 912 S Wood St,855 N,M-C 796, Chicago, IL 60062 USA.	aiyagari@uic.edu; diringerm@neuro.wusti.edu	Diringer, Michael N/C-1165-2008	Diringer, Michael N/0000-0003-2337-5537; Aiyagari, Venkatesh/0000-0001-8139-3819			Adams HP, 2003, STROKE, V34, P1056, DOI 10.1161/01.STR.0000064841.47697.22; Ahkee S, 1997, SOUTHERN MED J, V90, P296, DOI 10.1097/00007611-199703000-00006; Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; Baena RC, 1997, NEUROLOGY, V48, P768, DOI 10.1212/WNL.48.3.768; BEISEL WR, 1974, JAMA-J AM MED ASSOC, V228, P581, DOI 10.1001/jama.228.5.581; Bernard GR, 1997, NEW ENGL J MED, V336, P912, DOI 10.1056/NEJM199703273361303; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CHEN H, 1991, NEUROLOGY, V41, P1133, DOI 10.1212/WNL.41.7.1133; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Commichau C, 2003, NEUROLOGY, V60, P837, DOI 10.1212/01.WNL.0000047344.28843.EB; Cormio M, 2000, INTENS CARE MED, V26, P552, DOI 10.1007/s001340051203; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; Dippel DWJ, 2003, BMC CARDIOVASC DISOR, V3, DOI 10.1186/1471-2261-3-2; Dippel DWJ, 2001, STROKE, V32, P1607, DOI 10.1161/01.STR.32.7.1607; Diringer MN, 2004, CRIT CARE MED, V32, P1489, DOI 10.1097/01.CCM.0000129484.61912.84; Diringer MN, 2004, CRIT CARE MED, V32, P559, DOI 10.1097/01.CCM.0000108868.97433.3F; DORAN TF, 1989, J PEDIATR-US, V114, P1045, DOI 10.1016/S0022-3476(89)80461-5; FRIEDMAN PL, 1981, NEW ENGL J MED, V305, P1171, DOI 10.1056/NEJM198111123052002; Geffroy A, 2004, INTENS CARE MED, V30, P785, DOI 10.1007/s00134-004-2280-y; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; Gozzoli V, 2001, ARCH INTERN MED, V161, P121, DOI 10.1001/archinte.161.1.121; GRAHAM NMH, 1990, J INFECT DIS, V162, P1277, DOI 10.1093/infdis/162.6.1277; Hacke W, 2000, CEREBROVASC DIS, V10, P22, DOI 10.1159/000047578; Hickey RW, 2000, PEDIATRICS, V106, P118, DOI 10.1542/peds.106.1.118; Holzer M, 2002, NEW ENGL J MED, V346, P549; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Jiang QQ, 2000, INFECT IMMUN, V68, P1265, DOI 10.1128/IAI.68.3.1265-1270.2000; Kasner SE, 2002, STROKE, V33, P130, DOI 10.1161/hs0102.101477; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Kim Y, 1996, STROKE, V27, P2274, DOI 10.1161/01.STR.27.12.2274; KINMONTH AL, 1992, BRIT MED J, V305, P1134, DOI 10.1136/bmj.305.6862.1134; Koennecke HC, 2001, NEUROLOGY, V57, P2301, DOI 10.1212/WNL.57.12.2301; Kuikka A, 1998, EUR J CLIN MICROBIOL, V17, P701, DOI 10.1007/s100960050164; Kuikka A, 1997, EUR J CLIN MICROBIOL, V16, P125, DOI 10.1007/BF01709471; Mackowiak PA, 2000, ARCH INTERN MED, V160, P2680; MAHAR AF, 1994, CLIN PEDIATR, V33, P227, DOI 10.1177/000992289403300407; Mayer SA, 2001, NEUROLOGY, V56, P292, DOI 10.1212/WNL.56.3.292; Mayer SA, 2004, CRIT CARE MED, V32, P2508, DOI 10.1097/01.CCM.0000147441.39670.37; MEDEN P, 1994, BRAIN RES, V647, P131, DOI 10.1016/0006-8993(94)91407-9; MEMEZAWA H, 1995, BRAIN RES, V670, P48, DOI 10.1016/0006-8993(94)01251-C; Natale JE, 2000, CRIT CARE MED, V28, P2608, DOI 10.1097/00003246-200007000-00071; NEWMAN J, 1985, CAN MED ASSOC J, V132, P641; Plaisance KI, 2000, ARCH INTERN MED, V160, P449, DOI 10.1001/archinte.160.4.449; Polderman KH, 2004, CRIT CARE MED, V32, P2558, DOI 10.1097/01.CCM.0000148087.41418.0A; RAIZNER AE, 1980, CIRCULATION, V62, P925, DOI 10.1161/01.CIR.62.5.925; SAPER CB, 1994, NEW ENGL J MED, V330, P1880; Schmutzhard E, 2002, CRIT CARE MED, V30, P2481, DOI 10.1097/00003246-200211000-00013; SCHNAIDERMAN D, 1993, EUR J PEDIATR, V152, P747, DOI 10.1007/BF01953992; STANLEY ED, 1975, JAMA-J AM MED ASSOC, V231, P1248, DOI 10.1001/jama.231.12.1248; Stocchetti N, 2002, INTENS CARE MED, V28, P1555, DOI 10.1007/s00134-002-1513-1; Sulter G, 2004, CEREBROVASC DIS, V17, P118, DOI 10.1159/000075779; Takasu A, 2001, RESUSCITATION, V49, P273, DOI 10.1016/S0300-9572(00)00360-9; TAKINO M, 1991, INTENS CARE MED, V17, P419, DOI 10.1007/BF01720680; Todd MM, 2005, NEW ENGL J MED, V352, P135, DOI 10.1056/NEJMoa040975; UHARI M, 1995, J PEDIATR-US, V126, P991, DOI 10.1016/S0022-3476(95)70231-8; van Breda EJ, 2004, CEREBROVASC DIS, V18, P350, DOI 10.1159/000081813; van Stuijvenberg M, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.5.e51; ZAREMBA J, 2004, INT MED J EXPT CLIN, V10, pRA148; Zeiner A, 2001, ARCH INTERN MED, V161, P2007, DOI 10.1001/archinte.161.16.2007	61	40	41	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	OCT 15	2007	261	1-2					39	46		10.1016/j.jns.2007.04.030			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	216JO	WOS:000249874500005	17537459				2021-06-18	
J	Raghupathi, R; Huh, JW				Raghupathi, Ramesh; Huh, Jimmy W.			Diffuse brain injury in the immature rat: Evidence for an age-at-injury effect on cognitive function and histopathologic damage	JOURNAL OF NEUROTRAUMA			English	Article						children; closed head injury; cognition; infants; traumatic axonal injury; traumatic brain injury	TRAUMATIC AXONAL INJURY; CLOSED-HEAD INJURY; FLUID PERCUSSION; CORTICAL IMPACT; NERVOUS-SYSTEM; NEONATAL PIG; CHILDREN; MODEL; VULNERABILITY; MATURATION	Diffuse axonal injury is a significant component of the pathology of moderate-severe pediatric traumatic brain injury in children less than 4 years of age, and is associated with poor cognitive outcome. However, cognitive deficits or gross histopathologic abnormalities are typically not observed following moderate-severe diffuse brain injury in the immature (17-day-old) rat. In order to test whether the age of the immature animal may influence post-traumatic outcome, non-contusive brain trauma was induced in post-natal day (PND) 11 or 17 rats. Brain injury in the PND11 rat, but not in the. PND17 rat, was associated with a significant acquisition deficit at 28 days post-injury (p < 0.0005 compared with age-matched sham rats, and with brain-injured PND17 rats). All brain-injured animals exhibited a retention deficit in the probe trial (p < 0.001), but also demonstrated a significant visual deficit in the visible platform trial (p < 0.05 compared to sham animals). Although significantly longer times of apnea and loss of righting reflex were observed in brain-injured PND17 rats compared to PND11 rats (P < 0.05), overt cytoarchitectural alterations and reactive gliosis were not observed in the older age group. No focal pathology was observed in the cortex below the impact site in the PND11 rat but by 28 days, the brain-injured PND11 rat exhibited atrophy in multiple brain regions and an enlarged lateral ventricle in the impact hemisphere. Quantitative analysis revealed a time-dependent increase in tissue loss in the injured hemisphere (7-10%) in the younger animals, and a modest extent of tissue loss in the older animals (3-4%). Traumatic axonal injury was observed to similar extents in the white matter and thalamus below the impact site in both brain-injured PND11 and 17 rats. These data demonstrate that non-contusive (diffuse) brain injury of moderate severity in the immature rat is associated with chronic cognitive deficits and long-term histopathologic alterations and suggest that the age-at-injury is an important parameter of behavioral and pathologic outcome following closed head injury in the immature age group.	Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19129 USA	Raghupathi, R (corresponding author), Drexel Univ, Coll Med, Dept Neurobiol & Anat, 2900 Queen Lane, Philadelphia, PA 19129 USA.	rramesh@drexelmed.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS41561, K08-NS053651] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041561, K08NS053651] Funding Source: NIH RePORTER		Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Chiaretti A, 1998, Pediatr Med Chir, V20, P393; Ciurea AV, 2005, ACT NEUR S, V93, P209; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Duhaime AC, 1999, EXP TOXICOL PATHOL, V51, P172, DOI 10.1016/S0940-2993(99)80091-8; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Durham SR, 2000, PEDIATR NEUROSURG, V33, P76, DOI 10.1159/000028980; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; GOTSCHALL CS, 1995, J NEUROTRAUM, V12, P611, DOI 10.1089/neu.1995.12.611; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; Kolb B, 1999, CAN J EXP PSYCHOL, V53, P62, DOI 10.1037/h0087300; LANGLOIS JA, 1997, MMWR-MORBID MORTAL W, V52, P1; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Ommaya AK, 1967, 11 STAPP CAR CRASH C, P73; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; PORTERFIELD SP, 1994, ENVIRON HEALTH PERSP, V102, P125, DOI 10.2307/3431829; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.2307/3454543; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Verger K, 2000, BRAIN INJURY, V14, P495; Yager JY, 1997, NEUROSCI BIOBEHAV R, V21, P167, DOI 10.1016/S0149-7634(96)00006-1	40	40	41	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2007	24	10					1596	1608		10.1089/neu.2007.3790			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	227HZ	WOS:000250649100006	17970623				2021-06-18	
J	Verhaeghe, STL; van Zuuren, FJ; Defloor, T; Duijnstee, MSH; Grypdonck, MHF				Verhaeghe, Sofie T. L.; van Zuuren, Florence J.; Defloor, Tom; Duijnstee, Mia S. H.; Grypdonck, Mieke H. F.			The process and the meaning of hope for family members of traumatic coma patients in intensive care	QUALITATIVE HEALTH RESEARCH			English	Article						hope; traumatic coma; intensive care; experiences; family members	OF-THE-LITERATURE; CRITICALLY ILL PATIENTS; QUALITATIVE-ANALYSIS; PERCEIVED NEEDS; ADULT PATIENTS; BRAIN-INJURY; NURSES; PERCEPTIONS; EXPERIENCES; RELATIVES	In this study, the authors examined the process that family members go through when they are confronted with traumatic coma. They conducted 24 semistructured interviews with 22 family members of 16 coma patients and analyzed the data using the constant comparative method as proposed by grounded theory. Hope was the most prominent theme. It can be described as keeping a possible positive outcome in mind in an uncertain situation, knowing that this outcome is unlikely to happen. Hope was found to evolve stepwise up and down, dependent on further events and information: big steps at first, smaller later on. Hope helps family members to keep going and to manage care for the patient and for each other. Family members were found to protect themselves against false or unjustified hope by seeking valid information. They alternate their moments of despair, and in their interactions they respect each other's hope.	Univ Ghent, B-9000 Ghent, Belgium; Univ Amsterdam, NL-1012 WX Amsterdam, Netherlands; Univ Utrecht, Med Ctr, Utrecht, Netherlands	Verhaeghe, STL (corresponding author), Univ Ghent, B-9000 Ghent, Belgium.			Verhaeghe, Sofie/0000-0002-2063-5033; Beeckman, Dimitri/0000-0003-3080-8716			Bijttebier P, 2001, INTENS CARE MED, V27, P160, DOI 10.1007/s001340000750; Campbell C H, 1988, Rehabil Nurs, V13, P320; Centers LC, 2001, J PALLIATIVE CARE, V17, P259, DOI 10.1177/082585970101700407; CLAEYS M, 2002, NAH VLAANDEREN VANDA; Cutcliffe J, 1996, Br J Nurs, V5, P687; Cutcliffe John R, 2002, Br J Nurs, V11, P1190; DALEY L, 1984, HEART LUNG, V13, P231; DAVISMARTIN S, 1994, HEART LUNG, V23, P515; Eliott J, 2002, QUAL HEALTH RES, V12, P173, DOI 10.1177/104973230201200204; Engli M, 1993, J Neurosci Nurs, V25, P78; Engstrom Asa, 2004, Intensive Crit Care Nurs, V20, P299; FORRESTER DA, 1990, HEART LUNG, V19, P655; FREICHELS T A, 1991, Critical Care Nursing Quarterly, V14, P16; Gelling L, 1999, Nurs Stand, V14, P33; Gelling L., 1999, NURSING CRITICAL CAR, V4, P214; Glaser B. G., 1967, DISCOVERY GROUNDED T; HAMPE SO, 1975, NURS RES, V24, P113; JACONO J, 1990, HEART LUNG, V19, P72; Jamerson PA, 1996, HEART LUNG, V25, P467, DOI 10.1016/S0147-9563(96)80049-5; Johnson L H, 1996, J Trauma Nurs, V3, P72; Johnson L H, 1996, J Neurosci Nurs, V28, P259; Johnson S K, 1995, Image J Nurs Sch, V27, P238, DOI 10.1111/j.1547-5069.1995.tb00866.x; KARS MC, 2003, ZIJN WIJZE WAAROP OU; Kleiber C, 1994, Am J Crit Care, V3, P70; Kleinpell R M, 1992, Appl Nurs Res, V5, P2; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Kuyper MB, 1998, QUAL HEALTH RES, V8, P237, DOI 10.1177/104973239800800207; Kylma J, 1997, J ADV NURS, V25, P364, DOI 10.1046/j.1365-2648.1997.1997025364.x; Laskiwski S., 1993, CAN J REHABIL, V6, P143; LYNNMCHALE DJ, 1988, HEART LUNG, V17, P447; Mathis M, 1984, J Neurosurg Nurs, V16, P36; Mendonca D, 1998, Crit Care Nurs Q, V21, P58; Miller J F, 1991, AACN Clin Issues Crit Care Nurs, V2, P307; MILLER JD, 1989, REACTIONS COORDINATE, V2, P1; MOLTER NC, 1979, HEART LUNG, V8, P332; Morse J M, 1995, Image J Nurs Sch, V27, P277; Morse J. M., 1996, NURSING RES APPL QUA; MORSE JM, 1995, J ADV NURS, V21, P886, DOI 10.1046/j.1365-2648.1995.21050886.x; MURPHY PA, 1992, HEART LUNG, V21, P25; Neabel B, 2000, HEART LUNG, V29, P196, DOI 10.1067/mhl.2000.106938; NORRIS LO, 1986, HEART LUNG, V15, P194; OMALLEY P, 1991, HEART LUNG, V20, P189; Penrod J, 1997, Oncol Nurs Forum, V24, P1055; PRICE DM, 1991, HEART LUNG, V20, P183; ROSENSTEIN JM, 1995, CELL TRANSPLANT, V4, P83, DOI 10.1016/0963-6897(94)00041-H; STEPHENSON C, 1991, J ADV NURS, V16, P1456, DOI 10.1111/j.1365-2648.1991.tb01593.x; Van Dongen-Melman JEWM, 1998, PATIENT EDUC COUNS, V34, P185, DOI 10.1016/S0738-3991(98)00031-7; VANDALEN EA, 1998, KIND ADOLESCENT, V19, P250; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Verhaeghe S, 2005, J CLIN NURS, V14, P501, DOI 10.1111/j.1365-2702.2004.01081.x; VERHAEGHE S, IN PRESS J CLIN NURS; Warren N A, 1993, Crit Care Nurs Q, V16, P56; Warren N A, 1994, Crit Care Nurs Q, V17, P67; WERTZ FJ, 1987, ADV QUALITATIVE PSYC, P1; Wester F., 1987, STRATEGIEEN KWALITAT; YATES P, 1993, J ADV NURS, V18, P701, DOI 10.1046/j.1365-2648.1993.18050701.x	56	40	40	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1049-7323	1552-7557		QUAL HEALTH RES	Qual. Health Res.	JUL	2007	17	6					730	743		10.1177/1049732307303242			14	Information Science & Library Science; Social Sciences, Interdisciplinary; Social Sciences, Biomedical	Information Science & Library Science; Social Sciences - Other Topics; Biomedical Social Sciences	180EV	WOS:000247346000003	17582017				2021-06-18	
J	Jakola, AS; Muller, K; Larsen, M; Waterloo, K; Romner, B; Ingebrigtsen, T				Jakola, A. S.; Muller, K.; Larsen, M.; Waterloo, K.; Romner, B.; Ingebrigtsen, T.			Five-year outcome after mild head injury: a prospective controlled study	ACTA NEUROLOGICA SCANDINAVICA			English	Article						neuropsychology; neurosurgery; trauma	POST-CONCUSSION SYMPTOMS; TRAUMATIC BRAIN-INJURY; S-100 PROTEIN MEASUREMENTS; QUALITY-OF-LIFE; PREDICTION; COMPLAINTS; RECOVERY; HEALTH	Objectives - To study the prevalence of post-concussion symptoms (PCS) 5-7 years after mild head injury (MHI) and to investigate whether patients suffer from more symptoms than the normal population. Methods - We conducted a 5- to 7-year follow-up of patients (n = 89) with MHI. Post-concussion symptoms were quantified with the Rivermead Post Concussion Symptoms Questionnaire (RPQ) and health-related quality of life (HRQL) was measured with the EuroQol-5D (EQ-5D). We also quantified subjective general health state with the EuroQol Visual Analogue Scale (EQ-VAS). An age- and sex-matched, but otherwise randomly chosen control group of 89 persons was recruited from the National Population Registry for a cross-sectional comparison. Twerity-eight patients (30%) and 27 (30%) controls responded. Results - Patients reported significantly (P = 0.017) more PCS (median RPQ score 10, 95% CI 2-20) than controls (median 2, 95% CI 0-4). They also reported significantly (P = 0.008) lower HRQL (median EQ-5D score 0.866, 95% CI 0.796-1.000) than controls (1.000, 95% CI 1.000 - 1.000), but there was no difference between the groups in their subjective ratings of general health state. Conclusions - Patients reported significantly more PCS and lower HRQL 5 to 7 years after MHI than age- and sex-matched controls from the normal population.	Univ Tromso Hosp, Dept Neurosurg, N-9038 Tromso, Norway; Univ Tromso, Fac Med, Tromso, Norway; Univ Tromso, Fac Psychol, Tromso, Norway; Univ Tromso, Dept Neurol, Tromso, Norway	Muller, K (corresponding author), Univ Tromso Hosp, Dept Neurosurg, N-9038 Tromso, Norway.	kay.muller@unn.no	Jakola, Asgeir S/J-1738-2018	Jakola, Asgeir S/0000-0002-2860-9331; Ingebrigtsen, Tor/0000-0001-5966-9786			BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Hasvold Toralf, 1993, Scandinavian Journal of Primary Health Care, V11, P219, DOI 10.3109/02813439308994834; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; NORD E, 1991, HEALTH POLICY, V18, P25, DOI 10.1016/0168-8510(91)90141-J; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; WANG Y, 2006, ARCH CLIN NEUROPSYCH; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	28	40	40	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6314	1600-0404		ACTA NEUROL SCAND	Acta Neurol. Scand.	JUN	2007	115	6					398	402		10.1111/j.1600-0404.2007.00827.x			5	Clinical Neurology	Neurosciences & Neurology	174RK	WOS:000246960300005	17511848				2021-06-18	
J	Cardoso, EDS; Romero, MG; Chan, F; Dutta, A; Rahimi, M				da Silva Cardoso, Elizabeth; Romero, Maria G.; Chan, Fong; Dutta, Alo; Rahimi, Maryam			Disparities in vocational rehabilitation services and outcomes for Hispanic clients with traumatic brain injury: Do they exist?	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						employment; Hispanic; traumatic brain injury; vocational rehabilitation services	EMPLOYMENT; INDIVIDUALS; WORK; LIFE	Objective: Examine disparities in vocational rehabilitation (VR) services for Hispanic clients with traumatic brain injury. Design: Logistic regression analysis of secondary data. Participants: Five thousand eight hundred thirtyone European American and Hispanic clients. Main Outcome Measures: Type of services and employment status. Results: European Americans were 1.27 times more likely to obtain employment than were Hispanics. Hispanics with work disincentives had lower odds of returning to work and had more unmet basic needs (eg, food, shelter, and transportation) that need to be addressed in the rehabilitation process. job placement and on-the-job support services were found to significantly improve employment outcomes. However, on-the-job support services were more likely to be provided to European Americans than to Hispanics.	CUNY Hunter Coll, Dept Educ Fdn & Counseling, New York, NY 10021 USA; Univ Wisconsin, Dept Rehabil Psychol & Special Educ, Madison, WI 53706 USA; So Univ, Dept Rehabil & Disabil Studies, Baton Rouge, LA USA; Univ Maryland Eastern Shore, Dept Rehabil Studies, Princess Anne, MD 21853 USA	Cardoso, EDS (corresponding author), CUNY Hunter Coll, Dept Educ Fdn & Counseling, 695 Pk Ave,W1017, New York, NY 10021 USA.	ecardoso@huntencury.edu					ALSTON RJ, 1992, J APPL REHABILITATIO, V23, P12; Burnett DM, 2000, BRAIN INJURY, V14, P713; Capella ME, 2002, REHABIL COUNS BULL, V45, P143, DOI 10.1177/003435520204500303; Cardoso ED, 2006, REHABIL PSYCHOL, V51, P175, DOI 10.1037/0090-5550.51.2.175; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Fawber HL, 1987, J HEAD TRAUMA REHAB, V2, P27; Gamble D, 2003, J REHABIL, V69, P31; Gamble D., 2002, J APPL REHABILITATIO, V33, P41, DOI DOI 10.1891/0047-2220.33.3.41; Gamble D, 2003, J VOCATIONAL REHABIL, V19, P47; Hennessey JC, 1997, SOC SECUR BULL, V60, P3; Ingraham K., 1992, J APPL REHABILITATIO, V23, P18; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Johnstone B, 1999, J HEAD TRAUMA REHAB, V14, P220, DOI 10.1097/00001199-199906000-00003; Sherer M, 1999, BRAIN INJURY, V13, P973; *SPSS, 2005, SPSS STAT PACK SOC S; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Wilson KB, 2005, J COUNS DEV, V83, P86, DOI 10.1002/j.1556-6678.2005.tb00583.x	18	40	40	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2007	22	2					85	94					10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	152NU	WOS:000245369500003	17414310				2021-06-18	
J	Jacobs, ML; Donders, J				Jacobs, Monica L.; Donders, Jacobus			Criterion validity of the California Verbal Learning Test-Second Edition (CVLT-II) after traumatic brain injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						learning; memory; traumatic brain injury	PERFORMANCE; DIAGNOSIS; MEMORY; SCORES	The California Verbal Learning Test-Second Edition (CVLT-II) was performed by 200 participants, divided into moderate-severe traumatic brain injury (n = 43), mild traumatic brain injury (n = 57) and demographically matched control (n = 100) groups. Participants with complicating premorbid histories or who scored below 15/16 on the CVLT-II forced choice recognition trial were excluded. There were statistically significant (p <.0001) effects of group status on the CVLT-II total recall discrim inability and recognition discriminability indices. Logistic regression revealed that, in the classification of control versus moderate-severe traumatic brain injury, CVLT-II variables were accurate 66-71% overall, but false positive rates ranged from 49 to 54%. In conclusion, average scores on the CVLT-II differ meaningfully between patients with various degrees of severity of traumatic brain injury and controls, but this test should not be used in isolation to determine the presence or absence of acquired memory impairment. (c) 2006 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Mary Free Bed Rehabil Hosp, Psychol Serv, Grand Rapids, MI 49503 USA	Donders, J (corresponding author), Mary Free Bed Rehabil Hosp, Psychol Serv, 235 Wealthy,SE, Grand Rapids, MI 49503 USA.	jacobus.donders@maryfreebed.com					American Educational Research Association American Psychological Association & National Council on Measurement in Education, 1999, STAND ED PSYCH TEST; Anonymous, 2006, Morbidity and Mortality Weekly Report, V55, P201; Baldo JV, 2002, J INT NEUROPSYCH SOC, V8, P539, DOI 10.1017/S135561770281428X; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Binder LM, 1996, AM J PSYCHIAT, V153, P7; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; CROSSON B, 1993, NEUROPSYCHOLOGY, V7, P193, DOI DOI 10.1037/0894-4105.7.2.193; Curtiss G, 2001, J INT NEUROPSYCH SOC, V7, P574, DOI 10.1017/S1355617701755051; Delis DC, 2005, J INT NEUROPSYCH SOC, V11, P708, DOI 10.1017/S1355617705050812; DELIS DC, 2000, CVLT 2 COMPREHENSIVE; Delis DC, 2000, CALIFORNIA VERBAL LE; Delis DC, 1987, CALIFORNIA VERBAL LE; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; DONDERS J, IN PRESS J INT NEURO; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; Hanks RA, 2004, DIFFERENTIAL DIAGNOSIS IN ADULT NEUROPSYCHOLOGICAL ASSESSMENT, P218; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Larrabee G, 2005, FORENSIC NEUROPSYCHO, P209; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Rosenfeld B, 2000, ARCH CLIN NEUROPSYCH, V15, P349, DOI 10.1016/S0887-6177(99)00025-6; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925	27	40	41	0	8	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	FEB	2007	22	2					143	149		10.1016/j.acn.2006.12.002			7	Psychology, Clinical; Psychology	Psychology	154WT	WOS:000245539300002	17207963	Bronze			2021-06-18	
J	Lemke, DM				Lemke, Denise M.			Sympathetic storming - After severe traumatic brain injury	CRITICAL CARE NURSE			English	Article							AUTONOMIC DYSFUNCTION; DYSAUTONOMIA; MANAGEMENT		Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53033 USA	Lemke, DM (corresponding author), Med Coll Wisconsin, Dept Neurol, 9200 W Wisconsin Ave, Milwaukee, WI 53033 USA.	dlemke@mcw.edu					Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 2004, BRAIN INJURY, V18, P409, DOI 10.1080/02699050310001645775; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; Do D, 2000, J NEUROL NEUROSUR PS, V69, P832, DOI 10.1136/jnnp.69.6.832; FRANCOIS B, 2000, J TRAUMA INJ INFECT, V50, P158; King ML, 1997, BRAIN INJURY, V11, P445; KISHNER S, POST HEAD INJURY AUT; LEMKE DM, 2003, J NEUROSCI NURS, V36, P4; Macmillan CSA, 2002, INTENS CARE MED, V28, P1012, DOI 10.1007/s00134-002-1382-7; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Russo RN, 2000, J PAEDIATR CHILD H, V36, P283, DOI 10.1046/j.1440-1754.2000.00485.x; SAHR YL, 2002, PROG CARDIOVASC DIS, V45, P67; Scott JS, 1997, AM J PHYS MED REHAB, V76, P200, DOI 10.1097/00002060-199705000-00007; Stanford G G, 1994, Crit Care Nurs Clin North Am, V6, P693; Thorley RR, 2001, ARCH PHYS MED REHAB, V82, P246, DOI 10.1053/apmr.2001.18698	17	40	45	0	2	AMER ASSOC CRITICAL CARE NURSES	ALISO VIEJO	101 COLUMBIA, ALISO VIEJO, CA 92656 USA	0279-5442	1940-8250		CRIT CARE NURSE	Crit. Care Nurse	FEB	2007	27	1					30	37					8	Critical Care Medicine; Nursing	General & Internal Medicine; Nursing	135QF	WOS:000244167400005	17244857				2021-06-18	
J	Neese, SL; Sherill, LK; Tan, AA; Roosevelt, RW; Browning, RA; Smith, DC; Duke, A; Clough, RW				Neese, Steven L.; Sherill, Luke K.; Tan, Arlene A.; Roosevelt, Rodney W.; Browning, Ronald A.; Smith, Douglas C.; Duke, Andrea; Clough, Rich W.			Vagus nerve stimulation may protect GABAergic neurons following traumatic brain injury in rats: An immunocytochemical study	BRAIN RESEARCH			English	Article						GABA; fluid percussion injury; epilepsy; GAD; cerebral cortex; hippocampus; neuroprotection	FLUID PERCUSSION INJURY; LOCUS-COERULEUS LESIONS; POSTTRAUMATIC EPILEPSY; RECOVERY; SEIZURE; HIPPOCAMPUS; PENTYLENETETRAZOL; ELECTROSHOCK; FOS	Seizures and subclinical seizures occur following experimental brain injury in rats and may result from inhibitory neuron loss. This study numerically compares cortical and hippocampal glutamic acid decarboxylase (GAD) positive neurons between sham fluid percussion injury (FPI), FPI with sham Vagus Nerve Simulation (VNS), and FPI with chronic intermittent VNS initiated at 24 h post FPI in rats. Rats (n=8/group) were prepared for immunocytochemistry of GAD at 15 days post FPI. Serial sections were collected and GAD immunoreactive neurons were counted in the hippocampal hilus and two levels of the cerebral cortex. Numbers of quantifiable GAD cells in the rostral cerebral cortices were different between groups, both ipsilateral and contralateral to the FPI. Post hoc analysis of cell counts rostral to the ipsilateral epicenter, revealed a significant 26% reduction in the number of GAD cells/unit area of cerebral cortex following FPI. In the FPI-VNS group, this percentage loss was attenuated to only an 8.5% reduction, a value not significantly different from the sham group. In the contralateral side of the rostral cerebral cortex, FPI induced a significant 24% reduction in GAD cells/unit area; whereas, the VNS-treated rats showed no appreciable diminution of GAD cells rostral to the contralateral epicenter. Hippocampal analysis revealed a similar reduction of GAD cells in the FPI group; however, unlike the cortex this was not statistically significant. In the FPI-VNS group, a trend towards increased numbers of hilar GAD cells was observed, even over and above that of the sham FPI group; however, this was also not statistically significant. Together, these data suggest that VNS protects cortical GAD cells from death subsequent to FPI and may increase GAD cell counts in the hippocampal hilus of the injured brain. (c) 2006 Elsevier B.V. All rights reserved.	So Illinois Univ, Sch Med, Dept Anat, Carbondale, IL 62901 USA; So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA; So Illinois Univ, Dept Psychol, Brain & Cognit Sci Program, Carbondale, IL 62901 USA; So Illinois Univ, SIU Ctr Integrated Res Cognit & Neural Sci, Carbondale, IL 62901 USA	Clough, RW (corresponding author), So Illinois Univ, Sch Med, Dept Anat, Carbondale, IL 62901 USA.	rclough@siumed.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS041551, R01 NS041551-04, R01 NS041551] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041551] Funding Source: NIH RePORTER		Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; BENMENACHEM E, 1995, EPILEPSY RES, V20, P221, DOI 10.1016/0920-1211(94)00083-9; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BROWNING RA, 1987, NEUROTRANSMITTERS EP, P277; BUTERBAUGH GG, 1977, NEUROPHARMACOLOGY, V16, P617, DOI 10.1016/0028-3908(77)90032-6; CLOUGH RW, 1994, J NEURAL TRANSP PLAS, V5, P65, DOI 10.1155/NP.1994.65; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Eells JB, 1997, NEUROSCI LETT, V233, P21, DOI 10.1016/S0304-3940(97)00611-3; ELIAS H, 1980, AM J ANAT, V159, P411, DOI 10.1002/aja.1001590407; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Goldstein LB, 1997, RESTOR NEUROL NEUROS, V11, P55, DOI 10.3233/RNN-1997-111206; JOBE PC, 1986, J PHARMACOL EXP THER, V222, P662; KILIAN M, 1973, NEUROPHARMACOLOGY, V12, P681, DOI 10.1016/0028-3908(73)90121-4; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; Krahl SE, 1998, EPILEPSIA, V39, P709, DOI 10.1111/j.1528-1157.1998.tb01155.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Marrosu F, 2003, EPILEPSY RES, V55, P59, DOI 10.1016/S0920-1211(03)00107-4; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Maynert E W, 1975, Adv Neurol, V13, P79; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTYRE DC, 1980, EXP NEUROL, V69, P395, DOI 10.1016/0014-4886(80)90222-8; NARITOKU DK, 1995, EPILEPSY RES, V22, P53, DOI 10.1016/0920-1211(95)00035-9; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; ROOSEVELT RW, IN PRESS BRAIN RES; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Schachter SC, 2002, NEUROLOGY, V59, pS1, DOI 10.1212/WNL.59.6_suppl_4.S1; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DC, 2006, J NEUROTRAUM, V23, P1549, DOI 10.1089/neu.2006.23.1549; Soghomonian JJ, 1998, TRENDS PHARMACOL SCI, V19, P500, DOI 10.1016/S0165-6147(98)01270-X; Toth Z, 1997, J NEUROSCI, V17, P8106; Weinshenker D, 2002, PHARMACOL THERAPEUT, V94, P213, DOI 10.1016/S0163-7258(02)00218-8	36	40	48	1	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 12	2007	1128	1					157	163		10.1016/j.brainres.2006.09.073			7	Neurosciences	Neurosciences & Neurology	135CC	WOS:000244130400018	17125748	Green Accepted			2021-06-18	
J	Sundstrom, T; Sollid, S; Wentzel-Larsen, T; Wester, K				Sundstrom, Terje; Sollid, Snorre; Wentzel-Larsen, Tore; Wester, Knut			Head injury mortality in the Nordic countries	JOURNAL OF NEUROTRAUMA			English	Article						death; neurosurgery; Nordic countries; trauma; traumatic brain injury	TRAUMATIC BRAIN-INJURY; MANAGEMENT; EPIDEMIOLOGY; GUIDELINES; DEATH; ADULTS; DISABILITY; SEVERITY; PEOPLE; TRENDS	Traumatic brain injury (TBI) is a major cause of morbidity and mortality in Western countries. Effective management planning for these patients requires knowledge of TBI epidemiology. The purpose of this study was to describe and analyze the development of TBI mortality in the Nordic countries during the period 1987-2001. Data on TBI deaths were retrieved from the national official statistical agencies according to specified diagnostic codes. We also collected data on the number of operations for acute TBI in the year 2000 from all Nordic hospitals admitting trauma patients. Finland had about twice as high a TBI mortality rate as the other countries. Similarly, the Finnish incidence of acute TBI operations was nearly twice that of the other countries. The median TBI death rate for Finland was 21.2 per 100,000 per year, and for Denmark, Norway, and Sweden 11.5, 10.4, and 9.5, respectively. There were more male than female deaths in all countries. The mortality rate from extracranial injuries was relatively equal between the countries. We observed a sizeable reduction in TBI mortality rates for all countries, except in Finland. Younger age groups had the most pronounced decrease in TBI mortality rates. The oldest age group had the least favorable development of TBI mortality rates, and the mean age of TBI casualties increased substantially during the study period. This study demonstrates considerable differences in and between the Nordic countries regarding TBI mortality. Preventive measures and implementation of regional guidelines are needed to assure a positive development in the future.	Univ Bergen, Dept Surg Sci, N-5020 Bergen, Norway; Haukeland Hosp, Dept Neurosurg, N-5021 Bergen, Norway; Haukeland Hosp, Clin Res Ctr, N-5021 Bergen, Norway; Univ Hosp N Norway, Dept Neurosurg, Tromso, Norway	Wester, K (corresponding author), Univ Bergen, Dept Surg Sci, N-5020 Bergen, Norway.	kgwe@helse-bergen.no		Sundstrom, Terje/0000-0002-6503-7141			Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; AKEDOYA N, 2002, MMWR SURVEILL SUMM, V51, P1; American Association for the Surgery of Trauma, 2003, J Trauma, V54, pS235; Bullock RM, 2000, J NEUROTRAUM, V17, P449; CIPRIANI F, 2001, SUBSTANCE ABUSE, V22, P55; Engberg A, 1995, Acta Neurol Scand Suppl, V164, P1; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; *EUROSTAT, 2002, HLTH STAT ATL MOR EU; Gabriel Edward J., 2002, Journal of Neurotrauma, V19, P111; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Ingebrigtsen T, 1998, NEUROEPIDEMIOLOGY, V17, P139, DOI 10.1159/000026165; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Jansson B, 1997, J CLIN EPIDEMIOL, V50, P367, DOI 10.1016/S0895-4356(96)00426-X; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kannus P, 1999, AM J EPIDEMIOL, V149, P143; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Kleiven Svein, 2003, Inj Control Saf Promot, V10, P173, DOI 10.1076/icsp.10.3.173.14552; Kristiansen I S, 2000, Tidsskr Nor Laegeforen, V120, P2023; LUCHTER S, 1995, J NEUROTRAUM, V12, P517, DOI 10.1089/neu.1995.12.517; Lunetta P, 2001, ALCOHOL CLIN EXP RES, V25, P1654; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MACKENZIE EJ, 1988, J TRAUMA, V28, P281, DOI 10.1097/00005373-198803000-00003; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Melinder KA, 1998, SCAND J SOC MED, V26, P190, DOI 10.1177/14034948980260030901; Muller K, 2003, J TRAUMA, V55, P1029, DOI 10.1097/01.TA.0000100371.49160.2A; Munro PT, 2002, BRIT MED J, V325, P1001, DOI 10.1136/bmj.325.7371.1001; Murphy LS, 1999, BRIT J NEUROSURG, V13, P564, DOI 10.1080/02688699943060; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; *NOMESCO, 2003, HLTH STAT NORD COUNT; Paljarvi T, 2005, ADDICTION, V100, P1851, DOI 10.1111/j.1360-0443.2005.01258.x; Piek J, 1998, INTENS CARE MED, V24, P1221, DOI 10.1007/s001340050748; Rasanen P, 2002, J AFFECT DISORDERS, V71, P51, DOI 10.1016/S0165-0327(01)00411-6; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; *STAT NORW, 2003, STAT YB NORW 2003 AR; *STAT SWED, 2004, PERS KILL SEV SLIGHT; Sundstrom Terje, 2005, Tidsskr Nor Laegeforen, V125, P1310; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; THEELE DS, 2000, TIDDSKR NOR LAEGEFOR, V120, P2018; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; *WHO, 2006, PERC URB POP BOTH SE; *WHO, 2006, SDR HOM INT INJ ALL; *WHO, 2006, PUR ALC CONS LITR CA; *WHO, 2006, SDR SUIC SELF INFL I	49	40	41	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					147	153		10.1089/neu.2006.0099			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100014	17263678				2021-06-18	
J	Atkins, CM; Chen, SY; Alonso, OF; Dietrich, WD; Hu, BR				Atkins, Coleen M.; Chen, Shaoyi; Alonso, Ofelia F.; Dietrich, W. Dalton; Hu, Bing-Ren			Activation of calcium/calmodulin-dependent protein kinases after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						CaMKI; CaMKII; CaMKIV; CPEB; GluR1; traumatic brain injury	LONG-TERM POTENTIATION; POSTSYNAPTIC DENSITY PROTEIN; TRANSIENT CEREBRAL-ISCHEMIA; ELEMENT-BINDING PROTEIN; FLUID PERCUSSION INJURY; HIPPOCAMPAL CA1 REGION; SIGNAL-REGULATED KINASE; CLOSED-HEAD-INJURY; RAT HIPPOCAMPUS; SPATIAL MEMORY	A prominent cognitive impairment after traumatic brain injury (TBI) is hippocampal-dependent memory loss. Although the histopathologic changes in the brain are well documented after TBI, the underlying biochemical mechanisms that contribute to memory loss have yet to be thoroughly delineated. Thus, we determined if calcium/calmodulin-dependent protein kinases (CaMKs), known to be necessary for the formation of hippocampal-dependent memories, are regulated after TBI. Sprague-Dawley rats underwent moderate parasagittal fluid-percussion brain injury on the right side of the parietal cortex. The ipsilateral hippocampus and parietal cortex were Western blotted for phosphorylated, activated alpha-calcium/calmodulin-dependent protein kinase 11 (alpha-CaMKII), CaMKIV, and CaMKI. alpha-Calcium/calmodulin-dependent protein kinase 11 was activated in membrane subcellular fractions from the hippocampus and parietal cortex 30 mins after TBI. CaMKI and CaMKIV were activated in a more delayed manner, increasing in phosphorylation 1 h after TBI. The increase in activated alpha-CaMKII in membrane fractions was accompanied by a decrease in cytosolic total alpha-CaMKII, suggesting redistribution to the membrane. Using confocal microscopy, we observed that alpha-CaMKII was activated within hippocampal neurons of the dentate gyrus, CA3, and CA1 regions. Two downstream substrates of alpha-CaMKII, the AMPA-type glutamate receptor GluR1, and cytoplasmic polyadenylation element-binding protein, concomitantly increased in phosphorylation in the hippocampus and cortex 1 h after TBI. These results demonstrate that several of the biochemical cascades that subserve memory formation are activated unselectively in neurons after TBI. As memory formation requires activation of CaMKII signaling pathways at specific neuronal synapses, unselective activation of CaMKII signaling in all synapses may disrupt the machinery for memory formation, resulting in memory loss after TBI.	Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Neurotrauma Res Ctr, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA	Hu, BR (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol, POB 16960, Miami, FL 33136 USA.	bhu@med.miami.edu		Atkins, Coleen/0000-0003-4718-7493	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, R01NS042133] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291, NS42133] Funding Source: Medline		ARIZA M, 2005, IN PRESS NEUROPSYCHO; Atkins CM, 2005, J NEUROSCI, V25, P5604, DOI 10.1523/JNEUROSCI.5051-04.2005; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Atkins CM, 2004, J NEUROSCI, V24, P5193, DOI 10.1523/JNEUROSCI.0854-04.2004; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; Bayer KU, 2001, NATURE, V411, P801, DOI 10.1038/35081080; BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; Bevilaqua LR, 2005, NEUROSCIENCE, V136, P397, DOI 10.1016/j.neuroscience.2005.08.007; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Carbonell WS, 2003, J NEUROTRAUM, V20, P327, DOI 10.1089/089771503765172282; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; DASH PK, 1995, J NEUROSCI, V15, P2030; Derkach V, 1999, P NATL ACAD SCI USA, V96, P3269, DOI 10.1073/pnas.96.6.3269; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Elgersma Y, 2004, J NEUROSCI, V24, P8410, DOI 10.1523/JNEUROSCI.3622-04.2004; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; Fu XZ, 2004, NEUROSCI RES, V48, P85, DOI 10.1016/j.neures.2003.09.009; FUKUNAGA K, 1995, J BIOL CHEM, V270, P6119, DOI 10.1074/jbc.270.11.6119; Gao J, 2005, NEURON, V48, P635, DOI 10.1016/j.neuron.2005.10.011; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; GOLDENRING JR, 1984, J NEUROCHEM, V42, P1077, DOI 10.1111/j.1471-4159.1984.tb12713.x; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Hopkins RO, 2005, NEUROPSYCHOLOGY, V19, P233, DOI 10.1037/0894-4105.19.2.233; Hu BR, 1999, NEUROSCIENCE, V89, P437, DOI 10.1016/S0306-4522(98)00352-2; HU BR, 1995, J NEUROCHEM, V64, P1361; Hu BR, 2004, J CEREBR BLOOD F MET, V24, P934, DOI 10.1097/01.WCB.0000125888.56462.A1; HU BR, 1995, NEUROSCIENCE, V68, P1003, DOI 10.1016/0306-4522(95)00213-3; HU BR, 1995, J NEUROCHEM, V64, P277; Hu BR, 1998, J NEUROSCI, V18, P625; Kang HJ, 2001, CELL, V106, P771, DOI 10.1016/S0092-8674(01)00497-4; Kasahara J, 2001, J BIOL CHEM, V276, P24044, DOI 10.1074/jbc.M100247200; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Kurz JE, 2005, J NEUROTRAUM, V22, P476, DOI 10.1089/neu.2005.22.476; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lee HK, 2003, CELL, V112, P631, DOI 10.1016/S0092-8674(03)00122-3; Lee HK, 2000, NATURE, V405, P955; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; Liu CL, 2004, J CEREBR BLOOD F MET, V24, P1219, DOI 10.1097/01.WCB.0000136706.77918.21; Lotocki G, 2004, J NEUROSCI, V24, P11010, DOI 10.1523/JNEUROSCI.3823-04.2004; Lovell Mark R., 1994, P133; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; Mendez R, 2000, NATURE, V404, P302; Merrill MA, 2005, TRENDS PHARMACOL SCI, V26, P645, DOI 10.1016/j.tips.2005.10.003; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Mizuno K, 2005, J PHARMACOL SCI, V98, P191, DOI 10.1254/jphs.CRJ05005X; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Parker RS, 1996, J CLIN PSYCHOL, V52, P32, DOI 10.1002/(SICI)1097-4679(199601)52:1<32::AID-JCLP5>3.0.CO;2-Y; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Robison AJ, 2005, J BIOL CHEM, V280, P35329, DOI 10.1074/jbc.M502191200; Rodrigues SM, 2004, J NEUROSCI, V24, P3281, DOI 10.1523/JNEUROSCI.5303-03.2004; Sanders MJ, 1999, J NEUROTRAUM, V16, P915, DOI 10.1089/neu.1999.16.915; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Schmitt JM, 2005, J NEUROSCI, V25, P1281, DOI 10.1523/JNEUROSCI.4086-04.2005; Selcher JC, 2002, NEUROSCIENTIST, V8, P122, DOI 10.1177/107385840200800208; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Soderling TR, 2001, CHEM REV, V101, P2341, DOI 10.1021/cr0002386; Stratmann T, 1997, PROTEIN EXPRES PURIF, V11, P72, DOI 10.1006/prep.1997.0768; Takagi Y, 2003, NEUROSCI LETT, V341, P33, DOI 10.1016/S0304-3940(03)00153-8; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; Tang KX, 2004, J NEUROCHEM, V91, P429, DOI 10.1111/j.1471-4159.2004.02733.x; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Weeber EJ, 2000, J NEUROSCI, V20, P5906, DOI 10.1523/JNEUROSCI.20-16-05906.2000; Whyte J, 1996, J Int Neuropsychol Soc, V2, P274; Yan XB, 2004, NEUROSCI LETT, V355, P197, DOI 10.1016/j.neulet.2003.11.001; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	90	40	42	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	DEC	2006	26	12					1507	1518		10.1038/sj.jcbfm.9600301			12	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	111HJ	WOS:000242441700005	16570077	Bronze			2021-06-18	
J	Yadav, YR; Basoor, A; Jain, G; Nelson, A				Yadav, Yad R.; Basoor, Abhijeet; Jain, Gaurav; Nelson, Adam			Expanding traumatic intracerebral contusion/hematoma	NEUROLOGY INDIA			English	Article						delayed Intracerebral hematoma; head injury; secondary insult	PROGRESSIVE BRAIN INJURY; HEAD TRAUMA; INTRACRANIAL HEMATOMAS; HEMORRHAGE	Background and Alms: Delayed traumatic hematomas and expansion of already detected hematomas are not uncommon. Only few studies are available on risk factors of expanding hematomas. A prospective study was aimed to find out risk factors associated with such traumatic lesions. Materials and Methods: Present study is based on 262 cases of intracerebral hematomas / contusions out of which 43 (16.4%) hematomas expanded in size. computerized tomography (CT) scan was done in all the patients at the time of admission and within 24 hours of injury. Repeat CT scan was done within 24 hours, 4 days and 7 days. Midline shift if any, prothrombin time, activated partial thromboplastin time, bleeding time, clotting time and platelet counts, Glasgow coma scale at admission and discharge and Glasgow outcome score at 6 months follow up were recorded. Results: Twenty six percent, 11.3 and 0% patients developed expanding hematoma in Glasgow Coma scale (GCS) of 8 and below, 9-12 and 13-15 respectively. The chances of expanding hematomas were higher in patients with other associated hematomas (17.4%) as compared to isolated hematoma (4.8%) (Fisher's exact results P=0.216). All the cases of expanding hematoma had some degree of midline shift and considerably higher proportion had presence of coagulopathy. The results of logistic regression analysis showed GCS, midline shift and coagulopathy as significant predictors for the expanding hematoma. Thirty nine patients (90.7%) of the total expanding hematomas developed within 24 hours of injury. Conclusions: Enlargement of intracerebral hematomas is quite common and majority of them expand early after the injury. These lesions were common in patients with poor GCS, associated hematomas, associated coagulopathy and midline shift.	NSCB Med Coll, Neurosurg Unit, Jabalpur 482003, India	Yadav, YR (corresponding author), NSCB Med Coll, Neurosurg Unit, 105 Nehru Nagar, Jabalpur 482003, India.			Jain, Gaurav/0000-0001-7064-3763			Borthne Arne, 1992, Tidsskrift for den Norske Laegeforening, V112, P3425; Erol FS, 2004, PEDIATR NEUROSURG, V40, P238, DOI 10.1159/000082299; GOPINATH SP, 1995, J NEUROSURG, V83, P438, DOI 10.3171/jns.1995.83.3.0438; Halatsch ME, 1999, FUNCT NEUROL, V14, P155; HIRSH LF, 1979, NEUROSURGERY, V5, P653, DOI 10.1227/00006123-197912000-00001; KAUFMAN HH, 1980, NEUROSURGERY, V7, P445, DOI 10.1227/00006123-198011000-00003; KOJIMA N, 1991, Neurologia Medico-Chirurgica, V31, P165, DOI 10.2176/nmc.31.165; Lobato RD, 2005, NEUROCIRUGIA, V16, P217; MLAY SM, 1990, E AFR MED J, V67, P717; NINEHOJI T, 1984, ACTA NEUROCHIR WIEN, V71, P69; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Okada T, 1989, Nihon Ika Daigaku Zasshi, V56, P545; Park YS, 1997, NEUROL SURG TOKYO, V25, P1081; Sawauchi S, 2001, NEUROL SURG TOKYO, V29, P131; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Xia G D, 1989, Zhonghua Wai Ke Za Zhi, V27, P674; XIA GD, 1989, ZHONGHUA WAI KE ZA Z, V27, P702; Zhang G, 1995, Zhonghua Wai Ke Za Zhi, V33, P430; ZHANG G, 1998, FA YI XUE ZA ZHI, V14, P61; Zhang GH, 1998, ACTA MECH SINICA, V14, P1	22	40	52	0	3	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0028-3886	1998-4022		NEUROL INDIA	Neurol. India	DEC	2006	54	4					377	381		10.4103/0028-3886.28109			5	Neurosciences	Neurosciences & Neurology	110WW	WOS:000242413000016	17114846				2021-06-18	
J	Patrick, PD; Blackman, JA; Mabry, JL; Buck, ML; Gurka, MJ; Conaway, MR				Patrick, Peter D.; Blackman, James A.; Mabry, Jennifer L.; Buck, Marcia L.; Gurka, Matthew J.; Conaway, Mark R.			Dopamine agonist therapy in low-response children following traumatic brain injury	JOURNAL OF CHILD NEUROLOGY			English	Article; Proceedings Paper	59th Annual Meeting of the American-Academy-for-Cerebral-Palsy-and-Developmental-Medicine	SEP 14-17, 2005	Orlando, FL	Amer Acad Cerebral Palsy & Dev Med			VEGETATIVE STATE; CLINICAL-USE; AMANTADINE; COMA	The objective of this study was to determine whether a dopamine agonist could improve mental status among children in a low-response state following traumatic brain injury. In an 8-week, prospective, double-blind, randomized trial, 10 children and adolescents ages 8 to 21 years ((X) over bar = 16.7 years) with traumatic brain injury sustained at least 1 month previously and remaining in a low-response state (Rancho Los Amigos Scale level <= 3) received pramipexole or amantadine. Medication dosage was increased over 4 weeks, weaned over 2 weeks, and then discontinued. At baseline and weekly during the study, subjects were evaluated with the Coma Near Coma Scale, Western NeuroSensory Stimulation Profile, and Disability Rating Scale. Scores improved significantly from baseline to the medication phase on the Coma Near Coma Scale, Western NeuroSensory Stimulation Profile, and Disability Rating Scale (P < .005). The weekly rate of change was significantly better for all three measures on medication than off medication (P < .05). Rancho Los Amigos Scale levels improved significantly on medication as well (P < .05). There was no difference in efficacy between amantadine and pramipexole. No unexpected or significant side effects were observed with either drug.	Univ Virginia, Childrens Hosp, Kluge Childrens Rehabil Ctr & Res Inst, Dept Pediat, Charlottesville, VA 22901 USA; Univ Virginia, Dept Hlth Evaluat Sci, Charlottesville, VA USA	Blackman, JA (corresponding author), Univ Virginia, Childrens Hosp, Kluge Childrens Rehabil Ctr & Res Inst, Dept Pediat, 2270 Ivy Rd, Charlottesville, VA 22901 USA.	jab5u@virginia.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD039631] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5R24HD039631] Funding Source: Medline		Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; ANSELL BJ, 1989, ARCH PHYS MED REHAB, V70, P104; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Gerlach M, 2003, J NEURAL TRANSM, V110, P1119, DOI 10.1007/s00702-003-0027-5; Green LB, 2004, AM J PHYS MED REHAB, V83, P893, DOI 10.1097/01.PHM.0000143400.15346.C8; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; Hagen C., 1979, LEVELS COGNITIVE FUN; Hollander M, 1973, NONPARAMETRIC STAT M; Karli DC, 1999, BRAIN INJURY, V13, P63, DOI 10.1080/026990599121908; Kearns GL, 2003, NEW ENGL J MED, V349, P1157, DOI 10.1056/NEJMra035092; Kieburtz K, 1997, JAMA-J AM MED ASSOC, V278, P125; Lal S, 1988, Brain Inj, V2, P225, DOI 10.3109/02699058809150946; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; ODELL MW, 1996, MED REHABILITATION T, P103; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; Patrick PD, 2003, BRAIN INJURY, V17, P497, DOI 10.1080/0269905031000070279; PENNEY JB, 1996, NEUROPSYCHIATRY, P145; Povlishock J T, 2000, Clin Neurosurg, V46, P113; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SCHATZBERG AF, 2003, TXB PSYCHOPHARMACOLO; Schneider WN, 1999, BRAIN INJURY, V13, P863; Tang YP, 1997, EUR J NEUROSCI, V9, P1720, DOI 10.1111/j.1460-9568.1997.tb01529.x; VANWOERKOM TCAM, 1982, EUR NEUROL, V21, P227, DOI 10.1159/000115485; Waxham M, 1999, FUNDAMENTAL NEUROSCI, P235	28	40	43	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0883-0738	1708-8283		J CHILD NEUROL	J. Child Neurol.	OCT	2006	21	10					879	885		10.1177/08830738060210100901			7	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	122DU	WOS:000243206700009	17005105				2021-06-18	
J	Wijnen, VJM; Heutink, M; van Boxtel, GJM; Eilander, HJ; de Gelder, B				Wijnen, Viona J. M.; Heutink, Matagne; van Boxtel, Geert J. M.; Eilander, Henk J.; de Gelder, Beatrice			Autonomic reactivity to sensory stimulation is related to consciousness level after severe traumatic brain injury	CLINICAL NEUROPHYSIOLOGY			English	Article						severe traumatic brain injury; autonomic nervous system; consciousness; vegetative state; minimally conscious state; sensory stimulation	HEART-RATE-VARIABILITY; POWER SPECTRUM ANALYSIS; VEGETATIVE STATE; EVOKED-POTENTIALS; CINGULATE CORTEX; PROGNOSTIC VALUE; COMA; SCALE; CONNECTIVITY; DISABILITY	Objective: To examine changes in the activity of the autonomic nervous system (ANS) that are related to recovery to consciousness in the post-acute phase after severe traumatic brain injury (sTBI). Methods: Skin conductance and heart rate reactivity to sensory stimulation were recorded every 2 weeks for an average period of 3.5 months in 16 adolescent patients, during the assessment of their level of consciousness (LoC), and their cognitive and functional behaviour. Results: Both heart rate variability (HRV) and skin conductance level (SCL) in reaction to sensory stimulation changed with recovery to consciousness. Indices of HRV and SCL that represent sympathetic activity of the autonomic nervous system (ANS) increased with recovery, whereas indices that represent parasympathetic activity decreased. In addition, we observed an increase in sympathovagal balance of the ANS with recovery. Conclusions: Recovery to consciousness determined by clinical observation in sTBI in the post-acute phase is related to changes in SCL and HRV during sensory stimulation. ANS reactivity to environmental stimulation can therefore give objective supplementary information about the clinical state of sTBI patients, and can contribute to decision-making in the treatment policy of unresponsive patients. Significance: These findings demonstrate that autonomic reactivity can be informative concerning how a severely damaged nervous system reacts to environmental stimulation and how, in a recovering nervous system, this reactivity changes. (c) 2006 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	Tilburg Univ, Dept Psychol & Hlth, Cognit Neurosci Lab, NL-5000 LE Tilburg, Netherlands; Rehabil Ctr Leipk, Tilburg, Netherlands; Harvard Univ, Sch Med, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA	Wijnen, VJM (corresponding author), Warandelaan 2,POB 90153, NL-5000 LE Tilburg, Netherlands.	v.j.m.wijnen@gmail.com	Wijnen, Viona/G-1328-2016; Eilander, Henk/D-9643-2016	Wijnen, Viona/0000-0001-7797-1882; van Boxtel, Geert/0000-0002-9105-7963			Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; AKSELROD S, 1981, SCIENCE, V213, P220, DOI 10.1126/science.6166045; ALBENTOSA M, 1994, AQUACULTURE, V126, P315, DOI 10.1016/0044-8486(94)90048-5; Andrews K, 1996, BRAIN INJURY, V10, P797, DOI 10.1080/026990596123918; ANSELL BJ, 1989, W NEUROSENSORY STIMU, V24; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Baars BJ, 2003, TRENDS NEUROSCI, V26, P671, DOI 10.1016/j.tins.2003.09.015; Berntson GG, 1997, PSYCHOPHYSIOLOGY, V34, P623, DOI 10.1111/j.1469-8986.1997.tb02140.x; BERNTSON GG, 1991, PSYCHOL REV, V98, P459, DOI 10.1037/0033-295X.98.4.459; BERNTSON GG, 1995, PSYCHOPHYSIOLOGY, V32, P162, DOI 10.1111/j.1469-8986.1995.tb03308.x; Boly M, 2005, NEUROPSYCHOL REHABIL, V15, P283, DOI 10.1080/09602010443000371; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; Boucsein W., 1992, ELECTRODERMAL ACTIVI; *CDC INJ PREV, TRAUM BRAIN INJ FACT; Chiappa KH, 1998, ELECTROEN CLIN NEURO, V106, P149, DOI 10.1016/S0013-4694(97)00118-1; Critchley HD, 2003, BRAIN, V126, P2139, DOI 10.1093/brain/awg216; Critchley HD, 2002, NEURON, V33, P653, DOI 10.1016/S0896-6273(02)00588-3; deJong BM, 1997, CLIN NEUROL NEUROSUR, V99, P213, DOI 10.1016/S0303-8467(97)00024-3; Eilander HJ, 2005, BRAIN INJURY, V19, P425, DOI 10.1080/02699050400025299; EILANDER HJ, 2005, BRAIN INJURY, V20, P46; EILANDER HJ, UNPUB RELIABILITY VA; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Fischer C, 2004, NEUROLOGY, V63, P669, DOI 10.1212/01.WNL.0000134670.10384.E2; Fischer C, 2005, NEUROPSYCHOL REHABIL, V15, P372, DOI 10.1080/09602010443000434; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; Giacino J, 2005, J HEAD TRAUMA REHAB, V20, P30, DOI 10.1097/00001199-200501000-00005; Giacino JT, 1997, SEMIN NEUROL, V17, P105, DOI 10.1055/s-2008-1040919; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gueorguieva R, 2004, ARCH GEN PSYCHIAT, V61, P310, DOI 10.1001/archpsyc.61.3.310; Guerit J. M., 1993, Neurophysiologie Clinique, V23, P209, DOI 10.1016/S0987-7053(05)80231-X; Guerit JM, 1999, CLIN NEUROPHYSIOL, V110, P1260, DOI 10.1016/S1388-2457(99)00061-9; Hagen C., 1972, LEVELS COGNITIVE FUN; Hildebrandt H, 1998, EUR ARCH PSY CLIN N, V248, P46, DOI 10.1007/s004060050016; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT B, 1996, NEUROTRAUMA, P3; Kane NM, 2000, AUDIOL NEURO-OTOL, V5, P186, DOI 10.1159/000013879; Keselman HJ, 2001, BRIT J MATH STAT PSY, V54, P1, DOI 10.1348/000711001159357; King ML, 1997, BRAIN INJURY, V11, P445; Kotchoubey B, 2002, NEWS PHYSIOL SCI, V17, P38; Kotchoubey B, 2005, CLIN NEUROPHYSIOL, V116, P2441, DOI 10.1016/j.clinph.2005.03.028; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S, 2004, NEUROLOGY, V63, P916, DOI 10.1212/01.WNL.0000137421.30792.9B; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; LEHRER PM, 1989, PSYCHOPHYSIOLOGY, V26, P668, DOI 10.1111/j.1469-8986.1989.tb03169.x; Liu I, 2005, TEST-SPAIN, V14, P1, DOI 10.1007/BF02595397; LOWENSOHN RI, 1977, LANCET, V1, P626; Lyeth BG, 2001, HEAD TRAUMA, P115; Malliani A, 1998, CIRCULATION, V98, P2640; Matthews SC, 2004, NEUROIMAGE, V22, P1151, DOI 10.1016/j.neuroimage.2004.03.005; Menon DK, 1998, LANCET, V352, P200, DOI 10.1016/S0140-6736(05)77805-3; MULDER LJM, 1992, BIOL PSYCHOL, V34, P205, DOI 10.1016/0301-0511(92)90016-N; Neumann N, 2004, BRAIN RES PROTOC, V14, P25, DOI 10.1016/j.brainresprot.2004.09.001; Ohman A., 2000, HDB PSYCHOPHYSIOLOGY, P533; Owen AM, 2005, NEUROPSYCHOL REHABIL, V15, P290, DOI 10.1080/09602010443000579; Plum F, 1998, PHILOS T ROY SOC B, V353, P1929, DOI 10.1098/rstb.1998.0345; PLUM F, DIAGNOSIS STUPOR COM; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; Rosenzweig MR, 1996, BEHAV BRAIN RES, V78, P57, DOI 10.1016/0166-4328(95)00216-2; *ROYAL HOSP NEUR, 1996, INT WORK PART REP VE; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Schiff N, 1999, J COGNITIVE NEUROSCI, V11, P650, DOI 10.1162/089892999563715; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Su CF, 2005, CLIN NEUROPHYSIOL, V116, P1273, DOI 10.1016/j.clinph.2005.01.010; TEASDALE G, 1974, LANCET, V2, P81; TURKSTRA LS, 1995, BRAIN INJURY, V9, P61, DOI 10.3109/02699059509004573; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; WIJNEN VJM, 2005, BRAIN INJURY, V20, P107; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zeman A, 2001, BRAIN, V124, P1263, DOI 10.1093/brain/124.7.1263	75	40	40	0	9	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	AUG	2006	117	8					1794	1807	SICI d0.1016/j.clinph.2006.03.006	10.1016/j.clinph.2006.03.006			14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	075HY	WOS:000239876700018	16793340				2021-06-18	
J	Worthington, AD; Matthews, S; Melia, Y; Oddy, M				Worthington, Andrew D.; Matthews, Sarah; Melia, Yvonne; Oddy, Michael			Cost-benefits associated with social outcome from neurobehavioural rehabilitation	BRAIN INJURY			English	Article						rehabilitation; social outcome; cost-benefits	TRAUMATIC BRAIN-INJURY; SUPERVISION RATING-SCALE; CLOSED HEAD-INJURY; NEUROPSYCHOLOGICAL REHABILITATION; HEALTH; ADULTS; DISABILITY; PROGRAM; RETURN; WORK	Primary objective: To carry out a clinical and cost-outcome evaluation of a neurobehavioural post-acute rehabilitation programme in the UK. Research design: The study was a multi-centre prospective cohort study of adults with acquired brain injury admitted for residential rehabilitation. Comprehensive data were collected on type of residence, amount and type of care, functional independence, engagement in constructive occupation and participation in social roles. Procedures: Data were gathered on admission relating to individuals' levels of care and functioning, both pre-morbidly and at the time of admission (pre-rehabilitation). Additional information about functioning was collected upon discharge (post-rehabilitation). Follow-up data was collated in person, by telephone or by post after an average of 18 months by a researcher who was blind to the rehabilitation outcomes. The data were analysed in terms of clinical outcomes and support costs. Savings in costs of care or support were calculated on the basis of difference between pre-rehabilitation and follow-up support costs minus the costs of rehabilitation. Results: Significant gains were evident at discharge and follow-up in virtually all indices of social outcome. Improvements were recorded in type of accommodation, levels of care, functional ability, productive occupation and performance of social roles. Patients admitted within 1 year of injury made the most progress, but improvements were made regardless of time since injury. Patients continued to benefit from rehabilitation well beyond the period when most natural recovery would take place. Economic calculations suggested that the initial costs of rehabilitation are generally offset by savings in care costs within 2 years. Sensitivity analysis on estimated savings in care costs yielded projected lifetime savings of between,1.1-0.8 pound M for persons admitted for rehabilitation within 12 months of injury, 0.7- pound 0.5 pound M within 2 years of injury and, 0.5-0.36M pound for admissions after 2 years. Conclusions: Specialist rehabilitation for neurobehavioural disability produces comprehensive and sustainable improvements in the life of individuals with brain injury. The initial costs associated with neurobehavioural rehabilitation are offset by savings in costs of support in the medium and longer term.	Brain Injury Rehabil Trust, Birmingham, W Midlands, England; Disabil Trust, Burgess Hill, W Sussex, England	Worthington, AD (corresponding author), W Heath House,54 Ivy House Rd, Birmingham B38 8JW, W Midlands, England.	aworthington@birt.co.uk		Melia, Yvonne/0000-0003-4430-9379			Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; ASHLEY MJ, 1990, J INSURANCE MED, V22, P156; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BERG J, 2004, EUROPEAN J HLTH E S1, V6, pS84; Black N, 1996, BRIT MED J, V312, P1215; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Burke W H, 1988, Brain Inj, V2, P313, DOI 10.3109/02699058809150902; Cervelli L, 1997, ARCH PHYS MED REHAB, V78, pS36, DOI 10.1016/S0003-9993(97)90154-4; Chantler C, 2004, INT J TECHNOL ASSESS, V20, P87, DOI 10.1017/S0266462304000844; COPE D N, 1991, Brain Injury, V5, P127, DOI 10.3109/02699059109008084; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Drummond MF., 1997, METHODS EC EVALUATIO, V2nd; EAMES P, 1985, J NEUROL NEUROSUR PS, V48, P613, DOI 10.1136/jnnp.48.7.613; Eames P, 1996, BRAIN INJURY, V10, P631, DOI 10.1080/026990596124061; Gold M., 1996, Cost-Effectiveness in Health and Medicine.; Greiner KA, 2004, SOC SCI MED, V59, P2303, DOI 10.1016/j.socscimed.2004.03.023; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; Kinsella G, 1989, Int Disabil Stud, V11, P9; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Kreutzer JS, 2001, BRAIN INJURY, V15, P763, DOI 10.1080/02699050010025786; Lannoo E, 2004, BRAIN INJURY, V18, P203, DOI 10.1080/02699050310001596905; LERI JE, 1995, BRAIN INJURY, V9, P533, DOI 10.3109/02699059509008212; MALEC JF, 1993, BRAIN INJURY, V7, P383, DOI 10.3109/02699059309029682; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Masson F, 1997, J CLIN EPIDEMIOL, V50, P595, DOI 10.1016/S0895-4356(97)00012-7; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; McGregor K, 1997, SOC SCI MED, V45, P295, DOI 10.1016/S0277-9536(96)00345-0; MCKENNA M, 1992, IS REHABILITATION CO; McMillan TM, 2004, CLIN REHABIL, V18, P132, DOI 10.1191/0269215504cr712oa; Murray CJL, 2000, HEALTH ECON, V9, P235, DOI 10.1002/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-O; Murrey GJ, 2004, BRAIN INJURY, V18, P519, DOI 10.1080/02699050310001646125; *NIH, 1999, JAMA-J AM MED ASSOC, V8, P974; Normand C, 1998, J PUBLIC HEALTH MED, V20, P129, DOI 10.1093/oxfordjournals.pubmed.a024730; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; *OFF NAT STAT, 2005, SOC TRENDS OFF NATL, V35; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; POLLOCK C, 1993, CLIN REHABIL, V7, P63, DOI DOI 10.1177/026921559300700109; Polverejan E, 2003, HEALTH ECON, V12, P935, DOI 10.1002/hec.774; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; Reed K, 1999, ARCH CLIN NEUROPSYCH, V14, P795; ROBERTSON IH, 1994, NEUROPSYCHOLOGIA, V32, P1, DOI 10.1016/0028-3932(94)90064-7; *ROYAL COLL NURS, 2005, AG CHANG GUID NEW PA; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Seale GS, 2002, BRAIN INJURY, V16, P955, DOI 10.1080/02699050210155258; SMITH D, 2000, TECHNICAL PAPER SERI, V19; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Watts R, 1999, BRAIN INJURY, V13, P113, DOI 10.1080/026990599121773; WAX W, 1991, J NEUROSURG, V48, P673; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; Whyte J, 2002, ARCH PHYS MED REHAB, V83, P1320, DOI 10.1053/apmr.2002.34807; Wood RL, 1999, NEUROPSYCHOL REHABIL, V9, P505, DOI 10.1080/096020199389554; Wood RL, 2001, BRAIN DAM B, P133; Wood RL, 1999, BRAIN INJURY, V13, P69, DOI 10.1080/026990599121746; WORTHINGTON A, 2005, EFFECTIVENESS REHABI, P257; Worthington AD, 2006, CLIN REHABIL, V20, P79, DOI 10.1191/0269215506cr881oa	63	40	40	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2006	20	9					947	957		10.1080/02699050600888314			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	094ZN	WOS:000241278100007	17062426				2021-06-18	
J	Chung, CY; Chen, CL; Cheng, PT; See, LC; Tang, SFT; Wong, AMK				Chung, Chia-Ying; Chen, Chia-Ling; Cheng, Pao-Tsai; See, Lai-Chu; Tang, Simon Fuk-Tan; Wong, Alice May-Kuen			Critical score of Glasgow Coma Scale for pediatric traumatic brain injury	PEDIATRIC NEUROLOGY			English	Article							SEVERE HEAD-INJURY; DIFFUSE AXONAL INJURY; COMPUTED-TOMOGRAPHY; EARLY PREDICTION; OUTCOME PREDICTION; PRACTICAL SCALE; DATA-BANK; CHILDREN; CT; CHILDHOOD	The aim of this study is to determine the predictive critical value of the Glasgow Coma Scale for use as a determinant of outcome for children with traumatic brain injuries. A total of 309 children, aged 2-10 years, were enrolled in this study. Each subject underwent the following assessments: Glasgow Coma Scale; clinical data, brain computed tomography; and Glasgow Outcome Scale assessments. The receiver operating characteristic curve indicated that a critical point of the Glasgow Coma Scale set at 5 was most strongly correlated with outcome of pediatric traumatic brain injury. Subarachnoid hemorrhage with brain swelling and edema, subdural, intracerebral hemorrhage, and basal ganglion lesions were associated with severe injury and poor outcome (P < 0.05). However, cortical lesions did not affect injury severity and outcome. In injuries associated with traumatic brain injuries, only chest trauma had a tendency to be associated with poor outcome (P < 0.05). Of the factors analyzed, the score of the Glasgow Coma Scale was the most effective predictor for outcome in pediatric traumatic brain injury. Furthermore, the predictive critical score of the Glasgow Coma Scale should be set at 5 for pediatric traumatic brain injury. The computed tomographic findings also were important in determining injury severity and predicting outcome. (c) 2006 by Elsevier Inc. All rights reserved.	Chang Gung Mem Hosp, Dept Phys Med & Rehabil, Taoyuan, Taiwan	Chen, CL (corresponding author), Chang Gung Mem Hosp, Dept Phys Med & Rehabil, 5,Fuhsing St, Taoyuan, Taiwan.	clingchen@gmail.com	Wong, Alice M. K./ABI-1000-2020	Wong, Alice M. K./0000-0003-3586-1292; See, Lai-Chu/0000-0002-1379-8969			Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BRUCE DA, 1979, CHILD BRAIN, V5, P174; CALDER IM, 1984, J CLIN PATHOL, V37, P1095, DOI 10.1136/jcp.37.10.1095; Campbell CGN, 2004, CAN J NEUROL SCI, V31, P213, DOI 10.1017/S0317167100053853; CARDIA E, 1990, CHILD NERV SYST, V6, P23, DOI 10.1007/BF00262261; CHUGANI HT, 1986, SCIENCE, V231, P840, DOI 10.1126/science.3945811; Cusmano F, 1985, Acta Neurol (Napoli), V7, P14; DUBLIN AB, 1977, RADIOLOGY, V122, P365, DOI 10.1148/122.2.365; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Englander J, 2003, ARCH PHYS MED REHAB, V84, P214, DOI 10.1053/apmr.2003.50094; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENTRY LR, 1988, AM J NEURORADIOL, V9, P91; GIBSON RM, 1989, LANCET, V2, P369; GREWAL M, 1991, J PEDIATR SURG, V26, P1161, DOI 10.1016/0022-3468(91)90323-L; Hofer T, 1993, J Neurosci Nurs, V25, P218; JENNETT B, 1975, LANCET, V1, P480; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LEVI L, 1991, BRIT J NEUROSURG, V5, P617, DOI 10.3109/02688699109002885; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MURRAY RR, 1984, AM J NEURORADIOL, V5, P177; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; PASCUCCI RC, 1988, INTENS CARE MED, V14, P185, DOI 10.1007/BF00717985; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; RIVARA FP, 1984, DEV MED CHILD NEUROL, V26, P81; Roland EP, 1998, ANN NEUROL, V44, P161, DOI 10.1002/ana.410440205; Schisterman EF, 2005, EPIDEMIOLOGY, V16, P73, DOI 10.1097/01.ede.0000147512.81966.ba; TEASDALE G, 1974, LANCET, V2, P81; WAGSTYL J, 1987, J PEDIATR SURG, V22, P127, DOI 10.1016/S0022-3468(87)80427-X; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; Yaryura-Tobias JA, 2003, J CLIN PSYCHIAT, V64, P1495, DOI 10.4088/JCP.v64n1214; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300	45	40	41	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	MAY	2006	34	5					379	387		10.1016/j.pediatrneurol.2005.10.012			9	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	043XR	WOS:000237636700008	16647999				2021-06-18	
J	Gordon, KE; Dooley, JM; Wood, EP				Gordon, Kevin E.; Dooley, Joseph M.; Wood, Ellen P.			Descriptive epidemiology of concussion	PEDIATRIC NEUROLOGY			English	Article							BRAIN; INJURIES; SPORTS	To describe the epidemiology of reported concussion derived from a large, nationally representative health survey, the microdata flies of the Canadian National Population Health Survey (1996-1997) were analyzed. Respondents reported whether they had "any injuries that were serious enough to limit their normal activities" in the preceding 12 months and the nature of the most serious injury. A total of 99.8% of 81,804 eligible respondents, representing 28,606,100 Canadians, reported their injury experience within the preceding year, with 89 reporting a concussion. The annual prevalence of Canadians reporting a concussion as their most serious injury was 110 per 100,000 population (95% confidence interval: 80, 140). Those reporting concussion were more likely to be younger (P < 0.001) and male (P = 0.02). Males were significantly overrepresented in the 16-34 year-old group (P = 0.004). More than 54% of all concussions were sport-related (95% confidence interval: 39%, 67%), occurring at a place for recreation or sport, with sport having a role in > 85% of concussions in the 16-34 year-old group. This study presents annual prevalence estimates of reported concussion, derived from a sizeable, nationally representative population survey. (c) 2006 by Elsevier Inc. All rights reserved.	IWK Hlth Ctr, Dept Pediat, Halifax, NS B3K 6R8, Canada; Dalhousie Univ, Div Pediat Neurol, Dept Pediat, Halifax, NS B3H 3J5, Canada	Gordon, KE (corresponding author), IWK Hlth Ctr, Dept Pediat, 5850 Univ Ave, Halifax, NS B3K 6R8, Canada.	KEGOR@DAL.CA					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Body C, 1996, BRAIN INJURY, V10, P567, DOI 10.1080/026990596124133; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Grindel Scott H, 2003, Curr Sports Med Rep, V2, P18, DOI 10.1249/00149619-200302000-00005; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; *SPSS INC, 1998, SYSTAT; *STAT CAN, 1998, NAT POP HLTH SURV NP; *STAT CAN, 1998, NAT POP HLTH SURV 19; Tambay J L, 1995, Health Rep, V7, P29; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; Willer B, 2004, INJURY PREV, V10, P144, DOI 10.1136/ip.2003.005017	16	40	41	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	MAY	2006	34	5					376	378		10.1016/j.pediatrneurol.2005.09.007			3	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	043XR	WOS:000237636700007	16647998				2021-06-18	
J	Gordon, WA; Cantor, J; Ashman, T; Brown, M				Gordon, WA; Cantor, J; Ashman, T; Brown, M			Treatmeant of post-TBI executive dysfunction - Application of theory to clinical practice	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	Galveston Brain Injury Conference (GBIC)	APR, 2005	Galveston, TX	Moody Fdn		emotional regulation; executive functions; rehabilitation; theory; traumatic brain injury; problem solving	TRAUMATIC BRAIN-INJURY; COGNITIVE REHABILITATION; COMMUNITY INTEGRATION; GOAL MANAGEMENT; ATTENTION; INDIVIDUALS; PROGRAM; DEFICITS; OUTPATIENTS; IMPAIRMENT	The authors propose a theory-based model for the treatment of post-traumatic brain injury executive dysfunction that integrates (1) theories of cerebral function and organization, (2) cognitive-behavioral theory of problem solving, and (3) learning theory. The model delineates appropriate targets of and methods for the treatment of executive dysfunction. A practical application of the theoretical model is described in the form of a comprehensive day treatment program, Executive Plus. A test of the model is also discussed, focused on the comparison of Executive Plus and a standard day treatment program along parameters dictated by the model.	Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Community & Prevent Med, New York, NY USA	Gordon, WA (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA.		Ashman, Teresa/B-1621-2013				Beck A., 1979, COGNITIVE THERAPY EM; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; BENYISHAY Y, 1970, J ABNORM PSYCHOL, V75, P248, DOI 10.1037/h0029368; BENYISHAY Y, 1971, J ABNORM PSYCHOL, V78, P17, DOI 10.1037/h0031481; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone KD, 1992, NEUROREHABILITATION, V2, P12, DOI DOI 10.3233/NRE-1992-2304; Conners C., 2000, CONNERS CONTINUOUS P; D'Zurilla T. J., 1988, HDB COGNITIVE BEHAV; DZURILLA TJ, 1971, J ABNORM PSYCHOL, V78, P107, DOI 10.1037/h0031360; FOXX RM, 1989, BEHAV THER, V20, P61, DOI 10.1016/S0005-7894(89)80118-2; Gagne RM., 1965, CONDITIONS LEARNING, V1st; GOLDBERG E, 1986, HDB CLIN MEMORY ASSE; Goldman-Rakic P. S., 1993, J HEAD TRAUMA REHAB, V8, P13; Gordon WA, 1987, NEUROPSYCHOL REHABIL, P111; GORDON WA, 1992, NEUROPSYCHOLOGY, V6, P361; GORDON WA, 1991, NEUROBEHAVIOURAL SEQ, P175; Gray J. M., 1992, NEUROPSYCHOL REHABIL, V2, P97; Hart T, 1993, J HEAD TRAUMA REHAB, V8, P1; HEPPNER PP, 1982, J COUNS PSYCHOL, V29, P66, DOI 10.1037/0022-0167.29.1.66; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; Klonoff PS, 2000, ARCH PHYS MED REHAB, V81, P1535, DOI 10.1053/apmr.2000.9177; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Loeb P. A., 1996, INDEPENDENT LIVING S; Luria A. R., 1966, HIGHER CORTICAL FUNC; Luria A. R., 1963, RESTORATION FUNCTION; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; Mateer C A, 1999, Semin Clin Neuropsychiatry, V4, P50; MATEER CA, 1992, REHABILITATION POSTC, P143; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; MEICHENBAUM D, 1974, PSYCHOTHER-THEOR RES, V11, P103, DOI 10.1037/h0086326; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Palmese CA, 2000, BRAIN INJURY, V14, P535; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Rath JF, 2003, REHABIL PSYCHOL, V48, P137, DOI 10.1037/0090-5550.48.3.137; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Rieger M, 2002, NEUROPSYCHOLOGIA, V40, P76, DOI 10.1016/S0028-3932(01)00068-9; SCHERZER BP, 1986, ARCH PHYS MED REHAB, V67, P366; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1981, BRIT MED BULL, V37, P187, DOI 10.1093/oxfordjournals.bmb.a071699; Simon D, 2001, REHABIL PSYCHOL, V46, P330; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; Sohlberg MM, 2001, ATTENTION PROCESS TR; SOHLBERG MM, 1993, J HEAD TRAUMA REHAB, V8, P45, DOI DOI 10.1097/00001199-199303000-00006; Sturm W, 1997, NEUROPSYCHOL REHABIL, V7, P81, DOI 10.1080/713755526; Stuss D. T., 1987, J NEUROLOGICAL REHAB, V1, P19, DOI DOI 10.1177/136140968700100105; Stuss D.T., 1986, FRONTAL LOBES; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Whyte J, 2003, AM J PHYS MED REHAB, V82, P639, DOI 10.1097/01.PHM.0000078200.61840.2D; WHYTE J, 1986, J HEAD TRAUMA REHAB, V1, P64; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002; YLVISAKER M, 2004, 4 ANN GALV TBI C GAL	62	40	41	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2006	21	2					156	167		10.1097/00001199-200603000-00008			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	031PK	WOS:000236716300007	16569989				2021-06-18	
J	van Donkelaar, P; Langan, J; Rodriguez, E; Drew, A; Halterman, C; Osternig, LR; Chou, LS				van Donkelaar, P; Langan, J; Rodriguez, E; Drew, A; Halterman, C; Osternig, LR; Chou, LS			Attentional deficits in concussion	BRAIN INJURY			English	Article						concussion; attention; ANT; reaction time	TRAUMATIC BRAIN-INJURY; POSITRON-EMISSION-TOMOGRAPHY; CLOSED-HEAD INJURY; SPATIAL ATTENTION; RIGHT-HEMISPHERE; REACTION-TIME; PARIETAL; CONFLICT; CORTEX; SYMPTOMS	Primary objective: The purpose of the present study was to examine deficits in the alerting, orienting and executive components of attention in individuals who have recently suffered a concussion. Research design: A group design was used in which the performance by individuals with concussion was compared to control subjects matched for age, height, weight and activity level. Methods and procedures: Participants completed the Attentional Network Test ( ANT) that breaks down attention into alerting, orienting and executive components. Reaction time and response accuracy were the dependent variables. Main outcomes and results: It was found that only the orienting and executive components of attention were affected by concussion, whereas the alerting component was normal. Furthermore, participants with concussion required a significantly longer time than controls to initiate correct responses. Conclusions: These results suggest that the orienting and executive components of attention are most susceptible to the effects of concussion.	Univ Oregon, Inst Neurosci, Dept Human Physiol, Eugene, OR 97403 USA	van Donkelaar, P (corresponding author), Univ Oregon, Inst Neurosci, Dept Human Physiol, 122C Esslinger Hall, Eugene, OR 97403 USA.	paulvd@darkwing.uoregon.edu	Rodriguez-Torres, Erika Elizabeth/A-3843-2019	Rodriguez-Torres, Erika Elizabeth/0000-0002-7738-1863; Langan, Jeanne/0000-0003-1417-2180	NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [CDC-R49CCR 021735-01] Funding Source: Medline		Casey BJ, 2000, P NATL ACAD SCI USA, V97, P8728, DOI 10.1073/pnas.97.15.8728; Chan RCK, 2003, BRAIN INJURY, V17, P131, DOI 10.1080/0269905021000010168; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Daffner KR, 2000, BRAIN, V123, P927, DOI 10.1093/brain/123.5.927; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Fan J, 2003, NEUROIMAGE, V18, P42, DOI 10.1006/nimg.2002.1319; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Giza CC, 2001, J ATHL TRAINING, V36, P228; HEILMAN KM, 1980, NEUROLOGY, V30, P327, DOI 10.1212/WNL.30.3.327; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kim YH, 1999, NEUROIMAGE, V9, P269, DOI 10.1006/nimg.1999.0408; LANGAN J, 2003, SOC NEUR ABSTR, P363; Lorberboym M, 2002, AM J EMERG MED, V20, P310, DOI 10.1053/ajem.2002.34201; Mesulam MM, 1999, PHILOS T R SOC B, V354, P1325, DOI 10.1098/rstb.1999.0482; Nobre AC, 2004, J COGNITIVE NEUROSCI, V16, P363, DOI 10.1162/089892904322926700; Nobre AC, 1997, BRAIN, V120, P515, DOI 10.1093/brain/120.3.515; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; POSNER MI, 1984, J NEUROSCI, V4, P1863; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; POSNER MI, 1987, NEUROPSYCHOLOGIA, V25, P135, DOI 10.1016/0028-3932(87)90049-2; Ruff RM, 1999, BRAIN INJURY, V13, P943; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Sturm W, 1999, NEUROPSYCHOLOGIA, V37, P797, DOI 10.1016/S0028-3932(98)00141-9; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; STUSS DT, 1989, CAN J NEUROL SCI, V16, P161, DOI 10.1017/S0317167100028833; Vandenberghe R, 2001, NEUROIMAGE, V14, P661, DOI 10.1006/nimg.2001.0860; Weissman DH, 2003, NEUROIMAGE, V19, P1361, DOI 10.1016/S1053-8119(03)00167-8; Yantis S, 2002, NAT NEUROSCI, V5, P995, DOI 10.1038/nn921	32	40	40	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2005	19	12					1031	1039		10.1080/02699050500110363			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	983ZA	WOS:000233269700010	16263646				2021-06-18	
J	Arriaza, R; Leyes, M				Arriaza, R; Leyes, M			Injury profile in competitive karate: prospective analysis of three consecutive World Karate Championships	KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY			English	Article						karate; martial arts; injuries; trauma; prevention	SHOTOKAN KARATE; MARTIAL ARTS; CHILDREN; RATES	The goal of this paper was to document the injury rate in modern competitive karate. A prospective recording of the injuries resulting from 2,837 matches in three consecutive World Karate Championships (WKC) was performed. Eight hundred and ninety-one injuries were recorded, with an incidence of 0.31 injuries per match or 157.03 injuries per 1,000 athlete exposures. Occurrence of injuries was higher among lighter categories, under 60 kg in males (0.56) and under 53 kg in females (0.42). Punches (737, 82.7%) caused more injuries than kicks (75, 7.3%). The injuries were most commonly located in the face (646, 72.5%) followed by the head (103, 11.6%) and lower limbs (57, 6.4%). The injuries consisted primarily of contusions (448, 50.3%) epistaxis (144, 16.2%) and lacerations (122, 13.7%) followed by concussions (34, 3.8%) and sprains (31, 3.5%). There was some kind of external haemorrhage in 296 injuries (33.7%). The injury rate was similar in the three WKC but the number of severe injuries declined from 1996 to 2000. We conclude that competitive karate is associated with a relatively high injury rate; in one in every three matches medical attention is required, but mainly for minor injuries. Severe injuries are rare.	Clin CEMTRO, Dept Orthopaed Surg, Madrid 20035, Spain; USP Hosp Santa Teresa, Dept Orthopaed Surg, World Karate Fdn Med Comm, La Coruna 15008, Spain	Leyes, M (corresponding author), Clin CEMTRO, Dept Orthopaed Surg, Avda Ventisquero de la Condesa 42, Madrid 20035, Spain.	leyesm@yahoo.com					ADAMS CWM, 1989, J NEUROL NEUROSUR PS, V52, P600, DOI 10.1136/jnnp.52.5.600; ARRIAZA R, 1990, Journal of Sports Traumatology and Related Research, V12, P255; ARRIAZA R, 1989, ARCH MED DEPORTE, V21, P85; BIRRER RB, 1988, AM J SPORT MED, V16, P408, DOI 10.1177/036354658801600418; BIRRER RB, 1996, AM J SPORTS MED, V24, P72; Buschbacher R M, 1999, Phys Med Rehabil Clin N Am, V10, P35; CORSELLIS J, 1975, PSYCHOL MED, V3, P270; Critchley GR, 1999, BRIT J SPORT MED, V33, P174, DOI 10.1136/bjsm.33.3.174; Johannsen H V, 1986, Ugeskr Laeger, V148, P1786; KUJALA UM, 1995, BRIT MED J, V311, P1465, DOI 10.1136/bmj.311.7018.1465; McLatchie G, 1981, Br J Sports Med, V15, P84; Muller-Rath R, 2000, SPORTVERLETZ SPORTSC, V14, P20, DOI 10.1055/s-2000-3818; OLER M, 1991, J TRAUMA, V31, P251, DOI 10.1097/00005373-199131020-00017; Pieter W, 1997, J TRAUMA, V43, P89, DOI 10.1097/00005373-199707000-00020; Pieter W, 1999, J SPORT MED PHYS FIT, V39, P147; Plancher KD, 1996, CLIN SPORT MED, V15, P207; SCHMID L, 1969, J SPORTS MED PHYS FI, V8, P171; STRICEVIC MV, 1983, AM J SPORT MED, V11, P320, DOI 10.1177/036354658301100507; Trojanowski D, 1987, Lakartidningen, V84, P1858; Tuominen Risto, 1995, Scandinavian Journal of Medicine and Science in Sports, V5, P44; Wilkerson Leonard A., 1997, Journal of the American Osteopathic Association, V97, P221; Zetaruk MN, 2000, CLIN J SPORT MED, V10, P117, DOI 10.1097/00042752-200004000-00006; Zetaruk MN, 2000, ACCIDENT ANAL PREV, V32, P421, DOI 10.1016/S0001-4575(99)00120-7	23	40	41	0	15	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0942-2056	1433-7347		KNEE SURG SPORT TR A	Knee Surg. Sports Traumatol. Arthrosc.	OCT	2005	13	7					603	607		10.1007/s00167-004-0593-6			5	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	971RM	WOS:000232401700019	15678297				2021-06-18	
J	Clausen, T; Khaldi, A; Zauner, A; Reinert, M; Doppenberg, E; Menzel, M; Soukup, J; Alves, OL; Bullock, MR				Clausen, T; Khaldi, A; Zauner, A; Reinert, M; Doppenberg, E; Menzel, M; Soukup, J; Alves, OL; Bullock, MR			Cerebral acid-base homeostasis after severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; cerebral acid-base homeostasis; carbon dioxide; lactate/ischemia; multimodal monitoring	TISSUE OXYGEN-TENSION; ISCHEMIC CELL-DAMAGE; HUMAN HEAD-INJURY; SUBSTRATE DELIVERY; BLOOD-FLOW; GLUCOSE-UTILIZATION; INITIAL-EXPERIENCE; PERFUSION-PRESSURE; LACTIC-ACIDOSIS; FELINE BRAIN	Object. Brain tissue acidosis is known to mediate neuronal death. Therefore the authors measured the main parameters of cerebral acid-base homeostasis, as well as their interrelations, shortly after severe traumatic brain injury (TBI) in humans. Methods. Brain tissue pH, PCO2, PO2, and/or lactate were measured in 151 patients with severe head injuries, by using a Neurotrend sensor and/or a microdialysis probe. Monitoring was started as soon as possible after the injury and continued for up to 4 days. During the 1st day following the trauma, the brain tissue pH was significantly lower, compared with later time points, in patients who died or remained in a persistent vegetative state. Six hours after the injury, brain tissue PCO2 was significantly higher in patients with a poor outcome compared with patients with a good outcome. Furthermore, significant elevations in cerebral concentrations of lactate were found during the 1st day after the injury, compared with later time points. These increases in lactate were typically more pronounced in patients with a poor outcome. Similar biochemical changes were observed during later hypoxic events. Conclusions. Severe human TBI profoundly disturbs cerebral acid-base homeostasis. The observed pH changes persist for the first 24 hours after the trauma. Brain tissue acidosis is associated with increased tissue PCO2 and lactate concentration; these pathobiochemical changes are more severe in patients who remain in a persistent vegetative state or die. Furthermore, increased brain tissue PCO2 (> 60 mm Hg) appears to be a useful clinical indicator of critical cerebral ischemia, especially when accompanied by increased lactate concentrations.	Virginia Commonwealth Univ, Div Neurosurg, Hlth Syst, Richmond, VA 23298 USA; Univ Halle Wittenberg, Dept Anesthesiol & Intens Care Med, Halle An Der Saale, Germany; Univ Miami, Lois Pope Life Ctr, Dept Neurosurg, Miami, FL 33152 USA; Inselspital Bern, Dept Neurosurg, CH-3010 Bern, Switzerland; Univ Porto, Ctr Hosp Gaia, Fac Med, Serv Neurocirugia, P-4100 Oporto, Portugal	Bullock, MR (corresponding author), Virginia Commonwealth Univ, Div Neurosurg, Hlth Syst, POB 980631, Richmond, VA 23298 USA.	robulloc@mail2.vcu.edu	Reinert, Michael/AAA-3929-2019; Reinert, Michael/E-4964-2011	Reinert, Michael/0000-0002-0971-9543; 	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, P50NS012587] Funding Source: NIH RePORTER		Alessandri B, 1999, ACT NEUR S, V75, P25; ARTRU F, 1989, INTENS CARE MED, V15, P499, DOI 10.1007/BF00273560; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Charbel FT, 1997, SURG NEUROL, V48, P414, DOI 10.1016/S0090-3019(96)00473-9; Charbel FT, 2000, SURG NEUROL, V54, P432, DOI 10.1016/S0090-3019(00)00340-2; Chesler M, 2003, PHYSIOL REV, V83, P1183, DOI 10.1152/physrev.00010.2003; Chesnut R M, 1995, New Horiz, V3, P366; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; DESALLES AAF, 1987, NEUROSURGERY, V20, P297, DOI 10.1227/00006123-198702000-00017; Doppenberg EMR, 1997, J NEUROSURG, V87, P809, DOI 10.3171/jns.1997.87.6.0809; GENTLEMAN D, 1992, INT SURG, V77, P297; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Grande P O, 1997, Acta Anaesthesiol Scand Suppl, V110, P36; Hoffman WE, 1999, SURG NEUROL, V51, P654, DOI 10.1016/S0090-3019(99)00011-7; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; KALIMO H, 1981, J CEREBR BLOOD F MET, V1, P313, DOI 10.1038/jcbfm.1981.35; KRAIG RP, 1987, J CEREBR BLOOD F MET, V7, P379, DOI 10.1038/jcbfm.1987.80; Kristian T, 2001, J NEUROTRAUM, V18, P1059, DOI 10.1089/08977150152693755; Lang E W, 1995, New Horiz, V3, P400; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; MARMAROU A, 1992, J NEUROTRAUM, V9, pS551; Marmarou A, 1993, Acta Neurochir Suppl (Wien), V57, P160; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; REHNCRONA S, 1989, J CEREBR BLOOD F MET, V9, P65, DOI 10.1038/jcbfm.1989.9; Reinert M, 2000, ACTA NEUROCHIR SUPPL, V76, P439; ROSNER MJ, 1986, J NEUROSURG, V65, P636, DOI 10.3171/jns.1986.65.5.0636; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Savers S, 2000, J NEUROTRAUM, V17, P507; SCHMOKER JD, 1992, J TRAUMA, V32, P714, DOI 10.1097/00005373-199206000-00007; Schurr A, 1999, J NEUROSCI, V19, P34; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; WELSH FA, 1980, STROKE, V11, P355, DOI 10.1161/01.STR.11.4.355; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; ZAUNER A, 1995, NEUROSURGERY, V37, P1168, DOI 10.1227/00006123-199512000-00017; Zauner A, 2002, J NEUROSURG, V97, P643, DOI 10.3171/jns.2002.97.3.0643; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	49	40	40	0	9	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2005	103	4					597	607		10.3171/jns.2005.103.4.0597			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	971LG	WOS:000232385000005	16266040				2021-06-18	
J	Creamer, M; O'Donnell, ML; Pattison, P				Creamer, M; O'Donnell, ML; Pattison, P			Amnesia, traumatic brain injury, and posttraumatic stress disorder: a methodological inquiry	BEHAVIOUR RESEARCH AND THERAPY			English	Article						PTSD; MTBI; amnesia	MOTOR-VEHICLE ACCIDENTS; CONSCIOUSNESS; CONSEQUENCES; SYMPTOMS; SCALE	This study explored the relationship between mild traumatic brain injury (MTBI), amnesia, and posttraumatic stress disorder (PTSD). MTBI status and amnesia for the event were assessed in 307 consecutive admissions to a Level 1 Trauma Center. Amnesia did not always occur concurrently with MTBI: 18% of those with MTBI had full recall and over half had partial recall of the event. Just over 10% of participants developed PTSD by 12 months post-injury, with prevalence comparable across MTBI and non-MTBI groups. Non-significant differences in incidence of PTSD were apparent between those with full recall (9%), partial recall (14%) and no recall (7%). These data highlight the fact that PTSD may develop following trauma despite amnesia for the event, and illustrate the importance in both clinical and research settings of carefully examining the extent of amnesia. (c) 2005 Elsevier Ltd. All rights reserved.	Australian Ctr Posttraumat Mental Hlth, Heidelberg, Vic 3081, Australia; Univ Melbourne, Dept Psychiat, Parkville, Vic 3052, Australia; Univ Melbourne, Dept Psychol, Parkville, Vic 3052, Australia	Creamer, M (corresponding author), Australian Ctr Posttraumat Mental Hlth, ARMC Repat Campus,POB 5444, Heidelberg, Vic 3081, Australia.	markcc@unimelb.edu.au		O'Donnell, Meaghan/0000-0003-4349-0022; Pattison, Philippa/0000-0001-9626-2897			American Congress of Rehabilitation Medicine (ACRM), 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Bryant RA, 2001, J NERV MENT DIS, V189, P109, DOI 10.1097/00005053-200102000-00006; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Harvey AG, 2001, J TRAUMA STRESS, V14, P277, DOI 10.1023/A:1011108816888; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; MAROSSZEKY NEV, 1998, PTA PROTOCOLL GUIDEL; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; McMillan TM, 1997, CURR OPIN NEUROL, V10, P479, DOI 10.1097/00019052-199712000-00008; O'Brien M, 1998, BRIT J PSYCHIAT, V173, P102, DOI 10.1192/bjp.173.2.102; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Schnyder U, 2001, AM J PSYCHIAT, V158, P594, DOI 10.1176/appi.ajp.158.4.594; TEASDALE G, 1974, LANCET, V2, P81	19	40	40	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0005-7967	1873-622X		BEHAV RES THER	Behav. Res. Ther.	OCT	2005	43	10					1383	1389		10.1016/j.brat.2004.11.001			7	Psychology, Clinical	Psychology	971CT	WOS:000232359500010	16086988				2021-06-18	
J	Iwata, A; Browne, KD; Chen, XH; Yuguchi, T; Smith, DH				Iwata, A; Browne, KD; Chen, XH; Yuguchi, T; Smith, DH			Traumatic brain injury induces biphasic upregulation of ApoE and ApoJ protein in rats	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						traumatic brain injury; apolipoprotein E; apolipoprotein J; GFAP; amyloid-beta	ALZHEIMERS AMYLOID-BETA; APOLIPOPROTEIN-E POLYMORPHISM; LIPOPROTEIN RECEPTOR GENE; FIBRILLARY ACIDIC PROTEIN; LONG-TERM ACCUMULATION; FLUID-PERCUSSION MODEL; IN-SITU HYBRIDIZATION; E MESSENGER-RNA; HEAD-INJURY; NEURON DEATH	Apolipoproteins play an important role in cell repair and have been found to increase shortly after traumatic brain injury (TBI). In addition, apolipoproteins reduce amyloid-beta (A beta) accumulation in models of Alzheimer's disease. Considering that TBI induces progressive neurodegeneration including A beta accumulation, we explored potential long-term changes in the gene and protein expression of apolipoproteins E and J (ApoE and J) over 6 months after injury. Anesthetized male Sprague-Dawley rats were subjected to parasagittal fluid-percussion brain injury and their brains were evaluated at 2, 4, 7, 14 days, and 1 and 6 months after TBI, In situ hybridization, Western blot, and immunohistochemical analysis demonstrated that although there was a prolonged upregulation in both the gene expression and protein concentration of ApoE and J after injury, these responses were uncoupled. Upregulation of ApoE and J mRNA expression lasted from 4 days to 1 month after injury. In contrast, a biphasic increase in protein concentration and number of immunoreactive cells for ApoE and ApoJ was observed, initially peaking at 2 days (i.e., before increased mRNA expression), returning to baseline by 2 weeks and then gradually increasing through 6 months postinjury. In addition, ApoE and J were found to colocalize with A beta accumulation in neurons and astrocytes at 1-6 months after injury. Collectively, these data suggest that ApoE and J play a role in the acute sequelae of brain trauma and reemerge long after the initial insult, potentially to modulate progressive neurodegenerative changes. (C) 2005 Wiley-Liss, Inc.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Yukioka Hosp, Dept Neurosurg, Osaka, Japan	Smith, DH (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 105C Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	smithdou@mail.med.upenn.edu	smith, douglas/A-1321-2007		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K08AG021527] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG21527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38104] Funding Source: Medline		Ali SM, 1996, MOL BRAIN RES, V38, P37, DOI 10.1016/0169-328X(95)00301-8; Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; BISHOP RW, 1992, J LIPID RES, V33, P549; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Browne KD, 2004, J NEUROSCI RES, V77, P878, DOI 10.1002/jnr.20215; Calero M, 2000, MICROSC RES TECHNIQ, V50, P305, DOI 10.1002/1097-0029(20000815)50:4<305::AID-JEMT10>3.0.CO;2-L; CHEN WJ, 1994, J CELL BIOL, V127, P813, DOI 10.1083/jcb.127.3.813; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; CHOIMIURA NH, 1992, ACTA NEUROPATHOL, V83, P260, DOI 10.1007/BF00296787; Cole GM, 1999, J NEUROSCI RES, V57, P504, DOI 10.1002/(SICI)1097-4547(19990815)57:4<504::AID-JNR10>3.3.CO;2-8; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DeMattos RB, 2004, NEURON, V41, P193, DOI 10.1016/S0896-6273(03)00850-X; DeMattos RB, 2002, P NATL ACAD SCI USA, V99, P10843, DOI 10.1073/pnas.162228299; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; FRITZ IB, 1992, CLIN EXP IMMUNOL, V88, P375; FRITZ IB, 1993, TRENDS PHARMACOL SCI, V14, P355, DOI 10.1016/0165-6147(93)90093-Y; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; Giannakopoulos P, 1998, ACTA NEUROPATHOL, V95, P387, DOI 10.1007/s004010050815; Ginsberg MD, 1996, J NEUROSCI METH, V68, P225; GRISWOLD MD, 1986, BIOCHEMISTRY-US, V25, P7265, DOI 10.1021/bi00371a003; Han BH, 2001, NAT MED, V7, P338, DOI 10.1038/85487; Hayes R L, 1987, Brain Inj, V1, P93, DOI 10.3109/02699058709034449; Holtzman DM, 2001, J MOL NEUROSCI, V17, P147, DOI 10.1385/JMN:17:2:147; Horsburgh K, 1997, BRAIN RES, V763, P103, DOI 10.1016/S0006-8993(97)00411-3; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Iwata A, 1997, J NEUROTRAUM, V14, P201, DOI 10.1089/neu.1997.14.201; JENNE DE, 1992, TRENDS BIOCHEM SCI, V17, P154, DOI 10.1016/0968-0004(92)90325-4; Jones SE, 2002, INT J BIOCHEM CELL B, V34, P427, DOI 10.1016/S1357-2725(01)00155-8; JORDANSTARCK TC, 1994, J LIPID RES, V35, P194; LaDu MJ, 2000, ANN NY ACAD SCI, V903, P167, DOI 10.1111/j.1749-6632.2000.tb06365.x; Leoni MJ, 2000, EXP NEUROL, V166, P442, DOI 10.1006/exnr.2000.7513; MaatSchieman MLC, 1996, BRAIN PATHOL, V6, P115, DOI 10.1111/j.1750-3639.1996.tb00794.x; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Martin RL, 1997, BELL LABS TECH J, V2, P3, DOI 10.1002/bltj.2027; MATSUBARA E, 1995, J BIOL CHEM, V270, P7563, DOI 10.1074/jbc.270.13.7563; MAY PC, 1992, TRENDS NEUROSCI, V15, P391, DOI 10.1016/0166-2236(92)90190-J; MAY PC, 1990, NEURON, V5, P831, DOI 10.1016/0896-6273(90)90342-D; MCGEER PL, 1992, BRAIN RES, V579, P337, DOI 10.1016/0006-8993(92)90071-G; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCLEAN JW, 1983, J BIOL CHEM, V258, P8993; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, P28; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Nishio M, 2003, NEUROL RES, V25, P390, DOI 10.1179/016164103101201544; ODA T, 1995, EXP NEUROL, V136, P22, DOI 10.1006/exnr.1995.1080; Page KJ, 1998, NEUROSCIENCE, V85, P1161, DOI 10.1016/S0306-4522(97)00661-1; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; ROSENBERG ME, 1993, J LAB CLIN MED, V121, P205; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; Schauwecker PE, 1998, EXP NEUROL, V149, P87, DOI 10.1006/exnr.1997.6679; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Seitz A, 2003, J NEUROSCI RES, V71, P417, DOI 10.1002/jnr.10482; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Strittmatter WJ, 1996, ANNU REV NEUROSCI, V19, P53, DOI 10.1146/annurev.ne.19.030196.000413; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Van Beek J, 2000, GLIA, V31, P39, DOI 10.1002/(SICI)1098-1136(200007)31:1<39::AID-GLIA40>3.0.CO;2-1; Walton M, 1996, MOL BRAIN RES, V39, P137, DOI 10.1016/0169-328X(96)00019-8; Wiggins AK, 2003, MOL BRAIN RES, V114, P20, DOI 10.1016/S0169-328X(03)00124-4; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; Wisniewski T, 1997, NEUROBIOL DIS, V4, P313, DOI 10.1006/nbdi.1997.0147; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; Zlokovic BV, 1996, LIFE SCI, V59, P1483, DOI 10.1016/0024-3205(96)00310-4; ZLOKOVIC BV, 1994, BIOCHEM BIOPH RES CO, V205, P1431, DOI 10.1006/bbrc.1994.2825	78	40	44	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	OCT 1	2005	82	1					103	114		10.1002/jnr.20607			12	Neurosciences	Neurosciences & Neurology	972CK	WOS:000232431300011	16118797				2021-06-18	
J	Lima, EF; Riet-Correa, F; de Castro, RS; Gomes, AAB; Lima, FDS				Lima, EF; Riet-Correa, F; de Castro, RS; Gomes, AAB; Lima, FDS			Clinical signs, distribution of the lesions in the central nervous system and epidemiology of rabies in northeastern Brazil.	PESQUISA VETERINARIA BRASILEIRA			Portuguese	Article						rabies; cattle; sheep; goats; horses; pathology; clinical signs; economical impact	SEMIARID REGION; DIAGNOSIS; CATTLE; FEATURES; STRAINS; STATE	Twenty four outbreaks of rabies in cattle, 4 in horses, 2 in sheep, and 2 in goats are reported in northeastern Brazil. All outbreaks occurred in the state of Paraiba, except one in horses that occurred in the state of Rio Grande do Norte. All outbreaks, except one in sheep, were probably transmitted by vampire-bats, but the transmission by foxes (Dusicyon vetulus) is also possible. Clinical signs were characteristic for distribution of the lesions in the central nervous system (CNS). In cattle, signs were mainly of the paralytic form of rabies, caused by lesions on the spinal cord, brain stem and cerebellum; but some animals showed also depression, excitation and other signs due to cerebral lesions. In 3 out of 5 horses, the main clinical signs were due to lesions in the cerebrum, and 2 had the paralytic form. From 4 sheep and 2 goats affected, 4 showed clinical signs of the paralytic form; but in I goat and I sheep the main clinical signs were caused by cerebral lesions. All affected animals, except I goat, had a clinical manifestation period of 2-8 days. The only gross lesions were distention of the urinary bladder in 4 cattle and distention of the rectum in 2 others. Two horses had skin lesions due to traumatic injury. Histologic lesions were diffuse non-suppurative encephalomyelitis and meningitis. In the horses, and in one goat with a clinical manifestation period of 35 days, the lesions were more severe, with neuronal necrosis, neuronophagia, and presence of axonal spheroids. Negri bodies were found in 87% (20/23) of the cattle cases examined histologically. In small ruminants, Negri bodies were found in 83% (5/6) of the cases. In sheep, goats and cattle, Negri bodies were more frequent in the cerebellum, but they were found also in brain stem, spinal cord and cerebrum. In horses, Negri bodies were found in small amounts only in the cortex of one animal, and in the cortex and hippocampus of another. Histologic lesions and Negri bodies in the trigeminal ganglia were less frequent than in the CNS. These results show that in rabies of herbivores, clinical signs and distribution of lesions in the CNS are variable, so that for the diagnosis and adequate clinical evaluation, the histologic study of different areas of the CNS are necessary. This also suggests that when the fluorescent antibody test and mouse inoculation test are negative, they should be repeated with samples from different areas of the brain and spinal cord. Frequency data of diseases from 4 diagnostic laboratories were used to estimate cattle deaths due to rabies in 3 Brazilian states. In Paraiba, with a population of 918,262 cattle, the annual death rate is estimated in 8,609 heads. In Mato Grosso do Sul, with a population of 23 millions cattle, deaths caused by rabies are estimated in 149,500 heads, and in Rio Grande do Sul, with a cattle population of 13 millions, cattle deaths due to rabies are estimated in 13,000 to 16,250 heads. If these data are used to estimate cattle losses in Brazil, with a cattle population of 195 millions, it can be estimated that 842,688 deaths are caused annually by rabies.	UFCG, Curso Med Vet, Ctr Saude & Tecnol Rural, BR-58700000 Patos de Minas, PB, Brazil; Univ Fed Rural Pernambuco, Curso Med Vet, BR-52171900 Recife, PE, Brazil	Lima, EF (corresponding author), UFCG, Curso Med Vet, Ctr Saude & Tecnol Rural, Campus Patos, BR-58700000 Patos de Minas, PB, Brazil.	riet@cstr.ufcg.br					ACHA PN, 1986, ZOONOSIS ENFERMEDADE, P502; ARAUJO FAA, 2002, THESIS U FEDERAL MIN; BACON PJ, 1985, POPULATION DYNAMICS; BARROS CSL, 2003, COMUNICACAO PESSOAL; BARROS JS, 1989, ZOON REV INT, V1, P9; Batista-Morais N, 2000, MEM I OSWALDO CRUZ, V95, P609, DOI 10.1590/S0074-02762000000500003; Bingham J, 2002, J VIROL METHODS, V101, P85, DOI 10.1016/S0166-0934(01)00423-2; BRAUND KG, 1987, VET NEUROLOGY, P266; CARLTON WW, 1998, PATOLOGIA VET ESPECI; COELHO HE, 2002, PATOLOGIA VET; Dean D. J., 1996, P88; Fernandes C.G., 2001, DOENCAS RUMINANTES E, V1, P149; Germano P. M. L., 1977, Revista da Faculdade de Medicina Veterinaria e Zootecnia da Universidade de Sao Paulo, V14, P133; GERMANO P M L, 1990, Boletin de la Oficina Sanitaria Panamericana, V108, P39; GOLDWASSER RA, 1958, P SOC EXP BIOL MED, V98, P219, DOI 10.3181/00379727-98-23996; GOMES AAB, 2004, THESIS U SAO PAULO; HAYASHI Y, 1984, ARQ BIOL TECNOL, V27, P27; Heinemann MB, 2002, EPIDEMIOL INFECT, V128, P503, DOI 10.1017/S095026880200688X; Hudson LC, 1996, J VET MED B, V43, P85, DOI 10.1111/j.1439-0450.1996.tb00292.x; Jones T.C., 2000, PATOLOGIA VET; Jubb KVF, 1993, PATHOLOGY DOMESTIC A, P267; KING AA, 1993, J COMP PATHOL, V108, P1, DOI 10.1016/S0021-9975(08)80224-1; Koprowski H., 1996, P80; Langohr Ingeborg Maria, 2003, Cienc. Rural, V33, P125, DOI 10.1590/S0103-84782003000100020; LEMOS RRA, 2005, THESIS U ESTADUAL PA; Lima EF, 2005, PESQUI VET BRASIL, V25, P9, DOI 10.1590/S0100-736X2005000100003; MARCRUZ R, 1977, REV FAC MED VET ZOOT, V14, P123; MONTANO JA, 1987, ARQ BIOL TECNOL, V30, P367; MORI AE, 2004, SERIE QUALIFICACAO R, V2, P63; Nobre VMD, 2004, PESQUI VET BRASIL, V24, P132, DOI 10.1590/S0100-736X2004000300004; *ORG PAN AM SAL RI, 2001, ORG PAN AM SAL B, V33; Peixoto ZMP, 2000, BRAZ J MICROBIOL, V31, P72; Radostits O.M., 2002, CLIN VET TRATADO DOE; *RED INT INF SAUD, 2002, IND BAS SAUD BRAS CO, P150; Riet-Correa F, 2002, PESQUISA VET BRASIL, V22, P161, DOI 10.1590/S0100-736X2002000400006; RIET-CORREA F., 2003, SEMIARIDO FOCO, V1, P2; RIETCORREA F, 1999, RELATORIO ATIVIDADES; RIETCORREA F, 1983, RELATORIO ATIVIDADES; Rodrigues da Silva Andrea De Cassia, 2000, Revista do Instituto de Medicina Tropical de Sao Paulo, V42, P95; Rondon E. S., 1995, Revista Brasileira de Medicina Veterinaria, V17, P253; Sanches AWD, 2000, PESQUISA VET BRASIL, V20, P113, DOI 10.1590/S0100-736X2000000300005; Silva JA, 2001, ARQ BRAS MED VET ZOO, V53, P263; SILVA RA, 1974, PESQ AGROP BRAS SER, V9, P29; Summers BA., 1995, Veterinary Neuropathology; SWANEPOEL R, 1994, INFECT DIS LIVESTOCK, V1, P392; TIERKEL ES, 1975, NATURAL HIST RABIES, V2, P123; ZIMMER K, 1990, J VET MED B, V37, P392, DOI 10.1111/j.1439-0450.1990.tb01074.x	47	40	47	0	7	REVISTA PESQUISA VETERINARIA BRASILEIRA	RIO JANEIRO	EMBRAPA-SAUDE ANIMAL, KM47 SEROPEDICA, 23851-970 RIO JANEIRO, BRAZIL	0100-736X	1678-5150		PESQUI VET BRASIL	Pesqui. Vet. Bras.	OCT-DEC	2005	25	4					250	264		10.1590/S0100-736X2005000400011			15	Veterinary Sciences	Veterinary Sciences	010ZB	WOS:000235236300011		DOAJ Gold			2021-06-18	
J	Williams, G; Robertson, V; Greenwood, K; Goldie, P; Morris, ME				Williams, G; Robertson, V; Greenwood, K; Goldie, P; Morris, ME			The high-level mobility assessment tool (HiMAT) for traumatic brain injury. Part 1: Item generation	BRAIN INJURY			English	Article						brain injuries; rehabilitation; circuit disorders; neurologic; outcome assessment	FUNCTIONAL MOBILITY; OUTCOME MEASURE; BALANCE; MOTOR; REHABILITATION; STROKE; RECOVERY; PROFILE; ADULTS; IDENTIFICATION	Primary objective: To generate a comprehensive list of items for a scale suitable for assessing high-level mobility in people with traumatic brain injury (TBI). Research design: High-level mobility items were generated following a critical evaluation of existing adult and paediatric mobility scales and by surveying expert clinicians for opinions about items appropriate for inclusion on a high-level mobility scale. Main outcomes and results: The critical evaluation identified 18 different items from 31 mobility scales. These included nine walking items in addition to higher level activities such as stair use, running, jumping and hopping. Expert clinicians generated 157 items that were collated and condensed to 88 items for ranking on a questionnaire. Fifteen items on the questionnaire were rated as very important by 80% of the expert clinicians. These included walking forwards, walking on slopes and different surfaces, changing direction, walking long distances and stair use. Running items included forwards, backwards, on slopes and over different surfaces, changing direction, stopping and starting as well as running long distances. Balancing in single limb stance was also included. Conclusion: The final list comprised walking, running, hopping, skipping, jumping and balance items. This initial version of the HiMAT has face and content validity although requires further testing to investigate whether it is uni-dimensional and valid for people with TBI.	Epworth Med Fdn, Physiotherapy Dept, Richmond, Vic 3121, Australia; Univ Newcastle, Newcastle, NSW 2308, Australia; La Trobe Univ, Bundoora, Vic, Australia	Williams, G (corresponding author), Epworth Med Fdn, Physiotherapy Dept, 89 Bridge Rd, Richmond, Vic 3121, Australia.	gavinw@epworth.org.au	Greenwood, Kenneth M/J-8993-2015	Greenwood, Kenneth M/0000-0002-8420-6588; Morris, Meg/0000-0002-0114-4175; Williams, Gavin/0000-0003-2758-7473			Badke Mary Beth, 1993, Physiotherapy Canada, V45, P15; Baer HR, 2001, STROKE, V32, P973, DOI 10.1161/01.STR.32.4.973; Bayley N., 1969, MANUAL BAYLEY SCALES; BERG K, 1989, Physiotherapy Canada, V41, P304; Bobath B., 1990, ADULT HEMIPLEGIA EVA; BREWER K, 1998, PHYSIOTHER CAN, V50, P118; BURDON B, 1993, AUSTR DEV SCREENING; CARR JH, 1985, PHYS THER, V65, P175, DOI 10.1093/ptj/65.2.175; CARR JH, 1982, MOTOR RELEARNING PRO; Collen F M, 1991, Int Disabil Stud, V13, P50; DUNCAN P, 1995, DUKE MOBILITY SKILLS; ENZIN NK, 1994, HDB QUALITATIVE RES; Folio M. R., 1983, PEABODY DEV MOTOR SC; GOLDIE PA, 1994, ARCH PHYS MED REHAB, V75, P969; Goldie PA, 1996, ARCH PHYS MED REHAB, V77, P1074, DOI 10.1016/S0003-9993(96)90072-6; GOWLAND C, 1993, STROKE, V24, P58, DOI 10.1161/01.STR.24.1.58; Granger CV, 1983, GUIDE USE UNIFORM DA; Guttman L, 1944, AM SOCIOL REV, V9, P139, DOI 10.2307/2086306; HOLDEN MK, 1984, PHYS THER, V64, P35, DOI 10.1093/ptj/64.1.35; Holder-Powell HM, 2000, ARCH PHYS MED REHAB, V81, P265, DOI 10.1016/S0003-9993(00)90069-8; JOHANSSON G, 1991, Physiotherapy Theory and Practice, V7, P121, DOI 10.3109/09593989109106962; JONES J, 1996, QUALITATIVE RES HLTH; KORNERBITENSKY N, 1989, ARCH PHYS MED REHAB, V70, P95; Lincoln N, 1979, Physiotherapy, V65, P48; MAHONEY F I, 1965, Md State Med J, V14, P61; Martin J, 1988, PREVALENCE DISABILIT; McGuine TA, 2000, CLIN J SPORT MED, V10, P239, DOI 10.1097/00042752-200010000-00003; Means KM, 1996, J REHABIL RES DEV, V33, P413; Miller L. J., 1994, TIME TODDLER INFANT; Minichiello V., 1995, IN DEPTH INTERVIEWIN; MOORE M, 1994, GROUP TECHNIQUES IDE; MSALL ME, 1994, CLIN PEDIATR, V33, P431, DOI 10.1177/000992289403300709; Novacheck TF, 2000, J PEDIATR ORTHOPED, V20, P75, DOI 10.1097/00004694-200001000-00017; O'Connell M, 1998, GAIT POSTURE, V8, P136, DOI 10.1016/S0966-6362(98)00023-X; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; OREST MR, 2000, PHYSIOTHERAPY CANADA, V52, P131; Patla AE, 1999, J AGING PHYS ACTIV, V7, P7, DOI 10.1123/japa.7.1.7; PILON M, 1995, BRAIN INJURY, V9, P365, DOI 10.3109/02699059509005776; Platt W, 1998, PHYSIOTHER CAN, V50, P47; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; Quinn B, 2000, BRAIN INJURY, V14, P1063; RANKENBURG, 1975, REVISED DENVER DEV S; Russell D., 1993, GROSS MOTOR FUNCTION; SEABY L, 1989, Physiotherapy Canada, V41, P264; Shumway-Cook A., 1995, MOTOR CONTROL THEORY; SWAINE BR, 1994, BRAIN INJURY, V8, P323, DOI 10.3109/02699059409150983; Swaine BR, 1996, BRAIN INJURY, V10, P347, DOI 10.1080/026990596124368; Tang PF, 1998, J GERONTOL A-BIOL, V53, pM140, DOI 10.1093/gerona/53A.2.M140; Vitale AE, 1996, BRAIN INJURY, V10, P367, DOI 10.1080/026990596124377; Ware JE., 1993, SF 36 HLTH SURVEY MA; *WHO, 2001, ICF INT CLASS FUNCT; Williams G, 2004, AM J PHYS MED REHAB, V83, P910, DOI 10.1097/01.PHM.0000146503.25221.1D; Williams G, 2001, BRAIN INJURY, V15, P831; WRIGHT BD, 1989, ARCH PHYS MED REHAB, V70, P857	56	40	40	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2005	19	11					925	932		10.1080/02699050500058687			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	983YY	WOS:000233269500007	16243748				2021-06-18	
J	McAllister, TW; Rhodes, CH; Flashman, LA; McDonald, BC; Belloni, D; Saykin, AJ				McAllister, TW; Rhodes, CH; Flashman, LA; McDonald, BC; Belloni, D; Saykin, AJ			Effect of the dopamine D2 receptor T allele on response latency after mild traumatic brain injury	AMERICAN JOURNAL OF PSYCHIATRY			English	Article							DRD2; GENE; BINDING	Objective: The authors tested the hypothesis that the dopamine D2 receptor T allele ( formerly described as the A1 allele) would be associated with poorer performance on memory and attention tasks following mild traumatic brain injury. Method: Thirty-nine patients with mild traumatic brain injury and 27 comparison subjects were genotyped. All subjects completed memory and attention tests, including the California Verbal Learning Test recognition task and the Continuous Performance Test. Results: In both groups the T allele was associated with poorer performance on the California Verbal Learning Test recognition task. There was also a significant diagnosis-by-allele interaction on measures of response latency ( Continuous Performance Test): the subjects with mild traumatic brain injury and the T allele had the worst performance. Conclusions: Genetic polymorphisms modulating central dopaminergic tone can affect cognitive outcome following mild traumatic brain injury.	Dartmouth Coll, Hitchcock Med Ctr, Dept Psychiat, Sect Neuropsychiat, Lebanon, NH 03756 USA	McAllister, TW (corresponding author), Dartmouth Coll, Hitchcock Med Ctr, Dept Psychiat, Sect Neuropsychiat, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	thomas.w.mcallister@dartmouth.edu	Saykin, Andrew/A-1318-2007	Saykin, Andrew/0000-0002-1376-8532	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS-40472-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040472] Funding Source: NIH RePORTER		American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Comings DE, 1998, ALCOHOL, V16, P61, DOI 10.1016/S0741-8329(97)00178-X; Delis DC, 2000, CALIFORNIA VERBAL LE; Delis DC, 1987, CALIFORNIA VERBAL LE; First MB., 1997, STRUCTURED CLIN INTE; Gordon N, 1996, EUR J DISORDER COMM, V31, P359; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; MCALLISTER TW, 2003, J NEUROPSYCHIATRY CL, V15, P278; Neville MJ, 2004, HUM MUTAT, V23, P540, DOI 10.1002/humu.20039; *PSYCH CORP, 1997, WECHSL AD INT SCAL; Ritchie T, 2003, NEUROCHEM RES, V28, P73, DOI 10.1023/A:1021648128758; TEASDALE G, 1974, LANCET, V2, P81; Thompson J, 1997, PHARMACOGENETICS, V7, P479, DOI 10.1097/00008571-199712000-00006; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME	16	40	43	0	1	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0002-953X	1535-7228		AM J PSYCHIAT	Am. J. Psychiat.	SEP	2005	162	9					1749	1751		10.1176/appi.ajp.162.9.1749			3	Psychiatry	Psychiatry	959ZT	WOS:000231559300028	16135640				2021-06-18	
J	Maxwell, WL; Watson, A; Queen, R; Conway, B; Russell, D; Neilson, M; Graham, DI				Maxwell, WL; Watson, A; Queen, R; Conway, B; Russell, D; Neilson, M; Graham, DI			Slow, medium, or fast re-warming following post-traumatic hypothermia therapy? An ultrastructural perspective	JOURNAL OF NEUROTRAUMA			English	Article						post-traumatic hypothermia; re-warming; traumatic axonal injury	TRAUMATIC BRAIN-INJURY; NONDISRUPTIVE AXONAL INJURY; NEUROFILAMENT DISTRIBUTIONS; CYTOSKELETAL CHANGES; OPTIC-NERVE; DAMAGE; MICROTUBULES; MODEL	It was hypothesized that rapid rather than slow re-warming following traumatic brain injury (TBI) and short-term hypothermia results in secondary, ultrastructural pathology. After stretch injury to the right optic nerve, adult guinea pigs were randomly allocated to one of six experimental groups. Either (1) sham (all procedures but not stretch-injured; n = 4); injured and (2) maintained at normal temporalis core temperature (38.5 degrees C) for 8 hours (n = 6); (3) cooled rapidly to 32.5 degrees C (temporalis temperature), maintained for 4 h and re-warmed to 38.5 degrees C at 1 degrees C rise every 10 min (fast; n = 6); (4) cooled and re-warmed at 1 degrees C rise every 20 min (medium; n = 6); (5) cooled and re-warmed at 1 degrees C rise every 40 min (slow; n = 6) before being killed 8 h after injury; and (6) uninjured animals (n = 6) cooled to 32.5 degrees C for 4 h and then re-warmed at 1 degrees C every 10 min before killing 4 h later. Tissue was processed for light immunocytochemistry (beta-APP and RMO-14) and ultrastructural stereology. In both uninjured and injured fast re-warmed animals, there was almost total loss of axonal microtubules (MT) and an increased number of neurofilaments (NF) within the axoplasm. In the former, there was also compaction of NF. The number of MT was reduced to 40% of control values, NFs were increased but were not compacted after medium rate re-warming. Following slow re-warming the axonal cytoskeleton did not differ from that in control animals. It is concluded that re-warming faster than 1 degrees C every 40 min following mild post-traumatic hypothermia induces secondary axonal pathology.	Univ Glasgow, IBLS, Glasgow G12 8QQ, Lanark, Scotland; So Gen Hosp, Univ Unit Neuropathol, Glasgow G51 4TF, Lanark, Scotland	Maxwell, WL (corresponding author), Univ Glasgow, IBLS, Thomson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	w.maxwell@bio.gla.ac.uk					Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; DONAGHY M, 1988, J NEUROCYTOL, V17, P197, DOI 10.1007/BF01674207; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GUY J, 1989, J COMP NEUROL, V287, P446, DOI 10.1002/cne.902870404; Jafari SS, 1998, J NEUROTRAUM, V15, P955, DOI 10.1089/neu.1998.15.955; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Kumar S, 2002, J NEUROSCI RES, V68, P681, DOI 10.1002/jnr.10249; Kumar S, 2002, BIOPHYS J, V82, P2360, DOI 10.1016/S0006-3495(02)75581-1; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARK RJ, 1995, J NEUROSCI, V15, P6239; MATA M, 1992, J NEUROCYTOL, V21, P199, DOI 10.1007/BF01194978; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; Maxwell WL, 1999, J NEUROTRAUM, V16, P1225, DOI 10.1089/neu.1999.16.1225; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; OHNISHI A, 1976, J NEUROPATH EXP NEUR, V35, P167, DOI 10.1097/00005072-197603000-00004; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Suehiro E, 2001, EXP NEUROL, V172, P199, DOI 10.1006/exnr.2001.7765; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; TRAPP BD, 1989, J CELL BIOL, V109, P2417, DOI 10.1083/jcb.109.5.2417; WEGNER JE, 1976, BIOL GUINEA PIG	28	40	41	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2005	22	8					873	884		10.1089/neu.2005.22.873			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	955LH	WOS:000231226900003	16083354				2021-06-18	
J	Binder, S; Corrigan, JD; Langlois, JA				Binder, S; Corrigan, JD; Langlois, JA			The public health approach to traumatic brain injury - An overview of CDC's research and programs	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; craniocerebral trauma; public health		Every year, 50,000 people die with a traumatic brain injury (TBI). At least 5.3 million Americans live with long-term disabilities related to TBI. Through its TBI-associated research and programs, CDC's National Center for Injury Prevention and Control (NCIPC) seeks to reduce the adverse consequences of TBIs by ensuring that data, data systems, and public awareness about TBI are in place. The public health model provides a useful framework for identifying important efforts needed to reduce the impact of this potentially disabling injury.	Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA; Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA	Binder, S (corresponding author), 3958 Preston Court, Atlanta, GA 30319 USA.	scbinder@bellsouth.net	Corrigan, John D./E-2921-2011				Brooks CA, 1997, ARCH PHYS MED REHAB, V78, pS26, DOI 10.1016/S0003-9993(97)90152-0; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P151, DOI 10.1053/apmr.2003.50123; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P276; *CDCP NAT CTR INJ, 2003, MILD TRAUM BRAIN INJ; Centers for Disease Control and Prevention, 1999, TRAUM BRAIN INJ US R; Centers for Disease Control and Prevention, 2002, CDC INJ RES AG; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P1, DOI 10.1097/00001199-200102000-00004; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; GILLESPIE LD, 2004, COCHRANE LIB; Langlois J, 2005, TRAUMATIC BRAIN INJU; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Langlois JA, 2000, TRAUMATIC BRAIN INJU; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Peden M., 2002, INJURY LEADING CAUSE; PICKELSIMER E, 2002, BRIAN INJ SOURCE, V6, P18; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; Sample PL, 2005, J HEAD TRAUMA REHAB, V20, P270, DOI 10.1097/00001199-200505000-00009; SLEET DA, 1997, PRINCIPLES PUBLIC HL, P337; *STAT TERR INJ PRE, 2003, SAF STAT; Task Force on Community Preventive Services, GUID COMM PREV SERV; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Thurman DJ., 1995, GUIDELINES SURVEILLA; THURMAN DJ, 2001, HEAD TRAUMA BASIC PR	23	40	41	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2005	20	3					189	195		10.1097/00001199-200505000-00002			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	926ZZ	WOS:000229163500002	15908819				2021-06-18	
J	Willoughby, KA; Kleindienst, A; Muller, C; Chen, T; Muir, JK; Ellis, EF				Willoughby, KA; Kleindienst, A; Muller, C; Chen, T; Muir, JK; Ellis, EF			S100B protein is released by in vitro trauma and reduces delayed neuronal injury	JOURNAL OF NEUROCHEMISTRY			English	Article						cell culture; in vitro models; neurons; neuroprotection; S100B protein; traumatic brain injury	STRETCH-INDUCED INJURY; METABOTROPIC GLUTAMATE RECEPTORS; BRAIN-DAMAGE; CORTICAL-NEURONS; CALCIUM; S100-BETA; S-100B; ANTAGONISM; ACTIVATION; MARKERS	S100B protein in brain is produced primarily by astrocytes, has been used as a marker for brain injury and has also been shown to be neurotrophic and neuroprotective. Using a well characterized in vitro model of brain cell trauma, we examined the potential role of exogenous S100B in preventing delayed neuronal injury. Neuronal plus glial cultures were grown on a deformable Silastic membrane and then subjected to strain (stretch) injury produced by a 50 ms displacement of the membrane. We have previously shown that this injury causes an immediate, but transient, nuclear uptake of the fluorescent dye propidium iodide by astrocytes and a 24-48 h delayed uptake by neurons. Strain injury caused immediate release of S100-beta with further release by 24 and 48 h. Adding 10 or 100 nm S100B to injured cultures at 15 s, 6 h or 24 h after injury reduced delayed neuronal injury measured at 48 h. Exogenous S100B was present in the cultures through 48 h. These studies directly demonstrate the release and neuroprotective role of S100B after traumatic injury and that, unlike most receptor antagonists used for the treatment of trauma, S100B is neuroprotective when given at later, more therapeutically relevant time points.	Virginia Commonwealth Univ, Sch Med, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Sch Med, Dept Neurosurg, Richmond, VA USA; Humboldt Univ, Charite, Inst Lab Med & Pathobiochem, Berlin, Germany	Ellis, EF (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Pharmacol & Toxicol, Med Coll Virginia Campus, Richmond, VA 23298 USA.	eellis@mail2.vcu.edu	Kleindienst, Andrea/F-1674-2014	Kleindienst, Andrea/0000-0003-4758-0324	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL057869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214] Funding Source: NIH RePORTER; AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [HS 07288] Funding Source: Medline; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL 57869] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 27214] Funding Source: Medline		Ahmed SM, 2002, J NEUROTRAUM, V19, P1619, DOI 10.1089/089771502762300274; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; AHMED SM, 1998, J NEUROTRAUM, V15, P854; AZMITIA EC, 1990, BRAIN RES, V516, P354, DOI 10.1016/0006-8993(90)90942-5; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; BARGER SW, 1992, J BIOL CHEM, V267, P9689; BOYES BE, 1986, NEUROSCIENCE, V17, P857, DOI 10.1016/0306-4522(86)90050-3; Brewton LS, 2001, BRAIN RES, V912, P9, DOI 10.1016/S0006-8993(01)02519-7; Chen T, 2004, J NEUROTRAUM, V21, P271, DOI 10.1089/089771504322972068; Ciccarelli R, 1999, GLIA, V27, P275, DOI 10.1002/(SICI)1098-1136(199909)27:3<275::AID-GLIA9>3.3.CO;2-S; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Floyd CL, 2004, J NEUROTRAUM, V21, P205, DOI 10.1089/089771504322778668; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Hu JR, 1997, J NEUROCHEM, V69, P2294; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; Kao CQ, 2004, J NEUROTRAUM, V21, P259, DOI 10.1089/089771504322972059; Kleindienst A, 2004, J NEUROTRAUM, V21, P541, DOI 10.1089/089771504774129874; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; Leviton A, 2002, ACTA PAEDIATR, V91, P9, DOI 10.1080/080352502753457851; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Missler U, 2000, CLIN CHEM, V46, P993; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; MUIR JK, 2002, J NEUROTRAUM, V19, P1361; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Rothoerl RD, 2000, ACTA NEUROCHIR, V142, P199, DOI 10.1007/s007010050024; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; RZIGALINSKI BA, 1998, J NEUROTRAUM, V15, P894; RZIGALINSKI BA, 1999, J NEUROTRAUM, V16, P962; Schreiber D., 1995, P 1995 INT RES C BIO, P233; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; Slemmer JE, 2002, BRAIN, V125, P2699, DOI 10.1093/brain/awf271; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; Van Eldik LJ, 2003, RESTOR NEUROL NEUROS, V21, P97; VANELDIK LJ, 1988, J BIOL CHEM, V263, P7830; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082	40	40	42	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	DEC	2004	91	6					1284	1291		10.1111/j.1471-4159.2004.02812.x			8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	884VX	WOS:000226115900004	15584905	Bronze			2021-06-18	
J	Han, Y; Ciuffreda, KJ; Kapoor, N				Han, Y; Ciuffreda, KJ; Kapoor, N			Reading-related oculomotor testing and training protocols for acquired brain injury in humans	BRAIN RESEARCH PROTOCOLS			English	Article						oculomotor rehabilitation; reading; traumatic brain injury (TBI); cerebral vascular accident (CVA, stroke); acquired brain injury (ABI); oculomotor adaptation; visual attention; visual feedback; auditory feedback	EYE-MOVEMENTS	Many individuals with acquired brain injury (ABI) report reading problems of oculomotor origin. These may include frequent loss of place, skipping of lines and difficulty shifting to the next line of print. We describe two protocols for the testing and training of reading-related eye movements in adult individuals with ABI (traumatic brain injury [7131] and stroke with hemianopia), who experience oculomotor-based symptoms when reading. These protocols use objective eye movement recording techniques and computer-based stimulus presentation and analysis. One protocol tests and the other trains basic horizontal and vertical versional eye movements (fixation, saccades and pursuit), as well as reading eye movements using simulated single and multiple line dynamic arrays. In addition, a reading rating-scale questionnaire is administered before and after completion of training to assess subjective reading improvement. In all paradigms, the target consists of a 0.5degrees luminous square, which is displayed on a computer monitor positioned 40 cm from the subject along the midline. All testing and training are conducted under binocular viewing conditions with optical correction in place. There are two modes of training: normal internal oculomotor visual feedback either alone (4 weeks) or in conjunction with external oculomotor auditory feedback (4 weeks) administered in a counterbalanced manner within each diagnostic group. Training is performed 1 h, twice weekly for the 8 weeks. Oculomotor testing is conducted before, midway and after training. Following training, reading-related eye movements and reading ability improved as assessed both subjectively and objectively. These protocols provide a systematic approach to the quantitative and comprehensive testing and training of reading-related eye movement skills and behaviors in the ABI population manifesting oculomotor-based reading dysfunctions. Furthermore, the training protocol results in the rapid remediation of the eye movement deficits, which appear to transfer to activities of daily living. (C) 2004 Elsevier B.V. All rights reserved.	SUNY Coll Optometry, Dept Vis Sci, Raymond J Greenwald Rehabil Ctr, New York, NY 10036 USA; SUNY Coll Optometry, Dept Clin Sci, Raymond J Greenwald Rehabil Ctr, New York, NY 10036 USA	Ciuffreda, KJ (corresponding author), SUNY Coll Optometry, Dept Vis Sci, Raymond J Greenwald Rehabil Ctr, 33 W 42nd St, New York, NY 10036 USA.	kciuffreda@sunyopt.edu					Benjamin W. J., 1998, BORISHS CLIN REFRACT; Ciuffreda K., 1991, AMBLYOPIA BASIC CLIN; Ciuffreda K. J., 1996, J BEHAV OPTOM, V7, P31; CIUFFREDA KJ, 1983, AM J OPTOM PHYS OPT, V60, P242; CIUFFREDA KJ, 1976, AM J OPTOM PHYS OPT, V53, P389; CIUFFREDA KJ, 1985, AM J OPTOM PHYS OPT, V62, P844; CIUFFREDA KJ, UNPUB OCULOMOTOR REH; Ciuffreda KJ, 2001, VISUAL VESTIBULAR CO, P77; Ciuffreda KJ, 1995, EYE MOVEMENT BASICS; CIUFFREDA KJ, UNPUB NEUROL REHABIL; COOPER J, 1995, NEURO-OPHTHALMOLOGY, V15, P249, DOI 10.3109/01658109509044610; Cooper J, 2000, J NEURO-OPHTHALMOL, V20, P5, DOI 10.1097/00041327-200020010-00003; Fayos B, 1998, J BEHAV OPTOMETRY, V9, P143; FLETCHER J, 1993, J LEARN DISABIL, V26, P683, DOI 10.1177/002221949302601006; GIANUTSOS R, 2001, VISUAL VESTIBULAR CO, P48; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; GUR S, 1992, ISRAEL J MED SCI, V28, P622; HUNG GK, 1986, IEEE T BIO-MED ENG, V33, P1021, DOI 10.1109/TBME.1986.325868; Kapoor N, 2002, CLIN J PAIN, V18, P93, DOI 10.1097/00002508-200203000-00004; KAPOOR N, IN PRESS NEUROPSYCHI; KATZ M, 1984, AM J OPTOM PHYS OPT, V61, P196; KENYON RV, 1980, INVEST OPHTH VIS SCI, V19, P60; Koenig G S, 1997, J Am Optom Assoc, V68, P155; Leigh R.J., 1999, NEUROLOGY EYE MOVEME, V3rd ed.; REDING MJ, 1988, STROKE, V19, P1354, DOI 10.1161/01.STR.19.11.1354; ROBINSON GM, 1977, J EXP PSYCHOL HUMAN, V3, P83; Schor C. M., 1983, VERGENCE EYE MOVEMEN; SOLAN HA, 1985, AM J OPTOM PHYS OPT, V62, P812; STARK L, 1977, AM J OPTOM PHYS OPT, V54, P85; Suchoff IB, 2001, VISUAL VESTIBULAR CO; Tannen B, 1989, J Am Optom Assoc, V60, P748; Taylor EA., 1966, FUNDAMENTAL READING; ZIHL J, 1995, BRAIN, V118, P891, DOI 10.1093/brain/118.4.891; Zihl J., 2000, NEUROPSY REHABIL MOD; Zost MG, 2001, DIAGNOSIS MANAGEMENT, P75	35	40	40	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1385-299X			BRAIN RES PROTOC	Brain Res. Protoc.	NOV 1	2004	14	1					1	12		10.1016/j.brainresprot.2004.06.002			12	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	874KJ	WOS:000225349000001	15519946				2021-06-18	
J	Lu, DY; Mahmood, A; Qu, CS; Goussev, A; Lu, M; Chopp, M				Lu, DY; Mahmood, A; Qu, CS; Goussev, A; Lu, M; Chopp, M			Atorvastatin reduction of intracranial hematoma volume in rats subjected to controlled cortical impact	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; hematoma; atorvastatin; rat	TRAUMATIC BRAIN-INJURY; EXPERIMENTAL INTRACEREBRAL HEMORRHAGE; SYNAPTOGENESIS; ANGIOGENESIS; MECHANISMS; ISCHEMIA; PROTECTS; STATINS; EDEMA; CELLS	Object. Atorvastatin, a beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor, has pleiotropic effects such as improving thrombogenic profile, promoting angiogenesis, and reducing inflammatory responses and has shown promise in enhancing neurological functional improvement and promoting neuroplasticity in animal models of traumatic brain injury (TBI), stroke, and intracranial hemorrhage. The authors tested the effect of atorvastatin on intracranial hematoma after TBI. Methods. Mate Wistar rats were subjected to controlled cortical impact, and atorvastatin (1 mg/kg) was orally administered 1 day after TBI and daily for 7 days thereafter. Rats were killed at 1, 8, and 15 days post-TBI. The temporal profile of intraparenchymal hematoma was measured on brain tissue sections by using a MicroComputer Imaging Device and light microscopy. Conclusions. Data in this study showed that intraparenchymal and intraventricular hemorrhages are present 1 day after TBI and are absorbed at 15 days after TBI. Furthermore, atorvastatin reduces the volume of intracranial hematoma 8 days after TBI.	Henry Ford Hlth Sci Ctr, Dept Neurosurg, Detroit, MI USA; Henry Ford Hlth Sci Ctr, Dept Biostat, Detroit, MI USA; Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA; Oakland Univ, Dept Phys, Rochester, MI USA	Chopp, M (corresponding author), Henry Ford Hosp, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS40225] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [P01 42345] Funding Source: Medline		Aktas O, 2003, J EXP MED, V197, P725, DOI 10.1084/jem.20021425; Amin-Hanjani S, 2001, STROKE, V32, P980, DOI 10.1161/01.STR.32.4.980; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Bhasin RR, 2002, ACTA NEUROCHIR SUPPL, V81, P249; Bocan Thomas M A, 2002, Curr Opin Investig Drugs, V3, P1312; Brouet A, 2001, CIRC RES, V89, P866, DOI 10.1161/hh2201.100319; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Dalla Nora E, 2003, J ENDOCRINOL INVEST, V26, P73, DOI 10.1007/BF03345126; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eto M, 2003, ENDOTHELIUM-J ENDOTH, V10, P35, DOI 10.1080/10623320303359; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Golding EA, 2003, J CEREBR BLOOD F MET, V23, P210, DOI 10.1097/01.WCB.0000044739.64940.B5; Gong C, 2001, NEUROSURGERY, V48, P875, DOI 10.1097/00006123-200104000-00037; GOPINATH SP, 1995, J NEUROSURG, V83, P438, DOI 10.3171/jns.1995.83.3.0438; Gryglewski RJ, 2001, ANN NY ACAD SCI, V947, P229; Honjo M, 2002, ARCH OPHTHALMOL-CHIC, V120, P1707; Laufs U, 2000, STROKE, V31, P2442, DOI 10.1161/01.STR.31.10.2442; Laufs U, 2003, EUR J CLIN PHARMACOL, V58, P719, DOI 10.1007/s00228-002-0556-0; Laurer HL, 2000, EUR J TRAUMA, V26, P95, DOI DOI 10.1007/S000680050007; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mason JC, 2002, CIRC RES, V91, P696, DOI 10.1161/01.RES.0000038151.57577.19; Mital S, 2000, AM J PHYSIOL-HEART C, V279, pH2649; Regan RF, 2003, J NEUROTRAUM, V20, P111, DOI 10.1089/08977150360517236; Seyfried D, 2004, J NEUROSURG, V101, P104, DOI 10.3171/jns.2004.101.1.0104; Sparks D L, 2002, J Nutr Health Aging, V6, P324; Wagner KR, 2003, J CEREBR BLOOD F MET, V23, P629, DOI 10.1097/01.WCB.0000073905.87928.6D; Xi GH, 2001, STROKE, V32, P2932, DOI 10.1161/hs1201.099820	30	40	40	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2004	101	5					822	825		10.3171/jns.2004.101.5.0822			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	873UL	WOS:000225306500014	15540921				2021-06-18	
J	Wade, SL; Taylor, HG; Drotar, D; Stancin, T; Yeates, KO; Minich, NM				Wade, SL; Taylor, HG; Drotar, D; Stancin, T; Yeates, KO; Minich, NM			Interpersonal stressors and resources as predictors, of parental adaptation following pediatric traumatic injury	JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY			English	Article							BRAIN-INJURY; SOCIAL SUPPORT; FAMILY BURDEN; INITIAL YEAR; CHILDREN; IMPACT; ADOLESCENTS; DEPRESSION; RECOVERY; BEHAVIOR	The authors examined the relationship of preinjury interpersonal resources and stressors to parental adaptation following pediatric traumatic brain injury (TBI) and orthopedic injury. Parents of children with severe TBI (n = 53), moderate TBI (n = 56), and orthopedic injuries (n = 80) were assessed soon after injury, 6 and 12 months after the initial evaluation, and at an extended follow-up with a mean of 4 years postinjury. General linear model analyses provide support for both main and moderating effects of stressors and resources on parental adjustment. Support from friends and spouse was associated with less psychological distress, whereas family and spouse stressors were associated with greater distress. The results also reveal a marked decline in injury-related stress over follow-up for families in the severe TBI group who reported a combination of high stressors and high resources. The decline suggests that interpersonal resources attenuated long-term family burden because of severe TBI. The findings are discussed in terms of their implications for intervention following TBI.	Cincinnati Childrens Hosp Med Ctr, Div Pediat Phys Med & Rehabil, Dept Pediat, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; Univ Hosp Hlth Syst, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; Metrohlth Med Ctr, Cleveland, OH 44109 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Columbus Childrens Hosp, Columbus, OH USA	Wade, SL (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Pediat Phys Med & Rehabil, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org	Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36335] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036335] Funding Source: NIH RePORTER		ABBEY A, 1995, J PERS SOC PSYCHOL, V68, P455, DOI 10.1037/0022-3514.68.3.455; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROWN GW, 1986, PSYCHOL MED, V16, P813, DOI 10.1017/S0033291700011831; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; CICCHETTI DV, 1994, J CLIN EXP NEUROPSYC, V16, P339, DOI 10.1080/01688639408402644; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037/0033-2909.98.2.310; CRINIC KA, 1983, CHILD DEV, V54, P209; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DEROGATIS LR, 1982, BRIEF SYMPTOM INVENT, V1; DUNKELSCHETTER C, 1984, J SOC ISSUES, V40, P77, DOI 10.1111/j.1540-4560.1984.tb01108.x; EWART CK, 1991, HEALTH PSYCHOL, V10, P155, DOI 10.1037/0278-6133.10.3.155; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FINCH JF, 1989, AM J COMMUN PSYCHOL, V17, P585, DOI 10.1007/BF00922637; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; FRANCIS DJ, 1994, NEUROPSYCHOL REV, V4, P199, DOI 10.1007/BF01874892; Harris T, 1999, BRIT J PSYCHIAT, V174, P225, DOI 10.1192/bjp.174.3.225; Holahan CJ, 1997, J PERS SOC PSYCHOL, V72, P918, DOI 10.1037/0022-3514.72.4.918; Holmbeck GN, 1997, J CONSULT CLIN PSYCH, V65, P599, DOI 10.1037/0022-006X.65.4.599; JENNETT B, 1975, LANCET, V1, P480; KIECOLTGLASER JK, 1988, AM J COMMUN PSYCHOL, V16, P825, DOI 10.1007/BF00930895; KIECOLTGLASER JK, 1993, PSYCHOSOM MED, V55, P395, DOI 10.1097/00006842-199309000-00001; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Marks M, 1993, NeuroRehabilitation, V3, P1, DOI 10.3233/NRE-1993-3303; MASTEN AS, 1988, J CHILD PSYCHOL PSYC, V29, P745, DOI 10.1111/j.1469-7610.1988.tb00751.x; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 1998, ARCH PHYS MED REHAB, V79, P893, DOI 10.1016/S0003-9993(98)90084-3; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; Moos R, 1994, LIFE STRESSORS SOCIA; Moos RH, 1998, J FAM PSYCHOL, V12, P326, DOI 10.1037/0893-3200.12.3.326; MORGANDL, 1997, J CLIN GEROPSYCHOLOG, V3, P73; NORRIS VK, 1990, GERONTOLOGIST, V30, P535, DOI 10.1093/geront/30.4.535; PAGEL MD, 1987, J PERS SOC PSYCHOL, V53, P793, DOI 10.1037/0022-3514.53.4.793; RHODES JE, 1995, J COMMUNITY PSYCHOL, V23, P74, DOI 10.1002/1520-6629(199501)23:1<74::AID-JCOP2290230107>3.0.CO;2-D; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; ROOK KS, 1992, SER CLIN C, P157; ROOK KS, 1990, J SOC CLIN PSYCHOL, V9, P118, DOI 10.1521/jscp.1990.9.1.118; ROOK KS, 1984, J PERS SOC PSYCHOL, V46, P1097, DOI 10.1037/0022-3514.46.5.1097; Rook KS, 1998, DARK SIDE OF CLOSE RELATIONSHIPS, P369; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; *SAS I, 1990, STAT AN SYST VERS 6; Schafer JL., 1997, ANAL INCOMPLETE MULT; SCHEIER MF, 1992, COGNITIVE THER RES, V16, P201, DOI 10.1007/BF01173489; SCHUSTER TL, 1990, AM J COMMUN PSYCHOL, V18, P423, DOI 10.1007/BF00938116; Smith Carol E., 1994, Annals of Behavioral Medicine, V16, P352; Stein R, 1985, PACTS PAPERS AECOM T; STEPHENS MAP, 1987, PSYCHOL AGING, V2, P125, DOI 10.1037/0882-7974.2.2.125; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Taylor HG, 2000, NEUROPSYCHOLOGY, V14, P509, DOI 10.1037/0894-4105.14.4.509; WAALAND P, 1991, NEUROPSYCHOL REHABIL, V1, P19; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; ZARSKI J, 1988, J HEAD TRAUMA REHAB, V3, P31	62	40	40	0	9	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0022-006X			J CONSULT CLIN PSYCH	J. Consult. Clin. Psychol.	OCT	2004	72	5					776	784		10.1037/0022-006X.72.5.776			9	Psychology, Clinical	Psychology	858TU	WOS:000224215600004	15482036				2021-06-18	
J	Koponen, S; Taiminen, T; Kairisto, V; Portin, R; Isoniemi, H; Hinkka, S; Tenovuo, O				Koponen, S; Taiminen, T; Kairisto, V; Portin, R; Isoniemi, H; Hinkka, S; Tenovuo, O			APOE-epsilon 4 predicts dementia but not other psychiatric disorders after traumatic brain injury	NEUROLOGY			English	Article							APOLIPOPROTEIN-E POLYMORPHISM; ALZHEIMERS-DISEASE; HEAD-INJURY	The authors studied the association between APOE-epsilon4 genotype and axis I and II psychiatric disorders an average of 30 years after traumatic brain injury. Sixty patients were dichotomized into subjects with and without APOE-epsilon4 allele. Dementia and subclinical dementia were significantly more common with the presence of APOE-epsilon4. The occurrence of other psychiatric disorders did not differ between patients with and without APOE-epsilon4 allele.	Turku Univ Hosp, Dept Psychiat, FIN-20521 Turku, Finland; Turku Univ Hosp, Dept Clin Chem & Hematol, FIN-20521 Turku, Finland; Turku Univ Hosp, Dept Neurol, FIN-20521 Turku, Finland; Turku Univ Hosp, Dept Biostat, FIN-20521 Turku, Finland	Koponen, S (corresponding author), Turku Univ Hosp, Dept Psychiat, PL 52, FIN-20521 Turku, Finland.	salla.koponen@utu.fi					Donohoe GG, 1999, CLIN CHEM, V45, P143; EHNHOLM C, 1986, J LIPID RES, V27, P227; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Mauricio M, 2000, AM J GERIAT PSYCHIAT, V8, P196, DOI 10.1176/appi.ajgp.8.3.196; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Sorbi S, 1998, NEUROSCI LETT, V244, P118, DOI 10.1016/S0304-3940(98)00144-X; Spitzer R.L., 1989, STRUCTURED CLIN INTE; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; WING JK, 1990, ARCH GEN PSYCHIAT, V47, P589	10	40	42	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	AUG 24	2004	63	4					749	750		10.1212/01.WNL.0000134603.57107.2F			2	Clinical Neurology	Neurosciences & Neurology	848UP	WOS:000223493800035	15326261				2021-06-18	
J	Gupta, AK; Zygun, DA; Johnston, AJ; Steiner, LA; Al-Rawi, PG; Chatfield, D; Shepherd, E; Kirkpatrick, PJ; Hutchinson, PJ; Menon, DK				Gupta, AK; Zygun, DA; Johnston, AJ; Steiner, LA; Al-Rawi, PG; Chatfield, D; Shepherd, E; Kirkpatrick, PJ; Hutchinson, PJ; Menon, DK			Extracellular brain pH and outcome following severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						brain tissue pH; outcome; traumatic brain injury	CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; POSITRON-EMISSION-TOMOGRAPHY; VENOUS OXYGEN-SATURATION; NEUROSURGICAL PATIENTS; SUBSTRATE DELIVERY; MICRODIALYSIS; METABOLISM; HYPEROXIA; ISCHEMIA	The ability to measure brain tissue chemistry has led to valuable information regarding pathophysiological changes in patients with traumatic brain injury (TBI). Over the last few years, the focus has been on monitoring changes in brain tissue oxygen to determine thresholds of ischemia that affect outcome. However, the variability of this measurement suggests that it may not be a robust method. We have therefore investigated the relationship of brain tissue pH (pH(b)) and outcome in patients with TBI. We retrospectively analyzed prospectively collected data of 38 patients admitted to the Neurosciences Critical Care Unit with TBI between 1998 and 2003, and who had a multiparameter tissue gas sensor inserted into the brain. All patients were managed using an evidence-based protocol targeting CPP > 70 min Hg. Physiological variables were averaged over 4 min and analyzed using a generalized least squares random effects model to determine the temporal profile of pHb and its association with outcome. Median (IQR) minimum pHb was 7.00 (6.89, 7.08), median (IQR) maximum pHb was 7.25 (7.18, 7.33), and median (IQR) patient averaged pH(b) was 7.13 (7.07, 7.17). pH(b) was significantly lower in those who did not survive their hospital stay compared to those that survived. In addition, those with unfavorable neurological outcome had lower pH(b) values than those with favorable neurological outcome. pH(b) differentiated between survivors and non-survivors. Measurement of pH(b) may be a useful indicator of outcome in patients with TBI.	Addenbrookes Hosp, Neurosci Crit Care Unit, Dept Anesthesia, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Anesthesia, Cambridge CB2 2QQ, England; Univ Calgary, Dept Crit Care Med, Calgary, AB, Canada	Gupta, AK (corresponding author), Addenbrookes Hosp, Neurosci Crit Care Unit, Dept Anesthesia, Box 93,Hills Rd, Cambridge CB2 2QQ, England.	akg01@globalnet.co.uk	Steiner, Luzius/J-1987-2019				Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bouma G J, 1995, New Horiz, V3, P384; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Gupta AK, 2002, J NEUROSURG, V96, P263, DOI 10.3171/jns.2002.96.2.0263; Hoffman WE, 1996, ANESTH ANALG, V82, P582, DOI 10.1097/00000539-199603000-00027; Hutchinson PJA, 2000, BRIT J NEUROSURG, V14, P46; INOA S, 1988, J NEUROSURG, V69, P736; Johnston AJ, 2003, ACTA ANAESTH SCAND, V47, P391, DOI 10.1034/j.1399-6576.2003.00078.x; Kett-White R, 2002, NEUROSURGERY, V50, P1213, DOI 10.1097/00006123-200206000-00008; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; LJUNGGREN B, 1974, BRAIN RES, V73, P277, DOI 10.1016/0006-8993(74)91049-X; Marchal G, 1999, BRAIN, V122, P2387, DOI 10.1093/brain/122.12.2387; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; SALVANT JB, 1993, NEUROSURGERY, V33, P387; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; VANSANTBRINK H, 2003, ACTA NEUROSURG, V46, P868; Zauner A, 1997, NEUROL RES, V19, P265, DOI 10.1080/01616412.1997.11740812; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	25	40	40	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2004	21	6					678	684		10.1089/0897715041269722			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	836EG	WOS:000222537600004	15253796				2021-06-18	
J	Steiner, J; Rafols, D; Park, HK; Katar, MS; Rafols, JA; Petrov, T				Steiner, J; Rafols, D; Park, HK; Katar, MS; Rafols, JA; Petrov, T			Attenuation of iNOS mRNA exacerbates hypoperfusion and upregulates endothelin-1 expression in hippocampus and cortex after brain trauma	NITRIC OXIDE-BIOLOGY AND CHEMISTRY			English	Article						brain; endothelin-1; iNOS; microcirculation; antisense mRNA; in situ hybridization	NITRIC-OXIDE SYNTHASE; PROTEIN-SYNTHESIS; CEREBRAL-CIRCULATION; NEURONAL NOS; HEAD TRAUMA; BLOOD-FLOW; INJURY; RAT; PHOSPHORYLATION; HYPOTENSION	Nitric oxide (NO, a vasodilator) and endothelin-1 (ET-1, a powerful vasoconstrictor) participate in the regulation of brain's microcirculation influencing each other's expression and synthesis. Following injury to the brain, NO is derived largely from the inducible form of nitric oxide synthase (NOS). We used Marmarou's model of traumatic brain injury (TBI) to study the cerebral blood flow and expression (mRNA) of ET-1 in rats that were pretreated with antisense iNOS oligodeoxynucleotides (ODNs). Intracerebroventricular application of iNOS ODNs resulted in reduced synthesis of iNOS as detected by Western blot analysis. The cerebral blood flow (measured by laser Doppler flowmetry), generally decreased after TBI, was further markedly reduced in the treated animals and remained at low levels up to 48 It post-TBI. The expression of ET-1 (detected by in situ hybridization in cortex and hippocampus) was increased 2-3-fold following TBI alone and this increase reached 5-6-fold in animals pretreated with antisense iNOS ODNs. The results indicate that most likely, NO, generated primarily by iNOS, suppresses ET-1 production and that a decrease of NO results in upregulation of ET-I via transcriptional and translational mechanisms. Increased availability of ET-1 at the vascular bed and the neuropil may contribute to the altered microvascular reactivity and reduced perfusion of the brain following TBI. (C) 2004 Elsevier Inc. All rights reserved.	Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Neurol Surg, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Immunol & Microbiol, Detroit, MI 48201 USA	Petrov, T (corresponding author), Wayne State Univ, Sch Med, Dept Anat & Cell Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.	tpetrov@med.wayne.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039860] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39860] Funding Source: Medline		Armstead WM, 1999, AM J PHYSIOL-HEART C, V277, pH1884; ASHKENAZI A, 1989, NATURE, V340, P146, DOI 10.1038/340146a0; Atkins CM, 1999, J NEUROSCI, V19, P7241, DOI 10.1523/JNEUROSCI.19-17-07241.1999; Buchwald AB, 2002, J AM COLL CARDIOL, V39, P732, DOI 10.1016/S0735-1097(01)01797-1; BUXTON ILO, 1993, CIRC RES, V72, P387, DOI 10.1161/01.RES.72.2.387; CAZABON SM, 1998, INTRO BLOOD BRAIN BA, P338; Chen Y, 2003, AM J PHYSIOL-CELL PH, V284, pC243, DOI 10.1152/ajpcell.00305.2002; CHIASSON BJ, 1994, CELL MOL NEUROBIOL, V14, P507, DOI 10.1007/BF02088834; Cui JK, 2001, J BIOMED SCI, V8, P336, DOI 10.1007/BF02258375; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; FARACI FM, 1994, STROKE, V25, P692, DOI 10.1161/01.STR.25.3.692; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; HIROSE H, 1995, EUR J PHARMACOL, V277, P77, DOI 10.1016/0014-2999(95)00070-2; Kim YM, 1998, MOL MED, V4, P179, DOI 10.1007/BF03401915; Knerlich F, 1999, MOL BRAIN RES, V68, P73, DOI 10.1016/S0169-328X(99)00064-9; KOUREMBANAS S, 1993, J CLIN INVEST, V92, P99, DOI 10.1172/JCI116604; Lavallee M, 2001, Heart Fail Rev, V6, P265; LEFFLER CW, 1986, CIRC RES, V59, P562, DOI 10.1161/01.RES.59.5.562; MACRAE IM, 1993, J CEREBR BLOOD F MET, V13, P276, DOI 10.1038/jcbfm.1993.34; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; NEGUS RPM, 1995, J CLIN INVEST, V95, P2391, DOI 10.1172/JCI117933; PARK HK, 1999, J MENTAL HLTH, V3, P32; PETROV T, 1995, NEUROPHARMACOLOGY, V34, P509, DOI 10.1016/0028-3908(95)00002-N; Petrov T, 1995, J NEUROSCI RES, V42, P835, DOI 10.1002/jnr.490420612; Petrov T, 2003, J NEUROL SCI, V209, P31, DOI 10.1016/S0022-510X(02)00461-6; Petrov T, 2002, NEUROSCIENCE, V115, P275, DOI 10.1016/S0306-4522(02)00345-7; Petrov T, 2001, J NEUROTRAUM, V18, P799, DOI 10.1089/089771501316919166; Petrov T, 2001, NEUROL RES, V23, P139, DOI 10.1179/016164101101198479; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; Sercombe R, 2002, JPN J PHARMACOL, V88, P227, DOI 10.1254/jjp.88.227; Sventek P, 1996, HYPERTENSION, V27, P49, DOI 10.1161/01.HYP.27.1.49; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; SZYMKOWSKI DE, 2002, DRUG DISCOV TODAY, V7, P107, DOI DOI 10.1016/S1359-6446(01)02123-7; Takahashi A, 1997, ACTA NEUROPATHOL, V93, P354, DOI 10.1007/s004010050627; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Zingarelli B, 2002, FASEB J, V16, DOI 10.1096/fj.01-0533com	37	40	46	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1089-8603	1089-8611		NITRIC OXIDE-BIOL CH	Nitric Oxide-Biol. Chem.	MAY	2004	10	3					162	169		10.1016/j.niox.2004.03.005			8	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	828LG	WOS:000221974200006	15158696				2021-06-18	
J	Peloso, PM; Von Holst, H; Borg, J				Peloso, PM; Von Holst, H; Borg, J			Mild traumatic brain injuries presenting to Swedish hospitals in 1987-2000	JOURNAL OF REHABILITATION MEDICINE			English	Article						mild traumatic brain injury; epidemiology; incidence; aetiology	EXTERNAL CAUSES; HEAD-INJURY; EPIDEMIOLOGY; RESTRAINT; COMMUNITY; INCREASE; SEVERITY; OUTCOMES; CHILDREN; SWEDEN	Objective: To evaluate the incidence and causes of mild traumatic brain injury in Sweden. Design: Retrospective, population-based incidence cohort study. Subjects: All persons presenting to hospitals in Sweden between 1987 and 2000 with a discharge diagnosis of ICD-9 code 850 and ICD-10 code S0.60. Methods: Data source was the Hospital Discharge Register at the National Board of Health and Welfare ( Sweden). Incidence rates are stratified by age, gender, mechanism of injury and length of hospital stay. Results: Men had a mean of 209 mild traumatic brain injuries per 100,000 inhabitants and women averaged 148 per 100,000. Men had more mild traumatic brain injury than women at all ages. There were 2 incidence peaks, in the age strata 16-20 years and those over 65 years. Falls were the most common cause of mild traumatic brain injury overall and occurred commonly under the age of 10 years and over the age of 65 years. Motor vehicle and bicycle injuries were the second and third most common causes of mild traumatic brain injury, and had their peak incidence in those aged 16 35 years. Conclusion: Preventative strategies for mild traumatic brain injury should be age and gender specific.	Univ Iowa Hlth Care, Roy & Lucille Carver Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Karolinska Inst, Dept Neurosurg, Stockholm, Sweden; Uppsala Univ, Dept Neurosci, Uppsala, Sweden	Peloso, PM (corresponding author), Univ Iowa Hlth Care, Roy & Lucille Carver Coll Med, Dept Internal Med, Room E 330 GH,200 Hawkins Dr, Iowa City, IA 52242 USA.	paul-peloso@uiowa.edu		Borg, Jorgen/0000-0002-2372-7478			BRITTON M, 2000, 153 SBU SWED COUNC T; CARLSSON G, 1991, ACCIDENT ANAL PREV, V23, P175, DOI 10.1016/0001-4575(91)90047-9; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; *CTR EP SWED NAT B, 2002, SWED HOSP DISCH REG; Ekman R, 2001, ACCIDENT ANAL PREV, V33, P793, DOI 10.1016/S0001-4575(00)00093-2; Ekman R, 1997, ACCIDENT ANAL PREV, V29, P321, DOI 10.1016/S0001-4575(96)00086-3; Engberg A, 1998, EUR J EPIDEMIOL, V14, P165, DOI 10.1023/A:1007492025190; Gillespie LD, 2001, COCHRANE DB SYST REV, V3; Hung C C, 1991, J Formos Med Assoc, V90, P1227; Ingebrigtsen T, 1998, NEUROEPIDEMIOLOGY, V17, P139, DOI 10.1159/000026165; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRAUS JF, 1985, J OCCUP ENVIRON MED, V27, P757; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; KRAUS JF, 1987, AM J PUBLIC HEALTH, V77, P76, DOI 10.2105/AJPH.77.1.76; SCHELP L, 1990, PUBLIC HEALTH, V104, P55, DOI 10.1016/S0033-3506(05)80346-4; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; Wilmoth JR, 2000, SCIENCE, V289, P2366, DOI 10.1126/science.289.5488.2366	23	40	40	0	0	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	FEB	2004	36			43			22	27		10.1080/16501960410023714			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	800QR	WOS:000220043300006	15083869	DOAJ Gold			2021-06-18	
J	Drew, LB; Drew, WE				Drew, LB; Drew, WE			The contrecoup-coup phenomenon - A new understanding of the mechanism of closed head injury	NEUROCRITICAL CARE			English	Article						biomechanics; traumatic brain injury; pathology; contrecoup lesion	CEREBRAL CONTUSIONS; IMPACT	A common observation in closed head injuries is the contrecoup brain injury. As the in vivo brain is less dense than the cerebrospinal fluid (CSF), one hypothesis explaining this observation is that upon skull impact, the denser CSF moves toward the site of skull impact displacing the brain in the opposite direction, such that the initial impact of the brain parenchyma is at the contrecoup location. A simple model was developed consisting of a balloon filled with water of density 1.00 g/mL enclosed in a clear plastic jar containing salt water of density 1.04 g/mL, simulating the same relative densities of the CSF and brain. The initial movement of the balloon, modeling the brain, was toward the contrecoup location with subsequent movement toward the coup location. The pattern of brain injury in which the contrecoup injury is greater than the coup injury is a result of initial movement of the brain in the contrecoup location. During the process of closed head injury, the brain parenchyma is initially displaced away from the site of skull impact and toward the contrecoup site resulting in the more severe brain contusion.	Oakwood High Sch, Dayton, OH 45419 USA; Wright Patterson Med Ctr, Wright Patterson AFB, OH USA	Drew, LB (corresponding author), Oakwood High Sch, 1200 Far Hills Ave, Dayton, OH 45419 USA.	BrightEyesDear@Hotmail.com					DAWSON SL, 1980, HUM PATHOL, V11, P155, DOI 10.1016/S0046-8177(80)80136-5; Graham D.I., 2002, GREENFIELDS NEUROPAT; GURDJIAN ES, 1968, GEN PRACT, V37, P78; GURDJIAN ES, 1976, J TRAUMA, V16, P35, DOI 10.1097/00005373-197601000-00005; GURDJIAN ES, 1962, JAMA-J AM MED ASSOC, V182, P509, DOI 10.1001/jama.1962.03050440001001; Guyton A C, 2000, TXB MED PHYSL; Halliday D., 1970, FUNDAMENTALS PHYS; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Huang HM, 2000, MED BIOL ENG COMPUT, V38, P253, DOI 10.1007/BF02347044; Knight B., FORENSIC PATHOLOGY, V3rd; LINDENBERG R, 1960, ARCH PATHOL, V69, P440; LINDENBERG R, 1971, PATHOLOGY NERVOUS SY; LINDENBERG R, 1973, MEDICOLEGAL INVESTIG; VINKEN PJ, 1990, HEAD INJURY, V57	15	40	41	0	18	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care		2004	1	3					385	390		10.1385/NCC:1:3:385			6	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	945FQ	WOS:000230488800017	16174940				2021-06-18	
J	Rogatsky, GG; Sonn, J; Kamenir, Y; Zarchin, N; Mayevsky, A				Rogatsky, GG; Sonn, J; Kamenir, Y; Zarchin, N; Mayevsky, A			Relationship between intracranial pressure and cortical spreading depression following fluid percussion brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						cortical spreading depression; head injury; intracranial pressure; post-traumatic hypoxic insult	COMPRESSION CONTUSION TRAUMA; CEREBRAL BLOOD-FLOW; AMINO-ACID RELEASE; SEVERE HEAD-INJURY; CALCIUM TRANSIENTS; ENERGY-METABOLISM; ISCHEMIA; DAMAGE; MODEL; OXYGENATION	Traumatic brain injury (TBI) is known to be accompanied by an increase in intracranial pressure (ICP) and in some cases, by spontaneous generation of cortical spreading depression (CSD) cycles. However, the role of CSD in the pathophysiology of cerebral contusion is still unknown. A multi-parametric monitoring assembly was placed on the right hemisphere of the rat brain to evaluate ICP, DC potential, extracellular K+, cerebral blood flow (CBF), and electrocorticogram in 27 rats during 5 h. Fluid percussion brain injury (FPBI) with the magnitude of the impact 2.9, 3.3, 4.1, and 5.0 atmospheres was induced to the left parietal cortex in animal groups A, B, C, and D, respectively. A slow increase in ICP was evident, and was pronounced in group C and especially in group D, where four of nine animals died during the monitoring. At the end of the 5 h experiment, the mean ICP levels were 6.75 +/- 2.87, 8.40 +/- 2.70, 12.75 +/- 4.03, 29.56 +/- 9.25, and the mean total number of CSD cycles was 2.00 +/- 1.41, 4.29 +/- 4.23, 11.71 +/- 13.29, and 20.11 +/- 19.26 in groups A, B, C, and D, respectively. The maximal level of intensity of CSD cycle generation after FPBI was obtained in group D, where almost constant activity was maintained until the end of the experiment. A significant coefficient of correlation between ICP level and total number of CSD cycles was found for all ICP measurements (r = 0.47-0.63, p < 0.05, n = 27), however more significant (p < 0.001) was the coefficient during the period of monitoring between 2 and 4 h after FPBI. Our results suggest that numerous repeating CSD cycles are typical phenomena in moderate and especially severe forms of FPBI. The rising number of CSD cycles under condition of an ICP level greater than or equal to20 mm Hg may demonstrate, with high probability, the unfavorable development of TBI, caused by growing secondary hypoxic insult.	Bar Ilan Univ, Fac Life Sci, Ramat Gan, Israel	Mayevsky, A (corresponding author), Bar Ilan Univ, Fac Life Sci, Ramat Gan, Israel.	mayevsa@mail.biu.ac.il					BACK T, 1994, J CEREBR BLOOD F MET, V14, P12, DOI 10.1038/jcbfm.1994.3; Bardt TF, 1998, ACT NEUR S, V71, P153; BENVENISTE H, 1988, ACTA NEUROL SCAND, V78, P529, DOI 10.1111/j.1600-0404.1988.tb03697.x; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Czosnyka M, 1996, ACTA NEUROCHIR, V138, P531, DOI 10.1007/BF01411173; DIETRICH WD, 1994, J CEREBR BLOOD F MET, V14, P20, DOI 10.1038/jcbfm.1994.4; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Engelborghs K, 1997, ACT NEUR S, V70, P123; GIDO G, 1994, EXP BRAIN RES, V97, P397; Gido G, 1994, Neurobiol Dis, V1, P31, DOI 10.1006/nbdi.1994.0005; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Koroleva VI, 1996, P NATL ACAD SCI USA, V93, P3710, DOI 10.1073/pnas.93.8.3710; Koura SS, 1998, ACT NEUR S, V71, P244; KUBOTA M, 1989, Neurosurgical Review, V12, P393, DOI 10.1007/BF01790681; Lang E W, 1995, New Horiz, V3, P400; LAURITZEN M, 1987, ACTA NEUROL SCAND, V76, P9; Manor T, 2003, ADV EXP MED BIOL, V510, P409; Marmarou A, 1990, Adv Neurol, V52, P233; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Mayevsky A, 1998, ACT NEUR S, V71, P78; Mayevsky A, 1996, BRAIN RES, V740, P268, DOI 10.1016/S0006-8993(96)00874-8; MAYEVSKY A, 1992, ADV EXP MED BIOL, V317, P707; MAYEVSKY A, 1995, J APPL PHYSIOL, V78, P1188; Mayevsky A, 1999, ACT NEUR S, V75, P63; Mayevsky A, 1999, ADV EXP MED BIOL, V471, P133; Mayevsky A., 1993, MIGRAINE BASIC MECH, P379; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1992, J NEUROTRAUM, V9, pS317; MUTCH WAC, 1984, J CEREBR BLOOD F MET, V4, P17, DOI 10.1038/jcbfm.1984.3; NEDERGAARD M, 1993, J CEREBR BLOOD F MET, V13, P568, DOI 10.1038/jcbfm.1993.74; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; NORUSIS M. J, 1999, GUIDE DATA ANAL; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Otsuka H, 2000, EXP NEUROL, V162, P201, DOI 10.1006/exnr.1999.7326; OZAWA Y, 1991, Neurologia Medico-Chirurgica, V31, P685, DOI 10.2176/nmc.31.685; PFENNINGER J, 1984, Z KINDERCHIR, V39, P223; PIPER IR, 1990, J NEUROSURG, V73, P871, DOI 10.3171/jns.1990.73.6.0871; Rogatsky G, 1996, J Basic Clin Physiol Pharmacol, V7, P23; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Somjen GG, 2001, PHYSIOL REV, V81, P1065; Sonn J, 2000, BRAIN RES, V882, P212, DOI 10.1016/S0006-8993(00)02827-4; Stocchetti N, 1991, Minerva Anestesiol, V57, P327; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; Takano K, 1996, ANN NEUROL, V39, P308, DOI 10.1002/ana.410390307; Thomas S, 2000, ACTA NEUROCHIR SUPPL, V76, P203; Zauner A, 2002, NEUROSURGERY, V51, P289, DOI 10.1097/00006123-200208000-00003	57	40	40	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2003	20	12					1315	1325		10.1089/089771503322686111			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	756XH	WOS:000187510700004	14748980				2021-06-18	
J	Anderson, KJ; Fugaccia, I; Scheff, SW				Anderson, KJ; Fugaccia, I; Scheff, SW			Fluoro-Jade B stains quiescent and reactive astrocytes in the rodent spinal cord	JOURNAL OF NEUROTRAUMA			English	Article						astrocytes; brain; neuropathology; spinal cord	TRAUMATIC BRAIN-INJURY; CELL-DEATH; NEURONAL DEGENERATION; INTERMEDIATE FILAMENT; CORTICAL CONTUSION; STATUS EPILEPTICUS; RAT HIPPOCAMPUS; ADULT RATS; APOPTOSIS; CORTEX	In an attempt to label dying neurons in the injured spinal cord, we used the novel fluorescein derivative Fluoro-Jade B, which has been reported to specifically label dead or dying neurons in the brain. Rats and mice were subjected to a moderate level of spinal cord injury using an IH impact device and sacrificed at 1, 2, 4, 7, 14, and 21 days post injury. Spinal cord tissue was processed for Fluoro-Jade B histochemistry and included sections throughout the injured region of the cord. No Fluoro-Jade positive neurons were observed in sections from any time point postinjury at any level of the spinal cord. Instead, Fluoro-Jade labeled astrocytes in uninjured control animals and injured animals. The specificity of astrocytic staining was confirmed by co-localizaton of Fluoro-Jade with glial fibrillary acidic protein. We also subjected a group of rats to a sequential cortical contusion injury and spinal cord injury. Sections from these animals showed numerous Fluoro-Jade positive neurons in the hippocampal formation and thalamus underlying the cortical contusion; however, the staining pattern in the spinal cord was identical to those animals that had received spinal cord injury alone.	Univ Kentucky, Sanders Brown Ctr Aging 233, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; Univ Florida, Dept Physiol Sci, Gainesville, FL 32610 USA	Anderson, KJ (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging 233, Lexington, KY 40536 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 39828] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039828] Funding Source: NIH RePORTER		Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; Baldwin SA, 1996, GLIA, V16, P266; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Ballok DA, 2003, BRAIN RES, V964, P200, DOI 10.1016/S0006-8993(02)03980-X; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Bonde C, 2002, NEUROSCI LETT, V327, P49, DOI 10.1016/S0304-3940(02)00382-8; Butler TL, 2002, BRAIN RES, V929, P252, DOI 10.1016/S0006-8993(01)03371-6; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; Colombo JA, 2002, J HISTOCHEM CYTOCHEM, V50, P1135, DOI 10.1177/002215540205000815; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Harkany T, 2001, NEUROSCIENCE, V108, P611, DOI 10.1016/S0306-4522(01)00443-2; Hopkins KJ, 2000, BRAIN RES, V864, P69, DOI 10.1016/S0006-8993(00)02137-5; Krinke GJ, 2001, EXP TOXICOL PATHOL, V53, P365, DOI 10.1078/0940-2993-00202; Kubova H, 2001, J NEUROSCI, V21, P3593, DOI 10.1523/JNEUROSCI.21-10-03593.2001; Lagord C, 2002, MOL CELL NEUROSCI, V20, P69, DOI 10.1006/mcne.2002.1121; Liu XZ, 1997, J NEUROSCI, V17, P5395; LIUZZI FJ, 1987, BRAIN RES, V403, P385, DOI 10.1016/0006-8993(87)90081-3; O'Dell SJ, 2000, SYNAPSE, V37, P32, DOI 10.1002/(SICI)1098-2396(200007)37:1<32::AID-SYN4>3.3.CO;2-O; Obernier JA, 2002, ALCOHOL CLIN EXP RES, V26, P547, DOI 10.1111/j.1530-0277.2002.tb02573.x; Poirier JL, 2000, NEUROSCIENCE, V97, P59, DOI 10.1016/S0306-4522(00)00026-9; Rabchevsky AG, 2001, J NEUROTRAUM, V18, P513, DOI 10.1089/089771501300227314; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Savaskan NE, 2000, BRAIN RES, V864, P44, DOI 10.1016/S0006-8993(00)02148-X; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Shibuya S, 2002, NEUROSCIENCE, V114, P905, DOI 10.1016/S0306-4522(02)00323-8; Sriram K, 2002, NEUROSCIENCE, V115, P1335, DOI 10.1016/S0306-4522(02)00306-8; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Yune TY, 2003, J NEUROTRAUM, V20, P207, DOI 10.1089/08977150360547116	34	40	41	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2003	20	11					1223	1231		10.1089/089771503770802899			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	747BE	WOS:000186784600007	14651809				2021-06-18	
J	Duhaime, AC; Hunter, JV; Grate, LL; Kim, A; Golden, J; Demidenko, E; Harris, C				Duhaime, AC; Hunter, JV; Grate, LL; Kim, A; Golden, J; Demidenko, E; Harris, C			Magnetic resonance imaging studies of age-dependent responses to scaled focal brain injury in the piglet	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; magnetic resonance imaging; contusion; infant; pig	CENTRAL-NERVOUS-SYSTEM; CEREBRAL BLOOD-FLOW; HEAD-INJURY; DEVELOPMENTAL-CHANGES; CORTICAL IMPACT; MINIATURE SWINE; CHILDREN; PRESSURE; EDEMA; METABOLISM	Object. Whether the brain differs in its response to traumatic injury as a function of age remains unclear. To further investigate the age-dependent response of the brain to mechanical trauma, a cortical contusion model scaled for brain growth during maturation was used to study the evolution of injury over time as demonstrated on serial magnetic resonance (MR) imaging studies in piglets of different ages. Methods. Sixteen Yorkshire piglets received scaled cortical contusions. Animals were either 5 days (six animals), I month (five animals), or 4 months (five animals) of age at injury. These ages correspond developmentally to human infants, toddlers, and early adolescents, respectively. Serial MR imaging examinations, including fluid-attenuated inversion-recovery and T-1-, T-2-, and diffusion-weighted sequences were performed at 24 hours, I week, and I month after injury. Lesions were quantified and expressed as a ratio of the lesion volume divided by the volume of the uninjured hemisphere for each animal and each MR sequencing. Differences in relative lesion volume among the varied ages at a single time point and in lesion volume over time at each age were compared. In addition, the relationship between age and evolution of injury were analyzed using a two-compartment mathematical model. Histological features were examined at I month postinjury. Despite comparable injury inputs, the youngest animals had lesions whose volumes peaked earlier and resolved more quickly than those in older animals. The intermediate-age piglets (toddler) had the most pronounced swelling of any age group, and the oldest piglets (adolescent) had the latest peak in lesion volume. Conclusions. Scaled cortical contusions in piglets demonstrated age-dependent differences in injury response, both in magnitude and time course. These observations may shed light on development-related trauma response in the gyrencephalic brain.	Dartmouth Hitchcock Med Ctr, Dept Neurosurg, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Dept Biostat & Epidemiol, Lebanon, NH USA; Baylor Coll Med, Texas Childrens Hosp, Dept Neuroradiol, Houston, TX 77030 USA; Childrens Hosp Philadelphia, Dept Neuropathol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Neuroradiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA	Duhaime, AC (corresponding author), Dartmouth Hitchcock Med Ctr, Dept Neurosurg, 1 Med Ctr Dr, Lebanon, NH 03756 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29 NS37132] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29NS037132] Funding Source: NIH RePORTER		ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Baskaya MK, 2000, J NEUROTRAUM, V17, P93, DOI 10.1089/neu.2000.17.93; Brodhun M, 2001, ACTA NEUROPATHOL, V101, P424; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; DICKERSON JW, 1967, PROC R SOC SER B-BIO, V166, P384, DOI 10.1098/rspb.1967.0002; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Durham SR, 2000, PEDIATR NEUROSURG, V33, P76, DOI 10.1159/000028980; FLYNN TJ, 1984, NEUROCHEM RES, V9, P935, DOI 10.1007/BF00964525; GREENBERG RS, 1994, CRIT CARE MED, V22, P384, DOI 10.1097/00003246-199403000-00006; HARADA J, 1991, J NEUROSURG, V75, P103, DOI 10.3171/jns.1991.75.1.0103; JAKOBSSON KE, 1995, NEUROL RES, V17, P217, DOI 10.1080/01616412.1995.11740315; Kobayashi Ayame, 1996, No To Hattatsu, V28, P501; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; MADSEN FF, 1987, ACTA NEUROCHIR, V88, P65, DOI 10.1007/BF01400517; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; PAMPIGLIONE G, 1971, P ROY SOC MED, V64, P429, DOI 10.1177/003591577106400441; Prough DS, 1999, J NEUROSURG ANESTH, V11, P102, DOI 10.1097/00008506-199904000-00006; ROSNER MJ, 1987, NEUROSURGERY, V21, P147, DOI 10.1227/00006123-198708000-00003; Seber G.A.F., 1989, NONLINEAR REGRESSION; Shaver EG, 1996, PEDIATR NEUROSURG, V25, P123, DOI 10.1159/000121109; Takahashi T, 1999, AM J NEURORADIOL, V20, P917; THOMAS JM, 1971, GROWTH, V35, P259; TROUPP H, 1971, ACTA NEUROCHIR, V24, P89, DOI 10.1007/BF01403314; WOOTTON R, 1982, BIOL NEONATE, V41, P209; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	27	40	40	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	2003	99	3					542	548		10.3171/jns.2003.99.3.0542			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	715JZ	WOS:000184969500016	12959443				2021-06-18	
J	Malik, AS; Narayan, RK; Wendling, WW; Cole, RW; Pashko, LL; Schwartz, AG; Strauss, KI				Malik, AS; Narayan, RK; Wendling, WW; Cole, RW; Pashko, LL; Schwartz, AG; Strauss, KI			A novel dehydroepiandrosterone analog improves functional recovery in a rat traumatic brain injury model	JOURNAL OF NEUROTRAUMA			English	Article						cyclooxygenase-2; neurosteroid; rat traumatic brain injury	SYSTEMIC-LUPUS-ERYTHEMATOSUS; BOVINE CEREBRAL-ARTERIES; INDUCIBLE CYCLOOXYGENASE; LIPID-PEROXIDATION; SULFATE; INHIBITION; NEURONS; MEMORY; MICE; STEROIDS	The purpose of this study was to investigate the efficacy of a novel steroid, fluasterone (DHEF, a dehydroepiandrosterone (DHEA) analog), at improving functional recovery in a rat model of traumatic brain injury (TBI). The lateral cortical impact model was utilized in two studies of efficacy and therapeutic window. DHEF was given (25 mg/kg, intraperitoneally) at the initial time point and once a day for 2 more days. Study A included four groups: sham injury, vehicle treated (n = 22); injured, vehicle treated (n = 30); injured, pretreated (5-10 min prior to injury, n = 24); and injured, posttreated (initial dose 30 min postinjury, n = 15). Study B (therapeutic window) included five groups: sham injury, vehicle treated (n = 17); injured, vehicle treated (n = 26); and three post-treatment groups: initial dose at 30 min (n = 18), 2 h (n = 23), or 12 h (n = 16) postinjury. Three criteria were used to grade functional recovery. In study A, DHEF improved beam walk performance both with pretreatment (79%) and 30-min posttreatment group (54%; p < 0.01, Dunnett vs. injured vehicle). In study B, the 12-h posttreatment group showed a 97% improvement in beam walk performance (p < 0.01, Dunnett). The 30-min and 12-h posttreatment groups showed a decreased incidence of falls from the beam, which reached statistical significance (p < 0.05, Dunnett). Tests of memory (Morris water maze) and neurological reflexes both revealed significant improvements in all DHEF treatment groups. In cultured rat mesangial cells, DHEF (and DHEA) potently inhibited interleukin-1beta-induced cyclooxygenase-2 (COX2) mRNA and prostaglandin (PGE2) production. In contrast, DHEF treatment did not alter injury-induced COX2 mRNA levels in the cortex or hippocampus. However, DHEF (and DHEA) relaxed ex vivo bovine middle cerebral artery preparations by about 30%, with an IC50 approximate to 40 muM. This was a direct effect on the vascular smooth muscle, independent of the endothelial cell layer. Fluasterone (DHEF) treatments improved functional recovery in a rat TBI model. Possible mechanisms of action for this novel DHEA analog are discussed. These findings suggest an exciting potential use for this agent in the clinical treatment of traumatic brain injury.	Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA; Univ Texas, Hlth Sci Ctr, Dept Neurosurg, Houston, TX USA; Temple Univ, Sch Med, Dept Anesthesia, Philadelphia, PA 19122 USA; Temple Univ, Sch Med, Fels Inst, Philadelphia, PA 19122 USA	Strauss, KI (corresponding author), 231 Albert Sabin Way ML515, Cincinnati, OH 45267 USA.	kstrauss@uc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038654] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS038654, R01 NS38654] Funding Source: Medline		Aragno M, 2000, BIOCHEM PHARMACOL, V60, P389, DOI 10.1016/S0006-2952(00)00327-0; BABIOR BM, 1982, CAN J PHYSIOL PHARM, V60, P1353, DOI 10.1139/y82-202; Baulieu EE, 1996, J ENDOCRINOL, V150, pS221; Boccuzzi G, 1997, FREE RADICAL BIO MED, V22, P1289, DOI 10.1016/S0891-5849(96)00543-6; BOLOGA L, 1987, J NEUROSCI RES, V17, P225, DOI 10.1002/jnr.490170305; BREEN RA, 1961, J COMP PHYSIOL PSYCH, V54, P498, DOI 10.1037/h0046436; CERRO SD, 1995, GLIA, V14, P65; Derksen RHWM, 1998, SEMIN ARTHRITIS RHEU, V27, P335, DOI 10.1016/S0049-0172(98)80013-9; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ELLIS E F, 1989, Journal of Neurotrauma, V6, P31, DOI 10.1089/neu.1989.6.31; FENG JF, 1995, NEURAL PROCESS LETT, V2, P9, DOI 10.1007/BF02309009; FLOOD JF, 1988, BRAIN RES, V448, P178, DOI 10.1016/0006-8993(88)91116-X; FLOOD JF, 1988, BRAIN RES, V447, P269, DOI 10.1016/0006-8993(88)91129-8; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; GORDON G, 1995, ARCH BIOCHEM BIOPHYS, V318, P25, DOI 10.1006/abbi.1995.1199; HALL ED, 1996, NEUROTRAUMA, P1405; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HASTINGS LA, 1988, CARCINOGENESIS, V9, P1099, DOI 10.1093/carcin/9.6.1099; Hata T, 1996, ACTA OBSTET GYN SCAN, V75, P343, DOI 10.3109/00016349609033328; HERSCHMAN HR, 1995, BIOESSAYS, V17, P1031, DOI 10.1002/bies.950171207; HEUSER G, 1961, ENDOCRINOLOGY, V69, P915, DOI 10.1210/endo-69-5-915; Hewett SJ, 2000, J PHARMACOL EXP THER, V293, P417; Imamura M, 1998, BIOCHEM BIOPH RES CO, V243, P771, DOI 10.1006/bbrc.1998.8177; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; IRWIN S, 1966, SCIENCE, V152, P100, DOI 10.1126/science.152.3718.100; Kimonides VG, 1998, P NATL ACAD SCI USA, V95, P1852, DOI 10.1073/pnas.95.4.1852; Kipper-Galperin M, 1999, INT J DEV NEUROSCI, V17, P765, DOI 10.1016/S0736-5748(99)00067-2; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Li H, 2001, BRAIN RES, V888, P263, DOI 10.1016/S0006-8993(00)03077-8; Majewska MD, 1995, ANN NY ACAD SCI, V774, P111, DOI 10.1111/j.1749-6632.1995.tb17375.x; MAJEWSKA MD, 1990, BRAIN RES, V526, P143, DOI 10.1016/0006-8993(90)90261-9; MARCZYNSKI TJ, 1994, NEUROBIOL AGING, V15, P69, DOI 10.1016/0197-4580(94)90146-5; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MASFERRER JL, 1992, P NATL ACAD SCI USA, V89, P3917, DOI 10.1073/pnas.89.9.3917; Maurice T, 1997, BEHAV BRAIN RES, V83, P159, DOI 10.1016/S0166-4328(97)86061-5; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mei J. M., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P585; Moore SA, 1999, ADV EXP MED BIOL, V469, P125; MORALES AJ, 1994, J CLIN ENDOCR METAB, V78, P1360, DOI 10.1210/jc.78.6.1360; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PASHKO LL, 1991, CARCINOGENESIS, V12, P2189, DOI 10.1093/carcin/12.11.2189; RAINERI R, 1970, BIOCHEMISTRY-US, V9, P2233, DOI 10.1021/bi00813a003; RATKO TA, 1991, CANCER RES, V51, P481; Reddy DS, 1998, BRAIN RES, V791, P108, DOI 10.1016/S0006-8993(98)00085-7; ROBERTS E, 1987, BRAIN RES, V406, P357, DOI 10.1016/0006-8993(87)90807-9; Robertson C. S., 1996, NEUROTRAUMA, P487; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; SADOWSKI IJ, 1985, INT J BIOCHEM, V17, P1023, DOI 10.1016/0020-711X(85)90250-2; SARA SJ, 1994, BRAIN RES BULL, V35, P457, DOI 10.1016/0361-9230(94)90159-7; Schumacher M, 1996, DEV NEUROSCI-BASEL, V18, P6, DOI 10.1159/000111391; SCHWARTZ AG, 1994, J GERONTOL, V49, pB37, DOI 10.1093/geronj/49.2.B37; SCHWARTZ AG, 1988, CANCER RES, V48, P4817; SCHWARTZ AG, 1993, J CELL BIOCHEM, P73; SCHWARTZ AG, 1989, CARCINOGENESIS, V10, P1809; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SIOUTOS PJ, 1995, NEUROSURGERY, V36, P943, DOI 10.1227/00006123-199505000-00009; Soares HD, 1995, J NEUROSCI, V15, P8223; SPIVAK CE, 1994, SYNAPSE, V16, P113, DOI 10.1002/syn.890160205; STANTON PK, 1985, J NEUROSCI, V5, P2169; STEIN D, 1990, NEUROSCIENTIST, V4, P435; STRAUSS K, 1998, TRAUMA Q, V13, P353; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Strauss KI, 2002, J NEUROTRAUM, V19, P627, DOI 10.1089/089771502753754091; van Vollenhoven RF, 1998, J RHEUMATOL, V25, P285; VANVOLLENHOVEN RF, 1994, ARTHRITIS RHEUM, V37, P1305, DOI 10.1002/art.1780370906; vanVollenhoven RF, 1995, ARTHRITIS RHEUM, V38, P1826, DOI 10.1002/art.1780381216; WENDLING WW, 1987, STROKE, V18, P591, DOI 10.1161/01.STR.18.3.591; WENDLING WW, 1991, STROKE, V22, P66, DOI 10.1161/01.STR.22.1.66; WENDLING WW, 1994, J NEUROSURG ANESTH, V6, P186; Williams PJ, 1997, ARTHRITIS RHEUM-US, V40, P907, DOI 10.1002/art.1780400519; Wolkowitz OM, 1995, ANN NY ACAD SCI, V774, P337; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131	74	40	41	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2003	20	5					463	476		10.1089/089771503765355531			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	682MY	WOS:000183096900006	12803978	Green Accepted			2021-06-18	
J	Visser-Keizer, AC; Meyboom-De Jong, B; Deelman, BG; Berg, IJ; Gerritsen, MJJ				Visser-Keizer, AC; Meyboom-De Jong, B; Deelman, BG; Berg, IJ; Gerritsen, MJJ			Subjective changes in emotion, cognition and behaviour after stroke: Factors affecting the perception of patients and partners	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN INJURY; HOSPITAL ANXIETY; DEPRESSION SCALE; AWARENESS; UNAWARENESS; ANOSOGNOSIA; DISABILITY; LESIONS	The presence and severity of changes in emotion and cognition experienced by left- and right-sided stroke patients and observed by their partners were compared at 3 months poststroke. The results showed that, regardless of the side of stroke, several changes were reported by half of the stroke patients and their partners. It appeared that while left hemisphere stroke patients agreed with their partners on the number and severity of most changes, partners of right hemisphere patients reported more frequent and more severe changes than the patients themselves. The level of observability of the altered behaviour, distress of the partner, distress of left-sided stroke patients and hemispatial neglect of right-sided stroke patients emerged a factors related to disagreement between stroke patient and partner.	Univ Groningen, Dept Gen Practice, NL-9713 BZ Groningen, Netherlands; Acad Hosp Groningen, Dept Neuropsychol & Gerontol, Groningen, Netherlands	Visser-Keizer, AC (corresponding author), Univ Groningen, Dept Gen Practice, Bloemsingel 1, NL-9713 BZ Groningen, Netherlands.						Borod JC, 1998, NEUROPSYCHOLOGY, V12, P446, DOI 10.1037/0894-4105.12.3.446; Dam~asio A., 1999, FEELING WHAT HAPPENS; *DEP NEUR, 1986, DE 15 WOORD TEST 15; GAINOTTI G, 1993, COGNITION EMOTION, V7, P71, DOI 10.1080/02699939308409178; Gerritsen M, 2001, Tijdschr Gerontol Geriatr, V32, P24; GERRITSEN M, 2000, Z NEUROPSYCHOLOGIE, V10, P229; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; Heilman KM, 1998, PHILOS T R SOC B, V353, P1903, DOI 10.1098/rstb.1998.0342; HIBBARD MR, 1992, REHABIL PSYCHOL, V37, P103, DOI 10.1037/0090-5550.37.2.103; Hochstenbach J, 1997, TSG, V75, P479; HOCHSTENBACH J, 1999, COGNITIVE EMOTIONAL; HOLBROOK M, 1983, AGE AGEING, V12, P166, DOI 10.1093/ageing/12.2.166; JOHNSON BFG, 1995, CHEM-EUR J, V1, P252, DOI 10.1002/chem.19950010409; Knapp P, 1999, STROKE, V30, P934, DOI 10.1161/01.STR.30.5.934; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MAHONEY F I, 1965, Md State Med J, V14, P61; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MOTOMURA N, 1988, JPN J PSYCHIAT NEUR, V42, P747; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Rolls ET, 1999, BRAIN EMOTION; SCHURE LM, 1995, PARTNERS CVA PATIENT; Snijders J. T, 1988, SNIJDERS OOMEN NIET; Spinhoven P, 1997, PSYCHOL MED, V27, P363, DOI 10.1017/S0033291796004382; STARKSTEIN SE, 1992, STROKE, V23, P1446, DOI 10.1161/01.STR.23.10.1446; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; van den Burg W, 1999, ARCH CLIN NEUROPSYCH, V14, P545, DOI 10.1016/S0887-6177(98)00042-0; WILLANGER R, 1981, ACTA NEUROL SCAND, V64, P310; Wilson B., 1987, BEHAV INATTENTION TE; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	31	40	40	0	11	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	2002	24	8					1032	1045		10.1076/jcen.24.8.1032.8383			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	642HA	WOS:000180797100005	12650229				2021-06-18	
J	Chang, JW; Choi, JY; Lee, BW; Kang, UJ; Chung, SS				Chang, JW; Choi, JY; Lee, BW; Kang, UJ; Chung, SS			Unilateral globus pallidus internus stimulation improves delayed onset post-traumatic cervical dystonia with an ipsilateral focal basal ganglia lesion	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							HEMIDYSTONIA; PALLIDOTOMY	Treatment with unilateral left globus pallidus internus (GPi) deep brain stimulation is reported in a patient with severe delayed onset post-traumatic cervical dystonia. He had sustained severe head trauma at the age of 17 and had developed a mile right hemiparesis. Three years after the head injury, cervical dystonia with head turning to the left side developed. Magnetic resonance imaging (MRI) showed a discrete GPi lesion on the left side. At the age of 23, he underwent unilateral left GPi deep brain stimulation. he experienced immediate but short lasting benefit form the microlesioning effect of the electrode. With activation of deep brain stimulation, there was significant improvement of the cervical dystonia, persisting for 12 months of follow up. This case underlines the importance of the globus pallidus internus in the generation and amelioration of cervical dystonia.	Yonsei Univ, Coll Med, Dept Neurosurg, Seoul, South Korea; Yonsei Univ, Coll Med, Med Res Ctr, Brain Korea 21 Project, Seoul, South Korea; Univ Chicago, Dept Neurol, Chicago, IL 60637 USA	Chang, JW (corresponding author), Yonsei Univ, Coll Med, Dept Neurosurg, CPO Box 8044, Seoul, South Korea.		Kang, Un/AAV-2858-2020	Kang, Un/0000-0002-5970-6839; Lee, Bae H./0000-0003-4719-9021			Baron MS, 1996, ANN NEUROL, V40, P355, DOI 10.1002/ana.410400305; Berardelli A, 1998, BRAIN, V121, P1195, DOI 10.1093/brain/121.7.1195; BURTON K, 1984, NEUROLOGY, V34, P962, DOI 10.1212/WNL.34.7.962; Chang JW, 2001, BASAL GANGLIA AND THALAMUS IN HEALTH AND MOVEMENT DISORDERS, P341; Hedreen J C, 1988, Adv Neurol, V50, P123; Islekel S, 1999, STEREOT FUNCT NEUROS, V72, P248, DOI 10.1159/000029736; King RB, 2001, J NEUROSURG, V94, P309, DOI 10.3171/jns.2001.94.2.0309; Krauss JK, 1999, LANCET, V354, P837, DOI 10.1016/S0140-6736(99)80022-1; Krystkowiak P, 1998, J NEUROL NEUROSUR PS, V65, P703, DOI 10.1136/jnnp.65.5.703; Kulisevsky J, 2000, NEUROLOGY, V55, P1754, DOI 10.1212/WNL.55.11.1754; LEE MS, 1994, NEUROLOGY, V44, P1374, DOI 10.1212/WNL.44.8.1374; Loher TJ, 2000, J NEUROSURG, V92, P457, DOI 10.3171/jns.2000.92.3.0457; Lozano AM, 1997, MOVEMENT DISORD, V12, P865, DOI 10.1002/mds.870120606; MARSDEN CD, 1985, BRAIN, V108, P463, DOI 10.1093/brain/108.2.463; Munchau A, 2000, J NEUROL NEUROSUR PS, V69, P494, DOI 10.1136/jnnp.69.4.494; Obeso J A, 1988, Adv Neurol, V50, P113; Parkin S, 2001, MOVEMENT DISORD, V16, P489, DOI 10.1002/mds.1092; Tarsy D, 1998, MOVEMENT DISORD, V13, P481, DOI 10.1002/mds.870130318; Tasker RR, 1998, TXB STEREOTACTIC FUN, P1015	19	40	40	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	NOV	2002	73	5					588	590		10.1136/jnnp.73.5.588			3	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	612UK	WOS:000179093700027	12397158	Bronze, Green Published			2021-06-18	
J	Gavelli, G; Canini, R; Bertaccini, P; Battista, G; Bna, C; Fattori, R				Gavelli, G; Canini, R; Bertaccini, P; Battista, G; Bna, C; Fattori, R			Traumatic injuries: imaging of thoracic injuries	EUROPEAN RADIOLOGY			English	Article						chest trauma; thorax; thoracic injuries; imaging	TRANSESOPHAGEAL ECHOCARDIOGRAPHY; AORTIC RUPTURE; DIAPHRAGMATIC RUPTURE; CHEST RADIOGRAPHY; CT AORTOGRAPHY; BLUNT TRAUMA; DIAGNOSIS; MANAGEMENT; PNEUMOTHORAX; SENSITIVITY	Chest trauma is one of the most important causes of death, in particular in individuals under the age of 40 years. The mortality rate for chest trauma, often related to motor vehicle accidents, is approximately 15.5%; it increases dramatically to 77% with associated shock and head injury (Glasgow scores of 3-4). The accurate diagnosis of pathologies consequent to blunt chest trauma depends on a complete knowledge of the different clinical and radiological manifestations. The first diagnostic approach is classically based on chest X-ray often carried out on supine position at the hospital admission. A CT study must then be performed in all chest trauma patients in whom there is even the smallest diagnostic doubt on plain film. In particular, spiral CT (SCT) assumes a fundamental role in the demonstration of mediastinal hemorrhage and direct signs of aortic lesions. At present, SCT is routinely part of a diagnostic evaluation which also includes scans of the brain and the abdomen in polytraumatized patients. Magnetic resonance is the ideal method for visualizing diaphragmatic lesions. Furthermore, recent reports have demonstrated the high diagnostic value of MR in evaluating aortic injuries. The purpose of this article is to review the most common radiological patterns related to chest trauma.	Univ Bologna, Policlin S Orsola Malpighi, Dpto Clin Sci Radiol & Istocitopatol Radiodiagn, I-40136 Bologna, Italy	Gavelli, G (corresponding author), Univ Bologna, Policlin S Orsola Malpighi, Dpto Clin Sci Radiol & Istocitopatol Radiodiagn, Via Massarenti, I-40136 Bologna, Italy.	ggavelli@orsola-malpighi.med.unibo.it	Fattori, Rossella/L-1017-2016; Battista, Giuseppe/AAC-3362-2021	Battista, Giuseppe/0000-0003-3639-3494			BALL T, 1982, AM J ROENTGENOL, V138, P633, DOI 10.2214/ajr.138.4.633; BARMADA H, 1994, CHEST, V106, P74, DOI 10.1378/chest.106.1.74; BENMENACHEM Y, 1993, J TRAUMA, V35, P363, DOI 10.1097/00005373-199309000-00006; Bergin D, 2001, AM J ROENTGENOL, V177, P1137, DOI 10.2214/ajr.177.5.1771137; BUCKMASTER MJ, 1994, J TRAUMA, V37, P989, DOI 10.1097/00005373-199412000-00021; CASKEY CI, 1989, RADIOLOGY, V171, P385, DOI 10.1148/radiology.171.2.2704802; CHEN JC, 1991, AM SURGEON, V57, P810; Cohn SM, 1997, J TRAUMA, V42, P973, DOI 10.1097/00005373-199705000-00033; DELROSSI AJ, 1990, SURGERY, V108, P864; Fattori R, 1997, EUR RADIOL, V7, P51; Fattori R, 1996, CIRCULATION, V94, P2865, DOI 10.1161/01.CIR.94.11.2865; Fattori R, 1998, EUR J CARDIO-THORAC, V13, P582, DOI 10.1016/S1010-7940(98)00071-2; FERMANIS GG, 1985, AUST NZ J SURG, V55, P383, DOI 10.1111/j.1445-2197.1985.tb00905.x; Gavant ML, 1996, AM J ROENTGENOL, V166, P955, DOI 10.2214/ajr.166.4.8610581; GELMAN R, 1991, AM J ROENTGENOL, V156, P51, DOI 10.2214/ajr.156.1.1898570; Glasser DL, 1998, RADIOGRAPHICS, V18, P799, DOI 10.1148/radiographics.18.3.9599403; GORDON R, 1980, RADIOLOGY, V136, P25, DOI 10.1148/radiology.136.1.7384513; Greene R, 1987, J Thorac Imaging, V2, P1, DOI 10.1097/00005382-198707000-00004; Hunt JP, 1996, J TRAUMA, V40, P547, DOI 10.1097/00005373-199604000-00005; KRAM HB, 1987, J VASC SURG, V6, P168, DOI 10.1067/mva.1987.avs0060168; Ma OJ, 1997, ANN EMERG MED, V29, P312, DOI 10.1016/S0196-0644(97)70341-X; MARNOCHA KE, 1985, AM J ROENTGENOL, V144, P19, DOI 10.2214/ajr.144.1.19; Mirvis SE, 1996, RADIOLOGY, V200, P413, DOI 10.1148/radiology.200.2.8685335; MIRVIS SE, 1987, RADIOLOGY, V163, P487, DOI 10.1148/radiology.163.2.3562831; MORRIS L, 1999, RADIOL CLIN N AM, V37, P553; MORSE SS, 1988, AM J ROENTGENOL, V150, P793, DOI 10.2214/ajr.150.4.793; Murray JG, 1996, AM J ROENTGENOL, V166, P1035, DOI 10.2214/ajr.166.5.8615237; Olsovsky MR, 1997, ANGIOLOGY, V48, P423, DOI 10.1177/000331979704800506; PATE JW, 1995, WORLD J SURG, V19, P119, DOI 10.1007/BF00316994; PERCHINSKY MJ, 1995, ARCH SURG-CHICAGO, V40, P852; RAPTOPOULOS V, 1994, AM J ROENTGENOL, V162, P1053, DOI 10.2214/ajr.162.5.8165980; RHEA JT, 1979, RADIOLOGY, V133, P593, DOI 10.1148/133.3.593; RIZOLI SB, 1994, ANN THORAC SURG, V58, P1404, DOI 10.1016/0003-4975(94)91923-2; Rossbach MM, 1998, ANN THORAC SURG, V65, P182, DOI 10.1016/S0003-4975(97)01001-1; SHAH R, 1995, ANN THORAC SURG, V60, P1444, DOI 10.1016/0003-4975(95)00629-Y; Shanmuganathan K, 1999, RADIOL CLIN N AM, V37, P533, DOI 10.1016/S0033-8389(05)70110-X; SMITH MD, 1995, NEW ENGL J MED, V332, P356, DOI 10.1056/NEJM199502093320603; STARK P, 1993, RADIOLOGY THORACIC T, P54; Tack D, 2000, EUR RADIOL, V10, P719, DOI 10.1007/s003300050992; Tocino I, 1987, J Thorac Imaging, V2, P45, DOI 10.1097/00005382-198707000-00008; TOCINO IM, 1985, AM J ROENTGENOL, V144, P901, DOI 10.2214/ajr.144.5.901; VIGNON P, 1995, CIRCULATION, V92, P2959, DOI 10.1161/01.CIR.92.10.2959; Vignon P, 2001, ANESTHESIOLOGY, V94, P615, DOI 10.1097/00000542-200104000-00015; WALL SD, 1983, AM J ROENTGENOL, V141, P919, DOI 10.2214/ajr.141.5.919; Wan YL, 1997, AM J EMERG MED, V15, P176, DOI 10.1016/S0735-6757(97)90096-6; Wicky S, 1998, EUR RADIOL, V8, P828, DOI 10.1007/s003300050480; Wicky S, 2000, EUR RADIOL, V10, P1524, DOI 10.1007/s003300000435; WORTHY SA, 1995, RADIOLOGY, V194, P885, DOI 10.1148/radiology.194.3.7862996	48	40	42	0	0	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0938-7994	1432-1084		EUR RADIOL	Eur. Radiol.	JUN	2002	12	6					1273	1294		10.1007/s00330-002-1439-6			22	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	562LC	WOS:000176197400005	12042932				2021-06-18	
J	Albert, SM; Im, A; Brenner, L; Smith, M; Waxman, R				Albert, SM; Im, A; Brenner, L; Smith, M; Waxman, R			Effect of a social work liaison program on family caregivers to people with brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; caregiver burden; caregiving; mental health; social work	SEVERE HEAD-INJURY; RELATIVES; NEEDS; SUPPORT; MEMBER; IMPACT	Objective: We assessed the effect of a social work liaison program on caregiver outcomes for families caring for people with brain injury. Design: All telephone calls received by the team were entered into a standardized log form to record topics raised by caregivers. Main Outcome Measures: We compared the experience of this cohort of traumatic brain injury (TBI) caregivers with the experience of an earlier cohort by use of standard measures of caregiver mental health. Because patients in the cohort had mixed etiologies, we also examined the experience of caregivers according to type of brain injury, comparing cerebrovascular accident with TBI patients. Results: The social work liaison program offered benefit to caregivers on burden, satisfaction, and mastery outcomes. Conclusions: This research suggests that a relatively low-cost, nonintensive intervention may offer substantial benefit to families caring for people with brain injury.	Columbia Univ, Gertrude H Sergievsky Ctr, Dept Sociomed Sci, New York, NY 10032 USA; Columbia Univ, Sch Publ Hlth, Dept Sociomed Sci, New York, NY 10032 USA; Peninsula Hosp Ctr, Traumat Brain Injury Unit, Psychol Serv, Far Rockaway, NY USA	Albert, SM (corresponding author), Columbia Univ, Gertrude H Sergievsky Ctr, Dept Sociomed Sci, PH-19,630 W 168th St, New York, NY 10032 USA.	sma10@columbia.edu		Albert, Steven/0000-0001-6786-9956			BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Curtiss G, 2000, J HEAD TRAUMA REHAB, V15, P1113, DOI 10.1097/00001199-200010000-00005; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Frosch S, 1997, BRAIN INJURY, V11, P891; GORDON WA, 1992, NEUROPSYCHOLOGY, V6, P361; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; LAWTON MP, 1989, J GERONTOL, V44, pP61, DOI 10.1093/geronj/44.3.P61; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Leathem J, 1996, BRAIN INJURY, V10, P27; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; Liss M, 1990, Int J Rehabil Res, V13, P309, DOI 10.1097/00004356-199012000-00004; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; McPherson KM, 2000, INT J REHABIL RES, V23, P295, DOI 10.1097/00004356-200023040-00005; ROSENTHAL M, 1995, NEUROPSYCHOLOGY HDB, V2, P73; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; Simpson G, 2000, BRAIN INJURY, V14, P125, DOI 10.1080/026990500120790; Smith L.M., 1995, FAMILY SUPPORT PROGR; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wallace CA, 1998, BRAIN INJURY, V12, P483, DOI 10.1080/02699052.1998.11910751; WANTANABE Y, 2001, DISABILITY, V9, P370	30	40	40	1	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	2002	17	2					175	189		10.1097/00001199-200204000-00007			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	535YT	WOS:000174674500007	11909513				2021-06-18	
J	Spinella, M; Eaton, LA				Spinella, M; Eaton, LA			Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury	BRAIN INJURY			English	Article							GINKGO-BILOBA EXTRACT; ST.-JOHNS-WORT; BUSPIRONE-INDUCED MANIA; FORCED SWIMMING TEST; HYPERICUM-PERFORATUM; ANTIDEPRESSANT ACTIVITY; CLINICAL-TRIALS; VIVO REGULATION; DEPRESSION; EGB-761	The use of herbal medicines has become a very common practice. While many are safe enough to be available over-the-counter, they may pose risks due to interactions with pharmaceutical medications and effects in specific clinical populations. The case of a female patient with a history of mild traumatic brain injury and resulting depression is presented. She experienced hypomania after adding St John's wort and Ginkgo biloba to her regimen of fluoxetine and buspirone, which remitted after discontinuation of the herbal medicines. Implications for interactions between various psychopharmacologic agents, including herbal medicines and selective serotonin reuptake inhibitors (SSRIs), as well as the need for appropriate patient and health care provider education are discussed.	Richard Stockton Coll New Jersey, Div Social & Behav Sci, Pomona, NJ 08240 USA	Spinella, M (corresponding author), Richard Stockton Coll New Jersey, Div Social & Behav Sci, POB 195, Pomona, NJ 08240 USA.	marcello.s-pinella@stockton.edu					Amri H, 1997, ENDOCRINOLOGY, V138, P5415, DOI 10.1210/en.138.12.5415; Amri H, 1996, ENDOCRINOLOGY, V137, P5707, DOI 10.1210/en.137.12.5707; Artigas F, 1996, TRENDS NEUROSCI, V19, P378, DOI 10.1016/S0166-2236(96)10037-0; Barbenel DM, 2000, J PSYCHOPHARMACOL, V14, P84, DOI 10.1177/026988110001400113; Beck AT, 1993, MANUAL BECK ANXIETY; Beck AT., 1996, BECK DEPRESSION INVE, V2; Bennett DA, 1998, ANN PHARMACOTHER, V32, P1201, DOI 10.1345/aph.18026; Bersani G, 2000, PROG NEURO-PSYCHOPH, V24, P185, DOI 10.1016/S0278-5846(99)00097-4; BOLANOSJIMENEZ F, 1995, FUNDAM CLIN PHARM, V9, P169, DOI 10.1111/j.1472-8206.1995.tb00277.x; Brenner R, 2000, CLIN THER, V22, P411, DOI 10.1016/S0149-2918(00)89010-4; Butterweck V, 2000, PLANTA MED, V66, P3, DOI 10.1055/s-2000-11119; Butterweck V, 1997, PHARMACOPSYCHIATRY, V30, P117, DOI 10.1055/s-2007-979531; Butterweck V, 1998, PLANTA MED, V64, P291, DOI 10.1055/s-2006-957437; Chatterjee SS, 1998, LIFE SCI, V63, P499, DOI 10.1016/S0024-3205(98)00299-9; Chatterjee SS, 1998, PHARMACOPSYCHIATRY, V31, P7, DOI 10.1055/s-2007-979340; Dimpfel W, 1999, Eur J Med Res, V4, P303; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Fowler JS, 2000, LIFE SCI, V66, pPL141, DOI 10.1016/S0024-3205(99)00660-8; Gordon JB, 1998, AM FAM PHYSICIAN, V57, P950; Greeson JM, 2001, PSYCHOPHARMACOLOGY, V153, P402, DOI 10.1007/s002130000625; Harrer G, 1999, ARZNEIMITTEL-FORSCH, V49, P289; HARRER G, 1994, J GERIATR PSYCHIA S1, V7, P24; Hasenohrl RU, 1996, PHARMACOL BIOCHEM BE, V53, P271, DOI 10.1016/0091-3057(95)02001-2; Holsboer F, 1999, J PSYCHIATR RES, V33, P181, DOI 10.1016/S0022-3956(98)90056-5; HUGUET F, 1992, J PHARM PHARMACOL, V44, P24, DOI 10.1111/j.2042-7158.1992.tb14357.x; HUGUET F, 1994, J PHARM PHARMACOL, V46, P316, DOI 10.1111/j.2042-7158.1994.tb03802.x; Itil TM, 1998, PSYCHOPHARMACOL BULL, V34, P391; Kessler RC, 2001, AM J PSYCHIAT, V158, P289, DOI 10.1176/appi.ajp.158.2.289; Kim HL, 1999, J NERV MENT DIS, V187, P532, DOI 10.1097/00005053-199909000-00002; Labbate L A, 2000, Curr Psychiatry Rep, V2, P268, DOI 10.1007/s11920-996-0021-3; Leathem JM, 2000, J HEAD TRAUMA REHAB, V15, P1246, DOI 10.1097/00001199-200012000-00005; Leibenluft E, 1997, J CLIN PSYCHIAT, V58, P383, DOI 10.4088/JCP.v58n0902; LIEGGHIO NE, 1988, J CLIN PSYCHOPHARM, V8, P226, DOI 10.1097/00004714-198806000-00022; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; LINDE K, 2000, COCHRANE DB SYST REV, V2; Lingaerde O, 1999, ACTA PSYCHIAT SCAND, V100, P62, DOI 10.1111/j.1600-0447.1999.tb10915.x; LOU H, 1999, CHINESE MENTAL HLTH, V13, P167; Marcilhac A, 1998, LIFE SCI, V62, P2329, DOI 10.1016/S0024-3205(98)00214-8; MCDANIEL JS, 1990, AM J PSYCHIAT, V147, P125; MCIVOR RJ, 1991, BRIT J PSYCHIAT, V158, P136, DOI 10.1192/bjp.158.1.136; Miller LG, 1998, ARCH INTERN MED, V158, P2200, DOI 10.1001/archinte.158.20.2200; Nathan PJ, 2001, J PSYCHOPHARMACOL, V15, P47, DOI 10.1177/026988110101500109; Nierenberg AA, 1999, BIOL PSYCHIAT, V46, P1707, DOI 10.1016/S0006-3223(99)00233-4; O'Breasail AM, 1998, CAN J PSYCHIAT, V43, P746; Peebles CT, 2000, EPILEPSY BEHAV, V1, P74, DOI 10.1006/ebeh.2000.0031; Perino C, 2001, BRAIN INJURY, V15, P139, DOI 10.1080/026990501458371; PORSOLT RD, 1990, PHARMACOL BIOCHEM BE, V36, P963, DOI 10.1016/0091-3057(90)90107-S; Porsolt RD, 2000, ARZNEIMITTEL-FORSCH, V50, pE232; PRICE WA, 1989, J CLIN PSYCHOPHARM, V9, P150, DOI 10.1097/00004714-198904000-00025; RAPIN JR, 1994, GEN PHARMACOL-VASC S, V25, P1009, DOI 10.1016/0306-3623(94)90111-2; Schneck C, 1998, J CLIN PSYCHIAT, V59, P689, DOI 10.4088/JCP.v59n1208d; Schrader E, 2000, INT CLIN PSYCHOPHARM, V15, P61, DOI 10.1097/00004850-200015020-00001; Schulz H, 1994, J Geriatr Psychiatry Neurol, V7 Suppl 1, pS39, DOI 10.1177/089198879400700111; Sharpley AL, 1998, PSYCHOPHARMACOLOGY, V139, P286, DOI 10.1007/s002130050718; Shelton RC, 2001, JAMA-J AM MED ASSOC, V285, P1978, DOI 10.1001/jama.285.15.1978; Singer A, 1999, J PHARMACOL EXP THER, V290, P1363; Spinella M, 2001, PSYCHOPHARMACOLOGY H; Stein DJ, 1997, S AFR MED J, V87, P763; Sussman N, 1998, J CLIN PSYCHIAT, V59, P42; TAYLOR A, 1994, PSYCHIAT RES, V54, P241, DOI 10.1016/0165-1781(94)90018-3; TeufelMayer R, 1997, PHARMACOPSYCHIATRY, V30, P113, DOI 10.1055/s-2007-979530; Volz HP, 2000, COMPR PSYCHIAT, V41, P133, DOI 10.1016/S0010-440X(00)80019-X; Winter JC, 1999, PHARMACOL BIOCHEM BE, V62, P543, DOI 10.1016/S0091-3057(98)00190-7	63	40	42	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2002	16	4					359	367		10.1080/02699050110103319			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	541CM	WOS:000174967700007	11953006				2021-06-18	
J	Horiuchi, T; Dietrich, HH; Hongo, K; Goto, T; Dacey, RG				Horiuchi, T; Dietrich, HH; Hongo, K; Goto, T; Dacey, RG			Role of endothelial nitric oxide and smooth muscle potassium channels in cerebral arteriolar dilation in response to acidosis	STROKE			English	Article						acid-base equilibrium; cerebral circulation; hydrogen-ion concentration; microcirculation; rats	TRAUMATIC BRAIN INJURY; BLOOD-FLOW; INTRACEREBRAL ARTERIOLES; BASILAR ARTERIES; CYCLIC-GMP; HYPERCAPNIA; SYNTHASE; RATS; PH; BICARBONATE	Background and Purpose-Potassium channels or nitric oxide or both are major mediators of acidosis-induced dilation in the cerebral circulation. However, these contributions depend on a variety or factors such as species and vessel location. The present study was designed to clarify whether potassium channels and endothelial nitric oxide are involved in acidosis-induced dilation of isolated rat cerebral arterioles. Methods-Cerebral arterioles were cannulated and monitored with an inverted microscope. Acidosis (pH 6.8 to 7.4) produced by adding hydrogen ions mediated dilation of the cerebral arterioles in a concentration-dependent manner. The role of nitric oxide and potassium channels in response to acidosis was examined with several specific inhibitors and endothelial damage. Results-The dilation was significantly inhibited by potassium chloride (30 mmol/L) and glibenclamide (3 mumol/L; ATP-sensitive potassium channel inhibitor). We found that 30 mumol/L BaCl2 (concentration-dependent potassium channel inhibitor) also affected the dilation; however, an additional treatment of 3 mumol/L glibenclamide did not produce further inhibition. Tetraethylammonium ion (1 mmol/L; calcium-activated potassium channel inhibitor) and 4-aminopyridine (100 mumol/L; voltage-dependent potassium channel inhibitor) as well as ouabain (10 mumol/L; Na-K ATPase inhibitor) and N-methylsulphonyl-6-(2-proparglytoxyphenyl) hexanamide (1 mumol/L, cytochrome P450 epoxygenase inhibitor) did not alter acidotic dilation. N-omega-Monomethyl-L-arginine (10 mumol/L) and N-omega-nitro-L-arginine (10 mumol/L) as nitric oxide synthase inhibitor blunted the dilation. Furthermore, the dilation was significantly attenuated after the endothelial impairment. Additional treatment with glibenclamide (3 mumol/L) further reduced the dilation in response to acidosis. Conclusions-Endothelial nitric oxide and smooth muscle ATP-sensitive potassium channels contribute to acidosis-induced dilation of rat cerebral arterioles. Endothelial damage caused by pathological conditions such as subarachnoid hemorrhage or traumatic brain injury may contribute to reduced blood flow despite injury-induced cerebral acidosis.	Washington Univ, Sch Med, Dept Neurosurg, St Louis, MO 63110 USA; Shinshu Univ, Sch Med, Dept Neurosurg, Matsumoto, Nagano 390, Japan	Dietrich, HH (corresponding author), Washington Univ, Sch Med, Dept Neurosurg, Box 8057,660 S Euclid Ave, St Louis, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R29HL057540] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS030555] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL57540] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30555] Funding Source: Medline		Aalkjaer C, 1996, J VASC RES, V33, P347, DOI 10.1159/000159163; Aalkjaer C, 1997, ACTA PHYSIOL SCAND, V161, P557, DOI 10.1046/j.1365-201X.1997.00263.x; ADEAGBO ASO, 1993, J CARDIOVASC PHARM, V21, P423, DOI 10.1097/00005344-199303000-00011; Alagarsamy S, 1998, J NEUROTRAUM, V15, P627, DOI 10.1089/neu.1998.15.627; BONNET P, 1991, PFLUG ARCH EUR J PHY, V418, P292, DOI 10.1007/BF00370529; CHARDWAJ A, 2000, AM J PHYSIOL, V279, pH1616; Chrissobolis S, 2000, AM J PHYSIOL-HEART C, V279, pH2704; DACEY RG, 1987, AM J PHYSIOL, V253, pH1253; DACEY RG, 1982, AM J PHYSIOL, V243, pH598; DIETRICH HH, 1994, J NEUROSURG, V81, P437, DOI 10.3171/jns.1994.81.3.0437; DIETRICH HH, 1997, MICROCIRCULATION, V4, P169; DIETRICH HH, 1994, AM J PHYSIOL, V266, pH168; Faraci FM, 1998, PHYSIOL REV, V78, P53; FARACI FM, 1994, STROKE, V25, P1679, DOI 10.1161/01.STR.25.8.1679; Fisslthaler B, 1999, NATURE, V401, P493, DOI 10.1038/46816; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; Hoffman WE, 2000, ANESTHESIOLOGY, V92, P442, DOI 10.1097/00000542-200002000-00026; Horiuchi T, 2001, STROKE, V32, P218, DOI 10.1161/01.STR.32.1.218; Horiuchi T, 2001, AM J PHYSIOL-HEART C, V280, pH767; IADECOLA C, 1994, AM J PHYSIOL, V266, pR546; IADECOLA C, 1994, J CEREB BLOOD FLOW M, V14, P1475; IGNARRO LJ, 1989, FASEB J, V3, P31; IRIKURA K, 1995, P NATL ACAD SCI USA, V92, P6823, DOI 10.1073/pnas.92.15.6823; Johnson TD, 1998, AM J PHYSIOL-REG I, V274, pR541; Kajita Y, 1998, NEUROSURGERY, V42, P834, DOI 10.1097/00006123-199804000-00087; KIMURA M, 1994, STROKE, V25, P2227, DOI 10.1161/01.STR.25.11.2227; Kinoshita H, 1997, STROKE, V28, P433, DOI 10.1161/01.STR.28.2.433; KONTOS HA, 1977, STROKE, V8, P358, DOI 10.1161/01.STR.8.3.358; Lindauer U, 2001, AM J PHYSIOL-HEART C, V281, pH1353; MIRRO R, 1993, J APPL PHYSIOL, V75, P1300; NELSON MT, 1995, AM J PHYSIOL, V268, P799; Nguyen TS, 2000, AM J PHYSIOL-HEART C, V278, pH878; Park KW, 2001, ANESTH ANALG, V92, P990; ROSENBLUM WI, 1974, STROKE, V5, P425, DOI 10.1161/01.STR.5.4.425; SUZUKI M, 1995, AM J PHYSIOL-CELL PH, V269, pC496; TIAN R, 1995, CIRC RES, V76, P269, DOI 10.1161/01.RES.76.2.269; TODA N, 1993, AM J PHYSIOL, V265, pH929; TODA N, 1989, AM J PHYSIOL, V257, pH141; Toda N, 1996, J CEREBR BLOOD F MET, V16, P1068, DOI 10.1097/00004647-199609000-00032; Wang MH, 1998, J PHARMACOL EXP THER, V284, P966; WANG Q, 1992, J CEREBR BLOOD F MET, V12, P947, DOI 10.1038/jcbfm.1992.131; WANG Q, 1995, J CEREBR BLOOD F MET, V15, P774, DOI 10.1038/jcbfm.1995.97; Wang QO, 1998, BRAIN RES, V793, P187, DOI 10.1016/S0006-8993(98)00173-5; YOU JP, 1994, ACTA PHYSIOL SCAND, V152, P391, DOI 10.1111/j.1748-1716.1994.tb09821.x	45	40	48	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	MAR	2002	33	3					844	849		10.1161/hs0302.104112			6	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	527RL	WOS:000174200600034	11872913	Bronze, Green Published			2021-06-18	
J	Bay, E; Hagerty, BM; Williams, RA; Kirsch, N; Gillespie, B				Bay, E; Hagerty, BM; Williams, RA; Kirsch, N; Gillespie, B			Chronic stress, sense of belonging, and depression among survivors of traumatic brain injury	JOURNAL OF NURSING SCHOLARSHIP			English	Article						chronic stress; sense of belonging; traumatic brain injury; depression	CLOSED-HEAD INJURY; SOCIAL SUPPORT; MAJOR DEPRESSION; DEFICITS; RECOVERY; MEMORY; MODEL; IMPAIRMENT; DISABILITY; INVENTORY	Purpose: To test whether chronic stress, interpersonal relatedness, and cognitive burden could explain depression after traumatic-brain injury (TBI). Design: A nonprobability sample of 75 mild-to-moderately injured TBI survivors and their significant others, were recruited from five TBI day-rehabilitation programs. All participants were within 2 years of the date of injury and were living in the community. Methods: During face-to-face interviews, demographic information, and estimates of brain injury severity were obtained and participants completed a cognitive battery of tests of directed attention and short-term memory, responses to the Perceived Stress Scale, Interpersonal Relatedness Inventory, Sense of Belonging Instrument, Neurobehavioral Functioning Inventory, and Center for Epidemiological Studies Depression Scale;. Findings:Chronic stress was significantly and positively related to post-TBI depression. Depression and postinjury sense of belonging were negatively related. Social support and results from the cognitive battery did not explain depression. Conclusions: Postinjury chronic stress and sense of belonging were strong predictors of postinjury depression and are variables amenable to interventions by nurses in community health, neurological centers, or rehabilitation clinics. Future studies are needed to examine bow these variables change over time during the recovery process.	Michigan State Univ, Dearborn, MI USA; Univ Michigan, Adult TBI Program, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Stat Consulting & Res, Ann Arbor, MI 48109 USA	Bay, E (corresponding author), 2106 Kratage Court, Commerce, MI 48382 USA.						*AM C REH MED, 1993, J HEAD INJURY REHABI, V8, P6; [Anonymous], 1998, REH PERS TRAUM BRAIN; ATTEBERRYBENNETT J, 1986, INT J CLIN NEUROPSYC, V8, P114; BAUM A, 1983, J CONSULT CLIN PSYCH, V51, P565, DOI 10.1037/0022-006X.51.4.565; BAY E, 2000, J NEUROSCIENCE NURSI, V32, P169; BRAND AN, 1992, J AFFECT DISORDERS, V25, P77, DOI 10.1016/0165-0327(92)90095-N; BRAND N, 1987, PSYCHOL MED, V17, P145, DOI 10.1017/S0033291700013040; BRESLAU N, 1986, ARCH GEN PSYCHIAT, V43, P309; BROOKS G, 1999, THESIS U MICHIGAN AN; BURT DB, 1995, PSYCHOL BULL, V117, P285, DOI 10.1037/0033-2909.117.2.285; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Cassens G, 1990, J Neuropsychiatry Clin Neurosci, V2, P202; Channon S, 1999, J NEUROL NEUROSUR PS, V66, P162, DOI 10.1136/jnnp.66.2.162; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037/0033-2909.98.2.310; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; COHEN S, 1995, MEASURING STRESS GUI, V1; Devins GM, 1985, TEST CRITIQUES, P144; Hagerty B M, 1992, Arch Psychiatr Nurs, V6, P172, DOI 10.1016/0883-9417(92)90028-H; Hagerty BM, 1999, NURS RES, V48, P215, DOI 10.1097/00006199-199907000-00004; Hagerty BM, 1996, ARCH PSYCHIAT NURS, V10, P235, DOI 10.1016/S0883-9417(96)80029-X; Hagerty BM, 1997, AM J ORTHOPSYCHIAT, V67, P308, DOI 10.1037/h0080234; HAGERTY BMK, 1995, NURS RES, V44, P9; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1126/science.3399889; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; LEZAK M, 1987, J HEAD INJURY REHABI, V3, P57; MACNIVEN E, 1993, BRAIN INJURY, V7, P241, DOI 10.3109/02699059309029676; Martelli MF, 1998, NEUROREHABILITATION, V11, P51, DOI 10.1016/S1053-8135(98)00009-2; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; MONTGOMERY GK, 1995, BRAIN INJURY, V9, P453, DOI 10.3109/02699059509008205; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TILDEN VP, 1990, NURS RES, V39, P337; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Veiel HOF, 1997, J CLIN EXP NEUROPSYC, V19, P587, DOI 10.1080/01688639708403745; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; Williams RA, 2000, J PSYCHIAT RES, V34, P227, DOI 10.1016/S0022-3956(00)00012-1	48	40	41	0	10	SIGMA THETA TAU INT	INDIANAPOLIS	550 W NORTH STREET, INDIANAPOLIS, IN 46202 USA	1527-6546			J NURS SCHOLARSHIP	J. Nurs. Scholarsh.		2002	34	3					221	226		10.1111/j.1547-5069.2002.00221.x			6	Nursing	Nursing	636FX	WOS:000180444900013	12237983	Green Published			2021-06-18	
J	Cocchini, G; Beschin, N; Della Sala, S				Cocchini, G; Beschin, N; Della Sala, S			Chronic anosognosia: a case report and theoretical account	NEUROPSYCHOLOGIA			English	Article						anosognosia; hemiplegia; neglect; amnesia; executive functions	VESTIBULAR STIMULATION; UNILATERAL NEGLECT; PERSONAL NEGLECT; HEMIPLEGIA; HYPOTHESIS; AWARENESS; UNAWARENESS; REMISSION; HEMISPHERE; LESIONS	Unawareness of motor disorders (anosognosia) has often been reported after brain lesions, and it has been considered a temporary condition common in the acute and post-acute phases. The presence of anosognosia in a chronic phase (i.e. lasting more than few weeks) is a rare occurrence, thought to be the result of reasoning deficits which prevent patients from performing an adequate check of reality. Although this assumption is widely shared amongst researchers, only a few studies have actually addressed this issue. We report on the case of a patient (NS) who was still showing anosognosia for hemiplegia I year after a traumatic brain-head injury, while his reasoning abilities were well preserved. By means of a series of tests and experiments, we evaluated the main theoretical approaches. NS's long-lasting anosognosia is discussed in terms of a combination of clinical manifestations, whereby personal neglect and motor-sensory information play a key role in preventing awareness, whereas memory difficulties in updating pre-existing personal schema may be crucial in maintaining NS's anosognosic status. (C) 2002 Elsevier Science Ltd. All rights reserved.	Univ E London, Sch Psychol, London E15 4LZ, England; Gallarate Hosp, Unit Rehabil Somma Lombardo, Varese, Italy; Univ Aberdeen, Dept Psychol, Neuropsychol Res Grp, Aberdeen, Scotland	Cocchini, G (corresponding author), Univ E London, Sch Psychol, London E15 4LZ, England.						Adair JC, 1997, J NEUROL NEUROSUR PS, V63, P798, DOI 10.1136/jnnp.63.6.798; Adair JC, 1995, NEUROLOGY, V45, P2195, DOI 10.1212/WNL.45.12.2195; Azouvi P, 1996, NEUROPSYCHOL REHABIL, V6, P133, DOI 10.1080/713755501; Babinski J., 1914, REV NEUROL-FRANCE, V27, P845; Bakchine S, 1997, J NEUROL NEUROSUR PS, V63, P686, DOI 10.1136/jnnp.63.5.686; BARAT L, 1912, J PSYCHOL NORMALE PA, P163; BEAUMONT JG, 1996, BLACKWELL DICT NEURO, P80; Berti A, 1996, J Int Neuropsychol Soc, V2, P426; Berti E., 1998, COGN NEUROPSYCHIATRY, V3, P21, DOI DOI 10.1080/135468098396233; Beschin N, 1997, CORTEX, V33, P379, DOI 10.1016/S0010-9452(08)70013-3; BISIACH E, 1990, QUANT AN B, V9, P3; BISIACH E, 1986, NEUROPSYCHOLOGIA, V24, P471, DOI 10.1016/0028-3932(86)90092-8; Bisiach E, 1995, HIGHER BRAIN FUNCTIO, V15, P113; CAPPA S, 1987, NEUROPSYCHOLOGIA, V25, P775, DOI 10.1016/0028-3932(87)90115-1; Carlesimo GA, 1996, EUR NEUROL, V36, P378, DOI 10.1159/000117297; CARPENTER K, 1995, BRAIN, V118, P243, DOI 10.1093/brain/118.1.243; Cocchini G, 2001, NEUROPSYCHOL REHABIL, V11, P17, DOI 10.1080/09602010042000132; CRITCHLEY M, 1953, PARIETAL LOBE; CUTTING J, 1978, J NEUROL NEUROSUR PS, V41, P548, DOI 10.1136/jnnp.41.6.548; DYWAN CA, 1995, J CLIN EXP NEUROPSYC, V17, P431, DOI 10.1080/01688639508405134; Ellis S, 1997, STROKE, V28, P67, DOI 10.1161/01.STR.28.1.67; Feinberg T.E., 1997, BEHAV NEUROLOGY NEUR, P369; Feinberg TE, 2000, J NEUROL NEUROSUR PS, V68, P511, DOI 10.1136/jnnp.68.4.511; GIALANELLA B, 1992, NEUROPSYCHOL REHABIL, V2, P169, DOI DOI 10.1080/09602019208401406; GILLIATT RW, 1952, J NEUROL NEUROSUR PS, V15, P264, DOI 10.1136/jnnp.15.4.264; GILMORE RL, 1992, NEUROLOGY, V42, P925, DOI 10.1212/WNL.42.4.925; GOLD M, 1994, NEUROLOGY, V44, P1804, DOI 10.1212/WNL.44.10.1804; Goldberg E., 1991, AWARENESS DEFICIT BR, P152; Heilman K., 1991, AWARENESS DEFICIT BR, P53; Heilman KM, 1998, PHILOS T R SOC B, V353, P1903, DOI 10.1098/rstb.1998.0342; Johnson MK., 1991, REALITY MONITORING E, P176; KAPLAN RF, 1993, J CLIN EXP NEUROPSYC, V15, P383; Knight Robert T., 1995, P1357; LEVINE DN, 1990, BRAIN COGNITION, V13, P233, DOI 10.1016/0278-2626(90)90052-P; LEVINE DN, 1991, NEUROLOGY, V41, P1770, DOI 10.1212/WNL.41.11.1770; Liebson E, 2000, J NEUROL NEUROSUR PS, V68, P107, DOI 10.1136/jnnp.68.1.107; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; NATHANSON M, 1952, AMA ARCH NEUROL PSY, V68, P380, DOI 10.1001/archneurpsyc.1952.02320210090010; NOVELLI C, 1986, ARCH NEUROLOGIA PSIC, V47, P278; Ramachandran VS, 2000, MEMORY, BRAIN, AND BELIEF, P87; Ramachandran VS, 1998, PHANTOMS BRAIN PROBI, P127; Rode G, 1998, CORTEX, V34, P253; RODE G, 1992, CORTEX, V28, P203, DOI 10.1016/S0010-9452(13)80048-2; RUBENS AB, 1985, NEUROLOGY, V35, P1019, DOI 10.1212/WNL.35.7.1019; SANDIFER PH, 1946, BRAIN, V69, P122, DOI 10.1093/brain/69.2.122; SCHACTER DL, 1991, AWARENESS DEFICIT BR, P127; Schacter DL., 1991, AWARENESS DEFICIT BR, P17; Spinnler H, 1987, ITAL J NEUROL SCI S8, V6, P1; STARKSTEIN SE, 1992, STROKE, V23, P1446, DOI 10.1161/01.STR.23.10.1446; STONE SP, 1993, AGE AGEING, V22, P46, DOI 10.1093/ageing/22.1.46; Tei H, 2000, J NEUROL NEUROSUR PS, V69, P274, DOI 10.1136/jnnp.69.2.274; TERZIAN H, 1964, Acta Neurochir (Wien), V12, P230, DOI 10.1007/BF01402095; UYSAL S, 1993, J CLIN EXP NEUROPSYC, V15, P24; VALLAR G, 1990, CORTEX, V26, P123, DOI 10.1016/S0010-9452(13)80078-0; WADA J, 1949, MED BIOL TOKYO, V14, P221; Wechsler D., 1992, WAIS SCALA INTELLIGE; Weinstein E. A., 1955, DENIAL ILLNESS SYMBO	57	40	40	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia		2002	40	12					2030	2038	PII S0028-3932(02)00054-4	10.1016/S0028-3932(02)00054-4			9	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	601AJ	WOS:000178423700018	12208000				2021-06-18	
J	Sander, AM; Roebuck, TM; Struchen, MA; Sherer, M; High, WM				Sander, AM; Roebuck, TM; Struchen, MA; Sherer, M; High, WM			Long-term maintenance of gains obtained in postacute rehabilitation by persons with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						long-term services; postacute rehabilitation; TBI	DISABILITY RATING-SCALE; COMMUNITY INTEGRATION QUESTIONNAIRE; GLASGOW OUTCOME SCALE; SEVERE HEAD-INJURY; COGNITIVE REHABILITATION; IMPAIRED AWARENESS; RECOVERY; PREDICTION; LENGTH; STAY	Objective: To investigate maintenance of gains after discharge from a postacute rehabilitation program. Design: Longitudinal cohort study, with inclusion based on availability of subjects at three time points. Setting: Comprehensive postacute rehabilitation program in the Southern United States. Participants: Thirty-four persons with medically documented complicated mild to severe traumatic brain injury; primarily male Caucasians with some college. Main Outcome Measures: Disability Rating Scale and the Community Integration Questionnaire completed at admission, discharge. and two follow-up time points, Results: Repeated measures analyses, using time from injury to discharge as a covariate, revealed significant improvements on all measures from admission to discharge, with no significant change from discharge to either of the follow-up periods. However, substantial changes were noted in individual cases. Conclusions: The results indicate that gains made by persons with traumatic brain injury during postacute rehabilitation are generally maintained at long-term follow-up, but changes occur in individual cases. Long-term services may help prevent decline in individual cases.	Baylor Coll Med, Dept Phys Med & Rehabil, Brain Injury Res Ctr, TIRR, Houston, TX 77030 USA; Univ Mississippi, Med Ctr, Methodist Rehabil Ctr, Dept Neuropsychol, Jackson, MS 39216 USA	Sander, AM (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, Brain Injury Res Ctr, TIRR, 2455 S Braeswood, Houston, TX 77030 USA.	sandea@tirr.tmc.edu					BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; COPE D N, 1991, Brain Injury, V5, P127, DOI 10.3109/02699059109008084; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; High WM, 1996, J HEAD TRAUMA REHAB, V11, P85, DOI 10.1097/00001199-199610000-00008; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; JOHNSTON M V, 1991, Brain Injury, V5, P141, DOI 10.3109/02699059109008085; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; MALEC JF, 1993, BRAIN INJURY, V7, P383, DOI 10.3109/02699059309029682; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; MCCAULEY SR, IN PRESS J INT NEURO; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Ottenbacher KJ, 2000, AM J PUBLIC HEALTH, V90, P1920, DOI 10.2105/AJPH.90.12.1920; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reitan RM, 1988, TRAUMATIC BRAIN INJU, VII; RUFF RM, 1991, J NEUROSURG, V75, pS50, DOI 10.3171/sup.1991.75.1s.0s50; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Sherer M, 1997, CANCER, V80, P250, DOI 10.1002/(SICI)1097-0142(19970715)80:2<250::AID-CNCR13>3.3.CO;2-T; Sherer M, 1999, BRAIN INJURY, V13, P973; Sherer M, 1998, NEUROREHABILITATION, V10, P25, DOI 10.3233/NRE-1998-10104; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Struchen MA, 2001, J NEUROTRAUM, V18, P115, DOI 10.1089/08977150150502569; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009	37	40	40	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	2001	16	4					356	373		10.1097/00001199-200108000-00006			18	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	459YA	WOS:000170278000006	11461658				2021-06-18	
J	Otto, VI; Stahel, PF; Rancan, M; Kariya, K; Shohami, E; Yatsiv, I; Eugster, HP; Kossmann, T; Trentz, O; Moreganti-Kossmann, MC				Otto, VI; Stahel, PF; Rancan, M; Kariya, K; Shohami, E; Yatsiv, I; Eugster, HP; Kossmann, T; Trentz, O; Moreganti-Kossmann, MC			Regulation of chemokines and chemokine receptors after experimental closed head injury	NEUROREPORT			English	Article						chemokines; chemokine receptors; cytokines; knockout mice; neuroinflammation; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; TRAUMATIC BRAIN INJURY; TUMOR-NECROSIS-FACTOR; ALZHEIMERS-DISEASE; EXPRESSION; ASTROCYTES; ALPHA; CCR5; RAT; INTERLEUKIN-8	The expression of the chemokines macrophage inflammatory protein (MIP)-2 and MIP-1 alpha and of their receptors CXCR2 and CCR5 was assessed in wild type (WT) and TNF/lymphotoxin-alpha knockout (TNF/LT-alpha-/-) mice subjected to closed head injury (CHI). At 4 h after trauma intracerebral MIP-2 and MIP-1 alpha levels were increased in both groups with MIP-2 concentrations being significantly higher in WT than in TNF/LT-alpha-/- animals (p<0.05). Thereafter, MIP-2 production declined rapidly, whereas MIP-1<alpha> remained elevated for 7 days. Expression of CXCR2 was confined to astrocytes and increased dramatically within 24 h in both mouse types. Contrarily, CCR5 expression remained constitutively low and was mainly localized to microglia. These results show that after CHI, chemokines and their receptors are regulated differentially and with independent kinetics. NeuroReport 12:2059-2064 (C) 2001 Lippincott Williams & Wilkins.	Univ Zurich Hosp, Dept Surg, Div Res, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Med, Clin Immunol Sect, CH-8091 Zurich, Switzerland; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Pharmacol, IL-91010 Jerusalem, Israel	Stahel, PF (corresponding author), Univ Zurich Hosp, Dept Surg, Div Res, CH-8091 Zurich, Switzerland.			Morganti-Kossmann, Cristina/0000-0002-0807-2063			Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; Berman JW, 1996, J IMMUNOL, V156, P3017; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cota M, 2000, J NEUROVIROL, V6, P75, DOI 10.3109/13550280009006384; Eugster HP, 1996, INT IMMUNOL, V8, P23, DOI 10.1093/intimm/8.1.23; Galasso JM, 2000, EXP NEUROL, V165, P295, DOI 10.1006/exnr.2000.7466; Galasso JM, 1998, AM J PATHOL, V153, P1631, DOI 10.1016/S0002-9440(10)65752-5; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Ghirnikar RS, 1996, J NEUROSCI RES, V46, P727; Grzybicki D, 1998, ACTA NEUROPATHOL, V95, P98, DOI 10.1007/s004010050770; Hesselgesser J, 1999, J NEUROVIROL, V5, P13, DOI 10.3109/13550289909029741; Horuk R, 1997, J IMMUNOL, V158, P2882; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Luo Y, 2000, J IMMUNOL, V165, P4015, DOI 10.4049/jimmunol.165.7.4015; MUELLERLADNER U, 1996, J NEUROL SCI, V144, P135; Otto VI, 2000, J NEUROSCI RES, V60, P733, DOI 10.1002/1097-4547(20000615)60:6<733::AID-JNR5>3.0.CO;2-X; Ransohoff RM, 1998, TRENDS NEUROSCI, V21, P154, DOI 10.1016/S0166-2236(97)01198-3; Sanders VJ, 1998, AIDS, V12, P1021, DOI 10.1097/00002030-199809000-00008; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Simpson J, 2000, J NEUROIMMUNOL, V108, P192, DOI 10.1016/S0165-5728(00)00274-5; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Xia MQ, 1998, AM J PATHOL, V153, P31, DOI 10.1016/S0002-9440(10)65542-3; Xia MQ, 1997, AM J PATHOL, V150, P1267; Xiao BG, 1998, J NEUROCYTOL, V27, P575, DOI 10.1023/A:1006918110952	25	40	41	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	JUL 3	2001	12	9					2059	2064		10.1097/00001756-200107030-00053			6	Neurosciences	Neurosciences & Neurology	446HZ	WOS:000169509000048	11435946				2021-06-18	
J	Mueller, FO				Mueller, FO			Catastrophic head injuries in high school and collegiate sports	JOURNAL OF ATHLETIC TRAINING			English	Article						fatality; brain injury	FOOTBALL PLAYERS; CONCUSSION	Objective: To describe the incidence of catastrophic head injuries in a variety of high school and college sports. Design and Setting: Data on catastrophic head injuries were compiled in a national surveillance system maintained by the National Center for Catastrophic Sports Injury Research. The data were compiled with the assistance of coaches, athletic trainers, athletic directors, executive officers of state and national athletic organizations, a national newspaper clipping service, professional associates of the researchers, and national sport organizations. Subjects: Data included all high school and college athletic programs in the United States. Measurements: Background information on the athlete (age, height, weight, experience, previous injury, etc), accident information, immediate and postaccident medical care, type of injury, and equipment involved. Autopsy reports were used when available. Results: A football-related fatality has occurred every year from 1945 through 1999, except for 1990. Head-related deaths accounted for 69% of football fatalities, cervical spinal injuries for 16.3%, and other injuries for 14.7%. High school football produced the greatest number of football head-related deaths. From 1984 through 1999, 69 football head-related injuries resulted in permanent disability. Sixty-three of the injuries were associated with high school football and 6 with college football. Although football has received the most attention, other sports have also been associated with head-related deaths and permanent disability injuries. From 1982 through 1999, 20 deaths and 19 permanent disability injuries occurred in a variety of sports. Track and field, baseball, and cheerleading had the highest incidence of these catastrophic injuries. Three deaths and 3 injuries resulting in permanent disability have occurred in female participants. Conclusions/Recommendations: Reliable data collection systems and continual analysis of the data can help us to reduce the number of catastrophic head-related injuries. I include additional recommendations for injury prevention.	Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA	Mueller, FO (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, CB 8700,204 Fetzer Gymnasium, Chapel Hill, NC 27599 USA.						Cantu R., 1992, PHYSICIAN SPORTSMED, V20, P14; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P224; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; JANE JA, 1981, ART SCI SPORTS MED; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; MUELLER FO, 2000, ANN SURVEY FOOTBALL, P1; NELSON WE, 1981, PHYSICIAN SPORTSMED, V9, P886; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schneider R., 1973, HEAD NECK INJURIES F	11	40	41	1	16	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2001	36	3					312	315					4	Sport Sciences	Sport Sciences	557NC	WOS:000175913800016	12937502				2021-06-18	
J	Vos, PE; Van Voskuilen, AC; Beems, T; Krabbe, PFM; Vogels, OJM				Vos, PE; Van Voskuilen, AC; Beems, T; Krabbe, PFM; Vogels, OJM			Evaluation of the traumatic coma data bank computed tomography classification for severe head injury	JOURNAL OF NEUROTRAUMA			English	Article						computed tomography scan; Glasgow Outcome Scale; outcome; prognostic factor; severe head injury; traumatic brain injury; Traumatic Coma Data Bank classification	SUBARACHNOID HEMORRHAGE; IMPAIRED CONSCIOUSNESS; BRAIN INJURY; NIMODIPINE; SCAN; HEMATOMA; TRIALS	This study determines the interrater and intrarater reliability of the Traumatic Coma Data Bank (TCDB) computed tomography (CT) scan classification for severe head injury. This classification grades the severity of the injury as follows: I = normal, II = diffuse injury, III = diffuse injury with swelling, IV = diffuse injury with shift, V = mass lesion surgically evacuated, or VI = mass lesion not operated. Patients with severe closed head injury were included. Outcome was assessed using the Glasgow Outcome Score (GOS) at 3 and 6 months. Four observers, two of them classifying the scans twice, independently evaluated CT scans. Of the initial CT scans of 63 patients (36 males, 27 females; age, 34 +/- 24 years), 6.3% were class I, 26.9% class II, 28.6% class III, 6.3% class IV, 22.2% were class V, and 9.6% class VI. The overall interrater and intrarater reliability was 0.80 and 0.85, respectively. Separate analyses resulted in higher inter- and intrarater reliabilities for the mass lesion categories (V and VI), 0.94 and 0.91, respectively, than the diffuse categories (I-IV) 0.71 and 0.67. Merging category III with IV, and V with VI resulted in inter- and intrarater reliabilities of 0.93 and 0.78, respectively. Glasgow outcome scores after 6 months were as follows: 19 dead (30%), one vegetative (2%), five severely disabled (8%), 17 moderately disabled (27%), and 21 good recovery (33%). Association measures (Sommers' D) between CT and GOS scores were statistically significant for all observers. This study shows a high intra- and interobserver agreement in the assessment of CT scan abnormalities and confirms the predictive power on outcome when the TCDB classification is used.	Univ Med Ctr Nijmegen, Dept Neurol, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Nijmegen, Dept Neurosurg, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Nijmegen, Dept Med Technol Assessment, NL-6500 HB Nijmegen, Netherlands	Vos, PE (corresponding author), Univ Med Ctr Nijmegen, Dept Neurol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	p.vos@czzoneu.azn.nl	Krabbe, Paul/B-2563-2013; Vos, Pieter/A-6043-2012; Krabbe, Paul/AAO-6590-2020	Krabbe, Paul/0000-0001-6042-1243; Krabbe, Paul/0000-0001-6042-1243			BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; BRAAKMAN R, 1977, CLIN NEUROL NEUROSUR, V80, P104; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; JENNETT B, 1975, LANCET, V1, P480; Kakarieka A, 1997, NEUROL RES, V19, P230, DOI 10.1080/01616412.1997.11740804; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; Marmarou A, 1999, J NEUROTRAUM, V16, P431, DOI 10.1089/neu.1999.16.431; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Murray GD, 1996, ACTA NEUROCHIR, V138, P1163, DOI 10.1007/BF01809745; PASQUALIN A, 1991, NEUROSURGERY, V28, P370, DOI 10.1227/00006123-199103000-00006; Servadei F, 2000, NEUROSURGERY, V46, P70; SHAVELSON RJ, 1989, AM PSYCHOL, V44, P922, DOI 10.1037/0003-066X.44.6.922; Siegel S., 1988, NONPARAMETRIC STAT B; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; SMITH HK, 1991, NEUROSURGERY, V29, P258, DOI 10.1227/00006123-199108000-00016; Stocchetti N, 2000, J NEUROL NEUROSUR PS, V68, P14, DOI 10.1136/jnnp.68.1.14; Streiner D., 1995, HLTH MEASUREMENT SCA, V2; TEASDALE G, 1978, J NEUROL NEUROSUR PS, V41, P603, DOI 10.1136/jnnp.41.7.603; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE G, 1992, J NEUROTRAUM, V9, pS249; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; YAMAKI T, 1990, ACTA NEUROCHIR, V103, P112, DOI 10.1007/BF01407516	25	40	41	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2001	18	7					649	655		10.1089/089771501750357591			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	457CK	WOS:000170119400001	11497091				2021-06-18	
J	Greenwald, BD; Cifu, DX; Marwitz, JH; Enders, LJ; Brown, AW; Englander, JS; Zafonte, RD				Greenwald, BD; Cifu, DX; Marwitz, JH; Enders, LJ; Brown, AW; Englander, JS; Zafonte, RD			Factors associated with balance deficits on admission to rehabilitation after traumatic brain injury: A multicenter analysis	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						activities of daily living; adult; ambulation; balance; brain injuries; equilibrium; Glasgow Coma Score; human; medical complication; rehabilitation	ACUTE STROKE; HEAD-INJURY; INPATIENT REHABILITATION; BODY SWAY; LENGTH; STAY; OUTCOMES; PERFORMANCE; PREDICTORS; DISABILITY	Objective: To evaluate how demographics, measures of injury severity, and acute care complications relate to sitting and standing balance in patients with traumatic brain injury (TBI). Design: Multicenter analysis of consecutive admissions to designated TBI Model Systems of Care (TBIMS). Setting: Ten National Institute for Disability and Rehabilitation Research TBI Model System centers for coordinated acute and rehabilitation care. Participants: 908 adults with TBI were included in the study. Main Outcome Measures: Sitting and standing balance were assessed within 72 hours of admission to inpatient rehabilitation. Results: Age less than 50 years had a significant association with normal sitting and standing balance (P = .001 and .05, respectively). Measures of severity of traumatic brain injury, including admission Glasgow Coma Score, length of posttraumatic amnesia ( PTA), Length of coma, and acute care length of stay were each significantly related to impaired sitting and standing balance ratings (P < .01). Initial abnormalities in pupillary response had a significant relationship with impairment of sitting (P = .009) but not standing balance. Incidence of respiratory failure, pneumonia, soft tissue infections, and urinary tract infections were all related to impaired sitting balance (P < .01). Presence of intracranial hemorrhages did not have a significant relationship with either sitting or standing balance. Intracranial compression had a significant relationship with standing (P = .05) but not sitting balance. A discriminant function analysis, which included neuroradiological findings, injury severity, and medical complications, could not accurately predict impaired balance ratings. Conclusions: This study demonstrated that rehabilitation admission balance ratings have a significant relationship with age, multiple measures of severity, and acute care medical complications after TBI. Prospective studies are indicated to evaluate the role balance at rehabilitation admission plays in the functional prognosis of patients with TBI.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN USA; Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA; Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA	Greenwald, BD (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, 150 Bergen St,UH B261, Newark, NJ 07103 USA.			Brown, Allen W./0000-0001-7228-3351; Cifu, David/0000-0003-1600-9387			ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; BERG K, 1995, SCAND J REHABIL MED, V27, P27; BERG K, 1989, Physiotherapy Canada, V41, P304; BERG KO, 1992, ARCH PHYS MED REHAB, V73, P1073; Bohannon RW, 1997, INT J REHABIL RES, V20, P107, DOI 10.1097/00004356-199703000-00011; BOHANNON RW, 1995, ARCH PHYS MED REHAB, V76, P994, DOI 10.1016/S0003-9993(95)81035-8; Brosseau L, 1996, AM J PHYS MED REHAB, V75, P422, DOI 10.1097/00002060-199611000-00005; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Englander JS, 1996, J HEAD TRAUMA REHAB, V11, P15, DOI 10.1097/00001199-199610000-00003; Feigin L, 1996, GERONTOLOGY, V42, P348, DOI 10.1159/000213814; Franchignoni FP, 1997, STROKE, V28, P1382, DOI 10.1161/01.STR.28.7.1382; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; HAMRIN E, 1982, UPSALA J MED SCI, V87, P11, DOI 10.3109/03009738209178405; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; High WM, 1996, J HEAD TRAUMA REHAB, V11, P85, DOI 10.1097/00001199-199610000-00008; Hillier SL, 1997, BRAIN INJURY, V11, P661; Juneja G, 1998, AM J PHYS MED REHAB, V77, P388, DOI 10.1097/00002060-199809000-00005; KEENAN MA, 1984, CLIN ORTHOP RELAT R, P165; KOLLEGGER H, 1992, EUR NEUROL, V32, P253, DOI 10.1159/000116836; Kwakkel G, 1996, AGE AGEING, V25, P479, DOI 10.1093/ageing/25.6.479; Lee MY, 1997, AM J PHYS MED REHAB, V76, P401, DOI 10.1097/00002060-199709000-00011; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LOEWEN SC, 1990, STROKE, V21, P78, DOI 10.1161/01.STR.21.1.78; MAYO NE, 1991, AM J PHYS MED REHAB, V70, P118, DOI 10.1097/00002060-199106000-00002; Miyai I, 1997, NEUROLOGY, V48, P95, DOI 10.1212/WNL.48.1.95; Nichols DS, 1996, ARCH PHYS MED REHAB, V77, P865, DOI 10.1016/S0003-9993(96)90271-3; PRESCOTT RJ, 1982, STROKE, V13, P641, DOI 10.1161/01.STR.13.5.641; SANDIN KJ, 1990, STROKE, V21, P82, DOI 10.1161/01.STR.21.1.82; Shumway-Cook A, 1990, J HEAD TRAUMA REHAB, V5, P51, DOI DOI 10.1097/00001199-199012000-00007; SINCLAIR A J, 1990, Comprehensive Therapy, V16, P44; Smith MT, 1999, ARCH PHYS MED REHAB, V80, P442, DOI 10.1016/S0003-9993(99)90283-6; Tabachnik BG, 1989, USING MULTIVARIATE S, V2nd; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Wee JYM, 1999, ARCH PHYS MED REHAB, V80, P448, DOI 10.1016/S0003-9993(99)90284-8; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	41	40	41	0	2	ASPEN PUBL INC	GAITHERSBURG	200 ORCHARD RIDGE DR, STE 200, GAITHERSBURG, MD 20878 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	2001	16	3					238	252		10.1097/00001199-200106000-00003			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	442YY	WOS:000169313600003	11346446				2021-06-18	
J	Lewen, A; Skoglosa, Y; Clausen, F; Marklund, N; Chan, PH; Lindholm, D; Hillered, L				Lewen, A; Skoglosa, Y; Clausen, F; Marklund, N; Chan, PH; Lindholm, D; Hillered, L			Paradoxical increase in neuronal DNA fragmentation after neuroprotective free radical scavenger treatment in experimental traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						traumatic brain injury; cell death; apoptosis; necrosis; behavior; Outcome; caspases	TERT-BUTYL NITRONE; APOPTOTIC CELL-DEATH; RAT-BRAIN; DELAYED TREATMENT; CONTUSION TRAUMA; NECROSIS; PBN; DYSFUNCTION; ACTIVATION; DEFICITS	The mechanisms and role of nerve cell death after traumatic brain injury (TBI) are not fully understood. The authors investigated the effect of pretreatment with the oxygen free radical spin trap alpha -phenyl-N-tert-butyl-nitrone (PBN) on the number of neurons undergoing apoptosis after TBI in rats. Apoptotic cells were identified by the TUNEL method combined with the nuclear stain, Hoechst 33258, and immunohistochemistry for the active form of caspase-3. Numerous neurons became positive for activated caspase-3 and TUNEL in the cortex at 24 hours after injury, suggesting ongoing biochemical apoptosis. In PBN-treated rats, a significantly greater number of cells were found to be TUNEL positive at 24 hours compared with controls. However, PEN treatment resulted in a reduced cortical lesion volume and improved behavioral outcome two weeks after injury. The authors conclude that a treatment producing an increase in DNA fragmentation in the early phase may be compatible with an overall beneficial effect on outcome after TBI. This should be considered in the screening process for future neuroprotective remedies.	Univ Uppsala Hosp, Div Neurosurg, Dept Neurosci, SE-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Med Sci Clin Chem, SE-75185 Uppsala, Sweden; Ctr Biomed, Div Neurobiol, Dept Neurosci, Uppsala, Sweden; Stanford Univ, Sch Med, Dept Neurosurg, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Program Neurosci, Palo Alto, CA 94304 USA	Hillered, L (corresponding author), Univ Uppsala Hosp, Div Neurosurg, Dept Neurosci, SE-75185 Uppsala, Sweden.		Lindholm, Dan/B-3777-2014; Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348; Marklund, Niklas/0000-0002-9797-5626; Clausen, Fredrik/0000-0003-3592-4417			CARNEY JM, 1991, J MOL NEUROSCI, V3, P47, DOI 10.1007/BF02896848; Chan P.H, 1988, CELLULAR ANTIOXIDANT, VVolume 3, P89; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; Eguchi Y, 1997, CANCER RES, V57, P1835; Eguchi Y, 1999, CANCER RES, V59, P2174; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FOLBERGROVA J, 1995, P NATL ACAD SCI USA, V92, P5057, DOI 10.1073/pnas.92.11.5057; Folbergrova J, 1999, NEUROSCI LETT, V266, P121, DOI 10.1016/S0304-3940(99)00279-7; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HILLERED L, 1983, J CEREBR BLOOD F MET, V3, P207, DOI 10.1038/jcbfm.1983.28; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kuroda S, 1996, NEUROBIOL DIS, V3, P149, DOI 10.1006/nbdi.1996.0015; Lelli JL, 1998, FREE RADICAL BIO MED, V25, P694, DOI 10.1016/S0891-5849(98)00107-5; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lewen A, 1999, ACTA NEUROCHIR, V141, P193, DOI 10.1007/s007010050286; Lieberthal W, 1998, AM J PHYSIOL-RENAL, V274, pF315; McDonald JW, 1997, BRAIN RES, V759, P228, DOI 10.1016/S0006-8993(97)00248-5; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Povlishock J T, 1992, Hum Cell, V5, P345; RINK A, 1995, AM J PATHOL, V147, P1575; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; Samali A, 1999, BIOCHEM BIOPH RES CO, V255, P6, DOI 10.1006/bbrc.1998.0139; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; ZHAO Q, 1994, ACTA PHYSIOL SCAND, V152, P349, DOI 10.1111/j.1748-1716.1994.tb09816.x	39	40	40	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2001	21	4					344	350		10.1097/00004647-200104000-00003			7	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	421PT	WOS:000168073300003	11323520	Bronze			2021-06-18	
J	Penkowa, M; Giralt, M; Thomsen, PS; Carrasco, J; Hidalgo, J				Penkowa, M; Giralt, M; Thomsen, PS; Carrasco, J; Hidalgo, J			Zinc or copper deficiency-induced impaired inflammatory response to brain trauma may be caused by the concomitant metallothionein changes	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; Cu.Zn-SOD; gliosis; iNOS; MDA; MT-KO; NF-kappa B; NITT; oxidative stress; TUNEL	GROWTH-INHIBITORY FACTOR; III MESSENGER-RNA; RAT-BRAIN; OXIDATIVE STRESS; TRANSGENIC MICE; NEURODEGENERATIVE-DISORDERS; STAB WOUNDS; INDUCED HEPATOTOXICITY; REACTIVE ASTROCYTES; I-DEFICIENT	The role of zinc- and copper-deficient diets on the inflammatory response to traumatic brain injury (TBI) has been evaluated in adult rats. As expected, zinc deficiency decreased food intake and body weight gain, and the latter effect was higher than that observed in pair-fed rats. In noninjured brains, zinc deficiency only affected significantly lectin (increasing) and glial fibrillary acidic protein (GFAP) and Cu,Zn-superoxide dismutase (Cu,Zn-SOD) (decreasing) immunoreactivities (irs). In injured brains, a profound gliosis was observed in the area surrounding the lesion, along with severe damage to neurons as indicated by neuron specific enolase (NSE) ir, and the number of cells undergoing apoptosis (measured by TUNEL) was dramatically increased. Zinc deficiency significantly altered brain response to TBI, potentiating the microgliosis and reducing the astrogliosis, while increasing the number of apoptotic cells. Metallothioneins (MTs) are important zinc- and copper-binding proteins in the CNS, which could influence significantly the brain response to TBI because of their putative roles in metal homeostasis and antioxidant defenses. MT-I+II expression was dramatically increased by TBI, and this response was significantly blunted by zinc deficiency. The MT-III isoform was moderately increased by both TBI and zinc deficiency. TBI strongly increased oxidative stress levels, as demonstrated by malondialdehyde (MDA), protein tyrosine nitration (NITT), and nuclear factor kappaB (NF-kappaB) levels irs, all of which were potentiated by zinc deficiency. Further analysis revealed unbalanced expression of prooxidant and antioxidant proteins besides MT, since the levels of inducible nitric oxide synthase (iNOS) and Cu,Zn-SOD were increased and decreased, respectively, by zinc deficiency. All these effects were attributable to zinc deficiency, since pair-fed rats did not differ from normally fed rats. In general, copper deficiency caused a similar pattern of responses, albeit more moderate. Results obtained in mice with a null mutation for the MT-I+II isoforms strongly suggest that most of the effects observed in the rat brain after zinc and copper deficiencies are attributable to the concomitant changes in the MT expression.	Univ Autonoma Barcelona, Fac Ciencias, Dept Biol Celular Fisiol & Immunol, Unidad Fisiol Anim, E-08193 Barcelona, Spain; Univ Copenhagen, Panum Inst, Dept Med Anat, DK-2200 Copenhagen, Denmark	Hidalgo, J (corresponding author), Univ Autonoma Barcelona, Fac Ciencias, Dept Biol Celular Fisiol & Immunol, Unidad Fisiol Anim, E-08193 Barcelona, Spain.	Juan.Hidalgo@uab.es	Carrasco, Javier/C-9732-2011; Giralt, Mercedes/K-1626-2014; Hidalgo, Juan/C-9082-2011	Carrasco, Javier/0000-0001-6436-0863; Giralt, Mercedes/0000-0002-1806-1528; Hidalgo, Juan/0000-0003-0921-1122			Acarin L, 1999, NEUROSCIENCE, V92, P827, DOI 10.1016/S0306-4522(99)00022-6; Acarin L, 1999, J NEUROPATH EXP NEUR, V58, P389, DOI 10.1097/00005072-199904000-00009; Amat JA, 1996, GLIA, V16, P368, DOI 10.1002/(SICI)1098-1136(199604)16:4<368::AID-GLIA9>3.0.CO;2-W; ANEZAKI T, 1995, NEUROCHEM INT, V27, P89, DOI 10.1016/0197-0186(94)00170-Y; Bains JS, 1997, BRAIN RES REV, V25, P335, DOI 10.1016/S0165-0173(97)00045-3; BREMNER I, 1987, PROG FOOD NUTR SCI, V11, P1; BREMNER I, 1987, J NUTR, V117, P1595; CAMPAGNE MV, 1999, J CEREB BLOOD FLOW M, V19, pS138; Carrasco J, 1998, EXP NEUROL, V153, P184, DOI 10.1006/exnr.1998.6861; Carrasco J, 1999, J NEUROTRAUM, V16, P1115, DOI 10.1089/neu.1999.16.1115; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; COUSINS RJ, 1985, PHYSIOL REV, V65, P238; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Cuajungco MP, 1997, NEUROBIOL DIS, V4, P137, DOI 10.1006/nbdi.1997.0163; DALTON T, 1995, NEUROCHEM INT, V27, P59, DOI 10.1016/0197-0186(94)00168-T; EBADI M, 1985, BIOL TRACE ELEM RES, V7, P129, DOI 10.1007/BF02916535; ERICKSON JC, 1994, BRAIN RES, V649, P297, DOI 10.1016/0006-8993(94)91076-6; Erickson JC, 1997, J NEUROSCI, V17, P1271; FREDERICKSON C, 1984, NEUROBIOLOGY ZINC A; Fu K, 1998, PANCREAS, V17, P238, DOI 10.1097/00006676-199810000-00003; GASULL T, 1993, J IMMUNOASSAY, V14, P209, DOI 10.1080/15321819308019851; GASULL T, 1994, AM J PHYSIOL, V266, pE760; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.bi.55.070186.004405; Hanada K, 1998, J INVEST DERMATOL, V111, P582, DOI 10.1046/j.1523-1747.1998.00342.x; Hensley K, 1997, INT REV NEUROBIOL, V40, P299; Hernandez J, 1997, J ENDOTOXIN RES, V4, P363, DOI 10.1177/096805199700400508; HIDALGO J, 1990, J NEUROCHEM, V55, P651, DOI 10.1111/j.1471-4159.1990.tb04182.x; HIDALGO J, 1994, CHEM-BIOL INTERACT, V93, P197, DOI 10.1016/0009-2797(94)90020-5; HIDALGO J, 1997, CURR TOPICS NEUROCHE, V1, P1; HOZUMI I, 1995, BRAIN RES, V688, P143, DOI 10.1016/0006-8993(95)00522-R; Hozumi I, 1996, BRAIN RES, V741, P197, DOI 10.1016/S0006-8993(96)00912-2; IMAGAWA M, 1995, J BIOL CHEM, V270, P20898, DOI 10.1074/jbc.270.36.20898; Inuzuka T, 1996, BRAIN RES, V709, P151, DOI 10.1016/0006-8993(95)01444-6; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; Kang YJ, 1997, J CLIN INVEST, V100, P1501, DOI 10.1172/JCI119672; Keen CL, 1998, AM J CLIN NUTR, V67, p1003S, DOI 10.1093/ajcn/67.5.1003S; Kondo Y, 1997, MOL PHARMACOL, V52, P195; LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506; Liu J, 1998, TOXICOL APPL PHARM, V149, P24, DOI 10.1006/taap.1997.8325; Liu J, 1999, J PHARMACOL EXP THER, V289, P580; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; MASTERS BA, 1994, J NEUROSCI, V14, P5844; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; NALBANDYAN RM, 1983, NEUROCHEM RES, V8, P1211, DOI 10.1007/BF00963993; NARUSE S, 1994, GENE, V144, P283, DOI 10.1016/0378-1119(94)90391-3; Neal JW, 1996, NEUROPATH APPL NEURO, V22, P243; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; PALMITER RD, 1992, P NATL ACAD SCI USA, V89, P6333, DOI 10.1073/pnas.89.14.6333; Penkowa M, 1997, BRAIN RES, V774, P256, DOI 10.1016/S0006-8993(97)81716-7; PENKOWA M, 1995, GLIA, V13, P217, DOI 10.1002/glia.440130308; Penkowa M, 1999, GLIA, V25, P343; Penkowa M, 1999, EXP NEUROL, V156, P149, DOI 10.1006/exnr.1998.7009; Penkowa M, 1999, J NEUROSCI, V19, P2535; QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SEWELL AK, 1995, BIOCHEMISTRY-US, V34, P4740, DOI 10.1021/bi00014a031; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SMITT PAES, 1992, NEUROSCI LETT, V144, P107, DOI 10.1016/0304-3940(92)90727-O; Stichel CC, 1998, PROG NEUROBIOL, V56, P119, DOI 10.1016/S0301-0082(98)00033-1; SUZUKI K, 1992, ACTA HISTOCHEM CYTOC, V25, P617, DOI 10.1267/ahc.25.617; Uauy R, 1998, AM J CLIN NUTR, V67, p952S, DOI 10.1093/ajcn/67.5.952S; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; Uchida Yoko, 1994, Biological Signals, V3, P211; VALLEE B L, 1988, Biofactors, V1, P31; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Vela JM, 1997, BRAIN RES, V767, P345, DOI 10.1016/S0006-8993(97)00628-8; YAGLE MK, 1985, MOL CELL BIOL, V5, P291, DOI 10.1128/MCB.5.2.291; YOUNG JK, 1991, GLIA, V4, P602, DOI 10.1002/glia.440040607; YUGUCHI T, 1995, MOL BRAIN RES, V28, P181, DOI 10.1016/0169-328X(94)00205-S; YUGUCHI T, 1995, J NEUROTRAUM, V12, P299, DOI 10.1089/neu.1995.12.299; ZHENG H, 1995, NEUROCHEM INT, V27, P43, DOI 10.1016/0197-0186(94)00167-S	74	40	47	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2001	18	4					447	463		10.1089/089771501750171056			17	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	425TP	WOS:000168308000008	11336445				2021-06-18	
J	Francois, B; Vacher, P; Roustan, J; Salle, JY; Vidal, J; Moreau, JJ; Vignon, P				Francois, B; Vacher, P; Roustan, J; Salle, JY; Vidal, J; Moreau, JJ; Vignon, P			Intrathecal baclofen after traumatic brain injury: Early treatment using a new technique to prevent spasticity	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							SPINAL SPASTICITY; PROGRAMMABLE PUMP; CEREBRAL ORIGIN; EXPERIENCE; INFUSION; TETANUS	Background: In the early course of severe head trauma, the clinical value of intrathecal administration of baclofen to reduce autonomic disorders and spasticity has not been established. Methods: We studied four patients (Glasgow Coma Scale score 3 or 4) with autonomic disorders and spasticity who failed to respond to conventional treatment during the early course of head injury, Baclofen (25 mug/mL) was infused continuously through an intrathecal catheter inserted at patient bedside and subcutaneously tunneled. When this treatment was successful, the spinal catheter was removed and surgically replaced by another catheter connected to a subcutaneous pump. Clinical follow-up was obtained at 6 months after the head injury, Results: Mean delay for the initiation of intrathecal baclofen was 25 days (range, 21 to 31 days), and optimal dose was 385 +/- 185 mug/day. In all patients, the Ashworth score was consistently reduced (3.5 +/- 0.5. vs. 4.5 +/- 0.5 for upper limbs and 2 +/- 0.5 vs. 4.5 +/- 0.5 for lower limbs), as were both the frequency and intensity of autonomic disorders. The spinal catheters were used during a mean period of 9.5 +/- 1.7 days without complications. All three survivors were equipped with a programmable pump and had a lower Ashworth score at 6 months. Autonomic disorders had disappeared in two patients and remained modest in the remaining patient. Conclusion: Continuous administration of baclofen via the intrathecal route using this new technique seems to reduce autonomic disorders and spasticity during the early course of severe traumatic head injury.	Dupuytren Univ Hosp, Intens Care Unit, Limoges, France; Dupuytren Univ Hosp, Dept Rehabil, Limoges, France; Dupuytren Univ Hosp, Dept Neurosurg, Limoges, France	Francois, B (corresponding author), CHU Dupuytren, Serv Reanimat Polyvalente, 2 Ave Martin Luther King, F-87042 Limoges, France.		Vignon, Philippe/O-8886-2016; Francois, Bruno/O-8404-2016	Vignon, Philippe/0000-0003-4551-5772; Francois, Bruno/0000-0002-2531-1652			ABEL NA, 1994, ARCH PHYS MED REHAB, V75, P54; ALBRIGHT AL, 1993, JAMA-J AM MED ASSOC, V270, P2475, DOI 10.1001/jama.270.20.2475; Armstrong RW, 1997, J NEUROSURG, V87, P409, DOI 10.3171/jns.1997.87.3.0409; Becker R, 1997, J NEUROL, V244, P160, DOI 10.1007/s004150050067; COFFEY RJ, 1993, J NEUROSURG, V78, P226, DOI 10.3171/jns.1993.78.2.0226; Francois B, 1997, PRESSE MED, V26, P1045; Meythaler JM, 1999, ARCH PHYS MED REHAB, V80, P13, DOI 10.1016/S0003-9993(99)90301-5; Meythaler JM, 1999, AM J PHYS MED REHAB, V78, P247, DOI 10.1097/00002060-199905000-00012; MEYTHALER JM, 1994, J NEUROSURG, V57, P582; Middel B, 1997, J NEUROL NEUROSUR PS, V63, P204, DOI 10.1136/jnnp.63.2.204; Ordia JI, 1996, J NEUROSURG, V85, P452, DOI 10.3171/jns.1996.85.3.0452; PENN RD, 1992, J NEUROSURG, V77, P236, DOI 10.3171/jns.1992.77.2.0236; PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303; SILBERT PL, 1993, ANESTHESIOLOGY, V79, P199, DOI 10.1097/00000542-199307000-00049	14	40	41	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2001	50	1					158	161		10.1097/00005373-200101000-00035			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	392UQ	WOS:000166431300035	11231690				2021-06-18	
J	Dolinak, D; Smith, C; Graham, DI				Dolinak, D; Smith, C; Graham, DI			Global hypoxia per se is an unusual cause of axonal injury	ACTA NEUROPATHOLOGICA			English	Article						human global hypoxia; axonal injury; raised intracranial pressure	AMYLOID PRECURSOR PROTEIN; ISCHEMIC BRAIN-DAMAGE; MISSILE HEAD-INJURY; INTRACRANIAL-PRESSURE; DIAGNOSIS; TRAUMA; PATHOLOGY; MODEL; MILD	Irreversible hypoxic brain damage and axonal injury are present in over 90% of fatal blunt head injuries. Given the frequency each, difficulties arise as to whether or not they are due to different mechanisms and, as such, can be separately recognised and quantified. Recent literature has raised the possible role of hypoxia in the formation of axonal bulbs. The present study of 17 cases of cardio-respiratory arrest, 12 of status epilepticus, 3 of carbon monoxide poisoning and 12 controls was designed to test the relationship between hypoxia and axonal injury and to test the hypothesis whether or not the two entities can be separated into primary and secondary forms of traumatic brain injury. Axonal damage was seen in 9/17 and 7/12 of the cases with cardiac arrest and status epilepticus, respectively, in most of whom there was also evidence of raised intracranial pressure (ICP). All 3 cases of carbon monoxide poisoning had evidence of white matter damage in keeping with the classical pattern of selective vulnerability. It is concluded that the great majority of axonal damage identified in cases dying after cardiac arrest and status epilepticus can be attributed to raised ICP and the vascular complications of internal herniation. However, in some cases, axonal damage was seen in the absence of an elevated ICP, although its amount and distribution were different from diffuse axonal injury. In many cases there was an increase in expression of neuronal beta amyloid precursor protein.	Univ Glasgow, Inst Neurol Sci, Dept Neuropathol, S Glasgow Univ Hosp NHS Trust, Glasgow G51 4TF, Lanark, Scotland	Graham, DI (corresponding author), Univ Glasgow, Inst Neurol Sci, Dept Neuropathol, S Glasgow Univ Hosp NHS Trust, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.	D.Graham@clinmed.gla.ac.uk					ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adle-Biassette H, 1999, NEUROPATH APPL NEURO, V25, P123; AUER RN, 1997, GREENFIELDS NEUROPAT, P263; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BRIERLEY JB, 1994, GREENFIELDS NEUROPAT, P125; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Geddes JF, 1997, J CLIN PATHOL, V50, P271, DOI 10.1136/jcp.50.4.271; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gentleman SM, 1999, NEUROPATH APPL NEURO, V25, P41; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Graham D.I., 1993, HEAD INJURY, P91; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; GRAHAM DI, 1987, NEUROPATH APPL NEURO, V13, P209, DOI 10.1111/j.1365-2990.1987.tb00184.x; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P197; GRAHAM DI, 2000, IN PRESS HEAD INJURY; JELLINGER K, 1970, J NEUROL SCI, V10, P51, DOI 10.1016/0022-510X(70)90091-2; Jellinger KA, 1977, APALLIC SYNDROME, P88; Kaur B, 1999, J CLIN PATHOL, V52, P203, DOI 10.1136/jcp.52.3.203; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Oehmichen M, 1999, INT J LEGAL MED, V112, P261, DOI 10.1007/s004140050246; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; PETERS G, 1977, APALLIC SYNDROME, P78; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; STRICH SJ, 1969, LATE EFFECTS HEAD IN, P501; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	39	40	42	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	NOV	2000	100	5					553	560		10.1007/s004010000218			8	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	352GK	WOS:000089206800014	11045678				2021-06-18	
J	O'Neill, MJ; Murray, TK; McCarty, DR; Hicks, CA; Dell, CP; Patrick, KE; Ward, MA; Osborne, DJ; Wiernicki, TR; Roman, CR; Lodge, D; Fleisch, JH; Singh, J				O'Neill, MJ; Murray, TK; McCarty, DR; Hicks, CA; Dell, CP; Patrick, KE; Ward, MA; Osborne, DJ; Wiernicki, TR; Roman, CR; Lodge, D; Fleisch, JH; Singh, J			ARL 17477, a selective nitric oxide synthase inhibitor, with neuroprotective effects in animal models of global and focal cerebral ischaemia	BRAIN RESEARCH			English	Article						cerebral ischemia; ARL 17477; nitric oxide; mongolian gerbil; rat; neuroprotection	ARGININE METHYL-ESTER; TRAUMATIC BRAIN INJURY; ARTERY OCCLUSION; 1-(2-TRIFLUOROMETHYLPHENYL) IMIDAZOLE; RECEPTOR ANTAGONIST; 7-NITRO INDAZOLE; INFARCT VOLUME; NOS INHIBITOR; ISCHEMIA; RAT	In the present studies, we have evaluated the effects of N-[4-(2-{[( 3-Chlorophenyl)methyl]amino}ethyl)phenyl]-2-thiophenecarboximidamide dihydrochloride (ARL 17477) on recombinant human neuronal NOS (nNOS) and endothelial NOS (eNOS). We then carried out pharmacokinetic studies and measured cortical nitric oxide synthase (NOS) inhibition to determine that the compound crossed the blood brain barrier. Finally, the compound was evaluated in a model of global ischaemia in the gerbil and two models of transient focal ischaemia in the rat. The IC50 values for ARL 17477 on human recombinant human nNOS and eNOS were 1 and 17 mu M, respectively. ARL 17477 (50 mg/kg i.p.) produced a significant reduction in the ischaemia-induced hippocampal damage following global ischaemia when administered immediately post-occlusion, but failed to protect when administration was delayed until 30 min post-occlusion. In the endothelin-l model of focal ischaemia, ARL 17477 (1 mg/kg i.v.) significantly attenuated the infarct volume when administered at either 0, 1 or 2 h post-endothelin-1 (P<0.05). In the intraluminal suture model, ARL 17477 at both 1 and 3 mg/kg i.v. failed to reduce the infarct volume measured at 1, 3 or 7 days post-occlusion. These results demonstrate that ARL 17477 protects against global ischaemia in gerbils and provides some reduction in infarct volume following transient middle cerebral artery occlusion in rats, indicating that nNOS inhibition may be a useful treatment of ischaemic conditions. (C) 2000 Elsevier Science B.V. All rights reserved.	Eli Lilly & Co Ltd, Lilly Res Ctr, Windlesham GU20 6PH, Surrey, England; Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA	O'Neill, MJ (corresponding author), Eli Lilly & Co Ltd, Lilly Res Ctr, Erl Wood Manor, Windlesham GU20 6PH, Surrey, England.	oneill_michael_j@lilly.com					BABBEDGE RC, 1993, BRIT J PHARMACOL, V110, P225, DOI 10.1111/j.1476-5381.1993.tb13796.x; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Boxer PA, 1997, DRUG DISCOV TODAY, V2, P219, DOI 10.1016/S1359-6446(97)01045-3; BUISSON A, 1993, J NEUROCHEM, V61, P690; CALDWELL M, 1994, EUR J PHARMACOL, V260, P191, DOI 10.1016/0014-2999(94)90337-9; CALDWELL M, 1995, EUR J PHARMACOL, V285, P203, DOI 10.1016/0014-2999(95)00502-C; Chabrier PE, 1999, CELL MOL LIFE SCI, V55, P1029, DOI 10.1007/s000180050353; CHABRIER PE, 1999, P NATL ACAD SCI USA, V14, P10557; CHOI DW, 1993, P NATL ACAD SCI USA, V90, P9741, DOI 10.1073/pnas.90.21.9741; Coert BA, 1999, J NEUROSURG, V90, P332, DOI 10.3171/jns.1999.90.2.0332; DAWSON DA, 1994, BRIT J PHARMACOL, V113, P247, DOI 10.1111/j.1476-5381.1994.tb16201.x; DAWSON DA, 1994, CEREBROVAS BRAIN MET, V6, P299; Dawson VL, 1996, J NEUROSCI, V16, P2479; Escott KJ, 1998, J CEREBR BLOOD F MET, V18, P281, DOI 10.1097/00004647-199803000-00006; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; GENTILE RJ, 1995, Patent No. 05363; Green IC, 1999, DRUG DISCOV TODAY, V4, P47, DOI 10.1016/S1359-6446(98)01296-3; HANDY RLC, 1995, BRIT J PHARMACOL, V116, P2349, DOI 10.1111/j.1476-5381.1995.tb15078.x; Harukuni I, 1999, CRIT CARE MED, V27, P2508, DOI 10.1097/00003246-199911000-00030; Hicks CA, 1999, EUR J PHARMACOL, V381, P113, DOI 10.1016/S0014-2999(99)00543-9; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Lei BP, 1999, STROKE, V30, P669, DOI 10.1161/01.STR.30.3.669; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; MONCADA S, 1991, PHARMACOL REV, V43, P109; Moore PK, 1997, TRENDS PHARMACOL SCI, V18, P204, DOI 10.1016/S0165-6147(97)90624-6; NAGAFUJI T, 1995, MOL CHEM NEUROPATHOL, V26, P107, DOI 10.1007/BF02815009; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; O'Neill MJ, 2000, NEUROPHARMACOLOGY, V39, P1575, DOI 10.1016/S0028-3908(99)00250-6; Olesen SP, 1997, ACTA NEUROL SCAND, V95, P219, DOI 10.1111/j.1600-0404.1997.tb00102.x; ONeill MJ, 1996, EUR J PHARMACOL, V310, P115, DOI 10.1016/0014-2999(96)00387-1; ONeill MJ, 1997, BRAIN RES, V760, P170, DOI 10.1016/S0006-8993(97)00293-X; Panahian N, 1996, NEUROSCIENCE, V72, P343, DOI 10.1016/0306-4522(95)00563-3; QUAST MJ, 1995, BRAIN RES, V677, P204, DOI 10.1016/0006-8993(95)00134-C; Schmid-Elsaesser R, 1999, BRAIN RES, V816, P471, DOI 10.1016/S0006-8993(98)01197-4; Schulz JB, 1996, J NEUROCHEM, V67, P430; SHARKEY J, 1994, NATURE, V371, P336, DOI 10.1038/371336a0; SHARKEY J, 1994, J AUTONOM NERV SYST, V49, pS177; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; Spinnewyn B, 1999, J CEREBR BLOOD F MET, V19, P139; Togashi H, 1998, NEUROSCI LETT, V240, P53, DOI 10.1016/S0304-3940(97)00918-X; TRAYSTMAN RJ, 1991, J APPL PHYSIOL, V71, P1185; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WEISSMAN BA, 1992, NEUROSCI LETT, V146, P139, DOI 10.1016/0304-3940(92)90062-C; YOSHIDA T, 1994, J CEREBR BLOOD F MET, V14, P924, DOI 10.1038/jcbfm.1994.123; YOSHIDA T, 1995, NEUROSCI LETT, V194, P214, DOI 10.1016/0304-3940(95)11752-I; Zhang FY, 1996, STROKE, V27, P317, DOI 10.1161/01.STR.27.2.317; Zhang ZG, 1996, J CEREBR BLOOD F MET, V16, P599, DOI 10.1097/00004647-199607000-00009	51	40	51	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 21	2000	871	2					234	244		10.1016/S0006-8993(00)02471-9			11	Neurosciences	Neurosciences & Neurology	337TG	WOS:000088377300008	10899290				2021-06-18	
J	Siren, AL; Knerlich, F; Schilling, L; Kamrowski-Kruck, H; Hahn, A; Ehrenreich, H				Siren, AL; Knerlich, F; Schilling, L; Kamrowski-Kruck, H; Hahn, A; Ehrenreich, H			Differential glial and vascular expression of endothelins and their receptors in rat brain after neurotrauma	NEUROCHEMICAL RESEARCH			English	Article						cryogenic cortical lesion; ET-1; ET-3; ETA-receptor; ETB-receptor; immunohistochemistry; RT PCR	CEREBROSPINAL-FLUID; CONVERTING-ENZYME; BASILAR ARTERY; B RECEPTORS; SUBARACHNOID HEMORRHAGE; GLOBAL-ISCHEMIA; PARIETAL CORTEX; MESSENGER-RNA; INJURY; IMMUNOREACTIVITY	We characterized the time-course, intensity of expression and cellular origin of components of the endothelin (ET) system in the rat brain after a standardized neurotrauma (cryogenic lesion of the parietal cortex). ET mRNAs were expressed at sham level after neurotrauma, whereas immunoreactivity for ET-1 was enhanced in glia and endothelium of the lesioned hemisphere and both hippocampi. The number of ET-3 positive mononuclear cells in the lesion perimeter increased starting at 24h after injury. At 48h after neurotrauma, ET-receptor immunoreactivity was increased in astrocytes. In basilar artery endothelium, ETB-immunoreactivity was reduced at 48h to 72h recovering at 7 days whereas ETA-receptor and ET-peptide immunoreactivities were not altered. In summary, neurotrauma leads to a multicellular stimulation of endothelins in the brain along with a delayed selective loss of vascular ETB-receptors. These changes seem to be posttranscriptional and cell type specific. They favor vasoconstriction increasing the risk of late vasospasm and ischemia.	Max Planck Inst Expt Med, D-37075 Gottingen, Germany; Univ Gottingen, Dept Psychiat, D-37075 Gottingen, Germany; Univ Gottingen, Dept Neurol, D-37075 Gottingen, Germany; Univ Heidelberg Hosp, Dept Neurosurg, D-68167 Mannheim, Germany; Knoll AG, Dept Cardiovasc Res, D-6700 Ludwigshafen, Germany	Siren, AL (corresponding author), Max Planck Inst Expt Med, Hermann Rein Str 3, D-37075 Gottingen, Germany.	Siren@em.mpg.de	Knerlich-Lukoschus, Friederike/A-3233-2011; Knerlich-Lukoschus, Friederike F/J-2895-2016; Siren, Anna-Leena/AAE-1374-2019	Knerlich-Lukoschus, Friederike F/0000-0002-6284-0449; Siren, Anna-Leena/0000-0002-2217-0081; Ehrenreich, Hannelore/0000-0001-8371-5711			Armstead WM, 1996, J NEUROSURG, V85, P901, DOI 10.3171/jns.1996.85.5.0901; BARONE FC, 1994, J CEREBR BLOOD F MET, V14, P337, DOI 10.1038/jcbfm.1994.41; BERGER SL, 1989, METHOD ENZYMOL, V180, P3; Dawson DA, 1999, NEUROCHEM RES, V24, P1499, DOI 10.1023/A:1021139713026; DOUGLAS SA, 1994, TRENDS PHARMACOL SCI, V15, P313, DOI 10.1016/0165-6147(94)90019-1; EHRENREICH H, 1993, BRAIN RES, V600, P201, DOI 10.1016/0006-8993(93)91374-2; Ehrenreich H, 1999, BIOCHEM BIOPH RES CO, V261, P149, DOI 10.1006/bbrc.1999.0924; Ehrenreich H, 1999, NEUROSCIENCE, V91, P1067, DOI 10.1016/S0306-4522(98)00663-0; EHRENREICH H, 1993, J IMMUNOL, V150, P4601; EHRENREICH H, 1991, BRAIN RES, V538, P54, DOI 10.1016/0006-8993(91)90375-6; EHRENREICH H, 1995, CLEV CLIN J MED, V62, P105, DOI 10.3949/ccjm.62.2.105; EHRENREICH H, 1990, J EXP MED, V172, P1741, DOI 10.1084/jem.172.6.1741; EHRENREICH H, 1992, RES EXP MED, V192, P257, DOI 10.1007/BF02576282; FEGER GI, 1994, J CEREBR BLOOD F MET, V14, P845, DOI 10.1038/jcbfm.1994.106; FEUERSTEIN G, 1994, PEPTIDES, V15, P467, DOI 10.1016/0196-9781(94)90207-0; GAETANI P, 1994, J NEUROL NEUROSUR PS, V57, P66, DOI 10.1136/jnnp.57.1.66; GIAID A, 1991, HISTOCHEMISTRY, V95, P303; GIAID A, 1989, P NATL ACAD SCI USA, V86, P7634, DOI 10.1073/pnas.86.19.7634; Gorlach C, 1998, J CEREBR BLOOD F MET, V18, P1357; Hama H, 1997, J NEUROSCI RES, V47, P590, DOI 10.1002/(SICI)1097-4547(19970315)47:6<590::AID-JNR4>3.0.CO;2-8; Hasselblatt M, 1998, BRAIN RES, V785, P253, DOI 10.1016/S0006-8993(97)01368-1; Hermann DM, 1998, NEUROREPORT, V9, P1249, DOI 10.1097/00001756-199804200-00053; JIANG MH, 1993, NEUROREPORT, V4, P935, DOI 10.1097/00001756-199307000-00024; Kasemsri T, 1997, STROKE, V28, P190, DOI 10.1161/01.STR.28.1.190; KITAZONO T, 1995, J PHARMACOL EXP THER, V273, P1; Knerlich F, 1999, MOL BRAIN RES, V68, P73, DOI 10.1016/S0169-328X(99)00064-9; Lampl Y, 1997, STROKE, V28, P1951, DOI 10.1161/01.STR.28.10.1951; MACCUMBER MW, 1990, P NATL ACAD SCI USA, V87, P2359, DOI 10.1073/pnas.87.6.2359; Maeda M, 1997, ACTA NEUROPATHOL, V94, P116, DOI 10.1007/s004010050682; MASAKI T, 1992, MED RES REV, V12, P391, DOI 10.1002/med.2610120405; NUYTINCK HK, 1987, PROG CLIN BIOL RES, P55; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Patel TR, 1996, J CEREBR BLOOD F MET, V16, P950, DOI 10.1097/00004647-199609000-00019; Patel TR, 1996, J CEREBR BLOOD F MET, V16, P490, DOI 10.1097/00004647-199605000-00016; Sairanen TR, 1997, J CEREBR BLOOD F MET, V17, P1107, DOI 10.1097/00004647-199710000-00013; Sato M, 1998, BRAIN RES, V809, P39, DOI 10.1016/S0006-8993(98)00817-8; SCHILLING L, 1995, J CEREBR BLOOD F MET, V15, P699, DOI 10.1038/jcbfm.1995.86; SCHILLING L, 1994, ACTA NEUROCHIR, P79; SCHMIDT M, 1994, FEBS LETT, V356, P238, DOI 10.1016/0014-5793(94)01277-6; Spatz M, 1996, BRAIN RES, V726, P242, DOI 10.1016/0006-8993(96)00409-X; Touzani O, 1997, J CEREBR BLOOD F MET, V17, P1157, DOI 10.1097/00004647-199711000-00004; WILLETTE RN, 1993, LIFE SCI, V52, P35, DOI 10.1016/0024-3205(93)90286-C; Wu W, 1996, Chin Med Sci J, V11, P228; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YAMADA G, 1995, J CARDIOVASC PHARM, V26, pS486; Yanagisawa H, 1998, DEVELOPMENT, V125, P825	46	40	41	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	JUL	2000	25	7					957	969		10.1023/A:1007552408463			13	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	344AB	WOS:000088734500008	10959492				2021-06-18	
J	Kluger, G; Kochs, A; Holthausen, H				Kluger, G; Kochs, A; Holthausen, H			Heterotopic ossification in childhood and adolescence	JOURNAL OF CHILD NEUROLOGY			English	Article							PARA-ARTICULAR OSSIFICATIONS; SPINAL-CORD INJURY; NEW-BONE FORMATION; LONG-TERM COMA; MYOSITIS-OSSIFICANS; CLINICAL-FEATURES; PROGRESSIVA; CHILDREN; THERAPY; HISTORY	Heterotopic ossification, or myositis ossificans, denotes true bone in an abnormal place. The pathogenic mechanism is still unclear A total of 643 patients (mean age, 9.1 years) admitted for neuropediatric rehabilitation were analyzed retrospectively with respect to the existence of neurogenic heterotopic ossification. The purpose of this study was to obtain information about incidence, etiology, clinical aspect, and consequences for diagnosis and therapy of this condition in childhood and adolescence. Heterotopic ossification was diagnosed in 32 patients (mean age, 14.8 years) with average time of onset of 4 months after traumatic brain injury, near drowning, strangulation, cerebral hemorrhage, hydrocephalus, or spinal cord injury. The sex ratio was not significant. In contrast to what has been found in adult studies, serum alkaline phosphatase was not elevated during heterotopic ossification formation. A persistent vegetative state for longer than 30 days proved to be a significant risk factor for heterotopic ossification. The incidence of neurogenic heterotopic ossification in children seems to be lower than in adults. A genetic predisposition to heterotopic ossification is suspected but not proven. As a prophylactic regimen against heterotopic ossification we use salicylates for those patients in a coma or persistent vegetative state with warm and painful swelling of a joint and consider continuous intrathecal baclofen infusion and botulinum toxin injection for those patients with severe spasticity. We prefer to wait at least 1 year after trauma before excision of heterotopic ossification.	Behandlungszentrum Vogtareuth, Neuropediat Dept, Neuropadiat Abt, D-83569 Vogtareuth, Germany; CHU Montpellier, Serv Orthoped & Traumatol Pediat, Hop Lapeyronie, Montpellier, France	Kluger, G (corresponding author), Behandlungszentrum Vogtareuth, Neuropediat Dept, Neuropadiat Abt, Krankenhausstr 20, D-83569 Vogtareuth, Germany.						AHRENGART L, 1993, CLIN ORTHOP RELAT R, P153; AN HS, 1987, CLIN ORTHOP RELAT R, P291; AYERS DC, 1991, CLIN ORTHOP RELAT R, P87; BANOVAC K, 1993, PARAPLEGIA, V31, P660, DOI 10.1038/sc.1993.106; BOS CFA, 1993, J BONE JOINT SURG, V5, P1940; BRESSLER L, 1987, AM J ROENTGENOL, V48, P931; COHEN RB, 1993, J BONE JOINT SURG AM, V75A, P215, DOI 10.2106/00004623-199302000-00008; CONNOR JM, 1982, J BONE JOINT SURG BR, V64, P76; CONNOR JM, 1983, SOFT TISSUE OSSIFICA; CUSHNER FD, 1995, ORTHOPEDICS, V18, P287; Delatycki M, 1998, CLIN ORTHOP RELAT R, P15; DICKERSON RC, 1971, CLIN ORTHOP RELAT R, P42; EKELUND A, 1991, CLIN ORTHOP RELAT R, P102; EVANS EB, 1991, CLIN ORTHOP RELAT R, P94; FINERMAN GAM, 1981, METAB BONE DIS RELAT, V3, P337, DOI 10.1016/0221-8747(81)90050-3; FREED JH, 1982, PARAPLEGIA, V20, P208, DOI 10.1038/sc.1982.39; GARLAND DE, 1989, CLIN ORTHOP RELAT R, P303; GARLAND DE, 1984, ARCH PHYS MED REHAB, V65, P531; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; GARLAND DE, 1991, CLIN ORTHOP RELAT R, P13; GARLAND DE, 1989, CLIN ORTHOPAEDICS, V242, P16; Heindl UT, 1996, NEUROPEDIATRICS, V27, P94, DOI 10.1055/s-2007-973756; HERNANDEZ AM, 1978, PARAPLEGIA, V16, P272, DOI 10.1038/sc.1978.52; HOFFER MM, 1978, J TRAUMA, V18, P667, DOI 10.1097/00005373-197809000-00009; Hung JCC, 1997, DEV MED CHILD NEUROL, V39, P775; JACOBS P, 1962, ARCH DIS CHILD, V37, P90, DOI 10.1136/adc.37.191.90; Kaplan FS, 1998, CLIN ORTHOP RELAT R, P134; LAL S, 1989, ARCH PHYS MED REHAB, V70, P387; LORBER J, 1953, ARCH DIS CHILD, V28, P98, DOI 10.1136/adc.28.138.98; LORBER J, 1963, ARCH DIS CHILD, V28, P98; MAJOR P, 1980, RADIOLOGY, V136, P797, DOI 10.1148/radiology.136.3.6773108; MIELANTS H, 1975, ACTA ORTHOP SCAND, V46, P190, DOI 10.3109/17453677508989207; MINAIRE P, 1980, ARCH PHYS MED REHAB, V61, P14; MITAL MA, 1987, J PEDIATR ORTHOPED, V7, P83, DOI 10.1097/01241398-198701000-00017; *MULT SOC TASK FOR, 1994, CLIN ORTHOPAEDICS, V330, P1499; OGILVIEHARRIS DJ, 1980, J BONE JOINT SURG AM, V62, P1274, DOI 10.2106/00004623-198062080-00006; ORZEL JA, 1985, J NUCL MED, V26, P125; Ritter M, 1979, J BONE JOINT SURG, V61, P113; ROBERTS JB, 1979, J BONE JOINT SURG AM, V61, P760, DOI 10.2106/00004623-197961050-00018; ROGERS JG, 1979, J BONE JOINT SURG AM, V61, P909, DOI 10.2106/00004623-197961060-00019; ROSER B, 1989, ACTA ORTHOP SCAND, V60, P457; ROSSIER AB, 1973, PARAPLEGIA, V11, P36; SAZBON L, 1981, J BONE JOINT SURG BR, V63, P120; Smith R, 1998, CLIN ORTHOP RELAT R, P7; SMITH R, 1976, J BONE JOINT SURG BR, V58, P48; SMITH R, 1998, J BONE JOINT SURG, V346, P7; SODEMANN B, 1988, CLIN ORTHOPAEDICS, V237, P159; Tsur A, 1996, BRAIN INJURY, V10, P259, DOI 10.1080/026990596124430; URIST MR, 1978, ARCH PATHOL LAB MED, V102, P312; Valentin P, 1969, Rev Chir Orthop Reparatrice Appar Mot, V55, P351; WILKES LL, 1975, CLIN ORTHOP RELAT R, V118, P151; Wozney JM, 1998, CLIN ORTHOP RELAT R, P26	52	40	41	0	1	DECKER PERIODICALS INC	HAMILTON	4 HUGHSON STREET SOUTH PO BOX 620, LCD 1, HAMILTON, ONTARIO L8N 3K7, CANADA	0883-0738			J CHILD NEUROL	J. Child Neurol.	JUN	2000	15	6					406	413		10.1177/088307380001500610			16	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	321QG	WOS:000087465700011	10868785				2021-06-18	
J	Fins, JJ				Fins, JJ			A proposed ethical framework for interventional cognitive neuroscience: A consideration of deep brain stimulation in impaired consciousness	NEUROLOGICAL RESEARCH			English	Article						neuropsychiatric research ethics; neuromodulation; traumatic brain injury; persistent vegetative state; minimally conscious state; clinical pragmatism	PATIENT; STATES	Advances in neuromodulation techniques offer the promise of new therapeutic interventions for patients with neuropsychiatric maladies. Several complex social, ethical and policy issues will attend developments in this area. In this paper an ethical framework for clinical research in interventional cognitive neuroscience is advanced. Deep brain stimulation in traumatic brain injury is considered as a paradigm case to examine ethical obligations in human subject research. These include balancing access to novel therapies versus protection of vulnerable study populations, rational evaluation of study design and research strategies, informed consent, and the importance of achieving societal consensus for this line of scientific inquiry.	Cornell Univ, Weill Med Coll, Dept Med, New York, NY USA; Cornell Univ, Weill Med Coll, Dept Psychiat Med, New York, NY USA	Fins, JJ (corresponding author), Cornell Univ, New York Presbyterian Hosp, Weill Med Coll, 525 E 68th St F-173, New York, NY 10021 USA.						ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bejjani BP, 1999, NEW ENGL J MED, V340, P1476, DOI 10.1056/NEJM199905133401905; Brody B.A, 1998, CONSENT SEEKING JUST, P32; Buchanan A.E., 1990, DECIDING OTHERS ETHI; COHADON F, 1985, NEUROSTIMULATION OVE, P249; DELIAC P, 1993, NEUROCHIRURGIE, V39, P293; Dresser R, 1996, JAMA-J AM MED ASSOC, V276, P67, DOI 10.1001/jama.276.1.67; Fins JJ, 1997, KENNEDY INST ETHIC J, V7, P129, DOI 10.1353/ken.1997.0013; Fins JJ, 1999, HASTINGS CENT REP, V29, P49, DOI 10.2307/3528356; Fins JJ, 1997, ARCH GEN PSYCHIAT, V54, P415; FINS JJ, 1999, HMS BEAGLE      0223; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; HOSOBUCHI Y, 1993, ELECT MAGNETIC STIMU, P249; Kennedy PR, 1998, NEUROREPORT, V9, P1707, DOI 10.1097/00001756-199806010-00007; LEVINE RJ, 1986, ETHICS REGULATION CL, P95; Macciocchi SN, 1997, NEUROSURG REV, V20, P161, DOI 10.1007/BF01105559; Michels R, 1999, NEW ENGL J MED, V340, P1427, DOI 10.1056/NEJM199905063401811; Miller FG, 1999, ARCH GEN PSYCHIAT, V56, P701, DOI 10.1001/archpsyc.56.8.701; *NAT BIOETH ADV CO, 1998, RES INV PERS MENT DI; National Commission for the Protection of Human Subjects, 1978, DHEW PUBL; *OFF PROT RES RISK, 1993, PROT HUM RES SUBJ; OSBORN CL, 1998, OVER MY HEAD; Purpura KP, 1997, NEUROSCIENTIST, V3, P8, DOI 10.1177/107385849700300110; Rinaldi P. C., 1996, Society for Neuroscience Abstracts, V22, P904; Sachs G.A., 1991, J CRIT ILLNESS, V6, P348; Schiff N. D., 1999, NEUROLOGY IMPAIRED C; Schiff ND, 2000, NEUROL RES, V22, P267; Schiff ND, 1999, P ROY SOC B-BIOL SCI, V266, P421, DOI 10.1098/rspb.1999.0654; Teno J, 1997, J AM GERIATR SOC, V45, P500, DOI 10.1111/j.1532-5415.1997.tb05178.x; Thomas L, 1974, TECHNOLOGY MED, P31; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; TSUBOKAWA T, 1998, TXB STEREOTACTIC FUN; Valenstein E.S., 1986, GREAT DESPERATE CURE; Winslade W., 1998, CONFRONTING TRAUMATI; 1949, TRIALS WAR CRIMINALS, V2, P181	35	40	41	1	14	FOREFRONT PUBL GROUP	WILTON	C/O MARY J RAWLINS, 5 RIVER RD, STE 113, WILTON, CT 06897 USA	0161-6412			NEUROL RES	Neurol. Res.	APR	2000	22	3					273	278					6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	302VE	WOS:000086385700006	10769820				2021-06-18	
J	Giri, BK; Krishnappa, IK; Bryan, RM; Robertson, C				Giri, BK; Krishnappa, IK; Bryan, RM; Robertson, C			Regional cerebral blood flow after cortical impact injury complicated by a secondary insult in rats	STROKE			English	Article						brain injuries; cerebral blood flow; cerebral ischemia; trauma	SEVERE HEAD-INJURY; FLUID-PERCUSSION INJURY; TRAUMATIC BRAIN INJURY; AUTO-REGULATION; AUTOREGULATION; ISOFLURANE; METABOLISM; HYPOTENSION; HYPOXIA; PO2	Background and Purpose-Traumatic injury makes the brain susceptible to secondary insults. An uncomplicated mild lateral cortical impact injury (3 m/s, 2.5-mm deformation) that causes little or no permanent sequelae results in a large contusion at the impact site when the traumatic injury is complicated by a secondary insult, such as 40 minutes of bilateral carotid occlusion. Methods-To determine whether the increased sensitivity to secondary insults in this model is caused by a vascular mechanism, cerebral blood flow (CBF) was measured with C-14-isopropyliodoamphetamine quantitative autoradiography, and brain tissue Po-2 (Pbto(2)) was measured at the impact site and in the contralateral parietal cortex. Results-In animals that underwent bilateral carotid occlusion 1 hour after the impact injury, CBF and Pbto(2) were lower at the impact site than they were in animals that had either the impact injury or the carotid occlusion alone. In the immediate area of the impact, CBF was 14+/-6 mL . 100 g(-1) . min(-1) in the animals with the impact injury followed by carotid occlusion compared with 53+/-24 mL . 100 g(-1) . min(-1) in the animals with the impact injury alone and 74+/-14 mL . 100 g(-1) . min(-1) in the animals with the carotid occlusion alone (P<0.001). At the time of this very low CBF value in the animals with the carotid occlusion after the impact injury, Pbto(2) at the impact site averaged 1.3+/-1.6 mm Hg and was <3 mm Hg in 5 of the 6 animals. In contrast, Pbto(2) in the animals with the impact injury alone averaged 9.3+/-2.9 mm Hg, and none of the animals had a Pbto(2) of <3 mm Hg (P=0.008). Conclusions-The CBF and Pbto(2) findings in this model suggest that the reduced CBF after traumatic injury predisposes the brain to secondary insults and results in ischemia when confronted with a reduction in cerebral perfusion pressure.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Anesthesiol, Houston, TX 77030 USA	Robertson, C (corresponding author), Baylor Coll Med, Dept Neurosurg, 1 Baylor Plaza, Houston, TX 77030 USA.	claudiar@bcm.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS27616] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER		Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BRYAN RM, 1988, AM J PHYSIOL, V255, pR295; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; Chesnut R M, 1995, New Horiz, V3, P366; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DEWITT DS, 1995, NEW HORIZ, V3, P76; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; HOFFMAN WE, 1991, ANESTH ANALG, V73, P753; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JONES PA, 1993, J NEUROTRAUMA S1, V10, pS102; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; KOHI YM, 1984, INJURY, V16, P25, DOI 10.1016/0020-1383(84)90110-4; KOHMURA E, 1990, J CEREBR BLOOD F MET, V10, P877, DOI 10.1038/jcbfm.1990.144; LEE JG, 1994, ANESTH ANALG, V79, P58; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; MEIXENSBERGER J, 1993, ACTA NEUROCHIR, P58; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MUIR JK, 1995, J NEUROTRAUM, V12, P179, DOI 10.1089/neu.1995.12.179; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; MURR R, 1993, ANESTH ANALG, V77, P898; Newell DW, 1996, NEUROSURGERY, V39, P35, DOI 10.1097/00006123-199607000-00008; Palkovits M., 1988, MAPS GUIDE MICRODISS; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; PROCTOR HJ, 1988, J TRAUMA, V28, P347, DOI 10.1097/00005373-198803000-00010; TSUJI O, 1994, INTRACRANIAL PRESSUR, V9, P268; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; WALD S, 1991, Journal of Trauma, V31, P1041, DOI 10.1097/00005373-199107000-00102; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	41	40	41	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	APR	2000	31	4					961	967		10.1161/01.STR.31.4.961			7	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	300WR	WOS:000086277200030	10754006	Bronze, Green Published			2021-06-18	
J	Goozee, JV; Murdoch, BE; Theodoros, DG; Stokes, PD				Goozee, JV; Murdoch, BE; Theodoros, DG; Stokes, PD			Kinematic analysis of tongue movements in dysarthria following traumatic brain injury using electromagnetic articulography	BRAIN INJURY			English	Article							CLOSED-HEAD INJURY; ARTICULATORY MOVEMENTS; DYNAMICS	Electromagnetic articulography (EMA), a technique that uses alternating magnetic fields to track the movement of miniature receiver coils affixed to the articulators, was used to assess the speed and accuracy of tongue movements exhibited by an individual with dysarthria following severe traumatic brain injury (TBI). Three receiver coils were attached to the TBI subject's tongue and the movements of these coils were recorded during five productions of three single syllable real words consisting of the lingual consonants /t, s, k/ in the word-initial position. A non-neurologically impaired adult male served as a control subject. A range of kinematic parameters was analysed from the consonant productions including the movement trajectories, velocity, acceleration, distance, and duration of tongue movements. Examination of the complex interactions between the kinematic parameters recorded for the TBI subject revealed a disturbance in the 'control' of tongue speed rather than a disturbance in speed per se, as it was found that the TBI subject exhibited difficulty in decelerating his tongue movements appropriately on the approach up to the palate during consonant production. The difficulty noted in deceleration resulted in inaccurate tongue movements that overshot the point of intent (in the case of /t/) and may have been instrumental in reducing the length of time that the tongue remained at the palate (in the case of /s/ and /k/) in comparison to the control subject. The disturbances identified in the kinematic parameters recorded provided objective insights into the nature of the articulatory disturbances responsible for the deviant speech feature, consonant imprecision, perceived in the TBI subject's speech. The study stresses the importance of examining a range of kinematic parameters and the interactions between these parameters in attempting to determine the nature of articulatory disturbances exhibited by individuals with dysarthria following TBI.	Univ Queensland, Dept Speech Pathol & Audiol, Motor Speech Res Unit, Brisbane, Qld 4072, Australia	Murdoch, BE (corresponding author), Univ Queensland, Dept Speech Pathol & Audiol, Motor Speech Res Unit, Brisbane, Qld 4072, Australia.		Theodoros, Deborah/F-1362-2010; Murdoch, Bruce E/C-1397-2012				Darley F., 1975, MOTOR SPEECH DISORDE; HARDCASTLE W, 1976, PHYSL SPEECH PRODUCT; HARDCASTLE WJ, 1981, WORK PROGR, V3, P51; HIROSE H, 1986, FOLIA PHONIATR, V38, P61, DOI 10.1159/000265824; HIROSE H, 1982, FOLIA PHONIATR, V34, P210, DOI 10.1159/000265651; HIROSE H, 1978, J SPEECH HEAR DISORD, V43, P96, DOI 10.1044/jshd.4301.96; KENT R, 1975, J SPEECH HEAR DISORD, V40, P115, DOI 10.1044/jshd.4001.115; KENT RD, 1975, J SPEECH HEAR DISORD, V40, P467, DOI 10.1044/jshd.4004.467; KIRITANI S, 1986, SPEECH COMMUN, V5, P119, DOI 10.1016/0167-6393(86)90003-8; Kuehn D. P., 1976, J PHONETICS, V4, P303; Marquardt TP, 1990, TRAUMATIC BRAIN INJU, P181; Murdoch B. E., 1990, ACQUIRED SPEECH LANG; Murdoch B. E., 1987, AUSTR J HUMAN COMMUN, V15, P15; MURDOCH BE, 1997, CLIN MANAGEMENT SENS, P287; PERKELL JS, 1992, J ACOUST SOC AM, V92, P3078, DOI 10.1121/1.404204; SCHONLE PW, 1987, BRAIN LANG, V31, P26, DOI 10.1016/0093-934X(87)90058-7; THEODOROS DG, 1994, BRAIN INJURY, V8, P101, DOI 10.3109/02699059409150963; THEODOROS DG, 1995, BRAIN INJURY, V9, P237, DOI 10.3109/02699059509008196; TULLER B, 1990, J ACOUST SOC AM, V88, P674, DOI 10.1121/1.399771; Yorkston K.M., 1981, ASSESSMENT INTELLIGI	20	40	42	0	6	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2000	14	2					153	174		10.1080/026990500120817			22	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	281GW	WOS:000085151000005	10695571				2021-06-18	
J	Zoccolotti, P; Matano, A; Deloche, G; Cantagallo, A; Passadori, A; Leclercq, M; Braga, L; Cremel, N; Pittau, P; Renom, M; Rousseaux, M; Truche, A; Fimm, B; Zimmermann, P				Zoccolotti, P; Matano, A; Deloche, G; Cantagallo, A; Passadori, A; Leclercq, M; Braga, L; Cremel, N; Pittau, P; Renom, M; Rousseaux, M; Truche, A; Fimm, B; Zimmermann, P			Patterns of attentional impairment following closed head injury: A collaborative European study	CORTEX			English	Article						head injury; attention; selective attention; divided attention; alertness; vigilance	SUSTAINED ATTENTION; REACTION-TIME; DEFICITS; PERFORMANCE	A comprehensive assessment of both selective (focused attention, divided attention) and intensive (alertness and vigilance) attentional processes was performed on 106 patients with closed head injury using a computerised battery for the evaluation of attention. All patients were tested at least five months after their accident. A high percentage of patients were pathological in tests mapping the selective components of attention while only a minority were impaired on tests mapping the intensive components of attention. Three different subgroups of patients with consistent performance patterns were evidenced. The psychometric characteristics of the battery and its possible clinical usefulness are discussed.	Osped S Lucia, IRCCS, Rome, Italy; Univ Reims, CIRLEP, Reims, France; Unita Operat Med Riabilitat, Ferrara, Italy; Ctr Readaptat Mulhouse, Mulhouse, France; Ctr Neurol William Lennox, Ottignies, Belgium; Sarah Hosp, Brasilia, DF, Brazil; USL Grossetana, Div Neurol, Grossetana, Italy; Hosp Santa Creu & Sant Pau, EPL, Barcelona, Spain; Serv Reeducat & Convalescence Neurol, Lille, France; Ctr Reeduc & Etud Activ Mnes, Tassin La Demi Lune, France; Neurol Clin, Aachen, Germany; Univ Freiburg, Inst Physiol, D-7800 Freiburg, Germany	Zoccolotti, P (corresponding author), IRCCS S Lucia, Ctr Ric, Via Ardeatina 306, I-00179 Rome, Italy.	zoccolotti@axrma.uniroma1.it	Braga, Lucia/AAQ-1030-2020; Zoccolotti, Pierluigi/H-4437-2019	Zoccolotti, Pierluigi/0000-0002-6351-2455; Renom, Marta/0000-0002-2490-494X			ALEXANDER MP, 1982, PSYCHIAT ASPECTS NEU, P219; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; Cicerone KD, 1997, CLIN NEUROPSYCHOL, V11, P266, DOI 10.1080/13854049708400455; DOMHOLDT E, 1993, PHYSICAL THERAPY RES; GODEFROY O, 1994, J NEUROL SCI, V126, P168, DOI 10.1016/0022-510X(94)90268-2; Gray C, 1998, BRAIN INJURY, V12, P429, DOI 10.1080/026990598122548; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; LEVIN HS, 1988, SCAND J REHABIL MED, P33; LOKEN WJ, 1995, NEUROPSYCHOLOGY, V9, P592, DOI 10.1037/0894-4105.9.4.592; Miller E, 1970, Cortex, V6, P121; NORRMAN B, 1961, ACTA PSYCHIAT SCAND, V37, P236, DOI 10.1111/j.1600-0447.1961.tb07359.x; ODDY M, 1978, J NEUROL NEUROSUR PS, V48, P21; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967; WHITE J, 1992, NEUROPSYCHOLOGIA, V35, P313; Zimmermann P., 1992, TESTBATTERIE AUFMERK	25	40	41	0	3	ELSEVIER MASSON, CORPORATION OFFICE	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	0010-9452	1973-8102		CORTEX	Cortex	FEB	2000	36	1					93	107		10.1016/S0010-9452(08)70839-6			15	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	291MN	WOS:000085740800008	10728900				2021-06-18	
J	Benrud-Larson, LM; Wegener, ST				Benrud-Larson, LM; Wegener, ST			Chronic pain in neurorehabilitation populations: Prevalence, severity and impact	NEUROREHABILITATION			English	Article						chronic pain; neurological disability; rehabilitation	SPINAL-CORD INJURY; PHANTOM LIMB PAIN; TRAUMATIC BRAIN INJURY; MULTIPLE-SCLEROSIS PATIENTS; CENTRAL POSTSTROKE PAIN; STROKE REHABILITATION; STUMP PAIN; COPING STRATEGIES; CEREBRAL-PALSY; DEPRESSION	Extensive data document the adverse impact chronic pain can have on physical and psychosocial functioning. However, only recently has chronic pain received attention as a secondary complication in neurorehabilitation populations such as spinal cord injury, multiple sclerosis, and cerebral palsy. It is not unreasonable to expect that chronic pain might exacerbate impairments already present due to a chronic, disabling condition. The current paper reviews what is known about the prevalence, severity, and psychosocial impact of chronic pain in neurorehabilitation populations. Although there is variation among different conditions, available data suggest that considerable proportions of these patient populations experience chronic pain and associated sequelae similar to that reported in the extant chronic pain literature (e.g., psychological distress). Research needs to continue investigating the impact of chronic pain in neurorehabilitation populations and work toward development of effective interventions to manage pain and disability in these patients. It is likely that effective pain management will lead to more effective rehabilitation and improved quality of life.	Johns Hopkins Univ, Dept Phys Med & Rehabil, Baltimore, MD 21239 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA	Wegener, ST (corresponding author), Johns Hopkins Univ, Dept Phys Med & Rehabil, Good Samaritan Prof Bldg,Suite 406,5601 Loch Rave, Baltimore, MD 21239 USA.	swegener@jhmi.edu					Andary MT, 1997, CLIN J PAIN, V13, P244, DOI 10.1097/00002508-199709000-00010; ANDERSEN G, 1995, PAIN, V61, P187, DOI 10.1016/0304-3959(94)00144-4; ARCHIBALD CJ, 1994, PAIN, V58, P89, DOI 10.1016/0304-3959(94)90188-0; ARENA JG, 1990, J PSYCHOSOM RES, V34, P71, DOI 10.1016/0022-3999(90)90009-S; Banks SM, 1996, PSYCHOL BULL, V119, P95, DOI 10.1037/0033-2909.119.1.95; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BERDE CB, 1999, TXB PAIN; Black-Schaffer RM, 1999, ARCH PHYS MED REHAB, V80, pS8, DOI 10.1016/S0003-9993(99)90096-5; Cairns DM, 1996, ARCH PHYS MED REHAB, V77, P329, DOI 10.1016/S0003-9993(96)90079-9; CARABELLI RA, 1985, ARCH PHYS MED REHAB, V66, P466; DAVIS RW, 1993, ARCH PHYS MED REHAB, V74, P79; Dekker JHM, 1997, AM J PHYS MED REHAB, V76, P43, DOI 10.1097/00002060-199701000-00008; DROMERICK A, 1994, STROKE, V25, P358, DOI 10.1161/01.STR.25.2.358; Dworkin RH, 1997, PAIN FORUM, V6, P127; DWORKIN RH, 1992, J ABNORM PSYCHOL, V101, P200, DOI 10.1037/0021-843X.101.1.200; Elliott TR, 1991, NEUROREHABILITATION, V1, P7; Ernst JL, 1998, SCI PSYCHOSOCIAL PRO, V10, P127; FENOLLOSA P, 1993, PARAPLEGIA, V31, P722, DOI 10.1038/sc.1993.114; Flick CL, 1999, ARCH PHYS MED REHAB, V80, pS21, DOI 10.1016/S0003-9993(99)90098-9; Gallagher P, 1999, BEHAV MED, V25, P117, DOI 10.1080/08964289909596741; GATCHEL RJ, 1996, PSYCHOSOCIAL FACTORS; HAYTHORNTHWAITE JA, 1991, PAIN, V46, P177, DOI 10.1016/0304-3959(91)90073-7; HILL A, 1993, PAIN, V55, P347, DOI 10.1016/0304-3959(93)90010-M; Hill A, 1999, J PAIN SYMPTOM MANAG, V17, P125, DOI 10.1016/S0885-3924(98)00136-5; HILL A, 1995, PAIN, V62, P79, DOI 10.1016/0304-3959(94)00253-B; Hillier SL, 1997, BRAIN INJURY, V11, P661; Indaco A, 1994, Acta Neurol (Napoli), V16, P97; JENSEN MP, 1991, PAIN, V47, P249, DOI 10.1016/0304-3959(91)90216-K; JENSEN TS, 1995, PAIN, V61, P161, DOI 10.1016/0304-3959(94)00227-6; JENSEN TS, 1983, PAIN, V17, P243, DOI 10.1016/0304-3959(83)90097-0; JENSEN TS, 1985, PAIN, V21, P267, DOI 10.1016/0304-3959(85)90090-9; Jensen TS., 1994, TXB PAIN, P651; KALRA L, 1995, STROKE, V26, P990, DOI 10.1161/01.STR.26.6.990; KEEFE FJ, 1989, PAIN, V37, P51, DOI 10.1016/0304-3959(89)90152-8; KEEFE FJ, 1986, J CONSULT CLIN PSYCH, V54, P665, DOI 10.1037/0022-006X.54.5.665; Kennedy P, 1997, SPINAL CORD, V35, P814, DOI 10.1038/sj.sc.3100569; KERNS RD, 1992, HDB PAIN ASSESSMENT, P235; KROLY P, 1987, MULTIMETHOD ASSESSME; Lahz S, 1997, J HEAD TRAUMA REHAB, V12, P85, DOI 10.1097/00001199-199706000-00009; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; LEIJON G, 1989, PAIN, V36, P13, DOI 10.1016/0304-3959(89)90107-3; LERNER RK, 1991, ARCH PHYS MED REHAB, V72, P122; LINDESAY JEB, 1985, J ROY SOC MED, V78, P452, DOI 10.1177/014107688507800606; Loubser PG, 1996, NEUROTRAUMA, P1311; LUNDQVIST C, 1991, SPINE, V16, P78, DOI 10.1097/00007632-199101000-00014; MARIANO AJ, 1992, CLIN J PAIN, V8, P87, DOI 10.1097/00002508-199206000-00005; MARSHALL M, 1992, CLIN J PAIN, V8, P351, DOI 10.1097/00002508-199212000-00010; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; Montoya P, 1997, PAIN, V72, P87, DOI 10.1016/S0304-3959(97)00004-3; Moulin DE, 1998, NEUROL CLIN, V16, P889, DOI 10.1016/S0733-8619(05)70103-1; MOULIN DE, 1988, NEUROLOGY, V38, P1830, DOI 10.1212/WNL.38.12.1830; MURRAY TJ, 1995, NEUROL CLIN, V13, P197; NEPOMUCENO C, 1979, ARCH PHYS MED REHAB, V60, P605; PARKES CM, 1973, J PSYCHOSOM RES, V17, P97, DOI 10.1016/0022-3999(73)90010-X; PARKES CM, 1984, EMOTIONAL REHABILITA; Rintala DH, 1998, ARCH PHYS MED REHAB, V79, P604, DOI 10.1016/S0003-9993(98)90032-6; ROMANO JM, 1985, PSYCHOL BULL, V97, P18, DOI 10.1037/0033-2909.97.1.18; ROY CW, 1995, CLIN REHABIL, V9, P21, DOI DOI 10.1177/026921559500900103; SANDFORD PR, 1992, ARCH PHYS MED REHAB, V73, P300; Schwartz L, 1999, ARCH PHYS MED REHAB, V80, P1243, DOI 10.1016/S0003-9993(99)90023-0; SHERMAN RA, 1989, BIOFEEDBACK SELF-REG, V14, P267, DOI 10.1007/BF00999118; SHERMAN RA, 1984, PAIN, V18, P83, DOI 10.1016/0304-3959(84)90128-3; SHERMAN RA, 1987, PAIN, V28, P285, DOI 10.1016/0304-3959(87)90064-9; SPINHOVEN P, 1991, PAIN, V45, P29, DOI 10.1016/0304-3959(91)90161-P; STENAGER E, 1991, ACTA NEUROL SCAND, V84, P197, DOI 10.1111/j.1600-0404.1991.tb04937.x; Stormer S, 1997, SPINAL CORD, V35, P446, DOI 10.1038/sj.sc.3100411; SULLIVAN MJL, 1990, J ABNORM PSYCHOL, V99, P260, DOI 10.1037/0021-843X.99.3.260; SUMMERS JD, 1991, PAIN, V47, P183, DOI 10.1016/0304-3959(91)90203-A; Teasell R W, 1999, Phys Med Rehabil Clin N Am, V10, P237; Thompson AJ, 1998, CURR OPIN NEUROL, V11, P305, DOI 10.1097/00019052-199808000-00005; Turk DC, 1997, PROG PAIN RES MANAG, V8, P185; TURK DC, 1997, CAMBRIDGE HDB PSYCHO, P146; Turk Dennis C., 1996, P3; Turk MA, 1997, ARCH PHYS MED REHAB, V78, pS10, DOI 10.1016/S0003-9993(97)90216-1; UMLAUF RL, 1992, CLIN J PAIN, V8, P111, DOI 10.1097/00002508-199206000-00008; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; VEIT CT, 1983, J CONSULT CLIN PSYCH, V51, P730, DOI 10.1037/0022-006X.51.5.730; VERMOTE R, 1986, CLIN NEUROL NEUROSUR, V88, P87, DOI 10.1016/S0303-8467(86)80002-6; VONKORFF M, 1992, PAIN, V50, P133, DOI 10.1016/0304-3959(92)90154-4; WALL PD, 1999, TXB PAIN; Warnell P, 1991, Axone, V13, P26; Waters RL, 1998, ARCH PHYS MED REHAB, V79, P1237, DOI 10.1016/S0003-9993(98)90268-4; WEGENER ST, 1992, CLIN J PAIN, V8, P93, DOI 10.1097/00002508-199206000-00006; Weinstein SM, 1998, NEUROL CLIN, V16, P919, DOI 10.1016/S0733-8619(05)70105-5; Widerstrom-Noga EG, 1999, ARCH PHYS MED REHAB, V80, P580, DOI 10.1016/S0003-9993(99)90203-4; WOOLSEY RM, 1986, J AM PARAPLEGIA SOC, V9, P27; Zorowitz RD, 1996, AM J OCCUP THER, V50, P194, DOI 10.5014/ajot.50.3.194	87	40	40	0	5	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2000	14	3					127	137					11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	357PD	WOS:000089509300002					2021-06-18	
J	Tate, PS; Freed, DM; Bombardier, CH; Harter, SL; Brinkman, S				Tate, PS; Freed, DM; Bombardier, CH; Harter, SL; Brinkman, S			Traumatic brain injury: influence of blood alcohol level on post-acute cognitive function	BRAIN INJURY			English	Article							SUBSTANCE-ABUSE; HEAD-INJURY; INTOXICATION; REHABILITATION; ETHANOL	Alcohol intoxication frequently contributes to the occurrence of traumatic brain injury. Few studies, however, have examined whether acute pre-injury alcohol intoxication or premorbid history of alcohol abuse exacerbate cognitive impairments that commonly result from traumatic brain injury. This study examined the influence of blood alcohol level at time of hospital admission on cognitive functioning during the pose-acute stage of recovery from traumatic brain injury. After controlling for pre-injury history of alcohol abuse, hospital admission blood alcohol level was predictive of poorer delayed verbal memory, greater decrement in verbal memory over time, and poorer visuospatial functioning. Moreover, there were non-significant trends for higher blood alcohol levels to predict poorer performance on measures of immediate verbal memory and perseveration.	Texas Tech Univ, Dept Psychol, Lubbock, TX 79409 USA; Texas Tech Univ, Hlth Sci Ctr, Dept Neuropsychiat, Lubbock, TX 79409 USA; Univ Washington, Harborview Med Ctr, Dept Rehabil Med, Seattle, WA 98104 USA; Neuropsychol Clin, Abilene, TX USA	Tate, PS (corresponding author), 1416 McMillan Ave,Suite A-3, Summer, WA 98390 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR011714] Funding Source: Medline		Allen JP, 1997, ALCOHOL CLIN EXP RES, V21, P613, DOI 10.1097/00000374-199706000-00008; AXELROD BN, 1993, CLIN NEUROPSYCHOL, V7, P205, DOI 10.1080/13854049308401523; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; Bigler ED, 1996, BRAIN INJURY, V10, P197, DOI 10.1080/026990596124511; BOMBARDIER CH, 1995, WESTERN J MED, V162, P150; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; Bombardier CH, 1997, ARCH PHYS MED REHAB, V78, P592, DOI 10.1016/S0003-9993(97)90424-X; Bombardier CH, 1999, REHABIL PSYCHOL, V44, P52, DOI 10.1037/0090-5550.44.1.52; BRICKLEY MR, 1995, INJURY, V26, P311, DOI 10.1016/0020-1383(95)00034-7; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; CALLAHAN D, 1968, Q J STUD ALCOHOL, V29, P130; ChathamShowalter PE, 1996, PSYCHOSOMATICS, V37, P285, DOI 10.1016/S0033-3182(96)71567-0; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cohen J., 1983, APPL MULTIPLE REGRES; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; DELIS D, 1987, CALIFORNIA VERBAL LE; Dikmen S. S., 1993, NEUROPSYCHOLOGIA, V7, P296, DOI DOI 10.1037/0894-4105.7.3.296; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Drubach D A, 1993, Md Med J, V42, P989; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FULLER MG, 1994, J NEUROPSYCH CLIN N, V6, P143; Golden C., 1978, STROOP COLOR WORD TE; Heaton RK, 1993, WISCONSIN CARD SORT; HILLBOM M, 1986, J NEUROL NEUROSUR PS, V49, P1348, DOI 10.1136/jnnp.49.12.1348; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; Kraus Jess F., 1994, P3; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; Kreutzer JS, 1993, J HEAD TRAUMA REHAB, V8, P47; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; LEMKUHL LD, 1993, J HEAD TRAUMA REHAB, V8, P88; LEONARD BE, 1995, NEUROCHEM INT, V26, P343, DOI 10.1016/0197-0186(94)00141-G; LEZAK MD, 1995, NEURSYCHOLOGICAL ASS; MARZAUX JM, 1997, ARCH PHYSICAL MED RE, V78, P1316; NACHSHON K, 1998, C NEUR SURG SEATL WA; NATH FP, 1986, INJURY, V17, P150, DOI 10.1016/0020-1383(86)90320-7; NEVO I, 1995, NEUROCHEM INT, V26, P305, DOI 10.1016/0197-0186(94)00139-L; PARSONS OA, 1993, NEUROL CLIN, V11, P205; PORKORNY AD, 1972, AM J PSYCHIAT, V129, P342; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RIMEL R, 1992, NEUROSURGERY, V11, P344; RIVARA FP, 1993, JAMA-J AM MED ASSOC, V270, P1962, DOI 10.1001/jama.270.16.1962; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; SABHESAN S, 1987, Indian Journal of Psychological Medicine, V10, P61; Sander AM, 1997, J HEAD TRAUMA REHAB, V12, P28, DOI 10.1097/00001199-199710000-00004; Shapira Y, 1997, J NEUROSURG ANESTH, V9, P118, DOI 10.1097/00008506-199704000-00003; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; Tabachnick B.G., 1989, USING MULTIVARIATE S; WALLENBURG HCS, 1986, LANCET, V1, P1; Wechsler D., 1987, MANUAL WECHSLER MEMO; Wechsler D., 1981, WAIS R MANUAL WECHSL; WEINSTEIN DD, 1995, AM J ADDICTION, V4, P285; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P205, DOI 10.1111/j.1530-0277.1990.tb00473.x; YAMAKAMI I, 1995, J NEUROSURG, V82, P813, DOI 10.3171/jns.1995.82.5.0813; Zauner A, 1998, NEUROL RES, V20, pS85; Zink BJ, 1998, ACAD EMERG MED, V5, P9, DOI 10.1111/j.1553-2712.1998.tb02568.x	64	40	40	0	6	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	1999	13	10					767	784					18	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	247TV	WOS:000083236800003	10576461				2021-06-18	
J	Kaipio, ML; Alho, K; Winkler, I; Escera, C; Surma-aho, O; Naatanen, R				Kaipio, ML; Alho, K; Winkler, I; Escera, C; Surma-aho, O; Naatanen, R			Event-related brain potentials reveal covert distractibility in closed head injuries	NEUROREPORT			English	Article						attention; audition; closed head injury; distractibility; event-related brain potential (ERP); mismatch negativity; novel sounds; P3a	INTRACEREBRAL POTENTIALS; MISMATCH NEGATIVITY; AUDITORY-CORTEX; FRONTAL-CORTEX; VISUAL-STIMULI; RARE TARGET; PERFORMANCE; ATTENTION; LESIONS	EVENT-RELATED brain potentials (ERPs) to auditory stimuli were recorded from 11 closed head injured (CHI) and 10 age-matched healthy adults. Auditory stimuli consisted of sequences of repetitive standard tones (600 Hz), occasionally replaced by deviant tones (660 Hz) or by natural novel sounds. Subjects were instructed to ignore auditory stimuli while concentrating on a demanding visuo-motor tracking task. CHI patients showed, in comparison to control subjects, significantly enhanced late P3a component in the ERPs to novel sounds. This suggests that novel stimuli cause greater distraction in CHI patients than in controls, demonstrating that ERPs provide a powerful tool to determine the physiological basis of attentional deficits in CHI patients. NeuroReport 10:2125-2129 (C) 1999 Lippincott Williams &Wilkins.	Univ Helsinki, Dept Psychol, Cognit Brain Res Unit, FIN-00014 Helsinki, Finland; Univ Barcelona, Dept Psychiat & Clin Psychobiol, Neurodynam Lab, E-08035 Barcelona, Catalonia, Spain; Hungarian Acad Sci, Inst Psychol, H-1394 Budapest, Hungary	Kaipio, ML (corresponding author), Univ Helsinki, Dept Psychol, Cognit Brain Res Unit, POB 13, FIN-00014 Helsinki, Finland.		Escera, Carles/A-8658-2010; Winkler, Istvan/A-7659-2008; Alho, Kimmo/G-2997-2013	Escera, Carles/0000-0001-8203-2951; Winkler, Istvan/0000-0002-3344-6151; Alho, Kimmo/0000-0001-8563-2792			Alain C, 1998, BRAIN RES, V812, P23, DOI 10.1016/S0006-8993(98)00851-8; Alho K, 1998, PSYCHOPHYSIOLOGY, V35, P211, DOI 10.1017/S004857729800211X; Alho K, 1997, NEUROREPORT, V8, P3233, DOI 10.1097/00001756-199710200-00010; ALHO K, 1994, ELECTROEN CLIN NEURO, V91, P353, DOI 10.1016/0013-4694(94)00173-1; BAUDENA P, 1995, ELECTROEN CLIN NEURO, V94, P251, DOI 10.1016/0013-4694(95)98476-O; Campbell K. B., 1995, HDB NEUROPSYCHOLOGY, V10, P269; Damasio A., 1994, DESCARTESERROR EMOTI; Dywan J, 1996, J HEAD TRAUMA REHAB, V11, P79, DOI 10.1097/00001199-199604000-00008; Escera C, 1998, J COGNITIVE NEUROSCI, V10, P590, DOI 10.1162/089892998562997; GIARD MH, 1990, PSYCHOPHYSIOLOGY, V27, P627, DOI 10.1111/j.1469-8986.1990.tb03184.x; HALGREN E, 1995, ELECTROEN CLIN NEURO, V94, P191, DOI 10.1016/0013-4694(94)00259-N; ICHISE M, 1994, J NUCL MED, V35, P217; KNIGHT RT, 1984, ELECTROEN CLIN NEURO, V59, P9, DOI 10.1016/0168-5597(84)90016-9; KNIGHT RT, 1989, BRAIN RES, V502, P109, DOI 10.1016/0006-8993(89)90466-6; Levanen S, 1996, CEREB CORTEX, V6, P288, DOI 10.1093/cercor/6.2.288; LEVIN HS, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P89; Mateer CA, 1996, J HEAD TRAUMA REHAB, V11, P1; NAATANEN R, 1995, EAR HEARING, V16, P6; Naatanen R., 1992, ATTENTION BRAIN FUNC; RICHARDSON JTE, 1990, CLIN NEUROPSYCHOLOGI; Scherg M, 1989, J Cogn Neurosci, V1, P336, DOI 10.1162/jocn.1989.1.4.336; SchmitterEdgecombe M, 1996, J HEAD TRAUMA REHAB, V11, P17, DOI 10.1097/00001199-199604000-00003; Schroger E, 1996, J COGNITIVE NEUROSCI, V8, P527, DOI 10.1162/jocn.1996.8.6.527; VANZOMEREN AH, 1994, CLIN NEUROPSYCHOLOGY, P63	24	40	40	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	JUL 13	1999	10	10					2125	2129		10.1097/00001756-199907130-00024			5	Neurosciences	Neurosciences & Neurology	214YB	WOS:000081354200024	10424686				2021-06-18	
J	Dogan, A; Rao, AM; Baskaya, MK; Hatcher, J; Temiz, C; Rao, VLR; Dempsey, RJ				Dogan, A; Rao, AM; Baskaya, MK; Hatcher, J; Temiz, C; Rao, VLR; Dempsey, RJ			Contribution of polyamine oxidase to brain injury after trauma	JOURNAL OF NEUROSURGERY			English	Article						cerebral edema; cerebral ischemia; interconversion pathway; N-1,N-4-bis(2,3-butadienyl)-1,4-butanediamine 2HCl; polyamine oxidase; rat	CELL-DEATH; ORNITHINE DECARBOXYLASE; ISCHEMIA; BARRIER; EDEMA; RAT; FLUID	Object. The possible role of the polyamine interconversion pathway on edema. formation, traumatic injury volume, and tissue polyamine levels after traumatic brain injury (TBI) was studied using an inhibitor of the interconversion pathway enzyme, polyamine oxidase. Methods. Experimental TBI was induced in Sprague-Dawley mts by using a controlled cortical impact device at a velocity of 3 m/second, resulting in a 2-mm deformation. Immediately after TBI was induced, 100 mg/kg of N',N'-bis(2,3-butadienyl)-1,-4-butanediamine 2HCl (MDL 72527) or saline was injected intraperitoneally. Brain water content and tissue polyamine levels were measured at 24 hours after TBI. Traumatic injury volume was evaluated using 2% cresyl violet solution 7 days after TBI occurred. The MDL 72527 treatment significantly reduced brain edema (80.4 +/- 0.8% compared with 81.2 +/- 1.2%, p < 0.05) and injury volume(30.1 +/- 6.6 mm(3) compared with 42.7 +/- 13.3 mm(3), p < 0.05 compared with the saline treatment. The TBI caused a significant increase in tissue putrescine levels at the traumatized site (65.5 +/- 26.5 pmol/g in the cortex and 70.9 +/- 22.4 pmol/g in the hippocampus) compared with the nontraumatized site (7 +/- 2.4 pmol/g in the cortex and 11.4 +/- 6.4 pmol/g in the hippocampus). The increase in putrescine levels in both the traumatized and nontraumatized cortex and hippocampus was reduced by a mean of 60% with MDL 72527 treatment. Conclusions. These results demonstrate, for the first time, that the polyamine interconversion pathway has an important role in the increase of putrescine levels after TBI and that the polyamine oxidase inhibitors, blockers of the interconversion pathway, can be neuroprotective against edema formation and necrotic cavitation after TBI.	Univ Wisconsin, Ctr Clin Sci H4 338, Dept Neurol Surg, Madison, WI 53792 USA; Vet Adm Hosp, Madison, WI USA; Louisiana State Univ, Med Ctr, Dept Neurol Surg, Shreveport, LA USA	Dempsey, RJ (corresponding author), Univ Wisconsin, Ctr Clin Sci H4 338, Dept Neurol Surg, 600 Highland Ave, Madison, WI 53792 USA.		Dogan, Aclan/AAF-8305-2019				Baskaya MFK, 1996, NEUROSURGERY, V38, P140; Baskaya MK, 1996, J NEUROTRAUM, V13, P85, DOI 10.1089/neu.1996.13.85; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; BOLKENIUS FN, 1985, BIOCHIM BIOPHYS ACTA, V838, P69, DOI 10.1016/0304-4165(85)90251-X; Cockroft Kevin M., 1995, Surgical Forum, V46, P578; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIENEL GA, 1985, J NEUROCHEM, V44, P600, DOI 10.1111/j.1471-4159.1985.tb05454.x; DIXON CE, 1991, J NEUROSCI METH, V39, P253; GILAD GM, 1992, LIFE SCI, V50, pPL149, DOI 10.1016/0024-3205(92)90289-2; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; Henley CM, 1996, J NEUROTRAUM, V13, P487, DOI 10.1089/neu.1996.13.487; IENTILE R, 1988, J NEUROCHEM, V51, P677, DOI 10.1111/j.1471-4159.1988.tb01797.x; Ivanova S, 1998, J EXP MED, V188, P327, DOI 10.1084/jem.188.2.327; KABRA PM, 1986, J CHROMATOGR, V380, P19, DOI 10.1016/S0378-4347(00)83621-X; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KLEIHUES P, 1975, BRAIN RES, V95, P61, DOI 10.1016/0006-8993(75)90207-3; KOENIG H, 1983, BIOCHEM BIOPH RES CO, V116, P1039, DOI 10.1016/S0006-291X(83)80247-2; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; RINK A, 1995, AM J PATHOL, V147, P1575; SEILER N, 1985, NEUROCHEM RES, V10, P529, DOI 10.1007/BF00964656; Seiler N, 1995, PROG BRAIN RES, V106, P333; SHOHAMI E, 1992, EXP NEUROL, V117, P189, DOI 10.1016/0014-4886(92)90126-B; TASDEMIROGLU E, 1994, ACTA NEUROCHIR, V131, P302, DOI 10.1007/BF01808631	23	40	41	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	1999	90	6					1078	1082		10.3171/jns.1999.90.6.1078			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	198PK	WOS:000080433000014	10350255				2021-06-18	
J	Muir, JK; Raghupathi, R; Saatman, KE; Wilson, CA; Lee, VMY; Trojanowski, JQ; Philips, MF; McIntosh, TK				Muir, JK; Raghupathi, R; Saatman, KE; Wilson, CA; Lee, VMY; Trojanowski, JQ; Philips, MF; McIntosh, TK			Terminally differentiated human neurons survive and integrate following transplantation into the traumatically injured rat brain	JOURNAL OF NEUROTRAUMA			English	Article						fluid percussion; motor dysfunction; neuronal grafts; NT2N cells; traumatic brain injury	NERVE GROWTH-FACTOR; NEURAL PROGENITOR CELLS; FLUID-PERCUSSION MODEL; ADULT-RAT; SPINAL-CORD; STEM-CELLS; FUNCTIONAL RECOVERY; PARKINSONS-DISEASE; FACTOR INFUSION; NTERA-2 CELLS	The present study evaluated the survival and integration of human postmitotic neurons (hNT) following transplantation into the traumatically injured rodent brain. Anesthetized male Sprague-Dawley rats (n = 47) were subjected to lateral fluid percussion brain injury of moderate severity (2.4-2.6 atm). Sham animals (n = 28) were surgically prepared, but did not receive brain injury. At 24 h following injury or sham surgery, the rats were re-anesthetized and similar to 100,000 hNT cells (freshly cultured or previously frozen) or vehicle were stereotactically injected into the ipsilateral cortex. Animals were examined for neuromotor function at 48 h, 7 days, and 14 days posttransplantation using a standard battery of motor tests. Animals were sacrificed at 2 weeks postinjury and viability of hNT grafts was assessed by Nissl staining and MOC-1 immunohistochemistry, which recognizes human neural cell adhesion molecules (NCAM) expressed on hNT cells. Transplanted hNT grafts remained viable in 83% of brain-injured animals at 2 weeks following transplantation of either fresh or frozen hNT cells. Glial fibrillary acidic protein (GFAP) immunohistochemistry revealed a marked increase in the number of reactive astrocytes following brain injury in both vehicle and hNT implanted animals. These reactive astrocytes appeared not to impede grafted cells from sending projections into host tissue. Despite the survival of transplanted cells in the traumatically injured brain, hNT cells had no significant effect on posttraumatic neurologic motor function during the acute posttraumatic period. Since hNT cells are transfectable, prolonged survival of these transplanted cells in the posttraumatic milieu suggests that grafted hNT cells may be a suitable means for delivery of therapeutic, exogenous proteins into the CNS for treatment of traumatic brain injury.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	McIntosh, TK (corresponding author), Univ Penn, Dept Neurosurg, 105 C Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P01NS008803] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS08803, R01-NS26818] Funding Source: Medline		ANDERSON DK, 1995, BRAIN PATHOL, V5, P451, DOI 10.1111/j.1750-3639.1995.tb00624.x; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; Bjorklund A, 1992, Curr Opin Neurobiol, V2, P683, DOI 10.1016/0959-4388(92)90039-N; BJORKLUND A, 1993, NATURE, V362, P414, DOI 10.1038/362414a0; Borlongan CV, 1998, EXP NEUROL, V149, P310, DOI 10.1006/exnr.1997.6730; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIETRICH DW, 1994, J NEUROTRAUM, V13, P289; DiProspero NA, 1997, EXP NEUROL, V148, P628, DOI 10.1006/exnr.1997.6700; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Elsayed MH, 1996, EXP NEUROL, V137, P127, DOI 10.1006/exnr.1996.0013; Emerich DF, 1996, J NEUROSCI, V16, P5168; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.ne.18.030195.001111; GAGE FH, 1991, NEURON, V6, P1, DOI 10.1016/0896-6273(91)90116-H; HAGG T, 1990, J NEUROSCI, V10, P3087; HANSEN JT, 1991, CRIT REV NEUROBIOL, V6, P79; HARDY M, 1994, J NEUROCHEM, V63, P482; HEFTI F, 1986, J NEUROSCI, V6, P2155; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Hodges H, 1996, NEUROSCIENCE, V72, P959, DOI 10.1016/0306-4522(96)00004-8; IWASHITA Y, 1994, NATURE, V367, P167, DOI 10.1038/367167a0; JAKEMAN LB, 1991, J COMP NEUROL, V307, P311, DOI 10.1002/cne.903070211; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KLEPPNER SR, 1995, J COMP NEUROL, V357, P618, DOI 10.1002/cne.903570410; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; MAMPALAM TJ, 1988, J NEUROSURG, V69, P904, DOI 10.3171/jns.1988.69.6.0904; MartinezSerrano A, 1997, TRENDS NEUROSCI, V20, P530, DOI 10.1016/S0166-2236(97)01119-3; MartinezSerrano A, 1996, CLIN NEUROSCI, V3, P301; MartinezSerrano A, 1996, J NEUROSCI, V16, P4604; MARTINEZSERRANO A, 1995, J NEUROSCI, V15, P5668; Mattsson B, 1997, STROKE, V28, P1225, DOI 10.1161/01.STR.28.6.1225; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MIYAJIMA Y, 1995, INT J PEDIAT HEM ONC, V2, P73; MIYAZONO M, 1996, J COMP NEUROL, V376, P1; MOLENAAR WM, 1991, ACTA NEUROPATHOL, V83, P46, DOI 10.1007/BF00294429; NIIJIMA K, 1995, J NEUROSCI, V15, P1180; NIKKHAH G, 1994, J NEUROSCI, V14, P3449; Paxinos G, 1986, RAT BRAIN STEREOTAXI; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; Powell EM, 1997, CELL TISSUE RES, V290, P385, DOI 10.1007/s004410050945; REIER PJ, 1992, J NEUROTRAUM, V9, pS223; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Snyder EY, 1996, CLIN NEUROSCI, V3, P310; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; Soares HD, 1995, J NEUROSCI, V15, P8223; SPENCER DD, 1992, NEW ENGL J MED, V327, P1541, DOI 10.1056/NEJM199211263272201; STEIN DG, 1988, BEHAV NEUROSCI, V102, P260, DOI 10.1037/0735-7044.102.2.260; Tannock GW, 1992, LACTIC ACID BACTERIA, P21; TROJANOWSKI JQ, 1993, EXP NEUROL, V122, P283, DOI 10.1006/exnr.1993.1128; Trojanowski JQ, 1997, EXP NEUROL, V144, P92, DOI 10.1006/exnr.1996.6393; TUSZYNSKI MH, 1994, EXP NEUROL, V126, P1, DOI 10.1006/exnr.1994.1037; WALICKE LR, 1986, P NATL ACAD SCI USA, V83, P9231; Whittemore SR, 1996, MOL NEUROBIOL, V12, P13, DOI 10.1007/BF02740745; YOUNKIN DP, 1993, P NATL ACAD SCI USA, V90, P2174, DOI 10.1073/pnas.90.6.2174	72	40	43	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	1999	16	5					403	414		10.1089/neu.1999.16.403			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	200WC	WOS:000080562200006	10369560				2021-06-18	
J	Stover, JF; Morganti-Kossmann, MC; Lenzlinger, PM; Stocker, R; Kempski, OS; Kossmann, T				Stover, JF; Morganti-Kossmann, MC; Lenzlinger, PM; Stocker, R; Kempski, OS; Kossmann, T			Glutamate and taurine are increased in ventricular cerebrospinal fluid of severely brain-injured patients	JOURNAL OF NEUROTRAUMA			English	Article						brain edema; cell swelling; cerebrospinal fluid; contusion; glutamate; taurine; traumatic brain injury	EXCITATORY AMINO-ACIDS; CEREBRAL BLOOD-FLOW; CORTICAL EXTRACELLULAR LEVELS; RAT HIPPOCAMPAL SLICES; CONTUSION TRAUMA; HEAD-INJURY; RELEASE; LOCALIZATION; ASTROCYTES; MECHANISMS	Glutamate contributes to secondary brain damage, resulting in cell swelling and brain edema. Under in vitro conditions, increased extracellular levels of the amino acid taurine reflect glutamate-induced osmotic cell swelling. In vivo, increases in cerebrospinal fluid (CSF) taurine could, therefore, unmask glutamate-mediated cytotoxic edema formation and possibly differentiate it from vasogenic edema. To test this hypothesis, ventricular CSF glutamate and taurine levels were measured in 28 severely brain-injured patients on days 1, 5, and 14 after trauma. Posttraumatic changes in CSF amino acids were investigated in regard to extent of tissue damage and alterations in brain edema as estimated by computerized tomography. On day 1, CSF glutamate and taurine levels were significantly increased in patients with subdural or epidural hematomas (8 +/- 0.8/71 +/- 12 mu M), contusions (21 +/- 4.1/122 +/- 18 mu M), and generalized brain edema (13 +/- 3.2/80 +/- 15 mu M) compared to lumbar control CSF (1.3 +/- 0.1/12 +/- 1 mu M; P < 0.001). CSF amino acids, however, did not reflect edema formation and resolution as estimated by computerized tomography. CSF taurine correlated positively with glutamate, eventually depicting glutamate-induced cell swelling. However, parallel neuronal release of taurine with its inhibitory function cannot be excluded. Thus, the sensitivity of taurine in unmasking cytotoxic edema formation is weakened by the inability in defining its origin and function under the conditions chosen in the present study. Overall, persisting pathologic ventricular CSF glutamate and taurine levels are highly suggestive of ongoing glial and neuronal impairment in humans following severe traumatic brain injury.	Univ Zurich Hosp, Dept Trauma Surg, CH-8091 Zurich, Switzerland; Inst Neurosurg Pathophysiol, Mainz, Germany	Kossmann, T (corresponding author), Univ Zurich Hosp, Dept Trauma Surg, Ramistr 100, CH-8091 Zurich, Switzerland.	kossmann@chi.usz.ch	Lenzlinger, Philipp/A-3822-2008	Morganti-Kossmann, Cristina/0000-0002-0807-2063			BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; CHOI DW, 1987, J NEUROSCI, V7, P357; DANBOLT NC, 1994, PROG NEUROBIOL, V44, P377, DOI 10.1016/0301-0082(94)90033-7; DUTTON GR, 1991, ANN NY ACAD SCI, V633, P489; ERISKAT J, 1994, ACTA NEUROCHIR, P425; FURST P, 1990, J CHROMATOGR, V499, P557, DOI 10.1016/S0021-9673(00)97000-6; HAGBERG H, 1985, J CEREBR BLOOD F MET, V5, P413, DOI 10.1038/jcbfm.1985.56; HOLOPAINEN I, 1989, NEUROSCIENCE, V29, P425, DOI 10.1016/0306-4522(89)90069-9; KAMISAKI Y, 1993, BRAIN RES, V627, P181; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1992, BRAIN RES, V577, P121, DOI 10.1016/0006-8993(92)90544-J; Kempski O, 1990, Adv Neurol, V52, P219; KIMELBERG HK, 1989, J NEUROSCI, V9, P1141; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; Landolt H, 1996, EUR J ANAESTH, V13, P269, DOI 10.1046/j.1365-2346.1996.00975.x; MADL JE, 1993, J NEUROSCI, V13, P4429; MAGNUSSON KR, 1991, BRAIN RES, V549, P1, DOI 10.1016/0006-8993(91)90592-J; Mayhan WG, 1996, STROKE, V27, P965, DOI 10.1161/01.STR.27.5.965; McIntosh TK, 1996, LAB INVEST, V74, P315; MENENDEZ N, 1989, NEUROSCI LETT, V102, P64, DOI 10.1016/0304-3940(89)90308-X; MUIZELAAR JP, 1994, CAN J NEUROL SCI, V21, pS6, DOI 10.1017/S0084255900003685; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; OKAMOTO K, 1983, BRAIN RES, V265, P163, DOI 10.1016/0006-8993(83)91350-1; OTTERSEN OP, 1988, ANAT EMBRYOL, V178, P407, DOI 10.1007/BF00306047; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PASANTESMORALES H, 1990, GLIA, V3, P427, DOI 10.1002/glia.440030514; SARANSAARI P, 1991, NEUROSCIENCE, V45, P451, DOI 10.1016/0306-4522(91)90240-O; SCHNEIDER GH, 1992, CAN J PHYSIOL PHARM, V70, pS334, DOI 10.1139/y92-280; SCHOUSBOE A, 1992, CAN J PHYSIOL PHARM, V70, pS356, DOI 10.1139/y92-283; SHIMADA N, 1993, J NEUROCHEM, V60, P66, DOI 10.1111/j.1471-4159.1993.tb05823.x; STOCKER R, 1995, INTEGRATED APPROACH, P196; STORMMATHISEN J, 1992, MOL NEUROPHARMACOL, V2, P7; Stover JF, 1997, EUR J CLIN INVEST, V27, P1038, DOI 10.1046/j.1365-2362.1997.2250774.x; TABER KH, 1986, BRAIN RES, V386, P113, DOI 10.1016/0006-8993(86)90147-2; VANHARREVELD A, 1971, EXP MOL PATHOL, V15, P61, DOI 10.1016/0014-4800(71)90019-0; VOLTERRA A, 1994, MOL PHARMACOL, V46, P986; WESTERGREN I, 1994, J NEUROCHEM, V62, P159; Zauner A, 1996, ACT NEUR S, V67, P40; ZUCCARELLO M, 1993, J NEUROTRAUM, V10, P397, DOI 10.1089/neu.1993.10.397	46	40	40	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	1999	16	2					135	142		10.1089/neu.1999.16.135			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	173BA	WOS:000078960000003	10098958	Green Accepted			2021-06-18	
J	Cifu, DX; Kreutzer, JS; Marwitz, JH; Miller, M; Hsu, GM; Seel, RT; Englander, J; High, WM; Zafonte, R				Cifu, DX; Kreutzer, JS; Marwitz, JH; Miller, M; Hsu, GM; Seel, RT; Englander, J; High, WM; Zafonte, R			Etiology and incidence of rehospitalization after traumatic brain injury: A multicenter analysis	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SPINAL-CORD INJURY; COMMUNITY; IMPACT; REHABILITATION; TRENDS; LENGTH; STAY	Objective: To investigate incidence and etiology of rehospitalizations at 1, 2, and 3 years after traumatic brain injury. Design: Descriptive statistics were computed in a prospective study of etiology and incidence of rehospitalization at years 1, 2, and 3 postinjury. Analysis of variance (ANOVA) and chi(2) were used to identify factors relating to rehospitalization; factors included length of stay, admission and discharge functional status, payer source, medical complications, injury severity, and demographics. Setting: Four medical centers in the federally sponsored Traumatic Brain Injury Model Systems. In each setting, the continuum of care includes emergency medical services, intensive and acute medical care, inpatient rehabilitation, and a spectrum of community rehabilitation services. Participants: Six hundred sixty-five rehabilitation patients admitted to acute care within 24 hours of traumatic brain injury between 1989 and 1996. Main Outcome Measures: Annual incidence and etiology of rehospitalization. Results: The annual incidence of rehospitalization ranged from 20% to 22.5%. Approximately half the rehospitalizations were for elective reasons. The most common reason for rehospitalization was for orthopedic or reconstructive surgery, followed by infectious disorders and general health maintenance. After the first year, the incidence of readmissions for seizures and psychiatric difficulties increased substantially. ANOVA and chi(2) analyses were performed on data from the first year postinjury. No statistically significant associations were noted between incidence and etiology of rehospitalization and: demographics; injury severity; payer source for rehabilitation; concurrent injuries; acute care and rehabilitation length of stays; discharge Functional Assessment Measure; and discharge residence (p > .05). Conclusions: There is a relatively stable but high rate of rehospitalization for at least 3 years after injury. The costs of rehospitalization should be considered when evaluating the long-term consequences of injury. (C) 1999 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; Thomas Jefferson Univ, AI DuPont Childrens Med Ctr, Philadelphia, PA 19107 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Wayne State Univ, Dept Phys Med & Rehabil, Detroit, MI USA	Cifu, DX (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, MCV Box 980677, Richmond, VA 23298 USA.			Cifu, David/0000-0003-1600-9387			Bontke C. F., 1993, J HEAD TRAUMA REHAB, V8, P34; BURNS TJ, 1990, ARCH PHYS MED REHAB, V71, P138; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DAVIDOFF G, 1990, ARCH PHYS MED REHAB, V71, P121; DeVivo M, 1995, SPINAL CORD INJURY C, P234; DEVIVO MJ, 1992, ARCH PHYS MED REHAB, V73, P424; DINCIN J, 1993, HOSP COMMUNITY PSYCH, V44, P833; Englander JS, 1996, J HEAD TRAUMA REHAB, V11, P15, DOI 10.1097/00001199-199610000-00003; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; High WM, 1996, J HEAD TRAUMA REHAB, V11, P85, DOI 10.1097/00001199-199610000-00008; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Sander AM, 1997, J HEAD TRAUMA REHAB, V12, P28, DOI 10.1097/00001199-199710000-00004; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; THORNGREN M, 1990, STROKE, V21, P236, DOI 10.1161/01.STR.21.2.236; TUEL S M, 1992, Brain Injury, V6, P363, DOI 10.3109/02699059209034951; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206	24	40	41	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	1999	80	1					85	90		10.1016/S0003-9993(99)90312-X			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	155XZ	WOS:000077973000013	9915377				2021-06-18	
J	Bombardier, CH; Rimmele, CT				Bombardier, CH; Rimmele, CT			Alcohol use and readiness to change after spinal cord injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; CHANGE QUESTIONNAIRE; FUTURE-DIRECTIONS; DRINKERS; INTERVENTIONS; ISSUES; ABUSE	Objective: To describe alcohol use and motivation to change drinking among persons with recent spinal cord injury (SCI). Design: Survey Setting: Acute inpatient rehabilitation program Patients: Subjects were 58 patients with recent SCI assessed during inpatient rehabilitation. Main Outcome Measures: Short Michigan Alcoholism Screening Test (SMAST), Readiness to Change questionnaire (RTC), and alcohol use questions, Results: Subjects were on average 39 years old, 88% were male, and 86% were Caucasian. Thirty-five percent of the total sample scored in the "alcoholic" range on the SMAST, Twenty-nine (50%) of the sample were considered "at-risk" drinkers. Of these, 6 (21%) were in the precontemplation phase, 13 (45%) were in the contemplation phase, and 10 (34%) were in the action phase with respect to modifying their drinking habits. Multivariate analyses indicated that a positive history of alcoholism and higher daily consumption were associated with greater readiness to change. Conclusions: Soon after SCI, most at-risk drinkers are at least considering changes in their alcohol use. This situation may represent an underutilized window of opportunity to implement interventions designed to reduce postinjury alcohol abuse and related impairments. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; Vet Affairs Med Ctr, Seattle, WA 98108 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA	Bombardier, CH (corresponding author), Harborview Med Ctr, Box 359740,325 9th Ave, Seattle, WA 98104 USA.						ANTTIPOIKA I, 1988, ALCOHOL ALCOHOLISM, V23, P115; BABOR TF, 1987, J STUD ALCOHOL, V48, P410, DOI 10.15288/jsa.1987.48.410; Bombardier CH, 1997, ARCH PHYS MED REHAB, V78, P592, DOI 10.1016/S0003-9993(97)90424-X; CHARLIFUE SW, 1991, ARCH PHYS MED REHAB, V72, P488; CHICK J, 1985, BRIT MED J, V290, P965, DOI 10.1136/bmj.290.6473.965; DiClemente CC., 1992, PROGR BEHAV MODIFICA, P184; DONOVAN D, 1995, RES SOC ALC JUN STEA; Frisbie J H, 1984, J Am Paraplegia Soc, V7, P71; FULLETON D, 1981, ARCH GEN PSYCHIAT, V28, P1369; GENTILELLO LM, 1995, JAMA-J AM MED ASSOC, V274, P1043, DOI 10.1001/jama.274.13.1043; GENTILELLO LM, 1988, AM J SURG, V156, P558, DOI 10.1016/S0002-9610(88)80553-1; HARBURG E, 1988, J STUD ALCOHOL, V49, P522, DOI 10.15288/jsa.1988.49.522; HEATHER N, 1993, ADDICTION, V88, P1667, DOI 10.1111/j.1360-0443.1993.tb02042.x; Heinemann A. W., 1989, ALCOHOL HEALTH RES W, V13, P110; HEINEMANN AW, 1988, ARCH PHYS MED REHAB, V69, P619; HEINEMANN AW, 1989, REHABIL PSYCHOL, V34, P191, DOI 10.1037//0090-5550.34.3.191; JACOBSON GR, 1989, HDB ALCOHOLISM TREAT, P54; Krause J, 1992, NEUROREHABILITATION, V2, P45; Miller W. R., 1992, PROJECT MATCH MONOGR, V2; Miller WR, 1987, BRIEF DRINKER PROFIL; Miller WR, 1991, MOTIVATIONAL INTERVI; O'Donnell JJ, 1981, ALCOHOL HEALTH RES W, V6, P27; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; Radnitz CL, 1993, SCI PSYCHOSOC PROCES, V6, P85; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; ROLLNICK S, 1992, BRIT J ADDICT, V87, P743; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; SELZER ML, 1975, J STUD ALCOHOL, V36, P127; SOBELL LC, 1990, BEHAV ASSESS, V12, P77; Soderstrom CA, 1997, JAMA-J AM MED ASSOC, V277, P1769, DOI 10.1001/jama.277.22.1769; STOVER SL, 1986, SPINAL CORD INJURY F; WALLER JA, 1990, J TRAUMA, V30, P1548, DOI 10.1097/00005373-199012000-00020; YOUNG ME, 1995, ARCH PHYS MED REHAB, V76, P525, DOI 10.1016/S0003-9993(95)80506-0	33	40	41	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	1998	79	9					1110	1115		10.1016/S0003-9993(98)90180-0			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	118FX	WOS:000075828700016	9749693				2021-06-18	
J	Inoue, T; Kawaguchi, S; Kurisu, K				Inoue, T; Kawaguchi, S; Kurisu, K			Spontaneous regeneration of the pyramidal tract after transection in young rats	NEUROSCIENCE LETTERS			English	Article						brain injury; pyramidotomy; neural repair; axonal regeneration; axonal environment; gliosis; scar; aberrant projections	SPINAL-CORD; AXONS; RESTORATION; GROWTH; LIGHT	Spontaneous regeneration of the pyramidal tract after transection of the medullary pyramid was examined in young rats by the anterograde tracing method with wheat germ agglutinin-conjugated horseradish peroxidase. Care was taken to cut the tract as sharply as possible to minimize traumatic injuries. A very sharp cut produced edema-free lesions without subsequent formation of either cysts or scars, whereas a relatively blunt cut produced edema and later scars and/or cysts in the lesion. Regenerated projections in the latter cases were sparse, short, dispersed and largely aberrant as described in previous reports. By contrast, regenerated projections in the former cases were very much similar to normal in various respects: the amount, extension, path, formation of a compact bundle and termination. There was, however, a decisive difference from normal, that is, the additional aberrant projections. (C) 1998 Elsevier Science Ireland Ltd.	Kyoto Univ, Grad Sch Med, Dept Integrat Brain Sci, Kyoto 6068501, Japan; Hiroshima Univ, Sch Med, Dept Neurosurg, Hiroshima 7348551, Japan	Kawaguchi, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Integrat Brain Sci, Kyoto 6068501, Japan.						BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; DEOLMOS J, 1977, NEUROSCI LETT, V6, P107, DOI 10.1016/0304-3940(77)90004-0; HOLZER W, 1921, ALLGEM Z PSYCHIAT, V77, P358; IWASHITA Y, 1994, NATURE, V367, P167, DOI 10.1038/367167a0; KALIL K, 1982, J COMP NEUROL, V211, P265, DOI 10.1002/cne.902110305; KALIL K, 1979, SCIENCE, V205, P1158, DOI 10.1126/science.472734; KAWAGUCHI S, 1986, J COMP NEUROL, V245, P258, DOI 10.1002/cne.902450208; MATTHEWS MA, 1971, J COMP NEUROL, V142, P1, DOI 10.1002/cne.901420102; MCGEER PL, 1987, MOL NEUROBIOLOGY MAM, P448; NAGASHIMA M, 1994, NEUROSCI RES, V19, P81, DOI 10.1016/0168-0102(94)90011-6; REH T, 1981, J COMP NEUROL, V200, P55, DOI 10.1002/cne.902000105; Reier PJ, 1983, SPINAL CORD RECONSTR, P163; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; TOLBERT DL, 1987, J COMP NEUROL, V260, P299, DOI 10.1002/cne.902600210; YING L, 1997, SCIENCE, V277, P2000	16	40	40	0	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	MAY 15	1998	247	2-3					151	154		10.1016/S0304-3940(98)00297-3			4	Neurosciences	Neurosciences & Neurology	ZP335	WOS:000073742000020	9655615				2021-06-18	
J	McCrory, PR; Berkovic, SF				McCrory, PR; Berkovic, SF			Concussive convulsions - Incidence in sport and treatment recommendations	SPORTS MEDICINE			English	Article							CEREBRAL CONCUSSION; SYNCOPE; GUIDELINES; EPISODES	Concussive convulsions (CC) are nonepileptic phenomena which are an immediate sequelae of concussive brain injury. Although uncommon, occurring with an approximate incidence of 1 case per 70 concussions, these episodes are often confused with post-traumatic epilepsy which may occur with more severe structural brain injury. The pathophysiological mechanism of CC remains speculative, but may involve a transient traumatic functional decerebration with loss of cortical inhibition and release of brainstem activity. The phenomenology of the CC is somewhat akin to convulsive syncope, with an initial tonic phase occurring within 2 seconds of impact, followed by a clonic or myoclonic phase which may last several minutes. Lateralising features are common during the convulsions. There is no evidence of structural or permanent brain injury on clinical assessment, neuropsychological testing or neuroimaging studies. Long term outcome is universally good with no evidence of long term epilepsy and athletes are usually able to return to sport within 2 weeks. The correct management of these episodes centres on the appropriate management of the associated concussive injury and the exclusion of other cerebral injury by medical assessment. The CC requires no specific management beyond immediate onfield first aid measures such protection of the airway. Antiepileptic therapy is not indicated and prolonged absence from spc,rt is unwarranted. These episodes, although dramatic, are relatively straightforward to manage and all team physicians and those involved in athlete care need to be aware of this condition.	Olymp Pk Sports Med Ctr, Melbourne, Vic 3004, Australia; Univ Melbourne, Austin & Repatriat Med Ctr, Dept Med Neurol, Heidelberg, Vic, Australia	McCrory, PR (corresponding author), Olymp Pk Sports Med Ctr, Swan St, Melbourne, Vic 3004, Australia.	pmccrory@compuserve.com	McCrory, Paul/Q-8688-2019				AMINOFF MJ, 1988, ANN INTERN MED, V108, P791, DOI 10.7326/0003-4819-108-6-791; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BOVE AA, 1973, AEROSPACE MED, V44, P245; BRUKNER P, 1993, CLIN SPORTS MED, P608; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Chadwick D, 1997, BRIT MED J, V314, P1283; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DUVOISIN RC, 1962, ARCH NEUROL-CHICAGO, V7, P219, DOI 10.1001/archneur.1962.04210030057008; GASTAUT H, 1957, LANCET, V2, P1018; GASTAUT H, 1974, HDB CLIN NEUROLOGY; GASTAUT H, 1972, EPILEPTIC SEIZURES C, P186; GOWERS WR, 1907, BORDERLAND EPILEPSY, P45; GOWERS WR, 1881, EPILEPSY CHRONIC CON, P24; HOWARD P, 1951, BRIT MED J, V2, P382, DOI 10.1136/bmj.2.4728.382; JENNETT B, 1975, EPILEPSY NONMISSILE, P13; KHURANA RK, 1980, ANN NEUROL, V7, P144, DOI 10.1002/ana.410070209; Lempert T, 1996, J ROY SOC MED, V89, P372; LEMPERT T, 1994, ANN NEUROL, V36, P233, DOI 10.1002/ana.410360217; LIN JTY, 1982, ANN NEUROL, V11, P525, DOI 10.1002/ana.410110513; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; MADDOCKS DL, 1991, J CLIN EXP NEUROPSYC, V13, P439; McCrory PR, 1997, MED SCI SPORT EXER, V29, pS207; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; ORCHARD J, 1995, AFL VSFL INJURIES 19; ORCHARD J, 1995, AFL 1995 INJURY REPO; PHILLIPS G, 1954, J NEUROL NEUROSUR PS, V17, P1, DOI 10.1136/jnnp.17.1.1; ROBERTS WO, 1992, PHYSICIAN SPORTSMED, V20, P66, DOI 10.1080/00913847.1992.11710295; Roos R, 1996, PHYSICIAN SPORTSMED, V24, P67, DOI 10.3810/psm.1996.10.1327; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x; STEPHENSON JBP, 1990, FITS FAINTS, P112; TORG JF, 1991, ATHLETIC INJURIES HE, P270; WESTPHAL CFO, 1871, BERLINER FKLIN WOCHE, V1, P39; WESTPHAL CFO, 1872, BRIT MED J, V1, P399; WHINNERY JE, 1990, ARCH NEUROL-CHICAGO, V47, P764, DOI 10.1001/archneur.1990.00530070058012; WLAKER AE, 1969, LATE EFFECTS HEAD IN, P23	38	40	42	0	8	ADIS INTERNATIONAL LTD	AUCKLAND	41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 10, NEW ZEALAND	0112-1642			SPORTS MED	Sports Med.	FEB	1998	25	2					131	136		10.2165/00007256-199825020-00005			6	Sport Sciences	Sport Sciences	YZ634	WOS:000072273900007	9519401				2021-06-18	
J	Thakker, JC; Splaingard, M; Zhu, J; Babel, K; Bresnahan, J; Havens, PL				Thakker, JC; Splaingard, M; Zhu, J; Babel, K; Bresnahan, J; Havens, PL			Survival and functional outcome of children requiring endotracheal intubation during therapy for severe traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; brain injury; pediatric; outcome	SEVERE HEAD-INJURY; AGGRESSIVE TREATMENT; MANAGEMENT; MORTALITY; PROGNOSIS; SCALE; CARE; COMA	Objective: To determine the predictors of survival and functional outcome of pediatric patients with traumatic brain injury severe enough to require endotracheal intubation and mechanical ventilation. Design: Retrospective, observational cohort study. Setting: Pediatric intensive care unit (ICU) at a tertiary care children's hospital. Patients: All children (n =105) admitted over a 5-yr period with traumatic brain injury severe enough to require endotracheal intubation and mechanical ventilation, The median age was 43 months (range 1 month to 14 yrs), Of these children, 74% were male and 70% were white. Interventions: None. Measurements and Main Results: Variables studied included vital signs during the first 24 hrs of admission, Pediatric Risk of Mortality (PRISM) score, Glasgow Coma Score, duration of mechanical ventilation, and number of pediatric ICU and hospital days, Functional status was graded as normal, independent, partially dependent, or dependent in the areas of locomotion, self-care, and communication, This status was assessed at hospital discharge by chart review and at follow-up by telephone interview, The median Glasgow Coma Score was 6 (range 3 to 14) and the median PRISM score was 13 (range 1 to 51). There were 19 (18.1%) deaths, 17 in the pediatric ICU and two after hospital discharge, Of the patients who survived to hospital discharge, 39 (37.1%) patients were completely normal or independent, 42 (40%) patients were partially dependent, and seven (6.7%) patients were dependent in all three areas of function, Follow-up evaluations were available for 80 patients, with a median follow-up time of 24.5 months (range 8 to 70), Of the 78 patients who survived and were available for follow-up, the number who were functionally normal or independent increased to 69 (65.7%), At follow-up, there were eight (7.6%) patients remaining with partial dependency in at least one area of function while one (0.9%) patient continued to be dependent in all three areas of function, Mortality and dependent functional outcome were more likely in patients with younger age, lower Glasgow Coma Score, and higher PRISM score at hospital admission, Of the 27 patients with a Glasgow Coma Score of less than or equal to 5, 11 (40.7%) survived with normal or independent functional status at follow up. Of the 24 patients with PRISM scores of greater than or equal to 20, only five (20.8%) were functionally normal or independent at follow-up, The relative risk of a bad outcome for patients with a Glasgow Coma Score of less than or equal to 5 and a PRISM score of greater than or equal to 20 was ten times higher than the group of patients with a Glasgow Coma Score of less than or equal to 5 but a PRISM score of <20. Conclusions: Children with severe traumatic brain injury who survive to hospital discharge will continue to improve in their functional status over the next few years, Although low Glasgow Coma Score is strongly associated with death or poor functional outcome after therapy for traumatic brain injury, many patients with Glasgow Coma Score of less than or equal to 5 can Survive with good function. PRISM scores add to the power of Glasgow Coma Score to predict survival and functional outcome in tracheally intubated pediatric patients with Glasgow Coma Score of less than or equal to 5.	MED COLL WISCONSIN, DEPT PEDIAT, MILWAUKEE, WI 53226 USA; CHILDRENS HOSP WISCONSIN, MILWAUKEE, WI 53201 USA; MED COLL WISCONSIN, DEPT PHYS MED & REHABIL, MILWAUKEE, WI 53226 USA			Splaingard, Mark/AAL-7356-2021; Splaingard, Mark L/D-9206-2012	Splaingard, Mark/0000-0002-1361-4947			BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BOWERS SA, 1977, NEUROSURGERY, V47, P491; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BROWN JK, 1993, DEV MED CHILD NEUROL, V35, P849; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; CASEY R, 1986, PEDIATRICS, V78, P497; DAVIS RJ, 1992, TXB PEDIAT INTENSIVE, P805; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; HAHN YS, 1988, CHILD NERV SYST, V4, P34; HUMPHREYS PR, 1984, CONCEPTS PEDIAT NEUR, V4, P230; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KUMAR R, 1991, CHILD NERV SYST, V7, P299, DOI 10.1007/BF00304824; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; LUNDAR T, 1985, CHILD NERV SYST, V1, P24, DOI 10.1007/BF00706726; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; RAPHAELY RC, 1980, PEDIATR CLIN N AM, V27, P715; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SPLAINGARD ML, 1989, ARCH PHYS MED REHAB, V70, P318; TEASDALE G, 1974, LANCET, V2, P81; TEPAS JJ, 1990, J PEDIATR SURG, V25, P92, DOI 10.1016/S0022-3468(05)80170-8; ZUCCARELLO M, 1985, CHILD NERV SYST, V1, P158, DOI 10.1007/BF00735731	24	40	41	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	AUG	1997	25	8					1396	1401		10.1097/00003246-199708000-00030			6	Critical Care Medicine	General & Internal Medicine	XQ994	WOS:A1997XQ99400030	9267956				2021-06-18	
J	Mechanick, JI; Pomerantz, F; Flanagan, S; Stein, A; Gordon, WA; Ragnarsson, KT				Mechanick, JI; Pomerantz, F; Flanagan, S; Stein, A; Gordon, WA; Ragnarsson, KT			Parathyroid hormone suppression in spinal cord injury patients is associated with the degree of neurologic impairment and not the level of injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							BONE LOSS; IMMOBILIZATION; HYPERCALCEMIA; OSTEOPOROSIS; SECRETION; INVITRO; MEN	Objective: To demonstrate that after spinal cord injury (SCI) suppression of the parathyroid-vitamin D axis is associated with the degree of neurologic impairment and not the level of injury, Design: A retrospective analysis of clinical and biochemical data obtained from hospital records of patients with SCI compared to a control group of patients with traumatic brain injury (TBI). Setting: The inpatient rehabilitation unit of a tertiary care hospital. Subjects: The medical records of 82 consecutive admissions to the rehabilitation unit with a diagnosis of SCI or TBI were reviewed. Patients with SCI were classified by the American Spinal injury Association (ASIA) impairment scale and then grouped based on the completeness and level of injury. Main Outcome Measure: Comparisons of serum parathyroid hormone (PTH), 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D (1,25-D) were planned. Multiple comparisons were performed for total and ionized serum calcium levels, serum phosphorus levels, and 24-hour urinary calcium excretion rates to reflect changes in mineral homeostasis. Multiple comparisons were also performed for serum albumin, prolactin, thyroid function tests, and AM cortisol levels, as well as 24-hour urinary urea nitrogen and cortisol excretion rates to reflect metabolic responses to stress. Results: Patients with SCI had significant suppression in PTH (p < .000009) and 1,25-D (p < .02) levels with elevated phosphorus (p < 0.03) and prolactin (p < .03) levels compared to patients with TBI. Also, more patients with SCI were hypoalbuminemic (p < .003) than patients with TBI. Patients with complete SCI (ASIA A) had more suppressed PTH (p < .03) and higher urinary urea nitrogen (p < .05) levels than SCI patients with incomplete injuries (ASIA B-D). Patients with complete, but not incomplete, SCI had lower albumin levels than patients with TBI (p < .05). These differences were not found between patients with tetraplegic and paraplegic SCI. ASIA motor scores did not correlate with any of the measured parameters but when used as a covariate did abolish differences in PTH and 1,25-D among the study groups by ANOVA. Conclusion: In patients with SCI, the degree of neurologic impairment. and not the level of injury, is associated with PTH suppression and markers of metabolic stress. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	CUNY MT SINAI SCH MED, DEPT REHABIL MED, NEW YORK, NY 10029 USA	Mechanick, JI (corresponding author), CUNY MT SINAI SCH MED, DIV ENDOCRINOL & METAB, NEW YORK, NY 10029 USA.			Flanagan, Steven/0000-0001-9005-5897	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [H133NS0008] Funding Source: Medline		Albright F, 1941, J CLIN ENDOCRINOL, V1, P711, DOI 10.1210/jcem-1-9-711; American Spinal Injury Association/International Medical Society of Paraplegia, 1992, INT STAND NEUR FUNCT; CANALIS E, 1987, ENDOCRINOLOGY, V121, P1596, DOI 10.1210/endo-121-5-1596; CHAPPARD D, 1995, J BONE MINER RES, V10, P112; CLAUSWALKER J, 1977, J CLIN ENDOCR METAB, V44, P530, DOI 10.1210/jcem-44-3-530; FUJIYAMA K, 1995, J CLIN ENDOCR METAB, V80, P2135, DOI 10.1210/jc.80.7.2135; GARLAND DE, 1992, J ORTHOPAED RES, V10, P371, DOI 10.1002/jor.1100100309; GOWEN M, 1986, J IMMUNOL, V136, P2478; HYMAN LR, 1972, AM J DIS CHILD, V124, P723, DOI 10.1001/archpedi.1972.02110170101017; Keating J F, 1992, Disabil Rehabil, V14, P108; Kolmogoroff A, 1941, ANN MATH STAT, V12, P461, DOI 10.1214/aoms/1177731684; KRUSKAL WILLIAM H., 1952, JOUR AMER STATIST ASSOC, V47, P583, DOI 10.2307/2280779; LAWRENCE GD, 1973, J BONE JOINT SURG AM, VA 55, P87, DOI 10.2106/00004623-197355010-00008; LERMAN S, 1977, J CLIN ENDOCR METAB, V45, P425, DOI 10.1210/jcem-45-3-425; LESLIE WD, 1993, ARCH PHYS MED REHAB, V74, P960; LOGUE FC, 1990, J CLIN ENDOCR METAB, V71, P1556, DOI 10.1210/jcem-71-6-1556; MALLETTE LE, 1989, J BONE MINER RES, V4, P143; MAYNARD FM, 1977, ARCH PHYS MED REHAB, V58, P16; Mechanick JI, 1993, RES STAFF PHYS, V39, P87; NAFTCHI NE, 1980, ARCH PHYS MED REHAB, V61, P139; PIETSCHMANN P, 1992, PARAPLEGIA, V30, P204, DOI 10.1038/sc.1992.56; PILONCHERY G, 1983, CLIN ORTHOP RELAT R, P230; RAGNARSSON KT, 1981, ARCH PHYS MED REHAB, V62, P418; RODRIGUEZ GP, 1989, ARCH PHYS MED REHAB, V70, P442, DOI 10.1016/0003-9993(89)90003-8; Saltzstein R J, 1992, J Am Paraplegia Soc, V15, P232; SHETTY KR, 1993, AM J MED SCI, V305, P95, DOI 10.1097/00000441-199302000-00006; STEWART AF, 1982, NEW ENGL J MED, V306, P1136, DOI 10.1056/NEJM198205133061903; STOVER SL, 1991, CLIN ORTHOP RELAT R, P71; TORI JA, 1978, PARAPLEGIA, V16, P357; UEBELHART D, 1994, SCAND J REHABIL MED, V26, P197; VAZIRI ND, 1994, ARCH PHYS MED REHAB, V75, P766	31	40	41	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	1997	78	7					692	696		10.1016/S0003-9993(97)90075-7			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	XK216	WOS:A1997XK21600003	9228870				2021-06-18	
J	Warden, CR; Brownstein, DR; DelBeccaro, MA				Warden, CR; Brownstein, DR; DelBeccaro, MA			Predictors of abnormal findings of computed tomography of the head in pediatric patients presenting with seizures	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Region IX and X of the Ambulatory-Pediatric-Association Meeting	FEB, 1996	CARMEL, CA	Ambulatory Pediat Assoc, Reg IX, Ambulatory Pediat Assoc, Reg X			RULES; RADIOGRAPHY; CHILDHOOD; DISORDERS; SELECTION; CHILDREN; INJURIES; SCANS	Study objective: To develop a preliminary clinical decision guideline, using characteristics of ED pediatric patients presenting with seizures, that successfully predicts all abnormal results of computed tomography (CT) of the head. Methods: We assembled a retrospective case series in the ED of a tertiary care children's hospital without trauma designation. The series comprised all patients who presented between January 1, 1992, and December 31, 1994, with seizures (febrile and afebrile) who underwent head CT as part of ED evaluation Results: Our inclusion criteria were met by 203 patients. Of these patients, who had a median age of 3.1 years, 53% were boys; 18% had been transferred from another facility; 25% had received anticonvulsant medication in the field, at the referring facility, or both; 32% had a history of seizures before the presenting episode; 6% had sustained a closed-head injury (CHI); 15% had a cerebrospinal fluid (CSF) shunt; 4% had an underlying malignancy or neurocutaneous disorder (NCT); and 30% had a documented fever. CT findings were abnormal in 25 patients (12%). CT showed evidence of hemorrhage in eight patients (32%), small focal abnormalities in four (16%), cerebral edema in three (12%), and shunt obstruction in two (8%). chi(2) Recursive-partitioning analysis revealed that CT scan results were always normal when the patient did not have an underlying high-risk condition (malignancy, NCT, recent CHI, or recent CSF shunt revision), was older than 6 months, had sustained a seizure of 15 minutes or less, and did not have a history of a new-onset focal neurologic deficit. Retrospective application of these criteria revealed that 41% of the CT scans could have been deferred. Conclusion: In this case series, the absence of defined high-risk factors predicted normal head CT findings. The deferral of emergency CT in this population should be considered.		Warden, CR (corresponding author), UNIV WASHINGTON,DEPT PEDIAT,CHILDRENS HOSP,EMERGENCY SERV,SEATTLE,WA 98195, USA.						*AM COLL EM PHYS, 1993, ANN EMERG MED, V22, P875; BACHMAN DS, 1976, PEDIATRICS, V58, P828; CIAMPI A, 1988, J CLIN EPIDEMIOL, V8, P737; COOK EF, 1984, J CHRON DIS, V37, P721, DOI 10.1016/0021-9681(84)90041-9; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; Ferry P C, 1992, Pediatr Rev, V13, P248, DOI 10.1542/pir.13-7-248; Fleiss JL, 1981, STATISTICAL METHODS; FLOSNER B, 1995, FUNDAMENTALS STAT; FRIEDMAN JH, 1977, IEEE T COMPUT, V16, P404; GRANETO JW, 1993, TXB PEDIAT EMERGENCY, P464; Landfish N, 1992, J Fla Med Assoc, V79, P697; MARSHALL RJ, 1986, STAT MED, V5, P517, DOI 10.1002/sim.4780050516; MCABEE GN, 1989, PEDIATR NEUROL, V5, P102, DOI 10.1016/0887-8994(89)90034-9; MCCONNOCHIE KM, 1993, MED DECIS MAKING, V13, P30, DOI 10.1177/0272989X9301300105; MEYERS A, 1978, AM J DIS CHILD, V132, P25, DOI 10.1001/archpedi.1978.02120260027003; Reinus WR, 1996, INVEST RADIOL, V31, P101, DOI 10.1097/00004424-199602000-00007; REINUS WR, 1993, ANN EMERG MED, V22, P1298, DOI 10.1016/S0196-0644(05)80111-8; REINUS WR, 1993, RADIOLOGY, V186, P763, DOI 10.1148/radiology.186.3.8430185; RIVARA F, 1987, PEDIATRICS, V80, P579; SCHUTZMAN SA, 1993, TXB PEDIAT EMERGENCY, P268; STIELL IG, 1992, ANN EMERG MED, V21, P384, DOI 10.1016/S0196-0644(05)82656-3; STIELL IG, 1995, ANN EMERG MED, V26, P405, DOI 10.1016/S0196-0644(95)70106-0; Vining E P, 1986, Pediatr Rev, V8, P185, DOI 10.1542/pir.8-6-185; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; YANG PJ, 1979, NEUROLOGY, V29, P1084, DOI 10.1212/WNL.29.8.1084	25	40	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	APR	1997	29	4					518	523		10.1016/S0196-0644(97)70226-9			6	Emergency Medicine	Emergency Medicine	WQ539	WOS:A1997WQ53900010	9095014				2021-06-18	
J	Gennarelli, TA				Gennarelli, TA			The pathobiology of traumatic brain injury	NEUROSCIENTIST			English	Article						brain trauma; injury; calcium; axonal injury; mechanisms of cell damage	CHOLINERGIC RECEPTOR-BINDING; CENTRAL-NERVOUS-SYSTEM; DIFFUSE AXONAL INJURY; HEAD-INJURY; RAT-BRAIN; C-FOS; GENE-EXPRESSION; PROTEIN; TISSUE; INTERLEUKIN-6	The recent appreciation that traumatic brain injury is a dynamic process, initiated at the time of injury but not concluded for hours to days afterward, has resulted in the expectation that treatments can be designed to interrupt the processes that result in delayed cellular dysfunction and, thus, can decrease the amount of traumatic brain damage. Thus, for the first time, treatments specific for brain damage are envisioned. These can provide a fundamentally different approach to the treatment of the damaged brain than currently used treatments that deal with epiphenomena of traumatic injury, such as increased intracranial pressure or secondary ischemia. The processes that result in delayed cellular damage may be initiated by transient ionic fluxes induced by traumatic, temporary holes in the cell membrane lipid bilayer (mechanoporation). Resulting changes in intracellular ionic composition, if uncorrected, result in I)traumatic depolarization with resultant neurotransmitter release, postsynaptic receptor dysfunction, and excitability changes; 2) calcium-mediated activation of proteases and phospholipases, with resultant cytoskeletal protein dissolution and free radical-induced lipid peroxidation; 3) inflammatory processes that elicit tissue-damaging cytokines; and 4) immediate and delayed activation of numerous genes with a resultant production of a panoply of new proteins. The future challenge to neurotrauma investigators is to better understand these processes and to develop interventions that will halt them before permanent brain damage occurs.	ALLEGHENY UNIV HLTH SCI, CTR NEUROSCI, PHILADELPHIA, PA 19102 USA; ALLEGHENY UNIV HLTH SCI, DEPT NEUROSURG, PHILADELPHIA, PA 19102 USA							ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; CHAN KH, 1993, NEUROSURGERY, V32, P247; CHOPP M, 1993, CURR OPIN NEUROL NEU, V6, P6; D'MELLO SR, 1991, MOL BRAIN RES, V11, P255, DOI 10.1016/0169-328X(91)90034-U; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; FERN R, 1995, NEUROSCIENTIST, V1, P253; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1994, J NEUROSURG, V80, P409; Gennarelli TA, 1993, HEAD INJURY, P137; GENNARELLI TA, 1996, IN PRESS NEUROPATHOL; GENNARELLI TA, 1983, ACTA NEUROCHIR     S, V2, P1; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; GRAHAM DI, 1996, GREENFIELDS NEUROPAT, P197; GRAHAM DI, 1981, MILD MODERATE HEAD I, P3; Hall E D, 1985, Cent Nerv Syst Trauma, V2, P75; HALL ED, 1993, RES P ARNMD, V71, P81; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; HAYES RL, 1995, J NEUROTRAUMA, V12, P791; HAYES RL, 1981, BRAIN RES, V225, P271; HEIZER ML, 1988, FASEB J, V2, pA1519; JIANG JY, 1994, BRAIN RES, V651, P123, DOI 10.1016/0006-8993(94)90687-4; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; LESLIE JB, 1985, J NEUROSURG, V63, P659, DOI 10.3171/jns.1985.63.5.0659; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; McLellan D, 1986, COMA TRAUMATIQUE, P165; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; NOWAK TS, 1990, STROKE, V21, P107; NOWAK TS, 1990, CEREBROVAS BRAIN MET, V2, P345; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; QUITSCHKE WW, 1992, J BIOL CHEM, V267, P17362; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; RINK AD, 1995, J NEUROTRAUM, V12, P137; SAATMAN KE, 1994, SOC NEUR ABSTR, V20, P115; SAUNDERS RD, 1987, J NEUROCHEM, V49, P24, DOI 10.1111/j.1471-4159.1987.tb03388.x; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SHAPIRA Y, 1989, Neurological Research, V11, P169; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Soares HD, 1995, J NEUROSCI, V15, P8223; THIBAULT LE, 1992, INT RES COUNCIL BIOM, V14, P3; TSUIKI K, 1995, J NEUROCHEM, V64, P1319; WEST M, 1981, BRAIN RES, V225, P271, DOI 10.1016/0006-8993(81)90835-0; WINSTON FK, 1993, J BIOMECH ENG-T ASME, V115, P160, DOI 10.1115/1.2894116; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; YAN HQ, 1992, EUR J IMMUNOL, V22, P2693; YAWO H, 1983, SCIENCE, V222, P1351, DOI 10.1126/science.6658457	66	40	42	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-8584			NEUROSCIENTIST	Neuroscientist	JAN	1997	3	1					73	81		10.1177/107385849700300117			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	WC678	WOS:A1997WC67800017					2021-06-18	
J	Lannoo, E; Vingerhoets, G				Lannoo, E; Vingerhoets, G			Flemish normative data on common neuropsychological tests: Influence of age, education, and gender	PSYCHOLOGICA BELGICA			English	Article							CLOSED-HEAD-INJURY; COLOR-WORD TEST; REY-OSTERRIETH; COMPLEX FIGURE; STROOP; RECOVERY; DEFICITS	Normative data on a large, neurologically intact, nonpsychiatric sample of 200 adult Flemish subjects (male=106, female=94) are presented according to age, education, and gender. The neuropsychological test battery included the Bourdon Wiersma Dot Cancellation, the Paced Auditory Serial Addition Test (PASAT), the Stroop Color-Word Test (SCWT), the Trail Making Test (TMT), the Rey or Taylor Complex Figure Test, version A or B of the Auditory Verbal Learning Test (AVLT), version F or G of the Benton Visual Retention Test (BVRT), and the Controlled Oral Word Association Test (COWAT). Stepwise linear regression analyses reveal a significant effect of education on all measures except Dot Cancellation and an interference score of the SCWT. Age contributed significantly to performance on memory tests and timed tests. Gender only accounted for a proportion of the variance in the copy score of the Taylor Complex Figure, the delayed recall score of the Rey Complex Figure, and the results of the AVLT. The two alternate versions of the AVLT are interchangeable. The Rey and Taylor Complex Figures are not of equivalent difficulty and differentially influenced by demographic factors, as well as versions F and G of the BVRT.	STATE UNIV GHENT,B-9000 GHENT,BELGIUM							BANKEN JA, 1985, J CLIN PSYCHOL, V41, P686, DOI 10.1002/1097-4679(198509)41:5<686::AID-JCLP2270410517>3.0.CO;2-D; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BENTON AL, 1961, BENTON TEST HDB; Berry D.T., 1991, CLIN NEUROPSYCHOL, V5, P143, DOI [10.1080/13854049108403298, DOI 10.1080/13854049108403298, https://doi.org/10.1080/13854049108403298]; BERRY DTR, 1992, CLIN NEUROPSYCHOL, V6, P80, DOI DOI 10.1080/13854049208404119; Bohnen N, 1992, Clin Neuropsychol, V6, P178, DOI 10.1080/13854049208401854; CORWIN J, 1993, CLIN NEUROPSYCHOL, V7, P3, DOI 10.1080/13854049308401883; DEZEEUW J, 1981, ALGEMENE PSYCHODIAGN, V1; DULEY JF, 1993, CLIN NEUROPSYCHOL, V7, P29, DOI DOI 10.1080/13854049308401885; FISHER LM, 1990, J CLIN EXP NEUROPSYC, V12, P745, DOI 10.1080/01688639008401016; GHYS AJ, 1985, TIJDSCHRIFT KLINISCH, V15, P197; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hammes J., 1971, STROOP KLEUR WOORDTE; Kaplan E., 1991, WAIS R NEUROPSYCHOLO; KAUFMAN AS, 1991, J CLIN PSYCHOL, V47, P548; KOSS E, 1984, INT J NEUROSCI, V24, P53, DOI 10.3109/00207458409079534; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; Osterrieth P. A, 1944, ARCH PSYCHOL, V30, P286; PARKS RW, 1988, J CLIN EXP NEUROPSYC, V10, P565, DOI 10.1080/01688638808402795; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; RYAN JJ, 1984, INT J CLIN NEUROPSYC, V6, P239; Spreen O., 1991, COMPENDIUM NEUROPSYC; Strauss E, 1990, Arch Clin Neuropsychol, V5, P417, DOI 10.1016/0887-6177(90)90020-P; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TAYLOR LB, 1979, FUNCTIONAL NEUROSRUG; VANZOMEREN AH, 1997, NEUROBEHAVIORAL RECO, P398; VINGERHOETS G, UNPUB REY OSTERRIETH; VONZOMEREN AH, 1994, CLIN NEUROPSYCHOLOGY; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th	35	40	40	1	15	BELGIAN PSYCHOL SOC	LOUVAIN	TIENSESTRAAT 102, 3000 LOUVAIN, BELGIUM	0033-2879			PSYCHOL BELG	Psychol. Belg.		1997	37	3					141	155					15	Psychology, Multidisciplinary	Psychology	YH623	WOS:A1997YH62300001					2021-06-18	
J	Barry, CT; Taylor, HG; Klein, S; Yeates, KO				Barry, CT; Taylor, HG; Klein, S; Yeates, KO			Validity of neurobehavioral symptoms reported in children with traumatic brain injury	CHILD NEUROPSYCHOLOGY			English	Article							MILD HEAD-INJURY; FOLLOW-UP; FAMILY; PERFORMANCE; ADOLESCENTS; SEQUELAE	Few studies have examined the validity of neurobehavioral symptoms as correlates of the severity of traumatic brain injury (TBI) or as predictors of the neuropsychological and family consequences of injury. In the present study, 68 children with moderate to severe TBI, together with 53 children with orthopedic injuries only, were followed prospectively from the time of hospitalization. Postinjury behavior symptoms and other child and family outcomes were assessed at a baseline evaluation and again at a 6-month follow-up. The TBI group had more behavior symptoms than the orthopedic injury group at baseline and follow-up. For the TBI group, behavior symptoms at both assessments correlated with injury severity. Greater numbers of symptoms at baseline were associated with poorer neuropsychological performances and family distress at baseline, as well as more negative changes over follow-up in the child. The present findings support the utility of neurobehavioral symptoms as markers of injury severity and predictors of child and family sequelae.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PEDIAT,CLEVELAND,OH 44106; OHIO STATE UNIV,COLL MED,DEPT PEDIAT,COLUMBUS,OH 43210; COLUMBUS CHILDRENS HOSP,COLUMBUS,OH	Barry, CT (corresponding author), CASE WESTERN RESERVE UNIV,RAINBOW BABIES & CHILDRENS HOSP,DEPT PEDIAT,11100 EUCLID AVE,CLEVELAND,OH 44106, USA.		Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892			Achenbach T.M., 1991, MANUAL TEACHERS REPO; ACHENBACH TM, 1991, MANUAL CHILD BEHAVIO; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; ANDERSON JC, 1987, ARCH GEN PSYCHIAT, V44, P69; ARCIA E, 1993, BRAIN INJURY, V7, P481, DOI 10.3109/02699059309008175; BEERY KE, 1989, REVISED ADM SCORING; BLACK P, 1970, PHYSICAL TRAUMA ETIO, P142; BOHNEN N, 1993, NEUROPSY NEUROPSY BE, V6, P193; BOHNEN N, 1992, NEUROSURGERY, V30, P692; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; BOLL TJ, 1983, J CLIN CHILD PSYCHOL, V12, P74, DOI 10.1080/15374418309533114; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Brown L., 1990, TEST NONVERBAL INTEL; BROWN S, 1994, J NEUROPSYCHIATRY CL, V6, P12; DELIS DC, 1986, CALIFORNIA VERBAL LE; DENNIS M, 1991, DEV NEUROPSYCHOL, V7, P327, DOI 10.1080/87565649109540497; DEROGATIS LR, 1982, BRIEF SYMPTOM INVENT, V1; DiSimoni F., 1978, TOKEN TEST CHILDREN; DROTAR D, 1996, UNPUB FAMILY BURDEN; EVANS RW, 1992, NEUROL CLIN, V10, P815; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; Fletcher J M, 1991, Brain Inj, V5, P337, DOI 10.3109/02699059109008106; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KNIGHTS RM, 1980, REVISED SMOOTHED NOR; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LINDGREN S, 1984, PEDIAT ASSESSMENT CO; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; MOOS R, 1988, LIFE STRESSORS SOCIA; MOOS RH, 1987, HLTH DAILY LIVING FO; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; ROURKE BP, 1977, J ABNORM CHILD PSYCH, V5, P9, DOI 10.1007/BF00915756; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; RUTTER M, 1984, DEV NEUROPSYCHIATRY, P83; Secord, 1989, TEST LANGUAGE COMPET; Sparrow S., 1984, VINELAND ADAPTIVE BE; Spreen O., 1991, COMPENDIUM NEUROPSYC; Stein R, 1985, PACTS PAPERS AECOM T; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; TAYLOR HG, 1987, J PEDIATR PSYCHOL, V12, P395, DOI 10.1093/jpepsy/12.3.395; TAYLOR HG, 1992, ADV CHILD NEUROPSYCH, V1, P50; Walker H.M., 1988, WALKER MCCONNELL SCA; Wechsler D., 1991, WISC 3 WECHSLER INTE; Woodcock R.W., 1989, WOODCOCK JOHNSON TES; YEATES KO, 1994, CLIN NEUROPSYCHOL, V8, P91, DOI 10.1080/13854049408401546; YLVISAKER M, 1993, NEUROPSYCHOL REHABIL, V3, P367, DOI 10.1080/09602019308401447	52	40	40	0	2	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0929-7049			CHILD NEUROPSYCHOL	Child Neuropsychol.	DEC	1996	2	3					213	226		10.1080/09297049608402254			14	Clinical Neurology	Neurosciences & Neurology	WM941	WOS:A1996WM94100006					2021-06-18	
J	Schwartz, AE; Stone, JG; Finck, AD; Sandhu, AA; Mongero, LB; Adams, DC; Jonassen, AE; Young, WL; Michler, RE				Schwartz, AE; Stone, JG; Finck, AD; Sandhu, AA; Mongero, LB; Adams, DC; Jonassen, AE; Young, WL; Michler, RE			Isolated cerebral hypothermia by single carotid artery perfusion of extracorporeally cooled blood in baboons	NEUROSURGERY			English	Article						brain hypothermia; cerebrovascular circulation; extracorporeal circulation	PROLONGED HYPOTHERMIA; TEMPERATURE; ISCHEMIA; ARREST; FLOW	OBJECTIVE: Hypothermia has been demonstrated to protect the brain from ischemic or traumatic injury. Previous efforts to induce cerebral hypothermia have relied on techniques requiring total body cooling that have resulted in serious cardiovascular derangements. A technique to selectively cool the brain, without systemic hypothermia, may have applications for the treatment of neurological disease. METHODS: After induction of general anesthesia in 12 baboons, the right common carotid artery and ipsilateral femoral artery were each occlusively cannulated and joined to a centrifugal pump. In a closed-circuit system, blood was continually withdrawn from the femoral artery, cooled by water bath, and infused through the common carotid artery with its external branches occluded. Pump flow was varied so that right carotid pressure approximated systemic blood pressure. In six animals, perfusate was cooled to decrease right cerebral temperature to <19 degrees C for 30 minutes. In six animals, right cerebral temperature was decreased to <25 degrees C for 3 hours. In those six animals, Xe-133 was injected into the right carotid artery before, during, and after hypothermia. Peak radioactivity and washout curves were recorded from bilateral cranial detectors. Systemic warming was accomplished by convective air and warm water blankets. Esophageal, rectal, and bilateral cerebral temperatures were continuously recorded. RESULTS: In animals cooled to <19 degrees C, right cerebral temperature decreased from 34 degrees C to 18.5 +/- 1.1 degrees C (mean +/- standard deviation), P < 0.01, in 26 +/- 13 minutes. Simultaneously, left cerebral temperature decreased to 20.7 +/- 1.6 degrees C. During 30 minutes of stable cerebral hypothermia, esophageal temperature decreased from 35.1 +/- 2.3 degrees C to 34.2 +/- 2.2 degrees C, P < 0.05. In animals cooled to <25 degrees C, right cerebral temperature decreased from 34 degrees C to 24.5 +/- 0.6 degrees C in 12.0 +/- 6.0 minutes, P < 0.01. Simultaneously, left cerebral temperature decreased to 26.3 +/- 4.8 degrees C. After 3 hours of stable cerebral hypothermia, esophageal temperature was 34.4 +/- 0.5 degrees C, P < 0.05. Right hemispheric cerebral blood flow decreased during hypothermia (26 +/- 16 ml/min/100 g) compared to values before and after hypothermia (63 +/- 29 and 51 +/- 34 ml/min/100 g, respectively; P < 0.05). Furthermore, hypothermic perfusion resulted in a proportionally increased radioactivity peak detected in the left cerebral hemisphere after right carotid artery injection of Xe-133 (0.8 +/- 0.2:1, left:right) compared to normothermia before and after hypothermia (0.3 +/- 2 and 0.3 +/- 1, respectively; P < 0.05). Normal heart rhythm, systemic arterial blood pressure, and arterial blood gas values were preserved during hypothermia in all animals. CONCLUSION: Bilateral cerebral deep or moderate hypothermia can be induced by selective perfusion of a single internal carotid artery, with minimal systemic cooling and without cardiovascular instability. This global brain hypothermia results from profoundly altered collateral cerebral circulation during artificial hypothermic perfusion. This technique may have clinical applications for neurosurgery, stroke, or traumatic brain injury.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT SURG,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT NEUROL SURG,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT RADIOL,NEW YORK,NY 10032	Schwartz, AE (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT ANESTHESIOL,BOX 46,630 W 168TH ST,NEW YORK,NY 10032, USA.		Schwartz, Arthur/ABC-3474-2020		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R0-NS27713] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027713] Funding Source: NIH RePORTER		ALBERTS MJ, 1995, ANN INTERN MED, V122, P622, DOI 10.7326/0003-4819-122-8-199504150-00013; ALTHAUS U, 1982, ANN SURG, V195, P492, DOI 10.1097/00000658-198204000-00018; ANGELAKOS ET, 1959, J PHARMACOL EXP THER, V127, P137; BIGELOW WG, 1950, ANN SURG, V132, P849, DOI 10.1097/00000658-195011000-00001; CHEN RYZ, 1980, J APPL PHYSIOL, V49, P178; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; GRIEPP EB, 1992, J CARDIAC SURG, V7, P134, DOI 10.1111/j.1540-8191.1992.tb00790.x; KIMOTO S, 1956, SURGERY, V39, P592; LEVY WJ, 1984, ANESTHESIOLOGY, V60, P291, DOI 10.1097/00000542-198404000-00004; MICHENFELDER JD, 1977, STROKE, V8, P87, DOI 10.1161/01.STR.8.1.87; Olesen J, 1971, STROKE, V2, P519, DOI 10.1161/01.STR.2.6.519; PARKINS WM, 1954, ANN SURG, V140, P284, DOI 10.1097/00000658-195409000-00004; PEARCY WC, 1959, ANESTHESIOLOGY, V20, P341, DOI 10.1097/00000542-195905000-00014; SCHWARTZ AE, 1994, ANESTHESIOLOGY, V81, P959, DOI 10.1097/00000542-199410000-00023; Sistino J J, 1993, J Extra Corpor Technol, V25, P15; SPETZLER RF, 1980, NEUROSURGERY, V7, P257, DOI 10.1227/00006123-198009000-00009; STEEN PA, 1979, STROKE, V10, P522, DOI 10.1161/01.STR.10.5.522; STEEN PA, 1980, ANESTHESIOLOGY, V52, P224, DOI 10.1097/00000542-198003000-00007; STONE JG, 1993, ANESTHESIOLOGY, V79, P36, DOI 10.1097/00000542-199307000-00008; VANDAM LD, 1959, NEW ENGL J MED, V261, P546, DOI 10.1056/NEJM195909102611106; YOUNG WL, 1990, ANESTHESIOLOGY, V73, P637, DOI 10.1097/00000542-199010000-00009; ZARINS CK, 1973, J SURG RES, V14, P97, DOI 10.1016/0022-4804(73)90015-2	22	40	40	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	SEP	1996	39	3					577	581					5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	VE304	WOS:A1996VE30400067	8875489				2021-06-18	
J	Dywan, J; Segalowitz, SJ				Dywan, J; Segalowitz, SJ			Self- and family ratings of adaptive behavior after traumatic brain injury: Psychometric scores and frontally generated ERPs	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adaptive functioning; attention; Brock Adaptive Functioning Questionnaire; contingent negative variation; frontal lobe; sequelae; traumatic brain injury	HEAD-INJURY; PREFRONTAL CORTEX; PATIENT; LOBE; MONKEYS; TESTS; LIFE; CNV	Reported hem are self- and family ratings on five scales reflecting planning, initiation, attention/memory, arousal/inhibition, and social monitoring among survivors of traumatic brain injury (TBI). The contingent negative variation, a frontally generated electrophysiological response elicited during a simple attentional task, was strongly predictive of planning and initiation as described in everyday life. Most traditional psychometric measures were relatively poor predictors of adaptive behavior ratings. Results are consistent with hypothesized dissociations in executive functions and they support the growing appreciation that self- and family reports of adaptation in everyday life are essential in evaluating the behavioral sequelae of TBI.		Dywan, J (corresponding author), BROCK UNIV, DEPT PSYCHOL, ST CATHARINES, ON L2S 3A1, CANADA.						Benton AL, 1983, MULTILINGUAL APHASIA; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BROUWER W, 1990, TENNET MONTR PQ OCT; CASSIDY JW, 1994, NEUROPSYCHIATRY TRAU; Chelune GJ, 1986, ADV CLIN NEUROPSYCHO, V3; CHELUNE GJ, 1986, NEUROPSYCHOLOGY HDB; Cohen J., 1983, APPL MULTIPLE REGRES; Cummings JL, 1985, CLIN NEUROPSYCHIATRY; Damasio A. R., 1994, DESCARTESERROR; DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4; Damasio AR, 1991, FRONTAL LOBE FUNCTIO; Delis DC, 1987, CALIFORNIA VERBAL LE; DIAMOND A, 1990, ANN NY ACAD SCI, V608, P637, DOI 10.1111/j.1749-6632.1990.tb48913.x; DIPELLEGRINO G, 1991, BRAIN, V114, P951; DYWAN J, 1993, BRAIN COGNITION, V21, P20, DOI 10.1006/brcg.1993.1002; DYWAN J, 1994, PSYCHOL AGING, V9, P568, DOI 10.1037/0882-7974.9.4.568; DYWAN J, 1995, INT NEUR SOC SEATT F; DYWAN J, 1992, MEMORY SOURCE MONITO; ENTON A, 1983, CONTRIBUTIONS NEUROP; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; FLORIAN V, 1991, NEUROPSYCHOLOGY, V5, P267, DOI DOI 10.1037/0894-4105.5.4.267; Fuster J, 1989, PREFRONTAL CORTEX; FUSTER JM, 1990, ANN NY ACAD SCI, V608, P318, DOI 10.1111/j.1749-6632.1990.tb48901.x; GRAFMAN J, 1994, HDB NEUROPSYCHOLOGY, V9; HALL RE, 1977, J NEUROSURG, V46, P638, DOI 10.3171/jns.1977.46.5.0638; HAYES RI, 1989, MILD HEAD INJURY; Heaton R. K, 1981, WISCONSIN CARD SORTI; HEATON RK, 1978, J NERV MENT DIS, V166, P408, DOI 10.1097/00005053-197806000-00004; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; KOJIMA S, 1982, BRAIN RES, V248, P43, DOI 10.1016/0006-8993(82)91145-3; LEVIN HS, 1985, J NEUROL NEUROSUR PS, V48, P556, DOI 10.1136/jnnp.48.6.556; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; NAUTA WJH, 1971, J PSYCHIAT RES, V8, P167, DOI 10.1016/0022-3956(71)90017-3; POSNER MI, 1988, CLIN NEUROPSYCHOL BR; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; RUCHKIN DS, 1986, ELECTROEN CLIN NEURO, V63, P445, DOI 10.1016/0013-4694(86)90127-6; SAVER JL, 1991, NEUROPSYCHOLOGIA, V29, P1241, DOI 10.1016/0028-3932(91)90037-9; SEGALOWITZ SJ, 1992, DEV NEUROPSYCHOL, V8, P279, DOI 10.1080/87565649209540528; SEGALOWITZ SJ, 1992, J CLIN EXP NEUROPSYC, V14, P545, DOI 10.1080/01688639208402844; SIEGEL LS, 1994, INT J BEHAV DEV, V17, P109, DOI 10.1177/016502549401700107; Silver J. M., 1991, NEUROPSY NEUROPSY BE, V4, P12; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; STAMBROOK M, 1991, J CLIN EXP NEUROPSYC, V13, P521, DOI 10.1080/01688639108401068; Stuss D.T., 1986, FRONTAL LOBES; Stuss DT., 1991, AWARENESS DEFICIT BR, P63; TECCE JJ, 1972, PSYCHOL BULL, V77, P73, DOI 10.1037/h0032177; TRANEL D, 1994, NEUROPSYCHOLOGICAL A; Wechsler D., 1974, MANUAL WECHSLER INTE; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; WILSON BA, 1995, INT NEUR SOC SEATT F; WOODS DL, 1986, NEUROLOGY, V36, P212, DOI 10.1212/WNL.36.2.212; YAMAMOTO T, 1986, JAPANESE J EEG EMG, V14, P103	64	40	40	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	1996	11	2					79	95		10.1097/00001199-199604000-00008			17	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	UD674	WOS:A1996UD67400008					2021-06-18	
J	Mattioli, F; Grassi, F; Perani, D; Cappa, SF; Miozzo, A; Fazio, F				Mattioli, F; Grassi, F; Perani, D; Cappa, SF; Miozzo, A; Fazio, F			Persistent post-traumatic retrograde amnesia: A neuropsychological and (18F)FDG PET study	CORTEX			English	Article							MAGNETIC-RESONANCE; MEMORY; HIPPOCAMPUS; IMPAIRMENT; ACTIVATION; DEFICIT; HUMANS; BRAIN	We report the case of a 48-year old woman who, after a severe closed head injury, developed a severe and persistent disruption of retrograde memory, associated with a mild impairment of learning abilities. The patient's dense amnesia spared only the childhood period and included both explicit memory (autobiographical and semantic) and procedural skills. Because of her partially spared learning ability and intact language, intensive training by family members resulted in the reacquisition and retention of many autobiographical events and of some skills she had lost after the accident. Brain CT scan and MRI were normal; a PET study with (18F)FDG revealed a significant bilateral reduction of metabolism in the hippocampus and anterior cingulate cortex, suggesting a role for these structures in memory for past events.	UNIV BRESCIA,NEUROL CLIN,I-25125 BRESCIA,ITALY; UNIV MILAN,IST SCI SAN RAFFAELE,MILAN,ITALY; UNIV MILAN,IST NEUROSCI & BIOIMMAGINI,CNR,MILAN,ITALY; UNIV MILAN,DIPARTIMENTO MED NUCL,MILAN,ITALY			Perani, Daniela/AAN-3221-2020; Cappa, Stefano/B-1874-2014	Cappa, Stefano/0000-0003-1003-3925			ALVAREZ P, 1994, P NATL ACAD SCI USA, V91, P7041, DOI 10.1073/pnas.91.15.7041; ANDREWS E, 1982, CORTEX, V18, P441, DOI 10.1016/S0010-9452(82)80041-5; BETTINARDI V, 1991, J COMPUT ASSIST TOMO, V15, P886, DOI 10.1097/00004728-199109000-00034; BORRINI G, 1989, PSYCHOL MED, V19, P215, DOI 10.1017/S0033291700011181; Costa M, 1989, ARCH PSICOLOGIA NEUR, V50, P735; DERENZI E, 1993, CORTEX, V29, P449, DOI 10.1016/S0010-9452(13)80253-5; FAZIO F, 1992, J CEREBR BLOOD F MET, V12, P353, DOI 10.1038/jcbfm.1992.52; FRISTON KJ, 1989, J CEREBR BLOOD F MET, V9, P690, DOI 10.1038/jcbfm.1989.97; GOLDBERG E, 1981, SCIENCE, V213, P1392, DOI 10.1126/science.7268442; GRASBY PM, 1993, BRAIN, V116, P1, DOI 10.1093/brain/116.1.1; KAPUR N, 1993, CORTEX, V29, P217, DOI 10.1016/S0010-9452(13)80177-3; KAPUR N, 1992, BRAIN, V115, P73, DOI 10.1093/brain/115.1.73; KAPUR N, 1988, MEMORY DISORDERS CLI; KOPELMAN MD, 1991, BRAIN, V114, P117; KOPELMAN MD, 1993, HDB NEUROPSYCHOLOGY, V8, P215; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MARIANI C, 1991, J NEUROL, V238, P395, DOI 10.1007/BF00319859; MARKOWITSCH HJ, 1993, J NEUROL NEUROSUR PS, V56, P988, DOI 10.1136/jnnp.56.9.988; MARKOWITSCH HJ, 1993, J CLIN EXP NEUROPSYC, V15, P947, DOI 10.1080/01688639308402610; MAYES AR, 1991, CURR OPIN NEUROL NEU, V4, P115; PERANI D, 1993, BRAIN, V116, P903, DOI 10.1093/brain/116.4.903; REIVICH M, 1985, J CEREBR BLOOD F MET, V5, P179, DOI 10.1038/jcbfm.1985.24; ROMANCAMPOS G, 1980, CORTEX, V16, P509, DOI 10.1016/S0010-9452(80)80053-0; ROUSSEAUX M, 1984, CORTEX, V20, P575, DOI 10.1016/S0010-9452(84)80060-X; SCHACTER DL, 1989, HDB NEUROPSYCHOLOGY, V3, P209; SCHACTER DL, 1989, FDN COGNITIVE SCI; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Shallice T., 1990, NEUROPSYCHOLOGICAL I, P11, DOI [10.1017/CBO9780511665547.003, DOI 10.1017/CBO9780511665547.003]; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; Spinnler H., 1987, ITAL J NEUROL SCI, V8, P6; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; Talairach J., 1988, COPLANAR STEREOTAXIC; Tulving, 1972, ORG MEMORY; VONCRAMON DY, 1985, BRAIN, V108, P993, DOI 10.1093/brain/108.4.993; ZOLAMORGAN S, 1986, BEHAV NEUROSCI, V100, P155, DOI 10.1037/0735-7044.100.2.155	35	40	40	0	2	MASSON DIVISIONE PERIODICI	MILAN	VIA STATUTO 2/4, 20121 MILAN, ITALY	0010-9452			CORTEX	Cortex	MAR	1996	32	1					121	129		10.1016/S0010-9452(96)80021-9			9	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	UB975	WOS:A1996UB97500008	8697743				2021-06-18	
J	Jansen, HML; vanderNaalt, J; vanZomeren, AH; Paans, AMJ; VeenmavanderDuin, L; Hew, JM; Pruim, J; Minderhoud, JM; Korf, J				Jansen, HML; vanderNaalt, J; vanZomeren, AH; Paans, AMJ; VeenmavanderDuin, L; Hew, JM; Pruim, J; Minderhoud, JM; Korf, J			Cobalt-55 positron emission tomography in traumatic brain injury: A pilot study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						traumatic brain injury; PET; cobalt-55	CLOSED-HEAD-INJURY; SPECT	Traumatic brain injury is usually assessed with the Glasgow coma scale (GCS), CT, or MRI. After such injury, the injured brain tissue is characterised by calcium mediated neuronal damage and inflammation. Positron emission tomography with the isotope cobalt-55 (Go-PET) as a calcium tracer enables imaging of affected tissue in traumatic brain injury. The aim was to determine whether additional information can be gained by Go-PET in the diagnosis of moderate traumatic brain injury and to assess any prognostic value of Co-PET. Five patients with recent moderately severe traumatic brain injury were studied. CT was performed on the day of admission, EEG within one week, and MRI and Co-PET within four weeks of injury. Clinical assessment included neurological examination, GCS, neuropsychological testing, and Glasgow outcome scale (GOS) after one year. Co-PET showed focal uptake that extended beyond the morphological abnormalities shown by MRI and CT, in brain regions that were actually diagnosed with EEG. Thus Co-PET is potentially useful for diagnostic localisation of both structural and functional abnormalities in moderate traumatic brain injury.	UNIV GRONINGEN HOSP,DEPT BIOL PSYCHIAT,9700 RB GRONINGEN,NETHERLANDS; UNIV GRONINGEN HOSP,DEPT NEUROL,9700 RB GRONINGEN,NETHERLANDS; UNIV GRONINGEN HOSP,DEPT NEUROPSYCHOL,9700 RB GRONINGEN,NETHERLANDS; UNIV GRONINGEN HOSP,NATL PET RES CTR,9700 RB GRONINGEN,NETHERLANDS; UNIV GRONINGEN HOSP,DEPT NEURORADIOL,9700 RB GRONINGEN,NETHERLANDS							APASOV S, 1993, CURR OPIN IMMUNOL, V5, P404, DOI 10.1016/0952-7915(93)90060-6; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; IKEDA Y, 1990, NEUROSURGERY, V27, P1; JACOBS A, 1994, J NUCL MED, V35, P942; JANSEN HML, 1995, J NEUROL SCI, V132, P139, DOI 10.1016/0022-510X(95)00139-S; JANSEN HML, 1994, J NUCL MED, V35, P456; JENNETT B, 1975, LANCET, V3, P480; KAO CH, 1991, NUCL MED COMMUN, V12, P1007, DOI 10.1097/00006231-199112000-00002; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; ROPER SN, 1991, J NUCL MED, V32, P1684; TEASDALE G, 1974, LANCET, V2, P81; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21	13	40	40	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	FEB	1996	60	2					221	224		10.1136/jnnp.60.2.221			4	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	TU932	WOS:A1996TU93200024	8708661	Green Published, Bronze			2021-06-18	
J	EDWARDS, DF; CHEN, YW; DIRINGER, MN				EDWARDS, DF; CHEN, YW; DIRINGER, MN			UNIFIED NEUROLOGICAL STROKE SCALE IS VALID IN ISCHEMIC AND HEMORRHAGIC STROKE	STROKE			English	Article						CEREBRAL ISCHEMIA; INTRACEREBRAL HEMORRHAGE; STROKE ASSESSMENT; STROKE OUTCOME; SUBARACHNOID HEMORRHAGE	ACUTE CEREBRAL-ISCHEMIA; WEIGHTED LEAST-SQUARES; RELIABILITY ASSESSMENT; TRIALS	Background and Purpose The growing interest in testing new therapeutic agents for acute brain injury has lead to increased use of stroke scales. The reliability and validity of these measures need to be examined more completely. We used structural equation modeling, a technique that merges the analytic procedures of factor analysis and multiple regression, to examine the reliability and construct validity of the Middle Cerebral Artery Neurological Scale and the Scandinavian Neurological Stroke Scale used together as the Unified Neurological Stroke Scale. We also analyzed the predictive validity, sensitivity, and specificity of the scales in predicting mortality and functional outcome. Methods We prospectively studied 84 consecutive patients admitted to a neurology/neurosurgery intensive care unit with intracerebral hemorrhage (n=30), subarachnoid hemorrhage (n=15), ischemic stroke (n=15), and traumatic brain injury (n=24). Patients were evaluated within 24 hours of admission and at 48-hour intervals until intensive care unit discharge. A total of 386 assessments were obtained. The Functional Independence Measure was administered by telephone 3 months after hospital discharge. Results High levels of reliability and construct validity were observed for the majority of the Unified Stroke Scale items. Facial palsy and eye movement items had the lowest reliability and validity. Both the Middle Cerebral Artery and Scandinavian Scales were significant predictors of outcome. Sensitivity and specificity varied by diagnosis. Predictive validity of functional outcome was best in groups with ischemic and hemorrhagic stroke rather than traumatic brain injury and subarachnoid hemorrhage. Conclusions The Unified Stroke Scale demonstrates reliability and construct and predictive validity, and its use is supported in ischemic and hemorrhagic stroke. Structural equation modeling is an appropriate technique for use with scales of this type.	WASHINGTON UNIV, SCH MED, GEORGE WARREN BROWN SCH SOCIAL WORK, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT NEUROL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, NEUROL NEUROSURG INTENS CARE UNIT, ST LOUIS, MO 63110 USA	EDWARDS, DF (corresponding author), WASHINGTON UNIV, SCH MED, PROGRAM OCCUPAT THERAPY, BOX 8505, ST LOUIS, MO 63110 USA.		Diringer, Michael N/C-1165-2008	Diringer, Michael N/0000-0003-2337-5537			ADAMS RJ, 1989, CLIN TRIAL METHODOLO, P54; AISH AM, 1990, QUAL QUANT, V24, P405, DOI 10.1007/BF00152013; ASPLUND K, 1985, STROKE, V16, P885; ASPLUND K, 1987, STROKE, V18, P528, DOI 10.1161/01.STR.18.2.528; Bollen K.A., 1989, STRUCTURAL EQUATIONS, P179; BOYSEN G, 1993, STROKE, V25, P1885; Browne M.W., 1993, TESTING STRUCTURAL E, P136, DOI DOI 10.1177/0049124192021002005; Candelise L, 1992, CEREBROVASC DIS, V2, P239; COTE R, 1988, CAN J NEUROL SCI, V15, P261, DOI 10.1017/S0317167100027712; COTE R, 1989, NEUROLOGY, V39, P638, DOI 10.1212/WNL.39.5.638; DEHAAN R, 1993, STROKE, V24, P1178, DOI 10.1161/01.STR.24.8.1178; ECOB R, 1987, STRUCTURAL EQUATION, P10; Edward G., 1991, RELIABILITY VALIDITY; Feinstein AR., 1987, CLINIMETRICS; GOLDSTEIN LB, 1989, ARCH NEUROL-CHICAGO, V46, P660, DOI 10.1001/archneur.1989.00520420080026; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; HANTSON L, 1994, STROKE, V25, P2215, DOI 10.1161/01.STR.25.11.2215; Joreskog K.G., 1993, LISREL 8 GUIDE PROGR; JORESKOG KG, 1990, QUAL QUANT, V24, P387, DOI 10.1007/BF00152012; Joreskog KG., 1993, SAGE FOCUS EDITIONS, V154, P294; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LENZI GL, 1991, CEREBROVAS BRAIN MET, V3, P179; LYDEN P, 1994, STROKE, V25, P2220, DOI 10.1161/01.STR.25.11.2220; LYDEN PD, 1991, STROKE, V22, P1345, DOI 10.1161/01.STR.22.11.1345; Nunnally J., 1979, PSYCHOMETRIC THEORY; ORGOGOZO JM, 1992, STROKE, V23, P1678, DOI 10.1161/01.STR.23.11.1678; ORGOGOZO JM, 1991, CEREBROVASC DIS, V1, P100, DOI 10.1159/000108904; ORGOGOZO JM, 1986, ACUTE BRAIN ISCHEMIA, P282; PORTNOY LG, 1993, F CLIN RES APPLICATI; SHINAR D, 1985, ARCH NEUROL-CHICAGO, V42, P557, DOI 10.1001/archneur.1985.04060060059010; VANGIJN J, 1992, CEREBROVASC DIS, V2, P23, DOI 10.1159/000109059	32	40	40	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	OCT	1995	26	10					1852	1858		10.1161/01.STR.26.10.1852			7	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	RX185	WOS:A1995RX18500021	7570738				2021-06-18	
J	HAGGARD, P; MIALL, RC; WADE, D; FOWLER, S; RICHARDSON, A; ANSLOW, P; STEIN, J				HAGGARD, P; MIALL, RC; WADE, D; FOWLER, S; RICHARDSON, A; ANSLOW, P; STEIN, J			DAMAGE TO CEREBELLOCORTICAL PATHWAYS AFTER CLOSED-HEAD INJURY - A BEHAVIORAL AND MAGNETIC-RESONANCE-IMAGING STUDY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						MAGNETIC RESONANCE IMAGING; CEREBELLAR ATAXIA; CEREBELLAR PEDUNCLES; VISUOMOTOR TRACKING	TRACKING	The objective was to investigate the anatomical substrate of ataxia seen after severe head injury. Five patients were recruited from present and former inpatients at Rivermead Rehabilitation Centre. Ah patients had had a closed head injury and all had cerebellar type ataxia. Four normal controls were also studied. Brain MRI, clinical examination, computer based recording, and analysis of visuomotor tracking were carried out. Focal damage was found in the superior cerebellar peduncle in all five ataxic patients. The patients' tracking movements showed profound tremor, and unusual reliance on visual feedback. Ataxia seen after severe head injury can arise from damage to the superior cerebellar peduncle, which may interfere with the cerebellocortical circuits involved in coordinated movement.	UNIV OXFORD,PHYSIOL LAB,OXFORD OX1 3PT,ENGLAND; RIVERMEAD REHABIL CTR,OXFORD OX1 4XD,ENGLAND; RADCLIFFE INFIRM,DEPT NEURORADIOL,OXFORD OX2 6HE,ENGLAND			Miall, R. Chris/B-7449-2013; Haggard, Patrick/A-5081-2010	Miall, R. Chris/0000-0003-3002-1251; Wade, Derick/0000-0002-1188-8442; Haggard, Patrick/0000-0001-7798-793X; Stein, John/0000-0001-5843-8986	Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Annett M., 1992, HDB NEUROPSYCHOLOGIC; BEPPU H, 1984, BRAIN, V107, P787, DOI 10.1093/brain/107.3.787; CHESTER CS, 1987, ANN NEUROL, V22, P79; Collen F M, 1991, Int Disabil Stud, V13, P50; Collen F M, 1990, Int Disabil Stud, V12, P6; KATZMAN R, 1983, AM J PSYCHIAT, V140, P734; KOTSORIS HO, 1987, J NEURO REHAB, V2, P73; Krzanowski WJ., 1988, PRINCIPLES MULTIVARI; MIALL RC, 1993, J MOTOR BEHAV, V25, P53, DOI 10.1080/00222895.1993.9941639; MILLER E, BR J CLIN PSYCHOL, V23, P53; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; ORMEROD IEC, 1994, J NEUROL NEUROSUR PS, V57, P51, DOI 10.1136/jnnp.57.1.51; RICHARDSON RR, 1989, STEREOT FUNCT NEUROS, V53, P105, DOI 10.1159/000099525	15	40	40	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	APR	1995	58	4					433	438		10.1136/jnnp.58.4.433			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	QT682	WOS:A1995QT68200008	7738549	Green Published, Bronze			2021-06-18	
J	ARMSTEAD, WM; KURTH, CD				ARMSTEAD, WM; KURTH, CD			THE ROLE OF OPIOIDS IN NEWBORN PIG-FLUID PERCUSSION BRAIN INJURY	BRAIN RESEARCH			English	Article						CEREBRAL CIRCULATION; FLUID PERCUSSION BRAIN INJURY; OPIOID	CEREBRAL BLOOD-FLOW; SPINAL-CORD INJURY; ENDOGENOUS OPIOIDS; HEAD-INJURY; CEREBROSPINAL-FLUID; CATS; CIRCULATION; METABOLISM; RESPONSES; NALOXONE	The present study was designed to characterize the relationship between cerebral opioid concentration, cerebral hemodynamics, and cerebral oxygenation following percussion brain injury in neonatal pigs. Previous research found that opioids represent a significant vasoactive component in the regulation of the neonatal piglet cerebral circulation. Anesthetized newborn (1-5 days old) pigs equipped with a closed cranial window were connected to a percussion device consisting of a saline-filled cylindrical reservoir with a metal pendulum. Brain injury of moderate severity (1.9-2.3 atm.) was produced by allowing the pendulum to strike a piston on the cylinder. Fluid percussion brain injury decreased pial arteriolar diameter (132 +/- 5 to 110 +/- 5 mu m within 10 min). Cerebral blood flow also fell within 10 min of injury and continued to fall progressively for 3 h, resulting in a 46 +/- 4% decrease. Within 30 s of brain injury, there was a transient increase in cerebral hemoglobin-O-2 saturation that was reversed to a progressive profound decrease in cerebral hemoglobin-O-2 saturation for the next 3 h, as measured by near infrared spectroscopy. CSF opioid concentrations were increased 10 min after brain injury; dynorphin showed the largest proportional increase (5.8 +/- 0.9 fold). The CSF concentration for other opioids continued to increase over 180 min while the dynorphin concentration progressively decreased with time. In naloxone (1 mg/kg i.v.) pretreated piglets, the brain injury induced decrease in arteriolar diameter was attenuated (129 +/- 5 to 121 +/- 5 mu m within 10 min). Similarly, the decrease in regional cerebral blood flow and cerebral hemoglobin-O-2 saturation observed following brain injury were also blunted by naloxone. These data show that CSF opioid concentrations increase following brain injury and that the time course and relative increase in CSF concentration vary from opioid to opioid. These data also indicate that in the immature animal, opioids contribute to arteriolar constriction, decreased cerebral blood flow, decreased cerebral oxygenation, and could play a role in causing ischemia after brain injury.	UNIV PENN,DEPT ANESTHESIA,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PHYSIOL,PHILADELPHIA,PA 19104	ARMSTEAD, WM (corresponding author), CHILDRENS HOSP PHILADELPHIA,DEPT ANESTHESIA,34TH & CIV CTR BLVD,PHILADELPHIA,PA 19104, USA.						ARMSTEAD WM, 1990, J PHARMACOL EXP THER, V255, P1083; ARMSTEAD WM, 1991, J CEREBR BLOOD F MET, V11, P380, DOI 10.1038/jcbfm.1991.78; ARMSTEAD WM, 1991, CIRC RES, V68, P922, DOI 10.1161/01.RES.68.4.922; BASKIN DS, 1985, NEUROPEPTIDES, V5, P307, DOI 10.1016/0143-4179(85)90014-9; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; COLOMBANI PM, 1985, J PEDIATR SURG, V20, P8, DOI 10.1016/S0022-3468(85)80382-1; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; FADEN AI, 1988, J PHARMACOL EXP THER, V245, P742; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; GURDJIAN ES, 1954, NEUROLOGY, V4, P674, DOI 10.1212/WNL.4.9.674; HALL ED, 1987, BRAIN RES, V435, P174, DOI 10.1016/0006-8993(87)91599-X; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HAYES RL, 1990, J NEUROSURG, V72, P252, DOI 10.3171/jns.1990.72.2.0252; HOLADAY JW, 1980, BRAIN RES, V189, P295, DOI 10.1016/0006-8993(80)90032-3; KURTH CD, 1993, J CLIN MONITOR, V9, P163, DOI 10.1007/BF01617023; LAPTOOK AR, 1983, BRAIN RES, V276, P51, DOI 10.1016/0006-8993(83)90547-4; LEFFLER CW, 1985, PEDIATR RES, V19, P1160, DOI 10.1203/00006450-198511000-00009; MCINTOSH T K, 1988, Society for Neuroscience Abstracts, V14, P1152; MCINTOSH TK, 1992, J NEUROTRAUM, V9, pS201; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P373, DOI 10.1089/neu.1993.10.373; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1988, PHARM APPROACH TREAT, P89; MCINTOSH TK, 1991, J CEREB BLOOD FLOW M, V11, pS734; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PEROUTKA SJ, 1980, SCIENCE, V208, P610, DOI 10.1126/science.6102801; PERRY DC, 1990, NEUR ABSTR, V16, P242; SHIBATA M, 1993, J NEUROSURG, V79, P696, DOI 10.3171/jns.1993.79.5.0696; THURESONKLEIN A, 1989, BLOOD VESSELS, V26, P177; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; VINK R, 1990, J NEUROSCI, V10, P3524; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; ZIMMERMAN RS, 1990, NEUROSURGERY, V26, P764, DOI 10.1227/00006123-199005000-00005	36	40	44	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	OCT 10	1994	660	1					19	26		10.1016/0006-8993(94)90834-6			8	Neurosciences	Neurosciences & Neurology	PJ969	WOS:A1994PJ96900003	7827998				2021-06-18	
J	HARRICK, L; KREFTING, L; JOHNSTON, J; CARLSON, P; MINNES, P				HARRICK, L; KREFTING, L; JOHNSTON, J; CARLSON, P; MINNES, P			STABILITY OF FUNCTIONAL OUTCOMES FOLLOWING TRANSITIONAL LIVING PROGRAM PARTICIPATION - 3-YEAR FOLLOW-UP	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY	The functional status and perceived problems of 21 persons with severe brain injury were reported at admission, and at 1 and 3 years post-discharge from a community-based post-acute rehabilitation programme. Functional status was measured by participation in productive activity, financial support, place of residence and level of supervision required. Improvements observed at 1-year follow-up remained stable or had improved at 3-year follow-up. Loneliness and depression, while not reported at admission, increased over time to become the two problems reported most frequently at 3-year follow-up.	QUEENS UNIV,DEPT PSYCHOL,KINGSTON K7L 3N6,ONTARIO,CANADA; KINGSTON GEN HOSP,KINGSTON K7L 2V7,ONTARIO,CANADA							BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Burke W H, 1988, Brain Inj, V2, P313, DOI 10.3109/02699058809150902; CARLSON P, 1991, ONTARIO PSYCHOL, V23, P12; CERVELLI L, 1990, REHABILITATION ADULT, P463; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; Evans R W, 1991, J Insur Med, V23, P192; Evans RW, 1992, J HEAD TRAUMA REHAB, V7, P24; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JOHNSTON M V, 1991, Brain Injury, V5, P141, DOI 10.3109/02699059109008085; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; MALEC JF, 1991, ARCH PHYS MED REHAB, V72, P138; MILLS V M, 1992, Brain Injury, V6, P219, DOI 10.3109/02699059209029663; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Vogenthaler D R, 1989, Brain Inj, V3, P355, DOI 10.3109/02699058909004560; WILKINSON L, 1989, SYSTAT SYSTEM STATIS	17	40	40	0	5	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1994	8	5					439	447		10.3109/02699059409150995			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	NW122	WOS:A1994NW12200005	7951206				2021-06-18	
J	LYETH, BG; JIANG, JY; DELAHUNTY, TM; PHILLIPS, LL; HAMM, RJ				LYETH, BG; JIANG, JY; DELAHUNTY, TM; PHILLIPS, LL; HAMM, RJ			MUSCARINIC CHOLINERGIC RECEPTOR-BINDING IN RAT-BRAIN FOLLOWING TRAUMATIC BRAIN INJURY	BRAIN RESEARCH			English	Article						[H-3]QNB BINDING; HOMOGENATE; HIPPOCAMPUS; NEOCORTEX; BRAIN STEM; CEREBELLUM; TRAUMATIC BRAIN INJURY; FLUID PERCUSSION	DESENSITIZATION; SUPPRESSION; DEFICITS; BEHAVIOR; MOTOR	Recent evidence suggests that excessive activation of muscarinic cholinergic receptors (mAChRs) contributes significantly to the pathophysiological consequences of traumatic brain injury (TBI). To examine possible alterations in mAChRs after TBI, the affinity (K(d)) and maximum number of binding sites (B(max)) of mAChRs in hippocampus, neocortex, brain stem and cerebellum were determined by [H-3]QNB binding. Three groups of rats were examined: 1 h post-TBI (n = 21), 24 h post-TBI (n = 21) and sham-injured rats (n = 21). K(d) values were significantly higher in hippocampus and brain stem at 1 but not 24 h post-TBI compared with sham-injured controls (P < 0.05). K(d) values did not significantly differ in neocortex and cerebellum at 1 or 24 h post-TBI compared with sham-injured controls. B(max) values did not significantly differ in any brain areas at 1 or 24 h post-TBI compared with sham-injured controls. These results show that TBI significantly decreases the affinity of mAChRs in hippocampus and brain stem at an early stage post-TBI, which may contribute to desensitization of mAChRs after TBI. The findings of no change in B(max) values are consistent with a transient elevation in ACh concentrations after TBI.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHOL,RICHMOND,VA 23298	LYETH, BG (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT SURG,BOX 693,MCV STN,RICHMOND,VA 23298, USA.			Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029995, P01NS012587, P50NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587, NS 29995] Funding Source: Medline		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOU C-L, 1991, Society for Neuroscience Abstracts, V17, P722; Deangelis M. M., 1992, Society for Neuroscience Abstracts, V18, P172; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELFAKAHANY EE, 1990, MEMBRANE BIOCHEM, V9, P9, DOI 10.3109/09687689009026820; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HABER B, 1980, NEUROBIOLOGY CEREBRO, P345; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HARDEN TK, 1985, J BIOL CHEM, V260, P3060; Hayes R L, 1986, Cent Nerv Syst Trauma, V3, P163; HAYES RL, 1988, J NEUROTRAUM, V5, P287; HAYES RL, 1984, SCIENCE, V20, P301; HEPPNER F, 1958, Monatsschr Unfallheilkd Versicherungsmed, V61, P257; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; INOUE M, 1986, NATURE, V324, P156, DOI 10.1038/324156a0; JENKINS LW, 1988, J NEUROTRAUM, V5, P303; KATAYAMA Y, 1984, BRAIN RES, V296, P241, DOI 10.1016/0006-8993(84)90062-3; KWARTA MM, 1987, J BIOL CHEM, V262, P16314; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; LYETH BG, 1992, J NEUROTRAUM, V9, pS463; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MEYER MR, 1982, MOL PHARMACOL, V21, P280; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OLENIAK L D, 1988, Society for Neuroscience Abstracts, V14, P1151; PERRY DC, 1992, MOL CHEM NEUROPATHOL, V16, P95, DOI 10.1007/BF03159963; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; SCHIMERLIK MI, 1989, ANNU REV PHYSIOL, V51, P217, DOI 10.1146/annurev.ph.51.030189.001245; SIMAN RG, 1979, P NATL ACAD SCI USA, V76, P4141, DOI 10.1073/pnas.76.8.4141; TAYLOR JE, 1979, LIFE SCI, V25, P2181, DOI 10.1016/0024-3205(79)90090-0; THOMPSON AK, 1990, J PHARMACOL EXP THER, V252, P744; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; WARD A, 1950, J NEUROSURG, V7, P398, DOI 10.3171/jns.1950.7.5.0398; YAMAMURA HI, 1974, P NATL ACAD SCI USA, V71, P1725, DOI 10.1073/pnas.71.5.1725	45	40	42	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAR 21	1994	640	1-2					240	245		10.1016/0006-8993(94)91879-1			6	Neurosciences	Neurosciences & Neurology	NB938	WOS:A1994NB93800030	8004451				2021-06-18	
J	MUTTAQIN, Z; UOZUMI, T; KUWABARA, S; ARITA, K; KURISU, K; OHBA, S; KOHNO, H; OGASAWARA, H; OHTANI, M; MIKAMI, T				MUTTAQIN, Z; UOZUMI, T; KUWABARA, S; ARITA, K; KURISU, K; OHBA, S; KOHNO, H; OGASAWARA, H; OHTANI, M; MIKAMI, T			HYPEREMIA PRIOR TO ACUTE CEREBRAL SWELLING IN SEVERE HEAD-INJURIES - THE ROLE OF TRANSCRANIAL DOPPLER MONITORING	ACTA NEUROCHIRURGICA			English	Article						CEREBRAL HYPEREMIA; TRANSCRANIAL DOPPLER; SEVERE HEAD INJURY; CEREBRAL EDEMA	BLOOD-FLOW; INTRACRANIAL-PRESSURE; VELOCITY-MEASUREMENTS; COMATOSE PATIENTS; BRAIN EDEMA; ULTRASOUND; METABOLISM; CHILDREN; ULTRASONOGRAPHY; VASOSPASM	Acute cerebrovascular congestion after a closed head injury is significantly related to intracranial hypertension. As an indirect method of cerebral blood flow measurement, transcranial doppler sonography (TCD) provides a rapid and noninvasive assessment of cerebral haemodynamics, including hyperaemic conditions. TCD examinations was serially performed in 35 patients with severe head injury with intact cerebral circulation; i.e. the mean flow velocity (MFV) patterns of the middle cerebral artery (MCA) did not show signs of cerebral circulatory arrest such as systolic spike, to and fro, or no flow. The results showed that the MFV of the MCAs and ipsilateral extracranial internal carotid arteries (ICAs) in 9 of these patients increased sharply and pulsatility index (PI) decreased during 48-96 hours after the injury. This was soon followed by patterns of high intracranial resistance, consistent with elevated intracranial pressure (ICP) in monitored patients and acute brain swelling on repeated computed tomographic (CT) scans. The correlation between increased MFVs, decreased PIs, and cerebral haemodynamic changes leading to acute brain swelling is discussed. The number of patients who ended with severe disability, vegetative state, or death was 66% in this group of 9 patients, compared to only 34% for the 35 patients overall with severe head injury. Though the morbidity and mortality rates largely depend on the primary injury, the presence of acute cerebral swelling aggravate the grave course in these patients. And the ability of TCD to monitor the hyperaemic state prior to oedema should lead us to adjust the therapy in order to minimize the secondary insult related to intracranial hypertension.	HIROSHIMA UNIV,SCH MED,DEPT NEUROSURG,HIROSHIMA 730,JAPAN; HIROSHIMA UNIV,SCH MED,DIV EMERGENCY MED & INTENS CARE MED,HIROSHIMA 730,JAPAN	MUTTAQIN, Z (corresponding author), DIPONEGORO UNIV,SCH MED,DEPT NEUROSURG,JL DR SUTOMO 18,SEMARANG,INDONESIA.						AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; AASLID R, 1976, TRANSCRANIAL DOPPLER; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1979, CHILD BRAIN, V5, P174; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; GOMEZ CR, 1991, SURG NEUROL, V35, P30, DOI 10.1016/0090-3019(91)90198-I; GOSLING RG, 1974, P ROY SOC MED, V67, P447, DOI 10.1177/00359157740676P113; HARDERS A, 1986, NEUROSURGICAL APPLIC; HASSLER W, 1988, J NEUROSURG, V68, P745; HENNERICI M, 1987, SURG NEUROL, V27, P439, DOI 10.1016/0090-3019(87)90251-5; KONTOS HA, 1989, STROKE, V20, P1; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; MCHEDLISHVILI G, 1988, NEUROSURG REV, V11, P7, DOI 10.1007/BF01795688; MCHEDLISHVILI G, 1986, ARTERIAL BEHAVIOUR B; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; ROZSA L, 1989, NEUROSURG REV, V12, P133, DOI 10.1007/BF01741486; SHIGEMORI M, 1990, ACTA NEUROCHIR, V107, P5, DOI 10.1007/BF01402605; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; YOSHINO E, 1985, J NEUROSURG, V63, P830, DOI 10.3171/jns.1985.63.6.0830	22	40	41	0	1	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1993	123	1-2					76	81		10.1007/BF01476289			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	LR013	WOS:A1993LR01300012	8105640				2021-06-18	
J	GLANCY, KE; GLANCY, CJ; LUCKE, JF; MAHURIN, K; RHODES, M; TINKOFF, GH				GLANCY, KE; GLANCY, CJ; LUCKE, JF; MAHURIN, K; RHODES, M; TINKOFF, GH			A STUDY OF RECOVERY IN TRAUMA PATIENTS	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							CLOSED HEAD-INJURY; SEVERITY SCORE; SOCIAL SUPPORT; BRAIN INJURY; DEATH SCORE; SCALE; CARE; PROBABILITY; DISABILITY; SYSTEMS	Although the majority of trauma patients are discharged home rather than to a rehabilitation facility, the timeliness of their return to function (RTF) has received little study. The present prospective study attempted to identify those factors that would predict delayed RTF. The study group consisted of patients admitted to a level I trauma center for at least 24 hours, who were of working age (18-64 years), who passed a cognitive screening examination, and who were discharged home. Demographic data and psychological profiles were collected on all participants. Patients were followed by telephone at approximately 1 1/2, 3, and 6 months after discharge. Five hundred seventy patients were entered into the study; complete follow-up data were available for 441. Statistical methods were modeled after survival analysis using a proportional hazards multiple regression to identify variables prognostic of RTF time. This type analysis is independent of time, providing a "risk" of RTF at any point in time after the injury. It also allowed the calculation a relative hazards ratio (RHR), which quantifies the impact of a prognostic variable on RTF time. Injury Severity Score (ISS) and age were found to be associated with RTF (p < 0.0001 for each). After correcting for ISS and age, five additional factors were found to be associated with RTF. Higher educational level and living in a non-family household were associated with faster RTF. Less than 100% income replacement by disability income, pre-injury hostility, and litigation related to the injury were associated with slower RTF. There were a number of other demographic, work-related, and psychosocial factors that were not related with RTF. We conclude that we have identified five factors in addition to ISS and age which may affect RTF. These data may suggest interventions directed at enhancing RTF.								BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; BROOKS DN, 1984, J CLIN NEUROPSYCHOL, V6, P71, DOI 10.1080/01688638408401198; BUZZARD F, 1928, P R MED SOC, V21, P353; CALES RH, 1985, ANN EMERG MED, V14, P853, DOI 10.1016/S0196-0644(85)80633-8; CALES RH, 1985, JAMA-J AM MED ASSOC, V254, P1059, DOI 10.1001/jama.254.8.1059; CIVIL ID, 1988, J TRAUMA, V28, P87, DOI 10.1097/00005373-198801000-00012; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; COPES WS, 1988, J TRAUMA, V28, P78, DOI 10.1097/00005373-198801000-00011; COX DR, 1985, ANAL SURVIVAL DATA; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; DRUDGE OW, 1984, J CLIN PSYCHOL, V40, P259, DOI 10.1002/1097-4679(198401)40:1<259::AID-JCLP2270400149>3.0.CO;2-C; EPPERSON-SEBOUR M M, 1985, MMJ (Maryland Medical Journal), V34, P1187; FOEGE WH, 1985, INJURY AM CONTINUING; Gennarelli TA, 1985, ABBREVIATED INJURY S; GENSEMER IB, 1988, J TRAUMA, V28, P44, DOI 10.1097/00005373-198801000-00006; HOPKINS A, 1985, BMDP STATISTICAL SOF, P576; JACOBS JW, 1977, ANN INTERN MED, V86, P40, DOI 10.7326/0003-4819-86-1-40; KELLY MP, 1986, J CLIN PSYCHOL, V42, P318; KELLY R, 1975, Forensic Science, V6, P17, DOI 10.1016/0300-9432(75)90219-8; LEE ET, 1985, STATISTICAL METHODS; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MACKENZIE EJ, 1990, J TRAUMA, V30, P1096, DOI 10.1097/00005373-199009000-00005; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MACKENZIE EJ, 1986, MED CARE, V24, P377, DOI 10.1097/00005650-198605000-00001; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P1084, DOI 10.1136/jnnp.46.12.1084; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; MORRIS JA, 1991, J TRAUMA, V31, P827, DOI 10.1097/00005373-199106000-00014; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; RHODES M, 1988, J TRAUMA, V28, P931, DOI 10.1097/00005373-198807000-00005; SCHERZER BP, 1986, ARCH PHYS MED REHAB, V67, P366; SCHULZ R, 1985, J PERS SOC PSYCHOL, V48, P1162, DOI 10.1037/0022-3514.48.5.1162; SOMERS RL, 1983, ACCIDENT ANAL PREV, V15, P259, DOI 10.1016/0001-4575(83)90050-7; SOMERS RL, 1983, ACCIDENT ANAL PREV, V15, P247, DOI 10.1016/0001-4575(83)90049-0; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; WILLIAMS JM, 1984, J NEUROSURG, V61, P581, DOI 10.3171/jns.1984.61.3.0581; ZIMET GD, 1988, J PERS ASSESS, V52, P30, DOI 10.1207/s15327752jpa5201_2; 1990, STATA REFERENCE MANU	39	40	42	0	5	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	1992	33	4					602	609		10.1097/00005373-199210000-00017			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	JY184	WOS:A1992JY18400018	1433408				2021-06-18	
J	BOUCHER, BA; KUHL, DA; FABIAN, TC; ROBERTSON, JT				BOUCHER, BA; KUHL, DA; FABIAN, TC; ROBERTSON, JT			EFFECT OF NEUROTRAUMA ON HEPATIC DRUG CLEARANCE	CLINICAL PHARMACOLOGY & THERAPEUTICS			English	Article							SEVERE HEAD-INJURY; INDOCYANINE GREEN; METABOLIC RESPONSE; TRAUMA PATIENTS; PLASMA-LEVELS; PHARMACOKINETICS; ANTIPYRINE; DISPOSITION; INDUCTION; LORAZEPAM	Lorazepam, antipyrine, and indocyanine green were administered to 10 patients with severe head injuries as marker substrates of hepatic glucuronidation, oxidation, and hepatic blood flow, respectively. Pharmacokinetic parameter estimates were determined at baseline (20 to 80 hours after injury) and up to three additional times thereafter (study days 4, 7, and 14). Antipyrine clearance was increased significantly from baseline (0.50 +/- 0.31 ml/min/kg) on study days 4, 7, and 14 (p < 0.0001). Increases in antipyrine clearance from baseline to the last study day were observed in all study patients ranging from 14% to 207%. A significant increase was also observed in lorazepam clearance on study day 14 relative to baseline (1.39 +/- 0.56 ml/min/kg) (p < 0.005). Increases in lorazepam clearance occurred in seven of nine patients over time ranging from 9% to 13O%. The unbound fraction of lorazepam did not change significantly over the study period. Likewise, no significant change was observed in the clearance of indocyanine green over time. Antipyrine clearance and alpha-1-acid glycoprotein (r = 0.41), and lorazepam clearance and C-reactive protein (r = -0.38) were significantly correlated (p < 0.05). Similarly, antipyrine and lorazepam clearances were significantly correlated with injury severity based on the Acute Physiologic and Chronic Health Evaluation (APACHE II) score (r = -0.43 and r = -O.37, respectively). These findings suggest that hepatic oxidative and conjugative metabolism increase significantly over time in patients after acute head injury. An awareness of the potential for pharmacokinetic alterations in similarly metabolized drugs used for patients with severe head injuries is recommended.	UNIV TENNESSEE CTR HLTH SCI,DEPT SURG,MEMPHIS,TN 38163; UNIV TENNESSEE CTR HLTH SCI,DEPT NEUROSURG,MEMPHIS,TN 38163; REG MED CTR,MEMPHIS,TN	BOUCHER, BA (corresponding author), UNIV TENNESSEE CTR HLTH SCI,DEPT CLIN PHARM,26 S DUNLAP,ROOM 202,MEMPHIS,TN 38163, USA.						ANDREASEN PB, 1974, CLIN PHARMACOL THER, V16, P1059; BACHMANN KA, IN PRESS XENOBIOTICA; BAYLIFF CD, 1985, CLIN PHARMACOL THER, V38, P457, DOI 10.1038/clpt.1985.204; BOUCHER BA, 1988, CLIN PHARMACOL THER, V44, P675, DOI 10.1038/clpt.1988.211; BURCZYNSKI FJ, 1987, AM J PHYSIOL, V252, pH953; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; CROM WR, 1987, CLIN PHARMACOL THER, V41, P645, DOI 10.1038/clpt.1987.90; DANHOF M, 1982, BRIT J CLIN PHARMACO, V13, P379, DOI 10.1111/j.1365-2125.1982.tb01389.x; DINARELLO CA, 1988, FASEB J, V2, P108; Gibaldi M., 1982, PHARMACOKINETICS, P45; GOTTLIEB ME, 1984, ARCH SURG-CHICAGO, V119, P264; HEINEMEYER G, 1986, THER DRUG MONIT, V8, P145, DOI 10.1097/00007691-198606000-00003; HERMAN RJ, 1989, CLIN PHARMACOL THER, V46, P18, DOI 10.1038/clpt.1989.101; HUANG J, 1983, J PHARM SCI, V72, P1368, DOI 10.1002/jps.2600721137; KAUFMAN HH, 1987, NEUROSURGERY, V20, P254, DOI 10.1227/00006123-198702000-00010; KHOLOUSSY AM, 1984, CRIT CARE MED, V12, P115, DOI 10.1097/00003246-198402000-00007; KIRKWOOD CF, 1986, J TRAUMA, V26, P1090, DOI 10.1097/00005373-198612000-00005; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KRAUS JW, 1978, CLIN PHARMACOL THER, V24, P411; LOFT S, 1987, EUR J CLIN PHARMACOL, V32, P35, DOI 10.1007/BF00609955; MARTYN J, 1987, CLIN PHARMACOL THER, V43, P250; MARTYN JAJ, 1983, ANESTH ANALG, V62, P293; OTT L, 1987, JPEN-PARENTER ENTER, V11, P488, DOI 10.1177/0148607187011005488; PECK CC, 1984, J PHARMACOKINET BIOP, V12, P545, DOI 10.1007/BF01060132; PERKINS MW, 1989, DICP ANN PHARMAC, V23, P316, DOI 10.1177/106002808902300408; POLLACK DS, 1979, SURG GYNECOL OBSTET, V149, P852; POWELL JR, 1986, APPLIED PHARMACOKINE, P139; REISTER EF, 1980, CLIN PHARMACOL THER, V28, P384; RELLING MV, 1987, CLIN PHARMACOL THER, V41, P651, DOI 10.1038/clpt.1987.91; SKAK C, 1987, LIVER, V7, P155; VESELL ES, 1979, CLIN PHARMACOL THER, V26, P287; WERMELING DP, 1987, DRUG INTEL CLIN PHAR, V21, P459, DOI 10.1177/106002808702100517; WILKINSON GR, 1975, CLIN PHARMACOL THER, V18, P377; YOUNG B, 1985, NEUROSURGERY, V17, P784, DOI 10.1227/00006123-198511000-00010	34	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0009-9236			CLIN PHARMACOL THER	Clin. Pharmacol. Ther.	NOV	1991	50	5	1				487	497		10.1038/clpt.1991.173			11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	GT114	WOS:A1991GT11400002	1934861				2021-06-18	
J	RUDY, EB; TURNER, BS; BAUN, M; STONE, KS; BRUCIA, J				RUDY, EB; TURNER, BS; BAUN, M; STONE, KS; BRUCIA, J			ENDOTRACHEAL SUCTIONING IN ADULTS WITH HEAD-INJURY	HEART & LUNG			English	Article								The purpose of this study was to determine the method of endotracheal suctioning (ETS) that resulted in the least compromise to the cerebrovascular status of adult patients with severe head injuries. A two-group (two vs three ETS), two-protocol (100% tidal volume [VT] vs 135% VT) design was used. The dependent variables were mean intracranial pressure (MICP), mean arterial pressure (MAP), cerebral perfusion pressure (CPP), heart rate (HR), and oxygen saturation (SaO2). By random assignment, 14 subjects were in the two-ETS group and 16 subjects were in the three-ETS group. Intracranial pressure response to ETS in these patients with head injury can be characterized as falling into three patterns: (1) a rise in baseline beginning with ETS and continuing throughout the ETS sequences; (2) intracranial pressure spiking during the suctioning component of the protocol; (3) a combination of both a rising baseline and spiking. There was a significant (p less-than-or-equal-to 0.001) increase from baseline for both two- and three-ETS groups with both hyperoxygenation protocols (100% VT VS 135% VT) for MICP, MAP, HR, and CPP. No significant difference was found for Sao2 for either of the protocols regardless of number of suction passes. No significant differences were found between two- and three-ETS groups for any of the dependent variables. All groups, however, regardless of number of suction passes, demonstrated a cumulative increase in MICP. MAP, and CPP with each consecutive suction sequence. We conclude that patients with severe closed head injury (Glasgow Coma Scale score less-than-or-equal-to 8), particularly those who respond with a spiking intracranial pressure Pattern, are at risk for periods of cerebral hypertension during an ETS procedure. In some patients the response to ETS is cumulative, making multiple suction passes particularly dangerous. Preoxygenation of patients with 100% oxygen is not adequate to prevent extreme rises in MICP. It is recommended that the number of suction passes be limited to two per procedure, combined with an adequate preoxygenation routine.		RUDY, EB (corresponding author), CASE WESTERN RESERVE UNIV,SCH NURSING,1900 EUCLID AVE,CLEVELAND,OH 44106, USA.				NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR001525] Funding Source: NIH RePORTER; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01 NR01525] Funding Source: Medline			0	40	41	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0147-9563			HEART LUNG	Heart Lung	NOV	1991	20	6					667	674					8	Cardiac & Cardiovascular Systems; Nursing; Respiratory System	Cardiovascular System & Cardiology; Nursing; Respiratory System	GU138	WOS:A1991GU13800010	1960071				2021-06-18	
J	Goldman, H; Hodgson, V; Morehead, M; Hazlett, J; Murphy, S				Goldman, Harold; Hodgson, Voigt; Morehead, Marilyn; Hazlett, James; Murphy, Sharon			Cerebrovascular Changes in a Rat Model of Moderate Closed-Head Injury	JOURNAL OF NEUROTRAUMA			English	Article								We have developed and tested a rat (Wistar) model of moderate concussion. Concussion is produced by controlled and repeatable mechanical fixed, closed-head injury. Moderate concussion in this model is characterized by 4 to 10 minutes of unconsciousness, absence of skull fractures or brain contusions, and few, if any, acute neurologic symptoms. By 2 hours postinjury, the subsequent trauma is further characterized by regional and global increases in cerebrovascular permeability and decreases in cerebral blood flow. Such changes are accompanied by brain swelling and two phases of elevated intracranial pressure; one lasting about 5 hours with a peak of aboui 10 mmHg, the other lasting more than 3 days postinjury with a peak of about 30 mmHg. Regional neurohistologic damage detected between 3 and 4 days postinjury correlates for the most part with earlier changes in regional permeability and blood flow. Significant morphologic changes which are characterized by patchy neuronal degeneration can be found in numerous forebrain locations, particularly in the frontal (coup) and entorhinal (contre coup) cortices. These observations have important parallels in human head trauma and suggest that this reliable physiological model may be a useful, relatively simple and inexpensive tool for investigating the mechanisms and therapeutics of head trauma.	[Goldman, Harold; Morehead, Marilyn; Murphy, Sharon] Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; [Hodgson, Voigt] Wayne State Univ, Sch Med, Dept Neurosurg, Detroit, MI 48201 USA; [Hazlett, James] Wayne State Univ, Sch Med, Dept Anat, Detroit, MI 48201 USA	Goldman, H (corresponding author), Wayne State Univ, Sch Med, Dept Pharmacol, 540 E Canfield Ave, Detroit, MI 48201 USA.				NIDRR [G0087C2022]; Southeastern Michigan Traumatic Brain Injury System; CDCCentre National de la Recherche Scientifique (CNRS)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [CCR49-502351]; Wayne State University Injury Prevention Research Cente; Michigan Automobile Association	This work was supported by NIDRR Grant G0087C2022 to the Southeastern Michigan Traumatic Brain Injury System, by CDC Grant CCR49-502351 to the Wayne State University Injury Prevention Research Center, and a grant from the Michigan Automobile Association.	BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; BEAN JW, 1969, J APPL PHYSIOL, V37, P807; BECKMAN DL, 1970, J APPL PHYSIOL, V29, P631; BLASBERG RG, 1983, J CEREBR BLOOD F MET, V3, P215, DOI 10.1038/jcbfm.1983.29; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1988, J NEUROTRAUM, V5, P99; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; GENNARELLI TA, 1982, BRAIN RES, V211, P564; GOLDMAN H, 1973, AM J PHYSIOL, V224, P122; GURDJIAN ES, 1954, NEUROLOGY, V4, P882; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HANSEN AJ, 1985, PHYSIOL REV, V65, P101; Hayes R L, 1987, Brain Inj, V1, P93, DOI 10.3109/02699058709034449; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lindgren S., 1965, BIOPHYSIK, V2, P20; MCHEDLISHVILI G, 1987, STROKE MICROCIRCULAT, P63; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; OHNO K, 1979, SURG NEUROL, V12, P323; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; Paxinos G., 1982, RAT BRAIN STEREOTAXI; RAPOPORT SI, 1980, AM J PHYSIOL, V238, pR421; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59; SAPIRSTEIN LA, 1958, AM J PHYSIOL, V193, P161; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHAW NA, 1985, PHYSIOL BEHAV, V35, P637, DOI 10.1016/0031-9384(85)90154-4; SIESJO BK, 1990, NEWS PHYSIOL SCI, V5, P120; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	31	40	41	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SUM	1991	8	2					129	144		10.1089/neu.1991.8.129			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	V07US	WOS:000207286700004	1870136				2021-06-18	
J	JOHANSSON, E; RONNKVIST, M; FUGLMEYER, AR				JOHANSSON, E; RONNKVIST, M; FUGLMEYER, AR			TRAUMATIC BRAIN INJURY IN NORTHERN SWEDEN - INCIDENCE AND PREVALENCE OF LONG-STANDING IMPAIRMENTS AND DISABILITIES	SCANDINAVIAN JOURNAL OF REHABILITATION MEDICINE			English	Article						TRAUMATIC BRAIN INJURY; BRAIN INJURY; BRAIN CONCUSSION; INCIDENCE; IMPAIRMENT; DISABILITY		Based on a retrospective survey of hospital admissions and autopsies the incidence of traumatic brain injury (TBI) for the age range 16-60 was found to be 24.9/10 000 in the Umea district of Northern Sweden. In male youngsters aged 16-19 the incidence was remarkably high in comparison with reports from other parts of the western hemisphere. Self-reports on the prevalence of impairments and disabilities 11/2-3 years after the injury were obtained by a mailed questionnaire. Among the subjects with brain concussion 1/3 reported impairments and 1/10 disabilities, most commonly leisure-disability. By factor analysis impairments and disabilities could be logically grouped into three factors. Two of these factors clearly circumscribed combinations of impairments and disabilities, one of them being dominated by instrumental ADL, the other by basic self-care ADL. The third factor incorporated the classic post-concussion triad and memory. Taken together the findings indicate that many subjects with an early diagnosis of brain concussion, hospitalized for only one day, experienced losses in pre-injury functions and abilities. It is therefore suggested that not only radiologically and/or operatively confirmed TBIs but also subjects with brain concussion should be followed after discharge in order to minimize losses in social well-being.	UMEA UNIV HOSP,DEPT PHYS MED & REHABIL,S-90185 UMEA,SWEDEN								0	40	41	0	10	SCANDINAVIAN UNIVERSITY PRESS	OSLO	PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO, NORWAY	0036-5505			SCAND J REHABIL MED	Scand. J. Rehabil. Med.		1991	23	4					179	185					7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	GZ301	WOS:A1991GZ30100001	1838430				2021-06-18	
J	ROBINSON, SE; FOXX, SD; POSNER, MG; MARTIN, RM; DAVIS, TR; GUO, HZ; ENTERS, EK				ROBINSON, SE; FOXX, SD; POSNER, MG; MARTIN, RM; DAVIS, TR; GUO, HZ; ENTERS, EK			THE EFFECT OF M1 MUSCARINIC BLOCKADE ON BEHAVIOR AND PHYSIOLOGICAL-RESPONSES FOLLOWING TRAUMATIC BRAIN INJURY IN THE RAT	BRAIN RESEARCH			English	Article										ROBINSON, SE (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,RICHMOND,VA 23298, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS024413] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS07288, NS24413] Funding Source: Medline		ABDELLATIF AA, 1986, PHARMACOL REV, V38, P227; ASHE JH, 1984, NEUROPHARMACOLOGY, V23, P1321, DOI 10.1016/0028-3908(84)90053-4; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BORNSTEIN MB, 1946, J NEUROPHYSIOL, V9, P349; BROWN DA, 1983, TRENDS NEUROSCI, V6, P302, DOI 10.1016/0166-2236(83)90144-3; DESALLES AAF, 1987, J NEUROSURG, V66, P102, DOI 10.3171/jns.1987.66.1.0102; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EGLEN RM, 1986, J AUTON PHARMACOL, V5, P323; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FISHER SK, 1987, J NEUROCHEM, V48, P999, DOI 10.1111/j.1471-4159.1987.tb05618.x; GIACHETTI A, 1986, BRIT J PHARMACOL, V89, P83, DOI 10.1111/j.1476-5381.1986.tb11123.x; GIL DW, 1986, J PHARMACOL EXP THER, V237, P577; GOWER AJ, 1987, EUR J PHARMACOL, V139, P79, DOI 10.1016/0014-2999(87)90500-0; HABER B, 1980, NEUROBIOLOGY CEREBRO, P345; HAGAN JJ, 1988, N-S ARCH PHARMACOL, V338, P476, DOI 10.1007/BF00179317; HAYES RL, 1984, SCIENCE, V233, P301; HOSS W, 1985, INT REV NEUROBIOL, V26, P151, DOI 10.1016/S0074-7742(08)60074-4; ISHII S, 1969, LATE EFFECTS HEAD IN, P123; Keppel G., 1982, DESIGN ANAL RES HDB, V2nd; KUNYSZ EL, 1988, BRIT J PHARMACOL, V93, P491, DOI 10.1111/j.1476-5381.1988.tb10303.x; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; MCGEER E, 1985, CAN J PHARM, V64, P363; METZ B, 1971, J NEUROSURG, V35, P523, DOI 10.3171/jns.1971.35.5.0523; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; MOCHIDA S, 1988, BRAIN RES, V455, P9, DOI 10.1016/0006-8993(88)90107-2; Newcombe F, 1980, Int Rehabil Med, V2, P133; OLNEY JW, 1983, BRAIN RES BULL, V10, P699, DOI 10.1016/0361-9230(83)90038-2; OLNEY JW, 1983, NATURE, V301, P520, DOI 10.1038/301520a0; RASCOL O, 1988, BRAIN RES, V446, P303, DOI 10.1016/0006-8993(88)90889-X; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; ROBINSON SE, IN PRESS BRAIN RES; ROSNER MJ, 1982, 5TH P INT S INTR PRE, P154; ROWE MJ, 1980, ARCH NEUROL-CHICAGO, V37, P679, DOI 10.1001/archneur.1980.00500600027002; RUGE D, 1946, J NEUROSURG, V11, P77; RUTHERFORD WH, 1977, LANCET, V1, P1; SACHS E, 1957, J NEUROSURG, V14, P22, DOI 10.3171/jns.1957.14.1.0022; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; SLOVITER RS, 1983, BRAIN RES BULL, V10, P675, DOI 10.1016/0361-9230(83)90037-0; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Toglia JU, 1969, LATE EFFECTS HEAD IN, P72; TOWER DB, 1949, CAN J RES E, V27, P105, DOI 10.1139/cjr49e-016; TURSKI WA, 1983, EXPERIENTIA, V39, P1408, DOI 10.1007/BF01990130; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEISS SJ, 1982, BIOCHEM J, P587; Winer BJ., 1971, STAT PRINCIPLES EXPT	54	40	40	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAR 12	1990	511	1					141	148		10.1016/0006-8993(90)90233-2			8	Neurosciences	Neurosciences & Neurology	CX001	WOS:A1990CX00100016	2331611				2021-06-18	
J	Hall, ED; Braughler, JM; McCall, JM				Hall, Edward D.; Braughler, J. Mark; McCall, John M.			New Pharmacological Treatment of Acute Spinal Cord Trauma	JOURNAL OF NEUROTRAUMA			English	Article								Numerous experimental studies of blunt spinal cord injury have shown that while a variable degree of immediate mechanical damage occurs to spinal blood vessels and axons in proportion to the magnitude of the injury force, a considerable amount of posttraumatic tissue degeneration is due to a secondary pathophysiological process that may be modifiable by appropriate therapeutic intervention. A growing body of biochemical, physiological, and pharmacological evidence has suggested that oxygen free radical-induced lipid peroxidation, working in concert with aberrant calcium fluxes and eicosanoid generation in particular, plays a key role in progressive post-traumatic spinal cord degeneration. Of particular importance, lipid peroxidation has been linked to microvascular damage and hypoperfusion which, if severe enough, can lead to a secondary ischemie insult to the tissue. The ability of intensive dosing with the glucocorticoid steroid methylprednisolone to beneficially affect post-traumatic ischemia and to promote chronic neurologic recovery in spinal cord injured animals has been correlated not with its glucocorticoid activity, but rather with the ability to inhibit post-traumatic spinal lipid peroxidation. In view of this, a novel series of non-glucocorticoid 21-aminosteroids has been developed which lack glucocorticoid activity but are more effective inhibitors of nervous tissue lipid peroxidation than the glucocorticoid steroids. One of these, U74006F, has now been studied in some detail and appears to be a promising new agent for the acute treatment of spinal cord (and brain) trauma. The background and pre-clinical development of this compound to date is reviewed.	[Hall, Edward D.; Braughler, J. Mark; McCall, John M.] Upjohn Co, Cent Nervous Syst Dis Res Unit, Kalamazoo, MI 49001 USA	Hall, ED (corresponding author), Upjohn Co, Cent Nervous Syst Dis Res Unit, Kalamazoo, MI 49001 USA.		Hall, Edward D/F-8930-2013				ANDERSON D K, 1987, Society for Neuroscience Abstracts, V13, P1499; Anderson D K, 1985, Cent Nerv Syst Trauma, V2, P257; ANDERSON DK, 1982, J NEUROSURG, V56, P106, DOI 10.3171/jns.1982.56.1.0106; BAXTER JD, 1979, GLUCOCORTICOID HORMO, P1; BRAUGHLER JM, 1987, J BIOL CHEM, V262, P10438; BRAUGHLER JM, 1988, J PHARMACOL EXP THER, V244, P423; BRAUGHLER JM, 1983, J NEUROSURG, V58, P538; BRAUGHLER JM, 1983, J NEUROSURG, V59, P256, DOI 10.3171/jns.1983.59.2.0256; BRAUGHLER JM, 1984, J NEUROSURG, V61, P290, DOI 10.3171/jns.1984.61.2.0290; BRAUGHLER JM, 1987, J NEUROSURG, V67, P102, DOI 10.3171/jns.1987.67.1.0102; CLARK CR, 1981, BRAIN RES, V217, P412, DOI 10.1016/0006-8993(81)90020-2; DEMOPOULOS HB, 1982, CAN J PHYSIOL PHARM, V60, P1415, DOI 10.1139/y82-210; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; Dimlich R. V. W., 1987, TRIENN M INT SOC STU; Hall E D, 1986, Cent Nerv Syst Trauma, V3, P281; HALL ED, 1982, SURG NEUROL, V18, P320, DOI 10.1016/0090-3019(82)90140-9; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1982, J NEUROSURG, V57, P247, DOI 10.3171/jns.1982.57.2.0247; HALL ED, 1987, J PHARMACOL EXP THER, V242, P137; HALL ED, 1984, J NEUROSURG, V61, P124, DOI 10.3171/jns.1984.61.1.0124; HALL ED, 1986, J NEUROSURG, V64, P951, DOI 10.3171/jns.1986.64.6.0951; Haynes Jr RC, 1985, PHARMACOL BASIS THER, P1459; IIZUKA H, 1986, J NEUROSURG, V65, P92, DOI 10.3171/jns.1986.65.1.0092; Kontos H.A., 1987, CNS TRAUMA, V3, P257; SAMUELS HH, 1970, J MOL BIOL, V52, P57, DOI 10.1016/0022-2836(70)90177-4; Windle W.F., 1980, SPINAL CORD ITS REAC, P205; YOUNG W, 1982, J NEUROSURG, V57, P667, DOI 10.3171/jns.1982.57.5.0667; YOUNG W, 1985, CENTRAL NERVOUS SYST, P463	29	40	41	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma		1988	5	1					81	89		10.1089/neu.1988.5.81			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	V22HC	WOS:000208265300007	3057217				2021-06-18	
J	Mez, J; Daneshvar, DH; Abdolmohammadi, B; Chua, AS; Alosco, ML; Kiernan, PT; Evers, L; Marshall, L; Martin, BM; Palmisano, JN; Nowinski, CJ; Mahar, I; Cherry, JD; Alvarez, VE; Dwyer, B; Huber, BR; Stein, TD; Goldstein, LE; Katz, DI; Cantu, RC; Au, R; Kowall, NW; Stern, RA; McClean, MD; Weuve, J; Tripodis, Y; McKee, AC				Mez, Jesse; Daneshvar, Daniel H.; Abdolmohammadi, Bobak; Chua, Alicia S.; Alosco, Michael L.; Kiernan, Patrick T.; Evers, Laney; Marshall, Laura; Martin, Brett M.; Palmisano, Joseph N.; Nowinski, Christopher J.; Mahar, Ian; Cherry, Jonathan D.; Alvarez, Victor E.; Dwyer, Brigid; Huber, Bertrand R.; Stein, Thor D.; Goldstein, Lee E.; Katz, Douglas, I; Cantu, Robert C.; Au, Rhoda; Kowall, Neil W.; Stern, Robert A.; McClean, Michael D.; Weuve, Jennifer; Tripodis, Yorghos; McKee, Ann C.			Duration of American Football Play and Chronic Traumatic Encephalopathy	ANNALS OF NEUROLOGY			English	Article							ALZHEIMERS ASSOCIATION GUIDELINES; 21ST-CENTURY BRAIN BANKING; NEUROPATHOLOGIC ASSESSMENT; NATIONAL INSTITUTE; NERVOUS-SYSTEM; 1ST EXPOSURE; DEMENTIA; DISEASE; IMPACT; CONCUSSION	Objective Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease associated with exposure to contact and collision sports, including American football. We hypothesized a dose-response relationship between duration of football played and CTE risk and severity. Methods In a convenience sample of 266 deceased American football players from the Veterans Affairs-Boston University-Concussion Legacy Foundation and Framingham Heart Study Brain Banks, we estimated the association of years of football played with CTE pathological status and severity. We evaluated the ability of years played to classify CTE status using receiver operating characteristic curve analysis. Simulation analyses quantified conditions that might lead to selection bias. Results In total, 223 of 266 participants met neuropathological diagnostic criteria for CTE. More years of football played were associated with having CTE (odds ratio [OR] = 1.30 per year played, 95% confidence interval [CI] = 1.19-1.41; p = 3.8 x 10(-9)) and with CTE severity (severe vs mild; OR = 1.14 per year played, 95% CI = 1.07-1.22; p = 3.1 x 10(-4)). Participants with CTE were 1/10th as likely to have played <4.5 years (negative likelihood ratio [LR] = 0.102, 95% CI = 0.100-0.105) and were 10 times as likely to have played >14.5 years (positive LR = 10.2, 95% CI = 9.8-10.7) compared with participants without CTE. Sensitivity and specificity were maximized at 11 years played. Simulation demonstrated that years played remained adversely associated with CTE status when years played and CTE status were both related to brain bank selection across widely ranging scenarios. Interpretation The odds of CTE double every 2.6 years of football played. After accounting for brain bank selection, the magnitude of the relationship between years played and CTE status remained consistent. ANN NEUROL 2019	[Mez, Jesse; Daneshvar, Daniel H.; Abdolmohammadi, Bobak; Chua, Alicia S.; Alosco, Michael L.; Kiernan, Patrick T.; Evers, Laney; Marshall, Laura; Martin, Brett M.; Palmisano, Joseph N.; Nowinski, Christopher J.; Mahar, Ian; Cherry, Jonathan D.; Alvarez, Victor E.; Huber, Bertrand R.; Stein, Thor D.; Goldstein, Lee E.; Cantu, Robert C.; Au, Rhoda; Kowall, Neil W.; Stern, Robert A.; Tripodis, Yorghos; McKee, Ann C.] Boston Univ, Sch Med, Alzheimers Dis & Chron Traumat Encephalopathy Ctr, Boston, MA 02118 USA; [Mez, Jesse; Abdolmohammadi, Bobak; Alosco, Michael L.; Kiernan, Patrick T.; Evers, Laney; Marshall, Laura; Mahar, Ian; Dwyer, Brigid; Huber, Bertrand R.; Goldstein, Lee E.; Katz, Douglas, I; Cantu, Robert C.; Kowall, Neil W.; Stern, Robert A.; McKee, Ann C.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Mez, Jesse; Stein, Thor D.; Au, Rhoda; McKee, Ann C.] Boston Univ, Framingham Heart Study, Sch Med, Boston, MA 02118 USA; [Daneshvar, Daniel H.] Stanford Univ, Sch Med, Dept Rehabil Med, Stanford, CA 94305 USA; [Chua, Alicia S.; Tripodis, Yorghos] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA; [Kiernan, Patrick T.] Midwestern Univ, Arizona Coll Osteopath Med, Glendale, AZ USA; [Martin, Brett M.; Palmisano, Joseph N.] Boston Univ, Data Coordinating Ctr, Sch Publ Hlth, Boston, MA 02118 USA; [Nowinski, Christopher J.; Cantu, Robert C.] Concuss Legacy Fdn, Boston, MA USA; [Cherry, Jonathan D.; Alvarez, Victor E.; Huber, Bertrand R.; Stein, Thor D.; Kowall, Neil W.; McKee, Ann C.] US Dept Vet Affairs, VA Boston Healthcare Syst, Boston, MA USA; [Cherry, Jonathan D.; Alvarez, Victor E.; Huber, Bertrand R.; Stein, Thor D.; McKee, Ann C.] Dept Vet Affairs Med Ctr, Bedford, MA USA; [Dwyer, Brigid; Katz, Douglas, I] Braintree Rehabil Hosp, Braintree, MA USA; [Stein, Thor D.; Goldstein, Lee E.; Kowall, Neil W.; McKee, Ann C.] Boston Univ, Dept Pathol & Lab Med, Sch Med, Boston, MA 02118 USA; [Goldstein, Lee E.] Boston Univ, Dept Psychiat, Sch Med, Boston, MA 02118 USA; [Goldstein, Lee E.] Boston Univ, Dept Biomed Engn, Coll Engn, Boston, MA 02118 USA; [Cantu, Robert C.; Stern, Robert A.] Boston Univ, Dept Neurosurg, Sch Med, Boston, MA 02118 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Au, Rhoda; Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Au, Rhoda; Weuve, Jennifer] Boston Univ, Dept Epidemiol, Sch Publ Hlth, Boston, MA 02118 USA; [McClean, Michael D.] Boston Univ, Dept Environm Hlth, Sch Publ Hlth, Boston, MA 02118 USA	McKee, AC (corresponding author), Boston Univ, AD&CTE Ctr, 72 E Concord St,Robinson Suite 7800, Boston, MA 02118 USA.	amckee@bu.edu	, Bob/ABA-8507-2020; Dwyer, Brigid/AAI-6199-2020; Lang, Steven/AAE-8102-2021	Dwyer, Brigid/0000-0002-6446-8054; Lang, Steven/0000-0003-1669-9146; Mez, Jesse/0000-0003-1438-5442	NIH National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086659, U01NS093334, R01NS078337, R56NS078337, K23NS10 2399]; NIH National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG13846, 0572063345, R01AG057902, R01AG061028, K23AG046377, R01AG1649, R21HD089088, F32NS09 6803]; Department of Veterans AffairsUS Department of Veterans Affairs [I01 CX001135, CSP 501, B6796-C]; Department of DefenseUnited States Department of Defense [W81XWH13-2-0095, W81XWH-13-2-0064, W81XWH1810580, PRARP-13267017]; Alzheimer's AssociationAlzheimer's Association [NIRG15-362697, NIRG-305779]; National Operating Committee on Standards for Athletic Equipment; Nick and Lynn Buoniconti Foundation; Concussion Legacy Foundation; Andlinger Foundation; World Wrestling Entertainment; NFL	This work was supported by the NIH National Institute of Neurological Disorders and Stroke (U01NS086659, U01NS093334, R01NS078337, R56NS078337, K23NS10 2399), NIH National Institute on Aging (P30AG13846; supplement 0572063345, R01AG057902, R01AG061028, K23AG046377, R01AG1649, R21HD089088, F32NS09 6803), Department of Veterans Affairs (I01 CX001135, CSP 501, B6796-C), Department of Defense (W81XWH13-2-0095, W81XWH-13-2-0064, W81XWH1810580, PRARP-13267017), Alzheimer's Association (NIRG15-362697, NIRG-305779), National Operating Committee on Standards for Athletic Equipment, Nick and Lynn Buoniconti Foundation, Concussion Legacy Foundation, Andlinger Foundation, World Wrestling Entertainment, and NFL.; We thank VA Boston Healthcare System (Boston, MA) and the Edith Nourse Rogers Memorial Veterans Hospital (Bedford, MA) for the use of resources and facilities; all members of the Boston University CTE Center, the VA-BU-CLF Brain Bank (including Kerry Cormier, Carol Kubilus, Rebecca Mathias, Ray Nicks and Madeline Uretsky), and the Concussion Legacy Foundation (including Lisa McHale); and the individuals and families whose participation and contributions made this work possible.	Adams JW, 2018, J NEUROPATH EXP NEUR, V77, P757, DOI 10.1093/jnen/nly065; Alosco ML, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.197; Alosco ML, 2018, ANN NEUROL, V83, P886, DOI 10.1002/ana.25245; Asken BM, 2017, JAMA NEUROL, V74, P1255, DOI 10.1001/jamaneurol.2017.2396; Au R, 2012, CURR ALZHEIMER RES, V9, P673; Baugh CM, 2015, J NEUROTRAUM, V32, P314, DOI 10.1089/neu.2014.3582; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Braak H, 2008, NEUROLOGY, V70, P1916, DOI 10.1212/01.wnl.0000312279.49272.9f; BROWNELL B, 1970, J NEUROL NEUROSUR PS, V33, P338, DOI 10.1136/jnnp.33.3.338; Cairns NJ, 2007, AM J PATHOL, V171, P227, DOI 10.2353/ajpath.2007.070182; Chene G, 2015, ALZHEIMERS DEMENT, V11, P310, DOI 10.1016/j.jalz.2013.10.005; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Dickson DW, 2010, INT J CLIN EXP PATHO, V3, P1; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Haneuse S, 2009, NEUROEPIDEMIOLOGY, V32, P229, DOI 10.1159/000197389; Hernan MA, 2004, EPIDEMIOLOGY, V15, P615, DOI 10.1097/01.ede.0000135174.63482.43; Hyman BT, 2012, ALZHEIMERS DEMENT, V8, P1, DOI 10.1016/j.jalz.2011.10.007; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; Ling HL, 2017, ACTA NEUROPATHOL, V133, P337, DOI 10.1007/s00401-017-1680-3; Ling HL, 2015, ACTA NEUROPATHOL, V130, P891, DOI 10.1007/s00401-015-1496-y; Litvan I, 1996, J NEUROPATH EXP NEUR, V55, P97, DOI 10.1097/00005072-199601000-00010; Liu XH, 2012, STAT MED, V31, P2676, DOI 10.1002/sim.4509; Mackenzie IRA, 2010, ACTA NEUROPATHOL, V119, P1, DOI 10.1007/s00401-009-0612-2; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKeith IG, 2006, ALZHEIMER'S DISEASE: A CENTURY OF SCIENTIFIC AND CLINICAL RESEARCH, P417; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Mez J, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0148-8; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Montine TJ, 2012, ACTA NEUROPATHOL, V123, P1, DOI 10.1007/s00401-011-0910-3; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Saczynski JS, 2010, NEUROLOGY, V75, P35, DOI 10.1212/WNL.0b013e3181e62138; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Vogel BL, 2019, STUDENT ATHLETES VS; Vonsattel JPG, 2008, CELL TISSUE BANK, V9, P247, DOI 10.1007/s10561-008-9079-y; Vonsattel JPG, 2008, ACTA NEUROPATHOL, V115, P509, DOI 10.1007/s00401-007-0311-9	45	39	39	3	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	JAN	2020	87	1					116	131		10.1002/ana.25611		NOV 2019	16	Clinical Neurology; Neurosciences	Neurosciences & Neurology	LS0BE	WOS:000498077700001	31589352	Other Gold, Green Published			2021-06-18	
J	Stein, MB; Jain, S; Giacino, JT; Levin, H; Dikmen, S; Nelson, LD; Vassar, MJ; Okonkwo, DO; Diaz-Arrastia, R; Robertson, CS; Mukherjee, P; McCrea, M; MacDonald, CL; Yue, JK; Yuh, E; Sun, XY; Campbell-Sills, L; Temkin, N; Manley, GT; Adeoye, O; Badjatia, N; Boase, K; Bodien, Y; Bullock, MR; Chesnut, R; Corrigan, JD; Crawford, K; Diaz-Arrastia, R; Dikmen, S; Duhaime, AC; Ellenbogen, R; Feeser, VR; Ferguson, A; Foreman, B; Gardner, R; Gaudette, E; Giacino, JT; Gonzalez, L; Gopinath, S; Gullapalli, R; Hemphill, JC; Hotz, G; Jain, S; Korley, F; Kramer, J; Kreitzer, N; Levin, H; Lindsell, C; Machamer, J; Madden, C; Martin, A; McAllister, T; McCrea, M; Merchant, R; Mukherjee, P; Nelson, LD; Noel, F; Okonkwo, DO; Palacios, E; Perl, D; Puccio, A; Rabinowitz, M; Robertson, CS; Rosand, J; Sander, A; Satris, G; Schnyer, D; Seabury, S; Sherer, M; Stein, MB; Taylor, S; Toga, A; Temkin, N; Valadka, A; Vassar, MJ; Vespa, P; Wang, K; Yue, JK; Yuh, E; Zafonte, R				Stein, Murray B.; Jain, Sonia; Giacino, Joseph T.; Levin, Harvey; Dikmen, Sureyya; Nelson, Lindsay D.; Vassar, Mary J.; Okonkwo, David O.; Diaz-Arrastia, Ramon; Robertson, Claudia S.; Mukherjee, Pratik; McCrea, Michael; MacDonald, Christine L.; Yue, John K.; Yuh, Esther; Sun, Xiaoying; Campbell-Sills, Laura; Temkin, Nancy; Manley, Geoffrey T.; Adeoye, Opeolu; Badjatia, Neeraj; Boase, Kim; Bodien, Yelena; Bullock, M. Ross; Chesnut, Randall; Corrigan, John D.; Crawford, Karen; Diaz-Arrastia, Ramon; Dikmen, Sureyya; Duhaime, Ann-Christine; Ellenbogen, Richard; Feeser, V. Ramana; Ferguson, Adam; Foreman, Brandon; Gardner, Raquel; Gaudette, Etienne; Giacino, Joseph T.; Gonzalez, Luis; Gopinath, Shankar; Gullapalli, Rao; Hemphill, J. Claude; Hotz, Gillian; Jain, Sonia; Korley, Frederick; Kramer, Joel; Kreitzer, Natalie; Levin, Harvey; Lindsell, Chris; Machamer, Joan; Madden, Christopher; Martin, Alastair; McAllister, Thomas; McCrea, Michael; Merchant, Randall; Mukherjee, Pratik; Nelson, Lindsay D.; Noel, Florence; Okonkwo, David O.; Palacios, Eva; Perl, Daniel; Puccio, Ava; Rabinowitz, Miri; Robertson, Claudia S.; Rosand, Jonathan; Sander, Angelle; Satris, Gabriela; Schnyer, David; Seabury, Seth; Sherer, Mark; Stein, Murray B.; Taylor, Sabrina; Toga, Arthur; Temkin, Nancy; Valadka, Alex; Vassar, Mary J.; Vespa, Paul; Wang, Kevin; Yue, John K.; Yuh, Esther; Zafonte, Ross		TRACK-TBI Investigators	Risk of Posttraumatic Stress Disorder and Major Depression in Civilian Patients After Mild Traumatic Brain Injury A TRACK-TBI Study	JAMA PSYCHIATRY			English	Article							QUALITY-OF-LIFE; POSTCONCUSSIVE SYMPTOMS; PREDICTORS; ASSOCIATION; PROGNOSIS; VETERANS; CONCUSSION; MANAGEMENT; DIAGNOSIS; MILITARY	IMPORTANCE Traumatic brain injury (TBI) has been associated with adverse mental health outcomes, such as posttraumatic stress disorder (PTSD) and major depressive disorder (MDD), but little is known about factors that modify risk for these psychiatric sequelae, particularly in the civilian sector. OBJECTIVE To ascertain prevalence of and risk factors for PTSD and MDD among patients evaluated in the emergency department for mild TBI (mTBI). DESIGN. SETTING. AND PARTICIPANTS Prospective longitudinal cohort study (February 2014 to May 2018). Posttraumatic stress disorder and MDD symptoms were assessed using the PTSD Checklist for DSM-5 and the Patient Health Questionnaire-9 Item. Risk factors evaluated included preinjury and injury characteristics. Propensity score weights-adjusted multivariable logistic regression models were performed to assess associations with PTSD and MDD. A total of 1155 patients with mTBI (Glasgow Coma Scale score, 13-15) and 230 patients with nonhead orthopedic trauma injuries 17 years and older seen in 11 US hospitals with level 1 trauma centers were included in this study. MAIN OUTCOMES AND MEASURES Probable PTSD (PTSD Checklist for DSM-5 score, >= 33) and MDD (Patient Health Questionnaire -9 Item score, >= 15) at 3, 6, and 12 months postinjury. RESULTS Participants were 1155 patients (752 men [65.1%]; mean [SD] age, 40.5 [17.2] years) with mTBI and 230 patients (155 men [67.4%]; mean [SD] age, 40.4 [15.6] years) with nonhead orthopedic trauma injuries. Weights-adjusted prevalence of PTSD and/or MDD in the mTBI vs orthopedic trauma comparison groups at 3 months was 20.0% (SE, 1.4%) vs 8.7% (SE, 2.2%) (P<.001) and at 6 months was 21.2% (SE, 1.5%) vs 12.1% (SE, 3.2%) (P = .03). Risk factors for probable PTSD at 6 months after mTBI included less education (adjusted odds ratio, 0.89; 95% Cl, 0.82-0.97 per year), being black (adjusted odds ratio, 5.11; 95% Cl, 2.89-9.05), self-reported psychiatric history (adjusted odds ratio, 3.57; 95% Cl, 2.09-6.09), and injury resulting from assault or other violence (adjusted odds ratio, 3.43; 95% Cl, 1.56-7.54). Risk factors for probable MDD after mTBI were similar with the exception that cause of injury was not associated with increased risk. CONCLUSIONS AND RELEVANCE After mTBI, some individuals, on the basis of education, race/ethnicity, history of mental health problems, and cause of injury were at substantially increased risk of PTSD and/or MDD. These findings should influence recognition of at-risk individuals and inform efforts at surveillance, follow-up, and intervention.	[Stein, Murray B.; Campbell-Sills, Laura] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Stein, Murray B.; Jain, Sonia; Sun, Xiaoying] Univ Calif San Diego, Dept Family Med & Publ Hlth, La Jolla, CA 92093 USA; [Stein, Murray B.] VA San Diego Healthcare Syst, San Diego, CA USA; [Giacino, Joseph T.; Zafonte, Ross] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA 02115 USA; [Giacino, Joseph T.] Spaulding Rehabil Hosp, Charlestown, MA USA; [Levin, Harvey; Robertson, Claudia S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Dikmen, Sureyya; Boase, Kim; Machamer, Joan] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Nelson, Lindsay D.; McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Nelson, Lindsay D.; McCrea, Michael] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Vassar, Mary J.; Mukherjee, Pratik; Yue, John K.; Yuh, Esther; Manley, Geoffrey T.; Satris, Gabriela] Zuckerberg San Francisco Gen Hosp & Trauma Ctr, Brain & Spinal Cord Injury Ctr, San Francisco, CA USA; [Vassar, Mary J.; Manley, Geoffrey T.; Ferguson, Adam; Taylor, Sabrina] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Okonkwo, David O.; Puccio, Ava] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA; [Diaz-Arrastia, Ramon; Rabinowitz, Miri] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Mukherjee, Pratik; Yuh, Esther; Martin, Alastair; Palacios, Eva] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA; [Mukherjee, Pratik; Yuh, Esther] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [MacDonald, Christine L.; Temkin, Nancy; Chesnut, Randall; Ellenbogen, Richard] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Adeoye, Opeolu; Foreman, Brandon; Kreitzer, Natalie] Univ Cincinnati, Cincinnati, OH USA; [Badjatia, Neeraj; Gullapalli, Rao] Univ Maryland, College Pk, MD 20742 USA; [Bodien, Yelena; Rosand, Jonathan] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Bullock, M. Ross; Hotz, Gillian] Univ Miami, Coral Gables, FL 33124 USA; [Corrigan, John D.] Ohio State Univ, Columbus, OH 43210 USA; [Crawford, Karen; Gaudette, Etienne; Seabury, Seth; Toga, Arthur] Univ Southern Calif, Los Angeles, CA USA; [Duhaime, Ann-Christine] MassGen Hosp Children, Boston, MA USA; [Feeser, V. Ramana] Virginia Commonwealth Univ, Dept Emergency Med, Richmond, VA USA; [Gardner, Raquel; Hemphill, J. Claude; Kramer, Joel] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Gonzalez, Luis; Sherer, Mark] TIRR Mem Hermann, Houston, TX USA; [Gopinath, Shankar] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Korley, Frederick] Univ Michigan, Med Sch, Dept Emergency Med, Ann Arbor, MI USA; [Lindsell, Chris] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA; [Madden, Christopher] UT Southwestern Med Ctr, Dept Neurol Surg, Dallas, TX USA; [McAllister, Thomas] Indiana Univ, Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [Merchant, Randall] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA USA; [Noel, Florence] Baylor Coll Med, Dan L Duncan Inst Clin & Translat Res, Houston, TX 77030 USA; [Perl, Daniel] Uniformed Serv Univ Hlth Sci, Dept Pathol, Bethesda, MD USA; [Schnyer, David] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Valadka, Alex] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA; [Vespa, Paul] Univ Calif Los Angeles, Dept Neurol, Los Angeles Sch Med, Los Angeles, CA 90024 USA; [Wang, Kevin] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA	Stein, MB (corresponding author), Univ Calif San Diego, Dept Psychiat, Altman Clin & Translat Res Inst, 9500 Gilman Dr,MC 0855, La Jolla, CA 92093 USA.	mstein@ucsd.edu	Yue, John K/P-1348-2015; Giacino, Joseph/AAF-1952-2021	Yue, John K/0000-0001-9694-7722; Giacino, Joseph/0000-0002-7916-9698; Bodien, Yelena/0000-0003-4858-2903; Ferguson, Adam/0000-0001-7102-1608; Hemphill, Claude/0000-0003-4019-7525; Wang, Kevin/0000-0002-9343-6473	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U01 NS086090]; US Department of DefenseUnited States Department of Defense [W81XWH-14-2-0176]; Abbott LaboratoriesAbbott Laboratories; One Mind; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS047996] Funding Source: NIH RePORTER	This research was supported by the National Institutes of Health (grant U01 NS086090) and US Department of Defense (grant W81XWH-14-2-0176). Abbott Laboratories provided funding for add-in TRACK-TBI clinical studies. One Mind provided funding for TRACK-TBI patients stipends and support to clinical sites.	Armistead-Jehle P, 2017, PHYS MED REH CLIN N, V28, P323, DOI 10.1016/j.pmr.2016.12.008; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Bell KR, 2017, J NEUROTRAUM, V34, P313, DOI 10.1089/neu.2016.4444; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bovin MJ, 2016, PSYCHOL ASSESSMENT, V28, P1379, DOI 10.1037/pas0000254; Bryant RA, 2015, BRIT J PSYCHIAT, V206, P417, DOI 10.1192/bjp.bp.114.145516; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Cnossen MC, 2018, J NEUROTRAUM, V35, P2691, DOI 10.1089/neu.2017.5486; Cnossen MC, 2017, J NEUROPSYCH CLIN N, V29, P206, DOI 10.1176/appi.neuropsych.16090165; Dikmen S, 2017, J NEUROTRAUM, V34, P1524, DOI 10.1089/neu.2016.4618; Dyer JR, 2016, J HEAD TRAUMA REHAB, V31, P225, DOI 10.1097/HTR.0000000000000177; Fann JR, 2018, LANCET PSYCHIAT, V5, P424, DOI 10.1016/S2215-0366(18)30065-8; Fann JR, 2017, J HEAD TRAUMA REHAB, V32, P332, DOI 10.1097/HTR.0000000000000322; Fazel S, 2014, JAMA PSYCHIAT, V71, P326, DOI 10.1001/jamapsychiatry.2013.3935; Foks KA, 2017, J NEUROTRAUM, V34, P2529, DOI 10.1089/neu.2016.4919; Gardner RC, 2018, NEUROLOGY, V90, pE1771, DOI 10.1212/WNL.0000000000005522; Gordon EM, 2018, J NEUROTRAUM, V35, P767, DOI 10.1089/neu.2017.5428; Haagsma JA, 2015, J NEUROTRAUM, V32, P853, DOI 10.1089/neu.2013.3283; Hiploylee C, 2017, J NEUROTRAUM, V34, P1511, DOI 10.1089/neu.2016.4677; Holster JL, 2017, J HEAD TRAUMA REHAB, V32, P25, DOI 10.1097/HTR.0000000000000237; Howlett J.R., 2016, TRANSLATIONAL RES TR; Ioannidis JPA, 2018, JAMA-J AM MED ASSOC, V319, P1429, DOI 10.1001/jama.2018.1536; Kaplan GB, 2018, J NEUROTRAUM, V35, P210, DOI 10.1089/neu.2016.4953; Kroenke K, 2010, GEN HOSP PSYCHIAT, V32, P345, DOI 10.1016/j.genhosppsych.2010.03.006; Lagarde E, 2014, JAMA PSYCHIAT, V71, P1032, DOI 10.1001/jamapsychiatry.2014.666; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Mac Donald CL, 2017, JAMA NEUROL, V74, P821, DOI 10.1001/jamaneurol.2017.0143; Madsen T, 2018, JAMA-J AM MED ASSOC, V320, P580, DOI 10.1001/jama.2018.10211; Manners JL, 2016, J NEUROTRAUM, V33, P1796, DOI 10.1089/neu.2015.4245; McCaffrey DF, 2004, PSYCHOL METHODS, V9, P403, DOI 10.1037/1082-989X.9.4.403; McCrea MA, 2017, PHYS MED REH CLIN N, V28, P271, DOI 10.1016/j.pmr.2016.12.005; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; Nordstrom A, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002496; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; Perry DC, 2016, J NEUROSURG, V124, P511, DOI 10.3171/2015.2.JNS14503; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Porter KE, 2018, J PSYCHIATR RES, V102, P8, DOI 10.1016/j.jpsychires.2018.03.004; Rabinowitz AR, 2015, J NEUROTRAUM, V32, P1488, DOI 10.1089/neu.2014.3555; Radhakrishnan R, 2016, LANCET PSYCHIAT, V3, P1166, DOI 10.1016/S2215-0366(16)30266-8; Ritterband LM, 2017, JAMA PSYCHIAT, V74, P68, DOI 10.1001/jamapsychiatry.2016.3249; Roden-Foreman K, 2017, J ORTHOP TRAUMA, V31, pE275, DOI 10.1097/BOT.0000000000000884; Schiehser DM, 2015, J HEAD TRAUMA REHAB, V30, pE21, DOI 10.1097/HTR.0000000000000065; Schwab K, 2017, NEUROLOGY, V88, P1571, DOI 10.1212/WNL.0000000000003839; Seabury SA, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.0210; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Stein MB, 2016, J NEUROTRAUM, V33, P2125, DOI 10.1089/neu.2015.4320; Stein MB, 2015, AM J PSYCHIAT, V172, P1101, DOI 10.1176/appi.ajp.2015.14121572; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; van der Naalt J, 2017, LANCET NEUROL, V16, P532, DOI 10.1016/S1474-4422(17)30117-5; Vuletic S, 2016, J HEAD TRAUMA REHAB, V31, P147, DOI 10.1097/HTR.0000000000000221; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970	55	39	40	4	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-622X	2168-6238		JAMA PSYCHIAT	JAMA Psychiatry	MAR	2019	76	3					249	258		10.1001/jamapsychiatry.2018.4288			10	Psychiatry	Psychiatry	HN9GA	WOS:000460506700008	30698636	Green Published, Bronze	Y	N	2021-06-18	
J	Asken, BM; Bauer, RM; Guskiewicz, KM; McCrea, MA; Schmidt, JD; Giza, CC; Snyder, AR; Houck, ZM; Kontos, AP; McAllister, TW; Broglio, SP; Clugston, JR				Asken, Breton M.; Bauer, Russell M.; Guskiewicz, Kevin M.; McCrea, Michael A.; Schmidt, Julianne D.; Giza, Christopher C.; Snyder, Aliyah R.; Houck, Zachary M.; Kontos, Anthony P.; McAllister, Thomas W.; Broglio, Steven P.; Clugston, James R.		CARE Consortium Investigators	Immediate Removal From Activity After Sport-Related Concussion Is Associated With Shorter Clinical Recovery and Less Severe Symptoms in Collegiate Student-Athletes	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						brain injury; concussion reporting; CARE Consortium; mTBI	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; FOOTBALL PLAYERS; VOLUNTARY EXERCISE; PROLONGED RECOVERY; MILD CONCUSSION; NCAA CONCUSSION; UP-REGULATION; HEAD-INJURY; MANAGEMENT	Background: Timely removal from activity after concussion symptoms remains problematic despite heightened awareness. Previous studies indicated potential adverse effects of continuing to participate in physical activity immediately after sustaining a concussion. Hypothesis/Purpose: The purpose was to determine the effect of timing of removal from play after concussion on clinical outcomes. It was hypothesized that immediate removal from activity after sport-related concussion (SRC) would be associated with less time missed from sport, a shorter symptomatic period, and better outcomes on acute clinical measures. Study Design: Cohort study; Level of evidence, 3. Methods: Data were reported from the National Collegiate Athletic Association and Department of Defense Grand Alliance: Concussion Awareness, Research, and Education (CARE) Consortium. Participants with 506 diagnosed SRCs from 18 sports and 25 institutions and military service academies were analyzed and classified as either immediate removal from activity (I-RFA) or delayed removal from activity (D-RFA). Outcomes of interest included time missed from sport attributed to their SRC, symptom duration, and clinical assessment scores. Results: There were 322 participants (63.6%) characterized as D-RFA. I-RFA status was associated with significantly less time missed from sport (R-2 change = .022-.024, P < .001 to P = .001) and shorter symptom duration (R-2 change = .044-.046, P < .001 [all imputations]) while controlling for other SRC recovery modifiers. These athletes missed approximately 3 fewer days from sport participation. I-RFA athletes had significantly less severe acute SRC symptoms and were at lower risk of recovery taking >= 14 days (relative risk = .614, P < .001, small-medium effect size) and >= 21 days (relative risk = .534, P = .010, small effect size). Conclusion: I-RFA is a protective factor associated with less severe acute symptoms and shorter recovery after SRC. Conveying this message to athletes, coaches, and others involved in the care of athletes may promote timely injury reporting.	[Asken, Breton M.; Bauer, Russell M.; Guskiewicz, Kevin M.; McCrea, Michael A.; Schmidt, Julianne D.; Giza, Christopher C.; Snyder, Aliyah R.; Houck, Zachary M.; Kontos, Anthony P.; McAllister, Thomas W.; Broglio, Steven P.; Clugston, James R.; CARE Consortium Investigators] Univ Florida, Gainesville, FL USA	Asken, BM (corresponding author), Univ Florida, Dept Clin & Hlth Psychol, POB 100165, Gainesville, FL 32610 USA.	basken8@phhp.ufl.edu	Rowson, Steven/B-1270-2012; Snyder, Aliyah/AAT-6250-2020	Rowson, Steven/0000-0002-3227-0596; Snyder, Aliyah/0000-0003-1185-7424; Clugston, James/0000-0002-2103-1039; Asken, Breton/0000-0001-8419-142X; Chrisman, Sara/0000-0001-5373-7223	Grand Alliance Concussion Assessment, Research, and Education Consortium; National Collegiate Athletic Association; Department of DefenseUnited States Department of Defense; Office of the Assistant Secretary of Defense for Health Affairs through Psychological Health and Traumatic Brain Injury Program [W81XWH-14-2-0151]; National Center for Advancing Translational SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 RR029890]; Veterans Health Administration Office of Research and Development [1 I21 RX001730]; Veterans AffairsUS Department of Veterans Affairs [I21RX001730] Funding Source: NIH RePORTER	This publication was supported in part by the Grand Alliance Concussion Assessment, Research, and Education Consortium, which receives funding from the National Collegiate Athletic Association and the Department of Defense. The US Army Medical Research Acquisition Activity is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program (award W81XWH-14-2-0151). The study was also supported by National Center for Advancing Translational Sciences (UL1 RR029890) and Veterans Health Administration Office of Research and Development (1 I21 RX001730; R.M.B.).	Asken BM, 2017, ARCH CLIN NEUROPSYCH, V32, P963, DOI 10.1093/arclin/acx018; Asken BM, 2017, CLIN NEUROPSYCHOL, V31, P138, DOI 10.1080/13854046.2016.1246672; Asken BM, 2016, J ATHL TRAINING, V51, P329, DOI 10.4085/1062-6050-51.5.02; Baugh CM, 2014, J LAW MED ETHICS, V42, P314, DOI 10.1111/jlme.12148; Broglio SP, 2017, SPORTS MED, V47, P1437, DOI 10.1007/s40279-017-0707-1; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, pe333; Collins MW, 2016, NEUROSURGERY, V79, P912, DOI 10.1227/NEU.0000000000001447; Derogatis L. R., 2001, BSI 18 BRIEF SYMPTOM; Dvorak J, 2007, BRIT J SPORT MED, V41, pI44, DOI 10.1136/bjsm.2007.037960; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Elbin RJ, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0910; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Graham JW, 2007, PREV SCI, V8, P206, DOI 10.1007/s11121-007-0070-9; Griesbach GS, 2011, PM&R, V3, pS64, DOI 10.1016/j.pmrj.2011.02.008; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Heyer GL, 2016, J PEDIATR-US, V174, P33, DOI 10.1016/j.jpeds.2016.03.014; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097729; Iverson GL, 2015, JAMA PEDIATR, V169, P1132, DOI 10.1001/jamapediatrics.2015.2374; Kamins J, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097464; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Mainwaring LM, 2004, J SPORT EXERCISE PSY, V26, P119, DOI 10.1123/jsep.26.1.119; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mychasiuk R, 2016, EUR J NEUROSCI, V44, P2407, DOI 10.1111/ejn.13360; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Sakurai A, 2012, J NEUROTRAUM, V29, P313, DOI 10.1089/neu.2011.2152; Schneider KJ, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097475; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Terwilliger VK, 2016, J NEUROTRAUM, V33, P761, DOI 10.1089/neu.2015.4082; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Titus DJ, 2015, EXP NEUROL, V263, P254, DOI 10.1016/j.expneurol.2014.10.020; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339	50	39	39	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAY	2018	46	6					1465	1474		10.1177/0363546518757984			10	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	GF7IB	WOS:000432140700024	29558195	Green Accepted			2021-06-18	
J	Gollihue, JL; Patel, SP; Eldahan, KC; Cox, DH; Donahue, RR; Taylor, BK; Sullivan, PG; Rabchevsky, AG				Gollihue, Jenna L.; Patel, Samir P.; Eldahan, Khalid C.; Cox, David H.; Donahue, Renee R.; Taylor, Bradley K.; Sullivan, Patrick G.; Rabchevsky, Alexander G.			Effects of Mitochondrial Transplantation on Bioenergetics, Cellular Incorporation, and Functional Recovery after Spinal Cord Injury	JOURNAL OF NEUROTRAUMA			English	Article						Basso; Beattie; Bresnahan locomotor rating scale; mitochondrial respiration; transgenic labeling; Von Frey hair test	ACETYL-L-CARNITINE; TRAUMATIC BRAIN; OXIDATIVE STRESS; NONSYNAPTIC MITOCHONDRIA; ANTIOXIDANT THERAPIES; UNCOUPLING AGENT; DYSFUNCTION; NEURONS; 2,4-DINITROPHENOL; PROTECTS	Our previous studies reported that pharmacological maintenance of mitochondrial bioenergetics after experimental spinal cord injury (SCI) provided functional neuroprotection. Recent evidence indicates that endogenous mitochondrial transfer is neuroprotective as well, and, therefore, we extended these studies with a novel approach to transplanting exogenous mitochondria into the injured rat spinal cord. Using a rat model of L1/L2 contusion SCI, we herein report that transplantation of exogenous mitochondria derived from either cell culture or syngeneic leg muscle maintained acute bioenergetics of the injured spinal cord in a concentration-dependent manner. Moreover, transplanting transgenically labeled turbo green fluorescent (tGFP) PC12-derived mitochondria allowed for visualization of their incorporation in both a time-dependent and cell-specific manner at 24h, 48h, and 7 days post-injection. tGFP mitochondria co-localized with multiple resident cell types, although they were absent in neurons. Despite their contribution to the maintenance of normal bioenergetics, mitochondrial transplantation did not yield long-term functional neuroprotection as assessed by overall tissue sparing or recovery of motor and sensory functions. These experiments are the first to investigate mitochondrial transplantation as a therapeutic approach to treating spinal cord injury. Our initial bioenergetic results are encouraging, and although they did not translate into improved long-term outcome measures, caveats and technical hurdles are discussed that can be addressed in future studies to potentially increase long-term efficacy of transplantation strategies.	[Gollihue, Jenna L.; Patel, Samir P.; Eldahan, Khalid C.; Donahue, Renee R.; Taylor, Bradley K.; Rabchevsky, Alexander G.] Univ Kentucky, Dept Physiol, Lexington, KY USA; [Sullivan, Patrick G.] Univ Kentucky, Dept Neurosci, Lexington, KY USA; [Gollihue, Jenna L.; Patel, Samir P.; Eldahan, Khalid C.; Cox, David H.; Taylor, Bradley K.; Sullivan, Patrick G.; Rabchevsky, Alexander G.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, B471,BBSRB 741 S Limestone, Lexington, KY 40536 USA	Rabchevsky, AG (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, B471,BBSRB 741 S Limestone, Lexington, KY 40536 USA.	agrab@uky.edu	Rabchevsky, Alexander/AAQ-2451-2021; Donahue, Renee/AAI-3512-2020	Rabchevsky, Alexander/0000-0002-1991-0915; Cox, David/0000-0002-9483-5900; Donahue, Renee/0000-0002-3344-5650	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [F31 NS093904-01A1]; Conquer Paralysis Now; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 NS096670]; Spinal Cord and Brain Injury Research Center (SCoBIRC) Chair Endowment; NIH/National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2P30NS051220]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS062306, R01NS045954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG057461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA037621] Funding Source: NIH RePORTER	This study was supported by National Institutes of Health (NIH) F31 NS093904-01A1 (J.L.G.), Conquer Paralysis Now (A.G.R.), NIH R21 NS096670 (A.G.R.), Spinal Cord and Brain Injury Research Center (SCoBIRC) Chair Endowment (A.G.R.), and NIH/National Institute of Neurological Disorders and Stroke (NINDS) 2P30NS051220.	Ahmed LA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108889; Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001; Aygok GA, 2008, ACTA NEUROCHIR SUPPL, V102, P57, DOI 10.1007/978-3-211-85578-2_12; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Baumann N, 2001, PHYSIOL REV, V81, P871; Bolanos JP, 2009, ADV DRUG DELIVER REV, V61, P1299, DOI 10.1016/j.addr.2009.05.009; Brand MD, 2005, CELL METAB, V2, P85, DOI 10.1016/j.cmet.2005.06.002; Brightwell JJ, 2009, NEUROSCIENCE, V160, P174, DOI 10.1016/j.neuroscience.2009.02.023; CARTA A, 1991, ANN NY ACAD SCI, V640, P228; Chang J., 2013, CHANGHUA J MED, V11, P8; Chang JC, 2016, TRANSL RES, V170, P40, DOI 10.1016/j.trsl.2015.12.003; Chang JC, 2013, NEUROSIGNALS, V21, P160, DOI 10.1159/000341981; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; CLARK MA, 1982, NATURE, V295, P605, DOI 10.1038/295605a0; Cowan DB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160889; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; Fernandez-Vizarra E, 2011, MITOCHONDRION, V11, P207, DOI 10.1016/j.mito.2010.09.011; Garg AD, 2010, BBA-REV CANCER, V1805, P53, DOI 10.1016/j.bbcan.2009.08.003; Gollihue JL, 2017, MITOCHONDRION, V35, P70, DOI 10.1016/j.mito.2017.05.007; Gollihue JL, 2017, J NEUROSCI METH, V287, P1, DOI 10.1016/j.jneumeth.2017.05.023; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hamilton Nicola B, 2010, Front Neuroenergetics, V2, DOI 10.3389/fnene.2010.00005; Hayakawa K, 2016, NATURE, V535, P551, DOI 10.1038/nature18928; Hou SP, 2008, J COMP NEUROL, V509, P382, DOI 10.1002/cne.21771; Ide T, 2001, CIRC RES, V88, P529, DOI 10.1161/01.RES.88.5.529; Intondi AB, 2008, PAIN, V137, P352, DOI 10.1016/j.pain.2007.09.016; Islam MN, 2012, NAT MED, V18, P759, DOI 10.1038/nm.2736; Rodriguez-Jimenez FJ, 2012, STEM CELLS, V30, P2221, DOI 10.1002/stem.1189; Jin H, 2014, BBA-MOL BASIS DIS, V1842, P1282, DOI 10.1016/j.bbadis.2013.09.007; Jin Y, 2004, J NEUROTRAUM, V21, P1396, DOI 10.1089/neu.2004.21.1396; Katrangi E, 2007, REJUV RES, V10, P561, DOI 10.1089/rej.2007.0575; Kaza AK, 2017, J THORAC CARDIOV SUR, V153, P934, DOI 10.1016/j.jtcvs.2016.10.077; Koyanagi M, 2005, CIRC RES, V96, P1039, DOI 10.1161/01.RES.0000168650.23479.0c; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Laird MD, 2013, TRANSL STROKE RES, V4, P643, DOI 10.1007/s12975-013-0275-0; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Liu JK, 2002, P NATL ACAD SCI USA, V99, P2356, DOI 10.1073/pnas.261709299; Magnuson DSK, 2005, J NEUROTRAUM, V22, P529, DOI 10.1089/neu.2005.22.529; Maragos WF, 2003, BRAIN RES, V966, P312, DOI 10.1016/S0006-8993(02)04225-7; Markiewicz I, 2006, ACTA NEUROBIOL EXP, V66, P343; Masuzawa A, 2013, AM J PHYSIOL-HEART C, V304, pH966, DOI 10.1152/ajpheart.00883.2012; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; McCully JD, 2017, MITOCHONDRION, V34, P127, DOI 10.1016/j.mito.2017.03.004; McCully JD, 2009, AM J PHYSIOL-HEART C, V296, pH94, DOI 10.1152/ajpheart.00567.2008; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; MIZUNO Y, 1989, BIOCHEM BIOPH RES CO, V163, P1450, DOI 10.1016/0006-291X(89)91141-8; Muramatsu R, 2014, NEUROSCI RES, V81-82, P38, DOI 10.1016/j.neures.2014.01.007; Pacak CA, 2015, BIOL OPEN, V4, P622, DOI 10.1242/bio.201511478; Pandya JD, 2014, EXP NEUROL, V257, P106, DOI 10.1016/j.expneurol.2014.04.020; Patel SP, 2012, NEUROSCIENCE, V210, P296, DOI 10.1016/j.neuroscience.2012.03.006; Patel SP, 2014, EXP NEUROL, V257, P95, DOI 10.1016/j.expneurol.2014.04.026; Patel SP, 2010, J NEUROCHEM, V114, P291, DOI 10.1111/j.1471-4159.2010.06764.x; Patel SP, 2009, J NEUROSCI RES, V87, P130, DOI 10.1002/jnr.21814; PETRUZZELLA V, 1992, ARCH GERONTOL GERIAT, V14, P131, DOI 10.1016/0167-4943(92)90048-9; PUCA FM, 1990, INT J CLIN PHARM RES, V10, P139; Rabchevsky AG, 2002, J NEUROSCI RES, V68, P7, DOI 10.1002/jnr.10187; Rabchevsky AG, 2001, J NEUROTRAUM, V18, P513, DOI 10.1089/089771501300227314; Robb EL, 2008, BIOCHEM BIOPH RES CO, V372, P254, DOI 10.1016/j.bbrc.2008.05.028; Rowland JW, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E2; Sauerbeck A, 2011, J NEUROSCI METH, V198, P36, DOI 10.1016/j.jneumeth.2011.03.007; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Schwartz M, 2003, J CEREBR BLOOD F MET, V23, P385, DOI 10.1097/01.WCB.0000061881.75234.5E; Sheu SS, 2006, BBA-MOL BASIS DIS, V1762, P256, DOI 10.1016/j.bbadis.2005.10.007; Shi XX, 2017, MITOCHONDRION, V34, P91, DOI 10.1016/j.mito.2017.02.005; Smith RAJ, 2008, ANN NY ACAD SCI, V1147, P105, DOI 10.1196/annals.1427.003; Sullivan PG, 2007, J NEUROTRAUM, V24, P991, DOI 10.1089/neu.2006.0242; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Swerdlow RH, 2004, MED HYPOTHESES, V63, P8, DOI 10.1016/j.mehy.2003.12.045; Tata M, 2015, MECH DEVELOP, V138, P26, DOI 10.1016/j.mod.2015.07.001; Ungvari Z, 2009, AM J PHYSIOL-HEART C, V297, pH1876, DOI 10.1152/ajpheart.00375.2009; Wang X, 2015, CELL DEATH DIFFER, V22, P1181, DOI 10.1038/cdd.2014.211; Winkler EA, 2011, NAT NEUROSCI, V14, P1398, DOI 10.1038/nn.2946; Winklhofer KF, 2010, BBA-MOL BASIS DIS, V1802, P29, DOI 10.1016/j.bbadis.2009.08.013; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xiong YQ, 2009, EXP NEUROL, V216, P105, DOI 10.1016/j.expneurol.2008.11.025	76	39	40	2	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2018	35	15					1800	1818		10.1089/neu.2017.5605		APR 2018	19	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GL8IW	WOS:000431110300001	29648982	Green Published			2021-06-18	
J	Churchill, NW; Hutchison, MG; Richards, D; Leung, G; Graham, SJ; Schweizer, TA				Churchill, Nathan W.; Hutchison, Michael G.; Richards, Doug; Leung, General; Graham, Simon J.; Schweizer, Tom A.			Neuroimaging of sport concussion: persistent alterations in brain structure and function at medical clearance	SCIENTIFIC REPORTS			English	Article							PARTIAL LEAST-SQUARES; DEFAULT-MODE NETWORK; RESTING-STATE FMRI; RECURRENT CONCUSSION; FOOTBALL PLAYERS; INJURY; METAANALYSIS; INDIVIDUALS; RECOVERY; GENDER	The medical decision of return to play (RTP) after a sport concussion is largely based on symptom status following a graded exercise protocol. However, it is currently unknown how objective markers of brain structure and function relate to clinical recovery. The goal of this study was to determine whether differences in brain structure and function at acute injury remain present at RTP. In this longitudinal study, 54 active varsity athletes were scanned using magnetic resonance imaging (MRI), including 27 with recent concussion, imaged at both acute injury and medical clearance, along with 27 matched controls. Diffusion tensor imaging was used to measure fractional anisotropy (FA) and mean diffusivity (MD) of white matter and resting-state functional MRI was used to measure global functional connectivity (Gconn). At acute injury, concussed athletes had reduced FA and increased MD, along with elevated Gconn; these effects remained present at RTP. Athletes who took longer to reach RTP also showed elevated Gconn in dorsal brain regions, but no significant white matter effects. This study presents the first evidence of altered brain structure and function at the time of medical clearance to RTP, with greater changes in brain function for athletes with a longer recovery time.	[Churchill, Nathan W.; Schweizer, Tom A.] St Michaels Hosp, Neurosci Res Program, Toronto, ON, Canada; [Churchill, Nathan W.; Hutchison, Michael G.; Leung, General; Schweizer, Tom A.] St Michaels Hosp, Keenan Res Ctr Biomed Sci, Toronto, ON, Canada; [Hutchison, Michael G.; Richards, Doug] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Leung, General] Univ Toronto, Dept Med Imaging, Toronto, ON, Canada; [Graham, Simon J.] Univ Toronto, Sunnybrook Hosp, Dept Med Biophys, Toronto, ON, Canada; [Graham, Simon J.] Sunnybrook Res Inst, Sunnybrook Hlth Sci Ctr, Phys Sci Platform, Toronto, ON, Canada; [Schweizer, Tom A.] Univ Toronto, Fac Med Neurosurg, Toronto, ON, Canada	Churchill, NW (corresponding author), St Michaels Hosp, Neurosci Res Program, Toronto, ON, Canada.; Churchill, NW (corresponding author), St Michaels Hosp, Keenan Res Ctr Biomed Sci, Toronto, ON, Canada.	nchurchill.research@gmail.com			Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [RN294001-367456]; Defence Research and Development Canada (DRDC); Canadian Institutes of Military and Veterans Health (CIMVHR) [W7714-145967]; Siemens Canada, Ltd.	This work was supported by the Canadian Institutes of Health Research (CIHR) [grant number RN294001-367456]; the Defence Research and Development Canada (DRDC) and the Canadian Institutes of Military and Veterans Health (CIMVHR) [grant number W7714-145967]; and pilot funding from Siemens Canada, Ltd.	Abrahams S, 2014, BRIT J SPORT MED, V48, P91, DOI 10.1136/bjsports-2013-092734; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Binder JR, 2009, CEREB CORTEX, V19, P2767, DOI 10.1093/cercor/bhp055; Churchill N., 2016, J NEUROTRAU IN PRESS; Churchill N., 2016, BRAIN INJUR IN PRESS; Churchill NW, 2017, NEUROIMAGE-CLIN, V14, P480, DOI 10.1016/j.nicl.2017.02.015; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Derrfuss J, 2005, HUM BRAIN MAPP, V25, P22, DOI 10.1002/hbm.20127; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Giza CC, 2001, J ATHL TRAINING, V36, P228; Grefkes C, 2014, LANCET NEUROL, V13, P206, DOI 10.1016/S1474-4422(13)70264-3; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hillary FG, 2015, NEUROPSYCHOLOGY, V29, P59, DOI 10.1037/neu0000110; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Krishnan A, 2011, NEUROIMAGE, V56, P455, DOI 10.1016/j.neuroimage.2010.07.034; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Marmarou A, 2007, NEUROSURG FOCUS, V22, pE1, DOI DOI 10.3171/F0C.2007.22.5.2; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McIntosh AR, 2004, NEUROIMAGE, V23, P764, DOI 10.1016/j.neuroimage.2004.05.018; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Rosipal R, 2006, LECT NOTES COMPUT SC, V3940, P34, DOI 10.1007/11752790_2; Sasaki Takeshi, 2014, J Neurosurg, V120, P882, DOI 10.3171/2013.12.JNS132092; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; van den Heuvel MP, 2010, EUR NEUROPSYCHOPHARM, V20, P519, DOI 10.1016/j.euroneuro.2010.03.008; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Yuh Esther L, 2014, Neurosurgery, V75 Suppl 4, pS50, DOI 10.1227/NEU.0000000000000491; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413	39	39	39	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	AUG 24	2017	7								8297	10.1038/s41598-017-07742-3			9	Multidisciplinary Sciences	Science & Technology - Other Topics	FE8FC	WOS:000408440000001	28839132	DOAJ Gold, Green Published			2021-06-18	
J	Schwedt, TJ; Chong, CD; Peplinski, J; Ross, K; Berisha, V				Schwedt, Todd J.; Chong, Catherine D.; Peplinski, Jacob; Ross, Katherine; Berisha, Visar			Persistent post-traumatic headache vs. migraine: an MRI study demonstrating differences in brain structure	JOURNAL OF HEADACHE AND PAIN			English	Article						Post-traumatic headache; Migraine; Traumatic brain injury; Magnetic resonance imaging; Brain structure; Brain volume; Brain curvature; Brain surface area; Cortical thickness	MEDICATION-OVERUSE HEADACHE; FUNCTIONAL CONNECTIVITY; PAIN SENSITIVITY; RESTING-STATE; SEGMENTATION; ACCURATE; TRAUMA	Background: The majority of individuals with post-traumatic headache have symptoms that are indistinguishable from migraine. The overlap in symptoms amongst these individuals raises the question as to whether post-traumatic headache has a unique pathophysiology or if head trauma triggers migraine. The objective of this study was to compare brain structure in individuals with persistent post-traumatic headache (i.e. headache lasting at least 3 months following a traumatic brain injury) attributed to mild traumatic brain injury to that of individuals with migraine. Methods: Twenty-eight individuals with persistent post-traumatic headache attributed to mild traumatic brain injury and 28 individuals with migraine underwent brain magnetic resonance imaging on a 3 T scanner. Regional volumes, cortical thickness, surface area and curvature measurements were calculated from T1-weighted sequences and compared between subject groups using ANCOVA. MRI data from 28 healthy control subjects were used to interpret the differences in brain structure between migraine and persistent post-traumatic headache. Results: Differences in regional volumes, cortical thickness, surface area and brain curvature were identified when comparing the group of individuals with persistent post-traumatic headache to the group with migraine. Structure was different between groups for regions within the right lateral orbitofrontal lobe, left caudal middle frontal lobe, left superior frontal lobe, left precuneus and right supramarginal gyrus (p < .05). Considering these regions only, there were differences between individuals with persistent post-traumatic headache and healthy controls within the right lateral orbitofrontal lobe, right supramarginal gyrus, and left superior frontal lobe and no differences when comparing the migraine cohort to healthy controls. Conclusions: In conclusion, persistent post-traumatic headache and migraine are associated with differences in brain structure, perhaps suggesting differences in their underlying pathophysiology. Additional studies are needed to further delineate similarities and differences in brain structure and function that are associated with post-traumatic headache and migraine and to determine their specificity for each of the headache types.	[Schwedt, Todd J.; Chong, Catherine D.] Mayo Clin Arizona, 5777 East Mayo Blvd, Phoenix, AZ 85255 USA; [Ross, Katherine] Phoenix VA Hlth Care Syst, Phoenix, AZ USA; [Chong, Catherine D.; Peplinski, Jacob; Berisha, Visar] Arizona State Univ, Phoenix, AZ USA	Schwedt, TJ (corresponding author), Mayo Clin Arizona, 5777 East Mayo Blvd, Phoenix, AZ 85255 USA.	Schwedt.todd@mayo.edu		Berisha, Visar/0000-0001-8804-8874	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIH K23NS070891]; Office of the Assistant Secretary of Defense for Health Affairs, through the Peer Reviewed Medical Research Program [W81XWH-15-1-0286]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS070891] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (NIH) grant NIH K23NS070891 and by the Office of the Assistant Secretary of Defense for Health Affairs, through the Peer Reviewed Medical Research Program under Award No. W81XWH-15-1-0286. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense. The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office.	Beck AT., 1996, BECK DEPRESSION INVE, V2; Becker S, 2012, NEUROSCI LETT, V520, P182, DOI 10.1016/j.neulet.2012.03.013; Chanraud S, 2014, CEPHALALGIA, V34, P605, DOI 10.1177/0333102413519514; Chiapparini L, 2009, NEUROL SCI, V30, pS71, DOI 10.1007/s10072-009-0077-z; Chou KH, 2016, CEPHALALGIA; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Emerson NM, 2014, PAIN, V155, P566, DOI 10.1016/j.pain.2013.12.004; Erickson JC, 2011, HEADACHE, V51, P932, DOI 10.1111/j.1526-4610.2011.01909.x; Eskridge SL, 2012, INJURY, V43, P1678, DOI 10.1016/j.injury.2012.05.027; Ferraro S, 2012, PAIN MED, V13, P255, DOI 10.1111/j.1526-4637.2011.01183.x; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Goffaux P, 2014, BRAIN TOPOGR, V27, P366, DOI 10.1007/s10548-013-0291-0; Gronenschild EHBM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038234; Jia ZH, 2017, NEUROIMAGE-CLIN, V14, P130, DOI 10.1016/j.nicl.2017.01.019; Jin CW, 2013, NMR BIOMED, V26, P58, DOI 10.1002/nbm.2819; King JB, 2016, NEUROIMAGE-CLIN, V11, P81, DOI 10.1016/j.nicl.2016.01.003; Kong J, 2006, HUM BRAIN MAPP, V27, P715, DOI 10.1002/hbm.20213; Lamm C, 2011, NEUROIMAGE, V54, P2492, DOI 10.1016/j.neuroimage.2010.10.014; Meier TB, 2016, J NEUROTRAUM, V33, P330, DOI 10.1089/neu.2015.3919; Michels L, 2017, CEPHALALGIA, V37, P764, DOI 10.1177/0333102416652625; Moulton EA, 2012, J NEUROSCI, V32, P6024, DOI 10.1523/JNEUROSCI.0006-12.2012; Obermann M, 2009, NEUROLOGY, V73, P978, DOI 10.1212/WNL.0b013e3181b8791a; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Sarmento E, 2009, HEADACHE, V49, P1345, DOI 10.1111/j.1526-4610.2009.01494.x; Schwedt TJ, 2017, HEADACHE, V57, P1051, DOI 10.1111/head.13121; Schwedt TJ, 2017, HEADACHE, V57, P1173, DOI 10.1111/head.13037; Schwedt TJ, 2015, HEADACHE, V55, P762, DOI 10.1111/head.12584; Schwedt TJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099791; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Spielberger CD, 1983, STATE TRAIT ANXIETY; Spielberger CD., 1989, MANUAL STATE TRAIT A, V2; Sussman D, 2017, NEUROSCI LETT, V650, P52, DOI 10.1016/j.neulet.2017.04.026; Tessitore A, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-89; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Xue T, 2013, NMR BIOMED, V26, P1051, DOI 10.1002/nbm.2917; Yang FC, 2015, J NEUROL NEUROSUR PS, V86, P437, DOI 10.1136/jnnp-2014-308122; Zhang JL, 2016, J HEADACHE PAIN, V17, DOI 10.1186/s10194-016-0692-z	41	39	39	0	10	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1129-2369	1129-2377		J HEADACHE PAIN	J. Headache Pain	AUG 22	2017	18								87	10.1186/s10194-017-0796-0			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	FE3UZ	WOS:000408142500002	28831776	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Hislop, MD; Stokes, KA; Williams, S; Mckay, CD; England, ME; Kemp, SPT; Trewartha, G				Hislop, Michael D.; Stokes, Keith A.; Williams, Sean; Mckay, Carly D.; England, Mike E.; Kemp, Simon P. T.; Trewartha, Grant			Reducing musculoskeletal injury and concussion risk in schoolboy rugby players with a pre-activity movement control exercise programme: a cluster randomised controlled trial	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							LOWER-LIMB INJURIES; CERVICAL RANGE; SPORTS INJURY; WARM-UP; TRAINING-PROGRAM; YOUTH FOOTBALL; HOCKEY PLAYERS; PREVENTION; UNION; STRATEGIES	Background Injury risk in youth rugby has received much attention, highlighting the importance of establishing evidence-based injury reduction strategies. Aim To determine the efficacy of a movement control exercise programme in reducing injuries in youth rugby players and to investigate the effect of programme dose on injury measures. Methods In a cluster-randomised controlled trial, 40 independent schools (118 teams, 3188 players aged 14-18 years) were allocated to receive either the intervention or a reference programme, both of which were to be delivered by school coaches. The intervention comprised balance training, whole-body resistance training, plyometric training, and controlled rehearsal of landing and cutting manoeuvres. Time-loss (> 24 hours) injuries arising from school rugby matches were recorded by coaches and medical staff. Results 441 time-loss match injuries (intervention, 233; control, 208) were reported across 15 938 match exposure-hours (intervention, 9083; control, 6855). Intention-to-treat results indicated unclear effects of trial arm on overall match injury incidence (rate ratio (RR)=0.85, 90% confidence limits 0.61 to 1.17), although clear reductions were evident in the intervention arm for concussion incidence (RR=0.71, 0.48 to 1.05). When trial arm comparisons were limited to teams who had completed three or more weekly programme sessions on average, clear reductions in overall match injury incidence (RR=0.28, 0.14 to 0.51) and concussion incidence (RR=0.41, 0.17 to 0.99) were noted in the intervention group. Conclusion A preventive movement control exercise programme can reduce match injury outcomes, including concussion, in schoolboy rugby players when compared with a standardised control exercise programme, although to realise the greatest effects players should complete the programme at least three times per week.	[Hislop, Michael D.; Stokes, Keith A.; Williams, Sean; Mckay, Carly D.; Trewartha, Grant] Univ Bath, Dept Hlth, Bath BA2 7AY, Avon, England; [England, Mike E.; Kemp, Simon P. T.] Rugby Football Union, Twickenham, England	Stokes, KA (corresponding author), Univ Bath, Dept Hlth, Bath BA2 7AY, Avon, England.	k.stokes@bath.ac.uk	Hislop, Michael David/I-2339-2019; Stokes, Keith/C-2605-2009	Stokes, Keith/0000-0002-5049-2838; Williams, Sean/0000-0003-1460-0085; Kemp, Simon/0000-0002-3250-2713; McKay, Carly/0000-0001-7664-3211			Andersson SH, 2016, BR J SPORTS MED; Archbold HA, 2017, BR J SPORTS MED, V51; Batten J, 2016, BRIT J SPORT MED, V50, P1293, DOI 10.1136/bjsports-2015-095949; Batterham AM, 2006, INTJ SPORT PHYSIOL, V1, P50, DOI 10.1123/ijspp.1.1.50; Benson BW, 2013, BRIT J SPORT MED, V47, P321, DOI 10.1136/bjsports-2013-092216; Bleakley C, 2011, J ATHL TRAINING, V46, P555; Brooks JHM, 2008, CLIN SPORT MED, V27, P51, DOI 10.1016/j.csm.2007.09.001; Carter M, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h26; Collins CL, 2014, J PRIM PREV, V35, P309, DOI 10.1007/s10935-014-0355-2; Finch C, 2006, J SCI MED SPORT, V9, P3, DOI 10.1016/j.jsams.2006.02.009; Fortington LV, 2015, J SCI MED SPORT, V18, P272, DOI 10.1016/j.jsams.2014.05.001; Fuller CW, 2007, CLIN J SPORT MED, V17, P177, DOI 10.1097/JSM.0b013e31803220b3; Grooms DR, 2013, J ATHL TRAINING, V48, P782, DOI 10.4085/1062-6050-48.4.08; Hagglund M, 2013, BRIT J SPORT MED, V47, P974, DOI 10.1136/bjsports-2013-092644; Hamilton DF, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-004975; Hanson D, 2014, BRIT J SPORT MED, V48, P682, DOI 10.1136/bjsports-2012-091434; Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319; Herman K, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-75; Hislop M.D., 2016, BMJ OPEN SPORT EXERC, V2, P000043, DOI [10.1136/bmjsem-2015-000043, DOI 10.1136/BMJSEM-2015-000043]; Hopkins WG, 2016, SPORTSCI, V20; Hopkins WG, 2007, SPORTSCI, V11; Hopkins WG, 2010, SPORTSCI, V14; Impellizzeri FM, 2013, J SPORT SCI, V31, P1491, DOI 10.1080/02640414.2013.802926; Junge A, 2004, BRIT J SPORT MED, V38, P168, DOI 10.1136/bjsm.2002.003020; Lark SD, 2007, J SPORT SCI, V25, P887, DOI 10.1080/02640410600944543; Lark SD, 2010, J SPORT SCI, V28, P649, DOI 10.1080/02640411003631968; Lark SD, 2009, J SPORT SCI, V27, P491, DOI 10.1080/02640410802632136; Longo UG, 2012, AM J SPORT MED, V40, P996, DOI 10.1177/0363546512438761; Maconi F, 2016, SPORT SCI HLTH, V12, P443, DOI DOI 10.1007/s11332-016-0314-9; Maffulli N, 2010, BRIT J SPORT MED, V44, P21, DOI 10.1136/bjsm.2009.069526; Maffulli N, 2010, PHYSICIAN SPORTSMED, V38, P29, DOI 10.3810/psm.2010.06.1780; Niederbracht Y, 2008, J STRENGTH COND RES, V22, P140, DOI 10.1519/JSC.0b013e31815f5634; Ogaki R, 2014, INT J SPORT HLTH SCI, V12, P31; Owoeye OBA, 2014, J SPORT SCI MED, V13, P321; Palmer-Green DS, 2013, AM J SPORT MED, V41, P749, DOI 10.1177/0363546512473818; Patel DR, 2005, SPORTS MED, V35, P671, DOI 10.2165/00007256-200535080-00002; Pollock AM, 2016, BRIT J SPORT MED, V50, P963, DOI 10.1136/bjsports-2016-096220; Rae K, 2007, CLIN J SPORT MED, V17, P201, DOI 10.1097/JSM.0b013e318059b536; Schneider KJ, 2013, CLIN J SPORT MED, V23, P267, DOI 10.1097/JSM.0b013e318281f09f; Schneider KJ, 2010, BRIT J SPORT MED, V44, P1112, DOI 10.1136/bjsm.2009.071266; Schulz KF, 2010, ANN INTERN MED, V152, P726, DOI 10.7326/0003-4819-152-11-201006010-00232; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; Silvers-Granelli H, 2015, AM J SPORT MED, V43, P2628, DOI 10.1177/0363546515602009; Soligard T, 2010, BRIT J SPORT MED, V44, P787, DOI 10.1136/bjsm.2009.070672; Steffen K, 2010, EUR J SPORT SCI, V10, P223, DOI 10.1080/17461390903585173; Sugimoto D, 2016, BRIT J SPORT MED, V50, P1259, DOI 10.1136/bjsports-2015-095596; Sugimoto Dai, 2015, Curr Phys Med Rehabil Rep, V3, P43; Sugimoto D, 2014, SPORTS MED, V44, P551, DOI 10.1007/s40279-013-0135-9; Tucker R, 2016, BRIT J SPORT MED, V50, P921, DOI 10.1136/bjsports-2016-096322; Twomey D, 2009, J SCI MED SPORT, V12, P452, DOI 10.1016/j.jsams.2008.04.002	50	39	39	0	32	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2017	51	15					1140	+		10.1136/bjsports-2016-097434			8	Sport Sciences	Sport Sciences	FA9US	WOS:000405792300010	28515056	Other Gold, Green Published			2021-06-18	
J	Perez, EJ; Tapanes, SA; Loris, ZB; Balu, DT; Sick, TJ; Coyle, JT; Liebl, DJ				Perez, Enmanuel J.; Tapanes, Stephen A.; Loris, Zachary B.; Balu, Darrick T.; Sick, Thomas J.; Coyle, Joseph T.; Liebl, Daniel J.			Enhanced astrocytic D-serine underlies synaptic damage after traumatic brain injury	JOURNAL OF CLINICAL INVESTIGATION			English	Article							METHYL-D-ASPARTATE; NMDA RECEPTORS; HIPPOCAMPAL THETA; AMINO-ACIDS; RAT-BRAIN; RACEMASE; NEURONS; EXCITOTOXICITY; PLASTICITY; GLUTAMATE	After traumatic brain injury (TBI), glial cells have both beneficial and deleterious roles in injury progression and recovery. However, few studies have examined the influence of reactive astrocytes in the tripartite synapse following TBI. Here, we have demonstrated that hippocampal synaptic damage caused by controlled cortical impact (CCI) injury in mice results in a switch from neuronal to astrocytic D-serine release. Under nonpathological conditions, D-serine functions as a neurotransmitter and coagonist for NMDA receptors and is involved in mediating synaptic plasticity. The phasic release of neuronal D-serine is important in maintaining synaptic function, and deficiencies lead to reductions in synaptic function and plasticity. Following CCI injury, hippocampal neurons downregulated D-serine levels, while astrocytes enhanced production and release of D-serine. We further determined that this switch in the cellular source of D-serine, together with the release of basal levels of glutamate, contributes to synaptic damage and dysfunction. Astrocyte-specific elimination of the astrocytic D-serine-synthesizing enzyme serine racemase after CCI injury improved synaptic plasticity, brain oscillations, and learning behavior. We conclude that the enhanced tonic release of D-serine from astrocytes after TBI underlies much of the synaptic damage associated with brain injury.	[Perez, Enmanuel J.; Tapanes, Stephen A.; Loris, Zachary B.; Liebl, Daniel J.] Univ Miami, Miller Sch Med, Dept Neurosurg, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Balu, Darrick T.] McLean Hosp, Translat Psychiat Lab, 115 Mill St, Belmont, MA 02178 USA; [Sick, Thomas J.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA; [Coyle, Joseph T.] McLean Hosp, Lab Psychiat & Mol Neurosci, 115 Mill St, Belmont, MA 02178 USA	Liebl, DJ (corresponding author), Univ Miami, Miami Project Cure Paralysis, Neurol Surg, 1095 NW 14th Terrace,R-48, Miami, FL 33136 USA.	dliebl@miami.edu	Balu, Darrick/AAT-7454-2020	Balu, Darrick/0000-0003-3505-6832	Miami Project to Cure Paralysis, NIH [R01NS098740, K99MH099252, R00MH099252, R01MH05190, F31NS089335]; Lois Pope Life fellowship; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K99MH099252, R00MH099252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS098740, F31NS089335] Funding Source: NIH RePORTER	We thank Jennifer Brazill for critical reading of our manuscript, Maria Cepero for her experimental support, and Jose Mier for assistance with animal husbandry. We also thank Ken McCarthy for the generous donations of the human glial fibrillary acidic protein mice. This work was supported by the Miami Project to Cure Paralysis, NIH R01NS098740 (to DJL), K99MH099252 and R00MH099252 (to DTB), R01MH05190 (to JTC), F31NS089335, and the Lois Pope Life fellowship (to EJP).	ALBIN RL, 1992, NEUROLOGY, V42, P733, DOI 10.1212/WNL.42.4.733; Araque A, 1999, TRENDS NEUROSCI, V22, P208, DOI 10.1016/S0166-2236(98)01349-6; Araque A, 1998, J NEUROSCI, V18, P6822; Assis-Nascimento P, 2016, J NEUROSCI METH, V263, P57, DOI 10.1016/j.jneumeth.2016.01.025; Balu DT, 2014, CELL MOL NEUROBIOL, V34, P419, DOI 10.1007/s10571-014-0027-z; Benneyworth MA, 2012, CELL MOL NEUROBIOL, V32, P613, DOI 10.1007/s10571-012-9808-4; BLAND BH, 1986, PROG NEUROBIOL, V26, P1, DOI 10.1016/0301-0082(86)90019-5; Bland BH, 2016, HIPPOCAMPUS, V26, P289, DOI 10.1002/hipo.22521; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Casper KB, 2007, GENESIS, V45, P292, DOI 10.1002/dvg.20287; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; Chung K, 2013, NAT METHODS, V10, P508, DOI [10.1038/nmeth.2481, 10.1038/NMETH.2481]; Derkach VA, 2007, NAT REV NEUROSCI, V8, P101, DOI 10.1038/nrn2055; DeVito LM, 2011, GENES BRAIN BEHAV, V10, P210, DOI 10.1111/j.1601-183X.2010.00656.x; Erreger K, 2007, MOL PHARMACOL, V72, P907, DOI 10.1124/mol.107.037333; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fedor M, 2010, J NEUROTRAUM, V27, P1605, DOI 10.1089/neu.2010.1370; Furman JL, 2016, J NEUROSCI, V36, P1502, DOI 10.1523/JNEUROSCI.1930-15.2016; Guo JD, 2005, NEUROSCI LETT, V384, P245, DOI 10.1016/j.neulet.2005.04.096; HABLITZ JJ, 1986, J NEUROSCI, V6, P102; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hardingham GE, 2010, NAT REV NEUROSCI, V11, P682, DOI 10.1038/nrn2911; HASHIMOTO A, 1992, FEBS LETT, V296, P33, DOI 10.1016/0014-5793(92)80397-Y; Hassanpoor H, 2014, CELL BIOL INT, V38, P1355, DOI 10.1002/cbin.10326; Ikonomidou C, 1995, CURR OPIN NEUROL, V8, P487, DOI 10.1097/00019052-199512000-00017; Inoue R, 2008, J NEUROSCI, V28, P14486, DOI 10.1523/JNEUROSCI.5034-08.2008; Kartvelishvily E, 2006, J BIOL CHEM, V281, P14151, DOI 10.1074/jbc.M512927200; Katsuki H, 2004, J PHARMACOL EXP THER, V311, P836, DOI 10.1124/jpet.104.070912; Korotkova T, 2010, NEURON, V68, P557, DOI 10.1016/j.neuron.2010.09.017; Le Bail M, 2015, P NATL ACAD SCI USA, V112, pE204, DOI 10.1073/pnas.1416668112; MATSUI T, 1995, J NEUROCHEM, V65, P454; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Miya K, 2008, J COMP NEUROL, V510, P641, DOI 10.1002/cne.21822; Mustafa AK, 2010, J NEUROSCI, V30, P1413, DOI 10.1523/JNEUROSCI.4297-09.2010; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Paoletti P, 2013, NAT REV NEUROSCI, V14, P383, DOI 10.1038/nrn3504; Papouin T, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0601; Papouin T, 2012, CELL, V150, P633, DOI 10.1016/j.cell.2012.06.029; Paterno R, 2016, J NEUROTRAUM, V33, P1645, DOI 10.1089/neu.2015.4107; Perea G, 2009, TRENDS NEUROSCI, V32, P421, DOI 10.1016/j.tins.2009.05.001; Perez EJ, 2016, NEUROBIOL DIS, V94, P73, DOI 10.1016/j.nbd.2016.06.007; Rosenberg D, 2013, J NEUROSCI, V33, P3533, DOI 10.1523/JNEUROSCI.3836-12.2013; Rosenberg D, 2010, FASEB J, V24, P2951, DOI 10.1096/fj.09-147967; Santello M, 2012, ADV EXP MED BIOL, V970, P307, DOI 10.1007/978-3-7091-0932-8_14; SCHELL MJ, 1995, P NATL ACAD SCI USA, V92, P3948, DOI 10.1073/pnas.92.9.3948; Schell MJ, 1997, J NEUROSCI, V17, P1604; Shleper M, 2005, J NEUROSCI, V25, P9413, DOI 10.1523/JNEUROSCI.3190-05.2005; Theus MH, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.165; Tomer R, 2014, NAT PROTOC, V9, P1682, DOI 10.1038/nprot.2014.123; Traynelis SF, 2010, PHARMACOL REV, V62, P405, DOI 10.1124/pr.109.002451; Tyzack GE, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5294; Warren KM, 2012, J NEUROTRAUM, V29, P1922, DOI 10.1089/neu.2012.2383; Wirkner K, 2007, CEREB CORTEX, V17, P621, DOI 10.1093/cercor/bhk012; Wolosker H, 1999, P NATL ACAD SCI USA, V96, P13409, DOI 10.1073/pnas.96.23.13409; Wolosker H, 1999, P NATL ACAD SCI USA, V96, P721, DOI 10.1073/pnas.96.2.721; Wolosker H, 2016, TRENDS NEUROSCI, V39, P712, DOI 10.1016/j.tins.2016.09.007	59	39	40	0	4	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA	0021-9738	1558-8238		J CLIN INVEST	J. Clin. Invest.	AUG 1	2017	127	8					3114	3125		10.1172/JCI92300			12	Medicine, Research & Experimental	Research & Experimental Medicine	FC2PD	WOS:000406679500023	28714867	Bronze, Green Published			2021-06-18	
J	Mac Donald, CL; Johnson, AM; Wierzechowski, L; Kassner, E; Stewart, T; Nelson, EC; Werner, NJ; Adam, OR; Rivet, DJ; Flaherty, SF; Oh, JS; Zonies, D; Fang, R; Brody, DL				Mac Donald, Christine L.; Johnson, Ann M.; Wierzechowski, Linda; Kassner, Elizabeth; Stewart, Theresa; Nelson, Elliot C.; Werner, Nicole J.; Adam, Octavian R.; Rivet, Dennis J.; Flaherty, Stephen F.; Oh, John S.; Zonies, David; Fang, Raymond; Brody, David L.			Outcome Trends after US Military Concussive Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						blast TBI; clinical outcomes; concussive TBI; PTSD	POSTTRAUMATIC-STRESS-DISORDER; NEUROBEHAVIORAL RATING-SCALE; MENTAL-HEALTH PROBLEMS; HEAD-INJURY; STRUCTURED INTERVIEWS; COMBAT VETERANS; BLAST; SYMPTOMS; IRAQ; PERSONNEL	Care for US military personnel with combat-related concussive traumatic brain injury (TBI) has substantially changed in recent years, yet trends in clinical outcomes remain largely unknown. Our prospective longitudinal studies of US military personnel with concussive TBI from 2008-2013 at Landstuhl Regional Medical Center in Germany and twp sites in Afghanistan provided an opportunity to assess for changes in outcomes over time and analyze correlates of overall disability. We enrolled 321 active-duty US military personnel who sustained concussive TBI in theater and 254 military controls. We prospectively assessed clinical outcomes 6-12 months later in 199 with concussive TBI and 148 controls. Global disability, neurobehavioral impairment, depression severity, and post-traumatic stress disorder (PTSD) severity were worse in concussive TBI groups in comparison with controls in all cohorts. Global disability primarily reflected a combination of work-related and nonwork-related disability. There was a modest but statistically significant trend toward less PTSD in later cohorts. Specifically, there was a decrease of 5.9 points of 136 possible on the Clinician Administered PTSD Scale (-4.3%) per year (95% confidence interval, 2.8-9.0 points, p=0.0037 linear regression, p=0.03 including covariates in generalized linear model). No other significant trends in outcomes were found. Global disability was more common in those with TBI, those evacuated from theater, and those with more severe depression and PTSD. Disability was not significantly related to neuropsychological performance, age, education, self-reported sleep deprivation, injury mechanism, or date of enrollment. Thus, across multiple cohorts of US military personnel with combat-related concussion, 6-12 month outcomes have improved only modestly and are often poor. Future focus on early depression and PTSD after concussive TBI appears warranted. Adverse outcomes are incompletely explained, however, and additional studies with prospective collection of data on acute injury severity and polytrauma, as well as reduced attrition before follow-up will be required to fully address the root causes of persistent disability after wartime injury.	[Mac Donald, Christine L.; Johnson, Ann M.; Nelson, Elliot C.; Werner, Nicole J.; Brody, David L.] Washington Univ, Sch Med, St Louis, MO USA; [Mac Donald, Christine L.] Univ Washington, Dept Neurol Surg, 325 9th Ave,Box 359924, Seattle, WA 98104 USA; [Wierzechowski, Linda; Kassner, Elizabeth; Stewart, Theresa; Flaherty, Stephen F.; Oh, John S.; Zonies, David; Fang, Raymond] Landstuhl Reg Med Ctr, Landstuhl, Germany; [Adam, Octavian R.; Rivet, Dennis J.] Naval Med Ctr Portsmouth, Portsmouth, VA USA; [Adam, Octavian R.] Berkshire Med Ctr, Med Ctr, Pittsfield, MA USA; [Rivet, Dennis J.] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA; [Flaherty, Stephen F.] Acute Surg Care Specialists, El Paso, TX USA; [Oh, John S.] Walter Reed Natl Mil Med Ctr, Crit Care & Acute Care Surg, Bethesda, MD USA; [Zonies, David] Oregon Hlth & Sci Univ, Trauma & Crit Care, Portland, OR 97201 USA; [Fang, Raymond] Univ Maryland, R Adams Cowley Shock Trauma Ctr, US Air Force Ctr Sustainment Trauma & Readiness S, Baltimore, MD 21201 USA	Mac Donald, CL (corresponding author), Univ Washington, Dept Neurol Surg, 325 9th Ave,Box 359924, Seattle, WA 98104 USA.; Brody, DL (corresponding author), Washington Univ, Dept Neurol, 660 S Euclid Ave,Box 8111, St Louis, MO 63110 USA.	cmacd@uw.edu; brodyd@neuro.wustl.edu	Oh, John/AAS-9557-2020; Zonies, David/B-6497-2011	Oh, John/0000-0001-9010-0627; 	Congressionally Directed Medical Research ProgramUnited States Department of Defense; Defense Advanced Research Projects AgencyUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	Funded by grants from the Congressionally Directed Medical Research Program and Defense Advanced Research Projects Agency (DLB) with additional support from NIH fellowships to CLM and DLB. The funding agencies played no role in the acquisition, analysis, or interpretation of the data.	AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; [Anonymous], 1999, J Clin Psychiatry, V60 Suppl 16, P3; Attari A, 2014, J RES MED SCI, V19, P592; Benton AL, 1983, MULTILINGUAL APHASIA; Boyle Eleanor, 2014, Arch Phys Med Rehabil, V95, pS230, DOI 10.1016/j.apmr.2013.08.297; Castro CA, 2014, EUR J PSYCHOTRAUMATO, V5, DOI 10.3402/ejpt.v5.24713; Chapman JC, 2014, ALZHEIMERS DEMENT, V10, pS97, DOI 10.1016/j.jalz.2014.04.012; Conners C., 2000, CONNERS CONTINUOUS P; Delis DC, 2000, CALIFORNIA VERBAL LE; Dempsey Kenneth E, 2009, J Trauma Nurs, V16, P6, DOI 10.1097/01.JTN.0000348063.41099.a7; Eskridge SL, 2013, J NEUROTRAUM, V30, P1391, DOI 10.1089/neu.2012.2537; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Galea S, 2012, TREATMENT POSTTRAUMA; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Helmick KM, 2015, BRAIN IMAGING BEHAV, V9, P358, DOI 10.1007/s11682-015-9399-z; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Isoniemi H, 2006, J NEUROTRAUM, V23, P1600, DOI 10.1089/neu.2006.23.1600; Jeffreys M., 2014, CLIN GUIDE MEDICATIO; Karlin BE, 2010, J TRAUMA STRESS, V23, P663, DOI 10.1002/jts.20588; Kennedy JE, 2010, NEUROREHABILITATION, V26, P191, DOI 10.3233/NRE-2010-0555; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; Lynn W. J., 2010, POLICY GUIDANCE MANA; Mac Donald CL, 2015, BRAIN, V138, P1314, DOI 10.1093/brain/awv038; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MacDonald Christine L, 2014, J Neurotrauma, V31, P889, DOI 10.1089/neu.2013.3173; Matthews C, 1964, INSTRUCTION MANUAL A; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Raskind MA, 2003, AM J PSYCHIAT, V160, P371, DOI 10.1176/appi.ajp.160.2.371; Raskind MA, 2007, BIOL PSYCHIAT, V61, P928, DOI 10.1016/j.biopsych.2006.06.032; Reid MW, 2014, J NEUROTRAUM, V31, P1899, DOI 10.1089/neu.2014.3455; Reitan R. M., 1992, TRAIL MAKING TEST MA; Rutherford G., 2009, IOM I MED LONG TERM, V7; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Shalev AY, 2012, ARCH GEN PSYCHIAT, V69, P166, DOI 10.1001/archgenpsychiatry.2011.127; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Verfaellie M, 2013, J INT NEUROPSYCH SOC, V19, P1, DOI 10.1017/S1355617712000902; Warner CH, 2011, ARCH GEN PSYCHIAT, V68, P1065, DOI 10.1001/archgenpsychiatry.2011.112; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wechsler D., 2001, WECHSLER TEST ADULT; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wood RLI, 2006, J NEUROL NEUROSUR PS, V77, P1180, DOI 10.1136/jnnp.2006.091553; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080; Zatzick D, 2004, ARCH GEN PSYCHIAT, V61, P498, DOI 10.1001/archpsyc.61.5.498	56	39	39	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 15	2017	34	14					2206	2219		10.1089/neu.2016.4434			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EZ8RQ	WOS:000404995000003	27198861	Green Published			2021-06-18	
J	Li, D; Liu, N; Zhao, HH; Zhang, X; Kawano, H; Liu, L; Zhao, L; Li, HP				Li, Dan; Liu, Nan; Zhao, Hai-Hua; Zhang, Xu; Kawano, Hitoshi; Liu, Lu; Zhao, Liang; Li, Hong-Peng			Interactions between Sirt1 and MAPKs regulate astrocyte activation induced by brain injury in vitro and in vivo	JOURNAL OF NEUROINFLAMMATION			English	Article						Brain injury; Sirt1; ERK pathway; JNK pathway; p38MAPK pathway; Astrocyte activation	FIBRILLARY ACIDIC PROTEIN; KINASE SIGNALING PATHWAY; OXIDATIVE STRESS; MITOCHONDRIAL-FUNCTION; HISTONE DEACETYLASE; REACTIVE GLIOSIS; NITRIC-OXIDE; P38 MAPK; INHIBITION; EXPRESSION	Background: Astrocyte activation is a hallmark of traumatic brain injury resulting in neurological dysfunction or death for an overproduction of inflammatory cytokines and glial scar formation. Both the silent mating type information (Sirt1) expression and mitogen-activated protein kinase ( MAPK) signal pathway activation represent a promising therapeutic target for several models of neurodegenerative diseases. We investigated the potential effects of Sirt1 upregulation and MAPK pathway pharmacological inhibition on astrocyte activation in vitro and in vivo. Moreover, we attempted to confirm the underlying interactions between Sirt1 and MAPK pathways in astrocyte activation after brain injury. Methods: The present study employs an interleukin-1 beta IL-1 beta) stimulated primary cortical astrocyte model in vitro and a nigrostriatal pathway injury model in vivo to mimic the astrocyte activation induced by traumatic brain injury. The activation of GFAP, Sirt1, and MAPK pathways were detected by Western blot; astrocyte morphological hypertrophy was assessed using immunofluorescence staining; in order to explore the neuroprotective effect of regulation Sirt1 expression and MAPK pathway activation, the motor and neurological function tests were assessed after injury. Results: GFAP level and morphological hypertrophy of astrocytes are elevated after injury in vitro or in vivo. Furthermore, the expressions of phosphorylated extracellular regulated protein kinases p-ERK), phosphorylated c-Jun N-terminal kinase p-JNK), and phosphorylated p38 activation p- p38) are upregulated, but the Sirt1 expression is downregulated. Overexpression of Sirt1 significantly increases the p- ERK expression and reduces the p-JNK and p- p38 expressions. Inhibition of ERK, JNK, or p38 activation respectively with their inhibitors significantly elevated the Sirt1 expression and attenuated the astrocyte activation. Both the overproduction of Sirt1 and inhibition of ERK, JNK, or p38 activation can alleviate the astrocyte activation, thereby improving the neurobehavioral function according to the modified neurological severity scores mNSS) and balance latency test. C onclusions: Thus, Sirt1 plays a protective role against astrocyte activation, which may be associated with the regulation of the MAPK pathway activation induced by brain injury in vitro and in vivo.	[Li, Dan; Liu, Nan; Zhao, Hai-Hua; Zhang, Xu; Liu, Lu; Zhao, Liang; Li, Hong-Peng] China Med Univ, Dept Human Anat, Coll Basic Med Sci, Shenyang, Peoples R China; [Kawano, Hitoshi] Teikyo Heisei Univ, Dept Hlth & Dietet, Fac Hlth & Med Sci, Tokyo 1708445, Japan	Li, HP (corresponding author), China Med Univ, Dept Human Anat, Coll Basic Med Sci, Shenyang, Peoples R China.	hpli@cmu.edu.cn			National Natural Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [NSFC-81171248]	This research was supported by the National Natural Science Foundation of China (NSFC) (belongs to Hong-Peng Li), Grant No: NSFC-81171248.	Armstead WM, 2012, NEUROL RES, V34, P530, DOI 10.1179/1743132812Y.0000000039; Armstead WM, 2011, NEUROL RES, V33, P726, DOI 10.1179/016164110X12807570509853; Becatti M, 2012, CELL MOL LIFE SCI, V69, P2245, DOI 10.1007/s00018-012-0925-5; Bellaver B, 2015, NEUROCHEM RES, V40, P1600, DOI 10.1007/s11064-015-1636-8; Burda JE, 2014, NEURON, V81, P229, DOI 10.1016/j.neuron.2013.12.034; Chang CF, 2011, AM J PATHOL, V178, P1749, DOI 10.1016/j.ajpath.2010.12.023; Chang HM, 2009, J PINEAL RES, V47, P211, DOI 10.1111/j.1600-079X.2009.00704.x; Chen CC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115694; Chen CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030294; Chen J, 2005, J BIOL CHEM, V280, P40364, DOI 10.1074/jbc.M509329200; Chen T, 2011, NEUROSCIENCE, V183, P203, DOI 10.1016/j.neuroscience.2011.03.038; Cheng YD, 2016, APOPTOSIS, V21, P905, DOI 10.1007/s10495-016-1258-x; Cheng Y, 2014, J NEUROIMMUNOL, V269, P38, DOI 10.1016/j.jneuroim.2014.02.001; Davis CHO, 2014, P NATL ACAD SCI USA, V111, P9633, DOI 10.1073/pnas.1404651111; Donmez G, 2012, TRENDS PHARMACOL SCI, V33, P494, DOI 10.1016/j.tips.2012.05.007; Donmez G, 2012, J NEUROSCI, V32, P124, DOI 10.1523/JNEUROSCI.3442-11.2012; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Falchi M, 2010, ARCH ITAL BIOL, V148, P389, DOI 10.4449/aib.v148i4.1241; GHIRNIKAR RS, 1994, J NEUROSCI RES, V38, P376, DOI 10.1002/jnr.490380403; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Guan QH, 2006, BRAIN RES, V1092, P36, DOI 10.1016/j.brainres.2006.03.086; Guerra B, 2004, J NEUROCHEM, V91, P99, DOI 10.1111/j.1471-4159.2004.02695.x; Guo WJ, 2011, J NEUROSCI RES, V89, P1723, DOI 10.1002/jnr.22725; Hisahara S, 2008, P NATL ACAD SCI USA, V105, P15599, DOI 10.1073/pnas.0800612105; Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293; Huang WY, 2015, J CELL PHYSIOL, V230, P2461, DOI 10.1002/jcp.24981; Jiang T, 2014, AGING CELL, V13, P1059, DOI 10.1111/acel.12268; Kawano H, 2005, J NEUROSCI RES, V80, P191, DOI 10.1002/jnr.20441; Kong LY, 1996, BRAIN RES, V729, P102, DOI 10.1016/0006-8993(96)00417-9; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Lee JH, 2009, DIABETES, V58, P344, DOI 10.2337/db07-1795; Lemieux ME, 2005, MECH AGEING DEV, V126, P1097, DOI 10.1016/j.mad.2005.04.006; Lennmyr F, 2003, ACTA NEUROL SCAND, V108, P339, DOI 10.1034/j.1600-0404.2003.00129.x; Li D, 2017, BRAIN RES, V1654, P1, DOI 10.1016/j.brainres.2016.10.013; Li D, 2016, BRAIN RES, V1648, P90, DOI 10.1016/j.brainres.2016.07.008; Li Y, 2008, CELL METAB, V8, P38, DOI 10.1016/j.cmet.2008.05.004; Luo CL, 2013, BRAIN RES, V1502, P1, DOI 10.1016/j.brainres.2013.01.037; Maragakis NJ, 2006, NAT CLIN PRACT NEURO, V2, P679, DOI 10.1038/ncpneuro0355; Martin A, 2015, IMMUNOL RES, V61, P187, DOI 10.1007/s12026-014-8557-5; Nemoto W, 2015, NEUROPHARMACOLOGY, V99, P221, DOI 10.1016/j.neuropharm.2015.07.022; Paraiso A, 2013, MOL NEUROBIOL, V48, P681, DOI 10.1007/s12035-013-8459-x; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Pekny M, 2004, J PATHOL, V204, P428, DOI 10.1002/path.1645; Pekny M, 2014, PHYSIOL REV, V94, P1077, DOI 10.1152/physrev.00041.2013; Pousset F, 1999, GLIA, V26, P12, DOI 10.1002/(SICI)1098-1136(199903)26:1<12::AID-GLIA2>3.0.CO;2-S; Pousset F, 2001, J NEUROCHEM, V79, P726, DOI 10.1046/j.1471-4159.2001.00569.x; Qu Y, 2012, NEUROSCI LETT, V525, P168, DOI 10.1016/j.neulet.2012.07.025; Ramadori G, 2008, J NEUROSCI, V28, P9989, DOI 10.1523/JNEUROSCI.3257-08.2008; Sakamoto J, 2004, FEBS LETT, V556, P281, DOI 10.1016/S0014-5793(03)01444-3; Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870; Shen T, 2013, INT J CARDIOL, V168, P3704, DOI 10.1016/j.ijcard.2013.06.018; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Sticozzi C, 2013, NEUROSCIENCE, V252, P367, DOI 10.1016/j.neuroscience.2013.07.061; Tang BL, 2008, MOL ASPECTS MED, V29, P187, DOI 10.1016/j.mam.2007.02.001; Voloboueva LA, 2007, J NEUROCHEM, V102, P1383, DOI 10.1111/j.1471-4159.2007.04634.x; Wang LW, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-175; Wang ZQ, 2004, BRAIN RES, V996, P55, DOI 10.1016/j.brainres.2003.09.074; Wei L, 2014, CLIN EXP PHARMACOL P, V41, P134, DOI 10.1111/1440-1681.12186; Wu CY, 2008, J NEUROCHEM, V105, P1499, DOI 10.1111/j.1471-4159.2008.05318.x; Yoshioka N, 2010, J COMP NEUROL, V518, P3867, DOI 10.1002/cne.22431; YU ACH, 1993, J NEUROSCI RES, V34, P295, DOI 10.1002/jnr.490340306; Zhang F, 2011, PROG NEUROBIOL, V95, P373, DOI 10.1016/j.pneurobio.2011.09.001; Zhao YB, 2012, EXP NEUROL, V237, P489, DOI 10.1016/j.expneurol.2012.07.004; Zhou XM, 2014, J NEUROSCI RES, V92, P714, DOI 10.1002/jnr.23359; Zhu W, 2016, IMMUNOPHARM IMMUNOT, V38, P205, DOI 10.3109/08923973.2016.1168433	67	39	44	2	6	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	MAR 29	2017	14								67	10.1186/s12974-017-0841-6			13	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	EP9BS	WOS:000397669300001	28356158	DOAJ Gold, Green Published			2021-06-18	
J	Saber, M; Kokiko-Cochran, O; Puntambekar, SS; Lathia, JD; Lamb, BT				Saber, Maha; Kokiko-Cochran, Olga; Puntambekar, Shweta S.; Lathia, Justin D.; Lamb, Bruce T.			Triggering Receptor Expressed on Myeloid Cells 2 Deficiency Alters Acute Macrophage Distribution and Improves Recovery after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						behavior; immunohistochemistry; inflammation; neurodegenerative disorders; traumatic brain injury	ALZHEIMERS-DISEASE; FRONTOTEMPORAL DEMENTIA; INFLAMMATORY RESPONSE; COGNITIVE DEFICITS; RISK-FACTOR; EX-VIVO; TREM2; MICROGLIA; PATHOLOGY; PATHOPHYSIOLOGY	Traumatic brain injury (TBI) affects 1.7 million persons annually in the United States (Centers for Disease Control and Prevention). There is increasing evidence that persons exposed to TBI have increased risk of the development of multiple neurodegenerative conditions, including Alzheimer disease (AD). TBI triggers a strong neuroinflammatory response characterized by astrogliosis, activation of microglia, and infiltration of peripheral monocytes. Recent evidence suggests that alterations in innate immunity promote neurodegeneration. This includes genetic studies demonstrating that mutations in triggering receptor expressed on myeloid cells 2 (TREM2) is associated with a higher risk for not only AD but also multiple neurodegenerative diseases. To examine whether TREM2 deficiency affects pathological outcomes of TBI, Trem2 knockout (Trem2(-/-)) and C57BL/6J (B6) mice were given a lateral fluid percussion injury (FPI) and sacrificed at 3 and 120 days post-injury (DPI) to look at both acute and chronic consequences of TREM2 deficiency. Notably, at 3 DPI, B6 mice exposed to TBI exhibited increased expression of TREM2 in the brain. Further, Trem2(-/-) mice exposed to TBI exhibited enhanced macrophage activation near the lesion, but significantly less macrophage activation away from the lesion when compared with B6 mice exposed to TBI. In addition, at 120 DPI, Trem2(-/-) mice exposed to TBI demonstrated reduced hippocampal atrophy and rescue of TBI-induced behavioral changes when compared with B6 mice exposed to TBI. Taken together, this study suggests that TREM2 deficiency influences both acute and chronic responses to TBI, leading to an altered macrophage response at early time points, and improved pathological and functional outcomes at later time points.	[Saber, Maha; Lamb, Bruce T.] Cleveland Clin, Dept Neurosci, Cleveland, OH 44106 USA; [Lathia, Justin D.] Cleveland Clin, Dept Cellular Mol Med, Cleveland, OH 44106 USA; [Saber, Maha] Case Western Reserve Univ, Dept Mol Med, Cleveland, OH 44106 USA; [Kokiko-Cochran, Olga; Puntambekar, Shweta S.; Lamb, Bruce T.] Stark Neurosci Res Inst, Indianapolis, IN USA	Lamb, BT (corresponding author), Indiana Univ Sch Med, Stark Neurosci Res Inst, Neurosci Bldg,Suite 414 320 W 15th St,NB Bldg, Indianapolis, IN 46202 USA.	btlamb@iu.edu			Department of DefenseUnited States Department of Defense [W81XWH-14-1-0265]	This work was supported by the Department of Defense (W81XWH-14-1-0265, Bruce Lamb).	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Bamberger ME, 2002, NEUROSCIENTIST, V8, P276, DOI 10.1177/1073858402008003013; Basiratnia Reza, 2015, Adv Biomed Res, V4, P192, DOI 10.4103/2277-9175.166153; Becher B, 1996, GLIA, V18, P1; Borroni B, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.09.017; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Breunig JJ, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00026; Cameron B, 2010, NEUROBIOL DIS, V37, P503, DOI 10.1016/j.nbd.2009.10.006; Chincarini A, 2016, NEUROIMAGE, V125, P834, DOI 10.1016/j.neuroimage.2015.10.065; Dardiotis E, 2012, BRAIN INJURY PATHOGE, P23; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Doragna D, 2003, J NEUROL NEUROSUR PS, V74, P825, DOI 10.1136/jnnp.74.6.825-a; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Driscoll I, 2012, ACTA NEUROPATHOL, V124, P823, DOI 10.1007/s00401-012-1025-1; El Khoury J, 2007, NAT MED, V13, P432, DOI 10.1038/nm1555; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; FORD AL, 1995, J IMMUNOL, V154, P4309; Ford JW, 2009, CURR OPIN IMMUNOL, V21, P38, DOI 10.1016/j.coi.2009.01.009; Franzblau M, 2013, MED HYPOTHESES, V81, P842, DOI 10.1016/j.mehy.2013.09.012; Gao XL, 2013, MOL MED REP, V7, P921, DOI 10.3892/mmr.2013.1268; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guderian S, 2015, J NEUROSCI, V35, P14123, DOI 10.1523/JNEUROSCI.0801-15.2015; Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hamm RJ, 1996, J NEUROTRAUM, V13, P325, DOI 10.1089/neu.1996.13.325; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hickman SE, 2013, NAT NEUROSCI, V16, P1896, DOI 10.1038/nn.3554; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Hsieh CL, 2009, J NEUROCHEM, V109, P1144, DOI 10.1111/j.1471-4159.2009.06042.x; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Ito H, 2012, EUR J IMMUNOL, V42, P176, DOI 10.1002/eji.201141679; Jay TR, 2015, J EXP MED, V212, P287, DOI 10.1084/jem.20142322; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103; Kawabori M, 2015, J NEUROSCI, V35, P3384, DOI 10.1523/JNEUROSCI.2620-14.2015; Kim E, 2002, NEUROREHABILITATION, V17, P297; Kokiko-Cochran O., 2015, J NEUROTRAUMA; Komada M, 2008, J VIS EXP; Llado A, 2007, J NEURAL TRANSM, V114, P1051, DOI 10.1007/s00702-007-0716-6; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Malik M, 2013, J NEUROSCI, V33, P13320, DOI 10.1523/JNEUROSCI.1224-13.2013; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Neumann H, 2009, BRAIN, V132, P288, DOI 10.1093/brain/awn109; Numasawa Y, 2011, EUR J NEUROL, V18, P1179, DOI 10.1111/j.1468-1331.2010.03311.x; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Paloneva J, 2003, J EXP MED, V198, P669, DOI 10.1084/jem.20030027; Pang FC, 2002, INT J GERIATR PSYCH, V17, P29, DOI 10.1002/gps.510; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pottier C, 2013, J ALZHEIMERS DIS, V35, P45, DOI 10.3233/JAD-122311; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Rayaprolu S, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-19; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Schmidt OI, 2007, ORTHOPADE, V36, P248, DOI 10.1007/s00132-007-1061-z; Sessa G, 2004, EUR J NEUROSCI, V20, P2617, DOI 10.1111/j.1460-9568.2004.03729.x; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Shultz SR, 2014, J NEUROTRAUM, V31, P976, DOI 10.1089/neu.2013.3106; Sieber MW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052982; Singaraja RR, 2013, CLIN GENET, V83, P525, DOI 10.1111/cge.12108; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Takahashi K, 2005, J EXP MED, V201, P647, DOI 10.1084/jem.20041611; Takahashi K, 2007, PLOS MED, V4, P675, DOI 10.1371/journal.pmed.0040124; Thrash JC, 2009, NEUROCHEM RES, V34, P38, DOI 10.1007/s11064-008-9657-1; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; WHITEGBADEBO D, 1993, J NEUROTRAUM, V10, P297, DOI 10.1089/neu.1993.10.297; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Wu K, 2015, J EXP MED, V212, P681, DOI 10.1084/jem.20141732; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	81	39	40	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2017	34	2					423	+		10.1089/neu.2016.4401			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EH4QD	WOS:000391754800018	26976047				2021-06-18	
J	Westerlind, E; Persson, HC; Sunnerhagen, KS				Westerlind, Emma; Persson, Hanna C.; Sunnerhagen, Katharina S.			Return to Work after a Stroke in Working Age Persons; A Six-Year Follow Up	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; SICK LEAVE; HEALTH; SCALE; DISABILITY; BEHAVIOR; PEOPLE; EQ-5D; CARE	Objectives Stroke is one of the most common and resource intensive diseases for society. Stroke in the working age population is increasing in different parts of the world. An incomplete return to work (RTW) after sick leave post stroke entails negative consequences for the affected person and an economical burden for society. The aim of this study was to explore the RTW rate and factors associated with RTW in a six-year follow up post stroke. Methods Data from 174 persons 63 years or younger, with first ever stroke in 2009-2010 in Gothenburg were analyzed. Baseline characteristics were collected through medical records and the Swedish Health Insurance Office provided information on sick leave up to 6 years post stroke. Time-to-event was presented and cox regression as well as logistic regression were used to analyze risk factors for no-RTW. Results The RTW rate was 74.7%, at the end of follow up. Participants continued to RTW until just over 3 years post stroke. Dependency at discharge (in the modified Rankin Scale) and sick leave prior to the stroke were significant risk factors for no-RTW after 1 year with odds ratio 4.595 and 3.585, respectively. The same factors were significant in time-to-event within six years post stroke with hazard ratio 2.651 and 1.929, respectively. Conclusions RTW after a stroke is incomplete, however RTW is possible over a longer period of time than previously thought. More severe disability at discharge from hospital and sick leave prior to the stroke were shown to be risk factors for no-RTW. This knowledge can contribute to more individualized vocational rehabilitation.	[Westerlind, Emma; Persson, Hanna C.; Sunnerhagen, Katharina S.] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci & Rehabil, Gothenburg, Sweden	Westerlind, E (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci & Rehabil, Gothenburg, Sweden.	westerlind.emma@gmail.com	Westerlind, Emma/AAN-7227-2021; Sunnerhagen, Katharina Stibrant/AAE-2405-2020	Sunnerhagen, Katharina Stibrant/0000-0002-5940-4400	Swedish Heart and Lung FoundationSwedish Heart-Lung Foundation; Swedish Brain Foundation	This study was funded in part by the Swedish Heart and Lung Foundation and the Swedish Brain Foundation.	Altman D, 1991, PRACTICAL STAT MED R; Anema JR, 2009, J OCCUP REHABIL, V19, P419, DOI 10.1007/s10926-009-9202-3; Ayis SA, 2013, J NEUROL NEUROSUR PS, V84, P604, DOI 10.1136/jnnp-2012-303525; Bonner B, 2016, EUR J NEUROL, V23, P548, DOI 10.1111/ene.12887; Burstrom K, 2014, QUAL LIFE RES, V23, P431, DOI 10.1007/s11136-013-0496-4; Busch MA, 2009, J NEUROL NEUROSUR PS, V80, P888, DOI 10.1136/jnnp.2008.163295; Chang WH, 2016, J REHABIL MED; Cioncoloni D, 2012, NEUROREHABILITATION, V30, P315, DOI 10.3233/NRE-2012-0761; Clayton S, 2012, EUR J PUBLIC HEALTH, V22, P434, DOI 10.1093/eurpub/ckr101; Cumming TB, 2010, CEREBROVASC DIS, V30, P7, DOI 10.1159/000313438; de Groot V, 2003, J CLIN EPIDEMIOL, V56, P221, DOI 10.1016/S0895-4356(02)00585-1; Endo M, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009682; Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4; Ghatnekar O, 2014, INT J TECHNOL ASSESS, V30, P203, DOI 10.1017/S0266462314000075; Hackett ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041795; Hannerz H, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000180; Krishnamurthi RV, 2013, LANCET GLOB HEALTH, V1, pE259, DOI 10.1016/S2214-109X(13)70089-5; Larsen LP, 2016, J REHABIL MED, V48, P339, DOI 10.2340/16501977-2061; Larsson J, 2010, SCAND J PUBLIC HEALT, V38, P541, DOI 10.1177/1403494810371143; Maruthappu M, 2015, INT J STROKE, V10, P364, DOI 10.1111/ijs.12408; Medin J, 2007, BRAIN INJURY, V21, P457, DOI 10.1080/02699050701317643; Mishra NK, 2010, STROKE, V41, P2612, DOI 10.1161/STROKEAHA.110.589317; Nielsen MBD, 2015, EUR J PUBLIC HEALTH, V25, P96, DOI 10.1093/eurpub/cku016; Persson HC, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-162; Peters GO, 2013, DISABIL REHABIL, V35, P455, DOI 10.3109/09638288.2012.697251; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; Riks-Stroke (the Swedish Stroke Register), 2015, ETT EFT STROK; Roding J, 2010, J REHABIL MED, V42, P155, DOI 10.2340/16501977-0497; Rosengren A, 2013, STROKE, V44, P2388, DOI 10.1161/STROKEAHA.113.001170; Singam A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144344; Stam M, 2013, WORK, V46, P207, DOI 10.3233/WOR-131747; Tanaka H, 2011, ARCH PHYS MED REHAB, V92, P743, DOI 10.1016/j.apmr.2010.12.009; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Treger I, 2007, DISABIL REHABIL, V29, P1397, DOI 10.1080/09638280701314923; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Vestling M, 2003, J REHABIL MED, V35, P127, DOI 10.1080/16501970310010475; Vikholmen K, 2015, ACTA NEUROL SCAND, V132, P329, DOI 10.1111/ane.12404; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wang YC, 2014, WORK, V47, P553, DOI 10.3233/WOR-131627; Wolfenden B, 2009, INT J REHABIL RES, V32, P93, DOI 10.1097/MRR.0b013e328325a358; Wozniak MA, 2002, NEUROEPIDEMIOLOGY, V21, P159, DOI 10.1159/000059516; Young FB, 2005, STROKE, V36, P2187, DOI 10.1161/01.STR.0000181089.41324.70	42	39	39	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 6	2017	12	1							e0169759	10.1371/journal.pone.0169759			14	Multidisciplinary Sciences	Science & Technology - Other Topics	EH3AX	WOS:000391641500135	28061507	DOAJ Gold, Green Published			2021-06-18	
J	Churchill, NW; Hutchison, MG; Richards, D; Leung, G; Graham, SJ; Schweizer, TA				Churchill, Nathan W.; Hutchison, Michael G.; Richards, Doug; Leung, General; Graham, Simon J.; Schweizer, Tom A.			The first week after concussion: Blood flow, brain function and white matter microstructure	NEUROIMAGE-CLINICAL			English	Article						Concussion; MRI; Cerebral blood flow; Functional MRI; Diffusion tensor imaging	SPORTS-RELATED CONCUSSION; PROFESSIONAL FOOTBALL PLAYERS; DEFAULT-MODE NETWORK; RESTING-STATE FMRI; RECURRENT CONCUSSION; COGNITIVE DYSFUNCTION; NCAA CONCUSSION; INJURY; CONNECTIVITY; CORTEX	Concussion is a major health concern, associated with short-term deficits in physical function, emotion and cognition, along with negative long-term health outcomes. However, we remain in the early stages of characterizing MRI markers of concussion, particularly during the first week post-injury when symptoms are most severe. In this study, 52 varsity athletes were scanned using Magnetic Resonance Imaging (MRI), including 26 athletes with acute concussion (scanned 1-7 days post-injury) and 26 matched control athletes. A comprehensive set of functional and structural MRI measures were analyzed, including cerebral blood flow (CBF) and global functional connectivity (Gconn) of grey matter, along with fractional anisotropy (FA) and mean diffusivity (MD) of white matter. An analysis comparing acutely concussed athletes and controls showed limited evidence for reliable mean effects of acute concussion, with only MD showing spatially extensive differences between groups. We subsequently demonstrated that the number of days post-injury explained a significant proportion of inter-subject variability in MRI markers of acutely concussed athletes. Athletes scanned at early acute injury (1-3 days) had elevated CBF and Gconn and reduced FA, but those scanned at late acute injury (5-7 days) had the opposite response. In contrast, MD showed a more complex, spatially-dependent relationship with days post-injury. These novel findings highlight the variability of MRI markers during the acute phase of concussion and the critical importance of considering the acute injury time interval, which has significant implications for studies relating acute MRI data to concussion outcomes. (C) 2017 The Authors. Published by Elsevier Inc.	[Churchill, Nathan W.; Hutchison, Michael G.; Leung, General; Schweizer, Tom A.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr Biomed Sci, 209 Victoria St, Toronto, ON M5B 1M8, Canada; [Hutchison, Michael G.; Richards, Doug] Univ Toronto, Fac Kinesiol & Phys Educ, 55 Harbord St, Toronto, ON M5S 2W6, Canada; [Leung, General] Univ Toronto, Dept Med Imaging, Keenan Res Ctr, Li Ka Shing Knowledge Inst,St Michaels Hosp, 209 Victoria St, Toronto, ON M5B 1M8, Canada; [Graham, Simon J.] Univ Toronto, Sunnybrook Hosp, Dept Med Biophys, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada; [Graham, Simon J.] Sunnybrook Res Inst, Phys Sci, Toronto, ON, Canada; [Schweizer, Tom A.] Univ Toronto, Fac Med Neurosurg, Toronto, ON, Canada; [Schweizer, Tom A.] Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada	Churchill, NW (corresponding author), St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr Biomed Sci, 209 Victoria St, Toronto, ON M5B 1M8, Canada.	nchurchill.research@gmail.com; michael.hutchison@utoronto.ca; doug.richards@utoronto.ca; leungge@smh.ca; sgraham@sri.utoronto.ca; schweizert@smh.ca			Defence Research & Development Canada (DRDC); Canadian Institutes of Military and Veterans Health (CIMVHR) grant [W7714-145967]; Canadian Institutes of Health Research (CIHR) Project GrantCanadian Institutes of Health Research (CIHR) [RN294001-367456]	This research received funding from the Defence Research & Development Canada (DRDC) and the Canadian Institutes of Military and Veterans Health (CIMVHR) grant W7714-145967. This study was approved by the Canadian Forces Surgeon General's Health Research Program. This study was also partially funded by a Canadian Institutes of Health Research (CIHR) Project Grant RN294001-367456.	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Abrahams S, 2014, BRIT J SPORT MED, V48, P91, DOI 10.1136/bjsports-2013-092734; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Casson IR, 2014, SPORTS HEALTH, V6, P384, DOI 10.1177/1941738114540270; Chamard E, 2013, BRAIN INJURY, V27, P1038, DOI 10.3109/02699052.2013.794968; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; Churchill N, 2017, J NEUROTRAUM, V34, P765, DOI 10.1089/neu.2016.4531; Cole MW, 2012, J NEUROSCI, V32, P8988, DOI 10.1523/JNEUROSCI.0536-12.2012; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Covassin T, 2003, J ATHL TRAINING, V38, P238; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; Derrfuss J, 2005, HUM BRAIN MAPP, V25, P22, DOI 10.1002/hbm.20127; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Graham D, 2002, TRAUMA GREENFIELDS N; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Hillary FG, 2015, NEUROPSYCHOLOGY, V29, P59, DOI 10.1037/neu0000110; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Hutchison M., 2016, J HEAD TRAUMA REHAB; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Liang X, 2013, P NATL ACAD SCI USA, V110, P1929, DOI 10.1073/pnas.1214900110; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Monaco EA, 2015, NEUROSURGERY, V76, pN10, DOI 10.1227/NEU.0000000000000700; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Sasaki Takeshi, 2014, J Neurosurg, V120, P882, DOI 10.3171/2013.12.JNS132092; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; Zhang L, 2006, AM J NEURORADIOL, V27, P2000; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413	50	39	39	1	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2017	14						480	489		10.1016/j.nicl.2017.02.015			10	Neuroimaging	Neurosciences & Neurology	FB2OY	WOS:000405984300051	28280686	DOAJ Gold, Green Published			2021-06-18	
J	Feng, Y; Lee, CH; Sun, LN; Ji, SH; Zhao, XF				Feng, Yuan; Lee, Chung-Hao; Sun, Lining; Ji, Songhai; Zhao, Xuefeng			Characterizing white matter tissue in large strain via asymmetric indentation and inverse finite element modeling	JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS			English	Article						Soft tissue; Mechanical properties; Transversely isotropic material; Indentation; Genetic algorithm	ISOTROPIC MATERIAL MODELS; BIOLOGICAL SOFT-TISSUES; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; IN-VIVO; MECHANICAL-PROPERTIES; MITRAL-VALVE; PARAMETER-IDENTIFICATION; UNCONFINED COMPRESSION; SIMPLE SHEAR	Characterizing the mechanical properties of white matter is important to understand and model brain development and injury. With embedded aligned axonal fibers, white matter is typically modeled as a transversely isotropic material. However, most studies characterize the white matter tissue using models with a single anisotropic invariant or in a small-strain regime. In this study, we combined a single experimental procedure asymmetric indentation with inverse finite element (FE) modeling to estimate the nearly incompressible transversely isotropic material parameters of white matter. A minimal form comprising three parameters was employed to simulate indentation responses in the large-strain regime. The parameters were estimated using a global optimization procedure based on a genetic algorithm (GA). Experimental data from two indentation configurations of porcine white matter, parallel and perpendicular to the axonal fiber direction, were utilized to estimate model parameters. Results in this study confirmed a strong mechanical anisotropy of white matter in large strain. Further, our results suggested that both indentation configurations are needed to estimate the parameters with sufficient accuracy, and that the indenter-sample friction is important. Finally, we also showed that the estimated parameters were consistent with those previously obtained via a trial-and-error forward FE method in the small-strain regime. These findings are useful in modeling and parameterization of white matter, especially under large deformation, and demonstrate the potential of the proposed asymmetric indentation technique to characterize other soft biological tissues with transversely isotropic properties. (C) 2016 Elsevier Ltd. All rights reserved.	[Feng, Yuan; Sun, Lining; Zhao, Xuefeng] Soochow Univ, Sch Mech & Elect Engn, Room 1107 Engn Bldg,178 Gan Jiang Dong Lu, Suzhou 215021, Jiangsu, Peoples R China; [Feng, Yuan; Sun, Lining] Soochow Univ, Robot & Microsyst Ctr, Suzhou 215021, Jiangsu, Peoples R China; [Lee, Chung-Hao] Univ Oklahoma, Sch Aerosp & Mech Engn, Norman, OK 73019 USA; [Lee, Chung-Hao] Univ Texas Austin, Inst Computat Engn & Sci, Austin, TX 78705 USA; [Ji, Songhai] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA	Feng, Y (corresponding author), Soochow Univ, Sch Mech & Elect Engn, Room 1107 Engn Bldg,178 Gan Jiang Dong Lu, Suzhou 215021, Jiangsu, Peoples R China.	fengyuan@suda.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [61503267]; Jiangsu Province [BK20140356, 16KJB460018]; Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education MinistryScientific Research Foundation for the Returned Overseas Chinese Scholars [K511701515]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS092853]; School of Aerospace and Mechanical Engineering (AME) at the University of Oklahoma (CHL); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS088781, R01NS092853] Funding Source: NIH RePORTER	Funding is provided by Grant 61503267 (YF) from National Natural Science Foundation of China, Grant BK20140356 (YF), 16KJB460018 (YF) from Jiangsu Province, and by Grant K511701515 (YF) from Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry. In addition, supports from the NIH R01 NS092853 (SJ) and the start-up funds from the School of Aerospace and Mechanical Engineering (AME) at the University of Oklahoma (CHL) are also acknowledged.	Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; Arbogast KB, 1997, J BIOMECH, V30, P757, DOI 10.1016/S0021-9290(97)00023-7; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bischoff JE, 2004, J BIOMECH ENG-T ASME, V126, P498, DOI 10.1115/1.1785808; Bol M, 2013, J MECH BEHAV BIOMED, V27, P204, DOI 10.1016/j.jmbbm.2013.04.009; Budday S, 2015, J MECH BEHAV BIOMED, V46, P318, DOI 10.1016/j.jmbbm.2015.02.024; Chai CK, 2014, J BIOMECH, V47, P784, DOI 10.1016/j.jbiomech.2014.01.018; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; Cheng S, 2007, J BIOMECH, V40, P117, DOI 10.1016/j.jbiomech.2005.11.004; Cheng S, 2008, MED ENG PHYS, V30, P1318, DOI 10.1016/j.medengphy.2008.06.003; Coudrillier B, 2013, BIOMECH MODEL MECHAN, V12, P941, DOI 10.1007/s10237-012-0455-y; Cox MAJ, 2008, J BIOMECH, V41, P422, DOI 10.1016/j.jbiomech.2007.08.006; Destrade M, 2015, INT J NONLIN MECH, V75, P54, DOI 10.1016/j.ijnonlinmec.2015.02.014; Destrade M, 2013, COMPUT MECH, V52, P959, DOI 10.1007/s00466-013-0857-4; Elkin BS, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4004494; Fahlstedt M, 2015, J BIOMECH, V48, P1331, DOI 10.1016/j.jbiomech.2015.02.057; Feng Y, 2016, J MECH BEHAV BIOMED, V61, P554, DOI 10.1016/j.jmbbm.2016.04.024; Feng Y, 2013, J MECH BEHAV BIOMED, V23, P117, DOI 10.1016/j.jmbbm.2013.04.007; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Harb N, 2014, STRUCT MULTIDISCIP O, V49, P337, DOI 10.1007/s00158-013-0973-y; Harb N, 2011, COMPUT METHOD APPL M, V200, P208, DOI 10.1016/j.cma.2010.08.005; Hatami-Marbini H, 2013, J BIOMECH, V46, P1752, DOI 10.1016/j.jbiomech.2013.03.013; Holmes JH, 2014, J BIOMED INFORM, V49, P11, DOI 10.1016/j.jbi.2014.05.008; Horgan CO, 2012, J ELASTICITY, V108, P179, DOI 10.1007/s10659-011-9363-0; Hortin M, 2015, J MECH BEHAV BIOMED, V45, P75, DOI 10.1016/j.jmbbm.2015.01.020; Hrapko M, 2008, BIORHEOLOGY, V45, P663, DOI 10.3233/BIR-2008-0512; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Ji SB, 2015, J NEUROTRAUM, V32, P441, DOI 10.1089/neu.2013.3268; Jiang Y, 2015, BIOMECH MODEL MECHAN, V14, P1119, DOI 10.1007/s10237-015-0658-0; Kaster T, 2011, J BIOMECH, V44, P1158, DOI 10.1016/j.jbiomech.2011.01.019; Khalil Ahmad S, 2006, Cardiovasc Eng, V6, P93, DOI 10.1007/s10558-006-9013-5; Kulkarni S., 2014, MATH MECH SOLIDS; LAURER HL, 2002, ENCY HUMAN BRAIN, P93; Lee C.-H., 2013, P 7 INT C FUNCT IM M, P416; Lee CH, 2015, BIOMECH MODEL MECHAN, V14, P1281, DOI 10.1007/s10237-015-0674-0; Lee CH, 2015, J THEOR BIOL, V373, P26, DOI 10.1016/j.jtbi.2015.03.004; Lee CH, 2014, J BIOMECH, V47, P2055, DOI 10.1016/j.jbiomech.2013.10.058; Liu YX, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.0835; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Miller K, 2000, J BIOMECH, V33, P1369, DOI 10.1016/S0021-9290(00)00120-2; Namani R, 2012, J BIOMECH ENG-T ASME, V134, DOI 10.1115/1.4006848; Nguyen TD, 2011, BIOMECH MODEL MECHAN, V10, P323, DOI 10.1007/s10237-010-0237-3; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Ning XG, 2006, J BIOMECH ENG-T ASME, V128, P925, DOI 10.1115/1.2354208; Prange M T, 2000, Stapp Car Crash J, V44, P205; Rashid B, 2013, J MECH BEHAV BIOMED, V28, P71, DOI 10.1016/j.jmbbm.2013.07.017; Reiter R, 2014, J BIOMECH, V47, P1665, DOI 10.1016/j.jbiomech.2014.02.034; Robertson D, 2013, J MECH BEHAV BIOMED, V17, P34, DOI 10.1016/j.jmbbm.2012.07.009; Slomka N, 2011, J MECH BEHAV BIOMED, V4, P1559, DOI 10.1016/j.jmbbm.2011.04.006; Smith SL, 2011, GENETIC EVOLUTIONARY; Svensson RB, 2010, J MECH BEHAV BIOMED, V3, P112, DOI 10.1016/j.jmbbm.2009.01.005; Thomopoulos S., 2012, ORTHOP BIOMECH, V49; van Dommelen JAW, 2010, J MECH BEHAV BIOMED, V3, P158, DOI 10.1016/j.jmbbm.2009.09.001; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; Witzenburg C, 2012, J BIOMECH, V45, P842, DOI 10.1016/j.jbiomech.2011.11.025; Wright AH., 1991, FDN GENETIC ALGORITH, V1, P205, DOI DOI 10.1016/B978-0-08-050684-5.50016-1; Wright RM, 2012, BIOMECH MODEL MECHAN, V11, P245, DOI 10.1007/s10237-011-0307-1; Yang L, 2012, J MECH BEHAV BIOMED, V6, P148, DOI 10.1016/j.jmbbm.2011.11.008; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang MG, 2014, BIOMECH MODEL MECHAN, V13, P1, DOI 10.1007/s10237-013-0481-4; Zhang W, 2015, J BIOMECH ENG-T ASME, V137, DOI 10.1115/1.4029266	62	39	41	1	25	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1751-6161	1878-0180		J MECH BEHAV BIOMED	J. Mech. Behav. Biomed. Mater.	JAN	2017	65						490	501		10.1016/j.jmbbm.2016.09.020			12	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	EF9BG	WOS:000390625100043	27665084	Green Accepted			2021-06-18	
J	Prasad, MR; Swank, PR; Ewing-Cobbs, L				Prasad, Mary R.; Swank, Paul R.; Ewing-Cobbs, Linda			Long-Term School Outcomes of Children and Adolescents With Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						children; school outcomes; special education; traumatic brain injury	ACADEMIC-ACHIEVEMENT; COGNITIVE PREDICTORS; YOUNG-CHILDREN; STUDENTS; TBI; RECOMMENDATIONS; CHILDHOOD; RECOVERY; SERVICES; BEHAVIOR	Objective: To better understand the impact of age at injury, severity of injury, and time since injury on long-term school outcomes of children with traumatic brain injury (TBI). Participants: Four groups of children: complicated mild/moderate TBI (n = 23), severe TBI (n = 56), orthopedic injury (n = 35), and healthy controls (n = 42). Children with TBI were either 2 years postinjury or 6 years postinjury. Design: Cross-sectional design. Measures: School records as well as parental ratings of functional academic skills and school competency. Results: Children with severe TBI had consistently high usage of school services and low school competency ratings than children with orthopedic injuries and healthy controls. In contrast, children with complicated-mild/moderate TBI were significantly more likely to receive school support services and have lower competence ratings at 6 years than at 2 years postinjury. Students injured at younger ages had lower functional academic skill ratings than those injured at older ages. Conclusions: These findings highlight the increasing academic challenges faced over time by students with complicated-mild/moderate TBI and the vulnerability of younger children to poorer development of functional academic skills.	[Prasad, Mary R.; Ewing-Cobbs, Linda] UT Hlth, Childrens Learning Inst, 7000 Fannin, Houston, TX 77030 USA; [Swank, Paul R.] UT Hlth, Sch Publ Hlth, Houston, TX USA	Prasad, MR (corresponding author), UT Hlth, Childrens Learning Inst, 7000 Fannin, Houston, TX 77030 USA.	Mary.R.Prasad@uth.tmc.edu			National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046308]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046308] Funding Source: NIH RePORTER	This manuscript was supported by grant number R01NS046308 from the National Institute of Neurological Disorders and Stroke to Dr Linda Ewing-Cobbs. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke or the National Institutes of Health.	Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Arnett AB, 2013, J INT NEUROPSYCH SOC, V19, P881, DOI 10.1017/S1355617713000635; Centers for Disease Control and Prevention, 2004, NAT INF CTR CHIILDR; Dettmer J, 2014, J HEAD TRAUMA REHAB, V29, P224, DOI 10.1097/HTR.0b013e3182a1cd68; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Fulton JB, 2012, NEUROPSYCHOLOGY, V26, P314, DOI 10.1037/a0027973; Gfroerer SD, 2008, BRAIN INJURY, V22, P649, DOI 10.1080/02699050802227162; Glang A, 2008, NEUROREHABILITATION, V23, P477; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Rivara FP, 2012, AM J PUBLIC HEALTH, V102, P2074, DOI 10.2105/AJPH.2012.300696; Taylor HG, 2008, J INT NEUROPSYCH SOC, V14, P734, DOI 10.1017/S1355617708081150; Taylor HG, 2003, REHABIL PSYCHOL, V48, P227, DOI 10.1037/0090-5550.48.4.227; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Ylvisaker M, 2001, J HEAD TRAUMA REHAB, V16, P76, DOI 10.1097/00001199-200102000-00009	26	39	39	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2017	32	1					E24	E32		10.1097/HTR.0000000000000218			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EI2GH	WOS:000392304400010	26828713	Green Accepted			2021-06-18	
J	Davenport, EM; Apkarian, K; Whitlow, CT; Urban, JE; Jensen, JH; Szuch, E; Espeland, MA; Jung, Y; Rosenbaum, DA; Gioia, GA; Powers, AK; Stitzel, JD; Maldjian, JA				Davenport, Elizabeth M.; Apkarian, Kalyna; Whitlow, Christopher T.; Urban, Jillian E.; Jensen, Jens H.; Szuch, Eliza; Espeland, Mark A.; Jung, Youngkyoo; Rosenbaum, Daryl A.; Gioia, Gerard A.; Powers, Alexander K.; Stitzel, Joel D.; Maldjian, Joseph A.			Abnormalities in Diffusional Kurtosis Metrics Related to Head Impact Exposure in a Season of High School Varsity Football	JOURNAL OF NEUROTRAUMA			English	Article						concussion; diffusion kurtosis imaging; football; Head Impact Telemetry System; Risk Weighted Cumulative Exposure	TRAUMATIC BRAIN-INJURY; CEREBRAL CONCUSSION; IN-VIVO; PLAYERS	The purpose of this study was to determine whether the effects of cumulative head impacts during a season of high school football produce changes in diffusional kurtosis imaging (DKI) metrics in the absence of clinically diagnosed concussion. Subjects were recruited from a high school football team and were outfitted with the Head Impact Telemetry System (HITS) during all practices and games. Biomechanical head impact exposure metrics were calculated, including: total impacts, summed acceleration, and Risk Weighted Cumulative Exposure (RWE). Twenty-four players completed pre-and post-season magnetic resonance imaging, including DKI; players who experienced clinical concussion were excluded. Fourteen subjects completed pre-and post-season Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT). DKI-derived metrics included mean kurtosis (MK), axial kurtosis (K axial), and radial kurtosis (K radial), and white matter modeling (WMM) parameters included axonal water fraction, tortuosity of the extra-axonal space, extra-axonal diffusivity (De axial and radial), and intra-axonal diffusivity (Da). These metrics were used to determine the total number of abnormal voxels, defined as 2 standard deviations above or below the group mean. Linear regression analysis revealed a statistically significant relationship between RWE combined probability (RWECP) and MK. Secondary analysis of other DKI-derived and WMM metrics demonstrated statistically significant linear relationships with RWECP after covariate adjustment. These results were compared with the results of DTI-derived metrics from the same imaging sessions in this exact same cohort. Several of the DKI-derived scalars (Da, MK, K axial, and K radial) explained more variance, compared with RWECP, suggesting that DKI may be more sensitive to subconcussive head impacts. No significant relationships between DKI-derived metrics and ImPACT measures were found. It is important to note that the pathological implications of these metrics are not well understood. In summary, we demonstrate a single season of high school football can produce DKI measurable changes in the absence of clinically diagnosed concussion.	[Davenport, Elizabeth M.; Maldjian, Joseph A.] Wake Forest Sch Med, Adv Neurosci Imaging Res ANSIR Lab, Winston Salem, NC USA; [Davenport, Elizabeth M.; Maldjian, Joseph A.] Wake Forest Sch Med, Dept Radiol, Winston Salem, NC USA; [Whitlow, Christopher T.; Jung, Youngkyoo] Wake Forest Sch Med, Dept Radiol Neuroradiol, Winston Salem, NC USA; [Apkarian, Kalyna; Whitlow, Christopher T.; Urban, Jillian E.; Jung, Youngkyoo; Rosenbaum, Daryl A.; Stitzel, Joel D.] Wake Forest Sch Med, Dept Biomed Engn, Winston Salem, NC USA; [Espeland, Mark A.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA; Wake Forest Sch Med, Dept Family & Community Med, Winston Salem, NC USA; [Powers, Alexander K.] Wake Forest Sch Med, Dept Neurosurg, Winston Salem, NC USA; [Whitlow, Christopher T.; Stitzel, Joel D.] Wake Forest Sch Med, Translat Sci Inst, Winston Salem, NC USA; [Urban, Jillian E.; Jung, Youngkyoo; Stitzel, Joel D.] Wake Forest Sch Med, Virginia Tech Wake Forest Sch Biomed Engn, Winston Salem, NC USA; [Szuch, Eliza] Wake Forest Sch Med, MD Program, Winston Salem, NC USA; [Powers, Alexander K.] Wake Forest Sch Med, Childress Inst Pediat Trauma, Winston Salem, NC USA; [Gioia, Gerard A.] George Washington Univ, Sch Med, Childrens Natl Med Ctr, Div Pediat Neuropsychol, Rockville, MD USA; [Jensen, Jens H.] Med Univ South Carolina, Ctr Biomed Imaging, Dept Radiol & Radiol Sci, Charleston, SC USA	Whitlow, CT (corresponding author), Wake Forest Univ Hlth Sci, Adv Neurosci Imaging Res Core, Translat Sci Inst, Dept Radiol Neuroradiol, Winston Salem, NC 27157 USA.	cwhitlow@wakehealth.edu	Stitzel, Joel/B-4045-2012; Jensen, Jens H/A-8334-2009	Stitzel, Joel/0000-0001-9762-3033; Jensen, Jens H/0000-0003-3219-4287; Maldjian, Joseph/0000-0002-6384-1072; Jung, Youngkyoo/0000-0002-7236-8897	Childress Institute for Pediatric Trauma at Wake Forest Baptist Medical Center; National Science FoundationNational Science Foundation (NSF) [DGE-0907738]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS082453, NS088125, R01NS091602]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR001421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS091602, R03NS088082] Funding Source: NIH RePORTER	The authors would like to thank the Reagan High School, especially Ashley Lake, ATC, Corbin Ratcliffe, Lauren Smith, and the football program. Thank you to Ben Wagner and all those who contributed to the study development. Special thanks to the Childress Institute for Pediatric Trauma at Wake Forest Baptist Medical Center for providing support for this study. This material is based upon work supported by the National Science Foundation Graduate Research Fellowship under Grant No. DGE-0907738. Any opinion, findings, and conclusions or recommendations expressed in this material are those of the authors(s) and do not necessarily reflect the views of the National Science Foundation. Support for this research also was provided by National Institutes of Health grant NS082453 (JAM,JDS), NS088125 (JAM), and R01NS091602 (CTW, JAM, JDS).	Adisetiyo V, 2014, HUM BRAIN MAPP, V35, P2148, DOI 10.1002/hbm.22317; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Benitez A, 2014, NEUROIMAGE-CLIN, V4, P64, DOI 10.1016/j.nicl.2013.11.001; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Cheung MM, 2009, NEUROIMAGE, V45, P386, DOI 10.1016/j.neuroimage.2008.12.018; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Das SK, 2016, CLIN NEURORADIOL; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; DeCarlo LT, 1997, PSYCHOL METHODS, V2, P292, DOI 10.1037/1082-989X.2.3.292; Dhital B, 2015, P INT SOC MAGN RESON, P2788; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Fieremans E, 2013, AM J NEURORADIOL, V34, P2105, DOI 10.3174/ajnr.A3553; Fieremans E, 2011, NEUROIMAGE, V58, P177, DOI 10.1016/j.neuroimage.2011.06.006; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Hui ES, 2015, NEUROIMAGE, V106, P391, DOI 10.1016/j.neuroimage.2014.11.015; Hui ES, 2012, STROKE, V43, P2968, DOI 10.1161/STROKEAHA.112.657742; Jelescu IO, 2015, NEUROIMAGE, V107, P242, DOI 10.1016/j.neuroimage.2014.12.009; Jensen JH, 2011, NMR BIOMED, V24, P452, DOI 10.1002/nbm.1610; Jensen JH, 2010, NMR BIOMED, V23, P698, DOI 10.1002/nbm.1518; Jensen JH, 2005, MAGNET RESON MED, V53, P1432, DOI 10.1002/mrm.20508; Kullmann S, 2016, NEUROIMAGE, V125, P36, DOI 10.1016/j.neuroimage.2015.10.006; Lazar M, 2014, NEUROIMAGE-CLIN, V4, P417, DOI 10.1016/j.nicl.2014.01.014; Lazar M, 2010, NMR BIOMED, V23, P821, DOI 10.1002/nbm.1579; Lovell MR., 2000, IMPACT IMMEDIATE POS; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Mills KL, 2014, DEV COGN NEUROS-NETH, V9, P172, DOI 10.1016/j.dcn.2014.04.004; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; Ono K., 1980, 801303 SAE; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Stern Y, 2009, NEUROPSYCHOLOGIA, V47, P2015, DOI 10.1016/j.neuropsychologia.2009.03.004; Stokum JA, 2015, BRAIN INJURY, V29, P47, DOI 10.3109/02699052.2014.947628; Tabesh A, 2011, MAGN RESON MED, V65, P823, DOI 10.1002/mrm.22655; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; Wong RH, 2014, CLIN NEUROL NEUROSUR, V118, P1, DOI 10.1016/j.clineuro.2013.11.036; Zhang D, 2010, MOL NEUROBIOL, V41, P232, DOI 10.1007/s12035-010-8098-4; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	48	39	39	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2016	33	23					2133	2146		10.1089/neu.2015.4267			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ED2JG	WOS:000388669800009	27042763	Green Published			2021-06-18	
J	Pischiutta, F; Brunelli, L; Romele, P; Silini, A; Sammali, E; Paracchini, L; Marchini, S; Talamini, L; Bigini, P; Boncoraglio, GB; Pastorelli, R; De Simoni, MG; Parolini, O; Zanier, ER				Pischiutta, Francesca; Brunelli, Laura; Romele, Pietro; Silini, Antonietta; Sammali, Eliana; Paracchini, Lara; Marchini, Sergio; Talamini, Laura; Bigini, Paolo; Boncoraglio, Giorgio B.; Pastorelli, Roberta; De Simoni, Maria-Grazia; Parolini, Ornella; Zanier, Elisa R.			Protection of Brain Injury by Amniotic Mesenchymal Stromal Cell-Secreted Metabolites	CRITICAL CARE MEDICINE			English	Article						brain protection; human amniotic mesenchymal stromal cells; metabolites; secretome; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; ALPHA-AMINOADIPIC ACID; MEMBRANE-DERIVED CELLS; STEM-CELLS; BONE-MARROW; CONDITIONED MEDIUM; FUNCTIONAL RECOVERY; INDUCED NEURODEGENERATION; KYNURENINE PATHWAY; EFFECTOR FUNCTIONS	Objectives: To define the features of human amniotic mesenchymal stromal cell secretome and its protective properties in experimental models of acute brain injury. Design: Prospective experimental study. Setting: Laboratory research. Subjects: C57Bl/6 mice. Interventions: Mice subjected to sham or traumatic brain injury by controlled cortical impact received human amniotic mesenchymal stromal cells or phosphate-buffered saline infused intracerebroventricularly or intravenously 24 hours after injury. Organotypic cortical brain slices exposed to ischemic injury by oxygen-glucose deprivation were treated with human amniotic mesenchymal stromal cells or with their secretome (conditioned medium) in a transwell system. Measurements and Main Results: Traumatic brain injured mice receiving human amniotic mesenchymal stromal cells intravenously or intracerebroventricularly showed early and lasting functional and anatomical brain protection. cortical slices injured by oxigen-glucose deprivation and treated with human amniotic mesenchymal stromal cells or conditioned medium showed comparable protective effects (neuronal rescue, promotion of M2 microglia polarization, induction of trophic factors) indicating that the exposure of human amniotic mesenchymal stromal cells to the injured tissue is not necessary for the release of bioactive factors. Using sequential size-exclusion and gel-filtration chromatography, we identified a conditioned medium subfraction, which specifically displays these highly protective properties and we found that this fraction was rich in bioactive molecules with molecular weight smaller than 700 Da. Quantitative RNA analysis and mass spectrometry-based peptidomics showed that the active factors are not proteins or RNAs. The metabolomic profiling of six metabolic classes identified a list of molecules whose abundance was selectively elevated in the active conditioned medium fraction. Conclusions: Human amniotic mesenchymal stromal cell-secreted factors protect the brain after acute injury. Importantly, a fraction rich in metabolites, and containing neither proteic nor ribonucleic molecules was protective. This study indicates the profiling of protective factors that could be useful in cell-free therapeutic approaches for acute brain injury.	[Pischiutta, Francesca; Sammali, Eliana; De Simoni, Maria-Grazia; Zanier, Elisa R.] IRCCS Ist Ric Farmacol Mario Negri, Dept Neurosci, Milan, Italy; [Brunelli, Laura; Pastorelli, Roberta] IRCCS Ist Ric Farmacol Mario Negri, Dept Environm Hlth Sci, Milan, Italy; [Romele, Pietro; Silini, Antonietta; Parolini, Ornella] Fdn Poliambulanza, Ist Osped, Ctr Ric E Menni, Brescia, Italy; [Sammali, Eliana; Boncoraglio, Giorgio B.] Fdn IRCCS, Ist Neurol Carlo Besta, Dept Cerebrovasc Dis, Milan, Italy; [Paracchini, Lara; Marchini, Sergio] IRCCS Ist Ric Farmacol Mario Negri, Dept Oncol, Milan, Italy; [Talamini, Laura; Bigini, Paolo] IRCCS Ist Ric Farmacol Mario Negri, Dept Biochem, Milan, Italy	Zanier, ER (corresponding author), IRCCS Ist Ric Farmacol Mario Negri, Dept Neurosci, Milan, Italy.	elisa.zanier@marionegri.it	PAROLINI, ORNELLA/C-7946-2013; PAROLINI, ORNELLA/ABI-7862-2020; Boncoraglio, Giorgio Battista/B-8647-2011; Bigini, Paolo/AAB-2901-2020; Zanier, Elisa/AAA-8095-2020; De Simoni, Maria Grazia/I-6021-2012; Marchini, sergio/J-3968-2018; Pastorelli, Roberta/AAA-6736-2020; Pischiutta, Francesca/AAA-7927-2020; Sammali, Eliana/AAA-2464-2019; Brunelli, Laura/J-8664-2018; Paracchini, Lara/AAH-4149-2021; Silini, Antonietta Rosa/K-7638-2016	PAROLINI, ORNELLA/0000-0002-5211-6430; Boncoraglio, Giorgio Battista/0000-0002-2551-525X; Bigini, Paolo/0000-0002-0239-9532; De Simoni, Maria Grazia/0000-0001-6695-5297; Marchini, sergio/0000-0003-1783-7651; Pastorelli, Roberta/0000-0001-5097-600X; Pischiutta, Francesca/0000-0002-7151-0812; Paracchini, Lara/0000-0003-1832-5471; Talamini, Laura/0000-0001-6010-2947; Zanier, Elisa/0000-0002-3011-8718; Silini, Antonietta Rosa/0000-0001-6208-3583; Brunelli, Laura/0000-0002-5465-9586	Competitiveness Regional Operational Programme of the European Regional Development Fund (ROP ERDF) of the Lombardy Region (ROP ERDF-Progetto NUTEC-NUoveTECnologie) [30263049]; Societa Italiana di Farmacologia, SIF-MSD Italia; Fondazione Umberto Veronesi (FUV)Fondazione Umberto Veronesi	Supported, in part, by Competitiveness Regional Operational Programme of the European Regional Development Fund (ROP ERDF) 2007-2013 of the Lombardy Region (ROP ERDF-Progetto NUTEC-NUoveTECnologie-ID:n.30263049).; Dr. Pischiutta received a fellowship by "Societa Italiana di Farmacologia, SIF-MSD Italia." Dr. Brunelli received a fellowship from Fondazione Umberto Veronesi (FUV2014-2015). The remaining authors have disclosed that they do not have any potential conflicts of interest.	Acosta SA, 2015, STROKE, V46, P2616, DOI 10.1161/STROKEAHA.115.009854; Adibhatla RM, 2002, BRAIN RES, V938, P81, DOI 10.1016/S0006-8993(02)02447-2; Ajmo CT, 2008, J NEUROSCI RES, V86, P2227, DOI 10.1002/jnr.21661; Amori L, 2009, J NEUROCHEM, V109, P316, DOI 10.1111/j.1471-4159.2009.05893.x; Antonucci I, 2012, CURR PHARM DESIGN, V18, P1846, DOI 10.2174/138161212799859602; Baglio SR, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00359; Bao XJ, 2011, BRAIN RES, V1367, P103, DOI 10.1016/j.brainres.2010.10.063; Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886; Cargnoni A, 2014, CYTOTHERAPY, V16, P17, DOI 10.1016/j.jcyt.2013.07.002; Cargnoni A, 2012, CYTOTHERAPY, V14, P153, DOI 10.3109/14653249.2011.613930; Chang CP, 2013, CLIN SCI, V124, P165, DOI 10.1042/CS20120226; Chen JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115316; Chen ZY, 2009, J NEUROTRAUM, V26, P1987, DOI 10.1089/neu.2008.0863; Chuang TJ, 2012, J TRAUMA ACUTE CARE, V73, P1161, DOI 10.1097/TA.0b013e318265d128; Clark EA, 2014, STEM CELLS, V32, P1074, DOI 10.1002/stem.1623; de Girolamo L, 2013, CURR PHARM DESIGN, V19, P2459, DOI 10.2174/1381612811319130015; Dela Pena I, 2014, J NEUROSURG SCI, V58, P145; Deng-Bryant Y, 2015, RESTOR NEUROL NEUROS, V33, P189, DOI 10.3233/RNN-140455; Deng-Bryant Y, 2012, J TRAUMA ACUTE CARE, V73, pS156, DOI 10.1097/TA.0b013e3182625f5f; Dossi E, 2013, CEREB CORTEX, V23, P2905, DOI 10.1093/cercor/bhs275; Drago D, 2013, BIOCHIMIE, V95, P2271, DOI 10.1016/j.biochi.2013.06.020; Fierabracci A, 2015, EXPERT OPIN BIOL TH, V15, P613, DOI 10.1517/14712598.2015.1000856; Gesuete R, 2011, STROKE, V42, P1445, DOI 10.1161/STROKEAHA.110.603266; Gibb SL, 2015, STEM CELLS, V33, P3530, DOI 10.1002/stem.2189; Giunti D, 2012, STEM CELLS, V30, P2044, DOI 10.1002/stem.1174; Gnecchi M, 2005, NAT MED, V11, P367, DOI 10.1038/nm0405-367; Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826; Groh ME, 2005, EXP HEMATOL, V33, P928, DOI 10.1016/j.exphem.2005.05.002; Guidetti P, 2003, MOL BRAIN RES, V118, P132, DOI 10.1016/j.molbrainres.2003.08.004; Gutierrez-Fernandez M, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt159; HALL JG, 1977, J PHYSIOL-LONDON, V272, pP52; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Hegyi B, 2014, STEM CELLS DEV, V23, P2600, DOI 10.1089/scd.2014.0088; HUCK S, 1984, NEUROSCIENCE, V12, P783, DOI 10.1016/0306-4522(84)90170-2; Hung SC, 2007, STEM CELLS, V25, P2363, DOI 10.1634/stemcells.2006-0686; Johnson TV, 2014, BRAIN, V137, P503, DOI 10.1093/brain/awt292; KATO S, 1990, NEUROSCIENCE, V36, P145, DOI 10.1016/0306-4522(90)90357-A; Kondoh T, 2010, FRONT INTEGR NEUROSC, V4, DOI 10.3389/fnint.2010.00018; Kumar A., 2015, J NEUROTRAUMA; Lakshmipathy U, 2008, STEM CELLS, V26, P356, DOI 10.1634/stemcells.2007-0625; Li F, 2012, MOL MED REP, V6, P625, DOI 10.3892/mmr.2012.968; Li M, 2011, J TRAUMA, V71, P141, DOI [10.1097/TA.0b013e3181f30fc9, 10.1088/1742-5468/2011/12/P12001]; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Liang XT, 2014, CELL TRANSPLANT, V23, P1045, DOI 10.3727/096368913X667709; Lovaas E, 1997, Adv Pharmacol, V38, P119; Magatti M, 2015, MESENCHYMAL STEM CEL, P233; Magatti M, 2008, STEM CELLS, V26, P182, DOI 10.1634/stemcells.2007-0491; Magatti M, 2015, CELL TRANSPLANT, V24, P1733, DOI 10.3727/096368914X684033; Magatti M, 2012, J CELL MOL MED, V16, P2208, DOI 10.1111/j.1582-4934.2012.01531.x; Magatti M, 2009, CELL TRANSPLANT, V18, P899, DOI 10.3727/096368909X471314; Menge T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004660; Menzie J, 2013, BRAIN SCI, V3, P877, DOI 10.3390/brainsci3020877; Nakajima H, 2012, J NEUROTRAUM, V29, P1614, DOI 10.1089/neu.2011.2109; Nakano N, 2010, NEUROSCI LETT, V483, P57, DOI 10.1016/j.neulet.2010.07.062; Offner H, 2006, J CEREBR BLOOD F MET, V26, P654, DOI 10.1038/sj.jcbfm.9600217; Offner H, 2012, TRANSL STROKE RES, V3, P324, DOI 10.1007/s12975-012-0187-4; Ohtaki H, 2008, P NATL ACAD SCI USA, V105, P14638, DOI 10.1073/pnas.0803670105; Ooi YY, 2015, NEUROIMMUNOMODULAT, V22, P233, DOI 10.1159/000365483; Parolini O, 2014, ARTHRITIS RHEUMATOL, V66, P327, DOI 10.1002/art.38206; Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174; Pianta S, 2015, STEM CELL REV REP, V11, P394, DOI 10.1007/s12015-014-9558-4; Pischiutta F, 2014, NEUROPHARMACOLOGY, V79, P119, DOI 10.1016/j.neuropharm.2013.11.001; Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1; Rossi D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046956; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014; Tao J, 2012, BRAIN RES, V1448, P1, DOI 10.1016/j.brainres.2012.01.069; Teixeira FG, 2013, CELL MOL LIFE SCI, V70, P3871, DOI 10.1007/s00018-013-1290-8; Tsai MJ, 2014, J BIOMED SCI, V21, DOI 10.1186/1423-0127-21-5; Vecsei L, 2013, NAT REV DRUG DISCOV, V12, P64, DOI 10.1038/nrd3793; Vendrame M, 2005, STEM CELLS DEV, V14, P595, DOI 10.1089/scd.2005.14.595; Vendrame M, 2006, EXP NEUROL, V199, P191, DOI 10.1016/j.expneurol.2006.03.017; Verderio Claudia, 2013, Front Physiol, V4, P163, DOI 10.3389/fphys.2013.00163; Wakabayashi K, 2010, J NEUROSCI RES, V88, P1017, DOI 10.1002/jnr.22279; WAKAKURA M, 1992, DOC OPHTHALMOL, V80, P385, DOI 10.1007/BF00154389; Walker PA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-228; Walker PA, 2012, SURGERY, V152, P790, DOI 10.1016/j.surg.2012.06.006; Watanabe J, 2013, NEUROBIOL DIS, V59, P86, DOI 10.1016/j.nbd.2013.06.017; Xin HQ, 2013, STEM CELLS, V31, P2737, DOI 10.1002/stem.1409; Xin HQ, 2012, STEM CELLS, V30, P1556, DOI 10.1002/stem.1129; Yan EB, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0328-2; Yan ZJ, 2013, NEUROCHEM RES, V38, P1022, DOI 10.1007/s11064-013-1012-5; Yoo SW, 2008, EXP MOL MED, V40, P387, DOI 10.3858/emm.2008.40.4.387; Zacharek A, 2007, J CEREBR BLOOD F MET, V27, P1684, DOI 10.1038/sj.jcbfm.9600475; Zahedi K, 2010, J NEUROTRAUM, V27, P515, DOI 10.1089/neu.2009.1097; Zanier ER, 2016, J NEUROTRAUM, V33, P1060, DOI 10.1089/neu.2015.4041; Zanier ER, 2014, NEUROTHERAPEUTICS, V11, P679, DOI 10.1007/s13311-014-0277-y; Zanier ER, 2011, CRIT CARE MED, V39, P2501, DOI 10.1097/CCM.0b013e31822629ba; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106	89	39	40	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	NOV	2016	44	11					E1118	E1131		10.1097/CCM.0000000000001864			14	Critical Care Medicine	General & Internal Medicine	EU1ZL	WOS:000400824800012	27441900				2021-06-18	
J	Tirabassi, J; Brou, L; Khodaee, M; Lefort, R; Fields, SK; Comstock, RD				Tirabassi, Jill; Brou, Lina; Khodaee, Morteza; Lefort, Roxanna; Fields, Sarah K.; Comstock, R. Dawn			Epidemiology of High School Sports-Related Injuries Resulting in Medical Disqualification 2005-2006 Through 2013-2014 Academic Years	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						adolescent; fracture; concussion; ligaments	REHABILITATION; PREVENTION; PATTERNS; ATHLETE	Background: Although rare, season-or career-ending injuries in young athletes are concerning because they can result in time lost from sport participation and school, social costs, and economic costs of medical care. Purpose: To describe rates and patterns of medically disqualifying (MDQ) injuries among United States high school athletes overall and by sport, sex, type of athletic activity, and mechanism. Study Design: Descriptive epidemiological study. Methods: Sports-related injury data on high school athletes were collected during the 2005-2006 through 2013-2014 academic years from a large national sample of United States high schools via High School Reporting Information Online (RIO). MDQ injuries were defined as season-or career-ending injuries. Results: From 2005-2006 through 2013-2014, High School RIO captured 59,862 total injuries including 3599 MDQ injuries (6.0% of all injuries). Most MDQ injuries (60.4%) occurred in competition. Football had the highest injury rate (26.5 per 100,000 athlete-exposures), followed by gymnastics (18.6) and wrestling (17.9). MDQ injury rates were higher among girls in the sex-comparable sports of basketball (rate ratio [RR], 1.6; 95% CI, 1.3-2.0), cross-country (RR, 2.6; 95% CI, 1.0-7.5), soccer (RR, 1.6; 95% CI, 1.3-1.9), and track and field (RR, 2.6; 95% CI, 1.7-4.0). Player-player contact (48.2%) was the most common MDQ injury mechanism. The most commonly injured body site was the knee (33.7%). The most common MDQ injury diagnosis was sprains/strains (35.9%); the most common specific MDQ injury was knee sprains/strains (25.4%), with the anterior cruciate ligament being the most commonly injured knee structure. Among boys, fracture was the most common diagnosis in 3 sports, and sprain/strain was the most common in 6 sports. Among girls, sprain/strain was the most common diagnosis in 9 sports, and fracture was the most common only in softball. Conclusion: MDQ injuries vary by sport, sex, and type of athletic activity and occur most frequently as a result of player-player contact. These findings should prompt additional research into the development, implementation, and evaluation of targeted injury prevention efforts.	[Tirabassi, Jill; Brou, Lina; Khodaee, Morteza; Lefort, Roxanna; Fields, Sarah K.; Comstock, R. Dawn] Univ Colorado, Sch Med, Dept Family Med, 3055 Roslyn St,Suite 100, Denver, CO 80238 USA; [Brou, Lina; Lefort, Roxanna; Comstock, R. Dawn] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA; [Fields, Sarah K.] Univ Colorado, Dept Commun, Denver, CO 80202 USA; [Comstock, R. Dawn] Univ Colorado, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA	Tirabassi, J (corresponding author), Univ Colorado, Sch Med, Dept Family Med, 3055 Roslyn St,Suite 100, Denver, CO 80238 USA.	jill.tirabassi@gmail.com		Lefort, Roxanna/0000-0002-5631-1233	Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE000674-01, R49/CE001172-01]; National Federation of State High School Associations; National Operating Committee on Standards for Athletic Equipment; DonJoy Orthotics; EyeBlack; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000674, R49CE001172] Funding Source: NIH RePORTER	One or more of the authors has declared the following potential conflict of interest or source of funding: The content of this report provided by the High School Reporting Information Online (RIO) surveillance system was funded in part by the Centers for Disease Control and Prevention (grant No. R49/CE000674-01 and R49/CE001172-01). The author responsible for High School RIO, R.D.C., also acknowledges the generous research funding contributions of the National Federation of State High School Associations, National Operating Committee on Standards for Athletic Equipment, DonJoy Orthotics, and EyeBlack.	Agel J, 2007, J ATHL TRAINING, V42, P270; Arvinen-Barrow M, 2014, J ATHL TRAINING, V49, P764, DOI 10.4085/1062-6050-49.3.44; Badgeley MA, 2013, J PHYS ACT HEALTH, V10, P160, DOI 10.1123/jpah.10.2.160; Carter CW, 2011, CLIN SPORT MED, V30, P679, DOI 10.1016/j.csm.2011.06.004; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Covassin T, 2015, CLIN SPORT MED, V34, P199, DOI 10.1016/j.csm.2014.12.004; Crossman J, 1997, SPORTS MED, V23, P333, DOI 10.2165/00007256-199723050-00005; Darrow CJ, 2009, AM J SPORT MED, V37, P1798, DOI 10.1177/0363546509333015; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Feeley BT, 2008, AM J SPORT MED, V36, P1597, DOI 10.1177/0363546508316021; Fields SK, 2005, SPORT SOC-SERIES, P1; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Kerr ZY, 2011, CLIN PEDIATR, V50, P594, DOI 10.1177/0009922810390513; LEDDY MH, 1994, RES Q EXERCISE SPORT, V65, P347, DOI 10.1080/02701367.1994.10607639; Mansell J, 2005, J ATHL TRAINING, V40, P310; Mitchell J, 2015, AM J SPORT MED, V43, P1676, DOI 10.1177/0363546515577786; National Federation of State High School Associations, 2014, 2013 2014 HIGH SCH A; Powell JW, 1999, J ATHL TRAINING, V34, P277; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Ross MJ, 1996, J CONSULT CLIN PSYCH, V64, P406, DOI 10.1037/0022-006X.64.2.406; Swenson DM, 2012, AM J SPORT MED, V40, P2078, DOI 10.1177/0363546512453304; United States Census Bureau, CENS REG DIV US; vanMechelen W, 1997, SPORTS MED, V24, P176, DOI 10.2165/00007256-199724030-00006; Vertinsky P.A., 1994, ETERNALLY WOUNDED WO; Washington RL, 2001, PEDIATRICS, V107, P1459	26	39	40	1	22	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	NOV	2016	44	11					2925	2932		10.1177/0363546516644604			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	EB4RE	WOS:000387359900005	27166289				2021-06-18	
J	Impellizzeri, D; Campolo, M; Bruschetta, G; Crupi, R; Cordaro, M; Paterniti, I; Cuzzocrea, S; Esposito, E				Impellizzeri, Daniela; Campolo, Michela; Bruschetta, Giuseppe; Crupi, Rosalia; Cordaro, Marika; Paterniti, Irene; Cuzzocrea, Salvatore; Esposito, Emanuela			Traumatic Brain Injury Leads to Development of Parkinson's Disease Related Pathology in Mice	FRONTIERS IN NEUROSCIENCE			English	Article						chronic traumatic brain injury; Parkinson's disease; e-synuclein; nuclear factor-kappa B; microglia; astrocytes; neurotrophic factors; non-motor symptoms	NF-KAPPA-B; ALPHA-SYNUCLEIN; SUBSTANTIA-NIGRA; DOPAMINERGIC-NEURONS; TREATMENT STRATEGIES; ANXIETY; RATS; PATHOGENESIS; ASTROCYTES; EXPRESSION	Traumatic brain injury (TBI) is a major health and socio-economic problem that affects all societies. This condition results from the application of external physical strength to the brain that leads to transitory or permanent structural and functional impairments. Moreover, TBI is a risk factor for neurodegeneration and can e.g., increase the risk for Parkinson's disease (PD), a late-onset neurodegenerative disorder with loss of dopaminergic neurons in substantia nigra. In this study, we wanted to explore the possible development of PD-related pathology within the context of an experimental model of TBI. Traumatic brain injury was induced in mice by controlled cortical impact. At different time points behavioral tests (open field, elevated plus maze tests, and Barnes maze) were performed: The animals were sacrificed 30 days after the impact and the brains were processed for Western blot and immunohistochemical analyses. Following TBI there was a significant decrease in expression of tyrosine hydroxylase and dopamine transporter in the substantia nigra as well as significant behavioral alterations. In addition, a strong increase in neuroinflammation was evident, as shown by increased levels of cyclooxygenase-2 and inducible nitric oxide synthase as well as I kappa B-alpha degradation and nuclear-KB translocation. Moreover, neurotrophic factors such as brain-derived neurotrophic factor, neurotrophin-3, nerve growth factor, and glial cell line-derived neurotrophic factor were decreased 30 days post-TBI. Interestingly, we observed a significant accumulation of alpha-synuclein in microglia compared to astrocytes. This study suggests that PD-related molecular events can be triggered upon TBI. The biological mechanisms linking brain trauma and neurodegenerative diseases need to be further investigated.	[Impellizzeri, Daniela; Campolo, Michela; Bruschetta, Giuseppe; Crupi, Rosalia; Cordaro, Marika; Paterniti, Irene; Cuzzocrea, Salvatore; Esposito, Emanuela] Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, Messina, Italy; [Cuzzocrea, Salvatore] St Louis Univ, Dept Physiol & Pharmacol, St Louis, MO 63103 USA	Esposito, E (corresponding author), Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, Messina, Italy.	eesposito@unime.it	Crupi, Rosalia/U-4364-2019; Cordaro, Marika/K-7329-2016; Campolo, Michela/K-6432-2016	Cordaro, Marika/0000-0002-3980-0043; Crupi, Rosalia/0000-0002-7629-3132; Cuzzocrea, Salvatore/0000-0001-6131-3690; Impellizzeri, Daniela/0000-0001-9492-3161			Acosta SA, 2015, J CELL PHYSIOL, V230, P1024, DOI 10.1002/jcp.24830; Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baquet ZC, 2005, J NEUROSCI, V25, P6251, DOI 10.1523/JNEUROSCI.4601-04.2005; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Bonito-Oliva A, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00290; Bourque MJ, 2000, EUR J NEUROSCI, V12, P3172, DOI 10.1046/j.1460-9568.2000.00219.x; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Brandt I, 2008, PEPTIDES, V29, P1472, DOI 10.1016/j.peptides.2008.05.005; Burke RE, 1998, J NEUROCHEM, V71, P517; Campolo M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0196-1; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Davis A E, 2000, Crit Care Nurs Q, V23, P1; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Ding W, 2012, ANIM REPROD SCI, V131, P172, DOI 10.1016/j.anireprosci.2012.02.013; Engler H, 2009, BRAIN BEHAV IMMUN, V23, P518, DOI 10.1016/j.bbi.2009.01.018; Esposito E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-66; Ettenhofer ML, 2009, J CLIN EXP NEUROPSYC, V31, P363, DOI 10.1080/13803390802175270; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Grandoso L, 2007, INT J PHARMACEUT, V343, P69, DOI 10.1016/j.ijpharm.2007.05.027; Grilli M, 1999, BIOCHEM PHARMACOL, V57, P1, DOI 10.1016/S0006-2952(98)00214-7; Hoyer W, 2002, J MOL BIOL, V322, P383, DOI 10.1016/S0022-2836(02)00775-1; Jomova K, 2010, MOL CELL BIOCHEM, V345, P91, DOI 10.1007/s11010-010-0563-x; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Kirkwood M, 2013, MILD TRAUMATIC BRAIN; Li XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071341; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mallajosyula JK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001616; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; MENZA MA, 1993, BIOL PSYCHIAT, V34, P465, DOI 10.1016/0006-3223(93)90237-8; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; Newell KL, 1999, J NEUROPATH EXP NEUR, V58, P1263, DOI 10.1097/00005072-199912000-00007; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Oueslati A, 2010, PROG BRAIN RES, V183, P115, DOI 10.1016/S0079-6123(10)83007-9; Ozen LJ, 2012, ARCH CLIN NEUROPSYCH, V27, P85, DOI 10.1093/arclin/acr087; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Peterson AL, 2008, NEUROTHERAPEUTICS, V5, P270, DOI 10.1016/j.nurt.2008.02.003; Phani Sudarshan, 2012, Parkinsonism Relat Disord, V18 Suppl 1, pS207, DOI 10.1016/S1353-8020(11)70064-5; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Przedborski Serge, 2007, Handb Clin Neurol, V83, P535, DOI 10.1016/S0072-9752(07)83026-0; Rappold PM, 2010, NEUROTHERAPEUTICS, V7, P413, DOI 10.1016/j.nurt.2010.07.001; Saing T, 2012, J NEUROTRAUM, V29, P1054, DOI 10.1089/neu.2011.1957; Shahaduzzaman M, 2013, MED HYPOTHESES, V81, P675, DOI 10.1016/j.mehy.2013.07.025; SIMON P, 1994, BEHAV BRAIN RES, V61, P59, DOI 10.1016/0166-4328(94)90008-6; Stahl K, 2011, BRAIN RES, V1378, P105, DOI 10.1016/j.brainres.2010.12.090; Tajiri N, 2014, BRAIN RES, V1559, P65, DOI 10.1016/j.brainres.2014.02.041; Ulusoy A, 2013, MOL NEUROBIOL, V47, P484, DOI 10.1007/s12035-012-8329-y; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; von Bohlen und Halbach O, 2005, FASEB J, V19, P1740, DOI 10.1096/fj.05-3845fje; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zhao S, 2016, MOL NEUROBIOL, V53, P1884, DOI 10.1007/s12035-015-9128-z; Zhou DJ, 2011, J INFECT DIS, V203, P1647, DOI 10.1093/infdis/jir163	58	39	41	0	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.	OCT 13	2016	10								458	10.3389/fnins.2016.00458			13	Neurosciences	Neurosciences & Neurology	DY7GD	WOS:000385296700001	27790086	DOAJ Gold, Green Published			2021-06-18	
J	Tan, XL; Wright, DK; Liu, SJ; Hovens, C; O'Brien, TJ; Shultz, SR				Tan, Xin L.; Wright, David K.; Liu, Shijie; Hovens, Christopher; O'Brien, Terence J.; Shultz, Sandy R.			Sodium selenate, a protein phosphatase 2A activator, mitigates hyperphosphorylated tau and improves repeated mild traumatic brain injury outcomes	NEUROPHARMACOLOGY			English	Article						concussion; chronic traumatic encephalopathy; MRI; diffusion tensor imaging; traumatic brain injury; tauopathy	FLUID PERCUSSION INJURY; OXIDATIVE STRESS; ANIMAL-MODEL; RAT MODEL; REDUCES NEUROINFLAMMATION; ALZHEIMERS-DISEASE; PHOSPHORYLATION; NEURODEGENERATION; UBIQUITIN; ANTIBODY	Mild traumatic brain injuries may result in cumulative brain damage and neurodegenerative disease. To date, there is no pharmaceutical intervention known to prevent these consequences. Hyperphosphorylated tau has been associated in this process, and protein phosphatase 2A 55 kDa regulatory B subunit (PP2A/PR55) - the major tau phosphatase-is decreased after a brain insult. Sodium selenate up-regulates PP2A/PR55 and dephosphorylates tau, and may hold promise as a treatment in the mild brain injury setting. Here we investigated sodium selenate treatment in rats given repeated mild traumatic brain injuries. Rats were given three mild fluid percussion injuries or three sham-injuries, and treated with sodium selenate (1 mg/kg/day) or saline-vehicle for three months before undergoing behavioral testing, MRI, and post-mortem analysis of brain tissue. Repeated mild traumatic brain injuries increased the phosphorylation of tau and decreased PP2A/PR55, whilst inducing brain atrophy and cognitive and sensorimotor deficits. Sodium selenate treatment increased PP2A/PR55, and decreased tau phosphorylation, brain damage, and cognitive and motor impairments in rats given repeated mild traumatic brain injuries. Our findings implicate PP2A/PR55 and tau as important mechanisms in the pathophysiological aftermath of repeated mild brain traumas, and support sodium selenate as a novel and translatable treatment for these common injuries. (C) 2016 Elsevier Ltd. All rights reserved.	[Tan, Xin L.; Liu, Shijie; O'Brien, Terence J.; Shultz, Sandy R.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3050, Australia; [Wright, David K.] Univ Melbourne, Anat & Neurosci, Parkville, Vic 3010, Australia; [Wright, David K.] Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3052, Australia; [Hovens, Christopher] Univ Melbourne, Royal Melbourne Hosp, Dept Surg, Parkville, Vic 3050, Australia	Shultz, SR (corresponding author), Univ Melbourne, Dept Med, Off 1 02, Melbourne Brain Ctr, Parkville, Vic 3052, Australia.	sshultz@unimelb.edu.au		Wright, David/0000-0002-7535-8651; O'Brien, Terence/0000-0002-7198-8621; Hovens, Christopher/0000-0002-0610-1289	NHMRCNational Health and Medical Research Council of Australia [1062653]; Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR); NHMRCNational Health and Medical Research Council of Australia	This study was funded by a grant to SRS from the NHMRC (#1062653), and fellowships to SRS from the Canadian Institute of Health Research and the NHMRC. The authors declare that there are no competing financial interests in relation to this work.	Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Avants BB, 2011, NEUROIMAGE, V54, P2033, DOI 10.1016/j.neuroimage.2010.09.025; Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bolognin S, 2012, ACTA NEUROPATHOL, V123, P133, DOI 10.1007/s00401-011-0908-x; Calamante F, 2010, NEUROIMAGE, V53, P1233, DOI 10.1016/j.neuroimage.2010.07.024; Chen LJ, 2010, J NEUROTRAUM, V27, P1657, DOI 10.1089/neu.2010.1308; Cheng JS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115765; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Corcoran NM, 2010, BRIT J CANCER, V103, P462, DOI 10.1038/sj.bjc.6605798; Corcoran NM, 2010, J CLIN NEUROSCI, V17, P1025, DOI 10.1016/j.jocn.2010.04.020; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; Dias-Santagata D, 2007, J CLIN INVEST, V117, P236, DOI 10.1172/JCI28769; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; Gendron TF, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-13; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Gotz J, 2010, BBA-MOL BASIS DIS, V1802, P860, DOI 10.1016/j.bbadis.2009.09.008; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; Hylin MJ, 2013, J NEUROTRAUM, V30, P702, DOI 10.1089/neu.2012.2630; Iqbal K, 2009, ACTA NEUROPATHOL, V118, P53, DOI 10.1007/s00401-009-0486-3; Johnstone VPA, 2015, J NEUROTRAUM, V32, P1333, DOI 10.1089/neu.2014.3785; Johnstone VPA, 2014, J NEUROTRAUM, V31, P1881, DOI 10.1089/neu.2014.3343; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Koh PO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054217; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Lauckner J, 2003, NEUROBIOL AGING, V24, P767, DOI 10.1016/S0197-4580(02)00228-2; Lee MJ, 2013, PROG NEUROBIOL, V105, P49, DOI 10.1016/j.pneurobio.2013.03.001; Li B, 2007, ACTA NEUROPATHOL, V113, P501, DOI 10.1007/s00401-007-0207-8; Liang ZH, 2009, J ALZHEIMERS DIS, V17, P531, DOI 10.3233/JAD-2009-1069; Lim MM, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007092; Liu F, 2005, EUR J NEUROSCI, V22, P1942, DOI 10.1111/j.1460-9568.2005.04391.x; Liu S., 2016, BRAIN IN PRESS; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Morris M, 2011, NEURON, V70, P410, DOI 10.1016/j.neuron.2011.04.009; Oberg EA, 2012, J BIOL CHEM, V287, P43378, DOI 10.1074/jbc.M112.420281; Pannek K, 2011, NEUROIMAGE, V55, P133, DOI 10.1016/j.neuroimage.2010.12.010; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Sengupta A, 1998, ARCH BIOCHEM BIOPHYS, V357, P299, DOI 10.1006/abbi.1998.0813; Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006; Shultz SR, 2015, J CEREBR BLOOD F MET, V35, P1339, DOI 10.1038/jcbfm.2015.56; Shultz SR, 2015, BRAIN, V138, P1297, DOI 10.1093/brain/awv053; Shultz SR, 2015, BEHAV BRAIN RES, V278, P542, DOI 10.1016/j.bbr.2014.10.050; Shultz SR, 2014, J NEUROTRAUM, V31, P976, DOI 10.1089/neu.2013.3106; Shultz SR, 2014, NEUROTHERAPEUTICS, V11, P347, DOI 10.1007/s13311-014-0258-1; Shultz SR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-26; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Sontag E, 2004, J NEUROPATH EXP NEUR, V63, P287, DOI 10.1093/jnen/63.4.287; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Sun KJ, 2013, BRAIN RES, V1506, P132, DOI 10.1016/j.brainres.2013.02.011; Tournier JD, 2013, NMR BIOMED, V26, P1775, DOI 10.1002/nbm.3017; van Eersel J, 2010, P NATL ACAD SCI USA, V107, P13888, DOI 10.1073/pnas.1009038107; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Wang JZ, 2007, EUR J NEUROSCI, V25, P59, DOI 10.1111/j.1460-9568.2006.05226.x; Wang JZ, 1996, MOL BRAIN RES, V38, P200, DOI 10.1016/0169-328X(95)00316-K; Wang T, 2013, RESTOR NEUROL NEUROS, V31, P647, DOI 10.3233/RNN-130316; Weaver LC, 2015, EXP NEUROL, V271, P409, DOI 10.1016/j.expneurol.2015.07.003; Webster KM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0457-7; Xu YH, 2008, MOL CELL, V31, P873, DOI 10.1016/j.molcel.2008.08.006; Yao XL, 2007, BRAIN RES, V1182, P116, DOI 10.1016/j.brainres.2007.08.076; Zheng P, 2014, MOL NEUROBIOL, V49, P1532, DOI 10.1007/s12035-013-8601-9; Zhu XW, 2000, J NEUROPATH EXP NEUR, V59, P880, DOI 10.1093/jnen/59.10.880	67	39	39	0	43	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	SEP	2016	108						382	393		10.1016/j.neuropharm.2016.05.001			12	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	DQ1IA	WOS:000378953500038	27163189				2021-06-18	
J	Winter, CC; Katiyar, KS; Hernandez, NS; Song, YJ; Struzyna, LA; Harris, JP; Cullen, DK				Winter, Carla C.; Katiyar, Kritika S.; Hernandez, Nicole S.; Song, Yeri J.; Struzyna, Laura A.; Harris, James P.; Cullen, D. Kacy			Transplantable living scaffolds comprised of micro-tissue engineered aligned astrocyte networks to facilitate central nervous system regeneration	ACTA BIOMATERIALIA			English	Article						Tissue engineering; Living scaffold; Glial cell transplant; Biomaterials; Regeneration; Neurotrauma; Neurodegeneration; Traumatic brain injury; Cell migration; Axon pathfinding; Neural stem cells	ROSTRAL MIGRATORY STREAM; SPINAL-CORD-INJURY; NEURAL STEM-CELLS; NEURITE OUTGROWTH; IN-VITRO; SUBSTRATE CURVATURE; TRACT AXONS; GLIAL SCAR; BRAIN; ALIGNMENT	Neurotrauma, stroke, and neurodegenerative disease may result in widespread loss of neural cells as well as the complex interconnectivity necessary for proper central nervous system function, generally resulting in permanent functional deficits. Potential regenerative strategies involve the recruitment of endogenous neural stem cells and/or directed axonal regeneration through the use of tissue engineered "living scaffolds" built to mimic features of three-dimensional (3-D) in vivo migratory or guidance pathways. Accordingly, we devised a novel biomaterial encasement scheme using tubular hydrogel-collagen micro-columns that facilitated the self-assembly of seeded astrocytes into 3-D living scaffolds consisting of long, cable-like aligned astrocytic networks. Here, robust astrocyte alignment was achieved within a micro-column inner diameter (ID) of 180 mu m or 300-350 mu m but not 1.0 mm, suggesting that radius of curvature dictated the extent of alignment. Moreover, within small ID micro-columns, >70% of the astrocytes assumed a bi-polar morphology, versus similar to 10% in larger micro-columns or planar surfaces. Cell-cell interactions also influenced the aligned architecture, as extensive astrocyte-collagen contraction was achieved at high (9-12 x 10(5) cells/mL) but not lower (2-6 x 10(5) cells/mL) seeding densities. This high density micro-column seeding led to the formation of ultra-dense 3-D "bundles" of aligned bi-polar astrocytes within collagen measuring up to 150 mu m in diameter yet extending to a remarkable length of over 2.5 cm. Importantly, co-seeded neurons extended neurites directly along the aligned astrocytic bundles, demonstrating permissive cues for neurite extension. These transplantable cable-like astrocytic networks structurally mimic the glial tube that guides neuronal progenitor migration in vivo along the rostral migratory stream, and therefore may be useful to guide progenitor cells to repopulate sites of widespread neurodegeneration. Statement of Significance This manuscript details our development of novel micro-tissue engineering techniques to generate robust networks of longitudinally aligned astrocytes within transplantable micro-column hydrogels. We report a novel biomaterial encasement scheme that facilitated the self-assembly of seeded astrocytes into long, aligned regenerative pathways. These miniature "living scaffold" constructs physically emulate the glial tube - a pathway in the brain consisting of aligned astrocytes that guide the migration of neuronal progenitor cells - and therefore may facilitate directed neuronal migration for central nervous system repair. The small size and self-contained design of these aligned astrocyte constructs will permit minimally invasive transplantation in models of central nervous system injury in future studies. (C) 2016 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.	[Winter, Carla C.; Katiyar, Kritika S.; Hernandez, Nicole S.; Song, Yeri J.; Struzyna, Laura A.; Harris, James P.; Cullen, D. Kacy] Univ Penn, Perelman Sch Med, Ctr Brain Injury & Repair, Dept Neurosurg, Philadelphia, PA 19104 USA; [Winter, Carla C.; Struzyna, Laura A.] Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA; [Winter, Carla C.; Katiyar, Kritika S.; Struzyna, Laura A.; Harris, James P.; Cullen, D. Kacy] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA; [Katiyar, Kritika S.] Drexel Univ, Sch Biomed Engn, Philadelphia, PA 19104 USA; [Hernandez, Nicole S.; Song, Yeri J.; Cullen, D. Kacy] Univ Penn, Perelman Sch Med, Neurosci Grad Grp, Philadelphia, PA 19104 USA	Cullen, DK (corresponding author), 105E Hayden Hall 3320 Smith Walk, Philadelphia, PA 19104 USA.	dkacy@mail.med.upenn.edu		Harris, James/0000-0002-8458-5434	Penn Medicine Neuroscience Center; National Science FoundationNational Science Foundation (NSF) [DGE-1321851]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32-NS043126, F31-NS090746]; Michael J. Fox Foundation (Therapeutic Pipeline Program) [9998]; Department of Veterans Affairs (RRD Merit Review)US Department of Veterans Affairs [B1097-I]; U.S. Army Medical Research and Materiel Command through the Joint Warfighter Medical Research Program [W81XWH-13-207004]; Penn's Center for Undergraduate Research Fellowships; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS090746, U01NS094340, T32NS043126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA028874] Funding Source: NIH RePORTER	Financial support was provided by the Penn Medicine Neuroscience Center, National Science Foundation (Graduate Research Fellowship DGE-1321851), National Institutes of Health (T32-NS043126; F31-NS090746), Michael J. Fox Foundation (Therapeutic Pipeline Program #9998), Department of Veterans Affairs (RR&D Merit Review #B1097-I), U.S. Army Medical Research and Materiel Command through the Joint Warfighter Medical Research Program (#W81XWH-13-207004), and Penn's Center for Undergraduate Research & Fellowships. We thank Patricia Murphy for technical assistance in these studies.	Abematsu M., 2012, J CLIN INVEST, P3255; Alexander JK, 2006, NEURON GLIA BIOL, V2, P93, DOI 10.1017/S1740925X0600010X; Alonso M, 2008, J NEUROSCI, V28, P11089, DOI 10.1523/JNEUROSCI.3713-08.2008; Arellano JI, 2011, NATURE, V478, P333, DOI 10.1038/478333a; Aubin H, 2010, BIOMATERIALS, V31, P6941, DOI 10.1016/j.biomaterials.2010.05.056; Barry DS, 2013, J ANAT, V222, P203, DOI 10.1111/joa.12006; Biran R, 2003, EXP NEUROL, V184, P141, DOI 10.1016/S0014-4886(03)00253-X; Bonfanti L, 2007, PROG NEUROBIOL, V83, P24, DOI 10.1016/j.pneurobio.2006.11.002; Bradbury EJ, 2011, BRAIN RES BULL, V84, P306, DOI 10.1016/j.brainresbull.2010.06.015; Burda JE, 2014, NEURON, V81, P229, DOI 10.1016/j.neuron.2013.12.034; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Cullen DK, 2007, J NEUROSCI RES, V85, P3642, DOI 10.1002/jnr.21434; Cullen DK, 2012, TISSUE ENG PT A, V18, P2280, DOI [10.1089/ten.tea.2011.0534, 10.1089/ten.TEA.2011.0534]; Cullen D. Kacy, 2011, Critical Reviews in Biomedical Engineering, V39, P201; Cullen D. Kacy, 2011, Critical Reviews in Biomedical Engineering, V39, P241; Cullen DK, 2010, BRAIN RES, V1359, P44, DOI 10.1016/j.brainres.2010.08.058; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; East E, 2010, TISSUE ENG PT A, V16, P3173, DOI 10.1089/ten.tea.2010.0017; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Granger N, 2012, BRAIN, V135, P3227, DOI 10.1093/brain/aws268; Gros T, 2010, BIOMATERIALS, V31, P6719, DOI 10.1016/j.biomaterials.2010.04.035; Harris JP, 2016, J NEURAL ENG, V13, DOI 10.1088/1741-2560/13/1/016019; HATTEN ME, 1990, EXPERIENTIA, V46, P907, DOI 10.1007/BF01939383; Houle JD, 2006, J NEUROSCI, V26, P7405, DOI 10.1523/JNEUROSCI.1166-06.2006; Hsiao TW, 2015, BIOMATERIALS, V39, P124, DOI 10.1016/j.biomaterials.2014.10.062; Huang JH, 2009, TISSUE ENG PT A, V15, P1677, DOI 10.1089/ten.tea.2008.0294; Irons HR, 2008, J NEURAL ENG, V5, P333, DOI 10.1088/1741-2560/5/3/006; JOOSTEN EAJ, 1989, NEUROSCIENCE, V31, P439, DOI 10.1016/0306-4522(89)90386-2; Katiyar K. S., 2016, J TISSUE EN IN PRESS; Kawano H, 2012, CELL TISSUE RES, V349, P169, DOI 10.1007/s00441-012-1336-5; KIM SU, 1983, BRAIN RES, V274, P79, DOI 10.1016/0006-8993(83)90522-X; Ladewig J, 2014, NAT NEUROSCI, V17, P24, DOI 10.1038/nn.3583; LaPlaca MC, 2010, ARTECH HSE METH BIOE, P187; Lu P, 2014, NEURON, V83, P789, DOI 10.1016/j.neuron.2014.07.014; Lu P, 2012, CELL, V150, P1264, DOI 10.1016/j.cell.2012.08.020; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MORRISON RS, 1981, P NATL ACAD SCI-BIOL, V78, P7205, DOI 10.1073/pnas.78.11.7205; NEUGEBAUER KM, 1988, J CELL BIOL, V107, P1177, DOI 10.1083/jcb.107.3.1177; Peretto P, 1997, BRAIN RES BULL, V42, P9, DOI 10.1016/S0361-9230(96)00116-5; REIER PJ, 1979, BRAIN RES, V164, P61, DOI 10.1016/0006-8993(79)90006-4; Rivet Christopher J, 2015, Biomatter, V5, pe1005527, DOI 10.1080/21592535.2015.1005527; Sanai N, 2011, NATURE, V478, P382, DOI 10.1038/nature10487; Shear DA, 2011, RESTOR NEUROL NEUROS, V29, P215, DOI 10.3233/RNN-2011-0593; Smeal RM, 2005, ANN BIOMED ENG, V33, P376, DOI 10.1007/s10439-005-1740-z; Smeal RM, 2008, EXP NEUROL, V213, P281, DOI 10.1016/j.expneurol.2008.05.026; SMITH GM, 1986, J COMP NEUROL, V251, P23, DOI 10.1002/cne.902510103; Sofroniew MV, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020420; STOPAK D, 1982, DEV BIOL, V90, P383, DOI 10.1016/0012-1606(82)90388-8; Struzyna LA, 2015, TISSUE ENG PT A, V21, P2744, DOI [10.1089/ten.tea.2014.0557, 10.1089/ten.TEA.2014.0557]; Struzyna LA, 2015, NEURAL REGEN RES, V10, P679, DOI 10.4103/1673-5374.156943; Struzyna LA, 2014, CURR OPIN SOLID ST M, V18, P308, DOI 10.1016/j.cossms.2014.07.004; Thompson LH, 2015, NEUROBIOL DIS, V79, P28, DOI 10.1016/j.nbd.2015.04.003; Wang CM, 2011, CELL RES, V21, P1534, DOI 10.1038/cr.2011.83; Zukor KA, 2011, NEURAL DEV, V6, DOI 10.1186/1749-8104-6-1	56	39	39	0	60	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1742-7061	1878-7568		ACTA BIOMATER	Acta Biomater.	JUL 1	2016	38						44	58		10.1016/j.actbio.2016.04.021			15	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	DQ1LZ	WOS:000378963800005	27090594	Green Accepted			2021-06-18	
J	Pham, PV; Truong, NC; Le, PTB; Tran, TDX; Vu, NB; Bui, KHT; Phan, NK				Phuc Van Pham; Nhat Chau Truong; Phuong Thi-Bich Le; Tung Dang-Xuan Tran; Ngoc Bich Vu; Khanh Hong-Thien Bui; Ngoc Kim Phan			Isolation and proliferation of umbilical cord tissue derived mesenchymal stem cells for clinical applications	CELL AND TISSUE BANKING			English	Article						Activated platelet rich plasma; Clinical application of mesenchymal stem cells; Umbilical cord; Umbilical cord derived mesenchymal stem cells; Good manufacturing practice; UC-MSCs	SYSTEMIC-LUPUS-ERYTHEMATOSUS; PLATELET-RICH PLASMA; FETAL BOVINE SERUM; TRAUMATIC BRAIN-INJURY; STROMAL CELLS; LIVER-FUNCTION; BONE-MARROW; BLOOD-SERUM; TRANSPLANTATION; EXPANSION	Umbilical cord (UC) is a rich source of rapidly proliferating mesenchymal stem cells (MSCs) that are easily cultured on a large-scale. Clinical applications of UC-MSCs include graft-versus-host disease, and diabetes mellitus types 1 and 2. UC-MSCs should be isolated and proliferated according to good manufacturing practice (GMP) with animal component-free medium, quality assurance, and quality control for their use in clinical applications. This study developed a GMP standard protocol for UC-MSC isolation and culture. UC blood and UC were collected from the same donors. Blood vasculature was removed from UC. UC blood was used as a source of activated platelet rich plasma (aPRP). Small fragments (1-2 mm(2)) of UC membrane and Wharton's jelly were cut and cultured in DMEM/F12 medium containing 1 % antibiotic-antimycotic, aPRP (2.5, 5, 7.5 and 10 %) at 37 A degrees C in 5 % CO2. The MSC properties of UC-MSCs at passage 5 such as osteoblast, chondroblast and adipocyte differentiation, and markers including CD13, CD14, CD29, CD34, CD44, CD45, CD73, CD90, CD105, and HLA-DR were confirmed. UC-MSCs also were analyzed for karyotype, expression of tumorigenesis related genes, cell cycle, doubling time as well as in vivo tumor formation in NOD/SCID mice. Control cells consisted of UC-MSCs cultured in DMEM/F12 plus 1 % antibiotic-antimycotic, and 10 % fetal bovine serum (FBS). All UC-MSC (n = 30) samples were successfully cultured in medium containing 7.5 and 10 % aPRP, 92 % of samples grew in 5.0 % aPRP, 86 % of samples in 2.5 % aPRP, and 72 % grew in 10 % FBS. UC-MSCs in these four groups exhibited similar marker profiles. Moreover, the proliferation rates in medium with PRP, especially 7.5 and 10 %, were significantly quicker compared with 2.5 and 5 % aPRP or 10 % FBS. These cells maintained a normal karyotype for 15 sub-cultures, and differentiated into osteoblasts, chondroblasts, and adipocytes. The analysis of pluripotent cell markers showed UC-MSCs maintained the expression of the oncogenes Nanog and Oct4 after long term culture but failed to transfer tumors in NOD/SCID mice. Replacing FBS with aPRP in the culture medium for UC tissues allowed the successful isolation of UC-MSCs that satisfy the minimum standards for clinical applications.	[Phuc Van Pham; Nhat Chau Truong; Ngoc Bich Vu; Ngoc Kim Phan] Vietnam Natl Univ, Univ Sci, Lab Stem Cell Res & Applicat, Ho Chi Minh City, Vietnam; [Phuong Thi-Bich Le; Tung Dang-Xuan Tran] Van Hanh Hosp, Van Hanh Stem Cell Unit, Ho Chi Minh City, Vietnam; [Khanh Hong-Thien Bui] Univ Med & Pharm, Univ Med Ctr, Ho Chi Minh City, Vietnam	Pham, PV (corresponding author), Vietnam Natl Univ, Univ Sci, Lab Stem Cell Res & Applicat, Ho Chi Minh City, Vietnam.	pvphuc@hcmuns.edu.vn; tcnhat@hcmus.edu.vn; drbphuong@gmail.com; drxuantung@gmail.com; vbngoc@hcmus.edu.vn; khanhbui1969@yahoo.com; pvphuc@hcmus.edu.vn	Truong, Nhat/AAH-4931-2021; tdx, tung/T-8246-2019; Van Pham, Phuc/L-6131-2013	Van Pham, Phuc/0000-0001-7254-0717	Ministry of Science and TechnologyMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [DTDL.2012-G/23]	This research was funded by Ministry of Science and Technology via project Grant No. DTDL.2012-G/23.	Baba K, 2013, J CRANIO MAXILL SURG, V41, P775, DOI 10.1016/j.jcms.2013.01.025; Badraiq Heba, 2015, Methods Mol Biol, V1283, P65, DOI 10.1007/7651_2014_116; Bieback K, 2009, STEM CELLS, V27, P2331, DOI 10.1002/stem.139; Blande IS, 2009, TRANSFUSION, V49, P2680, DOI 10.1111/j.1537-2995.2009.02346.x; Buyl K, 2015, TOXICOL IN VITRO, V29, P1254, DOI 10.1016/j.tiv.2014.12.008; Chen Guang-hua, 2012, Zhonghua Xue Ye Xue Za Zhi, V33, P303; Cheng HB, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0253-7; Ding DC, 2015, CELL TRANSPLANT, V24, P339, DOI 10.3727/096368915X686841; Ding Y, 2013, IN VITRO CELL DEV-AN, V49, P771, DOI 10.1007/s11626-013-9663-8; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Escobedo-Lucea C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067870; Fekete N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043255; Gu F, 2014, CLIN RHEUMATOL, V33, P1611, DOI 10.1007/s10067-014-2754-4; Han DM, 2011, CYTOTHERAPY, V13, P913, DOI 10.3109/14653249.2011.579958; Iftimia-Mander A, 2013, BIOPRESERV BIOBANK, V11, P291, DOI 10.1089/bio.2013.0027; Jiang YJ, 2013, CELL TRANSPLANT, V22, P2291, DOI 10.3727/096368912X658818; Jin JL, 2013, CURR NEUROVASC RES, V10, P11, DOI 10.2174/156720213804805936; Jonsdottir-Buch SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068984; Kim JW, 2004, ANN HEMATOL, V83, P733, DOI 10.1007/s00277-004-0918-z; Kocaoemer A, 2007, STEM CELLS, V25, P1270, DOI 10.1634/stemcells.2006-0627; Kong DX, 2014, CLIN LAB, V60, P1969, DOI 10.7754/Clin.Lab.2014.140305; Lee JY, 2011, IN VITRO CELL DEV-AN, V47, P157, DOI 10.1007/s11626-010-9364-5; Lee OK, 2004, BLOOD, V103, P1669, DOI 10.1182/blood-2003-05-1670; Liu J, 2013, CYTOTHERAPY, V15, P185, DOI 10.1016/j.jcyt.2012.09.005; Lv YT, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-196; Ma HY, 2012, CELL TRANSPLANT, V21, P857, DOI 10.3727/096368911X612486; Mareschi K, 2001, HAEMATOLOGICA, V86, P1099; Marx RE, 2004, J ORAL MAXIL SURG, V62, P489, DOI 10.1016/j.joms.2003.12.003; Mori Y, 2015, TISSUE ENG PART C-ME, V21, P367, DOI [10.1089/ten.tec.2014.0385, 10.1089/ten.TEC.2014.0385]; Murphy MB, 2012, BIOMATERIALS, V33, P5308, DOI 10.1016/j.biomaterials.2012.04.007; Nascimento DS, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt394; Otte A, 2013, TISSUE ENG PART C-ME, V19, P937, DOI [10.1089/ten.TEC.2013.0007, 10.1089/ten.tec.2013.0007]; Peng WJ, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0034-0; Phuc PV, 2012, CELL TISSUE BANK, V13, P341, DOI 10.1007/s10561-011-9262-4; Pham PV, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-56; Pineault N, 2015, EXP HEMATOL, V43, P498, DOI 10.1016/j.exphem.2015.04.011; Rauch C, 2011, ALTEX-ALTERN ANIM EX, V28, P305, DOI 10.14573/altex.2011.4.305; Romanov YA, 2003, STEM CELLS, V21, P105, DOI 10.1634/stemcells.21-1-105; Shetty P, 2007, CELL BIOL INT, V31, P293, DOI 10.1016/j.cellbi.2006.11.010; Shi DY, 2012, CLIN RHEUMATOL, V31, P841, DOI 10.1007/s10067-012-1943-2; Shi M, 2012, STEM CELL TRANSL MED, V1, P725, DOI 10.5966/sctm.2012-0034; Sun LY, 2010, ARTHRITIS RHEUM-US, V62, P2467, DOI 10.1002/art.27548; Van Pham Phuc, 2015, Methods Mol Biol, V1283, P73, DOI 10.1007/7651_2014_125; Wang DD, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4520; Wang DD, 2013, CELL TRANSPLANT, V22, P2267, DOI [10.3727/096368911X582769c, 10.3727/096368911X582769]; Wang LF, 2013, J GASTROEN HEPATOL, V28, P85, DOI 10.1111/jgh.12029; Wang S, 2013, BRAIN RES, V1532, P76, DOI 10.1016/j.brainres.2013.08.001; Woodworth TG, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4677; Wu KH, 2013, CELL TRANSPLANT, V22, P2041, DOI 10.3727/096368912X663533; Wu KH, 2013, TRANSPLANTATION, V95, P773, DOI 10.1097/TP.0b013e31827a93dd; Zhang H, 2012, CELL BIOCHEM FUNCT, V30, P643, DOI 10.1002/cbf.2843; Zhang Z, 2012, J GASTROEN HEPATOL, V27, P112, DOI 10.1111/j.1440-1746.2011.07024.x	52	39	40	1	27	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1389-9333	1573-6814		CELL TISSUE BANK	Cell Tissue Banking	JUN	2016	17	2					289	302		10.1007/s10561-015-9541-6			14	Cell Biology; Engineering, Biomedical	Cell Biology; Engineering	DN3UD	WOS:000376988400014	26679929				2021-06-18	
J	Shen, X; Ma, L; Dong, WW; Wu, Q; Gao, Y; Luo, CL; Zhang, MY; Chen, XP; Tao, LY				Shen, Xi; Ma, Lu; Dong, Wenwen; Wu, Qiong; Gao, Yuan; Luo, Chengliang; Zhang, Mingyang; Chen, Xiping; Tao, Luyang			Autophagy regulates intracerebral hemorrhage induced neural damage via apoptosis and NF-kappa B pathway	NEUROCHEMISTRY INTERNATIONAL			English	Article						Intracerebral hemorrhage; Neuron; Autophagy; Apoptosis; Inflammation	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; CELL-DEATH; PLASMALEMMA PERMEABILITY; RAT MODEL; RECEPTOR; ACTIVATION; NEUROPROTECTION; INHIBITION; EXPRESSION	Autophagy can be a pro-survival or a pro-death mechanism depending on the context. The role of autophagy in intracerebral hemorrhage (ICH) remains elusive. In this study, in vivo and in vitro experiments have been carried out to investigate the role of autophagy after ICH. Collagenase-induced ICH model in mouse was made for in vivo experiments. Primary cortical neurons cultures were exposed to hemin to mimic ICH in vitro. 3-Methyladenine (3-MA) and rapamycin (RAP) were administrated both in vivo and in vitro. We first measured brain water content and cell death after ICH in model. Expression of LC3, p62/SQSTM1 (p62), Beclin1, Caspase3 and Bcl-2, which have been found related to autophagy and apoptosis, were assessed both in vivo and in vitro. Furthermore, NF-kappa B was detected to explore the potential mechanisms. We found brain edema in ICH model in mouse and the number of Propidium Iodide (PI)-positive cells both in vivo and in vitro were decreased by 3-MA pretreated. Simultaneously, both in vivo and in vitro, 3-MA significantly decreased the expression of LC3-II and Beclin-1, and maintained p62 at high level after ICH. Furthermore, pretreatment with 3-MA downregulated the level of cleaved caspase-3 but upregulated the Bcl-2 level. Conversely, RAP pretreatment reversed all these results above. These data indicated that autophagy activation may deprave ICH induced brain injury in ICH model and neuro-damage may be related to regulating of NF-kappa B pathway and thereby promote inflammation and apoptosis, thus might provide novel therapeutic interventions for ICH. (C) 2016 Elsevier Ltd. All rights reserved.	[Shen, Xi; Ma, Lu; Wu, Qiong; Gao, Yuan; Luo, Chengliang; Zhang, Mingyang; Chen, Xiping; Tao, Luyang] Soochow Univ, Sch Med, Dept Forens Sci, 178 Ganjiang East Rd, Suzhou 215123, Peoples R China; [Dong, Wenwen] China Med Univ, Sch Forens Med, Dept Forens Pathol, Shenyang 110122, Peoples R China	Tao, LY (corresponding author), Soochow Univ, Sch Med, Dept Forens Sci, 178 Ganjiang East Rd, Suzhou 215123, Peoples R China.	luyang.tao@163.com	Mingyang, Zhang/J-7412-2019	Mingyang, Zhang/0000-0001-7084-6237; Shen, Xi/0000-0001-7568-7335; Zhang, Mingyang/0000-0003-1612-0763	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81530062, 81271379, 81373251, 81301039, 81400999]; National High Technology Research and Development Program of China (863 Program)National High Technology Research and Development Program of China [2015AA020503]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This study was supported by grants 81530062, 81271379, 81373251, 81301039 and 81400999 from the National Natural Science Foundation of China, National High Technology Research and Development Program of China (863 Program, No.2015AA020503), and a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Adeoye O, 2011, TRANSL STROKE RES, V2, P17, DOI 10.1007/s12975-010-0037-1; Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Adhami F, 2006, AM J PATHOL, V169, P566, DOI 10.2353/ajpath.2006.051066; Carloni S, 2008, NEUROBIOL DIS, V32, P329, DOI 10.1016/j.nbd.2008.07.022; CARO LHP, 1988, EUR J BIOCHEM, V175, P325, DOI 10.1111/j.1432-1033.1988.tb14200.x; Chang P, 2014, J MOL NEUROSCI, V52, P242, DOI 10.1007/s12031-013-0132-3; Chen CW, 2012, AUTOPHAGY, V8, P1510, DOI 10.4161/auto.21289; Clark W, 1998, STROKE, V29, P2136, DOI 10.1161/01.STR.29.10.2136; Colleran A, 2011, J BIOL CHEM, V286, P22886, DOI 10.1074/jbc.M110.199950; Criollo A, 2012, CELL CYCLE, V11, P194, DOI 10.4161/cc.11.1.18669; Cui CM, 2015, MOL MED REP, V12, P2323, DOI 10.3892/mmr.2015.3611; Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33; Gao C., 2015, PLOS ONE, V10; Ginet V, 2014, AUTOPHAGY, V10, P846, DOI 10.4161/auto.28264; Ginet V, 2009, AM J PATHOL, V175, P1962, DOI 10.2353/ajpath.2009.090463; Gleixner A. M., 2015, MOL NEUROBIOL; Gong C, 2000, BRAIN RES, V871, P57, DOI 10.1016/S0006-8993(00)02427-6; He Y, 2008, J CEREBR BLOOD F MET, V28, P897, DOI 10.1038/sj.jcbfm.9600578; Hu SK, 2011, BRAIN RES, V1424, P60, DOI 10.1016/j.brainres.2011.09.062; Hwang BY, 2011, CEREBROVASC DIS, V31, P211, DOI 10.1159/000321870; Ichimura Y, 2008, J BIOL CHEM, V283, P22847, DOI 10.1074/jbc.M802182200; Jeruc J, 2006, AM J KIDNEY DIS, V48, P410, DOI 10.1053/j.ajkd.2006.05.019; Jing CH, 2012, NEUROSCIENCE, V213, P144, DOI 10.1016/j.neuroscience.2012.03.055; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Krafft PR, 2012, STROKE, V43, P844, DOI 10.1161/STROKEAHA.111.639989; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Lamark T, 2009, CELL CYCLE, V8, P1986, DOI 10.4161/cc.8.13.8892; Lee IN, 2015, J NEUROSCI RES, V93, P178, DOI 10.1002/jnr.23454; Lee JY, 2009, BRAIN RES, V1287, P126, DOI 10.1016/j.brainres.2009.06.028; Lin S, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-46; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo CL, 2013, J NEUROTRAUM, V30, P597, DOI 10.1089/neu.2012.2425; MacLellan CL, 2008, J CEREBR BLOOD F MET, V28, P516, DOI 10.1038/sj.jcbfm.9600548; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Manaenko A, 2011, NEUROCHEM INT, V58, P542, DOI 10.1016/j.neuint.2011.01.018; Matsushita K, 2000, J CEREBR BLOOD F MET, V20, P396, DOI 10.1097/00004647-200002000-00022; Mohan S, 2015, NEUROTOXICOLOGY, V46, P53, DOI 10.1016/j.neuro.2014.10.012; Mohan S, 2013, FRONT MOL NEUROSCI, V6, DOI 10.3389/fnmol.2013.00031; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Pan T, 2009, NEUROSCIENCE, V164, P541, DOI 10.1016/j.neuroscience.2009.08.014; Park J, 2012, J CEREBR BLOOD F MET, V32, P330, DOI 10.1038/jcbfm.2011.131; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Qin ZH, 1999, J NEUROSCI, V19, P4023; Qureshi AI, 2003, NEUROSURGERY, V52, P1041, DOI 10.1227/01.NEU.0000057694.96978.BC; Rami A, 2008, NEUROBIOL DIS, V29, P132, DOI 10.1016/j.nbd.2007.08.005; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Smith CM, 2011, NEUROBIOL DIS, V43, P52, DOI 10.1016/j.nbd.2010.09.014; Su MF, 2013, J ONCOL, V2013, DOI 10.1155/2013/102735; Tang JP, 2004, J CEREBR BLOOD F MET, V24, P1133, DOI 10.1097/01.WCB.0000135593.05952.DE; Tang PF, 2014, MOL NEUROBIOL, V49, P276, DOI 10.1007/s12035-013-8518-3; Wang JA, 2010, PROG NEUROBIOL, V92, P463, DOI 10.1016/j.pneurobio.2010.08.001; Wang L. F., 2015, PLOS ONE, V10; Wang Y, 2008, AUTOPHAGY, V4, P214, DOI 10.4161/auto.5369; Wang YC, 2013, STROKE, V44, P2545, DOI 10.1161/STROKEAHA.113.001038; Wang YQ, 2012, NEUROCHEM RES, V37, P1849, DOI 10.1007/s11064-012-0791-4; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Xiao GT, 2007, CYTOKINE GROWTH F R, V18, P233, DOI 10.1016/j.cytogfr.2007.04.006; Yan JH, 2008, EXP NEUROL, V214, P37, DOI 10.1016/j.expneurol.2008.07.006; Yang Y, 2014, J RECEPT SIG TRANSD, V22, P1; Yang Z, 2015, J NEUROIMMUNOL, V278, P232, DOI 10.1016/j.jneuroim.2014.11.010; Yuan DM, 2014, CELL MOL NEUROBIOL, V34, P951, DOI 10.1007/s10571-014-0081-6; Zhang XD, 2009, AUTOPHAGY, V5, P339, DOI 10.4161/auto.5.3.8174; Zhao XR, 2015, J NEUROCHEM, V133, P144, DOI 10.1111/jnc.12974; Zhou QB, 2014, INFLAMMATION, V37, P107, DOI 10.1007/s10753-013-9717-9; Zhu XX, 2012, STROKE, V43, P524, DOI 10.1161/STROKEAHA.111.635672	67	39	42	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	JUN	2016	96						100	112		10.1016/j.neuint.2016.03.004			13	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	DN1DO	WOS:000376806700011	26964766				2021-06-18	
J	Zhao, YH; Gibb, SL; Zhao, J; Moore, AN; Hylin, MJ; Menge, T; Xue, HS; Baimukanova, G; Potter, D; Johnson, EM; Holcomb, JB; Cox, CS; Dash, PK; Pati, S				Zhao, Yuhai; Gibb, Stuart L.; Zhao, Jing; Moore, Anthony N.; Hylin, Michael J.; Menge, Tyler; Xue, Hasen; Baimukanova, Gyulnar; Potter, Daniel; Johnson, Evan M.; Holcomb, John B.; Cox, Charles S., Jr.; Dash, Pramod K.; Pati, Shibani			Wnt3a, a Protein Secreted by Mesenchymal Stem Cells Is Neuroprotective and Promotes Neurocognitive Recovery Following Traumatic Brain Injury	STEM CELLS			English	Article						Mesenchymal stem cells; Wnt3a; Traumatic brain injury; Neuroprotection; Neurogenesis	ADULT HIPPOCAMPAL NEUROGENESIS; PATTERN SEPARATION; DENTATE GYRUS; OBJECT RECOGNITION; NEURONS; MICE; TRANSPLANTATION; ACTIVATION; MEMORY; TSG-6	Intravenous administration of bone marrow derived mesenchymal stem cells (MSCs) has been shown to reduce blood brain barrier compromise and improve neurocognition following traumatic brain injury (TBI). These effects occur in the absence of engraftment and differentiation of these cells in the injured brain. Recent studies have shown that soluble factors produced by MSCs mediate a number of the therapeutic effects. In this study, we sought to determine if intravenous administration of MSCs (IV-MSCs) could enhance hippocampal neurogenesis following TBI. Our results demonstrate that IV-MSC treatment attenuates loss of neural stem cells and promotes hippocampal neurogenesis in TBI injured mice. As Wnt signaling has been implicated in neurogenesis, we measured circulating Wnt3a levels in serum following IV-MSC administration and found a significant increase in Wnt3a. Concurrent with this increase, we detected increased activation of the Wnt/beta-catenin signaling pathway in hippocampal neurons. Furthermore, IV recombinant Wnt3a treatment provided neuroprotection, promoted neurogenesis, and improved neurocognitive function in TBI injured mice. Taken together, our results demonstrate a role for Wnt3a in the therapeutic potential of MSCs and identify Wnt3a as a potential stand-alone therapy or as part of a combination therapeutic strategy for the treatment of TBI.	[Zhao, Yuhai] Louisiana State Univ, Hlth Sci Ctr, Neurosci Ctr Excellence, New Orleans, LA USA; [Gibb, Stuart L.; Menge, Tyler; Baimukanova, Gyulnar; Potter, Daniel; Dash, Pramod K.] Blood Syst Res Inst, 270 Masonic Ave, San Francisco, CA 94118 USA; [Gibb, Stuart L.; Baimukanova, Gyulnar; Potter, Daniel] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; [Zhao, Jing; Moore, Anthony N.; Hylin, Michael J.] Univ Texas Hlth Sci Ctr Houston, Dept Neurobiol & Anat, Houston, TX 77030 USA; [Xue, Hasen; Johnson, Evan M.; Holcomb, John B.; Pati, Shibani] Univ Texas Hlth Sci Ctr Houston, Dept Surg, Houston, TX 77030 USA; [Xue, Hasen; Johnson, Evan M.; Holcomb, John B.; Pati, Shibani] Univ Texas Hlth Sci Ctr Houston, Ctr Translat Injury Res, Houston, TX 77030 USA; [Cox, Charles S., Jr.] Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, Houston, TX 77030 USA; [Hylin, Michael J.; Pati, Shibani] So Illinois Univ, Dept Psychol, Carbondale, IL 62901 USA	Pati, S (corresponding author), Blood Syst Res Inst, 270 Masonic Ave, San Francisco, CA 94118 USA.	SPati@bloodsystems.org	Hylin, Michael/U-2878-2019	Dash, Pramod/0000-0001-6746-1002; holcomb, john/0000-0001-8312-9157	Blood Systems Research Institute	We thank Scott Holmes for graphic work and Dr. Peng, Zhanglong for assistance in imaging data analysis. TIRR Foundation Mission Connect and intramural grant funding from Blood Systems Research Institute supported this work.	Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003; Aimone JB, 2014, PHYSIOL REV, V94, P991, DOI 10.1152/physrev.00004.2014; Bao XJ, 2011, BRAIN RES, V1367, P103, DOI 10.1016/j.brainres.2010.10.063; Bedi SS, 2013, STEM CELL TRANSL MED, V2, P953, DOI 10.5966/sctm.2013-0100; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Bian GL, 2007, BRAIN RES, V1150, P55, DOI 10.1016/j.brainres.2007.02.078; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; Burke SN, 2010, BEHAV NEUROSCI, V124, P559, DOI 10.1037/a0020893; Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Dhamdhere GR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083650; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Frankland PW, 1998, BEHAV NEUROSCI, V112, P863, DOI 10.1037/0735-7044.112.4.863; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gibb SL, 2015, STEM CELLS, V33, P3530, DOI 10.1002/stem.2189; Goldring CEP, 2011, CELL STEM CELL, V8, P618, DOI 10.1016/j.stem.2011.05.012; Grigorian AS, 2011, B EXP BIOL MED+, V150, P551, DOI 10.1007/s10517-011-1187-1; Hylin MJ, 2013, LEARN MEMORY, V20, P267, DOI 10.1101/lm.030197.112; Jessberger S, 2009, LEARN MEMORY, V16, P147, DOI 10.1101/lm.1172609; Joyce N, 2010, REGEN MED, V5, P933, DOI [10.2217/rme.10.72, 10.2217/RME.10.72]; Khakoo AY, 2006, J EXP MED, V203, P1235, DOI 10.1084/jem.20051921; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Kuwabara T, 2009, NAT NEUROSCI, V12, P1097, DOI 10.1038/nn.2360; Lee RH, 2014, P NATL ACAD SCI USA, V111, P16766, DOI 10.1073/pnas.1416121111; Leutgeb JK, 2007, SCIENCE, V315, P961, DOI 10.1126/science.1135801; Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Maltman DJ, 2011, NEUROCHEM INT, V59, P347, DOI 10.1016/j.neuint.2011.06.008; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Menge T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004660; Monti JM, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00041; Oh SH, 2015, CELL TRANSPLANT, V24, P1097, DOI 10.3727/096368914X679237; Pati S, 2011, STEM CELLS DEV, V20, P89, DOI 10.1089/scd.2010.0013; Piccin D, 2011, STEM CELLS, V29, P528, DOI 10.1002/stem.589; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; Rachmany L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079837; Roddy GW, 2011, STEM CELLS, V29, P1572, DOI 10.1002/stem.708; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Tajiri N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074857; Tfilin M, 2010, MOL PSYCHIATR, V15, P1164, DOI 10.1038/mp.2009.110; Varela-Nallar L, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00100; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; Watanabe J, 2013, NEUROBIOL DIS, V59, P86, DOI 10.1016/j.nbd.2013.06.017; Yan YF, 2014, NEURAL REGEN RES, V9, P798, DOI 10.4103/1673-5374.131596; Yassa MA, 2011, TRENDS NEUROSCI, V34, P515, DOI 10.1016/j.tins.2011.06.006; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	50	39	41	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	MAY	2016	34	5					1263	1272		10.1002/stem.2310			10	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	DL8MU	WOS:000375896900012	26840479	Bronze			2021-06-18	
J	Boccia, M; D'Amico, S; Bianchini, F; Marano, A; Giannini, AM; Piccardi, L				Boccia, Maddalena; D'Amico, Simonetta; Bianchini, Filippo; Marano, Assunta; Giannini, Anna Maria; Piccardi, Laura			Different neural modifications underpin PTSD after different traumatic events: an fMRI meta-analytic study	BRAIN IMAGING AND BEHAVIOR			English	Article						PTSD; fMRI; ALE meta-analysis	POSTTRAUMATIC-STRESS-DISORDER; CHILDHOOD SEXUAL-ABUSE; SCRIPT-DRIVEN IMAGERY; FUNCTIONAL CONNECTIVITY; HIPPOCAMPAL VOLUME; AUTOBIOGRAPHICAL MEMORY; DISSOCIATIVE RESPONSES; NEUROCIRCUITRY MODELS; SYMPTOM PROVOCATION; DECLARATIVE MEMORY	Post-traumatic stress disorder (PTSD) is an anxiety condition that can develop after exposure to trauma such as physical or sexual assault, injury, combat-related trauma, natural disaster or death. Although an increasing number of neurobiological studies carried out over the past 20 years have allowed clarifying the neural substrate of PTSD, the neural modifications underpinning PTSD are still unclear. Here we used activation likelihood estimation meta-analysis (ALE) to determine whether PTSD has a consistent neural substrate. We also explored the possibility that different traumatic events produce different alterations in the PTSD neural network. In neuroimaging studies of PTSD, we found evidence of a consistent neural network including the bilateral insula and cingulate cortex as well as the parietal, frontal and limbic areas. We also found that specific networks of brain areas underpin PTSD after different traumatic events and that these networks may be related to specific aspects of the traumatic events. We discuss our results in light of the functional segregation of the brain areas involved in PTSD.	[Boccia, Maddalena; Bianchini, Filippo; Piccardi, Laura] IRCCS Fdn Santa Lucia Rome, Neuropsychol Unit, Rome, Italy; [Boccia, Maddalena; Bianchini, Filippo; Giannini, Anna Maria] Univ Roma La Sapienza, Dept Psychol, Via Marsi 78, I-00185 Rome, Italy; [D'Amico, Simonetta; Marano, Assunta; Piccardi, Laura] Univ Aquila, Dept Life Hlth & Environm Sci, I-67100 Laquila, Italy	Boccia, M (corresponding author), IRCCS Fdn Santa Lucia Rome, Neuropsychol Unit, Rome, Italy.; Boccia, M (corresponding author), Univ Roma La Sapienza, Dept Psychol, Via Marsi 78, I-00185 Rome, Italy.	maddalena.boccia@uniroma1.it	GIANNINI, Anna Maria/AAE-5896-2021; Boccia, Maddalena/I-4575-2018	Boccia, Maddalena/0000-0002-2044-8326; Piccardi, Laura/0000-0002-1322-5538; D'AMICO, SIMONETTA/0000-0002-4418-4978	Italian Association of Psychology (AIP); ANIA Foundation	This research was supported by a grant from the Italian Association of Psychology (AIP) to the Faculty of Psychology, University of L'Aquila, after the earthquake of April 6, 2009 and ANIA Foundation.	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Boccia M, 2014, NEUROPSYCHOL REV, V24, P236, DOI 10.1007/s11065-014-9247-8; Bohbot VD, 2007, HIPPOCAMPUS, V17, P863, DOI 10.1002/hipo.20313; Brandes D, 2002, PSYCHIAT RES, V110, P231, DOI 10.1016/S0165-1781(02)00125-7; Bremner JD, 2003, BIOL PSYCHIAT, V53, P879, DOI 10.1016/S0006-3223(02)01891-7; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; Britton JC, 2005, BIOL PSYCHIAT, V57, P832, DOI 10.1016/j.biopsych.2004.12.025; Bustamante V, 2001, J TRAUMA STRESS, V14, P791, DOI 10.1023/A:1013050423901; Chen SL, 2009, BMC PSYCHIATRY, V9, DOI 10.1186/1471-244X-9-39; Craig AD, 2002, NAT REV NEUROSCI, V3, P655, DOI 10.1038/nrn894; Critchley HD, 2005, J COMP NEUROL, V493, P154, DOI 10.1002/cne.20749; Dam~asio A., 1999, FEELING WHAT HAPPENS; Ditlevsen DN, 2012, ANN GEN PSYCHIATR, V11, DOI 10.1186/1744-859X-11-26; Eickhoff SB, 2009, HUM BRAIN MAPP, V30, P2907, DOI 10.1002/hbm.20718; EKMAN P, 1993, AM PSYCHOL, V48, P384, DOI 10.1037/0003-066X.48.4.384; Elzinga BM, 2002, J AFFECT DISORDERS, V70, P1, DOI 10.1016/S0165-0327(01)00351-2; Epstein RA, 2012, NEUROPSYCHOLOGIA, V50, P530, DOI 10.1016/j.neuropsychologia.2011.09.042; Etkin A, 2007, AM J PSYCHIAT, V164, P1476, DOI 10.1176/appi.ajp.2007.07030504; Etkin A, 2006, NEURON, V51, P871, DOI 10.1016/j.neuron.2006.07.029; Falconer E, 2008, J PSYCHIATR NEUROSCI, V33, P413; Fox PT, 2014, ANNU REV NEUROSCI, V37, P409, DOI 10.1146/annurev-neuro-062012-170320; Geuze E, 2007, ARCH GEN PSYCHIAT, V64, P76, DOI 10.1001/archpsyc.64.1.76; Gilbertson MW, 2001, J TRAUMA STRESS, V14, P413, DOI 10.1023/A:1011181305501; Gill T., 1990, J TRAUMA STRESS, V3, P29, DOI DOI 10.1002/JTS.2490030104; GURVITS TV, 1993, J NEUROPSYCH CLIN N, V5, P183; Gurvits TV, 1996, BIOL PSYCHIAT, V40, P1091, DOI 10.1016/S0006-3223(96)00229-6; Gurvits TV, 2002, PSYCHIAT RES, V112, P263, DOI 10.1016/S0165-1781(02)00234-2; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P500, DOI 10.1037/0022-006X.66.3.500; Hassabis D, 2007, TRENDS COGN SCI, V11, P299, DOI 10.1016/j.tics.2007.05.001; Hayes JP, 2012, BIOL MOOD ANXIETY DI, V2, DOI 10.1186/2045-5380-2-9; Herry C, 2010, EUR J NEUROSCI, V31, P599, DOI 10.1111/j.1460-9568.2010.07101.x; Hopper JW, 2007, J TRAUMA STRESS, V20, P713, DOI 10.1002/jts.20284; Hou CL, 2007, BRAIN RES, V1144, P165, DOI 10.1016/j.brainres.2007.01.089; Husarewycz MN, 2014, GEN HOSP PSYCHIAT, V36, P26, DOI 10.1016/j.genhosppsych.2013.06.003; Jenkins MA, 2000, CLIN NEUROPSYCHOL, V14, P7, DOI 10.1076/1385-4046(200002)14:1;1-8;FT007; Kalisch R, 2005, J COGNITIVE NEUROSCI, V17, P874, DOI 10.1162/0898929054021184; KANDEL ER, 1991, PRINCIPLES NEURAL SC; Karl A, 2006, NEUROSCI BIOBEHAV R, V30, P1004, DOI 10.1016/j.neubiorev.2006.03.004; Kasai K, 2008, BIOL PSYCHIAT, V63, P550, DOI 10.1016/j.biopsych.2007.06.022; Kitayama N, 2005, J AFFECT DISORDERS, V88, P79, DOI 10.1016/j.jad.2005.05.014; Koenen KC, 2001, BRAIN COGNITION, V45, P64, DOI 10.1006/brcg.2000.1256; Lanius RA, 2002, BIOL PSYCHIAT, V52, P305, DOI 10.1016/S0006-3223(02)01367-7; Lanius RA, 2005, BIOL PSYCHIAT, V57, P873, DOI 10.1016/j.biopsych.2005.01.011; Lanius RA, 2004, AM J PSYCHIAT, V161, P36, DOI 10.1176/appi.ajp.161.1.36; Lanius RA, 2003, BIOL PSYCHIAT, V53, P204, DOI 10.1016/S0006-3223(02)01466-X; Lanius RA, 2007, PSYCHIAT RES-NEUROIM, V155, P45, DOI 10.1016/j.pscychresns.2006.11.006; Mazza M, 2012, BRAIN IMAGING BEHAV, V6, P374, DOI 10.1007/s11682-012-9151-x; MCNALLY RJ, 1995, BEHAV RES THER, V33, P619, DOI 10.1016/0005-7967(95)00007-K; Milad MR, 2012, ANNU REV PSYCHOL, V63, P129, DOI 10.1146/annurev.psych.121208.131631; Milner B, 2005, PSYCHIAT CLIN N AM, V28, P599, DOI 10.1016/j.psc.2005.06.002; Misra G, 2014, CEREB CORTEX; Morey RA, 2008, PSYCHIAT RES-NEUROIM, V162, P59, DOI 10.1016/j.pscychresns.2007.07.007; Morrow BA, 1999, NEUROSCIENCE, V92, P553, DOI 10.1016/S0306-4522(99)00014-7; Moscovitch M, 2005, J ANAT, V207, P35, DOI 10.1111/j.1469-7580.2005.00421.x; Moscovitch M, 2006, CURR OPIN NEUROBIOL, V16, P179, DOI 10.1016/j.conb.2006.03.013; Patel R, 2012, NEUROSCI BIOBEHAV R, V36, P2130, DOI 10.1016/j.neubiorev.2012.06.003; Perrin M, 2013, SOC PSYCHIAT PSYCHIA; Pissiota A, 2002, EUR ARCH PSY CLIN N, V252, P68, DOI 10.1007/s004060200014; Pitman RK, 2012, NAT REV NEUROSCI, V13, P769, DOI 10.1038/nrn3339; Polak A. R., 2012, BMC PSYCHIAT, V12; Portas CM, 1998, J NEUROSCI, V18, P8979; Protopopescu X, 2005, BIOL PSYCHIAT, V57, P464, DOI 10.1016/j.biopsych.2004.12.026; Rabinak Christine A, 2011, Front Psychiatry, V2, P62, DOI 10.3389/fpsyt.2011.00062; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Rauch SAM, 2012, J REHABIL RES DEV, V49, P679, DOI 10.1682/JRRD.2011.08.0152; Rauch SL, 2000, BIOL PSYCHIAT, V47, P769, DOI 10.1016/S0006-3223(00)00828-3; Robinson JL, 2010, HUM BRAIN MAPP, V31, P173, DOI 10.1002/hbm.20854; Sakamoto H, 2005, NEUROIMAGE, V26, P813, DOI 10.1016/j.neuroimage.2005.02.032; Santiago PN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059236; Shaw ME, 2002, NEUROIMAGE, V15, P661, DOI 10.1006/nimg.2001.1024; Shin LM, 2010, NEUROPSYCHOPHARMACOL, V35, P169, DOI 10.1038/npp.2009.83; Shin LM, 1999, AM J PSYCHIAT, V156, P575; Shin LM, 2004, HIPPOCAMPUS, V14, P292, DOI 10.1002/hipo.10183; Shin LM, 1997, ARCH GEN PSYCHIAT, V54, P233; Simmons AN, 2008, BIOL PSYCHIAT, V64, P681, DOI 10.1016/j.biopsych.2008.05.027; Simmons AN, 2011, BIOL MOOD ANXIETY DI, V1, DOI 10.1186/2045-5380-1-6; Smith ME, 2005, HIPPOCAMPUS, V15, P798, DOI 10.1002/hipo.20102; Sripada RK, 2012, J PSYCHIATR NEUROSCI, V37, P241, DOI 10.1503/jpn.110069; Stein MB, 1997, PSYCHOL MED, V27, P951, DOI 10.1017/S0033291797005242; Sullivan K, 2003, J PSYCHOPATHOL BEHAV, V25, P95, DOI 10.1023/A:1023342915425; Taylor SF, 2003, NEUROIMAGE, V18, P650, DOI 10.1016/S1053-8119(02)00051-4; Vann SD, 2009, NAT REV NEUROSCI, V10, P792, DOI 10.1038/nrn2733; Vasterling J.J., 2005, NEUROPSYCHOLOGY PTSD, P178; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; Vincent JL, 2006, J NEUROPHYSIOL, V96, P3517, DOI 10.1152/jn.00048.2006; Vogt BA, 2005, NAT REV NEUROSCI, V6, P533, DOI 10.1038/nrn1704	87	39	39	0	20	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	MAR	2016	10	1					226	237		10.1007/s11682-015-9387-3			12	Neuroimaging	Neurosciences & Neurology	DO5NJ	WOS:000377829500024	25913645				2021-06-18	
J	Ibrahim, S; Hu, WP; Wang, XT; Gao, X; He, CY; Chen, JH				Ibrahim, Sara; Hu, Weipeng; Wang, Xiaoting; Gao, Xiang; He, Chunyan; Chen, Jinhui			Traumatic Brain Injury Causes Aberrant Migration of Adult-Born Neurons in the Hippocampus	SCIENTIFIC REPORTS			English	Article							CONTROLLED CORTICAL IMPACT; INDUCED CELL-PROLIFERATION; MODERATE HEAD-INJURY; DENTATE GYRUS; ENHANCED NEUROGENESIS; COGNITIVE RECOVERY; MOUSE MODEL; DIFFERENTIATION; PROTEIN; DEATH	Traumatic brain injury (TBI) promotes neural stem/progenitor cell (NSC) proliferation in an attempt to initiate innate repair mechanisms. However, all immature neurons in the CNS are required to migrate from their birthplace to their final destination to develop into functional neurons. Here we assessed the destination of adult-born neurons following TBI. We found that a large percentage of immature neurons migrated past their normal stopping site at the inner granular cell layer (GCL), and became misplaced in the outer GCL of the hippocampal dentate gyrus. The aberrant migration of adult-born neurons in the hippocampus occurred 48 hours after TBI, and lasted for 8 weeks, resulting in a great number of newly generated neurons misplaced in the outer GCL in the hippocampus. Those misplaced neurons were able to become mature and differentiate into granular neurons, but located ectopically in the outer GCL with reduced dendritic complexity after TBI. The adult-born neurons at the misplaced position may make wrong connections with inappropriate nearby targets in the pre-existing neural network. These results suggest that although stimulation of endogenous NSCs following TBI might offer new avenues for cell-based therapy, additional intervention is required to further enhance successful neurogenesis for repairing the damaged brain.	[Ibrahim, Sara; Wang, Xiaoting; Gao, Xiang; Chen, Jinhui] Stark Neurosci Res Inst, Dept Neurosurg, Spinal Cord & Brain Injury Res Grp, Indianapolis, IN USA; [Hu, Weipeng] Fujian Med Univ, Affiliated Hosp 2, Dept Neurosurg, Quanzhou 362000, Peoples R China; [He, Chunyan] Huaqiao Univ, Sch Biomed Sci, Quanzhou 362000, Peoples R China	Chen, JH (corresponding author), Stark Neurosci Res Inst, Dept Neurosurg, Spinal Cord & Brain Injury Res Grp, Indianapolis, IN USA.	chen204@iupui.edu			Indiana Spinal Cord & Brain Injury Research Grants; Ralph W. and Grace M. Showalter Research Award; Indiana University Biological Research Grant; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21NS075733, 1R21NS072631-01A]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS072631, R21NS075733] Funding Source: NIH RePORTER	This work was supported through funding from the Indiana Spinal Cord & Brain Injury Research Grants, the Ralph W. and Grace M. Showalter Research Award, Indiana University Biological Research Grant, and NIH grants R21NS075733 and 1R21NS072631-01A.	BLACKSTAD TW, 1956, J COMP NEUROL, V105, P417, DOI 10.1002/cne.901050305; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; Braun H, 2002, J NEUROTRAUM, V19, P975, DOI 10.1089/089771502320317122; Brose K, 2000, CURR OPIN NEUROBIOL, V10, P95, DOI 10.1016/S0959-4388(99)00066-5; Bye N, 2011, J NEUROSCI RES, V89, P986, DOI 10.1002/jnr.22635; Chen JH, 2001, J NEUROSCI, V21, P1548; Chen JH, 2000, NEUROSCIENCE, V96, P231, DOI 10.1016/S0306-4522(99)00408-X; Chen L, 2015, J NEUROPATH EXP NEUR, V74, P557, DOI 10.1097/NEN.0000000000000199; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Compagnone C, 2009, NEUROSURGERY, V64, P690, DOI 10.1227/01.NEU.0000340796.18738.F7; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Duan X, 2007, CELL, V130, P1146, DOI 10.1016/j.cell.2007.07.010; Dyer MA, 2003, CELL CYCLE, V2, P350, DOI 10.4161/cc.2.4.429; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Forster E, 2006, NAT REV NEUROSCI, V7, P259, DOI 10.1038/nrn1882; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2013, EXP NEUROL, V239, P38, DOI 10.1016/j.expneurol.2012.09.012; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Gao X, 2009, EXP NEUROL, V219, P516, DOI 10.1016/j.expneurol.2009.07.007; Gao X, 2009, EXP NEUROL, V215, P178, DOI 10.1016/j.expneurol.2008.10.009; Gleeson JG, 1999, NEURON, V23, P257, DOI 10.1016/S0896-6273(00)80778-3; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hatten ME, 1999, ANNU REV NEUROSCI, V22, P511, DOI 10.1146/annurev.neuro.22.1.511; Hatten ME, 2002, SCIENCE, V297, P1660, DOI 10.1126/science.1074572; Kempermann G, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a018812; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Magavi SS, 2000, NATURE, V405, P951; Marin O, 2003, ANNU REV NEUROSCI, V26, P441, DOI 10.1146/annurev.neuro.26.041002.131058; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; Prigatano GP, 2005, ACT NEUR S, V93, P39; RAKIC P, 1990, EXPERIENTIA, V46, P882, DOI 10.1007/BF01939380; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Romine J, 2014, JOVE-J VIS EXP, DOI 10.3791/51781; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; SHOLL D A, 1956, Prog Neurobiol, P324; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Song HJ, 2002, NAT NEUROSCI, V5, P438, DOI 10.1038/nn844; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun D, 2015, J NEUROTRAUM, V32, P495, DOI 10.1089/neu.2014.3545; Sun D, 2014, NEURAL REGEN RES, V9, P688, DOI 10.4103/1673-5374.131567; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Toni N, 2008, NAT NEUROSCI, V11, P901, DOI 10.1038/nn.2156; UYLINGS HBM, 1986, J NEUROSCI METH, V18, P127, DOI 10.1016/0165-0270(86)90116-0; Villasana LE, 2015, ENEURO, V2, DOI 10.1523/ENEURO.0056-15.2015; Wu W, 1999, NATURE, V400, P331; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Yuan WL, 1999, DEV BIOL, V212, P290, DOI 10.1006/dbio.1999.9371; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006; Zhao S, 2016, MOL NEUROBIOL, V53, P1884, DOI 10.1007/s12035-015-9128-z; Zhou HZ, 2012, J NEUROPATH EXP NEUR, V71, P348, DOI 10.1097/NEN.0b013e31824ea078; ZIMMER J, 1971, J COMP NEUROL, V142, P393, DOI 10.1002/cne.901420402	64	39	39	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	FEB 22	2016	6								21793	10.1038/srep21793			12	Multidisciplinary Sciences	Science & Technology - Other Topics	DE3GF	WOS:000370514800001	26898165	DOAJ Gold, Green Published			2021-06-18	
J	Edlow, BL; Copen, WA; Izzy, S; Bakhadirov, K; van der Kouwe, A; Glenn, MB; Greenberg, SM; Greer, DM; Wu, O				Edlow, Brian L.; Copen, William A.; Izzy, Saef; Bakhadirov, Khamid; van der Kouwe, Andre; Glenn, Mel B.; Greenberg, Steven M.; Greer, David M.; Wu, Ona			Diffusion tensor imaging in acute-to-subacute traumatic brain injury: a longitudinal analysis	BMC NEUROLOGY			English	Article						Traumatic axonal injury (TAI); Fractional anisotropy (FA); Corpus callosum; Disability rating scale (DRS)	WHITE-MATTER INJURY; AXONAL INJURY; OUTCOME PREDICTION; HEAD TRAUMA; BIOMARKERS; MRI; SPECTROSCOPY; ANISOTROPY; FEATURES; DAMAGE	Background: Diffusion tensor imaging (DTI) may have prognostic utility in patients with traumatic brain injury (TBI), but the optimal timing of DTI data acquisition is unknown because of dynamic changes in white matter water diffusion during the acute and subacute stages of TBI. We aimed to characterize the direction and magnitude of early longitudinal changes in white matter fractional anisotropy (FA) and to determine whether acute or subacute FA values correlate more reliably with functional outcomes after TBI. Methods: From a prospective TBI outcomes database, 11 patients who underwent acute (<= 7 days) and subacute (8 days to rehabilitation discharge) DTI were retrospectively analyzed. Longitudinal changes in FA were measured in 11 white matter regions susceptible to traumatic axonal injury. Correlations were assessed between acute FA, subacute FA and the disability rating scale (DRS) score, which was ascertained at discharge from inpatient rehabilitation. Results: FA declined from the acute-to-subacute period in the genu of the corpus callosum (0.70 +/- 0.02 vs. 0.55 +/- 0.11, p < 0.05) and inferior longitudinal fasciculus (0.54+/-0.07 vs. 0.49+/-0.07, p < 0.01). Acute correlations between FA and DRS score were variable: higher FA in the body (R = -0.78, p = 0.02) and splenium (R = -0.83, p = 0.003) of the corpus callosum was associated with better outcomes (i.e. lower DRS scores), whereas higher FA in the genu of the corpus callosum (R = 0.83, p = 0.02) corresponded with worse outcomes (i.e. higher DRS scores). In contrast, in the subacute period higher FA in the splenium correlated with better outcomes (R = -0.63, p < 0.05) and no inverse correlations were observed. Conclusions: White matter FA declined during the acute-to-subacute stages of TBI. Variability in acute FA correlations with outcome suggests that the optimal timing of DTI for TBI prognostication may be in the subacute period.	[Edlow, Brian L.; Izzy, Saef; Bakhadirov, Khamid; Greenberg, Steven M.; Greer, David M.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Copen, William A.; Wu, Ona] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Edlow, Brian L.; van der Kouwe, Andre; Wu, Ona] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA; [Glenn, Mel B.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Boston, MA USA; [Greer, David M.] Yale Univ, Sch Med, Dept Neurol, Yale New Haven Hosp, New Haven, CT 06510 USA	Edlow, BL (corresponding author), Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA.	bedlow@mgh.harvard.edu	Demchuk, Andrew M/E-1103-2012	Demchuk, Andrew M/0000-0002-4930-7789; Greer, David/0000-0002-2026-8333; Wu, Ona/0000-0002-5509-9461	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R25NS065743, K23NS094538, R01NS059775, P41EB015896]; American Academy of Neurology/American Brain Foundation; National Institute on Disability and Rehabilitation Research, U.S. Department of EducationUS Department of Education [H133A020513]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS094538, R25NS065743, R01NS059775] Funding Source: NIH RePORTER	This study was supported by the National Institutes of Health (R25NS065743, K23NS094538, R01NS059775, and P41EB015896), the American Academy of Neurology/American Brain Foundation, and the National Institute on Disability and Rehabilitation Research, U.S. Department of Education (H133A020513).	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Edlow BL, 2013, J NEUROPATH EXP NEUR, V72, P505, DOI 10.1097/NEN.0b013e3182945bf6; Edlow BL, 2012, SEMIN NEUROL, V32, P374, DOI 10.1055/s-0032-1331810; Galanaud D, 2012, ANESTHESIOLOGY, V117, P1300, DOI 10.1097/ALN.0b013e3182755558; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Jansen JFA, 2007, INVEST RADIOL, V42, P327, DOI 10.1097/01.rli.0000262757.10271.e5; Jones DK, 2004, MAGNET RESON MED, V51, P807, DOI 10.1002/mrm.20033; Jones NR, 1998, J CLIN NEUROSCI, V5, P73, DOI 10.1016/S0967-5868(98)90207-7; Kessler LG, 2015, STAT METHODS MED RES, V24, P9, DOI 10.1177/0962280214537333; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Li J, 2011, EUR J NEUROSCI, V33, P933, DOI 10.1111/j.1460-9568.2010.07573.x; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Newcombe V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019214; Newcombe VFJ, 2010, J NEUROL NEUROSUR PS, V81, P552, DOI 10.1136/jnnp.2009.196246; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sorensen AG, 1999, RADIOLOGY, V212, P785, DOI 10.1148/radiology.212.3.r99se24785; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wang JY, 2011, NEUROLOGY, V77, P818, DOI 10.1212/WNL.0b013e31822c61d7; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wang JY, 2012, NEUROIMAGE, V60, P1127, DOI 10.1016/j.neuroimage.2011.12.062; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171	49	39	45	0	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1471-2377		BMC NEUROL	BMC Neurol.	JAN 11	2016	16								2	10.1186/s12883-015-0525-8			11	Clinical Neurology	Neurosciences & Neurology	DA4SU	WOS:000367791600001	26754948	DOAJ Gold, Green Published			2021-06-18	
J	Halaweish, I; Bambakidis, T; Chang, ZG; Wei, H; Liu, BL; Li, YQ; Bonthrone, T; Srinivasan, A; Bonham, T; Chtraklin, K; Alam, HB				Halaweish, Ihab; Bambakidis, Ted; Chang, Zhigang; Wei, He; Liu, Baoling; Li, Yongqing; Bonthrone, Toby; Srinivasan, Ashok; Bonham, Tess; Chtraklin, Kiril; Alam, Hasan B.			Addition of low-dose valproic acid to saline resuscitation provides neuroprotection and improves long-term outcomes in a large animal model of combined traumatic brain injury and hemorrhagic shock	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	45th Annual Meeting of the Western-Trauma-Association	MAR 01-06, 2015	Telluride, CO	Western Trauma Assoc		Traumatic brain injury; hemorrhagic shock; HDACI; valproic acid; swine	HISTONE DEACETYLASE INHIBITOR; PHARMACOLOGICAL RESUSCITATION; SWINE MODEL; PLATELET ACTIVATION; BARRIER DISRUPTION; ISCHEMIA; HYPOTHERMIA; STRATEGIES; LETHALITY; PROFILES	BACKGROUND Combined traumatic brain injury (TBI) and hemorrhagic shock (HS) is highly lethal. In a nonsurvival model of TBI + HS, addition of high-dose valproic acid (VPA) (300 mg/kg) to hetastarch reduced brain lesion size and associated swelling 6 hours after injury; whether this would have translated into better neurologic outcomes remains unknown. It is also unclear whether lower doses of VPA would be neuroprotective. We hypothesized that addition of low-dose VPA to normal saline (NS) resuscitation would result in improved long-term neurologic recovery and decreased brain lesion size. METHODS TBI was created in anesthetized swine (40-43 kg) by controlled cortical impact, and volume-controlled hemorrhage (40% volume) was induced concurrently. After 2 hours of shock, animals were randomized (n = 5 per group) to NS (3x shed blood) or NS + VPA (150 mg/kg). Six hours after resuscitation, packed red blood cells were transfused, and animals were recovered. Peripheral blood mononuclear cells were analyzed for acetylated histone-H3 at lysine-9. A Neurological Severity Score (NSS) was assessed daily for 30 days. Brain magnetic resonance imaging was performed on Days 3 and 10. Cognitive performance was assessed by training animals to retrieve food from color-coded boxes. RESULTS There was a significant increase in histone acetylation in the NS + VPA-treated animals compared with NS treatment. The NS + VPA group demonstrated significantly decreased neurologic impairment and faster speed of recovery as well as smaller brain lesion size compared with the NS group. Although the final cognitive function scores were similar between the groups, the VPA-treated animals reached the goal significantly faster than the NS controls. CONCLUSION In this long-term survival model of TBI + HS, addition of low-dose VPA to saline resuscitation resulted in attenuated neurologic impairment, faster neurologic recovery, smaller brain lesion size, and a quicker normalization of cognitive functions.	[Halaweish, Ihab; Bambakidis, Ted; Liu, Baoling; Li, Yongqing; Bonthrone, Toby; Bonham, Tess; Chtraklin, Kiril; Alam, Hasan B.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; [Srinivasan, Ashok] Univ Michigan, Dept Radiol, Neuroradiol Sect, Ann Arbor, MI 48109 USA; [Chang, Zhigang] Beijing Hosp, Minist Hlth, Dept Surg Crit Care, Beijing, Peoples R China; [Wei, He] Southeast Univ, Sch Med, Dept Cardiothorac Surg, Zhongda Hosp, Nanjing, Jiangsu, Peoples R China	Alam, HB (corresponding author), Univ Michigan Hosp, 2920 Taubman Ctr 5331,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	alamh@med.umich.edu			US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [GRANTT00521959]; Joyce and Don Massey Family Foundation	This research was funded by a grant from the US Army Medical Research and Materiel Command (GRANTT00521959) to H.B.A. and supported by a research endowment from the Joyce and Don Massey Family Foundation.	Alam HB, 2011, J TRAUMA, V70, P636, DOI 10.1097/TA.0b013e31820d0dcc; Alam HB, 2009, SURGERY, V146, P325, DOI 10.1016/j.surg.2009.04.007; Alam HB, 2004, RESUSCITATION, V60, P91, DOI 10.1016/j.resuscitation.2003.08.006; Alam HB, 2002, SURGERY, V132, P278, DOI 10.1067/msy.2002.125787; [Anonymous], 1999, JAMA, V282, P974; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Brain Trauma Founction, GUID PREH MAN TRAUM; Burns JW, 2012, INT J BURNS TRAUMA, V2, P59; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Causey MW, 2013, J SURG RES, V184, P533, DOI 10.1016/j.jss.2013.03.087; Chen S, 2014, NEUROCHEM RES, V39, P1621, DOI 10.1007/s11064-014-1241-2; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Dekker SE, 2014, J TRAUMA ACUTE CARE, V77, P906, DOI 10.1097/TA.0000000000000345; Dekker SE, 2014, J SURG RES, V190, P312, DOI 10.1016/j.jss.2014.02.049; Difede J, 2010, ANN NY ACAD SCI, V1208, P1, DOI 10.1111/j.1749-6632.2010.05795.x; Engelhardt B, 2008, J NEUROL SCI, V274, P23, DOI 10.1016/j.jns.2008.05.019; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fuss Ivan J, 2009, Curr Protoc Immunol, VChapter 7, DOI 10.1002/0471142735.im0701s85; Gonzales E, 2006, SHOCK, V25, P395, DOI 10.1097/01.shk.0000209522.28120.c8; Gonzales ER, 2008, J TRAUMA, V65, P554, DOI 10.1097/TA.0b013e31818233ef; Halaweish I, 2015, SHOCK; Hwabejire JO, 2014, J SURG RES, V186, P363, DOI 10.1016/j.jss.2013.09.016; Hwabejire JO, 2013, SURGERY, V154, P234, DOI 10.1016/j.surg.2013.04.008; Imam AM, 2013, SURGERY, V154, P388, DOI 10.1016/j.surg.2013.05.008; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Jin G, 2012, J TRAUMA ACUTE CARE, V73, P1461, DOI 10.1097/TA.0b013e3182782641; Jin G, 2012, SHOCK, V38, P49, DOI 10.1097/SHK.0b013e3182574778; Lee JY, 2012, J NEUROCHEM, V121, P818, DOI 10.1111/j.1471-4159.2012.07731.x; Li YQ, 2008, J TRAUMA, V64, P863, DOI 10.1097/TA.0b013e318166b822; Liu ZC, 2014, SHOCK, V41, P104, DOI 10.1097/SHK.0000000000000074; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; Meyer S, 2005, KLIN PADIATR, V217, P82, DOI 10.1055/s-2004-822676; Morland C, 2004, J CEREBR BLOOD F MET, V24, P1226, DOI 10.1097/01.WCB.0000138666.25305.A7; Nanau RM, 2013, CLIN BIOCHEM, V46, P1323, DOI 10.1016/j.clinbiochem.2013.06.012; Navarro JC, 2012, J NEUROTRAUM, V29, P322, DOI 10.1089/neu.2011.1979; Nichol AD, 2009, INJURY, V40, P471, DOI 10.1016/j.injury.2009.01.002; Prevost TP, 2011, ACTA BIOMATER, V7, P4090, DOI 10.1016/j.actbio.2011.06.032; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Rhee P, 2000, J TRAUMA, V48, P439, DOI 10.1097/00005373-200003000-00011; Rhind SG, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-5; Safar P, 1996, STROKE, V27, P105, DOI 10.1161/01.STR.27.1.105; Shults C, 2008, J TRAUMA, V64, P629, DOI 10.1097/TA.0b013e3181650ff3; Sztajnkrycer MD, 2002, J TOXICOL-CLIN TOXIC, V40, P789, DOI 10.1081/CLT-120014645; Tai YT, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/980657; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; Wang ZF, 2011, J CEREBR BLOOD F MET, V31, P52, DOI 10.1038/jcbfm.2010.195; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375; Zhang C, 2014, BRAIN RES, V1555, P1, DOI 10.1016/j.brainres.2014.01.051	50	39	39	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	DEC	2015	79	6					911	919		10.1097/TA.0000000000000789			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	CX4TD	WOS:000365692300005	26680134				2021-06-18	
J	Grabher, P; Callaghan, MF; Ashburner, J; Weiskopf, N; Thompson, AJ; Curt, A; Freund, P				Grabher, Patrick; Callaghan, Martina F.; Ashburner, John; Weiskopf, Nikolaus; Thompson, Alan J.; Curt, Armin; Freund, Patrick			Tracking sensory system atrophy and outcome prediction in spinal cord injury	ANNALS OF NEUROLOGY			English	Article							NEUROPATHIC PAIN; MAGNETIZATION-TRANSFER; BRAIN-STEM; CORTICAL REORGANIZATION; WALLERIAN DEGENERATION; SOMATOSENSORY CORTEX; MOTOR CORTEX; RECOVERY; FIELD; MAPS	ObjectiveIn patients with subacute spinal cord injury (SCI), the motor system undergoes progressive structural changes rostral to the lesion, which are associated with motor outcome. The extent to which the sensory system is affected and how this relates to sensory outcome are uncertain. MethodsChanges in the sensory system were prospectively followed by applying a comprehensive magnetic resonance imaging (MRI) protocol to 14 patients with subacute traumatic SCI at baseline, 2 months, 6 months, and 12 months after injury, combined with a full neurological examination and comprehensive pain assessment. Eighteen controls underwent the same MRI protocol. T1-weighted volumes, myelin-sensitive magnetization transfer saturation (MT), and longitudinal relaxation rate (R1) mapping provided data on spinal cord and brain morphometry and microstructure. Regression analysis assessed the relationship between MRI readouts and sensory outcomes. ResultsAt 12 months from baseline, sensory scores were unchanged and below-level neuropathic pain became prominent. Compared with controls, patients showed progressive degenerative changes in cervical cord and brain morphometry across the sensory system. At 12 months, MT and R1 were reduced in areas of structural decline. Sensory scores at 12 months correlated with rate of change in cord area and brain volume and decreased MT in the spinal cord at 12 months. InterpretationThis study has demonstrated progressive atrophic and microstructural changes across the sensory system with a close relation to sensory outcome. Structural MRI protocols remote from the site of lesion provide new insights into neuronal degeneration underpinning sensory disturbance and have potential as responsive biomarkers of rehabilitation and treatment interventions. Ann Neurol 2015;78:Ann Neurol 2015;78:679-696	[Grabher, Patrick; Curt, Armin; Freund, Patrick] Univ Zurich, Univ Zurich Hosp, Spinal Cord Injury Ctr Balgrist, CH-8008 Zurich, Switzerland; [Callaghan, Martina F.; Ashburner, John; Weiskopf, Nikolaus; Freund, Patrick] UCL, UCL Inst Neurol, Wellcome Trust Ctr Neuroimaging, London, England; [Weiskopf, Nikolaus; Freund, Patrick] Max Planck Inst Human Cognit & Brain Sci, Dept Neurophys, Leipzig, Germany; [Thompson, Alan J.; Freund, Patrick] UCL, UCL Inst Neurol, Dept Brain Repair & Rehabil, London, England	Freund, P (corresponding author), Univ Zurich, Univ Zurich Hosp, Spinal Cord Injury Ctr Balgrist, Forchstr 340, CH-8008 Zurich, Switzerland.	pfreund@paralab.balgrist.ch	Callaghan, Martina F/H-5297-2019; Ashburner, John/I-3757-2013; Weiskopf, Nikolaus/ABI-5713-2020; Thompson, Alan J/C-2654-2008; Freund, Patrick/D-4193-2013	Callaghan, Martina F/0000-0003-0374-1659; Ashburner, John/0000-0001-7605-2518; Weiskopf, Nikolaus/0000-0001-5239-1881; Thompson, Alan J/0000-0002-4333-8496; Freund, Patrick/0000-0002-4851-2246; Grabher, Patrick/0000-0002-5420-6114	University of Zurich; Wellcome TrustWellcome TrustEuropean Commission [091593/Z/10/Z]	We thank all participants who spent their valuable time, all colleagues involved in this study, and the staff of the Department of Radiology at the University Hospital Balgrist. The SRH Holding, Wings for Life, and the Clinical Research Priority Program "NeuroRehab" of the University of Zurich funded this study. The Wellcome Trust Centre for Neuroimaging is supported by core funding from the Wellcome Trust (091593/Z/10/Z).	Aguilar J, 2010, J NEUROSCI, V30, P7528, DOI 10.1523/JNEUROSCI.0379-10.2010; Anderson K, 2008, J SPINAL CORD MED, V31, P133, DOI 10.1080/10790268.2008.11760704; Apps R, 2005, NAT REV NEUROSCI, V6, P297, DOI 10.1038/nrn1646; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Ashburner J, 2013, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00197; Benarroch EE, 2013, NEUROLOGY, V80, P1148, DOI 10.1212/WNL.0b013e3182886a76; Buss A, 2003, GLIA, V42, P424, DOI 10.1002/glia.10220; Cadotte DW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045560; Callaghan MF, 2015, MAGN RESON MED, V73, P1309, DOI 10.1002/mrm.25210; Callaghan MF, 2014, NEUROBIOL AGING, V35, P1862, DOI 10.1016/j.neurobiolaging.2014.02.008; Cerminara NL, 2009, EUR J NEUROSCI, V29, P2197, DOI 10.1111/j.1460-9568.2009.06760.x; Chen LM, 2012, J NEUROSCI, V32, P14649, DOI 10.1523/JNEUROSCI.1841-12.2012; Cohen-Adad J, 2011, NEUROIMAGE, V55, P1024, DOI 10.1016/j.neuroimage.2010.11.089; Diedrichsen J, 2006, NEUROIMAGE, V33, P127, DOI 10.1016/j.neuroimage.2006.05.056; Draganski B, 2011, NEUROIMAGE, V55, P1423, DOI 10.1016/j.neuroimage.2011.01.052; Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034; Eippert F, 2009, NEURON, V63, P533, DOI 10.1016/j.neuron.2009.07.014; Ellaway PH, 2011, BRAIN RES BULL, V84, P343, DOI 10.1016/j.brainresbull.2010.08.007; Freund P, 2013, LANCET NEUROL, V12, P873, DOI 10.1016/S1474-4422(13)70146-7; Freund P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051729; Freund P, 2011, BRAIN, V134, P1610, DOI 10.1093/brain/awr093; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; Furlan JC, 2011, J NEUROTRAUM, V28, P1445, DOI 10.1089/neu.2009.1152; Garcia-Larrea L, 2013, PAIN, V154, pS29, DOI 10.1016/j.pain.2013.09.001; Ghosh A, 2009, J NEUROSCI, V29, P12210, DOI 10.1523/JNEUROSCI.1828-09.2009; Gustin SM, 2014, PAIN, V155, P1027, DOI 10.1016/j.pain.2014.02.008; Gustin SM, 2010, CEREB CORTEX, V20, P1409, DOI 10.1093/cercor/bhp205; Haefeli J, 2014, NEUROREHAB NEURAL RE, V28, P494, DOI 10.1177/1545968313517755; Harkins KD, 2016, MAGN RESON MED, V75, P1341, DOI 10.1002/mrm.25709; Hassanpour K, 2012, J NEUROL, V259, P1142, DOI 10.1007/s00415-011-6316-2; Helms G, 2009, NEUROIMAGE, V47, P194, DOI 10.1016/j.neuroimage.2009.03.053; Helms G, 2008, MAGN RESON MED, V60, P1396, DOI 10.1002/mrm.21732; Horsfield MA, 2010, NEUROIMAGE, V50, P446, DOI 10.1016/j.neuroimage.2009.12.121; Huber E, 2015, CURR OPIN NEUROL, V28, P365, DOI 10.1097/WCO.0000000000000224; Jahn K, 2008, NEUROIMAGE, V39, P786, DOI 10.1016/j.neuroimage.2007.09.047; Jain N, 2000, P NATL ACAD SCI USA, V97, P5546, DOI 10.1073/pnas.090572597; Jones EG, 1998, SCIENCE, V282, P1121, DOI 10.1126/science.282.5391.1121; Kaas JH, 1999, NEURON, V22, P657, DOI 10.1016/S0896-6273(00)80725-4; Kaas JH, 2008, EXP NEUROL, V209, P407, DOI 10.1016/j.expneurol.2007.06.014; Kirshblum SC, 2011, J SPINAL CORD MED, V34, P547, DOI 10.1179/107902611X13186000420242; Kuhn F, 2012, J NEUROTRAUM, V29, P1829, DOI 10.1089/neu.2011.2277; Lundell H, 2011, SPINAL CORD, V49, P70, DOI 10.1038/sc.2010.87; Makin TR, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2571; Miyanji F, 2007, RADIOLOGY, V243, P820, DOI 10.1148/radiol.2433060583; Mole TB, 2014, NEUROIMAGE-CLIN, V5, P28, DOI 10.1016/j.nicl.2014.05.014; Moulton EA, 2010, BRAIN RES REV, V65, P14, DOI 10.1016/j.brainresrev.2010.05.005; Moxon KA, 2014, NEUROSCIENCE, V283, P78, DOI 10.1016/j.neuroscience.2014.06.056; MURRAY EA, 1984, BEHAV BRAIN RES, V11, P67, DOI 10.1016/0166-4328(84)90009-3; Ogino Y, 2007, CEREB CORTEX, V17, P1139, DOI 10.1093/cercor/bhl023; Ray S, 2008, J NEUROSCI, V28, P7334, DOI 10.1523/JNEUROSCI.1588-08.2008; Rooney WD, 2007, MAGN RESON MED, V57, P308, DOI 10.1002/mrm.21122; Schmierer K, 2004, ANN NEUROL, V56, P407, DOI 10.1002/ana.20202; Siddall PJ, 2001, SPINAL CORD, V39, P63, DOI 10.1038/sj.sc.3101116; Siddall PJ, 2003, PAIN, V103, P249, DOI 10.1016/S0304-3959(02)00452-9; Stroman PW, 2002, NEUROIMAGE, V17, P1854, DOI 10.1006/nimg.2002.1305; Tardif CL, 2009, NEUROIMAGE, V44, P827, DOI 10.1016/j.neuroimage.2008.09.053; Tattersall TL, 2014, NAT NEUROSCI, V17, P449, DOI 10.1038/nn.3642; Turati L, 2015, NMR BIOMED, V28, P327, DOI 10.1002/nbm.3253; Villiger M, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00254; Weiskopf N, 2015, CURR OPIN NEUROL, V28, P313, DOI 10.1097/WCO.0000000000000222; Weiskopf N, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00095; Weiskopf N, 2011, NEUROIMAGE, V54, P2116, DOI 10.1016/j.neuroimage.2010.10.023; Widerstrom-Noga E, 2014, SPINAL CORD, V52, P282, DOI 10.1038/sc.2014.4; Widerstrom-Noga E, 2013, PAIN, V154, P204, DOI 10.1016/j.pain.2012.07.022; Wrigley PJ, 2009, PAIN, V141, P52, DOI 10.1016/j.pain.2008.10.007; Wrigley PJ, 2009, CEREB CORTEX, V19, P224, DOI 10.1093/cercor/bhn072; Yague JG, 2011, EXP NEUROL, V227, P252, DOI 10.1016/j.expneurol.2010.11.011; Zariffa J, 2011, SPINAL CORD, V49, P463, DOI 10.1038/sc.2010.140; Zhang JY, 2009, J NEUROSCI, V29, P3160, DOI 10.1523/JNEUROSCI.3941-08.2009	70	39	40	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	NOV	2015	78	5					751	761		10.1002/ana.24508			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CU7NP	WOS:000363727900010	26290444	Green Published, Green Accepted			2021-06-18	
J	Twamley, EW; Thomas, KR; Gregory, AM; Jak, AJ; Bondi, MW; Delis, DC; Lohr, JB				Twamley, Elizabeth W.; Thomas, Kelsey R.; Gregory, Amber M.; Jak, Amy J.; Bondi, Mark W.; Delis, Dean C.; Lohr, James B.			CogSMART Compensatory Cognitive Training for Traumatic Brain Injury: Effects Over 1 Year	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; cognitive rehabilitation; depression; employment; posttraumatic stress disorder; rehabilitation; unemployment	MILD HEAD-INJURY; NEUROPSYCHOLOGICAL OUTCOMES; METAANALYSIS; REHABILITATION; SYMPTOMS; MEMORY; REMEDIATION; EMPLOYMENT; VETERANS; QUALITY	Objective: There are very few evidence-based treatments for individuals with mild to moderate traumatic brain injuries. We developed and tested a 12-week, manualized, compensatory cognitive training intervention, Cognitive Symptom Management and Rehabilitation Therapy (CogSMART), which targeted postconcussive symptom management, prospective memory, attention, learning/memory, and executive functioning. The intervention focused on psychoeducation and compensatory strategies such as calendar use, self-talk, note taking, and a 6-step problem-solving method. Setting: VA Healthcare System. Participants: A total of 50 Veterans with mild to moderate traumatic brain injuries receiving supported employment. Design: Twelve-month randomized controlled trial with participants assigned to receive CogSMART or additional supported employment sessions for the first 12 weeks. Outcome assessments were administered at baseline and 3, 6, and 12 months. Main Measures: Assessments measured postconcussive symptoms, neuropsychological performance, functional capacity, psychiatric symptom severity, quality of life, and weeks worked during the 12-month trial. Results: Hierarchical linear modeling analyses using all 4 time points demonstrated significant CogSMART-associated reductions in postconcussive symptoms (r = -0.28, P =.026, d = 0.64) and improvements in prospective memory (r = 0.35, P =.031, d = 0.55) and quality of life (r = 0.34, P =.009, d = 1.0). The groups did not differ on weeks worked during the trial. Conclusion: CogSMART has the potential to improve postconcussive symptoms, cognitive performance, and self-rated quality of life in individuals with mild to moderate traumatic brain injuries.	[Twamley, Elizabeth W.; Jak, Amy J.; Delis, Dean C.; Lohr, James B.] VA San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, San Diego, CA 92161 USA; [Twamley, Elizabeth W.; Jak, Amy J.; Bondi, Mark W.; Lohr, James B.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Thomas, Kelsey R.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA; [Gregory, Amber M.] Univ Alabama Birmingham, Birmingham, AL USA; [Jak, Amy J.; Bondi, Mark W.] VA San Diego Healthcare Syst, Psychol Serv, San Diego, CA 92161 USA	Twamley, EW (corresponding author), VA San Diego Healthcare Syst, Neuropsychol Unit, Ctr Excellence Stress & Mental Hlth, 3350 La Jolla Village Dr 116A, San Diego, CA 92161 USA.	etwamley@ucsd.edu			Department of DefenseUnited States Department of Defense [W81XWH-08-2-0193]	This research was funded by Department of Defense Award W81XWH-08-2-0193 to Dr Twamley.	Andelic N, 2012, BRAIN INJURY, V26, P261, DOI 10.3109/02699052.2012.654589; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler ED, 2013, CLIN NEUROPSYCHOL, V27, P176, DOI 10.1080/13854046.2012.693950; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cicerone KA, 2009, ARCH PHYS MED REHAB, V90, pS52, DOI 10.1016/j.apmr.2009.05.019; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Congressional Research Service, 2007, US MIL CAS STAT OP I; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; HAMILTON M, 1967, BRIT J SOC CLIN PSYC, V6, P278; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hrobjartsson A, 2013, CAN MED ASSOC J, V185, pE201, DOI 10.1503/cmaj.120744; Institute of Medicine, 2011, COGN REH THER TRAUM; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kongs SK, 2000, WISCONSIN CARD SORTI; Kreutzer J S, 1988, Brain Inj, V2, P205, DOI 10.3109/02699058809150945; Kwok FY, 2008, BRAIN INJURY, V22, P740, DOI 10.1080/02699050802336989; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; Leahy BJ, 1998, BRAIN INJURY, V12, P1025, DOI 10.1080/026990598121936; LEHMAN AF, 1988, EVAL PROGRAM PLANN, V11, P51, DOI 10.1016/0149-7189(88)90033-X; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; McGurk SR, 2007, AM J PSYCHIAT, V164, P1791, DOI 10.1176/appi.ajp.2007.07060906; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Raskin S, 2004, J INT NEUROPSYCHO S1, V10, P110, DOI DOI 10.1017/S1355617704040019; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147; Singer J.D., 2003, APPL LONGITUDINAL DA; Sitzer DI, 2006, ACTA PSYCHIAT SCAND, V114, P75, DOI 10.1111/j.1600-0447.2006.00789.x; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Twamley EW, 2014, J REHABIL RES DEV, V51, P59, DOI 10.1682/JRRD.2013.01.0020; Twamley EW, 2013, J REHABIL RES DEV, V50, P663, DOI 10.1682/JRRD.2012.08.0137; Twamley EW, 2012, J CLIN PSYCHIAT, V73, P1212, DOI 10.4088/JCP.12m07686; Twamley EW, 2003, SCHIZOPHRENIA BULL, V29, P359, DOI 10.1093/oxfordjournals.schbul.a007011; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Wilkinson G.S., 1993, WRAT 3 WIDE RANGE AC; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Woods SP, 2012, J INT NEUROPSYCH SOC, V18, P134, DOI 10.1017/S1355617711001263; Wykes T, 2011, AM J PSYCHIAT, V168, P472, DOI 10.1176/appi.ajp.2010.10060855; Zogg JB, 2012, J BEHAV MED, V35, P47, DOI 10.1007/s10865-011-9341-9	56	39	39	0	32	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2015	30	6					391	401		10.1097/HTR.0000000000000076			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DD0JN	WOS:000369606300011	25033034				2021-06-18	
J	Harris, JL; Choi, IY; Brooks, WM				Harris, Janna L.; Choi, In-Young; Brooks, William M.			Probing astrocyte metabolism in vivo: proton magnetic resonance spectroscopy in the injured and aging brain	FRONTIERS IN AGING NEUROSCIENCE			English	Article						proton magnetic resonance spectroscopy; astrocytes; traumatic brain injury (TBI); aging; myo-inositol; glutathione; glutamic acid; lactic acid	H-1 MR SPECTROSCOPY; NEUROCHEMICAL PROFILE; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; SYNAPTIC PROTEINS; TRANSGENIC MICE; MOUSE-BRAIN; HEAD-INJURY; TIME-COURSE; GLUTATHIONE	Following a brain injury, the mobilization of reactive astrocytes is part of a complex neuroinflammatory response that may have both harmful and beneficial effects. There is also evidence that astrocytes progressively accumulate in the normal aging brain, increasing in both number and size. These astrocyte changes in normal brain aging may, in the event of an injury, contribute to the exacerbated injury response and poorer outcomes observed in older traumatic brain injury (TBI) survivors. Here we present our view that proton magnetic resonance spectroscopy (H-1-MRS), a neuroimaging approach that probes brain metabolism within a defined region of interest, is a promising technique that may provide insight into astrocyte metabolic changes in the injured and aging brain in vivo. Although H-1-MRS does not specifically differentiate between cell types, it quantifies certain metabolites that are highly enriched in astrocytes (e.g., Myo-inositol, mins), or that are involved in metabolic shuttling between astrocytes and neurons (e.g., glutamate and glutamine). Here we focus on metabolites detectable by H-1-MRS that may serve as markers of astrocyte metabolic status. We review the physiological roles of these metabolites, discuss recent H-1-MRS findings in the injured and aging brain, and describe how an astrocyte metabolite profile approach might be useful in clinical medicine and clinical trials.	[Harris, Janna L.; Choi, In-Young; Brooks, William M.] Univ Kansas, Med Ctr, Hoglund Brain Imaging Ctr, Kansas City, KS 66103 USA; [Harris, Janna L.] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66103 USA; [Choi, In-Young; Brooks, William M.] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66103 USA; [Choi, In-Young; Brooks, William M.] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66103 USA	Harris, JL (corresponding author), Univ Kansas, Med Ctr, Hoglund Brain Imaging Ctr, Kansas City, KS 66103 USA.	jharris2@kumc.edu	Brooks, William/AAF-8299-2019	Brooks, William/0000-0001-6227-7636	U.S. National Institutes of Health through the University of Kansas Alzheimer's Center [P30 AG035982]; Heartland Institute for Clinical & Translational Research [UL1 TR000001, R21 NS091920]; KUMC Lied Endowed Basic Science; Hoglund Family Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS091920] Funding Source: NIH RePORTER	This work was supported in part by the U.S. National Institutes of Health through the University of Kansas Alzheimer's Center (P30 AG035982), Frontiers: The Heartland Institute for Clinical & Translational Research (UL1 TR000001), R21 NS091920, KUMC Lied Endowed Basic Science grants to Drs. Harris and Brooks, and the Hoglund Family Foundation. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.	Allaman I, 2011, TRENDS NEUROSCI, V34, P76, DOI 10.1016/j.tins.2010.12.001; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Ashwal S, 1997, ANN NEUROL, V41, P470, DOI 10.1002/ana.410410410; Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/neu.2004.21.1539; Bartnik-Olson Brenda L, 2013, Front Neuroenergetics, V5, P8, DOI 10.3389/fnene.2013.00008; Bitsch A, 1999, AM J NEURORADIOL, V20, P1619; Bluml S, 2013, MR SPECTROSCOPY PEDI, P11, DOI [DOI 10.1007/978-1-4419-5864-8_2, 10.1007/978-1-4419-5864-8_2]; Boumezbeur F, 2010, J CEREBR BLOOD F MET, V30, P211, DOI 10.1038/jcbfm.2009.197; BRAND A, 1993, DEV NEUROSCI-BASEL, V15, P289, DOI 10.1159/000111347; Brooks WM, 1999, MAGNET RESON MED, V41, P193, DOI 10.1002/(SICI)1522-2594(199901)41:1<193::AID-MRM27>3.0.CO;2-P; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; BROWN LAS, 1994, AM J PHYSIOL, V266, pL172; Chang L, 1996, LIFE SCI, V58, P2049, DOI 10.1016/0024-3205(96)00197-X; Chang LD, 2013, J NEUROIMMUNE PHARM, V8, P576, DOI 10.1007/s11481-013-9460-x; Chen SQ, 2012, J ALZHEIMERS DIS, V28, P71, DOI 10.3233/JAD-2010-110893; Chen SQ, 2009, DEMENT GERIATR COGN, V28, P558, DOI 10.1159/000261646; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Choi IY, 2011, MULT SCLER J, V17, P289, DOI 10.1177/1352458510384010; Cotrina ML, 2002, J NEUROSCI RES, V67, P1; Di Pietro V, 2014, FREE RADICAL BIO MED, V69, P258, DOI 10.1016/j.freeradbiomed.2014.01.032; Duarte JMN, 2014, NEUROBIOL AGING, V35, P1660, DOI 10.1016/j.neurobiolaging.2014.01.135; Emir UE, 2011, NMR BIOMED, V24, P888, DOI 10.1002/nbm.1646; Filibian M, 2012, EPILEPSIA, V53, P1907, DOI 10.1111/j.1528-1167.2012.03685.x; Franceschi C, 2007, MECH AGEING DEV, V128, P92, DOI 10.1016/j.mad.2006.11.016; Gilmer LK, 2010, J NEUROTRAUM, V27, P939, DOI 10.1089/neu.2009.1181; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Harris JL, 2014, NEUROBIOL AGING, V35, P1686, DOI 10.1016/j.neurobiolaging.2014.01.018; Harris JL, 2012, J CEREBR BLOOD F MET, V32, P2122, DOI 10.1038/jcbfm.2012.114; Hurd R, 2004, MAGNET RESON MED, V51, P435, DOI 10.1002/mrm.20007; Kaiser LG, 2005, NEUROBIOL AGING, V26, P665, DOI 10.1016/j.neurobiolaging.2004.07.001; Kierans AS, 2014, NEUROLOGY, V82, P521, DOI 10.1212/WNL.0000000000000105; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KREIS R, 1992, RADIOLOGY, V182, P19, DOI 10.1148/radiology.182.1.1345760; Lei HX, 2009, J CEREBR BLOOD F MET, V29, P811, DOI 10.1038/jcbfm.2009.8; Lescot T, 2010, J NEUROTRAUM, V27, P463, DOI 10.1089/neu.2009.0982-C; Lin AP, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0094-5; Maher P, 2005, AGEING RES REV, V4, P288, DOI 10.1016/j.arr.2005.02.005; MICHAELIS T, 1993, RADIOLOGY, V187, P219, DOI 10.1148/radiology.187.1.8451417; Murray ME, 2014, J NEUROSCI, V34, P16247, DOI 10.1523/JNEUROSCI.2027-14.2014; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Paban V, 2010, EUR J NEUROSCI, V31, P1063, DOI 10.1111/j.1460-9568.2010.07126.x; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; PETROFF OAC, 1995, MAGN RESON IMAGING, V13, P1197, DOI 10.1016/0730-725X(95)02033-P; Pfeuffer J, 1999, J MAGN RESON, V141, P104, DOI 10.1006/jmre.1999.1895; Popa-Wagner A, 2011, AGEING RES REV, V10, P71, DOI 10.1016/j.arr.2009.10.008; Rae CD, 2014, NEUROCHEM RES, V39, P1, DOI 10.1007/s11064-013-1199-5; Reyngoudt H, 2012, EUR J RADIOL, V81, pE223, DOI 10.1016/j.ejrad.2011.01.106; Rice ME, 1998, NEUROSCIENCE, V82, P1213; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rothermundt M, 2007, PROG NEURO-PSYCHOPH, V31, P361, DOI 10.1016/j.pnpbp.2006.09.013; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Sharrock M., 2015, NAT NEUR S, pA, DOI [10.1089/neu.2015.29000, DOI 10.1089/NEU.2015.29000]; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; STRANGE K, 1994, GLIA, V12, P35, DOI 10.1002/glia.440120105; Sun XJ, 2006, J BIOL CHEM, V281, P17420, DOI 10.1074/jbc.M601567200; Terpstra M, 2003, MAGN RESON MED, V50, P19, DOI 10.1002/mrm.10499; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Trabesinger AH, 2001, MAGN RESON MED, V45, P708, DOI 10.1002/mrm.1094; Urrila AS, 2004, J SLEEP RES, V13, P111, DOI 10.1111/j.1365-2869.2004.00401.x; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739; Yokobori S, 2011, J TRAUMA, V71, P1235, DOI 10.1097/TA.0b013e3182140dd7; Zhang XR, 2013, BRAIN RES, V1507, P28, DOI 10.1016/j.brainres.2013.02.033; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283	68	39	39	0	9	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1663-4365			FRONT AGING NEUROSCI	Front. Aging Neurosci.	OCT 28	2015	7								202	10.5589/fnagi.2015.00202			8	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	CV3JA	WOS:000364154300001	26578948	DOAJ Gold			2021-06-18	
J	Pearce, AJ; Hoy, K; Rogers, MA; Corp, DT; Davies, CB; Maller, JJ; Fitzgerald, PB				Pearce, Alan J.; Hoy, Kate; Rogers, Mark A.; Corp, Daniel T.; Davies, Charlotte B.; Maller, Jerome J.; Fitzgerald, Paul B.			Acute motor, neurocognitive and neurophysiological change following concussion injury in Australian amateur football. A prospective multimodal investigation	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Transcranial magnetic stimulation; Motor cortex inhibition; Sports concussion; Australian football	TRANSCRANIAL MAGNETIC STIMULATION; SPORT-RELATED CONCUSSION; BRAIN-INJURY; LONG-TERM; INHIBITION; CORTEX; TASKS	Objectives: This multimodal study investigated the motor, neurocognitive and neurophysiological responses following a sports related concussion injury in the acute-phase (up to 10 days) in sub-elite Australian football players. Design: Between-group, repeated measures. Methods: Over the course of one season (six months), 43 male players from one football club (25.1 +/- 4.5 years) were assessed for fine motor dexterity, visuomotor reaction time, implicit learning and attention. Motor cortex excitability and inhibition were assessed using transcranial magnetic stimulation. Results: Of the 43 players, eight suffered concussion injuries, and were compared to 15 non-concussed players (active control) who returned for follow up testing. Post-concussion assessments using the aforementioned tests were carried out at 48 and 96 h, and 10 days. Compared to the non-concussed players, those who suffered concussion showed slowed fine dexterity (P = 0.02), response (P = 0.02) and movement times (P = 0.01) 48 h post-Concussion. Similarly, attentional performance was reduced in the concussed group at all time points (48h: P<0.01; 96h: P<0.01; and 10 days: P = 0.02) post-concussion. TMS revealed significantly increased corticospinal inhibition at 48 (P = 0.04) and 96 h post concussion (P = 0.02) with significant correlations between increased corticospinal inhibition and response (r = 0.48; P < 0.01), movement time (r = 0.42; P = 0.02), and attention performance (r = 0.44; P = 0.01). Conclusions: This study has demonstrated that acutely concussed Australian football players show abnormalities in motor, cognitive and neurophysiological measures with variable rates of recovery. These. findings suggest that measuring the recovery of concussed athletes should incorporate a range of testing modalities rather than relying on one area of measurement in determining return to play. (C) 2014 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Pearce, Alan J.; Rogers, Mark A.; Corp, Daniel T.; Davies, Charlotte B.] Deakin Univ, Sch Psychol, Cognit Neurosci Lab, Melbourne, Vic, Australia; [Hoy, Kate; Maller, Jerome J.; Fitzgerald, Paul B.] Monash Univ, Alfred & Cent Clin Sch, Monash Alfred Psychiat Res Ctr, Melbourne, Vic 3004, Australia	Pearce, AJ (corresponding author), Deakin Univ, Sch Psychol, Cognit Neurosci Lab, Melbourne, Vic, Australia.	alan.pearce@deakin.edu.au	Fitzgerald, Paul B/A-1225-2008; Pearce, Alan J/W-1195-2018; Maller, Jerome J/H-4963-2014	Fitzgerald, Paul B/0000-0003-4217-8096; Pearce, Alan J/0000-0002-9264-9880; Maller, Jerome J/0000-0003-4685-1508; Corp, Daniel/0000-0003-2435-077X; Hoy, Kate/0000-0003-0694-9674; Rogers, Mark/0000-0002-6808-9545	Smart Head Play; NHMRC fellowshipNational Health and Medical Research Council of Australia; NHMRC Practitioner FellowshipNational Health and Medical Research Council of Australia [606907]; Cervel Neurotech	This study was supported, in part, by a seeding grant from Smart Head Play. JM is supported by a NHMRC fellowship. PBF is supported by a NHMRC Practitioner Fellowship (606907). PBF has received equipment for research from MagVenture A/S, Medtronic Ltd., Cervel Neurotech and Brainsway Ltd., and commercial funding for research from Cervel Neurotech. The authors sincerely thank Mr. Matthew Gray and the Hampton Rovers amateur football club for assistance with participant recruitment, and Ms Hannah Drury for advice with neuropsychological tests.	Abbruzzese G, 1999, J PHYSIOL-LONDON, V514, P895, DOI 10.1111/j.1469-7793.1999.895ad.x; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Berger MAM, 2009, APPL ERGON, V40, P145, DOI 10.1016/j.apergo.2008.01.014; Blok J., 1999, EUROPEAN RECOMMENDAT; Chipchase L, 2012, CLIN NEUROPHYSIOL, V123, P1698, DOI 10.1016/j.clinph.2012.05.003; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; CORLETT EN, 1971, OCCUP PSYCHOL, V45, P57; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Hallett M, 2000, NATURE, V406, P147, DOI 10.1038/35018000; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Killane I, 2013, IEEE ENG MED BIO, P6397, DOI 10.1109/EMBC.2013.6611018; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Livingston SC, 2012, J CLIN NEUROPHYSIOL, V29, P23, DOI 10.1097/WNP.0b013e318246ae46; Miller NR, 2014, BRAIN INJURY, V28, P1270, DOI 10.3109/02699052.2014.915987; Pearce AJ, 2014, J NEUROTRAUM, V31, P1139, DOI 10.1089/neu.2013.3219; Pearce AJ, 2013, BRAIN STIMUL, V6, P306, DOI 10.1016/j.brs.2012.05.010; Pearce AJ, 2010, J SCI MED SPORT, V13, P167, DOI 10.1016/j.jsams.2008.12.632; Pearce AJ, 2009, J SCI MED SPORT, V12, P280, DOI 10.1016/j.jsams.2007.12.005; Rossini PM, 2013, FRONT NEUROSCI, P207; Sandberg MA, 2011, ENCY CLIN NEUROPSYCH, P480; Schlogl A, 2002, P 5 INT WORKSH PRES; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; White PE, 2014, BRIT J SPORT MED, V48, P119, DOI 10.1136/bjsports-2013-092785; WILSON SA, 1993, J NEUROL SCI, V114, P216, DOI 10.1016/0022-510X(93)90301-E; Yancosek KE, 2009, J HAND THER, V22, P258, DOI 10.1016/j.jht.2008.11.004	30	39	39	0	18	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	SEP	2015	18	5					500	506		10.1016/j.jsams.2014.07.010			7	Sport Sciences	Sport Sciences	CP9AM	WOS:000360186100002	25104044				2021-06-18	
J	Villiger, M; Grabher, P; Hepp-Reymond, MC; Kiper, D; Curt, A; Bolliger, M; Hotz-Boendermaker, S; Kollias, S; Eng, K; Freund, P				Villiger, Michael; Grabher, Patrick; Hepp-Reymond, Marie-Claude; Kiper, Daniel; Curt, Armin; Bolliger, Marc; Hotz-Boendermaker, Sabina; Kollias, Spyros; Eng, Kynan; Freund, Patrick			Relationship between structural brainstem and brain plasticity and lower-limb training in spinal cord injury: a longitudinal pilot study	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						spinal cord injury; structural plasticity; lower limb; virtual reality-augmented neurorehabilitation; tensor-based morphometry; voxel-based morphometry	VOXEL-BASED MORPHOMETRY; TENSOR-BASED MORPHOMETRY; VIRTUAL-REALITY; CEREBELLAR DEGENERATION; CORTICAL THICKNESS; RAPID PLASTICITY; NEUROPATHIC PAIN; MOTOR CORTEX; GRAY; MRI	Rehabilitative training has shown to improve significantly motor outcomes and functional walking capacity in patients with incomplete spinal cord injury (iSCI). However, whether performance improvements during rehabilitation relate to brain plasticity or whether it is based on functional adaptation of movement strategies remain uncertain. This study assessed training improvement-induced structural brain plasticity in chronic iSCI patients using longitudinal MRI. We used tensor-based morphometry (TBM) to analyze longitudinal brain volume changes associated with intensive virtual reality (VR)-augmented lower limb training in nine traumatic iSCI patients. The MRI data was acquired before and after a 4-week training period (16-20 training sessions). Before training, voxel-based morphometry (VBM) and voxel-based cortical thickness (VBCT) assessed baseline morphometric differences in nine iSCI patients compared to 14 healthy controls. The intense VR-augmented training of limb control improved significantly balance, walking speed, ambulation, and muscle strength in patients. Retention of clinical improvements was confirmed by the 3-4 months follow-up. In patients relative to controls, VBM revealed reductions of white matter volume within the brainstem and cerebellum and VBCT showed cortical thinning in the primary motor cortex. Over time, TBM revealed significant improvement-induced volume increases in the left middle temporal and occipital gyrus, left temporal pole and fusiform gyrus, both hippocampi, cerebellum, corpus callosum, and brainstem in iSCI patients. This study demonstrates structural plasticity at the cortical and brainstem level as a consequence of VR-augmented training in iSCI patients. These structural changes may serve as neuroimaging biomarkers of VR-augmented lower limb neurorehabilitation in addition to performance measures to detect improvements in rehabilitative training.	[Villiger, Michael; Grabher, Patrick; Curt, Armin; Bolliger, Marc; Hotz-Boendermaker, Sabina; Freund, Patrick] Univ Zurich, Spinal Cord Injury Ctr Balgrist, CH-8008 Zurich, Switzerland; [Villiger, Michael] Univ Coll Physiotherapy Thim van der Laan, Landquart, Switzerland; [Hepp-Reymond, Marie-Claude; Kiper, Daniel; Eng, Kynan] Univ Zurich, Inst Neuroinformat, Zurich, Switzerland; [Hepp-Reymond, Marie-Claude; Kiper, Daniel; Eng, Kynan] ETH, Zurich, Switzerland; [Kollias, Spyros] Univ Zurich, Univ Zurich Hosp, Inst Neuroradiol, Zurich, Switzerland; [Freund, Patrick] UCL, Dept Brain Repair & Rehabil, UCL Inst Neurol, London, England; [Freund, Patrick] UCL, Wellcome Trust Ctr Neuroimaging, UCL Inst Neurol, London, England	Villiger, M (corresponding author), Univ Zurich, Spinal Cord Injury Ctr Balgrist, Forchstr 340, CH-8008 Zurich, Switzerland.	michael.villiger@gmail.com; pfreund@paralab.balgrist.ch	Bolliger, Marc/AAC-8076-2020; Freund, Patrick/D-4193-2013; Hotz, S/AAL-7043-2020	Bolliger, Marc/0000-0001-9059-0304; Freund, Patrick/0000-0002-4851-2246; Hotz, S/0000-0001-9455-6074; Eng, Kynan/0000-0002-1434-8767; Grabher, Patrick/0000-0002-5420-6114	International Foundation for Research in Paraplegia (IRP); Clinical Research Priority Program (CRPP); Neuro-Rehab UZH; Swiss National Science Foundation (SNP)Swiss National Science Foundation (SNSF) [51NF40-144619/PMPDP3-124282]; OPO Foundation Zurich; Neuroscience Center Zurich (ZNZ); Wings for Life [WFL-CH-007/14]	Thanks to Pawel Pyk, Jeremy Spillmann and Bruno Meilick for their technical support, to Chris Schmidt for his critical review of a former version of this manuscript and to all participants for their generous help. There is a commercial interest of two authors (Kiper and Eng) relevant to the subject of the manuscript. All other authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. This research was supported by the International Foundation for Research in Paraplegia (IRP), Clinical Research Priority Program (CRPP), Neuro-Rehab UZH, Swiss National Science Foundation (SNP; Grant Number 51NF40-144619/PMPDP3-124282), OPO Foundation Zurich, the Neuroscience Center Zurich (ZNZ) and Wings for Life (WFL-CH-007/14).	Adamovich SV, 2009, NEUROREHABILITATION, V25, P29, DOI 10.3233/NRE-2009-0497; Albouy G, 2008, NEURON, V58, P261, DOI 10.1016/j.neuron.2008.02.008; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Ashburner J, 2013, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00197; BERG K, 1995, SCAND J REHABIL MED, V27, P27; Bohil CJ, 2011, NAT REV NEUROSCI, V12, P752, DOI 10.1038/nrn3122; Bryce TN, 2012, SPINAL CORD, V50, P404, DOI 10.1038/sc.2012.2; Burciu RG, 2013, J NEUROSCI, V33, P4594, DOI 10.1523/JNEUROSCI.3381-12.2013; Catz A, 2007, SPINAL CORD, V45, P275, DOI 10.1038/sj.sc.3101960; Classen J, 1998, J NEUROPHYSIOL, V79, P1117; Cohen-Adad J, 2011, NEUROIMAGE, V55, P1024, DOI 10.1016/j.neuroimage.2010.11.089; Deliagina TG, 2008, BRAIN RES REV, V57, P212, DOI 10.1016/j.brainresrev.2007.06.017; Draganski B, 2008, BEHAV BRAIN RES, V192, P137, DOI 10.1016/j.bbr.2008.02.015; Draganski B, 2004, NATURE, V427, P311, DOI 10.1038/427311a; Driemeyer J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002669; Freund P, 2013, LANCET NEUROL, V12, P873, DOI 10.1016/S1474-4422(13)70146-7; Freund P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051729; Freund P, 2012, J NEUROL NEUROSUR PS, V83, P629, DOI 10.1136/jnnp-2011-301875; Freund P, 2011, BRAIN, V134, P1610, DOI 10.1093/brain/awr093; Furlan JC, 2010, NEUROBIOL AGING, V31, P434, DOI 10.1016/j.neurobiolaging.2008.05.003; Ghosh A, 2010, NAT NEUROSCI, V13, P97, DOI 10.1038/nn.2448; Hassanpour K, 2012, J NEUROL, V259, P1142, DOI 10.1007/s00415-011-6316-2; Holden MK, 2005, CYBERPSYCHOL BEHAV, V8, P187, DOI 10.1089/cpb.2005.8.187; Houk JC, 1996, BEHAV BRAIN SCI, V19, P368, DOI 10.1017/S0140525X00081474; Hua X, 2013, NEUROIMAGE, V66, P648, DOI 10.1016/j.neuroimage.2012.10.086; Hutton C, 2008, NEUROIMAGE, V40, P1701, DOI 10.1016/j.neuroimage.2008.01.027; Hutton C, 2009, NEUROIMAGE, V48, P371, DOI 10.1016/j.neuroimage.2009.06.043; Kantak SS, 2013, NEUROSCIENCE, V247, P55, DOI 10.1016/j.neuroscience.2013.05.001; Koeneke S, 2006, EXP BRAIN RES, V174, P199, DOI 10.1007/s00221-006-0440-8; Landi SM, 2011, J NEUROSCI, V31, P11808, DOI 10.1523/JNEUROSCI.2253-11.2011; Maguire EA, 2000, P NATL ACAD SCI USA, V97, P4398, DOI 10.1073/pnas.070039597; Marino RJ., 2003, J SPINAL CORD MED, V26, pS50, DOI [10.1080/10790268.2003.11754575, DOI 10.1080/10790268.2003.11754575]; Markham JA, 2004, NEURON GLIA BIOL, V1, P351, DOI 10.1017/S1740925X05000219; Moseley GL, 2007, PAIN, V130, P294, DOI 10.1016/j.pain.2007.01.007; PASCUALLEONE A, 1995, J NEUROPHYSIOL, V74, P1037; Perez MA, 2004, EXP BRAIN RES, V159, P197, DOI 10.1007/s00221-004-1947-5; Quallo MM, 2009, P NATL ACAD SCI USA, V106, P18379, DOI 10.1073/pnas.0909751106; Rabe K, 2009, J NEUROPHYSIOL, V101, P1961, DOI 10.1152/jn.91069.2008; Sagi Y, 2012, NEURON, V73, P1195, DOI 10.1016/j.neuron.2012.01.025; Sampaio-Baptista C, 2015, NEUROIMAGE, V106, P15, DOI 10.1016/j.neuroimage.2014.11.032; Schendan HE, 2003, NEURON, V37, P1013, DOI 10.1016/S0896-6273(03)00123-5; Sehm B, 2014, NEUROBIOL AGING, V35, P232, DOI 10.1016/j.neurobiolaging.2013.06.021; Tao GZ, 2009, J NEUROL SCI, V282, P39, DOI 10.1016/j.jns.2008.12.035; Taubert M, 2011, NEUROIMAGE, V57, P1492, DOI 10.1016/j.neuroimage.2011.05.078; Taubert M, 2010, J NEUROSCI, V30, P11670, DOI 10.1523/JNEUROSCI.2567-10.2010; Tessa C, 2014, HUM BRAIN MAPP, V35, P3932, DOI 10.1002/hbm.22449; van Hedel H, 2006, SPINAL CORD, V44, P352, DOI 10.1038/sj.sc.3101853; van Hedel HJ, 2005, ARCH PHYS MED REHAB, V86, P190, DOI 10.1016/j.apmr.2004.02.010; Villiger M., 2011, INT C VIRT REH ICVR; Villiger M, 2013, NEUROREHAB NEURAL RE, V27, P675, DOI 10.1177/1545968313490999; Walz AD, 2015, BEHAV BRAIN RES, V278, P393, DOI 10.1016/j.bbr.2014.08.044; Wyndaele M, 2006, SPINAL CORD, V44, P523, DOI 10.1038/sj.sc.3101893; Zorner B, 2014, BRAIN, V137, P1716, DOI 10.1093/brain/awu078	55	39	41	2	23	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	MAY 6	2015	9								254	10.3389/fnhum.2015.00254			10	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	CK2AL	WOS:000356011600001	25999842	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Ponsford, JL; Spitz, G				Ponsford, Jennie L.; Spitz, Gershon			Stability of Employment Over the First 3 Years Following Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						employment; productivity; return to work; traumatic brain injury	POSTTRAUMATIC AMNESIA; COMMUNITY INTEGRATION; ACUTE PREDICTORS; RETURN; WORK; PRODUCTIVITY; MULTICENTER; MODERATE; OUTCOMES; LIFE	Objective: To examine the stability of employment between 1 and 3 years following traumatic brain injury (TBI) and to identify the variables associated with continued employment throughout this time span. Participants: This study included 236 individuals with predominantly moderate to very severe TBI, who had received rehabilitation in the context of a no-fault accident compensation system. Participants were eligible for the current study if they were employed before injury and reported their employment status at 1, 2, and 3 years following their injury as part of a longitudinal head injury outcome study. Results: Only 44% of participants remained employed at each of the 3 years following TBI. There was also substantial transition into and out of employment across the 3 years. Significantly greater instability in employment was reported by individuals who were machinery operators or laborers before injury, had a longer duration of posttraumatic amnesia, reported more cognitive difficulties, and were less mobile 1 year following their injury. Conclusion: A number of important factors determine the likelihood of achieving stability in employment following TBI. Findings from the current study support the continued need to identify ways in which physical as well as cognitive changes contribute to employment following TBI. Further examination is needed to identify possible compensatory strategies or job modifications to maximize the likelihood of job retention.	[Ponsford, Jennie L.] Monash Univ, Sch Psychol Sci, Melbourne, Vic 3800, Australia; Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia	Ponsford, JL (corresponding author), Monash Univ, Sch Psychol Sci, Bldg 17,Clayton Campus,Wellington Rd, Melbourne, Vic 3800, Australia.	Jennie.Ponsford@monash.edu	Spitz, Gershon/H-7755-2014	Spitz, Gershon/0000-0002-7810-1480			Access Economics, 2009, EC COST SPINAL CORD; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Australian Bureau of Statistics, 2013, LAB FORC AUSTR CAT 6; Australian Bureau of Statistics, 2006, ANZC AUSTR NZ STAND; Bootes K, 2010, WORK, V36, P207, DOI [10.3233/WOR-2010-1021, 10.3233/WOR-2010-01021]; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Dawson DR, 2006, BRAIN COGNITION, V60, P214; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Erez ABH, 2009, AM J OCCUP THER, V63, P634; FABIANO RJ, 1995, REHABIL PSYCHOL, V40, P223, DOI 10.1037/0090-5550.40.3.223; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Gary KW, 2009, ARCH PHYS MED REHAB, V90, P1699, DOI 10.1016/j.apmr.2009.04.014; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; Goran DA, 1997, ARCH CLIN NEUROPSYCH, V12, P691, DOI 10.1016/S0887-6177(97)00004-8; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS51, DOI 10.1016/j.apmr.2008.09.552; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; McCrimmon S, 2006, BRAIN INJURY, V20, P1037, DOI 10.1080/02699050600909656; Nakase-Richardson R, 2007, J NEUROL NEUROSUR PS, V78, P872, DOI 10.1136/jnnp.2006.104190; O'Connell MJ, 2000, REHABIL PSYCHOL, V45, P212, DOI 10.1037/0090-5550.45.2.212; O'Neill L J, 1998, Br J Nurs, V7, P842; Ouellet MC, 2009, J HEAD TRAUMA REHAB, V24, P262, DOI 10.1097/HTR.0b013e3181a68b73; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Ponsford J, 1999, NEUROPSYCHOL REHABIL, V9, P517, DOI 10.1080/096020199389563; Ponsford J, 2012, TRAUMATIC BRAIN INJU; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Possl O, 2001, BRAIN INJURY, V15, P15; Sander AM, 1997, J HEAD TRAUMA REHAB, V12, P28, DOI 10.1097/00001199-199710000-00004; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Schonberger M, 2011, J NEUROL NEUROSUR PS, V82, P936, DOI 10.1136/jnnp.2010.210021; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Tsaousides T, 2008, REHABIL PSYCHOL, V53, P456, DOI 10.1037/a0012579; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335	44	39	39	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2015	30	3					E1	E11		10.1097/HTR.0000000000000033			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CH8PJ	WOS:000354298100001	24816157				2021-06-18	
J	Popernack, ML; Gray, N; Reuter-Rice, K				Popernack, Myra L.; Gray, Nicola; Reuter-Rice, Karin			Moderate-to-Severe Traumatic Brain Injury in Children: Complications and Rehabilitation Strategies	JOURNAL OF PEDIATRIC HEALTH CARE			English	Article						Traumatic brain injury; pediatric; Rancho; Glasgow Coma Score; outcome; cognitive function	COMA SCALE SCORE; DECOMPRESSIVE CRANIECTOMY; UNITED-STATES; BACLOFEN	Traumatic brain injury (TBI) is the leading cause of death in children in the United States. Each year 37,200 children sustain a severe TBI, with up to 1.3 million life-years potentially adversely affected. Severe pediatric TBI is associated with significant mortality and morbidity. Of the children who survive their injury, more than 50% experience unfavorable outcomes 6 months after the injury. Although TBI-associated death rates decreased between 1997-2007, disabilities for TBI survivors continue to have both a direct and indirect impact on the economic and human integrity of our society.The degree of disability varies with the severity and mechanism of the injury, but a realm of physical and emotional deficits may be evident for years after the injury occurs. This article describes the pathophysiology of moderate to severe TBI, its associated complications, and opportunities to improve patient outcomes through use of acute management and rehabilitation strategies. To address the many challenges for TBI survivors and their families, including significant financial and emotional burdens, a collaborative effort is necessary to help affected children transition seamlessly from acute care through long-term rehabilitation.	[Popernack, Myra L.] Penn State Hershey Childrens Hosp, Dept Pediat Rehabil & Dev, Hershey, PA 17033 USA; [Gray, Nicola; Reuter-Rice, Karin] Duke Univ, Sch Nursing, Durham, NC USA; [Reuter-Rice, Karin] Duke Univ, Sch Med, Durham, NC USA; [Reuter-Rice, Karin] Duke Inst Brain Sci, Dept Pediat, Durham, NC USA	Popernack, ML (corresponding author), Penn State Hershey Childrens Hosp, 500 Univ Dr, Hershey, PA 17033 USA.	mpopernack@hmc.psu.edu		Reuter-Rice, Karin/0000-0003-1501-8994	NIH-NINR Adaptive Leadership for Cognitive Affective Symptom Science (ADAPT) [1P30 NR014139-01]; Institute of Nursing Research Center of Excellence; Robert Wood Johnson Foundation as a Nurse Faculty Scholar Project [71244]; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [P30NR014139] Funding Source: NIH RePORTER	Karin Reuter-Rice received support for this work by NIH-NINR 1P30 NR014139-01 Adaptive Leadership for Cognitive Affective Symptom Science (ADAPT), Institute of Nursing Research Center of Excellence (2012-2015) in addition to funding by the Robert Wood Johnson Foundation as a Nurse Faculty Scholar Project #71244 (2013-2016).	Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Bansal S, 2014, J NEUROSURG-PEDIATR, V13, P209, DOI 10.3171/2013.10.PEDS13256; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Catroppa C, 2006, Pediatr Rehabil, V9, P89, DOI 10.1080/13638490500155458; Centers for Disease Control and Prevention (CDC), 2014, TBI DAT STAT; Chung M., 2014, NEUROLOGY, V82; Cicero MX, 2013, PEDIATR EMERG CARE, V29, P43, DOI 10.1097/PEC.0b013e31827b52bf; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Doeltgen SH, 2012, ARCH PHYS MED REHAB, V93, P207, DOI 10.1016/j.apmr.2011.08.030; Gooch JL, 2004, DEV MED CHILD NEUROL, V46, P548, DOI 10.1017/S001216220400091X; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hagen D., 1972, LEVEL COGNITIVE FUNC; Intiso D, 2012, J TOXICOL-US, V2012, DOI 10.1155/2012/802893; Kheder Ammar, 2012, Pract Neurol, V12, P289, DOI 10.1136/practneurol-2011-000155; Kirk KA, 2012, DEV MED CHILD NEUROL, V54, P759, DOI 10.1111/j.1469-8749.2012.04322.x; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518; Lubsch L, 2006, J CHILD NEUROL, V21, P1090, DOI 10.1177/7010.2006.00134; Miller C. K., 2011, ICAN: Infant, Child & Adolescent Nutrition, V3, P336, DOI 10.1177/1941406411423967; Nesiama JAO, 2012, PEDIATR EMERG CARE, V28, P1027, DOI 10.1097/PEC.0b013e31826cac31; O'Brien N., 2012, PEDIAT ACUTE CARE GU, P1197; Suarez EP, 2011, J TRAUMA, V71, P133, DOI 10.1097/TA.0b013e318211071f; Perkes I, 2010, ANN NEUROL, V68, P126, DOI 10.1002/ana.22066; Suskauer SJ, 2009, J PEDIATR REHAB MED, V2, P297, DOI 10.3233/PRM-2009-0092; Uniform Data System for Medical Rehabilitation, 2006, WEEFIM CLIN GUID VER; van Rhijn J, 2005, BRAIN INJURY, V19, P331, DOI 10.1080/02699050400013675; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zebrack M, 2009, PEDIATRICS, V124, P56, DOI 10.1542/peds.2008-1006	30	39	40	2	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0891-5245	1532-656X		J PEDIATR HEALTH CAR	J. Pediatr. Health Care	MAY-JUN	2015	29	3					E1	E7		10.1016/j.pedhc.2014.09.003			7	Health Policy & Services; Nursing; Pediatrics	Health Care Sciences & Services; Nursing; Pediatrics	CK1HC	WOS:000355956900002	25449002	Green Accepted			2021-06-18	
J	Lavigne, G; Khoury, S; Chauny, JM; Desautels, A				Lavigne, Gilles; Khoury, Samar; Chauny, Jean-Marc; Desautels, Alex			Pain and sleep in post-concussion/mild traumatic brain injury	PAIN			English	Article						Pain; Widespread pain; Diffuse pain; Central pain; Sleep; Minor traumatic brain injury; Biomarkers; BDNF genotype; Depression; Anxiety; Hyperarousal; Chronification	BDNF VAL66MET POLYMORPHISM; PERSISTENT POSTSURGICAL PAIN; POSTTRAUMATIC HEADACHE; RISK-FACTORS; NEUROTROPHIC FACTOR; PRACTICE PARAMETERS; WAKE DISTURBANCES; PREVALENCE; INSOMNIA; DISORDERS	Concussion after a force to the head is called mild traumatic brain injury (mTBI). Approximately 1 in 5 patients with mTBI will develop chronic pain (headache and widespread pain, possibly of central origin) and/or sleep problems (insomnia, disordered breathing, periodic limb movements). However, the predisposing mechanisms for chronic pain in patients with mTBI are unknown. Mild traumatic brain injury is a rare model to prospectively assess the risk factors and mechanisms for pain chronification from the injury onset in the absence of pretrauma comorbidity or medication. In the acute phase, headaches and sleep disturbances seem to predict the poorest long-term cognitive and mood outcomes. Although recent studies suggest that certain brain biomarkers and mood alterations (eg, anxiety, depression) contribute, the causality of chronic pain remains unclear. In mTBI patients with pain, poor sleep quality was correlated with fast beta and gamma electroencephalographic activity in frontal, central, and occipital electroencephalographic (EEG) derivations in all sleep stages. Sleep recuperative function seems to be disturbed by persistent wake EEG activity, corroborating patient complaints such as feeling awake when asleep. Pain and sleep management in mTBI is not yet evidence-based. Treatments include cognitive behavioral and light therapies, medications, and continuous positive airway pressure (CPAP) or oral appliances for disordered sleep breathing. Customized approaches are indicated for mTBI, pain, and sleep complaints. Further studies in pediatric, sport, and transportation populations are needed to prevent TBI chronification. Improvements are emerging in biomarker sensitivity and specificity and management strategies for TBI, pain, and sleep comorbidities.	[Lavigne, Gilles; Khoury, Samar; Chauny, Jean-Marc; Desautels, Alex] Univ Montreal, Dept Med Family Med Emergency Med, Montreal, PQ H3C 3J7, Canada; [Lavigne, Gilles; Khoury, Samar; Chauny, Jean-Marc; Desautels, Alex] Univ Montreal, Dept Neurosci, Montreal, PQ H3C 3J7, Canada; [Lavigne, Gilles; Khoury, Samar; Chauny, Jean-Marc; Desautels, Alex] Hop Sacre Coeur Montreal, Res Ctr, Trauma Unit, Montreal, PQ, Canada; [Lavigne, Gilles; Khoury, Samar; Chauny, Jean-Marc; Desautels, Alex] Hop Sacre Coeur Montreal, Ctr Adv Study Sleep Med, Montreal, PQ, Canada; [Khoury, Samar; Desautels, Alex] McGill Univ, Dept Anesthesia, Montreal, PQ H3A 2T5, Canada; [Desautels, Alex] Hop Sacre Coeur Montreal, Fac Med, Serv Neurol, Montreal, PQ, Canada	Lavigne, G (corresponding author), Univ Montreal, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	gilles.lavigne@umontreal.ca	Meijer, Anna/K-5118-2016		Fonds de Recherche du Quebec-Sante/Quebec Pain Research Network partnership; Ronald Denis Trauma Foundation, Montreal, Canada	The first author (GL) holds a Canada Research Chair in Pain, Sleep and Trauma. The author's projects cited in this review were funded by the Fonds de Recherche du Quebec-Sante/Quebec Pain Research Network partnership and the Ronald Denis Trauma Foundation, Montreal, Canada.	Aarabi B, 2009, CURR OPIN CRIT CARE, V15, P548, DOI 10.1097/MCC.0b013e32833190da; Ancoli-Israel S, 2003, SLEEP, V26, P342, DOI 10.1093/sleep/26.3.342; Apkarian AV, 2013, CURR OPIN NEUROL, V26, P360, DOI 10.1097/WCO.0b013e32836336ad; Apkarian AV, 2004, J NEUROSCI, V24, P10410, DOI 10.1523/JNEUROSCI.2541-04.2004; Aurora RN, 2012, SLEEP, V35, P1039, DOI 10.5665/sleep.1988; Aurora RN, 2012, SLEEP, V35, P17, DOI 10.5665/sleep.1580; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Bachmann V, 2012, SLEEP, V35, P335, DOI 10.5665/sleep.1690; Bastuji H, 2008, PAIN, V137, P589, DOI 10.1016/j.pain.2007.10.027; Baumann CR, 2012, NEUROMOL MED, V14, P205, DOI 10.1007/s12017-012-8178-x; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Bonnet MH, 2010, SLEEP MED REV, V14, P9, DOI 10.1016/j.smrv.2009.05.002; Burgess HJ, 2002, SLEEP MED REV, V6, P407, DOI 10.1053/smrv.2001.0215; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cao M, 2014, J CLIN SLEEP MED, V10, P855, DOI 10.5664/jcsm.3954; Carney N, 2014, NEUROSURGERY, V75, pS3, DOI 10.1227/NEU.0000000000000433; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Casey CY, 2008, PAIN, V134, P69, DOI 10.1016/j.pain.2007.03.032; Castillo RC, 2006, PAIN, V124, P321, DOI 10.1016/j.pain.2006.04.020; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Castriotta RJ, 2009, J CLIN SLEEP MED, V5, P137; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Cervero F, 1996, PROG BRAIN RES, V110, P3; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; Chen PY, 2014, J HEAD TRAUMA REHABI; Chen ZY, 2006, SCIENCE, V314, P140, DOI 10.1126/science.1129663; Cheng JP, 2007, NEUROSCI LETT, V416, P165, DOI 10.1016/j.neulet.2007.02.006; Choiniere M, 2014, CAN MED ASSOC J, V186, pE213, DOI 10.1503/cmaj.131012; Clay FJ, 2010, J PAIN, V11, P420, DOI 10.1016/j.jpain.2009.12.002; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223; Davidson J., 2014, NEUROSCIENTIST; De Beaumont L, 2013, BEHAV BRAIN RES, V253, P152, DOI 10.1016/j.bbr.2013.07.002; Defrin R, 2015, J NEUROTRAUM, V32, P28, DOI 10.1089/neu.2014.3359; Defrin R, 2014, J MAN MANIP THER, V22, P36, DOI 10.1179/2042618613Y.0000000053; Defrin R, 2010, EUR J PAIN, V14, P924, DOI 10.1016/j.ejpain.2010.03.004; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Ding K, 2014, NEUROCHEM INT, V76, P23, DOI 10.1016/j.neuint.2014.06.015; Dobscha SK, 2009, PAIN MED, V10, P1200, DOI 10.1111/j.1526-4637.2009.00721.x; Doufas AG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040891; Duclos C, 2014, NEUROREHAB NEURAL RE, V28, P472, DOI 10.1177/1545968313517756; Failla MD, 2015, NEUROREHAB NEURAL RE, V29, P234, DOI 10.1177/1545968314542617; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Feala JD, 2013, J NEUROTRAUM, V30, P1101, DOI 10.1089/neu.2012.2631; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Finnerup NB, 2013, PAIN, V154, pS71, DOI 10.1016/j.pain.2012.12.007; Finnerup NB, 2012, CURR PAIN HEADACHE R, V16, P207, DOI 10.1007/s11916-012-0259-x; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gaetz M, 2001, J HEAD TRAUMA REHAB, V16, P386, DOI 10.1097/00001199-200108000-00008; Gagnon JF, 2002, NEUROLOGY, V59, P585, DOI 10.1212/WNL.59.4.585; Ganti L, 2013, ADV PREV MED, V2013, DOI DOI 10.1155/2013/450195; Gauthier L, 2012, CAN RESPIR J, V19, P307, DOI 10.1155/2012/631803; Gosselin N, 2012, J NEUROTRAUM, V29, P2625, DOI 10.1089/neu.2012.2312; Gosselin N, 2009, SLEEP MED, V10, P35, DOI 10.1016/j.sleep.2007.11.023; Gravel J, 2013, SYST REV, V2, DOI 10.1186/2046-4053-2-63; Guilleminault C, 2010, LUNG, V188, P459, DOI 10.1007/s00408-010-9254-3; Haack M, 2007, SLEEP, V30, P1145, DOI 10.1093/sleep/30.9.1145; Hanlon EC, 2011, CURR TOP MED CHEM, V11, P2472; Hornyak M, 2014, SLEEP MED REV, V18, P153, DOI 10.1016/j.smrv.2013.03.004; Ilvesmaki T, 2014, BRAIN, V137, P1876, DOI 10.1093/brain/awu095; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jamora CW, 2013, BRAIN INJURY, V27, P1134, DOI 10.3109/02699052.2013.804196; Jazi MS, 2014, COMPUT METHOD BIOMEC, V17, P1368, DOI 10.1080/10255842.2012.748755; Jungquist CR, 2012, PAIN MANAG NURS, V13, P70, DOI 10.1016/j.pmn.2010.04.003; Kaiser PR, 2010, NEUROLOGY, V75, P1780, DOI 10.1212/WNL.0b013e3181fd62a2; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Katz J, 2009, EXPERT REV NEUROTHER, V9, P723, DOI 10.1586/ERN.09.20; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Khoury S, 2014, 15 WORLD C PAIN INT; Khoury S, 2010, 13 WORLD C PAIN INT; Khoury S, 2013, J NEUROTRAUM, V30, P633, DOI 10.1089/neu.2012.2519; Kinnaman KA, 2014, PEDIATR EMERG CARE, V30, P458, DOI 10.1097/PEC.0000000000000161; Korinthenberg R, 2004, BRAIN DEV-JPN, V26, P113, DOI 10.1016/S0387-7604(03)00110-4; Kristman Vicki L, 2014, Arch Phys Med Rehabil, V95, pS265, DOI 10.1016/j.apmr.2013.04.026; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Lautenbacher S, 2009, CLIN J PAIN, V25, P92, DOI 10.1097/AJP.0b013e3181850dce; Lavigne G, 2000, PAIN, V84, P283, DOI 10.1016/S0304-3959(99)00213-4; LAVIGNE G, 2007, SLEEP PAIN, P235; Lavigne G, 2011, PRINCIPLES PRACTICE, P1442; Lavigne GJ, 2011, CURR RHEUMATOL REP, V13, P535, DOI 10.1007/s11926-011-0209-3; Lavigne GJ, 2011, SLEEP MED, V12, P179, DOI 10.1016/j.sleep.2010.07.015; Lavigne GJ, 2007, SLEEP DISORDERS THEI, P193; Liu BC, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004333.pub3; Lotsch J, 2013, PHARMACOL THERAPEUT, V139, P60, DOI 10.1016/j.pharmthera.2013.04.004; Lucas S, 2014, CEPHALALGIA, V34, P93, DOI 10.1177/0333102413499645; Luoto TM, 2013, J NEUROTRAUM, V30, P11, DOI 10.1089/neu.2012.2611; Mansour AR, 2014, RESTOR NEUROL NEUROS, V32, P129, DOI 10.3233/RNN-139003; Mansour AR, 2013, PAIN, V154, P2160, DOI 10.1016/j.pain.2013.06.044; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; McAllister TW, 2012, J NEUROTRAUM, V29, P1111, DOI 10.1089/neu.2011.1930; McDermid AJ, 1996, PAIN, V66, P133, DOI 10.1016/0304-3959(96)03059-X; Melemedjian OK, 2013, MOL PAIN, V9, DOI 10.1186/1744-8069-9-12; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Menon JP, 2012, IEEE ENG MED BIO, P1354, DOI 10.1109/EMBC.2012.6346189; Mogil JS, 2012, TRENDS GENET, V28, P258, DOI 10.1016/j.tig.2012.02.004; Morin CM, 2011, SLEEP, V34, P601, DOI 10.1093/sleep/34.5.601; Morin-Moncet O, 2014, J NEUROPHYSIOL, V111, P2094, DOI 10.1152/jn.00388.2013; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Nardone R, 2011, J NEUROTRAUM, V28, P1165, DOI 10.1089/neu.2010.1748; Nordstrom A, 2014, BR J SPORTS MED; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Obermann M, 2010, CEPHALALGIA, V30, P528, DOI 10.1111/j.1468-2982.2009.01972.x; Obermann M, 2009, EXPERT REV NEUROTHER, V9, P1361, DOI 10.1586/ERN.09.84; Obermann M, 2010, HEADACHE, V50, P710, DOI 10.1111/j.1526-4610.2010.01644.x; Ofek H, 2007, PAIN, V131, P330, DOI 10.1016/j.pain.2007.06.015; Ohayon MM, 2005, J PSYCHIAT RES, V39, P151, DOI 10.1016/j.jpsychires.2004.07.001; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Ponsford JL, 2013, NEUROREHABIL NEURAL; Prichep LS, 2014, J NEUROTRAUMA; Radresa O, 2014, J TRAUMA ACUTE CARE, V76, P1142, DOI 10.1097/TA.0000000000000188; Rao V, 2014, BRAIN INJURY, V28, P20, DOI 10.3109/02699052.2013.847210; Rose AR, 2014, J CLIN SLEEP MED, V10, P847, DOI 10.5664/jcsm.3950; Rostami E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027389; Rusnak M, 2013, NAT REV NEUROL, V9, P186, DOI 10.1038/nrneurol.2013.38; Sarhan M, 2013, INT J NEUROPSYCHOPH, V16, P1649, DOI 10.1017/S146114571200168X; Schug SA, 2011, PAIN CLIN UPDATE, P19; Schug SA, 2012, PAIN, V153, P1344, DOI 10.1016/j.pain.2012.02.041; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Smith MT, 2008, PAIN, V138, P497, DOI 10.1016/j.pain.2008.01.028; Sommerauer M, 2013, J SLEEP RES, V22, P634, DOI 10.1111/jsr.12068; Strigo IA, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2013.116; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Sullivan-Singh SJ, 2014, ARCH PHYS MED REHAB, V95, P1100, DOI 10.1016/j.apmr.2014.02.001; Tang NKY, 2007, J SLEEP RES, V16, P85, DOI 10.1111/j.1365-2869.2007.00571.x; Tang NKY, 2012, SLEEP, V35, P675, DOI 10.5665/sleep.1830; Tang Nicole K Y, 2009, Curr Rheumatol Rep, V11, P451; Taylor PA, 2014, BRAIN INJURY, V28, P879, DOI 10.3109/02699052.2014.888478; Theodorou AA, 2007, J CLIN SLEEP MED, V3, P347; Tracey I, 2011, NAT REV NEUROL, V7, P173, DOI 10.1038/nrneurol.2011.4; Tracey I, 2010, NAT MED, V16, P1277, DOI 10.1038/nm.2229; Ucar T, 2005, ACTA NEUROL SCAND, V112, P163, DOI 10.1111/j.1600-0404.2005.00463.x; Venkatesan UM, 2015, J NEUROTRAUM, V32, P252, DOI 10.1089/neu.2013.3318; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Vitiello MV, 2013, J AM GERIATR SOC, V61, P947, DOI 10.1111/jgs.12275; Walker WC, 2004, J HEAD TRAUMA REHAB, V19, P72, DOI 10.1097/00001199-200401000-00007; West TA, 2014, J NEUROTRAUM, V31, P159, DOI 10.1089/neu.2013.3031; Whittom S, 2010, SLEEP MED, V11, P351, DOI 10.1016/j.sleep.2009.12.008; Williams BR, 2008, CLIN NEUROPHYSIOL, V119, P429, DOI 10.1016/j.clinph.2007.11.003; Wortzel HS, 2014, NEUROREHABILITATION, V34, P613, DOI 10.3233/NRE-141086; Wortzel HS, 2012, CURR TREAT OPTION NE, V14, P493, DOI 10.1007/s11940-012-0193-6; Zelman DC, 2005, J PAIN SYMPTOM MANAG, V29, P401, DOI 10.1016/j.jpainsymman.2004.06.018; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	154	39	40	0	42	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	APR	2015	156	4		1			S75	S85		10.1097/j.pain.0000000000000111			11	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	CF1TP	WOS:000352331100011	25789439				2021-06-18	
J	Hahn, YK; Podhaizer, EM; Farris, SP; Miles, MF; Hauser, KF; Knapp, PE				Hahn, Yun Kyung; Podhaizer, Elizabeth M.; Farris, Sean P.; Miles, Michael F.; Hauser, Kurt F.; Knapp, Pamela E.			Effects of chronic HIV-1 Tat exposure in the CNS: heightened vulnerability of males versus females to changes in cell numbers, synaptic integrity, and behavior	BRAIN STRUCTURE & FUNCTION			English	Article						Striatum; NeuroAIDS; Tat; HIV-1; Sex; Behavior	HUMAN-IMMUNODEFICIENCY-VIRUS; FIBRILLARY ACIDIC PROTEIN; MULTICENTER AIDS COHORT; TRAUMATIC BRAIN-INJURY; LIGHT/DARK BOX TEST; NEUROCOGNITIVE DISORDERS; ANTIRETROVIRAL THERAPY; OXIDATIVE STRESS; PARKINSONS-DISEASE; GENDER-DIFFERENCES	HIV-associated damage to the central nervous system results in cognitive and motor deficits. Anti-retroviral therapies reduce the severity of symptoms, yet the proportion of patients affected has remained the same or increased. Although approximately half of HIV-infected patients worldwide are women, the question of whether biological sex influences outcomes of HIV infection has received little attention. We explored this question for both behavioral and cellular/morphologic endpoints, using a transgenic mouse that inducibly expresses HIV-1 Tat in the brain. After 3 months of HIV-1 Tat exposure, both sexes showed similar reduced open field ambulation. Male Tat(+) mice also showed reduced forelimb grip strength and enhanced anxiety in a light-dark box assay. Tat(+) males did not improve over 12 weeks of repeated rotarod testing, indicating a motor memory deficit. Male mice also had more cellular deficits in the striatum. Neither sex showed a change in volume or total neuron numbers. Both had equally reduced oligodendroglial populations and equivalent microglial increases. However, astrogliosis and microglial nitrosative stress were higher in males. Dendrites on medium spiny neurons in male Tat(+) mice had fewer spines, and levels of excitatory and inhibitory pre- and post-synaptic proteins were disrupted. Our results predict sex as a determinant of HIV effects in brain. Increased behavioral deficits in males correlated with glial activation and synaptic damage, both of which are implicated in cognitive/motor impairments in patients. Tat produced by residually infected cells despite antiretroviral therapy may be an important determinant of the synaptodendritic instability and behavioral deficits accompanying chronic infection.	[Hahn, Yun Kyung; Knapp, Pamela E.] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; [Podhaizer, Elizabeth M.; Farris, Sean P.; Miles, Michael F.; Hauser, Kurt F.; Knapp, Pamela E.] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; [Miles, Michael F.; Hauser, Kurt F.; Knapp, Pamela E.] Virginia Commonwealth Univ, Inst Drug & Alcohol Studies, Richmond, VA 23298 USA	Knapp, PE (corresponding author), Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Med Coll Virginia MCV Campus,POB 980709, Richmond, VA 23298 USA.	peknapp@vcu.edu	Hauser, Kurt/AAX-8361-2020	Farris, Sean/0000-0002-9158-1984; Hauser, Kurt/0000-0001-7886-0332	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA024461, NS069216, DA018633, DA027374, U01AA016667]; NIH-NINDS CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P30NS047463]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463, R21NS069216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [U01AA016667] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA018633, R01DA024461, K02DA027374] Funding Source: NIH RePORTER	We gratefully acknowledge NIH support: DA024461 and NS069216 (PEK); DA018633 and DA027374 (KFH); U01AA016667 (MFM). Electron microscopy was performed at the VCU-Dept. Anatomy and Neurobiology Microscopy Facility, supported in part with funding from NIH-NINDS Center Core Grant 5P30NS047463.	Adams SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037540; Adams SM, 2010, SYNAPSE, V64, P829, DOI 10.1002/syn.20793; Antinori A, 2007, NEUROLOGY, V69, P1789, DOI 10.1212/01.WNL.0000287431.88658.8b; Asin SN, 2008, AIDS RES HUM RETROV, V24, P701, DOI 10.1089/aid.2007.0108; Balleine BW, 2007, J NEUROSCI, V27, P8161, DOI 10.1523/JNEUROSCI.1554-07.2007; Basso MR, 2000, J CLIN EXP NEUROPSYC, V22, P208, DOI 10.1076/1380-3395(200004)22:2;1-1;FT208; Bourin M, 2003, EUR J PHARMACOL, V463, P55, DOI 10.1016/S0014-2999(03)01274-3; Bouwman FH, 1998, NEUROLOGY, V50, P1814, DOI 10.1212/WNL.50.6.1814; Brooke S, 1997, P NATL ACAD SCI USA, V94, P9457, DOI 10.1073/pnas.94.17.9457; Brooks SP, 2009, NAT REV NEUROSCI, V10, P519, DOI 10.1038/nrn2652; Bruce-Keller AJ, 2008, GLIA, V56, P1414, DOI 10.1002/glia.20708; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Burger ME, 2005, PHARMACOL BIOCHEM BE, V81, P608, DOI 10.1016/j.pbb.2005.05.002; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Carey AN, 2013, PROG NEURO-PSYCHOPH, V43, P49, DOI 10.1016/j.pnpbp.2012.12.018; Carey AN, 2012, BEHAV BRAIN RES, V229, P48, DOI 10.1016/j.bbr.2011.12.019; Centers for Disease Control and Prevention, 2009, HIV SURV REP DIAGN H, V21; Cheng HW, 1997, EXP NEUROL, V147, P287, DOI 10.1006/exnr.1997.6618; Cheng JA, 2010, STEROIDS, V75, P754, DOI 10.1016/j.steroids.2009.10.014; Chiesi A, 1996, J ACQ IMMUN DEF SYND, V11, P39, DOI 10.1097/00042560-199601010-00005; Cho W, 2009, J NEUROCHEM, V110, P343, DOI 10.1111/j.1471-4159.2009.06146.x; Cohen RA, 2010, J NEUROVIROL, V16, P435, DOI 10.3109/13550284.2010.520817; Corasaniti MT, 2005, NEUROTOXICOLOGY, V26, P893, DOI 10.1016/j.neuro.2005.01.019; Cordeau P, 2008, STROKE, V39, P935, DOI 10.1161/STROKEAHA.107.501460; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Crabbe JC, 2003, GENES BRAIN BEHAV, V2, P201, DOI 10.1034/j.1601-183X.2003.00023.x; CRAWLEY J, 1980, PHARMACOL BIOCHEM BE, V13, P167, DOI 10.1016/0091-3057(80)90067-2; Cryan JF, 2005, NAT REV DRUG DISCOV, V4, P775, DOI 10.1038/nrd1825; D'Astous M, 2004, NEUROPHARMACOLOGY, V47, P1180, DOI 10.1016/j.neuropharm.2004.08.020; Das Gupta J, 2007, J NEUROVIROL, V13, P195, DOI 10.1080/13550280701258407; de Lau LML, 2006, LANCET NEUROL, V5, P525, DOI 10.1016/S1474-4422(06)70471-9; Dhandapani KM, 2005, ENDOCRINOLOGY, V146, P2749, DOI 10.1210/en.2005-0014; Disshon KA, 1999, BRAIN RES, V842, P399, DOI 10.1016/S0006-8993(99)01863-6; Dore GJ, 2003, AIDS, V17, P1539, DOI 10.1097/00002030-200307040-00015; Ellis R, 2007, NAT REV NEUROSCI, V8, P33, DOI 10.1038/nrn2040; European Centre for Disease Prevention and Control/WHO Regional Office for Europe, 2011, HIV AIDS SURV EUR 20; Everall IP, 1999, BRAIN PATHOL, V9, P209; Failde-Garrido JM, 2008, PSYCHIAT CLIN NEUROS, V62, P494, DOI 10.1111/j.1440-1819.2008.01841.x; Farinpour R, 2003, J CLIN EXP NEUROPSYC, V25, P654, DOI 10.1076/jcen.25.5.654.14577; FERRANTE RJ, 1991, J NEUROSCI, V11, P3877; Fitting S, 2013, BIOL PSYCHIAT, V73, P443, DOI 10.1016/j.biopsych.2012.09.026; Fitting S, 2010, AM J PATHOL, V177, P1397, DOI 10.2353/ajpath.2010.090945; Fitting S, 2010, HIPPOCAMPUS, V20, P469, DOI 10.1002/hipo.20648; Fitting S, 2010, J PROTEOME RES, V9, P1795, DOI 10.1021/pr900926n; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Gillies GE, 2010, HORM BEHAV, V57, P23, DOI 10.1016/j.yhbeh.2009.06.002; Giordano G, 2013, FREE RADICAL BIO MED, V58, P98, DOI 10.1016/j.freeradbiomed.2013.01.019; Gongvatana A, 2013, J NEUROVIROL, V19, P209, DOI 10.1007/s13365-013-0162-1; Gonzalez-Scarano F, 2005, NAT REV IMMUNOL, V5, P69, DOI 10.1038/nri1527; Goodkin K, 1997, NEUROIMAG CLIN N AM, V7, P561; Grant I, 1995, CURR TOP MICROBIOL, V202, P11; Gupta S, 2010, NEUROSCI LETT, V485, P233, DOI 10.1016/j.neulet.2010.09.019; Hahn YK, 2012, GLIA, V60, P1871, DOI 10.1002/glia.22403; Hahn YK, 2010, J NEUROCHEM, V114, P97, DOI 10.1111/j.1471-4159.2010.06744.x; HAUSER KF, 1989, J COMP NEUROL, V281, P13, DOI 10.1002/cne.902810103; Hauser KF, 2009, GLIA, V57, P194, DOI 10.1002/glia.20746; Heaton R K, 1995, J Int Neuropsychol Soc, V1, P231; Heaton RK, 2010, NEUROLOGY, V75, P2087, DOI 10.1212/WNL.0b013e318200d727; Heaton RK, 2011, J NEUROVIROL, V17, P3, DOI 10.1007/s13365-010-0006-1; Hel Z, 2010, ENDOCR REV, V31, P79, DOI 10.1210/er.2009-0018; Helfinstein SM, 2012, DEV PSYCHOL, V48, P815, DOI 10.1037/a0026402; Herson PS, 2009, SEMIN REPROD MED, V27, P229, DOI 10.1055/s-0029-1216276; Hestad KA, 2012, J NERV MENT DIS, V200, P336, DOI 10.1097/NMD.0b013e31824cc225; Hoffman GE, 2006, ENDOCRINE, V29, P217, DOI 10.1385/ENDO:29:2:217; Johnson TP, 2013, P NATL ACAD SCI USA, V110, P13588, DOI 10.1073/pnas.1308673110; Joint United Nations Programme on HIV/AIDS, 2010, GLOB REP UNAIDS REP; Joint United Nations Programme on HIV/AIDS, 2010, OUTL UNAIDS OUTL REP; JONES BJ, 1968, J PHARM PHARMACOL, V20, P302, DOI 10.1111/j.2042-7158.1968.tb09743.x; Joska JA, 2011, AIDS BEHAV, V15, P1197, DOI 10.1007/s10461-010-9744-6; Kim BO, 2003, AM J PATHOL, V162, P1693, DOI 10.1016/S0002-9440(10)64304-0; Kipp M, 2009, FRONT NEUROENDOCRIN, V30, P188, DOI 10.1016/j.yfrne.2009.04.004; Kumar P, 2011, NEUROSCI LETT, V502, P56, DOI 10.1016/j.neulet.2011.07.024; Lawrence DM, 2002, MICROBES INFECT, V4, P301, DOI 10.1016/S1286-4579(02)01542-3; Lee AW, 1997, AIDS RES HUM RETROV, V13, P1235, DOI 10.1089/aid.1997.13.1235; Ligon KL, 2006, GLIA, V54, P1, DOI 10.1002/glia.20273; Liu M, 2010, J NEUROCHEM, V112, P773, DOI 10.1111/j.1471-4159.2009.06497.x; Liu X, 1996, J NeuroAIDS, V1, P17, DOI 10.1300/J128v01n04_03; Lopes M, 2012, J CLIN PSYCHIAT, V73, P384, DOI 10.4088/JCP.10m06304; Lundkvist J, 1999, AM J PHYSIOL-REG I, V276, pR644; Maki PM, 2009, NEUROPSYCHOL REV, V19, P204, DOI 10.1007/s11065-009-9093-2; Malmberg-Aiello P, 2002, PHARMACOL BIOCHEM BE, V71, P313, DOI 10.1016/S0091-3057(01)00691-8; Masliah E, 1997, ANN NEUROL, V42, P963, DOI 10.1002/ana.410420618; McArthur JC, 2010, ANN NEUROL, V67, P699, DOI 10.1002/ana.22053; MCNEILL TH, 1988, BRAIN RES, V455, P148, DOI 10.1016/0006-8993(88)90124-2; Mehal JM, 2013, AMYOTROPH LAT SCL FR, V14, P346, DOI 10.3109/21678421.2013.787629; MOUTON PR, 2002, PRINCIPLES PRACTICES; Murray HE, 2003, NEUROSCIENCE, V116, P213, DOI 10.1016/S0306-4522(02)00578-X; Nakasujja N, 2005, J NEUROVIROL, V11, P26, DOI 10.1080/13550280500511782; Ramezani A, 2011, PHARMACOL BIOCHEM BE, V100, P144, DOI 10.1016/j.pbb.2011.07.010; Rao AK, 2011, J STEROID BIOCHEM, V127, P382, DOI 10.1016/j.jsbmb.2011.06.008; Rau SW, 2003, J NEUROSCI, V23, P11420; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; Robertson KR, 2007, AIDS, V21, P1915, DOI 10.1097/QAD.0b013e32828e4e27; Robertson KR, 2004, JAIDS-J ACQ IMM DEF, V36, P817, DOI 10.1097/00126334-200407010-00008; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Russo R, 2005, NEUROTOXICOLOGY, V26, P905, DOI 10.1016/j.neuro.2005.01.009; Ryu JK, 2006, EXP NEUROL, V198, P552, DOI 10.1016/j.expneurol.2005.12.016; Sa MJ, 2004, ACTA NEUROPATHOL, V107, P97, DOI 10.1007/s00401-003-0781-3; Sacktor N, 2001, NEUROLOGY, V56, P257, DOI 10.1212/WNL.56.2.257; Shavali S, 2006, NEUROCHEM RES, V31, P85, DOI 10.1007/s11064-005-9233-x; Shin AH, 2012, BRIT J PHARMACOL, V166, P1002, DOI 10.1111/j.1476-5381.2011.01805.x; Shin AH, 2013, MOL CELL NEUROSCI, V54, P22, DOI 10.1016/j.mcn.2012.12.005; Shiotsuki H, 2010, J NEUROSCI METH, V189, P180, DOI 10.1016/j.jneumeth.2010.03.026; Shishehbor Mehdi H, 2004, Curr Atheroscler Rep, V6, P243, DOI 10.1007/s11883-004-0038-1; Simioni S, 2010, AIDS, V24, P1243, DOI 10.1097/QAD.0b013e3283354a7b; Simpkins JW, 2010, BBA-GEN SUBJECTS, V1800, P1113, DOI 10.1016/j.bbagen.2009.11.013; Suzuki M, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-78; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Tozzi V, 2005, AIDS RES HUM RETROV, V21, P706, DOI 10.1089/aid.2005.21.706; Van Den Eeden SK, 2003, AM J EPIDEMIOL, V157, P1015, DOI 10.1093/aje/kwg068; Viviani B, 2006, J BIOL CHEM, V281, P30212, DOI 10.1074/jbc.M602156200; Voytek B, 2010, P NATL ACAD SCI USA, V107, P18167, DOI 10.1073/pnas.1007277107; Vu QB, 2009, AM J TROP MED HYG, V81, P747, DOI 10.4269/ajtmh.2009.09-0214; Wallace DR, 2006, SYNAPSE, V59, P51, DOI 10.1002/syn.20214; Wallace VCJ, 2008, NEUROSCI LETT, V448, P153, DOI 10.1016/j.neulet.2008.10.005; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wojna V, 2006, J NEUROVIROL, V12, P356, DOI 10.1080/13550280600964576; Wong MH, 2007, NEUROLOGY, V68, P350, DOI 10.1212/01.wnl.0000252811.48891.6d; Woodruff RH, 2001, INT J DEV NEUROSCI, V19, P379, DOI 10.1016/S0736-5748(00)00083-6; Woods SP, 2009, NEUROPSYCHOL REV, V19, P152, DOI 10.1007/s11065-009-9102-5; Yang YJ, 2011, GLIA, V59, P200, DOI 10.1002/glia.21089; Yune TY, 2008, J NEUROTRAUM, V25, P1121, DOI 10.1089/neu.2008.0544; Zhang MJ, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-82; Zou W, 2007, AM J PATHOL, V171, P1923, DOI 10.2353/ajpath.2007.070333	124	39	40	0	8	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1863-2653	1863-2661		BRAIN STRUCT FUNCT	Brain Struct. Funct.	MAR	2015	220	2					605	623		10.1007/s00429-013-0676-6			19	Anatomy & Morphology; Neurosciences	Anatomy & Morphology; Neurosciences & Neurology	CC4UU	WOS:000350350300002	24352707	Other Gold, Green Published			2021-06-18	
J	Ip, IK; Raja, AS; Gupta, A; Andruchow, J; Sodickson, A; Khorasani, R				Ip, Ivan K.; Raja, Ali S.; Gupta, Anurag; Andruchow, James; Sodickson, Aaron; Khorasani, Ramin			Impact of clinical decision support on head computed tomography use in patients with mild traumatic brain injury in the ED	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							NEW-ORLEANS CRITERIA; PHYSICIAN ORDER ENTRY; EMERGENCY-DEPARTMENT; CT; RULE; IMPLEMENTATION; STRATEGIES; MANAGEMENT; SYSTEM; ADULTS	Background: Reduction of unnecessary head computed tomographies (CTs) in patients with mild traumatic brain injury (MTBI) was recently endorsed by American College of Emergency Physicians (ACEP) in the "Choosing Wisely" campaign. We examined the impact of computerized clinical decision support (CDS) on head CT utilization in MTBI emergency department (ED) visits. Methods: We conducted a 2-year cohort study at a level 1 trauma center and compared our results with the National Hospital Ambulatory Medical Care Survey from 2009 to 2010. All adult patients discharged from the ED with MTBI-associated diagnoses were included. After a baseline observation period at our institution, real-time CDS was implemented. Based upon the clinical history entered, low utility orders triggered an alert to clinicians, suggesting imaging studies might not adhere to evidence-based guidelines. Clinicians could cancel the order or ignore the alert. Primary outcome was intensity of head CT use in MTBI ED visits. Secondary outcomes included rates of delayed imaging and delays in diagnosing radiologically significant findings chi(2), logistic regression, and process control chart assessed preintervention and postintervention differences. Results: In study patients, 58.1% of MTBI-related visits resulted in head CT preintervention vs 50.3% postintervention (13.4% relative decrease, P = .005), a change not detected in controls (73.3% vs 76.9%, P = .272). Study cohort patients not receiving a head CT during their index visit were neither more nor less likely to receive one in the subsequent 7 days (6.7% preintervention vs 9.4% postintervention, P=.231). Rates of delayed diagnosis of radiologically significant findings were unchanged (0% vs 0%). Conclusions: Evidence-based CDS can reduce low utility imaging for MTBI. (C) 2014 Elsevier Inc. All rights reserved.	[Ip, Ivan K.; Raja, Ali S.; Gupta, Anurag; Andruchow, James; Sodickson, Aaron; Khorasani, Ramin] Harvard Univ, Sch Med, Ctr Evidence Based Imaging, Boston, MA USA; [Ip, Ivan K.; Raja, Ali S.; Gupta, Anurag; Andruchow, James; Sodickson, Aaron; Khorasani, Ramin] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Ip, Ivan K.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Raja, Ali S.; Gupta, Anurag; Andruchow, James] Harvard Univ, Sch Med, Dept Emergency Med, Boston, MA USA; [Ip, Ivan K.; Raja, Ali S.; Gupta, Anurag; Andruchow, James; Sodickson, Aaron; Khorasani, Ramin] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA	Ip, IK (corresponding author), Brigham & Womens Hosp, Dept Radiol & Med, Ctr Evidence Based Imaging, 20 Kent St,Second Floor, Boston, MA 02445 USA.	iip@partners.org	Raja, Ali S./AAE-5103-2019; Khorasani, Ramin/AAM-8526-2021	Sodickson, Aaron/0000-0003-1275-681X			Andruchow JE, 2012, ARCH INTERN MED, V172, P660, DOI 10.1001/archinternmed.2011.2243; [Anonymous], 2001, MED I CROSSING QUALI; Ash JS, 2007, J AM MED INFORM ASSN, V14, P415, DOI 10.1197/jamia.M2373; Campbell EM, 2006, J AM MED INFORM ASSN, V13, P547, DOI 10.1197/jamia.M2042; Carspecken W, 2013, PEDIATRICS, V131, pE1970, DOI 10.1542/peds.2012-3252; Cheung YY, 2012, RADIOGRAPHICS, V32, P2113, DOI 10.1148/rg.327125713; Glatter R., 2013, FORBES; Gupta A, 2014, J AM MED INFORM ASS; Han YY, 2005, PEDIATRICS, V116, P1506, DOI 10.1542/peds.2005-1287; Harnan SE, 2011, J TRAUMA, V71, P245, DOI 10.1097/TA.0b013e31820d090f; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Heskestad B, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-32; Heskestad B, 2008, J TRAUMA, V65, P1309, DOI 10.1097/TA.0b013e31815e40cd; Ip IK, 2012, J AM COLL RADIOL, V9, P129, DOI 10.1016/j.jacr.2011.10.010; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Magid S, 2012, APPL CLIN INFORM, V3, P377, DOI 10.4338/ACI-2012-01-RA-0002; Mannix R, 2013, NEUROSURGERY, V73, P129, DOI 10.1227/01.neu.0000429846.14579.41; Melnick ER, 2012, JT COMM J QUAL PATIE, V38, P483, DOI 10.1016/S1553-7250(12)38064-1; Melnick ER, 2010, ANN EMERG MED, V56, P317, DOI 10.1016/j.annemergmed.2010.03.006; Mower WR, 2005, J TRAUMA, V59, P954, DOI 10.1097/01.ta.0000187813.79047.42; Papa L, 2012, ACAD EMERG MED, V19, P2, DOI 10.1111/j.1553-2712.2011.01247.x; Prevedello LM, 2012, AM J MED, V125, P356, DOI 10.1016/j.amjmed.2011.06.023; Raja AS, 2012, RADIOLOGY, V262, P468, DOI 10.1148/radiol.11110951; Sharpe RE, 2013, J AM COLL RADIOL, V10, P599, DOI 10.1016/j.jacr.2013.01.023; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Smits M, 2010, RADIOLOGY, V254, P532, DOI 10.1148/radiol.2541081672; Sodickson A, 2009, RADIOLOGY, V251, P175, DOI 10.1148/radiol.2511081296; Solomon DH, 1998, JAMA-J AM MED ASSOC, V280, P2020, DOI 10.1001/jama.280.23.2020; Stiell IG, 2007, ACAD EMERG MED, V14, P955, DOI 10.1197/j.aem.2007.06.039; Stiell IG, 2010, CAN MED ASSOC J, V182, P1527, DOI 10.1503/cmaj.091974; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Welch H. G. L. M., 2011, OVERDIAGNOSED MAKING; Wilson IB, 2001, ARCH INTERN MED, V161, P256, DOI 10.1001/archinte.161.2.256	36	39	40	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	MAR	2015	33	3					320	325		10.1016/j.ajem.2014.11.005			6	Emergency Medicine	Emergency Medicine	CE6GP	WOS:000351935100002	25572644				2021-06-18	
J	Borich, M; Babul, AN; Yuan, PH; Boyd, L; Virji-Babul, N				Borich, Michael; Babul, Aliya-Nur; Yuan, Po Hsiang; Boyd, Lara; Virji-Babul, Naznin			Alterations in Resting-State Brain Networks in Concussed Adolescent Athletes	JOURNAL OF NEUROTRAUMA			English	Article						fMRI; resting-state networks; concussion; adolescents	INDEPENDENT COMPONENT ANALYSIS; SPORTS-RELATED CONCUSSION; CEREBRAL BLOOD-FLOW; HEAD-INJURED CHILDREN; DEFAULT-MODE; FUNCTIONAL CONNECTIVITY; HIGH-SCHOOL; HYPOTHESIS; CORTEX; FMRI	Sports-related concussion in adolescents is a major public health issue; however, little is known about the underlying changes in functional brain connectivity. We evaluated connectivity of resting-state brain networks to determine whether alterations in specific networks distinguish adolescents with sports-related concussion from a group of healthy, active control adolescents. Twelve adolescents with a clinical diagnosis of subacute concussion and ten healthy adolescents matched for age, gender, and physical activity completed functional magnetic resonance imaging (fMRI) scanning. Functional connectivity of resting-state brain networks was evaluated in both groups using probabilistic independent component analysis (ICA). Altered functional connectivity was found within three resting-state networks in adolescents with concussion. Specifically, we noted: a) alterations within the default mode network; b) increased connectivity in the right frontal pole in the executive function network; and c) increased connectivity in the left frontal operculum cortex associated with the ventral attention network. This preliminary report shows that whole-brain functional connectivity is altered in networks related to cognition and attention in adolescents in the subacute phase following sports-related concussion. This first report in adolescents should be used to inform future studies in larger cohorts of adolescents with sports-related concussion. Increased knowledge of these changes may lead to improvements in clinical management and help to develop rehabilitation programs.	[Borich, Michael; Babul, Aliya-Nur; Yuan, Po Hsiang; Boyd, Lara; Virji-Babul, Naznin] Univ British Columbia, Dept Phys Therapy, Vancouver, BC V6T 1Z3, Canada; [Virji-Babul, Naznin] Child & Family Res Inst, Vancouver, BC, Canada	Virji-Babul, N (corresponding author), Univ British Columbia, Dept Phys Therapy, 212-2177 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	nvb31@mail.ubc.ca	Meijer, Anna/K-5118-2016	Virji-Babul, Naznin/0000-0002-8984-5848	Martha Piper Research Fund, University of British Columbia; Brain Research Centre, University of British Columbia; BC Hockey; Heart and Stroke FoundationHeart & Stroke Foundation of Canada; Canada Research ChairNatural Resources CanadaCanadian Forest ServiceCanada Research Chairs; Michael Smith Foundation for Health ResearchMichael Smith Foundation for Health Research	This research was supported by the Martha Piper Research Fund, University of British Columbia and the Brain Research Centre, University of British Columbia. We would like to thank BC Hockey for their support and all the participants, trainers and coaches who took part in this study. We would also like to thank Suejin Lin for her help with the initial fMRI analysis. MRB received salary support from the Heart and Stroke Foundation. LAB is supported by a Canada Research Chair and Michael Smith Foundation for Health Research awards. Dr. Naznin Virji-Babul had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.	Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bauer R, 2004, EXP TOXICOL PATHOL, V56, P65, DOI 10.1016/j.etp.2004.04.002; Beckmann CF, 2005, NEUROIMAGE, V25, P294, DOI 10.1016/j.neuroimage.2004.10.043; Beckmann CF, 2004, IEEE T MED IMAGING, V23, P137, DOI 10.1109/TMI.2003.822821; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Borich M, 2013, J NEUROTRAUM, V30, P1243, DOI 10.1089/neu.2012.2818; Broyd SJ, 2009, NEUROSCI BIOBEHAV R, V33, P279, DOI 10.1016/j.neubiorev.2008.09.002; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Burgess PW, 2007, TRENDS COGN SCI, V11, P290, DOI 10.1016/j.tics.2007.05.004; Cordes D, 2000, AM J NEURORADIOL, V21, P1636; Coronado VG, 2010, TRAUMATIC BRAIN INJU, P891, DOI [10.1016/B978-0-444-52910-7.00011-8, DOI 10.1016/B978-0-444-52910-7.00011-8]; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Filippini N, 2009, P NATL ACAD SCI USA, V106, P7209, DOI 10.1073/pnas.0811879106; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fox MD, 2006, P NATL ACAD SCI USA, V103, P10046, DOI 10.1073/pnas.0604187103; Fox MD, 2010, FRONT SYST NEUROSCI, V4, DOI [10.3389/fnsys.2010.00019, 10.3389/fnsys.2010.0001]; Fransson P, 2005, HUM BRAIN MAPP, V26, P15, DOI 10.1002/hbm.20113; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; Higo T, 2011, P NATL ACAD SCI USA, V108, P4230, DOI 10.1073/pnas.1013361108; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; Lehericy S, 2004, ANN NEUROL, V55, P522, DOI 10.1002/ana.20030; Maddock RJ, 1999, TRENDS NEUROSCI, V22, P310, DOI 10.1016/S0166-2236(98)01374-5; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Palacios EM, 2013, JAMA NEUROL, V70, P845, DOI 10.1001/jamaneurol.2013.38; Raichle ME, 2006, ANNU REV NEUROSCI, V29, P449, DOI 10.1146/annurev.neuro.29.051605.112819; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Schmahmann JD, 2007, BRAIN, V130, P630, DOI 10.1093/brain/awl359; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Virji-Babul N, 2013, PEDIATR NEUROL, V48, P24, DOI 10.1016/j.pediatrneurol.2012.09.005	50	39	40	0	23	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2015	32	4					265	271		10.1089/neu.2013.3269			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CB0KN	WOS:000349314900007	25010041				2021-06-18	
J	Mayeux, JP; Teng, SX; Katz, PS; Gilpin, NW; Molina, PE				Mayeux, Jacques P.; Teng, Sophie X.; Katz, Paige S.; Gilpin, Nicholas W.; Molina, Patricia E.			Traumatic brain injury induces neuroinflammation and neuronal degeneration that is associated with escalated alcohol self-administration in rats	BEHAVIOURAL BRAIN RESEARCH			English	Article						Traumatic brain injury; Alcohol; Self-administration; Neuroinflammation; Anxiety	DRUG-USE; STRESS; ANXIETY; RECEPTOR; ACTIVATION; DEPRESSION; DISORDERS; SYMPTOMS; SEQUELAE; RISK	Background: Traumatic brain injury (TBI) affects millions of people each year and is characterized by direct tissue injury followed by a neuroinflammatory response. The post-TBI recovery period can be associated with a negative emotional state characterized by alterations in affective behaviors implicated in the development of Alcohol Use Disorder in humans. The aim of this study was to test the hypothesis that post-TBI neuroinflammation is associated with behavioral dysfunction, including escalated alcohol intake. Methods: Adult male Wistar rats were trained to self-administer alcohol prior to counterbalanced assignment into naive, craniotomy, and TBI groups by baseline drinking. TBI was produced by lateral fluid percussion (LFP; >2 ATM; 25 ms). Alcohol drinking and neurobehavioral function were measured at baseline and following TBI in all experimental groups. Markers of neuroinflammation (GFAP and ED1) and neurodegeneration (FJC) were determined by fluorescence histochemistry in brains excised at sacrifice 19 days post-TBI. Results: The cumulative increase in alcohol intake over the 15 days post-TBI was greater in TBI animals compared to naive controls. A higher rate of pre-injury alcohol intake was associated with a greater increase in post-injury alcohol intake in both TBI and craniotomy animals. Immediately following TBI, both TBI and craniotomy animals exhibited greater neurobehavioral dysfunction compared to naive animals. GFAP, IBA-1, ED1, and FJC immunoreactivity at 19 days post-TBI was significantly higher in brains from TBI animals compared to both craniotomy and naive animals. Conclusions: These results show an association between post-TBI escalation of alcohol drinking and marked localized neuroinflammation at the site of injury. Moreover, these results highlight the relevance of baseline alcohol preference in determining post-TBI alcohol drinking. Further investigation to determine the contribution of neuroinflammation to increased alcohol drinking post-TBI is warranted. (C) 2014 Elsevier B.V. All rights reserved.	[Mayeux, Jacques P.; Teng, Sophie X.; Katz, Paige S.; Gilpin, Nicholas W.; Molina, Patricia E.] Louisiana State Univ, Hlth Sci Ctr, Dept Physiol, New Orleans, LA 70112 USA; [Mayeux, Jacques P.; Teng, Sophie X.; Katz, Paige S.; Gilpin, Nicholas W.; Molina, Patricia E.] Louisiana State Univ, Hlth Sci Ctr, Alcohol & Drug Abuse Ctr Excellence, New Orleans, LA 70112 USA	Molina, PE (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Alcohol & Drug Abuse Ctr Excellence, Dept Physiol, 1901 Perdido St,Room 7205, New Orleans, LA 70112 USA.	pmolin@lsuhsc.edu	Molina, Patricia E./AAK-9814-2021; Gilpin, Nicholas/V-1266-2019	Molina, Patricia E./0000-0002-3598-384X; 	 [T-32 AA007577];  [F30 AA022838];  [LEQSF-EPS(2012)-PFUND-283]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [F30AA022838, T32AA007577] Funding Source: NIH RePORTER	The authors thank Rebecca Gonzales for editorial assistance, Drs. Scott Edwards and Liz Simon for scientific discussions during the preparation of this manuscript, Dr. Luis Del Valle for guidance with brain IHC imaging, and John Maxi and Renata Impastato for assistance with animal surgeries. This research was supported by T-32 AA007577, F30 AA022838, and LEQSF-EPS(2012)-PFUND-283.	Al Nimer F, 2013, BRAIN BEHAV IMMUN, V27, P109, DOI 10.1016/j.bbi.2012.10.002; Blednov YA, 2011, BRAIN BEHAV IMMUN, V25, pS92, DOI 10.1016/j.bbi.2011.01.008; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Breese GR, 2005, ALCOHOL CLIN EXP RES, V29, P185, DOI 10.1097/01.ALC.0000153544.83656.3C; CDC, 2003, REP C MILD TRAUM BRA; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Crews FT, 2013, BIOL PSYCHIAT, V73, P602, DOI 10.1016/j.biopsych.2012.09.030; CRONE C, 1982, BRAIN RES, V241, P49, DOI 10.1016/0006-8993(82)91227-6; EDVINSSO.L, 1972, ACTA PATH MICRO IM A, VA 80, P134; Garden N, 2010, NEUROPSYCHOLOGY, V24, P168, DOI 10.1037/a0017431; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Koob GF, 2009, BRAIN RES, V1293, P61, DOI 10.1016/j.brainres.2009.03.038; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Kushner MG, 1999, AM J PSYCHIAT, V156, P723; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; McIntosh TK, 1996, LAB INVEST, V74, P315; Miller SC, 2013, AM J PSYCHIAT, V170, P383, DOI 10.1176/appi.ajp.2012.12010126; Moller C, 1997, ALCOHOL CLIN EXP RES, V21, P656, DOI 10.1111/j.1530-0277.1997.tb03818.x; Moonat S, 2012, ALCOHOL RES-CURR REV, V34, P495; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; NAVARI RM, 1978, MICROVASC RES, V16, P304, DOI 10.1016/0026-2862(78)90064-X; OLESEN SP, 1987, ACTA PHYSIOL SCAND, V130, P63, DOI 10.1111/j.1748-1716.1987.tb08112.x; ONAIVI ES, 1989, PROG NEURO-PSYCHOPH, V13, P963, DOI 10.1016/0278-5846(89)90047-X; Osterndorff-Kahanek E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059870; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; POHORECKY LA, 1991, ALCOHOL CLIN EXP RES, V15, P438, DOI 10.1111/j.1530-0277.1991.tb00543.x; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; Primeaux SD, 2006, ALCOHOL CLIN EXP RES, V30, P791, DOI 10.1111/j.1530-0277.2006.00092.x; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Reger ML, 2012, BIOL PSYCHIAT, V71, P335, DOI 10.1016/j.biopsych.2011.11.007; Roltsch EA, 2014, NEUROPHARMACOLOGY, V79, P83, DOI 10.1016/j.neuropharm.2013.11.005; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Spanagel R, 1995, PSYCHOPHARMACOLOGY, V122, P369, DOI 10.1007/BF02246268; STEWART RB, 1993, ALCOHOL, V10, P1, DOI 10.1016/0741-8329(93)90046-Q; Taylor AN, 2013, J NEUROTRAUM, V30, P1250, DOI 10.1089/neu.2012.2847; Teng SX, 2014, J NEUROTRAUM, V31, P378, DOI 10.1089/neu.2013.3093; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Zamora-Martinez ER, 2014, FRONT INTEGR NEUROSC, V8, DOI 10.3389/fnint.2014.00024	45	39	39	0	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	FEB 15	2015	279						22	30		10.1016/j.bbr.2014.10.053			9	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	AZ5IO	WOS:000348255200004	25446758	Green Accepted			2021-06-18	
J	Kesinger, MR; Kumar, RG; Wagner, AK; Puyana, JC; Peitzman, AP; Billiar, TR; Sperry, JL				Kesinger, Matthew Ryan; Kumar, Raj G.; Wagner, Amy K.; Puyana, Juan Carlos; Peitzman, Andrew P.; Billiar, Timothy R.; Sperry, Jason L.			Hospital-acquired pneumonia is an independent predictor of poor global outcome in severe traumatic brain injury up to 5 years after discharge	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						TBI; pneumonia; hospital-acquired pneumonia; outcomes; rehabilitation	VENTILATOR-ASSOCIATED PNEUMONIA; NOSOCOMIAL PNEUMONIA; HEAD-INJURY; REHABILITATION; INFLAMMATION; DISABILITY; INSTITUTE; HEALTH; IMPACT	BACKGROUND: Long-term outcomes following traumatic brain injury (TBI) correlate with initial head injury severity and other acute factors. Hospital-acquired pneumonia (HAP) is a common complication in TBI. Limited information exists regarding the significance of infectious complications on long-term outcomes after TBI. We sought to characterize risks associated with HAP on outcomes 5 years after TBI. METHODS: This study involved data from the merger of an institutional trauma registry and the Traumatic Brain Injury Model Systems outcome data. Individuals with severe head injuries (Abbreviated Injury Scale [AIS] score >= 4) who survived to rehabilitation were analyzed. Primary outcome was Glasgow Outcome Scale-Extended (GOSE) at 1, 2, and 5 years. GOSE was dichotomized into low (GOSE score <6) and high (GOSE score >= 6). Logistic regression was used to determine adjusted odds of low GOSE score associated with HAP after controlling for age, sex, head and overall injury severity, cranial surgery, Glasgow Coma Scale (GCS) score, ventilation days, and other important confounders. A general estimating equation model was used to analyze all outcome observations simultaneously while controlling for within-patient correlation. RESULTS: A total of 141 individuals met inclusion criteria, with a 30% incidence of HAP. Individuals with and without HAP had similar demographic profiles, presenting vitals, head injury severity, and prevalence of cranial surgery. Individuals with HAP had lower presenting GCS score. Logistic regression demonstrated that HAP was independently associated with low GOSE scores at follow-up (1 year: odds ratio [OR], 6.39; 95% confidence interval [CI], 1.76-23.14; p = 0.005) (2 years: OR, 7.30; 95% CI, 1.87-27.89; p = 0.004) (5-years: OR, 6.89; 95% CI, 1.42-33.39; p = 0.017). Stratifying by GCS score of 8 or lower and early intubation, HAP remained a significant independent predictor of low GOSE score in all strata. In the general estimating equation model, HAP continued to be an independent predictor of low GOSE score (OR, 4.59; 95% CI, 1.82-11.60; p = 0.001). CONCLUSION: HAP is independently associated with poor outcomes in severe TBI extending 5 years after injury. This suggests that precautions should be taken to reduce the risk of HAP in individuals with severe TBI. (Copyright (C) 2015 by Wolters Kluwer Health, Inc. All rights reserved.) LEVEL OF EVIDENCE: Prognostic study, level III.	[Puyana, Juan Carlos; Peitzman, Andrew P.; Billiar, Timothy R.; Sperry, Jason L.] Univ Pittsburgh, Dept Surg, Div Trauma & Gen Surg, Pittsburgh, PA 15213 USA; [Kumar, Raj G.; Wagner, Amy K.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Kesinger, Matthew Ryan] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA	Sperry, JL (corresponding author), Univ Pittsburgh, Dept Surg, 200 Lothrop St, Pittsburgh, PA 15213 USA.	sperryjl@upmc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [TL1TR000145, R25 MH054318]; NIH NIGMSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K23GM093032]; NIDRR [H133A120087]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [TL1TR000145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K23GM093032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R25MH054318] Funding Source: NIH RePORTER	This study was funded in part by NIH TL1TR000145, NIH R25 MH054318, NIH NIGMS K23GM093032, and NIDRR H133A120087.	Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cordaro M., 2014, J NEUROTRAUMA; Croce MA, 2013, J TRAUMA ACUTE CARE, V74, P354, DOI 10.1097/TA.0b013e31827a0c65; Deans KJ, 2013, J TRAUMA ACUTE CARE, V75, P157, DOI 10.1097/TA.0b013e3182984acb; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gary KW, 2009, BRAIN INJURY, V23, P775, DOI 10.1080/02699050903200563; GOODPASTURE HC, 1977, J NEUROSURG, V47, P228, DOI 10.3171/jns.1977.47.2.0228; Grauwmeijer E, 2014, ARCH PHYS MED REHAB, V95, P1268, DOI 10.1016/j.apmr.2014.02.002; Greenwald BD, 2001, J HEAD TRAUMA REHAB, V16, P238, DOI 10.1097/00001199-200106000-00003; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Heffernan DS, 2011, J TRAUMA, V70, P527, DOI 10.1097/TA.0b013e31820d0ed7; Heimes J, 2011, SURG INFECT, V12, P99, DOI 10.1089/sur.2009.028; Heltemes KJ, 2012, INJURY, V43, P1990, DOI 10.1016/j.injury.2011.07.021; Holevar M, 2009, J TRAUMA, V67, P870, DOI 10.1097/TA.0b013e3181b5a960; Hoth JJ, 2003, J TRAUMA, V55, P249, DOI 10.1097/01.TA.0000083334.93868.65; Irdesel J, 2007, NEUROCIRUGIA, V18, P5; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kallel H, 2005, J TRAUMA, V59, P705, DOI 10.1097/01.ta.0000177749.09844.c6; Kumar R., 2014, J HEAD TRAUMA REHABI; Leone M, 2002, CRIT CARE MED, V30, P1741, DOI 10.1097/00003246-200208000-00011; Liberati A, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000022.pub3; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Monton C, 1999, CRIT CARE MED, V27, P1745, DOI 10.1097/00003246-199909000-00008; Moore F, 2013, J TRAUMA ACUTE CARE, V74, P360; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Ottochian M, 2009, AM J SURG, V197, P155, DOI 10.1016/j.amjsurg.2008.09.008; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Pretz CR, 2013, ARCH PHYS MED REHAB, V94, P579, DOI 10.1016/j.apmr.2012.08.197; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Richards MJ, 2000, INFECT CONT HOSP EP, V21, P510, DOI 10.1086/501795; Rincon-Ferrari MD, 2004, J TRAUMA, V57, P1234, DOI 10.1097/01.TA.0000119200.70853.23; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shafi S, 2007, J TRAUMA, V63, P1263, DOI 10.1097/TA.0b013e31815b8f00; Shermer CR, 2007, J TRAUMA, V63, P1268; Sigurdardottir S, 2014, J HEAD TRAUMA REHABI; Sirvent JM, 1997, AM J RESP CRIT CARE, V155, P1729, DOI 10.1164/ajrccm.155.5.9154884; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Wang KW, 2013, J NEUROSURG, V118, P358, DOI 10.3171/2012.10.JNS127; Zygun DA, 2006, NEUROCRIT CARE, V5, P108, DOI 10.1385/NCC:5:2:108	42	39	50	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	FEB	2015	78	2					396	402		10.1097/TA.0000000000000526			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	CA3TF	WOS:000348828300026	25757128	Green Accepted			2021-06-18	
J	Gosseries, O; Sarasso, S; Casarotto, S; Boly, M; Schnakers, C; Napolitani, M; Bruno, MA; Ledoux, D; Tshibanda, JF; Massimini, M; Laureys, S; Rosanova, M				Gosseries, Olivia; Sarasso, Simone; Casarotto, Silvia; Boly, Melanie; Schnakers, Caroline; Napolitani, Martino; Bruno, Marie-Aurelie; Ledoux, Didier; Tshibanda, Jean-Flory; Massimini, Marcello; Laureys, Steven; Rosanova, Mario			On the Cerebral Origin of EEG Responses to TMS: Insights From Severe Cortical Lesions	BRAIN STIMULATION			English	Article						Transcranial magnetic stimulation; Electroencephalography; Brain-injury; Biological artifacts	TRANSCRANIAL MAGNETIC STIMULATION; EFFECTIVE CONNECTIVITY; VEGETATIVE STATE; RECOVERY; COMA; BREAKDOWN	Background: Transcranial magnetic stimulation combined with electroencephalography (TMS/EEG) represents a valuable tool to probe cortical excitability and connectivity. Although several procedures have been devised to abolish TMS-related artifacts, direct evidence that it is possible to record TMS-evoked potentials (TEPs) that purely reflect cortical responses to TMS are still lacking. Objective: To demonstrate that when TMS is delivered on a human head with intact nerves, scalp and ocular muscles, TEPs are present only if a functional portion of cortex is targeted and is absent otherwise. Methods: We performed extensive navigated TMS/EEG mappings in three vegetative state patients and in eight healthy controls. Patients were selected based on the extension of their cortical lesions as revealed by structural/functional imaging: the cerebral cortex was globally damaged in Patient 1 due to cerebral anoxia, Patient 2 showed a traumatic damage affecting one cerebral hemisphere, while Patient 3 was characterized by one left sided and one right-sided focal ischemic lesion. Results: In Patient 1, TMS performed at any targeted cortical site did not elicit statistically significant TEPs. In Patient 2, TEPs were absent when the damaged hemisphere was targeted, while were present over the healthy side. In Patient 3, significant TEPs were absent when cortical lesions were targeted and present otherwise. Significant TEPs were always present in healthy controls. Conclusions: These findings suggest that, provided that appropriate experimental procedures are employed, TEPs are genuine cortical responses detectable only when preserved cortical tissue is stimulated. Hence, a dependable assessment of cortical excitability and connectivity in brain-injured patients requires the use of neuronavigated TMS. (C) 2015 Elsevier Inc. All rights reserved.	[Gosseries, Olivia; Boly, Melanie; Schnakers, Caroline; Bruno, Marie-Aurelie; Ledoux, Didier; Tshibanda, Jean-Flory; Laureys, Steven] Univ Liege, Cyclotron Res Ctr, Coma Sci Grp, Liege, Belgium; [Gosseries, Olivia; Boly, Melanie; Schnakers, Caroline; Bruno, Marie-Aurelie; Ledoux, Didier; Tshibanda, Jean-Flory; Laureys, Steven; Rosanova, Mario] Univ Liege, Dept Neurol, Liege, Belgium; [Gosseries, Olivia; Boly, Melanie; Schnakers, Caroline; Bruno, Marie-Aurelie; Ledoux, Didier; Tshibanda, Jean-Flory; Laureys, Steven; Rosanova, Mario] Univ Hosp Liege, Liege, Belgium; [Gosseries, Olivia] Univ Wisconsin, Postle Lab, Madison, WI USA; [Gosseries, Olivia] Univ Wisconsin, Dept Psychiat & Psychol, Ctr Sleep & Consciousness, Madison, WI USA; [Sarasso, Simone; Casarotto, Silvia; Napolitani, Martino; Massimini, Marcello; Rosanova, Mario] Univ Milan, Dept Biomed & Clin Sci Luigi Sacco, I-20122 Milan, Italy; [Massimini, Marcello] IRCCS Fdn Don Carlo Gnocchi, Milan, Italy; [Rosanova, Mario] FERB Onlus, Fdn Europea Ric Biomed, Milan, Italy	Rosanova, M (corresponding author), Univ Milan, Hosp Luigi Sacco, Dept Biomed & Clin Sci L Sacco, Via GB Grassi 74, I-20122 Milan, Italy.	mario.rosanova@unimi.it	Casarotto, Silvia/F-1251-2015; Gosseries, Olivia/AAB-6469-2020; Laureys, Steven/A-3349-2011; Rosanova, Mario/S-8440-2017; Casarotto, Silvia/Q-9402-2019; Sarasso, Simone/C-7817-2012; Laureys, Steven/AAN-2097-2021; Massimini, Marcello/T-8115-2017	Casarotto, Silvia/0000-0002-7548-7664; Rosanova, Mario/0000-0001-7486-7617; Casarotto, Silvia/0000-0002-7548-7664; Sarasso, Simone/0000-0001-9984-4710; Laureys, Steven/0000-0002-3096-3807; Massimini, Marcello/0000-0003-2271-957X; Gosseries, Olivia/0000-0001-9011-7496; Ledoux, Didier/0000-0002-9314-6564; Boly, Melanie/0000-0001-9584-0907	James S. McDonnell Foundation Scholar Award; EUEuropean Commission [FP7-ICT-2011-9, 600806]; Public Utility Foundation; Belgian National Funds for Scientific Research (FNRS)Fonds de la Recherche Scientifique - FNRS; Belgian American Educational Foundation; Wallonie Bruxelles International; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [MH095984]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH095984] Funding Source: NIH RePORTER	This study was funded by James S. McDonnell Foundation Scholar Award 2013, EU grant FP7-ICT-2011-9, n. 600806 " Corticonics" and PRIN 2010 to MM; Public Utility Foundation " Universite Europeenne du Travail"; Belgian National Funds for Scientific Research (FNRS); Belgian American Educational Foundation and Wallonie Bruxelles International. OG and MAB are Postdoctoral Researchers and SL is Research Director at FNRS. OG received support from NIH grant MH095984 to Bradley R. Postle and from Giulio Tononi.	Ammermann H, 2007, J NEUROL SCI, V260, P65, DOI 10.1016/j.jns.2007.03.026; Bruno MA, 2012, J NEUROL, V259, P1087, DOI 10.1007/s00415-011-6303-7; Bruno MA, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-35; Casali AG, 2010, NEUROIMAGE, V49, P1459, DOI 10.1016/j.neuroimage.2009.09.026; Corthout E, 2000, NEUROREPORT, V11, P2345, DOI 10.1097/00001756-200008030-00003; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Ferrarelli F, 2010, P NATL ACAD SCI USA, V107, P2681, DOI 10.1073/pnas.0913008107; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Ilmoniemi RJ, 2010, BRAIN TOPOGR, V22, P233, DOI 10.1007/s10548-009-0123-4; Ilmoniemi RJ, 1997, NEUROREPORT, V8, P3537, DOI 10.1097/00001756-199711100-00024; Komssi S, 2007, NEUROREPORT, V18, P13, DOI 10.1097/WNR.0b013e328011b89a; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; LEHMANN D, 1980, ELECTROEN CLIN NEURO, V48, P609, DOI 10.1016/0013-4694(80)90419-8; Lv J, 2007, MED ENG PHYS, V29, P191, DOI 10.1016/j.medengphy.2006.03.001; Massimini M, 2005, SCIENCE, V309, P2228, DOI 10.1126/science.1117256; McCubbin J, 2008, J NEUROSCI METH, V168, P265, DOI 10.1016/j.jneumeth.2007.10.003; Miniussi C, 2010, BRAIN TOPOGR, V22, P249, DOI 10.1007/s10548-009-0083-8; Mutanen T, 2013, BRAIN STIMUL, V6, P371, DOI 10.1016/j.brs.2012.07.005; Nikouline V, 1999, CLIN NEUROPHYSIOL, V110, P1325, DOI 10.1016/S1388-2457(99)00070-X; Rogasch NC, 2013, HUM BRAIN MAPP, V34, P1652, DOI 10.1002/hbm.22016; Rosanova M, 2012, BRAIN, V135, P1308, DOI 10.1093/brain/awr340; Rosanova M, 2009, J NEUROSCI, V29, P7679, DOI 10.1523/JNEUROSCI.0445-09.2009; Schnakers C, 2008, BRAIN INJURY, V22, P786, DOI 10.1080/02699050802403557; TERBRAACK EM, 2013, BRAIN TOPOGR; Thibaut A, 2012, J REHABIL MED, V44, P487, DOI 10.2340/16501977-0940; Veniero D, 2009, CLIN NEUROPHYSIOL, V120, P1392, DOI 10.1016/j.clinph.2009.04.023; Virtanen J, 1999, MED BIOL ENG COMPUT, V37, P322, DOI 10.1007/BF02513307; Ziemann U, 2011, NEUROSCIENTIST, V17, P368, DOI 10.1177/1073858410390225	29	39	40	1	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1935-861X	1876-4754		BRAIN STIMUL	Brain Stimul.	JAN-FEB	2015	8	1					142	149		10.1016/j.brs.2014.10.008			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AX1ZA	WOS:000346741700018	25481074	Green Published			2021-06-18	
J	Fujii, M; Sherchan, P; Soejima, Y; Hasegawa, Y; Flores, J; Doycheva, D; Zhang, JH				Fujii, Mutsumi; Sherchan, Prativa; Soejima, Yoshiteru; Hasegawa, Yu; Flores, Jerry; Doycheva, Desislava; Zhang, John H.			Cannabinoid receptor type 2 agonist attenuates apoptosis by activation of phosphorylated CREB-Bcl-2 pathway after subarachnoid hemorrhage in rats	EXPERIMENTAL NEUROLOGY			English	Article						Cannabinoid receptor type 2; JWH133; Subarachnoid hemorrhage; Apoptosis; Brain edema; CREB	TRAUMATIC BRAIN-INJURY; CB2 RECEPTOR; PROTEIN; MODEL; CREB; INVOLVEMENT; DYSFUNCTION; INHIBITION; EXPRESSION; INDUCTION	Early brain injury (EBI) which comprises of vasogenic edema and apoptotic cell death is an important component of subarachnoid hemorrhage (SAH) pathophysiology. This study evaluated whether cannabinoid receptor type 2 (CB2R) agonist, JWH133, attenuates EBI after SAH and whether CB2R stimulation reduces pro-apoptotic caspase-3 via up-regulation of cAMP response element-binding protein (CREB)-Bcl-2 signaling pathway. Male Sprague-Dawley rats (n = 123) were subjected to SAN by endovascular perforation. Rats received vehicle or JWH133 at 1 h after SAH. Neurological deficits and brain water content were evaluated at 24 h after SAN. Western blot was performed to quantify phosphorylated CREB (pCREB), Bcl-2, and cleaved caspase-3 levels. Neuronal cell death was evaluated with terminal deoxynucleotidyl transferase-mediated uridine 5'-triphosphate-biotin nick end-labeling staining. Additionally, CREB siRNA was administered to manipulate the proposed pathway. JWH133 (1.0 mg/kg) improved neurological deficits and reduced brain water content in left hemisphere 24 h after SAN. JWH133 significantly increased activated CREB (pCREB) and Bcl-2 levels and significantly decreased cleaved caspase-3 levels in left hemisphere 24 h after SAH. CREB siRNA reversed the effects of treatment. TUNEL positive neurons in the cortex were reduced with JWH133 treatment. Thus, CB2R stimulation attenuated EBI after SAN possibly through activation of pCREB-Bcl-2 pathway. (C) 2014 Elsevier Inc. All rights reserved.	[Fujii, Mutsumi; Sherchan, Prativa; Soejima, Yoshiteru; Hasegawa, Yu; Flores, Jerry; Doycheva, Desislava; Zhang, John H.] Loma Linda Univ, Dept Physiol, Loma Linda, CA 92354 USA; [Zhang, John H.] Loma Linda Univ, Dept Neurosurg, Loma Linda, CA 92354 USA; [Zhang, John H.] Loma Linda Univ, Dept Anesthesiol, Loma Linda, CA 92354 USA	Zhang, JH (corresponding author), Loma Linda Univ, Med Ctr, Dept Neurosurg, 11234 Anderson St, Loma Linda, CA 92354 USA.	johnzhang3910@yahoo.com		Doycheva, Desislava/0000-0001-7795-5989; Sherchan, Prativa/0000-0002-2909-283X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS081740, NS082184]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS082184, R01NS081740] Funding Source: NIH RePORTER	This research was supported by NIH grant NS081740 and NS082184 to Dr. Zhang.	Amenta PS, 2012, J NEUROSCI RES, V90, P2293, DOI 10.1002/jnr.23114; Bahjat FR, 2013, TRANSL STROKE RES, V4, P89, DOI 10.1007/s12975-012-0223-4; BEDERSON JB, 1995, STROKE, V26, P1086, DOI 10.1161/01.STR.26.6.1086; Borner C, 2009, J BIOL CHEM, V284, P35450, DOI 10.1074/jbc.M109.006338; Chen S, 2013, NEUROBIOL DIS, V58, P296, DOI 10.1016/j.nbd.2013.06.011; Choi IY, 2013, AM J PATHOL, V182, P928, DOI 10.1016/j.ajpath.2012.11.024; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Cohen-Yeshurun A, 2011, J CEREBR BLOOD F MET, V31, P1768, DOI 10.1038/jcbfm.2011.53; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; Fujii M, 2013, TRANSL STROKE RES, V4, P432, DOI 10.1007/s12975-013-0257-2; Fujii M, 2012, NEUROCHEM INT, V60, P327, DOI 10.1016/j.neuint.2011.12.014; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Glass M, 1999, MOL PHARMACOL, V56, P1362; Ichiki T, 2006, ARTERIOSCL THROM VAS, V26, P449, DOI 10.1161/01.ATV.0000196747.79349.d1; Lapchak PA, 2013, TRANSL STROKE RES, V4, P328, DOI 10.1007/s12975-012-0200-y; Liu GM, 2006, J BIOL CHEM, V281, P29479, DOI 10.1074/jbc.M600579200; Meller R, 2005, J CEREBR BLOOD F MET, V25, P234, DOI 10.1038/sj.jcbfm.9600024; Murikinati S, 2010, FASEB J, V24, P788, DOI 10.1096/fj.09-141275; Negoescu A, 1996, J HISTOCHEM CYTOCHEM, V44, P959, DOI 10.1177/44.9.8773561; Ofek O, 2011, J BONE MINER RES, V26, P308, DOI 10.1002/jbmr.228; Onaivi ES, 2012, J PSYCHOPHARMACOL, V26, P92, DOI 10.1177/0269881111400652; Palazuelos J, 2009, BRAIN, V132, P3152, DOI 10.1093/brain/awp239; Park S, 2004, STROKE, V35, P2412, DOI 10.1161/01.STR.0000141162.29864.e9; Peters M, 2009, GENES BRAIN BEHAV, V8, P320, DOI 10.1111/j.1601-183X.2009.00474.x; Ramirez SH, 2012, J NEUROSCI, V32, P4004, DOI 10.1523/JNEUROSCI.4628-11.2012; Simard JM, 2012, TRANSL STROKE RES, V3, pS155, DOI 10.1007/s12975-012-0166-9; Sugawara T, 2008, J NEUROSCI METH, V167, P327, DOI 10.1016/j.jneumeth.2007.08.004; Suzuki H, 2010, STROKE, V41, P1783, DOI 10.1161/STROKEAHA.110.586537; Tajiri N, 2013, TRANSL STROKE RES, V4, P308, DOI 10.1007/s12975-012-0241-2; Tokudome T, 2004, ENDOCRINOLOGY, V145, P2458, DOI 10.1210/en.2003-1322; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Yamamoto W, 2008, EUR J PHARMACOL, V583, P56, DOI 10.1016/j.ejphar.2008.01.010; Zarruk JG, 2012, STROKE, V43, P211, DOI 10.1161/STROKEAHA.111.631044; Zhang JH, 2012, NAT REV NEUROL, V8, P711, DOI 10.1038/nrneurol.2012.210; Zhang M, 2009, MICROVASC RES, V78, P86, DOI 10.1016/j.mvr.2009.03.005; Zhang M, 2009, J NEUROIMMUNE PHARM, V4, P249, DOI 10.1007/s11481-009-9148-4	36	39	42	0	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	NOV	2014	261						396	403		10.1016/j.expneurol.2014.07.005			8	Neurosciences	Neurosciences & Neurology	AR4AX	WOS:000343531500042	25058046	Green Accepted			2021-06-18	
J	Xu, JG; Wang, HD; Lu, XY; Ding, K; Zhang, L; He, J; Wei, WT; Wu, Y				Xu, Jianguo; Wang, Handong; Lu, Xinyu; Ding, Ke; Zhang, Li; He, Jin; Wei, Wuting; Wu, Yong			Posttraumatic administration of luteolin protects mice from traumatic brain injury: Implication of autophagy and inflammation	BRAIN RESEARCH			English	Article						Traumatic brain injury; Luteolin; Neuroprotection; Autophagy; Inflammation	NF-KAPPA-B; RAW 264.7 CELLS; NEUROPROTECTION; EXPRESSION; MODEL; MODULATION; FLAVONOIDS; RESPONSES; ISCHEMIA; DISEASE	Secondary brain insult induced by traumatic brain injury (TBI), including excitotoxicity, oxidative stress, inflammatory response, and neuronal degeneration, is sensitive to therapeutic interventions; therefore, searching for neuroprotective agents represents a promising therapeutic strategy for TBI treatment. Luteolin, a member of the flavonoid family, has recently been proven to modulate autophagy. However, whether it activates autophagy after TBI thereby alleviating the secondary insult is not yet understood. Here, we aimed to evaluate the neuroprotection of luteolin against TBI and the potential role of autophagy where it is involved. For this purpose, mice were randomly divided into four groups and then subjected to TBI. The treatment mice received luteolin at a dose of 30 mg/kg 30 min post-TBI based on our previous study. We employed western blot, immunofluorescence and quantitative real-time PCR to determine autophagy process and inflammatory response among different groups. Autophagy was found to be enhanced after luteolin treatment according to the expressions of autophagic markers. Furthermore, luteolin decreased nuclear accumulation of p65 induced by TBI, indicating attenuation of inflammation. In line with these observations, luteolin decreased mRNA and protein expressions of pro-inflammatory factors IL-1b and TNF-a. At last, luteolin reduced neuronal degeneration, and alleviated brain edema and blood-brain barrier (BBB) disruption. In conclusion, these results implied that luteolin protected mice brain from traumatic brain injury by inhibiting inflammatory response, and luteolin-induced autophagy might play a pivotal role in its neuroprotection. (C) 2014 Elsevier B.V. All rights reserved.	[Xu, Jianguo; Wang, Handong; Lu, Xinyu; Ding, Ke; Zhang, Li; He, Jin; Wu, Yong] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210008, Jiangsu, Peoples R China; [Wei, Wuting] Southern Med Univ Guangzhou, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China	Wang, HD (corresponding author), Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371357]; Jiangsu Provincial Science and Technology Department [BL2013027]	This work was supported by Grants from the National Natural Science Foundation of China (No. 81371357) and Jiangsu Provincial Science and Technology Department (No. BL2013027).	Brooks JC, 2013, ARCH PHYS MED REHAB, V94, P2203, DOI 10.1016/j.apmr.2013.07.005; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Dajas Federico, 2013, Central Nervous System Agents in Medicinal Chemistry, V13, P30; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fujishima Y, 2011, ARCH BIOCHEM BIOPHYS, V506, P223, DOI 10.1016/j.abb.2010.12.009; Ghavami S, 2014, PROG NEUROBIOL, V112, P24, DOI 10.1016/j.pneurobio.2013.10.004; Huang HC, 2010, J AGR FOOD CHEM, V58, P8699, DOI 10.1021/jf101003v; Kim J, 2013, NEUROBIOL DIS, V59, P80, DOI 10.1016/j.nbd.2013.07.011; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Li L, 2014, FOOD CHEM TOXICOL, V63, P166, DOI 10.1016/j.fct.2013.08.036; Lin XL, 2013, DNA CELL BIOL, V32, P220, DOI 10.1089/dna.2012.1915; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Lv LH, 2011, INFLAMMATION, V34, P620, DOI 10.1007/s10753-010-9271-7; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Miracco C, 2007, INT J ONCOL, V30, P429; Murrow L, 2013, ANNU REV PATHOL-MECH, V8, P105, DOI 10.1146/annurev-pathol-020712-163918; Park CM, 2013, NUTR RES PRACT, V7, P423, DOI 10.4162/nrp.2013.7.6.423; Park CM, 2011, EUR J PHARMACOL, V660, P454, DOI 10.1016/j.ejphar.2011.04.007; Park SH, 2013, FOOD CHEM TOXICOL, V56, P100, DOI 10.1016/j.fct.2013.02.022; Qiao HM, 2012, NEUROCHEM RES, V37, P2014, DOI 10.1007/s11064-012-0822-1; Qiao HM, 2012, BRAIN RES, V1448, P71, DOI 10.1016/j.brainres.2012.02.003; Romagnolo Donato F., 2012, Journal of Nutrition in Gerontology and Geriatrics, V31, P206, DOI 10.1080/21551197.2012.702534; Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802; Rubinsztein DC, 2011, CELL, V146, P682, DOI 10.1016/j.cell.2011.07.030; Ryter SW, 2013, MOL CELLS, V36, P7, DOI 10.1007/s10059-013-0140-8; Sawmiller D, 2014, INT J MOL SCI, V15, P895, DOI 10.3390/ijms15010895; Sharma V, 2007, BRAIN RES BULL, V73, P55, DOI 10.1016/j.brainresbull.2007.01.016; Tan CC, 2014, NEUROBIOL AGING, V35, P941, DOI 10.1016/j.neurobiolaging.2013.11.019; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; Viscomi MT, 2012, AUTOPHAGY, V8, P222, DOI 10.4161/auto.8.2.18599; Wang JA, 2007, FREE RADICAL BIO MED, V43, P408, DOI 10.1016/j.freeradbiomed.2007.04.020; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873; Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0; Zhang YC, 2013, FOOD CHEM TOXICOL, V59, P272, DOI 10.1016/j.fct.2013.05.058; Zhao G, 2011, J NUTR BIOCHEM, V22, P929, DOI 10.1016/j.jnutbio.2010.07.014	39	39	40	0	16	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 25	2014	1582						237	246		10.1016/j.brainres.2014.07.042			10	Neurosciences	Neurosciences & Neurology	AR1PM	WOS:000343357100023	25093609				2021-06-18	
J	Marmarou, CR; Liang, X; Abidi, NH; Parveen, S; Taya, K; Henderson, SC; Young, HF; Filippidis, AS; Baumgarten, CM				Marmarou, Christina R. p; Liang, Xiuyin; Abidi, Naqeeb H.; Parveen, Shanaz; Taya, Keisuke; Henderson, Scott C.; Young, Harold F.; Filippidis, Aristotelis S.; Baumgarten, Clive M.			Selective vasopressin-1a receptor antagonist prevents brain edema, reduces astrocytic cell swelling and GFAP, V1aR and AQP4 expression after focal traumatic brain injury	BRAIN RESEARCH			English	Article						Traumatic brain injury; Edema; Aquaporin 4; Vasopressin; Astrocyte; SR49059	PHORBOL-MYRISTATE ACETATE; FIBRILLARY ACIDIC PROTEIN; ATRIAL-NATRIURETIC-PEPTIDE; CEREBRAL-ARTERY OCCLUSION; KINASE-C ACTIVATOR; ARGININE-VASOPRESSIN; AQUAPORIN-4 EXPRESSION; WATER PERMEABILITY; CEREBROSPINAL-FLUID; V-2 RECEPTORS	A secondary and often lethal consequence of traumatic brain injury is cellular edema that we posit is due to astrocytic swelling caused by transmembrane water fluxes augmented by vasopressin-regulated aquaporin-4 (AQP4). We therefore tested whether vasopressin la receptor (V1aR) inhibition would suppress astrocyte AQP4, reduce astrocytic edema, and thereby diminish TBI-induced edematous changes. V1aR inhibition by SR49059 significantly reduced brain edema after cortical contusion injury (CCI) in rat 5 h post-injury. Injured-hemisphere brain water content (n=6 animals/group) and astrocytic area (n=3/group) were significantly higher in CCI-vehicle (80.5 +/- 0.3%; 18.0 +/- 1.4 mu m(2)) versus sham groups (78.3 +/- 0.1%; 9.5 +/- 0.91 mu m(2)), and SR49059 blunted CCI-induced increases in brain edema (79.0 +/- 0.2%; 9.4 +/- 00.8 mu m(2)). CCI significantly up-regulated GFAP, V1aR and AQP4 protein levels and SR49059 suppressed injury induced up regulation (n=6/group). In CCI-vehicle, sham and CCI-SR49059 groups, GFAP was 1.58 +/- 0.04, 0.47 +/- 0.02, and 0.81+0.03, respectively; V1aR was 1.00 +/- 0.06, 0.45 +/- 0.05, and 0.46 +/- 0.09; and AQP4 was 2.03 +/- 0.34, 0.49 +/- 30.04, and 0.92 +/- 0.22. Confocal immunohistochemistry gave analogous results. In CCI-vehicle, sham and CCI-SR49059 groups, fluorescence intensity of GFAP was 349 +/- 38, 56 +/- 5, and 244 +/- 30, respectively, V1aR was 601 +/- 71, 117.8 +/- 14, and 390 +/- 76, and AQP4 was 818 +/- 117, 158 +/- 5, and 458 +/- 55 (n=3/group). The results support that edema was predominantly cellular following CCI and documented that VlaR inhibition with SR49059 suppressed injury-induced up regulation of GFAP, VIA and AQP4, blunting edematous changes. Our findings suggest V1aR inhibitors may be potential therapeutic tools to prevent cellular swelling and provide treatment for post-traumatic brain edema. (C) 2014 Elsevier B.V. All rights reserved.	[Marmarou, Christina R. p; Liang, Xiuyin; Abidi, Naqeeb H.; Parveen, Shanaz; Taya, Keisuke; Young, Harold F.; Filippidis, Aristotelis S.] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23298 USA; [Marmarou, Christina R. p; Baumgarten, Clive M.] Virginia Commonwealth Univ, Dept Phys & Biophys, Richmond, VA 23298 USA; [Henderson, Scott C.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA	Marmarou, CR (corresponding author), Virginia Commonwealth Univ, Dept Neurosurg, 9-036-9-039 Sanger Hall,1101 East Marshall St, Richmond, VA 23298 USA.	crmarmar@vcu.edu	Henderson, Scott/AAP-2785-2021	Henderson, Scott/0000-0002-1076-3867	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R01NS019235]; NIH-NINDS Center Core grant [5P30NS047463]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463, R01NS019235] Funding Source: NIH RePORTER	This work was supported by grant 5R01NS019235 from the National Institute of Health. Microscopy was performed at the VCU-Department of Anatomy and Neurobiology Microscopy Facility, supported in part with funding from NIH-NINDS Center Core grant (5P30NS047463). We wish to acknowledge the technical help of Mr. Andrew McCall, and the generous gift of SR49059 from Sanofi-Aventis.	Amiry-Moghaddam M, 2003, NAT REV NEUROSCI, V4, P991, DOI 10.1038/nrn1252; Amorini AM, 2003, ACT NEUR S, V86, P261; Bagheri M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076526; Bemana I, 1999, NEUROSURGERY, V44, P148, DOI 10.1097/00006123-199901000-00091; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Carrasco E, 2007, DIABETES CARE, V30, P2902, DOI 10.2337/dc07-0332; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; CSERR HF, 1992, PROG BRAIN RES, V91, P3; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; DICKINSON LD, 1992, J CEREBR BLOOD F MET, V12, P681, DOI 10.1038/jcbfm.1992.93; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DOCZI T, 1984, NEUROSURGERY, V14, P436, DOI 10.1227/00006123-198404000-00008; DOCZI T, 1982, NEUROSURGERY, V11, P402; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Fattore L, 2002, NEUROSCIENCE, V110, P1, DOI 10.1016/S0306-4522(01)00598-X; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Fazzina G, 2010, J NEUROTRAUM, V27, P453, DOI 10.1089/neu.2008.0782; Filippidis AS, 2014, J NEUROTRAUM, V31, P1258, DOI 10.1089/neu.2013.3063; Floyd CL, 2007, PROG BRAIN RES, V161, P61, DOI 10.1016/S0079-6123(06)61005-4; Girardi E, 2004, NEUROCHEM RES, V29, P371, DOI 10.1023/B:NERE.0000013739.15160.a8; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Haj-Yasein NN, 2011, P NATL ACAD SCI USA, V108, P17815, DOI 10.1073/pnas.1110655108; Hamby ME, 2010, NEUROTHERAPEUTICS, V7, P494, DOI 10.1016/j.nurt.2010.07.003; Hernando F, 2001, ENDOCRINOLOGY, V142, P1659, DOI 10.1210/en.142.4.1659; Huang WD, 2008, J ENDOCRINOL INVEST, V31, P996, DOI 10.1007/BF03345638; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Kagawa M, 1996, J NEUROTRAUM, V13, P273, DOI 10.1089/neu.1996.13.273; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; Kleindienst A, 2006, ACTA NEUROCHIR SUPPL, V96, P303; Kleindienst A, 2006, ACTA NEUROCHIR SUPPL, V96, P393; Kleindienst A, 2010, ACTA NEUROCHIR SUPPL, V106, P221, DOI 10.1007/978-3-211-98811-4_41; Kleindienst A, 2013, ACTA NEUROCHIR, V155, P151, DOI 10.1007/s00701-012-1558-z; LANDGRAF R, 1992, PROG BRAIN RES, V91, P29; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LATZKOVITS L, 1993, AM J PHYSIOL, V264, pC603; Liu XQ, 2010, NEUROCRIT CARE, V12, P124, DOI 10.1007/s12028-009-9277-x; Lo Pizzo M, 2013, NEUROL SCI, V34, P1309, DOI 10.1007/s10072-012-1233-4; Manaenko A, 2011, ACTA NEUROCHIR SUPPL, V111, P191, DOI 10.1007/978-3-7091-0693-8_32; Manaenko A, 2011, NEUROCHEM INT, V58, P542, DOI 10.1016/j.neuint.2011.01.018; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; MARMAROU A, 1994, AM J PHYSIOL, V267, pH514; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Neal CJ, 2007, J NEUROTRAUM, V24, P1609, DOI 10.1089/neu.2007.0301; Nielsen S, 1997, J NEUROSCI, V17, P171; Niermann H, 2001, J NEUROSCI, V21, P3045, DOI 10.1523/JNEUROSCI.21-09-03045.2001; Okuno K, 2008, ACTA NEUROCHIR SUPPL, V102, P431, DOI 10.1007/978-3-211-85578-2_84; OSTROWSKI NL, 1994, ENDOCRINOLOGY, V135, P1511, DOI 10.1210/en.135.4.1511; Pascale CL, 2006, J PHYSIOL PHARMACOL, V57, P161; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; RAICHLE ME, 1978, BRAIN RES, V143, P191, DOI 10.1016/0006-8993(78)90766-7; Rao KVR, 2011, J NEUROTRAUM, V28, P371, DOI 10.1089/neu.2010.1705; Rauen K, 2013, J NEUROTRAUM, V30, P1442, DOI 10.1089/neu.2012.2807; ROSENBERG GA, 1992, STROKE, V23, P1767, DOI 10.1161/01.STR.23.12.1767; SERRADEILLEGAL C, 1993, J CLIN INVEST, V92, P224, DOI 10.1172/JCI116554; Shuaib A, 2002, STROKE, V33, P3033, DOI 10.1161/01.STR.0000039405.31526.06; Solenov E, 2004, AM J PHYSIOL-CELL PH, V286, pC426, DOI 10.1152/ajpcell.00298.2003; SORENSEN PS, 1985, J NEUROL NEUROSUR PS, V48, P50, DOI 10.1136/jnnp.48.1.50; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Suzuki R, 2006, ACTA NEUROCHIR SUPPL, V96, P398; Szmydynger-Chodobska J, 2004, J NEUROTRAUM, V21, P1090, DOI 10.1089/0897715041651033; Szmydynger-Chodobska J, 2011, J CEREBR BLOOD F MET, V31, P47, DOI 10.1038/jcbfm.2010.188; Szmydynger-Chodobska J, 2010, J NEUROTRAUM, V27, P1449, DOI 10.1089/neu.2010.1331; SZOT P, 1994, MOL BRAIN RES, V24, P1, DOI 10.1016/0169-328X(94)90111-2; Taya K, 2010, J NEUROTRAUM, V27, P229, DOI 10.1089/neu.2009.0933; Taya K, 2008, ACTA NEUROCHIR SUPPL, V102, P425, DOI 10.1007/978-3-211-85578-2_83; Thibonnier M, 1998, PROG BRAIN RES, V119, P147; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Trabold R, 2008, J NEUROTRAUM, V25, P1459, DOI 10.1089/neu.2008.0597; Vajda Z, 2001, NEUROSURGERY, V49, P697, DOI 10.1097/00006123-200109000-00031; Vakili A, 2005, J CEREBR BLOOD F MET, V25, P1012, DOI 10.1038/sj.jcbfm.9600097; Verkman AS, 2009, J EXP BIOL, V212, P1707, DOI 10.1242/jeb.024125; VIJAYAN VK, 1990, MOL CHEM NEUROPATHOL, V13, P107, DOI 10.1007/BF03159912; Zelenina M, 2002, AM J PHYSIOL-RENAL, V283, pF309, DOI 10.1152/ajprenal.00260.2001	78	39	40	0	15	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 18	2014	1581						89	102		10.1016/j.brainres.2014.06.005			14	Neurosciences	Neurosciences & Neurology	AQ1LE	WOS:000342542100009	24933327	Green Accepted			2021-06-18	
J	Fakhran, S; Yaeger, K; Collins, M; Alhilali, L				Fakhran, Saeed; Yaeger, Karl; Collins, Michael; Alhilali, Lea			Sex Differences in White Matter Abnormalities after Mild Traumatic Brain Injury: Localization and Correlation with Outcome	RADIOLOGY			English	Article							TENSOR IMAGING FINDINGS; CONCUSSION SYMPTOMS; NEUROPSYCHOLOGICAL FUNCTION; UNCINATE FASCICULUS; GENDER; AGE; ADOLESCENCE; MODERATE	Purpose: To evaluate sex differences in diffusion-tensor imaging (DTI) white matter abnormalities after mild traumatic brain injury (mTBI) using tract-based spatial statistics (TBSS) and to compare associated clinical outcomes. Materials and Methods: The institutional review board approved this study, with waiver of informed consent. DTI in 69 patients with mTBI (47 male and 22 female patients) and 21 control subjects (10 male and 11 female subjects) with normal conventional magnetic resonance (MR) images were retrospectively reviewed. Fractional anisotropy (FA) maps were generated as a measure of white matter integrity. Patients with mTBI underwent serial neurocognitive testing with Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT). Correlation between sex, white matter FA values, ImPACT scores, and time to symptom resolution (TSR) were analyzed with multivariate analysis and TBSS. Results: No significant difference in age was seen between males and females (control subjects, P = .3; patients with mTBI, P = .34). No significant difference was seen in initial ImPACT symptom scores (P = .33) between male and female patients with mTBI. Male patients with mTBI had significantly decreased FA values in the uncinate fasciculus (UF) bilaterally (mean FA, 0.425; 95% confidence interval: 0.375, 0.476) compared with female patients with mTBI and control subjects (P < .05), with a significantly longer TSR (P = .04). Multivariate analysis showed sex and UF FA values independently correlated with TSR longer than 3 months (adjusted odds ratios, 2.27 and 2.38; P = .04 and P < .001, respectively), but initial symptom severity did not (adjusted odds ratio, 1.15; P = .35). Conclusion: Relative sparing of the UF is seen in female compared with male patients after mTBI, with sex and UF FA values as stronger predictors of TSR than initial symptom severity. (C) RSNA, 2014	[Fakhran, Saeed; Yaeger, Karl; Alhilali, Lea] Univ Pittsburgh, Sch Med, Dept Radiol, Pittsburgh, PA 15213 USA; [Collins, Michael] Univ Pittsburgh, Sch Med, Sports Med Concuss Program, Pittsburgh, PA 15213 USA	Fakhran, S (corresponding author), Univ Pittsburgh, Sch Med, Dept Radiol, 200 Lothrop St,Presby South Tower,8th Floor, Pittsburgh, PA 15213 USA.	fakhrans@upmc.edu					Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Cantu RC, 2010, PM&R, V2, P1088, DOI 10.1016/j.pmrj.2010.07.483; Centers for Disease Control and Prevention (CDC), 2003, NATL CTR INJ PREV CO; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Farace E, 2000, Neurosurg Focus, V8, pe6; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Giorgio A, 2008, NEUROIMAGE, V39, P52, DOI 10.1016/j.neuroimage.2007.07.043; Giorgio A, 2010, NEUROIMAGE, V49, P94, DOI 10.1016/j.neuroimage.2009.08.003; Hasan KM, 2009, BRAIN RES, V1276, P67, DOI 10.1016/j.brainres.2009.04.025; Ibanez C, 2004, NEUROPATH APPL NEURO, V30, P80, DOI 10.1046/j.0305-1846.2003.00515.x; Inano S, 2011, AM J NEURORADIOL, V32, P2103, DOI 10.3174/ajnr.A2785; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Lee AJY, 2007, J APPL BIOMECH, V23, P173, DOI 10.1123/jab.23.3.173; Ma JP, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008409.pub3; Maghool F, 2013, BRAIN RES, V1497, P61, DOI 10.1016/j.brainres.2012.12.014; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Peters BD, 2012, SCHIZOPHRENIA BULL, V38, P1308, DOI 10.1093/schbul/sbs054; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Salimi-Khorshidi G, 2011, NEUROIMAGE, V54, P2006, DOI 10.1016/j.neuroimage.2010.09.088; Sato T, 2012, IEEE ENG MED BIO, P424, DOI 10.1109/EMBC.2012.6345958; Schumacher M, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00010; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Von Der Heide RJ, 2013, BRAIN, V136, P1692, DOI 10.1093/brain/awt094; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wang JY, 2011, NEUROLOGY, V77, P818, DOI 10.1212/WNL.0b013e31822c61d7; Wang YY, 2012, BRAIN RES, V1478, P1, DOI 10.1016/j.brainres.2012.08.038; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P404, DOI 10.1007/s11682-012-9150-y	36	39	39	1	16	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	SEP	2014	272	3					815	823		10.1148/radiol.14132512			9	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	AO2WX	WOS:000341188900022	24802388	Bronze			2021-06-18	
J	Lee, JH; Wei, L; Gu, XH; Wei, Z; Dix, TA; Yu, SP				Lee, Jin Hwan; Wei, Ling; Gu, Xiaohuan; Wei, Zheng; Dix, Thomas A.; Yu, Shan Ping			Therapeutic Effects of Pharmacologically Induced Hypothermia against Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; hypothermia; inflammation; neurotensin analogue; sensorimotor function; traumatic brain injury	CONTROLLED CORTICAL IMPACT; TRANSIENT GLOBAL-ISCHEMIA; MILD HYPOTHERMIA; MODERATE HYPOTHERMIA; INFLAMMATORY RESPONSE; FOREBRAIN ISCHEMIA; CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; PHASE-II; STROKE	Preclinical and clinical studies have shown therapeutic potential of mild-to-moderate hypothermia for treatments of stroke and traumatic brain injury (TBI). Physical cooling in humans, however, is usually slow, cumbersome, and necessitates sedation that prevents early application in clinical settings and causes several side effects. Our recent study showed that pharmacologically induced hypothermia (PIH) using a novel neurotensin receptor 1 (NTR1) agonist, HPI-201 (also known as ABS-201), is efficient and effective in inducing therapeutic hypothermia and protecting the brain from ischemic and hemorrhagic stroke in mice. The present investigation tested another second-generation NTR1 agonist, HPI-363, for its hypothermic and protective effect against TBI. Adult male mice were subjected to controlled cortical impact (CCI) (velocity = 3 m/sec, depth = 1.0 mm, contact time = 150 msec) to the exposed cortex. Intraperitoneal administration of HPI-363 (0.3 mg/kg) reduced body temperature by 3-5 degrees C within 30-60 min without triggering a shivering defensive reaction. An additional two injections sustained the hypothermic effect in conscious mice for up to 6 h. This PIH treatment was initiated 15, 60, or 120 min after the onset of TBI, and significantly reduced the contusion volume measured 3 days after TBI. HPI-363 attenuated caspase-3 activation, Bax expression, and TUNEL-positive cells in the pericontusion region. In blood-brain barrier assessments, HPI-363 ameliorated extravasation of Evans blue dye and immunoglobulin G, attenuated the MMP-9 expression, and decreased the number of microglia cells in the post-TBI brain. HPI-363 decreased the mRNA expression of tumor necrosis factor-a and interleukin-1 beta (IL-1 beta), but increased IL-6 and IL-10 levels. Compared with TBI control mice, HPI-363 treatments improved sensorimotor functional recovery after TBI. These findings suggest that the second generation NTR-1 agonists, such as HPI-363, are efficient hypothermic-inducing compounds that have a strong potential in the management of TBI.	[Lee, Jin Hwan; Wei, Ling; Gu, Xiaohuan; Wei, Zheng; Yu, Shan Ping] Emory Univ, Sch Med, Dept Anesthesiol, Atlanta, GA 30322 USA; [Wei, Ling] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Dix, Thomas A.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA; [Dix, Thomas A.] Halimed Pharmaceut Inc, Mt Pleasant, MI USA	Yu, SP (corresponding author), Emory Univ, Sch Med, 101 Woodruff Circle,WMB Suite 620, Atlanta, GA 30322 USA.	spyu@emory.edu	Wei, Zheng Zachory/I-2109-2019	Wei, Zheng Zachory/0000-0001-7682-9286	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS073378, NS0458710, NS075338, NS062097]; VA Merit grant; American Heart Association (AHA)American Heart Association [12GRNT12060222]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R41NS073378, R42NS073378, R01NS062097, R21NS075338] Funding Source: NIH RePORTER	This work was supported by the NIH grants NS073378 (TAD and SPY), NS0458710 (SPY), NS075338 (LW), NS062097 (LW), a VA Merit grant (SPY), the American Heart Association (AHA) grant 12GRNT12060222 (SPY), and the AHA Established Investigator Award (LW).	Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Arcure Jess, 2009, J Spec Oper Med, V9, P22; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CARRAWAY R, 1975, J BIOL CHEM, V250, P1912; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Choi KE, 2012, FASEB J, V26, P2799, DOI 10.1096/fj.11-201822; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Clifton GL, 2012, J NEUROSURG, V117, P714, DOI 10.3171/2012.6.JNS111690; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Demetrius L, 2005, EMBO REP, V6, pS39, DOI 10.1038/sj.embor.7400422; Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015; Dietrich WD, 1999, EXP NEUROL, V158, P444, DOI 10.1006/exnr.1999.7115; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dubuc I, 1999, J NEUROSCI, V19, P503; Erecinska M, 2003, J CEREBR BLOOD F MET, V23, P513, DOI 10.1097/01.WCB.0000066287.21705.21; Frink M, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/762840; Gibbons H, 2003, MOL BRAIN RES, V110, P63, DOI 10.1016/S0169-328X(02)00585-5; Guluma KZ, 2008, NEUROCRIT CARE, V8, P42, DOI 10.1007/s12028-007-9009-z; Hadden MK, 2005, NEUROPHARMACOLOGY, V49, P1149, DOI 10.1016/j.neuropharm.2005.06.010; Hanell A, 2012, J NEUROTRAUM, V29, P2660, DOI 10.1089/neu.2012.2376; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Heegaard W, 1997, ACAD EMERG MED, V4, P33, DOI 10.1111/j.1553-2712.1997.tb03640.x; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Janowitz T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000330; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Jiang JY, 2004, NEUROSURGERY, V54, P713, DOI 10.1227/01.NEU.0000109535.58429.49; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kammersgaard LP, 2000, STROKE, V31, P2251, DOI 10.1161/01.STR.31.9.2251; Katz LM, 2004, BRAIN RES, V1017, P85, DOI 10.1016/j.brainres.2004.05.020; Kida H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068877; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Kniesel U, 2000, CELL MOL NEUROBIOL, V20, P57, DOI 10.1023/A:1006995910836; Kokko KP, 2005, NEUROPHARMACOLOGY, V48, P417, DOI 10.1016/j.neuropharm.2004.10.008; Leon LR, 2006, J APPL PHYSIOL, V100, P1400, DOI 10.1152/japplphysiol.01040.2005; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Liu LP, 2007, FRONT BIOSCI-LANDMRK, V12, P816, DOI 10.2741/2104; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Lundberg George D, 2008, Medscape J Med, V10, P212; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; MIYAZAWA T, 1992, J CEREBR BLOOD F MET, V12, P817, DOI 10.1038/jcbfm.1992.113; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Nag S, 2007, ACTA NEUROPATHOL, V114, P459, DOI 10.1007/s00401-007-0274-x; Namas R, 2009, LIBYAN J MED, V4, P97, DOI 10.4176/090325; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Orwig KS, 2009, J MED CHEM, V52, P1803, DOI 10.1021/jm801072v; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Popovic R, 2000, ANESTHESIOLOGY, V92, P1343, DOI 10.1097/00000542-200005000-00024; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Runyan DK, 2008, AM J PREV MED, V34, pS112, DOI 10.1016/j.amepre.2008.01.011; Scheff SW, 2013, EXP NEUROL, V239, P183, DOI 10.1016/j.expneurol.2012.09.019; Schwab S, 1998, ACT NEUR S, V71, P131; Schwab S, 2001, STROKE, V32, P2033, DOI 10.1161/hs0901.095394; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Steele AD, 2007, P NATL ACAD SCI USA, V104, P1983, DOI 10.1073/pnas.0610779104; Stewart CR, 2010, PEDIATR CRIT CARE ME, V11, P109, DOI 10.1097/PCC.0b013e3181b01042; SYDENHAM E, 2009, COCHRANE DATABASE SY; Tomura S, 2012, J CEREBR BLOOD F MET, V32, P1939, DOI 10.1038/jcbfm.2012.99; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Tsuchiya D, 2002, J CEREBR BLOOD F MET, V22, P1231; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; van der Worp HB, 2010, J CEREBR BLOOD F MET, V30, P1079, DOI 10.1038/jcbfm.2010.44; Vilalta A, 2008, INTENS CARE MED, V34, P1384, DOI 10.1007/s00134-008-1056-1; Wei S, 2013, NEUROSCIENCE, V252, P489, DOI 10.1016/j.neuroscience.2013.07.052; Won SM, 2011, EXP MOL MED, V43, P121, DOI 10.3858/emm.2011.43.2.020; Wroblewski BA, 1996, J CLIN PSYCHIAT, V57, P582, DOI 10.4088/JCP.v57n1206; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375; Yeung D, 2008, ACTA NEUROPATHOL, V115, P635, DOI 10.1007/s00401-008-0364-4; Zhao QJ, 2011, J CRIT CARE, V26, P311, DOI 10.1016/j.jcrc.2010.08.014; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4	79	39	39	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG 15	2014	31	16					1417	1430		10.1089/neu.2013.3251			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AN4DB	WOS:000340536700005	24731132	Green Published			2021-06-18	
J	Beghi, E; Hesdorffer, D				Beghi, Ettore; Hesdorffer, Dale			Prevalence of epilepsy-An unknown quantity	EPILEPSIA			English	Article						Epidemiology; Incidence; Prevalence; Mortality; Remission; Epilepsy	SOCIOECONOMIC-STATUS; NATURAL-HISTORY; UNTREATED POPULATION; DEVELOPING-COUNTRIES; UNPROVOKED SEIZURES; SOCIAL DEPRIVATION; MORTALITY; RISK; MINNESOTA; COMMUNITY	The incidence, prevalence, and mortality of epilepsy vary across countries with different economies. Differences can be explained by methodological problems, premature mortality, seizure remission, socioeconomic factors, and stigma. Diagnostic misclassification-one possible explanation-may result from inclusion of patients with acute symptomatic or isolated unprovoked seizures. Other sources of bias include age and ethnic origin of the target population, definitions of epilepsy, retrospective versus prospective ascertainment, sources of cases, and experienced and perceived stigma. Premature mortality is an issue in low-income countries (LICs), where treatment gap, brain infections, and traumatic brain injuries are more common than in high-income countries (HICs). Death rates may reflect untreated continued seizures or inclusion of acute symptomatic seizures. Lack of compliance with antiepileptic drugs has been associated with increased risk for death, increased hospital admissions, motor vehicle accidents, and fractures in poor communities. Epilepsy is a self-remitting clinical condition in up to 50% of cases. Studies in untreated individuals from LICs have shown that the proportion of remissions overlaps that of countries where patients receive treatment. When the identification of patients is based on spontaneous reports (e. g., door-to-door surveys), patients in remission may be less likely to disclose the disease for fear of stigmatization with no concurrent benefits. This might lead to underascertainment of cases when assessing the lifetime prevalence of epilepsy. In LICs, the proportion of people living in poverty is greater than in HICs. Poverty is associated with risk factors for epilepsy, risk for developing epilepsy, and increased mortality. The high incidence and prevalence of epilepsy found in LICs is also observed in low income individuals from HICs. Epileptogenic conditions are associated with an increased mortality. This may partly explain the difference between incidence and lifetime prevalence of epilepsy in LICs. Poverty within LICs and HICs could be a preventable cause of mortality in epilepsy.	[Beghi, Ettore] IRCCS Mario Negri Inst Pharmacol Res, Dept Neurosci, I-20156 Milan, Italy; [Hesdorffer, Dale] Columbia Univ, Dept Epidemiol, New York, NY USA; [Hesdorffer, Dale] Columbia Univ, GH Sergievsky Ctr, New York, NY USA	Beghi, E (corresponding author), IRCCS Mario Negri Inst Pharmacol Res, Lab Neurol Disorders, Via Giuseppe La Masa 19, I-20156 Milan, Italy.	ettore.beghi@mari-onegri.it	Beghi, Ettore/AAA-7426-2020	Beghi, Ettore/0000-0003-2542-0469	UCB-PharmaUCB Pharma SA; Sanofi-AventisSanofi-Aventis; GlaxoSmithKlineGlaxoSmithKline; EisaiEisai Co Ltd; Upsher Smith	Dr. Beghi serves on the editorial advisory boards of Epilepsia, Amyotrophic Lateral Sclerosis, Clinical Neurology & Neurosurgery, and Neuro-epidemiology; has received money for board membership by Viropharma and Eisai; has received funding for travel and speaker honoraria from UCB-Pharma, Sanofi-Aventis, and GlaxoSmithKline, and has received funding for educational presentations from GlaxoSmithKline. Dr. Hesdorffer serves as an associate editor of Epilepsia, is on the editorial boards of Epilepsy & Behavior, and Epilepsy Research, and is a contributing editor for Epilepsy Currents. She has received consultant fees from Eisai and Upsher Smith and has received speaker honoraria from UCB-Pharma. We confirm that we have read the Journal position on issue involved in ethical publication and affirm that this report is consistent with these guidelines.	ANNEGERS JF, 1995, EPILEPSIA, V36, P327, DOI 10.1111/j.1528-1157.1995.tb01005.x; ANNEGERS JF, 1979, EPILEPSIA, V20, P729, DOI 10.1111/j.1528-1157.1979.tb04857.x; Annegers JR, 1984, ADV EPILEPTOL, P521; [Anonymous], 1993, EPILEPSIA, V34, P592; Beghi E, 2009, EXPERT REV NEUROTHER, V9, P291, DOI 10.1586/14737175.9.2.291; Bell GS, 2014, EPILEPSIA, V55, P958, DOI 10.1111/epi.12605; Bhalla D, 2013, EPILEPSIA, V54, P1342, DOI 10.1111/epi.12218; Carpio A, 2005, EPILEPSIA, V46, P28, DOI 10.1111/j.1528-1167.2005.00404.x; Chang CL, 2002, J CLIN EPIDEMIOL, V55, P741, DOI 10.1016/S0895-4356(02)00413-4; COCKERELL OC, 1995, J NEUROL NEUROSUR PS, V58, P570, DOI 10.1136/jnnp.58.5.570; Cubbin C, 2000, AM J PUBLIC HEALTH, V90, P70, DOI 10.2105/AJPH.90.1.70; Faggiano F, 1997, IARC Sci Publ, P65; Faught E, 2008, NEUROLOGY, V71, P1572, DOI 10.1212/01.wnl.0000319693.10338.b9; Forsgren L, 2005, EPILEPSIA, V46, P18, DOI 10.1111/j.1528-1167.2005.00403.x; GIUFFRA LA, 1994, PSYCHOL MED, V24, P375, DOI 10.1017/S0033291700027355; GOODRIDGE DMG, 1983, BRIT MED J, V287, P645, DOI 10.1136/bmj.287.6393.645; Guthmundsson K, 1997, Nord Med, V112, P169; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; Heaney DC, 2002, BMJ-BRIT MED J, V325, P1013, DOI 10.1136/bmj.325.7371.1013; Hemmingsson T, 1999, SOC SCI MED, V49, P1051, DOI 10.1016/S0277-9536(99)00191-4; Hesdorffer DC, 2009, EPILEPSIA, V50, P1102, DOI 10.1111/j.1528-1167.2008.01945.x; Hesdorffer DC, 2005, EPILEPSIA, V46, P1297, DOI 10.1111/j.1528-1167.2005.10705.x; Johnston SC, 2009, LANCET NEUROL, V8, P345, DOI 10.1016/S1474-4422(09)70023-7; Jones IR, 1997, BRIT MED J, V314, P794, DOI 10.1136/bmj.314.7083.794; Kaiboriboon K, 2013, NEUROLOGY, V80, P1942, DOI 10.1212/WNL.0b013e318293e1b4; Kaiser C, 1998, EPILEPSY RES, V30, P247, DOI 10.1016/S0920-1211(98)00007-2; Karp A, 2004, AM J EPIDEMIOL, V159, P175, DOI 10.1093/aje/kwh018; KERANEN T, 1993, BRIT MED J, V307, P483, DOI 10.1136/bmj.307.6902.483; Kotsopoulos IAW, 2002, EPILEPSIA, V43, P1402, DOI 10.1046/j.1528-1157.2002.t01-1-26901.x; Logroscino G, 2005, EPILEPSIA, V46, P3, DOI 10.1111/j.1528-1167.2005.00399.x; Meyer AC, 2010, B WORLD HEALTH ORGAN, V88, P260, DOI 10.2471/BLT.09.064147; Modi AC, 2011, JAMA-J AM MED ASSOC, V305, P1669, DOI 10.1001/jama.2011.506; Morgan CLI, 2000, J NEUROL NEUROSUR PS, V69, P13, DOI 10.1136/jnnp.69.1.13; Mu J, 2011, NEUROLOGY, V77, P132, DOI 10.1212/WNL.0b013e318223c784; Ngugi AK, 2011, NEUROLOGY, V77, P1005, DOI 10.1212/WNL.0b013e31822cfc90; Nguyen AT, 2010, EPILEPSIA, V51, P2377, DOI 10.1111/j.1528-1167.2010.02699.x; Nicoletti A, 2009, EPILEPSIA, V50, P2199, DOI 10.1111/j.1528-1167.2009.02174.x; Noronha ALA, 2007, EPILEPSIA, V48, P880, DOI 10.1111/j.1528-1167.2006.00974.x; PLACENCIA M, 1992, BRAIN, V115, P771, DOI 10.1093/brain/115.3.771; PLACENCIA M, 1994, J NEUROL NEUROSUR PS, V57, P320, DOI 10.1136/jnnp.57.3.320; SANDER JWAS, 1987, J NEUROL NEUROSUR PS, V50, P829, DOI 10.1136/jnnp.50.7.829; SENANAYAKE N, 1993, B WORLD HEALTH ORGAN, V71, P247; SHAMANSKY SL, 1979, EPILEPSIA, V20, P457, DOI 10.1111/j.1528-1157.1979.tb04828.x; Sillanpaa M, 2006, BRAIN, V129, P617, DOI 10.1093/brain/awh726; TEKLEHAIMANOT R, 1990, EPILEPSY RES, V7, P230, DOI 10.1016/0920-1211(90)90020-V; Thurman DJ, 2011, EPILEPSIA, V52, P2, DOI 10.1111/j.1528-1167.2011.03121.x; Tuan NA, 2008, EPILEPSIA, V49, P1634, DOI 10.1111/j.1528-1167.2008.01663.x; Vrijheid M, 2000, ARCH DIS CHILD, V82, P349, DOI 10.1136/adc.82.5.349; WATTS AE, 1992, EPILEPSIA, V33, P464, DOI 10.1111/j.1528-1157.1992.tb01692.x	50	39	41	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	JUL	2014	55	7					963	967		10.1111/epi.12579			5	Clinical Neurology	Neurosciences & Neurology	AN4YI	WOS:000340595500007	24966095	Bronze			2021-06-18	
J	Lee, S; Kim, J; Seo, SG; Choi, BR; Han, JS; Lee, KW; Kim, J				Lee, Siyoung; Kim, Jisung; Seo, Sang Gwon; Choi, Bo-Ryoung; Han, Jung-Soo; Lee, Ki Won; Kim, Jiyoung			Sulforaphane alleviates scopolamine-induced memory impairment in mice	PHARMACOLOGICAL RESEARCH			English	Article						Sulforaphane; Memory; Acetylcholine; Acetylcholinesterase; Choline acetyltransferase	CHOLINE-ACETYLTRANSFERASE ACTIVITY; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; NEUROTROPHIC FACTOR; GENE-EXPRESSION; RAT-BRAIN; ACETYLCHOLINE; NEURONS; DIFFERENTIATION; MODEL	Sulforaphane, an organosulfur compound present in cruciferous vegetables, has been shown to exert neuroprotective effects in experimental in vitro and in vivo models of neurodegeneration. To determine whether sulforaphane can preserve cognitive function, we examined its effects on scopolamine-induced memory impairment in mice using the Morris water maze test. Sulforaphane (10 or 50 mg/kg) was administered to C57BL/6 mice by oral gavage for 14 days (days 1-14), and memory impairment was induced by intraperitoneal injection of scopolamine (1 mg/kg) for 7 days (days 8-14). Mice that received scopolamine alone showed impaired learning and memory retention and considerably decreased cholinergic system reactivity in the hippocampus and frontal cortex, as indicated by a decreased acetylcholine (ACh) level and an increased acetylcholinesterase (AChE) activity. Sulforaphane significantly attenuated the scopolamine-induced memory impairment and improved cholinergic system reactivity, as indicated by an increased ACh level, decreased AChE activity, and increased choline acetyltransferase (ChAT) expression in the hippocampus and frontal cortex. These effects of sulforaphane on cholinergic system reactivity were confirmed in vitro. Sulforaphane (10 or 20 mu M) increased the ACh level, decreased the AChE activity, and increased ChAT expression in scopolamine-treated primary cortical neurons. These observations suggest that sulforaphane might exert a significant neuroprotective effect on cholinergic deficit and cognitive impairment. (C) 2014 Published by Elsevier Ltd.	[Lee, Siyoung; Kim, Jisung; Seo, Sang Gwon; Lee, Ki Won] Seoul Natl Univ, Dept Agr Biotechnol, WCU Biomodulat Major, Seoul 151742, South Korea; [Choi, Bo-Ryoung; Han, Jung-Soo] Konkuk Univ, Dept Biol Sci, Seoul 143701, South Korea; [Lee, Ki Won; Kim, Jiyoung] Seoul Natl Univ, Ctr Food & Bioconvergence, Seoul 151921, South Korea; [Seo, Sang Gwon; Lee, Ki Won] Seoul Natl Univ, Adv Inst Convergence Technol, Suwon 443270, South Korea; [Lee, Ki Won] Seoul Natl Univ, Inst Green Bio Sci & Technol, Res Inst Bio Food Ind, Pyeongchang 232916, South Korea; [Kim, Jiyoung] Seoul Natl Univ, Coll Vet Med, Res Inst Vet Sci, Toxicol Lab, Seoul 151742, South Korea	Kim, J (corresponding author), Seoul Natl Univ, Coll Vet Med, Res Inst Vet Sci, Toxicol Lab, Seoul 151742, South Korea.	kiwon@snu.ac.kr; jiyoungkim1107@snu.ac.kr	Kim, Jiyoung/A-9934-2014; Lee, Ki Won/M-4114-2018	Kim, Jiyoung/0000-0002-2999-3320; 	Basic Science Research Program, the National Research Foundation, Ministry of Education, Science and Technology, Republic of Korea [2012R1A1A3011954]	This project was funded by the Basic Science Research Program (2012R1A1A3011954), the National Research Foundation, Ministry of Education, Science and Technology, Republic of Korea.	ABE E, 1991, PSYCHOPHARMACOLOGY, V105, P310, DOI 10.1007/BF02244423; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BLUSZTAJN JK, 1983, SCIENCE, V221, P614, DOI 10.1126/science.6867732; Brandon EP, 2004, J NEUROSCI, V24, P5459, DOI 10.1523/JNEUROSCI.1106-04.2004; Burgess A, 2006, J NEUROCHEM, V99, P797, DOI 10.1111/j.1471-4159.2006.04110.x; Dash PK, 2009, NEUROSCI LETT, V460, P103, DOI 10.1016/j.neulet.2009.04.028; DAWSON GR, 1992, BEHAV PHARMACOL, V3, P285; Dinkova-Kostova AT, 2012, TRENDS MOL MED, V18, P337, DOI 10.1016/j.molmed.2012.04.003; Dong ZH, 2012, EUR J PHARMACOL, V683, P174, DOI 10.1016/j.ejphar.2012.03.009; Eichenbaum H, 1997, SCIENCE, V277, P330, DOI 10.1126/science.277.5324.330; Fu AL, 2005, BIOCHEM BIOPH RES CO, V336, P268, DOI 10.1016/j.bbrc.2005.07.199; Gasper AV, 2005, AM J CLIN NUTR, V82, P1283; Giacobini E, 2004, PHARMACOL RES, V50, P433, DOI 10.1016/j.phrs.2003.11.017; GIOVANNINI MG, 1991, PHARMACOL RES, V24, P395, DOI 10.1016/1043-6618(91)90044-X; Hartmann J, 2008, NEUROCHEM INT, V52, P972, DOI 10.1016/j.neuint.2007.10.008; Hirokawa S, 1996, J ETHNOPHARMACOL, V50, P77, DOI 10.1016/0378-8741(95)01332-6; Hu R, 2004, J PHARMACOL EXP THER, V310, P263, DOI 10.1124/jpet.103.064261; Huang L, 2013, CURR TOP MED CHEM, V13, P1864, DOI 10.2174/15680266113139990142; Iversen SD, 1997, LIFE SCI, V60, P1145, DOI 10.1016/S0024-3205(97)00059-3; JOHNSON JA, 1994, J BIOL CHEM, V269, P18856; Kim HV, 2013, AMYLOID, V20, P7, DOI 10.3109/13506129.2012.751367; Kitiyanant N, 2012, NEUROCHEM RES, V37, P143, DOI 10.1007/s11064-011-0592-1; Mohapel P, 2005, NEUROBIOL AGING, V26, P939, DOI 10.1016/j.neurobiolaging.2004.07.015; MOLCHAN SE, 1992, BRAIN RES REV, V17, P215, DOI 10.1016/0165-0173(92)90017-G; Morroni F, 2013, NEUROTOXICOLOGY, V36, P63, DOI 10.1016/j.neuro.2013.03.004; Oda Y, 1999, PATHOL INT, V49, P921, DOI 10.1046/j.1440-1827.1999.00977.x; Pardridge WM, 2007, DRUG DISCOV TODAY, V12, P54, DOI 10.1016/j.drudis.2006.10.013; Park HM, 2009, ARCH PHARM RES, V32, P109, DOI 10.1007/s12272-009-1124-2; Pepeu G, 2004, LEARN MEMORY, V11, P21, DOI 10.1101/lm.68104; RAY J, 1993, P NATL ACAD SCI USA, V90, P3602, DOI 10.1073/pnas.90.8.3602; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; Terry AV, 2003, J PHARMACOL EXP THER, V306, P821, DOI 10.1124/jpet.102.041616; Vauzour D, 2010, MOL NUTR FOOD RES, V54, P532, DOI 10.1002/mnfr.200900197; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; Zambrzycka A, 2002, NEUROCHEM RES, V27, P277, DOI 10.1023/A:1014951010834; Zhang YS, 2005, FREE RADICAL BIO MED, V38, P70, DOI 10.1016/j.freeradbiomed.2004.09.033; Zhao J, 2006, NEUROSCI LETT, V393, P108, DOI 10.1016/j.neulet.2005.09.065; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649	38	39	40	1	22	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	1043-6618			PHARMACOL RES	Pharmacol. Res.	JUL	2014	85						23	32		10.1016/j.phrs.2014.05.003			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AK4QS	WOS:000338409800005	24836869				2021-06-18	
J	Torrente, D; Avila, MF; Cabezas, R; Morales, L; Gonzalez, J; Samudio, I; Barreto, GE				Torrente, D.; Avila, M. F.; Cabezas, R.; Morales, L.; Gonzalez, J.; Samudio, I.; Barreto, G. E.			Paracrine factors of human mesenchymal stem cells increase wound closure and reduce reactive oxygen species production in a traumatic brain injury in vitro model	HUMAN & EXPERIMENTAL TOXICOLOGY			English	Article						Traumatic brain injury; mesenchymal stem cells; wound closure; reactive oxygen species	NEONATAL ISCHEMIC BRAIN; LOW-DENSITY-LIPOPROTEIN; BONE-MARROW; GLUCOSE DEPRIVATION; STROMAL CELLS; NERVOUS-SYSTEM; ADIPOSE-TISSUE; ASTROCYTES; MIGRATION; RAT	Traumatic brain injury (TBI) consists of a primary and a secondary insult characterized by a biochemical cascade that plays a crucial role in cell death in the brain. Despite the major improvements in the acute care of head injury victims, no effective strategies exist for preventing the secondary injury cascade. This lack of success might be due to that most treatments are aimed at targeting neuronal population, even if studies show that astrocytes play a key role after a brain damage. In this work, we propose a new model of in vitro traumatic brain-like injury and use paracrine factors released by human mesenchymal stem cells (hMSCs) as a neuroprotective strategy. Our results demonstrate that hMSC-conditioned medium increased wound closure and proliferation at 12 h and reduced superoxide production to control conditions. This was accompanied by changes in cell morphology and polarity index, as both parameters reflect the ability of cells to migrate toward the wound. These findings indicate that hMSC is an important regulator of oxidative stress production, enhances cells migration, and shall be considered as a useful neuroprotective approach for brain recovery following injury.	[Torrente, D.; Avila, M. F.; Cabezas, R.; Morales, L.; Gonzalez, J.; Samudio, I.; Barreto, G. E.] Pontificia Univ Javeriana, Dept Nutr & Bioquim, Fac Ciencias, Bogota, Colombia	Barreto, GE (corresponding author), Pontificia Univ Javeriana, Dept Nutr & Bioquim, Fac Ciencias, Bogota, Colombia.	gsampaio@javeriana.edu.co	Morales, Ludis/AAZ-7053-2020; Barreto, George E./AAD-7420-2020; Janneth Gonzalez Santos, M.Sc./AAB-9948-2020; Barreto, George E./B-5747-2014; Samudio, Ismael/D-3581-2013	Barreto, George E./0000-0002-6644-1971; Janneth Gonzalez Santos, M.Sc./0000-0003-2009-3374; Barreto, George E./0000-0002-6644-1971; Samudio, Ismael/0000-0001-8676-1035; Gonzalez, Janneth/0000-0003-4482-256X	PUJ [4327, 4367]	This work was supported in part by grants PUJ IDs 4327 and 4367 to GEB.	Allen JW, 1999, FASEB J, V13, P1875; Bonmati-Carrion MA, 2013, INT J MOL SCI, V14, P3901, DOI 10.3390/ijms14023901; AOKI H, 1993, NEUROSCIENCE, V56, P345, DOI 10.1016/0306-4522(93)90336-E; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bourguignon LYW, 2007, J NEUROCHEM, V101, P1002, DOI 10.1111/j.1471-4159.2007.04485.x; Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886; Caraballo-Miralles V, 2012, MOL CELL NEUROSCI, V49, P282, DOI 10.1016/j.mcn.2011.12.003; Chen SL, 2004, AM J CARDIOL, V94, P92, DOI 10.1016/j.amjcard.2004.03.034; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; de Joannon AC, 2000, NEUROSCI LETT, V285, P218, DOI 10.1016/S0304-3940(00)01051-X; Dhandapani KM, 2003, J BIOL CHEM, V278, P43329, DOI 10.1074/jbc.M305835200; Freeman MR, 2010, SCIENCE, V330, P774, DOI 10.1126/science.1190928; Gasque P, 1996, J IMMUNOL, V156, P2247; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gnecchi M, 2005, NAT MED, V11, P367, DOI 10.1038/nm0405-367; Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com; Hall MK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019317; Hawker KM, 1998, AM J PHYSIOL-LUNG C, V275, pL469; Izadpanah R, 2006, J CELL BIOCHEM, V99, P1285, DOI 10.1002/jcb.20904; Jo I, 2002, BIOCHEM BIOPH RES CO, V299, P102, DOI 10.1016/S0006-291X(02)02599-8; Jorgensen P, 2004, CURR BIOL, V14, pR1014, DOI 10.1016/j.cub.2004.11.027; Kimelberg HK, 2010, NEUROTHERAPEUTICS, V7, P338, DOI 10.1016/j.nurt.2010.07.006; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kurozumi K, 2005, MOL THER, V11, P96, DOI 10.1016/j.ymthe.2004.09.020; Lamers ML, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022865; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lee RH, 2006, P NATL ACAD SCI USA, V103, P17438, DOI 10.1073/pnas.0608249103; Lee SH, 2012, ANN DERMATOL, V24, P136, DOI 10.5021/ad.2012.24.2.136; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Lin Q, 2010, EXP LUNG RES, V36, P120, DOI 10.3109/01902140903214659; Mao XR, 2006, J BIOL CHEM, V281, P35863, DOI 10.1074/jbc.M604166200; Milusheva EA, 1996, NEUROCHEM INT, V28, P501, DOI 10.1016/0197-0186(95)00129-8; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; National Center for Injury Prevention and Control (CDC), 1999, EP TRAUM BRAIN INJ U; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Ouyang YB, 2007, J NEUROSCI, V27, P4253, DOI 10.1523/JNEUROSCI.0211-07.2007; Ouyang YB, 2006, CELL STRESS CHAPERON, V11, P180, DOI 10.1379/CSC-182R.1; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Qu RJ, 2007, NEUROPATHOLOGY, V27, P355, DOI 10.1111/j.1440-1789.2007.00792.x; Robin AM, 2006, J CEREBR BLOOD F MET, V26, P125, DOI 10.1038/sj.jcbfm.9600172; Rosado JA, 2002, CELL SIGNAL, V14, P547, DOI 10.1016/S0898-6568(01)00273-X; Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870; Seo SY, 1999, J NEUROSCI, V19, P8849, DOI 10.1523/JNEUROSCI.19-20-08849.1999; Stumm R, 2007, J MOL ENDOCRINOL, V38, P377, DOI 10.1677/JME-06-0032; van Aalst JA, 2004, J VASC SURG, V40, P1208, DOI 10.1016/j.jvs.2004.09.020; van Velthoven CTJ, 2012, PEDIATR RES, V71, P474, DOI 10.1038/pr.2011.64; van Velthoven CTJ, 2011, BRAIN BEHAV IMMUN, V25, P1342, DOI 10.1016/j.bbi.2011.03.021; van Velthoven CTJ, 2010, J NEUROSCI, V30, P9603, DOI 10.1523/JNEUROSCI.1835-10.2010; Walter MNM, 2010, EXP CELL RES, V316, P1271, DOI 10.1016/j.yexcr.2010.02.026; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105	56	39	40	0	6	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0960-3271	1477-0903		HUM EXP TOXICOL	Hum. Exp. Toxicol.	JUL	2014	33	7					673	684		10.1177/0960327113509659			12	Toxicology	Toxicology	AJ9GL	WOS:000338015700001	24178889				2021-06-18	
J	Wilcox, BJ; Machan, JT; Beckwith, JG; Greenwald, RM; Burmeister, E; Crisco, JJ				Wilcox, Bethany J.; Machan, Jason T.; Beckwith, Jonathan G.; Greenwald, Richard M.; Burmeister, Emily; Crisco, Joseph J.			Head-Impact Mechanisms in Men's and Women's Collegiate Ice Hockey	JOURNAL OF ATHLETIC TRAINING			English	Article						impact biomechanics; sport; concussion; sex	INJURY SURVEILLANCE SYSTEM; FOOTBALL PLAYERS; DESCRIPTIVE EPIDEMIOLOGY; CONCUSSION; EXPOSURE; ACCELERATION; MAGNITUDE; SEVERITY; LOCATION	Context: Concussion injury rates in men's and women's ice hockey are reported to be among the highest of all collegiate sports. Quantification of the frequency of head impacts and the magnitude of head acceleration as a function of the different impact mechanisms (eg, head contact with the ice) that occur in ice hockey could provide a better understanding of this high injury rate. Objective: To quantify and compare the per-game frequency and magnitude of head impacts associated with various impact mechanisms in men's and women's collegiate ice hockey players. Design: Cohort study. Setting: Collegiate ice hockey rink. Patients or Other Participants: Twenty-three men and 31 women from 2 National Collegiate Athletic Association Division I ice hockey teams. Main Outcome Measure(s): We analyzed magnitude and frequency (per game) of head impacts per player among impact mechanisms and between sexes using generalized mixed linear models and generalized estimating equations to account for repeated measures within players. Intervention(s): Participants wore helmets instrumented with accelerometers to allow us to collect biomechanical measures of head impacts sustained during play. Video footage from 53 games was synchronized with the biomechanical data. Head impacts were classified into 8 categories: contact with another player; the ice, boards or glass, stick, puck, or goal; indirect contact; and contact from celebrating. Results: For men and women, contact with another player was the most frequent impact mechanism, and contact with the ice generated the greatest-magnitude head accelerations. The men had higher per-game frequencies of head impacts from contact with another player and contact with the boards than did the women (P < .001), and these impacts were greater in peak rotational acceleration (P = .027). Conclusions: Identifying the impact mechanisms in collegiate ice hockey that result in frequent and high-magnitude head impacts will provide us with data that may improve our understanding of the high rate of concussion in the sport and inform injury-prevention strategies.	[Wilcox, Bethany J.; Machan, Jason T.; Crisco, Joseph J.] Brown Univ, Dept Orthopaed, Alpert Med Sch, Bioengn Lab, Providence, RI 02903 USA; [Wilcox, Bethany J.; Machan, Jason T.; Crisco, Joseph J.] Brown Univ, Rhode Isl Hosp, Providence, RI 02903 USA; [Burmeister, Emily] Brown Univ, Dept Athlet Training, Providence, RI 02903 USA; [Beckwith, Jonathan G.; Greenwald, Richard M.] Simbex, Lebanon, NH USA; [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA	Wilcox, BJ (corresponding author), Brown Univ, Dept Orthopaed, Alpert Med Sch, Bioengn Lab, Suite 404,1 Hoppin St, Providence, RI 02903 USA.	Bethany_Wilcox@brown.edu	Machan, Jason T/D-3897-2013; Burmeister, Elizabeth/B-9176-2008	Machan, Jason T/0000-0003-2048-4914; Burmeister, Elizabeth/0000-0003-2720-2596	National Collegiate Athletic Association; National Collegiate Athletic Association, National Institute of Health [R01HD048638]; National Operating Committee on Standards for Athletic Equipment; National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R25GM083270, R25GM083270-S1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM104937, R25GM083270] Funding Source: NIH RePORTER	Funding for this study was provided by the National Collegiate Athletic Association, National Institute of Health (R01HD048638), National Operating Committee on Standards for Athletic Equipment, and National Institute of General Medical Sciences (R25GM083270 and R25GM083270-S1). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, National Collegiate Athletic Association, or National Operating Committee on Standards for Athletic Equipment.	Agel J, 2007, J ATHL TRAINING, V42, P241; Agel J, 2007, J ATHL TRAINING, V42, P249; Agel J, 2010, CAN J SURG, V53, P319; Arndt SR, 2004, P HUMAN FACTOR ERGON, V48, P1973; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Hutchison M., 2011, THESIS U TORONTO ONT; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Mihalik JP, 2008, P I MECH ENG P-J SPO, V222, P45, DOI 10.1243/17543371JSET4; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2010, MED SCI SPORT EXER, V42, P1431, DOI 10.1249/MSS.0b013e3181d2521a; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schick DM, 2003, AM J SPORT MED, V31, P47, DOI 10.1177/03635465030310011901; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Tegner Y, 1991, Br J Sports Med, V25, P87	30	39	39	0	25	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-AUG	2014	49	4					514	520		10.4085/1062-6050-49.3.19			7	Sport Sciences	Sport Sciences	AQ4LO	WOS:000342768700011	25098659	Green Published			2021-06-18	
J	Dettmer, J; Ettel, D; Glang, A; McAvoy, K				Dettmer, Judy; Ettel, Deborah; Glang, Ann; McAvoy, Karen			Building Statewide Infrastructure for Effective Educational Services for Students With TBI: Promising Practices and Recommendations	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						education; interventions; traumatic brain injury; special education; school children	TRAUMATIC BRAIN-INJURY; COGNITIVE REHABILITATION; PROFESSIONAL-DEVELOPMENT; PARENTAL INVOLVEMENT; SUBSTANCE-ABUSE; SCREENING TOOL; UNITED-STATES; CHILDREN; IDENTIFICATION; RELIABILITY	Objective: To identify promising practices in educational service delivery. Methods: Consensus-building process with a multidisciplinary group of researchers, policy makers, and state Department of Education personnel. Results: This white paper presents the group's consensus on the essential components of a statewide educational infrastructure to support students with traumatic brain injury across the spectrum of injury severity: (a) identification, screening, and assessment practices; (b) systematic communication between medical and educational systems; (c) tracking of child's progress over time; and (d) professional development for school personnel. The white paper also presents key outcomes for measuring success and provides recommendations both for policy change and for furthering research in childhood brain injury.	[Dettmer, Judy] Colorado Dept Human Serv, Div Vocat Rehabil, Brain Injury Program, Denver, CO 80203 USA; [Ettel, Deborah; Glang, Ann] Univ Oregon, Ctr Brain Injury Res & Training, Eugene, OR 97403 USA; [McAvoy, Karen] Rocky Mt Hosp Children, Colorado Dept Educ, Denver, CO USA; [McAvoy, Karen] Rocky Mt Hosp Children, Ctr Concuss, Denver, CO USA	Dettmer, J (corresponding author), Colorado Dept Human Serv, Div Vocat Rehabil, 1575 Sherman St,4th Floor, Denver, CO 80203 USA.	judy.dettmer@state.co.us					Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Benedict EA, 2007, TOP EARLY CHILD SPEC, V27, P174, DOI 10.1177/02711214070270030801; Blosser J, 1997, J HEAD TRAUMA REHAB, V12, P21, DOI 10.1097/00001199-199704000-00004; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Borko H., 2004, EDUC RESEARCHER, V33, P3, DOI [DOI 10.3102/0013189X033008003, 10.3102/0013189X033008003]; Bowen JM, 2005, PREV SCH FAIL, V49, P34, DOI 10.3200/PSFL.49.4.34-41; Cantor JB, 2004, ARCH PHYS MED REHAB, V85, pS54, DOI 10.1016/j.apmr.2003.08.113; Cantor JB, 2006, J HEAD TRAUMA REHAB, V21, P424, DOI 10.1097/00001199-200609000-00039; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Clark E, 1996, J LEARN DISABIL, V29, P549, DOI 10.1177/002221949602900509; Cleary M., 2010, J SCH HLTH, V81, P1; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Darling-Hammond L.C., 2009, J STAFF DEV, V30, P42; Data Accountability Center, 2011, NUMB STUD AG 6 21 B; Dettmer JL, 2007, J HEAD TRAUMA REHAB, V22, P339, DOI 10.1097/01.HTR.0000300229.13490.c7; DiScala C, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199704000-00002; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Ettel D, 2012, NASDSE TBI SURVEY; Fan XT, 2001, EDUC PSYCHOL REV, V13, P1, DOI 10.1023/A:1009048817385; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fixsen DL, 2005, FMHI PUBLICATION, V231; FUCHS LS, 1992, SCHOOL PSYCHOL REV, V21, P45; Garet MS, 2001, AM EDUC RES J, V38, P915, DOI 10.3102/00028312038004915; Georgia Department of Education, TRAUM BRAIN INJ RUL; GERSTEN RM, 1982, ANAL INTERVEN DEVEL, V2, P305, DOI 10.1016/0270-4684(82)90026-X; Gersten R, 2009, REV EDUC RES, V79, P1202, DOI 10.3102/0034654309334431; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Glang A, 2011, FED INT C TBI JUN 13; Glang A, 2008, J HEAD TRAUMA REHAB, V23, P243, DOI 10.1097/01.HTR.0000327256.46504.9f; Glang A, 2007, J HEAD TRAUMA REHAB, V22, P198, DOI 10.1097/01.HTR.0000271121.42523.3a; Glang A, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P602; Glang A, 2010, J HEAD TRAUMA REHAB, V25, P426, DOI 10.1097/HTR.0b013e3181fb8f45; Glang A, 2008, NEUROREHABILITATION, V23, P477; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Gordon WA, 2011, NATO SCI PEACE SEC, V86, P31, DOI 10.3233/978-1-60750-797-0-31; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Jeynes WH, 2005, URBAN EDUC, V40, P237, DOI 10.1177/0042085905274540; Laatsch L, 2007, J HEAD TRAUMA REHAB, V22, P248, DOI 10.1097/01.HTR.0000281841.92720.0a; Lash M, 1993, NeuroRehabilitation, V3, P13, DOI 10.3233/NRE-1993-3304; Limond J, 2005, J CHILD PSYCHOL PSYC, V46, P339, DOI 10.1111/j.1469-7610.2004.00397.x; McAvoy K., 2012, COMMUNIQUE, V40, P23; Mohr JD, 2005, PREV SCH FAIL, V49, P53, DOI 10.3200/PSFL.49.4.53-57; Noell GH, 1997, SCHOOL PSYCHOL QUART, V12, P77, DOI 10.1037/h0088949; Odom SL, 2009, TOP EARLY CHILD SPEC, V29, P53, DOI 10.1177/0271121408329171; Sacks AL, 2009, J DUAL DIAGN, V5, P404, DOI 10.1080/15504260903182755; Sailors M, 2010, ELEM SCHOOL J, V110, P301, DOI 10.1086/648980; Savage R. C., 2003, BRAIN INJ SOURCE, V6, P8; Savage RC, 2001, NEUROREHABILITATION, V16, P49; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Slomine B, 2009, DEV DISABIL RES REV, V15, P133, DOI 10.1002/ddrr.56; Sohlberg McKay Moore, 2005, Seminars in Speech and Language, V26, P268, DOI 10.1055/s-2005-922105; Stein M., 2006, DESIGNING EFFECTIVE; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG., 2006, EXCEPTIONALITY, V14, P141, DOI [10.1207/s15327035ex1403_3, DOI 10.1207/S15327035EX1403_3, DOI 10.1207/S15327035EX1403_]; Turkstra LS, 2008, NEUROREHABILITATION, V23, P501; U.S. Department of Education, 2001, NO CHILD LEFT; US Government Accountability Office, 2008, REP CONGR REQ V A HL; Vaidya A., 2002, COGNITIVE TECHNOLOGY, V7, P38; Walker NW, 1999, CHILD NEUROPSYCHOL, V5, P137, DOI 10.1076/chin.5.2.137.3168; Walker R, 2007, J HEAD TRAUMA REHAB, V22, P360, DOI 10.1097/01.HTR.0000300231.90619.50; WEEKS M, 1981, J APPL BEHAV ANAL, V14, P449, DOI 10.1901/jaba.1981.14-449; Ylvisaker M, 2001, J HEAD TRAUMA REHAB, V16, P76, DOI 10.1097/00001199-200102000-00009; Ylvisaker Mark, 2005, Seminars in Speech and Language, V26, P256, DOI 10.1055/s-2005-922104; Yoon K.S., 2007, REV EVIDENCE TEACHER; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	68	39	39	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2014	29	3					224	232		10.1097/HTR.0b013e3182a1cd68			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AG9SE	WOS:000335759100010	23982791				2021-06-18	
J	Spittle, AJ; Thompson, DK; Brown, NC; Treyvaud, K; Cheong, JLY; Lee, KJ; Pace, CC; Olsen, J; Allinson, LG; Morgan, AT; Seal, M; Eeles, A; Judd, F; Doyle, LW; Anderson, PJ				Spittle, Alicia J.; Thompson, Deanne K.; Brown, Nisha C.; Treyvaud, Karli; Cheong, Jeanie L. Y.; Lee, Katherine J.; Pace, Carmen C.; Olsen, Joy; Allinson, Leesa G.; Morgan, Angela T.; Seal, Marc; Eeles, Abbey; Judd, Fiona; Doyle, Lex W.; Anderson, Peter J.			Neurobehaviour between birth and 40 weeks' gestation in infants born < 30 weeks' gestation and parental psychological wellbeing: predictors of brain development and child outcomes	BMC PEDIATRICS			English	Article						Preterm; Neurobehaviour; Magnetic resonance imaging; Neurodevelopment; Parent mental health; Parent-child interaction	INTENSIVE-CARE-UNIT; PRETERM INFANTS; WEIGHT INFANTS; EMOTIONAL AVAILABILITY; POSTPARTUM DEPRESSION; PREMATURE-INFANTS; MOTOR DEVELOPMENT; HOSPITAL ANXIETY; RISK-FACTORS; TERM	Background: Infants born < 30 weeks' gestation are at increased risk of long term neurodevelopmental problems compared with term born peers. The predictive value of neurobehavioural examinations at term equivalent age in very preterm infants has been reported for subsequent impairment. Yet there is little knowledge surrounding earlier neurobehavioural development in preterm infants prior to term equivalent age, and how it relates to perinatal factors, cerebral structure, and later developmental outcomes. In addition, maternal psychological wellbeing has been associated with child development. Given the high rate of psychological distress reported by parents of preterm children, it is vital we understand maternal and paternal wellbeing in the early weeks and months after preterm birth and how this influences the parent-child relationship and children's outcomes. Therefore this study aims to examine how 1) early neurobehaviour and 2) parental mental health relate to developmental outcomes for infants born preterm compared with infants born at term. Methods/Design: This prospective cohort study will describe the neurobehaviour of 150 infants born at < 30 weeks' gestational age from birth to term equivalent age, and explore how early neurobehavioural deficits relate to brain growth or injury determined by magnetic resonance imaging, perinatal factors, parental mental health and later developmental outcomes measured using standardised assessment tools at term, one and two years' corrected age. A control group of 150 healthy term-born infants will also be recruited for comparison of outcomes. To examine the effects of parental mental health on developmental outcomes, both parents of preterm and term-born infants will complete standardised questionnaires related to symptoms of anxiety, depression and post-traumatic stress at regular intervals from the first week of their child's birth until their child's second birthday. The parent-child relationship will be assessed at one and two years' corrected age. Discussion: Detailing the trajectory of infant neurobehaviour and parental psychological distress following very preterm birth is important not only to identify infants most at risk, further understand the parental experience and highlight potential times for intervention for the infant and/or parent, but also to gain insight into the effect this has on parent-child interaction and child development.	[Spittle, Alicia J.; Thompson, Deanne K.; Brown, Nisha C.; Treyvaud, Karli; Cheong, Jeanie L. Y.; Lee, Katherine J.; Pace, Carmen C.; Olsen, Joy; Allinson, Leesa G.; Seal, Marc; Eeles, Abbey; Doyle, Lex W.; Anderson, Peter J.] Murdoch Childrens Res Inst, Victorian Infant Brain Studies, Parkville, Vic 3052, Australia; [Spittle, Alicia J.; Allinson, Leesa G.] Univ Melbourne, Sch Hlth Sci, Dept Physiotherapy, Carlton, Vic 3053, Australia; [Spittle, Alicia J.; Cheong, Jeanie L. Y.; Judd, Fiona] Royal Womens Hosp, Serv Neonatol, Parkville, Vic 3052, Australia; [Thompson, Deanne K.; Treyvaud, Karli; Lee, Katherine J.; Morgan, Angela T.; Seal, Marc; Doyle, Lex W.; Anderson, Peter J.] Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia; [Cheong, Jeanie L. Y.; Olsen, Joy; Doyle, Lex W.; Anderson, Peter J.] Univ Melbourne, Dept Obstet & Gynaecol, Parkville, Vic 3052, Australia; [Pace, Carmen C.] Univ Melbourne, Melbourne Sch Psychol Sci, Parkville, Vic 3010, Australia; [Morgan, Angela T.] Murdoch Childrens Res Inst, Language & Literacy Grp, Parkville, Vic 3052, Australia	Spittle, AJ (corresponding author), Murdoch Childrens Res Inst, Victorian Infant Brain Studies, 4th Floor,Flemington Rd, Parkville, Vic 3052, Australia.	alicia.spittle@mcri.edu.au	Thompson, Deanne/W-7177-2019; Thompson, Deanne K/A-9502-2018; Anderson, Peter John/O-5302-2019; Lee, Katherine J/A-2519-2016; Anderson, Peter J/B-6839-2015; Olsen, Jorn/F-8801-2015; Seal, Marc L/J-9290-2019; Morgan, Angela/J-5235-2017	Thompson, Deanne/0000-0001-8017-5756; Thompson, Deanne K/0000-0001-8017-5756; Anderson, Peter John/0000-0001-7430-868X; Anderson, Peter J/0000-0001-7430-868X; Olsen, Jorn/0000-0001-7462-5140; Seal, Marc L/0000-0002-8396-140X; Morgan, Angela/0000-0003-1147-7405; Spittle, Alicia/0000-0002-6535-661X; Doyle, Lex/0000-0002-7667-7312; Brown, Nisha/0000-0002-2953-8045; Cheong, Jeanie/0000-0001-5901-0455	National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia [1024516]; Victorian Government's Operational Infrastructure Support Program; Early Career Fellowship [1053767]; Centre for Clinical Research Excellence [546519]; Centre for Research Excellence [1060733]; Senior Research Fellowship [628371]	This study is funded by grants from the National Health and Medical Research Council (NHMRC: Project Grant 1024516; Early Career Fellowship 1053767; Centre for Clinical Research Excellence 546519; Centre for Research Excellence 1060733, Senior Research Fellowship 628371). The Murdoch Childrens Research Institute is supported by the Victorian Government's Operational Infrastructure Support Program.; We would like to acknowledge Merilyn Bear, Emma McInnes, Brenda Argus, Bernice Mills and Nicole vander Linden for their input into recruitment of infants and their families for this study.	Abidin RR., 1995, PARENTING STRESS IND; Als H, 2004, PEDIATRICS, V113, P846, DOI 10.1542/peds.113.4.846; AMIELTISON C, 2001, FETAL NEONATAL NEURO, P99; Bayley N., 2005, BAYLEY SCALES INFANT, VThird; Bigsby R, 1996, INFANT BEHAV DEV, V19, P295, DOI 10.1016/S0163-6383(96)90030-2; Biringen Z, 2000, AM J ORTHOPSYCHIAT, V70, P104, DOI 10.1037/h0087711; Biringen Z., 2008, EMOTIONAL AVAILABILI, V4th; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Bornstein MH, 2006, INFANCY, V10, P1, DOI 10.1207/s15327078in1001_1; Brown NC, 2014, CURR PEDIAT IN PRESS; Brown NC, 2006, PEDIATRICS, V118, P2461, DOI 10.1542/peds.2006-0880; Brown NC, 2009, J PEDIATR-US, V155, P32, DOI 10.1016/j.jpeds.2009.01.038; Burns Y R, 1989, Aust J Physiother, V35, P141, DOI 10.1016/S0004-9514(14)60503-1; Carter A. S., 2000, INFANT TODDLER UNPUB; Carter JD, 2005, ARCH DIS CHILD-FETAL, V90, P109, DOI 10.1136/adc.2003.031641; Cheong JLY, 2009, AM J NEURORADIOL, V30, P623, DOI 10.3174/ajnr.A1399; Costa P., 1992, REVISED NEO PERSONAL; Daily DK, 2005, NEONATAL NETW, V24, P15, DOI 10.1891/0730-0832.24.1.15; Danks M, 2012, EARLY HUM DEV, V88, P637, DOI 10.1016/j.earlhumdev.2012.01.010; Davis Leigh, 2003, Int J Nurs Pract, V9, P374, DOI 10.1046/j.1440-172X.2003.00447.x; Dubowitz L, 1998, J PEDIATR-US, V133, P406, DOI 10.1016/S0022-3476(98)70279-3; DUFFY FH, 1990, CHILD DEV, V61, P1271, DOI 10.2307/1130893; Dunn W, 2002, INFANT TODDLER SENSO; Eadie PA, 2010, INT J LANG COMM DIS, V45, P572, DOI 10.3109/13682820903277944; Easterbrooks M A, 2000, Attach Hum Dev, V2, P123; Eeles AL, 2013, DEV MED CHILD NEUROL, V55, P314, DOI 10.1111/j.1469-8749.2012.04434.x; Einspieler C., 2004, PRECHTLS METHOD QUAL, V167; Endler NS, 1999, COPING INVENTORY STR; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Fenson L., 1993, MACARTHUR BATES COMM; Ferrari F, 2012, J MATERN-FETAL NEO M, V25, P2154, DOI 10.3109/14767058.2012.696164; Forcada-Guex M, 2006, PEDIATRICS, V118, pE107, DOI 10.1542/peds.2005-1145; Goldberg LR., 1999, PERSONALITY PSYCHOL, P7, DOI DOI 10.1016/J.JRP.2014.05.003; Gray RF, 2004, PEDIATRICS, V114, P736, DOI 10.1542/peds.2003-1150-L; Gui L, 2012, MED IMAGE ANAL, V16, P1565, DOI 10.1016/j.media.2012.07.006; Hadders-Algra M, 2010, DEV MED CHILD NEUROL, V52, P87, DOI 10.1111/j.1469-8749.2009.03305.x; Hagmann P, 2010, P NATL ACAD SCI USA, V107, P19067, DOI 10.1073/pnas.1009073107; Hilferty F, 2009, IMPLICATIONS POVERY; Holditch-Davis D, 2003, JOGNN, V32, P161, DOI 10.1177/0884217503252035; Huppi PS, 1996, PEDIATR RES, V39, P895; Jeng SF, 1998, EARLY HUM DEV, V51, P235, DOI 10.1016/S0378-3782(98)00035-8; JOHNSTON C, 1989, J CLIN CHILD PSYCHOL, V18, P167, DOI 10.1207/s15374424jccp1802_8; Kidokoro H, 2013, AM J NEURORADIOL, V34, P2208, DOI 10.3174/ajnr.A3521; Kuklisova-Murgasova M, 2011, NEUROIMAGE, V54, P2750, DOI 10.1016/j.neuroimage.2010.10.019; Lambrenos K, 1996, ARCH DIS CHILD, V74, P115, DOI 10.1136/adc.74.2.115; Le Bihan D, 2003, NAT REV NEUROSCI, V4, P469, DOI 10.1038/nrn1119; Lester BM, 2004, PEDIATRICS, V113, P641; Lester BM, 2004, PEDIATRICS, V113, P634; Miles MS, 2007, J DEV BEHAV PEDIATR, V28, P36, DOI 10.1097/01.DBP.0000257517.52459.7a; Milgrom J, 2010, PEDIATR RES, V67, P330, DOI 10.1203/PDR.0b013e3181cb8e2f; MULROW CD, 1995, ANN INTERN MED, V122, P913, DOI 10.7326/0003-4819-122-12-199506150-00004; Neil J, 2002, NMR BIOMED, V15, P543, DOI 10.1002/nbm.784; Nomura Y, 2002, J AM ACAD CHILD PSY, V41, P402, DOI 10.1097/00004583-200204000-00012; O'Hara MW, 2013, ANNU REV CLIN PSYCHO, V9, P379, DOI 10.1146/annurev-clinpsy-050212-185612; Pinelli J, 2000, Neonatal Netw, V19, P27; Pinelli J, 2008, J NEONATAL NURSING, V14, P156, DOI DOI 10.1016/J.JNN.2008.03.015; Piper M. C., 1994, MOTOR ASSESSMENT DEV; Pridham K, 2005, RES NURS HEALTH, V28, P252, DOI 10.1002/nur.20073; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Roberts G, 2008, J PAEDIATR CHILD H, V44, P276, DOI 10.1111/j.1440-1754.2007.01251.x; Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495, DOI 10.1023/A:1025714729117; Saigal S, 2003, ARCH PEDIAT ADOL MED, V157, P261, DOI 10.1001/archpedi.157.3.261; Saigal S, 2008, LANCET, V371, P261, DOI 10.1016/S0140-6736(08)60136-1; Shah DK, 2006, PEDIATR RES, V60, P97, DOI 10.1203/01.pdr.0000220324.27597.f0; Shields-Poe D, 1997, Neonatal Netw, V16, P29; SKUSE D, 1995, DYSPHAGIA, V10, P192, DOI 10.1007/BF00260976; Smyser CD, 2010, CEREB CORTEX, V20, P2852, DOI 10.1093/cercor/bhq035; Spittle AJ, 2008, DEV MED CHILD NEUROL, V50, P254, DOI 10.1111/j.1469-8749.2008.02025.x; Spittle AJ, 2013, DEV MED CHILD NEUROL, V55, P448, DOI 10.1111/dmcn.12049; Spittle AJ, 2009, PEDIATRICS, V123, P512, DOI 10.1542/peds.2008-0590; Thompson DK, 2008, ANN NEUROL, V63, P642, DOI 10.1002/ana.21367; Thompson DK, 2007, BRAIN, V130, P667, DOI 10.1093/brain/awl277; Thompson DK, 2011, NEUROIMAGE, V55, P479, DOI 10.1016/j.neuroimage.2010.12.025; Tronick E, 2013, J CHILD ADOL PS NURS, V26, P193, DOI 10.1111/jcap.12042; Vigod SN, 2010, BJOG-INT J OBSTET GY, V117, P540, DOI 10.1111/j.1471-0528.2009.02493.x; Volpe J., 2008, NEUROLOGY NEWBORN; WALLACE IF, 1995, J DEV BEHAV PEDIATR, V16, P309; Weathers F.W., 1996, MEASUREMENT STRESS T; Woodward LJ, 2006, NEW ENGL J MED, V355, P685, DOI 10.1056/NEJMoa053792; Zelkowitz P, 2007, INFANT MENT HEALTH J, V28, P296, DOI 10.1002/imhj.20137; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	81	39	40	2	41	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2431			BMC PEDIATR	BMC Pediatr.	APR 24	2014	14								111	10.1186/1471-2431-14-111			13	Pediatrics	Pediatrics	AG7IA	WOS:000335590400001	24758605	DOAJ Gold, Green Published			2021-06-18	
J	Bahraini, NH; Breshears, RE; Hernandez, TD; Schneider, AL; Forster, JE; Brenner, LA				Bahraini, Nazanin H.; Breshears, Ryan E.; Hernandez, Theresa D.; Schneider, Alexandra L.; Forster, Jeri E.; Brenner, Lisa A.			Traumatic Brain Injury and Posttraumatic Stress Disorder	PSYCHIATRIC CLINICS OF NORTH AMERICA			English	Article						Brain injury; Posttraumatic stress; Imaging; Pathophysiology; Evaluation; Treatment	1ST 6 MONTHS; COMBAT VETERANS; ENDURING FREEDOM; HEAD-INJURY; AXIS-I; PSYCHIATRIC-DISORDERS; SERVICE MEMBERS; SOCIAL SUPPORT; RISK-FACTORS; PTSD	Given the upsurge of research in posttraumatic stress disorder (PTSD) and traumatic brain injury (TBI), much of which has focused on military samples who served in Iraq and Afghanistan, the purpose of this article is to review the literature published after September 11th, 2001 that addresses the epidemiology, pathophysiology, evaluation, and treatment of PTSD in the context of TBI.	[Bahraini, Nazanin H.; Hernandez, Theresa D.; Schneider, Alexandra L.; Forster, Jeri E.; Brenner, Lisa A.] VISN, MIRECC 19, Dept Vet Affairs, Denver, CO 80220 USA; [Bahraini, Nazanin H.; Brenner, Lisa A.] Univ Colorado, Sch Med, Dept Psychiat, Aurora, CO 80045 USA; [Breshears, Ryan E.] Wellstar Hlth Syst, Psychol Serv, Marietta, GA 30060 USA; [Breshears, Ryan E.] Univ Georgia, Dept Counseling & Human Dev, Athens, GA 30602 USA; [Hernandez, Theresa D.] Univ Colorado, Dept Psychol & Neurosci, Boulder, CO 80309 USA; [Forster, Jeri E.] Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO 80045 USA; [Brenner, Lisa A.] Univ Colorado, Sch Med, Dept Neurol, Aurora, CO 80045 USA; [Brenner, Lisa A.] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Aurora, CO 80045 USA	Bahraini, NH (corresponding author), VISN, MIRECC 19, 1055 Clermont St, Denver, CO 80220 USA.	nazanin.bahraini@va.gov	Brenner, Lisa A./AAG-2442-2019				American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Amstadter AB, 2009, PSYCHIATRY, V72, P360, DOI 10.1521/psyc.2009.72.4.360; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Bahraini NH, 2009, MIL MED, V174, P1005, DOI 10.7205/MILMED-D-00-9509; Barnes SM, 2012, REHABIL PSYCHOL, V57, P18, DOI 10.1037/a0027007; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Brenner Lisa A, 2011, Dialogues Clin Neurosci, V13, P311; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brenner LA, 2009, MIL MED, V174, P347, DOI 10.7205/MILMED-D-01-5808; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Breslau N, 2001, BIOL PSYCHIAT, V50, P699, DOI 10.1016/S0006-3223(01)01167-2; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Briere J., 1995, TRAUMA SYMPTOM INVEN; Bryant RA, 2004, PSYCHOSOM MED, V66, P760, DOI 10.1097/01.psy.0000138121.13198.84; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Campbell TA, 2009, PSYCHIAT ANN, V39, P796, DOI 10.3928/00485713-20090728-01; Capehart B, 2012, J REHABIL RES DEV, V49, P789, DOI 10.1682/JRRD.2011.10.0185; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Chalton LD, 2009, BRAIN INJURY, V23, P77, DOI 10.1080/02699050802635273; Chard KM, 2011, J TRAUMA STRESS, V24, P347, DOI 10.1002/jts.20644; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Creamer M, 2005, BEHAV RES THER, V43, P1383, DOI 10.1016/j.brat.2004.11.001; Department of Veterans Affairs Department of Defense, VA DOD CLIN PRACT GU; Dolan S, 2012, NEUROPSYCHOL REV, V22, P21, DOI 10.1007/s11065-012-9190-5; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Faul M.D., 2010, TRAUMATIC BRAIN INJU; First MB., 2002, STRUCTURED CLIN INTE; Gaylord KM, 2008, J TRAUMA, V64, pS200, DOI 10.1097/TA.0b013e318160ba42; Genovese RF, 2013, NEUROSCIENCE, V254, P120, DOI 10.1016/j.neuroscience.2013.09.021; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Graner J, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00016; Greenspan AI, 2006, BRAIN INJURY, V20, P733, DOI 10.1080/02699050600773276; Harvey AG, 2003, J INT NEUROPSYCH SOC, V9, P663, DOI 10.1017/S1355617703940069; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; Herskovits EH, 2002, RADIOLOGY, V224, P345, DOI 10.1148/radiol.2242011439; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hill JJ, 2009, AM J PHYS MED REHAB, V88, P605, DOI 10.1097/PHM.0b013e3181ae0f83; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jones C, 2005, J TRAUMA STRESS, V18, P181, DOI 10.1002/jts.20031; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Jovanovic T, 2010, AM J PSYCHIAT, V167, P648, DOI 10.1176/appi.ajp.2009.09071074; KEANE TM, 1985, J CONSULT CLIN PSYCH, V53, P95, DOI 10.1037/0022-006X.53.1.95; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; King PR, 2012, J REHABIL RES DEV, V49, P879, DOI 10.1682/JRRD.2011.03.0051; Koenigs M, 2008, NAT NEUROSCI, V11, P232, DOI 10.1038/nn2032; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Koren D, 2005, AM J PSYCHIAT, V162, P276, DOI 10.1176/appi.ajp.162.2.276; Matthews SC, 2012, PSYCHIAT RES-NEUROIM, V204, P149, DOI 10.1016/j.pscychresns.2012.04.018; Max JE, 2011, J NEUROPSYCH CLIN N, V23, P29, DOI 10.1176/appi.neuropsych.23.1.29; McAllister TW, 2010, ANN NY ACAD SCI, V1208, P46, DOI 10.1111/j.1749-6632.2010.05720.x; McAllister TW, 2009, CLIN NEUROPSYCHOL, V23, P1338, DOI 10.1080/13854040903277289; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrea M, 2008, CLIN NEUROPSYCHOL, V22, P10, DOI 10.1080/13854040701760981; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Milad MR, 2009, BIOL PSYCHIAT, V66, P1075, DOI 10.1016/j.biopsych.2009.06.026; Mora AG, 2009, J TRAUMA, V66, pS178, DOI 10.1097/TA.0b013e31819ce2d6; Nelson LA, 2009, J HEAD TRAUMA REHAB, V24, P32, DOI 10.1097/HTR.0b013e3181957016; Palchak MJ, 2004, PEDIATRICS, V113, pE507, DOI 10.1542/peds.113.6.e507; Ragsdale KA, 2013, J ANXIETY DISORD, V27, P420, DOI 10.1016/j.janxdis.2013.04.003; Ramchand R, 2010, J TRAUMA STRESS, V23, P59, DOI 10.1002/jts.20486; RAND Center for Military Health Policy Research, 2008, INVISIBLE WOUNDS WAR; Raskind MA, 2003, AM J PSYCHIAT, V160, P371, DOI 10.1176/appi.ajp.160.2.371; Raskind MA, 2007, BIOL PSYCHIAT, V61, P928, DOI 10.1016/j.biopsych.2006.06.032; Raskind MA, 2013, AM J PSYCHIAT, V170, P1003, DOI 10.1176/appi.ajp.2013.12081133; Reger ML, 2012, BIOL PSYCHIAT, V71, P335, DOI 10.1016/j.biopsych.2011.11.007; Rona RJ, 2012, J HEAD TRAUMA REHAB, V27, P33, DOI 10.1097/HTR.0b013e318212f814; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Saltapidas H, 2007, J HEAD TRAUMA REHAB, V22, P132, DOI 10.1097/01.HTR.0000265101.75177.8d; SCHLENGER WE, 1992, J TRAUMA STRESS, V5, P333, DOI 10.1002/jts.2490050303; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schoenfeld FB, 2012, J REHABIL RES DEV, V49, P729, DOI 10.1682/JRRD.2011.09.0164; Scholten JD, 2012, BRAIN INJURY, V26, P1177, DOI 10.3109/02699052.2012.661914; Schwartz I, 2007, ARCH PHYS MED REHAB, V88, P440, DOI 10.1016/j.apmr.2007.01.001; Silver JM, 2012, AM J PSYCHIAT, V169, P1230, DOI 10.1176/appi.ajp.2012.12091230; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Simmons AN, 2012, NEUROPHARMACOLOGY, V62, P598, DOI 10.1016/j.neuropharm.2011.03.016; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Sumpter RE, 2005, BRIT J PSYCHIAT, V186, P423, DOI 10.1192/bjp.186.5.423; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Walter KH, 2012, REHABIL PSYCHOL, V57, P13, DOI 10.1037/a0026254; Weathers F. W., 1993, ANN M INT SOC TRAUM; Wei WH, 2005, ARCH PHYS MED REHAB, V86, P905, DOI 10.1016/j.apmr.2004.09.026; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Williams WH, 2002, BRAIN INJURY, V16, P673, DOI 10.1080/02699050210128861; Wolf GK, 2012, J HEAD TRAUMA REHAB, V27, P26, DOI 10.1097/HTR.0b013e31823cd01f; Xydakis MS, 2012, ANN NEUROL, V72, P673, DOI 10.1002/ana.23757; Zatzick D, 2013, ANN SURG, V257, P390, DOI 10.1097/SLA.0b013e31826bc313	102	39	39	0	27	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0193-953X	1558-3147		PSYCHIAT CLIN N AM	Psychiatr. Clin. North Amer.	MAR	2014	37	1					55	+		10.1016/j.psc.2013.11.002			22	Psychiatry	Psychiatry	AD8UM	WOS:000333541200005	24529423				2021-06-18	
J	Leunissen, I; Coxon, JP; Caeyenberghs, K; Michiels, K; Sunaert, S; Swinnen, SP				Leunissen, Inge; Coxon, James P.; Caeyenberghs, Karen; Michiels, Karla; Sunaert, Stefan; Swinnen, Stephan P.			Subcortical volume analysis in traumatic brain injury: The importance of the fronto-striato-thalamic circuit in task switching	CORTEX			English	Article						Traumatic brain injury; Task switching; Basal ganglia; Thalamus; Shape analysis; Diffusion tensor imaging	WHITE-MATTER INTEGRITY; HUMAN BASAL GANGLIA; COGNITIVE CONTROL; PREFRONTAL CORTEX; DIFFUSION-TENSOR; LONGITUDINAL CHANGES; RESPONSE-INHIBITION; FUNCTIONAL-ROLE; CONNECTIVITY; MODERATE	Traumatic brain injury (TBI) is associated with neuronal loss, diffuse axonal injury and executive dysfunction. Whereas executive dysfunction has traditionally been associated with prefrontal lesions, ample evidence suggests that those functions requiring behavioral flexibility critically depend on the interaction between frontal cortex, basal ganglia and thalamus. To test whether structural integrity of this fronto-striato-thalamic circuit can account for executive impairments in TBI we automatically segmented the thalamus, putamen and caudate of 25 patients and 21 healthy controls and obtained diffusion weighted images. We assessed components of executive function using the local-global task, which requires inhibition, updating and switching between actions. Shape analysis revealed localized atrophy of the limbic, executive and rostral-motor zones of the basal ganglia, whereas atrophy of the thalami was more global in TBI. This subcortical atrophy was related to white matter microstructural organization in TBI, suggesting that axonal injuries possibly contribute to subcortical volume loss. Global volume of the nuclei showed no clear relationship with task performance. However, the shape analysis revealed that participants with smaller volume of those subregions that have connections with the prefrontal cortex and rostral motor areas showed higher switch costs and mixing costs, and made more errors while switching. These results support the idea that flexible cognitive control over action depends on interactions within the fronto-striato-thalamic circuit. (C) 2013 Elsevier Ltd. All rights reserved.	[Leunissen, Inge; Caeyenberghs, Karen; Swinnen, Stephan P.] Katholieke Univ Leuven, Grp Biomed Sci, Movement Control & Neuroplast Res Grp, Louvain, Belgium; [Coxon, James P.] Univ Auckland, Movement Neurosci Lab, Auckland 1, New Zealand; [Caeyenberghs, Karen] Univ Ghent, Dept Phys Therapy & Motor Rehabil, B-9000 Ghent, Belgium; [Michiels, Karla] Univ Hosp, Dept Phys Med & Rehabil, Louvain, Belgium; [Sunaert, Stefan] Katholieke Univ Leuven, Grp Biomed Sci, Med Imaging Res Ctr, Louvain, Belgium; [Swinnen, Stephan P.] Leuven Res Inst Neurosci & Dis LIND, Louvain, Belgium	Leunissen, I (corresponding author), Tervuursevest 101, B-3001 Heverlee, Belgium.	inge.leunissen@faber.kuleuven.be	Coxon, James/S-1286-2019	Coxon, James/0000-0003-2351-8489; Leunissen, Inge/0000-0002-3977-3620; Caeyenberghs, Karen/0000-0001-7009-6843	Research Program of the Research Foundation - Flanders (FWO)FWO [G.0483.10, G.0482.10, G.A114.11]; Interuniversity Attraction Poles program of the Belgian Federal GovernmentBelgian Federal Science Policy Office [P7/11]; Research Foundation - Flanders (FWO)FWO	The authors thank Monique Geurts from the Movement Control and Neuroplasticity Research Group of the KU Leuven for assistance with data collection. This work was supported by the Research Program of the Research Foundation - Flanders (FWO) [G.0483.10 & Levenslijn G.0482.10 & G.A114.11] and the Interuniversity Attraction Poles program of the Belgian Federal Government [P7/11]. I.L. is funded by a PhD fellowship of the Research Foundation - Flanders (FWO). The computational resources and services used in this work were provided by the Hercules Foundation and the Flemish Government Department EWI.	ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; Aron AR, 2006, J NEUROSCI, V26, P2424, DOI 10.1523/JNEUROSCI.4682-05.2006; Baier B, 2010, J NEUROSCI, V30, P9788, DOI 10.1523/JNEUROSCI.1513-10.2010; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; BHATIA KP, 1994, BRAIN, V117, P859, DOI 10.1093/brain/117.4.859; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 2013, BRAIN, V136, P9, DOI 10.1093/brain/aws342; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; BRANDT J, 1996, NEUROPSYCHOLOGICAL A, P312; Braver TS, 2003, NEURON, V39, P713, DOI 10.1016/S0896-6273(03)00466-5; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Caeyenberghs K, 2014, BRAIN STRUCT FUNCT, V219, P193, DOI 10.1007/s00429-012-0494-2; Caeyenberghs K, 2012, BRAIN, V135, P1293, DOI 10.1093/brain/aws048; Coxon JP, 2012, J NEUROSCI, V32, P8401, DOI 10.1523/JNEUROSCI.6360-11.2012; Coxon JP, 2010, CEREB CORTEX, V20, P2368, DOI 10.1093/cercor/bhp306; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; Douaud G, 2007, BRAIN, V130, P2375, DOI 10.1093/brain/awm184; Draganski B, 2008, J NEUROSCI, V28, P7143, DOI 10.1523/JNEUROSCI.1486-08.2008; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Farbota KDM, 2012, J INT NEUROPSYCH SOC, V18, P1006, DOI 10.1017/S1355617712000835; Fearing MA, 2008, J CHILD NEUROL, V23, P729, DOI 10.1177/0883073808314159; Frank MJ, 2007, PHILOS T R SOC B, V362, P1641, DOI 10.1098/rstb.2007.2058; Frank MJ, 2011, CURR OPIN NEUROBIOL, V21, P381, DOI 10.1016/j.conb.2011.02.013; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Hikosaka O, 2010, TRENDS COGN SCI, V14, P154, DOI 10.1016/j.tics.2010.01.006; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Johansen-Berg H, 2005, CEREB CORTEX, V15, P31, DOI 10.1093/cercor/bhh105; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Krause M, 2012, CORTEX, V48, P97, DOI 10.1016/j.cortex.2011.03.014; Larson MJ, 2006, J CLIN EXP NEUROPSYC, V28, P968, DOI 10.1080/13803390600646860; Leunissen I, 2014, HUM BRAIN MAPP, V35, P2459, DOI 10.1002/hbm.22341; Leunissen I, 2013, HUM BRAIN MAPP, V34, P1254, DOI 10.1002/hbm.21508; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Levin HS, 2004, J CLIN EXP NEUROPSYC, V26, P589, DOI 10.1080/13803390490504434; Levy R, 2006, CEREB CORTEX, V16, P916, DOI 10.1093/cercor/bhj043; Los SA, 1996, ACTA PSYCHOL, V94, P145, DOI 10.1016/0001-6918(95)00050-X; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McKeown MJ, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-8; Mecklinger A, 1999, J CLIN EXP NEUROPSYC, V21, P606, DOI 10.1076/jcen.21.5.606.873; Middleton FA, 2002, CEREB CORTEX, V12, P926, DOI 10.1093/cercor/12.9.926; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; Mink JW, 1996, PROG NEUROBIOL, V50, P381, DOI 10.1016/S0301-0082(96)00042-1; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Miyata J, 2009, SCHIZOPHR RES, V111, P78, DOI 10.1016/j.schres.2009.03.010; Monchi O, 2006, ANN NEUROL, V59, P257, DOI 10.1002/ana.20742; Moustafa AA, 2008, NEUROPSYCHOLOGIA, V46, P3144, DOI 10.1016/j.neuropsychologia.2008.07.011; Nachev P, 2008, NAT REV NEUROSCI, V9, P856, DOI 10.1038/nrn2478; NAVON D, 1977, COGNITIVE PSYCHOL, V9, P353, DOI 10.1016/0010-0285(77)90012-3; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; Patenaude B, 2011, NEUROIMAGE, V56, P907, DOI 10.1016/j.neuroimage.2011.02.046; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Postuma RB, 2006, CEREB CORTEX, V16, P1508, DOI 10.1093/cercor/bhj088; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rubin O, 2005, J EXP PSYCHOL LEARN, V31, P1477, DOI 10.1037/0278-7393.31.6.1477; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Seignourel PJ, 2005, NEUROPSYCHOLOGY, V19, P578, DOI 10.1037/0894-4105.19.5.578; Shah S, 2012, BRAIN INJURY, V26, P201, DOI 10.3109/02699052.2012.654591; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Spitz G, 2013, BRAIN COGNITION, V83, P34, DOI 10.1016/j.bandc.2013.06.007; Stuss DT, 2011, CURR OPIN NEUROL, V24, P584, DOI 10.1097/WCO.0b013e32834c7eb9; TAYLOR AE, 1995, BRAIN COGNITION, V28, P281, DOI 10.1006/brcg.1995.1258; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Tziortzi AC, 2014, CEREB CORTEX, V24, P1165, DOI 10.1093/cercor/bhs397; van Schouwenburg MR, 2010, J NEUROSCI, V30, P9910, DOI 10.1523/JNEUROSCI.1111-10.2010; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020; Zarei M, 2010, NEUROIMAGE, V49, P1, DOI 10.1016/j.neuroimage.2009.09.001	77	39	39	0	8	ELSEVIER MASSON, CORPORATION OFFICE	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	0010-9452	1973-8102		CORTEX	Cortex	FEB	2014	51						67	81		10.1016/j.cortex.2013.10.009			15	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	AB5WC	WOS:000331858400007	24290948				2021-06-18	
J	Ritfeld, GJ; Rauck, BM; Novosat, TL; Park, D; Patel, P; Roos, RAC; Wang, YD; Oudega, M				Ritfeld, Gaby J.; Rauck, Britta M.; Novosat, Tabitha L.; Park, Daewon; Patel, Pavan; Roos, Raymund A. C.; Wang, Yadong; Oudega, Martin			The effect of a polyurethane-based reverse thermal gel on bone marrow stromal cell transplant survival and spinal cord repair	BIOMATERIALS			English	Article						Spinal cord injury; Cell therapy; ESHU; Antioxidant; Neuroprotection; Repair	TRAUMATIC BRAIN-INJURY; FUNCTIONAL RECOVERY; STEM-CELLS; ADULT-RATS; REGENERATIVE MEDICINE; SCHWANN-CELLS; IN-VITRO; CONTUSION; THERAPY; SYSTEM	Cell therapy for nervous tissue repair is limited by low transplant survival. We investigated the effects of a polyurethane-based reverse thermal gel, poly(ethylene glycol)-poly(serinol hexamethylene urethane) (ESHU) on bone marrow stromal cell (BMSC) transplant survival and repair using a rat model of spinal cord contusion. Transplantation of BMSCs in ESHU at three days post-contusion resulted in a 3.5-fold increase in BMSC survival at one week post-injury and a 66% increase in spared nervous tissue volume at four weeks post-injury. These improvements were accompanied by enhanced hindlimb motor and sensorimotor recovery. In vitro, we found that ESHU protected BMSCs from hydrogen peroxide-mediated death, resulting in a four-fold increase in BMSC survival with two-fold fewer BMSCs expressing the apoptosis marker, caspase 3 and the DNA oxidation marker, 8-oxo-deoxyguanosine. We argue that ESHU protected BMSCs transplanted is a spinal cord contusion from death thereby augmenting their effects on neuroprotection leading to improved behavioral restoration. The data show that the repair effects of intraneural BMSC transplants depend on the degree of their survival and may have a widespread impact on cell-based regenerative medicine. (C) 2013 Elsevier Ltd. All rights reserved.	[Ritfeld, Gaby J.; Novosat, Tabitha L.; Patel, Pavan; Oudega, Martin] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Park, Daewon; Oudega, Martin] Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA 15213 USA; [Rauck, Britta M.; Wang, Yadong; Oudega, Martin] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15213 USA; [Wang, Yadong] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA; [Rauck, Britta M.; Wang, Yadong] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15213 USA; [Park, Daewon] Univ Colorado Denver, Dept Bioengn, Aurora, CO USA; [Ritfeld, Gaby J.; Roos, Raymund A. C.] Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands	Oudega, M (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, W1452 BST,200 Lothrop St, Pittsburgh, PA 15213 USA.	yaw20@pitt.edu; moudega@pitt.edu	Park, Daewon/W-8128-2019; Wang, Yadong/AAC-3381-2020	Wang, Yadong/0000-0003-2067-382X; Patel, Pavan/0000-0002-7387-2083	LUMC [30229/5000]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32EB003392-07]; NSFNational Science Foundation (NSF) [DMR-1206589]; Department of Physical Medicine and Rehabilitation at the University of Pittsburgh; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [T32EB003392] Funding Source: NIH RePORTER	Financial support was provided by LUMC (grant #30229/5000) to GJR, NIH 5T32EB003392-07 (BR), NSF #DMR-1206589 (YW), and the Department of Physical Medicine and Rehabilitation at the University of Pittsburgh.	Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bernardo ME, 2012, BONE MARROW TRANSPL, V47, P164, DOI 10.1038/bmt.2011.81; Bolton DAE, 2006, BEHAV BRAIN RES, V168, P272, DOI 10.1016/j.bbr.2005.11.017; Bonilla C, 2012, J TRAUMA ACUTE CARE, V72, P1203, DOI 10.1097/TA.0b013e318248bdcf; Boyce RW, 2010, TOXICOL PATHOL, V38, P1011, DOI 10.1177/0192623310385140; Brodbeck WG, 2002, CYTOKINE, V18, P311, DOI 10.1006/cyto.2002.1048; BUNGE RP, 1993, ADV NEUROL, V59, P75; Caplan Al, 2009, J PATHOL, V217, P318; Christenson EM, 2004, J BIOMED MATER RES A, V70A, P245, DOI 10.1002/jbm.a.30067; Conget PA, 1999, J CELL PHYSIOL, V181, P67, DOI 10.1002/(SICI)1097-4652(199910)181:1<67::AID-JCP7>3.3.CO;2-3; Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838; Facchinetti F, 1998, CELL MOL NEUROBIOL, V18, P667, DOI 10.1023/A:1020221919154; Forraz N, 2013, J TISSUE ENG REGEN M, V7, P523, DOI 10.1002/term.552; Friberg TR, 2012, ARVO ANN M 2012; Hamann K, 2008, J NEUROCHEM, V107, P712, DOI 10.1111/j.1471-4159.2008.05622.x; Hawryluk GWJ, 2012, STEM CELLS DEV, V21, P2222, DOI 10.1089/scd.2011.0596; Hill CE, 2007, EUR J NEUROSCI, V26, P1433, DOI 10.1111/j.1460-9568.2007.05771.x; Himes BT, 2006, NEUROREHAB NEURAL RE, V20, P278, DOI 10.1177/1545968306286976; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Ichim TE, 2010, CELL IMMUNOL, V260, P75, DOI 10.1016/j.cellimm.2009.10.006; Joosten EAJ, 2004, J NEUROSCI RES, V77, P127, DOI 10.1002/jnr.20088; Kakulas B A, 1999, J Spinal Cord Med, V22, P119; Karimi-Abdolrezaee S, 2006, J NEUROSCI, V26, P3377, DOI 10.1523/JNEUROSCI.4184-05.2006; Kawabori M, 2013, NEUROPATHOLOGY, V33, P140, DOI 10.1111/j.1440-1789.2012.01335.x; Kigerl KA, 2012, EXP NEUROL, V233, P333, DOI 10.1016/j.expneurol.2011.10.025; Kong QM, 2010, CELL MOL LIFE SCI, V67, P1817, DOI 10.1007/s00018-010-0277-y; KUNKELBAGDEN E, 1992, EXP NEUROL, V116, P40, DOI 10.1016/0014-4886(92)90174-O; Lankhorst AJ, 1999, NEUROSCI RES COMMUN, V24, P135; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; McBane JE, 2007, J BIOMED MATER RES A, V82A, P984, DOI 10.1002/jbm.a.31263; Moon YJ, 2012, J NEUROSCI RES, V90, P243, DOI 10.1002/jnr.22734; Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood-2007-02-069716; Okano H, 2013, CIRC RES, V112, P523, DOI 10.1161/CIRCRESAHA.111.256149; Oudega M, 2007, ACTA PHYSIOL, V189, P181, DOI 10.1111/j.1748-1716.2006.01658.x; Park D, 2013, MACROMOL BIOSCI, V13, P464, DOI 10.1002/mabi.201200384; Park D, 2011, BIOMATERIALS, V32, P777, DOI 10.1016/j.biomaterials.2010.09.044; Parr AM, 2008, SURG NEUROL, V70, P600, DOI 10.1016/j.surneu.2007.09.043; Ritfeld GJ, 2012, CELL TRANSPLANT, V21, P1561, DOI 10.3727/096368912X640484; Ritfeld GJ, 2010, NEUROREPORT, V21, P221, DOI 10.1097/WNR.0b013e32833677cd; Ruff CA, 2010, PANMINERVA MED, V52, P125; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Seshi B, 2000, BLOOD CELL MOL DIS, V26, P234, DOI 10.1006/bcmd.2000.0301; Siriphorn A, 2010, J NEUROCHEM, V115, P864, DOI 10.1111/j.1471-4159.2010.06770.x; Swanger SA, 2005, CELL TRANSPLANT, V14, P775, DOI 10.3727/000000005783982594; Syntichaki P, 2003, NAT REV NEUROSCI, V4, P672, DOI 10.1038/nrn1174; Tewarie RDSN, 2009, J NEUROTRAUM, V26, P2313, DOI 10.1089/neu.2009.0987; Tschope C, 2011, CURR PHARM DESIGN, V17, P3295, DOI 10.2174/138161211797904136; Wu Liqin, 2012, Central Nervous System Agents in Medicinal Chemistry, V12, P122; Yasuhara T, 2009, STEM CELLS DEV, V18, P1501, DOI 10.1089/scd.2009.0011; Zhang YJ, 2012, J NEUROL SCI, V313, P64, DOI 10.1016/j.jns.2011.09.027; Zou JP, 2012, INT J LOW EXTR WOUND, V11, P244, DOI 10.1177/1534734612463935	54	39	45	1	33	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	FEB	2014	35	6					1924	1931		10.1016/j.biomaterials.2013.11.062			8	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	AA3UD	WOS:000331018700015	24331711	Green Accepted			2021-06-18	
J	Li, H; Wu, W; Sun, Q; Liu, M; Li, W; Zhang, XS; Zhou, ML; Hang, CH				Li, Hua; Wu, Wei; Sun, Qing; Liu, Ming; Li, Wei; Zhang, Xiang-sheng; Zhou, Meng-liang; Hang, Chun-hua			Expression and cell distribution of receptor for advanced glycation end-products in the rat cortex following experimental subarachnoid hemorrhage	BRAIN RESEARCH			English	Article						Receptor for advanced glycation end-product; Nuclear factor kappa B; Subarachnoid hemorrhage; Inflammation	TRAUMATIC BRAIN-INJURY; RESPONSE PROTEIN 88; ALZHEIMERS-DISEASE; CEREBRAL VASOSPASM; RAGE RECEPTOR; MOUSE MODEL; BETA; INFLAMMATION; ASTROCYTES; LIGANDS	Convincing evidence indicates that inflammation contributes to the adverse prognosis of subarachnoid hemorrhage (SAH). Some pro-inflammatory molecules such as high mobility group protein 1, S100 family of proteins, beta-amyloid peptide, and macrophage antigen complex 1 have been involved in the damaging inflammation process following SAH. The receptor for advanced glycation end-products (RAGE) is a transmembrane receptor that senses these molecules and plays central role in inflammatory processes. This study aimed to determine the expression and cell distribution of RAGE in the brain cortex after SAH. Male Sprague-Dawley rats were randomly divided into sham group and SAN groups at 6 h, 12 h and on day 1, day 2 and day 3 (n=6 for each subgroup). SAN groups suffered experimental SAN by injection of 0.3 ml autologous blood into the prechiasmatic cistern. RAGE expression was measured by Western blot, real-time PCR, immunohistochemistry and immunofluorescence. Nuclear expression of p65 protein, the major subunit of nuclear factor kappa B, was also detected. Our data demonstrated that the expression levels of RAGE and nuclear p65 protein were both markedly increased after SAN. Moreover, there was a significant positive correlation between the expression of RAGE and that of p65 protein. Double immunofluorescence staining showed that RAGE was expressed by neuron and microglia rather than astrocyte after SAH. These results suggest that RAGE may be directly involved in the inflammatory response after SAN, and there might be important implications for further studies using specific RAGE antagonists to decrease inflammation-mediated brain injury following SAH. (C) 2013 Elsevier B.V. All rights reserved.	[Li, Hua; Wu, Wei; Sun, Qing; Li, Wei; Zhou, Meng-liang; Hang, Chun-hua] Nanjing Univ, Sch Med, Dept Neurosurg, Jinling Hosp, Nanjing 210002, Jiangsu, Peoples R China; [Liu, Ming] Southern Med Univ Guangzhou, Sch Med, Dept Neurosurg, Jinling Hosp, Nanjing, Jiangsu, Peoples R China; [Zhang, Xiang-sheng] Second Mil Med Univ Shanghai, Sch Med, Dept Neurosurg, Jinling Hosp, Nanjing, Jiangsu, Peoples R China	Hang, CH (corresponding author), Nanjing Univ, Sch Med, Dept Neurosurg, Jinling Hosp, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	hang_neurosurgery@163.com		Li, Hua/0000-0001-5893-535X; Zhou, Meng-liang/0000-0002-1165-5489	National Natural Science Foundation, ChinaNational Natural Science Foundation of China (NSFC) [81171170]; Nature Science Foundation of Jiangsu Province, ChinaNatural Science Foundation of Jiangsu Province [BK2010459]; Scientific Research and Innovation Foundation of Universities in Jiangsu Province, China [CXZZ12_0067]	The authors acknowledge the support for this study by Grants from the National Natural Science Foundation, China (No. 81171170) and Nature Science Foundation of Jiangsu Province, China (BK2010459) and Scientific Research and Innovation Foundation of Universities in Jiangsu Province, China (CXZZ12_0067).	Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Chavakis T, 2004, MICROBES INFECT, V6, P1219, DOI 10.1016/j.micinf.2004.08.004; Deane R, 2012, J CLIN INVEST, V122, P1377, DOI 10.1172/JCI58642; Fang F, 2010, FASEB J, V24, P1043, DOI 10.1096/fj.09-139634; Fassbender K, 2001, J NEUROL NEUROSUR PS, V70, P534, DOI 10.1136/jnnp.70.4.534; Fritz G, 2011, TRENDS BIOCHEM SCI, V36, P625, DOI 10.1016/j.tibs.2011.08.008; Gao TL, 2012, J TRAUMA ACUTE CARE, V72, P643, DOI 10.1097/TA.0b013e31823c54a6; Kay A, 2003, STROKE, V34, pE240, DOI 10.1161/01.STR.0000100157.88508.2F; Larysz-Brysz M, 2012, CURR NEUROVASC RES, V9, P159, DOI 10.2174/156720212801619045; Lefranc F, 2005, NEUROPATH APPL NEURO, V31, P649, DOI 10.1111/j.1365-2990.2005.00682.x; Li GZ, 2011, BRAIN RES, V1396, P96, DOI 10.1016/j.brainres.2011.04.014; Li W, 2012, NEUROL SCI; Liliensiek B, 2004, J CLIN INVEST, V113, P1641, DOI 10.1172/JCI200418704; Lin L, 2009, FRONT BIOSCI-LANDMRK, V14, P1403, DOI 10.2741/3315; Ma L, 2004, BRAIN RES, V1018, P10, DOI 10.1016/j.brainres.2004.05.052; Ma L, 2003, BRAIN RES, V966, P167, DOI 10.1016/S0006-8993(02)04149-5; Muhammad S, 2008, J NEUROSCI, V28, P12023, DOI 10.1523/JNEUROSCI.2435-08.2008; Nakahara T, 2009, NEUROCRIT CARE, V11, P362, DOI 10.1007/s12028-009-9276-y; Ponath G, 2007, J NEUROIMMUNOL, V184, P214, DOI 10.1016/j.jneuroim.2006.12.011; Pradilla G, 2004, J NEUROSURG, V101, P88, DOI 10.3171/jns.2004.101.1.0088; Pradilla G, 2010, NEUROSURG CLIN N AM, V21, P365, DOI 10.1016/j.nec.2009.10.008; Sasaki N, 2002, NEUROSCI LETT, V326, P117, DOI 10.1016/S0304-3940(02)00310-5; Sasaki N, 2001, BRAIN RES, V888, P256, DOI 10.1016/S0006-8993(00)03075-4; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI200114002; Schmidt AM, 2009, CURR OPIN INVEST DR, V10, P672; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Sehba FA, 2011, MOL NEUROBIOL, V43, P27, DOI 10.1007/s12035-010-8155-z; Sparvero LJ, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-17; Sun Q, 2013, BRAIN RES, V1520, P134, DOI 10.1016/j.brainres.2013.05.010; Tang SC, 2007, P NATL ACAD SCI USA, V104, P13798, DOI 10.1073/pnas.0702553104; Venti M, 2012, FRONT NEUROL NEUROSC, V30, P149, DOI 10.1159/000333625; Xie JL, 2013, CELL SIGNAL, V25, P2185, DOI 10.1016/j.cellsig.2013.06.013; YAN SD, 1994, J BIOL CHEM, V269, P9889; You WC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060290; You WC, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/786242; Zhou ML, 2007, J CEREBR BLOOD F MET, V27, P1583, DOI 10.1038/sj.jcbfm.9600456	36	39	44	0	14	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 16	2014	1543						315	323		10.1016/j.brainres.2013.11.023			9	Neurosciences	Neurosciences & Neurology	300VE	WOS:000330491300035	24291745				2021-06-18	
J	Rowe, RK; Striz, M; Bachstetter, AD; Van Eldik, LJ; Donohue, KD; O'Hara, BF; Lifshitz, J				Rowe, Rachel K.; Striz, Martin; Bachstetter, Adam D.; Van Eldik, Linda J.; Donohue, Kevin D.; O'Hara, Bruce F.; Lifshitz, Jonathan			Diffuse Brain Injury Induces Acute Post-Traumatic Sleep	PLOS ONE			English	Article							CYTOKINES; WAKE; INTERLEUKIN-1-BETA; PATHOPHYSIOLOGY; ACTIVATION; DISORDERS	Objective: Clinical observations report excessive sleepiness immediately following traumatic brain injury (TBI); however, there is a lack of experimental evidence to support or refute the benefit of sleep following a brain injury. The aim of this study is to investigate acute post-traumatic sleep. Methods: Sham, mild or moderate diffuse TBI was induced by midline fluid percussion injury (mFPI) in male C57BL/6J mice at 9: 00 or 21: 00 to evaluate injury-induced sleep behavior at sleep and wake onset, respectively. Sleep profiles were measured post-injury using a non-invasive, piezoelectric cage system. In separate cohorts of mice, inflammatory cytokines in the neocortex were quantified by immunoassay, and microglial activation was visualized by immunohistochemistry. Results: Immediately after diffuse TBI, quantitative measures of sleep were characterized by a significant increase in sleep (>50%) for the first 6 hours post-injury, resulting from increases in sleep bout length, compared to sham. Acute post-traumatic sleep increased significantly independent of injury severity and time of injury (9: 00 vs 21: 00). The pro-inflammatory cytokine IL-1 beta increased in brain-injured mice compared to sham over the first 9 hours post-injury. Iba-1 positive microglia were evident in brain-injured cortex at 6 hours post-injury. Conclusion: Post-traumatic sleep occurs for up to 6 hours after diffuse brain injury in the mouse regardless of injury severity or time of day. The temporal profile of secondary injury cascades may be driving the significant increase in post-traumatic sleep and contribute to the natural course of recovery through cellular repair.	[Rowe, Rachel K.; Lifshitz, Jonathan] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ USA; [Rowe, Rachel K.; Lifshitz, Jonathan] Univ Arizona, Dept Child Hlth, Coll Med Phoenix, Phoenix, AZ USA; [Lifshitz, Jonathan] Phoenix Veteran Affairs Healthcare Syst, Phoenix, AZ USA; [Rowe, Rachel K.; Van Eldik, Linda J.; Lifshitz, Jonathan] Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY USA; [Striz, Martin; O'Hara, Bruce F.] Univ Kentucky, Dept Biol, Coll Arts & Sci, Lexington, KY USA; [Donohue, Kevin D.] Univ Kentucky, Dept Elect & Comp Engn, Coll Engn, Lexington, KY USA; [Lifshitz, Jonathan] Univ Kentucky, Coll Med, Dept Phys Med & Rehabil, Lexington, KY USA; [Rowe, Rachel K.; Van Eldik, Linda J.; O'Hara, Bruce F.; Lifshitz, Jonathan] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Lexington, KY USA; [Bachstetter, Adam D.; Van Eldik, Linda J.] Univ Kentucky, Coll Med, Sanders Brown Ctr Aging, Lexington, KY 40536 USA	Lifshitz, J (corresponding author), Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ USA.	jlifshitz@email.arizona.edu		Rowe, Rachel/0000-0002-9034-3159; Bachstetter, Adam/0000-0003-4646-6757	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 NS072611, R01 NS065052, R01 NS064247, KSCHIRT 10-5A, F32 AG037280]; National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS072611, R01NS064247, R01NS065052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [F32AG037280] Funding Source: NIH RePORTER	Support provided by National Institutes of Health (NIH) grants R21 NS072611 (JL/BFO), R01 NS065052 (JL), R01 NS064247 (LVE), KSCHIRT 10-5A, F32 AG037280 (ADB). RKR was supported by a Research Supplement to Promote Diversity by the National Institute of Neurological Disorders and Stroke (NINDS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albensi BC, 2003, BRAIN INJURY, V17, P653, DOI 10.1080/0269905031000107142; Alder J, 2011, JOVE-J VIS EXP, DOI 10.3791/3063; Arciniegas, 2000, Curr Treat Options Neurol, V2, P169; Bachstetter AD, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-79; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2012, NEUROMOL MED, V14, P205, DOI 10.1007/s12017-012-8178-x; Boone DR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046204; Borbely AA, 1999, J BIOL RHYTHM, V14, P557, DOI 10.1177/074873099129000894; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Chikahisa Sachiko, 2011, Front Neurol, V2, P87, DOI 10.3389/fneur.2011.00087; Chokroverty S, 2010, INDIAN J MED RES, V131, P126; Curry Parichat, 2011, Int J Crit Illn Inj Sci, V1, P27, DOI 10.4103/2229-5151.79279; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Donohue KD, 2008, BIOMED ENG ONLINE, V7, DOI 10.1186/1475-925X-7-14; Dworak M, 2010, J NEUROSCI, V30, P9007, DOI 10.1523/JNEUROSCI.1423-10.2010; FAN L, 1995, MOL BRAIN RES, V30, P125; Fang JD, 1998, AM J PHYSIOL-REG I, V274, pR655; Flores AE, 2007, IEEE T BIO-MED ENG, V54, P225, DOI 10.1109/TBME.2006.886938; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Gentleman D, 1999, BRIT MED BULL, V55, P910, DOI 10.1258/0007142991902718; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; Huber R, 2000, BRAIN RES, V857, P8, DOI 10.1016/S0006-8993(99)02248-9; Jin XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041892; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Krueger JM, 2007, SLEEP MED CLIN, V2, P161, DOI 10.1016/j.jsmc.2007.03.003; Krueger JM, 2008, CURR PHARM DESIGN, V14, P3408, DOI 10.2174/138161208786549281; KRUEGER JM, 1995, INT ARCH ALLERGY IMM, V106, P97, DOI 10.1159/000236827; Krueger JM, 2001, ANN NY ACAD SCI, V933, P211; Lifshitz J, 2008, ANIMAL MODELS ACUTE; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Lifshitz J, 2012, BRAIN STRUCT FUNCT, V217, P49, DOI 10.1007/s00429-011-0323-z; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McCoy JG, 2011, NEUROBIOL LEARN MEM, V96, P564, DOI 10.1016/j.nlm.2011.07.004; McNamara KCS, 2010, J NEUROTRAUM, V27, P695, DOI 10.1089/neu.2009.1237; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Tononi G, 2006, SLEEP MED REV, V10, P49, DOI 10.1016/j.smrv.2005.05.002; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wisor JP, 2011, SLEEP, V34, P261, DOI 10.1093/sleep/34.3.261; Yasuda T, 2005, SLEEP, V28, P177, DOI 10.1093/sleep/28.2.177; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	48	39	40	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2014	9	1							e82507	10.1371/journal.pone.0082507			10	Multidisciplinary Sciences	Science & Technology - Other Topics	291WL	WOS:000329862500018	24416145	DOAJ Gold, Green Published			2021-06-18	
J	Axelrod, BN; Meyers, JE; Davis, JJ				Axelrod, Bradley N.; Meyers, John E.; Davis, Jeremy J.			Finger Tapping Test Performance as a Measure of Performance Validity	CLINICAL NEUROPSYCHOLOGIST			English	Article						Performance validity; Motor testing; Effort testing	TRAUMATIC BRAIN-INJURY; COMPLEX FIGURE TEST; SYMPTOM VALIDITY; SUSPECT EFFORT; RESPONSE BIAS; NEUROPSYCHOLOGICAL ASSESSMENT; CLASSIFICATION ACCURACY; DISABILITY CLAIMANTS; CROSS-VALIDATION; HEAD-INJURY	The Finger Tapping Test (FTT) has been presented as an embedded measure of performance validity in most standard neuropsychological evaluations. The present study evaluated the utility of three different scoring systems intended to detect invalid performance based on FTT. The scoring systems were evaluated in neuropsychology cases from clinical and independent practices, in which credible performance was determined based on passing all performance validity measures or failing two or more validity indices. Each FTT scoring method presented with specificity rates at approximately 90% and sensitivity of slightly more than 40%. When suboptimal performance was based on the failure of any of the three scoring methods, specificity was unchanged and sensitivity improved to 50%. The results are discussed in terms of the utility of combining multiple scoring measures for the same test as well as benefits of embedded measures administered over the duration of the evaluation.	[Axelrod, Bradley N.] John D Dingell DVAMC, Psychol Sect, Detroit, MI 48201 USA; [Meyers, John E.] Meyers Neuropsychol Serv, Mililani, HI USA; [Davis, Jeremy J.] Univ Utah, Sch Med, Salt Lake City, UT USA	Axelrod, BN (corresponding author), John D Dingell DVAMC, Psychol Sect, 4646 John R, Detroit, MI 48201 USA.	bradley.axelrod@va.gov					Arentsen TJ, 2013, CLIN NEUROPSYCHOL, V27, P1060, DOI 10.1080/13854046.2013.803603; Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Backhaus SL, 2004, CLIN NEUROPSYCHOL, V18, P591, DOI 10.1080/13854040490888558; Boone, 2007, ASSESSMENT FEIGNED C; Boone KB, 2005, ARCH CLIN NEUROPSYCH, V20, P301, DOI 10.1016/j.acn.2004.08.001; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Butcher J. N., 1989, MMPI 2 MANUAL ADM SC; Camara WJ, 2000, PROF PSYCHOL-RES PR, V31, P141, DOI 10.1037/0735-7028.31.2.141; Davis JJ, 2013, J CLIN EXP NEUROPSYC, V35, P413, DOI 10.1080/13803395.2013.781134; Davis JJ, 2012, CLIN NEUROPSYCHOL, V26, P1397, DOI 10.1080/13854046.2012.728627; Davis JJ, 2012, CLIN NEUROPSYCHOL, V26, P850, DOI 10.1080/13854046.2012.686631; Davis JJ, 2011, ARCH CLIN NEUROPSYCH, V26, P768, DOI 10.1093/arclin/acr079; Delis D. C., 2000, CVLT 2 CALIFORNIA VE; Green, 2004, GREENS MED SYMPTOM V; Greve KW, 2007, CLIN NEUROPSYCHOL, V21, P318, DOI 10.1080/13854040500488552; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Heaton RK, 2004, REVISED COMPREHENSIV; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Iverson GL, 1998, BRAIN INJURY, V12, P275, DOI 10.1080/026990598122575; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Lees-Haley P. R., 1992, FORENSIC REPORTS, V5, P385; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; Meyers J. E., 2007, ASSESSMENT FEIGNED C; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Meyers JE, 2011, ARCH CLIN NEUROPSYCH, V26, P8, DOI 10.1093/arclin/acq083; Millis S. R., 2002, J FORENSIC NEUROPSYC, V2, P147; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P271, DOI 10.1016/0887-6177(95)00040-2; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P380, DOI 10.1080/13803390903066881; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Rapport LJ, 1998, J CLIN EXP NEUROPSYC, V20, P89, DOI 10.1076/jcen.20.1.89.1488; Reedy SD, 2013, ARCH CLIN NEUROPSYCH, V28, P30, DOI 10.1093/arclin/acs106; Reitan RM., 1985, HALSTEAD REITAN NEUR; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Ross SR, 2006, CLIN NEUROPSYCHOL, V20, P798, DOI 10.1080/13854040500328477; Schutte C., 2013, MILD TRAUMATIC BRAIN, P159; Schutte C, 2011, CLIN NEUROPSYCHOL, V25, P454, DOI 10.1080/13854046.2010.550635; Sherman DS, 2002, CLIN NEUROPSYCHOL, V16, P242, DOI 10.1076/clin.16.3.242.13860; Solomon RE, 2010, CLIN NEUROPSYCHOL, V24, P1243, DOI 10.1080/13854046.2010.514864; Tombaugh TN, 1996, TEST MEMORY MALINGER; Van Dyke SA, 2013, CLIN NEUROPSYCHOL, V27, P1234, DOI 10.1080/13854046.2013.835447; Whiteside D, 2011, CLIN NEUROPSYCHOL, V25, P287, DOI 10.1080/13854046.2010.538436; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791; Wolfson D., 1993, HALSTEAD REITAN NEUR	50	39	40	1	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 CHESTNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2014	28	5					876	888		10.1080/13854046.2014.907583			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	AP4MM	WOS:000342051100012	24738938				2021-06-18	
J	Chen, YC; Mao, HJ; Yang, KH; Abel, T; Meaney, DF				Chen, Yung Chia; Mao, Haojie; Yang, King H.; Abel, Ted; Meaney, David F.			A modified controlled cortical impact technique to model mild traumatic brain injury mechanics in mice	FRONTIERS IN NEUROLOGY			English	Article						controlled cortical impact; mild traumatic brain injury; biomechanics; strain rate; glia reactivity	CLOSED-HEAD-INJURY; AMYLOID PRECURSOR PROTEIN; FLUID PERCUSSION MODEL; FINITE-ELEMENT MODEL; AXONAL INJURY; PROFESSIONAL FOOTBALL; ANIMAL-MODEL; CONCUSSION; STRETCH; STRAIN	For the past 25 years, controlled cortical impact (CCI) has been a useful tool in traumatic brain injury (TBI) research, creating injury patterns that includes primary contusion, neuronal loss, and traumatic axonal damage. However, when CCI was first developed, very little was known on the underlying biomechanics of mild TBI. This paper uses information generated from recent computational models of mild TBI in humans to alter CCI and better reflect the biomechanical conditions of mild TBI. Using a finite element model of CCI in the mouse, we adjusted three primary features of CCI: the speed of the impact to achieve strain rates within the range associated with mild TBI, the shape, and material of the impounder to minimize strain concentrations in the brain, and the impact depth to control the peak deformation that occurred in the cortex and hippocampus. For these modified cortical impact conditions, we observed peak strains and strain rates throughout the brain were significantly reduced and consistent with estimated strains and strain rates observed in human mild TBI. We saw breakdown of the blood brain barrier but no primary hemorrhage. Moreover, neuronal degeneration, axonal injury, and both astrocytic and microglia reactivity were observed up to 8 days after injury. Significant deficits in rotarod performance appeared early after injury, but we observed no impairment in spatial object recognition or contextual fear conditioning response 5 and 8 days after injury, respectively. Together, these data show that simulating the biomechanical conditions of mild TBI with a modified cortical impact technique produces regions of cellular reactivity and neuronal loss that coincide with only a transient behavioral impairment.	[Chen, Yung Chia; Meaney, David F.] Univ Penn, Dept Bioengn, 2105 33rd St,240 Skirkanich Hall, Philadelphia, PA 19104 USA; [Mao, Haojie; Yang, King H.] Wayne State Univ, Bioengn Ctr, Detroit, MI USA; [Abel, Ted] Univ Penn, Dept Biol, Philadelphia, PA 19104 USA	Meaney, DF (corresponding author), Univ Penn, Dept Bioengn, 2105 33rd St,240 Skirkanich Hall, Philadelphia, PA 19104 USA.	dmeaney@seas.upenn.edu	Mao, Haojie/Q-7514-2018	Mao, Haojie/0000-0002-7563-9234; Meaney, David/0000-0002-0954-4122; Abel, Ted/0000-0003-2423-4592	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; New Jersey Commission for Brain Injury Research; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS088176] Funding Source: NIH RePORTER	We thank Mr. Nikhil Mone for his help in part of meshing and modeling work. Funding was provided by grants from the National Institutes of Health and the New Jersey Commission for Brain Injury Research.	Albert-WeiSSenberger Christiane, 2012, Exp Transl Stroke Med, V4, P1, DOI 10.1186/2040-7378-4-1; Anderson KJ, 2003, J NEUROTRAUM, V20, P1223, DOI 10.1089/089771503770802899; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bain AC, 1999, THRESHOLDS MECH INJU; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cloots RJH, 2013, BIOMECH MODEL MECHAN, V12, P137, DOI 10.1007/s10237-012-0387-6; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dokko Y, 2003, 18 INT TECHN C ENH S, P19; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Ellingson Benjamin M., 2005, V41, P86; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; Fijalkowski RJ, 2009, STAPP CAR CRASH JO, V53, P193; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Hamilton NA, 2010, SEMIN PEDIATR SURG, V19, P271, DOI 10.1053/j.sempedsurg.2010.06.005; Ho J, 2007, J BIOMECH, V40, P3006, DOI 10.1016/j.jbiomech.2007.02.011; Kilbourne M, 2009, J NEUROTRAUM, V26, P2233, DOI 10.1089/neu.2009.0968; Kimpara H, 2012, ANN BIOMED ENG, V40, P114, DOI 10.1007/s10439-011-0414-2; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Le TH, 2009, MT SINAI J MED, V76, P145, DOI 10.1002/msj.20102; Lee Bruce, 2005, NeuroRx, V2, P372; Levchakov A, 2006, J NEUROTRAUM, V23, P1570, DOI 10.1089/neu.2006.23.1570; Liying Zhang K.H.Y., 2003, P 2003 SUMM BIOENG C, P0137; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Mao HJ, 2010, BIOMECH MODEL MECHAN, V9, P763, DOI 10.1007/s10237-010-0212-z; Mao HJ, 2010, J NEUROTRAUM, V27, P877, DOI 10.1089/neu.2008.0616; Mao Haojie, 2006, Stapp Car Crash J, V50, P583; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P3, DOI 10.1111/j.1365-2214.2009.01006.x; Meaney D.F., 1990, P 1990 INT IRCOBI C, P215; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Miller R., 1998, FINITE ELEMENT MODEL; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison B, 2000, J BIOMECH ENG-T ASME, V122, P224, DOI 10.1115/1.429650; Morrison B., 2003, STAPP CAR CRASH J, V47, P93; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Oliveira AMM, 2011, LEARN MEMORY, V18, P161, DOI 10.1101/lm.1939811; Oliveira AMM, 2010, LEARN MEMORY, V17, P155, DOI 10.1101/lm.1625310; Patel TP, 2014, J NEUROSCI, V34, P4200, DOI 10.1523/JNEUROSCI.4172-13.2014; Pena A, 2005, ACT NEUR S, V95, P333; Pfister BJ, 2003, ANN BIOMED ENG, V31, P589, DOI 10.1114/1.1566445; Pleasant JM, 2011, J NEUROTRAUM, V28, P2245, DOI 10.1089/neu.2010.1499; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Rashid B, 2014, J MECH BEHAV BIOMED, V33, P43, DOI 10.1016/j.jmbbm.2012.07.015; Ruan J. S., 1993, FINITE ELEMENT MODEL; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; SHOHAMI E, 1988, NEUROSURGERY, V22, P859, DOI 10.1227/00006123-198805000-00007; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Shreiber DI, 1997, IN VIVO THRESHOLDS M; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; Singh Anita, 2006, Stapp Car Crash J, V50, P601; Singh P, 2012, J BIOL CHEM, V287, P4348, DOI 10.1074/jbc.M111.253740; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; TEASDALE G, 1974, LANCET, V2, P81; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C; Ward C. C, 1975, DEV DETAILED FINITE; Willinger R, 1999, ANN BIOMED ENG, V27, P403, DOI 10.1114/1.165; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yoganandan N, 2008, J BIOMECH, V41, P2253, DOI 10.1016/j.jbiomech.2008.04.019; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang Liying, 2002, Stapp Car Crash J, V46, P145; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	90	39	41	0	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2014	5								100	10.3389/fneur.2014.00100			14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	V42QW	WOS:000209629300097	24994996	DOAJ Gold, Green Published			2021-06-18	
J	Cusimano, MD; Chipman, M; Donnelly, P; Hutchison, MG				Cusimano, Michael D.; Chipman, Mary; Donnelly, Peter; Hutchison, Michael G.			Effectiveness of an educational video on concussion knowledge in minor league hockey players: a cluster randomised controlled trial	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Ice hockey; Injury Prevention; Concussion; Head injuries; Intervention effectiveness	YOUTH ICE HOCKEY; RUGBY UNION; INJURY PREVENTION; RISK-FACTORS; INTERVENTIONS; RULES	Background With the heightened awareness of concussions in all sports, the development and implementation of effective prevention strategies are necessary. Education has been advocated as an effective injury prevention intervention. Purpose To examine the effectiveness of the Smart Hockey: More Safety, More Fun' video on knowledge transfer among minor league hockey players. Study Design Cluster-randomised controlled trial. Methods A total of 267 participants from two age divisions and competitive levels were assigned to either a video or no-video group. The video was shown (or not shown) to the entire team as a result of random assignment. To evaluate the effectiveness of the educational video, questionnaires specific to concussion knowledge and players' attitudes and behaviours were completed. Results There was a significant increase in the players' concussion knowledge scores immediately following exposure to the video (F(1,103)=27.00, p<0.001). However, concussion knowledge at 2months was not significantly different between the video and no-video groups, after controlling for prior knowledge level, age and competitive level (F(1,115)=0.41, p=0.523). Similarly, players' attitudes and behaviour scores at 2months did not differ between groups (F(1,115)=0.41, p=0.507). Conclusions We were able to show that a single viewing of an educational video in hockey could immediately improve knowledge about concussion but that this effect was transient and lost at 2-month follow-up. Future prevention endeavours in hockey and other sports should attempt to incorporate strategies and modalities to enhance knowledge retention.	[Cusimano, Michael D.] Univ Toronto, Div Neurosurg, St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Chipman, Mary] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON M5B 1W8, Canada; [Donnelly, Peter; Hutchison, Michael G.] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON M5B 1W8, Canada	Cusimano, MD (corresponding author), Univ Toronto, Div Neurosurg, Injury Prevent Res Off, St Michaels Hosp, 3,30 Bond St, Toronto, ON M5B 1W8, Canada.	injuryprevention@smh.ca	Cusimano, Michael/X-4059-2019	Cusimano, Michael/0000-0002-9989-0650	Ontario Neurotrauma Foundation [ONF-02006-O]; Canadian Institutes of Health Research Strategic Team Grant in Applied Injury ResearchCanadian Institutes of Health Research (CIHR) [TIR-103946]	This study was funded by the Ontario Neurotrauma Foundation (# ONF-02006-O) and Canadian Institutes of Health Research Strategic Team Grant in Applied Injury Research (# TIR-103946). The funding organisations had no role in the design of the study and the collection, analysis and interpretation of the data.	BANDURA A, 1978, J COMMUN, V28, P12, DOI 10.1111/j.1460-2466.1978.tb01621.x; Biasca N, 2002, BRIT J SPORT MED, V36, P410, DOI 10.1136/bjsm.36.6.410; Biasca N., 2005, EUROPEAN J TRAUMA, V31, P105, DOI 10.1007/s00068-005-1050-z; Bjornson GL, 1997, CAN J PUBLIC HEALTH, V88, P405, DOI 10.1007/BF03403916; Braslow A, 1997, RESUSCITATION, V34, P207, DOI 10.1016/S0300-9572(97)01096-4; Brunelle JP, 2005, J SCI MED SPORT, V8, P294, DOI 10.1016/S1440-2440(05)80040-4; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; Cusimano MD, 2013, CAN MED ASSOC J, V185, pE57, DOI 10.1503/cmaj.112017; Cusimano Michael D, 2011, Open Med, V5, pe57; Cusimano MD, 2010, NEUROSURGERY, V67, P1404, DOI 10.1227/NEU.0b013e3181f209f1; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Emery CA, 2010, INJURY PREV, V16, P113, DOI 10.1136/ip.2009.022764; Freimuth VS, 1997, HEALTH EDUC BEHAV, V24, P555, DOI 10.1177/109019819702400504; Gianotti S, 2007, NEUROREHABILITATION, V22, P181; Gianotti S, 2010, J SCI MED SPORT, V13, P32, DOI 10.1016/j.jsams.2008.07.010; Gianotti SM, 2009, J SCI MED SPORT, V12, P371, DOI 10.1016/j.jsams.2008.01.002; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Goodman D, 2006, J ADOLESCENCE, V29, P351, DOI 10.1016/j.adolescence.2005.07.004; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; Grimshaw JM, 1998, J ROY SOC MED, V91, P20, DOI 10.1177/014107689809135S06; HockeyCanada, 2009, HOCK CAN ANN REP; Honey CR, 1998, CLIN J SPORT MED, V8, P43, DOI 10.1097/00042752-199801000-00010; JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101; Marchie A, 2003, CAN MED ASSOC J, V169, P124; McCauley J, 2003, ACAD MED, V78, P518, DOI 10.1097/00001888-200305000-00017; Mugno D A, 1985, Can J Appl Sport Sci, V10, P26; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Quarrie KL, 2007, BRIT MED J, V334, P1150, DOI 10.1136/bmj.39185.605914.AE; Roberts WO, 1996, ARCH PEDIAT ADOL MED, V150, P140, DOI 10.1001/archpedi.1996.02170270022003; Sawyer RJ, 2010, HEALTH PROMOT PRACT, V11, P34, DOI 10.1177/1524839907309377	32	39	39	0	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JAN	2014	48	2					141	U153		10.1136/bjsports-2012-091660			7	Sport Sciences	Sport Sciences	276KK	WOS:000328749000017	23918445				2021-06-18	
J	Huang, MX; Yurgil, KA; Robb, A; Angeles, A; Diwakar, M; Risbrough, VB; Nichols, SL; Mclay, R; Theilmann, RJ; Song, T; Huang, CW; Lee, RR; Baker, DG				Huang, Ming-Xiong; Yurgil, Kate A.; Robb, Ashley; Angeles, Annemarie; Diwakar, Mithun; Risbrough, Victoria B.; Nichols, Sharon L.; McLay, Robert; Theilmann, Rebecca J.; Song, Tao; Huang, Charles W.; Lee, Roland R.; Baker, Dewleen G.			Voxel-wise resting-state MEG source magnitude imaging study reveals neurocircuitry abnormality in active-duty service members and veterans with PTSD	NEUROIMAGE-CLINICAL			English	Article						MEG; Post-traumatic stress disorder; Amygdala; Ventromedial prefrontal cortex; Orbitofrontal cortex; Precuneous	POSTTRAUMATIC-STRESS-DISORDER; MEDIAL PREFRONTAL CORTEX; SIGNAL SPACE SEPARATION; TRAUMATIC BRAIN-INJURY; MIDLINE THETA-RHYTHM; CEREBRAL-BLOOD-FLOW; FUNCTIONAL CONNECTIVITY; DELTA WAVES; ORBITOFRONTAL CORTEX; HIPPOCAMPAL FUNCTION	Post-traumatic stress disorder (PTSD) is a leading cause of sustained impairment, distress, and poor quality of life in military personnel, veterans, and civilians. Indirect functional neuroimaging studies using PET or fMRI with fear-related stimuli support a PTSD neurocircuitry model that includes amygdala, hippocampus, and ventromedial prefrontal cortex (vmPFC). However, it is not clear if this model can fully account for PTSD abnormalities detected directly by electromagnetic-based source imaging techniques in resting-state. The present study examined resting-state magnetoencephalography (MEG) signals in 25 active-duty service members and veterans with PTSD and 30 healthy volunteers. In contrast to the healthy volunteers, individuals with PTSD showed: 1) hyperactivity from amygdala, hippocampus, posterolateral orbitofrontal cortex (OFC), dorsomedial prefrontal cortex (dmPFC), and insular cortex in high-frequency (i.e., beta, gamma, and high-gamma) bands; 2) hypoactivity from vmPFC, Frontal Pole (FP), and dorsolateral prefrontal cortex (dlPFC) in high-frequency bands; 3) extensive hypoactivity from dlPFC, FP, anterior temporal lobes, precuneous cortex, and sensorimotor cortex in alpha and low-frequency bands; and 4) in individuals with PTSD, MEG activity in the left amygdala and posterolateral OFC correlated positively with PTSD symptom scores, whereas MEG activity in vmPFC and precuneous correlated negatively with symptom score. The present study showed that MEG source imaging technique revealed new abnormalities in the resting-state electromagnetic signals from the PTSD neurocircuitry. Particularly, posterolateral OFC and precuneous may play important roles in the PTSD neurocircuitry model. Published by Elsevier Inc.	[Huang, Ming-Xiong; Yurgil, Kate A.; Robb, Ashley; Angeles, Annemarie; Risbrough, Victoria B.; Lee, Roland R.; Baker, Dewleen G.] VA San Diego Healthcare Syst, Serv Radiol, San Diego, CA USA; [Huang, Ming-Xiong; Yurgil, Kate A.; Robb, Ashley; Angeles, Annemarie; Risbrough, Victoria B.; Lee, Roland R.; Baker, Dewleen G.] VA San Diego Healthcare Syst, Res Serv, San Diego, CA USA; [Huang, Ming-Xiong; Yurgil, Kate A.; Robb, Ashley; Angeles, Annemarie; Risbrough, Victoria B.; Lee, Roland R.; Baker, Dewleen G.] VA San Diego Healthcare Syst, Psychiat Serv, San Diego, CA USA; [Huang, Ming-Xiong; Diwakar, Mithun; Theilmann, Rebecca J.; Song, Tao; Lee, Roland R.] Univ Calif San Diego, Dept Radiol, San Diego, CA 92103 USA; [Yurgil, Kate A.; Risbrough, Victoria B.; Baker, Dewleen G.] VA Ctr Excellence Stress & Mental Hlth, San Diego, CA USA; [Risbrough, Victoria B.; Baker, Dewleen G.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Nichols, Sharon L.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA; [McLay, Robert] Naval Med Ctr San Diego, San Diego, CA USA; [Huang, Charles W.] Univ Calif San Diego, Dept Bioengn, San Diego, CA 92121 USA	Huang, MX (corresponding author), Univ Calif San Diego, Radiol Imaging Lab, 3510 Dunhill St, San Diego, CA 92121 USA.	mxhuang@ucsd.edu	Risbrough, Victoria/X-3344-2019; Baker, Dewleen/O-4957-2019	Baker, Dewleen/0000-0002-1736-9838	Headquarters Marine Corps; Navy BUMED (MRS-II; Navy BUMED) [N62645-11-C-4037]; Department of Veterans AffairsUS Department of Veterans Affairs [I01-CX000499, NURC-022-10F, NEUC-044-06S]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007198] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX000499] Funding Source: NIH RePORTER	This work was supported in part by Headquarters Marine Corps and Navy BUMED to D. G. Baker, M. A. Geyer, M. X. Huang and V. B. Risbrough (MRS-II; Navy BUMED contract # N62645-11-C-4037) and Merit Review Grants from the Department of Veterans Affairs to M. X. Huang (I01-CX000499, NURC-022-10F, NEUC-044-06S). We acknowledge the MRS-II administrative core, Anjana Patel, Andrew De La Rosa, and members of the MRS-II Team, including logistic coordinators, clinician-interviewers, and data collection staff. We thank staff at the Veterans Medical Research Foundation (VRMF). We also thank the Marine, Navy and veteran volunteers for their military service and participation in this study.	American Psychiatric Association, 2004, PRACT GUID TREATM PA; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Anderson AK, 2003, J NEUROSCI, V23, P5627; [Anonymous], NEUROIMAGE, V20, P2291; Baayen JC, 2003, BRAIN TOPOGR, V16, P85, DOI 10.1023/B:BRAT.0000006332.71345.b7; Babiloni C, 2013, CLIN NEUROPHYSIOL, V124, P837, DOI 10.1016/j.clinph.2012.09.017; Bach DR, 2011, J NEUROSCI, V31, P618, DOI 10.1523/JNEUROSCI.2744-10.2011; BALL GJ, 1977, ELECTROEN CLIN NEURO, V43, P346, DOI 10.1016/0013-4694(77)90258-9; Benedetti F, 2011, BIPOLAR DISORD, V13, P414, DOI 10.1111/j.1399-5618.2011.00938.x; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bishop SJ, 2008, ANN NY ACAD SCI, V1129, P141, DOI 10.1196/annals.1417.016; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; BLANCHARD EB, 1995, BEHAV RES THER, V33, P471, DOI 10.1016/0005-7967(94)00064-Q; Bremner JD, 1999, AM J PSYCHIAT, V156, P1787; Brookes MJ, 2012, NEUROIMAGE, V63, P910, DOI 10.1016/j.neuroimage.2012.03.048; Brookes MJ, 2011, P NATL ACAD SCI USA, V108, P16783, DOI 10.1073/pnas.1112685108; Brookes MJ, 2011, NEUROIMAGE, V56, P1082, DOI 10.1016/j.neuroimage.2011.02.054; Bryant RA, 2005, BIOL PSYCHIAT, V58, P111, DOI 10.1016/j.biopsych.2005.03.021; Carlson N. R., 2013, PHYSL BEHAV; Carmichael ST, 1995, J COMP NEUROL, V363, P615, DOI 10.1002/cne.903630408; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Chung YA, 2006, CLIN NEUROPHYSIOL, V117, P637, DOI 10.1016/j.clinph.2005.10.020; Cohen D., 2002, P 13 INT C BIOM VDE; Corcoran KA, 2001, J NEUROSCI, V21, P1720; CZERVIONKE LF, 1988, AM J NEURORADIOL, V9, P1149; Davis M, 2001, MOL PSYCHIATR, V6, P13, DOI 10.1038/sj.mp.4000812; de Munck JC, 2009, NEUROIMAGE, V47, P69, DOI 10.1016/j.neuroimage.2009.04.029; DECKER DA, 1972, ELECTROEN CLIN NEURO, V33, P303, DOI 10.1016/0013-4694(72)90157-5; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dohrenwend BP, 2006, SCIENCE, V313, P979, DOI 10.1126/science.1128944; Dolcos F, 2004, NEURON, V42, P855, DOI 10.1016/S0896-6273(04)00289-2; Domsch S, 2013, MAGN RESON IMAGING, V31, P201, DOI 10.1016/j.mri.2012.06.020; Engdahl B, 2010, J NEURAL ENG, V7, DOI 10.1088/1741-2560/7/6/066005; Felmingham KL, 2009, PSYCHIAT RES-NEUROIM, V173, P59, DOI 10.1016/j.pscychresns.2008.12.005; Fransson P, 2008, NEUROIMAGE, V42, P1178, DOI 10.1016/j.neuroimage.2008.05.059; Freyer F, 2011, J NEUROSCI, V31, P6353, DOI 10.1523/JNEUROSCI.6693-10.2011; Georgopoulos AP, 2010, J NEURAL ENG, V7, DOI 10.1088/1741-2560/7/1/016011; Geuze E, 2007, ARCH GEN PSYCHIAT, V64, P76, DOI 10.1001/archpsyc.64.1.76; Geuze E, 2007, PROG BRAIN RES, V167, P293, DOI 10.1016/S0079-6123(07)67026-5; Ghuman AS, 2011, NEUROIMAGE, V56, P69, DOI 10.1016/j.neuroimage.2011.01.046; GLOOR P, 1977, NEUROLOGY, V27, P326, DOI 10.1212/WNL.27.4.326; Gold A.L., 2014, BIOL PSYCHI IN PRESS; Gramfort A, 2014, NEUROIMAGE, V86, P446, DOI 10.1016/j.neuroimage.2013.10.027; Hartley CA, 2010, NEUROPSYCHOPHARMACOL, V35, P136, DOI 10.1038/npp.2009.121; Hayes JP, 2009, PSYCHIAT RES-NEUROIM, V172, P7, DOI 10.1016/j.pscychresns.2008.05.005; He BYJ, 2008, P NATL ACAD SCI USA, V105, P16039, DOI 10.1073/pnas.0807010105; Hindriks R, 2013, NEUROIMAGE, V70, P150, DOI 10.1016/j.neuroimage.2012.12.018; Hinkley LBN, 2011, BIOL PSYCHIAT, V70, P1134, DOI 10.1016/j.biopsych.2011.06.029; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Huang MX, 2007, NEUROIMAGE, V37, P731, DOI 10.1016/j.neuroimage.2007.06.002; Huang MX, 2014, NEUROIMAGE-CLIN, V5, P109, DOI 10.1016/j.nicl.2014.06.004; Huang MX, 2014, NEUROIMAGE, V84, P585, DOI 10.1016/j.neuroimage.2013.09.022; Huang MX, 2012, NEUROIMAGE, V61, P1067, DOI 10.1016/j.neuroimage.2012.04.029; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Huang MX, 2006, NEUROIMAGE, V31, P1025, DOI 10.1016/j.neuroimage.2006.01.029; Hughes KC, 2011, EXPERT REV NEUROTHER, V11, P275, DOI [10.1586/ern.10.198, 10.1586/ERN.10.198]; Iversen AC, 2008, PSYCHOL MED, V38, P511, DOI 10.1017/S0033291708002778; Jackowski AP, 2012, REV BRAS PSIQUIATR, V34, P207, DOI 10.1590/S1516-44462012000200014; Jin C., 2013, P 4 INT SC WORKSH DA, P1, DOI DOI 10.1109/MWSYM.2013.6697734; Kandel E.R., 2000, PRINCIPLES NEURAL SC; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kopell N, 2000, P NATL ACAD SCI USA, V97, P1867, DOI 10.1073/pnas.97.4.1867; Lanius RA, 2007, PSYCHIAT RES-NEUROIM, V155, P45, DOI 10.1016/j.pscychresns.2006.11.006; Leahy RM, 1998, ELECTROEN CLIN NEURO, V107, P159, DOI 10.1016/S0013-4694(98)00057-1; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Lewine J D, 1995, Neuroimaging Clin N Am, V5, P575; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lindauer RJL, 2008, PSYCHOL MED, V38, P543, DOI 10.1017/S0033291707001432; Logothetis NK, 2003, J NEUROSCI, V23, P3963; Lyoo IK, 2011, ARCH GEN PSYCHIAT, V68, P701, DOI 10.1001/archgenpsychiatry.2011.70; Magruder KM, 2009, PSYCHIAT ANN, V39, P778, DOI 10.3928/00485713-20090728-04; McGaugh JL, 2004, ANNU REV NEUROSCI, V27, P1, DOI 10.1146/annurev.neuro.27.070203.144157; Mitchell DGV, 2011, BEHAV BRAIN RES, V217, P215, DOI 10.1016/j.bbr.2010.10.030; MIZUKI Y, 1980, ELECTROEN CLIN NEURO, V49, P345, DOI 10.1016/0013-4694(80)90229-1; MIZUKI Y, 1984, FOLIA PSYCHIAT NEU J, V38, P451; Moores KA, 2008, PSYCHIAT RES-NEUROIM, V163, P156, DOI 10.1016/j.pscychresns.2007.08.011; Morris JS, 1998, NATURE, V393, P467, DOI 10.1038/30976; Mosher JC, 1999, IEEE T BIO-MED ENG, V46, P245, DOI 10.1109/10.748978; Nagai M, 2007, EUR PSYCHIAT, V22, P387, DOI 10.1016/j.eurpsy.2007.02.006; NAGATA K, 1985, NEUROSURGERY, V17, P613, DOI 10.1227/00006123-198510000-00014; NAUTA WJH, 1979, FUNCTIONAL NEUROSURG, P7; Niedermeyer E, 2005, ELECTROENCEPHALOGRAP; Nir Y, 2008, NAT NEUROSCI, V11, P1100, DOI 10.1038/nn.2177; Passamonti L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048789; Rabinak C.A., 2014, DEPRESSION IN PRESS; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Rauch SL., 1998, CNS SPECTRUMS, V3, P30, DOI [10.1017/S1092852900007306, DOI 10.1017/S1092852900007306]; Renshaw KD, 2011, J AFFECT DISORDERS, V128, P321, DOI 10.1016/j.jad.2010.07.022; Robinson S.E., 1999, RECENT ADV BIOMAGNET, P302, DOI DOI 10.1016/J.NEUROIMAGE.2018.05.016; Rosen GM, 2008, CLIN PSYCHOL REV, V28, P837, DOI 10.1016/j.cpr.2007.12.002; Schaul N, 1998, ELECTROEN CLIN NEURO, V106, P101, DOI 10.1016/S0013-4694(97)00111-9; SCHAUL N, 1978, BRAIN RES, V143, P475, DOI 10.1016/0006-8993(78)90358-X; Scheeringa R, 2012, BRAIN CONNECT, V2, P254, DOI 10.1089/brain.2012.0088; Scholvinck ML, 2013, NEUROIMAGE, V80, P297, DOI 10.1016/j.neuroimage.2013.04.010; Scholvinck ML, 2010, P NATL ACAD SCI USA, V107, P10238, DOI 10.1073/pnas.0913110107; Sekihara K, 2001, IEEE T BIO-MED ENG, V48, P760, DOI 10.1109/10.930901; Semple WE, 2000, PSYCHIATRY, V63, P65, DOI 10.1080/00332747.2000.11024895; Shin LM, 2007, J TRAUMA STRESS, V20, P701, DOI 10.1002/jts.20231; Shin LM, 2006, ANN NY ACAD SCI, V1071, P67, DOI 10.1196/annals.1364.007; Shin LM, 2011, AM J PSYCHIAT, V168, P979, DOI 10.1176/appi.ajp.2011.09121812; Shin LM, 2010, NEUROPSYCHOPHARMACOL, V35, P169, DOI 10.1038/npp.2009.83; Shin LM, 2004, HIPPOCAMPUS, V14, P292, DOI 10.1002/hipo.10183; Shin LM, 2001, BIOL PSYCHIAT, V50, P932, DOI 10.1016/S0006-3223(01)01215-X; Shin LM, 2004, ARCH GEN PSYCHIAT, V61, P168, DOI 10.1001/archpsyc.61.2.168; Shmuel A, 2008, HUM BRAIN MAPP, V29, P751, DOI 10.1002/hbm.20580; Shu IW, 2014, J AFFECT DISORDERS, V155, P234, DOI 10.1016/j.jad.2013.06.057; Singer W, 1999, NEURON, V24, P49, DOI 10.1016/S0896-6273(00)80821-1; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Song T, 2008, MED BIOL ENG COMPUT, V46, P923, DOI 10.1007/s11517-007-0290-y; Sponheim SR, 2000, BIOL PSYCHIAT, V48, P1088, DOI 10.1016/S0006-3223(00)00907-0; Strigo IA, 2010, BIOL PSYCHIAT, V68, P442, DOI 10.1016/j.biopsych.2010.03.034; Takahashi N, 1997, CLIN ELECTROENCEPHAL, V28, P49, DOI 10.1177/155005949702800109; Talairach J., 1988, COPLANAR STEREOTACTI; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Tartaglione A, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-145; Taulu S, 2004, BRAIN TOPOGR, V16, P269, DOI 10.1023/b:brat.0000032864.93890.f9; Taulu S., 2004, NEUROLOGY CLIN NEURO, V35; VanVeen BD, 1997, IEEE T BIO-MED ENG, V44, P867, DOI 10.1109/10.623056; Vieth JB, 1996, BRAIN TOPOGR, V8, P215, DOI 10.1007/BF01184772; Weathers F. W., 1993, ANN M INT SOC TRAUM; Weathers FW, 1999, PSYCHOL ASSESSMENT, V11, P124, DOI 10.1037/1040-3590.11.2.124; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Whalen PJ, 2001, EMOTION, V1, P70, DOI 10.1037/1528-3542.1.1.70; Yan XD, 2013, NEUROSCI LETT, V547, P1, DOI 10.1016/j.neulet.2013.04.032	126	39	39	0	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2014	5						408	419		10.1016/j.nicl.2014.08.004			12	Neuroimaging	Neurosciences & Neurology	CB5LF	WOS:000349667800044	25180160	DOAJ Gold, Green Published			2021-06-18	
J	Colvin, JD; Thurm, C; Pate, BM; Newland, JG; Hall, M; Meehan, WP				Colvin, Jeffrey D.; Thurm, Cary; Pate, Brian M.; Newland, Jason G.; Hall, Matt; Meehan, William P., III			Diagnosis and acute management of patients with concussion at children's hospitals	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; SPORT-RELATED CONCUSSION; INTERNATIONAL-CONFERENCE; COMPUTED-TOMOGRAPHY; CONSENSUS STATEMENT; HEAD-INJURY; EMERGENCY; PREDICTION; IMPACT; EPIDEMIOLOGY	Objectives To describe the number of hospital admissions for concussion at paediatric hospitals in the USA. To describe the use of imaging and medications for acute concussion paediatric patients. Design Cross-sectional study. Setting Children's hospitals participating in the Pediatric Health Information System in the USA during a 10-year period. Patients All emergency department (ED) visits and inpatient admissions with the primary diagnosis of concussion, defined as International Classification of Diseases, Ninth Revision, Clinical Modification codes for: (1) concussion, (2) postconcussion syndrome or (3) skull fracture without mention of intracranial injury with concussion. Main outcome measures The proportion of concussion patients who were hospitalised, underwent imaging or received medication, and the adjusted costs of visits for concussion. Results The number of ED visits for concussion increased between 2001 and 2010 (2126 (0.36% of all ED visits) vs 4967 (0.62% of all ED visits); p<0.001), while the number of admissions remained stable. Of ED visits for concussion, 59.9% received CT and 47.7% received medications or intravenous fluids. Non-narcotic analgesics were the most common medication administered. Adjusted costs of patient visits were significantly higher when imaging was obtained (US$695, IQR US$472-$1009, vs US$191, IQR US$114-$287). An ED visit with CT, however, cost less than a hospitalisation without CT (US$1907, IQR US$1292-$3770). Conclusions Although the number of ED patients diagnosed with concussion has increased, the number admitted has remained stable. Concussion patients at paediatric hospitals in the USA commonly undergo CT imaging and receive medication.	[Colvin, Jeffrey D.; Pate, Brian M.] Univ Missouri, Childrens Mercy Hosp & Clin, Div Pediat Hosp Med, Dept Pediat, Kansas City, MO 64110 USA; [Thurm, Cary; Hall, Matt] Childrens Hosp Assoc, Dept Informat, Overland Pk, KS USA; [Newland, Jason G.] Univ Missouri, Dept Pediat, Div Infect Dis, Childrens Mercy Hosp & Clin, Kansas City, MO 64110 USA; [Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Meehan, William P., III] Childrens Hosp, Div Sports Med, Sports Concuss Clin, Boston, MA 02115 USA; [Meehan, William P., III] Childrens Hosp, Div Emergency Med, Boston, MA 02115 USA; [Meehan, William P., III] Childrens Hosp, Brain Injury Ctr, Boston, MA 02115 USA	Colvin, JD (corresponding author), Childrens Mercy Hosp, Sect Pediat Hosp Med, 2401 Gillham Rd, Kansas City, MO 64108 USA.	jdcolvin@cmh.edu	Colvin, Jeffrey/L-5492-2019		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD040128-06A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER	Dr Meehan is supported by award T32 HD040128-06A1 from the National Institutes of Health.	Adler RH, 2011, PM&R, V3, pS468, DOI 10.1016/j.pmrj.2011.08.006; [Anonymous], 2006, MED SCI SPORT EXER, V38, P395, DOI 10.1249/01.mss.0000202025.48774.31; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Bowser B., 2007, NEWSHOUR; Cantu RC, 2009, NEUROSURGERY, V64, P786, DOI 10.1227/01.NEU.0000348539.13887.D3; Carson J, 2006, CAN FAM PHYSICIAN, V52, P756; Crowe L, 2010, ARCH DIS CHILD, V95, P1017, DOI 10.1136/adc.2009.174854; Dalt L, 2005, EUR J PEDIATR, V165, P142; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Fackelmann K., 2003, US TODAY; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Grubenhoff JA, 2010, PEDIATRICS, V126, P688, DOI 10.1542/peds.2009-2804; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hendry SJ, 2005, ARCH DIS CHILD, V90, P629, DOI 10.1136/adc.2004.049502; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lockie FD, 2013, EMERG MED AUSTRALAS, V25, P75, DOI 10.1111/1742-6723.12019; Lueke L, 2011, J LEGAL MED, V32, P483, DOI 10.1080/01947648.2011.632710; MacMullan J., 2007, BOSTON GLOBE; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Mannix R, 2012, J PEDIATR-US, V160, P136, DOI 10.1016/j.jpeds.2011.06.024; Mannix R, 2011, ACAD EMERG MED, V18, P906, DOI 10.1111/j.1553-2712.2011.01154.x; Mannix R, 2010, ACAD EMERG MED, V17, P694, DOI 10.1111/j.1553-2712.2010.00797.x; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2002, BRIT J SPORT MED, V36, P3, DOI 10.1136/bjsm.36.1.3; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; MEADOWS B, 2007, PEOPLE MAGAZINE 1008, P107; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Muller K, 2003, J TRAUMA, V55, P1029, DOI 10.1097/01.TA.0000100371.49160.2A; Nigrovic LE, 2011, PEDIATRICS, V127, P1067, DOI 10.1542/peds.2010-3373; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Peterson SE, 2009, ANN EMERG MED, V53, P796, DOI 10.1016/j.annemergmed.2008.10.015; Rivara FP, 2012, ARCH PEDIAT ADOL MED, V166, P666, DOI 10.1001/archpediatrics.2011.1602; Schatz P, 2011, CLIN NEUROPSYCHOL, V25, P1042, DOI 10.1080/13854046.2011.556669; Schwarz A, 2007, NY TIMES; Shah SS, 2011, J HOSP MED, V6, P256, DOI 10.1002/jhm.872; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Truman CD, 2002, CAN J PUBLIC HEALTH, V93, P41, DOI 10.1007/BF03404416; Weiss AK, 2011, PEDIATRICS, V127, pE255, DOI 10.1542/peds.2010-0983; Williams A, 2009, ARCH DIS CHILD, V94, P817, DOI 10.1136/adc.2008.149823; Yang J, 2008, BRIT J SPORT MED, V42, P664, DOI 10.1136/bjsm.2007.040923	47	39	39	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888	1468-2044		ARCH DIS CHILD	Arch. Dis. Child.	DEC	2013	98	12					934	938		10.1136/archdischild-2012-303588			5	Pediatrics	Pediatrics	292JG	WOS:000329897400006	23852997	Bronze			2021-06-18	
J	Patton, DA; McIntosh, AS; Kleiven, S				Patton, Declan A.; McIntosh, Andrew S.; Kleiven, Svein			The Biomechanical Determinants of Concussion: Finite Element Simulations to Investigate Brain Tissue Deformations During Sporting Impacts to the Unprotected Head	JOURNAL OF APPLIED BIOMECHANICS			English	Article						biomechanics; head injury; modeling; sport	DIFFUSE AXONAL INJURY; BRIDGING VEINS; STRAIN-RATE; FOOTBALL; DAMAGE; RUGBY; ACCELERATION; EPIDEMIOLOGY; PREDICTORS; COLLEGIATE	Concussion is an injury of specific interest in collision and contact sports, resulting in a need to develop effective preventive strategies. A detailed finite element model of the human head was used to approximate the regional distribution of tissue deformations in the brain by simulating reconstructions of unhelmeted concussion and no-injury head impacts. The results were evaluated using logistic regression analysis and it was found that angular kinematics, in the coronal plane, and maximum principal strains, in all regions of the brain, were significantly associated with concussion. The results suggested that impacts to the temporal region of the head cause coronal rotations, which render injurious strain levels in the brain. Tentative strain tolerance levels of 0.13, 0.15, and 0.26 in the thalamus, corpus callosum, and white matter, respectively, for a 50% likelihood of concussion were determined by logistic regression. The tentative strain tolerance levels compared well with previously reported results from reconstruction studies of American football and single axon, optic nerve, and brain slice culture model studies. The methods used in the current study provide an opportunity to collect unique kinematic data of sporting impacts to the unprotected head, which can be employed in various ways to broaden the understanding of concussion.	[Patton, Declan A.; McIntosh, Andrew S.] Univ New S Wales, Fac Sci, Kensington, NSW 2033, Australia; [McIntosh, Andrew S.] Monash Univ, Australian Ctr Res Sports Injury & Its Prevent, Caulfield, Vic, Australia; [Kleiven, Svein] Royal Inst Technol, Sch Technol & Hlth, Stockholm, Sweden	Patton, DA (corresponding author), Univ New S Wales, Fac Sci, POB 1, Kensington, NSW 2033, Australia.						Ackerman MJ, 1998, P IEEE, V86, P504, DOI 10.1109/5.662875; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Allsop D. L., 1988, P 32 STAPP CAR CRASH, P139; [Anonymous], 2009, PASW STAT; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Baumgartner D, 2002, INT CRASHW C 2002 ME; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bewick V, 2005, CRIT CARE, V9, P112, DOI 10.1186/cc3045; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chinn B, 2001, COST 327 MOTORCYCLE; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Deck C, 2008, INT J CRASHWORTHINES, V13, P667, DOI 10.1080/13588260802411523; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Fournier E., 2000, IRCOBI INT RES COUNC, V2000, P223; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; Frechede B, 2009, MED SCI SPORT EXER, V41, P390, DOI 10.1249/MSS.0b013e318186b1c5; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Gennarelli T.A., 1971, P 15 STAPP CAR CRASH, V39, P797; Gennarelli T.A., 1972, STAPP CAR CRASH J, P296; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gordon KE, 2006, PEDIATR NEUROL, V34, P376, DOI 10.1016/j.pediatrneurol.2005.09.007; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hinton-Bayre AD, 2004, J SCI MED SPORT, V7, P400, DOI 10.1016/S1440-2440(04)80035-5; Ho J, 2009, INT J CRASHWORTHINES, V14, P555, DOI 10.1080/13588260902895708; Holbourn AHS, 1943, LANCET, V2, P438; JENNETT B, 1975, LANCET, V1, P480; Kimpara H, 2012, ANN BIOMED ENG, V40, P114, DOI 10.1007/s10439-011-0414-2; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Kleiven S., 2006, SCANDINAVIAN J FOREN, V2, P73; Kleiven S, 2002, THESIS SCH TECHNOLOG; Kleiven S, 2002, TRAFFIC INJ PREV, V3, P303, DOI DOI 10.1080/15389580214633; Kleiven Svein, 2003, Inj Control Saf Promot, V10, P173, DOI 10.1076/icsp.10.3.173.14552; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; LEE MC, 1989, J BIOMECH, V22, P537, DOI 10.1016/0021-9290(89)90005-5; LOWENHIELM P, 1974, Z RECHTSMED, V75, P131, DOI 10.1007/BF02114709; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; McCrory P, 2001, BRIT J SPORT MED, V35, P146, DOI 10.1136/bjsm.35.3.146; McIntosh AS, 2010, BRIT J SPORT MED, V44, P188, DOI 10.1136/bjsm.2007.041400; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; Mellor A, 2000, MOT ENG C EXP; Menard S, 1995, QUNAT APP SOC SCI; Monson KL, 2003, J BIOMECH ENG-T ASME, V125, P288, DOI 10.1115/1.1554412; Morrison B., 2003, STAPP CAR CRASH J, V47, P93; Newman J, 1999, INT RES COUNC BIOM I, P17; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Poirier MP, 2000, PEDIATR EMERG CARE, V16, P278, DOI 10.1097/00006565-200008000-00018; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schreiber DI, 1997, 41 STAPP CAR CRASH C, P277; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROSCI, V19, P4263; Takhounts EG, 2008, STAPP CAR C, V52, P1; Thibault L.E., 1990, P INT C BIOM IMP LYO, P191; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	63	39	40	1	20	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	1065-8483	1543-2688		J APPL BIOMECH	J. Appl. Biomech.	DEC	2013	29	6					721	730		10.1123/jab.29.6.721			10	Engineering, Biomedical; Sport Sciences	Engineering; Sport Sciences	AB7QX	WOS:000331986900010	23434739				2021-06-18	
J	Sumowski, JF; Chiaravalloti, N; Krch, D; Paxton, J; DeLuca, J				Sumowski, James F.; Chiaravalloti, Nancy; Krch, Denise; Paxton, Jessica; DeLuca, John			Education Attenuates the Negative Impact of Traumatic Brain Injury on Cognitive Status	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Cognitive disorders; Cognitive reserve; Neuropsychology; Rehabilitation	OLDER PERSONS; RESERVE; MEMORY	Objective: To investigate whether the cognitive reserve hypothesis helps to explain differential cognitive impairment among survivors of traumatic brain injury (TBI), whereby survivors with greater intellectual enrichment (estimated with education) are less vulnerable to cognitive impairment. Design: Cross-sectional study. Setting: Medical rehabilitation research center. Participants: Survivors of moderate or severe TBI (n=44) and healthy controls (n=36). Interventions: Not applicable. Main Outcome Measures: Intellectual enrichment was estimated with educational attainment. Group was defined as TBI or healthy control. Current cognitive status (processing speed, working memory, episodic memory) was evaluated with neuropsychological tasks. Results: TBI survivors exhibited worse cognitive status than healthy persons (P<.001), and education was positively correlated with cognitive status in TBI survivors (r=.54, P<.001). Most importantly, regression analysis revealed an interaction between group and education (R-2 change=.036, P=.004), whereas higher education attenuated the negative impact of TBI on cognitive status. TBI survivors with lower education performed much worse than matched healthy persons, but this TBI-related performance discrepancy was attenuated at higher levels of education. Conclusions: Higher intellectual enrichment (estimated with education) reduces the negative effect of TBI on cognitive outcomes, thereby supporting the cognitive reserve hypothesis in persons with TBI. Future work is necessary to investigate whether intellectual enrichment can build cognitive reserve as a rehabilitative intervention in survivors of TBI.	[Sumowski, James F.; Chiaravalloti, Nancy; Paxton, Jessica; DeLuca, John] Kessler Fdn, W Orange, NJ USA; [Sumowski, James F.; Chiaravalloti, Nancy; Krch, Denise; Paxton, Jessica; DeLuca, John] Rutgers New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ USA; [Chiaravalloti, Nancy; Krch, Denise] Kessler Fdn, Traumat Brain Injury Lab, W Orange, NJ USA; [DeLuca, John] Rutgers New Jersey Med Sch, Dept Neurol & Neurosci, Newark, NJ USA	Sumowski, JF (corresponding author), Kessler Fdn Res Ctr, 300 Execut Dr,Ste 70, W Orange, NJ 07052 USA.	jsumowski@kesslerfoundation.org		Chiaravalloti, Nancy/0000-0003-2943-7567	New Jersey Commission on Brain Injury Research [CBIR11PJT020]; National Institute on Disability and Rehabilitation Research [H133A070037]; Department of Education, National Institute on Disability and Rehabilitation Research [H133P090009]	Supported by the New Jersey Commission on Brain Injury Research (grant no. CBIR11PJT020); the National Institute on Disability and Rehabilitation Research (grant no. H133A070037); and a fellowship training grant from the Department of Education, National Institute on Disability and Rehabilitation Research (grant no. H133P090009).	Bennett DA, 2006, NEUROLOGY, V66, P1837, DOI 10.1212/01.wnl.0000219668.47116.e6; Bennett DA, 2003, NEUROLOGY, V60, P1909, DOI 10.1212/01.WNL.0000069923.64550.9F; Farmer JE, 2002, DEV NEUROPSYCHOL, V22, P455, DOI 10.1207/S15326942DN2202_2; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3; Hoofien D, 2001, BRAIN INJURY, V15, P189; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Raymont V, 2008, BRAIN, V131, P543, DOI 10.1093/brain/awm300; Roe CM, 2008, ARCH NEUROL-CHICAGO, V65, P1467, DOI 10.1001/archneur.65.11.1467; Satz P, 2011, J CLIN EXP NEUROPSYC, V33, P121, DOI 10.1080/13803395.2010.493151; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Sumowski JF, 2013, NEUROLOGY, V80, P2186, DOI 10.1212/WNL.0b013e318296e98b; Sumowski JF, 2010, NEUROLOGY, V74, P1942, DOI 10.1212/WNL.0b013e3181e396be	13	39	40	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2013	94	12					2562	2564		10.1016/j.apmr.2013.07.023			3	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	264UD	WOS:000327905600034	23932968				2021-06-18	
J	Lynall, RC; Laudner, KG; Mihalik, JP; Stanek, JM				Lynall, Robert C.; Laudner, Kevin G.; Mihalik, Jason P.; Stanek, Justin M.			Concussion-Assessment and -Management Techniques Used by Athletic Trainers	JOURNAL OF ATHLETIC TRAINING			English	Article						traumatic brain injuries; return-to-play guidelines; evaluation	SPORT-RELATED CONCUSSION; POSTURAL STABILITY; STATEMENT; SYMPTOMS	Context: Understanding concussion-assessmment and -management practices that athletic trainers (ATs) currently use will allow clinicians to identify potential strategies for enhancing the quality of care provided to patients. Objective: To assess current clinical concussion diagnostic and return-to-participation practices among ATs. Design: Cross-sectional study. Setting: Web-based survey. Patients or Other Participants: A link to the survey was sent randomly to a convenience sample of 3222 members of the National Athletic Trainers' Association. A total of 1053 (32.7%) certified ATs (experience as an AT = 11.2 +/- 9.1 years) responded to the survey. Intervention(s): Prospective participants received electronic correspondence informing them of the purpose of the study and providing a link to the Web-based survey instrument. A reminder e-mail was sent approximately 6 weeks later, and the survey remained online for a total of 8 weeks. Main Outcome Measure(s): We collected information on the annual number of concussions assessed and tools employed to diagnose, manage, and safely return an athlete to participation. Descriptive statistics were computed for each variable. Results: Participants reported observing 10.7 +/- 11.0 concussions per year. Clinical examination (n = 743, 70.6%) was the most commonly reported means for evaluating and diagnosing concussion. Less than half of our respondents employed the Standardized Assessment of Concussion (n = 467, 44.3%), any variation of the Romberg test (n = 461, 43.8%), and computerized neuropsychological testing (n = 459, 43.6%). Clinical examination (n = 773, 73.4%), return-to-participation guidelines (n = 713, 67.7%), physician recommendation (n = 660, 62.7%), or player self-report (n = 447, 42.5%) contributed to the return-to-participation decisions of ATs. Only 20.8% (n = 219) of ATs reported using all 3 recommended domains of the concussion battery. Conclusions: Our study demonstrated a growth in the number of ATs incorporating objective clinical measures of concussion as a part of their concussion management. Conversely, fewer ATs reported using a standard clinical examination in their concussion assessment. These findings suggest ATs must continue to increase their use of both objective concussion assessment tools and the standard clinical examination.	[Lynall, Robert C.; Laudner, Kevin G.; Stanek, Justin M.] Illinois State Univ, Sch Kinesiol & Recreat, Normal, IL 61761 USA; [Mihalik, Jason P.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA	Lynall, RC (corresponding author), Univ N Carolina, Stallings Evans Sports Med Ctr 2207, Campus Box 8700, Chapel Hill, NC 27599 USA.	rlynall@live.unc.edu	Lynall, Robert/M-2888-2014	Lynall, Robert/0000-0002-0785-6640; Mihalik, Jason/0000-0001-6085-8322			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Braithwaite D, 2003, FAM PRACT, V20, P545, DOI 10.1093/fampra/cmg509; Brasfield K., 2010, LEGISLATIVE REQUIREM; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2009, CLIN J SPORT MED, V19, P377, DOI 10.1097/JSM.0b013e3181b625fe; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Ferrara MS, 2001, J ATHL TRAINING, V36, P145; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Kelly JP, 1997, NEUROLOGY, V48, P581; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McLeod TCV, 2009, J ATHL TRAINING, V44, P663, DOI 10.4085/1062-6050-44.6.663; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006	23	39	39	0	15	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	NOV-DEC	2013	48	6					844	850		10.4085/1062-6050-48.6.04			7	Sport Sciences	Sport Sciences	268AW	WOS:000328141200015	24143906	Green Published			2021-06-18	
J	Hue, CD; Cao, SQ; Haider, SF; Vo, KV; Effgen, GB; Vogel, E; Panzer, MB; Bass, CR; Meaney, DF; Morrison, B				Hue, Christopher D.; Cao, Siqi; Haider, Syed F.; Vo, Kiet V.; Effgen, Gwen B.; Vogel, Edward, III; Panzer, Matthew B.; Bass, Cameron R. 'Dale'; Meaney, David F.; Morrison, Barclay, III			Blood-Brain Barrier Dysfunction after Primary Blast Injury in vitro	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; endothelial cells; primary blast injury; shock tube	CAPILLARY ENDOTHELIAL-CELLS; CLOSED-HEAD INJURY; TIGHT JUNCTIONS; GADOLINIUM-DTPA; SHOCK-WAVES; RAT MODEL; PERMEABILITY; EXPOSURE; EDEMA; DISRUPTION	The incidence of blast-induced traumatic brain injury (bTBI) has increased substantially in recent military conflicts. However, the consequences of bTBI on the blood-brain barrier (BBB), a specialized cerebrovascular structure essential for brain homeostasis, remain unknown. In this study, we utilized a shock tube driven by compressed gas to generate operationally relevant, ideal pressure profiles consistent with improvised explosive devices (IEDs). By multiple measures, the barrier function of an in vitro BBB model was disrupted following exposure to a range of controlled blast loading conditions. Trans-endothelial electrical resistance (TEER) decreased acutely in a dose-dependent manner that was most strongly correlated with impulse, as opposed to peak overpressure or duration. Significantly increased hydraulic conductivity and solute permeability post-injury further confirmed acute alterations in barrier function. Compromised ZO-1 immunostaining identified a structural basis for BBB breakdown. After blast exposure, TEER remained significantly depressed 2 days post-injury, followed by spontaneous recovery to pre-injury control levels at day 3. This study is the first to report immediate disruption of an in vitro BBB model following primary blast exposure, which may be important for the development of novel helmet designs to help mitigate the effects of blast on the BBB.	[Hue, Christopher D.; Cao, Siqi; Vo, Kiet V.; Effgen, Gwen B.; Vogel, Edward, III; Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA; [Panzer, Matthew B.; Bass, Cameron R. 'Dale'] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA; [Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Haider, Syed F.] CUNY City Coll, Dept Biol, New York, NY 10031 USA	Morrison, B (corresponding author), Columbia Univ, 351 Engn Terrace,MC8904 1210 Amsterdam Ave, New York, NY 10027 USA.	bm2119@columbia.edu	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864; Meaney, David/0000-0002-0954-4122; , Siqi/0000-0001-9779-4174	Multidisciplinary University Research Initiative from the Army Research Office [W911MF-10-1-0526]; National Science Foundation Graduate Research FellowshipNational Science Foundation (NSF) [DGE-07-07425]	We would like to thank Aaron Huang and Charles Levin for their assistance with experimental setup and operation of the blast injury device. This work was supported by a Multidisciplinary University Research Initiative from the Army Research Office (W911MF-10-1-0526) and a National Science Foundation Graduate Research Fellowship (to C.D.H.; DGE-07-07425). Portions of this work were previously presented at the 2012 International Research Council on the Biomechanics of Injury (IRCOBI), the 2012 National Neurotrauma Symposium, and the 2012 Annual Biomedical Research Conference for Minority Students (ABRCMS). The current manuscript has been significantly improved and expanded upon with new data compared to prior conference presentations of this work.	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Bershad EM, 2008, SEMIN NEUROL, V28, P690, DOI 10.1055/s-0028-1105968; Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653; Booth R, 2012, LAB CHIP, V12, P1784, DOI 10.1039/c2lc40094d; Brown RC, 2007, BRAIN RES, V1130, P17, DOI 10.1016/j.brainres.2006.10.083; Chen Y, 2011, BRAIN INJURY, V25, P641, DOI 10.3109/02699052.2011.580313; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; DELI MA, 1995, J NEUROSCI RES, V41, P717, DOI 10.1002/jnr.490410602; Deli MA, 2005, CELL MOL NEUROBIOL, V25, P59, DOI 10.1007/s10571-004-1377-8; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Diringer MN, 2004, NEUROCRIT CARE, V1, P219, DOI 10.1385/NCC:1:2:219; Effgen G. B., 2012, FRONT NEUROL, V3, P1; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Elliott MB, 2007, J NEUROTRAUM, V24, P195, DOI 10.1089/neu.2006.0094; ENTERS EK, 1992, BRAIN RES, V576, P271; Fanning AS, 2007, MOL BIOL CELL, V18, P721, DOI 10.1091/mbc.E06-08-0764; FENSTERMACHER JD, 1984, EDEMA, P383; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; Gaillard PJ, 2001, EUR J PHARM SCI, V12, P215, DOI 10.1016/S0928-0987(00)00123-8; GAMBIHLER S, 1992, NATURWISSENSCHAFTEN, V79, P328, DOI 10.1007/BF01138714; Garcia AN, 2011, METHODS MOL BIOL, V763, P333, DOI 10.1007/978-1-61779-191-8_23; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Gumbleton M, 2001, J PHARM SCI-US, V90, P1681, DOI 10.1002/jps.1119; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; HAWKINS CP, 1990, BRAIN, V113, P365, DOI 10.1093/brain/113.2.365; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; Hicks RR, 2010, J TRAUMA, V68, P1257, DOI 10.1097/TA.0b013e3181d8956d; Huber JD, 2001, TRENDS NEUROSCI, V24, P719, DOI 10.1016/S0166-2236(00)02004-X; Hyde D. W., 2004, CONWEP 2 1 0 8; Kirchhoff C, 2006, J NEUROTRAUM, V23, P943, DOI 10.1089/neu.2006.23.943; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; Kniesel U, 2000, CELL MOL NEUROBIOL, V20, P57, DOI 10.1023/A:1006995910836; Kodama T, 2000, BIOPHYS J, V79, P1821, DOI 10.1016/S0006-3495(00)76432-0; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Lai CH, 2005, BRAIN RES REV, V50, P7, DOI 10.1016/j.brainresrev.2005.03.007; LANDIS DMD, 1994, ANNU REV NEUROSCI, V17, P133, DOI 10.1146/annurev.ne.17.030194.001025; LARSSON HBW, 1990, MAGNET RESON MED, V16, P117, DOI 10.1002/mrm.1910160111; Li GL, 2010, ANN BIOMED ENG, V38, P2499, DOI 10.1007/s10439-010-0023-5; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; LIU HM, 1988, FORENSIC SCI INT, V38, P285, DOI 10.1016/0379-0738(88)90174-0; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Naik P, 2012, J PHARM SCI-US, V101, P1337, DOI 10.1002/jps.23022; Nelson TJ, 2008, J TRAUMA, V65, P212, DOI 10.1097/01.ta.0000196010.50246.9a; OHNO K, 1978, AM J PHYSIOL, V235, pH299; Olson JE, 1997, ACAD EMERG MED, V4, P662, DOI 10.1111/j.1553-2712.1997.tb03757.x; Omidi Y, 2003, BRAIN RES, V990, P95, DOI 10.1016/S0006-8993(03)03443-7; Panzer M. B., 2012, FRONT NEUROL, V3, P1; Panzer MB, 2012, ANN BIOMED ENG, V40, P1530, DOI 10.1007/s10439-012-0519-2; Panzer MB, 2012, J TRAUMA ACUTE CARE, V72, P454, DOI 10.1097/TA.0b013e31821e8270; Pardridge WM, 2007, DRUG DISCOV TODAY, V12, P54, DOI 10.1016/j.drudis.2006.10.013; Pardridge WM, 1999, J NEUROVIROL, V5, P556, DOI 10.3109/13550289909021285; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; RISAU W, 1990, TRENDS NEUROSCI, V13, P174, DOI 10.1016/0166-2236(90)90043-A; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; SILL HW, 1995, AM J PHYSIOL-HEART C, V268, pH535; Simard JM, 2009, STROKE, V40, P604, DOI 10.1161/STROKEAHA.108.522409; Simon MJ, 2011, ANN BIOMED ENG, V39, P394, DOI 10.1007/s10439-010-0144-x; Sonden A, 2000, LASER SURG MED, V26, P364, DOI 10.1002/(SICI)1096-9101(2000)26:4<364::AID-LSM4>3.0.CO;2-T; Sonden A, 2002, LASER SURG MED, V31, P233, DOI 10.1002/lsm.10093; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; TOFTS PS, 1991, MAGNET RESON MED, V17, P357, DOI 10.1002/mrm.1910170208; Tomkins O, 2008, J NEUROL NEUROSUR PS, V79, P774, DOI 10.1136/jnnp.2007.126425; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; vanAsperen J, 1997, J PHARM SCI, V86, P881, DOI 10.1021/js9701364; Victorino GP, 2003, SHOCK, V20, P171, DOI 10.1097/01.shk.0000079424.52617.92; Vilalta A, 2008, INTENS CARE MED, V34, P1384, DOI 10.1007/s00134-008-1056-1; Willis CL, 2004, GLIA, V45, P325, DOI 10.1002/glia.10333; Wolburg H, 2002, VASC PHARMACOL, V38, P323, DOI 10.1016/S1537-1891(02)00200-8; Yuan W, 2010, MICROVASC RES, V80, P148, DOI 10.1016/j.mvr.2010.03.011	83	39	42	0	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2013	30	19					1652	1663		10.1089/neu.2012.2773			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	227WQ	WOS:000325146800006	23581482				2021-06-18	
J	Jenkins, DD; Lee, T; Chiuzan, C; Perkel, JK; Rollins, LG; Wagner, CL; Katikaneni, LP; Bass, WT; Kaufman, DA; Horgan, MJ; Laungani, S; Givelichian, LM; Sankaran, K; Yager, JY; Martin, R				Jenkins, Dorothea D.; Lee, Timothy; Chiuzan, Cody; Perkel, Jessica K.; Rollins, Laura Grace; Wagner, Carol L.; Katikaneni, Lakshmi P.; Bass, W. Thomas; Kaufman, David A.; Horgan, Michael J.; Laungani, Sheela; Givelichian, Laurence M.; Sankaran, Koravangatta; Yager, Jerome Y.; Martin, Renee			Altered Circulating Leukocytes and Their Chemokines in a Clinical Trial of Therapeutic Hypothermia for Neonatal Hypoxic Ischemic Encephalopathy	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						chemokines; hypoxic ischemic brain injury; induced hypothermia; leukocytes	MONOCYTE CHEMOATTRACTANT PROTEIN-1; STROKE-INDUCED IMMUNODEPRESSION; TRAUMATIC BRAIN-INJURY; WHOLE-BODY HYPOTHERMIA; CENTRAL-NERVOUS-SYSTEM; MODERATE HYPOTHERMIA; BONE-MARROW; INFLAMMATORY RESPONSE; PROGENITOR CELLS; MICE LACKING	Objectives: To determine systemic hypothermia's effect on circulating immune cells and their corresponding chemokines after hypoxic ischemic encephalopathy in neonates. Design: In our randomized, controlled, multicenter trial of systemic hypothermia in neonatal hypoxic ischemic encephalopathy, we measured total and leukocyte subset and serum chemokine levels over time in both hypothermia and normothermia groups, as primary outcomes for safety. Setting: Neonatal ICUs participating in a Neurological Disorders and Stroke sponsored clinical trial of therapeutic hypothermia. Patients: Sixty-five neonates with moderate to severe hypoxic ischemic encephalopathy within 6 hours after birth. Interventions: Patients were randomized to normothermia of 37 degrees C or systemic hypothermia of 33 degrees C for 48 hours. Measurements and Main Results: Complete and differential leukocyte counts and serum chemokines were measured every 12 hours for 72 hours. The hypothermia group had significantly lower median circulating total WBC and leukocyte subclasses than the normothermia group before rewarming, with a nadir at 36 hours. Only the absolute neutrophil count rebounded after rewarming in the hypothermia group. Chemokines, monocyte chemotactic protein-1 and interleukin-8, which mediate leukocyte chemotaxis as well as bone marrow suppression, were negatively correlated with their target leukocytes in the hypothermia group, suggesting active chemokine and leukocyte modulation by hypothermia. Relative leukopenia at 60-72 hours correlated with an adverse outcome in the hypothermia group. Conclusions: Our data are consistent with chemokine-associated systemic immunosuppression with hypothermia treatment. In hypothermic neonates, persistence of lower leukocyte counts after rewarming is observed in infants with more severe CNS injury.	[Jenkins, Dorothea D.; Perkel, Jessica K.; Wagner, Carol L.; Katikaneni, Lakshmi P.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; [Lee, Timothy] Akron Childrens Hosp, Dept Pediat Emergency Med, Akron, OH USA; [Chiuzan, Cody; Martin, Renee] Med Univ S Carolina, Dept Med, Div Biostat & Epidemiol, Charleston, SC 29425 USA; [Rollins, Laura Grace] Univ Massachusetts, Dept Clin Psychol, Boston, MA 02125 USA; [Bass, W. Thomas] Eastern Virginia Med Sch, Dept Pediat, Norfolk, VA 23501 USA; [Kaufman, David A.] Univ Virginia, Dept Pediat, Charlottesville, VA USA; [Horgan, Michael J.] Albany Med Ctr, Dept Pediat, Albany, NY USA; [Laungani, Sheela] Brooklyn Hosp Ctr, Dept Pediat, Brooklyn, NY USA; [Givelichian, Laurence M.; Sankaran, Koravangatta] Univ Saskatchewan, Dept Pediat, Saskatoon, SK, Canada; [Yager, Jerome Y.] Univ Alberta, Dept Pediat, Edmonton, AB, Canada	Jenkins, DD (corresponding author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA.	jenkd@musc.edu	Chiuzan, Cody/K-8770-2019; Ward, LG/AAX-3500-2020; Chiuzan, Cody/M-9379-2019	Ward, LG/0000-0002-4792-5954; Chiuzan, Cody/0000-0001-8169-5032; horgan, michael/0000-0003-0991-6464	National Institutes of Neurologic Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS38602]; Saskatchewan Health Research foundation; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	Supported by R01 NS38602 from National Institutes of Neurologic Disorders and Stroke. The study sponsor had no input into the collection, analysis, and interpretation of data and the writing or submission of the manuscript for publication.; Dr. Givelichian's work on this project was supported by the Saskatchewan Health Research foundation. No form of payment was received for this manuscript. Dr. Jenkins received grant support from NINDS, is employed by the Medical University of SC and University Medical Associates, provided expert testimony for various legal firms, received grant support from the National Institutes of Health (NIH), other: NIH scientific review groups, and received support for article research from NIH. Drs. Rollins, Wagner, Katikaneni, Bass, Kaufman, Horgan, Laungani, and Sankaran received funding from NIH. Dr. Givelichian received funding from funding from NIH and the Saskatchewan Health Research Foundation. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; BALAJI S, 1991, BRIT HEART J, V66, P221; BIGGAR WD, 1983, INFECT IMMUN, V40, P708, DOI 10.1128/IAI.40.2.708-712.1983; Bona E, 1999, PEDIATR RES, V45, P500, DOI 10.1203/00006450-199904010-00008; Broxmeyer HE, 1996, J EXP MED, V184, P1825, DOI 10.1084/jem.184.5.1825; Buck BH, 2008, STROKE, V39, P355, DOI 10.1161/STROKEAHA.107.490128; Campbell SJ, 2005, AM J PATHOL, V166, P1487, DOI 10.1016/S0002-9440(10)62365-6; Ceulemans AG, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-74; Chapman KZ, 2009, J CEREBR BLOOD F MET, V29, P1764, DOI 10.1038/jcbfm.2009.113; Chen Y, 2003, J CEREBR BLOOD F MET, V23, P748, DOI 10.1097/01.WCB.0000071885.63724.20; Colditz IG, 2007, THROMB HAEMOSTASIS, V97, P688, DOI 10.1160/TH07-02-0105; Denes A, 2011, J CEREBR BLOOD F MET, V31, P1036, DOI 10.1038/jcbfm.2010.198; Deng H, 2003, STROKE, V34, P2495, DOI 10.1161/01.STR.0000091269.67384.E7; Dirnagl U, 2007, STROKE, V38, P770, DOI 10.1161/01.STR.0000251441.89665.bc; Downes CE, 2010, BRIT J PHARMACOL, V160, P1872, DOI 10.1111/j.1476-5381.2010.00864.x; Eicher DJ, 2005, PEDIATR NEUROL, V32, P18, DOI 10.1016/j.pediatrneurol.2004.06.015; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; GARCIA JH, 1993, AM J PATHOL, V142, P623; Gelderblom M, 2009, STROKE, V40, P1849, DOI 10.1161/STROKEAHA.108.534503; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Grau AJ, 2001, J NEUROL SCI, V192, P41, DOI 10.1016/S0022-510X(01)00590-1; Hug A, 2009, STROKE, V40, P3226, DOI 10.1161/STROKEAHA.109.557967; Hughes PM, 2002, J CEREBR BLOOD F MET, V22, P308, DOI 10.1097/00004647-200203000-00008; Jacobs SE, 2011, ARCH PEDIAT ADOL MED, V165, P692, DOI 10.1001/archpediatrics.2011.43; Jenkins DD, 2012, J CEREBR BLOOD F MET, V32, P1888, DOI 10.1038/jcbfm.2012.83; Jin YX, 2009, STROKE, V40, P3107, DOI 10.1161/STROKEAHA.109.549691; Kirchhoff C, 2008, EUR J MED RES, V13, P464; Klehmet J, 2009, NEUROSCIENCE, V158, P1184, DOI 10.1016/j.neuroscience.2008.07.044; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Liesz A, 2009, STROKE, V40, P2849, DOI 10.1161/STROKEAHA.109.549618; Liesz A, 2009, NAT MED, V15, P192, DOI 10.1038/nm.1927; MANROE BL, 1979, J PEDIATR-US, V95, P89, DOI 10.1016/S0022-3476(79)80096-7; MATTHYS D, 1995, PEDIATR CARDIOL, V16, P294, DOI 10.1007/BF00798065; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Newman TB, 2010, PEDIATRICS, V126, P903, DOI 10.1542/peds.2010-0935; Offner H, 2009, NEUROSCIENCE, V158, P1098, DOI 10.1016/j.neuroscience.2008.05.033; Ormstad H, 2011, J NEUROL, V258, P677, DOI 10.1007/s00415-011-6006-0; Oto J, 2008, J ANESTH, V22, P207, DOI 10.1007/s00540-008-0639-x; Pitchford SC, 2009, CELL STEM CELL, V4, P62, DOI 10.1016/j.stem.2008.10.017; Pruenster M, 2009, NAT IMMUNOL, V10, P101, DOI 10.1038/ni.1675; Reid S, 1999, BLOOD, V93, P1524, DOI 10.1182/blood.V93.5.1524.405k07_1524_1533; Shankaran S, 2008, PEDIATRICS, V122, pE791, DOI 10.1542/peds.2008-0456; Simbruner G, 2010, PEDIATRICS, V126, pE771, DOI 10.1542/peds.2009-2441; Smith CJ, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-2; Summers C, 2010, TRENDS IMMUNOL, V31, P318, DOI 10.1016/j.it.2010.05.006; VANOSS CJ, 1980, J RETICULOENDOTH SOC, V27, P561; Vogelgesang A, 2008, STROKE, V39, P237, DOI 10.1161/STROKEAHA.107.493635; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Wengner AM, 2008, BLOOD, V111, P42, DOI 10.1182/blood-2007-07-099648; Weston RM, 2007, J CEREBR BLOOD F MET, V27, P100, DOI 10.1038/sj.jcbfm.9600324; Zhou WH, 2010, J PEDIATR-US, V157, P367, DOI 10.1016/j.jpeds.2010.03.030; Zozulya AL, 2007, J IMMUNOL, V178, P520, DOI 10.4049/jimmunol.178.1.520	52	39	39	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	OCT	2013	14	8					786	795		10.1097/PCC.0b013e3182975cc9			10	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	AI0EF	WOS:000336518300012	23897243				2021-06-18	
J	Sheehan, B; Nigrovic, LE; Dayan, PS; Kuppermann, N; Ballard, DW; Alessandrini, E; Bajaj, L; Goldberg, H; Hoffman, J; Offerman, SR; Mark, DG; Swietlik, M; Tham, E; Tzimenatos, L; Vinson, DR; Jones, GS; Bakken, S				Sheehan, Barbara; Nigrovic, Lise E.; Dayan, Peter S.; Kuppermann, Nathan; Ballard, Dustin W.; Alessandrini, Evaline; Bajaj, Lalit; Goldberg, Howard; Hoffman, Jeffrey; Offerman, Steven R.; Mark, Dustin G.; Swietlik, Marguerite; Tham, Eric; Tzimenatos, Leah; Vinson, David R.; Jones, Grant S.; Bakken, Suzanne		Pediat Emergency Care Appl Res Net	Informing the design of clinical decision support services for evaluation of children with minor blunt head trauma in the emergency department: A sociotechnical analysis	JOURNAL OF BIOMEDICAL INFORMATICS			English	Article						Clinical decision support; Prediction rules; Traumatic brain injury; Emergency department; Pediatrics	HEALTH-CARE; ORDER-ENTRY; UNINTENDED CONSEQUENCES; INFORMATION-TECHNOLOGY; SYSTEMS; PRINCIPLES; QUALITY	Integration of clinical decision support services (CDSS) into electronic health records (EHRs) may be integral to widespread dissemination and use of clinical prediction rules in the emergency department (ED). However, the best way to design such services to maximize their usefulness in such a complex setting is poorly understood. We conducted a multi-site cross-sectional qualitative study whose aim was to describe the sociotechnical environment in the ED to inform the design of a CDSS intervention to implement the Pediatric Emergency Care Applied Research Network (PECARN) clinical prediction rules for children with minor blunt head trauma. Informed by a sociotechnical model consisting of eight dimensions, we conducted focus groups, individual interviews and workflow observations in 11 EDs, of which 5 were located in academic medical centers and 6 were in community hospitals. A total of 126 ED clinicians, information technology specialists, and administrators participated. We clustered data into 19 categories of sociotechnical factors through a process of thematic analysis and subsequently organized the categories into a sociotechnical matrix consisting of three high-level sociotechnical dimensions (workflow and communication, organizational factors, human factors) and three themes (interdisciplinary assessment processes, clinical practices related to prediction rules, EHR as a decision support tool). Design challenges that emerged from the analysis included the need to use structured data fields to support data capture and re-use while maintaining efficient care processes, supporting interdisciplinary communication, and facilitating family-clinician interaction for decision-making. (C) 2013 Elsevier Inc. All rights reserved.	[Sheehan, Barbara] Columbia Univ, Med Ctr, Fac Pract Org, New York, NY 10032 USA; [Nigrovic, Lise E.] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Dayan, Peter S.; Jones, Grant S.] Columbia Univ Coll Phys & Surg, Dept Pediat, Div Emergency Med, New York, NY 10032 USA; [Kuppermann, Nathan] Univ Calif Davis, Sch Med, Dept Pediat & Emergency Med, Sacramento, CA 95817 USA; [Ballard, Dustin W.] Kaiser Permanente, San Rafael Med Ctr, San Rafael, CA USA; [Alessandrini, Evaline] Univ Cincinnati, Coll Med, Dept Pediat, Div Emergency Med,Cincinnati Childrens Hosp & Med, Cincinnati, OH USA; [Bajaj, Lalit; Swietlik, Marguerite; Tham, Eric] Univ Colorado Denver, Childrens Hosp Colorado, Dept Pediat, Aurora, CO USA; [Goldberg, Howard] Partners HealthCare Syst, Boston, MA USA; [Hoffman, Jeffrey] Nationwide Childrens Hosp, Dept Pediat, Div Emergency Med, Columbus, OH USA; [Offerman, Steven R.] Kaiser Permanente, South Sacramento Med Ctr, Sacramento, CA USA; [Mark, Dustin G.] Kaiser Permanente, Oakland Med Ctr, Oakland, CA USA; [Tzimenatos, Leah] Univ Calif Davis, Sch Med, Dept Emergency Med, Sacramento, CA 95817 USA; [Vinson, David R.] Kaiser Permanente, Roseville Med Ctr, Roseville, NSW, Australia; [Vinson, David R.] Columbia Univ, Sch Nursing, New York, NY 10032 USA; [Vinson, David R.] Columbia Univ, Dept Biomed Informat, New York, NY 10032 USA	Sheehan, B (corresponding author), Columbia Univ, Med Ctr, Fac Pract Org, 51 Audubon Ave,6th Floor, New York, NY 10032 USA.	bs584@columbia.edu	Vinson, David R/AAK-3227-2020	Vinson, David R/0000-0001-6559-1858; Holubkov, Richard/0000-0003-0431-3381; Nigrovic, Lise/0000-0002-6369-3997	American Recovery and Reinvestment Act-Office of the Secretary (ARRA OS) [S02MC19289-01-00]; Health Resources and Services Administration (HRSA), Maternal and Child Health Bureau (MCHB), Emergency Medical Services for Children (EMSC) Program [U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, U03MC22685]	This work was supported by the American Recovery and Reinvestment Act-Office of the Secretary (ARRA OS): Grant #S02MC19289-01-00.; PECARN is supported by the Health Resources and Services Administration (HRSA), Maternal and Child Health Bureau (MCHB), Emergency Medical Services for Children (EMSC) Program through the following cooperative agreements: U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, and U03MC22685.	Agency for Healthcare Research and Quality (AHRQ), 2001, TRANSL RES PRACT TRI; Anderson NR, 2007, INT J MED INFORM, V76, P821, DOI 10.1016/j.ijmedinf.2006.09.022; Asaro PV, 2006, ACAD EMERG MED, V13, P452, DOI 10.1197/j.aem.2005.09.015; Ash JS, 2007, J AM MED INFORM ASSN, V14, P415, DOI 10.1197/jamia.M2373; Ash JS, 2012, BMC MED INFORM DECIS, V12, DOI 10.1186/1472-6947-12-6; Ash JS, 2004, J AM MED INFORM ASSN, V11, P104, DOI 10.1197/jamia.M1471; Bates DW, 2003, J AM MED INFORM ASSN, V10, P523, DOI 10.1197/jamia.M1370; Berg M, 1999, INT J MED INFORM, V55, P87, DOI 10.1016/S1386-5056(99)00011-8; Berg M, 2003, METHOD INFORM MED, V42, P297; BERNER ES, 2009, CLIN DECISION SUPPOR, P4; BEYER H, 2009, REPRESENTING WORK PU; Bright TJ, 2012, ANN INTERN MED, V157, P29, DOI 10.7326/0003-4819-157-1-201207030-00450; CHERNS A, 1976, HUM RELAT, V29, P783, DOI 10.1177/001872677602900806; Clegg CW, 2000, APPL ERGON, V31, P463, DOI 10.1016/S0003-6870(00)00009-0; Garg AX, 2005, JAMA-J AM MED ASSOC, V293, P1223, DOI 10.1001/jama.293.10.1223; Gooch P, 2011, J AM MED INFORM ASSN, V18, P738, DOI 10.1136/amiajnl-2010-000033; Griffey RT, 2012, J AM MED INFORM ASSN, V19, P86, DOI 10.1136/amiajnl-2011-000124; Handler JA, 2004, ACAD EMERG MED, V11, P1135, DOI 10.1197/j.aem.2004.08.007; Holtzblatt K., 2005, RAPID CONTEXTUAL DES; *KAIS PERM, CLIN RES EM SERV TRE; Karsh B., 2009, CLIN PRACTICE IMPROV; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Lin CP, 2008, J AM MED INFORM ASSN, V15, P620, DOI 10.1197/jamia.M2453; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Payne TH, 2002, AMIA 2002 SYMPOSIUM, PROCEEDINGS, P602; Payne TH, 2010, J AM MED INFORM ASSN, V17, P108, DOI 10.1197/jamia.M3173; Peleg M, 2009, INT J MED INFORM, V78, P482, DOI 10.1016/j.ijmedinf.2009.02.008; Porter SC, 2006, PEDIATRICS, V117, pE33, DOI 10.1542/peds.2005-0906; Porter SC, 2004, J AM MED INFORM ASSN, V11, P458, DOI 10.1197/jamia.M1569; Sittig DF, 2010, QUAL SAF HEALTH CARE, V19, pI68, DOI 10.1136/qshc.2010.042085; Terrell KM, 2009, J AM GERIATR SOC, V57, P1388, DOI 10.1111/j.1532-5415.2009.02352.x; Wagholikar KB, 2012, J AM MED INFORM ASSN, V19, P833, DOI 10.1136/amiajnl-2012-000820; Walker GH, 2008, THEOR ISS ERGON SCI, V9, P479, DOI 10.1080/14639220701635470; Wright A, 2008, J BIOMED INFORM, V41, P982, DOI 10.1016/j.jbi.2008.03.009	34	39	40	0	25	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1532-0464	1532-0480		J BIOMED INFORM	J. Biomed. Inform.	OCT	2013	46	5					905	913		10.1016/j.jbi.2013.07.005			9	Computer Science, Interdisciplinary Applications; Medical Informatics	Computer Science; Medical Informatics	223YO	WOS:000324848600016	23892207	Bronze			2021-06-18	
J	Testoni, D; Hornik, CP; Smith, PB; Benjamin, DK; McKinney, RE				Testoni, Daniela; Hornik, Christoph P.; Smith, P. Brian; Benjamin, Daniel K., Jr.; McKinney, Ross E., Jr.			Sports Medicine and Ethics	AMERICAN JOURNAL OF BIOETHICS			English	Article						sports medicine; ethics; conflict of interest; sports; football; athletes	LOCAL-ANESTHETIC INJECTIONS; INFORMED-CONSENT; PROFESSIONAL FOOTBALL; DECISION-MAKING; PHYSICIAN; RETURN; PLAY; PARTICIPATION; CONCUSSION	Physicians working in the world of competitive sports face unique ethical challenges, many of which center around conflicts of interest. Team-employed physicians have obligations to act in the club's best interest while caring for the individual athlete. As such, they must balance issues like protecting versus sharing health information, as well as issues regarding autonomous informed consent versus paternalistic decision making in determining whether an athlete may compete safely. Moreover, the physician has to deal with an athlete's decisions about performance enhancement and return to play, pursuit of which may not be in the athlete's long-term best interests but may benefit the athlete and team in the short term. These difficult tasks are complicated by the lack of evidence-based standards in a field influenced by the lure of financial gains for multiple parties involved. In this article, we review ethical issues in sports medicine with specific attention paid to American professional football.	[Testoni, Daniela] Univ Fed Sao Paulo, Sao Paulo, Brazil; [Hornik, Christoph P.; Smith, P. Brian; Benjamin, Daniel K., Jr.; McKinney, Ross E., Jr.] Duke Univ, Med Ctr, Durham, NC 27710 USA	McKinney, RE (corresponding author), Duke Univ, Med Ctr, DUMC Box 3461, Durham, NC 27710 USA.	ross.mckinney@duke.edu	NOBRE, DANIELA TESTONI COSTA/D-6657-2017; Smith, Phillip B/I-5565-2014	NOBRE, DANIELA TESTONI COSTA/0000-0001-7629-4904; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD060040, K24HD058735, R01HD057956] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K24 HD058735, K23 HD060040, R01 HD057956, HHSN275201000003I] Funding Source: Medline; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [HHSN267200700051C] Funding Source: Medline		Anderson L, 2008, J MED ETHICS, V34, DOI 10.1136/jme.2008.024794; Anderson LC, 2005, J MED ETHICS, V31, P88, DOI 10.1136/jme.2002.000836; [Anonymous], 2009, WORLD ANT COD; Attarian DE, 2001, J BONE JOINT SURG AM, V83A, P293, DOI 10.2106/00004623-200102000-00020; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Belson K., 2012, NY TIMES; Bernstein J, 2000, CLIN ORTHOP RELAT R, P50; Bowen M., 2011, NATL FOOTBALL POST; Bunch WH, 2004, CLIN SPORT MED, V23, P183, DOI 10.1016/j.csm.2004.01.004; Burgess T. L., 2011, South African Journal of Sports Medicine, V23, P138; Capozzi JD, 2000, J BONE JOINT SURG AM, V82A, P1668, DOI 10.2106/00004623-200011000-00022; Charles C, 1999, SOC SCI MED, V49, P651, DOI 10.1016/S0277-9536(99)00145-8; Dunn WR, 2007, AM J SPORT MED, V35, P840, DOI 10.1177/0363546506295177; Federation International de Medecine Sportive, 2009, PRINC ETH GUID HLTH; Federation International de Medecine Sportive, 2009, POS STAT DOP SPORT; Finnoff JT, 2010, PM&R, V2, P285, DOI 10.1016/j.pmrj.2010.03.016; GILLON R, 1994, BRIT MED J, V309, P184, DOI 10.1136/bmj.309.6948.184; Guadagnoli E, 1998, SOC SCI MED, V47, P329, DOI 10.1016/S0277-9536(98)00059-8; Hall DE, 2012, CAN MED ASSOC J, V184, P533, DOI 10.1503/cmaj.112120; Holm S, 2011, BRIT J SPORT MED, V45, P1170, DOI 10.1136/bjsm.2011.086124; Hopper KD, 1998, SURGERY, V123, P496, DOI 10.1067/msy.1998.87236; HYLAND DA, 1979, HASTINGS CENT REP, V9, P5, DOI 10.2307/3560268; Johnson DL, 2008, ORTHOPEDICS, V31, P534, DOI 10.3928/01477447-20080601-16; Johnson R, 2004, CLIN SPORT MED, V23, P175, DOI 10.1016/j.csm.2004.01.003; King N. M. P., 2008, STUDIES ETHICS LAW T, V1, P1; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Magee J. T., 2003, SPORTS MED UPDAT MAR; McNamee MJ, 2009, SPORTS MED, V39, P339, DOI 10.2165/00007256-200939050-00001; Meisel A, 1996, ARCH INTERN MED, V156, P2521, DOI 10.1001/archinte.156.22.2521; National Football League, 2012, LEAG POL PLAYERS; Nemeth P., 2009, MICHIGAN BAR J, P42; Orchard J, 2001, BRIT J SPORT MED, V35, P212, DOI 10.1136/bjsm.35.4.212; Orchard JW, 2010, AM J SPORT MED, V38, P2259, DOI 10.1177/0363546510372796; Orchard JW, 2002, BRIT J SPORT MED, V36, P209, DOI 10.1136/bjsm.36.3.209; Pelliccia A, 2005, EUR HEART J, V26, P1422, DOI 10.1093/eurheartj/ehi325; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; Polsky S, 1998, J Contemp Health Law Policy, V14, P503; Ross JR, 2012, J BONE JOINT SURG AM, V94A, P95, DOI 10.2106/JBJS.K.01423; Savulescu J, 2005, BRIT J SPORT MED, V39, P472, DOI 10.1136/bjsm.2005.017954; SIM J, 1993, BRIT J SPORT MED, V27, P95, DOI 10.1136/bjsm.27.2.95; Sjoqvist F, 2008, LANCET, V371, P1872, DOI 10.1016/S0140-6736(08)60801-6; Stoljar N, 2011, J MED PHILOS, V36, P375, DOI 10.1093/jmp/jhr029; Stovitz Steven D, 2006, Curr Sports Med Rep, V5, P120; Trusty Jane M, 2004, AACN Clin Issues, V15, P432, DOI 10.1097/00044067-200407000-00010; Tucker AM, 2004, CLIN SPORT MED, V23, P227, DOI 10.1016/j.csm.2004.01.001; Waddington I, 2002, BRIT J SPORT MED, V36, P118, DOI 10.1136/bjsm.36.2.118; Weir Dr, 2009, NATL FOOTBALL LEAGUE; Whitney SN, 2004, ANN INTERN MED, V140, P54, DOI 10.7326/0003-4819-140-1-200401060-00012; Williams J., 2009, WORLD MED ASS MED ET, V23; World Health Organization, 2012, CLASS HLTH WORK; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489	52	39	40	0	46	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1526-5161	1536-0075		AM J BIOETHICS	Am. J. Bioeth.	OCT 1	2013	13	10					4	12		10.1080/15265161.2013.828114			9	Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical	Social Sciences - Other Topics; Medical Ethics; Social Issues; Biomedical Social Sciences	217FV	WOS:000324345300002	24024796	Green Accepted			2021-06-18	
J	Turner, RC; Naser, ZJ; Logsdon, AF; DiPasquale, KH; Jackson, GJ; Robson, MJ; Gettens, RTT; Matsumoto, RR; Huber, JD; Rosen, CL				Turner, Ryan C.; Naser, Zachary J.; Logsdon, Aric F.; DiPasquale, Kenneth H.; Jackson, Garrett J.; Robson, Matthew J.; Gettens, Robert T. T.; Matsumoto, Rae R.; Huber, Jason D.; Rosen, Charles L.			Modeling clinically relevant blast parameters based on scaling principles produces functional & histological deficits in rats	EXPERIMENTAL NEUROLOGY			English	Article						Blast injury; Shock tube; Blast duration; Traumatic brain injury; Neural injury	TRAUMATIC BRAIN-INJURY; AXONAL INJURY; MOUSE MODEL; AIR-BLAST; MECHANISMS; MICROGLIA; ACTIVATION; STRESS	Blast-induced traumatic brain injury represents a leading cause of injury in modem warfare with injury pathogenesis poorly understood. Preclinical models of blast injury remain poorly standardized across laboratories and the clinical relevance unclear based upon pulmonary injury scaling laws. Models capable of high peak overpressures and of short duration may better replicate clinical exposure when scaling principles are considered. In this work we demonstrate a tabletop shock tube model capable of high peak overpressures and of short duration. By varying the thickness of the polyester membrane, peak overpressure can be controlled. We used membranes with a thickness of 0.003, 0.005, 0.007, and 0.010 in to generate peak reflected overpressures of 31.47, 50.72, 72.05, and 90.10 PSI, respectively. Blast exposure was shown to decrease total activity and produce neural degeneration as indicated by fluoro-jade B staining. Similarly, blast exposure resulted in increased glial activation as indicated by an increase in the number of glial fibrillary acidic protein expressing astrocytes compared to control within the corpus callosum, the region of greatest apparent injury following blast exposure. Similar findings were observed with regard to activated microglia, some of which displayed phagocytic-like morphology within the corpus callosum following blast exposure, particularly with higher peak overpressures. Furthermore, hematoxylin and eosin staining showed the presence of red blood cells within the parenchyma and red, swollen neurons following blast injury. Exposure to blast with 90.10 PSI peak reflected overpressure resulted in immediate mortality associated with extensive intracranial bleeding. This work demonstrates one of the first examples of blast-induced brain injury in the rodent when exposed to a blast wave scaled from human exposure based on scaling principles derived from pulmonary injury lethality curves. (C) 2013 Elsevier Inc. All rights reserved.	[Turner, Ryan C.; Naser, Zachary J.; Jackson, Garrett J.; Rosen, Charles L.] W Virginia Univ, Sch Med, Dept Neurosurg, Morgantown, WV 26506 USA; [Turner, Ryan C.; Naser, Zachary J.; Logsdon, Aric F.; DiPasquale, Kenneth H.; Jackson, Garrett J.; Robson, Matthew J.; Matsumoto, Rae R.; Huber, Jason D.; Rosen, Charles L.] W Virginia Univ, Sch Med, Ctr Neurosci, Morgantown, WV 26506 USA; [Logsdon, Aric F.; DiPasquale, Kenneth H.; Robson, Matthew J.; Matsumoto, Rae R.; Huber, Jason D.] W Virginia Univ, Sch Pharm, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA; [Gettens, Robert T. T.] Western New England Univ, Coll Engn, Dept Biomed Engn, Springfield, MA USA	Rosen, CL (corresponding author), W Virginia Univ, Sch Med, Dept Neurosurg, Hlth Sci Ctr, 1 Med Ctr Dr,Suite 4300,POB 9183, Morgantown, WV 26506 USA.	crosen@hsc.wvu.edu	Robson, Matthew/H-3127-2013	Robson, Matthew/0000-0002-3277-3062; Turner, Ryan/0000-0001-5523-0645	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32GM08174, 5RO1-NS061954, DA013978]; West Virginia University Department of Neurosurgery; American Society for Quality, Biomedical Division; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [S06GM008174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA013978] Funding Source: NIH RePORTER	The authors would like to thank Nicholas St. John for contributing to the design of the blast model, Brandon P. Lucke-Wold for his assistance with preliminary experiments, and Ms. Diana Richardson of the National Institute of Occupational Safety and Health (NIOSH) for her assistance in tissue preparation. The authors would also like to thank Mr. James Edward Robson and Mr. Peter Bennett for their assistance in model construction. The authors are also grateful to Dr. Kymberly Gyure for her assistance with neuropathological examination. This work was supported by grant funding provided to Ryan C. Turner (5T32GM08174), Jason D. Huber (5RO1-NS061954), and Rae R. Matsumoto (DA013978) by the National Institutes of Health. The West Virginia University Department of Neurosurgery also funded this work. Funding was also provided to Dr. Robert T.T. Gettens by the American Society for Quality, Biomedical Division in the form of the Dr. Richard J. Schlesinger Grant for construction of the blast model.	Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; BOWEN IG, 1968, ANN NY ACAD SCI, V152, P122, DOI 10.1111/j.1749-6632.1968.tb11971.x; Cemak I., 2010, J CEREB BLOOD FLOW M, V30, P255; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Covey Dana C, 2010, J Surg Orthop Adv, V19, P8; de Lanerolle NC, 2011, J NEUROPATH EXP NEUR, V70, P1046, DOI 10.1097/NEN.0b013e318235bef2; Duckworth JL, 2012, PATHOPHYSIOLOGY, V20, P23; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein L.E., 2012, SCI TRANSL MED, V4; Hyde D, 2004, CONVENTIONAL WEAPONS; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kane MJ, 2012, NEUROSCI LETT, V522, P47, DOI 10.1016/j.neulet.2012.06.012; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Lucca JJD, 2012, J NEUROL SCI, V318, P146, DOI 10.1016/j.jns.2012.02.002; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Panzer Matthew B, 2012, Front Neurol, V3, P46, DOI 10.3389/fneur.2012.00046; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Rafaels KA, 2012, J TRAUMA ACUTE CARE, V73, P895, DOI 10.1097/TA.0b013e31825a760e; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reneer DV, 2011, J NEUROTRAUM, V28, P95, DOI 10.1089/neu.2010.1513; RICHMOND DR, 1968, ANN NY ACAD SCI, V152, P103, DOI 10.1111/j.1749-6632.1968.tb11970.x; Risling Marten, 2012, Front Neurol, V3, P30, DOI 10.3389/fneur.2012.00030; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Scheibel RS, 2012, J INT NEUROPSYCH SOC, V18, P89, DOI 10.1017/S1355617711001433; Schmitz C, 2005, NEUROSCIENCE, V130, P813, DOI 10.1016/j.neuroscience.2004.08.050; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Shridharani Jay K, 2012, Front Neurol, V3, P70, DOI 10.3389/fneur.2012.00070; Smith DW, 2012, NEUROSURGERY, V70, P740, DOI 10.1227/NEU.0b013e318235b991; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Turner RC, 2012, J NEUROSURG, V117, P1110, DOI 10.3171/2012.8.JNS12358; Yeh DD, 2012, WORLD J SURG, V36, P966, DOI 10.1007/s00268-012-1500-9	41	39	40	0	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2013	248						520	529		10.1016/j.expneurol.2013.07.008			10	Neurosciences	Neurosciences & Neurology	261SJ	WOS:000327684600053	23876514				2021-06-18	
J	Bedi, SS; Smith, P; Hetz, RA; Xue, HS; Cox, CS				Bedi, Supinder S.; Smith, Philippa; Hetz, Robert A.; Xue, Hasen; Cox, Charles S.			Immunomagnetic enrichment and flow cytometric characterization of mouse microglia	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Traumatic brain injury; Microglia; Neuroinflammation; Flow cytometry	SPINAL-CORD-INJURY; CENTRAL-NERVOUS-SYSTEM; CELL PERMEABILIZATION; ACTIVATION; RESPONSES; BRAIN; IDENTIFICATION; MACROPHAGES; VIVO	Background: The inflammatory response after a CNS injury is regulated by microglia/macrophages. Changes in the ratio of M1 classically activated pro-inflammatory cells versus M2 alternatively activated anti-inflammatory cells reveal the direction of the immune response. These cells are routinely identified and enumerated by morphology and cell-surface markers using immunohistochemistry. New method: We used a controlled cortical impact (CCI) mouse model for traumatic brain injury (TBI), then isolated microglia/macrophages from neural cell suspensions using magnetic beads conjugated to CD11b monoclonal antibody to obtain the entire myeloid population. Polarization states of CD11b(+)CD45(lo) microglia were evaluated by expression of M1 surface marker F-c gamma RII/III and M2 surface marker CD206. Results: After TBI, we observed an increase in M1:M2 ratio in the ipsilateral hemisphere when compared to the contralateral side, indicating that 24h after CCI, a shift in microglia polarization occurs localized to the hemisphere of injury. Comparison with existing method(s): The major impetus for developing and refining the methods was the need to accurately quantify microglial activation states without reliance on manual morphometric counting of serial immunohistochemistry slides. Flow cytometric analysis of enriched cell suspensions provides quantitative measurement of microglial polarization states complementary to existing methods, but for entire populations of cells. Conclusions: In summary, we used immunomagnetic beads to isolate myeloid cells from injured brain, then stained surface antigens to flow cytometrically identify and categorize microglia as either classically activated M1 or alternatively activated M2, generating a ratio of M1:M2 cells which is useful in studying attempts to reduce or redirect neuroinflammation. (C) 2013 Elsevier B.V. All rights reserved.	[Bedi, Supinder S.; Smith, Philippa; Hetz, Robert A.; Xue, Hasen; Cox, Charles S.] Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, Houston, TX 77030 USA; [Hetz, Robert A.; Cox, Charles S.] Univ Texas Hlth Sci Ctr Houston, Dept Surg, Houston, TX 77030 USA; [Cox, Charles S.] Texas A&M Univ, Michael E DeBakey Inst Comparat Cardiovasc Sci &, College Stn, TX USA	Cox, CS (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, 6431 Fannin St,MSB 5-236, Houston, TX 77030 USA.	Charles.S.Cox@uth.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U44 NS077511] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U44NS077511] Funding Source: NIH RePORTER		David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; FORD AL, 1995, J IMMUNOL, V154, P4309; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; Jin XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041892; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Nakajima K, 2001, J BIOCHEM-TOKYO, V130, P169, DOI 10.1093/oxfordjournals.jbchem.a002969; Nikodemova M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-147; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; Papagno L, 2007, J IMMUNOL METHODS, V328, P182, DOI 10.1016/j.jim.2007.09.001; Pineau I, 2010, BRAIN BEHAV IMMUN, V24, P540, DOI 10.1016/j.bbi.2009.11.007; Pineau I, 2007, J COMP NEUROL, V500, P267, DOI 10.1002/cne.21149; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528; Guerrero AR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-40; Smith HS, 2010, PAIN PHYSICIAN, V13, P295; Stirling DP, 2008, J NEUROSCI RES, V86, P1944, DOI 10.1002/jnr.21659; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Verdier M, 2000, CYTOMETRY, V41, P55, DOI 10.1002/1097-0320(20000901)41:1<55::AID-CYTO8>3.0.CO;2-A; Walker PA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-228	21	39	40	0	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270			J NEUROSCI METH	J. Neurosci. Methods	SEP 30	2013	219	1					176	182		10.1016/j.jneumeth.2013.07.017			7	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	222HX	WOS:000324722900020	23928152	Green Accepted			2021-06-18	
J	Zhang, YK; Liu, JT; Peng, ZW; Fan, H; Yao, AH; Cheng, P; Liu, L; Ju, G; Kuang, F				Zhang, Yu-Kai; Liu, Jin-Tao; Peng, Zheng-Wu; Fan, Hong; Yao, An-Hui; Cheng, Peng; Liu, Ling; Ju, Gong; Kuang, Fang			Different TLR4 expression and microglia/macrophage activation induced by hemorrhage in the rat spinal cord after compressive injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Hemorrhage; Toll-like receptor 4; Microglia/macrophage; Spinal cord injury; Blood-spinal cord barrier; Rat	TOLL-LIKE RECEPTORS; I-KAPPA-B; SECONDARY INJURY; VASCULAR EVENTS; BRAIN-INJURY; INFLAMMATION; TOLL-LIKE-RECEPTOR-4; CONTRIBUTES; MECHANISMS; INHIBITOR	Background: Hemorrhage is a direct consequence of traumatic injury to the central nervous system and may cause innate immune reactions including cerebral Toll-like receptor (TLR) 4 upregulation which usually leads to poor outcome in the traumatic brain injury. In spinal cord injury (SCI), however, how hemorrhage induces innate immune reaction in spinal parenchyma remains unknown. The present study aimed to see whether blood component and/or other factor(s) induce TLR4 and microglia/macrophages involved innate immune reactions in the rat spinal cord after traumatic injury. Methods: Using the compressive SCI model of the rat, hemorrhage in the spinal cord was identified by hematoxylin-eosin staining. Microglia/macrophage activation, TLR4 expression, and cell apoptosis were investigated by immunohistochemistry. Nuclear factor (NF)-kappa B p50 level of the two segments of the cord was detected by western blotting assay. With carbon powder injection, blood origination of the hematoma was explored. The blood-spinal cord barrier (BSCB) states of the lesion site and the hematoma were compared with immunohistochemistry and tannic acid-ferric chloride staining. Results: Histological observation found blood accumulated in the center of compression lesion site (epicenter) and in the hematoma approximately 1.5 cm away from the epicenter. TLR4 expression, microglia//macrophage activation, and subsequent apoptosis in the area of far-away hematoma were late and weak in comparison to that in epicenter. In addition, TLR4 positive microglia/macrophages appeared to be phagocytotic in the far-away hematoma more obviously than that in the epicenter. Injected carbon powder indicated that accumulated blood of the far-away hematoma originated from the bleeding of the lesion epicenter, and the BSCB around the hematoma was not compromised in the early phase. Accordingly, at 3 days post injury, NF-kappa B p50 was upregulated based on the similar levels of blood component hemoglobin, and cell apoptosis was obvious in the epicenter but not in the far-away hematoma. Conclusion: These data suggest that besides blood component, BSCB compromise and the extent of tissue injury contribute more to TLR4 and microglia/macrophage responses to the spinal cord hemorrhage. Therefore, the innate immune environment is a necessary consideration for the SCI therapy targeting TLR4 and microglia/macrophages.	[Zhang, Yu-Kai; Liu, Jin-Tao; Fan, Hong; Yao, An-Hui; Cheng, Peng; Liu, Ling; Ju, Gong; Kuang, Fang] Fourth Mil Med Univ, Inst Neurosci, Xian 710032, Peoples R China; [Zhang, Yu-Kai] 208th Hosp PLA, Dept Neurosurg, Changchun 130011, Peoples R China; [Liu, Jin-Tao] Fourth Mil Med Univ, Sch Stomatol, Xian 710032, Peoples R China; [Peng, Zheng-Wu] Fourth Mil Med Univ, Xijing Hosp, Dept Psychosomat Med, Xian 710032, Peoples R China	Ju, G (corresponding author), Fourth Mil Med Univ, Inst Neurosci, Xian 710032, Peoples R China.	jugong@fmmu.edu.cn; kuangf@fmmu.edu.cn	Zhang, Xiaolei/E-2761-2012	Zhang, Xiaolei/0000-0003-0117-7599	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC); Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30500451]; Military 11th Five-year Special-Purpose Program for PLA [082028]; Chinese PLA National Scientific Technological Project [06G089]; Major Project of Military Medicine [08XJZ002]; Military 11th Five-year Development of MedicineNational Key Technology R&D Program [2006K15-G1]	The present work was supported by the National Natural Science Foundation of China, the Natural Science Foundation of China (30500451), the Military 11th Five-year Special-Purpose Program for PLA (082028), the Chinese PLA National Scientific Technological Project (06G089), the Major Project of Military Medicine (08XJZ002), and the Military 11th Five-year Development of Medicine (2006K15-G1).	Abu-Qare AW, 2001, J TOXICOL ENV HEAL B, V4, P313, DOI 10.1080/109374001301419737; Alonso A, 2011, BRAIN RES, V9, P18; Babcock AA, 2006, J NEUROSCI, V26, P12826, DOI 10.1523/JNEUROSCI.4937-05.2006; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Carty M, 2011, BIOCHEM PHARMACOL, V81, P825, DOI 10.1016/j.bcp.2011.01.003; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; FAROOQUE M, 1992, ACTA NEUROPATHOL, V84, P613; Filli L, 2012, ANN NEUROL, V72, P491, DOI 10.1002/ana.23630; Fitch MT, 1999, J NEUROSCI, V19, P8182; Griffiths MR, 2010, INT J INFLAMM, V2010, DOI 10.4061/2010/151097; Hanisch UK, 2008, TRENDS NEUROSCI, V31, P176, DOI 10.1016/j.tins.2008.01.005; Hanke ML, 2011, CLIN SCI, V121, P367, DOI 10.1042/CS20110164; Hua F, 2007, J NEUROIMMUNOL, V190, P101, DOI 10.1016/j.jneuroim.2007.08.014; Jia LY, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1155/2011/862197; Kakimura J, 2002, FASEB J, V16, P601, DOI 10.1096/fj.01-0530fje; Kigerl KA, 2007, J NEUROCHEM, V102, P37, DOI 10.1111/j.1471-4159.2007.04524.x; Kilic U, 2008, NEUROBIOL DIS, V31, P33, DOI 10.1016/j.nbd.2008.03.002; Kleinig TJ, 2009, CURR OPIN NEUROL, V22, P294, DOI 10.1097/WCO.0b013e32832b4db3; Larsen PH, 2007, SCI STKE, V2007, P4; Lehnardt S, 2008, J NEUROSCI, V28, P2320, DOI 10.1523/JNEUROSCI.4760-07.2008; Lin S, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-46; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; Mao SS, 2012, J NEUROTRAUM, V29, P1941, DOI 10.1089/neu.2011.2244; Maslinska D, 2004, FOLIA NEUROPATHOL, V42, P125; Mautes AEM, 2000, PHYS THER, V80, P673, DOI 10.1093/ptj/80.7.673; Napoli I, 2009, NEUROSCIENCE, V158, P1030, DOI 10.1016/j.neuroscience.2008.06.046; NOBLE LJ, 1989, BRAIN RES, V482, P57, DOI 10.1016/0006-8993(89)90542-8; NOBLE LJ, 1987, BRAIN RES, V424, P177, DOI 10.1016/0006-8993(87)91208-X; Oyinbo CA, 2011, J IMMUNOL, V71, P281; Pais TF, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-43; Pedras-Vasconcelos Joao, 2009, Front Biosci (Elite Ed), V1, P476; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Sansing LH, 2011, ANN NEUROL, V70, P646, DOI 10.1002/ana.22528; Sinescu Crina, 2010, J Med Life, V3, P254; Song M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-92; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Teng WY, 2009, MEDIAT INFLAMM, V2009, DOI 10.1155/2009/473276; Wang Z, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/848309; Yao AH, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/591298; Zhang ZR, 2012, NEUROIMMUNOMODULAT, V19, P10, DOI 10.1159/000326771; Zhou ML, 2007, INFLAMM RES, V56, P93, DOI 10.1007/s00011-006-6035-9; Ziegler G, 2009, BBA-MOL BASIS DIS, V1792, P1198, DOI 10.1016/j.bbadis.2009.10.003	42	39	40	0	16	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	SEP 10	2013	10								112	10.1186/1742-2094-10-112			15	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	216EJ	WOS:000324264200001	24015844	DOAJ Gold, Green Published			2021-06-18	
J	Coole, C; Radford, K; Grant, M; Terry, J				Coole, Carol; Radford, Kathryn; Grant, Mary; Terry, Jane			Returning to Work After Stroke: Perspectives of Employer Stakeholders, a Qualitative Study	JOURNAL OF OCCUPATIONAL REHABILITATION			English	Article						Stroke; Qualitative research; Employers; Work; Vocational rehabilitation; Return to work	TRAUMATIC BRAIN-INJURY; VOCATIONAL-REHABILITATION; LINE MANAGERS; SUPERVISORS; BARRIERS; FACILITATORS; ADULTS; BACK	Purpose More than 40 % of working age adults with stroke fail to return to work. The work context is a key factor in return to work, but little is known about the experiences of employers in supporting employees with stroke. The aim of this study was to explore return to work after stroke from the employer perspective, to identify key features associated with success and to seek participants' views regarding the role of healthcare in return to work. Methods Data was gathered through 18 semi-structured interviews with employer stakeholders and included small business owners, line managers, human resources and occupational health staff. Data was analysed thematically. Results The main themes identified were: the impact of stroke on the employer, characteristics of the employee, communication, knowledge and information, experience of other stakeholders, integrating healthcare in return to work. Conclusion Employers face complex emotional and practical issues when helping an employee return to work after stroke, for which many lack knowledge and experience. The range and quality of support networks that they access is variable and advice and support from clinicians is welcomed. Further research is necessary to investigate how such support could be funded and integrated within existing service provision.	[Coole, Carol] Univ Nottingham, Fac Med & Hlth Sci, Queens Med Ctr, Nottingham NG7 2HA, England; [Radford, Kathryn; Grant, Mary] Univ Nottingham, Div Rehabil & Ageing, Queens Med Ctr, Nottingham NG7 2UH, England; [Terry, Jane] Community Stroke Team, Nottingham NG7 5LR, England	Coole, C (corresponding author), Univ Nottingham, Fac Med & Hlth Sci, Queens Med Ctr, A Floor,South Block Link, Nottingham NG7 2HA, England.	Carolyn.coole@nottingham.ac.uk	Radford, Kate A/F-8571-2013	Radford, Kate A/0000-0001-6246-3180			Alaszewski A, 2007, DISABIL REHABIL, V29, P1858, DOI 10.1080/09638280601143356; Amir Z, 2010, J OCCUP REHABIL, V20, P435, DOI 10.1007/s10926-009-9197-9; [Anonymous], 2008, GOV RESP DC BLACKS R; Black C.D., 2011, HLTH WORK INDEPENDEN; Bond GR, 2008, PSYCHIATR REHABIL J, V31, P280, DOI 10.2975/31.4.2008.280.290; Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706qp063oa]; Carbonneau H., 2010, DEMENTIA INT J SOCIA, V9, P327, DOI [10.1177/1471301210375316, DOI 10.1177/1471301210375316]; Care Quality Commission, 2011, SUPP LIF STROK REV S; Cohen CA, 2002, INT J GERIATR PSYCH, V17, P184, DOI 10.1002/gps.561; Culler KH, 2011, TOP STROKE REHABIL, V18, P325, DOI 10.1310/tsr1804-325; Cunningham I, 2004, BRIT J MANAGE, V15, P273, DOI 10.1111/j.1467-8551.2004.00419.x; Daniel K, 2009, STROKE, V40, pE431, DOI [10.1161/STROKEAHA.108.534487, 10.1161/STROKEAHA.108.535088]; de Vries G, 2012, J AFFECT DISORDERS, V136, P1017, DOI 10.1016/j.jad.2011.06.035; *DEP WORK PENS, 2004, BUILD CAP WORK UK FR; Department for Work and Pensions Department of Health Health & Safety Executive, 2008, HLTH WORK WELL BEING; Department of Health, 2007, NAT STROK STRAT; Department of Health, 2010, NHS OUTC FRAM 2011 1; Deshpande P, 2004, VOCATIONAL ASSESSMEN; Doucet T., 2012, Annals of Physical and Rehabilitation Medicine, V55, P112, DOI 10.1016/j.rehab.2012.01.007; Fadyl JK, 2009, J HEAD TRAUMA REHAB, V24, P195, DOI 10.1097/HTR.0b013e3181a0d458; Frank AO, 2006, INT J THER REHABIL, V13, P126, DOI 10.12968/ijtr.2006.13.3.21364; Fylan B, 2011, 780 DEP WORK PENS; Gard Gunvor, 2006, Work, V26, P191; Glozier N, 2008, STROKE, V39, P1526, DOI 10.1161/STROKEAHA.107.503219; Haafkens JA, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-104; Hart T, 2006, J HEAD TRAUMA REHAB, V21, P467, DOI 10.1097/00001199-200611000-00002; Holmgren K, 2007, J OCCUP REHABIL, V17, P93, DOI 10.1007/s10926-006-9041-4; Hussey L, 2010, OCCUP MED-OXFORD, V60, P294, DOI 10.1093/occmed/kqq022; Intercollegiate Stroke Working Party, 2008, NAT CLIN GUID STROK, V3rd; Lambeek LC, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1035; Lemieux P, 2011, J OCCUP REHABIL, V21, P293, DOI 10.1007/s10926-011-9316-2; Lindstrom B, 2009, J REHABIL MED, V41, P714, DOI 10.2340/16501977-0423; Lock S, 2005, DISABIL SOC, V20, P33, DOI 10.1080/0968759042000283629; Munir F, 2012, J OCCUP REHABIL, V22, P196, DOI 10.1007/s10926-011-9331-3; Park CH, 2012, PSYCHO-ONCOLOGY, V21, P282, DOI 10.1002/pon.1893; Playford E., 2011, MAPPING VOCATIONAL R; Radford KA, 2011, INT J STROKE S2, V6, P49; Saeki S, 2010, J REHABIL MED, V42, P254, DOI 10.2340/16501977-0503; Saka O, 2009, AGE AGEING, V38, P27, DOI 10.1093/ageing/afn281; Sawney P, 2003, OCCUP MED-OXFORD, V53, P246, DOI 10.1093/occmed/kqg065; Sinclair A, 2012, 793 DEP WORK PENS; Soklaridis S, 2010, SOC SCI MED, V71, P1557, DOI 10.1016/j.socscimed.2010.08.017; Treger I, 2007, DISABIL REHABIL, V29, P1397, DOI 10.1080/09638280701314923; Tyerman A, 2004, VOCATIONAL ASSESSMEN; Vestling M, 2003, J REHABIL MED, V35, P127, DOI 10.1080/16501970310010475; Vocational Rehabilitation Society, 2007, STAND PRACT; Waddell G., 2008, VOCATIONAL REHABILIT; Wehman P, 2003, ARCH PHYS MED REHAB, V84, P192, DOI 10.1053/apmr.2003.50027; WILL MC, 1984, EXCEPT CHILDREN, V51, P11; Wolfenden B, 2009, INT J REHABIL RES, V32, P93, DOI 10.1097/MRR.0b013e328325a358	50	39	40	0	20	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1053-0487	1573-3688		J OCCUP REHABIL	J. Occup. Rehabil.	SEP	2013	23	3					406	418		10.1007/s10926-012-9401-1			13	Rehabilitation; Social Issues	Rehabilitation; Social Issues	197VS	WOS:000322880900011	23212240	Green Accepted, Green Published, Other Gold			2021-06-18	
J	Brooks, BR; Crumpacker, D; Fellus, J; Kantor, D; Kaye, RE				Brooks, Benjamin Rix; Crumpacker, David; Fellus, Jonathan; Kantor, Daniel; Kaye, Randall E.			PRISM: A Novel Research Tool to Assess the Prevalence of Pseudobulbar Affect Symptoms across Neurological Conditions	PLOS ONE			English	Article							EMOTIONAL EXPRESSION DISORDER; PATHOLOGICAL LAUGHTER; POSTSTROKE DEPRESSION; INCONTINENCE; EPIDEMIOLOGY; SCLEROSIS; DISEASE; STROKE; ALS; PATHOPHYSIOLOGY	Background: Pseudobulbar affect (PBA) is a neurological condition characterized by involuntary, sudden, and frequent episodes of laughing and/or crying, which can be socially disabling. Although PBA occurs secondary to many neurological conditions, with an estimated United States (US) prevalence of up to 2 million persons, it is thought to be under-recognized and undertreated. The PBA Registry Series (PRISM) was established to provide additional PBA symptom prevalence data in a large, representative US sample of patients with neurological conditions known to be associated with PBA. Methods: Participating clinicians were asked to enroll >= 20 consenting patients with any of 6 conditions: Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Parkinson's disease (PD), stroke, or traumatic brain injury (TBI). Patients (or their caregivers) completed the Center for Neurologic Study-Lability Scale (CNS-LS) and an 11-point scale measuring impact of the neurological condition on the patient's quality of life (QOL). Presence of PBA symptoms was defined as a CNS-LS score >= 13. Demographic data and current use of antidepressant or antipsychotic medications were also recorded. Results: PRISM enrolled 5290 patients. More than one third of patients (n = 1944; 36.7%) had a CNS-LS score >= 13, suggesting PBA symptoms. The mean (SD) score measuring impact of neurological condition on QOL was significantly higher (worse) in patients with CNS-LS >= 13 vs,13 (6.7 [2.5] vs. 4.7 [3.1], respectively; P<0.0001 two-sample t-test). A greater percentage of patients with CNS-LS >= 13 versus <13 were using antidepressant/antipsychotic medications (53.0% vs 35.4%, respectively; P<0.0001, chi-square test). Conclusions: Data from PRISM, the largest clinic-based study to assess PBA symptom prevalence, showed that PBA symptoms were common among patients with diverse neurological conditions. Higher CNS-LS scores were associated with impaired QOL and greater use of antipsychotic/antidepressant medications. These data underscore a need for greater awareness, recognition, and diagnosis of PBA.	[Brooks, Benjamin Rix] Univ N Carolina, Sch Med, Carolinas Med Ctr, Charlotte, NC 28223 USA; [Crumpacker, David] Baylor Univ, Med Ctr, Dallas, TX USA; [Fellus, Jonathan] Int Brain Res Fdn, Flanders, NJ USA; [Kantor, Daniel] Neurologique, Ponte Vedra Beach, FL USA; [Kaye, Randall E.] Avanir Pharmaceut Inc, Aliso Viejo, CA USA	Kaye, RE (corresponding author), Avanir Pharmaceut Inc, Aliso Viejo, CA USA.	RKaye@avanir.com			Avanir Pharmaceuticals, Inc.	Funding for the PRISM study and editorial support for manuscript preparation were provided by Avanir Pharmaceuticals, Inc. RK is an employee of Avanir and participated in study design, data analysis and contributed as an author. The data were gathered by the individual investigators and were analyzed by MMS Holdings. The decision to publish was that of the authors.	Arciniegas D B, 2000, Semin Clin Neuropsychiatry, V5, P290, DOI 10.1053/scnp.2000.9554; Calvert T, 1998, J NEUROL NEUROSUR PS, V65, P928, DOI 10.1136/jnnp.65.6.928; CAROSCIO JT, 1987, NEUROL CLIN, V5, P1; Chio A, 2009, NEUROLOGY, V72, P725, DOI 10.1212/01.wnl.0000343008.26874.d1; Choi-Kwon S, 2012, NEUROLOGY, V78, P1130, DOI 10.1212/WNL.0b013e31824f8090; Colamonico J, 2012, ADV THER, V29, P775, DOI 10.1007/s12325-012-0043-7; Cottrell SS, 1926, J NEUROL PSYCHOPATHO, V7, P1; Cummings JL, 2007, CNS SPECTRUMS, V12, P11; Cummings JL, 2006, CNS SPECTRUMS, V11, P1; Darwin C, 1872, EXPRESSION EMOTIONS; Davison C, 1939, ARCH NEURO PSYCHIATR, V42, P595, DOI 10.1001/archneurpsyc.1939.02270220011001; Di Poggio MB, 2013, AMYOTROPH LAT SCL FR, V14, P52, DOI 10.3109/17482968.2012.729062; Feinstein A, 1997, ARCH NEUROL-CHICAGO, V54, P1116, DOI 10.1001/archneur.1997.00550210050012; GALLAGHER JP, 1989, ACTA NEUROL SCAND, V80, P114, DOI 10.1111/j.1600-0404.1989.tb03851.x; HASTRUP JL, 1986, GERONTOLOGIST, V26, P91, DOI 10.1093/geront/26.1.91; HOUSE A, 1989, BMJ-BRIT MED J, V298, P991, DOI 10.1136/bmj.298.6679.991; Hurwitz BJ, 2009, NEUROLOGY S1, pS3; Kim JS, 2000, NEUROLOGY, V54, P1805, DOI 10.1212/WNL.54.9.1805; Kim JS, 2002, NEUROLOGY, V58, P1106, DOI 10.1212/WNL.58.7.1106; Langworthy OR, 1941, AM J PSYCHIAT, V98, P243, DOI 10.1176/ajp.98.2.243; Lopez OL, 1996, NEUROPSY NEUROPSY BE, V9, P154; McElvaney NG, 1997, CHEST, V111, P394, DOI 10.1378/chest.111.2.394; Miller A, 2011, EXPERT REV NEUROTHER, V11, P1077, DOI [10.1586/ERN.11.68, 10.1586/ern.11.68]; Moore SR, 1997, J NEUROL NEUROSUR PS, V63, P89, DOI 10.1136/jnnp.63.1.89; MORRIS PLP, 1993, AUST NZ J PSYCHIAT, V27, P601, DOI 10.3109/00048679309075822; MULLER R, 1952, ACTA PSYCH NEUROL, V27, P137; Newsom-Davis IC, 1999, J NEUROL SCI, V169, P22, DOI 10.1016/S0022-510X(99)00211-7; Nieuwenhuis-Mark RE, 2008, COGN BEHAV NEUROL, V21, P111, DOI 10.1097/WNN.0b013e31816be8f8; Oppenheim H., 1911, TXB NERVOUS DIS PHYS; Parvizi J, 2001, BRAIN, V124, P1708, DOI 10.1093/brain/124.9.1708; Parvizi J, 2007, MOVEMENT DISORD, V22, P798, DOI 10.1002/mds.21348; Parvizi J, 2009, J NEUROPSYCH CLIN N, V21, P75, DOI 10.1176/appi.neuropsych.21.1.75; Petracca GM, 2009, J NEUROPSYCH CLIN N, V21, P406, DOI 10.1176/appi.neuropsych.21.4.406; Phuong L, 2009, PARKINSONISM RELAT D, V15, P511, DOI 10.1016/j.parkreldis.2009.01.001; Pioro EP, 2011, DRUGS, V71, P1193, DOI 10.2165/11591450-000000000-00000; PRATT RTC, 1951, J NEUROL NEUROSUR PS, V14, P326, DOI 10.1136/jnnp.14.4.326; Reijnders JSAM, 2008, MOVEMENT DISORD, V23, P183, DOI 10.1002/mds.21803; ROBINSON RG, 1993, AM J PSYCHIAT, V150, P286; Rottenberg J, 2002, J ABNORM PSYCHOL, V111, P302, DOI 10.1037//0021-843X.111.2.302; Schiffer R, 2005, J NEUROPSYCH CLIN N, V17, P447, DOI 10.1176/appi.neuropsych.17.4.447; Siddiqui MS, 2009, WORLD J BIOL PSYCHIA, V10, P234, DOI 10.1080/15622970701639445; Siegert RJ, 2005, J NEUROL NEUROSUR PS, V76, P469, DOI 10.1136/jnnp.2004.054635; Smi CK, 2006, STROKE, V37, P156, DOI 10.1161/01.STR.0000190892.93663.e2; Smith RA, 2004, MULT SCLER, V10, P1; Smith RA, 2006, EXPERT OPIN PHARMACO, V7, P2581, DOI 10.1517/14656566.7.18.2581; STARKSTEIN SE, 1995, J NEUROL NEUROSUR PS, V59, P55, DOI 10.1136/jnnp.59.1.55; Strowd RE, 2010, J NEUROL, V257, P1382, DOI 10.1007/s00415-010-5550-3; Tang WK, 2009, J NEUROL NEUROSUR PS, V80, P1082, DOI 10.1136/jnnp.2009.175372; Tang WK, 2009, J INT NEUROPSYCH SOC, V15, P62, DOI 10.1017/S1355617708090061; Tang WK, 2004, J NEUROL, V251, P865, DOI 10.1007/s00415-004-0450-z; Tateno A, 2004, J NEUROPSYCH CLIN N, V16, P426, DOI 10.1176/appi.neuropsych.16.4.426; Vinceti M, 2012, Ann Ig, V24, P407; Vingerhoets AJJM, 2007, ACTA PSYCHIAT SCAND, V115, P340, DOI 10.1111/j.1600-0447.2006.00948.x; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wicks P, 2007, EUR J NEUROL, V14, P993, DOI 10.1111/j.1468-1331.2007.01843.x; Wilson SAK, 1924, J NEUROL PSYCHOPATHO, V4, P299; Work SS, 2011, ADV THER, V28, P586, DOI 10.1007/s12325-011-0031-3; Wortzel HS, 2008, CNS DRUGS, V22, P531, DOI 10.2165/00023210-200822070-00001; Zeilig G, 1996, BRAIN INJURY, V10, P591, DOI 10.1080/026990596124160; Ziegler LH, 1930, ARCH NEURO PSYCHIATR, V24, P930, DOI 10.1001/archneurpsyc.1930.02220170050006	60	39	39	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 21	2013	8	8							e72232	10.1371/journal.pone.0072232			8	Multidisciplinary Sciences	Science & Technology - Other Topics	218YW	WOS:000324470100088	23991068	DOAJ Gold, Green Published			2021-06-18	
J	Jones, A				Jones, Alvin			Test of Memory Malingering: Cutoff Scores for Psychometrically Defined Malingering Groups in a Military Sample	CLINICAL NEUROPSYCHOLOGIST			English	Article						Test of Memory Malingering; Performance validity; Malingering; Symptom validity	TRAUMATIC BRAIN-INJURY; SYMPTOM VALIDITY TEST; RESPONSE BIAS; CLASSIFICATION ACCURACY; REPEATABLE BATTERY; EFFORT INDEX; PERFORMANCE; VALIDATION; MILD; TOMM	This research examined cutoffs for the Test of Memory Malingering (TOMM) in a military sample composed primarily of mTBI patients. The results are consistent with previous research and provide additional evidence that cutoffs higher than those originally recommended for the TOMM can produce excellent classification and diagnostic statistics when a psychometrically defined non-malingering group is compared with three psychometrically defined malingering groups: Probable, Probable to Definite, and Definite Malingering. The groups were formed based on the number of symptom and performance validity tests passed or failed. Cutoffs that were 4-5 points higher for Trial 2 and the Retention Trial than originally recommended produced very low false positive rates (.0 to .06) and excellent positive predictive values (.75 to 1.00) for a base rate of malingering commonly found in TBI patients. Positive likelihood ratios were all above 10 for these two trials indicating excellent ability to rule in malingering. A range of cutoffs for Trial 1 were also examined, and classification and diagnostic statistics are presented for cutoffs ranging from 40 to 44 with results similar to the other TOMM trials.	Womack Army Med Ctr, Dept Brain Injury Med, Ft Bragg, NC 29310 USA	Jones, A (corresponding author), Womack Army Med Ctr, Dept Brain Injury Med, 2817 Riley Rd,Bldg 4-2817, Ft Bragg, NC 29310 USA.	alvin.jones2@us.army.mil					Allen LM, 2001, ARCH CLIN NEUROPSYCH, V16, P846; Armistead-Jehle P, 2011, APPL NEUROPSYCHOL, V18, P284, DOI 10.1080/09084282.2011.595455; Armistead-Jehle P, 2011, ARCH CLIN NEUROPSYCH, V26, P592, DOI 10.1093/arclin/acr049; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Bianchini Kevin J, 2005, Spine J, V5, P404, DOI 10.1016/j.spinee.2004.11.016; Boone KB, 2003, CLIN NEUROPSYCHOL, V17, P244, DOI 10.1076/clin.17.2.244.16497; Crawford JR, 2009, CLIN NEUROPSYCHOL, V23, P624, DOI 10.1080/13854040802524229; Denning JH, 2012, ARCH CLIN NEUROPSYCH, V27, P417, DOI 10.1093/arclin/acs044; Department of Veterans Affairs and Department of Defense, 2009, VA DOD CLIN PRACT GU; Gervais RO, 2007, ASSESSMENT, V14, P196, DOI 10.1177/1073191106295861; Green P., 2004, MANUAL NONVERBAL MED; Green P., 2007, ASSESSMENT FEIGNED C, P50; Green P, 2011, APPL NEUROPSYCHOL, V18, P18, DOI 10.1080/09084282.2010.523365; Greiffenstein MF, 2008, ARCH CLIN NEUROPSYCH, V23, P801, DOI 10.1016/j.acn.2008.07.005; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2006, ARCH CLIN NEUROPSYCH, V21, P439, DOI 10.1016/j.acn.2006.06.004; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2009, CLIN NEUROPSYCHOL, V23, P1250, DOI 10.1080/13854040902828272; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; Grote CL, 2000, J CLIN EXP NEUROPSYC, V22, P709, DOI 10.1076/jcen.22.6.709.958; Haber AH, 2006, CLIN NEUROPSYCHOL, V20, P524, DOI 10.1080/13854040590967595; Hayden SR, 1999, ANN EMERG MED, V33, P575, DOI 10.1016/S0196-0644(99)70346-X; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Jones A, 2011, CLIN NEUROPSYCHOL, V25, P1207, DOI 10.1080/13854046.2011.600726; Kaemmer B, 2001, MMPI-2: Manual for Administration and Scoring; Lange RT, 2012, ARCH CLIN NEUROPSYCH, V27, P480, DOI 10.1093/arclin/acs059; Larrabee G.J., 2007, ASSESSMENT MALINGERE, P334; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Nelson NW, 2003, CLIN NEUROPSYCHOL, V17, P263, DOI 10.1076/clin.17.2.263.16511; Randolph C, 1998, REPEATABLE BATTERY A; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rosenfeld B, 2000, ARCH CLIN NEUROPSYCH, V15, P349, DOI 10.1016/S0887-6177(99)00025-6; Schenk K, 2010, J CLIN EXP NEUROPSYC, V32, P752, DOI 10.1080/13803390903512678; Schroeder R, 2011, RNA BIOL, V8, P1; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Silverberg ND, 2007, CLIN NEUROPSYCHOL, V21, P841, DOI 10.1080/13854040600850958; Slick D., 1997, VICTORIA SYMPTOM VAL; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Sweet JJ, 1999, STUD NEUROPSYCHOL DE, P255; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Tombaugh TN, 1996, TEST MEMORY MALINGER; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682; Youngjohn J.R., 1995, ASSESSMENT, V2, DOI [https://doi.org/10.1177/1073191195002003007, DOI 10.1177/1073191195002003007]	51	39	39	0	12	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	AUG 1	2013	27	6					1043	1059		10.1080/13854046.2013.804949			17	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	197RA	WOS:000322867100010	23730741				2021-06-18	
J	Burk, JM; Munkasy, BA; Joyner, AB; Buckley, TA				Burk, John M.; Munkasy, Barry A.; Joyner, A. Barry; Buckley, Thomas A.			Balance Error Scoring System Performance Changes After a Competitive Athletic Season	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; balance error scoring system; postural control	SPORT-RELATED CONCUSSION; COLLEGIATE FOOTBALL PLAYERS; POSTURAL CONTROL; SOCCER; MANAGEMENT; SENSITIVITY; IMPAIRMENT; STABILITY; EXERCISE; DEFICITS	Objective: To evaluate the change in Balance Error Scoring System (BESS) performance after an athletic season. Design: A prospective longitudinal group study. Setting: University biomechanics research laboratory. Participants: A total of 58 college-aged females (23 soccer student-athletes, 16 volleyball student-athletes, and 19 recreationally active healthy college students) participated in the study. Interventions: The BESS test was administered on 2 occasions 90 days apart. For the student-athletes, the first test (PRE) was administered before the start of their athletic season and the second test (POST) was administered immediately after the season. For the recreationally active college students, the PRE test was at the beginning of the academic semester and the POST test exactly 90 days thereafter. Main Outcome Measures: Total BESS score at PRE and POST was compared with a 3 x 2 repeated measures analysis of variance. The overall change score and absolute value change score were also calculated and compared with a 1-sample t test to an expected change of zero errors. Results: There was no group by time interaction; however, there was a main effect for time. There was a significant improvement (P = 0.003) between PRE (9.00 +/- 2.97 errors) and POST (7.92 +/- 2.78 errors) BESS performance. There were significant differences for both the overall change score (1.08 errors) and the absolute value change score (2.00 errors). Conclusions: A clinically and statistically significant difference in BESS performance was identified after a 90-day intercollegiate athletic season.	[Burk, John M.] Optim Healthcare, Phys Therapy & Sports Med, Statesboro, GA USA; [Munkasy, Barry A.; Joyner, A. Barry; Buckley, Thomas A.] Georgia So Univ, Dept Hlth & Kinesiol, Statesboro, GA 30460 USA	Buckley, TA (corresponding author), Georgia So Univ, Dept Hlth & Kinesiol, POB 8076, Statesboro, GA 30460 USA.	tbuckley@georgiasouthern.edu	Buckley, Thomas A/B-7525-2016	Buckley, Thomas A/0000-0002-0515-0150			Baechle TR., 2008, ESSENTIALS STRENGTH; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2004, BRIT J SPORT MED, V38, P561, DOI 10.1136/bjsm.2003.004887; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Docherty CL, 2006, CLIN J SPORT MED, V16, P203, DOI 10.1097/00042752-200605000-00003; Erkmen N, 2009, ISOKINET EXERC SCI, V17, P121, DOI 10.3233/IES-2009-0343; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Fox ZG, 2008, J ATHL TRAINING, V43, P456, DOI 10.4085/1062-6050-43.5.456; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; Kaminski TW, 2008, RES Q EXERCISE SPORT, V79, P235; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; MANCUSO JJ, 2002, J ATHL TRAINING, V37, pS10; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; McCrory PR, 2003, BRIT MED J, V327, P351, DOI 10.1136/bmj.327.7411.351; McLeod TCV, 2009, J SPORT REHABIL, V18, P465, DOI 10.1123/jsr.18.4.465; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Onate JA, 2007, J ATHL TRAINING, V42, P446; Register-Mihalik JK, 2013, J HEAD TRAUMA REHAB, V28, P274, DOI 10.1097/HTR.0b013e3182585d37; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Valovich TC, 2003, J ATHL TRAINING, V38, P51	30	39	41	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2013	23	4					312	317		10.1097/JSM.0b013e318285633f			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	299AM	WOS:000330366700012	23558331				2021-06-18	
J	Liu, M; Gross, DW; Wheatley, BM; Concha, L; Beaulieu, C				Liu, Min; Gross, Donald W.; Wheatley, B. Matt; Concha, Luis; Beaulieu, Christian			The acute phase of Wallerian degeneration: Longitudinal diffusion tensor imaging of the fornix following temporal lobe surgery	NEUROIMAGE			English	Article						Wallerian degeneration; Diffusion tensor imaging; Epilepsy; Parallel diffusivity; Perpendicular diffusivity; Fractional anisotropy	RAT SPINAL-CORD; TRAUMATIC AXONAL INJURY; CENTRAL-NERVOUS-SYSTEM; IN-VIVO; MOUSE MODEL; RETINAL ISCHEMIA; WATER DIFFUSION; OPTIC-NERVE; EPILEPSY; LOBECTOMY	Numerous animal studies have shown the applicability of diffusion tensor imaging (DTI) to track Wallerian degeneration that occurs after injury to the neural fiber. Non-invasive biomarkers that may differentiate the early axonal breakdown and later myelin degradation have been attributed to either reduced parallel and elevated perpendicular diffusivity, respectively. While several human DTI studies have shown this potential at subacute and chronic time points, the diffusion changes that occur within the first week are unknown. Anterior temporal lobectomy (i.e. resection of hippocampus) is the standard surgical treatment of medically refractory temporal lobe epilepsy. The concomitant transection of the fimbria-fornix serves as a unique opportunity to examine the process of Wallerian degeneration since the timing is known. Six temporal lobe epilepsy patients underwent brain DTI before the surgery, three to four times within the first week post-operatively, and at one to four months following surgery. Both parallel and perpendicular diffusivities decreased markedly by a similar amount in the ipsilateral fornix within the first two days post-surgery. Approaching the end of the first week, perpendicular (but not parallel) diffusivity pseudo-recovered towards its pre-surgical value, but then increased dramatically months later. Fractional anisotropy, as a result of the combined action of the parallel and perpendicular diffusivities, stayed relatively stable within the first week and only reduced drastically at the chronic stage. DTI demonstrated acute water diffusion changes within days of transection that are not just limited to parallel diffusivity. While the chronic diffusion changes in the fornix are compatible with myelin degradation, the acute changes may reflect beading and swelling of axolemma, granular disintegration of the axonal neurofilaments, ischemia induced cytotoxic edema, and/or changes in the extra-axonal space including inflammatory changes and gliosis. (C) 2013 Elsevier Inc. All rights reserved.	[Liu, Min; Beaulieu, Christian] Univ Alberta, Dept Biomed Engn, Fac Med & Dent, Edmonton, AB T6G 2V2, Canada; [Gross, Donald W.] Univ Alberta, Fac Med & Dent, Dept Med, Div Neurol, Edmonton, AB T6G 2V2, Canada; [Wheatley, B. Matt] Univ Alberta, Fac Med & Dent, Dept Surg, Div Neurosurg, Edmonton, AB T6G 2V2, Canada; [Concha, Luis] Univ Nacl Autonoma Mexico, Inst Neurobiol, Queretaro, Mexico	Beaulieu, C (corresponding author), Univ Alberta, Dept Biomed Engn, Res Transit Facil 1098, Edmonton, AB T6G 2V2, Canada.	christian.beaulieu@ualberta.ca	Concha, Luis/G-5161-2011; Liu, Min/C-7301-2012; , DWG/AAF-9259-2020; Beaulieu, Christian/E-9796-2011; Concha, Luis/M-5720-2019	Concha, Luis/0000-0002-7842-3869; Liu, Min/0000-0002-4377-5864; Beaulieu, Christian/0000-0002-2342-3298; Gross, Donald/0000-0003-1344-4092	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Alberta Innovates-Health Solutions; China Scholarship CouncilChina Scholarship Council	This work was supported by Canadian Institutes of Health Research (D.W.G. and C.B.); Alberta Innovates-Health Solutions (C.B.); and China Scholarship Council (M.L.).	Beaulieu C, 1996, MAGNET RESON MED, V36, P627, DOI 10.1002/mrm.1910360419; Beirowski B, 2010, J NEUROPATH EXP NEUR, V69, P455, DOI 10.1097/NEN.0b013e3181da84db; Budde MD, 2008, NMR BIOMED, V21, P589, DOI 10.1002/nbm.1229; Budde MD, 2010, P NATL ACAD SCI USA, V107, P14472, DOI 10.1073/pnas.1004841107; Coleman MP, 2002, TRENDS NEUROSCI, V25, P532, DOI 10.1016/S0166-2236(02)02255-5; Concha L, 2005, AM J NEURORADIOL, V26, P2267; Concha L, 2005, ANN NEUROL, V57, P188, DOI 10.1002/ana.20334; Concha L, 2009, J NEUROL NEUROSUR PS, V80, P312, DOI 10.1136/jnnp.2007.139287; Concha L, 2007, EPILEPSIA, V48, P931, DOI 10.1111/j.1528-1167.2007.01006.x; Concha L, 2006, NEUROIMAGE, V32, P1090, DOI 10.1016/j.neuroimage.2006.04.187; Concha L, 2010, J NEUROSCI, V30, P996, DOI 10.1523/JNEUROSCI.1619-09.2010; FORD JC, 1994, MAGNET RESON MED, V31, P488, DOI 10.1002/mrm.1910310504; GEORGE EB, 1995, J NEUROSCI, V15, P6445; GEORGE R, 1994, EXP NEUROL, V129, P225, DOI 10.1006/exnr.1994.1164; Kerschensteiner M, 2005, NAT MED, V11, P572, DOI 10.1038/nm1229; Kim JH, 2007, MAGN RESON MED, V58, P253, DOI 10.1002/mrm.21316; Kozlowski P, 2008, J NEUROTRAUM, V25, P653, DOI 10.1089/neu.2007.0462; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Malykhin N, 2008, PSYCHIAT RES-NEUROIM, V164, P132, DOI 10.1016/j.pscychresns.2007.11.007; McDonald CR, 2010, NEUROLOGY, V75, P1631, DOI 10.1212/WNL.0b013e3181fb44db; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Nguyen D, 2011, EPILEPSY RES, V94, P189, DOI 10.1016/j.eplepsyres.2011.02.001; Papadakis NG, 2002, MAGNET RESON MED, V48, P394, DOI 10.1002/mrm.10204; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; Schoene-Bake JC, 2009, NEUROIMAGE, V46, P569, DOI 10.1016/j.neuroimage.2009.03.013; Sievers C, 2003, NEUROSCI RES, V46, P161, DOI 10.1016/S0168-0102(03)00039-7; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; STICHEL CC, 1994, GLIA, V10, P89, DOI 10.1002/glia.440100203; Sun SW, 2008, NEUROIMAGE, V40, P1, DOI 10.1016/j.neuroimage.2007.11.049; Taoka T, 2005, AM J NEURORADIOL, V26, P797; Vargas ME, 2007, ANNU REV NEUROSCI, V30, P153, DOI 10.1146/annurev.neuro.30.051606.094354; Vercauteren T, 2009, NEUROIMAGE, V45, pS61, DOI 10.1016/j.neuroimage.2008.10.040; Wheatley BM, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC/2008/25/9/E4; Wieshmann UC, 1999, EPILEPSIA, V40, P1155, DOI 10.1111/j.1528-1157.1999.tb00834.x; Xu JQ, 2008, NMR BIOMED, V21, P928, DOI 10.1002/nbm.1307; Yogarajah M, 2010, BRAIN, V133, P2348, DOI 10.1093/brain/awq175; Zhai QW, 2003, NEURON, V39, P217, DOI 10.1016/S0896-6273(03)00429-X; Zhang JY, 2009, J NEUROSCI, V29, P3160, DOI 10.1523/JNEUROSCI.3941-08.2009	40	39	40	0	23	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119			NEUROIMAGE	Neuroimage	JUL 1	2013	74						128	139		10.1016/j.neuroimage.2013.01.069			12	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	124CL	WOS:000317441300014	23396161				2021-06-18	
J	Furman, GR; Lin, CC; Bellanca, JL; Marchetti, GF; Collins, MW; Whitney, SL				Furman, Gabriel R.; Lin, Chia-Cheng; Bellanca, Jennica L.; Marchetti, Gregory F.; Collins, Michael W.; Whitney, Susan L.			Comparison of the Balance Accelerometer Measure and Balance Error Scoring System in Adolescent Concussions in Sports	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; balance; postural sway; accelerometer	PREDICT PROTRACTED RECOVERY; TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; POSTURAL STABILITY; FOOTBALL PLAYERS; SYMPTOMS	Background: High-technology methods demonstrate that balance problems may persist up to 30 days after a concussion, whereas with low-technology methods such as the Balance Error Scoring System (BESS), performance becomes normal after only 3 days based on previously published studies in collegiate and high school athletes. Purpose: To compare the National Institutes of Health's Balance Accelerometer Measure (BAM) with the BESS regarding the ability to detect differences in postural sway between adolescents with sports concussions and age-matched controls. Study Design: Cohort study (diagnosis); Level of evidence, 2. Methods: Forty-three patients with concussions and 27 control participants were tested with the standard BAM protocol, while sway was quantified using the normalized path length (mG/s) of pelvic accelerations in the anterior-posterior direction. The BESS was scored by experts using video recordings. Results: The BAM was not able to discriminate between healthy and concussed adolescents, whereas the BESS, especially the tandem stance conditions, was good at discriminating between healthy and concussed adolescents. A total BESS score of 21 or more errors optimally identified patients in the acute concussion group versus healthy participants at 60% sensitivity and 82% specificity. Conclusion: The BAM is not as effective as the BESS in identifying abnormal postural control in adolescents with sports concussions. The BESS, a simple and economical method of assessing postural control, was effective in discriminating between young adults with acute concussions and young healthy people, suggesting that the test has value in the assessment of acute concussions.	[Furman, Gabriel R.; Lin, Chia-Cheng; Bellanca, Jennica L.; Marchetti, Gregory F.; Collins, Michael W.; Whitney, Susan L.] Univ Pittsburgh, Ctr Sports Med, Pittsburgh, PA 15261 USA	Whitney, SL (corresponding author), Univ Pittsburgh, Dept Phys Therapy, 6035 Forbes Tower, Pittsburgh, PA 15261 USA.	whitney@pitt.edu			Department of Physical Therapy at the University of Pittsburgh; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG024827] Funding Source: NIH RePORTER	This study was sponsored by the Department of Physical Therapy at the University of Pittsburgh.	Cohen JS, 2009, CURR OPIN PEDIATR, V21, P288, DOI 10.1097/MOP.0b013e32832b1195; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; Monsell EM, 1997, OTOLARYNG HEAD NECK, V117, P394, DOI 10.1016/S0194-5998(97)70132-3; Register-Mihalik J, 2007, CLIN J SPORT MED, V17, P282, DOI 10.1097/JSM.0b013e31804ca68a; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rine RM, 2013, NEUROLOGY, V80, pS25, DOI 10.1212/WNL.0b013e3182872c6a; Sabin MJ, 2011, CLIN J SPORT MED, V21, P411, DOI 10.1097/JSM.0b013e318223f3a4; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Whitney SL, 2011, GAIT POSTURE, V33, P594, DOI 10.1016/j.gaitpost.2011.01.015; Yang CC, 2009, BRAIN INJURY, V23, P299, DOI 10.1080/02699050902788543	22	39	39	1	19	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JUN	2013	41	6					1404	1410		10.1177/0363546513484446			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	301HN	WOS:000330523500024	23585486	Green Accepted			2021-06-18	
J	Gatson, JW; Warren, V; Abdelfattah, K; Wolf, S; Hynan, LS; Moore, C; Diaz-Arrastia, R; Minei, JP; Madden, C; Wigginton, JG				Gatson, Joshua Wayne; Warren, Victoria; Abdelfattah, Kareem; Wolf, Steven; Hynan, Linda S.; Moore, Carol; Diaz-Arrastia, Ramon; Minei, Joseph P.; Madden, Christopher; Wigginton, Jane G.			Detection of beta-amyloid oligomers as a predictor of neurological outcome after brain injury Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						amyloid oligomers; amyloid-beta 42; biomarkers cerebrospinal fluid; traumatic brain injury	PRECURSOR PROTEIN IMMUNOREACTIVITY; SEVERE HEAD-INJURY; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; HUMANS; DEPOSITION; APOPTOSIS; SCALE; RAT; NEURODEGENERATION	Object. Traumatic brain injury (TBI) is known to be a risk factor for Alzheimer-like dementia. In previous studies, an increase in P-amyloid (A beta) monomers, such as beta-amyloid 42 (A beta 42), in the CSF of patients with TBI has been shown to correlate with a decrease in amyloid plaques in the brain and improved neurological outcomes. In this study, the authors hypothesized that the levels of toxic high-molecular-weight beta-amyloid oligomers are increased in the brain and are detectable within the CSF of TBI patients with poor neurological outcomes. Methods. Samples of CSF were collected from 18 patients with severe TBI (Glasgow Coma Scale Scores 3-8) and a ventriculostomy. In all cases the CSF was collected within 72 hours of injury. The CSF levels of neuron-specific enolase (NSE) and A beta 42 were measured using enzyme-linked immunosorbent assay. The levels of high-molecular-weight p-amyloid oligomers were measured using Western blot analysis. Results. Patients with good outcomes showed an increase in the levels of CSF A beta 42 (p = 0.003). Those with bad outcomes exhibited an increase in CSF levels of p-amyloid oligomers (p = 0.009) and NSE (p = 0.001). In addition, the CSF oligomer levels correlated with the scores on the extended Glasgow Outcome Scale (r = 0.89, p = 0.0001), disability rating scale scores (r = 0.77, p = 0.005), CSF A(342 levels (r = 0.42, p = 0.12), and CSF NSE levels (r = 0.70, p = 0.004). Additionally, the receiver operating characteristic curve yielded an area under the curve for P-amyloid oligomers of 0.8750 +/- 0.09. Conclusions. Detection of P-amyloid oligomers may someday become a useful clinical tool for determining injury severity and neurological outcomes in patients with TBI.	[Gatson, Joshua Wayne; Warren, Victoria; Abdelfattah, Kareem; Wolf, Steven; Hynan, Linda S.; Minei, Joseph P.; Madden, Christopher; Wigginton, Jane G.] Univ Texas SW Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA; [Moore, Carol; Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Rockville, MD USA	Gatson, JW (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Surg, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	joshua.gatson@utsw.edu	Hynan, Linda S/P-6473-2016	Wolf, Steven/0000-0003-2972-3440; Diaz-Arrastia, Ramon/0000-0001-6051-3594; Hynan, Linda/0000-0002-4642-7769; Wigginton, Jane/0000-0002-8561-3492			Adamides AA, 2006, ANZ J SURG, V76, P163, DOI 10.1111/j.1445-2197.2006.03674.x; Alderson P, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000196.pub2; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Bohmer AE, 2011, NEUROSURGERY, V68, P1624, DOI 10.1227/NEU.0b013e318214a81f; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Chen YN, 2006, BIOCHEM BIOPH RES CO, V341, P1, DOI 10.1016/j.bbrc.2005.12.150; Cizas P, 2010, ARCH BIOCHEM BIOPHYS, V496, P84, DOI 10.1016/j.abb.2010.02.001; CLINTON J, 1991, NEUROPATH APPL NEURO, V17, P69, DOI 10.1111/j.1365-2990.1991.tb00695.x; Conti AC, 1998, J NEUROSCI, V18, P5663; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Fagan AM, 2006, ANN NEUROL, V59, P512, DOI 10.1002/ana.20730; Ferretti MT, 2012, NEUROBIOL AGING, V33, P1329, DOI 10.1016/j.neurobiolaging.2011.01.007; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Klaver AC, 2011, J NEUROSCI METH, V195, P249, DOI 10.1016/j.jneumeth.2010.12.001; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Liao CW, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-84; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Nathoo N, 2004, J NEUROSURG, V101, P233, DOI 10.3171/jns.2004.101.2.0233; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Nimmrich V, 2008, J NEUROSCI, V28, P788, DOI 10.1523/JNEUROSCI.4771-07.2008; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; RINK A, 1995, AM J PATHOL, V147, P1575; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Sakono M, 2010, FEBS J, V277, P1348, DOI 10.1111/j.1742-4658.2010.07568.x; Salminen A, 2009, PROG NEUROBIOL, V87, P181, DOI 10.1016/j.pneurobio.2009.01.001; Sasaki A, 1997, ACTA NEUROPATHOL, V94, P316, DOI 10.1007/s004010050713; Shankar GM, 2007, J NEUROSCI, V27, P2866, DOI 10.1523/JNEUROSCI.4970-06.2007; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Tomasevic G, 2010, J NEUROSCI RES, V88, P3414, DOI 10.1002/jnr.22491; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005; Wakai A, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub2; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yan Q, 2003, J NEUROSCI, V23, P7504	49	39	39	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2013	118	6					1336	1342		10.3171/2013.2.JNS121771			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	150BY	WOS:000319366400034	23540266				2021-06-18	
J	Lange, RT; Iverson, GL; Brickell, TA; Staver, T; Pancholi, S; Bhagwat, A; French, LM				Lange, Rael T.; Iverson, Grant L.; Brickell, Tracey A.; Staver, Tara; Pancholi, Sonal; Bhagwat, Aditya; French, Louis M.			Clinical Utility of the Conners' Continuous Performance Test-II to Detect Poor Effort in US Military Personnel Following Traumatic Brain Injury	PSYCHOLOGICAL ASSESSMENT			English	Article						mild traumatic brain injury; poor effort; military service members; CPT-II; symptom validity testing	MALINGERED NEUROCOGNITIVE DYSFUNCTION; ADULT INTELLIGENCE SCALE; LEARNING TEST INDICATORS; RELIABLE DIGIT SPAN; CARD SORTING TEST; CLASSIFICATION ACCURACY; INADEQUATE EFFORT; CHRONIC PAIN; HEAD-INJURY; MILD	The purpose of this study is to examine the clinical utility of the Conners' Continuous Performance Test (CPT-II) as an embedded marker of poor effort in military personnel undergoing neuropsychological evaluations following traumatic brain injury. Participants were 158 U.S. military service members divided into 3 groups on the basis of brain injury severity and performance (pass/fail) on 2 symptom validity tests: Mild Traumatic Brain Injury (MTBI)-Pass (n = 87), MTBI-Fail (n = 42), and severe traumatic brain injury (STBI)-Pass (n = 29). The MTBI-Fail group performed worse on the majority of CPT-II measures compared with both the MTBI-Pass and STBI-Pass groups. When comparing the MTBI-Fail group and MTBI-Pass groups, the most accurate measure for identifying poor effort was the Commission T score. When selected measures were combined (i.e., Omissions, Commissions, and Perseverations), there was a very small increase in sensitivity (from .26 to .29). When comparing the MTBI-Fail group and STBI-Pass groups, the most accurate measure for identifying poor effort was the Omission and Commissions T score. When selected measures were combined, sensitivity again increased (from .24 to .45). Overall, these results suggest that individual CPT-II measures can be useful for identifying people who are suspected of providing poor effort from those who have provided adequate effort. However, due to low sensitivity and modest negative predictive power values, this measure cannot be used in isolation to detect poor effort, and is largely useful as a test to "rule in," not "rule out" poor effort.	[Lange, Rael T.; Iverson, Grant L.; Brickell, Tracey A.; Pancholi, Sonal; Bhagwat, Aditya; French, Louis M.] Def & Vet Brain Injury Ctr, Dept Res, North Bethesda, MD 20852 USA; [Lange, Rael T.; Brickell, Tracey A.; Bhagwat, Aditya; French, Louis M.] Walter Reed Natl Mil Med Ctr, Dept Orthopaed & Rehabil, Bethesda, MD USA; [Lange, Rael T.; Iverson, Grant L.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; [Brickell, Tracey A.] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD 20814 USA; [Staver, Tara] Natl Intrepid Ctr Excellence, Bethesda, MD USA; [Pancholi, Sonal] Ft Belvoir Community Hosp, Ft Belvoir, VA USA; [Bhagwat, Aditya] US PHS, Bethesda, MD USA; [French, Louis M.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA	Lange, RT (corresponding author), Def & Vet Brain Injury Ctr, 11300 Rockville Pike,Suite 1100, North Bethesda, MD 20852 USA.	rlange@dvbic.org	french, louis/AAB-2083-2020	Iverson, Grant/0000-0001-7348-9570; french, louis/0000-0002-9451-0604			Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Barney SJ, 2011, CLIN NEUROPSYCHOL, V25, P1145, DOI 10.1080/13854046.2011.595956; Brenner LA, 2009, MIL MED, V174, P347, DOI 10.7205/MILMED-D-01-5808; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Conners K., 2002, CONNERS CONTINUOUS P; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; Delis DC, 2000, CALIFORNIA VERBAL LE; Department of Veterans Affairs, 2009, CLIN PRACT GUID MAN; Etherton JL, 2005, ASSESSMENT, V12, P101, DOI 10.1177/1073191104270789; Galbiati S, 2009, NEUROPSYCHOLOGY, V23, P40, DOI 10.1037/a0013409; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Green, 2004, GREENS MED SYMPTOM V; Green P., 2003, GREENS WORD MEMORY T; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Greve KW, 2010, CLIN NEUROPSYCHOL, V24, P137, DOI 10.1080/13854040902927546; Greve KW, 2009, ASSESSMENT, V16, P237, DOI 10.1177/1073191108326227; Greve K, 2009, CLIN NEUROPSYCHOL, V23, P343, DOI 10.1080/13854040802054169; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Henry GK, 2007, APPL NEUROPSYCHOL, V14, P267, DOI 10.1080/09084280701719245; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Iverson GL, 2007, BRAIN INJURY MED PRI, P333; Iverson GL, 2008, NEUROPSYCHOLOGY HDB, P125; Iverson GL, 2011, LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH, P697, DOI 10.1007/978-0-387-76978-3_22; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Krishnan M, 2011, ARCH CLIN NEUROPSYCH, V26, P176, DOI 10.1093/arclin/acr010; Lange RT, 2012, ARCH CLIN NEUROPSYCH, V27, P480, DOI 10.1093/arclin/acs059; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P412, DOI 10.1080/13803390490520319; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2009, CLIN NEUROPSYCHOL, V23, P167, DOI 10.1080/13854040801968443; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; O'Bryant SE, 2003, CLIN NEUROPSYCHOL, V17, P69, DOI 10.1076/clin.17.1.69.15624; Ord JS, 2008, CLIN NEUROPSYCHOL, V22, P689, DOI 10.1080/13854040701425437; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P380, DOI 10.1080/13803390903066881; Park BS, 2009, APPL NEUROPSYCHOL, V16, P1, DOI 10.1080/09084280802636371; Pearson, 2009, ADV CLIN SOLUTIONS W, P71; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Ruffolo LF, 2000, CLIN NEUROPSYCHOL, V14, P223, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT223; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Skandsen T, 2010, ARCH PHYS MED REHAB, V91, P1904, DOI 10.1016/j.apmr.2010.08.021; Slick D., 1997, VICTORIA SYMPTOM VAL; Slick DJ, 2000, J CLIN EXP NEUROPSYC, V22, P569, DOI 10.1076/1380-3395(200010)22:5;1-9;FT569; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Sollman MJ, 2011, ARCH CLIN NEUROPSYCH, V26, P774, DOI 10.1093/arclin/acr066; Strauss E, 2006, COMPENDIUM NEUROPSYC, P3; TEASDALE G, 1974, LANCET, V2, P81; Tombaugh TN, 1996, TEST MEMORY MALINGER; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	56	39	40	0	13	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1040-3590	1939-134X		PSYCHOL ASSESSMENT	Psychol. Assess.	JUN	2013	25	2					339	352		10.1037/a0030915			14	Psychology, Clinical	Psychology	173DR	WOS:000321058800004	23244641				2021-06-18	
J	Liu, W; Wang, BQ; Wolfowitz, R; Yeh, PH; Nathan, DE; Graner, J; Tang, HY; Pan, H; Harper, J; Pham, D; Oakes, TR; French, LM; Riedy, G				Liu, Wei; Wang, Binquan; Wolfowitz, Rachel; Yeh, Ping-Hong; Nathan, Dominic E.; Graner, John; Tang, Haiying; Pan, Hai; Harper, Jamie; Dzung Pham; Oakes, Terrence R.; French, Louis M.; Riedy, Gerard			Perfusion deficits in patients with mild traumatic brain injury characterized by dynamic susceptibility contrast MRI	NMR IN BIOMEDICINE			English	Article						dynamic susceptibility-weighted MRI; perfusion; arterial input function; relative cerebral flood flow; traumatic brain injury	CEREBRAL-BLOOD-FLOW; ARTERIAL INPUT FUNCTION; POSTTRAUMATIC-STRESS-DISORDER; HIGH-RESOLUTION MEASUREMENT; TRACER BOLUS PASSAGES; NEUROPSYCHOLOGICAL OUTCOMES; ANTERIOR CINGULATE; SPECT; BLAST; IRAQ	Perfusion deficits in patients with mild traumatic brain injury (TBI) from a military population were characterized by dynamic susceptibility contrast perfusion imaging. Relative cerebral blood flow (rCBF) was calculated by a model-independent deconvolution approach from the tracer concentration curves following a bolus injection of gadolinium diethylenetriaminepentaacetate (Gd-DTPA) using both manually and automatically selected arterial input functions (AIFs). Linear regression analysis of the mean values of rCBF from selected regions of interest showed a very good agreement between the two approaches, with a regression coefficient of R=0.88 and a slope of 0.88. The BlandAltman plot also illustrated the good agreement between the two approaches, with a mean difference of 0.6 +/- 12.4mL/100g/min. Voxelwise analysis of rCBF maps from both approaches demonstrated multiple clusters of decreased perfusion (p<0.01) in the cerebellum, cuneus, cingulate and temporal gyrus in the group with mild TBI relative to the controls. MRI perfusion deficits in the cerebellum and anterior cingulate also correlated (p<0.01) with neurocognitive results, including the mean reaction time in the Automated Neuropsychological Assessment Metrics and commission error and detection T-scores in the Continuous Performance Test, as well as neurobehavioral scores in the Post-traumatic Stress Disorder ChecklistCivilian Version. In conclusion, rCBF calculated using AIFs selected from an automated approach demonstrated a good agreement with the corresponding results using manually selected AIFs. Group analysis of patients with mild TBI from a military population demonstrated scattered perfusion deficits, which showed significant correlations with measures of verbal memory, speed of reaction time and self-report of stress symptoms. Published 2013. This article is a U.S. Government work and is in the public domain in the USA.	[Liu, Wei; Wang, Binquan; Wolfowitz, Rachel; Yeh, Ping-Hong; Nathan, Dominic E.; Graner, John; Pan, Hai; Harper, Jamie; Oakes, Terrence R.; Riedy, Gerard] NCNC, Bethesda, MD USA; [Liu, Wei; Wang, Binquan; Wolfowitz, Rachel; Yeh, Ping-Hong; Nathan, Dominic E.; Pan, Hai] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA; [Wolfowitz, Rachel; Graner, John; Harper, Jamie; Oakes, Terrence R.; Riedy, Gerard] Natl Intrepid Ctr Excellence NICoE, Bethesda, MD USA; [Tang, Haiying; French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Dzung Pham; French, Louis M.] CNRM, Rockville, MD USA; [French, Louis M.] WRNMMC, Bethesda, MD USA	Riedy, G (corresponding author), Natl Intrepid Ctr Excellence, Bethesda, MD 20889 USA.	Gerard.riedy@med.navy.mil	Pham, Dzung/AAR-8263-2020; french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604	Center for Neuroscience and Regenerative Medicine (CNRM)United States Department of Defense [33333]; Congressionally Directed Medical Research Programs (CDMRP)United States Department of Defense [PT074437]	This research was supported by Center for Neuroscience and Regenerative Medicine (CNRM) grant #33333 and Congressionally Directed Medical Research Programs (CDMRP) grant PT074437. The authors would like to thank Dr. John A. Butman for providing the method for automated AIF selection and Dr Robert W. Cox, Dr Daniel Glen, Dr Richard Reynolds and Dr Ziad Saad for their support with the AFNI software.	Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bjornerud A, 2010, J CEREBR BLOOD F MET, V30, P1066, DOI 10.1038/jcbfm.2010.4; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Borghammer P, 2009, NEUROIMAGE, V45, P249, DOI 10.1016/j.neuroimage.2008.07.042; Bradshaw BGD, 2008, TBI TASK FORCE REPOR; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Butman JA, 2005, P INT SOC MAGN RESON, V13, P1126; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Carroll TJ, 2003, RADIOLOGY, V227, P593, DOI 10.1148/radiol.2272020092; Casey BJ, 1997, DEV PSYCHOBIOL, V30, P61, DOI 10.1002/(SICI)1098-2302(199701)30:1<61::AID-DEV6>3.3.CO;2-B; Conturo TE, 2005, J MAGN RESON IMAGING, V22, P697, DOI 10.1002/jmri.20457; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Dehaene S, 1998, P NATL ACAD SCI USA, V95, P14529, DOI 10.1073/pnas.95.24.14529; DETRE JA, 1994, NMR BIOMED, V7, P75, DOI 10.1002/nbm.1940070112; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Field AS, 2003, RADIOLOGY, V227, P129, DOI 10.1148/radiol.2271012173; Franklin TR, 2011, DRUG ALCOHOL DEPEN, V117, P176, DOI 10.1016/j.drugalcdep.2011.01.015; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Graner J, 2011, P INT SOC MAGN RESON, V3662; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Grunder G, 2009, NEUROIMAGE, V45, P258, DOI 10.1016/j.neuroimage.2008.10.042; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; ICHISE M, 1994, J NUCL MED, V35, P217; Jamora CW, 2012, BRAIN INJURY, V26, P36, DOI 10.3109/02699052.2011.635352; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kelly MP, 2012, ARCH CLIN NEUROPSYCH, V27, P375, DOI 10.1093/arclin/acs036; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; KUBOTA K, 1983, STROKE, V14, P720, DOI 10.1161/01.STR.14.5.720; LAMMERTSMA AA, 1984, J CEREBR BLOOD F MET, V4, P317, DOI 10.1038/jcbfm.1984.47; Lange RT, 2012, J INT NEUROPSYCH SOC, V18, P595, DOI 10.1017/S1355617712000239; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; MEIER P, 1954, J APPL PHYSIOL, V6, P731; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Miao Y, 2011, AM J NEURORADIOL, V32, P1280, DOI 10.3174/ajnr.A2540; Mlynash M, 2005, AM J NEURORADIOL, V26, P1479; Mukherjee P, 2003, AM J NEURORADIOL, V24, P862; Nakashima T, 2007, AM J NEURORADIOL, V28, P236; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Ostergaard L, 1998, J CEREBR BLOOD F MET, V18, P425, DOI 10.1097/00004647-199804000-00011; Ostergaard L, 1996, MAGNET RESON MED, V36, P726, DOI 10.1002/mrm.1910360511; Ostergaard L, 1996, MAGN RESON MED, V36, P715, DOI 10.1002/mrm.1910360510; Peruzzo D, 2011, COMPUT METH PROG BIO, V104, pE148, DOI 10.1016/j.cmpb.2011.02.012; Rausch M, 2000, MAGN RESON IMAGING, V18, P1235, DOI 10.1016/S0730-725X(00)00219-8; REMPP KA, 1994, RADIOLOGY, V193, P637, DOI 10.1148/radiology.193.3.7972800; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Ruminski J, 2005, ADV SOFT COMP, P671, DOI 10.1007/3-540-32390-2_79; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Shin YB, 2006, BRAIN INJURY, V20, P661, DOI 10.1080/02699050600677071; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stamatakis EA, 2002, J NUCL MED, V43, P476; Strick PL, 2009, ANNU REV NEUROSCI, V32, P413, DOI 10.1146/annurev.neuro.31.060407.125606; Swick D, 2002, NEUROPSYCHOLOGIA, V40, P1240, DOI 10.1016/S0028-3932(01)00226-3; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Van Laere KJ, 2002, J NUCL MED, V43, P458; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Vlassenko A, 2004, J NEUROPSYCH CLIN N, V16, P360, DOI 10.1176/appi.neuropsych.16.3.360; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WEISSKOFF RM, 1994, MAGNET RESON MED, V31, P601, DOI 10.1002/mrm.1910310605; WILLIAMS DS, 1992, P NATL ACAD SCI USA, V89, P212, DOI 10.1073/pnas.89.1.212; YAMASHITA K, 1988, GERONTOLOGY, V34, P199, DOI 10.1159/000212953; Zasler ND, 2006, BRAIN INJURY MED PRI, P333; Zysset S, 2002, NEUROIMAGE, V15, P983, DOI 10.1006/nimg.2001.1008	79	39	39	0	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0952-3480	1099-1492		NMR BIOMED	NMR Biomed.	JUN	2013	26	6					651	663		10.1002/nbm.2910			13	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	134RJ	WOS:000318231700007	23456696				2021-06-18	
J	Newcombe, VFJ; Williams, GB; Outtrim, JG; Chatfield, D; Abate, MG; Geeraerts, T; Manktelow, A; Room, H; Mariappen, L; Hutchinson, PJ; Coles, JP; Menon, DK				Newcombe, Virginia F. J.; Williams, Guy B.; Outtrim, Joanne G.; Chatfield, Doris; Abate, M. Gulia; Geeraerts, Thomas; Manktelow, Anne; Room, Hywel; Mariappen, Leela; Hutchinson, Peter J.; Coles, Jonathan P.; Menon, David K.			Microstructural basis of contusion expansion in traumatic brain injury: insights from diffusion tensor imaging	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						contusions; diffusion tensor imaging; traumatic brain injury	HEAD-INJURY; TIME-COURSE; CEREBRAL CONTUSION; EDEMA; COEFFICIENT; PERFUSION; STROKE; PROGRESSION; TOMOGRAPHY; MECHANISMS	Traumatic brain injury (TBI) is often exacerbated by events that lead to secondary brain injury, and represent potentially modifiable causes of mortality and morbidity. Diffusion tensor imaging was used to characterize tissue at-risk in a group of 35 patients scanned at a median of 50 hours after injury. Injury progression was assessed in a subset of 16 patients with two scans. All contusions within the first few days of injury showed a core of restricted diffusion, surrounded by an area of raised apparent diffusion coefficient (ADC). In addition to these two well-defined regions, a thinner rim of reduced ADC was observed surrounding the region of increased ADC in 91% of patients scanned within the first 3 days after injury. In patients who underwent serial imaging, the rim of ADC hypointensity was subsumed into the high ADC region as the contusion enlarged. Overall contusion enlargement tended to be more frequent with early lesions, but its extent was unrelated to the time of initial imaging, initial contusion size, or the presence of hemostatic abnormalities. This rim of hypointensity may characterize a region of microvascular failure resulting in cytotoxic edema, and may represent a 'traumatic penumbra' which may be rescued by effective therapy.	[Newcombe, Virginia F. J.; Outtrim, Joanne G.; Chatfield, Doris; Abate, M. Gulia; Geeraerts, Thomas; Manktelow, Anne; Room, Hywel; Mariappen, Leela; Coles, Jonathan P.; Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Div Anaesthesia, Cambridge CB2 2QQ, England; [Newcombe, Virginia F. J.; Williams, Guy B.; Coles, Jonathan P.; Menon, David K.] Univ Cambridge, Wolfson Brain Imaging Ctr, Dept Clin Neurosci, Cambridge CB2 2QQ, England; [Abate, M. Gulia] San Gerardo Hosp, Dept Perioperat Med & Intens Care, Milan, Italy; [Geeraerts, Thomas] Univ Toulouse 3, Univ Hosp Toulouse, Anesthesiol & Crit Care Dept, F-31062 Toulouse, France; [Hutchinson, Peter J.] Univ Cambridge, Acad Neurosurg Unit, Dept Clin Neurosci, Cambridge CB2 2QQ, England	Newcombe, VFJ (corresponding author), Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Div Anaesthesia, Box 93,Hills Rd, Cambridge CB2 2QQ, England.	vfjn2@cam.ac.uk		Newcombe, Virginia/0000-0001-6044-9035; Outtrim, Joanne/0000-0001-8118-6430	Medical Research Council (UK)UK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390 ID 65883]; UK National Institute of Health Research Biomedical Research Centre at CambridgeNational Institute for Health Research (NIHR); UK Department of Health; NIHRNational Institute for Health Research (NIHR); Academy of Medical Sciences/Health Foundation; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001354B, G0600986, G0001354, G1000183B, G9439390] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090, ACF-2009-14-007] Funding Source: researchfish	This work was supported by a Medical Research Council (UK) Program Grant (Acute brain injury: heterogeneity of mechanisms, therapeutic targets and outcome effects (G9439390 ID 65883)), the UK National Institute of Health Research Biomedical Research Centre at Cambridge, and the Technology Platform funding provided by the UK Department of Health. VFJN is supported by an NIHR academic clinical fellowship. PJAH is supported by an Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship. DKM is supported by an NIHR Senior Investigator Award. The funders had no role in study design, data collection and analyses, decision to publish, or preparation of the manuscript.	Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Copen WA, 2001, RADIOLOGY, V221, P27, DOI 10.1148/radiol.2211001397; Davis SM, 2008, LANCET NEUROL, V7, P299, DOI 10.1016/S1474-4422(08)70044-9; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Engstrom M, 2005, J NEUROSURG, V102, P460, DOI 10.3171/jns.2005.102.3.0460; Fiehler J, 2004, STROKE, V35, P514, DOI 10.1161/01.STR.0000114873.28023.C2; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Jacobs B, 2011, J NEUROTRAUM, V28, P203, DOI 10.1089/neu.2010.1558; Janowitz T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000330; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jones DK, 2000, NEUROSURGERY, V47, P306, DOI 10.1097/00006123-200008000-00008; Katayama Y, 2003, ACTA NEUROCHIR SUPPL, V86, P323; Kawai N, 2010, J NEUROTRAUM, V27, P2131, DOI 10.1089/neu.2010.1464; Kawamata T, 2000, ACTA NEUROCHIR SUPPL, V76, P9; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Kuroiwa T, 2000, ACT NEUR S, V76, P191; Liang Danny, 2007, Neurosurg Focus, V22, pE2, DOI 10.3171/foc.2007.22.5.3; Liu KF, 2001, STROKE, V32, P1897, DOI 10.1161/01.STR.32.8.1897; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Menon DK, 2003, ANESTHESIOLOGY, V98, P805, DOI 10.1097/00000542-200304000-00002; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Newcombe V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019214; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Pasco A, 2006, EUR RADIOL, V16, P1501, DOI 10.1007/s00330-005-0086-0; Pasco A, 2007, J NEUROTRAUM, V24, P1321, DOI 10.1089/neu.2006.0136; Plesnila N, 2003, NEUROSCI LETT, V345, P85, DOI 10.1016/S0304-3940(03)00396-3; Rae CL, 2012, NEUROIMAGE, V62, P1675, DOI 10.1016/j.neuroimage.2012.06.012; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smielewski Peter, 2002, J Clin Monit Comput, V17, P427, DOI 10.1023/A:1026293611455; WAGNER DP, 1984, MED DECIS MAKING, V4, P297, DOI 10.1177/0272989X8400400305; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246	40	39	41	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUN	2013	33	6					855	862		10.1038/jcbfm.2013.11			8	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	156KP	WOS:000319821100008	23423189	Green Published, Bronze			2021-06-18	
J	Johnson, EM; Traver, KL; Hoffman, SW; Harrison, CR; Herman, JP				Johnson, Erica M.; Traver, Kyle L.; Hoffman, Stuart W.; Harrison, Catherine R.; Herman, James P.			Environmental enrichment protects against functional deficits caused by traumatic brain injury	FRONTIERS IN BEHAVIORAL NEUROSCIENCE			English	Article						environmental enrichment; traumatic brain injury; morris water maze; controlled cortical impact; sensory neglect	EARLY-ONSET STIMULATION; ADULT-RAT; COGNITIVE FUNCTION; PREFRONTAL CORTEX; DENTATE GYRUS; RECOVERY; MICE; EXPRESSION; PLASTICITY; INCREASES	Environmental enrichment (EE) increases cortical weight, neuronal density, dendritic branching, and angiogenesis, all of which may be critical for functional recovery following insult. Our study was designed to determine possible benefits of pre-exposure to EE in preventing functional deficits following traumatic brain injury (TBI) to the prefrontal cortex. To examine the benefit of EE, adult male rats were placed in an enriched environment for 15 days. Enrichment was provided through social interaction, exercise, olfactory stimulation, and new objects/toys to explore. Following enrichment, experimental and age-matched controls were subjected to a moderate medial prefrontal cortex injury via controlled cortical impact (CCI). After 1 week recovery, animals were behaviorally tested to assess memory, anxiety, and sensory neglect. Lesion-induced deficits in spatial memory [Morris water maze (MWM)] were significantly attenuated in EE pre-exposed rats 18-21 days following injury. In addition, TBI-induced sensory neglect was significantly reduced in EE rats relative to non-enriched animals. No differences in anxiety-like behavior on the elevated plus maze (EPM) were detected. The behavioral data suggest that EE is neuroprotective when applied prior to TBI, resulting in improved recovery following injury.	[Johnson, Erica M.; Herman, James P.] Univ Cincinnati, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA; [Johnson, Erica M.; Traver, Kyle L.] USAF, Res Lab, Wright Patterson AFB, OH 45433 USA; [Hoffman, Stuart W.] US Dept Vet Affairs, Off Res & Dev, Washington, DC USA; [Harrison, Catherine R.] FAA, Washington, DC USA	Johnson, EM (corresponding author), USAF, Res Lab, 711th Human Performance Wing,2510 5th St, Wright Patterson AFB, OH 45433 USA.	erica.johnson.7@us.af.mil	Herman, James P/D-4960-2015	Herman, James P/0000-0003-3571-2406	Air Force Research Laboratory, Wright Patterson Air Force Base; Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs	This research was sponsored by the Air Force Research Laboratory, Wright Patterson Air Force Base, and was funded in part by the Defense and Veterans Brain Injury Center. The authors wish to thank Mr. Chuck Goodyear for his invaluable assistance with statistical analysis, the animal research support team for their excellent assistance with enrichment housing and behavioral testing and the University of Cincinnati Neuroscience graduate program for their generous support.	Barnett V., 1994, OUTLIERS STAT DATA; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Benaroya-Milshtein N, 2004, EUR J NEUROSCI, V20, P1341, DOI 10.1111/j.1460-9568.2004.03587.x; Briones TL, 2004, BRAIN RES, V1018, P130, DOI 10.1016/j.brainres.2004.06.001; Buccafusco JJ, 2009, FRONT NEUROSCI, P1; CHAMOVE AS, 1989, LAB ANIM, V23, P215, DOI 10.1258/002367789780810608; Chen X, 2005, NEUROSCIENCE, V135, P11, DOI 10.1016/j.neuroscience.2005.05.041; Cutler SM, 2006, PHARMACOL BIOCHEM BE, V84, P420, DOI 10.1016/j.pbb.2006.05.029; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; Eslinger P. J., 1996, ATTENTION MEMORY EXE, P367; Floden D, 2008, NEUROPSYCHOLOGIA, V46, P213, DOI 10.1016/j.neuropsychologia.2007.07.020; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gaulke LJ, 2005, MOL BRAIN RES, V141, P138, DOI 10.1016/j.molbrainres.2005.08.011; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; GREENOUGH WT, 1973, EXP NEUROL, V40, P491, DOI 10.1016/0014-4886(73)90090-3; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; HENDERSO.ND, 1970, SCIENCE, V169, P768; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Hoffman SW, 2003, J NEUROTRAUM, V20, P859, DOI 10.1089/089771503322385791; Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; Jones TA, 1999, J NEUROSCI, V19, P10153; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Komitova M, 2005, EUR J NEUROSCI, V21, P2397, DOI 10.1111/j.1460-9568.2005.04072.x; Kozlowski DA, 2004, J NEUROTRAUM, V21, P513, DOI 10.1089/089771504774129856; Lanosa Ximena A, 2011, Neuron Glia Biol, V7, P163, DOI 10.1017/S1740925X12000099; Larsson F, 2002, PHARMACOL BIOCHEM BE, V73, P193, DOI 10.1016/S0091-3057(02)00782-7; LEONARD CM, 1969, BRAIN RES, V12, P321, DOI 10.1016/0006-8993(69)90003-1; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; Lew HL, 2010, NEUROREHABILITATION, V26, P213, DOI 10.3233/NRE-2010-0557; Lippert-Gruener M, 2007, EXP NEUROL, V203, P82, DOI 10.1016/j.expneurol.2006.07.025; Maegele M, 2005, J NEUROTRAUM, V22, P772, DOI 10.1089/neu.2005.22.772; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Rampon C, 2000, P NATL ACAD SCI USA, V97, P12880, DOI 10.1073/pnas.97.23.12880; ROSENZWEIG MR, 1972, SCI AM, V226, P22, DOI 10.1038/scientificamerican0272-22; ROSENZWEIG MR, 1972, J COMP PHYSIOL PSYCH, V80, P304, DOI 10.1037/h0032978; Schrijver NCA, 2002, PHARMACOL BIOCHEM BE, V73, P209, DOI 10.1016/S0091-3057(02)00790-6; TURNER AM, 1985, BRAIN RES, V329, P195, DOI 10.1016/0006-8993(85)90525-6; van Dellen A, 2000, NATURE, V404, P721, DOI 10.1038/35008142; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Wagner AK, 2005, EXP NEUROL, V195, P475, DOI 10.1016/j.expneurol.2005.06.009; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; WILL BE, 1977, J COMP PHYSIOL PSYCH, V91, P33, DOI 10.1037/h0077306; Willmott C, 2009, NEUROPSYCHOLOGY, V23, P424, DOI 10.1037/a0015058; Young D, 1999, NAT MED, V5, P448	51	39	43	0	21	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5153			FRONT BEHAV NEUROSCI	Front. Behav. Neurosci.	MAY 21	2013	7								44	10.3389/fnbeh.2013.00044			7	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	148NV	WOS:000319252700001	23734108	DOAJ Gold, Green Published			2021-06-18	
J	Olivecrona, Z; Dahlqvist, P; Koskinen, LOD				Olivecrona, Zandra; Dahlqvist, Per; Koskinen, Lars-Owe D.			Acute neuro-endocrine profile and prediction of outcome after severe brain injury	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article						Severe traumatic brain injury; Hypopituitarism; Outcome; ICP targeted therapy; Hypothalamic-pituitary dysfunction; Prostacyclin	GROWTH-HORMONE; CRITICAL ILLNESS; HEAD-INJURY; SUBARACHNOID HEMORRHAGE; COMPUTED-TOMOGRAPHY; THYROID-FUNCTION; CRITICALLY-ILL; PROSTACYCLIN; NEUROPROTECTION; HYPOPITUITARISM	Object: The aim of the study was to evaluate the early changes in pituitary hormone levels after severe traumatic brain injury (sTBI) and compare hormone levels to basic neuro-intensive care data, a systematic scoring of the CT-findings and to evaluate whether hormone changes are related to outcome. Methods: Prospective study, including consecutive patients, 15-70 years, with sTBI, Glasgow Coma Scale (GCS) score <= 8, initial cerebral perfusion pressure > 10 mm Hg, and arrival to our level one trauma university hospital within 24 hours after head trauma (n = 48). Serum samples were collected in the morning (08-10 am) day 1 and day 4 after sTBI for analysis of cortisol, growth hormone (GH), prolactin, insulin-like growth factor 1 (IGF-1), thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), follicular stimulating hormone (FSH), luteinizing hormone (LH), testosterone and sex hormone-binding globulin (SHBG) (men). Serum for cortisol and GH was also obtained in the evening (17-19 pm) at day 1 and day 4. The first CT of the brain was classified according to Marshall. Independent staff evaluated outcome at 3 months using GOS-E. Results: Profound changes were found for most pituitary-dependent hormones in the acute phase after sTBI, i.e. low levels of thyroid hormones, strong suppression of the pituitary-gonadal axis and increased levels of prolactin. The main findings of this study were: 1) A large proportion (54% day 1 and 70% day 4) of the patients showed morning s-cortisol levels below the proposed cut-off levels for critical illness related corticosteroid insufficiency (CIRCI), i.e. < 276 nmol/L (= 10 ug/dL), 2) Low s-cortisol was not associated with higher mortality or worse outcome at 3 months, 3) There was a significant association between early (day 1) and strong suppression of the pituitary-gonadal axis and improved survival and favorable functional outcome 3 months after sTBI, 4) Significantly lower levels of fT3 and TSH at day 4 in patients with a poor outcome at 3 months. 5) A higher Marshall CT score was associated with higher day 1 LH/FSH-and lower day 4 TSH levels 6) In general no significant correlation between GCS, ICP or CPP and hormone levels were detected. Only ICPmax and LH day 1 in men was significantly correlated. Conclusion: Profound dynamic changes in hormone levels are found in the acute phase of sTBI. This is consistent with previous findings in different groups of critically ill patients, most of which are likely to be attributed to physiological adaptation to acute illness. Low cortisol levels were a common finding, and not associated with unfavorable outcome. A retained ability to a dynamic hormonal response, i.e. fast and strong suppression of the pituitary-gonadal axis (day 1) and ability to restore activity in the pituitary-thyroid axis (day 4) was associated with less severe injury according to CT-findings and favorable outcome.	[Olivecrona, Zandra; Koskinen, Lars-Owe D.] Umea Univ, Div Neurosurg, Dept Pharmacol & Clin Neurosci, SE-90185 Umea, Sweden; [Dahlqvist, Per] Umea Univ, Dept Publ Hlth & Clin Med, SE-90185 Umea, Sweden	Olivecrona, Z (corresponding author), Umea Univ, Div Neurosurg, Dept Pharmacol & Clin Neurosci, SE-90185 Umea, Sweden.	zandra.olivecrona@gmail.com	Koskinen, Lars-Owe/AAQ-8957-2020; Viani, Rafael/V-1196-2018	Koskinen, Lars-Owe/0000-0003-3528-8502	Department of Clinical Neuroscience; Kempe Foundation; Pfizer, SwedenPfizer	We wish to express our gratitude to Pedram Tabatabai, MD, Lukas Bobinski, MD, Magnus Olivecrona, MD, PhD, Marie Rodling-Wahlstrom, MD, PhD, Silvana Naredi, MD, PhD and our research nurses Kristin Nyman and Anna-Lena Ostlund for help with the study. The Department of Clinical Neuroscience, Kempe Foundation and Pfizer, Sweden financially supported this study.	Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; ALLOLIO B, 1980, BRIT J CLIN PHARMACO, V10, P626, DOI 10.1111/j.1365-2125.1980.tb00524.x; Annane D, 2010, CRIT CARE MED, V38, P721, DOI 10.1097/CCM.0b013e3181c54620; [Anonymous], 1914, DEUT MED WOCHENSCHR, V40, P322; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2002, METABOLISM, V51, P1363, DOI 10.1053/meta.2002.34714; Brorsson C, 2011, ACTA ANAESTH SCAND, V55, P944, DOI 10.1111/j.1399-6576.2011.02451.x; CHIOLERO RL, 1988, ACTA ENDOCRINOL-COP, V117, P80, DOI 10.1530/acta.0.1170080; Chisu V, 2006, ARCH ITAL BIOL, V144, P63; Christ-Crain M, 2007, AM J RESP CRIT CARE, V176, P913, DOI 10.1164/rccm.200702-307OC; CLAUSENSJOBOM N, 1987, ACTA MED SCAND, V222, P57; De Jongh FE, 2001, EUR J ENDOCRINOL, V144, P221, DOI 10.1530/eje.0.1440221; Debudaj Anna, 2010, Pol Merkur Lekarski, V28, P478; Della Corte F, 1998, CRIT CARE MED, V26, P1419; EDWARDS OM, 1986, MEDICINE, V65, P281; Escamilla R F, 1938, Cal West Med, V48, P343; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Grande PO, 2000, ACTA ANAESTH SCAND, V44, P886, DOI 10.1034/j.1399-6576.2000.440718.x; Grill E, 2013, J SURG RES, V179, P132, DOI 10.1016/j.jss.2012.09.008; GRIMEE R, 1995, LIFE SCI, V57, P69, DOI 10.1016/0024-3205(95)00244-Z; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; Hammond J, 2001, J NEUROCHEM, V77, P1319, DOI 10.1046/j.1471-4159.2001.00345.x; Hannon MJ, 2011, BEST PRACT RES CL EN, V25, P783, DOI 10.1016/j.beem.2011.06.001; Hassan-Smith Z, 2011, BEST PRACT RES CL EN, V25, P705, DOI 10.1016/j.beem.2011.04.002; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; LECKMAN JF, 1984, J AM ACAD CHILD PSY, V23, P174, DOI 10.1097/00004583-198403000-00008; Liu M, 2010, MINERVA ENDOCRINOL, V35, P127; Marik PE, 2002, CHEST, V122, P1784, DOI 10.1378/chest.122.5.1784; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MATSUURA H, 1985, NEUROSURGERY, V16, P791, DOI 10.1227/00006123-198506000-00009; MOORE RA, 1985, ANAESTHESIA, V40, P124; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Murakawa T, 1998, Masui, V47, P1350; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Napoli R, 2003, J CLIN ENDOCR METAB, V88, P2817, DOI 10.1210/jc.2003-030144; Nordstrom CH, 2007, INTENS CARE MED, V33, P558, DOI 10.1007/s00134-006-0521-y; Olivecrona M, 2009, J NEUROTRAUM, V26, P1251, DOI [10.1089/neu.2008.0605, 10.1089/neu.2008-0605]; Polo-Garvin A, 1993, Rev Esp Anestesiol Reanim, V40, P344; Savaridas T, 2004, INTENS CARE MED, V30, P1479, DOI 10.1007/s00134-004-2306-5; Scheepens A, 2001, NEUROSCIENCE, V104, P677, DOI 10.1016/S0306-4522(01)00109-9; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Silha JV, 2005, CLIN ENDOCRINOL, V63, P79, DOI 10.1111/j.1365-2265.2005.02303.x; SmithSwintosky VL, 1996, J CEREBR BLOOD F MET, V16, P585, DOI 10.1097/00004647-199607000-00008; SPRATT DI, 1993, J CLIN ENDOCR METAB, V76, P1548, DOI 10.1210/jc.76.6.1548; TAGAWA M, 1989, JPN J VET SCI, V51, P278; Takala J, 1999, NEW ENGL J MED, V341, P785, DOI 10.1056/NEJM199909093411102; Van den Berghe G, 2003, ENDOCRIN METAB CLIN, V32, P385, DOI 10.1016/S0889-8529(03)00005-7; Van den Berghe G, 1998, J CLIN ENDOCR METAB, V83, P1827, DOI 10.1210/jc.83.6.1827; Van den Berghe G, 2000, NEW ENGL J MED, V342, P135; Venkatesh B, 2011, BEST PRACT RES CL EN, V25, P719, DOI 10.1016/j.beem.2011.04.007; Vermeulen A, 1999, J CLIN ENDOCR METAB, V84, P3666, DOI 10.1210/jc.84.10.3666; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Wagner J, 2010, J NEUROTRAUM, V27, P1007, DOI 10.1089/neu.2009.1092; Wildburger R, 2001, WIEN KLIN WOCHENSCHR, V113, P119; WOOLF PD, 1988, AM J MED, V84, P201, DOI 10.1016/0002-9343(88)90414-7	58	39	44	0	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	APR 20	2013	21								33	10.1186/1757-7241-21-33			12	Emergency Medicine	Emergency Medicine	139PX	WOS:000318597100002	23601250	DOAJ Gold, Green Published			2021-06-18	
J	Ekmark-Lewen, S; Flygt, J; Kiwanuka, O; Meyerson, BJ; Lewen, A; Hillered, L; Marklund, N				Ekmark-Lewen, Sara; Flygt, Johanna; Kiwanuka, Olivia; Meyerson, Bengt J.; Lewen, Anders; Hillered, Lars; Marklund, Niklas			Traumatic axonal injury in the mouse is accompanied by a dynamic inflammatory response, astroglial reactivity and complex behavioral changes	JOURNAL OF NEUROINFLAMMATION			English	Article						Astrocytes; beta-amyloid precursor protein (beta-APP); Central fluid percussion injury; Diffuse traumatic axonal injury; Inflammatory response; Functional outcome; Mouse	AMYLOID PRECURSOR PROTEIN; CONTROLLED CORTICAL IMPACT; FIBRILLARY ACIDIC PROTEIN; EXPERIMENTAL BRAIN-INJURY; CONCENTRIC SQUARE FIELD; VASCULAR-PERMEABILITY; CONTUSION TRAUMA; UP-REGULATION; WHITE-MATTER; HEAD-INJURY	Background: Diffuse traumatic axonal injury (TAI), a common consequence of traumatic brain injury, is associated with high morbidity and mortality. Inflammatory processes may play an important role in the pathophysiology of TAI. In the central fluid percussion injury (cFPI) TAI model in mice, the neuroinflammatory and astroglial response and behavioral changes are unknown. Methods: Twenty cFPI injured and nine sham-injured mice were used, and the neuroinflammatory and astroglial response was evaluated by immunohistochemistry at 1, 3 and 7 days post-injury. The multivariate concentric square field test (MCSF) was used to compare complex behavioral changes in mice subjected to cFPI (n = 16) or sham injury (n = 10). Data was analyzed using non-parametric statistics and principal component analysis (MCSF data). Results: At all post-injury time points, beta-amyloid precursor protein (beta-APP) immunoreactivity revealed widespread bilateral axonal injury and IgG immunostaining showed increased blood-brain barrier permeability. Using vimentin and glial fibrillary acidic protein (GFAP) immunohistochemistry, glial cell reactivity was observed in cortical regions and important white matter tracts peaking at three days post-injury. Only vimentin was increased post-injury in the internal capsule and only GFAP in the thalamus. Compared to sham-injured controls, an increased number of activated microglia (MAC-2), infiltrating neutrophils (GR-1) and T-cells (CD3) appearing one day after TAI (P<0.05 for all cell types) was observed in subcortical white matter. In the MCSF, the behavioral patterns including general activity and exploratory behavior differed between cFPI mice and sham-injured controls. Conclusions: Traumatic axonal injury TAI resulted in marked bilateral astroglial and neuroinflammatory responses and complex behavioral changes. The cFPI model in mice appears suitable for the study of injury mechanisms, including neuroinflammation, and the development of treatments targeting TAI.	[Ekmark-Lewen, Sara; Flygt, Johanna; Kiwanuka, Olivia; Lewen, Anders; Hillered, Lars; Marklund, Niklas] Uppsala Univ, Dept Neurosci, Div Neurosurg, S-75185 Uppsala, Sweden; [Meyerson, Bengt J.] Uppsala Univ, Dept Neurosci, Biomed Ctr, Div Pharmacol, S-71523 Uppsala, Sweden	Marklund, N (corresponding author), Uppsala Univ, Dept Neurosci, Div Neurosurg, S-75185 Uppsala, Sweden.	niklas.marklund@neuro.uu.se	Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348; Marklund, Niklas/0000-0002-9797-5626; Kiwanuka, Olivia/0000-0003-3562-5513; Hillered, Lars/0000-0002-2808-9292	Swedish Research CouncilSwedish Research CouncilEuropean Commission; Swedish Brain Foundation; Uppsala University Hospital; Selander Foundation; Ahlen Foundation	This work was funded by grants from Swedish Research Council, The Swedish Brain Foundation, Uppsala University Hospital, The Selander Foundation and The Ahlen Foundation.The authors would like to acknowledge Dr John T. Povlishock and Dr John Greer for hands-on (to NM) technical information about the cFPI model.	AbouHamden A, 1997, J NEUROTRAUM, V14, P699, DOI 10.1089/neu.1997.14.699; Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Bignami A., 1991, DISCUSS NEUROSCI, V111, P9; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; CALVO JL, 1991, BRAIN RES, V566, P333, DOI 10.1016/0006-8993(91)91720-L; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Ekmark-Lewen S, 2010, J NEUROTRAUM, V27, P1643, DOI 10.1089/neu.2009.0953; Ekmark-Lewen S, 2010, RESTOR NEUROL NEUROS, V28, P311, DOI 10.3233/RNN-2010-0529; Eriksson L, 2004, ANAL BIOANAL CHEM, V380, P419, DOI 10.1007/s00216-004-2783-y; Eriksson L., 2006, MULTI MEGAVARIATE 1; Eriksson L, 2006, MOL DIVERS, V10, P187, DOI 10.1007/s11030-006-9026-4; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; Golarai G, 2001, J NEUROSCI, V21, P8523; Graham D I, 1983, Acta Neurochir Suppl (Wien), V32, P65; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; HAMM RJ, 1995, EXP NEUROL, V136, P143, DOI 10.1006/exnr.1995.1091; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Huebner EA, 2009, RESULTS PROBL CELL D, V48, P339, DOI 10.1007/400_2009_19; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Israelsson C, 2010, EUR J NEUROSCI, V31, P852, DOI 10.1111/j.1460-9568.2010.07105.x; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Johnson VE, 2012, EXP NEUROL; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17; Kharatishvili I, 2010, EPILEPSY RES, V90, P47, DOI 10.1016/j.eplepsyres.2010.03.007; KIMELBERG HK, 1994, NEUROBIOLOGY CENTRAL, P193; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lewen A, 1999, ACTA NEUROCHIR, V141, P193, DOI 10.1007/s007010050286; Li Y, 2011, J NEUROTRAUM, V28, P1767, DOI 10.1089/neu.2010.1687; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Lindbom L, 2003, CHEM IMMUNOL, V83, P146; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Marklund N, 2007, J NEUROSURG, V107, P844, DOI 10.3171/JNS-07/10/0844; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maruichi K, 2009, NEUROPATHOLOGY, V29, P422, DOI 10.1111/j.1440-1789.2008.00995.x; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Meyerson BJ, 2006, BEHAV BRAIN RES, V168, P100, DOI 10.1016/j.bbr.2005.10.020; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Pearson VL, 1999, GLIA, V25, P311, DOI 10.1002/(SICI)1098-1136(19990215)25:4<311::AID-GLIA1>3.0.CO;2-E; Pekny M, 1999, NEUROCHEM RES, V24, P1357, DOI 10.1023/A:1022572304626; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pittella JEH, 2004, ARQ NEURO-PSIQUIAT, V62, P406, DOI 10.1590/S0004-282X2004000300007; PIXLEY SKR, 1984, DEV BRAIN RES, V15, P201, DOI 10.1016/0165-3806(84)90097-X; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rafols JA, 2007, NEUROL RES, V29, P348, DOI 10.1179/016164107X204657; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Rogatsky GG, 2003, J NEUROTRAUM, V20, P1315, DOI 10.1089/089771503322686111; Roman E, 2006, HORM BEHAV, V50, P736, DOI 10.1016/j.yhbeh.2006.06.016; SCHIFFER D, 1986, BRAIN RES, V374, P110, DOI 10.1016/0006-8993(86)90399-9; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Stichel CC, 1998, CELL TISSUE RES, V294, P1, DOI 10.1007/s004410051151; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Vink R, 2004, EXPERT OPIN INV DRUG, V13, P1263, DOI 10.1517/13543784.13.10.1263; WEDMORE CV, 1981, NATURE, V289, P646, DOI 10.1038/289646a0; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje	90	39	45	0	14	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	APR 4	2013	10								44	10.1186/1742-2094-10-44			19	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	143FQ	WOS:000318852600001	23557178	DOAJ Gold, Green Published			2021-06-18	
J	Brandstack, N; Kurki, T; Tenovuo, O				Brandstack, Nina; Kurki, Timo; Tenovuo, Olli			Quantitative Diffusion-Tensor Tractography of Long Association Tracts in Patients with Traumatic Brain Injury without Associated Findings at Routine MR Imaging	RADIOLOGY			English	Article							WHITE-MATTER INJURY; AXONAL INJURY; FIBER TRACTOGRAPHY; HEAD-INJURY; INTEGRITY; ABNORMALITIES; IMPAIRMENT; DISABILITY; DISTORTION; SEQUELAE	Purpose: To evaluate whether quantitative diffusion-tensor tractography can show abnormalities in long association tracts of subjects with symptoms after traumatic brain injury without any visible signs of intracranial or intraparenchymal abnormalities of obvious traumatic origin at routine magnetic resonance (MR) imaging and to determine the number and type of these abnormalities. Materials and Methods: The study was approved by the local ethics committee, and informed consent was obtained from all subjects. Diffusion-tensor tractography was performed at 3.0 T in 106 consecutive clinical patients with traumatic brain injury without abnormalities at conventional MR imaging (age, 16-56 years) and 62 age- and sex-matched control subjects. Volume, mean apparent diffusion coefficient (ADC), and mean fractional anisotropy (FA) were measured in the following tracts: uncinate fasciculus, superior cingulum, temporal cingulum, superior longitudinal fasciculus, arcuate fasciculus, inferior fronto-occipital fasciculus, and inferior longitudinal fasciculus. Statistical analyses were based on repeated-measures analysis of covariance. Results: In control subjects, tract volumes showed large variability whereas FA and ADC showed small variability. In several tracts, mean FA values correlated negatively with the respective volumes. In patients with brain injury, FA values were reduced in both uncinate fasciculi, both inferior fronto-occipital fasciculi, and in the right inferior longitudinal fasciculus compared with control subjects (P < .05). Diffusivity was increased in half of the tracts (P < .05). The tract volumes were not significantly reduced. Conclusion: Quantitative diffusion-tensor tractography is able to show posttraumatic FA and ADC abnormalities in patients with normal findings at conventional MR imaging in several association tracts, most commonly the uncinate fasciculus. (C)RSNA, 2013	[Brandstack, Nina; Kurki, Timo] Turku Univ Hosp, Dept Radiol, FIN-20520 Turku, Finland; [Tenovuo, Olli] Turku Univ Hosp, Dept Neurol, FIN-20520 Turku, Finland; [Kurki, Timo] Pulssi Med Ctr, Dept Radiol, Turku, Finland	Brandstack, N (corresponding author), Helsinki Univ Hosp, Dept Radiol, PL 340, Helsinki 00029, HUS, Finland.	nimabr@utu.fi		Kurki, Timo/0000-0001-5532-3534			Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Borich MR, 2012, NEUROIMAGE, V59, P2393, DOI 10.1016/j.neuroimage.2011.09.009; Caeyenberghs K, 2010, HUM BRAIN MAPP, V31, P992, DOI 10.1002/hbm.20911; Catani M, 2008, CORTEX, V44, P953, DOI 10.1016/j.cortex.2008.04.002; Concha L, 2005, AM J NEURORADIOL, V26, P2267; Duffau H, 2009, J NEUROL, V256, P382, DOI 10.1007/s00415-009-0053-9; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Hasan KM, 2010, BRAIN STRUCT FUNCT, V214, P361, DOI 10.1007/s00429-009-0238-0; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Mukherjee P, 2008, AM J NEURORADIOL, V29, P843, DOI 10.3174/ajnr.A1052; Mukherjee P, 2008, AM J NEURORADIOL, V29, P632, DOI 10.3174/ajnr.A1051; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Netsch T, 2004, IEEE T MED IMAGING, V23, P789, DOI 10.1109/TMI.2004.827479; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Rohde GK, 2004, MAGN RESON MED, V51, P103, DOI 10.1002/mrm.10677; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schmahmann JD, 2008, ANN NY ACAD SCI, V1142, P266, DOI 10.1196/annals.1444.017; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	39	39	39	0	12	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	APR	2013	267	1					231	239		10.1148/radiol.12112570			9	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	112AX	WOS:000316565000024	23297328	Bronze			2021-06-18	
J	Haran, FJ; Tierney, R; Wright, WG; Keshner, E; Silter, M				Haran, F. J.; Tierney, R.; Wright, W. G.; Keshner, E.; Silter, M.			Acute Changes in Postural Control after Soccer Heading	INTERNATIONAL JOURNAL OF SPORTS MEDICINE			English	Article						concussion; MTBI; balance; stability; virtual environment	NEURON-SPECIFIC ENOLASE; NEUROPSYCHOLOGICAL IMPAIRMENT; SERUM CONCENTRATIONS; BIOCHEMICAL MARKERS; DAMAGE S-100B; BRAIN-INJURY; CONCUSSION; PLAYERS; STABILITY; FREQUENCY	This study intended to determine if an acute bout of soccer heading alters postural control and pronounced self-reported symptoms of cerebral concussion. Collegiate soccer players were randomly assigned to one of 2 groups. Each participant completed a baseline postural control assessment prior to heading. Participants either simulated (control group; CG) or performed (experimental group; EG) 10 headers at 11.2 m/s in 10 min. The postural assessment was repeated post heading at hrs 1, 24, and 48. The postural control parameter assessed was the root mean square (RMS) of the center of mass (COM). COM RMS were calculated for the anterior-posterior (AP) and medial-lateral (ML) time series. Compared to the CG, for the AP and ML time series COM RMS values were significantly higher in the EG at hr 24 (p < 0.05). An acute bout of heading results in quantifiable alterations in postural control that are detectable 24 h post heading and dissipate within an additional 24 h. The significant findings may be due to the dynamic postural control assessment that incorporated robust discordant environmental conditions.	[Haran, F. J.; Tierney, R.; Wright, W. G.; Keshner, E.; Silter, M.] Temple Univ, Philadelphia, PA 19122 USA	Haran, FJ (corresponding author), Temple Univ, 120 Pearson Hall, Philadelphia, PA 19122 USA.	fjharan@gmail.com			NIH-NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG26470]; NIH-NIDCDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [DC05235]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG026470] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC005235] Funding Source: NIH RePORTER	Supported by NIH-NIA grant AG26470 and NIH-NIDCD grant DC05235. We gratefully acknowledge VRCO, Inc., for the use of the CAVELIB to develop the VE.	Abreau F, 1990, NEUROPSYCHOLOGY, V4, P175, DOI 10.1037/0894-4105.4.3.175; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Broglio SP, 2004, BRIT J SPORT MED, V38, P561, DOI 10.1136/bjsm.2003.004887; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Haran F J, 2008, J Neurol Phys Ther, V32, P186, DOI 10.1097/NPT.0b013e31818dee39; Harriss DJ, 2011, INT J SPORTS MED, V32, P819, DOI 10.1055/s-0031-1287829; Higgins MJ, 2009, P I MECH ENG P-J SPO, V223, P117, DOI 10.1243/17543371JSET15; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kaminski TW, 2008, RES Q EXERCISE SPORT, V79, P235; Mangus Brent C, 2004, Sports Biomech, V3, P209, DOI 10.1080/14763140408522841; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Schmitt DM, 2004, INT J SPORTS MED, V25, P326, DOI 10.1055/s-2004-819941; Slaboda JC, 2009, IEEE ENG MED BIO, P1147, DOI 10.1109/IEMBS.2009.5333916; Stalnacke BM, 2006, BRIT J SPORT MED, V40, P313, DOI 10.1136/bjsm.2005.021584; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stephens R, 2005, CHILD NEUROPSYCHOL, V11, P513, DOI 10.1080/092970490959629; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI64, DOI 10.1136/bjsm.2005.019620; Streepey JW, 2007, EXP BRAIN RES, V176, P182, DOI 10.1007/s00221-006-0677-2; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Webbe FM, 2003, APPL NEUROPSYCHOL, V10, P31, DOI 10.1207/S15324826AN1001_5; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8	33	39	39	0	15	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0172-4622	1439-3964		INT J SPORTS MED	Int. J. Sports Med.	APR	2013	34	4					350	354		10.1055/s-0032-1304647			5	Sport Sciences	Sport Sciences	112TA	WOS:000316615100010	23175178	Bronze			2021-06-18	
J	Kim, N; Branch, CA; Kim, M; Lipton, ML				Kim, Namhee; Branch, Craig A.; Kim, Mimi; Lipton, Michael L.			Whole Brain Approaches for Identification of Microstructural Abnormalities in Individual Patients: Comparison of Techniques Applied to Mild Traumatic Brain Injury	PLOS ONE			English	Article							DIFFUSION TENSOR IMAGES; WHITE-MATTER INTEGRITY; AXONAL INJURY; FRACTIONAL ANISOTROPY; PERSONALIZED MEDICINE; VOXELWISE ANALYSIS; CORPUS-CALLOSUM; REGISTRATION; BIOMARKERS; PHARMACOGENOMICS	Purpose: Group-wise analyses of DTI in mTBI have demonstrated evidence of traumatic axonal injury (TAI), associated with adverse clinical outcomes. Although mTBI is likely to have a unique spatial pattern in each patient, group analyses implicitly assume that location of injury will be the same across patients. The purpose of this study was to optimize and validate a procedure for analysis of DTI images acquired in individual patients, which could detect inter-individual differences and be applied in the clinical setting, where patients must be assessed as individuals. Materials and Methods: After informed consent and in compliance with HIPAA, 34 mTBI patients and 42 normal subjects underwent 3.0 Tesla DTI. Four voxelwise assessment methods (standard Z-score, "one vs. many" t-test, Family-Wise Error Rate control using pseudo t-distribution, EZ-MAP) for use in individual patients, were applied to each patient's fractional anisotropy (FA) maps and tested for its ability to discriminate patients from controls. Receiver Operating Characteristic (ROC) analyses were used to define optimal thresholds (voxel-level significance and spatial extent) for reliable and robust detection of mTBI pathology. Results: ROC analyses showed EZ-MAP (specificity 71%, sensitivity 71%), "one vs. many" t-test and standard Z-score (sensitivity 65%, specificity 76% for both methods) resulted in a significant area under the curve (AUC) score for discriminating mTBI patients from controls in terms of the total number of abnormal white matter voxels detected while the FWER test was not significant. EZ-MAP is demonstrated to be robust to assumptions of Gaussian behavior and may serve as an alternative to methods that require strict Gaussian assumptions. Conclusion: EZ-MAP provides a robust approach for delineation of regional abnormal anisotropy in individual mTBI patients.	[Kim, Namhee; Branch, Craig A.; Lipton, Michael L.] Yeshiva Univ, Albert Einstein Coll Med, Gruss Magnet Resonance Res Ctr, Bronx, NY 10461 USA; [Kim, Namhee; Branch, Craig A.; Lipton, Michael L.] Yeshiva Univ, Albert Einstein Coll Med, Dept Radiol, Bronx, NY USA; [Branch, Craig A.] Yeshiva Univ, Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY USA; [Kim, Mimi] Yeshiva Univ, Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY USA; [Lipton, Michael L.] Yeshiva Univ, Albert Einstein Coll Med, Dept Psychiat & Behav Sci, Bronx, NY USA; [Lipton, Michael L.] Yeshiva Univ, Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY USA; [Lipton, Michael L.] Montefiore Med Ctr, Dept Radiol, Bronx, NY 10467 USA	Lipton, ML (corresponding author), Yeshiva Univ, Albert Einstein Coll Med, Gruss Magnet Resonance Res Ctr, Bronx, NY 10461 USA.	michael.lipton@einstein.yu.edu			Dana Foundation; David Mahoney Neuroimaging Program; National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS082432]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS082432] Funding Source: NIH RePORTER	This work was supported by The Dana Foundation, David Mahoney Neuroimaging Program and by National Institutes of Health/National Institute of Neurological Disorders and Stroke (R01 NS082432). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ardekani BA, 2005, J NEUROSCI METH, V142, P67, DOI 10.1016/j.jneumeth.2004.07.014; ARDEKANI BA, 1995, J COMPUT ASSIST TOMO, V19, P615, DOI 10.1097/00004728-199507000-00022; Beckmann CF, 2004, IEEE T MED IMAGING, V23, P137, DOI 10.1109/TMI.2003.822821; Becla L, 2011, INT J TECHNOL ASSESS, V27, P118, DOI 10.1017/S026646231100002X; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Curran ME, 2011, PHARMACOGENOMICS, V12, P465, DOI 10.2217/pgs.11.9; de la Plata CDM, 2011, J INT NEUROPSYCH SOC, V17, P24, DOI 10.1017/S1355617710001189; EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; Holli KK, 2010, ACAD RADIOL, V17, P1096, DOI 10.1016/j.acra.2010.04.009; Holmes CJ, 1998, J COMPUT ASSIST TOMO, V22, P324, DOI 10.1097/00004728-199803000-00032; Hong JH, 2009, BRAIN RES BULL, V80, P30, DOI 10.1016/j.brainresbull.2009.05.021; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar D, 2011, ANN I SUPER SANITA, V47, P31, DOI 10.4415/ANN_11_01_08; Li C, 2011, CLIN GENET, V79, P403, DOI 10.1111/j.1399-0004.2010.01609.x; Lim KO, 2006, AM J PSYCHIAT, V163, P2008, DOI 10.1176/appi.ajp.163.11.2008; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Ma Q, 2011, PHARMACOL REV, V63, P437, DOI 10.1124/pr.110.003533; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mathias JL, 2004, APPL NEUROPSYCHOL, V11, P134, DOI 10.1207/s15324826an1103_2; Muller HP, 2009, MAGN RESON IMAGING, V27, P324, DOI 10.1016/j.mri.2008.07.003; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Newcombe VFJ, 2010, J NEUROL NEUROSUR PS, V81, P552, DOI 10.1136/jnnp.2009.196246; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Patel SA, 2007, J MAGN RESON IMAGING, V26, P552, DOI 10.1002/jmri.21076; Peru A, 2003, NEUROPSYCHOLOGIA, V41, P634, DOI 10.1016/S0028-3932(02)00203-8; Plas J, 1999, REV NEUROL, V155, P569; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Sato Y, 2010, CURR PHARM DESIGN, V16, P2232, DOI 10.2174/138161210791792886; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2007, NAT PROTOC, V2, P499, DOI 10.1038/nprot.2007.45; Viviani R, 2007, HUM BRAIN MAPP, V28, P1075, DOI 10.1002/hbm.20332; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058	44	39	39	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2013	8	3							e59382	10.1371/journal.pone.0059382			14	Multidisciplinary Sciences	Science & Technology - Other Topics	123VE	WOS:000317418500037	23555665	DOAJ Gold, Green Published			2021-06-18	
J	Almonte, AG; Qadri, LH; Sultan, FA; Watson, JA; Mount, DJ; Rumbaugh, G; Sweatt, JD				Almonte, Antoine G.; Qadri, Laura H.; Sultan, Faraz A.; Watson, Jennifer A.; Mount, Daniel J.; Rumbaugh, Gavin; Sweatt, J. David			Protease-activated receptor-1 modulates hippocampal memory formation and synaptic plasticity	JOURNAL OF NEUROCHEMISTRY			English	Article						astrocyte; hippocampus; learning; long-term potentiation (LTP); memory; protease-activated receptor-1 (PAR1)	LONG-TERM POTENTIATION; TISSUE-PLASMINOGEN ACTIVATOR; THROMBIN RECEPTOR; PATTERNED STIMULATION; POSSIBLE INVOLVEMENT; ASTROCYTE CALCIUM; NEURONAL DAMAGE; MESSENGER-RNA; MICE LACKING; MAP KINASE	Protease-activated receptor-1 (PAR1) is an unusual G-protein coupled receptor (GPCR) that is activated through proteolytic cleavage by extracellular serine proteases. Although previous work has shown that inhibiting PAR1 activation is neuroprotective in models of ischemia, traumatic injury, and neurotoxicity, surprisingly little is known about PAR1's contribution to normal brain function. Here, we used PAR1-/- mice to investigate the contribution of PAR1 function to memory formation and synaptic function. We demonstrate that PAR1-/- mice have deficits in hippocampus-dependent memory. We also show that while PAR1-/- mice have normal baseline synaptic transmission at Schaffer collateral-CA1 synapses, they exhibit severe deficits in N-methyl-d-aspartate receptor (NMDAR)-dependent long-term potentiation (LTP). Mounting evidence indicates that activation of PAR1 leads to potentiation of NMDAR-mediated responses in CA1 pyramidal cells. Taken together, this evidence and our data suggest an important role for PAR1 function in NMDAR-dependent processes subserving memory formation and synaptic plasticity.	[Almonte, Antoine G.; Qadri, Laura H.; Sultan, Faraz A.; Watson, Jennifer A.; Mount, Daniel J.; Sweatt, J. David] Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL 35294 USA; [Almonte, Antoine G.; Qadri, Laura H.; Sultan, Faraz A.; Watson, Jennifer A.; Mount, Daniel J.; Sweatt, J. David] Univ Alabama Birmingham, Evelyn F McKnight Brain Inst, Birmingham, AL 35294 USA; [Rumbaugh, Gavin] Scripps Res Inst, Dept Neurosci, Jupiter, FL USA	Sweatt, JD (corresponding author), Univ Alabama Birmingham, Dept Neurobiol, 1825 Univ Blvd,Shelby 1010, Birmingham, AL 35294 USA.	dsweatt@nrc.uab.edu		Almonte, Antoine/0000-0002-8778-2724; Sweatt, J. David/0000-0003-3567-485X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [MH57014, AG031722, NS057098]; Evelyn F. McKnight Brain Research Foundation; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH096847, R01MH057014, R01MH091122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS064079, P30NS057098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG031722] Funding Source: NIH RePORTER	We thank Brandon Walters, Lynn Dobrunz (University of Alabama at Birmingham), Cendra Agulhon (University of North Carolina at Chapel Hill), and Stephen Traynelis (Emory University) for helpful discussions. We also thank Christopher Rex (University of California, Irvine) for help with theta-burst response analysis. We thank Kelsey Patterson and Dawn Eason (University of Alabama at Birmingham) for excellent technical assistance. This work was supported by NIH grants MH57014, AG031722, NS057098, and funds from the Evelyn F. McKnight Brain Research Foundation. The authors declare no conflicts of interest.	Agulhon C, 2008, NEURON, V59, P932, DOI 10.1016/j.neuron.2008.09.004; Agulhon C, 2010, SCIENCE, V327, P1250, DOI 10.1126/science.1184821; Almonte AG, 2007, NEUROBIOL LEARN MEM, V88, P295, DOI 10.1016/j.nlm.2007.04.004; Almonte AG, 2011, BRAIN RES, V1407, P107, DOI 10.1016/j.brainres.2011.06.042; ARAI A, 1994, HIPPOCAMPUS, V4, P1, DOI 10.1002/hipo.450040103; ARAI A, 1992, BRAIN RES, V598, P173, DOI 10.1016/0006-8993(92)90181-8; Arai AC, 2004, NEUROSCIENCE, V123, P1011, DOI 10.1016/j.neuroscience.2003.10.033; Bahr BA, 1997, J NEUROSCI, V17, P1320; Baranes D, 1998, NEURON, V21, P813, DOI 10.1016/S0896-6273(00)80597-8; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bourgognon J. M., 2008, 2008 NEUR M PLANN; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Day JJ, 2010, NAT NEUROSCI, V13, P1319, DOI 10.1038/nn.2666; DIAMOND DM, 1988, J NEUROSCI, V8, P4079; Dobrunz LE, 1997, NEURON, V18, P995, DOI 10.1016/S0896-6273(00)80338-4; Erreger K, 2005, J PHYSIOL-LONDON, V569, P381, DOI 10.1113/jphysiol.2005.095497; Erreger K., 2007, J PHYSL, V586, P763; Fellin T, 2009, J NEUROCHEM, V108, P533, DOI 10.1111/j.1471-4159.2008.05830.x; Fiacco TA, 2009, ANNU REV PHARMACOL, V49, P151, DOI 10.1146/annurev.pharmtox.011008.145602; Gingrich MB, 2000, J NEUROSCI, V20, P4582, DOI 10.1523/JNEUROSCI.20-12-04582.2000; Gomez-Gonzalo M, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000352; Grosshans DR, 2002, NAT NEUROSCI, V5, P27, DOI 10.1038/nn779; Guo H, 2004, NEURON, V41, P563, DOI 10.1016/S0896-6273(04)00019-4; Hamill CE, 2007, MOL PHARMACOL, V72, P653, DOI 10.1124/mol.107.038158; Hamill Cecily E, 2005, Clin Neurosurg, V52, P29; Hamill CE, 2009, EXP NEUROL, V217, P136, DOI 10.1016/j.expneurol.2009.01.023; Hamilton NB, 2010, NAT REV NEUROSCI, V11, P227, DOI 10.1038/nrn2803; Han KS, 2011, MOL BRAIN, V4, DOI 10.1186/1756-6606-4-32; Hashimotodani Y, 2011, J NEUROSCI, V31, P3104, DOI 10.1523/JNEUROSCI.6000-10.2011; Haydon PG, 2006, PHYSIOL REV, V86, P1009, DOI 10.1152/physrev.00049.2005; Henneberger C, 2010, NATURE, V463, P232, DOI 10.1038/nature08673; Hermann GE, 2009, J NEUROSCI, V29, P9292, DOI 10.1523/JNEUROSCI.6063-08.2009; Huang YY, 1996, P NATL ACAD SCI USA, V93, P8699, DOI 10.1073/pnas.93.16.8699; Ito M, 2007, J NEUROCHEM, V101, P1392, DOI 10.1111/j.1471-4159.2006.04423.x; Junge CE, 2004, EXP NEUROL, V188, P94, DOI 10.1016/j.expneurol.2004.02.018; Junge CE, 2003, P NATL ACAD SCI USA, V100, P13019, DOI 10.1073/pnas.2235594100; Kramar EA, 2004, J NEUROSCI, V24, P5151, DOI 10.1523/JNEUROSCI.0800-04.2004; Kreda SM, 2008, BRIT J PHARMACOL, V153, P1528, DOI 10.1038/sj.bjp.0707692; Kuliopulos A, 1999, BIOCHEMISTRY-US, V38, P4572, DOI 10.1021/bi9824792; LARSON J, 1986, SCIENCE, V232, P985, DOI 10.1126/science.3704635; LARSON J, 1988, BRAIN RES, V441, P111, DOI 10.1016/0006-8993(88)91388-1; LARSON J, 1986, BRAIN RES, V368, P347, DOI 10.1016/0006-8993(86)90579-2; Lau CG, 2007, NAT REV NEUROSCI, V8, P413, DOI 10.1038/nrn2153; Lee CJ, 2007, J PHYSIOL-LONDON, V581, P1057, DOI 10.1113/jphysiol.2007.130377; Lee S, 2010, SCIENCE, V330, P790, DOI 10.1126/science.1184334; Lohman RJ, 2008, NEUROBIOL DIS, V30, P84, DOI 10.1016/j.nbd.2007.12.010; Lohman RJ, 2009, NEUROBIOL LEARN MEM, V92, P301, DOI 10.1016/j.nlm.2009.03.010; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Maggio N, 2008, J NEUROSCI, V28, P732, DOI 10.1523/JNEUROSCI.3665-07.2008; Mannaioni G, 2008, J BIOL CHEM, V283, P20600, DOI 10.1074/jbc.M803015200; Miller CA, 2007, NEURON, V53, P857, DOI 10.1016/j.neuron.2007.02.022; Mizutani A, 1996, BRAIN RES, V739, P276, DOI 10.1016/S0006-8993(96)00834-7; MULLER D, 1988, P NATL ACAD SCI USA, V85, P9346, DOI 10.1073/pnas.85.23.9346; Nagai T, 2006, J NEUROSCI, V26, P12374, DOI 10.1523/JNEUROSCI.3139-06.2006; Niclou SP, 1998, EUR J NEUROSCI, V10, P1590, DOI 10.1046/j.1460-9568.1998.00183.x; Nicole O, 2005, J NEUROSCI, V25, P4319, DOI 10.1523/JNEUROSCI.5200-04.2005; Nicoll RA, 1999, ANN NY ACAD SCI, V868, P515, DOI 10.1111/j.1749-6632.1999.tb11320.x; Niego B, 2011, BRAIN RES, V1381, P38, DOI 10.1016/j.brainres.2011.01.016; Noorbakhsh F, 2003, NAT REV NEUROSCI, V4, P981, DOI 10.1038/nrn1255; O'Brien PJ, 2001, ONCOGENE, V20, P1570, DOI 10.1038/sj.onc.1204194; Olson EE, 2004, J CEREBR BLOOD F MET, V24, P964, DOI 10.1097/01.WCB.0000128266.87474.BF; Pang PT, 2004, SCIENCE, V306, P487, DOI 10.1126/science.1100135; Park H, 2009, J NEUROSCI, V29, P13063, DOI 10.1523/JNEUROSCI.3193-09.2009; Pawlak R, 2005, P NATL ACAD SCI USA, V102, P18201, DOI 10.1073/pnas.0509232102; Pawlak R, 2002, NEUROSCIENCE, V113, P995, DOI 10.1016/S0306-4522(02)00166-5; Peng Y, 2010, HIPPOCAMPUS, V20, P646, DOI 10.1002/hipo.20654; Perez-Otano I, 2005, TRENDS NEUROSCI, V28, P229, DOI 10.1016/j.tins.2005.03.004; Ramachandran R, 2008, BRIT J PHARMACOL, V153, pS263, DOI 10.1038/sj.bjp.0707507; Selcher JC, 2003, LEARN MEMORY, V10, P26, DOI 10.1101/lm.51103; Shavit E, 2011, J NEUROCHEM, V119, P460, DOI 10.1111/j.1471-4159.2011.07436.x; Shigetomi E, 2008, J NEUROSCI, V28, P6659, DOI 10.1523/JNEUROSCI.1717-08.2008; Striggow F, 2001, EUR J NEUROSCI, V14, P595, DOI 10.1046/j.0953-816x.2001.01676.x; Sweatt JD, 2004, CURR OPIN NEUROBIOL, V14, P311, DOI 10.1016/j.conb.2004.04.001; Sweatt JD, 2010, MECHANISMS OF MEMORY, 2ND EDITION, P1, DOI 10.1016/B978-0-12-374951-2.00001-9; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Tongiorgi E, 2003, NEUROSCIENCE, V119, P1013, DOI 10.1016/S0306-4522(03)00196-9; Traynelis SF, 2010, PHARMACOL REV, V62, P405, DOI 10.1124/pr.109.002451; Walker DL, 2002, PHARMACOL BIOCHEM BE, V71, P379, DOI 10.1016/S0091-3057(01)00698-0; Watt AJ, 2004, NAT NEUROSCI, V7, P518, DOI 10.1038/nn1220; WEINSTEIN JR, 1995, J NEUROSCI, V15, P2906; Wenker I, 2010, J NEUROPHYSIOL, V104, P1216, DOI 10.1152/jn.00429.2010; Whitlock JR, 2006, SCIENCE, V313, P1093, DOI 10.1126/science.1128134; Zhao J, 2008, J NEUROSCI, V28, P3060, DOI 10.1523/JNEUROSCI.5450-07.2008; Zucker RS, 2002, ANNU REV PHYSIOL, V64, P355, DOI 10.1146/annurev.physiol.64.092501.114547	85	39	39	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JAN	2013	124	1					109	122		10.1111/jnc.12075			14	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	051NB	WOS:000312132900012	23113835	Green Accepted, Bronze			2021-06-18	
B	Coronado, VG; McGuire, LC; Faul, M; Sugerman, DE; Pearson, WS		Zasler, ND; Katz, DI; Zafonte, RD		Coronado, Victor G.; McGuire, Lisa C.; Faul, Mark; Sugerman, David E.; Pearson, William S.			Traumatic Brain Injury Epidemiology and Public Health Issues	BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION			English	Article; Book Chapter							SPORT-RELATED CONCUSSION; LONG-TERM DISABILITY; GLASGOW COMA SCALE; UNITED-STATES; HIGH-SCHOOL; RISK-FACTORS; HEAD-INJURY; FOLLOW-UP; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION		[Coronado, Victor G.; McGuire, Lisa C.] Ctr Dis Control & Prevent, Div Injury Response, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA; [Faul, Mark] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA; [Sugerman, David E.] Ctr Dis Control & Prevent, Div Injury Response, LCDR US Publ Hlth Serv, Atlanta, GA USA; [Pearson, William S.] Ctr Dis Control & Prevent, Div Injury Response, Atlanta, GA USA	Coronado, VG (corresponding author), Ctr Dis Control & Prevent, Div Injury Response, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.						Abellera J, 2005, STATES ARE COLLECTIN; Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Ahmed N, 2000, PUBLIC HEALTH, V114, P416, DOI 10.1038/sj.ph.1900646; Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Armed Forces Health Surveillance Center (AFHSC), 2011, MSMR, V18, P2; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Association for the Advancement of Automotive Medicine, ABBR INJ SCAL WHAT I; Baker SP, 1982, INJURY FACT BOOK; BASTOS PG, 1993, CRIT CARE MED, V21, P1459, DOI 10.1097/00003246-199310000-00012; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Berry C, 2010, AM SURGEON, V76, P1067; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Bowman SM, 2007, MED CARE, V45, P686, DOI 10.1097/MLR.0b013e31803dcdf3; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; Center for Disease Control and Prevention, 2010, MMWR-MORBID MORTAL W, V59, P303; Centers for Disease Control and Prevention, 1999, TRAUM BRAIN INJ US R; Centers for Disease Control and Prevention, 2009, NAT CTR HLTH STAT MU; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Cifu DX, REPETITIVE HEAD INJU; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Coronado VG, 2009, NEUROTRAUMA CRITICAL, P3; Coronado VG, 2011, 3 INT C TRAUM BRAIN; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Crossman J, 1998, INJURY, V29, P435, DOI 10.1016/S0020-1383(98)00079-5; Cubbin C, 2000, J EPIDEMIOL COMMUN H, V54, P517, DOI 10.1136/jech.54.7.517; Cumming RG, 1998, DRUG AGING, V12, P43, DOI 10.2165/00002512-199812010-00005; Daneshvar DH, 2011, CLIN SPORT MED, V30, P145, DOI 10.1016/j.csm.2010.09.006; Defense and Veterans Brain Injury Center, DOD WORLDW NUMB TRAU; Department of Veterans Affairs/Department of Defense Management of Concussion/mTBI Working Group, 2009, VA DOD CLIN PRACT GU, P17; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HADDON W, 1972, J TRAUM, V12, P193, DOI 10.1097/00005373-197203000-00002; HADDON W, 1980, PUBLIC HEALTH REP, V95, P411; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Heffernan DS, 2011, J TRAUMA, V70, P527, DOI 10.1097/TA.0b013e31820d0ed7; Himanen L, 2011, BRAIN INJURY, V25, P443, DOI 10.3109/02699052.2011.556580; Johnson R, 2009, STATE INJURY INDICAT; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Liu BC, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004333.pub3; Losiniecki A, 2010, CURR TREAT OPTION NE, V12, P142, DOI 10.1007/s11940-010-0063-z; Macdonald S, 2005, ADDICT BEHAV, V30, P103, DOI 10.1016/j.addbeh.2004.04.016; Macpherson A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005401.pub3; MacReady N, 2004, CLIN PSYCHIAT NEWS, V32, P55; Maier RV, 2005, J TRAUMA, V59, pS1, DOI 10.1097/01.ta.0000174904.24315.e5; Marr A, 2001, ANN DATA SUBMISSION; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Miele VJ, 2009, NEUROTRAUMA CRITICAL; MULLIE A, 1988, LANCET, V1, P137; Murray CJL., 1996, GLOBAL HLTH STAT COM; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; National Council of Youth Sports, 2008, REP TRENDS PART ORG; National Federation of State High School Athletic Associations, 2009 2010 HIGH SCH A; Navarro RR, 2011, CURR SPORT MED REP, V10, P27, DOI 10.1249/JSR.0b013e318205e072; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Orman JA, 2011, TXB TRAUMATIC BRAIN, V2nd, P3; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pickelsimer EE, 2006, J HEAD TRAUMA REHAB, V21, P491, DOI 10.1097/00001199-200611000-00004; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Reid SR, 2001, ARCH PEDIAT ADOL MED, V155, P784, DOI 10.1001/archpedi.155.7.784; Rodriguez SR, 2006, PUBLIC HEALTH REP, V121, P282, DOI 10.1177/003335490612100310; Runyan CW, 2003, EPIDEMIOL REV, V25, P60, DOI 10.1093/epirev/mxg005; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; Schootman M, 2000, BRAIN INJURY, V14, P373; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SEGATORE M, 1992, HEART LUNG, V21, P548; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Sendroy-Terrill M, 2010, ARCH PHYS MED REHAB, V91, P489, DOI 10.1016/j.apmr.2009.11.011; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Shandro JR, 2009, J TRAUMA, V66, P1584, DOI 10.1097/TA.0b013e318182af96; Shi JX, 2009, BRAIN INJURY, V23, P602, DOI 10.1080/02699050903014907; Shigaki CL, 2009, DISABIL REHABIL, V31, P484, DOI 10.1080/09638280802240449; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; Sosin DM, 1996, BRAIN INJURY, V10, P47; Steel J, 2010, J TRAUMA, V69, P523, DOI 10.1097/TA.0b013e3181e90c24; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; [The Congress of the United States Congressional Budget Office], 2012, CBO STUD VET HLTH AD; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Thurman DJ, 2007, BRAIN INJURY MED PRI, P45; Thurman DJ., 1995, GUIDELINES SURVEILLA; United Nations. Security Council, 2010, S2010579 UN SEC COUN; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Wagner AK, 2000, J TRAUMA, V49, P404, DOI 10.1097/00005373-200009000-00004; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Williams TM, 2008, J TRAUMA, V65, P772, DOI 10.1097/TA.0b013e3181877ff7; Wong DK, 2008, J TRAUMA, V65, P1303, DOI 10.1097/TA.0b013e318185e234; Xydakis MS, 2005, OTOLARYNG HEAD NECK, V133, P497, DOI 10.1016/j.otohns.2005.07.003; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	117	39	39	0	6	DEMOS MEDICAL PUBLICATIONS	NEW YORK	11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA			978-1-936287-27-7				2013							84	100					17	Clinical Neurology	Neurosciences & Neurology	BDJ25	WOS:000313536100008					2021-06-18	
J	Gurley, JM; Hujsak, BD; Kelly, JL				Gurley, James M.; Hujsak, Bryan D.; Kelly, Jennifer L.			Vestibular rehabilitation following mild traumatic brain injury	NEUROREHABILITATION			English	Article						Vestibular rehabilitation; traumatic brain injury; concussion	PAROXYSMAL POSITIONAL VERTIGO; STABILITY FOLLOWING CONCUSSION; DIZZINESS HANDICAP INVENTORY; PREDICT PROTRACTED RECOVERY; SPORTS-RELATED CONCUSSION; HEART-RATE-VARIABILITY; VESTIBULOOCULAR REFLEX; POSTURAL-CONTROL; SMOOTH-PURSUIT; FOOTBALL PLAYERS	INTRODUCTION: Vertigo, dizziness, and imbalance are a symptom complex that is commonly found following concussion. Early metabolic changes following concussion may lead to worsening of the injury and symptoms in individuals not properly managed from the outset. When symptoms do not recover spontaneously, skilled vestibular rehabilitation can be an effective modality in an attempt to normalize the individual's vestibular responses. PURPOSE: The purpose of this review is to appraise the current and accepted methods available to the skilled clinician in quantifying and treating vestibular dysfunction following concussion. Incidence and prognostic indicators will be reviewed along with common barriers to recovery. SUMMARY: Vestibular Rehabilitation following concussion utilizes similar tools and techniques employed when treating those solely with peripheral pathology. The clinician must not only have a solid understanding of when and why certain exercises are required, but also be willing to accept that less exercise may be indicated in this population. As injury to the system following mild traumatic brain injury can include both peripheral and central structures, the duration of therapy and the time to recovery may be prolonged. Co-morbidities including cognitive and behavioral issues, visual-perceptual dysfunction, metabolic dysfunction, and autonomic dysfunction may hamper the effectiveness of the traditional Vestibular Rehabilitation approach. As successful treatment does not occur in a vacuum, working closely with other disciplines well versed in treating these co-morbid issues will help the individual to obtain optimal recovery. CONCLUSION: Vestibular Rehabilitation is an effective modality for managing dizziness, vertigo, and imbalance following concussion. Careful consideration of the acuity of the injury, along with effective management of co-morbid conditions will optimize the result.	[Gurley, James M.] Mercy Coll, Phys Therapy Program, Dobbs Ferry, NY 10522 USA; [Gurley, James M.] James J Peters VAMC, Dept Otololaryngol, Bronx, NY USA; [Hujsak, Bryan D.; Kelly, Jennifer L.] New York Eye & Ear Infirm, Vestibular Rehabil Dept, New York, NY USA	Gurley, JM (corresponding author), Mercy Coll, Phys Therapy Program, 555 Broadway, Dobbs Ferry, NY 10522 USA.	jgurley@mercy.edu					Ahn S. K., 2010, TRAUMA, V20, P1; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Blatt PJ, 2000, AM J OTOL, V21, P356, DOI 10.1016/S0196-0709(00)80045-9; Brandt T, 1996, Audiol Neurootol, V1, P187; Celebisoy N, 2009, GAIT POSTURE, V29, P520, DOI 10.1016/j.gaitpost.2008.12.002; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Chang WC, 2006, OTOLARYNG HEAD NECK, V135, P534, DOI 10.1016/j.otohns.2005.10.001; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; COHEN H, 1993, PHYS THER, V73, P346, DOI 10.1093/ptj/73.6.346; DAVIES RA, 1995, J NEUROL, V242, P222, DOI 10.1007/BF00919595; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Di Girolamo S, 1998, ACTA OTO-LARYNGOL, V118, P289; Donaldson CJ, 2010, OTOLARYNG HEAD NECK, V143, P820, DOI 10.1016/j.otohns.2010.09.024; Fausti S. A., 2006, JRRD, V46, P797; Furman JM, 2000, PHYS THER, V80, P179, DOI 10.1093/ptj/80.2.179; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2011, SPORTS HEALTH, V3, P46, DOI 10.1177/1941738110391732; Gottshall K, 2011, NEUROREHABILITATION, V29, P167, DOI 10.3233/NRE-2011-0691; Gottshall KR, 2010, J NEUROL PHYS THER, V34, P94, DOI 10.1097/NPT.0b013e3181dead12; Gottshall Kim R, 2005, Int Tinnitus J, V11, P81; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Herdman S. J., 2007, VESTIBULAR REHABILIT, P314; Hillier S. L., 2007, COCHRANE DB SYST REV; Hillier SL, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005397.pub3; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; KEMP PM, 1995, J NEUROL NEUROSUR PS, V59, P368, DOI 10.1136/jnnp.59.4.368; Lajoie Y, 2002, ARCH GERONTOL GERIAT, V35, P215, DOI 10.1016/S0167-4943(02)00027-4; Larsen AI, 2004, EUR J CARDIOV PREV R, V11, P162, DOI 10.1097/01.hjr.0000124214.21584.bb; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; LISBERGER SG, 1984, J NEUROPHYSIOL, V52, P1140; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Mahboobin A, 2005, EXP BRAIN RES, V167, P260, DOI 10.1007/s00221-005-0053-7; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; MILES FA, 1981, ANNU REV NEUROSCI, V4, P273, DOI 10.1146/annurev.ne.04.030181.001421; NORRE M E, 1987, Acta Oto-Rhino-Laryngologica Belgica, V41, P436; PAIGE GD, 1994, EXP BRAIN RES, V98, P355; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2008, MED ENG PHYS, V30, P959, DOI 10.1016/j.medengphy.2007.12.006; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Pavlou M, 2010, J NEUROL PHYS THER, V34, P105, DOI 10.1097/NPT.0b013e3181dde6bf; Peterson MD, 2010, J HEAD TRAUMA REHAB, V25, P193, DOI 10.1097/HTR.0b013e3181dc82fa; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; POWELL LE, 1995, J GERONTOL A-BIOL, V50, pM28, DOI 10.1093/gerona/50A.1.M28; Rambold H, 2002, J NEUROPHYSIOL, V87, P912, DOI 10.1152/jn.00768.2000; Reddy CC, 2009, CURR SPORT MED REP, V8, P10, DOI 10.1249/JSR.0b013e31819539ca; REVEL M, 1991, ARCH PHYS MED REHAB, V72, P288; REVEL M, 1994, ARCH PHYS MED REHAB, V75, P895, DOI 10.1016/0003-9993(94)90115-5; Roy JE, 2001, J NEUROSCI, V21, P2131, DOI 10.1523/JNEUROSCI.21-06-02131.2001; Scherer MR, 2011, EXP BRAIN RES, V208, P399, DOI 10.1007/s00221-010-2490-1; Schubert MC, 2004, PHYS THER, V84, P373, DOI 10.1093/ptj/84.4.373; Schubert MC, 2008, EXP BRAIN RES, V191, P435, DOI 10.1007/s00221-008-1537-z; SHEPARD NT, 1995, OTOLARYNG HEAD NECK, V112, P173, DOI 10.1016/S0194-5998(95)70317-9; Shepard NT, 1996, PRACTICAL MANAGEMENT; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85; Suchoff I B, 1999, J Am Optom Assoc, V70, P301; Swait G, 2007, SPINE, V32, pE692, DOI 10.1097/BRS.0b013e31815a5a1b; Tjell C, 1998, AM J OTOL, V19, P76; Treleaven J, 2008, MANUAL THER, V13, P2, DOI 10.1016/j.math.2007.06.003; van de Calseyde P, 1976, Acta Otorhinolaryngol Belg, V30, P569; Viirre E, 2002, LARYNGOSCOPE, V112, P500, DOI 10.1097/00005537-200203000-00017; Whitney SL, 1999, J VESTIBUL RES-EQUIL, V9, P253; Whitney SL, 2011, NEUROREHABILITATION, V29, P157, DOI 10.3233/NRE-2011-0690; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Wrisley DM, 2000, J ORTHOP SPORT PHYS, V30, P755, DOI 10.2519/jospt.2000.30.12.755; Yang CC, 2009, BRAIN INJURY, V23, P299, DOI 10.1080/02699050902788543; YARDLEY L, 1992, J PSYCHOSOM RES, V36, P731, DOI 10.1016/0022-3999(92)90131-K	79	39	39	0	43	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2013	32	3					519	528		10.3233/NRE-130874			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	135DM	WOS:000318266200010	23648606				2021-06-18	
J	Linden, MA; Braiden, HJ; Miller, S				Linden, Mark A.; Braiden, Hannah-Jane; Miller, Sarah			Educational professionals' understanding of childhood traumatic brain injury	BRAIN INJURY			English	Article						Education; traumatic brain injury; children; misconceptions	COMMON MISCONCEPTIONS; CAUSAL ATTRIBUTIONS; FOLLOW-UP; CHILDREN; ATTITUDES; SURVIVORS; TERM; PREVALENCE; PREDICTORS; BEHAVIOR	Primary objectives: To determine the understanding of educational professionals around the topic of childhood brain injury and explore the factor structure of the Common Misconceptions about Traumatic Brain Injury Questionnaire (CM-TBI). Research design: Cross-sectional postal survey. Methods and procedures: The CM-TBI was posted to all educational establishments in one region of the UK. One representative from each school was asked to complete and return the questionnaire (n = 388). Main outcomes and results: Differences were demonstrated between those participants who knew someone with a brain injury and those who did not, with a similar pattern being shown for those educators who had taught a child with brain injury. Participants who had taught a child with brain injury demonstrated greater knowledge in areas such as seatbelts/prevention, brain damage, brain injury sequelae, amnesia, recovery and rehabilitation. Principal components analysis suggested the existence of four factors and the discarding of half the original items of the questionnaire. Conclusions: In the first European study to explore this issue, it is highlighted that teachers are ill-prepared to cope with children who have sustained a brain injury. Given the importance of a supportive school environment in return to life following hospitalization, the lack of understanding demonstrated by teachers in this research may significantly impact on a successful return to school.	[Linden, Mark A.] Queens Univ Belfast, Sch Nursing & Midwifery, Belfast BT9 7BL, Antrim, North Ireland; [Braiden, Hannah-Jane] Western Educ & Lib Board, Omagh, North Ireland; [Miller, Sarah] Queens Univ Belfast, Sch Educ, Belfast BT9 7BL, Antrim, North Ireland	Linden, MA (corresponding author), Queens Univ Belfast, Sch Nursing & Midwifery, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	m.linden@qub.ac.uk	Linden, Mark/L-7754-2019	Linden, Mark/0000-0002-3832-4102	Southern Health and Social Care trust	This research was supported by a grant from the Southern Health and Social Care trust. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.	Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Bjorkman T, 2008, SCAND J CARING SCI, V22, P170, DOI 10.1111/j.1471-6712.2007.00509.x; Catroppa C, 2009, NEUROPSYCHOL REHABIL, V19, P716, DOI 10.1080/09602010902732868; Costello A., 2005, PRACT ASSESS RES EVA, V10, DOI 10.7275/jyj1-4868.; Crothers IR, 2007, BRAIN INJURY, V21, P47, DOI 10.1080/02699050601149054; Deidrick KKM, 2005, PREV SCH FAIL, V49, P23, DOI 10.3200/PSFL.49.4.23-33; Department of Education Northern Ireland, 2011, COD PRACT ID ASS SPE; Ernst WJ, 2009, J HEAD TRAUMA REHAB, V24, P213, DOI 10.1097/HTR.0b013e3181a7ecd8; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Farmer JE, 1997, REHABIL PSYCHOL, V42, P273; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; Guilmette TJ, 2004, ARCH CLIN NEUROPSYCH, V19, P183, DOI 10.1016/S0887-6177(03)00025-8; Hawley CA, 2004, ARCH DIS CHILD, V89, P136, DOI 10.1136/adc.2002.025577; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; Hawley CA, 2002, BRAIN INJURY, V16, P969, DOI 10.1080/02699050210147239; Hooper SR, 2004, NEUROREHABILITATION, V19, P175; Hux K, 2006, BRAIN INJURY, V20, P547, DOI 10.1080/02699050600676784; Lehr E., 1990, REHABILITATION I CHI; Linden MA, 2006, ARCH CLIN NEUROPSYCH, V21, P763, DOI 10.1016/j.acn.2006.08.010; Linden MA, 2010, BRAIN INJURY, V24, P642, DOI 10.3109/02699051003601689; Linden M, 2012, J ADV NURS, V68, P1359, DOI 10.1111/j.1365-2648.2011.05848.x; Linden MA, 2012, NURS RES, V61, P58, DOI 10.1097/NNR.0b013e31823ca253; Linden MA, 2011, INT J NURS STUD, V48, P62, DOI 10.1016/j.ijnurstu.2010.05.011; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; McClure J, 2011, REHABIL PSYCHOL, V56, P85, DOI 10.1037/a0023354; Middleton JA, 2001, J CHILD PSYCHOL PSYC, V42, P165, DOI 10.1017/S0021963001006667; Pappadis MR, 2011, J HEAD TRAUMA REHAB, V26, P301, DOI 10.1097/HTR.0b013e3181e7832b; Parker JG, 1993, ADV PERSONAL RELATIO, V4, P195; Parkin AE., 1996, AUSTR OCCUPATIONAL T, V43, P133; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; Redpath SJ, 2010, BRAIN INJURY, V24, P802, DOI 10.3109/02699051003709623; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Sevigny R, 1999, INT J SOC PSYCHIATR, V45, P41, DOI 10.1177/002076409904500106; Springer JA, 1997, J HEAD TRAUMA REHAB, V12, P41, DOI 10.1097/00001199-199706000-00005; Stranmillis University College, 2012, PROSP ENTR 2012; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; Taylor HG, 2003, REHABIL PSYCHOL, V48, P227, DOI 10.1037/0090-5550.48.4.227; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; WILLER B, 1993, ARCH CLIN NEUROPSYCH, V8, P461, DOI 10.1016/0887-6177(93)90009-P; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; Ylvisaker M, 1998, TRAUMATIC BRAIN INJU, P369	42	39	39	0	16	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2013	27	1					92	102		10.3109/02699052.2012.722262			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	059IY	WOS:000312699300010	23252440	Green Published			2021-06-18	
J	Luoto, TM; Tenovuo, O; Kataja, A; Brander, A; Ohman, J; Iverson, GL				Luoto, Teemu M.; Tenovuo, Olli; Kataja, Anneli; Brander, Antti; Ohman, Juha; Iverson, Grant L.			Who Gets Recruited in Mild Traumatic Brain Injury Research?	JOURNAL OF NEUROTRAUMA			English	Article						head trauma; selection bias; traumatic brain injury	COLLABORATING-CENTER; TASK-FORCE; CLINICAL-TRIALS; BIAS; RECOMMENDATIONS; SYMPTOMS; MODERATE; IMPACT	Selection bias, common in traumatic brain injury research, limits the clinical usefulness and generalizability of study findings. The purpose of this study was to examine the effect of different inclusion and exclusion criteria on patient enrollment, and the implications for generalizability, in a mild traumatic brain injury (MTBI) study. The study was conducted at the emergency department (ED) of Tampere University Hospital. Our aim was to study outcome from MTBI in patients who do not have pre-existing conditions or other confounding factors. For this, all consecutive patients with acute head trauma (n = 1344) were screened. The study design included three inclusion criteria and nine exclusion criteria. The World Health Organization Collaborating Center for Neurotrauma Task Force criteria for MTBI were used. Of all patients screened, 934 (69.5%) fulfilled the MTBI criteria. For those fulfilling the MTBI criteria, various inclusion and exclusion criteria were applied in order to yield those eligible for the outcome study. Applying these criteria excluded 95.1% of MTBI patients, leaving only 46 patients in the final sample. The final sample and the excluded patients with MTBI significantly differed in age, mechanism of injury, and injury severity characteristics. Many studies recruit fundamentally biased samples that are not generalizable to the population of persons who sustain an MTBI. Studying carefully selected samples is often necessary to address specific research questions, but such studies have serious limitations in terms of translating research findings into clinical practice.	[Luoto, Teemu M.; Ohman, Juha] Tampere Univ Hosp, Dept Neurosci & Rehabil, FI-33521 Tampere, Finland; [Tenovuo, Olli] Univ Turku, Dept Neurol, FIN-20520 Turku, Finland; [Tenovuo, Olli] Turku Univ, Cent Hosp, Turku, Finland; [Kataja, Anneli; Brander, Antti] Tampere Univ Hosp, Dept Radiol, Med Imaging Ctr, FI-33521 Tampere, Finland; [Iverson, Grant L.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada	Luoto, TM (corresponding author), Tampere Univ Hosp, Dept Neurosci & Rehabil, POB 2000, FI-33521 Tampere, Finland.	teemu.luoto@pshp.fi	Luoto, Teemu/W-6468-2018	Luoto, Teemu/0000-0002-7329-3284; Iverson, Grant/0000-0001-7348-9570; Ohman, Juha/0000-0002-6592-1367			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Cancelliere C, 2012, SYST REV-LONDON, V1, DOI 10.1186/2046-4053-1-17; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Eldridge S, 2009, BMJ-BRIT MED J, V339, pb4006; Gluud LL, 2006, AM J EPIDEMIOL, V163, P493, DOI 10.1093/aje/kwj069; Gould KR, 2011, J HEAD TRAUMA REHAB, V26, P79, DOI 10.1097/HTR.0b013e3182036799; Hernan MA, 2004, EPIDEMIOLOGY, V15, P615, DOI 10.1097/01.ede.0000135174.63482.43; HOLDEN G, 1993, SOC WORK HEALTH CARE, V19, P1, DOI 10.1300/J010v19n02_01; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Poyry T, 2012, J HEAD TRAUMA REHABI; Sarani B, 2009, J TRAUMA, V67, P954, DOI 10.1097/TA.0b013e3181ae6d39; Schonberger M, 2011, J NEUROL NEUROSUR PS, V82, P936, DOI 10.1136/jnnp.2010.210021; Senathi-Raja D, 2010, NEUROPSYCHOLOGY, V24, P336, DOI 10.1037/a0018239; Sica GT, 2006, RADIOLOGY, V238, P780, DOI 10.1148/radiol.2383041109; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; Slieker FJA, 2008, NEUROSURGERY, V62, P1321, DOI 10.1227/01.neu.0000333304.79931.4d	23	39	39	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2013	30	1					11	16		10.1089/neu.2012.2611			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	061GU	WOS:000312837300003	22909262				2021-06-18	
J	Verfaellie, M; Lafleche, G; Spiro, A; Tun, C; Bousquet, K				Verfaellie, Mieke; Lafleche, Ginette; Spiro, Avron, III; Tun, Carlos; Bousquet, Kathryn			Chronic Postconcussion Symptoms and Functional Outcomes in OEF/OIF Veterans with Self-Report of Blast Exposure	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						TBI; Blast-injuries; PTSD; Depression; Postconcussion symptoms; Quality of life	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MILD HEAD-INJURY; NEUROPSYCHOLOGICAL PERFORMANCE; SOCIAL SUPPORT; CONCUSSION; DEPLOYMENT; IRAQ; QUESTIONNAIRE; MISDIAGNOSIS	Postconcussion symptoms (PCS) and functional outcomes were evaluated in 91 OEF/OIF outpatient veterans with reported histories of blast-exposure, with the goal of evaluating (1) the association between these outcomes and a clinical diagnosis of mild traumatic brain injury (mTBI) with or without loss of consciousness (LOC); and (2) the influence of post-traumatic stress disorder (PTSD) and depression on PCS reporting and perceived functional limitations. Individuals who reported mTBI with LOC had greater PCS complaints than individuals who reported mTBI without LOC or individuals without mTBI. However, after adjusting for severity of PTSD and depression symptoms, this group difference disappeared. Functional limitations were particularly prominent in the psychosocial domain. Again, PTSD was significantly associated with functional outcomes, but the mTBI with LOC group had greater psychosocial limitations than the other two groups, even when PTSD and depression symptoms were taken into account. These findings highlight the role of mental health in both outcomes, but additionally point to the impact of mTBI with LOC on long-term psychosocial adjustment. (JINS, 2013, 19, 1-10)	[Verfaellie, Mieke; Lafleche, Ginette; Bousquet, Kathryn] VA Boston Healthcare Syst, Memory Disorders Res Ctr, Boston, MA 02130 USA; [Verfaellie, Mieke; Lafleche, Ginette; Spiro, Avron, III; Bousquet, Kathryn] Boston Univ, Sch Med, Boston, MA 02118 USA; [Spiro, Avron, III] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA 02130 USA; [Spiro, Avron, III] Boston Univ, Sch Publ Hlth, Boston, MA USA; [Tun, Carlos] VA Boston Healthcare Syst, Polytrauma Network Site, Boston, MA 02130 USA; [Tun, Carlos] Harvard Univ, Sch Med, Boston, MA USA	Verfaellie, M (corresponding author), VA Boston Healthcare Syst, Memory Disorders Res Ctr 151A, 150 S Huntington Ave, Boston, MA 02130 USA.	verf@bu.edu		Verfaellie, Mieke/0000-0001-5535-4584; Spiro III, Avron/0000-0003-4080-8621	Clinical Science Research and Development; Rehabilitation Research and Development Services of the Department of Veterans AffairsUS Department of Veterans Affairs	This research was supported by the Clinical Science Research and Development and the Rehabilitation Research and Development Services of the Department of Veterans Affairs. The authors thank Laura Grande, Ph.D. and Susan McGlynn, Ph.D. for facilitating participant recruitment. The authors have no conflict of interest affecting this manuscript.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Bigler E. D., 2012, PTSD MILD TRAUMATIC, P15; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Bryant R.A., 2012, PTSD TRAUMATIC BRAIN, P235; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Caplain S., 2008, J REHABILITATION M S, V22, P528; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Cooper DB, 2011, ARCH CLIN NEUROPSYCH, V26, P718, DOI 10.1093/arclin/acr070; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; First MB., 2002, STRUCTURED CLIN INTE; Friedland JF, 2001, J NERV MENT DIS, V189, P426, DOI 10.1097/00005053-200107000-00003; Hill JJ, 2009, AM J PHYS MED REHAB, V88, P605, DOI 10.1097/PHM.0b013e3181ae0f83; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kehle SM, 2011, J PSYCHIATR RES, V45, P126, DOI 10.1016/j.jpsychires.2010.05.013; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrae M. A., 2008, MILD TRAUMATIC BRAIN; McDowell I., 1996, MEASURING HLTH OUTCO; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Mollica RF, 2002, BRIT J PSYCHIAT, V181, P339, DOI 10.1192/bjp.181.4.339; Nelson NW, 2011, BRAIN INJURY, V25, P511, DOI 10.3109/02699052.2011.558040; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P1390, DOI 10.1176/appi.ajp.161.8.1390; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Sbordone RJ, 2010, PSYCHOL INJ LAW, V3, P63, DOI 10.1007/s12207-010-9066-z; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schnurr PP, 2009, CLIN PSYCHOL REV, V29, P727, DOI 10.1016/j.cpr.2009.08.006; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tombaugh TN, 1996, TEST MEMORY MALINGER; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Verfaellie M, 2012, PTSD MILD TRAUMATIC, P82; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f	60	39	40	0	13	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2013	19	1					1	U32		10.1017/S1355617712000902			21	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	063NB	WOS:000313005400001	23095177				2021-06-18	
J	Watts, LT; Sprague, S; Zheng, W; Garling, RJ; Jimenez, D; Digicaylioglu, M; Lechleiter, J				Watts, Lora Talley; Sprague, Shane; Zheng, Wei; Garling, R. Justin; Jimenez, David; Digicaylioglu, Murat; Lechleiter, James			Purinergic 2Y(1) Receptor Stimulation Decreases Cerebral Edema and Reactive Gliosis in a Traumatic Brain Injury Model	JOURNAL OF NEUROTRAUMA			English	Article						aquaporin 4; edema; mitochondria; purinergic receptor; reactive gliosis; traumatic brain injury	FIBRILLARY ACIDIC PROTEIN; MITOCHONDRIAL DYSFUNCTION; CELLULAR EDEMA; BARRIER PERMEABILITY; ENERGY-METABOLISM; WATER CHANNELS; GLIAL-CELLS; AQUAPORIN-4; ASTROCYTES; DIFFUSION	Traumatic brain injury (TBI) is the leading cause of death and disability in children and young adults. Neuroprotective agents that may promote repair or counteract damage after injury do not currently exist. We recently reported that stimulation of the purinergic receptor subtype P2Y(1)R using 2-methylthioladenosine 5' diphosphate (2MeSADP) significantly reduced cytotoxic edema induced by photothrombosis. Here, we tested whether P2Y(1)R stimulation was neuroprotective after TBI. A controlled closed head injury model was established for mice using a pneumatic impact device. Brains were harvested at 1, 3, or 7 days post-injury and assayed for morphological changes by immunocytochemistry, Western blot analysis, and wet/dry weight. Cerebral edema and expression of both aquaporin type 4 and glial fibrillary acidic protein were increased at all time points examined. Immunocytochemical measurements in both cortical and hippocampal slices also revealed significant neuronal swelling and reactive gliosis. Treatment of mice with 2MeSADP (100 mu M) or MRS2365 (100 mu M) 30 min after trauma significantly reduced all post-injury symptoms of TBI including edema, neuronal swelling, reactive gliosis, and AQ4 expression. The neuroprotective effect was lost in IP(3)R2-/- mice treated with 2MeSADP. Immunocytochemical labeling of brain slices confirmed that P2Y(1)R expression was defined to cortical and hippocampal astrocytes, but not neurons. Taken together, the data show that stimulation of astrocytic P2Y(1)Rs significantly reduces brain injury after acute trauma and is mediated by the IP3-signaling pathway. We suggest that enhancing astrocyte mitochondrial metabolism offers a promising neuroprotective strategy for a broad range of brain injuries.	[Lechleiter, James] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, STRF Neurosci Program MC8253, Sch Med, San Antonio, TX 78229 USA; [Sprague, Shane; Garling, R. Justin; Jimenez, David; Digicaylioglu, Murat] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurosurg, Sch Med, San Antonio, TX 78229 USA	Lechleiter, J (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, STRF Neurosci Program MC8253, Sch Med, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.	lechleiter@uthscsa.edu					Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Adelson PD, 1998, ACT NEUR S, V71, P104; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; BAETHMANN A, 1988, CRIT CARE MED, V16, P972, DOI 10.1097/00003246-198810000-00008; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Barzo P, 1997, ACT NEUR S, V70, P119; BETZ AL, 1994, J CEREBR BLOOD F MET, V14, P29, DOI 10.1038/jcbfm.1994.5; Bloch Orin, 2007, Neurosurg Focus, V22, pE3; Brown AM, 2007, GLIA, V55, P1263, DOI 10.1002/glia.20557; Cherniak C, 1990, J Cogn Neurosci, V2, P58, DOI 10.1162/jocn.1990.2.1.58; Chu XF, 2007, BRAIN RES, V1149, P157, DOI 10.1016/j.brainres.2007.02.061; DENTON RM, 1985, AM J PHYSIOL, V249, pE543; DeWitt D S, 1995, New Horiz, V3, P376; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELLIOTT KAC, 1949, AM J PHYSIOL, V157, P122; ERISKAT J, 1994, ACTA NEUROCHIR, P425; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Ghirnikar RS, 1996, J NEUROSCI RES, V46, P727; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Hajnoczky G, 2000, J BIOENERG BIOMEMBR, V32, P15, DOI 10.1023/A:1005504210587; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; Hergenroeder G, 2008, J NEUROTRAUM, V25, P79, DOI 10.1089/neu.2007.0386; Hertz L, 2007, J CEREBR BLOOD F MET, V27, P219, DOI 10.1038/sj.jcbfm.9600343; HOZUMI I, 1990, BRAIN RES, V524, P64, DOI 10.1016/0006-8993(90)90492-T; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; James G, 2002, EUR J PHARMACOL, V447, P247, DOI 10.1016/S0014-2999(02)01756-9; Kimelberg HK, 2005, GLIA, V50, P389, DOI 10.1002/glia.20174; Li XD, 2005, CIRC RES, V96, P1274, DOI 10.1161/01.RES.0000172556.05576.4c; Loubinoux I, 1997, STROKE, V28, P419, DOI 10.1161/01.STR.28.2.419; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; Marmarou Anthony, 2004, Cleve Clin J Med, V71 Suppl 1, pS6; MATHEWSON AJ, 1985, BRAIN RES, V327, P61, DOI 10.1016/0006-8993(85)91499-4; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P479, DOI 10.1098/rstb.1990.0121; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391; MENZIES SA, 1993, J NEUROSURG, V78, P257, DOI 10.3171/jns.1993.78.2.0257; Nawashiro H, 1998, NEUROREPORT, V9, P1691, DOI 10.1097/00001756-199806010-00004; Nedergaard M, 2003, TRENDS NEUROSCI, V26, P523, DOI 10.1016/j.tins.2003.08.008; Nedergaard M, 2005, GLIA, V50, P281, DOI 10.1002/glia.20205; Nico B, 2003, GLIA, V42, P235, DOI 10.1002/glia.10216; Nielsen S, 1997, AM J PHYSIOL-CELL PH, V273, pC1549; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; NORTON WT, 1992, NEUROCHEM RES, V17, P877, DOI 10.1007/BF00993263; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Otani N, 2006, J CLIN NEUROSCI, V13, P934, DOI 10.1016/j.jocn.2005.10.018; Patro A, 2009, INDIAN J NEUROTRAUM, V6, P11, DOI 10.1016/S0973-0508(09)80021-X; Rao KVR, 2011, J NEUROTRAUM, V28, P371, DOI 10.1089/neu.2010.1705; Ribeiro MD, 2006, J NEUROSCI RES, V83, P1231, DOI 10.1002/jnr.20819; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Tait MJ, 2008, TRENDS NEUROSCI, V31, P37, DOI 10.1016/j.tins.2007.11.003; Tang YP, 2010, EXP NEUROL, V223, P485, DOI 10.1016/j.expneurol.2010.01.015; Taya K, 2010, J NEUROTRAUM, V27, P229, DOI 10.1089/neu.2009.0933; Tomura S, 2011, J NEUROTRAUM, V28, P237, DOI 10.1089/neu.2010.1443; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Venero JL, 2004, CURR PHARM DESIGN, V10, P2153, DOI 10.2174/1381612043384150; Verkhratsky A, 1996, TRENDS NEUROSCI, V19, P346, DOI 10.1016/0166-2236(96)10048-5; Verkman AS, 2006, BBA-BIOMEMBRANES, V1758, P1085, DOI 10.1016/j.bbamem.2006.02.018; Verkman AS, 2002, J ANAT, V200, P617, DOI 10.1046/j.1469-7580.2002.00058.x; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; VIJAYAN VK, 1990, MOL CHEM NEUROPATHOL, V13, P107, DOI 10.1007/BF03159912; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Woitzik J, 2008, FRONT BIOSCI-LANDMRK, V13, P1500, DOI 10.2741/2776; Wu J, 2007, J NEUROSCI, V27, P6510, DOI 10.1523/JNEUROSCI.1256-07.2007; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xiong Y, 2001, NEUROL RES, V23, P129, DOI 10.1179/016164101101198460; Yang BX, 2008, J BIOL CHEM, V283, P15280, DOI 10.1074/jbc.M801425200; Zador Zsolt, 2009, Handb Exp Pharmacol, P159, DOI 10.1007/978-3-540-79885-9_7; Zheng W, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014401	77	39	39	1	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2013	30	1					55	66		10.1089/neu.2012.2488			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	061GU	WOS:000312837300009	23046422				2021-06-18	
J	Wittwer, JE; Webster, KE; Hill, K				Wittwer, Joanne E.; Webster, Kate E.; Hill, Keith			Rhythmic auditory cueing to improve walking in patients with neurological conditions other than Parkinson's disease - what is the evidence?	DISABILITY AND REHABILITATION			English	Article						Acoustic simulation; gait; neurologic gait disorder; rhythmic auditory cueing	RANDOMIZED CLINICAL-TRIALS; GAIT VARIABILITY; PHYSICAL-THERAPY; RETEST RELIABILITY; MOVEMENT-DISORDERS; SYSTEMATIC REVIEWS; SYNCHRONOUS MUSIC; ATTENTIONAL COST; STIMULATION RAS; OLDER-ADULTS	Purpose: To investigate whether synchronising over-ground walking to rhythmic auditory cues improves temporal and spatial gait measures in adults with neurological clinical conditions other than Parkinson's disease. Method: A search was performed in June 2011 using the computerised databases AGELINE, AMED, AMI, CINAHL, Current Contents, EMBASE, MEDLINE, PsycINFO and PUBMED, and extended using hand-searching of relevant journals and article reference lists. Methodological quality was independently assessed by two reviewers. A best evidence synthesis was applied to rate levels of evidence. Results: Fourteen studies, four of which were randomized controlled trials (RCTs), met the inclusion criteria. Patient groups included those with stroke (six studies); Huntington's disease and spinal cord injury (two studies each); traumatic brain injury, dementia, multiple sclerosis and normal pressure hydrocephalus (one study each). The best evidence synthesis found moderate evidence of improved velocity and stride length of people with stroke following gait training with rhythmic music. Insufficient evidence was found for other included neurological disorders due to low study numbers and poor methodological quality of some studies. Conclusion: Synchronising walking to rhythmic auditory cues can result in short-term improvement in gait measures of people with stroke. Further high quality studies are needed before recommendations for clinical practice can be made.	[Wittwer, Joanne E.; Webster, Kate E.] La Trobe Univ, Fac Hlth Sci, Musculoskeletal Res Ctr, Bundoora, Vic 3086, Australia; [Wittwer, Joanne E.] La Trobe Univ, Sch Physiotherapy, Bundoora, Vic 3086, Australia; [Hill, Keith] Curtin Univ Technol, Sch Physiotherapy, Perth, WA, Australia	Wittwer, JE (corresponding author), La Trobe Univ, Fac Hlth Sci, Musculoskeletal Res Ctr, Room 216, Bundoora, Vic 3086, Australia.	J.Wittwer@latrobe.edu.au	Hill, Keith D/L-6398-2017; Wittwer, Joanne/M-9909-2015	Hill, Keith D/0000-0002-2191-0308; Wittwer, Joanne/0000-0002-7884-4356			Amatachaya S, 2009, SPINAL CORD, V47, P668, DOI 10.1038/sc.2008.168; Baker K, 2008, PARKINSONISM RELAT D, V14, P314, DOI 10.1016/j.parkreldis.2007.09.008; Baker K, 2007, ARCH PHYS MED REHAB, V88, P1593, DOI 10.1016/j.apmr.2007.07.026; Brach JS, 2007, J GERONTOL A-BIOL, V62, P983, DOI 10.1093/gerona/62.9.983; Bradt J, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006787.pub2; Brown LA, 2009, ARCH PHYS MED REHAB, V90, P1578, DOI 10.1016/j.apmr.2009.03.009; Clair AA, 2006, J MUSIC THER, V43, P154, DOI 10.1093/jmt/43.2.154; Conklyn D, 2010, NEUROREHAB NEURAL RE, V24, P835, DOI 10.1177/1545968310372139; de Bruin N, 2010, PARKINSONS DIS, P9; de I'Etoile SK, 2008, INT J REHABIL RES, V31, P155, DOI 10.1097/MRR.0b013e3282fc0f44; del Olmo MF, 2005, PARKINSONISM RELAT D, V11, P25, DOI 10.1016/j.parkreldis.2004.09.002; Delval A, 2008, MOVEMENT DISORD, V23, P1446, DOI 10.1002/mds.22125; Frenkel-Toledo S, 2005, MOVEMENT DISORD, V20, P1109, DOI 10.1002/mds.20507; Green J, 2002, CLIN REHABIL, V16, P306, DOI 10.1191/0269215502cr495oa; Hausdorff JM, 2007, EUR J NEUROSCI, V26, P2369, DOI 10.1111/j.1460-9568.2007.05810.x; Hausdorff JM, 2001, ARCH PHYS MED REHAB, V82, P1050, DOI 10.1053/apmr.2001.24893; Hayden R, 2009, INT J NEUROSCI, V119, P2183, DOI 10.3109/00207450903152609; Herbert Robert D., 2001, Physiotherapy Theory and Practice, V17, P201, DOI 10.1080/095939801317077650; HILL KD, 1994, ARCH PHYS MED REHAB, V75, P577; Hurt CP, 1998, J MUSIC THER, V35, P228, DOI 10.1093/jmt/35.4.228; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Karageorghis CI, 2009, J SPORT EXERCISE PSY, V31, P18, DOI 10.1123/jsep.31.1.18; Keus SHJ, 2007, MOVEMENT DISORD, V22, P451, DOI 10.1002/mds.21244; Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700; Lim I, 2005, CLIN REHABIL, V19, P695, DOI 10.1191/0269215505cr906oa; Maki BE, 1997, J AM GERIATR SOC, V45, P313, DOI 10.1111/j.1532-5415.1997.tb00946.x; Morris ME, 2000, PHYS THER, V80, P578, DOI 10.1093/ptj/80.6.578; Morris ME, 2010, PHYS THER, V90, P280, DOI 10.2522/ptj.20090091; Nieuwboer A, 2007, J NEUROL NEUROSUR PS, V78, P134, DOI 10.1136/jnnp.200X.097923; Nieuwboer A, 2009, NEUROREHAB NEURAL RE, V23, P831, DOI 10.1177/1545968309337136; Park IM, 2010, J PHYS THER SCI, V22, P295, DOI 10.1589/jpts.22.295; Prassas S, 1997, GAIT POSTURE, V6, P218, DOI 10.1016/S0966-6362(97)00010-6; Rochester L, 2007, J NEURAL TRANSM, V114, P1243, DOI 10.1007/s00702-007-0756-y; Rochester L, 2011, MOVEMENT DISORD, V26, P430, DOI 10.1002/mds.23450; Rochester L, 2009, MOVEMENT DISORD, V24, P839, DOI 10.1002/mds.22400; Royal Dutch Society for Physical Therapy, 2004, KNGF EV BAS CLIN PRA; Schmidt RA, 1991, CONT MANAGEMENT MOTO, P49; Simpson SD, 2006, J SPORT SCI, V24, P1095, DOI 10.1080/02640410500432789; Snijders AH, 2007, LANCET NEUROL, V6, P63, DOI 10.1016/S1474-4422(06)70678-0; Steultjens EMJ, 2003, STROKE, V34, P676, DOI 10.1161/01.STR.0000057576.77308.30; Stolze H, 2001, J NEUROL NEUROSUR PS, V70, P289, DOI 10.1136/jnnp.70.3.289; Styns F, 2007, HUM MOVEMENT SCI, V26, P769, DOI 10.1016/j.humov.2007.07.007; Terrier P, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-12; Thaut AH, 2007, NEUROREHAB NEURAL RE, V21, P455, DOI 10.1177/1545968307300523; Thaut M, 2008, RHYTHM MUSIC BRAIN S; Thaut M. H., 1997, INT J ARTS MED, V5, P4; Thaut MH, 1997, J NEUROL SCI, V151, P207, DOI 10.1016/S0022-510X(97)00146-9; Thaut MH, 1999, MOVEMENT DISORD, V14, P808, DOI 10.1002/1531-8257(199909)14:5<808::AID-MDS1014>3.0.CO;2-J; Thaut MH, 1999, IEEE ENG MED BIOL, V18, P101, DOI 10.1109/51.752991; Thaut MH, 1993, NEUROREHABIL NEURAL, V7, P9, DOI DOI 10.1177/136140969300700103; Thaut MH, 2010, MUSIC PERCEPT, V27, P263, DOI 10.1525/MP.2010.27.4.263; Thaut MH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002312; Urquhart DM, 1999, ARCH PHYS MED REHAB, V80, P696, DOI 10.1016/S0003-9993(99)90175-2; vanTulder MW, 1997, SPINE, V22, P2323, DOI 10.1097/00007632-199710150-00001; Verhagen AP, 1998, J CLIN EPIDEMIOL, V51, P1235, DOI 10.1016/S0895-4356(98)00131-0; Wittwer JE, 2008, GAIT POSTURE, V28, P392, DOI 10.1016/j.gaitpost.2008.01.007; Zatorre RJ, 2007, NAT REV NEUROSCI, V8, P547, DOI 10.1038/nrn2152	57	39	40	1	63	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2013	35	2					164	176		10.3109/09638288.2012.690495			13	Rehabilitation	Rehabilitation	067JX	WOS:000313291200010	22681598				2021-06-18	
J	Zhou, HH; Liu, Q; Cheng, G; Li, ZB				Zhou, Hai-Hua; Liu, Qi; Cheng, Gu; Li, Zu-Bing			Aetiology, pattern and treatment of mandibular condylar fractures in 549 patients: A 22-year retrospective study	JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY			English	Article						Condylar fracture; Retrospective Study; Prevalence; Surgical treatment; Open reduction and internal fixation	OPEN REDUCTION; CLOSED TREATMENT; INTERNAL-FIXATION; MAXILLOFACIAL FRACTURES; SUBCONDYLAR FRACTURES; CURRENT THOUGHTS; CLASSIFICATION; INJURIES; MULTICENTER; REFLECTIONS	Purpose: The The purpose of this study was to retrospectively investigate the aetiology, pattern, and treatment of mandibular condylar fractures in our department over the past 22 years. Patients and methods: Data of patients who sustained mandibular condylar fractures from 1988 to 2009 were recorded, including fracture aetiology, pattern of condylar fracture, time, age, sex, associated injury, patient transferred by other clinics, lag time and treatment method. Data analysis included X-2 test, Fisher exact test, t-test, Ridit analysis and Logistic regression analysis. Results: The sample was composed of 549 patients (749 condylar fractures), 404 male and 145 female (male:female = 2.79:1), with a mean age of 30.12 +/- 14.44 years. Road traffic accidents were the most common cause (248, 45.2%). Condylar head fractures were significantly related to a fall at ground level (p = .001). A fall from a height had a 3.19-fold risk of bilateral condylar fractures (odds ratio, 3.19; 95% confidence interval, 1.33 to 7.65; p = .010). A majority of the condylar fractures (693,92.5%) were treated by a surgical procedure. Condylar head were mostly removed (95.0%, p < .001), condylar neck and condylar base fractures were most frequently treated by open reduction and internal fixation with miniplates (74.4%, p < .001). Most of the dislocated condylar fractures were treated by open surgery (96.5%, p = .026). Conclusions: The anatomic position and uni/bilateral pattern of mandibular condylar fractures were positively related to situations when considerable force is involved. Open condylar surgery was based on the level of fracture and degree of displacement or dislocation. (C) 2012 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.	[Zhou, Hai-Hua; Liu, Qi; Cheng, Gu; Li, Zu-Bing] Wuhan Univ, State Key Lab Breeding Base Basic Sci Stomatol Hu, Sch & Hosp Stomatol, Wuhan 430079, Hubei, Peoples R China; [Zhou, Hai-Hua; Liu, Qi; Cheng, Gu; Li, Zu-Bing] Wuhan Univ, Key Lab Oral Biomed, Sch & Hosp Stomatol, Minist Educ, Wuhan 430079, Hubei, Peoples R China; [Zhou, Hai-Hua; Liu, Qi; Cheng, Gu; Li, Zu-Bing] Wuhan Univ, Dept Oral & Maxillofacial Surg, Coll & Hosp Stomatol, Wuhan 430079, Hubei, Peoples R China	Li, ZB (corresponding author), Wuhan Univ, Dept Oral & Maxillofacial Surg, Coll & Hosp Stomatol, 237 Luoyu Rd, Wuhan 430079, Hubei, Peoples R China.	lizubing0827@163.com	zhou, haihua/F-5179-2012	zhou, haihua/0000-0002-6838-0113			Abdel-Galil K, 2008, BRIT J ORAL MAX SURG, V46, P482, DOI 10.1016/j.bjoms.2007.11.025; Abdel-Galil K, 2010, BRIT J ORAL MAX SURG, V48, P520, DOI 10.1016/j.bjoms.2009.10.010; AMARATUNGA NAD, 1987, BRIT J ORAL MAX SURG, V25, P391, DOI 10.1016/0266-4356(87)90088-X; Brandt MT, 2003, J ORAL MAXIL SURG, V61, P1324, DOI 10.1016/S0278-2391(03)00735-3; Cenzi R, 2009, J CRANIOFAC SURG, V20, P24, DOI [10.1097/SCS.0b013e31819032a3, 10.1097/scs.0b013e31819032a3]; Czerwinski M, 2008, PLAST RECONSTR SURG, V122, P881, DOI 10.1097/PRS.0b013e3181811a3c; De Riu G, 2001, INT J ORAL MAX SURG, V30, P384, DOI 10.1054/ijom.2001.0103; DERDYN C, 1990, PLAST RECONSTR SURG, V86, P238, DOI 10.1097/00006534-199008000-00005; DERDYN C, 1990, PLAST RECONSTR SURG, V86, P246; DODSON TB, 1988, J ORAL MAXIL SURG, V46, P875, DOI 10.1016/0278-2391(88)90054-7; Eckelt U, 2006, J CRANIO MAXILL SURG, V34, P433, DOI 10.1016/j.jcms.2006.07.855; Eckelt U, 2006, J CRANIO MAXILL SURG, V34, P306, DOI 10.1016/j.jcms.2006.03.003; Eggensperger N, 2007, J CRANIO MAXILL SURG, V35, P161, DOI 10.1016/j.jcms.2007.01.002; Ellis E, 2005, J ORAL MAXIL SURG, V63, P115, DOI 10.1016/j.joms.2004.02.019; ELLIS E, 1985, ORAL SURG ORAL MED O, V59, P120, DOI 10.1016/0030-4220(85)90002-7; Erol BE, 2004, J CRANIO MAXILL SURG, V32, P308, DOI 10.1016/j.jcms.2004.04.006; Furr AM, 2006, LARYNGOSCOPE, V116, P427, DOI 10.1097/01.MLG.0000194844.87268.ED; Haug RH, 2001, J ORAL MAXIL SURG, V59, P370, DOI 10.1053/joms.2001.21868; Haug RH, 2007, PLAST RECONSTR SURG, V120, p90S, DOI 10.1097/01.prs.0000260730.43870.1b; He DM, 2009, J ORAL MAXIL SURG, V67, P1672, DOI 10.1016/j.joms.2009.02.012; Hlawitschka M, 2005, INT J ORAL MAX SURG, V34, P597, DOI 10.1016/j.ijom.2005.02.004; Hlawitschka M, 2002, J ORAL MAXIL SURG, V60, P784, DOI 10.1053/joms.2002.33246; Huang YH, 2011, ACCIDENT ANAL PREV, V43, P889, DOI 10.1016/j.aap.2010.11.009; Hyde N, 2002, BRIT J ORAL MAX SURG, V40, P19, DOI 10.1054/bjom.2001.0734; KENT JN, 1990, ORAL MAXILLOFAC SURG, V2, P69; Kermer C, 1998, INT J ORAL MAX SURG, V27, P191, DOI 10.1016/S0901-5027(98)80008-8; Li GH, 1997, AM J PUBLIC HEALTH, V87, P1049, DOI 10.2105/AJPH.87.6.1049; Li Z, 2006, J ORAL MAXIL SURG, V64, P1225, DOI 10.1016/j.joms.2006.04.018; LINDAHL L, 1977, INT J ORAL MAXILLOF, V6, P12, DOI 10.1016/S0300-9785(77)80067-7; Long X, 2007, J ORAL MAXIL SURG, V65, P1102, DOI 10.1016/j.joms.2006.06.307; Loukota RA, 2005, BRIT J ORAL MAX SURG, V43, P72, DOI 10.1016/j.bjoms.2004.08.018; MACLENNAN WD, 1952, BRIT J PLAST SURG, V5, P122; Marker P, 2000, BRIT J ORAL MAX SURG, V38, P422, DOI 10.1054/bjom.2000.0457; Marker P, 2000, BRIT J ORAL MAX SURG, V38, P417, DOI 10.1054/bjom.2000.0317; Nussbaum ML, 2008, J ORAL MAXIL SURG, V66, P1087, DOI 10.1016/j.joms.2008.01.025; Roccia F, 2010, J CRANIO MAXILL SURG, V38, P314, DOI 10.1016/j.jcms.2009.10.002; Sawazaki R, 2010, J ORAL MAXIL SURG, V68, P1252, DOI 10.1016/j.joms.2009.03.064; Schneider M, 2008, J ORAL MAXIL SURG, V66, P2537, DOI 10.1016/j.joms.2008.06.107; SILVENNOINEN U, 1992, J ORAL MAXIL SURG, V50, P1032, DOI 10.1016/0278-2391(92)90484-H; Spiessl B, 1972, SPEZIELLE FRAKTURE L, VI/I; STEELE RJC, 1983, LANCET, V2, P341; Thoren H, 1997, BRIT J ORAL MAX SURG, V35, P306, DOI 10.1016/S0266-4356(97)90401-0; Valiati Renato, 2008, Int J Med Sci, V5, P313; Vesnaver A, 2008, J ORAL MAXIL SURG, V66, P2123, DOI 10.1016/j.joms.2008.06.010; Villarreal PM, 2004, J ORAL MAXIL SURG, V62, P155, DOI 10.1016/j.joms.2003.08.010; Wang SY, 2008, LANCET, V372, P1765, DOI 10.1016/S0140-6736(08)61367-7; World Health Organization, 2006, TURN TID INJ VIOL PR; Zachariades N, 2006, J CRANIO MAXILL SURG, V34, P421, DOI 10.1016/j.jcms.2006.07.854; ZIDE MF, 1983, J ORAL MAXIL SURG, V41, P89, DOI 10.1016/0278-2391(83)90214-8; ZIDE MF, 1989, CLIN PLAST SURG, V16, P69; Zide MF, 2001, J ORAL MAXIL SURG, V59, P375, DOI 10.1053/joms.2001.21869	51	39	40	0	15	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1010-5182			J CRANIO MAXILL SURG	J. Cranio-MaxilloFac. Surg.	JAN	2013	41	1					34	41		10.1016/j.jcms.2012.05.007			8	Dentistry, Oral Surgery & Medicine; Surgery	Dentistry, Oral Surgery & Medicine; Surgery	082IL	WOS:000314385400008	22727898				2021-06-18	
J	Arango, JI; Deibert, CP; Brown, D; Bell, M; Dvorchik, I; Adelson, PD				Arango, Jorge I.; Deibert, Christopher P.; Brown, Danielle; Bell, Michael; Dvorchik, Igor; Adelson, P. David			Posttraumatic seizures in children with severe traumatic brain injury	CHILDS NERVOUS SYSTEM			English	Article						Pediatric; Traumatic brain injury; Seizures; Anticonvulsants; Prophylaxis; Head trauma	HEAD TRAUMA; PHENYTOIN; EPILEPSY; PROPHYLAXIS; POPULATION; PREVENTION; PREDICTORS; MANAGEMENT	Traumatic brain injury (TBI) remains a leading cause of childhood death and disability worldwide. Seizures are a common complication of TBI and they are particularly common in pediatric populations. The proper management of children sustaining severe TBI is still controversial. Our study aims to share our experience contributing to build evidence for better care. Retrospective chart review was performed on individuals ages 0 to < 18 who presented to a level 1 trauma center during a 10-year period with the diagnosis of severe TBI. Data analyzed included patient's demographics, event information, clinical and radiological presentation, management, and midterm follow-up. Presence of seizures was tracked through EEG monitoring, staff witnessing, or guardian referral. The incidence of early posttraumatic seizures (EPTS) observed in our population (19 %) exceeds those previously reported. Such findings likely reflect the importance of close monitoring including EEG. An association between the presence of EPTS and the development of late posttraumatic seizures (LPTS) was evidenced (p = 0.001; 95 % CI 2.2, 16.5), while this association should not be assumed as a measure of causality, it should be considered for the management of patients presenting EPTS. Non-accidental trauma and young age were identified as independent predictors for the development of seizures. Seizures are a common complication of severe TBI among children aged 0-3 years. Given the detrimental effects that seizures produce on the injured brain, close observation and appropriate monitoring with EEG are essential for the management of children sustaining severe TBI.	[Arango, Jorge I.; Brown, Danielle; Adelson, P. David] Phoenix Childrens Hosp, Barrow Neurol Inst, Dept Neurosurg & Neurosci Res, Phoenix, AZ 85016 USA; [Deibert, Christopher P.; Bell, Michael] Childrens Hosp Pittsburgh, Dept Neurosurg & Crit Care Med, Pittsburgh, PA 15213 USA; [Deibert, Christopher P.; Bell, Michael] Univ Pittsburgh, Pittsburgh, PA USA; [Dvorchik, Igor] Nationwide Childrens Hosp, Nationwide Childrens Hosp Res Inst, Columbus, OH USA	Adelson, PD (corresponding author), Phoenix Childrens Hosp, Barrow Neurol Inst, Dept Neurosurg & Neurosci Res, Ambulatory Bldg B,1919 E Thomas Rd, Phoenix, AZ 85016 USA.	dadelson@phoenixchildrens.com	Dvorchik, Igor/D-1749-2013; Adelson, David/W-2083-2019				ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Black P, 1975, CIBA F S, V34, P215; Chadwick D, 2000, LANCET, V355, P334, DOI 10.1016/S0140-6736(99)00452-3; Chiaretti A, 2002, CHILD NERV SYST, V18, P109, DOI 10.1007/s00381-002-0561-8; Haltiner AM, 1999, J NEUROSURG, V91, P588, DOI 10.3171/jns.1999.91.4.0588; HENDRICK EB, 1968, J TRAUM, V8, P547; Ikonomidou C, 2010, EPILEPSY RES, V88, P11, DOI 10.1016/j.eplepsyres.2009.09.019; JENNETT B, 1975, LANCET, V1, P480; Jones KE, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E3; Kuppermann N, 2008, PEDIATR RADIOL, V38, pS670, DOI 10.1007/s00247-008-0996-5; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LEWIS RJ, 1993, ANN EMERG MED, V22, P1114, DOI 10.1016/S0196-0644(05)80974-6; Mansfield RT, 1997, CRIT CARE CLIN, V13, P611, DOI 10.1016/S0749-0704(05)70331-6; Moshe S L, 1987, Epilepsia, V28 Suppl 1, pS3, DOI 10.1111/j.1528-1157.1987.tb05753.x; Ong LC, 1996, J PAEDIATR CHILD H, V32, P173, DOI 10.1111/j.1440-1754.1996.tb00917.x; Ratan SK, 1999, PEDIATR NEUROSURG, V30, P127, DOI 10.1159/000028779; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; SATO M, 1990, ELECTROEN CLIN NEURO, V76, P459, DOI 10.1016/0013-4694(90)90099-6; SERVIT Z, 1981, EPILEPSIA, V22, P315, DOI 10.1111/j.1528-1157.1981.tb04115.x; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Thomas K.E., 2009, STATE INJURY INDICAT; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037; WOHNS RNW, 1979, J NEUROSURG, V51, P507, DOI 10.3171/jns.1979.51.4.0507; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; Young KD, 2004, ANN EMERG MED, V43, P435, DOI 10.1016/j.annemergmed.2003.09.016	27	39	42	0	12	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	NOV	2012	28	11					1925	1929		10.1007/s00381-012-1863-0			5	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	021FY	WOS:000309871900015	22843174				2021-06-18	
J	Boucher, PA; Joos, B; Morris, CE				Boucher, Pierre-Alexandre; Joos, Bela; Morris, Catherine E.			Coupled left-shift of Nav channels: modeling the Na+-loading and dysfunctional excitability of damaged axons	JOURNAL OF COMPUTATIONAL NEUROSCIENCE			English	Article						Hodgkin-Huxley; Diffuse axonal injury; Myelinated; Arrhythmia; Neuropathic pain; Na/K-ATPase; Extracellular space	GATED SODIUM-CHANNELS; TRAUMATIC BRAIN-INJURY; NEUROPATHIC PAIN; LATENT ADDITION; STRETCH-INJURY; SENSORY AXONS; MEMBRANE; NEURONS; CURRENTS; OSCILLATIONS	Injury to neural tissue renders voltage-gated Na+ (Nav) channels leaky. Even mild axonal trauma initiates Na+ -loading, leading to secondary Ca2+-loading and white matter degeneration. The nodal isoform is Nav1.6 and for Nav1.6-expressing HEK-cells, traumatic whole cell stretch causes an immediate tetrodotoxin-sensitive Na+-leak. In stretch-damaged oocyte patches, Nav1.6 current undergoes damage-intensity dependent hyperpolarizing- (left-) shifts, but whether left-shift underlies injured-axon Nav-leak is uncertain. Nav1.6 inactivation (availability) is kinetically limited by (coupled to) Nav activation, yielding coupled left-shift (CLS) of the two processes: CLS should move the steady-state Nav1.6 "window conductance" closer to typical firing thresholds. Here we simulated excitability and ion homeostasis in free-running nodes of Ranvier to assess if hallmark injured-axon behaviors-Na+-loading, ectopic excitation, propagation block-would occur with Nav-CLS. Intact/traumatized axolemma ratios were varied, and for some simulations Na/K pumps were included, with varied in/outside volumes. We simulated saltatory propagation with one mid-axon node variously traumatized. While dissipating the [Na+] gradient and hyperactivating the Na/K pump, Nav-CLS generated neuropathic pain-like ectopic bursts. Depending on CLS magnitude, fraction of Nav channels affected, and pump intensity, tonic or burst firing or nodal inexcitability occurred, with [Na+] and [K+] fluctuating. Severe CLS-induced inexcitability did not preclude Na+-loading; in fact, the steady-state Na+-leaks elicited large pump currents. At a mid-axon node, mild CLS perturbed normal anterograde propagation, and severe CLS blocked saltatory propagation. These results suggest that in damaged excitable cells, Nav-CLS could initiate cellular deterioration with attendant hyper- or hypo-excitability. Healthy-cell versions of Nav-CLS, however, could contribute to physiological rhythmic firing.	[Boucher, Pierre-Alexandre; Joos, Bela] Univ Ottawa, Dept Phys, Ottawa, ON K1N 6N5, Canada; [Morris, Catherine E.] Ottawa Hosp, Res Inst, Ottawa, ON K1H 8M5, Canada	Joos, B (corresponding author), Univ Ottawa, Dept Phys, 150 Louis Pasteur, Ottawa, ON K1N 6N5, Canada.	pbouc040@uottawa.ca; bjoos@uottawa.ca; cmorris@uottawa.ca		Morris, Catherine/0000-0002-7401-6545; Joos, Bela/0000-0001-8576-5579	NSERCNatural Sciences and Engineering Research Council of Canada (NSERC); HSF; CIHRCanadian Institutes of Health Research (CIHR)	We thank Andre Longtin and Na Yu for helpful discussions during the preparation of this manuscript. Our research was supported by funds from NSERC, HSF and CIHR.	Allen DG, 2010, ADV EXP MED BIOL, V682, P297, DOI 10.1007/978-1-4419-6366-6_17; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Banderali U, 2010, CHANNELS, V4, P12, DOI 10.4161/chan.4.1.10260; Beyder A, 2010, J PHYSIOL-LONDON, V588, P4969, DOI 10.1113/jphysiol.2010.199034; Blyth BJ, 2010, EMERG MED CLIN N AM, V28, P571, DOI 10.1016/j.emc.2010.03.003; Borjesson SI, 2010, BIOPHYS J, V98, P396, DOI 10.1016/j.bpj.2009.10.026; Bostock H, 1997, J PHYSIOL-LONDON, V498, P277, DOI 10.1113/jphysiol.1997.sp021857; Bruno MJ, 2007, P NATL ACAD SCI USA, V104, P9638, DOI 10.1073/pnas.0701015104; Burbidge SA, 2002, MOL BRAIN RES, V103, P80, DOI 10.1016/S0169-328X(02)00188-2; Charras G, 2008, NAT REV MOL CELL BIO, V9, P730, DOI 10.1038/nrm2453; Coggan JS, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/6/065002; Coggan JS, 2010, P NATL ACAD SCI USA, V107, P20602, DOI 10.1073/pnas.1013798107; Devor M, 2009, EXP BRAIN RES, V196, P115, DOI 10.1007/s00221-009-1724-6; Di X, 2000, ACT NEUR S, V76, P379; Draeger A, 2011, BIOCHEM PHARMACOL, V81, P703, DOI 10.1016/j.bcp.2010.12.027; Duflocq A, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-66; Finol-Urdaneta RK, 2010, BIOPHYS J, V98, P762, DOI 10.1016/j.bpj.2009.10.053; Fried K, 2011, PAIN, V152, P2685, DOI 10.1016/j.pain.2011.08.004; Gu C, 2011, J BIOL CHEM, V286, P25835, DOI 10.1074/jbc.M111.219113; Hirn C, 2008, J GEN PHYSIOL, V132, P199, DOI 10.1085/jgp.200810024; HODGKIN AL, 1948, J PHYSIOL-LONDON, V107, P165, DOI 10.1113/jphysiol.1948.sp004260; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Hogg RC, 2002, EUR J NEUROSCI, V16, P242, DOI 10.1046/j.1460-9568.2002.02071.x; Huff TB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017176; Isose S, 2010, CLIN NEUROPHYSIOL, V121, P719, DOI 10.1016/j.clinph.2009.12.034; Izhikevich EM, 2001, NEURAL NETWORKS, V14, P883, DOI 10.1016/S0893-6080(01)00078-8; Kager H, 2000, J NEUROPHYSIOL, V84, P495; Kimelberg HK, 2004, ADV EXP MED BIOL, V559, P157; Kole MHP, 2011, NEURON, V71, P671, DOI 10.1016/j.neuron.2011.06.024; Kovalsky Y, 2009, J NEUROPHYSIOL, V102, P1430, DOI 10.1152/jn.00005.2009; Krepkiy D, 2009, NATURE, V462, P473, DOI 10.1038/nature08542; Krishnan GP, 2011, J NEUROSCI, V31, P8870, DOI 10.1523/JNEUROSCI.6200-10.2011; Kuwabara S, 2006, CLIN NEUROPHYSIOL, V117, P810, DOI 10.1016/j.clinph.2005.11.018; LAUGER P, 1991, DISTINGUISHED LECT S, V5; LEMIEUX DR, 1992, J THEOR BIOL, V154, P335, DOI 10.1016/S0022-5193(05)80175-4; Lenkey N, 2011, NEUROPHARMACOLOGY, V60, P191, DOI 10.1016/j.neuropharm.2010.08.005; Li GR, 2009, CARDIOVASC RES, V81, P286, DOI 10.1093/cvr/cvn322; Lorincz A, 2010, SCIENCE, V328, P906, DOI 10.1126/science.1187958; Mantegazza M, 2010, LANCET NEUROL, V9, P413, DOI 10.1016/S1474-4422(10)70059-4; Marques A., 1988, BIOCHEM PHARMACOL, V15, P601; Massimini M, 2009, PROG BRAIN RES, V177, P201, DOI 10.1016/S0079-6123(09)17714-2; Maxwell WL, 1996, MICROSC RES TECHNIQ, V34, P522, DOI 10.1002/(SICI)1097-0029(19960815)34:6<522::AID-JEMT4>3.0.CO;2-L; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; Misawa S, 2009, J PERIPHER NERV SYST, V14, P279, DOI 10.1111/j.1529-8027.2009.00239.x; Monnerie H, 2010, EXP NEUROL, V224, P415, DOI 10.1016/j.expneurol.2010.05.001; MORRIS C, 1981, BIOPHYS J, V35, P193, DOI 10.1016/S0006-3495(81)84782-0; Morris C.E., 2011, CELL PHYSL SOURCE BO, P493; Morris CE, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00019; Morris CE, 2011, FRONT PHYSIOL, V2, DOI 10.3389/fphys.2011.00025; Morris CE, 2011, CARDIAC MECHANOELECT, P42; Ochab-Marcinek A, 2009, PHYS REV E, V79, DOI 10.1103/PhysRevE.79.011904; Prescott SA, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000198; Ritter AM, 2009, NEUROSCI LETT, V452, P28, DOI 10.1016/j.neulet.2008.12.051; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916; Schafer DP, 2009, J NEUROSCI, V29, P13242, DOI 10.1523/JNEUROSCI.3376-09.2009; Schmidt D, 2008, P NATL ACAD SCI USA, V105, P19276, DOI 10.1073/pnas.0810187105; Seifert G, 2009, J NEUROSCI, V29, P7474, DOI 10.1523/JNEUROSCI.3790-08.2009; Shi RY, 2011, NEUROSCI BULL, V27, P36, DOI 10.1007/s12264-011-1048-y; Smit JE, 2009, BIOL CYBERN, V100, P49, DOI 10.1007/s00422-008-0280-7; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Stys PK, 2004, CURR MOL MED, V4, P113, DOI 10.2174/1566524043479220; STYS PK, 1993, P NATL ACAD SCI USA, V90, P6976, DOI 10.1073/pnas.90.15.6976; Sun GC, 2006, ACTA PHARMACOL SIN, V27, P1537, DOI 10.1111/j.1745-7254.2006.00452.x; Tabarean IV, 1999, BIOPHYS J, V77, P758, DOI 10.1016/S0006-3495(99)76930-4; Taddese A, 2002, NEURON, V33, P587, DOI 10.1016/S0896-6273(02)00574-3; Thomas EA, 2009, ANN NEUROL, V66, P219, DOI 10.1002/ana.21712; Tokuno HA, 2003, MUSCLE NERVE, V28, P212, DOI 10.1002/mus.10421; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Volman V, 2011, P NATL ACAD SCI USA, V108, P15402, DOI 10.1073/pnas.1112066108; Vucic S, 2010, J NEUROL NEUROSUR PS, V81, P222, DOI 10.1136/jnnp.2009.183079; Wan XD, 1999, AM J PHYSIOL-CELL PH, V276, pC318; Wang JA, 2009, AM J PHYSIOL-CELL PH, V297, pC823, DOI 10.1152/ajpcell.00505.2008; Weiss S, 2010, BRIT J PHARMACOL, V160, P1072, DOI 10.1111/j.1476-5381.2010.00766.x; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161	75	39	40	1	12	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0929-5313			J COMPUT NEUROSCI	J. Comput. Neurosci.	OCT	2012	33	2					301	319		10.1007/s10827-012-0387-7			19	Mathematical & Computational Biology; Neurosciences	Mathematical & Computational Biology; Neurosciences & Neurology	005BN	WOS:000308725400005	22476614				2021-06-18	
J	Grande, PO; Romner, B				Graende, Per-Olof; Romner, Bertil			Osmotherapy in Brain Edema: A Questionable Therapy	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						brain edema; mannitol; hypertonic saline; osmotherapy; rebound phenomenon; renal failure; traumatic brain injury	ELEVATED INTRACRANIAL-PRESSURE; SEVERE HEAD-INJURY; HYPERTONIC SALINE; INTRACEREBRAL HEMORRHAGE; CEREBRAL EDEMA; VOLUME REGULATION; MANNITOL; MANAGEMENT; RESUSCITATION; TRANSPORT	Despite the fact that it has been used since the 1960s in diseases associated with brain edema and has been investigated in > 150 publications on head injury, very little has been published on the outcome of osmotherapy. We can only speculate whether osmotherapy improves outcome, has no effect on outcome, or leads to worse outcome. Here we describe the action and potentially beneficial and adverse effects of the 2 most commonly used osmotic solutions, mannitol and hypertonic saline, and present some critical aspects of their use. There is a well-documented transient intracranial pressure (ICP)-reducing effect of osmotherapy, but an adverse rebound increase in ICP after its withdrawal has been discussed extensively in the literature and is an expected pathophysiological phenomenon. From side effects related to renal and pulmonary failure, electrolyte disturbances, and a rebound increase in ICP, osmotherapy can be negative for outcome, which may explain why we lack scientific support for its use. These drawbacks, and the fact that the most recent Cochrane meta-analyses of osmotherapy in brain edema and stroke could not find any beneficial effects on outcome, make routine use of osmotherapy in brain edema doubtful. Nevertheless, the use of osmotherapy as a temporary measure may be justified to acutely prevent brain stem compression until other measures, such as evacuation of space-occupying lesions or decompressive craniotomy, can be performed. This article is the Con part in a Pro-Con debate in the present journal on the general routine use of osmotherapy in brain edema.	[Graende, Per-Olof] Univ Lund Hosp, Dept Anesthesia & Intens Care, SE-22185 Lund, Sweden; [Romner, Bertil] Univ Lund Hosp, Dept Neurosurg, SE-22185 Lund, Sweden; [Romner, Bertil] Rigshosp, Dept Neurosurg, DK-2100 Copenhagen, Denmark	Grande, PO (corresponding author), Univ Lund Hosp, Dept Anesthesia & Intens Care, SE-22185 Lund, Sweden.	per-olof.grande@med.lu.se			Swedish Research Council, StockholmSwedish Research Council [11581]; Medical Faculty of Lund University; Region Skane (ALF), Lund, Sweden	Supported by Grants from the Swedish Research Council (#11581), Stockholm, the Medical Faculty of Lund University, and Region Skane (ALF), Lund, Sweden.	ANDREWS RJ, 1993, SURG NEUROL, V39, P218, DOI 10.1016/0090-3019(93)90186-5; Bereczki D, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001153.pub2; Bhardwaj A, 2007, CURR NEUROL NEUROSCI, V7, P513, DOI 10.1007/s11910-007-0079-2; Bhardwaj Anish, 2004, Curr Opin Crit Care, V10, P126, DOI 10.1097/00075198-200404000-00009; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock R, 1995, New Horiz, V3, P448; Cottenceau V, 2011, J NEUROTRAUM, V28, P2003, DOI 10.1089/neu.2011.1929; Cruz J, 2004, J NEUROSURG, V100, P376, DOI 10.3171/jns.2004.100.3.0376; Cruz J, 2002, NEUROSURGERY, V51, P628, DOI 10.1097/00006123-200209000-00006; Cruz J, 2001, NEUROSURGERY, V49, P864; Davis M, 1994, J Neurosci Nurs, V26, P170; Diringer MN, 2004, NEUROCRIT CARE, V1, P219, DOI 10.1385/NCC:1:2:219; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; Fang L, 2010, RENAL FAILURE, V32, P673, DOI 10.3109/0886022X.2010.486492; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; Georgiadis Alexandros L, 2003, Curr Neurol Neurosci Rep, V3, P524, DOI 10.1007/s11910-003-0058-1; Grande PO, 2006, INTENS CARE MED, V32, P1475, DOI 10.1007/s00134-006-0294-3; Hoffmann EK, 2009, PHYSIOL REV, V89, P193, DOI 10.1152/physrev.00037.2007; Holbeck S, 2002, CRIT CARE MED, V30, P212, DOI 10.1097/00003246-200201000-00030; JAMES HE, 1980, ACTA NEUROCHIR, V51, P161, DOI 10.1007/BF01406742; JAVID M, 1964, J NEUROSURG, V21, P1059, DOI 10.3171/jns.1964.21.12.1059; Kamat Pradip, 2003, Pediatr Crit Care Med, V4, P239, DOI 10.1097/01.PCC.0000059340.19010.CE; Kamel H, 2011, CRIT CARE MED, V39, P554, DOI 10.1097/CCM.0b013e318206b9be; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; Knapp JM, 2005, AACN ADV CRIT CARE, V16, P199, DOI 10.1097/00044067-200504000-00011; Lescot T, 2006, CRIT CARE MED, V34, P3029, DOI 10.1097/01.CCM.0000243797.42346.64; Levick JR, 1997, INT J MICROCIRC, V17, P241, DOI 10.1159/000179236; Lossinsky AS, 2004, HISTOL HISTOPATHOL, V19, P535, DOI 10.14670/HH-19.535; LUNDVALL J, 1969, ACTA PHYSIOL SCAND, V77, P224, DOI 10.1111/j.1748-1716.1969.tb04566.x; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHALL LF, 1978, J NEUROSURG, V48, P169, DOI 10.3171/jns.1978.48.2.0169; MAZZONI MC, 1990, CIRC SHOCK, V31, P407; MAZZONI MC, 1989, J CELL PHYSIOL, V140, P272, DOI 10.1002/jcp.1041400212; MCMANUS ML, 1993, ANESTHESIOLOGY, V78, P1132, DOI 10.1097/00000542-199306000-00017; McManus ML, 1998, ANESTHESIOLOGY, V88, P1586, DOI 10.1097/00000542-199806000-00023; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Misra UK, 2005, J NEUROL SCI, V234, P41, DOI 10.1016/j.jns.2005.03.038; Nau R, 2000, CLIN PHARMACOKINET, V38, P23, DOI 10.2165/00003088-200038010-00002; Node Y, 1990, Adv Neurol, V52, P359; Ogden AT, 2005, NEUROSURGERY, V57, P207, DOI 10.1227/01.NEU.0000166533.79031.D8; OKEN DE, 1994, RENAL FAILURE, V16, P147, DOI 10.3109/08860229409044856; Paczynski RP, 1997, CRIT CARE CLIN, V13, P105, DOI 10.1016/S0749-0704(05)70298-0; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; PROUGH DS, 1986, J NEUROSURG, V64, P627, DOI 10.3171/jns.1986.64.4.0627; Qureshi AI, 1999, NEUROSURGERY, V44, P1055, DOI 10.1097/00006123-199905000-00064; Qureshi AI, 1998, J NEUROSURG ANESTH, V10, P188, DOI 10.1097/00008506-199807000-00010; Qureshi AI, 2000, CRIT CARE MED, V28, P3301, DOI 10.1097/00003246-200009000-00032; RABETOY GM, 1993, ANN PHARMACOTHER, V27, P25, DOI 10.1177/106002809302700105; RAVUSSIN P, 1986, J NEUROSURG, V64, P104, DOI 10.3171/jns.1986.64.1.0104; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Roberts I, 2007, BRIT MED J, V334, P392, DOI 10.1136/bmj.39118.480023.BE; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sakellaridis N, 2011, J NEUROSURG, V114, P543; Wakai A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub4; WEAVER A, 1987, NEPHRON, V45, P233, DOI 10.1159/000184124; White H, 2008, EUR J ANAESTH, V25, P104, DOI 10.1017/S0265021507003420; White H, 2006, ANESTH ANALG, V102, P1836, DOI 10.1213/01.ane.0000217208.51017.56; WINKLER SR, 1995, SURG NEUROL, V43, P59, DOI 10.1016/0090-3019(95)80039-J; WISE BL, 1961, ARCH NEUROL-CHICAGO, V4, P200, DOI 10.1001/archneur.1961.00450080082009; Ziai WC, 2007, J NEUROL SCI, V261, P157, DOI 10.1016/j.jns.2007.04.048	61	39	40	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	OCT	2012	24	4					407	412					6	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	013GR	WOS:000309294400023	22955195				2021-06-18	
J	Gross, T; Schuepp, M; Attenberger, C; Pargger, H; Amsler, F				Gross, T.; Schueepp, M.; Attenberger, C.; Pargger, H.; Amsler, F.			Outcome in polytraumatized patients with and without brain injury	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							QUALITY-OF-LIFE; SF-36 HEALTH SURVEY; MULTIPLE TRAUMA; BASIC ISSUES; HEAD-INJURY; RECOMMENDATIONS; SCALE; SCORE; CARE; PREDICTORS	Background To investigate the long-term outcome in polytrauma victims with traumatic brain injury (TBI) and without traumatic brain injury (NTBI). Methods Cohort study based on prospectively collected data. Evaluation of functional outcome and quality of life at least 2 years (median 2.5) following trauma in 111 survivors [39.5?+/-?20.9 years; injury severity score (ISS) 27.9?+/-?8.2; TBI: n?=?45; NTBI: n?=?66] out of a total of 211 consecutive multiply-injured patients with an ISS >?16, all primarily admitted to the intensive care unit. Results Significantly fewer TBI patients lived independently compared with NTBI patients (71% vs. 95%; P?<?0.001). TBI patients showed a higher decrease in their capacity to work compared with NTBI patients (P?<?0.002). Both study groups experienced a significantly reduced long-term outcome in comparison with pre-injury level in all dimensions of the short form (SF)-36. Following stepwise logistic regression, the mental sum component of the SF-36 and the Nottingham Health Profile discriminated independently between TBI and NTBI patients (R 2?=?0.219; P?<?0.001). Conclusion More than 2 years after injury, polytraumatized patients with and without TBI suffer from a reduction in functional outcome and quality of life, but TBI patients are doing importantly worse. Any comparison of trauma patient cohorts should consider these differences between TBI and NTBI patients. Given their discriminatory potential, the sensitivity of self-reported measures needs further affirmation with neuropsychological assessments.	[Gross, T.] Kantonsspital, Dept Surg, Trauma Unit, CH-5001 Aarau, Switzerland; [Gross, T.; Schueepp, M.; Attenberger, C.; Amsler, F.] Univ Basel Hosp, Comp Assisted Radiol & Surg Switzerland CARCAS, Basel, Switzerland; [Schueepp, M.; Pargger, H.] Univ Basel Hosp, Dept Anesthesia & Intens Care Med, CH-4031 Basel, Switzerland; [Attenberger, C.] Klinikum Augsburg, Augsburg, Germany; [Amsler, F.] Http Www Amslerconsulting Ch, Basel, Switzerland	Gross, T (corresponding author), Kantonsspital, Dept Surg, Trauma Unit, Tellstr, CH-5001 Aarau, Switzerland.	thomas.gross@ksa.ch		Amsler, Felix/0000-0003-4259-7004	Scientific Foundation of the Swiss Accident Insurance Fund (SUVA); Voluntary Academic Society (FAG) Basel, Swiss Intervention; Swiss National Information Center for Accident Prevention (BFU)	This investigation was financially supported by the Scientific Foundation of the Swiss Accident Insurance Fund (SUVA), the Voluntary Academic Society (FAG) Basel, Swiss Intervention, and the Swiss National Information Center for Accident Prevention (BFU). There are no conflicts of interest, especially not with the organizations involved.	Arbabi S, 2004, J TRAUMA, V56, P1029, DOI 10.1097/01.TA.0000123036.20919.4B; Attenberger C, 2012, INJURY, V43, P1566, DOI 10.1016/j.injury.2011.01.002; Bouillon B, 2002, RESTOR NEUROL NEUROS, V20, P125; Bouillon B, 1998, LANGENBECK ARCH SURG, V383, P228, DOI 10.1007/s004230050123; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Brasel KJ, 2010, J TRAUMA, V68, P263, DOI 10.1097/TA.0b013e3181caa58f; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; BULLINGER M, 1995, SOC SCI MED, V41, P1359, DOI 10.1016/0277-9536(95)00115-N; Butcher N, 2009, INJURY, V40, pS12, DOI 10.1016/j.injury.2009.10.032; Committee on Trauma American College of Surgeons, 1997, ADV TRAUM LIF SUPP P; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; Dimopoulou I, 2004, AM J PHYS MED REHAB, V83, P171, DOI 10.1097/01.PHM.0000107497.77487.C1; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Fuglistaler-Montali I, 2009, WORLD J SURG, V33, P2477, DOI 10.1007/s00268-009-0193-1; Gennarelli T.A., 1990, ABBREVIATED INJURY S; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; Grote S, 2011, J NEUROTRAUM, V28, P527, DOI 10.1089/neu.2010.1433; Harris I, 2008, J TRAUMA, V64, P696; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Holtslag HR, 2007, J TRAUMA, V62, P919, DOI 10.1097/01.ta.0000224124.47646.62; HUNT SM, 1985, J ROY COLL GEN PRACT, V35, P185; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; JENNETT B, 1975, LANCET, V1, P480; Klein M, 2009, J TRAUMA, V67, P890; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Lefering R, 2008, J TRAUMA, V65, P1036, DOI 10.1097/TA.0b013e318184ee48; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Lehmann U, 1999, EUR J SURG, V165, P1116, DOI 10.1080/110241599750007603; Lippert-Gruner M, 2007, BRAIN INJURY, V21, P451, DOI 10.1080/02699050701343961; Livingston DH, 2009, J TRAUMA, V67, P341, DOI 10.1097/TA.0b013e3181a5cc34; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; MacKenzie EJ, 2006, J TRAUMA, V61, P688, DOI 10.1097/01.ta.0000195985.56153.68; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; Moore L, 2006, J TRAUMA, V61, P718, DOI 10.1097/01.ta.0000197906.28846.87; Neugebauer E, 2002, RESTOR NEUROL NEUROS, V20, P161; Neugebauer E, 2002, RESTOR NEUROL NEUROS, V20, P87; Neugebauer E, 2006, EUROPEAN J TRAUMA, V32, P44, DOI [10.1007/s00068-006-0150-8, DOI 10.1007/S00068-006-0150-8]; Nichol AD, 2011, INJURY, V42, P281, DOI 10.1016/j.injury.2010.11.047; Orwelius L, 2011, INTENS CARE MED, V37, P831, DOI 10.1007/s00134-011-2137-0; Redmill DA, 2006, INJURY, V37, P243, DOI 10.1016/j.injury.2005.11.014; Ringdal M, 2009, J TRAUMA, V66, P1226, DOI 10.1097/TA.0b013e318181b8e3; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Sluys K, 2005, J TRAUMA, V59, P223, DOI 10.1097/01.TA.0000173832.01547.CB; Soberg HL, 2007, J TRAUMA, V62, P471, DOI 10.1097/TA.0b013e31802e95f4; Sumann Gunther, 2002, Curr Opin Crit Care, V8, P587, DOI 10.1097/00075198-200212000-00017; Szende A, 2004, MEASURING SELF REPOR; TEASDALE G, 1974, LANCET, V2, P81; THIAGARAJAN J, 1994, ANAESTHESIA, V49, P211; Ulvik A, 2008, ACTA ANAESTH SCAND, V52, P195, DOI 10.1111/j.1399-6576.2007.01533.x; Vaishnavi S, 2009, PSYCHOSOMATICS, V50, P198, DOI 10.1176/appi.psy.50.3.198; Van Beeck EF, 2007, J TRAUMA, V62, P534, DOI 10.1097/TA.0b013e31802e70c7; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1167, DOI 10.1089/neu.2009.1076; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wilde EA, 2010, J NEUROTRAUM, V27, P975, DOI 10.1089/neu.2009.1193	56	39	39	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	OCT	2012	56	9					1163	1174		10.1111/j.1399-6576.2012.02724.x			12	Anesthesiology	Anesthesiology	003TW	WOS:000308635200013	22735047				2021-06-18	
J	Sander, AM; Maestas, KL; Pappadis, MR; Sherer, M; Hammond, FM; Hanks, R				Sander, Angelle M.; Maestas, Kacey Little; Pappadis, Monique R.; Sherer, Mark; Hammond, Flora M.; Hanks, Robin		Traumatic Brain Injury Model Syst	Sexual Functioning 1 Year After Traumatic Brain Injury: Findings From a Prospective Traumatic Brain Injury Model Systems Collaborative Study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Rehabilitation	HEAD-INJURY; ADENOCARCINOMA; PRETREATMENT; BEHAVIOR; IMPACT	Sander AM, Maestas KL, Pappadis MR, Sherer M, Hammond FM, Hanks R, and the NIDRR Traumatic Brain Injury Model Systems Module Project on Sexuality After TBI. Sexual functioning 1 year after traumatic brain injury: findings from a prospective Traumatic Brain Injury Model Systems collaborative study. Arch Phys Med Rehabil 2012;93:1331-7. Objective: To investigate the incidence and types of sexual difficulties in men and women with traumatic brain injury (TBI) 1 year after injury, as well as their comfort level in discussing problems with health care professionals. Design: Prospective cohort study. Setting Community. Participants: Persons with TBI (N = 223; 165 men and 58 women) who had been treated at I of 6 participating TBI Model 5) stems inpatient rehabilitation units and were living in the community. Interventions: None. Main Outcome Measures: Derogatis Interview for Sexual Functioning-self-report (DISF-SR); Global Sexual Satisfaction Index (GSSI); structured interview regarding changes in sexual functioning; and comfort level discussing sexuality with health care professionals. Results: Women with TBI scored significantly below the normative; sample for all subscales of the DISF-SR, including sexual cognition/fantasy, arousal, sexual behavior/experience, and orgasm. Men scored significantly below the normative sample on all scales except arousal. Women reported greater dysfunction than men for sexual cognition/fantasy and arousal. Twenty-nine percent of participants reported dissatisfaction with sexual functioning on the GSSI, with a greater percentage of men reporting dissatisfaction. Sixty-eight percent of participants indicated that they would spontaneously raise issues of sexual difficulties with health care professionals, while the remainder would either bring it up only if directly asked or would not discuss it at all. Conclusions: Sexual difficulties were present in a substantial portion of community-dwelling people with TB! at 1 year after injury. Educational interventions to increase awareness among people with TBI and rehabilitation professionals are warranted, as well as interventions to improve sexual functioning.	[Sander, Angelle M.; Maestas, Kacey Little; Pappadis, Monique R.; Sherer, Mark] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX 77019 USA; [Sander, Angelle M.; Maestas, Kacey Little] Harris Cty Hosp Dist, Houston, TX USA; [Sander, Angelle M.; Maestas, Kacey Little; Sherer, Mark] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Pappadis, Monique R.] Univ Houston, Grad Coll Social Work, Houston, TX USA; [Hammond, Flora M.] Carolinas Rehabil, Charlotte, NC USA; [Hammond, Flora M.] Indiana Univ, Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN USA; [Hanks, Robin] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; [Hanks, Robin] Rehabil Inst Michigan, Detroit, MI USA	Sander, AM (corresponding author), TIRR Mem Hermann, Brain Injury Res Ctr, 2323 S Shepherd Dr,Ste 907, Houston, TX 77019 USA.	asander@bcm.edu	Pappadis, Monique/Q-8639-2016	Pappadis, Monique/0000-0003-4742-4380	National Institute on Disability and Rehabilitation Research, U.S. Department of EducationUS Department of Education [H133B090023, H133A070043, H133A080014, H133P080007]	Supported in part by the National Institute on Disability and Rehabilitation Research, U.S. Department of Education (grant nos. H133B090023, H133A070043, H133A080014, and H133P080007).	Aloni A, 2003, SEXUAL DIFFICULTIES; Aloni R, 1999, BRAIN INJURY, V13, P269, DOI 10.1080/026990599121647; Blackerby WF, 1990, J HEAD TRAUMA REHAB, V5, P73; Derogatis L, 1987, DEROGATIS INTERVIEW; Derogatis L. R., 1975, DEROGATIS SEXUAL FUN; Derogatis LR, 1997, J SEX MARITAL THER, V23, P291; Garden F. H., 1990, J HEAD TRAUMA REHAB, V5, P52, DOI DOI 10.1097/00001199-199005020-00009; Gervasio AH, 1999, SEXUALITY SEXUAL DYS; Gill CJ, 2011, J HEAD TRAUMA REHAB, V26, P56, DOI 10.1097/HTR.0b013e3182048ee9; Hibbard MR, 2000, NEUROREHABILITATION, V15, P109; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; Kreuter M, 1998, BRAIN INJURY, V12, P349, DOI 10.1080/026990598122494; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; Nicolosi A, 2006, J SEX MARITAL THER, V32, P331, DOI 10.1080/00926230600666469; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Pistoia F, 2006, PHARMACOL RES, V54, P11, DOI 10.1016/j.phrs.2006.01.010; Ponsford J, 2003, NEUROPSYCHOL REHABIL, V13, P275, DOI 10.1080/09602010244000363; Rankin TM, 1999, NIH CONS DEV C REH P; Ripley DL, 2008, ARCH PHYS MED REHAB, V89, P1090, DOI 10.1016/j.apmr.2007.10.038; SABHESAN S, 1989, ARCH SEX BEHAV, V18, P349, DOI 10.1007/BF01541953; Sandel ME, 1996, BRAIN INJURY, V10, P719, DOI 10.1080/026990596123981; Sandel ME, 2007, SEXUALITY REPROD NEU; Strauss D, 1991, SEX DISABIL, V9, P49; Wood RL, 2005, BRAIN INJURY, V19, P845, DOI 10.1080/02699050500058778; Zasler ND, 1995, STATE ART REV PHYSIC, P361; ZINREICH ES, 1990, INT J RADIAT ONCOL, V19, P729, DOI 10.1016/0360-3016(90)90503-C; ZINREICH ES, 1990, INT J RADIAT ONCOL, V19, P1001, DOI 10.1016/0360-3016(90)90025-F	27	39	40	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2012	93	8					1331	1337		10.1016/j.apmr.2012.03.037			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	983XJ	WOS:000307151700006	22840831				2021-06-18	
J	Bouvier, D; Fournier, M; Dauphin, JB; Amat, F; Ughetto, S; Labbe, A; Sapin, V				Bouvier, Damien; Fournier, Mathilde; Dauphin, Jean-Benoit; Amat, Flore; Ughetto, Sylvie; Labbe, Andre; Sapin, Vincent			Serum S100B Determination in the Management of Pediatric Mild Traumatic Brain Injury	CLINICAL CHEMISTRY			English	Article							MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; CHILDREN; PROTEIN; MULTICENTER; FAMILY; ADULTS	BACKGROUND: The place of serum S100B measurement in mild traumatic brain injury (mTBI) management is still controversial. Our prospective study aimed to evaluate its utility in the largest child cohort described to date. METHODS: Children younger than 16 years presenting at a pediatric emergency department within 3 h after TBI were enrolled prospectively for blood sampling to determine serum S100B concentrations. The following information was collected: TBI severity determined by using the Masters classification [1: minimal or Glasgow Coma Scale (GCS) 15, 2: mild or GCS 13-15, and 3: severe or GCS <13]; whether hospitalized or not; good or bad clinical evolution (CE); whether cranial computed tomography (CCT) was prescribed; and related presence (CCT+) or absence (CCT-) of lesions. RESULTS: For the 446 children enrolled, the median concentrations of S100B were 0.21, 0.31, and 0.44 mu g/L in Masters groups 1, 2, and 3, respectively, with a statistically significant difference between these groups (P < 0.05). In Masters group 2, 65 CCT scans were carried out. Measurement of S100B identified patients as CCT+ with 100% (95% CI 85-100) sensitivity and 33% (95% CI 20-50) specificity. Of the 424 children scored Masters 1 or 2, 21 presented "bad CE." S100B identified bad CE patients with 100% (95% CI 84-100) sensitivity and 36% (95% CI 31-41) specificity. Of the 242 children hospitalized, 81 presented an S100B concentration within the reference interval. CONCLUSIONS: Serum S100B determination during the first 3 h of management of children with mTBI has the potential to reduce the number of CCT scans, thereby avoiding unnecessary irradiation, and to save hospitalization costs. (c) 2012 American Association for Clinical Chemistry	[Bouvier, Damien; Fournier, Mathilde; Sapin, Vincent] Clermont Ferrand Teaching Hosp, Dept Biochem, Clermont Ferrand, France; [Dauphin, Jean-Benoit; Amat, Flore; Labbe, Andre] Clermont Ferrand Teaching Hosp, Dept Paediat Emergency, Clermont Ferrand, France; [Ughetto, Sylvie] Clermont Ferrand Teaching Hosp, Dept Med Informat, Clermont Ferrand, France	Sapin, V (corresponding author), CHU Gabriel Montpied, Ctr Biol, Lab Biochim Med, Rue Montalembert, F-63000 Clermont Ferrand, France.	vsapin@chu-clermontferrand.fr		Bouvier, Damien/0000-0002-2707-4320			Alber B, 2005, CLIN CHEM LAB MED, V43, P557, DOI 10.1515/CCLM.2005.097; Astrand R, 2011, CLIN CHIM ACTA, V412, P2190, DOI 10.1016/j.cca.2011.08.009; Bechtel K, 2009, PEDIATRICS, V124, pE697, DOI 10.1542/peds.2008-1493; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Bergman DA, 1999, PEDIATRICS, V104, P1407; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Bouvier D, 2009, ANN BIOL CLIN-PARIS, V67, P425, DOI 10.1684/abc.2009.0347; Bouvier D, 2011, CLIN BIOCHEM, V44, P927, DOI 10.1016/j.clinbiochem.2011.05.004; Castellani C, 2009, ACTA PAEDIATR, V98, P1607, DOI 10.1111/j.1651-2227.2009.01423.x; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Filippidis AS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.8.FOCUS10185; Floret D, 2006, ARCH PEDIATRIE, V13, P528, DOI 10.1016/j.arcped.2006.03.017; Hall EJ, 2009, PEDIATR RADIOL, V39, pS57, DOI 10.1007/s00247-008-1027-2; Hallen M, 2010, J TRAUMA, V69, P284, DOI 10.1097/TA.0b013e3181ca060b; Homer CJ, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e78; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; TEPAS JJ, 1990, J PEDIATR SURG, V25, P92, DOI 10.1016/S0022-3468(05)80170-8; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	25	39	40	0	7	AMER ASSOC CLINICAL CHEMISTRY	WASHINGTON	2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA	0009-9147	1530-8561		CLIN CHEM	Clin. Chem.	JUL	2012	58	7					1116	1122		10.1373/clinchem.2011.180828			7	Medical Laboratory Technology	Medical Laboratory Technology	970AA	WOS:000306099300011	22529109	Bronze			2021-06-18	
J	Busch, DJ; Morgan, JR				Busch, David J.; Morgan, Jennifer R.			Synuclein accumulation is associated with cell-specific neuronal death after spinal cord injury	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						axotomy; Fluoro-Jade; C; lamprey; Nissl; Parkinson's disease; reticulospinal; ubiquitin	AXOTOMIZED RUBROSPINAL NEURONS; TRAUMATIC BRAIN-INJURY; HUMAN ALPHA-SYNUCLEIN; FLUORO-JADE-C; PARKINSONS-DISEASE; RETICULOSPINAL NEURONS; NEUROFILAMENT EXPRESSION; NERVOUS-SYSTEM; MOTOR-NEURONS; LAMPREY BRAIN	Spinal cord injury axotomizes neurons and induces many of them to die, whereas others survive. Therefore, it is important to identify factors that lead to neuronal death after injury as a first step toward developing better strategies for increasing neuronal survival and functional recovery. However, the intrinsic molecular pathways that govern whether an injured neuron lives or dies remain surprisingly unclear. To address this question, we took advantage of the large size of giant reticulospinal (RS) neurons in the brain of the lamprey, Petromyzon marinus. We report that axotomy of giant RS neurons induces a select subset of them to accumulate high levels of synuclein, a synaptic vesicle-associated protein whose abnormal accumulation is linked to Parkinson's disease. Injury-induced synuclein accumulation occurred only in neurons that were classified as poor survivors by both histological and Fluoro-Jade C staining. In contrast, post-injury synuclein immunofluorescence remained at control levels in neurons that were identified as good survivors. Synuclein accumulation appeared in the form of aggregated intracellular inclusions. Cells that accumulated synuclein also exhibited more ubiquitin-containing inclusions, similar to what occurs during disease states. When synuclein levels and cell vitality were measured in the same neurons, it became clear that synuclein accumulation preceded and strongly correlated with subsequent neuronal death. Thus, synuclein accumulation is identified as a marker and potential risk factor for forthcoming neuronal death after axotomy, expanding its implications beyond the neurodegenerative diseases. J. Comp. Neurol. 520:17511771, 2012. (C) 2011 Wiley Periodicals, Inc.	[Busch, David J.; Morgan, Jennifer R.] Univ Texas Austin, Sect Mol Cell & Dev Biol, Inst Cell & Mol Biol, Inst Neurosci, Austin, TX 78712 USA	Morgan, JR (corresponding author), Univ Texas Austin, Sect Mol Cell & Dev Biol, Inst Cell & Mol Biol, Inst Neurosci, 2401 Speedway, Austin, TX 78712 USA.	jmorgan@mail.utexas.edu			Morton Cure Paralysis Fund; University of Texas at Austin; Dorothea Bennett graduate fellowship	Grant sponsor: Morton Cure Paralysis Fund; and The University of Texas at Austin start-up funds (to J.R.M.), and a Dorothea Bennett graduate fellowship (to D.J.B.).	Alexander JK, 2009, PROG BRAIN RES, V175, P125, DOI 10.1016/S0079-6123(09)17508-8; Bellei B, 2010, J BIOL CHEM, V285, P7288, DOI 10.1074/jbc.M109.070573; Bloom O, 2003, J CELL BIOL, V161, P737, DOI 10.1083/jcb.200212140; Bloom OE, 2011, MOL CELL NEUROSCI, V48, P339, DOI 10.1016/j.mcn.2011.04.003; BUCHANAN JT, 1982, J NEUROPHYSIOL, V47, P948; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; Burre J, 2010, SCIENCE, V329, P1663, DOI 10.1126/science.1195227; Chandra S, 2005, CELL, V123, P383, DOI 10.1016/j.cell.2005.09.028; Chu YP, 2009, NEUROBIOL DIS, V35, P385, DOI 10.1016/j.nbd.2009.05.023; Cole NB, 2002, J BIOL CHEM, V277, P6344, DOI 10.1074/jbc.M108414200; Cookson MR, 2008, EXP NEUROL, V209, P5, DOI 10.1016/j.expneurol.2007.05.022; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Dawson TM, 2010, NEURON, V66, P646, DOI 10.1016/j.neuron.2010.04.034; Deliagina TG, 2000, J NEUROPHYSIOL, V83, P853; Desplats P, 2009, P NATL ACAD SCI USA, V106, P13010, DOI 10.1073/pnas.0903691106; Di Giovanni S, 2009, EXPERT OPIN THER TAR, V13, P1387, DOI 10.1517/14728220903307517; Dubuc R, 2008, BRAIN RES REV, V57, P172, DOI 10.1016/j.brainresrev.2007.07.016; Ehara A, 2009, ACTA HISTOCHEM CYTOC, V42, P171, DOI 10.1267/ahc.09018; Emmanouilidou E, 2010, J NEUROSCI, V30, P6838, DOI 10.1523/JNEUROSCI.5699-09.2010; Flann S, 1997, NEUROSCIENCE, V81, P173, DOI 10.1016/S0306-4522(97)00196-6; Gai WP, 2000, EXP NEUROL, V166, P324, DOI 10.1006/exnr.2000.7527; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Greten-Harrison B, 2010, P NATL ACAD SCI USA, V107, P19573, DOI 10.1073/pnas.1005005107; Gupta A, 2008, ANN NEUROL, V64, pS3, DOI 10.1002/ana.21573; Hains BC, 2003, J COMP NEUROL, V462, P328, DOI 10.1002/cne.10733; Houle JD, 1999, NEUROSCIENCE, V94, P929, DOI 10.1016/S0306-4522(99)00359-0; Hutson CB, 2011, J NEUROTRAUM, V28, P1783, DOI 10.1089/neu.2010.1723; Jacobs AJ, 1997, J NEUROSCI, V17, P5206; Kahle PJ, 2001, AM J PATHOL, V159, P2215, DOI 10.1016/S0002-9440(10)63072-6; KASICKI S, 1986, NEUROSCI LETT, V69, P239, DOI 10.1016/0304-3940(86)90486-6; Kwon BK, 2002, P NATL ACAD SCI USA, V99, P3246, DOI 10.1073/pnas.052308899; Larsen KE, 2006, J NEUROSCI, V26, P11915, DOI 10.1523/JNEUROSCI.3821-06.2006; Lau BYB, 2011, EXP NEUROL, V228, P283, DOI 10.1016/j.expneurol.2011.02.003; Lee BH, 2004, BRAIN RES, V1020, P37, DOI 10.1016/j.brainres.2004.05.113; Lee HJ, 2005, J NEUROSCI, V25, P6016, DOI 10.1523/JNEUROSCI.0692-05.2005; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Lee VMY, 2006, NEURON, V52, P33, DOI 10.1016/j.neuron.2006.09.026; Lin X, 2009, NEURON, V64, P807, DOI 10.1016/j.neuron.2009.11.006; Lu P, 2008, EXP NEUROL, V209, P313, DOI 10.1016/j.expneurol.2007.08.004; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; Matz Mikhail V, 2003, Methods Mol Biol, V221, P41; Matz Mikhail V, 2002, Methods Mol Biol, V183, P3; Morgan JR, 2004, J CELL BIOL, V167, P43, DOI 10.1083/jcb.200406020; Mori F, 1997, EXP NEUROL, V143, P45, DOI 10.1006/exnr.1996.6318; Mosharov EV, 2009, NEURON, V62, P218, DOI 10.1016/j.neuron.2009.01.033; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Nemani VM, 2010, NEURON, V65, P66, DOI 10.1016/j.neuron.2009.12.023; Nielson JL, 2010, J NEUROSCI, V30, P11516, DOI 10.1523/JNEUROSCI.1433-10.2010; Novikova LN, 2000, EUR J NEUROSCI, V12, P776, DOI 10.1046/j.1460-9568.2000.00978.x; Oliphint PA, 2010, J COMP NEUROL, V518, P2854, DOI 10.1002/cne.22368; Ono F, 2004, J NEUROSCI, V24, P5475, DOI 10.1523/JNEUROSCI.0851-04.2004; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; Pfefferkorn CM, 2011, BIOCH BIOPHYS ACTA; Pijak DS, 1996, J COMP NEUROL, V368, P569; ROVAINEN CM, 1967, J NEUROPHYSIOL, V30, P1000; Ruff RL, 2008, ANN NY ACAD SCI, V1142, P1, DOI 10.1196/annals.1444.004; Sakurai M, 2009, J CEREBR BLOOD F MET, V29, P752, DOI 10.1038/jcbfm.2008.167; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; SELZER ME, 1979, BRAIN RES, V163, P181, DOI 10.1016/0006-8993(79)90348-2; Shifman MI, 2008, J COMP NEUROL, V510, P269, DOI 10.1002/cne.21789; Shifman MI, 2000, NEUROREHAB NEURAL RE, V14, P49, DOI 10.1177/154596830001400106; Shifman MI, 2009, EXP NEUROL, V217, P242, DOI 10.1016/j.expneurol.2009.02.011; Smith J, 2011, BIOL BULL-US, V221, P18, DOI 10.1086/BBLv221n1p18; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Su E, 2010, DEV NEUROSCI-BASEL, V32, P385, DOI 10.1159/000321342; Sun F, 2010, CURR OPIN NEUROBIOL, V20, P510, DOI 10.1016/j.conb.2010.03.013; Sun ZH, 2008, DEV DYNAM, V237, P2490, DOI 10.1002/dvdy.21569; Surguchov A, 2008, INT REV CEL MOL BIO, V270, P225, DOI 10.1016/S1937-6448(08)01406-8; SWAIN GP, 1994, EXP NEUROL, V126, P256, DOI 10.1006/exnr.1994.1063; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; von Coelln R, 2006, J NEUROSCI, V26, P3685, DOI 10.1523/JNEUROSCI.0414-06.2006; Yamaguchi Y, 2010, J MOL BIOL, V395, P445, DOI 10.1016/j.jmb.2009.10.068; Yasuda T, 2010, APOPTOSIS, V15, P1312, DOI 10.1007/s10495-010-0486-8; Yoshida H, 2006, BIOCHEMISTRY-US, V45, P2599, DOI 10.1021/bi051993m; Zimprich A, 2004, NEURON, V44, P601, DOI 10.1016/j.neuron.2004.11.005	76	39	39	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9967	1096-9861		J COMP NEUROL	J. Comp. Neurol.	JUN 1	2012	520	8					1751	1771		10.1002/cne.23011			21	Neurosciences; Zoology	Neurosciences & Neurology; Zoology	918FU	WOS:000302235500010	22120153				2021-06-18	
J	Chen, T; Cao, L; Dong, WP; Luo, P; Liu, WB; Qu, Y; Fei, Z				Chen, Tao; Cao, Lei; Dong, WenPeng; Luo, Peng; Liu, WenBo; Qu, Yan; Fei, Zhou			Protective Effects of mGluR5 Positive Modulators Against Traumatic Neuronal Injury Through PKC-Dependent Activation of MEK/ERK Pathway	NEUROCHEMICAL RESEARCH			English	Article						Neuroprotective effect; Traumatic brain injury; ERK; PKC	METABOTROPIC GLUTAMATE RECEPTORS; PROTEIN-KINASE-C; BRAIN-INJURY; IN-VITRO; CORTICAL-NEURONS; ANTAGONISTS MPEP; MAP KINASES; CELLS; RAT; PHARMACOLOGY	Several previous studies utilizing selective pharmacological antagonists have demonstrated that type 5 metabotropic glutamate receptors (mGluR5) are potential therapeutic targets for the treatment of numerous disorders of the central nervous system, but the role of mGluR5 activation in traumatic brain injury (TBI) is not fully understood. Here in an in vitro TBI model, the mGluR5 agonist (RS)-2-chloro-5- hydroxyphenylglycine (CHPG) and the positive allosteric modulators 3-cyano-N-(1,3- diphenyl-1H-pyrazol-5-yl) benzamide (CDPPB) were used to investigate the neuroprotective potency of mGluR5 activation. Data showed that CHPG and CDPPB suppressed the increase of LDH release and caspase-3 activation induced by traumatic neuronal injury in a dose-dependent manner, and the salutary effects were also present when these compounds were added 1 h after injury. Western blot was used to examine the activation of three members of mitogen-activated protein kinases: extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 kinase (p38). CHPG and CDPPB enhanced the activation of ERK after traumatic neuronal injury, and PD98059 and U0126, two selective MEK/ERK inhibitors, partly revised the protective effects. Furthermore, we also investigated the role of protein kinase C (PKC) in CHPG and CDPPB-induced neuroprotection. With the pretreatment of chelerythrine chloride, a PKC inhibitor, the surpressing effects of CHPG and CDPPB on traumatic injury-evoked LDH release and caspase-3 activation were blocked. All of these findings extended the protective role of mGluR5 activation in an in vitro model of TBI and suggested that these protective effects might be mediated by the PKC-dependent activation of MEK/ERK pathway. These results may have important implications for the development of mGluR5 modulators to treat TBI.	[Chen, Tao; Luo, Peng; Liu, WenBo; Qu, Yan; Fei, Zhou] Fourth Mil Med Univ, Xijing Hosp, Xijing Inst Clin Neurosci, Dept Neurosurg, Xian 710032, Shaanxi, Peoples R China; [Cao, Lei] Xi An Jiao Tong Univ, Xian Cent Hosp, Dept Neurol Dis, Xian 710032, Shaanxi, Peoples R China; [Dong, WenPeng] Guangzhou Mil Command, Guangzhou Gen Hosp, Dept Cardiovasc Surg, Guangzhou 510010, Guangdong, Peoples R China	Fei, Z (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Xijing Inst Clin Neurosci, Dept Neurosurg, Xian 710032, Shaanxi, Peoples R China.	zhoufei@fmmu.edu.cn		Luo, Peng/0000-0003-0746-939X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30930093]	This work was financially supported by the National Natural Science Foundation of China (No. 30930093).	Bhave G, 2004, J NEUROBIOL, V61, P88, DOI 10.1002/neu.20083; Bright R, 2005, STROKE, V36, P2781, DOI 10.1161/01.STR.0000189996.71237.f7; Bruno V, 2001, J CEREBR BLOOD F MET, V21, P1013, DOI 10.1097/00004647-200109000-00001; Chen T, 2011, NEUROSCIENCE, V183, P203, DOI 10.1016/j.neuroscience.2011.03.038; Chen T, 2011, BRAIN RES BULL, V84, P163, DOI 10.1016/j.brainresbull.2010.11.015; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; D'Antoni S, 2008, NEUROCHEM RES, V33, P2436, DOI 10.1007/s11064-008-9694-9; Davis A E, 2000, Crit Care Nurs Clin North Am, V12, P447; De Blasi A, 2001, TRENDS PHARMACOL SCI, V22, P114, DOI 10.1016/S0165-6147(00)01635-7; Doherty AJ, 1997, NEUROPHARMACOLOGY, V36, P265, DOI 10.1016/S0028-3908(97)00001-4; Faden AI, 2001, EXP NEUROL, V167, P435, DOI 10.1006/exnr.2000.7577; Fei Z, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-96; Fei Z, 2006, J CLIN NEUROSCI, V13, P1023, DOI 10.1016/j.jocn.2005.11.042; Flor PJ, 2002, ADV EXP MED BIOL, V513, P197; Gold MS, 2005, NEUROSIGNALS, V14, P147, DOI 10.1159/000087653; Huang TT, 2009, J NEUROTRAUM, V26, P1535, DOI [10.1089/neu.2008.0743, 10.1089/neu.2008-0743]; Huang WD, 2005, NEUROSCI LETT, V389, P46, DOI 10.1016/j.neulet.2005.07.014; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Kew JNC, 2005, PSYCHOPHARMACOLOGY, V179, P4, DOI 10.1007/s00213-005-2200-z; Kim EK, 2010, BBA-MOL BASIS DIS, V1802, P396, DOI 10.1016/j.bbadis.2009.12.009; Liu F, 2005, J NEUROCHEM, V95, P1363, DOI 10.1111/j.1471-4159.2005.03474.x; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Morin N, 2010, NEUROPHARMACOLOGY, V58, P981, DOI 10.1016/j.neuropharm.2009.12.024; Movsesyan VA, 2004, J NEUROCHEM, V89, P1528, DOI 10.1111/j.1471-4159.2004.02451.x; Movsesyan VA, 2001, J PHARMACOL EXP THER, V296, P41; Nicoletti F, 1996, TRENDS NEUROSCI, V19, P267, DOI 10.1016/S0166-2236(96)20019-0; NISHIZUKA Y, 1995, FASEB J, V9, P484; O'Leary DM, 2000, BRIT J PHARMACOL, V131, P1429, DOI 10.1038/sj.bjp.0703715; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Parmentier-Batteur S, 2012, NEUROPHARMACOLOGY, V62, P1453, DOI 10.1016/j.neuropharm.2010.11.013; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Redmond L, 2002, NEURON, V34, P999, DOI 10.1016/S0896-6273(02)00737-7; Sugano T, 2006, J NEUROCHEM, V98, P20, DOI 10.1111/j.1471-4159.2006.03846.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44	36	39	40	1	6	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	MAY	2012	37	5					983	990		10.1007/s11064-011-0691-z			8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	920LC	WOS:000302404900010	22228200				2021-06-18	
J	Kasahara, K; Hashimoto, K; Abo, M; Senoo, A				Kasahara, Kazumi; Hashimoto, Keiji; Abo, Masahiro; Senoo, Atsushi			Voxel- and atlas-based analysis of diffusion tensor imaging may reveal focal axonal injuries in mild traumatic brain injury - comparison with diffuse axonal injury	MAGNETIC RESONANCE IMAGING			English	Article						Mild traumatic brain injury; Diffusion tensor imaging; Voxel-based analysis; Atlas-based analysis; Focal axonal injury; DARTEL	WHITE-MATTER INJURY; HEAD-INJURY; POSTCONCUSSION SYNDROME; EXECUTIVE DYSFUNCTION; CORPUS-CALLOSUM; MODERATE; ABNORMALITIES; DEGENERATION; IMPAIRMENT; INTEGRITY	Background: The diagnosis and management of mild traumatic brain injury (MTBI) continue to be subjects of debate, with varying opinions regarding the extent to which tissue-based impairments versus the impacts of other stressors cause ongoing disability. Detecting areas of the brain with abnormalities that can explain symptoms and behavior in patients with MTBI is important in order to confirm the diagnosis of MTBI. Methods: In this study, we calculated diffusion maps from results of diffusion tensor imaging (DTI) performed in an apparently healthy control group. We then compared these maps with those of patients with MTBI (MTBI group) or diffuse axonal injury (DAI group). All diffusion maps were normalized to the International Consortium for Brain Mapping atlas for atlas-based analysis and were segmented and normalized by the Diffeomorphic Anatomical Registration Through Exponentiated Lie tool in SPM8 to reduce misregistration. Results: All diffusion measures in the DAI group were lower than in the control group. There were significant differences in the body and splenium of the corpus callosum, fornix and right cerebral peduncle in the DAI group compared with the control group (P<.001). The MTBI group had higher axial diffusivity than the control group in the right corticospinal tract, left medial lemniscus, left inferior cerebellar peduncle, bilateral anterior limb of the internal capsule, right anterior corona radiata, bilateral cingulum (cingulate gyrus) and left superior frontooccipital fasciculus (P<.05). Conclusions: Voxel- and atlas-based analysis of DTI might suggest that patients with MTBI have focal axonal injury and that the pathophysiology is significantly different from that of DAI. These findings will help in the diagnosis of patients with MTBI. (C) 2012 Elsevier Inc. All rights reserved.	[Kasahara, Kazumi; Senoo, Atsushi] Tokyo Metropolitan Univ, Grad Sch Human Hlth Sci, Dept Radiol Sci, Tokyo 1168551, Japan; [Kasahara, Kazumi] Japan Soc Promot Sci, Saitama, Japan; [Hashimoto, Keiji; Abo, Masahiro] Jikei Univ, Sch Med, Dept Rehabil Med, Tokyo, Japan; [Hashimoto, Keiji] Natl Ctr Child Hlth & Dev, Div Rehabil Med, Tokyo 1578535, Japan	Hashimoto, K (corresponding author), Natl Ctr Child Hlth & Dev, Div Rehabil, Tokyo 1578535, Japan.	hashimoto-k@ncchd.go.jp		Kasahara, Kazumi/0000-0002-1306-3989; Abo, Masahiro/0000-0001-6701-4974	Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [10J06361] Funding Source: KAKEN		Abe O, 2010, NEURORADIOLOGY, V52, P699, DOI 10.1007/s00234-010-0716-3; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Ashburner J, 2009, MAGN RESON IMAGING, V27, P1163, DOI 10.1016/j.mri.2009.01.006; Ashburner J, 2009, NEUROIMAGE, V45, P333, DOI 10.1016/j.neuroimage.2008.12.008; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Faria AV, 2010, NEUROIMAGE, V52, P415, DOI 10.1016/j.neuroimage.2010.04.238; Friston K, 1999, HUM BRAIN MAPP, V8, P92, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<92::AID-HBM4>3.0.CO;2-#; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Gong GL, 2005, HUM BRAIN MAPP, V24, P92, DOI 10.1002/hbm.20072; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Hashimoto K, 2007, J REHABIL MED, V39, P418, DOI 10.2340/16501977-0065; Hashimoto K, 2009, J REHABIL MED, V41, P661, DOI 10.2340/16501977-0388; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Kinuya K, 2004, NUCL MED COMMUN, V25, P333, DOI 10.1097/00006231-200404000-00004; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; MARMAROU A, 1992, J NEUROTRAUM, V9, pS327; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; MYSIW W J, 1990, Brain Injury, V4, P247, DOI 10.3109/02699059009026174; Nakamae T, 2011, J PSYCHIATR RES, V45, P687, DOI 10.1016/j.jpsychires.2010.09.016; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Oishi K, 2009, NEUROIMAGE, V46, P486, DOI 10.1016/j.neuroimage.2009.01.002; Okamoto T, 2007, EUR J NEUROL, V14, P540, DOI 10.1111/j.1468-1331.2007.01742.x; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rosenblum WI, 2007, J NEUROPATH EXP NEUR, V66, P771, DOI 10.1097/nen.0b013e3181461965; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Sotak CH, 2002, NMR BIOMED, V15, P561, DOI 10.1002/nbm.786; Sugiyama K, 2009, J NEUROTRAUM, V26, P1879, DOI [10.1089/neu.2008.0839, 10.1089/neu.2008-0839]; Sun SW, 2007, NEUROBIOL DIS, V28, P30, DOI 10.1016/j.nbd.2007.06.011; Zhang JY, 2009, J NEUROSCI, V29, P3160, DOI 10.1523/JNEUROSCI.3941-08.2009	54	39	39	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0730-725X			MAGN RESON IMAGING	Magn. Reson. Imaging	MAY	2012	30	4					496	505		10.1016/j.mri.2011.12.018			10	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	929ST	WOS:000303086700004	22285880				2021-06-18	
J	Yeh, DD; Schecter, WP				Yeh, Daniel Dante; Schecter, William P.			Primary Blast Injuries-An Updated Concise Review	WORLD JOURNAL OF SURGERY			English	Article							TRAUMATIC BRAIN-INJURY; TYMPANIC-MEMBRANE PERFORATION; LUNG INJURY; EXPLOSIVE BLAST; CIVILIAN BUS; SURVIVORS; MANAGEMENT; DIAGNOSIS; PATHOLOGY; BOMBINGS	Blast injuries have been increasing in the civilian setting and clinicians need to understand the spectrum of injury and management strategies. Multisystem trauma associated with combined blunt and penetrating injuries is the rule. Explosions in closed spaces increase the likelihood of primary blast injury. Rupture of tympanic membranes is an inaccurate marker for severe primary blast injury. Blast lung injury manifests early and should be managed with lung-protective ventilation. Blast brain injury is more common than previously appreciated.	[Yeh, Daniel Dante] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA 02114 USA; [Schecter, William P.] Univ Calif San Francisco, San Francisco Gen Hosp, Div Surg, San Francisco, CA 94143 USA	Yeh, DD (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, 165 Cambridge St 810, Boston, MA 02114 USA.	dyeh2@partners.org					Aharonson-Daniel L, 2003, PEDIATRICS, V112, pE280, DOI 10.1542/peds.112.4.e280; Almogy G, 2005, ARCH SURG-CHICAGO, V140, P390, DOI 10.1001/archsurg.140.4.390; American College of Surgeons. Committe on Trauma, 2008, ADV TRAUM LIF SUPP D; Argyros GJ, 1997, TOXICOLOGY, V121, P105, DOI 10.1016/S0300-483X(97)03659-7; Avidan V, 2005, AM J SURG, V190, P927, DOI 10.1016/j.amjsurg.2005.08.022; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bochicchio GV, 2008, AM SURGEON, V74, P267; Braverman I, 2002, ISRAEL MED ASSOC J, V4, P528; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Covey CDC, 2002, J BONE JOINT SURG AM, V84A, P1221, DOI 10.2106/00004623-200207000-00022; Eshkol Z, 2005, INJURY, V36, P271, DOI 10.1016/j.injury.2004.06.016; FRYKBERG ER, 1988, ANN SURG, V208, P569, DOI 10.1097/00000658-198811000-00005; Garner Jeff, 2007, Anesthesiol Clin, V25, P147; HADDEN WA, 1978, BRIT J SURG, V65, P525, DOI 10.1002/bjs.1800650802; Harrison CD, 2009, J TRAUMA, V67, P210, DOI 10.1097/TA.0b013e3181a5f1db; Hirshberg B, 1999, CHEST, V116, P1683, DOI 10.1378/chest.116.6.1683; Ho AMH, 2002, MED HYPOTHESES, V59, P611, DOI 10.1016/S0306-9877(02)00153-6; HULL JB, 1992, BRIT J SURG, V79, P1303, DOI 10.1002/bjs.1800791220; Irwin RJ, 1997, J TRAUMA, V43, P650, DOI 10.1097/00005373-199710000-00015; Kapur GB, 2005, J TRAUMA, V59, P1436, DOI 10.1097/01.ta.0000197853.49084.3c; KATZ E, 1989, ANN SURG, V209, P484, DOI 10.1097/00000658-198904000-00016; Krohn PL, 1942, LANCET, V1, P252; Leibovici D, 1999, ANN EMERG MED, V34, P168, DOI 10.1016/S0196-0644(99)70225-8; Leibovici D, 1996, J TRAUMA, V41, P1030, DOI 10.1097/00005373-199612000-00015; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; MELINEK M, 1976, ISRAEL J MED SCI, V12, P560; Phillips YR, 1991, TXB MILITARY MED 1, P235; Pizov R, 1999, CHEST, V115, P165, DOI 10.1378/chest.115.1.165; Ritenour AE, 2008, CRIT CARE MED, V36, pS311, DOI 10.1097/CCM.0b013e31817e2a8c; Ropper A, 2011, NEW ENGL J MED, V364, P2156, DOI 10.1056/NEJMe1102187; Sasser SM, 2006, PREHOSP EMERG CARE, V10, P165, DOI 10.1080/10903120500540912; Sorkine P, 1998, J TRAUMA, V45, P35, DOI 10.1097/00005373-199807000-00006; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tatic V, 1996, J TRAUMA, V40, pS94, DOI 10.1097/00005373-199603001-00022; Weiss YG, 1999, J CLIN ANESTH, V11, P132, DOI 10.1016/S0952-8180(99)00006-9; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071	38	39	47	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-2313	1432-2323		WORLD J SURG	World J.Surg.	MAY	2012	36	5					966	972		10.1007/s00268-012-1500-9			7	Surgery	Surgery	943BZ	WOS:000304096700006	22411082				2021-06-18	
J	Driver, S; Ede, A; Dodd, Z; Stevens, L; Warren, AM				Driver, Simon; Ede, Alison; Dodd, Zane; Stevens, Laurel; Warren, Anne Marie			What barriers to physical activity do individuals with a recent brain injury face?	DISABILITY AND HEALTH JOURNAL			English	Article						Rehabilitation; Physical activity; Health; Barriers; Intention	PEOPLE; EXERCISE; HEALTH; DISABILITIES; EXPERIENCE; AQUATICS; OUTCOMES; FITNESS; ACCESS; ADULTS	Background and Objective: Traumatic brain injury (TBI) is a serious public health issue that challenges professionals to develop effective health promotion strategies to meet individual's diverse and unique needs. One effective health promotion strategy is physical activity (PA), although barriers to activity frequently prevent participation. Thus, there is a need to identify the barriers to participation, amount of weekly PA completed, and readiness to be active if effective health promotion programs are to be implemented. Methods: A convenience sample of 28 outpatients with a TBI completed a questionnaire before discharge from a comprehensive outpatient program and descriptive statistics were reported. In addition independent t tests and effect sizes were calculated between amount of PA and stage of change. Results: Our results indicated that participants only faced an average of 2.25 barriers (range 0-9), completed a mean of 46 minutes of PA each week, and reported being in the "action" stage of PA participation. Individuals in the action and maintenance stage completed significantly more PA (21.67; t [25] = -15.43; p < .001; Cohen's D effect size = 4.39) than precontemplators or contemplators. Conclusions: Individuals with a TBI face many different barriers that prevent them from being active, placing them at further risk of experiencing secondary and chronic conditions. Practitioners should acknowledge that each individual faces a unique set of barriers emphasizing the importance of individualized health promotion programs. (C) 2012 Elsevier Inc. All rights reserved.	[Driver, Simon] Oregon State Univ, Sch Biol & Populat Hlth, Corvallis, OR 97331 USA; [Ede, Alison] Michigan State Univ, E Lansing, MI 48824 USA; [Dodd, Zane] Univ N Texas, Denton, TX 76203 USA; [Stevens, Laurel] Baylor Inst Rehabil, Dallas, TX 75204 USA; [Warren, Anne Marie] Baylor Med Ctr, Dallas, TX 75246 USA	Driver, S (corresponding author), Oregon State Univ, Sch Biol & Populat Hlth, 206 Womens Bldg, Corvallis, OR 97331 USA.	simon.driver@oregonstate.edu		driver, simon/0000-0003-2356-432X; Warren, Ann Marie/0000-0002-3753-5573			[Anonymous], 1998, NIH Consens Statement, V16, P1; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; COHEN J, 1990, AM PSYCHOL, V45, P1304, DOI 10.1037/0003-066X.45.12.1304; COHEN J, 1994, AM PSYCHOL, V49, P997, DOI 10.1037/0003-066X.49.12.997; Cohen J, 1988, STAT ANAL BEHAV SCI; Driver S, 2006, BRAIN INJURY, V20, P133, DOI 10.1080/02699050500443822; Driver S, 2004, BRAIN INJURY, V18, P847, DOI 10.1080/02699050410001671856; Driver S, 2003, J COGNITIVE REHABILI, V21, P26; DRIVER S, 2003, J PHYS ED RECREATION, V74, P41; Dunton GF, 2007, PSYCHOL HEALTH, V22, P929, DOI 10.1080/14768320601124915; Gemmell C, 2006, BRAIN INJURY, V20, P151, DOI 10.1080/02699050500442998; Glenn M, 2005, APATHY EVALUATION SC; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Heath G W, 1997, Exerc Sport Sci Rev, V25, P195; HELLER T, 2001, EXERCISE NUTR HLTH E; Jackson AW, 2007, RES Q EXERCISE SPORT, V78, P24; Kahn EB, 2002, AM J PREV MED, V22, P73, DOI 10.1016/S0749-3797(02)00434-8; Kirchner CE, 2008, AM J PREV MED, V34, P349, DOI 10.1016/j.amepre.2008.01.005; Kosma M, 2006, ADAPT PHYS ACT Q, V23, P49, DOI 10.1123/apaq.23.1.49; Lee YS, 2005, J WOMEN AGING, V17, P55, DOI 10.1300/J074v17n01_05; LOX CL, 2003, PSYCHOL EXERCISE INT; Malec JF., 2005, The Mayo-Portland Adaptability Inventory; MARCUS BH, 1992, RES Q EXERCISE SPORT, V63, P60, DOI 10.1080/02701367.1992.10607557; National Data and Statistical Center, 2010 TBIMS NAT DAT U; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; PROCHASKA JO, 1982, PSYCHOTHER-THEOR RES, V19, P276, DOI 10.1037/h0088437; Rimmer JH, 2008, J REHABIL RES DEV, V45, P315, DOI 10.1682/JRRD.2007.02.0042; Rimmer JH, 2008, AM J LIFESTYLE MED, V2, P409, DOI 10.1177/1559827608317397; Rimmer JH, 2005, AM J PUBLIC HEALTH, V95, P2022, DOI 10.2105/AJPH.2004.051870; Rimmer JH, 2000, ARCH PHYS MED REHAB, V81, P182; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sample PL, 1998, BRAIN INJURY, V12, P855, DOI 10.1080/026990598122089; Sherer M., 2004, The Awareness Questionnaire. The center for outcome measurement in brain injury; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Sorensen M, 2008, SCAND J MED SCI SPOR, V18, P651, DOI 10.1111/j.1600-0838.2007.00686.x; U.S. Department of Health and Human Services, 2005, 209911 NCJ US DEP JU, P1; US Department of Health and Human Services, 2000, HLTH PEOPL 2010 UND; US Department of Health and Human Services, 2001, SURG GEN CALL ACT PR; US Department of Health and Human Services Public Health Service Centers for Disease Control and Prevention National Center for Chronic Disease Prevention and Health Promotion Division of Nutrition and Physical Activity, 1999, PROM PHYS ACT GUID C; Vanderploeg RD, 2007, J REHABIL RES DEV, V44, P937, DOI 10.1682/JRRD.2006.12.0163; Whiteneck GG, 2004, J HEAD TRAUMA REHAB, V19, P191, DOI 10.1097/00001199-200405000-00001; Wolfson D., 1993, HALSTEAD REITAN NEUR; Ylvisaker M, 2003, J HEAD TRAUMA REHAB, V18, P7, DOI 10.1097/00001199-200301000-00005	44	39	39	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1936-6574	1876-7583		DISABIL HEALTH J	Disabil. Health J.	APR	2012	5	2					117	125		10.1016/j.dhjo.2011.11.002			9	Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation	Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation	913HT	WOS:000301868700007	22429546				2021-06-18	
J	Farrer, TJ; Frost, RB; Hedges, DW				Farrer, Thomas J.; Frost, R. Brock; Hedges, Dawson W.			Prevalence of Traumatic Brain Injury in Intimate Partner Violence Offenders Compared to the General Population: A Meta-Analysis	TRAUMA VIOLENCE & ABUSE			English	Article						traumatic brain injury; domestic violence; intimate partner violence	BLUNT HEAD-INJURY; DOMESTIC VIOLENCE; AGGRESSIVE-BEHAVIOR; ASSOCIATION; ADJUSTMENT; RELATIVES; SYMPTOMS; COUPLES; CRIME; ABUSE	Intimate partner violence (IPV) is widespread. Several risk factors are associated with IPV perpetuation, including alcohol use and educational level. The aggression and violence associated with traumatic brain injury (TBI) suggest that brain trauma may also be a risk factor for IPV. To examine the association between TBI and IPV, the authors conducted a meta-analysis of peer-reviewed published studies reporting the prevalence of TBI in IPV perpetrators. The authors compared the frequency of TBI among IPV perpetuators to estimates of TBI in the general population using a single-sample test of proportions. Six studies containing a total of 222 subjects met inclusion criteria. Fifty-three percent (119) of the IPV perpetuators had a history of TBI, a prevalence significantly higher (p < .0001) than estimates of TBI in the general population. The prevalence of TBI among perpetuators of IPV appears significantly higher than the prevalence of TBI in the general population. To the extent that this association is causal, TBI may be a risk factor for interpersonal violence, although comparatively few source studies, lack of standardized information about TBI severity, and the inability to investigate potential confounding variables necessarily limit this conclusion.	[Farrer, Thomas J.; Frost, R. Brock; Hedges, Dawson W.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Hedges, Dawson W.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA	Farrer, TJ (corresponding author), Brigham Young Univ, Dept Psychol, 1001 SWKT,POB 25543, Provo, UT 84602 USA.	thomasfarrer@yahoo.com		Farrer, Thomas J./0000-0001-8092-6214			Abramsky T, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-109; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Bezeau SC, 2004, BRAIN INJURY, V18, P299, DOI 10.1080/02699050310001617398; Blais MC, 2005, BRAIN INJURY, V19, P1223, DOI 10.1080/02699050500309387; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cohen R A, 1999, Violence Vict, V14, P397; Cohen RA, 2003, J INT NEUROPSYCH SOC, V9, P760, DOI 10.1017/S1355617703950090; Cole WR, 2008, BRAIN INJURY, V22, P932, DOI 10.1080/02699050802454808; Dyer KFW, 2006, BRAIN INJURY, V20, P1163, DOI 10.1080/02699050601049312; Ellison CG, 1999, J FAM ISSUES, V20, P87, DOI 10.1177/019251399020001005; Farrer TJ, 2011, PROG NEURO-PSYCHOPH, V35, P390, DOI 10.1016/j.pnpbp.2011.01.007; Felson RB, 2002, CRIMINOLOGY, V40, P617, DOI 10.1111/j.1745-9125.2002.tb00968.x; Foran HM, 2008, CLIN PSYCHOL REV, V28, P1222, DOI 10.1016/j.cpr.2008.05.001; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; Marsh NV, 2006, BRAIN INJURY, V20, P61, DOI 10.1080/02699050500110645; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MCCAULEY J, 1995, ANN INTERN MED, V123, P737, DOI 10.7326/0003-4819-123-10-199511150-00001; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Pinto LA, 2010, AGGRESS VIOLENT BEH, V15, P387, DOI 10.1016/j.avb.2010.07.001; Plichta SB, 2004, J INTERPERS VIOLENCE, V19, P1296, DOI 10.1177/0886260504269685; ROSENBAUM A, 1994, J CONSULT CLIN PSYCH, V62, P1187, DOI 10.1037/0022-006X.62.6.1187; ROSENBAUM A, 1989, AM J PSYCHIAT, V146, P1048; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; Schofield P, 2011, BRAIN INJURY, V25, P74, DOI 10.3109/02699052.2010.531690; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Stith SM, 2004, AGGRESS VIOLENT BEH, V10, P65, DOI 10.1016/j.avb.2003.09.001; STRAUS MA, 1986, J MARRIAGE FAM, V48, P465, DOI 10.2307/352033; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; TEMPLER DI, 1992, PERCEPT MOTOR SKILL, V75, P195, DOI 10.2466/PMS.75.4.195-202; Tjaden P.G., 2000, FULL REPORT PREVALEN; Turkstra L, 2003, BRAIN INJURY, V17, P39, DOI 10.1080/0269905021000010122	37	39	39	0	27	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1524-8380	1552-8324		TRAUMA VIOLENCE ABUS	Trauma Violence Abus.	APR	2012	13	2					77	82		10.1177/1524838012440338			6	Criminology & Penology; Family Studies; Social Work	Criminology & Penology; Family Studies; Social Work	951DW	WOS:000304702000002	22467643				2021-06-18	
J	McCranor, BJ; Bozym, RA; Vitolo, MI; Fierke, CA; Bambrick, L; Polster, BM; Fiskum, G; Thompson, RB				McCranor, Bryan J.; Bozym, Rebecca A.; Vitolo, Michele I.; Fierke, Carol A.; Bambrick, Linda; Polster, Brian M.; Fiskum, Gary; Thompson, Richard B.			Quantitative imaging of mitochondrial and cytosolic free zinc levels in an in vitro model of ischemia/reperfusion	JOURNAL OF BIOENERGETICS AND BIOMEMBRANES			English	Article						Zinc; Oxidative stress; Mitochondria; Ischemia; Stroke; Fluorescence biosensor; Ratiometric; Carbonic anhydrase II	CARBONIC-ANHYDRASE; INTRACELLULAR ZINC; CELL-DEATH; ISCHEMIA; APOPTOSIS; OXYGEN; ZN2+; HIPPOCAMPUS; ION; NEURODEGENERATION	The role of zinc ion in cytotoxicity following ischemic stroke, prolonged status epilepticus, and traumatic brain injury remains controversial, but likely is the result of mitochondrial dysfunction. We describe an excitation ratiometric fluorescence biosensor based on human carbonic anhydrase II variants expressed in the mitochondrial matrix, permitting free zinc levels to be quantitatively imaged therein. We observed an average mitochondrial matrix free zinc concentration of 0.2 pM in the PC12 rat pheochromacytoma cell culture line. Cytoplasmic and mitochondrial free zinc levels were imaged in a cellular oxygen glucose deprivation (OGD) model of ischemia/reperfusion. We observed a significant increase in mitochondrial zinc 1 h following 3 h OGD, at a time point when cytosolic zinc levels were depressed. Following the increase, mitochondrial zinc levels returned to physiological levels, while cytosolic zinc increased gradually over a 24 h time period in viable cells. The increase in intramitochondrial zinc observed during reoxygenation after OGD may contribute to bioenergetic dysfunction and cell death that occurs with both in vitro and in vivo models of reperfusion.	[McCranor, Bryan J.; Bozym, Rebecca A.; Vitolo, Michele I.; Thompson, Richard B.] Univ Maryland Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; [Vitolo, Michele I.] Univ Maryland, Univ Maryland Marlene & Stewart Greenebaum NIH Ca, Baltimore, MD 21201 USA; [Fierke, Carol A.] Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; [Bambrick, Linda; Polster, Brian M.; Fiskum, Gary] Univ Maryland Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Bambrick, Linda; Polster, Brian M.; Fiskum, Gary] Univ Maryland Sch Med, Ctr Shock Trauma & Anesthesiol Res, Baltimore, MD 21201 USA	Thompson, RB (corresponding author), Univ Maryland Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.	rthompso@umaryland.edu		Polster, Brian/0000-0003-2571-7510; McCranor, Bryan/0000-0002-1573-5793; Vitolo, Michele/0000-0001-8055-9645	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIBIB RO1 EB03924, NINDS RO1 NS064978]; Susan G. Komen Breast Cancer FoundationSusan G. Komen Breast Cancer Foundation [PDF 0601045]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD016596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB003924] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS064978] Funding Source: NIH RePORTER	The authors gratefully acknowledge the National Institutes of Health (NIBIB RO1 EB03924 (R. B. T., B.J.M., R. A. B., C. A. F.); PO1 HD16596-25 (G. F., L. H.); NINDS RO1 NS064978 (B. M. P.) and the Susan G. Komen Breast Cancer Foundation (PDF 0601045 (M. I. V.) for their support. The fluorescence sensing technology was originally developed with support from the Office of Naval Research.	Aizenman E, 2000, J NEUROCHEM, V75, P1878, DOI 10.1046/j.1471-4159.2000.0751878.x; ATAR D, 1995, J BIOL CHEM, V270, P2473, DOI 10.1074/jbc.270.6.2473; Ayaz M, 2006, AM J PHYSIOL-HEART C, V290, pH1071, DOI 10.1152/ajpheart.00754.2005; Blomgren K, 2006, FREE RADICAL BIO MED, V40, P388, DOI 10.1016/j.freeradbiomed.2005.08.040; BOGAERT YE, 1994, FREE RADICAL BIO MED, V16, P811, DOI 10.1016/0891-5849(94)90197-X; Bossy-Wetzel E, 2004, NEURON, V41, P351, DOI 10.1016/S0896-6273(04)00015-7; Bozym R, 2008, METHOD ENZYMOL, V450, P287, DOI 10.1016/S0076-6879(08)03414-9; Bozym RA, 2006, ACS CHEM BIOL, V1, P103, DOI 10.1021/cb500043a; Bozym RA, 2010, EXP BIOL MED, V235, P741, DOI 10.1258/ebm.2010.009258; Caporale T, 2009, EXP NEUROL, V218, P228, DOI 10.1016/j.expneurol.2009.04.003; Danilov CA, 2008, GLIA, V56, P801, DOI 10.1002/glia.20655; Dittmer PJ, 2009, J BIOL CHEM, V284, P16289, DOI 10.1074/jbc.M900501200; Fierke CA, 2001, BIOMETALS, V14, P205, DOI 10.1023/A:1012980628412; Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001; Frederickson CJ, 2006, EXP NEUROL, V198, P285, DOI 10.1016/j.expneurol.2005.08.030; Galasso SL, 2007, MOL MED, V13, P380, DOI 10.2119/2007-00044.Galasso; Gazaryan IG, 2002, J BIOL CHEM, V277, P10064, DOI 10.1074/jbc.M108264200; Gazaryan IG, 2007, J BIOL CHEM, V282, P24373, DOI 10.1074/jbc.M611376200; Haase H, 2011, ZINC HUMAN HLTH; Haase H, 2008, J IMMUNOL, V181, P6491, DOI 10.4049/jimmunol.181.9.6491; Haase H, 2006, ANAL BIOCHEM, V352, P222, DOI 10.1016/j.ab.2006.02.009; Huang CC, 1996, BIOCHEMISTRY-US, V35, P3439, DOI 10.1021/bi9526692; Hunt JA, 1999, BIOCHEMISTRY-US, V38, P9054, DOI 10.1021/bi9900166; Hurst TK, 2010, BBA-PROTEINS PROTEOM, V1804, P393, DOI 10.1016/j.bbapap.2009.09.031; Hyun HJ, 2001, INVEST OPHTH VIS SCI, V42, P460; Jiang DM, 2001, J BIOL CHEM, V276, P47524, DOI 10.1074/jbc.M108834200; Jiang ZG, 2006, P NATL ACAD SCI USA, V103, P1581, DOI 10.1073/pnas.0510573103; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Krezel A, 2006, J BIOL INORG CHEM, V11, P1049, DOI 10.1007/s00775-006-0150-5; LINDSKOG S, 1971, ENZYMES, V5, P587; Masanta G, 2011, J AM CHEM SOC, V133, P5698, DOI 10.1021/ja200444t; McCall KA, 2004, BIOCHEMISTRY-US, V43, P3979, DOI 10.1021/bi0498914; Niizuma K, 2010, BBA-MOL BASIS DIS, V1802, P92, DOI 10.1016/j.bbadis.2009.09.002; PECK EJ, 1971, J BIOL CHEM, V246, P1160; Piantadosi CA, 1996, STROKE, V27, P327, DOI 10.1161/01.STR.27.2.327; PRASAD AS, 1968, J LAB CLIN MED, V72, P1006; Qin Y, 2011, P NATL ACAD SCI USA, DOI [10.1037/pnas.1015686108, DOI 10.1037/PNAS.1015686108]; Rothwell PM, 2004, LANCET, V363, P1925, DOI 10.1016/S0140-6736(04)16405-2; Rudolf E, 2010, BIOMETALS, V23, P339, DOI 10.1007/s10534-010-9302-8; Sensi SL, 2003, CELL CALCIUM, V34, P281, DOI 10.1016/S0143-4160(03)00122-2; Sensi SL, 1997, J NEUROSCI, V17, P9554; Sensi SL, 1999, P NATL ACAD SCI USA, V96, P2414, DOI 10.1073/pnas.96.5.2414; Shuttleworth CW, 2011, TRENDS PHARMACOL SCI, V32, P480, DOI 10.1016/j.tips.2011.04.001; Sims NR, 2010, BBA-MOL BASIS DIS, V1802, P80, DOI 10.1016/j.bbadis.2009.09.003; Soane L, 2010, APOPTOSIS PHYSL PATH; Starkov AA, 2004, J NEUROSCI, V24, P7779, DOI 10.1523/JNEUROSCI.1899-04.2004; Stork CJ, 2006, J NEUROSCI, V26, P10430, DOI 10.1523/JNEUROSCI.1588-06.2006; Stumm W., 1996, AQUATIC CHEM CHEM EQ, V126; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; TELFORD WG, 1995, J CELL PHYSIOL, V164, P259, DOI 10.1002/jcp.1041640206; Thompson RB, 2000, J NEUROSCI METH, V96, P35, DOI 10.1016/S0165-0270(99)00183-1; Thompson RB, 2002, J NEUROSCI METH, V118, P63, DOI 10.1016/S0165-0270(02)00144-9; Thompson RB, 2002, J BIOMED OPT, V7, P555, DOI 10.1117/1.1501886; Thompson RB, 2012, METAL IONS STROKE, DOI [10.1007/978-1-4419-9663-3_9, DOI 10.1007/978-1-4419-9663-3_9]; TONDER N, 1990, NEUROSCI LETT, V109, P247, DOI 10.1016/0304-3940(90)90002-Q; van Dongen EMWM, 2007, J AM CHEM SOC, V129, P3494, DOI 10.1021/ja069105d; Wang D, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3613926; WARING P, 1990, INT J IMMUNOPHARMACO, V12, P445, DOI 10.1016/0192-0561(90)90028-L; Wei G, 2004, NEUROSCIENCE, V125, P867, DOI 10.1016/j.neuroscience.2004.03.011; Weiss JH, 2000, TRENDS NEUROSCI, V23, P365, DOI 10.1016/S0166-2236(00)01610-6; Yin HZ, 2002, J NEUROSCI, V22, P1273, DOI 10.1523/JNEUROSCI.22-04-01273.2002; YOKOYAMA M, 1986, NEUROSCI LETT, V71, P351, DOI 10.1016/0304-3940(86)90646-4; ZALEWSKI PD, 1991, BIOCHEM INT, V24, P1093; Zeng HH, 2005, PROC SPIE, V5692, P51, DOI 10.1117/12.614168	64	39	40	0	23	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0145-479X	1573-6881		J BIOENERG BIOMEMBR	J. Bioenerg. Biomembr.	APR	2012	44	2					253	263		10.1007/s10863-012-9427-2			11	Biophysics; Cell Biology	Biophysics; Cell Biology	920NG	WOS:000302411200002	22430627	Green Accepted			2021-06-18	
J	Plantman, S; Ng, KC; Lu, J; Davidsson, J; Risling, M				Plantman, Stefan; Ng, Kian Chye; Lu, Jia; Davidsson, Johan; Risling, Marten			Characterization of a Novel Rat Model of Penetrating Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						animal studies; models of injury; penetrating ballistic-like brain injury; traumatic brain injury	CONTROLLED CORTICAL IMPACT; WOUND BALLISTICS; GUNSHOT WOUNDS; CELL-DEATH; REACTIVE ASTROCYTES; NEURITE OUTGROWTH; LESIONS; HEAD; MECHANISMS; EDEMA	A penetrating traumatic brain injury (pTBI) occurs when an object impacts the head with sufficient force to penetrate the skin, skull, and meninges, and inflict injury directly to the brain parenchyma. This type of injury has been notoriously difficult to model in small laboratory animals such as rats or mice. To this end, we have established a novel non-fatal model for pTBI based on a modified air rifle that accelerates a pellet, which in turn impacts a small probe that then causes the injury to the experimental animal's brain. In the present study, we have focused on the acute phase and characterized the tissue destruction, including increasing cavity formation, white matter degeneration, hemorrhage, edema, and gliosis. We also used a battery of behavioral models to examine the neurological outcome, with the most noteworthy finding being impairment of reference memory function. In conclusion, we have described a number of events taking place after pTBI in our model. We expect this model will prove useful in our efforts to unravel the biological events underlying injury and regeneration after pTBI and possibly serve as a useful animal model in the development of novel therapeutic and diagnostic approaches.	[Plantman, Stefan; Risling, Marten] Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden; [Ng, Kian Chye; Lu, Jia] Def Med & Environm Res Inst, DSO Natl Labs, Combat Care Lab, Singapore, Singapore; [Davidsson, Johan] Chalmers Univ Technol, Div Vehicle Safety, S-41296 Gothenburg, Sweden	Plantman, S (corresponding author), Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden.	Stefan.Plantman@ki.se	Davidsson, Johan/A-3229-2016	Davidsson, Johan/0000-0002-1717-1514; plantman, stefan/0000-0003-2236-4238			Adams RA, 2007, J EXP MED, V204, P571, DOI 10.1084/jem.20061931; Asher RA, 2000, J NEUROSCI, V20, P2427; Bellander BM, 2010, EXP BRAIN RES, V205, P103, DOI 10.1007/s00221-010-2342-z; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; CAREY ME, 1989, J NEUROSURG, V71, P754, DOI 10.3171/jns.1989.71.5.0754; Carey ME, 1990, J NEUROTRAUM, V7, P13, DOI 10.1089/neu.1990.7.13; Castano B, 2010, NEUROREHABILITATION, V27, P113, DOI 10.3233/NRE-2010-0586; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; CROCKARD HA, 1977, J NEUROSURG, V46, P776, DOI 10.3171/jns.1977.46.6.0776; Cullheim S, 2007, BRAIN RES REV, V55, P89, DOI 10.1016/j.brainresrev.2007.03.012; Davalos A, 2000, NEUROLOGY, V54, P1568, DOI 10.1212/WNL.54.8.1568; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Fackler ML, 1998, EMERG MED CLIN N AM, V16, P17, DOI 10.1016/S0733-8627(05)70346-1; FAWCETT J, 1994, J NEUROL, V242, pS25, DOI 10.1007/BF00939237; FINNIE JW, 1993, J COMP PATHOL, V108, P93, DOI 10.1016/S0021-9975(08)80231-9; FRISEN J, 1995, NEUROSCIENCE, V65, P293, DOI 10.1016/0306-4522(94)00467-J; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Gunnarson E, 2008, GLIA, V56, P587, DOI 10.1002/glia.20627; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Ishikawa E, 2000, NEUROL MED-CHIR, V40, P458, DOI 10.2176/nmc.40.458; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; KARGER B, 1995, INT J LEGAL MED, V108, P53, DOI 10.1007/BF01369905; KAUFMAN HH, 1987, NEUROSURGERY, V20, P254, DOI 10.1227/00006123-198702000-00010; Kluger Y, 2003, ISRAEL MED ASSOC J, V5, P235; Lecourtier L, 2005, NEUROPSYCHOPHARMACOL, V30, P484, DOI 10.1038/sj.npp.1300595; Lee D, 1997, OTOLARYNG HEAD NECK, V116, P372, DOI 10.1016/S0194-5998(97)70276-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Maddux JM, 2007, BEHAV NEUROSCI, V121, P63, DOI 10.1037/0735-7044.121.1.63; Maegele M, 2007, INFLAMM RES, V56, P318, DOI 10.1007/s00011-007-6141-3; Maiden N, 2009, FORENSIC SCI MED PAT, V5, P204, DOI 10.1007/s12024-009-9096-6; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MEYER K, 2008, J TRAUMA NURS, V15, P190; Meyer Kimberly, 2008, J Trauma Nurs, V15, P185, DOI 10.1097/01.JTN.0000343324.55087.de; Mitchell AS, 2005, EUR J NEUROSCI, V22, P973, DOI 10.1111/j.1460-9568.2005.04199.x; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Muir JL, 1996, CEREB CORTEX, V6, P470, DOI 10.1093/cercor/6.3.470; Neal CJ, 2007, J NEUROTRAUM, V24, P1609, DOI 10.1089/neu.2007.0301; Norwood KW, 2010, CLIN PEDIATR, V49, P1044, DOI 10.1177/0009922810376234; Oehmichen M, 2004, FORENSIC SCI INT, V146, P111, DOI 10.1016/j.forsciint.2004.06.023; ORDOG GJ, 1984, ANN EMERG MED, V13, P1113, DOI 10.1016/S0196-0644(84)80336-4; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Patradoon-Ho P, 2005, Pediatr Rehabil, V8, P303, DOI 10.1080/13638490500049578; Pleasant JM, 2011, J NEUROTRAUM, V28, P2245, DOI 10.1089/neu.2010.1499; Popovic Vera, 2005, Pituitary, V8, P239, DOI 10.1007/s11102-006-6047-z; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Schachtrup C, 2007, P NATL ACAD SCI USA, V104, P11814, DOI 10.1073/pnas.0704045104; Schachtrup C, 2010, J NEUROSCI, V30, P5843, DOI 10.1523/JNEUROSCI.0137-10.2010; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Solmaz I, 2009, TURK NEUROSURG, V19, P216; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Tan YH, 1998, J ORAL MAXIL SURG, V56, P345, DOI 10.1016/S0278-2391(98)90113-6; Tate CC, 2007, EXP NEUROL, V207, P13, DOI 10.1016/j.expneurol.2007.05.008; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Tom VJ, 2004, J NEUROSCI, V24, P9282, DOI 10.1523/JNEUROSCI.2120-04.2004; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vink R, 2001, J NEUROTRAUM, V18, P839, DOI 10.1089/089771501316919201; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Williams AJ, 2006, NEUROSCI LETT, V408, P183, DOI 10.1016/j.neulet.2006.08.086; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Wilson RF, 1998, J HEAD TRAUMA REHAB, V13, P11, DOI 10.1097/00001199-199802000-00005; Wu JM, 2002, BRAIN RES, V953, P45, DOI 10.1016/S0006-8993(02)03268-7; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; Yang L, 2010, J NEUROTRAUM, V27, P1541, DOI 10.1089/neu.2009.1244; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102	76	39	39	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1219	1232		10.1089/neu.2011.2182			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100022	22181060				2021-06-18	
J	Finan, JD; Elkin, BS; Pearson, EM; Kalbian, IL; Morrison, B				Finan, John D.; Elkin, Benjamin S.; Pearson, Erica M.; Kalbian, Irene L.; Morrison, Barclay, III			Viscoelastic Properties of the Rat Brain in the Sagittal Plane: Effects of Anatomical Structure and Age	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Neurotrauma; Indentation; Relaxation function; Biomechanics; Injury	DIFFUSE AXONAL INJURY; ANGULAR-ACCELERATION; MECHANICAL RESPONSE; IN-VITRO; TISSUE; MODEL; HEAD; HETEROGENEITY; INDENTATION; ANISOTROPY	Rat is the most commonly used animal model for the study of traumatic brain injury. Recent advances in imaging and computational modeling technology offer the promise of biomechanical models capable of resolving individual brain structures and offering greater insight into the causes and consequences of brain injury. However, there is insufficient data on the mechanical properties of brain structures available to populate these models. In this study, we used microindentation to determine viscoelastic properties of different anatomical structures in sagittal slices of juvenile and adult rat brain. We find that the rat brain is spatially heterogeneous in this anatomical plane supporting previous results in the coronal plane. In addition, the brain becomes stiffer and more heterogeneous as the animal matures. This dynamic, region-specific data will support the development of more biofidelic computational models of brain injury biomechanics and the testing of hypotheses about the manner in which different anatomical structures are injured in a head impact.	[Finan, John D.; Elkin, Benjamin S.; Pearson, Erica M.; Kalbian, Irene L.; Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, Neurotrauma & Repair Lab, New York, NY 10027 USA	Morrison, B (corresponding author), Columbia Univ, Dept Biomed Engn, Neurotrauma & Repair Lab, 351 Engn Terrace,1210 Amsterdam Ave MC 8904, New York, NY 10027 USA.	bm2119@columbia.edu	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864; Finan, John/0000-0003-4626-9702	NHTSA [DTNH22-08-C-00088]	The authors wish to thank Dr. Ed X. Guo for laboratory space and equipment. This study was supported by NHTSA Project # DTNH22-08-C-00088.	ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; Allen M.P., 1997, UNDERSTANDING REGRES; Begonia MT, 2010, ANN BIOMED ENG, V38, P3043, DOI 10.1007/s10439-010-0072-9; Bolander R, 2011, ANN BIOMED ENG, V39, P2550, DOI 10.1007/s10439-011-0343-0; Boretius S, 2004, MAGN RESON MATER PHY, V17, P339, DOI 10.1007/s10334-004-0069-1; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; Christ AF, 2010, J BIOMECH, V43, P2986, DOI 10.1016/j.jbiomech.2010.07.002; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Cloots RJH, 2011, BIOMECH MODEL MECHAN, V10, P413, DOI 10.1007/s10237-010-0243-5; Davidsson Johan, 2011, Front Neurol, V2, P41, DOI 10.3389/fneur.2011.00041; Elkin BS, 2007, J NEUROTRAUM, V24, P812, DOI 10.1089/neu.2006.0169; Elkin BS, 2011, J NEUROTRAUM, V28, P2235, DOI 10.1089/neu.2010.1604; Elkin BS, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000164; Elliott DM, 2001, J BIOMECH ENG-T ASME, V123, P256, DOI 10.1115/1.1374202; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; HAYES WC, 1972, J BIOMECH, V5, P541, DOI 10.1016/0021-9290(72)90010-3; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Kaster T, 2011, J BIOMECH, V44, P1158, DOI 10.1016/j.jbiomech.2011.01.019; Kilbourne M, 2009, J NEUROTRAUM, V26, P2233, DOI 10.1089/neu.2009.0968; Mao HJ, 2010, J NEUROTRAUM, V27, P877, DOI 10.1089/neu.2008.0616; MASSEY FJ, 1951, J AM STAT ASSOC, V46, P68, DOI 10.2307/2280095; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Pleasant JM, 2011, J NEUROTRAUM, V28, P2245, DOI 10.1089/neu.2010.1499; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schulze-Bauer CAJ, 2003, J BIOMECH ENG-T ASME, V125, P395, DOI 10.1115/1.1574331; Shulyakov AV, 2011, J MECH BEHAV BIOMED, V4, P484, DOI 10.1016/j.jmbbm.2010.12.012; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; van Dommelen JAW, 2010, J MECH BEHAV BIOMED, V3, P158, DOI 10.1016/j.jmbbm.2009.09.001; WAHI KK, 1977, ANN BIOMED ENG, V5, P303, DOI 10.1007/BF02367311; Wang HC, 2010, J NEUROTRAUM, V27, P707, DOI 10.1089/neu.2009.1071	37	39	39	1	14	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	JAN	2012	40	1			SI		70	78		10.1007/s10439-011-0394-2			9	Engineering, Biomedical	Engineering	895HJ	WOS:000300486700006	22012082				2021-06-18	
J	Jones, A; Ingram, MV; Ben-Porath, YS				Jones, Alvin; Ingram, M. Victoria; Ben-Porath, Yossef S.			Scores on the MMPI-2-RF Scales as a Function of Increasing Levels of Failure on Cognitive Symptom Validity Tests in a Military Sample	CLINICAL NEUROPSYCHOLOGIST			English	Article						Minnesota Multiphasic Personality Inventory-2-Restructured Form; MMPI-2-RF; Symptom validity tests; Military sample	PERSONAL-INJURY LITIGANTS; RESTRUCTURED CLINICAL RC; TRAUMATIC BRAIN-INJURY; REPEATABLE BATTERY; EVALUATION CONTEXT; FORENSIC SETTINGS; EFFORT INDEX; PERFORMANCE; VALIDATION; DISABILITY	This research examined associations between the full range of Minnesota Multiphasic Personality Inventory-2-Restructured Form (MMPI-2-RF) validity and substantive scales and increasing levels of cognitive symptom validity test (SVT) failure in a sample of 501 military members who completed a neuropsychological evaluation primarily for mild traumatic brain injury resulting from a closed head injury and blast exposure or heat injury. SVT failure was associated with significant linear increases in all of the over-reporting MMPI-2-RF validity scales and most of the substantive scales. For the validity scales, all over-reporting scales had large effect sizes (ESs) when comparing a group that failed no SVTs with a group that failed three SVTs. A comparison between these two groups for the substantive scales revealed the largest ESs for scales related to somatic/cognitive complaints and emotional dysfunction. RBS (Response Bias Scale) had the largest ES of all scales (d = 1.69), followed by FBS-r (Symptom Validity Scale; d = 1.34), AXY (Anxiety, d = 1.21), and COG (Cognitive Complaints, d = 1.19). The scales related to behavioral dysfunction had the smallest ESs of all of the substantive scales, and there were no significant associations between the vast majority of these scales and SVT failure. With respect to clinically significant elevations, those who did not fail SVTs had clinically significant elevations only on COG and NUC (Neurological Complaints), and MLS (Malaise) approached clinical significance. For those who failed SVTs, RBS was the only over-reporting scale that was elevated across all failure groups. Those who failed any SVT had clinically significant elevations on COG, MLS, NUC, and AXY. Those who failed three SVTs had additional elevations on scales related to emotional dysfunction.	[Jones, Alvin] Womack Army Med Ctr, Dept Med, Neurol Serv, Ft Bragg, NC 28310 USA; [Ingram, M. Victoria] Womack Army Med Ctr, Dept Behav Hlth, Ft Bragg, NC 28310 USA; [Ben-Porath, Yossef S.] Kent State Univ, Dept Psychol, Kent, OH 44242 USA	Jones, A (corresponding author), Womack Army Med Ctr, Dept Med, Neurol Serv, 2817 Riley Rd,Bldg 4-2817, Ft Bragg, NC 28310 USA.	alvin.jones@amedd.army.mil					Arbisi PA, 2008, J PERS ASSESS, V90, P122, DOI 10.1080/00223890701845146; Armistead-Jehle P, 2011, ARCH CLIN NEUROPSYCH, V26, P592, DOI 10.1093/arclin/acr049; Ben-Porath Y.S., 2008, MMPI 2 RF MINNESOTA; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Department of Veterans Affairs and Department of Defense, 2009, VA DOD CLIN PRACT GU; Gervais RO, 2011, J PERS ASSESS, V93, P508, DOI 10.1080/00223891.2011.594132; Gervais RO, 2010, ARCH CLIN NEUROPSYCH, V25, P473, DOI 10.1093/arclin/acq052; Gervais RO, 2010, ARCH CLIN NEUROPSYCH, V25, P274, DOI 10.1093/arclin/acq018; Green P., 2003, GREENS WORD MEMORY T; Grote CL, 2000, J CLIN EXP NEUROPSYC, V22, P709, DOI 10.1076/jcen.22.6.709.958; Harkness AR, 2012, PSYCHOL ASSESSMENT, V24, P432, DOI 10.1037/a0025830; Henry GK, 2008, CLIN NEUROPSYCHOL, V22, P158, DOI 10.1080/13825580601025916; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Jones A, 2011, CLIN NEUROPSYCHOL, V25, P1207, DOI 10.1080/13854046.2011.600726; Kaemmer B, 2001, MMPI-2: Manual for Administration and Scoring; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Randolph C, 1998, REPEATABLE BATTERY A; Sellbom M, 2010, PSYCHOL ASSESSMENT, V22, P22, DOI 10.1037/a0018222; Silverberg ND, 2007, CLIN NEUROPSYCHOL, V21, P841, DOI 10.1080/13854040600850958; Slick D., 1997, VICTORIA SYMPTOM VAL; Sweet JJ, 1999, STUD NEUROPSYCHOL DE, P255; Tellegen A., 2003, MMPI 2 RESTRUCTURED; Tellegen A., 2008, MMPI 2 RF MINNESOTA; Thomas ML, 2009, CLIN NEUROPSYCHOL, V23, P1067, DOI 10.1080/13854040902795000; Tombaugh TN, 1996, TEST MEMORY MALINGER; TYDECKS S, 2006, INT J FORENSIC PSYCH, V1, P29; Wallace A, 2005, ASSESSMENT, V12, P290, DOI 10.1177/1073191105276250; Wygant DB, 2005, ARCH CLIN NEUROPSYCH, V20, P892; Wygant DB, 2007, ARCH CLIN NEUROPSYCH, V22, P489, DOI 10.1016/j.acn.2007.01.027; Wygant DB, 2010, PSYCHOL ASSESSMENT, V22, P745, DOI 10.1037/a0020042; Wygant DB, 2009, ARCH CLIN NEUROPSYCH, V24, P671, DOI 10.1093/arclin/acp073; Youngjohn J.R., 1995, ASSESSMENT, V2, DOI [https://doi.org/10.1177/1073191195002003007, DOI 10.1177/1073191195002003007]; Youngjohn JR, 2011, CLIN NEUROPSYCHOL, V25, P463, DOI [10.1080/13854046.2011.554444, 10.1080/13854046.2010.550635]	38	39	40	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2012	26	5					790	815		10.1080/13854046.2012.693202			26	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	970EU	WOS:000306111700003	22709365				2021-06-18	
J	Potter, S; Brown, RG				Potter, Seb; Brown, Richard G.			Cognitive behavioural therapy and persistent post-concussional symptoms: Integrating conceptual issues and practical aspects in treatment	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Traumatic brain injury; Post-concussion syndrome; Cognitive-behavioural therapy	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MILD HEAD-INJURY; MEDICALLY UNEXPLAINED SYMPTOMS; STIMULUS-INDEPENDENT THOUGHT; CHRONIC-FATIGUE-SYNDROME; EMOTIONAL RISK-FACTORS; POSTCONCUSSION-SYNDROME; NEUROPSYCHOLOGICAL REHABILITATION; MISERABLE MINORITY	This paper seeks to integrate research findings in mild traumatic brain injury (MTBI) around three central themes relevant to psychological therapies for persistent post-concussional symptoms (PCS). These are (1) the relative lack of symptom specificity, (2) the extent to which subjective (but not necessarily objective) cognitive difficulties predominate, and (3) the role of psychological (especially cognitive-behavioural) processes in the evolution and maintenance of symptoms. Evidence-based models guiding cognitive-behavioural therapy (CBT) for similar symptoms in other clinical groups are considered in relation to persistent PCS, as well as some of the practical considerations in applying CBT with this client group. Outstanding research issues are identified and discussed, including the opportunities and risks of combining CBT and cognitive rehabilitation approaches.	[Potter, Seb] S London & Maudsley NHS Fdn Trust, Maudsley Hosp, Lishman Brain Injury Unit, London SE5 8AZ, England; [Brown, Richard G.] Kings Coll London, Inst Psychiat, Dept Psychol, London WC2R 2LS, England	Potter, S (corresponding author), S London & Maudsley NHS Fdn Trust, Maudsley Hosp, Lishman Brain Injury Unit, Denmark Hill, London SE5 8AZ, England.	s.potter@iop.kcl.ac.uk	Brown, Richard G/A-9599-2010	Brown, Richard G/0000-0001-9021-0172; Potter, Sebastian/0000-0002-2173-9870	NIHR Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust (SLaM); Institute of Psychiatry, King's College London	The authors would like to thank Ionie Lyon for her assistance in preparing this manuscript. The authors acknowledge support from the NIHR Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust (SLaM) and Institute of Psychiatry, King's College London.	Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Beck A. T., 1979, COGNITIVE THERAPY DE; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Blatt SJ, 1998, J CONSULT CLIN PSYCH, V66, P423, DOI 10.1037/0022-006X.66.2.423; Blenkiron P, 2005, BEHAV COGN PSYCHOTH, V33, P45, DOI 10.1017/S1352465804001766; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; Boone K. B., 2008, CLIN NEUROPSYCHOL, V23, P1016; Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS61, DOI 10.1016/j.apmr.2008.08.210; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; CLARK DM, 1986, BEHAV RES THER, V24, P461, DOI 10.1016/0005-7967(86)90011-2; Clark DM., 2001, INT HDB SOCIAL ANXIE, P405; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Davies R, 2005, BRAIN INJURY, V19, P941, DOI 10.1080/02699050400000565; Deale A, 1998, J PSYCHOSOM RES, V45, P77, DOI 10.1016/S0022-3999(98)00021-X; Deary V, 2007, CLIN PSYCHOL REV, V27, P781, DOI 10.1016/j.cpr.2007.07.002; Deikman Arthur J., 1969, ALTERED STATES CONSC; Delahanty DL, 1997, J CONSULT CLIN PSYCH, V65, P560, DOI 10.1037/0022-006X.65.4.560; Delis DC, 2007, ARCH CLIN NEUROPSYCH, V22, P589, DOI 10.1016/j.acn.2007.04.001; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; Elliott E., 1989, PSYCHOL HELPLESSNESS, P339, DOI DOI 10.1016/S0166-4115(08)60986-3; ERICHSEN JE, 1882, CONCUSSION SPINE NER; EVANS RW, 1994, HEADACHE, V34, P268, DOI 10.1111/j.1526-4610.1994.hed3405268.x; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Fairburn CG, 1999, ARCH GEN PSYCHIAT, V56, P468, DOI 10.1001/archpsyc.56.5.468; Fennell M.J., 1998, ADV PSYCHIAT TREATME, V4, P296, DOI [DOI 10.1192/APT.4.5.296, 10.1192/apt.4.5.296]; Ferguson R.J., 1996, SOURCEBOOK PSYCHOL T; Frank J. D., 1982, PSYCHOTHERAPY RES BE, P5; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gass CS., 1992, PSYCHOL ASSESSMENT, V4, P272, DOI [10.1037/1040-3590.4.3.272, DOI 10.1037/1040-3590.4.3.272]; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2002, J INT NEUROPSYCH SOC, V8, P37, DOI 10.1017/S1355617701020045; Gurr B, 2005, BRAIN INJURY, V19, P481, DOI 10.1080/02699050400005176; Gurr B, 2001, BRAIN INJURY, V15, P387, DOI 10.1080/02699050010005904; Haldorsen T, 2003, APPL NEUROPSYCHOL, V10, P170, DOI 10.1207/S15324826AN1003_06; Hart T, 2007, REHABIL PSYCHOL, V52, P152, DOI 10.1037/0090-5550.52.2.152; Ho MR, 1997, ARCH CLIN NEUROPSYCH, V12, P1; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson G. L., 2010, BRAIN INJURY, P1; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Jacobson NS, 1996, J CONSULT CLIN PSYCH, V64, P295, DOI 10.1037/0022-006X.64.2.295; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P74, DOI DOI 10.1097/00001199-199309000-00009; Kendall E, 2009, SOC SCI MED, V69, P947, DOI 10.1016/j.socscimed.2009.06.021; Khan-Bourne N, 2003, NEUROPSYCHOL REHABIL, V13, P89, DOI 10.1080/09602010244000318; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Kirk J., 1989, COGNITIVE BEHAV THER, P13; LACHMAN ME, 1992, J GERONTOL, V47, pP293, DOI 10.1093/geronj/47.5.P293; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Lange RT, 2010, ARCH CLIN NEUROPSYCH, V25, P442, DOI 10.1093/arclin/acq031; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Lewis A. J., 1942, P ROY SOC MED, V35, P607; Lilenfeld LR, 1998, ARCH GEN PSYCHIAT, V55, P603, DOI 10.1001/archpsyc.55.7.603; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; Mackenzie JA, 2005, BRIT J CLIN PSYCHOL, V44, P417, DOI 10.1348/014466505X35696; MARSH NV, 1995, BRAIN INJURY, V9, P553, DOI 10.3109/02699059509008214; Martelli MF, 1999, J HEAD TRAUMA REHAB, V14, P49, DOI 10.1097/00001199-199902000-00007; MASTERS RSW, 1993, PERS INDIV DIFFER, V14, P655, DOI 10.1016/0191-8869(93)90113-H; Mateer CA, 2005, J HEAD TRAUMA REHAB, V20, P62, DOI 10.1097/00001199-200501000-00007; Matthews G, 2000, HUMAN PERFORMANCE CO; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McGrath J, 1997, NEUROPSYCHOL REHABIL, V7, P231, DOI 10.1080/713755532; MCGRATH J, 2004, OXFORD GUIDE BEHAV E, P331; McLean SA, 2009, AM J EMERG MED, V27, P182, DOI 10.1016/j.ajem.2008.01.054; MCMILLAN TM, 1991, BRIT J PSYCHIAT, V159, P431, DOI 10.1192/bjp.159.3.431; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; MITTENBERG W, 1994, BRAIN INJURY, V8, P429, DOI 10.3109/02699059409150994; Mittenberg W, 1993, PSYCHOTHERAPY PRIVAT, V12, P37, DOI DOI 10.1300/1294V12N02_03; Moss-Morris R, 2005, J HEALTH PSYCHOL, V10, P245, DOI 10.1177/1359105305049774; Mulhern S, 2006, J PSYCHOSOM RES, V61, P439, DOI 10.1016/j.jpsychores.2006.03.004; Nezu AM, 2001, BEHAV THER, V32, P537, DOI 10.1016/S0005-7894(01)80035-6; Nicholson K, 2001, NEUROREHABILITATION, V16, P225; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; Padesky C.A., 1990, INT COGNITIVE THERAP, V6, P13; PADESKY CA, 1994, CLIN PSYCHOL PSYCHOT, V1, P267, DOI 10.1002/cpp.5640010502; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Potter S., 2010, BRAIN INJURY, V24, P205; Potter S., 2008, BRAIN INJURY S1, V22, P66; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Radanov BP, 1999, J NEUROL NEUROSUR PS, V66, P485, DOI 10.1136/jnnp.66.4.485; Riley GA, 2010, NEUROPSYCHOL REHABIL, V20, P869, DOI 10.1080/09602011.2010.503041; Rimes KA, 2010, J PSYCHOSOM RES, V68, P285, DOI 10.1016/j.jpsychores.2009.09.014; Ruff RM, 1999, BRAIN INJURY, V13, P943; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; Salkovskis P., 2001, HYPOCHONDRIASIS MODE, P202; Schmidt AJM, 2003, BEHAV RES THER, V41, P1243, DOI 10.1016/S0005-7967(03)00155-4; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Seligman MEP, 2005, AM PSYCHOL, V60, P410, DOI 10.1037/0003-066X.60.5.410; Shafran R, 2002, BEHAV RES THER, V40, P773, DOI 10.1016/S0005-7967(01)00059-6; Smith AM, 2000, SPORTS MED, V30, P423, DOI 10.2165/00007256-200030060-00004; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Snell DL, 2008, J CLIN EXP NEUROPSYC, V2, P1; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; STUSS DT, 1995, NEUROLOGY, V45, P1251, DOI 10.1212/WNL.45.7.1251; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Sullivan MJL, 2008, J OCCUP REHABIL, V18, P249, DOI 10.1007/s10926-008-9140-5; Sumpter RE, 2006, BRAIN INJURY, V20, P93, DOI 10.1080/02699050500394090; SURAWY C, 1995, BEHAV RES THER, V33, P535, DOI 10.1016/0005-7967(94)00077-W; TEASDALE JD, 1993, EUR J COGN PSYCHOL, V5, P417, DOI 10.1080/09541449308520128; TEASDALE JD, 1995, MEM COGNITION, V23, P551, DOI 10.3758/BF03197257; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Todd D, 1998, FORENSIC EXAMINER, V7, P14; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P; Veale D., 2003, ADV PSYCHIAT TREATME, V9, P258, DOI DOI 10.1192/APT.9.4.258; Wells A., 1997, COGNITIVE THERAPY AN; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Williams W H, 2003, Cogn Neuropsychiatry, V8, P1, DOI 10.1080/713752238; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P133, DOI 10.1080/09602010244000417; Wolters G, 2011, J HEAD TRAUMA REHAB, V26, P150, DOI 10.1097/HTR.0b013e3181e421dc; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; Zasler ND, 2003, NEUROPSYCHOL REHABIL, V13, P31, DOI 10.1080/09602010	140	39	39	0	23	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2012	22	1					1	25		10.1080/09602011.2011.630883			25	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	920KO	WOS:000302403500001	22175238				2021-06-18	
J	Thompson, HJ; Dikmen, S; Temkin, N				Thompson, Hilaire J.; Dikmen, Sureyya; Temkin, Nancy			Prevalence of Comorbidity and its Association with Traumatic Brain Injury and Outcomes in Older Adults	RESEARCH IN GERONTOLOGICAL NURSING			English	Article							SEVERITY SCORE; EARLY HYPERGLYCEMIA; HEALTH-CARE; MORTALITY; AGE; INDEX; RISK; TBI	The study aims were to examine the association between age, comorbidity, and cause of injury in older adults with traumatic brain injury (TBI); and to determine which comorbidities relate to mortality, length of stay, and functional outcome at hospital discharge, controlling for initial injury severity, age, and sex. A retrospective cohort study design was used; clinical and outcome trauma registry data were obtained for 196 adults 55 and older with TBI. The majority had at least one comorbid condition (e.g., hypertension, alcohol abuse). In-hospital mortality was 31%. Among the oldest-old, motor vehicle collisions and falls were significantly associated with specific chronic diseases. Prior myocardial infarction was significantly associated with an increased risk of in-hospital death. Injury Severity Score and Glasgow Coma Scale score were predictive of discharge function, but comorbidity did not add significantly to the model. Primary TBI prevention efforts in older adults must consider the impact of comorbidity and cause of injury, particularly in the oldest-old. Alcohol abuse is common in older adults with TBI; screening should be conducted and interventions developed to prevent future injury. Future study is warranted to understand the interplay between pathophysiology of comorbid disease and injury and how to best manage rehabilitation within the context of aging.	[Thompson, Hilaire J.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA; [Dikmen, Sureyya] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Neurosurg, Seattle, WA 98195 USA; [Thompson, Hilaire J.] Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA	Thompson, HJ (corresponding author), Univ Washington, Sch Nursing, Box 357266, Seattle, WA 98195 USA.	hilairet@uw.edu			John A. Hartford Foundation [06-202]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [KL2RR025015]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR025015] Funding Source: NIH RePORTER	The authors disclose that they have no significant :financial interests in any product or class of products discussed directly or indirectly in this activity. This work was supported in part by the John A. Hartford Foundation (grant 06-202) and the National Institutes of Health (grant KL2RR025015) to Dr. Thompson. Dr. Thompson acknowledges the mentorship of Dr. Sarah H. Kagan during her Claire M. Fagin Fellowship at which time this work was completed.	Alban RF, 2010, AM SURGEON, V76, P1108; Andelic Nada, 2010, J Trauma Manag Outcomes, V4, P6, DOI 10.1186/1752-2897-4-6; [Anonymous], 2005, INJ PREV CONTR DAT S; Ashman TA, 2004, BRAIN INJURY, V18, P191, DOI 10.1080/0269905031000149506; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bergstrom MF, 2011, INJURY PREV, V17, P108, DOI 10.1136/ip.2010.028951; Bolorunduro OB, 2011, J SURG RES, V166, P40, DOI 10.1016/j.jss.2010.04.012; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; BULL JP, 1975, ACCIDENT ANAL PREV, V7, P249, DOI 10.1016/0001-4575(75)90026-3; *CDCP, 2003, MORBIDITY MORTALITY, V52; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Colantonio A, 2010, CAN J NEUROL SCI, V37, P783, DOI 10.1017/S0317167100051441; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Donohue JT, 2007, J TRAUMA, V62, P419, DOI 10.1097/01.ta.0000219286.88179.18; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Federal Interagency Forum on Aging Related Statistics, 2010, OLD AM 2010 KEY IND; Gabbe BJ, 2005, ACAD EMERG MED, V12, P318, DOI 10.1197/j.aem.2004.12.002; Gale SC, 2007, AM SURGEON, V73, P454; Grimby A, 1997, AGING CLIN EXP RES, V9, P356, DOI 10.1007/BF03339614; Grossman MD, 2002, J TRAUMA, V52, P242, DOI 10.1097/00005373-200202000-00007; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Kennedy RL, 2002, J TRAUMA, V52, P660, DOI 10.1097/00005373-200204000-00008; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; LeMier M, 2001, Inj Prev, V7, P334, DOI 10.1136/ip.7.4.334; MACKENZIE EJ, 1984, AM J EMERG MED, V2, P537, DOI 10.1016/0735-6757(84)90081-0; McKenzie K, 2009, INJURY PREV, V15, P188, DOI 10.1136/ip.2008.020479; Meredith JW, 2002, J TRAUMA, V53, P621, DOI 10.1097/00005373-200210000-00001; Michael Y.L., 2010, PRIMARY CARE RELEVAN; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Norris SL, 2008, J AM GERIATR SOC, V56, P149, DOI 10.1111/j.1532-5415.2007.01530.x; Sperry JL, 2007, J TRAUMA, V63, P487, DOI 10.1097/TA.0b013e31812e51fc; Sperry JL, 2009, J TRAUMA, V66, P1076, DOI 10.1097/TA.0b013e31817db0de; Stevens JA, 2008, PREVENTING FALLS WHA; Taylor MD, 2002, J TRAUMA, V53, P407, DOI 10.1097/00005373-200209000-00001; TEASDALE G, 1974, LANCET, V2, P81; Thompson HJ, 2008, CRIT CARE MED, V36, P282, DOI 10.1097/01.CCM.0000297884.86058.8A; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Thompson HJ, 2010, ANN SURG, V252, P370, DOI 10.1097/SLA.0b013e3181df03d6	42	39	40	0	8	SLACK INC	THOROFARE	6900 GROVE RD, THOROFARE, NJ 08086 USA	1940-4921			RES GERONTOL NURS	Res. Gerontol. Nurs.	JAN	2012	5	1			SI		17	24		10.3928/19404921-20111206-02			8	Nursing	Nursing	879TE	WOS:000299354300004	22165997	Green Accepted			2021-06-18	
J	Vanderploeg, RD; Groer, S; Belanger, HG				Vanderploeg, Rodney D.; Groer, Shirley; Belanger, Heather G.			Initial developmental process of a VA semistructured clinical interview for TBI identification	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						brain injury; clinical reminder; concussion; diagnostic techniques; differential diagnosis; head injury; head trauma; interview; postconcussion syndrome; rehabilitation	TRAUMATIC BRAIN-INJURY; OIF/OEF SERVICE MEMBERS; NEUROPSYCHOLOGICAL OUTCOMES; DEMAND CHARACTERISTICS; EXPLOSION INJURIES; RELIABILITY; VALIDITY; IRAQ; DEPLOYMENT	Identification of a remote traumatic brain injury (TBI), particularly mild TBI, is a challenge. The acknowledged standard for determining a history of prior TBI is self-report elicited through a structured or in-depth clinical interview. In April 2007, the Veterans Health Administration (VHA) mandated that the four-section TBI Clinical Reminder screening instrument be completed on all individuals returning from deployment in the Operation Iraqi Freedom/Operation Enduring Freedom theaters of operation (VHA Directive 2007-013). If positive, a follow-up Second Level TBI Evaluation is to be completed. For validation studies of the TBI Clinical Reminder screening process and with the long-term goal of providing a structured methodology to complete the TBI history portion of the Second Level TBI Evaluation, we sought to develop a "criterion standard" semistructured clinical TBI identification interview. This tool was developed through consultation with TBI subject matter experts and built on the strengths of existing tools in the literature. This article describes the six-step developmental methodology and presents the resulting semistructured interview and accompanying manual.	[Vanderploeg, Rodney D.; Belanger, Heather G.] James A Haley Vet Hosp, Dept Mental Hlth & Behav Sci, Tampa, FL 33612 USA; [Vanderploeg, Rodney D.; Groer, Shirley; Belanger, Heather G.] James A Haley Vet Hosp, Hlth Sci Res & Dev R&D Rehabil R&D Ctr Excel Maxi, Tampa, FL 33612 USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat, Tampa, FL USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Neurosci, Tampa, FL USA; [Vanderploeg, Rodney D.; Belanger, Heather G.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Vanderploeg, Rodney D.; Belanger, Heather G.] Defense & Vet Brain Injury Ctr, Tampa, FL USA	Vanderploeg, RD (corresponding author), James A Haley Vet Hosp, 13000 Bruce B Downs Ave, Tampa, FL 33612 USA.	Rodney.Vanderploeg@va.gov			VAUS Department of Veterans Affairs; VHA [SDR HSRD 08-411- TBI]; James A. Haley Veterans' HospitalUS Department of Veterans Affairs	This material was based on work supported by the VA and VHA (grant SDR HSR&D 08-411- TBI Screening Instruments and Processes) and the James A. Haley Veterans' Hospital.	Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Cooper DB, 2008, ARCH CLIN NEUROPSYCH, V23, P731; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; DARKES J, 1993, J CONSULT CLIN PSYCH, V61, P344, DOI 10.1037/0022-006X.61.2.344; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Faith MS, 1998, OBES RES, V6, P134, DOI 10.1002/j.1550-8528.1998.tb00327.x; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GI, 2006, BRAIN INJURY MED PRI; Mercado JM, 2008, ARCH CLIN NEUROPSYCH, V23, P731; Mussack T, 2003, EUR J MED RES, V8, P457; Nichols AL, 2008, J GEN PSYCHOL, V135, P151, DOI 10.3200/GENP.135.2.151-166; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Tanielian T, 2008, INVISIBLE WOUNDS WAR; van der Vaart W, 2007, APPL COGNITIVE PSYCH, V21, P227, DOI 10.1002/acp.1338; Van Dyke SA, 2010, MIL MED, V175, P947, DOI 10.7205/MILMED-D-10-00337; Vanderploeg RD, 2006, PSYCHOLOGICAL KNOWLEDGE IN COURT: PTSD, PAIN, AND TBI, P279, DOI 10.1007/0-387-25610-5_16; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519	21	39	39	0	1	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.		2012	49	4					545	555		10.1682/JRRD.2011.04.0069			11	Rehabilitation	Rehabilitation	149EV	WOS:000319302700007	22773258	Bronze			2021-06-18	
J	Zhang, Z; Francisco, EM; Holden, JK; Dennis, RG; Tommerdahl, M				Zhang, Zheng; Francisco, Eric M.; Holden, Jameson K.; Dennis, Robert G.; Tommerdahl, Mark			Somatosensory information processing in the aging population	FRONTIERS IN AGING NEUROSCIENCE			English	Article						aging; sensory; plasticity; adaptation; tactile; somatosensory	STIMULUS-DRIVEN SYNCHRONIZATION; WHITE-MATTER INTEGRITY; VIBROTACTILE THRESHOLDS; REACTION-TIME; OLDER-ADULTS; CORTICAL REORGANIZATION; INDIVIDUAL-DIFFERENCES; AGE; BRAIN; VARIABILITY	While it is well known that skin physiology - and consequently sensitivity to peripheral stimuli - degrades with age, what is less appreciated is that centrally mediated mechanisms allow for maintenance of the same degree of functionality in processing these peripheral inputs and interacting with the external environment. In order to demonstrate this concept, we obtained observations of processing speed, sensitivity (thresholds), discriminative capacity, and adaptation metrics on subjects ranging in age from 18 to 70. The results indicate that although reaction speed and sensory thresholds change with age, discriminative capacity, and adaptation metrics do not. The significance of these findings is that similar metrics of adaptation have been demonstrated to change significantly when the central nervous system (CNS) is compromised. Such compromise has been demonstrated in subject populations with autism, chronic pain, acute NMDA receptor block, concussion, and with tactile-thermal interactions. If the metric of adaptation parallels cortical plasticity, the results of the current study suggest that the CNS in the aging population is still capable of plastic changes, and this cortical plasticity could be the mechanism that compensates for the degradations that are known to naturally occur with age. Thus, these quantitative measures - since they can be obtained efficiently and objectively, and appear to deviate from normative values significantly with systemic cortical alterations - could be useful indicators of cerebral cortical health.	[Zhang, Zheng; Francisco, Eric M.; Holden, Jameson K.; Dennis, Robert G.; Tommerdahl, Mark] Univ N Carolina, Dept Biomed Engn, Chapel Hill, NC 27599 USA	Tommerdahl, M (corresponding author), Univ N Carolina, Dept Biomed Engn, CB 7575, Chapel Hill, NC 27599 USA.	tommerda@med.unc.edu			Department of Defense, Congressionally Directed Medical Research Program (CDMRP) [W81XWH-07-1-0287, NIH 1-R21-NS072811-01A1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS072811] Funding Source: NIH RePORTER	This work was supported, in part by the Department of Defense, Congressionally Directed Medical Research Program (CDMRP) W81XWH-07-1-0287, and NIH 1-R21-NS072811-01A1.	Bartzokis G, 2003, ARCH NEUROL-CHICAGO, V60, P393, DOI 10.1001/archneur.60.3.393; Bunce D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013567; Deary IJ, 2006, NEUROLOGY, V66, P505, DOI 10.1212/01.wnl.0000199954.81900.e2; Dinse HR, 2005, ACTA NEUROCHIR SUPPL, V93, P79; Dinse HR, 2006, PROG BRAIN RES, V157, P57, DOI 10.1016/S0079-6123(06)57005-0; Dinse HR, 2006, ANN NEUROL, V60, P88, DOI 10.1002/ana.20862; Driscoll I, 2009, NEUROLOGY, V72, P1906, DOI 10.1212/WNL.0b013e3181a82634; Favorov OV, 2011, J NEUROPHYSIOL, V105, P1342, DOI 10.1152/jn.00708.2010; Fjell AM, 2009, J NEUROSCI, V29, P15223, DOI 10.1523/JNEUROSCI.3252-09.2009; Folger SE, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-87; FOZARD JL, 1994, J GERONTOL, V49, pP179, DOI 10.1093/geronj/49.4.P179; Francisco E, 2008, EXP BRAIN RES, V191, P49, DOI 10.1007/s00221-008-1494-6; Friedman RM, 2008, J NEUROPHYSIOL, V100, P3185, DOI 10.1152/jn.90278.2008; GESCHEIDER GA, 1994, SOMATOSENS MOT RES, V11, P345, DOI 10.3109/08990229409028878; Gorus E, 2008, J GERIATR PSYCH NEUR, V21, P204, DOI 10.1177/0891988708320973; Greenwood PM, 2007, NEUROPSYCHOLOGY, V21, P657, DOI 10.1037/0894-4105.21.6.657; Greenwood PM, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00150; Gunning-Dixon FM, 2009, INT J GERIATR PSYCH, V24, P109, DOI 10.1002/gps.2087; Gunning-Dixon FM, 2000, NEUROPSYCHOLOGY, V14, P224, DOI 10.1037//0894-4105.14.2.224; Hilbig H, 2002, J CHEM NEUROANAT, V23, P199, DOI 10.1016/S0891-0618(01)00159-4; Hultsch DF, 2000, NEUROPSYCHOLOGY, V14, P588, DOI 10.1037/0894-4105.14.4.588; Hultsch DF, 2002, J GERONTOL B-PSYCHOL, V57, pP101, DOI 10.1093/geronb/57.2.P101; Kalisch T, 2008, CLIN INTERV AGING, V3, P673, DOI 10.2147/CIA.S3174; Kalisch T, 2009, CEREB CORTEX, V19, P1530, DOI 10.1093/cercor/bhn190; Kattenstroth JC, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00031; KENSHALO DR, 1986, J GERONTOL, V41, P732, DOI 10.1093/geronj/41.6.732; Kohn A, 2007, J NEUROPHYSIOL, V97, P3155, DOI 10.1152/jn.00086.2007; LEE CJ, 1992, CEREB CORTEX, V2, P81, DOI 10.1093/cercor/2.2.81; LEE CJ, 1992, CEREB CORTEX, V2, P107, DOI 10.1093/cercor/2.2.107; Li SC, 2002, NEUROSCI BIOBEHAV R, V26, P729, DOI 10.1016/S0149-7634(02)00059-3; Lin YH, 2005, J PERIPHER NERV SYST, V10, P269, DOI 10.1111/j.1085-9489.2005.10305.x; Madden DJ, 2009, NEUROPSYCHOL REV, V19, P415, DOI 10.1007/s11065-009-9113-2; MAEDA S, 1994, ERGONOMICS, V37, P1391, DOI 10.1080/00140139408964917; Morioka M, 2002, INT ARCH OCC ENV HEA, V75, P78; MORSE CK, 1993, PSYCHOL AGING, V8, P156, DOI 10.1037/0882-7974.8.2.156; Penke L, 2010, J NEUROSCI, V30, P7569, DOI 10.1523/JNEUROSCI.1553-10.2010; Ratcliff R, 2001, PSYCHOL AGING, V16, P323, DOI 10.1037//0882-7974.16.2.323; Raz N, 2005, CEREB CORTEX, V15, P1676, DOI 10.1093/cercor/bhi044; Resnick SM, 2003, J NEUROSCI, V23, P3295; Simons SB, 2007, J NEUROPHYSIOL, V97, P2121, DOI 10.1152/jn.00513.2006; Simons SB, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-43; Tannan V, 2007, BRAIN RES, V1186, P164, DOI 10.1016/j.brainres.2007.10.024; Tannan V, 2007, J NEUROSCI METH, V164, P131, DOI 10.1016/j.jneumeth.2007.04.011; Tannan V, 2005, BEHAV BRAIN FUNCT, V1, DOI 10.1186/1744-9081-1-18; Tannan V, 2005, J NEUROSCI METH, V147, P75, DOI 10.1016/j.jneumeth.2005.05.001; Tannan V, 2006, BRAIN RES, V1102, P109, DOI 10.1016/j.brainres.2006.05.037; Tannan V, 2008, AUTISM RES, V1, P223, DOI 10.1002/aur.34; THORNBURY JM, 1981, J GERONTOL, V36, P34, DOI 10.1093/geronj/36.1.34; Tommerdahl M, 2007, BRAIN RES, V1154, P116, DOI 10.1016/j.brainres.2007.04.032; Tommerdahl M, 2008, BEHAV BRAIN FUNCT, V4, DOI 10.1186/1744-9081-4-19; Tommerdahl M, 2007, BEHAV BRAIN FUNCT, V3, DOI 10.1186/1744-9081-3-61; Tommerdahl M, 2010, NEUROSCI BIOBEHAV R, V34, P160, DOI 10.1016/j.neubiorev.2009.08.009; Van Petten C, 2004, NEUROPSYCHOLOGIA, V42, P1313, DOI 10.1016/j.neuropsychologia.2004.02.009; Vernooij MW, 2009, ARCH GEN PSYCHIAT, V66, P545, DOI 10.1001/archgenpsychiatry.2009.5; VERRILLO RT, 1980, J GERONTOL, V35, P185, DOI 10.1093/geronj/35.2.185; Verrillo RT, 2002, SOMATOSENS MOT RES, V19, P238, DOI 10.1080/0899022021000009161; VERRILLO RT, 1977, B PSYCHONOMIC SOC, V9, P197, DOI 10.3758/BF03336973; VERRILLO RT, 1979, SENS PROCESS, V3, P49; VERRILLO RT, 1982, PERCEPT PSYCHOPHYS, V32, P61, DOI 10.3758/BF03204869; Wilson RS, 2002, PSYCHOL AGING, V17, P179, DOI 10.1037/0882-7974.17.2.179; Zhang Z, 2008, BIOMED ENG ONLINE, V7, DOI 10.1186/1475-925X-7-12; Zhang Z, 2011, CLIN J PAIN, V27, P755, DOI 10.1097/AJP.0b013e31821c98ec; Zhang Z, 2009, BRAIN RES, V1302, P97, DOI 10.1016/j.brainres.2009.09.037	63	39	39	0	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1663-4365			FRONT AGING NEUROSCI	Front. Aging Neurosci.	DEC 8	2011	3								18	10.3389/fnagi.2011.00018			9	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	054KD	WOS:000312341500001	22163221	DOAJ Gold, Green Published			2021-06-18	
J	Timmons, SD; Bee, T; Webb, S; Diaz-Arrastia, RR; Hesdorffer, D				Timmons, Shelly D.; Bee, Tiffany; Webb, Sharon; Diaz-Arrastia, Ramon R.; Hesdorffer, Dale			Using the Abbreviated Injury Severity and Glasgow Coma Scale Scores to Predict 2-Week Mortality After Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Abbreviated Injury Severity Score; Glasgow Coma Scale; Mortality; Prediction; Outcome	SEVERE HEAD-INJURY; ADMISSION CHARACTERISTICS; CLASSIFICATION; VALIDATION; REVISION; OUTCOMES; TRIALS	Background: Prediction of outcome after traumatic brain injury (TBI) remains elusive. We tested the use of a single hospital Glasgow Coma Scale (GCS) Score, GCS Motor Score, and the Head component of the Abbreviated Injury Scale (AIS) Score to predict 2-week cumulative mortality in a large cohort of TBI patients admitted to the eight U. S. Level I trauma centers in the TBI Clinical Trials Network. Methods: Data on 2,808 TBI patients were entered into a centralized database. These TBI patients were categorized as severe (GCS score, 3-8), moderate (9-12), or complicated mild (13-15 with positive computed tomography findings). Intubation and chemical paralysis were recorded. The cumulative incidence of mortality in the first 2 weeks after head injury was calculated using Kaplan-Meier survival analysis. Cox proportional hazards regression was used to estimate the magnitude of the risk for 2-week mortality. Results: Two-week cumulative mortality was independently predicted by GCS, GCS Motor Score, and Head AIS. GCS Severity Category and GCS Motor Score were stronger predictors of 2-week mortality than Head AIS. There was also an independent effect of age (<60 vs. >60) on mortality after controlling for both GCS and Head AIS Scores. Conclusions: Anatomic and physiologic scales are useful in the prediction of mortality after TBI. We did not demonstrate any added benefit to combining the total GCS or GCS Motor Scores with the Head AIS Score in the short-term prediction of death after TBI.	[Timmons, Shelly D.] Semmes Murphey Clin, Dept Neurosurg, Memphis, TN USA; [Bee, Tiffany] Univ Tennessee Hlth Sci Ctr, Dept Surg, Memphis, TN USA; [Webb, Sharon] Univ S Carolina, Dept Neurosurg, Columbia, SC 29208 USA; [Diaz-Arrastia, Ramon R.] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Hesdorffer, Dale] Columbia Univ Gertrude H Sergievsky Ctr, New York, NY USA; [Hesdorffer, Dale] Dept Epidemiol, New York, NY USA	Timmons, SD (corresponding author), Geisinger Hlth Syst, MC 14-05, Danville, PA 17822 USA.	stimmons@mac.com		Diaz-Arrastia, Ramon/0000-0001-6051-3594	Traumatic Brain Injury Clinical Trials Network, National Institute of Child Health and Human Development, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)NIH National Institute of Neurological Disorders & Stroke (NINDS) [HD042823]	Supported by Traumatic Brain Injury Clinical Trials Network, National Institute of Child Health and Human Development, National Institutes of Health Grant Number HD042823.	Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CIVIL ID, 1988, J TRAUMA, V28, P87, DOI 10.1097/00005373-198801000-00012; Clark DE, 2002, HEALTH SERV RES, V37, P631, DOI 10.1111/1475-6773.00041; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Demetriades D, 2001, J AM COLL SURGEONS, V193, P250, DOI 10.1016/S1072-7515(01)00993-0; Demetriades D, 2006, J TRAUMA, V61, P868, DOI 10.1097/01.ta.0000219135.33398.f3; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Gennarelli TA, 2006, INJURY, V37, P1083, DOI 10.1016/j.injury.2006.07.009; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; JONES IS, 1989, J TRAUMA, V29, P646, DOI 10.1097/00005373-198905000-00020; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LISTED NA, 1971, JAMA-J AM MED ASSOC, V215, P277; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; TEASDALE G, 1974, LANCET, V2, P81; WALDER AD, 1995, INTENS CARE MED, V21, P606, DOI 10.1007/BF01700170	25	39	40	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2011	71	5					1172	1178		10.1097/TA.0b013e31822b0f4b			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	849IG	WOS:000297118600020	22071922				2021-06-18	
J	Zhao, JB; Li, GZ; Zhang, Y; Su, XF; Hang, CH				Zhao, Jinbing; Li, Guangzhao; Zhang, Yang; Su, Xingfen; Hang, Chunhua			The potential role of JAK2/STAT3 pathway on the anti-apoptotic effect of recombinant human erythropoietin (rhEPO) after experimental traumatic brain injury of rats	CYTOKINE			English	Article						JAK2; STAT3; Anti-apoptotic; Recombinant human erythropoietin; Traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; JAK-STAT PATHWAY; TRANSCRIPTION FACTORS; INCREASED EXPRESSION; SIGNALING PATHWAY; JAK/STAT PATHWAY; CORTICAL-NEURONS; CELL-DEATH; ACTIVATION; RECEPTOR	Previous studies indicate that administration of recombinant human erythropoietin (rhEPO) protects cortical neurons following traumatic brain injury (TBI). The mechanisms of rhEPO's neuroprotection are complex and interacting, including anti-apoptosis. Here we aim to demonstrate the role of janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway on the anti-apoptotic effect of rhEPO in Feeney free falling TBI model. Activation of JAK2/STAT3 in pericontusional cortex was analyzed among rats in Sham, TBI, TBI + rhEPO, TBI + rhEPO + AG490 groups (rhEPO: 5000 U/kg day; JAK2 inhibitor AG490: 5 mg/kg day, intraperitoneal) through Western blotting, electrophoretic mobility shift assay. Bcl-2 and Bcl-xl expression (Q-PCR, Western blotting) and cell apoptosis (TUNEL) in pericontusional cortex were also detected in each group. As a result, we found that TBI could activate JAK2 and STAT3, and increase cell apoptosis in pericontusional cortex. RhEPO enhanced the expression of p-JAK2 and p-STAT3, up-regulated the mRNA and protein levels of Bcl-2 and Bcl-xl, followed by increased cell survival. Moreover, AG490 attenuated rhEPO's neuroprotection by down-regulating rhEPO-induced activation of JAK2/STAT3, and inhibiting Bcl-2 and Bcl-xl. These results suggest the essential role of JAK2/STAT3 pathway on the anti-apoptotic benefit of post-TBI rhEPO treatment. (C) 2011 Elsevier Ltd. All rights reserved.	[Zhao, Jinbing; Zhang, Yang; Su, Xingfen; Hang, Chunhua] Nanjing Univ, Dept Neurosurg, Jinling Hosp, Sch Med, Nanjing 210002, Jiangsu Provinc, Peoples R China; [Li, Guangzhao; Hang, Chunhua] So Med Univ Guangzhou, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing 210002, Jiangsu Provinc, Peoples R China	Hang, CH (corresponding author), Nanjing Univ, Dept Neurosurg, Jinling Hosp, Sch Med, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu Provinc, Peoples R China.	hang.neurosurgery@gmail.com			Natural Science Foundation of Jiangsu ProvinceNatural Science Foundation of Jiangsu Province [BK2010459]; Jiangsu Province "333 High-Level Personnel Training Project" [BRA2010196]; Nanjing Military Command, China	This study was supported by Natural Science Foundation of Jiangsu Province (BK2010459), Jiangsu Province "333 High-Level Personnel Training Project" (BRA2010196) and Medical and Health Research Fund of Nanjing Military Command, China. We appreciate the help of Gen-bao Feng for his technical assistance.	Arishima Y, 2006, SPINE, V31, P2432, DOI 10.1097/01.brs.0000239124.41410.7a; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Bernaudin M, 2002, J CEREBR BLOOD F MET, V22, P393, DOI 10.1097/00004647-200204000-00003; Bolli R, 2003, TRENDS CARDIOVAS MED, V13, P72, DOI 10.1016/S1050-1738(02)00230-X; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Buemi M, 2002, CLIN SCI, V103, P275, DOI 10.1042/cs1030275; Cattaneo E, 1999, TRENDS NEUROSCI, V22, P365, DOI 10.1016/S0166-2236(98)01378-2; Chen G, 2009, CYTOKINE, V45, P162, DOI 10.1016/j.cyto.2008.11.015; Cotena S, 2008, PANMINERVA MED, V50, P185; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Genc S, 2004, BRAIN RES, V1000, P19, DOI 10.1016/j.brainres.2003.12.037; Gorina R, 2005, J NEUROCHEM, V92, P505, DOI 10.1111/j.1471-4159.2004.02878.x; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Jelkmann W, 2007, EUR J HAEMATOL, V78, P183, DOI 10.1111/j.1600-0609.2007.00818.x; Justicia C, 2000, GLIA, V30, P253, DOI 10.1002/(SICI)1098-1136(200005)30:3<253::AID-GLIA5>3.0.CO;2-O; Kirito K, 2002, BLOOD, V99, P102, DOI 10.1182/blood.V99.1.102; Kretz A, 2005, MOL CELL NEUROSCI, V29, P569, DOI 10.1016/j.mcn.2005.04.009; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee ST, 2006, J NEUROCHEM, V96, P1728, DOI 10.1111/j.1471-4159.2006.03697.x; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Li Y, 2007, J CEREBR BLOOD F MET, V27, P1043, DOI 10.1038/sj.jcbfm.9600417; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Masamune A, 2005, WORLD J GASTROENTERO, V11, P3385, DOI 10.3748/wjg.v11.i22.3385; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Mui ALF, 1999, CELL MOL LIFE SCI, V55, P1547, DOI 10.1007/s000180050394; Osuka K, 2006, BRAIN RES, V1072, P1, DOI 10.1016/j.brainres.2005.12.003; Satriotomo I, 2006, J NEUROCHEM, V98, P1353, DOI 10.1111/j.1471-4159.2006.04051.x; Schindler C, 1999, EXP CELL RES, V253, P7, DOI 10.1006/excr.1999.4670; Seki Y, 2000, CIRC RES, V87, P12, DOI 10.1161/01.RES.87.1.12; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Sola A, 2005, PEDIATR RES, V57, P481, DOI 10.1203/01.PDR.0000155760.88664.06; Spandou E, 2004, BRAIN RES, V1021, P167, DOI 10.1016/j.brainres.2004.06.057; Tacchini L, 2002, BIOCHEM PHARMACOL, V63, P139, DOI 10.1016/S0006-2952(01)00836-X; Wen TC, 2002, J NEUROSCI RES, V67, P795, DOI 10.1002/jnr.10166; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2010, J NEUROTRAUM, V27, P205, DOI 10.1089/neu.2009.1001; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; Zhang YL, 2009, BRAIN RES, V1294, P153, DOI 10.1016/j.brainres.2009.07.077	43	39	41	0	9	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	1043-4666			CYTOKINE	Cytokine	NOV	2011	56	2					343	350		10.1016/j.cyto.2011.07.018			8	Biochemistry & Molecular Biology; Cell Biology; Immunology	Biochemistry & Molecular Biology; Cell Biology; Immunology	837OX	WOS:000296214200031	21843949				2021-06-18	
J	Anderson, GD; Farin, FM; Bammler, TK; Beyer, RP; Swan, AA; Wilkerson, HW; Kantor, ED; Hoane, MR				Anderson, Gail D.; Farin, Federico M.; Bammler, Theo K.; Beyer, Richard P.; Swan, Alicia A.; Wilkerson, Hui-Wen; Kantor, Eric D.; Hoane, Michael R.			The Effect of Progesterone Dose on Gene Expression after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						CCI injury model; gene expression; neurotrauma; progesterone	INTERLEUKIN-1 RECEPTOR ANTAGONIST; CELL-DEATH; ALLOPREGNANOLONE; NEUROPROTECTION; INFLAMMATION; RECOVERY; CORTEX; MODERATE; PATHWAYS; PEPTIDE	Microarray-based transcriptional profiling was used to determine the effect of progesterone in the cortical contusion (CCI) model. Gene ontology (GO) analysis then evaluated the effect of dose on relevant biological pathways. Treatment (vehicle, progesterone 10 mg/kg or 20 mg/kg given i.p.) was started 4 h post-injury and administered every 12 h post-injury for up to 72 h, with the last injection 12 hr prior to death for the 24 h and 72 h groups. In the CCI-injured vehicle group compared to non-injured animals, expression of 1,114, 4,229, and 291 distinct genes changed > 1.5-fold (p < 0.05) at 24 h, 72 h, and 7 days, respectively. At 24 h, the effect of low-dose progesterone on differentially expressed genes was < 20% the effect of higher dose compared to vehicle. GO analysis identified a significant effect of low-and high-dose progesterone treatment compared to vehicle on DNA damage response. At 72 h, high-dose progesterone treatment compared to vehicle affected expression of almost twice as many genes as did low-dose progesterone. Both low-and high-dose progesterone resulted in expression of genes regulating inflammatory response and apoptosis. At 7 days, there was only a modest difference in high-dose progesterone compared to vehicle, with only 14 differentially expressed genes. In contrast, low-dose progesterone resulted in 551 differentially expressed genes compared to vehicle. GO analysis identified genes for the low-dose treatment involved in positive regulation of cell proliferation, innate immune response, positive regulation of anti-apoptosis, and blood vessel remodeling.	[Anderson, Gail D.; Kantor, Eric D.] Univ Washington, Dept Pharm, Seattle, WA 98195 USA; [Farin, Federico M.; Bammler, Theo K.; Beyer, Richard P.; Wilkerson, Hui-Wen] Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA; [Swan, Alicia A.; Hoane, Michael R.] So Illinois Univ, Dept Psychol, Carbondale, IL 62901 USA	Anderson, GD (corresponding author), Univ Washington, Dept Pharm, Box 357630,Hlth Sci Complex H-361A, Seattle, WA 98195 USA.	gaila@washington.edu	Swan, Alicia A/O-3536-2018	Swan, Alicia A/0000-0003-2412-0499; Hoane, Michael/0000-0001-7779-2657	National Institutes of Health/National Institute of Child, Health and DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)NIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 HD061944-01]; UW NIEHS [P30ES07033]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061944] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P30ES007033] Funding Source: NIH RePORTER	This research was supported by a grant from the National Institutes of Health/National Institute of Child, Health and Development (R01 HD061944-01). ). This work was also supported in part by the UW NIEHS sponsored Center for Ecogenetics & Environmental Health (P30ES07033).	Allison DB, 2006, NAT REV GENET, V7, P55, DOI 10.1038/nrg1749; Aragones G, 2010, ATHEROSCLEROSIS, V213, P329, DOI 10.1016/j.atherosclerosis.2010.07.026; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; Belelli D, 2002, NEUROPHARMACOLOGY, V43, P651, DOI 10.1016/S0028-3908(02)00172-7; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; Camon E, 2004, NUCLEIC ACIDS RES, V32, pD262, DOI 10.1093/nar/gkh021; *CDC, 2011, INJ PREV CONTR TRAUM; Chesik D, 2010, NEUROSCI LETT, V468, P178, DOI 10.1016/j.neulet.2009.10.051; Choi JS, 2008, NEUROSCI LETT, V438, P233, DOI 10.1016/j.neulet.2008.04.026; Choi SH, 2009, TRENDS PHARMACOL SCI, V30, P174, DOI 10.1016/j.tips.2009.01.002; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Creagh EM, 2003, IMMUNOL REV, V193, P10, DOI 10.1034/j.1600-065X.2003.00048.x; Cui LL, 2010, BRAIN RES, V1325, P164, DOI 10.1016/j.brainres.2010.02.036; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; DABNEY A, 2006, BIOCONDUCTORS QVALUE; Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb; Di Pietro V, 2010, J NEUROTRAUM, V27, P349, DOI 10.1089/neu.2009.1095; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Faden AI, 2007, ARCH NEUROL-CHICAGO, V64, P794, DOI 10.1001/archneur.64.6.794; Fairfax BP, 2010, HUM MOL GENET, V19, P720, DOI 10.1093/hmg/ddp530; Galasko D, 2010, BIOMARK MED, V4, P27, DOI 10.2217/BMM.09.89; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Goffus AM, 2010, OXID MED CELL LONGEV, V3, P145, DOI 10.4161/oxim.3.2.11315; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Halks-Miller M, 2003, ANN NEUROL, V54, P638, DOI 10.1002/ana.10733; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hoane MR, 2006, NEUROSCI LETT, V408, P35, DOI 10.1016/j.neulet.2006.07.011; Ishrat T, 2010, EXP NEUROL, V226, P183, DOI 10.1016/j.expneurol.2010.08.023; Ivins BJ, 2010, NEUROREHABILITATION, V26, P199, DOI 10.3233/NRE-2010-0556; Jia F, 2010, J NEUROTRAUM, V27, P1059, DOI 10.1089/neu.2009.1067; Kuhn H, 2006, PROG LIPID RES, V45, P334, DOI 10.1016/j.plipres.2006.02.003; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levy A, 2009, J NEUROTRAUM, V26, P1521, DOI 10.1089/neu.2008.0746; Li J, 2008, BRAIN RES, V1196, P22, DOI 10.1016/j.brainres.2007.12.028; Loddick SA, 1997, BIOCHEM BIOPH RES CO, V234, P211, DOI 10.1006/bbrc.1997.6436; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; Malavasi F, 2008, PHYSIOL REV, V88, P841, DOI 10.1152/physrev.00035.2007; Marciano PG, 2002, NEUROCHEM RES, V27, P1147, DOI 10.1023/A:1020973308941; McKallip RJ, 2002, INT IMMUNOL, V14, P1015, DOI 10.1093/intimm/dxf068; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Perez-Martin M, 2010, EUR J NEUROSCI, V31, P1533, DOI 10.1111/j.1460-9568.2010.07220.x; Quigley A, 2009, BRAIN RES, V1304, P138, DOI 10.1016/j.brainres.2009.09.062; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P1, DOI [DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027]; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; SNEED TB, 1994, CELL IMMUNOL, V153, P456, DOI 10.1006/cimm.1994.1042; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Stein DG, 2005, ANN NY ACAD SCI, V1052, P152, DOI 10.1196/annals.1347.011; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; Swan AA, 2011, J NEUROTRAUM, V28, P431, DOI 10.1089/neu.2010.1519; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Van Lint P, 2006, CYTOKINE GROWTH F R, V17, P217, DOI 10.1016/j.cytogfr.2006.04.001; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2005, J CLIN PHARMACOL, V45, P640, DOI 10.1177/0091270005276201; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; Yasuda M, 2002, HISTOL HISTOPATHOL, V17, P945, DOI 10.14670/HH-17.945	76	39	40	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2011	28	9					1827	1843		10.1089/neu.2011.1911			17	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	821AK	WOS:000294947000014	21770760	Green Published			2021-06-18	
J	Brenner, LA; Betthauser, LM; Homaifar, BY; Villarreal, E; Harwood, JEF; Staves, PJ; Huggins, JA				Brenner, Lisa A.; Betthauser, Lisa M.; Homaifar, Beeta Y.; Villarreal, Edgar; Harwood, Jeri E. F.; Staves, Pamela J.; Huggins, Joseph A.			Posttraumatic Stress Disorder, Traumatic Brain Injury, and Suicide Attempt History among Veterans Receiving Mental Health Services	SUICIDE AND LIFE-THREATENING BEHAVIOR			English	Article							EMOTIONAL RISK-FACTORS; CUMULATIVE DISADVANTAGE; IRAQ; AFGHANISTAN; ASSOCIATION; PREVALENCE; ADVERSITY; BURDEN	History of posttraumatic stress disorder (PTSD) or traumatic brain injury (TBI) has been found to increase risk of suicidal behavior. The association between suicide attempt history among veterans with PTSD and/or TBI was explored. Cases (N = 81) and 2: 1 matched controls (N = 160) were randomly selected from a Veterans Affairs Medical Center clinical database. PTSD history was associated with an increased risk for a suicide attempt (OR = 2.8; 95% CI: 1.5, 5.1). This increased risk was present for those with and without a history of TBI. Results support incorporating PTSD history when assessing suicide risk among veterans with and without TBI.	[Brenner, Lisa A.; Betthauser, Lisa M.; Homaifar, Beeta Y.; Staves, Pamela J.; Huggins, Joseph A.] VA VISN 19 Mental Illness Res Educ & Clin Ctr MIR, Denver, CO 80220 USA; [Brenner, Lisa A.; Homaifar, Beeta Y.; Harwood, Jeri E. F.] Univ Colorado Denver, Sch Med, Denver, CO USA; [Villarreal, Edgar] Texas A&M Univ, Dept Counseling Psychol, College Stn, TX USA	Brenner, LA (corresponding author), VA VISN 19 Mental Illness Res Educ & Clin Ctr MIR, 1055 Clermont St,4E-135, Denver, CO 80220 USA.	lisa.brenner@va.gov	Brenner, Lisa A./AAG-2442-2019	Huggins, Joe/0000-0001-8151-5062			Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brenner LA, 2009, MIL MED, V174, P347, DOI 10.7205/MILMED-D-01-5808; Brenner LA, 2009, REHABIL PSYCHOL, V54, P390, DOI 10.1037/a0017802; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; BULLMAN TA, 1994, J NERV MENT DIS, V182, P604, DOI 10.1097/00005053-199411000-00002; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; DAVIDSON JRT, 1991, PSYCHOL MED, V21, P713, DOI 10.1017/S0033291700022352; *DEP VET AFF, 2004, TRAUM BRAIN INJ CONT; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Ferraro KF, 2003, AM SOCIOL REV, V68, P707, DOI 10.2307/1519759; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Ivins BJ, 2003, J TRAUMA, V55, P617, DOI 10.1097/01.TA.0000052368.97573.D4; Jakupcak M, 2009, J TRAUMA STRESS, V22, P303, DOI 10.1002/jts.20423; Langlois JA, 2006, TRAUMATIC BRAIN INJU; McCarthy JF, 2009, AM J EPIDEMIOL, V169, P1033, DOI 10.1093/aje/kwp010; Morgan C, 2008, PSYCHOL MED, V38, P1701, DOI 10.1017/S0033291708004534; Oquendo MA, 2004, J NERV MENT DIS, V192, P430, DOI 10.1097/01.nmd.0000126706.53615.7b; ORand AM, 1996, GERONTOLOGIST, V36, P230, DOI 10.1093/geront/36.2.230; Preston SH, 1998, SOC SCI MED, V47, P1231, DOI 10.1016/S0277-9536(98)00180-4; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Seguin M, 2007, PSYCHOL MED, V37, P1575, DOI 10.1017/S0033291707000955; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2005, J NERV MENT DIS, V193, P680, DOI 10.1097/01.nmd.0000180743.65943.c8; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; VanCott AC, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-4; Walker R, 2007, J HEAD TRAUMA REHAB, V22, P360, DOI 10.1097/01.HTR.0000300231.90619.50	30	39	39	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0363-0234	1943-278X		SUICIDE LIFE-THREAT	Suicide Life-Threat. Behav.	AUG	2011	41	4					416	423		10.1111/j.1943-278X.2011.00041.x			8	Psychiatry; Psychology, Multidisciplinary	Psychiatry; Psychology	810VX	WOS:000294157200006	21599727				2021-06-18	
J	Kokshoorn, NE; Smit, JWA; Nieuwlaat, WA; Tiemensma, J; Bisschop, PH; Veldman, RG; Roelfsema, F; Franken, AAM; Wassenaar, MJE; Biermasz, NR; Romijn, JA; Pereira, AM				Kokshoorn, N. E.; Smit, J. W. A.; Nieuwlaat, W. A.; Tiemensma, J.; Bisschop, P. H.; Veldman, R. Groote; Roelfsema, F.; Franken, A. A. M.; Wassenaar, M. J. E.; Biermasz, N. R.; Romijn, J. A.; Pereira, A. M.			Low prevalence of hypopituitarism after traumatic brain injury: a multicenter study	EUROPEAN JOURNAL OF ENDOCRINOLOGY			English	Article							ANTERIOR-PITUITARY FUNCTION; POSTTRAUMATIC HYPOPITUITARISM; LONG-TERM; DYSFUNCTION; SCALE; INSUFFICIENCY; ASSOCIATION; DEFICIENCY; FATIGUE; VALUES	Objective: Hypopituitarism after traumatic brain injury (TBI) is considered to be a prevalent condition. However, prevalence rates differ considerably among reported studies, due to differences in definitions, endocrine assessments of hypopituitarism, and confounding factors, such as timing of evaluation and the severity of the trauma. Aim: To evaluate the prevalence of hypopituitarism in a large cohort of TBI patients after long-term follow-up using a standardized endocrine evaluation. Study design: Cross-sectional study. Patients and methods: We included 112 patients with TBI, hospitalized for at least 3 days and duration of follow-up>1 year after TBI from five (neurosurgical) referral centers. Evaluation of pituitary function included fasting morning hormone measurements and insulin tolerance test (n = 90) or, when contraindicated, ACTH stimulation and/or CRH stimulation tests and a GH releasing hormone-arginine test (n = 22). Clinical evaluation included quality of life questionnaires. Results: We studied 112 patients (75 males), with median age 48 years and mean body mass index (BMI) 26.7 +/- 4.8 kg/m(2). Mean duration of hospitalization was 11 (3-105), and 33% of the patients had a severe trauma (Glasgow Coma Scale < 9) after TBI. The mean duration of follow-up was 4 (1-12) years. Hypopituitarism was diagnosed in 5.4% (6/112) of patients: severe GH deficiency (n = 3), hypogonadism (n = 1), adrenal insufficiency (n = 2). Patients diagnosed with pituitary insufficiency had significantly higher BMI (P = 0.002). Conclusion: In this study, the prevalence of hypopituitarism during long-term follow-up after TBI was low. Prospective studies are urgently needed to find reliable predictive tools for the identification of patients with a significant pre-test likelihood for hypopituitarism after TBI.	[Kokshoorn, N. E.; Smit, J. W. A.; Tiemensma, J.; Roelfsema, F.; Wassenaar, M. J. E.; Biermasz, N. R.; Romijn, J. A.; Pereira, A. M.] Leiden Univ, Med Ctr, Dept Endocrinol & Metab Dis C4 R, NL-2300 RC Leiden, Netherlands; [Nieuwlaat, W. A.] St Elizabeth Hosp, Dept Internal Med, Tilburg, Netherlands; [Bisschop, P. H.] Univ Amsterdam, Acad Med Ctr, Dept Endocrinol & Metab, NL-1105 AZ Amsterdam, Netherlands; [Veldman, R. Groote] Med Spectrum Twente, Dept Internal Med, Enschede, Netherlands; [Franken, A. A. M.] Isala Clin, Dept Internal Med, Zwolle, Netherlands	Kokshoorn, NE (corresponding author), Leiden Univ, Med Ctr, Dept Endocrinol & Metab Dis C4 R, POB 9600, NL-2300 RC Leiden, Netherlands.	n.e.kokshoorn@lumc.nl	Smit, J.W.A./H-8091-2014; Pereira, Alberto M./Q-7175-2017	Smit, J.W.A./0000-0003-1052-9314; Pereira, Alberto M./0000-0002-1194-9866	PfizerPfizer	This research was supported by an unrestricted grant from Pfizer.	Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Blair JC, 2010, BRIT J NEUROSURG, V24, P10, DOI 10.3109/02688690903536637; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Brabant G, 2003, HORM RES, V60, P53, DOI 10.1159/000071871; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; Colao A, 2009, J CLIN ENDOCR METAB, V94, P4414, DOI 10.1210/jc.2009-1134; Corneli G, 2005, EUR J ENDOCRINOL, V153, P257, DOI 10.1530/eje.1.01967; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; Ho KKY, 2007, EUR J ENDOCRINOL, V157, P695, DOI 10.1530/EJE-07-0631; Hunt S M, 1980, Sociol Health Illn, V2, P231; HUNT SM, 1980, J EPIDEMIOL COMMUN H, V34, P281, DOI 10.1136/jech.34.4.281; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2008, PITUITARY, V11, P255, DOI 10.1007/s11102-008-0102-x; Klose M, 2007, J CLIN ENDOCR METAB, V92, P3861, DOI 10.1210/jc.2007-0901; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Kokshoorn NE, 2010, EUR J ENDOCRINOL, V162, P11, DOI 10.1530/EJE-09-0601; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Maric NP, 2010, J ENDOCRINOL INVEST, V33, P770, DOI [10.1007/BF03350340, 10.3275/7045]; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Ross HA, 2008, CLIN CHEM LAB MED, V46, P1334, DOI 10.1515/CCLM.2008.261; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; Tanriverdi F, 2008, CLIN ENDOCRINOL, V68, P573, DOI 10.1111/j.1365-2265.2007.03070.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; TEASDALE G, 1974, LANCET, V2, P81; van Aken M O, 2005, Pituitary, V8, P183; van der Eerden AW, 2010, EUR J ENDOCRINOL, V162, P19, DOI 10.1530/EJE-09-0436; Wachter D, 2009, J CLIN NEUROSCI, V16, P202, DOI 10.1016/j.jocn.2008.01.009; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	35	39	40	0	1	BIOSCIENTIFICA LTD	BRISTOL	EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND	0804-4643	1479-683X		EUR J ENDOCRINOL	Eur. J. Endocrinol.	AUG	2011	165	2					225	231		10.1530/EJE-11-0365			7	Endocrinology & Metabolism	Endocrinology & Metabolism	792FY	WOS:000292727400006	21646286	Bronze			2021-06-18	
J	Phelan, SM; Griffin, JM; Hellerstedt, WL; Sayer, NA; Jensen, AC; Burgess, DJ; van Ryn, M				Phelan, Sean M.; Griffin, Joan M.; Hellerstedt, Wendy L.; Sayer, Nina A.; Jensen, Agnes C.; Burgess, Diana J.; van Ryn, Michelle			Perceived stigma, strain, and mental health among caregivers of veterans with traumatic brain injury	DISABILITY AND HEALTH JOURNAL			English	Article						Social stigma; Brain injuries; Caregivers; Mental health; Social isolation; Veterans	SOCIAL SUPPORT; FAMILY CAREGIVERS; PSYCHOLOGICAL DISTRESS; LIFE SATISFACTION; BURDEN; ILLNESS; STRESS; DISCRIMINATION; INDIVIDUALS; DEPRESSION	Background: Family caregivers of individuals with stigmatized conditions can experience stigma-by-association and discrimination. Moderate-to-severe traumatic brain injury (TB!) may elicit a stigma response if there are visible physical or neurobehavioral effects of the injury. Stigma is a considerable source of stress and may contribute to caregiver strain and stress-related mental health outcomes. We measured the frequency of perceived stigma and discrimination among caregivers of veterans with TBI and examined whether perceived stigma and discrimination are associated with caregiver strain, social isolation, depression, and anxiety. Methods: Seventy caregivers of veterans with TBI completed a mailed survey that assessed perceptions of discrimination toward themselves or their care recipient, stigma associated with caregiving, and whether they felt the need to cover up or provide an explanation for their care recipient's injury. Caregiver strain, social isolation, depression, and anxiety were also assessed via the questionnaire. Multivariate linear regression was used to test the associations between stigma and discrimination measures and outcomes, controlling for potential confounders and other caregiver or care recipient characteristics. Results: Both perceptions of caregiver discrimination and stigma associated with caregiving were significantly associated with caregiver strain, social isolation, depression, and anxiety. Perceived discrimination against the individual with TBI was associated with caregiver strain and social isolation. Conclusions: Our findings suggest that perceived discrimination and stigma experienced by caregivers of individuals with TBI are stressors that may lead to poor caregiver mental health outcomes. In order to promote both caregiver and care recipient health, we suggest that mental health support services consider these important stressors. (C) 2011 Elsevier Inc. All rights reserved.	[Phelan, Sean M.; van Ryn, Michelle] Univ Minnesota, Dept Family Med & Community Hlth, Minneapolis, MN 55414 USA; [Phelan, Sean M.; Griffin, Joan M.; Sayer, Nina A.; Jensen, Agnes C.; Burgess, Diana J.] Minneapolis VA Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN 55414 USA; [Hellerstedt, Wendy L.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN 55414 USA	Phelan, SM (corresponding author), 925 Delaware St SE,Suite 220, Minneapolis, MN 55414 USA.	phel0085@umn.edu	Burgess, Diana/A-1946-2016; Sayer, Nina/E-3249-2016		Veterans Affairs Predoctoral Associated Health Rehabilitation Research Fellowship	This research was supported by a Veterans Affairs Predoctoral Associated Health Rehabilitation Research Fellowship.	Alspaugh MEL, 1999, PSYCHOL AGING, V14, P34, DOI 10.1037/0882-7974.14.1.34; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Angermeyer MC, 2003, SOC PSYCH PSYCH EPID, V38, P593, DOI 10.1007/s00127-003-0680-x; Baronet AM, 1999, CLIN PSYCHOL REV, V19, P819, DOI 10.1016/S0272-7358(98)00076-2; Clark R, 1999, AM PSYCHOL, V54, P805, DOI 10.1037/0003-066X.54.10.805; Corrigan PW, 2006, J FAM PSYCHOL, V20, P239, DOI 10.1037/0893-3200.20.2.239; DeWalt DA, 2007, MED CARE, V45, pS12, DOI 10.1097/01.mlr.0000254567.79743.e2; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Edwards AB, 2002, AGING MENT HEALTH, V6, P55, DOI 10.1080/13607860120101149; Edwards Nancy E, 2002, J Neurosci Nurs, V34, P184; Federal Poverty Level United States Department of Health and Human Services, 2009, FED REGISTER, V74, P4199; Gaugler JE, 2003, INT J AGING HUM DEV, V57, P91, DOI 10.2190/8MNF-QMA3-A5TX-6QQ3; Gaugler JE, 2004, AGING MENT HEALTH, V8, P65, DOI 10.1080/13607860310001613356; Goldstein NE, 2004, J PALLIAT CARE, V20, P38, DOI 10.1177/082585970402000108; Gonzalez J, 2007, PSCHIATRIC SERV, V58; Green SE, 2007, SOC SCI MED, V64, P150, DOI 10.1016/j.socscimed.2006.08.025; Green SE, 2003, SOC SCI MED, V57, P1361, DOI 10.1016/S0277-9536(02)00511-7; Griffin JM, 2009, J REHABIL RES DEV, V46, P879, DOI 10.1682/JRRD.2008.08.0104; Grunfeld E, 2004, CAN MED ASSOC J, V170, P1795, DOI 10.1503/cmaj.1031205; Halter MJ, 2008, ARCH PSYCHIAT NURS, V22, P20, DOI 10.1016/j.apnu.2007.03.003; Hebl MR, 2003, PERS SOC PSYCHOL B, V29, P28, DOI 10.1177/0146167202238369; Hughes ME, 2004, RES AGING, V26, P655, DOI 10.1177/0164027504268574; Kang E, 2006, AIDS PATIENT CARE ST, V20, P712, DOI 10.1089/apc.2006.20.712; Kessler RC, 1999, J HEALTH SOC BEHAV, V40, P208, DOI 10.2307/2676349; Kittikorn N, 2006, QUAL HEALTH RES, V16, P1286, DOI 10.1177/1049732306293992; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Larson JE, 2008, ACAD PSYCHIATR, V32, P87, DOI 10.1176/appi.ap.32.2.87; LaVeist TA, 2003, INT J HEALTH SERV, V33, P331, DOI 10.2190/TCAC-P90F-ATM5-B5U0; Lazarus R.S., 1984, STRESS APPRAISAL COP; Link BG, 1997, J HEALTH SOC BEHAV, V38, P177, DOI 10.2307/2955424; Magana SM, 2007, PSYCHIAT SERV, V58, P378, DOI 10.1176/appi.ps.58.3.378; Major B, 2005, ANNU REV PSYCHOL, V56, P393, DOI 10.1146/annurev.psych.56.091103.070137; Major B, 1999, J PERS SOC PSYCHOL, V77, P735, DOI 10.1037/0022-3514.77.4.735; MALONEBEACH EE, 1991, INT J AGING HUM DEV, V32, P103, DOI 10.2190/WKAL-WKPU-FJMT-6Y8U; Markowitz FE, 1998, J HEALTH SOC BEHAV, V39, P335, DOI 10.2307/2676342; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Martens L, 2001, SOC PSYCH PSYCH EPID, V36, P128, DOI 10.1007/s001270050301; McLellan T, 2010, J INT NEUROPSYCH SOC, V16, P705, DOI 10.1017/S1355617710000524; Mickelson KD, 2001, PERS SOC PSYCHOL B, V27, P1046, DOI 10.1177/0146167201278011; Myers A, 1999, INT J OBESITY, V23, P221, DOI 10.1038/sj.ijo.0800765; NOLENHOEKSEMA S, 1993, J ABNORM PSYCHOL, V102, P20, DOI 10.1037/0021-843X.102.1.20; PEEBLESKLEIGER MJ, 1994, J TRAUMA STRESS, V7, P173, DOI 10.1007/BF02102943; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; Perlick DA, 2001, PSYCHIAT SERV, V52, P1627, DOI 10.1176/appi.ps.52.12.1627; Perlick DA, 2004, PSYCHIAT SERV, V55, P1029, DOI 10.1176/appi.ps.55.9.1029; Puhl RM, 2010, AM J PUBLIC HEALTH, V100, P1019, DOI 10.2105/AJPH.2009.159491; Reeve BB, 2007, MED CARE, V45, pS22, DOI 10.1097/01.mlr.0000250483.85507.04; Reynolds M, 1998, BEHAV RES THER, V36, P135, DOI 10.1016/S0005-7967(98)00013-8; Rosenberg M., 1979, CONCEIVING SELF; Sallis J.F., 2002, HLTH BEHAV HLTH ED T; SCAMBLER G, 1986, SOCIOL HEALTH ILL, V8, P26, DOI 10.1111/1467-9566.ep11346455; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; Sherbourne C D, 1992, Qual Life Res, V1, P235, DOI 10.1007/BF00435632; SHERBOURNE CD, 1992, J BEHAV MED, V15, P447, DOI 10.1007/BF00844941; SHERBOURNE CD, 1995, J CONSULT CLIN PSYCH, V63, P345, DOI 10.1037/0022-006X.63.3.345; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; SHERBOURNE CD, 1990, J HEALTH SOC BEHAV, V31, P328, DOI 10.2307/2136817; Struening FL, 2001, PSYCHIATR SERV, V52, P1633; Szmukler GI, 1996, SOC PSYCH PSYCH EPID, V31, P137, DOI 10.1007/BF00785760; TOSELAND RW, 1995, SOC SCI MED, V40, P517, DOI 10.1016/0277-9536(94)E0093-8; TOSELAND RW, 1990, SOC WORK, V35, P209; Treasure J, 2001, SOC PSYCH PSYCH EPID, V36, P343, DOI 10.1007/s001270170039; Turner HA, 1998, J HEALTH SOC BEHAV, V39, P137, DOI 10.2307/2676396; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Visser-Meily JMA, 2004, CLIN REHABIL, V18, P601, DOI 10.1191/0269215504cr776oa; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Werner P, 2008, AGING MENT HEALTH, V12, P92, DOI 10.1080/13607860701616325; Werner P, 2008, INT PSYCHOGERIATR, V20, P174, DOI 10.1017/S1041610207005340; Williams DR, 2008, AM J PUBLIC HEALTH, V98, pS29, DOI 10.2105/AJPH.98.Supplement_1.S29; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649	71	39	40	0	25	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1936-6574	1876-7583		DISABIL HEALTH J	Disabil. Health J.	JUL	2011	4	3					177	184		10.1016/j.dhjo.2011.03.003			8	Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation	Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation	792XU	WOS:000292784500005	21723524				2021-06-18	
J	Li, GZ; Zhang, Y; Zhao, JB; Wu, GJ; Su, XF; Hang, CH				Li, Guang-Zhao; Zhang, Yang; Zhao, Jin-Bing; Wu, Guo-Jian; Su, Xing-Fen; Hang, Chun-Hua			Expression of myeloid differentiation primary response protein 88 (Myd88) in the cerebral cortex after experimental traumatic brain injury in rats	BRAIN RESEARCH			English	Article						Myeloid differentiation primary response protein 88; NF-kappa B; Inflammatory cytokine; ICAM-1; Traumatic brain injury	TOLL-LIKE RECEPTORS; NF-KAPPA-B; CENTRAL-NERVOUS-SYSTEM; CLOSED-HEAD INJURY; ISCHEMIA-REPERFUSION; CORTICAL CONTUSION; SIGNALING PATHWAY; PROINFLAMMATORY CYTOKINES; MICE; ACTIVATION	A growing body of evidence indicates that Toll-like receptors (TLRs) and Interleukin-1 (IL-1) family have been shown to be involved in the damaging inflammatory processes associated with stroke, infection, neoplasia, and other diseases in the central nervous system. Myeloid differentiation primary response protein 88 (Myd88) is a critical adaptor protein that transmits signals for TLRs and IL-1 family. Therefore, this study aimed to detect the expression of Myd88 protein and mRNA in a rat weight-dropping trauma model and to clarify the role of Myd88 after traumatic brain injury (TBI). A total of fifty-four Sprague Dawley (SD) rats were randomly divided into control group and TBI groups at hours 6, 12 and on day 1, day 2, day 3, and day 7. The TBI groups suffered experimental TBI by improved Feeney model. Myd88 expression is measured by Reverse Transcription PCR (RT-PCR), Western blot analysis and immunohistochemistry; and nuclear factor-kappaB (NF-kappa B) binding activity by electrophoretic mobility shift assay (EMSA); The levels of tumor necrosis factor-alpha (TNF-alpha) and Interleukin 1 beta (IL-1 beta) were measured by enzyme linked immunosorbent assay (ELISA) and the intercellular adhesion molecule-1 (ICAM-1) expression by immunohistochemistry. The expression of Myd88 in the injured brain was dramatically increased through 6 h and 7 days postinjury, and peaked on 3 days. NF-kappa B, TNF-alpha, IL-1 beta. and ICAM-1 also ascended significantly after TBI. Our data demonstrated that Myd88 was increasingly expressed in a parallel time course to the up-regulation of NF-kappa B, proinflammatory cytokines and ICAM-1 and there was a highly positive relationship among them. These findings might have important implications during the administration of specific Myd88 antagonists in order to prevent or reduce inflammatory response after TBI. (C) 2011 Elsevier B.V. All rights reserved.	[Li, Guang-Zhao; Hang, Chun-Hua] So Med Univ Guangzhou, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing 210002, Jiangsu Prov, Peoples R China; [Zhang, Yang; Zhao, Jin-Bing; Wu, Guo-Jian; Su, Xing-Fen; Hang, Chun-Hua] Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing 210008, Jiangsu Prov, Peoples R China	Hang, CH (corresponding author), So Med Univ Guangzhou, Jinling Hosp, Sch Med, Dept Neurosurg, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu Prov, Peoples R China.	lgzh718@tom.com; hangchunhua@yahoo.cn			Natural Science Foundation of Jiangsu Province, ChinaNatural Science Foundation of Jiangsu Province [BK2010459]	We would like to thank Dr. Gen-bao Feng and Drs. Meng-liang Zhou for their technical assistance. This study is supported by Natural Science Foundation of Jiangsu Province, China (BK2010459).	Babcock AA, 2008, J IMMUNOL, V181, P6481, DOI 10.4049/jimmunol.181.9.6481; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen G, 2007, MEDIAT INFLAMM, V2007, DOI 10.1155/2007/93431; Cook DN, 2004, NAT IMMUNOL, V5, P975, DOI 10.1038/ni1116; Davis CN, 2006, P NATL ACAD SCI USA, V103, P2953, DOI 10.1073/pnas.0510802103; Dinarello CA, 1999, J ALLERGY CLIN IMMUN, V103, P11, DOI 10.1016/S0091-6749(99)70518-X; Felderhoff-Mueser U, 2005, TRENDS NEUROSCI, V28, P487, DOI 10.1016/j.tins.2005.06.008; Feng Y, 2008, AM J PHYSIOL-HEART C, V295, pH1311, DOI 10.1152/ajpheart.00119.2008; Gao Y, 2009, BIOL PHARM BULL, V32, P1665, DOI 10.1248/bpb.32.1665; Gao Y, 2009, BIOMED PHARMACOTHER, V63, P442, DOI 10.1016/j.biopha.2008.06.028; Hang CH, 2005, NEUROL INDIA, V53, P312, DOI 10.4103/0028-3886.16930; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hoshino K, 2002, INT IMMUNOL, V14, P1225, DOI 10.1093/intimm/dxf089; Hua F, 2009, BIOCHEM BIOPH RES CO, V390, P678, DOI 10.1016/j.bbrc.2009.10.027; Kielian T, 2006, J NEUROSCI RES, V83, P711, DOI 10.1002/jnr.20767; Kielian T, 2007, J IMMUNOL, V178, P4528, DOI 10.4049/jimmunol.178.7.4528; Koedel U, 2007, AM J PATHOL, V171, P200, DOI 10.2353/ajpath.2007.060821; Landreth GE, 2009, CURR TOP MICROBIOL, V336, P137, DOI 10.1007/978-3-642-00549-7_8; Lehnardt S, 2007, J NEUROIMMUNOL, V190, P28, DOI 10.1016/j.jneuroim.2007.07.023; Loiarro M, 2007, J LEUKOCYTE BIOL, V82, P801, DOI 10.1189/jlb.1206746; Ma CX, 2009, CHINESE MED J-PEKING, V122, P1575, DOI 10.3760/cma.j.issn.0366-6999.2009.13.019; MCKEAN DJ, 1995, INT IMMUNOL, V7, P9, DOI 10.1093/intimm/7.1.9; Memet S, 2006, BIOCHEM PHARMACOL, V72, P1180, DOI 10.1016/j.bcp.2006.09.003; Mishra BB, 2009, CURR TOP MICROBIOL, V336, P83, DOI 10.1007/978-3-642-00549-7_5; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; O'Brien K, 2008, CURR MED CHEM, V15, P1105, DOI 10.2174/092986708784221458; Prendergast Catriona T., 2009, Endocrine Metabolic & Immune Disorders-Drug Targets, V9, P315; Racke MK, 2009, CURR TOP MICROBIOL, V336, P155, DOI 10.1007/978-3-642-00549-7_9; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Sette Claudio, 2007, J Leukoc Biol, V82, P811; Sifringer M, 2007, NEUROBIOL DIS, V25, P614, DOI 10.1016/j.nbd.2006.11.003; Stevens SL, 2008, J CEREBR BLOOD F MET, V28, P1040, DOI 10.1038/sj.jcbfm.9600606; Tang SC, 2007, P NATL ACAD SCI USA, V104, P13798, DOI 10.1073/pnas.0702553104; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Teng WY, 2009, MEDIAT INFLAMM, V2009, DOI 10.1155/2009/473276; Verstrepen L, 2008, CELL MOL LIFE SCI, V65, P2964, DOI 10.1007/s00018-008-8064-8; Yamamoto M, 2004, MOL IMMUNOL, V40, P861, DOI 10.1016/j.molimm.2003.10.006; Yang CM, 2010, J CELL PHYSIOL, V224, P516, DOI 10.1002/jcp.22153; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Zaheer A, 2007, BRAIN RES, V1144, P239, DOI 10.1016/j.brainres.2007.01.075	44	39	44	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUN 17	2011	1396						96	104		10.1016/j.brainres.2011.04.014			9	Neurosciences	Neurosciences & Neurology	788AD	WOS:000292416900011	21530945				2021-06-18	
J	Bohman, LE; Heuer, GG; Macyszyn, L; Maloney-Wilensky, E; Frangos, S; Le Roux, PD; Kofke, A; Levine, JM; Stiefel, MF				Bohman, Leif-Erik; Heuer, Gregory G.; Macyszyn, Lukascz; Maloney-Wilensky, Eileen; Frangos, Suzanne; Le Roux, Peter D.; Kofke, Andrew; Levine, Joshua M.; Stiefel, Michael F.			Medical Management of Compromised Brain Oxygen in Patients with Severe Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Brain tissue oxygen pressure; Brain hypoxia; Intracranial pressure; Cerebral perfusion pressure; Outcome; Traumatic brain injury; Head injury; Monitoring	CEREBRAL PERFUSION-PRESSURE; BLOOD-CELL TRANSFUSION; TISSUE OXYGEN; INTRACRANIAL-PRESSURE; REGIONAL OXYGENATION; HYPERTONIC SALINE; METABOLISM; AUGMENTATION; HYPERTENSION	Background Brain tissue oxygen (PbtO(2)) monitoring is used in severe traumatic brain injury (TBI) patients. How brain reduced PbtO(2) should be treated and its response to treatment is not clearly defined. We examined which medical therapies restore normal PbtO(2) in TBI patients. Methods Forty-nine (mean age 40 +/- A 19 years) patients with severe TBI (Glasgow Coma Scale [GCS] a parts per thousand currency sign 8) admitted to a University-affiliated, Level I trauma center who had at least one episode of compromised brain oxygen (PbtO(2) < 25 mmHg for > 10 min), were retrospectively identified from a prospective observational cohort study. Intracranial pressure (ICP), cerebral perfusion pressure (CPP), and PbtO(2) were monitored continuously. Episodes of compromised PbtO(2) and brain hypoxia (PbtO(2) < 15 mmHg for > 10 min) and the medical interventions that improved PbtO(2) were identified. Results Five hundred and sixty-four episodes of compromised PbtO2 were identified from 260 days of PbtO2 monitoring. Medical management used in a "cause-directed" manner successfully reversed 72% of the episodes of compromised PbtO(2), defined as restoration of a "normal" PbtO(2) (i.e. a parts per thousand yen25 mmHg). Ventilator manipulation, CPP augmentation, and sedation were the most frequent interventions. Increasing FiO(2) restored PbtO(2) 80% of the time. CPP augmentation and sedation were effective in 73 and 66% of episodes of compromised brain oxygen, respectively. ICP reduction using mannitol was effective in 73% of treated episodes, though was used only when PbtO(2) was compromised in the setting of elevated ICP. Successful medical treatment of brain hypoxia was associated with decreased mortality. Survivors (n = 38) had a 71% rate of response to treatment and non-survivors (n = 11) had a 44% rate of response (P = 0.01). Conclusion Reduced PbtO(2) may occur in TBI patients despite efforts to maintain CPP. Medical interventions other than those to treat ICP and CPP can improve PbtO(2). This may increase the number of therapies for severe TBI in the ICU.	[Bohman, Leif-Erik; Heuer, Gregory G.; Macyszyn, Lukascz; Maloney-Wilensky, Eileen; Frangos, Suzanne; Le Roux, Peter D.; Kofke, Andrew; Levine, Joshua M.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Levine, Joshua M.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Kofke, Andrew; Levine, Joshua M.] Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Stiefel, Michael F.] New York Med Coll, Westchester Med Ctr, Dept Neurosurg, Div NeuroTrauma, Valhalla, NY 10595 USA	Bohman, LE (corresponding author), Univ Penn, Dept Neurosurg, 3 Silverstein Pavilion,3400 Spruce St, Philadelphia, PA 19104 USA.	Leif-Erik.Bohman@uphs.upenn.edu		Bohman, Leif-Erik/0000-0002-3889-9328	Integra Foundation; Integra Neurosciences; Mary Elisabeth Groff Surgical and Medical Research Trust	This article was supported by Research Grants from the Integra Foundation (PDL), Integra Neurosciences (PDL), and the Mary Elisabeth Groff Surgical and Medical Research Trust (PDL). PDL is a member of Integra's Speaker's Bureau.	Adamides AA, 2009, ACTA NEUROCHIR, V151, P1399, DOI 10.1007/s00701-009-0398-y; American College of Surgeons, 2008, ATLS ADV TRAUM LIF S; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P1; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS21; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS65; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Chen HI, 2008, NEUROSURGERY, V63, P880, DOI 10.1227/01.NEU.0000327882.10629.06; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESTNUT RM, 2000, HEAD INJURY, P229; Dhar R, 2009, STROKE, V40, P3039, DOI 10.1161/STROKEAHA.109.556159; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Gracias VH, 2004, J TRAUMA, V56, P469, DOI 10.1097/01.TA.0000114274.95423.C0; GRACIAS VH, 2004, J TRAUMA, V56, P72; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Johnston AJ, 2004, INTENS CARE MED, V30, P791, DOI 10.1007/s00134-003-2155-7; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Ledwith MB, 2010, J NEUROSCI NURS, V42, P280, DOI 10.1097/JNN.0b013e3181ecafd4; Maloney-Wilensky E, 2009, CRIT CARE MED, V37, P2057, DOI 10.1097/CCM.0b013e3181a009f8; Martini RP, 2009, J NEUROSURG, V111, P644, DOI 10.3171/2009.2.JNS08998; McCarthy MC, 2009, SURGERY, V146, P585, DOI 10.1016/j.surg.2009.06.059; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Muench E, 2007, CRIT CARE MED, V35, P1844, DOI 10.1097/01.CCM.0000275392.08410.DD; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; Procaccio F, 2000, J Neurosurg Sci, V44, P11; Radolovich DK, 2010, ANESTH ANALG, V110, P165, DOI 10.1213/ANE.0b013e3181c0722f; Leal-Noval SR, 2008, CRIT CARE MED, V36, P1290, DOI 10.1097/CCM.0b013e3181692dfc; ROBERTSON C, 2004, YOUMANS NEUROLOGICAL, P5103; Rockswold GL, 2009, NEUROSURGERY, V65, P1035, DOI 10.1227/01.NEU.0000359533.16214.04; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; Weiner GM, 2010, NEUROSURGERY, V66, P1111, DOI 10.1227/01.NEU.0000369607.71913.3E; Wilensky Eileen Maloney, 2005, J Neurosci Nurs, V37, P278; Zygun DA, 2009, CRIT CARE MED, V37, P1074, DOI 10.1097/CCM.0b013e318194ad22	43	39	39	1	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	JUN	2011	14	3					361	369		10.1007/s12028-011-9526-7			9	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	759FT	WOS:000290226800006	21394543				2021-06-18	
J	Seifert, S; Pannell, M; Uckert, W; Farber, K; Kettenmann, H				Seifert, Stefanie; Pannell, Maria; Uckert, Wolfgang; Faerber, Katrin; Kettenmann, Helmut			Transmitter- and hormone-activated Ca2+ responses in adult microglia/brain macrophages in situ recorded after viral transduction of a recombinant Ca2+ sensor	CELL CALCIUM			English	Article						Microglia; Calcium; ATP; Endothelin-1; Serotonin; Substance P; Histamine; Neuropeptides; Neurotransmitter; Neurohormone; Stab wound	HISTAMINERGIC NEURON SYSTEM; TRAUMATIC BRAIN-INJURY; SUBSTANCE-P; BORRELIA-BURGDORFERI; RECEPTOR EXPRESSION; MURINE MICROGLIA; NEUROPATHIC PAIN; P2X(7) RECEPTOR; CEREBRAL-CORTEX; UP-REGULATION	In vitro studies show that microglia, the resident immune cells of the brain, express neurotransmitter and neuropeptide receptors which are linked to Ca2+ signaling. Here we describe an approach to obtain Ca2+ recordings from microglia in situ. We injected a retrovirus encoding a calcium sensor into the cortex of mice 2 days after stimulation of microglial proliferation by a stab wound injury. Microglial cells were identified with tomato lectin in acute slices prepared 3, 6, 21 and 42 days after the injury. The membrane current profile and the ameboid morphology indicated that microglial cells were activated at day 6 while at day 42 they resembled resting microglia. We recorded transient Ca2+ responses to application of ATP, endothelin-1, substance P. histamine and serotonin. The fluorescence amplitude of ATP was increased only at day 6 compared to other time points, while responses to all other ligands did not vary. Only half of the microglial cells that responded to ATP also responded to endothelin-1, serotonin and histamine. Substance P. in contrast, showed a complete overlap with the ATP responding microglial population at day 6, at day 42 this population was reduced to 55%. Cultured cells were less responsive to these ligands. This study shows that in situ microglia consist of heterogeneous populations with respect to their sensitivity to neuropeptides and -transmitters. (C) 2011 Elsevier Ltd. All rights reserved.	[Seifert, Stefanie; Pannell, Maria; Kettenmann, Helmut] Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; [Faerber, Katrin] Univ Wurzburg, Inst Mol Infect Biol, D-97080 Wurzburg, Germany	Kettenmann, H (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	kettenmann@mdc-berlin.de	Kettenmann, Helmut/AAJ-5142-2021	Kettenmann, Helmut/0000-0001-8208-0291	Transregio SFB [TR 43]; DFG graduate schoolGerman Research Foundation (DFG) [1258]	N1-GCaMP2 vector was a gift from Juchini Nakai (Saitama University Brain Science Institute, Saitama, Japan). CX3CR1-GFP mice were provided by Stefan Kaufmann, Max Planck Institut fur Infektionsbiologie. Berlin originally obtained from Skirball Institute of Biomolecular Medicine and Howard Hughes Medical Institute New York University Medical Center, New York. This work was supported by Transregio SFB TR 43 and the DFG graduate school 1258.	Abbracchio MP, 2009, TRENDS NEUROSCI, V32, P19, DOI 10.1016/j.tins.2008.10.001; Agnati LF, 2010, BRAIN RES REV, V64, P137, DOI 10.1016/j.brainresrev.2010.03.003; Amat JA, 1996, GLIA, V16, P368, DOI 10.1002/(SICI)1098-1136(199604)16:4<368::AID-GLIA9>3.0.CO;2-W; BADER MF, 1994, GLIA, V11, P336, DOI 10.1002/glia.440110406; Biber K, 2007, TRENDS NEUROSCI, V30, P596, DOI 10.1016/j.tins.2007.08.007; Block ML, 2006, FASEB J, V20, P251, DOI 10.1096/fj.05-4553com; Boucsein C, 2000, EUR J NEUROSCI, V12, P2049, DOI 10.1046/j.1460-9568.2000.00100.x; CHAO CC, 1992, J IMMUNOL, V149, P2736; Chauhan VS, 2008, J IMMUNOL, V180, P8241, DOI 10.4049/jimmunol.180.12.8241; COLTON CA, 1993, ADV NEUROL, V59, P321; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Engels B, 2003, HUM GENE THER, V14, P1155, DOI 10.1089/104303403322167993; Franke H, 2004, J NEUROPATH EXP NEUR, V63, P686, DOI 10.1093/jnen/63.7.686; Hampton DW, 2004, NEUROSCIENCE, V127, P813, DOI 10.1016/j.neuroscience.2004.05.028; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Inoue K, 2009, INT REV NEUROBIOL, V85, P159, DOI 10.1016/S0074-7742(09)85012-5; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Katoh Y, 2001, NEUROSCI LETT, V305, P181, DOI 10.1016/S0304-3940(01)01835-3; KESSLER IM, 2005, SURG NEUROL S1, V64, P2; Koizumi S, 2007, NATURE, V446, P1091, DOI 10.1038/nature05704; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kreutzberg GW, 1968, ACTA NEUROPATH    S4, V4, P141; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; Li JJ, 2010, NEUROSCIENCE, V167, P665, DOI 10.1016/j.neuroscience.2010.02.062; Maeda K, 1997, GERONTOLOGY, V43, P11; Mahe C, 2005, NEUROPHARMACOLOGY, V49, P40, DOI 10.1016/j.neuropharm.2005.01.025; Marek GJ, 1998, BIOL PSYCHIAT, V44, P1118, DOI 10.1016/S0006-3223(98)00036-5; MARTIN FC, 1993, J NEUROIMMUNOL, V42, P53, DOI 10.1016/0165-5728(93)90212-H; McLarnon JG, 2006, J NEUROPATH EXP NEUR, V65, P1090, DOI 10.1097/01.jnen.0000240470.97295.d3; Moller T, 1997, NEUROREPORT, V8, P2127; Moller T, 2000, BRAIN RES, V853, P49, DOI 10.1016/S0006-8993(99)02244-1; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Petrov T, 2002, NEUROSCIENCE, V115, P275, DOI 10.1016/S0306-4522(02)00345-7; Pocock JM, 2007, TRENDS NEUROSCI, V30, P527, DOI 10.1016/j.tins.2007.07.007; PRELL GD, 1986, ANNU REV NEUROSCI, V9, P209; Rasley A, 2004, J IMMUNOL, V172, P5707, DOI 10.4049/jimmunol.172.9.5707; Rasley A, 2002, GLIA, V37, P258, DOI 10.1002/glia.10034; SAWADA M, 1990, BRAIN RES, V509, P119, DOI 10.1016/0006-8993(90)90317-5; Stumm RK, 2001, J NEUROSCI, V21, P798; Tallini YN, 2006, P NATL ACAD SCI USA, V103, P4753, DOI 10.1073/pnas.0509378103; Tsuda M, 2008, GLIA, V56, P579, DOI 10.1002/glia.20641; Ulmann L, 2008, J NEUROSCI, V28, P11263, DOI 10.1523/JNEUROSCI.2308-08.2008; Vruwink M, 2001, J COMP NEUROL, V441, P288, DOI 10.1002/cne.1413; WADA H, 1991, BRAIN RES BULL, V27, P367, DOI 10.1016/0361-9230(91)90126-5; Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009; WATANABE T, 1984, BRAIN RES, V295, P13, DOI 10.1016/0006-8993(84)90811-4; Werry EL, 2006, J NEUROCHEM, V99, P924, DOI 10.1111/j.1471-4159.2006.04133.x; Wu CY, 2009, NEUROSCIENCE, V158, P1500, DOI 10.1016/j.neuroscience.2008.11.043; Zacest AC, 2010, ACTA NEUROCHIR SUPPL, V106, P211, DOI 10.1007/978-3-211-98811-4_39	51	39	39	0	9	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0143-4160	1532-1991		CELL CALCIUM	Cell Calcium	JUN	2011	49	6					365	375		10.1016/j.ceca.2011.03.005			11	Cell Biology	Cell Biology	791KL	WOS:000292664000002	21536328				2021-06-18	
J	Kirkman, E; Watts, S; Cooper, G				Kirkman, E.; Watts, S.; Cooper, G.			Blast injury research models	PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES			English	Article						blast; explosion; haemorrhage; trauma; resuscitation; oxygen	HYPERTONIC SALINE RESUSCITATION; VOLUME FLUID RESUSCITATION; TRAUMATIC BRAIN-INJURY; HYPOTENSIVE RESUSCITATION; BLOOD-LOSS; HEMORRHAGIC-SHOCK; BOMBING ATTACKS; RAT MODEL; SWINE; EPIDEMIOLOGY	Blast injuries are an increasing problem in both military and civilian practice. Primary blast injury to the lungs (blast lung) is found in a clinically significant proportion of casualties from explosions even in an open environment, and in a high proportion of severely injured casualties following explosions in confined spaces. Blast casualties also commonly suffer secondary and tertiary blast injuries resulting in significant blood loss. The presence of hypoxaemia owing to blast lung complicates the process of fluid resuscitation. Consequently, prolonged hypotensive resuscitation was found to be incompatible with survival after combined blast lung and haemorrhage. This article describes studies addressing new forward resuscitation strategies involving a hybrid blood pressure profile (initially hypotensive followed later by normotensive resuscitation) and the use of supplemental oxygen to increase survival and reduce physiological deterioration during prolonged resuscitation. Surprisingly, hypertonic saline dextran was found to be inferior to normal saline after combined blast injury and haemorrhage. New strategies have therefore been developed to address the needs of blast-injured casualties and are likely to be particularly useful under circumstances of enforced delayed evacuation to surgical care.								Alam HB, 2000, J SURG RES, V94, P145, DOI 10.1006/jsre.2000.6011; Almogy G, 2005, ARCH SURG-CHICAGO, V140, P390, DOI 10.1001/archsurg.140.4.390; [Anonymous], 2001, J R Army Med Corps, V147, P187; [Anonymous], 2006, BATTL ADV LIF SUPP; [Anonymous], 2004, NICE TECHNOLOGY APPR, V74; Bahrami S, 2006, SHOCK, V25, P283, DOI 10.1097/01.shk.0000208808.03148.ea; Belanger HG, 2005, J REHABIL RES DEV, V42, P403, DOI 10.1682/JRRD.2004.08.0095; BICKELL WH, 1991, SURGERY, V110, P529; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; BICKELL WH, 1989, CIRC SHOCK, V28, P321; Bilski TR, 2003, J TRAUMA, V54, P814, DOI 10.1097/01.TA.0000046627.87250.1D; Bohman HR, 2005, MIL MED, V170, P297, DOI 10.7205/MILMED.170.4.297; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Bulger EM, 2007, ANN SURG, V245, P635, DOI 10.1097/01.sla.0000251367.44890.ae; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Champion HR, 2003, J TRAUMA, V54, pS13, DOI 10.1097/01.TA.0000057151.02906.27; CLEMEDSON CJ, 1956, ACTA PHYSIOL SCAND, V37, P202; Cole DJ, 1999, SURGERY, V126, P510, DOI 10.1016/S0039-6060(99)70092-9; Cooper GJ, 1996, J TRAUMA, V40, pS38, DOI 10.1097/00005373-199603001-00007; DAMON EG, 1971, AEROSPACE MED, V42, P1; de Ceballos JPG, 2005, CRIT CARE, V9, P104, DOI 10.1186/cc2995; Dearden P, 2001, J R Army Med Corps, V147, P80; DRONEN SC, 1993, AM J EMERG MED, V11, P331, DOI 10.1016/0735-6757(93)90162-5; Dubick MA, 2003, J TRAUMA, V54, pS43, DOI 10.1097/01.TA.0000064514.42470.3B; Garner JP, 2009, WORLD J SURG, V33, P2194, DOI 10.1007/s00268-009-0105-4; Garner J, 2010, ANN SURG, V251, P1131, DOI 10.1097/SLA.0b013e3181e00fcb; Guy RJ, 1998, J TRAUMA, V45, P983, DOI 10.1097/00005373-199812000-00001; Harban FMJ, 2001, J PHYSIOL-LONDON, V533, p81P; Hodgetts TJ, 2006, EMERG MED J, V23, P745, DOI 10.1136/emj.2006.039610; Holcomb JB, 1999, J TRAUMA, V46, P49, DOI 10.1097/00005373-199901000-00009; Jeroukhimov I, 2002, J TRAUMA, V53, P1053, DOI 10.1097/00005373-200212000-00004; Kirkman E., 2006, DSTLTR19030; Klemcke HG, 2005, J TRAUMA, V59, P155, DOI 10.1097/01.TA.0000174557.89804.A2; KOWALENKO T, 1992, J TRAUMA, V33, P349, DOI 10.1097/00005373-199209000-00003; Leach RM, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a2790; Lee CC, 2001, ANN EMERG MED, V38, P170, DOI 10.1067/mem.2001.114313; Leibovici D, 1996, J TRAUMA, V41, P1030, DOI 10.1097/00005373-199612000-00015; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Marti M, 2006, EMERG RADIOL, V13, P113, DOI 10.1007/s10140-006-0534-4; Martinowitz U, 2001, J TRAUMA, V50, P721, DOI 10.1097/00005373-200104000-00021; Maynard R. L., 1989, TRAUMA; MELLOR SG, 1989, BRIT J SURG, V76, P1006, DOI 10.1002/bjs.1800761006; MOORE EE, 1995, J TRAUMA, V38, P323, DOI 10.1097/00005373-199503000-00001; Nelson TJ, 2006, J AM COLL SURGEONS, V202, P418, DOI 10.1016/j.jamcollsurg.2005.11.011; Ohnishi M, 2001, EXP PHYSIOL, V86, P357, DOI 10.1113/eph8602145; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pusateri AE, 2004, J TRAUMA, V57, P555, DOI 10.1097/01.TA.0000136155.97758.CD; Rafie AD, 2004, SHOCK, V22, P262, DOI 10.1097/01.shk.0000135255.59817.8c; Ramasamy A, 2008, J TRAUMA, V65, P910, DOI 10.1097/TA.0b013e3181848cf6; Ritenour AE, 2010, ANN SURG, V251, P1140, DOI 10.1097/SLA.0b013e3181e01270; Rizoli SB, 2006, ANN SURG, V243, P47, DOI 10.1097/01.sla.0000193608.93127.b1; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Sawdon M, 2002, EXP PHYSIOL, V87, P683, DOI 10.1113/eph8702432; SHEN L, 1983, J CLIN INVEST, V71, P1336, DOI 10.1172/JCI110885; Smith JE, 2011, PHILOS T R SOC B, V366, P291, DOI 10.1098/rstb.2010.0251; Sondeen JL, 2003, J TRAUMA, V54, pS110, DOI 10.1097/01.TA.0000047220.81795.3D; STERN SA, 1993, ANN EMERG MED, V22, P155, DOI 10.1016/S0196-0644(05)80195-7; White H, 2008, EUR J ANAESTH, V25, P104, DOI 10.1017/S0265021507003420; Yang H, 2010, BBA-GENE REGUL MECH, V1799, P149, DOI 10.1016/j.bbagrm.2009.11.019; Zakaria ER, 2006, SURGERY, V140, P579, DOI 10.1016/j.surg.2006.05.015; Zuckerman S., 1941, P ROY SOC MED, V34, P171; Zunic Gordana, 2005, Vojnosanit Pregl, V62, P273, DOI 10.2298/VSP0504273Z	62	39	43	0	9	ROYAL SOC	LONDON	6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND	0962-8436	1471-2970		PHILOS T R SOC B	Philos. Trans. R. Soc. B-Biol. Sci.	JAN 27	2011	366	1562					144	159		10.1098/rstb.2010.0240			16	Biology	Life Sciences & Biomedicine - Other Topics	693RA	WOS:000285241400004	21149352	Green Published			2021-06-18	
J	Kelso, ML; Scheff, NN; Scheff, SW; Pauly, JR				Kelso, Matthew L.; Scheff, Nicole N.; Scheff, Stephen W.; Pauly, James R.			Melatonin and minocycline for combinatorial therapy to improve functional and histopathological deficits following traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						Autoradiography; Morris water maze; Controlled cortical impact; Rat	FOCAL CEREBRAL-ISCHEMIA; CORTICAL IMPACT INJURY; MICROGLIAL ACTIVATION; IN-VIVO; NEUROPROTECTION; RECEPTORS; RAT; TETRACYCLINES; IMPAIRMENT; DAMAGE	The biochemical sequelae that follow traumatic brain injury (TBI) are numerous and affect many different brain functions at different points of time as the secondary cascades progress. The complexity of the resulting pathophysiology is such that a singular therapeutic intervention may not provide adequate benefit and a combination of drugs targeting different pathways may be needed. Two of the most widely studied injury mechanisms are oxidative stress and inflammation. Numerous studies have suggested that pharmacological agents targeting either of these pathways may produce an improvement in histological and functional outcome measures. We hypothesized that combining melatonin, a potent antioxidant, with minocycline, a bacteriostatic agent that also inhibit microglia, would provide better neuroprotection than either agent used alone. To test this hypothesis, we subjected anesthetized adult male rats to a 1.5 mm controlled cortical impact and administered melatonin or vehicle in the acute post-injury period followed by daily minocycline or vehicle injections beginning the following day in a 2 x 2 study design. The animals were allowed to recover for 5 days before undergoing Morris water maze (MWM) testing to assess cognitive functioning following injury. There was no significant difference in MWM performance between the vehicle, melatonin, minocycline, or combination treatments. Following sacrifice and histological examination for neuroprotection, we did not observe a significant difference between the groups in the amount of cortical tissue that was spared nor was there a significant difference in [H-3]-PK11195 binding, a marker for activated microglia. These results suggest that neither drug has therapeutic efficacy, however dosing and/or administration issues may have played a role. (C) 2010 Elsevier Ireland Ltd. All rights reserved.	[Kelso, Matthew L.; Scheff, Nicole N.; Pauly, James R.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY USA; [Kelso, Matthew L.; Scheff, Stephen W.; Pauly, James R.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA; [Scheff, Stephen W.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA	Kelso, ML (corresponding author), Univ Nebraska Med Ctr, Coll Pharm, Dept Pharm Practice, 986045 Nebraska Med Ctr, Omaha, NE 68198 USA.	mkelso@unmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021981] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG21981, R01 AG021981-05, R01 AG021981] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS042196, R01 NS042196-04, NS42196] Funding Source: Medline		Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Diguet E, 2004, EXP NEUROL, V189, P1, DOI 10.1016/j.expneurol.2004.05.016; Domercq M, 2004, TRENDS PHARMACOL SCI, V25, P609, DOI 10.1016/j.tips.2004.10.001; GUSEVA MV, 2008, J NEUROTRAUMA; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hayakawa K, 2008, STROKE, V39, P951, DOI 10.1161/STROKEAHA.107.495820; HIGASHIDA T, 2010, J NEUROSURG; Kelso ML, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-108; Kelso ML, 2006, BRAIN RES, V1083, P204, DOI 10.1016/j.brainres.2006.01.127; Koizumi S, 2007, NATURE, V446, P1091, DOI 10.1038/nature05704; Lai AY, 2008, GLIA, V56, P259, DOI 10.1002/glia.20610; Lampl Y, 2007, NEUROLOGY, V69, P1404, DOI 10.1212/01.wnl.0000277487.04281.db; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; MYERS R, 1991, J CEREBR BLOOD F MET, V11, P314, DOI 10.1038/jcbfm.1991.64; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Ozdemir D, 2005, NEUROSCI LETT, V385, P234, DOI 10.1016/j.neulet.2005.05.055; Paxinos G, 1986, RAT BRAIN STEROTAXIC; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Reiter RJ, 2000, J BIOMED SCI, V7, P444, DOI 10.1159/000025480; Reiter RJ, 1997, HORM METAB RES, V29, P363, DOI 10.1055/s-2007-979057; Sarrafzadeh AS, 2000, ACTA NEUROCHIR, V142, P1293, DOI 10.1007/s007010070028; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Ucar T, 2005, ACTA NEUROL SCAND, V112, P163, DOI 10.1111/j.1600-0404.2005.00463.x; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769	29	39	42	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	JAN 13	2011	488	1					60	64		10.1016/j.neulet.2010.11.003			5	Neurosciences	Neurosciences & Neurology	716UA	WOS:000286997800013	21056621	Green Accepted			2021-06-18	
J	Hayward, NMEA; Tuunanen, PI; Immonen, R; Ndode-Ekane, XE; Pitkanen, A; Grohn, O				Hayward, Nick Mark Edward Alexander; Tuunanen, Pasi I.; Immonen, Riikka; Ndode-Ekane, Xavier Ekolle; Pitkanen, Asla; Grohn, Olli			Magnetic resonance imaging of regional hemodynamic and cerebrovascular recovery after lateral fluid-percussion brain injury in rats	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						animal models; arterial spin labeling; cerebral hemodynamics; magnetic resonance imaging; traumatic brain injury; vascular density	CEREBRAL-BLOOD-FLOW; CONTROLLED CORTICAL IMPACT; PERFUSION; METABOLISM; TRAUMA; HYPOPERFUSION; CONTUSION; ISCHEMIA; EPILEPSY; HYPOXIA	Hemodynamic and cerebrovascular factors are crucially involved in secondary damage after traumatic brain injury (TBI). With magnetic resonance imaging, this study aimed to quantify regional cerebral blood flow (CBF) by arterial spin labeling and cerebral blood volume by using an intravascular contrast agent, during 14 days after lateral fluid-percussion injury (LFPI) in rats. Immunohistochemical analysis of vessel density was used to evaluate the contribution of vascular damage. Results show widespread ipsilateral and contralateral hypoperfusion, including both the cortex and the hippocampus bilaterally, as well as the ipsilateral thalamus. Hemodynamic unrest may partly be explained by an increase in blood vessel density over a period of 2 weeks in the ipsilateral hippocampus and perilesional cortex. Furthermore, three phases of perilesional alterations in CBF, progressing from hypoperfusion to normal and back to hypoperfusion within 2 weeks were shown for the first time in a rat TBI model. These three phases were similar to hemodynamic fluctuations reported in TBI patients. This makes it feasible to use LFPI in rats to study mechanisms behind hemodynamic changes and to explore novel therapeutic approaches for secondary brain damage after TBI. Journal of Cerebral Blood Flow & Metabolism (2011) 31, 166-177; doi:10.1038/jcbfm.2010.67; published online 19 May 2010	[Hayward, Nick Mark Edward Alexander; Tuunanen, Pasi I.; Immonen, Riikka; Grohn, Olli] Univ Eastern Finland, Biomed Imaging Unit, Dept Neurobiol, AI Virtanen Inst Mol Sci, FIN-70211 Kuopio, Finland; [Ndode-Ekane, Xavier Ekolle; Pitkanen, Asla] Univ Eastern Finland, Dept Neurobiol, Epilepsy Res Grp, AI Virtanen Inst Mol Sci, FIN-70211 Kuopio, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland	Grohn, O (corresponding author), Univ Eastern Finland, Biomed Imaging Unit, Dept Neurobiol, AI Virtanen Inst, POB 1627, FIN-70211 Kuopio, Finland.	olli.grohn@uef.fi		Hayward, Nicholas/0000-0001-9496-7332; Ndode-Ekane, Xavier Ekolle/0000-0001-5682-5632	Marie Curie Early Stage Trainee Research Fellowship [MEST-CT-2005-019217]; Academy of FinlandAcademy of FinlandEuropean Commission; Sigrid Juselius FoundationSigrid Juselius Foundation	This study was funded by a Marie Curie Early Stage Trainee Research Fellowship MEST-CT-2005-019217, by The Academy of Finland (AP, OG) and by The Sigrid Juselius Foundation (AP).	Barbier EL, 2001, J MAGN RESON IMAGING, V13, P496, DOI 10.1002/jmri.1073; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BOXERMAN JL, 1995, MAGNET RESON MED, V34, P555, DOI 10.1002/mrm.1910340412; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; Dunn JF, 2004, MAGN RESON MED, V51, P55, DOI 10.1002/mrm.10660; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; GEHRMANN J, 1995, NEUROPATH APPL NEURO, V21, P277, DOI 10.1111/j.1365-2990.1995.tb01062.x; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; Golding EM, 2002, BRAIN RES REV, V38, P377, DOI 10.1016/S0165-0173(02)00141-8; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; HANSEN TD, 1989, BRIT J ANAESTH, V63, P290, DOI 10.1093/bja/63.3.290; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Iltis I, 2005, J MAGN RESON IMAGING, V22, P242, DOI 10.1002/jmri.20352; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; Ndode-Ekane XE, 2010, NEUROSCIENCE, V166, P312, DOI 10.1016/j.neuroscience.2009.12.002; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Pasco A, 2007, J NEUROTRAUM, V24, P1321, DOI 10.1089/neu.2006.0136; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; RangeL-Castilla L, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E7; Richards HK, 2001, J CEREBR BLOOD F MET, V21, P779, DOI 10.1097/00004647-200107000-00002; Robertson CL, 2000, ACT NEUR S, V76, P187; Shen YM, 2007, MAGN RESON IMAGING, V25, P219, DOI 10.1016/j.mri.2006.09.018; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; van Zijl PCM, 1998, NAT MED, V4, P159, DOI 10.1038/nm0298-159; WILLIAMS DS, 1992, P NATL ACAD SCI USA, V89, P212, DOI 10.1073/pnas.89.1.212; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	47	39	39	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	2011	31	1					166	177		10.1038/jcbfm.2010.67			12	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	702BX	WOS:000285870700019	20485295	Bronze, Green Published			2021-06-18	
J	Liu, MC; Kobeissy, F; Zheng, WR; Zhang, ZQ; Hayes, RL; Wang, KKW				Liu, Ming Cheng; Kobeissy, Firas; Zheng, Wenrong; Zhang, Zhiqun; Hayes, Ronald L.; Wang, Kevin K. W.			Dual vulnerability of tau to calpains and caspase-3 proteolysis under neurotoxic and neurodegenerative conditions	ASN NEURO			English	Article						cell death; neurodegeneration; protease; tau protein; tauopathy; traumatic brain injury (TBI)	TRAUMATIC BRAIN-INJURY; ACID 5-METHOXY-3-OXAPENTYL ESTER; DIFFUSE AXONAL INJURY; ALPHA-II-SPECTRIN; ALZHEIMERS-DISEASE; NEURONAL DAMAGE; RAT-BRAIN; C-TAU; APOPTOSIS; PROTEIN	Axonally specific microtubule-associated protein tau is an important component of neurofibrillary tangles found in AD (Alzheimer's disease) and other tauopathy diseases such as CTE (chronic traumatic encephalopathy). Such tau aggregate is found to be hyperphosphorylated and often proteolytically fragmented. Similarly, tau is degraded following TBI (traumatic brain injury). In the present study, we examined the dual vulnerability of tau to calpain and caspase-3 under neurotoxic and neurodegenerative conditions. We first identified three novel calpain cleavage sites in rat tau (four-repeat isoform) as Ser(130)down arrow Lys(131), Gly(157)down arrow Ala(158) and Arg(380)down arrow Glu(381). Fragment-specific antibodies to target the major calpain-mediated TauBDP-35K (35 kDa tau-breakdown product) and the caspase-mediated TauBDP-45K respectively were developed. In rat cerebrocortical cultures treated with excitotoxin [NMDA (N-methyl-D-aspartate)], tau is significantly degraded into multiple fragments, including a dominant signal of calpain-mediated TauBDP-35K with minimal caspase-mediated TauBDP-45K. Following apoptosis-inducing EDTA treatment, tau was truncated only to TauBDP-48K/45K-exclusively by caspase. Cultures treated with another apoptosis inducer STS (staurosporine), dual fragmentation by calpain (TauBDP-35K) and caspase-3 (TauBDP-45K) was observed. Tau was also fragmented in injured rat cortex following TBI in vivo to BDPs of 45-42 kDa (minor), 35 kDa and 15 kDa, followed by TauBDP-25K. Calpain-mediated TauBDP-35K-specific antibody confirmed robust signals in the injured cortex, while caspase-mediated TauBDP-45K-specific antibody only detected faint signals. Furthermore, intravenous administration of a calpain-specific inhibitor SNJ-1945 strongly suppressed the TauBDP-35K formation. Taken together, these results suggest that tau protein is dually vulnerable to calpain and caspase-3 proteolysis under different neurotoxic and injury conditions.	[Liu, Ming Cheng; Kobeissy, Firas; Zheng, Wenrong; Zhang, Zhiqun; Hayes, Ronald L.; Wang, Kevin K. W.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL 32615 USA; [Kobeissy, Firas; Wang, Kevin K. W.] Univ Florida, Dept Psychiat, McKnight Brain Inst, Gainesville, FL 32610 USA; [Hayes, Ronald L.] Univ Florida, Dept Anesthesiol, Gainesville, FL 32610 USA	Liu, MC (corresponding author), Banyan Biomarkers Inc, Ctr Innovat Res, 12085 Res Dr, Alachua, FL 32615 USA.	mcLiu@banyanbio.com; kwang@banyanbio.com	Kobeissy, Firas/E-7042-2017	Kobeissy, Firas/0000-0002-5008-6944; Wang, Kevin/0000-0002-9343-6473	NINDS-NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R21NS052322, R01 NS049175]; Department of Defense (DoD)United States Department of Defense [DAMD17-03-1-0066]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049175, R21NS052322] Funding Source: NIH RePORTER	This work was supported by NINDS-NIH [1R21NS052322] (to M. C. L.), [R01 NS049175] (to K. K. W.); Department of Defense (DoD) [Grant No. DAMD17-03-1-0066] (to R.L.H.).	Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Arnaud LT, 2009, J NEUROCHEM, V110, P328, DOI 10.1111/j.1471-4159.2009.06142.x; Avila J, 2004, CURR ALZHEIMER RES, V1, P97, DOI 10.2174/1567205043332207; Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Bitsch A, 2002, EUR NEUROL, V47, P45, DOI 10.1159/000047946; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Canu N, 1998, J NEUROSCI, V18, P7061; Chiesa R, 1998, J NEUROCHEM, V70, P1474; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Chung CW, 2001, NEUROBIOL DIS, V8, P162, DOI 10.1006/nbdi.2000.0335; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Delobel P, 2005, FEBS LETT, V579, P1, DOI 10.1016/j.febslet.2004.11.018; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; Garcia ML, 2001, CURR OPIN CELL BIOL, V13, P41, DOI 10.1016/S0955-0674(00)00172-1; Guillozet-Bongaarts AL, 2005, NEUROBIOL AGING, V26, P1015, DOI 10.1016/j.neurobiolaging.2004.09.019; Higuchi M, 2002, NEUROMOL MED, V2, P131, DOI 10.1385/NMM:2:2:131; JOHNSON GVW, 1989, BIOCHEM BIOPH RES CO, V163, P1505, DOI 10.1016/0006-291X(89)91150-9; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; KOSIK KS, 1987, J NEUROSCI, V7, P3142; Koumura A, 2008, NEUROSCIENCE, V157, P309, DOI 10.1016/j.neuroscience.2008.09.007; Krishnamurthy S, 2002, ADV ANAT PATHOL, V9, P185, DOI 10.1097/00125480-200205000-00002; LITERSKY JM, 1993, BRAIN RES, V604, P32, DOI 10.1016/0006-8993(93)90349-R; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; McGinnis KM, 1999, BIOCHEM BIOPH RES CO, V263, P94, DOI 10.1006/bbrc.1999.1315; McIntosh TK, 1996, LAB INVEST, V74, P315; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; Nath R, 2000, NEUROCHEM INT, V36, P119, DOI 10.1016/S0197-0186(99)00112-6; Nath R, 1998, J NEUROCHEM, V71, P186; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; Oka T, 2006, NEUROSCIENCE, V141, P2139, DOI 10.1016/j.neuroscience.2006.05.060; Park SY, 2005, J NEUROSCI, V25, P5365, DOI 10.1523/JNEUROSCI.1125-05.2005; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Rohn TT, 2002, DRUG NEWS PERSPECT, V15, P549, DOI 10.1358/dnp.2002.15.9.740233; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Shimohama S, 1999, BIOCHEM BIOPH RES CO, V256, P381, DOI 10.1006/bbrc.1999.0344; Shirasaki Y, 2005, BIOORGAN MED CHEM, V13, P4473, DOI 10.1016/j.bmc.2005.04.059; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; Sinjoanu RC, 2008, NEUROCHEM INT, V53, P79, DOI 10.1016/j.neuint.2008.06.003; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Warren MW, 2006, J ADDICT DIS, V25, P115, DOI 10.1300/J069v25n04_11; Warren MW, 2005, LIFE SCI, V78, P301, DOI 10.1016/j.lfs.2005.04.058; WARREN MW, 2007, INT J NEUROPSYPHARM, V9, P1; Waterhouse N, 1996, J BIOL CHEM, V271, P29335, DOI 10.1074/jbc.271.46.29335; YANG LS, 1995, EUR J BIOCHEM, V233, P9, DOI 10.1111/j.1432-1033.1995.009_1.x; Yen S, 1999, FEBS LETT, V461, P91, DOI 10.1016/S0014-5793(99)01427-1; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Zemlan FP, 2003, NEUROSCIENCE, V121, P399, DOI 10.1016/S0306-4522(03)00459-7; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; Zhang JY, 2009, J ALZHEIMERS DIS, V16, P39, DOI 10.3233/JAD-2009-0908; Zhang ZQ, 2009, APOPTOSIS, V14, P1289, DOI 10.1007/s10495-009-0405-z	71	39	42	0	9	PORTLAND PRESS LTD	LONDON	THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND	1759-0914			ASN NEURO	ASN Neuro		2011	3	1					25	36	e00051	10.1042/AN20100012			12	Neurosciences	Neurosciences & Neurology	759QQ	WOS:000290263600003	21359008	DOAJ Gold, Green Published			2021-06-18	
J	O'Rourke, JJF; Beglinger, LJ; Smith, MM; Mills, J; Moser, DJ; Rowe, KC; Langbehn, DR; Duff, K; Stout, JC; Harrington, DL; Carlozzi, N; Paulsen, JS				O'Rourke, Justin J. F.; Beglinger, Leigh J.; Smith, Megan M.; Mills, James; Moser, David J.; Rowe, Kelly C.; Langbehn, Douglas R.; Duff, Kevin; Stout, Julie C.; Harrington, Deborah L.; Carlozzi, Noelle; Paulsen, Jane S.		PREDICT-HD Investigators	The Trail Making Test in prodromal Huntington disease: Contributions of disease progression to test performance	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Huntington disease; Cognition; Motor; Psychiatric; Neurodegenerative	TRAUMATIC BRAIN-INJURY; AGE-OF-ONSET; TEST INDEXES; COGNITIVE IMPAIRMENT; CONSTRUCT-VALIDITY; WORKING-MEMORY; DOUBLE-BLIND; PREDICT-HD; DEPRESSION; CARRIERS	We examined the Trail Making Test (TMT) in a sample of 767 participants with prodromal Huntington disease (prodromal HD) and 217 healthy comparisons to determine the contributions of motor, psychiatric, and cognitive changes to TMT scores. Eight traditional and derived TMT scores were also evaluated for their ability to differentiate prodromal participants closer to estimated age of diagnosis from those farther away and prodromal individuals from healthy comparisons. Results indicate that motor signs only mildly affected Part A, and psychiatric symptoms did not affect either part. Tests of perceptual processing, visual scanning, and attention were primarily associated with Part A, and executive functioning (response inhibition, set-shifting), processing speed, and working memory were associated with Part B. Additionally, TMT scores differentiated between healthy comparisons and prodromal HD individuals as far as 9-15 years before estimated diagnosis. In participants manifesting prodromal motor signs and psychiatric symptoms, the TMT primarily measures cognition and is able to discriminate between groups based on health status and estimated time to diagnosis.	[O'Rourke, Justin J. F.; Beglinger, Leigh J.; Smith, Megan M.; Mills, James; Moser, David J.; Rowe, Kelly C.; Langbehn, Douglas R.; Duff, Kevin; Paulsen, Jane S.] Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; [O'Rourke, Justin J. F.] Univ Iowa, Dept Counseling Psychol, Iowa City, IA 52242 USA; [Rowe, Kelly C.] Univ Iowa, Dept Neurosci, Iowa City, IA 52242 USA; [Stout, Julie C.] Monash Univ, Sch Psychol Psychiat & Psychol Med, Melbourne, Vic 3004, Australia; [Harrington, Deborah L.] Univ Calif San Diego, Dept Radiol, San Diego, CA 92103 USA; [Carlozzi, Noelle] Kessler Fdn Res Ctr, W Orange, NJ USA; [Paulsen, Jane S.] Univ Iowa, Dept Psychol, Iowa City, IA 52242 USA; [Paulsen, Jane S.] Univ Iowa, Dept Neurol, Iowa City, IA 52242 USA	Paulsen, JS (corresponding author), Univ Iowa, Dept Psychiat, 1-305 Med Educ Bldg, Iowa City, IA 52242 USA.	jane-paulsen@uiowa.edu	Schultz, Susan K./M-3516-2019; Leavitt, Blair R/G-1934-2012; Paulsen, Jane/AAQ-2932-2020; Warner, Thomas T/A-1454-2013	Warner, Thomas T/0000-0001-6195-6995; Stout, Julie/0000-0001-9637-8590; Langbehn, Douglas/0000-0002-7803-4679; Paulsen, Jane/0000-0002-0983-228X; Bijanki, Kelly/0000-0003-1624-8767; Moser, David/0000-0003-4102-5266	National Institutes for HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS40068]; CHDI Foundation, Inc.; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040068] Funding Source: NIH RePORTER	This research is supported by the National Institutes for Health, National Institute of Neurological Disorders and Stroke (NS40068), and CHDI Foundation, Inc. We thank the PREDICT-HD sites, the study participants, and the National Research Roster for Huntington Disease Patients and Families.	Austin MP, 1999, PSYCHOL MED, V29, P73, DOI 10.1017/S0033291798007788; Aylward EH, 2004, NEUROLOGY, V63, P66, DOI 10.1212/01.WNL.0000132965.14653.D1; Beck A.T., 1996, MANUAL BECK DEPRESSI; Bigal M, 2008, HEADACHE, V48, P1337, DOI 10.1111/j.1526-4610.2008.01083.x; Biglan KM, 2009, MOVEMENT DISORD, V24, P1763, DOI 10.1002/mds.22601; Brandt J, 2002, J INT NEUROPSYCH SOC, V8, P918, DOI 10.1017/S1355617702870060; Caviness JN, 2007, MOVEMENT DISORD, V22, P1272, DOI 10.1002/mds.21453; Chen P, 2000, NEUROLOGY, V55, P1847, DOI 10.1212/WNL.55.12.1847; Coffey CE, 2001, J NEUROPSYCH CLIN N, V13, P471, DOI 10.1176/appi.neuropsych.13.4.471; Crowe SF, 1998, J CLIN PSYCHOL, V54, P585, DOI 10.1002/(SICI)1097-4679(199808)54:5<585::AID-JCLP4>3.0.CO;2-K; Decruyenaere M., 1995, Genetic Counseling, V6, P1; DEROGATIS LR, 1994, SCL R SYMPTOM CHECKL; Dichgans M, 2008, LANCET NEUROL, V7, P310, DOI 10.1016/S1474-4422(08)70046-2; Drane DL, 2002, NEUROPSY NEUROPSY BE, V15, P39; Duff K, 2007, BIOL PSYCHIAT, V62, P1341, DOI 10.1016/j.biopsych.2006.11.034; Fagerlund B, 2007, CLIN NEUROPHARMACOL, V30, P3, DOI 10.1097/01.WNF.0000240940.67241.F6; FOROUD T, 1995, ANN NEUROL, V37, P657, DOI 10.1002/ana.410370516; Gohier B, 2009, J AFFECT DISORDERS, V116, P100, DOI 10.1016/j.jad.2008.10.028; Hammar A, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.026.2009; HEATON RK, 1985, J CONSULT CLIN PSYCH, V53, P103, DOI 10.1037/0022-006X.53.1.103; Horton AM, 2003, ARCH CLIN NEUROPSYCH, V18, P49, DOI 10.1016/S0887-6177(01)00183-4; Horton AM, 2001, INT J NEUROSCI, V111, P123, DOI 10.3109/00207450108986557; Horton AM, 2001, INT J NEUROSCI, V108, P281, DOI 10.3109/00207450108986518; Hoth KF, 2007, J CLIN EXP NEUROPSYC, V29, P365, DOI 10.1080/13803390600718958; Kieburtz K, 1996, MOVEMENT DISORD, V11, P136, DOI 10.1002/mds.870110204; LAMBERTY GJ, 1994, NEUROPSY NEUROPSY BE, V7, P230; Langbehn DR, 2007, NEUROLOGY, V68, P1710, DOI 10.1212/01.wnl.0000261918.90053.96; Langbehn DR, 2010, AM J MED GENET B, V153B, P397, DOI 10.1002/ajmg.b.30992; Langbehn DR, 2004, CLIN GENET, V65, P267, DOI 10.1111/j.1399-0004.2004.00241.x; LANGE H W, 1981, Verhandlungen der Anatomischen Gesellschaft, V75, P923; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; Larsson MU, 2008, NEUROPSYCHOLOGY, V22, P596, DOI 10.1037/0894-4105.22.5.596; Mahant N, 2003, NEUROLOGY, V61, P1085, DOI 10.1212/01.WNL.0000086373.32347.16; Misdraji EL, 2010, J CLIN EXP NEUROPSYC, V32, P159, DOI 10.1080/13803390902881942; OROURKE JJF, 2009, NEUROTHERAPEUTICS, V7, P147; Paulsen J, 1999, UNDERSTANDING BEHAV; PENNEY JB, 1990, MOVEMENT DISORD, V5, P93, DOI 10.1002/mds.870050202; Porter RJ, 2003, BRIT J PSYCHIAT, V182, P214, DOI 10.1192/bjp.182.3.214; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rios M, 2004, BRAIN INJURY, V18, P257, DOI 10.1080/02699050310001617442; Rosas HD, 2008, BRAIN, V131, P1057, DOI 10.1093/brain/awn025; Rosas HD, 2006, MOVEMENT DISORD, V21, P1317, DOI 10.1002/mds.20979; Sanchez-Cubillo I, 2009, J INT NEUROPSYCH SOC, V15, P438, DOI 10.1017/S1355617709090626; Saxton J, 2000, NEUROEPIDEMIOLOGY, V19, P312, DOI 10.1159/000026270; Schear J M, 1989, Arch Clin Neuropsychol, V4, P25, DOI 10.1016/0887-6177(89)90004-8; Smith A., 1991, SYMBOL DIGIT MODALIT; Spikman JM, 2001, BRAIN COGNITION, V47, P446, DOI 10.1006/brcg.2001.1320; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss DT, 2001, PSYCHOL ASSESSMENT, V13, P230, DOI 10.1037//1040-3590.13.2.230; Tekin S, 2002, J PSYCHOSOM RES, V53, P647, DOI 10.1016/S0022-3999(02)00428-2; Tombaugh TN, 2004, ARCH CLIN NEUROPSYCH, V19, P203, DOI 10.1016/S0887-6177(03)00039-8; Tremont G, 1998, CLIN NEUROPSYCHOL, V12, P560, DOI 10.1076/clin.12.4.560.7238; Verny C, 2007, EUR J NEUROL, V14, P1344, DOI 10.1111/j.1468-1331.2007.01975.x; Walker FO, 2007, LANCET, V369, P218, DOI 10.1016/S0140-6736(07)60111-1; Wechsler D., 1997, WAIS 3 ADM SCORING M; Yaffe K, 1999, ARCH GEN PSYCHIAT, V56, P425, DOI 10.1001/archpsyc.56.5.425	57	39	39	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2011	33	5					567	579	PII 933217830	10.1080/13803395.2010.541228			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	773AQ	WOS:000291279800008	21302170	Green Accepted			2021-06-18	
J	Youngjohn, JR; Wershba, R; Stevenson, M; Sturgeon, J; Thomas, ML				Youngjohn, James R.; Wershba, Rebecca; Stevenson, Matthew; Sturgeon, John; Thomas, Michael L.			Independent Validation of the MMPI-2-RF Somatic/Cognitive and Validity Scales in TBI Litigants Tested for Effort	CLINICAL NEUROPSYCHOLOGIST			English	Article						Minnesota Multiphasic Personality Inventory; MMPI-2-RF somatic; cognitive scales; MMPI-2-RF validity scales; Symptom validity tests; Traumatic brain injury	MALINGERED NEUROCOGNITIVE DYSFUNCTION; MULTIPHASIC PERSONALITY-INVENTORY; TRAUMATIC BRAIN-INJURY; FAKE BAD SCALE; HEAD-INJURY; BASE RATES; FORENSIC PRACTICE; METAANALYSIS; UTILITY; SYMPTOMATOLOGY	The MMPI-2 Restructured Form (MMPI-2-RF; Ben-Porath Tellegen, 2008) is replacing the MMPI-2 as the most widely used personality test in neuropsychological assessment, but additional validation studies are needed. Our study examines MMPI-2-RF Validity scales and the newly created Somatic/Cognitive scales in a recently reported sample of 82 traumatic brain injury (TBI) litigants who either passed or failed effort tests (Thomas Youngjohn, 2009). The restructured Validity scales FBS-r (restructured symptom validity), F-r (restructured infrequent responses), and the newly created Fs (infrequent somatic responses) were not significant predictors of TBI severity. FBS-r was significantly related to passing or failing effort tests, and Fs and F-r showed non-significant trends in the same direction. Elevations on the Somatic/Cognitive scales profile (MLS-malaise, GIC-gastrointestinal complaints, HPC-head pain complaints, NUC-neurological complaints, and COG-cognitive complaints) were significant predictors of effort test failure. Additionally, HPC had the anticipated paradoxical inverse relationship with head injury severity. The Somatic/Cognitive scales as a group were better predictors of effort test failure than the RF Validity scales, which was an unexpected finding. MLS arose as the single best predictor of effort test failure of all RF Validity and Somatic/Cognitive scales. Item overlap analysis revealed that all MLS items are included in the original MMPI-2 Hy scale, making MLS essentially a subscale of Hy. This study validates the MMPI-2-RF as an effective tool for use in neuropsychological assessment of TBI litigants.	[Youngjohn, James R.] Neuropsychol Clin, Scottsdale, AZ USA; [Wershba, Rebecca; Stevenson, Matthew; Sturgeon, John; Thomas, Michael L.] Arizona State Univ, Phoenix, AZ USA	Youngjohn, JR (corresponding author), 7533 E 1st St, Scottsdale, AZ 85251 USA.	drjyoungjohn@aol.com		Sturgeon, John/0000-0001-6388-0920			Ardolf BR, 2007, CLIN NEUROPSYCHOL, V21, P899, DOI 10.1080/13825580600966391; Ben-Porath Y. S., 2008, MMPI 2 RF MANUAL ADM; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; Boone K. B., 2002, DOT COUNTING TEST MA; Boone KB, 1999, CLIN NEUROPSYCHOL, V13, P414; Chafetz MD, 2008, CLIN NEUROPSYCHOL, V22, P529, DOI 10.1080/13854040701346104; GERVAIS RO, 2007, 2007 ANN M NAT AC NE; Gervais RO, 2010, ARCH CLIN NEUROPSYCH, V25, P274, DOI 10.1093/arclin/acq018; Gervais RO, 2009, CLIN NEUROPSYCHOL, V23, P996, DOI 10.1080/13854040902748249; Gough HG, 1946, J CLIN PSYCHOL, V2, P23, DOI 10.1002/1097-4679(194601)2:1<23::AID-JCLP2270020105>3.0.CO;2-Y; Graham JR, 1990, MMPI 2 ASSESSING PER; Green P., 1995, MANUAL ORAL WORD MEM; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Kaemmer B, 2001, MMPI-2: Manual for Administration and Scoring; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; LARRABEE GJ, 2005, FORENSIC NEUROPSYCHO, P115; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; Locke DEC, 2010, EPILEPSY BEHAV, V17, P252, DOI 10.1016/j.yebeh.2009.12.004; McKinley JC, 1944, J APPL PSYCHOL, V28, P153, DOI 10.1037/h0059245; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Nelson NW, 2010, CLIN NEUROPSYCHOL, V24, P701, DOI 10.1080/13854040903482863; Nelson NW, 2006, CLIN NEUROPSYCHOL, V20, P39, DOI 10.1080/13854040500459322; Nitch S. R., 2007, ASSESSMENT FEIGNED C, P78; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Rogers R, 2003, ASSESSMENT, V10, P160, DOI 10.1177/1073191103010002007; Sellbom M, 2010, PSYCHOL ASSESSMENT, V22, P22, DOI 10.1037/a0018222; Sellbom M, 2008, PSYCHOL ASSESSMENT, V20, P370, DOI 10.1037/a0012952; Smart CM, 2008, J INT NEUROPSYCH SOC, V14, P842, DOI 10.1017/S1355617708081034; Tellegen A., 2008, MMPI 2 RF TECHNICAL; Thomas ML, 2010, PSYCHOL ASSESSMENT, V22, P492, DOI 10.1037/a0019229; Thomas ML, 2009, CLIN NEUROPSYCHOL, V23, P1067, DOI 10.1080/13854040902795000; Wygant DB, 2007, ARCH CLIN NEUROPSYCH, V22, P489, DOI 10.1016/j.acn.2007.01.027; Wygant DB, 2009, ARCH CLIN NEUROPSYCH, V24, P671, DOI 10.1093/arclin/acp073; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593; Youngjohn JR, 1997, PSYCHOL ASSESSMENT, V9, P177, DOI 10.1037/1040-3590.9.3.177	38	39	39	0	13	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2011	25	3					463	476	PII 934589843	10.1080/13854046.2011.554444			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	751RU	WOS:000289636100009	21391149				2021-06-18	
J	Doig, E; Fleming, J; Kuipers, P; Cornwell, PL				Doig, Emmah; Fleming, Jennifer; Kuipers, Pim; Cornwell, Petrea L.			Clinical Utility of the Combined Use of the Canadian Occupational Performance Measure and Goal Attainment Scaling	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						brain injuries; goals; occupational therapy; outcome assessment (health care); patient-centered care	TRAUMATIC BRAIN-INJURY; SELF-AWARENESS; REHABILITATION; THERAPY; CLIENT; ADULTS; SATISFACTION; DEFICITS; OUTCOMES; COMA	OBJECTIVE. We investigated the clinical utility of combined use of Goal Attainment Scaling (GAS) and the Canadian Occupational Performance Measure (COPM) to plan goals and measure progress in a community rehabilitation setting. METHOD. Fourteen participants with traumatic brain injury completed an outpatient, goal-directed 12-wk occupational therapy program; 53 goals were generated. Performance and satisfaction self-ratings and GAS ratings were collected before and after intervention. Self-awareness, motivation to change, and perceived client-centeredness measures were taken before intervention. RESULTS. Sensitivity to change was demonstrated by significant improvements after intervention for total performance self-ratings on the COPM and GAS T scores. CONCLUSION. Combined use of these tools, although time consuming, resulted in goals that were perceived almost unanimously as client centered, despite most participants' having moderate or severe impairment in self-awareness. The process also enabled subjective and objective demonstration of goal achievement, thereby supporting the clinical utility and treatment validity of the combined use of these tools.	[Doig, Emmah] Univ Queensland, Sch Hlth & Rehabil Sci, Div Occupat Therapy, Brisbane, Qld 4072, Australia; [Kuipers, Pim] Princess Alexandra Hosp, Ctr Functioning Disabil & Hlth Res, Brisbane, Qld 4102, Australia; [Kuipers, Pim] Griffith Univ, Griffith Hlth Inst, Meadowbrook, Qld 4131, Australia; [Cornwell, Petrea L.] Queensland Hlth, Metro N Hlth Serv Dist, Brisbane, Qld, Australia; [Cornwell, Petrea L.] Griffith Univ, Sch Psychol, Brisbane, Qld 4111, Australia	Doig, E (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Div Occupat Therapy, Brisbane, Qld 4072, Australia.	emmah.doig@optusnet.com.au	Cornwell, Petrea/AAE-5547-2019; Fleming, Jennifer M/B-4436-2011; Doig, Emmah/AAG-6674-2021	Doig, Emmah/0000-0002-7020-053X; Kuipers, Pim/0000-0003-0340-2286			Barnes M, 2000, TXB REHABILITATION M; Bodiam C., 1999, BR J OCCUP THER, V62, P123, DOI DOI 10.1177/030802269906200310; Carswell Anne, 2004, Can J Occup Ther, V71, P210; Chiu T, 2002, AM J OCCUP THER, V56, P217, DOI 10.5014/ajot.56.2.217; Doig E, 2009, AM J OCCUP THER, V63, P559, DOI 10.5014/ajot.63.5.559; EAMES J, 1999, BRIT J OCCUPATIONAL, V62, P257; Fischer S, 2004, BRAIN INJURY, V18, P547, DOI 10.1080/02699050310001645793; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Haynes S.N., 2000, APPL CLIN P; Jenkinson N, 2007, BRAIN INJURY, V21, P1283, DOI 10.1080/02699050701739531; JOYCE BM, 1994, AM J PHYS MED REHAB, V73, P10, DOI 10.1097/00002060-199473010-00003; KIRESUK TJ, 1968, COMMUNITY MENT HLT J, V4, P443, DOI 10.1007/BF01530764; Kuipers P, 2003, DISABIL REHABIL, V25, P154, DOI 10.1080/0963828021000024898; Kuipers P., 2004, BRAIN IMPAIR, V5, P30, DOI DOI 10.1375/BRIM.5.1.30.35404; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Lannin Natasha, 2003, Occup Ther Health Care, V17, P43, DOI 10.1080/J003v17n01_04; Law M., 1994, CANADIAN OCCUPATIONA; Law M., 1990, CANADIAN OCCUPATIONA; Leach E, 2010, DISABIL REHABIL, V32, P159, DOI 10.3109/09638280903036605; MacLeod GM, 1996, SPINAL CORD, V34, P525, DOI 10.1038/sc.1996.95; Malec JF, 1999, NEUROPSYCHOL REHABIL, V9, P253, DOI 10.1080/096020199389365; MIRANTI VS, 2004, HDB MOTIVATIONAL COU; OTTENBACHER KJ, 1990, AM J OCCUP THER, V44, P519, DOI 10.5014/ajot.44.6.519; OTTENBACHER KJ, 1993, AM J OCCUP THER, V47, P349, DOI 10.5014/ajot.47.4.349; Ownsworth TL, 2002, BRAIN INJURY, V16, P291, DOI 10.1080/02699050110103986; PEDRETTI LW, 1996, OCCUPATIONAL THERAPY, P293; Phipps S, 2007, AM J OCCUP THER, V61, P328, DOI 10.5014/ajot.61.3.328; Playford ED, 2000, CLIN REHABIL, V14, P491, DOI 10.1191/0269215500cr343oa; PROCHASKA JO, 1982, PSYCHOTHER-THEOR RES, V19, P276, DOI 10.1037/h0088437; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rockwood K, 2003, J CLIN EPIDEMIOL, V56, P736, DOI 10.1016/S0895-4356(03)00132-X; Rockwood K, 1997, J CLIN EPIDEMIOL, V50, P581, DOI 10.1016/S0895-4356(97)00014-0; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; SHORDONE RJ, 1996, ECOLOGICAL VALIDITY; STEIN R, 2000, CLIN RES OCCUPATIONA; TEASDALE G, 1974, LANCET, V2, P81; Trombly CA, 2002, AM J OCCUP THER, V56, P489, DOI 10.5014/ajot.56.5.489; WILSON BA, 2003, BRAIN IMPAIR, V4, P25, DOI DOI 10.1375/BRIM.4.1.25.27030; World Health Organization, 2001, INT CLASS FUNCT DIS; Wressle E, 2002, J REHABIL MED, V34, P5, DOI 10.1080/165019702317242640	41	39	39	0	15	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490	1943-7676		AM J OCCUP THER	Am. J. Occup. Ther.	NOV-DEC	2010	64	6					904	914		10.5014/ajot.2010.08156			11	Rehabilitation	Rehabilitation	692SN	WOS:000285175500010	21218681	Green Published			2021-06-18	
J	Echlin, PS; Tator, CH; Cusimano, MD; Cantu, RC; Taunton, JE; Upshur, REG; Czarnota, M; Hall, CR; Johnson, AM; Forwell, LA; Driediger, M; Skopelja, EN				Echlin, Paul Sean; Tator, Charles H.; Cusimano, Michael D.; Cantu, Robert C.; Taunton, Jack E.; Upshur, Ross E. G.; Czarnota, Michael; Hall, Craig R.; Johnson, Andrew M.; Forwell, Lorie A.; Driediger, Molly; Skopelja, Elaine N.			Return to play after an initial or recurrent concussion in a prospective study of physician-observed junior ice hockey concussions: implications for return to play after a concussion	NEUROSURGICAL FOCUS			English	Article						concussion; return to play; traumatic brain injury; sports injury; ice hockey	COLLEGIATE FOOTBALL PLAYERS; SPORTS CONCUSSION; COGNITIVE IMPAIRMENT; RECOVERY; RISK; STATEMENT	Object. The authors investigated return-to-play duration for initial and recurrent concussion in the same season in 2 teams of junior (16-21-year-old) ice hockey players during a regular season. Methods. The authors conducted a prospective cohort study during 1 junior regular season (2009-2010) of 67 male fourth-tier ice hockey players (mean age 18.2 +/- 1.2 years [SD], range 16-21 years) from 2 teams. Prior to the start of the season, every player underwent baseline assessments that were determined using the Sideline Concussion Assessment Tool 2 (SCAT2) and the Immediate Post-Concussion Assessment and Cognitive Test (ImPACT). The study protocol also required players who entered the study during the season to complete a baseline SCAT2 and ImPACT. If the protocol was not followed, the postinjury test results of a player without true baseline test results were compared with previously established age-and sex-matched group normative levels. Each game was directly observed by a physician and at least 1 neutral nonphysician observer. Players suspected of suffering a concussion were evaluated by the physician during the game. If a concussion was diagnosed, the player underwent clinical evaluation at the physician's office within 24 hours. The return-to-play decision was based on clinical evaluation guided by the Zurich return-to-play protocol (contained in the consensus statement of international expert opinion at the 3rd International Conference on Concussion in Sport held in Zurich, November 2008). This clinical evaluation and return-to-play protocol was augmented by the 2 tests (SCAT2 and ImPACT) also recommended by the Zurich consensus statement, for which baseline values had been obtained. Results. Seventeen players sustained a physician-observed or self-reported, physician-diagnosed concussion during a physician-observed ice hockey game. The mean clinical return-to-play duration (in 15 cases) was 12.8 +/- 7.02 days (median 10 days, range 7-29 days); the mean number of physician office visits by players who suffered a concussion (15 cases) was 2.1 +/- 1.29 (median 1.5 visits). Five of the 17 players who sustained a concussion also suffered a recurrent or second concussion. One of the 5 individuals who suffered a repeat concussion sustained his initial concussion in a regular season game that was not observed by a physician, and as a result this single case was not included in the total of 21 concussions. This initial concussion of the player was identified during baseline testing 2 days after the injury and was subsequently medically diagnosed and treated. The mean interval between the first and second concussions in these 5 players was 78.6 +/- 39.8 days (median 82 days), and the mean time between the return-to-play date of the first and second concussions was 61.8 +/- 39.7 days (median 60 days). Conclusions. The mean rates of return to play for single and recurrent concussions were higher than rates cited in recent studies involving sport concussions. The time interval between the first and second concussions was also greater than previously cited. This difference may be the result of the methodology of direct independent physician observation, diagnosis, and adherence to the Zurich return-to-play protocol. (DOI: 10.3171/2010.9.FOCUS10210)	[Echlin, Paul Sean] AIM Hlth Grp Family Med, London, ON, Canada; [Tator, Charles H.; Cusimano, Michael D.] Univ Toronto, Div Neurosurg, Toronto, ON M5S 1A1, Canada; [Cantu, Robert C.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Taunton, Jack E.] Univ British Columbia, Fac Med, Div Sports Med, Vancouver, BC V5Z 1M9, Canada; [Taunton, Jack E.] Univ British Columbia, Sch Human Kinet, Vancouver, BC V5Z 1M9, Canada; [Upshur, Ross E. G.] Univ Toronto, Dept Family, Toronto, ON M5S 1A1, Canada; [Upshur, Ross E. G.] Univ Toronto, Dept Community Med, Toronto, ON M5S 1A1, Canada; [Czarnota, Michael] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; [Hall, Craig R.] Univ Western Ontario, Sch Kinesiol, London, ON, Canada; [Johnson, Andrew M.] Univ Western Ontario, Fac Hlth Sci, London, ON, Canada; [Forwell, Lorie A.] Univ Western Ontario, Dept Physiotherapy, London, ON, Canada; [Driediger, Molly] Univ Western Ontario, Dept Kinesiol, London, ON, Canada; [Skopelja, Elaine N.] Indiana Univ, Sch Med Lib, Indianapolis, IN 46204 USA	Echlin, PS (corresponding author), 320 Adelaide St, S London, ON N5Z 3L2, Canada.	p_echlinfp@hotmail.com	Cusimano, Michael/X-4059-2019; Johnson, Andrew M/B-2048-2012	Skopelja, Elaine/0000-0002-2847-8909; Johnson, Andrew M./0000-0002-7269-3016; Cusimano, Michael/0000-0002-9989-0650; Upshur, Ross/0000-0003-1128-0557	Ontario Trillium Foundation; Dr. Tom Pashby Safety Fund; Dave Irwin Foundation for Brain Injury; Canadian Institutes of Health Strategic Teams in Applied Injury ResearchCanadian Institutes of Health Research (CIHR)	This work was funded by the Ontario Trillium Foundation, the Dr. Tom Pashby Safety Fund, and the Dave Irwin Foundation for Brain Injury. The Ontario Neurotrauma Foundation is acknowledged for its administrative and facilitative contributions. Dr. Cusimano is funded by the Canadian Institutes of Health Strategic Teams in Applied Injury Research.	Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Broglio SP, 2009, CLIN J SPORT MED, V19, P377, DOI 10.1097/JSM.0b013e3181b625fe; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Makdissi M, 2009, AM J SPORT MED, V37, P877, DOI 10.1177/0363546508328118; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Putukian M, 2009, BRIT J SPORT MED, V43, pI28, DOI 10.1136/bjsm.2009.058230; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; SCHWARZ A, 2010, NY TIMES        0628; SCHWARZ A, 2010, NY TIMES        1217; Shuttleworth-Edwards AB, 2008, ARCH CLIN NEUROPSYCH, V23, P479, DOI 10.1016/j.acn.2008.07.002; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	29	39	39	1	27	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	NOV	2010	29	5							E5	10.3171/2010.9.FOCUS10210			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	675CE	WOS:000283801900006	21039139				2021-06-18	
J	Thomale, UW; Graetz, D; Vajkoczy, P; Sarrafzadeh, AS				Thomale, Ulrich-Wilhelm; Graetz, Daniela; Vajkoczy, Peter; Sarrafzadeh, Asita S.			Severe traumatic brain injury in children-a single center experience regarding therapy and long-term outcome	CHILDS NERVOUS SYSTEM			English	Article						Severe brain injury; Intracranial hypertension; ICP; Decompressive craniectomy; Glasgow Outcome Score	EARLY DECOMPRESSIVE CRANIECTOMY; CEREBRAL-BLOOD-FLOW; REFRACTORY INTRACRANIAL HYPERTENSION; HEAD-INJURY; PERFUSION-PRESSURE; HYPERVENTILATION; CRANIOTOMY; MANAGEMENT; TUMORS; TRIAL	Object The impact of intracranial pressure (ICP), decompressive craniectomy (DC), extent of ICP therapy, and extracranial complications on long-term outcome in a single-center pediatric patient population with severe traumatic brain injury (TBI) is examined. Methods Data of pediatric (<= 16 years) TBI patients were retrospectively reviewed using a prospectively acquired database on neurosurgical interventions between April 1996 and March 2007 at the Charite Berlin. The patients' records, neuroimages, admission Glasgow Coma Scale (GCS) score, the time to craniectomy for hematoma evacuation/DC, and the extent of ICP therapy were reviewed. Twelve-month and long-term outcome was evaluated (Glasgow Outcome Scale). Results Fifty-three pediatric TBI patients [mean age 8.41 (0-16) years] were studied. Patients were categorized into two groups, with DC (n=14) and without DC (n=39). DC was performed 3 +/- 3.98 median, quartiles 2 (0-3.75) days post-trauma. In the majority of children (n=9; 64%), surgical decompression was performed early within 2 days post-trauma. (0.8 +/- 0.9 days). The DC group tended to be older (median age 12 vs. 7 years, p=0.052), had a lower GCS (3 vs. 6.5, p<0.01), and had a 3-fold longer stay on the ICU (20 vs. 6.5 days, p<0.03) compared to the conservatively treated group. Mean follow-up duration (n=30) was 5.2 +/- 2.4 years (range 1-10.5). At the most recent follow-up examination, 92% of survivors had returned to school. Conclusion Though initial GCS was worse in pediatric TBI patients who underwent decompressive craniectomy compared to the conservatively treated patients, long-term outcome was comparable. In children, decompressive craniectomy might be favored early in the management of uncontrollable ICP.	[Sarrafzadeh, Asita S.] Univ Med Berlin, Dept Neurosurg, Charite Virchow Med Ctr, D-13353 Berlin, Germany; [Graetz, Daniela; Vajkoczy, Peter; Sarrafzadeh, Asita S.] Univ Med Berlin, Charite, Campus Virchow Klinikum, Dept Neurosurg, D-13353 Berlin, Germany	Sarrafzadeh, AS (corresponding author), Univ Med Berlin, Dept Neurosurg, Charite Virchow Med Ctr, Augustenburger Pl 1, D-13353 Berlin, Germany.	asita.sarrafzadeh@charite.de					ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P537; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Catala-Temprano A, 2007, J NEUROSURG, V106, P463, DOI 10.3171/ped.2007.106.6.463; Chambers Iain R, 2003, Neurosurg Focus, V15, pE3; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Curry R, 2008, PEDIATR CRIT CARE ME, V9, P141, DOI 10.1097/PCC.0B013e318166870e; Cushing H, 1905, SURG GYNECOL OBSTET, V1, P297; *FDN BT, 2003, PEDIATR CRIT CARE ME, V4, P45; Figaji AA, 2006, SAMJ S AFR MED J, V96, P969; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; Hejazi N, 2002, EUR J PEDIATR, V161, P99, DOI 10.1007/s00431-001-0864-x; Hieu PD, 1996, CHILD NERV SYST, V12, P270; Jagannathan J, 2007, J NEUROSURG, V106, pA761; Jorge RE, 2005, CURR OPIN PSYCHIATR, V18, P289, DOI 10.1097/01.yco.0000165600.90928.92; Josan VA, 2006, CHILD NERV SYST, V22, P1268, DOI 10.1007/s00381-006-0064-0; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kunze E, 1998, ACT NEUR S, V71, P16; Marion DW, 2000, CRIT CARE MED, V28, P16, DOI 10.1097/00003246-200001000-00003; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Morris KP, 2006, INTENS CARE MED, V32, P1606, DOI 10.1007/s00134-006-0285-4; Munch E, 2000, NEUROSURGERY, V47, P315; Murgio A, 1999, CHILD NERV SYST, V15, P318, DOI 10.1007/s003810050401; PFENNINGER J, 1983, INTENS CARE MED, V9, P13, DOI 10.1007/BF01693699; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Prabhakaran P, 2004, J NEUROSURG, V100, P454, DOI 10.3171/ped.2004.100.5.0454; Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361; Rutigliano D, 2006, J PEDIATR SURG, V41, P83, DOI 10.1016/j.jpedsurg.2005.10.010; Sahuquillo J, 2006, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD003983-PUB2; Sarrafzadeh A, 2003, STROKE, V34, P1382, DOI 10.1161/01.STR.0000074036.97859.02; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; SHARPLES PM, 1990, BRIT MED J, V301, P1193, DOI 10.1136/bmj.301.6762.1193; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; Skoglund TS, 2006, J NEUROTRAUM, V23, P1502, DOI 10.1089/neu.2006.23.1502; Spiller WG, 1906, J AMER MED ASSOC, V47, P679; Suzuki K., 1990, NAGOYA MED J, V34, P159; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	43	39	42	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	NOV	2010	26	11					1563	1573		10.1007/s00381-010-1103-4			11	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	683IY	WOS:000284470700018	20177687				2021-06-18	
J	Mirzatoni, A; Spence, RD; Naranjo, KC; Saldanha, CJ; Schlinger, BA				Mirzatoni, Anahid; Spence, Rory D.; Naranjo, Kevin C.; Saldanha, Colin J.; Schlinger, Barney A.			Injury-Induced Regulation of Steroidogenic Gene Expression in the Cerebellum	JOURNAL OF NEUROTRAUMA			English	Article						estradiol; neuroprotection; neurosteroids; songbirds	FINCH TAENIOPYGIA-GUTTATA; TRAUMATIC BRAIN-INJURY; FEMALE ZEBRA FINCHES; MESSENGER-RNA; RAT-BRAIN; AROMATASE EXPRESSION; BENZODIAZEPINE-RECEPTORS; SONGBIRD BRAIN; ESTROGEN; PROTEIN	Sex steroids assist adult neural tissue in the protection from and repair of damage resulting from neural injury; some steroids may be synthesized in the brain. Songbirds are especially useful models to explore steroidal neuroprotection and repair. First, the full suite of cholesterol transporters and steroidogenic enzymes are expressed in the zebra finch (ZF) brain. Second, estrogens promote recovery of behavioral function after damage to the adult ZF cerebellum. Third, the estrogen synthetic enzyme aromatase is rapidly upregulated in reactive glia following neural injury, including in the ZF cerebellum. We hypothesized that cerebellar injury would locally upregulate steroidogenic factors upstream of aromatase, providing the requisite substrate for neuroestrogen synthesis. We tested this hypothesis by lesioning the cerebellum of adult songbirds using both males and females that peripherally synthesize steroids in different amounts. We then used quantitative PCR to examine expression of mRNAs for the neurosteroidogenic factors TSPO, StAR, SCC, 3 beta-HSD, CYP17, and aromatase, at 2 and 8 days post-lesion. Compared to sham lesions, cerebellar lesions significantly upregulated mRNA levels of TSPO and aromatase. Sex differences in response to the lesions were detected for TSPO, StAR, and aromatase. All birds responded to experimental conditions by showing time-dependent changes in the expression of TSPO, SCC, and aromatase, suggesting that acute trauma or stress may impact neurosteroidogensis for many days. These data suggest that the cerebellum is an active site of steroid synthesis in the brain, and each steroidogenic factor likely provides neuroprotection and promotes repair.	[Mirzatoni, Anahid; Schlinger, Barney A.] Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA; [Mirzatoni, Anahid; Schlinger, Barney A.] Univ Calif Los Angeles, Dept Integrat Biol & Physiol, Los Angeles, CA 90095 USA; [Spence, Rory D.] Univ Calif Los Angeles, Neuroendocrinol Lab, Brain Res Inst, Los Angeles, CA 90095 USA; [Spence, Rory D.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA; [Naranjo, Kevin C.; Saldanha, Colin J.] Lehigh Univ, Dept Biol Sci, Bethlehem, PA USA	Schlinger, BA (corresponding author), Univ Calif Los Angeles, Dept Physiol Sci, 621 Charles Young Dr S,POB 951606, Los Angeles, CA 90095 USA.	schlinge@lifesci.ucla.edu			National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [NIMH-061944, NS-042767]; LNE [HD07228-26]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042767] Funding Source: NIH RePORTER	We thank Dr. Amnon Katz, Dr. Xuqi Chen, and Bradley Walters for their technical assistance. We thank Dr. Stephanie White for providing the surgery room. Funding was provided by National Institute of Mental Health grant NIMH-061944, NS-042767 and LNE Training Grant HD07228-26.	ADKINSREGAN E, 1990, GEN COMP ENDOCR, V78, P93, DOI 10.1016/0016-6480(90)90051-M; Arnold AP, 2004, TRENDS ENDOCRIN MET, V15, P6, DOI 10.1016/j.tem.2003.11.001; Azcoitia I, 2001, J NEUROBIOL, V47, P318, DOI 10.1002/neu.1038; Azcoitia I, 2003, ANN NY ACAD SCI, V1007, P298, DOI 10.1196/annals.1286.028; BALTHAZART J, 1990, J COMP NEUROL, V301, P276, DOI 10.1002/cne.903010210; Baulieu EE, 1997, MULT SCLER J, V3, P105, DOI 10.1177/135245859700300209; Chen XQ, 2005, P NATL ACAD SCI USA, V102, P7730, DOI 10.1073/pnas.0408350102; CHUNG B, 1986, P NATL ACAD SCI USA, V83, P8962, DOI 10.1073/pnas.83.23.8962; CORPECHOT C, 1981, P NATL ACAD SCI-BIOL, V78, P4704, DOI 10.1073/pnas.78.8.4704; CORPECHOT C, 1983, BRAIN RES, V270, P119, DOI 10.1016/0006-8993(83)90797-7; Culty M, 2002, J ANDROL, V23, P439; Fester L, 2009, HIPPOCAMPUS, V19, P692, DOI 10.1002/hipo.20548; Garcia-Ovejero D, 2005, BRAIN RES REV, V48, P273, DOI 10.1016/j.brainresrev.2004.12.018; Garcia-Segura LM, 1999, NEUROSCIENCE, V89, P567, DOI 10.1016/S0306-4522(98)00340-6; Garcia-Segura LM, 2003, PROG NEUROBIOL, V71, P31, DOI 10.1016/j.pneurobio.2003.09.005; GARCIASEGURA LM, 2009, ADV FRONT NEUROENDOC, V30, P5; Hashimoto N, 2003, NEUROSCI LETT, V340, P45, DOI 10.1016/S0304-3940(03)00079-X; Herson PS, 2009, SEMIN REPROD MED, V27, P229, DOI 10.1055/s-0029-1216276; Klein D, 1999, ELECTROPHORESIS, V20, P291, DOI 10.1002/(SICI)1522-2683(19990201)20:2<291::AID-ELPS291>3.0.CO;2-R; Kuhlmann AC, 2000, J NEUROCHEM, V74, P1694, DOI 10.1046/j.1471-4159.2000.0741694.x; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Lavaque E, 2006, J NEUROBIOL, V66, P308, DOI 10.1002/neu.20221; London S. E., 2003, Hormones and Behavior, V44, P62; London SE, 2007, J COMP NEUROL, V502, P507, DOI 10.1002/cne.21335; London SE, 2006, ENDOCRINOLOGY, V147, P5975, DOI 10.1210/en.2006-0154; MACLUSKY NJ, 1981, SCIENCE, V211, P1294, DOI 10.1126/science.6163211; Meffre D, 2007, J STEROID BIOCHEM, V104, P293, DOI 10.1016/j.jsbmb.2007.03.003; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; Papadopoulos V, 1997, J BIOL CHEM, V272, P32129, DOI 10.1074/jbc.272.51.32129; Peterson RS, 2001, J NEUROENDOCRINOL, V13, P317, DOI 10.1046/j.1365-2826.2001.00647.x; Pradhan DS, 2010, HORM BEHAV, V57, P381, DOI 10.1016/j.yhbeh.2010.01.008; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Remage-Healey L, 2008, NAT NEUROSCI, V11, P1327, DOI 10.1038/nn.2200; RYAN DW, 2008, GLIA, V56, P97; Saldanha CJ, 2005, GEN COMP ENDOCR, V141, P66, DOI 10.1016/j.ygcen.2004.11.013; Saldanha CJ, 2004, J COMP NEUROL, V469, P522, DOI 10.1002/cne.11035; Saldanha CJ, 2005, J NEUROBIOL, V64, P192, DOI 10.1002/neu.20147; Saldanha CJ, 2009, FRONT NEUROENDOCRIN, V30, P106, DOI 10.1016/j.yfrne.2009.04.016; Schlinger BA, 1997, BRAIN RES BULL, V44, P359, DOI 10.1016/S0361-9230(97)00215-3; SCHLINGER BA, 1993, ENDOCRINOLOGY, V133, P2610, DOI 10.1210/en.133.6.2610; SHEN P, 1994, MOL BRAIN RES, V24, P227, DOI 10.1016/0169-328X(94)90136-8; Sierra A, 2003, EUR J NEUROSCI, V18, P1458, DOI 10.1046/j.1460-9568.2003.02872.x; Soma KK, 2005, ENDOCRINOLOGY, V146, P4386, DOI 10.1210/en.2005-0569; Spence RD, 2009, EUR J NEUROSCI, V29, P1225, DOI 10.1111/j.1460-9568.2009.06685.x; Stocco DM, 1996, BIOCHEM PHARMACOL, V51, P197, DOI 10.1016/0006-2952(95)02093-4; Tsutsui K., 2001, P59; Tsutsui K, 2008, ENDOCRINOLOGY, V149, P2757, DOI 10.1210/en.2007-1592; VOCKEL A, 1990, J NEUROBIOL, V21, P808, DOI 10.1002/neu.480210514; Wise PM, 2002, TRENDS ENDOCRIN MET, V13, P229, DOI 10.1016/S1043-2760(02)00611-2	50	39	39	0	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2010	27	10					1875	1882		10.1089/neu.2010.1330			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	665OZ	WOS:000283046600011	20925573	Green Published			2021-06-18	
J	Rich, NJ; VanLandingham, JW; Figueiroa, S; Seth, R; Corniola, RS; Levenson, CW				Rich, Nicholas J.; VanLandingham, Jacob W.; Figueiroa, Silvia; Seth, Rohit; Corniola, Rikki S.; Levenson, Cathy W.			Chronic Caloric Restriction Reduces Tissue Damage and Improves Spatial Memory in a Rat Model of Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						TBI; morris water maze; p53; BDNF	DIETARY RESTRICTION; FOOD RESTRICTION; NEUROTROPHIC FACTOR; BEHAVIORAL DEFICITS; ALZHEIMERS-DISEASE; MOUSE MODEL; BDNF LEVELS; EXPRESSION; EXERCISE; ISCHEMIA	Although it has been known for some time that chronic caloric or dietary restriction reduces the risk of neurodegenerative disorders and injury following ischemia, the possible role of chronic restriction in improving outcomes after traumatic brain injury (TBI) has not been previously studied. Therefore, 2-month-old male Sprague-Dawley rats were divided into two dietary groups, an ad libitum fed group (AL) and a caloricrestriction group (CR) that was provided with 70% of the food intake of AL rats (n = 10/group). After 4 months, a weight-drop device (300 g) was used to produce a 2-mm bilateral medial frontal cortex contusion following craniotomy. Additional animals in each dietary group (n = 10) were used as sham-operated controls. The CR diet resulted in body weights that were reduced by 30% compared with AL controls. Not only did CR decrease the size of the cortical lesion after injury, there were marked improvements in spatial memory as measured by Morris water maze that included an increase in the number of animals successfully finding the platform as well as significantly reduced time to finding the hidden platform. Western analysis, used to examine the expression of proteins that play a role in neuronal survival, revealed significant increases in brain-derived neurotrophic factor (BDNF) in the cortical region around the site of injury and in the hippocampus in CR rats after injury. These findings suggest that molecular mechanisms involved in cell survival may play a role in reducing tissue damage and improving cognition after TBI and that these mechanisms can be regulated by dietary interventions. (C) 2010 Wiley-Liss, Inc.	[Levenson, Cathy W.] Florida State Univ, Coll Med, Program Neurosci, Tallahassee, FL 32306 USA; Florida State Univ, Coll Med, Dept Biomed Sci, Tallahassee, FL 32306 USA	Levenson, CW (corresponding author), Florida State Univ, Coll Med, Program Neurosci, 1115 W Call St, Tallahassee, FL 32306 USA.	cathy.levenson@med.fsu.edu		Levenson, Cathy W/0000-0003-4463-3136	Florida State University Council for Research and Creativity	Contract grant sponsor: Florida State University Council for Research and Creativity, Multidisciplinary Grants Program.	Andrade JP, 2006, NEUROSCI LETT, V399, P135, DOI 10.1016/j.neulet.2006.01.043; Araya AV, 2008, ENDOCRINE, V33, P300, DOI 10.1007/s12020-008-9090-x; Bellush LL, 1996, PHYSIOL BEHAV, V60, P541, DOI 10.1016/S0031-9384(96)80029-1; Burgener SC, 2008, J NUTR HEALTH AGING, V12, P18, DOI 10.1007/BF02982159; Chase HW, 2008, NEUROPSYCHOLOGIA, V46, P2650, DOI 10.1016/j.neuropsychologia.2008.04.021; Corniola RS, 2008, BRAIN RES, V1237, P52, DOI 10.1016/j.brainres.2008.08.040; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Duan WZ, 1999, J NEUROSCI RES, V57, P195, DOI 10.1002/(SICI)1097-4547(19990715)57:2&lt;195::AID-JNR5&gt;3.0.CO;2-P; Duan WZ, 2003, P NATL ACAD SCI USA, V100, P2911, DOI 10.1073/pnas.0536856100; Guimaraes LR, 2008, PROG NEURO-PSYCHOPH, V32, P1595, DOI 10.1016/j.pnpbp.2008.06.004; Halagappa VKM, 2007, NEUROBIOL DIS, V26, P212, DOI 10.1016/j.nbd.2006.12.019; Hansalik M, 2006, EXP GERONTOL, V41, P169, DOI 10.1016/j.exger.2005.11.002; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; Jacobs WB, 2006, J NEUROCHEM, V97, P1571, DOI 10.1111/j.1471-4159.2006.03980.x; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Lee J, 2002, J NEUROCHEM, V80, P539, DOI 10.1046/j.0022-3042.2001.00747.x; Lefevre M, 2009, ATHEROSCLEROSIS, V203, P206, DOI 10.1016/j.atherosclerosis.2008.05.036; Madeddu F, 2004, NEUROREPORT, V15, P2045, DOI 10.1097/00001756-200409150-00010; Maswood N, 2004, P NATL ACAD SCI USA, V101, P18171, DOI 10.1073/pnas.0405831102; Mattison JA, 2003, EXP GERONTOL, V38, P35, DOI 10.1016/S0531-5565(02)00146-8; Overton JM, 1997, J NUTR, V127, P655; Pasinetti Giulio Maria, 2007, V35, P159; Plunet WT, 2008, EXP NEUROL, V213, P28, DOI 10.1016/j.expneurol.2008.04.011; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Roberge MC, 2008, NEUROSCIENCE, V156, P11, DOI 10.1016/j.neuroscience.2008.05.062; Roberge MC, 2008, BEHAV BRAIN RES, V187, P123, DOI 10.1016/j.bbr.2007.09.002; Stranahan AM, 2009, HIPPOCAMPUS, V19, P951, DOI 10.1002/hipo.20577; Tedeschi A, 2009, CELL DEATH DIFFER, V16, P543, DOI 10.1038/cdd.2008.175; Tedeschi A, 2009, EMBO REP, V10, P576, DOI 10.1038/embor.2009.89; Ucar T, 2006, J TRAUMA, V60, P558, DOI 10.1097/01.ta.0000209172.75637.db; Wang J, 2005, FASEB J, V19, P659, DOI 10.1096/fj.04-3182fje; Weindruch R, 1997, NEW ENGL J MED, V337, P986, DOI 10.1056/NEJM199710023371407; Yu ZF, 1999, J NEUROSCI RES, V57, P830, DOI 10.1002/(SICI)1097-4547(19990915)57:6&lt;830::AID-JNR8&gt;3.0.CO;2-2	35	39	41	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	OCT	2010	88	13					2933	2939		10.1002/jnr.22443			7	Neurosciences	Neurosciences & Neurology	642OK	WOS:000281225100016	20544832				2021-06-18	
J	Berman, M; Ali, A; Ashley, E; Freed, D; Clarke, K; Tsui, S; Parameshwar, J; Large, S				Berman, Marius; Ali, Ayyaz; Ashley, Euan; Freed, Darren; Clarke, Kieran; Tsui, Steven; Parameshwar, Jayan; Large, Stephen			Is stress cardiomyopathy the underlying cause of ventricular dysfunction associated with brain death?	JOURNAL OF HEART AND LUNG TRANSPLANTATION			English	Article						heart transplantation; graft dysfunction; RV dysfunction; stress cardiomyopathy; Takotsubo cardiomyopathy	WALL-MOTION ABNORMALITIES; MYOCARDIAL DYSFUNCTION; HUMAN DONOR; TAKOTSUBO CARDIOMYOPATHY; SUBARACHNOID HEMORRHAGE; INJURY; HEART	Most deaths in the first 30 days after cardiac transplantation are due to failure of the donor heart, often with the clinical picture of right ventricular failure. Indeed, there is a significant reduction in contractility of the human donor heart and loss of contractile reserve before and soon after transplantation. This myocardial insult appears in association with brain death in the donor and follows a "catecholamine storm" associated with a rapidly rising intracranial pressure. Microscopy of the myocardium in organ donors shows a picture typical of catecholamine-induced injury and similar to changes found in endomyocardial specimens of stress cardiomyopathy (catecholamine-induced cardiomyopathy, or Takotsubo cardiomyopathy). There are 3 common features between stress cardiomyopathy and the heart of a brain-dead donor: exposure of the heart to unusually high catecholamine levels, ventricular dysfunction, and prompt recovery. Stress cardiomyopathy is a temporary myocardial dysfunction that has been described after sub-arachnoid hemorrhage, traumatic head injury, pheochromocytoma, acute emotional distress, exogenous administration of catecholamines, and non-related surgery. Given the common features of this catecholamine-mediated myocardial insult, we ask if brain-dead donor heart dysfunction is an extreme variant of stress cardiomyopathy? And, if so is it, like stress cardiomyopathy, reversible? Can we therefore expect recovery of the dysfunctional donor heart over time, thereby permitting increased use of hearts offered for transplantation? J Heart Lung Transplant 2010;29:957-65 (C) 2010 International Society for Heart and Lung Transplantation All rights reserved.	[Berman, Marius; Ali, Ayyaz; Tsui, Steven; Parameshwar, Jayan; Large, Stephen] Papworth Hosp, Dept Cardiothorac Surg, Cambridge CB23 3RE, England; [Ashley, Euan] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; [Freed, Darren] Univ Manitoba, Dept Surg, Sch Med, Winnipeg, MB R3T 2N2, Canada; [Clarke, Kieran] Univ Oxford, Dept Physiol, Oxford, England	Large, S (corresponding author), Papworth Hosp, Dept Cardiothorac Surg, Cambridge CB23 3RE, England.	Stephen.Large@papworth.nhs.uk		Freed, Darren/0000-0002-6239-1444			Abraham J, 2009, J AM COLL CARDIOL, V53, P1320, DOI 10.1016/j.jacc.2009.02.020; Akashi YJ, 2008, CIRCULATION, V118, P2754, DOI 10.1161/CIRCULATIONAHA.108.767012; Ako J, 2006, AM J MED, V119, P10, DOI 10.1016/j.amjmed.2005.08.022; Aretz H T, 1987, Am J Cardiovasc Pathol, V1, P3; BHATIA SJS, 1987, CIRCULATION, V76, P819, DOI 10.1161/01.CIR.76.4.819; Brandspiegel HZ, 1998, CIRCULATION, V98, P1349, DOI 10.1161/01.CIR.98.13.1349; Bybee KA, 2004, ANN INTERN MED, V141, P858, DOI 10.7326/0003-4819-141-11-200412070-00010; Dujardin KS, 2001, J HEART LUNG TRANSPL, V20, P350, DOI 10.1016/S1053-2498(00)00193-5; Elesber AA, 2006, J AM COLL CARDIOL, V47, P1082, DOI 10.1016/j.jacc.2005.12.004; Ellison GM, 2007, J BIOL CHEM, V282, P11397, DOI 10.1074/jbc.M607391200; Hurst RT, 2006, J AM COLL CARDIOL, V48, P579, DOI 10.1016/j.jacc.2006.06.015; Kneale BJ, 2000, J AM COLL CARDIOL, V36, P1233, DOI 10.1016/S0735-1097(00)00849-4; Kothavale A, 2006, NEUROCRIT CARE, V4, P199, DOI 10.1385/NCC:4:3:199; Lee VH, 2006, J NEUROSURG, V105, P264, DOI 10.3171/jns.2006.105.2.264; MANN DL, 1992, CIRCULATION, V85, P790, DOI 10.1161/01.CIR.85.2.790; MAYER SA, 1995, J NEUROSURG, V83, P889, DOI 10.3171/jns.1995.83.5.0889; MORI H, 1993, CARDIOVASC RES, V27, P192, DOI 10.1093/cvr/27.2.192; NOVITZKY D, 1989, TRANSPLANT P, V21, P2567; NOVITZKY D, 1986, ANN THORAC SURG, V41, P520, DOI 10.1016/S0003-4975(10)63032-9; Novitzky D, 1997, TRANSPLANT P, V29, P3770, DOI 10.1016/S0041-1345(97)01149-4; Parekh N, 2000, J AM COLL CARDIOL, V36, P1328, DOI 10.1016/S0735-1097(00)00857-3; POLLICK C, 1988, J AM COLL CARDIOL, V12, P600, DOI 10.1016/S0735-1097(88)80044-5; Riera Maria, 2010, J Trauma, V68, pE13, DOI 10.1097/TA.0b013e3181469d5b; Sanchez-Recalde A, 2006, CIRCULATION, V113, pE738, DOI 10.1161/CIRCULATIONAHA.105.581108; Sato M, 2006, CIRC J, V70, P947, DOI 10.1253/circj.70.947; SHIVALKAR B, 1993, CIRCULATION, V87, P230, DOI 10.1161/01.CIR.87.1.230; Stoica SC, 2004, TRANSPLANTATION, V78, P1193, DOI 10.1097/01.TP.0000137792.74940.4F; Stoica SC, 2003, EUR J CARDIO-THORAC, V23, P503, DOI 10.1016/S1010-7940(03)00019-8; Stoica SC, 2006, J THORAC CARDIOV SUR, V132, P116, DOI 10.1016/j.jtcvs.2005.12.061; Szabo G, 1998, EUR J CARDIO-THORAC, V13, P449, DOI 10.1016/S1010-7940(98)00049-9; TALAJ JA, 2007, J AM COLL CARDIOL, V50, P1064; Taylor DO, 2008, J HEART LUNG TRANSPL, V27, P943, DOI 10.1016/j.healun.2008.06.017; Van de Walle SOA, 2006, MAYO CLIN PROC, V81, P1499, DOI 10.4065/81.11.1499; VANTRIGT P, 1995, ANN SURG, V221, P666; VANVLIET PD, 1966, NEW ENGL J MED, V274, P1102, DOI 10.1056/NEJM196605192742002; WHITE M, 1995, CIRCULATION, V92, P2183, DOI 10.1161/01.CIR.92.8.2183; Wittstein IS, 2005, NEW ENGL J MED, V352, P539, DOI 10.1056/NEJMoa043046; Yoshikawa D, 1999, ANESTH ANALG, V89, P962; Zaroff JG, 2006, STROKE, V37, P1680, DOI 10.1161/01.STR.0000226461.52423.dd	39	39	41	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1053-2498	1557-3117		J HEART LUNG TRANSPL	J. Heart Lung Transplant.	SEP	2010	29	9					957	965		10.1016/j.healun.2010.04.008			9	Cardiac & Cardiovascular Systems; Respiratory System; Surgery; Transplantation	Cardiovascular System & Cardiology; Respiratory System; Surgery; Transplantation	645VR	WOS:000281494800001	20627624				2021-06-18	
J	Luchetti, S; Bossers, K; Frajese, GV; Swaab, DF				Luchetti, Sabina; Bossers, Koen; Frajese, Giovanni Vanni; Swaab, Dick F.			Neurosteroid Biosynthetic Pathway Changes in Substantia Nigra and Caudate Nucleus in Parkinson's Disease	BRAIN PATHOLOGY			English	Article						3 alpha lpha-hydroxysteroid dehydrogenase; 5 alpha lphareductase; GABA-A receptors; gene expression; neurosteroids; Parkinson's disease	INDUCED DOPAMINE DEPLETION; TRAUMATIC BRAIN-INJURY; DEHYDROEPIANDROSTERONE DHEA; PREGNENOLONE-SULFATE; GENE-EXPRESSION; PROGESTERONE METABOLITES; CELL-DEATH; HIPPOCAMPAL-NEURONS; RECEPTOR PLASTICITY; PROTEIN EXPRESSION	There is emerging evidence from animal studies for a neuroprotective role of sex steroids in neurodegenerative diseases, but studies in human brain are lacking. We have carried out an extensive study of the neurosteroid biosynthetic pathways in substantia nigra (SN), caudate nucleus (CN) and putamen (PU) of 7 Parkinson's disease (PD) patients and 7 matched controls. The mRNA levels of 37 genes including neurosteroid biosynthetic enzymes, hormone receptors and the neurosteroid-modulated gamma-amino-butyric acid -A (GABA-A) receptor subunits were analyzed by quantitative PCR (qPCR). In the SN, we found downregulation of 5 alpha-reductase type 1 (5 alpha-R1), sulfotransferase 2B1 (SULT2B1) and some GABA-A receptor subunits (alpha 4, beta 1) while in the CN, upregulation of 3 alpha-hydroxysteroid dehydrogenase type 3 (3 alpha-HSD3) and alpha 4 GABA-A receptor subunit (22-fold) was observed. No significant differences were found in the PU. These data imply an involvement of pregnane steroids and changes in GABAergic neurotransmission in the neurodegenerative process and suggest that neurosteroids may deserve further investigation as potential therapeutic agents in PD.	[Luchetti, Sabina; Bossers, Koen; Swaab, Dick F.] Royal Netherlands Acad Arts & Sci, Netherlands Inst Neurosci, Lab Neuropsychiat Disorders, NL-1105 BA Amsterdam, Netherlands; [Luchetti, Sabina] Santa Lucia Fdn, Inst Sci, Ist Dermopat Immacolata IDI IRCCS, Rome, Italy; [Frajese, Giovanni Vanni] Univ Roma Tor Vergata, Endocrinol lab, Dept Internal Med, Rome, Italy; [Frajese, Giovanni Vanni] Univ Cassino, Fac Motor Sci, I-03043 Cassino, Italy	Luchetti, S (corresponding author), Royal Netherlands Acad Arts & Sci, Netherlands Inst Neurosci, Lab Neuropsychiat Disorders, Meibergdreef 47, NL-1105 BA Amsterdam, Netherlands.	s.luchetti@nin.knaw.nl	Bossers, Koen/I-4002-2013	Bossers, Koen/0000-0002-0272-4518; Swaab, Dick/0000-0002-9665-7845			Baulieu EE, 2001, INT REV NEUROBIOL, V46, P1; Biggio F, 2006, PHARMACOL BIOCHEM BE, V84, P545, DOI 10.1016/j.pbb.2006.07.002; Biggio G, 2001, INT REV NEUROBIOL, V46, P207; Bixo M, 1997, BRAIN RES, V764, P173, DOI 10.1016/S0006-8993(97)00455-1; BOLAM JP, 1990, BRAIN RES, V529, P57, DOI 10.1016/0006-8993(90)90811-O; Bossers K, 2009, BRAIN PATHOL, V19, P91, DOI 10.1111/j.1750-3639.2008.00171.x; Bourque M, 2009, FRONT NEUROENDOCRIN, V30, P142, DOI 10.1016/j.yfrne.2009.04.014; BRAAK H, 1995, NEUROBIOL AGING, V16, P271, DOI 10.1016/0197-4580(95)00021-6; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Callier S, 2000, SYNAPSE, V37, P245, DOI 10.1002/1098-2396(20000915)37:4<245::AID-SYN1>3.0.CO;2-5; Callier S, 2001, SYNAPSE, V41, P131, DOI 10.1002/syn.1067; Calon F, 2003, MOVEMENT DISORD, V18, P241, DOI 10.1002/mds.10343; Carter RB, 1997, J PHARMACOL EXP THER, V280, P1284; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Compagnone NA, 2000, FRONT NEUROENDOCRIN, V21, P1, DOI 10.1006/frne.1999.0188; Concas A, 1999, EUR J PHARMACOL, V375, P225, DOI 10.1016/S0014-2999(99)00232-0; Concas A, 1998, P NATL ACAD SCI USA, V95, P13284, DOI 10.1073/pnas.95.22.13284; D'Astous M, 2003, SYNAPSE, V47, P10, DOI 10.1002/syn.10145; de Michele F, 2003, NEUROL SCI, V24, P172, DOI 10.1007/s10072-003-0115-1; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Do Rego JL, 2009, FRONT NEUROENDOCRIN, V30, P259, DOI 10.1016/j.yfrne.2009.05.006; Farrant M, 2005, NAT REV NEUROSCI, V6, P215, DOI 10.1038/nrn1625; Fleige Simone, 2006, Molecular Aspects of Medicine, V27, P126, DOI 10.1016/j.mam.2005.12.003; Follesa P, 2000, MOL PHARMACOL, V57, P1262; Garcia-Segura LM, 2006, NEUROENDOCRINOLOGY, V84, P275, DOI 10.1159/000097485; Gerlach M, 1996, BRAIN RES, V741, P142, DOI 10.1016/S0006-8993(96)00915-8; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Gillies GE, 2010, HORM BEHAV, V57, P23, DOI 10.1016/j.yhbeh.2009.06.002; Grandbois M, 2000, NEUROREPORT, V11, P343, DOI 10.1097/00001756-200002070-00024; Gulinello M, 2001, BRAIN RES, V910, P55, DOI 10.1016/S0006-8993(01)02565-3; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Horak M, 2004, J NEUROSCI, V24, P10318, DOI 10.1523/JNEUROSCI.2099-04.2004; Karishma KK, 2002, EUR J NEUROSCI, V16, P445, DOI 10.1046/j.1460-9568.2002.02099.x; Kask K, 2009, PHARMACOL BIOCHEM BE, V92, P608, DOI 10.1016/j.pbb.2009.02.014; Kimonides VG, 1998, P NATL ACAD SCI USA, V95, P1852, DOI 10.1073/pnas.95.4.1852; KISH SJ, 1986, ANN NEUROL, V20, P26, DOI 10.1002/ana.410200106; Lockhart EM, 2002, NEUROSCI LETT, V328, P33, DOI 10.1016/S0304-3940(02)00448-2; Lovick TA, 2005, NEUROSCIENCE, V131, P397, DOI 10.1016/j.neuroscience.2004.11.010; Luchetti S, 2006, J NEUROSCI METH, V153, P290, DOI 10.1016/j.jneumeth.2005.11.005; MAJEWSKA MD, 1987, BRAIN RES, V404, P355; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; Melcangi RC, 2008, CELL MOL LIFE SCI, V65, P777, DOI 10.1007/s00018-007-7403-5; Mellon SH, 2008, BRAIN RES REV, V57, P410, DOI 10.1016/j.brainresrev.2007.05.012; Morissette M, 2008, MOL CELL ENDOCRINOL, V290, P60, DOI 10.1016/j.mce.2008.04.008; Morita K, 2008, J MOL NEUROSCI, V34, P193, DOI 10.1007/s12031-007-9034-6; Nohria V, 2007, NEUROTHERAPEUTICS, V4, P102, DOI 10.1016/j.nurt.2006.11.003; PERRY TL, 1983, J NEUROCHEM, V40, P1120, DOI 10.1111/j.1471-4159.1983.tb08102.x; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pieribone VA, 2007, EPILEPSIA, V48, P1870, DOI 10.1111/j.1528-1167.2007.01182.x; Ramirez AD, 2003, NEUROENDOCRINOLOGY, V77, P223, DOI 10.1159/000070277; RINNE JO, 1988, NEUROSCI LETT, V94, P182, DOI 10.1016/0304-3940(88)90292-3; Sanna E, 2009, J NEUROSCI, V29, P1755, DOI 10.1523/JNEUROSCI.3684-08.2009; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Shirakawa H, 2005, EUR J NEUROSCI, V21, P2329, DOI 10.1111/j.1460-9568.2005.04079.x; Smith SS, 1998, NATURE, V392, P926, DOI 10.1038/31948; Stoffel-Wagner B, 2001, EUR J ENDOCRINOL, V145, P669, DOI 10.1530/eje.0.1450669; Suzuki M, 2004, P NATL ACAD SCI USA, V101, P3202, DOI 10.1073/pnas.0307325101; Tomita H, 2004, BIOL PSYCHIAT, V55, P346, DOI 10.1016/j.biopsych.2003.10.013; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wang JM, 2005, J NEUROSCI, V25, P4706, DOI 10.1523/JNEUROSCI.4520-04.2005; Wang JM, 2007, CURR ALZHEIMER RES, V4, P510, DOI 10.2174/156720507783018262; WU FS, 1991, MOL PHARMACOL, V40, P333	63	39	39	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305	1750-3639		BRAIN PATHOL	Brain Pathol.	SEP	2010	20	5					945	951		10.1111/j.1750-3639.2010.00396.x			7	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	635BA	WOS:000280629400007	20406233				2021-06-18	
J	Steel, J; Youssef, M; Pfeifer, R; Ramirez, JM; Probst, C; Sellei, R; Zelle, BA; Sittaro, NA; Khalifa, F; Pape, HC				Steel, Jennifer; Youssef, Michael; Pfeifer, Roman; Ramirez, Juliana M.; Probst, Christian; Sellei, Richard; Zelle, Boris A.; Sittaro, Nicola-Alexander; Khalifa, Farah; Pape, Hans Christoph			Health-Related Quality of Life in Patients With Multiple Injuries and Traumatic Brain Injury 10+Years Postinjury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	68th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	OCT 01-03, 2009	Pittsburgh, PA	Amer Assoc Surg Trauma			1ST 5 YEARS; FOLLOW-UP; HEAD-INJURY; SATISFACTION; DYSFUNCTION; DISABILITY; DEPRESSION; OUTCOMES; CANCER; MODEL	Background: The aim of this study was to examine the long-term physical and psychological consequences of multiple blunt forced trauma at >= 10-year follow-up for patients with and without traumatic brain injury (TBI). Methods: A total of 620 patients with multiple injuries were assessed with the Medical Outcomes Study-Short Form-12 and a physical reexamination at >= 10-year follow-up. Injury-related characteristics were collected from patients' medical record. Chi-square analysis, Analysis of Variance, and linear and logistic regression were performed to test differences between groups and examine predictors of physical and psychological functioning at >= 10-year follow-up. Results: Patients with multiple injuries who sustained a TBI (n = 398) were more likely to be female (p = 0.001), younger in age at the time of injury (p = 0.02), have higher Injury Severity Scores (p = 0.001), shorter ward stays (p = 0.001), and a greater number of upper extremity injuries (p = 0.02) when compared with those without TBI (n = 222). Patients with TBI reported poorer psychological functioning (p = 0.02) and more frequently reported chronic pain (p = 0.01). Patients with TBI used medical aids (p = 0.002) less frequently at follow-up when compared with patients without TBI. Significant predictors of health-related quality of life at >= 10-year follow-up included age at the time of injury (physical; p = 0.001), gender (p = 0.05), number of ventilation days (p = 0.02), satisfaction with rehabilitation (p = 0.001), disability caused by the injury (p = 0.001), and use of medical aids (physical p = 0.02). Conclusions: Prospective studies are needed with a broader range of measures that may be sensitive to the consequences of TBI. Evidence-based interventions to facilitate physical and psychological rehabilitation, designed to target at risk patients, are warranted.	[Steel, Jennifer; Youssef, Michael; Ramirez, Juliana M.; Khalifa, Farah] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15260 USA; [Steel, Jennifer] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA; [Zelle, Boris A.] Univ Pittsburgh, Sch Med, Dept Orthoped, Pittsburgh, PA 15260 USA; [Pfeifer, Roman; Pape, Hans Christoph] Univ Aachen, Dept Orthopaed & Trauma, Aachen, Germany; [Probst, Christian] Leibniz Univ Hannover, Dept Orthoped & Trauma, D-30167 Hannover, Germany; [Sittaro, Nicola-Alexander] Hannover Re Insurance, Hannover, Germany	Pape, HC (corresponding author), Univ Aachen, Dept Orthopaed & Trauma, Aachen, Germany.		/ABE-7042-2020	Pape, Hans-Christoph/0000-0002-2059-4980	NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [K07CA118576, R21CA127046] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [5K07CA118576-01, 5R21CA127046-01A1] Funding Source: Medline		Anke AGW, 2003, CLIN REHABIL, V17, P431, DOI 10.1191/0269215503cr629oa; BOUILLON B, 1989, LANGENBECKS ARCH C S, V2, P117; BURKE JM, 1994, BRAIN INJURY, V8, P71, DOI 10.3109/02699059409150960; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Elovic EP, 2003, J HEAD TRAUMA REHAB, V18, P541, DOI 10.1097/00001199-200311000-00008; Finset A, 1999, PSYCHOSOM MED, V61, P576, DOI 10.1097/00006842-199907000-00024; Gabbe BJ, 2006, J TRAUMA, V61, P1393, DOI 10.1097/01.ta.0000225926.34180.47; Gulseren S, 2006, ARCH MED RES, V37, P133, DOI 10.1016/j.arcmed.2005.05.008; HALCOMB E, AUST CRIT CARE, V18, P17; Israel BA, 1998, ANNU REV PUBL HEALTH, V19, P173, DOI 10.1146/annurev.publhealth.19.1.173; Lehmann U, 1999, EUR J SURG, V165, P1116, DOI 10.1080/110241599750007603; Lippert-Gruner M, 2007, BRAIN INJURY, V21, P451, DOI 10.1080/02699050701343961; MacKenzie EJ, 2002, QUAL LIFE RES, V11, P797, DOI 10.1023/A:1020820017658; Martelli MF, 2008, NEUROREHABILITATION, V23, P115; Mckenzie J, 2000, BRIT MED J, V321, P632; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Narushima K, 2003, J NEUROPSYCH CLIN N, V15, P422, DOI 10.1176/appi.neuropsych.15.4.422; Neuenschwander AU, 2002, EUR J CARDIO-THORAC, V22, P287, DOI 10.1016/S1010-7940(02)00263-4; Nicholson K, 2000, NEUROREHABILITATION, V14, P95; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Probst C, 2009, J TRAUMA, V66, P1212, DOI 10.1097/TA.0b013e318197b97c; Rainey T, 2009, RESUSCITATION, V80, P341, DOI 10.1016/j.resuscitation.2008.11.021; Resch JA, 2009, REHABIL PSYCHOL, V54, P51, DOI 10.1037/a0015051; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; Stalp M, 2002, J TRAUMA, V52, P1160, DOI 10.1097/00005373-200206000-00023; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; Thurston RJ, 1999, BRAIN INJURY MEMORY; Tsagarakis S, 2005, Pituitary, V8, P251, DOI 10.1007/s11102-006-6049-x	30	39	40	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2010	69	3					523	530		10.1097/TA.0b013e3181e90c24			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	649HX	WOS:000281760800007	20838121				2021-06-18	
J	Wagner, J; Dusick, JR; McArthur, DL; Cohan, P; Wang, C; Swerdloff, R; Boscardin, WJ; Kelly, DF				Wagner, Justin; Dusick, Joshua R.; McArthur, David L.; Cohan, Pejman; Wang, Christina; Swerdloff, Ronald; Boscardin, W. John; Kelly, Daniel F.			Acute Gonadotroph and Somatotroph Hormonal Suppression after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						estrogen; growth hormone; hypopituitarism; insulin-like growth factor-1; testosterone; traumatic brain injury	SEVERE HEAD-INJURY; TRANSIENT HYPOGONADOTROPIC HYPOGONADISM; CRITICALLY-ILL PATIENTS; BODY-MASS INDEX; GROWTH-HORMONE; CRITICAL ILLNESS; CLINICAL-TRIALS; MEDIATED NEUROPROTECTION; ENDOCRINE ABNORMALITIES; PROPOFOL INFUSION	Hormonal dysfunction is a known consequence of moderate and severe traumatic brain injury (TBI). In this study we determined the incidence, time course, and clinical correlates of acute post-TBI gonadotroph and somatotroph dysfunction. Patients had daily measurement of serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, estradiol, growth hormone, and insulin-like growth factor-1 (IGF-1) for up to 10 days post-injury. Values below the fifth percentile of a healthy cohort were considered abnormal, as were non-measurable growth hormone (GH) values. Outcome measures were frequency and time course of hormonal suppression, injury characteristics, and Glasgow Outcome Scale (GOS) score. The cohort consisted of 101 patients (82% males; mean age 35 years; Glasgow Coma Scale [GCS] score <= 8 in 87%). In men, 100% had at least one low testosterone value, and 93% of all values were low; in premenopausal women, 43% had at least one low estradiol value, and 39% of all values were low. Non-measurable GH levels occurred in 38% of patients, while low IGF-1 levels were observed in 77% of patients, but tended to normalize within 10 days. Multivariate analysis revealed associations of younger age with low FSH and low IGF-1, acute anemia with low IGF-1, and older age and higher body mass index (BMI) with low GH. Hormonal suppression was not predictive of GOS score. These results indicate that within 10 days of complicated mild, moderate, and severe TBI, testosterone suppression occurs in all men and estrogen suppression occurs in over 40% of women. Transient somatotroph suppression occurs in over 75% of patients. Although this acute neuroendocrine dysfunction may not be TBI-specific, low gonadal steroids, IGF-1, and GH may be important given their putative neuroprotective functions.	[Kelly, Daniel F.] St Johns Hlth Ctr, John Wayne Canc Inst, Brain Tumor Ctr, Santa Monica, CA 90404 USA; [Wagner, Justin] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA; [Dusick, Joshua R.; McArthur, David L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Cohan, Pejman] Univ Calif Los Angeles, Sch Med, Div Endocrinol, Los Angeles, CA USA; [Cohan, Pejman] Univ Calif Los Angeles, Sch Med, Gonda Diabet Ctr, Los Angeles, CA USA; [Wang, Christina; Swerdloff, Ronald] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Dept Med, Div Endocrinol, Torrance, CA USA; [Boscardin, W. John] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Boscardin, W. John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA	Kelly, DF (corresponding author), St Johns Hlth Ctr, John Wayne Canc Inst, Brain Tumor Ctr, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.	kellyd@jwci.org	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS 40777, K23 RR 1729801, MO1 RR 00425, M01 RR 00865, M01 RR 19975]; UC Davis Medical Centers; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000865, M01RR000425, K23RR017298, M01RR019975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040777] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grants R01 NS 40777 to D. F. K.; K23 RR 1729801 to P. C.; and MO1 RR 00425, M01 RR 00865, and M01 RR 19975 to the GCRCs at Harbor-UCLA, UCLA, and UC Davis Medical Centers, respectively.	Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; ALBANESE J, 1990, ANESTHESIOLOGY, V73, P214, DOI 10.1097/00000542-199008000-00004; Allen NE, 2002, CANCER CAUSE CONTROL, V13, P353, DOI 10.1023/A:1015238102830; Ariza M, 2004, J NEUROTRAUM, V21, P864, DOI 10.1089/0897715041526203; BAILIE GR, 1992, BRIT J ANAESTH, V68, P486, DOI 10.1093/bja/68.5.486; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Bhasin S, 2006, J CLIN ENDOCR METAB, V91, P1995, DOI 10.1210/jc.2005-2847; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Cernak I, 1997, WORLD J SURG, V21, P240, DOI 10.1007/s002689900223; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHIOLERO R, 1988, J TRAUMA, V28, P1368, DOI 10.1097/00005373-198809000-00011; CHIOLERO RL, 1988, ACTA ENDOCRINOL-COP, V117, P80, DOI 10.1530/acta.0.1170080; Chisu V, 2006, ARCH ITAL BIOL, V144, P63; Choi SC, 1998, J NEUROTRAUM, V15, P771, DOI 10.1089/neu.1998.15.771; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Cormio M, 1999, J NEUROTRAUM, V16, P927, DOI 10.1089/neu.1999.16.927; Della Corte F, 1998, CRIT CARE MED, V26, P1419; DErcole AJ, 1996, MOL NEUROBIOL, V13, P227, DOI 10.1007/BF02740625; Dimopoulou I, 2005, NEUROCRIT CARE, V3, P224, DOI 10.1385/NCC:3:3:224; Dimopoulou I, 2004, INTENS CARE MED, V30, P1051, DOI 10.1007/s00134-004-2257-x; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FLEISCHER AS, 1978, J NEUROSURG, V49, P650, DOI 10.3171/jns.1978.49.5.0650; Gapstur SM, 2002, CANCER EPIDEM BIOMAR, V11, P1041; GARCIAESTRADA J, 1993, BRAIN RES, V628, P271, DOI 10.1016/0006-8993(93)90964-O; GILMAN AG, 1980, GOODMAN GILMANS PHAR; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; Hammond J, 2001, J NEUROCHEM, V77, P1319, DOI 10.1046/j.1471-4159.2001.00345.x; Hana V, 2002, EUR J ENDOCRINOL, V147, P333, DOI 10.1530/eje.0.1470333; Harman SM, 2003, HORM RES, V60, P121, DOI 10.1159/000071236; HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198; HEINEN E, 1981, HORM METAB RES, V13, P284, DOI 10.1055/s-2007-1019245; Huppenbauer CB, 2005, J NEUROSCI, V25, P4004, DOI 10.1523/JNEUROSCI.5279-04.2005; ILLIEVICH UM, 1993, ANESTH ANALG, V77, P155; JENNETT B, 1975, LANCET, V1, P480; Jensen TK, 2004, FERTIL STERIL, V82, P863, DOI 10.1016/j.fertnstert.2004.03.056; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly DF, 1999, J NEUROSURG, V90, P1042, DOI 10.3171/jns.1999.90.6.1042; Kleindienst A, 2009, J NEUROTRAUM, V26, P1435, DOI 10.1089/neu.2008.0601; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Kraus JF, 2003, ANN EMERG MED, V41, P18, DOI 10.1067/mem.2003.1; LEE SC, 1994, BRAIN INJURY, V8, P571; Leon-Sanz M, 1997, Eur J Med Res, V2, P477; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Maas AIR, 2004, ACT NEUR S, V89, P113; Maiya B, 2008, INTENS CARE MED, V34, P468, DOI 10.1007/s00134-007-0902-x; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Napoli R, 2003, J CLIN ENDOCR METAB, V88, P2817, DOI 10.1210/jc.2003-030144; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Neuhaus J M, 1992, Stat Methods Med Res, V1, P249, DOI 10.1177/096228029200100303; Nguyen TVV, 2005, J NEUROCHEM, V94, P1639, DOI 10.1111/j.1471-4159.2005.03318.x; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; Page ST, 2005, J CLIN ENDOCR METAB, V90, P1502, DOI 10.1210/jc.2004-1933; Qoubaitary A, 2006, J ANDROL, V27, P853, DOI 10.2164/jandrol.106.000281; Qu XD, 2005, J CLIN ENDOCR METAB, V90, P1563, DOI 10.1210/jc.2004-1450; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Ragnarsson KT, 2002, RESTOR NEUROL NEUROS, V20, P103; Ramsden M, 2003, NEUROSCIENCE, V122, P573, DOI 10.1016/j.neuroscience.2003.08.048; Rice JA, 2001, BIOMETRICS, V57, P253, DOI 10.1111/j.0006-341X.2001.00253.x; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Sattler FR, 2009, J CLIN ENDOCR METAB, V94, P1991, DOI 10.1210/jc.2008-2338; Sawada H, 1998, J NEUROSCI RES, V54, P707, DOI 10.1002/(SICI)1097-4547(19981201)54:5<707::AID-JNR16>3.0.CO;2-T; Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676; Scheepens A, 2000, J PEDIATR ENDOCR MET, V13, P1483; Scheepens A, 2001, NEUROSCIENCE, V104, P677, DOI 10.1016/S0306-4522(01)00109-9; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; Sierra A, 2003, ENDOCRINE, V21, P43, DOI 10.1385/ENDO:21:1:43; Silha JV, 2005, CLIN ENDOCRINOL, V63, P79, DOI 10.1111/j.1365-2265.2005.02303.x; SLAG MF, 1981, JAMA-J AM MED ASSOC, V245, P43, DOI 10.1001/jama.245.1.43; Snyder PJ, 1999, J CLIN ENDOCR METAB, V84, P2647, DOI 10.1210/jc.84.8.2647; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; Takala J, 1999, NEW ENGL J MED, V341, P785, DOI 10.1056/NEJM199909093411102; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Tomei G, 1991, J Neurosurg Sci, V35, P61; Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666; Van den Berghe G, 2003, ENDOCRIN METAB CLIN, V32, P385, DOI 10.1016/S0889-8529(03)00005-7; Van den Berghe G, 2001, J CLIN ENDOCR METAB, V86, P3217, DOI 10.1210/jc.86.7.3217; VANDENBERGHE G, 1994, J CLIN ENDOCR METAB, V79, P1141, DOI 10.1210/jc.79.4.1141; VandenBerghe G, 1997, J CLIN ENDOCR METAB, V82, P590, DOI 10.1210/jc.82.2.590; VandenBerghe G, 1996, CRIT CARE MED, V24, P1580, DOI 10.1097/00003246-199609000-00024; Vandesteene A, 1988, Anaesthesia, V43 Suppl, P42, DOI 10.1111/j.1365-2044.1988.tb09067.x; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Wang C, 2004, J CLIN ENDOCR METAB, V89, P2085, DOI 10.1210/jc.2003-032006; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x; WOOLF PD, 1985, J CLIN ENDOCR METAB, V60, P444, DOI 10.1210/jcem-60-3-444; WOOLF PD, 1988, AM J MED, V84, P201, DOI 10.1016/0002-9343(88)90414-7; Ye P, 1999, ENDOCRINOLOGY, V140, P3063, DOI 10.1210/en.140.7.3063; Ye P, 2002, J NEUROSCI, V22, P6041; Zhang Y, 2004, J NEUROSCI, V24, P5315, DOI 10.1523/JNEUROSCI.0913-04.2004; Zhong J, 2005, J NEUROSCI RES, V80, P481, DOI 10.1002/jnr.20490	101	39	40	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2010	27	6					1007	1019		10.1089/neu.2009.1092			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	612VO	WOS:000278933300005	20214417	Green Published			2021-06-18	
J	Lojovich, JM				Lojovich, Jeanne M.			The Relationship Between Aerobic Exercise and Cognition: Is Movement Medicinal?	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						aerobic exercise; brain injury; cognition; memory; rehabilitation	TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; NEUROTROPHIC FACTOR; VOLUNTARY EXERCISE; BLOOD-FLOW; PHYSICAL-ACTIVITY; CONTUSION INJURY; GROWTH-FACTOR; UP-REGULATION; MOTOR CORTEX	Each year approximately 1.5 million individuals sustain traumatic brain injuries often resulting in difficulties in memory and executive function that limit independence. Aerobic exercise not only has been found to impact cardiovascular systems but has also shown benefits to brain function itself and specifically in the domain of memory and learning. Recent evidence is shedding light on the mechanisms possibly impacting cognitive performance following the participation in exercise. Literature has demonstrated increased hemodynamics within the brain, changes in neurotransmitters, and increasing levels of brain-derived neurotrophic factor that stimulates neurogenesis, and resistance to further injury. This review article explores the current literature and the possibility of exercise acting as an adjunct treatment to enhance the effectiveness of cognitive rehabilitation.	Univ Minnesota, Program Phys Therapy, Minneapolis, MN 55455 USA	Lojovich, JM (corresponding author), Univ Minnesota, Program Phys Therapy, MMC 388,420 Delaware St SE, Minneapolis, MN 55455 USA.	jablo005@umn.edu					Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Barnes DE, 2003, J AM GERIATR SOC, V51, P459, DOI 10.1046/j.1532-5415.2003.51153.x; BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Calof Anne L., 1995, Current Opinion in Neurobiology, V5, P19, DOI 10.1016/0959-4388(95)80082-4; Christensen LOD, 2000, EXP BRAIN RES, V135, P66, DOI 10.1007/s002210000493; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Colcombe SJ, 2004, P NATL ACAD SCI USA, V101, P3316, DOI 10.1073/pnas.0400266101; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Ding Q, 2006, NEUROSCIENCE, V140, P823, DOI 10.1016/j.neuroscience.2006.02.084; Ding Y, 2004, NEUROSCIENCE, V124, P583, DOI 10.1016/j.neuroscience.2003.12.029; Ding YH, 2006, CURR NEUROVASC RES, V3, P15, DOI 10.2174/156720206775541787; Edelberg JM, 2003, FRONT BIOSCI-LANDMRK, V8, pS1199, DOI 10.2741/1166; Ferris LT, 2007, MED SCI SPORT EXER, V39, P728, DOI 10.1249/mss.0b013e31802f04c7; Gonzalez-Alonso J, 2004, J PHYSIOL-LONDON, V557, P331, DOI 10.1113/jphysiol.2004.060574; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2009, J NEUROSCI RES, V87, P795, DOI 10.1002/jnr.21893; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gruber O, 2003, NEUROIMAGE, V19, P797, DOI 10.1016/S1053-8119(03)00089-2; Hassett LM, 2007, BRAIN INJURY, V21, P1069, DOI 10.1080/02699050701630375; Hellstrom G, 1996, J APPL PHYSIOL, V81, P413; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; Ide K, 1999, J APPL PHYSIOL, V87, P1604; Ide K, 2000, PROG NEUROBIOL, V61, P397, DOI 10.1016/S0301-0082(99)00057-X; JANKOWSKI LW, 1990, ARCH PHYS MED REHAB, V71, P500; JEZZARD P, 2002, FUNCTIONAL MRI INTRO, P12; Johnson RA, 2003, NEUROSCIENCE, V121, P1, DOI 10.1016/S0306-4522(03)00422-6; Jorgensen L G, 1995, Acta Physiol Scand Suppl, V625, P1; JORGENSEN LG, 1992, J APPL PHYSIOL, V72, P1123; Kleim JA, 1998, J NEUROPHYSIOL, V80, P3321; Kleim JA, 2002, BRAIN RES, V934, P1, DOI 10.1016/S0006-8993(02)02239-4; Komulainen P, 2008, NEUROBIOL LEARN MEM, V90, P596, DOI 10.1016/j.nlm.2008.07.014; Kramer AF, 1999, NATURE, V400, P418, DOI 10.1038/22682; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lu B, 2000, PROG BRAIN RES, V128, P231; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Molteni R, 2002, EUR J NEUROSCI, V16, P1107, DOI 10.1046/j.1460-9568.2002.02158.x; Mossberg KA, 2007, ARCH PHYS MED REHAB, V88, P315, DOI 10.1016/j.apmr.2006.12.006; Neeper SA, 1996, BRAIN RES, V726, P49, DOI 10.1016/0006-8993(96)00273-9; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; Nyberg L, 2003, NEUROPSYCHOLOGIA, V41, P371, DOI 10.1016/S0028-3932(02)00168-9; Pott F, 1996, ACTA PHYSIOL SCAND, V158, P349, DOI 10.1046/j.1365-201X.1996.564325000.x; Pozzo-Miller LD, 1999, J NEUROSCI, V19, P4972; Ranganath C, 2005, J COGNITIVE NEUROSCI, V17, P994, DOI 10.1162/0898929054475118; Ranganath C, 2003, NEUROPSYCHOLOGIA, V41, P378, DOI 10.1016/S0028-3932(02)00169-0; Scheibel RS, 2003, BRAIN INJURY, V17, P919, DOI 10.1080/0269905031000110472; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; SPIRDUSO WW, 1980, J GERONTOL, V35, P850, DOI 10.1093/geronj/35.6.850; Sutoo D, 1996, PHYSIOL BEHAV, V60, P177, DOI 10.1016/0031-9384(96)00011-X; Sutoo D, 2003, NEUROBIOL DIS, V13, P1, DOI 10.1016/S0969-9961(03)00030-5; Swain RA, 2003, NEUROSCIENCE, V117, P1037, DOI 10.1016/S0306-4522(02)00664-4; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 1999, NAT NEUROSCI, V2, P266; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; Weuve J, 2004, JAMA-J AM MED ASSOC, V292, P1454, DOI 10.1001/jama.292.12.1454	63	39	40	1	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2010	25	3					184	192		10.1097/HTR.0b013e3181dc78cd			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	606KG	WOS:000278423300005	20473092				2021-06-18	
J	Ekeh, AP; Dominguez, KM; Markert, RJ; McCarthy, MC				Ekeh, Akpofure Peter; Dominguez, Kathleen M.; Markert, Ronald J.; McCarthy, Mary C.			Incidence and Risk Factors for Deep Venous Thrombosis After Moderate and Severe Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Brain injury; Deep venous thrombosis; Incidence; Risk factors; Prophylaxis	MOLECULAR-WEIGHT HEPARIN; VEIN THROMBOSIS; TRAUMA PATIENTS; SURVEILLANCE BIAS; THROMBOEMBOLISM; PROPHYLAXIS; PREVENTION; EXTREMITY; CARE; DVT	Background: Patients with traumatic injuries possess a high risk of developing deep venous thrombosis (DVT), thus the need for appropriate prophylaxis. Patients with head injuries pose a unique challenge due to contraindication to the use of anticoagulation. We sought to determine the incidence of DVT and identify specific risk factors for its development in patients with head injuries. Methods: All head injury admissions between January 1, 2000, and July 31, 2006, with a length of stay >= 7 days were identified. Patient data including age, sex, injuries, Glasgow Coma Scale, Injury Severity Score (ISS), and venous duplex scan results were collected. Mechanical methods were routinely used for prophylaxis; heparin was not used in this population. Weekly duplex screening was commenced at 7 days to 10 days after admission. Results: There were 939 patients who met criteria for review, however, duplex scans were performed in only 677, which was the population studied. Overall, DVT was present in 31.6%. There were fewer DVTs in patients with isolated head injuries (25.8%) compared with patients with those with head and extracranial injuries (34.3%)-p = 0.026. Independent predictors for DVT identified included male gender (p = 0.04), age >= 55 (p < 0.001), ISS >= 15 (p = 0.014), subarachnoid hemorrhage (p = 0.006), and lower extremity injury (p = 0.001). Conclusions: DVT occurs in one third of moderately to severely brain injured patients. Isolated head injuries have a lower incidence. Older age, male gender, higher ISS, and the presence of a lower extremity injury are strong predictors for developing DVT. Regular screening and the use of prophylactic inferior vena cava filters in patients with risk factors should be strongly considered.	[Ekeh, Akpofure Peter; Dominguez, Kathleen M.; Markert, Ronald J.; McCarthy, Mary C.] Wright State Univ, Div Trauma Crit Care & Emergency Gen Surg, Dept Surg, Dayton, OH 45435 USA	Ekeh, AP (corresponding author), Miami Valley Hosp, CHE 7000,1 Wyoming St, Dayton, OH 45409 USA.	peter.ekeh@wright.edu					Brandt MM, 2007, AM J SURG, V193, P383; Britt LD, 1996, AM J SURG, V172, P13, DOI 10.1016/S0002-9610(96)00079-7; Buller HR, 2004, CHEST, V126, p401S, DOI 10.1378/chest.126.3_suppl.401S; Carlile MC, 2006, J HEAD TRAUMA REHAB, V21, P483, DOI 10.1097/00001199-200611000-00003; Cook D, 2005, CRIT CARE MED, V33, P1565, DOI 10.1097/01.CCM.0000171207.95319.B2; Cothren CC, 2007, WORLD J SURG, V31, P98, DOI 10.1007/s00268-006-0304-1; Crowther MA, 2005, J CRIT CARE, V20, P334, DOI 10.1016/j.jcrc.2005.09.011; Denson K, 2007, AM J SURG, V193, P380, DOI 10.1016/j.amjsurg.2006.12.004; Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S; Geerts William H, 2006, Hematology Am Soc Hematol Educ Program, P462; GERSIN K, 1994, J TRAUMA, V37, P205, DOI 10.1097/00005373-199408000-00009; GIANNOUKAS AD, 1995, EUR J VASC ENDOVASC, V10, P398, DOI 10.1016/S1078-5884(05)80161-3; Haut ER, 2007, J TRAUMA, V63, P1132, DOI 10.1097/TA.0b013e31814856ad; Hingorani A, 1997, AM J SURG, V174, P214, DOI 10.1016/S0002-9610(97)00088-3; Keller, 2000, Curr Surg, V57, P456, DOI 10.1016/S0149-7944(00)00314-7; Knudson MM, 1996, J TRAUMA, V41, P446, DOI 10.1097/00005373-199609000-00010; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; Labropoulos N, 1999, J VASC SURG, V30, P787, DOI 10.1016/S0741-5214(99)70002-9; Murakami M, 2003, J VASC SURG, V38, P923, DOI 10.1016/S0741-5214(03)00792-4; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Pierce CA, 2008, J TRAUMA, V64, P932, DOI 10.1097/TA.0b013e318166b808; Rogers FB, 2002, J TRAUMA, V53, P142, DOI 10.1097/00005373-200207000-00032; Shackford SR, 2004, ANN SURG, V240, P496; Sharma OP, 2007, AM SURGEON, V73, P1173; Sing R, 2007, J TRAUMA, V63, P1135; Stawicki SP, 2005, AM SURGEON, V71, P387; Tominaga GT, 2002, ARCH SURG-CHICAGO, V137, P701; Velmahos GC, 2006, WORLD J SURG, V30, P483, DOI 10.1007/s00268-005-0427-9; Wagner RH, 1999, J HEAD TRAUMA REHAB, V14, P558, DOI 10.1097/00001199-199912000-00004	29	39	43	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2010	68	4					912	915		10.1097/TA.0b013e3181b21cad			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	583GY	WOS:000276663100031	19996795				2021-06-18	
J	Harhausen, D; Khojasteh, U; Stahel, PF; Morgan, BP; Nietfeld, W; Dirnagl, U; Trendelenburg, G				Harhausen, Denise; Khojasteh, Uldus; Stahel, Philip F.; Morgan, B. Paul; Nietfeld, Wilfried; Dirnagl, Ulrich; Trendelenburg, George			Membrane attack complex inhibitor CD59a protects against focal cerebral ischemia in mice	JOURNAL OF NEUROINFLAMMATION			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; HUMAN NT2-N NEURONS; PROGESTERONE PROTECTS; REPERFUSION INJURY; INFARCTION VOLUME; STROKE; INFLAMMATION; EXPRESSION	Background: The complement system is a crucial mediator of inflammation and cell lysis after cerebral ischemia. However, there is little information about the exact contribution of the membrane attack complex (MAC) and its inhibitor-protein CD59. Methods: Transient focal cerebral ischemia was induced by middle cerebral artery occlusion (MCAO) in young male and female CD59a knockout and wild-type mice. Two models of MCAO were applied: 60 min MCAO and 48 h reperfusion, as well as 30 min MCAO and 72 h reperfusion. CD59a knockout animals were compared to wild-type animals in terms of infarct size, edema, neurological deficit, and cell death. Results and Discussion: CD59a-deficiency in male mice caused significantly increased infarct volumes and brain swelling when compared to wild-type mice at 72 h after 30 min-occlusion time, whereas no significant difference was observed after 1 h-MCAO. Moreover, CD59a-deficient mice had impaired neurological function when compared to wild-type mice after 30 min MCAO. Conclusion: We conclude that CD59a protects against ischemic brain damage, but depending on the gender and the stroke model used.	[Harhausen, Denise; Khojasteh, Uldus; Dirnagl, Ulrich; Trendelenburg, George] Charite, CCM, D-10117 Berlin, Germany; [Stahel, Philip F.] Univ Colorado, Sch Med, Denver Hlth Med Ctr, Dept Orthopaed Surg, Denver, CO 80204 USA; [Stahel, Philip F.] Univ Colorado, Sch Med, Denver Hlth Med Ctr, Dept Neurosurg, Denver, CO 80204 USA; [Morgan, B. Paul] Cardiff Univ, Sch Med, Dept Infect Immun & Biochem, Cardiff CF14 4XN, S Glam, Wales; [Nietfeld, Wilfried] Max Planck Inst Mol Genet, D-14195 Berlin, Germany	Trendelenburg, G (corresponding author), Charite, CCM, D-10117 Berlin, Germany.	george.trendelenburg@charite.de		Dirnagl, Ulrich/0000-0003-0755-6119; Morgan, Paul/0000-0003-4075-7676	Deutsche Forschungsgemeinschaft (DFG)German Research Foundation (DFG) [Tr742/1-1,2]	This work was supported by the Deutsche Forschungsgemeinschaft (DFG grant Tr742/1-1,2)	Arumugam TV, 2009, NEUROSCIENCE, V158, P1074, DOI 10.1016/j.neuroscience.2008.07.015; Arumugam TV, 2006, CLIN CHIM ACTA, V374, P33, DOI 10.1016/j.cca.2006.06.010; Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; Atkinson C, 2006, J IMMUNOL, V177, P7266, DOI 10.4049/jimmunol.177.10.7266; Baalasubramanian S, 2004, J IMMUNOL, V173, P3684, DOI 10.4049/jimmunol.173.6.3684; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846; Buerke M, 1998, J PHARMACOL EXP THER, V286, P429; Chan RK, 2006, J IMMUNOL, V177, P8080, DOI 10.4049/jimmunol.177.11.8080; Chen CH, 2005, STROKE, V36, P1557, DOI 10.1161/01.STR.0000169928.76321.3d; Cohen J., 1988, STAT POWER ANAL BEHA, DOI DOI 10.1234/12345678; Cowell RM, 2003, J NEUROSCI, V23, P9459; del Zoppo GJ, 1999, NAT MED, V5, P995, DOI 10.1038/12431; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; DIRNAGL U, 2009, NATURE PRECEDINGS; Ducruet AF, 2009, EXP NEUROL, V219, P398, DOI 10.1016/j.expneurol.2009.07.018; Figueroa E, 2005, NEUROSCI LETT, V380, P48, DOI 10.1016/j.neulet.2005.01.027; Gertz K, 2006, CIRC RES, V99, P1132, DOI 10.1161/01.RES.0000250175.14861.77; Griffiths MR, 2009, J NEUROPATH EXP NEUR, V68, P217, DOI 10.1097/NEN.0b013e3181996688; Hara H, 1996, J CEREBR BLOOD F MET, V16, P605, DOI 10.1097/00004647-199607000-00010; Holt DS, 2001, BLOOD, V98, P442, DOI 10.1182/blood.V98.2.442; Hossmann KA, 2006, CELL MOL NEUROBIOL, V26, P1057, DOI 10.1007/s10571-006-9008-1; Imm MD, 2002, NEUROSCI LETT, V325, P175, DOI 10.1016/S0304-3940(02)00271-9; Katchanov J, 2003, BRAIN PATHOL, V13, P452; Kilgore KS, 1996, AM J PATHOL, V149, P953; Kilgore KS, 1997, AM J PATHOL, V150, P2019; Kolev MV, 2010, PHARMACOGENOMICS J, V10, P12, DOI 10.1038/tpj.2009.52; Komotar RJ, 2009, CURR VASC PHARMACOL, V7, P287, DOI 10.2174/157016109788340677; Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13; Leinhase I, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-55; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; McColl BW, 2008, J NEUROSCI, V28, P9451, DOI 10.1523/JNEUROSCI.2674-08.2008; MERI S, 1990, IMMUNOLOGY, V71, P1; MORGAN BP, 1999, BIOCHEM J, V264, P1; Nijboer CHA, 2007, J CEREBR BLOOD F MET, V27, P282, DOI 10.1038/sj.jcbfm.9600342; Palmon SC, 1998, J CEREBR BLOOD F MET, V18, P1248, DOI 10.1097/00004647-199811000-00011; Pedersen ED, 2007, SCAND J IMMUNOL, V66, P345, DOI 10.1111/j.1365-3083.2007.01959.x; Pedersen ED, 2009, SCAND J IMMUNOL, V69, P555, DOI 10.1111/j.1365-3083.2009.02253.x; Pedersen ED, 2007, MOL IMMUNOL, V44, P2459, DOI 10.1016/j.molimm.2006.10.022; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Ramaglia V, 2009, MOL IMMUNOL, V46, P1892, DOI 10.1016/j.molimm.2009.01.017; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Singhrao SK, 2000, AM J PATHOL, V157, P905, DOI 10.1016/S0002-9440(10)64604-4; Stahel PF, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-2; Storini C, 2005, NEUROBIOL DIS, V19, P10, DOI 10.1016/j.nbd.2004.11.001; Sugita Y, 1995, IMMUNOTECHNOLOGY, V1, P157, DOI 10.1016/1380-2933(95)00018-6; Szeplaki G, 2009, ATHEROSCLEROSIS, V204, P315, DOI 10.1016/j.atherosclerosis.2008.07.044; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Tramontini NL, 2002, INFLAMMATION, V26, P311, DOI 10.1023/A:1021420903355; Trendelenburg G, 2008, J CEREBR BLOOD F MET, V28, P867, DOI 10.1038/sj.jcbfm.9600609; Trendelenburg M, 2007, SWISS MED WKLY, V137, P413; Turnberg D, 2004, AM J PATHOL, V165, P825, DOI 10.1016/S0002-9440(10)63345-7; UITENBROEK DG, 1997, SISA BINOMIAL; van Beek J, 2005, J IMMUNOL, V174, P2353, DOI 10.4049/jimmunol.174.4.2353; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2005, J CLIN PHARMACOL, V45, P640, DOI 10.1177/0091270005276201; Wu GX, 2009, CIRC RES, V104, P550, DOI 10.1161/CIRCRESAHA.108.191361; Xiong ZQ, 2003, J NEUROSCI, V23, P955; Yamada K, 2004, J IMMUNOL, V172, P3869, DOI 10.4049/jimmunol.172.6.3869	61	39	41	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	MAR 4	2010	7								15	10.1186/1742-2094-7-15			12	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	571BJ	WOS:000275723600001	20202211	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Helton, WS; Weil, L; Middlemiss, A; Sawers, A				Helton, William S.; Weil, Lena; Middlemiss, Annette; Sawers, Andrew			Global interference and spatial uncertainty in the Sustained Attention to Response Task (SART)	CONSCIOUSNESS AND COGNITION			English	Article						Attention; Impulsivity; Mindlessness; Speed-accuracy trade-offs; Sustained attention; Vigilance	TRAUMATIC BRAIN-INJURY; SENSITIVITY DECREMENT; SIGNAL SALIENCE; VIGILANCE; MINDLESSNESS; PERFORMANCE; LAPSES; MIND; PERCEPTION; FAILURES	The Sustained Attention to Response Task (SART) is a Go-No-Go signal detection task developed to measure lapses of sustained conscious attention. In this Study, we examined the impact global interference and spatial uncertainty has oil SART performance. Tell participants performed either a SART (high-Go) or a traditionally formatted (low-Go) version of a global-local stimuli detection task with spatially certain and uncertain signals Reaction time in the SART was insensitive to global interference and spatial uncertainty, whereas reaction time in the low-Go task was sensitive Spatial uncertainty increased errors of omission in the SART, which was not expected if the SART measures mindlessness There was a high correlation between participants' errors of commission rate and their reaction time in the SART The results. overall. support the view that the SART IF, a better measure of response strategy than lapses in sustained attention or mindlessness (C) 2010 Elsevier Inc All rights reserved	[Helton, William S.; Weil, Lena; Middlemiss, Annette; Sawers, Andrew] Univ Canterbury, Dept Psychol, Christchurch 1, New Zealand	Helton, WS (corresponding author), Univ Canterbury, Dept Psychol, Private Bag 4800, Christchurch 1, New Zealand.						BARTLETT MS, 1947, BIOMETRICS, V3, P39, DOI 10.2307/3001536; Cheyne J. A., 2009, CONSCIOUSNESS COGNIT; Cheyne JA, 2006, CONSCIOUS COGN, V15, P578, DOI 10.1016/j.concog.2005.11.009; Davies D.R., 1982, PSYCHOL VIGILANCE; DICKMAN S, 1985, J PERS SOC PSYCHOL, V48, P133, DOI 10.1037/0022-3514.48.1.133; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Forster S, 2009, COGNITION, V111, P345, DOI 10.1016/j.cognition.2009.02.006; GIAMBRA LM, 1995, CONSCIOUS COGN, V4, P1, DOI 10.1006/ccog.1995.1001; Greene CM, 2009, NEUROPSYCHOLOGIA, V47, P591, DOI 10.1016/j.neuropsychologia.2008.10.003; Grier RA, 2003, HUM FACTORS, V45, P349, DOI 10.1518/hfes.45.3.349.27253; Helton WS, 2008, ACTA PSYCHOL, V129, P18, DOI 10.1016/j.actpsy.2008.04.002; Helton WS, 2009, CONSCIOUS COGN, V18, P600, DOI 10.1016/j.concog.2009.06.002; Helton WS, 2009, ACTA PSYCHOL, V130, P204, DOI 10.1016/j.actpsy.2008.12.006; Helton WS, 2009, J CLIN EXP NEUROPSYC, V31, P39, DOI 10.1080/13803390801978856; Helton WS, 2005, BRIT J PSYCHOL, V96, P249, DOI 10.1348/000712605X38369; Hitchcock EM, 1999, HUM FACTORS, V41, P365, DOI 10.1518/001872099779610987; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P630, DOI 10.1016/j.neuropsychologia.2006.03.034; Mackworth NH, 1948, Q J EXP PSYCHOL, V1, P6, DOI 10.1080/17470214808416738; MACKWORTH NH, 1950, 2680 MED RES COUNC; MacLean KA, 2009, ATTEN PERCEPT PSYCHO, V71, P1042, DOI 10.3758/APP.71.5.1042; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; Matthews G, 2000, HUMAN PERFORMANCE CO; Maxwell S. E., 2004, DESIGNING EXPT ANAL; NAVON D, 1977, COGNITIVE PSYCHOL, V9, P353, DOI 10.1016/0010-0285(77)90012-3; NUECHTERLEIN KH, 1983, SCIENCE, V220, P327, DOI 10.1126/science.6836276; Peebles D, 2004, PROCEEDINGS OF THE SIXTH INTERNATIONAL CONFERENCE ON COGNITIVE MODELING, P231; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Scerbo M. W., 1998, VIEWING PSYCHOL WHOL, P145, DOI [10.1037/10290-006, DOI 10.1037/10290-006]; SEE JE, 1995, PSYCHOL BULL, V117, P230, DOI 10.1037/0033-2909.117.2.230; Smallwood J, 2004, CONSCIOUS COGN, V13, P657, DOI 10.1016/j.concog.2004.06.003; Smallwood J, 2006, PSYCHOL BULL, V132, P946, DOI 10.1037/0033-2909.132.6.946; Temple JG, 2000, HUM FACTORS, V42, P183, DOI 10.1518/001872000779656480; Warm J. S., 1984, SUSTAINED ATTENTION, P1; Warm J. S., 1993, WORKLOAD TRANSITION, P139; Warm JS, 2008, HUM FACTORS, V50, P433, DOI 10.1518/001872008X312152; WARM JS, 2008, PERFORMANCE STRESS, P116; Weissman DH, 2006, NAT NEUROSCI, V9, P971, DOI 10.1038/nn1727; Zordan L, 2008, BRAIN COGNITION, V66, P57, DOI 10.1016/j.bandc.2007.05.005	39	39	39	0	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8100			CONSCIOUS COGN	Conscious. Cogn.	MAR	2010	19	1					77	85		10.1016/j.concog.2010.01.006			9	Psychology, Experimental	Psychology	572FV	WOS:000275813800007	20138552				2021-06-18	
J	Couillet, J; Soury, S; Lebornec, G; Asloun, S; Joseph, PA; Mazaux, JM; Azouvi, P				Couillet, Josette; Soury, Stephane; Lebornec, Gaelle; Asloun, Sybille; Joseph, Pierre-Alain; Mazaux, Jean-Michel; Azouvi, Philippe			Rehabilitation of divided attention after severe traumatic brain injury: A randomised trial	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Divided attention; Traumatic brain injury; Cognitive rehabilitation	DUAL-TASK PERFORMANCE; WORKING-MEMORY; DEFICITS; IMPAIRMENTS	Patients with severe traumatic brain injury (TBI) frequently suffer from a difficulty in dealing with two tasks simultaneously. However, there has been little research on the rehabilitation of divided attention. The objective of the present study was to assess the effectiveness of a rehabilitation programme for divided attention after severe TBI. Twelve patients at a subacute/chronic stage after a severe TBI were included. A randomised AB vs. BA cross-over design was used. Training lasted six weeks, with four one-hour sessions per week. It was compared to a non-specific (control) cognitive training. During experimental treatment, patients were trained to perform two concurrent tasks simultaneously. Each one of the two tasks was first trained as a single task, then both tasks were given simultaneously. A progressive hierarchical order of difficulty was used, by progressively increasing task difficulty following each patient's individual improvement. Patients were randomised in two groups: one starting with dual-task training, the other with control training. Outcome measures included target dual-task measures, executive and working memory tasks, non-target tasks, and the Rating Scale of Attentional Behaviour addressing attentional problems in everyday life. Assessment was not blind to treatment condition. A significant training-related effect was found on dual-task measures and on the divided attention item of the Rating Scale of Attentional Behaviour. There was only little effect on executive measures, and no significant effect on non-target measures. These results suggest that training had specific effects on divided attention and helped patients to deal more rapidly and more accurately with dual-task situations.	[Couillet, Josette; Lebornec, Gaelle; Asloun, Sybille; Azouvi, Philippe] Hop Raymond Poincare, Serv Med Phys & Readaptat, AP HP, F-92380 Garches, France; [Soury, Stephane; Joseph, Pierre-Alain; Mazaux, Jean-Michel] Hop Pellegrin, Serv Med Phys & Readaptat, CHU Bordeaux, F-33076 Bordeaux, France; [Azouvi, Philippe] UPMC, ER 6, Paris, France; [Azouvi, Philippe] Univ Versailles St Quentin, Versailles, France	Azouvi, P (corresponding author), Hop Raymond Poincare, Serv Med Phys & Readaptat, AP HP, F-92380 Garches, France.	philippe.azouvi@rpc.aphp.fr			Programme Hospitalier de Recherche Clinique (PHRC) [AOM01025]; Assistance Publique-Hopitaux de Paris (AP-HP) [P01120]	This work was supported by grants from the Programme Hospitalier de Recherche Clinique (PHRC National 2001, AOM01025) and by Assistance Publique-Hopitaux de Paris (AP-HP, P01120).	Asloun S, 2008, J CLIN EXP NEUROPSYC, V30, P481, DOI 10.1080/13803390701550144; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Baddeley A. D., 2002, PRINCIPLES FRONTAL L, P246, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0016; BENYISHAY Y, 1987, NEUROPSYCHOL REHABIL, P165; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; Cicerone KD, 1992, NEUROREHABILITATION, V2, P12, DOI DOI 10.3233/NRE-1992-2304; Duval J, 2008, NEUROPSYCHOL REHABIL, V18, P430, DOI 10.1080/09602010701573950; Evans JJ, 2009, J INT NEUROPSYCH SOC, V15, P112, DOI 10.1017/S1355617708090152; Gray J M, 1989, Brain Inj, V3, P163, DOI 10.3109/02699058909004548; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Leclercq M, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P257; Leclercq M., 2007, BATTERIE ATTENTION W; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD J, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; Ponsford J., 2008, COGNITIVE NEUROREHAB, P507; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; Rabbitt P., 1997, METHODOLOGY FRONTAL, P1; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Serino A, 2007, BRAIN INJURY, V21, P11, DOI 10.1080/02699050601151811; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Sturm W, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P365; Sturm W, 1997, NEUROPSYCHOL REHABIL, V7, P81, DOI 10.1080/713755526; TEASDALE G, 1974, LANCET, V2, P81; Vallat C, 2005, BRAIN INJURY, V19, P1157, DOI 10.1080/02699050500110595; Vallat-Azouvi C, 2007, J INT NEUROPSYCH SOC, V13, P770, DOI 10.1017/S1355617707070993; Vallat-Azouvi C, 2009, BRAIN INJURY, V23, P585, DOI 10.1080/02699050902970711; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Westerberg H, 2007, BRAIN INJURY, V21, P21, DOI 10.1080/02699050601148726; Zimmermann P, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P110; Zimmermann P, 1995, TEST ATTENTIONAL PER	39	39	41	0	30	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2010	20	3					321	339	PII 919145662	10.1080/09602010903467746			19	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	598RZ	WOS:000277857200001	20146136				2021-06-18	
J	Huckans, M; Pavawalla, S; Demadura, T; Kolessar, M; Seelye, A; Roost, N; Twamley, EW; Storzbach, D				Huckans, Marilyn; Pavawalla, Shital; Demadura, Theresa; Kolessar, Michael; Seelye, Adriana; Roost, Noah; Twamley, Elizabeth W.; Storzbach, Daniel			A pilot study examining effects of group-based Cognitive Strategy Training treatment on self-reported cognitive problems, psychiatric symptoms, functioning, and compensatory strategy use in OIF/OEF combat veterans with persistent mild cognitive disorder and history of traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						blast injury; cognitive aids; cognitive rehabilitation; combat veterans; compensatory strategies; Operation Enduring Freedom (OEF); Operation Iraqi Freedom (OIF); postconcussive syndrome; posttraumatic stress disorder; traumatic brain injury	REHABILITATION OUTCOMES; HEAD TRAUMA; BLAST; IRAQ; WAR; SCHIZOPHRENIA; QUESTIONNAIRE; METAANALYSIS; PERSONNEL; MEMORY	We aimed to determine whether group-based Cognitive Strategy Training (CST) for combat veterans with mild cognitive disorder and a history of traumatic brain injury (TBI) has significant posttreatment effects on self-reported compensatory strategy usage, functioning, and psychiatric symptoms. Participants included 21 veterans returning from conflicts in Iraq or Afghanistan with a diagnosis of Cognitive Disorder, Not Otherwise Specified and a history of combat-related TBI. Participants attended 6- to 8-week structured CST groups designed to provide them training in and practice with a variety of compensatory cognitive strategies, including day planner usage. Of the participants, 16 completed pre- and posttreatment assessment measures. Following CST, participants reported significantly increased use of compensatory cognitive strategies and day planners; an increased perception that these strategies were useful to them; increased life satisfaction; and decreased depressive, memory, and cognitive symptom severity. Group-based CST is a promising intervention for veterans with mild cognitive disorder, and randomized controlled trials are required to further evaluate its efficacy.	[Huckans, Marilyn; Kolessar, Michael; Storzbach, Daniel] Portland Dept Vet Affairs VA Med Ctr, Div Res, Portland, OR USA; [Huckans, Marilyn; Demadura, Theresa; Roost, Noah; Storzbach, Daniel] Portland Dept Vet Affairs VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR USA; [Huckans, Marilyn] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA; [Pavawalla, Shital; Seelye, Adriana] Washington State Univ, Dept Psychol, Pullman, WA 99164 USA; [Pavawalla, Shital] VA Palo Alto Hlth Care Syst, Psychol Serv, Palo Alto, CA USA; [Kolessar, Michael] Pacific Univ, Sch Profess Psychol, Portland, OR USA; [Twamley, Elizabeth W.] VA San Diego Healthcare Syst, San Diego, CA USA; [Twamley, Elizabeth W.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA	Huckans, M (corresponding author), Portland VA Med Ctr P3MHN, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.	marilyn.huckans@va.gov			VA Rehabilitation Research and Development Service Merit Review Study [B5060R]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH080150] Funding Source: NIH RePORTER	This material was based on work supported in part by a VA Rehabilitation Research and Development Service Merit Review Study (grant B5060R) to Dr. Storzbach and a VA Career Development Award to Dr. Huckans.	Beck AT, 1996, BDI 2 BECK DEPRESSIO; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bell C.C., 2001, DIAGNOSTIC STAT MANU, VFourth; Benedict RHB, 2004, MULT SCLER J, V10, P675, DOI 10.1191/1352458504ms1098oa; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Cappa SF, 2005, EUR J NEUROL, V12, P665; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dixon RA, 2001, J CLIN EXP NEUROPSYC, V23, P650, DOI 10.1076/jcen.23.5.650.1242; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Gossop M, 2002, ADDICTION, V97, P169, DOI 10.1046/j.1360-0443.2002.00028.x; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Mateer CA, 2005, J HEAD TRAUMA REHAB, V20, P62, DOI 10.1097/00001199-200501000-00007; Mateer CA, 2006, NEUROREHABILITATION, V21, P315; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; McGurk SR, 2007, AM J PSYCHIAT, V164, P1791, DOI 10.1176/appi.ajp.2007.07060906; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; RITCHIE EC, 2006, COMBAT DISASTER PSYC; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Siddharthan K, 2008, REHABIL NURS, V33, P221, DOI 10.1002/j.2048-7940.2008.tb00231.x; Singer Pierre, 2005, Crit Care Med, V33, pS61, DOI 10.1097/01.CCM.0000151068.33935.3E; Smith G, 2000, MEMORY, V8, P311, DOI 10.1080/09658210050117735; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Sohlberg McKay Moore, 2005, Seminars in Speech and Language, V26, P268, DOI 10.1055/s-2005-922105; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Twamley EW, 2008, AM J PSYCHIATR REHAB, V11, P144, DOI 10.1080/15487760801963678; Twamley EW, 2003, SCHIZOPHRENIA BULL, V29, P359, DOI 10.1093/oxfordjournals.schbul.a007011; Vanderploeg RD, 2008, ARCH PHYS MED REHAB, V89, P2227, DOI 10.1016/j.apmr.2008.06.015; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Weathers F., 1996, MEASUREMENT STRESS T, P250; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103	40	39	39	0	17	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2010	47	1					43	60		10.1682/JRRD.2009.02.0019			18	Rehabilitation	Rehabilitation	577HH	WOS:000276212700006	20437326	Green Accepted, Bronze			2021-06-18	
J	Johnstone, B; Yoon, DP				Johnstone, Brick; Yoon, Dong Pil			Relationships Between the Brief Multidimensional Measure of Religiousness/Spirituality and Health Outcomes for a Heterogeneous Rehabilitation Population	REHABILITATION PSYCHOLOGY			English	Article						religion; spirituality; rehabilitation; traumatic brain injury; spinal cord injury; stroke; Brief Multidimensional Measure of Religiousness/Spirituality	QUALITY-OF-LIFE; MEDICAL REHABILITATION; RELIGIOUS SERVICES; SPIRITUALITY; PREDICTORS; ATTENDANCE; RECOVERY; STROKE; INTERVENTION; INDIVIDUALS	Purpose: To determine relationships between the Brief Multidimensional Measure of Religiousness/Spirituality (BMMRS; i.e., positive/negative spirituality, forgiveness, religious practices, positive/negative congregational support) and physical and mental health (Medical Outcomes Scale-Short Form 36; SF-36) for individuals with chronic disabilities. Research Method. A cross-sectional analysis of 118 individuals evaluated in outpatient settings, including 61 with traumatic brain injury (TBI), 32 with cerebral vascular accidents (CVA), and 25 with spinal cord injury (SCI). Results: Three of 6 BMMRS factor scores (i.e., positive spiritual experience, forgiveness, negative spiritual experience) were significantly correlated with the SF-36 General Health Perception (GHP) scale, and only I of 6 BMMRS factor scores (i.e., negative spiritual experience) was significantly and negatively correlated with the SF-36 General Mental Health (GMH) scale. BMMRS scales did not significantly predict either physical or mental health in hierarchical multiple regressions. Conclusions: Positive spiritual experiences and willingness to forgive are related to better physical health, while negative spiritual experiences are related to worse physical and mental health for individuals with chronic disabilities. Future research using the BMMRS will benefit from using a 6-factor model that evaluates positive/negative spiritual experiences, religious practices, and positive/negative congregationally support. Interventions to accentuate positive spiritual beliefs (e.g., forgiveness protocols, etc.) and reduce negative spiritual beliefs for individuals with chronic disabilities are suggested.	[Johnstone, Brick] Univ Missouri, Dept Hlth Psychol, Ctr Relig & Profess, Columbia, MO 65212 USA	Johnstone, B (corresponding author), Univ Missouri, Dept Hlth Psychol, Ctr Relig & Profess, DC116-88, Columbia, MO 65212 USA.	johnstoneg@health.missouri.edu		Johnstone, Brick/0000-0001-8845-9649			Ai AL, 1998, GERONTOLOGIST, V38, P591, DOI 10.1093/geront/38.5.591; Avants SK, 2001, J PSYCHOACTIVE DRUGS, V33, P39, DOI 10.1080/02791072.2001.10400467; Baskin TW, 2004, J COUNS DEV, V82, P79, DOI 10.1002/j.1556-6678.2004.tb00288.x; Berges IM, 2007, EXP AGING RES, V33, P1, DOI 10.1080/03610730601005893; Carson JW, 2005, J PAIN, V6, P84, DOI 10.1016/j.jpain.2004.10.012; COLANTONIO A, 1993, J GERONTOL, V48, pS261, DOI 10.1093/geronj/48.5.S261; COLANTONIO A, 1992, AM J EPIDEMIOL, V136, P884, DOI 10.1093/aje/136.7.884; Cooper-Effa M, 2001, J Am Board Fam Pract, V14, P116; Fetzer Institute & National Institute on Aging Working Group, 1999, MULT MEAS REL SPIR U; Fitchett G, 1999, REHABIL PSYCHOL, V44, P333, DOI 10.1037//0090-5550.44.4.333; Forchheimer M, 2004, AM J PHYS MED REHAB, V83, P390, DOI 10.1097/01.PHM.0000124441.78275.C9; Franska M, 2008, EUR J MASS SPECTROM, V14, P81, DOI 10.1255/ejms.914; Giaquinto S, 2007, STROKE, V38, P993, DOI 10.1161/01.STR.0000257996.26950.59; Haley KC, 2001, J RELIG HEALTH, V40, P305, DOI 10.1023/A:1012561909054; Hart T, 2007, REHABIL PSYCHOL, V52, P152, DOI 10.1037/0090-5550.52.2.152; Hummer RA, 1999, DEMOGRAPHY, V36, P273, DOI 10.2307/2648114; Idler EL, 1997, J GERONTOL B-PSYCHOL, V52, pS306, DOI 10.1093/geronb/52B.6.S306; Johnstone B, 2007, DISABIL REHABIL, V29, P1153, DOI 10.1080/09638280600955693; Johnstone B, 2009, J RELIG HEALTH, V48, P146, DOI 10.1007/s10943-008-9179-9; Johnstone B, 2008, J CLIN PSYCHOL MED S, V15, P308, DOI 10.1007/s10880-008-9128-5; Johnstone B, 2009, BRAIN INJURY, V23, P411, DOI 10.1080/02699050902788501; Kabat-Zinn J, 1998, PSYCHOSOM MED, V60, P625, DOI 10.1097/00006842-199809000-00020; Kim J, 2000, REHABIL PSYCHOL, V45, P365, DOI 10.1037/0090-5550.45.4.365; Koenig H.G., 2001, HDB RELIG HLTH; Mahalik J, 2007, J RELIG DISABIL HLTH, V11, P65; Matheis EN, 2006, REHABIL PSYCHOL, V51, P265, DOI 10.1037/0090-5550.51.3.265; Matthees BJ, 2001, HEART LUNG, V30, P258, DOI 10.1067/mhl.2001.116135; McColl MA, 2000, DISABIL REHABIL, V22, P555, DOI 10.1080/096382800416805; McCullough ME, 2001, CURR DIR PSYCHOL SCI, V10, P194, DOI 10.1111/1467-8721.00147; Murphy PL, 2000, NEUROLOGY, V55, P1581, DOI 10.1212/WNL.55.10.1581; Oman D, 2002, INT J PSYCHIAT MED, V32, P69, DOI 10.2190/RJY7-CRR1-HCW5-XVEG; PARGAMENT KI, 1994, J SCI STUD RELIG, V33, P347, DOI 10.2307/1386494; Pargament KI, 1995, J SOC ISSUES, V51, P13, DOI 10.1111/j.1540-4560.1995.tb01321.x; PARGAMENT KI, 1990, AM J COMMUN PSYCHOL, V18, P793, DOI 10.1007/BF00938065; Ray O, 2004, AM PSYCHOL, V59, P29, DOI 10.1037/0003-066X.59.1.29; Rippentrop AE, 2005, PAIN, V116, P311, DOI 10.1016/j.pain.2005.05.008; Samuel-Hodge CD, 2000, DIABETES CARE, V23, P928, DOI 10.2337/diacare.23.7.928; Schnoll RA, 2000, CANCER PRACT, V8, P298, DOI 10.1046/j.1523-5394.2000.86006.x; Seybold KS, 2001, CURR DIR PSYCHOL SCI, V10, P21, DOI 10.1111/1467-8721.00106; Shatenstein B, 1998, NUTRITION, V14, P223, DOI 10.1016/S0899-9007(97)00425-5; STERN RC, 1992, J ADOLESCENT HEALTH, V13, P612, DOI 10.1016/1054-139X(92)90376-M; Strawbridge WJ, 2001, ANN BEHAV MED, V23, P68, DOI 10.1207/S15324796ABM2301_10; Tate DG, 2002, AM J PHYS MED REHAB, V81, P400, DOI 10.1097/00002060-200206000-00002; Tix AP, 1998, J CONSULT CLIN PSYCH, V66, P411, DOI 10.1037/0022-006X.66.2.411; UnderwoodGordon L, 1997, AM J PHYS MED REHAB, V76, P255, DOI 10.1097/00002060-199705000-00021; Ware JE., 1993, SF 36 HLTH SURVEY MA	46	39	40	1	15	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2009	54	4					422	431		10.1037/a0017758			10	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	526YF	WOS:000272331600009	19929124				2021-06-18	
J	Nakase-Richardson, R; Yablon, SA; Sherer, M; Nick, TG; Evans, CC				Nakase-Richardson, R.; Yablon, S. A.; Sherer, M.; Nick, T. G.; Evans, C. C.			Emergence from minimally conscious state Insights from evaluation of posttraumatic confusion	NEUROLOGY			English	Article							PATIENTS OWN NAME; COGNITIVE TEST; RECOVERY; ORIENTATION; DEFINITION; VALIDATION; DISORDERS; DELIRIUM; SCALE; COMA	Background: Guidelines for defining the minimally conscious state (MCS) specify behaviors that characterize emergence, including "reliable and consistent" functional communication (accurate yes/no responding). Guidelines were developed by consensus because of lack of empirical data. Objective: To evaluate the utility of the operational threshold for emergence from posttraumatic MCS, by determining yes/no accuracy to questions of varied difficulty, including simple orientation questions, using all items from the Yes/No Subscale of the Mississippi Aphasia Screening Test. Method: Prospective observational study of a cohort of responsive patients recovering from traumatic brain injury in an acute inpatient brain injury rehabilitation program. Results: Of the 629 observations from 144 participants, name recognition was the easiest yes/no question, with nonconfused individuals responding with 100% accuracy, whereas only 75% to 78% of confused participants on initial evaluation answered this question correctly. Generalized Estimating Equations analysis revealed that confused participants were more likely to respond inaccurately to all yes/no questions. Nonconfused participants had a reduction in odds of inaccuracy ranging from 45.6% to 99.7% (p = 0.001 to 0.02) depending on the type of yes/no question. Conclusions: Accuracy for simple orientation yes/no questions remains challenging for responsive patients in early recovery from traumatic brain injury. Although name recognition questions are relatively easier than other types of yes/no questions, including situational orientation questions, confused patients still may answer these incorrectly. Results suggest the operational threshold for yes/no response accuracy as a diagnostic criterion for emergence from the minimally conscious state should be revisited, with particular consideration of the type of yes/no questions and the requisite accuracy threshold for responses. Neurology (R) 2009; 73: 1120-1126	[Nakase-Richardson, R.] James A Haley VAMC, Tampa, FL USA; [Nakase-Richardson, R.; Yablon, S. A.; Evans, C. C.] Methodist Rehabil Ctr, Jackson, MI USA; [Nakase-Richardson, R.; Yablon, S. A.; Evans, C. C.] Univ Mississippi, Med Ctr, Jackson, MI USA; [Sherer, M.] TIRR Mem Hermann & Baylor Coll Med, Houston, TX USA; [Nick, T. G.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA	Nakase-Richardson, R (corresponding author), James A Haley Vet Hosp, MH & BS Polytrauma 116B,13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	risa.richardson@va.gov			National Institute on Disability Rehabilitation and Research [H133A020514]	This study was part of the Traumatic Brain Injury Model System of Mississippi funded by the National Institute on Disability Rehabilitation and Research (H133A020514 Dr. Risa Nakase-Richardson, PI).	American Psychiatric Association, 1994, DIAGN STAT MAN MENT, P124; Bender R, 2001, J CLIN EPIDEMIOL, V54, P343, DOI 10.1016/S0895-4356(00)00314-0; Bernat JL, 2002, NEUROLOGY, V58, P337, DOI 10.1212/WNL.58.3.337; Bode RK, 2000, J HEAD TRAUMA REHAB, V15, P637, DOI 10.1097/00001199-200002000-00004; Coleman D, 2002, NEUROLOGY, V58, P506, DOI 10.1212/WNL.58.3.506; Di HB, 2007, NEUROLOGY, V68, P895, DOI 10.1212/01.wnl.0000258544.79024.d0; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215; Hart RP, 1996, PSYCHOSOMATICS, V37, P533, DOI 10.1016/S0033-3182(96)71517-7; HIGH WM, 1990, J CLIN EXP NEUROPSYC, V12, P703, DOI 10.1080/01688639008401013; Kalmar K, 2005, NEUROPSYCHOL REHABIL, V15, P454, DOI 10.1080/09602010443000425; Kennedy RE, 2003, PSYCHOSOMATICS, V44, P283, DOI 10.1176/appi.psy.44.4.283; KISTALOVA M, 2008, BRAIN, V22, P793; Laureys S, 2004, NEUROLOGY, V63, P916, DOI 10.1212/01.WNL.0000137421.30792.9B; Mack A, 2002, CONSCIOUS COGN, V11, P488, DOI 10.1016/S1053-8100(02)00028-4; Nakase-Richardson R, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.127795; Nakase-Thompson R, 2005, BRAIN INJURY, V19, P685, DOI 10.1080/02699050400025331; NAKASETHOMPSON R, 2003, J INT NEUROPSYCH SOC, V9, P303; Perrin F, 2006, ARCH NEUROL-CHICAGO, V63, P562, DOI 10.1001/archneur.63.4.562; Qin PM, 2008, NEUROSCI LETT, V448, P24, DOI 10.1016/j.neulet.2008.10.029; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Schnakers C, 2008, NEUROLOGY, V71, P1614, DOI 10.1212/01.wnl.0000334754.15330.69; Staffen W, 2006, J NEUROL NEUROSUR PS, V77, P1383, DOI 10.1136/jnnp.2006.095166; *TRAUM BRAIN INJ M, ON LIN SYLL	25	39	39	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	OCT 6	2009	73	14					1120	1126		10.1212/WNL.0b013e3181bacf34			7	Clinical Neurology	Neurosciences & Neurology	502QG	WOS:000270474500007	19805728				2021-06-18	
J	Levine, B; Svoboda, E; Turner, GR; Mandic, M; Mackey, A				Levine, Brian; Svoboda, Eva; Turner, Gary R.; Mandic, Marina; Mackey, Allison			Behavioral and functional neuroanatomical correlates of anterograde autobiographical memory in isolated retrograde amnesic patient ML	NEUROPSYCHOLOGIA			English	Article; Proceedings Paper	Meeting on Episodic Memory and the Brain	MAR, 2009	Tallinn, ESTONIA			Autonoetic consciousness; Episodic memory; fMRI; Autobiographical Interview; Case study	FRONTOTEMPORAL LOBAR DEGENERATION; MEDIAL-TEMPORAL-LOBE; EPISODIC MEMORY; RECOGNITION MEMORY; LIFE-SPAN; BRAIN; SELF; RETRIEVAL; FMRI; CONSCIOUSNESS	Patient M.L. [Levine, B., Black, S. E., Cabeza, R., Sinden, M., Mcintosh, A. R., Toth, J. P, et al. (1998). Episodic memory and the self in a case of isolated retrograde amnesia. Brain, 121, 1951-1973], lost memory for events occurring before his severe traumatic brain injury, yet his anterograde (post-injury) learning and memory appeared intact, a syndrome known as isolated or focal retrograde amnesia. Studies with M.L demonstrated a dissociation between episodic and semantic memory. His retrograde amnesia was specific to episodic autobiographical memory. Convergent behavioral and functional imaging data suggested that his anterograde memory, while appearing normal, was accomplished with reduced autonoetic awareness (awareness of the self as a continuous entity across time that is a crucial element of episodic memory). While previous research on M.L focused on anterograde memory of laboratory stimuli, in this study, M.L's autobiographical memory for post-injury events or anterograde autobiographical memory was examined using prospective collection of autobiographical events via audio diary with detailed behavioral and functional neuroanatomical analysis. Consistent with his reports of subjective disconnection from post-injury autobiographical events, M.L assigned fewer "remember" ratings to his autobiographical events than comparison subjects. His generation of event-specific details using the Autobiographical Interview [Levine, B., Svoboda, E., Hay, J., Winocur, G., & Moscovitch, M. (2002). Aging and autobiographical memory: dissociating episodic from semantic retrieval. Psychology and Aging, 17, 677-689] was low, but not significantly so, suggesting that it is possible to generate episodic-like details even when re-experiencing of those details is compromised. While listening to the autobiographical audio diary segments, M.L showed reduced activation relative to comparison subjects in midline frontal and posterior nodes previously identified as part of the autobiographical memory network. Reductions were also evident in M.L in association with personal semantic stimuli (e.g., recordings describing personal habits and routines). These data suggest an association between M.L's impoverished recollection of autobiographical material and reduced activation in midline sectors of the autobiographical memory network that support the autonoetic, first-person element of episodic memory. (C) 2009 Elsevier Ltd. All rights reserved.	[Levine, Brian; Svoboda, Eva; Turner, Gary R.; Mandic, Marina; Mackey, Allison] Univ Toronto, Rotman Res Inst, Baycrest Ctr Geriatr Care, Toronto, ON M6A 2E1, Canada; [Levine, Brian; Svoboda, Eva; Turner, Gary R.] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Levine, Brian] Univ Toronto, Dept Med Neurol, Toronto, ON, Canada	Levine, B (corresponding author), Univ Toronto, Rotman Res Inst, Baycrest Ctr Geriatr Care, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	blevine@rotman-baycrest.on.ca	Levine, Brian/O-2725-2019; Levine, Brian/G-4328-2010	Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X; Mackey, Allison/0000-0002-4404-3753	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042385] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD 42385-01] Funding Source: Medline		Addis DR, 2007, BRAIN, V130, P2327, DOI 10.1093/brain/awm166; ADDIS DR, 2006, NEUROPSYCHOLOGIA; Aggleton JP, 2006, TRENDS COGN SCI, V10, P455, DOI 10.1016/j.tics.2006.08.003; AGGLETON JP, 2002, NEURAL SYSTEMS UNDER; Brewer W.F., 1988, REMEMBERING RECONSID, P21, DOI DOI 10.1017/CBO9780511664014.004; Buckner RL, 2007, TRENDS COGN SCI, V11, P49, DOI 10.1016/j.tics.2006.11.004; Butler CR, 2008, BRAIN, V131, P2243, DOI 10.1093/brain/awn127; CERMAK LS, 1983, NEUROPSYCHOLOGIA, V21, P213, DOI 10.1016/0028-3932(83)90039-8; Conway MA, 1996, J EXP PSYCHOL GEN, V125, P69, DOI 10.1037/0096-3445.125.1.69; Cox RW, 1997, NMR BIOMED, V10, P171, DOI 10.1002/(SICI)1099-1492(199706/08)10:4/5<171::AID-NBM453>3.0.CO;2-L; Crawford JR, 1998, J CLIN EXP NEUROPSYC, V20, P898, DOI 10.1076/jcen.20.6.898.1112; GARDINER JM, 1988, MEM COGNITION, V16, P309, DOI 10.3758/BF03197041; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; Kapur N, 1999, PSYCHOL BULL, V125, P800, DOI 10.1037/0033-2909.125.6.800; Kelley WM, 2002, J COGNITIVE NEUROSCI, V14, P785, DOI 10.1162/08989290260138672; Kopelman MD, 2000, COGNITIVE NEUROPSYCH, V17, P585, DOI 10.1080/026432900750002172; Kopelman MD, 2003, HIPPOCAMPUS, V13, P879, DOI 10.1002/hipo.10140; Kopelman MD, 2001, PHILOS T R SOC B, V356, P1409, DOI 10.1098/rstb.2001.0942; Levine B, 2004, J COGNITIVE NEUROSCI, V16, P1633, DOI 10.1162/0898929042568587; Levine B, 2002, PSYCHOL AGING, V17, P677, DOI 10.1037//0882-7974.17.4.677; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; Levine B, 1999, NEUROCASE, V5, P263, DOI 10.1080/13554799908402731; Linton M., 1975, EXPLORATIONS COGNITI, P376; Maguire EA, 2001, PHILOS T R SOC B, V356, P1441, DOI 10.1098/rstb.2001.0944; Maguire EA, 2003, BRAIN, V126, P1511, DOI 10.1093/brain/awg157; Markowitsch HJ, 1995, BRAIN RES REV, V21, P117, DOI 10.1016/0165-0173(95)00007-0; McKinnon MC, 2008, J COGNITIVE NEUROSCI, V20, P1839, DOI 10.1162/jocn.2008.20126; MCKOON G, 1986, J EXP PSYCHOL LEARN, V12, P295, DOI 10.1037/0278-7393.12.2.295; Morris R, 1999, EUR J NEUROSCI, V11, P2506, DOI 10.1046/j.1460-9568.1999.00672.x; Petrides M., 2002, PRINCIPLES FRONTAL L; Piolino P, 2005, COGN NEUROPSYCHOL, V22, P1005, DOI 10.1080/02643290442000428; Piolino P, 2003, BRAIN, V126, P2203, DOI 10.1093/brain/awg222; Piolino P, 2002, MEMORY, V10, P239, DOI 10.1080/09658210143000353; Rosenbaum RS, 2008, J COGNITIVE NEUROSCI, V20, P1490, DOI 10.1162/jocn.2008.20105; Rosenbaum RS, 2007, HIPPOCAMPUS, V17, P1241, DOI 10.1002/hipo.20354; Rosenbaum RS, 2005, NEUROPSYCHOLOGIA, V43, P989, DOI 10.1016/j.neuropsychologia.2004.10.007; Rubin DC, 1997, MEM COGNITION, V25, P859, DOI 10.3758/BF03211330; Schacter DL, 2007, NAT REV NEUROSCI, V8, P657, DOI 10.1038/nrn2213; Soderlund H, 2008, NEUROPSYCHOLOGIA, V46, P127, DOI 10.1016/j.neuropsychologia.2007.08.003; Spreng RN, 2006, MEM COGNITION, V34, P1644, DOI 10.3758/BF03195927; Squire LR, 2007, NAT REV NEUROSCI, V8, P872, DOI 10.1038/nrn2154; SVOBODA EM, J NEUROSCIE IN PRESS; Svoboda E, 2006, NEUROPSYCHOLOGIA, V44, P2189, DOI 10.1016/j.neuropsychologia.2006.05.023; Talairach J., 1988, COPLANAR STEREOTAXIC; Tulving E, 2002, ANNU REV PSYCHOL, V53, P1, DOI 10.1146/annurev.psych.53.100901.135114; TULVING E, 1985, CAN PSYCHOL, V26, P1, DOI 10.1037/h0080017; Tulving E, 2001, PHILOS T R SOC B, V356, P1505, DOI 10.1098/rstb.2001.0937; TULVING E, 1989, EUROPEAN J COGNITIVE, V1, P3, DOI DOI 10.1080/09541448908403069; Tulving E, 1972, ORG MEMORY, P382; VALENSTEIN E, 1987, BRAIN, V110, P1631, DOI 10.1093/brain/110.6.1631	50	39	40	1	19	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia	SEP	2009	47	11					2188	2196		10.1016/j.neuropsychologia.2008.12.026			9	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	468SF	WOS:000267839900006	19154750				2021-06-18	
J	Kim, KS; Brophy, GM				Kim, Keri S.; Brophy, Gretchen M.			Symptomatic Venous Thromboembolism: Incidence and Risk Factors in Patients with Spontaneous or Traumatic Intracranial Hemorrhage	NEUROCRITICAL CARE			English	Article						Enoxaparin; Heparin; Neurosurgery; Risk factors; Venous thromboembolism	MOLECULAR-WEIGHT HEPARIN; NEUROSURGICAL PATIENTS; COMPRESSION STOCKINGS; PROPHYLAXIS; THROMBOSIS; PREVENTION; COMPLICATIONS; CRANIOTOMY; SURGERY	The objectives of this study are to determine the incidence of symptomatic venous thromboembolism (VTE) in neurosurgery intensive care unit (NSICU) patients with spontaneous or traumatic intracranial hemorrhage and to identify the common VTE risk factors by injury type. This retrospective, single-center cohort study included adult patients admitted to the NSICU between January 2001 and July 2004 with a primary diagnosis of subarachnoid hemorrhage (SAH), intracerebral hemorrhage (ICH), or traumatic brain injury (TBI). Patients and VTE events were identified using ICD-9 codes. All patients received low-dose unfractionated heparin or enoxaparin and intermittent pneumatic compression device. Descriptive statistics were used to describe patient characteristics. The overall incidence of symptomatic VTE was 3.8% (n = 1195). The incidence of VTE was 6.7% in SAH patients (n = 179), 2.9% in ICH patients (n = 516), and 3.8% in TBI patients (n = 500). The most commonly identified risk factors in the three groups were: greater than 40 years of age, immobility due to paresis or restrictions for mechanical ventilation, presumed infection, and presence of indwelling central venous catheter. There was no objective evidence of intracranial bleeding associated with pharmacologic VTE prophylaxis in VTE patients. This is the first study to determine symptomatic VTE incidence and to identify common risk factors by injury type in nontumor patients who are not routinely screened with venous duplex ultrasonography but receiving early IPC and LDUH. Further studies are needed to determine the overall incident of symptomatic and nonsymptomatic VTE and independent risk factors for VTE events in NSICU patients.	[Brophy, Gretchen M.] Virginia Commonwealth Univ, Dept Pharm & Neurosurg, Richmond, VA 23298 USA; [Kim, Keri S.] Univ Illinois, Med Ctr Chicago, Dept Pharm Practice, Chicago, IL USA	Brophy, GM (corresponding author), Virginia Commonwealth Univ, Dept Pharm & Neurosurg, Med Coll Virginia Campus,410 N 12th St,Room 336,P, Richmond, VA 23298 USA.	gbrophy@vcu.edu		Brophy, Gretchen/0000-0002-4749-2693; Kim, Keri/0000-0002-8480-4801			Agnelli G, 1998, NEW ENGL J MED, V339, P80, DOI 10.1056/NEJM199807093390204; *BRAIN TRAUM FDN A, 2007, J NEUROTRAUMA S1, V24, pS32, DOI DOI 10.1089/NEU.2007.9991; CMACDONALD RL, 1999, NEUROSURGERY, V45, P245, DOI DOI 10.1097/00006123-199908000-00008; Epstein NE, 2005, SURG NEUROL, V64, P295, DOI 10.1016/j.surneu.2005.04.039; FRIM DM, 1992, NEUROSURGERY, V30, P830, DOI 10.1227/00006123-199206000-00002; Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656; Gerlach R, 2003, NEUROSURGERY, V53, P1028, DOI 10.1227/01.NEU.0000088565.15719.22; Gnanalingham KK, 2003, J CLIN NEUROSCI, V10, P467, DOI 10.1016/S0967-5868(03)00060-2; Goldhaber SZ, 2002, CHEST, V122, P1933, DOI 10.1378/chest.122.6.1933; HAMILTON MG, 1994, NEUROSURGERY, V34, P280, DOI 10.1227/00006123-199402000-00012; Kleindienst A, 2003, ACTA NEUROCHIR, V145, P1085, DOI 10.1007/s00701-003-0142-y; Macdonald RL, 2003, SURG NEUROL, V59, P363, DOI 10.1016/S0090-3019(03)00111-3; Mack WJ, 2008, NEUROL RES, V30, P889, DOI 10.1179/174313208X327946; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Nurmohamed MT, 1996, THROMB HAEMOSTASIS, V75, P233; Ogata T, 2008, J NEUROL SCI, V272, P83, DOI 10.1016/j.jns.2008.04.032; Raabe A, 2001, ACTA NEUROCHIR, V143, P1, DOI 10.1007/s007010170131; Wen DY, 1998, SURG NEUROL, V50, P521, DOI 10.1016/S0090-3019(98)00083-4; Yablon SA, 2004, NEUROLOGY, V63, P485, DOI 10.1212/01.WNL.0000133009.24727.9F	19	39	48	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2009	11	1					28	33		10.1007/s12028-009-9201-4			6	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	468AU	WOS:000267786400006	19238588				2021-06-18	
J	Snaphaan, L; Rijpkema, M; van Uden, I; Fernandez, G; de Leeuw, FE				Snaphaan, Liselore; Rijpkema, Mark; van Uden, Inge; Fernandez, Guillen; de Leeuw, Frank-Erik			Reduced medial temporal lobe functionality in stroke patients: a functional magnetic resonance imaging study	BRAIN			English	Article						stroke; fMRI; MTL; imaging; n-back task	TRAUMATIC BRAIN-INJURY; MEMORY FUNCTION; WORKING-MEMORY; COGNITIVE DYSFUNCTION; HIPPOCAMPAL ATROPHY; CORTISOL-LEVELS; SCHIZOPHRENIA; DEPRESSION; FMRI; DEFICITS	Stroke is a leading cause of disability, not only because of motor limitations, but also because of the frequent occurrence of post-stroke cognitive impairment. This is illustrated by the fact that the risk of post-stroke dementia is reportedly higher than a recurrent stroke. The loss of subcortical and cortical functions in the post-stroke cognitive dysfunction spectrum is usually well explained by the size and location of the infarction. However, this does not apply for post-stroke memory dysfunction (especially episodic memory dysfunction), as there is almost never an infarction in the medial temporal lobe. Involvement of the medial temporal lobe in post-stroke memory dysfunction seems likely since this structure is essential for memory encoding and retrieval. For a proper episodic memory function, the medial temporal lobe depends on intact connections with virtually the whole brain. Disconnection from other brain areas due to the infarction could lead to a reduced medial temporal lobe function and the attendant reduced episodic memory function. We investigated medial temporal lobe functionality in 28 'first-ever' stroke patients and 22 healthy controls with the aid of functional magnetic resonance imaging. Stroke patients with a reduced episodic memory function 6-8 weeks after infarction had reduced medial temporal lobe functionality. Post-stroke reduced medial temporal lobe functionality may be responsible for the frequent observation of impaired post-stroke episodic memory function. Insight into this mechanism could be helpful in identifying which stroke patients may be at increased risk for developing post-stroke dementia and those who could benefit from early cognitive rehabilitation.	[Snaphaan, Liselore; van Uden, Inge; Fernandez, Guillen; de Leeuw, Frank-Erik] Radboud Univ Nijmegen, Dept Neurol, Donders Inst Brain Cognit & Behav, Med Ctr,Ctr Neurosci, NL-6500 HB Nijmegen, Netherlands; [Rijpkema, Mark; Fernandez, Guillen] Radboud Univ Nijmegen, Ctr Cognit Neuroimaging, Donders Inst Brain Cognit & Behav, NL-6500 HB Nijmegen, Netherlands	de Leeuw, FE (corresponding author), Radboud Univ Nijmegen, Dept Neurol, Donders Inst Brain Cognit & Behav, Med Ctr,Ctr Neurosci, POB 9101,HP 935, NL-6500 HB Nijmegen, Netherlands.	H.deLeeuw@neuro.umcn.nl	Rijpkema, Mark/D-1974-2010; Fernandez, Guillen/B-3771-2009; Grootjen, Franc/B-3915-2010; de Leeuw, H.F./L-4479-2015; van Uden, Inge/E-2396-2016; de Leeuw, Frank-Erik/E-4795-2012	Rijpkema, Mark/0000-0002-8495-4703; Fernandez, Guillen/0000-0002-5522-0604; 			Brierley B, 2002, BRAIN RES REV, V39, P84, DOI 10.1016/S0165-0173(02)00160-1; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Callicott JH, 2000, CEREB CORTEX, V10, P1078, DOI 10.1093/cercor/10.11.1078; Callicott JH, 1999, CEREB CORTEX, V9, P20, DOI 10.1093/cercor/9.1.20; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; de Jonghe J F, 1997, Tijdschr Gerontol Geriatr, V28, P224; de Quervain DJF, 2003, EUR J NEUROSCI, V17, P1296, DOI 10.1046/j.1460-9568.2003.02542.x; Delis DC, 1987, CALIFORNIA VERBAL LE; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Elgh E, 2006, BIOL PSYCHIAT, V59, P155, DOI 10.1016/j.biopsych.2005.06.017; FOLSTEIN M, 1973, BIOL PSYCHIAT, V7, P147; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Geuze E, 2005, MOL PSYCHIATR, V10, P147, DOI 10.1038/sj.mp.4001580; Harvey PO, 2005, NEUROIMAGE, V26, P860, DOI 10.1016/j.neuroimage.2005.02.048; HERMANN BP, 1987, EPILEPSIA, V28, P547, DOI 10.1111/j.1528-1157.1987.tb03687.x; Hofgren C, 2007, ACTA NEUROL SCAND, V115, P73, DOI 10.1111/j.1600-0404.2006.00768.x; Ibrahimagic Omer C, 2005, Med Arh, V59, P79; Johnson SC, 2001, J INT NEUROPSYCH SOC, V7, P55, DOI 10.1017/S135561770171106X; Kauhanen ML, 1999, STROKE, V30, P1875, DOI 10.1161/01.STR.30.9.1875; Kimberley TJ, 2008, EXP BRAIN RES, V186, P183, DOI 10.1007/s00221-007-1221-8; Kizilbash AH, 2002, ARCH CLIN NEUROPSYCH, V17, P57, DOI 10.1016/S0887-6177(00)00101-3; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Loewenstein DA, 2004, AM J GERIAT PSYCHIAT, V12, P395, DOI 10.1176/appi.ajgp.12.4.395; Lupien SJ, 1998, NAT NEUROSCI, V1, P69, DOI 10.1038/271; MAHONEY F I, 1965, Md State Med J, V14, P61; Marklund N, 2004, J INTERN MED, V256, P15, DOI 10.1111/j.1365-2796.2004.01334.x; Meisenzahl EM, 2006, EUR ARCH PSY CLIN N, V256, P522, DOI 10.1007/s00406-006-0687-x; Meyer-Lindenberg A, 2001, AM J PSYCHIAT, V158, P1809, DOI 10.1176/appi.ajp.158.11.1809; MUNGAS D, 1985, EPILEPSIA, V26, P340, DOI 10.1111/j.1528-1157.1985.tb05660.x; ONEILL PA, 1991, STROKE, V22, P842, DOI 10.1161/01.STR.22.7.842; Rasquin SMC, 2004, DEMENT GERIATR COGN, V18, P138, DOI 10.1159/000079193; Simons JS, 2003, NAT REV NEUROSCI, V4, P637, DOI 10.1038/nrn1178; Snaphaan L, 2007, STROKE, V38, P198, DOI 10.1161/01.STR.0000251842.34322.8f; Sullivan EV, 1996, BIOL PSYCHIAT, V39, P234, DOI 10.1016/0006-3223(95)00135-2; Suzuki WA, 2007, HIPPOCAMPUS, V17, P842, DOI 10.1002/hipo.20321; Szczudlik A, 2004, J ENDOCRINOL INVEST, V27, P37, DOI 10.1007/BF03350908; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; VERHAGE F, 1964, INTELIGENCE AGE; Wahlund LO, 2001, STROKE, V32, P1318, DOI 10.1161/01.STR.32.6.1318; Weinberger DR, 1996, NEUROIMAGE, V4, pS118, DOI 10.1006/nimg.1996.0062; Worsley KJ, 1996, HUM BRAIN MAPP, V4, P58, DOI 10.1002/(SICI)1097-0193(1996)4:1<58::AID-HBM4>3.0.CO;2-O; Yokota C, 2004, CEREBROVASC DIS, V18, P111, DOI 10.1159/000079258; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	43	39	48	0	12	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	JUL	2009	132		7				1882	1888		10.1093/brain/awp133			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	463OE	WOS:000267440700024	19482967	Bronze			2021-06-18	
J	San-Juan, OD; Chiappa, KH; Costello, DJ; Cole, AJ				San-juan, O. D.; Chiappa, K. H.; Costello, D. J.; Cole, A. J.			Periodic epileptiform discharges in hypoxic encephalopathy: BiPLEDs and GPEDs as a poor prognosis for survival	SEIZURE-EUROPEAN JOURNAL OF EPILEPSY			English	Article						PLEDs; BiPLEDs; GPEDs; Hypoxic encephalopathy; Prognosis	TRAUMATIC ENCEPHALOPATHIES; CLINICAL-SIGNIFICANCE; POSTANOXIC COMA; EEG PATTERNS; NEUROLOGY; ARREST	Introduction: Electrophysiologic tests in hypoxic encephalopathy consist of EEG and evoked/event-related potential studies. In most studies the generalized periodic epileptiform complexes have been reported combined with other EEG patterns and were indicators of a poor outcome in different etiologies of hypoxic encephalopathy (HE), but these have rarely been examined independently. Methodology: We analyzed from 2000 to 2007 the outcome of patients with HE and generalized periodic epileptiform complexes. We abstracted and tabulated clinical information, imaging findings, and outcome from the medical records. Results: We found 52 patients in our database. Fourteen patients (eight BiPLEDs and six GPEDs) were associated with HE. Patients with BIPLEDs were 68 +/- 19.4 years old, 5 female (62%) and 3 (38%) men. GPEDs patients were 52.5 +/- 19.1 years old, 2 women (20%) and 4 (80%) men. Myocardial infarction and ventricular tachycardia were responsible of 57% of the HE cases. Neuroimaging studies in both groups showed cortical structural lesions in 84%. All patients were comatose and died. Two GPEDs patients developed status epilepticus. Conclusion: GPEDs and BIPLEDs after an anoxic insult carried a poor prognosis for survival. Aggressive treatment of patients may not be warranted when these EEG patterns are seen after anoxic brain injury. (C) 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.	[San-juan, O. D.; Chiappa, K. H.; Costello, D. J.; Cole, A. J.] Massachusetts Gen Hosp, Epilepsy Serv, Dept Neurophysiol, Boston, MA 02114 USA	San-Juan, OD (corresponding author), Massachusetts Gen Hosp, Epilepsy Serv, Dept Neurophysiol, 55 Furit St, Boston, MA 02114 USA.	pegaso31@yahoo.com	San Juan, Daniel/AAU-3348-2020	San Juan, Daniel/0000-0001-6685-5851	Foundation Mexico (FMH) in Harvard; FMH Fellowship	The study was funded by grant from the Foundation Mexico (FMH) in Harvard. San-Juan OD is Supported by FMH Fellowship.	BASSETTI C, 1987, EEG-EMG-Z ELEK ELEKT, V18, P97; BRENNER RP, 1990, J CLIN NEUROPHYSIOL, V7, P249, DOI 10.1097/00004691-199004000-00007; Chiappa KH, 1998, ELECTROEN CLIN NEURO, V106, P149, DOI 10.1016/S0013-4694(97)00118-1; DELAPAZ D, 1981, ARCH NEUROL-CHICAGO, V38, P713, DOI 10.1001/archneur.1981.00510110073012; Fitzpatrick W, 2007, CAN J NEUROL SCI, V34, P443, DOI 10.1017/S0317167100007332; Fushimi M, 2003, ACTA NEUROL SCAND, V108, P55, DOI 10.1034/j.1600-0404.2003.00084.x; GLOOR P, 1968, BRAIN, V91, P779, DOI 10.1093/brain/91.4.779; Husain AM, 1999, J CLIN NEUROPHYSIOL, V16, P51, DOI 10.1097/00004691-199901000-00005; Khan SF, 2005, CLIN NEUROPHYSIOL, V116, P2454, DOI 10.1016/j.clinph.2005.06.024; KUROIWA Y, 1980, ARCH NEUROL-CHICAGO, V37, P15, DOI 10.1001/archneur.1980.00500500045005; Nicolai J, 2001, CLIN NEUROPHYSIOL, V112, P1726, DOI 10.1016/S1388-2457(01)00602-2; SCOLLOLAVIZZARI G, 1987, EUR NEUROL, V26, P161, DOI 10.1159/000116329; SYNEK VM, 1988, J CLIN NEUROPHYSIOL, V5, P161, DOI 10.1097/00004691-198804000-00003; SYNEK VM, 1990, CLIN ELECTROENCEPHAL, V21, P25, DOI 10.1177/155005949002100111; TREIMAN DM, 1997, J CLIN NEUROPHYSIOL, V14, P159; Wijdicks EFM, 2006, NEUROLOGY, V67, P203, DOI 10.1212/01.wnl.0000227183.21314.cd; Yemisci M, 2003, SEIZURE-EUR J EPILEP, V12, P465, DOI 10.1016/S1059-1311(02)00351-5; Young GB, 1999, J CLIN NEUROPHYSIOL, V16, P354, DOI 10.1097/00004691-199907000-00008; Young GB, 2005, NEUROCRIT CARE, V2, P5, DOI 10.1385/NCC:2:1:005; Young GB, 2004, J CLIN NEUROPHYSIOL, V21, P379	20	39	41	0	3	W B SAUNDERS CO LTD	LONDON	32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND	1059-1311	1532-2688		SEIZURE-EUR J EPILEP	Seizure	JUN	2009	18	5					365	368		10.1016/j.seizure.2009.01.003			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	453VM	WOS:000266641000011	19196524				2021-06-18	
J	Homaifar, BY; Brenner, LA; Gutierrez, PM; Harwood, JF; Thompson, C; Filley, CM; Kelly, JP; Adler, LE				Homaifar, Beeta Y.; Brenner, Lisa A.; Gutierrez, Peter M.; Harwood, Jeri F.; Thompson, Caitlin; Filley, Christopher M.; Kelly, James P.; Adler, Lawrence E.			Sensitivity and Specificity of the Beck Depression Inventory-II in Persons With Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	5th Annual Conference of the American-Academy-of-Clinical-Neuropsychology	JUN 07-09, 2007	Denver, CO	Amer Acad Clin Neuropsychol		Brain injuries; Depression; Rehabilitation; Veterans	FOLLOW-UP; AXIS-I; PSYCHIATRIC-DISORDERS; EMOTIONAL ADJUSTMENT; AWARENESS; INDIVIDUALS; CHALLENGES	Homaifar BY, Brenner LA, Gutierrez PM, Harwood JF, Thompson C, Filley CM, Kelly JP, Adler LE. Sensitivity and specificity of the Beck Depression Inventory-II in persons with traumatic brain injury. Arch Phys Med Rehabil 2009,90:652-6. Objectives: Our objective was to examine the Beck Depression Inventory-II (BDI-II) in a traumatic brain injury (TBI) sample using a receiver operating characteristic (ROC) Curve to determine how well the BDI-II identifies depression. An ROC curve allows for analysis of the sensitivity and specificity of a diagnostic test using various cutoff points to determine the number of true positives, true negatives, false positives, and false negatives. Design: This was a secondary analysis of data gathered from an observational study. We examined BDI-II scores in a sample of 52 veterans with remote histories of TBI. Setting: This study was completed at a Veterans Affairs (VA) Medical Center. Participants: Participants were veterans eligible to receive VA health care services. Interventions: Not applicable. Main Outcome Measures: Outcome measures included the BDI-II and the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-IV). Results: We generated an ROC curve to determine how well the BDI-II identifies depression using the SCID-TV as the criterion standard for diagnosing depression, defined here as a diagnosis of major depressive disorder. Results indicated a cutoff score of at least 19 if one has a mild TBI or at least 35 if one has a moderate or severe TBI. These scores maximize sensitivity (87%) and specificity (79%). Conclusions: Clinicians working with persons with TBI can use the BDI-II to determine whether depressive symptoms warrant further assessment.	[Homaifar, Beeta Y.; Brenner, Lisa A.; Gutierrez, Peter M.; Adler, Lawrence E.] Vet Affairs VISN 19 Mental Illness Res Educ & Cli, Denver, CO USA; [Brenner, Lisa A.; Kelly, James P.] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Denver, CO USA; [Homaifar, Beeta Y.; Brenner, Lisa A.; Gutierrez, Peter M.; Filley, Christopher M.; Adler, Lawrence E.] Univ Colorado, Sch Med, Dept Psychiat, Denver, CO 80262 USA; [Harwood, Jeri F.] Univ Colorado, Sch Med, Dept Pediat, Denver, CO USA; [Brenner, Lisa A.; Filley, Christopher M.] Univ Colorado, Sch Med, Dept Neurol, Denver, CO USA; [Kelly, James P.] Univ Colorado, Sch Med, Dept Neurosurg, Denver, CO USA; [Thompson, Caitlin] Univ Rochester, Med Ctr, Dept Psychiat, Rochester, NY 14642 USA; [Homaifar, Beeta Y.; Filley, Christopher M.] VA Eastern Colorado Hlth Care Syst, Denver, CO 80220 USA; [Harwood, Jeri F.] Sch Publ Hlth, Dept Biostat & Informat, Denver, CO USA	Homaifar, BY (corresponding author), VA Eastern Colorado Hlth Care Syst, MIRECC VISN 19,1055 Clermont St, Denver, CO 80220 USA.	beeta.homaifar1@va.gov	Brenner, Lisa A./AAG-2442-2019; Gutierrez, Peter/K-8905-2019	Gutierrez, Peter/0000-0001-8981-8404	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH020061] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32 MH020061] Funding Source: Medline; Intramural VA [VA999999] Funding Source: Medline		American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Beck A. T., 1996, BECK DEPRESSION INVE, VII; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BRENNER LA, MILITARY ME IN PRESS; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Colantonio A, 2004, INT J REHABIL RES, V27, P209, DOI 10.1097/00004356-200409000-00006; CONDER R, 1992, MANUAL COMPUTERIZED; *DEP VET AFF, 2004, VETEESA138 SP; Felicetti T, 2005, PROF CASE MANAG, V10, P264; Flanagan SR, 2006, CLIN GERIATR MED, V22, P449, DOI 10.1016/j.cger.2005.12.011; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Ownsworth T, 2007, NEUROPSYCHOL REHABIL, V17, P129, DOI 10.1080/09602010600615506; Robinson RG, 2005, TXB TRAUMATIC BRAIN, P201; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; Sawchyn JM, 2005, J HEAD TRAUMA REHAB, V20, P301, DOI 10.1097/00001199-200507000-00003; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; Spitzer R. l., 1995, STRUCTURED CLIN INTE; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Thurman DJ., 1995, GUIDELINES SURVEILLA; TRUDEL TM, 2005, BRAIN INJURY PROFESS, V2, P16	34	39	40	0	15	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2009	90	4					652	656		10.1016/j.apmr.2008.10.028			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	432TD	WOS:000265156200017	19345782	Green Accepted			2021-06-18	
J	Sparrey, CJ; Manley, GT; Keaveny, TM				Sparrey, Carolyn J.; Manley, Geoffrey T.; Keaveny, Tony M.			Effects of White, Grey, and Pia Mater Properties on Tissue Level Stresses and Strains in the Compressed Spinal Cord	JOURNAL OF NEUROTRAUMA			English	Article						age; finite element models; models of injury; traumatic spinal cord injury	MECHANICAL-PROPERTIES; BRAIN-TISSUE; GRAY-MATTER; IN-VITRO; INJURY; OUTCOMES	Recent demographics demonstrate an increase in the number of elderly spinal cord injury patients, motivating the desire for a better understanding of age effects on injury susceptibility. Knowing that age and disease affect neurological tissue, there is a need to better understand the sensitivity of spinal cord injury mechanics to variations in tissue behavior. To address this issue, a plane-strain, geometrically nonlinear, finite element model of a section of a generic human thoracic spinal cord was constructed to model the response to dorsal compression. The material models and stiffness responses for the grey and white matter and pia mater were varied across a range of reported values to observe the sensitivity of model outcomes to the assigned properties. Outcome measures were evaluated for percent change in magnitude and alterations in spatial distribution. In general, principal stresses (114-244% change) and pressure (75-119% change) were the outcomes most sensitive to material variation. Strain outcome measures were less sensitive (7-27% change) than stresses (74-244% change) to variations in material tangent modulus. The pia mater characteristics had limited (<4% change) effects on outcomes. Using linear elastic models to represent non-linear behavior had variable effects on outcome measures, and resulted in highly concentrated areas of elevated stresses and strains. Pressure measurements in both the grey and white matter were particularly sensitive to white matter properties, suggesting that degenerative changes in white matter may influence perfusion in a compressed spinal cord. Our results suggest that the mechanics of spinal cord compression are likely to be affected by changes in tissue resulting from aging and disease, indicating a need to study the biomechanical aspects of spinal cord injury in these specific populations.	[Sparrey, Carolyn J.; Keaveny, Tony M.] Univ Calif Berkeley, Dept Mech Engn, Berkeley, CA 94720 USA; [Manley, Geoffrey T.; Keaveny, Tony M.] Univ Calif Berkeley, Dept Neurol Surg, Berkeley, CA 94720 USA; [Keaveny, Tony M.] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA	Keaveny, TM (corresponding author), Univ Calif Berkeley, Dept Mech Engn, 6175 Etcheverry Hall, Berkeley, CA 94720 USA.	tmk@me.berkeley.edu		Sparrey, Carolyn/0000-0002-5524-4577	Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [UCSF-3915SC]; University of California-BerkeleyUniversity of California System	This work was funded in part by Centers for Disease Control and Prevention grant UCSF-3915SC and a Chancellor's Professorship (T. M. K.) from the University of California-Berkeley.	Aimedieu P, 2004, J NEUROSURG, V100, P111, DOI 10.3171/jns.2004.100.1.0111; ANDERSON TE, 1985, J NEUROSURG, V62, P115, DOI 10.3171/jns.1985.62.1.0115; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BEHRMANN DL, 1992, J NEUROTRAUM, V9, P197, DOI 10.1089/neu.1992.9.197; Bilston L, 1998, IRCOBI C GOT, P365; Bilston LE, 1996, ANN BIOMED ENG, V24, P67; Bot JCJ, 2004, RADIOLOGY, V233, P531, DOI 10.1148/radiol.2332031572; Bresnahan JC, 1991, J NEUROTRAUM, V8, P91, DOI 10.1089/neu.1991.8.91; Carlson GD, 1997, SPINE, V22, P1285, DOI 10.1097/00007632-199706150-00002; Carlson GD, 2000, SPINE, V25, P1218, DOI 10.1097/00007632-200005150-00004; CHANG GL, 1988, J BIOMECH ENG-T ASME, V110, P115, DOI 10.1115/1.3108415; Coats B, 2006, J BIOMECH, V39, P2521, DOI 10.1016/j.jbiomech.2005.07.020; Fiford RJ, 2005, J BIOMECH, V38, P1509, DOI 10.1016/j.jbiomech.2004.07.009; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Galle B, 2007, J BIOMECH, V40, P3029, DOI 10.1016/j.jbiomech.2007.03.014; Garo A, 2007, BIORHEOLOGY, V44, P51; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Greaves CY, 2008, ANN BIOMED ENG, V36, P396, DOI 10.1007/s10439-008-9440-0; Gruner JA, 1996, BRAIN RES, V729, P90, DOI 10.1016/S0006-8993(96)00366-6; HUNG TK, 1981, J BIOMECH ENG-T ASME, V103, P43, DOI 10.1115/1.3138244; Ichihara K, 2003, J NEUROSURG, V99, P278, DOI 10.3171/spi.2003.99.3.0278; Ichihara K, 2001, J NEUROTRAUM, V18, P361, DOI 10.1089/08977150151071053; Jackson AB, 2004, ARCH PHYS MED REHAB, V85, P1740, DOI 10.1016/j.apmr.2004.04.035; JAWAD SA, 1978, J MATER SCI, V13, P1381, DOI 10.1007/BF00553190; Jin Xin, 2006, Stapp Car Crash J, V50, P637; KEARNEY P A, 1988, Journal of Neurotrauma, V5, P187, DOI 10.1089/neu.1988.5.187; Lovas G, 2000, BRAIN, V123, P308, DOI 10.1093/brain/123.2.308; McKinley W, 2003, NEUROREHABILITATION, V18, P83; McKinley W, 2007, J SPINAL CORD MED, V30, P215, DOI 10.1080/10790268.2007.11753929; METZ H, 1970, J BIOMECH, V3, P453, DOI 10.1016/0021-9290(70)90017-5; NOYES DH, 1987, EXP NEUROL, V95, P535, DOI 10.1016/0014-4886(87)90298-6; Oakland RJ, 2006, P I MECH ENG H, V220, P489, DOI 10.1243/09544119JETM135; Ogden R.W., 1984, NONLINEAR ELASTIC DE; Ozawa H, 2004, J NEUROSURG-SPINE, V1, P122, DOI 10.3171/spi.2004.1.1.0122; Ozawa H, 2001, J NEUROSURG, V95, P221, DOI 10.3171/spi.2001.95.2.0221; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; SCHOENEN J, 2004, HUMAN NERVOUS SYSTEM, P1366; SCIFERT J, 2000, P 22 ANN EMBS INT C, P855; SPARREY CJ, 2004, MECH ENG	39	39	43	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2009	26	4					585	595		10.1089/neu.2008.0654			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	430OV	WOS:000264999300010	19292657	Green Published			2021-06-18	
J	Onyszchuk, G; LeVine, SM; Brooks, WM; Berman, NEJ				Onyszchuk, Gregory; LeVine, Steven M.; Brooks, William M.; Berman, Nancy E. J.			Post-acute pathological changes in the thalamus and internal capsule in aged mice following controlled cortical impact injury: A magnetic resonance imaging, iron histochemical, and glial immunohistochemical study	NEUROSCIENCE LETTERS			English	Article						T2 hypointensky; Iron; Traumatic brain injury; GFAP; Iba1	TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; T2 HYPOINTENSITY; MOUSE MODEL; RAT; MATTER; DEFEROXAMINE; ASTROCYTES; CHELATORS; TOXICITY	Traumatic brain injury (TBI) is a major cause of neurological disability across all ages, but the elderly are particularly vulnerable and have a worse prognosis than younger individuals. To advance the understanding of long-term pathogenesis induced by TBI in the elderly, aged mice (21-24 months) were given a controlled cortical impact (CCI) injury to the sensorimotor cortex, and their brains were analyzed by MRI and histopathology at 1 and 2 months after CCI injury, a post-acute period. A T2 hypointensity was observed in the ipsilateral thalamus but not in the contralateral thalamus or in the thalamus of sham operated, control mice. The hypointensity was co-localized with increased histochemical staining of iron, a paramagnetic substance that causes a shortening of the T2 relaxation time. Since iron catalyzes reactions that lead to toxic free radicals, the deposition of iron in the thalamus raises the possibility that it promotes pathogenesis following TBI. Astrocyte gliosis and microgliosis were also observed in the ipsilateral thalamus in the post-acute period. The ipsilateral internal capsule displayed a trend for a 12 hypointensity, however, unlike the thalamus it did not have an increase of iron or GFAP staining, but it did have evidence of microgliosis. In summary, areas of T2 hypointensity were revealed in both the thalamus and internal capsule during the post-acute period following CCI injury, but the underlying pathology appeared to be distinct between these regions. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Berman, Nancy E. J.] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA; [Onyszchuk, Gregory; Brooks, William M.] Univ Kansas, Med Ctr, Hoglund Brain Imaging Ctr, Kansas City, KS 66160 USA; [Onyszchuk, Gregory; Berman, Nancy E. J.] Univ Kansas, Med Ctr, Steve Palermo Nerve Regenerat Lab, Kansas City, KS 66160 USA; [Onyszchuk, Gregory; LeVine, Steven M.; Brooks, William M.] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; [Onyszchuk, Gregory; Berman, Nancy E. J.] Univ Kansas, Med Ctr, Dept Neurosurg, Kansas City, KS 66160 USA; [Brooks, William M.] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66160 USA	Berman, NEJ (corresponding author), Univ Kansas, Med Ctr, Dept Anat & Cell Biol, 3901 Rainbow Blvd,Mail Stop 3038, Kansas City, KS 66160 USA.	nberman@kumc.edu	Ritter, Stefanie L/D-9312-2012	brooks, william/0000-0001-6227-7636	Steve Palermo Endowment; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 AG026482, R01 NS039123, P20 RR016475, P30 HD 02528]; Hoglund Family Foundation;  [C76 HF00201];  [R21HD050534];  [R21AG029615];  [R03AG026374];  [P20RR015563]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD002528] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD050534] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR016475, P20RR015563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R03AG026374, R21AG029615, R01AG031140, R21AG026482] Funding Source: NIH RePORTER	We thank Dr. Yong-Yue He for assistance with the CCI procedures. The study was supported in part by the Steve Palermo Endowment and grants from the National Institutes of Health (R21 AG026482, R01 NS039123, P20 RR016475 and P30 HD 02528). The Hoglund Brain Imaging Center is supported by C76 HF00201 and the Hoglund Family Foundation. Dr. Brooks is supported by R21HD050534, R21AG029615, R03AG026374 and P20RR015563.	Agarwala S, 1998, J COMP NEUROL, V392, P252, DOI 10.1002/(SICI)1096-9861(19980309)392:2<252::AID-CNE7>3.0.CO;2-1; Barnabe N, 2002, FREE RADICAL BIO MED, V33, P266, DOI 10.1016/S0891-5849(02)00873-0; Bermel RA, 2005, ARCH NEUROL-CHICAGO, V62, P1371, DOI 10.1001/archneur.62.9.1371; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Brass SD, 2006, MULT SCLER J, V12, P437, DOI 10.1191/135248506ms1301oa; Brass Steven D, 2006, Top Magn Reson Imaging, V17, P31, DOI 10.1097/01.rmr.0000245459.82782.e4; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; CHENOUFI N, 1995, J HEPATOL, V23, P166, DOI 10.1016/0168-8278(95)80331-9; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Eybl V, 2002, TOXICOL LETT, V128, P169, DOI 10.1016/S0378-4274(01)00541-0; Forge JK, 1998, LIFE SCI, V63, P2271, DOI 10.1016/S0024-3205(98)00512-8; Fredenburg AM, 1996, TOXICOLOGY, V108, P191, DOI 10.1016/0300-483X(95)03301-U; Gaasch JA, 2007, NEUROCHEM RES, V32, P1196, DOI 10.1007/s11064-007-9290-4; Glickstein H, 2006, BLOOD, V108, P3195, DOI 10.1182/blood-2006-05-020867; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; HE W, 2005, 65 US CURRENT POPULA; Ke Y, 2007, PROG NEUROBIOL, V83, P149, DOI 10.1016/j.pneurobio.2007.07.009; LEVINE SM, 1991, J NEUROSCI RES, V29, P413, DOI 10.1002/jnr.490290317; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; Meguro R, 2007, ARCH HISTOL CYTOL, V70, P1, DOI 10.1679/aohc.70.1; Muessel MJ, 2002, MOL BRAIN RES, V103, P12, DOI 10.1016/S0169-328X(02)00158-4; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; PANTER SS, 1992, J NEUROTRAUM, V9, P47, DOI 10.1089/neu.1992.9.47; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Takeuchi Y, 2002, J NEUROL NEUROSUR PS, V72, P543; TODORICH, GLIA IN PRESS; Yi JH, 2005, BRAIN RES, V1033, P13, DOI 10.1016/j.brainres.2004.10.055; Young JK, 2004, J HISTOCHEM CYTOCHEM, V52, P1519, DOI 10.1369/jhc.4A6375.2004; Zamboni P, 2006, J ROY SOC MED, V99, P589, DOI 10.1258/jrsm.99.11.589; Zecca L, 2004, NAT REV NEUROSCI, V5, P863, DOI 10.1038/nrn1537; Zhang Y, 2007, MULT SCLER J, V13, P880, DOI 10.1177/1352458507076411	36	39	39	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	MAR 13	2009	452	2					204	208		10.1016/j.neulet.2009.01.049			5	Neurosciences	Neurosciences & Neurology	422ZM	WOS:000264466200025	19383440	Green Accepted			2021-06-18	
J	Catena, RD; van Donkelaar, P; Halterman, CI; Chou, LS				Catena, Robert D.; van Donkelaar, Paul; Halterman, Charlene I.; Chou, Li-Shan			Spatial orientation of attention and obstacle avoidance following concussion	EXPERIMENTAL BRAIN RESEARCH			English	Article						Spatial orientation of attention; Concussion; Obstacle avoidance; Trip	TRAUMATIC BRAIN-INJURY; DIVIDED ATTENTION; AUTOMATIC AVOIDANCE; DEFICITS; COORDINATION; BEHAVIOR; STEP	Re-injury to the brain during recovery from an initial concussion leads to increased probability of permanent brain damage or death. Recovery from concussion has been proposed to be ongoing even up to a month post-injury. The goal of the current study was to investigate the relationship between the visuospatial orientation of attention and obstacle avoidance during gait in individuals that have recently suffered a concussion (mTBI) over a month post-injury. MTBI subjects and matched control subjects performed the attentional network test (ANT), designed to isolate several different components of attention. Obstacle crossing during gait with and without a concurrent attention dividing task was also performed. Reaction times from the ANT and obstacle clearance measurements were the main dependent variables. We observed that concussed individuals had statistically more obstacle contacts than controls. The ability to orient attention in space was also statistically deficient immediately after a concussion, and this was correlated with lower obstacle clearances of the leading foot. Similar correlations could also be found between both leading and trailing foot avoidance and spatial orientation of attention in participants with concussion when attention was divided during obstacle crossing, and these relationships gradually weakened as recovery progressed. By contrast, spatial attention and obstacle clearance were not significantly correlated in control subjects. These findings indicate that patients with mTBI who display greater spatial attention deficits cross over the obstacle with a lower clearance than patients with less or without spatial attention deficits, leading to an increased probability of obstacle contact.	[Catena, Robert D.; van Donkelaar, Paul; Halterman, Charlene I.; Chou, Li-Shan] Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA	Chou, LS (corresponding author), Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA.	chou@uoregon.edu		Catena, Robert/0000-0001-9128-1343	Center for Disease Control and Prevention [R49/CCR021735, CCR023203]	This study was supported by the Center for Disease Control and Prevention (R49/CCR021735 and CCR023203). The authors gratefully acknowledge the assistance of Tonya M. Parker Ph.D. with data collection.	BELL R, 1977, AM FAM PHYSICIAN, V16, P145; BORG J, 2004, J REHABIL MED, V43, pS61; Cantin JF, 2007, BRAIN INJURY, V21, P327, DOI 10.1080/02699050701209972; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; CREMONAMETEYARD SL, 1992, NEUROPSYCHOLOGIA, V30, P123, DOI 10.1016/0028-3932(92)90022-E; Drew AS, 2007, NEUROSCI LETT, V417, P61, DOI 10.1016/j.neulet.2007.02.038; Drew T, 2008, BRAIN RES REV, V57, P199, DOI 10.1016/j.brainresrev.2007.07.017; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Humphreys GW, 2004, NAT NEUROSCI, V7, P693, DOI 10.1038/nn0704-693; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Johansson RS, 2001, J NEUROSCI, V21, P6917; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; McIntosh RD, 2004, P ROY SOC B-BIOL SCI, V271, P15, DOI 10.1098/rspb.2003.2545; Mohagheghi AA, 2004, EXP BRAIN RES, V155, P459, DOI 10.1007/s00221-003-1751-7; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Patla AE, 1997, NEUROREPORT, V8, P3661, DOI 10.1097/00001756-199712010-00002; Peker T, 1997, Morphologie, V81, P13; POSNER MI, 1988, SCIENCE, V240, P1627, DOI 10.1126/science.3289116; POSNER MI, 1984, J NEUROSCI, V4, P1863; Rice NJ, 2006, EXP BRAIN RES, V174, P176, DOI 10.1007/s00221-006-0435-5; Santangelo V, 2007, PERCEPTION, V36, P1497, DOI 10.1068/p5848; Santangelo V, 2007, J EXP PSYCHOL HUMAN, V33, P137, DOI 10.1037/0096-1523.33.1.137; Schindler I, 2004, NAT NEUROSCI, V7, P779, DOI 10.1038/nn1273; Tresilian JR, 1998, EXP BRAIN RES, V120, P352, DOI 10.1007/s002210050409; van Donkelaar P, 2006, EXERC SPORT SCI REV, V34, P77, DOI 10.1249/00003677-200604000-00007; van Donkelaar P, 2005, BRAIN INJURY, V19, P1031, DOI 10.1080/02699050500110363; Vandenberghe R, 2001, NEUROIMAGE, V14, P661, DOI 10.1006/nimg.2001.0860; Weerdesteyn V, 2003, J MOTOR BEHAV, V35, P53, DOI 10.1080/00222890309602121; WIJERS AA, 1989, BIOL PSYCHOL, V29, P213, DOI 10.1016/0301-0511(89)90021-5; WIJERS AA, 1987, BIOL PSYCHOL, V25, P33, DOI 10.1016/0301-0511(87)90066-4; Yantis S, 2002, NAT NEUROSCI, V5, P995, DOI 10.1038/nn921	40	39	40	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0014-4819	1432-1106		EXP BRAIN RES	Exp. Brain Res.	MAR	2009	194	1					67	77		10.1007/s00221-008-1669-1			11	Neurosciences	Neurosciences & Neurology	416YR	WOS:000264041900006	19082819				2021-06-18	
J	James, ML; Sullivan, PM; Lascola, CD; Vitek, MP; Laskowitz, DT				James, Michael L.; Sullivan, Patrick M.; Lascola, Christopher D.; Vitek, Michael P.; Laskowitz, Daniel T.			Pharmacogenomic Effects of Apolipoprotein E on Intracerebral Hemorrhage	STROKE			English	Article						apolipoprotein E; gene therapy; inflammation; intracerebral hemorrhage; mouse	NITRIC-OXIDE PRODUCTION; TRAUMATIC BRAIN-INJURY; APOE GENOTYPE; SUBARACHNOID HEMORRHAGE; TARGETED REPLACEMENT; MIMETIC PEPTIDES; E GENE; EXPRESSION; EDEMA; INFLAMMATION	Background and Purpose-The purpose of the study was to evaluate the effect of APOE genotype and the feasibility of administering an apolipoprotein E-mimetic therapeutic to modify outcomes in a murine model of intracerebral hemorrhage. Methods-Intracerebral hemorrhage was induced via stereotactic injection of 0.1 U Clostridial collagenase into the left basal ganglia of wild-type and apolipoprotein-E targeted-replacement mice, consisting of either homozygous 3/3 or 4/4 genotypes. Animals were randomized to receive either vehicle or apolipoprotein E-mimetic peptide. Outcomes included functional neurological tests (21-point neuroseverity score and Rotorod latency) over the initial 7 days after injury, radiographic and histological hemorrhage size at 3 and 7 days, brain water content for cerebral edema at 24 hours, and quantitative polymerase chain reaction for inflammatory markers at 6, 24, and 48 hours. Results-Apolipoprotein-E targeted-replacement mice consisting of homozygous 3/3 demonstrated superior neuroseverity scores and Rotorod latencies over the first 3 days after intracerebral hemorrhage, decreased cerebral edema at 24 hours, and reduced upregulation of IL-6 and endothelial nitric oxide synthase at 6 hours when compared to their apolipoprotein-E targeted-replacement mice consisting of homozygous 4/4 counterparts. After intravenous administration of 1 mg/kg apolipoprotein E-mimetic peptide, both wild-type and apolipoprotein-E targeted-replacement mice consisting of homozygous 4/4 exhibited improved functional outcomes over 7 days after intracerebral hemorrhage, less edema at 24 hours, and reduced upregulation of IL-6 and endothelial nitric oxide synthase when compared to mice that did not receive the peptide. Conclusions-Our data indicate that APOE genotype influences neurological outcome after intracerebral hemorrhage in a murine model. In particular APOE4 is associated with poor functional outcome and increased cerebral edema. Additionally, this outcome can be modified by the addition of an apolipoprotein E mimetic-peptide, COG1410. (Stroke. 2009;40:632-639.)	[James, Michael L.; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; [James, Michael L.; Vitek, Michael P.; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC 27710 USA; [Sullivan, Patrick M.] Duke Univ, Med Ctr, Dept Geriatr Med, Durham, NC 27710 USA; [Vitek, Michael P.; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; [James, Michael L.] Duke Univ, Med Ctr, Dept Surg Neurosurg, Durham, NC 27710 USA; [Lascola, Christopher D.] Duke Univ, Med Ctr, Dept Radiol Neuroradiol, Durham, NC 27710 USA; [James, Michael L.; Lascola, Christopher D.; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Multidisciplinary Neuroprotect Lab, Durham, NC 27710 USA; [Vitek, Michael P.] Cognosci Inc, Morrisville, NC USA	James, ML (corresponding author), Duke Univ, Med Ctr, Dept Anesthesiol, Box 3094, Durham, NC 27710 USA.	james040@mc.duke.edu	James, Michael L./AAJ-5592-2020; Lascola, Christopher D/B-9126-2017; tao, li/G-7956-2011	James, Michael L./0000-0002-8715-5210; Lascola, Christopher D/0000-0002-8031-782X; Vitek, Michael/0000-0001-8140-8048	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1UL1 RR024128-01, 2R44 AG 020473]; Institute for the Study of Aging; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R44AG020473] Funding Source: NIH RePORTER	This study was possible through funding by NIH 1UL1 RR024128-01 (D. T. L.), 2R44 AG 020473 (M. P. V.), and grants from The Institute for the Study of Aging.	ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Aono M, 2003, NEUROSCIENCE, V116, P437, DOI 10.1016/S0306-4522(02)00709-1; Colton CA, 2004, J NEUROIMMUNOL, V147, P62, DOI 10.1016/j.jneuroim.2003.10.015; Colton CA, 2001, BBA-MOL BASIS DIS, V1535, P134, DOI 10.1016/S0925-4439(00)00092-2; Duan RS, 2006, EXP NEUROL, V202, P373, DOI 10.1016/j.expneurol.2006.06.013; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gao J, 2006, NEUROCRIT CARE, V4, P25, DOI 10.1385/NCC:4:1:025; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Grunenfelder J, 2004, J THORAC CARDIOV SUR, V128, P92, DOI 10.1016/j.jtcvs.2004.02.022; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Herz J, 2000, NAT REV NEUROSCI, V1, P51, DOI 10.1038/35036221; Hoe HS, 2006, J BIOL CHEM, V281, P3425, DOI 10.1074/jbc.M509380200; Hoe HS, 2005, J NEUROCHEM, V93, P145, DOI 10.1111/j.1471-4159.2004.03007.x; James ML, 2007, NEUROCRIT CARE; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Martinez-Gonzalez NA, 2006, J NEUROL NEUROSUR PS, V77, P1329, DOI 10.1136/jnnp.2006.097543; McCarron MO, 2003, ACTA NEUROL SCAND, V107, P106, DOI 10.1034/j.1600-0404.2003.01365.x; McCarron MO, 1999, NEUROLOGY, V53, P2176, DOI 10.1212/WNL.53.9.2176; Moretti EW, 2005, CRIT CARE MED, V33, P2521, DOI 10.1097/01.CCM.0000186368.96146.FB; ROSENBERG GA, 1990, ACT NEUR S, V51, P280; Song EC, 2003, STROKE, V34, P2215, DOI 10.1161/01.STR.0000088060.83709.2C; Sullivan PM, 2004, NEUROSCIENCE, V124, P725, DOI 10.1016/j.neuroscience.2003.10.011; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Tlaskowitz D, 2007, PHARMACOGENOMICS, V8, P959, DOI 10.2217/14E22416.8.8.959; Tzourio C, 2008, NEUROLOGY, V70, P1322, DOI 10.1212/01.wnl.0000308819.43401.87; Woo D, 2005, STROKE, V36, P1874, DOI 10.1161/01.STR.0000177891.15082.b9; Xue Mengzhou, 2003, J Stroke Cerebrovasc Dis, V12, P152, DOI 10.1016/S1052-3057(03)00036-3; Zhang XJ, 2006, NEUROL INDIA, V54, P402	32	39	41	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	FEB	2009	40	2					632	639		10.1161/STROKEAHA.108.530402			8	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	399FD	WOS:000262784900046	19109539	Green Accepted, Bronze			2021-06-18	
J	Kraemer, WJ; Spiering, BA; Volek, JS; Martin, GJ; Howard, RL; Ratamess, NA; Hatfield, DL; Vingren, JL; Ho, JY; Fragala, MS; Thomas, GA; French, DN; Anderson, JM; Hakkinen, K; Maresh, CM				Kraemer, William J.; Spiering, Barry A.; Volek, Jeff S.; Martin, Gerard J.; Howard, Robert L.; Ratamess, Nicholas A.; Hatfield, Disa L.; Vingren, Jakob L.; Ho, Jen Yu; Fragala, Maren S.; Thomas, Gwendolyn A.; French, Duncan N.; Anderson, Jeffrey M.; Hakkinen, Keijo; Maresh, Carl M.			RECOVERY FROM A NATIONAL COLLEGIATE ATHLETIC ASSOCIATION DIVISION I FOOTBALL GAME: MUSCLE DAMAGE AND HORMONAL STATUS	JOURNAL OF STRENGTH AND CONDITIONING RESEARCH			English	Article						competition; contact sports; collision injury; endocrine; performance; recovery; skeletal muscle	SALIVA CORTISOL; CREATINE-KINASE; RUGBY MATCH; T/C RATIO; EXERCISE; TESTOSTERONE; PERFORMANCE; RESPONSES; STRENGTH; COMPETITION	Kraemer, WJ, Spiering, BA, Volek, JS, Martin, GJ, Howard, RL, Ratamess, NA, Hatfield, DL, Vingren, JL, Ho, JY, Fragala, MS, Thomas, GA, French, DN, Anderson, JM, Hakkinen, K, and Maresh, CM. Recovery from a National Collegiate Athletic Association Division I football game: muscle damage and hormonal status. J Strength Cond Res 23(1): 2-10, 2009-Recovery from an American football game has had limited study. The purpose of this study was to examine markers of skeletal muscle tissue damage and circulating anabolic and catabolic hormones to gain insight into the recovery process from Friday until Monday, when a new practice week begins. Twenty-eight National Collegiate Athletic Association Division I football players gave consent to participate in the investigation in the ninth game of the season. Sixteen players started the game and played the entire game (PL), and 12 others did not play and were on the bench during the game (DNP). Each player had fasted blood samples obtained at the same time of day between 1000 and 1200 hours the day before the game (Friday; T1), 18-20 hours after the game (Sunday; T2), and then 42-44 hours after the game (Monday; T3). Blood samples were analyzed for concentrations of creatine kinase (CK), lactate dehydrogenase (LDH), myoglobin, testosterone, and cortisol. The PL players showed significantly (p <= 0.05) increased concentrations of CK (T2 > T1 and T3), myoglobin (T2 > T1 and T3), and LDH (T2 > T1). In contrast, DNP players showed significant differences in cortisol (T3 < T1 and T2) and testosterone: cortisol (T3 > T1). Few changes were observed in testosterone and cortisol changes, indicating stability of the anabolic/catabolic hormones. In conclusion, these data indicate that participation in a college football game late in the season results in some degree of tissue damage but with minimal hormonal responses, which seem to have stabilized at resting concentrations without predominance of cortisol's catabolic presence. As previously noted in the literature, some type of "contact adaptation'' to the season may have occurred with regard to tissue damage responses. However, by the ninth game of a season, players do carry soft tissue damage levels above resting ranges into subsequent games, indicating that recovery should be monitored, with coaches being careful with scheduling scrimmage and full-contact drills. How such data implicate overuse injuries remains unclear, considering that hormonal status in this study was highly stable, with catabolic influences minimized by the high level of athlete conditioning. These data again support that high-level conditioning can stabilize anabolic and catabolic hormonal signals and limit acute soft tissue injury, making cerebral concussion (acute and chronic) and traumatic injury the biggest threats to a student-athlete's health and well-being during an American football game.	[Kraemer, William J.; Spiering, Barry A.; Volek, Jeff S.; Howard, Robert L.; Ratamess, Nicholas A.; Hatfield, Disa L.; Vingren, Jakob L.; Ho, Jen Yu; Fragala, Maren S.; Thomas, Gwendolyn A.; French, Duncan N.; Anderson, Jeffrey M.; Maresh, Carl M.] Univ Connecticut, Dept Kinesiol, Human Performance Lab, Storrs, CT 06269 USA; [Howard, Robert L.; Anderson, Jeffrey M.] Univ Connecticut, Dept Sports Med, Storrs, CT USA; [Martin, Gerard J.] Univ Connecticut, Div Athlet, Storrs, CT USA; [Hakkinen, Keijo] Univ Jyvaskyla, Dept Biol Phys Act, Jyvaskyla, Finland; [Hakkinen, Keijo] Univ Jyvaskyla, Neuromuscular Res Ctr, Jyvaskyla, Finland	Kraemer, WJ (corresponding author), Univ Connecticut, Dept Kinesiol, Human Performance Lab, Storrs, CT 06269 USA.	William.Kraemer@uconn.edu					ADLERCREUTZ H, 1986, INT J SPORTS MED, V7, P27; Borsheim E, 2004, J APPL PHYSIOL, V96, P674, DOI 10.1152/japplphysiol.00333.2003; Duda GN, 2008, EXERC SPORT SCI REV, V36, P64, DOI 10.1097/JES.0b013e318168eb88; Ehlers GG, 2002, J ATHL TRAINING, V37, P151; Elloumi M, 2003, EUR J APPL PHYSIOL, V90, P23, DOI 10.1007/s00421-003-0868-5; Ferri A, 2006, EUR J APPL PHYSIOL, V97, P272, DOI 10.1007/s00421-006-0168-y; FRY AC, 1994, MED SCI SPORT EXER, V26, P1165; Garry J P, 2000, MedGenMed, V2, pE4; Gonzalez-Bono E, 1999, HORM BEHAV, V35, P55, DOI 10.1006/hbeh.1998.1496; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Hawke TJ, 2005, EXERC SPORT SCI REV, V33, P63, DOI 10.1097/00003677-200504000-00002; Hoffman JR, 2005, MED SCI SPORT EXER, V37, P1237, DOI 10.1249/01.mss.0000170068.97498.26; Hoffman JR, 2002, MED SCI SPORT EXER, V34, P1845, DOI 10.1097/00005768-200211000-00023; Hubal MJ, 2007, MED SCI SPORT EXER, V39, P461, DOI 10.1249/01.mss.0000247007.19127.da; JAFFE AS, 1984, AM J CARDIOL, V53, P856, DOI 10.1016/0002-9149(84)90419-3; Kraemer WJ, 1997, J STRENGTH COND RES, V11, P131; Kraemer WJ, 2004, J STRENGTH COND RES, V18, P121; Kraemer WJ, 2001, MED SCI SPORT EXER, V33, P1367, DOI 10.1097/00005768-200108000-00019; KRAEMER WJ, 1995, J APPL PHYSIOL, V78, P976; Kraemer WJ, 2000, EXERCISE SPORT SCI, P798; Kvorning T, 2007, J PHYSIOL-LONDON, V578, P579, DOI 10.1113/jphysiol.2006.122671; Kvorning T, 2006, AM J PHYSIOL-ENDOC M, V291, pE1325, DOI 10.1152/ajpendo.00143.2006; Malm C, 2001, ACTA PHYSIOL SCAND, V171, P233, DOI 10.1046/j.1365-201x.2001.00825.x; Moore CA, 2007, J STRENGTH COND RES, V21, P793, DOI 10.1519/r-20906.1; Nosaka K, 1997, J SPORT SCI, V15, P477, DOI 10.1080/026404197367119; Passelergue P, 1999, INT J SPORTS MED, V20, P109; Salvador A, 2003, PSYCHONEUROENDOCRINO, V28, P364, DOI 10.1016/S0306-4530(02)00028-8; Smith JE, 2004, BRIT J SPORT MED, V38, P292, DOI 10.1136/bjsm.2002.002873; Spiering BA, 2008, SPORTS MED, V38, P527, DOI 10.2165/00007256-200838070-00001; Spiering BA, 2008, MED SCI SPORT EXER, V40, P1039, DOI 10.1249/MSS.0b013e31816722bd; Stuart Michael J, 2005, Med Sport Sci, V49, P62, DOI 10.1159/000085392; Takarada Y, 2003, BRIT J SPORT MED, V37, P416, DOI 10.1136/bjsm.37.5.416; Tidball JG, 2002, CLIN ORTHOP RELAT R, pS100, DOI 10.1097/01.blo.0000031311.06353.d6	33	39	41	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1064-8011	1533-4287		J STRENGTH COND RES	J. Strength Cond. Res.	JAN	2009	23	1					2	10		10.1519/JSC.0b013e31819306f2			9	Sport Sciences	Sport Sciences	514NB	WOS:000271400500002	19077734				2021-06-18	
J	Ley, EJ; Scehnet, J; Park, R; Schroff, S; Dagliyan, G; Conti, PS; Margulies, DR; Salim, A				Ley, Eric J.; Scehnet, Jeff; Park, Ryan; Schroff, Stu; Dagliyan, Grant; Conti, Peter S.; Margulies, Daniel R.; Salim, Ali			The In Vivo Effect of Propranolol on Cerebral Perfusion and Hypoxia After Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Trauma; Traumatic brain injury; Beta blocker; Propranolol; Perfusion	BETA-BLOCKER EXPOSURE; HEAD-INJURY; IMPROVED OUTCOMES; IMPROVED SURVIVAL; STROMAL CELLS; IMPACT; TBI; PET	Background. Recent epidemiologic evidence has identified beta-blockade as independently associated with improved survival in patients with isolated traumatic brain injury (TBI). Reduced sympathetic discharge and catecholamine release may improve circulation in the injured areas and influence delayed demise. The purpose of this study was to investigate the cerebral effect of beta-blockade in a murine TBI model using immunohistochemical and microPET analysis. Methods: Balb/c mice underwent TBI as in a previously described model and were randomized to receive treatment with propranolol or placebo in a blinded fashion. Immunofluorescent images were obtained for vessel density (CD31), vessel perfusion (Ricinus communis agglutinin [RCA]-lectin), and cerebral hypoxia (hypoxyprobe-1) and compared by digital quantification. Perfusion measurements were acquired using positron emission tomography microPET scans with [Cu-64]-pyruvaldehyde bis(N-4-methylthiosemicarbazone) ([Cu-64]-PTSM) and converted into standardized uptake values (SUV) for analysis. Results: On immunobistochemical analysis, the normal mouse cerebral perfusion was a quantitated mean of 325 +/- 21), the cerebral perfusion after TBI and treatment with placebo was 113 +/- 25, and the cerebral perfusion after TBI treated with propranolol was 172 +/- 23. Immunohistochemical analysis demonstrated treatment with propranolol improved cerebral perfusion by 152% (p value <0.01) and reduced cerebral hypoxia by 24.2% (p value <0.01) compared with treatment with placebo. MicroPET imaging of the normal mouse brain after injection with placebo measured a SUV of 0.7075 +/- 0.02; the normal mouse brain after treatment with propranolol measured a SUV of 0.400 +/- 0.02. After TBI and treatment with placebo, the SUV reduced to 0395 +/- 0.01; after treatment with propranolol the SUV measured 0.515 +/- 0.04. MicroPET imaging demonstrated propranolol improved cerebral perfusion after TBI to 130% of placebo (p value <0.01). Conclusion: Propranolol in vivo increased cerebral perfusion and decreased cerebral hypoxia. This research demonstrates beta-blockade may prevent additional brain damage after traumatic insult and should be the focus of future clinical trials.	[Ley, Eric J.; Scehnet, Jeff; Park, Ryan; Schroff, Stu; Dagliyan, Grant; Conti, Peter S.; Margulies, Daniel R.; Salim, Ali] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA	Salim, A (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Suite 8215N, Los Angeles, CA 90048 USA.	ali.salim@cshs.org					Alauddin MM, 2007, NUCL MED BIOL, V34, P267, DOI 10.1016/j.nucmedbio.2006.12.009; Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; Chiu W, 2007, J TRAUMA, V63, P510; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; Conti PS, 2008, NUCL MED BIOL, V35, P131, DOI 10.1016/j.nucmedbio.2007.09.003; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; EDVINSSON L, 1979, ACTA PHYSIOL SCAND, V107, P289, DOI 10.1111/j.1748-1716.1979.tb06478.x; Enderson BL, 2007, J TRAUMA, V62, P33; GREEN MA, 1990, J NUCL MED, V31, P1989; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Lewis JS, 1999, J NUCL MED, V40, P177; LIU MY, 1995, J FORMOS MED ASSOC, V94, P386; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Pryor JP, 2007, J TRAUMA, V62, P61; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; Riordan WP, 2007, J TRAUMA, V63, P503, DOI 10.1097/TA.0b013e3181271c34; Salim A, 2008, J TRAUMA, V64, P46, DOI 10.1097/TA.0b013e31815eb15a; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Young H, 1994, J Nucl Biol Med, V38, P89; Zhang ZX, 2008, CYTOTHERAPY, V10, P134, DOI 10.1080/14653240701883061	22	39	40	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2009	66	1					154	161		10.1097/TA.0b013e31819388be			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	395SJ	WOS:000262543500020	19131818				2021-06-18	
J	Silver, JM; Koumaras, B; Meng, XY; Potkin, SG; Reyes, PF; Harvey, PD; Katz, DI; Gunay, I; Arciniegas, DB				Silver, Jonathan M.; Koumaras, Barbara; Meng, Xiangyi; Potkin, Steven G.; Reyes, Patricio F.; Harvey, Philip D.; Katz, Douglas I.; Gunay, Ibrahim; Arciniegas, David B.			Long-term effects of rivastigmine capsules in patients with traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; open-label extension; rivastigmine; safety; efficacy	HEAD-INJURY; CHOLINE-ACETYLTRANSFERASE; ALZHEIMERS-DISEASE; FOLLOW-UP; DYSFUNCTION; FOREBRAIN; ATTENTION; MEMORY	Objective: To investigate the safety, tolerability and efficacy of rivastigmine capsules (3-12 mg/day) in a 26-week, multi-centre, open-label extension of a double-blind study. Methods: Patients with traumatic brain injury (TBI) and persistent cognitive impairment who had received rivastigmine (3-6 mg/day) or placebo for 12 weeks could enter the extension study and receive rivastigmine (12 mg/day). Patients were assessed using a range of cognitive tests including the Hopkins Verbal Learning Test (HVLT) and the Cambridge Neuropsychological Test Automated Battery Rapid Visual Information Processing (CANTAB RVIP) A' sub-test. Safety measures included monitoring of adverse events. Results: In the extension study (n = 127), the mean duration of rivastigmine treatment was 23.8 weeks and the mean final dosage was 7.9 mg/day. Approximately 40% of patients were responders (1.0 SD improvement from baseline) on CANTAB RVIP A' or HVLT total score at week 38 or endpoint. Statistically significant changes from week 12 at week 38 were observed for CANTAB-RVIP A' and HVLT-total word recall for the sub-group of ex-placebo patients with greater severity of initial impairment. The safety profile of rivastigmine capsules was consistent with the label. Conclusions: Treatment with rivastigmine for up to 38 weeks was safe in patients with TBI and cognitive impairment.	[Koumaras, Barbara; Meng, Xiangyi; Gunay, Ibrahim] Novartis Pharmaceut, E Hanover, NJ 07936 USA; [Silver, Jonathan M.] NYU, Sch Med, New York, NY USA; [Potkin, Steven G.] Univ Calif, Irvine Med Ctr, Orange, CA USA; [Reyes, Patricio F.] Creighton Univ, Sch Med, Omaha, NE USA; [Harvey, Philip D.] Mt Sinai Sch Med, New York, NY USA; [Katz, Douglas I.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Katz, Douglas I.] Braintree Rehabil Hosp, Braintree, MA USA; [Arciniegas, David B.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA; [Arciniegas, David B.] HealthONE Spalding Rehabil Hosp, Aurora, CO USA	Gunay, I (corresponding author), Novartis Pharmaceut, 1 Hlth Plaza, E Hanover, NJ 07936 USA.	ibrahim.gunay@novartis.com	Potkin, Steven G/A-2021-2013; Arciniegas, David/A-3792-2009	Katz, Douglas/0000-0002-7502-8505; Potkin, Steven/0000-0003-1028-1013	Novartis Pharmaceuticals CorporationNovartis	The authors B. Koumaras, X. Meng and I. Gunay are all employees of Novartis Pharmaceuticals Corporation. Dr Harvey was compensated by Novartis Pharmaceuticals during the clinical trial for research assistance. He received no compensation for the preparation of this paper. This study was supported by Novartis Pharmaceuticals Corporation.	Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Arciniegas DB, 2006, BEHAV NEUROL, V17, P25, DOI 10.1155/2006/460592; Arciniegas David B, 2003, Curr Psychiatry Rep, V5, P391, DOI 10.1007/s11920-003-0074-5; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; Corey-Bloom J, 1998, INT J GERIATR PSYCHO, V1, P55; Cummings Jeffrey, 2007, Expert Rev Neurother, V7, P1457, DOI 10.1586/14737175.7.11.1457; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; Dixon CE, 1997, BRAIN RES, V749, P127, DOI 10.1016/S0006-8993(96)01310-8; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Langlois JA, 2006, TRAUMATIC BRAIN INJU; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; *NOV PHARM CORP, 2000, EX RIV TARTR CAPS; Rosler M, 1999, BMJ-BRIT MED J, V318, P633, DOI 10.1136/bmj.318.7184.633; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Shapiro AM, 1999, CLIN NEUROPSYCHOL, V13, P348, DOI 10.1076/clin.13.3.348.1749; Silver JM, 2006, NEUROLOGY, V67, P748, DOI 10.1212/01.wnl.0000234062.98062.e9; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Winblad B, 2007, INT J GERIATR PSYCH, V22, P456, DOI 10.1002/gps.1788; Wood RLI, 2006, J NEUROL NEUROSUR PS, V77, P1180, DOI 10.1136/jnnp.2006.091553; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014	25	39	42	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	2					123	132	PII 908444636	10.1080/02699050802649696			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	403LD	WOS:000263083200006	19191091				2021-06-18	
J	Case, ME				Case, Mary E.			Accidental traumatic head injury in infants and young children	BRAIN PATHOLOGY			English	Article						epidural hemorrhage; head injury; short falls; subdural hemorrhage	EXTRADURAL HEMATOMA; AXONAL INJURY; FALLS	This article will discuss accidental head injuries in infants and young children. The first category of injury is the crushing head injury. Static forces applied slowly to the head result in multiple fractures of the skull and contusions and lacerations of the brain resulting from the bone fragments striking the brain. This article will discuss the subject of short falls in young children and the resulting head injuries. Because falls are frequent events in early life, many cases have been collected and many papers written on the subject. Study of these cases is informative about the injuries likely to occur in these falls. Most often, only a minor contact injury such as scalp bruise or laceration results. In a 2 to 3% of falls, a simple linear skull fracture occurs and the majority of these are uneventful in terms of neurological deficit or intracranial bleeding. In about 1% of the fractures, an epidural or subdural hemorrhage occurs. Each of these forms of contact hemorrhages will be discussed and illustrated. While these are relatively rare injuries, it is essential that they can be identified as consistent with an accidental mechanism so that an erroneous diagnosis of inflicted injury is not made.	St Louis Univ, Sch Med, Dept Pathol, Div Forens Pathol, St Louis, MO 63104 USA	Case, ME (corresponding author), St Louis Univ, Sch Med, Dept Pathol, Div Forens Pathol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	mcase@stlouisco.com					BARLOW B, 1983, J PEDIATR SURG, V18, P509, DOI 10.1016/S0022-3468(83)80210-3; BAYKANER K, 1988, SURG NEUROL, V30, P339, DOI 10.1016/0090-3019(88)90195-4; Bertocci GE, 2003, ARCH PEDIAT ADOL MED, V157, P480, DOI 10.1001/archpedi.157.5.480; CASE MES, 1994, CHILD MALTREATMENT, P75; CHADWICK DL, 1991, J TRAUMA, V31, P1353, DOI 10.1097/00005373-199110000-00006; CHADWICK DL, 1993, J TRAUMA, V35, P968, DOI 10.1097/00005373-199312000-00031; DAWSON SL, 1980, HUM PATHOL, V11, P155, DOI 10.1016/S0046-8177(80)80136-5; Denton S, 2003, AM J FOREN MED PATH, V24, P371, DOI 10.1097/01.paf.0000097851.18478.16; DUHAIME AC, 1995, NEUROSURGERY, V37, P401, DOI 10.1227/00006123-199509000-00005; FREYTAG E, 1963, ARCH PATHOL, V75, P402; HAHN YS, 1988, CHILD NERV SYST, V4, P34; HELFER RE, 1977, PEDIATRICS, V60, P533; HYMEL KP, 1998, CHILD MALTREATMENT, V3, P116, DOI DOI 10.1177/1077559598003002006; JAMIESON KG, 1968, J NEUROSURG, V29, P13, DOI 10.3171/jns.1968.29.1.0013; KRAVITZ H, 1969, PEDIATRICS, V44, P869; LYONS TJ, 1993, PEDIATRICS, V92, P125; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MUSEMECHE CA, 1991, J TRAUMA, V31, P1347, DOI 10.1097/00005373-199110000-00004; NIMITYONGSKUL P, 1987, J PEDIATR ORTHOPED, V7, P184, DOI 10.1097/01241398-198703000-00014; Ommaya AK, 2003, BRIT J NEUROSURG, V17, P201, DOI 10.1080/0268869031000110825; Prasad MR, 1999, J CHILD NEUROL, V14, P496, DOI 10.1177/088307389901400803; RIVAS JJ, 1988, NEUROSURGERY, V23, P44, DOI 10.1227/00006123-198807000-00010; Sauvageau A, 2008, J FORENSIC SCI, V53, P479, DOI 10.1111/j.1556-4029.2008.00664.x; Servadei F, 1997, ACTA NEUROCHIR, V139, P273, DOI 10.1007/BF01808821; WILLIAMS RA, 1991, J TRAUMA, V31, P1350, DOI 10.1097/00005373-199110000-00005	26	39	42	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305	1750-3639		BRAIN PATHOL	Brain Pathol.	OCT	2008	18	4					583	589		10.1111/j.1750-3639.2008.00203.x			7	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	347MW	WOS:000259146700013	18782170				2021-06-18	
J	Numa, R; Kohen, R; Poltyrev, T; Yaka, R				Numa, R.; Kohen, R.; Poltyrev, T.; Yaka, R.			Tempol diminishes cocaine-induced oxidative damage and attenuates the development and expression of behavioral sensitization	NEUROSCIENCE			English	Article						cocaine; oxidative stress; tempol; total antioxidant capacity; behavioral sensitization; antioxidants	CLOSED-HEAD INJURY; RADICAL ABSORBENCY CAPACITY; STABLE NITROXIDE; NITRIC-OXIDE; NORCOCAINE NITROXIDE; REPERFUSION INJURY; REDOX-REGULATION; IN-UTERO; BRAIN; RAT	A variety of mechanisms has been suggested for cocaine toxicity, including the possibility that cocaine induces an increase in oxidative stress (OS) due to excessive oxidation of dopamine (e.g. dopamine quinine), or by redox cycling of cocaine oxidized metabolites. However, the association between oxidative status in the brain and cocaine induced-behavior is poorly understood. Therefore, we examined the ability of the unique antioxidant tempol to attenuate cocaine-induced oxidative damage and behavioral response. Acute cocaine treatment significantly elevated OS markers in prefrontal cortex (PFC) and nucleus accumbens (NAc) in rats, both in slices and following a single cocaine injection, which corresponded with a decrease in total antioxidant capacity JAC). Tempol, at the optimal concentration we determined that was needed to observe an antioxidant non-toxic effect in vitro (1 mM) and in vivo (200 mg/kg), completely abolished the elevation of OS markers and prevented the reduction in TAC in these areas. Importantly, tempol injections, at a dose that does not affect the basal levels of locomotor activity, attenuated both the development and expression of cocaine-induced locomotor sensitization. Finally, in cocaine-sensitized animals, tempol prevented the elevation of OS markers in both PFC and NAc. Our findings suggest that oxidation of specific sites in the brain reward system by cocaine is accompanied with behavioral changes. Tempol has a neuroprotective effect against cocaine toxicity in these regions, and it may be beneficial in the treatment of cocaine addiction. (C) 2008 IBRO. Published by Elsevier Ltd. All rights reserved.	[Numa, R.; Poltyrev, T.; Yaka, R.] Hebrew Univ Jerusalem, Sch Pharm, Fac Med, Dept Pharmacol, IL-91120 Jerusalem, Israel; [Numa, R.; Kohen, R.] Hebrew Univ Jerusalem, Sch Pharm, Fac Med, Dept Pharmaceut, IL-91120 Jerusalem, Israel	Yaka, R (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Fac Med, Dept Pharmacol, IL-91120 Jerusalem, Israel.	yaka@md.huji.ac.il			Israel Science FoundationIsrael Science Foundation [292105]	This research was partially supported by the Israel Science Foundation (R. Y. grant No. 292105). R. Kohen and R. Yaka are affiliated with the David R. Bloom Center for Pharmacy and the Brettler Center for research in molecular pharmacology and therapeutics, School of Pharmacy, The Hebrew University of Jerusalem.	Aronovitch Y, 2007, FREE RADICAL BIO MED, V42, P1317, DOI 10.1016/j.freeradbiomed.2007.01.017; Bashkatova V, 2005, NEUROREPORT, V16, P1217, DOI 10.1097/00001756-200508010-00017; Bashkatova V, 2006, ANN NY ACAD SCI, V1074, P632, DOI 10.1196/annals.1369.061; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; Berridge KC, 1998, BRAIN RES REV, V28, P309, DOI 10.1016/S0165-0173(98)00019-8; BOELSTERLI UA, 1991, ARCH TOXICOL, V65, P351, DOI 10.1007/BF02284256; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAO G, 1995, CLIN CHEM, V41, P1738; Dietrich JB, 2005, NEUROPHARMACOLOGY, V48, P965, DOI 10.1016/j.neuropharm.2005.01.018; Fineschi V, 2001, INT J LEGAL MED, V114, P323, DOI 10.1007/s004140000194; Fraschini C, 2000, CARBOHYD RES, V328, P585, DOI 10.1016/S0008-6215(00)00129-4; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Gilgun-Sherki Y, 2001, NEUROPHARMACOLOGY, V40, P959, DOI 10.1016/S0028-3908(01)00019-3; Girault JA, 2007, CURR OPIN PHARMACOL, V7, P77, DOI 10.1016/j.coph.2006.08.012; Glantz L, 2005, EXP NEUROL, V192, P117, DOI 10.1016/j.expneurol.2004.11.012; HAHN SM, 1995, CAN J PHYSIOL PHARM, V73, P399, DOI 10.1139/y95-051; HAHN SM, 1992, CANCER RES, V52, P1750; Halliwell B, 1999, FREE RADICAL RES, V31, P651, DOI 10.1080/10715769900301221; Hermida-Ameijeiras A, 2004, NEUROCHEM INT, V45, P103, DOI 10.1016/j.neuint.2003.11.018; Israeli A, 2005, FREE RADICAL BIO MED, V38, P317, DOI 10.1016/j.freeradbiomed.2004.09.037; KARMELI F, 1995, GUT, V37, P386, DOI 10.1136/gut.37.3.386; KLOSS MW, 1984, BIOCHEM PHARMACOL, V33, P169, DOI 10.1016/0006-2952(84)90471-4; KLOSS MW, 1984, PSYCHOPHARMACOLOGY, V84, P221, DOI 10.1007/BF00427449; Kovacic P, 2005, MED HYPOTHESES, V64, P350, DOI 10.1016/j.mehy.2004.06.028; Kunz WS, 1999, J NEUROCHEM, V72, P1580, DOI 10.1046/j.1471-4159.1999.721580.x; Kwon TH, 2003, J NEUROTRAUM, V20, P337, DOI 10.1089/089771503765172291; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; Liang QH, 2005, BIOCHEM PHARMACOL, V70, P1371, DOI 10.1016/j.bcp.2005.04.011; Lu L, 2006, TRENDS NEUROSCI, V29, P695, DOI 10.1016/j.tins.2006.10.005; McCubrey JA, 2006, ANTIOXID REDOX SIGN, V8, P1775, DOI 10.1089/ars.2006.8.1775; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; Moor E, 2001, NEUROSCI LETT, V316, P169, DOI 10.1016/S0304-3940(01)02394-1; Moritz F, 2003, J CARDIOVASC PHARM, V42, P642, DOI 10.1097/00005344-200311000-00010; Ndikum-Moffor FM, 1998, J PHARMACOL EXP THER, V284, P413; Nestler EJ, 2004, TRENDS PHARMACOL SCI, V25, P210, DOI 10.1016/j.tips.2004.02.005; NIEHAUS WG, 1968, EUR J BIOCHEM, V6, P126, DOI 10.1111/j.1432-1033.1968.tb00428.x; Nishiyama A, 2004, J AM SOC NEPHROL, V15, P306, DOI 10.1097/01.ASN.0000108523.02100.E0; Ornoy A, 1999, TERATOLOGY, V60, P376, DOI 10.1002/(SICI)1096-9926(199912)60:6<376::AID-TERA10>3.0.CO;2-Q; Prior RL, 2003, J AGR FOOD CHEM, V51, P3273, DOI 10.1021/jf0262256; Rak R, 2000, J NEUROSURG, V92, P646, DOI 10.3171/jns.2000.92.4.0646; Rao RK, 2002, BIOCHEM BIOPH RES CO, V293, P610, DOI 10.1016/S0006-291X(02)00268-1; SAMUNI A, 1988, J BIOL CHEM, V263, P17921; Smythies J, 1998, BBA-GEN SUBJECTS, V1380, P159, DOI 10.1016/S0304-4165(97)00131-1; Soule BP, 2007, FREE RADICAL BIO MED, V42, P1632, DOI 10.1016/j.freeradbiomed.2007.02.030; Thiemermann C, 2003, CRIT CARE MED, V31, pS76, DOI 10.1097/00003246-200301001-00011; Torres M, 2003, BIOFACTORS, V17, P287, DOI 10.1002/biof.5520170128; Vetulani J, 2001, POL J PHARMACOL, V53, P303; Wink DA, 2001, ANTIOXID REDOX SIGN, V3, P203, DOI 10.1089/152308601300185179; Wise RA, 1996, ANNU REV NEUROSCI, V19, P319, DOI 10.1146/annurev.ne.19.030196.001535; Zeltcer G, 1997, FREE RADICAL RES, V27, P627, DOI 10.3109/10715769709097866	53	39	40	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	AUG 26	2008	155	3					649	658		10.1016/j.neuroscience.2008.05.058			10	Neurosciences	Neurosciences & Neurology	344RK	WOS:000258944800010	18619523				2021-06-18	
J	Deshpande, LS; Sun, DA; Sombati, S; Baranova, A; Wilson, MS; Attkisson, E; Hamm, RJ; DeLorenzo, RJ				Deshpande, Laxmikant S.; Sun, David A.; Sombati, Sompong; Baranova, Anya; Wilson, Margaret S.; Attkisson, Elisa; Hamm, Robert J.; DeLorenzo, Robert J.			Alterations in neuronal calcium levels are associated with cognitive deficits after traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						calcium dynamics; Fura-2; acute isolation of hippocampal neurons; morris water maze; neuronal death; Sprague-Dawley rats	GENE-EXPRESSION; CELL-DEATH; HOMEOSTATIC MECHANISMS; HIPPOCAMPAL-NEURONS; MEMORY IMPAIRMENT; HEAD-INJURY; AGED RATS; AREA CA1; CONCUSSION; NIMODIPINE	Traumatic brain injury (TBI) survivors often suffer from a post-traumatic syndrome with deficits in learning and memory. Calcium (Ca2+) has been implicated in the pathophysiology of TBI-induced neuronal death. However, the role of long-term changes in neuronal Call function in surviving neurons and the potential impact on TBI-induced cognitive impairments are less understood. Here we evaluated neuronal death and basal free intracellular Ca2+ ([Ca2+](i)) in acutely isolated rat CA3 hippocampal neurons using the Ca2+ indicator, Fura-2, at seven and thirty days after moderate central fluid percussion injury. In moderate TBI, cognitive deficits as evaluated by the Morris Water Maze (MWM), occur after injury but resolve after several weeks. Using MWM paradigm we compared alterations in [Ca2+](i) and cognitive deficits. Moderate TBI did not cause significant hippocampal neuronal death. However, basal [Ca2+](i) was significantly elevated when measured seven days post-TBI. At the same time, these animals exhibited significant cognitive impairment (F-2,F-25 = 3.43, p < 0.05). When measured 30 days post-TBI, both basal [Ca2+](i) and cognitive functions had returned to normal. Pretreatment with MK-801 blocked this elevation in [Ca2+](i) and also prevented MWM deficits. These studies provide evidence for a link between elevated [Ca2+](i) and altered cognition. Since no significant neuronal death was observed, the alterations in Ca2+ homeostasis in the traumatized, but surviving neurons may play a role in the pathophysiology of cognitive deficits that manifest in the acute setting after TBI and represent a novel target for therapeutic intervention following TBI. (C) 2008 Elsevier Ireland Ltd. All rights reserved.	[Deshpande, Laxmikant S.; Sombati, Sompong; Attkisson, Elisa; DeLorenzo, Robert J.] Virginia Commonwealth Univ, Sch Med, Dept Neurol, Richmond, VA 23298 USA; [DeLorenzo, Robert J.] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; [Baranova, Anya; Hamm, Robert J.] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23298 USA; [Sun, David A.] Vanderbilt Univ, Med Ctr, Dept Neurol Surg, Nashville, TN 37232 USA; [Wilson, Margaret S.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA	DeLorenzo, RJ (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Neurol, POB 980599, Richmond, VA 23298 USA.	rdeloren@hsc.vcu.edu	Deshpande, Laxmikant S./B-7679-2013	Deshpande, Laxmikant S./0000-0003-1491-1561	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052529, U01NS058213, R01NS051505] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 NS058213-04, R01 NS 051505, R01 NS051505, R01 NS051505-03, U01 NS058213-03, R01 NS052529, R01 NS051505-04, U01 NS 058213, R01 NS052529-04, R01 NS 052529, U01 NS058213] Funding Source: Medline		CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Clausen F, 2005, NEUROSURGERY, V57, P154, DOI 10.1227/01.NEU.0000163412.07546.57; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; Delorenzo RJ, 1999, NEUROSCIENTIST, V5, P86, DOI 10.1177/107385849900500213; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hong Jun, 2002, Chin J Traumatol, V5, P36; LEVERE TE, 1992, NEUROBIOL AGING, V13, P63, DOI 10.1016/0197-4580(92)90010-U; Lusardi TA, 2003, BIORHEOLOGY, V40, P401; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Macciocchi SN, 1998, CLIN SPORT MED, V17, P27, DOI 10.1016/S0278-5919(05)70058-2; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; Raza M, 2004, P NATL ACAD SCI USA, V101, P17522, DOI 10.1073/pnas.0408155101; Raza M, 2007, NEUROSCI LETT, V418, P77, DOI 10.1016/j.neulet.2007.03.005; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; Tonkikh A, 2006, EXP NEUROL, V197, P291, DOI 10.1016/j.expneurol.2005.06.014; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Veng LM, 2003, MOL BRAIN RES, V110, P193, DOI 10.1016/S0169-328X(02)00643-5; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	36	39	39	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	AUG 15	2008	441	1					115	119		10.1016/j.neulet.2008.05.113			5	Neurosciences	Neurosciences & Neurology	333TD	WOS:000258174400024	18583041	Green Accepted			2021-06-18	
J	Hoane, MR; Pierce, JL; Holland, MA; Anderson, GD				Hoane, M. R.; Pierce, J. L.; Holland, M. A.; Anderson, G. D.			Nicotinamide treatment induces behavioral recovery when administered up to 4 hours following cortical contusion injury in the rat	NEUROSCIENCE			English	Article						traumatic brain injury; therapy; window of opportunity; vitamin; recovery of function	IMPROVES FUNCTIONAL RECOVERY; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; INFARCT VOLUME; PERFORMANCE	Recent studies have demonstrated nicotinamide (NAM), a soluble B-group vitamin, to be an effective treatment in experimental models of traumatic brain injury (TBI). However, research on this compound has been limited to administration regimens starting shortly after injury. This study was conducted to establish the window of opportunity for NAM administration following controlled cortical impact (CCI) injury to the frontal cortex. Groups of rats were assigned to NAM (50 mg/kg), saline (1 ml/kg), or sham conditions and received contusion injuries or sham procedures. Injections of NAM or saline were administered at 15 min, 4 h, or 8 h post-injury, followed by five boosters at 24 h intervals. Following the last injection, blood was taken for serum NAM analysis. Animals were tested on a variety of tasks to assess somatosensory performance (bilateral tactile adhesive removal and vibrissae-forelimb placement) and cognitive performance (reference and working memory) in the Morris water maze. The results of the serum NAM analysis showed that NAM levels were significantly elevated in treated animals. Behavioral analysis on the tactile removal test showed that all NAM-treated groups facilitated recovery of function compared with saline treatment. On the vibrissae-forelimb placing test all NAM-treated groups also were significantly different from the saline-treated group. However, the acquisition of reference memory was only significantly improved in the 15-min and 4-h groups. In the working memory task both the 15-min and 4-h groups also improved working memory compared with saline treatment. The window of opportunity for NAM treatment is task-dependent and extends to 8 h for the sensorimotor tests but only extends to 4 h post-injury in the cognitive tests. These results suggest that a 50 mg/kg treatment regimen starting at the clinically relevant time point of 4 h may result in attenuated injury severity in the human TBI population. (C) 2008 IBRO. Published by Elsevier Ltd. All rights reserved.	[Hoane, M. R.; Pierce, J. L.; Holland, M. A.] So Illinois Univ, Restorat Neurosci Lab, Ctr Integrat Res Cognit & Neural Sci, Dept Psychol, Carbondale, IL 62901 USA; [Anderson, G. D.] Univ Washington, Dept Pharm, Seattle, WA 98195 USA	Hoane, MR (corresponding author), So Illinois Univ, Restorat Neurosci Lab, Ctr Integrat Res Cognit & Neural Sci, Dept Psychol, Life Sci 2,MC 6502, Carbondale, IL 62901 USA.	mhoane@siu.edu		Hoane, Michael/0000-0001-7779-2657	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15 NS045647, R15 NS045647-03] Funding Source: Medline		Ayoub IA, 1999, NEUROSCI LETT, V259, P21, DOI 10.1016/S0304-3940(98)00881-7; Ayoub IA, 2002, NEUROREPORT, V13, P213, DOI 10.1097/00001756-200202110-00008; Burkle A, 2001, CHEMBIOCHEM, V2, P725, DOI 10.1002/1439-7633(20011001)2:10<725::AID-CBIC725>3.0.CO;2-3; Chang ML, 2002, NEUROSCI LETT, V322, P137, DOI 10.1016/S0304-3940(01)02520-4; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Gilligan JE, 1999, MED J AUSTRALIA, V171, P617, DOI 10.5694/j.1326-5377.1999.tb123822.x; Gillmor HA, 1999, BIOMED CHROMATOGR, V13, P360, DOI 10.1002/(SICI)1099-0801(199908)13:5<360::AID-BMC893>3.0.CO;2-S; Hoane MR, 2007, J NEUROTRAUM, V24, P1108, DOI 10.1089/neu.2006.0254; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Hoane MR, 2006, NEUROSCI LETT, V408, P35, DOI 10.1016/j.neulet.2006.07.011; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoane MR, 2005, J NEUROTRAUM, V22, P1112, DOI 10.1089/neu.2005.22.1112; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Holland MA, 2008, J NEUROTRAUM, V25, P140, DOI 10.1089/neu.2007.0312; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li FQ, 2006, CURR MED CHEM, V13, P883, DOI 10.2174/092986706776361058; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Maiese K, 2003, TRENDS PHARMACOL SCI, V24, P228, DOI 10.1016/S0165-6147(03)00078-6; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Sadanaga-Akiyoshi F, 2003, NEUROCHEM RES, V28, P1227, DOI 10.1023/A:1024236614015; Sakakibara Y, 2000, NEUROSCI LETT, V281, P111, DOI 10.1016/S0304-3940(00)00854-5; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Tam D, 2005, ANN NY ACAD SCI, V1053, P258, DOI 10.1196/annals.1344.023; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Woodlee M.T., 2005, BEHAV LAB RAT HDB TE, P129; Yang J, 2002, MINI-REV MED CHEM, V2, P125, DOI 10.2174/1389557024605483	27	39	40	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JUN 26	2008	154	3					861	868		10.1016/j.neuroscience.2008.04.044			8	Neurosciences	Neurosciences & Neurology	319OE	WOS:000257172500001	18514428	Green Accepted			2021-06-18	
J	Bryant, RA; Creamer, M; O'Donnell, ML; Silove, D; McFarlane, AC				Bryant, Richard A.; Creamer, Mark; O'Donnell, Meaghan L.; Silove, Derrick; McFarlane, Alexander C.			A multisite study of the capacity of acute stress disorder diagnosis to predict posttraumatic stress disorder	JOURNAL OF CLINICAL PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; MOTOR-VEHICLE ACCIDENTS; SEPTEMBER-11 TERRORIST ATTACKS; 2-YEAR PROSPECTIVE EVALUATION; NEW-YORK-CITY; BURN INJURY; SELF-REPORT; HEART-RATE; SURVIVORS; PTSD	Objective: Previous studies investigating the relationship between acute stress disorder (ASD) and posuraumatic stress disorder (PTSD) have reported mixed findings and have been flawed by small sample sizes and single sites. This study addresses these limitations by conducting a large-scale and multisite study to evaluate the extent to which ASD predicts subsequent PTSD. Method: Between April 2004 and April 2005, patients admitted consecutively to 4 major trauma hospitals across Australia (N = 597) were randomly selected and assessed for ASD (DSM-IV criteria) during hospital admission (within I month of trauma exposure) and were subsequently reassessed for PTSD 3 months after the initial assessment (N = 507). Results: Thirty-three patients (6%) met criteria for ASD, and 49 patients (10%) met criteria for PTSD at the 3-month follow-up assessment. Fifteen patients (45%) diagnosed with ASD and 34 patients (7%) not diagnosed with ASD subsequently met criteria for PTSD. The positive predictive power of PTSD criteria in the acute phase (0.60) was a better predictor of chronic PTSD than the positive predictive power of ASD (0.46). Conclusions: The majority of people who develop PTSD do not initially meet criteria for ASD. These data challenge the proposition that the ASD diagnosis is an adequate tool to predict chronic PTSD.	[Bryant, Richard A.] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Silove, Derrick] Univ New S Wales, Psychiat Res & Teaching Unit, Sch Psychiat, Sydney, NSW 2052, Australia; [Silove, Derrick] Univ New S Wales, Ctr Populat Mental Hlth Res, Sch Psychiat, Sydney, NSW 2052, Australia; [Creamer, Mark] Univ Melbourne, Australian Ctr Posttraumat Mental Hlth, Melbourne, Vic 3010, Australia; [O'Donnell, Meaghan L.] Univ Melbourne, Dept Psychiat, Melbourne, Vic 3010, Australia; [McFarlane, Alexander C.] Univ Adelaide, Queen Elizabeth Hosp, Adelaide, SA 5005, Australia	Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	r.bryant@unswedu.au	Young, Alexander/A-1523-2009; Bryant, Richard/AAA-6479-2019	Young, Alexander/0000-0002-9367-9213; Bryant, Richard/0000-0002-9607-819X; O'Donnell, Meaghan/0000-0003-4349-0022			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Blanchard EB, 1996, BEHAV RES THER, V34, P775, DOI 10.1016/0005-7967(96)00038-1; Brewin CR, 1999, AM J PSYCHIAT, V156, P360; Bryant RA, 2003, BIOL PSYCHIAT, V53, P789, DOI 10.1016/S0006-3223(02)01895-4; Bryant RA, 2000, J ABNORM PSYCHOL, V109, P341, DOI 10.1037/0021-843X.109.2.341; Bryant RA, 1999, AM J PSYCHIAT, V156, P1780; Bryant RA, 1998, J CONSULT CLIN PSYCH, V66, P862, DOI 10.1037/0022-006X.66.5.862; Bryant RA, 1998, PSYCHOL ASSESSMENT, V10, P215, DOI 10.1037/1040-3590.10.3.215; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 2007, J ANXIETY DISORD, V21, P183, DOI 10.1016/j.janxdis.2006.09.012; CARDENA E, 1993, AM J PSYCHIAT, V150, P474; CREAMER M, 1992, J ABNORM PSYCHOL, V101, P452, DOI 10.1037/0021-843X.101.3.452; Creamer M, 2004, BEHAV RES THER, V42, P315, DOI 10.1016/S0005-7967(03)00141-4; Difede J, 2002, PSYCHOSOM MED, V64, P826, DOI 10.1097/01.PSY.0000024237.11538.08; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; Engelhard IM, 2002, BEHAV RES THER, V40, P1415, DOI 10.1016/S0005-7967(02)00018-9; Fuglsang AK, 2004, NORD J PSYCHIAT, V58, P223, DOI 10.1080/08039480410006278; Fuglsang AK, 2002, PSYCHOTHER PSYCHOSOM, V71, P214; Galea S, 2002, NEW ENGL J MED, V346, P982, DOI 10.1056/NEJMsa013404; Galea S, 2003, AM J EPIDEMIOL, V158, P514, DOI 10.1093/aje/kwg187; GREEN BL, 1990, AM J ORTHOPSYCHIAT, V60, P43, DOI 10.1037/h0079168; Guthrie R, 2000, BEHAV RES THER, V38, P899, DOI 10.1016/S0005-7967(99)00120-5; Harvey AG, 1999, J CONSULT CLIN PSYCH, V67, P985, DOI 10.1037/0022-006X.67.6.985; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Harvey AG, 2002, PSYCHOL BULL, V128, P886, DOI 10.1037//0033-2909.128.6.886; HERMAN JL, 1989, AM J PSYCHIAT, V146, P490; Holeva V, 2001, BEHAV THER, V32, P65, DOI 10.1016/S0005-7894(01)80044-7; Kangas M, 2005, J CONSULT CLIN PSYCH, V73, P360, DOI 10.1037/0022-006X.73.2.360; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KOOPMAN C, 1994, AM J PSYCHIAT, V151, P888; Koren D, 2002, AM J PSYCHIAT, V159, P855, DOI 10.1176/appi.ajp.159.5.855; MARMAR CR, 1994, AM J PSYCHIAT, V151, P902; MCFARLANE AC, 1988, J NERV MENT DIS, V176, P30, DOI 10.1097/00005053-198801000-00004; MCFARLANE AC, 1992, J NERV MENT DIS, V180, P439, DOI 10.1097/00005053-199207000-00006; Murray J, 2002, BRIT J PSYCHIAT, V180, P363, DOI 10.1192/bjp.180.4.363; O'Donnell ML, 2007, J TRAUMA STRESS, V20, P173, DOI 10.1002/jts.20198; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; PAULSEN AS, 1988, ARCH GEN PSYCHIAT, V45, P62; PERRY S, 1992, AM J PSYCHIAT, V149, P931; RIGGS DS, 1995, J INTERPERS VIOLENCE, V10, P201, DOI 10.1177/0886260595010002005; ROTHBAUM BO, 1992, J TRAUMA STRESS, V5, P455, DOI 10.1007/BF00977239; SHALEV AY, 1992, J NERV MENT DIS, V180, P505, DOI 10.1097/00005053-199208000-00005; Shalev AY, 1998, ARCH GEN PSYCHIAT, V55, P553, DOI 10.1001/archpsyc.55.6.553; Shalev AY, 1997, BRIT J PSYCHIAT, V170, P558, DOI 10.1192/bjp.170.6.558; Shalev AY, 1996, AM J PSYCHIAT, V153, P219; Shalev AY, 1998, AM J PSYCHIAT, V155, P630, DOI 10.1176/ajp.155.5.630; Silove D, 2003, J NERV MENT DIS, V191, P604, DOI 10.1097/01.nmd.0000087187.13408.e1; SOLOMON Z, 1989, PSYCHIATRY, V52, P428, DOI 10.1080/00332747.1989.11024467; Spitzer RL, 2007, J ANXIETY DISORD, V21, P233, DOI 10.1016/j.janxdis.2006.09.006; Staab JP, 1996, ANXIETY, V2, P219, DOI 10.1002/(SICI)1522-7154(1996)2:5<219::AID-ANXI3>3.0.CO;2-H; WEISAETH L, 1989, ACTA PSYCHIAT SCAND, V80, P25, DOI 10.1111/j.1600-0447.1989.tb05251.x; WELLS KB, 1988, J PSYCHIAT RES, V22, P207, DOI 10.1016/0022-3956(88)90006-4; Zatzick DF, 2005, BIOL PSYCHIAT, V57, P91, DOI 10.1016/j.biopsych.2004.10.005; ZATZICK DF, 1994, J NERV MENT DIS, V182, P576, DOI 10.1097/00005053-199410000-00008; Zatzick DF, 2002, AM J PSYCHIAT, V159, P941, DOI 10.1176/appi.ajp.159.6.941	60	39	39	1	9	PHYSICIANS POSTGRADUATE PRESS	MEMPHIS	P O BOX 752870, MEMPHIS, TN 38175-2870 USA	0160-6689	1555-2101		J CLIN PSYCHIAT	J. Clin. Psychiatry	JUN	2008	69	6					923	929		10.4088/JCP.v69n0606			7	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	318LI	WOS:000257092800006	18422396				2021-06-18	
J	Kivlin, JD; Currie, ML; Greenbaum, VJ; Simons, KB; Jentzen, J				Kivlin, Jane D.; Currie, Melissa L.; Greenbaum, V. Jordan; Simons, Kenneth B.; Jentzen, Jeffrey			Retinal hemorrhages in children following fatal motor vehicle crashes - A case series	ARCHIVES OF OPHTHALMOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; SHAKEN-BABY-SYNDROME; PEDIATRIC HEAD-INJURIES; YOUNG-CHILDREN; ABUSE VICTIMS; CARDIOPULMONARY-RESUSCITATION; OPHTHALMOLOGIC FINDINGS; VALSALVA RETINOPATHY; NONACCIDENTAL INJURY; SUBDURAL HEMATOMAS	Objective: To demonstrate the severity of ocular findings in young children who died of injuries due to motor vehicle crashes. Methods: Case series of 10 children younger than 3 years who were fatally injured in motor vehicle crashes between January 1, 1994, and December 31, 2002. All children underwent autopsy that included eye examination. All available medical and autopsy records, pathology slides and photographs, and police and traffic department reports were reviewed for each case. Results: Eight patients had retinal hemorrhages, which extended into the periphery in 13 eyes and were bilateral in 7 patients. Three patients had elevated circular retinal folds. Six patients had hemorrhages below the internal limiting membrane, but no patients had deeper splitting of the retina. Nine patients had optic nerve sheath hemorrhages. Conclusion: The association of extensive, sometimes severe, ocular hemorrhages with fatal accidental trauma, compared with previous reports of accidental trauma with no or few hemorrhages, indicates the severity of injury required to cause hemorrhages of this magnitude.	[Kivlin, Jane D.; Simons, Kenneth B.] Med Coll Wisconsin, Dept Ophthalmol, Milwaukee, WI 53226 USA; [Simons, Kenneth B.; Jentzen, Jeffrey] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA; [Jentzen, Jeffrey] Milwaukee Cty Med Examiners Off, Milwaukee, WI USA; [Currie, Melissa L.] Univ Louisville, Dept Pediat, Louisville, KY 40292 USA; [Greenbaum, V. Jordan] Childrens Healthcare Atlanta, Atlanta, GA USA	Kivlin, JD (corresponding author), Med Coll Wisconsin, Dept Ophthalmol, 925 N 87th St, Milwaukee, WI 53226 USA.	jkivlin@mcw.edu					Adams G, 2004, EYE, V18, P795, DOI 10.1038/sj.eye.6701643; ALARIO A, 1990, AJDC, V140, P445; Bechtel K, 2005, PEDIATRICS, V115, P192, DOI 10.1542/peds.2004-2150; Bechtel K, 2004, PEDIATRICS, V114, P165, DOI 10.1542/peds.114.1.165; Betz P, 1996, FORENSIC SCI INT, V78, P71, DOI 10.1016/0379-0738(95)01866-2; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; BUYS YM, 1992, OPHTHALMOLOGY, V99, P1718; Chandra P, 2005, EYE, V19, P914, DOI 10.1038/sj.eye.6701665; Christian CW, 1999, J PEDIATR-US, V135, P125, DOI 10.1016/S0022-3476(99)70343-4; Denton S, 2003, AM J FOREN MED PATH, V24, P371, DOI 10.1097/01.paf.0000097851.18478.16; DiScala C, 2000, ARCH PEDIAT ADOL MED, V154, P16; Duane T D, 1972, Trans Am Ophthalmol Soc, V70, P298; DUHAIME AC, 1992, PEDIATRICS, V90, P179; EISENBREY AB, 1979, CHILD BRAIN, V5, P40; ELDER JE, 1991, J PAEDIATR CHILD H, V27, P286, DOI 10.1111/j.1440-1754.1991.tb02539.x; Emerson MV, 2007, OPHTHALMOLOGY, V114, P1384, DOI 10.1016/j.ophtha.2007.04.015; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GILLILAND MGF, 1994, FORENSIC SCI INT, V68, P117, DOI 10.1016/0379-0738(94)90309-3; Gilliland MGF, 1996, J FORENSIC SCI, V41, P114; GILLILAND MGF, 1993, AM J FOREN MED PATH, V14, P187, DOI 10.1097/00000433-199309000-00003; Gnanaraj L, 2007, EYE, V21, P5, DOI 10.1038/sj.eye.6702174; GOETTING MG, 1990, PEDIATRICS, V85, P585; Goldman M, 2006, J PEDIATR-US, V148, P835, DOI 10.1016/j.jpeds.2005.12.052; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P1328, DOI 10.1097/00003246-199309000-00016; Green MA, 1996, BRIT J OPHTHALMOL, V80, P282, DOI 10.1136/bjo.80.4.282; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HANIGAN WC, 1987, PEDIATRICS, V80, P618; Herr S, 2004, PEDIATRICS, V113, P1658, DOI 10.1542/peds.113.6.1658; JOHNSON DL, 1993, NEUROSURGERY, V33, P231; KANTER RK, 1986, J PEDIATR-US, V108, P430, DOI 10.1016/S0022-3476(86)80890-3; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; KOSER M, 1995, ARCH PEDIAT ADOL MED, V149, P1275, DOI 10.1001/archpedi.1995.02170240093016; Lantz PE, 2004, BRIT MED J, V328, P754, DOI 10.1136/bmj.328.7442.754; Levin AV, 2000, RECENT ADV PAEDIAT, P151; Lueder GT, 2006, ARCH OPHTHALMOL-CHIC, V124, P1782, DOI 10.1001/archopht.124.12.1782; LUERSSEN TG, 1991, CONC PED N, V11, P87; MASSICOTTE SJ, 1991, OPHTHALMOLOGY, V98, P1124; Mehlman CT, 2000, J BONE JOINT SURG AM, V82A, P895, DOI 10.2106/00004623-200006000-00021; Meier P, 2005, GRAEF ARCH CLIN EXP, V243, P824, DOI 10.1007/s00417-005-1213-y; Mills M, 1998, J AAPOS, V2, P67, DOI 10.1016/S1091-8531(98)90066-0; MORRIS R, 1994, OPHTHALMOLOGY, V1, P101; Ness T, 2005, GRAEF ARCH CLIN EXP, V243, P859, DOI 10.1007/s00417-005-1131-z; OBI E, 2007, J AAPOS, V11, P99, DOI DOI 10.1016/J.JAAPOS.2007.01.031; Odom A, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.6.e3; Pierre-Kahn V, 2003, OPHTHALMOLOGY, V110, P1718, DOI 10.1016/S0161-6420(03)00581-5; Plunkett J, 2001, AM J FOREN MED PATH, V22, P417, DOI 10.1097/00000433-200112000-00020; Plunkett J, 2001, AM J FOREN MED PATH, V22, P1, DOI 10.1097/00000433-200103000-00001; RAO N, 1988, FORENSIC SCI INT, V39, P293, DOI 10.1016/0379-0738(88)90133-8; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; REIBER GD, 1993, AM J FOREN MED PATH, V14, P201, DOI 10.1097/00000433-199309000-00005; RIFFENBURGH RS, 1991, J FORENSIC SCI, V36, P741; RIFFENBURGH RS, 1991, OPHTHALMOLOGY, V98, P1519; Sandramouli S, 1997, ARCH DIS CHILD, V76, P449, DOI 10.1136/adc.76.5.449; Schloff S, 2002, OPHTHALMOLOGY, V109, P1472, DOI 10.1016/S0161-6420(02)01086-2; SEBAG J, 1991, ARCH OPHTHALMOL-CHIC, V109, P966, DOI 10.1001/archopht.1991.01080070078039; Shugerman RP, 1996, PEDIATRICS, V97, P664; Shukla D, 2005, AM J OPHTHALMOL, V140, P134, DOI 10.1016/j.ajo.2004.12.026; Starling SP, 2004, ARCH PEDIAT ADOL MED, V158, P454, DOI 10.1001/archpedi.158.5.454; Vinchon M, 2005, J NEUROSURG, V102, P380, DOI 10.3171/ped.2005.102.4.0380; Vinchon M, 2004, PRESSE MED, V33, P1174, DOI 10.1016/S0755-4982(04)98886-0; Vinchon M, 2002, PEDIATR NEUROSURG, V37, P245, DOI 10.1159/000066216; VINCHON M, 2004, CHILD NERV SYST, V20, P279; Wygnanski-Jaffe T, 2006, AM J OPHTHALMOL, V142, P233, DOI 10.1016/j.ajo.2006.03.038	65	39	41	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0003-9950	1538-3601		ARCH OPHTHALMOL-CHIC	Arch. Ophthalmol.	JUN	2008	126	6					800	804		10.1001/archopht.126.6.800			5	Ophthalmology	Ophthalmology	310RX	WOS:000256548900005	18541842	Bronze			2021-06-18	
J	Yager, PH; You, Z; Qin, T; Kim, HH; Takahashi, K; Ezekowitz, AB; Stahl, GL; Carroll, MC; Whalen, MJ				Yager, Phoebe H.; You, Zerong; Qin, Tao; Kim, Hyung-Hwan; Takahashi, Kazue; Ezekowitz, Alan B.; Stahl, Gregory L.; Carroll, Michael C.; Whalen, Michael J.			Mannose binding lectin gene deficiency increases susceptibility to traumatic brain injury in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cell death; complement; inflammation; lectins; mice; traumatic brain injury	CORTICAL IMPACT INJURY; CLOSED-HEAD INJURY; NITRIC-OXIDE; COMPLEMENT INHIBITION; ISCHEMIA-REPERFUSION; SPATIAL MEMORY; WATER MAZE; RATS; NEURODEGENERATION; DISEASE	Mannose binding lectin (MBL) initiates complement activation and exacerbates tissue damage after systemic ischemia/reperfusion. We tested the hypothesis that MBL activates complement and worsens outcome using two levels of controlled cortical impact (CCI) in mice. After moderate CCI (0.6 mm depth), MBL immunostaining was detected on injured endothelial cells of wild-type (WT) mice and C3d was detected in MBL KO (deficient in MBL A/C) and WT mice, suggesting that MBL is dispensable for terminal complement activation after CCI. Brain neutrophils, edema, blood-brain barrier permeability, gross histopathology, and motor dysfunction were similar in injured MBL KO and WT mice. In mice subjected to mild CCI (0.2 mm), MBL KO mice had almost two-fold increased acute CA3 cell degeneration at 6 h (P< 0.01 versus WT). Naive MBL KO mice had decreased brain volume but performed similar to WT mice in two distinct Morris water maze (MWM) paradigms. However, injured MBL KO mice had impaired performance in cued platform trials (P< 0.05 versus WT), suggesting a transient nonspatial learning deficit in injured MBL KO mice. The data suggest that MBL deficiency increases susceptibility to CCI through C3-independent mechanisms and that MBL-deficient patients may be at increased risk of poor outcome after traumatic brain injury.	[Yager, Phoebe H.; You, Zerong; Whalen, Michael J.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Charlestown, MA USA; [Yager, Phoebe H.; You, Zerong; Qin, Tao; Whalen, Michael J.] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Neurosci, Charlestown, MA USA; [Kim, Hyung-Hwan] Harvard Med Sch, Brigham & Womens Hosp, Vasc Med Res Unit, Boston, MA USA; [Takahashi, Kazue; Ezekowitz, Alan B.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pediat, Dev Immunol Lab, Charlestown, MA USA; [Stahl, Gregory L.] Harvard Med Sch, Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA USA; [Carroll, Michael C.] Harvard Med Sch, CBR Inst Biomed Res Inc, Boston, MA USA	Whalen, MJ (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Charlestown, MA USA.	mwhalen@partners.org		Stahl, Gregory/0000-0002-4805-8119	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R29HL052886, R01HL052886, R01HL056086, R56HL056086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R21AI042788, R01AI042788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047447, P30NS045776] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL56086, HL52886] Funding Source: Medline; NIAID NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [AI42788-04] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30 NS045776, R01NS47447] Funding Source: Medline		Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Chan RK, 2006, J IMMUNOL, V177, P8080, DOI 10.4049/jimmunol.177.11.8080; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; de la Torre JC, 2005, J CEREBR BLOOD F MET, V25, P663, DOI 10.1038/sj.jcbfm.9600057; Garthwaite G, 2006, J NEUROSCI, V26, P7730, DOI 10.1523/JNEUROSCI.1528-06.2006; Gerlai RT, 2002, BRAIN RES BULL, V57, P3, DOI 10.1016/S0361-9230(01)00630-X; Gong MN, 2007, CRIT CARE MED, V35, P48, DOI 10.1097/01.CCM.0000251132.10689.F3; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Han SH, 2000, ANN NY ACAD SCI, V903, P357, DOI 10.1111/j.1749-6632.2000.tb06387.x; Hart ML, 2005, J IMMUNOL, V174, P6373, DOI 10.4049/jimmunol.174.10.6373; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; LEHMANN S, 1993, BRAIN RES BULL, V30, P515, DOI 10.1016/0361-9230(93)90286-K; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Liu H, 2001, SCAND J IMMUNOL, V53, P489, DOI 10.1046/j.1365-3083.2001.00908.x; Madsen HO, 1998, J IMMUNOL, V161, P3169; Micheau J, 2004, BEHAV NEUROSCI, V118, P1022, DOI 10.1037/0735-7044.118.5.1022; Moller-Kristensen M, 2006, J IMMUNOL, V176, P1769, DOI 10.4049/jimmunol.176.3.1769; Moller-Kristensen M, 2005, SCAND J IMMUNOL, V61, P426, DOI 10.1111/j.1365-3083.2005.01591.x; Moller-Kristensen M, 2007, J INVEST DERMATOL, V127, P1524, DOI 10.1038/sj.jid.5700748; Otani N, 2006, J CLIN NEUROSCI, V13, P934, DOI 10.1016/j.jocn.2005.10.018; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Shi L, 2004, J EXP MED, V199, P1379, DOI 10.1084/jem.20032207; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Sorensen R, 2005, SPRINGER SEMIN IMMUN, V27, P299, DOI 10.1007/s00281-005-0006-z; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Steffensen R, 2000, J IMMUNOL METHODS, V241, P33, DOI 10.1016/S0022-1759(00)00198-8; Takahashi K, 2006, CURR OPIN IMMUNOL, V18, P16, DOI 10.1016/j.coi.2005.11.014; Tong XK, 2005, J NEUROSCI, V25, P11165, DOI 10.1523/JNEUROSCI.4031-05.2005; Wagner S, 2003, J IMMUNOL, V170, P1462, DOI 10.4049/jimmunol.170.3.1462; Walsh MC, 2005, J IMMUNOL, V175, P541, DOI 10.4049/jimmunol.175.1.541; Wang YM, 2006, BRAIN RES, V1115, P186, DOI 10.1016/j.brainres.2006.07.060; Wellmer A, 2000, NEUROSCI LETT, V296, P137, DOI 10.1016/S0304-3940(00)01645-1; White MK, 2002, EXP CELL RES, V280, P270, DOI 10.1006/excr.2002.5646; You ZR, 2007, J CEREBR BLOOD F MET, V27, P1954, DOI 10.1038/sj.jcbfm.9600497; Zanetta J P, 2003, Prog Mol Subcell Biol, V32, P75; Zhang M, 2006, J IMMUNOL, V177, P4727, DOI 10.4049/jimmunol.177.7.4727	42	39	39	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2008	28	5					1030	1039		10.1038/sj.jcbfm.9600605			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	292JC	WOS:000255261300017	18183030	Bronze			2021-06-18	
J	Runyan, DK				Runyan, Desmond K.			The challenges of assessing the incidence of inflicted traumatic brain injury - A world perspective	AMERICAN JOURNAL OF PREVENTIVE MEDICINE			English	Article							SHAKEN BABY SYNDROME; CHILDREN	Objective: Commentary on the methods available for ascertaining the incidence of inflicted traumatic brain injury (inflicted TBI) and the difficulties involved in defining and measuring this condition in young children. Design: Review of published and unpublished international data regarding parental shaking of infants compared to studies assessing incidence. Results: Review of parental report data reveal that the shaking of young children is a surprisingly common act in a wide variety of countries and cultures. While 2.6% of parents of children aged under 2 years in the U.S. report shaking their child as an act of "discipline," survey data from lesser-developed countries on four continents indicate that shaking, as a form of discipline, may be many times more common among infants in their countries and that the consequences, short of hospitalization or death, are inadequately studied. Methodologic challenges to epidemiologic work to develop better estimates are discussed. Conclusions: These data highlight the challenges faced in ascertaining the epidemiology of inflicted TBI in young children. While there is scientific evidence that the shaking of young children can produce profound destruction of children's brains and lives, these data reveal that there are many other children who are shaken by their caregivers but escape the acute clinical presentation of "shaken baby syndrome" or for whom the injuries are not recognized as due to inflicted TBI. The impact of these private acts must be further studied as there may be other long-lasting and serious intracranial impacts that have not been characterized.	Univ N Carolina, Dept Social Med, Chapel Hill, NC 27599 USA	Runyan, DK (corresponding author), Univ N Carolina, Dept Social Med, Campus Box 7240, Chapel Hill, NC 27599 USA.	drunyan@unc.edu	Runyan, Desmond/S-3974-2016	Runyan, Desmond/0000-0001-5571-9029			CAFFEY J, 1946, AM J ROENTGENOL, V56, P163; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; *GALL ORG, 1996, DISC CHILDR AM; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Keenan HT, 2004, AM J PREV MED, V26, P189, DOI 10.1016/j.amepre.2003.10.023; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; MINNS R, 2006, SHAKEN BABY SYNDROME; Minns RA, 2005, J ROY COLL PHYS EDIN, V35, P5; Runyan D., 2002, WORLD REPORT VIOLENC; Straus MA, 1998, CHILD ABUSE NEGLECT, V22, P249, DOI 10.1016/S0145-2134(97)00174-9; Theodore AD, 2005, PEDIATRICS, V115, pE331, DOI 10.1542/peds.2004-1033; *UNICEF STAT, 2005, MULT IND CLUST SURV	14	39	39	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0749-3797	1873-2607		AM J PREV MED	Am. J. Prev. Med.	APR	2008	34	4		S			S112	S115		10.1016/j.amepre.2008.01.011			4	Public, Environmental & Occupational Health; Medicine, General & Internal	Public, Environmental & Occupational Health; General & Internal Medicine	279TT	WOS:000254378300003	18374259				2021-06-18	
J	Bochicchio, GV; Lumpkins, K; O'Connor, J; Simard, M; Schaub, S; Conway, A; Bochicchio, K; Scalea, TM				Bochicchio, Grant V.; Lumpkins, Kimberly; O'Connor, James; Simard, Marc; Schaub, Stacey; Conway, Anne; Bochicchio, Kelly; Scalea, Thomas M.			Blast injury in a civilian trauma setting is associated with a delay in diagnosis of traumatic brain injury	AMERICAN SURGEON			English	Article							INDUCED NEUROTRAUMA; UNITED-STATES; OVERPRESSURE; EXPERIENCE; ISRAEL	High-pressure waves (blast) account for the majority of combat injuries and are becoming increasingly common in terrorist attacks. To our knowledge, there are no data evaluating the epidemiology of blast injury in a domestic nonterrorist setting. Data were analyzed retrospectively on patients admitted with any type of blast injury over a 10-year period at a busy urban trauma center. Injuries were classified by etiology of explosion and anatomical location. Eighty-nine cases of blast injury were identified in 57,392 patients (0.2%) treated over the study period. The majority of patients were male (78%) with a mean age of 40 +/- 17 years. The mean Injury Severity Score was 13 +/- 11 with an admission Trauma and Injury Severity Score of 0.9 +/- 0.2 and Revised Trauma Score of 7.5 +/- 0.8. The mean intensive care unit and hospital length of stay was 2 7 days and 4.6 +/- 10 days, respectively, with an overall mortality rate of 4.5 per cent. Private dwelling explosion [n = 31 (35%)] was the most common etiology followed by industrial pressure blast [n = 20 (22%)], industrial gas explosion [n = 16 (18%)], military training-related explosion [n = 15 (17%)], home explosive device [n = 8 (9%)], and fireworks explosion [n = 1 (1%)]. Maxillofacial injuries were the most common injury (n = 78) followed by upper extremity orthopedic (n = 29), head injury (n = 32), abdominal (n = 30), lower extremity orthopedic (n = 29), and thoracic (n = 19). The majority of patients with head injury [28 of 32 (88%)] presented with a Glasgow Coma Scale score of 15. CT scans on admission were initially positive for brain injury in 14 of 28 patients (50%). Seven patients (25%) who did not have a CT scan on admission had a CT performed later in their hospital course as a result of mental status change and were positive for traumatic brain injury (TBI). Three patients (11%) had a negative admission CT with a subsequently positive CT for TBI over the next 48 hours. The remaining four patients (14%) were diagnosed with skull fractures. All patients (n = 4) with an admission Glasgow Coma Scale score of less than 8 died from diffuse axonal injury. Blast injury is a complicated disease process, which may evolve over time, particularly with TBI. The missed injury rate for TBI in patients with a Glasgow Coma Scale score of 15 was 36 per cent. More studies are needed in the area of blast injury to better understand this disease process.	[Bochicchio, Grant V.; Lumpkins, Kimberly; O'Connor, James; Simard, Marc; Schaub, Stacey; Conway, Anne; Bochicchio, Kelly; Scalea, Thomas M.] Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Div Clin & Outcomes Res, Baltimore, MD 21201 USA	Bochicchio, GV (corresponding author), Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Div Clin & Outcomes Res, 22 S Greene St, Baltimore, MD 21201 USA.	gbochicchio@umm.edu		Lumpkins, Kimberly/0000-0002-5236-9411			Almogy G, 2005, ARCH SURG-CHICAGO, V140, P390, DOI 10.1001/archsurg.140.4.390; CEBALLOS JPD, 2005, CRIT CARE MED, V33, pS107; Cernak I, 1999, WORLD J SURG, V23, P44, DOI 10.1007/s002689900563; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; *DEP JUST, 1997 REP AV BOMBM IN; Helling ER, 2004, MIL MED, V169, P872, DOI 10.7205/MILMED.169.11.872; Kapur GB, 2005, J TRAUMA, V59, P1436, DOI 10.1097/01.ta.0000197853.49084.3c; LEVI L, 1990, ISRAEL J MED SCI, V26, P555; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Mallonee S, 1996, JAMA-J AM MED ASSOC, V276, P382, DOI 10.1001/jama.276.5.382; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Mine Safety and Health Administration- United States Department of Labor, HIST DAT MIN DIS US; Noji EK, 2005, MIL MED, V170, P595, DOI 10.7205/MILMED.170.7.595; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Peleg K, 2004, ANN SURG, V239, P311, DOI 10.1097/01.sla.0000114012.84732.be; Petras JM, 1997, TOXICOLOGY, V121, P41, DOI 10.1016/S0300-483X(97)03654-8; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Wightman JM, 2001, ANN EMERG MED, V37, P664, DOI 10.1067/mem.2001.114906	19	39	42	0	8	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA	0003-1348			AM SURGEON	Am. Surg.	MAR	2008	74	3					267	270					4	Surgery	Surgery	267OR	WOS:000253519000019	18376697				2021-06-18	
J	Milman, A; Zohar, O; Maayan, R; Weizman, R; Pick, CG				Milman, A.; Zohar, O.; Maayan, R.; Weizman, R.; Pick, C. G.			DHEAS repeated treatment improves cognitive and behavioral deficits after mild traumatic brain injury	EUROPEAN NEUROPSYCHOPHARMACOLOGY			English	Article						cognitive deficits; closed head trauma model; depressive-tike behavior; mild traumatic brain injury (mTBI); dehydroepiandrosterone sulfate (DHEAS)	RIGHT PARIETAL CORTEX; DEHYDROEPIANDROSTERONE-SULFATE; HIPPOCAMPAL-NEURONS; REACTIVE ASTROGLIA; NERVOUS-SYSTEM; MICE; RAT; NEUROSTEROIDS; STEROIDS; PREGNENOLONE	Mild traumatic brain injury (mTBI) is characterized by diffused symptoms, which when combined are called "post-concussion syndrome". Dehydroepiandrosterone sulfate (DHEAS) is a neuroactive neurosteroid. Previously, we have reported that closed head mTBI causes long tasting cognitive deficits and depressive-like behavior. In the present study we describe the effects of DHEAS on the behavior of mice that suffered closed head mTBI. Following the induction of mTBI, mice were treated once a week with DHEAS (s.c. 20 mg/kg) and their performance in the passive avoidance test and the forced swimming test (FST) were evaluated 7, 30, 60 and 90 days post-injury. The most important interactions were between injury and injection (passive avoidance; p<0.001 and FST, p= 0.001), meaning that DHEAS has beneficial effects only when given to injured animals. Our results demonstrate that the tong-term cognitive and behavioral effects induced by mTBI may be improved by a repeated weekly treatment with DHEAS. (c) 2007 Elsevier B.V. and ECNP. All rights reserved.	[Milman, A.; Pick, C. G.] Tel Aviv Univ, Dept Anat & Anthropol, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Zohar, O.] Johns Hopkins Univ, Blanchette Rockfeller Neurosci Inst, Rockville, MD 20850 USA; [Maayan, R.] Tel Aviv Univ, Lab Biol Psychiat, Felsentstein Med Res Ctr, Rabin Med Ctr, Tel Aviv, Israel; [Maayan, R.] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Weizman, R.] Sackler Fac Med, Dept Psychiat, Tel Aviv, Israel; [Weizman, R.] Tel Aviv Community Mental Hlth Ctr, Tel Aviv, Israel	Pick, CG (corresponding author), Tel Aviv Univ, Dept Anat & Anthropol, Sackler Fac Med, IL-69978 Tel Aviv, Israel.	anatmilman@gmail.com; zohar@engram.brni-jhu.org; rmayan@post.tau.ac.il; weizmana@post.tau.ac.il; pickc@post.tau.ac.il	Pick, Chaim/D-4789-2009	Milman, Anat/0000-0002-8551-4101			Avital A, 2006, BRAIN RES BULL, V68, P419, DOI 10.1016/j.brainresbull.2005.09.015; Baulieu EE, 1998, PSYCHONEUROENDOCRINO, V23, P963, DOI 10.1016/S0306-4530(98)00071-7; BOLOGA L, 1987, J NEUROSCI RES, V17, P225, DOI 10.1002/jnr.490170305; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Cardounel A, 1999, P SOC EXP BIOL MED, V222, P145, DOI 10.1046/j.1525-1373.1999.d01-124.x; Compagnone NA, 1998, P NATL ACAD SCI USA, V95, P4678, DOI 10.1073/pnas.95.8.4678; FLOOD JF, 1992, P NATL ACAD SCI USA, V89, P1567, DOI 10.1073/pnas.89.5.1567; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; GORDON G, 1995, ARCH BIOCHEM BIOPHYS, V318, P25, DOI 10.1006/abbi.1995.1199; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hoffman SW, 2003, J NEUROTRAUM, V20, P859, DOI 10.1089/089771503322385791; Hogg S, 1998, BEHAV BRAIN RES, V93, P143, DOI 10.1016/S0166-4328(97)00146-0; Hogg S, 1998, BEHAV BRAIN RES, V93, P157, DOI 10.1016/S0166-4328(97)00145-9; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Jorge R, 2003, INT REV PSYCHIATR, V15, P317, DOI 10.1080/09540260310001606700; Juhasz-Vedres G, 2006, ENDOCRINOLOGY, V147, P683, DOI 10.1210/en.2005-0693; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kimonides VG, 1998, P NATL ACAD SCI USA, V95, P1852, DOI 10.1073/pnas.95.4.1852; Lapchak PA, 2001, INT REV NEUROBIOL, V46, P379; LeRoux PD, 1996, EXP NEUROL, V137, P49, DOI 10.1006/exnr.1996.0006; Maayan R, 2005, NEUROSCI LETT, V377, P130, DOI 10.1016/j.neulet.2004.11.086; Malik AS, 2003, J NEUROTRAUM, V20, P463, DOI 10.1089/089771503765355531; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; Prasad A, 1997, PHYSIOL BEHAV, V62, P1053, DOI 10.1016/S0031-9384(97)00239-4; Reddy DS, 1998, NEUROREPORT, V9, P3069, DOI 10.1097/00001756-199809140-00028; Reddy DS, 1998, BRAIN RES, V799, P215, DOI 10.1016/S0006-8993(98)00419-3; Reddy DS, 1998, BRAIN RES, V791, P108, DOI 10.1016/S0006-8993(98)00085-7; Rupprecht R, 2003, PSYCHONEUROENDOCRINO, V28, P139, DOI 10.1016/S0306-4530(02)00064-1; Schumacher M, 2000, J NEUROCYTOL, V29, P307, DOI 10.1023/A:1007152904926; Schwartz AG, 2004, AGEING RES REV, V3, P171, DOI 10.1016/j.arr.2003.05.001; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Vallee M, 2001, BRAIN RES REV, V37, P301, DOI 10.1016/S0165-0173(01)00135-7; Wolf OT, 1999, BRAIN RES REV, V30, P264, DOI 10.1016/S0165-0173(99)00021-1; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	37	39	40	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0924-977X	1873-7862		EUR NEUROPSYCHOPHARM	Eur. Neuropsychopharmacol.	MAR	2008	18	3					181	187		10.1016/j.euroneuro.2007.05.007			7	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	265AA	WOS:000253330300003	17669633				2021-06-18	
J	Feighery, L; Smyth, A; Keely, S; Baird, AW; O'Connor, WT; Callanan, JJ; Brayden, DJ				Feighery, Linda; Smyth, Aoife; Keely, Simon; Baird, Alan W.; O'Connor, William T.; Callanan, John J.; Brayden, David J.			Increased intestinal permeability in rats subjected to traumatic frontal lobe percussion brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	44th Annual Meeting of the American-Society-for-Cell-Biology	DEC 04-08, 2004	Washington, DC	Amer Soc Cell Biol		traumatic brain injury; intestinal permeability; gut-brain axis	TIGHT JUNCTION PERMEABILITY; BACTERIAL TRANSLOCATION; BARRIER DYSFUNCTION; CHLORIDE SECRETION; IN-VITRO; TRANSPORT; SODIUM; MUCOSA; PATHOGENESIS; JEJUNUM	Background: Dysfunction of the gastrointestinal tract is a common occurrence after traumatic brain injury (TBI). We hypothesized that increased intestinal permeability may result from a precisely controlled percussion injury to the exposed brains of anesthetized rats and that such an effect could be assessed in vitro using excised intestinal mucosae mounted in Ussing chambers. Methods: After craniotomy over the left medial prefrontal cortex on anesthetized rats, neurotrauma was produced using a pneumatically driven impactor on the exposed brain. Control rats were subjected to identical procedures but did not receive an impact. Muscle-stripped rat intestinal ileal and colonic segments were mounted in Ussing chambers within 30 minutes of death. Transepithelial electrical resistance (TEER) and the apparent permeability coefficient (Papp) of [C-14]-mannitol were recorded from intestinal tissue for 120 minutes. Histopathologic analysis was also performed to determine any gross morphologic changes in the intestine. Results: Ileal and colonic mucosae showed no differences in TEER in ileum or colon of TBI rats compared with controls. The Papp of mannitol was significantly increased in ilea from rats previously exposed to TBI compared with controls. Histologic analysis showed gross changes to 50% of the ileal but not the colonic sections from TBI rats. Conclusion: TBI results in significantly reduced ileal barrier function, most likely mediated by open tight junctions. For patients with acute head injury, this may have implications for subsequent oral absorption of nutrients. Systemic delivery of luminal endotoxins may contribute to multiple organ failure.	[Feighery, Linda; Smyth, Aoife; Keely, Simon; Baird, Alan W.; O'Connor, William T.; Callanan, John J.; Brayden, David J.] Univ Coll Dublin, UCD Conway Inst, Dublin 4, Ireland; [Feighery, Linda; Smyth, Aoife; Keely, Simon; Baird, Alan W.; O'Connor, William T.; Callanan, John J.; Brayden, David J.] Univ Coll Dublin, Sch Agr Food Sci & Vet Med, Dublin 4, Ireland	Brayden, DJ (corresponding author), Univ Coll Dublin, UCD Conway Inst, Vet Sci Bldg, Dublin 4, Ireland.	david.brayden@ucd.ie	O'Connor, William T./I-7459-2015; Brayden, David J/J-3215-2019; Keely, Simon/AAV-9973-2020	Brayden, David J/0000-0002-8781-8344; Keely, Simon/0000-0002-1248-9590; Baird, Alan/0000-0002-3926-9838; Callanan, John/0000-0003-4356-1783; O'Connor, William/0000-0003-0082-1119			ADEKOYA N, 2004, MMWR SURVEIL SUMM, V51, P1; Aydin S, 2005, SURG TODAY, V35, P751, DOI 10.1007/s00595-005-3034-3; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; Brayden D, 1997, PHARM RES-DORDR, V14, P1772, DOI 10.1023/A:1012192115828; Castillo L, 1999, REV MED CHILE, V127, P639; Clayburgh DR, 2005, J CLIN INVEST, V115, P2702, DOI 10.1172/JCI24970; CUTHBERT AW, 1987, BRIT J PHARMACOL, V91, P503, DOI 10.1111/j.1476-5381.1987.tb11243.x; CUTHBERT AW, 1982, BRIT J PHARMACOL, V75, P587, DOI 10.1111/j.1476-5381.1982.tb09178.x; Dublineau I, 1998, DIGEST DIS SCI, V43, P652, DOI 10.1023/A:1018839930552; Fink MP, 2005, CRIT CARE CLIN, V21, P177, DOI 10.1016/j.ccc.2005.01.005; GAO J, 2000, CURR PROTOCOLS PHARM; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Hang CH, 2005, WORLD J GASTROENTERO, V11, P1149, DOI 10.3748/wjg.v11.i8.1149; Hang CH, 2004, WORLD J GASTROENTERO, V10, P875; KAMADA T, 1977, J TRAUMA, V17, P44, DOI 10.1097/00005373-197701000-00006; Kao CH, 1998, AM J GASTROENTEROL, V93, P1108; Kiliaan AJ, 1998, AM J PHYSIOL-GASTR L, V275, pG1037; Lemaire LCJM, 1997, BRIT J SURG, V84, P1340; Lindhardt K, 2003, INT J PHARM, V252, P181, DOI 10.1016/S0378-5173(02)00629-4; Mayer Emeran A., 1999, American Journal of Medicine, V107, p12S; MERTSOLA J, 1991, J INFECT DIS, V164, P353, DOI 10.1093/infdis/164.2.353; NORTON JA, 1988, J NEUROSURG, V68, P62, DOI 10.3171/jns.1988.68.1.0062; PEDOTO MJ, 1995, ARCH PHYS MED REHAB, V76, P871, DOI 10.1016/S0003-9993(95)80555-9; Pilitsis JG, 2001, NEUROL RES, V23, P227, DOI 10.1179/016164101101198389; Rhoney DH, 2002, NEUROL RES, V24, P613, DOI 10.1179/016164102101200456; RUSSELL DH, 1995, SHOCK, V4, P50, DOI 10.1097/00024382-199507000-00008; SARTOR RB, 1995, GASTROENTEROL CLIN N, V24, P475; Saunders PR, 2002, DIGEST DIS SCI, V47, P208, DOI 10.1023/A:1013204612762; SAUNDERS PR, 1994, AM J PHYSIOL, V367, pG794; Schurmann G, 1999, INT J COLORECTAL DIS, V14, P41, DOI 10.1007/s003840050181; SHELDON RJ, 1990, J PHARMACOL EXP THER, V252, P636; Soderholm JD, 2002, GUT, V50, P307, DOI 10.1136/gut.50.3.307; Soderholm JD, 1998, DIGEST DIS SCI, V43, P1547, DOI 10.1023/A:1018823100761; Soni J, 2006, J CONTROL RELEASE, V115, P68, DOI 10.1016/j.jconrel.2006.06.021; Swank GM, 1996, WORLD J SURG, V20, P411, DOI 10.1007/s002689900065; Tsutsumi K, 2003, J PHARM SCI, V92, P344, DOI 10.1002/jps.10278; Van Oudenhove L, 2004, BEST PRACT RES CL GA, V18, P663, DOI 10.1016/j.bpg.2004.04.010; Vyrostek Sara B., 2004, Morbidity and Mortality Weekly Report, V53, P1; Zhong C, 2006, J NEUROCHEM, V97, P1015, DOI 10.1111/j.1471-4159.2006.03786.x	39	39	40	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2008	64	1					131	137		10.1097/TA.0b013e3181568d9f			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	250UE	WOS:000252325700028	18188111				2021-06-18	
J	Schnyder, U; Wittmann, L; Friedrich-Perez, J; Hepp, U; Moergeli, H				Schnyder, Ulrich; Wittmann, Lutz; Friedrich-Perez, Josefina; Hepp, Urs; Moergeli, Hanspeter			Posttraumatic stress disorder following accidental injury: Rule or exception in Switzerland?	PSYCHOTHERAPY AND PSYCHOSOMATICS			English	Article						trauma; accidents, injury; posttraumatic stress disorder; acute stress disorder; traumatic brain injury; language proficiency; sense coherence	MOTOR-VEHICLE ACCIDENTS; TRAUMATIC BRAIN-INJURY; PERITRAUMATIC DISSOCIATION; PTSD SYMPTOMS; PREDICTORS; COHERENCE; SURVIVORS; VICTIMS; ADULTS; SCALE	Background: There is still marked variability in the findings concerning psychiatric disorders associated with traumatic injury. The aim of this study was to determine the incidence of acute stress disorder (ASD) and posttraumatic stress disorder (PTSD) following accidental injuries, and to predict the PTSD symptom level at 6 months, taking into particular consideration the role of pre-existing psychiatric morbidity and insufficient command of the local language. Method: A total of 255 accident survivors who were hospitalized for at least 2 consecutive nights at a Swiss university hospital for treatment of recently acquired physical injuries were interviewed within 2 weeks of the trauma and 6 months after the accident. Patients who did not have a good command of German but were fluent in Italian, Spanish, Portuguese, Serbo-Croatian or Albanian were assessed using interpreters. The main outcome measure was the Clinician-Administered PTSD Scale. Results: Ten patients (3.9%) were diagnosed as having ASD. At 6 months, 8 patients (3.1%) had PTSD. A regression model using 12 potential predictor variables explained 40% of the variance of PTSD symptoms; mild traumatic brain injury ( p < 0.001), pain ( p < 0.05), ASD symptom level ( p < 0.001) and emotional coping ( p = 0.001) predicted higher PTSD symptom levels, while high Sense of Coherence ( p < 0.05) and perceived responsibility for the accident ( p < 0.01) were associated with lower PTSD symptom levels at follow-up. Conclusions: ASD and PTSD seem to occur less frequently following accidental injuries than previously reported in the literature. Pre-existing psychiatric morbidity and lack of proficiency in the locally spoken language do not appear to play an important role in the development of PTSD. Copyright (c) 2008 S. Karger AG, Basel.	[Schnyder, Ulrich; Wittmann, Lutz; Friedrich-Perez, Josefina; Hepp, Urs; Moergeli, Hanspeter] Univ Zurich Hosp, Dept Psychiat, CH-8091 Zurich, Switzerland	Schnyder, U (corresponding author), Univ Zurich Hosp, Dept Psychiat, Culmannstr 8, CH-8091 Zurich, Switzerland.	ulrich.schnyder@psyp.uzh.ch		Schnyder, Ulrich/0000-0003-3556-7990			ANTONOVSKY A, 1993, SOC SCI MED, V36, P725, DOI 10.1016/0277-9536(93)90033-Z; Antonovsky A., 1987, UNRAVELING MYSTERY H; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Blake DD, 1998, CLIN ADM PTSD SCALE; BLANCHARD EB, 1995, J NERV MENT DIS, V183, P495, DOI 10.1097/00005053-199508000-00001; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P626, DOI 10.1001/archpsyc.55.7.626; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Creamer M, 2001, PSYCHOL MED, V31, P1237, DOI 10.1017/S0033291701004287; Creamer M, 1998, AUST PSYCHOL, V33, P125, DOI 10.1080/00050069808257393; Delahanty DL, 1997, J CONSULT CLIN PSYCH, V65, P560, DOI 10.1037/0022-006X.65.4.560; Endler N. S., 2000, COPING HLTH INJURIES; Fedoroff I. C., 2000, BEHAV COGN PSYCHOTH, V28, P5, DOI DOI 10.1017/S1352465800000023; Fuglsang AK, 2002, PSYCHOTHER PSYCHOSOM, V71, P214; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Harvey AG, 1999, J TRAUMA STRESS, V12, P519, DOI 10.1023/A:1024723205259; Harvey AG, 2001, J TRAUMA STRESS, V14, P277, DOI 10.1023/A:1011108816888; Hepp U, 2006, EUR ARCH PSY CLIN N, V256, P151, DOI 10.1007/s00406-005-0621-7; Hepp U, 2005, PSYCHOTHER PSYCHOSOM, V74, P379, DOI 10.1159/000087786; Hickling EJ, 1999, J TRAUMA STRESS, V12, P345, DOI 10.1023/A:1024784711484; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Koren D, 1999, AM J PSYCHIAT, V156, P367; Maier T, 2006, MED HYPOTHESES, V66, P103, DOI 10.1016/j.mehy.2005.07.028; Malt U F, 1992, Psychiatr Med, V10, P135; Marmar Charles R., 1997, P412; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Moore A D, 1994, Int J Rehabil Res, V17, P39, DOI 10.1097/00004356-199403000-00004; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P1390, DOI 10.1176/appi.ajp.161.8.1390; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; Ozer EJ, 2003, PSYCHOL BULL, V129, P52, DOI 10.1037//0033-2909.129.1.52; PEERONIGG A, 2000, ACTA PSYCHIAT SCAND, V101, P46; Schnyder U, 2000, PSYCHOTHER PSYCHOSOM, V69, P296, DOI 10.1159/000012411; Schnyder U, 1999, PSYCHOTHER PSYCHOSOM, V68, P102, DOI 10.1159/000012320; Schnyder U, 2002, J TRAUMA STRESS, V15, P487, DOI 10.1023/A:1020922023090; Schnyder U, 2001, AM J PSYCHIAT, V158, P594, DOI 10.1176/appi.ajp.158.4.594; SCOTT J, 1976, PAIN, V2, P175, DOI 10.1016/0304-3959(76)90113-5; Sijbrandij M, 2006, BRIT J PSYCHIAT, V189, P150, DOI 10.1192/bjp.bp.105.021121; Sommer I, 2004, J PSYCHOSOM RES, V57, P329, DOI 10.1016/j.jpsychores.2004.01.010; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Tabachnick BG, 2013, USING MULTIVARIATE S; TEASDALE G, 1974, LANCET, V2, P81; Ursano RJ, 1999, AM J PSYCHIAT, V156, P1808; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; Wittmann L, 2006, J TRAUMA STRESS, V19, P639, DOI 10.1002/jts.20154	47	39	42	0	13	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0033-3190			PSYCHOTHER PSYCHOSOM	Psychother. Psychosom.	JAN	2008	77	2					111	118		10.1159/000112888			8	Psychiatry; Psychology	Psychiatry; Psychology	262EI	WOS:000253131400006	18230944	Green Accepted			2021-06-18	
J	Sterr, A; Herron, K; Dijk, DJ; Ellis, J				Sterr, Annette; Herron, Katherine; Dijk, Derk-Jan; Ellis, Jason			Time to wake-up: Sleep problems and daytime sleepiness in long-term stroke survivors	BRAIN INJURY			English	Article						sleepiness; sleep disturbance; chronic illness; stroke; well-being	TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; DEPRESSION SCALE; HOSPITAL ANXIETY; INDEX; APNEA; RELIABILITY; INSOMNIA; VALIDITY	Background and purpose: In work with chronic stroke patients the authors observed that patients frequently appear sleepy and often comment on their poor sleep. Sleep difficulties are frequently reported and indeed clinically recognized in the acute phase post-stroke, but little is known about the sleep and daytime sleepiness of chronic stroke patients with sustained disabilities. The latter, however, deserves clarification because sleep is a critical modulator of health, daytime performance and wellbeing. The present study therefore explored the sleep and sleepiness in a chronic stroke population with sustained physical deficits. Methods: An opportunity sample of 20 patients with chronic low-functioning hemiplegia (12 months) completed the Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Medical Outcome Study Short Form 36 and Hospital Anxiety and Depression Scale. Results: Compared to a normative healthy population, long-term stroke survivors reported poorer sleep and greater daytime sleepiness. Increased levels of sleepiness were associated with longer chronicity, whereas nocturnal sleep parameters were not. Conclusions: In line with clinical observations, stroke survivors with sustained physical disabilities report poorer sleep and experience greater levels of sleepiness. Further research in a larger cohort and including objective sleep measures is necessary to investigate the nature and scale of sleep difficulties and daytime sleepiness in more detail so that care and treatment strategies can be developed in due course.	[Sterr, Annette; Herron, Katherine] Univ Surrey, Dept Psychol, Guildford GU2 7XH, Surrey, England; [Dijk, Derk-Jan] Univ Surrey, Surrey Sleep Res Ctr, Guildford GU2 7XH, Surrey, England; [Ellis, Jason] Univ Glasgow, Div Psychol Med, Glasgow G12 8QQ, Lanark, Scotland	Sterr, A (corresponding author), Univ Surrey, Dept Psychol, Guildford GU2 7XH, Surrey, England.	a.sterr@surrey.ac.uk	Dijk, Derk-Jan/D-8387-2011; Ellis, Jason/E-7783-2013	Ellis, Jason/0000-0002-8496-520X; Sterr, Annette/0000-0003-4490-985X	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0200128] Funding Source: Medline		Adamson Joy, 2004, J Stroke Cerebrovasc Dis, V13, P171, DOI 10.1016/j.jstrokecerebrovasdis.2004.06.003; Backhaus J, 2002, J PSYCHOSOM RES, V53, P737, DOI 10.1016/S0022-3999(02)00330-6; Bassetti C, 1999, SLEEP, V22, P217, DOI 10.1093/sleep/22.2.217; Bassetti CL, 2005, SEMIN NEUROL, V25, P19, DOI 10.1055/s-2005-867073; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Broadley SA, 2007, J CLIN NEUROSCI, V14, P328, DOI 10.1016/j.jocn.2006.01.017; Buck D, 2000, STROKE, V31, P2004, DOI 10.1161/01.STR.31.8.2004; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cadilhac DA, 2005, J CLIN NEUROSCI, V12, P632, DOI 10.1016/j.jocn.2004.08.014; Carpenter JS, 1998, J PSYCHOSOM RES, V45, P5, DOI 10.1016/S0022-3999(97)00298-5; Catalano T., 2003, AUSTR J PRIMARY HLTH, V9, P80; Chervin RD, 1997, J PSYCHOSOM RES, V42, P145, DOI 10.1016/S0022-3999(96)00239-5; Dyken ME, 1996, STROKE, V27, P401, DOI 10.1161/01.STR.27.3.401; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; *FRAM HEART STUD N, 1996, HEART STROK STAT UPD; JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Johnston M, 2000, J PSYCHOSOM RES, V48, P579, DOI 10.1016/S0022-3999(00)00102-1; Leppavuori A, 2002, CEREBROVASC DIS, V14, P90, DOI 10.1159/000064737; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Manocchia M, 2001, QUAL LIFE RES, V10, P331, DOI 10.1023/A:1012299519637; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; PALOMAKI H, 1989, STROKE, V20, P1311, DOI 10.1161/01.STR.20.10.1311; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Siengsuhon CF, 2008, TOP STROKE REHABIL, V15, P1, DOI 10.1310/tsr1501-1; Vock J, 2002, J SLEEP RES, V11, P331, DOI 10.1046/j.1365-2869.2002.00316.x; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	30	39	41	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	7-8					575	579		10.1080/02699050802189727			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	318MG	WOS:000257095300008	18568710	Green Accepted			2021-06-18	
J	Zhang, ZY; Zhang, ZR; Fauser, U; Schluesener, HJ				Zhang, Zhi-Yuan; Zhang, Zhiren; Fauser, Uwe; Schluesener, Hermann J.			Global hypomethylation defines a sub-population of reactive microglia/macrophages in experimental traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						traumatic brain injury; hypomethylation; 5-methylcytosine; microglia/macrophages; dexamethasone	DNA METHYLATION; HEAD-INJURY; SPINAL-CORD; MICROGLIA; RATS; ACTIVATION; EXPRESSION; CHROMATIN; IMPACT; CELLS	Global alterations in gene expression have been observed indifferent traumatic brain injury (TBI) models and are considered of crucial importance to the development of subsequent tissue injury and repair. Cytosine methylation is a well-known process of endogenous DNA modification in mammals and the primary mechanism responsible for changes in epigenetic gene expression. Here we have investigated the early global spatio-temporal changes of the status of cellular DNA methylation in a rat TBI model by immunohistochemistry and analyzed the effects of dexamethasone on these changes. Global cellular hypomethylation was seen as early as day 1 in pannecrosis and day 2 in peripannecrosis following TBI. A subpopulation of reactive microglia/macrophages was identified as the major source of hypomethylated cells by double-staining experiments. Further, peripheral administration of dexamethasone suppressed this lesional hypomethylation at day 2 post-injury. In sum, our data suggest that lesional hypomethylation defines a sub-population of activated microglia/macrophages involved in the early processes following traumatic brain injury. (c) 2007 Elsevier Ireland Ltd. All rights reserved.	[Zhang, Zhi-Yuan; Zhang, Zhiren; Fauser, Uwe; Schluesener, Hermann J.] Univ Tubingen, Inst Brain Res, D-72076 Tubingen, Germany	Zhang, ZR (corresponding author), Univ Tubingen, Inst Brain Res, Calwer St 3, D-72076 Tubingen, Germany.	zhangzhiren@yahoo.com	Zhang, Zhiren/O-1012-2019; zhang, zhiren/I-1046-2014	Zhang, Zhiren/0000-0002-5238-2835; zhang, zhiren/0000-0002-5238-2835; Zhang, Zhi-Yuan/0000-0001-9067-0670			AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Attwood JT, 2002, CELL MOL LIFE SCI, V59, P241, DOI 10.1007/s00018-002-8420-z; Carmichael ST, 2003, CURR OPIN NEUROL, V16, P699, DOI 10.1097/00019052-200312000-00009; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb; De Capoa A, 1999, FASEB J, V13, P89; Drew PD, 2000, BRAIN RES BULL, V52, P391, DOI 10.1016/S0361-9230(00)00275-6; Endres M, 2001, NEUROREPORT, V12, P3763, DOI 10.1097/00001756-200112040-00032; Endres M, 2000, J NEUROSCI, V20, P3175, DOI 10.1523/JNEUROSCI.20-09-03175.2000; Garcia-Segura LM, 2006, GLIA, V54, P485, DOI 10.1002/glia.20404; Gloria L, 1996, CANCER, V78, P2300, DOI 10.1002/(SICI)1097-0142(19961201)78:11<2300::AID-CNCR5>3.0.CO;2-Q; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; Holmin, 1996, ACTA NEUROCHIR, V138, P418, DOI 10.1007/BF01420304; Kempermann G, 2003, SCIENCE, V302, P1689, DOI 10.1126/science.1092864; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Ladeby R, 2005, BRAIN RES REV, V48, P196, DOI 10.1016/j.brainresrev.2004.12.009; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; Seifert HH, 2007, EXP MOL PATHOL, V82, P292, DOI 10.1016/j.yexmp.2006.08.002; Sharma RP, 2005, J PSYCHIATR NEUROSCI, V30, P257; Smith SS, 2000, J MOL BIOL, V302, P1, DOI 10.1006/jmbi.2000.4046; Stenvinkel P, 2007, J INTERN MED, V261, P488, DOI 10.1111/j.1365-2796.2007.01777.x; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Woods AG, 1999, NEUROSCIENCE, V91, P1277, DOI 10.1016/S0306-4522(98)00685-X; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Zhang ZY, 2007, ACTA NEUROPATHOL, V113, P675, DOI 10.1007/s00401-007-0195-8	29	39	39	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	DEC 11	2007	429	1					1	6		10.1016/j.neulet.2007.09.061			6	Neurosciences	Neurosciences & Neurology	245UP	WOS:000251964600001	17996371				2021-06-18	
J	Innes, CRH; Jones, RD; Dalrymple-Alford, JC; Hayes, S; Hollobon, S; Severinsen, J; Smith, G; Nicholls, A; Anderson, TJ				Innes, Carrie R. H.; Jones, Richard D.; Dalrymple-Alford, John C.; Hayes, Sarah; Hollobon, Sue; Severinsen, Julie; Smith, Gwyneth; Nicholls, Angela; Anderson, Tim J.			Sensory-motor and cognitive tests predict driving ability of persons with brain disorders	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						driving; brain disorders; prediction; sensory-motor; cognitive; human performance	IDENTIFY OLDER DRIVERS; SIMULATED CAR CRASHES; ON-ROAD; PERFORMANCE; IMPAIRMENT; BATTERY; DEMENTIA; VALIDITY; DEFICITS; RISK	Objective: Brain disorders can lead to a decreased ability to perform the physical and cognitive functions necessary for safe driving. This study aimed to determine how accurately a battery of computerized sensory-motor and cognitive tests (SMCTests(TM)) could predict driving abilities in persons with brain disorders. Methods: SMCTests and an independent on-road driving assessment were applied to 50 experienced drivers with brain disorders referred to a hospital-based driving assessment service. The patients comprised 36 males and 14 females, a mean age of 71.3 years (range 43-85 years) and diagnoses of 35 stroke, 4 traumatic brain injury, 4 Alzheimer's disease, and 7 other. Binary logistic regression (BLR) and nonlinear causal resource analysis (NCRA) were used to build model equations for prediction of on-road driving ability based on SMCTests performance. Results: BLR and NCRA correctly classified 94% and 90% of referrals respectively as on-road pass or fail. Leave-one-out cross-validation estimated that BLR and NCRA would correctly predict the classification of 86% and 76% respectively of an independent referral group as on-road pass or fail. Conclusions: Compared with other studies, SMCTests have shown the highest predictive accuracy against true on-road driving ability as estimated in an independent data set and in persons with brain disorders. SMCTests also have the advantage of being able to comprehensively and objectively assess both sensory-motor and higher cognitive functions related to driving. (c) 2007 Elsevier B.V. All rights reserved.	Van Veer Inst Parkinsons & Brain Res, Christchurch, New Zealand; Christchurch Hosp, Dept Med Phys & Bioengn, Christchurch, New Zealand; Univ Canterbury, Dept Elect & Comp Engn, Christchurch 1, New Zealand; Univ Canterbury, Dept Psychol, Christchurch, New Zealand; Burwood Hosp, Dept Occupat, Christchurch, New Zealand; Christchurch Hosp, Dept Neurol, Christchurch, New Zealand	Innes, CRH (corresponding author), Van Veer Inst Parkinsons & Brain Res, 66 Stewart St, Christchurch, New Zealand.	carrie.innes@vanderveer.org.nz		Jones, Richard/0000-0003-2287-3358; Innes, Carrie/0000-0003-4230-7791			Ball K, 1993, J Am Optom Assoc, V64, P71; Brown LB, 2005, ARCH CLIN NEUROPSYCH, V20, P209, DOI 10.1016/j.acn.2004.06.003; CROFT D, 1987, BRIT J OCCUPATIONAL, V50, P357; Dalrymple-Alford JC, 2003, J STUD ALCOHOL, V64, P93, DOI 10.15288/jsa.2003.64.93; DALRYMPLEALFORD JC, 1994, J NEUROL NEUROSUR PS, V57, P360, DOI 10.1136/jnnp.57.3.360; DAWSON B, 2001, STAT METHODS MULTIPL; De Raedt R, 2000, J AM GERIATR SOC, V48, P1664, DOI 10.1111/j.1532-5415.2000.tb03880.x; DOBBS AR, 2000, CAN FAM PHYSICIAN, V46, P142; DOBBS AR, 1997, EVALUATIONS RISK EXP; DOBBS AR, 2005, CAN MUTL ROAD SAF C; Fischer CA, 2002, P ANN INT IEEE EMBS, P2473, DOI 10.1109/IEMBS.2002.1053382; Fox GK, 1997, J AM GERIATR SOC, V45, P949, DOI 10.1111/j.1532-5415.1997.tb02965.x; Fox GK, 1998, ARCH PHYS MED REHAB, V79, P1288, DOI 10.1016/S0003-9993(98)90277-5; GALSKI T, 1993, AM J OCCUP THER, V47, P391, DOI 10.5014/ajot.47.5.391; GALSKI T, 1990, AM J OCCUP THER, V44, P709, DOI 10.5014/ajot.44.8.709; GIANUTSOS R, 1994, BEHAV RES METH INSTR, V26, P183, DOI 10.3758/BF03204615; Graydon FX, 2004, TRANSPORT RES F-TRAF, V7, P271, DOI 10.1016/j.trf.2004.09.006; Hawley CA, 2001, J NEUROL NEUROSUR PS, V70, P761, DOI 10.1136/jnnp.70.6.761; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Hoffman JD, 2002, TRANSPORT RES REC, P59; HOPKINS WG, 2000, NEW VIEW STAT, V2004; HUNT L, 1993, J AM GERIATR SOC, V41, P747, DOI 10.1111/j.1532-5415.1993.tb07465.x; Johnson J E, 1999, J Gerontol Nurs, V25, P12; Jones R., 2006, 2006 IEEE Power Engineering Society General Meeting; JONES R, 1983, AM J OCCUP THER, V37, P754, DOI 10.5014/ajot.37.11.754; Jones R D, 1990, Int Disabil Stud, V12, P141; Jones RD, 2002, HUM MOVEMENT SCI, V21, P603, DOI 10.1016/S0167-9457(02)00165-3; JONES RD, 1992, MOVEMENT DISORD, V7, P232, DOI 10.1002/mds.870070308; Jones RD, 1996, IEEE T BIO-MED ENG, V43, P1001, DOI 10.1109/10.536901; JONES RD, 1989, BRAIN, V112, P113, DOI 10.1093/brain/112.1.113; JONES RD, 1995, J NEUROL SCI, V131, P43, DOI 10.1016/0022-510X(95)00043-2; KONDRASKE GV, 2006, ELEMENTAL RESOURCE M, P1; Lee HC, 2003, J SAFETY RES, V34, P453, DOI 10.1016/j.jsr.2003.09.007; Lee HC, 2003, ACCIDENT ANAL PREV, V35, P797, DOI 10.1016/S0001-4575(02)00083-0; Lew HL, 2005, BRAIN INJURY, V19, P177, DOI 10.1080/02699050400017171; Lings S, 1991, Int Disabil Stud, V13, P74; LIU L, 1999, CYBERPSYCHOL BEHAV, V2, P1; Lundqvist A, 2000, APPL COGNITIVE PSYCH, V14, P135, DOI 10.1002/(SICI)1099-0720(200003/04)14:2<135::AID-ACP628>3.0.CO;2-S; Marottoli RA, 1998, J AM GERIATR SOC, V46, P562, DOI 10.1111/j.1532-5415.1998.tb01071.x; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; McKenna P, 2004, BRIT J CLIN PSYCHOL, V43, P325, DOI 10.1348/0144665031752952; McKnight AJ, 1999, ACCIDENT ANAL PREV, V31, P445, DOI 10.1016/S0001-4575(98)00082-7; Myers RS, 2000, PERCEPT MOTOR SKILL, V91, P279, DOI 10.2466/PMS.91.5.279-290; Nouri F M, 1987, Int Disabil Stud, V9, P110; Nouri F.M., 1992, CLIN REHABIL, V6, DOI [https://doi.org/10.1177/026921559200600402, DOI 10.1177/026921559200600402]; NOURI FM, 1993, BRIT MED J, V307, P482, DOI 10.1136/bmj.307.6902.482; Reger MA, 2004, NEUROPSYCHOLOGY, V18, P85, DOI 10.1037/0894-4105.18.1.85; Rizzo M, 2001, ALZ DIS ASSOC DIS, V15, P10, DOI 10.1097/00002093-200101000-00002; Rizzo M, 1997, ARCH NEUROL-CHICAGO, V54, P545, DOI 10.1001/archneur.1997.00550170027011; Schanke AK, 2000, SCAND J PSYCHOL, V41, P113, DOI 10.1111/1467-9450.00179; Sims RV, 2000, J GERONTOL A-BIOL, V55, pM22; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; Stolwyk RJ, 2006, J CLIN EXP NEUROPSYC, V28, P898, DOI 10.1080/13803390591000909; Uc EY, 2006, J NEUROL SCI, V251, P35, DOI 10.1016/j.jns.2006.08.011; *US DEP TRANSP, 1999, SAF MOB OLD PEOP NOT; Wald JL, 2000, CYBERPSYCHOL BEHAV, V3, P643, DOI 10.1089/109493100420232; WITTON IH, 1999, CREDIBILITY EVALUATI, P119; Wood JM, 2005, J NEUROL NEUROSUR PS, V76, P176, DOI 10.1136/jnnp.2004.047118; 2002, MED ASPECTS FITNESS	59	39	40	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	SEP 15	2007	260	1-2					188	198		10.1016/j.jns.2007.04.052			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	208JG	WOS:000249315000029	17544448				2021-06-18	
J	Warren, MW; Larner, SF; Kobeissy, FH; Brezing, CA; Jeung, JA; Hayes, RL; Gold, MS; Wang, KKW				Warren, Matthew W.; Larner, Stephen F.; Kobeissy, Firas H.; Brezing, Christina A.; Jeung, Jennifer A.; Hayes, Ronald L.; Gold, Mark S.; Wang, Kevin K. W.			Calpain and caspase proteolytic markers co-localize with rat cortical neurons after exposure to methamphetamine and MDMA	ACTA NEUROPATHOLOGICA			English	Article						calpain; caspase; MDMA; methamphetamine; spectrin	TRAUMATIC BRAIN-INJURY; INCREASED EXPRESSION; INDUCED APOPTOSIS; II-SPECTRIN; DOPAMINE; NEUROTOXICITY; ACTIVATION; ECSTASY; SEROTONIN; DEATH	Abuse of the club drugs Methamphetamine (Meth) and Ecstasy (MDMA) is an international problem. The seriousness of this problem is the result of what appears to be programmed cell death (PCD) occurring within the brain following their use. This follow up study focused on determining which cell types, neurons and/or glial cells, were affected in the brains of drug-injected rats. Two proteolytic enzyme families involved in PCD, calpains and caspases, were previously shown to be activated and to degrade the brain cytoskeletal associated protein all-spectrin. Using methods employed and confirmed in traumatic brain injury (TBI) studies, rat brain tissues were examined, 24 and 48 h after Meth and MDMA exposure, for the activation of calpain-1 and caspase-3, and their subsequent alpha II-spectrin cleavage breakdown products (SBDPs), SBDP145, and SBDP120, respectively. Based upon our previous studies we know that activated calpain-1 and caspase-3 were up-regulated after drug use as were the levels of their cleaved SBDPs, SBDP145, and SBDP120, respectively, which is indicative of PCD. Here we show that activated calpain-1 and caspase-3 increases could be localized to neurons in the cortex where the products of their cleaved targets were found to be concentrated, particularly, to the axonal regions. These findings support the hypothesis that calpains and caspases mediate PCD in cortical neurons following club drug abuse and, more importantly, appear to contribute to the neuropathology suffered by abusers.	Univ Florida, McKnight Brain Inst, Dept Psychiat, Ctr Neuroproteom & Biomarkers Res, Gainesville, FL 32610 USA; Univ Florida, McKnight Brain Inst, Dept Neurosci, Ctr Traumat Brain Injury Studies, Gainesville, FL 32610 USA; Univ Florida, Dept Psychiat, Gainesville, FL 32610 USA	Warren, MW (corresponding author), Univ Florida, McKnight Brain Inst, Dept Psychiat, Ctr Neuroproteom & Biomarkers Res, Box 100256,100 S Newell Dr, Gainesville, FL 32610 USA.	warren@ufl.edu; kwang@psychiatry.ufl.edu	Kobeissy, Firas/E-7042-2017	Kobeissy, Firas/0000-0002-5008-6944; Wang, Kevin/0000-0002-9343-6473			Baumann MH, 2007, PSYCHOPHARMACOLOGY, V189, P407, DOI 10.1007/s00213-006-0322-6; Cadet JL, 1997, SYNAPSE, V25, P176; Cadet JL, 1998, NEUROCHEM INT, V32, P117, DOI 10.1016/S0197-0186(97)00031-4; Deng XL, 2000, MOL BRAIN RES, V83, P121, DOI 10.1016/S0169-328X(00)00169-8; Deng XL, 2002, MOL PHARMACOL, V62, P993, DOI 10.1124/mol.62.5.993; Eisch AJ, 1998, SYNAPSE, V30, P329, DOI 10.1002/(SICI)1098-2396(199811)30:3<329::AID-SYN10>3.3.CO;2-H; Ernst T, 2000, NEUROLOGY, V54, P1344, DOI 10.1212/WNL.54.6.1344; Fleckenstein AE, 2007, ANNU REV PHARMACOL, V47, P681, DOI 10.1146/annurev.pharmtox.47.120505.105140; Fumagalli F, 1999, J NEUROSCI, V19, P2424; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; Hirata H, 1997, BRAIN RES, V768, P345, DOI 10.1016/S0006-8993(97)00798-1; Jayanthi S, 2001, FASEB J, V15, P1745, DOI 10.1096/fj.01-0025com; Jimenez A, 2004, TOXICOL APPL PHARM, V196, P223, DOI 10.1016/j.taap.2003.12.017; Kanthasamy A, 2006, ANN NY ACAD SCI, V1074, P234, DOI 10.1196/annals.1369.022; Larner SF, 2005, J NEUROCHEM, V94, P97, DOI 10.1111/j.1471-4159.2005.03172.x; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Larsen KE, 2002, J NEUROSCI, V22, P8951; McCann UD, 1998, LANCET, V352, P1433, DOI 10.1016/S0140-6736(98)04329-3; McKay R, 1988, Ann N Y Acad Sci, V540, P47, DOI 10.1111/j.1749-6632.1988.tb27050.x; Meyer JS, 2004, INT J DEV NEUROSCI, V22, P261, DOI 10.1016/j.ijdevneu.2004.04.007; NASH JF, 1991, EUR J PHARMACOL, V200, P53, DOI 10.1016/0014-2999(91)90664-C; *NAT I DRUG AB, 2005, NAT SURV RES DRUG US; Nath R, 2000, NEUROCHEM INT, V37, P351, DOI 10.1016/S0197-0186(00)00040-1; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; O'Dell SJ, 2000, SYNAPSE, V37, P32, DOI 10.1002/(SICI)1098-2396(200007)37:1<32::AID-SYN4>3.3.CO;2-O; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; PU CF, 1994, BRAIN RES, V649, P217, DOI 10.1016/0006-8993(94)91067-7; Rawson RA, 2002, J SUBST ABUSE TREAT, V23, P145, DOI 10.1016/S0740-5472(02)00256-8; Ricaurte G A, 1989, NIDA Res Monogr, V94, P306; SCHMIDT CJ, 1987, BIOCHEM PHARMACOL, V36, P4095, DOI 10.1016/0006-2952(87)90566-1; SIKORSKI AF, 1991, J CELL BIOL, V114, P313, DOI 10.1083/jcb.114.2.313; Simantov R, 1997, FASEB J, V11, P141; STUFFLEBEAM R, 2006, NEURONS SYNAPSES NEU; Stumm G, 1999, FASEB J, V13, P1065; Substance Abuse and Mental Health Services Administration (SAMHSA), 2004, DHHS PUBL; Tamburini I, 2006, ANN NY ACAD SCI, V1074, P377, DOI 10.1196/annals.1369.037; Thiriet N, 2001, MOL BRAIN RES, V90, P202, DOI 10.1016/S0169-328X(01)00093-6; Thomas DM, 2004, NEUROSCI LETT, V367, P349, DOI 10.1016/j.neulet.2004.06.065; Wallace TL, 1999, J NEUROSCI, V19, P9141, DOI 10.1523/JNEUROSCI.19-20-09141.1999; Wallace TL, 2003, NEUROSCIENCE, V116, P1063, DOI 10.1016/S0306-4522(02)00795-9; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Warren MW, 2006, J ADDICT DIS, V25, P115, DOI 10.1300/J069v25n04_11; Warren MW, 2005, LIFE SCI, V78, P301, DOI 10.1016/j.lfs.2005.04.058; WARREN MW, 2006, INT J NEUROPSYCHOPH, P1; WHITE SR, 1994, NEUROSCIENCE, V62, P41, DOI 10.1016/0306-4522(94)90313-1; Xu WJ, 2005, SYNAPSE, V58, P110, DOI 10.1002/syn.20185; Yuan J, 2001, J NEUROCHEM, V77, P1338, DOI 10.1046/j.1471-4159.2001.00339.x; Zhu JPQ, 2006, NEUROSCIENCE, V140, P607, DOI 10.1016/j.neuroscience.2006.02.055; Zhu JPQ, 2005, BRAIN RES, V1049, P171, DOI 10.1016/j.brainres.2005.04.089	51	39	39	0	0	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	SEP	2007	114	3					277	286		10.1007/s00401-007-0259-9			10	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	205XT	WOS:000249149200009	17647000				2021-06-18	
J	Pasco, A; Lemaire, L; Franconi, F; Lefur, Y; Noury, F; Saint-Andre, JP; Benoit, JP; Cozzone, PJ; Le Jeune, JJ				Pasco, Anne; Lemaire, Laurent; Franconi, Florence; Lefur, Yann; Noury, Fanny; Saint-Andre, Jean-Paul; Benoit, Jean-Pierre; Cozzone, Patrick J.; Le Jeune, Jean-Jacques			Perfusional deficit and the dynamics of cerebral edemas in experimental traumatic brain injury using perfusion and diffusion-weighted magnetic resonance imaging	JOURNAL OF NEUROTRAUMA			English	Article						ADC; diffusion; DSC; edema; fluid lateral percussion; perfusion; quantitative magnetic resonance imaging; traumatic brain injury	HIGH-RESOLUTION MEASUREMENT; FLUID PERCUSSION INJURY; TRACER BOLUS PASSAGES; CLOSED-HEAD INJURY; BLOOD-FLOW; SECONDARY HYPOXIA; PUBLIC-HEALTH; MRI; RATS; METABOLISM	The aim of this work was to characterize edema dynamics, cerebral blood volume, and flow alterations in an experimental model of brain trauma using quantitative diffusion and perfusion magnetic resonance imaging (MRI). Associated with an influx of water in the intracellular space 1-5 h post-trauma as demonstrated by the 40% reduction in apparent diffusion coefficient, a 70-80% reduction in cerebral blood flow was measured within the lesioned region. Transient hypoperfusion (40-50%) was also observed in the non-traumatized contralateral hemisphere, although there was no evidence of edema formation. After the initial cytotoxic edema, a clear evolution toward extracellular water accumulation was observed, demonstrated by an increase in apparent diffusion coefficient.	INSERM, U 646, F-49100 Angers, France; Univ Angers, F-49100 Angers, France; Univ Angers, Serv Commun Anal Spectroscop, Angers, France; Ctr Resonance Magnet Biol & Med, CNRS, UMR 6612, Marseille, France; CHU Angers, Anat Pathol Lab, Angers, France	Lemaire, L (corresponding author), INSERM, U 646, 10 Rue Andre Boquel, F-49100 Angers, France.	laurent.lemaire@univ-angers.fr	NOURY, Fanny/N-8177-2015; FRANCONI, Florence/K-4258-2015; Benoit, Jean-Pierre/K-4387-2015; LEMAIRE, Laurent/A-3100-2011	FRANCONI, Florence/0000-0001-6725-0803; LEMAIRE, Laurent/0000-0002-1308-9345; BENOIT, Jean-Pierre/0000-0002-6178-7199			Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bauman RA, 2005, BEHAV BRAIN RES, V160, P25, DOI 10.1016/j.bbr.2004.11.031; Beaumont A, 2006, ACTA NEUROCHIR SUPPL, V96, P171; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Besson VC, 2005, NEUROSCI LETT, V388, P7, DOI 10.1016/j.neulet.2005.06.019; HAASE A, 1990, MAGN RESON MED, V13, P77, DOI 10.1002/mrm.1910130109; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; LAURER HL, 2000, EUR J TRAUMA, V26, P995; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; Lythgoe MF, 1997, MAGN RESON MED, V38, P662, DOI 10.1002/mrm.1910380421; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Mathe JF, 2005, ANN FR ANESTH, V24, P688, DOI 10.1016/j.annfar.2005.03.029; Ostergaard L, 1998, J CEREBR BLOOD F MET, V18, P425, DOI 10.1097/00004647-199804000-00011; Ostergaard L, 1996, MAGNET RESON MED, V36, P726, DOI 10.1002/mrm.1910360511; Ostergaard L, 1996, MAGN RESON MED, V36, P715, DOI 10.1002/mrm.1910360510; Pasco A, 2006, EUR RADIOL, V16, P1501, DOI 10.1007/s00330-005-0086-0; Reinert M, 2000, J NEUROSURG, V93, P800, DOI 10.3171/jns.2000.93.5.0800; Reinert M, 2004, J NEUROSURG, V101, P323, DOI 10.3171/jns.2004.101.2.0323; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Schneider G, 2002, MAGN RESON MATER PHY, V14, P233, DOI 10.1016/S1352-8661(02)00068-6; Shen Q, 2005, J CEREBR BLOOD F MET, V25, P1265, DOI 10.1038/sj.jcbfm.9600132; Shen Q, 2005, J CEREBR BLOOD F MET, V25, P1336, DOI 10.1038/sj.jcbfm.9600126; Simonsen CZ, 1999, JMRI-J MAGN RESON IM, V9, P342, DOI 10.1002/(SICI)1522-2586(199902)9:2<342::AID-JMRI29>3.0.CO;2-B; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Viant MR, 2005, NMR BIOMED, V18, P507, DOI 10.1002/nbm.980; VILLRINGER A, 1988, MAGNET RESON MED, V6, P164, DOI 10.1002/mrm.1910060205; Vonarbourg A, 2004, MAGN RESON MATER PHY, V17, P133, DOI 10.1007/s10334-004-0049-5; WINDLE V, 2001, EXP NEUROL, P324; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117	45	39	41	0	10	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2007	24	8					1321	1330		10.1089/neu.2006.0136			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	202QQ	WOS:000248918500003	17711393	Green Accepted			2021-06-18	
J	Banks, ME				Banks, Martha E.			Overlooked but critical - Traumatic brain injury as a consequence of interpersonal violence	TRAUMA VIOLENCE & ABUSE			English	Article						traumatic brain injury; intimate partner violence; rehabilitation; prevention; neuropsychology; assessment; memory; emotions	DOMESTIC VIOLENCE; BATTERED WOMEN; HEAD-INJURY; ABUSE; IMPAIRMENT; VICTIMS	Despite evidence that more than 80% of female victims of intimate partner violence, seen for medical treatment of violence-related injuries, have sustained facial injuries, traumatic brain injury is often overlooked as a consequence of those injuries. This article reviews the scant literature available and examines research on equivalent injuries sustained by athletes. Practical domains of symptoms are described, as is a review of literature pertinent to culturally relevant rehabilitation for victims sustaining traumatic brain injuries.	Coll Wooster, Wooster, OH 44691 USA	Banks, ME (corresponding author), Abackans DCP, Akron, OH USA.		Banks, Martha/AAB-2391-2021	Banks, Martha/0000-0002-5367-2076			Ackerman RJ, 2003, WOMEN THER, V26, P343, DOI 10.1300/J015v26n03_11; ACKERMAN RJ, 2003, PROSTITUTION DISSOCI; ACKERMAN RJ, 2006, ACKERMAN BANKS NEURO; Ackerman Rosalie J, 2004, Phys Med Rehabil Clin N Am, V15, P919, DOI 10.1016/j.pmr.2004.04.001; Banks M. E., 2003, WOMEN VISIBLE INVISI, pxxi; Banks Martha E, 2003, Cultur Divers Ethnic Minor Psychol, V9, P367, DOI 10.1037/1099-9809.9.4.367; Banks ME, 2002, WOMEN THER, V25, P133, DOI 10.1300/J015v25n03_10; BANKS ME, 1997, POST ASSAULT TRAUMAT; BANKS ME, 2007, ENCY DOMESTIC VIOLEN; Belgrave FZ, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P585, DOI 10.1037/10361-028; BELL CC, 2000, VIOLENCE AGAINST WOM, V6, P515; Brewer TL, 2002, RES NURS HEALTH, V25, P269, DOI 10.1002/nur.10045; Browne A., 1999, VIOLENCE AGAINST WOM, V5, P393, DOI DOI 10.1177/10778019922181284; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Campbell J, 2005, HDB WOMEN STRESS TRA, P123; Campbell JC, 1999, J INTERPERS VIOLENCE, V14, P21, DOI 10.1177/088626099014001002; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Cox AL, 2006, J NEUROIMMUNOL, V174, P180, DOI 10.1016/j.jneuroim.2006.01.007; Diaz-Olavarrieta C, 1999, ARCH NEUROL-CHICAGO, V56, P681, DOI 10.1001/archneur.56.6.681; FARLEY M, 2003, WOMEN VISIBLE INVISB, P247; FERRARO FR, 2002, MINORITY CROSSCULTUR; Gagnon J, 2006, B MENNINGER CLIN, V70, P1, DOI 10.1521/bumc.2006.70.1.1; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; Hassouneh-Phillips D, 2002, REHABIL COUNS BULL, V45, P96, DOI 10.1177/003435520204500204; Jackson H, 2004, AP PRA H PS, P233; Kozorovitskiy Y, 2003, J CLIN EXP NEUROPSYC, V25, P721, DOI 10.1076/jcen.25.5.721.14580; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Kyriacou DN, 1999, NEW ENGL J MED, V341, P1892, DOI 10.1056/NEJM199912163412505; Malec JF, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P417, DOI 10.1037/10361-020; Malec JF, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P15; Manetta AA, 1999, J BLACK STUD, V29, P510, DOI 10.1177/002193479902900403; Manly JJ, 2002, STUD NEUROPSYCHOL DE, P79; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; Monahan K, 1999, HEALTH SOC WORK, V24, P269, DOI 10.1093/hsw/24.4.269; MORTON RL, 2004, TRAUMATIC BRAIN INJU, P183; Muelleman RL, 1998, AM J EMERG MED, V16, P128, DOI 10.1016/S0735-6757(98)90028-6; Muelleman RL, 1996, ANN EMERG MED, V28, P486, DOI 10.1016/S0196-0644(96)70110-5; MUKHERJEE D, 2003, WOMEN VISIBLE INVISI, P3; Nosek MA, 2001, SEX DISABIL, V19, P177, DOI 10.1023/A:1013152530758; Ochs HA, 1996, J AM DENT ASSOC, V127, P757, DOI 10.14219/jada.archive.1996.0311; Plichta SB, 2004, J INTERPERS VIOLENCE, V19, P1296, DOI 10.1177/0886260504269685; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Raskin SA, 1997, BRAIN INJURY, V11, P587, DOI 10.1080/026990597123287; Schootman M, 2000, BRAIN INJURY, V14, P373; SHERR RL, 1992, NEUROPSYCHOLOGY, V6, P417, DOI DOI 10.1037/0894-4105.6.4.417; Shore AD, 2005, BRAIN INJURY, V19, P613, DOI 10.1080/02699050400013568; SIKORA E, 2003, DISS ABSTR INT, V63, pB3939; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Tellier A, 1999, BRAIN INJURY, V13, P463; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tjaden P., 2000, EXTENT NATURE CONSEQ; Tjaden P., 1998, **DROPPED REF**; Uzzell BP, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P1; Valera EM, 2003, J CONSULT CLIN PSYCH, V71, P797, DOI 10.1037/0022-006X.71.4.797; Voller B, 2001, BRAIN INJURY, V15, P107, DOI 10.1080/026990501458344; Wadman MC, 1999, AM J EMERG MED, V17, P689, DOI 10.1016/S0735-6757(99)90161-4; Wolkenstein BH, 1998, PROF PSYCHOL-RES PR, V29, P341, DOI 10.1037/0735-7028.29.4.341; Wuest J., 1999, VIOLENCE AGAINST WOM, V5, P110, DOI DOI 10.1177/1077801299005002002; ZEITLIN SB, 1993, AM J PSYCHIAT, V150, P661	61	39	39	1	14	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1524-8380	1552-8324		TRAUMA VIOLENCE ABUS	Trauma Violence Abus.	JUL	2007	8	3					290	298		10.1177/1524838007303503			9	Criminology & Penology; Family Studies; Social Work	Criminology & Penology; Family Studies; Social Work	183QF	WOS:000247586600005	17596346				2021-06-18	
J	Bartnik, BL; Lee, SM; Hovda, DA; Sutton, RL				Bartnik, Brenda L.; Lee, Stefan M.; Hovda, David A.; Sutton, Richard L.			The fate of glucose during the period of decreased metabolism after fluid percussion injury: A C-13 NMR study	JOURNAL OF NEUROTRAUMA			English	Article						[1, 2 C-13(2)] glucose; C-13 NMR; fluid percussion injury; glutamate; glutamine; pentose phosphate pathway; rat brain	TRAUMATIC BRAIN-INJURY; ENERGY-RELATED METABOLITES; PENTOSE-PHOSPHATE PATHWAY; CEREBRAL METABOLISM; HEAD-INJURY; BLOOD-FLOW; RAT-BRAIN; NOREPINEPHRINE TURNOVER; CORTICAL CONTUSION; LIPID-PEROXIDATION	The present study determined the metabolic fate of [1, 2 C-13(2)] glucose in male control rats and in rats with moderate lateral fluid percussion injured (FPI) at 3.5 h and 24 h post-surgery. After a 3h infusion, the amount of C-13-labeled glucose increased bilaterally (26% in left/injured cerebral cortex and 45% in right cerebral cortex) at 3.5 h after FPI and in injured cortex (45%) at 24 h after injury, indicating an accumulation of unmetabolised glucose not seen in controls. No evidence of an increase in anaerobic glycolysis above control levels was found after FPI, as C-13-labeled lactate tended to decrease at both time points and was significantly reduced (33%) in the injured cortex at 24 h post- FPI. A bilateral decrease in the C-13-labeling of both glutamate and glutamine was observed in the FPI rats at 3.5 h and the glutamine pool remained significantly decreased in the injured cortex at 24 h, suggesting reduced oxidative metabolism in both neuronal and astrocyte compartments after injury. The percentage of glucose metabolism through the pentose phosphate pathway (PPP) increased in the injured (13%) and contralateral (11%) cortex at 3.5 h post- FPI and in the injured cortex (9%) at 24 h post- injury. Based upon the changes in metabolite pools, our results show an injury-induced decrease in glucose utilization and oxidation within the first 24 h after FPI. Increased metabolism through the PPP would result in increased NADPH synthesis, suggesting a need for reducing equivalents after FPI to help restore the intracellular redox state and/or in response to free radical stress.	Univ Calif Los Angeles, Brain Injury Res Ctr, Div Neurosurg, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA USA	Bartnik, BL (corresponding author), Loma Linda Univ, Dept Radiol, 234 Anderson St,Room B623, Loma Linda, CA 92354 USA.	bbartnik@llu.edu		Bartnik-Olson, Brenda/0000-0002-1137-9437	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 36373, NS 27544] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544] Funding Source: NIH RePORTER		Alves OL, 2005, J NEUROTRAUM, V22, P733, DOI 10.1089/neu.2005.22.733; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Aureli T, 1997, BRAIN RES, V765, P218, DOI 10.1016/S0006-8993(97)00514-3; BADARGOFFER RS, 1990, BIOCHEM J, V266, P133, DOI 10.1042/bj2660133; BAQUER NZ, 1988, CURR TOP CELL REGUL, V29, P265; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Bentzer P, 2000, J NEUROTRAUM, V17, P441, DOI 10.1089/neu.2000.17.441; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Brain K, 2006, J CLIN ONCOL, V24, P95, DOI 10.1200/JCO.2006.10.064; BRAND A, 1992, BIOCHIMIE, V74, P941, DOI 10.1016/0300-9084(92)90078-S; CERDAN S, 1990, J BIOL CHEM, V265, P12916; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; CHIOLERO R, 1989, JPEN-PARENTER ENTER, V13, P5, DOI 10.1177/014860718901300105; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; Cornford EM, 1996, J NEUROTRAUM, V13, P523, DOI 10.1089/neu.1996.13.523; Cruz F, 1998, J NEUROCHEM, V70, P2613; Cruz F, 1999, NMR BIOMED, V12, P451, DOI 10.1002/(SICI)1099-1492(199911)12:7<451::AID-NBM571>3.3.CO;2-5; DEUTSCHMAN CS, 1986, J NEUROSURG, V64, P89, DOI 10.3171/jns.1986.64.1.0089; Dhillon HS, 1999, J NEUROTRAUM, V16, P455, DOI 10.1089/neu.1999.16.455; Dunn-Meynell AA, 1998, BRAIN RES, V800, P245, DOI 10.1016/S0006-8993(98)00524-1; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; ERECINSKA M, 1988, J NEUROCHEM, V51, P892, DOI 10.1111/j.1471-4159.1988.tb01826.x; GAITONDE MK, 1983, J NEUROCHEM, V41, P1253, DOI 10.1111/j.1471-4159.1983.tb00819.x; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; HOTHERSALL JS, 1982, J NEUROCHEM, V39, P1325, DOI 10.1111/j.1471-4159.1982.tb12574.x; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; KUNNECKE B, 1993, NMR BIOMED, V6, P264, DOI 10.1002/nbm.1940060406; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; LEVIN BE, 1995, BRAIN RES, V674, P307, DOI 10.1016/0006-8993(95)00032-L; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OPII WO, 2005, PROTEOMIC IDENTIFICA; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; OTT L, 1987, JPEN-PARENTER ENTER, V11, P488, DOI 10.1177/0148607187011005488; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Preece NE, 1996, J NEUROCHEM, V67, P1718; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Rose ME, 2002, BRAIN RES, V935, P40, DOI 10.1016/S0006-8993(02)02445-9; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; SCHRADER MC, 1993, BIOCHIM BIOPHYS ACTA, V1182, P162, DOI 10.1016/0925-4439(93)90138-Q; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; SUTTON RL, 1994, ACTA NEUROCHIR, P446; SUTTON RL, 2005, OXIDATIVE METABOLISM; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Ying WH, 2005, J NEUROSCI RES, V79, P216, DOI 10.1002/jnr.20289; Ying WH, 2002, J CEREBR BLOOD F MET, V22, P774, DOI 10.1097/00004647-200207000-00002; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	65	39	39	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2007	24	7					1079	1092		10.1089/neu.2006.0210			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	186DV	WOS:000247760200001	17610349				2021-06-18	
J	Wilson, JTL; Slieker, FJA; Legrand, V; Murray, G; Stocchetti, N; Maas, AIR				Wilson, J. T. Lindsay; Slieker, Frans J. A.; Legrand, Valerie; Murray, Gordon; Stocchetti, Nino; Maas, Andrew I. R.			Observer variation in the assessment of outcome in traumatic brain injury: Experience from a multicenter, international randomized clinical trial	NEUROSURGERY			English	Article						clinical trials; observer variation; outcome; traumatic brain injury	EFFICACY	OBJECTIVE: Accurate and consistent outcome assessment is essential to randomized clinical trials. We aimed to explore observer variation in the assessment of outcome in a recently completed trial of dexanabinol in head injury and to consider steps to reduce such variation. METHODS: Eight hundred sixty-one patients with severe traumatic brain injury who were admitted to 86 centers were included in a multicenter, placebo-controlled, Phase III trial. Outcome was assessed at 3 and 6 months postinjury using the extended Glasgow Outcome Scale; standardized assessment was facilitated by the use of a structured interview. Before initiation of trial centers, outcome ratings were obtained for sample cases to establish initial levels of agreement. Training sessions in outcome assessment were held, and problems in assigning outcome were investigated. During the trial, a process of central review was established to monitor performance. Interobserver variation was analyzed using the K statistic. RESULTS: Substantial observer variation was found in the rating of sample cases (weighted K, 0.72; confidence interval, 0.68-0.75) and in assigning outcome based on completed structured interviews (weighted K, 0.61; confidence interval, 0.57-0.64). In the early stages of the trial, a relatively large number of discrepancies (29-3 7%) were identified on central review. This number declined as the trial progressed and coincided with investigator training and feedback from central review. Centers with higher enrollment rates showed better performance. CONCLUSION: Observer variation in outcome assessment is a significant problem for head injury trials. Consistency can be improved by standardizing procedures, training assessors, and monitoring the quality of assessments and providing feedback to interviewers.	Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland; Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands; Quintiles, Paris, France; Univ Edinburgh, Sch Med, Edinburgh EH8 9YL, Midlothian, Scotland; Univ Milan, IRCCS, Osped Policlin, Neurosci Intens Care Unit, I-20122 Milan, Italy	Wilson, JTL (corresponding author), Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland.	J.T.L.Wilson@stir.ac.uk	Wilson, Lindsay/A-3659-2009; Wilson, Lindsay/O-8883-2019; Stocchetti, Nino/O-7444-2017; Maas, Andrew IR/C-5584-2013	Wilson, Lindsay/0000-0003-4113-2328; Wilson, Lindsay/0000-0003-4113-2328; Stocchetti, Nino/0000-0003-3250-6834; Maas, Andrew IR/0000-0003-1612-1264; Murray, Gordon/0000-0001-9866-4734			BRENNAN P, 1992, BMJ-BRIT MED J, V304, P1491, DOI 10.1136/bmj.304.6840.1491; BULLOCK MR, 2002, NEUROSURG FOCUS, V13; Choi SC, 2002, J NEUROTRAUM, V19, P17, DOI 10.1089/089771502753460204; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; JENNETT B, 1975, LANCET, V1, P480; Kobak KA, 2004, J CLIN PSYCHOPHARM, V24, P113, DOI 10.1097/01.jcp.0000116651.91923.54; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; MAAS AIR, 1983, J NEUROSURG, V58, P321, DOI 10.3171/jns.1983.58.3.0321; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; Scheibel RS, 1998, J NEUROTRAUM, V15, P685, DOI 10.1089/neu.1998.15.685; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	13	39	40	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	2007	61	1					123	128		10.1227/01.neu.0000279732.21145.9e			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	185AF	WOS:000247683000027	17621027				2021-06-18	
J	Collins, JM; Despa, F; Lee, RC				Collins, John M.; Despa, Florin; Lee, Raphael C.			Structural and functional recovery of electropermeabilized skeletal muscle in-vivo after treatment with surfactant poloxamer 188	BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES			English	Article						electroporation; poloxamer 188; skeletal muscle; action potential; MRI	T-2 RELAXATION DECAY; PURIFIED POLOXAMER-188; ACTIVE AGENT; RAT; PHARMACOKINETICS; KINETICS; INJURY; MODEL	A critical requirement for cell survival after trauma is sealing of breaks in the cell membrane [M. Bier, S.M. Hammer, D.J. Canaday, RC Lee, Kinetics of sealing for transient electropores in isolated mammalian skeletal muscle cells, Bioelectromagnetics 20 (1999) 194-201; R.C. Lee, D.C. Gaylor, D. Bhatt, D.A. Israel, Role of cell membrane rupture in the pathogenesis of electrical trauma, J. Surg. Res. 44 (1988) 709-719; R.C. Lee, J.F. Burke, E.G. Cravalho (Eds.), Electrical Trauma: The Pathophysiology, Manifestations, and Clinical Management, Cambridge University Press, 1992; B.I. Tropea, R.C. Lee, Thermal injury kinetics in electrical trauma, J. Biomech. Engr. 114 (1992) 241-250; F. Despa, D.P. Orgill, J. Newalder, R.C Lee, The relative thermal stability of tissue macromolecules and cellular structure in burn injury, Burns 31 (2005) 568-577; T.A. Block, J.N. Aarsvold, K.L. Matthews II, R.A. Mintzer, L.P. River, M. Capelli-Schellpfeffer, R.L. Wollman, S. Tripathi, C.T. Chen, R.C. Lee, The 1995 Lindberg Award. Nonthermally mediated muscle injury and necrosis in electrical trauma, J. Burn Care and Rehabil. 16 (1995) 581-588; K. Miyake, P.L. McNeil, Mechanical injury and repair of cells, Crit. Care Med. 31 (2003) S496-S501; R.C. Lee, L.P. River, F.S. Pan, R.L. Wollmann, Surfactant-induced sealing of electropermeabilized skeletal muscle membranes in vivo, Proc. Natl. Acad. Sci. 89 (1992) 4524-4528; J.D. Marks, C.Y. Pan, T. Bushell, W. Cromie, R.C. Lee, Amphiphilic, tri-block copolymers provide potent membrane-targeted neuroprotection, FASEB J. 15 (2001) 11071109; B. Greenebaum, K. Blossfield, J. Hannig, C.S. Carrillo, M.A. Beckett, R.R. Weichselbaum, R.C. Lee, Poloxamer 188 prevents acute necrosis of adult skeletal muscle cells following high-dose irradiation, Burns 30 (2004) 539-547; G. Serbest, J. Horwitz, K. Barbee, The effect of poloxamer-188 on neuronal cell recovery from mechanical injury, J. Neurotrauma 22 (2005) 119-132]. The triblock copolymer surfactant Poloxamer 188 (P 188) is known to increase the cell survival after membrane electroporation [R.C. Lee, L.P. River, F.S. Pan, R.L. Wollmann, Surfactant-induced sealing of electropermeabilized skeletal muscle membranes in vivo, Proc. Natl. Acad. Sci. 89 (1992) 4524-4528; Z. Ababneh, H. Beloeil, C.B. Berde, G. Gambarota, S.E. Maier, R.V Mulkern, Biexponential parametrization of T2 and diffusion decay curves in a rat muscle edema model: Decay curve components and water compartments, Magn. Reson. Med. 54 (2005) 524-53 1]. Here, we use a rat hind-limb model of electroporation injury to determine if the intravenous administration of PI 88 improves the recovery of the muscle function. Rat hind-limbs received a sequence of either 0, 3, 6, 9, or 12 electrical current pulses (2 A, 4 ms duration, 10 s duty cycle). Magnetic resonance imaging (MRI) analysis, muscle water content and compound muscle action potential (CMAP) amplitudes were compared. Electroporation injury manifested edema formation and depression of the CMAP amplitudes. P 188 (one bolus of 1 mg/mI of blood) was administrated 30 or 60 min after injury. Animals receiving P 188 exhibited reduced tissue edema (p < 0.05) and increased CMAP amplitudes (p < 0.03). By comparison, treatment with 10 kDa neutral dextran, which produces similar serum osmotic effects as P 188, had no effect on post-electroporation recovery. Noteworthy, the present results suggest that a single intravenous dose of P 188 is effective to restore the structural integrity of damaged tissues with intact circulation. (c) 2007 Elsevier B.V. All rights reserved.	Univ Chicago, Dept Surg, Chicago, IL 60637 USA; Univ Chicago, Dept Organismal Biol & Anat, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	Lee, RC (corresponding author), Univ Chicago, Dept Surg, 5841 S Maryland Ave, Chicago, IL 60637 USA.	r-lee@uchicago.edu			NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM61101, R01-GM64757-04, R01 GM064757, R01 GM061101] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM061101, R01GM064757] Funding Source: NIH RePORTER		Ababneh Z, 2005, MAGNET RESON MED, V54, P524, DOI 10.1002/mrm.20610; Abramov GS, 1996, BURNS, V22, P602, DOI 10.1016/S0305-4179(96)00055-1; BARRATT TM, 1969, J CLIN INVEST, V48, P56, DOI 10.1172/JCI105974; Baskaran H, 2001, J SURG RES, V101, P56, DOI 10.1006/jsre.2001.6262; Bertram HC, 2001, J AGR FOOD CHEM, V49, P3092, DOI 10.1021/jf001402t; Bier M, 1999, BIOELECTROMAGNETICS, V20, P194, DOI 10.1002/(SICI)1521-186X(1999)20:3<194::AID-BEM6>3.0.CO;2-0; Block Thomas A., 1995, Journal of Burn Care and Rehabilitation, V16, P581, DOI 10.1097/00004630-199511000-00004; Clausen T, 2005, ANN NY ACAD SCI, V1066, P286, DOI 10.1196/annals.1363.021; Despa F, 2005, BURNS, V31, P568, DOI 10.1016/j.burns.2005.01.015; Firestone MA, 2003, BIOMACROMOLECULES, V4, P1539, DOI 10.1021/bm034134r; FLECKENSTEIN JL, 1996, ENCY NUCL MAGNETIC R, P4430; Foley JM, 1999, J APPL PHYSIOL, V87, P2311; Gambarota G, 2001, MAGNET RESON MED, V46, P592, DOI 10.1002/mrm.1232; Gissel H, 2005, ANN NY ACAD SCI, V1066, P272, DOI 10.1196/annals.1363.024; Greenebaum B, 2004, BURNS, V30, P539, DOI 10.1016/j.burns.2004.02.009; Grindel JM, 2002, BIOPHARM DRUG DISPOS, V23, P87, DOI 10.1002/bdd.297; Grindel JM, 2002, J PHARM SCI-US, V91, P1936, DOI 10.1002/jps.10190; HAACKE EM, 2005, MAGNETIC RESONANCE I; Jewell RC, 1997, J PHARM SCI, V86, P808, DOI 10.1021/js960491e; LEE RC, 1988, J SURG RES, V44, P709, DOI 10.1016/0022-4804(88)90105-9; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; LEE RC, 1992, ELECT TRAUMA PATHOPH; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; Maskarinec SA, 2002, BIOPHYS J, V82, P1453, DOI 10.1016/S0006-3495(02)75499-4; Matthews KL, 2006, BURNS, V32, P755, DOI 10.1016/j.burns.2006.01.011; Merletti R, 1999, IEEE T BIO-MED ENG, V46, P810, DOI 10.1109/10.771190; Miyake K, 2003, CRIT CARE MED, V31, pS496, DOI 10.1097/01.CCM.0000081432.72812.16; OKeefe JH, 1996, AM J CARDIOL, V78, P747, DOI 10.1016/S0002-9149(96)00414-6; Orringer EP, 2001, JAMA-J AM MED ASSOC, V286, P2099, DOI 10.1001/jama.286.17.2099; Saab G, 1999, MAGNET RESON MED, V42, P150, DOI 10.1002/(SICI)1522-2594(199907)42:1<150::AID-MRM20>3.0.CO;2-5; Serbest G, 2005, J NEUROTRAUM, V22, P119, DOI 10.1089/neu.2005.22.119; TROPEA BI, 1992, J BIOMECH ENG-T ASME, V114, P241, DOI 10.1115/1.2891378; Wu GH, 2005, BIOPHYS J, V89, P3159, DOI 10.1529/biophysj.104.052290; Yasuda S, 2005, NATURE, V436, P1025, DOI 10.1038/nature03844	34	39	39	0	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0005-2736	1879-2642		BBA-BIOMEMBRANES	Biochim. Biophys. Acta-Biomembr.	MAY	2007	1768	5					1238	1246		10.1016/j.bbamem.2007.01.012			9	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	162MF	WOS:000246091000024	17382288	Green Accepted			2021-06-18	
J	Goldenberg, G; Hartmann-Schmid, K; Surer, F; Daumuller, M; Hermsdorfer, J				Goldenberg, Georg; Hartmann-Schmid, Karoline; Suerer, Fatma; Daumueller, Meike; Hermsdoerfer, Joachim			The impact of dysexecutive syndrome on use of tools and technical devices	CORTEX			English	Article						apraxia; tool-use; dysexecutive syndrome; working memory; activities of daily living	CLOSED-HEAD-INJURY; NATURALISTIC ACTION; IDEATIONAL APRAXIA; ACTION IMPAIRMENT; BRAIN; KNOWLEDGE; DEFICIT; LONDON; STROKE; DAMAGE	We present two studies aimed at elucidating why patients with dysexecutive syndrome encounter difficulties with the use of tools and technical devices. Two different groups of patients with dysexecutive syndrome took part in them. Their results were compared with those of two groups of normal controls and in the first study also with those of patients with posterior left or right brain lesions. The first study contrasted single step with multi-step actions and explored the role of novelty and consecutive demands on problem solving. Dysexecutive patients encountered problems only with the multistep actions. The rank order of strength of impairment corresponded to the presumed rank order of demands on problem solving, but the analysis of individual results demonstrated high variability of this pattern which moreover could not be fully replicated when the same tests were applied in the second study. The second study pursued the hypothesis that maintenance of goals and constraints in working memory is the crucial factor for difficulties of dysexecutive patients. Support for this hypothesis was less ambiguous, but as this study did not include patients with posterior lesions it remains open whether this factor is specific for dysexecutive syndrome and prefrontal brain damage or applies to brain damage regardless of its location.	Bogenhausen Hosp, Neuropsychol Dept, D-81925 Munich, Germany	Goldenberg, G (corresponding author), Bogenhausen Hosp, Neuropsychol Dept, Englschaulkingerstr 77, D-81925 Munich, Germany.	Georg.Goldenberg@extem.lrz-muenchen.de					Baddeley A. D., 1986, WORKING MEMORY; Berg WK, 2002, J CLIN EXP NEUROPSYC, V24, P586, DOI 10.1076/jcen.24.5.586.1006; Buxbaum LJ, 1998, COGNITIVE NEUROPSYCH, V15, P617, DOI 10.1080/026432998381032; DERENZI E, 1988, BRAIN, V111, P1173, DOI 10.1093/brain/111.5.1173; DERENZI E, 1968, NEUROPSYCHOLOGIA, V6, P41, DOI 10.1016/0028-3932(68)90037-7; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; Goldenberg G, 1998, NEUROPSYCHOLOGIA, V36, P581, DOI 10.1016/S0028-3932(97)00165-6; Goldenberg G, 2003, NEUROPSYCHOLOGIA, V41, P1565, DOI 10.1016/S0028-3932(03)00120-9; Goldenberg G, 2002, NEUROPSYCHOLOGIE ALL; Hartmann K, 2005, NEUROPSYCHOLOGIA, V43, P625, DOI 10.1016/j.neuropsychologia.2004.07.015; Hodges JR, 1999, P NATL ACAD SCI USA, V96, P9444, DOI 10.1073/pnas.96.16.9444; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2nd; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Morlaas J., 1928, CONTRIBUTION ETUDE A; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; PICK A, 1905, STUDIENT MOTORISCHEN; POECK K, 1982, ARCH ITAL BIOL, V120, P361; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; Rumiati RI, 2001, COGN NEUROPSYCHOL, V18, P617, DOI 10.1080/02643290126375; Schwartz M. F., 2002, NATURALISTIC ACTION; Schwartz MF, 1999, NEUROPSYCHOLOGIA, V37, P51; Schwartz MF, 1998, NEUROPSYCHOLOGY, V12, P13, DOI 10.1037/0894-4105.12.1.13; Schwartz MF, 2002, NEUROPSYCHOL REHABIL, V12, P311, DOI 10.1080/09602010244000084; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Spatt J, 2002, J NEUROL, V249, P601, DOI 10.1007/s004150200070; Sunderland A, 2000, NEUROPSYCHOLOGIA, V38, P923, DOI 10.1016/S0028-3932(00)00021-X; Sunderland A, 1999, STROKE, V30, P949, DOI 10.1161/01.STR.30.5.949; Unterrainer JM, 2004, J CLIN EXP NEUROPSYC, V26, P846, DOI 10.1080/13803390490509574; Zhang JJ, 1997, COGNITIVE SCI, V21, P179	31	39	39	0	1	ELSEVIER MASSON	MILANO	VIA PALEOCAPA 7, 20121 MILANO, ITALY	0010-9452			CORTEX	Cortex	APR	2007	43	3					424	435		10.1016/S0010-9452(08)70467-2			12	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	169QI	WOS:000246606300014	17533765				2021-06-18	
J	Hebb, MO; McArthur, DL; Alger, J; Etchepare, M; Glenn, TC; Bergsneider, M; Martin, N; Vespa, PM				Hebb, Matthew O.; McArthur, David L.; Alger, Jeffry; Etchepare, Maria; Glenn, Thomas C.; Bergsneider, Marvin; Martin, Neil; Vespa, Paul M.			Impaired percent alpha variability on continuous electroencephalography is associated with thalamic injury and predicts poor long-term outcome after human traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; electrophysiology; outcome measures; recovery; secondary insult	SEVERE HEAD-INJURY; CEREBRAL-CORTEX; METABOLIC-RATE; EEG FREQUENCY; CLASSIFICATION; RHYTHMS; STEM; MECHANISMS; PROGNOSIS; COMA	Continuous electroencephalography (cEEG) is potentially useful in determining prognosis in patients with traumatic brain injuries (TBI). The objective of this prospective, observational cohort study was to determine if the percent alpha variability (PAV) on cEEG was predictive of outcome following TBI. Injury characteristics were indexed to assess whether lesions in specific cerebral loci were correlated with PAV and patient recovery. Fifty-three TBI patients were studied using cEEG recording and serial neuroimaging. Clinical recovery was assessed at regular intervals in hospital and following discharge. The principal outcome measures included the mean 3-day PAV score, the 7-day PAV pattern, delineation of the anatomical sites of brain injury, and the 6-month clinical outcome, as measured by the Glasgow Outcome Scale (GOS). Significant univariate (p = 0.030) and multivariate (p = 0.008) relations were identified between PAV and GOS scores. PAV offered good discrimination between favorable and unfavorable 6-month outcomes (AUC 0.76) and, with a cut-point of 0.20, had a sensitivity of 87% and negative predictive value of 82%. Multivariate modeling revealed that injuries of the thalamus (p = 0.009) and basal ganglia (p = 0.016), and the presence of diffuse edema (p = 0.009), were the key anatomical predictors of PAV. Brainstem injuries (p = 0.020) and indicators of diffuse cerebral trauma, such as deep white matter shearing (p = 0.036) and multiple subcortical lesions (p = 0.033), were the principal determinants of 6-month recovery. Inclusion of PAV enhanced the accuracy of prediction models that encompassed a selective combination of clinical and anatomical variables (adjusted R-2 = 0.458, p < 0.001). The two main results of this study are (1) PAV is a sensitive predictor of 6-month clinical outcomes following TBI, and (2) injury to the thalamus is related to impaired PAV. PAV appears best utilized as a functional adjunct to traditional clinical and anatomical predictors.	Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; Dalhousie Univ, Brain Repair Ctr, Div Neurosurg, Halifax, NS, Canada	Vespa, PM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Brain Injury Res Ctr, CHS 18-218,10833 LeConte Ave, Los Angeles, CA 90095 USA.	pvespa@mednet.ucla.edu	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314; Glenn, Thomas/0000-0003-4273-3408; Martin, Neil/0000-0002-6565-4131			ANDERSEN P, 1968, PHYSL BASIS ALPHA RH; BALDYMOULINIER M, 1968, EXP BRAIN RES, V5, P55; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bullock RM, 2000, J NEUROTRAUM, V17, P449; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; Combes P, 1996, INTENS CARE MED, V22, P1391, DOI 10.1007/s001340050269; Danos P, 2001, NEUROPSYCHOBIOLOGY, V43, P265, DOI 10.1159/000054901; DASILVA FHL, 1980, ELECTROEN CLIN NEURO, V50, P449, DOI 10.1016/0013-4694(80)90011-5; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Firsching R, 2002, NEUROL RES, V24, P145, DOI 10.1179/016164102101199684; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; Goldman RI, 2002, NEUROREPORT, V13, P2487, DOI 10.1097/00001756-200212200-00022; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Hughes SW, 2005, NEUROSCIENTIST, V11, P357, DOI 10.1177/1073858405277450; INGVAR DH, 1976, ELECTROEN CLIN NEURO, V41, P268, DOI 10.1016/0013-4694(76)90119-X; IRAGUI VJ, 1983, J NEUROL NEUROSUR PS, V46, P632, DOI 10.1136/jnnp.46.7.632; Kaplan PW, 1999, CLIN NEUROPHYSIOL, V110, P205, DOI 10.1016/S1388-2457(98)00046-7; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRAUS JF, 2000, FEUROSURG FOCUS, V8, P1; Larson CL, 1998, PSYCHOPHYSIOLOGY, V35, P162, DOI 10.1017/S0048577298001620; Lindgren KA, 1999, BIOL PSYCHIAT, V45, P943, DOI 10.1016/S0006-3223(98)00350-3; Littell R. C. G. A., 1996, SAS SYSTEM MIXED MOD; LIU HM, 1995, J TRAUMA, V38, P330, DOI 10.1097/00005373-199503000-00003; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; LOPESDASILVA FH, 1973, ELECTROEN CLIN NEURO, V35, P627, DOI 10.1016/0013-4694(73)90216-2; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MORISON RS, 1945, J NEUROPHYSIOL, V8, P309; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Niedermeyer E, 1997, INT J PSYCHOPHYSIOL, V26, P31, DOI 10.1016/S0167-8760(97)00754-X; Nuwer M R, 1994, Neurosurg Clin N Am, V5, P647; OHMOTO T, 1978, APPL NEUROPHYSIOL, V41, P188; R DEVELOPMENT CORE TEAM, 2005, R LANG ENV STAT COMP; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Schreckenberger M, 2004, NEUROIMAGE, V22, P637, DOI 10.1016/j.neuroimage.2004.01.047; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; SING T, 2004, ROCR R PACKAGE VISUA; Slewa-Younan S, 2004, ARCH PHYS MED REHAB, V85, P376, DOI 10.1016/j.apmr.2003.05.007; Steriade M, 1997, CEREB CORTEX, V7, P583, DOI 10.1093/cercor/7.6.583; Stocchetti N, 2000, J NEUROL NEUROSUR PS, V68, P14, DOI 10.1136/jnnp.68.1.14; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tooth L, 2001, BRAIN INJURY, V15, P613, DOI 10.1080/02699050010013923; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 1997, ELECTROEN CLIN NEURO, V103, P607, DOI 10.1016/S0013-4694(97)00071-0; Vespa PM, 2002, J NEUROSURG, V97, P84, DOI 10.3171/jns.2002.97.1.0084; VONKROSIGK M, 1993, SCIENCE, V261, P361, DOI 10.1126/science.8392750; Vos PE, 2001, J NEUROTRAUM, V18, P649, DOI 10.1089/089771501750357591; Wedekind C, 2002, BRIT J NEUROSURG, V16, P256, DOI 10.1080/02688690220148842; WESTMORELAND BF, 1975, ARCH NEUROL-CHICAGO, V32, P713, DOI 10.1001/archneur.1975.00490530035001; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; Yazawa S, 2001, INTERNAL MED, V40, P443, DOI 10.2169/internalmedicine.40.443	53	39	41	1	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2007	24	4					579	590		10.1089/neu.2006.0146			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	159NE	WOS:000245872000001	17439342				2021-06-18	
J	Mishra, MK; Koli, P; Bhowmick, S; Basu, A				Mishra, Manoj Kumar; Koli, Preeti; Bhowmick, Sourojit; Basu, Anirban			Neuroprotection conferred by astrocytes is insufficient to protect animals from succumbing to Japanese encephalitis	NEUROCHEMISTRY INTERNATIONAL			English	Article						astrocytes; Japanese encephalitis virus; glutamate transporters; ceruloplasmin; neurotrophic factors; reactive oxygen species	CILIARY NEUROTROPHIC FACTOR; TRAUMATIC BRAIN-INJURY; VIRUS-INFECTION; SPINAL-CORD; PROINFLAMMATORY MEDIATORS; REACTIVE ASTROCYTES; CEREBROSPINAL-FLUID; FACTOR EXPRESSION; OXIDATIVE STRESS; TYPE-1 RECEPTOR	Astrocytes play a key role in regulating aspects of inflammation and in the homeostatic maintenance of the central nervous system (CNS). However, the role of astrocytes in viral encephalitis mediated inflammation is not well documented. As Japanese encephalitis virus (JEV) infection is localized to neurons and considering the importance of astrocytes in supporting neuronal survival and function, we have exploited an experimental model of Japanese encephalitis (JE) to better understand the role of astrocytes in JE. Suckling mice pups were inoculated with the virus and 2 and 4 days later we analyzed a panel of molecules characteristic of reactive astrogliosis. We show that JEV infection increases the expression of astrocyte-specific glial fibrillary acidic protein (GFAP), the glutamate aspartate transporter (GLAST), glutamate transporter-1 (GLT-1) and ceruloplasmin (CP). The transcript levels of growth factors produced predominantly by activated astrocytes such as nerve growth factor (NGF) and ciliary neurotrophin factor (CNTF) were elevated following JEV infection. The transcript level of brain-derived neurotrophic factor (BDNF) was also elevated following JEV infection. Both NGF and CNTF were capable of preventing ROS mediated neuronal death following in vitro JEV infection to a certain extent. Taken altogether, these data indicate that increased astrogliosis following JEV infection is accompanied by the enhanced ability of astrocytes to detoxify glutamate, inactivate free radical and produce neurotrophic factors that are involved in neuronal protection. However, this elevated physiological state of astrocyte is insufficient in conferring neuroprotection, as infected animals eventually succumb to infection. The response of astrocytes to JE can be amplified to modulate the adaptive response of brain to induce neuroprotection. (c) 2007 Elsevier Ltd. All rights reserved.	Natl Brain Res Ctr, Manesar 122050, Haryana, India	Basu, A (corresponding author), Natl Brain Res Ctr, Manesar 122050, Haryana, India.	anirban@nbrc.res.in	BASU, ANIRBAN/C-1166-2009; Mishra, Manoj/A-7105-2018	Mishra, Manoj/0000-0001-9636-4930; Basu, Anirban/0000-0002-5200-2054			ALBRECHT M, 2002, SILICO BIOL, V2, P1; Appaiahgari MB, 2006, MICROBES INFECT, V8, P92, DOI 10.1016/j.micinf.2005.05.023; Aschner M, 1998, NEUROTOXICOLOGY, V19, P269; Aschner M, 1998, NEUROTOXICOLOGY, V19, P7; Basu A, 2005, J CEREBR BLOOD F MET, V25, P17, DOI 10.1038/sj.jcbfm.9600002; Basu A, 2002, J NEUROSCI, V22, P6071; Betteridge DJ, 2000, METABOLISM, V49, P3, DOI 10.1016/S0026-0495(00)80077-3; BIGNAMI A, 1989, INT J DEV NEUROSCI, V7, P343, DOI 10.1016/0736-5748(89)90056-7; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; CHATURVEDI UC, 1979, CLIN EXP IMMUNOL, V38, P492; Chen CJ, 2002, J GEN VIROL, V83, P1897, DOI 10.1099/0022-1317-83-8-1897; Chen J, 2000, Health Rep, V11, P9; Chiaretti A, 2004, ACTA PAEDIATR, V93, P1178, DOI 10.1080/08035250410031314; Ciriolo MR, 2005, ANTIOXID REDOX SIGN, V7, P432, DOI 10.1089/ars.2005.7.432; Delaney CL, 1996, J NEUROSCI, V16, P6908; Dreyfus CF, 1999, J NEUROSCI RES, V56, P1, DOI 10.1002/(SICI)1097-4547(19990401)56:1<1::AID-JNR1>3.0.CO;2-3; Dringen R, 2000, EUR J BIOCHEM, V267, P4912, DOI 10.1046/j.1432-1327.2000.01597.x; DRINGEN R, 1995, DEV NEUROSCI-BASEL, V17, P63, DOI 10.1159/000111275; DRINGEN R, 1993, BRAIN RES, V623, P208, DOI 10.1016/0006-8993(93)91429-V; Eng DL, 1997, BRAIN RES, V778, P215, DOI 10.1016/S0006-8993(97)01093-7; ENG LF, 1992, PROG BRAIN RES, V94, P353; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FRIEDMAN WJ, 1990, J NEUROSCI RES, V27, P374, DOI 10.1002/jnr.490270316; Ghoshal A, 2007, GLIA, V55, P483, DOI 10.1002/glia.20474; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; Halliwell B, 2001, DRUG AGING, V18, P685, DOI 10.2165/00002512-200118090-00004; HASE T, 1992, VIRCHOWS ARCH B, V63, P25; Ichiyama T, 2000, J NEUROL SCI, V177, P146, DOI 10.1016/S0022-510X(00)00366-X; Kaur N, 2005, J NEUROCHEM, V92, P1521, DOI 10.1111/j.1471-4159.2004.02990.x; Kaur R, 2003, J NEUROVIROL, V9, P421, DOI 10.1080/13550280390218454; Krady JK, 2005, DIABETES, V54, P1559, DOI 10.2337/diabetes.54.5.1559; Krum JM, 2002, EXP NEUROL, V174, P137, DOI 10.1006/exnr.2002.7867; Kuhlow CJ, 2003, GLIA, V44, P76, DOI 10.1002/glia.10273; Lin HW, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-15; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; Liu HL, 2003, J NEUROCHEM, V86, P1553, DOI 10.1046/j.1471-4159.2003.01978.x; Lombard DB, 2005, CELL, V120, P497, DOI 10.1016/j.cell.2005.01.028; MATHUR A, 1988, BRIT J EXP PATHOL, V69, P423; MATHUR A, 1992, INT J EXP PATHOL, V73, P603; Messersmith DJ, 2000, J NEUROSCI RES, V62, P241, DOI 10.1002/1097-4547(20001015)62:2<241::AID-JNR9>3.0.CO;2-D; MUCKE L, 1993, FASEB J, V7, P1226; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; NORTON WT, 1992, NEUROCHEM RES, V17, P877, DOI 10.1007/BF00993263; Palmer C, 1999, J NEUROSCI RES, V56, P60, DOI 10.1002/(SICI)1097-4547(19990401)56:1<60::AID-JNR8>3.0.CO;2-A; Patel BN, 2002, J NEUROSCI, V22, P6578; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Raivich G, 1999, ACTA NEUROCHIR SUPPL, V73, P21; Reier P J, 1988, Adv Neurol, V47, P87; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; ROSENBERG PA, 1989, NEUROSCI LETT, V103, P162, DOI 10.1016/0304-3940(89)90569-7; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; RUDGE JS, 1995, J NEUROSCI, V15, P6856; SCHOUSBOE A, 1992, PROG BRAIN RES, V94, P199; SCHRECK R, 1994, METHOD ENZYMOL, V234, P151; SCHWARTZ JP, 1994, PERSPECT DEV NEUROBI, V2, P251; Sibson NR, 2001, J NEUROCHEM, V76, P975, DOI 10.1046/j.1471-4159.2001.00074.x; SPRANGERS SA, 1990, ENDOCRINOLOGY, V126, P1133, DOI 10.1210/endo-126-2-1133; TRAUGOTT U, 1988, J NEUROL SCI, V84, P257, DOI 10.1016/0022-510X(88)90130-X; Uchida K, 1998, J NEUROL, V245, P781, DOI 10.1007/s004150050287; Vrati S, 1999, J GEN VIROL, V80, P1665, DOI 10.1099/0022-1317-80-7-1665; Vrati S, 1999, AM J TROP MED HYG, V61, P677, DOI 10.4269/ajtmh.1999.61.677; Wallin C, 2000, DEV BRAIN RES, V125, P51, DOI 10.1016/S0165-3806(00)00112-7; Watase K, 1998, EUR J NEUROSCI, V10, P976, DOI 10.1046/j.1460-9568.1998.00108.x; Wilson JX, 1997, CAN J PHYSIOL PHARM, V75, P1149, DOI 10.1139/cjpp-75-10-11-1149	66	39	43	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186			NEUROCHEM INT	Neurochem. Int.	APR	2007	50	5					764	773		10.1016/j.neuint.2007.01.014			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	160QC	WOS:000245956400012	17353066				2021-06-18	
J	Pirris, SM; Pollack, IF; Snyderman, CH; Carrau, RL; Spiro, RM; Tyler-Kabara, E; Kassam, AB				Pirris, Stephen M.; Pollack, Ian F.; Snyderman, Carl H.; Carrau, Ricardo L.; Spiro, Richard M.; Tyler-Kabara, Elizabeth; Kassam, Amin B.			Corridor surgery: the current paradigm for skull base surgery	CHILDS NERVOUS SYSTEM			English	Article						chordoma; endoscopic endonasal approach; clival tumors; pediatric skull base tumors; carotid-vertebral window	CHORDOMAS	Clival chordomas are rare tumors, especially in the pediatric population. In this report, we present the case of a 3-year-old boy who was found to have a large posterior pharyngeal, clival, and posterior fossa tumor detected on a CT scan after a closed head injury. Further questioning revealed a history of ataxia and dysphagia. Imaging confirmed severe extrinsic brain stem compression. The tumor was resected in multiple stages utilizing a minimally invasive endoscopic endonasal technique along with open transfacetal, transcondylar approach through the carotid-vertebral window. The child suffered no permanent complications as a result of our treatment and his dysphagia significantly improved. Although a complete resection was not feasible due to vascular encasement by the tumor, extensive decompression was obtained with minimal morbidity. We present this case to illustrate a new paradigm of skull base surgical approaches for large clival lesions in pediatric patients that allows aggressive resection with minimal morbidity.	Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA 15213 USA	Kassam, AB (corresponding author), Univ Pittsburgh, Med Ctr, Dept Neurol Surg, 200 Lothrop St PUH B-400, Pittsburgh, PA 15213 USA.	kassamab@upmc.edu	Tyler-Kabara, Elizabeth/H-4930-2013	Tyler-Kabara, Elizabeth/0000-0003-3286-1094			Cavallo Luigi M, 2005, Neurosurg Focus, V19, pE2; Colli B O, 2001, Neurosurg Focus, V10, pE1; GAY E, 1995, NEUROSURGERY, V36, P887, DOI 10.1227/00006123-199505000-00001; GAY E, 1995, NEUROSURGERY, V36, P896; HEFFELFINGER MJ, 1973, CANCER-AM CANCER SOC, V32, P410, DOI 10.1002/1097-0142(197308)32:2<410::AID-CNCR2820320219>3.0.CO;2-S; Kassam AB, 2005, NEUROSURGERY, V57, P213, DOI 10.1227/01.NEU.0000163687.64774.E4; Kassam Amin, 2005, Neurosurg Focus, V19, pE4; Kassam Amin B, 2005, Ear Nose Throat J, V84, P312; MCMAHON PJ, 1995, HAND UPP E, V12, P1; ONEILL P, 1985, NEUROSURGERY, V16, P166, DOI 10.1227/00006123-198502000-00007	10	39	41	0	2	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	APR	2007	23	4					377	384		10.1007/s00381-006-0281-6			8	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	143UH	WOS:000244750900004	17226036				2021-06-18	
J	Gouveia, PAR; Brucki, SMD; Malheiros, SMF; Bueno, OFA				Rodrigues Gouveia, Paula Adriana; Dom Brucki, Sonia Maria; Fleury Malheiros, Suzana Maria; Amodeo Bueno, Orlando Francisco			Disorders in planning and strategy application in frontal lobe lesion patients	BRAIN AND COGNITION			English	Article						executive functions; planning; neuropsychological tests; frontal lobe lesion; ecological tests	TOWER-OF-LONDON; TRAUMATIC BRAIN-INJURY; CARD SORTING TEST; DYSEXECUTIVE SYNDROME; PERFORMANCE; DAMAGE; TASK; IMPAIRMENTS; ACTIVATION; DEFICITS	The aim of this study was to investigate deficits in planning ability using an adapted version of the Modified Six Elements Test, from the Behavioral Assessment of the Dysexecutive Syndrome-BADS [Wilson, B. A., Alderman, N., Burgess, P. W., Emslie, H., & Evans, J. J. (1996). Behavioural Assessment of the Dysexecutiue Syndrome (BADS). Bury St Edmunds, U.K.: Thames Valley Test Company. Trans. Ricardo O Souza, Sergio L Schmidt. Rio de Janeiro: Cognicao]. Subjects were left- and right-frontal lobe lesion patients. Other measures of executive dysfunctions used were verbal fluency, the Wisconsin Card Sorting Test, and the Trail Making Test. These other instruments were sensitive to detect executive deficits in the left frontal lobe lesion group, except the Wisconsin Card Sorting Test, which showed impairment only for the frontal lobe lesion group as a whole. The Modified Six Elements Test detected planning disorders in left frontal lobe lesion patients. The deficit of these patients was due to a greater likelihood to break the rules of the task, that is, in plan-following processes, rather than in planning the strategic approach to solve it. (c) 2006 Elsevier Inc. All rights reserved.	Univ Fed Sao Paulo, Sao Paulo, Brazil; Hosp Santa Marcelina, Sao Paulo, Brazil	Gouveia, PAR (corresponding author), Univ Fed Sao Paulo, Sao Paulo, Brazil.	paula-gouveia@uol.com.br	Malheiros, Suzana M. F./O-2620-2013; Brucki, Sonia MD/B-5736-2014; Brucki, Sonia/L-4201-2019	Brucki, Sonia MD/0000-0002-8303-6732; Brucki, Sonia/0000-0002-8303-6732			Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; ARMSTRONG C, 1993, NEUROLOGY, V43, P1961, DOI 10.1212/WNL.43.10.1961; AXELROD BN, 1993, CLIN NEUROPSYCHOL, V7, P205, DOI 10.1080/13854049308401523; Baddeley A, 1997, NEUROPSYCHOLOGY, V11, P187, DOI 10.1037/0894-4105.11.2.187; Barcelo F, 2000, REV NEUROLOGIA, V30, P855, DOI 10.33588/rn.3009.99451; Beauchamp MH, 2003, NEUROIMAGE, V20, P1649, DOI 10.1016/j.neuroimage.2003.07.003; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P606, DOI 10.1017/S1355617705050721; BRANDAO E, 1987, THESIS PONTIFICIA U; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Carlin D, 2000, NEUROPSYCHOLOGIA, V38, P655, DOI 10.1016/S0028-3932(99)00102-5; Cazalis F, 2003, EUR J NEUROSCI, V17, P2219, DOI 10.1046/j.1460-9568.2003.02633.x; Chan RCK, 2004, EUR ARCH PSY CLIN N, V254, P256, DOI 10.1007/s00406-00-0492-3; Chan RCK, 2003, BRAIN INJURY, V17, P131, DOI 10.1080/0269905021000010168; Chan RCK, 2002, J INT NEUROPSYCH SOC, V8, P771, DOI 10.1017/S1355617702860052; Evans JJ, 1997, PSYCHOL MED, V27, P635, DOI 10.1017/S0033291797004790; Garden SE, 2001, NEUROPSYCHOLOGY, V15, P472, DOI 10.1037//0894-4105.15.4.472; GOEL V, 1995, NEUROPSYCHOLOGIA, V33, P623, DOI 10.1016/0028-3932(95)90866-P; Goethals I, 2004, NUCL MED COMMUN, V25, P177, DOI 10.1097/00006231-200402000-00015; Heaton R. K, 1981, WISCONSIN CARD SORTI; Ihara H, 2000, J NEUROL NEUROSUR PS, V68, P731, DOI 10.1136/jnnp.68.6.731; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; Morris RG, 1997, NEUROPSYCHOLOGIA, V35, P1147, DOI 10.1016/S0028-3932(97)00009-2; Newman SD, 2003, NEUROPSYCHOLOGIA, V41, P1668, DOI 10.1016/S0028-3932(03)00091-5; Nilsson JP, 2005, J SLEEP RES, V14, P1, DOI 10.1111/j.1365-2869.2005.00442.x; Owen AM, 1996, EUR J NEUROSCI, V8, P353, DOI 10.1111/j.1460-9568.1996.tb01219.x; Reitan RM., 1985, HALSTEAD REITAN NEUR; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; Spreen O, 1969, NEUROSENSORY CTR COM; Stuss DT, 2000, NEUROPSYCHOLOGIA, V38, P388, DOI 10.1016/S0028-3932(99)00093-7; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; van den Heuvel OA, 2003, NEUROIMAGE, V18, P367, DOI 10.1016/S1053-8119(02)00010-1; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wilson BA, 1996, BEHAV ASSESSMENT DYS	39	39	44	0	27	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626	1090-2147		BRAIN COGNITION	Brain Cogn.	APR	2007	63	3					240	246		10.1016/j.bandc.2006.09.001			7	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	154SF	WOS:000245527200004	17049704				2021-06-18	
J	Alderman, N				Alderman, Nick			Prevalence, characteristics and causes of aggressive behaviour observed within a neurobehavioural rehabilitation service: Predictors and implications for management	BRAIN INJURY			English	Article						neurobehavioural disability; aggression; neurorehabilitation; OAS-MNR	TRAUMATIC BRAIN-INJURY; CONTINGENT RESTRAINT; PHYSICAL AGGRESSION; OVERT AGGRESSION; SETTING EVENTS; OAS-MNR; STAFF; REDUCTION; SCALE	Primary objective: To describe the characteristics and determinants of aggressive behaviour observed within a neurobehavioural unit. Research design: Statistical analysis of a database of routinely administered clinical measures, including the Overt Aggression Scale-Modified for Neurorehabilitation. Methods and procedures: Records of aggressive behaviour shown by 108 patients over 14 days were studied. Patient characteristics were also captured using 23 items from the Rehabilitation Institute of Chicago-Functional Assessment Scale. Four factors were identified: 'communication', ` cognition/ function', ` neurobehavioural disability' and ` mood & self-esteem'. Relationships between patient characteristics, external factors and their interactions with aggression were examined. Main outcomes and results: Many ( 5548) episodes of aggression were recorded. Whilst most comprised verbal aggression, 729 physical assaults were made on others. Aggressive behaviour typically followed staff prompting or no obvious antecedent. Medical intervention was rare, most aggression was managed by staff not reinforcing this behaviour. Over 80% of physical assaults were made by people rated as having severe symptoms of neurobehavioural disability and poor communication. Conclusions: Neurobehavioural units require sufficient staff resources to engage patients in purposeful activities as these were associated with the least severe aggression. Despite increased OAS-MNR usage, a standardized methodology for investigating aggression is required to ensure compatibility between datasets.	St Andreas Hosp, St Andrews Healthcare Kemsley, Consultant Clin Neuropsychol & Special Lead, Northampton NN1 5DG, England	Alderman, N (corresponding author), St Andreas Hosp, St Andrews Healthcare Kemsley, Consultant Clin Neuropsychol & Special Lead, Billing Rd, Northampton NN1 5DG, England.	alderman@standrew.co.uk		Alderman, Nick/0000-0002-8523-4142			Alderman N, 2003, STUD NEUROPSYCHOL DE, P171; Alderman N, 2001, BRAIN DAM B, P175; Alderman N, 2002, BRAIN INJURY, V16, P469, DOI 10.1080/02699050110118458; Alderman N, 1999, NEUROPSYCHOL REHABIL, V9, P385, DOI 10.1080/096020199389455; Alderman N, 1997, BRAIN INJURY, V11, P503, DOI 10.1080/713802182; Alderman N, 1999, BRAIN INJURY, V13, P669; Alderman N, 1997, BRAIN INJURY, V11, P79, DOI 10.1080/026990597123683; ALDERMAN N, 2002, EVIDENCE MENTAL HLTH, P142; ALDERMAN N, 1990, COGNITIVE REHABILITA, P204; ALDERMAN N, 2003, NEUROLOGICAL REHABIL, P327; ALDERMAN N, 2004, RAHABILITATION NEURO, P269; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Beaulieu CL, 1997, ARCH CLIN NEUROPSYCH, V12, P285, DOI 10.1093/arclin/12.4.285a; Brodaty H, 2001, INT J GERIATR PSYCH, V16, P504, DOI 10.1002/gps.382; Brower MC, 2001, J NEUROL NEUROSUR PS, V71, P720, DOI 10.1136/jnnp.71.6.720; BURGESS PW, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P110; BURKE WH, 1988, INT J REHABIL RES, V11, P235, DOI 10.1097/00004356-198809000-00003; Cunningham J, 2003, AGGRESSIVE BEHAV, V29, P31, DOI 10.1002/ab.10027; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Fleminger S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003299.pub2; Fluharty G, 2001, BRAIN INJURY, V15, P995, DOI 10.1080/02699050010025795; Freyne A, 1996, INT J GERIATR PSYCH, V11, P57, DOI 10.1002/(SICI)1099-1166(199601)11:1<57::AID-GPS290>3.3.CO;2-Q; Giles GM, 2005, BRAIN INJURY, V19, P753, DOI 10.1080/02699050500110108; Granger CV, 1986, GUIDE USE UNIFORM DA; GRIEVE KW, 2002, PERSONALITY INDIVIDU, V32, P639; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hoaken PNS, 2003, AGGRESSIVE BEHAV, V29, P15, DOI 10.1002/ab.10023; Howell D. C., 1997, STAT METHODS PSYCHOL; Howes HFR, 2005, BRAIN INJURY, V19, P403, DOI 10.1080/02699050400025158; Johnson R., 1996, CLIN REHABIL, V10, P173, DOI [DOI 10.1177/026921559601000215, 10.1177/026921559601000215]; KAY SR, 1988, J NERV MENT DIS, V176, P547, DOI 10.1097/00005053-198809000-00008; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KINNEAR PR, 1994, SPDD WINDOWS MADE SI; Lazaro F, 2000, PSYCHIAT B, V24, P264; Manchester D, 1997, BRAIN INJURY, V11, P605, DOI 10.1080/026990597123296; McGill P, 2003, BEHAV MODIF, V27, P265, DOI 10.1177/0145445503251604; McMillan TM, 2001, BRAIN DAM B, P257; MILLER L, 1994, J OFFENDER REHABILIT, V21, P91, DOI DOI 10.1300/J076; Novaco RW, 2004, PSYCHOL ASSESSMENT, V16, P42, DOI 10.1037/1040-3590.16.1.42; Persel CS, 1997, BRAIN INJURY, V11, P751; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Poggi G, 2003, BRAIN INJURY, V17, P835, DOI 10.1080/0269905031000088612; PRIGATANO GP, 1987, BNI Q, V3, P2; Pryor J, 2004, DISABIL REHABIL, V26, P974, DOI 10.1080/09638280410001702397; Pryor Julie, 2005, J Neurosci Nurs, V37, P117; *REH I CHIC, 1992, REH I CHIC FUNCT ASS; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; WAHLER RG, 1981, J APPL BEHAV ANAL, V14, P327, DOI 10.1901/jaba.1981.14-327; Watson C, 2001, BRAIN INJURY, V15, P1003, DOI 10.1080/02699050010022662; Willis TJ, 2003, J HEAD TRAUMA REHAB, V18, P75, DOI 10.1097/00001199-200301000-00008; WILSON BA, 1991, HDB BEHAV THERAPY PS, P227; Winstanley S, 2004, AGGRESSIVE BEHAV, V30, P534, DOI 10.1002/ab.20052; Wood R. L., 1987, BRAIN INJURY REHABIL; Wood RL, 2001, BRAIN DAM B, P133; Wood RL, 2001, BRAIN DAM B, P107; Wood RL, 2001, BRAIN DAM B, P3; Wood RL, 1981, APPL CONDITIONING TH, P81; Wood RL, 2006, J NEUROPSYCH CLIN N, V18, P333, DOI 10.1176/appi.neuropsych.18.3.333; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	59	39	39	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	9					891	911		10.1080/02699050701543560			21	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	202ZA	WOS:000248942600002	17729043				2021-06-18	
J	Dhikav, V; Anand, KS				Dhikav, Vikas; Anand, Kujeet Singh			Is hippocampal atrophy a future drug target?	MEDICAL HYPOTHESES			English	Article							CA3 PYRAMIDAL NEURONS; ADULT-RAT HIPPOCAMPUS; ALZHEIMERS-DISEASE; MOOD STABILIZERS; CHRONIC STRESS; ANTIDEPRESSANT TREATMENT; CELL-PROLIFERATION; NEUROGENESIS; TIANEPTINE; PHENYTOIN	Hippocampus is the brain structure, vital for episodic and declarative memory. Atrophy of the human hippocampus is seen in a variety of psychiatric and neurological disorders e.g. recurrent depression, schizophrenia, bipolar disorder, post-traumatic stress disorder, epilepsy, head injury, and Alzheimer's disease (AD). Importantly, aging hippocampus also undergoes atrophy. In many instances, for example, AD, the atrophy precedes the development of symptoms while in others, there is a temporal relationship between atrophy and symptomatology. The presence of atrophied hippocampus is one of the most consistent features of many common psychiatric disorders. Several factors contribute to this atrophy. Stress is one of the most profound factors implicated and the mechanisms involve glucocorticoids, serotonin, excitatory amino acids etc. Hippocampal formation as a whole can undergo atrophy or its individual structural components e.g. apical dendrities can exhibit atrophy. Several drugs of unrelated classes have been shown to prevent atrophy indicating heterogenous manner in which hippocampal atrophy is produced. These include, tianeptine (affects structural plasticity in hippocampus and is an effective antidepressant); phenytoin (antiseizure and neuroprotective); fluoxetine (downregulates neurodegenerative enzyme and increases neuroprotective hippocampal S100beta); lithium (neu ro protective and antiapoptotic); tricyclic antidepressants (increase hippocampal. neurogenesis); antipsychotics (reduce hippocampal neuronal suppression); sodium valproate (increases neurogenesis) and mifepristone (antioxidant, neuroprotective and anti-glucocorticoid). Now the most important question is: to what extent does the hippocampal atrophy play a role in the genesis of symptoms of diseases or their progression? And if it does, can we achieve the same degree of prevention or reversal seen in experimental animals, in humans also. An even more important question is: whether the prevention of atrophy would be clinically useful in affecting disease, viz slowing its progression, reducing morbidity, complications or positively affecting the outcome of one or more of its clinically important aspects. If the answer to this is yes, we would have to know at what stage of the disease we use the drugs, dose, duration, follow-up and efficacy. The use of these drugs in the above mentioned conditions can not only test the potential of atrophy as a future drug target, but could also help in Learning more about the hippocampus in both health and diseases. 0 2006 Elsevier Ltd. All rights reserved.	All India Inst Med Sci, Dept Pharmacol, New Delhi 110029, India; GSS IP Univ, Dr RML Hosp, PGIMER, Dept Neurol, New Delhi 110001, India	Dhikav, V (corresponding author), All India Inst Med Sci, Dept Pharmacol, New Delhi 110029, India.	vikasdhikav@hotmail.com; Kutjeet_anand@rediffmail.com					Belanoff JK, 2002, J MOL NEUROSCI, V19, P201, DOI 10.1007/s12031-002-0033-3; Bremner JD, 2005, J PSYCHOPHARMACOL, V19, P159, DOI 10.1177/0269881105048996; BRODERICK PA, 1991, BRAIN RES BULL, V27, P689, DOI 10.1016/0361-9230(91)90046-M; Chen G, 2000, J NEUROCHEM, V75, P1729, DOI 10.1046/j.1471-4159.2000.0751729.x; Chuang DM, 2005, ANN NY ACAD SCI, V1053, P195, DOI 10.1196/annals.1344.018; Conrad CD, 1996, BEHAV NEUROSCI, V110, P1321, DOI 10.1037/0735-7044.110.6.1321; Dawirs RR, 1998, J NEURAL TRANSM, V105, P317, DOI 10.1007/s007020050061; de la Torre JC, 2003, NEUROL RES, V25, P635, DOI 10.1179/016164103101201931; DeBattista C, 2006, TRENDS ENDOCRIN MET, V17, P117, DOI 10.1016/j.tem.2006.02.006; Dhikav V, 2006, MED HYPOTHESES, V67, P725, DOI 10.1016/j.mehy.2006.04.038; DRAGUNOW M, 1990, NEUROSCI LETT, V109, P128, DOI 10.1016/0304-3940(90)90550-S; Eberling JL, 2003, NEUROBIOL AGING, V24, P725, DOI 10.1016/S0197-4580(02)00056-8; Fester L, 2006, J NEUROCHEM, V97, P1136, DOI 10.1111/j.1471-4159.2006.03809.x; Franklin TB, 2006, PSYCHONEUROENDOCRINO, V31, P38, DOI 10.1016/j.psyneuen.2005.05.008; GARCIAJIMENEZ A, 2002, BRAIN AGING, V2, P7; Halim ND, 2004, NEUROPSYCHOPHARMACOL, V29, P1063, DOI 10.1038/sj.npp.1300422; HALIM ND, EFFECTS CHRONIC HALO; Hao YL, 2004, J NEUROSCI, V24, P6590, DOI 10.1523/JNEUROSCI.5747-03.2004; Hashimoto M, 2005, AM J PSYCHIAT, V162, P676, DOI 10.1176/appi.ajp.162.4.676; Henderson VW, 2006, NEUROSCIENCE, V138, P1031, DOI 10.1016/j.neuroscience.2005.06.017; Kim JS, 2004, J NEUROCHEM, V89, P324, DOI 10.1046/j.1471-4159.2004.02329.x; Krishnan KRR, 2003, AM J PSYCHIAT, V160, P2003, DOI 10.1176/appi.ajp.160.11.2003; Liu XH, 1997, NEUROSCI LETT, V235, P93, DOI 10.1016/S0304-3940(97)00675-7; Luo L, 2001, ACTA PHARMACOL SIN, V22, P865; Magarinos AM, 1999, EUR J PHARMACOL, V371, P113, DOI 10.1016/S0014-2999(99)00163-6; MAGARINOS AM, 1995, NEUROSCIENCE, V69, P89, DOI 10.1016/0306-4522(95)00259-L; Malberg JE, 2003, NEUROPSYCHOPHARMACOL, V28, P1562, DOI 10.1038/sj.npp.1300234; Malberg JE, 2000, J NEUROSCI, V20, P9104, DOI 10.1523/jneurosci.20-24-09104.2000; Manev R, 2001, EUR J PHARMACOL, V420, pR1, DOI 10.1016/S0014-2999(01)00989-X; Manji HK, 2000, BIOL PSYCHIAT, V48, P740, DOI 10.1016/S0006-3223(00)00979-3; McEwen BS, 2005, MOL PSYCHIATR, V10, P525, DOI 10.1038/sj.mp.4001648; McEwen BS, 2002, EUR PSYCHIAT, V17, p318S; Pomara N, 2002, NEUROLOGY, V58, P1436, DOI 10.1212/WNL.58.9.1436; Pomara Nunzio, 2003, Psychopharmacol Bull, V37, P120; Reagan LP, 1999, NEUROSCIENCE, V91, P211, DOI 10.1016/S0306-4522(98)00615-0; Reagan LP, 2004, P NATL ACAD SCI USA, V101, P2179, DOI 10.1073/pnas.0307294101; RIEKKINEN P, 1995, NEUROREPORT, V6, P1297, DOI 10.1097/00001756-199506090-00017; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Son H, 2003, J NEUROCHEM, V85, P872, DOI 10.1046/j.1471-4159.2003.01725.x; Velakoulis D, 2006, ARCH GEN PSYCHIAT, V63, P139, DOI 10.1001/archpsyc.63.2.139; Wagstaff AJ, 2001, CNS DRUGS, V15, P231, DOI 10.2165/00023210-200115030-00006; Wang HD, 2004, NEUROPSYCHOPHARMACOL, V29, P1230, DOI 10.1038/sj.npp.1300449; Wang WP, 2006, BRAIN RES, V1084, P210, DOI 10.1016/j.brainres.2006.02.024; Warner-Schmidt JL, 2006, HIPPOCAMPUS, V16, P239, DOI 10.1002/hipo.20156; WATANABE Y, 1992, EUR J PHARMACOL, V222, P157, DOI 10.1016/0014-2999(92)90830-W; Wood GE, 2004, P NATL ACAD SCI USA, V101, P3973, DOI 10.1073/pnas.0400208101; Zhang YM, 2003, ACTA PHARMACOL SIN, V24, P403; Zhou R, 2005, J NEUROSCI, V25, P4493, DOI 10.1523/JNEUROSCI.4530-04.2005	48	39	41	0	8	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0306-9877	1532-2777		MED HYPOTHESES	Med. Hypotheses		2007	68	6					1300	1306		10.1016/j.mehy.2006.09.040			7	Medicine, Research & Experimental	Research & Experimental Medicine	168QV	WOS:000246540000020	17098374				2021-06-18	
J	Kaminski, TW; Wikstrom, AM; Gutierrez, GM; Glutting, JJ				Kaminski, Thomas W.; Wikstrom, April M.; Gutierrez, Gregory M.; Glutting, Joseph J.			Purposeful heading during a season does not influence cognitive function or balance in female soccer players	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							POSTURAL STABILITY; FOOTBALL PLAYERS; BRAIN-INJURIES; CONCUSSION; IMPAIRMENT; TRAUMA; IMPACT	Soccer participation, especially among females, is growing in popularity in the United States. Purposeful heading, an important soccer skill, has recently been scrutinized for safety reasons. The purpose of this study was to determine whether there was a relationship between purposeful heading and scores on cognitive function and balance in high-school and collegiate female soccer players. Prior to and following the soccer season, all players and members of the control group were given a battery of neuropsychological and balance tests. There were no significant correlations found between the total number of game headers and performance on either balance or neuropsychological testing. Differences were noted in adjusted balance scores postseason between the collegiate players and the other two groups. However, no differences were revealed in neurocognitive performance between the three groups.	Univ Delaware, Dept Hlth Nutr & Exercise Sci, Athlet Training Res Lab, Newark, DE 19716 USA; Univ Delaware, Sch Educ, Newark, DE USA	Kaminski, TW (corresponding author), Univ Delaware, Dept Hlth Nutr & Exercise Sci, Human Performance Lab, 159 Fred Rust Ice Arens,541 S Coll Ave, Newark, DE 19716 USA.	kaminski@udel.edu	Gutierrez, Gregory/A-9420-2009	Gutierrez, Gregory/0000-0002-4261-8066			Baroff GS, 1998, J HEAD TRAUMA REHAB, V13, P45, DOI 10.1097/00001199-199804000-00007; Barth JT., 1989, MILD HEAD INJURY, P257; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI 10.1080/13854049108403297.; Broglio SP, 2004, BRIT J SPORT MED, V38, P561, DOI 10.1136/bjsm.2003.004887; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Covassin T, 2003, J ATHL TRAINING, V38, P238; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; GUSKIEWICZ KM, 1997, MED SCI SPORTS EXERC, V29, P213; *HIFA, 2005, FIFA WOM WORLD CUP P; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kaminski T. W., 2002, Medicine & Science in Sports & Exercise, V34, pS2, DOI 10.1097/00005768-200205001-00009; Lees K., 1988, SCI FOOTBALL, P385; MAGNUS BC, 2004, SPORT BIOMECH, V3, P209; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; *NCAA, 2003, NCAA INJ SURV SYST A; *NCAA, 2004, 198182200304 NCAA; *NCAA, 2005, 2004 05 WOM SOCC INJ; Oliaro SM, 1998, J ATHL TRAINING, V33, P36; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; Schmitt DM, 2004, INT J SPORTS MED, V25, P326, DOI 10.1055/s-2004-819941; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421	37	39	39	0	13	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2007	29	7					742	751		10.1080/13825580600976911			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	229CO	WOS:000250779200008	17852597				2021-06-18	
J	Mansson, R; Hansson, MJ; Morota, S; Uchino, H; Ekdahl, CT; Elmer, E				Mansson, Roland; Hansson, Magnus J.; Morota, Saori; Uchino, Hiroyuki; Ekdahl, Christine T.; Elmer, Eskil			Re-evaluation of mitochondrial permeability transition as a primary neuroprotective target of minocycline	NEUROBIOLOGY OF DISEASE			English	Article						neurodegeneration; amyotrophic lateral sclerosis; Huntington's disease; Parkinson's disease; motor neuron disease; spinal cord injury; ischemia; apoptosis; cyclospotin; minocycline; neuroprotection; brain mitochondria	AMYOTROPHIC-LATERAL-SCLEROSIS; CYTOCHROME-C RELEASE; TRANSGENIC MOUSE MODEL; TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; CYCLOSPORINE-A; HUNTINGTONS-DISEASE; CELL-DEATH; MICROGLIAL ACTIVATION; DOPAMINERGIC-NEURONS	Minocycline has been shown to be neuroprotective in ischemic and neurodegenerative disease models and could potentially be relevant for clinical use. We revisited the hypothesis that minocycline acts through direct inhibition of calcium-induced mitochondrial permeability transition (mPT) resulting in reduced release of cytochrome c (cyt c). Minocycline, at high dosage, was found to prevent calcium-induced mitochondrial swelling under energized conditions similarly to the mPT inhibitor cyclosporin A (CsA) in rodent mitochondria derived from the CNS. In contrast to CsA, minocycline dose-dependently reduced mitochondrial calcium retention capacity (CRC) and respiratory control ratios and was ineffective in the de-energized mPT assay. Further, minocycline did not inhibit calcium- or tBid-induced cyt c release. We conclude that the neuroprotective mechanism of minocycline is likely not related to direct inhibition of mPT and propose that the mitochondrial effects of minocycline may contribute to toxicity rather than tissue protection at high dosing in animals and humans. (c) 2006 Elsevier Inc. All rights reserved.	Lund Univ, Dept Clin Sci, Sect Restorat Neurol, Lund, Sweden; Tokyo Univ Pharm & Life Sci, Sch Life Sci, Lab Cellular Neurobiol, Hachioji, Tokyo, Japan; Tokyo Med Univ, Hachioji Med Ctr, Dept Anesthesiol, Hachioji, Tokyo, Japan	Mansson, R (corresponding author), Wallenberg Neurosci Ctr, Lab Expt Brain Res, BMC A13, SE-22184 Lund, Sweden.	roland.mansson@med.lu.se	Elmer, Eskil/F-9341-2014; Hansson, Magnus/G-4486-2014	Elmer, Eskil/0000-0001-7901-1826; Hansson, Magnus/0000-0002-0201-0638	Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [18591724] Funding Source: KAKEN		Arvin KL, 2002, ANN NEUROL, V52, P54, DOI 10.1002/ana.10242; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brustovetsky N, 2003, J NEUROCHEM, V84, P196, DOI 10.1046/j.1471-4159.2003.01545.x; Casarejos MJ, 2006, J NEUROCHEM, V97, P934, DOI 10.1111/j.1471-4159.2006.03777.x; Cha JH, 2004, NEUROLOGY, V63, P547; Chalmers S, 2003, J BIOL CHEM, V278, P19062, DOI 10.1074/jbc.M212661200; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Choi SH, 2005, J NEUROCHEM, V95, P1755, DOI 10.1111/j.1471-4159.2005.03503.x; Cornet S, 2004, EUR J PHARMACOL, V505, P111, DOI 10.1016/j.ejphar.2004.10.039; Damiano M, 2006, J NEUROCHEM, V96, P1349, DOI 10.1111/j.1471-4159.2006.03619.x; Diguet E, 2004, EUR J NEUROSCI, V19, P3266, DOI 10.1111/j.0953-816X.2004.03372.x; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Fagan SC, 2004, EXP NEUROL, V186, P248, DOI 10.1016/j.expneurol.2003.12.006; Fernandez-Gomez FJ, 2005, NEUROSCIENCE, V133, P959, DOI 10.1016/j.neuroscience.2005.03.019; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; Friberg H, 1998, J NEUROSCI, V18, P5151; Gordon PH, 2004, NEUROLOGY, V62, P1845, DOI 10.1212/01.WNL.0000125321.92112.7E; Halestrap AP, 2004, CARDIOVASC RES, V61, P372, DOI 10.1016/S0008-6363(03)00533-9; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; Hansson MJ, 2004, J NEUROCHEM, V89, P715, DOI 10.1111/j.1471-4159.2004.02400.x; Hansson MJ, 2003, BRAIN RES, V960, P99, DOI 10.1016/S0006-8993(02)03798-8; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; Karlsson J, 2004, J NEUROSURG, V101, P128, DOI 10.3171/jns.2004.101.1.0128; Keep M, 2001, BRAIN RES, V894, P327, DOI 10.1016/S0006-8993(01)02012-1; Kraus RL, 2005, J NEUROCHEM, V94, P819, DOI 10.1111/j.1471-4159.2005.03219.x; Kriz J, 2002, NEUROBIOL DIS, V10, P268, DOI 10.1006/nbdi.2002.0487; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; Ryu JK, 2004, GLIA, V48, P85, DOI 10.1002/glia.20051; Scarabelli TM, 2004, J AM COLL CARDIOL, V43, P865, DOI 10.1016/j.jacc.2003.09.050; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Smith DL, 2003, ANN NEUROL, V54, P186, DOI 10.1002/ana.10614; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; Tsuji M, 2004, EXP NEUROL, V189, P58, DOI 10.1016/j.expneurol.2004.01.011; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Van Den Bosch L, 2002, NEUROREPORT, V13, P1067, DOI 10.1097/00001756-200206120-00018; Wang JZ, 2004, J BIOL CHEM, V279, P19948, DOI 10.1074/jbc.M313629200; Wang X, 2003, P NATL ACAD SCI USA, V100, P10483, DOI 10.1073/pnas.1832501100; Yang LC, 2003, J NEUROSCI RES, V74, P278, DOI 10.1002/jnr.10709; Yong VW, 2004, LANCET NEUROL, V3, P744, DOI 10.1016/S1474-4422(04)00937-8; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	47	39	43	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961			NEUROBIOL DIS	Neurobiol. Dis.	JAN	2007	25	1					198	205		10.1016/j.nbd.2006.09.008			8	Neurosciences	Neurosciences & Neurology	114KN	WOS:000242665200021	17067803				2021-06-18	
J	Macdonald, S; Cherpitel, CJ; DeSouza, A; Stockwell, T; Borges, G; Giesbrecht, N				Macdonald, Scott; Cherpitel, Cheryl J.; DeSouza, Amanda; Stockwell, Tim; Borges, Guilherme; Giesbrecht, Norman			Variations of alcohol impairment in different types, causes and contexts of injuries: Results of emergency room studies from 16 countries	ACCIDENT ANALYSIS AND PREVENTION			English	Article						injury; alcohol; violence; severity; location	RISK-FACTOR; ABUSE; DEATH; FALLS; WORK	Objective: The purpose of this paper is to document alcohol impairment (based on a blood alcohol content (BAC) of at least 80 mg%) for different types, causes and location contexts of injuries. Design and setting: Data from 45 studies with 11,536 injury patients were merged to determine variations in the percent of alcohol impairment among injury patients. In each study, emergency room (ER) injury patients were given a short interview on the circumstances of their injury and BAC was measured. Results: Injury severity, measured by number of body regions injured was significantly associated with BACs over 80 mg%. The highest percentage of injury type to involve alcohol was head injury/concussion. In terms of causes of injuries, patients with alcohol impairment were significantly more likely to be involved in violence than any other cause (i.e., vehicle, failing, poisoning or burns). Finally, injuries occurring at a bar or restaurant were significantly more likely to involve alcohol impairment than any other setting. Conclusions: The results demonstrate considerable variation in the circumstances where alcohol is involved in injuries. These results may be useful for the development of prevention initiatives. (c) 2006 Elsevier Ltd. All rights reserved.	Univ Victoria, Ctr Addict Res BC, Victoria, BC V8W 2Y2, Canada; Univ Victoria, Sch Hlth Informat Sci, Victoria, BC V8W 2Y2, Canada; Inst Publ Hlth, Alcohol Res Grp, Berkeley, CA 94709 USA; Ctr Addict & Mental Hlth, London, ON N6G 4X8, Canada; Univ Victoria, Dept Psychol, Victoria, BC V8W 2Y2, Canada; Univ Autsnoma Metropoilitana Xochimilco, Mexico City 14370, DF, Mexico; Inst Nacl Psiquiatria, Mexico City 14370, DF, Mexico; Ctr Addict & Mental Hlth, Toronto, ON, Canada	Macdonald, S (corresponding author), Univ Victoria, Ctr Addict Res BC, BP POB 1700 STN CSC, Victoria, BC V8W 2Y2, Canada.	scottmac@uvic.ca		Borges, Guilherme/0000-0002-3269-0507; Stockwell, Tim/0000-0002-5696-6803			Boles SM, 2003, AGGRESS VIOLENT BEH, V8, P155, DOI 10.1016/S1359-1789(01)00057-X; BORGES G, 1994, DRUG ALCOHOL DEPEN, V36, P1, DOI 10.1016/0376-8716(94)90002-7; Cherpitel CJ, 2003, ADDICTION, V98, P1277, DOI 10.1046/j.1360-0443.2003.00459.x; COMPTON RP, 2002, ALCOHOL DRUGS TRAFFI; DONELSON AC, 1988, SOCIAL CONTROL DRINK, P3; Graham K, 1998, ADDICTION, V93, P659, DOI 10.1046/j.1360-0443.1998.9356593.x; Graham K, 2000, ADDICTION, V95, P847, DOI 10.1046/j.1360-0443.2000.9568473.x; HINGSON R, 1993, ADDICTION, V88, P877, DOI 10.1111/j.1360-0443.1993.tb02105.x; HINGSON R, 1987, J STUD ALCOHOL, V48, P212, DOI 10.15288/jsa.1987.48.212; Hoaken PNS, 2003, ADDICT BEHAV, V28, P1533, DOI 10.1016/j.addbeh.2003.08.033; Johnston JJE, 2004, EMERG MED J, V21, P185, DOI 10.1136/emj.2003.006130; Langley J, 1996, ADDICTION, V91, P985, DOI 10.1111/j.1360-0443.1996.tb03595.x; Levy DT, 2004, MED SCI MONITOR, V10, pCR17; Li GH, 1997, J TRAUMA, V42, P562, DOI 10.1097/00005373-199703000-00032; Macdonald S, 2005, ADDICT BEHAV, V30, P103, DOI 10.1016/j.addbeh.2004.04.016; Macdonald S, 1998, ACCIDENT ANAL PREV, V30, P21, DOI 10.1016/S0001-4575(97)00058-4; MacDonald S, 1997, DRUG ALCOHOL REV, V16, P251, DOI 10.1080/09595239800187431; McLeod R, 2003, ACCIDENT ANAL PREV, V35, P71, DOI 10.1016/S0001-4575(01)00091-4; *NAT HIGHW TRAFF S, 2004, TRAFF SAF FACTS COMP; NORTON RN, 1989, ALCOHOL ALCOHOLISM, V24, P565, DOI 10.1093/oxfordjournals.alcalc.a044960; Rehm J, 2003, EUR ADDICT RES, V9, P157, DOI 10.1159/000072222; ROWE B, 1992, CAN MED ASSOC J, V146, P147; Smith GS, 1999, ANN EMERG MED, V33, P659, DOI 10.1016/S0196-0644(99)70195-2; STALLONES L, 1993, ADDICTION, V88, P945, DOI 10.1111/j.1360-0443.1993.tb02112.x; WALSH ME, 1983, INJURY, V15, P62, DOI 10.1016/0020-1383(83)90165-1; Watt K, 2005, ALCOHOL ALCOHOLISM, V40, P263, DOI 10.1093/alcalc/agh164; WEBB GR, 1994, J STUD ALCOHOL, V55, P434, DOI 10.15288/jsa.1994.55.434; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; Young DJ, 2004, J STUD ALCOHOL, V65, P605, DOI 10.15288/jsa.2004.65.605	29	39	41	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575	1879-2057		ACCIDENT ANAL PREV	Accid. Anal. Prev.	NOV	2006	38	6					1107	1112		10.1016/j.aap.2006.04.019			6	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	103AB	WOS:000241854300010	16828047				2021-06-18	
J	Jimenez, R; Casado-Flores, J; Nieto, M; Garcia-Teresa, MA				Jimenez, Raquel; Casado-Flores, Juan; Nieto, Monserrat; Garcia-Teresa, Maria Angeles			Cerebral salt wasting syndrome in children with acute central nervous system injury	PEDIATRIC NEUROLOGY			English	Article							ATRIAL-NATRIURETIC-PEPTIDE; HYPONATREMIA; MENINGITIS; HORMONE; DISEASE	The purpose of this investigation was to describe the causes, clinical pattern, and treatment of cerebral salt wasting syndrome in children with acute central nervous system injury. This retrospective study focused on patients <= 15 years old diagnosed with cerebral salt wasting syndrome, over a period of 7 years, in the pediatric intensive care unit of a tertiary care hospital. Selection criteria included evidence of hyponatremia (serum sodium < 130 mEq/L), polyuria, elevated urine sodium (> 120 mEq/L), and volume depletion. Fourteen patients were identified with cerebral salt wasting syndrome, 12 after a neurosurgical procedure (8 brain tumor, 4 hydrocephalus) and 2 after severe brain trauma. In 11 patients the cerebral salt wasting syndrome was diagnosed during the first 48 hours of admission. Prevalence of cerebral salt wasting syndrome in neurosurgical children was 11.3/1000 surgical procedures. The minimum sodium was 122 +/- 7 mEq/L, the maximum urine osmolarity 644 +/- 59 mOsm/kgH(2)O. The maximum sodium supply was 1 mEq/kg/h (range, 0.1-2.4). The mean duration of cerebral salt wasting syndrome was 6 +/- 5 days (range 1-9). In conclusion, cerebral salt wasting syndrome can complicate the postoperative course of children with brain injury; it is frequently present after surgery for brain tumors and hydrocephalus and in patients with severe head trauma. Close monitoring of salt and fluid balance is essential to prevent severe neurologic and hemodynamic complications. (c) 2006 by Elsevier Inc. All rights reserved.	Univ Autonoma Madrid, Pediat Intens Care Unit, Hosp Infant Nino Jesus, Madrid, Spain	Casado-Flores, J (corresponding author), Univ Autonoma Madrid, Pediat Intens Care Unit, Hosp Infant Nino Jesus, Avenida Menendez Pelayo 65, Madrid, Spain.	jcasadof@line-pro.es		Garcia Teresa, Maria de los Angeles/0000-0002-3474-7087			Brouh Y, 2004, ANN FR ANESTH, V23, P39, DOI 10.1016/j.annfar.2003.09.009; Bussmann C, 2001, CHILD NERV SYST, V17, P58; Erduran E, 1997, ACTA PAEDIATR, V86, P1150, DOI 10.1111/j.1651-2227.1997.tb14830.x; ESPINER EA, 1994, J INTERN MED, V235, P527, DOI 10.1111/j.1365-2796.1994.tb01261.x; GANONG CA, 1993, AM J DIS CHILD, V147, P167, DOI 10.1001/archpedi.1993.02160260057022; Harrigan MR, 1996, NEUROSURGERY, V38, P152, DOI 10.1097/00006123-199601000-00035; Ibarra de la Rosa I, 1999, AN ESP PEDIATR, V51, P27; Kappy M S, 1996, Adv Pediatr, V43, P271; MINAMINO N, 1991, BIOCHEM BIOPH RES CO, V179, P535, DOI 10.1016/0006-291X(91)91404-Z; NAROTAM PK, 1994, NEUROSURGERY, V34, P982, DOI 10.1227/00006123-199406000-00005; OSTER JR, 1983, ARCH INTERN MED, V143, P2187, DOI 10.1001/archinte.143.11.2187; PETERS JP, 1950, T ASSOC AM PHYSICIAN, V63, P57; WEINAND ME, 1989, NEUROSURGERY, V25, P781, DOI 10.1227/00006123-198911000-00014	13	39	42	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	OCT	2006	35	4					261	263		10.1016/j.pediatrneurol.2006.05.004			3	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	095PK	WOS:000241319700006	16996399				2021-06-18	
J	Mulhern, S; McMillan, TM				Mulhern, Sharon; McMillan, Thomas M.			Knowledge and expectation of postconcussion symptoms in the general population	JOURNAL OF PSYCHOSOMATIC RESEARCH			English	Article						mild brain injury; postconcussion syndrome	POST-CONCUSSIONAL SYNDROME; MILD HEAD-INJURY; BRAIN INJURY; BASE RATES; ANXIETY; DEPRESSION; COMPLAINTS; STRESS; DISORDER; ABILITY	Objective: Beliefs about mild traumatic brain injury (MTBI) may affect complaints and their persistence. This study investigates the relationships between knowledge, experience, and expectation in the general population. Methods: One hundred seventy-one people reported symptoms expected from vignettes about MTBI, depression, posttraumatic stress disorder (PTSD), and orthopedic injury. Then they completed a postconcussional syndrome (PCS) checklist about these vignettes and about personal symptoms. Results: The ability to generate symptoms from vignettes was poor for PCs, depression, and PTSD, and was greatly improved using a PCs checklist, probably by symptom guessing. No postconcussion symptoms were associated specifically with MTBI. Those with more personal symptoms expected more symptoms. Past experience of MTBI did not improve symptom knowledge. Beliefs about the 'undesirability' of conditions were associated with expected outcomes. Conclusions: People know little about PCs. Expectations about MTBI are influenced by psychological factors that are relevant if we consider information given in hospitals. Symptom overlap means that psychological conditions such as depression may be misdiagnosed as PCs, and checklists should not be used for diagnosis. (c) 2006 Elsevier Inc. All rights reserved.	Univ Glasgow, Gartnavel Royal Hosp, Fac Med, Glasgow G12 0XH, Lanark, Scotland	McMillan, TM (corresponding author), Univ Glasgow, Gartnavel Royal Hosp, Fac Med, Glasgow G12 0XH, Lanark, Scotland.	t.m.mcmillan@clinmed.gla.ac.uk					AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; ALVES WM, 1993, PHYS MED REHABIL, V6, P21; American Psychiatric Association (APA), 1994, DIAGN STAT MAN MENT, V4th; BADDELEY AD, 1992, MANUAL SPEED CAPACIT; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Burges C, 2001, BRIT J CLIN PSYCHOL, V40, P209, DOI 10.1348/014466501163544; Conway M., 1986, HDB MOTIVATION COGNI, V1, P122; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2002, J INT NEUROPSYCH SOC, V8, P37, DOI 10.1017/S1355617701020045; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Hahn RA, 1997, PREV MED, V26, P607, DOI 10.1006/pmed.1996.0124; Hochstrasser B, 1996, EUR ARCH PSY CLIN N, V246, P261, DOI 10.1007/BF02190278; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEESHALEY PR, 1994, J CLIN PSYCHOL, V50, P252, DOI 10.1002/1097-4679(199403)50:2<252::AID-JCLP2270500217>3.0.CO;2-T; Mackenzie JA, 2005, BRIT J CLIN PSYCHOL, V44, P417, DOI 10.1348/014466505X35696; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; *SCOTT INT GUID NE, 2000, EARL MAN PAT HEAD IN; SEEMILLERSMITH L, 2003, BRAIN INJURY, V17, P199; *SPSS INC, 1997, STAT PACK SOC SCI VE; Stern RA, 1996, J NEUROPSYCH CLIN N, V8, P181; Wearden AJ, 1996, J PSYCHOSOM RES, V41, P197, DOI 10.1016/0022-3999(96)00131-6; Weinman, 1997, PERCEPTIONS HLTH ILL, P1; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	33	39	41	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-3999	1879-1360		J PSYCHOSOM RES	J. Psychosomat. Res.	OCT	2006	61	4					439	445		10.1016/j.jpsychores.2006.03.004			7	Psychiatry	Psychiatry	094SP	WOS:000241259600003	17011350				2021-06-18	
J	Nekludov, M; Bellander, BM; Mure, M				Nekludov, M.; Bellander, B. -M.; Mure, M.			Oxygenation and cerebral perfusion pressure improved in the prone position	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						intracranial pressure; cerebral perfusion pressure; prone position; traumatic brain injury; acute respiratory failure	INTRACRANIAL-PRESSURE; BLOOD-FLOW; MICRODIALYSIS; HEMODYNAMICS; POSTURE; SUPINE	Background: Treatment of patients in the prone position is a well-established method to improve oxygenation in general intensive care unit (ICU) practice. This method is rarely used in a neurosurgical ICU, considering the risk of intracranial hypertension. The aim of this study was to analyse the effect of prone position on intracranial pressure (ICP), cerebral perfusion pressure (CPP) and systemic oxygenation in patients with reduced intracranial compliance. We hypothesize that the beneficial effects of prone position can outweigh the hazardous effects on the intracranial pressure. Methods: Eight patients with traumatic brain injury or subarachnoid hemorrhage (SAH) were studied in the supine and prone posture. Hemodynamics, arterial oxygenation, respiratory mechanics, ICP and CPP were continuously measured. Results: A significant improvement in PaO2 was observed in the prone position, from 12.6 +/- 1.4 kPa to 15.7 +/- 3.2 kPa (P = 0.02). Both intracranial pressure and mean arterial pressure increased in the prone position, from 12 +/- 6 to 15 +/- 4 mmHg (P = 0.03) and from 78 +/- 8 to 88 +/- 8 mmHg (P = 0.005), respectively. Arterial pressure increased to a greater extent than ICP, resulting in improved CPP, from 66 +/- 7 to 73 +/- 8 mmHg (P = 0.03) in the prone position. Conclusions: The prone position can be used to improve the oxygenation as well as CPP in patients with traumatic brain injury or SAH. However, this method results in raised ICP, and should be used cautiously in patients with reduced intracranial compliance.	Karolinska Univ Hosp & Inst, Dept Anesthesiol & Intens Care, Stockholm, Sweden; Karolinska Univ Hosp & Inst, Dept Neurosurg, Stockholm, Sweden	Nekludov, M (corresponding author), Karolinska Univ Hosp, Dept Anesthesiol & Intens Care, S-17176 Stockholm, Sweden.	michael.nekludov@karolinska.se		Nekludov, Michael/0000-0001-9916-7086			Bein T, 2002, INTENS CARE MED, V28, P554, DOI 10.1007/s00134-002-1273-y; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; FELDMAN Z, 1992, J NEUROSURG, V76, P207, DOI 10.3171/jns.1992.76.2.0207; FORTUNE JB, 1995, J TRAUMA, V39, P463; Hering R, 2001, ANESTH ANALG, V92, P1226, DOI 10.1097/00000539-200105000-00027; Jolliet P, 1998, CRIT CARE MED, V26, P1977, DOI 10.1097/00003246-199812000-00023; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; LEE ST, 1989, HEART LUNG, V18, P411; Mure M, 2001, ACTA ANAESTH SCAND, V45, P150, DOI 10.1034/j.1399-6576.2001.450204.x; Ng I, 2004, NEUROSURGERY, V54, P593, DOI 10.1227/01.NEU.0000108639.16783.39; Nuckton TJ, 2002, NEW ENGL J MED, V346, P1281, DOI 10.1056/NEJMoa012835; Pelosi P, 2002, EUR RESPIR J, V20, P1017, DOI 10.1183/09031936.02.00401702; Reinprecht A, 2003, CRIT CARE MED, V31, P1831, DOI 10.1097/01.CCM.0000063453.93855.0A; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Venet C, 2001, INTENS CARE MED, V27, P1352, DOI 10.1007/s001340101023; Walther SM, 1999, CRIT CARE MED, V27, P37, DOI 10.1097/00003246-199901000-00024; Wang J, 2002, ACTA ANAESTH SCAND, V46, P1094, DOI 10.1034/j.1399-6576.2002.460907.x; Young Jeffrey S, 2003, Neurosurg Focus, V15, pE2; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	21	39	40	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	SEP	2006	50	8					932	936		10.1111/j.1399-6576.2006.01099.x			5	Anesthesiology	Anesthesiology	076EF	WOS:000239939100004	16923086				2021-06-18	
J	Larson, MJ; Perlstein, WM; Demery, JA; Stigge-Kaufman, DA				Larson, Michael J.; Perlstein, William M.; Demery, Jason A.; Stigge-Kaufman, David A.			Cognitive control impairments in traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							ANTERIOR CINGULATE CORTEX; CLOSED-HEAD INJURY; PREFRONTAL CORTEX; WORKING-MEMORY; POSTTRAUMATIC AMNESIA; CONFLICT; DEFICITS; CONTEXT; DYSFUNCTION; SCHIZOPHRENIA	The componential nature of impaired cognitive control following traumatic brain injury (TBI) remains uncertain. We examined regulative and evaluative components of cognitive control in mild and moderate-to-severe (M/S) TBI patients and demographically-matched comparison participants using the AX-CPT task. We also examined relationships of cognitive control impairment to ratings of cognitive, behavioral, and affective symptomatology on the Dysexecutive Questionnaire (DEX). Results revealed that M/S, but not mild TBI patients showed deficits in context-processing and post-error strategic adjustments-extent of impairments correlated with TBI-related symptomatology. Thus, patients with MISS TBI evidence cognitive control dysfunction in the processing and active maintenance of context representations.	Univ Florida, Dept Clin & Hlth Psychol, HSC, Gainesville, FL 32610 USA; Univ Florida, Dept Psychiat, Gainesville, FL 32610 USA; Univ Florida, Dept McKnight Brain Inst, Gainesville, FL 32610 USA	Perlstein, WM (corresponding author), Univ Florida, Dept Clin & Hlth Psychol, HSC, Box 100165, Gainesville, FL 32610 USA.	wperlste@phhp.ufl.edu	Larson, Michael J/C-8543-2012	Larson, Michael J/0000-0002-8199-8065	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K01MH001857, R21MH073076] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K01 MH01857, R21 MH073076] Funding Source: Medline		Barch DM, 1997, NEUROPSYCHOLOGIA, V35, P1373, DOI 10.1016/S0028-3932(97)00072-9; Barch DM, 2001, ARCH GEN PSYCHIAT, V58, P280, DOI 10.1001/archpsyc.58.3.280; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Blair JR., 1989, CLIN NEUROPSYCHOL, V3, P129; BOND MR, 1986, NEUROPSYCHOLOGICAL A, P347; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Braver TS, 2001, J EXP PSYCHOL GEN, V130, P746, DOI 10.1037//0096-3445.130.4.746; Braver TS, 1999, BIOL PSYCHIAT, V46, P312, DOI 10.1016/S0006-3223(99)00116-X; Chapman LJ, 2001, J ABNORM PSYCHOL, V110, P31, DOI 10.1037/0021-843X.110.1.31; COHEN J, 1993, BEHAV RES METH INSTR, V25, P257, DOI 10.3758/BF03204507; COHEN J, 1988, STAT PWOER ANAL BEHA; COHEN JD, 1992, PSYCHOL REV, V99, P45, DOI 10.1037/0033-295X.99.1.45; Cohen JD, 1999, J ABNORM PSYCHOL, V108, P120, DOI 10.1037/0021-843X.108.1.120; Gehring WJ, 2001, J NEUROSCI, V21, P9430, DOI 10.1523/JNEUROSCI.21-23-09430.2001; Gehring WJ, 2000, NAT NEUROSCI, V3, P516, DOI 10.1038/74899; Gerstenbrand F, 2001, BRAIN INJURY, V15, P95; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Huynh H, 1976, J EDUC STATIST, V1, P69, DOI DOI 10.3102/10769986001001069; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; KLEVINE B, 2002, PRINCIPLES FRONTAL L, P504; LARSON MJ, 2005, IN PRESS 33 ANN M IN; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; MacDonald AW, 2003, J ABNORM PSYCHOL, V112, P689, DOI 10.1037/0021-843X.112.4.689; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; Miltner WHR, 2003, BIOL PSYCHOL, V64, P157, DOI 10.1016/S0301-0511(03)00107-8; Neter J., 1985, APPL LINEAR STAT MOD; Nieuwenhuis S, 2001, PSYCHOPHYSIOLOGY, V38, P752, DOI 10.1017/S0048577201001111; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Perlstein WM, 2003, BIOL PSYCHIAT, V53, P25, DOI 10.1016/S0006-3223(02)01675-X; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; RABBITT PMA, 1968, Q J EXP PSYCHOL, V20, P179, DOI 10.1080/14640746808400146; RABBITT PMA, 1966, J EXP PSYCHOL, V71, P264, DOI 10.1037/h0022853; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; RATCLIFF R, 1993, PSYCHOL BULL, V114, P510, DOI 10.1037/0033-2909.114.3.510; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rosnow RL, 1996, PSYCHOL METHODS, V1, P331, DOI 10.1037/1082-989X.1.4.331; Seignourel PJ, 2005, NEUROPSYCHOLOGY, V19, P578, DOI 10.1037/0894-4105.19.5.578; ServanSchreiber D, 1996, ARCH GEN PSYCHIAT, V53, P1105; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Spielberger C.D., 1970, STATE TRAIT ANXIETY; Strauss ME, 2001, J ABNORM PSYCHOL, V110, P6, DOI 10.1037//0021-843X.110.1.6; STUSS DT, 1991, SELF : INTERDISCIPLINARY APPROACHES, P255; TEASDALE G, 1974, LANCET, V2, P81; van Veen V, 2002, J COGNITIVE NEUROSCI, V14, P593, DOI 10.1162/08989290260045837; van Veen V, 2002, PHYSIOL BEHAV, V77, P477, DOI 10.1016/S0031-9384(02)00930-7; Wechsler D, 1985, WECHSLER ADULT INTEL; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Yeung N, 2004, PSYCHOL REV, V111, P931, DOI [10.1037/0033-295X.111.4.931, 10.1037/0033-295x.111.4.931]	56	39	40	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	AUG	2006	28	6					968	986		10.1080/13803390600646860			19	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	055LI	WOS:000238451800009	16822736				2021-06-18	
J	Rassovsky, Y; Satz, P; Alfano, MS; Light, RK; Zaucha, K; McArthur, DL; Hovda, D				Rassovsky, Y; Satz, P; Alfano, MS; Light, RK; Zaucha, K; McArthur, DL; Hovda, D			Functional outcome in TBI II: Verbal memory and information processing speed mediators	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; HEAD-INJURY; HIV-1 INFECTION; SCHIZOPHRENIA; MODERATE; SCALE; DISABILITIES; IMPAIRMENT; PREVALENCE; PREDICTORS	Following traumatic brain injury (TBI), patients often report memory difficulties, as well as reduced information processing speed. However, it remains unclear the extent to which these deficits contribute to functional impairment. In the present study, we compared the relative contribution of verbal memory and information processing speed to functional impairment at 12-month post-injury, in 87 patients with moderate-to-severe TBI. Employing structural equation modeling, we found that information processing speed, but not verbal memory functions, significantly mediated the relationship between TBI severity and post-TBI adaptive functioning. These findings suggest that despite the pervasive memory complaints among patients with TBI, it is the impact of neurotrauma on frontal systems that appears to be primarily responsible for patients' difficulties in social and occupational functioning.	Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, Neuropsychol Div, Los Angeles, CA 90024 USA; Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; Daniel Freeman Mem Hosp, Inglewood, CA USA; Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, Dept Child Psychiat, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90024 USA	Rassovsky, Y (corresponding author), Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, Neuropsychol Div, Room C8-747,760 Westwood Plaza, Los Angeles, CA 90024 USA.	yurir@ucla.edu	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314; Rassovsky, Yuri/0000-0002-6362-9944			BENTLER PM, 1996, EQS STRUCTURAL EQUAT; Benton A.L., 1983, CONTRIBUTIONS NEUROP; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Brekke JS, 1997, SCHIZOPHRENIA BULL, V23, P19, DOI 10.1093/schbul/23.1.19; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; DELIA LF, 1996, COLOR TRAILS TEST AD; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Goodkin K, 2001, PSYCHIAT ANN, V31, P37, DOI 10.3928/0048-5713-20010101-09; Green MF, 1999, SCHIZOPHRENIA BULL, V25, P309, DOI 10.1093/oxfordjournals.schbul.a033380; Green MF, 1996, AM J PSYCHIAT, V153, P321; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; KlOve H, 1963, MED CLIN N AM; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Light R, 1987, J HEAD TRAUMA REHAB, V2, P11, DOI DOI 10.1097/00001199-198703000-00005; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; MOSCATO BS, 1994, J NEUROPSYCH CLIN N, V6, P134; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; ODDY M, 1984, CLOSED HEAD INJURY; PANIAK CE, 1992, ARCH CLIN NEUROPSYCH, V7, P529, DOI 10.1016/0887-6177(92)90143-B; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Prigatano GP, 2003, NEUROREHABILITATION, V18, P47; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P29; RASSOVSKY Y, IN PRESS J CLIN EXPT; Rey A, 1964, EXAMEN CLIN PSYCHOL; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Smith A., 1982, SYMBOL DIGIT MODALIT; *STAT U NEW YORK, 1993, AD FUNCT IND MEAS VE; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; Ullman J. B., 2001, USING MULTIVARIATE S, V4th, P653; Vogenthaler D R, 1987, Brain Inj, V1, P113; Wilkie FL, 1998, J NEUROPSYCH CLIN N, V10, P125, DOI 10.1176/jnp.10.2.125	43	39	39	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	MAY	2006	28	4					581	591		10.1080/13803390500434474			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	033MX	WOS:000236853600009	16624785				2021-06-18	
J	Zhang, L; Zhang, WP; Hu, H; Wang, ML; Sheng, WW; Yao, HT; Ding, W; Chen, Z; Wei, EQ				Zhang, L; Zhang, WP; Hu, H; Wang, ML; Sheng, WW; Yao, HT; Ding, W; Chen, Z; Wei, EQ			Expression patterns of 5-lipoxygenase in human brain with traumatic injury and astrocytoma	NEUROPATHOLOGY			English	Article						astrocytoma; 5-lipoxygenase; traumatic brain injury	ARACHIDONATE 5-LIPOXYGENASE; NORDIHYDROGUAIARETIC ACID; ACTIVATING PROTEIN; NUCLEAR-ENVELOPE; LEUKOTRIENE C-4; CELL-DEATH; LOCALIZATION; BIOSYNTHESIS; INHIBITION; ISCHEMIA	5-Lipoxygenase (5-LOX) is a key enzyme in the metabolism of arachidonic acid to leukotrienes. The levels of leukotrienes increase after brain injury and when tumors are present. It has been reported that 5-LOX is widely expressed in the brain and that 5-LOX inhibition provides neuroprotection. However, there is still no information available for the expression patterns of 5-LOX in human brain following trauma or with astrocytomas. We investigated its expression patterns by immunohistochemistry. We found that 5-LOX is normally expressed in neurons and glial cells. In neurons, it was expressed in two patterns: in the cytosol and nucleus or only in the cytosol. In traumatic brain injury, 5-LOX expression increased in glial cells and neutrophils. Double-labeling immunohistochemistry showed that part of the 5-LOX-positive glial cells were GFAP positive. No 5-LOX expression was found in brain microvessel endothelia, except in the regenerated endothelia of a patient 8 days following brain trauma. Furthermore, 5-LOX expression increased and showed a granular pattern in high-grade (grade III/IV) astrocytoma. These results indicate that 5-LOX has multiple expression patterns, and can be induced by brain injury, which implies that 5-LOX might have pathophysiological roles in the human brain.	Zhejiang Univ, Sch Med, Dept Pharmacol, Hangzhou 310031, Peoples R China; Zhejiang Univ, Dept Neurosurg, Affiliated Hosp 2, Sch Med, Hangzhou 310031, Peoples R China; Zhejiang Univ, Dept Pathol, Affiliated Hosp 1, Sch Med, Hangzhou 310031, Peoples R China	Wei, EQ (corresponding author), Zhejiang Univ, Sch Med, Dept Pharmacol, Hangzhou 310031, Peoples R China.	weieq2001@yahoo.com	Zhang, Lei/F-2603-2011				Arai K, 2001, BRAIN RES, V904, P167, DOI 10.1016/S0006-8993(01)02491-X; BOADO RJ, 1992, P NATL ACAD SCI USA, V89, P9044, DOI 10.1073/pnas.89.19.9044; BROCK TG, 1994, J BIOL CHEM, V269, P22059; Brock TG, 1999, J IMMUNOL, V162, P1669; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; CHEN XS, 1995, J BIOL CHEM, V270, P17993, DOI 10.1074/jbc.270.30.17993; Cowburn AS, 1999, J IMMUNOL, V163, P456; Dhillon HS, 1996, J NEUROTRAUM, V13, P781, DOI 10.1089/neu.1996.13.781; Di Gennaro A, 2004, FASEB J, V18, P842, DOI 10.1096/fj.03-0599fje; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Ghosh J, 2003, BIOCHEM BIOPH RES CO, V307, P342, DOI 10.1016/S0006-291X(03)01201-4; Golubic M, 2003, ADV EXP MED BIOL, V525, P205; Hashizume K, 2002, J NEUROPATH EXP NEUR, V61, P725, DOI 10.1093/jnen/61.8.725; KIWAK KJ, 1985, J NEUROSURG, V62, P865, DOI 10.3171/jns.1985.62.6.0865; Lammers CH, 1996, J NEUROCHEM, V66, P147; Lebeau A, 2001, NEUROREPORT, V12, P2199, DOI 10.1097/00001756-200107200-00031; Luo M, 2003, P NATL ACAD SCI USA, V100, P12165, DOI 10.1073/pnas.2133253100; NAMURA Y, 1994, ACTA NEUROCHIR, P296; OHTSUKI T, 1995, AM J PHYSIOL-HEART C, V268, pH1249; PALMER MR, 1980, NEUROSCI LETT, V18, P173, DOI 10.1016/0304-3940(80)90322-5; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; Seufferlein T, 2002, BRIT J CANCER, V86, P1188, DOI 10.1038/sj/bjc/6600186; Shishido Y, 2001, PHARMACOL BIOCHEM BE, V69, P469, DOI 10.1016/S0091-3057(01)00572-X; SIMMET T, 1990, J NEUROCHEM, V54, P2091, DOI 10.1111/j.1471-4159.1990.tb04915.x; Song Y, 2004, NEUROREPORT, V15, P2181, DOI 10.1097/00001756-200410050-00007; Stewart LR, 2001, J NEUROSCI RES, V65, P565, DOI 10.1002/jnr.1186; TEASDALE G, 1974, LANCET, V2, P81; Tomimoto H, 2002, ACTA NEUROPATHOL, V104, P601, DOI 10.1007/s00401-002-0590-0; Unterberg A, 1990, Adv Neurol, V52, P211; Uz T, 1998, FASEB J, V12, P439; Uz T, 2001, EUR J PHARMACOL, V418, P15, DOI 10.1016/S0014-2999(01)00924-4; Walker JL, 2002, AM J PHYSIOL-HEART C, V282, pH585, DOI 10.1152/ajpheart.00003.2001; Whitney LW, 2001, J NEUROIMMUNOL, V121, P40, DOI 10.1016/S0165-5728(01)00438-6; WOODS JW, 1995, J CLIN INVEST, V95, P2035, DOI 10.1172/JCI117889; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; Ye YN, 2004, TOXICOLOGY, V203, P179, DOI 10.1016/j.tox.2004.06.004	36	39	44	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-6544	1440-1789		NEUROPATHOLOGY	Neuropathology	APR	2006	26	2					99	106		10.1111/j.1440-1789.2006.00658.x			8	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	029GL	WOS:000236548800001	16708542				2021-06-18	
J	Park, E; McKnight, S; Ai, JL; Baker, AJ				Park, Eugene; McKnight, Sarah; Ai, Jinglu; Baker, Andrew J.			Purkinje cell vulnerability to mild and severe forebrain head trauma	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						apoptosis; cerebellum; fluid percussion injury (FPI); Purkinje cell; traumatic brain injury; TUNEL	CONTROLLED CORTICAL IMPACT; EXPERIMENTAL BRAIN-INJURY; LATERAL FLUID-PERCUSSION; EXTRACELLULAR POTASSIUM; NEURONAL APOPTOSIS; COGNITIVE DEFICITS; MOTOR COORDINATION; AMPA NEUROTOXICITY; CEREBELLAR DAMAGE; GLUTAMATE UPTAKE	Pathophysiological changes in the cortex, thalamus, and hippocampus have been implicated as contributors to motor and cognitive deficits in a number of animal models of traumatic brain injury (TBI). Indirect cerebellar injury may contribute to TBI pathophysiology because impairment of motor function and coordination are common consequences of TBI, but are also domains associated with cerebellar function. However, there is a lack of direct evidence to support this claim. Hence, in this study, a dose-response relationship of the cerebellum's susceptibility was determined at four grades of fluid percussion injury (1.5, 2.0, 2.5, and 3.0 atm) applied in the right lateral cerebral cortex of adult male Sprague-Dawley rats. Evidence suggests primary and secondary injury mechanisms resulting in selective cerebellar Purkinje neuron (PN) loss, whereas intemeurons of the molecular layer were spared. The posterior region of the cerebellar vermis displayed significant PN loss (p = 0.001) at 1 day postinjury, whereas the gyrus of the horizontal fissure and gyrus of lobules III and IV exhibited delayed PN loss at higher levels of injury severity. Interestingly, neither terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL) or cleaved caspase-3 colocalized with PNs at any time point or injury severity. Expression of calbindin-28k increased in regions of greatest PN loss, suggesting that the surviving PNs possess higher calcium-buffering capacities, which may account for their survival.	St Michaels Hosp, Cara Phelan Ctr Trauma Res, Toronto, ON M5B 1W8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada	Baker, AJ (corresponding author), Cara Phelan Ctr Trauma Res, 7086 Bond Wing,30 Bond St, Toronto, ON M5B 1W8, Canada.	bakera@smh.toronto.on.ca		AI, JINGLU/0000-0001-7414-0207			Airaksinen MS, 1997, P NATL ACAD SCI USA, V94, P1488, DOI 10.1073/pnas.94.4.1488; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Barski JJ, 2003, J NEUROSCI, V23, P3469; Bastianelli E, 2003, CEREBELLUM, V2, P242, DOI 10.1080/14734220310022289; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; BRORSON JR, 1994, J NEUROSCI, V14, P187; CELIO MR, 1990, NEUROSCIENCE, V35, P375, DOI 10.1016/0306-4522(90)90091-H; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; Ding YC, 2001, NEUROL RES, V23, P193, DOI 10.1179/016164101101198334; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FIEZ JA, 1992, BRAIN, V115, P155, DOI 10.1093/brain/115.1.155; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; GARTHWAITE G, 1991, EUR J NEUROSCI, V3, P715, DOI 10.1111/j.1460-9568.1991.tb01668.x; GARTHWAITE G, 1991, EUR J NEUROSCI, V3, P729, DOI 10.1111/j.1460-9568.1991.tb01669.x; GOLDSTEIN LB, 1990, BRAIN RES, V508, P305, DOI 10.1016/0006-8993(90)90413-6; Gorrie C, 2002, J NEUROTRAUM, V19, P1171, DOI 10.1089/08977150260337976; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hamberger A, 2003, J NEUROTRAUM, V20, P169, DOI 10.1089/08977150360547080; Hattori N, 2003, J NUCL MED, V44, P1709; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; Joyal CC, 1996, BRAIN RES, V739, P1, DOI 10.1016/S0006-8993(96)00333-2; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Lalonde R, 2003, CEREBELLUM, V2, P300, DOI 10.1080/14734220310017456; Leggio MG, 2000, P NATL ACAD SCI USA, V97, P2320, DOI 10.1073/pnas.040554297; Longuemare MC, 1999, NEUROSCIENCE, V93, P285, DOI 10.1016/S0306-4522(99)00152-9; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LUCHTER S, 1995, J NEUROTRAUM, V12, P517, DOI 10.1089/neu.1995.12.517; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Middleton FA, 1998, TRENDS NEUROSCI, V21, P367, DOI 10.1016/S0166-2236(98)01330-7; MORRIS RGM, 1990, EUR J NEUROSCI, V2, P1016, DOI 10.1111/j.1460-9568.1990.tb00014.x; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Petrosini L, 1998, PROG NEUROBIOL, V56, P191, DOI 10.1016/S0301-0082(98)00036-7; Piot-Grosjean O, 2001, NEUROBIOL DIS, V8, P1082, DOI 10.1006/nbdi.2001.0450; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; RINK A, 1995, AM J PATHOL, V147, P1575; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; SCHMAHMANN JD, 1991, ARCH NEUROL-CHICAGO, V48, P1178, DOI 10.1001/archneur.1991.00530230086029; Schmidt H, 2003, J PHYSIOL-LONDON, V551, P13, DOI 10.1113/jphysiol.2002.035824; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Soto-Ares G, 2001, CHILD NERV SYST, V17, P263, DOI 10.1007/s003810000411; Strahlendorf JC, 1996, BRAIN RES, V729, P197, DOI 10.1016/S0006-8993(96)00367-8; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	61	39	39	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAR	2006	65	3					226	234		10.1097/01.jnen.0000202888.29705.93			9	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	050EQ	WOS:000238070700004	16651884	Bronze			2021-06-18	
J	Skelton, RW; Ross, SP; Nerad, L; Livingstone, SA				Skelton, RW; Ross, SP; Nerad, L; Livingstone, SA			Human spatial navigation deficits after traumatic brain injury shown in the arena maze, a virtual Morris water maze	BRAIN INJURY			English	Article						topographical disorientation; spatial cognition; cognitive map; place learning; allocentric; closed head injury	UNILATERAL TEMPORAL LOBECTOMY; TOPOGRAPHICAL DISORIENTATION; HEAD-INJURY; PLACE NAVIGATION; HIPPOCAMPAL-LESIONS; STIMULUS-CONTROL; MEMORY DEFICITS; LOBE LESIONS; OPTIC FLOW; RATS	Objective: Survivors of traumatic brain injury (TBI) often have spatial navigation deficits. This study examined such deficits and conducted a detailed analysis of navigational behaviour in a virtual environment. Design: TBI survivors were tested in a computer simulation of the Morris water maze task that required them to find and remember the location of an invisible platform that was always in the same location. A follow-up questionnaire assessed everyday spatial ability. Method: Fourteen survivors of moderate-to-severe TBI were compared to 12 non-injured participants. Results: TBI survivors navigated to a visible platform but could not learn the location of the invisible platform. The difference between TBI survivors and uninjured participants was best indicated by two new dependent variables, path efficacy and spatial scores. Conclusion: This study confirms the capacity of virtual environments to reveal spatial navigation deficits after TBI and establishes the best way to identify such deficits.	Univ Victoria, Dept Psychol, Victoria, BC V8W 3P5, Canada	Skelton, RW (corresponding author), Univ Victoria, Dept Psychol, POB 3050, Victoria, BC V8W 3P5, Canada.	skelton@uvic.ca	Skelton, Ronald/E-5605-2012	Ross, Shelley/0000-0001-9581-3191			ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Aguirre GK, 1999, BRAIN, V122, P1613, DOI 10.1093/brain/122.9.1613; Astur RS, 2002, BEHAV BRAIN RES, V132, P77, DOI 10.1016/S0166-4328(01)00399-0; Astur RS, 1998, BEHAV BRAIN RES, V93, P185, DOI 10.1016/S0166-4328(98)00019-9; BADDELEY A, 1987, NEUROBEHAVIORAL RECO, P295; Barrash J, 1998, J CLIN EXP NEUROPSYC, V20, P807, DOI 10.1076/jcen.20.6.807.1114; Barrash J, 2000, NEUROPSYCHOLOGIA, V38, P820, DOI 10.1016/S0028-3932(99)00131-1; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bohbot VD, 2004, NEUROPSYCHOLOGY, V18, P418, DOI 10.1037/0894-4105.18.3.418; Bohbot VD, 2002, PHYSIOL RES, V51, pS49; Bohbot VD, 2000, ANN NY ACAD SCI, V911, P355; BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; CORKIN S, 1965, NEUROPSYCHOLOGIA, V3, P339, DOI 10.1016/0028-3932(65)90006-0; Darken RP, 2002, HUM FAC ER, P493; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; EICHENBAUM H, 1990, J NEUROSCI, V10, P3531; Feigenbaum JD, 1996, NEUROPSYCHOLOGIA, V34, P163, DOI 10.1016/0028-3932(95)00107-7; GAGE FH, 1986, J NEUROSCI, V6, P2837; HABIB M, 1987, CORTEX, V23, P73, DOI 10.1016/S0010-9452(87)80020-5; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; Hu C, 1999, ONLINE CLIN CALCULAT; Iaria G, 2003, J NEUROSCI, V23, P5945; Jacobs WJ, 1998, LEARN MOTIV, V29, P288, DOI 10.1006/lmot.1998.1008; Jacobs WJ, 1997, LEARN MOTIV, V28, P521, DOI 10.1006/lmot.1997.0977; Kearns MJ, 2002, PERCEPTION, V31, P349, DOI 10.1068/p3311; Kirschen MP, 2000, PERCEPTION, V29, P801, DOI 10.1068/p3096; KOLB B, 1983, BEHAV NEUROSCI, V97, P13, DOI 10.1037/0735-7044.97.1.13; Kolb B, 2000, NEUROPHARMACOLOGY, V39, P756, DOI 10.1016/S0028-3908(99)00260-9; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Maguire EA, 1998, SCIENCE, V280, P921, DOI 10.1126/science.280.5365.921; Maguire EA, 1998, J COGNITIVE NEUROSCI, V10, P61, DOI 10.1162/089892998563789; Maguire EA, 1996, NEUROPSYCHOLOGIA, V34, P993, DOI 10.1016/0028-3932(96)00022-X; MCDANIEL WF, 1991, BEHAV BRAIN RES, V44, P107, DOI 10.1016/S0166-4328(05)80245-1; MCNAMARA RK, 1993, BRAIN RES REV, V18, P33, DOI 10.1016/0165-0173(93)90006-L; Milner B., 1970, BIOL MEMORY, P29, DOI 10.1016/B978-0-12-564350-4.50011-7; Moffat SD, 2002, BEHAV NEUROSCI, V116, P851, DOI 10.1037//0735-7044.116.5.851; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; Nadel L, 2000, HIPPOCAMPUS, V10, P352, DOI 10.1002/1098-1063(2000)10:4<352::AID-HIPO2>3.0.CO;2-D; Nadel L., 1991, Hippocampus, V1, P221, DOI 10.1002/hipo.450010302; O'Keefe J., 1978, HIPPOCAMPUS COGNITIV; OLSEN GM, 1994, BEHAV NEUROSCI, V108, P681, DOI 10.1037/0735-7044.108.4.681; PANG D, 1989, ASSESSMENT BEHAV CON, P1; Paterson A, 1944, BRAIN, V67, P331, DOI 10.1093/brain/67.4.331; Pizzamiglio L, 1998, CORTEX, V34, P719, DOI 10.1016/S0010-9452(08)70775-5; Previc FH, 1998, PSYCHOL BULL, V124, P123, DOI 10.1037/0033-2909.124.2.123; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; REID IC, 1996, NEUR ABSTR, V21, P1446; REITAN RM, 1994, NEUROPSYCHOL REV, V4, P161, DOI 10.1007/BF01874891; Rizzo AA, 2004, NEUROPSYCHOL REHABIL, V14, P207, DOI 10.1080/09602010343000183; ROD MR, 1990, CAN J PSYCHOL, V44, P196, DOI 10.1037/h0084242; Rose FD, 1999, DISABIL REHABIL, V21, P548; Sandstrom NJ, 1998, COGNITIVE BRAIN RES, V6, P351, DOI 10.1016/S0926-6410(98)00002-0; SCHENK F, 1998, HDB SPATIAL RES PARA, V2, P145; Skelton R., 2000, NEUR ABSTR, V26, P1440; Skelton RW, 2000, J CLIN EXP NEUROPSYC, V22, P157, DOI 10.1076/1380-3395(200004)22:2;1-1;FT157; Skelton RW, 1998, BEHAV BRAIN RES, V96, P13, DOI 10.1016/S0166-4328(97)00199-X; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH ML, 1981, NEUROPSYCHOLOGIA, V19, P781, DOI 10.1016/0028-3932(81)90090-7; Spiers HJ, 2001, BRAIN, V124, P2476, DOI 10.1093/brain/124.12.2476; Spiers HJ, 2001, NEUROCASE, V7, P357, DOI 10.1076/neur.7.5.357.16245; Spreen O., 1998, COMPENDIUM NEUROPSYC; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SUZUKI S, 1980, LEARN MOTIV, V11, P1, DOI 10.1016/0023-9690(80)90018-1; Tabachnick B., 2001, USING MULTIVARIATE S; TOLMAN EC, 1948, PSYCHOL REV, V55, P189, DOI 10.1037/h0061626; Trullier O, 1999, EUR J NEUROSCI, V11, P4381, DOI 10.1046/j.1460-9568.1999.00839.x; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; White NM, 2002, NEUROBIOL LEARN MEM, V77, P125, DOI 10.1006/nlme.2001.4008	73	39	39	0	15	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2006	20	2					189	203		10.1080/02699050500456410			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	003KX	WOS:000234681700009	16421068				2021-06-18	
J	Ahn, YH; Kim, SH; Han, BS; Kim, OL; Ahn, SH; Cho, YW; Kwon, YH; Jang, SH				Ahn, Young Hwan; Kim, Seong Ho; Han, Bong Soo; Kim, Oh Lyong; Ahn, Sang Ho; Cho, Yoon Woo; Kwon, Yong-Hyun; Jang, Sung Ho			Focal lesions of the corticospinal tract demonstrated by diffusion tensor imaging in patients with diffuse axonal injury	NEUROREHABILITATION			English	Article						motor recovery; diffusion tensor imaging; corticospinal tract; diffuse axonal injury	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD TRAUMA; FIBER TRACKING; FUNCTIONAL MRI; TRACTOGRAPHY; RECOVERY	Objectives: Diffusion tensor imaging (DTI) with fiber tractography (FT) could be useful for exploration of the state of the corticospinal tract (CST) at the subcortical white matter level. The purpose of this study was to demonstrate focal lesions of the CST in patients with diffuse axonal injury (DAI), using DTI with FT. Design: Two patients with DAI and six normal control subjects were recruited to this study. DTI was performed using 1.5-T with a synergy-L Sensitivity Encoding ( SENSE) head coil. Fractional anisotropy ( FA) and apparent diffusion coefficients (ADC) were measured using a region of interest (ROI) method. FTs were obtained with FA < 0.3 and an angle change > 45. as termination criteria. Results: On the DTI with FT, the focal lesions, which could not observed using routine brain MRI, were detected in the left brainstem of patient 1 and in the right pons and the left and right medulla of patient 2. The patients showed significantly decreased FA values in the focal lesions compared to normal controls. Conclusions: DTI with FT demonstrated focal lesions at the brainstem that had not been revealed by conventional brain MRI; these focal lesions explained the weaknesses of the patients. We conclude that DTI with FT may be a useful modality for use in investigating the status of CST in patients with DAI.	Yeungnam Univ, Sch Med, Dept Phys Med & Rehabil, Taegu 705717, South Korea; Ajou Univ, Sch Med, Dept Neurosurg, Suwon 441749, South Korea; Yeungnam Univ, Sch Med, Dept Neurosurg, Taegu 705717, South Korea; Yonsei Univ, Coll Hlth Sci, Dept Radiol Sci, Kangwon Do, South Korea	Jang, SH (corresponding author), Yeungnam Univ, Sch Med, Dept Phys Med & Rehabil, 317-1 Daemyungdong, Taegu 705717, South Korea.	strokerehab@hanmail.net	Han, Bong Soo/AAL-6704-2020				ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; DEMEURISSE G, 1980, EUR NEUROL, V19, P382, DOI 10.1159/000115178; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jang SH, 2005, RESTOR NEUROL NEUROS, V23, P11; Jang SH, 2005, RESTOR NEUROL NEUROS, V23, P265; Jang SH, 2005, RESTOR NEUROL NEUROS, V23, P51; Katz DI, 1998, ARCH PHYS MED REHAB, V79, P488, DOI 10.1016/S0003-9993(98)90060-0; Kim YH, 2004, NEUROREPORT, V15, P1899, DOI 10.1097/00001756-200408260-00013; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Naganawa S, 2004, AM J NEURORADIOL, V25, P1553; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Ronen I, 2005, MAGN RESON MED, V54, P317, DOI 10.1002/mrm.20542; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530	20	39	39	0	0	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2006	21	3					239	243					5	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	120KV	WOS:000243084500007	17167193				2021-06-18	
J	Catalano, D; Pereira, AP; Wu, MY; Ho, H; Chan, F				Catalano, Denise; Pereira, Ana Paula; Wu, Ming-Yi; Ho, Hanson; Chan, Fong			Service patterns related to successful employment outcomes of persons with traumatic brain injury in vocational rehabilitation	NEUROREHABILITATION			English	Article; Proceedings Paper	1st International Conference on Vocational Outcomes in Traumatic Brain Injury	APR 14-16, 2005	Vancouver, CANADA			Traumatic Brain Injury (TBI); state-federal vocational rehabilitation services; employment outcomes; job placement; work disincentives; CHAID analysis	SPINAL-CORD-INJURY; SUBSTANCE-ABUSE; PREDICTION; WORK; CONSEQUENCES; INDIVIDUALS; VARIABLES; ALCOHOL; CLIENTS; SAMPLE	This study analyzed the Rehabilitation Services Administration (RSA) case service report (RSA-911) data for fiscal year 2004 to examine effects of demographic characteristics, work disincentives, and vocational rehabilitation services patterns on employment outcomes of persons with traumatic brain injuries (TBI). The results indicated that European Americans (53%) had appreciably higher competitive employment rates than Native American (50%), Asian Americans (44%), African Americans (42%), and Hispanic/Latino Americans (41%). Clients without co-occurring psychiatric disabilities had a higher employment rate (51%) than those with psychiatric disabilities (45%). Clients without work disincentives showed better employment outcomes (58%) than those with disincentives (45%). An important finding from this analysis was the central role of job search assistance, job placement assistance, and on-the-job support services for persons with TBI in predicting employment outcomes. A data mining technique, the exhaustive CHAID analysis, was used to examine the interaction effects of race, gender, work disincentives and service variables on employment outcomes. The results indicated that the TBI clients in this study could be segmented into 29 homogeneous subgroups with employment rates ranging from a low of 11% to a high of 82%, and these differences can be explained by differences in work disincentives, race, and rehabilitation service patterns.	Univ N Texas, Dept Rehabil Social Work & Addict, Denton, TX 76203 USA; Univ Fed Parana, Dept Psychol, BR-80060000 Curitiba, Parana, Brazil; Natl Kaohsiung Normal Univ, Grad Inst Rehabil Counseling, Kaohsiung, Taiwan; Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; Univ Wisconsin, Dept Rehabil Psychol & Special Educ, Madison, WI 53706 USA	Catalano, D (corresponding author), Univ N Texas, Dept Rehabil Social Work & Addict, Denton, TX 76203 USA.	Catalano@pacs.unt.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A031705] Funding Source: Medline		Basford JR, 2002, ARCH PHYS MED REHAB, V83, P517, DOI 10.1053/apmr.2002.30922; BOLTON B, 1972, PREDICTING CLIENT OU; Bolton B. F., 2002, REHABILITATION COUNS, V44, P10; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; Bombardier CH, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P399, DOI 10.1037/10361-019; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BYRD EK, 1978, REHABIL COUNS BULL, V21, P350; CARDOSO E, IN PRESS REHABILITAT; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; *CDC, 2005, FACTS TRAUM BRAIN IN; Chan F., 2005, J APPL REHABILITATIO, V36, P3; Chan Fong, 2005, Work, V25, P77; CHRONISTER JA, 2005, CASE MANAGEMENT REHA, V2, P369; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; CUNNINGHAM JM, 2005, CASE MANAGEMENT REHA, V2, P91; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIXON TM, 1999, MED ASPECTS DISABILI, P98; FABIANO RJ, 1995, REHABIL PSYCHOL, V40, P223, DOI 10.1037/0090-5550.40.3.223; Forthofer MS, 2000, AM J HEALTH BEHAV, V24, P36, DOI 10.5993/AJHB.24.1.6; Frazier PA, 2004, J COUNS PSYCHOL, V51, P115, DOI 10.1037/0022-0167.51.1.115; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Gamble D, 2003, J REHABIL, V69, P31; Gamble D., 2002, J APPL REHABILITATIO, V33, P41, DOI DOI 10.1891/0047-2220.33.3.41; Gamble D, 2003, J VOCATIONAL REHABIL, V19, P47; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Gouick J, 2004, TRAUMA, V6, P285, DOI DOI 10.1191/1460408604TA3230A; Gurr B, 2001, BRAIN INJURY, V15, P387, DOI 10.1080/02699050010005904; Habeck RV, 1997, PHYS MED REHAB CLIN, V8, P263; HANLEYMAXWELL C, 1992, REHABILITATION COUNS, P135; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Hennessey JC, 1997, SOC SECUR BULL, V60, P3; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; HOUTENVILLE AJ, DISABILITY STAT US; Ingraham K., 1992, J APPL REHABILITATIO, V23, P18; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P161, DOI 10.1053/apmr.2003.50098; Johnstone B, 1999, J HEAD TRAUMA REHAB, V14, P220, DOI 10.1097/00001199-199906000-00003; Jorge RE, 2005, CURR OPIN PSYCHIATR, V18, P289, DOI 10.1097/01.yco.0000165600.90928.92; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; KREUTZER JS, 1991, J HEAD TRAUMA REHAB, V6, P12; LAM CS, 1991, REHABIL COUNS BULL, V35, P68; MA TC, 2000, THESIS U IOWA; Marini I., 1999, J REHABILITATION ADM, V23, P31; NONG, 2003, HDB DATA MINING; O'Connell MJ, 2000, REHABIL PSYCHOL, V45, P212, DOI 10.1037/0090-5550.45.2.212; Radnitz CL, 1996, J NERV MENT DIS, V184, P431, DOI 10.1097/00005053-199607000-00006; ROSENTHAL DA, IN PRESS J REHABILIT; Sherer M, 1999, BRAIN INJURY, V13, P973; SHUTTER LA, 1998, TRAUMA Q, V14, P61; Simpson A, 2002, BRAIN INJURY, V16, P1075, DOI 10.1080/02699050210155249; Skeel RL, 2003, REHABIL PSYCHOL, V48, P145, DOI 10.1037/0090-5550.48.3.145; Sohlberg M. M., 2001, COGNITIVE REHABILITA; *SPSS, 1998, ANSWERTREE 2 0 US GU; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; *TRAUM BRAIN INJ N, 2005, TRAUM BRAIN INJ FACT; Turner AP, 2003, ARCH PHYS MED REHAB, V84, P358, DOI 10.1053/apmr.2003.50107; WALLACE MD, 1982, INT STUD QUART, V26, P37, DOI 10.2307/2600598; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472	60	39	39	0	15	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2006	21	4					279	293					15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	145VU	WOS:000244894700003	17361045				2021-06-18	
J	Kochanek, AR; Kline, AE; Gao, WM; Chadha, M; Lai, YC; Clark, RSB; Dixon, CE; Jenkins, LW				Kochanek, Ashley R.; Kline, Anthony E.; Gao, Wei-Min; Chadha, Mandeep; Lai, Yichen; Clark, Robert S. B.; Dixon, C. Edward; Jenkins, Larry W.			Gel-based hippocampal proteomic analysis 2 weeks following traumatic brain injury to immature rats using controlled cortical impact	DEVELOPMENTAL NEUROSCIENCE			English	Article						hippocampus; phosphorylation; pyruvate; protein oxidation; mitochondria; rat brain; pediatric traumatic brain injury	PYRUVATE-DEHYDROGENASE ACTIVITY; SYNAPTIC PLASTICITY; PHOSPHORYLATION; INHIBITION; PROTEINS; COMPLEX; STRESS	Traumatic brain injury (TBI) to postnatal day 17 rats has been shown to produce acute changes in hippocampal global protein levels and spatial learning and memory deficits. The purpose of the present study was to analyze global hippocampal protein changes 2 weeks after a moderate ipsilateral controlled cortical impact in postnatal day 17 rats using 2-dimensional difference gel electrophoresis and mass spectrometry. Paired sham and ipsilateral injured hippocampal lysates were independently labeled with different fluorescent cyanine dyes and coseparated within the same immobilized pH gradient strips and slab gel based on isoelectric point and molecular mass. Significant changes in key proteins involved in glial and neuronal stress, oxidative metabolism, calcium uptake and neurotransmitter function were found 2 weeks after injury, and their potential roles in hippocampal plasticity and cognitive dysfunction were discussed. Copyright (c) 2006 S. Karger AG, Basel.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Texas Tech Univ, Inst Environm & Human Hlth, Dept Environm Toxicol, Lubbock, TX 79409 USA	Jenkins, LW (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 201 Hill Bldg,3434 5th Ave, Pittsburgh, PA 15260 USA.	ljenkins@pitt.edu		Lai, Yi-Chen/0000-0002-9450-5506	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD040686, T-32 HD 40686] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS42648, R01 NS042648-04, R01 NS042648] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042648] Funding Source: NIH RePORTER		Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; BAUDRY M, 1982, NEUROSCI LETT, V31, P41, DOI 10.1016/0304-3940(82)90051-9; BROWNING M, 1981, J NEUROCHEM, V36, P1932, DOI 10.1111/j.1471-4159.1981.tb10817.x; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Clayton DF, 1999, J NEUROSCI RES, V58, P120, DOI 10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.3.CO;2-5; Darling DL, 2005, CURR TOP DEV BIOL, V68, P281, DOI 10.1016/S0070-2153(05)68010-6; Dougherty KD, 2000, NEUROBIOL DIS, V7, P574, DOI 10.1006/nbdi.2000.0318; Fiskum G, 2004, J BIOENERG BIOMEMBR, V36, P347, DOI 10.1023/B:JOBB.0000041766.71376.81; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Herschkowitz N, 2000, BRAIN DEV-JPN, V22, P411, DOI 10.1016/S0387-7604(00)00185-6; Hertz L, 2004, J CEREBR BLOOD F MET, V24, P1241, DOI 10.1097/00004647-200411000-00008; Ikonomidou C, 2000, P NATL ACAD SCI USA, V97, P12885, DOI 10.1073/pnas.220412197; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Korotchkina LG, 2001, J BIOL CHEM, V276, P5731, DOI 10.1074/jbc.M007558200; Lai Y, 2005, J NEUROCHEM, V94, P360, DOI 10.1111/j.1471-4159.2005.03212.x; Lai YC, 2004, J NEUROTRAUM, V21, P229, DOI 10.1089/089771504322972022; Lambert K G, 2000, Stress, V3, P275, DOI 10.3109/10253890009001133; Lister R, 2005, MOL MEMBR BIOL, V22, P87, DOI 10.1080/09687860500041247; Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003; Morel N, 2003, BIOL CELL, V95, P453, DOI 10.1016/S0248-4900(03)00075-3; Patel MS, 2001, EXP MOL MED, V33, P191, DOI 10.1038/emm.2001.32; Peluffo H, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-12; Philippe JM, 2002, GLIA, V37, P365, DOI 10.1002/glia.10041.abs; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Prins ML, 2003, DEV BRAIN RES, V140, P93, DOI 10.1016/S0165-3806(02)00588-6; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.2307/3454543; Samikkannu T, 2003, CHEM RES TOXICOL, V16, P409, DOI 10.1021/tx025615j; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Stevenson K. L., 2000, Journal of Neurotrauma, V17, P944; Suginta W, 2001, BIOCHEM J, V359, P55, DOI 10.1042/0264-6021:3590055; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Weeber EJ, 2002, J BIOL CHEM, V277, P18891, DOI 10.1074/jbc.M201649200; Wu WW, 2006, J PROTEOME RES, V5, P651, DOI 10.1021/pr050405o; Yang B, 2003, NEUROSCI RES, V46, P333, DOI 10.1016/S0168-0102(03)00096-8; Yoo BC, 2001, ELECTROPHORESIS, V22, P172, DOI 10.1002/1522-2683(200101)22:1<172::AID-ELPS172>3.0.CO;2-P	38	39	40	0	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2006	28	4-5					410	419		10.1159/000094167			10	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	080ZS	WOS:000240287600018	16943664	Green Accepted, Bronze			2021-06-18	
J	Kerman, M; Cirak, B; Ozguner, MF; Dagtekin, A; Sutcu, R; Altuntas, I; Delibas, N				Kerman, M; Cirak, B; Ozguner, MF; Dagtekin, A; Sutcu, R; Altuntas, I; Delibas, N			Does melatonin protect or treat brain damage from traumatic oxidative stress?	EXPERIMENTAL BRAIN RESEARCH			English	Article						melatonin; antioxidant enzymes; lipid peroxidation; experimental brain damage	CENTRAL-NERVOUS-SYSTEM; GLUTATHIONE-PEROXIDASE; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; ALPHA-TOCOPHEROL; FREE-RADICALS; INJURY; ANTIOXIDANTS	A variety of experimental studies have demonstrated the neuroprotective effects of melatonin, based on its antioxidant activity. In a prospective randomized study, the effects of melatonin were investigated in experimental head trauma-induced oxidative stress in rabbits. The experimental study was performed on 30 rabbits. The animals were divided into three groups. Group I (sham procedure): a right parietal craniotomy was performed on each animal, and the dura mater was left intact. Group II: experimental brain trauma (EBT) was performed on each animal using a 1 cm inner diameter x 10 cm long glass tube, through which a 20 g weight (0.5 cm diameter) was dropped onto the brain at the craniotomy site, causing a contusional head trauma. Group III: the same EBT model was performed, but 2.5 mg/kg melatonin was injected intraperitoneally four times (total dose 10 mg/kg); these injections were performed 20 min before the operation, during the trauma, 1 h later and 2 h later. The rabbits were sacrificed after the EBT at 24 h after the brain trauma. The activities of the three principal antioxidant enzymes-catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px)-were determined, and the levels of malondialdehyde (MDA), a product of lipid peroxidation, and glutathione (GSH) were measured in brain homogenates. MDA levels were found to be higher in the EBT group than in the EBT+melatonin group or the sham procedure group. The SOD activity was found to be higher in the EBT group than in the sham procedure group. Enzymatic parameters (except for SOD) were significantly higher in melatonin-treated animals than in EBT animals. GSH levels in melatonin-treated animals were decreased compared with EBT animals. In conclusion, the data indicate that melatonin protects against free radical-mediated oxidative changes in brain tissue by boosting antioxidant enzymes, and in particular lowering lipid peroxidation in rabbits with EBT.	S Demirel Univ, Sch Med, Dept Neurosurg, Isparta, Turkey; Pamukkale Univ, Dept Neurosurg, Denizli, Turkey; S Demirel Univ, Sch Med, Dept Physiol, Isparta, Turkey; S Demirel Univ, Sch Med, Dept Clin Biochem, Isparta, Turkey	Cirak, B (corresponding author), Pamukkale Univ, Tip Fak, Beyin Sinir Cerrahisi Klin, Kinikli Denizli, Turkey.	bayramcirak@yahoo.com	Dagtekin, Ahmet/E-7905-2016; Dagtekin, Ahmet/AAE-2408-2020; DELIBAS, NAMIK/I-8378-2013; Delibas, Namik/N-1695-2017	Dagtekin, Ahmet/0000-0001-7368-6937; DELIBAS, NAMIK/0000-0001-8014-6189; Delibas, Namik/0000-0002-1354-8927			AEBI H, 1984, METHOD ENZYMOL, V105, P121; BARLOWWALDEN LR, 1995, NEUROCHEM INT, V26, P497, DOI 10.1016/0197-0186(94)00154-M; BEUTLER E, 1963, J LAB CLIN MED, V61, P882; BULLOCK R, 1993, SCHWEIZ MED WSCHR, V123, P449; CADET JL, 1988, INT J NEUROSCI, V40, P13, DOI 10.3109/00207458808985722; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; DRAPER HH, 1990, METHOD ENZYMOL, V186, P421; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; Farooqui AA, 1998, CELL MOL NEUROBIOL, V18, P599, DOI 10.1023/A:1020261600498; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Franceschini D, 1999, ADV EXP MED BIOL, V467, P207; HALL ED, 1993, ANN EMERG MED, V22, P1022, DOI 10.1016/S0196-0644(05)82745-3; HARA H, 1990, BRAIN RES, V510, P335, DOI 10.1016/0006-8993(90)91386-U; Horakova L, 2000, GEN PHYSIOL BIOPHYS, V19, P195; IKEDA Y, 1989, Neurological Research, V11, P213; IKEDA Y, 1990, NEUROSURGERY, V27, P1; IKEDA Y, 1989, NEUROSURGERY, V24, P679, DOI 10.1227/00006123-198905000-00004; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LONG DM, 1972, STEROIDS BRAIN EDEMA, P87; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; MEYDANI SN, 1990, AM J CLIN NUTR, V52, P557; NISHIBE M, 1989, Hokkaido Journal of Medical Science, V64, P301; Okatani Y, 2000, J PINEAL RES, V28, P89, DOI 10.1034/j.1600-079X.2001.280204.x; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; REITER RJ, 1993, BRAZ J MED BIOL RES, V26, P1141; Reiter Russel J., 1994, Acta Neurobiologiae Experimentalis (Warsaw), V54, P31; Sarrafzadeh AS, 2000, ACTA NEUROCHIR, V142, P1293, DOI 10.1007/s007010070028; SHIN SM, 1994, BRAIN RES, V653, P45, DOI 10.1016/0006-8993(94)90370-0; Vural H, 2001, J PINEAL RES, V31, P193, DOI 10.1034/j.1600-079X.2001.310301.x; Wada K, 1999, NEUROSURGERY, V45, P601, DOI 10.1097/00006123-199909000-00031; Zang LY, 1998, BBA-GEN SUBJECTS, V1425, P469, DOI 10.1016/S0304-4165(98)00099-3	35	39	40	0	8	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0014-4819	1432-1106		EXP BRAIN RES	Exp. Brain Res.	JUN	2005	163	3					406	410		10.1007/s00221-005-2338-2			5	Neurosciences	Neurosciences & Neurology	933GV	WOS:000229617800015	15856200				2021-06-18	
J	Elf, K; Nilsson, P; Ronne-Engstrom, E; Howells, T; Enblad, P				Elf, K; Nilsson, P; Ronne-Engstrom, E; Howells, T; Enblad, P			Cerebral perfusion pressure between 50 and 60 mm Hg may be beneficial in head-injured patients: A computerized secondary insult monitoring study	NEUROSURGERY			English	Article						head injury; multimodality monitoring; neurointensive care; outcome; secondary insults	TRAUMATIC BRAIN-INJURY; INTRACRANIAL HYPERTENSION; NEUROINTENSIVE CARE; NEUROSURGICAL UNIT; COMPLICATIONS; MANAGEMENT; BURDEN; AUDIT	OBJECTIVE: To describe the occurrence of secondary insults using a computerized monitoring data collecting system and to investigate their relationship to outcome when the neurointensive care was dedicated to avoiding secondary insults. METHODS: Patients 16 to 79 years old admitted to the neurointensive care unit between August 1998 and December 2002 with traumatic brain injury and 54 hours or more of valid monitoring within the first 120 hours after trauma (one value/min) were included. Monitoring of intracranial pressure (ICP), cerebral perfusion pressure (CPP), systolic blood pressure (BPS), and mean blood pressure (BPm) was required, and insult levels were defined (ICP > 25/> 35, BPS < 100/< 90/> 160/> 180, BPm < 80/< 70/> 110/> 120, and CPP < 60/< 50/> 70/> 80 mm Hg). Insults were quantified as proportion of valid monitoring time at the insult level. Logistic regression analyses were performed with admission and secondary insult variables as explanatory variables and favorable outcome as dependent variable. RESULTS: Eighty-one patients, 63 men and 18 women, with a mean age of 43.0 years, fulfilled the inclusion criteria. Seventy-two patients (89%) had Glasgow Coma Scale scores of 8 or less. Thirty-one patients (38%) had diffuse injury, and 50 (62%) had mass lesions. Mean Injury Severity Score was 26.6. After 6 months, 54% of the patients had achieved a favorable outcome. Most patients spent 5% or less of the monitoring time at the insult level except for CPP greater than 70 mm Hg. Low age, high Glasgow Coma Scale motor score, low Injury Severity Score, and CPP less than 60 mm Hg insults were significant predictors of favorable outcome in the final multiple logistic regression model. CONCLUSION: Overall, the secondary insults were rare, except for high CPP. The results suggest that patients with traumatic brain injury might benefit from a CPP slightly less than 60 mm Hg.	Univ Uppsala Hosp, Dept Neurosci, Neurosurg Sect, S-75185 Uppsala, Sweden	Enblad, P (corresponding author), Univ Uppsala Hosp, Dept Neurosci, Neurosurg Sect, S-75185 Uppsala, Sweden.	Per.Enblad@neurokir.uu.se					ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Chambers IR, 2000, BRIT J NEUROSURG, V14, P424; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Chieregato A, 2003, ACTA NEUROCHIR SUPPL, V86, P361; COOKE RS, 1995, INJURY, V26, P395, DOI 10.1016/0020-1383(95)00003-R; CORTBUS F, 1994, ACTA NEUROCHIR, V130, P117, DOI 10.1007/BF01405511; Dunn LT, 1997, INJURY, V28, P427, DOI 10.1016/S0020-1383(97)00051-X; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Elf K, 2003, EUR J TRAUMA, V29, P74; Enblad P, 1997, J NEUROL NEUROSUR PS, V62, P512, DOI 10.1136/jnnp.62.5.512; GENTLEMAN D, 1990, LANCET, V335, P330, DOI 10.1016/0140-6736(90)90615-C; GENTLEMAN D, 1992, INT SURG, V77, P297; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Olesen J, 2003, EUR J NEUROL, V10, P471, DOI 10.1046/j.1468-1331.2003.00682.x; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; REILLY PL, 1975, LANCET, V2, P375; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSE J, 1977, BRIT MED J, V2, P615, DOI 10.1136/bmj.2.6087.615; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Signorini DF, 1997, CRIT CARE MED, V25, P2048, DOI 10.1097/00003246-199712000-00024; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	32	39	39	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAY	2005	56	5					962	970		10.1227/01.NEU.0000158317.00603.40			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	925LJ	WOS:000229054300032	15854244				2021-06-18	
J	Sturms, LM; van der Sluis, CK; Stewart, RE; Groothoff, JW; ten Duis, HJ; Eisma, WH				Sturms, LM; van der Sluis, CK; Stewart, RE; Groothoff, JW; ten Duis, HJ; Eisma, WH			A prospective study on paediatric traffic injuries: health-related quality of life and post-traumatic stress	CLINICAL REHABILITATION			English	Article							TRAUMATIC BRAIN-INJURY; MOTOR-VEHICLE ACCIDENTS; EVENT SCALE; PSYCHOLOGICAL CONSEQUENCES; CHILDREN; DISORDER; IMPACT; ADOLESCENTS; CHILDHOOD; PARENTS	Objectives: To examine children's reports of their health- related quality of life ( HRQoL) following paediatric traffic injury, to explore child and parental post- traumatic stress, and to identify children and parents with adverse outcomes. Design: Prospective cohort study. Assessments: shortly after the injury, three months and six months post injury. Setting: Department of Traumatology, University Hospital. Subjects: Fifty- one young traffic injury victims aged 8 - 15 years. Main measures: TNO- AZL Children's Quality of Life questionnaire and the Impact of Event Scale. Results: Short- term adverse changes in the child's HRQoL were observed for the child's motor functioning and autonomy. At three months, 12% of the children and 16% of the parents reported serious post- traumatic stress symptoms. Increased stress at three months, or across follow- up, was observed among hospitalized children, children with head injuries, and children injured in a motor vehicle accident. Parental stress was related to low socioeconomic status and the seriousness of the child's injury and accident ( hospitalization, head injury, serious injury, motor vehicle involved, others injured). Conclusions: The children reported only temporary effects in their motor functioning and autonomy. Post- traumatic stress symptoms following paediatric traffic injury were not only experienced by the children, but also by their parents.	Univ Groningen Hosp, Dept Rehabil Med, NL-9700 RB Groningen, Netherlands; Univ Groningen, No Ctr Healthcare Res, Groningen, Netherlands; Univ Groningen Hosp, Dept Surg, Traumatol Sect, Groningen, Netherlands	van der Sluis, CK (corresponding author), Univ Groningen Hosp, Dept Rehabil Med, POB 30-001, NL-9700 RB Groningen, Netherlands.	c.k.van.der.sluis@rev.umcg.nl					Aitken ME, 1999, ARCH PHYS MED REHAB, V80, P889, DOI 10.1016/S0003-9993(99)90079-5; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BASSON MD, 1991, J TRAUMA, V31, P1363, DOI 10.1097/00005373-199110000-00008; Beers SR, 2002, AM J PSYCHIAT, V159, P483, DOI 10.1176/appi.ajp.159.3.483; Brom D., 1985, NEDERLANDS TIJDSCHRI, V40, P164; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; CANTERBURY J, 1997, AFTERMATH ROAD ACCID; Commission on Professional and Hospital Activities, 1978, INT CLASS DIS 9 REV; de Vries APJ, 1999, PEDIATRICS, V104, P1293, DOI 10.1542/peds.104.6.1293; DiGallo A, 1997, BRIT J PSYCHIAT, V170, P358, DOI 10.1192/bjp.170.4.358; Dyregrov A, 1996, SCAND J PSYCHOL, V37, P339, DOI 10.1111/j.1467-9450.1996.tb00667.x; Eiser C, 2001, Health Technol Assess, V5, P1; Famularo R, 1996, CHILD ABUSE NEGLECT, V20, P1245, DOI 10.1016/S0145-2134(96)00119-6; Figley C. R., 1995, TRAUMA CULTURAL SOC, P75, DOI DOI 10.1007/978-1-4757-9421-2_5; FOY DW, 1996, J SCH PSYCHOL, V34, P113; Gofin R, 1999, J TRAUMA, V47, P15, DOI 10.1097/00005373-199907000-00004; HARRIS BH, 1989, J PEDIATR SURG, V24, P103, DOI 10.1016/S0022-3468(89)80311-2; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; HU XH, 1994, J TRAUMA, V37, P209, DOI 10.1097/00005373-199408000-00010; Joseph S, 2000, J TRAUMA STRESS, V13, P101, DOI 10.1023/A:1007777032063; Keppel-Benson JM, 2002, J CHILD PSYCHOL PSYC, V43, P203, DOI 10.1111/1469-7610.00013; Krug EG, 2000, AM J PUBLIC HEALTH, V90, P523, DOI 10.2105/AJPH.90.4.523; Landolt MA, 1998, J PAEDIATR CHILD H, V34, P539, DOI 10.1046/j.1440-1754.1998.00303.x; LESCOHIER I, 1993, PEDIATRICS, V91, P721; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; McDermott BM, 2000, AUST NZ J PSYCHIAT, V34, P446, DOI 10.1046/j.1440-1614.2000.00753.x; Mirza KAH, 1998, BRIT J PSYCHIAT, V172, P443, DOI 10.1192/bjp.172.5.443; NADER K, 1990, AM J PSYCHIAT, V147, P1526; Scheeringa MS, 2001, J TRAUMA STRESS, V14, P799, DOI 10.1023/A:1013002507972; Stallard P, 1998, BRIT MED J, V317, P1619, DOI 10.1136/bmj.317.7173.1619; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Stancin T, 1998, J TRAUMA, V45, P1031, DOI 10.1097/00005373-199812000-00010; Sturms LM, 2002, J TRAUMA, V52, P88, DOI 10.1097/00005373-200201000-00016; Sturms LM, 2003, ARCH PHYS MED REHAB, V84, P431, DOI 10.1053/apmr.2003.50015; Sundin EC, 2002, BRIT J PSYCHIAT, V180, P205, DOI 10.1192/bjp.180.3.205; Theunissen NCM, 1998, QUAL LIFE RES, V7, P387, DOI 10.1023/A:1008801802877; Verrips EGH, 1999, EUR J PUBLIC HEALTH, V9, P188, DOI 10.1093/eurpub/9.3.188; Vogels T, 2000, TACQOL MANUAL PARENT; WESSON DE, 1992, J TRAUMA, V33, P252, DOI 10.1097/00005373-199208000-00015; Winje D, 1998, J CHILD PSYCHOL PSYC, V39, P635, DOI 10.1017/S0021963098002479; Winston FK, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.6.e90; YULE W, 1991, BRIT J CLIN PSYCHOL, V30, P131, DOI 10.1111/j.2044-8260.1991.tb00928.x; YULE W, 1999, POST TRAUMATIC STRES; Yule W, 1990, J TRAUMA STRESS, V3, P279, DOI DOI 10.1002/JTS.2490030209; YULE W, 1999, INT HDB ROAD TRAFFIC	47	39	42	0	6	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	MAY	2005	19	3					312	322		10.1191/0269215505cr867oa			11	Rehabilitation	Rehabilitation	907QU	WOS:000227733800010	15859532				2021-06-18	
J	Sumpter, RE; McMillan, TM				Sumpter, RE; McMillan, TM			Misdiagnosis of post-traumatic stress disorder following severe traumatic brain injury	BRITISH JOURNAL OF PSYCHIATRY			English	Article							HEAD-INJURY; SCALE; SYMPTOMS; CLINICIAN; AMNESIA	Background The incidence of posttraumatic stress disorder (PTSD) after traumatic brain injury is unclear. One issue involves the validity of diagnosis using self-report questionnaires. Aims. To compare PTSD 'caseness' arising from questionnaire self-report and structured interview. Method. Participants (n = 34) with traumatic brain injury were recruited. Screening measures and self-report questionnaires were administered, followed by the structured interview. Results. Using questionnaires, 59% fulfilled criteria for PTSD on the Posttraumatic Diagnostic Scale and 44% on the Impact of Events Scale, whereas using structured interview (Clinician-Administered PTSD Scale) only 3% were 'cases'. This discrepancy may arise from confusions between effects of PTSD and traumatic brain injury. Conclusions. After traumatic brain injury, PTSD self-report measures might be used for screening but not diagnosis. Declaration of Interest. None.	Univ Glasgow, Gartnavel Royal Hosp, Fac Med, Glasgow G12 0XH, Lanark, Scotland; Community Treatment Ctr Acquired Brain Injury, Glasgow, Lanark, Scotland	McMillan, TM (corresponding author), Univ Glasgow, Gartnavel Royal Hosp, Fac Med, 1055 Great Western Rd, Glasgow G12 0XH, Lanark, Scotland.	t.m.mcmillan@clinmed.gla.ac.uk					American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Baddeley A.D., 1992, SPEED CAPACITY LANGU; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Corneil W, 1999, J Occup Health Psychol, V4, P131, DOI 10.1037/1076-8998.4.2.131; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; McMillan TM, 2003, NEUROPSYCHOL REHABIL, V13, P149, DOI 10.1080/09602010244000453; McMillan TM, 2001, BRAIN INJURY, V15, P39, DOI 10.1080/02699050150209110; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Turnbull SJ, 2001, BRAIN INJURY, V15, P775, DOI 10.1080/02699050110034334; Williams WH, 2002, J TRAUMA STRESS, V15, P397, DOI 10.1023/A:1020185325026; Wilson, 1991, NATL ADULT READING T; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	20	39	40	0	5	CAMBRIDGE UNIV PRESS	CAMBRIDGE	EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND	0007-1250	1472-1465		BRIT J PSYCHIAT	Br. J. Psychiatry	MAY	2005	186						423	426		10.1192/bjp.186.5.423			4	Psychiatry	Psychiatry	923LK	WOS:000228911200012	15863748	Bronze			2021-06-18	
J	Pentland, B; Hutton, LS; Jones, PA				Pentland, B; Hutton, LS; Jones, PA			Late mortality after head injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; SUICIDE; POPULATION; DISABILITY; ALCOHOL	Objectives: To investigate mortality trends in a cohort of people admitted to a regional head injury unit with all severities of injury in the calendar year 1981. Methods: A computerised database with details of 1919 admissions was compared with deaths registered by the NHS Central Register, Scotland for the years 1981 to mid-2002. Death certificate information for matches was analysed. Results: The 1919 admissions referred to 1871 individuals, comprising 93 severe, 205 moderate, and 1573 minor injuries according to Glasgow coma scale criteria. There were 57 deaths (42 severe head injuries, eight moderate, seven minor) during the initial admission, and 340 (six severe, 33 moderate, 301 minor) in the subsequent years. Substance abuse, principally alcohol, was a factor in 37 deaths, suicide accounted for 20, and accidents for 25. The great majority of these latter deaths were in people under the age of 70 years. Conclusion: Premature deaths after predominantly minor head injury are commonly alcohol related or the result of suicide or accidents.	Astley Ainslie Hosp, Scottish Brain Injury Rehabil Serv, Edinburgh EH9 2HL, Midlothian, Scotland; Univ Edinburgh, Dept Child Life & Hlth, Edinburgh EH8 9YL, Midlothian, Scotland	Pentland, B (corresponding author), Astley Ainslie Hosp, Scottish Brain Injury Rehabil Serv, Edinburgh EH9 2HL, Midlothian, Scotland.	Brian.Pentland@lpct.scot.nhs.uk					ACHTE KA, 1971, ACTA PSYCHIAT SCAN S, V225, P1; Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Baguley I, 2000, BRAIN INJURY, V14, P505; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; Corrigan J. D., 1999, REHABILITATION ADULT; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Dischinger PC, 2001, J TRAUMA, V51, P877, DOI 10.1097/00005373-200111000-00009; GOLDACRE MJ, 1996, OXFORD TXB MED, P39; Hammond F. M., 2000, ARCH PHYS MED REHAB, V81, P1260; Harris EC, 1997, BRIT J PSYCHIAT, V170, P205, DOI 10.1192/bjp.170.3.205; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; JENNETT B, 1998, EPIDEMIOLOGY NEUROLO, P75; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; KLONOFF PS, 1995, J HEAD TRAUMA REHAB, V10, P16, DOI 10.1097/00001199-199512000-00005; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; Kraus J. F., 1999, REHABILITATION ADULT, P3; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; MILLER JD, 1985, LANCET, V1, P1141; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; RUSSELL WR, 1951, J NEUROL NEUROSUR PS, V14, P35, DOI 10.1136/jnnp.14.1.35; *SCOTT EX, 2002, CHOOS LIF NAT STRAT; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Tate R, 1997, J HEAD TRAUMA REHAB, V12, P16, DOI 10.1097/00001199-199712000-00003; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; VAUHKONEN K, 1959, ACTA PSYCHIAT NEUR S, V137, P90; WALKER AE, 1971, ARCH NEUROL-CHICAGO, V24, P95, DOI 10.1001/archneur.1971.00480320023001	35	39	39	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAR	2005	76	3					395	400		10.1136/jnnp.2004.037861			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	901TM	WOS:000227304800022	15716535	Bronze, Green Published			2021-06-18	
J	Di Russo, F; Incoccia, C; Formisano, R; Sabatini, U; Zoccolotti, P				Di Russo, F; Incoccia, C; Formisano, R; Sabatini, U; Zoccolotti, P			Abnormal motor preparation in severe traumatic brain injury with good recovery	JOURNAL OF NEUROTRAUMA			English	Article						MRCP; readiness potentials; source analysis; TBI	CLOSED-HEAD-INJURY; CORTICAL POTENTIALS; PARKINSONS-DISEASE; ATTENTIONAL PROCESSES; INTRACEREBRAL HEMORRHAGE; REACTION-TIME; MOVEMENT; TOPOGRAPHY; SCALE; AREA	Movement-related cortical potentials (MRCPs) were examined in seven patients with severe traumatic brain injury (TBI) and 12 matched control subjects. All patients had clinically established good recovery by the time of testing. Flexion movements of the index finger of the left or right hand were recorded in two (alternating and repetitive) self-paced conditions and in one externally triggered condition. In control subjects, the bereitschaftspotential (BP) component of MRCP was detected approximately 2000 msec prior to movement onset in the self-paced conditions and was larger and earlier in the alternating compared to the repetitive condition. The BP component was absent in the externally triggered condition. In TBI patients, the BP was greatly reduced and no difference between the alternating-repetitive conditions was detected; in contrast, only small differences were present in the controls for the negative slope (NS) and MP components and no difference for the reafferent positivity (RAP) component. A dipole analysis indicated the supplementary motor area and the premotor area as the likely generators of BP and NS' components, respectively. Gradient-recalled echo magnetic resonance imaging allowed the detection of a number of small hypointense lesions primarily located in the frontal lobes, as in diffuse axonal injury. This pattern of results indicates a selective deficit in motor preparation and a relatively spared pattern of activation during and following movement in these patients. Imaging data appear generally consistent with the pattern of MRCPs observed in the patient group. Implications of these results for the problem of slowness in TBI patients are discussed.	Fdz Santa Lucia, Ctr Ric Neuropsicol, I-00179 Rome, Italy; IUSM, Rome, Italy; Univ Rome, Dept Psychol, Rome, Italy	Di Russo, F (corresponding author), Fdz Santa Lucia, Ctr Ric Neuropsicol, Via Ardeatina,36, I-00179 Rome, Italy.	fdirusso@iusm.it	Sabatini, Umberto/A-8484-2010; Zoccolotti, Pierluigi/H-4437-2019; Sabatini, Umberto/K-4659-2016; Di Russo, Francesco/N-6686-2015	Zoccolotti, Pierluigi/0000-0002-6351-2455; Sabatini, Umberto/0000-0001-5321-8626; Di Russo, Francesco/0000-0002-3127-9433; Incoccia, Chiara/0000-0003-4068-6548			Adams R. D., 1976, PRINCIPLES NEUROLOGY; ADAMS RJ, 1987, STROKE, V18, P665, DOI 10.1161/01.STR.18.3.665; Becker W, 1980, Prog Brain Res, V54, P189, DOI 10.1016/S0079-6123(08)61624-6; BOTZEL K, 1993, ELECTROEN CLIN NEURO, V89, P187, DOI 10.1016/0168-5597(93)90132-9; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; DICK JPR, 1989, BRAIN, V112, P233, DOI 10.1093/brain/112.1.233; Dirnberger G, 2002, CLIN NEUROPHYSIOL, V113, P254, DOI 10.1016/S1388-2457(01)00728-3; Dirnberger G, 2000, EXP BRAIN RES, V135, P231, DOI 10.1007/s002210000522; Fazekas F, 1999, AM J NEURORADIOL, V20, P637; Filipovic SR, 1997, J NEUROL SCI, V147, P177, DOI 10.1016/S0022-510X(96)05344-0; Gerstenbrand F., 1967, APALLISCHE SYNDROM; Graham DI, 1996, NEUROTRAUMA, P43; Gray C, 1998, BRAIN INJURY, V12, P429, DOI 10.1080/026990598122548; Incoccia C, 2004, CORTEX, V40, P111, DOI 10.1016/S0010-9452(08)70924-9; Jellinger K, 1966, Wien Z Nervenheilkd Grenzgeb, V23, P40; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT B, 1974, LANCET, V13, P81; Kuzma BB, 2000, SURG NEUROL, V53, P400; Leclercq M, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P257; LINDENBERG R, 1964, Dtsch Z Nervenheilkd, V185, P637; Miller E, 1970, Cortex, V6, P121; MILTNER W, 1994, ELECTROEN CLIN NEURO, V91, P295, DOI 10.1016/0013-4694(94)90193-7; Morsier G, 1960, PSYCHIAT NEUROL, V139, P60; NAYERNOURI T, 1985, SURG NEUROL, V24, P263, DOI 10.1016/0090-3019(85)90035-7; Niedermeyer E., 1993, ELECTROENCEPHALOGRAP; NORRMAN B, 1961, ACTA PSYCHIAT SCAND, V37, P236, DOI 10.1111/j.1600-0447.1961.tb07359.x; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Patel MR, 1999, AM J ROENTGENOL, V173, P479, DOI 10.2214/ajr.173.2.10430158; Peppe A, 1998, ELECTROEN CLIN NEURO, V106, P374, DOI 10.1016/S0013-4694(97)00075-8; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Sabatini U, 2000, BRAIN, V123, P394, DOI 10.1093/brain/123.2.394; SHIBASAKI H, 1980, ELECTROEN CLIN NEURO, V49, P213, DOI 10.1016/0013-4694(80)90216-3; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; SHUM DHK, 1994, J CLIN EXP NEUROPSYC, V16, P547, DOI 10.1080/01688639408402666; SINGH J, 1990, BRAIN RES, V531, P45, DOI 10.1016/0006-8993(90)90756-2; TARKKA IM, 1991, J CLIN NEUROPHYSIOL, V8, P331, DOI 10.1097/00004691-199107010-00009; TARKKA IM, 1994, INT J PSYCHOPHYSIOL, V16, P81, DOI 10.1016/0167-8760(94)90044-2; Toma K, 2002, NEUROIMAGE, V17, P161, DOI 10.1006/nimg.2002.1165; TORO C, 1993, ELECTROEN CLIN NEURO, V86, P167, DOI 10.1016/0013-4694(93)90004-F; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; VANZOMEREN AH, 1994, CLIN NEUROPSYCHOL AT; Wardlaw JM, 2000, NEURORADIOLOGY, V42, P81, DOI 10.1007/s002340050019	43	39	39	0	3	MARY ANN LIEBERT INC	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2005	22	2					297	312					16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	900XU	WOS:000227248400009	15716635				2021-06-18	
J	Leclercq, PD; Murray, LS; Smith, C; Graham, DI; Nicoll, JAR; Gentleman, SM				Leclercq, PD; Murray, LS; Smith, C; Graham, DI; Nicoll, JAR; Gentleman, SM			Cerebral amyloid angiopathy in traumatic brain injury: association with apolipoprotein E genotype	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							E EPSILON-4 ALLELE; ALZHEIMERS-DISEASE; HEAD-INJURY; BETA-PROTEIN; INTRACEREBRAL HEMORRHAGE; CEREBROVASCULAR-DISEASE; A-BETA; SUBARACHNOID HEMORRHAGE; HIGH-FREQUENCY; E POLYMORPHISM	Objective: In view of the association of the apolipoprotein E (APOE) epsilon4 allele with poor outcome after traumatic brain injury we determined the frequency of cerebral amyloid angiopathy ( CAA) and the extent of haemorrhagic pathology in relation to APOE genotype in an autopsy series of 88 head injured cases. Methods: Tissue sections from the frontal and temporal lobes were immunostained for amyloid-beta peptide (Abeta) and stained for Congo red to identify vascular amyloid pathology. A semiquantitative assessment of contusions, the total contusion index, was used to estimate the severity of the haemorrhagic pathology. APOE genotypes were determined by polymerase chain reaction of genomic DNA extracted from paraffin embedded tissue sections. Results: CAA was present in 7/40 (18%) epsilon4 carriers compared with 1/48 (2%) non-epsilon4 carriers ( p = 0.021, 95% confidence interval (CI) for difference in proportions with CAA 3% to 29%) with 6/40 (4 with CAA) epsilon4 carriers being homozygotes. Thus the risk of having CAA for epsilon4 carriers was 8.4 times that for the non-epsilon4 carriers. However, there was no clear tendency for patients with CAA to have more severe or more numerous contusions (median contusion index 19 (CAA) v 14.5, p = 0.23, 95% CI for difference in medians 25 to 14). Conclusions: Presence of CAA in head injured cases was significantly associated with possession of an APOE epsilon4 allele but not with the severity of contusions.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Neurosci & Psychol Med, London W6 8RP, England; So Gen Hosp, Inst Neurol Sci, Univ Acad Unit Neuropathol, Glasgow G51 4TF, Lanark, Scotland; Univ Edinburgh, Western Gen Hosp, Dept Pathol, Neuropathol Lab, Edinburgh, Midlothian, Scotland; Univ Southampton, Southampton Gen Hosp, Southampton, Hants, England	Gentleman, SM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Neurosci & Psychol Med, Charing Cross Campus,St Dunstans Rd, London W6 8RP, England.	s.gentleman@imperial.ac.uk	Nicoll, James/I-9253-2017	Nicoll, James/0000-0002-9444-7246			ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Alonzo NC, 1998, J NEUROPATH EXP NEUR, V57, P353, DOI 10.1097/00005072-199804000-00008; BANCROFT JD, 1994, MANUAL HISTOLOGICAL, P114; Beach TG, 2000, NEUROSCI LETT, V283, P9, DOI 10.1016/S0304-3940(00)00916-2; CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569; Coria F, 1996, NEUROPATH APPL NEURO, V22, P216; DADA MA, 1993, AM J FOREN MED PATH, V14, P319, DOI 10.1097/00000433-199312000-00009; Davis DG, 1999, J NEUROPATH EXP NEUR, V58, P376, DOI 10.1097/00005072-199904000-00008; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Dunn LT, 2001, NEUROSURGERY, V48, P1006, DOI 10.1097/00006123-200105000-00007; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Greenberg SM, 1998, NEUROLOGY, V50, P961, DOI 10.1212/WNL.50.4.961; GREENBERG SM, 1995, ANN NEUROL, V38, P254, DOI 10.1002/ana.410380219; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kalaria RH, 2001, TRENDS NEUROSCI, V24, P392, DOI 10.1016/S0166-2236(00)01836-1; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; MASUDA J, 1988, STROKE, V19, P205, DOI 10.1161/01.STR.19.2.205; McCarron MO, 1999, NEUROLOGY, V53, P1308, DOI 10.1212/WNL.53.6.1308; McCarron MO, 1998, STROKE, V29, P1882, DOI 10.1161/01.STR.29.9.1882; McCarron MO, 2000, NEUROREPORT, V11, P937, DOI 10.1097/00001756-200004070-00008; McCarron MO, 1998, NEUROSCI LETT, V247, P45, DOI 10.1016/S0304-3940(98)00286-9; McCarron MO, 1999, J NEUROPATH EXP NEUR, V58, P711, DOI 10.1097/00005072-199907000-00005; McCarron MO, 1999, NEUROLOGY, V53, P2176, DOI 10.1212/WNL.53.9.2176; McCarron MO, 1999, STROKE, V30, P1643, DOI 10.1161/01.STR.30.8.1643; Murdoch I, 2002, J NEUROTRAUM, V19, P279, DOI 10.1089/08977150252807018; Nicoll JAR, 1997, ANN NEUROL, V41, P716, DOI 10.1002/ana.410410607; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Niskakangas T, 2001, STROKE, V32, P1181, DOI 10.1161/01.STR.32.5.1181; O'Donnell HC, 2000, NEW ENGL J MED, V342, P240, DOI 10.1056/NEJM200001273420403; Olichney JM, 1996, NEUROLOGY, V47, P190, DOI 10.1212/WNL.47.1.190; Premkumar DRD, 1996, AM J PATHOL, V148, P2083; Prior R, 2000, ANN NY ACAD SCI, V903, P180, DOI 10.1111/j.1749-6632.2000.tb06367.x; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Smith G, 2002, DRUG DEV IND PHARM, V28, P151, DOI 10.1081/DDC-120002448; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; VINTERS HV, 1983, STROKE, V14, P924, DOI 10.1161/01.STR.14.6.924; VINTERS HV, 1987, STROKE, V18, P311, DOI 10.1161/01.STR.18.2.311; WAKUI K, 1988, Neurological Surgery, V16, P1287; Weir CJ, 2001, NEUROLOGY, V57, P1097, DOI 10.1212/WNL.57.6.1097; Weller RO, 2000, ANN NY ACAD SCI, V903, P110, DOI 10.1111/j.1749-6632.2000.tb06356.x; WyssCoray T, 1997, NATURE, V389, P603, DOI 10.1038/39321; Yamada M, 2000, NEUROPATHOLOGY, V20, P8, DOI 10.1046/j.1440-1789.2000.00268.x	48	39	40	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	FEB	2005	76	2					229	233		10.1136/jnnp.2003.025528			5	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	890WJ	WOS:000226541500017	15654038	Bronze, Green Published			2021-06-18	
J	Wagner, AK; Fabio, A; Puccio, AM; Hirschberg, R; Li, W; Zafonte, RD; Marion, DW				Wagner, AK; Fabio, A; Puccio, AM; Hirschberg, R; Li, W; Zafonte, RD; Marion, DW			Gender associations with cerebrospinal fluid glutamate and lactate/pyruvate levels after severe traumatic brain injury	CRITICAL CARE MEDICINE			English	Article; Proceedings Paper	20th National Neurotrauma-Society	OCT 27-NOV 01, 2002	Tampa, FL	Neurotrauma Soc		gender; glutamate; hypothermia; lactate; traumatic brain injury	SEVERE HEAD-INJURY; EXCITATORY AMINO-ACIDS; THERAPEUTIC HYPOTHERMIA; EXTRACELLULAR GLUTAMATE; LIPID-PEROXIDATION; CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; BASE-BALANCE; ESTROGEN; LACTATE	Objective: Female sex hormones appear to be neuroprotective after traumatic brain injury by attenuating multiple mechanisms of secondary insult, including excitotoxicity and ischemia. The purpose of this study was to evaluate associations between gender and cerebrospinal fluid glutamate and lactate/pyruvate production and the role of hypothermia with gender in attenuating these markers. Design: Prospectively collected data were analyzed for adult patients with severe traumatic brain injury. Gender comparisons for cerebrospinal fluid glutamate and lactate/pyruvate production were determined using ventricular samples obtained over the first 48 hrs postinjury. Setting: University-based level I trauma center. Patients: There were 123 patients, male n = 93 and female n 30 (n = 686 cerebrospinal fluid samples), with severe traumatic brain injury (Glasgow Coma Scale score less than or equal to 8). Interventions: A portion of these patients were part of a randomized controlled trial evaluating the effect of (48 hrs) therapeutic hypothermia after severe traumatic brain injury. The remainder received hypothermia (24 hrs) if they met clinical care criteria. Patients were cooled to 32-33degreesC (within similar to8 hrs) for either 24 or 48 hrs and then were rewarmed or remained normothermic. Measurements and Main Results: Regression analyses using generalized estimating equations for repeated measures showed significant increases in cerebrospinal fluid glutamate production for males compared with females (p = .0023) and a significant interaction between glutamate concentration, gender, and time (p = .0035) by 24 hrs postinjury. Females had lower lactate/pyruvate ratios than males (p = .0006), and there was a significant interaction between lactate/pyruvate, gender, and time (p = .0045) throughout the first 48 hrs postinjury. Hypothermia attenuated glutamate levels, particularly for males, over the time course studied. Conclusions: These data suggest significant gender differences with glutamate and lactate/pyruvate production after severe traumatic brain injury. Gender- and hormone-mediated differences in central nervous system pathophysiology should be considered with clinical trials in traumatic brain injury.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Publ Hlth, Pittsburgh, PA 15260 USA; Harvard Univ, Spaulding Rehabil Inst, Cambridge, MA 02138 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA.		Marion, Donald/AAR-5749-2021	Fabio, Anthony/0000-0002-6808-4939	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD040833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD40833] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS30318] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133P970013-00] Funding Source: Medline		BAKAY RAE, 1986, NEUROSURGERY, V18, P234, DOI 10.1227/00006123-198602000-00023; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bayir H, 2003, CRIT CARE MED, V31, pS112, DOI 10.1097/01.CCM.0000042464.46603.0E; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Boris-Moller F, 1998, EXP BRAIN RES, V121, P277, DOI 10.1007/s002210050461; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; ELOVIC E, 1996, MED REHABILITATION T, P11; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; FUJISHIMA M, 1975, STROKE, V6, P707, DOI 10.1161/01.STR.6.6.707; Garcia-Segura LM, 1999, J NEUROBIOL, V40, P574, DOI 10.1002/(SICI)1097-4695(19990915)40:4<574::AID-NEU12>3.0.CO;2-8; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Gopinath SP, 2000, ACT NEUR S, V76, P437; GRANHOLM L, 1969, SCAND J CLIN LAB INV, V23, P361, DOI 10.3109/00365516909081702; Henker RA, 1998, NEUROSURGERY, V42, P1071, DOI 10.1097/00006123-199805000-00071; Hoffman SW, 2003, J NEUROTRAUM, V20, P859, DOI 10.1089/089771503322385791; Huang FP, 1998, NEUROCHEM RES, V23, P991, DOI 10.1023/A:1021088523137; ILLIEVICH UM, 1994, ANESTHESIOLOGY, V80, P177, DOI 10.1097/00000542-199401000-00025; KumeKick J, 1996, BRAIN RES, V738, P8, DOI 10.1016/0006-8993(96)00744-5; LEVINTHAL R, 1977, SURG NEUROL, V7, P269; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Love S, 1999, BRAIN PATHOL, V9, P119; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mendelowitsch A, 2001, BRAIN RES, V901, P230, DOI 10.1016/S0006-8993(01)02359-9; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; Nilsen J, 2002, BRAIN RES, V930, P216, DOI 10.1016/S0006-8993(02)02254-0; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; Pellerin L, 1996, DEV NEUROSCI-BASEL, V18, P336, DOI 10.1159/000111426; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Reinert M, 2000, ACTA NEUROCHIR SUPPL, V76, P439; Resnick DK, 1997, J TRAUMA, V42, P1108, DOI 10.1097/00005373-199706000-00021; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Shiogai T, 1999, ACT NEUR S, V75, P49; Siesj_o B K, 1978, BRAIN ENERGY METABOL; SIESJO BK, 1970, ACTA PHYSIOL SCAND, V79, P114, DOI 10.1111/j.1748-1716.1970.tb04707.x; SIESJO BK, 1970, ACTA NEUROL SCAND, V46, P187, DOI 10.1111/j.1600-0404.1970.tb05615.x; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; SMITH SS, 1994, PROG NEUROBIOL, V44, P55, DOI 10.1016/0301-0082(94)90057-4; Suzuki T, 2003, EXP NEUROL, V184, P1017, DOI 10.1016/S0014-4886(03)00389-3; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Wagner AK, 2000, ARCH PHYS MED REHAB, V81, P1267; Weaver CE, 1997, BRAIN RES, V761, P338, DOI 10.1016/S0006-8993(97)00449-6; Yamamoto T, 1999, ACT NEUR S, V75, P17; Yang CS, 1996, FREE RADICAL BIO MED, V20, P245, DOI 10.1016/0891-5849(95)02042-X; Yang SH, 2002, J APPL PHYSIOL, V92, P195; Zhang H, 2003, J CHROMATOGR B, V784, P131, DOI 10.1016/S1570-0232(02)00788-2; Zhang H, 2001, CLIN CHEM, V47, P1458; Zhang YQ, 1998, BRAIN RES, V784, P321, DOI 10.1016/S0006-8993(97)00502-7	62	39	39	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2005	33	2					407	413		10.1097/01.CCM.0000153931.23488.DD			7	Critical Care Medicine	General & Internal Medicine	898LE	WOS:000227077500017	15699846				2021-06-18	
J	Lee, BHY; Schofer, JL; Koppelman, FS				Lee, BHY; Schofer, JL; Koppelman, FS			Bicycle safety helmet legislation and bicycle-related non-fatal injuries in California	ACCIDENT ANALYSIS AND PREVENTION			English	Article						bicycle safety helmet; legislation; non-fatal injuries; case-control; odds ratio; multinomial logit model	HEAD-INJURIES; EDUCATION; CHILDREN; LAWS	The objective of this study was to determine whether the bicycle safety helmet legislation in California, enacted in 1994, was associated with statistically significant reductions in head injuries among bicyclists aged 17 years and under who were subjected to the law. The study used 44.069 patient discharge cases from all public hospitals in California, from 1991 through 2000, and a case-control design to make direct comparisons between those subjected to the law (Youth) and those who were not (Adult) across the pre- and post-legislation periods. An aggregate data analysis approach and a pooled disaggregate data fitting technique using multinomial logit models were applied. The legislation was found to be associated with a reduction of 18.2% (99% confidence interval: 11.5-24.3%) in the proportion of traumatic brain injuries (Head-TBI) among Youth bicyclists. The proportions of other head, face, and neck injuries were not significantly changed across the pre- and post-legislation periods in this age group but there was a corresponding increase of 9% (5-13%) in the proportion of all other injuries. On the other hand, there was no statistically significant change in the proportions of injury outcomes for Adult bicyclists. The youngest riders, aged 0-9 years, had the greatest decrease in the proportion of Head-TBI. The reduction was the same for motor vehicle and non-motor-vehicle-related incidents. The bicycle safety helmet legislation was associated with a decrease in the likelihood of Head-TBI for non-urban residents but not for urbanites, for males but not for females, and for Whites, Asians, and Hispanics, but not Blacks and others. (C) 2004 Elsevier Ltd. All rights reserved.	Univ Washington, Coll Architecture & Urban Planning, Dept Urban Design & Planning, Seattle, WA 98195 USA; Northwestern Univ, Robert R McCormick Sch Engn & Appl Sci, Dept Civil & Environm Engn, Inst Technol, Evanston, IL 60208 USA	Lee, BHY (corresponding author), Univ Washington, Coll Architecture & Urban Planning, Dept Urban Design & Planning, 3949 15th Ave NE,410 Gould Hall,Box 355740, Seattle, WA 98195 USA.	bhylee@u.washington.edu	Koppelman, Frank S/B-7024-2009; Schofer, Joseph L/B-7090-2009				Abularrage JJ, 1997, ARCH PEDIAT ADOL MED, V151, P41, DOI 10.1001/archpedi.1997.02170380045007; Attewell RG, 2001, ACCIDENT ANAL PREV, V33, P345, DOI 10.1016/S0001-4575(00)00048-8; Borgialli D A, 1997, J Am Osteopath Assoc, V97, P399; CAMERON MH, 1994, ACCIDENT ANAL PREV, V26, P325, DOI 10.1016/0001-4575(94)90006-X; COTE TR, 1992, PEDIATRICS, V89, P1216; Cryer P C, 1998, Inj Prev, V4, P106; DANNENBERG AL, 1993, AM J PUBLIC HEALTH, V83, P667, DOI 10.2105/AJPH.83.5.667; Dowswell T, 1996, Inj Prev, V2, P140, DOI 10.1136/ip.2.2.140; EPPERSON B, 1995, TRANSPORT RES REC, V1502, P58; FINCH C, 1993, 45 MON U ACC RES CTR; Finch C F, 1996, Inj Prev, V2, P126, DOI 10.1136/ip.2.2.126; Gilchrist J, 2000, PEDIATRICS, V106, P6, DOI 10.1542/peds.106.1.6; Graitcer P L, 1995, Inj Prev, V1, P122, DOI 10.1136/ip.1.2.122; GRANT D, 2002, EFFECT BICYCLE HELME; HATZIANDREU EJ, 1995, 110 PUBL HLTH REP, P251; HEATHCOTE B, 1994, TB941 TRAFF BOARD W; HENDRIE D, 1999, P C ROAD SAF SPEAK P, P29; KING M, 1994, P 1994 AUSTR PED BIC, P177; Lajunen T, 2001, J SAFETY RES, V32, P323, DOI 10.1016/S0022-4375(01)00056-1; LeBlanc JC, 2002, CAN MED ASSOC J, V166, P592; Linn S, 1998, Inj Prev, V4, P122; MACKNIN ML, 1994, ARCH PEDIAT ADOL MED, V148, P255, DOI 10.1001/archpedi.1994.02170030025005; Macpherson A K, 2001, Inj Prev, V7, P228, DOI 10.1136/ip.7.3.228; Macpherson AK, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.5.e60; Marshall J, 1994, EVALUATION COMPULSOR; MCDERMOTT FT, 1993, J TRAUMA, V34, P834, DOI 10.1097/00005373-199306000-00015; Ni HY, 1997, ARCH PEDIAT ADOL MED, V151, P59, DOI 10.1001/archpedi.1997.02170380063010; Povey LJ, 1999, ACCIDENT ANAL PREV, V31, P763, DOI 10.1016/S0001-4575(99)00033-0; Rivara FP, 1998, ANNU REV PUBL HEALTH, V19, P293, DOI 10.1146/annurev.publhealth.19.1.293; Rodgers GB, 2002, INJ PREV, V8, P42, DOI 10.1136/ip.8.1.42; RODGERS GB, 1998, BICYCLE BICYCLE HELM, V31, P149; SACKS JJ, 1991, JAMA-J AM MED ASSOC, V266, P3016, DOI 10.1001/jama.266.21.3016; Schieber RA, 1996, ARCH PEDIAT ADOL MED, V150, P707, DOI 10.1001/archpedi.1996.02170320053009; Schiffrin D, 2000, NARRAT INQ, V10, P1, DOI 10.1075/ni.10.1.01sch; Scuffham P, 2000, ACCIDENT ANAL PREV, V32, P565, DOI 10.1016/S0001-4575(99)00081-0; SMITH NC, 1994, P 1994 PED BIC SAF T, P153; THOMAS S, 1994, BRIT MED J, V308, P173, DOI 10.1136/bmj.308.6922.173; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1974, DOI 10.1001/jama.276.24.1974; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; THOMPSON DC, 2002, HELMETS PREVENTING H; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101	41	39	39	0	10	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575	1879-2057		ACCIDENT ANAL PREV	Accid. Anal. Prev.	JAN	2005	37	1					93	102		10.1016/j.aap.2004.07.001			10	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	886VO	WOS:000226261100012	15607280				2021-06-18	
S	Sharma, HS		Slikker, W; Andrews, RJ; Trembly, B		Sharma, HS			Neuroprotective effects of neurotrophins and melanocortins in spinal cord - Injury an experimental study in the rat using pharmacological and morphological approaches	NEUROPROTECTIVE AGENTS	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	7th International Conference on Neuroprotective Agents	NOV 14-19, 2004	Pacific Grove, CA	Cent Arkansas Chapter SIGMA XI, FDA, Natl Ctr Toxicol Res, US EPA		spinal cord injury; melanocortins; brain-derived neurotrophic factor; insulin-like growth factor-1; blood-spinal cord barrier; neuroprotection	NITRIC-OXIDE SYNTHASE; TOPICAL APPLICATION; TRAUMATIC INJURY; AXONAL INJURY; REDUCES EDEMA; UP-REGULATION; CELL CHANGES; INHIBITOR; INDOMETHACIN; REGENERATION	Spinal cord injury (SCI) induces lifetime disability, and no suitable therapy is available to treat victims or to minimze their sufferings. Recently, neurotrophins and compounds acting at melanocortin receptors have been been identified as potential neuroprotective agents. In this investigation, the neuroprotective effects of neurotrophins and melanocortins on the pathophysiology of SCI were examined in a rat model. The SCI was produced by making a longitudinal incision into the right dorsal horn of the T10-11 segments under equithesin anesthesia. In separate groups, neurotrophins [BDNF or IGF-1 (0.1-1 mu g/10 mu L in saline)] or melanocortins (ME10092, ME10354, ME10393, ME10431, and ME10501, having affinities to melanocortin receptors; 1-10 mu g in saline) were applied topically over the traumatized cord segment within 5-10 min after SCI and the rats were allowed to survive for 5 h. A, focal SCI resulted in widespread disruption of the blood-spinal cord barrier (BSCB) to Evans blue albumin (EBA), ([131])iodine, or lanthanum tracers and exhibited profound edema formation and cell or tissue destruction. Topical application of BDNF, IGF-1, or ME10501 (having high affinity to melanocortin-4 receptor, MCR-4) in high quantity markedly attenuated BSCB disruption, edema formation, and nerve cell, glial cell, and axonal injuries. On the other hand, low doses of neurotrophins or melanocortins were not effective in attenuating pathophysiology of SCI. These observations suggest that neurotrophins (BDNF and IGF-1) and melanocortins (with high affinity to MCR-4) are capable of inducing neuroprotection if applied shortly after trauma in high doses. Taken together, the results indicate that neurotrophins and melanocortins participate in the pathophysiology of spinal cord cell and tissue injury following trauma.	Univ Uppsala Hosp, Dept Surg Sci Anesthesiol & Intens Care Med, Lab Cerebrovasc Res, SE-75185 Uppsala, Sweden	Sharma, HS (corresponding author), Univ Uppsala Hosp, Dept Surg Sci Anesthesiol & Intens Care Med, Lab Cerebrovasc Res, SE-75185 Uppsala, Sweden.	sharma@surgsci.uu.se					Barde Y A, 1994, Prog Clin Biol Res, V390, P45; Dawson VL, 1996, J CHEM NEUROANAT, V10, P179, DOI 10.1016/0891-0618(96)00148-2; Iannotti C, 2004, EXP NEUROL, V189, P317, DOI 10.1016/j.expneurol.2004.05.033; Kakulas BA, 2004, SPINAL CORD, V42, P549, DOI 10.1038/sj.sc.3101670; Lu P, 2004, J NEUROSCI, V24, P6402, DOI 10.1523/JNEUROSCI.1492-04.2004; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; NOVIKOV L, 1995, NEUROSCI LETT, V200, P45, DOI 10.1016/0304-3940(95)12078-I; PAN W, 2004, INT J NEUROPROTEC NE, V1, P32; Schwab ME, 1996, PHYSIOL REV, V76, P319; Sharma, 2004, BLOOD SPINAL CORD BR, P437; Sharma H. S., 2004, BLOOD SPINAL CORD BR, P191; Sharma HS, 1997, ACT NEUR S, V70, P130; Sharma HS, 2005, CURR PHARM DESIGN, V11, P1353, DOI 10.2174/1381612053507837; Sharma HS, 2003, ACT NEUR S, V86, P399; Sharma HS, 2003, ACT NEUR S, V86, P383; Sharma HS, 1997, ACT NEUR S, V70, P155; SHARMA HS, 1993, ACTA NEUROPATHOL, V86, P422; Sharma HS, 1998, AMINO ACIDS, V14, P121, DOI 10.1007/BF01345252; SHARMA HS, 1995, RESTOR NEUROL NEUROS, V7, P207, DOI 10.3233/RNN-1994-7403; Sharma HS, 1996, NEUROSCI RES, V24, P373, DOI 10.1016/0168-0102(95)01015-7; SHARMA HS, 1991, J NEUROL SCI, V102, P150, DOI 10.1016/0022-510X(91)90063-D; Sharma HS, 1998, SPINAL CORD MONITORING, P181; SHARMA HS, 1993, ACTA NEUROPATHOL, V85, P145; SHARMA HS, 1990, ACTA NEUROPATHOL, V79, P604, DOI 10.1007/BF00294237; SHARMA HS, 2004, INT J NEUROPROTEC NE, V1, P8; Sharma HS, 2004, BLOOD SPINAL CORD BR; SHARMA HS, 2005, ANN N Y ACAD SCI; van der Kraan M, 1999, MOL BRAIN RES, V63, P276, DOI 10.1016/S0169-328X(98)00291-5; vandeMeent HV, 1997, NEUROSURGERY, V40, P122, DOI 10.1097/00006123-199701000-00028; Vrinten DH, 2001, EUR J PHARMACOL, V429, P61, DOI 10.1016/S0014-2999(01)01306-1; Winkler T, 2003, ACTA NEUROCHIR SUPPL, V86, P425; Winkler T, 1998, SPINAL CORD MONITORING, P283; WOLTERINK G, 1990, BRAIN RES, V507, P101, DOI 10.1016/0006-8993(90)90527-I; WU W, 2000, HAND CHEM N, V17, P315	34	39	46	0	3	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-578-8	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2005	1053						407	421		10.1196/annals.1344.036			15	Multidisciplinary Sciences; Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Science & Technology - Other Topics; Neurosciences & Neurology; Pharmacology & Pharmacy	BDR63	WOS:000235109800042	16179548				2021-06-18	
J	Thornton, KE; Carmody, DP				Thornton, KE; Carmody, DP			Electroencephalogram biofeedback for reading disability and traumatic brain injury	CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA			English	Article							CLOSED-HEAD-INJURY; COGNITIVE REHABILITATION; DEVELOPMENTAL DYSLEXIA; LEARNING-DISABILITIES; EEG BIOFEEDBACK; ACTIVATION PROFILES; WORD RECOGNITION; CHILDREN; IMPROVEMENT/REHABILITATION; REMEDIATION	The application of electroencephalogram (EEG) biofeedback with reading disability and traumatic brain injury (TBI) is relatively recent. There are many studies regarding the effectiveness (improving attention and IQ scores) of EEG biofeedback in patients with attention deficit hyperactivity disorder, who are known to have a high rate of comorbidity for learning disabilities. This suggests the possibility that EEG biofeedback specifically aimed at remediating reading disability and TBI would be effective. This article provides strong initial support for this idea and provides reason to believe that assessment and training under task conditions are likely to be fruitful. Given the significance of these problems and the absence of very effective alternatives for remediation of these conditions, efforts to complete the needed research seem warranted. Clinical use of this intervention seems to be warranted with informed consent.	Ctr Hlth Psychol, S Plainfield, NJ 07080 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pediat, Inst Study Child Dev, New Brunswick, NJ 08903 USA	Thornton, KE (corresponding author), Ctr Hlth Psychol, Suite 2A,2509 Pk Ave, S Plainfield, NJ 07080 USA.	ket@chp-neurotherapy.com	Carmody, Dennis P./AAS-7734-2020	Carmody, Dennis/0000-0002-1288-104X; thornton, kirtley/0000-0002-3303-4747			BASAREROGLU C, 1996, INT J PSYCHOPHYSIOL, V24, P110; BENEDICT RHB, 1989, CLIN PSYCHOL REV, V9, P605; BIRD BL, 1978, BIOFEEDBACK SELF-REG, V3, P1, DOI 10.1007/BF00998559; Birsh J. R., 1999, MULTISENSORY TEACHIN; BYERS AP, 1995, J NEUROTHERAPY, V1, P22, DOI DOI 10.1300/J184V01N01_; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; FREEMAN M R, 1992, Brain Injury, V6, P65, DOI 10.3109/02699059209008124; GALABURDA AM, 1985, ANN NEUROL, V18, P222, DOI 10.1002/ana.410180210; Giannitrapani D., 1988, EEG MENTAL ACTIVITIE, P153; GLISKY EL, 1986, J HEAD TRAUMA REHAB, V1, P54, DOI DOI 10.1097/00001199-198609000-00009; Hoffman D. A., 1995, J NEUROTHERAPY, V1, P14, DOI [10.1300/ J184v01n01_03, DOI 10.1300/J184V01N01_03]; HOFFMAN DA, 1996, CLIN ELECTROENCEPHAL, V27, P6; Horwitz B, 1998, P NATL ACAD SCI USA, V95, P8939, DOI 10.1073/pnas.95.15.8939; Hughes JR, 1999, J NEUROPSYCH CLIN N, V11, P190, DOI 10.1176/jnp.11.2.190; Kaiser D. A., 2000, J NEUROTHERAPY, V4, P5, DOI [10.1300/J184v04n01_02, DOI 10.1300/J184V04N01_02, DOI 10.1300/J184v04n01_02]; Keller I., 2001, J NEUROTHER, V5, P19, DOI DOI 10.1300/J184V05N01_03; Klingberg T, 2000, NEURON, V25, P493, DOI 10.1016/S0896-6273(00)80911-3; Linden M, 1996, BIOFEEDBACK SELF-REG, V21, P35, DOI 10.1007/BF02214148; Lloyd D, 2000, J INT NEUROPSYCH SOC, V6, P627, DOI 10.1017/S1355617700655121; LYON GR, 1988, J CONSULT CLIN PSYCH, V56, P830, DOI 10.1037/0022-006X.56.6.830; MARKER T, 1996, COGPACK PROGRAMMPAKE; McCandliss BD, 2003, MENT RETARD DEV D R, V9, P196, DOI 10.1002/mrdd.10080; McEvoy LK, 2000, CLIN NEUROPHYSIOL, V111, P457, DOI 10.1016/S1388-2457(99)00258-8; McKinlay W W, 1992, Brain Inj, V6, P107, DOI 10.3109/02699059209029649; Miltner WHR, 1999, NATURE, V397, P434, DOI 10.1038/17126; Oakland T, 1998, J LEARN DISABIL, V31, P140, DOI 10.1177/002221949803100204; OCHS L, 1994, BERR HEAD INJ C LAS; ORLANDO PC, IN PRESS J NEUROTHER; OTHMER S, 1992, EEG BIOFEEDBACK TRAI; Paulesu E, 1996, BRAIN, V119, P143, DOI 10.1093/brain/119.1.143; RANDOLPH C, 1988, NEUROPSYCHOBIOLOGY, V20, P43, DOI 10.1159/000118471; ROSSITER R, 2002, J NEUROTHERAPY, V6, P9; Rumsey JM, 1997, ARCH NEUROL-CHICAGO, V54, P562, DOI 10.1001/archneur.1997.00550170042013; Rumsey JM, 1997, BRAIN, V120, P739, DOI 10.1093/brain/120.5.739; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; SANDFORD JA, 1993, CAPTAINS LOG COGNITI; SANDFORD JA, 1995, INTERMEDIATE VISUAL; SANDFORD JA, 1996, ALPHABET BINGO COMPU; Schoenberger NE, 2001, J HEAD TRAUMA REHAB, V16, P260, DOI 10.1097/00001199-200106000-00005; Shaywitz BA, 2002, BIOL PSYCHIAT, V52, P101, DOI 10.1016/S0006-3223(02)01365-3; Shaywitz SE, 2003, BIOL PSYCHIAT, V54, P25, DOI 10.1016/S0006-3223(02)01836-X; Shaywitz SE, 1998, P NATL ACAD SCI USA, V95, P2636, DOI 10.1073/pnas.95.5.2636; Sheer D.E., 1984, SELF REGULATION BRAI; Sheer DE, 1976, NEUROPHYSIOLOGY LEAR; SHEER DE, 1974, LEARNING DISABLED CH; SHEER DE, 1977, BIOFEEDBACK SELF CON, P435; SIEGMUND K, 1999, NEUROSOFT INTEGRIERT; Simos PG, 2002, J CHILD NEUROL, V17, P159, DOI 10.1177/088307380201700301; Simos PG, 2001, DEV NEUROPSYCHOL, V19, P191, DOI 10.1207/S15326942DN1902_4; Simos PG, 2000, NEUROSCI LETT, V290, P61, DOI 10.1016/S0304-3940(00)01322-7; TABANO MT, 1988, ELECTROENCEPHALOGRAP, V70, P185; TANIUS TP, 2000, J NEUROTHERAPY, V4, P27; TANSEY MA, 1991, AUST J PSYCHOL, V43, P147, DOI 10.1080/00049539108260139; Temple E, 2003, P NATL ACAD SCI USA, V100, P2860, DOI 10.1073/pnas.0030098100; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; Thatcher RW, 1998, NEUROIMAGE, V7, P352, DOI 10.1006/nimg.1998.0330; Thatcher RW, 2000, CLIN ELECTROENCEPHAL, V31, P38, DOI 10.1177/155005940003100110; Thompson L, 1998, APPL PSYCHOPHYS BIOF, V23, P243, DOI 10.1023/A:1022213731956; Thorne A, 2000, PERS SOC PSYCHOL REV, V4, P45, DOI 10.1207/S15327957PSPR0401_5; Thornton K, 2000, J HEAD TRAUMA REHAB, V15, P1285, DOI 10.1097/00001199-200012000-00008; Thornton K, 2002, ARCH CLIN NEUROPSYCH, V17, P1; Thornton K., 2000, J NEUROTHERAPY, V3, P1, DOI DOI 10.1300/J184V03N03_01; Thornton KE, 2002, NEUROREHABILITATION, V17, P69; Thornton KE, 1999, BRAIN INJURY, V13, P477, DOI 10.1080/026990599121395; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Van Egren L., 1996, CLIN ELECTROENCEPHAL, V27, P164; Walker J.E., 2002, J NEUROTHER, V6, P31, DOI [10.1300/J184v06n02_05, DOI 10.1300/J184v06n02_05, DOI 10.1300/J184V06N02_]; Watts R, 2003, MENT RETARD DEV D R, V9, P168, DOI 10.1002/mrdd.10077; Winters CA, 1997, ADOLESCENCE, V32, P451; WOOD R, 2004, TRILLION DOLLAR SHAM	72	39	40	1	15	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	1056-4993			CHILD ADOL PSYCH CL	Child Adolesc. Psychiatr. N. Am.	JAN	2005	14	1					137	+		10.1016/j.chc.2004.07.001			27	Psychiatry	Psychiatry	883CS	WOS:000225988400009	15564056				2021-06-18	
J	Tomaiuolo, F; Worsley, KJ; Lerch, J; Di Paola, M; Carlesimo, GA; Bonanni, R; Caltagirone, C; Paus, T				Tomaiuolo, F; Worsley, KJ; Lerch, J; Di Paola, M; Carlesimo, GA; Bonanni, R; Caltagirone, C; Paus, T			Changes in white matter in long-term survivors of severe non-missile traumatic brain injury: A computational analysis of magnetic resonance images	JOURNAL OF NEUROTRAUMA			English	Article						anatomical and behavioral correlation; MRI; severe head trauma; white matter	CLOSED-HEAD-INJURY; COGNITIVE IMPAIRMENT; HIPPOCAMPAL ATROPHY; MRI; FORNIX; DAMAGE; DEGENERATION; MORPHOLOGY; MEMORY; VOLUME	The aim of this study was to investigate long-term consequences of severe non-missile traumatic brain injury (nmTBI) in patients without macroscopic focal brain lesions (>1.6 cm(3)) on regional white-matter density (WMd), and possible correlations with days of coma and memory performances. T1-weighted magnetic-resonance images (MRI) were acquired in 19 nmTBI patients, 3-113 months following the injury, and in 19 control subjects matched for age and gender. In addition, nmTBI patients underwent a battery of standardised memory tests. The MRIs were processed in a fully automatic system using voxel-by-voxel methods. Corpus callosum, fornix, anterior limb of the internal capsule, superior frontal gyrus, para-hippocampal gyrus, optic radiation and chiasma showed significant WMd reduction in nmTBI when compared to control subjects. None of the correlations between days of coma and memory performance scores with nmTBI voxels value that showed WMd reduction reached significance, with the exception of a significant negative correlation between WMd in the mid body of corpus callosum and short-story delayed recall. We detected reductions in WM density in several brain locations similar to those described in previous postmortem investigations. In addition, we observed WMd reduction in the optic chiasma and in the optic radiations; this finding may reflect transneural degeneration along the visual pathway. The weak correlations between specific anatomical sites of the reduced WMd and behavior may reflect the diffuse nature of the brain damage and/or the different time of onset between behavioral manifestations and neuropathological modifications occurring in nmTBI.	IRCCS, Fdn Santa Lucia, I-00179 Rome, Italy; McGill Univ, Dept Math & Stat, Montreal, PQ, Canada; Univ Roma Tor Vergata, Neurol Clin, Rome, Italy; McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada	Tomaiuolo, F (corresponding author), IRCCS, Fdn Santa Lucia, Via Ardeatina 309, I-00179 Rome, Italy.	tomaiuoio@hsantalucia.it	Di Paola, Margherita/A-8480-2010; Tomaiuolo, Francesco/AAC-1534-2019; Caltagirone, Carlo/B-4930-2013	Tomaiuolo, Fancesco/0000-0003-1230-2770			ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Adams JH, 1990, HDB CLIN NEUROLOGY, P43; Adams JH, 1994, INTRO NEUROPATHOLOGY; Ashburner J, 2003, LANCET NEUROL, V2, P79, DOI 10.1016/S1474-4422(03)00304-1; BEATTY RM, 1982, J NEUROL NEUROSUR PS, V45, P143, DOI 10.1136/jnnp.45.2.143; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; CAPITANI E, 1987, IT J NEUROL SCI S, V8, P14; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Carlesimo G.A., 2002, NUOVA RIV NEUROLOGIA, V12, P1, DOI DOI 10.1080/17408989.2016.1268591; Carlesimo GA, 1996, EUR NEUROL, V36, P378, DOI 10.1159/000117297; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; Kovalev VA, 2003, NEUROIMAGE, V19, P895, DOI 10.1016/S1053-8119(03)00140-X; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Paus T, 1999, SCIENCE, V283, P1908, DOI 10.1126/science.283.5409.1908; Rey A., 1968, REATTIVO FIGURA COMP; Scahill RI, 2003, ARCH NEUROL-CHICAGO, V60, P989, DOI 10.1001/archneur.60.7.989; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Spalletta G, 2003, SCHIZOPHR RES, V64, P15, DOI 10.1016/S0920-9964(03)00010-0; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328; Worsley KJ, 1996, HUM BRAIN MAPP, V4, P58, DOI 10.1002/(SICI)1097-0193(1996)4:1<58::AID-HBM4>3.0.CO;2-O; ZIJDENBOS AP, 1998, P 1 INT C MED IM COM, P439	37	39	42	0	1	MARY ANN LIEBERT INC	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2005	22	1					76	82		10.1089/neu.2005.22.76			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	889OF	WOS:000226451600004	15665603				2021-06-18	
J	Graham, DI; Smith, C; Reichard, R; Leclercq, PD; Gentleman, SM				Graham, DI; Smith, C; Reichard, R; Leclercq, PD; Gentleman, SM			Trials and tribulations of using beta-amyloid precursor protein immunohistochemistry to evaluate traumatic brain injury in adults	FORENSIC SCIENCE INTERNATIONAL			English	Article						traumatic brain injury; hypoglycaemia; CO poisoning; beta APP immunohistochemistry	DIFFUSE AXONAL INJURY; NONMISSILE HEAD-INJURY; CALPAIN ACTIVATION; DIAGNOSIS; APP; NEUROPATHOLOGY; HYPOXIA	Axonal pathology is increasingly identified by P-amyloid precursor protein (PAPP) immunohistochemistry in the brains of patients who may or may not have a history of trauma. The presence of betaAPP-IR+ has been variously interpreted as either that diffuse traumatic axonal injury (TAI) is indeed a universal finding in cases of fatal traumatic brain injury (TBI) or there are other causes of betaAPP-IR+ axons which under certain circumstances may be sufficient to mimic TBI and therefore make the medicolegal interpretation of certain cases very difficult. To address some of the uncertainties we have undertaken a detailed analysis of the amount and distribution of PAPP immunohistochemistry in 63 cases of fatal TBI, 17 cases of patients dying after cardiac arrest, 12 cases dying in association with status epilepticus, 3 cases of carbon monoxide (CO) poisoning, 13 cases of hypoglycaemia and in 60 controls. Three patterns of betaAPP-IR+ were identified. First, diffuse multi-focal, second, corresponding to the outline of an infarct or haematoma, and thirdly a mixture of the two. The first pattern was seen in cases of the lesser grades of TAI, CO poisoning, and hypoglycaemia, the second pattern in cases in which there was evidence of raised intracranial pressure and the third in cases of severe TAL It is concluded that the proper interpretation of cases requires the examination of a sufficient number of blocks (n = 15), processing using standardised protocols including PAPP immunohistochemistry and in some cases the mapping of any IR+ on anatomical line diagrams. PAPP carried out on a small number of randomly taken blocks is likely to lead to misinterpretation of the clinico-pathological correlations and possibly to a miscarriage of justice. (C) 2003 Elsevier Ireland Ltd. All rights reserved.	So Gen Hosp, NHS Trust, Inst Neurol Sci, Div Clin Neurosci,Acad Unit Neuropathol, Glasgow G51 4TF, Lanark, Scotland; Univ Edinburgh, Western Gen Hosp, Dept Pathol, Edinburgh EH4 2XU3, Midlothian, Scotland; Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA; Univ London Imperial Coll Sci Technol & Med, Dept Neuroinflammat, Div Neurosci & Psychol Disorders, London W6 8RP, England	Graham, DI (corresponding author), So Gen Hosp, NHS Trust, Inst Neurol Sci, Div Clin Neurosci,Acad Unit Neuropathol, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.	d.graham@clinmed.gla.ac.uk					ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1986, J NEUROL NEUROSUR PS, V49, P1039, DOI 10.1136/jnnp.49.9.1039; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Dolinak D, 2000, NEUROPATH APPL NEURO, V26, P448, DOI 10.1046/j.1365-2990.2000.00273.x; Dolinak D, 2000, ACTA NEUROPATHOL, V100, P553, DOI 10.1007/s004010000218; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; Gennarelli TA, 1997, NEUROSCIENTIST, V3, P73, DOI 10.1177/107385849700300117; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; Kaur B, 1999, J CLIN PATHOL, V52, P203, DOI 10.1136/jcp.52.3.203; Lambri M, 2001, CLIN NEUROPATHOL, V20, P263; Leclercq PD, 2002, J NEUROTRAUM, V19, P1183, DOI 10.1089/08977150260337985; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; MCKENZIE JE, 1994, NEUROREPORT, V6, P161, DOI 10.1097/00001756-199412300-00041; Oehmichen M, 1998, FORENSIC SCI INT, V95, P67, DOI 10.1016/S0379-0738(98)00075-9; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Wilkinson AE, 1999, ACTA NEUROPATHOL, V98, P197, DOI 10.1007/s004010051069	28	39	45	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	DEC 16	2004	146	2-3					89	96		10.1016/S0379-0738(03)00274-3			8	Medicine, Legal	Legal Medicine	879OZ	WOS:000225728400004	15542268				2021-06-18	
J	Donders, J; Nesbit-Greene, K				Donders, J; Nesbit-Greene, K			Predictors of neuropsychological test performance after pediatric traumatic brain injury	ASSESSMENT			English	Article						demographic variables; neuropsychological test performance	CHILDRENS CATEGORY TEST; HEAD-INJURY; CLUSTER SUBTYPES; STANDARDIZATION SAMPLE; SEX-DIFFERENCES; SHORT-TERM; INTELLIGENCE; MODERATOR; RECOVERY; VALIDITY	The influence of neurological and demographic variables on neuropsychological test performance was examined in 100 9- to 16-year-old children with traumatic brain injury (TBI). Regression analyses were conducted to determine the relative contributions of coma, neuroimaging findings, ethnicity, socioeconomic status, and gender to variance in performance on the Wechsler Intelligence Scale for Children-Third Edition (WISC-III), California Verbal Learning Test-Children's Version (CVLT-C), and the Children's Category Test. Both neurological and demographic variables contributed to performance on various WISC-III factor index scores as well as the CVLT-C. No evidence for a moderating effect of demographic variables was found, but speed of information processing mediated the effect of neurological and demographic variables on CLVT-C performance. It is concluded that demographic variables have an incremental effect on the neuropsychological test performance of children with TBI above and beyond the influence of injury severity.	Mary Free Bed Rehabil Hosp, Grand Rapids, MI USA; Mt Washington Pediat Hosp, Baltimore, MD USA	Donders, J (corresponding author), Mary Free Bed Rehabil Hosp, Grand Rapids, MI USA.	jdonders@mfbrc.com					Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Bjorklund D. F., 1997, DEV MEMORY CHILDHOOD, P201; BOLL T, 1993, CHILDRENS CATEGORY T; Chapman SB, 2000, J COMMUN DISORD, V33, P333, DOI 10.1016/S0021-9924(00)00029-0; Coscia JM, 2001, J PEDIATR PSYCHOL, V26, P321, DOI 10.1093/jpepsy/26.6.321; Delis D, 1994, CALIFORNIA VERBAL LE; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Donders J, 1996, PSYCHOL ASSESSMENT, V8, P312, DOI 10.1037/1040-3590.8.3.312; Donders J, 1997, CHILD NEUROPSYCHOL, V3, P71, DOI 10.1080/09297049708401369; Donders J, 1999, DEV NEUROPSYCHOL, V16, P163, DOI 10.1207/S15326942DN1602_2; Donders J, 2003, J HEAD TRAUMA REHAB, V18, P106, DOI 10.1097/00001199-200303000-00002; Donders J, 1998, CHILD NEUROPSYCHOL, V4, P178; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; DONDERS J, 1998, HDB PEDIAT PSYCHOL P, V2, P166; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Fox J., 1991, REGRESSION DIAGNOSTI; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P428, DOI 10.1001/archneur.1985.04060050026008; Glutting J. J., 1997, CONT INTELLECTUAL AS, P349; Harrell Frank E., 2001, REGRESSION MODELING; Heaton R. K., 2003, CLIN INTERPRETATION, P181, DOI [DOI 10.1016/B978-012703570-3/50010-9, 10.1016/B978-012703570-3/50010-9]; Hoffman N, 2000, ARCH CLIN NEUROPSYCH, V15, P47, DOI 10.1016/S0887-6177(98)00156-5; Holmbeck GN, 2002, J PEDIATR PSYCHOL, V27, P87, DOI 10.1093/jpepsy/27.1.87; Kramer JH, 1997, NEUROPSYCHOLOGY, V11, P577, DOI 10.1037/0894-4105.11.4.577; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Kwate N. O. A., 2001, J BLACK PSYCHOL, V27, P221, DOI DOI 10.1177/0095798401027002005; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Levin HS, 2000, J CLIN EXP NEUROPSYC, V22, P1, DOI 10.1076/1380-3395(200002)22:1;1-8;FT001; MCGLONE J, 1980, BEHAV BRAIN SCI, V3, P215, DOI 10.1017/S0140525X00004398; Miller LJ, 2003, REHABIL PSYCHOL, V48, P237, DOI 10.1037/0090-5550.48.4.237; Millis SR, 2003, CHILD NEUROPSYCHOL, V9, P221, DOI 10.1076/chin.9.3.221.16455; Moses JA, 1999, ARCH CLIN NEUROPSYCH, V14, P445, DOI 10.1016/S0887-6177(98)00030-4; Murphy KR, 2004, STAT POWER ANAL; Neisser U, 1996, AM PSYCHOL, V51, P77, DOI 10.1037/0003-066X.51.2.77; Nesbit-Greene K, 2002, J CLIN EXP NEUROPSYC, V24, P194, DOI 10.1076/jcen.24.2.194.996; Prifitera A., 1998, WISC 3 CLIN USE INTE, P1, DOI DOI 10.1016/B978-012564930-8/50002-4; RAZ S, 1995, DEV PSYCHOL, V31, P958, DOI 10.1037/0012-1649.31.6.958; Reitan RM, 1995, CHILD NEUROPSYCHOL, V1, P165, DOI 10.1080/09297049508400222; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Sherrill-Pattison S, 2000, CLIN NEUROPSYCHOL, V14, P496, DOI 10.1076/clin.14.4.496.7196; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Suzuki LA, 1997, AM PSYCHOL, V52, P1103, DOI 10.1037/0003-066X.52.10.1103; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Tremont G, 1999, CHILD NEUROPSYCHOL, V5, P104, DOI 10.1076/chin.5.2.104.3166; Vanderploeg RD, 1997, CLIN NEUROPSYCHOL, V11, P210, DOI 10.1080/13854049708407054; Verger K, 2001, BRAIN INJURY, V15, P211; Wechsler D., 2003, WECHSLER INTELLIGENC; Wechsler D., 1991, WECHSLER INTELLIGENC; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	56	39	40	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911	1552-3489		ASSESSMENT	Assessment	DEC	2004	11	4					275	284		10.1177/1073191104268914			10	Psychology, Clinical	Psychology	869SX	WOS:000225005600001	15486164				2021-06-18	
J	Boman, IL; Lindstedt, M; Hemmingsson, H; Bartfai, A				Boman, IL; Lindstedt, M; Hemmingsson, H; Bartfai, A			Cognitive training in home environment	BRAIN INJURY			English	Article							TRAUMATIC BRAIN-INJURY; REHABILITATION; ATTENTION; ADULTS; DEFICITS; REMEDIATION; RECOVERY; THERAPY	Primary objective: To examine the efficacy of cognitive rehabilitation in the patient's home or vocational environment. Research design: Pre-post-follow-up design. Methods and procedures: Ten outpatients with acquired attention and memory problems received cognitive training three times weekly, for 3 weeks. They received individual attention training with Attention Process Training, training for generalization for everyday activities and education in compensatory strategies for self-selected cognitive problems. Treatment effects were evaluated with neuropsychological and occupational therapy instruments before and after the training and after 3 months on impairment, activity and participation levels. Main outcomes and results: The results indicated a positive effect on some measures on impairment level, but no differences on activity or participation levels at follow-up. Conclusions: The study indicates that home-based cognitive training improves some attentional and memory functions and facilitates learning of strategies. Future controlled studies are needed to confirm the results and analyse the efficacy of different aspects of home-based training.	Danderyd Hosp, Dept Rehabil Med, S-18288 Danderyd, Sweden; Karolinska Univ Hosp, Dept Rehabil Med, Huddinge, Sweden	Boman, IL (corresponding author), Danderyd Hosp, Dept Rehabil Med, S-18288 Danderyd, Sweden.	inga-lill.boman@reh.ds.sll.se		Bartfai, Aniko/0000-0002-0815-2485; Boman, Inga-Lill/0000-0002-4533-1036			ABREU BC, 1987, AM J OCCUP THER, V41, P439, DOI 10.5014/ajot.41.7.439; Adamovich BL, 1991, COGNITIVE REHABILITA, P75; AHLSIO B, 1984, STROKE, V15, P886, DOI 10.1161/01.STR.15.5.886; BENYISHAY Y, 1987, NEUROPSYCHOL REHABIL, P165; Berg I. J., 1991, NEUROPSYCHOL REHABIL, V1, P97, DOI [DOI 10.1080/09602019108401384, 10.1080/09602019108401384]; Bergquist TF, 1994, J HEAD TRAUMA REHAB, V9, P50, DOI 10.1097/00001199-199412000-00007; Bernspang B, 1995, SCANDINAVIAN J OCCUP, V1, P3; BURKE JM, 1994, BRAIN INJURY, V8, P71, DOI 10.3109/02699059409150960; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Chen SHA, 1997, BRAIN INJURY, V11, P197; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; CLAESON LE, 1971, COGNITIVE TRAINING H; Davis AM, 1995, CLIN REHABIL, V9, P238, DOI DOI 10.1177/026921559500900310; Dirette DK, 1999, J HEAD TRAUMA REHAB, V14, P595, DOI 10.1097/00001199-199912000-00008; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fisher AG, 1998, AM J OCCUP THER, V52, P509, DOI 10.5014/ajot.52.7.509; FISHER AG, 1997, ASSESSMENT MOTOR PRO; GIANUTSOS R, 1991, Brain Injury, V5, P353, DOI 10.3109/02699059109008108; GLISKY EL, 1986, J HEAD TRAUMA REHAB, V1, P54, DOI DOI 10.1097/00001199-198609000-00009; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; KAPLAN E, 1994, WAIS R NEUROPSYCHOLO; Katz Noomi, 2002, Can J Occup Ther, V69, P281; Kielhofner G., 1995, MODEL HUMAN OCCUPATI; Kielhofner G., 1997, CONCEPTUAL FDN OCCUP; Klonoff H, 1995, TRAUMATIC HEAD INJUR, P219; Kolb B., 1996, FUNDAMENTALS HUMAN N; Laatsch L, 1999, BRAIN INJURY, V13, P555, DOI 10.1080/026990599121304; Lee S S, 2001, Can J Occup Ther, V68, P41; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LOFGREN H, 1989, STAT DATAANALYS; MATEER CA, 1990, COGNITIVE REHABILITA, P68; MATEER CM, 1987, J HEAD TRAUMA REHAB, V2, P79; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P1084, DOI 10.1136/jnnp.46.12.1084; NEISTADT ME, 1994, AM J OCCUP THER, V48, P421, DOI 10.5014/ajot.48.5.421; NYMAN H, 1998, CLAESONDAHL TEST; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Park NW, 1999, NEUROPSYCHOL REHABIL, V9, P135, DOI 10.1080/713755595; PEPIN M, 1995, J COGNITIVE REHABILI, V13, P8; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1999, J HEAD TRAUMA REHAB, V14, P308, DOI 10.1097/00001199-199906000-00009; PRIGATANO GP, 1987, J LEARN DISABIL-US, V20, P603, DOI 10.1177/002221948702001006; ROBERTSON IH, 1993, UNILATERAL NEGLECT C, P279; SCHWARTZ SM, 1995, AM J OCCUP THER, V49, P655, DOI 10.5014/ajot.49.7.655; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 1996, J HEAD TRAUMA REHAB, V11, P65, DOI 10.1097/00001199-199604000-00007; SOHLBERG MM, 1986, ATTENTION PROCESS TR; Sturm W, 1997, NEUROPSYCHOL REHABIL, V7, P81, DOI 10.1080/713755526; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; THAM K, 1998, UNILATERAL NEGLECT A; TOGLIA JP, 1991, AM J OCCUP THER, V45, P505, DOI 10.5014/ajot.45.6.505; Trombly CA, 2002, AM J OCCUP THER, V56, P489, DOI 10.5014/ajot.56.5.489; UOMOTO JM, 1992, PHYS MED REHABILITAT, V3, P291; WECHSLER D, 1981, WAIS R MANUAL WECHLE; WILSON B, 1989, J CLIN EXP NEUROPSYC, V11, P855, DOI 10.1080/01688638908400940; Wilson B. A., 1991, RIVERMEAD BEHAV MEMO; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wood R L, 1987, Int Disabil Stud, V9, P149; ZENICUS A, 1990, BRAIN INJURY, V4, P33	64	39	39	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2004	18	10					985	995		10.1080/02699050410001672396			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	845LQ	WOS:000223244600003	15370898				2021-06-18	
J	Kadyan, V; Mysiw, WJ; Bogner, JA; Corrigan, JD; Fugate, LP; Clinchot, DM				Kadyan, V; Mysiw, WJ; Bogner, JA; Corrigan, JD; Fugate, LP; Clinchot, DM			Gender differences in agitation after traumatic brain injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						agitation; traumatic brain injury; gender difference; outcome	NURSING-HOME RESIDENTS; ESTROGEN; PATIENT	Objective: To determine sex differences in extent and type of posttraumatic agitation during acute rehabilitation. Design: This prospective, observational study was performed at a Midwest, regional, university-based acute rehabilitation center. Results: In a total of 158 subjects, comprising 120 men (76%) and 38 women (24%), there were no significant differences between male and female subjects for age, Glasgow Coma Scale score, Rancho Los Amigos Level of Cognitive Functioning Scale, Mini Mental State Exam, days in acute hospital, and days in rehabilitation. No difference in incidence was observed between sexes based on the criterion of agitation as three or more abnormal total Agitated Behavior Scale scores in 48 hrs (P = 0.890). Also, no difference in posttraumatic agitation between the two sexes (P = 0.396) was observed with the criterion of agitation as two or more abnormal total Agitated Behavior Scale scores in 2 days. There were no differences observed between the sexes for peak intensity and average intensity for the total score or each of the factor scores of the Agitated Behavior Scale. Conclusion: Posttraumatic agitation is seen in approximately 50% of patients after traumatic brain injury and usually lasts for <10 days. There are no significant sex differences in the frequency, duration, presentation, or extent of posttraurnatic agitation. These data imply that both sexes, despite any predetermined notions, should be treated equally with respect to posttraurnatic agitation management.	Ohio State Univ, Coll Med, Dept Phys Med & Rehabil, Columbus, OH 43210 USA	Kadyan, V (corresponding author), 480 W 9th Ave, Columbus, OH 43210 USA.		Corrigan, John D./E-2921-2011; Mysiw, Walter/E-3724-2011	Clinchot, Daniel/0000-0002-2810-7227			Bogner JA, 1999, J HEAD TRAUMA REHAB, V14, P91, DOI 10.1097/00001199-199902000-00012; Bogner JA, 2000, J HEAD TRAUMA REHAB, V15, P656, DOI 10.1097/00001199-200002000-00005; Bogner JA, 2001, AM J PHYS MED REHAB, V80, P636, DOI 10.1097/00002060-200109000-00002; Burgio LD, 2000, INT PSYCHOGERIATR, V12, P495, DOI 10.1017/S104161020000661X; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, pS8, DOI 10.1053/apmr.2003.50046; Centers for Disease Control and Prevention, 2001, TRAUM BRAIN INJ US R; COHEN D, 1993, J AM GERIATR SOC, V41, P229, DOI 10.1111/j.1532-5415.1993.tb06697.x; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; CORRIGAN J D, 1992, Brain Injury, V6, P155, DOI 10.3109/02699059209029653; CORRIGAN JD, 1994, J CLIN EXP NEUROPSYC, V16, P386, DOI 10.1080/01688639408402649; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fugate LP, 1997, ARCH PHYS MED REHAB, V78, P924, DOI 10.1016/S0003-9993(97)90051-4; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Kadyan V, 2003, BRAIN INJURY, V17, P631, DOI 10.1080/0269905031000070224; Mysiw WJ, 1997, ARCH PHYS MED REHAB, V78, P213, DOI 10.1016/S0003-9993(97)90266-5; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; Schreiner AS, 2001, INT J GERIATR PSYCH, V16, P209, DOI 10.1002/1099-1166(200102)16:2<209::AID-GPS314>3.0.CO;2-9	21	39	39	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	OCT	2004	83	10					747	752		10.1097/01.PHM.0000140790.30468.F4			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	857ST	WOS:000224139300001	15385782				2021-06-18	
J	Kapoor, N; Ciuffreda, KJ; Han, Y				Kapoor, N; Ciuffreda, KJ; Han, Y			Oculomotor rehabilitation in acquired brain injury: A case series	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology	MAY 04-09, 2003	FT LAUDERDALE, FL	Assoc Res Vis & Ophthalmol		attention; brain injuries; ocular motility disorder; reading; stroke; rehabilitation	DISORDERS	Objective: To investigate the effects of systematic, oculomotor rehabilitation on basic versional ocular motility, as well as reading eye movements, in subjects with acquired brain injury, using objective eye movement recording and subjective rating of reading ability. Design: Case series. Setting: Clinical research laboratory. Participants: Two men with acquired brain injury: one with traumatic brain injury and one with stroke. Interventions: Versional oculomotor training was performed for 1 hour, twice weekly for 8 weeks. There were 2 feedback modes of training: normal internal oculomotor visual feedback alone (4wk), or that feedback in conjunction with external oculomotor auditory feedback (4wk). Testing was conducted before and after training. Main Outcome Measures: Objective outcome measures included both basic eye movement parameters (fixational accuracy, saccadic gain and latency, pursuit gain, mean saccade frequency ratio for simulated reading), and reading eye movement parameters (words per minute, grade level equivalent, fixations per 100 words, regressions per 100 words, percentage of reading comprehension, duration of fixation in seconds). Subjective outcome measures included the subject's ability to read based on the responses to the reading rating-scale questionnaire. Results: Both subjects improved objectively in terms of basic versional oculomotor accuracy and reading ability. These findings concurred with their subjective impressions. Conclusions: This case series provides objective documentation of the positive effects of oculomotor rehabilitation on basic ocular motility and reading ability in selected cases with acquired brain injury, thus suggesting the need for a larger clinical trial in this area. (C) 2004 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	SUNY State Coll Optometry, Raymond J Greenwald Rehabil Ctr, Dept Clin Sci, New York, NY 10036 USA; SUNY State Coll Optometry, Raymond J Greenwald Rehabil Ctr, Dept Vis Sci, New York, NY 10036 USA	Kapoor, N (corresponding author), SUNY State Coll Optometry, Raymond J Greenwald Rehabil Ctr, Dept Clin Sci, 33 W 42nd St, New York, NY 10036 USA.	nkapoor@sunyopt.edu					BAKER RS, 1991, SURV OPHTHALMOL, V35, P245, DOI 10.1016/0039-6257(91)90046-I; Benjamin W. J., 1998, BORISHS CLIN REFRACT; BERNETHY B, 1997, BIOPHYSICAL FDN HUMA; BYL NN, 2001, DOWNEY DARLINGS PHYS, P609; Ciuffreda K. J., 1996, J BEHAV OPTOM, V7, P31; Ciuffreda Kenneth J, 2002, Optometry, V73, P735; Ciuffreda KJ, 1999, CLIN EYE VIS CARE, V11, P41, DOI DOI 10.1016/S0953-4431(99)00010-7; Ciuffreda KJ, 2001, VISUAL VESTIBULAR CO, P77; Ciuffreda KJ, 1995, EYE MOVEMENT BASICS; DANGELO CM, 1994, J AM OPTOM ASSOC, V64, P60; Desmurget M, 1998, NAT NEUROSCI, V1, P524, DOI 10.1038/2241; Fayos B, 1998, J BEHAV OTPOM, V9, P1; Garzia R P, 1990, J Am Optom Assoc, V61, P124; GIANUTSOS R, 1988, ARCH PHYS MED REHAB, V69, P573; GOTTLIEB GL, 1988, EXP BRAIN RES, V73, P436; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; GUR S, 1992, ISRAEL J MED SCI, V28, P622; HAN Y, IN PRESS BRAIN RES P; Hellerstein L F, 1995, J Am Optom Assoc, V66, P634; Hibbard M. R., 2001, VISUAL VESTIBULAR CO, P32; KEELE SW, 1986, HDB PERCEPTION HUMAN, V2, P1; KELLEY RE, 1989, NEUROLOGY NONNEUROLO, P52; Keren O, 2001, BRAIN INJURY, V15, P633, DOI 10.1080/02699050010009568; Koenig G S, 1997, J Am Optom Assoc, V68, P155; LEIGH RJ, 1909, NEUROLOGY EYE MOVEME; LEPORE FE, 1995, ARCH NEUROL-CHICAGO, V52, P924, DOI 10.1001/archneur.1995.00540330106022; LISBERGER SG, 1988, SCIENCE, V242, P728, DOI 10.1126/science.3055293; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Mateer CA, 1996, J HEAD TRAUMA REHAB, V11, P1; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; MUELLER C, 1993, DEV MED CHILD NEUROL, V35, P163; Nag S, 1999, NEUROL INDIA, V47, P32; *NIH, 1999, NIH PUBL; OBINSON GM, 1977, J EXP PSYCHOL HUMAN, V3, P83; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Quinn B, 2000, BRAIN INJURY, V14, P1063; REDING MJ, 1988, STROKE, V19, P1354, DOI 10.1161/01.STR.19.11.1354; Richter E. F., 2001, VISUAL VESTIBULAR CO, P10; RON S, 1978, SCAND J REHABIL MED, V10, P39; SABATES NR, 1991, J CLIN NEURO-OPHTHAL, V11, P273; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SCHLAGETER K, 1993, BRAIN INJURY, V7, P439, DOI 10.3109/02699059309029687; Schmitter-Edgecombe M, 2001, J INT NEUROPSYCH SOC, V7, P615, DOI 10.1017/S1355617701755099; SEMMLOW JL, 1989, J EXP PSYCHOL HUMAN, V15, P249, DOI 10.1037/0096-1523.15.2.249; SUCHOFF I, 2000, PHYS MED REHABILITAT, P608; Suchoff I., 2001, Visual Vestibular Conseq Acq Brain Inj, P1; Suchoff I B, 1999, J Am Optom Assoc, V70, P301; SUCHOFF IB, 2000, LIGHTHOUSE HDB VISIO, P517; SUTER PS, 1995, TRAUMATIC BRAIN INJU, P198; Taylor EA., 1966, FUNDAMENTAL READING; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; ZIHL J, 1995, NEUROPSYCHOLOGIA, V33, P287, DOI 10.1016/0028-3932(94)00119-A; ZIHL J, 1995, BRAIN, V118, P891, DOI 10.1093/brain/118.4.891; Zihl J., 2000, NEUROPSY REHABIL MOD; ZIUFFREDA KJ, 2003, 7K ANN M ASS RES VIS; ZOST MG, 1995, DIAGNOSIS MANAGEMENT, pCH4	57	39	39	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2004	85	10					1667	1678		10.1016/j.apmr.2003.12.044			12	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	861GS	WOS:000224404700017	15468029				2021-06-18	
J	McManus, T; Sadgrove, M; Pringle, AK; Chad, JE; Sundstrom, LE				McManus, T; Sadgrove, M; Pringle, AK; Chad, JE; Sundstrom, LE			Intraischaemic hypothermia reduces free radical production and protects against ischaemic insults in cultured hippocampal slices	JOURNAL OF NEUROCHEMISTRY			English	Article						cerebral ischaemia; free radical; hypothermia; neuroprotection; nitric oxide	FOCAL CEREBRAL-ISCHEMIA; NMDA RECEPTOR ANTAGONISTS; TRANSIENT GLOBAL-ISCHEMIA; TRAUMATIC BRAIN INJURY; EXCITATORY AMINO-ACIDS; NITRIC-OXIDE SYNTHESIS; MILD HYPOTHERMIA; POSTISCHEMIC HYPOTHERMIA; NEURONAL DAMAGE; IN-VITRO	Hypothermia has been demonstrated to be an effective neuroprotective strategy in a number of models of ischaemic and excitotoxic neurodegeneration in vitro and in vivo. Reduced glutamate release and free radical production have been postulated as potential mechanisms underlying this effect but no definitive mechanism has yet been reported. In the current study, we have used oxygen-glucose deprivation in organotypic hippocampal slice cultures as an in vitro model of cerebral ischaemia. When assessed by propidium iodide fluorescence, reducing the temperature during oxygen-glucose deprivation to 31-33degreesC was significantly neuroprotective but this effect was lost if the initiation of hypothermia was delayed until the post-insult recovery period. The neuroprotective effects of hypothermia were associated with a significant decrease in both nitric oxide production, as assessed by 3-amino-4-aminomethyl-2',7'-difluorofluorescein fluorescence, and superoxide formation. Further, hypothermia significantly attenuated NMDA-induced nitric oxide formation in the absence of hypoxia/hypoglycaemia. We conclude that the neuroprotective effects of hypothermia are mediated through a reduction in nitric oxide and superoxide formation and that this effect is likely to be downstream of NMDA receptor activation.	Univ Southampton, Sch Med, Div Clin Neurosci, Southampton SO16 7PX, Hants, England; Univ Southampton, Sch Biol Sci, Neurosci Grp, Southampton, Hants, England	Pringle, AK (corresponding author), Univ Southampton, Sch Med, Div Clin Neurosci, Biomed Sci Bldg,Bassett Crescent E, Southampton SO16 7PX, Hants, England.	akp1@soton.ac.uk		Pringle, Ashley/0000-0003-2421-4380			Adamchik Y, 2000, BRAIN RES PROTOC, V5, P153, DOI 10.1016/S1385-299X(00)00007-6; Amorim P, 1999, BRAIN RES, V844, P143, DOI 10.1016/S0006-8993(99)01944-7; Barth A, 1996, EXP NEUROL, V141, P330, DOI 10.1006/exnr.1996.0168; Berger C, 2002, STROKE, V33, P519, DOI 10.1161/hs0102.100878; Berman F W, 1996, J Biochem Toxicol, V11, P111, DOI 10.1002/(SICI)1522-7146(1996)11:3<111::AID-JBT2>3.0.CO;2-N; BRUNO VMG, 1994, J NEUROCHEM, V63, P1398; BUCHAN A, 1990, J NEUROSCI, V10, P311; Budd SL, 1997, FEBS LETT, V415, P21, DOI 10.1016/S0014-5793(97)01088-0; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Cater HL, 2001, J PHYSIOL-LONDON, V531, P459, DOI 10.1111/j.1469-7793.2001.0459i.x; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Coimbra C, 1996, STROKE, V27, P1578, DOI 10.1161/01.STR.27.9.1578; Colbourne F, 1997, MOL NEUROBIOL, V14, P171, DOI 10.1007/BF02740655; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; Corbett D, 2000, BRAIN PATHOL, V10, P145; Dietrich WD, 1999, EXP NEUROL, V158, P444, DOI 10.1006/exnr.1999.7115; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; Dietrich WD, 1996, ADV NEUROL, V71, P177; Erecinska M, 2003, J CEREBR BLOOD F MET, V23, P513, DOI 10.1097/01.WCB.0000066287.21705.21; Frantseva MV, 1999, J NEUROSCI METH, V89, P25, DOI 10.1016/S0165-0270(99)00030-8; Gray J, 2001, J BIOL CHEM, V276, P32750, DOI 10.1074/jbc.M103150200; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; Greene JG, 1996, PROG NEUROBIOL, V48, P613, DOI 10.1016/0301-0082(96)00006-8; Greiner C, 1998, BRAIN RES, V786, P267, DOI 10.1016/S0006-8993(97)01465-0; Han HS, 2002, J NEUROSCI, V22, P3921, DOI 10.1523/JNEUROSCI.22-10-03921.2002; HU BR, 1995, NEUROSCIENCE, V68, P1003, DOI 10.1016/0306-4522(95)00213-3; Huh PW, 2000, J NEUROSURG, V92, P91, DOI 10.3171/jns.2000.92.1.0091; Iadecola C, 2001, CURR OPIN NEUROL, V14, P89, DOI 10.1097/00019052-200102000-00014; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Karabiyikoglu M, 2003, J NEUROSURG, V98, P1271, DOI 10.3171/jns.2003.98.6.1271; Keynes RG, 2004, EUR J NEUROSCI, V19, P1163, DOI 10.1111/j.1460-9568.2004.03217.x; Kil HY, 1996, J CEREBR BLOOD F MET, V16, P100, DOI 10.1097/00004647-199601000-00012; Kim Y, 1996, STROKE, V27, P2274, DOI 10.1161/01.STR.27.12.2274; KRISTIAN T, 1992, ACTA PHYSIOL SCAND, V146, P531, DOI 10.1111/j.1748-1716.1992.tb09457.x; LOUGHEED WM, 1955, J NEUROSURG, V12, P240, DOI 10.3171/jns.1955.12.3.0240; Maier CM, 2002, NEUROBIOL DIS, V11, P28, DOI 10.1006/nbdi.2002.0513; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; Marion Donald W, 2002, Curr Opin Crit Care, V8, P111, DOI 10.1097/00075198-200204000-00004; MITANI A, 1991, NEUROSCIENCE, V42, P661, DOI 10.1016/0306-4522(91)90035-M; Morrison B, 2002, BRIT J PHARMACOL, V137, P1255, DOI 10.1038/sj.bjp.0704986; Nedergaard M, 1996, ADV NEUROL, V71, P75; NEWELL DW, 1995, BRAIN RES, V675, P38, DOI 10.1016/0006-8993(95)00039-S; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Popovic R, 2000, ANESTHESIOLOGY, V92, P1343, DOI 10.1097/00000542-200005000-00024; Pringle AK, 2000, EUR J NEUROSCI, V12, P3833, DOI 10.1046/j.1460-9568.2000.00272.x; Pringle AK, 1997, BRAIN RES, V755, P36, DOI 10.1016/S0006-8993(97)00089-9; Ren YB, 2004, J CEREBR BLOOD F MET, V24, P42, DOI 10.1097/01.WCB.0000095802.98378.91; RIDENOUR TR, 1992, STROKE, V23, P733, DOI 10.1161/01.STR.23.5.733; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; Schuppe H, 2002, J NEUROBIOL, V53, P361, DOI 10.1002/neu.10117; Shima H, 2003, J NEUROTRAUM, V20, P1179, DOI 10.1089/089771503770802862; Siesjo BK, 1999, ACTA NEUROCHIR SUPPL, V73, P7; Stewart VC, 2003, FREE RADICAL BIO MED, V34, P287, DOI 10.1016/S0891-5849(02)01327-8; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; STRASSER U, 1995, J NEUROSCI METH, V57, P177, DOI 10.1016/0165-0270(94)00147-9; Suehiro E, 1999, J NEUROTRAUM, V16, P285, DOI 10.1089/neu.1999.16.285; Takei Y, 2004, BRAIN DEV-JPN, V26, P176, DOI 10.1016/S0387-7604(03)00123-2; TANIMOTO M, 1987, BRAIN RES, V417, P239, DOI 10.1016/0006-8993(87)90448-3; TAYLOR CP, 1993, NEUROSCIENCE, V52, P555, DOI 10.1016/0306-4522(93)90405-5; Taylor CP, 1999, J NEUROSCI, V19, P619; Toyoda T, 1996, NEUROSURGERY, V39, P1200, DOI 10.1097/00006123-199612000-00024; Tymianski M, 1998, J CEREBR BLOOD F MET, V18, P848, DOI 10.1097/00004647-199808000-00005; Venturini G, 1999, NITRIC OXIDE-BIOL CH, V3, P375, DOI 10.1006/niox.1999.0250; WELSH FA, 1990, J CEREBR BLOOD F MET, V10, P557, DOI 10.1038/jcbfm.1990.98; WIDMANN R, 1993, J NEUROCHEM, V61, P200, DOI 10.1111/j.1471-4159.1993.tb03556.x; WILLIAMS GR, 1958, ANN SURG, V148, P462, DOI 10.1097/00000658-195809000-00014; Yamamoto H, 1999, NEUROSCIENCE, V91, P501, DOI 10.1016/S0306-4522(98)00648-4; Yanamoto H, 1999, STROKE, V30, P2720, DOI 10.1161/01.STR.30.12.2720; Yanamoto H, 1996, BRAIN RES, V718, P207, DOI 10.1016/0006-8993(96)00122-9; ZEEVALK GD, 1993, J NEUROCHEM, V61, P1445, DOI 10.1111/j.1471-4159.1993.tb13639.x; Zhao W, 1996, J NEUROSCI RES, V45, P282, DOI 10.1002/(SICI)1097-4547(19960801)45:3<282::AID-JNR10>3.0.CO;2-6; Zimmer J, 2000, AMINO ACIDS, V19, P7, DOI 10.1007/s007260070029	74	39	42	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	OCT	2004	91	2					327	336		10.1111/j.1471-4159.2004.02711.x			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	856UH	WOS:000224070100008	15447666	Bronze			2021-06-18	
J	Jonsson, CA; Horneman, G; Emanuelson, I				Jonsson, CA; Horneman, G; Emanuelson, I			Neuropsychological progress during 14 years after severe traumatic brain injury in childhood and adolescence	BRAIN INJURY			English	Article							EXECUTIVE FUNCTION; NORMATIVE DATA; HEAD-INJURIES; CHILDREN; TERM; AGE; OUTCOMES; RECOVERY; FLUENCY; SKILLS	Objective: To investigate the impact of time since injury on neuropsychological and psychosocial outcome after serious TBI in childhood or adolescence. Methods: The subjects were eight patients with serious TBI sustained at a mean age of 14 years who had been assessed neuropsychologically at 1, 7 and 14 years after TBI. A retrospective longitudinal design was chosen to describe the development in six neuropsychological domains on the basis of the assessments. Psychosocial data were gathered from clinical knowledge and a semi-structured interview 14 years after TBI. Results: Performance of verbal IQ shows a declining trend over the three assessments, that the performance of attention and working memory is low and that verbal learning is the cognitive domain which exhibits the largest impairments. The main psychosocial result is that three of the eight subjects went from a school situation with no adjustments to adult life with early retirement. Conclusions: Time since insult is an important factor when assessing outcome after TBI in childhood and adolescence and that assessment of final outcome should not be done before adulthood.	Ostersund Hosp, Ostersund, Sweden; Univ Gothenburg, Dept Psychol, S-40020 Gothenburg, Sweden; Univ Gothenburg, Inst Hlth Women & Children, Gothenburg, Sweden	Jonsson, CA (corresponding author), Ostersund Hosp, Ostersund, Sweden.	catherine.aaro.jonsson@jll.se					Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHRISTENSEN AL, 1984, LURIAS NEUROPSYCHOLO; DERENZI E, 1978, CORTEX, V14, P41, DOI 10.1016/S0010-9452(78)80006-9; Dunn L., 1981, PEABODY PICTURE VOCA; Emanuelson I, 1998, Pediatr Rehabil, V2, P65; Emanuelson I, 1997, ACTA PAEDIATR, V86, P730, DOI 10.1111/j.1651-2227.1997.tb08576.x; Enlund Mats, 1996, Upsala Journal of Medical Sciences, V101, P97; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Geffen Gina, 1990, Clin Neuropsychol, V4, P45, DOI 10.1080/13854049008401496; Hanten G, 2002, CHILD NEUROPSYCHOL, V8, P107, DOI 10.1076/chin.8.2.107.8729; Hanten G, 2000, DEV NEUROPSYCHOL, V18, P383, DOI 10.1207/S1532694206Hanten; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Lehnung M, 2003, BRAIN INJURY, V17, P855, DOI 10.1080/0269905031000089369; Lehnung M, 2001, CHILD NEUROPSYCHOL, V7, P59, DOI 10.1076/chin.7.2.59.3129; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; *PSYK, 1996, MAN WAIS R; *PSYK AB, 1977, MAN WISC; Rydberg S., 1974, SPIQ SNABBT PERFORMA; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Tombaugh TN, 1999, ARCH CLIN NEUROPSYCH, V14, P167, DOI 10.1016/S0887-6177(97)00095-4; Ward H, 2002, J CLIN EXP NEUROPSYC, V24, P458, DOI 10.1076/jcen.24.4.458.1032; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	34	39	39	1	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2004	18	9					921	934		10.1080/02699050410001671900			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	831FG	WOS:000222178700007	15223744				2021-06-18	
